Naloxone	NOUN	O	Chemical	1
reverses	VERB	O	O	1
the	PRON	O	O	1
antihypertensive	ADV	O	O	1
effect	VERB	O	O	1
of	ADP	O	O	1
clonidine	NOUN	O	Chemical	1
.	PUNCT	O	O	1
In	ADP	O	O	2
unanesthetized	ADJ	O	O	2
,	PUNCT	O	O	2
spontaneously	ADV	O	O	2
hypertensive	ADJ	O	Disease	2
rats	NOUN	O	O	2
the	PRON	O	O	2
decrease	VERB	O	O	2
in	ADP	O	O	2
blood	NOUN	O	O	2
pressure	NOUN	O	O	2
and	CCONJ	O	O	2
heart	NOUN	O	O	2
rate	NOUN	O	O	2
produced	VERB	O	O	2
by	ADP	O	O	2
intravenous	ADJ	O	O	2
clonidine	NOUN	O	Chemical	2
,	PUNCT	O	O	2
5	NUM	O	O	2
to	PART	O	O	2
20	NUM	O	O	2
micrograms	NOUN	O	O	2
/	PUNCT	O	O	2
kg	VERB	O	O	2
,	PUNCT	O	O	2
was	AUX	O	O	2
inhibited	VERB	O	O	2
or	CCONJ	O	O	2
reversed	VERB	O	O	2
by	ADP	O	O	2
nalozone	NOUN	O	O	2
,	PUNCT	O	O	2
0.2	NUM	O	O	2
to	PART	O	O	2
2	X	O	O	2
mg	VERB	O	O	2
/	PUNCT	O	O	2
kg	VERB	O	O	2
.	PUNCT	O	O	2
The	PRON	O	O	3
hypotensive	ADJ	O	Disease	3
effect	VERB	O	O	3
of	ADP	O	O	3
100	NUM	O	O	3
mg	VERB	O	O	3
/	PUNCT	O	O	3
kg	VERB	O	O	3
alpha	PROPN	O	O	3
-	PUNCT	O	O	3
methyldopa	ADJ	O	Chemical	3
was	AUX	O	O	3
also	ADV	O	O	3
partially	ADV	O	O	3
reversed	VERB	O	O	3
by	ADP	O	O	3
naloxone	NOUN	O	Chemical	3
.	PUNCT	O	O	3
Naloxone	NOUN	O	Chemical	4
alone	ADV	O	O	4
did	VERB	O	O	4
not	PART	O	O	4
affect	VERB	O	O	4
either	ADV	O	O	4
blood	NOUN	O	O	4
pressure	NOUN	O	O	4
or	CCONJ	O	O	4
heart	NOUN	O	O	4
rate	NOUN	O	O	4
.	PUNCT	O	O	4
In	ADP	O	O	5
brain	NOUN	O	O	5
membranes	NOUN	O	O	5
from	ADP	O	O	5
spontaneously	ADV	O	O	5
hypertensive	ADJ	O	Disease	5
rats	NOUN	O	O	5
clonidine	NOUN	O	Chemical	5
,	PUNCT	O	O	5
10(-8	NOUN	O	O	5
)	PUNCT	O	O	5
to	PART	O	O	5
10(-5	NUM	O	O	5
)	PUNCT	O	O	5
M	NOUN	O	Chemical	6
,	PUNCT	O	O	6
did	VERB	O	O	6
not	PART	O	O	6
influence	NOUN	O	O	6
stereoselective	NOUN	O	O	6
binding	VERB	O	O	6
of	ADP	O	O	6
[	X	O	O	6
3H]-naloxone	NUM	O	O	6
(	PUNCT	O	O	6
8	NUM	O	O	6
nM	NOUN	O	O	6
)	PUNCT	O	O	6
,	PUNCT	O	O	6
and	CCONJ	O	O	6
naloxone	NOUN	O	Chemical	6
,	PUNCT	O	O	6
10(-8	NOUN	O	O	6
)	PUNCT	O	O	6
to	PART	O	O	6
10(-4	NUM	O	O	6
)	PUNCT	O	O	6
M	NOUN	O	Chemical	7
,	PUNCT	O	O	7
did	VERB	O	O	7
not	PART	O	O	7
influence	NOUN	O	O	7
clonidine	NOUN	O	Chemical	7
-	PUNCT	O	O	7
suppressible	VERB	O	O	7
binding	VERB	O	O	7
of	ADP	O	O	7
[	X	O	O	7
3H]-dihydroergocryptine	NUM	O	O	7
(	PUNCT	O	O	7
1	X	O	O	7
nM	NOUN	O	O	7
)	PUNCT	O	O	7
.	PUNCT	O	O	7
These	PRON	O	O	8
findings	NOUN	O	O	8
indicate	VERB	O	O	8
that	SCONJ	O	O	8
in	ADP	O	O	8
spontaneously	ADV	O	O	8
hypertensive	ADJ	O	Disease	8
rats	NOUN	O	O	8
the	PRON	O	O	8
effects	NOUN	O	O	8
of	ADP	O	O	8
central	ADJ	O	O	8
alpha	PROPN	O	O	8
-	PUNCT	O	O	8
adrenoceptor	NOUN	O	O	8
stimulation	NOUN	O	O	8
involve	VERB	O	O	8
activation	NOUN	O	O	8
of	ADP	O	O	8
opiate	NOUN	O	O	8
receptors	NOUN	O	O	8
.	PUNCT	O	O	8
As	ADP	O	O	9
naloxone	NOUN	O	Chemical	9
and	CCONJ	O	O	9
clonidine	NOUN	O	Chemical	9
do	VERB	O	O	9
not	PART	O	O	9
appear	VERB	O	O	9
to	PART	O	O	9
interact	VERB	O	O	9
with	ADP	O	O	9
the	PRON	O	O	9
same	ADJ	O	O	9
receptor	NOUN	O	O	9
site	NOUN	O	O	9
,	PUNCT	O	O	9
the	PRON	O	O	9
observed	VERB	O	O	9
functional	ADJ	O	O	9
antagonism	NOUN	O	O	9
suggests	VERB	O	O	9
the	PRON	O	O	9
release	NOUN	O	O	9
of	ADP	O	O	9
an	PRON	O	O	9
endogenous	ADJ	O	O	9
opiate	NOUN	O	O	9
by	ADP	O	O	9
clonidine	NOUN	O	Chemical	9
or	CCONJ	O	O	9
alpha	PROPN	O	O	9
-	PUNCT	O	O	9
methyldopa	ADJ	O	Chemical	9
and	CCONJ	O	O	9
the	PRON	O	O	9
possible	ADJ	O	O	9
role	NOUN	O	O	9
of	ADP	O	O	9
the	PRON	O	O	9
opiate	NOUN	O	O	9
in	ADP	O	O	9
the	PRON	O	O	9
central	ADJ	O	O	9
control	VERB	O	O	9
of	ADP	O	O	9
sympathetic	ADJ	O	O	9
tone	NOUN	O	O	9
.	PUNCT	O	O	9
Lidocaine	PROPN	O	O	12
-	PUNCT	O	O	12
induced	VERB	O	O	12
cardiac	ADJ	O	O	12
asystole	NOUN	O	Disease	12
.	PUNCT	O	O	12
Intravenous	PROPN	O	O	13
administration	NOUN	O	O	13
of	ADP	O	O	13
a	PRON	O	O	13
single	ADJ	O	O	13
50-mg	NOUN	O	O	13
bolus	NOUN	O	O	13
of	ADP	O	O	13
lidocaine	NOUN	O	Chemical	13
in	ADP	O	O	13
a	PRON	O	O	13
67-year	NOUN	O	O	13
-	PUNCT	O	O	13
old	ADJ	O	O	13
man	NOUN	O	O	13
resulted	VERB	O	O	13
in	ADP	O	O	13
profound	ADJ	O	O	13
depression	PROPN	O	Disease	13
of	ADP	O	O	13
the	PRON	O	O	13
activity	NOUN	O	O	13
of	ADP	O	O	13
the	PRON	O	O	13
sinoatrial	NOUN	O	O	13
and	CCONJ	O	O	13
atrioventricular	ADJ	O	O	13
nodal	ADJ	O	O	13
pacemakers	NOUN	O	O	13
.	PUNCT	O	O	13
The	PRON	O	O	14
patient	NOUN	O	O	14
had	VERB	O	O	14
no	PRON	O	O	14
apparent	ADJ	O	O	14
associated	VERB	O	O	14
conditions	NOUN	O	O	14
which	PRON	O	O	14
might	AUX	O	O	14
have	VERB	O	O	14
predisposed	ADJ	O	O	14
him	PRON	O	O	14
to	PART	O	O	14
the	PRON	O	O	14
development	NOUN	O	O	14
of	ADP	O	O	14
bradyarrhythmias	PROPN	O	Disease	14
;	PUNCT	O	O	14
and	CCONJ	O	O	14
,	PUNCT	O	O	14
thus	ADV	O	O	14
,	PUNCT	O	O	14
this	PRON	O	O	14
probably	ADV	O	O	14
represented	VERB	O	O	14
a	PRON	O	O	14
true	ADJ	O	O	14
idiosyncrasy	PROPN	O	O	14
to	PART	O	O	14
lidocaine	NOUN	O	Chemical	14
.	PUNCT	O	O	14
Suxamethonium	NOUN	O	O	17
infusion	NOUN	O	O	17
rate	NOUN	O	O	17
and	CCONJ	O	O	17
observed	VERB	O	O	17
fasciculations	NOUN	O	O	17
.	PUNCT	O	O	17
Suxamethonium	NOUN	O	O	18
chloride	NOUN	O	Chemical	18
(	PUNCT	O	O	18
Sch	ADJ	O	Chemical	18
)	PUNCT	O	O	18
was	AUX	O	O	18
administered	VERB	O	O	18
i.v	NOUN	O	O	18
.	PUNCT	O	O	18
to	PART	O	O	18
36	NUM	O	O	18
adult	NOUN	O	O	18
males	NOUN	O	O	18
at	ADP	O	O	18
six	NUM	O	O	18
rates	NOUN	O	O	18
:	PUNCT	O	O	18
The	PRON	O	O	19
infusion	NOUN	O	O	19
was	AUX	O	O	19
discontinued	VERB	O	O	19
either	ADV	O	O	19
when	SCONJ	O	O	19
there	ADV	O	O	19
was	AUX	O	O	19
no	PRON	O	O	19
muscular	ADJ	O	O	19
response	NOUN	O	O	19
to	PART	O	O	19
tetanic	ADJ	O	Disease	19
stimulation	NOUN	O	O	19
of	ADP	O	O	19
the	PRON	O	O	19
ulnar	ADJ	O	O	19
nerve	NOUN	O	O	19
or	CCONJ	O	O	19
when	SCONJ	O	O	19
Sch	ADJ	O	Chemical	19
120	NUM	O	O	19
mg	VERB	O	O	19
was	AUX	O	O	19
exceeded	VERB	O	O	19
.	PUNCT	O	O	19
Fasciculations	NOUN	O	O	20
in	ADP	O	O	20
six	NUM	O	O	20
areas	NOUN	O	O	20
of	ADP	O	O	20
the	PRON	O	O	20
body	NOUN	O	O	20
were	AUX	O	O	20
scored	VERB	O	O	20
from	ADP	O	O	20
0	NUM	O	O	20
to	PART	O	O	20
3	X	O	O	20
and	CCONJ	O	O	20
summated	VERB	O	O	20
as	ADP	O	O	20
a	PRON	O	O	20
total	ADJ	O	O	20
fasciculation	NOUN	O	Disease	20
score	VERB	O	O	20
.	PUNCT	O	O	20
The	PRON	O	O	21
times	NOUN	O	O	21
to	PART	O	O	21
first	ADV	O	O	21
fasciculation	NOUN	O	Disease	21
,	PUNCT	O	O	21
twitch	VERB	O	O	21
suppression	NOUN	O	O	21
and	CCONJ	O	O	21
tetanus	NOUN	O	O	21
suppression	NOUN	O	O	21
were	AUX	O	O	21
inversely	ADV	O	O	21
related	ADJ	O	O	21
to	PART	O	O	21
the	PRON	O	O	21
infusion	NOUN	O	O	21
rates	NOUN	O	O	21
.	PUNCT	O	O	21
Fasciculations	NOUN	O	O	22
in	ADP	O	O	22
the	PRON	O	O	22
six	NUM	O	O	22
areas	NOUN	O	O	22
and	CCONJ	O	O	22
the	PRON	O	O	22
total	ADJ	O	O	22
fasciculation	NOUN	O	Disease	22
score	VERB	O	O	22
were	AUX	O	O	22
related	ADJ	O	O	22
directly	ADV	O	O	22
to	PART	O	O	22
the	PRON	O	O	22
rate	NOUN	O	O	22
of	ADP	O	O	22
infusion	NOUN	O	O	22
.	PUNCT	O	O	22
Total	ADJ	O	O	23
fasciculation	NOUN	O	Disease	23
scores	NOUN	O	O	23
in	ADP	O	O	23
the	PRON	O	O	23
30-mg	NOUN	O	O	23
bolus	NOUN	O	O	23
group	NOUN	O	O	23
and	CCONJ	O	O	23
the	PRON	O	O	23
5-mg	NOUN	O	O	23
s-1	NOUN	O	O	23
and	CCONJ	O	O	23
20-mg	NOUN	O	O	23
s-1	NOUN	O	O	23
infusion	NOUN	O	O	23
groups	NOUN	O	O	23
were	AUX	O	O	23
not	PART	O	O	23
significantly	ADV	O	O	23
different	ADJ	O	O	23
.	PUNCT	O	O	23
Galanthamine	PROPN	O	O	26
hydrobromide	NOUN	O	O	26
,	PUNCT	O	O	26
a	PRON	O	O	26
longer	ADV	O	O	26
acting	VERB	O	O	26
anticholinesterase	PROPN	O	O	26
drug	NOUN	O	O	26
,	PUNCT	O	O	26
in	ADP	O	O	26
the	PRON	O	O	26
treatment	NOUN	O	O	26
of	ADP	O	O	26
the	PRON	O	O	26
central	ADJ	O	O	26
effects	NOUN	O	O	26
of	ADP	O	O	26
scopolamine	NOUN	O	Chemical	26
(	PUNCT	O	O	26
Hyoscine	NOUN	O	O	26
)	PUNCT	O	O	26
.	PUNCT	O	O	26
Galanthamine	PROPN	O	O	27
hydrobromide	NOUN	O	O	27
,	PUNCT	O	O	27
an	PRON	O	O	27
anticholinesterase	PROPN	O	O	27
drug	NOUN	O	O	27
capable	ADJ	O	O	27
of	ADP	O	O	27
penetrating	VERB	O	O	27
the	PRON	O	O	27
blood	NOUN	O	O	27
-	PUNCT	O	O	27
brain	NOUN	O	O	27
barrier	NOUN	O	O	27
,	PUNCT	O	O	27
was	AUX	O	O	27
used	VERB	O	O	27
in	ADP	O	O	27
a	PRON	O	O	27
patient	NOUN	O	O	27
demonstrating	VERB	O	O	27
central	ADJ	O	O	27
effects	NOUN	O	O	27
of	ADP	O	O	27
scopolamine	NOUN	O	Chemical	27
(	PUNCT	O	O	27
hyoscine	NOUN	O	O	27
)	PUNCT	O	O	27
overdosage	NOUN	O	O	28
.	PUNCT	O	O	28
It	PRON	O	O	29
is	AUX	O	O	29
longer	ADV	O	O	29
acting	VERB	O	O	29
than	ADP	O	O	29
physostigmine	NOUN	O	Chemical	29
and	CCONJ	O	O	29
is	AUX	O	O	29
used	VERB	O	O	29
in	ADP	O	O	29
anaesthesia	NOUN	O	O	29
to	PART	O	O	29
reverse	VERB	O	O	29
the	PRON	O	O	29
non	ADJ	O	O	29
-	PUNCT	O	O	29
depolarizing	VERB	O	O	29
neuromuscular	ADJ	O	O	29
block	NOUN	O	O	29
.	PUNCT	O	O	29
However	ADV	O	O	30
,	PUNCT	O	O	30
studies	NOUN	O	O	30
into	ADP	O	O	30
the	PRON	O	O	30
dose	NOUN	O	O	30
necessary	ADJ	O	O	30
to	PART	O	O	30
combating	VERB	O	O	30
scopolamine	NOUN	O	Chemical	30
intoxication	NOUN	O	O	30
are	AUX	O	O	30
indicated	VERB	O	O	30
.	PUNCT	O	O	30
Effects	NOUN	O	O	33
of	ADP	O	O	33
uninephrectomy	ADJ	O	O	33
and	CCONJ	O	O	33
high	ADJ	O	O	33
protein	NOUN	O	O	33
feeding	VERB	O	O	33
on	ADP	O	O	33
lithium	NOUN	O	Chemical	33
-	PUNCT	O	O	33
induced	VERB	O	O	33
chronic	ADJ	O	O	33
renal failure	NOUN	O	Disease	33
in	ADP	O	O	33
rats	NOUN	O	O	33
.	PUNCT	O	O	33
Rats	NOUN	O	O	34
with	ADP	O	O	34
lithium	NOUN	O	Chemical	34
-	PUNCT	O	O	34
induced	VERB	O	O	34
nephropathy	NOUN	O	Disease	34
were	AUX	O	O	34
subjected	VERB	O	O	34
to	PART	O	O	34
high	ADJ	O	O	34
protein	NOUN	O	O	34
(	PUNCT	O	O	34
HP	PROPN	O	O	34
)	PUNCT	O	O	34
feeding	VERB	O	O	34
,	PUNCT	O	O	34
uninephrectomy	ADJ	O	O	34
(	PUNCT	O	O	34
NX	PROPN	O	O	34
)	PUNCT	O	O	34
or	CCONJ	O	O	34
a	PRON	O	O	34
combination	NOUN	O	O	34
of	ADP	O	O	34
these	PRON	O	O	34
,	PUNCT	O	O	34
in	ADP	O	O	34
an	PRON	O	O	34
attempt	VERB	O	O	34
to	PART	O	O	34
induce	VERB	O	O	34
glomerular	ADJ	O	O	34
hyperfiltration	NOUN	O	O	34
and	CCONJ	O	O	34
further	ADV	O	O	34
progression	NOUN	O	O	34
of	ADP	O	O	34
renal failure	NOUN	O	Disease	34
.	PUNCT	O	O	34
Newborn	ADJ	O	O	35
female	ADJ	O	O	35
Wistar	PROPN	O	O	35
rats	NOUN	O	O	35
were	AUX	O	O	35
fed	VERB	O	O	35
a	PRON	O	O	35
lithium	NOUN	O	Chemical	35
-	PUNCT	O	O	35
containing	VERB	O	O	35
diet	PROPN	O	O	35
(	PUNCT	O	O	35
50	NUM	O	O	35
mmol	NOUN	O	O	35
/	PUNCT	O	O	35
kg	VERB	O	O	35
)	PUNCT	O	O	35
for	ADP	O	O	35
8	NUM	O	O	35
weeks	NOUN	O	O	35
and	CCONJ	O	O	35
then	ADV	O	O	35
randomized	VERB	O	O	35
to	PART	O	O	35
normal	ADJ	O	O	35
diet	PROPN	O	O	35
,	PUNCT	O	O	35
HP	PROPN	O	O	35
diet	PROPN	O	O	35
(	PUNCT	O	O	35
40	NUM	O	O	35
vs.	CCONJ	O	O	35
19%	NOUN	O	O	35
)	PUNCT	O	O	35
,	PUNCT	O	O	35
NX	PROPN	O	O	35
or	CCONJ	O	O	35
HP+NX	VERB	O	O	35
for	ADP	O	O	35
another	PRON	O	O	35
8	NUM	O	O	35
weeks	NOUN	O	O	35
.	PUNCT	O	O	35
Corresponding	VERB	O	O	36
non	ADJ	O	O	36
-	PUNCT	O	O	36
lithium	NOUN	O	Chemical	36
pretreated	VERB	O	O	36
groups	NOUN	O	O	36
were	AUX	O	O	36
generated	VERB	O	O	36
.	PUNCT	O	O	36
When	SCONJ	O	O	37
comparing	VERB	O	O	37
all	PRON	O	O	37
lithium	NOUN	O	Chemical	37
treated	VERB	O	O	37
versus	ADP	O	O	37
non	ADJ	O	O	37
-	PUNCT	O	O	37
lithium	NOUN	O	Chemical	37
-	PUNCT	O	O	37
treated	VERB	O	O	37
groups	NOUN	O	O	37
,	PUNCT	O	O	37
lithium	NOUN	O	Chemical	37
caused	VERB	O	O	37
a	PRON	O	O	37
reduction	NOUN	O	O	37
in	ADP	O	O	37
glomerular	ADJ	O	O	37
filtration	NOUN	O	O	37
rate	NOUN	O	O	37
(	PUNCT	O	O	37
GFR	NOUN	O	O	37
)	PUNCT	O	O	37
without	ADP	O	O	37
significant	ADJ	O	O	37
changes	VERB	O	O	37
in	ADP	O	O	37
effective	ADJ	O	O	37
renal	ADJ	O	O	37
plasma	NOUN	O	O	37
flow	NOUN	O	O	37
(	PUNCT	O	O	37
as	ADP	O	O	37
determined	VERB	O	O	37
by	ADP	O	O	37
a	PRON	O	O	37
marker	NOUN	O	O	37
secreted	VERB	O	O	37
into	ADP	O	O	37
the	PRON	O	O	37
proximal	ADJ	O	O	37
tubules	NOUN	O	O	37
)	PUNCT	O	O	37
or	CCONJ	O	O	37
lithium	NOUN	O	Chemical	37
clearance	NOUN	O	O	37
.	PUNCT	O	O	37
Consequently	ADV	O	O	38
,	PUNCT	O	O	38
lithium	NOUN	O	Chemical	38
pretreatment	NOUN	O	O	38
caused	VERB	O	O	38
a	PRON	O	O	38
fall	VERB	O	O	38
in	ADP	O	O	38
filtration	NOUN	O	O	38
fraction	NOUN	O	O	38
and	CCONJ	O	O	38
an	PRON	O	O	38
increase	VERB	O	O	38
in	ADP	O	O	38
fractional	ADJ	O	O	38
Li	PROPN	O	Chemical	38
excretion	NOUN	O	O	38
.	PUNCT	O	O	38
Lithium	NOUN	O	Chemical	39
also	ADV	O	O	39
caused	VERB	O	O	39
proteinuria	X	O	Disease	39
and	CCONJ	O	O	39
systolic	ADV	O	O	39
hypertension	NOUN	O	Disease	39
in	ADP	O	O	39
absence	NOUN	O	O	39
of	ADP	O	O	39
glomerulosclerosis	PROPN	O	O	39
.	PUNCT	O	O	39
HP	PROPN	O	O	40
failed	VERB	O	O	40
to	PART	O	O	40
accentuante	NOUN	O	O	40
progression	NOUN	O	O	40
of	ADP	O	O	40
renal failure	NOUN	O	Disease	40
and	CCONJ	O	O	40
in	ADP	O	O	40
fact	NOUN	O	O	40
tended	VERB	O	O	40
to	PART	O	O	40
increase	VERB	O	O	40
GFR	NOUN	O	O	40
and	CCONJ	O	O	40
decrease	VERB	O	O	40
plasma	NOUN	O	O	40
creatinine	PROPN	O	Chemical	40
levels	NOUN	O	O	40
in	ADP	O	O	40
lithium	NOUN	O	Chemical	40
pretreated	VERB	O	O	40
rats	NOUN	O	O	40
.	PUNCT	O	O	40
NX+HP	X	O	O	41
caused	VERB	O	O	41
a	PRON	O	O	41
further	ADV	O	O	41
rise	VERB	O	O	41
in	ADP	O	O	41
blood	NOUN	O	O	41
pressure	NOUN	O	O	41
in	ADP	O	O	41
Li	PROPN	O	Chemical	41
-	PUNCT	O	O	41
pretreated	VERB	O	O	41
rats	NOUN	O	O	41
.	PUNCT	O	O	41
The	PRON	O	O	42
results	VERB	O	O	42
indicate	VERB	O	O	42
that	SCONJ	O	O	42
Li	PROPN	O	Chemical	42
-	PUNCT	O	O	42
induced	VERB	O	O	42
nephropathy	NOUN	O	Disease	42
,	PUNCT	O	O	42
even	ADV	O	O	42
when	SCONJ	O	O	42
the	PRON	O	O	42
GFR	NOUN	O	O	42
is	AUX	O	O	42
only	ADV	O	O	42
modestly	ADV	O	O	42
reduced	VERB	O	O	42
,	PUNCT	O	O	42
is	AUX	O	O	42
associated	VERB	O	O	42
with	ADP	O	O	42
proteinuria	X	O	Disease	42
and	CCONJ	O	O	42
arterial	ADJ	O	O	42
systolic	ADV	O	O	42
hypertension	NOUN	O	Disease	42
.	PUNCT	O	O	42
In	ADP	O	O	43
this	PRON	O	O	43
model	NOUN	O	O	43
of	ADP	O	O	43
chronic	ADJ	O	O	43
renal failure	NOUN	O	Disease	43
the	PRON	O	O	43
decline	VERB	O	O	43
in	ADP	O	O	43
GFR	NOUN	O	O	43
is	AUX	O	O	43
not	PART	O	O	43
accompanied	VERB	O	O	43
by	ADP	O	O	43
a	PRON	O	O	43
corresponding	VERB	O	O	43
fall	VERB	O	O	43
in	ADP	O	O	43
effective	ADJ	O	O	43
renal	ADJ	O	O	43
plasma	NOUN	O	O	43
flow	NOUN	O	O	43
,	PUNCT	O	O	43
which	PRON	O	O	43
may	AUX	O	O	43
be	AUX	O	O	43
the	PRON	O	O	43
functional	ADJ	O	O	43
expression	NOUN	O	O	43
of	ADP	O	O	43
the	PRON	O	O	43
formation	NOUN	O	O	43
of	ADP	O	O	43
nonfiltrating	NOUN	O	O	43
atubular	ADJ	O	O	43
glomeruli	VERB	O	O	43
.	PUNCT	O	O	43
Treatment	NOUN	O	O	46
of	ADP	O	O	46
Crohn	PROPN	O	O	46
's	AUX	O	O	46
disease	PROPN	O	O	46
with	ADP	O	O	46
fusidic	ADJ	O	O	46
acid	PROPN	O	O	46
:	PUNCT	O	O	46
an	PRON	O	O	46
antibiotic	ADJ	O	O	46
with	ADP	O	O	46
immunosuppressive	ADJ	O	O	46
properties	NOUN	O	O	46
similar	ADJ	O	O	46
to	PART	O	O	46
cyclosporin	NOUN	O	O	46
.	PUNCT	O	O	46
Fusidic	ADJ	O	O	47
acid	PROPN	O	O	47
is	AUX	O	O	47
an	PRON	O	O	47
antibiotic	ADJ	O	O	47
with	ADP	O	O	47
T	NOUN	O	Chemical	47
-	PUNCT	O	O	47
cell	NOUN	O	O	47
specific	ADJ	O	O	47
immunosuppressive	ADJ	O	O	47
effects	NOUN	O	O	47
similar	ADJ	O	O	47
to	PART	O	O	47
those	PRON	O	O	47
of	ADP	O	O	47
cyclosporin	NOUN	O	O	47
.	PUNCT	O	O	47
Because	SCONJ	O	O	48
of	ADP	O	O	48
the	PRON	O	O	48
need	VERB	O	O	48
for	ADP	O	O	48
the	PRON	O	O	48
development	NOUN	O	O	48
of	ADP	O	O	48
new	ADJ	O	O	48
treatments	NOUN	O	O	48
for	ADP	O	O	48
Crohn	PROPN	O	O	48
's	AUX	O	O	48
disease	PROPN	O	O	48
,	PUNCT	O	O	48
a	PRON	O	O	48
pilot	NOUN	O	O	48
study	VERB	O	O	48
was	AUX	O	O	48
undertaken	VERB	O	O	48
to	PART	O	O	48
estimate	VERB	O	O	48
the	PRON	O	O	48
pharmacodynamics	NOUN	O	O	48
and	CCONJ	O	O	48
tolerability	NOUN	O	O	48
of	ADP	O	O	48
fusidic	ADJ	O	O	48
acid	PROPN	O	O	48
treatment	NOUN	O	O	48
in	ADP	O	O	48
chronic	ADJ	O	O	48
active	ADJ	O	O	48
,	PUNCT	O	O	48
therapy	NOUN	O	O	48
-	PUNCT	O	O	48
resistant	ADJ	O	O	48
patients	NOUN	O	O	48
.	PUNCT	O	O	48
Eight	NUM	O	O	49
Crohn	PROPN	O	O	49
's	AUX	O	O	49
disease	PROPN	O	O	49
patients	NOUN	O	O	49
were	AUX	O	O	49
included	VERB	O	O	49
.	PUNCT	O	O	49
Fusidic	ADJ	O	O	50
acid	PROPN	O	O	50
was	AUX	O	O	50
administered	VERB	O	O	50
orally	ADV	O	O	50
in	ADP	O	O	50
a	PRON	O	O	50
dose	NOUN	O	O	50
of	ADP	O	O	50
500	NUM	O	O	50
mg	VERB	O	O	50
t.d.s	VERB	O	O	50
.	PUNCT	O	O	50
Five	NUM	O	O	51
of	ADP	O	O	51
8	NUM	O	O	51
patients	NOUN	O	O	51
(	PUNCT	O	O	51
63%	NOUN	O	O	51
)	PUNCT	O	O	51
improved	VERB	O	O	51
during	ADP	O	O	51
fusidic	ADJ	O	O	51
acid	PROPN	O	O	51
treatment	NOUN	O	O	51
:	PUNCT	O	O	51
3	X	O	O	51
at	ADP	O	O	51
two	NUM	O	O	51
weeks	NOUN	O	O	51
and	CCONJ	O	O	51
2	X	O	O	51
after	ADP	O	O	51
four	NUM	O	O	51
weeks	NOUN	O	O	51
.	PUNCT	O	O	51
There	ADV	O	O	52
were	AUX	O	O	52
no	PRON	O	O	52
serious	ADJ	O	O	52
clinical	ADJ	O	O	52
side	NOUN	O	O	52
effects	NOUN	O	O	52
,	PUNCT	O	O	52
but	CCONJ	O	O	52
dose	NOUN	O	O	52
reduction	NOUN	O	O	52
was	AUX	O	O	52
required	VERB	O	O	52
in	ADP	O	O	52
two	NUM	O	O	52
patients	NOUN	O	O	52
because	SCONJ	O	O	52
of	ADP	O	O	52
nausea	NOUN	O	Disease	52
.	PUNCT	O	O	52
The	PRON	O	O	53
results	VERB	O	O	53
of	ADP	O	O	53
this	PRON	O	O	53
pilot	NOUN	O	O	53
study	VERB	O	O	53
suggest	VERB	O	O	53
that	SCONJ	O	O	53
fusidic	ADJ	O	O	53
acid	PROPN	O	O	53
may	AUX	O	O	53
be	AUX	O	O	53
of	ADP	O	O	53
benefit	VERB	O	O	53
in	ADP	O	O	53
selected	VERB	O	O	53
chronic	ADJ	O	O	53
active	ADJ	O	O	53
Crohn	PROPN	O	O	53
's	AUX	O	O	53
disease	PROPN	O	O	53
patients	NOUN	O	O	53
in	ADP	O	O	53
whom	PRON	O	O	53
conventional	ADJ	O	O	53
treatment	NOUN	O	O	53
is	AUX	O	O	53
ineffective	ADJ	O	O	53
.	PUNCT	O	O	53
Because	SCONJ	O	O	54
there	ADV	O	O	54
seems	VERB	O	O	54
to	PART	O	O	54
exist	VERB	O	O	54
a	PRON	O	O	54
scientific	ADJ	O	O	54
rationale	NOUN	O	O	54
for	ADP	O	O	54
the	PRON	O	O	54
use	VERB	O	O	54
of	ADP	O	O	54
fusidic	ADJ	O	O	54
acid	PROPN	O	O	54
at	ADP	O	O	54
the	PRON	O	O	54
cytokine	NOUN	O	O	54
level	VERB	O	O	54
in	ADP	O	O	54
inflammatory	ADJ	O	O	54
bowel	ADJ	O	O	54
disease	PROPN	O	O	54
,	PUNCT	O	O	54
we	PRON	O	O	54
suggest	VERB	O	O	54
that	SCONJ	O	O	54
the	PRON	O	O	54
role	NOUN	O	O	54
of	ADP	O	O	54
this	PRON	O	O	54
treatment	NOUN	O	O	54
should	AUX	O	O	54
be	AUX	O	O	54
further	ADV	O	O	54
investigated	VERB	O	O	54
.	PUNCT	O	O	54
Electrocardiographic	NOUN	O	O	57
evidence	NOUN	O	O	57
of	ADP	O	O	57
myocardial injury	NOUN	O	Disease	57
in	ADP	O	O	57
psychiatrically	ADV	O	O	57
hospitalized	VERB	O	O	57
cocaine abusers	NOUN	O	O	57
.	PUNCT	O	O	57
The	PRON	O	O	58
electrocardiograms	VERB	O	O	58
(	PUNCT	O	O	58
ECG	PROPN	O	O	58
)	PUNCT	O	O	58
of	ADP	O	O	58
99	NUM	O	O	58
cocaine	NOUN	O	Chemical	58
-	PUNCT	O	O	58
abusing	VERB	O	O	58
patients	NOUN	O	O	58
were	AUX	O	O	58
compared	VERB	O	O	58
with	ADP	O	O	58
the	PRON	O	O	58
ECGs	X	O	O	58
of	ADP	O	O	58
50	NUM	O	O	58
schizophrenic	ADJ	O	Disease	58
controls	VERB	O	O	58
.	PUNCT	O	O	58
Eleven	NUM	O	O	59
of	ADP	O	O	59
the	PRON	O	O	59
cocaine abusers	NOUN	O	O	59
and	CCONJ	O	O	59
none	NOUN	O	O	59
of	ADP	O	O	59
the	PRON	O	O	59
controls	VERB	O	O	59
had	VERB	O	O	59
ECG	PROPN	O	O	59
evidence	NOUN	O	O	59
of	ADP	O	O	59
significant	ADJ	O	O	59
myocardial injury	NOUN	O	Disease	59
defined	VERB	O	O	59
as	ADP	O	O	59
myocardial infarction	NOUN	O	Disease	59
,	PUNCT	O	O	59
ischemia	NOUN	O	Disease	59
,	PUNCT	O	O	59
and	CCONJ	O	O	59
bundle	VERB	O	O	59
branch	NOUN	O	O	59
block	NOUN	O	O	59
.	PUNCT	O	O	59
Sulpiride	NOUN	O	O	62
-	PUNCT	O	O	62
induced	VERB	O	O	62
tardive	ADJ	O	O	62
dystonia	NOUN	O	Disease	62
.	PUNCT	O	O	62
Sulpiride	NOUN	O	O	63
is	AUX	O	O	63
a	PRON	O	O	63
selective	ADJ	O	O	63
D2-receptor	NOUN	O	O	63
antagonist	NOUN	O	O	63
with	ADP	O	O	63
antipsychotic	ADJ	O	O	63
and	CCONJ	O	O	63
antidepressant	NOUN	O	O	63
properties	NOUN	O	O	63
.	PUNCT	O	O	63
Although	SCONJ	O	O	64
initially	ADV	O	O	64
thought	VERB	O	O	64
to	PART	O	O	64
be	AUX	O	O	64
free	ADJ	O	O	64
of	ADP	O	O	64
extrapyramidal	ADJ	O	O	64
side	NOUN	O	O	64
effects	NOUN	O	O	64
,	PUNCT	O	O	64
sulpiride	NOUN	O	Chemical	64
-	PUNCT	O	O	64
induced	VERB	O	O	64
tardive dyskinesia	NOUN	O	Disease	64
and	CCONJ	O	O	64
parkinsonism	NOUN	O	Disease	64
have	VERB	O	O	64
been	AUX	O	O	64
reported	VERB	O	O	64
occasionally	ADV	O	O	64
.	PUNCT	O	O	64
We	PRON	O	O	65
studied	VERB	O	O	65
a	PRON	O	O	65
37-year	NOUN	O	O	65
-	PUNCT	O	O	65
old	ADJ	O	O	65
man	NOUN	O	O	65
who	PRON	O	O	65
developed	VERB	O	O	65
persistent	ADJ	O	O	65
segmental	ADJ	O	O	65
dystonia	NOUN	O	Disease	65
within	ADP	O	O	65
2	X	O	O	65
months	NOUN	O	O	65
after	ADP	O	O	65
starting	VERB	O	O	65
sulpiride	NOUN	O	Chemical	65
therapy	NOUN	O	O	65
.	PUNCT	O	O	65
We	PRON	O	O	66
could	AUX	O	O	66
not	PART	O	O	66
find	VERB	O	O	66
any	PRON	O	O	66
previous	ADJ	O	O	66
reports	VERB	O	O	66
of	ADP	O	O	66
sulpiride	NOUN	O	Chemical	66
-	PUNCT	O	O	66
induced	VERB	O	O	66
tardive	ADJ	O	O	66
dystonia	NOUN	O	Disease	66
.	PUNCT	O	O	66
Ocular	ADJ	O	O	69
and	CCONJ	O	O	69
auditory	NOUN	O	O	69
toxicity	NOUN	O	Disease	69
in	ADP	O	O	69
hemodialyzed	VERB	O	O	69
patients	NOUN	O	O	69
receiving	VERB	O	O	69
desferrioxamine	NOUN	O	O	69
.	PUNCT	O	O	69
During	ADP	O	O	70
an	PRON	O	O	70
18-month	NOUN	O	O	70
period	NOUN	O	O	70
of	ADP	O	O	70
study	VERB	O	O	70
41	NUM	O	O	70
hemodialyzed	VERB	O	O	70
patients	NOUN	O	O	70
receiving	VERB	O	O	70
desferrioxamine	NOUN	O	O	70
(	PUNCT	O	O	70
10	NUM	O	O	70
-	PUNCT	O	O	70
40	NUM	O	O	70
mg	VERB	O	O	70
/	PUNCT	O	O	70
kg	VERB	O	O	70
BW/3	NUM	O	O	70
times	NOUN	O	O	70
weekly	ADV	O	O	70
)	PUNCT	O	O	70
for	ADP	O	O	70
the	PRON	O	O	70
first	ADV	O	O	70
time	NOUN	O	O	70
were	AUX	O	O	70
monitored	VERB	O	O	70
for	ADP	O	O	70
detection	NOUN	O	O	70
of	ADP	O	O	70
audiovisual	ADJ	O	O	70
toxicity	NOUN	O	Disease	70
.	PUNCT	O	O	70
6	NUM	O	O	71
patients	NOUN	O	O	71
presented	VERB	O	O	71
clinical	ADJ	O	O	71
symptoms	NOUN	O	O	71
of	ADP	O	O	71
visual	ADJ	O	O	71
or	CCONJ	O	O	71
auditory	NOUN	O	O	71
toxicity	NOUN	O	Disease	71
.	PUNCT	O	O	71
Visual	ADJ	O	O	72
toxicity	NOUN	O	Disease	72
was	AUX	O	O	72
of	ADP	O	O	72
retinal	ADJ	O	O	72
origin	NOUN	O	O	72
and	CCONJ	O	O	72
was	AUX	O	O	72
characterized	VERB	O	O	72
by	ADP	O	O	72
a	PRON	O	O	72
tritan	ADJ	O	O	72
-	PUNCT	O	O	72
type	NOUN	O	O	72
dyschromatopsy	PROPN	O	O	72
,	PUNCT	O	O	72
sometimes	ADV	O	O	72
associated	VERB	O	O	72
with	ADP	O	O	72
a	PRON	O	O	72
loss	NOUN	O	O	72
of	ADP	O	O	72
visual	ADJ	O	O	72
acuity	NOUN	O	O	72
and	CCONJ	O	O	72
pigmentary	NOUN	O	O	72
retinal	ADJ	O	O	72
deposits	NOUN	O	O	72
.	PUNCT	O	O	72
Auditory	NOUN	O	O	73
toxicity	NOUN	O	Disease	73
was	AUX	O	O	73
characterized	VERB	O	O	73
by	ADP	O	O	73
a	PRON	O	O	73
mid-	ADV	O	O	73
to	PART	O	O	73
high	ADJ	O	O	73
-	PUNCT	O	O	73
frequency	NOUN	O	O	73
neurosensorial	ADJ	O	O	73
hearing loss	NOUN	O	Disease	73
and	CCONJ	O	O	73
the	PRON	O	O	73
lesion	NOUN	O	O	73
was	AUX	O	O	73
of	ADP	O	O	73
the	PRON	O	O	73
cochlear	VERB	O	O	73
type	NOUN	O	O	73
.	PUNCT	O	O	73
Desferrioxamine	NOUN	O	O	74
withdrawal	NOUN	O	O	74
resulted	VERB	O	O	74
in	ADP	O	O	74
a	PRON	O	O	74
complete	VERB	O	O	74
recovery	NOUN	O	O	74
of	ADP	O	O	74
visual	ADJ	O	O	74
function	NOUN	O	O	74
in	ADP	O	O	74
1	X	O	O	74
patient	NOUN	O	O	74
and	CCONJ	O	O	74
partial	ADJ	O	O	74
recovery	NOUN	O	O	74
in	ADP	O	O	74
3	X	O	O	74
,	PUNCT	O	O	74
and	CCONJ	O	O	74
a	PRON	O	O	74
complete	VERB	O	O	74
reversal	NOUN	O	O	74
of	ADP	O	O	74
hearing loss	NOUN	O	Disease	74
in	ADP	O	O	74
3	X	O	O	74
patients	NOUN	O	O	74
and	CCONJ	O	O	74
partial	ADJ	O	O	74
recovery	NOUN	O	O	74
in	ADP	O	O	74
3	X	O	O	74
.	PUNCT	O	O	74
This	PRON	O	O	75
toxicity	NOUN	O	Disease	75
appeared	VERB	O	O	75
in	ADP	O	O	75
patients	NOUN	O	O	75
receiving	VERB	O	O	75
the	PRON	O	O	75
higher	ADJ	O	O	75
doses	NOUN	O	O	75
of	ADP	O	O	75
desferrioxamine	NOUN	O	O	75
or	CCONJ	O	O	75
coincided	VERB	O	O	75
with	ADP	O	O	75
the	PRON	O	O	75
normalization	NOUN	O	O	75
of	ADP	O	O	75
ferritin	NOUN	O	O	75
or	CCONJ	O	O	75
aluminium	NOUN	O	O	75
serum	NOUN	O	O	75
levels	NOUN	O	O	75
.	PUNCT	O	O	75
The	PRON	O	O	76
data	NOUN	O	O	76
indicate	VERB	O	O	76
that	SCONJ	O	O	76
audiovisual	ADJ	O	O	76
toxicity	NOUN	O	Disease	76
is	AUX	O	O	76
not	PART	O	O	76
an	PRON	O	O	76
infrequent	ADJ	O	O	76
complication	NOUN	O	O	76
in	ADP	O	O	76
hemodialyzed	VERB	O	O	76
patients	NOUN	O	O	76
receiving	VERB	O	O	76
desferrioxamine	NOUN	O	O	76
.	PUNCT	O	O	76
Myasthenia	PROPN	O	O	79
gravis	PROPN	O	O	79
presenting	VERB	O	O	79
as	ADP	O	O	79
weakness	NOUN	O	Disease	79
after	ADP	O	O	79
magnesium	NOUN	O	Chemical	79
administration	NOUN	O	O	79
.	PUNCT	O	O	79
We	PRON	O	O	80
studied	VERB	O	O	80
a	PRON	O	O	80
patient	NOUN	O	O	80
with	ADP	O	O	80
no	PRON	O	O	80
prior	ADV	O	O	80
history	NOUN	O	O	80
of	ADP	O	O	80
neuromuscular	ADJ	O	O	80
disease	PROPN	O	O	80
who	PRON	O	O	80
became	VERB	O	O	80
virtually	ADV	O	O	80
quadriplegic	NOUN	O	O	80
after	ADP	O	O	80
parenteral	ADJ	O	O	80
magnesium	NOUN	O	Chemical	80
administration	NOUN	O	O	80
for	ADP	O	O	80
preeclampsia	NOUN	O	O	80
.	PUNCT	O	O	80
The	PRON	O	O	81
serum	NOUN	O	O	81
magnesium	NOUN	O	Chemical	81
concentration	NOUN	O	O	81
was	AUX	O	O	81
3.0	NUM	O	O	81
mEq	VERB	O	O	81
/	PUNCT	O	O	81
L	NOUN	O	O	81
,	PUNCT	O	O	81
which	PRON	O	O	81
is	AUX	O	O	81
usually	ADV	O	O	81
well	ADV	O	O	81
tolerated	VERB	O	O	81
.	PUNCT	O	O	81
The	PRON	O	O	82
magnesium	NOUN	O	Chemical	82
was	AUX	O	O	82
stopped	VERB	O	O	82
and	CCONJ	O	O	82
she	PRON	O	O	82
recovered	VERB	O	O	82
over	ADP	O	O	82
a	PRON	O	O	82
few	ADJ	O	O	82
days	NOUN	O	O	82
.	PUNCT	O	O	82
While	SCONJ	O	O	83
she	PRON	O	O	83
was	AUX	O	O	83
weak	ADJ	O	O	83
,	PUNCT	O	O	83
2-Hz	NOUN	O	O	83
repetitive	ADJ	O	O	83
stimulation	NOUN	O	O	83
revealed	VERB	O	O	83
a	PRON	O	O	83
decrement	NOUN	O	O	83
without	ADP	O	O	83
significant	ADJ	O	O	83
facilitation	NOUN	O	O	83
at	ADP	O	O	83
rapid	ADJ	O	O	83
rates	NOUN	O	O	83
or	CCONJ	O	O	83
after	ADP	O	O	83
exercise	VERB	O	O	83
,	PUNCT	O	O	83
suggesting	VERB	O	O	83
postsynaptic	ADJ	O	O	83
neuromuscular blockade	NOUN	O	Disease	83
.	PUNCT	O	O	83
Her	PRON	O	O	84
acetylcholine	NOUN	O	Chemical	84
receptor	NOUN	O	O	84
antibody	NOUN	O	O	84
level	VERB	O	O	84
was	AUX	O	O	84
markedly	ADV	O	O	84
elevated	ADJ	O	O	84
.	PUNCT	O	O	84
Although	SCONJ	O	O	85
paralysis	NOUN	O	Disease	85
after	ADP	O	O	85
magnesium	NOUN	O	Chemical	85
administration	NOUN	O	O	85
has	VERB	O	O	85
been	AUX	O	O	85
described	VERB	O	O	85
in	ADP	O	O	85
patients	NOUN	O	O	85
with	ADP	O	O	85
known	VERB	O	O	85
myasthenia gravis	PROPN	O	Disease	85
,	PUNCT	O	O	85
it	PRON	O	O	85
has	VERB	O	O	85
not	PART	O	O	85
previously	ADV	O	O	85
been	AUX	O	O	85
reported	VERB	O	O	85
to	PART	O	O	85
be	AUX	O	O	85
the	PRON	O	O	85
initial	ADJ	O	O	85
or	CCONJ	O	O	85
only	ADV	O	O	85
manifestation	NOUN	O	O	85
of	ADP	O	O	85
the	PRON	O	O	85
disease	PROPN	O	O	85
.	PUNCT	O	O	85
Patients	NOUN	O	O	86
who	PRON	O	O	86
are	AUX	O	O	86
unusually	ADV	O	O	86
sensitive	ADJ	O	O	86
to	PART	O	O	86
the	PRON	O	O	86
neuromuscular	ADJ	O	O	86
effects	NOUN	O	O	86
of	ADP	O	O	86
magnesium	NOUN	O	Chemical	86
should	AUX	O	O	86
be	AUX	O	O	86
suspected	VERB	O	O	86
of	ADP	O	O	86
having	VERB	O	O	86
an	PRON	O	O	86
underlying	VERB	O	O	86
disorder	NOUN	O	O	86
of	ADP	O	O	86
neuromuscular	ADJ	O	O	86
transmission	NOUN	O	O	86
.	PUNCT	O	O	86
Chloroacetaldehyde	PROPN	O	O	89
and	CCONJ	O	O	89
its	PRON	O	O	89
contribution	NOUN	O	O	89
to	PART	O	O	89
urotoxicity	NOUN	O	O	89
during	ADP	O	O	89
treatment	NOUN	O	O	89
with	ADP	O	O	89
cyclophosphamide	VERB	O	Chemical	89
or	CCONJ	O	O	89
ifosfamide	ADP	O	Chemical	89
.	PUNCT	O	O	89
Based	VERB	O	O	90
on	ADP	O	O	90
clinical	ADJ	O	O	90
data	NOUN	O	O	90
,	PUNCT	O	O	90
indicating	VERB	O	O	90
that	SCONJ	O	O	90
chloroacetaldehyde	NOUN	O	O	90
(	PUNCT	O	O	90
CAA	PROPN	O	O	90
)	PUNCT	O	O	90
is	AUX	O	O	90
an	PRON	O	O	90
important	ADJ	O	O	90
metabolite	NOUN	O	O	90
of	ADP	O	O	90
oxazaphosphorine	NOUN	O	O	90
cytostatics	NOUN	O	O	90
,	PUNCT	O	O	90
an	PRON	O	O	90
experimental	ADJ	O	O	90
study	VERB	O	O	90
was	AUX	O	O	90
carried	VERB	O	O	90
out	ADP	O	O	90
in	ADP	O	O	90
order	NOUN	O	O	90
to	PART	O	O	90
elucidate	VERB	O	O	90
the	PRON	O	O	90
role	NOUN	O	O	90
of	ADP	O	O	90
CAA	PROPN	O	O	90
in	ADP	O	O	90
the	PRON	O	O	90
development	NOUN	O	O	90
of	ADP	O	O	90
hemorrhagic cystitis	NOUN	O	Disease	90
.	PUNCT	O	O	90
The	PRON	O	O	91
data	NOUN	O	O	91
demonstrate	VERB	O	O	91
that	SCONJ	O	O	91
CAA	PROPN	O	O	91
after	ADP	O	O	91
i.v	NOUN	O	O	91
.	PUNCT	O	O	91
administration	NOUN	O	O	92
does	VERB	O	O	92
not	PART	O	O	92
contribute	VERB	O	O	92
to	PART	O	O	92
bladder	NOUN	O	O	92
damage	NOUN	O	O	92
.	PUNCT	O	O	92
When	SCONJ	O	O	93
instilled	VERB	O	O	93
directly	ADV	O	O	93
into	ADP	O	O	93
the	PRON	O	O	93
bladder	NOUN	O	O	93
,	PUNCT	O	O	93
CAA	PROPN	O	O	93
exerts	VERB	O	O	93
urotoxic	PROPN	O	O	93
effects	NOUN	O	O	93
,	PUNCT	O	O	93
it	PRON	O	O	93
is	AUX	O	O	93
,	PUNCT	O	O	93
however	ADV	O	O	93
,	PUNCT	O	O	93
susceptible	ADJ	O	O	93
to	PART	O	O	93
detoxification	NOUN	O	O	93
with	ADP	O	O	93
mesna	NOUN	O	Chemical	93
.	PUNCT	O	O	93
Source	NOUN	O	O	96
of	ADP	O	O	96
pain	NOUN	O	Disease	96
and	CCONJ	O	O	96
primitive	ADJ	O	O	96
dysfunction	NOUN	O	O	96
in	ADP	O	O	96
migraine	NOUN	O	Disease	96
:	PUNCT	O	O	96
an	PRON	O	O	96
identical	ADJ	O	O	96
site	NOUN	O	O	96
?	PUNCT	O	O	96
Twenty	NUM	O	O	97
common	ADJ	O	O	97
migraine	NOUN	O	Disease	97
patients	NOUN	O	O	97
received	VERB	O	O	97
a	PRON	O	O	97
one	NUM	O	O	97
sided	VERB	O	O	97
frontotemporal	PROPN	O	O	97
application	NOUN	O	O	97
of	ADP	O	O	97
nitroglycerin	PROPN	O	Chemical	97
(	PUNCT	O	O	97
10	NUM	O	O	97
patients	NOUN	O	O	97
)	PUNCT	O	O	97
or	CCONJ	O	O	97
placebo	NOUN	O	O	97
ointment	NOUN	O	O	97
(	PUNCT	O	O	97
10	NUM	O	O	97
patients	NOUN	O	O	97
)	PUNCT	O	O	97
in	ADP	O	O	97
a	PRON	O	O	97
double	ADJ	O	O	97
blind	ADJ	O	Disease	97
study	VERB	O	O	97
.	PUNCT	O	O	97
Early	ADJ	O	O	98
onset	VERB	O	O	98
migraine	NOUN	O	Disease	98
attacks	NOUN	O	O	98
were	AUX	O	O	98
induced	VERB	O	O	98
by	ADP	O	O	98
nitroglycerin	PROPN	O	Chemical	98
in	ADP	O	O	98
seven	NUM	O	O	98
out	ADP	O	O	98
of	ADP	O	O	98
10	NUM	O	O	98
patients	NOUN	O	O	98
versus	ADP	O	O	98
no	PRON	O	O	98
patient	NOUN	O	O	98
in	ADP	O	O	98
the	PRON	O	O	98
placebo	NOUN	O	O	98
group	NOUN	O	O	98
.	PUNCT	O	O	98
Subsequently	PROPN	O	O	99
20	NUM	O	O	99
migraine	NOUN	O	Disease	99
patients	NOUN	O	O	99
,	PUNCT	O	O	99
who	PRON	O	O	99
developed	VERB	O	O	99
an	PRON	O	O	99
early	ADV	O	O	99
onset	VERB	O	O	99
attack	VERB	O	O	99
with	ADP	O	O	99
frontotemporal	PROPN	O	O	99
nitroglycerin	PROPN	O	Chemical	99
,	PUNCT	O	O	99
received	VERB	O	O	99
the	PRON	O	O	99
drug	NOUN	O	O	99
in	ADP	O	O	99
a	PRON	O	O	99
second	ADV	O	O	99
induction	NOUN	O	O	99
test	NOUN	O	O	99
at	ADP	O	O	99
other	ADJ	O	O	99
body	NOUN	O	O	99
areas	NOUN	O	O	99
.	PUNCT	O	O	99
No	PRON	O	O	100
early	ADV	O	O	100
onset	VERB	O	O	100
migraine	NOUN	O	Disease	100
was	AUX	O	O	100
observed	VERB	O	O	100
.	PUNCT	O	O	100
Thus	ADV	O	O	101
the	PRON	O	O	101
migraine	NOUN	O	Disease	101
-	PUNCT	O	O	101
inducing	VERB	O	O	101
effect	VERB	O	O	101
of	ADP	O	O	101
nitroglycerin	PROPN	O	Chemical	101
seems	VERB	O	O	101
to	PART	O	O	101
depend	VERB	O	O	101
on	ADP	O	O	101
direct	ADJ	O	O	101
stimulation	NOUN	O	O	101
of	ADP	O	O	101
the	PRON	O	O	101
habitual	ADJ	O	O	101
site	NOUN	O	O	101
of	ADP	O	O	101
pain	NOUN	O	Disease	101
,	PUNCT	O	O	101
suggesting	VERB	O	O	101
that	SCONJ	O	O	101
the	PRON	O	O	101
frontotemporal	PROPN	O	O	101
region	NOUN	O	O	101
is	AUX	O	O	101
of	ADP	O	O	101
crucial	ADJ	O	O	101
importance	NOUN	O	O	101
in	ADP	O	O	101
the	PRON	O	O	101
development	NOUN	O	O	101
of	ADP	O	O	101
a	PRON	O	O	101
migraine	NOUN	O	Disease	101
crisis	NOUN	O	O	101
.	PUNCT	O	O	101
This	PRON	O	O	102
is	AUX	O	O	102
not	PART	O	O	102
consistent	ADJ	O	O	102
with	ADP	O	O	102
a	PRON	O	O	102
CNS	PROPN	O	O	102
origin	NOUN	O	O	102
of	ADP	O	O	102
migraine	NOUN	O	Disease	102
attack	VERB	O	O	102
.	PUNCT	O	O	102
Clotiazepam	NOUN	O	O	105
-	PUNCT	O	O	105
induced	VERB	O	O	105
acute	ADJ	O	O	105
hepatitis	NOUN	O	Disease	105
.	PUNCT	O	O	105
We	PRON	O	O	106
report	VERB	O	O	106
the	PRON	O	O	106
case	NOUN	O	O	106
of	ADP	O	O	106
a	PRON	O	O	106
patient	NOUN	O	O	106
who	PRON	O	O	106
developed	VERB	O	O	106
acute	ADJ	O	O	106
hepatitis	NOUN	O	Disease	106
with	ADP	O	O	106
extensive	ADJ	O	O	106
hepatocellular	NOUN	O	O	106
necrosis	NOUN	O	Disease	106
,	PUNCT	O	O	106
7	NUM	O	O	106
months	NOUN	O	O	106
after	ADP	O	O	106
the	PRON	O	O	106
onset	VERB	O	O	106
of	ADP	O	O	106
administration	NOUN	O	O	106
of	ADP	O	O	106
clotiazepam	NOUN	O	O	106
,	PUNCT	O	O	106
a	PRON	O	O	106
thienodiazepine	NOUN	O	O	106
derivative	ADJ	O	O	106
.	PUNCT	O	O	106
Clotiazepam	NOUN	O	O	107
withdrawal	NOUN	O	O	107
was	AUX	O	O	107
followed	VERB	O	O	107
by	ADP	O	O	107
prompt	PROPN	O	O	107
recovery	NOUN	O	O	107
.	PUNCT	O	O	107
The	PRON	O	O	108
administration	NOUN	O	O	108
of	ADP	O	O	108
several	ADJ	O	O	108
benzodiazepines	NOUN	O	Chemical	108
,	PUNCT	O	O	108
chemically	ADV	O	O	108
related	ADJ	O	O	108
to	PART	O	O	108
clotiazepam	NOUN	O	O	108
,	PUNCT	O	O	108
did	VERB	O	O	108
not	PART	O	O	108
interfere	VERB	O	O	108
with	ADP	O	O	108
recovery	NOUN	O	O	108
and	CCONJ	O	O	108
did	VERB	O	O	108
not	PART	O	O	108
induce	VERB	O	O	108
any	PRON	O	O	108
relapse	VERB	O	O	108
of	ADP	O	O	108
hepatitis	NOUN	O	Disease	108
.	PUNCT	O	O	108
This	PRON	O	O	109
observation	NOUN	O	O	109
shows	VERB	O	O	109
that	SCONJ	O	O	109
clotiazepam	NOUN	O	O	109
can	AUX	O	O	109
induce	VERB	O	O	109
acute	ADJ	O	O	109
hepatitis	NOUN	O	Disease	109
and	CCONJ	O	O	109
suggests	VERB	O	O	109
that	SCONJ	O	O	109
there	ADV	O	O	109
is	AUX	O	O	109
no	PRON	O	O	109
cross	VERB	O	O	109
hepatotoxicity	NOUN	O	Disease	109
between	ADP	O	O	109
clotiazepam	NOUN	O	O	109
and	CCONJ	O	O	109
several	ADJ	O	O	109
benzodiazepines	NOUN	O	Chemical	109
.	PUNCT	O	O	109
Arterial	ADJ	O	O	112
hypertension	NOUN	O	Disease	112
as	ADP	O	O	112
a	PRON	O	O	112
complication	NOUN	O	O	112
of	ADP	O	O	112
prolonged	VERB	O	O	112
ketoconazole	PROPN	O	Chemical	112
treatment	NOUN	O	O	112
.	PUNCT	O	O	112
Two	NUM	O	O	113
of	ADP	O	O	113
14	NUM	O	O	113
patients	NOUN	O	O	113
with	ADP	O	O	113
Cushing	NOUN	O	O	113
's	AUX	O	O	113
syndrome	NOUN	O	O	113
treated	VERB	O	O	113
on	ADP	O	O	113
a	PRON	O	O	113
long	ADV	O	O	113
-	PUNCT	O	O	113
term	NOUN	O	O	113
basis	NOUN	O	O	113
with	ADP	O	O	113
ketoconazole	PROPN	O	Chemical	113
developed	VERB	O	O	113
sustained	VERB	O	O	113
hypertension	NOUN	O	Disease	113
.	PUNCT	O	O	113
In	ADP	O	O	114
both	PRON	O	O	114
cases	NOUN	O	O	114
normal	ADJ	O	O	114
plasma	NOUN	O	O	114
and	CCONJ	O	O	114
urinary	ADJ	O	O	114
free	ADJ	O	O	114
cortisol	NOUN	O	O	114
levels	NOUN	O	O	114
had	VERB	O	O	114
been	AUX	O	O	114
achieved	VERB	O	O	114
following	VERB	O	O	114
ketoconazole	PROPN	O	Chemical	114
therapy	NOUN	O	O	114
,	PUNCT	O	O	114
yet	ADV	O	O	114
continuous	ADJ	O	O	114
blood	NOUN	O	O	114
pressure	NOUN	O	O	114
monitoring	NOUN	O	O	114
demonstrated	VERB	O	O	114
hypertension	NOUN	O	Disease	114
31	NUM	O	O	114
(	PUNCT	O	O	114
patient	NOUN	O	O	114
1	X	O	O	114
)	PUNCT	O	O	114
and	CCONJ	O	O	114
52	NUM	O	O	114
weeks	NOUN	O	O	114
(	PUNCT	O	O	114
patient	NOUN	O	O	114
2	X	O	O	114
)	PUNCT	O	O	114
after	ADP	O	O	114
treatment	NOUN	O	O	114
.	PUNCT	O	O	114
In	ADP	O	O	115
patient	NOUN	O	O	115
1	X	O	O	115
,	PUNCT	O	O	115
plasma	NOUN	O	O	115
levels	NOUN	O	O	115
of	ADP	O	O	115
deoxycorticosterone	VERB	O	Chemical	115
and	CCONJ	O	O	115
11-deoxycortisol	NOUN	O	O	115
were	AUX	O	O	115
elevated	ADJ	O	O	115
.	PUNCT	O	O	115
In	ADP	O	O	116
patient	NOUN	O	O	116
2	X	O	O	116
,	PUNCT	O	O	116
in	ADP	O	O	116
addition	NOUN	O	O	116
to	PART	O	O	116
an	PRON	O	O	116
increase	VERB	O	O	116
in	ADP	O	O	116
both	PRON	O	O	116
deoxycorticosterone	VERB	O	Chemical	116
and	CCONJ	O	O	116
11-deoxycortisol	NOUN	O	O	116
levels	NOUN	O	O	116
,	PUNCT	O	O	116
plasma	NOUN	O	O	116
aldosterone	NOUN	O	Chemical	116
values	NOUN	O	O	116
were	AUX	O	O	116
raised	VERB	O	O	116
,	PUNCT	O	O	116
with	ADP	O	O	116
a	PRON	O	O	116
concomitant	ADJ	O	O	116
suppression	NOUN	O	O	116
of	ADP	O	O	116
renin	PROPN	O	O	116
levels	NOUN	O	O	116
.	PUNCT	O	O	116
Our	PRON	O	O	117
findings	NOUN	O	O	117
show	VERB	O	O	117
that	SCONJ	O	O	117
long	ADV	O	O	117
-	PUNCT	O	O	117
term	NOUN	O	O	117
treatment	NOUN	O	O	117
with	ADP	O	O	117
high	ADJ	O	O	117
doses	NOUN	O	O	117
of	ADP	O	O	117
ketoconazole	PROPN	O	Chemical	117
may	AUX	O	O	117
induce	VERB	O	O	117
enzyme	NOUN	O	O	117
blockade	VERB	O	O	117
leading	VERB	O	O	117
to	PART	O	O	117
mineralocorticoid	PROPN	O	O	117
-	PUNCT	O	O	117
related	ADJ	O	O	117
hypertension	NOUN	O	Disease	117
.	PUNCT	O	O	117
Effects	NOUN	O	O	120
of	ADP	O	O	120
an	PRON	O	O	120
inhibitor	NOUN	O	O	120
of	ADP	O	O	120
angiotensin	NOUN	O	Chemical	120
converting	VERB	O	O	120
enzyme	NOUN	O	O	120
(	PUNCT	O	O	120
Captopril	PROPN	O	Chemical	120
)	PUNCT	O	O	120
on	ADP	O	O	120
pulmonary	ADJ	O	O	120
and	CCONJ	O	O	120
renal insufficiency	NOUN	O	Disease	120
due	ADJ	O	O	120
to	PART	O	O	120
intravascular	ADJ	O	O	120
coagulation	NOUN	O	O	120
in	ADP	O	O	120
the	PRON	O	O	120
rat	NOUN	O	O	120
.	PUNCT	O	O	120
Induction	NOUN	O	O	121
of	ADP	O	O	121
intravascular	ADJ	O	O	121
coagulation	NOUN	O	O	121
and	CCONJ	O	O	121
inhibition	NOUN	O	O	121
of	ADP	O	O	121
fibrinolysis	VERB	O	O	121
by	ADP	O	O	121
injection	NOUN	O	O	121
of	ADP	O	O	121
thrombin	PROPN	O	O	121
and	CCONJ	O	O	121
tranexamic acid	PROPN	O	Chemical	121
(	PUNCT	O	O	121
AMCA	PROPN	O	O	121
)	PUNCT	O	O	121
in	ADP	O	O	121
the	PRON	O	O	121
rat	NOUN	O	O	121
gives	VERB	O	O	121
rise	VERB	O	O	121
to	PART	O	O	121
pulmonary	ADJ	O	O	121
and	CCONJ	O	O	121
renal insufficiency	NOUN	O	Disease	121
resembling	VERB	O	O	121
that	SCONJ	O	O	121
occurring	VERB	O	O	121
after	ADP	O	O	121
trauma	NOUN	O	O	121
or	CCONJ	O	O	121
sepsis	NOUN	O	Disease	121
in	ADP	O	O	121
man	NOUN	O	O	121
.	PUNCT	O	O	121
Injection	NOUN	O	O	122
of	ADP	O	O	122
Captopril	PROPN	O	Chemical	122
(	PUNCT	O	O	122
1	X	O	O	122
mg	VERB	O	O	122
/	PUNCT	O	O	122
kg	VERB	O	O	122
)	PUNCT	O	O	122
,	PUNCT	O	O	122
an	PRON	O	O	122
inhibitor	NOUN	O	O	122
of	ADP	O	O	122
angiotensin	NOUN	O	Chemical	122
converting	VERB	O	O	122
enzyme	NOUN	O	O	122
(	PUNCT	O	O	122
ACE	PROPN	O	O	122
)	PUNCT	O	O	122
,	PUNCT	O	O	122
reduced	VERB	O	O	122
both	PRON	O	O	122
pulmonary	ADJ	O	O	122
and	CCONJ	O	O	122
renal insufficiency	NOUN	O	Disease	122
in	ADP	O	O	122
this	PRON	O	O	122
rat	NOUN	O	O	122
model	NOUN	O	O	122
.	PUNCT	O	O	122
The	PRON	O	O	123
contents	NOUN	O	O	123
of	ADP	O	O	123
albumin	PROPN	O	O	123
in	ADP	O	O	123
the	PRON	O	O	123
lungs	VERB	O	O	123
were	AUX	O	O	123
not	PART	O	O	123
changed	VERB	O	O	123
,	PUNCT	O	O	123
indicating	VERB	O	O	123
that	SCONJ	O	O	123
Captopril	PROPN	O	Chemical	123
did	VERB	O	O	123
not	PART	O	O	123
influence	NOUN	O	O	123
the	PRON	O	O	123
extravasation	NOUN	O	O	123
of	ADP	O	O	123
protein	NOUN	O	O	123
.	PUNCT	O	O	123
Renal	NOUN	O	O	124
damage	NOUN	O	O	124
as	ADP	O	O	124
reflected	VERB	O	O	124
by	ADP	O	O	124
an	PRON	O	O	124
increase	VERB	O	O	124
in	ADP	O	O	124
serum	NOUN	O	O	124
urea	PROPN	O	Chemical	124
and	CCONJ	O	O	124
in	ADP	O	O	124
kidney	NOUN	O	O	124
weight	NOUN	O	O	124
was	AUX	O	O	124
prevented	VERB	O	O	124
by	ADP	O	O	124
Captopril	PROPN	O	Chemical	124
.	PUNCT	O	O	124
The	PRON	O	O	125
amount	NOUN	O	O	125
of	ADP	O	O	125
fibrin	PROPN	O	O	125
in	ADP	O	O	125
the	PRON	O	O	125
kidneys	NOUN	O	O	125
was	AUX	O	O	125
also	ADV	O	O	125
considerably	ADV	O	O	125
lower	ADJ	O	O	125
than	ADP	O	O	125
in	ADP	O	O	125
animals	NOUN	O	O	125
which	PRON	O	O	125
received	VERB	O	O	125
thrombin	PROPN	O	O	125
and	CCONJ	O	O	125
AMCA	PROPN	O	O	125
alone	ADV	O	O	125
.	PUNCT	O	O	125
It	PRON	O	O	126
is	AUX	O	O	126
suggested	VERB	O	O	126
that	SCONJ	O	O	126
the	PRON	O	O	126
effects	NOUN	O	O	126
of	ADP	O	O	126
Captopril	PROPN	O	Chemical	126
on	ADP	O	O	126
the	PRON	O	O	126
lungs	VERB	O	O	126
may	AUX	O	O	126
be	AUX	O	O	126
attributable	ADJ	O	O	126
to	PART	O	O	126
a	PRON	O	O	126
vasodilatory	NOUN	O	O	126
effect	VERB	O	O	126
due	ADJ	O	O	126
to	PART	O	O	126
a	PRON	O	O	126
reduction	NOUN	O	O	126
in	ADP	O	O	126
the	PRON	O	O	126
circulating	VERB	O	O	126
level	VERB	O	O	126
of	ADP	O	O	126
Angiotension	NOUN	O	O	126
II	NUM	O	O	126
and	CCONJ	O	O	126
an	PRON	O	O	126
increase	VERB	O	O	126
in	ADP	O	O	126
prostacyclin	NOUN	O	Chemical	126
(	PUNCT	O	O	126
secondary	ADJ	O	O	126
to	PART	O	O	126
an	PRON	O	O	126
increase	VERB	O	O	126
in	ADP	O	O	126
bradykinin	NOUN	O	O	126
)	PUNCT	O	O	126
.	PUNCT	O	O	126
Captopril	PROPN	O	Chemical	127
may	AUX	O	O	127
,	PUNCT	O	O	127
by	ADP	O	O	127
the	PRON	O	O	127
same	ADJ	O	O	127
mechanism	NOUN	O	O	127
,	PUNCT	O	O	127
reduce	VERB	O	O	127
the	PRON	O	O	127
increase	VERB	O	O	127
in	ADP	O	O	127
glomerular	ADJ	O	O	127
filtration	NOUN	O	O	127
that	SCONJ	O	O	127
is	AUX	O	O	127
known	VERB	O	O	127
to	PART	O	O	127
occur	VERB	O	O	127
after	ADP	O	O	127
an	PRON	O	O	127
injection	NOUN	O	O	127
of	ADP	O	O	127
thrombin	PROPN	O	O	127
,	PUNCT	O	O	127
thereby	ADV	O	O	127
diminishing	VERB	O	O	127
the	PRON	O	O	127
aggregation	NOUN	O	O	127
of	ADP	O	O	127
fibrin	PROPN	O	O	127
monomers	NOUN	O	O	127
in	ADP	O	O	127
the	PRON	O	O	127
glomeruli	VERB	O	O	127
,	PUNCT	O	O	127
with	ADP	O	O	127
the	PRON	O	O	127
result	VERB	O	O	127
that	SCONJ	O	O	127
less	ADV	O	O	127
fibrin	PROPN	O	O	127
will	AUX	O	O	127
be	AUX	O	O	127
deposited	VERB	O	O	127
and	CCONJ	O	O	127
thus	ADV	O	O	127
less	ADV	O	O	127
kidney	NOUN	O	O	127
damage	NOUN	O	O	127
will	AUX	O	O	127
be	AUX	O	O	127
produced	VERB	O	O	127
.	PUNCT	O	O	127
A	PRON	O	O	130
randomized	VERB	O	O	130
comparison	NOUN	O	O	130
of	ADP	O	O	130
labetalol	NOUN	O	Chemical	130
and	CCONJ	O	O	130
nitroprusside	ADV	O	Chemical	130
for	ADP	O	O	130
induced	VERB	O	O	130
hypotension	NOUN	O	Disease	130
.	PUNCT	O	O	130
In	ADP	O	O	131
a	PRON	O	O	131
randomized	VERB	O	O	131
study	VERB	O	O	131
,	PUNCT	O	O	131
labetalol	NOUN	O	Chemical	131
-	PUNCT	O	O	131
induced	VERB	O	O	131
hypotension	NOUN	O	Disease	131
and	CCONJ	O	O	131
nitroprusside	ADV	O	Chemical	131
-	PUNCT	O	O	131
induced	VERB	O	O	131
hypotension	NOUN	O	Disease	131
were	AUX	O	O	131
compared	VERB	O	O	131
in	ADP	O	O	131
20	NUM	O	O	131
patients	NOUN	O	O	131
(	PUNCT	O	O	131
10	NUM	O	O	131
in	ADP	O	O	131
each	PRON	O	O	131
group	NOUN	O	O	131
)	PUNCT	O	O	131
scheduled	VERB	O	O	131
for	ADP	O	O	131
major	ADJ	O	O	131
orthopedic	ADJ	O	O	131
procedures	NOUN	O	O	131
.	PUNCT	O	O	131
Each	PRON	O	O	132
patient	NOUN	O	O	132
was	AUX	O	O	132
subjected	VERB	O	O	132
to	PART	O	O	132
an	PRON	O	O	132
identical	ADJ	O	O	132
anesthetic	NOUN	O	O	132
protocol	PROPN	O	O	132
and	CCONJ	O	O	132
similar	ADJ	O	O	132
drug	NOUN	O	O	132
-	PUNCT	O	O	132
induced	VERB	O	O	132
reductions	NOUN	O	O	132
in	ADP	O	O	132
mean	VERB	O	O	132
arterial	ADJ	O	O	132
blood	NOUN	O	O	132
pressure	NOUN	O	O	132
(	PUNCT	O	O	132
BP	PROPN	O	O	132
)	PUNCT	O	O	132
(	PUNCT	O	O	132
50	NUM	O	O	132
to	PART	O	O	132
55	NUM	O	O	132
mmHg	PROPN	O	O	132
)	PUNCT	O	O	132
.	PUNCT	O	O	132
Nitroprusside	PROPN	O	O	133
infusion	NOUN	O	O	133
was	AUX	O	O	133
associated	VERB	O	O	133
with	ADP	O	O	133
a	PRON	O	O	133
significant	ADJ	O	O	133
(	PUNCT	O	O	133
p	NOUN	O	O	133
less	ADV	O	O	133
than	ADP	O	O	133
0.05	NUM	O	O	133
)	PUNCT	O	O	133
increase	VERB	O	O	133
in	ADP	O	O	133
heart	NOUN	O	O	133
rate	NOUN	O	O	133
and	CCONJ	O	O	133
cardiac	ADJ	O	O	133
output	NOUN	O	O	133
;	PUNCT	O	O	133
rebound	VERB	O	O	133
hypertension	NOUN	O	Disease	133
was	AUX	O	O	133
observed	VERB	O	O	133
in	ADP	O	O	133
three	NUM	O	O	133
patients	NOUN	O	O	133
after	ADP	O	O	133
discontinuation	NOUN	O	O	133
of	ADP	O	O	133
nitroprusside	ADV	O	Chemical	133
.	PUNCT	O	O	133
Labetalol	NOUN	O	O	134
administration	NOUN	O	O	134
was	AUX	O	O	134
not	PART	O	O	134
associated	VERB	O	O	134
with	ADP	O	O	134
any	PRON	O	O	134
of	ADP	O	O	134
these	PRON	O	O	134
findings	NOUN	O	O	134
.	PUNCT	O	O	134
Arterial	ADJ	O	O	135
PO2	PROPN	O	O	135
decreased	VERB	O	O	135
in	ADP	O	O	135
both	PRON	O	O	135
groups	NOUN	O	O	135
.	PUNCT	O	O	135
It	PRON	O	O	136
was	AUX	O	O	136
concluded	VERB	O	O	136
that	SCONJ	O	O	136
labetalol	NOUN	O	Chemical	136
offers	VERB	O	O	136
advantages	NOUN	O	O	136
over	ADP	O	O	136
nitroprusside	ADV	O	Chemical	136
.	PUNCT	O	O	136
Chronic	NOUN	O	O	139
carbamazepine	NOUN	O	Chemical	139
treatment	NOUN	O	O	139
in	ADP	O	O	139
the	PRON	O	O	139
rat	NOUN	O	O	139
:	PUNCT	O	O	139
efficacy	NOUN	O	O	139
,	PUNCT	O	O	139
toxicity	NOUN	O	Disease	139
,	PUNCT	O	O	139
and	CCONJ	O	O	139
effect	VERB	O	O	139
on	ADP	O	O	139
plasma	NOUN	O	O	139
and	CCONJ	O	O	139
tissue	NOUN	O	O	139
folate	VERB	O	Chemical	139
concentrations	NOUN	O	O	139
.	PUNCT	O	O	139
Folate	NOUN	O	O	140
depletion	NOUN	O	O	140
has	VERB	O	O	140
often	ADV	O	O	140
been	AUX	O	O	140
a	PRON	O	O	140
problem	NOUN	O	O	140
in	ADP	O	O	140
chronic	ADJ	O	O	140
antiepileptic	ADJ	O	O	140
drug	NOUN	O	O	140
(	PUNCT	O	O	140
AED	PROPN	O	O	140
)	PUNCT	O	O	140
therapy	NOUN	O	O	140
.	PUNCT	O	O	140
Carbamazepine	NOUN	O	Chemical	141
(	PUNCT	O	O	141
CBZ	PROPN	O	Chemical	141
)	PUNCT	O	O	141
,	PUNCT	O	O	141
a	PRON	O	O	141
commonly	ADV	O	O	141
used	VERB	O	O	141
AED	PROPN	O	O	141
,	PUNCT	O	O	141
has	VERB	O	O	141
been	AUX	O	O	141
implicated	VERB	O	O	141
in	ADP	O	O	141
some	PRON	O	O	141
clinical	ADJ	O	O	141
studies	NOUN	O	O	141
.	PUNCT	O	O	141
A	PRON	O	O	142
rat	NOUN	O	O	142
model	NOUN	O	O	142
was	AUX	O	O	142
developed	VERB	O	O	142
to	PART	O	O	142
examine	VERB	O	O	142
the	PRON	O	O	142
effects	NOUN	O	O	142
of	ADP	O	O	142
chronic	ADJ	O	O	142
CBZ	PROPN	O	Chemical	142
treatment	NOUN	O	O	142
on	ADP	O	O	142
folate	VERB	O	Chemical	142
concentrations	NOUN	O	O	142
in	ADP	O	O	142
the	PRON	O	O	142
rat	NOUN	O	O	142
.	PUNCT	O	O	142
In	ADP	O	O	143
the	PRON	O	O	143
course	NOUN	O	O	143
of	ADP	O	O	143
developing	VERB	O	O	143
this	PRON	O	O	143
model	NOUN	O	O	143
,	PUNCT	O	O	143
a	PRON	O	O	143
common	ADJ	O	O	143
vehicle	NOUN	O	O	143
,	PUNCT	O	O	143
propylene	PROPN	O	O	143
glycol	NOUN	O	O	143
,	PUNCT	O	O	143
by	ADP	O	O	143
itself	PRON	O	O	143
in	ADP	O	O	143
high	ADJ	O	O	143
doses	NOUN	O	O	143
,	PUNCT	O	O	143
was	AUX	O	O	143
found	VERB	O	O	143
to	PART	O	O	143
exhibit	VERB	O	O	143
protective	ADJ	O	O	143
properties	NOUN	O	O	143
against	ADP	O	O	143
induced	VERB	O	O	143
seizures	NOUN	O	Disease	143
and	CCONJ	O	O	143
inhibited	VERB	O	O	143
weight	NOUN	O	O	143
gain	VERB	O	O	143
.	PUNCT	O	O	143
Seizures	NOUN	O	Disease	144
induced	VERB	O	O	144
by	ADP	O	O	144
hexafluorodiethyl	NOUN	O	O	144
ether	X	O	O	144
(	PUNCT	O	O	144
HFDE	PROPN	O	O	144
)	PUNCT	O	O	144
were	AUX	O	O	144
also	ADV	O	O	144
found	VERB	O	O	144
to	PART	O	O	144
be	AUX	O	O	144
a	PRON	O	O	144
more	ADJ	O	O	144
sensitive	ADJ	O	O	144
measure	VERB	O	O	144
of	ADP	O	O	144
protection	NOUN	O	O	144
by	ADP	O	O	144
CBZ	PROPN	O	Chemical	144
than	ADP	O	O	144
seizures	NOUN	O	Disease	144
induced	VERB	O	O	144
by	ADP	O	O	144
maximal	ADJ	O	O	144
electroshock	NOUN	O	O	144
(	PUNCT	O	O	144
MES	PROPN	O	O	144
)	PUNCT	O	O	144
.	PUNCT	O	O	144
Oral	NOUN	O	O	145
administration	NOUN	O	O	145
of	ADP	O	O	145
CBZ	PROPN	O	Chemical	145
as	ADP	O	O	145
an	PRON	O	O	145
aqueous	ADJ	O	O	145
suspension	NOUN	O	O	145
every	PRON	O	O	145
8	NUM	O	O	145
h	X	O	O	145
at	ADP	O	O	145
a	PRON	O	O	145
dose	NOUN	O	O	145
of	ADP	O	O	145
250	NUM	O	O	145
mg	VERB	O	O	145
/	PUNCT	O	O	145
kg	VERB	O	O	145
was	AUX	O	O	145
continuously	ADV	O	O	145
protective	ADJ	O	O	145
against	ADP	O	O	145
HFDE	PROPN	O	O	145
-	PUNCT	O	O	145
induced	VERB	O	O	145
seizures	NOUN	O	Disease	145
and	CCONJ	O	O	145
was	AUX	O	O	145
minimally	ADV	O	O	145
toxic	ADJ	O	O	145
as	ADP	O	O	145
measured	VERB	O	O	145
by	ADP	O	O	145
weight	NOUN	O	O	145
gain	VERB	O	O	145
over	ADP	O	O	145
8	NUM	O	O	145
weeks	NOUN	O	O	145
of	ADP	O	O	145
treatment	NOUN	O	O	145
.	PUNCT	O	O	145
The	PRON	O	O	146
CBZ	PROPN	O	Chemical	146
levels	NOUN	O	O	146
measured	VERB	O	O	146
in	ADP	O	O	146
plasma	NOUN	O	O	146
and	CCONJ	O	O	146
brain	NOUN	O	O	146
of	ADP	O	O	146
these	PRON	O	O	146
animals	NOUN	O	O	146
,	PUNCT	O	O	146
however	ADV	O	O	146
,	PUNCT	O	O	146
were	AUX	O	O	146
below	ADP	O	O	146
those	PRON	O	O	146
normally	ADV	O	O	146
considered	VERB	O	O	146
protective	ADJ	O	O	146
.	PUNCT	O	O	146
This	PRON	O	O	147
treatment	NOUN	O	O	147
with	ADP	O	O	147
CBZ	PROPN	O	Chemical	147
had	VERB	O	O	147
no	PRON	O	O	147
apparent	ADJ	O	O	147
adverse	ADJ	O	O	147
effect	VERB	O	O	147
on	ADP	O	O	147
folate	VERB	O	Chemical	147
concentrations	NOUN	O	O	147
in	ADP	O	O	147
the	PRON	O	O	147
rat	NOUN	O	O	147
,	PUNCT	O	O	147
and	CCONJ	O	O	147
,	PUNCT	O	O	147
indeed	ADV	O	O	147
,	PUNCT	O	O	147
the	PRON	O	O	147
folate	VERB	O	Chemical	147
concentration	NOUN	O	O	147
increased	VERB	O	O	147
in	ADP	O	O	147
liver	NOUN	O	O	147
after	ADP	O	O	147
6	NUM	O	O	147
weeks	NOUN	O	O	147
of	ADP	O	O	147
treatment	NOUN	O	O	147
and	CCONJ	O	O	147
in	ADP	O	O	147
plasma	NOUN	O	O	147
at	ADP	O	O	147
8	NUM	O	O	147
weeks	NOUN	O	O	147
of	ADP	O	O	147
treatment	NOUN	O	O	147
.	PUNCT	O	O	147
In	ADP	O	O	150
six	NUM	O	O	150
conscious	ADJ	O	O	150
,	PUNCT	O	O	150
trained	VERB	O	O	150
dogs	NOUN	O	O	150
,	PUNCT	O	O	150
maintained	VERB	O	O	150
on	ADP	O	O	150
a	PRON	O	O	150
normal	ADJ	O	O	150
sodium	NOUN	O	Chemical	150
intake	PROPN	O	O	150
of	ADP	O	O	150
2	X	O	O	150
to	PART	O	O	150
4	NUM	O	O	150
mEq	VERB	O	O	150
/	PUNCT	O	O	150
kg	VERB	O	O	150
/	PUNCT	O	O	150
day	NOUN	O	O	150
,	PUNCT	O	O	150
sympathetic	ADJ	O	O	150
activity	NOUN	O	O	150
was	AUX	O	O	150
assessed	VERB	O	O	150
as	ADP	O	O	150
the	PRON	O	O	150
release	NOUN	O	O	150
rate	NOUN	O	O	150
of	ADP	O	O	150
norepinephrine	NOUN	O	Chemical	150
and	CCONJ	O	O	150
epinephrine	NOUN	O	Chemical	150
during	ADP	O	O	150
15-minute	NOUN	O	O	150
i.v	NOUN	O	O	150
.	PUNCT	O	O	150
6%	NOUN	O	O	151
(	PUNCT	O	O	151
p	NOUN	O	O	151
less	ADV	O	O	151
than	ADP	O	O	151
0.001	NUM	O	O	151
)	PUNCT	O	O	151
,	PUNCT	O	O	151
respectively	ADV	O	O	151
,	PUNCT	O	O	151
but	CCONJ	O	O	151
no	PRON	O	O	151
tachycardia	PROPN	O	Disease	151
and	CCONJ	O	O	151
no	PRON	O	O	151
augmentation	NOUN	O	O	151
of	ADP	O	O	151
the	PRON	O	O	151
norepinephrine	NOUN	O	Chemical	151
release	NOUN	O	O	151
rate	NOUN	O	O	151
(	PUNCT	O	O	151
up	ADP	O	O	151
to	PART	O	O	151
0.3	NUM	O	O	151
microgram	PROPN	O	O	151
/	PUNCT	O	O	151
kg	VERB	O	O	151
/	PUNCT	O	O	151
min	NOUN	O	O	151
)	PUNCT	O	O	151
were	AUX	O	O	151
observed	VERB	O	O	151
,	PUNCT	O	O	151
which	PRON	O	O	151
is	AUX	O	O	151
in	ADP	O	O	151
contrast	NOUN	O	O	151
to	PART	O	O	151
comparable	ADJ	O	O	151
hypotension	NOUN	O	Disease	151
induced	VERB	O	O	151
by	ADP	O	O	151
hydralazine	NOUN	O	O	151
or	CCONJ	O	O	151
nitroglycerin	PROPN	O	Chemical	151
.	PUNCT	O	O	151
The	PRON	O	O	152
release	NOUN	O	O	152
rate	NOUN	O	O	152
of	ADP	O	O	152
epinephrine	NOUN	O	Chemical	152
(	PUNCT	O	O	152
control	VERB	O	O	152
,	PUNCT	O	O	152
6.7	NUM	O	O	152
+	ADP	O	O	152
/-	PUNCT	O	O	152
Death	NOUN	O	O	155
from	ADP	O	O	155
chemotherapy	NOUN	O	O	155
in	ADP	O	O	155
gestational	ADJ	O	O	155
trophoblastic	NOUN	O	O	155
disease	PROPN	O	O	155
.	PUNCT	O	O	155
Multiple	ADJ	O	O	156
cytotoxic	ADJ	O	O	156
drug	NOUN	O	O	156
administration	NOUN	O	O	156
is	AUX	O	O	156
the	PRON	O	O	156
generally	ADV	O	O	156
accepted	VERB	O	O	156
treatment	NOUN	O	O	156
of	ADP	O	O	156
patients	NOUN	O	O	156
with	ADP	O	O	156
a	PRON	O	O	156
high	ADJ	O	O	156
-	PUNCT	O	O	156
risk	NOUN	O	O	156
stage	NOUN	O	O	156
of	ADP	O	O	156
choriocarcinoma	PROPN	O	O	156
.	PUNCT	O	O	156
The	PRON	O	O	157
multiple	ADJ	O	O	157
drug	NOUN	O	O	157
schema	VERB	O	O	157
consisted	VERB	O	O	157
of	ADP	O	O	157
:	PUNCT	O	O	157
Etoposide	NOUN	O	Chemical	157
16.213	NUM	O	O	157
,	PUNCT	O	O	157
Methotrexate	NOUN	O	O	157
,	PUNCT	O	O	157
Cyclophosphamide	PROPN	O	Chemical	157
,	PUNCT	O	O	157
Actomycin	PROPN	O	O	157
-	PUNCT	O	O	157
D	NOUN	O	O	157
,	PUNCT	O	O	157
and	CCONJ	O	O	157
Cisplatin	PROPN	O	O	157
.	PUNCT	O	O	157
On	ADP	O	O	158
the	PRON	O	O	158
first	ADV	O	O	158
day	NOUN	O	O	158
of	ADP	O	O	158
the	PRON	O	O	158
schedule	NOUN	O	O	158
,	PUNCT	O	O	158
moderate	ADJ	O	O	158
high	ADJ	O	O	158
doses	NOUN	O	O	158
of	ADP	O	O	158
Methotrexate	NOUN	O	O	158
,	PUNCT	O	O	158
Etoposide	NOUN	O	Chemical	158
and	CCONJ	O	O	158
Cyclophosphamide	PROPN	O	Chemical	158
were	AUX	O	O	158
administered	VERB	O	O	158
.	PUNCT	O	O	158
Within	ADP	O	O	159
8	NUM	O	O	159
hours	NOUN	O	O	159
after	ADP	O	O	159
initiation	NOUN	O	O	159
of	ADP	O	O	159
therapy	NOUN	O	O	159
the	PRON	O	O	159
patient	NOUN	O	O	159
died	VERB	O	O	159
with	ADP	O	O	159
a	PRON	O	O	159
clinical	ADJ	O	O	159
picture	NOUN	O	O	159
resembling	VERB	O	O	159
massive	ADJ	O	O	159
pulmonary	ADJ	O	O	159
obstruction	NOUN	O	O	159
due	ADJ	O	O	159
to	PART	O	O	159
choriocarcinomic	PROPN	O	O	159
tissue	NOUN	O	O	159
plugs	NOUN	O	O	159
,	PUNCT	O	O	159
probably	ADV	O	O	159
originating	VERB	O	O	159
from	ADP	O	O	159
the	PRON	O	O	159
uterus	NOUN	O	O	159
.	PUNCT	O	O	159
Formation	NOUN	O	O	160
of	ADP	O	O	160
these	PRON	O	O	160
plugs	NOUN	O	O	160
was	AUX	O	O	160
probably	ADV	O	O	160
due	ADJ	O	O	160
to	PART	O	O	160
extensive	ADJ	O	O	160
tumor	NOUN	O	Disease	160
necrosis	NOUN	O	Disease	160
at	ADP	O	O	160
the	PRON	O	O	160
level	VERB	O	O	160
of	ADP	O	O	160
the	PRON	O	O	160
walls	NOUN	O	O	160
of	ADP	O	O	160
the	PRON	O	O	160
major	ADJ	O	O	160
uterine	ADJ	O	O	160
veins	NOUN	O	O	160
,	PUNCT	O	O	160
which	PRON	O	O	160
resulted	VERB	O	O	160
in	ADP	O	O	160
an	PRON	O	O	160
open	VERB	O	O	160
exchange	VERB	O	O	160
of	ADP	O	O	160
tumor	NOUN	O	Disease	160
plugs	NOUN	O	O	160
to	PART	O	O	160
the	PRON	O	O	160
vascular	ADJ	O	O	160
spaces	NOUN	O	O	160
;	PUNCT	O	O	160
decrease	VERB	O	O	160
in	ADP	O	O	160
tumor	NOUN	O	Disease	160
tissue	NOUN	O	O	160
coherence	VERB	O	O	160
secondary	ADJ	O	O	160
to	PART	O	O	160
chemotherapy	NOUN	O	O	160
may	AUX	O	O	160
have	VERB	O	O	160
further	ADV	O	O	160
contributed	VERB	O	O	160
to	PART	O	O	160
the	PRON	O	O	160
formation	NOUN	O	O	160
of	ADP	O	O	160
tumor	NOUN	O	Disease	160
emboli	NOUN	O	O	160
.	PUNCT	O	O	160
In	ADP	O	O	161
view	VERB	O	O	161
of	ADP	O	O	161
the	PRON	O	O	161
close	ADV	O	O	161
time	NOUN	O	O	161
association	PROPN	O	O	161
between	ADP	O	O	161
the	PRON	O	O	161
start	VERB	O	O	161
of	ADP	O	O	161
chemotherapy	NOUN	O	O	161
and	CCONJ	O	O	161
the	PRON	O	O	161
acute	ADJ	O	O	161
onset	VERB	O	O	161
of	ADP	O	O	161
massive	ADJ	O	O	161
embolism	NOUN	O	O	161
other	ADJ	O	O	161
explanations	NOUN	O	O	161
,	PUNCT	O	O	161
such	ADJ	O	O	161
as	ADP	O	O	161
spontaneous	ADJ	O	O	161
necrosis	NOUN	O	Disease	161
,	PUNCT	O	O	161
must	AUX	O	O	161
be	AUX	O	O	161
considered	VERB	O	O	161
less	ADV	O	O	161
likely	ADV	O	O	161
.	PUNCT	O	O	161
Patients	NOUN	O	O	162
with	ADP	O	O	162
large	ADJ	O	O	162
pelvic	VERB	O	O	162
tumor	NOUN	O	Disease	162
loads	NOUN	O	O	162
are	AUX	O	O	162
,	PUNCT	O	O	162
according	VERB	O	O	162
to	PART	O	O	162
existing	VERB	O	O	162
classifications	NOUN	O	O	162
,	PUNCT	O	O	162
at	ADP	O	O	162
high	ADJ	O	O	162
risk	NOUN	O	O	162
to	PART	O	O	162
die	VERB	O	O	162
and	CCONJ	O	O	162
to	PART	O	O	162
develop	VERB	O	O	162
drug	NOUN	O	O	162
resistance	NOUN	O	O	162
.	PUNCT	O	O	162
Sexual	ADJ	O	O	165
dysfunction	NOUN	O	O	165
among	ADP	O	O	165
patients	NOUN	O	O	165
with	ADP	O	O	165
arthritis	NOUN	O	Disease	165
.	PUNCT	O	O	165
The	PRON	O	O	166
relationship	NOUN	O	O	166
of	ADP	O	O	166
arthritis	NOUN	O	Disease	166
and	CCONJ	O	O	166
sexual dysfunction	NOUN	O	Disease	166
was	AUX	O	O	166
investigated	VERB	O	O	166
among	ADP	O	O	166
169	NUM	O	O	166
patients	NOUN	O	O	166
with	ADP	O	O	166
rheumatoid arthritis	NOUN	O	Disease	166
,	PUNCT	O	O	166
osteoarthritis	NOUN	O	Disease	166
and	CCONJ	O	O	166
spondyloarthropathy	PROPN	O	O	166
,	PUNCT	O	O	166
130	NUM	O	O	166
of	ADP	O	O	166
whom	PRON	O	O	166
were	AUX	O	O	166
pair	ADJ	O	O	166
-	PUNCT	O	O	166
matched	VERB	O	O	166
to	PART	O	O	166
controls	VERB	O	O	166
.	PUNCT	O	O	166
Assessments	NOUN	O	O	167
of	ADP	O	O	167
marital	NOUN	O	O	167
happiness	NOUN	O	O	167
and	CCONJ	O	O	167
depressed	ADJ	O	O	167
mood	NOUN	O	O	167
were	AUX	O	O	167
also	ADV	O	O	167
made	VERB	O	O	167
using	VERB	O	O	167
the	PRON	O	O	167
CES	PROPN	O	O	167
-	PUNCT	O	O	167
D	NOUN	O	O	167
and	CCONJ	O	O	167
the	PRON	O	O	167
Azrin	NOUN	O	O	167
Marital	NOUN	O	O	167
Happiness	NOUN	O	O	167
Scale	NOUN	O	O	167
(	PUNCT	O	O	167
AMHS	PROPN	O	O	167
)	PUNCT	O	O	167
.	PUNCT	O	O	167
Sexual	ADJ	O	O	168
dysfunctions	NOUN	O	O	168
were	AUX	O	O	168
found	VERB	O	O	168
to	PART	O	O	168
be	AUX	O	O	168
common	ADJ	O	O	168
among	ADP	O	O	168
patients	NOUN	O	O	168
and	CCONJ	O	O	168
controls	VERB	O	O	168
,	PUNCT	O	O	168
the	PRON	O	O	168
majority	NOUN	O	O	168
in	ADP	O	O	168
both	PRON	O	O	168
groups	NOUN	O	O	168
reporting	VERB	O	O	168
one	NUM	O	O	168
or	CCONJ	O	O	168
more	ADJ	O	O	168
dysfunctions	NOUN	O	O	168
.	PUNCT	O	O	168
Impotence	NOUN	O	O	169
was	AUX	O	O	169
more	ADJ	O	O	169
common	ADJ	O	O	169
among	ADP	O	O	169
male	NOUN	O	O	169
patients	NOUN	O	O	169
than	ADP	O	O	169
controls	VERB	O	O	169
and	CCONJ	O	O	169
was	AUX	O	O	169
found	VERB	O	O	169
to	PART	O	O	169
be	AUX	O	O	169
associated	VERB	O	O	169
with	ADP	O	O	169
co	NOUN	O	O	169
-	PUNCT	O	O	169
morbidity	NOUN	O	O	169
and	CCONJ	O	O	169
the	PRON	O	O	169
taking	VERB	O	O	169
of	ADP	O	O	169
methotrexate	CCONJ	O	Chemical	169
.	PUNCT	O	O	169
Depressed	ADJ	O	O	170
mood	NOUN	O	O	170
was	AUX	O	O	170
more	ADJ	O	O	170
common	ADJ	O	O	170
among	ADP	O	O	170
patients	NOUN	O	O	170
and	CCONJ	O	O	170
was	AUX	O	O	170
associated	VERB	O	O	170
with	ADP	O	O	170
certain	ADJ	O	O	170
sexual	ADJ	O	O	170
difficulties	NOUN	O	O	170
,	PUNCT	O	O	170
but	CCONJ	O	O	170
not	PART	O	O	170
with	ADP	O	O	170
impotence	NOUN	O	Disease	170
.	PUNCT	O	O	170
Marital	NOUN	O	O	171
unhappiness	NOUN	O	O	171
,	PUNCT	O	O	171
as	ADP	O	O	171
indicated	VERB	O	O	171
by	ADP	O	O	171
AMHS	PROPN	O	O	171
scores	NOUN	O	O	171
,	PUNCT	O	O	171
was	AUX	O	O	171
not	PART	O	O	171
associated	VERB	O	O	171
with	ADP	O	O	171
arthritis	NOUN	O	Disease	171
but	CCONJ	O	O	171
was	AUX	O	O	171
associated	VERB	O	O	171
with	ADP	O	O	171
sexual dysfunction	NOUN	O	Disease	171
,	PUNCT	O	O	171
sexual	ADJ	O	O	171
dissatisfaction	NOUN	O	O	171
and	CCONJ	O	O	171
being	AUX	O	O	171
female	ADJ	O	O	171
.	PUNCT	O	O	171
Does	VERB	O	O	174
paracetamol	PROPN	O	Chemical	174
cause	VERB	O	O	174
urothelial cancer	NOUN	O	Disease	174
or	CCONJ	O	O	174
renal papillary necrosis	NOUN	O	Disease	174
?	PUNCT	O	O	174
The	PRON	O	O	175
risk	NOUN	O	O	175
of	ADP	O	O	175
developing	VERB	O	O	175
renal papillary necrosis	NOUN	O	Disease	175
or	CCONJ	O	O	175
cancer	NOUN	O	Disease	175
of	ADP	O	O	175
the	PRON	O	O	175
renal	ADJ	O	O	175
pelvis	ADJ	O	O	175
,	PUNCT	O	O	175
ureter	NOUN	O	O	175
or	CCONJ	O	O	175
bladder	NOUN	O	O	175
associated	VERB	O	O	175
with	ADP	O	O	175
consumption	NOUN	O	O	175
of	ADP	O	O	175
either	ADV	O	O	175
phenacetin	VERB	O	O	175
or	CCONJ	O	O	175
paracetamol	PROPN	O	Chemical	175
was	AUX	O	O	175
calculated	VERB	O	O	175
from	ADP	O	O	175
data	NOUN	O	O	175
acquired	VERB	O	O	175
by	ADP	O	O	175
questionnaire	NOUN	O	O	175
from	ADP	O	O	175
381	NUM	O	O	175
cases	NOUN	O	O	175
and	CCONJ	O	O	175
808	NUM	O	O	175
controls	VERB	O	O	175
.	PUNCT	O	O	175
The	PRON	O	O	176
risk	NOUN	O	O	176
of	ADP	O	O	176
renal papillary necrosis	NOUN	O	Disease	176
was	AUX	O	O	176
increased	VERB	O	O	176
nearly	ADV	O	O	176
20-fold	ADV	O	O	176
by	ADP	O	O	176
consumption	NOUN	O	O	176
of	ADP	O	O	176
phenacetin	VERB	O	O	176
,	PUNCT	O	O	176
which	PRON	O	O	176
also	ADV	O	O	176
increased	VERB	O	O	176
the	PRON	O	O	176
risk	NOUN	O	O	176
for	ADP	O	O	176
cancer	NOUN	O	Disease	176
of	ADP	O	O	176
the	PRON	O	O	176
renal	ADJ	O	O	176
pelvis	ADJ	O	O	176
and	CCONJ	O	O	176
bladder	NOUN	O	O	176
but	CCONJ	O	O	176
not	PART	O	O	176
for	ADP	O	O	176
ureteric	ADJ	O	O	176
cancer	NOUN	O	Disease	176
.	PUNCT	O	O	176
By	ADP	O	O	177
contrast	NOUN	O	O	177
,	PUNCT	O	O	177
we	PRON	O	O	177
were	AUX	O	O	177
unable	ADJ	O	O	177
to	PART	O	O	177
substantiate	VERB	O	O	177
an	PRON	O	O	177
increased	VERB	O	O	177
risk	NOUN	O	O	177
from	ADP	O	O	177
paracetamol	PROPN	O	Chemical	177
consumption	NOUN	O	O	177
for	ADP	O	O	177
renal papillary necrosis	NOUN	O	Disease	177
or	CCONJ	O	O	177
any	PRON	O	O	177
of	ADP	O	O	177
these	PRON	O	O	177
cancers	NOUN	O	Disease	177
although	SCONJ	O	O	177
there	ADV	O	O	177
was	AUX	O	O	177
a	PRON	O	O	177
suggestion	NOUN	O	O	177
of	ADP	O	O	177
an	PRON	O	O	177
association	PROPN	O	O	177
with	ADP	O	O	177
cancer	NOUN	O	Disease	177
of	ADP	O	O	177
the	PRON	O	O	177
ureter	NOUN	O	O	177
.	PUNCT	O	O	177
Dapsone	PROPN	O	O	180
-	PUNCT	O	O	180
associated	VERB	O	O	180
Heinz	PROPN	O	O	180
body	NOUN	O	O	180
hemolytic anemia	NOUN	O	Disease	180
in	ADP	O	O	180
a	PRON	O	O	180
Cambodian	ADJ	O	O	180
woman	NOUN	O	O	180
with	ADP	O	O	180
hemoglobin	NOUN	O	O	180
E	NOUN	O	Chemical	180
trait	NOUN	O	O	180
.	PUNCT	O	O	180
A	PRON	O	O	181
Cambodian	ADJ	O	O	181
woman	NOUN	O	O	181
with	ADP	O	O	181
hemoglobin	NOUN	O	O	181
E	NOUN	O	Chemical	181
trait	NOUN	O	O	181
(	PUNCT	O	O	181
AE	PROPN	O	O	181
)	PUNCT	O	O	181
and	CCONJ	O	O	181
leprosy	NOUN	O	O	181
developed	VERB	O	O	181
a	PRON	O	O	181
Heinz	PROPN	O	O	181
body	NOUN	O	O	181
hemolytic anemia	NOUN	O	Disease	181
while	SCONJ	O	O	181
taking	VERB	O	O	181
a	PRON	O	O	181
dose	NOUN	O	O	181
of	ADP	O	O	181
dapsone	NOUN	O	O	181
(	PUNCT	O	O	181
50	NUM	O	O	181
mg	VERB	O	O	181
/	PUNCT	O	O	181
day	NOUN	O	O	181
)	PUNCT	O	O	181
not	PART	O	O	181
usually	ADV	O	O	181
associated	VERB	O	O	181
with	ADP	O	O	181
clinical	ADJ	O	O	181
hemolysis	NOUN	O	Disease	181
.	PUNCT	O	O	181
Her	PRON	O	O	182
red	ADJ	O	O	182
blood	NOUN	O	O	182
cells	NOUN	O	O	182
(	PUNCT	O	O	182
RBCs	NOUN	O	O	182
)	PUNCT	O	O	182
had	VERB	O	O	182
increased	VERB	O	O	182
incubated	VERB	O	O	182
Heinz	PROPN	O	O	182
body	NOUN	O	O	182
formation	NOUN	O	O	182
,	PUNCT	O	O	182
decreased	VERB	O	O	182
reduced glutathione	NOUN	O	Chemical	182
(	PUNCT	O	O	182
GSH	PROPN	O	O	182
)	PUNCT	O	O	182
,	PUNCT	O	O	182
and	CCONJ	O	O	182
decreased	VERB	O	O	182
GSH	PROPN	O	O	182
stability	PROPN	O	O	182
.	PUNCT	O	O	182
The	PRON	O	O	183
pentose	NOUN	O	O	183
phosphate	NOUN	O	Chemical	183
shunt	VERB	O	O	183
activity	NOUN	O	O	183
of	ADP	O	O	183
the	PRON	O	O	183
dapsone	NOUN	O	O	183
-	PUNCT	O	O	183
exposed	VERB	O	O	183
AE	PROPN	O	O	183
RBCs	NOUN	O	O	183
was	AUX	O	O	183
increased	VERB	O	O	183
compared	VERB	O	O	183
to	PART	O	O	183
normal	ADJ	O	O	183
RBCs	NOUN	O	O	183
.	PUNCT	O	O	183
Although	SCONJ	O	O	184
the	PRON	O	O	184
AE	PROPN	O	O	184
RBCs	NOUN	O	O	184
from	ADP	O	O	184
an	PRON	O	O	184
individual	ADJ	O	O	184
not	PART	O	O	184
taking	VERB	O	O	184
dapsone	NOUN	O	O	184
had	VERB	O	O	184
increased	VERB	O	O	184
incubated	VERB	O	O	184
Heinz	PROPN	O	O	184
body	NOUN	O	O	184
formation	NOUN	O	O	184
,	PUNCT	O	O	184
the	PRON	O	O	184
GSH	PROPN	O	O	184
content	NOUN	O	O	184
and	CCONJ	O	O	184
GSH	PROPN	O	O	184
stability	PROPN	O	O	184
were	AUX	O	O	184
normal	ADJ	O	O	184
.	PUNCT	O	O	184
The	PRON	O	O	185
pentose	NOUN	O	O	185
phosphate	NOUN	O	Chemical	185
shunt	VERB	O	O	185
activity	NOUN	O	O	185
of	ADP	O	O	185
the	PRON	O	O	185
non	ADJ	O	O	185
-	PUNCT	O	O	185
dapsone	NOUN	O	O	185
-	PUNCT	O	O	185
exposed	VERB	O	O	185
AE	PROPN	O	O	185
RBCs	NOUN	O	O	185
was	AUX	O	O	185
decreased	VERB	O	O	185
compared	VERB	O	O	185
to	PART	O	O	185
normal	ADJ	O	O	185
RBCs	NOUN	O	O	185
.	PUNCT	O	O	185
Thus	ADV	O	O	186
,	PUNCT	O	O	186
AE	PROPN	O	O	186
RBCs	NOUN	O	O	186
appear	VERB	O	O	186
to	PART	O	O	186
have	VERB	O	O	186
an	PRON	O	O	186
increased	VERB	O	O	186
sensitivity	NOUN	O	O	186
to	PART	O	O	186
oxidant	ADJ	O	O	186
stress	NOUN	O	O	186
both	PRON	O	O	186
in	ADP	O	O	186
vitro	X	O	O	186
and	CCONJ	O	O	186
in	ADP	O	O	186
vivo	VERB	O	O	186
,	PUNCT	O	O	186
since	SCONJ	O	O	186
dapsone	NOUN	O	O	186
does	VERB	O	O	186
not	PART	O	O	186
cause	VERB	O	O	186
hemolytic anemia	NOUN	O	Disease	186
at	ADP	O	O	186
this	PRON	O	O	186
dose	NOUN	O	O	186
in	ADP	O	O	186
hematologically	NOUN	O	O	186
normal	ADJ	O	O	186
individuals	NOUN	O	O	186
.	PUNCT	O	O	186
Given	VERB	O	O	187
the	PRON	O	O	187
influx	VERB	O	O	187
of	ADP	O	O	187
Southeast	NOUN	O	O	187
Asians	PROPN	O	O	187
into	ADP	O	O	187
the	PRON	O	O	187
United	PROPN	O	O	187
States	NOUN	O	O	187
,	PUNCT	O	O	187
oxidant	ADJ	O	O	187
medications	NOUN	O	O	187
should	AUX	O	O	187
be	AUX	O	O	187
used	VERB	O	O	187
with	ADP	O	O	187
caution	NOUN	O	O	187
,	PUNCT	O	O	187
especially	ADV	O	O	187
if	SCONJ	O	O	187
an	PRON	O	O	187
infection	NOUN	O	Disease	187
is	AUX	O	O	187
present	NOUN	O	O	187
,	PUNCT	O	O	187
in	ADP	O	O	187
individuals	NOUN	O	O	187
of	ADP	O	O	187
ethnic	ADJ	O	O	187
backgrounds	NOUN	O	O	187
that	SCONJ	O	O	187
have	VERB	O	O	187
an	PRON	O	O	187
increased	VERB	O	O	187
prevalence	NOUN	O	O	187
of	ADP	O	O	187
hemoglobin	NOUN	O	O	187
E.	PROPN	O	O	187
Severe	ADJ	O	O	190
complications	NOUN	O	O	190
of	ADP	O	O	190
antianginal	ADJ	O	O	190
drug	NOUN	O	O	190
therapy	NOUN	O	O	190
in	ADP	O	O	190
a	PRON	O	O	190
patient	NOUN	O	O	190
identified	VERB	O	O	190
as	ADP	O	O	190
a	PRON	O	O	190
poor	ADJ	O	O	190
metabolizer	ADJ	O	O	190
of	ADP	O	O	190
metoprolol	NOUN	O	Chemical	190
,	PUNCT	O	O	190
propafenone	NOUN	O	O	190
,	PUNCT	O	O	190
diltiazem	VERB	O	Chemical	190
,	PUNCT	O	O	190
and	CCONJ	O	O	190
sparteine	NOUN	O	Chemical	190
.	PUNCT	O	O	190
A	PRON	O	O	191
47-year	NOUN	O	O	191
-	PUNCT	O	O	191
old	ADJ	O	O	191
patient	NOUN	O	O	191
suffering	VERB	O	O	191
from	ADP	O	O	191
coronary artery disease	NOUN	O	Disease	191
was	AUX	O	O	191
admitted	VERB	O	O	191
to	PART	O	O	191
the	PRON	O	O	191
CCU	PROPN	O	O	191
in	ADP	O	O	191
shock	NOUN	O	O	191
with	ADP	O	O	191
III	NUM	O	O	191
.	PUNCT	O	O	191
AV	NOUN	O	O	192
block	NOUN	O	O	192
,	PUNCT	O	O	192
severe	ADJ	O	O	192
hypotension	NOUN	O	Disease	192
,	PUNCT	O	O	192
and	CCONJ	O	O	192
impairment	NOUN	O	O	192
of	ADP	O	O	192
ventricular	ADJ	O	O	192
function	NOUN	O	O	192
.	PUNCT	O	O	192
One	NUM	O	O	193
week	NOUN	O	O	193
prior	ADV	O	O	193
to	PART	O	O	193
admission	NOUN	O	O	193
a	PRON	O	O	193
therapy	NOUN	O	O	193
with	ADP	O	O	193
standard	PROPN	O	O	193
doses	NOUN	O	O	193
of	ADP	O	O	193
metoprolol	NOUN	O	Chemical	193
(	PUNCT	O	O	193
100	NUM	O	O	193
mg	VERB	O	O	193
t.i.d	ADJ	O	O	193
.	PUNCT	O	O	193
and	CCONJ	O	O	193
then	ADV	O	O	193
100	NUM	O	O	193
mg	VERB	O	O	193
b.i.d	PROPN	O	O	193
.	PUNCT	O	O	193
)	PUNCT	O	O	193
had	VERB	O	O	193
been	AUX	O	O	193
initiated	VERB	O	O	193
.	PUNCT	O	O	193
Two	NUM	O	O	194
days	NOUN	O	O	194
before	ADP	O	O	194
admission	NOUN	O	O	194
diltiazem	VERB	O	Chemical	194
(	PUNCT	O	O	194
60	NUM	O	O	194
mg	VERB	O	O	194
b.i.d	PROPN	O	O	194
.	PUNCT	O	O	194
)	PUNCT	O	O	194
was	AUX	O	O	194
prescribed	VERB	O	O	194
in	ADP	O	O	194
addition	NOUN	O	O	194
.	PUNCT	O	O	194
Analyses	NOUN	O	O	195
of	ADP	O	O	195
a	PRON	O	O	195
blood	NOUN	O	O	195
sample	NOUN	O	O	195
revealed	VERB	O	O	195
unusually	ADV	O	O	195
high	ADJ	O	O	195
plasma	NOUN	O	O	195
concentrations	NOUN	O	O	195
of	ADP	O	O	195
metoprolol	NOUN	O	Chemical	195
(	PUNCT	O	O	195
greater	ADJ	O	O	195
than	ADP	O	O	195
3000	NUM	O	O	195
ng	PROPN	O	O	195
/	PUNCT	O	O	195
ml	ADP	O	O	195
)	PUNCT	O	O	195
and	CCONJ	O	O	195
diltiazem	VERB	O	Chemical	195
(	PUNCT	O	O	195
526	NUM	O	O	195
ng	PROPN	O	O	195
/	PUNCT	O	O	195
ml	ADP	O	O	195
)	PUNCT	O	O	195
.	PUNCT	O	O	195
Three	NUM	O	O	196
months	NOUN	O	O	196
later	ADV	O	O	196
the	PRON	O	O	196
patient	NOUN	O	O	196
was	AUX	O	O	196
exposed	VERB	O	O	196
to	PART	O	O	196
a	PRON	O	O	196
single	ADJ	O	O	196
dose	NOUN	O	O	196
of	ADP	O	O	196
metoprolol	NOUN	O	Chemical	196
,	PUNCT	O	O	196
diltiazem	VERB	O	Chemical	196
,	PUNCT	O	O	196
propafenone	NOUN	O	O	196
(	PUNCT	O	O	196
since	SCONJ	O	O	196
he	PRON	O	O	196
had	VERB	O	O	196
received	VERB	O	O	196
this	PRON	O	O	196
drug	NOUN	O	O	196
in	ADP	O	O	196
the	PRON	O	O	196
past	ADP	O	O	196
)	PUNCT	O	O	196
,	PUNCT	O	O	196
and	CCONJ	O	O	196
sparteine	NOUN	O	Chemical	196
(	PUNCT	O	O	196
as	ADP	O	O	196
a	PRON	O	O	196
probe	NOUN	O	O	196
for	ADP	O	O	196
the	PRON	O	O	196
debrisoquine	NOUN	O	Chemical	196
/	PUNCT	O	O	196
sparteine	NOUN	O	Chemical	196
type	NOUN	O	O	196
polymorphism	NOUN	O	O	196
of	ADP	O	O	196
oxidative	NOUN	O	O	196
drug	NOUN	O	O	196
metabolism	NOUN	O	O	196
)	PUNCT	O	O	196
.	PUNCT	O	O	196
Therefore	ADV	O	O	197
,	PUNCT	O	O	197
patients	NOUN	O	O	197
belonging	VERB	O	O	197
to	PART	O	O	197
the	PRON	O	O	197
poor	ADJ	O	O	197
-	PUNCT	O	O	197
metabolizer	ADJ	O	O	197
phenotype	NOUN	O	O	197
of	ADP	O	O	197
sparteine	NOUN	O	Chemical	197
/	PUNCT	O	O	197
debrisoquine	NOUN	O	Chemical	197
polymorphism	NOUN	O	O	197
in	ADP	O	O	197
drug	NOUN	O	O	197
metabolism	NOUN	O	O	197
,	PUNCT	O	O	197
which	PRON	O	O	197
constitutes	VERB	O	O	197
6.4%	NOUN	O	O	197
of	ADP	O	O	197
the	PRON	O	O	197
German	ADJ	O	O	197
population	NOUN	O	O	197
,	PUNCT	O	O	197
may	AUX	O	O	197
experience	NOUN	O	O	197
adverse	ADJ	O	O	197
drug	NOUN	O	O	197
reactions	NOUN	O	O	197
when	SCONJ	O	O	197
treated	VERB	O	O	197
with	ADP	O	O	197
standard	PROPN	O	O	197
doses	NOUN	O	O	197
of	ADP	O	O	197
one	NUM	O	O	197
of	ADP	O	O	197
these	PRON	O	O	197
drugs	NOUN	O	O	197
alone	ADV	O	O	197
.	PUNCT	O	O	197
Triazolam	PROPN	O	O	200
-	PUNCT	O	O	200
induced	VERB	O	O	200
brief	PROPN	O	O	200
episodes	NOUN	O	O	200
of	ADP	O	O	200
secondary	ADJ	O	O	200
mania	NOUN	O	O	200
in	ADP	O	O	200
a	PRON	O	O	200
depressed	ADJ	O	O	200
patient	NOUN	O	O	200
.	PUNCT	O	O	200
Large	ADJ	O	O	201
doses	NOUN	O	O	201
of	ADP	O	O	201
triazolam	NOUN	O	O	201
repeatedly	ADV	O	O	201
induced	VERB	O	O	201
brief	PROPN	O	O	201
episodes	NOUN	O	O	201
of	ADP	O	O	201
mania	NOUN	O	O	201
in	ADP	O	O	201
a	PRON	O	O	201
depressed	ADJ	O	O	201
elderly	ADJ	O	O	201
woman	NOUN	O	O	201
.	PUNCT	O	O	201
Features	NOUN	O	O	202
of	ADP	O	O	202
organic	ADJ	O	O	202
mental	ADJ	O	O	202
disorder	NOUN	O	O	202
(	PUNCT	O	O	202
delirium	NOUN	O	Disease	202
)	PUNCT	O	O	202
were	AUX	O	O	202
not	PART	O	O	202
present	NOUN	O	O	202
.	PUNCT	O	O	202
Manic	ADJ	O	O	203
excitement	NOUN	O	O	203
was	AUX	O	O	203
coincident	VERB	O	O	203
with	ADP	O	O	203
the	PRON	O	O	203
duration	NOUN	O	O	203
of	ADP	O	O	203
action	NOUN	O	O	203
of	ADP	O	O	203
triazolam	NOUN	O	O	203
.	PUNCT	O	O	203
The	PRON	O	O	204
possible	ADJ	O	O	204
contribution	NOUN	O	O	204
of	ADP	O	O	204
the	PRON	O	O	204
triazolo	PROPN	O	O	204
group	NOUN	O	O	204
to	PART	O	O	204
changes	VERB	O	O	204
in	ADP	O	O	204
affective	ADJ	O	O	204
status	NOUN	O	O	204
is	AUX	O	O	204
discussed	VERB	O	O	204
.	PUNCT	O	O	204
On	ADP	O	O	207
the	PRON	O	O	207
mechanisms	NOUN	O	O	207
of	ADP	O	O	207
the	PRON	O	O	207
development	NOUN	O	O	207
of	ADP	O	O	207
tolerance	NOUN	O	O	207
to	PART	O	O	207
the	PRON	O	O	207
muscular rigidity	NOUN	O	Disease	207
produced	VERB	O	O	207
by	ADP	O	O	207
morphine	NOUN	O	Chemical	207
in	ADP	O	O	207
rats	NOUN	O	O	207
.	PUNCT	O	O	207
The	PRON	O	O	208
development	NOUN	O	O	208
of	ADP	O	O	208
tolerance	NOUN	O	O	208
to	PART	O	O	208
the	PRON	O	O	208
muscular rigidity	NOUN	O	Disease	208
produced	VERB	O	O	208
by	ADP	O	O	208
morphine	NOUN	O	Chemical	208
was	AUX	O	O	208
studied	VERB	O	O	208
in	ADP	O	O	208
rats	NOUN	O	O	208
.	PUNCT	O	O	208
Saline	NOUN	O	O	209
-	PUNCT	O	O	209
pretreated	VERB	O	O	209
controls	VERB	O	O	209
given	VERB	O	O	209
a	PRON	O	O	209
test	NOUN	O	O	209
dose	NOUN	O	O	209
of	ADP	O	O	209
morphine	NOUN	O	Chemical	209
(	PUNCT	O	O	209
20	NUM	O	O	209
mg	VERB	O	O	209
/	PUNCT	O	O	209
kg	VERB	O	O	209
i.p	NOUN	O	O	209
.	PUNCT	O	O	209
)	PUNCT	O	O	209
showed	VERB	O	O	209
a	PRON	O	O	209
pronounced	VERB	O	O	209
rigidity	NOUN	O	Disease	209
recorded	VERB	O	O	209
as	ADP	O	O	209
tonic	PROPN	O	O	209
activity	NOUN	O	O	209
in	ADP	O	O	209
the	PRON	O	O	209
electromyogram	PROPN	O	O	209
.	PUNCT	O	O	209
Rats	NOUN	O	O	210
treated	VERB	O	O	210
for	ADP	O	O	210
11	NUM	O	O	210
days	NOUN	O	O	210
with	ADP	O	O	210
morphine	NOUN	O	Chemical	210
and	CCONJ	O	O	210
withdrawn	VERB	O	O	210
for	ADP	O	O	210
36	NUM	O	O	210
-	PUNCT	O	O	210
40	NUM	O	O	210
h	X	O	O	210
showed	VERB	O	O	210
differences	NOUN	O	O	210
in	ADP	O	O	210
the	PRON	O	O	210
development	NOUN	O	O	210
of	ADP	O	O	210
tolerance	NOUN	O	O	210
:	PUNCT	O	O	210
about	ADP	O	O	210
half	NOUN	O	O	210
of	ADP	O	O	210
the	PRON	O	O	210
animals	NOUN	O	O	210
showed	VERB	O	O	210
a	PRON	O	O	210
rigidity	NOUN	O	Disease	210
after	ADP	O	O	210
the	PRON	O	O	210
test	NOUN	O	O	210
dose	NOUN	O	O	210
of	ADP	O	O	210
morphine	NOUN	O	Chemical	210
that	SCONJ	O	O	210
was	AUX	O	O	210
not	PART	O	O	210
significantly	ADV	O	O	210
less	ADV	O	O	210
than	ADP	O	O	210
in	ADP	O	O	210
the	PRON	O	O	210
controls	VERB	O	O	210
and	CCONJ	O	O	210
were	AUX	O	O	210
akinetic	ADJ	O	Disease	210
(	PUNCT	O	O	210
A	PRON	O	O	210
group	NOUN	O	O	210
)	PUNCT	O	O	210
.	PUNCT	O	O	210
The	PRON	O	O	211
other	ADJ	O	O	211
rats	NOUN	O	O	211
showed	VERB	O	O	211
a	PRON	O	O	211
strong	ADJ	O	O	211
decrease	VERB	O	O	211
in	ADP	O	O	211
the	PRON	O	O	211
rigidity	NOUN	O	Disease	211
and	CCONJ	O	O	211
the	PRON	O	O	211
occurrence	NOUN	O	O	211
of	ADP	O	O	211
stereotyped	VERB	O	O	211
(	PUNCT	O	O	211
S	NOUN	O	O	211
)	PUNCT	O	O	211
licking	VERB	O	O	211
and/or	CCONJ	O	O	211
gnawing	VERB	O	O	211
in	ADP	O	O	211
presence	NOUN	O	O	211
of	ADP	O	O	211
akinetic	ADJ	O	Disease	211
or	CCONJ	O	O	211
hyperkinetic	ADJ	O	Disease	211
(	PUNCT	O	O	211
K	PROPN	O	Chemical	211
)	PUNCT	O	O	211
behaviour	NOUN	O	O	211
(	PUNCT	O	O	211
AS	ADP	O	O	211
/	PUNCT	O	O	211
KS	PROPN	O	O	211
group	NOUN	O	O	211
)	PUNCT	O	O	211
,	PUNCT	O	O	211
suggesting	VERB	O	O	211
signs	NOUN	O	O	211
of	ADP	O	O	211
dopaminergic	ADJ	O	O	211
activation	NOUN	O	O	211
.	PUNCT	O	O	211
The	PRON	O	O	212
rigidity	NOUN	O	Disease	212
was	AUX	O	O	212
considerably	ADV	O	O	212
decreased	VERB	O	O	212
in	ADP	O	O	212
both	PRON	O	O	212
groups	NOUN	O	O	212
after	ADP	O	O	212
20	NUM	O	O	212
days	NOUN	O	O	212
'	PUNCT	O	O	212
treatment	NOUN	O	O	212
.	PUNCT	O	O	212
In	ADP	O	O	213
a	PRON	O	O	213
further	ADV	O	O	213
series	PROPN	O	O	213
of	ADP	O	O	213
experiments	NOUN	O	O	213
,	PUNCT	O	O	213
haloperidol	NOUN	O	Chemical	213
(	PUNCT	O	O	213
0.2	NUM	O	O	213
mg	VERB	O	O	213
/	PUNCT	O	O	213
kg	VERB	O	O	213
i.p	NOUN	O	O	213
.	PUNCT	O	O	213
)	PUNCT	O	O	213
was	AUX	O	O	213
used	VERB	O	O	213
in	ADP	O	O	213
order	NOUN	O	O	213
to	PART	O	O	213
block	NOUN	O	O	213
the	PRON	O	O	213
dopaminergic	ADJ	O	O	213
activation	NOUN	O	O	213
and	CCONJ	O	O	213
to	PART	O	O	213
estimate	VERB	O	O	213
the	PRON	O	O	213
real	ADV	O	O	213
degree	PROPN	O	O	213
of	ADP	O	O	213
the	PRON	O	O	213
tolerance	NOUN	O	O	213
to	PART	O	O	213
the	PRON	O	O	213
rigidity	NOUN	O	Disease	213
without	ADP	O	O	213
any	PRON	O	O	213
dopaminergic	ADJ	O	O	213
interference	NOUN	O	O	213
.	PUNCT	O	O	213
Haloperidol	NOUN	O	Chemical	214
enhanced	VERB	O	O	214
the	PRON	O	O	214
rigidity	NOUN	O	Disease	214
in	ADP	O	O	214
the	PRON	O	O	214
A	PRON	O	O	214
group	NOUN	O	O	214
.	PUNCT	O	O	214
The	PRON	O	O	215
results	VERB	O	O	215
suggest	VERB	O	O	215
that	SCONJ	O	O	215
rigidity	NOUN	O	Disease	215
,	PUNCT	O	O	215
which	PRON	O	O	215
is	AUX	O	O	215
assumed	VERB	O	O	215
to	PART	O	O	215
be	AUX	O	O	215
due	ADJ	O	O	215
to	PART	O	O	215
an	PRON	O	O	215
action	NOUN	O	O	215
of	ADP	O	O	215
morphine	NOUN	O	Chemical	215
in	ADP	O	O	215
the	PRON	O	O	215
striatum	NOUN	O	O	215
,	PUNCT	O	O	215
can	AUX	O	O	215
be	AUX	O	O	215
antagonized	VERB	O	O	215
by	ADP	O	O	215
another	PRON	O	O	215
process	NOUN	O	O	215
leading	VERB	O	O	215
to	PART	O	O	215
dopaminergic	ADJ	O	O	215
activation	NOUN	O	O	215
in	ADP	O	O	215
the	PRON	O	O	215
striatum	NOUN	O	O	215
.	PUNCT	O	O	215
The	PRON	O	O	216
rapid	ADJ	O	O	216
alternations	NOUN	O	O	216
of	ADP	O	O	216
rigidity	NOUN	O	Disease	216
and	CCONJ	O	O	216
the	PRON	O	O	216
signs	NOUN	O	O	216
of	ADP	O	O	216
dopaminergic	ADJ	O	O	216
activation	NOUN	O	O	216
observed	VERB	O	O	216
in	ADP	O	O	216
the	PRON	O	O	216
animals	NOUN	O	O	216
of	ADP	O	O	216
the	PRON	O	O	216
AS	ADP	O	O	216
/	PUNCT	O	O	216
KS	PROPN	O	O	216
group	NOUN	O	O	216
might	AUX	O	O	216
be	AUX	O	O	216
due	ADJ	O	O	216
to	PART	O	O	216
rapid	ADJ	O	O	216
shifts	NOUN	O	O	216
in	ADP	O	O	216
the	PRON	O	O	216
predominance	NOUN	O	O	216
of	ADP	O	O	216
various	ADJ	O	O	216
DA	NOUN	O	Chemical	216
-	PUNCT	O	O	216
innervated	VERB	O	O	216
structures	NOUN	O	O	216
.	PUNCT	O	O	216
Compression	NOUN	O	O	219
neuropathy	NOUN	O	Disease	219
of	ADP	O	O	219
the	PRON	O	O	219
radial	ADJ	O	O	219
nerve	NOUN	O	O	219
due	ADJ	O	O	219
to	PART	O	O	219
pentazocine	NOUN	O	O	219
-	PUNCT	O	O	219
induced	VERB	O	O	219
fibrous	ADJ	O	O	219
myopathy	PROPN	O	Disease	219
.	PUNCT	O	O	219
Fibrous	ADJ	O	O	220
myopathy	PROPN	O	Disease	220
is	AUX	O	O	220
a	PRON	O	O	220
common	ADJ	O	O	220
,	PUNCT	O	O	220
well	ADV	O	O	220
-	PUNCT	O	O	220
known	VERB	O	O	220
side	NOUN	O	O	220
effect	VERB	O	O	220
of	ADP	O	O	220
repeated	VERB	O	O	220
pentazocine	NOUN	O	O	220
injection	NOUN	O	O	220
.	PUNCT	O	O	220
However	ADV	O	O	221
,	PUNCT	O	O	221
compression	NOUN	O	O	221
neuropathy	NOUN	O	Disease	221
due	ADJ	O	O	221
to	PART	O	O	221
fibrotic	ADJ	O	O	221
muscle	NOUN	O	O	221
affected	VERB	O	O	221
by	ADP	O	O	221
pentazocine	NOUN	O	O	221
-	PUNCT	O	O	221
induced	VERB	O	O	221
myopathy	PROPN	O	Disease	221
has	VERB	O	O	221
not	PART	O	O	221
previously	ADV	O	O	221
been	AUX	O	O	221
reported	VERB	O	O	221
.	PUNCT	O	O	221
In	ADP	O	O	222
a	PRON	O	O	222
37-year	NOUN	O	O	222
-	PUNCT	O	O	222
old	ADJ	O	O	222
woman	NOUN	O	O	222
with	ADP	O	O	222
documented	VERB	O	O	222
pentazocine	NOUN	O	O	222
-	PUNCT	O	O	222
induced	VERB	O	O	222
fibrous	ADJ	O	O	222
myopathy	PROPN	O	Disease	222
of	ADP	O	O	222
triceps	NOUN	O	O	222
and	CCONJ	O	O	222
deltoid	PROPN	O	O	222
muscles	NOUN	O	O	222
bilaterally	ADV	O	O	222
and	CCONJ	O	O	222
a	PRON	O	O	222
three	NUM	O	O	222
-	PUNCT	O	O	222
week	NOUN	O	O	222
history	NOUN	O	O	222
of	ADP	O	O	222
right	ADV	O	O	222
wrist	NOUN	O	O	222
drop	VERB	O	O	222
,	PUNCT	O	O	222
electrodiagnostic	NOUN	O	O	222
examination	NOUN	O	O	222
showed	VERB	O	O	222
a	PRON	O	O	222
severe	ADJ	O	O	222
but	CCONJ	O	O	222
partial	ADJ	O	O	222
lesion	NOUN	O	O	222
of	ADP	O	O	222
the	PRON	O	O	222
right	ADV	O	O	222
radial	ADJ	O	O	222
nerve	NOUN	O	O	222
distal	NOUN	O	O	222
to	PART	O	O	222
the	PRON	O	O	222
branches	NOUN	O	O	222
to	PART	O	O	222
the	PRON	O	O	222
triceps	NOUN	O	O	222
,	PUNCT	O	O	222
in	ADP	O	O	222
addition	NOUN	O	O	222
to	PART	O	O	222
the	PRON	O	O	222
fibrous	ADJ	O	O	222
myopathy	PROPN	O	Disease	222
.	PUNCT	O	O	222
Recurrent	ADJ	O	O	225
reversible	ADJ	O	O	225
acute	ADJ	O	O	225
renal failure	NOUN	O	Disease	225
from	ADP	O	O	225
amphotericin	PRON	O	O	225
.	PUNCT	O	O	225
A	PRON	O	O	226
patient	NOUN	O	O	226
with	ADP	O	O	226
cryptogenic	ADJ	O	O	226
cirrhosis	NOUN	O	Disease	226
and	CCONJ	O	O	226
disseminated	VERB	O	O	226
sporotrichosis	NOUN	O	O	226
developed	VERB	O	O	226
acute	ADJ	O	O	226
renal failure	NOUN	O	Disease	226
immediately	ADV	O	O	226
following	VERB	O	O	226
the	PRON	O	O	226
administration	NOUN	O	O	226
of	ADP	O	O	226
amphotericin B	NOUN	O	Chemical	226
on	ADP	O	O	226
four	NUM	O	O	226
separate	VERB	O	O	226
occasions	NOUN	O	O	226
.	PUNCT	O	O	226
The	PRON	O	O	227
abruptness	ADJ	O	O	227
of	ADP	O	O	227
the	PRON	O	O	227
renal failure	NOUN	O	Disease	227
and	CCONJ	O	O	227
its	PRON	O	O	227
reversibility	NOUN	O	O	227
within	ADP	O	O	227
days	NOUN	O	O	227
suggests	VERB	O	O	227
that	SCONJ	O	O	227
there	ADV	O	O	227
was	AUX	O	O	227
a	PRON	O	O	227
functional	ADJ	O	O	227
component	NOUN	O	O	227
to	PART	O	O	227
the	PRON	O	O	227
renal dysfunction	NOUN	O	Disease	227
.	PUNCT	O	O	227
We	PRON	O	O	228
propose	VERB	O	O	228
that	SCONJ	O	O	228
amphotericin	PRON	O	O	228
,	PUNCT	O	O	228
in	ADP	O	O	228
the	PRON	O	O	228
setting	VERB	O	O	228
of	ADP	O	O	228
reduced	VERB	O	O	228
effective	ADJ	O	O	228
arterial	ADJ	O	O	228
volume	PROPN	O	O	228
,	PUNCT	O	O	228
may	AUX	O	O	228
activate	VERB	O	O	228
tubuloglomerular	ADJ	O	O	228
feedback	VERB	O	O	228
,	PUNCT	O	O	228
thereby	ADV	O	O	228
contributing	VERB	O	O	228
to	PART	O	O	228
acute	ADJ	O	O	228
renal failure	NOUN	O	Disease	228
.	PUNCT	O	O	228
Pneumonitis	NOUN	O	O	231
with	ADP	O	O	231
pleural	PROPN	O	O	231
and	CCONJ	O	O	231
pericardial	ADJ	O	O	231
effusion	NOUN	O	O	231
and	CCONJ	O	O	231
neuropathy	NOUN	O	Disease	231
during	ADP	O	O	231
amiodarone	NOUN	O	Chemical	231
therapy	NOUN	O	O	231
.	PUNCT	O	O	231
A	PRON	O	O	232
patient	NOUN	O	O	232
with	ADP	O	O	232
sinuatrial	PROPN	O	O	232
disease	PROPN	O	O	232
and	CCONJ	O	O	232
implanted	VERB	O	O	232
pacemaker	NOUN	O	O	232
was	AUX	O	O	232
treated	VERB	O	O	232
with	ADP	O	O	232
amiodarone	NOUN	O	Chemical	232
(	PUNCT	O	O	232
maximum	ADV	O	O	232
dose	NOUN	O	O	232
1000	NUM	O	O	232
mg	VERB	O	O	232
,	PUNCT	O	O	232
maintenance	NOUN	O	O	232
dose	NOUN	O	O	232
800	NUM	O	O	232
mg	VERB	O	O	232
daily	ADV	O	O	232
)	PUNCT	O	O	232
for	ADP	O	O	232
10	NUM	O	O	232
months	NOUN	O	O	232
,	PUNCT	O	O	232
for	ADP	O	O	232
control	VERB	O	O	232
of	ADP	O	O	232
supraventricular tachyarrhythmias	NOUN	O	O	232
.	PUNCT	O	O	232
He	PRON	O	O	233
developed	VERB	O	O	233
pneumonitis	NOUN	O	Disease	233
,	PUNCT	O	O	233
pleural	PROPN	O	O	233
and	CCONJ	O	O	233
pericardial	ADJ	O	O	233
effusions	NOUN	O	O	233
,	PUNCT	O	O	233
and	CCONJ	O	O	233
a	PRON	O	O	233
predominantly	ADV	O	O	233
proximal	ADJ	O	O	233
motor	NOUN	O	O	233
neuropathy	NOUN	O	Disease	233
.	PUNCT	O	O	233
Immediate	ADJ	O	O	234
but	CCONJ	O	O	234
gradual	ADJ	O	O	234
improvement	NOUN	O	O	234
followed	VERB	O	O	234
withdrawal	NOUN	O	O	234
of	ADP	O	O	234
amiodarone	NOUN	O	Chemical	234
and	CCONJ	O	O	234
treatment	NOUN	O	O	234
with	ADP	O	O	234
prednisolone	NOUN	O	Chemical	234
.	PUNCT	O	O	234
Review	NOUN	O	O	235
of	ADP	O	O	235
this	PRON	O	O	235
and	CCONJ	O	O	235
previously	ADV	O	O	235
reported	VERB	O	O	235
cases	NOUN	O	O	235
indicates	VERB	O	O	235
the	PRON	O	O	235
need	VERB	O	O	235
for	ADP	O	O	235
early	ADV	O	O	235
diagnosis	NOUN	O	O	235
of	ADP	O	O	235
amiodarone	NOUN	O	Chemical	235
pneumonitis	NOUN	O	Disease	235
,	PUNCT	O	O	235
immediate	ADJ	O	O	235
withdrawal	NOUN	O	O	235
of	ADP	O	O	235
amiodarone	NOUN	O	Chemical	235
,	PUNCT	O	O	235
and	CCONJ	O	O	235
prompt	PROPN	O	O	235
but	CCONJ	O	O	235
continued	VERB	O	O	235
steroid	NOUN	O	Chemical	235
therapy	NOUN	O	O	235
to	PART	O	O	235
ensure	VERB	O	O	235
full	ADJ	O	O	235
recovery	NOUN	O	O	235
.	PUNCT	O	O	235
Indomethacin	PROPN	O	Chemical	238
-	PUNCT	O	O	238
induced	VERB	O	O	238
renal insufficiency	NOUN	O	Disease	238
:	PUNCT	O	O	238
recurrence	NOUN	O	O	238
on	ADP	O	O	238
rechallenge	VERB	O	O	238
.	PUNCT	O	O	238
We	PRON	O	O	239
have	VERB	O	O	239
reported	VERB	O	O	239
a	PRON	O	O	239
case	NOUN	O	O	239
of	ADP	O	O	239
acute	ADJ	O	O	239
oliguric	PROPN	O	O	239
renal failure	NOUN	O	Disease	239
with	ADP	O	O	239
hyperkalemia	NOUN	O	O	239
in	ADP	O	O	239
a	PRON	O	O	239
patient	NOUN	O	O	239
with	ADP	O	O	239
cirrhosis	NOUN	O	Disease	239
,	PUNCT	O	O	239
ascites	NOUN	O	Disease	239
,	PUNCT	O	O	239
and	CCONJ	O	O	239
cor	PROPN	O	O	239
pulmonale	PROPN	O	O	239
after	ADP	O	O	239
indomethacin	VERB	O	Chemical	239
therapy	NOUN	O	O	239
.	PUNCT	O	O	239
Prompt	NOUN	O	O	240
restoration	NOUN	O	O	240
of	ADP	O	O	240
renal	ADJ	O	O	240
function	NOUN	O	O	240
followed	VERB	O	O	240
drug	NOUN	O	O	240
withdrawal	NOUN	O	O	240
,	PUNCT	O	O	240
while	SCONJ	O	O	240
re	ADP	O	O	240
-	PUNCT	O	O	240
exposure	NOUN	O	O	240
to	PART	O	O	240
a	PRON	O	O	240
single	ADJ	O	O	240
dose	NOUN	O	O	240
of	ADP	O	O	240
indomethacin	VERB	O	Chemical	240
caused	VERB	O	O	240
recurrence	NOUN	O	O	240
of	ADP	O	O	240
acute	ADJ	O	O	240
reversible	ADJ	O	O	240
oliguria	PROPN	O	O	240
.	PUNCT	O	O	240
Our	PRON	O	O	241
case	NOUN	O	O	241
supports	VERB	O	O	241
the	PRON	O	O	241
hypothesis	NOUN	O	O	241
that	SCONJ	O	O	241
endogenous	ADJ	O	O	241
renal	ADJ	O	O	241
prostaglandins	NOUN	O	Chemical	241
play	VERB	O	O	241
a	PRON	O	O	241
role	NOUN	O	O	241
in	ADP	O	O	241
the	PRON	O	O	241
maintenance	NOUN	O	O	241
of	ADP	O	O	241
renal	ADJ	O	O	241
blood	NOUN	O	O	241
flow	NOUN	O	O	241
when	SCONJ	O	O	241
circulating	VERB	O	O	241
plasma	NOUN	O	O	241
volume	PROPN	O	O	241
is	AUX	O	O	241
diminished	VERB	O	O	241
.	PUNCT	O	O	241
Since	SCONJ	O	O	242
nonsteroidal	ADJ	O	O	242
anti	ADJ	O	O	242
-	PUNCT	O	O	242
inflammatory	ADJ	O	O	242
agents	NOUN	O	O	242
interfere	VERB	O	O	242
with	ADP	O	O	242
this	PRON	O	O	242
compensatory	ADJ	O	O	242
mechanism	NOUN	O	O	242
and	CCONJ	O	O	242
may	AUX	O	O	242
cause	VERB	O	O	242
acute	ADJ	O	O	242
renal failure	NOUN	O	Disease	242
,	PUNCT	O	O	242
they	PRON	O	O	242
should	AUX	O	O	242
be	AUX	O	O	242
used	VERB	O	O	242
with	ADP	O	O	242
caution	NOUN	O	O	242
in	ADP	O	O	242
such	ADJ	O	O	242
patients	NOUN	O	O	242
.	PUNCT	O	O	242
administration	NOUN	O	O	245
of	ADP	O	O	245
flunitrazepam	VERB	O	O	245
in	ADP	O	O	245
volunteers	NOUN	O	O	245
.	PUNCT	O	O	245
Flunitrazepam	VERB	O	O	246
0.5	NUM	O	O	246
,	PUNCT	O	O	246
1.0	NUM	O	O	246
or	CCONJ	O	O	246
2.0	NUM	O	O	246
mg	VERB	O	O	246
was	AUX	O	O	246
given	VERB	O	O	246
by	ADP	O	O	246
the	PRON	O	O	246
oral	ADJ	O	O	246
or	CCONJ	O	O	246
i.m	PROPN	O	O	246
.	PUNCT	O	O	246
Dizziness	NOUN	O	O	247
was	AUX	O	O	247
less	ADV	O	O	247
marked	VERB	O	O	247
than	ADP	O	O	247
sedation	NOUN	O	O	247
,	PUNCT	O	O	247
but	CCONJ	O	O	247
increased	VERB	O	O	247
with	ADP	O	O	247
the	PRON	O	O	247
dose	NOUN	O	O	247
.	PUNCT	O	O	247
There	ADV	O	O	248
was	AUX	O	O	248
pain	NOUN	O	Disease	248
on	ADP	O	O	248
i.m	PROPN	O	O	248
.	PUNCT	O	O	248
injection	NOUN	O	O	249
of	ADP	O	O	249
flunitrazepam	VERB	O	O	249
significantly	ADV	O	O	249
more	ADJ	O	O	249
often	ADV	O	O	249
than	ADP	O	O	249
with	ADP	O	O	249
isotonic	ADJ	O	O	249
saline	NOUN	O	O	249
.	PUNCT	O	O	249
Changes	NOUN	O	O	252
in	ADP	O	O	252
heart	NOUN	O	O	252
size	NOUN	O	O	252
during	ADP	O	O	252
long	ADV	O	O	252
-	PUNCT	O	O	252
term	NOUN	O	O	252
timolol	PROPN	O	Chemical	252
treatment	NOUN	O	O	252
after	ADP	O	O	252
myocardial infarction	NOUN	O	Disease	252
.	PUNCT	O	O	252
The	PRON	O	O	253
effect	VERB	O	O	253
of	ADP	O	O	253
long	ADV	O	O	253
-	PUNCT	O	O	253
term	NOUN	O	O	253
timolol	PROPN	O	Chemical	253
treatment	NOUN	O	O	253
on	ADP	O	O	253
heart	NOUN	O	O	253
size	NOUN	O	O	253
after	ADP	O	O	253
myocardial infarction	NOUN	O	Disease	253
was	AUX	O	O	253
evaluated	VERB	O	O	253
by	ADP	O	O	253
X	NOUN	O	O	253
-	PUNCT	O	O	253
ray	PROPN	O	O	253
in	ADP	O	O	253
a	PRON	O	O	253
double	ADJ	O	O	253
-	PUNCT	O	O	253
blind	ADJ	O	Disease	253
study	VERB	O	O	253
including	VERB	O	O	253
241	NUM	O	O	253
patients	NOUN	O	O	253
(	PUNCT	O	O	253
placebo	NOUN	O	O	253
126	NUM	O	O	253
,	PUNCT	O	O	253
timolol	PROPN	O	Chemical	253
115	NUM	O	O	253
)	PUNCT	O	O	253
.	PUNCT	O	O	253
The	PRON	O	O	254
timolol	PROPN	O	Chemical	254
-	PUNCT	O	O	254
treated	VERB	O	O	254
patients	NOUN	O	O	254
showed	VERB	O	O	254
a	PRON	O	O	254
small	ADJ	O	O	254
but	CCONJ	O	O	254
significant	ADJ	O	O	254
increase	VERB	O	O	254
in	ADP	O	O	254
heart	NOUN	O	O	254
size	NOUN	O	O	254
from	ADP	O	O	254
baseline	VERB	O	O	254
in	ADP	O	O	254
contrast	NOUN	O	O	254
to	PART	O	O	254
a	PRON	O	O	254
decrease	VERB	O	O	254
in	ADP	O	O	254
the	PRON	O	O	254
placebo	NOUN	O	O	254
group	NOUN	O	O	254
.	PUNCT	O	O	254
These	PRON	O	O	255
differences	NOUN	O	O	255
may	AUX	O	O	255
be	AUX	O	O	255
caused	VERB	O	O	255
by	ADP	O	O	255
timolol	PROPN	O	Chemical	255
-	PUNCT	O	O	255
induced	VERB	O	O	255
bradycardia	NOUN	O	Disease	255
and	CCONJ	O	O	255
a	PRON	O	O	255
compensatory	ADJ	O	O	255
increase	VERB	O	O	255
in	ADP	O	O	255
end	VERB	O	O	255
-	PUNCT	O	O	255
diastolic	ADV	O	O	255
volume	PROPN	O	O	255
.	PUNCT	O	O	255
The	PRON	O	O	256
timolol	PROPN	O	Chemical	256
-	PUNCT	O	O	256
related	ADJ	O	O	256
increase	VERB	O	O	256
in	ADP	O	O	256
heart	NOUN	O	O	256
size	NOUN	O	O	256
was	AUX	O	O	256
observed	VERB	O	O	256
only	ADV	O	O	256
in	ADP	O	O	256
patients	NOUN	O	O	256
with	ADP	O	O	256
normal	ADJ	O	O	256
and	CCONJ	O	O	256
borderline	ADJ	O	O	256
heart	NOUN	O	O	256
size	NOUN	O	O	256
.	PUNCT	O	O	256
In	ADP	O	O	257
patients	NOUN	O	O	257
with	ADP	O	O	257
cardiomegaly	PROPN	O	O	257
,	PUNCT	O	O	257
the	PRON	O	O	257
increase	VERB	O	O	257
in	ADP	O	O	257
heart	NOUN	O	O	257
size	NOUN	O	O	257
was	AUX	O	O	257
similar	ADJ	O	O	257
in	ADP	O	O	257
both	PRON	O	O	257
groups	NOUN	O	O	257
.	PUNCT	O	O	257
After	ADP	O	O	258
re	ADP	O	O	258
-	PUNCT	O	O	258
infarction	NOUN	O	O	258
,	PUNCT	O	O	258
heart	NOUN	O	O	258
size	NOUN	O	O	258
increased	VERB	O	O	258
in	ADP	O	O	258
the	PRON	O	O	258
placebo	NOUN	O	O	258
group	NOUN	O	O	258
and	CCONJ	O	O	258
remained	VERB	O	O	258
unchanged	ADJ	O	O	258
in	ADP	O	O	258
the	PRON	O	O	258
timolol	PROPN	O	Chemical	258
group	NOUN	O	O	258
.	PUNCT	O	O	258
Vitamin	NOUN	O	O	261
D3	PROPN	O	O	261
toxicity	NOUN	O	Disease	261
in	ADP	O	O	261
dairy	NOUN	O	O	261
cows	NOUN	O	O	261
.	PUNCT	O	O	261
Large	ADJ	O	O	262
parenteral	ADJ	O	O	262
doses	NOUN	O	O	262
of	ADP	O	O	262
vitamin D3	PROPN	O	O	262
(	PUNCT	O	O	262
15	NUM	O	O	262
to	PART	O	O	262
17.5	NUM	O	O	262
x	X	O	O	262
10(6	NUM	O	O	262
)	PUNCT	O	O	262
IU	PROPN	O	O	263
vitamin D3	PROPN	O	O	263
)	PUNCT	O	O	263
were	AUX	O	O	263
associated	VERB	O	O	263
with	ADP	O	O	263
prolonged	VERB	O	O	263
hypercalcemia	NOUN	O	Disease	263
,	PUNCT	O	O	263
hyperphosphatemia	NOUN	O	Disease	263
,	PUNCT	O	O	263
and	CCONJ	O	O	263
large	ADJ	O	O	263
increases	VERB	O	O	263
of	ADP	O	O	263
vitamin D3	PROPN	O	O	263
and	CCONJ	O	O	263
its	PRON	O	O	263
metabolites	VERB	O	O	263
in	ADP	O	O	263
the	PRON	O	O	263
blood	NOUN	O	O	263
plasma	NOUN	O	O	263
of	ADP	O	O	263
nonlactating	VERB	O	O	263
nonpregnant	ADJ	O	O	263
and	CCONJ	O	O	263
pregnant	ADJ	O	O	263
Jersey	PROPN	O	O	263
cows	NOUN	O	O	263
.	PUNCT	O	O	263
Calcium	NOUN	O	O	264
concentrations	NOUN	O	O	264
1	X	O	O	264
day	NOUN	O	O	264
postpartum	PROPN	O	O	264
were	AUX	O	O	264
higher	ADJ	O	O	264
in	ADP	O	O	264
cows	NOUN	O	O	264
treated	VERB	O	O	264
with	ADP	O	O	264
vitamin D3	PROPN	O	O	264
about	ADP	O	O	264
32	NUM	O	O	264
days	NOUN	O	O	264
prepartum	PROPN	O	O	264
(	PUNCT	O	O	264
8.8	NUM	O	O	264
mg/100	VERB	O	O	264
ml	ADP	O	O	264
)	PUNCT	O	O	264
than	ADP	O	O	264
in	ADP	O	O	264
control	VERB	O	O	264
cows	NOUN	O	O	264
(	PUNCT	O	O	264
5.5	NUM	O	O	264
mg/100	VERB	O	O	264
ml	ADP	O	O	264
)	PUNCT	O	O	264
.	PUNCT	O	O	264
None	NOUN	O	O	265
of	ADP	O	O	265
the	PRON	O	O	265
cows	NOUN	O	O	265
treated	VERB	O	O	265
with	ADP	O	O	265
vitamin D3	PROPN	O	O	265
showed	VERB	O	O	265
signs	NOUN	O	O	265
of	ADP	O	O	265
milk	NOUN	O	O	265
fever	NOUN	O	Disease	265
during	ADP	O	O	265
the	PRON	O	O	265
peripartal	VERB	O	O	265
period	NOUN	O	O	265
;	PUNCT	O	O	265
however	ADV	O	O	265
,	PUNCT	O	O	265
22%	NOUN	O	O	265
of	ADP	O	O	265
the	PRON	O	O	265
control	VERB	O	O	265
cows	NOUN	O	O	265
developed	VERB	O	O	265
clinical	ADJ	O	O	265
signs	NOUN	O	O	265
of	ADP	O	O	265
milk	NOUN	O	O	265
fever	NOUN	O	Disease	265
during	ADP	O	O	265
this	PRON	O	O	265
period	NOUN	O	O	265
.	PUNCT	O	O	265
Signs	NOUN	O	O	266
of	ADP	O	O	266
vitamin D3	PROPN	O	O	266
toxicity	NOUN	O	Disease	266
were	AUX	O	O	266
not	PART	O	O	266
observed	VERB	O	O	266
in	ADP	O	O	266
nonlactating	VERB	O	O	266
nonpregnant	ADJ	O	O	266
cows	NOUN	O	O	266
;	PUNCT	O	O	266
however	ADV	O	O	266
,	PUNCT	O	O	266
pregnant	ADJ	O	O	266
cows	NOUN	O	O	266
commonly	ADV	O	O	266
developed	VERB	O	O	266
severe	ADJ	O	O	266
signs	NOUN	O	O	266
of	ADP	O	O	266
vitamin D3	PROPN	O	O	266
toxicity	NOUN	O	Disease	266
and	CCONJ	O	O	266
10	NUM	O	O	266
of	ADP	O	O	266
17	NUM	O	O	266
cows	NOUN	O	O	266
died	VERB	O	O	266
.	PUNCT	O	O	266
Because	SCONJ	O	O	267
of	ADP	O	O	267
the	PRON	O	O	267
extreme	ADJ	O	O	267
toxicity	NOUN	O	Disease	267
of	ADP	O	O	267
vitamin D3	PROPN	O	O	267
in	ADP	O	O	267
pregnant	ADJ	O	O	267
Jersey	PROPN	O	O	267
cows	NOUN	O	O	267
and	CCONJ	O	O	267
the	PRON	O	O	267
low	ADJ	O	O	267
margin	NOUN	O	O	267
of	ADP	O	O	267
safety	NOUN	O	O	267
between	ADP	O	O	267
doses	NOUN	O	O	267
of	ADP	O	O	267
vitamin D3	PROPN	O	O	267
that	SCONJ	O	O	267
prevent	VERB	O	O	267
milk	NOUN	O	O	267
fever	NOUN	O	Disease	267
and	CCONJ	O	O	267
doses	NOUN	O	O	267
that	SCONJ	O	O	267
induce	VERB	O	O	267
milk	NOUN	O	O	267
fever	NOUN	O	Disease	267
,	PUNCT	O	O	267
we	PRON	O	O	267
concluded	VERB	O	O	267
that	SCONJ	O	O	267
vitamin D3	PROPN	O	O	267
can	AUX	O	O	267
not	PART	O	O	267
be	AUX	O	O	267
used	VERB	O	O	267
practically	ADV	O	O	267
to	PART	O	O	267
prevent	VERB	O	O	267
milk	NOUN	O	O	267
fever	NOUN	O	Disease	267
when	SCONJ	O	O	267
injected	VERB	O	O	267
several	ADJ	O	O	267
weeks	NOUN	O	O	267
prepartum	PROPN	O	O	267
.	PUNCT	O	O	267
Diseases	NOUN	O	O	270
of	ADP	O	O	270
peripheral	ADJ	O	O	270
nerves	NOUN	O	O	270
as	ADP	O	O	270
seen	VERB	O	O	270
in	ADP	O	O	270
the	PRON	O	O	270
Nigerian	PROPN	O	O	270
African	ADJ	O	O	270
.	PUNCT	O	O	270
The	PRON	O	O	271
anatomical	ADJ	O	O	271
and	CCONJ	O	O	271
aetiological	ADJ	O	O	271
diagnoses	NOUN	O	O	271
of	ADP	O	O	271
peripheral	ADJ	O	O	271
nerve	NOUN	O	O	271
disease	PROPN	O	O	271
excluding	VERB	O	O	271
its	PRON	O	O	271
primary	NOUN	O	O	271
benign	ADJ	O	O	271
and	CCONJ	O	O	271
malignant	ADJ	O	O	271
disorders	NOUN	O	O	271
,	PUNCT	O	O	271
as	ADP	O	O	271
seen	VERB	O	O	271
in	ADP	O	O	271
358	NUM	O	O	271
Nigerians	PROPN	O	O	271
are	AUX	O	O	271
presented	VERB	O	O	271
.	PUNCT	O	O	271
Sensori	NOUN	O	O	272
-	PUNCT	O	O	272
motor	NOUN	O	O	272
neuropathy	NOUN	O	Disease	272
was	AUX	O	O	272
the	PRON	O	O	272
commonest	ADJ	O	O	272
presentation	NOUN	O	O	272
(	PUNCT	O	O	272
50%	NOUN	O	O	272
)	PUNCT	O	O	272
.	PUNCT	O	O	272
Guillain	NOUN	O	O	273
-	PUNCT	O	O	273
Barr	PROPN	O	O	273
syndrome	NOUN	O	O	273
was	AUX	O	O	273
the	PRON	O	O	273
commonest	ADJ	O	O	273
identifiable	ADJ	O	O	273
cause	VERB	O	O	273
(	PUNCT	O	O	273
15.6%	NOUN	O	O	273
)	PUNCT	O	O	273
,	PUNCT	O	O	273
accounting	VERB	O	O	273
for	ADP	O	O	273
half	NOUN	O	O	273
of	ADP	O	O	273
the	PRON	O	O	273
cases	NOUN	O	O	273
with	ADP	O	O	273
motor	NOUN	O	O	273
neuropathy	NOUN	O	Disease	273
.	PUNCT	O	O	273
Peripheral neuropathy	NOUN	O	Disease	274
due	ADJ	O	O	274
to	PART	O	O	274
nutritional	ADJ	O	O	274
deficiency	NOUN	O	O	274
of	ADP	O	O	274
thiamine	NOUN	O	Chemical	274
and	CCONJ	O	O	274
riboflavin	NOUN	O	O	274
was	AUX	O	O	274
common	ADJ	O	O	274
(	PUNCT	O	O	274
10.1%	NOUN	O	O	274
)	PUNCT	O	O	274
and	CCONJ	O	O	274
presented	VERB	O	O	274
mainly	ADV	O	O	274
as	ADP	O	O	274
sensory	ADJ	O	O	274
and	CCONJ	O	O	274
sensori	NOUN	O	O	274
-	PUNCT	O	O	274
motor	NOUN	O	O	274
neuropathy	NOUN	O	Disease	274
.	PUNCT	O	O	274
Diabetes mellitus	NOUN	O	Disease	275
was	AUX	O	O	275
the	PRON	O	O	275
major	ADJ	O	O	275
cause	VERB	O	O	275
of	ADP	O	O	275
autonomic	ADJ	O	O	275
neuropathy	NOUN	O	Disease	275
.	PUNCT	O	O	275
Isoniazid	PROPN	O	Chemical	276
was	AUX	O	O	276
the	PRON	O	O	276
most	ADV	O	O	276
frequent	ADJ	O	O	276
agent	NOUN	O	O	276
in	ADP	O	O	276
drug	NOUN	O	O	276
-	PUNCT	O	O	276
induced	VERB	O	O	276
neuropathy	NOUN	O	Disease	276
.	PUNCT	O	O	276
Migraine	NOUN	O	O	277
(	PUNCT	O	O	277
20%	NOUN	O	O	277
)	PUNCT	O	O	277
was	AUX	O	O	277
not	PART	O	O	277
an	PRON	O	O	277
uncommon	ADJ	O	O	277
cause	VERB	O	O	277
of	ADP	O	O	277
cranial	ADJ	O	O	277
neuropathy	NOUN	O	Disease	277
although	SCONJ	O	O	277
malignancies	NOUN	O	O	277
arising	VERB	O	O	277
from	ADP	O	O	277
the	PRON	O	O	277
reticuloendothelial	ADJ	O	O	277
system	NOUN	O	O	277
or	CCONJ	O	O	277
related	ADJ	O	O	277
structures	NOUN	O	O	277
of	ADP	O	O	277
the	PRON	O	O	277
head	NOUN	O	O	277
and	CCONJ	O	O	277
neck	NOUN	O	O	277
were	AUX	O	O	277
more	ADJ	O	O	277
frequent	ADJ	O	O	277
(	PUNCT	O	O	277
26%	NOUN	O	O	277
)	PUNCT	O	O	277
.	PUNCT	O	O	277
In	ADP	O	O	278
26.5%	NOUN	O	O	278
of	ADP	O	O	278
all	PRON	O	O	278
the	PRON	O	O	278
cases	NOUN	O	O	278
,	PUNCT	O	O	278
the	PRON	O	O	278
aetiology	NOUN	O	O	278
of	ADP	O	O	278
the	PRON	O	O	278
neuropathy	NOUN	O	Disease	278
was	AUX	O	O	278
undetermined	ADJ	O	O	278
.	PUNCT	O	O	278
Heredofamilial	NOUN	O	O	279
and	CCONJ	O	O	279
connective	ADJ	O	O	279
tissue	NOUN	O	O	279
disorders	NOUN	O	O	279
were	AUX	O	O	279
rare	ADJ	O	O	279
.	PUNCT	O	O	279
Some	PRON	O	O	280
of	ADP	O	O	280
the	PRON	O	O	280
factors	NOUN	O	O	280
related	ADJ	O	O	280
to	PART	O	O	280
the	PRON	O	O	280
clinical	ADJ	O	O	280
presentation	NOUN	O	O	280
and	CCONJ	O	O	280
pathogenesis	NOUN	O	O	280
of	ADP	O	O	280
the	PRON	O	O	280
neuropathies	NOUN	O	O	280
are	AUX	O	O	280
briefly	ADV	O	O	280
discussed	VERB	O	O	280
.	PUNCT	O	O	280
A	PRON	O	O	283
double	ADJ	O	O	283
-	PUNCT	O	O	283
blind	ADJ	O	Disease	283
study	VERB	O	O	283
of	ADP	O	O	283
the	PRON	O	O	283
efficacy	NOUN	O	O	283
and	CCONJ	O	O	283
safety	NOUN	O	O	283
of	ADP	O	O	283
dothiepin	NOUN	O	O	283
hydrochloride	NOUN	O	O	283
in	ADP	O	O	283
the	PRON	O	O	283
treatment	NOUN	O	O	283
of	ADP	O	O	283
major	ADJ	O	O	283
depressive	ADJ	O	Disease	283
disorder	NOUN	O	O	283
.	PUNCT	O	O	283
In	ADP	O	O	284
a	PRON	O	O	284
6-week	NOUN	O	O	284
double	ADJ	O	O	284
-	PUNCT	O	O	284
blind	ADJ	O	Disease	284
parallel	ADJ	O	O	284
treatment	NOUN	O	O	284
study	VERB	O	O	284
,	PUNCT	O	O	284
dothiepin	NOUN	O	O	284
and	CCONJ	O	O	284
amitriptyline	PROPN	O	Chemical	284
were	AUX	O	O	284
compared	VERB	O	O	284
to	PART	O	O	284
placebo	NOUN	O	O	284
in	ADP	O	O	284
the	PRON	O	O	284
treatment	NOUN	O	O	284
of	ADP	O	O	284
33	NUM	O	O	284
depressed	ADJ	O	O	284
outpatients	NOUN	O	O	284
.	PUNCT	O	O	284
Dothiepin	NOUN	O	O	285
and	CCONJ	O	O	285
amitriptyline	PROPN	O	Chemical	285
were	AUX	O	O	285
equally	ADV	O	O	285
effective	ADJ	O	O	285
in	ADP	O	O	285
alleviating	VERB	O	O	285
the	PRON	O	O	285
symptoms	NOUN	O	O	285
of	ADP	O	O	285
depressive	ADJ	O	Disease	285
illness	VERB	O	O	285
,	PUNCT	O	O	285
and	CCONJ	O	O	285
both	PRON	O	O	285
were	AUX	O	O	285
significantly	ADV	O	O	285
superior	PROPN	O	O	285
to	PART	O	O	285
placebo	NOUN	O	O	285
.	PUNCT	O	O	285
The	PRON	O	O	286
overall	ADV	O	O	286
incidence	NOUN	O	O	286
of	ADP	O	O	286
side	NOUN	O	O	286
effects	NOUN	O	O	286
and	CCONJ	O	O	286
the	PRON	O	O	286
frequency	NOUN	O	O	286
and	CCONJ	O	O	286
severity	NOUN	O	O	286
of	ADP	O	O	286
blurred	VERB	O	O	286
vision	PROPN	O	O	286
,	PUNCT	O	O	286
dry mouth	NOUN	O	Disease	286
,	PUNCT	O	O	286
and	CCONJ	O	O	286
drowsiness	NOUN	O	Disease	286
were	AUX	O	O	286
significantly	ADV	O	O	286
less	ADV	O	O	286
with	ADP	O	O	286
dothiepin	NOUN	O	O	286
than	ADP	O	O	286
with	ADP	O	O	286
amitriptyline	PROPN	O	Chemical	286
.	PUNCT	O	O	286
Dothiepin	NOUN	O	O	287
also	ADV	O	O	287
produced	VERB	O	O	287
fewer	ADJ	O	O	287
CNS	PROPN	O	O	287
and	CCONJ	O	O	287
cardiovascular	ADJ	O	O	287
effects	NOUN	O	O	287
.	PUNCT	O	O	287
Dothiepin	NOUN	O	O	288
thus	ADV	O	O	288
was	AUX	O	O	288
found	VERB	O	O	288
to	PART	O	O	288
be	AUX	O	O	288
an	PRON	O	O	288
effective	ADJ	O	O	288
antidepressant	NOUN	O	O	288
drug	NOUN	O	O	288
associated	VERB	O	O	288
with	ADP	O	O	288
fewer	ADJ	O	O	288
side	NOUN	O	O	288
effects	NOUN	O	O	288
than	ADP	O	O	288
amitriptyline	PROPN	O	Chemical	288
in	ADP	O	O	288
the	PRON	O	O	288
treatment	NOUN	O	O	288
of	ADP	O	O	288
depressed	ADJ	O	O	288
outpatients	NOUN	O	O	288
.	PUNCT	O	O	288
Behavioral	NOUN	O	O	291
effects	NOUN	O	O	291
of	ADP	O	O	291
diazepam	NOUN	O	Chemical	291
and	CCONJ	O	O	291
propranolol	NOUN	O	Chemical	291
in	ADP	O	O	291
patients	NOUN	O	O	291
with	ADP	O	O	291
panic	VERB	O	O	291
disorder	NOUN	O	O	291
and	CCONJ	O	O	291
agoraphobia	VERB	O	O	291
.	PUNCT	O	O	291
The	PRON	O	O	292
effects	NOUN	O	O	292
of	ADP	O	O	292
oral	ADJ	O	O	292
doses	NOUN	O	O	292
of	ADP	O	O	292
diazepam	NOUN	O	Chemical	292
(	PUNCT	O	O	292
single	ADJ	O	O	292
dose	NOUN	O	O	292
of	ADP	O	O	292
10	NUM	O	O	292
mg	VERB	O	O	292
and	CCONJ	O	O	292
a	PRON	O	O	292
median	ADJ	O	O	292
dose	NOUN	O	O	292
of	ADP	O	O	292
30	NUM	O	O	292
mg	VERB	O	O	292
/	PUNCT	O	O	292
day	NOUN	O	O	292
for	ADP	O	O	292
2	X	O	O	292
weeks	NOUN	O	O	292
)	PUNCT	O	O	292
and	CCONJ	O	O	292
propranolol	NOUN	O	Chemical	292
(	PUNCT	O	O	292
single	ADJ	O	O	292
dose	NOUN	O	O	292
of	ADP	O	O	292
80	NUM	O	O	292
mg	VERB	O	O	292
and	CCONJ	O	O	292
a	PRON	O	O	292
median	ADJ	O	O	292
dose	NOUN	O	O	292
of	ADP	O	O	292
240	NUM	O	O	292
mg	VERB	O	O	292
/	PUNCT	O	O	292
day	NOUN	O	O	292
for	ADP	O	O	292
2	X	O	O	292
weeks	NOUN	O	O	292
)	PUNCT	O	O	292
on	ADP	O	O	292
psychological	ADJ	O	O	292
performance	NOUN	O	O	292
of	ADP	O	O	292
patients	NOUN	O	O	292
with	ADP	O	O	292
panic	VERB	O	O	292
disorders	NOUN	O	O	292
and	CCONJ	O	O	292
agoraphobia	VERB	O	O	292
were	AUX	O	O	292
investigated	VERB	O	O	292
in	ADP	O	O	292
a	PRON	O	O	292
double	ADJ	O	O	292
-	PUNCT	O	O	292
blind	ADJ	O	Disease	292
,	PUNCT	O	O	292
randomized	VERB	O	O	292
and	CCONJ	O	O	292
crossover	NOUN	O	O	292
design	NOUN	O	O	292
.	PUNCT	O	O	292
Both	PRON	O	O	293
drugs	NOUN	O	O	293
impaired	VERB	O	O	293
immediate	ADJ	O	O	293
free	ADJ	O	O	293
recall	VERB	O	O	293
but	CCONJ	O	O	293
the	PRON	O	O	293
decrease	VERB	O	O	293
was	AUX	O	O	293
greater	ADJ	O	O	293
for	ADP	O	O	293
diazepam	NOUN	O	Chemical	293
than	ADP	O	O	293
propranolol	NOUN	O	Chemical	293
.	PUNCT	O	O	293
Delayed	VERB	O	O	294
free	ADJ	O	O	294
recall	VERB	O	O	294
was	AUX	O	O	294
also	ADV	O	O	294
impaired	VERB	O	O	294
but	CCONJ	O	O	294
the	PRON	O	O	294
two	NUM	O	O	294
drugs	NOUN	O	O	294
did	VERB	O	O	294
not	PART	O	O	294
differ	VERB	O	O	294
.	PUNCT	O	O	294
Patients	NOUN	O	O	295
tapped	VERB	O	O	295
faster	ADV	O	O	295
after	ADP	O	O	295
propranolol	NOUN	O	Chemical	295
than	ADP	O	O	295
diazepam	NOUN	O	Chemical	295
and	CCONJ	O	O	295
they	PRON	O	O	295
were	AUX	O	O	295
more	ADJ	O	O	295
sedated	VERB	O	O	295
after	ADP	O	O	295
diazepam	NOUN	O	Chemical	295
than	ADP	O	O	295
propranolol	NOUN	O	Chemical	295
.	PUNCT	O	O	295
Accumulation	NOUN	O	O	296
of	ADP	O	O	296
drugs	NOUN	O	O	296
was	AUX	O	O	296
not	PART	O	O	296
reflected	VERB	O	O	296
in	ADP	O	O	296
prolonged	VERB	O	O	296
behavioral	ADJ	O	O	296
impairment	NOUN	O	O	296
.	PUNCT	O	O	296
Effect	VERB	O	O	299
of	ADP	O	O	299
aspirin	NOUN	O	Chemical	299
on	ADP	O	O	299
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	NOUN	O	O	299
-	PUNCT	O	O	299
induced	VERB	O	O	299
epithelial	ADJ	O	O	299
proliferation	NOUN	O	O	299
in	ADP	O	O	299
the	PRON	O	O	299
urinary	ADJ	O	O	299
bladder	NOUN	O	O	299
and	CCONJ	O	O	299
forestomach	PROPN	O	O	299
of	ADP	O	O	299
the	PRON	O	O	299
rat	NOUN	O	O	299
.	PUNCT	O	O	299
The	PRON	O	O	300
co	NOUN	O	O	300
-	PUNCT	O	O	300
administration	NOUN	O	O	300
of	ADP	O	O	300
aspirin	NOUN	O	Chemical	300
with	ADP	O	O	300
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	NOUN	O	O	300
(	PUNCT	O	O	300
FANFT	PROPN	O	O	300
)	PUNCT	O	O	300
to	PART	O	O	300
rats	NOUN	O	O	300
resulted	VERB	O	O	300
in	ADP	O	O	300
a	PRON	O	O	300
reduced	VERB	O	O	300
incidence	NOUN	O	O	300
of	ADP	O	O	300
FANFT	PROPN	O	O	300
-	PUNCT	O	O	300
induced	VERB	O	O	300
bladder carcinomas	NOUN	O	Disease	300
but	CCONJ	O	O	300
a	PRON	O	O	300
concomitant	ADJ	O	O	300
induction	NOUN	O	O	300
of	ADP	O	O	300
forestomach tumors	NOUN	O	Disease	300
.	PUNCT	O	O	300
An	PRON	O	O	301
autoradiographic	ADV	O	O	301
study	VERB	O	O	301
was	AUX	O	O	301
performed	VERB	O	O	301
on	ADP	O	O	301
male	NOUN	O	O	301
F-344	NOUN	O	O	301
rats	NOUN	O	O	301
fed	VERB	O	O	301
diet	PROPN	O	O	301
containing	VERB	O	O	301
FANFT	PROPN	O	O	301
at	ADP	O	O	301
a	PRON	O	O	301
level	VERB	O	O	301
of	ADP	O	O	301
0.2%	NOUN	O	O	301
and/or	CCONJ	O	O	301
aspirin	NOUN	O	Chemical	301
at	ADP	O	O	301
a	PRON	O	O	301
level	VERB	O	O	301
of	ADP	O	O	301
0.5%	NOUN	O	O	301
to	PART	O	O	301
evaluate	VERB	O	O	301
the	PRON	O	O	301
effect	VERB	O	O	301
of	ADP	O	O	301
aspirin	NOUN	O	Chemical	301
on	ADP	O	O	301
the	PRON	O	O	301
increased	VERB	O	O	301
cell	NOUN	O	O	301
proliferation	NOUN	O	O	301
induced	VERB	O	O	301
by	ADP	O	O	301
FANFT	PROPN	O	O	301
in	ADP	O	O	301
the	PRON	O	O	301
forestomach	PROPN	O	O	301
and	CCONJ	O	O	301
bladder	NOUN	O	O	301
.	PUNCT	O	O	301
FANFT	PROPN	O	O	302
-	PUNCT	O	O	302
induced	VERB	O	O	302
cell	NOUN	O	O	302
proliferation	NOUN	O	O	302
in	ADP	O	O	302
the	PRON	O	O	302
bladder	NOUN	O	O	302
was	AUX	O	O	302
significantly	ADV	O	O	302
suppressed	VERB	O	O	302
by	ADP	O	O	302
aspirin	NOUN	O	Chemical	302
co	NOUN	O	O	302
-	PUNCT	O	O	302
administration	NOUN	O	O	302
after	ADP	O	O	302
4	NUM	O	O	302
weeks	NOUN	O	O	302
but	CCONJ	O	O	302
not	PART	O	O	302
after	ADP	O	O	302
12	NUM	O	O	302
weeks	NOUN	O	O	302
.	PUNCT	O	O	302
In	ADP	O	O	303
the	PRON	O	O	303
forestomach	PROPN	O	O	303
,	PUNCT	O	O	303
and	CCONJ	O	O	303
also	ADV	O	O	303
in	ADP	O	O	303
the	PRON	O	O	303
liver	NOUN	O	O	303
,	PUNCT	O	O	303
aspirin	NOUN	O	Chemical	303
did	VERB	O	O	303
not	PART	O	O	303
affect	VERB	O	O	303
the	PRON	O	O	303
FANFT	PROPN	O	O	303
-	PUNCT	O	O	303
induced	VERB	O	O	303
increase	VERB	O	O	303
in	ADP	O	O	303
labeling	NOUN	O	O	303
index	NOUN	O	O	303
.	PUNCT	O	O	303
The	PRON	O	O	304
present	NOUN	O	O	304
results	VERB	O	O	304
are	AUX	O	O	304
consistent	ADJ	O	O	304
with	ADP	O	O	304
the	PRON	O	O	304
carcinogenicity	NOUN	O	O	304
experiment	NOUN	O	O	304
suggesting	VERB	O	O	304
that	SCONJ	O	O	304
different	ADJ	O	O	304
mechanisms	NOUN	O	O	304
are	AUX	O	O	304
involved	VERB	O	O	304
in	ADP	O	O	304
FANFT	PROPN	O	O	304
carcinogenesis	NOUN	O	Disease	304
in	ADP	O	O	304
the	PRON	O	O	304
bladder	NOUN	O	O	304
and	CCONJ	O	O	304
forestomach	PROPN	O	O	304
,	PUNCT	O	O	304
and	CCONJ	O	O	304
that	SCONJ	O	O	304
aspirin	NOUN	O	Chemical	304
's	AUX	O	O	304
effect	VERB	O	O	304
on	ADP	O	O	304
FANFT	PROPN	O	O	304
in	ADP	O	O	304
the	PRON	O	O	304
forestomach	PROPN	O	O	304
is	AUX	O	O	304
not	PART	O	O	304
due	ADJ	O	O	304
to	PART	O	O	304
an	PRON	O	O	304
irritant	NOUN	O	O	304
effect	VERB	O	O	304
associated	VERB	O	O	304
with	ADP	O	O	304
increased	VERB	O	O	304
cell	NOUN	O	O	304
proliferation	NOUN	O	O	304
.	PUNCT	O	O	304
Also	ADV	O	O	305
,	PUNCT	O	O	305
there	ADV	O	O	305
appears	VERB	O	O	305
to	PART	O	O	305
be	AUX	O	O	305
an	PRON	O	O	305
adaptation	NOUN	O	O	305
by	ADP	O	O	305
the	PRON	O	O	305
rats	NOUN	O	O	305
to	PART	O	O	305
the	PRON	O	O	305
chronic	ADJ	O	O	305
ingestion	NOUN	O	O	305
of	ADP	O	O	305
aspirin	NOUN	O	Chemical	305
.	PUNCT	O	O	305
Provocation	NOUN	O	O	308
of	ADP	O	O	308
postural	ADJ	O	O	308
hypotension	NOUN	O	Disease	308
by	ADP	O	O	308
nitroglycerin	PROPN	O	Chemical	308
in	ADP	O	O	308
diabetic	ADJ	O	Disease	308
autonomic	ADJ	O	O	308
neuropathy	NOUN	O	Disease	308
?	PUNCT	O	O	308
The	PRON	O	O	309
effect	VERB	O	O	309
of	ADP	O	O	309
nitroglycerin	PROPN	O	Chemical	309
on	ADP	O	O	309
heart	NOUN	O	O	309
rate	NOUN	O	O	309
and	CCONJ	O	O	309
systolic	ADV	O	O	309
blood	NOUN	O	O	309
pressure	NOUN	O	O	309
was	AUX	O	O	309
compared	VERB	O	O	309
in	ADP	O	O	309
5	NUM	O	O	309
normal	ADJ	O	O	309
subjects	NOUN	O	O	309
,	PUNCT	O	O	309
12	NUM	O	O	309
diabetic	ADJ	O	Disease	309
subjects	NOUN	O	O	309
without	ADP	O	O	309
autonomic	ADJ	O	O	309
neuropathy	NOUN	O	Disease	309
,	PUNCT	O	O	309
and	CCONJ	O	O	309
5	NUM	O	O	309
diabetic	ADJ	O	Disease	309
subjects	NOUN	O	O	309
with	ADP	O	O	309
autonomic	ADJ	O	O	309
neuropathy	NOUN	O	Disease	309
.	PUNCT	O	O	309
The	PRON	O	O	310
magnitude	NOUN	O	O	310
and	CCONJ	O	O	310
time	NOUN	O	O	310
course	NOUN	O	O	310
of	ADP	O	O	310
the	PRON	O	O	310
increase	VERB	O	O	310
in	ADP	O	O	310
heart	NOUN	O	O	310
rate	NOUN	O	O	310
and	CCONJ	O	O	310
the	PRON	O	O	310
decrease	VERB	O	O	310
in	ADP	O	O	310
systolic	ADV	O	O	310
blood	NOUN	O	O	310
pressure	NOUN	O	O	310
after	ADP	O	O	310
nitroglycerin	PROPN	O	Chemical	310
were	AUX	O	O	310
similar	ADJ	O	O	310
in	ADP	O	O	310
the	PRON	O	O	310
normal	ADJ	O	O	310
and	CCONJ	O	O	310
diabetic	ADJ	O	Disease	310
subjects	NOUN	O	O	310
without	ADP	O	O	310
autonomic	ADJ	O	O	310
neuropathy	NOUN	O	Disease	310
,	PUNCT	O	O	310
whereas	SCONJ	O	O	310
a	PRON	O	O	310
lesser	ADJ	O	O	310
increase	VERB	O	O	310
in	ADP	O	O	310
heart	NOUN	O	O	310
rate	NOUN	O	O	310
and	CCONJ	O	O	310
a	PRON	O	O	310
greater	ADJ	O	O	310
decrease	VERB	O	O	310
in	ADP	O	O	310
systolic	ADV	O	O	310
blood	NOUN	O	O	310
pressure	NOUN	O	O	310
occurred	VERB	O	O	310
in	ADP	O	O	310
the	PRON	O	O	310
diabetic	ADJ	O	Disease	310
subjects	NOUN	O	O	310
with	ADP	O	O	310
autonomic	ADJ	O	O	310
neuropathy	NOUN	O	Disease	310
.	PUNCT	O	O	310
It	PRON	O	O	311
is	AUX	O	O	311
therefore	ADV	O	O	311
suggested	VERB	O	O	311
that	SCONJ	O	O	311
caution	NOUN	O	O	311
should	AUX	O	O	311
be	AUX	O	O	311
exercised	VERB	O	O	311
when	SCONJ	O	O	311
prescribing	VERB	O	O	311
vasodilator	NOUN	O	O	311
drugs	NOUN	O	O	311
in	ADP	O	O	311
diabetic	ADJ	O	Disease	311
patients	NOUN	O	O	311
,	PUNCT	O	O	311
particularly	ADV	O	O	311
those	PRON	O	O	311
with	ADP	O	O	311
autonomic	ADJ	O	O	311
neuropathy	NOUN	O	Disease	311
.	PUNCT	O	O	311
Characterization	NOUN	O	O	314
of	ADP	O	O	314
estrogen	PROPN	O	Chemical	314
-	PUNCT	O	O	314
induced	VERB	O	O	314
adenohypophyseal	VERB	O	O	314
tumors	NOUN	O	Disease	314
in	ADP	O	O	314
the	PRON	O	O	314
Fischer	PROPN	O	O	314
344	NUM	O	O	314
rat	NOUN	O	O	314
.	PUNCT	O	O	314
Pituitary	NOUN	O	O	315
tumors	NOUN	O	Disease	315
were	AUX	O	O	315
induced	VERB	O	O	315
in	ADP	O	O	315
F344	PROPN	O	O	315
female	ADJ	O	O	315
rats	NOUN	O	O	315
by	ADP	O	O	315
chronic	ADJ	O	O	315
treatment	NOUN	O	O	315
with	ADP	O	O	315
diethylstilbestrol	NOUN	O	O	315
(	PUNCT	O	O	315
DES	PROPN	O	O	315
,	PUNCT	O	O	315
8	NUM	O	O	315
-	PUNCT	O	O	315
10	NUM	O	O	315
mg	VERB	O	O	315
)	PUNCT	O	O	315
implanted	VERB	O	O	315
subcutaneously	ADV	O	O	315
in	ADP	O	O	315
silastic	ADJ	O	O	315
capsules	NOUN	O	O	315
.	PUNCT	O	O	315
Over	ADP	O	O	316
a	PRON	O	O	316
range	VERB	O	O	316
of	ADP	O	O	316
1	X	O	O	316
-	PUNCT	O	O	316
150	NUM	O	O	316
days	NOUN	O	O	316
of	ADP	O	O	316
DES	PROPN	O	O	316
treatment	NOUN	O	O	316
,	PUNCT	O	O	316
pairs	NOUN	O	O	316
of	ADP	O	O	316
control	VERB	O	O	316
and	CCONJ	O	O	316
DES	PROPN	O	O	316
-	PUNCT	O	O	316
treated	VERB	O	O	316
rats	NOUN	O	O	316
were	AUX	O	O	316
sacrificed	VERB	O	O	316
,	PUNCT	O	O	316
and	CCONJ	O	O	316
their	PRON	O	O	316
pituitaries	NOUN	O	O	316
dissociated	VERB	O	O	316
enzymatically	ADV	O	O	316
into	ADP	O	O	316
single	ADJ	O	O	316
-	PUNCT	O	O	316
cell	NOUN	O	O	316
preparations	NOUN	O	O	316
.	PUNCT	O	O	316
The	PRON	O	O	317
cell	NOUN	O	O	317
populations	NOUN	O	O	317
were	AUX	O	O	317
examined	VERB	O	O	317
regarding	VERB	O	O	317
total	ADJ	O	O	317
cell	NOUN	O	O	317
recovery	NOUN	O	O	317
correlated	VERB	O	O	317
with	ADP	O	O	317
gland	NOUN	O	O	317
weight	NOUN	O	O	317
,	PUNCT	O	O	317
intracellular	ADJ	O	O	317
prolactin	PROPN	O	O	317
(	PUNCT	O	O	317
PRL	NOUN	O	Chemical	317
)	PUNCT	O	O	317
content	NOUN	O	O	317
and	CCONJ	O	O	317
subsequent	ADJ	O	O	317
release	NOUN	O	O	317
in	ADP	O	O	317
primary	NOUN	O	O	317
culture	NOUN	O	O	317
,	PUNCT	O	O	317
immunocytochemical	ADJ	O	O	317
PRL	NOUN	O	Chemical	317
staining	VERB	O	O	317
,	PUNCT	O	O	317
density	NOUN	O	O	317
and/or	CCONJ	O	O	317
size	NOUN	O	O	317
alterations	NOUN	O	O	317
via	ADP	O	O	317
separation	NOUN	O	O	317
on	ADP	O	O	317
Ficoll	NOUN	O	O	317
-	PUNCT	O	O	317
Hypaque	NOUN	O	Chemical	317
and	CCONJ	O	O	317
by	ADP	O	O	317
unit	NOUN	O	O	317
gravity	NOUN	O	O	317
sedimentation	NOUN	O	O	317
,	PUNCT	O	O	317
and	CCONJ	O	O	317
cell	NOUN	O	O	317
cycle	PROPN	O	O	317
analysis	NOUN	O	O	317
,	PUNCT	O	O	317
after	ADP	O	O	317
acriflavine	PROPN	O	O	317
DNA	NOUN	O	O	317
staining	VERB	O	O	317
,	PUNCT	O	O	317
by	ADP	O	O	317
laser	NOUN	O	O	317
flow	NOUN	O	O	317
cytometry	NOUN	O	O	317
.	PUNCT	O	O	317
Total	ADJ	O	O	318
cell	NOUN	O	O	318
yields	VERB	O	O	318
from	ADP	O	O	318
DES	PROPN	O	O	318
-	PUNCT	O	O	318
treated	VERB	O	O	318
pituitaries	NOUN	O	O	318
increased	VERB	O	O	318
from	ADP	O	O	318
1.3	NUM	O	O	318
times	NOUN	O	O	318
control	VERB	O	O	318
yields	VERB	O	O	318
at	ADP	O	O	318
8	NUM	O	O	318
days	NOUN	O	O	318
of	ADP	O	O	318
treatment	NOUN	O	O	318
to	PART	O	O	318
58.9	NUM	O	O	318
times	NOUN	O	O	318
control	VERB	O	O	318
values	NOUN	O	O	318
by	ADP	O	O	318
day	NOUN	O	O	318
150	NUM	O	O	318
.	PUNCT	O	O	318
Intracellular	PROPN	O	O	319
PRL	NOUN	O	Chemical	319
content	NOUN	O	O	319
ranged	VERB	O	O	319
from	ADP	O	O	319
1.9	NUM	O	O	319
to	PART	O	O	319
9.4	NUM	O	O	319
times	NOUN	O	O	319
control	VERB	O	O	319
levels	NOUN	O	O	319
,	PUNCT	O	O	319
and	CCONJ	O	O	319
PRL	NOUN	O	Chemical	319
release	NOUN	O	O	319
in	ADP	O	O	319
vitro	X	O	O	319
was	AUX	O	O	319
significantly	ADV	O	O	319
and	CCONJ	O	O	319
consistently	ADV	O	O	319
higher	ADJ	O	O	319
than	ADP	O	O	319
controls	VERB	O	O	319
,	PUNCT	O	O	319
after	ADP	O	O	319
at	ADP	O	O	319
least	ADJ	O	O	319
8	NUM	O	O	319
days	NOUN	O	O	319
of	ADP	O	O	319
DES	PROPN	O	O	319
exposure	NOUN	O	O	319
.	PUNCT	O	O	319
Beyond	ADP	O	O	320
8	NUM	O	O	320
days	NOUN	O	O	320
of	ADP	O	O	320
DES	PROPN	O	O	320
exposure	NOUN	O	O	320
,	PUNCT	O	O	320
the	PRON	O	O	320
immunochemically	ADV	O	O	320
PRL	NOUN	O	Chemical	320
-	PUNCT	O	O	320
positive	ADJ	O	O	320
proportion	NOUN	O	O	320
of	ADP	O	O	320
cells	NOUN	O	O	320
increased	VERB	O	O	320
to	PART	O	O	320
over	ADP	O	O	320
50%	NOUN	O	O	320
of	ADP	O	O	320
the	PRON	O	O	320
total	ADJ	O	O	320
population	NOUN	O	O	320
.	PUNCT	O	O	320
All	PRON	O	O	321
these	PRON	O	O	321
effects	NOUN	O	O	321
of	ADP	O	O	321
DES	PROPN	O	O	321
were	AUX	O	O	321
more	ADJ	O	O	321
pronounced	VERB	O	O	321
among	ADP	O	O	321
previously	ADV	O	O	321
ovariectomized	VERB	O	O	321
animals	NOUN	O	O	321
.	PUNCT	O	O	321
The	PRON	O	O	322
data	NOUN	O	O	322
extend	VERB	O	O	322
the	PRON	O	O	322
findings	NOUN	O	O	322
of	ADP	O	O	322
other	ADJ	O	O	322
investigators	NOUN	O	O	322
,	PUNCT	O	O	322
further	ADV	O	O	322
establishing	VERB	O	O	322
the	PRON	O	O	322
DES	PROPN	O	O	322
-	PUNCT	O	O	322
induced	VERB	O	O	322
tumor	NOUN	O	Disease	322
as	ADP	O	O	322
a	PRON	O	O	322
model	NOUN	O	O	322
for	ADP	O	O	322
study	VERB	O	O	322
of	ADP	O	O	322
PRL	NOUN	O	Chemical	322
cellular	NOUN	O	O	322
control	VERB	O	O	322
mechanisms	NOUN	O	O	322
.	PUNCT	O	O	322
Triamterene	PROPN	O	O	325
nephrolithiasis	NOUN	O	Disease	325
complicating	VERB	O	O	325
dyazide	PROPN	O	O	325
therapy	NOUN	O	O	325
.	PUNCT	O	O	325
A	PRON	O	O	326
case	NOUN	O	O	326
of	ADP	O	O	326
triamterene	PROPN	O	O	326
nephrolithiasis	NOUN	O	Disease	326
is	AUX	O	O	326
reported	VERB	O	O	326
in	ADP	O	O	326
a	PRON	O	O	326
man	NOUN	O	O	326
after	ADP	O	O	326
4	NUM	O	O	326
years	NOUN	O	O	326
of	ADP	O	O	326
hydrochlorothiazide	ADV	O	Chemical	326
-	PUNCT	O	O	326
triamterene	PROPN	O	O	326
therapy	NOUN	O	O	326
for	ADP	O	O	326
hypertension	NOUN	O	Disease	326
.	PUNCT	O	O	326
The	PRON	O	O	327
stone	PROPN	O	O	327
passed	VERB	O	O	327
spontaneously	ADV	O	O	327
and	CCONJ	O	O	327
was	AUX	O	O	327
found	VERB	O	O	327
to	PART	O	O	327
contain	VERB	O	O	327
a	PRON	O	O	327
triamterene	PROPN	O	O	327
metabolite	NOUN	O	O	327
admixed	VERB	O	O	327
with	ADP	O	O	327
uric acid	NOUN	O	Chemical	327
salts	NOUN	O	O	327
.	PUNCT	O	O	327
Factors	NOUN	O	O	328
affecting	VERB	O	O	328
triamterene	PROPN	O	O	328
nephrolithiasis	NOUN	O	Disease	328
are	AUX	O	O	328
discussed	VERB	O	O	328
and	CCONJ	O	O	328
2	X	O	O	328
previously	ADV	O	O	328
reported	VERB	O	O	328
cases	NOUN	O	O	328
are	AUX	O	O	328
reviewed	VERB	O	O	328
.	PUNCT	O	O	328
Metabolic	NOUN	O	O	331
involvement	NOUN	O	O	331
in	ADP	O	O	331
adriamycin	PROPN	O	Chemical	331
cardiotoxicity	NOUN	O	Disease	331
.	PUNCT	O	O	331
The	PRON	O	O	332
cardiotoxic	ADJ	O	Disease	332
effects	NOUN	O	O	332
of	ADP	O	O	332
adriamycin	PROPN	O	Chemical	332
were	AUX	O	O	332
studied	VERB	O	O	332
in	ADP	O	O	332
mammalian	ADJ	O	O	332
myocardial	ADJ	O	O	332
cells	NOUN	O	O	332
in	ADP	O	O	332
culture	NOUN	O	O	332
as	ADP	O	O	332
a	PRON	O	O	332
model	NOUN	O	O	332
system	NOUN	O	O	332
.	PUNCT	O	O	332
Adriamycin	PROPN	O	Chemical	333
inhibited	VERB	O	O	333
cell	NOUN	O	O	333
growth	NOUN	O	O	333
and	CCONJ	O	O	333
the	PRON	O	O	333
rhythmic	ADJ	O	O	333
contractions	NOUN	O	O	333
characteristic	ADJ	O	O	333
of	ADP	O	O	333
myocardial	ADJ	O	O	333
cells	NOUN	O	O	333
in	ADP	O	O	333
culture	NOUN	O	O	333
.	PUNCT	O	O	333
A	PRON	O	O	334
possible	ADJ	O	O	334
involvement	NOUN	O	O	334
of	ADP	O	O	334
energy	PROPN	O	O	334
metabolism	NOUN	O	O	334
was	AUX	O	O	334
suggested	VERB	O	O	334
previously	ADV	O	O	334
,	PUNCT	O	O	334
and	CCONJ	O	O	334
in	ADP	O	O	334
this	PRON	O	O	334
study	VERB	O	O	334
the	PRON	O	O	334
adenylate	ADJ	O	O	334
energy	PROPN	O	O	334
charge	NOUN	O	O	334
and	CCONJ	O	O	334
phosphorylcreatine	PROPN	O	O	334
mole	NOUN	O	O	334
fraction	NOUN	O	O	334
were	AUX	O	O	334
determined	VERB	O	O	334
in	ADP	O	O	334
the	PRON	O	O	334
adriamycin	PROPN	O	Chemical	334
-	PUNCT	O	O	334
treated	VERB	O	O	334
cells	NOUN	O	O	334
.	PUNCT	O	O	334
The	PRON	O	O	335
adenylate	ADJ	O	O	335
energy	PROPN	O	O	335
charge	NOUN	O	O	335
was	AUX	O	O	335
found	VERB	O	O	335
to	PART	O	O	335
be	AUX	O	O	335
significantly	ADV	O	O	335
decreased	VERB	O	O	335
,	PUNCT	O	O	335
while	SCONJ	O	O	335
the	PRON	O	O	335
phophorylcreatine	PROPN	O	O	335
mole	NOUN	O	O	335
fraction	NOUN	O	O	335
was	AUX	O	O	335
unchanged	ADJ	O	O	335
.	PUNCT	O	O	335
Such	ADJ	O	O	336
disparity	NOUN	O	O	336
suggests	VERB	O	O	336
an	PRON	O	O	336
inhibition	NOUN	O	O	336
of	ADP	O	O	336
creatine	PROPN	O	Chemical	336
phosphokinase	NOUN	O	O	336
.	PUNCT	O	O	336
The	PRON	O	O	337
addition	NOUN	O	O	337
of	ADP	O	O	337
1	X	O	O	337
mM	ADJ	O	O	337
adenosine	PROPN	O	Chemical	337
to	PART	O	O	337
the	PRON	O	O	337
myocardial	ADJ	O	O	337
cell	NOUN	O	O	337
cultures	NOUN	O	O	337
markedly	ADV	O	O	337
increases	VERB	O	O	337
the	PRON	O	O	337
ATP	PROPN	O	Chemical	337
concentration	NOUN	O	O	337
through	ADP	O	O	337
a	PRON	O	O	337
pathway	NOUN	O	O	337
reportedly	ADV	O	O	337
leading	VERB	O	O	337
to	PART	O	O	337
a	PRON	O	O	337
compartmentalized	VERB	O	O	337
ATP	PROPN	O	Chemical	337
pool	NOUN	O	O	337
.	PUNCT	O	O	337
In	ADP	O	O	338
the	PRON	O	O	338
adriamycin	PROPN	O	Chemical	338
-	PUNCT	O	O	338
treated	VERB	O	O	338
cells	NOUN	O	O	338
,	PUNCT	O	O	338
the	PRON	O	O	338
addition	NOUN	O	O	338
of	ADP	O	O	338
adenosine	PROPN	O	Chemical	338
increased	VERB	O	O	338
the	PRON	O	O	338
adenylate	ADJ	O	O	338
charge	NOUN	O	O	338
and	CCONJ	O	O	338
,	PUNCT	O	O	338
concomitant	ADJ	O	O	338
with	ADP	O	O	338
this	PRON	O	O	338
inrcease	PROPN	O	O	338
,	PUNCT	O	O	338
the	PRON	O	O	338
cells	NOUN	O	O	338
'	PUNCT	O	O	338
functional	ADJ	O	O	338
integrity	NOUN	O	O	338
,	PUNCT	O	O	338
in	ADP	O	O	338
terms	NOUN	O	O	338
of	ADP	O	O	338
percentage	NOUN	O	O	338
of	ADP	O	O	338
beating	VERB	O	O	338
cells	NOUN	O	O	338
and	CCONJ	O	O	338
rate	NOUN	O	O	338
of	ADP	O	O	338
contractions	NOUN	O	O	338
,	PUNCT	O	O	338
was	AUX	O	O	338
maintained	VERB	O	O	338
.	PUNCT	O	O	338
Age	NOUN	O	O	341
-	PUNCT	O	O	341
dependent	ADJ	O	O	341
sensitivity	NOUN	O	O	341
of	ADP	O	O	341
the	PRON	O	O	341
rat	NOUN	O	O	341
to	PART	O	O	341
neurotoxic	ADJ	O	Disease	341
effects	NOUN	O	O	341
of	ADP	O	O	341
streptomycin	PROPN	O	Chemical	341
.	PUNCT	O	O	341
Streptomycin	PROPN	O	Chemical	342
sulfate	NOUN	O	O	342
(	PUNCT	O	O	342
300	NUM	O	O	342
mg	VERB	O	O	342
/	PUNCT	O	O	342
kg	VERB	O	O	342
s.c	PROPN	O	O	342
.	PUNCT	O	O	342
)	PUNCT	O	O	342
was	AUX	O	O	342
injected	VERB	O	O	342
for	ADP	O	O	342
various	ADJ	O	O	342
periods	NOUN	O	O	342
into	ADP	O	O	342
preweanling	VERB	O	O	342
rats	NOUN	O	O	342
and	CCONJ	O	O	342
for	ADP	O	O	342
3	X	O	O	342
weeks	NOUN	O	O	342
into	ADP	O	O	342
weanling	VERB	O	O	342
rats	NOUN	O	O	342
.	PUNCT	O	O	342
Abnormal	ADJ	O	O	343
movements	NOUN	O	O	343
and	CCONJ	O	O	343
deafness	NOUN	O	O	343
occurred	VERB	O	O	343
only	ADV	O	O	343
in	ADP	O	O	343
rats	NOUN	O	O	343
treated	VERB	O	O	343
during	ADP	O	O	343
the	PRON	O	O	343
preweaning	VERB	O	O	343
period	NOUN	O	O	343
;	PUNCT	O	O	343
within	ADP	O	O	343
this	PRON	O	O	343
period	NOUN	O	O	343
the	PRON	O	O	343
greatest	ADJ	O	O	343
sensitivities	NOUN	O	O	343
for	ADP	O	O	343
these	PRON	O	O	343
abnormalities	NOUN	O	O	343
occurred	VERB	O	O	343
from	ADP	O	O	343
2	X	O	O	343
to	PART	O	O	343
11	NUM	O	O	343
-	PUNCT	O	O	343
17	NUM	O	O	343
and	CCONJ	O	O	343
5	NUM	O	O	343
to	PART	O	O	343
11	NUM	O	O	343
days	NOUN	O	O	343
of	ADP	O	O	343
age	NOUN	O	O	343
,	PUNCT	O	O	343
respectively	ADV	O	O	343
,	PUNCT	O	O	343
indicating	VERB	O	O	343
that	SCONJ	O	O	343
the	PRON	O	O	343
cochlea	NOUN	O	O	343
is	AUX	O	O	343
more	ADJ	O	O	343
sensitive	ADJ	O	O	343
to	PART	O	O	343
streptomycin	PROPN	O	Chemical	343
than	ADP	O	O	343
the	PRON	O	O	343
site	NOUN	O	O	343
(	PUNCT	O	O	343
vestibular	ADJ	O	O	343
or	CCONJ	O	O	343
central	ADJ	O	O	343
)	PUNCT	O	O	343
responsible	ADJ	O	O	343
for	ADP	O	O	343
the	PRON	O	O	343
dyskinesias	PROPN	O	Disease	343
.	PUNCT	O	O	343
Crescentic	NOUN	O	O	346
fibrillary	NOUN	O	O	346
glomerulonephritis	NOUN	O	Disease	346
associated	VERB	O	O	346
with	ADP	O	O	346
intermittent	ADJ	O	O	346
rifampin	ADV	O	Chemical	346
therapy	NOUN	O	O	346
for	ADP	O	O	346
pulmonary	ADJ	O	O	346
tuberculosis	NOUN	O	Disease	346
.	PUNCT	O	O	346
This	PRON	O	O	347
case	NOUN	O	O	347
study	VERB	O	O	347
reveals	VERB	O	O	347
an	PRON	O	O	347
unusual	ADJ	O	O	347
finding	VERB	O	O	347
of	ADP	O	O	347
rapidly	ADV	O	O	347
proliferative	ADJ	O	O	347
crescentic	ADJ	O	O	347
glomerulonephritis	NOUN	O	Disease	347
in	ADP	O	O	347
a	PRON	O	O	347
patient	NOUN	O	O	347
treated	VERB	O	O	347
with	ADP	O	O	347
rifampin	ADV	O	Chemical	347
who	PRON	O	O	347
had	VERB	O	O	347
no	PRON	O	O	347
other	ADJ	O	O	347
identifiable	ADJ	O	O	347
causes	VERB	O	O	347
for	ADP	O	O	347
developing	VERB	O	O	347
this	PRON	O	O	347
disease	PROPN	O	O	347
.	PUNCT	O	O	347
This	PRON	O	O	348
patient	NOUN	O	O	348
underwent	VERB	O	O	348
a	PRON	O	O	348
10-month	NOUN	O	O	348
regimen	NOUN	O	O	348
of	ADP	O	O	348
rifampin	ADV	O	Chemical	348
and	CCONJ	O	O	348
isoniazid	NOUN	O	Chemical	348
for	ADP	O	O	348
pulmonary	ADJ	O	O	348
tuberculosis	NOUN	O	Disease	348
and	CCONJ	O	O	348
was	AUX	O	O	348
discovered	VERB	O	O	348
to	PART	O	O	348
have	VERB	O	O	348
developed	VERB	O	O	348
signs	NOUN	O	O	348
of	ADP	O	O	348
severe	ADJ	O	O	348
renal failure	NOUN	O	Disease	348
five	NUM	O	O	348
weeks	NOUN	O	O	348
after	ADP	O	O	348
completion	NOUN	O	O	348
of	ADP	O	O	348
therapy	NOUN	O	O	348
.	PUNCT	O	O	348
Renal	NOUN	O	O	349
biopsy	PROPN	O	O	349
revealed	VERB	O	O	349
severe	ADJ	O	O	349
glomerulonephritis	NOUN	O	Disease	349
with	ADP	O	O	349
crescents	NOUN	O	O	349
,	PUNCT	O	O	349
electron	NOUN	O	O	349
dense	ADJ	O	O	349
fibrillar	NOUN	O	O	349
deposits	NOUN	O	O	349
and	CCONJ	O	O	349
moderate	ADJ	O	O	349
lymphocytic	NOUN	O	O	349
interstitial	ADJ	O	O	349
infiltrate	VERB	O	O	349
.	PUNCT	O	O	349
Other	ADJ	O	O	350
possible	ADJ	O	O	350
causes	VERB	O	O	350
of	ADP	O	O	350
rapidly	ADV	O	O	350
progressive	ADJ	O	O	350
glomerulonephritis	NOUN	O	Disease	350
were	AUX	O	O	350
investigated	VERB	O	O	350
and	CCONJ	O	O	350
ruled	VERB	O	O	350
out	ADP	O	O	350
.	PUNCT	O	O	350
This	PRON	O	O	351
report	VERB	O	O	351
documents	NOUN	O	O	351
the	PRON	O	O	351
unusual	ADJ	O	O	351
occurrence	NOUN	O	O	351
of	ADP	O	O	351
rapidly	ADV	O	O	351
progressive	ADJ	O	O	351
glomerulonephritis	NOUN	O	Disease	351
with	ADP	O	O	351
crescents	NOUN	O	O	351
and	CCONJ	O	O	351
fibrillar	NOUN	O	O	351
glomerulonephritis	NOUN	O	Disease	351
in	ADP	O	O	351
a	PRON	O	O	351
patient	NOUN	O	O	351
treated	VERB	O	O	351
with	ADP	O	O	351
rifampin	ADV	O	Chemical	351
.	PUNCT	O	O	351
Time	NOUN	O	O	354
course	NOUN	O	O	354
of	ADP	O	O	354
lipid	NOUN	O	O	354
peroxidation	NOUN	O	O	354
in	ADP	O	O	354
puromycin aminonucleoside	NOUN	O	Chemical	354
-	PUNCT	O	O	354
induced	VERB	O	O	354
nephropathy	NOUN	O	Disease	354
.	PUNCT	O	O	354
Reactive	ADJ	O	O	355
oxygen	NOUN	O	Chemical	355
species	NOUN	O	O	355
have	VERB	O	O	355
been	AUX	O	O	355
implicated	VERB	O	O	355
in	ADP	O	O	355
the	PRON	O	O	355
pathogenesis	NOUN	O	O	355
of	ADP	O	O	355
acute	ADJ	O	O	355
puromycin aminonucleoside	NOUN	O	Chemical	355
(	PUNCT	O	O	355
PAN)-induced	VERB	O	O	355
nephropathy	NOUN	O	Disease	355
,	PUNCT	O	O	355
with	ADP	O	O	355
antioxidants	NOUN	O	O	355
significantly	ADV	O	O	355
reducing	VERB	O	O	355
the	PRON	O	O	355
proteinuria	X	O	Disease	355
.	PUNCT	O	O	355
The	PRON	O	O	356
temporal	ADJ	O	O	356
relationship	NOUN	O	O	356
between	ADP	O	O	356
lipid	NOUN	O	O	356
peroxidation	NOUN	O	O	356
in	ADP	O	O	356
the	PRON	O	O	356
kidney	NOUN	O	O	356
and	CCONJ	O	O	356
proteinuria	X	O	Disease	356
was	AUX	O	O	356
examined	VERB	O	O	356
in	ADP	O	O	356
this	PRON	O	O	356
study	VERB	O	O	356
.	PUNCT	O	O	356
Rats	NOUN	O	O	357
were	AUX	O	O	357
treated	VERB	O	O	357
with	ADP	O	O	357
a	PRON	O	O	357
single	ADJ	O	O	357
IV	NUM	O	O	357
injection	NOUN	O	O	357
of	ADP	O	O	357
puromycin aminonucleoside	NOUN	O	Chemical	357
,	PUNCT	O	O	357
(	PUNCT	O	O	357
PAN	PROPN	O	Chemical	357
,	PUNCT	O	O	357
7.5	NUM	O	O	357
mg	VERB	O	O	357
/	PUNCT	O	O	357
kg	VERB	O	O	357
)	PUNCT	O	O	357
and	CCONJ	O	O	357
24	NUM	O	O	357
hour	NOUN	O	O	357
urine	NOUN	O	O	357
samples	NOUN	O	O	357
were	AUX	O	O	357
obtained	VERB	O	O	357
prior	ADV	O	O	357
to	PART	O	O	357
sacrifice	VERB	O	O	357
on	ADP	O	O	357
days	NOUN	O	O	357
3,5,7,10,17,27,41	NUM	O	O	357
(	PUNCT	O	O	357
N	NUM	O	O	357
=	PUNCT	O	O	357
5	NUM	O	O	357
-	PUNCT	O	O	357
10	NUM	O	O	357
per	ADP	O	O	357
group	NOUN	O	O	357
)	PUNCT	O	O	357
.	PUNCT	O	O	357
Tissue	NOUN	O	O	358
lipid	NOUN	O	O	358
peroxidation	NOUN	O	O	358
was	AUX	O	O	358
measured	VERB	O	O	358
in	ADP	O	O	358
whole	NOUN	O	O	358
homogenates	VERB	O	O	358
as	ADP	O	O	358
well	ADV	O	O	358
as	ADP	O	O	358
in	ADP	O	O	358
lipid	NOUN	O	O	358
extracts	VERB	O	O	358
from	ADP	O	O	358
homogenates	VERB	O	O	358
as	ADP	O	O	358
thiobarbituric acid reactive substances	NOUN	O	Chemical	358
.	PUNCT	O	O	358
Proteinuria	PROPN	O	Disease	359
was	AUX	O	O	359
evident	ADJ	O	O	359
at	ADP	O	O	359
day	NOUN	O	O	359
5	NUM	O	O	359
,	PUNCT	O	O	359
peaked	VERB	O	O	359
at	ADP	O	O	359
day	NOUN	O	O	359
7	NUM	O	O	359
and	CCONJ	O	O	359
persisted	VERB	O	O	359
to	PART	O	O	359
day	NOUN	O	O	359
27	NUM	O	O	359
.	PUNCT	O	O	359
This	PRON	O	O	360
study	VERB	O	O	360
supports	VERB	O	O	360
the	PRON	O	O	360
role	NOUN	O	O	360
of	ADP	O	O	360
lipid	NOUN	O	O	360
peroxidation	NOUN	O	O	360
in	ADP	O	O	360
mediating	VERB	O	O	360
the	PRON	O	O	360
proteinuric	ADJ	O	O	360
injury	NOUN	O	O	360
in	ADP	O	O	360
PAN	PROPN	O	Chemical	360
nephropathy	NOUN	O	Disease	360
.	PUNCT	O	O	360
Clomipramine	NOUN	O	O	363
-	PUNCT	O	O	363
induced	VERB	O	O	363
sleep	VERB	O	O	363
disturbance	NOUN	O	O	363
does	VERB	O	O	363
not	PART	O	O	363
impair	VERB	O	O	363
its	PRON	O	O	363
prolactin	PROPN	O	O	363
-	PUNCT	O	O	363
releasing	VERB	O	O	363
action	NOUN	O	O	363
.	PUNCT	O	O	363
The	PRON	O	O	364
present	NOUN	O	O	364
study	VERB	O	O	364
was	AUX	O	O	364
undertaken	VERB	O	O	364
to	PART	O	O	364
examine	VERB	O	O	364
the	PRON	O	O	364
role	NOUN	O	O	364
of	ADP	O	O	364
sleep	VERB	O	O	364
disturbance	NOUN	O	O	364
,	PUNCT	O	O	364
induced	VERB	O	O	364
by	ADP	O	O	364
clomipramine	NOUN	O	Chemical	364
administration	NOUN	O	O	364
,	PUNCT	O	O	364
on	ADP	O	O	364
the	PRON	O	O	364
secretory	NOUN	O	O	364
rate	NOUN	O	O	364
of	ADP	O	O	364
prolactin	PROPN	O	O	364
(	PUNCT	O	O	364
PRL	NOUN	O	Chemical	364
)	PUNCT	O	O	364
in	ADP	O	O	364
addition	NOUN	O	O	364
to	PART	O	O	364
the	PRON	O	O	364
direct	ADJ	O	O	364
drug	NOUN	O	O	364
effect	VERB	O	O	364
.	PUNCT	O	O	364
Each	PRON	O	O	365
subject	ADJ	O	O	365
received	VERB	O	O	365
a	PRON	O	O	365
single	ADJ	O	O	365
50	NUM	O	O	365
mg	VERB	O	O	365
dose	NOUN	O	O	365
of	ADP	O	O	365
clomipramine	NOUN	O	Chemical	365
given	VERB	O	O	365
orally	ADV	O	O	365
2	X	O	O	365
hours	NOUN	O	O	365
before	ADP	O	O	365
blood	NOUN	O	O	365
collection	NOUN	O	O	365
.	PUNCT	O	O	365
During	ADP	O	O	366
the	PRON	O	O	366
night	NOUN	O	O	366
clomipramine	NOUN	O	Chemical	366
ingestion	NOUN	O	O	366
altered	VERB	O	O	366
the	PRON	O	O	366
complete	VERB	O	O	366
sleep	VERB	O	O	366
architecture	NOUN	O	O	366
in	ADP	O	O	366
that	SCONJ	O	O	366
it	PRON	O	O	366
suppressed	VERB	O	O	366
REM	NOUN	O	O	366
sleep	VERB	O	O	366
and	CCONJ	O	O	366
the	PRON	O	O	366
sleep	VERB	O	O	366
cycles	NOUN	O	O	366
and	CCONJ	O	O	366
induced	VERB	O	O	366
increased	VERB	O	O	366
wakefulness	NOUN	O	O	366
.	PUNCT	O	O	366
10%	NOUN	O	O	367
)	PUNCT	O	O	367
,	PUNCT	O	O	367
it	PRON	O	O	367
can	AUX	O	O	367
be	AUX	O	O	367
concluded	VERB	O	O	367
that	SCONJ	O	O	367
the	PRON	O	O	367
observed	VERB	O	O	367
sleep	VERB	O	O	367
disturbance	NOUN	O	O	367
did	VERB	O	O	367
not	PART	O	O	367
interfere	VERB	O	O	367
with	ADP	O	O	367
the	PRON	O	O	367
drug	NOUN	O	O	367
action	NOUN	O	O	367
per	ADP	O	O	367
se	X	O	O	367
.	PUNCT	O	O	367
The	PRON	O	O	368
presence	NOUN	O	O	368
of	ADP	O	O	368
REM	NOUN	O	O	368
sleep	VERB	O	O	368
was	AUX	O	O	368
shown	VERB	O	O	368
not	PART	O	O	368
to	PART	O	O	368
be	AUX	O	O	368
a	PRON	O	O	368
determining	VERB	O	O	368
factor	NOUN	O	O	368
either	ADV	O	O	368
for	ADP	O	O	368
secretory	NOUN	O	O	368
pulse	NOUN	O	O	368
amplitude	VERB	O	O	368
and	CCONJ	O	O	368
frequency	NOUN	O	O	368
,	PUNCT	O	O	368
as	ADP	O	O	368
,	PUNCT	O	O	368
for	ADP	O	O	368
both	PRON	O	O	368
,	PUNCT	O	O	368
mean	VERB	O	O	368
nocturnal	ADJ	O	O	368
values	NOUN	O	O	368
were	AUX	O	O	368
similar	ADJ	O	O	368
with	ADP	O	O	368
and	CCONJ	O	O	368
without	ADP	O	O	368
prior	ADV	O	O	368
clomipramine	NOUN	O	Chemical	368
ingestion	NOUN	O	O	368
.	PUNCT	O	O	368
Angioedema	PROPN	O	Disease	371
following	VERB	O	O	371
the	PRON	O	O	371
intravenous	ADJ	O	O	371
administration	NOUN	O	O	371
of	ADP	O	O	371
metoprolol	NOUN	O	Chemical	371
.	PUNCT	O	O	371
A	PRON	O	O	372
72-year	NOUN	O	O	372
-	PUNCT	O	O	372
old	ADJ	O	O	372
woman	NOUN	O	O	372
was	AUX	O	O	372
admitted	VERB	O	O	372
to	PART	O	O	372
the	PRON	O	O	372
hospital	PROPN	O	O	372
with	ADP	O	O	372
""""	PUNCT	O	O	372
flash	VERB	O	O	372
""""	PUNCT	O	O	372
pulmonary edema	NOUN	O	Disease	372
,	PUNCT	O	O	372
preceded	VERB	O	O	372
by	ADP	O	O	372
chest pain	NOUN	O	Disease	372
,	PUNCT	O	O	372
requiring	VERB	O	O	372
intubation	NOUN	O	O	372
.	PUNCT	O	O	372
Her	PRON	O	O	373
medical	ADJ	O	O	373
history	NOUN	O	O	373
included	VERB	O	O	373
coronary artery disease	NOUN	O	Disease	373
with	ADP	O	O	373
previous	ADJ	O	O	373
myocardial infarctions	NOUN	O	O	373
,	PUNCT	O	O	373
hypertension	NOUN	O	Disease	373
,	PUNCT	O	O	373
and	CCONJ	O	O	373
diabetes mellitus	ADJ	O	Disease	373
.	PUNCT	O	O	373
A	PRON	O	O	374
history	NOUN	O	O	374
of	ADP	O	O	374
angioedema	NOUN	O	Disease	374
secondary	ADJ	O	O	374
to	PART	O	O	374
lisinopril	PROPN	O	O	374
therapy	NOUN	O	O	374
was	AUX	O	O	374
elicited	VERB	O	O	374
.	PUNCT	O	O	374
Current	ADJ	O	O	375
medications	NOUN	O	O	375
did	VERB	O	O	375
not	PART	O	O	375
include	VERB	O	O	375
angiotensin	NOUN	O	Chemical	375
-	PUNCT	O	O	375
converting	VERB	O	O	375
enzyme	NOUN	O	O	375
inhibitors	NOUN	O	O	375
or	CCONJ	O	O	375
beta	NOUN	O	O	375
-	PUNCT	O	O	375
blockers	NOUN	O	O	375
.	PUNCT	O	O	375
During	ADP	O	O	376
the	PRON	O	O	376
first	ADV	O	O	376
day	NOUN	O	O	376
of	ADP	O	O	376
hospitalization	NOUN	O	O	376
(	PUNCT	O	O	376
while	SCONJ	O	O	376
intubated	VERB	O	O	376
)	PUNCT	O	O	376
,	PUNCT	O	O	376
intravenous	ADJ	O	O	376
metoprolol	NOUN	O	Chemical	376
was	AUX	O	O	376
given	VERB	O	O	376
,	PUNCT	O	O	376
resulting	VERB	O	O	376
in	ADP	O	O	376
severe	ADJ	O	O	376
angioedema	NOUN	O	Disease	376
.	PUNCT	O	O	376
The	PRON	O	O	377
angioedema	NOUN	O	Disease	377
resolved	VERB	O	O	377
after	ADP	O	O	377
therapy	NOUN	O	O	377
with	ADP	O	O	377
intravenous	ADJ	O	O	377
steroids	NOUN	O	Chemical	377
and	CCONJ	O	O	377
diphenhydramine	NOUN	O	O	377
hydrochloride	NOUN	O	O	377
.	PUNCT	O	O	377
Effect	VERB	O	O	380
of	ADP	O	O	380
coniine	NOUN	O	O	380
on	ADP	O	O	380
the	PRON	O	O	380
developing	VERB	O	O	380
chick	PROPN	O	O	380
embryo	NOUN	O	O	380
.	PUNCT	O	O	380
Coniine	NOUN	O	O	381
,	PUNCT	O	O	381
an	PRON	O	O	381
alkaloid	NOUN	O	O	381
from	ADP	O	O	381
Conium	PROPN	O	O	381
maculatum	PROPN	O	O	381
(	PUNCT	O	O	381
poison	NOUN	O	O	381
hemlock	PROPN	O	O	381
)	PUNCT	O	O	381
,	PUNCT	O	O	381
has	VERB	O	O	381
been	AUX	O	O	381
shown	VERB	O	O	381
to	PART	O	O	381
be	AUX	O	O	381
teratogenic	ADJ	O	O	381
in	ADP	O	O	381
livestock	NOUN	O	O	381
.	PUNCT	O	O	381
The	PRON	O	O	382
major	ADJ	O	O	382
teratogenic	ADJ	O	O	382
outcome	NOUN	O	O	382
is	AUX	O	O	382
arthrogryposis	NOUN	O	O	382
,	PUNCT	O	O	382
presumably	ADV	O	O	382
due	ADJ	O	O	382
to	PART	O	O	382
nicotinic	ADJ	O	O	382
receptor	NOUN	O	O	382
blockade	VERB	O	O	382
.	PUNCT	O	O	382
However	ADV	O	O	383
,	PUNCT	O	O	383
coniine	NOUN	O	O	383
has	VERB	O	O	383
failed	VERB	O	O	383
to	PART	O	O	383
produce	VERB	O	O	383
arthrogryposis	NOUN	O	O	383
in	ADP	O	O	383
rats	NOUN	O	O	383
or	CCONJ	O	O	383
mice	NOUN	O	O	383
and	CCONJ	O	O	383
is	AUX	O	O	383
only	ADV	O	O	383
weakly	ADV	O	O	383
teratogenic	ADJ	O	O	383
in	ADP	O	O	383
rabbits	NOUN	O	O	383
.	PUNCT	O	O	383
The	PRON	O	O	384
purpose	NOUN	O	O	384
of	ADP	O	O	384
this	PRON	O	O	384
study	VERB	O	O	384
was	AUX	O	O	384
to	PART	O	O	384
evaluate	VERB	O	O	384
and	CCONJ	O	O	384
compare	VERB	O	O	384
the	PRON	O	O	384
effects	NOUN	O	O	384
of	ADP	O	O	384
coniine	NOUN	O	O	384
and	CCONJ	O	O	384
nicotine	NOUN	O	Chemical	384
in	ADP	O	O	384
the	PRON	O	O	384
developing	VERB	O	O	384
chick	PROPN	O	O	384
.	PUNCT	O	O	384
Concentrations	NOUN	O	O	385
of	ADP	O	O	385
coniine	NOUN	O	O	385
and	CCONJ	O	O	385
nicotine	NOUN	O	Chemical	385
sulfate	NOUN	O	O	385
were	AUX	O	O	385
0.015%	NOUN	O	O	385
,	PUNCT	O	O	385
0.03%	NOUN	O	O	385
,	PUNCT	O	O	385
0.075%	NOUN	O	O	385
,	PUNCT	O	O	385
0.15%	NOUN	O	O	385
,	PUNCT	O	O	385
0.75%	NOUN	O	O	385
,	PUNCT	O	O	385
1.5%	NOUN	O	O	385
,	PUNCT	O	O	385
3%	NOUN	O	O	385
,	PUNCT	O	O	385
and	CCONJ	O	O	385
6%	NOUN	O	O	385
and	CCONJ	O	O	385
1%	NOUN	O	O	385
,	PUNCT	O	O	385
5%	NOUN	O	O	385
,	PUNCT	O	O	385
and	CCONJ	O	O	385
10%	NOUN	O	O	385
,	PUNCT	O	O	385
respectively	ADV	O	O	385
.	PUNCT	O	O	385
Both	PRON	O	O	386
compounds	NOUN	O	O	386
caused	VERB	O	O	386
deformations	NOUN	O	O	386
and	CCONJ	O	O	386
lethality	NOUN	O	O	386
in	ADP	O	O	386
a	PRON	O	O	386
dose	NOUN	O	O	386
-	PUNCT	O	O	386
dependent	ADJ	O	O	386
manner	VERB	O	O	386
.	PUNCT	O	O	386
All	PRON	O	O	387
concentrations	NOUN	O	O	387
of	ADP	O	O	387
nicotine	NOUN	O	Chemical	387
sulfate	NOUN	O	O	387
caused	VERB	O	O	387
some	PRON	O	O	387
lethality	NOUN	O	O	387
but	CCONJ	O	O	387
a	PRON	O	O	387
no	PRON	O	O	387
effect	VERB	O	O	387
level	VERB	O	O	387
for	ADP	O	O	387
coniine	NOUN	O	O	387
lethality	NOUN	O	O	387
was	AUX	O	O	387
0.75%	NOUN	O	O	387
.	PUNCT	O	O	387
The	PRON	O	O	388
deformations	NOUN	O	O	388
caused	VERB	O	O	388
by	ADP	O	O	388
both	PRON	O	O	388
coniine	NOUN	O	O	388
and	CCONJ	O	O	388
nicotine	NOUN	O	Chemical	388
sulfate	NOUN	O	O	388
were	AUX	O	O	388
excessive	ADJ	O	O	388
flexion	NOUN	O	O	388
or	CCONJ	O	O	388
extension	NOUN	O	O	388
of	ADP	O	O	388
one	NUM	O	O	388
or	CCONJ	O	O	388
more	ADJ	O	O	388
toes	NOUN	O	O	388
.	PUNCT	O	O	388
No	PRON	O	O	389
histopathological	ADJ	O	O	389
alterations	NOUN	O	O	389
or	CCONJ	O	O	389
differences	NOUN	O	O	389
in	ADP	O	O	389
bone	NOUN	O	O	389
formation	NOUN	O	O	389
were	AUX	O	O	389
seen	VERB	O	O	389
in	ADP	O	O	389
the	PRON	O	O	389
limbs	NOUN	O	O	389
or	CCONJ	O	O	389
toes	NOUN	O	O	389
of	ADP	O	O	389
any	PRON	O	O	389
chicks	NOUN	O	O	389
from	ADP	O	O	389
any	PRON	O	O	389
group	NOUN	O	O	389
;	PUNCT	O	O	389
however	ADV	O	O	389
,	PUNCT	O	O	389
extensive	ADJ	O	O	389
cranial	ADJ	O	O	389
hemorrhage	NOUN	O	Disease	389
occurred	VERB	O	O	389
in	ADP	O	O	389
all	PRON	O	O	389
nicotine	NOUN	O	Chemical	389
sulfate	NOUN	O	O	389
-	PUNCT	O	O	389
treated	VERB	O	O	389
chicks	NOUN	O	O	389
.	PUNCT	O	O	389
There	ADV	O	O	390
was	AUX	O	O	390
a	PRON	O	O	390
statistically	ADV	O	O	390
significant	ADJ	O	O	390
(	PUNCT	O	O	390
P	NOUN	O	Chemical	390
<	X	O	O	390
or	CCONJ	O	O	390
=	PUNCT	O	O	390
0.01	NUM	O	O	390
)	PUNCT	O	O	390
decrease	VERB	O	O	390
in	ADP	O	O	390
movement	NOUN	O	O	390
in	ADP	O	O	390
coniine	NOUN	O	O	390
and	CCONJ	O	O	390
nicotine	NOUN	O	Chemical	390
sulfate	NOUN	O	O	390
treated	VERB	O	O	390
chicks	NOUN	O	O	390
as	ADP	O	O	390
determined	VERB	O	O	390
by	ADP	O	O	390
ultrasound	VERB	O	O	390
.	PUNCT	O	O	390
Control	NOUN	O	O	391
chicks	NOUN	O	O	391
were	AUX	O	O	391
in	ADP	O	O	391
motion	NOUN	O	O	391
an	PRON	O	O	391
average	ADJ	O	O	391
of	ADP	O	O	391
33.67%	NOUN	O	O	391
of	ADP	O	O	391
the	PRON	O	O	391
time	NOUN	O	O	391
,	PUNCT	O	O	391
while	SCONJ	O	O	391
coniine	NOUN	O	O	391
-	PUNCT	O	O	391
treated	VERB	O	O	391
chicks	NOUN	O	O	391
were	AUX	O	O	391
only	ADV	O	O	391
moving	VERB	O	O	391
8.95%	NOUN	O	O	391
of	ADP	O	O	391
a	PRON	O	O	391
5-min	NOUN	O	O	391
interval	NOUN	O	O	391
,	PUNCT	O	O	391
and	CCONJ	O	O	391
no	PRON	O	O	391
movement	NOUN	O	O	391
was	AUX	O	O	391
observed	VERB	O	O	391
for	ADP	O	O	391
nicotine	NOUN	O	Chemical	391
sulfate	NOUN	O	O	391
treated	VERB	O	O	391
chicks	NOUN	O	O	391
.	PUNCT	O	O	391
In	ADP	O	O	392
summary	NOUN	O	O	392
,	PUNCT	O	O	392
the	PRON	O	O	392
chick	PROPN	O	O	392
embryo	NOUN	O	O	392
provides	VERB	O	O	392
a	PRON	O	O	392
reliable	ADJ	O	O	392
and	CCONJ	O	O	392
simple	ADJ	O	O	392
experimental	ADJ	O	O	392
animal	NOUN	O	O	392
model	NOUN	O	O	392
of	ADP	O	O	392
coniine	NOUN	O	O	392
-	PUNCT	O	O	392
induced	VERB	O	O	392
arthrogryposis	NOUN	O	O	392
.	PUNCT	O	O	392
Epidural	NOUN	O	O	395
blood	NOUN	O	O	395
flow	NOUN	O	O	395
during	ADP	O	O	395
prostaglandin E1	NOUN	O	O	395
or	CCONJ	O	O	395
trimethaphan	ADP	O	O	395
induced	VERB	O	O	395
hypotension	NOUN	O	Disease	395
.	PUNCT	O	O	395
To	PART	O	O	396
evaluate	VERB	O	O	396
the	PRON	O	O	396
effect	VERB	O	O	396
of	ADP	O	O	396
prostaglandin E1	NOUN	O	O	396
(	PUNCT	O	O	396
PGE1	NOUN	O	O	396
)	PUNCT	O	O	396
or	CCONJ	O	O	396
trimethaphan	ADP	O	O	396
(	PUNCT	O	O	396
TMP	PROPN	O	O	396
)	PUNCT	O	O	396
induced	VERB	O	O	396
hypotension	NOUN	O	Disease	396
on	ADP	O	O	396
epidural	ADV	O	O	396
blood	NOUN	O	O	396
flow	NOUN	O	O	396
(	PUNCT	O	O	396
EBF	PROPN	O	O	396
)	PUNCT	O	O	396
during	ADP	O	O	396
spinal	NOUN	O	O	396
surgery	NOUN	O	O	396
,	PUNCT	O	O	396
EBF	PROPN	O	O	396
was	AUX	O	O	396
measured	VERB	O	O	396
using	VERB	O	O	396
the	PRON	O	O	396
heat	NOUN	O	O	396
clearance	NOUN	O	O	396
method	NOUN	O	O	396
in	ADP	O	O	396
30	NUM	O	O	396
patients	NOUN	O	O	396
who	PRON	O	O	396
underwent	VERB	O	O	396
postero	NOUN	O	O	396
-	PUNCT	O	O	396
lateral	PROPN	O	O	396
interbody	NOUN	O	O	396
fusion	NOUN	O	O	396
under	ADP	O	O	396
isoflurane	NOUN	O	Chemical	396
anaesthesia	NOUN	O	O	396
.	PUNCT	O	O	396
An	PRON	O	O	397
initial	ADJ	O	O	397
dose	NOUN	O	O	397
of	ADP	O	O	397
0.1	NUM	O	O	397
microgram.kg-1.min-1	VERB	O	O	397
of	ADP	O	O	397
PGE1	NOUN	O	O	397
(	PUNCT	O	O	397
15	NUM	O	O	397
patients	NOUN	O	O	397
)	PUNCT	O	O	397
,	PUNCT	O	O	397
or	CCONJ	O	O	397
10	NUM	O	O	397
micrograms.kg-1.min-1	VERB	O	O	397
of	ADP	O	O	397
TMP	PROPN	O	O	397
(	PUNCT	O	O	397
15	NUM	O	O	397
patients	NOUN	O	O	397
)	PUNCT	O	O	397
was	AUX	O	O	397
administered	VERB	O	O	397
intravenously	ADV	O	O	397
after	ADP	O	O	397
the	PRON	O	O	397
dural	NOUN	O	O	397
opening	VERB	O	O	397
and	CCONJ	O	O	397
the	PRON	O	O	397
dose	NOUN	O	O	397
was	AUX	O	O	397
adjusted	VERB	O	O	397
to	PART	O	O	397
maintain	VERB	O	O	397
the	PRON	O	O	397
mean	VERB	O	O	397
arterial	ADJ	O	O	397
blood	NOUN	O	O	397
pressure	NOUN	O	O	397
(	PUNCT	O	O	397
MAP	PROPN	O	O	397
)	PUNCT	O	O	397
at	ADP	O	O	397
about	ADP	O	O	397
60	NUM	O	O	397
mmHg	PROPN	O	O	397
.	PUNCT	O	O	397
The	PRON	O	O	398
hypotensive	ADJ	O	Disease	398
drug	NOUN	O	O	398
was	AUX	O	O	398
discontinued	VERB	O	O	398
at	ADP	O	O	398
the	PRON	O	O	398
completion	NOUN	O	O	398
of	ADP	O	O	398
the	PRON	O	O	398
operative	NOUN	O	O	398
procedure	NOUN	O	O	398
.	PUNCT	O	O	398
After	ADP	O	O	399
starting	VERB	O	O	399
PGE1	NOUN	O	O	399
or	CCONJ	O	O	399
TMP	PROPN	O	O	399
,	PUNCT	O	O	399
MAP	PROPN	O	O	399
and	CCONJ	O	O	399
rate	NOUN	O	O	399
pressure	NOUN	O	O	399
product	NOUN	O	O	399
(	PUNCT	O	O	399
RPP	PROPN	O	O	399
)	PUNCT	O	O	399
decreased	VERB	O	O	399
significantly	ADV	O	O	399
compared	VERB	O	O	399
with	ADP	O	O	399
preinfusion	NOUN	O	O	399
values	NOUN	O	O	399
(	PUNCT	O	O	400
P	NOUN	O	Chemical	400
<	X	O	O	400
0.01	NUM	O	O	400
)	PUNCT	O	O	400
,	PUNCT	O	O	400
and	CCONJ	O	O	400
the	PRON	O	O	400
degree	PROPN	O	O	400
of	ADP	O	O	400
hypotension	NOUN	O	Disease	400
due	ADJ	O	O	400
to	PART	O	O	400
PGE1	NOUN	O	O	400
remained	VERB	O	O	400
constant	ADJ	O	O	400
until	ADP	O	O	400
60	NUM	O	O	400
min	NOUN	O	O	400
after	ADP	O	O	400
its	PRON	O	O	400
discontinuation	NOUN	O	O	400
.	PUNCT	O	O	400
EBFF	PROPN	O	O	401
did	VERB	O	O	401
not	PART	O	O	401
change	VERB	O	O	401
during	ADP	O	O	401
PGE1	NOUN	O	O	401
infusion	NOUN	O	O	401
whereas	SCONJ	O	O	401
in	ADP	O	O	401
the	PRON	O	O	401
TMP	PROPN	O	O	401
group	NOUN	O	O	401
,	PUNCT	O	O	401
EBF	PROPN	O	O	401
decreased	VERB	O	O	401
significantly	ADV	O	O	401
at	ADP	O	O	401
30	NUM	O	O	401
and	CCONJ	O	O	401
60	NUM	O	O	401
min	NOUN	O	O	401
after	ADP	O	O	401
the	PRON	O	O	401
start	VERB	O	O	401
of	ADP	O	O	401
TMP	PROPN	O	O	401
(	PUNCT	O	O	401
preinfusion	NOUN	O	O	401
:	PUNCT	O	O	401
45.9	NUM	O	O	401
These	PRON	O	O	402
results	VERB	O	O	402
suggest	VERB	O	O	402
that	SCONJ	O	O	402
PGE1	NOUN	O	O	402
may	AUX	O	O	402
be	AUX	O	O	402
preferable	ADJ	O	O	402
to	PART	O	O	402
TMP	PROPN	O	O	402
for	ADP	O	O	402
hypotensive	ADJ	O	Disease	402
anaesthesia	NOUN	O	O	402
in	ADP	O	O	402
spinal	NOUN	O	O	402
surgery	NOUN	O	O	402
because	SCONJ	O	O	402
TMP	PROPN	O	O	402
decreased	VERB	O	O	402
EBF	PROPN	O	O	402
.	PUNCT	O	O	402
Immunohistochemical	PROPN	O	O	405
studies	NOUN	O	O	405
with	ADP	O	O	405
antibodies	NOUN	O	O	405
to	PART	O	O	405
neurofilament	NOUN	O	O	405
proteins	NOUN	O	O	405
on	ADP	O	O	405
axonal	ADJ	O	O	405
damage	NOUN	O	O	405
in	ADP	O	O	405
experimental	ADJ	O	O	405
focal	ADJ	O	O	405
lesions	NOUN	O	O	405
in	ADP	O	O	405
rat	NOUN	O	O	405
.	PUNCT	O	O	405
Immunohistochemistry	NOUN	O	O	406
with	ADP	O	O	406
monoclonal	NOUN	O	O	406
antibodies	NOUN	O	O	406
against	ADP	O	O	406
neurofilament	NOUN	O	O	406
(	PUNCT	O	O	406
NF	PROPN	O	O	406
)	PUNCT	O	O	406
proteins	NOUN	O	O	406
of	ADP	O	O	406
middle	ADJ	O	O	406
and	CCONJ	O	O	406
high	ADJ	O	O	406
molecular	ADJ	O	O	406
weight	NOUN	O	O	406
class	NOUN	O	O	406
,	PUNCT	O	O	406
NF	PROPN	O	O	406
-	PUNCT	O	O	406
M	NOUN	O	Chemical	406
and	CCONJ	O	O	406
NF	PROPN	O	O	406
-	PUNCT	O	O	406
H	NOUN	O	Chemical	406
,	PUNCT	O	O	406
was	AUX	O	O	406
used	VERB	O	O	406
to	PART	O	O	406
study	VERB	O	O	406
axonal	ADJ	O	O	406
injury	NOUN	O	O	406
in	ADP	O	O	406
the	PRON	O	O	406
borderzone	NOUN	O	O	406
of	ADP	O	O	406
focal	ADJ	O	O	406
lesions	NOUN	O	O	406
in	ADP	O	O	406
rats	NOUN	O	O	406
.	PUNCT	O	O	406
Focal	ADJ	O	O	407
injury	NOUN	O	O	407
in	ADP	O	O	407
the	PRON	O	O	407
cortex	VERB	O	O	407
was	AUX	O	O	407
produced	VERB	O	O	407
by	ADP	O	O	407
infusion	NOUN	O	O	407
of	ADP	O	O	407
lactate	NOUN	O	Chemical	407
at	ADP	O	O	407
acid	PROPN	O	O	407
pH	NOUN	O	O	407
or	CCONJ	O	O	407
by	ADP	O	O	407
stab	VERB	O	O	407
caused	VERB	O	O	407
by	ADP	O	O	407
needle	NOUN	O	O	407
insertion	NOUN	O	O	407
.	PUNCT	O	O	407
Infarcts	NOUN	O	O	408
in	ADP	O	O	408
substantia	X	O	O	408
nigra	NOUN	O	O	408
pars	NOUN	O	O	408
reticulata	NOUN	O	O	408
were	AUX	O	O	408
evoked	VERB	O	O	408
by	ADP	O	O	408
prolonged	VERB	O	O	408
pilocarpine	NOUN	O	Chemical	408
-	PUNCT	O	O	408
induced	VERB	O	O	408
status epilepticus	VERB	O	Disease	408
.	PUNCT	O	O	408
These	PRON	O	O	409
immunohistochemical	ADJ	O	O	409
changes	VERB	O	O	409
of	ADP	O	O	409
NFs	NOUN	O	O	409
can	AUX	O	O	409
serve	VERB	O	O	409
as	ADP	O	O	409
a	PRON	O	O	409
marker	NOUN	O	O	409
for	ADP	O	O	409
axonal	ADJ	O	O	409
damage	NOUN	O	O	409
in	ADP	O	O	409
various	ADJ	O	O	409
experimental	ADJ	O	O	409
traumatic	ADJ	O	O	409
or	CCONJ	O	O	409
ischemic	VERB	O	Disease	409
lesions	NOUN	O	O	409
.	PUNCT	O	O	409
Increase	VERB	O	O	412
of	ADP	O	O	412
Parkinson	NOUN	O	O	412
disability	NOUN	O	O	412
after	ADP	O	O	412
fluoxetine	NOUN	O	Chemical	412
medication	NOUN	O	O	412
.	PUNCT	O	O	412
Depression	NOUN	O	O	413
is	AUX	O	O	413
a	PRON	O	O	413
major	ADJ	O	O	413
clinical	ADJ	O	O	413
feature	VERB	O	O	413
of	ADP	O	O	413
Parkinson	NOUN	O	O	413
's	AUX	O	O	413
disease	PROPN	O	O	413
.	PUNCT	O	O	413
We	PRON	O	O	414
report	VERB	O	O	414
the	PRON	O	O	414
increased	VERB	O	O	414
amount	NOUN	O	O	414
of	ADP	O	O	414
motor	NOUN	O	O	414
disability	NOUN	O	O	414
in	ADP	O	O	414
four	NUM	O	O	414
patients	NOUN	O	O	414
with	ADP	O	O	414
idiopathic	ADJ	O	O	414
Parkinson	NOUN	O	O	414
's	AUX	O	O	414
disease	PROPN	O	O	414
after	ADP	O	O	414
exposure	NOUN	O	O	414
to	PART	O	O	414
the	PRON	O	O	414
antidepressant	NOUN	O	O	414
fluoxetine	NOUN	O	Chemical	414
.	PUNCT	O	O	414
The	PRON	O	O	415
possibility	NOUN	O	O	415
of	ADP	O	O	415
a	PRON	O	O	415
clinically	ADV	O	O	415
relevant	ADJ	O	O	415
dopamine	NOUN	O	Chemical	415
-	PUNCT	O	O	415
antagonistic	ADJ	O	O	415
capacity	NOUN	O	O	415
of	ADP	O	O	415
fluoxetine	NOUN	O	Chemical	415
in	ADP	O	O	415
Parkinson	NOUN	O	O	415
's	AUX	O	O	415
disease	PROPN	O	O	415
patients	NOUN	O	O	415
must	AUX	O	O	415
be	AUX	O	O	415
considered	VERB	O	O	415
.	PUNCT	O	O	415
Acetaminophen	PROPN	O	O	418
-	PUNCT	O	O	418
induced	VERB	O	O	418
hypotension	NOUN	O	Disease	418
.	PUNCT	O	O	418
Through	ADP	O	O	419
30	NUM	O	O	419
years	NOUN	O	O	419
of	ADP	O	O	419
widespread	ADJ	O	O	419
use	VERB	O	O	419
,	PUNCT	O	O	419
acetaminophen	PROPN	O	Chemical	419
has	VERB	O	O	419
been	AUX	O	O	419
shown	VERB	O	O	419
to	PART	O	O	419
be	AUX	O	O	419
a	PRON	O	O	419
remarkably	ADV	O	O	419
safe	ADJ	O	O	419
medication	NOUN	O	O	419
in	ADP	O	O	419
therapeutic	ADJ	O	O	419
dosages	NOUN	O	O	419
.	PUNCT	O	O	419
The	PRON	O	O	420
potential	ADJ	O	O	420
for	ADP	O	O	420
acetaminophen	PROPN	O	Chemical	420
to	PART	O	O	420
produce	VERB	O	O	420
cardiovascular	ADJ	O	O	420
toxicities	NOUN	O	Disease	420
is	AUX	O	O	420
very	ADV	O	O	420
low	ADJ	O	O	420
.	PUNCT	O	O	420
However	ADV	O	O	421
,	PUNCT	O	O	421
acetaminophen	PROPN	O	Chemical	421
has	VERB	O	O	421
been	AUX	O	O	421
demonstrated	VERB	O	O	421
to	PART	O	O	421
produce	VERB	O	O	421
symptoms	NOUN	O	O	421
of	ADP	O	O	421
anaphylaxis	NOUN	O	O	421
,	PUNCT	O	O	421
including	VERB	O	O	421
hypotension	NOUN	O	Disease	421
,	PUNCT	O	O	421
in	ADP	O	O	421
sensitive	ADJ	O	O	421
individuals	NOUN	O	O	421
.	PUNCT	O	O	421
This	PRON	O	O	422
article	NOUN	O	O	422
describes	VERB	O	O	422
two	NUM	O	O	422
critically	ADV	O	O	422
ill	PROPN	O	O	422
patients	NOUN	O	O	422
in	ADP	O	O	422
whom	PRON	O	O	422
transient	ADJ	O	O	422
episodes	NOUN	O	O	422
of	ADP	O	O	422
hypotension	NOUN	O	Disease	422
reproducibly	ADV	O	O	422
developed	VERB	O	O	422
after	ADP	O	O	422
administration	NOUN	O	O	422
of	ADP	O	O	422
acetaminophen	PROPN	O	Chemical	422
.	PUNCT	O	O	422
Other	ADJ	O	O	423
symptoms	NOUN	O	O	423
of	ADP	O	O	423
allergic	ADJ	O	O	423
reactions	NOUN	O	O	423
were	AUX	O	O	423
not	PART	O	O	423
clinically	ADV	O	O	423
detectable	ADJ	O	O	423
.	PUNCT	O	O	423
The	PRON	O	O	424
hypotensive	ADJ	O	Disease	424
episodes	NOUN	O	O	424
were	AUX	O	O	424
severe	ADJ	O	O	424
enough	ADV	O	O	424
to	PART	O	O	424
require	VERB	O	O	424
vasopressor	NOUN	O	O	424
administration	NOUN	O	O	424
.	PUNCT	O	O	424
The	PRON	O	O	425
reports	VERB	O	O	425
illustrate	VERB	O	O	425
the	PRON	O	O	425
need	VERB	O	O	425
for	ADP	O	O	425
clinicians	NOUN	O	O	425
to	PART	O	O	425
consider	VERB	O	O	425
acetaminophen	PROPN	O	Chemical	425
in	ADP	O	O	425
patients	NOUN	O	O	425
with	ADP	O	O	425
hypotension	NOUN	O	Disease	425
of	ADP	O	O	425
unknown	ADJ	O	O	425
origin	NOUN	O	O	425
.	PUNCT	O	O	425
Acute	PROPN	O	O	428
hepatitis	NOUN	O	Disease	428
,	PUNCT	O	O	428
autoimmune	PROPN	O	O	428
hemolytic anemia	NOUN	O	Disease	428
,	PUNCT	O	O	428
and	CCONJ	O	O	428
erythroblastocytopenia	NOUN	O	O	428
induced	VERB	O	O	428
by	ADP	O	O	428
ceftriaxone	NOUN	O	O	428
.	PUNCT	O	O	428
An	PRON	O	O	429
80-yr	NOUN	O	O	429
-	PUNCT	O	O	429
old	ADJ	O	O	429
man	NOUN	O	O	429
developed	VERB	O	O	429
acute	ADJ	O	O	429
hepatitis	NOUN	O	Disease	429
shortly	ADV	O	O	429
after	ADP	O	O	429
ingesting	VERB	O	O	429
oral	ADJ	O	O	429
ceftriaxone	NOUN	O	O	429
.	PUNCT	O	O	429
Although	SCONJ	O	O	430
the	PRON	O	O	430
transaminases	NOUN	O	O	430
gradually	ADV	O	O	430
returned	VERB	O	O	430
to	PART	O	O	430
baseline	VERB	O	O	430
after	ADP	O	O	430
withholding	VERB	O	O	430
the	PRON	O	O	430
beta	NOUN	O	O	430
lactam	NOUN	O	O	430
antibiotic	ADJ	O	O	430
,	PUNCT	O	O	430
there	ADV	O	O	430
was	AUX	O	O	430
a	PRON	O	O	430
gradual	ADJ	O	O	430
increase	VERB	O	O	430
in	ADP	O	O	430
serum	NOUN	O	O	430
bilirubin	ADJ	O	Chemical	430
and	CCONJ	O	O	430
a	PRON	O	O	430
decrease	VERB	O	O	430
in	ADP	O	O	430
hemoglobin	NOUN	O	O	430
concentration	NOUN	O	O	430
caused	VERB	O	O	430
by	ADP	O	O	430
an	PRON	O	O	430
autoimmune	PROPN	O	O	430
hemolytic anemia	NOUN	O	Disease	430
and	CCONJ	O	O	430
erythroblastocytopenia	NOUN	O	O	430
.	PUNCT	O	O	430
These	PRON	O	O	431
responded	VERB	O	O	431
to	PART	O	O	431
systemic	ADJ	O	O	431
steroids	NOUN	O	Chemical	431
and	CCONJ	O	O	431
immunoglobulins	VERB	O	O	431
.	PUNCT	O	O	431
Despite	SCONJ	O	O	432
the	PRON	O	O	432
widespread	ADJ	O	O	432
use	VERB	O	O	432
of	ADP	O	O	432
these	PRON	O	O	432
agents	NOUN	O	O	432
this	PRON	O	O	432
triad	PROPN	O	O	432
of	ADP	O	O	432
side	NOUN	O	O	432
effects	NOUN	O	O	432
has	VERB	O	O	432
not	PART	O	O	432
previously	ADV	O	O	432
been	AUX	O	O	432
reported	VERB	O	O	432
in	ADP	O	O	432
connection	NOUN	O	O	432
with	ADP	O	O	432
beta	NOUN	O	O	432
lactam	NOUN	O	O	432
antibiotics	VERB	O	O	432
.	PUNCT	O	O	432
Conventional	ADJ	O	O	435
agents	NOUN	O	O	435
are	AUX	O	O	435
associated	VERB	O	O	435
with	ADP	O	O	435
unwanted	ADJ	O	O	435
central	ADJ	O	O	435
nervous	ADJ	O	O	435
system	NOUN	O	O	435
effects	NOUN	O	O	435
,	PUNCT	O	O	435
including	VERB	O	O	435
extrapyramidal symptoms	NOUN	O	Disease	435
(	PUNCT	O	O	435
EPS	PROPN	O	Disease	435
)	PUNCT	O	O	435
,	PUNCT	O	O	435
tardive dyskinesia	NOUN	O	Disease	435
,	PUNCT	O	O	435
sedation	NOUN	O	O	435
,	PUNCT	O	O	435
and	CCONJ	O	O	435
possible	ADJ	O	O	435
impairment	NOUN	O	O	435
of	ADP	O	O	435
some	PRON	O	O	435
cognitive	ADJ	O	O	435
measures	NOUN	O	O	435
,	PUNCT	O	O	435
as	ADP	O	O	435
well	ADV	O	O	435
as	ADP	O	O	435
cardiac	ADJ	O	O	435
effects	NOUN	O	O	435
,	PUNCT	O	O	435
orthostatic hypotension	NOUN	O	Disease	435
,	PUNCT	O	O	435
hepatic	ADJ	O	O	435
changes	VERB	O	O	435
,	PUNCT	O	O	435
anticholinergic	ADJ	O	O	435
side	NOUN	O	O	435
effects	NOUN	O	O	435
,	PUNCT	O	O	435
sexual dysfunction	NOUN	O	Disease	435
,	PUNCT	O	O	435
and	CCONJ	O	O	435
weight	NOUN	O	O	435
gain	VERB	O	O	435
.	PUNCT	O	O	435
The	PRON	O	O	436
newer	ADJ	O	O	436
atypical	ADJ	O	O	436
agents	NOUN	O	O	436
have	VERB	O	O	436
a	PRON	O	O	436
lower	ADJ	O	O	436
risk	NOUN	O	O	436
of	ADP	O	O	436
EPS	PROPN	O	Disease	436
,	PUNCT	O	O	436
but	CCONJ	O	O	436
are	AUX	O	O	436
associated	VERB	O	O	436
in	ADP	O	O	436
varying	VERB	O	O	436
degrees	NOUN	O	O	436
with	ADP	O	O	436
sedation	NOUN	O	O	436
,	PUNCT	O	O	436
cardiovascular	ADJ	O	O	436
effects	NOUN	O	O	436
,	PUNCT	O	O	436
anticholinergic	ADJ	O	O	436
effects	NOUN	O	O	436
,	PUNCT	O	O	436
weight	NOUN	O	O	436
gain	VERB	O	O	436
,	PUNCT	O	O	436
sexual dysfunction	NOUN	O	Disease	436
,	PUNCT	O	O	436
hepatic	ADJ	O	O	436
effects	NOUN	O	O	436
,	PUNCT	O	O	436
lowered	VERB	O	O	436
seizure	NOUN	O	Disease	436
threshold	NOUN	O	O	436
(	PUNCT	O	O	436
primarily	ADV	O	O	436
clozapine	PROPN	O	Chemical	436
)	PUNCT	O	O	436
,	PUNCT	O	O	436
and	CCONJ	O	O	436
agranulocytosis	ADJ	O	O	436
(	PUNCT	O	O	436
clozapine	PROPN	O	Chemical	436
only	ADV	O	O	436
)	PUNCT	O	O	436
.	PUNCT	O	O	436
Effects	NOUN	O	O	439
of	ADP	O	O	439
tetrandrine	NOUN	O	O	439
and	CCONJ	O	O	439
fangchinoline	PROPN	O	O	439
on	ADP	O	O	439
experimental	ADJ	O	O	439
thrombosis	NOUN	O	Disease	439
in	ADP	O	O	439
mice	NOUN	O	O	439
and	CCONJ	O	O	439
human	PROPN	O	O	439
platelet aggregation	NOUN	O	Disease	439
.	PUNCT	O	O	439
Tetrandrine	NOUN	O	O	440
(	PUNCT	O	O	440
TET	PROPN	O	O	440
)	PUNCT	O	O	440
and	CCONJ	O	O	440
fangchinoline	PROPN	O	O	440
(	PUNCT	O	O	440
FAN	NOUN	O	O	440
)	PUNCT	O	O	440
are	AUX	O	O	440
two	NUM	O	O	440
naturally	ADV	O	O	440
occurring	VERB	O	O	440
analogues	NOUN	O	O	440
with	ADP	O	O	440
a	PRON	O	O	440
bisbenzylisoquinoline	PROPN	O	O	440
structure	NOUN	O	O	440
.	PUNCT	O	O	440
The	PRON	O	O	441
present	NOUN	O	O	441
study	VERB	O	O	441
was	AUX	O	O	441
undertaken	VERB	O	O	441
to	PART	O	O	441
investigate	VERB	O	O	441
the	PRON	O	O	441
effects	NOUN	O	O	441
of	ADP	O	O	441
TET	PROPN	O	O	441
and	CCONJ	O	O	441
FAN	NOUN	O	O	441
on	ADP	O	O	441
the	PRON	O	O	441
experimental	ADJ	O	O	441
thrombosis	NOUN	O	Disease	441
induced	VERB	O	O	441
by	ADP	O	O	441
collagen	NOUN	O	O	441
plus	CCONJ	O	O	441
epinephrine	NOUN	O	Chemical	441
(	PUNCT	O	O	441
EP	PROPN	O	O	441
)	PUNCT	O	O	441
in	ADP	O	O	441
mice	NOUN	O	O	441
,	PUNCT	O	O	441
and	CCONJ	O	O	441
platelet aggregation	NOUN	O	Disease	441
and	CCONJ	O	O	441
blood coagulation	NOUN	O	Disease	441
in	ADP	O	O	441
vitro	X	O	O	441
.	PUNCT	O	O	441
In	ADP	O	O	442
the	PRON	O	O	442
in	ADP	O	O	442
vivo	VERB	O	O	442
study	VERB	O	O	442
,	PUNCT	O	O	442
the	PRON	O	O	442
administration	NOUN	O	O	442
(	PUNCT	O	O	442
50	NUM	O	O	442
mg	VERB	O	O	442
/	PUNCT	O	O	442
kg	VERB	O	O	442
,	PUNCT	O	O	442
i.p	NOUN	O	O	442
.	PUNCT	O	O	442
)	PUNCT	O	O	442
of	ADP	O	O	442
TET	PROPN	O	O	442
and	CCONJ	O	O	442
FAN	NOUN	O	O	442
in	ADP	O	O	442
mice	NOUN	O	O	442
showed	VERB	O	O	442
the	PRON	O	O	442
inhibition	NOUN	O	O	442
of	ADP	O	O	442
thrombosis	NOUN	O	Disease	442
by	ADP	O	O	442
55%	NOUN	O	O	442
and	CCONJ	O	O	442
35%	NOUN	O	O	442
,	PUNCT	O	O	442
respectively	ADV	O	O	442
,	PUNCT	O	O	442
while	SCONJ	O	O	442
acetylsalicylic acid	NOUN	O	Chemical	442
(	PUNCT	O	O	442
ASA	PROPN	O	Chemical	442
,	PUNCT	O	O	442
50	NUM	O	O	442
mg	VERB	O	O	442
/	PUNCT	O	O	442
kg	VERB	O	O	442
,	PUNCT	O	O	442
i.p	NOUN	O	O	442
.	PUNCT	O	O	442
)	PUNCT	O	O	442
,	PUNCT	O	O	442
a	PRON	O	O	442
positive	ADJ	O	O	442
control	VERB	O	O	442
,	PUNCT	O	O	442
showed	VERB	O	O	442
only	ADV	O	O	442
30%	NOUN	O	O	442
inhibition	NOUN	O	O	442
.	PUNCT	O	O	442
In	ADP	O	O	443
the	PRON	O	O	443
vitro	X	O	O	443
human	PROPN	O	O	443
platelet aggregations	NOUN	O	O	443
induced	VERB	O	O	443
by	ADP	O	O	443
the	PRON	O	O	443
agonists	NOUN	O	O	443
used	VERB	O	O	443
in	ADP	O	O	443
tests	VERB	O	O	443
,	PUNCT	O	O	443
TET	PROPN	O	O	443
and	CCONJ	O	O	443
FAN	NOUN	O	O	443
showed	VERB	O	O	443
the	PRON	O	O	443
inhibitions	NOUN	O	O	443
dose	NOUN	O	O	443
dependently	ADV	O	O	443
.	PUNCT	O	O	443
In	ADP	O	O	444
addition	NOUN	O	O	444
,	PUNCT	O	O	444
neither	ADV	O	O	444
TET	PROPN	O	O	444
nor	CCONJ	O	O	444
FAN	NOUN	O	O	444
showed	VERB	O	O	444
any	PRON	O	O	444
anticoagulation	NOUN	O	O	444
activities	NOUN	O	O	444
in	ADP	O	O	444
the	PRON	O	O	444
measurement	NOUN	O	O	444
of	ADP	O	O	444
the	PRON	O	O	444
activated	VERB	O	O	444
partial	ADJ	O	O	444
thromboplastin	VERB	O	O	444
time	NOUN	O	O	444
(	PUNCT	O	O	444
APTT	PROPN	O	O	444
)	PUNCT	O	O	444
,	PUNCT	O	O	444
prothrombin	ADJ	O	O	444
time	NOUN	O	O	444
(	PUNCT	O	O	444
PT	NOUN	O	O	444
)	PUNCT	O	O	444
and	CCONJ	O	O	444
thrombin	PROPN	O	O	444
time	NOUN	O	O	444
(	PUNCT	O	O	444
TT	PROPN	O	O	444
)	PUNCT	O	O	444
using	VERB	O	O	444
human	PROPN	O	O	444
-	PUNCT	O	O	444
citrated	VERB	O	O	444
plasma	NOUN	O	O	444
.	PUNCT	O	O	444
These	PRON	O	O	445
results	VERB	O	O	445
suggest	VERB	O	O	445
that	SCONJ	O	O	445
antithrombosis	NOUN	O	O	445
of	ADP	O	O	445
TET	PROPN	O	O	445
and	CCONJ	O	O	445
FAN	NOUN	O	O	445
in	ADP	O	O	445
mice	NOUN	O	O	445
may	AUX	O	O	445
be	AUX	O	O	445
mainly	ADV	O	O	445
related	ADJ	O	O	445
to	PART	O	O	445
the	PRON	O	O	445
antiplatelet aggregation	NOUN	O	O	445
activities	NOUN	O	O	445
.	PUNCT	O	O	445
Gemcitabine	NOUN	O	O	448
plus	CCONJ	O	O	448
vinorelbine	VERB	O	O	448
in	ADP	O	O	448
nonsmall	NOUN	O	O	448
cell	NOUN	O	O	448
lung	NOUN	O	O	448
carcinoma	NOUN	O	Disease	448
patients	NOUN	O	O	448
age	NOUN	O	O	448
70	NUM	O	O	448
years	NOUN	O	O	448
or	CCONJ	O	O	448
older	ADJ	O	O	448
or	CCONJ	O	O	448
patients	NOUN	O	O	448
who	PRON	O	O	448
can	AUX	O	O	448
not	PART	O	O	448
receive	VERB	O	O	448
cisplatin	NOUN	O	Chemical	448
.	PUNCT	O	O	448
Although	SCONJ	O	O	449
the	PRON	O	O	449
prevalence	NOUN	O	O	449
of	ADP	O	O	449
nonsmall	NOUN	O	O	449
cell	NOUN	O	O	449
lung	NOUN	O	O	449
carcinoma	NOUN	O	Disease	449
(	PUNCT	O	O	449
NSCLC	PROPN	O	Disease	449
)	PUNCT	O	O	449
is	AUX	O	O	449
high	ADJ	O	O	449
among	ADP	O	O	449
elderly	ADJ	O	O	449
patients	NOUN	O	O	449
,	PUNCT	O	O	449
few	ADJ	O	O	449
data	NOUN	O	O	449
are	AUX	O	O	449
available	ADJ	O	O	449
regarding	VERB	O	O	449
the	PRON	O	O	449
efficacy	NOUN	O	O	449
and	CCONJ	O	O	449
toxicity	NOUN	O	Disease	449
of	ADP	O	O	449
chemotherapy	NOUN	O	O	449
in	ADP	O	O	449
this	PRON	O	O	449
group	NOUN	O	O	449
of	ADP	O	O	449
patients	NOUN	O	O	449
.	PUNCT	O	O	449
Recent	ADJ	O	O	450
reports	VERB	O	O	450
indicate	VERB	O	O	450
that	SCONJ	O	O	450
single	ADJ	O	O	450
agent	NOUN	O	O	450
therapy	NOUN	O	O	450
with	ADP	O	O	450
vinorelbine	VERB	O	O	450
(	PUNCT	O	O	450
VNB	NOUN	O	O	450
)	PUNCT	O	O	450
or	CCONJ	O	O	450
gemcitabine	NOUN	O	O	450
(	PUNCT	O	O	450
GEM	NOUN	O	O	450
)	PUNCT	O	O	450
may	AUX	O	O	450
obtain	VERB	O	O	450
a	PRON	O	O	450
response	NOUN	O	O	450
rate	NOUN	O	O	450
of	ADP	O	O	450
20	NUM	O	O	450
-	PUNCT	O	O	450
30%	NOUN	O	O	450
in	ADP	O	O	450
elderly	ADJ	O	O	450
patients	NOUN	O	O	450
,	PUNCT	O	O	450
with	ADP	O	O	450
acceptable	ADJ	O	O	450
toxicity	NOUN	O	Disease	450
and	CCONJ	O	O	450
improvement	NOUN	O	O	450
in	ADP	O	O	450
symptoms	NOUN	O	O	450
and	CCONJ	O	O	450
quality	NOUN	O	O	450
of	ADP	O	O	450
life	NOUN	O	O	450
.	PUNCT	O	O	450
In	ADP	O	O	451
the	PRON	O	O	451
current	ADJ	O	O	451
study	VERB	O	O	451
the	PRON	O	O	451
efficacy	NOUN	O	O	451
and	CCONJ	O	O	451
toxicity	NOUN	O	Disease	451
of	ADP	O	O	451
the	PRON	O	O	451
combination	NOUN	O	O	451
of	ADP	O	O	451
GEM	NOUN	O	O	451
and	CCONJ	O	O	451
VNB	NOUN	O	O	451
in	ADP	O	O	451
elderly	ADJ	O	O	451
patients	NOUN	O	O	451
with	ADP	O	O	451
advanced	ADJ	O	O	451
NSCLC	PROPN	O	Disease	451
or	CCONJ	O	O	451
those	PRON	O	O	451
with	ADP	O	O	451
some	PRON	O	O	451
contraindication	NOUN	O	O	451
to	PART	O	O	451
receiving	VERB	O	O	451
cisplatin	NOUN	O	Chemical	451
were	AUX	O	O	451
assessed	VERB	O	O	451
.	PUNCT	O	O	451
METHODS	NOUN	O	O	452
:	PUNCT	O	O	452
Forty	NUM	O	O	452
-	PUNCT	O	O	452
nine	NUM	O	O	452
patients	NOUN	O	O	452
with	ADP	O	O	452
advanced	ADJ	O	O	452
NSCLC	PROPN	O	Disease	452
were	AUX	O	O	452
included	VERB	O	O	452
,	PUNCT	O	O	452
38	NUM	O	O	452
of	ADP	O	O	452
whom	PRON	O	O	452
were	AUX	O	O	452
age	NOUN	O	O	452
>	PUNCT	O	O	452
/=	PUNCT	O	O	452
70	NUM	O	O	452
years	NOUN	O	O	452
and	CCONJ	O	O	452
11	NUM	O	O	452
were	AUX	O	O	452
age	NOUN	O	O	452
<	X	O	O	453
70	NUM	O	O	453
years	NOUN	O	O	453
but	CCONJ	O	O	453
who	PRON	O	O	453
had	VERB	O	O	453
some	PRON	O	O	453
contraindication	NOUN	O	O	453
to	PART	O	O	453
receiving	VERB	O	O	453
cisplatin	NOUN	O	Chemical	453
.	PUNCT	O	O	453
All	PRON	O	O	454
patients	NOUN	O	O	454
were	AUX	O	O	454
evaluable	ADJ	O	O	454
for	ADP	O	O	454
response	NOUN	O	O	454
and	CCONJ	O	O	454
toxicity	NOUN	O	Disease	454
.	PUNCT	O	O	454
Treatment	NOUN	O	O	455
was	AUX	O	O	455
comprised	VERB	O	O	455
of	ADP	O	O	455
VNB	NOUN	O	O	455
,	PUNCT	O	O	455
25	NUM	O	O	455
mg	VERB	O	O	455
/	PUNCT	O	O	455
m(2	NUM	O	O	455
)	PUNCT	O	O	455
,	PUNCT	O	O	455
plus	CCONJ	O	O	455
GEM	NOUN	O	O	455
,	PUNCT	O	O	455
1000	NUM	O	O	455
mg	VERB	O	O	455
/	PUNCT	O	O	455
m(2	NUM	O	O	455
)	PUNCT	O	O	455
,	PUNCT	O	O	455
both	PRON	O	O	455
on	ADP	O	O	455
Days	NOUN	O	O	455
1	X	O	O	455
,	PUNCT	O	O	455
8	NUM	O	O	455
,	PUNCT	O	O	455
and	CCONJ	O	O	455
15	NUM	O	O	455
every	PRON	O	O	455
28	NUM	O	O	455
days	NOUN	O	O	455
.	PUNCT	O	O	455
Toxicity	NOUN	O	Disease	456
was	AUX	O	O	456
mild	ADJ	O	O	456
.	PUNCT	O	O	456
Six	NUM	O	O	457
patients	NOUN	O	O	457
(	PUNCT	O	O	457
12%	NOUN	O	O	457
)	PUNCT	O	O	457
had	VERB	O	O	457
World	NOUN	O	O	457
Health	NOUN	O	O	457
Organization	PROPN	O	O	457
Grade	NOUN	O	O	457
3	X	O	O	457
-	PUNCT	O	O	457
4	NUM	O	O	457
neutropenia	ADJ	O	Disease	457
,	PUNCT	O	O	457
2	X	O	O	457
patients	NOUN	O	O	457
(	PUNCT	O	O	457
4%	NOUN	O	O	457
)	PUNCT	O	O	457
had	VERB	O	O	457
Grade	NOUN	O	O	457
3	X	O	O	457
-	PUNCT	O	O	457
4	NUM	O	O	457
thrombocytopenia	PROPN	O	Disease	457
,	PUNCT	O	O	457
and	CCONJ	O	O	457
2	X	O	O	457
patients	NOUN	O	O	457
(	PUNCT	O	O	457
4%	NOUN	O	O	457
)	PUNCT	O	O	457
had	VERB	O	O	457
Grade	NOUN	O	O	457
3	X	O	O	457
neurotoxicity	NOUN	O	Disease	457
.	PUNCT	O	O	457
Three	NUM	O	O	458
patients	NOUN	O	O	458
with	ADP	O	O	458
severe	ADJ	O	O	458
neutropenia	ADJ	O	Disease	458
(	PUNCT	O	O	458
6%	NOUN	O	O	458
)	PUNCT	O	O	458
died	VERB	O	O	458
of	ADP	O	O	458
sepsis	NOUN	O	Disease	458
.	PUNCT	O	O	458
The	PRON	O	O	459
median	ADJ	O	O	459
age	NOUN	O	O	459
of	ADP	O	O	459
those	PRON	O	O	459
patients	NOUN	O	O	459
developing	VERB	O	O	459
Grade	NOUN	O	O	459
3	X	O	O	459
-	PUNCT	O	O	459
4	NUM	O	O	459
neutropenia	ADJ	O	Disease	459
was	AUX	O	O	459
significantly	ADV	O	O	459
higher	ADJ	O	O	459
than	ADP	O	O	459
that	SCONJ	O	O	459
of	ADP	O	O	459
the	PRON	O	O	459
remaining	VERB	O	O	459
patients	NOUN	O	O	459
(	PUNCT	O	O	459
75	NUM	O	O	459
years	NOUN	O	O	459
vs.	CCONJ	O	O	459
72	NUM	O	O	459
years	NOUN	O	O	459
;	PUNCT	O	O	459
P	NOUN	O	Chemical	459
=	PUNCT	O	O	459
0.047	NUM	O	O	459
)	PUNCT	O	O	459
.	PUNCT	O	O	459
The	PRON	O	O	460
combination	NOUN	O	O	460
of	ADP	O	O	460
GEM	NOUN	O	O	460
and	CCONJ	O	O	460
VNB	NOUN	O	O	460
is	AUX	O	O	460
moderately	ADV	O	O	460
active	ADJ	O	O	460
and	CCONJ	O	O	460
well	ADV	O	O	460
tolerated	VERB	O	O	460
except	SCONJ	O	O	460
in	ADP	O	O	460
patients	NOUN	O	O	460
age	NOUN	O	O	460
>	PUNCT	O	O	460
/=	PUNCT	O	O	460
75	NUM	O	O	460
years	NOUN	O	O	460
.	PUNCT	O	O	460
This	PRON	O	O	461
age	NOUN	O	O	461
group	NOUN	O	O	461
had	VERB	O	O	461
an	PRON	O	O	461
increased	VERB	O	O	461
risk	NOUN	O	O	461
of	ADP	O	O	461
myelosuppression	NOUN	O	Disease	461
.	PUNCT	O	O	461
New	ADJ	O	O	462
chemotherapy	NOUN	O	O	462
combinations	NOUN	O	O	462
with	ADP	O	O	462
higher	ADJ	O	O	462
activity	NOUN	O	O	462
and	CCONJ	O	O	462
lower	ADJ	O	O	462
toxicity	NOUN	O	Disease	462
are	AUX	O	O	462
needed	VERB	O	O	462
for	ADP	O	O	462
elderly	ADJ	O	O	462
patients	NOUN	O	O	462
with	ADP	O	O	462
advanced	ADJ	O	O	462
NSCLC	PROPN	O	Disease	462
.	PUNCT	O	O	462
Warfarin	PROPN	O	Chemical	465
-	PUNCT	O	O	465
induced	VERB	O	O	465
artery	NOUN	O	O	465
calcification	NOUN	O	O	465
is	AUX	O	O	465
accelerated	VERB	O	O	465
by	ADP	O	O	465
growth	NOUN	O	O	465
and	CCONJ	O	O	465
vitamin D.	PROPN	O	O	465
The	PRON	O	O	466
present	NOUN	O	O	466
studies	NOUN	O	O	466
demonstrate	VERB	O	O	466
that	SCONJ	O	O	466
growth	NOUN	O	O	466
and	CCONJ	O	O	466
vitamin D	NOUN	O	Chemical	466
treatment	NOUN	O	O	466
enhance	VERB	O	O	466
the	PRON	O	O	466
extent	NOUN	O	O	466
of	ADP	O	O	466
artery	NOUN	O	O	466
calcification	NOUN	O	O	466
in	ADP	O	O	466
rats	NOUN	O	O	466
given	VERB	O	O	466
sufficient	ADJ	O	O	466
doses	NOUN	O	O	466
of	ADP	O	O	466
Warfarin	PROPN	O	Chemical	466
to	PART	O	O	466
inhibit	VERB	O	O	466
gamma	PROPN	O	O	466
-	PUNCT	O	O	466
carboxylation	NOUN	O	O	466
of	ADP	O	O	466
matrix	NOUN	O	O	466
Gla	NOUN	O	O	466
protein	NOUN	O	O	466
,	PUNCT	O	O	466
a	PRON	O	O	466
calcification	NOUN	O	O	466
inhibitor	NOUN	O	O	466
known	VERB	O	O	466
to	PART	O	O	466
be	AUX	O	O	466
expressed	VERB	O	O	466
by	ADP	O	O	466
smooth	VERB	O	O	466
muscle	NOUN	O	O	466
cells	NOUN	O	O	466
and	CCONJ	O	O	466
macrophages	VERB	O	O	466
in	ADP	O	O	466
the	PRON	O	O	466
artery	NOUN	O	O	466
wall	PROPN	O	O	466
.	PUNCT	O	O	466
The	PRON	O	O	467
first	ADV	O	O	467
series	PROPN	O	O	467
of	ADP	O	O	467
experiments	NOUN	O	O	467
examined	VERB	O	O	467
the	PRON	O	O	467
influence	NOUN	O	O	467
of	ADP	O	O	467
age	NOUN	O	O	467
and	CCONJ	O	O	467
growth	NOUN	O	O	467
status	NOUN	O	O	467
on	ADP	O	O	467
artery	NOUN	O	O	467
calcification	NOUN	O	O	467
in	ADP	O	O	467
Warfarin	PROPN	O	Chemical	467
-	PUNCT	O	O	467
treated	VERB	O	O	467
rats	NOUN	O	O	467
.	PUNCT	O	O	467
Treatment	NOUN	O	O	468
for	ADP	O	O	468
2	X	O	O	468
weeks	NOUN	O	O	468
with	ADP	O	O	468
Warfarin	PROPN	O	Chemical	468
caused	VERB	O	O	468
massive	ADJ	O	O	468
focal	ADJ	O	O	468
calcification	NOUN	O	O	468
of	ADP	O	O	468
the	PRON	O	O	468
artery	NOUN	O	O	468
media	NOUN	O	O	468
in	ADP	O	O	468
20-day	NOUN	O	O	468
-	PUNCT	O	O	468
old	ADJ	O	O	468
rats	NOUN	O	O	468
and	CCONJ	O	O	468
less	ADV	O	O	468
extensive	ADJ	O	O	468
focal	ADJ	O	O	468
calcification	NOUN	O	O	468
in	ADP	O	O	468
42-day	NOUN	O	O	468
-	PUNCT	O	O	468
old	ADJ	O	O	468
rats	NOUN	O	O	468
.	PUNCT	O	O	468
In	ADP	O	O	469
contrast	NOUN	O	O	469
,	PUNCT	O	O	469
no	PRON	O	O	469
artery	NOUN	O	O	469
calcification	NOUN	O	O	469
could	AUX	O	O	469
be	AUX	O	O	469
detected	VERB	O	O	469
in	ADP	O	O	469
10-month	NOUN	O	O	469
-	PUNCT	O	O	469
old	ADJ	O	O	469
adult	NOUN	O	O	469
rats	NOUN	O	O	469
even	ADV	O	O	469
after	ADP	O	O	469
4	NUM	O	O	469
weeks	NOUN	O	O	469
of	ADP	O	O	469
Warfarin	PROPN	O	Chemical	469
treatment	NOUN	O	O	469
.	PUNCT	O	O	469
To	PART	O	O	470
directly	ADV	O	O	470
examine	VERB	O	O	470
the	PRON	O	O	470
importance	NOUN	O	O	470
of	ADP	O	O	470
growth	NOUN	O	O	470
to	PART	O	O	470
Warfarin	PROPN	O	Chemical	470
-	PUNCT	O	O	470
induced	VERB	O	O	470
artery	NOUN	O	O	470
calcification	NOUN	O	O	470
in	ADP	O	O	470
animals	NOUN	O	O	470
of	ADP	O	O	470
the	PRON	O	O	470
same	ADJ	O	O	470
age	NOUN	O	O	470
,	PUNCT	O	O	470
20-day	NOUN	O	O	470
-	PUNCT	O	O	470
old	ADJ	O	O	470
rats	NOUN	O	O	470
were	AUX	O	O	470
fed	VERB	O	O	470
for	ADP	O	O	470
2	X	O	O	470
weeks	NOUN	O	O	470
either	ADV	O	O	470
an	PRON	O	O	470
ad	NOUN	O	O	470
libitum	NOUN	O	O	470
diet	PROPN	O	O	470
or	CCONJ	O	O	470
a	PRON	O	O	470
6-g	NOUN	O	O	470
/	PUNCT	O	O	470
d	X	O	O	470
restricted	VERB	O	O	470
diet	PROPN	O	O	470
that	SCONJ	O	O	470
maintains	VERB	O	O	470
weight	NOUN	O	O	470
but	CCONJ	O	O	470
prevents	VERB	O	O	470
growth	NOUN	O	O	470
.	PUNCT	O	O	470
Concurrent	ADJ	O	O	471
treatment	NOUN	O	O	471
of	ADP	O	O	471
both	PRON	O	O	471
dietary	ADJ	O	O	471
groups	NOUN	O	O	471
with	ADP	O	O	471
Warfarin	PROPN	O	Chemical	471
produced	VERB	O	O	471
massive	ADJ	O	O	471
focal	ADJ	O	O	471
calcification	NOUN	O	O	471
of	ADP	O	O	471
the	PRON	O	O	471
artery	NOUN	O	O	471
media	NOUN	O	O	471
in	ADP	O	O	471
the	PRON	O	O	471
ad	NOUN	O	O	471
libitum	NOUN	O	O	471
-	PUNCT	O	O	471
fed	VERB	O	O	471
rats	NOUN	O	O	471
but	CCONJ	O	O	471
no	PRON	O	O	471
detectable	ADJ	O	O	471
artery	NOUN	O	O	471
calcification	NOUN	O	O	471
in	ADP	O	O	471
the	PRON	O	O	471
restricted	VERB	O	O	471
-	PUNCT	O	O	471
diet	PROPN	O	O	471
,	PUNCT	O	O	471
growth	NOUN	O	O	471
-	PUNCT	O	O	471
inhibited	VERB	O	O	471
group	NOUN	O	O	471
.	PUNCT	O	O	471
Although	SCONJ	O	O	472
the	PRON	O	O	472
explanation	NOUN	O	O	472
for	ADP	O	O	472
the	PRON	O	O	472
association	PROPN	O	O	472
between	ADP	O	O	472
artery	NOUN	O	O	472
calcification	NOUN	O	O	472
and	CCONJ	O	O	472
growth	NOUN	O	O	472
status	NOUN	O	O	472
can	AUX	O	O	472
not	PART	O	O	472
be	AUX	O	O	472
determined	VERB	O	O	472
from	ADP	O	O	472
the	PRON	O	O	472
present	NOUN	O	O	472
study	VERB	O	O	472
,	PUNCT	O	O	472
there	ADV	O	O	472
was	AUX	O	O	472
a	PRON	O	O	472
relationship	NOUN	O	O	472
between	ADP	O	O	472
higher	ADJ	O	O	472
serum	NOUN	O	O	472
phosphate	NOUN	O	Chemical	472
and	CCONJ	O	O	472
susceptibility	NOUN	O	O	472
to	PART	O	O	472
artery	NOUN	O	O	472
calcification	NOUN	O	O	472
,	PUNCT	O	O	472
with	ADP	O	O	472
30%	NOUN	O	O	472
higher	ADJ	O	O	472
levels	NOUN	O	O	472
of	ADP	O	O	472
serum	NOUN	O	O	472
phosphate	NOUN	O	Chemical	472
in	ADP	O	O	472
young	ADJ	O	O	472
,	PUNCT	O	O	472
ad	NOUN	O	O	472
libitum	NOUN	O	O	472
-	PUNCT	O	O	472
fed	VERB	O	O	472
rats	NOUN	O	O	472
compared	VERB	O	O	472
with	ADP	O	O	472
either	ADV	O	O	472
of	ADP	O	O	472
the	PRON	O	O	472
groups	NOUN	O	O	472
that	SCONJ	O	O	472
was	AUX	O	O	472
resistant	ADJ	O	O	472
to	PART	O	O	472
Warfarin	PROPN	O	Chemical	472
-	PUNCT	O	O	472
induced	VERB	O	O	472
artery	NOUN	O	O	472
calcification	NOUN	O	O	472
,	PUNCT	O	O	472
ie	ADV	O	O	472
,	PUNCT	O	O	472
the	PRON	O	O	472
10-month	NOUN	O	O	472
-	PUNCT	O	O	472
old	ADJ	O	O	472
rats	NOUN	O	O	472
and	CCONJ	O	O	472
the	PRON	O	O	472
restricted	VERB	O	O	472
-	PUNCT	O	O	472
diet	PROPN	O	O	472
,	PUNCT	O	O	472
growth	NOUN	O	O	472
-	PUNCT	O	O	472
inhibited	VERB	O	O	472
young	ADJ	O	O	472
rats	NOUN	O	O	472
.	PUNCT	O	O	472
This	PRON	O	O	473
observation	NOUN	O	O	473
suggests	VERB	O	O	473
that	SCONJ	O	O	473
increased	VERB	O	O	473
susceptibility	NOUN	O	O	473
to	PART	O	O	473
Warfarin	PROPN	O	Chemical	473
-	PUNCT	O	O	473
induced	VERB	O	O	473
artery	NOUN	O	O	473
calcification	NOUN	O	O	473
could	AUX	O	O	473
be	AUX	O	O	473
related	ADJ	O	O	473
to	PART	O	O	473
higher	ADJ	O	O	473
serum	NOUN	O	O	473
phosphate	NOUN	O	Chemical	473
levels	NOUN	O	O	473
.	PUNCT	O	O	473
The	PRON	O	O	474
second	ADV	O	O	474
set	VERB	O	O	474
of	ADP	O	O	474
experiments	NOUN	O	O	474
examined	VERB	O	O	474
the	PRON	O	O	474
possible	ADJ	O	O	474
synergy	PROPN	O	O	474
between	ADP	O	O	474
vitamin D	NOUN	O	Chemical	474
and	CCONJ	O	O	474
Warfarin	PROPN	O	Chemical	474
in	ADP	O	O	474
artery	NOUN	O	O	474
calcification	NOUN	O	O	474
.	PUNCT	O	O	474
High	ADJ	O	O	475
doses	NOUN	O	O	475
of	ADP	O	O	475
vitamin D	NOUN	O	Chemical	475
are	AUX	O	O	475
known	VERB	O	O	475
to	PART	O	O	475
cause	VERB	O	O	475
calcification	NOUN	O	O	475
of	ADP	O	O	475
the	PRON	O	O	475
artery	NOUN	O	O	475
media	NOUN	O	O	475
in	ADP	O	O	475
as	ADP	O	O	475
little	ADJ	O	O	475
as	ADP	O	O	475
3	X	O	O	475
to	PART	O	O	475
4	NUM	O	O	475
days	NOUN	O	O	475
.	PUNCT	O	O	475
High	ADJ	O	O	476
doses	NOUN	O	O	476
of	ADP	O	O	476
the	PRON	O	O	476
vitamin	NOUN	O	O	476
K	PROPN	O	Chemical	476
antagonist	NOUN	O	O	476
Warfarin	PROPN	O	Chemical	476
are	AUX	O	O	476
also	ADV	O	O	476
known	VERB	O	O	476
to	PART	O	O	476
cause	VERB	O	O	476
calcification	NOUN	O	O	476
of	ADP	O	O	476
the	PRON	O	O	476
artery	NOUN	O	O	476
media	NOUN	O	O	476
,	PUNCT	O	O	476
but	CCONJ	O	O	476
at	ADP	O	O	476
treatment	NOUN	O	O	476
times	NOUN	O	O	476
of	ADP	O	O	476
2	X	O	O	476
weeks	NOUN	O	O	476
or	CCONJ	O	O	476
longer	ADV	O	O	476
yet	ADV	O	O	476
not	PART	O	O	476
at	ADP	O	O	476
1	X	O	O	476
week	NOUN	O	O	476
.	PUNCT	O	O	476
In	ADP	O	O	477
the	PRON	O	O	477
current	ADJ	O	O	477
study	VERB	O	O	477
,	PUNCT	O	O	477
we	PRON	O	O	477
investigated	VERB	O	O	477
the	PRON	O	O	477
synergy	PROPN	O	O	477
between	ADP	O	O	477
these	PRON	O	O	477
2	X	O	O	477
treatments	NOUN	O	O	477
and	CCONJ	O	O	477
found	VERB	O	O	477
that	SCONJ	O	O	477
concurrent	ADJ	O	O	477
Warfarin	PROPN	O	Chemical	477
administration	NOUN	O	O	477
dramatically	ADV	O	O	477
increased	VERB	O	O	477
the	PRON	O	O	477
extent	NOUN	O	O	477
of	ADP	O	O	477
calcification	NOUN	O	O	477
in	ADP	O	O	477
the	PRON	O	O	477
media	NOUN	O	O	477
of	ADP	O	O	477
vitamin D	NOUN	O	Chemical	477
-	PUNCT	O	O	477
treated	VERB	O	O	477
rats	NOUN	O	O	477
at	ADP	O	O	477
3	X	O	O	477
and	CCONJ	O	O	477
4	NUM	O	O	477
days	NOUN	O	O	477
.	PUNCT	O	O	477
There	ADV	O	O	478
was	AUX	O	O	478
a	PRON	O	O	478
close	ADV	O	O	478
parallel	ADJ	O	O	478
between	ADP	O	O	478
the	PRON	O	O	478
effect	VERB	O	O	478
of	ADP	O	O	478
vitamin D	NOUN	O	Chemical	478
dose	NOUN	O	O	478
on	ADP	O	O	478
artery	NOUN	O	O	478
calcification	NOUN	O	O	478
and	CCONJ	O	O	478
the	PRON	O	O	478
effect	VERB	O	O	478
of	ADP	O	O	478
vitamin D	NOUN	O	Chemical	478
dose	NOUN	O	O	478
on	ADP	O	O	478
the	PRON	O	O	478
elevation	NOUN	O	O	478
of	ADP	O	O	478
serum	NOUN	O	O	478
calcium	NOUN	O	Chemical	478
,	PUNCT	O	O	478
which	PRON	O	O	478
suggests	VERB	O	O	478
that	SCONJ	O	O	478
vitamin D	NOUN	O	Chemical	478
may	AUX	O	O	478
induce	VERB	O	O	478
artery	NOUN	O	O	478
calcification	NOUN	O	O	478
through	ADP	O	O	478
its	PRON	O	O	478
effect	VERB	O	O	478
on	ADP	O	O	478
serum	NOUN	O	O	478
calcium	NOUN	O	Chemical	478
.	PUNCT	O	O	478
Because	SCONJ	O	O	479
Warfarin	PROPN	O	Chemical	479
treatment	NOUN	O	O	479
had	VERB	O	O	479
no	PRON	O	O	479
effect	VERB	O	O	479
on	ADP	O	O	479
the	PRON	O	O	479
elevation	NOUN	O	O	479
in	ADP	O	O	479
serum	NOUN	O	O	479
calcium	NOUN	O	Chemical	479
produced	VERB	O	O	479
by	ADP	O	O	479
vitamin D	NOUN	O	Chemical	479
,	PUNCT	O	O	479
the	PRON	O	O	479
synergy	PROPN	O	O	479
between	ADP	O	O	479
Warfarin	PROPN	O	Chemical	479
and	CCONJ	O	O	479
vitamin D	NOUN	O	Chemical	479
is	AUX	O	O	479
probably	ADV	O	O	479
best	ADV	O	O	479
explained	VERB	O	O	479
by	ADP	O	O	479
the	PRON	O	O	479
hypothesis	NOUN	O	O	479
that	SCONJ	O	O	479
Warfarin	PROPN	O	Chemical	479
inhibits	VERB	O	O	479
the	PRON	O	O	479
activity	NOUN	O	O	479
of	ADP	O	O	479
matrix	NOUN	O	O	479
Gla	NOUN	O	O	479
protein	NOUN	O	O	479
as	ADP	O	O	479
a	PRON	O	O	479
calcification	NOUN	O	O	479
inhibitor	NOUN	O	O	479
.	PUNCT	O	O	479
High	ADJ	O	O	480
levels	NOUN	O	O	480
of	ADP	O	O	480
matrix	NOUN	O	O	480
Gla	NOUN	O	O	480
protein	NOUN	O	O	480
are	AUX	O	O	480
found	VERB	O	O	480
at	ADP	O	O	480
sites	NOUN	O	O	480
of	ADP	O	O	480
artery	NOUN	O	O	480
calcification	NOUN	O	O	480
in	ADP	O	O	480
rats	NOUN	O	O	480
treated	VERB	O	O	480
with	ADP	O	O	480
vitamin D	NOUN	O	Chemical	480
plus	CCONJ	O	O	480
Warfarin	PROPN	O	Chemical	480
,	PUNCT	O	O	480
and	CCONJ	O	O	480
chemical	PROPN	O	O	480
analysis	NOUN	O	O	480
showed	VERB	O	O	480
that	SCONJ	O	O	480
the	PRON	O	O	480
protein	NOUN	O	O	480
that	SCONJ	O	O	480
accumulated	VERB	O	O	480
was	AUX	O	O	480
indeed	ADV	O	O	480
not	PART	O	O	480
gamma	PROPN	O	O	480
-	PUNCT	O	O	480
carboxylated	VERB	O	O	480
.	PUNCT	O	O	480
These	PRON	O	O	481
observations	NOUN	O	O	481
indicate	VERB	O	O	481
that	SCONJ	O	O	481
although	SCONJ	O	O	481
the	PRON	O	O	481
gamma	PROPN	O	O	481
-	PUNCT	O	O	481
carboxyglutamate	ADJ	O	O	481
residues	NOUN	O	O	481
of	ADP	O	O	481
matrix	NOUN	O	O	481
Gla	NOUN	O	O	481
protein	NOUN	O	O	481
are	AUX	O	O	481
apparently	ADV	O	O	481
required	VERB	O	O	481
for	ADP	O	O	481
its	PRON	O	O	481
function	NOUN	O	O	481
as	ADP	O	O	481
a	PRON	O	O	481
calcification	NOUN	O	O	481
inhibitor	NOUN	O	O	481
,	PUNCT	O	O	481
they	PRON	O	O	481
are	AUX	O	O	481
not	PART	O	O	481
required	VERB	O	O	481
for	ADP	O	O	481
its	PRON	O	O	481
accumulation	NOUN	O	O	481
at	ADP	O	O	481
calcification	NOUN	O	O	481
sites	NOUN	O	O	481
.	PUNCT	O	O	481
Antidepressant	NOUN	O	O	484
-	PUNCT	O	O	484
induced	VERB	O	O	484
mania	NOUN	O	O	484
in	ADP	O	O	484
bipolar	ADJ	O	O	484
patients	NOUN	O	O	484
:	PUNCT	O	O	484
identification	NOUN	O	O	484
of	ADP	O	O	484
risk	NOUN	O	O	484
factors	NOUN	O	O	484
.	PUNCT	O	O	484
Concerns	NOUN	O	O	485
about	ADP	O	O	485
possible	ADJ	O	O	485
risks	NOUN	O	O	485
of	ADP	O	O	485
switching	VERB	O	O	485
to	PART	O	O	485
mania	NOUN	O	O	485
associated	VERB	O	O	485
with	ADP	O	O	485
antidepressants	NOUN	O	O	485
continue	VERB	O	O	485
to	PART	O	O	485
interfere	VERB	O	O	485
with	ADP	O	O	485
the	PRON	O	O	485
establishment	NOUN	O	O	485
of	ADP	O	O	485
an	PRON	O	O	485
optimal	ADJ	O	O	485
treatment	NOUN	O	O	485
paradigm	NOUN	O	O	485
for	ADP	O	O	485
bipolar	ADJ	O	O	485
depression	PROPN	O	Disease	485
.	PUNCT	O	O	485
The	PRON	O	O	486
response	NOUN	O	O	486
of	ADP	O	O	486
44	NUM	O	O	486
patients	NOUN	O	O	486
meeting	NOUN	O	O	486
DSM	PROPN	O	O	486
-	PUNCT	O	O	486
IV	NUM	O	O	486
criteria	NOUN	O	O	486
for	ADP	O	O	486
bipolar disorder	NOUN	O	Disease	486
to	PART	O	O	486
naturalistic	ADJ	O	O	486
treatment	NOUN	O	O	486
was	AUX	O	O	486
assessed	VERB	O	O	486
for	ADP	O	O	486
at	ADP	O	O	486
least	ADJ	O	O	486
6	NUM	O	O	486
weeks	NOUN	O	O	486
using	VERB	O	O	486
the	PRON	O	O	486
Montgomery	PROPN	O	O	486
-	PUNCT	O	O	486
Asberg	PROPN	O	O	486
Depression	NOUN	O	O	486
Rating	NOUN	O	O	486
Scale	NOUN	O	O	486
and	CCONJ	O	O	486
the	PRON	O	O	486
Bech	PROPN	O	O	486
-	PUNCT	O	O	486
Rafaelson	NOUN	O	O	486
Mania	NOUN	O	O	486
Rating	NOUN	O	O	486
Scale	NOUN	O	O	486
.	PUNCT	O	O	486
Patients	NOUN	O	O	487
who	PRON	O	O	487
experienced	ADJ	O	O	487
a	PRON	O	O	487
manic	ADJ	O	O	487
or	CCONJ	O	O	487
hypomanic	ADJ	O	O	487
switch	VERB	O	O	487
were	AUX	O	O	487
compared	VERB	O	O	487
with	ADP	O	O	487
those	PRON	O	O	487
who	PRON	O	O	487
did	VERB	O	O	487
not	PART	O	O	487
on	ADP	O	O	487
several	ADJ	O	O	487
variables	NOUN	O	O	487
including	VERB	O	O	487
age	NOUN	O	O	487
,	PUNCT	O	O	487
sex	NOUN	O	O	487
,	PUNCT	O	O	487
diagnosis	NOUN	O	O	487
(	PUNCT	O	O	487
DSM	PROPN	O	O	487
-	PUNCT	O	O	487
IV	NUM	O	O	487
bipolar	ADJ	O	O	487
I	PRON	O	O	487
vs.	CCONJ	O	O	487
bipolar	ADJ	O	O	487
II	NUM	O	O	487
)	PUNCT	O	O	487
,	PUNCT	O	O	487
number	NOUN	O	O	487
of	ADP	O	O	487
previous	ADJ	O	O	487
manic	ADJ	O	O	487
episodes	NOUN	O	O	487
,	PUNCT	O	O	487
type	NOUN	O	O	487
of	ADP	O	O	487
antidepressant	NOUN	O	O	487
therapy	NOUN	O	O	487
used	VERB	O	O	487
(	PUNCT	O	O	487
electroconvulsive	VERB	O	O	487
therapy	NOUN	O	O	487
vs.	CCONJ	O	O	487
antidepressant	NOUN	O	O	487
drugs	NOUN	O	O	487
and	CCONJ	O	O	487
,	PUNCT	O	O	487
more	ADJ	O	O	487
particularly	ADV	O	O	487
,	PUNCT	O	O	487
selective	ADJ	O	O	487
serotonin	PROPN	O	Chemical	487
reuptake	PROPN	O	O	487
inhibitors	NOUN	O	O	487
[	X	O	O	487
SSRIs	NOUN	O	O	487
]	PUNCT	O	O	487
)	PUNCT	O	O	487
,	PUNCT	O	O	487
use	VERB	O	O	487
and	CCONJ	O	O	487
type	NOUN	O	O	487
of	ADP	O	O	487
mood	NOUN	O	O	487
stabilizers	NOUN	O	O	487
(	PUNCT	O	O	487
lithium	NOUN	O	Chemical	487
vs.	CCONJ	O	O	487
anticonvulsants	NOUN	O	O	487
)	PUNCT	O	O	487
,	PUNCT	O	O	487
and	CCONJ	O	O	487
temperament	NOUN	O	O	487
of	ADP	O	O	487
the	PRON	O	O	487
patient	NOUN	O	O	487
,	PUNCT	O	O	487
assessed	VERB	O	O	487
during	ADP	O	O	487
a	PRON	O	O	487
normothymic	PROPN	O	O	487
period	NOUN	O	O	487
using	VERB	O	O	487
the	PRON	O	O	487
hyperthymia	PROPN	O	O	487
component	NOUN	O	O	487
of	ADP	O	O	487
the	PRON	O	O	487
Semi	ADJ	O	O	487
-	PUNCT	O	O	487
structured	VERB	O	O	487
Affective	ADJ	O	O	487
Temperament	NOUN	O	O	487
Interview	NOUN	O	O	487
.	PUNCT	O	O	487
Switches	NOUN	O	O	488
to	PART	O	O	488
hypomania	PROPN	O	Disease	488
or	CCONJ	O	O	488
mania	NOUN	O	O	488
occurred	VERB	O	O	488
in	ADP	O	O	488
27%	NOUN	O	O	488
of	ADP	O	O	488
all	PRON	O	O	488
patients	NOUN	O	O	488
(	PUNCT	O	O	488
N	NUM	O	O	488
=	PUNCT	O	O	488
12	NUM	O	O	488
)	PUNCT	O	O	488
(	PUNCT	O	O	488
and	CCONJ	O	O	488
in	ADP	O	O	488
24%	NOUN	O	O	488
of	ADP	O	O	488
the	PRON	O	O	488
subgroup	PROPN	O	O	488
of	ADP	O	O	488
patients	NOUN	O	O	488
treated	VERB	O	O	488
with	ADP	O	O	488
SSRIs	NOUN	O	O	488
[	X	O	O	488
8/33	NUM	O	O	488
]	PUNCT	O	O	488
)	PUNCT	O	O	488
;	PUNCT	O	O	488
16%	NOUN	O	O	488
(	PUNCT	O	O	488
N	NUM	O	O	488
=	PUNCT	O	O	488
7	NUM	O	O	488
)	PUNCT	O	O	488
experienced	ADJ	O	O	488
manic	ADJ	O	O	488
episodes	NOUN	O	O	488
,	PUNCT	O	O	488
and	CCONJ	O	O	488
11%	NOUN	O	O	488
(	PUNCT	O	O	488
N	NUM	O	O	488
=	PUNCT	O	O	488
5	NUM	O	O	488
)	PUNCT	O	O	488
experienced	ADJ	O	O	488
hypomanic	ADJ	O	O	488
episodes	NOUN	O	O	488
.	PUNCT	O	O	488
Sex	NOUN	O	O	489
,	PUNCT	O	O	489
age	NOUN	O	O	489
,	PUNCT	O	O	489
diagnosis	NOUN	O	O	489
(	PUNCT	O	O	489
bipolar	ADJ	O	O	489
I	PRON	O	O	489
vs.	CCONJ	O	O	489
bipolar	ADJ	O	O	489
II	NUM	O	O	489
)	PUNCT	O	O	489
,	PUNCT	O	O	489
and	CCONJ	O	O	489
additional	ADJ	O	O	489
treatment	NOUN	O	O	489
did	VERB	O	O	489
not	PART	O	O	489
affect	VERB	O	O	489
the	PRON	O	O	489
risk	NOUN	O	O	489
of	ADP	O	O	489
switching	VERB	O	O	489
.	PUNCT	O	O	489
In	ADP	O	O	490
contrast	NOUN	O	O	490
,	PUNCT	O	O	490
mood	NOUN	O	O	490
switches	VERB	O	O	490
were	AUX	O	O	490
less	ADV	O	O	490
frequent	ADJ	O	O	490
in	ADP	O	O	490
patients	NOUN	O	O	490
receiving	VERB	O	O	490
lithium	NOUN	O	Chemical	490
(	PUNCT	O	O	490
15%	NOUN	O	O	490
,	PUNCT	O	O	490
4/26	NUM	O	O	490
)	PUNCT	O	O	490
than	ADP	O	O	490
in	ADP	O	O	490
patients	NOUN	O	O	490
not	PART	O	O	490
treated	VERB	O	O	490
with	ADP	O	O	490
lithium	NOUN	O	Chemical	490
(	PUNCT	O	O	490
44%	NOUN	O	O	490
,	PUNCT	O	O	490
8/18	NUM	O	O	490
;	PUNCT	O	O	490
p	NOUN	O	O	490
=	PUNCT	O	O	490
.04	NUM	O	O	490
)	PUNCT	O	O	490
.	PUNCT	O	O	490
The	PRON	O	O	491
number	NOUN	O	O	491
of	ADP	O	O	491
previous	ADJ	O	O	491
manic	ADJ	O	O	491
episodes	NOUN	O	O	491
did	VERB	O	O	491
not	PART	O	O	491
affect	VERB	O	O	491
the	PRON	O	O	491
probability	NOUN	O	O	491
of	ADP	O	O	491
switching	VERB	O	O	491
,	PUNCT	O	O	491
whereas	SCONJ	O	O	491
a	PRON	O	O	491
high	ADJ	O	O	491
score	VERB	O	O	491
on	ADP	O	O	491
the	PRON	O	O	491
hyperthymia	PROPN	O	O	491
component	NOUN	O	O	491
of	ADP	O	O	491
the	PRON	O	O	491
Semistructured	VERB	O	O	491
Affective	ADJ	O	O	491
Temperament	NOUN	O	O	491
Interview	NOUN	O	O	491
was	AUX	O	O	491
associated	VERB	O	O	491
with	ADP	O	O	491
a	PRON	O	O	491
greater	ADJ	O	O	491
risk	NOUN	O	O	491
of	ADP	O	O	491
switching	VERB	O	O	491
(	PUNCT	O	O	491
p	NOUN	O	O	491
=	PUNCT	O	O	491
.008	NUM	O	O	491
)	PUNCT	O	O	491
.	PUNCT	O	O	491
The	PRON	O	O	492
frequency	NOUN	O	O	492
of	ADP	O	O	492
mood	NOUN	O	O	492
switching	VERB	O	O	492
associated	VERB	O	O	492
with	ADP	O	O	492
acute	ADJ	O	O	492
antidepressant	NOUN	O	O	492
therapy	NOUN	O	O	492
may	AUX	O	O	492
be	AUX	O	O	492
reduced	VERB	O	O	492
by	ADP	O	O	492
lithium	NOUN	O	Chemical	492
treatment	NOUN	O	O	492
.	PUNCT	O	O	492
Caffeine	NOUN	O	Chemical	495
-	PUNCT	O	O	495
induced	VERB	O	O	495
cardiac arrhythmia	NOUN	O	Disease	495
:	PUNCT	O	O	495
an	PRON	O	O	495
unrecognised	ADJ	O	O	495
danger	NOUN	O	O	495
of	ADP	O	O	495
healthfood	NOUN	O	O	495
products	NOUN	O	O	495
.	PUNCT	O	O	495
We	PRON	O	O	496
describe	VERB	O	O	496
a	PRON	O	O	496
25-year	NOUN	O	O	496
-	PUNCT	O	O	496
old	ADJ	O	O	496
woman	NOUN	O	O	496
with	ADP	O	O	496
pre	VERB	O	O	496
-	PUNCT	O	O	496
existing	VERB	O	O	496
mitral	ADJ	O	O	496
valve	PROPN	O	O	496
prolapse	NOUN	O	O	496
who	PRON	O	O	496
developed	VERB	O	O	496
intractable	ADJ	O	O	496
ventricular fibrillation	NOUN	O	Disease	496
after	ADP	O	O	496
consuming	VERB	O	O	496
a	PRON	O	O	496
""""	PUNCT	O	O	496
natural	ADJ	O	O	496
energy	PROPN	O	O	496
""""	PUNCT	O	O	496
guarana	NOUN	O	O	496
health	NOUN	O	O	496
drink	VERB	O	O	496
containing	VERB	O	O	496
a	PRON	O	O	496
high	ADJ	O	O	496
concentration	NOUN	O	O	496
of	ADP	O	O	496
caffeine	NOUN	O	Chemical	496
.	PUNCT	O	O	496
Bladder	NOUN	O	O	499
retention	NOUN	O	O	499
of	ADP	O	O	499
urine	NOUN	O	O	499
as	ADP	O	O	499
a	PRON	O	O	499
result	VERB	O	O	499
of	ADP	O	O	499
continuous	ADJ	O	O	499
intravenous	ADJ	O	O	499
infusion	NOUN	O	O	499
of	ADP	O	O	499
fentanyl	ADJ	O	Chemical	499
:	PUNCT	O	O	499
2	X	O	O	499
case	NOUN	O	O	499
reports	VERB	O	O	499
.	PUNCT	O	O	499
Sedation	NOUN	O	O	500
has	VERB	O	O	500
been	AUX	O	O	500
commonly	ADV	O	O	500
used	VERB	O	O	500
in	ADP	O	O	500
the	PRON	O	O	500
neonate	NOUN	O	O	500
to	PART	O	O	500
decrease	VERB	O	O	500
the	PRON	O	O	500
stress	NOUN	O	O	500
and	CCONJ	O	O	500
pain	NOUN	O	Disease	500
from	ADP	O	O	500
the	PRON	O	O	500
noxious	ADJ	O	O	500
stimuli	NOUN	O	O	500
and	CCONJ	O	O	500
invasive	ADJ	O	O	500
procedures	NOUN	O	O	500
in	ADP	O	O	500
the	PRON	O	O	500
neonatal	NOUN	O	O	500
intensive	ADJ	O	O	500
care	VERB	O	O	500
unit	NOUN	O	O	500
,	PUNCT	O	O	500
as	ADP	O	O	500
well	ADV	O	O	500
as	ADP	O	O	500
to	PART	O	O	500
facilitate	VERB	O	O	500
synchrony	NOUN	O	O	500
between	ADP	O	O	500
ventilator	NOUN	O	O	500
and	CCONJ	O	O	500
spontaneous	ADJ	O	O	500
breaths	NOUN	O	O	500
.	PUNCT	O	O	500
Fentanyl	NOUN	O	O	501
,	PUNCT	O	O	501
an	PRON	O	O	501
opioid	NOUN	O	O	501
analgesic	PROPN	O	O	501
,	PUNCT	O	O	501
is	AUX	O	O	501
frequently	ADV	O	O	501
used	VERB	O	O	501
in	ADP	O	O	501
the	PRON	O	O	501
neonatal	NOUN	O	O	501
intensive	ADJ	O	O	501
care	VERB	O	O	501
unit	NOUN	O	O	501
setting	VERB	O	O	501
for	ADP	O	O	501
these	PRON	O	O	501
very	ADV	O	O	501
purposes	NOUN	O	O	501
.	PUNCT	O	O	501
Various	ADJ	O	O	502
reported	VERB	O	O	502
side	NOUN	O	O	502
effects	NOUN	O	O	502
of	ADP	O	O	502
fentanyl	ADJ	O	Chemical	502
administration	NOUN	O	O	502
include	VERB	O	O	502
chest	NOUN	O	O	502
wall	PROPN	O	O	502
rigidity	NOUN	O	Disease	502
,	PUNCT	O	O	502
hypotension	NOUN	O	Disease	502
,	PUNCT	O	O	502
respiratory depression	NOUN	O	Disease	502
,	PUNCT	O	O	502
and	CCONJ	O	O	502
bradycardia	NOUN	O	Disease	502
.	PUNCT	O	O	502
Here	ADV	O	O	503
,	PUNCT	O	O	503
2	X	O	O	503
cases	NOUN	O	O	503
of	ADP	O	O	503
urinary	ADJ	O	O	503
bladder	NOUN	O	O	503
retention	NOUN	O	O	503
leading	VERB	O	O	503
to	PART	O	O	503
renal	ADJ	O	O	503
pelvocalyceal	NOUN	O	O	504
dilatation	NOUN	O	O	504
mimicking	VERB	O	O	504
hydronephrosis	NOUN	O	O	504
as	ADP	O	O	504
a	PRON	O	O	504
result	VERB	O	O	504
of	ADP	O	O	504
continuous	ADJ	O	O	504
infusion	NOUN	O	O	504
of	ADP	O	O	504
fentanyl	ADJ	O	Chemical	504
are	AUX	O	O	504
reported	VERB	O	O	504
.	PUNCT	O	O	504
Combined	VERB	O	O	507
antiretroviral	ADJ	O	O	507
therapy	NOUN	O	O	507
causes	VERB	O	O	507
cardiomyopathy	ADJ	O	Disease	507
and	CCONJ	O	O	507
elevates	VERB	O	O	507
plasma	NOUN	O	O	507
lactate	NOUN	O	Chemical	507
in	ADP	O	O	507
transgenic	NOUN	O	O	507
AIDS	PROPN	O	Disease	507
mice	NOUN	O	O	507
.	PUNCT	O	O	507
Highly	ADV	O	O	508
active	ADJ	O	O	508
antiretroviral	ADJ	O	O	508
therapy	NOUN	O	O	508
(	PUNCT	O	O	508
HAART	PROPN	O	O	508
)	PUNCT	O	O	508
is	AUX	O	O	508
implicated	VERB	O	O	508
in	ADP	O	O	508
cardiomyopathy	ADJ	O	Disease	508
(	PUNCT	O	O	508
CM	PROPN	O	Disease	508
)	PUNCT	O	O	508
and	CCONJ	O	O	508
in	ADP	O	O	508
elevated	ADJ	O	O	508
plasma	NOUN	O	O	508
lactate	NOUN	O	Chemical	508
(	PUNCT	O	O	508
LA	PROPN	O	O	508
)	PUNCT	O	O	508
in	ADP	O	O	508
AIDS	PROPN	O	Disease	508
through	ADP	O	O	508
mechanisms	NOUN	O	O	508
of	ADP	O	O	508
mitochondrial	ADJ	O	O	508
dysfunction	NOUN	O	O	508
.	PUNCT	O	O	508
To	PART	O	O	509
determine	VERB	O	O	509
mitochondrial	ADJ	O	O	509
events	NOUN	O	O	509
from	ADP	O	O	509
HAART	PROPN	O	O	509
in	ADP	O	O	509
vivo	VERB	O	O	509
,	PUNCT	O	O	509
8-week	NOUN	O	O	509
-	PUNCT	O	O	509
old	ADJ	O	O	509
hemizygous	ADJ	O	O	509
transgenic	NOUN	O	O	509
AIDS	PROPN	O	Disease	509
mice	NOUN	O	O	509
(	PUNCT	O	O	509
NL4	PROPN	O	O	509
-	PUNCT	O	O	509
3Delta	PROPN	O	O	509
gag	NOUN	O	O	509
/	PUNCT	O	O	509
pol	PROPN	O	O	509
;	PUNCT	O	O	509
TG	PROPN	O	O	509
)	PUNCT	O	O	509
and	CCONJ	O	O	509
wild	ADJ	O	O	509
-	PUNCT	O	O	509
type	NOUN	O	O	509
FVB	PROPN	O	O	509
/	PUNCT	O	O	509
n	CCONJ	O	O	510
littermates	NOUN	O	O	510
were	AUX	O	O	510
treated	VERB	O	O	510
with	ADP	O	O	510
the	PRON	O	O	510
HAART	PROPN	O	O	510
combination	NOUN	O	O	510
of	ADP	O	O	510
zidovudine	NOUN	O	Chemical	510
,	PUNCT	O	O	510
lamivudine	NOUN	O	Chemical	510
,	PUNCT	O	O	510
and	CCONJ	O	O	510
indinavir	NOUN	O	O	510
or	CCONJ	O	O	510
vehicle	NOUN	O	O	510
control	VERB	O	O	510
for	ADP	O	O	510
10	NUM	O	O	510
days	NOUN	O	O	510
or	CCONJ	O	O	510
35	NUM	O	O	510
days	NOUN	O	O	510
.	PUNCT	O	O	510
At	ADP	O	O	511
termination	NOUN	O	O	511
of	ADP	O	O	511
the	PRON	O	O	511
experiments	NOUN	O	O	511
,	PUNCT	O	O	511
mice	NOUN	O	O	511
underwent	VERB	O	O	511
echocardiography	NOUN	O	O	511
,	PUNCT	O	O	511
quantitation	NOUN	O	O	511
of	ADP	O	O	511
abundance	NOUN	O	O	511
of	ADP	O	O	511
molecular	ADJ	O	O	511
markers	NOUN	O	O	511
of	ADP	O	O	511
CM	PROPN	O	Disease	511
(	PUNCT	O	O	511
ventricular	ADJ	O	O	511
mRNA	PROPN	O	O	511
encoding	VERB	O	O	511
atrial	ADJ	O	O	511
natriuretic	ADJ	O	O	511
factor	NOUN	O	O	511
[	X	O	O	511
ANF	PROPN	O	O	511
]	PUNCT	O	O	511
and	CCONJ	O	O	511
sarcoplasmic	NOUN	O	O	511
calcium	NOUN	O	Chemical	511
ATPase	X	O	O	511
[	X	O	O	511
SERCA2	NOUN	O	O	511
]	PUNCT	O	O	511
)	PUNCT	O	O	511
,	PUNCT	O	O	511
and	CCONJ	O	O	511
determination	NOUN	O	O	511
of	ADP	O	O	511
plasma	NOUN	O	O	511
LA	PROPN	O	O	511
.	PUNCT	O	O	511
Biochemically	ADV	O	O	512
,	PUNCT	O	O	512
LA	PROPN	O	O	512
was	AUX	O	O	512
elevated	ADJ	O	O	512
(	PUNCT	O	O	512
8.5	NUM	O	O	512
+	ADP	O	O	512
/-	PUNCT	O	O	512
Results	NOUN	O	O	513
show	VERB	O	O	513
that	SCONJ	O	O	513
cumulative	ADJ	O	O	513
HAART	PROPN	O	O	513
caused	VERB	O	O	513
mitochondrial	ADJ	O	O	513
CM	PROPN	O	Disease	513
with	ADP	O	O	513
elevated	ADJ	O	O	513
LA	PROPN	O	O	513
in	ADP	O	O	513
AIDS	PROPN	O	Disease	513
transgenic	NOUN	O	O	513
mice	NOUN	O	O	513
.	PUNCT	O	O	513
Oral	NOUN	O	O	516
contraceptives	NOUN	O	O	516
and	CCONJ	O	O	516
the	PRON	O	O	516
risk	NOUN	O	O	516
of	ADP	O	O	516
myocardial infarction	NOUN	O	Disease	516
.	PUNCT	O	O	516
BACKGROUND	NOUN	O	O	517
:	PUNCT	O	O	517
An	PRON	O	O	517
association	PROPN	O	O	517
between	ADP	O	O	517
the	PRON	O	O	517
use	VERB	O	O	517
of	ADP	O	O	517
oral contraceptives	NOUN	O	Chemical	517
and	CCONJ	O	O	517
the	PRON	O	O	517
risk	NOUN	O	O	517
of	ADP	O	O	517
myocardial infarction	NOUN	O	Disease	517
has	VERB	O	O	517
been	AUX	O	O	517
found	VERB	O	O	517
in	ADP	O	O	517
some	PRON	O	O	517
,	PUNCT	O	O	517
but	CCONJ	O	O	517
not	PART	O	O	517
all	PRON	O	O	517
,	PUNCT	O	O	517
studies	NOUN	O	O	517
.	PUNCT	O	O	517
We	PRON	O	O	518
investigated	VERB	O	O	518
this	PRON	O	O	518
association	PROPN	O	O	518
,	PUNCT	O	O	518
according	VERB	O	O	518
to	PART	O	O	518
the	PRON	O	O	518
type	NOUN	O	O	518
of	ADP	O	O	518
progestagen	PROPN	O	O	518
included	VERB	O	O	518
in	ADP	O	O	518
third	ADV	O	O	518
-	PUNCT	O	O	518
generation	NOUN	O	O	518
(	PUNCT	O	O	518
i.e.	X	O	O	518
,	PUNCT	O	O	518
desogestrel	VERB	O	O	518
or	CCONJ	O	O	518
gestodene	PROPN	O	O	518
)	PUNCT	O	O	518
and	CCONJ	O	O	518
second	ADV	O	O	518
-	PUNCT	O	O	518
generation	NOUN	O	O	518
(	PUNCT	O	O	518
i.e.	X	O	O	518
,	PUNCT	O	O	518
levonorgestrel	NOUN	O	Chemical	518
)	PUNCT	O	O	518
oral contraceptives	NOUN	O	Chemical	518
,	PUNCT	O	O	519
the	PRON	O	O	519
dose	NOUN	O	O	519
of	ADP	O	O	519
estrogen	PROPN	O	Chemical	519
,	PUNCT	O	O	519
and	CCONJ	O	O	519
the	PRON	O	O	519
presence	NOUN	O	O	519
or	CCONJ	O	O	519
absence	NOUN	O	O	519
of	ADP	O	O	519
prothrombotic	NOUN	O	O	519
mutations	NOUN	O	O	519
METHODS	NOUN	O	O	519
:	PUNCT	O	O	519
In	ADP	O	O	519
a	PRON	O	O	519
nationwide	ADV	O	O	519
,	PUNCT	O	O	519
population	NOUN	O	O	519
-	PUNCT	O	O	519
based	VERB	O	O	519
,	PUNCT	O	O	519
case	NOUN	O	O	519
-	PUNCT	O	O	519
control	VERB	O	O	519
study	VERB	O	O	519
,	PUNCT	O	O	519
we	PRON	O	O	519
identified	VERB	O	O	519
and	CCONJ	O	O	519
enrolled	VERB	O	O	519
248	NUM	O	O	519
women	NOUN	O	O	519
18	NUM	O	O	519
through	ADP	O	O	519
49	NUM	O	O	519
years	NOUN	O	O	519
of	ADP	O	O	519
age	NOUN	O	O	519
who	PRON	O	O	519
had	VERB	O	O	519
had	VERB	O	O	519
a	PRON	O	O	519
first	ADV	O	O	519
myocardial infarction	NOUN	O	Disease	519
between	ADP	O	O	519
1990	NUM	O	O	519
and	CCONJ	O	O	519
1995	NUM	O	O	519
and	CCONJ	O	O	519
925	NUM	O	O	519
control	VERB	O	O	519
women	NOUN	O	O	519
who	PRON	O	O	519
had	VERB	O	O	519
not	PART	O	O	519
had	VERB	O	O	519
a	PRON	O	O	519
myocardial infarction	NOUN	O	Disease	519
and	CCONJ	O	O	519
who	PRON	O	O	519
were	AUX	O	O	519
matched	VERB	O	O	519
for	ADP	O	O	519
age	NOUN	O	O	519
,	PUNCT	O	O	519
calendar	NOUN	O	O	519
year	NOUN	O	O	519
of	ADP	O	O	519
the	PRON	O	O	519
index	NOUN	O	O	519
event	NOUN	O	O	519
,	PUNCT	O	O	519
and	CCONJ	O	O	519
area	NOUN	O	O	519
of	ADP	O	O	519
residence	NOUN	O	O	519
.	PUNCT	O	O	519
Subjects	NOUN	O	O	520
supplied	VERB	O	O	520
information	NOUN	O	O	520
on	ADP	O	O	520
oral	ADJ	O	O	520
-	PUNCT	O	O	520
contraceptive	NOUN	O	O	520
use	VERB	O	O	520
and	CCONJ	O	O	520
major	ADJ	O	O	520
cardiovascular	ADJ	O	O	520
risk	NOUN	O	O	520
factors	NOUN	O	O	520
.	PUNCT	O	O	520
An	PRON	O	O	521
analysis	NOUN	O	O	521
for	ADP	O	O	521
factor	NOUN	O	O	521
V	NOUN	O	O	521
Leiden	PROPN	O	O	521
and	CCONJ	O	O	521
the	PRON	O	O	521
G20210A	ADJ	O	O	521
mutation	NOUN	O	O	521
in	ADP	O	O	521
the	PRON	O	O	521
prothrombin	ADJ	O	O	521
gene	NOUN	O	O	521
was	AUX	O	O	521
conducted	VERB	O	O	521
in	ADP	O	O	521
217	NUM	O	O	521
patients	NOUN	O	O	521
and	CCONJ	O	O	521
763	NUM	O	O	521
controls	VERB	O	O	521
RESULTS	VERB	O	O	521
:	PUNCT	O	O	521
The	PRON	O	O	521
odds	NOUN	O	O	521
ratio	NOUN	O	O	521
for	ADP	O	O	521
myocardial infarction	NOUN	O	Disease	521
among	ADP	O	O	521
women	NOUN	O	O	521
who	PRON	O	O	521
used	VERB	O	O	521
any	PRON	O	O	521
type	NOUN	O	O	521
of	ADP	O	O	521
combined	VERB	O	O	521
oral contraceptive	NOUN	O	Chemical	521
,	PUNCT	O	O	521
as	ADP	O	O	521
compared	VERB	O	O	521
with	ADP	O	O	521
nonusers	NOUN	O	O	521
,	PUNCT	O	O	521
was	AUX	O	O	521
2.0	NUM	O	O	521
(	PUNCT	O	O	521
95	NUM	O	O	521
percent	NOUN	O	O	521
confidence	NOUN	O	O	521
interval	NOUN	O	O	521
,	PUNCT	O	O	521
1.5	NUM	O	O	521
to	PART	O	O	521
2.8	NUM	O	O	521
)	PUNCT	O	O	521
.	PUNCT	O	O	521
The	PRON	O	O	522
adjusted	VERB	O	O	522
odds	NOUN	O	O	522
ratio	NOUN	O	O	522
was	AUX	O	O	522
2.5	NUM	O	O	522
(	PUNCT	O	O	522
95	NUM	O	O	522
percent	NOUN	O	O	522
confidence	NOUN	O	O	522
interval	NOUN	O	O	522
,	PUNCT	O	O	522
1.5	NUM	O	O	522
to	PART	O	O	522
4.1	NUM	O	O	522
)	PUNCT	O	O	522
among	ADP	O	O	522
women	NOUN	O	O	522
who	PRON	O	O	522
used	VERB	O	O	522
second	ADV	O	O	522
-	PUNCT	O	O	522
generation	NOUN	O	O	522
oral contraceptives	NOUN	O	Chemical	522
and	CCONJ	O	O	522
1.3	NUM	O	O	522
(	PUNCT	O	O	522
95	NUM	O	O	522
percent	NOUN	O	O	522
confidence	NOUN	O	O	522
interval	NOUN	O	O	522
,	PUNCT	O	O	522
0.7	NUM	O	O	522
to	PART	O	O	522
2.5	NUM	O	O	522
)	PUNCT	O	O	522
among	ADP	O	O	522
those	PRON	O	O	522
who	PRON	O	O	522
used	VERB	O	O	522
third	ADV	O	O	522
-	PUNCT	O	O	522
generation	NOUN	O	O	522
oral contraceptives	NOUN	O	Chemical	522
.	PUNCT	O	O	522
Among	ADP	O	O	523
women	NOUN	O	O	523
who	PRON	O	O	523
used	VERB	O	O	523
oral contraceptives	NOUN	O	Chemical	523
,	PUNCT	O	O	523
the	PRON	O	O	523
odds	NOUN	O	O	523
ratio	NOUN	O	O	523
was	AUX	O	O	523
2.1	NUM	O	O	523
(	PUNCT	O	O	523
95	NUM	O	O	523
percent	NOUN	O	O	523
confidence	NOUN	O	O	523
interval	NOUN	O	O	523
,	PUNCT	O	O	523
1.5	NUM	O	O	523
to	PART	O	O	523
3.0	NUM	O	O	523
)	PUNCT	O	O	523
for	ADP	O	O	523
those	PRON	O	O	523
without	ADP	O	O	523
a	PRON	O	O	523
prothrombotic	NOUN	O	O	523
mutation	NOUN	O	O	523
and	CCONJ	O	O	523
1.9	NUM	O	O	523
(	PUNCT	O	O	523
95	NUM	O	O	523
percent	NOUN	O	O	523
confidence	NOUN	O	O	523
interval	NOUN	O	O	523
,	PUNCT	O	O	523
0.6	NUM	O	O	523
to	PART	O	O	523
5.5	NUM	O	O	523
)	PUNCT	O	O	523
for	ADP	O	O	523
those	PRON	O	O	523
with	ADP	O	O	523
a	PRON	O	O	523
mutation	NOUN	O	O	523
CONCLUSIONS	NOUN	O	O	523
:	PUNCT	O	O	523
The	PRON	O	O	523
risk	NOUN	O	O	523
of	ADP	O	O	523
myocardial infarction	NOUN	O	Disease	523
was	AUX	O	O	523
increased	VERB	O	O	523
among	ADP	O	O	523
women	NOUN	O	O	523
who	PRON	O	O	523
used	VERB	O	O	523
second	ADV	O	O	523
-	PUNCT	O	O	523
generation	NOUN	O	O	523
oral contraceptives	NOUN	O	Chemical	523
.	PUNCT	O	O	523
The	PRON	O	O	524
results	VERB	O	O	524
with	ADP	O	O	524
respect	VERB	O	O	524
to	PART	O	O	524
the	PRON	O	O	524
use	VERB	O	O	524
of	ADP	O	O	524
third	ADV	O	O	524
-	PUNCT	O	O	524
generation	NOUN	O	O	524
oral contraceptives	NOUN	O	Chemical	524
were	AUX	O	O	524
inconclusive	ADJ	O	O	524
but	CCONJ	O	O	524
suggested	VERB	O	O	524
that	SCONJ	O	O	524
the	PRON	O	O	524
risk	NOUN	O	O	524
was	AUX	O	O	524
lower	ADJ	O	O	524
than	ADP	O	O	524
the	PRON	O	O	524
risk	NOUN	O	O	524
associated	VERB	O	O	524
with	ADP	O	O	524
second	ADV	O	O	524
-	PUNCT	O	O	524
generation	NOUN	O	O	524
oral contraceptives	NOUN	O	Chemical	524
.	PUNCT	O	O	524
The	PRON	O	O	525
risk	NOUN	O	O	525
of	ADP	O	O	525
myocardial infarction	NOUN	O	Disease	525
was	AUX	O	O	525
similar	ADJ	O	O	525
among	ADP	O	O	525
women	NOUN	O	O	525
who	PRON	O	O	525
used	VERB	O	O	525
oral contraceptives	NOUN	O	Chemical	525
whether	SCONJ	O	O	525
or	CCONJ	O	O	525
not	PART	O	O	525
they	PRON	O	O	525
had	VERB	O	O	525
a	PRON	O	O	525
prothrombotic	NOUN	O	O	525
mutation	NOUN	O	O	525
.	PUNCT	O	O	525
Effects	NOUN	O	O	528
of	ADP	O	O	528
5-HT1B	NOUN	O	O	528
receptor	NOUN	O	O	528
ligands	NOUN	O	O	528
microinjected	VERB	O	O	528
into	ADP	O	O	528
the	PRON	O	O	528
accumbal	ADJ	O	O	528
shell	PROPN	O	O	528
or	CCONJ	O	O	528
core	NOUN	O	O	528
on	ADP	O	O	528
the	PRON	O	O	528
cocaine	NOUN	O	Chemical	528
-	PUNCT	O	O	528
induced	VERB	O	O	528
locomotor hyperactivity	NOUN	O	Disease	528
in	ADP	O	O	528
rats	NOUN	O	O	528
.	PUNCT	O	O	528
The	PRON	O	O	529
present	NOUN	O	O	529
study	VERB	O	O	529
was	AUX	O	O	529
designed	VERB	O	O	529
to	PART	O	O	529
examine	VERB	O	O	529
the	PRON	O	O	529
effect	VERB	O	O	529
of	ADP	O	O	529
5-HT1B	NOUN	O	O	529
receptor	NOUN	O	O	529
ligands	NOUN	O	O	529
microinjected	VERB	O	O	529
into	ADP	O	O	529
the	PRON	O	O	529
subregions	NOUN	O	O	529
of	ADP	O	O	529
the	PRON	O	O	529
nucleus	PROPN	O	O	529
accumbens	NOUN	O	O	529
(	PUNCT	O	O	529
the	PRON	O	O	529
shell	PROPN	O	O	529
and	CCONJ	O	O	529
the	PRON	O	O	529
core	NOUN	O	O	529
)	PUNCT	O	O	529
on	ADP	O	O	529
the	PRON	O	O	529
locomotor hyperactivity	NOUN	O	Disease	529
induced	VERB	O	O	529
by	ADP	O	O	529
cocaine	NOUN	O	Chemical	529
in	ADP	O	O	529
rats	NOUN	O	O	529
.	PUNCT	O	O	529
Male	NOUN	O	O	530
Wistar	PROPN	O	O	530
rats	NOUN	O	O	530
were	AUX	O	O	530
implanted	VERB	O	O	530
bilaterally	ADV	O	O	530
with	ADP	O	O	530
cannulae	NOUN	O	O	530
into	ADP	O	O	530
the	PRON	O	O	530
accumbens	NOUN	O	O	530
shell	PROPN	O	O	530
or	CCONJ	O	O	530
core	NOUN	O	O	530
,	PUNCT	O	O	530
and	CCONJ	O	O	530
then	ADV	O	O	530
were	AUX	O	O	530
locally	ADV	O	O	530
injected	VERB	O	O	530
with	ADP	O	O	530
GR	PROPN	O	O	530
55562	NUM	O	O	530
(	PUNCT	O	O	530
an	PRON	O	O	530
antagonist	NOUN	O	O	530
of	ADP	O	O	530
5-HT1B	NOUN	O	O	530
receptors	NOUN	O	O	530
)	PUNCT	O	O	530
or	CCONJ	O	O	530
CP	PROPN	O	Chemical	530
93129	NUM	O	O	530
(	PUNCT	O	O	530
an	PRON	O	O	530
agonist	NOUN	O	O	530
of	ADP	O	O	530
5-HT1B	NOUN	O	O	530
receptors	NOUN	O	O	530
)	PUNCT	O	O	530
.	PUNCT	O	O	530
Given	VERB	O	O	531
alone	ADV	O	O	531
to	PART	O	O	531
any	PRON	O	O	531
accumbal	ADJ	O	O	531
subregion	NOUN	O	O	531
,	PUNCT	O	O	531
GR	PROPN	O	O	531
55562	NUM	O	O	531
(	PUNCT	O	O	531
0.1	NUM	O	O	531
-	PUNCT	O	O	531
10	NUM	O	O	531
microg	PROPN	O	O	531
/	PUNCT	O	O	531
side	NOUN	O	O	531
)	PUNCT	O	O	531
or	CCONJ	O	O	531
CP	PROPN	O	Chemical	531
93129	NUM	O	O	531
(	PUNCT	O	O	531
0.1	NUM	O	O	531
-	PUNCT	O	O	531
10	NUM	O	O	531
microg	PROPN	O	O	531
/	PUNCT	O	O	531
side	NOUN	O	O	531
)	PUNCT	O	O	531
did	VERB	O	O	531
not	PART	O	O	531
change	VERB	O	O	531
basal	PROPN	O	O	531
locomotor	PROPN	O	O	531
activity	NOUN	O	O	531
.	PUNCT	O	O	531
Systemic	ADJ	O	O	532
cocaine	NOUN	O	Chemical	532
(	PUNCT	O	O	532
10	NUM	O	O	532
mg	VERB	O	O	532
/	PUNCT	O	O	532
kg	VERB	O	O	532
)	PUNCT	O	O	532
significantly	ADV	O	O	532
increased	VERB	O	O	532
the	PRON	O	O	532
locomotor	PROPN	O	O	532
activity	NOUN	O	O	532
of	ADP	O	O	532
rats	NOUN	O	O	532
.	PUNCT	O	O	532
GR	PROPN	O	O	533
55562	NUM	O	O	533
(	PUNCT	O	O	533
0.1	NUM	O	O	533
-	PUNCT	O	O	533
10	NUM	O	O	533
microg	PROPN	O	O	533
/	PUNCT	O	O	533
side	NOUN	O	O	533
)	PUNCT	O	O	533
,	PUNCT	O	O	533
administered	VERB	O	O	533
intra	ADJ	O	O	533
-	PUNCT	O	O	533
accumbens	NOUN	O	O	533
shell	PROPN	O	O	533
prior	ADV	O	O	533
to	PART	O	O	533
cocaine	NOUN	O	Chemical	533
,	PUNCT	O	O	533
dose	NOUN	O	O	533
-	PUNCT	O	O	533
dependently	ADV	O	O	533
attenuated	VERB	O	O	533
the	PRON	O	O	533
psychostimulant	NOUN	O	O	533
-	PUNCT	O	O	533
induced	VERB	O	O	533
locomotor hyperactivity	NOUN	O	Disease	533
.	PUNCT	O	O	533
Such	ADJ	O	O	534
attenuation	NOUN	O	O	534
was	AUX	O	O	534
not	PART	O	O	534
found	VERB	O	O	534
in	ADP	O	O	534
animals	NOUN	O	O	534
which	PRON	O	O	534
had	VERB	O	O	534
been	AUX	O	O	534
injected	VERB	O	O	534
with	ADP	O	O	534
GR	PROPN	O	O	534
55562	NUM	O	O	534
into	ADP	O	O	534
the	PRON	O	O	534
accumbens	NOUN	O	O	534
core	NOUN	O	O	534
.	PUNCT	O	O	534
When	SCONJ	O	O	535
injected	VERB	O	O	535
into	ADP	O	O	535
the	PRON	O	O	535
accumbens	NOUN	O	O	535
shell	PROPN	O	O	535
(	PUNCT	O	O	535
but	CCONJ	O	O	535
not	PART	O	O	535
the	PRON	O	O	535
core	NOUN	O	O	535
)	PUNCT	O	O	535
before	ADP	O	O	535
cocaine	NOUN	O	Chemical	535
,	PUNCT	O	O	535
CP	PROPN	O	Chemical	535
93129	NUM	O	O	535
(	PUNCT	O	O	535
0.1	NUM	O	O	535
-	PUNCT	O	O	535
10	NUM	O	O	535
microg	PROPN	O	O	535
/	PUNCT	O	O	535
side	NOUN	O	O	535
)	PUNCT	O	O	535
enhanced	VERB	O	O	535
the	PRON	O	O	535
locomotor	PROPN	O	O	535
response	NOUN	O	O	535
to	PART	O	O	535
cocaine	NOUN	O	Chemical	535
;	PUNCT	O	O	535
the	PRON	O	O	535
maximum	ADV	O	O	535
effect	VERB	O	O	535
being	AUX	O	O	535
observed	VERB	O	O	535
after	ADP	O	O	535
10	NUM	O	O	535
microg	PROPN	O	O	535
/	PUNCT	O	O	535
side	NOUN	O	O	535
of	ADP	O	O	535
the	PRON	O	O	535
agonist	NOUN	O	O	535
.	PUNCT	O	O	535
The	PRON	O	O	536
later	ADV	O	O	536
enhancement	NOUN	O	O	536
was	AUX	O	O	536
attenuated	VERB	O	O	536
after	ADP	O	O	536
intra	ADJ	O	O	536
-	PUNCT	O	O	536
accumbens	NOUN	O	O	536
shell	PROPN	O	O	536
treatment	NOUN	O	O	536
with	ADP	O	O	536
GR	PROPN	O	O	536
55562	NUM	O	O	536
(	PUNCT	O	O	536
1	X	O	O	536
microg	PROPN	O	O	536
/	PUNCT	O	O	536
side	NOUN	O	O	536
)	PUNCT	O	O	536
.	PUNCT	O	O	536
Our	PRON	O	O	537
findings	NOUN	O	O	537
indicate	VERB	O	O	537
that	SCONJ	O	O	537
cocaine	NOUN	O	Chemical	537
induced	VERB	O	O	537
hyperlocomotion	NOUN	O	Disease	537
is	AUX	O	O	537
modified	VERB	O	O	537
by	ADP	O	O	537
5-HT1B	NOUN	O	O	537
receptor	NOUN	O	O	537
ligands	NOUN	O	O	537
microinjected	VERB	O	O	537
into	ADP	O	O	537
the	PRON	O	O	537
accumbens	NOUN	O	O	537
shell	PROPN	O	O	537
,	PUNCT	O	O	537
but	CCONJ	O	O	537
not	PART	O	O	537
core	NOUN	O	O	537
,	PUNCT	O	O	537
this	PRON	O	O	537
modification	NOUN	O	O	537
consisting	VERB	O	O	537
in	ADP	O	O	537
inhibitory	ADJ	O	O	537
and	CCONJ	O	O	537
facilitatory	PROPN	O	O	537
effects	NOUN	O	O	537
of	ADP	O	O	537
the	PRON	O	O	537
5-HT1B	NOUN	O	O	537
receptor	NOUN	O	O	537
antagonist	NOUN	O	O	537
(	PUNCT	O	O	537
GR	PROPN	O	O	537
55562	NUM	O	O	537
)	PUNCT	O	O	537
and	CCONJ	O	O	537
agonist	NOUN	O	O	537
(	PUNCT	O	O	537
CP	PROPN	O	Chemical	537
93129	NUM	O	O	537
)	PUNCT	O	O	537
,	PUNCT	O	O	537
respectively	ADV	O	O	537
.	PUNCT	O	O	537
Ticlopidine	NOUN	O	O	540
-	PUNCT	O	O	540
induced	VERB	O	O	540
cholestatic hepatitis	NOUN	O	Disease	540
.	PUNCT	O	O	540
OBJECTIVE	VERB	O	O	541
:	PUNCT	O	O	541
To	PART	O	O	541
report	VERB	O	O	541
2	X	O	O	541
cases	NOUN	O	O	541
of	ADP	O	O	541
ticlopidine	ADV	O	O	541
-	PUNCT	O	O	541
induced	VERB	O	O	541
cholestatic hepatitis	NOUN	O	Disease	541
,	PUNCT	O	O	541
investigate	VERB	O	O	541
its	PRON	O	O	541
mechanism	NOUN	O	O	541
,	PUNCT	O	O	541
and	CCONJ	O	O	541
compare	VERB	O	O	541
the	PRON	O	O	541
observed	VERB	O	O	541
main	ADJ	O	O	541
characteristics	NOUN	O	O	541
with	ADP	O	O	541
those	PRON	O	O	541
of	ADP	O	O	541
the	PRON	O	O	541
published	VERB	O	O	541
cases	NOUN	O	O	541
.	PUNCT	O	O	541
CASE	NOUN	O	O	542
SUMMARIES	NOUN	O	O	542
:	PUNCT	O	O	542
Two	NUM	O	O	542
patients	NOUN	O	O	542
developed	VERB	O	O	542
prolonged	VERB	O	O	542
cholestatic hepatitis	NOUN	O	Disease	542
after	ADP	O	O	542
receiving	VERB	O	O	542
ticlopidine	ADV	O	O	542
following	VERB	O	O	542
percutaneous	ADJ	O	O	542
coronary	ADJ	O	O	542
angioplasty	ADJ	O	O	542
,	PUNCT	O	O	542
with	ADP	O	O	542
complete	VERB	O	O	542
remission	NOUN	O	O	542
during	ADP	O	O	542
the	PRON	O	O	542
follow	VERB	O	O	542
-	PUNCT	O	O	542
up	ADP	O	O	542
period	NOUN	O	O	542
.	PUNCT	O	O	542
T	NOUN	O	Chemical	543
-	PUNCT	O	O	543
cell	NOUN	O	O	543
stimulation	NOUN	O	O	543
by	ADP	O	O	543
therapeutic	ADJ	O	O	543
concentration	NOUN	O	O	543
of	ADP	O	O	543
ticlopidine	ADV	O	O	543
was	AUX	O	O	543
demonstrated	VERB	O	O	543
in	ADP	O	O	543
vitro	X	O	O	543
in	ADP	O	O	543
the	PRON	O	O	543
patients	NOUN	O	O	543
,	PUNCT	O	O	543
but	CCONJ	O	O	543
not	PART	O	O	543
in	ADP	O	O	543
healthy	ADJ	O	O	543
controls	VERB	O	O	543
.	PUNCT	O	O	543
DISCUSSION	NOUN	O	O	544
:	PUNCT	O	O	544
Cholestatic	NOUN	O	O	544
hepatitis	NOUN	O	Disease	544
is	AUX	O	O	544
a	PRON	O	O	544
rare	ADJ	O	O	544
complication	NOUN	O	O	544
of	ADP	O	O	544
the	PRON	O	O	544
antiplatelet	ADV	O	O	544
agent	NOUN	O	O	544
ticlopidine	ADV	O	O	544
;	PUNCT	O	O	544
several	ADJ	O	O	544
cases	NOUN	O	O	544
have	VERB	O	O	544
been	AUX	O	O	544
reported	VERB	O	O	544
but	CCONJ	O	O	544
few	ADJ	O	O	544
in	ADP	O	O	544
the	PRON	O	O	544
English	PROPN	O	O	544
literature	NOUN	O	O	544
.	PUNCT	O	O	544
Our	PRON	O	O	545
patients	NOUN	O	O	545
developed	VERB	O	O	545
jaundice	NOUN	O	Disease	545
following	VERB	O	O	545
treatment	NOUN	O	O	545
with	ADP	O	O	545
ticlopidine	ADV	O	O	545
and	CCONJ	O	O	545
showed	VERB	O	O	545
the	PRON	O	O	545
clinical	ADJ	O	O	545
and	CCONJ	O	O	545
laboratory	NOUN	O	O	545
characteristics	NOUN	O	O	545
of	ADP	O	O	545
cholestatic hepatitis	NOUN	O	Disease	545
,	PUNCT	O	O	545
which	PRON	O	O	545
resolved	VERB	O	O	545
after	ADP	O	O	545
discontinuation	NOUN	O	O	545
of	ADP	O	O	545
the	PRON	O	O	545
drug	NOUN	O	O	545
.	PUNCT	O	O	545
Hepatitis	NOUN	O	O	546
may	AUX	O	O	546
develop	VERB	O	O	546
weeks	NOUN	O	O	546
after	ADP	O	O	546
discontinuation	NOUN	O	O	546
of	ADP	O	O	546
the	PRON	O	O	546
drug	NOUN	O	O	546
and	CCONJ	O	O	546
may	AUX	O	O	546
run	VERB	O	O	546
a	PRON	O	O	546
prolonged	VERB	O	O	546
course	NOUN	O	O	546
,	PUNCT	O	O	546
but	CCONJ	O	O	546
complete	VERB	O	O	546
remission	NOUN	O	O	546
was	AUX	O	O	546
observed	VERB	O	O	546
in	ADP	O	O	546
all	PRON	O	O	546
reported	VERB	O	O	546
cases	NOUN	O	O	546
.	PUNCT	O	O	546
An	PRON	O	O	547
objective	VERB	O	O	547
causality	NOUN	O	O	547
assessment	NOUN	O	O	547
revealed	VERB	O	O	547
that	SCONJ	O	O	547
the	PRON	O	O	547
adverse	ADJ	O	O	547
drug	NOUN	O	O	547
event	NOUN	O	O	547
was	AUX	O	O	547
probably	ADV	O	O	547
related	ADJ	O	O	547
to	PART	O	O	547
the	PRON	O	O	547
use	VERB	O	O	547
of	ADP	O	O	547
ticlopidine	ADV	O	O	547
.	PUNCT	O	O	547
The	PRON	O	O	548
mechanisms	NOUN	O	O	548
of	ADP	O	O	548
this	PRON	O	O	548
ticlopidine	ADV	O	O	548
-	PUNCT	O	O	548
induced	VERB	O	O	548
cholestasis	NOUN	O	Disease	548
are	AUX	O	O	548
unclear	ADJ	O	O	548
.	PUNCT	O	O	548
Immune	PROPN	O	O	549
mechanisms	NOUN	O	O	549
may	AUX	O	O	549
be	AUX	O	O	549
involved	VERB	O	O	549
in	ADP	O	O	549
the	PRON	O	O	549
drug	NOUN	O	O	549
's	AUX	O	O	549
hepatotoxicity	NOUN	O	Disease	549
,	PUNCT	O	O	549
as	ADP	O	O	549
suggested	VERB	O	O	549
by	ADP	O	O	549
the	PRON	O	O	549
T	NOUN	O	Chemical	549
-	PUNCT	O	O	549
cell	NOUN	O	O	549
stimulation	NOUN	O	O	549
study	VERB	O	O	549
reported	VERB	O	O	549
here	ADV	O	O	549
.	PUNCT	O	O	549
Cholestatic	NOUN	O	O	550
hepatitis	NOUN	O	Disease	550
is	AUX	O	O	550
a	PRON	O	O	550
rare	ADJ	O	O	550
adverse	ADJ	O	O	550
effect	VERB	O	O	550
of	ADP	O	O	550
ticlopidine	ADV	O	O	550
that	SCONJ	O	O	550
may	AUX	O	O	550
be	AUX	O	O	550
immune	NOUN	O	O	550
mediated	VERB	O	O	550
.	PUNCT	O	O	550
This	PRON	O	O	551
complication	NOUN	O	O	551
will	AUX	O	O	551
be	AUX	O	O	551
observed	VERB	O	O	551
even	ADV	O	O	551
less	ADV	O	O	551
often	ADV	O	O	551
in	ADP	O	O	551
the	PRON	O	O	551
future	NOUN	O	O	551
as	ADP	O	O	551
ticlopidine	ADV	O	O	551
is	AUX	O	O	551
being	AUX	O	O	551
replaced	VERB	O	O	551
by	ADP	O	O	551
the	PRON	O	O	551
newer	ADJ	O	O	551
antiplatelet	ADV	O	O	551
agent	NOUN	O	O	551
clopidogrel	NOUN	O	O	551
.	PUNCT	O	O	551
Epithelial	PROPN	O	O	554
sodium	NOUN	O	Chemical	554
channel	PROPN	O	O	554
(	PUNCT	O	O	554
ENaC	PROPN	O	O	554
)	PUNCT	O	O	554
subunit	NOUN	O	O	554
mRNA	PROPN	O	O	554
and	CCONJ	O	O	554
protein	NOUN	O	O	554
expression	NOUN	O	O	554
in	ADP	O	O	554
rats	NOUN	O	O	554
with	ADP	O	O	554
puromycin aminonucleoside	NOUN	O	Chemical	554
-	PUNCT	O	O	554
induced	VERB	O	O	554
nephrotic syndrome	NOUN	O	Disease	554
.	PUNCT	O	O	554
In	ADP	O	O	555
experimental	ADJ	O	O	555
nephrotic syndrome	NOUN	O	Disease	555
,	PUNCT	O	O	555
urinary	ADJ	O	O	555
sodium	NOUN	O	Chemical	555
excretion	NOUN	O	O	555
is	AUX	O	O	555
decreased	VERB	O	O	555
during	ADP	O	O	555
the	PRON	O	O	555
early	ADV	O	O	555
phase	NOUN	O	O	555
of	ADP	O	O	555
the	PRON	O	O	555
disease	PROPN	O	O	555
.	PUNCT	O	O	555
The	PRON	O	O	556
rate	NOUN	O	O	556
-	PUNCT	O	O	556
limiting	VERB	O	O	556
constituent	NOUN	O	O	556
of	ADP	O	O	556
collecting	VERB	O	O	556
duct	NOUN	O	O	556
sodium	NOUN	O	Chemical	556
transport	NOUN	O	O	556
is	AUX	O	O	556
the	PRON	O	O	556
epithelial	ADJ	O	O	556
sodium	NOUN	O	Chemical	556
channel	PROPN	O	O	556
(	PUNCT	O	O	556
ENaC	PROPN	O	O	556
)	PUNCT	O	O	556
.	PUNCT	O	O	556
We	PRON	O	O	557
examined	VERB	O	O	557
the	PRON	O	O	557
abundance	NOUN	O	O	557
of	ADP	O	O	557
ENaC	PROPN	O	O	557
subunit	NOUN	O	O	557
mRNAs	NUM	O	O	557
and	CCONJ	O	O	557
proteins	NOUN	O	O	557
in	ADP	O	O	557
puromycin aminonucleoside	NOUN	O	Chemical	557
(	PUNCT	O	O	557
PAN)-induced	VERB	O	O	557
nephrotic syndrome	NOUN	O	Disease	557
.	PUNCT	O	O	557
The	PRON	O	O	558
time	NOUN	O	O	558
courses	NOUN	O	O	558
of	ADP	O	O	558
urinary	ADJ	O	O	558
sodium	NOUN	O	Chemical	558
excretion	NOUN	O	O	558
,	PUNCT	O	O	558
plasma	NOUN	O	O	558
aldosterone	NOUN	O	Chemical	558
concentration	NOUN	O	O	558
and	CCONJ	O	O	558
proteinuria	X	O	Disease	558
were	AUX	O	O	558
studied	VERB	O	O	558
in	ADP	O	O	558
male	NOUN	O	O	558
Sprague	PROPN	O	O	558
-	PUNCT	O	O	558
Dawley	NOUN	O	O	558
rats	NOUN	O	O	558
treated	VERB	O	O	558
with	ADP	O	O	558
a	PRON	O	O	558
single	ADJ	O	O	558
dose	NOUN	O	O	558
of	ADP	O	O	558
either	ADV	O	O	558
PAN	PROPN	O	Chemical	558
or	CCONJ	O	O	558
vehicle	NOUN	O	O	558
.	PUNCT	O	O	558
The	PRON	O	O	559
kinetics	NOUN	O	O	559
of	ADP	O	O	559
urinary	ADJ	O	O	559
sodium	NOUN	O	Chemical	559
excretion	NOUN	O	O	559
and	CCONJ	O	O	559
the	PRON	O	O	559
appearance	NOUN	O	O	559
of	ADP	O	O	559
proteinuria	X	O	Disease	559
were	AUX	O	O	559
comparable	ADJ	O	O	559
with	ADP	O	O	559
those	PRON	O	O	559
reported	VERB	O	O	559
previously	ADV	O	O	559
.	PUNCT	O	O	559
Sodium	NOUN	O	Chemical	560
retention	NOUN	O	O	560
occurred	VERB	O	O	560
on	ADP	O	O	560
days	NOUN	O	O	560
2	X	O	O	560
,	PUNCT	O	O	560
3	X	O	O	560
and	CCONJ	O	O	560
6	NUM	O	O	560
after	ADP	O	O	560
PAN	PROPN	O	Chemical	560
injection	NOUN	O	O	560
.	PUNCT	O	O	560
A	PRON	O	O	561
significant	ADJ	O	O	561
up	ADP	O	O	561
-	PUNCT	O	O	561
regulation	NOUN	O	O	561
of	ADP	O	O	561
alphaENaC	PROPN	O	O	561
and	CCONJ	O	O	561
betaENaC	VERB	O	O	561
mRNA	PROPN	O	O	561
abundance	NOUN	O	O	561
on	ADP	O	O	561
days	NOUN	O	O	561
1	X	O	O	561
and	CCONJ	O	O	561
2	X	O	O	561
preceded	VERB	O	O	561
sodium	NOUN	O	Chemical	561
retention	NOUN	O	O	561
on	ADP	O	O	561
days	NOUN	O	O	561
2	X	O	O	561
and	CCONJ	O	O	561
3	X	O	O	561
.	PUNCT	O	O	561
Conversely	ADV	O	O	562
,	PUNCT	O	O	562
down	ADP	O	O	562
-	PUNCT	O	O	562
regulation	NOUN	O	O	562
of	ADP	O	O	562
alphaENaC	PROPN	O	O	562
,	PUNCT	O	O	562
betaENaC	VERB	O	O	562
and	CCONJ	O	O	562
gammaENaC	PROPN	O	O	562
mRNA	PROPN	O	O	562
expression	NOUN	O	O	562
on	ADP	O	O	562
day	NOUN	O	O	562
3	X	O	O	562
occurred	VERB	O	O	562
in	ADP	O	O	562
the	PRON	O	O	562
presence	NOUN	O	O	562
of	ADP	O	O	562
high	ADJ	O	O	562
aldosterone	NOUN	O	Chemical	562
concentrations	NOUN	O	O	562
,	PUNCT	O	O	562
and	CCONJ	O	O	562
was	AUX	O	O	562
followed	VERB	O	O	562
by	ADP	O	O	562
a	PRON	O	O	562
return	VERB	O	O	562
of	ADP	O	O	562
sodium	NOUN	O	Chemical	562
excretion	NOUN	O	O	562
to	PART	O	O	562
control	VERB	O	O	562
values	NOUN	O	O	562
.	PUNCT	O	O	562
The	PRON	O	O	563
amounts	VERB	O	O	563
of	ADP	O	O	563
alphaENaC	PROPN	O	O	563
,	PUNCT	O	O	563
betaENaC	VERB	O	O	563
and	CCONJ	O	O	563
gammaENaC	PROPN	O	O	563
proteins	NOUN	O	O	563
were	AUX	O	O	563
not	PART	O	O	563
increased	VERB	O	O	563
during	ADP	O	O	563
PAN	PROPN	O	Chemical	563
-	PUNCT	O	O	563
induced	VERB	O	O	563
sodium	NOUN	O	Chemical	563
retention	NOUN	O	O	563
.	PUNCT	O	O	563
In	ADP	O	O	564
conclusion	NOUN	O	O	564
,	PUNCT	O	O	564
ENaC	PROPN	O	O	564
mRNA	PROPN	O	O	564
expression	NOUN	O	O	564
,	PUNCT	O	O	564
especially	ADV	O	O	564
alphaENaC	PROPN	O	O	564
,	PUNCT	O	O	564
is	AUX	O	O	564
increased	VERB	O	O	564
in	ADP	O	O	564
the	PRON	O	O	564
very	ADV	O	O	564
early	ADV	O	O	564
phase	NOUN	O	O	564
of	ADP	O	O	564
the	PRON	O	O	564
experimental	ADJ	O	O	564
model	NOUN	O	O	564
of	ADP	O	O	564
PAN	PROPN	O	Chemical	564
-	PUNCT	O	O	564
induced	VERB	O	O	564
nephrotic syndrome	NOUN	O	Disease	564
in	ADP	O	O	564
rats	NOUN	O	O	564
,	PUNCT	O	O	564
but	CCONJ	O	O	564
appears	VERB	O	O	564
to	PART	O	O	564
escape	VERB	O	O	564
from	ADP	O	O	564
the	PRON	O	O	564
regulation	NOUN	O	O	564
by	ADP	O	O	564
aldosterone	NOUN	O	Chemical	564
after	ADP	O	O	564
day	NOUN	O	O	564
3	X	O	O	564
.	PUNCT	O	O	564
NO	PRON	O	Chemical	567
-	PUNCT	O	O	567
induced	VERB	O	O	567
migraine	NOUN	O	Disease	567
attack	VERB	O	O	567
:	PUNCT	O	O	567
strong	ADJ	O	O	567
increase	VERB	O	O	567
in	ADP	O	O	567
plasma	NOUN	O	O	567
calcitonin	NOUN	O	O	567
gene	NOUN	O	O	567
-	PUNCT	O	O	567
related	ADJ	O	O	567
peptide	NOUN	O	O	567
(	PUNCT	O	O	567
CGRP	NOUN	O	O	567
)	PUNCT	O	O	567
concentration	NOUN	O	O	567
and	CCONJ	O	O	567
negative	ADJ	O	O	567
correlation	NOUN	O	O	567
with	ADP	O	O	567
platelet	NOUN	O	O	567
serotonin	PROPN	O	Chemical	567
release	NOUN	O	O	567
.	PUNCT	O	O	567
The	PRON	O	O	568
aim	VERB	O	O	568
of	ADP	O	O	568
the	PRON	O	O	568
present	NOUN	O	O	568
study	VERB	O	O	568
was	AUX	O	O	568
to	PART	O	O	568
investigate	VERB	O	O	568
changes	VERB	O	O	568
in	ADP	O	O	568
the	PRON	O	O	568
plasma	NOUN	O	O	568
calcitonin	NOUN	O	O	568
gene	NOUN	O	O	568
-	PUNCT	O	O	568
related	ADJ	O	O	568
peptide	NOUN	O	O	568
(	PUNCT	O	O	568
CGRP	NOUN	O	O	568
)	PUNCT	O	O	568
concentration	NOUN	O	O	568
and	CCONJ	O	O	568
platelet	NOUN	O	O	568
serotonin	PROPN	O	Chemical	568
(	PUNCT	O	O	568
5-hydroxytriptamine	NOUN	O	O	568
,	PUNCT	O	O	568
5-HT	NOUN	O	Chemical	568
)	PUNCT	O	O	568
content	NOUN	O	O	568
during	ADP	O	O	568
the	PRON	O	O	568
immediate	ADJ	O	O	568
headache	PROPN	O	Disease	568
and	CCONJ	O	O	568
the	PRON	O	O	568
delayed	VERB	O	O	568
genuine	ADJ	O	O	568
migraine	NOUN	O	Disease	568
attack	VERB	O	O	568
provoked	VERB	O	O	568
by	ADP	O	O	568
nitroglycerin	PROPN	O	Chemical	568
.	PUNCT	O	O	568
Fifteen	NUM	O	O	569
female	ADJ	O	O	569
migraineurs	NOUN	O	Disease	569
(	PUNCT	O	O	569
without	ADP	O	O	569
aura	NOUN	O	O	569
)	PUNCT	O	O	569
and	CCONJ	O	O	569
eight	NUM	O	O	569
controls	VERB	O	O	569
participated	VERB	O	O	569
in	ADP	O	O	569
the	PRON	O	O	569
study	VERB	O	O	569
.	PUNCT	O	O	569
Sublingual	PROPN	O	O	570
nitroglycerin	PROPN	O	Chemical	570
(	PUNCT	O	O	570
0.5	NUM	O	O	570
mg	VERB	O	O	570
)	PUNCT	O	O	570
was	AUX	O	O	570
administered	VERB	O	O	570
.	PUNCT	O	O	570
Blood	NOUN	O	O	571
was	AUX	O	O	571
collected	VERB	O	O	571
from	ADP	O	O	571
the	PRON	O	O	571
antecubital	ADJ	O	O	571
vein	NOUN	O	O	571
four	NUM	O	O	571
times	NOUN	O	O	571
:	PUNCT	O	O	571
60	NUM	O	O	571
min	NOUN	O	O	571
before	ADP	O	O	571
and	CCONJ	O	O	571
after	ADP	O	O	571
the	PRON	O	O	571
nitroglycerin	PROPN	O	Chemical	571
application	NOUN	O	O	571
,	PUNCT	O	O	571
and	CCONJ	O	O	571
60	NUM	O	O	571
and	CCONJ	O	O	571
120	NUM	O	O	571
min	NOUN	O	O	571
after	ADP	O	O	571
the	PRON	O	O	571
beginning	VERB	O	O	571
of	ADP	O	O	571
the	PRON	O	O	571
migraine	NOUN	O	Disease	571
attack	VERB	O	O	571
(	PUNCT	O	O	571
mean	VERB	O	O	571
344	NUM	O	O	571
and	CCONJ	O	O	571
404	NUM	O	O	571
min	NOUN	O	O	571
;	PUNCT	O	O	571
12	NUM	O	O	571
subjects	NOUN	O	O	571
)	PUNCT	O	O	571
.	PUNCT	O	O	571
In	ADP	O	O	572
those	PRON	O	O	572
subjects	NOUN	O	O	572
who	PRON	O	O	572
had	VERB	O	O	572
no	PRON	O	O	572
migraine	NOUN	O	Disease	572
attack	VERB	O	O	572
(	PUNCT	O	O	572
11	NUM	O	O	572
subjects	NOUN	O	O	572
)	PUNCT	O	O	572
a	PRON	O	O	572
similar	ADJ	O	O	572
time	NOUN	O	O	572
schedule	NOUN	O	O	572
was	AUX	O	O	572
used	VERB	O	O	572
.	PUNCT	O	O	572
Plasma	NOUN	O	O	573
CGRP	NOUN	O	O	573
concentration	NOUN	O	O	573
increased	VERB	O	O	573
significantly	ADV	O	O	573
(	PUNCT	O	O	573
P<0.01	ADV	O	O	573
)	PUNCT	O	O	573
during	ADP	O	O	573
the	PRON	O	O	573
migraine	NOUN	O	Disease	573
attack	VERB	O	O	573
and	CCONJ	O	O	573
returned	VERB	O	O	573
to	PART	O	O	573
baseline	VERB	O	O	573
after	ADP	O	O	573
the	PRON	O	O	573
cessation	NOUN	O	O	573
of	ADP	O	O	573
the	PRON	O	O	573
migraine	NOUN	O	Disease	573
.	PUNCT	O	O	573
In	ADP	O	O	574
addition	NOUN	O	O	574
,	PUNCT	O	O	574
both	PRON	O	O	574
change	VERB	O	O	574
and	CCONJ	O	O	574
peak	PROPN	O	O	574
,	PUNCT	O	O	574
showed	VERB	O	O	574
significant	ADJ	O	O	574
positive	ADJ	O	O	574
correlations	NOUN	O	O	574
with	ADP	O	O	574
migraine headache	PROPN	O	Disease	574
intensity	NOUN	O	O	574
(	PUNCT	O	O	574
P<0.001	ADJ	O	O	574
)	PUNCT	O	O	574
.	PUNCT	O	O	574
However	ADV	O	O	575
,	PUNCT	O	O	575
plasma	NOUN	O	O	575
CGRP	NOUN	O	O	575
concentrations	NOUN	O	O	575
failed	VERB	O	O	575
to	PART	O	O	575
change	VERB	O	O	575
during	ADP	O	O	575
immediate	ADJ	O	O	575
headache	PROPN	O	Disease	575
and	CCONJ	O	O	575
in	ADP	O	O	575
the	PRON	O	O	575
subjects	NOUN	O	O	575
with	ADP	O	O	575
no	PRON	O	O	575
migraine	NOUN	O	Disease	575
attack	VERB	O	O	575
.	PUNCT	O	O	575
Basal	PROPN	O	O	576
CGRP	NOUN	O	O	576
concentration	NOUN	O	O	576
was	AUX	O	O	576
significantly	ADV	O	O	576
higher	ADJ	O	O	576
and	CCONJ	O	O	576
platelet	NOUN	O	O	576
5-HT	NOUN	O	Chemical	576
content	NOUN	O	O	576
tended	VERB	O	O	576
to	PART	O	O	576
be	AUX	O	O	576
lower	ADJ	O	O	576
in	ADP	O	O	576
subjects	NOUN	O	O	576
who	PRON	O	O	576
experienced	ADJ	O	O	576
a	PRON	O	O	576
migraine	NOUN	O	Disease	576
attack	VERB	O	O	576
.	PUNCT	O	O	576
Platelet	NOUN	O	O	577
serotonin	PROPN	O	Chemical	577
content	NOUN	O	O	577
decreased	VERB	O	O	577
significantly	ADV	O	O	577
(	PUNCT	O	O	577
P<0.01	ADV	O	O	577
)	PUNCT	O	O	577
after	ADP	O	O	577
nitroglycerin	PROPN	O	Chemical	577
in	ADP	O	O	577
subjects	NOUN	O	O	577
with	ADP	O	O	577
no	PRON	O	O	577
migraine	NOUN	O	Disease	577
attack	VERB	O	O	577
but	CCONJ	O	O	577
no	PRON	O	O	577
consistent	ADJ	O	O	577
change	VERB	O	O	577
was	AUX	O	O	577
observed	VERB	O	O	577
in	ADP	O	O	577
patients	NOUN	O	O	577
with	ADP	O	O	577
migraine	NOUN	O	Disease	577
attack	VERB	O	O	577
.	PUNCT	O	O	577
In	ADP	O	O	578
conclusion	NOUN	O	O	578
,	PUNCT	O	O	578
the	PRON	O	O	578
fact	NOUN	O	O	578
that	SCONJ	O	O	578
plasma	NOUN	O	O	578
CGRP	NOUN	O	O	578
concentration	NOUN	O	O	578
correlates	VERB	O	O	578
with	ADP	O	O	578
the	PRON	O	O	578
timing	NOUN	O	O	578
and	CCONJ	O	O	578
severity	NOUN	O	O	578
of	ADP	O	O	578
a	PRON	O	O	578
migraine headache	PROPN	O	Disease	578
suggests	VERB	O	O	578
a	PRON	O	O	578
direct	ADJ	O	O	578
relationship	NOUN	O	O	578
between	ADP	O	O	578
CGRP	NOUN	O	O	578
and	CCONJ	O	O	578
migraine	NOUN	O	Disease	578
.	PUNCT	O	O	578
In	ADP	O	O	579
contrast	NOUN	O	O	579
,	PUNCT	O	O	579
serotonin	PROPN	O	Chemical	579
release	NOUN	O	O	579
from	ADP	O	O	579
platelets	VERB	O	O	579
does	VERB	O	O	579
not	PART	O	O	579
provoke	VERB	O	O	579
migraine	NOUN	O	Disease	579
,	PUNCT	O	O	579
it	PRON	O	O	579
may	AUX	O	O	579
even	ADV	O	O	579
counteract	VERB	O	O	579
the	PRON	O	O	579
headache	PROPN	O	Disease	579
and	CCONJ	O	O	579
the	PRON	O	O	579
concomitant	ADJ	O	O	579
CGRP	NOUN	O	O	579
release	NOUN	O	O	579
in	ADP	O	O	579
this	PRON	O	O	579
model	NOUN	O	O	579
.	PUNCT	O	O	579
Coronary	ADJ	O	O	582
aneurysm	PROPN	O	O	582
after	ADP	O	O	582
implantation	NOUN	O	O	582
of	ADP	O	O	582
a	PRON	O	O	582
paclitaxel	NOUN	O	Chemical	582
-	PUNCT	O	O	582
eluting	VERB	O	O	582
stent	VERB	O	O	582
.	PUNCT	O	O	582
Formation	NOUN	O	O	583
of	ADP	O	O	583
coronary	ADJ	O	O	583
aneurysm	PROPN	O	O	583
is	AUX	O	O	583
a	PRON	O	O	583
rare	ADJ	O	O	583
complication	NOUN	O	O	583
of	ADP	O	O	583
stenting	VERB	O	O	583
with	ADP	O	O	583
bare	PROPN	O	O	583
metal	NOUN	O	O	583
stents	NOUN	O	O	583
,	PUNCT	O	O	583
but	CCONJ	O	O	583
based	VERB	O	O	583
on	ADP	O	O	583
experimental	ADJ	O	O	583
studies	NOUN	O	O	583
drug	NOUN	O	O	583
-	PUNCT	O	O	583
eluting	VERB	O	O	583
stents	NOUN	O	O	583
may	AUX	O	O	583
induce	VERB	O	O	583
toxic	ADJ	O	O	583
effects	NOUN	O	O	583
on	ADP	O	O	583
the	PRON	O	O	583
vessel	NOUN	O	O	583
wall	PROPN	O	O	583
with	ADP	O	O	583
incomplete	ADJ	O	O	583
stent	VERB	O	O	583
apposition	NOUN	O	O	583
,	PUNCT	O	O	583
aneurysm	PROPN	O	O	583
formation	NOUN	O	O	583
and	CCONJ	O	O	583
with	ADP	O	O	583
the	PRON	O	O	583
potential	ADJ	O	O	583
of	ADP	O	O	583
stent	VERB	O	O	583
thrombosis	NOUN	O	Disease	583
or	CCONJ	O	O	583
vessel	NOUN	O	O	583
rupture	NOUN	O	Disease	583
.	PUNCT	O	O	583
We	PRON	O	O	584
present	NOUN	O	O	584
a	PRON	O	O	584
43-year	NOUN	O	O	584
-	PUNCT	O	O	584
old	ADJ	O	O	584
man	NOUN	O	O	584
who	PRON	O	O	584
developed	VERB	O	O	584
a	PRON	O	O	584
coronary	ADJ	O	O	584
aneurysm	PROPN	O	O	584
in	ADP	O	O	584
the	PRON	O	O	584
right	ADV	O	O	584
coronary	ADJ	O	O	584
artery	NOUN	O	O	584
6	NUM	O	O	584
months	NOUN	O	O	584
after	ADP	O	O	584
receiving	VERB	O	O	584
a	PRON	O	O	584
paclitaxel	NOUN	O	Chemical	584
-	PUNCT	O	O	584
eluting	VERB	O	O	584
stent	VERB	O	O	584
.	PUNCT	O	O	584
The	PRON	O	O	585
patient	NOUN	O	O	585
was	AUX	O	O	585
asymptomatic	ADJ	O	O	585
and	CCONJ	O	O	585
the	PRON	O	O	585
aneurysm	PROPN	O	O	585
was	AUX	O	O	585
detected	VERB	O	O	585
in	ADP	O	O	585
a	PRON	O	O	585
routine	ADJ	O	O	585
control	VERB	O	O	585
.	PUNCT	O	O	585
Angiography	NOUN	O	O	586
and	CCONJ	O	O	586
intracoronary	NOUN	O	O	586
ultrasound	VERB	O	O	586
demonstrated	VERB	O	O	586
lack	VERB	O	O	586
of	ADP	O	O	586
contact	NOUN	O	O	586
between	ADP	O	O	586
stent	VERB	O	O	586
and	CCONJ	O	O	586
vessel	NOUN	O	O	586
wall	PROPN	O	O	586
in	ADP	O	O	586
a	PRON	O	O	586
15-mm	NOUN	O	O	586
long	ADV	O	O	586
segment	NOUN	O	O	586
with	ADP	O	O	586
maximal	ADJ	O	O	586
aneurysm	PROPN	O	O	586
diameter	NOUN	O	O	586
of	ADP	O	O	586
6.0	NUM	O	O	586
mm	INTJ	O	O	586
.	PUNCT	O	O	586
Behavioral	NOUN	O	O	589
effects	NOUN	O	O	589
of	ADP	O	O	589
urotensin	VERB	O	O	589
-	PUNCT	O	O	589
II	NUM	O	O	589
centrally	ADV	O	O	589
administered	VERB	O	O	589
in	ADP	O	O	589
mice	NOUN	O	O	589
.	PUNCT	O	O	589
Urotensin	NOUN	O	O	590
-	PUNCT	O	O	590
II	NUM	O	O	590
(	PUNCT	O	O	590
U	NOUN	O	O	590
-	PUNCT	O	O	590
II	NUM	O	O	590
)	PUNCT	O	O	590
receptors	NOUN	O	O	590
are	AUX	O	O	590
widely	ADV	O	O	590
distributed	VERB	O	O	590
in	ADP	O	O	590
the	PRON	O	O	590
central	ADJ	O	O	590
nervous	ADJ	O	O	590
system	NOUN	O	O	590
.	PUNCT	O	O	590
Intracerebroventricular	PROPN	O	O	591
(	PUNCT	O	O	591
i.c.v	NOUN	O	O	591
.	PUNCT	O	O	591
)	PUNCT	O	O	591
injection	NOUN	O	O	591
of	ADP	O	O	591
U	NOUN	O	O	591
-	PUNCT	O	O	591
II	NUM	O	O	591
causes	VERB	O	O	591
hypertension	NOUN	O	Disease	591
and	CCONJ	O	O	591
bradycardia	NOUN	O	Disease	591
and	CCONJ	O	O	591
stimulates	VERB	O	O	591
prolactin	PROPN	O	O	591
and	CCONJ	O	O	591
thyrotropin	ADP	O	O	591
secretion	NOUN	O	O	591
.	PUNCT	O	O	591
However	ADV	O	O	592
,	PUNCT	O	O	592
the	PRON	O	O	592
behavioral	ADJ	O	O	592
effects	NOUN	O	O	592
of	ADP	O	O	592
centrally	ADV	O	O	592
administered	VERB	O	O	592
U	NOUN	O	O	592
-	PUNCT	O	O	592
II	NUM	O	O	592
have	VERB	O	O	592
received	VERB	O	O	592
little	ADJ	O	O	592
attention	NOUN	O	O	592
.	PUNCT	O	O	592
injections	NOUN	O	O	593
of	ADP	O	O	593
U	NOUN	O	O	593
-	PUNCT	O	O	593
II	NUM	O	O	593
on	ADP	O	O	593
behavioral	ADJ	O	O	593
,	PUNCT	O	O	593
metabolic	ADJ	O	O	593
,	PUNCT	O	O	593
and	CCONJ	O	O	593
endocrine	NOUN	O	O	593
responses	NOUN	O	O	593
in	ADP	O	O	593
mice	NOUN	O	O	593
.	PUNCT	O	O	593
Administration	NOUN	O	O	594
of	ADP	O	O	594
graded	VERB	O	O	594
doses	NOUN	O	O	594
of	ADP	O	O	594
U	NOUN	O	O	594
-	PUNCT	O	O	594
II	NUM	O	O	594
(	PUNCT	O	O	594
1	X	O	O	594
-	PUNCT	O	O	594
10,000	NUM	O	O	594
ng	PROPN	O	O	594
/	PUNCT	O	O	594
mouse	PROPN	O	O	594
)	PUNCT	O	O	594
provoked	VERB	O	O	594
:	PUNCT	O	O	594
(	PUNCT	O	O	594
1	X	O	O	594
)	PUNCT	O	O	594
a	PRON	O	O	594
dose	NOUN	O	O	594
-	PUNCT	O	O	594
dependent	ADJ	O	O	594
reduction	NOUN	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
number	NOUN	O	O	594
of	ADP	O	O	594
head	NOUN	O	O	594
dips	VERB	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
hole	NOUN	O	O	594
-	PUNCT	O	O	594
board	PROPN	O	O	594
test	NOUN	O	O	594
;	PUNCT	O	O	594
(	PUNCT	O	O	594
2	X	O	O	594
)	PUNCT	O	O	594
a	PRON	O	O	594
dose	NOUN	O	O	594
-	PUNCT	O	O	594
dependent	ADJ	O	O	594
reduction	NOUN	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
number	NOUN	O	O	594
of	ADP	O	O	594
entries	NOUN	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
white	ADJ	O	O	594
chamber	PROPN	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
black	ADJ	O	O	594
-	PUNCT	O	O	594
and	CCONJ	O	O	594
-	PUNCT	O	O	594
white	ADJ	O	O	594
compartment	NOUN	O	O	594
test	NOUN	O	O	594
,	PUNCT	O	O	594
and	CCONJ	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
number	NOUN	O	O	594
of	ADP	O	O	594
entries	NOUN	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
central	ADJ	O	O	594
platform	NOUN	O	O	594
and	CCONJ	O	O	594
open	VERB	O	O	594
arms	NOUN	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
plus	CCONJ	O	O	594
-	PUNCT	O	O	594
maze	NOUN	O	O	594
test	NOUN	O	O	594
;	PUNCT	O	O	594
and	CCONJ	O	O	594
(	PUNCT	O	O	594
3	X	O	O	594
)	PUNCT	O	O	594
a	PRON	O	O	594
dose	NOUN	O	O	594
-	PUNCT	O	O	594
dependent	ADJ	O	O	594
increase	VERB	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
duration	NOUN	O	O	594
of	ADP	O	O	594
immobility	NOUN	O	O	594
in	ADP	O	O	594
the	PRON	O	O	594
forced	VERB	O	O	594
-	PUNCT	O	O	594
swimming	VERB	O	O	594
test	NOUN	O	O	594
and	CCONJ	O	O	594
tail	NOUN	O	O	594
suspension	NOUN	O	O	594
test	NOUN	O	O	594
.	PUNCT	O	O	594
Intracerebroventricular	PROPN	O	O	595
injection	NOUN	O	O	595
of	ADP	O	O	595
U	NOUN	O	O	595
-	PUNCT	O	O	595
II	NUM	O	O	595
also	ADV	O	O	595
caused	VERB	O	O	595
an	PRON	O	O	595
increase	VERB	O	O	595
in	ADP	O	O	595
:	PUNCT	O	O	595
food	NOUN	O	O	595
intake	PROPN	O	O	595
at	ADP	O	O	595
doses	NOUN	O	O	595
of	ADP	O	O	595
100	NUM	O	O	595
and	CCONJ	O	O	595
1,000	NUM	O	O	595
ng	PROPN	O	O	595
/	PUNCT	O	O	595
mouse	PROPN	O	O	595
,	PUNCT	O	O	595
water	PROPN	O	O	595
intake	PROPN	O	O	595
at	ADP	O	O	595
doses	NOUN	O	O	595
of	ADP	O	O	595
100	NUM	O	O	595
-	PUNCT	O	O	595
10,000	NUM	O	O	595
ng	PROPN	O	O	595
/	PUNCT	O	O	595
mouse	PROPN	O	O	595
,	PUNCT	O	O	595
and	CCONJ	O	O	595
horizontal	PROPN	O	O	595
locomotion	NOUN	O	O	595
activity	NOUN	O	O	595
at	ADP	O	O	595
a	PRON	O	O	595
dose	NOUN	O	O	595
of	ADP	O	O	595
10,000	NUM	O	O	595
ng	PROPN	O	O	595
/	PUNCT	O	O	595
mouse	PROPN	O	O	595
.	PUNCT	O	O	595
Whatever	PRON	O	O	596
was	AUX	O	O	596
the	PRON	O	O	596
dose	NOUN	O	O	596
,	PUNCT	O	O	596
the	PRON	O	O	596
central	ADJ	O	O	596
administration	NOUN	O	O	596
of	ADP	O	O	596
U	NOUN	O	O	596
-	PUNCT	O	O	596
II	NUM	O	O	596
had	VERB	O	O	596
no	PRON	O	O	596
effect	VERB	O	O	596
on	ADP	O	O	596
body	NOUN	O	O	596
temperature	NOUN	O	O	596
,	PUNCT	O	O	596
nociception	NOUN	O	O	596
,	PUNCT	O	O	596
apomorphine	PROPN	O	Chemical	596
-	PUNCT	O	O	596
induced	VERB	O	O	596
penile	NOUN	O	O	596
erection	VERB	O	O	596
and	CCONJ	O	O	596
climbing	VERB	O	O	596
behavior	NOUN	O	O	596
,	PUNCT	O	O	596
and	CCONJ	O	O	596
stress	NOUN	O	O	596
-	PUNCT	O	O	596
induced	VERB	O	O	596
plasma	NOUN	O	O	596
corticosterone	NOUN	O	Chemical	596
level	VERB	O	O	596
.	PUNCT	O	O	596
Taken	VERB	O	O	597
together	ADV	O	O	597
,	PUNCT	O	O	597
the	PRON	O	O	597
present	NOUN	O	O	597
study	VERB	O	O	597
demonstrates	VERB	O	O	597
that	SCONJ	O	O	597
the	PRON	O	O	597
central	ADJ	O	O	597
injection	NOUN	O	O	597
of	ADP	O	O	597
U	NOUN	O	O	597
-	PUNCT	O	O	597
II	NUM	O	O	597
at	ADP	O	O	597
doses	NOUN	O	O	597
of	ADP	O	O	597
1	X	O	O	597
-	PUNCT	O	O	597
10,000	NUM	O	O	597
ng	PROPN	O	O	597
/	PUNCT	O	O	597
mouse	PROPN	O	O	597
induces	VERB	O	O	597
anxiogenic-	ADV	O	O	597
and	CCONJ	O	O	597
depressant	NOUN	O	O	597
-	PUNCT	O	O	597
like	INTJ	O	O	597
effects	NOUN	O	O	597
in	ADP	O	O	597
mouse	PROPN	O	O	597
.	PUNCT	O	O	597
These	PRON	O	O	598
data	NOUN	O	O	598
suggest	VERB	O	O	598
that	SCONJ	O	O	598
U	NOUN	O	O	598
-	PUNCT	O	O	598
II	NUM	O	O	598
may	AUX	O	O	598
be	AUX	O	O	598
involved	VERB	O	O	598
in	ADP	O	O	598
some	PRON	O	O	598
aspects	NOUN	O	O	598
of	ADP	O	O	598
psychiatric disorders	NOUN	O	Disease	598
.	PUNCT	O	O	598
Recurrent	ADJ	O	O	601
dysphonia	PROPN	O	O	601
and	CCONJ	O	O	601
acitretin	NOUN	O	O	601
.	PUNCT	O	O	601
We	PRON	O	O	602
report	VERB	O	O	602
the	PRON	O	O	602
case	NOUN	O	O	602
of	ADP	O	O	602
a	PRON	O	O	602
woman	NOUN	O	O	602
complaining	VERB	O	O	602
of	ADP	O	O	602
dysphonia	PROPN	O	O	602
while	SCONJ	O	O	602
she	PRON	O	O	602
was	AUX	O	O	602
treated	VERB	O	O	602
by	ADP	O	O	602
acitretin	NOUN	O	O	602
.	PUNCT	O	O	602
Her	PRON	O	O	603
symptoms	NOUN	O	O	603
totally	ADV	O	O	603
regressed	VERB	O	O	603
after	ADP	O	O	603
drug	NOUN	O	O	603
withdrawal	NOUN	O	O	603
and	CCONJ	O	O	603
reappeared	VERB	O	O	603
when	SCONJ	O	O	603
acitretin	NOUN	O	O	603
was	AUX	O	O	603
reintroduced	VERB	O	O	603
.	PUNCT	O	O	603
To	PART	O	O	604
our	PRON	O	O	604
knowledge	NOUN	O	O	604
,	PUNCT	O	O	604
this	PRON	O	O	604
is	AUX	O	O	604
the	PRON	O	O	604
first	ADV	O	O	604
case	NOUN	O	O	604
of	ADP	O	O	604
acitretin	NOUN	O	O	604
-	PUNCT	O	O	604
induced	VERB	O	O	604
dysphonia	PROPN	O	O	604
.	PUNCT	O	O	604
Pharmacological	ADJ	O	O	607
modulation	NOUN	O	O	607
of	ADP	O	O	607
pain	NOUN	O	Disease	607
-	PUNCT	O	O	607
related	ADJ	O	O	607
brain	NOUN	O	O	607
activity	NOUN	O	O	607
during	ADP	O	O	607
normal	ADJ	O	O	607
and	CCONJ	O	O	607
central	ADJ	O	O	607
sensitization	NOUN	O	O	607
states	VERB	O	O	607
in	ADP	O	O	607
humans	NOUN	O	O	607
.	PUNCT	O	O	607
Abnormal	ADJ	O	O	608
processing	NOUN	O	O	608
of	ADP	O	O	608
somatosensory	NOUN	O	O	608
inputs	NOUN	O	O	608
in	ADP	O	O	608
the	PRON	O	O	608
central	ADJ	O	O	608
nervous	ADJ	O	O	608
system	NOUN	O	O	608
(	PUNCT	O	O	608
central	ADJ	O	O	608
sensitization	NOUN	O	O	608
)	PUNCT	O	O	608
is	AUX	O	O	608
the	PRON	O	O	608
mechanism	NOUN	O	O	608
accounting	VERB	O	O	608
for	ADP	O	O	608
the	PRON	O	O	608
enhanced	VERB	O	O	608
pain	NOUN	O	Disease	608
sensitivity	NOUN	O	O	608
in	ADP	O	O	608
the	PRON	O	O	608
skin	NOUN	O	O	608
surrounding	VERB	O	O	608
tissue	NOUN	O	O	608
injury	NOUN	O	O	608
(	PUNCT	O	O	608
secondary	ADJ	O	O	608
hyperalgesia	NOUN	O	Disease	608
)	PUNCT	O	O	608
.	PUNCT	O	O	608
Secondary	ADJ	O	O	609
hyperalgesia	NOUN	O	Disease	609
shares	NOUN	O	O	609
clinical	ADJ	O	O	609
characteristics	NOUN	O	O	609
with	ADP	O	O	609
neurogenic	ADJ	O	O	609
hyperalgesia	NOUN	O	Disease	609
in	ADP	O	O	609
patients	NOUN	O	O	609
with	ADP	O	O	609
neuropathic pain	NOUN	O	Disease	609
.	PUNCT	O	O	609
Abnormal	ADJ	O	O	610
brain	NOUN	O	O	610
responses	NOUN	O	O	610
to	PART	O	O	610
somatosensory	NOUN	O	O	610
stimuli	NOUN	O	O	610
have	VERB	O	O	610
been	AUX	O	O	610
found	VERB	O	O	610
in	ADP	O	O	610
patients	NOUN	O	O	610
with	ADP	O	O	610
hyperalgesia	NOUN	O	Disease	610
as	ADP	O	O	610
well	ADV	O	O	610
as	ADP	O	O	610
in	ADP	O	O	610
normal	ADJ	O	O	610
subjects	NOUN	O	O	610
during	ADP	O	O	610
experimental	ADJ	O	O	610
central	ADJ	O	O	610
sensitization	NOUN	O	O	610
.	PUNCT	O	O	610
The	PRON	O	O	611
aim	VERB	O	O	611
of	ADP	O	O	611
this	PRON	O	O	611
study	VERB	O	O	611
was	AUX	O	O	611
to	PART	O	O	611
assess	VERB	O	O	611
the	PRON	O	O	611
effects	NOUN	O	O	611
of	ADP	O	O	611
gabapentin	NOUN	O	O	611
,	PUNCT	O	O	611
a	PRON	O	O	611
drug	NOUN	O	O	611
effective	ADJ	O	O	611
in	ADP	O	O	611
neuropathic pain	NOUN	O	Disease	611
patients	NOUN	O	O	611
,	PUNCT	O	O	611
on	ADP	O	O	611
brain	NOUN	O	O	611
processing	NOUN	O	O	611
of	ADP	O	O	611
nociceptive	ADJ	O	O	611
information	NOUN	O	O	611
in	ADP	O	O	611
normal	ADJ	O	O	611
and	CCONJ	O	O	611
central	ADJ	O	O	611
sensitization	NOUN	O	O	611
states	VERB	O	O	611
.	PUNCT	O	O	611
Using	VERB	O	O	612
functional	ADJ	O	O	612
magnetic	ADJ	O	O	612
resonance	NOUN	O	O	612
imaging	VERB	O	O	612
(	PUNCT	O	O	612
fMRI	PROPN	O	O	612
)	PUNCT	O	O	612
in	ADP	O	O	612
normal	ADJ	O	O	612
volunteers	NOUN	O	O	612
,	PUNCT	O	O	612
we	PRON	O	O	612
studied	VERB	O	O	612
the	PRON	O	O	612
gabapentin	NOUN	O	O	612
-	PUNCT	O	O	612
induced	VERB	O	O	612
modulation	NOUN	O	O	612
of	ADP	O	O	612
brain	NOUN	O	O	612
activity	NOUN	O	O	612
in	ADP	O	O	612
response	NOUN	O	O	612
to	PART	O	O	612
nociceptive	ADJ	O	O	612
mechanical	ADJ	O	O	612
stimulation	NOUN	O	O	612
of	ADP	O	O	612
normal	ADJ	O	O	612
skin	NOUN	O	O	612
and	CCONJ	O	O	612
capsaicin	NOUN	O	Chemical	612
-	PUNCT	O	O	612
induced	VERB	O	O	612
secondary	ADJ	O	O	612
hyperalgesia	NOUN	O	Disease	612
.	PUNCT	O	O	612
The	PRON	O	O	613
dose	NOUN	O	O	613
of	ADP	O	O	613
gabapentin	NOUN	O	O	613
was	AUX	O	O	613
1,800	NUM	O	O	613
mg	VERB	O	O	613
per	ADP	O	O	613
os	INTJ	O	O	613
,	PUNCT	O	O	613
in	ADP	O	O	613
a	PRON	O	O	613
single	ADJ	O	O	613
administration	NOUN	O	O	613
.	PUNCT	O	O	613
We	PRON	O	O	614
found	VERB	O	O	614
that	SCONJ	O	O	614
(	PUNCT	O	O	614
i	PRON	O	O	614
)	PUNCT	O	O	614
gabapentin	NOUN	O	O	614
reduced	VERB	O	O	614
the	PRON	O	O	614
activations	VERB	O	O	614
in	ADP	O	O	614
the	PRON	O	O	614
bilateral	ADJ	O	O	614
operculoinsular	NOUN	O	O	614
cortex	VERB	O	O	614
,	PUNCT	O	O	614
independently	ADV	O	O	614
of	ADP	O	O	614
the	PRON	O	O	614
presence	NOUN	O	O	614
of	ADP	O	O	614
central	ADJ	O	O	614
sensitization	NOUN	O	O	614
;	PUNCT	O	O	614
(	PUNCT	O	O	614
ii	PROPN	O	O	614
)	PUNCT	O	O	614
gabapentin	NOUN	O	O	614
reduced	VERB	O	O	614
the	PRON	O	O	614
activation	NOUN	O	O	614
in	ADP	O	O	614
the	PRON	O	O	614
brainstem	NOUN	O	O	614
,	PUNCT	O	O	614
only	ADV	O	O	614
during	ADP	O	O	614
central	ADJ	O	O	614
sensitization	NOUN	O	O	614
;	PUNCT	O	O	614
(	PUNCT	O	O	614
iii	X	O	O	614
)	PUNCT	O	O	614
gabapentin	NOUN	O	O	614
suppressed	VERB	O	O	614
stimulus	NOUN	O	O	614
-	PUNCT	O	O	614
induced	VERB	O	O	614
deactivations	NOUN	O	O	614
,	PUNCT	O	O	614
only	ADV	O	O	614
during	ADP	O	O	614
central	ADJ	O	O	614
sensitization	NOUN	O	O	614
;	PUNCT	O	O	614
this	PRON	O	O	614
effect	VERB	O	O	614
was	AUX	O	O	614
more	ADJ	O	O	614
robust	ADJ	O	O	614
than	ADP	O	O	614
the	PRON	O	O	614
effect	VERB	O	O	614
on	ADP	O	O	614
brain	NOUN	O	O	614
activation	NOUN	O	O	614
.	PUNCT	O	O	614
These	PRON	O	O	615
findings	NOUN	O	O	615
indicate	VERB	O	O	615
that	SCONJ	O	O	615
gabapentin	NOUN	O	O	615
has	VERB	O	O	615
a	PRON	O	O	615
measurable	ADJ	O	O	615
antinociceptive	VERB	O	O	615
effect	VERB	O	O	615
and	CCONJ	O	O	615
a	PRON	O	O	615
stronger	ADJ	O	O	615
antihyperalgesic	NOUN	O	O	615
effect	VERB	O	O	615
most	ADV	O	O	615
evident	ADJ	O	O	615
in	ADP	O	O	615
the	PRON	O	O	615
brain	NOUN	O	O	615
areas	NOUN	O	O	615
undergoing	VERB	O	O	615
deactivation	NOUN	O	O	615
,	PUNCT	O	O	615
thus	ADV	O	O	615
supporting	VERB	O	O	615
the	PRON	O	O	615
concept	NOUN	O	O	615
that	SCONJ	O	O	615
gabapentin	NOUN	O	O	615
is	AUX	O	O	615
more	ADJ	O	O	615
effective	ADJ	O	O	615
in	ADP	O	O	615
modulating	VERB	O	O	615
nociceptive	ADJ	O	O	615
transmission	NOUN	O	O	615
when	SCONJ	O	O	615
central	ADJ	O	O	615
sensitization	NOUN	O	O	615
is	AUX	O	O	615
present	NOUN	O	O	615
.	PUNCT	O	O	615
MDMA	PROPN	O	Chemical	618
polydrug	NOUN	O	O	618
users	NOUN	O	O	618
show	VERB	O	O	618
process	NOUN	O	O	618
-	PUNCT	O	O	618
specific	ADJ	O	O	618
central	ADJ	O	O	618
executive	NOUN	O	O	618
impairments	VERB	O	O	618
coupled	VERB	O	O	618
with	ADP	O	O	618
impaired	VERB	O	O	618
social	ADJ	O	O	618
and	CCONJ	O	O	618
emotional	ADJ	O	O	618
judgement	NOUN	O	O	618
processes	NOUN	O	O	618
.	PUNCT	O	O	618
In	ADP	O	O	619
recent	ADJ	O	O	619
years	NOUN	O	O	619
working	VERB	O	O	619
memory	NOUN	O	O	619
deficits	NOUN	O	O	619
have	VERB	O	O	619
been	AUX	O	O	619
reported	VERB	O	O	619
in	ADP	O	O	619
users	NOUN	O	O	619
of	ADP	O	O	619
MDMA	PROPN	O	Chemical	619
(	PUNCT	O	O	619
3,4-methylenedioxymethamphetamine	NOUN	O	Chemical	619
,	PUNCT	O	O	619
ecstasy	NOUN	O	Chemical	619
)	PUNCT	O	O	619
.	PUNCT	O	O	619
The	PRON	O	O	620
current	ADJ	O	O	620
study	VERB	O	O	620
aimed	VERB	O	O	620
to	PART	O	O	620
assess	VERB	O	O	620
the	PRON	O	O	620
impact	NOUN	O	O	620
of	ADP	O	O	620
MDMA	PROPN	O	Chemical	620
use	VERB	O	O	620
on	ADP	O	O	620
three	NUM	O	O	620
separate	VERB	O	O	620
central	ADJ	O	O	620
executive	NOUN	O	O	620
processes	NOUN	O	O	620
(	PUNCT	O	O	620
set	VERB	O	O	620
shifting	VERB	O	O	620
,	PUNCT	O	O	620
inhibition	NOUN	O	O	620
and	CCONJ	O	O	620
memory	NOUN	O	O	620
updating	NOUN	O	O	620
)	PUNCT	O	O	620
and	CCONJ	O	O	620
also	ADV	O	O	620
on	ADP	O	O	620
""""	PUNCT	O	O	620
prefrontal	ADJ	O	O	620
""""	PUNCT	O	O	620
mediated	VERB	O	O	620
social	ADJ	O	O	620
and	CCONJ	O	O	620
emotional	ADJ	O	O	620
judgement	NOUN	O	O	620
processes	NOUN	O	O	620
.	PUNCT	O	O	620
Fifteen	NUM	O	O	621
polydrug	NOUN	O	O	621
ecstasy	NOUN	O	Chemical	621
users	NOUN	O	O	621
and	CCONJ	O	O	621
15	NUM	O	O	621
polydrug	NOUN	O	O	621
non	ADJ	O	O	621
-	PUNCT	O	O	621
ecstasy	NOUN	O	Chemical	621
user	NOUN	O	O	621
controls	VERB	O	O	621
completed	VERB	O	O	621
a	PRON	O	O	621
general	ADJ	O	O	621
drug	NOUN	O	O	621
use	VERB	O	O	621
questionnaire	NOUN	O	O	621
,	PUNCT	O	O	621
the	PRON	O	O	621
Brixton	PROPN	O	O	621
Spatial	NOUN	O	O	621
Anticipation	NOUN	O	O	621
task	NOUN	O	O	621
(	PUNCT	O	O	621
set	VERB	O	O	621
shifting	VERB	O	O	621
)	PUNCT	O	O	621
,	PUNCT	O	O	621
Backward	ADJ	O	O	621
Digit	NOUN	O	O	621
Span	NOUN	O	O	621
procedure	NOUN	O	O	621
(	PUNCT	O	O	621
memory	NOUN	O	O	621
updating	NOUN	O	O	621
)	PUNCT	O	O	621
,	PUNCT	O	O	621
Inhibition	NOUN	O	O	621
of	ADP	O	O	621
Return	VERB	O	O	621
(	PUNCT	O	O	621
inhibition	NOUN	O	O	621
)	PUNCT	O	O	621
,	PUNCT	O	O	621
an	PRON	O	O	621
emotional	ADJ	O	O	621
intelligence	NOUN	O	O	621
scale	NOUN	O	O	621
,	PUNCT	O	O	621
the	PRON	O	O	621
Tromso	PROPN	O	O	621
Social	ADJ	O	O	621
Intelligence	NOUN	O	O	621
Scale	NOUN	O	O	621
and	CCONJ	O	O	621
the	PRON	O	O	621
Dysexecutive	PROPN	O	O	621
Questionnaire	NOUN	O	O	621
(	PUNCT	O	O	621
DEX	PROPN	O	O	621
)	PUNCT	O	O	621
.	PUNCT	O	O	621
Compared	VERB	O	O	622
with	ADP	O	O	622
MDMA	PROPN	O	Chemical	622
-	PUNCT	O	O	622
free	ADJ	O	O	622
polydrug	NOUN	O	O	622
controls	VERB	O	O	622
,	PUNCT	O	O	622
MDMA	PROPN	O	Chemical	622
polydrug	NOUN	O	O	622
users	NOUN	O	O	622
showed	VERB	O	O	622
impairments	VERB	O	O	622
in	ADP	O	O	622
set	VERB	O	O	622
shifting	VERB	O	O	622
and	CCONJ	O	O	622
memory	NOUN	O	O	622
updating	NOUN	O	O	622
,	PUNCT	O	O	622
and	CCONJ	O	O	622
also	ADV	O	O	622
in	ADP	O	O	622
social	ADJ	O	O	622
and	CCONJ	O	O	622
emotional	ADJ	O	O	622
judgement	NOUN	O	O	622
processes	NOUN	O	O	622
.	PUNCT	O	O	622
These	PRON	O	O	623
data	NOUN	O	O	623
lend	VERB	O	O	623
further	ADV	O	O	623
support	NOUN	O	O	623
to	PART	O	O	623
the	PRON	O	O	623
proposal	NOUN	O	O	623
that	SCONJ	O	O	623
cognitive	ADJ	O	O	623
processes	NOUN	O	O	623
mediated	VERB	O	O	623
by	ADP	O	O	623
the	PRON	O	O	623
prefrontal	ADJ	O	O	623
cortex	VERB	O	O	623
may	AUX	O	O	623
be	AUX	O	O	623
impaired	VERB	O	O	623
by	ADP	O	O	623
recreational	ADJ	O	O	623
ecstasy	NOUN	O	Chemical	623
use	VERB	O	O	623
.	PUNCT	O	O	623
Severe	ADJ	O	O	626
citrate	PROPN	O	Chemical	626
toxicity	NOUN	O	Disease	626
complicating	VERB	O	O	626
volunteer	PROPN	O	O	626
apheresis	NOUN	O	O	626
platelet	NOUN	O	O	626
donation	NOUN	O	O	626
.	PUNCT	O	O	626
We	PRON	O	O	627
report	VERB	O	O	627
a	PRON	O	O	627
case	NOUN	O	O	627
of	ADP	O	O	627
severe	ADJ	O	O	627
citrate	PROPN	O	Chemical	627
toxicity	NOUN	O	Disease	627
during	ADP	O	O	627
volunteer	PROPN	O	O	627
donor	NOUN	O	O	627
apheresis	NOUN	O	O	627
platelet	NOUN	O	O	627
collection	NOUN	O	O	627
.	PUNCT	O	O	627
Past	ADJ	O	O	628
medical	ADJ	O	O	628
history	NOUN	O	O	628
was	AUX	O	O	628
remarkable	ADJ	O	O	628
for	ADP	O	O	628
hypertension	NOUN	O	Disease	628
,	PUNCT	O	O	628
hyperlipidemia	NOUN	O	Disease	628
,	PUNCT	O	O	628
and	CCONJ	O	O	628
depression	PROPN	O	Disease	628
.	PUNCT	O	O	628
Reported	VERB	O	O	629
medications	NOUN	O	O	629
included	VERB	O	O	629
bumetanide	ADV	O	O	629
,	PUNCT	O	O	629
pravastatin	PROPN	O	Chemical	629
,	PUNCT	O	O	629
and	CCONJ	O	O	629
paroxetine	NOUN	O	Chemical	629
.	PUNCT	O	O	629
She	PRON	O	O	630
then	ADV	O	O	630
very	ADV	O	O	630
rapidly	ADV	O	O	630
developed	VERB	O	O	630
acute	ADJ	O	O	630
onset	VERB	O	O	630
of	ADP	O	O	630
severe	ADJ	O	O	630
facial	ADJ	O	O	630
and	CCONJ	O	O	630
extremity	NOUN	O	O	630
tetany	NOUN	O	Disease	630
.	PUNCT	O	O	630
Empirical	PROPN	O	O	631
treatment	NOUN	O	O	631
with	ADP	O	O	631
intravenous	ADJ	O	O	631
calcium	NOUN	O	Chemical	631
gluconate	VERB	O	O	631
was	AUX	O	O	631
initiated	VERB	O	O	631
,	PUNCT	O	O	631
and	CCONJ	O	O	631
muscle	NOUN	O	O	631
contractions	NOUN	O	O	631
slowly	ADV	O	O	631
subsided	VERB	O	O	631
over	ADP	O	O	631
approximately	ADV	O	O	631
10	NUM	O	O	631
to	PART	O	O	631
15	NUM	O	O	631
minutes	NOUN	O	O	631
.	PUNCT	O	O	631
The	PRON	O	O	632
events	NOUN	O	O	632
are	AUX	O	O	632
consistent	ADJ	O	O	632
with	ADP	O	O	632
a	PRON	O	O	632
severe	ADJ	O	O	632
reaction	NOUN	O	O	632
to	PART	O	O	632
calcium	NOUN	O	Chemical	632
chelation	NOUN	O	O	632
by	ADP	O	O	632
sodium citrate	NOUN	O	Chemical	632
anticoagulant	ADJ	O	O	632
resulting	VERB	O	O	632
in	ADP	O	O	632
symptomatic	ADJ	O	O	632
systemic	ADJ	O	O	632
hypocalcemia	NOUN	O	Disease	632
.	PUNCT	O	O	632
Upon	SCONJ	O	O	633
additional	ADJ	O	O	633
retrospective	ADJ	O	O	633
analysis	NOUN	O	O	633
,	PUNCT	O	O	633
it	PRON	O	O	633
was	AUX	O	O	633
noted	VERB	O	O	633
that	SCONJ	O	O	633
bumetanide	ADV	O	O	633
is	AUX	O	O	633
a	PRON	O	O	633
loop	NOUN	O	O	633
diuretic	ADJ	O	Chemical	633
that	SCONJ	O	O	633
may	AUX	O	O	633
cause	VERB	O	O	633
significant	ADJ	O	O	633
hypocalcemia	NOUN	O	Disease	633
.	PUNCT	O	O	633
We	PRON	O	O	634
conclude	VERB	O	O	634
that	SCONJ	O	O	634
careful	ADJ	O	O	634
screening	VERB	O	O	634
for	ADP	O	O	634
medications	NOUN	O	O	634
and	CCONJ	O	O	634
underlying	VERB	O	O	634
conditions	NOUN	O	O	634
predisposing	VERB	O	O	634
to	PART	O	O	634
hypocalcemia	NOUN	O	Disease	634
is	AUX	O	O	634
recommended	VERB	O	O	634
to	PART	O	O	634
help	VERB	O	O	634
prevent	VERB	O	O	634
severe	ADJ	O	O	634
reactions	NOUN	O	O	634
due	ADJ	O	O	634
to	PART	O	O	634
citrate	PROPN	O	Chemical	634
toxicity	NOUN	O	Disease	634
.	PUNCT	O	O	634
Laboratory	NOUN	O	O	635
measurement	NOUN	O	O	635
of	ADP	O	O	635
pre	VERB	O	O	635
-	PUNCT	O	O	635
procedure	NOUN	O	O	635
serum	NOUN	O	O	635
calcium	NOUN	O	Chemical	635
levels	NOUN	O	O	635
in	ADP	O	O	635
selected	VERB	O	O	635
donors	NOUN	O	O	635
may	AUX	O	O	635
identify	VERB	O	O	635
cases	NOUN	O	O	635
requiring	VERB	O	O	635
heightened	VERB	O	O	635
vigilance	NOUN	O	O	635
.	PUNCT	O	O	635
Proteinuria	PROPN	O	Disease	638
after	ADP	O	O	638
conversion	NOUN	O	O	638
to	PART	O	O	638
sirolimus	NOUN	O	Chemical	638
in	ADP	O	O	638
renal	ADJ	O	O	638
transplant	NOUN	O	O	638
recipients	NOUN	O	O	638
.	PUNCT	O	O	638
Sirolimus	NOUN	O	Chemical	639
(	PUNCT	O	O	639
SRL	PROPN	O	O	639
)	PUNCT	O	O	639
is	AUX	O	O	639
a	PRON	O	O	639
new	ADJ	O	O	639
,	PUNCT	O	O	639
potent	ADJ	O	O	639
immunosuppressive	ADJ	O	O	639
agent	NOUN	O	O	639
.	PUNCT	O	O	639
More	ADJ	O	O	640
recently	ADV	O	O	640
,	PUNCT	O	O	640
proteinuria	X	O	Disease	640
has	VERB	O	O	640
been	AUX	O	O	640
reported	VERB	O	O	640
as	ADP	O	O	640
a	PRON	O	O	640
consequence	NOUN	O	O	640
of	ADP	O	O	640
sirolimus	NOUN	O	Chemical	640
therapy	NOUN	O	O	640
,	PUNCT	O	O	640
although	SCONJ	O	O	640
the	PRON	O	O	640
mechanism	NOUN	O	O	640
has	VERB	O	O	640
remained	VERB	O	O	640
unclear	ADJ	O	O	640
.	PUNCT	O	O	640
We	PRON	O	O	641
retrospectively	ADV	O	O	641
examined	VERB	O	O	641
the	PRON	O	O	641
records	NOUN	O	O	641
of	ADP	O	O	641
25	NUM	O	O	641
renal	ADJ	O	O	641
transplant	NOUN	O	O	641
patients	NOUN	O	O	641
,	PUNCT	O	O	641
who	PRON	O	O	641
developed	VERB	O	O	641
or	CCONJ	O	O	641
displayed	VERB	O	O	641
increased	VERB	O	O	641
proteinuria	X	O	Disease	641
after	ADP	O	O	641
SRL	PROPN	O	O	641
conversion	NOUN	O	O	641
.	PUNCT	O	O	641
The	PRON	O	O	642
patient	NOUN	O	O	642
cohort	NOUN	O	O	642
(	PUNCT	O	O	642
14	NUM	O	O	642
men	NOUN	O	O	642
,	PUNCT	O	O	642
11	NUM	O	O	642
women	NOUN	O	O	642
)	PUNCT	O	O	642
was	AUX	O	O	642
treated	VERB	O	O	642
with	ADP	O	O	642
SRL	PROPN	O	O	642
as	ADP	O	O	642
conversion	NOUN	O	O	642
therapy	NOUN	O	O	642
,	PUNCT	O	O	642
due	ADJ	O	O	642
to	PART	O	O	642
chronic	ADJ	O	O	642
allograft	NOUN	O	O	642
nephropathy	NOUN	O	Disease	642
(	PUNCT	O	O	642
CAN	AUX	O	O	642
)	PUNCT	O	O	642
(	PUNCT	O	O	642
n	CCONJ	O	O	642
=	PUNCT	O	O	642
15	NUM	O	O	642
)	PUNCT	O	O	642
neoplasia	NOUN	O	Disease	643
(	PUNCT	O	O	643
n	CCONJ	O	O	643
=	PUNCT	O	O	643
8)	NUM	O	O	643
;	PUNCT	O	O	643
Kaposi	PROPN	O	O	643
's	AUX	O	O	643
sarcoma	NOUN	O	Disease	643
,	PUNCT	O	O	643
Four	NUM	O	O	643
skin	NOUN	O	O	643
cancers	NOUN	O	Disease	643
,	PUNCT	O	O	643
One	NUM	O	O	643
intestinal	ADJ	O	Disease	643
tumors	NOUN	O	Disease	643
,	PUNCT	O	O	643
One	NUM	O	O	643
renal	ADJ	O	O	643
cell	NOUN	O	O	643
carsinom	PROPN	O	O	643
)	PUNCT	O	O	643
or	CCONJ	O	O	643
BK	PROPN	O	O	643
virus	NOUN	O	O	643
nephropathy	NOUN	O	Disease	643
(	PUNCT	O	O	643
n	CCONJ	O	O	643
=	PUNCT	O	O	643
2	X	O	O	643
)	PUNCT	O	O	643
.	PUNCT	O	O	643
SRL	PROPN	O	O	644
was	AUX	O	O	644
started	VERB	O	O	644
at	ADP	O	O	644
a	PRON	O	O	644
mean	VERB	O	O	644
of	ADP	O	O	644
78	NUM	O	O	644
+	ADP	O	O	644
/-	PUNCT	O	O	644
Mean	VERB	O	O	645
follow	VERB	O	O	645
-	PUNCT	O	O	645
up	ADP	O	O	645
on	ADP	O	O	645
SRL	PROPN	O	O	645
therapy	NOUN	O	O	645
was	AUX	O	O	645
20	NUM	O	O	645
+	ADP	O	O	645
/-	PUNCT	O	O	645
Proteinuria	PROPN	O	Disease	646
increased	VERB	O	O	646
from	ADP	O	O	646
0.445	NUM	O	O	646
(	PUNCT	O	O	646
0	NUM	O	O	646
to	PART	O	O	646
1.5	NUM	O	O	646
)	PUNCT	O	O	646
Before	ADP	O	O	647
conversion	NOUN	O	O	647
8	NUM	O	O	647
(	PUNCT	O	O	647
32%	NOUN	O	O	647
)	PUNCT	O	O	647
patients	NOUN	O	O	647
had	VERB	O	O	647
no	PRON	O	O	647
proteinuria	X	O	Disease	647
,	PUNCT	O	O	647
whereas	SCONJ	O	O	647
afterwards	ADV	O	O	647
all	PRON	O	O	647
patients	NOUN	O	O	647
had	VERB	O	O	647
proteinuria	X	O	Disease	647
.	PUNCT	O	O	647
In	ADP	O	O	648
28%	NOUN	O	O	648
of	ADP	O	O	648
patients	NOUN	O	O	648
proteinuria	X	O	Disease	648
remained	VERB	O	O	648
unchanged	ADJ	O	O	648
,	PUNCT	O	O	648
whereas	SCONJ	O	O	648
it	PRON	O	O	648
increased	VERB	O	O	648
in	ADP	O	O	648
68%	NOUN	O	O	648
of	ADP	O	O	648
patients	NOUN	O	O	648
.	PUNCT	O	O	648
Twenty	NUM	O	O	649
-	PUNCT	O	O	649
eight	NUM	O	O	649
percent	NOUN	O	O	649
of	ADP	O	O	649
patients	NOUN	O	O	649
showed	VERB	O	O	649
increased	VERB	O	O	649
proteinuria	X	O	Disease	649
to	PART	O	O	649
the	PRON	O	O	649
nephrotic	NOUN	O	Disease	649
range	VERB	O	O	649
.	PUNCT	O	O	649
Biopsies	NOUN	O	O	650
performed	VERB	O	O	650
in	ADP	O	O	650
five	NUM	O	O	650
patients	NOUN	O	O	650
revealed	VERB	O	O	650
new	ADJ	O	O	650
pathological	ADJ	O	O	650
changes	VERB	O	O	650
:	PUNCT	O	O	650
One	NUM	O	O	650
membranoproliferative	PROPN	O	O	650
glomerulopathy	ADJ	O	O	650
and	CCONJ	O	O	650
interstitial nephritis	NOUN	O	Disease	650
.	PUNCT	O	O	650
Serum	NOUN	O	O	651
creatinine	PROPN	O	Chemical	651
values	NOUN	O	O	651
did	VERB	O	O	651
not	PART	O	O	651
change	VERB	O	O	651
significantly	ADV	O	O	651
:	PUNCT	O	O	651
1.98	NUM	O	O	651
+	ADP	O	O	651
/-	PUNCT	O	O	651
0.8	NUM	O	O	652
mg	VERB	O	O	652
/	PUNCT	O	O	652
dL	VERB	O	O	652
before	ADP	O	O	652
SRL	PROPN	O	O	652
therapy	NOUN	O	O	652
and	CCONJ	O	O	652
2.53	NUM	O	O	652
+	ADP	O	O	652
/-	PUNCT	O	O	652
Five	NUM	O	O	653
patients	NOUN	O	O	653
displayed	VERB	O	O	653
CAN	AUX	O	O	653
and	CCONJ	O	O	653
Kaposi	PROPN	O	O	653
's	AUX	O	O	653
sarcoma	NOUN	O	Disease	653
.	PUNCT	O	O	653
Mean	VERB	O	O	654
serum	NOUN	O	O	654
creatinine	PROPN	O	Chemical	654
level	VERB	O	O	654
before	ADP	O	O	654
conversion	NOUN	O	O	654
was	AUX	O	O	654
2.21	NUM	O	O	654
mg	VERB	O	O	654
/	PUNCT	O	O	654
dL	VERB	O	O	654
and	CCONJ	O	O	654
thereafter	ADV	O	O	654
,	PUNCT	O	O	654
4.93	NUM	O	O	654
mg	VERB	O	O	654
/	PUNCT	O	O	654
dL	VERB	O	O	654
(	PUNCT	O	O	654
P	NOUN	O	Chemical	654
=	PUNCT	O	O	654
.02	NUM	O	O	654
)	PUNCT	O	O	654
.	PUNCT	O	O	654
Heavy	ADJ	O	O	655
proteinuria	X	O	Disease	655
was	AUX	O	O	655
common	ADJ	O	O	655
after	ADP	O	O	655
the	PRON	O	O	655
use	VERB	O	O	655
of	ADP	O	O	655
SRL	PROPN	O	O	655
as	ADP	O	O	655
rescue	NOUN	O	O	655
therapy	NOUN	O	O	655
for	ADP	O	O	655
renal	ADJ	O	O	655
transplantation	NOUN	O	O	655
.	PUNCT	O	O	655
Therefore	ADV	O	O	656
,	PUNCT	O	O	656
conversion	NOUN	O	O	656
should	AUX	O	O	656
be	AUX	O	O	656
considered	VERB	O	O	656
for	ADP	O	O	656
patients	NOUN	O	O	656
who	PRON	O	O	656
have	VERB	O	O	656
not	PART	O	O	656
developed	VERB	O	O	656
advanced	ADJ	O	O	656
CAN	AUX	O	O	656
and	CCONJ	O	O	656
proteinuria	X	O	Disease	656
.	PUNCT	O	O	656
glomerular	ADJ	O	O	657
pathology	NOUN	O	O	657
under	ADP	O	O	657
SRL	PROPN	O	O	657
treatment	NOUN	O	O	657
requires	VERB	O	O	657
further	ADV	O	O	657
investigation	NOUN	O	O	657
by	ADP	O	O	657
renal	ADJ	O	O	657
biopsy	PROPN	O	O	657
.	PUNCT	O	O	657
In	ADP	O	O	660
vitro	X	O	O	660
characterization	NOUN	O	O	660
of	ADP	O	O	660
parasympathetic	ADJ	O	O	660
and	CCONJ	O	O	660
sympathetic	ADJ	O	O	660
responses	NOUN	O	O	660
in	ADP	O	O	660
cyclophosphamide	VERB	O	Chemical	660
-	PUNCT	O	O	660
induced	VERB	O	O	660
cystitis	NOUN	O	Disease	660
in	ADP	O	O	660
the	PRON	O	O	660
rat	NOUN	O	O	660
.	PUNCT	O	O	660
In	ADP	O	O	661
cyclophosphamide	VERB	O	Chemical	661
-	PUNCT	O	O	661
induced	VERB	O	O	661
cystitis	NOUN	O	Disease	661
in	ADP	O	O	661
the	PRON	O	O	661
rat	NOUN	O	O	661
,	PUNCT	O	O	661
detrusor	NOUN	O	O	661
function	NOUN	O	O	661
is	AUX	O	O	661
impaired	VERB	O	O	661
and	CCONJ	O	O	661
the	PRON	O	O	661
expression	NOUN	O	O	661
and	CCONJ	O	O	661
effects	NOUN	O	O	661
of	ADP	O	O	661
muscarinic	PROPN	O	O	661
receptors	NOUN	O	O	661
altered	VERB	O	O	661
.	PUNCT	O	O	661
Whether	SCONJ	O	O	662
or	CCONJ	O	O	662
not	PART	O	O	662
the	PRON	O	O	662
neuronal	ADJ	O	O	662
transmission	NOUN	O	O	662
may	AUX	O	O	662
be	AUX	O	O	662
affected	VERB	O	O	662
by	ADP	O	O	662
cystitis	NOUN	O	Disease	662
was	AUX	O	O	662
presently	ADV	O	O	662
investigated	VERB	O	O	662
.	PUNCT	O	O	662
Responses	NOUN	O	O	663
of	ADP	O	O	663
urinary	ADJ	O	O	663
strip	VERB	O	O	663
preparations	NOUN	O	O	663
from	ADP	O	O	663
control	VERB	O	O	663
and	CCONJ	O	O	663
cyclophosphamide	VERB	O	Chemical	663
-	PUNCT	O	O	663
pretreated	VERB	O	O	663
rats	NOUN	O	O	663
to	PART	O	O	663
electrical	ADJ	O	O	663
field	NOUN	O	O	663
stimulation	NOUN	O	O	663
and	CCONJ	O	O	663
to	PART	O	O	663
agonists	NOUN	O	O	663
were	AUX	O	O	663
assessed	VERB	O	O	663
in	ADP	O	O	663
the	PRON	O	O	663
absence	NOUN	O	O	663
and	CCONJ	O	O	663
presence	NOUN	O	O	663
of	ADP	O	O	663
muscarinic	PROPN	O	O	663
,	PUNCT	O	O	663
adrenergic	NOUN	O	O	663
and	CCONJ	O	O	663
purinergic	NOUN	O	O	663
receptor	NOUN	O	O	663
antagonists	NOUN	O	O	663
.	PUNCT	O	O	663
Generally	ADV	O	O	664
,	PUNCT	O	O	664
atropine	NOUN	O	Chemical	664
reduced	VERB	O	O	664
contractions	NOUN	O	O	664
,	PUNCT	O	O	664
but	CCONJ	O	O	664
in	ADP	O	O	664
contrast	NOUN	O	O	664
to	PART	O	O	664
controls	VERB	O	O	664
,	PUNCT	O	O	664
it	PRON	O	O	664
also	ADV	O	O	664
reduced	VERB	O	O	664
responses	NOUN	O	O	664
to	PART	O	O	664
low	ADJ	O	O	664
electrical	ADJ	O	O	664
field	NOUN	O	O	664
stimulation	NOUN	O	O	664
intensity	NOUN	O	O	664
(	PUNCT	O	O	664
1	X	O	O	664
-	PUNCT	O	O	664
5	NUM	O	O	664
Hz	NOUN	O	O	664
)	PUNCT	O	O	664
in	ADP	O	O	664
inflamed	VERB	O	O	664
preparations	NOUN	O	O	664
.	PUNCT	O	O	664
In	ADP	O	O	665
both	PRON	O	O	665
types	NOUN	O	O	665
,	PUNCT	O	O	665
purinoceptor	PROPN	O	O	665
desensitization	NOUN	O	O	665
with	ADP	O	O	665
alpha	PROPN	O	O	665
,	PUNCT	O	O	665
beta	NOUN	O	O	665
-	PUNCT	O	O	665
methylene	VERB	O	O	665
adenosine-5'-triphosphate	NOUN	O	O	665
(	PUNCT	O	O	665
alpha	PROPN	O	O	665
,	PUNCT	O	O	665
beta	NOUN	O	O	665
-	PUNCT	O	O	665
meATP	NOUN	O	O	665
)	PUNCT	O	O	665
caused	VERB	O	O	665
further	ADV	O	O	665
reductions	NOUN	O	O	665
at	ADP	O	O	665
low	ADJ	O	O	665
frequencies	NOUN	O	O	665
(	PUNCT	O	O	665
<	X	O	O	665
10	NUM	O	O	665
Hz	NOUN	O	O	665
)	PUNCT	O	O	665
.	PUNCT	O	O	665
The	PRON	O	O	666
muscarinic	PROPN	O	O	666
receptor	NOUN	O	O	666
antagonists	NOUN	O	O	666
atropine	NOUN	O	Chemical	666
,	PUNCT	O	O	666
4-diphenylacetoxy	ADJ	O	O	666
-	PUNCT	O	O	666
N	NUM	O	O	666
-	PUNCT	O	O	666
methylpiperidine	PROPN	O	O	666
(	PUNCT	O	O	666
4-DAMP	ADJ	O	Chemical	666
)	PUNCT	O	O	666
(	PUNCT	O	O	666
'	PUNCT	O	O	666
M(1)/M(3)/M(5)-selective	PROPN	O	O	666
'	PUNCT	O	O	666
)	PUNCT	O	O	666
,	PUNCT	O	O	666
methoctramine	NOUN	O	O	666
(	PUNCT	O	O	666
'	PUNCT	O	O	666
M(2)-selective	NOUN	O	O	666
'	PUNCT	O	O	666
)	PUNCT	O	O	666
and	CCONJ	O	O	666
pirenzepine	NOUN	O	O	666
(	PUNCT	O	O	666
'	PUNCT	O	O	666
M(1)-selective	ADV	O	O	666
'	PUNCT	O	O	666
)	PUNCT	O	O	666
antagonized	VERB	O	O	666
the	PRON	O	O	666
tonic	PROPN	O	O	666
component	NOUN	O	O	666
of	ADP	O	O	666
the	PRON	O	O	666
electrical	ADJ	O	O	666
field	NOUN	O	O	666
stimulation	NOUN	O	O	666
-	PUNCT	O	O	666
evoked	VERB	O	O	666
contractile	ADJ	O	O	666
response	NOUN	O	O	666
more	ADJ	O	O	666
potently	ADV	O	O	666
than	ADP	O	O	666
the	PRON	O	O	666
phasic	ADJ	O	O	666
component	NOUN	O	O	666
.	PUNCT	O	O	666
4-DAMP	ADJ	O	Chemical	667
inhibited	VERB	O	O	667
the	PRON	O	O	667
tonic	PROPN	O	O	667
contractions	NOUN	O	O	667
in	ADP	O	O	667
controls	VERB	O	O	667
more	ADJ	O	O	667
potently	ADV	O	O	667
than	ADP	O	O	667
methoctramine	NOUN	O	O	667
and	CCONJ	O	O	667
pirenzepine	NOUN	O	O	667
.	PUNCT	O	O	667
In	ADP	O	O	668
inflamed	VERB	O	O	668
preparations	NOUN	O	O	668
,	PUNCT	O	O	668
the	PRON	O	O	668
muscarinic	PROPN	O	O	668
receptor	NOUN	O	O	668
antagonism	NOUN	O	O	668
on	ADP	O	O	668
the	PRON	O	O	668
phasic	ADJ	O	O	668
component	NOUN	O	O	668
of	ADP	O	O	668
the	PRON	O	O	668
electrical	ADJ	O	O	668
field	NOUN	O	O	668
stimulation	NOUN	O	O	668
-	PUNCT	O	O	668
evoked	VERB	O	O	668
contraction	NOUN	O	O	668
was	AUX	O	O	668
decreased	VERB	O	O	668
and	CCONJ	O	O	668
the	PRON	O	O	668
pirenzepine	NOUN	O	O	668
and	CCONJ	O	O	668
4-DAMP	ADJ	O	Chemical	668
antagonism	NOUN	O	O	668
on	ADP	O	O	668
the	PRON	O	O	668
tonic	PROPN	O	O	668
component	NOUN	O	O	668
was	AUX	O	O	668
much	ADJ	O	O	668
less	ADV	O	O	668
efficient	ADJ	O	O	668
than	ADP	O	O	668
in	ADP	O	O	668
controls	VERB	O	O	668
.	PUNCT	O	O	668
In	ADP	O	O	669
contrast	NOUN	O	O	669
to	PART	O	O	669
controls	VERB	O	O	669
,	PUNCT	O	O	669
methoctramine	NOUN	O	O	669
increased	VERB	O	O	669
--	PUNCT	O	O	669
instead	ADV	O	O	669
of	ADP	O	O	669
decreased	VERB	O	O	669
--	PUNCT	O	O	669
the	PRON	O	O	669
tonic	PROPN	O	O	669
responses	NOUN	O	O	669
at	ADP	O	O	669
high	ADJ	O	O	669
frequencies	NOUN	O	O	669
.	PUNCT	O	O	669
While	SCONJ	O	O	670
contractions	NOUN	O	O	670
to	PART	O	O	670
carbachol	NOUN	O	Chemical	670
and	CCONJ	O	O	670
ATP	PROPN	O	Chemical	670
were	AUX	O	O	670
the	PRON	O	O	670
same	ADJ	O	O	670
in	ADP	O	O	670
inflamed	VERB	O	O	670
and	CCONJ	O	O	670
in	ADP	O	O	670
control	VERB	O	O	670
strips	NOUN	O	O	670
when	SCONJ	O	O	670
related	ADJ	O	O	670
to	PART	O	O	670
a	PRON	O	O	670
reference	NOUN	O	O	670
potassium	NOUN	O	Chemical	670
response	NOUN	O	O	670
,	PUNCT	O	O	670
isoprenaline	PROPN	O	O	670
-	PUNCT	O	O	670
induced	VERB	O	O	670
relaxations	NOUN	O	O	670
were	AUX	O	O	670
smaller	ADJ	O	O	670
in	ADP	O	O	670
inflamed	VERB	O	O	670
strips	NOUN	O	O	670
.	PUNCT	O	O	670
Thus	ADV	O	O	671
,	PUNCT	O	O	671
in	ADP	O	O	671
cystitis	NOUN	O	Disease	671
substantial	ADJ	O	O	671
changes	VERB	O	O	671
of	ADP	O	O	671
the	PRON	O	O	671
efferent	VERB	O	O	671
functional	ADJ	O	O	671
responses	NOUN	O	O	671
occur	VERB	O	O	671
.	PUNCT	O	O	671
Associations	NOUN	O	O	674
between	ADP	O	O	674
use	VERB	O	O	674
of	ADP	O	O	674
benzodiazepines	NOUN	O	Chemical	674
or	CCONJ	O	O	674
related	ADJ	O	O	674
drugs	NOUN	O	O	674
and	CCONJ	O	O	674
health	NOUN	O	O	674
,	PUNCT	O	O	674
physical	ADJ	O	O	674
abilities	NOUN	O	O	674
and	CCONJ	O	O	674
cognitive	ADJ	O	O	674
function	NOUN	O	O	674
:	PUNCT	O	O	674
a	PRON	O	O	674
non	ADJ	O	O	674
-	PUNCT	O	O	674
randomised	VERB	O	O	674
clinical	ADJ	O	O	674
study	VERB	O	O	674
in	ADP	O	O	674
the	PRON	O	O	674
elderly	ADJ	O	O	674
.	PUNCT	O	O	674
OBJECTIVE	VERB	O	O	675
:	PUNCT	O	O	675
To	PART	O	O	675
describe	VERB	O	O	675
associations	NOUN	O	O	675
between	ADP	O	O	675
the	PRON	O	O	675
use	VERB	O	O	675
of	ADP	O	O	675
benzodiazepines	NOUN	O	Chemical	675
or	CCONJ	O	O	675
related	ADJ	O	O	675
drugs	NOUN	O	O	675
(	PUNCT	O	O	675
BZDs	NOUN	O	O	675
/	PUNCT	O	O	675
RDs	NOUN	O	O	675
)	PUNCT	O	O	675
and	CCONJ	O	O	675
health	NOUN	O	O	675
,	PUNCT	O	O	675
functional	ADJ	O	O	675
abilities	NOUN	O	O	675
and	CCONJ	O	O	675
cognitive	ADJ	O	O	675
function	NOUN	O	O	675
in	ADP	O	O	675
the	PRON	O	O	675
elderly	ADJ	O	O	675
.	PUNCT	O	O	675
Of	ADV	O	O	676
these	PRON	O	O	676
,	PUNCT	O	O	676
nearly	ADV	O	O	676
half	NOUN	O	O	676
(	PUNCT	O	O	676
n	CCONJ	O	O	676
=	PUNCT	O	O	676
78	NUM	O	O	676
)	PUNCT	O	O	676
had	VERB	O	O	676
used	VERB	O	O	676
BZDs	NOUN	O	O	676
/	PUNCT	O	O	676
RDs	NOUN	O	O	676
before	ADP	O	O	676
admission	NOUN	O	O	676
,	PUNCT	O	O	676
and	CCONJ	O	O	676
the	PRON	O	O	676
remainder	NOUN	O	O	676
(	PUNCT	O	O	676
n	CCONJ	O	O	676
=	PUNCT	O	O	676
86	NUM	O	O	676
)	PUNCT	O	O	676
were	AUX	O	O	676
non	ADJ	O	O	676
-	PUNCT	O	O	676
users	NOUN	O	O	676
.	PUNCT	O	O	676
Data	NOUN	O	O	677
on	ADP	O	O	677
use	VERB	O	O	677
of	ADP	O	O	677
BZDs	NOUN	O	O	677
/	PUNCT	O	O	677
RDs	NOUN	O	O	677
before	ADP	O	O	677
admission	NOUN	O	O	677
,	PUNCT	O	O	677
current	ADJ	O	O	677
medications	NOUN	O	O	677
and	CCONJ	O	O	677
discharge	VERB	O	O	677
diagnoses	NOUN	O	O	677
were	AUX	O	O	677
collected	VERB	O	O	677
from	ADP	O	O	677
medical	ADJ	O	O	677
records	NOUN	O	O	677
.	PUNCT	O	O	677
The	PRON	O	O	678
residual	ADJ	O	O	678
serum	NOUN	O	O	678
concentrations	NOUN	O	O	678
of	ADP	O	O	678
oxazepam	NOUN	O	O	678
,	PUNCT	O	O	678
temazepam	NOUN	O	O	678
and	CCONJ	O	O	678
zopiclone	NOUN	O	O	678
were	AUX	O	O	678
analysed	VERB	O	O	678
.	PUNCT	O	O	678
Two	NUM	O	O	679
or	CCONJ	O	O	679
three	NUM	O	O	679
BZDs	NOUN	O	O	679
/	PUNCT	O	O	679
RDs	NOUN	O	O	679
were	AUX	O	O	679
concomitantly	ADV	O	O	679
taken	VERB	O	O	679
by	ADP	O	O	679
26%	NOUN	O	O	679
of	ADP	O	O	679
users	NOUN	O	O	679
(	PUNCT	O	O	679
n	CCONJ	O	O	679
=	PUNCT	O	O	679
20	NUM	O	O	679
)	PUNCT	O	O	679
.	PUNCT	O	O	679
Long	ADV	O	O	680
-	PUNCT	O	O	680
term	NOUN	O	O	680
use	VERB	O	O	680
of	ADP	O	O	680
these	PRON	O	O	680
drugs	NOUN	O	O	680
was	AUX	O	O	680
associated	VERB	O	O	680
with	ADP	O	O	680
female	ADJ	O	O	680
sex	NOUN	O	O	680
and	CCONJ	O	O	680
use	VERB	O	O	680
of	ADP	O	O	680
a	PRON	O	O	680
higher	ADJ	O	O	680
number	NOUN	O	O	680
of	ADP	O	O	680
drugs	NOUN	O	O	680
with	ADP	O	O	680
effects	NOUN	O	O	680
on	ADP	O	O	680
the	PRON	O	O	680
CNS	PROPN	O	O	680
,	PUNCT	O	O	680
which	PRON	O	O	680
tended	VERB	O	O	680
to	PART	O	O	680
be	AUX	O	O	680
related	ADJ	O	O	680
to	PART	O	O	680
diagnosed	VERB	O	O	680
dementia	NOUN	O	Disease	680
.	PUNCT	O	O	680
After	ADP	O	O	681
adjustment	NOUN	O	O	681
for	ADP	O	O	681
these	PRON	O	O	681
variables	NOUN	O	O	681
as	ADP	O	O	681
confounders	NOUN	O	O	681
,	PUNCT	O	O	681
use	VERB	O	O	681
of	ADP	O	O	681
BZDs	NOUN	O	O	681
/	PUNCT	O	O	681
RDs	NOUN	O	O	681
was	AUX	O	O	681
not	PART	O	O	681
associated	VERB	O	O	681
with	ADP	O	O	681
cognitive	ADJ	O	O	681
function	NOUN	O	O	681
as	ADP	O	O	681
measured	VERB	O	O	681
by	ADP	O	O	681
the	PRON	O	O	681
MMSE	PROPN	O	O	681
.	PUNCT	O	O	681
However	ADV	O	O	682
,	PUNCT	O	O	682
use	VERB	O	O	682
of	ADP	O	O	682
BZDs	NOUN	O	O	682
/	PUNCT	O	O	682
RDs	NOUN	O	O	682
was	AUX	O	O	682
associated	VERB	O	O	682
with	ADP	O	O	682
dizziness	NOUN	O	Disease	682
,	PUNCT	O	O	682
inability	NOUN	O	O	682
to	PART	O	O	682
sleep	VERB	O	O	682
after	ADP	O	O	682
awaking	VERB	O	O	682
at	ADP	O	O	682
night	NOUN	O	O	682
and	CCONJ	O	O	682
tiredness	VERB	O	O	682
in	ADP	O	O	682
the	PRON	O	O	682
mornings	NOUN	O	O	682
during	ADP	O	O	682
the	PRON	O	O	682
week	NOUN	O	O	682
prior	ADV	O	O	682
to	PART	O	O	682
admission	NOUN	O	O	682
and	CCONJ	O	O	682
with	ADP	O	O	682
stronger	ADJ	O	O	682
depressive symptoms	NOUN	O	Disease	682
measured	VERB	O	O	682
at	ADP	O	O	682
the	PRON	O	O	682
beginning	VERB	O	O	682
of	ADP	O	O	682
the	PRON	O	O	682
hospital	PROPN	O	O	682
stay	VERB	O	O	682
.	PUNCT	O	O	682
Use	VERB	O	O	683
of	ADP	O	O	683
BZDs	NOUN	O	O	683
/	PUNCT	O	O	683
RDs	NOUN	O	O	683
tended	VERB	O	O	683
to	PART	O	O	683
be	AUX	O	O	683
associated	VERB	O	O	683
with	ADP	O	O	683
a	PRON	O	O	683
reduced	VERB	O	O	683
ability	NOUN	O	O	683
to	PART	O	O	683
walk	VERB	O	O	683
and	CCONJ	O	O	683
shorter	ADJ	O	O	683
night	NOUN	O	O	683
-	PUNCT	O	O	683
time	NOUN	O	O	683
sleep	VERB	O	O	683
during	ADP	O	O	683
the	PRON	O	O	683
week	NOUN	O	O	683
prior	ADV	O	O	683
to	PART	O	O	683
admission	NOUN	O	O	683
.	PUNCT	O	O	683
A	PRON	O	O	684
higher	ADJ	O	O	684
residual	ADJ	O	O	684
serum	NOUN	O	O	684
concentration	NOUN	O	O	684
of	ADP	O	O	684
temazepam	NOUN	O	O	684
correlated	VERB	O	O	684
with	ADP	O	O	684
a	PRON	O	O	684
lower	ADJ	O	O	684
MMSE	PROPN	O	O	684
sum	NOUN	O	O	684
score	VERB	O	O	684
after	ADP	O	O	684
adjustment	NOUN	O	O	684
for	ADP	O	O	684
confounding	VERB	O	O	684
variables	NOUN	O	O	684
.	PUNCT	O	O	684
Acute	PROPN	O	O	687
vocal	ADJ	O	O	687
fold	VERB	O	O	687
palsy	PROPN	O	O	687
after	ADP	O	O	687
acute	ADJ	O	O	687
disulfiram	PROPN	O	Chemical	687
intoxication	NOUN	O	O	687
.	PUNCT	O	O	687
Acute	PROPN	O	O	688
peripheral neuropathy	NOUN	O	Disease	688
caused	VERB	O	O	688
by	ADP	O	O	688
a	PRON	O	O	688
disulfiram	PROPN	O	Chemical	688
overdose	NOUN	O	Disease	688
is	AUX	O	O	688
very	ADV	O	O	688
rare	ADJ	O	O	688
and	CCONJ	O	O	688
there	ADV	O	O	688
is	AUX	O	O	688
no	PRON	O	O	688
report	VERB	O	O	688
of	ADP	O	O	688
it	PRON	O	O	688
leading	VERB	O	O	688
to	PART	O	O	688
vocal	ADJ	O	O	688
fold	VERB	O	O	688
palsy	PROPN	O	O	688
.	PUNCT	O	O	688
A	PRON	O	O	689
49-year	NOUN	O	O	689
-	PUNCT	O	O	689
old	ADJ	O	O	689
woman	NOUN	O	O	689
was	AUX	O	O	689
transferred	VERB	O	O	689
to	PART	O	O	689
our	PRON	O	O	689
department	NOUN	O	O	689
because	SCONJ	O	O	689
of	ADP	O	O	689
quadriparesis	NOUN	O	O	689
,	PUNCT	O	O	689
lancinating	VERB	O	O	689
pain	NOUN	O	Disease	689
,	PUNCT	O	O	689
sensory	ADJ	O	O	689
loss	NOUN	O	O	689
,	PUNCT	O	O	689
and	CCONJ	O	O	689
paresthesia	NOUN	O	O	689
of	ADP	O	O	689
the	PRON	O	O	689
distal	NOUN	O	O	689
limbs	NOUN	O	O	689
.	PUNCT	O	O	689
One	NUM	O	O	690
month	NOUN	O	O	690
previously	ADV	O	O	690
,	PUNCT	O	O	690
she	PRON	O	O	690
had	VERB	O	O	690
taken	VERB	O	O	690
a	PRON	O	O	690
single	ADJ	O	O	690
high	ADJ	O	O	690
dose	NOUN	O	O	690
of	ADP	O	O	690
disulfiram	PROPN	O	Chemical	690
(	PUNCT	O	O	690
130	NUM	O	O	690
tablets	NOUN	O	O	690
of	ADP	O	O	690
ALCOHOL	NOUN	O	O	690
STOP	VERB	O	O	690
TAB	VERB	O	O	690
,	PUNCT	O	O	690
Shin	PROPN	O	O	690
-	PUNCT	O	O	690
Poong	PROPN	O	O	690
Pharm	NOUN	O	O	690
.	PUNCT	O	O	690
For	ADP	O	O	691
the	PRON	O	O	691
first	ADV	O	O	691
few	ADJ	O	O	691
days	NOUN	O	O	691
after	ADP	O	O	691
ingestion	NOUN	O	O	691
,	PUNCT	O	O	691
she	PRON	O	O	691
was	AUX	O	O	691
in	ADP	O	O	691
a	PRON	O	O	691
confused	ADJ	O	O	691
state	NOUN	O	O	691
and	CCONJ	O	O	691
had	VERB	O	O	691
mild	ADJ	O	O	691
to	PART	O	O	691
moderate	ADJ	O	O	691
ataxia	NOUN	O	Disease	691
and	CCONJ	O	O	691
giddiness	NOUN	O	O	691
.	PUNCT	O	O	691
She	PRON	O	O	692
noticed	VERB	O	O	692
hoarseness	NOUN	O	O	692
and	CCONJ	O	O	692
distally	ADV	O	O	692
accentuated	VERB	O	O	692
motor	NOUN	O	O	692
and	CCONJ	O	O	692
sensory	ADJ	O	O	692
dysfunction	NOUN	O	O	692
after	ADP	O	O	692
she	PRON	O	O	692
had	VERB	O	O	692
recovered	VERB	O	O	692
from	ADP	O	O	692
this	PRON	O	O	692
state	NOUN	O	O	692
.	PUNCT	O	O	692
A	PRON	O	O	693
nerve	NOUN	O	O	693
conduction	NOUN	O	O	693
study	VERB	O	O	693
was	AUX	O	O	693
consistent	ADJ	O	O	693
with	ADP	O	O	693
severe	ADJ	O	O	693
sensorimotor	PROPN	O	O	693
axonal	ADJ	O	O	693
polyneuropathy	ADJ	O	Disease	693
.	PUNCT	O	O	693
This	PRON	O	O	694
was	AUX	O	O	694
a	PRON	O	O	694
case	NOUN	O	O	694
of	ADP	O	O	694
acute	ADJ	O	O	694
palsy	PROPN	O	O	694
of	ADP	O	O	694
the	PRON	O	O	694
recurrent	ADJ	O	O	694
laryngeal	NOUN	O	O	694
nerve	NOUN	O	O	694
and	CCONJ	O	O	694
superimposed	VERB	O	O	694
severe	ADJ	O	O	694
acute	ADJ	O	O	694
sensorimotor	PROPN	O	O	694
axonal	ADJ	O	O	694
polyneuropathy	ADJ	O	Disease	694
caused	VERB	O	O	694
by	ADP	O	O	694
high	ADJ	O	O	694
-	PUNCT	O	O	694
dose	NOUN	O	O	694
disulfiram	PROPN	O	Chemical	694
intoxication	NOUN	O	O	694
.	PUNCT	O	O	694
Higher	ADV	O	O	697
optical	PROPN	O	O	697
density	NOUN	O	O	697
of	ADP	O	O	697
an	PRON	O	O	697
antigen	PROPN	O	O	697
assay	NOUN	O	O	697
predicts	VERB	O	O	697
thrombosis	NOUN	O	Disease	697
in	ADP	O	O	697
patients	NOUN	O	O	697
with	ADP	O	O	697
heparin	NOUN	O	Chemical	697
-	PUNCT	O	O	697
induced	VERB	O	O	697
thrombocytopenia	PROPN	O	Disease	697
.	PUNCT	O	O	697
OBJECTIVES	NOUN	O	O	698
:	PUNCT	O	O	698
To	PART	O	O	698
correlate	VERB	O	O	698
optical	PROPN	O	O	698
density	NOUN	O	O	698
and	CCONJ	O	O	698
percent	NOUN	O	O	698
inhibition	NOUN	O	O	698
of	ADP	O	O	698
a	PRON	O	O	698
two	NUM	O	O	698
-	PUNCT	O	O	698
step	VERB	O	O	698
heparin	NOUN	O	Chemical	698
-	PUNCT	O	O	698
induced	VERB	O	O	698
thrombocytopenia	PROPN	O	Disease	698
(	PUNCT	O	O	698
HIT	VERB	O	Disease	698
)	PUNCT	O	O	698
antigen	PROPN	O	O	698
assay	NOUN	O	O	698
with	ADP	O	O	698
thrombosis	NOUN	O	Disease	698
;	PUNCT	O	O	699
the	PRON	O	O	699
assay	NOUN	O	O	699
utilizes	VERB	O	O	699
reaction	NOUN	O	O	699
inhibition	NOUN	O	O	699
characteristics	NOUN	O	O	699
of	ADP	O	O	699
a	PRON	O	O	699
high	ADJ	O	O	699
heparin	NOUN	O	Chemical	699
concentration	NOUN	O	O	699
.	PUNCT	O	O	699
Patients	NOUN	O	O	700
with	ADP	O	O	700
more	ADJ	O	O	700
than	ADP	O	O	700
50%	NOUN	O	O	700
decrease	VERB	O	O	700
in	ADP	O	O	700
platelet	NOUN	O	O	700
count	VERB	O	O	700
or	CCONJ	O	O	700
thrombocytopenia	PROPN	O	Disease	700
(	PUNCT	O	O	700
<	X	O	O	700
150	NUM	O	O	700
x	X	O	O	700
10(9)/L	NUM	O	O	700
)	PUNCT	O	O	700
after	ADP	O	O	700
exposure	NOUN	O	O	700
to	PART	O	O	700
heparin	NOUN	O	Chemical	700
,	PUNCT	O	O	700
who	PRON	O	O	700
had	VERB	O	O	700
a	PRON	O	O	700
positive	ADJ	O	O	700
two	NUM	O	O	700
-	PUNCT	O	O	700
step	VERB	O	O	700
antigen	PROPN	O	O	700
assay	NOUN	O	O	700
[	X	O	O	700
optical	PROPN	O	O	700
density	NOUN	O	O	700
(	PUNCT	O	O	700
OD	NOUN	O	O	700
)	PUNCT	O	O	700
0.4	NUM	O	O	701
and	CCONJ	O	O	701
>	PUNCT	O	O	701
50	NUM	O	O	701
inhibition	NOUN	O	O	701
with	ADP	O	O	701
high	ADJ	O	O	701
concentration	NOUN	O	O	701
of	ADP	O	O	701
heparin	NOUN	O	Chemical	701
]	PUNCT	O	O	701
were	AUX	O	O	701
included	VERB	O	O	701
in	ADP	O	O	701
the	PRON	O	O	701
study	VERB	O	O	701
.	PUNCT	O	O	701
Forty	NUM	O	O	702
of	ADP	O	O	702
94	NUM	O	O	702
HIT	VERB	O	Disease	702
patients	NOUN	O	O	702
had	VERB	O	O	702
thrombosis	NOUN	O	Disease	702
at	ADP	O	O	702
diagnosis	NOUN	O	O	702
;	PUNCT	O	O	702
54/94	NUM	O	O	702
had	VERB	O	O	702
isolated	VERB	O	O	702
-	PUNCT	O	O	702
HIT	VERB	O	Disease	702
without	ADP	O	O	702
thrombosis	NOUN	O	Disease	702
.	PUNCT	O	O	702
Eight	NUM	O	O	703
of	ADP	O	O	703
the	PRON	O	O	703
isolated	VERB	O	O	703
-	PUNCT	O	O	703
HIT	VERB	O	Disease	703
patients	NOUN	O	O	703
developed	VERB	O	O	703
thrombosis	NOUN	O	Disease	703
within	ADP	O	O	703
the	PRON	O	O	703
next	ADV	O	O	703
30	NUM	O	O	703
d	X	O	O	703
;	PUNCT	O	O	703
thus	ADV	O	O	703
,	PUNCT	O	O	703
a	PRON	O	O	703
total	ADJ	O	O	703
of	ADP	O	O	703
48	NUM	O	O	703
patients	NOUN	O	O	703
had	VERB	O	O	703
thrombosis	NOUN	O	Disease	703
at	ADP	O	O	703
day	NOUN	O	O	703
30	NUM	O	O	703
.	PUNCT	O	O	703
At	ADP	O	O	704
diagnosis	NOUN	O	O	704
there	ADV	O	O	704
was	AUX	O	O	704
no	PRON	O	O	704
significant	ADJ	O	O	704
difference	NOUN	O	O	704
in	ADP	O	O	704
OD	NOUN	O	O	704
between	ADP	O	O	704
HIT	VERB	O	Disease	704
patients	NOUN	O	O	704
with	ADP	O	O	704
thrombosis	NOUN	O	Disease	704
and	CCONJ	O	O	704
those	PRON	O	O	704
with	ADP	O	O	704
isolated	VERB	O	O	704
-	PUNCT	O	O	704
HIT	VERB	O	Disease	704
.	PUNCT	O	O	704
However	ADV	O	O	705
,	PUNCT	O	O	705
OD	NOUN	O	O	705
was	AUX	O	O	705
significantly	ADV	O	O	705
higher	ADJ	O	O	705
in	ADP	O	O	705
all	PRON	O	O	705
patients	NOUN	O	O	705
with	ADP	O	O	705
thrombosis	NOUN	O	Disease	705
(	PUNCT	O	O	705
n	CCONJ	O	O	705
=	PUNCT	O	O	705
48	NUM	O	O	705
,	PUNCT	O	O	705
1.34	NUM	O	O	705
+	ADP	O	O	705
/-	PUNCT	O	O	705
0.89	NUM	O	O	706
)	PUNCT	O	O	706
,	PUNCT	O	O	706
including	VERB	O	O	706
isolated	VERB	O	O	706
-	PUNCT	O	O	706
HIT	VERB	O	Disease	706
patients	NOUN	O	O	706
who	PRON	O	O	706
later	ADV	O	O	706
developed	VERB	O	O	706
thrombosis	NOUN	O	Disease	706
within	ADP	O	O	706
30	NUM	O	O	706
d	X	O	O	706
(	PUNCT	O	O	706
n	CCONJ	O	O	706
=	PUNCT	O	O	706
8	NUM	O	O	706
,	PUNCT	O	O	706
1.84	NUM	O	O	706
+	ADP	O	O	706
/-	PUNCT	O	O	706
0.64	NUM	O	O	707
)	PUNCT	O	O	707
as	ADP	O	O	707
compared	VERB	O	O	707
to	PART	O	O	707
isolated	VERB	O	O	707
-	PUNCT	O	O	707
HIT	VERB	O	Disease	707
patients	NOUN	O	O	707
who	PRON	O	O	707
did	VERB	O	O	707
not	PART	O	O	707
develop	VERB	O	O	707
thrombosis	NOUN	O	Disease	707
(	PUNCT	O	O	707
0.96	NUM	O	O	707
+	ADP	O	O	707
/-	PUNCT	O	O	707
The	PRON	O	O	708
Receiver	NOUN	O	O	708
Operative	NOUN	O	O	708
Characteristic	ADJ	O	O	708
Curve	NOUN	O	O	708
showed	VERB	O	O	708
that	SCONJ	O	O	708
OD	NOUN	O	O	708
>	PUNCT	O	O	708
1.27	NUM	O	O	708
in	ADP	O	O	708
the	PRON	O	O	708
isolated	VERB	O	O	708
-	PUNCT	O	O	708
HIT	VERB	O	Disease	708
group	NOUN	O	O	708
had	VERB	O	O	708
a	PRON	O	O	708
significantly	ADV	O	O	708
higher	ADJ	O	O	708
chance	NOUN	O	O	708
of	ADP	O	O	708
developing	VERB	O	O	708
thrombosis	NOUN	O	Disease	708
by	ADP	O	O	708
day	NOUN	O	O	708
30	NUM	O	O	708
.	PUNCT	O	O	708
Multivariate	NOUN	O	O	709
analysis	NOUN	O	O	709
showed	VERB	O	O	709
a	PRON	O	O	709
2.8-fold	ADV	O	O	709
increased	VERB	O	O	709
risk	NOUN	O	O	709
of	ADP	O	O	709
thrombosis	NOUN	O	Disease	709
in	ADP	O	O	709
females	NOUN	O	O	709
.	PUNCT	O	O	709
Similarly	ADV	O	O	710
,	PUNCT	O	O	710
thrombotic	ADJ	O	Disease	710
risk	NOUN	O	O	710
increased	VERB	O	O	710
with	ADP	O	O	710
age	NOUN	O	O	710
and	CCONJ	O	O	710
OD	NOUN	O	O	710
values	NOUN	O	O	710
.	PUNCT	O	O	710
CONCLUSION	PROPN	O	O	711
:	PUNCT	O	O	711
Higher	ADV	O	O	711
OD	NOUN	O	O	711
is	AUX	O	O	711
associated	VERB	O	O	711
with	ADP	O	O	711
significant	ADJ	O	O	711
risk	NOUN	O	O	711
of	ADP	O	O	711
subsequent	ADJ	O	O	711
thrombosis	NOUN	O	Disease	711
in	ADP	O	O	711
patients	NOUN	O	O	711
with	ADP	O	O	711
isolated	VERB	O	O	711
-	PUNCT	O	O	711
HIT	VERB	O	Disease	711
;	PUNCT	O	O	711
percent	NOUN	O	O	711
inhibition	NOUN	O	O	711
,	PUNCT	O	O	711
however	ADV	O	O	711
,	PUNCT	O	O	711
was	AUX	O	O	711
not	PART	O	O	711
predictive	ADJ	O	O	711
.	PUNCT	O	O	711
Central	ADJ	O	O	714
retinal	ADJ	O	O	714
vein	NOUN	O	O	714
occlusion	NOUN	O	O	714
associated	VERB	O	O	714
with	ADP	O	O	714
clomiphene	PROPN	O	O	714
-	PUNCT	O	O	714
induced	VERB	O	O	714
ovulation	NOUN	O	O	714
.	PUNCT	O	O	714
OBJECTIVE	VERB	O	O	715
:	PUNCT	O	O	715
To	PART	O	O	715
report	VERB	O	O	715
a	PRON	O	O	715
case	NOUN	O	O	715
of	ADP	O	O	715
central	ADJ	O	O	715
retinal	ADJ	O	O	715
vein	NOUN	O	O	715
occlusion	NOUN	O	O	715
associated	VERB	O	O	715
with	ADP	O	O	715
clomiphene citrate	PROPN	O	Chemical	715
(	PUNCT	O	O	715
CC	NOUN	O	Chemical	715
)	PUNCT	O	O	715
.	PUNCT	O	O	715
PATIENT(S	NUM	O	O	716
)	PUNCT	O	O	716
:	PUNCT	O	O	716
A	PRON	O	O	716
36-year	NOUN	O	O	716
-	PUNCT	O	O	716
old	ADJ	O	O	716
woman	NOUN	O	O	716
referred	VERB	O	O	716
from	ADP	O	O	716
the	PRON	O	O	716
infertility	NOUN	O	O	716
clinic	NOUN	O	O	716
for	ADP	O	O	716
blurred	VERB	O	O	716
vision	PROPN	O	O	716
.	PUNCT	O	O	716
INTERVENTION(S	NUM	O	O	717
)	PUNCT	O	O	717
:	PUNCT	O	O	717
Ophthalmic	ADJ	O	O	717
examination	NOUN	O	O	717
after	ADP	O	O	717
CC	NOUN	O	Chemical	717
therapy	NOUN	O	O	717
.	PUNCT	O	O	717
MAIN	PROPN	O	O	718
OUTCOME	PROPN	O	O	718
MEASURE(S	NOUN	O	O	718
)	PUNCT	O	O	718
:	PUNCT	O	O	718
Central	ADJ	O	O	718
retinal	ADJ	O	O	718
vein	NOUN	O	O	718
occlusion	NOUN	O	O	718
after	ADP	O	O	718
ovulation	NOUN	O	O	718
induction	NOUN	O	O	718
with	ADP	O	O	718
CC	NOUN	O	Chemical	718
.	PUNCT	O	O	718
RESULT(S	NOUN	O	O	719
)	PUNCT	O	O	719
:	PUNCT	O	O	719
A	PRON	O	O	719
36-year	NOUN	O	O	719
-	PUNCT	O	O	719
old	ADJ	O	O	719
Chinese	PROPN	O	O	719
woman	NOUN	O	O	719
developed	VERB	O	O	719
central	ADJ	O	O	719
retinal	ADJ	O	O	719
vein	NOUN	O	O	719
occlusion	NOUN	O	O	719
after	ADP	O	O	719
eight	NUM	O	O	719
courses	NOUN	O	O	719
of	ADP	O	O	719
CC	NOUN	O	Chemical	719
.	PUNCT	O	O	719
A	PRON	O	O	720
search	NOUN	O	O	720
of	ADP	O	O	720
the	PRON	O	O	720
literature	NOUN	O	O	720
on	ADP	O	O	720
the	PRON	O	O	720
thromboembolic complications	NOUN	O	Disease	720
of	ADP	O	O	720
CC	NOUN	O	Chemical	720
does	VERB	O	O	720
not	PART	O	O	720
include	VERB	O	O	720
this	PRON	O	O	720
severe	ADJ	O	O	720
ophthalmic	ADJ	O	O	720
complication	NOUN	O	O	720
,	PUNCT	O	O	720
although	SCONJ	O	O	720
mild	ADJ	O	O	720
visual	ADJ	O	O	720
disturbance	NOUN	O	O	720
after	ADP	O	O	720
CC	NOUN	O	Chemical	720
intake	PROPN	O	O	720
is	AUX	O	O	720
not	PART	O	O	720
uncommon	ADJ	O	O	720
.	PUNCT	O	O	720
CONCLUSION(S	NOUN	O	O	721
)	PUNCT	O	O	721
:	PUNCT	O	O	721
This	PRON	O	O	721
is	AUX	O	O	721
the	PRON	O	O	721
first	ADV	O	O	721
reported	VERB	O	O	721
case	NOUN	O	O	721
of	ADP	O	O	721
central	ADJ	O	O	721
retinal	ADJ	O	O	721
vein	NOUN	O	O	721
occlusion	NOUN	O	O	721
after	ADP	O	O	721
treatment	NOUN	O	O	721
with	ADP	O	O	721
CC	NOUN	O	Chemical	721
.	PUNCT	O	O	721
Extra	ADJ	O	O	722
caution	NOUN	O	O	722
is	AUX	O	O	722
warranted	VERB	O	O	722
in	ADP	O	O	722
treating	VERB	O	O	722
infertility	NOUN	O	O	722
patients	NOUN	O	O	722
with	ADP	O	O	722
CC	NOUN	O	Chemical	722
,	PUNCT	O	O	722
and	CCONJ	O	O	722
patients	NOUN	O	O	722
should	AUX	O	O	722
be	AUX	O	O	722
well	ADV	O	O	722
informed	VERB	O	O	722
of	ADP	O	O	722
this	PRON	O	O	722
side	NOUN	O	O	722
effect	VERB	O	O	722
before	ADP	O	O	722
commencement	NOUN	O	O	722
of	ADP	O	O	722
therapy	NOUN	O	O	722
.	PUNCT	O	O	722
Nicotine	NOUN	O	Chemical	725
-	PUNCT	O	O	725
induced	VERB	O	O	725
nystagmus	VERB	O	Disease	725
correlates	VERB	O	O	725
with	ADP	O	O	725
midpontine	PROPN	O	O	725
activation	NOUN	O	O	725
.	PUNCT	O	O	725
The	PRON	O	O	726
pathomechanism	NOUN	O	O	726
of	ADP	O	O	726
nicotine	NOUN	O	Chemical	726
-	PUNCT	O	O	726
induced	VERB	O	O	726
nystagmus	VERB	O	Disease	726
(	PUNCT	O	O	726
NIN	PROPN	O	O	726
)	PUNCT	O	O	726
is	AUX	O	O	726
unknown	ADJ	O	O	726
.	PUNCT	O	O	726
The	PRON	O	O	727
aim	VERB	O	O	727
of	ADP	O	O	727
this	PRON	O	O	727
study	VERB	O	O	727
was	AUX	O	O	727
to	PART	O	O	727
delineate	VERB	O	O	727
brain	NOUN	O	O	727
structures	NOUN	O	O	727
that	SCONJ	O	O	727
are	AUX	O	O	727
involved	VERB	O	O	727
in	ADP	O	O	727
NIN	PROPN	O	O	727
generation	NOUN	O	O	727
.	PUNCT	O	O	727
Eight	NUM	O	O	728
healthy	ADJ	O	O	728
volunteers	NOUN	O	O	728
inhaled	VERB	O	O	728
nicotine	NOUN	O	Chemical	728
in	ADP	O	O	728
darkness	NOUN	O	O	728
during	ADP	O	O	728
a	PRON	O	O	728
functional	ADJ	O	O	728
magnetic	ADJ	O	O	728
resonance	NOUN	O	O	728
imaging	VERB	O	O	728
(	PUNCT	O	O	728
fMRI	PROPN	O	O	728
)	PUNCT	O	O	728
experiment	NOUN	O	O	728
;	PUNCT	O	O	728
eye	NOUN	O	O	728
movements	NOUN	O	O	728
were	AUX	O	O	728
registered	VERB	O	O	728
using	VERB	O	O	728
video	NOUN	O	O	728
-	PUNCT	O	O	728
oculography	NOUN	O	O	728
.	PUNCT	O	O	728
NIN	PROPN	O	O	729
correlated	VERB	O	O	729
with	ADP	O	O	729
blood	NOUN	O	O	729
oxygen	NOUN	O	Chemical	729
level	VERB	O	O	729
-	PUNCT	O	O	729
dependent	ADJ	O	O	729
(	PUNCT	O	O	729
BOLD	ADJ	O	O	729
)	PUNCT	O	O	729
activity	NOUN	O	O	729
levels	NOUN	O	O	729
in	ADP	O	O	729
a	PRON	O	O	729
midpontine	PROPN	O	O	729
site	NOUN	O	O	729
in	ADP	O	O	729
the	PRON	O	O	729
posterior	ADJ	O	O	729
basis	NOUN	O	O	729
pontis	PROPN	O	O	729
.	PUNCT	O	O	729
NIN	PROPN	O	O	730
-	PUNCT	O	O	730
induced	VERB	O	O	730
midpontine	PROPN	O	O	730
activation	NOUN	O	O	730
may	AUX	O	O	730
correspond	VERB	O	O	730
to	PART	O	O	730
activation	NOUN	O	O	730
of	ADP	O	O	730
the	PRON	O	O	730
dorsomedial	VERB	O	O	730
pontine	NOUN	O	O	730
nuclei	NOUN	O	O	730
and	CCONJ	O	O	730
the	PRON	O	O	730
nucleus	PROPN	O	O	730
reticularis	VERB	O	O	730
tegmenti	VERB	O	O	730
pontis	PROPN	O	O	730
,	PUNCT	O	O	730
structures	NOUN	O	O	730
known	VERB	O	O	730
to	PART	O	O	730
participate	VERB	O	O	730
in	ADP	O	O	730
the	PRON	O	O	730
generation	NOUN	O	O	730
of	ADP	O	O	730
multidirectional	ADJ	O	O	730
saccades	NOUN	O	O	730
and	CCONJ	O	O	730
smooth	VERB	O	O	730
pursuit	NOUN	O	O	730
eye	NOUN	O	O	730
movements	NOUN	O	O	730
.	PUNCT	O	O	730
Protective	NOUN	O	O	733
effect	VERB	O	O	733
of	ADP	O	O	733
verapamil	PROPN	O	Chemical	733
on	ADP	O	O	733
gastric	ADJ	O	O	733
hemorrhagic	ADJ	O	Disease	733
ulcers	NOUN	O	O	733
in	ADP	O	O	733
severe	ADJ	O	O	733
atherosclerotic	ADJ	O	O	733
rats	NOUN	O	O	733
.	PUNCT	O	O	733
Studies	NOUN	O	O	734
concerning	VERB	O	O	734
with	ADP	O	O	734
pathogenesis	NOUN	O	O	734
of	ADP	O	O	734
gastric	ADJ	O	O	734
hemorrhage	NOUN	O	Disease	734
and	CCONJ	O	O	734
mucosal	ADJ	O	O	734
ulceration	NOUN	O	O	734
produced	VERB	O	O	734
in	ADP	O	O	734
atherosclerotic	ADJ	O	O	734
rats	NOUN	O	O	734
are	AUX	O	O	734
lacking	VERB	O	O	734
.	PUNCT	O	O	734
The	PRON	O	O	735
aim	VERB	O	O	735
of	ADP	O	O	735
this	PRON	O	O	735
study	VERB	O	O	735
is	AUX	O	O	735
to	PART	O	O	735
examine	VERB	O	O	735
the	PRON	O	O	735
role	NOUN	O	O	735
of	ADP	O	O	735
gastric	ADJ	O	O	735
acid	PROPN	O	O	735
back	ADV	O	O	735
-	PUNCT	O	O	735
diffusion	NOUN	O	O	735
,	PUNCT	O	O	735
mast	NOUN	O	O	735
cell	NOUN	O	O	735
histamine	NOUN	O	Chemical	735
release	NOUN	O	O	735
,	PUNCT	O	O	735
lipid	NOUN	O	O	735
peroxide	NOUN	O	O	735
(	PUNCT	O	O	735
LPO	PROPN	O	Chemical	735
)	PUNCT	O	O	735
generation	NOUN	O	O	735
and	CCONJ	O	O	735
mucosal	ADJ	O	O	735
microvascular	ADJ	O	O	735
permeability	NOUN	O	O	735
in	ADP	O	O	735
modulating	VERB	O	O	735
gastric	ADJ	O	O	735
hemorrhage	NOUN	O	Disease	735
and	CCONJ	O	O	735
ulcer	NOUN	O	O	735
in	ADP	O	O	735
rats	NOUN	O	O	735
with	ADP	O	O	735
atherosclerosis	NOUN	O	Disease	735
induced	VERB	O	O	735
by	ADP	O	O	735
coadministration	NOUN	O	O	735
of	ADP	O	O	735
vitamin D2	PROPN	O	O	735
and	CCONJ	O	O	735
cholesterol	NOUN	O	Chemical	735
.	PUNCT	O	O	735
Additionally	ADV	O	O	736
,	PUNCT	O	O	736
the	PRON	O	O	736
protective	ADJ	O	O	736
effect	VERB	O	O	736
of	ADP	O	O	736
verapamil	PROPN	O	Chemical	736
on	ADP	O	O	736
this	PRON	O	O	736
ulcer	NOUN	O	O	736
model	NOUN	O	O	736
was	AUX	O	O	736
evaluated	VERB	O	O	736
.	PUNCT	O	O	736
kg	VERB	O	O	737
of	ADP	O	O	737
corn	NOUN	O	O	737
oil	NOUN	O	O	737
containing	VERB	O	O	737
vitamin D2	PROPN	O	O	737
and	CCONJ	O	O	737
cholesterol	NOUN	O	Chemical	737
to	PART	O	O	737
induce	VERB	O	O	737
atherosclerosis	NOUN	O	Disease	737
.	PUNCT	O	O	737
Gastric	ADJ	O	O	738
acid	PROPN	O	O	738
back	ADV	O	O	738
-	PUNCT	O	O	738
diffusion	NOUN	O	O	738
,	PUNCT	O	O	738
mucosal	ADJ	O	O	738
LPO	PROPN	O	Chemical	738
generation	NOUN	O	O	738
,	PUNCT	O	O	738
histamine	NOUN	O	Chemical	738
concentration	NOUN	O	O	738
,	PUNCT	O	O	738
microvascular	ADJ	O	O	738
permeability	NOUN	O	O	738
,	PUNCT	O	O	738
luminal	ADJ	O	O	738
hemoglobin	NOUN	O	O	738
content	NOUN	O	O	738
and	CCONJ	O	O	738
ulcer	NOUN	O	O	738
areas	NOUN	O	O	738
were	AUX	O	O	738
determined	VERB	O	O	738
.	PUNCT	O	O	738
Elevated	VERB	O	O	739
atherosclerotic	ADJ	O	O	739
parameters	NOUN	O	O	739
,	PUNCT	O	O	739
such	ADJ	O	O	739
as	ADP	O	O	739
serum	NOUN	O	O	739
calcium	NOUN	O	Chemical	739
,	PUNCT	O	O	739
total	ADJ	O	O	739
cholesterol	NOUN	O	Chemical	739
and	CCONJ	O	O	739
low	ADJ	O	O	739
-	PUNCT	O	O	739
density	NOUN	O	O	739
lipoprotein	NOUN	O	O	739
concentration	NOUN	O	O	739
were	AUX	O	O	739
obtained	VERB	O	O	739
in	ADP	O	O	739
atherosclerotic	ADJ	O	O	739
rats	NOUN	O	O	739
.	PUNCT	O	O	739
Severe	ADJ	O	O	740
gastric	ADJ	O	O	740
ulcers	NOUN	O	O	740
accompanied	VERB	O	O	740
with	ADP	O	O	740
increased	VERB	O	O	740
ulcerogenic	ADJ	O	O	740
factors	NOUN	O	O	740
,	PUNCT	O	O	740
including	VERB	O	O	740
gastric	ADJ	O	O	740
acid	PROPN	O	O	740
back	ADV	O	O	740
-	PUNCT	O	O	740
diffusion	NOUN	O	O	740
,	PUNCT	O	O	740
histamine	NOUN	O	Chemical	740
release	NOUN	O	O	740
,	PUNCT	O	O	740
LPO	PROPN	O	Chemical	740
generation	NOUN	O	O	740
and	CCONJ	O	O	740
luminal	ADJ	O	O	740
hemoglobin	NOUN	O	O	740
content	NOUN	O	O	740
were	AUX	O	O	740
also	ADV	O	O	740
observed	VERB	O	O	740
in	ADP	O	O	740
these	PRON	O	O	740
rats	NOUN	O	O	740
.	PUNCT	O	O	740
Moreover	ADV	O	O	741
,	PUNCT	O	O	741
a	PRON	O	O	741
positive	ADJ	O	O	741
correlation	NOUN	O	O	741
of	ADP	O	O	741
histamine	NOUN	O	Chemical	741
to	PART	O	O	741
gastric	ADJ	O	O	741
hemorrhage	NOUN	O	Disease	741
and	CCONJ	O	O	741
to	PART	O	O	741
ulcer	NOUN	O	O	741
was	AUX	O	O	741
found	VERB	O	O	741
in	ADP	O	O	741
those	PRON	O	O	741
atherosclerotic	ADJ	O	O	741
rats	NOUN	O	O	741
.	PUNCT	O	O	741
This	PRON	O	O	742
hemorrhagic	ADJ	O	Disease	742
ulcer	NOUN	O	O	742
and	CCONJ	O	O	742
various	ADJ	O	O	742
ulcerogenic	ADJ	O	O	742
parameters	NOUN	O	O	742
were	AUX	O	O	742
dose	NOUN	O	O	742
-	PUNCT	O	O	742
dependently	ADV	O	O	742
ameliorated	VERB	O	O	742
by	ADP	O	O	742
daily	ADV	O	O	742
intragastric	NOUN	O	O	742
verapamil	PROPN	O	Chemical	742
.	PUNCT	O	O	742
Atherosclerosis	NOUN	O	O	743
could	AUX	O	O	743
produce	VERB	O	O	743
gastric	ADJ	O	O	743
hemorrhagic	ADJ	O	Disease	743
ulcer	NOUN	O	O	743
via	ADP	O	O	743
aggravation	NOUN	O	O	743
of	ADP	O	O	743
gastric	ADJ	O	O	743
acid	PROPN	O	O	743
back	ADV	O	O	743
-	PUNCT	O	O	743
diffusion	NOUN	O	O	743
,	PUNCT	O	O	743
LPO	PROPN	O	Chemical	743
generation	NOUN	O	O	743
,	PUNCT	O	O	743
histamine	NOUN	O	Chemical	743
release	NOUN	O	O	743
and	CCONJ	O	O	743
microvascular	ADJ	O	O	743
permeability	NOUN	O	O	743
that	SCONJ	O	O	743
could	AUX	O	O	743
be	AUX	O	O	743
ameliorated	VERB	O	O	743
by	ADP	O	O	743
verapamil	PROPN	O	Chemical	743
in	ADP	O	O	743
rats	NOUN	O	O	743
.	PUNCT	O	O	743
Adriamycin	PROPN	O	Chemical	746
-	PUNCT	O	O	746
induced	VERB	O	O	746
autophagic	PROPN	O	O	746
cardiomyocyte	NOUN	O	O	746
death	NOUN	O	O	746
plays	VERB	O	O	746
a	PRON	O	O	746
pathogenic	ADJ	O	O	746
role	NOUN	O	O	746
in	ADP	O	O	746
a	PRON	O	O	746
rat	NOUN	O	O	746
model	NOUN	O	O	746
of	ADP	O	O	746
heart failure	NOUN	O	Disease	746
.	PUNCT	O	O	746
The	PRON	O	O	747
mechanisms	NOUN	O	O	747
underlying	VERB	O	O	747
heart failure	NOUN	O	Disease	747
induced	VERB	O	O	747
by	ADP	O	O	747
adriamycin	PROPN	O	Chemical	747
are	AUX	O	O	747
very	ADV	O	O	747
complicated	VERB	O	O	747
and	CCONJ	O	O	747
still	ADV	O	O	747
unclear	ADJ	O	O	747
.	PUNCT	O	O	747
The	PRON	O	O	748
aim	VERB	O	O	748
of	ADP	O	O	748
this	PRON	O	O	748
study	VERB	O	O	748
was	AUX	O	O	748
to	PART	O	O	748
investigate	VERB	O	O	748
whether	SCONJ	O	O	748
autophagy	PUNCT	O	O	748
was	AUX	O	O	748
involved	VERB	O	O	748
in	ADP	O	O	748
the	PRON	O	O	748
progression	NOUN	O	O	748
of	ADP	O	O	748
heart failure	NOUN	O	Disease	748
induced	VERB	O	O	748
by	ADP	O	O	748
adriamycin	PROPN	O	Chemical	748
,	PUNCT	O	O	748
so	ADV	O	O	748
that	SCONJ	O	O	748
we	PRON	O	O	748
can	AUX	O	O	748
develop	VERB	O	O	748
a	PRON	O	O	748
novel	NOUN	O	O	748
treatment	NOUN	O	O	748
strategy	NOUN	O	O	748
for	ADP	O	O	748
heart failure	NOUN	O	Disease	748
.	PUNCT	O	O	748
METHODS	NOUN	O	O	749
:	PUNCT	O	O	749
3-methyladenine	NOUN	O	O	749
(	PUNCT	O	O	749
3MA	NUM	O	O	749
)	PUNCT	O	O	749
,	PUNCT	O	O	749
a	PRON	O	O	749
specific	ADJ	O	O	749
inhibitor	NOUN	O	O	749
on	ADP	O	O	749
autophagy	PUNCT	O	O	749
was	AUX	O	O	749
used	VERB	O	O	749
in	ADP	O	O	749
a	PRON	O	O	749
heart failure	NOUN	O	Disease	749
model	NOUN	O	O	749
of	ADP	O	O	749
rats	NOUN	O	O	749
induced	VERB	O	O	749
by	ADP	O	O	749
adriamycin	PROPN	O	Chemical	749
.	PUNCT	O	O	749
Neonatal	NOUN	O	O	750
cardiomyocytes	NOUN	O	O	750
were	AUX	O	O	750
isolated	VERB	O	O	750
from	ADP	O	O	750
Sprague	PROPN	O	O	750
-	PUNCT	O	O	750
Dawley	NOUN	O	O	750
rat	NOUN	O	O	750
hearts	NOUN	O	O	750
and	CCONJ	O	O	750
randomly	ADV	O	O	750
divided	VERB	O	O	750
into	ADP	O	O	750
controls	VERB	O	O	750
,	PUNCT	O	O	750
an	PRON	O	O	750
adriamycin	PROPN	O	Chemical	750
-	PUNCT	O	O	750
treated	VERB	O	O	750
group	NOUN	O	O	750
,	PUNCT	O	O	750
and	CCONJ	O	O	750
a	PRON	O	O	750
3MA	NUM	O	O	750
plus	CCONJ	O	O	750
adriamycin	PROPN	O	Chemical	750
-	PUNCT	O	O	750
treated	VERB	O	O	750
group	NOUN	O	O	750
.	PUNCT	O	O	750
We	PRON	O	O	751
then	ADV	O	O	751
examined	VERB	O	O	751
the	PRON	O	O	751
morphology	NOUN	O	O	751
,	PUNCT	O	O	751
expression	NOUN	O	O	751
of	ADP	O	O	751
beclin	PROPN	O	O	751
1	X	O	O	751
gene	NOUN	O	O	751
,	PUNCT	O	O	751
mitochondrial	ADJ	O	O	751
permeability	NOUN	O	O	751
transition	NOUN	O	O	751
(	PUNCT	O	O	751
MPT	X	O	O	751
)	PUNCT	O	O	751
,	PUNCT	O	O	751
and	CCONJ	O	O	751
Na+-K+	PROPN	O	O	751
ATPase	X	O	O	751
activity	NOUN	O	O	751
in	ADP	O	O	751
vivo	VERB	O	O	751
.	PUNCT	O	O	751
RESULTS	VERB	O	O	752
:	PUNCT	O	O	752
3MA	NUM	O	O	752
significantly	ADV	O	O	752
improved	VERB	O	O	752
cardiac	ADJ	O	O	752
function	NOUN	O	O	752
and	CCONJ	O	O	752
reduced	VERB	O	O	752
mitochondrial injury	NOUN	O	Disease	752
.	PUNCT	O	O	752
Furthermore	ADV	O	O	753
,	PUNCT	O	O	753
adriamycin	PROPN	O	Chemical	753
induced	VERB	O	O	753
the	PRON	O	O	753
formation	NOUN	O	O	753
of	ADP	O	O	753
autophagic	PROPN	O	O	753
vacuoles	NOUN	O	O	753
,	PUNCT	O	O	753
and	CCONJ	O	O	753
3MA	NUM	O	O	753
strongly	ADV	O	O	753
downregulated	VERB	O	O	753
the	PRON	O	O	753
expression	NOUN	O	O	753
of	ADP	O	O	753
beclin	PROPN	O	O	753
1	X	O	O	753
in	ADP	O	O	753
adriamycin	PROPN	O	Chemical	753
-	PUNCT	O	O	753
induced	VERB	O	O	753
failing	VERB	O	O	753
heart	NOUN	O	O	753
and	CCONJ	O	O	753
inhibited	VERB	O	O	753
the	PRON	O	O	753
formation	NOUN	O	O	753
of	ADP	O	O	753
autophagic	PROPN	O	O	753
vacuoles	NOUN	O	O	753
.	PUNCT	O	O	753
CONCLUSION	PROPN	O	O	754
:	PUNCT	O	O	754
Autophagic	PROPN	O	O	754
cardiomyocyte	NOUN	O	O	754
death	NOUN	O	O	754
plays	VERB	O	O	754
an	PRON	O	O	754
important	ADJ	O	O	754
role	NOUN	O	O	754
in	ADP	O	O	754
the	PRON	O	O	754
pathogenesis	NOUN	O	O	754
of	ADP	O	O	754
heart failure	NOUN	O	Disease	754
in	ADP	O	O	754
rats	NOUN	O	O	754
induced	VERB	O	O	754
by	ADP	O	O	754
adriamycin	PROPN	O	Chemical	754
.	PUNCT	O	O	754
Mitochondrial	NOUN	O	O	755
injury	NOUN	O	O	755
may	AUX	O	O	755
be	AUX	O	O	755
involved	VERB	O	O	755
in	ADP	O	O	755
the	PRON	O	O	755
progression	NOUN	O	O	755
of	ADP	O	O	755
heart failure	NOUN	O	Disease	755
caused	VERB	O	O	755
by	ADP	O	O	755
adriamycin	PROPN	O	Chemical	755
via	ADP	O	O	755
the	PRON	O	O	755
autophagy	PUNCT	O	O	755
pathway	NOUN	O	O	755
.	PUNCT	O	O	755
Confusion	NOUN	O	O	758
,	PUNCT	O	O	758
a	PRON	O	O	758
rather	ADV	O	O	758
serious	ADJ	O	O	758
adverse	ADJ	O	O	758
drug	NOUN	O	O	758
reaction	NOUN	O	O	758
with	ADP	O	O	758
valproic acid	NOUN	O	Chemical	758
:	PUNCT	O	O	758
a	PRON	O	O	758
review	VERB	O	O	758
of	ADP	O	O	758
the	PRON	O	O	758
French	ADJ	O	O	758
Pharmacovigilance	NOUN	O	O	758
database	NOUN	O	O	758
.	PUNCT	O	O	758
Confusion	NOUN	O	O	759
is	AUX	O	O	759
an	PRON	O	O	759
adverse	ADJ	O	O	759
drug	NOUN	O	O	759
reaction	NOUN	O	O	759
frequently	ADV	O	O	759
observed	VERB	O	O	759
with	ADP	O	O	759
valproic acid	NOUN	O	Chemical	759
.	PUNCT	O	O	759
Using	VERB	O	O	760
the	PRON	O	O	760
French	ADJ	O	O	760
Pharmacovigilance	NOUN	O	O	760
database	NOUN	O	O	760
,	PUNCT	O	O	760
we	PRON	O	O	760
selected	VERB	O	O	760
the	PRON	O	O	760
cases	NOUN	O	O	760
of	ADP	O	O	760
confusion	NOUN	O	Disease	760
reported	VERB	O	O	760
since	SCONJ	O	O	760
1985	NUM	O	O	760
with	ADP	O	O	760
valproic acid	NOUN	O	Chemical	760
.	PUNCT	O	O	760
RESULTS	VERB	O	O	761
:	PUNCT	O	O	761
272	NUM	O	O	761
cases	NOUN	O	O	761
of	ADP	O	O	761
confusion	NOUN	O	Disease	761
were	AUX	O	O	761
reported	VERB	O	O	761
with	ADP	O	O	761
valproic acid	NOUN	O	Chemical	761
:	PUNCT	O	O	761
153	NUM	O	O	761
women	NOUN	O	O	761
and	CCONJ	O	O	761
119	NUM	O	O	761
men	NOUN	O	O	761
.	PUNCT	O	O	761
Confusion	NOUN	O	O	762
mostly	ADV	O	O	762
occurred	VERB	O	O	762
during	ADP	O	O	762
the	PRON	O	O	762
two	NUM	O	O	762
first	ADV	O	O	762
weeks	NOUN	O	O	762
following	VERB	O	O	762
valproic acid	NOUN	O	Chemical	762
exposure	NOUN	O	O	762
(	PUNCT	O	O	762
39.7%	NOUN	O	O	762
)	PUNCT	O	O	762
.	PUNCT	O	O	762
This	PRON	O	O	763
work	NOUN	O	O	763
shows	VERB	O	O	763
that	SCONJ	O	O	763
confusion	NOUN	O	Disease	763
with	ADP	O	O	763
valproic acid	NOUN	O	Chemical	763
is	AUX	O	O	763
a	PRON	O	O	763
serious	ADJ	O	O	763
,	PUNCT	O	O	763
rather	ADV	O	O	763
frequent	ADJ	O	O	763
but	CCONJ	O	O	763
reversible	ADJ	O	O	763
adverse	ADJ	O	O	763
drug	NOUN	O	O	763
reaction	NOUN	O	O	763
.	PUNCT	O	O	763
Learning	VERB	O	O	766
and	CCONJ	O	O	766
memory	NOUN	O	O	766
deficits	NOUN	O	O	766
in	ADP	O	O	766
ecstasy	NOUN	O	Chemical	766
users	NOUN	O	O	766
and	CCONJ	O	O	766
their	PRON	O	O	766
neural	NOUN	O	O	766
correlates	VERB	O	O	766
during	ADP	O	O	766
a	PRON	O	O	766
face	NOUN	O	O	766
-	PUNCT	O	O	766
learning	VERB	O	O	766
task	NOUN	O	O	766
.	PUNCT	O	O	766
It	PRON	O	O	767
has	VERB	O	O	767
been	AUX	O	O	767
consistently	ADV	O	O	767
shown	VERB	O	O	767
that	SCONJ	O	O	767
ecstasy	NOUN	O	Chemical	767
users	NOUN	O	O	767
display	NOUN	O	O	767
impairments	VERB	O	O	767
in	ADP	O	O	767
learning	VERB	O	O	767
and	CCONJ	O	O	767
memory	NOUN	O	O	767
performance	NOUN	O	O	767
.	PUNCT	O	O	767
In	ADP	O	O	768
addition	NOUN	O	O	768
,	PUNCT	O	O	768
working	VERB	O	O	768
memory	NOUN	O	O	768
processing	NOUN	O	O	768
in	ADP	O	O	768
ecstasy	NOUN	O	Chemical	768
users	NOUN	O	O	768
has	VERB	O	O	768
been	AUX	O	O	768
shown	VERB	O	O	768
to	PART	O	O	768
be	AUX	O	O	768
associated	VERB	O	O	768
with	ADP	O	O	768
neural	NOUN	O	O	768
alterations	NOUN	O	O	768
in	ADP	O	O	768
hippocampal	NOUN	O	O	768
and/or	CCONJ	O	O	768
cortical	ADJ	O	O	768
regions	NOUN	O	O	768
as	ADP	O	O	768
measured	VERB	O	O	768
by	ADP	O	O	768
functional	ADJ	O	O	768
magnetic	ADJ	O	O	768
resonance	NOUN	O	O	768
imaging	VERB	O	O	768
(	PUNCT	O	O	768
fMRI	PROPN	O	O	768
)	PUNCT	O	O	768
.	PUNCT	O	O	768
Using	VERB	O	O	769
functional	ADJ	O	O	769
imaging	VERB	O	O	769
and	CCONJ	O	O	769
a	PRON	O	O	769
face	NOUN	O	O	769
-	PUNCT	O	O	769
learning	VERB	O	O	769
task	NOUN	O	O	769
,	PUNCT	O	O	769
we	PRON	O	O	769
investigated	VERB	O	O	769
neural	NOUN	O	O	769
correlates	VERB	O	O	769
of	ADP	O	O	769
encoding	VERB	O	O	769
and	CCONJ	O	O	769
recalling	VERB	O	O	769
face	NOUN	O	O	769
-	PUNCT	O	O	769
name	NOUN	O	O	769
associations	NOUN	O	O	769
in	ADP	O	O	769
20	NUM	O	O	769
recreational	ADJ	O	O	769
drug	NOUN	O	O	769
users	NOUN	O	O	769
whose	DET	O	O	769
predominant	ADJ	O	O	769
drug	NOUN	O	O	769
use	VERB	O	O	769
was	AUX	O	O	769
ecstasy	NOUN	O	Chemical	769
and	CCONJ	O	O	769
20	NUM	O	O	769
controls	VERB	O	O	769
.	PUNCT	O	O	769
To	PART	O	O	770
address	NOUN	O	O	770
the	PRON	O	O	770
potential	ADJ	O	O	770
confounding	VERB	O	O	770
effects	NOUN	O	O	770
of	ADP	O	O	770
the	PRON	O	O	770
cannabis	NOUN	O	O	770
use	VERB	O	O	770
of	ADP	O	O	770
the	PRON	O	O	770
ecstasy	NOUN	O	Chemical	770
using	VERB	O	O	770
group	NOUN	O	O	770
,	PUNCT	O	O	770
a	PRON	O	O	770
second	ADV	O	O	770
analysis	NOUN	O	O	770
included	VERB	O	O	770
14	NUM	O	O	770
previously	ADV	O	O	770
tested	VERB	O	O	770
cannabis	NOUN	O	O	770
users	NOUN	O	O	770
(	PUNCT	O	O	770
Nestor	PROPN	O	O	770
,	PUNCT	O	O	770
L.	PROPN	O	O	770
,	PUNCT	O	O	770
Roberts	NOUN	O	O	770
,	PUNCT	O	O	770
G.	PROPN	O	O	770
,	PUNCT	O	O	770
Garavan	PROPN	O	O	770
,	PUNCT	O	O	770
H.	PROPN	O	O	770
,	PUNCT	O	O	770
Hester	PROPN	O	O	770
,	PUNCT	O	O	770
R.	PROPN	O	O	770
,	PUNCT	O	O	770
2008	NUM	O	O	770
.	PUNCT	O	O	770
Deficits	NOUN	O	O	771
in	ADP	O	O	771
learning	VERB	O	O	771
and	CCONJ	O	O	771
memory	NOUN	O	O	771
:	PUNCT	O	O	771
parahippocampal	ADJ	O	O	771
hyperactivity	NOUN	O	Disease	771
and	CCONJ	O	O	771
frontocortical	ADJ	O	O	771
hypoactivity	NOUN	O	O	771
in	ADP	O	O	771
cannabis	NOUN	O	O	771
users	NOUN	O	O	771
.	PUNCT	O	O	771
Ecstasy	NOUN	O	O	772
users	NOUN	O	O	772
performed	VERB	O	O	772
significantly	ADV	O	O	772
worse	ADJ	O	O	772
in	ADP	O	O	772
learning	VERB	O	O	772
and	CCONJ	O	O	772
memory	NOUN	O	O	772
compared	VERB	O	O	772
to	PART	O	O	772
controls	VERB	O	O	772
and	CCONJ	O	O	772
cannabis	NOUN	O	O	772
users	NOUN	O	O	772
.	PUNCT	O	O	772
A	PRON	O	O	773
conjunction	NOUN	O	O	773
analysis	NOUN	O	O	773
of	ADP	O	O	773
the	PRON	O	O	773
encode	VERB	O	O	773
and	CCONJ	O	O	773
recall	VERB	O	O	773
phases	NOUN	O	O	773
of	ADP	O	O	773
the	PRON	O	O	773
task	NOUN	O	O	773
revealed	VERB	O	O	773
ecstasy	NOUN	O	Chemical	773
-	PUNCT	O	O	773
specific	ADJ	O	O	773
hyperactivity	NOUN	O	Disease	773
in	ADP	O	O	773
bilateral	ADJ	O	O	773
frontal	ADJ	O	O	773
regions	NOUN	O	O	773
,	PUNCT	O	O	773
left	VERB	O	O	773
temporal	ADJ	O	O	773
,	PUNCT	O	O	773
right	ADV	O	O	773
parietal	ADJ	O	O	773
,	PUNCT	O	O	773
bilateral	ADJ	O	O	773
temporal	ADJ	O	O	773
,	PUNCT	O	O	773
and	CCONJ	O	O	773
bilateral	ADJ	O	O	773
occipital	ADJ	O	O	773
brain	NOUN	O	O	773
regions	NOUN	O	O	773
.	PUNCT	O	O	773
Ecstasy	NOUN	O	O	774
-	PUNCT	O	O	774
specific	ADJ	O	O	774
hypoactivity	NOUN	O	O	774
was	AUX	O	O	774
evident	ADJ	O	O	774
in	ADP	O	O	774
the	PRON	O	O	774
right	ADV	O	O	774
dorsal	PROPN	O	O	774
anterior	PROPN	O	O	774
cingulated	VERB	O	O	774
cortex	VERB	O	O	774
(	PUNCT	O	O	774
ACC	PROPN	O	O	774
)	PUNCT	O	O	774
and	CCONJ	O	O	774
left	VERB	O	O	774
posterior	ADJ	O	O	774
cingulated	VERB	O	O	774
cortex	VERB	O	O	774
.	PUNCT	O	O	774
In	ADP	O	O	775
both	PRON	O	O	775
ecstasy	NOUN	O	Chemical	775
and	CCONJ	O	O	775
cannabis	NOUN	O	O	775
groups	NOUN	O	O	775
brain	NOUN	O	O	775
activation	NOUN	O	O	775
was	AUX	O	O	775
decreased	VERB	O	O	775
in	ADP	O	O	775
the	PRON	O	O	775
right	ADV	O	O	775
medial	ADJ	O	O	775
frontal	ADJ	O	O	775
gyrus	PROPN	O	O	775
,	PUNCT	O	O	775
left	VERB	O	O	775
parahippocampal	ADJ	O	O	775
gyrus	PROPN	O	O	775
,	PUNCT	O	O	775
left	VERB	O	O	775
dorsal	PROPN	O	O	775
cingulate	NOUN	O	O	775
gyrus	PROPN	O	O	775
,	PUNCT	O	O	775
and	CCONJ	O	O	775
left	VERB	O	O	775
caudate	ADJ	O	O	775
.	PUNCT	O	O	775
These	PRON	O	O	776
results	VERB	O	O	776
elucidated	VERB	O	O	776
ecstasy	NOUN	O	Chemical	776
-	PUNCT	O	O	776
related	ADJ	O	O	776
deficits	NOUN	O	O	776
,	PUNCT	O	O	776
only	ADV	O	O	776
some	PRON	O	O	776
of	ADP	O	O	776
which	PRON	O	O	776
might	AUX	O	O	776
be	AUX	O	O	776
attributed	VERB	O	O	776
to	PART	O	O	776
cannabis	NOUN	O	O	776
use	VERB	O	O	776
.	PUNCT	O	O	776
These	PRON	O	O	777
ecstasy	NOUN	O	Chemical	777
-	PUNCT	O	O	777
specific	ADJ	O	O	777
effects	NOUN	O	O	777
may	AUX	O	O	777
be	AUX	O	O	777
related	ADJ	O	O	777
to	PART	O	O	777
the	PRON	O	O	777
vulnerability	NOUN	O	O	777
of	ADP	O	O	777
isocortical	ADJ	O	O	777
and	CCONJ	O	O	777
allocortical	ADJ	O	O	777
regions	NOUN	O	O	777
to	PART	O	O	777
the	PRON	O	O	777
neurotoxic	ADJ	O	Disease	777
effects	NOUN	O	O	777
of	ADP	O	O	777
ecstasy	NOUN	O	Chemical	777
.	PUNCT	O	O	777
Prolonged	VERB	O	O	780
elevation	NOUN	O	O	780
of	ADP	O	O	780
plasma	NOUN	O	O	780
argatroban	NOUN	O	O	780
in	ADP	O	O	780
a	PRON	O	O	780
cardiac	ADJ	O	O	780
transplant	NOUN	O	O	780
patient	NOUN	O	O	780
with	ADP	O	O	780
a	PRON	O	O	780
suspected	VERB	O	O	780
history	NOUN	O	O	780
of	ADP	O	O	780
heparin	NOUN	O	Chemical	780
-	PUNCT	O	O	780
induced	VERB	O	O	780
thrombocytopenia	PROPN	O	Disease	780
with	ADP	O	O	780
thrombosis	NOUN	O	Disease	780
.	PUNCT	O	O	780
BACKGROUND	NOUN	O	O	781
:	PUNCT	O	O	781
Direct	ADJ	O	O	781
thrombin	PROPN	O	O	781
inhibitors	NOUN	O	O	781
(	PUNCT	O	O	781
DTIs	NOUN	O	O	781
)	PUNCT	O	O	781
provide	VERB	O	O	781
an	PRON	O	O	781
alternative	ADV	O	O	781
method	NOUN	O	O	781
of	ADP	O	O	781
anticoagulation	NOUN	O	O	781
for	ADP	O	O	781
patients	NOUN	O	O	781
with	ADP	O	O	781
a	PRON	O	O	781
history	NOUN	O	O	781
of	ADP	O	O	781
heparin	NOUN	O	Chemical	781
-	PUNCT	O	O	781
induced	VERB	O	O	781
thrombocytopenia	PROPN	O	Disease	781
(	PUNCT	O	O	781
HIT	VERB	O	Disease	781
)	PUNCT	O	O	781
or	CCONJ	O	O	781
HIT	VERB	O	Disease	781
with	ADP	O	O	781
thrombosis	NOUN	O	Disease	781
(	PUNCT	O	O	781
HITT	PROPN	O	O	781
)	PUNCT	O	O	781
undergoing	VERB	O	O	781
cardiopulmonary	VERB	O	O	781
bypass	NOUN	O	O	781
(	PUNCT	O	O	781
CPB	PROPN	O	O	781
)	PUNCT	O	O	781
.	PUNCT	O	O	781
In	ADP	O	O	782
the	PRON	O	O	782
following	VERB	O	O	782
report	VERB	O	O	782
,	PUNCT	O	O	782
a	PRON	O	O	782
65-year	NOUN	O	O	782
-	PUNCT	O	O	782
old	ADJ	O	O	782
critically	ADV	O	O	782
ill	PROPN	O	O	782
patient	NOUN	O	O	782
with	ADP	O	O	782
a	PRON	O	O	782
suspected	VERB	O	O	782
history	NOUN	O	O	782
of	ADP	O	O	782
HITT	PROPN	O	O	782
was	AUX	O	O	782
administered	VERB	O	O	782
argatroban	NOUN	O	O	782
for	ADP	O	O	782
anticoagulation	NOUN	O	O	782
on	ADP	O	O	782
bypass	NOUN	O	O	782
during	ADP	O	O	782
heart	NOUN	O	O	782
transplantation	NOUN	O	O	782
.	PUNCT	O	O	782
The	PRON	O	O	783
patient	NOUN	O	O	783
required	VERB	O	O	783
massive	ADJ	O	O	783
transfusion	NOUN	O	O	783
support	NOUN	O	O	783
(	PUNCT	O	O	783
55	NUM	O	O	783
units	NOUN	O	O	783
of	ADP	O	O	783
red	ADJ	O	O	783
blood	NOUN	O	O	783
cells	NOUN	O	O	783
,	PUNCT	O	O	783
42	NUM	O	O	783
units	NOUN	O	O	783
of	ADP	O	O	783
fresh	ADJ	O	O	783
-	PUNCT	O	O	783
frozen	ADJ	O	O	783
plasma	NOUN	O	O	783
,	PUNCT	O	O	783
40	NUM	O	O	783
units	NOUN	O	O	783
of	ADP	O	O	783
cryoprecipitate	NOUN	O	O	783
,	PUNCT	O	O	783
40	NUM	O	O	783
units	NOUN	O	O	783
of	ADP	O	O	783
platelets	VERB	O	O	783
,	PUNCT	O	O	783
and	CCONJ	O	O	783
three	NUM	O	O	783
doses	NOUN	O	O	783
of	ADP	O	O	783
recombinant	ADJ	O	O	783
Factor	NOUN	O	O	783
VIIa	NOUN	O	O	783
)	PUNCT	O	O	783
for	ADP	O	O	783
severe	ADJ	O	O	783
intraoperative	ADJ	O	O	783
and	CCONJ	O	O	783
postoperative	ADJ	O	O	783
bleeding	VERB	O	Disease	783
.	PUNCT	O	O	783
STUDY	NOUN	O	O	784
DESIGN	NOUN	O	O	784
AND	CCONJ	O	O	784
METHODS	NOUN	O	O	784
:	PUNCT	O	O	784
Plasma	NOUN	O	O	784
samples	NOUN	O	O	784
from	ADP	O	O	784
before	ADP	O	O	784
and	CCONJ	O	O	784
after	ADP	O	O	784
CPB	PROPN	O	O	784
were	AUX	O	O	784
analyzed	VERB	O	O	784
postoperatively	PROPN	O	O	784
for	ADP	O	O	784
argatroban	NOUN	O	O	784
concentration	NOUN	O	O	784
using	VERB	O	O	784
a	PRON	O	O	784
modified	VERB	O	O	784
ecarin	PROPN	O	O	784
clotting	VERB	O	O	784
time	NOUN	O	O	784
(	PUNCT	O	O	784
ECT	NOUN	O	O	784
)	PUNCT	O	O	784
assay	NOUN	O	O	784
.	PUNCT	O	O	784
Unexpectedly	ADV	O	O	785
high	ADJ	O	O	785
concentrations	NOUN	O	O	785
of	ADP	O	O	785
argatroban	NOUN	O	O	785
were	AUX	O	O	785
measured	VERB	O	O	785
in	ADP	O	O	785
these	PRON	O	O	785
samples	NOUN	O	O	785
(	PUNCT	O	O	785
range	VERB	O	O	785
,	PUNCT	O	O	785
0	NUM	O	O	785
-	PUNCT	O	O	785
32	NUM	O	O	785
microg	PROPN	O	O	785
/	PUNCT	O	O	785
mL	PROPN	O	O	785
)	PUNCT	O	O	785
,	PUNCT	O	O	785
and	CCONJ	O	O	785
a	PRON	O	O	785
prolonged	VERB	O	O	785
plasma	NOUN	O	O	785
argatroban	NOUN	O	O	785
half	NOUN	O	O	785
life	NOUN	O	O	785
(	PUNCT	O	O	785
t(1/2	NUM	O	O	785
)	PUNCT	O	O	785
)	PUNCT	O	O	785
of	ADP	O	O	785
514	NUM	O	O	785
minutes	NOUN	O	O	785
was	AUX	O	O	785
observed	VERB	O	O	785
(	PUNCT	O	O	785
published	VERB	O	O	785
elimination	NOUN	O	O	785
t(1/2	NUM	O	O	785
)	PUNCT	O	O	785
is	AUX	O	O	785
39	NUM	O	O	785
-	PUNCT	O	O	785
51	NUM	O	O	785
minutes	NOUN	O	O	785
[	X	O	O	785
<	X	O	O	785
or	CCONJ	O	O	785
=	PUNCT	O	O	785
181	NUM	O	O	785
minutes	NOUN	O	O	785
with	ADP	O	O	785
hepatic	ADJ	O	O	785
impairment	NOUN	O	O	785
]	PUNCT	O	O	785
)	PUNCT	O	O	785
.	PUNCT	O	O	785
Correlation	NOUN	O	O	786
of	ADP	O	O	786
plasma	NOUN	O	O	786
argatroban	NOUN	O	O	786
concentration	NOUN	O	O	786
versus	ADP	O	O	786
the	PRON	O	O	786
patient	NOUN	O	O	786
's	AUX	O	O	786
coagulation	NOUN	O	O	786
variables	NOUN	O	O	786
and	CCONJ	O	O	786
clinical	ADJ	O	O	786
course	NOUN	O	O	786
suggest	VERB	O	O	786
that	SCONJ	O	O	786
prolonged	VERB	O	O	786
elevated	ADJ	O	O	786
levels	NOUN	O	O	786
of	ADP	O	O	786
plasma	NOUN	O	O	786
argatroban	NOUN	O	O	786
may	AUX	O	O	786
have	VERB	O	O	786
contributed	VERB	O	O	786
to	PART	O	O	786
the	PRON	O	O	786
patient	NOUN	O	O	786
's	AUX	O	O	786
extended	VERB	O	O	786
coagulopathy	VERB	O	Disease	786
.	PUNCT	O	O	786
This	PRON	O	O	787
is	AUX	O	O	787
the	PRON	O	O	787
first	ADV	O	O	787
report	VERB	O	O	787
to	PART	O	O	787
measure	VERB	O	O	787
plasma	NOUN	O	O	787
argatroban	NOUN	O	O	787
concentration	NOUN	O	O	787
in	ADP	O	O	787
the	PRON	O	O	787
context	NOUN	O	O	787
of	ADP	O	O	787
CPB	PROPN	O	O	787
and	CCONJ	O	O	787
extended	VERB	O	O	787
coagulopathy	VERB	O	Disease	787
.	PUNCT	O	O	787
Antituberculosis	NOUN	O	O	790
therapy	NOUN	O	O	790
-	PUNCT	O	O	790
induced	VERB	O	O	790
acute liver failure	NOUN	O	Disease	790
:	PUNCT	O	O	790
magnitude	NOUN	O	O	790
,	PUNCT	O	O	790
profile	NOUN	O	O	790
,	PUNCT	O	O	790
prognosis	VERB	O	O	790
,	PUNCT	O	O	790
and	CCONJ	O	O	790
predictors	NOUN	O	O	790
of	ADP	O	O	790
outcome	NOUN	O	O	790
.	PUNCT	O	O	790
Antituberculosis	NOUN	O	O	791
therapy	NOUN	O	O	791
(	PUNCT	O	O	791
ATT)-associated	PROPN	O	O	791
acute liver failure	NOUN	O	Disease	791
(	PUNCT	O	O	791
ATT	PROPN	O	O	791
-	PUNCT	O	O	791
ALF	PROPN	O	Disease	791
)	PUNCT	O	O	791
is	AUX	O	O	791
the	PRON	O	O	791
commonest	ADJ	O	O	791
drug	NOUN	O	O	791
-	PUNCT	O	O	791
induced	VERB	O	O	791
ALF	PROPN	O	Disease	791
in	ADP	O	O	791
South	NOUN	O	O	791
Asia	PROPN	O	O	791
.	PUNCT	O	O	791
Prospective	PROPN	O	O	792
studies	NOUN	O	O	792
on	ADP	O	O	792
ATT	PROPN	O	O	792
-	PUNCT	O	O	792
ALF	PROPN	O	Disease	792
are	AUX	O	O	792
lacking	VERB	O	O	792
.	PUNCT	O	O	792
The	PRON	O	O	793
current	ADJ	O	O	793
study	VERB	O	O	793
prospectively	ADV	O	O	793
evaluated	VERB	O	O	793
the	PRON	O	O	793
magnitude	NOUN	O	O	793
,	PUNCT	O	O	793
clinical	ADJ	O	O	793
course	NOUN	O	O	793
,	PUNCT	O	O	793
outcome	NOUN	O	O	793
,	PUNCT	O	O	793
and	CCONJ	O	O	793
prognostic	ADJ	O	O	793
factors	NOUN	O	O	793
in	ADP	O	O	793
ATT	PROPN	O	O	793
-	PUNCT	O	O	793
ALF	PROPN	O	Disease	793
.	PUNCT	O	O	793
From	ADP	O	O	794
January	PROPN	O	O	794
1986	NUM	O	O	794
to	PART	O	O	794
January	PROPN	O	O	794
2009	NUM	O	O	794
,	PUNCT	O	O	794
1223	NUM	O	O	794
consecutive	ADJ	O	O	794
ALF	PROPN	O	Disease	794
patients	NOUN	O	O	794
were	AUX	O	O	794
evaluated	VERB	O	O	794
:	PUNCT	O	O	794
ATT	PROPN	O	O	794
alone	ADV	O	O	794
was	AUX	O	O	794
the	PRON	O	O	794
cause	VERB	O	O	794
in	ADP	O	O	794
70	NUM	O	O	794
(	PUNCT	O	O	794
5.7%	NOUN	O	O	794
)	PUNCT	O	O	794
patients	NOUN	O	O	794
.	PUNCT	O	O	794
Another	PRON	O	O	795
15	NUM	O	O	795
(	PUNCT	O	O	795
1.2%	NOUN	O	O	795
)	PUNCT	O	O	795
had	VERB	O	O	795
ATT	PROPN	O	O	795
and	CCONJ	O	O	795
simultaneous	ADJ	O	O	795
hepatitis	NOUN	O	Disease	795
virus	NOUN	O	O	795
infection	NOUN	O	Disease	795
.	PUNCT	O	O	795
In	ADP	O	O	796
44	NUM	O	O	796
(	PUNCT	O	O	796
62.8%	NOUN	O	O	796
)	PUNCT	O	O	796
patients	NOUN	O	O	796
,	PUNCT	O	O	796
ATT	PROPN	O	O	796
was	AUX	O	O	796
prescribed	VERB	O	O	796
empirically	ADV	O	O	796
without	ADP	O	O	796
definitive	ADJ	O	O	796
evidence	NOUN	O	O	796
of	ADP	O	O	796
tuberculosis	NOUN	O	Disease	796
.	PUNCT	O	O	796
ATT	PROPN	O	O	797
-	PUNCT	O	O	797
ALF	PROPN	O	Disease	797
patients	NOUN	O	O	797
were	AUX	O	O	797
younger	ADJ	O	O	797
(	PUNCT	O	O	797
32.87	NUM	O	O	797
[	X	O	O	797
+	ADP	O	O	797
/-15.8	PUNCT	O	O	797
]	PUNCT	O	O	797
years	NOUN	O	O	797
)	PUNCT	O	O	797
,	PUNCT	O	O	797
and	CCONJ	O	O	797
49	NUM	O	O	797
(	PUNCT	O	O	797
70%	NOUN	O	O	797
)	PUNCT	O	O	797
of	ADP	O	O	797
them	PRON	O	O	797
were	AUX	O	O	797
women	NOUN	O	O	797
.	PUNCT	O	O	797
Most	ADV	O	O	798
had	VERB	O	O	798
hyperacute	VERB	O	O	798
presentation	NOUN	O	O	798
;	PUNCT	O	O	798
the	PRON	O	O	798
median	ADJ	O	O	798
icterus	PROPN	O	Disease	798
encephalopathy	NOUN	O	Disease	798
interval	NOUN	O	O	798
was	AUX	O	O	798
4.5	NUM	O	O	798
(	PUNCT	O	O	798
0	NUM	O	O	798
-	PUNCT	O	O	798
30	NUM	O	O	798
)	PUNCT	O	O	798
days	NOUN	O	O	798
.	PUNCT	O	O	798
The	PRON	O	O	799
median	ADJ	O	O	799
duration	NOUN	O	O	799
of	ADP	O	O	799
ATT	PROPN	O	O	799
before	ADP	O	O	799
ALF	PROPN	O	Disease	799
was	AUX	O	O	799
30	NUM	O	O	799
(	PUNCT	O	O	799
7	NUM	O	O	799
-	PUNCT	O	O	799
350	NUM	O	O	799
)	PUNCT	O	O	799
days	NOUN	O	O	799
.	PUNCT	O	O	799
At	ADP	O	O	800
presentation	NOUN	O	O	800
,	PUNCT	O	O	800
advanced	ADJ	O	O	800
encephalopathy	NOUN	O	Disease	800
and	CCONJ	O	O	800
cerebral edema	NOUN	O	Disease	800
were	AUX	O	O	800
present	NOUN	O	O	800
in	ADP	O	O	800
51	NUM	O	O	800
(	PUNCT	O	O	800
76%	NOUN	O	O	800
)	PUNCT	O	O	800
and	CCONJ	O	O	800
29	NUM	O	O	800
(	PUNCT	O	O	800
41.4%	NOUN	O	O	800
)	PUNCT	O	O	800
patients	NOUN	O	O	800
,	PUNCT	O	O	800
respectively	ADV	O	O	800
.	PUNCT	O	O	800
Gastrointestinal	ADJ	O	O	801
bleed	VERB	O	O	801
,	PUNCT	O	O	801
seizures	NOUN	O	Disease	801
,	PUNCT	O	O	801
infection	NOUN	O	Disease	801
,	PUNCT	O	O	801
and	CCONJ	O	O	801
acute	ADJ	O	O	801
renal failure	NOUN	O	Disease	801
were	AUX	O	O	801
documented	VERB	O	O	801
in	ADP	O	O	801
seven	NUM	O	O	801
(	PUNCT	O	O	801
10%	NOUN	O	O	801
)	PUNCT	O	O	801
,	PUNCT	O	O	801
five	NUM	O	O	801
(	PUNCT	O	O	801
7.1%	NOUN	O	O	801
)	PUNCT	O	O	801
,	PUNCT	O	O	801
26	NUM	O	O	801
(	PUNCT	O	O	801
37.1%	NOUN	O	O	801
)	PUNCT	O	O	801
,	PUNCT	O	O	801
and	CCONJ	O	O	801
seven	NUM	O	O	801
(	PUNCT	O	O	801
10%	NOUN	O	O	801
)	PUNCT	O	O	801
patients	NOUN	O	O	801
,	PUNCT	O	O	801
respectively	ADV	O	O	801
.	PUNCT	O	O	801
Compared	VERB	O	O	802
with	ADP	O	O	802
hepatitis	NOUN	O	Disease	802
E	NOUN	O	Chemical	802
virus	NOUN	O	O	802
(	PUNCT	O	O	802
HEV	VERB	O	O	802
)	PUNCT	O	O	802
and	CCONJ	O	O	802
non	ADJ	O	O	802
-	PUNCT	O	O	802
A	PRON	O	O	803
non	ADJ	O	O	803
-	PUNCT	O	O	803
E	NOUN	O	Chemical	803
-	PUNCT	O	O	803
induced	VERB	O	O	803
ALF	PROPN	O	Disease	803
,	PUNCT	O	O	803
ATT	PROPN	O	O	803
-	PUNCT	O	O	803
ALF	PROPN	O	Disease	803
patients	NOUN	O	O	803
had	VERB	O	O	803
nearly	ADV	O	O	803
similar	ADJ	O	O	803
presentations	NOUN	O	O	803
except	SCONJ	O	O	803
for	ADP	O	O	803
older	ADJ	O	O	803
age	NOUN	O	O	803
and	CCONJ	O	O	803
less	ADV	O	O	803
elevation	NOUN	O	O	803
of	ADP	O	O	803
liver	NOUN	O	O	803
enzymes	NOUN	O	O	803
.	PUNCT	O	O	803
The	PRON	O	O	804
mortality	NOUN	O	O	804
rate	NOUN	O	O	804
among	ADP	O	O	804
patients	NOUN	O	O	804
with	ADP	O	O	804
ATT	PROPN	O	O	804
-	PUNCT	O	O	804
ALF	PROPN	O	Disease	804
was	AUX	O	O	804
high	ADJ	O	O	804
(	PUNCT	O	O	804
67.1%	NOUN	O	O	804
,	PUNCT	O	O	804
n	CCONJ	O	O	804
=	PUNCT	O	O	804
47	NUM	O	O	804
)	PUNCT	O	O	804
,	PUNCT	O	O	804
and	CCONJ	O	O	804
only	ADV	O	O	804
23	NUM	O	O	804
(	PUNCT	O	O	804
32.9%	NOUN	O	O	804
)	PUNCT	O	O	804
patients	NOUN	O	O	804
recovered	VERB	O	O	804
with	ADP	O	O	804
medical	ADJ	O	O	804
treatment	NOUN	O	O	804
.	PUNCT	O	O	804
In	ADP	O	O	805
multivariate	ADJ	O	O	805
analysis	NOUN	O	O	805
,	PUNCT	O	O	805
three	NUM	O	O	805
factors	NOUN	O	O	805
independently	ADV	O	O	805
predicted	VERB	O	O	805
mortality	NOUN	O	O	805
:	PUNCT	O	O	805
serum	NOUN	O	O	805
bilirubin	ADJ	O	Chemical	805
(	PUNCT	O	O	805
>	PUNCT	O	O	805
or=10.8	PROPN	O	O	805
mg	VERB	O	O	805
/	PUNCT	O	O	805
dL	VERB	O	O	805
)	PUNCT	O	O	805
,	PUNCT	O	O	805
prothrombin	ADJ	O	O	805
time	NOUN	O	O	805
(	PUNCT	O	O	805
PT	NOUN	O	O	805
)	PUNCT	O	O	805
prolongation	NOUN	O	O	805
(	PUNCT	O	O	805
>	PUNCT	O	O	805
or=26	VERB	O	O	805
seconds	NOUN	O	O	805
)	PUNCT	O	O	805
,	PUNCT	O	O	805
and	CCONJ	O	O	805
grade	NOUN	O	O	805
III	NUM	O	O	805
/	PUNCT	O	O	805
IV	NUM	O	O	805
encephalopathy	NOUN	O	Disease	805
at	ADP	O	O	805
presentation	NOUN	O	O	805
.	PUNCT	O	O	805
CONCLUSION	PROPN	O	O	806
:	PUNCT	O	O	806
ATT	PROPN	O	O	806
-	PUNCT	O	O	806
ALF	PROPN	O	Disease	806
constituted	VERB	O	O	806
5.7%	NOUN	O	O	806
of	ADP	O	O	806
ALF	PROPN	O	Disease	806
at	ADP	O	O	806
our	PRON	O	O	806
center	PROPN	O	O	806
and	CCONJ	O	O	806
had	VERB	O	O	806
a	PRON	O	O	806
high	ADJ	O	O	806
mortality	NOUN	O	O	806
rate	NOUN	O	O	806
.	PUNCT	O	O	806
Central	ADJ	O	O	809
nervous	ADJ	O	O	809
system	NOUN	O	O	809
complications	NOUN	O	O	809
during	ADP	O	O	809
treatment	NOUN	O	O	809
of	ADP	O	O	809
acute	ADJ	O	O	809
lymphoblastic	NOUN	O	O	809
leukemia	NOUN	O	Disease	809
in	ADP	O	O	809
a	PRON	O	O	809
single	ADJ	O	O	809
pediatric	ADJ	O	O	809
institution	NOUN	O	O	809
.	PUNCT	O	O	809
Central	ADJ	O	O	810
nervous	ADJ	O	O	810
system	NOUN	O	O	810
(	PUNCT	O	O	810
CNS	PROPN	O	O	810
)	PUNCT	O	O	810
complications	NOUN	O	O	810
during	ADP	O	O	810
treatment	NOUN	O	O	810
of	ADP	O	O	810
childhood	NOUN	O	O	810
acute	ADJ	O	O	810
lymphoblastic	NOUN	O	O	810
leukemia	NOUN	O	Disease	810
(	PUNCT	O	O	810
ALL	PRON	O	O	810
)	PUNCT	O	O	810
remain	VERB	O	O	810
a	PRON	O	O	810
challenging	VERB	O	O	810
clinical	ADJ	O	O	810
problem	NOUN	O	O	810
.	PUNCT	O	O	810
This	PRON	O	O	811
study	VERB	O	O	811
analyzed	VERB	O	O	811
the	PRON	O	O	811
incidence	NOUN	O	O	811
of	ADP	O	O	811
neurological	ADJ	O	O	811
complications	NOUN	O	O	811
during	ADP	O	O	811
ALL	PRON	O	O	811
treatment	NOUN	O	O	811
in	ADP	O	O	811
a	PRON	O	O	811
single	ADJ	O	O	811
pediatric	ADJ	O	O	811
institution	NOUN	O	O	811
,	PUNCT	O	O	811
focusing	VERB	O	O	811
on	ADP	O	O	811
clinical	ADJ	O	O	811
,	PUNCT	O	O	811
radiological	ADJ	O	O	811
,	PUNCT	O	O	811
and	CCONJ	O	O	811
electrophysiological	ADJ	O	O	811
findings	NOUN	O	O	811
.	PUNCT	O	O	811
Exclusion	NOUN	O	O	812
criteria	NOUN	O	O	812
included	VERB	O	O	812
CNS	PROPN	O	O	812
leukemic	ADJ	O	O	812
infiltration	NOUN	O	O	812
at	ADP	O	O	812
diagnosis	NOUN	O	O	812
,	PUNCT	O	O	812
therapy	NOUN	O	O	812
-	PUNCT	O	O	812
related	ADJ	O	O	812
peripheral neuropathy	NOUN	O	Disease	812
,	PUNCT	O	O	812
late	ADV	O	O	812
-	PUNCT	O	O	812
onset	VERB	O	O	812
encephalopathy	NOUN	O	Disease	812
,	PUNCT	O	O	812
or	CCONJ	O	O	812
long	ADV	O	O	812
-	PUNCT	O	O	812
term	NOUN	O	O	812
neurocognitive	PROPN	O	O	812
defects	NOUN	O	O	812
.	PUNCT	O	O	812
During	ADP	O	O	813
a	PRON	O	O	813
9-year	NOUN	O	O	813
period	NOUN	O	O	813
,	PUNCT	O	O	813
we	PRON	O	O	813
retrospectively	ADV	O	O	813
collected	VERB	O	O	813
27	NUM	O	O	813
neurological	ADJ	O	O	813
events	NOUN	O	O	813
(	PUNCT	O	O	813
11%	NOUN	O	O	813
)	PUNCT	O	O	813
in	ADP	O	O	813
as	ADP	O	O	813
many	ADJ	O	O	813
patients	NOUN	O	O	813
,	PUNCT	O	O	813
from	ADP	O	O	813
253	NUM	O	O	813
children	NOUN	O	O	813
enrolled	VERB	O	O	813
in	ADP	O	O	813
the	PRON	O	O	813
ALL	PRON	O	O	813
front	NOUN	O	O	813
-	PUNCT	O	O	813
line	NOUN	O	O	813
protocol	PROPN	O	O	813
.	PUNCT	O	O	813
CNS	PROPN	O	O	814
complications	NOUN	O	O	814
included	VERB	O	O	814
posterior	ADJ	O	O	814
reversible	ADJ	O	O	814
leukoencephalopathy	ADJ	O	Disease	814
syndrome	NOUN	O	O	814
(	PUNCT	O	O	814
n	CCONJ	O	O	814
=	PUNCT	O	O	814
10	NUM	O	O	814
)	PUNCT	O	O	814
,	PUNCT	O	O	814
stroke	VERB	O	Disease	814
(	PUNCT	O	O	814
n	CCONJ	O	O	814
=	PUNCT	O	O	814
5	NUM	O	O	814
)	PUNCT	O	O	814
,	PUNCT	O	O	814
temporal lobe epilepsy	NOUN	O	Disease	814
(	PUNCT	O	O	814
n	CCONJ	O	O	814
=	PUNCT	O	O	814
2	X	O	O	814
)	PUNCT	O	O	814
,	PUNCT	O	O	814
high	ADJ	O	O	814
-	PUNCT	O	O	814
dose	NOUN	O	O	814
methotrexate	CCONJ	O	Chemical	814
toxicity	NOUN	O	Disease	814
(	PUNCT	O	O	814
n	CCONJ	O	O	814
=	PUNCT	O	O	814
2	X	O	O	814
)	PUNCT	O	O	814
,	PUNCT	O	O	814
syndrome	NOUN	O	O	814
of	ADP	O	O	814
inappropriate	ADJ	O	O	814
antidiuretic	ADJ	O	O	814
hormone	NOUN	O	O	814
secretion	NOUN	O	O	814
(	PUNCT	O	O	814
n	CCONJ	O	O	814
=	PUNCT	O	O	814
1	X	O	O	814
)	PUNCT	O	O	814
,	PUNCT	O	O	814
and	CCONJ	O	O	814
other	ADJ	O	O	814
unclassified	ADJ	O	O	814
events	NOUN	O	O	814
(	PUNCT	O	O	814
n	CCONJ	O	O	814
=	PUNCT	O	O	814
7	NUM	O	O	814
)	PUNCT	O	O	814
.	PUNCT	O	O	814
In	ADP	O	O	815
conclusion	NOUN	O	O	815
,	PUNCT	O	O	815
CNS	PROPN	O	O	815
complications	NOUN	O	O	815
are	AUX	O	O	815
frequent	ADJ	O	O	815
events	NOUN	O	O	815
during	ADP	O	O	815
ALL	PRON	O	O	815
therapy	NOUN	O	O	815
,	PUNCT	O	O	815
and	CCONJ	O	O	815
require	VERB	O	O	815
rapid	ADJ	O	O	815
detection	NOUN	O	O	815
and	CCONJ	O	O	815
prompt	PROPN	O	O	815
treatment	NOUN	O	O	815
to	PART	O	O	815
limit	NOUN	O	O	815
permanent	ADJ	O	O	815
damage	NOUN	O	O	815
.	PUNCT	O	O	815
Safety	NOUN	O	O	818
of	ADP	O	O	818
capecitabine	PROPN	O	Chemical	818
:	PUNCT	O	O	818
a	PRON	O	O	818
review	VERB	O	O	818
.	PUNCT	O	O	818
IMPORTANCE	NOUN	O	O	819
OF	ADP	O	O	819
THE	PRON	O	O	819
FIELD	NOUN	O	O	819
:	PUNCT	O	O	819
Fluoropyrimidines	NOUN	O	O	819
,	PUNCT	O	O	819
in	ADP	O	O	819
particular	ADJ	O	O	819
5-fluorouracil	NOUN	O	Chemical	819
(	PUNCT	O	O	819
5-FU	NOUN	O	Chemical	819
)	PUNCT	O	O	819
,	PUNCT	O	O	819
have	VERB	O	O	819
been	AUX	O	O	819
the	PRON	O	O	819
mainstay	NOUN	O	O	819
of	ADP	O	O	819
treatment	NOUN	O	O	819
for	ADP	O	O	819
several	ADJ	O	O	819
solid	ADJ	O	O	819
tumors	NOUN	O	Disease	819
,	PUNCT	O	O	819
including	VERB	O	O	819
colorectal	ADJ	O	O	819
,	PUNCT	O	O	819
breast	NOUN	O	O	819
and	CCONJ	O	O	819
head	NOUN	O	O	819
and	CCONJ	O	O	819
neck	NOUN	O	O	819
cancers	NOUN	O	Disease	819
,	PUNCT	O	O	819
for	ADP	O	O	819
>	PUNCT	O	O	819
40	NUM	O	O	819
years	NOUN	O	O	819
.	PUNCT	O	O	819
This	PRON	O	O	820
article	NOUN	O	O	820
reviews	NOUN	O	O	820
the	PRON	O	O	820
pharmacology	NOUN	O	O	820
and	CCONJ	O	O	820
efficacy	NOUN	O	O	820
of	ADP	O	O	820
capecitabine	PROPN	O	Chemical	820
with	ADP	O	O	820
a	PRON	O	O	820
special	ADJ	O	O	820
emphasis	NOUN	O	O	820
on	ADP	O	O	820
its	PRON	O	O	820
safety	NOUN	O	O	820
.	PUNCT	O	O	820
WHAT	PRON	O	O	821
THE	PRON	O	O	821
READER	NOUN	O	O	821
WILL	AUX	O	O	821
GAIN	NOUN	O	O	821
:	PUNCT	O	O	821
The	PRON	O	O	821
reader	NOUN	O	O	821
will	AUX	O	O	821
gain	VERB	O	O	821
better	ADV	O	O	821
insight	NOUN	O	O	821
into	ADP	O	O	821
the	PRON	O	O	821
safety	NOUN	O	O	821
of	ADP	O	O	821
capecitabine	PROPN	O	Chemical	821
in	ADP	O	O	821
special	ADJ	O	O	821
populations	NOUN	O	O	821
such	ADJ	O	O	821
as	ADP	O	O	821
patients	NOUN	O	O	821
with	ADP	O	O	821
advanced	ADJ	O	O	821
age	NOUN	O	O	821
,	PUNCT	O	O	821
renal	ADJ	O	O	821
and	CCONJ	O	O	821
kidney	NOUN	O	O	821
disease	PROPN	O	O	821
.	PUNCT	O	O	821
We	PRON	O	O	822
also	ADV	O	O	822
explore	VERB	O	O	822
different	ADJ	O	O	822
dosing	VERB	O	O	822
and	CCONJ	O	O	822
schedules	NOUN	O	O	822
of	ADP	O	O	822
capecitabine	PROPN	O	Chemical	822
administration	NOUN	O	O	822
.	PUNCT	O	O	822
Capecitabine	NOUN	O	O	823
is	AUX	O	O	823
an	PRON	O	O	823
oral	ADJ	O	O	823
prodrug	NOUN	O	O	823
of	ADP	O	O	823
5-FU	NOUN	O	Chemical	823
and	CCONJ	O	O	823
was	AUX	O	O	823
developed	VERB	O	O	823
to	PART	O	O	823
fulfill	VERB	O	O	823
the	PRON	O	O	823
need	VERB	O	O	823
for	ADP	O	O	823
a	PRON	O	O	823
more	ADJ	O	O	823
convenient	ADJ	O	O	823
therapy	NOUN	O	O	823
and	CCONJ	O	O	823
provide	VERB	O	O	823
an	PRON	O	O	823
improved	VERB	O	O	823
safety	NOUN	O	O	823
/	PUNCT	O	O	823
efficacy	NOUN	O	O	823
profile	NOUN	O	O	823
.	PUNCT	O	O	823
It	PRON	O	O	824
has	VERB	O	O	824
shown	VERB	O	O	824
promising	VERB	O	O	824
results	VERB	O	O	824
alone	ADV	O	O	824
or	CCONJ	O	O	824
in	ADP	O	O	824
combination	NOUN	O	O	824
with	ADP	O	O	824
other	ADJ	O	O	824
chemotherapeutic	NOUN	O	O	824
agents	NOUN	O	O	824
in	ADP	O	O	824
colorectal	ADJ	O	O	824
,	PUNCT	O	O	824
breast	NOUN	O	O	824
,	PUNCT	O	O	824
pancreaticobiliary	NOUN	O	O	824
,	PUNCT	O	O	824
gastric	ADJ	O	O	824
,	PUNCT	O	O	824
renal	ADJ	O	O	824
cell	NOUN	O	O	824
and	CCONJ	O	O	824
head	NOUN	O	O	824
and	CCONJ	O	O	824
neck	NOUN	O	O	824
cancers	NOUN	O	Disease	824
.	PUNCT	O	O	824
The	PRON	O	O	825
most	ADV	O	O	825
commonly	ADV	O	O	825
reported	VERB	O	O	825
toxic	ADJ	O	O	825
effects	NOUN	O	O	825
of	ADP	O	O	825
capecitabine	PROPN	O	Chemical	825
are	AUX	O	O	825
diarrhea	PROPN	O	Disease	825
,	PUNCT	O	O	825
nausea	NOUN	O	Disease	825
,	PUNCT	O	O	825
vomiting	VERB	O	Disease	825
,	PUNCT	O	O	825
stomatitis	PROPN	O	O	825
and	CCONJ	O	O	825
hand	NOUN	O	O	825
-	PUNCT	O	O	825
foot	NOUN	O	O	825
syndrome	NOUN	O	O	825
.	PUNCT	O	O	825
Capecitabine	NOUN	O	O	826
has	VERB	O	O	826
a	PRON	O	O	826
well	ADV	O	O	826
-	PUNCT	O	O	826
established	VERB	O	O	826
safety	NOUN	O	O	826
profile	NOUN	O	O	826
and	CCONJ	O	O	826
can	AUX	O	O	826
be	AUX	O	O	826
given	VERB	O	O	826
safely	ADV	O	O	826
to	PART	O	O	826
patients	NOUN	O	O	826
with	ADP	O	O	826
advanced	ADJ	O	O	826
age	NOUN	O	O	826
,	PUNCT	O	O	826
hepatic	ADJ	O	O	826
and	CCONJ	O	O	826
renal dysfunctions	NOUN	O	O	826
.	PUNCT	O	O	826
Effects	NOUN	O	O	829
of	ADP	O	O	829
pallidal	ADJ	O	O	829
neurotensin	ADP	O	O	829
on	ADP	O	O	829
haloperidol	NOUN	O	Chemical	829
-	PUNCT	O	O	829
induced	VERB	O	O	829
parkinsonian	PROPN	O	Disease	829
catalepsy	VERB	O	Disease	829
:	PUNCT	O	O	829
behavioral	ADJ	O	O	829
and	CCONJ	O	O	829
electrophysiological	ADJ	O	O	829
studies	NOUN	O	O	829
.	PUNCT	O	O	829
Previous	ADJ	O	O	830
studies	NOUN	O	O	830
have	VERB	O	O	830
indicated	VERB	O	O	830
that	SCONJ	O	O	830
the	PRON	O	O	830
globus	PROPN	O	O	830
pallidus	VERB	O	O	830
receives	VERB	O	O	830
neurotensinergic	ADV	O	O	830
innervation	NOUN	O	O	830
from	ADP	O	O	830
the	PRON	O	O	830
striatum	NOUN	O	O	830
,	PUNCT	O	O	830
and	CCONJ	O	O	830
systemic	ADJ	O	O	830
administration	NOUN	O	O	830
of	ADP	O	O	830
a	PRON	O	O	830
neurotensin	ADP	O	O	830
analog	NOUN	O	O	830
could	AUX	O	O	830
produce	VERB	O	O	830
antiparkinsonian	ADJ	O	O	830
effects	NOUN	O	O	830
.	PUNCT	O	O	830
The	PRON	O	O	831
present	NOUN	O	O	831
study	VERB	O	O	831
aimed	VERB	O	O	831
to	PART	O	O	831
investigate	VERB	O	O	831
the	PRON	O	O	831
effects	NOUN	O	O	831
of	ADP	O	O	831
pallidal	ADJ	O	O	831
neurotensin	ADP	O	O	831
on	ADP	O	O	831
haloperidol	NOUN	O	Chemical	831
-	PUNCT	O	O	831
induced	VERB	O	O	831
parkinsonian symptoms	NOUN	O	Disease	831
.	PUNCT	O	O	831
Bilateral	ADJ	O	O	832
infusions	NOUN	O	O	832
of	ADP	O	O	832
neurotensin	ADP	O	O	832
into	ADP	O	O	832
the	PRON	O	O	832
globus	PROPN	O	O	832
pallidus	VERB	O	O	832
reversed	VERB	O	O	832
haloperidol	NOUN	O	Chemical	832
-	PUNCT	O	O	832
induced	VERB	O	O	832
parkinsonian	PROPN	O	Disease	832
catalepsy	VERB	O	Disease	832
in	ADP	O	O	832
rats	NOUN	O	O	832
.	PUNCT	O	O	832
Electrophysiological	PROPN	O	O	833
recordings	NOUN	O	O	833
showed	VERB	O	O	833
that	SCONJ	O	O	833
microinjection	NOUN	O	O	833
of	ADP	O	O	833
neurotensin	ADP	O	O	833
induced	VERB	O	O	833
excitation	NOUN	O	O	833
of	ADP	O	O	833
pallidal	ADJ	O	O	833
neurons	NOUN	O	O	833
in	ADP	O	O	833
the	PRON	O	O	833
presence	NOUN	O	O	833
of	ADP	O	O	833
systemic	ADJ	O	O	833
haloperidol	NOUN	O	Chemical	833
administration	NOUN	O	O	833
.	PUNCT	O	O	833
The	PRON	O	O	834
neurotensin	ADP	O	O	834
type-1	NOUN	O	O	834
receptor	NOUN	O	O	834
antagonist	NOUN	O	O	834
SR48692	VERB	O	O	834
blocked	VERB	O	O	834
both	PRON	O	O	834
the	PRON	O	O	834
behavioral	ADJ	O	O	834
and	CCONJ	O	O	834
the	PRON	O	O	834
electrophysiological	ADJ	O	O	834
effects	NOUN	O	O	834
induced	VERB	O	O	834
by	ADP	O	O	834
neurotensin	ADP	O	O	834
.	PUNCT	O	O	834
CONCLUSION	PROPN	O	O	835
:	PUNCT	O	O	835
Activation	NOUN	O	O	835
of	ADP	O	O	835
pallidal	ADJ	O	O	835
neurotensin	ADP	O	O	835
receptors	NOUN	O	O	835
may	AUX	O	O	835
be	AUX	O	O	835
involved	VERB	O	O	835
in	ADP	O	O	835
neurotensin	ADP	O	O	835
-	PUNCT	O	O	835
induced	VERB	O	O	835
antiparkinsonian	ADJ	O	O	835
effects	NOUN	O	O	835
.	PUNCT	O	O	835
Antihypertensive	PROPN	O	O	838
drugs	NOUN	O	O	838
and	CCONJ	O	O	838
depression	PROPN	O	Disease	838
:	PUNCT	O	O	838
a	PRON	O	O	838
reappraisal	NOUN	O	O	838
.	PUNCT	O	O	838
new	ADJ	O	O	839
referral	NOUN	O	O	839
hypertensive	ADJ	O	Disease	839
out	ADP	O	O	839
-	PUNCT	O	O	839
patients	NOUN	O	O	839
and	CCONJ	O	O	839
46	NUM	O	O	839
new	ADJ	O	O	839
referral	NOUN	O	O	839
non	ADJ	O	O	839
-	PUNCT	O	O	839
hypertensive	ADJ	O	Disease	839
chronically	ADV	O	O	839
physically	ADV	O	O	839
ill	PROPN	O	O	839
out	ADP	O	O	839
-	PUNCT	O	O	839
patients	NOUN	O	O	839
completed	VERB	O	O	839
a	PRON	O	O	839
mood	NOUN	O	O	839
rating	NOUN	O	O	839
scale	NOUN	O	O	839
at	ADP	O	O	839
regular	ADJ	O	O	839
intervals	NOUN	O	O	839
for	ADP	O	O	839
one	NUM	O	O	839
year	NOUN	O	O	839
.	PUNCT	O	O	839
The	PRON	O	O	840
results	VERB	O	O	840
showed	VERB	O	O	840
a	PRON	O	O	840
high	ADJ	O	O	840
prevalence	NOUN	O	O	840
of	ADP	O	O	840
depression	PROPN	O	Disease	840
in	ADP	O	O	840
both	PRON	O	O	840
groups	NOUN	O	O	840
of	ADP	O	O	840
patients	NOUN	O	O	840
,	PUNCT	O	O	840
with	ADP	O	O	840
no	PRON	O	O	840
preponderance	NOUN	O	O	840
in	ADP	O	O	840
the	PRON	O	O	840
hypertensive	ADJ	O	Disease	840
group	NOUN	O	O	840
.	PUNCT	O	O	840
Hypertensive	NOUN	O	O	841
patients	NOUN	O	O	841
with	ADP	O	O	841
psychiatric	ADJ	O	Disease	841
histories	NOUN	O	O	841
had	VERB	O	O	841
a	PRON	O	O	841
higher	ADJ	O	O	841
prevalence	NOUN	O	O	841
of	ADP	O	O	841
depression	PROPN	O	Disease	841
than	ADP	O	O	841
the	PRON	O	O	841
comparison	NOUN	O	O	841
patients	NOUN	O	O	841
.	PUNCT	O	O	841
This	PRON	O	O	842
was	AUX	O	O	842
accounted	VERB	O	O	842
for	ADP	O	O	842
by	ADP	O	O	842
a	PRON	O	O	842
significant	ADJ	O	O	842
number	NOUN	O	O	842
of	ADP	O	O	842
depressions	NOUN	O	O	842
occurring	VERB	O	O	842
in	ADP	O	O	842
methyl	NOUN	O	O	842
dopa	PROPN	O	O	842
treated	VERB	O	O	842
patients	NOUN	O	O	842
with	ADP	O	O	842
psychiatric	ADJ	O	Disease	842
histories	NOUN	O	O	842
.	PUNCT	O	O	842
Pulmonary	NOUN	O	O	845
shunt	VERB	O	O	845
and	CCONJ	O	O	845
cardiovascular	ADJ	O	O	845
responses	NOUN	O	O	845
to	PART	O	O	845
CPAP	PROPN	O	O	845
during	ADP	O	O	845
nitroprusside	ADV	O	Chemical	845
-	PUNCT	O	O	845
induced	VERB	O	O	845
hypotension	NOUN	O	Disease	845
.	PUNCT	O	O	845
The	PRON	O	O	846
effects	NOUN	O	O	846
of	ADP	O	O	846
continuous	ADJ	O	O	846
positive	ADJ	O	O	846
airway	NOUN	O	O	846
pressure	NOUN	O	O	846
(	PUNCT	O	O	846
CPAP	PROPN	O	O	846
)	PUNCT	O	O	846
on	ADP	O	O	846
cardiovascular	ADJ	O	O	846
dynamics	NOUN	O	O	846
and	CCONJ	O	O	846
pulmonary	ADJ	O	O	846
shunt	VERB	O	O	846
(	PUNCT	O	O	846
QS	PROPN	O	O	846
/	PUNCT	O	O	846
QT	NOUN	O	O	846
)	PUNCT	O	O	846
were	AUX	O	O	846
investigated	VERB	O	O	846
in	ADP	O	O	846
12	NUM	O	O	846
dogs	NOUN	O	O	846
before	ADP	O	O	846
and	CCONJ	O	O	846
during	ADP	O	O	846
sodium	NOUN	O	Chemical	846
nitroprusside	ADV	O	Chemical	846
infusion	NOUN	O	O	846
that	SCONJ	O	O	846
decreased	VERB	O	O	846
mean	VERB	O	O	846
arterial	ADJ	O	O	846
blood	NOUN	O	O	846
pressure	NOUN	O	O	846
40	NUM	O	O	846
-	PUNCT	O	O	846
50	NUM	O	O	846
per	ADP	O	O	846
cent	NOUN	O	O	846
.	PUNCT	O	O	846
Before	ADP	O	O	847
nitroprusside	ADV	O	Chemical	847
infusion	NOUN	O	O	847
,	PUNCT	O	O	847
5	NUM	O	O	847
cm	NOUN	O	O	847
H2O	NOUN	O	O	847
CPAP	PROPN	O	O	847
significantly	ADV	O	O	847
,	PUNCT	O	O	847
P	NOUN	O	Chemical	847
less	ADV	O	O	847
than	ADP	O	O	847
.05	NUM	O	O	847
,	PUNCT	O	O	847
decreased	VERB	O	O	847
arterial	ADJ	O	O	847
blood	NOUN	O	O	847
pressure	NOUN	O	O	847
,	PUNCT	O	O	847
but	CCONJ	O	O	847
did	VERB	O	O	847
not	PART	O	O	847
significantly	ADV	O	O	847
alter	VERB	O	O	847
heart	NOUN	O	O	847
rate	NOUN	O	O	847
,	PUNCT	O	O	847
cardiac	ADJ	O	O	847
output	NOUN	O	O	847
,	PUNCT	O	O	847
systemic	ADJ	O	O	847
vascular	ADJ	O	O	847
resistance	NOUN	O	O	847
,	PUNCT	O	O	847
or	CCONJ	O	O	847
QS	PROPN	O	O	847
/	PUNCT	O	O	847
QT	NOUN	O	O	847
.	PUNCT	O	O	847
cm	NOUN	O	O	848
H2O	NOUN	O	O	848
CPAP	PROPN	O	O	848
before	ADP	O	O	848
nitroprusside	ADV	O	Chemical	848
infusion	NOUN	O	O	848
produced	VERB	O	O	848
a	PRON	O	O	848
further	ADV	O	O	848
decrease	VERB	O	O	848
in	ADP	O	O	848
arterial	ADJ	O	O	848
blood	NOUN	O	O	848
pressure	NOUN	O	O	848
and	CCONJ	O	O	848
significantly	ADV	O	O	848
increased	VERB	O	O	848
heart	NOUN	O	O	848
rate	NOUN	O	O	848
and	CCONJ	O	O	848
decreased	VERB	O	O	848
cardiac	ADJ	O	O	848
output	NOUN	O	O	848
and	CCONJ	O	O	848
QS	PROPN	O	O	848
/	PUNCT	O	O	848
QT	NOUN	O	O	848
.	PUNCT	O	O	848
Nitroprusside	PROPN	O	O	849
caused	VERB	O	O	849
significant	ADJ	O	O	849
decreases	VERB	O	O	849
in	ADP	O	O	849
arterial	ADJ	O	O	849
blood	NOUN	O	O	849
pressure	NOUN	O	O	849
and	CCONJ	O	O	849
systemic	ADJ	O	O	849
vascular	ADJ	O	O	849
resistance	NOUN	O	O	849
and	CCONJ	O	O	849
increases	VERB	O	O	849
in	ADP	O	O	849
heart	NOUN	O	O	849
rate	NOUN	O	O	849
,	PUNCT	O	O	849
but	CCONJ	O	O	849
did	VERB	O	O	849
not	PART	O	O	849
change	VERB	O	O	849
cardiac	ADJ	O	O	849
output	NOUN	O	O	849
or	CCONJ	O	O	849
QS	PROPN	O	O	849
/	PUNCT	O	O	849
QT	NOUN	O	O	849
.	PUNCT	O	O	849
H2O	NOUN	O	O	850
CPAP	PROPN	O	O	850
during	ADP	O	O	850
nitroprusside	ADV	O	Chemical	850
did	VERB	O	O	850
not	PART	O	O	850
further	ADV	O	O	850
alter	VERB	O	O	850
any	PRON	O	O	850
of	ADP	O	O	850
the	PRON	O	O	850
above	ADP	O	O	850
-	PUNCT	O	O	850
mentioned	VERB	O	O	850
variables	NOUN	O	O	850
.	PUNCT	O	O	850
However	ADV	O	O	851
,	PUNCT	O	O	851
10	NUM	O	O	851
cm	NOUN	O	O	851
H2O	NOUN	O	O	851
CPAP	PROPN	O	O	851
decreased	VERB	O	O	851
arterial	ADJ	O	O	851
blood	NOUN	O	O	851
pressure	NOUN	O	O	851
,	PUNCT	O	O	851
cardiac	ADJ	O	O	851
output	NOUN	O	O	851
,	PUNCT	O	O	851
and	CCONJ	O	O	851
QS	PROPN	O	O	851
/	PUNCT	O	O	851
QT	NOUN	O	O	851
.	PUNCT	O	O	851
These	PRON	O	O	852
data	NOUN	O	O	852
indicate	VERB	O	O	852
that	SCONJ	O	O	852
nitroprusside	ADV	O	Chemical	852
infusion	NOUN	O	O	852
rates	NOUN	O	O	852
that	SCONJ	O	O	852
decrease	VERB	O	O	852
mean	VERB	O	O	852
arterial	ADJ	O	O	852
blood	NOUN	O	O	852
pressure	NOUN	O	O	852
by	ADP	O	O	852
40	NUM	O	O	852
-	PUNCT	O	O	852
50	NUM	O	O	852
per	ADP	O	O	852
cent	NOUN	O	O	852
do	VERB	O	O	852
not	PART	O	O	852
change	VERB	O	O	852
cardiac	ADJ	O	O	852
output	NOUN	O	O	852
or	CCONJ	O	O	852
QS	PROPN	O	O	852
/	PUNCT	O	O	852
QT	NOUN	O	O	852
.	PUNCT	O	O	852
During	ADP	O	O	853
nitroprusside	ADV	O	Chemical	853
infusion	NOUN	O	O	853
low	ADJ	O	O	853
levels	NOUN	O	O	853
of	ADP	O	O	853
CPAP	PROPN	O	O	853
do	VERB	O	O	853
not	PART	O	O	853
markedly	ADV	O	O	853
alter	VERB	O	O	853
cardiovascular	ADJ	O	O	853
dynamics	NOUN	O	O	853
,	PUNCT	O	O	853
but	CCONJ	O	O	853
high	ADJ	O	O	853
levels	NOUN	O	O	853
of	ADP	O	O	853
CPAP	PROPN	O	O	853
(	PUNCT	O	O	853
10	NUM	O	O	853
cm	NOUN	O	O	853
H2O	NOUN	O	O	853
)	PUNCT	O	O	853
,	PUNCT	O	O	853
while	SCONJ	O	O	853
decreasing	VERB	O	O	853
QS	PROPN	O	O	853
/	PUNCT	O	O	853
QT	NOUN	O	O	853
,	PUNCT	O	O	853
produce	VERB	O	O	853
marked	VERB	O	O	853
decreases	VERB	O	O	853
in	ADP	O	O	853
arterial	ADJ	O	O	853
blood	NOUN	O	O	853
pressure	NOUN	O	O	853
and	CCONJ	O	O	853
cardiac	ADJ	O	O	853
output	NOUN	O	O	853
.	PUNCT	O	O	853
Mediation	NOUN	O	O	856
of	ADP	O	O	856
enhanced	VERB	O	O	856
reflex	NOUN	O	O	856
vagal	ADJ	O	O	856
bradycardia	NOUN	O	Disease	856
by	ADP	O	O	856
L	NOUN	O	O	856
-	PUNCT	O	O	856
dopa	PROPN	O	O	856
via	ADP	O	O	856
central	ADJ	O	O	856
dopamine	NOUN	O	Chemical	856
formation	NOUN	O	O	856
in	ADP	O	O	856
dogs	NOUN	O	O	856
.	PUNCT	O	O	856
L	NOUN	O	O	857
-	PUNCT	O	O	857
Dopa	NOUN	O	O	857
(	PUNCT	O	O	857
5	NUM	O	O	857
mg	VERB	O	O	857
/	PUNCT	O	O	857
kg	VERB	O	O	857
i.v	NOUN	O	O	857
.	PUNCT	O	O	857
)	PUNCT	O	O	857
decreased	VERB	O	O	857
blood	NOUN	O	O	857
pressure	NOUN	O	O	857
and	CCONJ	O	O	857
heart	NOUN	O	O	857
rate	NOUN	O	O	857
after	ADP	O	O	857
extracerebral	ADJ	O	O	857
decarboxylase	PROPN	O	O	857
inhibition	NOUN	O	O	857
with	ADP	O	O	857
MK-486	PRON	O	O	857
(	PUNCT	O	O	857
25	NUM	O	O	857
mg	VERB	O	O	857
/	PUNCT	O	O	857
kg	VERB	O	O	857
i.v	NOUN	O	O	857
.	PUNCT	O	O	857
)	PUNCT	O	O	857
in	ADP	O	O	857
anesthetize	VERB	O	O	858
MAO	PROPN	O	O	858
-	PUNCT	O	O	858
inhibited	VERB	O	O	858
dogs	NOUN	O	O	858
.	PUNCT	O	O	858
In	ADP	O	O	859
addition	NOUN	O	O	859
,	PUNCT	O	O	859
reflex	NOUN	O	O	859
bradycardia	NOUN	O	Disease	859
caused	VERB	O	O	859
by	ADP	O	O	859
injected	VERB	O	O	859
norepinephrine	NOUN	O	Chemical	859
was	AUX	O	O	859
significantly	ADV	O	O	859
enhanced	VERB	O	O	859
by	ADP	O	O	859
L	NOUN	O	O	859
-	PUNCT	O	O	859
dopa	PROPN	O	O	859
,	PUNCT	O	O	859
DL	NOUN	O	O	859
-	PUNCT	O	O	859
Threo	PROPN	O	O	859
-	PUNCT	O	O	859
dihydroxyphenylserine	ADJ	O	O	859
had	VERB	O	O	859
no	PRON	O	O	859
effect	VERB	O	O	859
on	ADP	O	O	859
blood	NOUN	O	O	859
pressure	NOUN	O	O	859
,	PUNCT	O	O	859
heart	NOUN	O	O	859
rate	NOUN	O	O	859
or	CCONJ	O	O	859
reflex	NOUN	O	O	859
responses	NOUN	O	O	859
to	PART	O	O	859
norepinephrine	NOUN	O	Chemical	859
.	PUNCT	O	O	859
FLA-63	AUX	O	O	860
,	PUNCT	O	O	860
a	PRON	O	O	860
dopamine	NOUN	O	Chemical	860
-	PUNCT	O	O	860
beta	NOUN	O	O	860
-	PUNCT	O	O	860
oxidase	NOUN	O	O	860
inhibitor	NOUN	O	O	860
,	PUNCT	O	O	860
did	VERB	O	O	860
not	PART	O	O	860
have	VERB	O	O	860
any	PRON	O	O	860
effect	VERB	O	O	860
on	ADP	O	O	860
the	PRON	O	O	860
hypotension	NOUN	O	Disease	860
,	PUNCT	O	O	860
bradycardia	NOUN	O	Disease	860
or	CCONJ	O	O	860
reflex	NOUN	O	O	860
-	PUNCT	O	O	860
enhancing	VERB	O	O	860
effect	VERB	O	O	860
of	ADP	O	O	860
L	NOUN	O	O	860
-	PUNCT	O	O	860
dopa	PROPN	O	O	860
.	PUNCT	O	O	860
Pimozide	PROPN	O	O	861
did	VERB	O	O	861
not	PART	O	O	861
affect	VERB	O	O	861
the	PRON	O	O	861
actions	NOUN	O	O	861
of	ADP	O	O	861
L	NOUN	O	O	861
-	PUNCT	O	O	861
dopa	PROPN	O	O	861
on	ADP	O	O	861
blood	NOUN	O	O	861
pressure	NOUN	O	O	861
and	CCONJ	O	O	861
heart	NOUN	O	O	861
rate	NOUN	O	O	861
but	CCONJ	O	O	861
completely	ADV	O	O	861
blocked	VERB	O	O	861
the	PRON	O	O	861
enhancement	NOUN	O	O	861
of	ADP	O	O	861
reflexes	NOUN	O	O	861
.	PUNCT	O	O	861
Removal	NOUN	O	O	862
of	ADP	O	O	862
the	PRON	O	O	862
carotid	NOUN	O	O	862
sinuses	NOUN	O	O	862
caused	VERB	O	O	862
an	PRON	O	O	862
elevation	NOUN	O	O	862
blood	NOUN	O	O	862
pressure	NOUN	O	O	862
and	CCONJ	O	O	862
heart	NOUN	O	O	862
rate	NOUN	O	O	862
and	CCONJ	O	O	862
abolished	VERB	O	O	862
the	PRON	O	O	862
negative	ADJ	O	O	862
chronotropic	NOUN	O	O	862
effect	VERB	O	O	862
of	ADP	O	O	862
norepinephrine	NOUN	O	Chemical	862
.	PUNCT	O	O	862
However	ADV	O	O	863
,	PUNCT	O	O	863
L	NOUN	O	O	863
-	PUNCT	O	O	863
dopa	PROPN	O	O	863
restored	VERB	O	O	863
the	PRON	O	O	863
bradycardia	NOUN	O	Disease	863
caused	VERB	O	O	863
by	ADP	O	O	863
norepinephrine	NOUN	O	Chemical	863
in	ADP	O	O	863
addition	NOUN	O	O	863
to	PART	O	O	863
decreasing	VERB	O	O	863
blood	NOUN	O	O	863
pressure	NOUN	O	O	863
and	CCONJ	O	O	863
heart	NOUN	O	O	863
rate	NOUN	O	O	863
.	PUNCT	O	O	863
5-HTP	NOUN	O	Chemical	864
(	PUNCT	O	O	864
5	NUM	O	O	864
mg	VERB	O	O	864
/	PUNCT	O	O	864
kg	VERB	O	O	864
i.v	NOUN	O	O	864
.	PUNCT	O	O	864
)	PUNCT	O	O	864
decreased	VERB	O	O	865
blood	NOUN	O	O	865
pressure	NOUN	O	O	865
and	CCONJ	O	O	865
heart	NOUN	O	O	865
rate	NOUN	O	O	865
and	CCONJ	O	O	865
decreased	VERB	O	O	865
the	PRON	O	O	865
reflex	NOUN	O	O	865
bradycardia	NOUN	O	Disease	865
to	PART	O	O	865
norepinephrine	NOUN	O	Chemical	865
.	PUNCT	O	O	865
It	PRON	O	O	866
is	AUX	O	O	866
concluded	VERB	O	O	866
that	SCONJ	O	O	866
L	NOUN	O	O	866
-	PUNCT	O	O	866
dopa	PROPN	O	O	866
enhances	VERB	O	O	866
reflex	NOUN	O	O	866
bradycardia	NOUN	O	Disease	866
through	ADP	O	O	866
central	ADJ	O	O	866
alpha	PROPN	O	O	866
-	PUNCT	O	O	866
receptor	NOUN	O	O	866
stimulation	NOUN	O	O	866
.	PUNCT	O	O	866
Furthermore	ADV	O	O	867
,	PUNCT	O	O	867
the	PRON	O	O	867
effects	NOUN	O	O	867
are	AUX	O	O	867
mediated	VERB	O	O	867
through	ADP	O	O	867
dopamine	NOUN	O	Chemical	867
rather	ADV	O	O	867
than	ADP	O	O	867
norepinephrine	NOUN	O	Chemical	867
and	CCONJ	O	O	867
do	VERB	O	O	867
not	PART	O	O	867
require	VERB	O	O	867
the	PRON	O	O	867
carotid	NOUN	O	O	867
sinus	NOUN	O	O	867
baroreceptors	NOUN	O	O	867
.	PUNCT	O	O	867
Cocaine	NOUN	O	Chemical	870
-	PUNCT	O	O	870
induced	VERB	O	O	870
myocardial infarction	NOUN	O	Disease	870
:	PUNCT	O	O	870
clinical	ADJ	O	O	870
observations	NOUN	O	O	870
and	CCONJ	O	O	870
pathogenetic	NOUN	O	O	870
considerations	NOUN	O	O	870
.	PUNCT	O	O	870
Clinical	NOUN	O	O	871
and	CCONJ	O	O	871
experimental	ADJ	O	O	871
data	NOUN	O	O	871
published	VERB	O	O	871
to	PART	O	O	871
date	PROPN	O	O	871
suggest	VERB	O	O	871
several	ADJ	O	O	871
possible	ADJ	O	O	871
mechanisms	NOUN	O	O	871
by	ADP	O	O	871
which	PRON	O	O	871
cocaine	NOUN	O	Chemical	871
may	AUX	O	O	871
result	VERB	O	O	871
in	ADP	O	O	871
acute	ADJ	O	O	871
myocardial infarction	NOUN	O	Disease	871
.	PUNCT	O	O	871
In	ADP	O	O	872
individuals	NOUN	O	O	872
with	ADP	O	O	872
preexisting	VERB	O	O	872
,	PUNCT	O	O	872
high	ADJ	O	O	872
-	PUNCT	O	O	872
grade	NOUN	O	O	872
coronary	ADJ	O	O	872
arterial	ADJ	O	O	872
narrowing	VERB	O	O	872
,	PUNCT	O	O	872
acute	ADJ	O	O	872
myocardial infarction	NOUN	O	Disease	872
may	AUX	O	O	872
result	VERB	O	O	872
from	ADP	O	O	872
an	PRON	O	O	872
increase	VERB	O	O	872
in	ADP	O	O	872
myocardial	ADJ	O	O	872
oxygen	NOUN	O	Chemical	872
demand	NOUN	O	O	872
associated	VERB	O	O	872
with	ADP	O	O	872
cocaine	NOUN	O	Chemical	872
-	PUNCT	O	O	872
induced	VERB	O	O	872
increase	VERB	O	O	872
in	ADP	O	O	872
rate	NOUN	O	O	872
-	PUNCT	O	O	872
pressure	NOUN	O	O	872
product	NOUN	O	O	872
.	PUNCT	O	O	872
In	ADP	O	O	873
other	ADJ	O	O	873
individuals	NOUN	O	O	873
with	ADP	O	O	873
no	PRON	O	O	873
underlying	VERB	O	O	873
atherosclerotic	ADJ	O	O	873
obstruction	NOUN	O	O	873
,	PUNCT	O	O	873
coronary occlusion	NOUN	O	Disease	873
may	AUX	O	O	873
be	AUX	O	O	873
due	ADJ	O	O	873
to	PART	O	O	873
spasm	NOUN	O	Disease	873
,	PUNCT	O	O	873
thrombus	NOUN	O	Disease	873
,	PUNCT	O	O	873
or	CCONJ	O	O	873
both	PRON	O	O	873
.	PUNCT	O	O	873
With	ADP	O	O	874
regard	NOUN	O	O	874
to	PART	O	O	874
spasm	NOUN	O	Disease	874
,	PUNCT	O	O	874
the	PRON	O	O	874
clinical	ADJ	O	O	874
findings	NOUN	O	O	874
are	AUX	O	O	874
largely	ADV	O	O	874
circumstantial	ADJ	O	O	874
,	PUNCT	O	O	874
and	CCONJ	O	O	874
the	PRON	O	O	874
locus	NOUN	O	O	874
of	ADP	O	O	874
cocaine	NOUN	O	Chemical	874
-	PUNCT	O	O	874
induced	VERB	O	O	874
vasoconstriction	NOUN	O	O	874
remains	VERB	O	O	874
speculative	ADJ	O	O	874
.	PUNCT	O	O	874
Although	SCONJ	O	O	875
certain	ADJ	O	O	875
clinical	ADJ	O	O	875
and	CCONJ	O	O	875
experimental	ADJ	O	O	875
findings	NOUN	O	O	875
support	NOUN	O	O	875
the	PRON	O	O	875
hypothesis	NOUN	O	O	875
that	SCONJ	O	O	875
spasm	NOUN	O	Disease	875
involves	VERB	O	O	875
the	PRON	O	O	875
epicardial	ADJ	O	O	875
,	PUNCT	O	O	875
medium	ADJ	O	O	875
-	PUNCT	O	O	875
size	NOUN	O	O	875
vessels	NOUN	O	O	875
,	PUNCT	O	O	875
other	ADJ	O	O	875
data	NOUN	O	O	875
suggest	VERB	O	O	875
intramural	ADJ	O	O	875
vasoconstriction	NOUN	O	O	875
.	PUNCT	O	O	875
Diffuse	VERB	O	O	876
intramural	ADJ	O	O	876
vasoconstriction	NOUN	O	O	876
is	AUX	O	O	876
not	PART	O	O	876
consistent	ADJ	O	O	876
with	ADP	O	O	876
reports	VERB	O	O	876
of	ADP	O	O	876
segmental	ADJ	O	O	876
,	PUNCT	O	O	876
discrete	ADJ	O	O	876
infarction	NOUN	O	O	876
.	PUNCT	O	O	876
The	PRON	O	O	877
finding	VERB	O	O	877
of	ADP	O	O	877
cocaine	NOUN	O	Chemical	877
-	PUNCT	O	O	877
induced	VERB	O	O	877
vasoconstriction	NOUN	O	O	877
in	ADP	O	O	877
segments	NOUN	O	O	877
of	ADP	O	O	877
(	PUNCT	O	O	877
noninnervated	VERB	O	O	877
)	PUNCT	O	O	877
human	PROPN	O	O	877
umbilical	ADJ	O	O	877
artery	NOUN	O	O	877
suggests	VERB	O	O	877
that	SCONJ	O	O	877
the	PRON	O	O	877
presence	NOUN	O	O	877
or	CCONJ	O	O	877
absence	NOUN	O	O	877
of	ADP	O	O	877
intact	ADJ	O	O	877
innervation	NOUN	O	O	877
is	AUX	O	O	877
not	PART	O	O	877
sufficient	ADJ	O	O	877
to	PART	O	O	877
explain	VERB	O	O	877
the	PRON	O	O	877
discrepant	ADJ	O	O	877
data	NOUN	O	O	877
involving	VERB	O	O	877
the	PRON	O	O	877
possibility	NOUN	O	O	877
of	ADP	O	O	877
alpha	PROPN	O	O	877
-	PUNCT	O	O	877
mediated	VERB	O	O	877
effects	NOUN	O	O	877
.	PUNCT	O	O	877
Finally	ADV	O	O	878
,	PUNCT	O	O	878
the	PRON	O	O	878
contribution	NOUN	O	O	878
of	ADP	O	O	878
a	PRON	O	O	878
primary	NOUN	O	O	878
,	PUNCT	O	O	878
thrombotic	ADJ	O	Disease	878
effect	VERB	O	O	878
of	ADP	O	O	878
cocaine	NOUN	O	Chemical	878
has	VERB	O	O	878
not	PART	O	O	878
been	AUX	O	O	878
excluded	VERB	O	O	878
.	PUNCT	O	O	878
Rabbit	NOUN	O	O	881
syndrome	NOUN	O	O	881
,	PUNCT	O	O	881
antidepressant	NOUN	O	O	881
use	VERB	O	O	881
,	PUNCT	O	O	881
and	CCONJ	O	O	881
cerebral	ADJ	O	O	881
perfusion	NOUN	O	O	881
SPECT	PROPN	O	O	881
scan	VERB	O	O	881
findings	NOUN	O	O	881
.	PUNCT	O	O	881
The	PRON	O	O	882
rabbit	NOUN	O	O	882
syndrome	NOUN	O	O	882
is	AUX	O	O	882
an	PRON	O	O	882
extrapyramidal	ADJ	O	O	882
side	NOUN	O	O	882
effect	VERB	O	O	882
associated	VERB	O	O	882
with	ADP	O	O	882
chronic	ADJ	O	O	882
neuroleptic	NOUN	O	O	882
therapy	NOUN	O	O	882
.	PUNCT	O	O	882
Its	PRON	O	O	883
occurrence	NOUN	O	O	883
in	ADP	O	O	883
a	PRON	O	O	883
patient	NOUN	O	O	883
being	AUX	O	O	883
treated	VERB	O	O	883
with	ADP	O	O	883
imipramine	X	O	O	883
is	AUX	O	O	883
described	VERB	O	O	883
,	PUNCT	O	O	883
representing	VERB	O	O	883
the	PRON	O	O	883
first	ADV	O	O	883
reported	VERB	O	O	883
case	NOUN	O	O	883
of	ADP	O	O	883
this	PRON	O	O	883
syndrome	NOUN	O	O	883
in	ADP	O	O	883
conjunction	NOUN	O	O	883
with	ADP	O	O	883
antidepressants	NOUN	O	O	883
.	PUNCT	O	O	883
Repeated	VERB	O	O	884
cerebral	ADJ	O	O	884
perfusion	NOUN	O	O	884
SPECT	PROPN	O	O	884
scans	VERB	O	O	884
revealed	VERB	O	O	884
decreased	VERB	O	O	884
basal	PROPN	O	O	884
ganglia	NOUN	O	O	884
perfusion	NOUN	O	O	884
while	SCONJ	O	O	884
the	PRON	O	O	884
movement disorder	NOUN	O	Disease	884
was	AUX	O	O	884
present	NOUN	O	O	884
,	PUNCT	O	O	884
and	CCONJ	O	O	884
a	PRON	O	O	884
return	VERB	O	O	884
to	PART	O	O	884
normal	ADJ	O	O	884
perfusion	NOUN	O	O	884
when	SCONJ	O	O	884
the	PRON	O	O	884
rabbit	NOUN	O	O	884
syndrome	NOUN	O	O	884
resolved	VERB	O	O	884
.	PUNCT	O	O	884
Acute	PROPN	O	O	887
bronchodilating	VERB	O	O	887
effects	NOUN	O	O	887
of	ADP	O	O	887
ipratropium	PROPN	O	O	887
bromide	NOUN	O	O	887
and	CCONJ	O	O	887
theophylline	ADV	O	Chemical	887
in	ADP	O	O	887
chronic	ADJ	O	O	887
obstructive	ADJ	O	O	887
pulmonary	ADJ	O	O	887
disease	PROPN	O	O	887
.	PUNCT	O	O	887
The	PRON	O	O	888
bronchodilator	NOUN	O	O	888
effects	NOUN	O	O	888
of	ADP	O	O	888
a	PRON	O	O	888
single	ADJ	O	O	888
dose	NOUN	O	O	888
of	ADP	O	O	888
ipratropium	PROPN	O	O	888
bromide	NOUN	O	O	888
aerosol	NOUN	O	O	888
(	PUNCT	O	O	888
36	NUM	O	O	888
micrograms	NOUN	O	O	888
)	PUNCT	O	O	888
and	CCONJ	O	O	888
short	ADJ	O	O	888
-	PUNCT	O	O	888
acting	VERB	O	O	888
theophylline	ADV	O	Chemical	888
tablets	NOUN	O	O	888
(	PUNCT	O	O	888
dose	NOUN	O	O	888
titrated	VERB	O	O	888
to	PART	O	O	888
produce	VERB	O	O	888
serum	NOUN	O	O	888
levels	NOUN	O	O	888
of	ADP	O	O	888
10	NUM	O	O	888
-	PUNCT	O	O	888
20	NUM	O	O	888
micrograms	NOUN	O	O	888
/	PUNCT	O	O	888
mL	PROPN	O	O	888
)	PUNCT	O	O	888
were	AUX	O	O	888
compared	VERB	O	O	888
in	ADP	O	O	888
a	PRON	O	O	888
double	ADJ	O	O	888
-	PUNCT	O	O	888
blind	ADJ	O	Disease	888
,	PUNCT	O	O	888
placebo	NOUN	O	O	888
-	PUNCT	O	O	888
controlled	VERB	O	O	888
crossover	NOUN	O	O	888
study	VERB	O	O	888
in	ADP	O	O	888
21	NUM	O	O	888
patients	NOUN	O	O	888
with	ADP	O	O	888
stable	ADJ	O	O	888
,	PUNCT	O	O	888
chronic	ADJ	O	O	888
obstructive	ADJ	O	O	888
pulmonary	ADJ	O	O	888
disease	PROPN	O	O	888
.	PUNCT	O	O	888
Mean	VERB	O	O	889
peak	PROPN	O	O	889
forced	VERB	O	O	889
expiratory	NOUN	O	O	889
volume	PROPN	O	O	889
in	ADP	O	O	889
1	X	O	O	889
second	ADV	O	O	889
(	PUNCT	O	O	889
FEV1	PROPN	O	O	889
)	PUNCT	O	O	889
increases	VERB	O	O	889
over	ADP	O	O	889
baseline	VERB	O	O	889
and	CCONJ	O	O	889
the	PRON	O	O	889
proportion	NOUN	O	O	889
of	ADP	O	O	889
patients	NOUN	O	O	889
attaining	VERB	O	O	889
at	ADP	O	O	889
least	ADJ	O	O	889
a	PRON	O	O	889
15%	NOUN	O	O	889
increase	VERB	O	O	889
in	ADP	O	O	889
the	PRON	O	O	889
FEV1	PROPN	O	O	889
(	PUNCT	O	O	889
responders	NOUN	O	O	889
)	PUNCT	O	O	889
were	AUX	O	O	889
31%	NOUN	O	O	889
and	CCONJ	O	O	889
90%	NOUN	O	O	889
,	PUNCT	O	O	889
respectively	ADV	O	O	889
,	PUNCT	O	O	889
for	ADP	O	O	889
ipratropium	PROPN	O	O	889
and	CCONJ	O	O	889
17%	NOUN	O	O	889
and	CCONJ	O	O	889
50%	NOUN	O	O	889
,	PUNCT	O	O	889
respectively	ADV	O	O	889
,	PUNCT	O	O	889
for	ADP	O	O	889
theophylline	ADV	O	Chemical	889
.	PUNCT	O	O	889
The	PRON	O	O	890
average	ADJ	O	O	890
FEV1	PROPN	O	O	890
increases	VERB	O	O	890
during	ADP	O	O	890
the	PRON	O	O	890
6-hour	NOUN	O	O	890
observation	NOUN	O	O	890
period	NOUN	O	O	890
were	AUX	O	O	890
18%	NOUN	O	O	890
for	ADP	O	O	890
ipratropium	PROPN	O	O	890
and	CCONJ	O	O	890
8%	NOUN	O	O	890
for	ADP	O	O	890
theophylline	ADV	O	Chemical	890
.	PUNCT	O	O	890
The	PRON	O	O	891
mean	VERB	O	O	891
duration	NOUN	O	O	891
of	ADP	O	O	891
action	NOUN	O	O	891
was	AUX	O	O	891
3.8	NUM	O	O	891
hours	NOUN	O	O	891
with	ADP	O	O	891
ipratropium	PROPN	O	O	891
and	CCONJ	O	O	891
2.4	NUM	O	O	891
hours	NOUN	O	O	891
with	ADP	O	O	891
theophylline	ADV	O	Chemical	891
.	PUNCT	O	O	891
While	SCONJ	O	O	892
side	NOUN	O	O	892
effects	NOUN	O	O	892
were	AUX	O	O	892
rare	ADJ	O	O	892
,	PUNCT	O	O	892
those	PRON	O	O	892
experienced	ADJ	O	O	892
after	ADP	O	O	892
theophylline	ADV	O	Chemical	892
use	VERB	O	O	892
did	VERB	O	O	892
involve	VERB	O	O	892
the	PRON	O	O	892
cardiovascular	ADJ	O	O	892
and	CCONJ	O	O	892
gastrointestinal	ADJ	O	O	892
systems	NOUN	O	O	892
.	PUNCT	O	O	892
These	PRON	O	O	893
results	VERB	O	O	893
show	VERB	O	O	893
that	SCONJ	O	O	893
ipratropium	PROPN	O	O	893
is	AUX	O	O	893
a	PRON	O	O	893
more	ADJ	O	O	893
potent	ADJ	O	O	893
bronchodilator	NOUN	O	O	893
than	ADP	O	O	893
oral	ADJ	O	O	893
theophylline	ADV	O	Chemical	893
in	ADP	O	O	893
patients	NOUN	O	O	893
with	ADP	O	O	893
chronic	ADJ	O	O	893
airflow	NOUN	O	O	893
obstruction	NOUN	O	O	893
.	PUNCT	O	O	893
Irreversible	PROPN	O	O	896
damage	NOUN	O	O	896
to	PART	O	O	896
the	PRON	O	O	896
medullary	ADJ	O	O	896
interstitium	NOUN	O	O	896
in	ADP	O	O	896
experimental	ADJ	O	O	896
analgesic	PROPN	O	O	896
nephropathy	NOUN	O	Disease	896
in	ADP	O	O	896
F344	PROPN	O	O	896
rats	NOUN	O	O	896
.	PUNCT	O	O	896
Renal papillary necrosis	NOUN	O	Disease	897
(	PUNCT	O	O	897
RPN	PROPN	O	Disease	897
)	PUNCT	O	O	897
and	CCONJ	O	O	897
a	PRON	O	O	897
decreased	VERB	O	O	897
urinary	ADJ	O	O	897
concentrating	VERB	O	O	897
ability	NOUN	O	O	897
developed	VERB	O	O	897
during	ADP	O	O	897
continuous	ADJ	O	O	897
long	ADV	O	O	897
-	PUNCT	O	O	897
term	NOUN	O	O	897
treatment	NOUN	O	O	897
with	ADP	O	O	897
aspirin	NOUN	O	Chemical	897
and	CCONJ	O	O	897
paracetamol	PROPN	O	Chemical	897
in	ADP	O	O	897
female	ADJ	O	O	897
Fischer	PROPN	O	O	897
344	NUM	O	O	897
rats	NOUN	O	O	897
.	PUNCT	O	O	897
This	PRON	O	O	898
study	VERB	O	O	898
shows	VERB	O	O	898
that	SCONJ	O	O	898
prolonged	VERB	O	O	898
analgesic	PROPN	O	O	898
treatment	NOUN	O	O	898
in	ADP	O	O	898
Fischer	PROPN	O	O	898
344	NUM	O	O	898
rats	NOUN	O	O	898
causes	VERB	O	O	898
progressive	ADJ	O	O	898
and	CCONJ	O	O	898
irreversible	ADJ	O	O	898
damage	NOUN	O	O	898
to	PART	O	O	898
the	PRON	O	O	898
interstitial	ADJ	O	O	898
matrix	NOUN	O	O	898
and	CCONJ	O	O	898
type	NOUN	O	O	898
1	X	O	O	898
interstitial	ADJ	O	O	898
cells	NOUN	O	O	898
leading	VERB	O	O	898
to	PART	O	O	898
RPN	PROPN	O	Disease	898
.	PUNCT	O	O	898
Less	ADV	O	O	901
frequent	ADJ	O	O	901
lithium	NOUN	O	Chemical	901
administration	NOUN	O	O	901
and	CCONJ	O	O	901
lower	ADJ	O	O	901
urine	NOUN	O	O	901
volume	PROPN	O	O	901
.	PUNCT	O	O	901
This	PRON	O	O	902
study	VERB	O	O	902
was	AUX	O	O	902
designed	VERB	O	O	902
to	PART	O	O	902
determine	VERB	O	O	902
whether	SCONJ	O	O	902
patients	NOUN	O	O	902
maintained	VERB	O	O	902
on	ADP	O	O	902
a	PRON	O	O	902
regimen	NOUN	O	O	902
of	ADP	O	O	902
lithium	NOUN	O	Chemical	902
on	ADP	O	O	902
a	PRON	O	O	902
once	ADV	O	O	902
-	PUNCT	O	O	902
per	ADP	O	O	902
-	PUNCT	O	O	902
day	NOUN	O	O	902
schedule	NOUN	O	O	902
have	VERB	O	O	902
lower	ADJ	O	O	902
urine	NOUN	O	O	902
volumes	NOUN	O	O	902
than	ADP	O	O	902
do	VERB	O	O	902
patients	NOUN	O	O	902
receiving	VERB	O	O	902
multiple	ADJ	O	O	902
doses	NOUN	O	O	902
per	ADP	O	O	902
day	NOUN	O	O	902
.	PUNCT	O	O	902
This	PRON	O	O	903
was	AUX	O	O	903
a	PRON	O	O	903
cross	VERB	O	O	903
-	PUNCT	O	O	903
sectional	ADJ	O	O	903
study	VERB	O	O	903
of	ADP	O	O	903
85	NUM	O	O	903
patients	NOUN	O	O	903
from	ADP	O	O	903
a	PRON	O	O	903
lithium	NOUN	O	Chemical	903
clinic	NOUN	O	O	903
who	PRON	O	O	903
received	VERB	O	O	903
different	ADJ	O	O	903
dose	NOUN	O	O	903
schedules	NOUN	O	O	903
.	PUNCT	O	O	903
Patients	NOUN	O	O	904
were	AUX	O	O	904
admitted	VERB	O	O	904
to	PART	O	O	904
the	PRON	O	O	904
hospital	PROPN	O	O	904
for	ADP	O	O	904
measurement	NOUN	O	O	904
of	ADP	O	O	904
lithium	NOUN	O	Chemical	904
level	VERB	O	O	904
,	PUNCT	O	O	904
creatinine	PROPN	O	Chemical	904
clearance	NOUN	O	O	904
,	PUNCT	O	O	904
urine	NOUN	O	O	904
volume	PROPN	O	O	904
,	PUNCT	O	O	904
and	CCONJ	O	O	904
maximum	ADV	O	O	904
osmolality	NOUN	O	O	904
.	PUNCT	O	O	904
Multiple	ADJ	O	O	905
daily	ADV	O	O	905
doses	NOUN	O	O	905
of	ADP	O	O	905
lithium	NOUN	O	Chemical	905
were	AUX	O	O	905
associated	VERB	O	O	905
with	ADP	O	O	905
higher	ADJ	O	O	905
urine	NOUN	O	O	905
volumes	NOUN	O	O	905
.	PUNCT	O	O	905
The	PRON	O	O	906
dosing	VERB	O	O	906
schedule	NOUN	O	O	906
,	PUNCT	O	O	906
duration	NOUN	O	O	906
of	ADP	O	O	906
lithium	NOUN	O	Chemical	906
treatment	NOUN	O	O	906
,	PUNCT	O	O	906
and	CCONJ	O	O	906
daily	ADV	O	O	906
dose	NOUN	O	O	906
of	ADP	O	O	906
lithium	NOUN	O	Chemical	906
did	VERB	O	O	906
not	PART	O	O	906
affect	VERB	O	O	906
maximum	ADV	O	O	906
osmolality	NOUN	O	O	906
or	CCONJ	O	O	906
creatinine	PROPN	O	Chemical	906
clearance	NOUN	O	O	906
.	PUNCT	O	O	906
CONCLUSIONS	NOUN	O	O	907
:	PUNCT	O	O	907
Urine	NOUN	O	O	907
volume	PROPN	O	O	907
can	AUX	O	O	907
be	AUX	O	O	907
reduced	VERB	O	O	907
by	ADP	O	O	907
giving	VERB	O	O	907
lithium	NOUN	O	Chemical	907
once	ADV	O	O	907
daily	ADV	O	O	907
and/or	CCONJ	O	O	907
by	ADP	O	O	907
lowering	VERB	O	O	907
the	PRON	O	O	907
total	ADJ	O	O	907
daily	ADV	O	O	907
dose	NOUN	O	O	907
.	PUNCT	O	O	907
Lithium	NOUN	O	Chemical	908
-	PUNCT	O	O	908
induced	VERB	O	O	908
polyuria	PROPN	O	Disease	908
seems	VERB	O	O	908
to	PART	O	O	908
be	AUX	O	O	908
related	ADJ	O	O	908
to	PART	O	O	908
extrarenal	ADJ	O	O	908
as	ADP	O	O	908
well	ADV	O	O	908
as	ADP	O	O	908
to	PART	O	O	908
renal	ADJ	O	O	908
effects	NOUN	O	O	908
.	PUNCT	O	O	908
Effect	VERB	O	O	911
of	ADP	O	O	911
adriamycin	PROPN	O	Chemical	911
combined	VERB	O	O	911
with	ADP	O	O	911
whole	NOUN	O	O	911
body	NOUN	O	O	911
hyperthermia	NOUN	O	Disease	911
on	ADP	O	O	911
tumor	NOUN	O	Disease	911
and	CCONJ	O	O	911
normal	ADJ	O	O	911
tissues	NOUN	O	O	911
.	PUNCT	O	O	911
Thermal	ADJ	O	O	912
enhancement	NOUN	O	O	912
of	ADP	O	O	912
Adriamycin	PROPN	O	Chemical	912
-	PUNCT	O	O	912
mediated	VERB	O	O	912
antitumor	PROPN	O	O	912
activity	NOUN	O	O	912
and	CCONJ	O	O	912
normal	ADJ	O	O	912
tissue	NOUN	O	O	912
toxicities	NOUN	O	Disease	912
by	ADP	O	O	912
whole	NOUN	O	O	912
body	NOUN	O	O	912
hyperthermia	NOUN	O	Disease	912
were	AUX	O	O	912
compared	VERB	O	O	912
using	VERB	O	O	912
a	PRON	O	O	912
F344	PROPN	O	O	912
rat	NOUN	O	O	912
model	NOUN	O	O	912
.	PUNCT	O	O	912
Antitumor	PROPN	O	O	913
activity	NOUN	O	O	913
was	AUX	O	O	913
studied	VERB	O	O	913
using	VERB	O	O	913
a	PRON	O	O	913
tumor	NOUN	O	Disease	913
growth	NOUN	O	O	913
delay	NOUN	O	O	913
assay	NOUN	O	O	913
.	PUNCT	O	O	913
Acute	PROPN	O	O	914
normal	ADJ	O	O	914
tissue	NOUN	O	O	914
toxicities	NOUN	O	Disease	914
(	PUNCT	O	O	914
i.e.	X	O	O	914
,	PUNCT	O	O	914
leukopenia	PROPN	O	Disease	914
and	CCONJ	O	O	914
thrombocytopenia	PROPN	O	Disease	914
)	PUNCT	O	O	914
and	CCONJ	O	O	914
late	ADV	O	O	914
normal	ADJ	O	O	914
tissue	NOUN	O	O	914
toxicities	NOUN	O	Disease	914
(	PUNCT	O	O	914
i.e.	X	O	O	914
,	PUNCT	O	O	914
myocardial	ADJ	O	O	914
and	CCONJ	O	O	914
kidney	NOUN	O	O	914
injury	NOUN	O	O	914
)	PUNCT	O	O	914
were	AUX	O	O	914
evaluated	VERB	O	O	914
by	ADP	O	O	914
functional	ADJ	O	O	914
/	PUNCT	O	O	914
physiological	ADJ	O	O	914
assays	NOUN	O	O	914
and	CCONJ	O	O	914
by	ADP	O	O	914
morphological	ADJ	O	O	914
techniques	NOUN	O	O	914
.	PUNCT	O	O	914
Whole	NOUN	O	O	915
body	NOUN	O	O	915
hyperthermia	NOUN	O	Disease	915
(	PUNCT	O	O	915
120	NUM	O	O	915
min	NOUN	O	O	915
at	ADP	O	O	915
41.5	NUM	O	O	915
degrees	NOUN	O	O	915
C	NOUN	O	O	915
)	PUNCT	O	O	915
enhanced	VERB	O	O	915
both	PRON	O	O	915
Adriamycin	PROPN	O	Chemical	915
-	PUNCT	O	O	915
mediated	VERB	O	O	915
antitumor	PROPN	O	O	915
activity	NOUN	O	O	915
and	CCONJ	O	O	915
toxic	ADJ	O	O	915
side	NOUN	O	O	915
effects	NOUN	O	O	915
.	PUNCT	O	O	915
Thermal	ADJ	O	O	916
enhancement	NOUN	O	O	916
ratios	VERB	O	O	916
estimated	VERB	O	O	916
for	ADP	O	O	916
""""	PUNCT	O	O	916
acute	ADJ	O	O	916
""""	PUNCT	O	O	916
hematological	ADJ	O	O	916
changes	VERB	O	O	916
were	AUX	O	O	916
1.3	NUM	O	O	916
,	PUNCT	O	O	916
whereas	SCONJ	O	O	916
those	PRON	O	O	916
estimated	VERB	O	O	916
for	ADP	O	O	916
""""	PUNCT	O	O	916
late	ADV	O	O	916
""""	PUNCT	O	O	916
damage	NOUN	O	O	916
(	PUNCT	O	O	916
based	VERB	O	O	916
on	ADP	O	O	916
morphological	ADJ	O	O	916
cardiac	ADJ	O	O	916
and	CCONJ	O	O	916
renal lesions	NOUN	O	Disease	916
)	PUNCT	O	O	916
varied	ADJ	O	O	916
between	ADP	O	O	916
2.4	NUM	O	O	916
and	CCONJ	O	O	916
4.3	NUM	O	O	916
.	PUNCT	O	O	916
Thus	ADV	O	O	917
,	PUNCT	O	O	917
while	SCONJ	O	O	917
whole	NOUN	O	O	917
body	NOUN	O	O	917
hyperthermia	NOUN	O	Disease	917
enhances	VERB	O	O	917
Adriamycin	PROPN	O	Chemical	917
-	PUNCT	O	O	917
mediated	VERB	O	O	917
antitumor	PROPN	O	O	917
effect	VERB	O	O	917
,	PUNCT	O	O	917
normal	ADJ	O	O	917
tissue	NOUN	O	O	917
toxicity	NOUN	O	Disease	917
is	AUX	O	O	917
also	ADV	O	O	917
increased	VERB	O	O	917
,	PUNCT	O	O	917
and	CCONJ	O	O	917
the	PRON	O	O	917
potential	ADJ	O	O	917
therapeutic	ADJ	O	O	917
gain	VERB	O	O	917
of	ADP	O	O	917
the	PRON	O	O	917
combined	VERB	O	O	917
modality	NOUN	O	O	917
treatment	NOUN	O	O	917
is	AUX	O	O	917
eroded	VERB	O	O	917
.	PUNCT	O	O	917
Prazosin	NOUN	O	O	920
-	PUNCT	O	O	920
induced	VERB	O	O	920
stress	NOUN	O	O	920
incontinence	NOUN	O	O	920
.	PUNCT	O	O	920
A	PRON	O	O	921
case	NOUN	O	O	921
of	ADP	O	O	921
genuine	ADJ	O	O	921
stress	NOUN	O	O	921
incontinence	NOUN	O	O	921
due	ADJ	O	O	921
to	PART	O	O	921
prazosin	NOUN	O	Chemical	921
,	PUNCT	O	O	921
a	PRON	O	O	921
common	ADJ	O	O	921
antihypertensive	ADV	O	O	921
drug	NOUN	O	O	921
,	PUNCT	O	O	921
is	AUX	O	O	921
presented	VERB	O	O	921
.	PUNCT	O	O	921
Prazosin	NOUN	O	O	922
exerts	VERB	O	O	922
its	PRON	O	O	922
antihypertensive	ADV	O	O	922
effects	NOUN	O	O	922
through	ADP	O	O	922
vasodilatation	NOUN	O	O	922
caused	VERB	O	O	922
by	ADP	O	O	922
selective	ADJ	O	O	922
blockade	VERB	O	O	922
of	ADP	O	O	922
postsynaptic	ADJ	O	O	922
alpha-1	NUM	O	O	922
adrenergic	NOUN	O	O	922
receptors	NOUN	O	O	922
.	PUNCT	O	O	922
The	PRON	O	O	923
patient	NOUN	O	O	923
's	AUX	O	O	923
clinical	ADJ	O	O	923
course	NOUN	O	O	923
is	AUX	O	O	923
described	VERB	O	O	923
and	CCONJ	O	O	923
correlated	VERB	O	O	923
with	ADP	O	O	923
initial	ADJ	O	O	923
urodynamic	ADJ	O	O	923
studies	NOUN	O	O	923
while	SCONJ	O	O	923
on	ADP	O	O	923
prazosin	NOUN	O	Chemical	923
and	CCONJ	O	O	923
subsequent	ADJ	O	O	923
studies	NOUN	O	O	923
while	SCONJ	O	O	923
taking	VERB	O	O	923
verapamil	PROPN	O	Chemical	923
.	PUNCT	O	O	923
Her	PRON	O	O	924
incontinence	NOUN	O	O	924
resolved	VERB	O	O	924
with	ADP	O	O	924
the	PRON	O	O	924
change	VERB	O	O	924
of	ADP	O	O	924
medication	NOUN	O	O	924
.	PUNCT	O	O	924
Patients	NOUN	O	O	925
who	PRON	O	O	925
present	NOUN	O	O	925
with	ADP	O	O	925
stress	NOUN	O	O	925
incontinence	NOUN	O	O	925
while	SCONJ	O	O	925
taking	VERB	O	O	925
prazosin	NOUN	O	Chemical	925
should	AUX	O	O	925
change	VERB	O	O	925
their	PRON	O	O	925
antihypertensive	ADV	O	O	925
medication	NOUN	O	O	925
before	ADP	O	O	925
considering	VERB	O	O	925
surgery	NOUN	O	O	925
,	PUNCT	O	O	925
because	SCONJ	O	O	925
their	PRON	O	O	925
incontinence	NOUN	O	O	925
may	AUX	O	O	925
resolve	VERB	O	O	925
spontaneously	ADV	O	O	925
with	ADP	O	O	925
a	PRON	O	O	925
change	VERB	O	O	925
in	ADP	O	O	925
drug	NOUN	O	O	925
therapy	NOUN	O	O	925
.	PUNCT	O	O	925
Myocardial infarction	NOUN	O	Disease	928
following	VERB	O	O	928
sublingual	PROPN	O	O	928
administration	NOUN	O	O	928
of	ADP	O	O	928
isosorbide	NOUN	O	Chemical	928
dinitrate	NOUN	O	O	928
.	PUNCT	O	O	928
A	PRON	O	O	929
78-year	NOUN	O	O	929
-	PUNCT	O	O	929
old	ADJ	O	O	929
with	ADP	O	O	929
healed	VERB	O	O	929
septal	ADJ	O	O	929
necrosis	NOUN	O	Disease	929
suffered	VERB	O	O	929
a	PRON	O	O	929
recurrent	ADJ	O	O	929
myocardial infarction	NOUN	O	Disease	929
of	ADP	O	O	929
the	PRON	O	O	929
anterior	PROPN	O	O	929
wall	PROPN	O	O	929
following	VERB	O	O	929
the	PRON	O	O	929
administration	NOUN	O	O	929
of	ADP	O	O	929
isosorbide	NOUN	O	Chemical	929
dinitrate	NOUN	O	O	929
5	NUM	O	O	929
mg	VERB	O	O	929
sublingually	ADV	O	O	929
.	PUNCT	O	O	929
After	ADP	O	O	930
detailing	VERB	O	O	930
the	PRON	O	O	930
course	NOUN	O	O	930
of	ADP	O	O	930
events	NOUN	O	O	930
,	PUNCT	O	O	930
we	PRON	O	O	930
discuss	VERB	O	O	930
the	PRON	O	O	930
role	NOUN	O	O	930
of	ADP	O	O	930
paradoxical	ADJ	O	O	930
coronary spasm	NOUN	O	Disease	930
and	CCONJ	O	O	930
hypotension	NOUN	O	Disease	930
-	PUNCT	O	O	930
mediated	VERB	O	O	930
myocardial ischemia	NOUN	O	Disease	930
occurring	VERB	O	O	930
downstream	ADJ	O	O	930
to	PART	O	O	930
significant	ADJ	O	O	930
coronary	ADJ	O	O	930
arterial	ADJ	O	O	930
stenosis	NOUN	O	O	930
in	ADP	O	O	930
the	PRON	O	O	930
pathophysiology	NOUN	O	O	930
of	ADP	O	O	930
acute	ADJ	O	O	930
coronary	ADJ	O	O	930
insufficiency	NOUN	O	O	930
.	PUNCT	O	O	930
Fluoxetine	NOUN	O	Chemical	933
-	PUNCT	O	O	933
induced	VERB	O	O	933
akathisia	PROPN	O	Disease	933
:	PUNCT	O	O	933
clinical	ADJ	O	O	933
and	CCONJ	O	O	933
theoretical	ADJ	O	O	933
implications	NOUN	O	O	933
.	PUNCT	O	O	933
Five	NUM	O	O	934
patients	NOUN	O	O	934
receiving	VERB	O	O	934
fluoxetine	NOUN	O	Chemical	934
for	ADP	O	O	934
the	PRON	O	O	934
treatment	NOUN	O	O	934
of	ADP	O	O	934
obsessive compulsive disorder	NOUN	O	Disease	934
or	CCONJ	O	O	934
major	ADJ	O	O	934
depression	PROPN	O	Disease	934
developed	VERB	O	O	934
akathisia	PROPN	O	Disease	934
.	PUNCT	O	O	934
The	PRON	O	O	935
typical	ADJ	O	O	935
fluoxetine	NOUN	O	Chemical	935
-	PUNCT	O	O	935
induced	VERB	O	O	935
symptoms	NOUN	O	O	935
of	ADP	O	O	935
restlessness	NOUN	O	Disease	935
,	PUNCT	O	O	935
constant	ADJ	O	O	935
pacing	NOUN	O	O	935
,	PUNCT	O	O	935
purposeless	ADJ	O	O	935
movements	NOUN	O	O	935
of	ADP	O	O	935
the	PRON	O	O	935
feet	NOUN	O	O	935
and	CCONJ	O	O	935
legs	NOUN	O	O	935
,	PUNCT	O	O	935
and	CCONJ	O	O	935
marked	VERB	O	O	935
anxiety	NOUN	O	Disease	935
were	AUX	O	O	935
indistinguishable	ADJ	O	O	935
from	ADP	O	O	935
those	PRON	O	O	935
of	ADP	O	O	935
neuroleptic	NOUN	O	O	935
-	PUNCT	O	O	935
induced	VERB	O	O	935
akathisia	PROPN	O	Disease	935
.	PUNCT	O	O	935
Three	NUM	O	O	936
patients	NOUN	O	O	936
who	PRON	O	O	936
had	VERB	O	O	936
experienced	ADJ	O	O	936
neuroleptic	NOUN	O	O	936
-	PUNCT	O	O	936
induced	VERB	O	O	936
akathisia	PROPN	O	Disease	936
in	ADP	O	O	936
the	PRON	O	O	936
past	ADP	O	O	936
reported	VERB	O	O	936
that	SCONJ	O	O	936
the	PRON	O	O	936
symptoms	NOUN	O	O	936
of	ADP	O	O	936
fluoxetine	NOUN	O	Chemical	936
-	PUNCT	O	O	936
induced	VERB	O	O	936
akathisia	PROPN	O	Disease	936
were	AUX	O	O	936
identical	ADJ	O	O	936
,	PUNCT	O	O	936
although	SCONJ	O	O	936
somewhat	ADV	O	O	936
milder	ADJ	O	O	936
.	PUNCT	O	O	936
Akathisia	PROPN	O	Disease	937
appeared	VERB	O	O	937
to	PART	O	O	937
be	AUX	O	O	937
a	PRON	O	O	937
common	ADJ	O	O	937
side	NOUN	O	O	937
effect	VERB	O	O	937
of	ADP	O	O	937
fluoxetine	NOUN	O	Chemical	937
and	CCONJ	O	O	937
generally	ADV	O	O	937
responded	VERB	O	O	937
well	ADV	O	O	937
to	PART	O	O	937
treatment	NOUN	O	O	937
with	ADP	O	O	937
the	PRON	O	O	937
beta	NOUN	O	O	937
-	PUNCT	O	O	937
adrenergic	NOUN	O	O	937
antagonist	NOUN	O	O	937
propranolol	NOUN	O	Chemical	937
,	PUNCT	O	O	937
dose	NOUN	O	O	937
reduction	NOUN	O	O	937
,	PUNCT	O	O	937
or	CCONJ	O	O	937
both	PRON	O	O	937
.	PUNCT	O	O	937
The	PRON	O	O	938
authors	NOUN	O	O	938
suggest	VERB	O	O	938
that	SCONJ	O	O	938
fluoxetine	NOUN	O	Chemical	938
-	PUNCT	O	O	938
induced	VERB	O	O	938
akathisia	PROPN	O	Disease	938
may	AUX	O	O	938
be	AUX	O	O	938
caused	VERB	O	O	938
by	ADP	O	O	938
serotonergically	ADV	O	O	938
mediated	VERB	O	O	938
inhibition	NOUN	O	O	938
of	ADP	O	O	938
dopaminergic	ADJ	O	O	938
neurotransmission	NOUN	O	O	938
and	CCONJ	O	O	938
that	SCONJ	O	O	938
the	PRON	O	O	938
pathophysiology	NOUN	O	O	938
of	ADP	O	O	938
fluoxetine	NOUN	O	Chemical	938
-	PUNCT	O	O	938
induced	VERB	O	O	938
akathisia	PROPN	O	Disease	938
and	CCONJ	O	O	938
tricyclic	ADJ	O	O	938
antidepressant	NOUN	O	O	938
-	PUNCT	O	O	938
induced	VERB	O	O	938
""""	PUNCT	O	O	938
jitteriness	NOUN	O	O	938
""""	PUNCT	O	O	938
may	AUX	O	O	938
be	AUX	O	O	938
identical	ADJ	O	O	938
.	PUNCT	O	O	938
Chronic	NOUN	O	O	941
active	ADJ	O	O	941
hepatitis	NOUN	O	Disease	941
associated	VERB	O	O	941
with	ADP	O	O	941
diclofenac sodium	NOUN	O	Chemical	941
therapy	NOUN	O	O	941
.	PUNCT	O	O	941
Diclofenac	PROPN	O	O	942
sodium	NOUN	O	Chemical	942
(	PUNCT	O	O	942
Voltarol	NOUN	O	O	942
,	PUNCT	O	O	942
Geigy	PROPN	O	O	942
Pharmaceuticals	NOUN	O	O	942
)	PUNCT	O	O	942
is	AUX	O	O	942
a	PRON	O	O	942
non	ADJ	O	O	942
-	PUNCT	O	O	942
steroidal	ADJ	O	O	942
anti	ADJ	O	O	942
-	PUNCT	O	O	942
inflammatory	ADJ	O	O	942
derivative	ADJ	O	O	942
of	ADP	O	O	942
phenylacetic acid	NOUN	O	O	942
.	PUNCT	O	O	942
Although	SCONJ	O	O	943
generally	ADV	O	O	943
well	ADV	O	O	943
-	PUNCT	O	O	943
tolerated	VERB	O	O	943
,	PUNCT	O	O	943
asymptomatic	ADJ	O	O	943
abnormalities	NOUN	O	O	943
of	ADP	O	O	943
liver	NOUN	O	O	943
function	NOUN	O	O	943
have	VERB	O	O	943
been	AUX	O	O	943
recorded	VERB	O	O	943
and	CCONJ	O	O	943
,	PUNCT	O	O	943
less	ADV	O	O	943
commonly	ADV	O	O	943
,	PUNCT	O	O	943
severe	ADJ	O	O	943
hepatitis	NOUN	O	Disease	943
induced	VERB	O	O	943
by	ADP	O	O	943
diclofenac	PROPN	O	Chemical	943
.	PUNCT	O	O	943
The	PRON	O	O	944
patient	NOUN	O	O	944
described	VERB	O	O	944
developed	VERB	O	O	944
chronic	ADJ	O	O	944
active	ADJ	O	O	944
hepatitis	NOUN	O	Disease	944
after	ADP	O	O	944
six	NUM	O	O	944
months	NOUN	O	O	944
therapy	NOUN	O	O	944
with	ADP	O	O	944
diclofenac sodium	NOUN	O	Chemical	944
which	PRON	O	O	944
progressed	VERB	O	O	944
despite	SCONJ	O	O	944
the	PRON	O	O	944
withdrawal	NOUN	O	O	944
of	ADP	O	O	944
the	PRON	O	O	944
drug	NOUN	O	O	944
,	PUNCT	O	O	944
a	PRON	O	O	944
finding	VERB	O	O	944
not	PART	O	O	944
previously	ADV	O	O	944
reported	VERB	O	O	944
.	PUNCT	O	O	944
Stroke	VERB	O	Disease	947
associated	VERB	O	O	947
with	ADP	O	O	947
cocaine	NOUN	O	Chemical	947
use	VERB	O	O	947
.	PUNCT	O	O	947
We	PRON	O	O	948
describe	VERB	O	O	948
eight	NUM	O	O	948
patients	NOUN	O	O	948
in	ADP	O	O	948
whom	PRON	O	O	948
cocaine	NOUN	O	Chemical	948
use	VERB	O	O	948
was	AUX	O	O	948
related	ADJ	O	O	948
to	PART	O	O	948
stroke	VERB	O	Disease	948
and	CCONJ	O	O	948
review	VERB	O	O	948
39	NUM	O	O	948
cases	NOUN	O	O	948
from	ADP	O	O	948
the	PRON	O	O	948
literature	NOUN	O	O	948
.	PUNCT	O	O	948
Stroke	VERB	O	Disease	949
followed	VERB	O	O	949
cocaine	NOUN	O	Chemical	949
use	VERB	O	O	949
by	ADP	O	O	949
inhalation	NOUN	O	O	949
,	PUNCT	O	O	949
intranasal	NOUN	O	O	949
,	PUNCT	O	O	949
intravenous	ADJ	O	O	949
,	PUNCT	O	O	949
and	CCONJ	O	O	949
intramuscular	ADJ	O	O	949
routes	NOUN	O	O	949
.	PUNCT	O	O	949
Intracranial	ADJ	O	O	950
aneurysms	NOUN	O	O	950
or	CCONJ	O	O	950
arteriovenous	ADJ	O	O	950
malformations	NOUN	O	Disease	950
were	AUX	O	O	950
present	NOUN	O	O	950
in	ADP	O	O	950
17	NUM	O	O	950
of	ADP	O	O	950
32	NUM	O	O	950
patients	NOUN	O	O	950
studied	VERB	O	O	950
angiographically	ADV	O	O	950
or	CCONJ	O	O	950
at	ADP	O	O	950
autopsy	ADJ	O	O	950
;	PUNCT	O	O	950
cerebral	ADJ	O	O	950
vasculitis	NOUN	O	Disease	950
was	AUX	O	O	950
present	NOUN	O	O	950
in	ADP	O	O	950
two	NUM	O	O	950
patients	NOUN	O	O	950
.	PUNCT	O	O	950
Cerebral	ADJ	O	O	951
infarction	NOUN	O	O	951
occurred	VERB	O	O	951
in	ADP	O	O	951
10	NUM	O	O	951
patients	NOUN	O	O	951
(	PUNCT	O	O	951
22%	NOUN	O	O	951
)	PUNCT	O	O	951
,	PUNCT	O	O	951
intracerebral hemorrhage	NOUN	O	Disease	951
in	ADP	O	O	951
22	NUM	O	O	951
(	PUNCT	O	O	951
49%	NOUN	O	O	951
)	PUNCT	O	O	951
,	PUNCT	O	O	951
and	CCONJ	O	O	951
subarachnoid hemorrhage	NOUN	O	Disease	951
in	ADP	O	O	951
13	NUM	O	O	951
(	PUNCT	O	O	951
29%	NOUN	O	O	951
)	PUNCT	O	O	951
.	PUNCT	O	O	951
These	PRON	O	O	952
data	NOUN	O	O	952
indicate	VERB	O	O	952
that	SCONJ	O	O	952
(	PUNCT	O	O	952
1	X	O	O	952
)	PUNCT	O	O	952
the	PRON	O	O	952
apparent	ADJ	O	O	952
incidence	NOUN	O	O	952
of	ADP	O	O	952
stroke	VERB	O	Disease	952
related	ADJ	O	O	952
to	PART	O	O	952
cocaine	NOUN	O	Chemical	952
use	VERB	O	O	952
is	AUX	O	O	952
increasing	VERB	O	O	952
;	PUNCT	O	O	952
(	PUNCT	O	O	952
2	X	O	O	952
)	PUNCT	O	O	952
cocaine	NOUN	O	Chemical	952
-	PUNCT	O	O	952
associated	VERB	O	O	952
stroke	VERB	O	Disease	952
occurs	VERB	O	O	952
primarily	ADV	O	O	952
in	ADP	O	O	952
young	ADJ	O	O	952
adults	NOUN	O	O	952
;	PUNCT	O	O	952
(	PUNCT	O	O	952
3	X	O	O	952
)	PUNCT	O	O	952
stroke	VERB	O	Disease	952
may	AUX	O	O	952
follow	VERB	O	O	952
any	PRON	O	O	952
route	VERB	O	O	952
of	ADP	O	O	952
cocaine	NOUN	O	Chemical	952
administration	NOUN	O	O	952
;	PUNCT	O	O	952
(	PUNCT	O	O	952
4	NUM	O	O	952
)	PUNCT	O	O	952
stroke	VERB	O	Disease	952
after	ADP	O	O	952
cocaine	NOUN	O	Chemical	952
use	VERB	O	O	952
is	AUX	O	O	952
frequently	ADV	O	O	952
associated	VERB	O	O	952
with	ADP	O	O	952
intracranial	ADJ	O	O	952
aneurysms	NOUN	O	O	952
and	CCONJ	O	O	952
arteriovenous	ADJ	O	O	952
malformations	NOUN	O	Disease	952
;	PUNCT	O	O	952
and	CCONJ	O	O	952
(	PUNCT	O	O	953
5	NUM	O	O	953
)	PUNCT	O	O	953
in	ADP	O	O	953
cocaine	NOUN	O	Chemical	953
-	PUNCT	O	O	953
associated	VERB	O	O	953
stroke	VERB	O	Disease	953
,	PUNCT	O	O	953
the	PRON	O	O	953
frequency	NOUN	O	O	953
of	ADP	O	O	953
intracranial	ADJ	O	O	953
hemorrhage	NOUN	O	Disease	953
exceeds	VERB	O	O	953
that	SCONJ	O	O	953
of	ADP	O	O	953
cerebral infarction	NOUN	O	Disease	953
.	PUNCT	O	O	953
Glyburide	PROPN	O	O	956
-	PUNCT	O	O	956
induced	VERB	O	O	956
hepatitis	NOUN	O	Disease	956
.	PUNCT	O	O	956
Drug	NOUN	O	O	957
-	PUNCT	O	O	957
induced	VERB	O	O	957
hepatotoxicity	NOUN	O	Disease	957
,	PUNCT	O	O	957
although	SCONJ	O	O	957
common	ADJ	O	O	957
,	PUNCT	O	O	957
has	VERB	O	O	957
been	AUX	O	O	957
reported	VERB	O	O	957
only	ADV	O	O	957
infrequently	ADV	O	O	957
with	ADP	O	O	957
sulfonylureas	VERB	O	O	957
.	PUNCT	O	O	957
For	ADP	O	O	958
glyburide	NOUN	O	O	958
,	PUNCT	O	O	958
a	PRON	O	O	958
second	ADV	O	O	958
-	PUNCT	O	O	958
generation	NOUN	O	O	958
sulfonylurea	NOUN	O	O	958
,	PUNCT	O	O	958
only	ADV	O	O	958
two	NUM	O	O	958
brief	PROPN	O	O	958
reports	VERB	O	O	958
of	ADP	O	O	958
hepatotoxicity	NOUN	O	Disease	958
exist	VERB	O	O	958
.	PUNCT	O	O	958
Two	NUM	O	O	959
patients	NOUN	O	O	959
with	ADP	O	O	959
type	NOUN	O	O	959
II	NUM	O	O	959
diabetes mellitus	ADJ	O	Disease	959
developed	VERB	O	O	959
an	PRON	O	O	959
acute	ADJ	O	O	959
hepatitis	NOUN	O	Disease	959
-	PUNCT	O	O	959
like	INTJ	O	O	959
syndrome	NOUN	O	O	959
soon	ADV	O	O	959
after	ADP	O	O	959
initiation	NOUN	O	O	959
of	ADP	O	O	959
glyburide	NOUN	O	O	959
therapy	NOUN	O	O	959
.	PUNCT	O	O	959
There	ADV	O	O	960
was	AUX	O	O	960
no	PRON	O	O	960
serologic	NOUN	O	O	960
evidence	NOUN	O	O	960
of	ADP	O	O	960
viral	ADJ	O	O	960
infection	NOUN	O	Disease	960
,	PUNCT	O	O	960
and	CCONJ	O	O	960
a	PRON	O	O	960
liver	NOUN	O	O	960
biopsy	PROPN	O	O	960
sample	NOUN	O	O	960
showed	VERB	O	O	960
a	PRON	O	O	960
histologic	ADJ	O	O	960
pattern	NOUN	O	O	960
consistent	ADJ	O	O	960
with	ADP	O	O	960
drug	NOUN	O	O	960
-	PUNCT	O	O	960
induced	VERB	O	O	960
hepatitis	NOUN	O	Disease	960
.	PUNCT	O	O	960
Both	PRON	O	O	961
patients	NOUN	O	O	961
recovered	VERB	O	O	961
quickly	ADV	O	O	961
after	ADP	O	O	961
stopping	VERB	O	O	961
glyburide	NOUN	O	O	961
therapy	NOUN	O	O	961
and	CCONJ	O	O	961
have	VERB	O	O	961
remained	VERB	O	O	961
well	ADV	O	O	961
for	ADP	O	O	961
a	PRON	O	O	961
follow	VERB	O	O	961
-	PUNCT	O	O	961
up	ADP	O	O	961
period	NOUN	O	O	961
of	ADP	O	O	961
1	X	O	O	961
year	NOUN	O	O	961
.	PUNCT	O	O	961
Glyburide	PROPN	O	O	962
can	AUX	O	O	962
produce	VERB	O	O	962
an	PRON	O	O	962
acute	ADJ	O	O	962
hepatitis	NOUN	O	Disease	962
-	PUNCT	O	O	962
like	INTJ	O	O	962
illness	VERB	O	O	962
in	ADP	O	O	962
some	PRON	O	O	962
persons	NOUN	O	O	962
.	PUNCT	O	O	962
Systolic	PROPN	O	O	965
pressure	NOUN	O	O	965
variation	NOUN	O	O	965
is	AUX	O	O	965
greater	ADJ	O	O	965
during	ADP	O	O	965
hemorrhage	NOUN	O	Disease	965
than	ADP	O	O	965
during	ADP	O	O	965
sodium	NOUN	O	Chemical	965
nitroprusside	ADV	O	Chemical	965
-	PUNCT	O	O	965
induced	VERB	O	O	965
hypotension	NOUN	O	Disease	965
in	ADP	O	O	965
ventilated	VERB	O	O	965
dogs	NOUN	O	O	965
.	PUNCT	O	O	965
The	PRON	O	O	966
systolic	ADV	O	O	966
pressure	NOUN	O	O	966
variation	NOUN	O	O	966
(	PUNCT	O	O	966
SPV	NOUN	O	O	966
)	PUNCT	O	O	966
,	PUNCT	O	O	966
which	PRON	O	O	966
is	AUX	O	O	966
the	PRON	O	O	966
difference	NOUN	O	O	966
between	ADP	O	O	966
the	PRON	O	O	966
maximal	ADJ	O	O	966
and	CCONJ	O	O	966
minimal	ADJ	O	O	966
values	NOUN	O	O	966
of	ADP	O	O	966
the	PRON	O	O	966
systolic	ADV	O	O	966
blood	NOUN	O	O	966
pressure	NOUN	O	O	966
(	PUNCT	O	O	966
SBP	NOUN	O	O	966
)	PUNCT	O	O	966
after	ADP	O	O	966
one	NUM	O	O	966
positive	ADJ	O	O	966
-	PUNCT	O	O	966
pressure	NOUN	O	O	966
breath	NOUN	O	O	966
,	PUNCT	O	O	966
was	AUX	O	O	966
studied	VERB	O	O	966
in	ADP	O	O	966
ventilated	VERB	O	O	966
dogs	NOUN	O	O	966
subjected	VERB	O	O	966
to	PART	O	O	966
hypotension	NOUN	O	Disease	966
.	PUNCT	O	O	966
Mean	VERB	O	O	967
arterial	ADJ	O	O	967
pressure	NOUN	O	O	967
was	AUX	O	O	967
decreased	VERB	O	O	967
to	PART	O	O	967
50	NUM	O	O	967
mm	INTJ	O	O	967
Hg	PROPN	O	O	967
for	ADP	O	O	967
30	NUM	O	O	967
minutes	NOUN	O	O	967
either	ADV	O	O	967
by	ADP	O	O	967
hemorrhage	NOUN	O	Disease	967
(	PUNCT	O	O	967
HEM	VERB	O	O	967
,	PUNCT	O	O	967
n	CCONJ	O	O	967
=	PUNCT	O	O	967
7	NUM	O	O	967
)	PUNCT	O	O	967
or	CCONJ	O	O	967
by	ADP	O	O	967
continuous	ADJ	O	O	967
infusion	NOUN	O	O	967
of	ADP	O	O	967
sodium	NOUN	O	Chemical	967
nitroprusside	ADV	O	Chemical	967
(	PUNCT	O	O	967
SNP	PROPN	O	O	967
,	PUNCT	O	O	967
n	CCONJ	O	O	967
=	PUNCT	O	O	967
7	NUM	O	O	967
)	PUNCT	O	O	967
.	PUNCT	O	O	967
During	ADP	O	O	968
HEM	VERB	O	O	968
-	PUNCT	O	O	968
induced	VERB	O	O	968
hypotension	NOUN	O	Disease	968
the	PRON	O	O	968
cardiac	ADJ	O	O	968
output	NOUN	O	O	968
was	AUX	O	O	968
significantly	ADV	O	O	968
lower	ADJ	O	O	968
and	CCONJ	O	O	968
systemic	ADJ	O	O	968
vascular	ADJ	O	O	968
resistance	NOUN	O	O	968
higher	ADJ	O	O	968
compared	VERB	O	O	968
with	ADP	O	O	968
that	SCONJ	O	O	968
in	ADP	O	O	968
the	PRON	O	O	968
SNP	PROPN	O	O	968
group	NOUN	O	O	968
.	PUNCT	O	O	968
The	PRON	O	O	969
SPV	NOUN	O	O	969
during	ADP	O	O	969
hypotension	NOUN	O	Disease	969
was	AUX	O	O	969
15.7	NUM	O	O	969
+	ADP	O	O	969
/-	PUNCT	O	O	969
6.7	NUM	O	O	970
mm	INTJ	O	O	970
Hg	PROPN	O	O	970
in	ADP	O	O	970
the	PRON	O	O	970
HEM	VERB	O	O	970
group	NOUN	O	O	970
,	PUNCT	O	O	970
compared	VERB	O	O	970
with	ADP	O	O	970
9.1	NUM	O	O	970
+	ADP	O	O	970
/-	PUNCT	O	O	970
2.0	NUM	O	O	971
mm	INTJ	O	O	971
Hg	PROPN	O	O	971
in	ADP	O	O	971
the	PRON	O	O	971
SNP	PROPN	O	O	971
group	NOUN	O	O	971
(	PUNCT	O	O	971
P	NOUN	O	Chemical	971
less	ADV	O	O	971
than	ADP	O	O	971
0.02	NUM	O	O	971
)	PUNCT	O	O	971
.	PUNCT	O	O	971
3.8	NUM	O	O	972
mm	INTJ	O	O	972
Hg	PROPN	O	O	972
in	ADP	O	O	972
the	PRON	O	O	972
HEM	VERB	O	O	972
and	CCONJ	O	O	972
SNP	PROPN	O	O	972
groups	NOUN	O	O	972
,	PUNCT	O	O	972
respectively	ADV	O	O	972
,	PUNCT	O	O	972
during	ADP	O	O	972
hypotension	NOUN	O	Disease	972
(	PUNCT	O	O	972
P	NOUN	O	Chemical	972
less	ADV	O	O	972
than	ADP	O	O	972
0.02	NUM	O	O	972
)	PUNCT	O	O	972
.	PUNCT	O	O	972
It	PRON	O	O	973
is	AUX	O	O	973
concluded	VERB	O	O	973
that	SCONJ	O	O	973
increases	VERB	O	O	973
in	ADP	O	O	973
the	PRON	O	O	973
SPV	NOUN	O	O	973
and	CCONJ	O	O	973
the	PRON	O	O	973
delta	PROPN	O	O	973
down	ADP	O	O	973
are	AUX	O	O	973
characteristic	ADJ	O	O	973
of	ADP	O	O	973
a	PRON	O	O	973
hypotensive	ADJ	O	Disease	973
state	NOUN	O	O	973
due	ADJ	O	O	973
to	PART	O	O	973
a	PRON	O	O	973
predominant	ADJ	O	O	973
decrease	VERB	O	O	973
in	ADP	O	O	973
preload	NOUN	O	O	973
.	PUNCT	O	O	973
They	PRON	O	O	974
are	AUX	O	O	974
thus	ADV	O	O	974
more	ADJ	O	O	974
important	ADJ	O	O	974
during	ADP	O	O	974
absolute	ADJ	O	O	974
hypovolemia	NOUN	O	O	974
than	ADP	O	O	974
during	ADP	O	O	974
deliberate	VERB	O	O	974
hypotension	NOUN	O	Disease	974
.	PUNCT	O	O	974
Drug	NOUN	O	O	977
-	PUNCT	O	O	977
induced	VERB	O	O	977
arterial	ADJ	O	O	977
spasm	NOUN	O	Disease	977
relieved	VERB	O	O	977
by	ADP	O	O	977
lidocaine	NOUN	O	Chemical	977
.	PUNCT	O	O	977
Following	VERB	O	O	978
major	ADJ	O	O	978
intracranial	ADJ	O	O	978
surgery	NOUN	O	O	978
in	ADP	O	O	978
a	PRON	O	O	978
35-year	NOUN	O	O	978
-	PUNCT	O	O	978
old	ADJ	O	O	978
man	NOUN	O	O	978
,	PUNCT	O	O	978
sodium	NOUN	O	Chemical	978
pentothal	VERB	O	O	978
was	AUX	O	O	978
intravenously	ADV	O	O	978
infused	VERB	O	O	978
to	PART	O	O	978
minimize	VERB	O	O	978
cerebral	ADJ	O	O	978
ischaemia	NOUN	O	O	978
.	PUNCT	O	O	978
Intense	ADJ	O	O	979
vasospasm	NOUN	O	Disease	979
with	ADP	O	O	979
threatened	VERB	O	O	979
gangrene	VERB	O	Disease	979
arose	VERB	O	O	979
in	ADP	O	O	979
the	PRON	O	O	979
arm	VERB	O	O	979
used	VERB	O	O	979
for	ADP	O	O	979
the	PRON	O	O	979
infusion	NOUN	O	O	979
.	PUNCT	O	O	979
Since	SCONJ	O	O	980
the	PRON	O	O	980
cranial	ADJ	O	O	980
condition	NOUN	O	O	980
precluded	VERB	O	O	980
use	VERB	O	O	980
of	ADP	O	O	980
more	ADJ	O	O	980
usual	ADJ	O	O	980
methods	NOUN	O	O	980
,	PUNCT	O	O	980
lidocaine	NOUN	O	Chemical	980
was	AUX	O	O	980
given	VERB	O	O	980
intra	ADJ	O	O	980
-	PUNCT	O	O	980
arterially	ADV	O	O	980
,	PUNCT	O	O	980
with	ADP	O	O	980
careful	ADJ	O	O	980
cardiovascular	ADJ	O	O	980
monitoring	NOUN	O	O	980
,	PUNCT	O	O	980
to	PART	O	O	980
counteract	VERB	O	O	980
the	PRON	O	O	980
vasospasm	NOUN	O	Disease	980
.	PUNCT	O	O	980
Cerebral	ADJ	O	O	983
blood	NOUN	O	O	983
flow	NOUN	O	O	983
and	CCONJ	O	O	983
metabolism	NOUN	O	O	983
during	ADP	O	O	983
isoflurane	NOUN	O	Chemical	983
-	PUNCT	O	O	983
induced	VERB	O	O	983
hypotension	NOUN	O	Disease	983
in	ADP	O	O	983
patients	NOUN	O	O	983
subjected	VERB	O	O	983
to	PART	O	O	983
surgery	NOUN	O	O	983
for	ADP	O	O	983
cerebral	ADJ	O	O	983
aneurysms	NOUN	O	O	983
.	PUNCT	O	O	983
Cerebral	ADJ	O	O	984
blood	NOUN	O	O	984
flow	NOUN	O	O	984
and	CCONJ	O	O	984
cerebral	ADJ	O	O	984
metabolic	ADJ	O	O	984
rate	NOUN	O	O	984
for	ADP	O	O	984
oxygen	NOUN	O	Chemical	984
were	AUX	O	O	984
measured	VERB	O	O	984
during	ADP	O	O	984
isoflurane	NOUN	O	Chemical	984
-	PUNCT	O	O	984
induced	VERB	O	O	984
hypotension	NOUN	O	Disease	984
in	ADP	O	O	984
10	NUM	O	O	984
patients	NOUN	O	O	984
subjected	VERB	O	O	984
to	PART	O	O	984
craniotomy	NOUN	O	O	984
for	ADP	O	O	984
clipping	VERB	O	O	984
of	ADP	O	O	984
a	PRON	O	O	984
cerebral	ADJ	O	O	984
aneurysm	PROPN	O	O	984
.	PUNCT	O	O	984
Flow	NOUN	O	O	985
and	CCONJ	O	O	985
metabolism	NOUN	O	O	985
were	AUX	O	O	985
measured	VERB	O	O	985
5	NUM	O	O	985
-	PUNCT	O	O	985
13	NUM	O	O	985
days	NOUN	O	O	985
after	ADP	O	O	985
the	PRON	O	O	985
subarachnoid haemorrhage	NOUN	O	Disease	985
by	ADP	O	O	985
a	PRON	O	O	985
modification	NOUN	O	O	985
of	ADP	O	O	985
the	PRON	O	O	985
classical	ADJ	O	O	985
Kety	NOUN	O	O	985
-	PUNCT	O	O	985
Schmidt	PROPN	O	O	985
technique	NOUN	O	O	985
using	VERB	O	O	985
xenon-133	VERB	O	O	985
i.v	NOUN	O	O	985
.	PUNCT	O	O	985
Anaesthesia	NOUN	O	O	986
was	AUX	O	O	986
maintained	VERB	O	O	986
with	ADP	O	O	986
an	PRON	O	O	986
inspired	VERB	O	O	986
isoflurane	NOUN	O	Chemical	986
concentration	NOUN	O	O	986
of	ADP	O	O	986
0.75%	NOUN	O	O	986
(	PUNCT	O	O	986
plus	CCONJ	O	O	986
67%	NOUN	O	O	986
nitrous oxide	NOUN	O	Chemical	986
in	ADP	O	O	986
oxygen	NOUN	O	Chemical	986
)	PUNCT	O	O	986
,	PUNCT	O	O	986
during	ADP	O	O	986
which	PRON	O	O	986
CBF	PROPN	O	O	986
and	CCONJ	O	O	986
CMRO2	NOUN	O	O	986
were	AUX	O	O	986
34.3	NUM	O	O	986
+	ADP	O	O	986
/-	PUNCT	O	O	986
Controlled	VERB	O	O	987
hypotension	NOUN	O	Disease	987
to	PART	O	O	987
an	PRON	O	O	987
average	ADJ	O	O	987
MAP	PROPN	O	O	987
of	ADP	O	O	987
50	NUM	O	O	987
-	PUNCT	O	O	987
55	NUM	O	O	987
mm	INTJ	O	O	987
Hg	PROPN	O	O	987
was	AUX	O	O	987
induced	VERB	O	O	987
by	ADP	O	O	987
increasing	VERB	O	O	987
the	PRON	O	O	987
dose	NOUN	O	O	987
of	ADP	O	O	987
isoflurane	NOUN	O	Chemical	987
,	PUNCT	O	O	987
and	CCONJ	O	O	987
maintained	VERB	O	O	987
at	ADP	O	O	987
an	PRON	O	O	987
inspired	VERB	O	O	987
concentration	NOUN	O	O	987
of	ADP	O	O	987
2.2	NUM	O	O	987
+	ADP	O	O	987
/-	PUNCT	O	O	987
After	ADP	O	O	988
the	PRON	O	O	988
clipping	VERB	O	O	988
of	ADP	O	O	988
the	PRON	O	O	988
aneurysm	PROPN	O	O	988
the	PRON	O	O	988
isoflurane	NOUN	O	Chemical	988
concentration	NOUN	O	O	988
was	AUX	O	O	988
reduced	VERB	O	O	988
to	PART	O	O	988
0.75%	NOUN	O	O	988
.	PUNCT	O	O	988
There	ADV	O	O	989
was	AUX	O	O	989
a	PRON	O	O	989
significant	ADJ	O	O	989
increase	VERB	O	O	989
in	ADP	O	O	989
CBF	PROPN	O	O	989
,	PUNCT	O	O	989
although	SCONJ	O	O	989
CMRO2	NOUN	O	O	989
was	AUX	O	O	989
unchanged	ADJ	O	O	989
,	PUNCT	O	O	989
compared	VERB	O	O	989
with	ADP	O	O	989
pre	VERB	O	O	989
-	PUNCT	O	O	989
hypotensive	ADJ	O	Disease	989
values	NOUN	O	O	989
.	PUNCT	O	O	989
These	PRON	O	O	990
changes	VERB	O	O	990
might	AUX	O	O	990
offer	VERB	O	O	990
protection	NOUN	O	O	990
to	PART	O	O	990
brain	NOUN	O	O	990
tissue	NOUN	O	O	990
during	ADP	O	O	990
periods	NOUN	O	O	990
of	ADP	O	O	990
induced	VERB	O	O	990
hypotension	NOUN	O	Disease	990
.	PUNCT	O	O	990
Allergic	ADJ	O	O	993
reaction	NOUN	O	O	993
to	PART	O	O	993
5-fluorouracil	NOUN	O	Chemical	993
infusion	NOUN	O	O	993
.	PUNCT	O	O	993
An	PRON	O	O	994
allergic	ADJ	O	O	994
reaction	NOUN	O	O	994
consisting	VERB	O	O	994
of	ADP	O	O	994
angioneurotic edema	NOUN	O	Disease	994
secondary	ADJ	O	O	994
to	PART	O	O	994
continuous	ADJ	O	O	994
infusion	NOUN	O	O	994
5-fluorouracil	NOUN	O	Chemical	994
occurred	VERB	O	O	994
in	ADP	O	O	994
a	PRON	O	O	994
patient	NOUN	O	O	994
with	ADP	O	O	994
recurrent	ADJ	O	O	994
carcinoma	NOUN	O	Disease	994
of	ADP	O	O	994
the	PRON	O	O	994
oral	ADJ	O	O	994
cavity	NOUN	O	O	994
,	PUNCT	O	O	994
cirrhosis	NOUN	O	Disease	994
,	PUNCT	O	O	994
and	CCONJ	O	O	994
cisplatin	NOUN	O	Chemical	994
-	PUNCT	O	O	994
induced	VERB	O	O	994
impaired renal function	NOUN	O	Disease	994
.	PUNCT	O	O	994
Oral	NOUN	O	O	995
diphenhydramine	NOUN	O	O	995
and	CCONJ	O	O	995
prednisone	NOUN	O	Chemical	995
were	AUX	O	O	995
ineffective	ADJ	O	O	995
in	ADP	O	O	995
preventing	VERB	O	O	995
the	PRON	O	O	995
recurrence	NOUN	O	O	995
of	ADP	O	O	995
the	PRON	O	O	995
allergic	ADJ	O	O	995
reaction	NOUN	O	O	995
.	PUNCT	O	O	995
Amiodarone	NOUN	O	Chemical	998
-	PUNCT	O	O	998
induced	VERB	O	O	998
sinoatrial	NOUN	O	O	998
block	NOUN	O	O	998
.	PUNCT	O	O	998
We	PRON	O	O	999
observed	VERB	O	O	999
sinoatrial	NOUN	O	O	999
block	NOUN	O	O	999
due	ADJ	O	O	999
to	PART	O	O	999
chronic	ADJ	O	O	999
amiodarone	NOUN	O	Chemical	999
administration	NOUN	O	O	999
in	ADP	O	O	999
a	PRON	O	O	999
5-year	NOUN	O	O	999
-	PUNCT	O	O	999
old	ADJ	O	O	999
boy	NOUN	O	O	999
with	ADP	O	O	999
primary	NOUN	O	O	999
cardiomyopathy	ADJ	O	Disease	999
,	PUNCT	O	O	999
Wolff	NOUN	O	O	999
-	PUNCT	O	O	999
Parkinson	NOUN	O	O	999
-	PUNCT	O	O	999
White	ADJ	O	O	999
syndrome	NOUN	O	O	999
and	CCONJ	O	O	999
supraventricular tachycardia	NOUN	O	O	999
.	PUNCT	O	O	999
Reduction	NOUN	O	O	1000
in	ADP	O	O	1000
the	PRON	O	O	1000
dosage	NOUN	O	O	1000
of	ADP	O	O	1000
amiodarone	NOUN	O	Chemical	1000
resulted	VERB	O	O	1000
in	ADP	O	O	1000
the	PRON	O	O	1000
disappearance	NOUN	O	O	1000
of	ADP	O	O	1000
the	PRON	O	O	1000
sinoatrial	NOUN	O	O	1000
block	NOUN	O	O	1000
and	CCONJ	O	O	1000
the	PRON	O	O	1000
persistence	NOUN	O	O	1000
of	ADP	O	O	1000
asymptomatic	ADJ	O	O	1000
sinus	NOUN	O	O	1000
bradycardia	NOUN	O	Disease	1000
.	PUNCT	O	O	1000
Possible	ADJ	O	O	1003
teratogenicity	NOUN	O	O	1003
of	ADP	O	O	1003
sulphasalazine	VERB	O	Chemical	1003
.	PUNCT	O	O	1003
Three	NUM	O	O	1004
infants	NOUN	O	O	1004
,	PUNCT	O	O	1004
born	VERB	O	O	1004
of	ADP	O	O	1004
two	NUM	O	O	1004
mothers	NOUN	O	O	1004
with	ADP	O	O	1004
inflammatory	ADJ	O	O	1004
bowel	ADJ	O	O	1004
disease	PROPN	O	O	1004
who	PRON	O	O	1004
received	VERB	O	O	1004
treatment	NOUN	O	O	1004
with	ADP	O	O	1004
sulphasalazine	VERB	O	Chemical	1004
throughout	ADP	O	O	1004
pregnancy	NOUN	O	O	1004
,	PUNCT	O	O	1004
were	AUX	O	O	1004
found	VERB	O	O	1004
to	PART	O	O	1004
have	VERB	O	O	1004
major	ADJ	O	O	1004
congenital	NOUN	O	O	1004
anomalies	NOUN	O	O	1004
.	PUNCT	O	O	1004
In	ADP	O	O	1005
the	PRON	O	O	1005
singleton	PROPN	O	O	1005
pregnancy	NOUN	O	O	1005
,	PUNCT	O	O	1005
the	PRON	O	O	1005
mother	NOUN	O	O	1005
had	VERB	O	O	1005
ulcerative colitis	NOUN	O	Disease	1005
,	PUNCT	O	O	1005
and	CCONJ	O	O	1005
the	PRON	O	O	1005
infant	NOUN	O	O	1005
,	PUNCT	O	O	1005
a	PRON	O	O	1005
male	NOUN	O	O	1005
,	PUNCT	O	O	1005
had	VERB	O	O	1005
coarctation	NOUN	O	O	1005
of	ADP	O	O	1005
the	PRON	O	O	1005
aorta	NOUN	O	O	1005
and	CCONJ	O	O	1005
a	PRON	O	O	1005
ventricular septal defect	NOUN	O	Disease	1005
.	PUNCT	O	O	1005
In	ADP	O	O	1006
the	PRON	O	O	1006
twin	ADJ	O	O	1006
pregnancy	NOUN	O	O	1006
,	PUNCT	O	O	1006
the	PRON	O	O	1006
mother	NOUN	O	O	1006
had	VERB	O	O	1006
Crohn	PROPN	O	O	1006
's	AUX	O	O	1006
disease	PROPN	O	O	1006
.	PUNCT	O	O	1006
The	PRON	O	O	1007
first	ADV	O	O	1007
twin	ADJ	O	O	1007
,	PUNCT	O	O	1007
a	PRON	O	O	1007
female	ADJ	O	O	1007
,	PUNCT	O	O	1007
had	VERB	O	O	1007
a	PRON	O	O	1007
left	VERB	O	O	1007
Potter	NOUN	O	O	1007
-	PUNCT	O	O	1007
type	NOUN	O	O	1007
IIa	NOUN	O	O	1007
polycystic	NOUN	O	O	1007
kidney	NOUN	O	O	1007
and	CCONJ	O	O	1007
a	PRON	O	O	1007
rudimentary	ADJ	O	O	1007
left	VERB	O	O	1007
uterine	ADJ	O	O	1007
cornu	NOUN	O	O	1007
.	PUNCT	O	O	1007
The	PRON	O	O	1008
second	ADV	O	O	1008
twin	ADJ	O	O	1008
,	PUNCT	O	O	1008
a	PRON	O	O	1008
male	NOUN	O	O	1008
,	PUNCT	O	O	1008
had	VERB	O	O	1008
some	PRON	O	O	1008
features	VERB	O	O	1008
of	ADP	O	O	1008
Potter	NOUN	O	O	1008
's	AUX	O	O	1008
facies	NOUN	O	O	1008
,	PUNCT	O	O	1008
hypoplastic	ADJ	O	O	1008
lungs	VERB	O	O	1008
,	PUNCT	O	O	1008
absent	ADJ	O	O	1008
kidneys	NOUN	O	O	1008
and	CCONJ	O	O	1008
ureters	NOUN	O	O	1008
,	PUNCT	O	O	1008
and	CCONJ	O	O	1008
talipes	NOUN	O	O	1008
equinovarus	PROPN	O	O	1008
.	PUNCT	O	O	1008
Despite	SCONJ	O	O	1009
reports	VERB	O	O	1009
to	PART	O	O	1009
the	PRON	O	O	1009
contrary	ADV	O	O	1009
,	PUNCT	O	O	1009
it	PRON	O	O	1009
is	AUX	O	O	1009
suggested	VERB	O	O	1009
that	SCONJ	O	O	1009
sulphasalazine	VERB	O	Chemical	1009
may	AUX	O	O	1009
be	AUX	O	O	1009
teratogenic	ADJ	O	O	1009
.	PUNCT	O	O	1009
Veno	PROPN	O	O	1012
-	PUNCT	O	O	1012
occlusive	ADJ	O	O	1012
liver disease	NOUN	O	Disease	1012
after	ADP	O	O	1012
dacarbazine	NOUN	O	O	1012
therapy	NOUN	O	O	1012
(	PUNCT	O	O	1012
DTIC	PROPN	O	O	1012
)	PUNCT	O	O	1012
for	ADP	O	O	1012
melanoma	NOUN	O	O	1012
.	PUNCT	O	O	1012
A	PRON	O	O	1013
case	NOUN	O	O	1013
of	ADP	O	O	1013
veno	VERB	O	O	1013
-	PUNCT	O	O	1013
occlusive	ADJ	O	O	1013
disease	PROPN	O	O	1013
of	ADP	O	O	1013
the	PRON	O	O	1013
liver	NOUN	O	O	1013
with	ADP	O	O	1013
fatal	ADJ	O	O	1013
outcome	NOUN	O	O	1013
after	ADP	O	O	1013
dacarbazine	NOUN	O	O	1013
(	PUNCT	O	O	1013
DTIC	PROPN	O	O	1013
)	PUNCT	O	O	1013
therapy	NOUN	O	O	1013
for	ADP	O	O	1013
melanoma	NOUN	O	O	1013
is	AUX	O	O	1013
reported	VERB	O	O	1013
.	PUNCT	O	O	1013
There	ADV	O	O	1014
was	AUX	O	O	1014
a	PRON	O	O	1014
fulminant	ADJ	O	O	1014
clinical	ADJ	O	O	1014
course	NOUN	O	O	1014
from	ADP	O	O	1014
start	VERB	O	O	1014
of	ADP	O	O	1014
symptoms	NOUN	O	O	1014
until	ADP	O	O	1014
death	NOUN	O	O	1014
.	PUNCT	O	O	1014
At	ADP	O	O	1015
autopsy	ADJ	O	O	1015
the	PRON	O	O	1015
liver	NOUN	O	O	1015
was	AUX	O	O	1015
enlarged	VERB	O	O	1015
and	CCONJ	O	O	1015
firm	NOUN	O	O	1015
with	ADP	O	O	1015
signs	NOUN	O	O	1015
of	ADP	O	O	1015
venous	ADJ	O	O	1015
congestion	NOUN	O	O	1015
.	PUNCT	O	O	1015
Small-	PROPN	O	O	1016
and	CCONJ	O	O	1016
medium	ADJ	O	O	1016
-	PUNCT	O	O	1016
sized	ADJ	O	O	1016
hepatic	ADJ	O	O	1016
veins	NOUN	O	O	1016
were	AUX	O	O	1016
blocked	VERB	O	O	1016
by	ADP	O	O	1016
thrombosis	NOUN	O	Disease	1016
.	PUNCT	O	O	1016
A	PRON	O	O	1019
case	NOUN	O	O	1019
of	ADP	O	O	1019
tardive dyskinesia	NOUN	O	Disease	1019
caused	VERB	O	O	1019
by	ADP	O	O	1019
metoclopramide	NOUN	O	Chemical	1019
.	PUNCT	O	O	1019
Abnormal	ADJ	O	O	1020
involuntary movements	NOUN	O	Disease	1020
appeared	VERB	O	O	1020
in	ADP	O	O	1020
the	PRON	O	O	1020
mouth	PROPN	O	O	1020
,	PUNCT	O	O	1020
tongue	NOUN	O	O	1020
,	PUNCT	O	O	1020
neck	NOUN	O	O	1020
and	CCONJ	O	O	1020
abdomen	PROPN	O	O	1020
of	ADP	O	O	1020
a	PRON	O	O	1020
64-year	NOUN	O	O	1020
-	PUNCT	O	O	1020
old	ADJ	O	O	1020
male	NOUN	O	O	1020
patient	NOUN	O	O	1020
after	ADP	O	O	1020
he	PRON	O	O	1020
took	VERB	O	O	1020
metoclopramide	NOUN	O	Chemical	1020
for	ADP	O	O	1020
gastrointestinal	ADJ	O	O	1020
disorder	NOUN	O	O	1020
in	ADP	O	O	1020
a	PRON	O	O	1020
regimen	NOUN	O	O	1020
of	ADP	O	O	1020
30	NUM	O	O	1020
mg	VERB	O	O	1020
per	ADP	O	O	1020
day	NOUN	O	O	1020
for	ADP	O	O	1020
a	PRON	O	O	1020
total	ADJ	O	O	1020
of	ADP	O	O	1020
about	ADP	O	O	1020
260	NUM	O	O	1020
days	NOUN	O	O	1020
.	PUNCT	O	O	1020
When	SCONJ	O	O	1021
the	PRON	O	O	1021
metoclopramide	NOUN	O	Chemical	1021
administration	NOUN	O	O	1021
was	AUX	O	O	1021
discontinued	VERB	O	O	1021
,	PUNCT	O	O	1021
the	PRON	O	O	1021
abnormal movements	NOUN	O	Disease	1021
gradually	ADV	O	O	1021
improved	VERB	O	O	1021
to	PART	O	O	1021
a	PRON	O	O	1021
considerable	ADJ	O	O	1021
extent	NOUN	O	O	1021
.	PUNCT	O	O	1021
Attention	NOUN	O	O	1022
to	PART	O	O	1022
the	PRON	O	O	1022
possible	ADJ	O	O	1022
induction	NOUN	O	O	1022
of	ADP	O	O	1022
specific	ADJ	O	O	1022
tardive dyskinesia	NOUN	O	Disease	1022
is	AUX	O	O	1022
called	VERB	O	O	1022
for	ADP	O	O	1022
in	ADP	O	O	1022
the	PRON	O	O	1022
use	VERB	O	O	1022
of	ADP	O	O	1022
this	PRON	O	O	1022
drug	NOUN	O	O	1022
.	PUNCT	O	O	1022
Further	ADV	O	O	1025
observations	NOUN	O	O	1025
on	ADP	O	O	1025
the	PRON	O	O	1025
electrophysiologic	VERB	O	O	1025
effects	NOUN	O	O	1025
of	ADP	O	O	1025
oral	ADJ	O	O	1025
amiodarone	NOUN	O	Chemical	1025
therapy	NOUN	O	O	1025
.	PUNCT	O	O	1025
A	PRON	O	O	1026
case	NOUN	O	O	1026
is	AUX	O	O	1026
presented	VERB	O	O	1026
of	ADP	O	O	1026
a	PRON	O	O	1026
reversible	ADJ	O	O	1026
intra	ADJ	O	O	1026
-	PUNCT	O	O	1026
Hisian	PROPN	O	O	1026
block	NOUN	O	O	1026
occurring	VERB	O	O	1026
under	ADP	O	O	1026
amiodarone	NOUN	O	Chemical	1026
treatment	NOUN	O	O	1026
for	ADP	O	O	1026
atrial	ADJ	O	O	1026
tachycardia	PROPN	O	Disease	1026
in	ADP	O	O	1026
a	PRON	O	O	1026
patient	NOUN	O	O	1026
without	ADP	O	O	1026
clear	ADJ	O	O	1026
intraventricular	PROPN	O	O	1026
conduction	NOUN	O	O	1026
abnormalities	NOUN	O	O	1026
.	PUNCT	O	O	1026
His	PRON	O	O	1027
bundle	VERB	O	O	1027
recordings	NOUN	O	O	1027
showed	VERB	O	O	1027
an	PRON	O	O	1027
atrial	ADJ	O	O	1027
tachycardia	PROPN	O	Disease	1027
with	ADP	O	O	1027
intermittent	ADJ	O	O	1027
exit	NOUN	O	O	1027
block	NOUN	O	O	1027
and	CCONJ	O	O	1027
greatly	ADV	O	O	1027
prolonged	VERB	O	O	1027
BH	NOUN	O	O	1027
and	CCONJ	O	O	1027
HV	PROPN	O	O	1027
intervals	NOUN	O	O	1027
(	PUNCT	O	O	1027
40	NUM	O	O	1027
and	CCONJ	O	O	1027
100	NUM	O	O	1027
msec	PROPN	O	O	1027
,	PUNCT	O	O	1027
respectively	ADV	O	O	1027
)	PUNCT	O	O	1027
.	PUNCT	O	O	1027
Thirty	NUM	O	O	1028
days	NOUN	O	O	1028
after	ADP	O	O	1028
amiodarone	NOUN	O	Chemical	1028
discontinuation	NOUN	O	O	1028
,	PUNCT	O	O	1028
His	PRON	O	O	1028
bundle	VERB	O	O	1028
electrograms	NOUN	O	O	1028
showed	VERB	O	O	1028
atrial flutter	NOUN	O	Disease	1028
without	ADP	O	O	1028
intra	ADJ	O	O	1028
-	PUNCT	O	O	1028
Hisian	PROPN	O	O	1028
or	CCONJ	O	O	1028
infra	NOUN	O	O	1028
-	PUNCT	O	O	1028
Hisian	PROPN	O	O	1028
delay	NOUN	O	O	1028
.	PUNCT	O	O	1028
Amiodarone	NOUN	O	Chemical	1029
should	AUX	O	O	1029
be	AUX	O	O	1029
used	VERB	O	O	1029
with	ADP	O	O	1029
caution	NOUN	O	O	1029
during	ADP	O	O	1029
long	ADV	O	O	1029
-	PUNCT	O	O	1029
term	NOUN	O	O	1029
oral	ADJ	O	O	1029
therapy	NOUN	O	O	1029
in	ADP	O	O	1029
patients	NOUN	O	O	1029
with	ADP	O	O	1029
or	CCONJ	O	O	1029
without	ADP	O	O	1029
clear	ADJ	O	O	1029
intraventricular	PROPN	O	O	1029
conduction	NOUN	O	O	1029
defects	NOUN	O	O	1029
.	PUNCT	O	O	1029
Busulfan	PROPN	O	O	1032
-	PUNCT	O	O	1032
induced	VERB	O	O	1032
hemorrhagic cystitis	NOUN	O	Disease	1032
.	PUNCT	O	O	1032
A	PRON	O	O	1033
case	NOUN	O	O	1033
of	ADP	O	O	1033
a	PRON	O	O	1033
busulfan	VERB	O	O	1033
-	PUNCT	O	O	1033
induced	VERB	O	O	1033
hemorrhage	NOUN	O	Disease	1033
cystitis	NOUN	O	Disease	1033
is	AUX	O	O	1033
reported	VERB	O	O	1033
.	PUNCT	O	O	1033
The	PRON	O	O	1034
similarity	NOUN	O	O	1034
between	ADP	O	O	1034
the	PRON	O	O	1034
histologic	ADJ	O	O	1034
appearances	NOUN	O	O	1034
of	ADP	O	O	1034
busulfan	VERB	O	O	1034
cystitis	NOUN	O	Disease	1034
and	CCONJ	O	O	1034
both	PRON	O	O	1034
radiation	NOUN	O	O	1034
and	CCONJ	O	O	1034
cyclophosphamide	VERB	O	Chemical	1034
-	PUNCT	O	O	1034
induced	VERB	O	O	1034
cystitis	NOUN	O	Disease	1034
is	AUX	O	O	1034
discussed	VERB	O	O	1034
and	CCONJ	O	O	1034
the	PRON	O	O	1034
world	NOUN	O	O	1034
literature	NOUN	O	O	1034
reviewed	VERB	O	O	1034
.	PUNCT	O	O	1034
In	ADP	O	O	1035
view	VERB	O	O	1035
of	ADP	O	O	1035
the	PRON	O	O	1035
known	VERB	O	O	1035
tendency	NOUN	O	O	1035
of	ADP	O	O	1035
busulfan	VERB	O	O	1035
to	PART	O	O	1035
induce	VERB	O	O	1035
cellular	NOUN	O	O	1035
atypia	PROPN	O	O	1035
and	CCONJ	O	O	1035
carcinoma	NOUN	O	Disease	1035
in	ADP	O	O	1035
other	ADJ	O	O	1035
sites	NOUN	O	O	1035
,	PUNCT	O	O	1035
periodic	ADJ	O	O	1035
urinary	ADJ	O	O	1035
cytology	NOUN	O	O	1035
is	AUX	O	O	1035
suggested	VERB	O	O	1035
in	ADP	O	O	1035
patients	NOUN	O	O	1035
on	ADP	O	O	1035
long	ADV	O	O	1035
-	PUNCT	O	O	1035
term	NOUN	O	O	1035
therapy	NOUN	O	O	1035
.	PUNCT	O	O	1035
Rebound	VERB	O	O	1038
hypertensive	ADJ	O	Disease	1038
after	ADP	O	O	1038
sodium	NOUN	O	Chemical	1038
nitroprusside	ADV	O	Chemical	1038
prevented	VERB	O	O	1038
by	ADP	O	O	1038
saralasin	PROPN	O	O	1038
in	ADP	O	O	1038
rats	NOUN	O	O	1038
.	PUNCT	O	O	1038
The	PRON	O	O	1039
role	NOUN	O	O	1039
of	ADP	O	O	1039
the	PRON	O	O	1039
renin	PROPN	O	O	1039
--	PUNCT	O	O	1039
angiotensin	NOUN	O	Chemical	1039
system	NOUN	O	O	1039
in	ADP	O	O	1039
the	PRON	O	O	1039
maintenance	NOUN	O	O	1039
of	ADP	O	O	1039
blood	NOUN	O	O	1039
pressure	NOUN	O	O	1039
during	ADP	O	O	1039
halothane	VERB	O	Chemical	1039
anesthesia	NOUN	O	O	1039
and	CCONJ	O	O	1039
sodium	NOUN	O	Chemical	1039
nitroprusside	ADV	O	Chemical	1039
(	PUNCT	O	O	1039
SNP)-induced	ADJ	O	O	1039
hypotension	NOUN	O	Disease	1039
was	AUX	O	O	1039
evaluated	VERB	O	O	1039
.	PUNCT	O	O	1039
Control	NOUN	O	O	1040
rats	NOUN	O	O	1040
received	VERB	O	O	1040
halothane	VERB	O	Chemical	1040
anesthesia	NOUN	O	O	1040
(	PUNCT	O	O	1040
1	X	O	O	1040
MAC	PROPN	O	O	1040
)	PUNCT	O	O	1040
for	ADP	O	O	1040
one	NUM	O	O	1040
hour	NOUN	O	O	1040
,	PUNCT	O	O	1040
followed	VERB	O	O	1040
by	ADP	O	O	1040
SNP	PROPN	O	O	1040
infusion	NOUN	O	O	1040
,	PUNCT	O	O	1040
40	NUM	O	O	1040
microgram	PROPN	O	O	1040
/	PUNCT	O	O	1040
kg	VERB	O	O	1040
/	PUNCT	O	O	1040
min	NOUN	O	O	1040
,	PUNCT	O	O	1040
for	ADP	O	O	1040
30	NUM	O	O	1040
min	NOUN	O	O	1040
,	PUNCT	O	O	1040
followed	VERB	O	O	1040
by	ADP	O	O	1040
a	PRON	O	O	1040
30-min	NOUN	O	O	1040
recovery	NOUN	O	O	1040
period	NOUN	O	O	1040
.	PUNCT	O	O	1040
A	PRON	O	O	1041
second	ADV	O	O	1041
group	NOUN	O	O	1041
of	ADP	O	O	1041
rats	NOUN	O	O	1041
was	AUX	O	O	1041
treated	VERB	O	O	1041
identically	ADV	O	O	1041
and	CCONJ	O	O	1041
,	PUNCT	O	O	1041
in	ADP	O	O	1041
addition	NOUN	O	O	1041
,	PUNCT	O	O	1041
received	VERB	O	O	1041
an	PRON	O	O	1041
infusion	NOUN	O	O	1041
of	ADP	O	O	1041
saralasin	PROPN	O	O	1041
(	PUNCT	O	O	1041
a	PRON	O	O	1041
competitive	ADJ	O	O	1041
inhibitor	NOUN	O	O	1041
of	ADP	O	O	1041
angiotensin II	PROPN	O	Chemical	1041
)	PUNCT	O	O	1041
throughout	ADP	O	O	1041
the	PRON	O	O	1041
experimental	ADJ	O	O	1041
period	NOUN	O	O	1041
.	PUNCT	O	O	1041
In	ADP	O	O	1042
each	PRON	O	O	1042
group	NOUN	O	O	1042
,	PUNCT	O	O	1042
SNP	PROPN	O	O	1042
infusion	NOUN	O	O	1042
resulted	VERB	O	O	1042
in	ADP	O	O	1042
an	PRON	O	O	1042
initial	ADJ	O	O	1042
decrease	VERB	O	O	1042
in	ADP	O	O	1042
blood	NOUN	O	O	1042
pressure	NOUN	O	O	1042
from	ADP	O	O	1042
86	NUM	O	O	1042
torr	PROPN	O	O	1042
and	CCONJ	O	O	1042
83	NUM	O	O	1042
torr	PROPN	O	O	1042
,	PUNCT	O	O	1042
respectively	ADV	O	O	1042
,	PUNCT	O	O	1042
to	PART	O	O	1042
48	NUM	O	O	1042
torr	PROPN	O	O	1042
.	PUNCT	O	O	1042
During	ADP	O	O	1043
the	PRON	O	O	1043
SNP	PROPN	O	O	1043
infusion	NOUN	O	O	1043
the	PRON	O	O	1043
control	VERB	O	O	1043
animals	NOUN	O	O	1043
demonstrated	VERB	O	O	1043
a	PRON	O	O	1043
progressive	ADJ	O	O	1043
increase	VERB	O	O	1043
in	ADP	O	O	1043
blood	NOUN	O	O	1043
pressure	NOUN	O	O	1043
to	PART	O	O	1043
61	NUM	O	O	1043
torr	PROPN	O	O	1043
,	PUNCT	O	O	1043
whereas	SCONJ	O	O	1043
the	PRON	O	O	1043
saralasin	PROPN	O	O	1043
-	PUNCT	O	O	1043
treated	VERB	O	O	1043
animals	NOUN	O	O	1043
showed	VERB	O	O	1043
no	PRON	O	O	1043
change	VERB	O	O	1043
.	PUNCT	O	O	1043
Following	VERB	O	O	1044
discontinuation	NOUN	O	O	1044
of	ADP	O	O	1044
SNP	PROPN	O	O	1044
,	PUNCT	O	O	1044
blood	NOUN	O	O	1044
pressure	NOUN	O	O	1044
in	ADP	O	O	1044
the	PRON	O	O	1044
control	VERB	O	O	1044
animals	NOUN	O	O	1044
rebounded	VERB	O	O	1044
to	PART	O	O	1044
94	NUM	O	O	1044
torr	PROPN	O	O	1044
,	PUNCT	O	O	1044
as	ADP	O	O	1044
compared	VERB	O	O	1044
with	ADP	O	O	1044
78	NUM	O	O	1044
torr	PROPN	O	O	1044
in	ADP	O	O	1044
the	PRON	O	O	1044
saralasin	PROPN	O	O	1044
-	PUNCT	O	O	1044
treated	VERB	O	O	1044
rats	NOUN	O	O	1044
.	PUNCT	O	O	1044
This	PRON	O	O	1045
study	VERB	O	O	1045
indicates	VERB	O	O	1045
that	SCONJ	O	O	1045
with	ADP	O	O	1045
stable	ADJ	O	O	1045
halothane	VERB	O	Chemical	1045
anesthesia	NOUN	O	O	1045
,	PUNCT	O	O	1045
the	PRON	O	O	1045
partial	ADJ	O	O	1045
recovery	NOUN	O	O	1045
of	ADP	O	O	1045
blood	NOUN	O	O	1045
pressure	NOUN	O	O	1045
during	ADP	O	O	1045
SNP	PROPN	O	O	1045
infusion	NOUN	O	O	1045
and	CCONJ	O	O	1045
the	PRON	O	O	1045
post	VERB	O	O	1045
-	PUNCT	O	O	1045
SNP	PROPN	O	O	1045
rebound	VERB	O	O	1045
of	ADP	O	O	1045
blood	NOUN	O	O	1045
pressure	NOUN	O	O	1045
can	AUX	O	O	1045
be	AUX	O	O	1045
completely	ADV	O	O	1045
blocked	VERB	O	O	1045
by	ADP	O	O	1045
saralasin	PROPN	O	O	1045
.	PUNCT	O	O	1045
This	PRON	O	O	1046
demonstrates	VERB	O	O	1046
the	PRON	O	O	1046
participation	NOUN	O	O	1046
of	ADP	O	O	1046
the	PRON	O	O	1046
renin	PROPN	O	O	1046
--	PUNCT	O	O	1046
angiotensin	NOUN	O	Chemical	1046
system	NOUN	O	O	1046
in	ADP	O	O	1046
antagonizing	VERB	O	O	1046
the	PRON	O	O	1046
combined	VERB	O	O	1046
hypotensive	ADJ	O	Disease	1046
effects	NOUN	O	O	1046
of	ADP	O	O	1046
halothane	VERB	O	Chemical	1046
and	CCONJ	O	O	1046
SNP	PROPN	O	O	1046
.	PUNCT	O	O	1046
Toxic	ADJ	O	O	1049
hepatitis	NOUN	O	Disease	1049
induced	VERB	O	O	1049
by	ADP	O	O	1049
antithyroid	ADJ	O	O	1049
drugs	NOUN	O	O	1049
:	PUNCT	O	O	1049
four	NUM	O	O	1049
cases	NOUN	O	O	1049
including	VERB	O	O	1049
one	NUM	O	O	1049
with	ADP	O	O	1049
cross	VERB	O	O	1049
-	PUNCT	O	O	1049
reactivity	NOUN	O	O	1049
between	ADP	O	O	1049
carbimazole	PROPN	O	Chemical	1049
and	CCONJ	O	O	1049
benzylthiouracil	NOUN	O	O	1049
.	PUNCT	O	O	1049
This	PRON	O	O	1050
study	VERB	O	O	1050
was	AUX	O	O	1050
conducted	VERB	O	O	1050
to	PART	O	O	1050
assess	VERB	O	O	1050
the	PRON	O	O	1050
occurrence	NOUN	O	O	1050
of	ADP	O	O	1050
hepatic	ADJ	O	O	1050
adverse	ADJ	O	O	1050
effects	NOUN	O	O	1050
encountered	VERB	O	O	1050
with	ADP	O	O	1050
antithyroid	ADJ	O	O	1050
drugs	NOUN	O	O	1050
.	PUNCT	O	O	1050
Retrospective	ADJ	O	O	1051
review	VERB	O	O	1051
of	ADP	O	O	1051
medical	ADJ	O	O	1051
records	NOUN	O	O	1051
of	ADP	O	O	1051
236	NUM	O	O	1051
patients	NOUN	O	O	1051
with	ADP	O	O	1051
hyperthyroidism	NOUN	O	Disease	1051
admitted	VERB	O	O	1051
in	ADP	O	O	1051
our	PRON	O	O	1051
department	NOUN	O	O	1051
(	PUNCT	O	O	1051
in-	PROPN	O	O	1051
or	CCONJ	O	O	1051
out	ADP	O	O	1051
-	PUNCT	O	O	1051
patients	NOUN	O	O	1051
)	PUNCT	O	O	1051
from	ADP	O	O	1051
1986	NUM	O	O	1051
to	PART	O	O	1051
1992	NUM	O	O	1051
.	PUNCT	O	O	1051
Four	NUM	O	O	1052
patients	NOUN	O	O	1052
(	PUNCT	O	O	1052
1.7%	NOUN	O	O	1052
)	PUNCT	O	O	1052
were	AUX	O	O	1052
identified	VERB	O	O	1052
with	ADP	O	O	1052
toxic	ADJ	O	O	1052
hepatitis	NOUN	O	Disease	1052
which	PRON	O	O	1052
could	AUX	O	O	1052
reasonably	ADV	O	O	1052
be	AUX	O	O	1052
attributed	VERB	O	O	1052
to	PART	O	O	1052
the	PRON	O	O	1052
use	VERB	O	O	1052
of	ADP	O	O	1052
antithyroid	ADJ	O	O	1052
agent	NOUN	O	O	1052
.	PUNCT	O	O	1052
Two	NUM	O	O	1053
patients	NOUN	O	O	1053
had	VERB	O	O	1053
a	PRON	O	O	1053
cholestatic hepatitis	NOUN	O	Disease	1053
induced	VERB	O	O	1053
by	ADP	O	O	1053
carbimazole	PROPN	O	Chemical	1053
(	PUNCT	O	O	1053
N	NUM	O	O	1053
omercazole	NOUN	O	O	1053
)	PUNCT	O	O	1053
.	PUNCT	O	O	1053
Two	NUM	O	O	1054
others	NOUN	O	O	1054
had	VERB	O	O	1054
a	PRON	O	O	1054
mixed	VERB	O	O	1054
(	PUNCT	O	O	1054
cholestatic	ADJ	O	Disease	1054
and	CCONJ	O	O	1054
cytolytic	ADJ	O	O	1054
)	PUNCT	O	O	1054
hepatitis	NOUN	O	Disease	1054
following	VERB	O	O	1054
carbimazole	PROPN	O	Chemical	1054
.	PUNCT	O	O	1054
One	NUM	O	O	1055
of	ADP	O	O	1055
the	PRON	O	O	1055
latter	ADJ	O	O	1055
two	NUM	O	O	1055
patients	NOUN	O	O	1055
further	ADV	O	O	1055
experienced	ADJ	O	O	1055
a	PRON	O	O	1055
cytolytic	ADJ	O	O	1055
hepatitis	NOUN	O	Disease	1055
which	PRON	O	O	1055
appeared	VERB	O	O	1055
after	ADP	O	O	1055
Benzylthiouracil	NOUN	O	O	1055
(	PUNCT	O	O	1055
Basd	NOUN	O	O	1055
ne	X	O	O	1055
)	PUNCT	O	O	1055
had	VERB	O	O	1055
replaced	VERB	O	O	1055
carbimazole	PROPN	O	Chemical	1055
.	PUNCT	O	O	1055
Biological	ADJ	O	O	1056
features	VERB	O	O	1056
of	ADP	O	O	1056
hepatitis	NOUN	O	Disease	1056
disappeared	VERB	O	O	1056
in	ADP	O	O	1056
all	PRON	O	O	1056
cases	NOUN	O	O	1056
after	ADP	O	O	1056
cessation	NOUN	O	O	1056
of	ADP	O	O	1056
the	PRON	O	O	1056
incriminated	VERB	O	O	1056
drug	NOUN	O	O	1056
,	PUNCT	O	O	1056
while	SCONJ	O	O	1056
biliary	ADJ	O	O	1056
,	PUNCT	O	O	1056
viral	ADJ	O	O	1056
and	CCONJ	O	O	1056
immunological	ADJ	O	O	1056
searches	VERB	O	O	1056
were	AUX	O	O	1056
negative	ADJ	O	O	1056
.	PUNCT	O	O	1056
Only	ADV	O	O	1057
2	X	O	O	1057
patients	NOUN	O	O	1057
of	ADP	O	O	1057
our	PRON	O	O	1057
retrospective	ADJ	O	O	1057
study	VERB	O	O	1057
experienced	ADJ	O	O	1057
a	PRON	O	O	1057
mild	ADJ	O	O	1057
or	CCONJ	O	O	1057
severe	ADJ	O	O	1057
neutropenia	ADJ	O	Disease	1057
.	PUNCT	O	O	1057
CONCLUSION	PROPN	O	O	1058
:	PUNCT	O	O	1058
Toxic	ADJ	O	O	1058
hepatitis	NOUN	O	Disease	1058
is	AUX	O	O	1058
a	PRON	O	O	1058
potential	ADJ	O	O	1058
adverse	ADJ	O	O	1058
effect	VERB	O	O	1058
of	ADP	O	O	1058
antithyroid	ADJ	O	O	1058
drugs	NOUN	O	O	1058
which	PRON	O	O	1058
warrants	NOUN	O	O	1058
,	PUNCT	O	O	1058
as	ADP	O	O	1058
for	ADP	O	O	1058
haematological	NOUN	O	O	1058
disturbances	NOUN	O	O	1058
,	PUNCT	O	O	1058
a	PRON	O	O	1058
pre	VERB	O	O	1058
-	PUNCT	O	O	1058
therapeutic	ADJ	O	O	1058
determination	NOUN	O	O	1058
and	CCONJ	O	O	1058
a	PRON	O	O	1058
careful	ADJ	O	O	1058
follow	VERB	O	O	1058
-	PUNCT	O	O	1058
up	ADP	O	O	1058
of	ADP	O	O	1058
relevant	ADJ	O	O	1058
biological	ADJ	O	O	1058
markers	NOUN	O	O	1058
.	PUNCT	O	O	1058
Moreover	ADV	O	O	1059
,	PUNCT	O	O	1059
hepatotoxicity	NOUN	O	Disease	1059
may	AUX	O	O	1059
not	PART	O	O	1059
be	AUX	O	O	1059
restricted	VERB	O	O	1059
to	PART	O	O	1059
one	NUM	O	O	1059
class	NOUN	O	O	1059
of	ADP	O	O	1059
antithyroid	ADJ	O	O	1059
agents	NOUN	O	O	1059
.	PUNCT	O	O	1059
Study	NOUN	O	O	1062
of	ADP	O	O	1062
the	PRON	O	O	1062
role	NOUN	O	O	1062
of	ADP	O	O	1062
vitamin	NOUN	O	O	1062
B12	NOUN	O	O	1062
and	CCONJ	O	O	1062
folinic	PROPN	O	O	1062
acid	PROPN	O	O	1062
supplementation	NOUN	O	O	1062
in	ADP	O	O	1062
preventing	VERB	O	O	1062
hematologic toxicity	NOUN	O	Disease	1062
of	ADP	O	O	1062
zidovudine	NOUN	O	Chemical	1062
.	PUNCT	O	O	1062
A	PRON	O	O	1063
prospective	ADJ	O	O	1063
,	PUNCT	O	O	1063
randomized	VERB	O	O	1063
study	VERB	O	O	1063
was	AUX	O	O	1063
conducted	VERB	O	O	1063
to	PART	O	O	1063
evaluate	VERB	O	O	1063
the	PRON	O	O	1063
role	NOUN	O	O	1063
of	ADP	O	O	1063
vitamin	NOUN	O	O	1063
B12	NOUN	O	O	1063
and	CCONJ	O	O	1063
folinic	PROPN	O	O	1063
acid	PROPN	O	O	1063
supplementation	NOUN	O	O	1063
in	ADP	O	O	1063
preventing	VERB	O	O	1063
zidovudine	NOUN	O	Chemical	1063
(	PUNCT	O	O	1063
ZDV)-induced	VERB	O	O	1063
bone	NOUN	O	O	1063
marrow suppression	NOUN	O	Disease	1063
.	PUNCT	O	O	1063
Seventy	NUM	O	O	1064
-	PUNCT	O	O	1064
five	NUM	O	O	1064
human	PROPN	O	O	1064
immunodeficiency	NOUN	O	Disease	1064
virus	NOUN	O	O	1064
(	PUNCT	O	O	1064
HIV)-infected	VERB	O	O	1064
patients	NOUN	O	O	1064
with	ADP	O	O	1064
CD4	PROPN	O	O	1064
+	ADP	O	O	1064
cell	NOUN	O	O	1064
counts	VERB	O	O	1064
<	X	O	O	1065
500/mm3	NOUN	O	O	1065
were	AUX	O	O	1065
randomized	VERB	O	O	1065
to	PART	O	O	1065
receive	VERB	O	O	1065
either	ADV	O	O	1065
ZDV	PROPN	O	O	1065
(	PUNCT	O	O	1065
500	NUM	O	O	1065
mg	VERB	O	O	1065
daily	ADV	O	O	1065
)	PUNCT	O	O	1065
alone	ADV	O	O	1065
(	PUNCT	O	O	1065
group	NOUN	O	O	1065
I	PRON	O	O	1065
,	PUNCT	O	O	1065
n	CCONJ	O	O	1065
=	PUNCT	O	O	1065
38	NUM	O	O	1065
)	PUNCT	O	O	1065
or	CCONJ	O	O	1065
in	ADP	O	O	1065
combination	NOUN	O	O	1065
with	ADP	O	O	1065
folinic	PROPN	O	O	1065
acid	PROPN	O	O	1065
(	PUNCT	O	O	1065
15	NUM	O	O	1065
mg	VERB	O	O	1065
daily	ADV	O	O	1065
)	PUNCT	O	O	1065
and	CCONJ	O	O	1065
intramascular	ADJ	O	O	1065
vitamin	NOUN	O	O	1065
B12	NOUN	O	O	1065
(	PUNCT	O	O	1065
1000	NUM	O	O	1065
micrograms	NOUN	O	O	1065
monthly	ADV	O	O	1065
)	PUNCT	O	O	1065
(	PUNCT	O	O	1065
group	NOUN	O	O	1065
II	NUM	O	O	1065
,	PUNCT	O	O	1065
n	CCONJ	O	O	1065
=	PUNCT	O	O	1065
37	NUM	O	O	1065
)	PUNCT	O	O	1065
.	PUNCT	O	O	1065
Finally	ADV	O	O	1066
,	PUNCT	O	O	1066
15	NUM	O	O	1066
patients	NOUN	O	O	1066
were	AUX	O	O	1066
excluded	VERB	O	O	1066
from	ADP	O	O	1066
the	PRON	O	O	1066
study	VERB	O	O	1066
(	PUNCT	O	O	1066
noncompliance	NOUN	O	O	1066
14	NUM	O	O	1066
,	PUNCT	O	O	1066
death	NOUN	O	O	1066
1	X	O	O	1066
)	PUNCT	O	O	1066
;	PUNCT	O	O	1066
thus	ADV	O	O	1066
,	PUNCT	O	O	1066
60	NUM	O	O	1066
patients	NOUN	O	O	1066
(	PUNCT	O	O	1066
31	NUM	O	O	1066
in	ADP	O	O	1066
group	NOUN	O	O	1066
I	PRON	O	O	1066
and	CCONJ	O	O	1066
29	NUM	O	O	1066
in	ADP	O	O	1066
group	NOUN	O	O	1066
II	NUM	O	O	1066
)	PUNCT	O	O	1066
were	AUX	O	O	1066
eligible	ADJ	O	O	1066
for	ADP	O	O	1066
analysis	NOUN	O	O	1066
.	PUNCT	O	O	1066
During	ADP	O	O	1067
the	PRON	O	O	1067
study	VERB	O	O	1067
,	PUNCT	O	O	1067
vitamin	NOUN	O	O	1067
B12	NOUN	O	O	1067
and	CCONJ	O	O	1067
folate	VERB	O	Chemical	1067
levels	NOUN	O	O	1067
were	AUX	O	O	1067
significantly	ADV	O	O	1067
higher	ADJ	O	O	1067
in	ADP	O	O	1067
group	NOUN	O	O	1067
II	NUM	O	O	1067
patients	NOUN	O	O	1067
;	PUNCT	O	O	1067
however	ADV	O	O	1067
,	PUNCT	O	O	1067
no	PRON	O	O	1067
differences	NOUN	O	O	1067
in	ADP	O	O	1067
hemoglobin	NOUN	O	O	1067
,	PUNCT	O	O	1067
hematocrit	PROPN	O	O	1067
,	PUNCT	O	O	1067
mean	VERB	O	O	1067
corpuscular	ADJ	O	O	1067
volume	PROPN	O	O	1067
,	PUNCT	O	O	1067
and	CCONJ	O	O	1067
white	ADJ	O	O	1067
-	PUNCT	O	O	1067
cell	NOUN	O	O	1067
,	PUNCT	O	O	1067
neutrophil	ADJ	O	O	1067
and	CCONJ	O	O	1067
platelet	NOUN	O	O	1067
counts	VERB	O	O	1067
were	AUX	O	O	1067
observed	VERB	O	O	1067
between	ADP	O	O	1067
groups	NOUN	O	O	1067
at	ADP	O	O	1067
3	X	O	O	1067
,	PUNCT	O	O	1067
6	NUM	O	O	1067
,	PUNCT	O	O	1067
9	NUM	O	O	1067
and	CCONJ	O	O	1067
12	NUM	O	O	1067
months	NOUN	O	O	1067
.	PUNCT	O	O	1067
Severe	ADJ	O	O	1068
hematologic toxicity	NOUN	O	Disease	1068
(	PUNCT	O	O	1068
neutrophil	ADJ	O	O	1068
count	VERB	O	O	1068
<	X	O	O	1068
1000/mm3	NOUN	O	O	1068
and/or	CCONJ	O	O	1068
hemoglobin	NOUN	O	O	1068
<	X	O	O	1068
8	NUM	O	O	1068
g	X	O	O	1068
/	PUNCT	O	O	1068
dl	X	O	O	1068
)	PUNCT	O	O	1068
occurred	VERB	O	O	1068
in	ADP	O	O	1068
4	NUM	O	O	1068
patients	NOUN	O	O	1068
assigned	VERB	O	O	1068
to	PART	O	O	1068
group	NOUN	O	O	1068
I	PRON	O	O	1068
and	CCONJ	O	O	1068
7	NUM	O	O	1068
assigned	VERB	O	O	1068
to	PART	O	O	1068
group	NOUN	O	O	1068
II	NUM	O	O	1068
.	PUNCT	O	O	1068
There	ADV	O	O	1069
was	AUX	O	O	1069
no	PRON	O	O	1069
correlation	NOUN	O	O	1069
between	ADP	O	O	1069
vitamin	NOUN	O	O	1069
B12	NOUN	O	O	1069
or	CCONJ	O	O	1069
folate	VERB	O	Chemical	1069
levels	NOUN	O	O	1069
and	CCONJ	O	O	1069
development	NOUN	O	O	1069
of	ADP	O	O	1069
myelosuppression	NOUN	O	Disease	1069
.	PUNCT	O	O	1069
Vitamin	NOUN	O	O	1070
B12	NOUN	O	O	1070
and	CCONJ	O	O	1070
folinic	PROPN	O	O	1070
acid	PROPN	O	O	1070
supplementation	NOUN	O	O	1070
of	ADP	O	O	1070
ZDV	PROPN	O	O	1070
therapy	NOUN	O	O	1070
does	VERB	O	O	1070
not	PART	O	O	1070
seem	VERB	O	O	1070
useful	ADJ	O	O	1070
in	ADP	O	O	1070
preventing	VERB	O	O	1070
or	CCONJ	O	O	1070
reducing	VERB	O	O	1070
ZDV	PROPN	O	O	1070
-	PUNCT	O	O	1070
induced	VERB	O	O	1070
myelotoxicity	NOUN	O	O	1070
in	ADP	O	O	1070
the	PRON	O	O	1070
overall	ADV	O	O	1070
treated	VERB	O	O	1070
population	NOUN	O	O	1070
,	PUNCT	O	O	1070
although	SCONJ	O	O	1070
a	PRON	O	O	1070
beneficial	ADJ	O	O	1070
effect	VERB	O	O	1070
in	ADP	O	O	1070
certain	ADJ	O	O	1070
subgroups	NOUN	O	O	1070
of	ADP	O	O	1070
patients	NOUN	O	O	1070
can	AUX	O	O	1070
not	PART	O	O	1070
be	AUX	O	O	1070
excluded	VERB	O	O	1070
.	PUNCT	O	O	1070
Acute	PROPN	O	O	1073
confusion	NOUN	O	Disease	1073
induced	VERB	O	O	1073
by	ADP	O	O	1073
a	PRON	O	O	1073
high	ADJ	O	O	1073
-	PUNCT	O	O	1073
dose	NOUN	O	O	1073
infusion	NOUN	O	O	1073
of	ADP	O	O	1073
5-fluorouracil	NOUN	O	Chemical	1073
and	CCONJ	O	O	1073
folinic	PROPN	O	O	1073
acid	PROPN	O	O	1073
.	PUNCT	O	O	1073
A	PRON	O	O	1074
61-year	NOUN	O	O	1074
-	PUNCT	O	O	1074
old	ADJ	O	O	1074
man	NOUN	O	O	1074
was	AUX	O	O	1074
treated	VERB	O	O	1074
with	ADP	O	O	1074
combination	NOUN	O	O	1074
chemotherapy	NOUN	O	O	1074
incorporating	VERB	O	O	1074
cisplatinum	VERB	O	O	1074
,	PUNCT	O	O	1074
etoposide	ADV	O	Chemical	1074
,	PUNCT	O	O	1074
high	ADJ	O	O	1074
-	PUNCT	O	O	1074
dose	NOUN	O	O	1074
5-fluorouracil	NOUN	O	Chemical	1074
(	PUNCT	O	O	1074
2,250	NUM	O	O	1074
mg	VERB	O	O	1074
/	PUNCT	O	O	1074
m2/24	NOUN	O	O	1074
hours	NOUN	O	O	1074
)	PUNCT	O	O	1074
and	CCONJ	O	O	1074
folinic	PROPN	O	O	1074
acid	PROPN	O	O	1074
for	ADP	O	O	1074
an	PRON	O	O	1074
inoperable	ADJ	O	O	1074
gastric adenocarcinoma	NOUN	O	Disease	1074
.	PUNCT	O	O	1074
He	PRON	O	O	1075
developed	VERB	O	O	1075
acute	ADJ	O	O	1075
neurologic	ADJ	O	O	1075
symptoms	NOUN	O	O	1075
of	ADP	O	O	1075
mental	ADJ	O	O	1075
confusion	NOUN	O	Disease	1075
,	PUNCT	O	O	1075
disorientation	NOUN	O	O	1075
and	CCONJ	O	O	1075
irritability	NOUN	O	Disease	1075
,	PUNCT	O	O	1075
and	CCONJ	O	O	1075
then	ADV	O	O	1075
lapsed	VERB	O	O	1075
into	ADP	O	O	1075
a	PRON	O	O	1075
deep	ADJ	O	O	1075
coma	NOUN	O	Disease	1075
,	PUNCT	O	O	1075
lasting	VERB	O	O	1075
for	ADP	O	O	1075
approximately	ADV	O	O	1075
40	NUM	O	O	1075
hours	NOUN	O	O	1075
during	ADP	O	O	1075
the	PRON	O	O	1075
first	ADV	O	O	1075
dose	NOUN	O	O	1075
(	PUNCT	O	O	1075
day	NOUN	O	O	1075
2	X	O	O	1075
)	PUNCT	O	O	1075
of	ADP	O	O	1075
5-fluorouracil	NOUN	O	Chemical	1075
and	CCONJ	O	O	1075
folinic	PROPN	O	O	1075
acid	PROPN	O	O	1075
infusion	NOUN	O	O	1075
.	PUNCT	O	O	1075
This	PRON	O	O	1076
complication	NOUN	O	O	1076
reappeared	VERB	O	O	1076
on	ADP	O	O	1076
day	NOUN	O	O	1076
25	NUM	O	O	1076
during	ADP	O	O	1076
the	PRON	O	O	1076
second	ADV	O	O	1076
dose	NOUN	O	O	1076
of	ADP	O	O	1076
5-fluorouracil	NOUN	O	Chemical	1076
and	CCONJ	O	O	1076
folinic	PROPN	O	O	1076
acid	PROPN	O	O	1076
,	PUNCT	O	O	1076
which	PRON	O	O	1076
were	AUX	O	O	1076
then	ADV	O	O	1076
the	PRON	O	O	1076
only	ADV	O	O	1076
drugs	NOUN	O	O	1076
given	VERB	O	O	1076
.	PUNCT	O	O	1076
Because	SCONJ	O	O	1077
folinic	PROPN	O	O	1077
acid	PROPN	O	O	1077
was	AUX	O	O	1077
unlikely	ADJ	O	O	1077
to	PART	O	O	1077
be	AUX	O	O	1077
associated	VERB	O	O	1077
with	ADP	O	O	1077
this	PRON	O	O	1077
condition	NOUN	O	O	1077
,	PUNCT	O	O	1077
neurotoxicity	NOUN	O	Disease	1077
due	ADJ	O	O	1077
to	PART	O	O	1077
high	ADJ	O	O	1077
-	PUNCT	O	O	1077
dose	NOUN	O	O	1077
5-fluorouracil	NOUN	O	Chemical	1077
was	AUX	O	O	1077
highly	ADV	O	O	1077
suspected	VERB	O	O	1077
.	PUNCT	O	O	1077
The	PRON	O	O	1078
pathogenesis	NOUN	O	O	1078
of	ADP	O	O	1078
5-fluorouracil	NOUN	O	Chemical	1078
neurotoxicity	NOUN	O	Disease	1078
may	AUX	O	O	1078
be	AUX	O	O	1078
due	ADJ	O	O	1078
to	PART	O	O	1078
a	PRON	O	O	1078
Krebs	PROPN	O	O	1078
cycle	PROPN	O	O	1078
blockade	VERB	O	O	1078
by	ADP	O	O	1078
fluoroacetate	VERB	O	O	1078
and	CCONJ	O	O	1078
fluorocitrate	NOUN	O	O	1078
,	PUNCT	O	O	1078
thiamine	NOUN	O	Chemical	1078
deficiency	NOUN	O	O	1078
,	PUNCT	O	O	1078
or	CCONJ	O	O	1078
dihydrouracil	NOUN	O	O	1078
dehydrogenase	NOUN	O	O	1078
deficiency	NOUN	O	O	1078
.	PUNCT	O	O	1078
High	ADJ	O	O	1079
-	PUNCT	O	O	1079
dose	NOUN	O	O	1079
5-fluorouracil	NOUN	O	Chemical	1079
/	PUNCT	O	O	1079
folinic	PROPN	O	O	1079
acid	PROPN	O	O	1079
infusion	NOUN	O	O	1079
therapy	NOUN	O	O	1079
has	VERB	O	O	1079
recently	ADV	O	O	1079
become	VERB	O	O	1079
a	PRON	O	O	1079
popular	ADJ	O	O	1079
regimen	NOUN	O	O	1079
for	ADP	O	O	1079
various	ADJ	O	O	1079
cancers	NOUN	O	Disease	1079
.	PUNCT	O	O	1079
Effect	VERB	O	O	1082
of	ADP	O	O	1082
switching	VERB	O	O	1082
carbamazepine	NOUN	O	Chemical	1082
to	PART	O	O	1082
oxcarbazepine	NOUN	O	O	1082
on	ADP	O	O	1082
the	PRON	O	O	1082
plasma	NOUN	O	O	1082
levels	NOUN	O	O	1082
of	ADP	O	O	1082
neuroleptics	NOUN	O	O	1082
.	PUNCT	O	O	1082
Carbamazepine	NOUN	O	Chemical	1083
was	AUX	O	O	1083
switched	VERB	O	O	1083
to	PART	O	O	1083
its	PRON	O	O	1083
10-keto	NOUN	O	O	1083
analogue	NOUN	O	O	1083
oxcarbazepine	NOUN	O	O	1083
among	ADP	O	O	1083
six	NUM	O	O	1083
difficult	ADJ	O	O	1083
-	PUNCT	O	O	1083
to	PART	O	O	1083
-	PUNCT	O	O	1083
treat	VERB	O	O	1083
schizophrenic	ADJ	O	Disease	1083
or	CCONJ	O	O	1083
organic	ADJ	O	O	1083
psychotic	ADJ	O	O	1083
patients	NOUN	O	O	1083
using	VERB	O	O	1083
concomitantly	ADV	O	O	1083
haloperidol	NOUN	O	Chemical	1083
,	PUNCT	O	O	1083
chlorpromazine	NOUN	O	Chemical	1083
or	CCONJ	O	O	1083
clozapine	PROPN	O	Chemical	1083
.	PUNCT	O	O	1083
This	PRON	O	O	1084
change	VERB	O	O	1084
resulted	VERB	O	O	1084
within	ADP	O	O	1084
2	X	O	O	1084
-	PUNCT	O	O	1084
4	NUM	O	O	1084
weeks	NOUN	O	O	1084
in	ADP	O	O	1084
the	PRON	O	O	1084
50	NUM	O	O	1084
-	PUNCT	O	O	1084
200%	NOUN	O	O	1084
increase	VERB	O	O	1084
in	ADP	O	O	1084
the	PRON	O	O	1084
plasma	NOUN	O	O	1084
levels	NOUN	O	O	1084
of	ADP	O	O	1084
these	PRON	O	O	1084
neuroleptics	NOUN	O	O	1084
and	CCONJ	O	O	1084
the	PRON	O	O	1084
appearance	NOUN	O	O	1084
of	ADP	O	O	1084
extrapyramidal symptoms	NOUN	O	Disease	1084
.	PUNCT	O	O	1084
The	PRON	O	O	1085
results	VERB	O	O	1085
of	ADP	O	O	1085
this	PRON	O	O	1085
case	NOUN	O	O	1085
report	VERB	O	O	1085
support	NOUN	O	O	1085
the	PRON	O	O	1085
idea	NOUN	O	O	1085
that	SCONJ	O	O	1085
in	ADP	O	O	1085
contrast	NOUN	O	O	1085
with	ADP	O	O	1085
carbamazepine	NOUN	O	Chemical	1085
oxcarbazepine	NOUN	O	O	1085
does	VERB	O	O	1085
not	PART	O	O	1085
induce	VERB	O	O	1085
the	PRON	O	O	1085
hepatic	ADJ	O	O	1085
microsomal	PROPN	O	O	1085
enzyme	NOUN	O	O	1085
systems	NOUN	O	O	1085
regulating	VERB	O	O	1085
the	PRON	O	O	1085
inactivation	NOUN	O	O	1085
of	ADP	O	O	1085
antipsychotic	ADJ	O	O	1085
drugs	NOUN	O	O	1085
.	PUNCT	O	O	1085
Erythema	NOUN	O	O	1088
multiforme	NOUN	O	O	1088
and	CCONJ	O	O	1088
hypersensitivity	NOUN	O	Disease	1088
myocarditis	ADV	O	Disease	1088
caused	VERB	O	O	1088
by	ADP	O	O	1088
ampicillin	PROPN	O	O	1088
.	PUNCT	O	O	1088
OBJECTIVE	VERB	O	O	1089
:	PUNCT	O	O	1089
To	PART	O	O	1089
report	VERB	O	O	1089
a	PRON	O	O	1089
case	NOUN	O	O	1089
of	ADP	O	O	1089
erythema	NOUN	O	O	1089
multiforme	NOUN	O	O	1089
and	CCONJ	O	O	1089
hypersensitivity	NOUN	O	Disease	1089
myocarditis	ADV	O	Disease	1089
caused	VERB	O	O	1089
by	ADP	O	O	1089
ampicillin	PROPN	O	O	1089
.	PUNCT	O	O	1089
A	PRON	O	O	1090
13-year	NOUN	O	O	1090
-	PUNCT	O	O	1090
old	ADJ	O	O	1090
boy	NOUN	O	O	1090
was	AUX	O	O	1090
treated	VERB	O	O	1090
with	ADP	O	O	1090
ampicillin	PROPN	O	O	1090
and	CCONJ	O	O	1090
gentamicin	VERB	O	Chemical	1090
because	SCONJ	O	O	1090
of	ADP	O	O	1090
suspected	VERB	O	O	1090
septicemia	VERB	O	O	1090
.	PUNCT	O	O	1090
Medications	NOUN	O	O	1091
were	AUX	O	O	1091
discontinued	VERB	O	O	1091
when	SCONJ	O	O	1091
erythema	NOUN	O	O	1091
multiforme	NOUN	O	O	1091
and	CCONJ	O	O	1091
congestive	ADJ	O	O	1091
heart failure	NOUN	O	Disease	1091
caused	VERB	O	O	1091
by	ADP	O	O	1091
myocarditis	ADV	O	Disease	1091
occurred	VERB	O	O	1091
.	PUNCT	O	O	1091
The	PRON	O	O	1092
patient	NOUN	O	O	1092
was	AUX	O	O	1092
treated	VERB	O	O	1092
with	ADP	O	O	1092
methylprednisolone	NOUN	O	Chemical	1092
and	CCONJ	O	O	1092
gradually	ADV	O	O	1092
improved	VERB	O	O	1092
.	PUNCT	O	O	1092
Macrophage	NOUN	O	O	1093
-	PUNCT	O	O	1093
migration	NOUN	O	O	1093
inhibition	NOUN	O	O	1093
(	PUNCT	O	O	1093
MIF	PROPN	O	O	1093
)	PUNCT	O	O	1093
test	NOUN	O	O	1093
with	ADP	O	O	1093
ampicillin	PROPN	O	O	1093
was	AUX	O	O	1093
positive	ADJ	O	O	1093
.	PUNCT	O	O	1093
After	ADP	O	O	1094
most	ADV	O	O	1094
infections	NOUN	O	Disease	1094
causing	VERB	O	O	1094
erythema	NOUN	O	O	1094
multiforme	NOUN	O	O	1094
and	CCONJ	O	O	1094
myocarditis	ADV	O	Disease	1094
were	AUX	O	O	1094
ruled	VERB	O	O	1094
out	ADP	O	O	1094
,	PUNCT	O	O	1094
a	PRON	O	O	1094
drug	NOUN	O	O	1094
-	PUNCT	O	O	1094
induced	VERB	O	O	1094
allergic	ADJ	O	O	1094
reaction	NOUN	O	O	1094
was	AUX	O	O	1094
suspected	VERB	O	O	1094
.	PUNCT	O	O	1094
Positive	PROPN	O	O	1095
MIF	PROPN	O	O	1095
test	NOUN	O	O	1095
for	ADP	O	O	1095
ampicillin	PROPN	O	O	1095
showed	VERB	O	O	1095
sensitization	NOUN	O	O	1095
of	ADP	O	O	1095
the	PRON	O	O	1095
patient	NOUN	O	O	1095
's	AUX	O	O	1095
lymphocytes	VERB	O	O	1095
to	PART	O	O	1095
ampicillin	PROPN	O	O	1095
.	PUNCT	O	O	1095
Hypersensitivity	NOUN	O	Disease	1096
myocarditis	ADV	O	Disease	1096
is	AUX	O	O	1096
a	PRON	O	O	1096
rare	ADJ	O	O	1096
and	CCONJ	O	O	1096
dangerous	ADJ	O	O	1096
manifestation	NOUN	O	O	1096
of	ADP	O	O	1096
allergy	PROPN	O	O	1096
to	PART	O	O	1096
penicillins	NOUN	O	Chemical	1096
.	PUNCT	O	O	1096
Immediate	ADJ	O	O	1099
allergic	ADJ	O	O	1099
reactions	NOUN	O	O	1099
to	PART	O	O	1099
amoxicillin	PROPN	O	O	1099
.	PUNCT	O	O	1099
A	PRON	O	O	1100
large	ADJ	O	O	1100
group	NOUN	O	O	1100
of	ADP	O	O	1100
patients	NOUN	O	O	1100
with	ADP	O	O	1100
suspected	VERB	O	O	1100
allergic	ADJ	O	O	1100
reactions	NOUN	O	O	1100
to	PART	O	O	1100
beta	NOUN	O	O	1100
-	PUNCT	O	O	1100
lactam	NOUN	O	O	1100
antibiotics	VERB	O	O	1100
was	AUX	O	O	1100
evaluated	VERB	O	O	1100
.	PUNCT	O	O	1100
A	PRON	O	O	1101
detailed	VERB	O	O	1101
clinical	ADJ	O	O	1101
history	NOUN	O	O	1101
,	PUNCT	O	O	1101
together	ADV	O	O	1101
with	ADP	O	O	1101
skin	NOUN	O	O	1101
tests	VERB	O	O	1101
,	PUNCT	O	O	1101
RAST	NOUN	O	O	1101
(	PUNCT	O	O	1101
radioallergosorbent	NOUN	O	O	1101
test	NOUN	O	O	1101
)	PUNCT	O	O	1101
,	PUNCT	O	O	1101
and	CCONJ	O	O	1101
controlled	VERB	O	O	1101
challenge	NOUN	O	O	1101
tests	VERB	O	O	1101
,	PUNCT	O	O	1101
was	AUX	O	O	1101
used	VERB	O	O	1101
to	PART	O	O	1101
establish	VERB	O	O	1101
whether	SCONJ	O	O	1101
patients	NOUN	O	O	1101
allergic	ADJ	O	O	1101
to	PART	O	O	1101
beta	NOUN	O	O	1101
-	PUNCT	O	O	1101
lactam	NOUN	O	O	1101
antibiotics	VERB	O	O	1101
had	VERB	O	O	1101
selective	ADJ	O	O	1101
immediate	ADJ	O	O	1101
allergic	ADJ	O	O	1101
responses	NOUN	O	O	1101
to	PART	O	O	1101
amoxicillin	PROPN	O	O	1101
(	PUNCT	O	O	1101
AX	NOUN	O	O	1101
)	PUNCT	O	O	1101
or	CCONJ	O	O	1101
were	AUX	O	O	1101
cross	VERB	O	O	1101
-	PUNCT	O	O	1101
reacting	VERB	O	O	1101
with	ADP	O	O	1101
other	ADJ	O	O	1101
penicillin	NOUN	O	Chemical	1101
derivatives	NOUN	O	O	1101
.	PUNCT	O	O	1101
Skin	NOUN	O	O	1102
tests	VERB	O	O	1102
were	AUX	O	O	1102
performed	VERB	O	O	1102
with	ADP	O	O	1102
benzylpenicilloyl	VERB	O	O	1102
-	PUNCT	O	O	1102
poly	NOUN	O	O	1102
-	PUNCT	O	O	1102
L	NOUN	O	O	1102
-	PUNCT	O	O	1102
lysine	PROPN	O	O	1102
(	PUNCT	O	O	1102
BPO	PROPN	O	O	1102
-	PUNCT	O	O	1102
PLL	PROPN	O	O	1102
)	PUNCT	O	O	1102
,	PUNCT	O	O	1102
benzylpenicilloate	NOUN	O	O	1102
,	PUNCT	O	O	1102
benzylpenicillin	PROPN	O	O	1102
(	PUNCT	O	O	1103
PG	PROPN	O	Chemical	1103
)	PUNCT	O	O	1103
,	PUNCT	O	O	1103
ampicillin	PROPN	O	O	1103
(	PUNCT	O	O	1103
AMP	NOUN	O	Chemical	1103
)	PUNCT	O	O	1103
,	PUNCT	O	O	1103
and	CCONJ	O	O	1103
AX	NOUN	O	O	1103
.	PUNCT	O	O	1103
RAST	NOUN	O	O	1104
for	ADP	O	O	1104
BPO	PROPN	O	O	1104
-	PUNCT	O	O	1104
PLL	PROPN	O	O	1104
and	CCONJ	O	O	1104
AX	NOUN	O	O	1104
-	PUNCT	O	O	1104
PLL	PROPN	O	O	1104
was	AUX	O	O	1104
done	VERB	O	O	1104
.	PUNCT	O	O	1104
When	SCONJ	O	O	1105
both	PRON	O	O	1105
skin	NOUN	O	O	1105
test	NOUN	O	O	1105
and	CCONJ	O	O	1105
RAST	NOUN	O	O	1105
for	ADP	O	O	1105
BPO	PROPN	O	O	1105
were	AUX	O	O	1105
negative	ADJ	O	O	1105
,	PUNCT	O	O	1105
single	ADJ	O	O	1105
-	PUNCT	O	O	1105
blind	ADJ	O	Disease	1105
,	PUNCT	O	O	1105
placebo	NOUN	O	O	1105
-	PUNCT	O	O	1105
controlled	VERB	O	O	1105
challenge	NOUN	O	O	1105
tests	VERB	O	O	1105
were	AUX	O	O	1105
done	VERB	O	O	1105
to	PART	O	O	1105
ensure	VERB	O	O	1105
tolerance	NOUN	O	O	1105
of	ADP	O	O	1105
PG	PROPN	O	Chemical	1105
or	CCONJ	O	O	1105
sensitivity	NOUN	O	O	1105
to	PART	O	O	1105
AX	NOUN	O	O	1105
.	PUNCT	O	O	1105
A	PRON	O	O	1106
total	ADJ	O	O	1106
of	ADP	O	O	1106
177	NUM	O	O	1106
patients	NOUN	O	O	1106
were	AUX	O	O	1106
diagnosed	VERB	O	O	1106
as	ADP	O	O	1106
allergic	ADJ	O	O	1106
to	PART	O	O	1106
beta	NOUN	O	O	1106
-	PUNCT	O	O	1106
lactam	NOUN	O	O	1106
antibiotics	VERB	O	O	1106
.	PUNCT	O	O	1106
We	PRON	O	O	1107
selected	VERB	O	O	1107
the	PRON	O	O	1107
54	NUM	O	O	1107
(	PUNCT	O	O	1107
30.5%	NOUN	O	O	1107
)	PUNCT	O	O	1107
cases	NOUN	O	O	1107
of	ADP	O	O	1107
immediate	ADJ	O	O	1107
AX	NOUN	O	O	1107
allergy	PROPN	O	O	1107
with	ADP	O	O	1107
good	ADJ	O	O	1107
tolerance	NOUN	O	O	1107
of	ADP	O	O	1107
PG	PROPN	O	Chemical	1107
.	PUNCT	O	O	1107
Anaphylaxis	NOUN	O	O	1108
was	AUX	O	O	1108
seen	VERB	O	O	1108
in	ADP	O	O	1108
37	NUM	O	O	1108
patients	NOUN	O	O	1108
(	PUNCT	O	O	1108
69%	NOUN	O	O	1108
)	PUNCT	O	O	1108
,	PUNCT	O	O	1108
the	PRON	O	O	1108
other	ADJ	O	O	1108
17	NUM	O	O	1108
(	PUNCT	O	O	1108
31%	NOUN	O	O	1108
)	PUNCT	O	O	1108
having	VERB	O	O	1108
urticaria	PROPN	O	Disease	1108
and/or	CCONJ	O	O	1108
angioedema	NOUN	O	Disease	1108
.	PUNCT	O	O	1108
All	PRON	O	O	1109
the	PRON	O	O	1109
patients	NOUN	O	O	1109
were	AUX	O	O	1109
skin	NOUN	O	O	1109
test	NOUN	O	O	1109
negative	ADJ	O	O	1109
to	PART	O	O	1109
BPO	PROPN	O	O	1109
;	PUNCT	O	O	1109
49	NUM	O	O	1109
of	ADP	O	O	1109
51	NUM	O	O	1109
(	PUNCT	O	O	1109
96%	NOUN	O	O	1109
)	PUNCT	O	O	1109
were	AUX	O	O	1109
also	ADV	O	O	1109
negative	ADJ	O	O	1109
to	PART	O	O	1109
MDM	PROPN	O	O	1109
,	PUNCT	O	O	1109
and	CCONJ	O	O	1109
44	NUM	O	O	1109
of	ADP	O	O	1109
46	NUM	O	O	1109
(	PUNCT	O	O	1109
96%	NOUN	O	O	1109
)	PUNCT	O	O	1109
to	PART	O	O	1109
PG	PROPN	O	Chemical	1109
.	PUNCT	O	O	1109
Skin	NOUN	O	O	1110
tests	VERB	O	O	1110
with	ADP	O	O	1110
AX	NOUN	O	O	1110
were	AUX	O	O	1110
positive	ADJ	O	O	1110
in	ADP	O	O	1110
34	NUM	O	O	1110
(	PUNCT	O	O	1110
63%	NOUN	O	O	1110
)	PUNCT	O	O	1110
patients	NOUN	O	O	1110
.	PUNCT	O	O	1110
RAST	NOUN	O	O	1111
was	AUX	O	O	1111
positive	ADJ	O	O	1111
for	ADP	O	O	1111
AX	NOUN	O	O	1111
in	ADP	O	O	1111
22	NUM	O	O	1111
patients	NOUN	O	O	1111
(	PUNCT	O	O	1111
41%	NOUN	O	O	1111
)	PUNCT	O	O	1111
and	CCONJ	O	O	1111
to	PART	O	O	1111
BPO	PROPN	O	O	1111
in	ADP	O	O	1111
just	ADV	O	O	1111
5	NUM	O	O	1111
(	PUNCT	O	O	1111
9%	NOUN	O	O	1111
)	PUNCT	O	O	1111
.	PUNCT	O	O	1111
None	NOUN	O	O	1112
of	ADP	O	O	1112
the	PRON	O	O	1112
sera	PROPN	O	O	1112
with	ADP	O	O	1112
negative	ADJ	O	O	1112
RAST	NOUN	O	O	1112
for	ADP	O	O	1112
AX	NOUN	O	O	1112
were	AUX	O	O	1112
positive	ADJ	O	O	1112
to	PART	O	O	1112
BPO	PROPN	O	O	1112
.	PUNCT	O	O	1112
Challenge	NOUN	O	O	1113
tests	VERB	O	O	1113
with	ADP	O	O	1113
AX	NOUN	O	O	1113
were	AUX	O	O	1113
performed	VERB	O	O	1113
in	ADP	O	O	1113
23	NUM	O	O	1113
subjects	NOUN	O	O	1113
(	PUNCT	O	O	1113
43%	NOUN	O	O	1113
)	PUNCT	O	O	1113
to	PART	O	O	1113
establish	VERB	O	O	1113
the	PRON	O	O	1113
diagnosis	NOUN	O	O	1113
of	ADP	O	O	1113
immediate	ADJ	O	O	1113
allergic	ADJ	O	O	1113
reaction	NOUN	O	O	1113
to	PART	O	O	1113
AX	NOUN	O	O	1113
,	PUNCT	O	O	1113
and	CCONJ	O	O	1113
in	ADP	O	O	1113
15	NUM	O	O	1113
cases	NOUN	O	O	1113
(	PUNCT	O	O	1113
28%	NOUN	O	O	1113
)	PUNCT	O	O	1113
both	PRON	O	O	1113
skin	NOUN	O	O	1113
test	NOUN	O	O	1113
and	CCONJ	O	O	1113
RAST	NOUN	O	O	1113
for	ADP	O	O	1113
AX	NOUN	O	O	1113
were	AUX	O	O	1113
negative	ADJ	O	O	1113
.	PUNCT	O	O	1113
PG	PROPN	O	Chemical	1114
was	AUX	O	O	1114
well	ADV	O	O	1114
tolerated	VERB	O	O	1114
by	ADP	O	O	1114
all	PRON	O	O	1114
54	NUM	O	O	1114
patients	NOUN	O	O	1114
.	PUNCT	O	O	1114
We	PRON	O	O	1115
describe	VERB	O	O	1115
the	PRON	O	O	1115
largest	ADJ	O	O	1115
group	NOUN	O	O	1115
of	ADP	O	O	1115
AX	NOUN	O	O	1115
-	PUNCT	O	O	1115
allergic	ADJ	O	O	1115
patients	NOUN	O	O	1115
who	PRON	O	O	1115
have	VERB	O	O	1115
tolerated	VERB	O	O	1115
PG	PROPN	O	Chemical	1115
reported	VERB	O	O	1115
so	ADV	O	O	1115
far	ADV	O	O	1115
.	PUNCT	O	O	1115
Diagnosis	NOUN	O	O	1116
of	ADP	O	O	1116
these	PRON	O	O	1116
patients	NOUN	O	O	1116
can	AUX	O	O	1116
be	AUX	O	O	1116
achieved	VERB	O	O	1116
only	ADV	O	O	1116
if	SCONJ	O	O	1116
specific	ADJ	O	O	1116
AX	NOUN	O	O	1116
-	PUNCT	O	O	1116
related	ADJ	O	O	1116
reagents	NOUN	O	O	1116
are	AUX	O	O	1116
employed	VERB	O	O	1116
.	PUNCT	O	O	1116
Persistent	ADJ	O	O	1119
paralysis	NOUN	O	Disease	1119
after	ADP	O	O	1119
prolonged	VERB	O	O	1119
use	VERB	O	O	1119
of	ADP	O	O	1119
atracurium	PROPN	O	O	1119
in	ADP	O	O	1119
the	PRON	O	O	1119
absence	NOUN	O	O	1119
of	ADP	O	O	1119
corticosteroids	NOUN	O	Chemical	1119
.	PUNCT	O	O	1119
Reports	NOUN	O	O	1120
of	ADP	O	O	1120
persistent	ADJ	O	O	1120
paralysis	NOUN	O	Disease	1120
after	ADP	O	O	1120
the	PRON	O	O	1120
discontinuance	NOUN	O	O	1120
of	ADP	O	O	1120
these	PRON	O	O	1120
drugs	NOUN	O	O	1120
have	VERB	O	O	1120
most	ADV	O	O	1120
often	ADV	O	O	1120
involved	VERB	O	O	1120
aminosteroid	NOUN	O	O	1120
-	PUNCT	O	O	1120
based	VERB	O	O	1120
NMBAs	NOUN	O	O	1120
such	ADJ	O	O	1120
as	ADP	O	O	1120
vecuronium	NOUN	O	Chemical	1120
bromide	NOUN	O	O	1120
,	PUNCT	O	O	1120
especially	ADV	O	O	1120
when	SCONJ	O	O	1120
used	VERB	O	O	1120
in	ADP	O	O	1120
conjunction	NOUN	O	O	1120
with	ADP	O	O	1120
corticosteroids	NOUN	O	Chemical	1120
.	PUNCT	O	O	1120
Atracurium	PROPN	O	O	1121
besylate	PROPN	O	O	1121
,	PUNCT	O	O	1121
a	PRON	O	O	1121
short	ADJ	O	O	1121
-	PUNCT	O	O	1121
acting	VERB	O	O	1121
benzylisoquinolinium	NOUN	O	O	1121
NMBA	ADJ	O	O	1121
that	SCONJ	O	O	1121
is	AUX	O	O	1121
eliminated	VERB	O	O	1121
independently	ADV	O	O	1121
of	ADP	O	O	1121
renal	ADJ	O	O	1121
or	CCONJ	O	O	1121
hepatic	ADJ	O	O	1121
function	NOUN	O	O	1121
,	PUNCT	O	O	1121
has	VERB	O	O	1121
also	ADV	O	O	1121
been	AUX	O	O	1121
associated	VERB	O	O	1121
with	ADP	O	O	1121
persistent	ADJ	O	O	1121
paralysis	NOUN	O	Disease	1121
,	PUNCT	O	O	1121
but	CCONJ	O	O	1121
only	ADV	O	O	1121
when	SCONJ	O	O	1121
used	VERB	O	O	1121
with	ADP	O	O	1121
corticosteroids	NOUN	O	Chemical	1121
.	PUNCT	O	O	1121
We	PRON	O	O	1122
report	VERB	O	O	1122
a	PRON	O	O	1122
case	NOUN	O	O	1122
of	ADP	O	O	1122
atracurium	PROPN	O	O	1122
-	PUNCT	O	O	1122
related	ADJ	O	O	1122
paralysis	NOUN	O	Disease	1122
persisting	VERB	O	O	1122
for	ADP	O	O	1122
approximately	ADV	O	O	1122
50	NUM	O	O	1122
hours	NOUN	O	O	1122
in	ADP	O	O	1122
a	PRON	O	O	1122
patient	NOUN	O	O	1122
who	PRON	O	O	1122
was	AUX	O	O	1122
not	PART	O	O	1122
treated	VERB	O	O	1122
with	ADP	O	O	1122
corticosteroids	NOUN	O	Chemical	1122
.	PUNCT	O	O	1122
Habitual	ADJ	O	O	1125
use	VERB	O	O	1125
of	ADP	O	O	1125
acetaminophen	PROPN	O	Chemical	1125
as	ADP	O	O	1125
a	PRON	O	O	1125
risk	NOUN	O	O	1125
factor	NOUN	O	O	1125
for	ADP	O	O	1125
chronic	ADJ	O	O	1125
renal failure	NOUN	O	Disease	1125
:	PUNCT	O	O	1125
a	PRON	O	O	1125
comparison	NOUN	O	O	1125
with	ADP	O	O	1125
phenacetin	VERB	O	O	1125
.	PUNCT	O	O	1125
Six	NUM	O	O	1126
epidemiologic	ADJ	O	O	1126
studies	NOUN	O	O	1126
in	ADP	O	O	1126
the	PRON	O	O	1126
United	PROPN	O	O	1126
States	NOUN	O	O	1126
and	CCONJ	O	O	1126
Europe	PROPN	O	O	1126
indicate	VERB	O	O	1126
that	SCONJ	O	O	1126
habitual	ADJ	O	O	1126
use	VERB	O	O	1126
of	ADP	O	O	1126
phenacetin	VERB	O	O	1126
is	AUX	O	O	1126
associated	VERB	O	O	1126
with	ADP	O	O	1126
the	PRON	O	O	1126
development	NOUN	O	O	1126
of	ADP	O	O	1126
chronic	ADJ	O	O	1126
renal failure	NOUN	O	Disease	1126
and	CCONJ	O	O	1126
end	VERB	O	O	1126
-	PUNCT	O	O	1126
stage	NOUN	O	O	1126
renal disease	NOUN	O	Disease	1126
(	PUNCT	O	O	1126
ESRD	PROPN	O	Disease	1126
)	PUNCT	O	O	1126
,	PUNCT	O	O	1126
with	ADP	O	O	1126
a	PRON	O	O	1126
relative	ADJ	O	O	1126
risk	NOUN	O	O	1126
in	ADP	O	O	1126
the	PRON	O	O	1126
range	VERB	O	O	1126
of	ADP	O	O	1126
4	NUM	O	O	1126
to	PART	O	O	1126
19	NUM	O	O	1126
.	PUNCT	O	O	1126
As	ADP	O	O	1127
a	PRON	O	O	1127
result	VERB	O	O	1127
of	ADP	O	O	1127
these	PRON	O	O	1127
and	CCONJ	O	O	1127
other	ADJ	O	O	1127
studies	NOUN	O	O	1127
,	PUNCT	O	O	1127
phenacetin	VERB	O	O	1127
has	VERB	O	O	1127
now	ADV	O	O	1127
been	AUX	O	O	1127
withdrawn	VERB	O	O	1127
from	ADP	O	O	1127
the	PRON	O	O	1127
market	NOUN	O	O	1127
in	ADP	O	O	1127
most	ADV	O	O	1127
countries	NOUN	O	O	1127
.	PUNCT	O	O	1127
However	ADV	O	O	1128
,	PUNCT	O	O	1128
three	NUM	O	O	1128
case	NOUN	O	O	1128
control	VERB	O	O	1128
studies	NOUN	O	O	1128
,	PUNCT	O	O	1128
one	NUM	O	O	1128
each	PRON	O	O	1128
in	ADP	O	O	1128
North	NOUN	O	O	1128
Carolina	PROPN	O	O	1128
,	PUNCT	O	O	1128
northern	ADJ	O	O	1128
Maryland	PROPN	O	O	1128
,	PUNCT	O	O	1128
and	CCONJ	O	O	1128
West	NOUN	O	O	1128
Berlin	PROPN	O	O	1128
,	PUNCT	O	O	1128
Germany	PROPN	O	O	1128
,	PUNCT	O	O	1128
showed	VERB	O	O	1128
that	SCONJ	O	O	1128
habitual	ADJ	O	O	1128
use	VERB	O	O	1128
of	ADP	O	O	1128
acetaminophen	PROPN	O	Chemical	1128
is	AUX	O	O	1128
also	ADV	O	O	1128
associated	VERB	O	O	1128
with	ADP	O	O	1128
chronic	ADJ	O	O	1128
renal failure	NOUN	O	Disease	1128
and	CCONJ	O	O	1128
ESRD	PROPN	O	Disease	1128
,	PUNCT	O	O	1128
with	ADP	O	O	1128
a	PRON	O	O	1128
relative	ADJ	O	O	1128
risk	NOUN	O	O	1128
in	ADP	O	O	1128
the	PRON	O	O	1128
range	VERB	O	O	1128
of	ADP	O	O	1128
2	X	O	O	1128
to	PART	O	O	1128
4	NUM	O	O	1128
.	PUNCT	O	O	1128
These	PRON	O	O	1129
studies	NOUN	O	O	1129
suggest	VERB	O	O	1129
that	SCONJ	O	O	1129
both	PRON	O	O	1129
phenacetin	VERB	O	O	1129
and	CCONJ	O	O	1129
acetaminophen	PROPN	O	Chemical	1129
may	AUX	O	O	1129
contribute	VERB	O	O	1129
to	PART	O	O	1129
the	PRON	O	O	1129
burden	VERB	O	O	1129
of	ADP	O	O	1129
ESRD	PROPN	O	Disease	1129
,	PUNCT	O	O	1129
with	ADP	O	O	1129
the	PRON	O	O	1129
risk	NOUN	O	O	1129
of	ADP	O	O	1129
the	PRON	O	O	1129
latter	ADJ	O	O	1129
being	AUX	O	O	1129
somewhat	ADV	O	O	1129
less	ADV	O	O	1129
than	ADP	O	O	1129
that	SCONJ	O	O	1129
of	ADP	O	O	1129
the	PRON	O	O	1129
former	ADJ	O	O	1129
.	PUNCT	O	O	1129
This	PRON	O	O	1130
apparent	ADJ	O	O	1130
difference	NOUN	O	O	1130
in	ADP	O	O	1130
risk	NOUN	O	O	1130
may	AUX	O	O	1130
not	PART	O	O	1130
be	AUX	O	O	1130
due	ADJ	O	O	1130
to	PART	O	O	1130
differences	NOUN	O	O	1130
in	ADP	O	O	1130
nephrotoxic	NOUN	O	Disease	1130
potential	ADJ	O	O	1130
of	ADP	O	O	1130
the	PRON	O	O	1130
drugs	NOUN	O	O	1130
themselves	PRON	O	O	1130
.	PUNCT	O	O	1130
A	PRON	O	O	1131
lower	ADJ	O	O	1131
relative	ADJ	O	O	1131
risk	NOUN	O	O	1131
would	AUX	O	O	1131
be	AUX	O	O	1131
expected	VERB	O	O	1131
for	ADP	O	O	1131
acetaminophen	PROPN	O	Chemical	1131
if	SCONJ	O	O	1131
the	PRON	O	O	1131
risk	NOUN	O	O	1131
of	ADP	O	O	1131
both	PRON	O	O	1131
drugs	NOUN	O	O	1131
in	ADP	O	O	1131
combination	NOUN	O	O	1131
with	ADP	O	O	1131
other	ADJ	O	O	1131
analgesics	NOUN	O	O	1131
was	AUX	O	O	1131
higher	ADJ	O	O	1131
than	ADP	O	O	1131
the	PRON	O	O	1131
risk	NOUN	O	O	1131
of	ADP	O	O	1131
either	ADV	O	O	1131
agent	NOUN	O	O	1131
alone	ADV	O	O	1131
.	PUNCT	O	O	1131
Thus	ADV	O	O	1132
,	PUNCT	O	O	1132
acetaminophen	PROPN	O	Chemical	1132
has	VERB	O	O	1132
been	AUX	O	O	1132
used	VERB	O	O	1132
both	PRON	O	O	1132
as	ADP	O	O	1132
a	PRON	O	O	1132
single	ADJ	O	O	1132
agent	NOUN	O	O	1132
and	CCONJ	O	O	1132
in	ADP	O	O	1132
combination	NOUN	O	O	1132
with	ADP	O	O	1132
other	ADJ	O	O	1132
analgesics	NOUN	O	O	1132
,	PUNCT	O	O	1132
whereas	SCONJ	O	O	1132
phenacetin	VERB	O	O	1132
was	AUX	O	O	1132
available	ADJ	O	O	1132
only	ADV	O	O	1132
in	ADP	O	O	1132
combinations	NOUN	O	O	1132
.	PUNCT	O	O	1132
The	PRON	O	O	1133
possibility	NOUN	O	O	1133
that	SCONJ	O	O	1133
habitual	ADJ	O	O	1133
use	VERB	O	O	1133
of	ADP	O	O	1133
acetaminophen	PROPN	O	Chemical	1133
alone	ADV	O	O	1133
increases	VERB	O	O	1133
the	PRON	O	O	1133
risk	NOUN	O	O	1133
of	ADP	O	O	1133
ESRD	PROPN	O	Disease	1133
has	VERB	O	O	1133
not	PART	O	O	1133
been	AUX	O	O	1133
clearly	ADV	O	O	1133
demonstrated	VERB	O	O	1133
,	PUNCT	O	O	1133
but	CCONJ	O	O	1133
can	AUX	O	O	1133
not	PART	O	O	1133
be	AUX	O	O	1133
dismissed	VERB	O	O	1133
.	PUNCT	O	O	1133
Reduction	NOUN	O	O	1136
of	ADP	O	O	1136
heparan	NOUN	O	O	1136
sulphate	NOUN	O	O	1136
-	PUNCT	O	O	1136
associated	VERB	O	O	1136
anionic	ADJ	O	O	1136
sites	NOUN	O	O	1136
in	ADP	O	O	1136
the	PRON	O	O	1136
glomerular	ADJ	O	O	1136
basement	NOUN	O	O	1136
membrane	NOUN	O	O	1136
of	ADP	O	O	1136
rats	NOUN	O	O	1136
with	ADP	O	O	1136
streptozotocin	PROPN	O	Chemical	1136
-	PUNCT	O	O	1136
induced	VERB	O	O	1136
diabetic nephropathy	NOUN	O	Disease	1136
.	PUNCT	O	O	1136
Heparan	PROPN	O	O	1137
sulphate	NOUN	O	O	1137
-	PUNCT	O	O	1137
associated	VERB	O	O	1137
anionic	ADJ	O	O	1137
sites	NOUN	O	O	1137
in	ADP	O	O	1137
the	PRON	O	O	1137
glomerular	ADJ	O	O	1137
basement	NOUN	O	O	1137
membrane	NOUN	O	O	1137
were	AUX	O	O	1137
studied	VERB	O	O	1137
in	ADP	O	O	1137
rats	NOUN	O	O	1137
8	NUM	O	O	1137
months	NOUN	O	O	1137
after	ADP	O	O	1137
induction	NOUN	O	O	1137
of	ADP	O	O	1137
diabetes	NOUN	O	Disease	1137
by	ADP	O	O	1137
streptozotocin	PROPN	O	Chemical	1137
and	CCONJ	O	O	1137
in	ADP	O	O	1137
age-	ADJ	O	O	1137
adn	PROPN	O	O	1137
sex	NOUN	O	O	1137
-	PUNCT	O	O	1137
matched	VERB	O	O	1137
control	VERB	O	O	1137
rats	NOUN	O	O	1137
,	PUNCT	O	O	1137
employing	VERB	O	O	1137
the	PRON	O	O	1137
cationic	ADJ	O	O	1137
dye	NOUN	O	O	1137
cuprolinic	NOUN	O	O	1137
blue	ADJ	O	O	1137
.	PUNCT	O	O	1137
The	PRON	O	O	1138
heparan	NOUN	O	O	1138
sulphate	NOUN	O	O	1138
specificity	NOUN	O	O	1138
of	ADP	O	O	1138
the	PRON	O	O	1138
cuprolinic	NOUN	O	O	1138
blue	ADJ	O	O	1138
staining	VERB	O	O	1138
was	AUX	O	O	1138
demonstrated	VERB	O	O	1138
by	ADP	O	O	1138
glycosaminoglycan	NOUN	O	O	1138
-	PUNCT	O	O	1138
degrading	VERB	O	O	1138
enzymes	NOUN	O	O	1138
,	PUNCT	O	O	1138
showing	VERB	O	O	1138
that	SCONJ	O	O	1138
pretreatment	NOUN	O	O	1138
of	ADP	O	O	1138
the	PRON	O	O	1138
sections	NOUN	O	O	1138
with	ADP	O	O	1138
heparitinase	NOUN	O	O	1138
abolished	VERB	O	O	1138
all	PRON	O	O	1138
staining	VERB	O	O	1138
,	PUNCT	O	O	1138
whereas	SCONJ	O	O	1138
chondroitinase	PROPN	O	O	1138
ABC	PROPN	O	O	1138
had	VERB	O	O	1138
no	PRON	O	O	1138
effect	VERB	O	O	1138
.	PUNCT	O	O	1138
The	PRON	O	O	1139
majority	NOUN	O	O	1139
of	ADP	O	O	1139
anionic	ADJ	O	O	1139
sites	NOUN	O	O	1139
(	PUNCT	O	O	1139
74%	NOUN	O	O	1139
in	ADP	O	O	1139
diabetic	ADJ	O	Disease	1139
and	CCONJ	O	O	1139
81%	NOUN	O	O	1139
in	ADP	O	O	1139
control	VERB	O	O	1139
rats	NOUN	O	O	1139
)	PUNCT	O	O	1139
were	AUX	O	O	1139
found	VERB	O	O	1139
within	ADP	O	O	1139
the	PRON	O	O	1139
lamina	ADJ	O	O	1139
rara	PROPN	O	O	1139
externa	VERB	O	O	1139
of	ADP	O	O	1139
the	PRON	O	O	1139
glomerular	ADJ	O	O	1139
basement	NOUN	O	O	1139
membrane	NOUN	O	O	1139
.	PUNCT	O	O	1139
A	PRON	O	O	1140
minority	NOUN	O	O	1140
of	ADP	O	O	1140
anionic	ADJ	O	O	1140
sites	NOUN	O	O	1140
were	AUX	O	O	1140
scattered	VERB	O	O	1140
throughout	ADP	O	O	1140
the	PRON	O	O	1140
lamina	ADJ	O	O	1140
densa	NOUN	O	O	1140
and	CCONJ	O	O	1140
lamina	ADJ	O	O	1140
rara	PROPN	O	O	1140
interna	PROPN	O	O	1140
,	PUNCT	O	O	1140
and	CCONJ	O	O	1140
were	AUX	O	O	1140
significantly	ADV	O	O	1140
smaller	ADJ	O	O	1140
than	ADP	O	O	1140
those	PRON	O	O	1140
in	ADP	O	O	1140
the	PRON	O	O	1140
lamina	ADJ	O	O	1140
rara	PROPN	O	O	1140
externa	VERB	O	O	1140
of	ADP	O	O	1140
the	PRON	O	O	1140
glomerular	ADJ	O	O	1140
basement	NOUN	O	O	1140
membrane	NOUN	O	O	1140
(	PUNCT	O	O	1140
p<0.001	ADJ	O	O	1140
and	CCONJ	O	O	1140
p<0.01	ADV	O	O	1140
for	ADP	O	O	1140
diabetic	ADJ	O	Disease	1140
and	CCONJ	O	O	1140
control	VERB	O	O	1140
rats	NOUN	O	O	1140
,	PUNCT	O	O	1140
respectively	ADV	O	O	1140
)	PUNCT	O	O	1140
.	PUNCT	O	O	1140
Diabetic	ADJ	O	O	1141
rats	NOUN	O	O	1141
progressively	ADV	O	O	1141
developed	VERB	O	O	1141
albuminuria	PROPN	O	Disease	1141
reaching	VERB	O	O	1141
40.3	NUM	O	O	1141
(	PUNCT	O	O	1141
32.2	NUM	O	O	1141
-	PUNCT	O	O	1141
62.0	NUM	O	O	1141
)	PUNCT	O	O	1141
At	ADP	O	O	1142
the	PRON	O	O	1142
same	ADJ	O	O	1142
time	NOUN	O	O	1142
,	PUNCT	O	O	1142
the	PRON	O	O	1142
number	NOUN	O	O	1142
of	ADP	O	O	1142
heparan	NOUN	O	O	1142
sulphate	NOUN	O	O	1142
anionic	ADJ	O	O	1142
sites	NOUN	O	O	1142
and	CCONJ	O	O	1142
the	PRON	O	O	1142
total	ADJ	O	O	1142
anionic	ADJ	O	O	1142
site	NOUN	O	O	1142
surface	NOUN	O	O	1142
(	PUNCT	O	O	1142
number	NOUN	O	O	1142
of	ADP	O	O	1142
anionic	ADJ	O	O	1142
sites	NOUN	O	O	1142
x	X	O	O	1142
mean	VERB	O	O	1142
anionic	ADJ	O	O	1142
site	NOUN	O	O	1142
surface	NOUN	O	O	1142
)	PUNCT	O	O	1142
in	ADP	O	O	1142
the	PRON	O	O	1142
lamina	ADJ	O	O	1142
rara	PROPN	O	O	1142
externa	VERB	O	O	1142
of	ADP	O	O	1142
the	PRON	O	O	1142
glomerular	ADJ	O	O	1142
basement	NOUN	O	O	1142
membrane	NOUN	O	O	1142
was	AUX	O	O	1142
reduced	VERB	O	O	1142
by	ADP	O	O	1142
19%	NOUN	O	O	1142
(	PUNCT	O	O	1142
p<0.021	NOUN	O	O	1142
)	PUNCT	O	O	1142
and	CCONJ	O	O	1142
by	ADP	O	O	1142
26%	NOUN	O	O	1142
(	PUNCT	O	O	1142
p<0.02	PROPN	O	O	1142
)	PUNCT	O	O	1142
,	PUNCT	O	O	1142
respectively	ADV	O	O	1142
.	PUNCT	O	O	1142
We	PRON	O	O	1143
conclude	VERB	O	O	1143
that	SCONJ	O	O	1143
in	ADP	O	O	1143
streptozotocin	PROPN	O	Chemical	1143
-	PUNCT	O	O	1143
diabetic	ADJ	O	Disease	1143
rats	NOUN	O	O	1143
with	ADP	O	O	1143
an	PRON	O	O	1143
increased	VERB	O	O	1143
urinary	ADJ	O	O	1143
albumin	PROPN	O	O	1143
excretion	NOUN	O	O	1143
,	PUNCT	O	O	1143
a	PRON	O	O	1143
reduced	VERB	O	O	1143
heparan	NOUN	O	O	1143
sulphate	NOUN	O	O	1143
charge	NOUN	O	O	1143
barrier	NOUN	O	O	1143
/	PUNCT	O	O	1143
density	NOUN	O	O	1143
is	AUX	O	O	1143
found	VERB	O	O	1143
at	ADP	O	O	1143
the	PRON	O	O	1143
lamina	ADJ	O	O	1143
rara	PROPN	O	O	1143
externa	VERB	O	O	1143
of	ADP	O	O	1143
the	PRON	O	O	1143
glomerular	ADJ	O	O	1143
basement	NOUN	O	O	1143
membrane	NOUN	O	O	1143
.	PUNCT	O	O	1143
Effect	VERB	O	O	1146
of	ADP	O	O	1146
some	PRON	O	O	1146
anticancer	NOUN	O	O	1146
drugs	NOUN	O	O	1146
and	CCONJ	O	O	1146
combined	VERB	O	O	1146
chemotherapy	NOUN	O	O	1146
on	ADP	O	O	1146
renal toxicity	NOUN	O	Disease	1146
.	PUNCT	O	O	1146
The	PRON	O	O	1147
nephrotoxic	NOUN	O	Disease	1147
action	NOUN	O	O	1147
of	ADP	O	O	1147
anticancer	NOUN	O	O	1147
drugs	NOUN	O	O	1147
such	ADJ	O	O	1147
as	ADP	O	O	1147
nitrogranulogen	NOUN	O	O	1147
(	PUNCT	O	O	1147
NG	PROPN	O	O	1147
)	PUNCT	O	O	1147
,	PUNCT	O	O	1147
methotrexate	CCONJ	O	Chemical	1147
(	PUNCT	O	O	1147
MTX	PROPN	O	O	1147
)	PUNCT	O	O	1147
,	PUNCT	O	O	1147
5-fluorouracil	NOUN	O	Chemical	1147
(	PUNCT	O	O	1147
5-FU	NOUN	O	Chemical	1147
)	PUNCT	O	O	1147
and	CCONJ	O	O	1147
cyclophosphamide	VERB	O	Chemical	1147
(	PUNCT	O	O	1147
CY	PROPN	O	O	1148
)	PUNCT	O	O	1148
administered	VERB	O	O	1148
alone	ADV	O	O	1148
or	CCONJ	O	O	1148
in	ADP	O	O	1148
combination	NOUN	O	O	1148
[	X	O	O	1148
MTX	PROPN	O	O	1148
+	ADP	O	O	1148
5-FU	NOUN	O	Chemical	1148
+	ADP	O	O	1148
CY	PROPN	O	O	1148
(	PUNCT	O	O	1148
CMF	PROPN	O	O	1148
)	PUNCT	O	O	1148
]	PUNCT	O	O	1148
was	AUX	O	O	1148
evaluated	VERB	O	O	1148
in	ADP	O	O	1148
experiments	NOUN	O	O	1148
on	ADP	O	O	1148
Wistar	PROPN	O	O	1148
rats	NOUN	O	O	1148
.	PUNCT	O	O	1148
After	ADP	O	O	1149
drug	NOUN	O	O	1149
administration	NOUN	O	O	1149
,	PUNCT	O	O	1149
creatinine	PROPN	O	Chemical	1149
concentrations	NOUN	O	O	1149
in	ADP	O	O	1149
the	PRON	O	O	1149
plasma	NOUN	O	O	1149
and	CCONJ	O	O	1149
in	ADP	O	O	1149
the	PRON	O	O	1149
urine	NOUN	O	O	1149
of	ADP	O	O	1149
the	PRON	O	O	1149
rats	NOUN	O	O	1149
were	AUX	O	O	1149
determined	VERB	O	O	1149
,	PUNCT	O	O	1149
as	ADP	O	O	1149
well	ADV	O	O	1149
as	ADP	O	O	1149
creatinine	PROPN	O	Chemical	1149
clearance	NOUN	O	O	1149
.	PUNCT	O	O	1149
After	ADP	O	O	1150
MTX	PROPN	O	O	1150
administration	NOUN	O	O	1150
a	PRON	O	O	1150
significant	ADJ	O	O	1150
increase	VERB	O	O	1150
(	PUNCT	O	O	1150
p	NOUN	O	O	1150
=	PUNCT	O	O	1150
0.0228	NUM	O	O	1150
)	PUNCT	O	O	1150
in	ADP	O	O	1150
the	PRON	O	O	1150
plasma	NOUN	O	O	1150
creatinine	PROPN	O	Chemical	1150
concentration	NOUN	O	O	1150
and	CCONJ	O	O	1150
a	PRON	O	O	1150
significant	ADJ	O	O	1150
(	PUNCT	O	O	1150
p	NOUN	O	O	1150
=	PUNCT	O	O	1150
0.0001	NUM	O	O	1150
)	PUNCT	O	O	1150
decrease	VERB	O	O	1150
in	ADP	O	O	1150
creatinine	PROPN	O	Chemical	1150
clearance	NOUN	O	O	1150
was	AUX	O	O	1150
noted	VERB	O	O	1150
compared	VERB	O	O	1150
to	PART	O	O	1150
controls	VERB	O	O	1150
.	PUNCT	O	O	1150
After	ADP	O	O	1151
the	PRON	O	O	1151
administration	NOUN	O	O	1151
of	ADP	O	O	1151
NG	PROPN	O	O	1151
,	PUNCT	O	O	1151
5-FU	NOUN	O	Chemical	1151
and	CCONJ	O	O	1151
CY	PROPN	O	O	1151
neither	ADV	O	O	1151
a	PRON	O	O	1151
statistically	ADV	O	O	1151
significant	ADJ	O	O	1151
increase	VERB	O	O	1151
in	ADP	O	O	1151
creatinine	PROPN	O	Chemical	1151
concentration	NOUN	O	O	1151
nor	CCONJ	O	O	1151
an	PRON	O	O	1151
increase	VERB	O	O	1151
in	ADP	O	O	1151
creatinine	PROPN	O	Chemical	1151
clearance	NOUN	O	O	1151
was	AUX	O	O	1151
observed	VERB	O	O	1151
compared	VERB	O	O	1151
to	PART	O	O	1151
the	PRON	O	O	1151
group	NOUN	O	O	1151
receiving	VERB	O	O	1151
no	PRON	O	O	1151
cytostatics	NOUN	O	O	1151
.	PUNCT	O	O	1151
Following	VERB	O	O	1152
polytherapy	PROPN	O	O	1152
according	VERB	O	O	1152
to	PART	O	O	1152
the	PRON	O	O	1152
CMF	PROPN	O	O	1152
regimen	NOUN	O	O	1152
,	PUNCT	O	O	1152
a	PRON	O	O	1152
statistically	ADV	O	O	1152
significant	ADJ	O	O	1152
decrease	VERB	O	O	1152
(	PUNCT	O	O	1152
p	NOUN	O	O	1152
=	PUNCT	O	O	1152
0.0343	NUM	O	O	1152
)	PUNCT	O	O	1152
in	ADP	O	O	1152
creatinine	PROPN	O	Chemical	1152
clearance	NOUN	O	O	1152
was	AUX	O	O	1152
found	VERB	O	O	1152
,	PUNCT	O	O	1152
but	CCONJ	O	O	1152
creatinine	PROPN	O	Chemical	1152
concentration	NOUN	O	O	1152
did	VERB	O	O	1152
not	PART	O	O	1152
increase	VERB	O	O	1152
significantly	ADV	O	O	1152
compared	VERB	O	O	1152
to	PART	O	O	1152
controls	VERB	O	O	1152
.	PUNCT	O	O	1152
CY	PROPN	O	O	1153
caused	VERB	O	O	1153
hemorrhagic cystitis	NOUN	O	Disease	1153
in	ADP	O	O	1153
40%	NOUN	O	O	1153
of	ADP	O	O	1153
rats	NOUN	O	O	1153
,	PUNCT	O	O	1153
but	CCONJ	O	O	1153
it	PRON	O	O	1153
did	VERB	O	O	1153
not	PART	O	O	1153
cause	VERB	O	O	1153
this	PRON	O	O	1153
complication	NOUN	O	O	1153
when	SCONJ	O	O	1153
combined	VERB	O	O	1153
with	ADP	O	O	1153
5-FU	NOUN	O	Chemical	1153
and	CCONJ	O	O	1153
MTX	PROPN	O	O	1153
.	PUNCT	O	O	1153
Histologic	NOUN	O	O	1154
changes	VERB	O	O	1154
were	AUX	O	O	1154
found	VERB	O	O	1154
in	ADP	O	O	1154
rat	NOUN	O	O	1154
kidneys	NOUN	O	O	1154
after	ADP	O	O	1154
administration	NOUN	O	O	1154
of	ADP	O	O	1154
MTX	PROPN	O	O	1154
,	PUNCT	O	O	1154
CY	PROPN	O	O	1154
and	CCONJ	O	O	1154
NG	PROPN	O	O	1154
,	PUNCT	O	O	1154
while	SCONJ	O	O	1154
no	PRON	O	O	1154
such	ADJ	O	O	1154
change	VERB	O	O	1154
was	AUX	O	O	1154
observed	VERB	O	O	1154
after	ADP	O	O	1154
5-FU	NOUN	O	Chemical	1154
and	CCONJ	O	O	1154
joint	ADJ	O	O	1154
administration	NOUN	O	O	1154
of	ADP	O	O	1154
MTX	PROPN	O	O	1154
+	ADP	O	O	1154
5-FU	NOUN	O	Chemical	1154
+	ADP	O	O	1155
CY	PROPN	O	O	1155
compared	VERB	O	O	1155
to	PART	O	O	1155
controls	VERB	O	O	1155
.	PUNCT	O	O	1155
Our	PRON	O	O	1156
studies	NOUN	O	O	1156
indicate	VERB	O	O	1156
that	SCONJ	O	O	1156
nephrotoxicity	NOUN	O	Disease	1156
of	ADP	O	O	1156
MTX	PROPN	O	O	1156
+	ADP	O	O	1156
5-FU	NOUN	O	Chemical	1156
+	ADP	O	O	1156
CY	PROPN	O	O	1156
administered	VERB	O	O	1156
jointly	ADV	O	O	1156
is	AUX	O	O	1156
lower	ADJ	O	O	1156
than	ADP	O	O	1156
in	ADP	O	O	1156
monotherapy	X	O	O	1156
.	PUNCT	O	O	1156
Lithium	NOUN	O	Chemical	1159
-	PUNCT	O	O	1159
associated	VERB	O	O	1159
cognitive	ADJ	O	O	1159
and	CCONJ	O	O	1159
functional	ADJ	O	O	1159
deficits	NOUN	O	O	1159
reduced	VERB	O	O	1159
by	ADP	O	O	1159
a	PRON	O	O	1159
switch	VERB	O	O	1159
to	PART	O	O	1159
divalproex	PROPN	O	Chemical	1159
sodium	NOUN	O	Chemical	1159
:	PUNCT	O	O	1159
a	PRON	O	O	1159
case	NOUN	O	O	1159
series	PROPN	O	O	1159
.	PUNCT	O	O	1159
Lithium	NOUN	O	Chemical	1160
remains	VERB	O	O	1160
a	PRON	O	O	1160
first	ADV	O	O	1160
-	PUNCT	O	O	1160
line	NOUN	O	O	1160
treatment	NOUN	O	O	1160
for	ADP	O	O	1160
the	PRON	O	O	1160
acute	ADJ	O	O	1160
and	CCONJ	O	O	1160
maintenance	NOUN	O	O	1160
treatment	NOUN	O	O	1160
of	ADP	O	O	1160
bipolar disorder	NOUN	O	Disease	1160
.	PUNCT	O	O	1160
Although	SCONJ	O	O	1161
much	ADJ	O	O	1161
has	VERB	O	O	1161
been	AUX	O	O	1161
written	VERB	O	O	1161
about	ADP	O	O	1161
the	PRON	O	O	1161
management	NOUN	O	O	1161
of	ADP	O	O	1161
the	PRON	O	O	1161
more	ADJ	O	O	1161
common	ADJ	O	O	1161
adverse	ADJ	O	O	1161
effects	NOUN	O	O	1161
of	ADP	O	O	1161
lithium	NOUN	O	Chemical	1161
,	PUNCT	O	O	1161
such	ADJ	O	O	1161
as	ADP	O	O	1161
polyuria	PROPN	O	Disease	1161
and	CCONJ	O	O	1161
tremor	NOUN	O	Disease	1161
,	PUNCT	O	O	1161
more	ADJ	O	O	1161
subtle	ADJ	O	O	1161
lithium	NOUN	O	Chemical	1161
side	NOUN	O	O	1161
effects	NOUN	O	O	1161
such	ADJ	O	O	1161
as	ADP	O	O	1161
cognitive deficits	NOUN	O	Disease	1161
,	PUNCT	O	O	1161
loss	NOUN	O	O	1161
of	ADP	O	O	1161
creativity	NOUN	O	O	1161
,	PUNCT	O	O	1161
and	CCONJ	O	O	1161
functional	ADJ	O	O	1161
impairments	VERB	O	O	1161
remain	VERB	O	O	1161
understudied	ADJ	O	O	1161
.	PUNCT	O	O	1161
This	PRON	O	O	1162
report	VERB	O	O	1162
summarizes	VERB	O	O	1162
our	PRON	O	O	1162
experience	NOUN	O	O	1162
in	ADP	O	O	1162
switching	VERB	O	O	1162
bipolar	ADJ	O	O	1162
patients	NOUN	O	O	1162
from	ADP	O	O	1162
lithium	NOUN	O	Chemical	1162
to	PART	O	O	1162
divalproex	PROPN	O	Chemical	1162
sodium	NOUN	O	Chemical	1162
to	PART	O	O	1162
alleviate	VERB	O	O	1162
such	ADJ	O	O	1162
cognitive	ADJ	O	O	1162
and	CCONJ	O	O	1162
functional	ADJ	O	O	1162
impairments	VERB	O	O	1162
.	PUNCT	O	O	1162
We	PRON	O	O	1163
report	VERB	O	O	1163
seven	NUM	O	O	1163
cases	NOUN	O	O	1163
where	SCONJ	O	O	1163
substitution	NOUN	O	O	1163
of	ADP	O	O	1163
lithium	NOUN	O	Chemical	1163
,	PUNCT	O	O	1163
either	ADV	O	O	1163
fully	ADV	O	O	1163
or	CCONJ	O	O	1163
partially	ADV	O	O	1163
,	PUNCT	O	O	1163
with	ADP	O	O	1163
divalproex	PROPN	O	Chemical	1163
sodium	NOUN	O	Chemical	1163
was	AUX	O	O	1163
extremely	ADV	O	O	1163
helpful	ADJ	O	O	1163
in	ADP	O	O	1163
reducing	VERB	O	O	1163
the	PRON	O	O	1163
cognitive	ADJ	O	O	1163
,	PUNCT	O	O	1163
motivational	ADJ	O	O	1163
,	PUNCT	O	O	1163
or	CCONJ	O	O	1163
creative	ADJ	O	O	1163
deficits	NOUN	O	O	1163
attributed	VERB	O	O	1163
to	PART	O	O	1163
lithium	NOUN	O	Chemical	1163
in	ADP	O	O	1163
our	PRON	O	O	1163
bipolar	ADJ	O	O	1163
patients	NOUN	O	O	1163
.	PUNCT	O	O	1163
In	ADP	O	O	1164
this	PRON	O	O	1164
preliminary	ADJ	O	O	1164
report	VERB	O	O	1164
,	PUNCT	O	O	1164
divalproex	PROPN	O	Chemical	1164
sodium	NOUN	O	Chemical	1164
was	AUX	O	O	1164
a	PRON	O	O	1164
superior	PROPN	O	O	1164
alternative	ADV	O	O	1164
to	PART	O	O	1164
lithium	NOUN	O	Chemical	1164
in	ADP	O	O	1164
bipolar	ADJ	O	O	1164
patients	NOUN	O	O	1164
experiencing	VERB	O	O	1164
cognitive deficits	NOUN	O	Disease	1164
,	PUNCT	O	O	1164
loss	NOUN	O	O	1164
of	ADP	O	O	1164
creativity	NOUN	O	O	1164
,	PUNCT	O	O	1164
and	CCONJ	O	O	1164
functional	ADJ	O	O	1164
impairments	VERB	O	O	1164
.	PUNCT	O	O	1164
Treatment	NOUN	O	O	1167
of	ADP	O	O	1167
previously	ADV	O	O	1167
treated	VERB	O	O	1167
metastatic	ADJ	O	O	1167
breast cancer	NOUN	O	Disease	1167
by	ADP	O	O	1167
mitoxantrone	NOUN	O	Chemical	1167
and	CCONJ	O	O	1167
48-hour	NOUN	O	O	1167
continuous	ADJ	O	O	1167
infusion	NOUN	O	O	1167
of	ADP	O	O	1167
high	ADJ	O	O	1167
-	PUNCT	O	O	1167
dose	NOUN	O	O	1167
5-FU	NOUN	O	Chemical	1167
and	CCONJ	O	O	1167
leucovorin	NOUN	O	O	1167
(	PUNCT	O	O	1167
MFL	PROPN	O	O	1167
)	PUNCT	O	O	1167
:	PUNCT	O	O	1167
low	ADJ	O	O	1167
palliative	NOUN	O	O	1167
benefit	VERB	O	O	1167
and	CCONJ	O	O	1167
high	ADJ	O	O	1167
treatment	NOUN	O	O	1167
-	PUNCT	O	O	1167
related	ADJ	O	O	1167
toxicity	NOUN	O	Disease	1167
.	PUNCT	O	O	1167
For	ADP	O	O	1168
previously	ADV	O	O	1168
treated	VERB	O	O	1168
advanced	ADJ	O	O	1168
breast cancer	NOUN	O	Disease	1168
,	PUNCT	O	O	1168
there	ADV	O	O	1168
is	AUX	O	O	1168
no	PRON	O	O	1168
standard	PROPN	O	O	1168
second	ADV	O	O	1168
-	PUNCT	O	O	1168
line	NOUN	O	O	1168
therapy	NOUN	O	O	1168
.	PUNCT	O	O	1168
Combination	NOUN	O	O	1169
chemotherapy	NOUN	O	O	1169
with	ADP	O	O	1169
mitoxantrone	NOUN	O	Chemical	1169
,	PUNCT	O	O	1169
high	ADJ	O	O	1169
-	PUNCT	O	O	1169
dose	NOUN	O	O	1169
5-fluorouracil	NOUN	O	Chemical	1169
(	PUNCT	O	O	1169
5-FU	NOUN	O	Chemical	1169
)	PUNCT	O	O	1169
and	CCONJ	O	O	1169
leucovorin	NOUN	O	O	1169
(	PUNCT	O	O	1169
MFL	PROPN	O	O	1169
regimen	NOUN	O	O	1169
)	PUNCT	O	O	1169
had	VERB	O	O	1169
been	AUX	O	O	1169
reported	VERB	O	O	1169
as	ADP	O	O	1169
an	PRON	O	O	1169
effective	ADJ	O	O	1169
and	CCONJ	O	O	1169
well	ADV	O	O	1169
tolerated	VERB	O	O	1169
regimen	NOUN	O	O	1169
.	PUNCT	O	O	1169
From	ADP	O	O	1170
October	PROPN	O	O	1170
1993	NUM	O	O	1170
to	PART	O	O	1170
November	PROPN	O	O	1170
1995	NUM	O	O	1170
,	PUNCT	O	O	1170
we	PRON	O	O	1170
treated	VERB	O	O	1170
13	NUM	O	O	1170
patients	NOUN	O	O	1170
with	ADP	O	O	1170
previously	ADV	O	O	1170
chemotherapy	NOUN	O	O	1170
-	PUNCT	O	O	1170
treated	VERB	O	O	1170
metastatic	ADJ	O	O	1170
breast cancer	NOUN	O	Disease	1170
by	ADP	O	O	1170
mitoxantrone	NOUN	O	Chemical	1170
,	PUNCT	O	O	1170
12	NUM	O	O	1170
mg	VERB	O	O	1170
/	PUNCT	O	O	1170
m2	PROPN	O	O	1170
,	PUNCT	O	O	1170
on	ADP	O	O	1170
day	NOUN	O	O	1170
1	X	O	O	1170
and	CCONJ	O	O	1170
continuous	ADJ	O	O	1170
infusion	NOUN	O	O	1170
of	ADP	O	O	1170
5-FU	NOUN	O	Chemical	1170
,	PUNCT	O	O	1170
3000	NUM	O	O	1170
mg	VERB	O	O	1170
/	PUNCT	O	O	1170
m2	PROPN	O	O	1170
,	PUNCT	O	O	1170
together	ADV	O	O	1170
with	ADP	O	O	1170
leucovorin	NOUN	O	O	1170
,	PUNCT	O	O	1170
300	NUM	O	O	1170
mg	VERB	O	O	1170
/	PUNCT	O	O	1170
m2	PROPN	O	O	1170
,	PUNCT	O	O	1170
for	ADP	O	O	1170
48	NUM	O	O	1170
h	X	O	O	1170
from	ADP	O	O	1170
day	NOUN	O	O	1170
1	X	O	O	1170
to	PART	O	O	1170
2	X	O	O	1170
.	PUNCT	O	O	1170
Seven	NUM	O	O	1171
patients	NOUN	O	O	1171
had	VERB	O	O	1171
been	AUX	O	O	1171
treated	VERB	O	O	1171
with	ADP	O	O	1171
anthracycline	NOUN	O	Chemical	1171
.	PUNCT	O	O	1171
Median	ADJ	O	O	1172
number	NOUN	O	O	1172
of	ADP	O	O	1172
courses	NOUN	O	O	1172
of	ADP	O	O	1172
MFL	PROPN	O	O	1172
regimen	NOUN	O	O	1172
given	VERB	O	O	1172
was	AUX	O	O	1172
six	NUM	O	O	1172
and	CCONJ	O	O	1172
the	PRON	O	O	1172
median	ADJ	O	O	1172
cumulative	ADJ	O	O	1172
dose	NOUN	O	O	1172
of	ADP	O	O	1172
mitoxantrone	NOUN	O	Chemical	1172
was	AUX	O	O	1172
68.35	NUM	O	O	1172
mg	VERB	O	O	1172
/	PUNCT	O	O	1172
m2	PROPN	O	O	1172
.	PUNCT	O	O	1172
Major	ADJ	O	O	1173
toxicities	NOUN	O	Disease	1173
were	AUX	O	O	1173
cardiotoxicity	NOUN	O	Disease	1173
and	CCONJ	O	O	1173
leukopenia	PROPN	O	Disease	1173
.	PUNCT	O	O	1173
Eight	NUM	O	O	1174
patients	NOUN	O	O	1174
were	AUX	O	O	1174
dead	ADJ	O	O	1174
in	ADP	O	O	1174
the	PRON	O	O	1174
last	VERB	O	O	1174
follow	VERB	O	O	1174
-	PUNCT	O	O	1174
up	ADP	O	O	1174
;	PUNCT	O	O	1174
two	NUM	O	O	1174
of	ADP	O	O	1174
them	PRON	O	O	1174
died	VERB	O	O	1174
of	ADP	O	O	1174
treatment	NOUN	O	O	1174
-	PUNCT	O	O	1174
related	ADJ	O	O	1174
toxicity	NOUN	O	Disease	1174
.	PUNCT	O	O	1174
The	PRON	O	O	1175
MFL	PROPN	O	O	1175
regimen	NOUN	O	O	1175
achieves	VERB	O	O	1175
little	ADJ	O	O	1175
palliative	NOUN	O	O	1175
benefit	VERB	O	O	1175
and	CCONJ	O	O	1175
induces	VERB	O	O	1175
severe	ADJ	O	O	1175
toxicity	NOUN	O	Disease	1175
at	ADP	O	O	1175
a	PRON	O	O	1175
fairly	ADV	O	O	1175
high	ADJ	O	O	1175
rate	NOUN	O	O	1175
.	PUNCT	O	O	1175
Administration	NOUN	O	O	1176
of	ADP	O	O	1176
this	PRON	O	O	1176
regimen	NOUN	O	O	1176
to	PART	O	O	1176
breast cancer	NOUN	O	Disease	1176
patients	NOUN	O	O	1176
who	PRON	O	O	1176
have	VERB	O	O	1176
been	AUX	O	O	1176
treated	VERB	O	O	1176
by	ADP	O	O	1176
chemotherapy	NOUN	O	O	1176
and	CCONJ	O	O	1176
those	PRON	O	O	1176
with	ADP	O	O	1176
impaired	VERB	O	O	1176
heart	NOUN	O	O	1176
function	NOUN	O	O	1176
requires	VERB	O	O	1176
careful	ADJ	O	O	1176
attention	NOUN	O	O	1176
.	PUNCT	O	O	1176
Upregulation	PROPN	O	O	1179
of	ADP	O	O	1179
the	PRON	O	O	1179
expression	NOUN	O	O	1179
of	ADP	O	O	1179
vasopressin	NOUN	O	Chemical	1179
gene	NOUN	O	O	1179
in	ADP	O	O	1179
the	PRON	O	O	1179
paraventricular	ADJ	O	O	1179
and	CCONJ	O	O	1179
supraoptic	ADJ	O	O	1179
nuclei	NOUN	O	O	1179
of	ADP	O	O	1179
the	PRON	O	O	1179
lithium	NOUN	O	Chemical	1179
-	PUNCT	O	O	1179
induced	VERB	O	O	1179
diabetes insipidus	NOUN	O	Disease	1179
rat	NOUN	O	O	1179
.	PUNCT	O	O	1179
The	PRON	O	O	1180
expression	NOUN	O	O	1180
of	ADP	O	O	1180
arginine	PROPN	O	O	1180
vasopressin	NOUN	O	Chemical	1180
(	PUNCT	O	O	1180
AVP	NOUN	O	O	1180
)	PUNCT	O	O	1180
gene	NOUN	O	O	1180
in	ADP	O	O	1180
the	PRON	O	O	1180
paraventricular	ADJ	O	O	1180
(	PUNCT	O	O	1180
PVN	PROPN	O	O	1180
)	PUNCT	O	O	1180
and	CCONJ	O	O	1180
supraoptic	ADJ	O	O	1180
nuclei	NOUN	O	O	1180
(	PUNCT	O	O	1180
SON	PROPN	O	O	1180
)	PUNCT	O	O	1180
was	AUX	O	O	1180
investigated	VERB	O	O	1180
in	ADP	O	O	1180
rats	NOUN	O	O	1180
with	ADP	O	O	1180
lithium	NOUN	O	Chemical	1180
(	PUNCT	O	O	1180
Li)-induced	VERB	O	O	1180
polyuria	PROPN	O	Disease	1180
,	PUNCT	O	O	1180
using	VERB	O	O	1180
in	ADP	O	O	1180
situ	PROPN	O	O	1180
hybridization	NOUN	O	O	1180
histochemistry	NOUN	O	O	1180
and	CCONJ	O	O	1180
radioimmunoassay	PROPN	O	O	1180
.	PUNCT	O	O	1180
The	PRON	O	O	1181
male	NOUN	O	O	1181
Wistar	PROPN	O	O	1181
rats	NOUN	O	O	1181
consuming	VERB	O	O	1181
a	PRON	O	O	1181
diet	PROPN	O	O	1181
that	SCONJ	O	O	1181
contained	VERB	O	O	1181
LiCl	NOUN	O	Chemical	1181
(	PUNCT	O	O	1181
60	NUM	O	O	1181
mmol	NOUN	O	O	1181
/	PUNCT	O	O	1181
kg	VERB	O	O	1181
)	PUNCT	O	O	1181
for	ADP	O	O	1181
4	NUM	O	O	1181
weeks	NOUN	O	O	1181
developed	VERB	O	O	1181
marked	VERB	O	O	1181
polyuria	PROPN	O	Disease	1181
.	PUNCT	O	O	1181
The	PRON	O	O	1182
Li	PROPN	O	Chemical	1182
-	PUNCT	O	O	1182
treated	VERB	O	O	1182
rats	NOUN	O	O	1182
produced	VERB	O	O	1182
a	PRON	O	O	1182
large	ADJ	O	O	1182
volume	PROPN	O	O	1182
of	ADP	O	O	1182
hypotonic	ADJ	O	O	1182
urine	NOUN	O	O	1182
with	ADP	O	O	1182
low	ADJ	O	O	1182
ionic	NOUN	O	O	1182
concentrations	NOUN	O	O	1182
.	PUNCT	O	O	1182
Plasma	NOUN	O	O	1183
sodium	NOUN	O	Chemical	1183
concentrations	NOUN	O	O	1183
were	AUX	O	O	1183
found	VERB	O	O	1183
to	PART	O	O	1183
be	AUX	O	O	1183
slightly	ADV	O	O	1183
increased	VERB	O	O	1183
in	ADP	O	O	1183
the	PRON	O	O	1183
Li	PROPN	O	Chemical	1183
-	PUNCT	O	O	1183
treated	VERB	O	O	1183
rats	NOUN	O	O	1183
compared	VERB	O	O	1183
with	ADP	O	O	1183
those	PRON	O	O	1183
in	ADP	O	O	1183
controls	VERB	O	O	1183
.	PUNCT	O	O	1183
Plasma	NOUN	O	O	1184
concentration	NOUN	O	O	1184
of	ADP	O	O	1184
AVP	NOUN	O	O	1184
and	CCONJ	O	O	1184
transcripts	NOUN	O	O	1184
of	ADP	O	O	1184
AVP	NOUN	O	O	1184
gene	NOUN	O	O	1184
in	ADP	O	O	1184
the	PRON	O	O	1184
PVN	PROPN	O	O	1184
and	CCONJ	O	O	1184
SON	PROPN	O	O	1184
were	AUX	O	O	1184
significantly	ADV	O	O	1184
increased	VERB	O	O	1184
in	ADP	O	O	1184
the	PRON	O	O	1184
Li	PROPN	O	Chemical	1184
-	PUNCT	O	O	1184
treated	VERB	O	O	1184
rats	NOUN	O	O	1184
compared	VERB	O	O	1184
with	ADP	O	O	1184
controls	VERB	O	O	1184
.	PUNCT	O	O	1184
These	PRON	O	O	1185
results	VERB	O	O	1185
suggest	VERB	O	O	1185
that	SCONJ	O	O	1185
dehydration	NOUN	O	Disease	1185
and/or	CCONJ	O	O	1185
the	PRON	O	O	1185
activation	NOUN	O	O	1185
of	ADP	O	O	1185
visceral	ADJ	O	O	1185
afferent	NOUN	O	O	1185
inputs	NOUN	O	O	1185
may	AUX	O	O	1185
contribute	VERB	O	O	1185
to	PART	O	O	1185
the	PRON	O	O	1185
elevation	NOUN	O	O	1185
of	ADP	O	O	1185
plasma	NOUN	O	O	1185
AVP	NOUN	O	O	1185
and	CCONJ	O	O	1185
the	PRON	O	O	1185
upregulation	NOUN	O	O	1185
of	ADP	O	O	1185
AVP	NOUN	O	O	1185
gene	NOUN	O	O	1185
expression	NOUN	O	O	1185
in	ADP	O	O	1185
the	PRON	O	O	1185
PVN	PROPN	O	O	1185
and	CCONJ	O	O	1185
the	PRON	O	O	1185
SON	PROPN	O	O	1185
of	ADP	O	O	1185
the	PRON	O	O	1185
Li	PROPN	O	Chemical	1185
-	PUNCT	O	O	1185
induced	VERB	O	O	1185
diabetes insipidus	NOUN	O	Disease	1185
rat	NOUN	O	O	1185
.	PUNCT	O	O	1185
Suxamethonium	NOUN	O	O	1188
-	PUNCT	O	O	1188
induced	VERB	O	O	1188
cardiac arrest	NOUN	O	Disease	1188
and	CCONJ	O	O	1188
death	NOUN	O	O	1188
following	VERB	O	O	1188
5	NUM	O	O	1188
days	NOUN	O	O	1188
of	ADP	O	O	1188
immobilization	NOUN	O	O	1188
.	PUNCT	O	O	1188
The	PRON	O	O	1189
present	NOUN	O	O	1189
report	VERB	O	O	1189
describes	VERB	O	O	1189
a	PRON	O	O	1189
case	NOUN	O	O	1189
of	ADP	O	O	1189
cardiac arrest	NOUN	O	Disease	1189
and	CCONJ	O	O	1189
subsequent	ADJ	O	O	1189
death	NOUN	O	O	1189
as	ADP	O	O	1189
a	PRON	O	O	1189
result	VERB	O	O	1189
of	ADP	O	O	1189
hyperkalaemia	PROPN	O	O	1189
following	VERB	O	O	1189
the	PRON	O	O	1189
use	VERB	O	O	1189
of	ADP	O	O	1189
suxamethonium	NOUN	O	O	1189
in	ADP	O	O	1189
a	PRON	O	O	1189
23-year	NOUN	O	O	1189
-	PUNCT	O	O	1189
old	ADJ	O	O	1189
Malawian	ADJ	O	O	1189
woman	NOUN	O	O	1189
.	PUNCT	O	O	1189
Five	NUM	O	O	1190
days	NOUN	O	O	1190
after	ADP	O	O	1190
the	PRON	O	O	1190
onset	VERB	O	O	1190
of	ADP	O	O	1190
the	PRON	O	O	1190
symptoms	NOUN	O	O	1190
of	ADP	O	O	1190
meningitis	PROPN	O	O	1190
,	PUNCT	O	O	1190
the	PRON	O	O	1190
patient	NOUN	O	O	1190
aspirated	VERB	O	O	1190
stomach	NOUN	O	O	1190
contents	NOUN	O	O	1190
and	CCONJ	O	O	1190
needed	VERB	O	O	1190
endotracheal	VERB	O	O	1190
intubation	NOUN	O	O	1190
.	PUNCT	O	O	1190
Forty	NUM	O	O	1191
seconds	NOUN	O	O	1191
after	ADP	O	O	1191
injection	NOUN	O	O	1191
of	ADP	O	O	1191
suxamethonium	NOUN	O	O	1191
,	PUNCT	O	O	1191
bradycardia	NOUN	O	Disease	1191
and	CCONJ	O	O	1191
cardiac arrest	NOUN	O	Disease	1191
occurred	VERB	O	O	1191
.	PUNCT	O	O	1191
The	PRON	O	O	1192
serum	NOUN	O	O	1192
level	VERB	O	O	1192
of	ADP	O	O	1192
potassium	NOUN	O	Chemical	1192
was	AUX	O	O	1192
observed	VERB	O	O	1192
to	PART	O	O	1192
be	AUX	O	O	1192
8.4	NUM	O	O	1192
mequiv	ADP	O	O	1192
Apart	ADV	O	O	1193
from	ADP	O	O	1193
the	PRON	O	O	1193
reduction	NOUN	O	O	1193
in	ADP	O	O	1193
the	PRON	O	O	1193
patient	NOUN	O	O	1193
's	AUX	O	O	1193
level	VERB	O	O	1193
of	ADP	O	O	1193
consciousness	NOUN	O	O	1193
,	PUNCT	O	O	1193
there	ADV	O	O	1193
were	AUX	O	O	1193
no	PRON	O	O	1193
signs	NOUN	O	O	1193
of	ADP	O	O	1193
motor	NOUN	O	O	1193
neurone	NOUN	O	O	1193
damage	NOUN	O	O	1193
or	CCONJ	O	O	1193
of	ADP	O	O	1193
any	PRON	O	O	1193
of	ADP	O	O	1193
the	PRON	O	O	1193
other	ADJ	O	O	1193
known	VERB	O	O	1193
predisposing	VERB	O	O	1193
conditions	NOUN	O	O	1193
for	ADP	O	O	1193
hyperkalaemia	PROPN	O	O	1193
following	VERB	O	O	1193
the	PRON	O	O	1193
administration	NOUN	O	O	1193
of	ADP	O	O	1193
suxamethonium	NOUN	O	O	1193
.	PUNCT	O	O	1193
It	PRON	O	O	1194
is	AUX	O	O	1194
postulated	VERB	O	O	1194
that	SCONJ	O	O	1194
her	PRON	O	O	1194
death	NOUN	O	O	1194
was	AUX	O	O	1194
caused	VERB	O	O	1194
by	ADP	O	O	1194
hypersensitivity	NOUN	O	Disease	1194
to	PART	O	O	1194
suxamethonium	NOUN	O	O	1194
,	PUNCT	O	O	1194
associated	VERB	O	O	1194
with	ADP	O	O	1194
her	PRON	O	O	1194
5-day	NOUN	O	O	1194
immobilization	NOUN	O	O	1194
.	PUNCT	O	O	1194
An	PRON	O	O	1197
unusual	ADJ	O	O	1197
toxic	ADJ	O	O	1197
reaction	NOUN	O	O	1197
to	PART	O	O	1197
axillary	ADJ	O	O	1197
block	NOUN	O	O	1197
by	ADP	O	O	1197
mepivacaine	NOUN	O	Chemical	1197
with	ADP	O	O	1197
adrenaline	NOUN	O	Chemical	1197
.	PUNCT	O	O	1197
An	PRON	O	O	1198
increase	VERB	O	O	1198
in	ADP	O	O	1198
blood	NOUN	O	O	1198
pressure	NOUN	O	O	1198
,	PUNCT	O	O	1198
accompanied	VERB	O	O	1198
by	ADP	O	O	1198
atrial fibrillation	NOUN	O	Disease	1198
,	PUNCT	O	O	1198
agitation	NOUN	O	Disease	1198
,	PUNCT	O	O	1198
incomprehensible	ADJ	O	O	1198
shouts	VERB	O	O	1198
and	CCONJ	O	O	1198
loss	NOUN	O	O	1198
of	ADP	O	O	1198
consciousness	NOUN	O	O	1198
,	PUNCT	O	O	1198
was	AUX	O	O	1198
observed	VERB	O	O	1198
in	ADP	O	O	1198
an	PRON	O	O	1198
elderly	ADJ	O	O	1198
,	PUNCT	O	O	1198
ASA	PROPN	O	Chemical	1198
classification	NOUN	O	O	1198
group	NOUN	O	O	1198
II	NUM	O	O	1198
,	PUNCT	O	O	1198
cardiovascularly	ADV	O	O	1198
medicated	VERB	O	O	1198
male	NOUN	O	O	1198
,	PUNCT	O	O	1198
12	NUM	O	O	1198
min	NOUN	O	O	1198
after	ADP	O	O	1198
performance	NOUN	O	O	1198
of	ADP	O	O	1198
axillary	ADJ	O	O	1198
block	NOUN	O	O	1198
with	ADP	O	O	1198
mepivacaine	NOUN	O	Chemical	1198
850	NUM	O	O	1198
mg	VERB	O	O	1198
containing	VERB	O	O	1198
adrenaline	NOUN	O	Chemical	1198
0.225	NUM	O	O	1198
mg	VERB	O	O	1198
,	PUNCT	O	O	1198
for	ADP	O	O	1198
correction	PROPN	O	O	1198
of	ADP	O	O	1198
Dupuytren	PROPN	O	O	1198
's	AUX	O	O	1198
contracture	NOUN	O	O	1198
.	PUNCT	O	O	1198
After	ADP	O	O	1199
intravenous	ADJ	O	O	1199
administration	NOUN	O	O	1199
of	ADP	O	O	1199
labetalol	NOUN	O	Chemical	1199
,	PUNCT	O	O	1199
metoprolol	NOUN	O	Chemical	1199
and	CCONJ	O	O	1199
midazolam	PROPN	O	Chemical	1199
the	PRON	O	O	1199
patient	NOUN	O	O	1199
's	AUX	O	O	1199
condition	NOUN	O	O	1199
improved	VERB	O	O	1199
,	PUNCT	O	O	1199
and	CCONJ	O	O	1199
15	NUM	O	O	1199
min	NOUN	O	O	1199
later	ADV	O	O	1199
he	PRON	O	O	1199
woke	VERB	O	O	1199
up	ADP	O	O	1199
.	PUNCT	O	O	1199
The	PRON	O	O	1200
block	NOUN	O	O	1200
was	AUX	O	O	1200
successful	ADJ	O	O	1200
and	CCONJ	O	O	1200
surgery	NOUN	O	O	1200
was	AUX	O	O	1200
conducted	VERB	O	O	1200
as	ADP	O	O	1200
scheduled	VERB	O	O	1200
despite	SCONJ	O	O	1200
persisting	VERB	O	O	1200
atrial fibrillation	NOUN	O	Disease	1200
.	PUNCT	O	O	1200
Both	PRON	O	O	1201
the	PRON	O	O	1201
temporal	ADJ	O	O	1201
relationship	NOUN	O	O	1201
of	ADP	O	O	1201
events	NOUN	O	O	1201
and	CCONJ	O	O	1201
the	PRON	O	O	1201
response	NOUN	O	O	1201
to	PART	O	O	1201
treatment	NOUN	O	O	1201
suggest	VERB	O	O	1201
that	SCONJ	O	O	1201
a	PRON	O	O	1201
rapid	ADJ	O	O	1201
systemic	ADJ	O	O	1201
absorption	NOUN	O	O	1201
of	ADP	O	O	1201
mepivacaine	NOUN	O	Chemical	1201
with	ADP	O	O	1201
adrenaline	NOUN	O	Chemical	1201
and/or	CCONJ	O	O	1201
interaction	NOUN	O	O	1201
of	ADP	O	O	1201
these	PRON	O	O	1201
drugs	NOUN	O	O	1201
with	ADP	O	O	1201
the	PRON	O	O	1201
patient	NOUN	O	O	1201
's	AUX	O	O	1201
cardiovascular	ADJ	O	O	1201
medications	NOUN	O	O	1201
were	AUX	O	O	1201
responsible	ADJ	O	O	1201
for	ADP	O	O	1201
the	PRON	O	O	1201
perioperative	ADJ	O	O	1201
complications	NOUN	O	O	1201
.	PUNCT	O	O	1201
Clinical	NOUN	O	O	1204
and	CCONJ	O	O	1204
histopathologic	VERB	O	O	1204
examination	NOUN	O	O	1204
of	ADP	O	O	1204
renal	ADJ	O	O	1204
allografts	PROPN	O	O	1204
treated	VERB	O	O	1204
with	ADP	O	O	1204
tacrolimus	NOUN	O	Chemical	1204
(	PUNCT	O	O	1204
FK506	NOUN	O	Chemical	1204
)	PUNCT	O	O	1204
for	ADP	O	O	1204
at	ADP	O	O	1204
least	ADJ	O	O	1204
one	NUM	O	O	1204
year	NOUN	O	O	1204
.	PUNCT	O	O	1204
We	PRON	O	O	1205
clinically	ADV	O	O	1205
and	CCONJ	O	O	1205
pathologically	ADV	O	O	1205
analyzed	VERB	O	O	1205
renal	ADJ	O	O	1205
allografts	PROPN	O	O	1205
from	ADP	O	O	1205
1	X	O	O	1205
9	NUM	O	O	1205
renal	ADJ	O	O	1205
transplant	NOUN	O	O	1205
patients	NOUN	O	O	1205
treated	VERB	O	O	1205
with	ADP	O	O	1205
tacrolimus	NOUN	O	Chemical	1205
(	PUNCT	O	O	1205
FK506	NOUN	O	Chemical	1205
)	PUNCT	O	O	1205
for	ADP	O	O	1205
more	ADJ	O	O	1205
than	ADP	O	O	1205
1	X	O	O	1205
year	NOUN	O	O	1205
.	PUNCT	O	O	1205
The	PRON	O	O	1206
main	ADJ	O	O	1206
pathologic	ADJ	O	O	1206
diagnoses	NOUN	O	O	1206
(	PUNCT	O	O	1206
some	PRON	O	O	1206
overlap	VERB	O	O	1206
)	PUNCT	O	O	1206
were	AUX	O	O	1206
acute	ADJ	O	O	1206
rejection	NOUN	O	O	1206
(	PUNCT	O	O	1206
AR	PROPN	O	O	1206
;	PUNCT	O	O	1206
n	CCONJ	O	O	1206
=	PUNCT	O	O	1206
4	NUM	O	O	1206
)	PUNCT	O	O	1206
,	PUNCT	O	O	1206
chronic	ADJ	O	O	1206
rejection	NOUN	O	O	1206
(	PUNCT	O	O	1206
CR	NOUN	O	O	1206
;	PUNCT	O	O	1206
n=5	ADP	O	O	1206
)	PUNCT	O	O	1206
,	PUNCT	O	O	1206
AR+CR	INTJ	O	O	1206
(	PUNCT	O	O	1206
n	CCONJ	O	O	1206
=	PUNCT	O	O	1206
4	NUM	O	O	1206
)	PUNCT	O	O	1206
,	PUNCT	O	O	1206
recurrent	ADJ	O	O	1206
IgA	PROPN	O	O	1206
nephropathy	NOUN	O	Disease	1206
(	PUNCT	O	O	1206
n	CCONJ	O	O	1206
=	PUNCT	O	O	1206
5	NUM	O	O	1206
)	PUNCT	O	O	1206
,	PUNCT	O	O	1206
normal	ADJ	O	O	1206
findings	NOUN	O	O	1206
(	PUNCT	O	O	1206
n	CCONJ	O	O	1206
=	PUNCT	O	O	1206
2	X	O	O	1206
)	PUNCT	O	O	1206
,	PUNCT	O	O	1206
minimal	ADJ	O	O	1206
-	PUNCT	O	O	1206
type	NOUN	O	O	1206
chronic	ADJ	O	O	1206
FK506	NOUN	O	Chemical	1206
nephropathy	NOUN	O	Disease	1206
(	PUNCT	O	O	1206
n	CCONJ	O	O	1206
=	PUNCT	O	O	1206
9	NUM	O	O	1206
)	PUNCT	O	O	1206
,	PUNCT	O	O	1206
and	CCONJ	O	O	1206
mild	ADJ	O	O	1206
-	PUNCT	O	O	1206
type	NOUN	O	O	1206
FK506	NOUN	O	Chemical	1206
nephropathy	NOUN	O	Disease	1206
(	PUNCT	O	O	1206
n	CCONJ	O	O	1206
=	PUNCT	O	O	1206
11	NUM	O	O	1206
)	PUNCT	O	O	1206
.	PUNCT	O	O	1206
Of	ADV	O	O	1207
the	PRON	O	O	1207
nonepisode	PROPN	O	O	1207
biopsies	NOUN	O	O	1207
,	PUNCT	O	O	1207
7	NUM	O	O	1207
and	CCONJ	O	O	1207
4	NUM	O	O	1207
biopsies	NOUN	O	O	1207
showed	VERB	O	O	1207
minimal	ADJ	O	O	1207
-	PUNCT	O	O	1207
type	NOUN	O	O	1207
and	CCONJ	O	O	1207
mild	ADJ	O	O	1207
-	PUNCT	O	O	1207
type	NOUN	O	O	1207
chronic	ADJ	O	O	1207
FK506	NOUN	O	Chemical	1207
nephropathy	NOUN	O	Disease	1207
,	PUNCT	O	O	1207
respectively	ADV	O	O	1207
.	PUNCT	O	O	1207
Chronic	NOUN	O	O	1208
FK506	NOUN	O	Chemical	1208
nephropathy	NOUN	O	Disease	1208
consisted	VERB	O	O	1208
of	ADP	O	O	1208
rough	ADJ	O	O	1208
and	CCONJ	O	O	1208
foamy	NOUN	O	O	1208
tubular	ADJ	O	O	1208
vacuolization	NOUN	O	O	1208
(	PUNCT	O	O	1208
5	NUM	O	O	1208
biopsies	NOUN	O	O	1208
)	PUNCT	O	O	1208
,	PUNCT	O	O	1208
arteriolopathy	PROPN	O	O	1208
(	PUNCT	O	O	1208
angiodegeneration	NOUN	O	O	1208
of	ADP	O	O	1208
the	PRON	O	O	1208
arteriolar	ADJ	O	O	1208
wall	PROPN	O	O	1208
;	PUNCT	O	O	1208
20	NUM	O	O	1208
biopsies	NOUN	O	O	1208
)	PUNCT	O	O	1208
,	PUNCT	O	O	1208
focal	ADJ	O	O	1208
segmental	ADJ	O	O	1208
glomerulosclerosis	PROPN	O	O	1208
(	PUNCT	O	O	1208
4	NUM	O	O	1208
biopsies	NOUN	O	O	1208
)	PUNCT	O	O	1208
and	CCONJ	O	O	1208
the	PRON	O	O	1208
striped	ADJ	O	O	1208
form	NOUN	O	O	1208
of	ADP	O	O	1208
interstitial	ADJ	O	O	1208
fibrosis	NOUN	O	Disease	1208
(	PUNCT	O	O	1208
11	NUM	O	O	1208
biopsies	NOUN	O	O	1208
)	PUNCT	O	O	1208
.	PUNCT	O	O	1208
The	PRON	O	O	1209
serum	NOUN	O	O	1209
creatinine	PROPN	O	Chemical	1209
levels	NOUN	O	O	1209
of	ADP	O	O	1209
patients	NOUN	O	O	1209
in	ADP	O	O	1209
the	PRON	O	O	1209
mild	ADJ	O	O	1209
-	PUNCT	O	O	1209
type	NOUN	O	O	1209
chronic	ADJ	O	O	1209
FK506	NOUN	O	Chemical	1209
nephropathy	NOUN	O	Disease	1209
group	NOUN	O	O	1209
,	PUNCT	O	O	1209
which	PRON	O	O	1209
included	VERB	O	O	1209
7	NUM	O	O	1209
episode	PROPN	O	O	1209
biopsies	NOUN	O	O	1209
,	PUNCT	O	O	1209
were	AUX	O	O	1209
statistically	ADV	O	O	1209
higher	ADJ	O	O	1209
than	ADP	O	O	1209
those	PRON	O	O	1209
in	ADP	O	O	1209
the	PRON	O	O	1209
minimum	ADJ	O	O	1209
-	PUNCT	O	O	1209
type	NOUN	O	O	1209
chronic	ADJ	O	O	1209
FK506-nephropathy	NOUN	O	O	1209
group	NOUN	O	O	1209
(	PUNCT	O	O	1209
P	NOUN	O	Chemical	1209
This	PRON	O	O	1210
study	VERB	O	O	1210
demonstrates	VERB	O	O	1210
that	SCONJ	O	O	1210
chronic	ADJ	O	O	1210
FK506	NOUN	O	Chemical	1210
nephropathy	NOUN	O	Disease	1210
consists	VERB	O	O	1210
primarily	ADV	O	O	1210
of	ADP	O	O	1210
arteriolopathy	PROPN	O	O	1210
manifesting	VERB	O	O	1210
as	ADP	O	O	1210
insudative	VERB	O	O	1210
hyalinosis	VERB	O	O	1210
of	ADP	O	O	1210
the	PRON	O	O	1210
arteriolar	ADJ	O	O	1210
wall	PROPN	O	O	1210
,	PUNCT	O	O	1210
and	CCONJ	O	O	1210
suggests	VERB	O	O	1210
that	SCONJ	O	O	1210
mild	ADJ	O	O	1210
-	PUNCT	O	O	1210
type	NOUN	O	O	1210
chronic	ADJ	O	O	1210
FK506	NOUN	O	Chemical	1210
nephropathy	NOUN	O	Disease	1210
is	AUX	O	O	1210
a	PRON	O	O	1210
condition	NOUN	O	O	1210
which	PRON	O	O	1210
may	AUX	O	O	1210
lead	VERB	O	Chemical	1210
to	PART	O	O	1210
deterioration	NOUN	O	O	1210
of	ADP	O	O	1210
renal	ADJ	O	O	1210
allograft	NOUN	O	O	1210
function	NOUN	O	O	1210
.	PUNCT	O	O	1210
Memory	NOUN	O	O	1213
facilitation	NOUN	O	O	1213
and	CCONJ	O	O	1213
stimulation	NOUN	O	O	1213
of	ADP	O	O	1213
endogenous	ADJ	O	O	1213
nerve	NOUN	O	O	1213
growth	NOUN	O	O	1213
factor	NOUN	O	O	1213
synthesis	NOUN	O	O	1213
by	ADP	O	O	1213
the	PRON	O	O	1213
acetylcholine	NOUN	O	Chemical	1213
releaser	NOUN	O	O	1213
PG-9	NUM	O	O	1213
.	PUNCT	O	O	1213
The	PRON	O	O	1214
effects	NOUN	O	O	1214
of	ADP	O	O	1214
PG-9	NUM	O	O	1214
(	PUNCT	O	O	1214
3alpha	NUM	O	O	1214
-	PUNCT	O	O	1214
tropyl	NOUN	O	O	1214
2-(p	NUM	O	O	1214
-	PUNCT	O	O	1214
bromophenyl)propionate	PRON	O	O	1214
)	PUNCT	O	O	1214
,	PUNCT	O	O	1214
the	PRON	O	O	1214
acetylcholine	NOUN	O	Chemical	1214
releaser	NOUN	O	O	1214
,	PUNCT	O	O	1214
on	ADP	O	O	1214
memory	NOUN	O	O	1214
processes	NOUN	O	O	1214
and	CCONJ	O	O	1214
nerve	NOUN	O	O	1214
growth	NOUN	O	O	1214
factor	NOUN	O	O	1214
(	PUNCT	O	O	1214
NGF	PROPN	O	O	1214
)	PUNCT	O	O	1214
synthesis	NOUN	O	O	1214
were	AUX	O	O	1214
evaluated	VERB	O	O	1214
.	PUNCT	O	O	1214
In	ADP	O	O	1215
the	PRON	O	O	1215
mouse	PROPN	O	O	1215
passive	ADJ	O	O	1215
-	PUNCT	O	O	1215
avoidance	NOUN	O	O	1215
test	NOUN	O	O	1215
,	PUNCT	O	O	1215
PG-9	NUM	O	O	1215
(	PUNCT	O	O	1215
10	NUM	O	O	1215
-	PUNCT	O	O	1215
30	NUM	O	O	1215
mg	VERB	O	O	1215
/	PUNCT	O	O	1215
kg	VERB	O	O	1215
,	PUNCT	O	O	1215
i.p	NOUN	O	O	1215
.	PUNCT	O	O	1215
)	PUNCT	O	O	1215
,	PUNCT	O	O	1215
administered	VERB	O	O	1215
20	NUM	O	O	1215
min	NOUN	O	O	1215
before	ADP	O	O	1215
the	PRON	O	O	1215
training	NOUN	O	O	1215
session	NOUN	O	O	1215
,	PUNCT	O	O	1215
prevented	VERB	O	O	1215
amnesia	NOUN	O	Disease	1215
induced	VERB	O	O	1215
by	ADP	O	O	1215
both	PRON	O	O	1215
the	PRON	O	O	1215
non	ADJ	O	O	1215
selective	ADJ	O	O	1215
antimuscarinic	NOUN	O	O	1215
drug	NOUN	O	O	1215
scopolamine	NOUN	O	Chemical	1215
and	CCONJ	O	O	1215
the	PRON	O	O	1215
M1-selective	PROPN	O	O	1215
antagonist	NOUN	O	O	1215
S-(-)-ET-126	X	O	O	1215
.	PUNCT	O	O	1215
In	ADP	O	O	1216
the	PRON	O	O	1216
same	ADJ	O	O	1216
experimental	ADJ	O	O	1216
conditions	NOUN	O	O	1216
,	PUNCT	O	O	1216
PG-9	NUM	O	O	1216
(	PUNCT	O	O	1216
5	NUM	O	O	1216
-	PUNCT	O	O	1216
20	NUM	O	O	1216
microg	PROPN	O	O	1216
per	ADP	O	O	1216
mouse	PROPN	O	O	1216
,	PUNCT	O	O	1216
i.c.v	NOUN	O	O	1216
.	PUNCT	O	O	1216
)	PUNCT	O	O	1216
was	AUX	O	O	1216
also	ADV	O	O	1216
able	ADJ	O	O	1216
to	PART	O	O	1216
prevent	VERB	O	O	1216
antimuscarine	VERB	O	O	1216
-	PUNCT	O	O	1216
induced	VERB	O	O	1216
amnesia	NOUN	O	Disease	1216
,	PUNCT	O	O	1216
demonstrating	VERB	O	O	1216
a	PRON	O	O	1216
central	ADJ	O	O	1216
localization	NOUN	O	O	1216
of	ADP	O	O	1216
the	PRON	O	O	1216
activity	NOUN	O	O	1216
.	PUNCT	O	O	1216
At	ADP	O	O	1217
the	PRON	O	O	1217
highest	ADJ	O	O	1217
effective	ADJ	O	O	1217
doses	NOUN	O	O	1217
,	PUNCT	O	O	1217
PG-9	NUM	O	O	1217
did	VERB	O	O	1217
not	PART	O	O	1217
produce	VERB	O	O	1217
any	PRON	O	O	1217
collateral	NOUN	O	O	1217
symptoms	NOUN	O	O	1217
as	ADP	O	O	1217
revealed	VERB	O	O	1217
by	ADP	O	O	1217
the	PRON	O	O	1217
Irwin	PROPN	O	O	1217
test	NOUN	O	O	1217
,	PUNCT	O	O	1217
and	CCONJ	O	O	1217
it	PRON	O	O	1217
did	VERB	O	O	1217
not	PART	O	O	1217
modify	VERB	O	O	1217
spontaneous	ADJ	O	O	1217
motility	NOUN	O	O	1217
and	CCONJ	O	O	1217
inspection	NOUN	O	O	1217
activity	NOUN	O	O	1217
,	PUNCT	O	O	1217
as	ADP	O	O	1217
revealed	VERB	O	O	1217
by	ADP	O	O	1217
the	PRON	O	O	1217
hole	NOUN	O	O	1217
-	PUNCT	O	O	1217
board	PROPN	O	O	1217
test	NOUN	O	O	1217
.	PUNCT	O	O	1217
PG-9	NUM	O	O	1217
The	PRON	O	O	1218
maximal	ADJ	O	O	1218
NGF	PROPN	O	O	1218
contents	NOUN	O	O	1218
obtained	VERB	O	O	1218
by	ADP	O	O	1218
PG-9	NUM	O	O	1218
were	AUX	O	O	1218
17.6-fold	ADV	O	O	1218
of	ADP	O	O	1218
the	PRON	O	O	1218
control	VERB	O	O	1218
value	NOUN	O	O	1218
.	PUNCT	O	O	1218
During	ADP	O	O	1219
culture	NOUN	O	O	1219
,	PUNCT	O	O	1219
no	PRON	O	O	1219
morphological	ADJ	O	O	1219
changes	VERB	O	O	1219
were	AUX	O	O	1219
found	VERB	O	O	1219
at	ADP	O	O	1219
effective	ADJ	O	O	1219
concentrations	NOUN	O	O	1219
of	ADP	O	O	1219
PG-9	NUM	O	O	1219
.	PUNCT	O	O	1219
The	PRON	O	O	1220
current	ADJ	O	O	1220
work	NOUN	O	O	1220
indicates	VERB	O	O	1220
the	PRON	O	O	1220
ability	NOUN	O	O	1220
of	ADP	O	O	1220
PG-9	NUM	O	O	1220
to	PART	O	O	1220
induce	VERB	O	O	1220
beneficial	ADJ	O	O	1220
effects	NOUN	O	O	1220
on	ADP	O	O	1220
cognitive	ADJ	O	O	1220
processes	NOUN	O	O	1220
and	CCONJ	O	O	1220
stimulate	VERB	O	O	1220
activity	NOUN	O	O	1220
of	ADP	O	O	1220
NGF	PROPN	O	O	1220
synthesis	NOUN	O	O	1220
in	ADP	O	O	1220
astroglial	ADV	O	O	1220
cells	NOUN	O	O	1220
.	PUNCT	O	O	1220
Therefore	ADV	O	O	1221
,	PUNCT	O	O	1221
PG-9	NUM	O	O	1221
could	AUX	O	O	1221
represent	VERB	O	O	1221
a	PRON	O	O	1221
potential	ADJ	O	O	1221
useful	ADJ	O	O	1221
drug	NOUN	O	O	1221
able	ADJ	O	O	1221
to	PART	O	O	1221
improve	VERB	O	O	1221
the	PRON	O	O	1221
function	NOUN	O	O	1221
of	ADP	O	O	1221
impaired	VERB	O	O	1221
cognitive	ADJ	O	O	1221
processes	NOUN	O	O	1221
.	PUNCT	O	O	1221
Angioedema	PROPN	O	Disease	1224
due	ADJ	O	O	1224
to	PART	O	O	1224
ACE	PROPN	O	O	1224
inhibitors	NOUN	O	O	1224
:	PUNCT	O	O	1224
common	ADJ	O	O	1224
and	CCONJ	O	O	1224
inadequately	ADV	O	O	1224
diagnosed	VERB	O	O	1224
.	PUNCT	O	O	1224
The	PRON	O	O	1225
estimated	VERB	O	O	1225
incidence	NOUN	O	O	1225
of	ADP	O	O	1225
angioedema	NOUN	O	Disease	1225
during	ADP	O	O	1225
angiotensin	NOUN	O	Chemical	1225
-	PUNCT	O	O	1225
converting	VERB	O	O	1225
enzyme	NOUN	O	O	1225
(	PUNCT	O	O	1225
ACE	PROPN	O	O	1225
)	PUNCT	O	O	1225
inhibitor	NOUN	O	O	1225
treatment	NOUN	O	O	1225
is	AUX	O	O	1225
between	ADP	O	O	1225
1	X	O	O	1225
and	CCONJ	O	O	1225
7	NUM	O	O	1225
per	ADP	O	O	1225
thousand	NUM	O	O	1225
patients	NOUN	O	O	1225
.	PUNCT	O	O	1225
Accumulation	NOUN	O	O	1228
of	ADP	O	O	1228
atracurium	PROPN	O	O	1228
in	ADP	O	O	1228
the	PRON	O	O	1228
intravenous	ADJ	O	O	1228
line	NOUN	O	O	1228
led	VERB	O	O	1228
to	PART	O	O	1228
recurarization	NOUN	O	O	1228
after	ADP	O	O	1228
flushing	VERB	O	Disease	1228
the	PRON	O	O	1228
line	NOUN	O	O	1228
in	ADP	O	O	1228
the	PRON	O	O	1228
recovery	NOUN	O	O	1228
room	NOUN	O	O	1228
.	PUNCT	O	O	1228
A	PRON	O	O	1229
respiratory arrest	NOUN	O	Disease	1229
with	ADP	O	O	1229
severe	ADJ	O	O	1229
desaturation	NOUN	O	O	1229
and	CCONJ	O	O	1229
bradycardia	NOUN	O	Disease	1229
occurred	VERB	O	O	1229
.	PUNCT	O	O	1229
Circumstances	NOUN	O	O	1230
leading	VERB	O	O	1230
to	PART	O	O	1230
this	PRON	O	O	1230
event	NOUN	O	O	1230
and	CCONJ	O	O	1230
the	PRON	O	O	1230
mechanisms	NOUN	O	O	1230
enabling	VERB	O	O	1230
a	PRON	O	O	1230
neuromuscular blockade	NOUN	O	Disease	1230
to	PART	O	O	1230
occur	VERB	O	O	1230
,	PUNCT	O	O	1230
following	VERB	O	O	1230
the	PRON	O	O	1230
administration	NOUN	O	O	1230
of	ADP	O	O	1230
a	PRON	O	O	1230
small	ADJ	O	O	1230
dose	NOUN	O	O	1230
of	ADP	O	O	1230
relaxant	NOUN	O	O	1230
,	PUNCT	O	O	1230
are	AUX	O	O	1230
discussed	VERB	O	O	1230
.	PUNCT	O	O	1230
Recurrent	ADJ	O	O	1233
use	VERB	O	O	1233
of	ADP	O	O	1233
newer	ADJ	O	O	1233
oral contraceptives	NOUN	O	Chemical	1233
and	CCONJ	O	O	1233
the	PRON	O	O	1233
risk	NOUN	O	O	1233
of	ADP	O	O	1233
venous thromboembolism	NOUN	O	Disease	1233
.	PUNCT	O	O	1233
The	PRON	O	O	1234
epidemiological	ADJ	O	O	1234
studies	NOUN	O	O	1234
that	SCONJ	O	O	1234
assessed	VERB	O	O	1234
the	PRON	O	O	1234
risk	NOUN	O	O	1234
of	ADP	O	O	1234
venous thromboembolism	NOUN	O	Disease	1234
(	PUNCT	O	O	1234
VTE	PROPN	O	Disease	1234
)	PUNCT	O	O	1234
associated	VERB	O	O	1234
with	ADP	O	O	1234
newer	ADJ	O	O	1234
oral contraceptives	NOUN	O	Chemical	1234
(	PUNCT	O	O	1234
OC	PROPN	O	O	1234
)	PUNCT	O	O	1234
did	VERB	O	O	1234
not	PART	O	O	1234
distinguish	VERB	O	O	1234
between	ADP	O	O	1234
patterns	NOUN	O	O	1234
of	ADP	O	O	1234
OC	PROPN	O	O	1234
use	VERB	O	O	1234
,	PUNCT	O	O	1234
namely	ADV	O	O	1234
first	ADV	O	O	1234
-	PUNCT	O	O	1234
time	NOUN	O	O	1234
users	NOUN	O	O	1234
,	PUNCT	O	O	1234
repeaters	NOUN	O	O	1234
and	CCONJ	O	O	1234
switchers	NOUN	O	O	1234
.	PUNCT	O	O	1234
Data	NOUN	O	O	1235
from	ADP	O	O	1235
a	PRON	O	O	1235
Transnational	PROPN	O	O	1235
case	NOUN	O	O	1235
-	PUNCT	O	O	1235
control	VERB	O	O	1235
study	VERB	O	O	1235
were	AUX	O	O	1235
used	VERB	O	O	1235
to	PART	O	O	1235
assess	VERB	O	O	1235
the	PRON	O	O	1235
risk	NOUN	O	O	1235
of	ADP	O	O	1235
VTE	PROPN	O	Disease	1235
for	ADP	O	O	1235
the	PRON	O	O	1235
latter	ADJ	O	O	1235
patterns	NOUN	O	O	1235
of	ADP	O	O	1235
use	VERB	O	O	1235
,	PUNCT	O	O	1235
while	SCONJ	O	O	1235
accounting	VERB	O	O	1235
for	ADP	O	O	1235
duration	NOUN	O	O	1235
of	ADP	O	O	1235
use	VERB	O	O	1235
.	PUNCT	O	O	1235
Over	ADP	O	O	1236
the	PRON	O	O	1236
period	NOUN	O	O	1236
1993	NUM	O	O	1236
-	PUNCT	O	O	1236
1996	NUM	O	O	1236
,	PUNCT	O	O	1236
551	NUM	O	O	1236
cases	NOUN	O	O	1236
of	ADP	O	O	1236
VTE	PROPN	O	Disease	1236
were	AUX	O	O	1236
identified	VERB	O	O	1236
in	ADP	O	O	1236
Germany	PROPN	O	O	1236
and	CCONJ	O	O	1236
the	PRON	O	O	1236
UK	PROPN	O	O	1236
along	ADV	O	O	1236
with	ADP	O	O	1236
2066	NUM	O	O	1236
controls	VERB	O	O	1236
.	PUNCT	O	O	1236
The	PRON	O	O	1237
adjusted	VERB	O	O	1237
rate	NOUN	O	O	1237
ratio	NOUN	O	O	1237
of	ADP	O	O	1237
VTE	PROPN	O	Disease	1237
for	ADP	O	O	1237
repeat	VERB	O	O	1237
users	NOUN	O	O	1237
of	ADP	O	O	1237
third	ADV	O	O	1237
generation	NOUN	O	O	1237
OC	PROPN	O	O	1237
was	AUX	O	O	1237
0.6	NUM	O	O	1237
(	PUNCT	O	O	1237
95%	NOUN	O	O	1237
CI:0.3	PRON	O	O	1237
-	PUNCT	O	O	1237
1.2	NUM	O	O	1237
)	PUNCT	O	O	1237
relative	ADJ	O	O	1237
to	PART	O	O	1237
repeat	VERB	O	O	1237
users	NOUN	O	O	1237
of	ADP	O	O	1237
second	ADV	O	O	1237
generation	NOUN	O	O	1237
pills	NOUN	O	O	1237
,	PUNCT	O	O	1237
whereas	SCONJ	O	O	1237
it	PRON	O	O	1237
was	AUX	O	O	1237
1.3	NUM	O	O	1237
(	PUNCT	O	O	1237
95%	NOUN	O	O	1237
CI:0.7	VERB	O	O	1237
-	PUNCT	O	O	1237
2.4	NUM	O	O	1237
)	PUNCT	O	O	1237
for	ADP	O	O	1237
switchers	NOUN	O	O	1237
from	ADP	O	O	1237
second	ADV	O	O	1237
to	PART	O	O	1237
third	ADV	O	O	1237
generation	NOUN	O	O	1237
pills	NOUN	O	O	1237
relative	ADJ	O	O	1237
to	PART	O	O	1237
switchers	NOUN	O	O	1237
from	ADP	O	O	1237
third	ADV	O	O	1237
to	PART	O	O	1237
second	ADV	O	O	1237
generation	NOUN	O	O	1237
pills	NOUN	O	O	1237
.	PUNCT	O	O	1237
We	PRON	O	O	1238
conclude	VERB	O	O	1238
that	SCONJ	O	O	1238
second	ADV	O	O	1238
and	CCONJ	O	O	1238
third	ADV	O	O	1238
generation	NOUN	O	O	1238
agents	NOUN	O	O	1238
are	AUX	O	O	1238
associated	VERB	O	O	1238
with	ADP	O	O	1238
equivalent	ADJ	O	O	1238
risks	NOUN	O	O	1238
of	ADP	O	O	1238
VTE	PROPN	O	Disease	1238
when	SCONJ	O	O	1238
the	PRON	O	O	1238
same	ADJ	O	O	1238
agent	NOUN	O	O	1238
is	AUX	O	O	1238
used	VERB	O	O	1238
repeatedly	ADV	O	O	1238
after	ADP	O	O	1238
interruption	NOUN	O	O	1238
periods	NOUN	O	O	1238
or	CCONJ	O	O	1238
when	SCONJ	O	O	1238
users	NOUN	O	O	1238
are	AUX	O	O	1238
switched	VERB	O	O	1238
between	ADP	O	O	1238
the	PRON	O	O	1238
two	NUM	O	O	1238
generations	NOUN	O	O	1238
of	ADP	O	O	1238
pills	NOUN	O	O	1238
.	PUNCT	O	O	1238
These	PRON	O	O	1239
analyses	NOUN	O	O	1239
suggest	VERB	O	O	1239
that	SCONJ	O	O	1239
the	PRON	O	O	1239
higher	ADJ	O	O	1239
risk	NOUN	O	O	1239
observed	VERB	O	O	1239
for	ADP	O	O	1239
the	PRON	O	O	1239
newer	ADJ	O	O	1239
OC	PROPN	O	O	1239
in	ADP	O	O	1239
other	ADJ	O	O	1239
studies	NOUN	O	O	1239
may	AUX	O	O	1239
be	AUX	O	O	1239
the	PRON	O	O	1239
result	VERB	O	O	1239
of	ADP	O	O	1239
inadequate	ADJ	O	O	1239
comparisons	NOUN	O	O	1239
of	ADP	O	O	1239
pill	NOUN	O	O	1239
users	NOUN	O	O	1239
with	ADP	O	O	1239
different	ADJ	O	O	1239
patterns	NOUN	O	O	1239
of	ADP	O	O	1239
pill	NOUN	O	O	1239
use	VERB	O	O	1239
.	PUNCT	O	O	1239
Development	NOUN	O	O	1242
of	ADP	O	O	1242
apomorphine	PROPN	O	Chemical	1242
-	PUNCT	O	O	1242
induced	VERB	O	O	1242
aggressive behavior	NOUN	O	Disease	1242
:	PUNCT	O	O	1242
comparison	NOUN	O	O	1242
of	ADP	O	O	1242
adult	NOUN	O	O	1242
male	NOUN	O	O	1242
and	CCONJ	O	O	1242
female	ADJ	O	O	1242
Wistar	PROPN	O	O	1242
rats	NOUN	O	O	1242
.	PUNCT	O	O	1242
The	PRON	O	O	1243
development	NOUN	O	O	1243
of	ADP	O	O	1243
apomorphine	PROPN	O	Chemical	1243
-	PUNCT	O	O	1243
induced	VERB	O	O	1243
(	PUNCT	O	O	1243
1.0	NUM	O	O	1243
mg	VERB	O	O	1243
/	PUNCT	O	O	1243
kg	VERB	O	O	1243
s.c	PROPN	O	O	1243
.	PUNCT	O	O	1243
once	ADV	O	O	1244
daily	ADV	O	O	1244
)	PUNCT	O	O	1244
aggressive behavior	NOUN	O	Disease	1244
of	ADP	O	O	1244
adult	NOUN	O	O	1244
male	NOUN	O	O	1244
and	CCONJ	O	O	1244
female	ADJ	O	O	1244
Wistar	PROPN	O	O	1244
rats	NOUN	O	O	1244
obtained	VERB	O	O	1244
from	ADP	O	O	1244
the	PRON	O	O	1244
same	ADJ	O	O	1244
breeder	NOUN	O	O	1244
was	AUX	O	O	1244
studied	VERB	O	O	1244
in	ADP	O	O	1244
two	NUM	O	O	1244
consecutive	ADJ	O	O	1244
sets	VERB	O	O	1244
.	PUNCT	O	O	1244
In	ADP	O	O	1245
male	NOUN	O	O	1245
animals	NOUN	O	O	1245
,	PUNCT	O	O	1245
repeated	VERB	O	O	1245
apomorphine	PROPN	O	Chemical	1245
treatment	NOUN	O	O	1245
induced	VERB	O	O	1245
a	PRON	O	O	1245
gradual	ADJ	O	O	1245
development	NOUN	O	O	1245
of	ADP	O	O	1245
aggressive behavior	NOUN	O	Disease	1245
as	ADP	O	O	1245
evidenced	VERB	O	O	1245
by	ADP	O	O	1245
the	PRON	O	O	1245
increased	VERB	O	O	1245
intensity	NOUN	O	O	1245
of	ADP	O	O	1245
aggressiveness	NOUN	O	Disease	1245
and	CCONJ	O	O	1245
shortened	VERB	O	O	1245
latency	VERB	O	O	1245
before	ADP	O	O	1245
the	PRON	O	O	1245
first	ADV	O	O	1245
attack	VERB	O	O	1245
toward	ADP	O	O	1245
the	PRON	O	O	1245
opponent	NOUN	O	O	1245
.	PUNCT	O	O	1245
In	ADP	O	O	1246
female	ADJ	O	O	1246
rats	NOUN	O	O	1246
,	PUNCT	O	O	1246
only	ADV	O	O	1246
a	PRON	O	O	1246
weak	ADJ	O	O	1246
tendency	NOUN	O	O	1246
toward	ADP	O	O	1246
aggressiveness	NOUN	O	Disease	1246
was	AUX	O	O	1246
found	VERB	O	O	1246
.	PUNCT	O	O	1246
In	ADP	O	O	1247
conclusion	NOUN	O	O	1247
,	PUNCT	O	O	1247
the	PRON	O	O	1247
present	NOUN	O	O	1247
study	VERB	O	O	1247
demonstrates	VERB	O	O	1247
gender	NOUN	O	O	1247
differences	NOUN	O	O	1247
in	ADP	O	O	1247
the	PRON	O	O	1247
development	NOUN	O	O	1247
of	ADP	O	O	1247
the	PRON	O	O	1247
apomorphine	PROPN	O	Chemical	1247
-	PUNCT	O	O	1247
induced	VERB	O	O	1247
aggressive behavior	NOUN	O	Disease	1247
and	CCONJ	O	O	1247
indicates	VERB	O	O	1247
that	SCONJ	O	O	1247
the	PRON	O	O	1247
female	ADJ	O	O	1247
rats	NOUN	O	O	1247
do	VERB	O	O	1247
not	PART	O	O	1247
fill	VERB	O	O	1247
the	PRON	O	O	1247
validation	NOUN	O	O	1247
criteria	NOUN	O	O	1247
for	ADP	O	O	1247
use	VERB	O	O	1247
in	ADP	O	O	1247
this	PRON	O	O	1247
method	NOUN	O	O	1247
.	PUNCT	O	O	1247
Serotonergic	NOUN	O	O	1250
antidepressants	NOUN	O	O	1250
and	CCONJ	O	O	1250
urinary	ADJ	O	O	1250
incontinence	NOUN	O	O	1250
.	PUNCT	O	O	1250
Many	ADJ	O	O	1251
new	ADJ	O	O	1251
serotonergic	ADJ	O	O	1251
antidepressants	NOUN	O	O	1251
have	VERB	O	O	1251
been	AUX	O	O	1251
introduced	VERB	O	O	1251
over	ADP	O	O	1251
the	PRON	O	O	1251
past	ADP	O	O	1251
decade	NOUN	O	O	1251
.	PUNCT	O	O	1251
Although	SCONJ	O	O	1252
urinary	ADJ	O	O	1252
incontinence	NOUN	O	O	1252
is	AUX	O	O	1252
listed	VERB	O	O	1252
as	ADP	O	O	1252
one	NUM	O	O	1252
side	NOUN	O	O	1252
effect	VERB	O	O	1252
of	ADP	O	O	1252
these	PRON	O	O	1252
drugs	NOUN	O	O	1252
in	ADP	O	O	1252
their	PRON	O	O	1252
package	NOUN	O	O	1252
inserts	VERB	O	O	1252
there	ADV	O	O	1252
is	AUX	O	O	1252
only	ADV	O	O	1252
one	NUM	O	O	1252
report	VERB	O	O	1252
in	ADP	O	O	1252
the	PRON	O	O	1252
literature	NOUN	O	O	1252
.	PUNCT	O	O	1252
This	PRON	O	O	1253
concerns	NOUN	O	O	1253
2	X	O	O	1253
male	NOUN	O	O	1253
patients	NOUN	O	O	1253
who	PRON	O	O	1253
experienced	ADJ	O	O	1253
incontinence	NOUN	O	O	1253
while	SCONJ	O	O	1253
taking	VERB	O	O	1253
venlafaxine	NOUN	O	Chemical	1253
.	PUNCT	O	O	1253
In	ADP	O	O	1254
the	PRON	O	O	1254
present	NOUN	O	O	1254
paper	PROPN	O	O	1254
the	PRON	O	O	1254
authors	NOUN	O	O	1254
describe	VERB	O	O	1254
2	X	O	O	1254
female	ADJ	O	O	1254
patients	NOUN	O	O	1254
who	PRON	O	O	1254
developed	VERB	O	O	1254
incontinence	NOUN	O	O	1254
secondary	ADJ	O	O	1254
to	PART	O	O	1254
the	PRON	O	O	1254
selective	ADJ	O	O	1254
serotonin	PROPN	O	Chemical	1254
reuptake	PROPN	O	O	1254
inhibitors	NOUN	O	O	1254
paroxetine	NOUN	O	Chemical	1254
and	CCONJ	O	O	1254
sertraline	PROPN	O	Chemical	1254
,	PUNCT	O	O	1254
as	ADP	O	O	1254
well	ADV	O	O	1254
as	ADP	O	O	1254
a	PRON	O	O	1254
third	ADV	O	O	1254
who	PRON	O	O	1254
developed	VERB	O	O	1254
this	PRON	O	O	1254
side	NOUN	O	O	1254
effect	VERB	O	O	1254
on	ADP	O	O	1254
venlafaxine	NOUN	O	Chemical	1254
.	PUNCT	O	O	1254
In	ADP	O	O	1255
2	X	O	O	1255
of	ADP	O	O	1255
the	PRON	O	O	1255
3	X	O	O	1255
cases	NOUN	O	O	1255
the	PRON	O	O	1255
patients	NOUN	O	O	1255
were	AUX	O	O	1255
also	ADV	O	O	1255
taking	VERB	O	O	1255
lithium carbonate	NOUN	O	Chemical	1255
and	CCONJ	O	O	1255
beta	NOUN	O	O	1255
-	PUNCT	O	O	1255
blockers	NOUN	O	O	1255
,	PUNCT	O	O	1255
both	PRON	O	O	1255
of	ADP	O	O	1255
which	PRON	O	O	1255
could	AUX	O	O	1255
have	VERB	O	O	1255
contributed	VERB	O	O	1255
to	PART	O	O	1255
the	PRON	O	O	1255
incontinence	NOUN	O	O	1255
.	PUNCT	O	O	1255
Animal	NOUN	O	O	1256
studies	NOUN	O	O	1256
suggest	VERB	O	O	1256
that	SCONJ	O	O	1256
incontinence	NOUN	O	O	1256
secondary	ADJ	O	O	1256
to	PART	O	O	1256
serotonergic	ADJ	O	O	1256
antidepressants	NOUN	O	O	1256
could	AUX	O	O	1256
be	AUX	O	O	1256
mediated	VERB	O	O	1256
by	ADP	O	O	1256
the	PRON	O	O	1256
5HT4	NUM	O	O	1256
receptors	NOUN	O	O	1256
found	VERB	O	O	1256
on	ADP	O	O	1256
the	PRON	O	O	1256
bladder	NOUN	O	O	1256
.	PUNCT	O	O	1256
Hypotension	NOUN	O	Disease	1259
following	VERB	O	O	1259
the	PRON	O	O	1259
initiation	NOUN	O	O	1259
of	ADP	O	O	1259
tizanidine	NOUN	O	O	1259
in	ADP	O	O	1259
a	PRON	O	O	1259
patient	NOUN	O	O	1259
treated	VERB	O	O	1259
with	ADP	O	O	1259
an	PRON	O	O	1259
angiotensin	NOUN	O	Chemical	1259
converting	VERB	O	O	1259
enzyme	NOUN	O	O	1259
inhibitor	NOUN	O	O	1259
for	ADP	O	O	1259
chronic	ADJ	O	O	1259
hypertension	NOUN	O	Disease	1259
.	PUNCT	O	O	1259
Centrally	ADV	O	O	1260
acting	VERB	O	O	1260
alpha-2	NUM	O	O	1260
adrenergic	NOUN	O	O	1260
agonists	NOUN	O	O	1260
are	AUX	O	O	1260
one	NUM	O	O	1260
of	ADP	O	O	1260
several	ADJ	O	O	1260
pharmacologic	ADJ	O	O	1260
agents	NOUN	O	O	1260
used	VERB	O	O	1260
in	ADP	O	O	1260
the	PRON	O	O	1260
treatment	NOUN	O	O	1260
of	ADP	O	O	1260
spasticity	NOUN	O	O	1260
related	ADJ	O	O	1260
to	PART	O	O	1260
disorders	NOUN	O	O	1260
of	ADP	O	O	1260
the	PRON	O	O	1260
central	ADJ	O	O	1260
nervous	ADJ	O	O	1260
system	NOUN	O	O	1260
.	PUNCT	O	O	1260
In	ADP	O	O	1261
addition	NOUN	O	O	1261
to	PART	O	O	1261
their	PRON	O	O	1261
effects	NOUN	O	O	1261
on	ADP	O	O	1261
spasticity	NOUN	O	O	1261
,	PUNCT	O	O	1261
certain	ADJ	O	O	1261
adverse	ADJ	O	O	1261
cardiorespiratory	NOUN	O	O	1261
effects	NOUN	O	O	1261
have	VERB	O	O	1261
been	AUX	O	O	1261
reported	VERB	O	O	1261
.	PUNCT	O	O	1261
Adults	NOUN	O	O	1262
chronically	ADV	O	O	1262
treated	VERB	O	O	1262
with	ADP	O	O	1262
angiotensin	NOUN	O	Chemical	1262
converting	VERB	O	O	1262
enzyme	NOUN	O	O	1262
inhibitors	NOUN	O	O	1262
may	AUX	O	O	1262
have	VERB	O	O	1262
a	PRON	O	O	1262
limited	VERB	O	O	1262
ability	NOUN	O	O	1262
to	PART	O	O	1262
respond	VERB	O	O	1262
to	PART	O	O	1262
hypotension	NOUN	O	Disease	1262
when	SCONJ	O	O	1262
the	PRON	O	O	1262
sympathetic	ADJ	O	O	1262
response	NOUN	O	O	1262
is	AUX	O	O	1262
simultaneously	ADV	O	O	1262
blocked	VERB	O	O	1262
.	PUNCT	O	O	1262
The	PRON	O	O	1263
authors	NOUN	O	O	1263
present	NOUN	O	O	1263
a	PRON	O	O	1263
10-year	NOUN	O	O	1263
-	PUNCT	O	O	1263
old	ADJ	O	O	1263
boy	NOUN	O	O	1263
chronically	ADV	O	O	1263
treated	VERB	O	O	1263
with	ADP	O	O	1263
lisinopril	PROPN	O	O	1263
,	PUNCT	O	O	1263
an	PRON	O	O	1263
angiotensin	NOUN	O	Chemical	1263
converting	VERB	O	O	1263
enzyme	NOUN	O	O	1263
inhibitor	NOUN	O	O	1263
,	PUNCT	O	O	1263
to	PART	O	O	1263
control	VERB	O	O	1263
hypertension	NOUN	O	Disease	1263
who	PRON	O	O	1263
developed	VERB	O	O	1263
hypotension	NOUN	O	Disease	1263
following	VERB	O	O	1263
the	PRON	O	O	1263
addition	NOUN	O	O	1263
of	ADP	O	O	1263
tizanidine	NOUN	O	O	1263
,	PUNCT	O	O	1263
an	PRON	O	O	1263
alpha-2	NUM	O	O	1263
agonist	NOUN	O	O	1263
,	PUNCT	O	O	1263
for	ADP	O	O	1263
the	PRON	O	O	1263
treatment	NOUN	O	O	1263
of	ADP	O	O	1263
spasticity	NOUN	O	O	1263
.	PUNCT	O	O	1263
The	PRON	O	O	1264
possible	ADJ	O	O	1264
interaction	NOUN	O	O	1264
of	ADP	O	O	1264
tizanidine	NOUN	O	O	1264
and	CCONJ	O	O	1264
other	ADJ	O	O	1264
antihypertensive	ADV	O	O	1264
agents	NOUN	O	O	1264
should	AUX	O	O	1264
be	AUX	O	O	1264
kept	VERB	O	O	1264
in	ADP	O	O	1264
mind	VERB	O	O	1264
when	SCONJ	O	O	1264
prescribing	VERB	O	O	1264
therapy	NOUN	O	O	1264
to	PART	O	O	1264
treat	VERB	O	O	1264
either	ADV	O	O	1264
hypertension	NOUN	O	Disease	1264
or	CCONJ	O	O	1264
spasticity	NOUN	O	O	1264
in	ADP	O	O	1264
such	ADJ	O	O	1264
patients	NOUN	O	O	1264
.	PUNCT	O	O	1264
Peritubular	PROPN	O	O	1267
capillary	NOUN	O	O	1267
basement	NOUN	O	O	1267
membrane	NOUN	O	O	1267
reduplication	NOUN	O	O	1267
in	ADP	O	O	1267
allografts	PROPN	O	O	1267
and	CCONJ	O	O	1267
native	ADJ	O	O	1267
kidney	NOUN	O	O	1267
disease	PROPN	O	O	1267
:	PUNCT	O	O	1267
a	PRON	O	O	1267
clinicopathologic	ADJ	O	O	1267
study	VERB	O	O	1267
of	ADP	O	O	1267
278	NUM	O	O	1267
consecutive	ADJ	O	O	1267
renal	ADJ	O	O	1267
specimens	NOUN	O	O	1267
.	PUNCT	O	O	1267
BACKGROUND	NOUN	O	O	1268
:	PUNCT	O	O	1268
An	PRON	O	O	1268
association	PROPN	O	O	1268
has	VERB	O	O	1268
been	AUX	O	O	1268
found	VERB	O	O	1268
between	ADP	O	O	1268
transplant	NOUN	O	O	1268
glomerulopathy	ADJ	O	O	1268
(	PUNCT	O	O	1268
TG	PROPN	O	O	1268
)	PUNCT	O	O	1268
and	CCONJ	O	O	1268
reduplication	NOUN	O	O	1268
of	ADP	O	O	1268
peritubular	ADJ	O	O	1268
capillary	NOUN	O	O	1268
basement	NOUN	O	O	1268
membranes	NOUN	O	O	1268
(	PUNCT	O	O	1268
PTCR	PROPN	O	O	1268
)	PUNCT	O	O	1268
.	PUNCT	O	O	1268
In	ADP	O	O	1269
addition	NOUN	O	O	1269
to	PART	O	O	1269
renal	ADJ	O	O	1269
allografts	PROPN	O	O	1269
with	ADP	O	O	1269
TG	PROPN	O	O	1269
,	PUNCT	O	O	1269
we	PRON	O	O	1269
also	ADV	O	O	1269
examined	VERB	O	O	1269
grafts	NOUN	O	O	1269
with	ADP	O	O	1269
acute	ADJ	O	O	1269
rejection	NOUN	O	O	1269
,	PUNCT	O	O	1269
recurrent	ADJ	O	O	1269
glomerulonephritis	NOUN	O	Disease	1269
,	PUNCT	O	O	1269
chronic	ADJ	O	O	1269
allograft	NOUN	O	O	1269
nephropathy	NOUN	O	Disease	1269
and	CCONJ	O	O	1269
stable	ADJ	O	O	1269
grafts	NOUN	O	O	1269
(	PUNCT	O	O	1269
""""	PUNCT	O	O	1269
protocol	PROPN	O	O	1269
biopsies	NOUN	O	O	1269
""""	PUNCT	O	O	1269
)	PUNCT	O	O	1269
.	PUNCT	O	O	1269
Native	ADJ	O	O	1270
kidney	NOUN	O	O	1270
specimens	NOUN	O	O	1270
included	VERB	O	O	1270
a	PRON	O	O	1270
wide	ADV	O	O	1270
range	VERB	O	O	1270
of	ADP	O	O	1270
glomerulopathies	NOUN	O	O	1270
as	ADP	O	O	1270
well	ADV	O	O	1270
as	ADP	O	O	1270
cases	NOUN	O	O	1270
of	ADP	O	O	1270
thrombotic	ADJ	O	Disease	1270
microangiopathy	VERB	O	Disease	1270
,	PUNCT	O	O	1270
malignant	ADJ	O	O	1270
hypertension	NOUN	O	Disease	1270
,	PUNCT	O	O	1270
acute	ADJ	O	O	1270
interstitial nephritis	NOUN	O	Disease	1270
,	PUNCT	O	O	1270
and	CCONJ	O	O	1270
acute	ADJ	O	O	1270
tubular necrosis	NOUN	O	Disease	1270
.	PUNCT	O	O	1270
We	PRON	O	O	1271
found	VERB	O	O	1271
PTCR	PROPN	O	O	1271
in	ADP	O	O	1271
14	NUM	O	O	1271
of	ADP	O	O	1271
15	NUM	O	O	1271
cases	NOUN	O	O	1271
of	ADP	O	O	1271
TG	PROPN	O	O	1271
,	PUNCT	O	O	1271
in	ADP	O	O	1271
7	NUM	O	O	1271
transplant	NOUN	O	O	1271
biopsy	PROPN	O	O	1271
specimens	NOUN	O	O	1271
without	ADP	O	O	1271
TG	PROPN	O	O	1271
,	PUNCT	O	O	1271
and	CCONJ	O	O	1271
in	ADP	O	O	1271
13	NUM	O	O	1271
of	ADP	O	O	1271
143	NUM	O	O	1271
native	ADJ	O	O	1271
kidney	NOUN	O	O	1271
biopsy	PROPN	O	O	1271
specimens	NOUN	O	O	1271
.	PUNCT	O	O	1271
These	PRON	O	O	1272
13	NUM	O	O	1272
included	VERB	O	O	1272
cases	NOUN	O	O	1272
of	ADP	O	O	1272
malignant	ADJ	O	O	1272
hypertension	NOUN	O	Disease	1272
,	PUNCT	O	O	1272
thrombotic	ADJ	O	Disease	1272
microangiopathy	VERB	O	Disease	1272
,	PUNCT	O	O	1272
lupus	PROPN	O	Disease	1272
nephritis	NOUN	O	Disease	1272
,	PUNCT	O	O	1272
Henoch	PROPN	O	O	1272
-	PUNCT	O	O	1272
Schonlein	PROPN	O	O	1272
nephritis	NOUN	O	Disease	1272
,	PUNCT	O	O	1272
crescentic	ADJ	O	O	1272
glomerulonephritis	NOUN	O	Disease	1272
,	PUNCT	O	O	1272
and	CCONJ	O	O	1272
cocaine	NOUN	O	Chemical	1272
-	PUNCT	O	O	1272
related	ADJ	O	O	1272
acute	ADJ	O	O	1272
renal failure	NOUN	O	Disease	1272
.	PUNCT	O	O	1272
Mild	NOUN	O	O	1273
PTCR	PROPN	O	O	1273
in	ADP	O	O	1273
allografts	PROPN	O	O	1273
without	ADP	O	O	1273
TG	PROPN	O	O	1273
did	VERB	O	O	1273
not	PART	O	O	1273
predict	VERB	O	O	1273
renal failure	NOUN	O	Disease	1273
or	CCONJ	O	O	1273
significant	ADJ	O	O	1273
proteinuria	X	O	Disease	1273
after	ADP	O	O	1273
follow	VERB	O	O	1273
-	PUNCT	O	O	1273
up	ADP	O	O	1273
periods	NOUN	O	O	1273
of	ADP	O	O	1273
between	ADP	O	O	1273
3	X	O	O	1273
months	NOUN	O	O	1273
and	CCONJ	O	O	1273
1	X	O	O	1273
year	NOUN	O	O	1273
.	PUNCT	O	O	1273
CONCLUSIONS	NOUN	O	O	1274
:	PUNCT	O	O	1274
We	PRON	O	O	1274
conclude	VERB	O	O	1274
that	SCONJ	O	O	1274
in	ADP	O	O	1274
transplants	NOUN	O	O	1274
,	PUNCT	O	O	1274
there	ADV	O	O	1274
is	AUX	O	O	1274
a	PRON	O	O	1274
strong	ADJ	O	O	1274
association	PROPN	O	O	1274
between	ADP	O	O	1274
well	ADV	O	O	1274
-	PUNCT	O	O	1274
developed	VERB	O	O	1274
PTCR	PROPN	O	O	1274
and	CCONJ	O	O	1274
TG	PROPN	O	O	1274
,	PUNCT	O	O	1274
while	SCONJ	O	O	1274
the	PRON	O	O	1274
significance	NOUN	O	O	1274
of	ADP	O	O	1274
mild	ADJ	O	O	1274
PTCR	PROPN	O	O	1274
and	CCONJ	O	O	1274
its	PRON	O	O	1274
predictive	ADJ	O	O	1274
value	NOUN	O	O	1274
in	ADP	O	O	1274
the	PRON	O	O	1274
absence	NOUN	O	O	1274
of	ADP	O	O	1274
TG	PROPN	O	O	1274
is	AUX	O	O	1274
unclear	ADJ	O	O	1274
.	PUNCT	O	O	1274
PTCR	PROPN	O	O	1275
also	ADV	O	O	1275
occurs	VERB	O	O	1275
in	ADP	O	O	1275
certain	ADJ	O	O	1275
native	ADJ	O	O	1275
kidney	NOUN	O	O	1275
diseases	NOUN	O	O	1275
,	PUNCT	O	O	1275
though	SCONJ	O	O	1275
the	PRON	O	O	1275
association	PROPN	O	O	1275
is	AUX	O	O	1275
not	PART	O	O	1275
as	ADP	O	O	1275
strong	ADJ	O	O	1275
as	ADP	O	O	1275
that	SCONJ	O	O	1275
for	ADP	O	O	1275
TG	PROPN	O	O	1275
.	PUNCT	O	O	1275
We	PRON	O	O	1276
suggest	VERB	O	O	1276
that	SCONJ	O	O	1276
repeated	VERB	O	O	1276
endothelial	NOUN	O	O	1276
injury	NOUN	O	O	1276
,	PUNCT	O	O	1276
including	VERB	O	O	1276
immunologic	ADJ	O	O	1276
injury	NOUN	O	O	1276
,	PUNCT	O	O	1276
may	AUX	O	O	1276
be	AUX	O	O	1276
the	PRON	O	O	1276
cause	VERB	O	O	1276
of	ADP	O	O	1276
this	PRON	O	O	1276
lesion	NOUN	O	O	1276
both	PRON	O	O	1276
in	ADP	O	O	1276
allografts	PROPN	O	O	1276
and	CCONJ	O	O	1276
native	ADJ	O	O	1276
kidneys	NOUN	O	O	1276
.	PUNCT	O	O	1276
Conformationally	NOUN	O	O	1279
restricted	VERB	O	O	1279
analogs	NOUN	O	O	1279
of	ADP	O	O	1279
BD1008	NOUN	O	O	1279
and	CCONJ	O	O	1279
an	PRON	O	O	1279
antisense	NOUN	O	O	1279
oligodeoxynucleotide	NOUN	O	O	1279
targeting	VERB	O	O	1279
sigma1	ADJ	O	O	1279
receptors	NOUN	O	O	1279
produce	VERB	O	O	1279
anti	ADJ	O	O	1279
-	PUNCT	O	O	1279
cocaine	NOUN	O	Chemical	1279
effects	NOUN	O	O	1279
in	ADP	O	O	1279
mice	NOUN	O	O	1279
.	PUNCT	O	O	1279
Cocaine	NOUN	O	Chemical	1280
's	AUX	O	O	1280
ability	NOUN	O	O	1280
to	PART	O	O	1280
interact	VERB	O	O	1280
with	ADP	O	O	1280
sigma	PROPN	O	O	1280
receptors	NOUN	O	O	1280
suggests	VERB	O	O	1280
that	SCONJ	O	O	1280
these	PRON	O	O	1280
proteins	NOUN	O	O	1280
mediate	VERB	O	O	1280
some	PRON	O	O	1280
of	ADP	O	O	1280
its	PRON	O	O	1280
behavioral	ADJ	O	O	1280
effects	NOUN	O	O	1280
.	PUNCT	O	O	1280
Therefore	ADV	O	O	1281
,	PUNCT	O	O	1281
three	NUM	O	O	1281
novel	NOUN	O	O	1281
sigma	PROPN	O	O	1281
receptor	NOUN	O	O	1281
ligands	NOUN	O	O	1281
with	ADP	O	O	1281
antagonist	NOUN	O	O	1281
activity	NOUN	O	O	1281
were	AUX	O	O	1281
evaluated	VERB	O	O	1281
in	ADP	O	O	1281
Swiss	PROPN	O	O	1281
Webster	PROPN	O	O	1281
mice	NOUN	O	O	1281
:	PUNCT	O	O	1281
BD1018	NOUN	O	O	1281
(	PUNCT	O	O	1281
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	NOUN	O	O	1281
)	PUNCT	O	O	1281
,	PUNCT	O	O	1281
BD1063	VERB	O	O	1281
(	PUNCT	O	O	1281
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	NOUN	O	O	1281
)	PUNCT	O	O	1281
,	PUNCT	O	O	1281
and	CCONJ	O	O	1281
LR132	NUM	O	O	1281
(	PUNCT	O	O	1281
1R,2S-(+)-cis	NUM	O	O	1281
-	PUNCT	O	O	1281
N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine	NOUN	O	O	1281
)	PUNCT	O	O	1281
.	PUNCT	O	O	1281
The	PRON	O	O	1282
three	NUM	O	O	1282
compounds	NOUN	O	O	1282
vary	VERB	O	O	1282
in	ADP	O	O	1282
their	PRON	O	O	1282
affinities	VERB	O	O	1282
for	ADP	O	O	1282
sigma2	NOUN	O	O	1282
receptors	NOUN	O	O	1282
and	CCONJ	O	O	1282
exhibit	VERB	O	O	1282
negligible	ADJ	O	O	1282
affinities	VERB	O	O	1282
for	ADP	O	O	1282
dopamine	NOUN	O	Chemical	1282
,	PUNCT	O	O	1282
opioid	NOUN	O	O	1282
,	PUNCT	O	O	1282
GABA(A	X	O	O	1282
)	PUNCT	O	O	1282
and	CCONJ	O	O	1282
NMDA	PROPN	O	Chemical	1282
receptors	NOUN	O	O	1282
.	PUNCT	O	O	1282
In	ADP	O	O	1283
behavioral	ADJ	O	O	1283
studies	NOUN	O	O	1283
,	PUNCT	O	O	1283
pre	VERB	O	O	1283
-	PUNCT	O	O	1283
treatment	NOUN	O	O	1283
of	ADP	O	O	1283
mice	NOUN	O	O	1283
with	ADP	O	O	1283
BD1018	NOUN	O	O	1283
,	PUNCT	O	O	1283
BD1063	VERB	O	O	1283
,	PUNCT	O	O	1283
or	CCONJ	O	O	1283
LR132	NUM	O	O	1283
significantly	ADV	O	O	1283
attenuated	VERB	O	O	1283
cocaine	NOUN	O	Chemical	1283
-	PUNCT	O	O	1283
induced	VERB	O	O	1283
convulsions	NOUN	O	Disease	1283
and	CCONJ	O	O	1283
lethality	NOUN	O	O	1283
.	PUNCT	O	O	1283
Moreover	ADV	O	O	1284
,	PUNCT	O	O	1284
post	VERB	O	O	1284
-	PUNCT	O	O	1284
treatment	NOUN	O	O	1284
with	ADP	O	O	1284
LR132	NUM	O	O	1284
prevented	VERB	O	O	1284
cocaine	NOUN	O	Chemical	1284
-	PUNCT	O	O	1284
induced	VERB	O	O	1284
lethality	NOUN	O	O	1284
in	ADP	O	O	1284
a	PRON	O	O	1284
significant	ADJ	O	O	1284
proportion	NOUN	O	O	1284
of	ADP	O	O	1284
animals	NOUN	O	O	1284
.	PUNCT	O	O	1284
In	ADP	O	O	1285
contrast	NOUN	O	O	1285
to	PART	O	O	1285
the	PRON	O	O	1285
protection	NOUN	O	O	1285
provided	VERB	O	O	1285
by	ADP	O	O	1285
the	PRON	O	O	1285
putative	ADJ	O	O	1285
antagonists	NOUN	O	O	1285
,	PUNCT	O	O	1285
the	PRON	O	O	1285
well	ADV	O	O	1285
-	PUNCT	O	O	1285
characterized	VERB	O	O	1285
sigma	PROPN	O	O	1285
receptor	NOUN	O	O	1285
agonist	NOUN	O	O	1285
di	PROPN	O	O	1285
-	PUNCT	O	O	1285
o	INTJ	O	O	1285
-	PUNCT	O	O	1285
tolylguanidine	VERB	O	O	1285
(	PUNCT	O	O	1285
DTG	PROPN	O	O	1285
)	PUNCT	O	O	1285
and	CCONJ	O	O	1285
the	PRON	O	O	1285
novel	NOUN	O	O	1285
sigma	PROPN	O	O	1285
receptor	NOUN	O	O	1285
agonist	NOUN	O	O	1285
BD1031	NOUN	O	O	1285
(	PUNCT	O	O	1285
3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	NOUN	O	O	1285
)	PUNCT	O	O	1285
each	PRON	O	O	1285
worsened	VERB	O	O	1285
the	PRON	O	O	1285
behavioral	ADJ	O	O	1285
toxicity	NOUN	O	Disease	1285
of	ADP	O	O	1285
cocaine	NOUN	O	Chemical	1285
.	PUNCT	O	O	1285
At	ADP	O	O	1286
doses	NOUN	O	O	1286
where	SCONJ	O	O	1286
alone	ADV	O	O	1286
,	PUNCT	O	O	1286
they	PRON	O	O	1286
produced	VERB	O	O	1286
no	PRON	O	O	1286
significant	ADJ	O	O	1286
effects	NOUN	O	O	1286
on	ADP	O	O	1286
locomotion	NOUN	O	O	1286
,	PUNCT	O	O	1286
BD1018	NOUN	O	O	1286
,	PUNCT	O	O	1286
BD1063	VERB	O	O	1286
and	CCONJ	O	O	1286
LR132	NUM	O	O	1286
significantly	ADV	O	O	1286
attenuated	VERB	O	O	1286
the	PRON	O	O	1286
locomotor	PROPN	O	O	1286
stimulatory	ADJ	O	O	1286
effects	NOUN	O	O	1286
of	ADP	O	O	1286
cocaine	NOUN	O	Chemical	1286
.	PUNCT	O	O	1286
To	PART	O	O	1287
further	ADV	O	O	1287
validate	VERB	O	O	1287
the	PRON	O	O	1287
hypothesis	NOUN	O	O	1287
that	SCONJ	O	O	1287
the	PRON	O	O	1287
anti	ADJ	O	O	1287
-	PUNCT	O	O	1287
cocaine	NOUN	O	Chemical	1287
effects	NOUN	O	O	1287
of	ADP	O	O	1287
the	PRON	O	O	1287
novel	NOUN	O	O	1287
ligands	NOUN	O	O	1287
involved	VERB	O	O	1287
antagonism	NOUN	O	O	1287
of	ADP	O	O	1287
sigma	PROPN	O	O	1287
receptors	NOUN	O	O	1287
,	PUNCT	O	O	1287
an	PRON	O	O	1287
antisense	NOUN	O	O	1287
oligodeoxynucleotide	NOUN	O	O	1287
against	ADP	O	O	1287
sigma1	ADJ	O	O	1287
receptors	NOUN	O	O	1287
was	AUX	O	O	1287
also	ADV	O	O	1287
shown	VERB	O	O	1287
to	PART	O	O	1287
significantly	ADV	O	O	1287
attenuate	VERB	O	O	1287
the	PRON	O	O	1287
convulsive	ADJ	O	Disease	1287
and	CCONJ	O	O	1287
locomotor	PROPN	O	O	1287
stimulatory	ADJ	O	O	1287
effects	NOUN	O	O	1287
of	ADP	O	O	1287
cocaine	NOUN	O	Chemical	1287
.	PUNCT	O	O	1287
Together	ADV	O	O	1288
,	PUNCT	O	O	1288
the	PRON	O	O	1288
data	NOUN	O	O	1288
suggests	VERB	O	O	1288
that	SCONJ	O	O	1288
functional	ADJ	O	O	1288
antagonism	NOUN	O	O	1288
of	ADP	O	O	1288
sigma	PROPN	O	O	1288
receptors	NOUN	O	O	1288
is	AUX	O	O	1288
capable	ADJ	O	O	1288
of	ADP	O	O	1288
attenuating	VERB	O	O	1288
a	PRON	O	O	1288
number	NOUN	O	O	1288
of	ADP	O	O	1288
cocaine	NOUN	O	Chemical	1288
-	PUNCT	O	O	1288
induced	VERB	O	O	1288
behaviors	NOUN	O	O	1288
.	PUNCT	O	O	1288
Pharmacokinetic	NOUN	O	O	1291
/	PUNCT	O	O	1291
pharmacodynamic	ADJ	O	O	1291
assessment	NOUN	O	O	1291
of	ADP	O	O	1291
the	PRON	O	O	1291
effects	NOUN	O	O	1291
of	ADP	O	O	1291
E4031	NOUN	O	O	1291
,	PUNCT	O	O	1291
cisapride	ADV	O	Chemical	1291
,	PUNCT	O	O	1291
terfenadine	NOUN	O	O	1291
and	CCONJ	O	O	1291
terodiline	NOUN	O	O	1291
on	ADP	O	O	1291
monophasic	ADJ	O	O	1291
action	NOUN	O	O	1291
potential	ADJ	O	O	1291
duration	NOUN	O	O	1291
in	ADP	O	O	1291
dog	NOUN	O	O	1291
Torsades	NOUN	O	O	1292
de	VERB	O	O	1292
pointes	VERB	O	O	1292
(	PUNCT	O	O	1292
TDP	PROPN	O	Disease	1292
)	PUNCT	O	O	1292
is	AUX	O	O	1292
a	PRON	O	O	1292
potentially	ADV	O	O	1292
fatal	ADJ	O	O	1292
ventricular tachycardia	NOUN	O	Disease	1292
associated	VERB	O	O	1292
with	ADP	O	O	1292
increases	VERB	O	O	1292
in	ADP	O	O	1292
QT	NOUN	O	O	1292
interval	NOUN	O	O	1292
and	CCONJ	O	O	1292
monophasic	ADJ	O	O	1292
action	NOUN	O	O	1292
potential	ADJ	O	O	1292
duration	NOUN	O	O	1292
(	PUNCT	O	O	1292
MAPD	PROPN	O	O	1292
)	PUNCT	O	O	1292
.	PUNCT	O	O	1292
TDP	PROPN	O	Disease	1293
is	AUX	O	O	1293
a	PRON	O	O	1293
side	NOUN	O	O	1293
-	PUNCT	O	O	1293
effect	VERB	O	O	1293
that	SCONJ	O	O	1293
has	VERB	O	O	1293
led	VERB	O	O	1293
to	PART	O	O	1293
withdrawal	NOUN	O	O	1293
of	ADP	O	O	1293
several	ADJ	O	O	1293
drugs	NOUN	O	O	1293
from	ADP	O	O	1293
the	PRON	O	O	1293
market	NOUN	O	O	1293
(	PUNCT	O	O	1293
e.g.	ADV	O	O	1293
terfenadine	NOUN	O	O	1293
and	CCONJ	O	O	1293
terodiline	NOUN	O	O	1293
)	PUNCT	O	O	1293
.	PUNCT	O	O	1293
The	PRON	O	O	1294
potential	ADJ	O	O	1294
of	ADP	O	O	1294
compounds	NOUN	O	O	1294
to	PART	O	O	1294
cause	VERB	O	O	1294
TDP	PROPN	O	Disease	1294
was	AUX	O	O	1294
evaluated	VERB	O	O	1294
by	ADP	O	O	1294
monitoring	NOUN	O	O	1294
their	PRON	O	O	1294
effects	NOUN	O	O	1294
on	ADP	O	O	1294
MAPD	PROPN	O	O	1294
in	ADP	O	O	1294
dog	NOUN	O	O	1294
.	PUNCT	O	O	1294
Four	NUM	O	O	1295
compounds	NOUN	O	O	1295
known	VERB	O	O	1295
to	PART	O	O	1295
increase	VERB	O	O	1295
QT	NOUN	O	O	1295
interval	NOUN	O	O	1295
and	CCONJ	O	O	1295
cause	VERB	O	O	1295
TDP	PROPN	O	Disease	1295
were	AUX	O	O	1295
investigated	VERB	O	O	1295
:	PUNCT	O	O	1295
terfenadine	NOUN	O	O	1295
,	PUNCT	O	O	1295
terodiline	NOUN	O	O	1295
,	PUNCT	O	O	1295
cisapride	ADV	O	Chemical	1295
and	CCONJ	O	O	1295
E4031	NOUN	O	O	1295
.	PUNCT	O	O	1295
These	PRON	O	O	1296
data	NOUN	O	O	1296
indicate	VERB	O	O	1296
that	SCONJ	O	O	1296
the	PRON	O	O	1296
free	ADJ	O	O	1296
ED50	PROPN	O	O	1296
in	ADP	O	O	1296
plasma	NOUN	O	O	1296
for	ADP	O	O	1296
terfenadine	NOUN	O	O	1296
(	PUNCT	O	O	1296
1.9	NUM	O	O	1296
nM	NOUN	O	O	1296
)	PUNCT	O	O	1296
,	PUNCT	O	O	1296
terodiline	NOUN	O	O	1296
(	PUNCT	O	O	1296
76	NUM	O	O	1296
nM	NOUN	O	O	1296
)	PUNCT	O	O	1296
,	PUNCT	O	O	1296
cisapride	ADV	O	Chemical	1296
(	PUNCT	O	O	1296
11	NUM	O	O	1296
nM	NOUN	O	O	1296
)	PUNCT	O	O	1296
and	CCONJ	O	O	1296
E4031	NOUN	O	O	1296
(	PUNCT	O	O	1296
1.9	NUM	O	O	1296
nM	NOUN	O	O	1296
)	PUNCT	O	O	1296
closely	ADV	O	O	1296
correlate	VERB	O	O	1296
with	ADP	O	O	1296
the	PRON	O	O	1296
free	ADJ	O	O	1296
concentration	NOUN	O	O	1296
in	ADP	O	O	1296
man	NOUN	O	O	1296
causing	VERB	O	O	1296
QT	NOUN	O	O	1296
effects	NOUN	O	O	1296
.	PUNCT	O	O	1296
For	ADP	O	O	1297
compounds	NOUN	O	O	1297
that	SCONJ	O	O	1297
have	VERB	O	O	1297
shown	VERB	O	O	1297
TDP	PROPN	O	Disease	1297
in	ADP	O	O	1297
the	PRON	O	O	1297
clinic	NOUN	O	O	1297
(	PUNCT	O	O	1297
terfenadine	NOUN	O	O	1297
,	PUNCT	O	O	1297
terodiline	NOUN	O	O	1297
,	PUNCT	O	O	1297
cisapride	ADV	O	Chemical	1297
)	PUNCT	O	O	1297
there	ADV	O	O	1297
is	AUX	O	O	1297
little	ADJ	O	O	1297
differentiation	NOUN	O	O	1297
between	ADP	O	O	1297
the	PRON	O	O	1297
dog	NOUN	O	O	1297
ED50	PROPN	O	O	1297
and	CCONJ	O	O	1297
the	PRON	O	O	1297
efficacious	ADJ	O	O	1297
free	ADJ	O	O	1297
plasma	NOUN	O	O	1297
concentrations	NOUN	O	O	1297
in	ADP	O	O	1297
man	NOUN	O	O	1297
(	PUNCT	O	O	1297
<	X	O	O	1297
10-fold	ADV	O	O	1297
)	PUNCT	O	O	1297
reflecting	VERB	O	O	1297
their	PRON	O	O	1297
limited	VERB	O	O	1297
safety	NOUN	O	O	1297
margins	NOUN	O	O	1297
.	PUNCT	O	O	1297
These	PRON	O	O	1298
data	NOUN	O	O	1298
underline	VERB	O	O	1298
the	PRON	O	O	1298
need	VERB	O	O	1298
to	PART	O	O	1298
maximize	VERB	O	O	1298
the	PRON	O	O	1298
therapeutic	ADJ	O	O	1298
ratio	NOUN	O	O	1298
with	ADP	O	O	1298
respect	VERB	O	O	1298
to	PART	O	O	1298
TDP	PROPN	O	Disease	1298
in	ADP	O	O	1298
potential	ADJ	O	O	1298
development	NOUN	O	O	1298
candidates	NOUN	O	O	1298
and	CCONJ	O	O	1298
the	PRON	O	O	1298
importance	NOUN	O	O	1298
of	ADP	O	O	1298
using	VERB	O	O	1298
free	ADJ	O	O	1298
drug	NOUN	O	O	1298
concentrations	NOUN	O	O	1298
in	ADP	O	O	1298
pharmacokinetic	VERB	O	O	1298
/	PUNCT	O	O	1298
pharmacodynamic	ADJ	O	O	1298
studies	NOUN	O	O	1298
.	PUNCT	O	O	1298
Fatal	ADJ	O	O	1301
myeloencephalopathy	PROPN	O	O	1301
due	ADJ	O	O	1301
to	PART	O	O	1301
accidental	ADJ	O	O	1301
intrathecal	ADJ	O	O	1301
vincristin	PROPN	O	O	1301
administration	NOUN	O	O	1301
:	PUNCT	O	O	1301
a	PRON	O	O	1301
report	VERB	O	O	1301
of	ADP	O	O	1301
two	NUM	O	O	1301
cases	NOUN	O	O	1301
.	PUNCT	O	O	1301
We	PRON	O	O	1302
report	VERB	O	O	1302
on	ADP	O	O	1302
two	NUM	O	O	1302
fatal	ADJ	O	O	1302
cases	NOUN	O	O	1302
of	ADP	O	O	1302
accidental	ADJ	O	O	1302
intrathecal	ADJ	O	O	1302
vincristine	NOUN	O	Chemical	1302
instillation	NOUN	O	O	1302
in	ADP	O	O	1302
a	PRON	O	O	1302
5-year	NOUN	O	O	1302
old	ADJ	O	O	1302
girl	NOUN	O	O	1302
with	ADP	O	O	1302
recurrent	ADJ	O	O	1302
acute	ADJ	O	O	1302
lymphoblastic	NOUN	O	O	1302
leucemia	NOUN	O	O	1302
and	CCONJ	O	O	1302
a	PRON	O	O	1302
57-year	NOUN	O	O	1302
old	ADJ	O	O	1302
man	NOUN	O	O	1302
with	ADP	O	O	1302
lymphoblastic	NOUN	O	O	1302
lymphoma	PROPN	O	Disease	1302
.	PUNCT	O	O	1302
The	PRON	O	O	1303
girl	NOUN	O	O	1303
died	VERB	O	O	1303
seven	NUM	O	O	1303
days	NOUN	O	O	1303
,	PUNCT	O	O	1303
the	PRON	O	O	1303
man	NOUN	O	O	1303
four	NUM	O	O	1303
weeks	NOUN	O	O	1303
after	ADP	O	O	1303
intrathecal	ADJ	O	O	1303
injection	NOUN	O	O	1303
of	ADP	O	O	1303
vincristine	NOUN	O	Chemical	1303
.	PUNCT	O	O	1303
Clinically	ADV	O	O	1304
,	PUNCT	O	O	1304
the	PRON	O	O	1304
onset	VERB	O	O	1304
was	AUX	O	O	1304
characterized	VERB	O	O	1304
by	ADP	O	O	1304
the	PRON	O	O	1304
signs	NOUN	O	O	1304
of	ADP	O	O	1304
opistothonus	VERB	O	O	1304
,	PUNCT	O	O	1304
sensory	ADJ	O	O	1304
and	CCONJ	O	O	1304
motor	NOUN	O	O	1304
dysfunction	NOUN	O	O	1304
and	CCONJ	O	O	1304
ascending	VERB	O	O	1304
paralysis	NOUN	O	Disease	1304
.	PUNCT	O	O	1304
Histological	NOUN	O	O	1305
and	CCONJ	O	O	1305
immunohistochemical	ADJ	O	O	1305
investigations	NOUN	O	O	1305
(	PUNCT	O	O	1305
HE	PRON	O	O	1305
-	PUNCT	O	O	1305
LFB	PROPN	O	O	1305
,	PUNCT	O	O	1305
CD-68	NUM	O	O	1305
,	PUNCT	O	O	1305
Neurofilament	NOUN	O	O	1305
)	PUNCT	O	O	1305
revealed	VERB	O	O	1305
degeneration	NOUN	O	O	1305
of	ADP	O	O	1305
myelin	NOUN	O	O	1305
and	CCONJ	O	O	1305
axons	NOUN	O	O	1305
as	ADP	O	O	1305
well	ADV	O	O	1305
as	ADP	O	O	1305
pseudocystic	ADJ	O	O	1305
transformation	NOUN	O	O	1305
in	ADP	O	O	1305
areas	NOUN	O	O	1305
exposed	VERB	O	O	1305
to	PART	O	O	1305
vincristine	NOUN	O	Chemical	1305
,	PUNCT	O	O	1305
accompanied	VERB	O	O	1305
by	ADP	O	O	1305
secondary	ADJ	O	O	1305
changes	VERB	O	O	1305
with	ADP	O	O	1305
numerous	ADJ	O	O	1305
prominent	ADJ	O	O	1305
macrophages	VERB	O	O	1305
.	PUNCT	O	O	1305
A	PRON	O	O	1306
better	ADV	O	O	1306
controlled	VERB	O	O	1306
regimen	NOUN	O	O	1306
for	ADP	O	O	1306
administering	VERB	O	O	1306
vincristine	NOUN	O	Chemical	1306
and	CCONJ	O	O	1306
Intravenous	PROPN	O	O	1309
administration	NOUN	O	O	1309
of	ADP	O	O	1309
prochlorperazine	PROPN	O	Chemical	1309
by	ADP	O	O	1309
15-minute	NOUN	O	O	1309
infusion	NOUN	O	O	1309
versus	ADP	O	O	1309
2-minute	NOUN	O	O	1309
bolus	NOUN	O	O	1309
does	VERB	O	O	1309
not	PART	O	O	1309
affect	VERB	O	O	1309
the	PRON	O	O	1309
incidence	NOUN	O	O	1309
of	ADP	O	O	1309
akathisia	PROPN	O	Disease	1309
:	PUNCT	O	O	1309
a	PRON	O	O	1309
prospective	ADJ	O	O	1309
,	PUNCT	O	O	1309
randomized	VERB	O	O	1309
,	PUNCT	O	O	1309
controlled	VERB	O	O	1309
trial	NOUN	O	O	1309
.	PUNCT	O	O	1309
STUDY	NOUN	O	O	1310
OBJECTIVE	VERB	O	O	1310
:	PUNCT	O	O	1310
We	PRON	O	O	1310
sought	VERB	O	O	1310
to	PART	O	O	1310
compare	VERB	O	O	1310
the	PRON	O	O	1310
rate	NOUN	O	O	1310
of	ADP	O	O	1310
akathisia	PROPN	O	Disease	1310
after	ADP	O	O	1310
administration	NOUN	O	O	1310
of	ADP	O	O	1310
intravenous	ADJ	O	O	1310
prochlorperazine	PROPN	O	Chemical	1310
as	ADP	O	O	1310
a	PRON	O	O	1310
2-minute	NOUN	O	O	1310
bolus	NOUN	O	O	1310
or	CCONJ	O	O	1310
15-minute	NOUN	O	O	1310
infusion	NOUN	O	O	1310
.	PUNCT	O	O	1310
Patients	NOUN	O	O	1311
aged	ADJ	O	O	1311
18	NUM	O	O	1311
years	NOUN	O	O	1311
or	CCONJ	O	O	1311
older	ADJ	O	O	1311
treated	VERB	O	O	1311
with	ADP	O	O	1311
prochlorperazine	PROPN	O	Chemical	1311
for	ADP	O	O	1311
headache	PROPN	O	Disease	1311
,	PUNCT	O	O	1311
nausea	NOUN	O	Disease	1311
,	PUNCT	O	O	1311
or	CCONJ	O	O	1311
vomiting	VERB	O	Disease	1311
were	AUX	O	O	1311
eligible	ADJ	O	O	1311
for	ADP	O	O	1311
inclusion	NOUN	O	O	1311
.	PUNCT	O	O	1311
Study	NOUN	O	O	1312
participants	NOUN	O	O	1312
were	AUX	O	O	1312
randomized	VERB	O	O	1312
to	PART	O	O	1312
receive	VERB	O	O	1312
10	NUM	O	O	1312
mg	VERB	O	O	1312
of	ADP	O	O	1312
prochlorperazine	PROPN	O	Chemical	1312
administered	VERB	O	O	1312
intravenously	ADV	O	O	1312
by	ADP	O	O	1312
means	VERB	O	O	1312
of	ADP	O	O	1312
2-minute	NOUN	O	O	1312
push	VERB	O	O	1312
(	PUNCT	O	O	1312
bolus	NOUN	O	O	1312
group	NOUN	O	O	1312
)	PUNCT	O	O	1312
or	CCONJ	O	O	1312
10	NUM	O	O	1312
mg	VERB	O	O	1312
diluted	VERB	O	O	1312
in	ADP	O	O	1312
50	NUM	O	O	1312
mL	PROPN	O	O	1312
of	ADP	O	O	1312
normal	ADJ	O	O	1312
saline	NOUN	O	O	1312
solution	NOUN	O	O	1312
administered	VERB	O	O	1312
by	ADP	O	O	1312
means	VERB	O	O	1312
of	ADP	O	O	1312
intravenous	ADJ	O	O	1312
infusion	NOUN	O	O	1312
during	ADP	O	O	1312
a	PRON	O	O	1312
15-minute	NOUN	O	O	1312
period	NOUN	O	O	1312
(	PUNCT	O	O	1312
infusion	NOUN	O	O	1312
group	NOUN	O	O	1312
)	PUNCT	O	O	1312
.	PUNCT	O	O	1312
The	PRON	O	O	1313
main	ADJ	O	O	1313
outcome	NOUN	O	O	1313
was	AUX	O	O	1313
the	PRON	O	O	1313
number	NOUN	O	O	1313
of	ADP	O	O	1313
study	VERB	O	O	1313
participants	NOUN	O	O	1313
experiencing	VERB	O	O	1313
akathisia	PROPN	O	Disease	1313
within	ADP	O	O	1313
60	NUM	O	O	1313
minutes	NOUN	O	O	1313
of	ADP	O	O	1313
administration	NOUN	O	O	1313
.	PUNCT	O	O	1313
Akathisia	PROPN	O	Disease	1314
was	AUX	O	O	1314
defined	VERB	O	O	1314
as	ADP	O	O	1314
either	ADV	O	O	1314
a	PRON	O	O	1314
spontaneous	ADJ	O	O	1314
report	VERB	O	O	1314
of	ADP	O	O	1314
restlessness	NOUN	O	Disease	1314
or	CCONJ	O	O	1314
agitation	NOUN	O	Disease	1314
or	CCONJ	O	O	1314
a	PRON	O	O	1314
change	VERB	O	O	1314
of	ADP	O	O	1314
2	X	O	O	1314
or	CCONJ	O	O	1314
more	ADJ	O	O	1314
in	ADP	O	O	1314
the	PRON	O	O	1314
patient	NOUN	O	O	1314
-	PUNCT	O	O	1314
reported	VERB	O	O	1314
akathisia	PROPN	O	Disease	1314
rating	NOUN	O	O	1314
scale	NOUN	O	O	1314
and	CCONJ	O	O	1314
a	PRON	O	O	1314
change	VERB	O	O	1314
of	ADP	O	O	1314
at	ADP	O	O	1314
least	ADJ	O	O	1314
1	X	O	O	1314
in	ADP	O	O	1314
the	PRON	O	O	1314
investigator	NOUN	O	O	1314
-	PUNCT	O	O	1314
observed	VERB	O	O	1314
akathisia	PROPN	O	Disease	1314
rating	NOUN	O	O	1314
scale	NOUN	O	O	1314
.	PUNCT	O	O	1314
The	PRON	O	O	1315
intensity	NOUN	O	O	1315
of	ADP	O	O	1315
headache	PROPN	O	Disease	1315
and	CCONJ	O	O	1315
nausea	NOUN	O	Disease	1315
was	AUX	O	O	1315
measured	VERB	O	O	1315
with	ADP	O	O	1315
a	PRON	O	O	1315
100-mm	NOUN	O	O	1315
visual	ADJ	O	O	1315
analog	NOUN	O	O	1315
scale	NOUN	O	O	1315
.	PUNCT	O	O	1315
Seventy	NUM	O	O	1316
-	PUNCT	O	O	1316
three	NUM	O	O	1316
percent	NOUN	O	O	1316
(	PUNCT	O	O	1316
73/99	NUM	O	O	1316
)	PUNCT	O	O	1316
of	ADP	O	O	1316
the	PRON	O	O	1316
study	VERB	O	O	1316
participants	NOUN	O	O	1316
were	AUX	O	O	1316
treated	VERB	O	O	1316
for	ADP	O	O	1316
headache	PROPN	O	Disease	1316
and	CCONJ	O	O	1316
70%	NOUN	O	O	1316
(	PUNCT	O	O	1316
70/99	NUM	O	O	1316
)	PUNCT	O	O	1316
for	ADP	O	O	1316
nausea	NOUN	O	Disease	1316
.	PUNCT	O	O	1316
In	ADP	O	O	1317
the	PRON	O	O	1317
bolus	NOUN	O	O	1317
group	NOUN	O	O	1317
,	PUNCT	O	O	1317
26.0%	NOUN	O	O	1317
(	PUNCT	O	O	1317
13/50	NUM	O	O	1317
)	PUNCT	O	O	1317
had	VERB	O	O	1317
akathisia	PROPN	O	Disease	1317
compared	VERB	O	O	1317
with	ADP	O	O	1317
32.7%	NOUN	O	O	1317
(	PUNCT	O	O	1317
16/49	NUM	O	O	1317
)	PUNCT	O	O	1317
in	ADP	O	O	1317
the	PRON	O	O	1317
infusion	NOUN	O	O	1317
group	NOUN	O	O	1317
The	PRON	O	O	1318
difference	NOUN	O	O	1318
between	ADP	O	O	1318
the	PRON	O	O	1318
bolus	NOUN	O	O	1318
and	CCONJ	O	O	1318
infusion	NOUN	O	O	1318
groups	NOUN	O	O	1318
in	ADP	O	O	1318
the	PRON	O	O	1318
percentage	NOUN	O	O	1318
of	ADP	O	O	1318
participants	NOUN	O	O	1318
who	PRON	O	O	1318
saw	VERB	O	O	1318
a	PRON	O	O	1318
50%	NOUN	O	O	1318
reduction	NOUN	O	O	1318
in	ADP	O	O	1318
their	PRON	O	O	1318
headache	PROPN	O	Disease	1318
intensity	NOUN	O	O	1318
within	ADP	O	O	1318
30	NUM	O	O	1318
minutes	NOUN	O	O	1318
was	AUX	O	O	1318
11.8%	NOUN	O	O	1318
(	PUNCT	O	O	1318
95%	NOUN	O	O	1318
CI	NOUN	O	O	1318
-9.6%	NOUN	O	O	1318
to	PART	O	O	1318
33.3%	NOUN	O	O	1318
)	PUNCT	O	O	1318
.	PUNCT	O	O	1318
The	PRON	O	O	1319
difference	NOUN	O	O	1319
in	ADP	O	O	1319
the	PRON	O	O	1319
percentage	NOUN	O	O	1319
of	ADP	O	O	1319
patients	NOUN	O	O	1319
with	ADP	O	O	1319
a	PRON	O	O	1319
50%	NOUN	O	O	1319
reduction	NOUN	O	O	1319
in	ADP	O	O	1319
their	PRON	O	O	1319
nausea	NOUN	O	Disease	1319
was	AUX	O	O	1319
12.6%	NOUN	O	O	1319
(	PUNCT	O	O	1319
95%	NOUN	O	O	1319
CI	NOUN	O	O	1319
-4.6%	NOUN	O	O	1319
to	PART	O	O	1319
29.8%	NOUN	O	O	1319
)	PUNCT	O	O	1319
.	PUNCT	O	O	1319
A	PRON	O	O	1320
50%	NOUN	O	O	1320
reduction	NOUN	O	O	1320
in	ADP	O	O	1320
the	PRON	O	O	1320
incidence	NOUN	O	O	1320
of	ADP	O	O	1320
akathisia	PROPN	O	Disease	1320
when	SCONJ	O	O	1320
prochlorperazine	PROPN	O	Chemical	1320
was	AUX	O	O	1320
administered	VERB	O	O	1320
by	ADP	O	O	1320
means	VERB	O	O	1320
of	ADP	O	O	1320
15-minute	NOUN	O	O	1320
intravenous	ADJ	O	O	1320
infusion	NOUN	O	O	1320
versus	ADP	O	O	1320
a	PRON	O	O	1320
2-minute	NOUN	O	O	1320
intravenous	ADJ	O	O	1320
push	VERB	O	O	1320
was	AUX	O	O	1320
not	PART	O	O	1320
detected	VERB	O	O	1320
.	PUNCT	O	O	1320
The	PRON	O	O	1321
efficacy	NOUN	O	O	1321
of	ADP	O	O	1321
prochlorperazine	PROPN	O	Chemical	1321
in	ADP	O	O	1321
the	PRON	O	O	1321
treatment	NOUN	O	O	1321
of	ADP	O	O	1321
headache	PROPN	O	Disease	1321
and	CCONJ	O	O	1321
nausea	NOUN	O	Disease	1321
likewise	ADV	O	O	1321
did	VERB	O	O	1321
not	PART	O	O	1321
appear	VERB	O	O	1321
to	PART	O	O	1321
be	AUX	O	O	1321
affected	VERB	O	O	1321
by	ADP	O	O	1321
the	PRON	O	O	1321
rate	NOUN	O	O	1321
of	ADP	O	O	1321
administration	NOUN	O	O	1321
,	PUNCT	O	O	1321
although	SCONJ	O	O	1321
no	PRON	O	O	1321
formal	ADJ	O	O	1321
statistical	ADJ	O	O	1321
comparisons	NOUN	O	O	1321
were	AUX	O	O	1321
made	VERB	O	O	1321
.	PUNCT	O	O	1321
Antithymocyte	NOUN	O	O	1324
globulin	NOUN	O	O	1324
in	ADP	O	O	1324
the	PRON	O	O	1324
treatment	NOUN	O	O	1324
of	ADP	O	O	1324
D	NOUN	O	O	1324
-	PUNCT	O	O	1324
penicillamine	NOUN	O	Chemical	1324
-	PUNCT	O	O	1324
induced	VERB	O	O	1324
aplastic anemia	NOUN	O	Disease	1324
.	PUNCT	O	O	1324
A	PRON	O	O	1325
patient	NOUN	O	O	1325
who	PRON	O	O	1325
received	VERB	O	O	1325
antithymocyte	PROPN	O	O	1325
globulin	NOUN	O	O	1325
therapy	NOUN	O	O	1325
for	ADP	O	O	1325
aplastic anemia	NOUN	O	Disease	1325
due	ADJ	O	O	1325
to	PART	O	O	1325
D	NOUN	O	O	1325
-	PUNCT	O	O	1325
penicillamine	NOUN	O	Chemical	1325
therapy	NOUN	O	O	1325
is	AUX	O	O	1325
described	VERB	O	O	1325
.	PUNCT	O	O	1325
Use	VERB	O	O	1326
of	ADP	O	O	1326
antithymocyte	PROPN	O	O	1326
globulin	NOUN	O	O	1326
may	AUX	O	O	1326
be	AUX	O	O	1326
the	PRON	O	O	1326
optimal	ADJ	O	O	1326
treatment	NOUN	O	O	1326
of	ADP	O	O	1326
D	NOUN	O	O	1326
-	PUNCT	O	O	1326
penicillamine	NOUN	O	Chemical	1326
-	PUNCT	O	O	1326
induced	VERB	O	O	1326
aplastic anemia	NOUN	O	Disease	1326
.	PUNCT	O	O	1326
The	PRON	O	O	1329
relationship	NOUN	O	O	1329
between	ADP	O	O	1329
hippocampal	NOUN	O	O	1329
acetylcholine	NOUN	O	Chemical	1329
release	NOUN	O	O	1329
and	CCONJ	O	O	1329
cholinergic	ADJ	O	O	1329
convulsant	ADJ	O	O	1329
sensitivity	NOUN	O	O	1329
in	ADP	O	O	1329
withdrawal	NOUN	O	O	1329
seizure	NOUN	O	Disease	1329
-	PUNCT	O	O	1329
prone	ADJ	O	O	1329
and	CCONJ	O	O	1329
withdrawal	NOUN	O	O	1329
seizure	NOUN	O	Disease	1329
-	PUNCT	O	O	1329
resistant	ADJ	O	O	1329
selected	VERB	O	O	1329
mouse	PROPN	O	O	1329
lines	NOUN	O	O	1329
.	PUNCT	O	O	1329
The	PRON	O	O	1330
septo	VERB	O	O	1330
-	PUNCT	O	O	1330
hippocampal	NOUN	O	O	1330
cholinergic	ADJ	O	O	1330
pathway	NOUN	O	O	1330
has	VERB	O	O	1330
been	AUX	O	O	1330
implicated	VERB	O	O	1330
in	ADP	O	O	1330
epileptogenesis	NOUN	O	O	1330
,	PUNCT	O	O	1330
and	CCONJ	O	O	1330
genetic	ADJ	O	O	1330
factors	NOUN	O	O	1330
influence	NOUN	O	O	1330
the	PRON	O	O	1330
response	NOUN	O	O	1330
to	PART	O	O	1330
cholinergic	ADJ	O	O	1330
agents	NOUN	O	O	1330
,	PUNCT	O	O	1330
but	CCONJ	O	O	1330
limited	VERB	O	O	1330
data	NOUN	O	O	1330
are	AUX	O	O	1330
available	ADJ	O	O	1330
on	ADP	O	O	1330
cholinergic	ADJ	O	O	1330
involvement	NOUN	O	O	1330
in	ADP	O	O	1330
alcohol	NOUN	O	Chemical	1330
withdrawal	NOUN	O	O	1330
severity	NOUN	O	O	1330
.	PUNCT	O	O	1330
Thus	ADV	O	O	1331
,	PUNCT	O	O	1331
the	PRON	O	O	1331
relationship	NOUN	O	O	1331
between	ADP	O	O	1331
cholinergic	ADJ	O	O	1331
activity	NOUN	O	O	1331
and	CCONJ	O	O	1331
responsiveness	NOUN	O	O	1331
and	CCONJ	O	O	1331
alcohol	NOUN	O	Chemical	1331
withdrawal	NOUN	O	O	1331
was	AUX	O	O	1331
investigated	VERB	O	O	1331
in	ADP	O	O	1331
a	PRON	O	O	1331
genetic	ADJ	O	O	1331
animal	NOUN	O	O	1331
model	NOUN	O	O	1331
of	ADP	O	O	1331
ethanol	NOUN	O	Chemical	1331
withdrawal	NOUN	O	O	1331
severity	NOUN	O	O	1331
.	PUNCT	O	O	1331
Cholinergic	ADJ	O	O	1332
convulsant	ADJ	O	O	1332
sensitivity	NOUN	O	O	1332
was	AUX	O	O	1332
examined	VERB	O	O	1332
in	ADP	O	O	1332
alcohol	NOUN	O	Chemical	1332
-	PUNCT	O	O	1332
na	INTJ	O	O	1332
ve	VERB	O	O	1332
Withdrawal	NOUN	O	O	1333
Seizure	NOUN	O	Disease	1333
-	PUNCT	O	O	1333
Prone	ADJ	O	O	1333
(	PUNCT	O	O	1333
WSP	NOUN	O	O	1333
)	PUNCT	O	O	1333
and	CCONJ	O	O	1333
-	PUNCT	O	O	1333
Resistant	ADJ	O	O	1333
(	PUNCT	O	O	1333
WSR	PROPN	O	O	1333
)	PUNCT	O	O	1333
mice	NOUN	O	O	1333
.	PUNCT	O	O	1333
Animals	NOUN	O	O	1334
were	AUX	O	O	1334
administered	VERB	O	O	1334
nicotine	NOUN	O	Chemical	1334
,	PUNCT	O	O	1334
carbachol	NOUN	O	Chemical	1334
,	PUNCT	O	O	1334
or	CCONJ	O	O	1334
neostigmine	NOUN	O	O	1334
via	ADP	O	O	1334
timed	VERB	O	O	1334
tail	NOUN	O	O	1334
vein	NOUN	O	O	1334
infusion	NOUN	O	O	1334
,	PUNCT	O	O	1334
and	CCONJ	O	O	1334
the	PRON	O	O	1334
latencies	NOUN	O	O	1334
to	PART	O	O	1334
onset	VERB	O	O	1334
of	ADP	O	O	1334
tremor	NOUN	O	Disease	1334
and	CCONJ	O	O	1334
clonus	NOUN	O	O	1334
were	AUX	O	O	1334
recorded	VERB	O	O	1334
and	CCONJ	O	O	1334
converted	VERB	O	O	1334
to	PART	O	O	1334
threshold	NOUN	O	O	1334
dose	NOUN	O	O	1334
.	PUNCT	O	O	1334
We	PRON	O	O	1335
also	ADV	O	O	1335
used	VERB	O	O	1335
microdialysis	NOUN	O	O	1335
to	PART	O	O	1335
measure	VERB	O	O	1335
basal	PROPN	O	O	1335
and	CCONJ	O	O	1335
potassium	NOUN	O	Chemical	1335
-	PUNCT	O	O	1335
stimulated	VERB	O	O	1335
acetylcholine	NOUN	O	Chemical	1335
(	PUNCT	O	O	1335
ACh	PROPN	O	Chemical	1335
)	PUNCT	O	O	1335
release	NOUN	O	O	1335
in	ADP	O	O	1335
the	PRON	O	O	1335
CA1	PROPN	O	O	1335
region	NOUN	O	O	1335
of	ADP	O	O	1335
the	PRON	O	O	1335
hippocampus	NOUN	O	O	1335
.	PUNCT	O	O	1335
Potassium	NOUN	O	Chemical	1336
was	AUX	O	O	1336
applied	VERB	O	O	1336
by	ADP	O	O	1336
reverse	VERB	O	O	1336
dialysis	NOUN	O	O	1336
twice	ADV	O	O	1336
,	PUNCT	O	O	1336
separated	VERB	O	O	1336
by	ADP	O	O	1336
75	NUM	O	O	1336
min	NOUN	O	O	1336
.	PUNCT	O	O	1336
Hippocampal	NOUN	O	O	1337
ACh	PROPN	O	Chemical	1337
also	ADV	O	O	1337
was	AUX	O	O	1337
measured	VERB	O	O	1337
during	ADP	O	O	1337
testing	NOUN	O	O	1337
for	ADP	O	O	1337
handling	VERB	O	O	1337
-	PUNCT	O	O	1337
induced	VERB	O	O	1337
convulsions	NOUN	O	Disease	1337
.	PUNCT	O	O	1337
Sensitivity	NOUN	O	O	1338
to	PART	O	O	1338
several	ADJ	O	O	1338
convulsion	NOUN	O	Disease	1338
endpoints	NOUN	O	O	1338
induced	VERB	O	O	1338
by	ADP	O	O	1338
nicotine	NOUN	O	Chemical	1338
,	PUNCT	O	O	1338
carbachol	NOUN	O	Chemical	1338
,	PUNCT	O	O	1338
and	CCONJ	O	O	1338
neostigmine	NOUN	O	O	1338
were	AUX	O	O	1338
significantly	ADV	O	O	1338
greater	ADJ	O	O	1338
in	ADP	O	O	1338
WSR	PROPN	O	O	1338
versus	ADP	O	O	1338
WSP	NOUN	O	O	1338
mice	NOUN	O	O	1338
.	PUNCT	O	O	1338
In	ADP	O	O	1339
microdialysis	NOUN	O	O	1339
experiments	NOUN	O	O	1339
,	PUNCT	O	O	1339
the	PRON	O	O	1339
lines	NOUN	O	O	1339
did	VERB	O	O	1339
not	PART	O	O	1339
differ	VERB	O	O	1339
in	ADP	O	O	1339
basal	PROPN	O	O	1339
release	NOUN	O	O	1339
of	ADP	O	O	1339
ACh	PROPN	O	Chemical	1339
,	PUNCT	O	O	1339
and	CCONJ	O	O	1339
50	NUM	O	O	1339
mM	ADJ	O	O	1339
KCl	PROPN	O	Chemical	1339
increased	VERB	O	O	1339
ACh	PROPN	O	Chemical	1339
output	NOUN	O	O	1339
in	ADP	O	O	1339
both	PRON	O	O	1339
lines	NOUN	O	O	1339
of	ADP	O	O	1339
mice	NOUN	O	O	1339
.	PUNCT	O	O	1339
However	ADV	O	O	1340
,	PUNCT	O	O	1340
the	PRON	O	O	1340
increase	VERB	O	O	1340
in	ADP	O	O	1340
release	NOUN	O	O	1340
of	ADP	O	O	1340
ACh	PROPN	O	Chemical	1340
produced	VERB	O	O	1340
by	ADP	O	O	1340
the	PRON	O	O	1340
first	ADV	O	O	1340
application	NOUN	O	O	1340
of	ADP	O	O	1340
KCl	PROPN	O	Chemical	1340
was	AUX	O	O	1340
2-fold	VERB	O	O	1340
higher	ADJ	O	O	1340
in	ADP	O	O	1340
WSP	NOUN	O	O	1340
versus	ADP	O	O	1340
WSR	PROPN	O	O	1340
mice	NOUN	O	O	1340
.	PUNCT	O	O	1340
When	SCONJ	O	O	1341
hippocampal	NOUN	O	O	1341
ACh	PROPN	O	Chemical	1341
was	AUX	O	O	1341
measured	VERB	O	O	1341
during	ADP	O	O	1341
testing	NOUN	O	O	1341
for	ADP	O	O	1341
handling	VERB	O	O	1341
-	PUNCT	O	O	1341
induced	VERB	O	O	1341
convulsions	NOUN	O	Disease	1341
,	PUNCT	O	O	1341
extracellular	ADJ	O	O	1341
ACh	PROPN	O	Chemical	1341
was	AUX	O	O	1341
significantly	ADV	O	O	1341
elevated	ADJ	O	O	1341
(	PUNCT	O	O	1341
192%	NOUN	O	O	1341
)	PUNCT	O	O	1341
in	ADP	O	O	1341
WSP	NOUN	O	O	1341
mice	NOUN	O	O	1341
,	PUNCT	O	O	1341
but	CCONJ	O	O	1341
was	AUX	O	O	1341
nonsignificantly	ADV	O	O	1341
elevated	ADJ	O	O	1341
(	PUNCT	O	O	1341
59%	NOUN	O	O	1341
)	PUNCT	O	O	1341
in	ADP	O	O	1341
WSR	PROPN	O	O	1341
mice	NOUN	O	O	1341
.	PUNCT	O	O	1341
These	PRON	O	O	1342
results	VERB	O	O	1342
suggest	VERB	O	O	1342
that	SCONJ	O	O	1342
differences	NOUN	O	O	1342
in	ADP	O	O	1342
cholinergic	ADJ	O	O	1342
activity	NOUN	O	O	1342
and	CCONJ	O	O	1342
postsynaptic	ADJ	O	O	1342
sensitivity	NOUN	O	O	1342
to	PART	O	O	1342
cholinergic	ADJ	O	O	1342
convulsants	NOUN	O	O	1342
may	AUX	O	O	1342
be	AUX	O	O	1342
associated	VERB	O	O	1342
with	ADP	O	O	1342
ethanol	NOUN	O	Chemical	1342
withdrawal	NOUN	O	O	1342
severity	NOUN	O	O	1342
and	CCONJ	O	O	1342
implicate	VERB	O	O	1342
cholinergic	ADJ	O	O	1342
mechanisms	NOUN	O	O	1342
in	ADP	O	O	1342
alcohol	NOUN	O	Chemical	1342
withdrawal	NOUN	O	O	1342
.	PUNCT	O	O	1342
Specifically	ADV	O	O	1343
,	PUNCT	O	O	1343
WSP	NOUN	O	O	1343
mice	NOUN	O	O	1343
may	AUX	O	O	1343
have	VERB	O	O	1343
lower	ADJ	O	O	1343
sensitivity	NOUN	O	O	1343
to	PART	O	O	1343
cholinergic	ADJ	O	O	1343
convulsants	NOUN	O	O	1343
compared	VERB	O	O	1343
with	ADP	O	O	1343
WSR	PROPN	O	O	1343
because	SCONJ	O	O	1343
of	ADP	O	O	1343
postsynaptic	ADJ	O	O	1343
receptor	NOUN	O	O	1343
desensitization	NOUN	O	O	1343
brought	VERB	O	O	1343
on	ADP	O	O	1343
by	ADP	O	O	1343
higher	ADJ	O	O	1343
activity	NOUN	O	O	1343
of	ADP	O	O	1343
cholinergic	ADJ	O	O	1343
neurons	NOUN	O	O	1343
.	PUNCT	O	O	1343
Prenatal	NOUN	O	O	1346
dexamethasone	NOUN	O	Chemical	1346
programs	NOUN	O	O	1346
hypertension	NOUN	O	Disease	1346
and	CCONJ	O	O	1346
renal injury	NOUN	O	Disease	1346
in	ADP	O	O	1346
the	PRON	O	O	1346
rat	NOUN	O	O	1346
.	PUNCT	O	O	1346
The	PRON	O	O	1347
purpose	NOUN	O	O	1347
of	ADP	O	O	1347
the	PRON	O	O	1347
present	NOUN	O	O	1347
study	VERB	O	O	1347
was	AUX	O	O	1347
to	PART	O	O	1347
determine	VERB	O	O	1347
if	SCONJ	O	O	1347
prenatal	ADJ	O	O	1347
dexamethasone	NOUN	O	Chemical	1347
programmed	VERB	O	O	1347
a	PRON	O	O	1347
progressive	ADJ	O	O	1347
increase	VERB	O	O	1347
in	ADP	O	O	1347
blood	NOUN	O	O	1347
pressure	NOUN	O	O	1347
and	CCONJ	O	O	1347
renal injury	NOUN	O	Disease	1347
in	ADP	O	O	1347
rats	NOUN	O	O	1347
.	PUNCT	O	O	1347
Pregnant	ADJ	O	O	1348
rats	NOUN	O	O	1348
were	AUX	O	O	1348
given	VERB	O	O	1348
either	ADV	O	O	1348
vehicle	NOUN	O	O	1348
or	CCONJ	O	O	1348
2	X	O	O	1348
daily	ADV	O	O	1348
intraperitoneal	ADJ	O	O	1348
injections	NOUN	O	O	1348
of	ADP	O	O	1348
dexamethasone	NOUN	O	Chemical	1348
(	PUNCT	O	O	1348
0.2	NUM	O	O	1348
mg	VERB	O	O	1348
/	PUNCT	O	O	1348
kg	VERB	O	O	1348
body	NOUN	O	O	1348
weight	NOUN	O	O	1348
)	PUNCT	O	O	1348
on	ADP	O	O	1348
gestational	ADJ	O	O	1348
days	NOUN	O	O	1348
11	NUM	O	O	1348
and	CCONJ	O	O	1348
12	NUM	O	O	1348
,	PUNCT	O	O	1348
13	NUM	O	O	1348
and	CCONJ	O	O	1348
14	NUM	O	O	1348
,	PUNCT	O	O	1348
15	NUM	O	O	1348
and	CCONJ	O	O	1348
16	NUM	O	O	1348
,	PUNCT	O	O	1348
17	NUM	O	O	1348
and	CCONJ	O	O	1348
18	NUM	O	O	1348
,	PUNCT	O	O	1348
or	CCONJ	O	O	1348
19	NUM	O	O	1348
and	CCONJ	O	O	1348
20	NUM	O	O	1348
.	PUNCT	O	O	1348
Offspring	NOUN	O	O	1349
of	ADP	O	O	1349
rats	NOUN	O	O	1349
administered	VERB	O	O	1349
dexamethasone	NOUN	O	Chemical	1349
on	ADP	O	O	1349
days	NOUN	O	O	1349
15	NUM	O	O	1349
and	CCONJ	O	O	1349
16	NUM	O	O	1349
gestation	NOUN	O	O	1349
had	VERB	O	O	1349
a	PRON	O	O	1349
20%	NOUN	O	O	1349
reduction	NOUN	O	O	1349
in	ADP	O	O	1349
glomerular	ADJ	O	O	1349
number	NOUN	O	O	1349
compared	VERB	O	O	1349
with	ADP	O	O	1349
control	VERB	O	O	1349
at	ADP	O	O	1349
6	NUM	O	O	1349
to	PART	O	O	1349
9	NUM	O	O	1349
months	NOUN	O	O	1349
of	ADP	O	O	1349
age	NOUN	O	O	1349
(	PUNCT	O	O	1349
22	NUM	O	O	1349
527+/-509	NUM	O	O	1349
versus	ADP	O	O	1349
28	NUM	O	O	1349
050+/-561	X	O	O	1349
,	PUNCT	O	O	1349
P<0.05	NOUN	O	O	1349
)	PUNCT	O	O	1349
,	PUNCT	O	O	1349
which	PRON	O	O	1349
was	AUX	O	O	1349
comparable	ADJ	O	O	1349
to	PART	O	O	1349
the	PRON	O	O	1349
percent	NOUN	O	O	1349
reduction	NOUN	O	O	1349
in	ADP	O	O	1349
glomeruli	VERB	O	O	1349
measured	VERB	O	O	1349
at	ADP	O	O	1349
3	X	O	O	1349
weeks	NOUN	O	O	1349
of	ADP	O	O	1349
age	NOUN	O	O	1349
.	PUNCT	O	O	1349
Six-	PUNCT	O	O	1350
to	PART	O	O	1350
9-month	NOUN	O	O	1350
old	ADJ	O	O	1350
rats	NOUN	O	O	1350
receiving	VERB	O	O	1350
prenatal	ADJ	O	O	1350
dexamethasone	NOUN	O	Chemical	1350
on	ADP	O	O	1350
days	NOUN	O	O	1350
17	NUM	O	O	1350
and	CCONJ	O	O	1350
18	NUM	O	O	1350
of	ADP	O	O	1350
gestation	NOUN	O	O	1350
had	VERB	O	O	1350
a	PRON	O	O	1350
17%	NOUN	O	O	1350
reduction	NOUN	O	O	1350
in	ADP	O	O	1350
glomeruli	VERB	O	O	1350
(	PUNCT	O	O	1350
23	NUM	O	O	1350
380+/-587	ADJ	O	O	1350
)	PUNCT	O	O	1350
compared	VERB	O	O	1350
with	ADP	O	O	1350
control	VERB	O	O	1350
rats	NOUN	O	O	1350
(	PUNCT	O	O	1350
P<0.05	NOUN	O	O	1350
)	PUNCT	O	O	1350
.	PUNCT	O	O	1350
Male	NOUN	O	O	1351
rats	NOUN	O	O	1351
that	SCONJ	O	O	1351
received	VERB	O	O	1351
prenatal	ADJ	O	O	1351
dexamethasone	NOUN	O	Chemical	1351
on	ADP	O	O	1351
days	NOUN	O	O	1351
15	NUM	O	O	1351
and	CCONJ	O	O	1351
16	NUM	O	O	1351
,	PUNCT	O	O	1351
17	NUM	O	O	1351
and	CCONJ	O	O	1351
18	NUM	O	O	1351
,	PUNCT	O	O	1351
and	CCONJ	O	O	1351
13	NUM	O	O	1351
and	CCONJ	O	O	1351
14	NUM	O	O	1351
of	ADP	O	O	1351
gestation	NOUN	O	O	1351
had	VERB	O	O	1351
elevated	ADJ	O	O	1351
blood	NOUN	O	O	1351
pressures	NOUN	O	O	1351
at	ADP	O	O	1351
6	NUM	O	O	1351
months	NOUN	O	O	1351
of	ADP	O	O	1351
age	NOUN	O	O	1351
;	PUNCT	O	O	1351
the	PRON	O	O	1351
latter	ADJ	O	O	1351
group	NOUN	O	O	1351
did	VERB	O	O	1351
not	PART	O	O	1351
have	VERB	O	O	1351
a	PRON	O	O	1351
reduction	NOUN	O	O	1351
in	ADP	O	O	1351
glomerular	ADJ	O	O	1351
number	NOUN	O	O	1351
.	PUNCT	O	O	1351
Adult	NOUN	O	O	1352
rats	NOUN	O	O	1352
given	VERB	O	O	1352
dexamethasone	NOUN	O	Chemical	1352
on	ADP	O	O	1352
days	NOUN	O	O	1352
15	NUM	O	O	1352
and	CCONJ	O	O	1352
16	NUM	O	O	1352
of	ADP	O	O	1352
gestation	NOUN	O	O	1352
had	VERB	O	O	1352
more	ADJ	O	O	1352
glomeruli	VERB	O	O	1352
with	ADP	O	O	1352
glomerulosclerosis	PROPN	O	O	1352
than	ADP	O	O	1352
control	VERB	O	O	1352
rats	NOUN	O	O	1352
.	PUNCT	O	O	1352
This	PRON	O	O	1353
study	VERB	O	O	1353
shows	VERB	O	O	1353
that	SCONJ	O	O	1353
prenatal	ADJ	O	O	1353
dexamethasone	NOUN	O	Chemical	1353
in	ADP	O	O	1353
rats	NOUN	O	O	1353
results	VERB	O	O	1353
in	ADP	O	O	1353
a	PRON	O	O	1353
reduction	NOUN	O	O	1353
in	ADP	O	O	1353
glomerular	ADJ	O	O	1353
number	NOUN	O	O	1353
,	PUNCT	O	O	1353
glomerulosclerosis	PROPN	O	O	1353
,	PUNCT	O	O	1353
and	CCONJ	O	O	1353
hypertension	NOUN	O	Disease	1353
when	SCONJ	O	O	1353
administered	VERB	O	O	1353
at	ADP	O	O	1353
specific	ADJ	O	O	1353
points	VERB	O	O	1353
during	ADP	O	O	1353
gestation	NOUN	O	O	1353
.	PUNCT	O	O	1353
Hypertension	NOUN	O	Disease	1354
was	AUX	O	O	1354
observed	VERB	O	O	1354
in	ADP	O	O	1354
animals	NOUN	O	O	1354
that	SCONJ	O	O	1354
had	VERB	O	O	1354
a	PRON	O	O	1354
reduction	NOUN	O	O	1354
in	ADP	O	O	1354
glomeruli	VERB	O	O	1354
as	ADP	O	O	1354
well	ADV	O	O	1354
as	ADP	O	O	1354
in	ADP	O	O	1354
a	PRON	O	O	1354
group	NOUN	O	O	1354
that	SCONJ	O	O	1354
did	VERB	O	O	1354
not	PART	O	O	1354
have	VERB	O	O	1354
a	PRON	O	O	1354
reduction	NOUN	O	O	1354
in	ADP	O	O	1354
glomerular	ADJ	O	O	1354
number	NOUN	O	O	1354
,	PUNCT	O	O	1354
suggesting	VERB	O	O	1354
that	SCONJ	O	O	1354
a	PRON	O	O	1354
reduction	NOUN	O	O	1354
in	ADP	O	O	1354
glomerular	ADJ	O	O	1354
number	NOUN	O	O	1354
is	AUX	O	O	1354
not	PART	O	O	1354
the	PRON	O	O	1354
sole	NOUN	O	O	1354
cause	VERB	O	O	1354
for	ADP	O	O	1354
the	PRON	O	O	1354
development	NOUN	O	O	1354
of	ADP	O	O	1354
hypertension	NOUN	O	Disease	1354
.	PUNCT	O	O	1354
The	PRON	O	O	1357
risk	NOUN	O	O	1357
of	ADP	O	O	1357
venous thromboembolism	NOUN	O	Disease	1357
in	ADP	O	O	1357
women	NOUN	O	O	1357
prescribed	VERB	O	O	1357
cyproterone acetate	NOUN	O	Chemical	1357
in	ADP	O	O	1357
combination	NOUN	O	O	1357
with	ADP	O	O	1357
ethinyl estradiol	NOUN	O	Chemical	1357
:	PUNCT	O	O	1357
a	PRON	O	O	1357
nested	VERB	O	O	1357
cohort	NOUN	O	O	1357
analysis	NOUN	O	O	1357
and	CCONJ	O	O	1357
case	NOUN	O	O	1357
-	PUNCT	O	O	1357
control	VERB	O	O	1357
study	VERB	O	O	1357
.	PUNCT	O	O	1357
Cyproterone	NOUN	O	O	1358
acetate	NOUN	O	O	1358
combined	VERB	O	O	1358
with	ADP	O	O	1358
ethinyl estradiol	NOUN	O	Chemical	1358
(	PUNCT	O	O	1358
CPA	NOUN	O	Chemical	1358
/	PUNCT	O	O	1358
EE	NOUN	O	Chemical	1358
)	PUNCT	O	O	1358
is	AUX	O	O	1358
licensed	VERB	O	O	1358
in	ADP	O	O	1358
the	PRON	O	O	1358
UK	PROPN	O	O	1358
for	ADP	O	O	1358
the	PRON	O	O	1358
treatment	NOUN	O	O	1358
of	ADP	O	O	1358
women	NOUN	O	O	1358
with	ADP	O	O	1358
acne	NOUN	O	O	1358
and	CCONJ	O	O	1358
hirsutism	NOUN	O	O	1358
and	CCONJ	O	O	1358
is	AUX	O	O	1358
also	ADV	O	O	1358
a	PRON	O	O	1358
treatment	NOUN	O	O	1358
option	NOUN	O	O	1358
for	ADP	O	O	1358
polycystic	NOUN	O	O	1358
ovary	ADJ	O	O	1358
syndrome	NOUN	O	O	1358
(	PUNCT	O	O	1358
PCOS	NOUN	O	O	1358
)	PUNCT	O	O	1358
.	PUNCT	O	O	1358
Previous	ADJ	O	O	1359
studies	NOUN	O	O	1359
have	VERB	O	O	1359
demonstrated	VERB	O	O	1359
an	PRON	O	O	1359
increased	VERB	O	O	1359
risk	NOUN	O	O	1359
of	ADP	O	O	1359
venous thromboembolism	NOUN	O	Disease	1359
(	PUNCT	O	O	1359
VTE	PROPN	O	Disease	1359
)	PUNCT	O	O	1359
associated	VERB	O	O	1359
with	ADP	O	O	1359
CPA	NOUN	O	Chemical	1359
/	PUNCT	O	O	1359
EE	NOUN	O	Chemical	1359
compared	VERB	O	O	1359
with	ADP	O	O	1359
conventional	ADJ	O	O	1359
combined oral contraceptives	NOUN	O	Chemical	1359
(	PUNCT	O	O	1359
COCs	NOUN	O	Chemical	1359
)	PUNCT	O	O	1359
.	PUNCT	O	O	1359
Using	VERB	O	O	1360
the	PRON	O	O	1360
General	ADJ	O	O	1360
Practice	VERB	O	O	1360
Research	NOUN	O	O	1360
Database	NOUN	O	O	1360
we	PRON	O	O	1360
conducted	VERB	O	O	1360
a	PRON	O	O	1360
cohort	NOUN	O	O	1360
analysis	NOUN	O	O	1360
and	CCONJ	O	O	1360
case	NOUN	O	O	1360
-	PUNCT	O	O	1360
control	VERB	O	O	1360
study	VERB	O	O	1360
nested	VERB	O	O	1360
within	ADP	O	O	1360
a	PRON	O	O	1360
population	NOUN	O	O	1360
of	ADP	O	O	1360
women	NOUN	O	O	1360
aged	ADJ	O	O	1360
between	ADP	O	O	1360
15	NUM	O	O	1360
and	CCONJ	O	O	1360
39	NUM	O	O	1360
years	NOUN	O	O	1360
with	ADP	O	O	1360
acne	NOUN	O	O	1360
,	PUNCT	O	O	1360
hirsutism	NOUN	O	O	1360
or	CCONJ	O	O	1360
PCOS	NOUN	O	O	1360
to	PART	O	O	1360
estimate	VERB	O	O	1360
the	PRON	O	O	1360
risk	NOUN	O	O	1360
of	ADP	O	O	1360
VTE	PROPN	O	Disease	1360
associated	VERB	O	O	1360
with	ADP	O	O	1360
CPA	NOUN	O	Chemical	1360
/	PUNCT	O	O	1360
EE	NOUN	O	Chemical	1360
.	PUNCT	O	O	1360
The	PRON	O	O	1361
age	NOUN	O	O	1361
-	PUNCT	O	O	1361
adjusted	VERB	O	O	1361
incidence	NOUN	O	O	1361
rate	NOUN	O	O	1361
ratio	NOUN	O	O	1361
for	ADP	O	O	1361
CPA	NOUN	O	Chemical	1361
/	PUNCT	O	O	1361
EE	NOUN	O	Chemical	1361
versus	ADP	O	O	1361
conventional	ADJ	O	O	1361
COCs	NOUN	O	Chemical	1361
was	AUX	O	O	1361
2.20	NUM	O	O	1361
[	X	O	O	1361
95%	NOUN	O	O	1361
confidence	NOUN	O	O	1361
interval	NOUN	O	O	1361
(	PUNCT	O	O	1361
CI	NOUN	O	O	1361
)	PUNCT	O	O	1361
1.35	NUM	O	O	1361
-	PUNCT	O	O	1361
3.58	NUM	O	O	1361
]	PUNCT	O	O	1361
.	PUNCT	O	O	1361
Using	VERB	O	O	1362
as	ADP	O	O	1362
the	PRON	O	O	1362
reference	NOUN	O	O	1362
group	NOUN	O	O	1362
women	NOUN	O	O	1362
who	PRON	O	O	1362
were	AUX	O	O	1362
not	PART	O	O	1362
using	VERB	O	O	1362
oral contraception	NOUN	O	Chemical	1362
,	PUNCT	O	O	1362
had	VERB	O	O	1362
no	PRON	O	O	1362
recent	ADJ	O	O	1362
pregnancy	NOUN	O	O	1362
or	CCONJ	O	O	1362
menopausal	PROPN	O	O	1362
symptoms	NOUN	O	O	1362
,	PUNCT	O	O	1362
the	PRON	O	O	1362
case	NOUN	O	O	1362
-	PUNCT	O	O	1362
control	VERB	O	O	1362
analysis	NOUN	O	O	1362
gave	VERB	O	O	1362
an	PRON	O	O	1362
adjusted	VERB	O	O	1362
odds	NOUN	O	O	1362
ratio	NOUN	O	O	1362
(	PUNCT	O	O	1362
OR(adj	NUM	O	O	1362
)	PUNCT	O	O	1362
)	PUNCT	O	O	1362
of	ADP	O	O	1362
7.44	NUM	O	O	1362
(	PUNCT	O	O	1362
95%	NOUN	O	O	1362
CI	NOUN	O	O	1362
3.67	NUM	O	O	1362
-	PUNCT	O	O	1362
15.08	NUM	O	O	1362
)	PUNCT	O	O	1362
for	ADP	O	O	1362
CPA	NOUN	O	Chemical	1362
/	PUNCT	O	O	1362
EE	NOUN	O	Chemical	1362
use	VERB	O	O	1362
compared	VERB	O	O	1362
with	ADP	O	O	1362
an	PRON	O	O	1362
OR(adj	NUM	O	O	1362
)	PUNCT	O	O	1362
of	ADP	O	O	1362
2.58	NUM	O	O	1362
(	PUNCT	O	O	1362
95%	NOUN	O	O	1362
CI	NOUN	O	O	1362
1.60	NUM	O	O	1362
-	PUNCT	O	O	1362
4.18	NUM	O	O	1362
)	PUNCT	O	O	1362
for	ADP	O	O	1362
use	VERB	O	O	1362
of	ADP	O	O	1362
conventional	ADJ	O	O	1362
COCs	NOUN	O	Chemical	1362
.	PUNCT	O	O	1362
:	PUNCT	O	O	1363
We	PRON	O	O	1363
have	VERB	O	O	1363
demonstrated	VERB	O	O	1363
an	PRON	O	O	1363
increased	VERB	O	O	1363
risk	NOUN	O	O	1363
of	ADP	O	O	1363
VTE	PROPN	O	Disease	1363
associated	VERB	O	O	1363
with	ADP	O	O	1363
the	PRON	O	O	1363
use	VERB	O	O	1363
of	ADP	O	O	1363
CPA	NOUN	O	Chemical	1363
/	PUNCT	O	O	1363
EE	NOUN	O	Chemical	1363
in	ADP	O	O	1363
women	NOUN	O	O	1363
with	ADP	O	O	1363
acne	NOUN	O	O	1363
,	PUNCT	O	O	1363
hirsutism	NOUN	O	O	1363
or	CCONJ	O	O	1363
PCOS	NOUN	O	O	1363
although	SCONJ	O	O	1363
residual	ADJ	O	O	1363
confounding	VERB	O	O	1363
by	ADP	O	O	1363
indication	NOUN	O	O	1363
can	AUX	O	O	1363
not	PART	O	O	1363
be	AUX	O	O	1363
excluded	VERB	O	O	1363
.	PUNCT	O	O	1363
Pseudoacromegaly	PROPN	O	O	1366
induced	VERB	O	O	1366
by	ADP	O	O	1366
the	PRON	O	O	1366
long	ADV	O	O	1366
-	PUNCT	O	O	1366
term	NOUN	O	O	1366
use	VERB	O	O	1366
of	ADP	O	O	1366
minoxidil	PROPN	O	O	1366
.	PUNCT	O	O	1366
Acromegaly	NOUN	O	O	1367
is	AUX	O	O	1367
an	PRON	O	O	1367
endocrine	NOUN	O	O	1367
disorder	NOUN	O	O	1367
caused	VERB	O	O	1367
by	ADP	O	O	1367
chronic	ADJ	O	O	1367
excessive	ADJ	O	O	1367
growth	NOUN	O	O	1367
hormone	NOUN	O	O	1367
secretion	NOUN	O	O	1367
from	ADP	O	O	1367
the	PRON	O	O	1367
anterior	PROPN	O	O	1367
pituitary	NOUN	O	O	1367
gland	NOUN	O	O	1367
.	PUNCT	O	O	1367
Significant	ADJ	O	O	1368
disfiguring	VERB	O	O	1368
changes	VERB	O	O	1368
occur	VERB	O	O	1368
as	ADP	O	O	1368
a	PRON	O	O	1368
result	VERB	O	O	1368
of	ADP	O	O	1368
bone	NOUN	O	O	1368
,	PUNCT	O	O	1368
cartilage	NOUN	O	O	1368
,	PUNCT	O	O	1368
and	CCONJ	O	O	1368
soft	ADJ	O	O	1368
tissue	NOUN	O	O	1368
hypertrophy	VERB	O	Disease	1368
,	PUNCT	O	O	1368
including	VERB	O	O	1368
the	PRON	O	O	1368
thickening	NOUN	O	O	1368
of	ADP	O	O	1368
the	PRON	O	O	1368
skin	NOUN	O	O	1368
,	PUNCT	O	O	1368
coarsening	VERB	O	O	1368
of	ADP	O	O	1368
facial	ADJ	O	O	1368
features	VERB	O	O	1368
,	PUNCT	O	O	1368
and	CCONJ	O	O	1368
cutis	NOUN	O	O	1368
verticis	NOUN	O	O	1368
gyrata	PROPN	O	O	1368
.	PUNCT	O	O	1368
Pseudoacromegaly	PROPN	O	O	1369
,	PUNCT	O	O	1369
on	ADP	O	O	1369
the	PRON	O	O	1369
other	ADJ	O	O	1369
hand	NOUN	O	O	1369
,	PUNCT	O	O	1369
is	AUX	O	O	1369
the	PRON	O	O	1369
presence	NOUN	O	O	1369
of	ADP	O	O	1369
similar	ADJ	O	O	1369
acromegaloid	PROPN	O	O	1369
features	VERB	O	O	1369
in	ADP	O	O	1369
the	PRON	O	O	1369
absence	NOUN	O	O	1369
of	ADP	O	O	1369
elevated	ADJ	O	O	1369
growth	NOUN	O	O	1369
hormone	NOUN	O	O	1369
or	CCONJ	O	O	1369
insulin	NOUN	O	O	1369
-	PUNCT	O	O	1369
like	INTJ	O	O	1369
growth	NOUN	O	O	1369
factor	NOUN	O	O	1369
levels	NOUN	O	O	1369
.	PUNCT	O	O	1369
We	PRON	O	O	1370
present	NOUN	O	O	1370
a	PRON	O	O	1370
patient	NOUN	O	O	1370
with	ADP	O	O	1370
pseudoacromegaly	NOUN	O	O	1370
that	SCONJ	O	O	1370
resulted	VERB	O	O	1370
from	ADP	O	O	1370
the	PRON	O	O	1370
long	ADV	O	O	1370
-	PUNCT	O	O	1370
term	NOUN	O	O	1370
use	VERB	O	O	1370
of	ADP	O	O	1370
minoxidil	PROPN	O	O	1370
at	ADP	O	O	1370
an	PRON	O	O	1370
unusually	ADV	O	O	1370
high	ADJ	O	O	1370
dose	NOUN	O	O	1370
.	PUNCT	O	O	1370
This	PRON	O	O	1371
is	AUX	O	O	1371
the	PRON	O	O	1371
first	ADV	O	O	1371
case	NOUN	O	O	1371
report	VERB	O	O	1371
of	ADP	O	O	1371
pseudoacromegaly	NOUN	O	O	1371
as	ADP	O	O	1371
a	PRON	O	O	1371
side	NOUN	O	O	1371
effect	VERB	O	O	1371
of	ADP	O	O	1371
minoxidil	PROPN	O	O	1371
use	VERB	O	O	1371
.	PUNCT	O	O	1371
Combined	VERB	O	O	1374
androgen	PROPN	O	Chemical	1374
blockade	VERB	O	O	1374
-	PUNCT	O	O	1374
induced	VERB	O	O	1374
anemia	NOUN	O	Disease	1374
in	ADP	O	O	1374
prostate cancer	NOUN	O	Disease	1374
patients	NOUN	O	O	1374
without	ADP	O	O	1374
bone	NOUN	O	O	1374
involvement	NOUN	O	O	1374
.	PUNCT	O	O	1374
BACKGROUND	NOUN	O	O	1375
:	PUNCT	O	O	1375
To	PART	O	O	1375
determine	VERB	O	O	1375
the	PRON	O	O	1375
onset	VERB	O	O	1375
and	CCONJ	O	O	1375
extent	NOUN	O	O	1375
of	ADP	O	O	1375
combined	VERB	O	O	1375
androgen	PROPN	O	Chemical	1375
blockade	VERB	O	O	1375
(	PUNCT	O	O	1375
CAB)-induced	VERB	O	O	1375
anemia	NOUN	O	Disease	1375
in	ADP	O	O	1375
prostate cancer	NOUN	O	Disease	1375
patients	NOUN	O	O	1375
without	ADP	O	O	1375
bone	NOUN	O	O	1375
involvement	NOUN	O	O	1375
.	PUNCT	O	O	1375
Forty	NUM	O	O	1376
-	PUNCT	O	O	1376
two	NUM	O	O	1376
patients	NOUN	O	O	1376
with	ADP	O	O	1376
biopsy	PROPN	O	O	1376
-	PUNCT	O	O	1376
proven	VERB	O	O	1376
prostatic	ADJ	O	O	1376
adenocarcinoma	NOUN	O	O	1376
[	X	O	O	1376
26	NUM	O	O	1376
with	ADP	O	O	1376
stage	NOUN	O	O	1376
C	NOUN	O	O	1376
(	PUNCT	O	O	1376
T3N0M0	VERB	O	O	1376
)	PUNCT	O	O	1376
and	CCONJ	O	O	1376
16	NUM	O	O	1376
with	ADP	O	O	1376
stage	NOUN	O	O	1376
D1	PROPN	O	O	1376
(	PUNCT	O	O	1376
T3N1M0	PUNCT	O	O	1376
)	PUNCT	O	O	1376
]	PUNCT	O	O	1376
were	AUX	O	O	1376
included	VERB	O	O	1376
in	ADP	O	O	1376
this	PRON	O	O	1376
study	VERB	O	O	1376
.	PUNCT	O	O	1376
All	PRON	O	O	1377
patients	NOUN	O	O	1377
received	VERB	O	O	1377
CAB	NOUN	O	O	1377
[	X	O	O	1377
leuprolide	NOUN	O	O	1377
acetate	NOUN	O	O	1377
(	PUNCT	O	O	1377
LHRH	PROPN	O	O	1377
-	PUNCT	O	O	1377
A	PRON	O	O	1377
)	PUNCT	O	O	1377
3.75	NUM	O	O	1377
mg	VERB	O	O	1377
,	PUNCT	O	O	1377
intramuscularly	ADV	O	O	1377
,	PUNCT	O	O	1377
every	PRON	O	O	1377
28	NUM	O	O	1377
days	NOUN	O	O	1377
plus	CCONJ	O	O	1377
250	NUM	O	O	1377
mg	VERB	O	O	1377
flutamide	NOUN	O	O	1377
,	PUNCT	O	O	1377
tid	PROPN	O	O	1377
,	PUNCT	O	O	1377
per	ADP	O	O	1377
Os	NOUN	O	O	1377
]	PUNCT	O	O	1377
and	CCONJ	O	O	1377
were	AUX	O	O	1377
evaluated	VERB	O	O	1377
for	ADP	O	O	1377
anemia	NOUN	O	Disease	1377
by	ADP	O	O	1377
physical	ADJ	O	O	1377
examination	NOUN	O	O	1377
and	CCONJ	O	O	1377
laboratory	NOUN	O	O	1377
tests	VERB	O	O	1377
at	ADP	O	O	1377
baseline	VERB	O	O	1377
and	CCONJ	O	O	1377
4	NUM	O	O	1377
subsequent	ADJ	O	O	1377
intervals	NOUN	O	O	1377
(	PUNCT	O	O	1377
1	X	O	O	1377
,	PUNCT	O	O	1377
2	X	O	O	1377
,	PUNCT	O	O	1377
3	X	O	O	1377
and	CCONJ	O	O	1377
6	NUM	O	O	1377
months	NOUN	O	O	1377
post	VERB	O	O	1377
-	PUNCT	O	O	1377
CAB	NOUN	O	O	1377
)	PUNCT	O	O	1377
.	PUNCT	O	O	1377
Hb	NOUN	O	O	1378
,	PUNCT	O	O	1378
PSA	PROPN	O	O	1378
and	CCONJ	O	O	1378
Testosterone	PROPN	O	O	1378
measurements	NOUN	O	O	1378
were	AUX	O	O	1378
recorded	VERB	O	O	1378
.	PUNCT	O	O	1378
Severe	ADJ	O	O	1379
and	CCONJ	O	O	1379
clinically	ADV	O	O	1379
evident	ADJ	O	O	1379
anemia	NOUN	O	Disease	1379
of	ADP	O	O	1379
Hb	NOUN	O	O	1379
<	X	O	O	1379
11	NUM	O	O	1379
g	X	O	O	1379
/	PUNCT	O	O	1379
dl	X	O	O	1379
with	ADP	O	O	1379
clinical	ADJ	O	O	1379
symptoms	NOUN	O	O	1379
was	AUX	O	O	1379
detected	VERB	O	O	1379
in	ADP	O	O	1379
6	NUM	O	O	1379
patients	NOUN	O	O	1379
(	PUNCT	O	O	1379
14.3%	NOUN	O	O	1379
)	PUNCT	O	O	1379
.	PUNCT	O	O	1379
This	PRON	O	O	1380
CAB	NOUN	O	O	1380
-	PUNCT	O	O	1380
induced	VERB	O	O	1380
anemia	NOUN	O	Disease	1380
was	AUX	O	O	1380
normochromic	ADJ	O	O	1380
and	CCONJ	O	O	1380
normocytic	ADJ	O	O	1380
.	PUNCT	O	O	1380
At	ADP	O	O	1381
six	NUM	O	O	1381
months	NOUN	O	O	1381
post	VERB	O	O	1381
-	PUNCT	O	O	1381
CAB	NOUN	O	O	1381
,	PUNCT	O	O	1381
patients	NOUN	O	O	1381
with	ADP	O	O	1381
severe	ADJ	O	O	1381
anemia	NOUN	O	Disease	1381
had	VERB	O	O	1381
a	PRON	O	O	1381
Hb	NOUN	O	O	1381
mean	VERB	O	O	1381
value	NOUN	O	O	1381
of	ADP	O	O	1381
10.2	NUM	O	O	1381
+	ADP	O	O	1381
/-	PUNCT	O	O	1381
SE	PROPN	O	O	1382
)	PUNCT	O	O	1382
,	PUNCT	O	O	1382
whereas	SCONJ	O	O	1382
the	PRON	O	O	1382
other	ADJ	O	O	1382
patients	NOUN	O	O	1382
had	VERB	O	O	1382
mild	ADJ	O	O	1382
anemia	NOUN	O	Disease	1382
with	ADP	O	O	1382
Hb	NOUN	O	O	1382
mean	VERB	O	O	1382
value	NOUN	O	O	1382
of	ADP	O	O	1382
13.2	NUM	O	O	1382
+	ADP	O	O	1382
/-	PUNCT	O	O	1382
The	PRON	O	O	1383
development	NOUN	O	O	1383
of	ADP	O	O	1383
severe	ADJ	O	O	1383
anemia	NOUN	O	Disease	1383
at	ADP	O	O	1383
6	NUM	O	O	1383
months	NOUN	O	O	1383
post	VERB	O	O	1383
-	PUNCT	O	O	1383
CAB	NOUN	O	O	1383
was	AUX	O	O	1383
predictable	ADJ	O	O	1383
by	ADP	O	O	1383
the	PRON	O	O	1383
reduction	NOUN	O	O	1383
of	ADP	O	O	1383
Hb	NOUN	O	O	1383
baseline	VERB	O	O	1383
value	NOUN	O	O	1383
of	ADP	O	O	1383
more	ADJ	O	O	1383
than	ADP	O	O	1383
2.5	NUM	O	O	1383
g	X	O	O	1383
/	PUNCT	O	O	1383
dl	X	O	O	1383
after	ADP	O	O	1383
3	X	O	O	1383
months	NOUN	O	O	1383
of	ADP	O	O	1383
CAB	NOUN	O	O	1383
(	PUNCT	O	O	1383
p	NOUN	O	O	1383
=	PUNCT	O	O	1383
0.01	NUM	O	O	1383
)	PUNCT	O	O	1383
.	PUNCT	O	O	1383
The	PRON	O	O	1384
development	NOUN	O	O	1384
of	ADP	O	O	1384
severe	ADJ	O	O	1384
CAB	NOUN	O	O	1384
-	PUNCT	O	O	1384
induced	VERB	O	O	1384
anemia	NOUN	O	Disease	1384
in	ADP	O	O	1384
prostate cancer	NOUN	O	Disease	1384
patients	NOUN	O	O	1384
did	VERB	O	O	1384
not	PART	O	O	1384
correlate	VERB	O	O	1384
with	ADP	O	O	1384
T	NOUN	O	Chemical	1384
baseline	VERB	O	O	1384
values	NOUN	O	O	1384
(	PUNCT	O	O	1384
T	NOUN	O	Chemical	1384
<	X	O	O	1384
3	X	O	O	1384
Severe	ADJ	O	O	1385
and	CCONJ	O	O	1385
clinically	ADV	O	O	1385
evident	ADJ	O	O	1385
anemia	NOUN	O	Disease	1385
was	AUX	O	O	1385
easily	ADV	O	O	1385
corrected	VERB	O	O	1385
by	ADP	O	O	1385
subcutaneous	ADJ	O	O	1385
injections	NOUN	O	O	1385
(	PUNCT	O	O	1385
3	X	O	O	1385
times	NOUN	O	O	1385
/	PUNCT	O	O	1385
week	NOUN	O	O	1385
for	ADP	O	O	1385
1	X	O	O	1385
month	NOUN	O	O	1385
)	PUNCT	O	O	1385
of	ADP	O	O	1385
recombinant	ADJ	O	O	1385
erythropoietin	NOUN	O	O	1385
(	PUNCT	O	O	1385
rHuEPO	ADJ	O	O	1385
-	PUNCT	O	O	1385
beta	NOUN	O	O	1385
)	PUNCT	O	O	1385
.	PUNCT	O	O	1385
Our	PRON	O	O	1386
data	NOUN	O	O	1386
suggest	VERB	O	O	1386
that	SCONJ	O	O	1386
rHuEPO	ADJ	O	O	1386
-	PUNCT	O	O	1386
beta	NOUN	O	O	1386
correctable	ADJ	O	O	1386
CAB	NOUN	O	O	1386
-	PUNCT	O	O	1386
induced	VERB	O	O	1386
anemia	NOUN	O	Disease	1386
occurs	VERB	O	O	1386
in	ADP	O	O	1386
14.3%	NOUN	O	O	1386
of	ADP	O	O	1386
prostate cancer	NOUN	O	Disease	1386
patients	NOUN	O	O	1386
after	ADP	O	O	1386
6	NUM	O	O	1386
months	NOUN	O	O	1386
of	ADP	O	O	1386
therapy	NOUN	O	O	1386
.	PUNCT	O	O	1386
Reversible	ADJ	O	O	1389
dilated	ADJ	O	O	1389
cardiomyopathy	ADJ	O	Disease	1389
related	ADJ	O	O	1389
to	PART	O	O	1389
amphotericin B	NOUN	O	Chemical	1389
therapy	NOUN	O	O	1389
.	PUNCT	O	O	1389
We	PRON	O	O	1390
describe	VERB	O	O	1390
a	PRON	O	O	1390
patient	NOUN	O	O	1390
who	PRON	O	O	1390
developed	VERB	O	O	1390
dilated	ADJ	O	O	1390
cardiomyopathy	ADJ	O	Disease	1390
and	CCONJ	O	O	1390
clinical	ADJ	O	O	1390
congestive	ADJ	O	O	1390
heart failure	NOUN	O	Disease	1390
after	ADP	O	O	1390
2	X	O	O	1390
months	NOUN	O	O	1390
of	ADP	O	O	1390
therapy	NOUN	O	O	1390
with	ADP	O	O	1390
amphotericin B	NOUN	O	Chemical	1390
(	PUNCT	O	O	1390
AmB	PROPN	O	Chemical	1390
)	PUNCT	O	O	1390
for	ADP	O	O	1390
disseminated	VERB	O	O	1390
coccidioidomycosis	NOUN	O	O	1390
.	PUNCT	O	O	1390
His	PRON	O	O	1391
echocardiographic	NOUN	O	O	1391
abnormalities	NOUN	O	O	1391
and	CCONJ	O	O	1391
heart failure	NOUN	O	Disease	1391
resolved	VERB	O	O	1391
after	ADP	O	O	1391
posaconazole	PROPN	O	O	1391
was	AUX	O	O	1391
substituted	VERB	O	O	1391
for	ADP	O	O	1391
AmB.	NOUN	O	O	1391
It	PRON	O	O	1391
is	AUX	O	O	1391
important	ADJ	O	O	1391
to	PART	O	O	1391
recognize	VERB	O	O	1391
the	PRON	O	O	1391
rare	ADJ	O	O	1391
and	CCONJ	O	O	1391
potentially	ADV	O	O	1391
reversible	ADJ	O	O	1391
toxicity	NOUN	O	Disease	1391
of	ADP	O	O	1391
AmB.	NOUN	O	O	1391
Risks	NOUN	O	O	1394
of	ADP	O	O	1394
the	PRON	O	O	1394
consumption	NOUN	O	O	1394
of	ADP	O	O	1394
beverages	NOUN	O	O	1394
containing	VERB	O	O	1394
quinine	NOUN	O	Chemical	1394
.	PUNCT	O	O	1394
Although	SCONJ	O	O	1395
the	PRON	O	O	1395
United	PROPN	O	O	1395
States	NOUN	O	O	1395
Food	NOUN	O	O	1395
and	CCONJ	O	O	1395
Drug	NOUN	O	O	1395
Administration	NOUN	O	O	1395
banned	VERB	O	O	1395
its	PRON	O	O	1395
use	VERB	O	O	1395
for	ADP	O	O	1395
nocturnal	ADJ	O	O	1395
leg	NOUN	O	O	1395
cramps	NOUN	O	O	1395
due	ADJ	O	O	1395
to	PART	O	O	1395
lack	VERB	O	O	1395
of	ADP	O	O	1395
safety	NOUN	O	O	1395
and	CCONJ	O	O	1395
efficacy	NOUN	O	O	1395
,	PUNCT	O	O	1395
quinine	NOUN	O	Chemical	1395
is	AUX	O	O	1395
widely	ADV	O	O	1395
available	ADJ	O	O	1395
in	ADP	O	O	1395
beverages	NOUN	O	O	1395
including	VERB	O	O	1395
tonic	PROPN	O	O	1395
water	PROPN	O	O	1395
and	CCONJ	O	O	1395
bitter	ADJ	O	O	1395
lemon	NOUN	O	O	1395
.	PUNCT	O	O	1395
Numerous	ADJ	O	O	1396
anecdotal	ADJ	O	O	1396
reports	VERB	O	O	1396
suggest	VERB	O	O	1396
that	SCONJ	O	O	1396
products	NOUN	O	O	1396
containing	VERB	O	O	1396
quinine	NOUN	O	Chemical	1396
may	AUX	O	O	1396
produce	VERB	O	O	1396
neurological	ADJ	O	O	1396
complications	NOUN	O	O	1396
,	PUNCT	O	O	1396
including	VERB	O	O	1396
confusion	NOUN	O	Disease	1396
,	PUNCT	O	O	1396
altered	VERB	O	O	1396
mental	ADJ	O	O	1396
status	NOUN	O	O	1396
,	PUNCT	O	O	1396
seizures	NOUN	O	Disease	1396
,	PUNCT	O	O	1396
and	CCONJ	O	O	1396
coma	NOUN	O	Disease	1396
,	PUNCT	O	O	1396
particularly	ADV	O	O	1396
in	ADP	O	O	1396
older	ADJ	O	O	1396
women	NOUN	O	O	1396
.	PUNCT	O	O	1396
Psychologists	NOUN	O	O	1397
need	VERB	O	O	1397
to	PART	O	O	1397
inquire	VERB	O	O	1397
about	ADP	O	O	1397
consumption	NOUN	O	O	1397
of	ADP	O	O	1397
quinine	NOUN	O	Chemical	1397
-	PUNCT	O	O	1397
containing	VERB	O	O	1397
beverages	NOUN	O	O	1397
as	ADP	O	O	1397
part	NOUN	O	O	1397
of	ADP	O	O	1397
an	PRON	O	O	1397
evaluation	NOUN	O	O	1397
process	NOUN	O	O	1397
.	PUNCT	O	O	1397
Organophosphate	NOUN	O	O	1400
-	PUNCT	O	O	1400
induced	VERB	O	O	1400
convulsions	NOUN	O	Disease	1400
and	CCONJ	O	O	1400
prevention	NOUN	O	O	1400
of	ADP	O	O	1400
neuropathological	PROPN	O	O	1400
damages	NOUN	O	O	1400
.	PUNCT	O	O	1400
Such	ADJ	O	O	1401
organophosphorus	PROPN	O	Chemical	1401
(	PUNCT	O	O	1401
OP	NOUN	O	O	1401
)	PUNCT	O	O	1401
compounds	NOUN	O	O	1401
as	ADP	O	O	1401
diisopropylfluorophosphate	NOUN	O	O	1401
(	PUNCT	O	O	1401
DFP	PROPN	O	Chemical	1401
)	PUNCT	O	O	1401
,	PUNCT	O	O	1401
sarin	NOUN	O	O	1401
and	CCONJ	O	O	1401
soman	PROPN	O	O	1401
are	AUX	O	O	1401
potent	ADJ	O	O	1401
inhibitors	NOUN	O	O	1401
of	ADP	O	O	1401
acetylcholinesterases	VERB	O	O	1401
(	PUNCT	O	O	1401
AChEs	NOUN	O	O	1401
)	PUNCT	O	O	1401
and	CCONJ	O	O	1401
butyrylcholinesterases	NOUN	O	O	1401
(	PUNCT	O	O	1401
BChEs	PROPN	O	O	1401
)	PUNCT	O	O	1401
.	PUNCT	O	O	1401
The	PRON	O	O	1402
acute	ADJ	O	O	1402
toxicity	NOUN	O	Disease	1402
of	ADP	O	O	1402
OPs	NOUN	O	O	1402
is	AUX	O	O	1402
the	PRON	O	O	1402
result	VERB	O	O	1402
of	ADP	O	O	1402
their	PRON	O	O	1402
irreversible	ADJ	O	O	1402
binding	VERB	O	O	1402
with	ADP	O	O	1402
AChEs	NOUN	O	O	1402
in	ADP	O	O	1402
the	PRON	O	O	1402
central	ADJ	O	O	1402
nervous	ADJ	O	O	1402
system	NOUN	O	O	1402
(	PUNCT	O	O	1402
CNS	PROPN	O	O	1402
)	PUNCT	O	O	1402
,	PUNCT	O	O	1402
which	PRON	O	O	1402
elevates	VERB	O	O	1402
acetylcholine	NOUN	O	Chemical	1402
(	PUNCT	O	O	1402
ACh	PROPN	O	Chemical	1402
)	PUNCT	O	O	1402
levels	NOUN	O	O	1402
.	PUNCT	O	O	1402
The	PRON	O	O	1403
protective	ADJ	O	O	1403
action	NOUN	O	O	1403
of	ADP	O	O	1403
subcutaneously	ADV	O	O	1403
(	PUNCT	O	O	1403
SC	PROPN	O	O	1403
)	PUNCT	O	O	1403
administered	VERB	O	O	1403
antidotes	NOUN	O	O	1403
or	CCONJ	O	O	1403
their	PRON	O	O	1403
combinations	NOUN	O	O	1403
in	ADP	O	O	1403
DFP	PROPN	O	Chemical	1403
(	PUNCT	O	O	1403
2.0	NUM	O	O	1403
mg	VERB	O	O	1403
/	PUNCT	O	O	1403
kg	VERB	O	O	1403
BW	NOUN	O	O	1403
)	PUNCT	O	O	1403
intoxication	NOUN	O	O	1403
was	AUX	O	O	1403
studied	VERB	O	O	1403
in	ADP	O	O	1403
9	NUM	O	O	1403
-	PUNCT	O	O	1403
10-weeks	NOUN	O	O	1403
-	PUNCT	O	O	1403
old	ADJ	O	O	1403
Han	PROPN	O	O	1403
-	PUNCT	O	O	1403
Wistar	PROPN	O	O	1403
male	NOUN	O	O	1403
rats	NOUN	O	O	1403
.	PUNCT	O	O	1403
The	PRON	O	O	1404
rats	NOUN	O	O	1404
received	VERB	O	O	1404
AChE	PROPN	O	O	1404
reactivator	PROPN	O	O	1404
pralidoxime-2-chloride	NOUN	O	O	1404
(	PUNCT	O	O	1404
2PAM	NUM	O	O	1404
)	PUNCT	O	O	1404
(	PUNCT	O	O	1404
30.0	NUM	O	O	1404
mg	VERB	O	O	1404
/	PUNCT	O	O	1404
kg	VERB	O	O	1404
BW	NOUN	O	O	1404
)	PUNCT	O	O	1404
,	PUNCT	O	O	1404
anticonvulsant	ADJ	O	O	1404
diazepam	NOUN	O	Chemical	1404
(	PUNCT	O	O	1404
2.0	NUM	O	O	1404
mg	VERB	O	O	1404
/	PUNCT	O	O	1404
kg	VERB	O	O	1404
BW	NOUN	O	O	1404
)	PUNCT	O	O	1404
,	PUNCT	O	O	1404
A(1)-adenosine	ADJ	O	O	1404
receptor	NOUN	O	O	1404
agonist	NOUN	O	O	1404
N(6)-cyclopentyl	NOUN	O	O	1405
adenosine	PROPN	O	Chemical	1405
(	PUNCT	O	O	1405
CPA	NOUN	O	Chemical	1405
)	PUNCT	O	O	1405
(	PUNCT	O	O	1405
2.0	NUM	O	O	1405
mg	VERB	O	O	1405
/	PUNCT	O	O	1405
kg	VERB	O	O	1405
BW	NOUN	O	O	1405
)	PUNCT	O	O	1405
,	PUNCT	O	O	1405
NMDA	PROPN	O	Chemical	1405
-	PUNCT	O	O	1405
receptor	NOUN	O	O	1405
antagonist	NOUN	O	O	1405
dizocilpine	PROPN	O	Chemical	1405
maleate	NOUN	O	O	1405
(	PUNCT	O	O	1405
+	ADP	O	O	1405
-MK801	NOUN	O	O	1405
hydrogen	PROPN	O	O	1405
maleate	NOUN	O	O	1405
)	PUNCT	O	O	1405
(	PUNCT	O	O	1405
2.0	NUM	O	O	1405
mg	VERB	O	O	1405
/	PUNCT	O	O	1405
kg	VERB	O	O	1405
BW	NOUN	O	O	1405
)	PUNCT	O	O	1405
or	CCONJ	O	O	1405
their	PRON	O	O	1405
combinations	NOUN	O	O	1405
with	ADP	O	O	1405
cholinolytic	ADJ	O	O	1405
drug	NOUN	O	O	1405
atropine	NOUN	O	Chemical	1405
sulfate	NOUN	O	O	1405
(	PUNCT	O	O	1405
50.0	NUM	O	O	1405
mg	VERB	O	O	1405
/	PUNCT	O	O	1405
kg	VERB	O	O	1405
BW	NOUN	O	O	1405
)	PUNCT	O	O	1405
immediately	ADV	O	O	1405
or	CCONJ	O	O	1405
30	NUM	O	O	1405
min	NOUN	O	O	1405
after	ADP	O	O	1405
the	PRON	O	O	1405
single	ADJ	O	O	1405
SC	PROPN	O	O	1405
injection	NOUN	O	O	1405
of	ADP	O	O	1405
DFP	PROPN	O	Chemical	1405
.	PUNCT	O	O	1405
The	PRON	O	O	1406
control	VERB	O	O	1406
rats	NOUN	O	O	1406
received	VERB	O	O	1406
atropine	NOUN	O	Chemical	1406
sulfate	NOUN	O	O	1406
,	PUNCT	O	O	1406
but	CCONJ	O	O	1406
also	ADV	O	O	1406
saline	NOUN	O	O	1406
and	CCONJ	O	O	1406
olive	NOUN	O	O	1406
oil	NOUN	O	O	1406
instead	ADV	O	O	1406
of	ADP	O	O	1406
other	ADJ	O	O	1406
antidotes	NOUN	O	O	1406
and	CCONJ	O	O	1406
DFP	PROPN	O	Chemical	1406
,	PUNCT	O	O	1406
respectively	ADV	O	O	1406
.	PUNCT	O	O	1406
All	PRON	O	O	1407
rats	NOUN	O	O	1407
were	AUX	O	O	1407
terminated	VERB	O	O	1407
either	ADV	O	O	1407
24	NUM	O	O	1407
h	X	O	O	1407
or	CCONJ	O	O	1407
3	X	O	O	1407
weeks	NOUN	O	O	1407
after	ADP	O	O	1407
the	PRON	O	O	1407
DFP	PROPN	O	Chemical	1407
injection	NOUN	O	O	1407
.	PUNCT	O	O	1407
The	PRON	O	O	1408
rats	NOUN	O	O	1408
treated	VERB	O	O	1408
with	ADP	O	O	1408
DFP	PROPN	O	Chemical	1408
-	PUNCT	O	O	1408
atropine	NOUN	O	Chemical	1408
showed	VERB	O	O	1408
severe	ADJ	O	O	1408
typical	ADJ	O	O	1408
OP	NOUN	O	O	1408
-	PUNCT	O	O	1408
induced	VERB	O	O	1408
toxicity	NOUN	O	Disease	1408
signs	NOUN	O	O	1408
.	PUNCT	O	O	1408
When	SCONJ	O	O	1409
CPA	NOUN	O	Chemical	1409
,	PUNCT	O	O	1409
diazepam	NOUN	O	Chemical	1409
or	CCONJ	O	O	1409
2PAM	NUM	O	O	1409
was	AUX	O	O	1409
given	VERB	O	O	1409
immediately	ADV	O	O	1409
after	ADP	O	O	1409
DFP	PROPN	O	Chemical	1409
-	PUNCT	O	O	1409
atropine	NOUN	O	Chemical	1409
,	PUNCT	O	O	1409
these	PRON	O	O	1409
treatments	NOUN	O	O	1409
prevented	VERB	O	O	1409
,	PUNCT	O	O	1409
delayed	VERB	O	O	1409
or	CCONJ	O	O	1409
shortened	VERB	O	O	1409
the	PRON	O	O	1409
occurrence	NOUN	O	O	1409
of	ADP	O	O	1409
serious	ADJ	O	O	1409
signs	NOUN	O	O	1409
of	ADP	O	O	1409
poisoning	VERB	O	O	1409
.	PUNCT	O	O	1409
Atropine	NOUN	O	Chemical	1410
-	PUNCT	O	O	1410
MK801	PROPN	O	O	1410
did	VERB	O	O	1410
not	PART	O	O	1410
offer	VERB	O	O	1410
any	PRON	O	O	1410
additional	ADJ	O	O	1410
protection	NOUN	O	O	1410
against	ADP	O	O	1410
DFP	PROPN	O	Chemical	1410
toxicity	NOUN	O	Disease	1410
.	PUNCT	O	O	1410
In	ADP	O	O	1411
conclusion	NOUN	O	O	1411
,	PUNCT	O	O	1411
CPA	NOUN	O	Chemical	1411
,	PUNCT	O	O	1411
diazepam	NOUN	O	Chemical	1411
and	CCONJ	O	O	1411
2PAM	NUM	O	O	1411
in	ADP	O	O	1411
combination	NOUN	O	O	1411
with	ADP	O	O	1411
atropine	NOUN	O	Chemical	1411
prevented	VERB	O	O	1411
the	PRON	O	O	1411
occurrence	NOUN	O	O	1411
of	ADP	O	O	1411
serious	ADJ	O	O	1411
signs	NOUN	O	O	1411
of	ADP	O	O	1411
poisoning	VERB	O	O	1411
and	CCONJ	O	O	1411
thus	ADV	O	O	1411
reduced	VERB	O	O	1411
the	PRON	O	O	1411
toxicity	NOUN	O	Disease	1411
of	ADP	O	O	1411
DFP	PROPN	O	Chemical	1411
in	ADP	O	O	1411
rat	NOUN	O	O	1411
.	PUNCT	O	O	1411
Differential	ADJ	O	O	1414
modulation	NOUN	O	O	1414
by	ADP	O	O	1414
estrogen	PROPN	O	Chemical	1414
of	ADP	O	O	1414
alpha2-adrenergic	NOUN	O	O	1414
and	CCONJ	O	O	1414
I1-imidazoline	NOUN	O	O	1414
receptor	NOUN	O	O	1414
-	PUNCT	O	O	1414
mediated	VERB	O	O	1414
hypotension	NOUN	O	Disease	1414
in	ADP	O	O	1414
female	ADJ	O	O	1414
rats	NOUN	O	O	1414
.	PUNCT	O	O	1414
We	PRON	O	O	1415
have	VERB	O	O	1415
recently	ADV	O	O	1415
shown	VERB	O	O	1415
that	SCONJ	O	O	1415
estrogen	PROPN	O	Chemical	1415
negatively	ADV	O	O	1415
modulates	VERB	O	O	1415
the	PRON	O	O	1415
hypotensive	ADJ	O	Disease	1415
effect	VERB	O	O	1415
of	ADP	O	O	1415
clonidine	NOUN	O	Chemical	1415
(	PUNCT	O	O	1415
mixed	VERB	O	O	1415
alpha2-/I1-receptor	NOUN	O	O	1415
agonist	NOUN	O	O	1415
)	PUNCT	O	O	1415
in	ADP	O	O	1415
female	ADJ	O	O	1415
rats	NOUN	O	O	1415
and	CCONJ	O	O	1415
implicates	VERB	O	O	1415
the	PRON	O	O	1415
cardiovascular	ADJ	O	O	1415
autonomic	ADJ	O	O	1415
control	VERB	O	O	1415
in	ADP	O	O	1415
this	PRON	O	O	1415
interaction	NOUN	O	O	1415
.	PUNCT	O	O	1415
The	PRON	O	O	1416
present	NOUN	O	O	1416
study	VERB	O	O	1416
investigated	VERB	O	O	1416
whether	SCONJ	O	O	1416
this	PRON	O	O	1416
effect	VERB	O	O	1416
of	ADP	O	O	1416
estrogen	PROPN	O	Chemical	1416
involves	VERB	O	O	1416
interaction	NOUN	O	O	1416
with	ADP	O	O	1416
alpha2-	NOUN	O	O	1416
and/or	CCONJ	O	O	1416
I1-receptors	NOUN	O	O	1416
.	PUNCT	O	O	1416
Changes	NOUN	O	O	1417
evoked	VERB	O	O	1417
by	ADP	O	O	1417
a	PRON	O	O	1417
single	ADJ	O	O	1417
intraperitoneal	ADJ	O	O	1417
injection	NOUN	O	O	1417
of	ADP	O	O	1417
rilmenidine	PROPN	O	O	1417
(	PUNCT	O	O	1417
600	NUM	O	O	1417
microg	PROPN	O	O	1417
/	PUNCT	O	O	1417
kg	VERB	O	O	1417
)	PUNCT	O	O	1417
or	CCONJ	O	O	1417
alpha	PROPN	O	O	1417
-	PUNCT	O	O	1417
methyldopa	ADJ	O	Chemical	1417
(	PUNCT	O	O	1417
100	NUM	O	O	1417
mg	VERB	O	O	1417
/	PUNCT	O	O	1417
kg	VERB	O	O	1417
)	PUNCT	O	O	1417
,	PUNCT	O	O	1417
selective	ADJ	O	O	1417
I1-	INTJ	O	O	1417
and	CCONJ	O	O	1417
alpha2-receptor	NOUN	O	O	1417
agonists	NOUN	O	O	1417
,	PUNCT	O	O	1417
respectively	ADV	O	O	1417
,	PUNCT	O	O	1417
in	ADP	O	O	1417
blood	NOUN	O	O	1417
pressure	NOUN	O	O	1417
,	PUNCT	O	O	1417
hemodynamic	ADJ	O	O	1417
variability	NOUN	O	O	1417
,	PUNCT	O	O	1417
and	CCONJ	O	O	1417
locomotor	PROPN	O	O	1417
activity	NOUN	O	O	1417
were	AUX	O	O	1417
assessed	VERB	O	O	1417
in	ADP	O	O	1417
radiotelemetered	VERB	O	O	1417
sham	NOUN	O	O	1417
-	PUNCT	O	O	1417
operated	VERB	O	O	1417
and	CCONJ	O	O	1417
ovariectomized	VERB	O	O	1417
(	PUNCT	O	O	1417
Ovx	NOUN	O	O	1417
)	PUNCT	O	O	1417
Sprague	PROPN	O	O	1418
-	PUNCT	O	O	1418
Dawley	NOUN	O	O	1418
female	ADJ	O	O	1418
rats	NOUN	O	O	1418
with	ADP	O	O	1418
or	CCONJ	O	O	1418
without	ADP	O	O	1418
12-wk	NOUN	O	O	1418
estrogen	PROPN	O	Chemical	1418
replacement	NOUN	O	O	1418
.	PUNCT	O	O	1418
In	ADP	O	O	1419
sham	NOUN	O	O	1419
-	PUNCT	O	O	1419
operated	VERB	O	O	1419
rats	NOUN	O	O	1419
,	PUNCT	O	O	1419
rilmenidine	PROPN	O	O	1419
or	CCONJ	O	O	1419
alpha	PROPN	O	O	1419
-	PUNCT	O	O	1419
methyldopa	ADJ	O	Chemical	1419
elicited	VERB	O	O	1419
similar	ADJ	O	O	1419
hypotension	NOUN	O	Disease	1419
that	SCONJ	O	O	1419
lasted	VERB	O	O	1419
at	ADP	O	O	1419
least	ADJ	O	O	1419
5	NUM	O	O	1419
h	X	O	O	1419
and	CCONJ	O	O	1419
was	AUX	O	O	1419
associated	VERB	O	O	1419
with	ADP	O	O	1419
reductions	NOUN	O	O	1419
in	ADP	O	O	1419
standard	PROPN	O	O	1419
deviation	NOUN	O	O	1419
of	ADP	O	O	1419
mean	VERB	O	O	1419
arterial	ADJ	O	O	1419
pressure	NOUN	O	O	1419
.	PUNCT	O	O	1419
SDRR	NOUN	O	O	1420
was	AUX	O	O	1420
reduced	VERB	O	O	1420
only	ADV	O	O	1420
by	ADP	O	O	1420
alpha	PROPN	O	O	1420
-	PUNCT	O	O	1420
methyldopa	ADJ	O	Chemical	1420
.	PUNCT	O	O	1420
Ovx	NOUN	O	O	1421
significantly	ADV	O	O	1421
enhanced	VERB	O	O	1421
the	PRON	O	O	1421
hypotensive	ADJ	O	Disease	1421
response	NOUN	O	O	1421
to	PART	O	O	1421
alpha	PROPN	O	O	1421
-	PUNCT	O	O	1421
methyldopa	ADJ	O	Chemical	1421
,	PUNCT	O	O	1421
in	ADP	O	O	1421
contrast	NOUN	O	O	1421
to	PART	O	O	1421
no	PRON	O	O	1421
effect	VERB	O	O	1421
on	ADP	O	O	1421
rilmenidine	PROPN	O	O	1421
hypotension	NOUN	O	Disease	1421
.	PUNCT	O	O	1421
The	PRON	O	O	1422
enhanced	VERB	O	O	1422
alpha	PROPN	O	O	1422
-	PUNCT	O	O	1422
methyldopa	ADJ	O	Chemical	1422
hypotension	NOUN	O	Disease	1422
in	ADP	O	O	1422
Ovx	NOUN	O	O	1422
rats	NOUN	O	O	1422
was	AUX	O	O	1422
paralleled	VERB	O	O	1422
with	ADP	O	O	1422
further	ADV	O	O	1422
reduction	NOUN	O	O	1422
in	ADP	O	O	1422
SDRR	NOUN	O	O	1422
and	CCONJ	O	O	1422
a	PRON	O	O	1422
reduced	VERB	O	O	1422
locomotor	PROPN	O	O	1422
activity	NOUN	O	O	1422
.	PUNCT	O	O	1422
Estrogen	NOUN	O	O	1423
replacement	NOUN	O	O	1423
(	PUNCT	O	O	1423
17beta	NUM	O	O	1423
-	PUNCT	O	O	1423
estradiol	VERB	O	Chemical	1423
subcutaneous	ADJ	O	O	1423
pellet	NOUN	O	O	1423
,	PUNCT	O	O	1423
14.2	NUM	O	O	1423
microg	PROPN	O	O	1423
/	PUNCT	O	O	1423
day	NOUN	O	O	1423
,	PUNCT	O	O	1423
12	NUM	O	O	1423
wk	X	O	O	1423
)	PUNCT	O	O	1423
of	ADP	O	O	1423
Ovx	NOUN	O	O	1423
rats	NOUN	O	O	1423
restored	VERB	O	O	1423
the	PRON	O	O	1423
hemodynamic	ADJ	O	O	1423
and	CCONJ	O	O	1423
locomotor	PROPN	O	O	1423
effects	NOUN	O	O	1423
of	ADP	O	O	1423
alpha	PROPN	O	O	1423
-	PUNCT	O	O	1423
methyldopa	ADJ	O	Chemical	1423
to	PART	O	O	1423
sham	NOUN	O	O	1423
-	PUNCT	O	O	1423
operated	VERB	O	O	1423
levels	NOUN	O	O	1423
.	PUNCT	O	O	1423
These	PRON	O	O	1424
findings	NOUN	O	O	1424
suggest	VERB	O	O	1424
that	SCONJ	O	O	1424
estrogen	PROPN	O	Chemical	1424
downregulates	VERB	O	O	1424
alpha2-	NOUN	O	O	1424
but	CCONJ	O	O	1424
not	PART	O	O	1424
I1-receptor	NOUN	O	O	1424
-	PUNCT	O	O	1424
mediated	VERB	O	O	1424
hypotension	NOUN	O	Disease	1424
and	CCONJ	O	O	1424
highlight	VERB	O	O	1424
a	PRON	O	O	1424
role	NOUN	O	O	1424
for	ADP	O	O	1424
the	PRON	O	O	1424
cardiac	ADJ	O	O	1424
autonomic	ADJ	O	O	1424
control	VERB	O	O	1424
in	ADP	O	O	1424
alpha	PROPN	O	O	1424
-	PUNCT	O	O	1424
methyldopa	ADJ	O	Chemical	1424
-	PUNCT	O	O	1424
estrogen	PROPN	O	Chemical	1424
interaction	NOUN	O	O	1424
.	PUNCT	O	O	1424
Cardioprotective	PROPN	O	O	1427
effect	VERB	O	O	1427
of	ADP	O	O	1427
tincture	NOUN	O	O	1427
of	ADP	O	O	1427
Crataegus	NOUN	O	O	1427
on	ADP	O	O	1427
isoproterenol	NOUN	O	Chemical	1427
-	PUNCT	O	O	1427
induced	VERB	O	O	1427
myocardial infarction	NOUN	O	Disease	1427
in	ADP	O	O	1427
rats	NOUN	O	O	1427
.	PUNCT	O	O	1427
Tincture	NOUN	O	O	1428
of	ADP	O	O	1428
Crataegus	NOUN	O	O	1428
(	PUNCT	O	O	1428
TCR	PROPN	O	O	1428
)	PUNCT	O	O	1428
,	PUNCT	O	O	1428
an	PRON	O	O	1428
alcoholic	ADJ	O	O	1428
extract	VERB	O	O	1428
of	ADP	O	O	1428
the	PRON	O	O	1428
berries	NOUN	O	O	1428
of	ADP	O	O	1428
hawthorn	NOUN	O	O	1428
(	PUNCT	O	O	1428
Crataegus	NOUN	O	O	1428
oxycantha	NOUN	O	O	1428
)	PUNCT	O	O	1428
,	PUNCT	O	O	1428
is	AUX	O	O	1428
used	VERB	O	O	1428
in	ADP	O	O	1428
herbal	ADJ	O	O	1428
and	CCONJ	O	O	1428
homeopathic	PROPN	O	O	1428
medicine	NOUN	O	O	1428
.	PUNCT	O	O	1428
The	PRON	O	O	1429
present	NOUN	O	O	1429
study	VERB	O	O	1429
was	AUX	O	O	1429
done	VERB	O	O	1429
to	PART	O	O	1429
investigate	VERB	O	O	1429
the	PRON	O	O	1429
protective	ADJ	O	O	1429
effect	VERB	O	O	1429
of	ADP	O	O	1429
TCR	PROPN	O	O	1429
on	ADP	O	O	1429
experimentally	ADV	O	O	1429
induced	VERB	O	O	1429
myocardial infarction	NOUN	O	Disease	1429
in	ADP	O	O	1429
rats	NOUN	O	O	1429
.	PUNCT	O	O	1429
Pretreatment	NOUN	O	O	1430
of	ADP	O	O	1430
TCR	PROPN	O	O	1430
,	PUNCT	O	O	1430
at	ADP	O	O	1430
a	PRON	O	O	1430
dose	NOUN	O	O	1430
of	ADP	O	O	1430
0.5	NUM	O	O	1430
mL/100	X	O	O	1430
g	X	O	O	1430
bodyweight	NOUN	O	O	1430
per	ADP	O	O	1430
day	NOUN	O	O	1430
,	PUNCT	O	O	1430
orally	ADV	O	O	1430
for	ADP	O	O	1430
30	NUM	O	O	1430
days	NOUN	O	O	1430
,	PUNCT	O	O	1430
prevented	VERB	O	O	1430
the	PRON	O	O	1430
increase	VERB	O	O	1430
in	ADP	O	O	1430
lipid	NOUN	O	O	1430
peroxidation	NOUN	O	O	1430
and	CCONJ	O	O	1430
activity	NOUN	O	O	1430
of	ADP	O	O	1430
marker	NOUN	O	O	1430
enzymes	NOUN	O	O	1430
observed	VERB	O	O	1430
in	ADP	O	O	1430
isoproterenol	NOUN	O	Chemical	1430
-	PUNCT	O	O	1430
induced	VERB	O	O	1430
rats	NOUN	O	O	1430
(	PUNCT	O	O	1430
85	NUM	O	O	1430
mg	VERB	O	O	1430
kg(-1	NOUN	O	O	1430
)	PUNCT	O	O	1430
s.	PROPN	O	O	1430
c.	PROPN	O	O	1430
for	ADP	O	O	1430
2	X	O	O	1430
days	NOUN	O	O	1430
at	ADP	O	O	1430
an	PRON	O	O	1430
interval	NOUN	O	O	1430
of	ADP	O	O	1430
24	NUM	O	O	1430
h	X	O	O	1430
)	PUNCT	O	O	1430
.	PUNCT	O	O	1430
TCR	PROPN	O	O	1431
prevented	VERB	O	O	1431
the	PRON	O	O	1431
isoproterenol	NOUN	O	Chemical	1431
-	PUNCT	O	O	1431
induced	VERB	O	O	1431
decrease	VERB	O	O	1431
in	ADP	O	O	1431
antioxidant	ADJ	O	O	1431
enzymes	NOUN	O	O	1431
in	ADP	O	O	1431
the	PRON	O	O	1431
heart	NOUN	O	O	1431
and	CCONJ	O	O	1431
increased	VERB	O	O	1431
the	PRON	O	O	1431
rate	NOUN	O	O	1431
of	ADP	O	O	1431
ADP	PROPN	O	Chemical	1431
-	PUNCT	O	O	1431
stimulated	VERB	O	O	1431
oxygen	NOUN	O	Chemical	1431
uptake	NOUN	O	O	1431
and	CCONJ	O	O	1431
respiratory	NOUN	O	O	1431
coupling	NOUN	O	O	1431
ratio	NOUN	O	O	1431
.	PUNCT	O	O	1431
TCR	PROPN	O	O	1432
protected	VERB	O	O	1432
against	ADP	O	O	1432
pathological	ADJ	O	O	1432
changes	VERB	O	O	1432
induced	VERB	O	O	1432
by	ADP	O	O	1432
isoproterenol	NOUN	O	Chemical	1432
in	ADP	O	O	1432
rat	NOUN	O	O	1432
heart	NOUN	O	O	1432
.	PUNCT	O	O	1432
The	PRON	O	O	1433
results	VERB	O	O	1433
show	VERB	O	O	1433
that	SCONJ	O	O	1433
pretreatment	NOUN	O	O	1433
with	ADP	O	O	1433
TCR	PROPN	O	O	1433
may	AUX	O	O	1433
be	AUX	O	O	1433
useful	ADJ	O	O	1433
in	ADP	O	O	1433
preventing	VERB	O	O	1433
the	PRON	O	O	1433
damage	NOUN	O	O	1433
induced	VERB	O	O	1433
by	ADP	O	O	1433
isoproterenol	NOUN	O	Chemical	1433
in	ADP	O	O	1433
rat	NOUN	O	O	1433
heart	NOUN	O	O	1433
.	PUNCT	O	O	1433
Safety	NOUN	O	O	1436
and	CCONJ	O	O	1436
adverse	ADJ	O	O	1436
effects	NOUN	O	O	1436
associated	VERB	O	O	1436
with	ADP	O	O	1436
raloxifene	PUNCT	O	O	1436
:	PUNCT	O	O	1436
multiple	ADJ	O	O	1436
outcomes	NOUN	O	O	1436
of	ADP	O	O	1436
raloxifene	PUNCT	O	O	1436
evaluation	NOUN	O	O	1436
.	PUNCT	O	O	1436
OBJECTIVE	VERB	O	O	1437
:	PUNCT	O	O	1437
To	PART	O	O	1437
examine	VERB	O	O	1437
the	PRON	O	O	1437
effect	VERB	O	O	1437
of	ADP	O	O	1437
raloxifene	PUNCT	O	O	1437
on	ADP	O	O	1437
major	ADJ	O	O	1437
adverse	ADJ	O	O	1437
events	NOUN	O	O	1437
that	SCONJ	O	O	1437
occur	VERB	O	O	1437
with	ADP	O	O	1437
postmenopausal	NOUN	O	O	1437
estrogen	PROPN	O	Chemical	1437
therapy	NOUN	O	O	1437
or	CCONJ	O	O	1437
tamoxifen	PROPN	O	Chemical	1437
.	PUNCT	O	O	1437
The	PRON	O	O	1438
Multiple	ADJ	O	O	1438
Outcomes	NOUN	O	O	1438
of	ADP	O	O	1438
Raloxifene	NOUN	O	O	1438
Evaluation	NOUN	O	O	1438
,	PUNCT	O	O	1438
a	PRON	O	O	1438
multicenter	ADJ	O	O	1438
,	PUNCT	O	O	1438
randomized	VERB	O	O	1438
,	PUNCT	O	O	1438
double	ADJ	O	O	1438
-	PUNCT	O	O	1438
blind	ADJ	O	Disease	1438
trial	NOUN	O	O	1438
,	PUNCT	O	O	1438
enrolled	VERB	O	O	1438
7,705	NUM	O	O	1438
postmenopausal	NOUN	O	O	1438
women	NOUN	O	O	1438
with	ADP	O	O	1438
osteoporosis	NOUN	O	Disease	1438
.	PUNCT	O	O	1438
Women	NOUN	O	O	1439
were	AUX	O	O	1439
randomly	ADV	O	O	1439
assigned	VERB	O	O	1439
to	PART	O	O	1439
raloxifene	PUNCT	O	O	1439
60	NUM	O	O	1439
mg	VERB	O	O	1439
/	PUNCT	O	O	1439
d	X	O	O	1439
or	CCONJ	O	O	1439
120	NUM	O	O	1439
mg	VERB	O	O	1439
/	PUNCT	O	O	1439
d	X	O	O	1439
or	CCONJ	O	O	1439
placebo	NOUN	O	O	1439
.	PUNCT	O	O	1439
Outcomes	NOUN	O	O	1440
included	VERB	O	O	1440
venous thromboembolism	NOUN	O	Disease	1440
,	PUNCT	O	O	1440
cataracts	NOUN	O	Disease	1440
,	PUNCT	O	O	1440
gallbladder disease	NOUN	O	Disease	1440
,	PUNCT	O	O	1440
and	CCONJ	O	O	1440
endometrial	ADJ	O	O	1440
hyperplasia	NOUN	O	Disease	1440
or	CCONJ	O	O	1440
cancer	NOUN	O	Disease	1440
.	PUNCT	O	O	1440
During	ADP	O	O	1441
a	PRON	O	O	1441
mean	VERB	O	O	1441
follow	VERB	O	O	1441
-	PUNCT	O	O	1441
up	ADP	O	O	1441
of	ADP	O	O	1441
3.3	NUM	O	O	1441
years	NOUN	O	O	1441
,	PUNCT	O	O	1441
raloxifene	PUNCT	O	O	1441
was	AUX	O	O	1441
associated	VERB	O	O	1441
with	ADP	O	O	1441
an	PRON	O	O	1441
increased	VERB	O	O	1441
risk	NOUN	O	O	1441
for	ADP	O	O	1441
venous thromboembolism	NOUN	O	Disease	1441
(	PUNCT	O	O	1441
relative	ADJ	O	O	1441
risk	NOUN	O	O	1441
[	X	O	O	1441
RR	NOUN	O	O	1441
]	PUNCT	O	O	1441
2.1	NUM	O	O	1441
;	PUNCT	O	O	1441
95%	NOUN	O	O	1441
confidence	NOUN	O	O	1441
interval	NOUN	O	O	1441
[	X	O	O	1441
CI	NOUN	O	O	1441
]	PUNCT	O	O	1441
1.2	NUM	O	O	1441
-	PUNCT	O	O	1441
3.8	NUM	O	O	1441
)	PUNCT	O	O	1441
.	PUNCT	O	O	1441
Risk	NOUN	O	O	1442
in	ADP	O	O	1442
the	PRON	O	O	1442
raloxifene	PUNCT	O	O	1442
group	NOUN	O	O	1442
was	AUX	O	O	1442
higher	ADJ	O	O	1442
than	ADP	O	O	1442
in	ADP	O	O	1442
the	PRON	O	O	1442
placebo	NOUN	O	O	1442
group	NOUN	O	O	1442
for	ADP	O	O	1442
the	PRON	O	O	1442
first	ADV	O	O	1442
2	X	O	O	1442
years	NOUN	O	O	1442
,	PUNCT	O	O	1442
but	CCONJ	O	O	1442
decreased	VERB	O	O	1442
to	PART	O	O	1442
about	ADP	O	O	1442
the	PRON	O	O	1442
same	ADJ	O	O	1442
rate	NOUN	O	O	1442
as	ADP	O	O	1442
in	ADP	O	O	1442
the	PRON	O	O	1442
placebo	NOUN	O	O	1442
group	NOUN	O	O	1442
thereafter	ADV	O	O	1442
.	PUNCT	O	O	1442
Raloxifene	NOUN	O	O	1443
did	VERB	O	O	1443
not	PART	O	O	1443
increase	VERB	O	O	1443
risk	NOUN	O	O	1443
for	ADP	O	O	1443
cataracts	NOUN	O	Disease	1443
(	PUNCT	O	O	1443
RR	NOUN	O	O	1443
0.9	NUM	O	O	1443
;	PUNCT	O	O	1443
95%	NOUN	O	O	1443
CI	NOUN	O	O	1443
0.8	NUM	O	O	1443
-	PUNCT	O	O	1443
1.1	NUM	O	O	1443
)	PUNCT	O	O	1443
,	PUNCT	O	O	1443
gallbladder disease	NOUN	O	Disease	1443
(	PUNCT	O	O	1443
RR	NOUN	O	O	1443
1.0	NUM	O	O	1443
;	PUNCT	O	O	1443
95%	NOUN	O	O	1443
CI	NOUN	O	O	1443
0.7	NUM	O	O	1443
-	PUNCT	O	O	1443
1.3	NUM	O	O	1443
)	PUNCT	O	O	1443
,	PUNCT	O	O	1443
endometrial	ADJ	O	O	1443
hyperplasia	NOUN	O	Disease	1443
(	PUNCT	O	O	1443
RR	NOUN	O	O	1443
1.3	NUM	O	O	1443
;	PUNCT	O	O	1443
95%	NOUN	O	O	1443
CI	NOUN	O	O	1443
0.4	NUM	O	O	1443
-	PUNCT	O	O	1443
5.1	NUM	O	O	1443
)	PUNCT	O	O	1443
,	PUNCT	O	O	1443
or	CCONJ	O	O	1443
endometrial cancer	NOUN	O	Disease	1443
(	PUNCT	O	O	1443
RR	NOUN	O	O	1443
0.9	NUM	O	O	1443
;	PUNCT	O	O	1443
95%	NOUN	O	O	1443
CI	NOUN	O	O	1443
0.3	NUM	O	O	1443
-	PUNCT	O	O	1443
2.7	NUM	O	O	1443
)	PUNCT	O	O	1443
.	PUNCT	O	O	1443
Raloxifene	NOUN	O	O	1444
was	AUX	O	O	1444
associated	VERB	O	O	1444
with	ADP	O	O	1444
an	PRON	O	O	1444
increased	VERB	O	O	1444
risk	NOUN	O	O	1444
for	ADP	O	O	1444
venous thromboembolism	NOUN	O	Disease	1444
,	PUNCT	O	O	1444
but	CCONJ	O	O	1444
there	ADV	O	O	1444
was	AUX	O	O	1444
no	PRON	O	O	1444
increased	VERB	O	O	1444
risk	NOUN	O	O	1444
for	ADP	O	O	1444
cataracts	NOUN	O	Disease	1444
,	PUNCT	O	O	1444
gallbladder disease	NOUN	O	Disease	1444
,	PUNCT	O	O	1444
endometrial	ADJ	O	O	1444
hyperplasia	NOUN	O	Disease	1444
,	PUNCT	O	O	1444
or	CCONJ	O	O	1444
endometrial cancer	NOUN	O	Disease	1444
.	PUNCT	O	O	1444
Ceftriaxone	NOUN	O	O	1447
-	PUNCT	O	O	1447
associated	VERB	O	O	1447
biliary	ADJ	O	O	1447
pseudolithiasis	NOUN	O	O	1447
in	ADP	O	O	1447
paediatric	ADJ	O	O	1447
surgical	ADJ	O	O	1447
patients	NOUN	O	O	1447
.	PUNCT	O	O	1447
It	PRON	O	O	1448
is	AUX	O	O	1448
well	ADV	O	O	1448
known	VERB	O	O	1448
that	SCONJ	O	O	1448
ceftriaxone	NOUN	O	O	1448
leads	VERB	O	O	1448
to	PART	O	O	1448
pseudolithiasis	NOUN	O	O	1448
in	ADP	O	O	1448
some	PRON	O	O	1448
patients	NOUN	O	O	1448
.	PUNCT	O	O	1448
Clinical	NOUN	O	O	1449
and	CCONJ	O	O	1449
experimental	ADJ	O	O	1449
studies	NOUN	O	O	1449
also	ADV	O	O	1449
suggest	VERB	O	O	1449
that	SCONJ	O	O	1449
situations	NOUN	O	O	1449
causing	VERB	O	O	1449
gallbladder dysfunction	NOUN	O	O	1449
,	PUNCT	O	O	1449
such	ADJ	O	O	1449
as	ADP	O	O	1449
fasting	VERB	O	O	1449
,	PUNCT	O	O	1449
may	AUX	O	O	1449
have	VERB	O	O	1449
a	PRON	O	O	1449
role	NOUN	O	O	1449
for	ADP	O	O	1449
the	PRON	O	O	1449
development	NOUN	O	O	1449
of	ADP	O	O	1449
pseudolithiasis	NOUN	O	O	1449
.	PUNCT	O	O	1449
In	ADP	O	O	1450
this	PRON	O	O	1450
study	VERB	O	O	1450
,	PUNCT	O	O	1450
we	PRON	O	O	1450
prospectively	ADV	O	O	1450
evaluated	VERB	O	O	1450
the	PRON	O	O	1450
incidence	NOUN	O	O	1450
and	CCONJ	O	O	1450
clinical	ADJ	O	O	1450
importance	NOUN	O	O	1450
of	ADP	O	O	1450
pseudolithiasis	NOUN	O	O	1450
in	ADP	O	O	1450
paediatric	ADJ	O	O	1450
surgical	ADJ	O	O	1450
patients	NOUN	O	O	1450
receiving	VERB	O	O	1450
ceftriaxone	NOUN	O	O	1450
treatment	NOUN	O	O	1450
,	PUNCT	O	O	1450
who	PRON	O	O	1450
often	ADV	O	O	1450
had	VERB	O	O	1450
to	PART	O	O	1450
fast	ADV	O	O	1450
in	ADP	O	O	1450
the	PRON	O	O	1450
post	VERB	O	O	1450
-	PUNCT	O	O	1450
operative	NOUN	O	O	1450
period	NOUN	O	O	1450
.	PUNCT	O	O	1450
Fifty	NUM	O	O	1451
children	NOUN	O	O	1451
who	PRON	O	O	1451
were	AUX	O	O	1451
given	VERB	O	O	1451
ceftriaxone	NOUN	O	O	1451
were	AUX	O	O	1451
evaluated	VERB	O	O	1451
by	ADP	O	O	1451
serial	ADJ	O	O	1451
abdominal	ADJ	O	O	1451
sonograms	NOUN	O	O	1451
.	PUNCT	O	O	1451
Comparison	NOUN	O	O	1452
of	ADP	O	O	1452
the	PRON	O	O	1452
patients	NOUN	O	O	1452
with	ADP	O	O	1452
or	CCONJ	O	O	1452
without	ADP	O	O	1452
pseudolithiasis	NOUN	O	O	1452
revealed	VERB	O	O	1452
no	PRON	O	O	1452
significant	ADJ	O	O	1452
difference	NOUN	O	O	1452
with	ADP	O	O	1452
respect	VERB	O	O	1452
to	PART	O	O	1452
age	NOUN	O	O	1452
,	PUNCT	O	O	1452
sex	NOUN	O	O	1452
,	PUNCT	O	O	1452
duration	NOUN	O	O	1452
of	ADP	O	O	1452
the	PRON	O	O	1452
treatment	NOUN	O	O	1452
and	CCONJ	O	O	1452
starvation	NOUN	O	O	1452
variables	NOUN	O	O	1452
.	PUNCT	O	O	1452
After	ADP	O	O	1453
cessation	NOUN	O	O	1453
of	ADP	O	O	1453
the	PRON	O	O	1453
treatment	NOUN	O	O	1453
,	PUNCT	O	O	1453
pseudolithiasis	NOUN	O	O	1453
resolved	VERB	O	O	1453
spontaneously	ADV	O	O	1453
within	ADP	O	O	1453
a	PRON	O	O	1453
short	ADJ	O	O	1453
period	NOUN	O	O	1453
.	PUNCT	O	O	1453
The	PRON	O	O	1454
incidence	NOUN	O	O	1454
of	ADP	O	O	1454
pseudolithiasis	NOUN	O	O	1454
is	AUX	O	O	1454
not	PART	O	O	1454
affected	VERB	O	O	1454
by	ADP	O	O	1454
fasting	VERB	O	O	1454
.	PUNCT	O	O	1454
Evaluation	NOUN	O	O	1457
of	ADP	O	O	1457
the	PRON	O	O	1457
anticocaine	NOUN	O	O	1457
monoclonal	NOUN	O	O	1457
antibody	NOUN	O	O	1457
GNC92H2	ADJ	O	O	1457
as	ADP	O	O	1457
an	PRON	O	O	1457
immunotherapy	NOUN	O	O	1457
for	ADP	O	O	1457
cocaine	NOUN	O	Chemical	1457
overdose	NOUN	O	Disease	1457
.	PUNCT	O	O	1457
The	PRON	O	O	1458
illicit	ADJ	O	O	1458
use	VERB	O	O	1458
of	ADP	O	O	1458
cocaine	NOUN	O	Chemical	1458
continues	VERB	O	O	1458
in	ADP	O	O	1458
epidemic	NOUN	O	O	1458
proportions	NOUN	O	O	1458
and	CCONJ	O	O	1458
treatment	NOUN	O	O	1458
for	ADP	O	O	1458
cocaine	NOUN	O	Chemical	1458
overdose	NOUN	O	Disease	1458
remains	VERB	O	O	1458
elusive	ADJ	O	O	1458
.	PUNCT	O	O	1458
The	PRON	O	O	1459
therapeutic	ADJ	O	O	1459
potential	ADJ	O	O	1459
of	ADP	O	O	1459
the	PRON	O	O	1459
anticocaine	NOUN	O	O	1459
antibody	NOUN	O	O	1459
GNC92H2	ADJ	O	O	1459
was	AUX	O	O	1459
examined	VERB	O	O	1459
using	VERB	O	O	1459
a	PRON	O	O	1459
model	NOUN	O	O	1459
of	ADP	O	O	1459
cocaine	NOUN	O	Chemical	1459
overdose	NOUN	O	Disease	1459
.	PUNCT	O	O	1459
Swiss	PROPN	O	O	1460
albino	PROPN	O	O	1460
mice	NOUN	O	O	1460
prepared	VERB	O	O	1460
with	ADP	O	O	1460
intrajugular	ADJ	O	O	1460
catheters	NOUN	O	O	1460
were	AUX	O	O	1460
tested	VERB	O	O	1460
in	ADP	O	O	1460
photocell	NOUN	O	O	1460
cages	NOUN	O	O	1460
after	ADP	O	O	1460
administration	NOUN	O	O	1460
of	ADP	O	O	1460
93	NUM	O	O	1460
mg	VERB	O	O	1460
/	PUNCT	O	O	1460
kg	VERB	O	O	1460
(	PUNCT	O	O	1460
LD50	PROPN	O	O	1460
)	PUNCT	O	O	1460
of	ADP	O	O	1460
cocaine	NOUN	O	Chemical	1460
and	CCONJ	O	O	1460
GNC92H2	ADJ	O	O	1460
infusions	NOUN	O	O	1460
ranging	VERB	O	O	1460
from	ADP	O	O	1460
30	NUM	O	O	1460
to	PART	O	O	1460
190	NUM	O	O	1460
mg	VERB	O	O	1460
/	PUNCT	O	O	1460
kg	VERB	O	O	1460
.	PUNCT	O	O	1460
GNC92H2	ADJ	O	O	1461
was	AUX	O	O	1461
delivered	VERB	O	O	1461
30	NUM	O	O	1461
min	NOUN	O	O	1461
before	ADP	O	O	1461
,	PUNCT	O	O	1461
concomitantly	ADV	O	O	1461
or	CCONJ	O	O	1461
3	X	O	O	1461
min	NOUN	O	O	1461
after	ADP	O	O	1461
cocaine	NOUN	O	Chemical	1461
treatment	NOUN	O	O	1461
.	PUNCT	O	O	1461
Significant	ADJ	O	O	1462
blockade	VERB	O	O	1462
of	ADP	O	O	1462
cocaine	NOUN	O	Chemical	1462
toxicity	NOUN	O	Disease	1462
was	AUX	O	O	1462
observed	VERB	O	O	1462
with	ADP	O	O	1462
the	PRON	O	O	1462
higher	ADJ	O	O	1462
dose	NOUN	O	O	1462
of	ADP	O	O	1462
GNC92H2	ADJ	O	O	1462
(	PUNCT	O	O	1462
190	NUM	O	O	1462
mg	VERB	O	O	1462
/	PUNCT	O	O	1462
kg	VERB	O	O	1462
)	PUNCT	O	O	1462
,	PUNCT	O	O	1462
where	SCONJ	O	O	1462
premorbid	NOUN	O	O	1462
behaviors	NOUN	O	O	1462
were	AUX	O	O	1462
reduced	VERB	O	O	1462
up	ADP	O	O	1462
to	PART	O	O	1462
40%	NOUN	O	O	1462
,	PUNCT	O	O	1462
seizures	NOUN	O	Disease	1462
up	ADP	O	O	1462
to	PART	O	O	1462
77%	NOUN	O	O	1462
and	CCONJ	O	O	1462
death	NOUN	O	O	1462
by	ADP	O	O	1462
72%	NOUN	O	O	1462
.	PUNCT	O	O	1462
Importantly	ADV	O	O	1463
,	PUNCT	O	O	1463
GNC92H2	ADJ	O	O	1463
prevented	VERB	O	O	1463
death	NOUN	O	O	1463
even	ADV	O	O	1463
post	VERB	O	O	1463
-	PUNCT	O	O	1463
cocaine	NOUN	O	Chemical	1463
injection	NOUN	O	O	1463
.	PUNCT	O	O	1463
The	PRON	O	O	1464
results	VERB	O	O	1464
support	NOUN	O	O	1464
the	PRON	O	O	1464
important	ADJ	O	O	1464
potential	ADJ	O	O	1464
of	ADP	O	O	1464
GNC92H2	ADJ	O	O	1464
as	ADP	O	O	1464
a	PRON	O	O	1464
therapeutic	ADJ	O	O	1464
tool	NOUN	O	O	1464
against	ADP	O	O	1464
cocaine	NOUN	O	Chemical	1464
overdose	NOUN	O	Disease	1464
.	PUNCT	O	O	1464
The	PRON	O	O	1467
effects	NOUN	O	O	1467
of	ADP	O	O	1467
short	ADJ	O	O	1467
-	PUNCT	O	O	1467
term	NOUN	O	O	1467
raloxifene	PUNCT	O	O	1467
therapy	NOUN	O	O	1467
on	ADP	O	O	1467
fibrinolysis	VERB	O	O	1467
markers	NOUN	O	O	1467
:	PUNCT	O	O	1467
TAFI	PROPN	O	O	1467
,	PUNCT	O	O	1467
tPA	PROPN	O	O	1467
,	PUNCT	O	O	1467
and	CCONJ	O	O	1467
PAI-1	NOUN	O	O	1467
.	PUNCT	O	O	1467
inhibitor-1	NUM	O	O	1468
(	PUNCT	O	O	1468
PAI-1	NOUN	O	O	1468
)	PUNCT	O	O	1468
levels	NOUN	O	O	1468
were	AUX	O	O	1468
studied	VERB	O	O	1468
for	ADP	O	O	1468
the	PRON	O	O	1468
evaluation	NOUN	O	O	1468
of	ADP	O	O	1468
short	ADJ	O	O	1468
-	PUNCT	O	O	1468
term	NOUN	O	O	1468
effects	NOUN	O	O	1468
of	ADP	O	O	1468
raloxifene	PUNCT	O	O	1468
administration	NOUN	O	O	1468
in	ADP	O	O	1468
postmenopausal	NOUN	O	O	1468
women	NOUN	O	O	1468
.	PUNCT	O	O	1468
METHODS	NOUN	O	O	1469
:	PUNCT	O	O	1469
Thirty	NUM	O	O	1469
-	PUNCT	O	O	1469
nine	NUM	O	O	1469
postmenopausal	NOUN	O	O	1469
women	NOUN	O	O	1469
with	ADP	O	O	1469
osteopenia	NOUN	O	O	1469
or	CCONJ	O	O	1469
osteoporosis	NOUN	O	Disease	1469
were	AUX	O	O	1469
included	VERB	O	O	1469
in	ADP	O	O	1469
this	PRON	O	O	1469
prospective	ADJ	O	O	1469
,	PUNCT	O	O	1469
controlled	VERB	O	O	1469
clinical	ADJ	O	O	1469
study	VERB	O	O	1469
.	PUNCT	O	O	1469
Twenty	NUM	O	O	1470
-	PUNCT	O	O	1470
five	NUM	O	O	1470
women	NOUN	O	O	1470
were	AUX	O	O	1470
given	VERB	O	O	1470
raloxifene	PUNCT	O	O	1470
hydrochloride	NOUN	O	O	1470
(	PUNCT	O	O	1470
60	NUM	O	O	1470
mg	VERB	O	O	1470
/	PUNCT	O	O	1470
day	NOUN	O	O	1470
)	PUNCT	O	O	1470
plus	CCONJ	O	O	1470
calcium	NOUN	O	Chemical	1470
(	PUNCT	O	O	1470
500	NUM	O	O	1470
mg	VERB	O	O	1470
/	PUNCT	O	O	1470
day	NOUN	O	O	1470
)	PUNCT	O	O	1470
.	PUNCT	O	O	1470
Age	NOUN	O	O	1471
-	PUNCT	O	O	1471
matched	VERB	O	O	1471
controls	VERB	O	O	1471
(	PUNCT	O	O	1471
n	CCONJ	O	O	1471
=	PUNCT	O	O	1471
14	NUM	O	O	1471
)	PUNCT	O	O	1471
were	AUX	O	O	1471
given	VERB	O	O	1471
only	ADV	O	O	1471
calcium	NOUN	O	Chemical	1471
.	PUNCT	O	O	1471
RESULTS	VERB	O	O	1472
:	PUNCT	O	O	1472
Three	NUM	O	O	1472
months	NOUN	O	O	1472
of	ADP	O	O	1472
raloxifene	PUNCT	O	O	1472
treatment	NOUN	O	O	1472
was	AUX	O	O	1472
associated	VERB	O	O	1472
with	ADP	O	O	1472
a	PRON	O	O	1472
significant	ADJ	O	O	1472
decrease	VERB	O	O	1472
in	ADP	O	O	1472
the	PRON	O	O	1472
plasma	NOUN	O	O	1472
TAFI	PROPN	O	O	1472
antigen	PROPN	O	O	1472
concentrations	NOUN	O	O	1472
(	PUNCT	O	O	1472
16%	NOUN	O	O	1472
change	VERB	O	O	1472
,	PUNCT	O	O	1472
P	NOUN	O	Chemical	1472
<	X	O	O	1472
0.01	NUM	O	O	1472
)	PUNCT	O	O	1472
,	PUNCT	O	O	1472
and	CCONJ	O	O	1472
a	PRON	O	O	1472
significant	ADJ	O	O	1472
increase	VERB	O	O	1472
in	ADP	O	O	1472
tPA	PROPN	O	O	1472
antigen	PROPN	O	O	1472
concentrations	NOUN	O	O	1472
(	PUNCT	O	O	1472
25%	NOUN	O	O	1472
change	VERB	O	O	1472
,	PUNCT	O	O	1472
P	NOUN	O	Chemical	1472
<	X	O	O	1472
0.05	NUM	O	O	1472
)	PUNCT	O	O	1472
.	PUNCT	O	O	1472
A	PRON	O	O	1473
significant	ADJ	O	O	1473
correlation	NOUN	O	O	1473
was	AUX	O	O	1473
found	VERB	O	O	1473
between	ADP	O	O	1473
baseline	VERB	O	O	1473
TAFI	PROPN	O	O	1473
antigen	PROPN	O	O	1473
concentrations	NOUN	O	O	1473
and	CCONJ	O	O	1473
the	PRON	O	O	1473
duration	NOUN	O	O	1473
of	ADP	O	O	1473
amenorrhea	PROPN	O	O	1473
(	PUNCT	O	O	1473
P	NOUN	O	Chemical	1473
<	X	O	O	1473
0.05	NUM	O	O	1473
;	PUNCT	O	O	1473
r	X	O	O	1473
=	PUNCT	O	O	1473
0.33	NUM	O	O	1473
)	PUNCT	O	O	1473
.	PUNCT	O	O	1473
:	PUNCT	O	O	1474
We	PRON	O	O	1474
suggest	VERB	O	O	1474
that	SCONJ	O	O	1474
the	PRON	O	O	1474
increased	VERB	O	O	1474
risk	NOUN	O	O	1474
of	ADP	O	O	1474
venous thromboembolism	NOUN	O	Disease	1474
due	ADJ	O	O	1474
to	PART	O	O	1474
raloxifene	PUNCT	O	O	1474
treatment	NOUN	O	O	1474
may	AUX	O	O	1474
be	AUX	O	O	1474
related	ADJ	O	O	1474
to	PART	O	O	1474
increased	VERB	O	O	1474
tPA	PROPN	O	O	1474
levels	NOUN	O	O	1474
,	PUNCT	O	O	1474
but	CCONJ	O	O	1474
not	PART	O	O	1474
TAFI	PROPN	O	O	1474
levels	NOUN	O	O	1474
.	PUNCT	O	O	1474
Ketoconazole	PROPN	O	O	1477
induced	VERB	O	O	1477
torsades de pointes	NOUN	O	Disease	1477
without	ADP	O	O	1477
concomitant	ADJ	O	O	1477
use	VERB	O	O	1477
of	ADP	O	O	1477
QT	NOUN	O	O	1477
interval	NOUN	O	O	1477
-	PUNCT	O	O	1477
prolonging	VERB	O	O	1477
drug	NOUN	O	O	1477
.	PUNCT	O	O	1477
Ketoconazole	PROPN	O	O	1478
is	AUX	O	O	1478
not	PART	O	O	1478
known	VERB	O	O	1478
to	PART	O	O	1478
be	AUX	O	O	1478
proarrhythmic	ADJ	O	O	1478
without	ADP	O	O	1478
concomitant	ADJ	O	O	1478
use	VERB	O	O	1478
of	ADP	O	O	1478
QT	NOUN	O	O	1478
interval	NOUN	O	O	1478
-	PUNCT	O	O	1478
prolonging	VERB	O	O	1478
drugs	NOUN	O	O	1478
.	PUNCT	O	O	1478
We	PRON	O	O	1479
report	VERB	O	O	1479
a	PRON	O	O	1479
woman	NOUN	O	O	1479
with	ADP	O	O	1479
coronary artery disease	NOUN	O	Disease	1479
who	PRON	O	O	1479
developed	VERB	O	O	1479
a	PRON	O	O	1479
markedly	ADV	O	O	1479
prolonged	VERB	O	O	1479
QT	NOUN	O	O	1479
interval	NOUN	O	O	1479
and	CCONJ	O	O	1479
torsades de pointes	NOUN	O	Disease	1479
(	PUNCT	O	O	1479
TdP	NOUN	O	Disease	1479
)	PUNCT	O	O	1479
after	ADP	O	O	1479
taking	VERB	O	O	1479
ketoconazole	PROPN	O	Chemical	1479
for	ADP	O	O	1479
treatment	NOUN	O	O	1479
of	ADP	O	O	1479
fungal infection	NOUN	O	Disease	1479
.	PUNCT	O	O	1479
Her	PRON	O	O	1480
QT	NOUN	O	O	1480
interval	NOUN	O	O	1480
returned	VERB	O	O	1480
to	PART	O	O	1480
normal	ADJ	O	O	1480
upon	SCONJ	O	O	1480
withdrawal	NOUN	O	O	1480
of	ADP	O	O	1480
ketoconazole	PROPN	O	Chemical	1480
.	PUNCT	O	O	1480
We	PRON	O	O	1481
postulate	VERB	O	O	1481
that	SCONJ	O	O	1481
by	ADP	O	O	1481
virtue	NOUN	O	O	1481
of	ADP	O	O	1481
its	PRON	O	O	1481
direct	ADJ	O	O	1481
blocking	VERB	O	O	1481
action	NOUN	O	O	1481
on	ADP	O	O	1481
IKr	NOUN	O	O	1481
,	PUNCT	O	O	1481
ketoconazole	PROPN	O	Chemical	1481
alone	ADV	O	O	1481
may	AUX	O	O	1481
prolong	VERB	O	O	1481
QT	NOUN	O	O	1481
interval	NOUN	O	O	1481
and	CCONJ	O	O	1481
induce	VERB	O	O	1481
TdP.	NOUN	O	O	1481
This	PRON	O	O	1482
calls	VERB	O	O	1482
for	ADP	O	O	1482
attention	NOUN	O	O	1482
when	SCONJ	O	O	1482
ketoconazole	PROPN	O	Chemical	1482
is	AUX	O	O	1482
administered	VERB	O	O	1482
to	PART	O	O	1482
patients	NOUN	O	O	1482
with	ADP	O	O	1482
risk	NOUN	O	O	1482
factors	NOUN	O	O	1482
for	ADP	O	O	1482
acquired	VERB	O	O	1482
long QT syndrome	NOUN	O	Disease	1482
.	PUNCT	O	O	1482
Pharmacological	ADJ	O	O	1485
evidence	NOUN	O	O	1485
for	ADP	O	O	1485
the	PRON	O	O	1485
potential	ADJ	O	O	1485
of	ADP	O	O	1485
Daucus	NOUN	O	O	1485
carota	NOUN	O	O	1485
in	ADP	O	O	1485
the	PRON	O	O	1485
management	NOUN	O	O	1485
of	ADP	O	O	1485
cognitive dysfunctions	NOUN	O	O	1485
.	PUNCT	O	O	1485
The	PRON	O	O	1486
present	NOUN	O	O	1486
study	VERB	O	O	1486
was	AUX	O	O	1486
aimed	VERB	O	O	1486
at	ADP	O	O	1486
investigating	VERB	O	O	1486
the	PRON	O	O	1486
effects	NOUN	O	O	1486
of	ADP	O	O	1486
Daucus	NOUN	O	O	1486
carota	NOUN	O	O	1486
seeds	NOUN	O	O	1486
on	ADP	O	O	1486
cognitive	ADJ	O	O	1486
functions	VERB	O	O	1486
,	PUNCT	O	O	1486
total	ADJ	O	O	1486
serum	NOUN	O	O	1486
cholesterol	NOUN	O	Chemical	1486
levels	NOUN	O	O	1486
and	CCONJ	O	O	1486
brain	NOUN	O	O	1486
cholinesterase	NOUN	O	O	1486
activity	NOUN	O	O	1486
in	ADP	O	O	1486
mice	NOUN	O	O	1486
.	PUNCT	O	O	1486
The	PRON	O	O	1487
ethanolic	NOUN	O	O	1487
extract	VERB	O	O	1487
of	ADP	O	O	1487
Daucus	NOUN	O	O	1487
carota	NOUN	O	O	1487
seeds	NOUN	O	O	1487
(	PUNCT	O	O	1487
DCE	PROPN	O	O	1487
)	PUNCT	O	O	1487
was	AUX	O	O	1487
administered	VERB	O	O	1487
orally	ADV	O	O	1487
in	ADP	O	O	1487
three	NUM	O	O	1487
doses	NOUN	O	O	1487
(	PUNCT	O	O	1487
100	NUM	O	O	1487
,	PUNCT	O	O	1487
200	NUM	O	O	1487
,	PUNCT	O	O	1487
400	NUM	O	O	1487
mg	VERB	O	O	1487
/	PUNCT	O	O	1487
kg	VERB	O	O	1487
)	PUNCT	O	O	1487
for	ADP	O	O	1487
seven	NUM	O	O	1487
successive	ADV	O	O	1487
days	NOUN	O	O	1487
to	PART	O	O	1487
different	ADJ	O	O	1487
groups	NOUN	O	O	1487
of	ADP	O	O	1487
young	ADJ	O	O	1487
and	CCONJ	O	O	1487
aged	ADJ	O	O	1487
mice	NOUN	O	O	1487
.	PUNCT	O	O	1487
Diazepam-	PROPN	O	O	1488
,	PUNCT	O	O	1488
scopolamine-	PUNCT	O	O	1488
and	CCONJ	O	O	1488
ageing	VERB	O	O	1488
-	PUNCT	O	O	1488
induced	VERB	O	O	1488
amnesia	NOUN	O	Disease	1488
served	VERB	O	O	1488
as	ADP	O	O	1488
the	PRON	O	O	1488
interoceptive	PROPN	O	O	1488
behavioral	ADJ	O	O	1488
models	NOUN	O	O	1488
.	PUNCT	O	O	1488
DCE	PROPN	O	O	1489
(	PUNCT	O	O	1489
200	NUM	O	O	1489
,	PUNCT	O	O	1489
400	NUM	O	O	1489
mg	VERB	O	O	1489
/	PUNCT	O	O	1489
kg	VERB	O	O	1489
,	PUNCT	O	O	1489
p.o	PROPN	O	O	1489
.	PUNCT	O	O	1489
)	PUNCT	O	O	1489
showed	VERB	O	O	1489
significant	ADJ	O	O	1489
improvement	NOUN	O	O	1489
in	ADP	O	O	1489
memory	NOUN	O	O	1489
scores	NOUN	O	O	1489
of	ADP	O	O	1489
young	ADJ	O	O	1489
and	CCONJ	O	O	1489
aged	ADJ	O	O	1489
mice	NOUN	O	O	1489
.	PUNCT	O	O	1489
The	PRON	O	O	1490
extent	NOUN	O	O	1490
of	ADP	O	O	1490
memory	NOUN	O	O	1490
improvement	NOUN	O	O	1490
evoked	VERB	O	O	1490
by	ADP	O	O	1490
DCE	PROPN	O	O	1490
was	AUX	O	O	1490
23%	NOUN	O	O	1490
at	ADP	O	O	1490
the	PRON	O	O	1490
dose	NOUN	O	O	1490
of	ADP	O	O	1490
200	NUM	O	O	1490
mg	VERB	O	O	1490
/	PUNCT	O	O	1490
kg	VERB	O	O	1490
and	CCONJ	O	O	1490
35%	NOUN	O	O	1490
at	ADP	O	O	1490
the	PRON	O	O	1490
dose	NOUN	O	O	1490
of	ADP	O	O	1490
400	NUM	O	O	1490
mg	VERB	O	O	1490
/	PUNCT	O	O	1490
kg	VERB	O	O	1490
in	ADP	O	O	1490
young	ADJ	O	O	1490
mice	NOUN	O	O	1490
using	VERB	O	O	1490
elevated	ADJ	O	O	1490
plus	CCONJ	O	O	1490
maze	NOUN	O	O	1490
.	PUNCT	O	O	1490
Furthermore	ADV	O	O	1491
,	PUNCT	O	O	1491
DCE	PROPN	O	O	1491
reversed	VERB	O	O	1491
the	PRON	O	O	1491
amnesia	NOUN	O	Disease	1491
induced	VERB	O	O	1491
by	ADP	O	O	1491
scopolamine	NOUN	O	Chemical	1491
(	PUNCT	O	O	1491
0.4	NUM	O	O	1491
mg	VERB	O	O	1491
/	PUNCT	O	O	1491
kg	VERB	O	O	1492
,	PUNCT	O	O	1492
i.p	NOUN	O	O	1492
.	PUNCT	O	O	1492
)	PUNCT	O	O	1492
and	CCONJ	O	O	1492
diazepam	NOUN	O	Chemical	1492
(	PUNCT	O	O	1492
1	X	O	O	1492
mg	VERB	O	O	1492
/	PUNCT	O	O	1492
kg	VERB	O	O	1492
,	PUNCT	O	O	1492
i.p	NOUN	O	O	1492
.	PUNCT	O	O	1492
)	PUNCT	O	O	1492
.	PUNCT	O	O	1492
Daucus	NOUN	O	O	1493
carota	NOUN	O	O	1493
extract	VERB	O	O	1493
(	PUNCT	O	O	1493
200	NUM	O	O	1493
,	PUNCT	O	O	1493
400	NUM	O	O	1493
mg	VERB	O	O	1493
/	PUNCT	O	O	1493
kg	VERB	O	O	1493
,	PUNCT	O	O	1493
p.o	PROPN	O	O	1493
.	PUNCT	O	O	1493
)	PUNCT	O	O	1493
reduced	VERB	O	O	1494
significantly	ADV	O	O	1494
the	PRON	O	O	1494
brain	NOUN	O	O	1494
acetylcholinesterase	NOUN	O	O	1494
activity	NOUN	O	O	1494
and	CCONJ	O	O	1494
cholesterol	NOUN	O	Chemical	1494
levels	NOUN	O	O	1494
in	ADP	O	O	1494
young	ADJ	O	O	1494
and	CCONJ	O	O	1494
aged	ADJ	O	O	1494
mice	NOUN	O	O	1494
.	PUNCT	O	O	1494
The	PRON	O	O	1495
extent	NOUN	O	O	1495
of	ADP	O	O	1495
inhibition	NOUN	O	O	1495
of	ADP	O	O	1495
brain	NOUN	O	O	1495
cholinesterase	NOUN	O	O	1495
activity	NOUN	O	O	1495
evoked	VERB	O	O	1495
by	ADP	O	O	1495
DCE	PROPN	O	O	1495
at	ADP	O	O	1495
the	PRON	O	O	1495
dose	NOUN	O	O	1495
of	ADP	O	O	1495
400	NUM	O	O	1495
mg	VERB	O	O	1495
/	PUNCT	O	O	1495
kg	VERB	O	O	1495
was	AUX	O	O	1495
22%	NOUN	O	O	1495
in	ADP	O	O	1495
young	ADJ	O	O	1495
and	CCONJ	O	O	1495
19%	NOUN	O	O	1495
in	ADP	O	O	1495
aged	ADJ	O	O	1495
mice	NOUN	O	O	1495
.	PUNCT	O	O	1495
There	ADV	O	O	1496
was	AUX	O	O	1496
a	PRON	O	O	1496
remarkable	ADJ	O	O	1496
reduction	NOUN	O	O	1496
in	ADP	O	O	1496
total	ADJ	O	O	1496
cholesterol	NOUN	O	Chemical	1496
level	VERB	O	O	1496
as	ADP	O	O	1496
well	ADV	O	O	1496
,	PUNCT	O	O	1496
to	PART	O	O	1496
the	PRON	O	O	1496
extent	NOUN	O	O	1496
of	ADP	O	O	1496
23%	NOUN	O	O	1496
in	ADP	O	O	1496
young	ADJ	O	O	1496
and	CCONJ	O	O	1496
21%	NOUN	O	O	1496
in	ADP	O	O	1496
aged	ADJ	O	O	1496
animals	NOUN	O	O	1496
with	ADP	O	O	1496
this	PRON	O	O	1496
dose	NOUN	O	O	1496
of	ADP	O	O	1496
DCE	PROPN	O	O	1496
.	PUNCT	O	O	1496
Therefore	ADV	O	O	1497
,	PUNCT	O	O	1497
DCE	PROPN	O	O	1497
may	AUX	O	O	1497
prove	VERB	O	O	1497
to	PART	O	O	1497
be	AUX	O	O	1497
a	PRON	O	O	1497
useful	ADJ	O	O	1497
remedy	NOUN	O	O	1497
for	ADP	O	O	1497
the	PRON	O	O	1497
management	NOUN	O	O	1497
of	ADP	O	O	1497
cognitive dysfunctions	NOUN	O	O	1497
on	ADP	O	O	1497
account	VERB	O	O	1497
of	ADP	O	O	1497
its	PRON	O	O	1497
multifarious	ADJ	O	O	1497
beneficial	ADJ	O	O	1497
effects	NOUN	O	O	1497
such	ADJ	O	O	1497
as	ADP	O	O	1497
,	PUNCT	O	O	1497
memory	NOUN	O	O	1497
improving	VERB	O	O	1497
property	NOUN	O	O	1497
,	PUNCT	O	O	1497
cholesterol	NOUN	O	Chemical	1497
lowering	VERB	O	O	1497
property	NOUN	O	O	1497
and	CCONJ	O	O	1497
anticholinesterase	PROPN	O	O	1497
activity	NOUN	O	O	1497
.	PUNCT	O	O	1497
Cauda equina syndrome	NOUN	O	Disease	1500
after	ADP	O	O	1500
epidural	ADV	O	O	1500
steroid	NOUN	O	Chemical	1500
injection	NOUN	O	O	1500
:	PUNCT	O	O	1500
a	PRON	O	O	1500
case	NOUN	O	O	1500
report	VERB	O	O	1500
.	PUNCT	O	O	1500
Conventional	ADJ	O	O	1501
treatment	NOUN	O	O	1501
methods	NOUN	O	O	1501
of	ADP	O	O	1501
lumbusacral	ADJ	O	O	1501
radiculopathy	PROPN	O	O	1501
are	AUX	O	O	1501
physical	ADJ	O	O	1501
therapy	NOUN	O	O	1501
,	PUNCT	O	O	1501
epidural	ADV	O	O	1501
steroid	NOUN	O	Chemical	1501
injections	NOUN	O	O	1501
,	PUNCT	O	O	1501
oral	ADJ	O	O	1501
medications	NOUN	O	O	1501
,	PUNCT	O	O	1501
and	CCONJ	O	O	1501
spinal	NOUN	O	O	1501
manipulative	ADJ	O	O	1501
therapy	NOUN	O	O	1501
.	PUNCT	O	O	1501
Cauda equina syndrome	NOUN	O	Disease	1502
is	AUX	O	O	1502
a	PRON	O	O	1502
rare	ADJ	O	O	1502
complication	NOUN	O	O	1502
of	ADP	O	O	1502
epidural	ADV	O	O	1502
anesthesia	NOUN	O	O	1502
.	PUNCT	O	O	1502
The	PRON	O	O	1503
following	VERB	O	O	1503
case	NOUN	O	O	1503
is	AUX	O	O	1503
a	PRON	O	O	1503
report	VERB	O	O	1503
of	ADP	O	O	1503
cauda equina syndrome	NOUN	O	Disease	1503
possibly	ADV	O	O	1503
caused	VERB	O	O	1503
by	ADP	O	O	1503
epidural	ADV	O	O	1503
injection	NOUN	O	O	1503
of	ADP	O	O	1503
triamcinolone	NOUN	O	Chemical	1503
and	CCONJ	O	O	1503
bupivacaine	NOUN	O	Chemical	1503
.	PUNCT	O	O	1503
A	PRON	O	O	1504
50-year	NOUN	O	O	1504
-	PUNCT	O	O	1504
old	ADJ	O	O	1504
woman	NOUN	O	O	1504
with	ADP	O	O	1504
low	ADJ	O	O	1504
back	ADV	O	O	1504
and	CCONJ	O	O	1504
right	ADV	O	O	1504
leg	NOUN	O	O	1504
pain	NOUN	O	Disease	1504
was	AUX	O	O	1504
scheduled	VERB	O	O	1504
for	ADP	O	O	1504
epidural	ADV	O	O	1504
steroid	NOUN	O	Chemical	1504
injection	NOUN	O	O	1504
.	PUNCT	O	O	1504
After	ADP	O	O	1505
verifying	VERB	O	O	1505
the	PRON	O	O	1505
epidural	ADV	O	O	1505
space	NOUN	O	O	1505
,	PUNCT	O	O	1505
bupivacaine	NOUN	O	Chemical	1505
and	CCONJ	O	O	1505
triamcinolone	NOUN	O	Chemical	1505
diacetate	NOUN	O	O	1505
were	AUX	O	O	1505
injected	VERB	O	O	1505
.	PUNCT	O	O	1505
Three	NUM	O	O	1506
hours	NOUN	O	O	1506
later	ADV	O	O	1506
,	PUNCT	O	O	1506
she	PRON	O	O	1506
complained	VERB	O	O	1506
of	ADP	O	O	1506
perineal	NOUN	O	O	1506
numbness	NOUN	O	Disease	1506
and	CCONJ	O	O	1506
lower	ADJ	O	O	1506
extremity	NOUN	O	O	1506
weakness	NOUN	O	Disease	1506
.	PUNCT	O	O	1506
The	PRON	O	O	1507
neurologic	ADJ	O	O	1507
evaluation	NOUN	O	O	1507
revealed	VERB	O	O	1507
loss	NOUN	O	O	1507
of	ADP	O	O	1507
sensation	NOUN	O	O	1507
in	ADP	O	O	1507
the	PRON	O	O	1507
saddle	NOUN	O	O	1507
area	NOUN	O	O	1507
and	CCONJ	O	O	1507
medial	ADJ	O	O	1507
aspect	NOUN	O	O	1507
of	ADP	O	O	1507
her	PRON	O	O	1507
right	ADV	O	O	1507
leg	NOUN	O	O	1507
.	PUNCT	O	O	1507
Complications	NOUN	O	O	1508
associated	VERB	O	O	1508
with	ADP	O	O	1508
epidural	ADV	O	O	1508
steroid	NOUN	O	Chemical	1508
injections	NOUN	O	O	1508
are	AUX	O	O	1508
rare	ADJ	O	O	1508
.	PUNCT	O	O	1508
Clinical	NOUN	O	O	1509
examination	NOUN	O	O	1509
and	CCONJ	O	O	1509
continued	VERB	O	O	1509
vigilance	NOUN	O	O	1509
for	ADP	O	O	1509
neurologic	ADJ	O	O	1509
deterioration	NOUN	O	O	1509
after	ADP	O	O	1509
epidural	ADV	O	O	1509
steroid	NOUN	O	Chemical	1509
injections	NOUN	O	O	1509
is	AUX	O	O	1509
important	ADJ	O	O	1509
.	PUNCT	O	O	1509
High	ADJ	O	O	1512
-	PUNCT	O	O	1512
dose	NOUN	O	O	1512
testosterone	PROPN	O	Chemical	1512
is	AUX	O	O	1512
associated	VERB	O	O	1512
with	ADP	O	O	1512
atherosclerosis	NOUN	O	Disease	1512
in	ADP	O	O	1512
postmenopausal	NOUN	O	O	1512
women	NOUN	O	O	1512
.	PUNCT	O	O	1512
OBJECTIVES	NOUN	O	O	1513
:	PUNCT	O	O	1513
To	PART	O	O	1513
study	VERB	O	O	1513
the	PRON	O	O	1513
long	ADV	O	O	1513
-	PUNCT	O	O	1513
term	NOUN	O	O	1513
effects	NOUN	O	O	1513
of	ADP	O	O	1513
androgen	PROPN	O	Chemical	1513
treatment	NOUN	O	O	1513
on	ADP	O	O	1513
atherosclerosis	NOUN	O	Disease	1513
in	ADP	O	O	1513
postmenopausal	NOUN	O	O	1513
women	NOUN	O	O	1513
.	PUNCT	O	O	1513
In	ADP	O	O	1514
a	PRON	O	O	1514
population	NOUN	O	O	1514
-	PUNCT	O	O	1514
based	VERB	O	O	1514
study	VERB	O	O	1514
in	ADP	O	O	1514
513	NUM	O	O	1514
naturally	ADV	O	O	1514
postmenopausal	NOUN	O	O	1514
women	NOUN	O	O	1514
aged	ADJ	O	O	1514
54	NUM	O	O	1514
-	PUNCT	O	O	1514
67	NUM	O	O	1514
years	NOUN	O	O	1514
,	PUNCT	O	O	1514
we	PRON	O	O	1514
studied	VERB	O	O	1514
the	PRON	O	O	1514
association	PROPN	O	O	1514
between	ADP	O	O	1514
self	VERB	O	O	1514
-	PUNCT	O	O	1514
reported	VERB	O	O	1514
intramuscularly	ADV	O	O	1514
administered	VERB	O	O	1514
high	ADJ	O	O	1514
-	PUNCT	O	O	1514
dose	NOUN	O	O	1514
estrogen	PROPN	O	Chemical	1514
-	PUNCT	O	O	1514
testosterone	PROPN	O	Chemical	1514
therapy	NOUN	O	O	1514
(	PUNCT	O	O	1514
estradiol-	NOUN	O	O	1514
and	CCONJ	O	O	1514
testosterone	PROPN	O	Chemical	1514
esters	NOUN	O	O	1514
)	PUNCT	O	O	1514
and	CCONJ	O	O	1514
aortic	ADJ	O	O	1514
atherosclerosis	NOUN	O	Disease	1514
.	PUNCT	O	O	1514
Aortic	ADJ	O	O	1515
atherosclerosis	NOUN	O	Disease	1515
was	AUX	O	O	1515
diagnosed	VERB	O	O	1515
by	ADP	O	O	1515
radiographic	ADJ	O	O	1515
detection	NOUN	O	O	1515
of	ADP	O	O	1515
calcified	VERB	O	O	1515
deposits	NOUN	O	O	1515
in	ADP	O	O	1515
the	PRON	O	O	1515
abdominal	ADJ	O	O	1515
aorta	NOUN	O	O	1515
,	PUNCT	O	O	1515
which	PRON	O	O	1515
have	VERB	O	O	1515
been	AUX	O	O	1515
shown	VERB	O	O	1515
to	PART	O	O	1515
reflect	VERB	O	O	1515
intima	X	O	O	1515
atherosclerosis	NOUN	O	Disease	1515
.	PUNCT	O	O	1515
In	ADP	O	O	1516
almost	ADV	O	O	1516
half	NOUN	O	O	1516
of	ADP	O	O	1516
these	PRON	O	O	1516
women	NOUN	O	O	1516
severe	ADJ	O	O	1516
atherosclerosis	NOUN	O	Disease	1516
of	ADP	O	O	1516
the	PRON	O	O	1516
aorta	NOUN	O	O	1516
was	AUX	O	O	1516
present	NOUN	O	O	1516
(	PUNCT	O	O	1516
n=11	PROPN	O	O	1516
)	PUNCT	O	O	1516
,	PUNCT	O	O	1516
while	SCONJ	O	O	1516
in	ADP	O	O	1516
women	NOUN	O	O	1516
without	ADP	O	O	1516
hormone	NOUN	O	O	1516
use	VERB	O	O	1516
severe	ADJ	O	O	1516
atherosclerosis	NOUN	O	Disease	1516
of	ADP	O	O	1516
the	PRON	O	O	1516
aorta	NOUN	O	O	1516
was	AUX	O	O	1516
present	NOUN	O	O	1516
in	ADP	O	O	1516
less	ADV	O	O	1516
than	ADP	O	O	1516
20%	NOUN	O	O	1516
(	PUNCT	O	O	1516
OR	CCONJ	O	O	1516
3.1	NUM	O	O	1516
;	PUNCT	O	O	1516
95%	NOUN	O	O	1516
CI	NOUN	O	O	1516
,	PUNCT	O	O	1516
1.1	NUM	O	O	1516
-	PUNCT	O	O	1516
8.5	NUM	O	O	1516
,	PUNCT	O	O	1516
adjusted	VERB	O	O	1516
for	ADP	O	O	1516
age	NOUN	O	O	1516
,	PUNCT	O	O	1516
years	NOUN	O	O	1516
since	SCONJ	O	O	1516
menopause	NOUN	O	O	1516
,	PUNCT	O	O	1516
smoking	VERB	O	O	1516
,	PUNCT	O	O	1516
and	CCONJ	O	O	1516
body	NOUN	O	O	1516
mass	PROPN	O	O	1516
index	NOUN	O	O	1516
)	PUNCT	O	O	1516
.	PUNCT	O	O	1516
The	PRON	O	O	1517
association	PROPN	O	O	1517
remained	VERB	O	O	1517
after	ADP	O	O	1517
additional	ADJ	O	O	1517
adjustment	NOUN	O	O	1517
for	ADP	O	O	1517
diabetes	NOUN	O	Disease	1517
,	PUNCT	O	O	1517
cholesterol	NOUN	O	Chemical	1517
level	VERB	O	O	1517
,	PUNCT	O	O	1517
systolic	ADV	O	O	1517
blood	NOUN	O	O	1517
pressure	NOUN	O	O	1517
,	PUNCT	O	O	1517
or	CCONJ	O	O	1517
alcohol	NOUN	O	Chemical	1517
use	VERB	O	O	1517
.	PUNCT	O	O	1517
CONCLUSION	PROPN	O	O	1518
:	PUNCT	O	O	1518
Our	PRON	O	O	1518
results	VERB	O	O	1518
suggest	VERB	O	O	1518
that	SCONJ	O	O	1518
high	ADJ	O	O	1518
-	PUNCT	O	O	1518
dose	NOUN	O	O	1518
testosterone	PROPN	O	Chemical	1518
therapy	NOUN	O	O	1518
may	AUX	O	O	1518
adversely	ADV	O	O	1518
affect	VERB	O	O	1518
atherosclerosis	NOUN	O	Disease	1518
in	ADP	O	O	1518
postmenopausal	NOUN	O	O	1518
women	NOUN	O	O	1518
and	CCONJ	O	O	1518
indicate	VERB	O	O	1518
that	SCONJ	O	O	1518
androgen	PROPN	O	Chemical	1518
replacement	NOUN	O	O	1518
in	ADP	O	O	1518
these	PRON	O	O	1518
women	NOUN	O	O	1518
may	AUX	O	O	1518
not	PART	O	O	1518
be	AUX	O	O	1518
harmless	ADJ	O	O	1518
.	PUNCT	O	O	1518
Sirolimus	NOUN	O	Chemical	1521
-	PUNCT	O	O	1521
associated	VERB	O	O	1521
proteinuria	X	O	Disease	1521
and	CCONJ	O	O	1521
renal dysfunction	NOUN	O	Disease	1521
.	PUNCT	O	O	1521
Sirolimus	NOUN	O	Chemical	1522
is	AUX	O	O	1522
a	PRON	O	O	1522
novel	NOUN	O	O	1522
immunosuppressant	ADJ	O	O	1522
with	ADP	O	O	1522
potent	ADJ	O	O	1522
antiproliferative	PROPN	O	O	1522
actions	NOUN	O	O	1522
through	ADP	O	O	1522
its	PRON	O	O	1522
ability	NOUN	O	O	1522
to	PART	O	O	1522
inhibit	VERB	O	O	1522
the	PRON	O	O	1522
raptor	NOUN	O	O	1522
-	PUNCT	O	O	1522
containing	VERB	O	O	1522
mammalian	ADJ	O	O	1522
target	NOUN	O	O	1522
of	ADP	O	O	1522
rapamycin	NOUN	O	Chemical	1522
protein	NOUN	O	O	1522
kinase	VERB	O	O	1522
.	PUNCT	O	O	1522
Sirolimus	NOUN	O	Chemical	1523
represents	VERB	O	O	1523
a	PRON	O	O	1523
major	ADJ	O	O	1523
therapeutic	ADJ	O	O	1523
advance	VERB	O	O	1523
in	ADP	O	O	1523
the	PRON	O	O	1523
prevention	NOUN	O	O	1523
of	ADP	O	O	1523
acute	ADJ	O	O	1523
renal	ADJ	O	O	1523
allograft	NOUN	O	O	1523
rejection	NOUN	O	O	1523
and	CCONJ	O	O	1523
chronic	ADJ	O	O	1523
allograft	NOUN	O	O	1523
nephropathy	NOUN	O	Disease	1523
.	PUNCT	O	O	1523
Its	PRON	O	O	1524
role	NOUN	O	O	1524
in	ADP	O	O	1524
the	PRON	O	O	1524
therapy	NOUN	O	O	1524
of	ADP	O	O	1524
glomerulonephritis	NOUN	O	Disease	1524
,	PUNCT	O	O	1524
autoimmunity	NOUN	O	O	1524
,	PUNCT	O	O	1524
cystic	PROPN	O	O	1524
renal diseases	NOUN	O	O	1524
and	CCONJ	O	O	1524
renal	ADJ	O	O	1524
cancer	NOUN	O	Disease	1524
is	AUX	O	O	1524
under	ADP	O	O	1524
investigation	NOUN	O	O	1524
.	PUNCT	O	O	1524
Because	SCONJ	O	O	1525
sirolimus	NOUN	O	Chemical	1525
does	VERB	O	O	1525
not	PART	O	O	1525
share	VERB	O	O	1525
the	PRON	O	O	1525
vasomotor	NOUN	O	O	1525
renal	ADJ	O	O	1525
adverse	ADJ	O	O	1525
effects	NOUN	O	O	1525
exhibited	VERB	O	O	1525
by	ADP	O	O	1525
calcineurin	NOUN	O	O	1525
inhibitors	NOUN	O	O	1525
,	PUNCT	O	O	1525
it	PRON	O	O	1525
has	VERB	O	O	1525
been	AUX	O	O	1525
designated	VERB	O	O	1525
a	PRON	O	O	1525
'	PUNCT	O	O	1525
non	ADJ	O	O	1525
-	PUNCT	O	O	1525
nephrotoxic	NOUN	O	Disease	1525
drug	NOUN	O	O	1525
'	PUNCT	O	O	1525
.	PUNCT	O	O	1525
However	ADV	O	O	1526
,	PUNCT	O	O	1526
clinical	ADJ	O	O	1526
reports	VERB	O	O	1526
suggest	VERB	O	O	1526
that	SCONJ	O	O	1526
,	PUNCT	O	O	1526
under	ADP	O	O	1526
some	PRON	O	O	1526
circumstances	NOUN	O	O	1526
,	PUNCT	O	O	1526
sirolimus	NOUN	O	Chemical	1526
is	AUX	O	O	1526
associated	VERB	O	O	1526
with	ADP	O	O	1526
proteinuria	X	O	Disease	1526
and	CCONJ	O	O	1526
acute	ADJ	O	O	1526
renal dysfunction	NOUN	O	Disease	1526
.	PUNCT	O	O	1526
A	PRON	O	O	1527
common	ADJ	O	O	1527
risk	NOUN	O	O	1527
factor	NOUN	O	O	1527
appears	VERB	O	O	1527
to	PART	O	O	1527
be	AUX	O	O	1527
presence	NOUN	O	O	1527
of	ADP	O	O	1527
pre	VERB	O	O	1527
-	PUNCT	O	O	1527
existing	VERB	O	O	1527
chronic	ADJ	O	O	1527
renal damage	NOUN	O	Disease	1527
.	PUNCT	O	O	1527
The	PRON	O	O	1528
mechanisms	NOUN	O	O	1528
of	ADP	O	O	1528
sirolimus	NOUN	O	Chemical	1528
-	PUNCT	O	O	1528
associated	VERB	O	O	1528
proteinuria	X	O	Disease	1528
are	AUX	O	O	1528
multifactorial	ADJ	O	O	1528
and	CCONJ	O	O	1528
may	AUX	O	O	1528
be	AUX	O	O	1528
due	ADJ	O	O	1528
to	PART	O	O	1528
an	PRON	O	O	1528
increase	VERB	O	O	1528
in	ADP	O	O	1528
glomerular	ADJ	O	O	1528
capillary	NOUN	O	O	1528
pressure	NOUN	O	O	1528
following	VERB	O	O	1528
calcineurin	NOUN	O	O	1528
inhibitor	NOUN	O	O	1528
withdrawal	NOUN	O	O	1528
.	PUNCT	O	O	1528
It	PRON	O	O	1529
has	VERB	O	O	1529
also	ADV	O	O	1529
been	AUX	O	O	1529
suggested	VERB	O	O	1529
that	SCONJ	O	O	1529
sirolimus	NOUN	O	Chemical	1529
directly	ADV	O	O	1529
causes	VERB	O	O	1529
increased	VERB	O	O	1529
glomerular	ADJ	O	O	1529
permeability	NOUN	O	O	1529
/	PUNCT	O	O	1529
injury	NOUN	O	O	1529
,	PUNCT	O	O	1529
but	CCONJ	O	O	1529
evidence	NOUN	O	O	1529
for	ADP	O	O	1529
this	PRON	O	O	1529
mechanism	NOUN	O	O	1529
is	AUX	O	O	1529
currently	ADV	O	O	1529
inconclusive	ADJ	O	O	1529
.	PUNCT	O	O	1529
The	PRON	O	O	1530
acute	ADJ	O	O	1530
renal dysfunction	NOUN	O	Disease	1530
associated	VERB	O	O	1530
with	ADP	O	O	1530
sirolimus	NOUN	O	Chemical	1530
(	PUNCT	O	O	1530
such	ADJ	O	O	1530
as	ADP	O	O	1530
in	ADP	O	O	1530
delayed	VERB	O	O	1530
graft	NOUN	O	O	1530
function	NOUN	O	O	1530
)	PUNCT	O	O	1530
may	AUX	O	O	1530
be	AUX	O	O	1530
due	ADJ	O	O	1530
to	PART	O	O	1530
suppression	NOUN	O	O	1530
of	ADP	O	O	1530
compensatory	ADJ	O	O	1530
renal	ADJ	O	O	1530
cell	NOUN	O	O	1530
proliferation	NOUN	O	O	1530
and	CCONJ	O	O	1530
survival	NOUN	O	O	1530
/	PUNCT	O	O	1530
repair	PROPN	O	O	1530
processes	NOUN	O	O	1530
.	PUNCT	O	O	1530
Although	SCONJ	O	O	1531
these	PRON	O	O	1531
adverse	ADJ	O	O	1531
effects	NOUN	O	O	1531
occur	VERB	O	O	1531
in	ADP	O	O	1531
some	PRON	O	O	1531
patients	NOUN	O	O	1531
,	PUNCT	O	O	1531
their	PRON	O	O	1531
occurrence	NOUN	O	O	1531
could	AUX	O	O	1531
be	AUX	O	O	1531
minimised	VERB	O	O	1531
by	ADP	O	O	1531
knowledge	NOUN	O	O	1531
of	ADP	O	O	1531
the	PRON	O	O	1531
molecular	ADJ	O	O	1531
effects	NOUN	O	O	1531
of	ADP	O	O	1531
sirolimus	NOUN	O	Chemical	1531
on	ADP	O	O	1531
the	PRON	O	O	1531
kidney	NOUN	O	O	1531
,	PUNCT	O	O	1531
the	PRON	O	O	1531
use	VERB	O	O	1531
of	ADP	O	O	1531
sirolimus	NOUN	O	Chemical	1531
in	ADP	O	O	1531
appropriate	ADJ	O	O	1531
patient	NOUN	O	O	1531
populations	NOUN	O	O	1531
,	PUNCT	O	O	1531
close	ADV	O	O	1531
monitoring	NOUN	O	O	1531
of	ADP	O	O	1531
proteinuria	X	O	Disease	1531
and	CCONJ	O	O	1531
renal	ADJ	O	O	1531
function	NOUN	O	O	1531
,	PUNCT	O	O	1531
use	VERB	O	O	1531
of	ADP	O	O	1531
angiotensin	NOUN	O	Chemical	1531
-	PUNCT	O	O	1531
converting	VERB	O	O	1531
enzyme	NOUN	O	O	1531
inhibitors	NOUN	O	O	1531
or	CCONJ	O	O	1531
angiotensin II	PROPN	O	Chemical	1531
receptor	NOUN	O	O	1531
blockers	NOUN	O	O	1531
if	SCONJ	O	O	1531
proteinuria	X	O	Disease	1531
occurs	VERB	O	O	1531
and	CCONJ	O	O	1531
withdrawal	NOUN	O	O	1531
if	SCONJ	O	O	1531
needed	VERB	O	O	1531
.	PUNCT	O	O	1531
Further	ADV	O	O	1532
long	ADV	O	O	1532
-	PUNCT	O	O	1532
term	NOUN	O	O	1532
analysis	NOUN	O	O	1532
of	ADP	O	O	1532
renal	ADJ	O	O	1532
allograft	NOUN	O	O	1532
studies	NOUN	O	O	1532
using	VERB	O	O	1532
sirolimus	NOUN	O	Chemical	1532
as	ADP	O	O	1532
de	VERB	O	O	1532
novo	PROPN	O	O	1532
Progressive	PROPN	O	O	1535
myopathy	PROPN	O	Disease	1535
with	ADP	O	O	1535
up	ADP	O	O	1535
-	PUNCT	O	O	1535
regulation	NOUN	O	O	1535
of	ADP	O	O	1535
MHC	PROPN	O	O	1535
-	PUNCT	O	O	1535
I	PRON	O	O	1535
associated	VERB	O	O	1535
with	ADP	O	O	1535
statin	PROPN	O	O	1535
therapy	NOUN	O	O	1535
.	PUNCT	O	O	1535
Statins	NOUN	O	O	1536
can	AUX	O	O	1536
cause	VERB	O	O	1536
a	PRON	O	O	1536
necrotizing myopathy	NOUN	O	Disease	1536
and	CCONJ	O	O	1536
hyperCKaemia	NOUN	O	O	1536
which	PRON	O	O	1536
is	AUX	O	O	1536
reversible	ADJ	O	O	1536
on	ADP	O	O	1536
cessation	NOUN	O	O	1536
of	ADP	O	O	1536
the	PRON	O	O	1536
drug	NOUN	O	O	1536
.	PUNCT	O	O	1536
What	PRON	O	O	1537
is	AUX	O	O	1537
less	ADV	O	O	1537
well	ADV	O	O	1537
known	VERB	O	O	1537
is	AUX	O	O	1537
a	PRON	O	O	1537
phenomenon	NOUN	O	O	1537
whereby	ADV	O	O	1537
statins	NOUN	O	O	1537
may	AUX	O	O	1537
induce	VERB	O	O	1537
a	PRON	O	O	1537
myopathy	PROPN	O	Disease	1537
,	PUNCT	O	O	1537
which	PRON	O	O	1537
persists	VERB	O	O	1537
or	CCONJ	O	O	1537
may	AUX	O	O	1537
progress	VERB	O	O	1537
after	ADP	O	O	1537
stopping	VERB	O	O	1537
the	PRON	O	O	1537
drug	NOUN	O	O	1537
.	PUNCT	O	O	1537
All	PRON	O	O	1538
had	VERB	O	O	1538
myofibre	NOUN	O	O	1538
necrosis	NOUN	O	Disease	1538
but	CCONJ	O	O	1538
only	ADV	O	O	1538
3	X	O	O	1538
had	VERB	O	O	1538
an	PRON	O	O	1538
inflammatory	ADJ	O	O	1538
infiltrate	VERB	O	O	1538
.	PUNCT	O	O	1538
In	ADP	O	O	1539
all	PRON	O	O	1539
cases	NOUN	O	O	1539
there	ADV	O	O	1539
was	AUX	O	O	1539
diffuse	VERB	O	O	1539
or	CCONJ	O	O	1539
multifocal	ADJ	O	O	1539
up	ADP	O	O	1539
-	PUNCT	O	O	1539
regulation	NOUN	O	O	1539
of	ADP	O	O	1539
MHC	PROPN	O	O	1539
-	PUNCT	O	O	1539
I	PRON	O	O	1539
expression	NOUN	O	O	1539
even	ADV	O	O	1539
in	ADP	O	O	1539
non	ADJ	O	O	1539
-	PUNCT	O	O	1539
necrotic	ADJ	O	O	1539
fibres	NOUN	O	O	1539
.	PUNCT	O	O	1539
Progressive	PROPN	O	O	1540
improvement	NOUN	O	O	1540
occurred	VERB	O	O	1540
in	ADP	O	O	1540
7	NUM	O	O	1540
cases	NOUN	O	O	1540
after	ADP	O	O	1540
commencement	NOUN	O	O	1540
of	ADP	O	O	1540
prednisolone	NOUN	O	Chemical	1540
and	CCONJ	O	O	1540
methotrexate	CCONJ	O	Chemical	1540
,	PUNCT	O	O	1540
and	CCONJ	O	O	1540
in	ADP	O	O	1540
one	NUM	O	O	1540
case	NOUN	O	O	1540
spontaneously	ADV	O	O	1540
.	PUNCT	O	O	1540
These	PRON	O	O	1541
observations	NOUN	O	O	1541
suggest	VERB	O	O	1541
that	SCONJ	O	O	1541
statins	NOUN	O	O	1541
may	AUX	O	O	1541
initiate	VERB	O	O	1541
an	PRON	O	O	1541
immune	NOUN	O	O	1541
-	PUNCT	O	O	1541
mediated	VERB	O	O	1541
myopathy	PROPN	O	Disease	1541
that	SCONJ	O	O	1541
persists	VERB	O	O	1541
after	ADP	O	O	1541
withdrawal	NOUN	O	O	1541
of	ADP	O	O	1541
the	PRON	O	O	1541
drug	NOUN	O	O	1541
and	CCONJ	O	O	1541
responds	VERB	O	O	1541
to	PART	O	O	1541
immunosuppressive	ADJ	O	O	1541
therapy	NOUN	O	O	1541
.	PUNCT	O	O	1541
The	PRON	O	O	1542
mechanism	NOUN	O	O	1542
of	ADP	O	O	1542
this	PRON	O	O	1542
myopathy	PROPN	O	Disease	1542
is	AUX	O	O	1542
uncertain	ADJ	O	O	1542
but	CCONJ	O	O	1542
may	AUX	O	O	1542
involve	VERB	O	O	1542
the	PRON	O	O	1542
induction	NOUN	O	O	1542
by	ADP	O	O	1542
statins	NOUN	O	O	1542
of	ADP	O	O	1542
an	PRON	O	O	1542
endoplasmic	NOUN	O	O	1542
reticulum	NOUN	O	O	1542
stress	NOUN	O	O	1542
response	NOUN	O	O	1542
with	ADP	O	O	1542
associated	VERB	O	O	1542
up	ADP	O	O	1542
-	PUNCT	O	O	1542
regulation	NOUN	O	O	1542
of	ADP	O	O	1542
MHC	PROPN	O	O	1542
-	PUNCT	O	O	1542
I	PRON	O	O	1542
expression	NOUN	O	O	1542
and	CCONJ	O	O	1542
antigen	PROPN	O	O	1542
presentation	NOUN	O	O	1542
by	ADP	O	O	1542
muscle	NOUN	O	O	1542
fibres	NOUN	O	O	1542
.	PUNCT	O	O	1542
Direct	ADJ	O	O	1545
inhibition	NOUN	O	O	1545
of	ADP	O	O	1545
cardiac	ADJ	O	O	1545
hyperpolarization	NOUN	O	O	1545
-	PUNCT	O	O	1545
activated	VERB	O	O	1545
cyclic	PROPN	O	O	1545
nucleotide	NOUN	O	O	1545
-	PUNCT	O	O	1545
gated	VERB	O	O	1545
pacemaker	NOUN	O	O	1545
channels	NOUN	O	O	1545
by	ADP	O	O	1545
clonidine	NOUN	O	Chemical	1545
.	PUNCT	O	O	1545
BACKGROUND	NOUN	O	O	1546
:	PUNCT	O	O	1546
Inhibition	NOUN	O	O	1546
of	ADP	O	O	1546
cardiac	ADJ	O	O	1546
sympathetic	ADJ	O	O	1546
tone	NOUN	O	O	1546
represents	VERB	O	O	1546
an	PRON	O	O	1546
important	ADJ	O	O	1546
strategy	NOUN	O	O	1546
for	ADP	O	O	1546
treatment	NOUN	O	O	1546
of	ADP	O	O	1546
cardiovascular disease	NOUN	O	Disease	1546
,	PUNCT	O	O	1546
including	VERB	O	O	1546
arrhythmia	NOUN	O	Disease	1546
,	PUNCT	O	O	1546
coronary	ADJ	O	O	1546
heart disease	NOUN	O	Disease	1546
,	PUNCT	O	O	1546
and	CCONJ	O	O	1546
chronic	ADJ	O	O	1546
heart failure	NOUN	O	Disease	1546
.	PUNCT	O	O	1546
Activation	NOUN	O	O	1547
of	ADP	O	O	1547
presynaptic	ADJ	O	O	1547
alpha2-adrenoceptors	NOUN	O	O	1547
is	AUX	O	O	1547
the	PRON	O	O	1547
most	ADV	O	O	1547
widely	ADV	O	O	1547
accepted	VERB	O	O	1547
mechanism	NOUN	O	O	1547
of	ADP	O	O	1547
action	NOUN	O	O	1547
of	ADP	O	O	1547
the	PRON	O	O	1547
antisympathetic	ADJ	O	O	1547
drug	NOUN	O	O	1547
clonidine	NOUN	O	Chemical	1547
;	PUNCT	O	O	1547
however	ADV	O	O	1547
,	PUNCT	O	O	1547
other	ADJ	O	O	1547
target	NOUN	O	O	1547
proteins	NOUN	O	O	1547
have	VERB	O	O	1547
been	AUX	O	O	1547
postulated	VERB	O	O	1547
to	PART	O	O	1547
contribute	VERB	O	O	1547
to	PART	O	O	1547
the	PRON	O	O	1547
in	ADP	O	O	1547
vivo	VERB	O	O	1547
actions	NOUN	O	O	1547
of	ADP	O	O	1547
clonidine	NOUN	O	Chemical	1547
.	PUNCT	O	O	1547
METHODS	NOUN	O	O	1548
AND	CCONJ	O	O	1548
RESULTS	VERB	O	O	1548
:	PUNCT	O	O	1548
To	PART	O	O	1548
test	NOUN	O	O	1548
whether	SCONJ	O	O	1548
clonidine	NOUN	O	Chemical	1548
elicits	VERB	O	O	1548
pharmacological	ADJ	O	O	1548
effects	NOUN	O	O	1548
independent	ADJ	O	O	1548
of	ADP	O	O	1548
alpha2-adrenoceptors	NOUN	O	O	1548
,	PUNCT	O	O	1548
we	PRON	O	O	1548
have	VERB	O	O	1548
generated	VERB	O	O	1548
mice	NOUN	O	O	1548
with	ADP	O	O	1548
a	PRON	O	O	1548
targeted	VERB	O	O	1548
deletion	NOUN	O	O	1548
of	ADP	O	O	1548
all	PRON	O	O	1548
3	X	O	O	1548
alpha2-adrenoceptor	NOUN	O	O	1548
subtypes	NOUN	O	O	1548
(	PUNCT	O	O	1548
alpha2ABC-/-	ADJ	O	O	1548
)	PUNCT	O	O	1548
.	PUNCT	O	O	1548
Alpha2ABC-/-	PROPN	O	O	1549
mice	NOUN	O	O	1549
were	AUX	O	O	1549
completely	ADV	O	O	1549
unresponsive	ADJ	O	O	1549
to	PART	O	O	1549
the	PRON	O	O	1549
analgesic	PROPN	O	O	1549
and	CCONJ	O	O	1549
hypnotic	ADJ	O	O	1549
effects	NOUN	O	O	1549
of	ADP	O	O	1549
clonidine	NOUN	O	Chemical	1549
;	PUNCT	O	O	1549
however	ADV	O	O	1549
,	PUNCT	O	O	1549
clonidine	NOUN	O	Chemical	1549
significantly	ADV	O	O	1549
lowered	VERB	O	O	1549
heart	NOUN	O	O	1549
rate	NOUN	O	O	1549
in	ADP	O	O	1549
alpha2ABC-/-	ADJ	O	O	1549
mice	NOUN	O	O	1549
by	ADP	O	O	1549
up	ADP	O	O	1549
to	PART	O	O	1549
150	NUM	O	O	1549
bpm	VERB	O	O	1549
.	PUNCT	O	O	1549
Clonidine	NOUN	O	Chemical	1550
-	PUNCT	O	O	1550
induced	VERB	O	O	1550
bradycardia	NOUN	O	Disease	1550
in	ADP	O	O	1550
conscious	ADJ	O	O	1550
alpha2ABC-/-	ADJ	O	O	1550
mice	NOUN	O	O	1550
was	AUX	O	O	1550
32.3%	NOUN	O	O	1550
(	PUNCT	O	O	1550
10	NUM	O	O	1550
microg	PROPN	O	O	1550
/	PUNCT	O	O	1550
kg	VERB	O	O	1550
)	PUNCT	O	O	1550
and	CCONJ	O	O	1550
26.6%	NOUN	O	O	1550
(	PUNCT	O	O	1550
100	NUM	O	O	1550
microg	PROPN	O	O	1550
/	PUNCT	O	O	1550
kg	VERB	O	O	1550
)	PUNCT	O	O	1550
of	ADP	O	O	1550
the	PRON	O	O	1550
effect	VERB	O	O	1550
in	ADP	O	O	1550
wild	ADJ	O	O	1550
-	PUNCT	O	O	1550
type	NOUN	O	O	1550
mice	NOUN	O	O	1550
.	PUNCT	O	O	1550
A	PRON	O	O	1551
similar	ADJ	O	O	1551
bradycardic	NOUN	O	O	1551
effect	VERB	O	O	1551
of	ADP	O	O	1551
clonidine	NOUN	O	Chemical	1551
was	AUX	O	O	1551
observed	VERB	O	O	1551
in	ADP	O	O	1551
isolated	VERB	O	O	1551
spontaneously	ADV	O	O	1551
beating	VERB	O	O	1551
right	ADV	O	O	1551
atria	ADV	O	O	1551
from	ADP	O	O	1551
alpha2ABC	PROPN	O	O	1551
-	PUNCT	O	O	1551
knockout	NOUN	O	O	1551
and	CCONJ	O	O	1551
wild	ADJ	O	O	1551
-	PUNCT	O	O	1551
type	NOUN	O	O	1551
mice	NOUN	O	O	1551
.	PUNCT	O	O	1551
Clonidine	NOUN	O	Chemical	1552
inhibited	VERB	O	O	1552
the	PRON	O	O	1552
native	ADJ	O	O	1552
pacemaker	NOUN	O	O	1552
current	ADJ	O	O	1552
(	PUNCT	O	O	1552
I(f	NOUN	O	O	1552
)	PUNCT	O	O	1552
)	PUNCT	O	O	1552
in	ADP	O	O	1552
isolated	VERB	O	O	1552
sinoatrial	NOUN	O	O	1552
node	NOUN	O	O	1552
pacemaker	NOUN	O	O	1552
cells	NOUN	O	O	1552
and	CCONJ	O	O	1552
the	PRON	O	O	1552
I(f)-generating	VERB	O	O	1552
hyperpolarization	NOUN	O	O	1552
-	PUNCT	O	O	1552
activated	VERB	O	O	1552
cyclic	PROPN	O	O	1552
nucleotide	NOUN	O	O	1552
-	PUNCT	O	O	1552
gated	VERB	O	O	1552
(	PUNCT	O	O	1552
HCN	NOUN	O	O	1552
)	PUNCT	O	O	1552
2	X	O	O	1552
and	CCONJ	O	O	1552
HCN4	PROPN	O	O	1552
channels	NOUN	O	O	1552
in	ADP	O	O	1552
transfected	VERB	O	O	1552
HEK293	PROPN	O	O	1552
cells	NOUN	O	O	1552
.	PUNCT	O	O	1552
As	ADP	O	O	1553
a	PRON	O	O	1553
consequence	NOUN	O	O	1553
of	ADP	O	O	1553
blocking	VERB	O	O	1553
I(f	NOUN	O	O	1553
)	PUNCT	O	O	1553
,	PUNCT	O	O	1553
clonidine	NOUN	O	Chemical	1553
reduced	VERB	O	O	1553
the	PRON	O	O	1553
slope	NOUN	O	O	1553
of	ADP	O	O	1553
the	PRON	O	O	1553
diastolic	ADV	O	O	1553
depolarization	NOUN	O	O	1553
and	CCONJ	O	O	1553
the	PRON	O	O	1553
frequency	NOUN	O	O	1553
of	ADP	O	O	1553
pacemaker	NOUN	O	O	1553
potentials	NOUN	O	O	1553
in	ADP	O	O	1553
sinoatrial	NOUN	O	O	1553
node	NOUN	O	O	1553
cells	NOUN	O	O	1553
from	ADP	O	O	1553
wild	ADJ	O	O	1553
-	PUNCT	O	O	1553
type	NOUN	O	O	1553
and	CCONJ	O	O	1553
alpha2ABC	PROPN	O	O	1553
-	PUNCT	O	O	1553
knockout	NOUN	O	O	1553
mice	NOUN	O	O	1553
.	PUNCT	O	O	1553
Direct	ADJ	O	O	1554
inhibition	NOUN	O	O	1554
of	ADP	O	O	1554
cardiac	ADJ	O	O	1554
HCN	NOUN	O	O	1554
pacemaker	NOUN	O	O	1554
channels	NOUN	O	O	1554
contributes	VERB	O	O	1554
to	PART	O	O	1554
the	PRON	O	O	1554
bradycardic	NOUN	O	O	1554
effects	NOUN	O	O	1554
of	ADP	O	O	1554
clonidine	NOUN	O	Chemical	1554
gene	NOUN	O	O	1554
-	PUNCT	O	O	1554
targeted	VERB	O	O	1554
mice	NOUN	O	O	1554
in	ADP	O	O	1554
vivo	VERB	O	O	1554
,	PUNCT	O	O	1554
and	CCONJ	O	O	1554
thus	ADV	O	O	1554
,	PUNCT	O	O	1554
clonidine	NOUN	O	Chemical	1554
-	PUNCT	O	O	1554
like	INTJ	O	O	1554
drugs	NOUN	O	O	1554
represent	VERB	O	O	1554
novel	NOUN	O	O	1554
structures	NOUN	O	O	1554
for	ADP	O	O	1554
future	NOUN	O	O	1554
HCN	NOUN	O	O	1554
channel	PROPN	O	O	1554
inhibitors	NOUN	O	O	1554
.	PUNCT	O	O	1554
Influence	NOUN	O	O	1557
of	ADP	O	O	1557
smoking	VERB	O	O	1557
on	ADP	O	O	1557
developing	VERB	O	O	1557
cochlea	NOUN	O	O	1557
.	PUNCT	O	O	1557
Does	VERB	O	O	1558
smoking	VERB	O	O	1558
during	ADP	O	O	1558
pregnancy	NOUN	O	O	1558
affect	VERB	O	O	1558
the	PRON	O	O	1558
amplitudes	NOUN	O	O	1558
of	ADP	O	O	1558
transient	ADJ	O	O	1558
evoked	VERB	O	O	1558
otoacoustic	ADJ	O	O	1558
emissions	NOUN	O	O	1558
in	ADP	O	O	1558
newborns	NOUN	O	O	1558
?	PUNCT	O	O	1558
Maternal	ADJ	O	O	1559
tobacco	NOUN	O	O	1559
smoking	VERB	O	O	1559
has	VERB	O	O	1559
negative	ADJ	O	O	1559
effects	NOUN	O	O	1559
on	ADP	O	O	1559
fetal	ADJ	O	O	1559
growth	NOUN	O	O	1559
.	PUNCT	O	O	1559
The	PRON	O	O	1560
influence	NOUN	O	O	1560
of	ADP	O	O	1560
smoking	VERB	O	O	1560
during	ADP	O	O	1560
pregnancy	NOUN	O	O	1560
on	ADP	O	O	1560
the	PRON	O	O	1560
developing	VERB	O	O	1560
cochlea	NOUN	O	O	1560
has	VERB	O	O	1560
not	PART	O	O	1560
been	AUX	O	O	1560
estimated	VERB	O	O	1560
,	PUNCT	O	O	1560
although	SCONJ	O	O	1560
smoking	VERB	O	O	1560
has	VERB	O	O	1560
been	AUX	O	O	1560
positively	ADV	O	O	1560
associated	VERB	O	O	1560
with	ADP	O	O	1560
hearing loss	NOUN	O	Disease	1560
in	ADP	O	O	1560
adults	NOUN	O	O	1560
.	PUNCT	O	O	1560
The	PRON	O	O	1561
objective	VERB	O	O	1561
of	ADP	O	O	1561
this	PRON	O	O	1561
study	VERB	O	O	1561
was	AUX	O	O	1561
to	PART	O	O	1561
determine	VERB	O	O	1561
the	PRON	O	O	1561
effects	NOUN	O	O	1561
of	ADP	O	O	1561
maternal	ADJ	O	O	1561
smoking	VERB	O	O	1561
on	ADP	O	O	1561
transient	ADJ	O	O	1561
evoked	VERB	O	O	1561
otoacoustic	ADJ	O	O	1561
emissions	NOUN	O	O	1561
(	PUNCT	O	O	1561
TEOAEs	NOUN	O	O	1561
)	PUNCT	O	O	1561
of	ADP	O	O	1561
healthy	ADJ	O	O	1561
neonates	NOUN	O	O	1561
.	PUNCT	O	O	1561
This	PRON	O	O	1562
study	VERB	O	O	1562
was	AUX	O	O	1562
undertaken	VERB	O	O	1562
as	ADP	O	O	1562
part	NOUN	O	O	1562
of	ADP	O	O	1562
neonatal	NOUN	O	O	1562
screening	VERB	O	O	1562
for	ADP	O	O	1562
hearing impairment	NOUN	O	Disease	1562
and	CCONJ	O	O	1562
involved	VERB	O	O	1562
both	PRON	O	O	1562
ears	NOUN	O	O	1562
of	ADP	O	O	1562
200	NUM	O	O	1562
newborns	NOUN	O	O	1562
.	PUNCT	O	O	1562
Newborns	NOUN	O	O	1563
whose	DET	O	O	1563
mothers	NOUN	O	O	1563
reported	VERB	O	O	1563
smoking	VERB	O	O	1563
during	ADP	O	O	1563
pregnancy	NOUN	O	O	1563
(	PUNCT	O	O	1563
n=200	NUM	O	O	1563
ears	NOUN	O	O	1563
)	PUNCT	O	O	1563
were	AUX	O	O	1563
compared	VERB	O	O	1563
to	PART	O	O	1563
a	PRON	O	O	1563
control	VERB	O	O	1563
group	NOUN	O	O	1563
of	ADP	O	O	1563
newborns	NOUN	O	O	1563
(	PUNCT	O	O	1563
n=200	NUM	O	O	1563
ears	NOUN	O	O	1563
)	PUNCT	O	O	1563
,	PUNCT	O	O	1563
whose	DET	O	O	1563
mothers	NOUN	O	O	1563
were	AUX	O	O	1563
non	ADJ	O	O	1563
-	PUNCT	O	O	1563
smokers	NOUN	O	O	1563
.	PUNCT	O	O	1563
However	ADV	O	O	1564
,	PUNCT	O	O	1564
by	ADP	O	O	1564
comparing	VERB	O	O	1564
each	PRON	O	O	1564
subgroup	PROPN	O	O	1564
to	PART	O	O	1564
control	VERB	O	O	1564
group	NOUN	O	O	1564
,	PUNCT	O	O	1564
we	PRON	O	O	1564
found	VERB	O	O	1564
statistically	ADV	O	O	1564
significant	ADJ	O	O	1564
decreases	VERB	O	O	1564
of	ADP	O	O	1564
TEOAEs	NOUN	O	O	1564
amplitudes	NOUN	O	O	1564
at	ADP	O	O	1564
4000Hz	NUM	O	O	1564
for	ADP	O	O	1564
all	PRON	O	O	1564
three	NUM	O	O	1564
groups	NOUN	O	O	1564
.	PUNCT	O	O	1564
In	ADP	O	O	1565
utero	NOUN	O	O	1565
,	PUNCT	O	O	1565
exposure	NOUN	O	O	1565
to	PART	O	O	1565
tobacco	NOUN	O	O	1565
smoking	VERB	O	O	1565
seems	VERB	O	O	1565
to	PART	O	O	1565
have	VERB	O	O	1565
a	PRON	O	O	1565
small	ADJ	O	O	1565
impact	NOUN	O	O	1565
on	ADP	O	O	1565
outer	NOUN	O	O	1565
hair	NOUN	O	O	1565
cells	NOUN	O	O	1565
.	PUNCT	O	O	1565
Further	ADV	O	O	1566
studies	NOUN	O	O	1566
are	AUX	O	O	1566
needed	VERB	O	O	1566
in	ADP	O	O	1566
order	NOUN	O	O	1566
to	PART	O	O	1566
establish	VERB	O	O	1566
a	PRON	O	O	1566
potential	ADJ	O	O	1566
negative	ADJ	O	O	1566
effect	VERB	O	O	1566
of	ADP	O	O	1566
maternal	ADJ	O	O	1566
smoking	VERB	O	O	1566
on	ADP	O	O	1566
the	PRON	O	O	1566
neonate	NOUN	O	O	1566
's	AUX	O	O	1566
hearing	NOUN	O	O	1566
acuity	NOUN	O	O	1566
.	PUNCT	O	O	1566
Neuroinflammation	NOUN	O	O	1569
and	CCONJ	O	O	1569
behavioral	ADJ	O	O	1569
abnormalities	NOUN	O	O	1569
after	ADP	O	O	1569
neonatal	NOUN	O	O	1569
terbutaline	NOUN	O	Chemical	1569
treatment	NOUN	O	O	1569
in	ADP	O	O	1569
rats	NOUN	O	O	1569
:	PUNCT	O	O	1569
implications	NOUN	O	O	1569
for	ADP	O	O	1569
autism	NOUN	O	O	1569
.	PUNCT	O	O	1569
Autism	NOUN	O	O	1570
is	AUX	O	O	1570
a	PRON	O	O	1570
neurodevelopmental	ADJ	O	O	1570
disorder	NOUN	O	O	1570
presenting	VERB	O	O	1570
before	ADP	O	O	1570
3	X	O	O	1570
years	NOUN	O	O	1570
of	ADP	O	O	1570
age	NOUN	O	O	1570
with	ADP	O	O	1570
deficits	NOUN	O	O	1570
in	ADP	O	O	1570
communication	NOUN	O	O	1570
and	CCONJ	O	O	1570
social	ADJ	O	O	1570
skills	NOUN	O	O	1570
and	CCONJ	O	O	1570
repetitive	ADJ	O	O	1570
behaviors	NOUN	O	O	1570
.	PUNCT	O	O	1570
In	ADP	O	O	1571
addition	NOUN	O	O	1571
to	PART	O	O	1571
genetic	ADJ	O	O	1571
influences	NOUN	O	O	1571
,	PUNCT	O	O	1571
recent	ADJ	O	O	1571
studies	NOUN	O	O	1571
suggest	VERB	O	O	1571
that	SCONJ	O	O	1571
prenatal	ADJ	O	O	1571
drug	NOUN	O	O	1571
or	CCONJ	O	O	1571
chemical	PROPN	O	O	1571
exposures	NOUN	O	O	1571
are	AUX	O	O	1571
risk	NOUN	O	O	1571
factors	NOUN	O	O	1571
for	ADP	O	O	1571
autism	NOUN	O	O	1571
.	PUNCT	O	O	1571
Terbutaline	NOUN	O	O	1572
,	PUNCT	O	O	1572
a	PRON	O	O	1572
beta2-adrenoceptor	NOUN	O	O	1572
agonist	NOUN	O	O	1572
used	VERB	O	O	1572
to	PART	O	O	1572
arrest	VERB	O	O	1572
preterm	NOUN	O	O	1572
labor	NOUN	O	O	1572
,	PUNCT	O	O	1572
has	VERB	O	O	1572
been	AUX	O	O	1572
associated	VERB	O	O	1572
with	ADP	O	O	1572
increased	VERB	O	O	1572
concordance	NOUN	O	O	1572
for	ADP	O	O	1572
autism	NOUN	O	O	1572
in	ADP	O	O	1572
dizygotic	ADJ	O	O	1572
twins	NOUN	O	O	1572
.	PUNCT	O	O	1572
We	PRON	O	O	1573
studied	VERB	O	O	1573
the	PRON	O	O	1573
effects	NOUN	O	O	1573
of	ADP	O	O	1573
terbutaline	NOUN	O	Chemical	1573
on	ADP	O	O	1573
microglial	PROPN	O	O	1573
activation	NOUN	O	O	1573
in	ADP	O	O	1573
different	ADJ	O	O	1573
brain	NOUN	O	O	1573
regions	NOUN	O	O	1573
and	CCONJ	O	O	1573
behavioral	ADJ	O	O	1573
outcomes	NOUN	O	O	1573
in	ADP	O	O	1573
developing	VERB	O	O	1573
rats	NOUN	O	O	1573
.	PUNCT	O	O	1573
Newborn	ADJ	O	O	1574
rats	NOUN	O	O	1574
were	AUX	O	O	1574
given	VERB	O	O	1574
terbutaline	NOUN	O	Chemical	1574
(	PUNCT	O	O	1574
10	NUM	O	O	1574
mg	VERB	O	O	1574
/	PUNCT	O	O	1574
kg	VERB	O	O	1574
)	PUNCT	O	O	1574
daily	ADV	O	O	1574
on	ADP	O	O	1574
postnatal	ADJ	O	O	1574
days	NOUN	O	O	1574
(	PUNCT	O	O	1574
PN	PROPN	O	O	1574
)	PUNCT	O	O	1574
2	X	O	O	1574
to	PART	O	O	1574
5	NUM	O	O	1574
or	CCONJ	O	O	1574
PN	PROPN	O	O	1574
11	NUM	O	O	1574
to	PART	O	O	1574
14	NUM	O	O	1574
and	CCONJ	O	O	1574
examined	VERB	O	O	1574
24	NUM	O	O	1574
h	X	O	O	1574
after	ADP	O	O	1574
the	PRON	O	O	1574
last	VERB	O	O	1574
dose	NOUN	O	O	1574
and	CCONJ	O	O	1574
at	ADP	O	O	1574
PN	PROPN	O	O	1574
30	NUM	O	O	1574
.	PUNCT	O	O	1574
Immunohistochemical	PROPN	O	O	1575
studies	NOUN	O	O	1575
showed	VERB	O	O	1575
that	SCONJ	O	O	1575
administration	NOUN	O	O	1575
of	ADP	O	O	1575
terbutaline	NOUN	O	Chemical	1575
on	ADP	O	O	1575
PN	PROPN	O	O	1575
2	X	O	O	1575
to	PART	O	O	1575
5	NUM	O	O	1575
produced	VERB	O	O	1575
a	PRON	O	O	1575
robust	ADJ	O	O	1575
increase	VERB	O	O	1575
in	ADP	O	O	1575
microglial	PROPN	O	O	1575
activation	NOUN	O	O	1575
on	ADP	O	O	1575
PN	PROPN	O	O	1575
30	NUM	O	O	1575
in	ADP	O	O	1575
the	PRON	O	O	1575
cerebral	ADJ	O	O	1575
cortex	VERB	O	O	1575
,	PUNCT	O	O	1575
as	ADP	O	O	1575
well	ADV	O	O	1575
as	ADP	O	O	1575
in	ADP	O	O	1575
cerebellar	ADJ	O	O	1575
and	CCONJ	O	O	1575
cerebrocortical	ADJ	O	O	1575
white	ADJ	O	O	1575
matter	VERB	O	O	1575
.	PUNCT	O	O	1575
None	NOUN	O	O	1576
of	ADP	O	O	1576
these	PRON	O	O	1576
effects	NOUN	O	O	1576
occurred	VERB	O	O	1576
in	ADP	O	O	1576
animals	NOUN	O	O	1576
given	VERB	O	O	1576
terbutaline	NOUN	O	Chemical	1576
on	ADP	O	O	1576
PN	PROPN	O	O	1576
11	NUM	O	O	1576
to	PART	O	O	1576
14	NUM	O	O	1576
.	PUNCT	O	O	1576
In	ADP	O	O	1577
behavioral	ADJ	O	O	1577
tests	VERB	O	O	1577
,	PUNCT	O	O	1577
animals	NOUN	O	O	1577
treated	VERB	O	O	1577
with	ADP	O	O	1577
terbutaline	NOUN	O	Chemical	1577
on	ADP	O	O	1577
PN	PROPN	O	O	1577
2	X	O	O	1577
to	PART	O	O	1577
5	NUM	O	O	1577
showed	VERB	O	O	1577
consistent	ADJ	O	O	1577
patterns	NOUN	O	O	1577
of	ADP	O	O	1577
hyper	ADJ	O	O	1577
-	PUNCT	O	O	1577
reactivity	NOUN	O	O	1577
to	PART	O	O	1577
novelty	NOUN	O	O	1577
and	CCONJ	O	O	1577
aversive	ADJ	O	O	1577
stimuli	NOUN	O	O	1577
when	SCONJ	O	O	1577
assessed	VERB	O	O	1577
in	ADP	O	O	1577
a	PRON	O	O	1577
novel	NOUN	O	O	1577
open	VERB	O	O	1577
field	NOUN	O	O	1577
,	PUNCT	O	O	1577
as	ADP	O	O	1577
well	ADV	O	O	1577
as	ADP	O	O	1577
in	ADP	O	O	1577
the	PRON	O	O	1577
acoustic	ADJ	O	O	1577
startle	VERB	O	Disease	1577
response	NOUN	O	O	1577
test	NOUN	O	O	1577
.	PUNCT	O	O	1577
Our	PRON	O	O	1578
findings	NOUN	O	O	1578
indicate	VERB	O	O	1578
that	SCONJ	O	O	1578
beta2-adrenoceptor	NOUN	O	O	1578
overstimulation	NOUN	O	O	1578
during	ADP	O	O	1578
an	PRON	O	O	1578
early	ADV	O	O	1578
critical	ADJ	O	O	1578
period	NOUN	O	O	1578
results	VERB	O	O	1578
in	ADP	O	O	1578
microglial	PROPN	O	O	1578
activation	NOUN	O	O	1578
associated	VERB	O	O	1578
with	ADP	O	O	1578
innate	VERB	O	O	1578
neuroinflammatory	NOUN	O	O	1578
pathways	NOUN	O	O	1578
and	CCONJ	O	O	1578
behavioral	ADJ	O	O	1578
abnormalities	NOUN	O	O	1578
,	PUNCT	O	O	1578
similar	ADJ	O	O	1578
to	PART	O	O	1578
those	PRON	O	O	1578
described	VERB	O	O	1578
in	ADP	O	O	1578
autism	NOUN	O	O	1578
.	PUNCT	O	O	1578
This	PRON	O	O	1579
study	VERB	O	O	1579
provides	VERB	O	O	1579
a	PRON	O	O	1579
useful	ADJ	O	O	1579
animal	NOUN	O	O	1579
model	NOUN	O	O	1579
for	ADP	O	O	1579
understanding	NOUN	O	O	1579
the	PRON	O	O	1579
neuropathological	PROPN	O	O	1579
processes	NOUN	O	O	1579
underlying	VERB	O	O	1579
autism	NOUN	O	O	1579
spectrum	NOUN	O	O	1579
disorders	NOUN	O	O	1579
.	PUNCT	O	O	1579
Acute	PROPN	O	O	1582
myocarditis	ADV	O	Disease	1582
associated	VERB	O	O	1582
with	ADP	O	O	1582
clozapine	PROPN	O	Chemical	1582
.	PUNCT	O	O	1582
A	PRON	O	O	1583
case	NOUN	O	O	1583
of	ADP	O	O	1583
acute	ADJ	O	O	1583
myocarditis	ADV	O	Disease	1583
associated	VERB	O	O	1583
with	ADP	O	O	1583
the	PRON	O	O	1583
commencement	NOUN	O	O	1583
of	ADP	O	O	1583
clozapine	PROPN	O	Chemical	1583
is	AUX	O	O	1583
described	VERB	O	O	1583
,	PUNCT	O	O	1583
highlighting	VERB	O	O	1583
the	PRON	O	O	1583
onset	VERB	O	O	1583
,	PUNCT	O	O	1583
course	NOUN	O	O	1583
and	CCONJ	O	O	1583
possible	ADJ	O	O	1583
contributing	VERB	O	O	1583
factors	NOUN	O	O	1583
.	PUNCT	O	O	1583
There	ADV	O	O	1584
is	AUX	O	O	1584
an	PRON	O	O	1584
urgent	ADJ	O	O	1584
need	VERB	O	O	1584
to	PART	O	O	1584
raise	VERB	O	O	1584
awareness	NOUN	O	O	1584
about	ADP	O	O	1584
this	PRON	O	O	1584
potentially	ADV	O	O	1584
fatal	ADJ	O	O	1584
complication	NOUN	O	O	1584
of	ADP	O	O	1584
clozapine	PROPN	O	Chemical	1584
use	VERB	O	O	1584
.	PUNCT	O	O	1584
A	PRON	O	O	1585
20-year	NOUN	O	O	1585
-	PUNCT	O	O	1585
old	ADJ	O	O	1585
male	NOUN	O	O	1585
with	ADP	O	O	1585
schizophrenia	PROPN	O	Disease	1585
developed	VERB	O	O	1585
a	PRON	O	O	1585
sudden	ADJ	O	O	1585
onset	VERB	O	O	1585
of	ADP	O	O	1585
myocarditis	ADV	O	Disease	1585
after	ADP	O	O	1585
commencement	NOUN	O	O	1585
of	ADP	O	O	1585
clozapine	PROPN	O	Chemical	1585
.	PUNCT	O	O	1585
The	PRON	O	O	1586
symptoms	NOUN	O	O	1586
occurred	VERB	O	O	1586
around	ADV	O	O	1586
2	X	O	O	1586
weeks	NOUN	O	O	1586
after	ADP	O	O	1586
starting	VERB	O	O	1586
clozapine	PROPN	O	Chemical	1586
in	ADP	O	O	1586
an	PRON	O	O	1586
inpatient	ADJ	O	O	1586
setting	VERB	O	O	1586
.	PUNCT	O	O	1586
Possible	ADJ	O	O	1587
contributing	VERB	O	O	1587
factors	NOUN	O	O	1587
may	AUX	O	O	1587
have	VERB	O	O	1587
been	AUX	O	O	1587
concomitant	ADJ	O	O	1587
antidepressant	NOUN	O	O	1587
use	VERB	O	O	1587
and	CCONJ	O	O	1587
unaccustomed	ADJ	O	O	1587
physical	ADJ	O	O	1587
activity	NOUN	O	O	1587
.	PUNCT	O	O	1587
Myocarditis	PROPN	O	Disease	1588
is	AUX	O	O	1588
an	PRON	O	O	1588
increasingly	ADV	O	O	1588
recognized	VERB	O	O	1588
complication	NOUN	O	O	1588
associated	VERB	O	O	1588
with	ADP	O	O	1588
the	PRON	O	O	1588
use	VERB	O	O	1588
of	ADP	O	O	1588
clozapine	PROPN	O	Chemical	1588
.	PUNCT	O	O	1588
Considering	VERB	O	O	1589
that	SCONJ	O	O	1589
clozapine	PROPN	O	Chemical	1589
remains	VERB	O	O	1589
the	PRON	O	O	1589
gold	NOUN	O	Chemical	1589
standard	PROPN	O	O	1589
in	ADP	O	O	1589
treatment	NOUN	O	O	1589
of	ADP	O	O	1589
resistant	ADJ	O	O	1589
psychosis	VERB	O	Disease	1589
,	PUNCT	O	O	1589
there	ADV	O	O	1589
is	AUX	O	O	1589
an	PRON	O	O	1589
urgent	ADJ	O	O	1589
need	VERB	O	O	1589
to	PART	O	O	1589
raise	VERB	O	O	1589
awareness	NOUN	O	O	1589
among	ADP	O	O	1589
medical	ADJ	O	O	1589
and	CCONJ	O	O	1589
paramedical	ADJ	O	O	1589
staff	NOUN	O	O	1589
involved	VERB	O	O	1589
in	ADP	O	O	1589
the	PRON	O	O	1589
care	VERB	O	O	1589
of	ADP	O	O	1589
these	PRON	O	O	1589
patients	NOUN	O	O	1589
.	PUNCT	O	O	1589
There	ADV	O	O	1590
are	AUX	O	O	1590
also	ADV	O	O	1590
implications	NOUN	O	O	1590
for	ADP	O	O	1590
recommendations	NOUN	O	O	1590
and	CCONJ	O	O	1590
regulations	NOUN	O	O	1590
regarding	VERB	O	O	1590
the	PRON	O	O	1590
use	VERB	O	O	1590
of	ADP	O	O	1590
clozapine	PROPN	O	Chemical	1590
.	PUNCT	O	O	1590
Encephalopathy	NOUN	O	O	1593
induced	VERB	O	O	1593
by	ADP	O	O	1593
levetiracetam	VERB	O	O	1593
added	VERB	O	O	1593
to	PART	O	O	1593
valproate	VERB	O	Chemical	1593
.	PUNCT	O	O	1593
BACKGROUND	NOUN	O	O	1594
:	PUNCT	O	O	1594
We	PRON	O	O	1594
report	VERB	O	O	1594
on	ADP	O	O	1594
the	PRON	O	O	1594
manifestation	NOUN	O	O	1594
of	ADP	O	O	1594
a	PRON	O	O	1594
levetiracetam	VERB	O	O	1594
(	PUNCT	O	O	1594
LEV)-induced	PROPN	O	O	1594
encephalopathy	NOUN	O	Disease	1594
.	PUNCT	O	O	1594
A	PRON	O	O	1595
28-year	NOUN	O	O	1595
-	PUNCT	O	O	1595
old	ADJ	O	O	1595
man	NOUN	O	O	1595
suffering	VERB	O	O	1595
from	ADP	O	O	1595
idiopathic	ADJ	O	O	1595
epilepsy	NOUN	O	Disease	1595
with	ADP	O	O	1595
generalized	VERB	O	O	1595
seizures	NOUN	O	Disease	1595
was	AUX	O	O	1595
treated	VERB	O	O	1595
with	ADP	O	O	1595
LEV	PROPN	O	O	1595
(	PUNCT	O	O	1595
3000	NUM	O	O	1595
mg	VERB	O	O	1595
)	PUNCT	O	O	1595
added	VERB	O	O	1595
to	PART	O	O	1595
valproate	VERB	O	Chemical	1595
(	PUNCT	O	O	1595
VPA	PROPN	O	Chemical	1595
)	PUNCT	O	O	1595
(	PUNCT	O	O	1595
2000	NUM	O	O	1595
mg	VERB	O	O	1595
)	PUNCT	O	O	1595
.	PUNCT	O	O	1595
Frequency	NOUN	O	O	1596
of	ADP	O	O	1596
generalized	VERB	O	O	1596
tonic	PROPN	O	O	1596
-	PUNCT	O	O	1596
clonic	ADJ	O	O	1596
seizures	NOUN	O	Disease	1596
increased	VERB	O	O	1596
from	ADP	O	O	1596
one	NUM	O	O	1596
per	ADP	O	O	1596
6	NUM	O	O	1596
months	NOUN	O	O	1596
to	PART	O	O	1596
two	NUM	O	O	1596
per	ADP	O	O	1596
month	NOUN	O	O	1596
.	PUNCT	O	O	1596
Neuropsychological	NOUN	O	O	1597
testing	NOUN	O	O	1597
showed	VERB	O	O	1597
impaired	VERB	O	O	1597
word	NOUN	O	O	1597
fluency	NOUN	O	O	1597
,	PUNCT	O	O	1597
psychomotor	NOUN	O	O	1597
speed	NOUN	O	O	1597
and	CCONJ	O	O	1597
working	VERB	O	O	1597
memory	NOUN	O	O	1597
.	PUNCT	O	O	1597
Following	VERB	O	O	1598
discontinuation	NOUN	O	O	1598
of	ADP	O	O	1598
LEV	PROPN	O	O	1598
,	PUNCT	O	O	1598
EEG	NOUN	O	O	1598
and	CCONJ	O	O	1598
neuropsychological	ADJ	O	O	1598
findings	NOUN	O	O	1598
improved	VERB	O	O	1598
and	CCONJ	O	O	1598
seizure	NOUN	O	Disease	1598
frequency	NOUN	O	O	1598
decreased	VERB	O	O	1598
.	PUNCT	O	O	1598
Norepinephrine	NOUN	O	O	1601
signaling	VERB	O	O	1601
through	ADP	O	O	1601
beta	NOUN	O	O	1601
-	PUNCT	O	O	1601
adrenergic	NOUN	O	O	1601
receptors	NOUN	O	O	1601
is	AUX	O	O	1601
critical	ADJ	O	O	1601
for	ADP	O	O	1601
expression	NOUN	O	O	1601
of	ADP	O	O	1601
cocaine	NOUN	O	Chemical	1601
-	PUNCT	O	O	1601
induced	VERB	O	O	1601
anxiety	NOUN	O	Disease	1601
.	PUNCT	O	O	1601
Cocaine	NOUN	O	Chemical	1602
is	AUX	O	O	1602
a	PRON	O	O	1602
widely	ADV	O	O	1602
abused	VERB	O	O	1602
psychostimulant	NOUN	O	O	1602
that	SCONJ	O	O	1602
has	VERB	O	O	1602
both	PRON	O	O	1602
rewarding	VERB	O	O	1602
and	CCONJ	O	O	1602
aversive	ADJ	O	O	1602
properties	NOUN	O	O	1602
.	PUNCT	O	O	1602
While	SCONJ	O	O	1603
the	PRON	O	O	1603
mechanisms	NOUN	O	O	1603
underlying	VERB	O	O	1603
cocaine	NOUN	O	Chemical	1603
's	AUX	O	O	1603
rewarding	VERB	O	O	1603
effects	NOUN	O	O	1603
have	VERB	O	O	1603
been	AUX	O	O	1603
studied	VERB	O	O	1603
extensively	ADV	O	O	1603
,	PUNCT	O	O	1603
less	ADV	O	O	1603
attention	NOUN	O	O	1603
has	VERB	O	O	1603
been	AUX	O	O	1603
paid	VERB	O	O	1603
to	PART	O	O	1603
the	PRON	O	O	1603
unpleasant	ADJ	O	O	1603
behavioral	ADJ	O	O	1603
states	VERB	O	O	1603
induced	VERB	O	O	1603
by	ADP	O	O	1603
cocaine	NOUN	O	Chemical	1603
,	PUNCT	O	O	1603
such	ADJ	O	O	1603
as	ADP	O	O	1603
anxiety	NOUN	O	Disease	1603
.	PUNCT	O	O	1603
:	PUNCT	O	O	1604
In	ADP	O	O	1604
this	PRON	O	O	1604
study	VERB	O	O	1604
,	PUNCT	O	O	1604
we	PRON	O	O	1604
evaluated	VERB	O	O	1604
the	PRON	O	O	1604
performance	NOUN	O	O	1604
of	ADP	O	O	1604
dopamine	NOUN	O	Chemical	1604
beta	NOUN	O	O	1604
-	PUNCT	O	O	1604
hydroxylase	NOUN	O	O	1604
knockout	NOUN	O	O	1604
(	PUNCT	O	O	1604
Dbh	NOUN	O	O	1604
-/-	PROPN	O	O	1604
)	PUNCT	O	O	1604
mice	NOUN	O	O	1604
,	PUNCT	O	O	1604
which	PRON	O	O	1604
lack	VERB	O	O	1604
norepinephrine	NOUN	O	Chemical	1604
(	PUNCT	O	O	1604
NE	PROPN	O	Chemical	1604
)	PUNCT	O	O	1604
,	PUNCT	O	O	1604
in	ADP	O	O	1604
the	PRON	O	O	1604
elevated	ADJ	O	O	1604
plus	CCONJ	O	O	1604
maze	NOUN	O	O	1604
(	PUNCT	O	O	1604
EPM	PROPN	O	O	1604
)	PUNCT	O	O	1604
to	PART	O	O	1604
examine	VERB	O	O	1604
the	PRON	O	O	1604
contribution	NOUN	O	O	1604
of	ADP	O	O	1604
noradrenergic	ADJ	O	O	1604
signaling	VERB	O	O	1604
to	PART	O	O	1604
cocaine	NOUN	O	Chemical	1604
-	PUNCT	O	O	1604
induced	VERB	O	O	1604
anxiety	NOUN	O	Disease	1604
.	PUNCT	O	O	1604
We	PRON	O	O	1605
found	VERB	O	O	1605
that	SCONJ	O	O	1605
cocaine	NOUN	O	Chemical	1605
dose	NOUN	O	O	1605
-	PUNCT	O	O	1605
dependently	ADV	O	O	1605
increased	VERB	O	O	1605
anxiety	NOUN	O	Disease	1605
-	PUNCT	O	O	1605
like	INTJ	O	O	1605
behavior	NOUN	O	O	1605
in	ADP	O	O	1605
control	VERB	O	O	1605
(	PUNCT	O	O	1605
Dbh	NOUN	O	O	1605
+	ADP	O	O	1605
/-	PUNCT	O	O	1605
mice	NOUN	O	O	1606
had	VERB	O	O	1606
normal	ADJ	O	O	1606
baseline	VERB	O	O	1606
performance	NOUN	O	O	1606
in	ADP	O	O	1606
the	PRON	O	O	1606
EPM	PROPN	O	O	1606
but	CCONJ	O	O	1606
were	AUX	O	O	1606
completely	ADV	O	O	1606
resistant	ADJ	O	O	1606
to	PART	O	O	1606
the	PRON	O	O	1606
anxiogenic	ADJ	O	O	1606
effects	NOUN	O	O	1606
of	ADP	O	O	1606
cocaine	NOUN	O	Chemical	1606
.	PUNCT	O	O	1606
Cocaine	NOUN	O	Chemical	1607
-	PUNCT	O	O	1607
induced	VERB	O	O	1607
anxiety	NOUN	O	Disease	1607
was	AUX	O	O	1607
also	ADV	O	O	1607
attenuated	VERB	O	O	1607
in	ADP	O	O	1607
Dbh	NOUN	O	O	1607
+	ADP	O	O	1607
/-	PUNCT	O	O	1607
mice	NOUN	O	O	1608
following	VERB	O	O	1608
administration	NOUN	O	O	1608
of	ADP	O	O	1608
disulfiram	PROPN	O	Chemical	1608
,	PUNCT	O	O	1608
a	PRON	O	O	1608
dopamine	NOUN	O	Chemical	1608
beta	NOUN	O	O	1608
-	PUNCT	O	O	1608
hydroxylase	NOUN	O	O	1608
(	PUNCT	O	O	1608
DBH	PROPN	O	O	1608
)	PUNCT	O	O	1608
inhibitor	NOUN	O	O	1608
.	PUNCT	O	O	1608
In	ADP	O	O	1609
experiments	NOUN	O	O	1609
using	VERB	O	O	1609
specific	ADJ	O	O	1609
adrenergic	NOUN	O	O	1609
antagonists	NOUN	O	O	1609
,	PUNCT	O	O	1609
we	PRON	O	O	1609
found	VERB	O	O	1609
that	SCONJ	O	O	1609
pretreatment	NOUN	O	O	1609
with	ADP	O	O	1609
the	PRON	O	O	1609
beta	NOUN	O	O	1609
-	PUNCT	O	O	1609
adrenergic	NOUN	O	O	1609
receptor	NOUN	O	O	1609
antagonist	NOUN	O	O	1609
propranolol	NOUN	O	Chemical	1609
blocked	VERB	O	O	1609
cocaine	NOUN	O	Chemical	1609
-	PUNCT	O	O	1609
induced	VERB	O	O	1609
anxiety	NOUN	O	Disease	1609
-	PUNCT	O	O	1609
like	INTJ	O	O	1609
behavior	NOUN	O	O	1609
in	ADP	O	O	1609
Dbh	NOUN	O	O	1609
+	ADP	O	O	1609
/-	PUNCT	O	O	1609
and	CCONJ	O	O	1610
wild	ADJ	O	O	1610
-	PUNCT	O	O	1610
type	NOUN	O	O	1610
C57BL6/J	PROPN	O	O	1610
mice	NOUN	O	O	1610
,	PUNCT	O	O	1610
while	SCONJ	O	O	1610
the	PRON	O	O	1610
alpha(1	ADJ	O	O	1610
)	PUNCT	O	O	1610
antagonist	NOUN	O	O	1610
prazosin	NOUN	O	Chemical	1610
and	CCONJ	O	O	1610
the	PRON	O	O	1610
alpha(2	NOUN	O	O	1610
)	PUNCT	O	O	1610
antagonist	NOUN	O	O	1610
yohimbine	NOUN	O	Chemical	1610
had	VERB	O	O	1610
no	PRON	O	O	1610
effect	VERB	O	O	1610
.	PUNCT	O	O	1610
These	PRON	O	O	1611
results	VERB	O	O	1611
indicate	VERB	O	O	1611
that	SCONJ	O	O	1611
noradrenergic	ADJ	O	O	1611
signaling	VERB	O	O	1611
via	ADP	O	O	1611
beta	NOUN	O	O	1611
-	PUNCT	O	O	1611
adrenergic	NOUN	O	O	1611
receptors	NOUN	O	O	1611
is	AUX	O	O	1611
required	VERB	O	O	1611
for	ADP	O	O	1611
cocaine	NOUN	O	Chemical	1611
-	PUNCT	O	O	1611
induced	VERB	O	O	1611
anxiety	NOUN	O	Disease	1611
in	ADP	O	O	1611
mice	NOUN	O	O	1611
.	PUNCT	O	O	1611
Clonidine	NOUN	O	Chemical	1614
for	ADP	O	O	1614
attention	NOUN	O	O	1614
-	PUNCT	O	O	1614
deficit	NOUN	O	O	1614
/	PUNCT	O	O	1614
hyperactivity	NOUN	O	Disease	1614
disorder	NOUN	O	O	1614
:	PUNCT	O	O	1614
OBJECTIVE	VERB	O	O	1615
:	PUNCT	O	O	1615
To	PART	O	O	1615
examine	VERB	O	O	1615
the	PRON	O	O	1615
safety	NOUN	O	O	1615
and	CCONJ	O	O	1615
tolerability	NOUN	O	O	1615
of	ADP	O	O	1615
clonidine	NOUN	O	Chemical	1615
used	VERB	O	O	1615
alone	ADV	O	O	1615
or	CCONJ	O	O	1615
with	ADP	O	O	1615
methylphenidate	VERB	O	Chemical	1615
in	ADP	O	O	1615
children	NOUN	O	O	1615
with	ADP	O	O	1615
attention	NOUN	O	O	1615
-	PUNCT	O	O	1615
deficit	NOUN	O	O	1615
/	PUNCT	O	O	1615
hyperactivity	NOUN	O	Disease	1615
disorder	NOUN	O	O	1615
(	PUNCT	O	O	1615
ADHD	PROPN	O	O	1615
)	PUNCT	O	O	1615
.	PUNCT	O	O	1615
In	ADP	O	O	1616
a	PRON	O	O	1616
16-week	NOUN	O	O	1616
multicenter	ADJ	O	O	1616
,	PUNCT	O	O	1616
double	ADJ	O	O	1616
-	PUNCT	O	O	1616
blind	ADJ	O	Disease	1616
trial	NOUN	O	O	1616
,	PUNCT	O	O	1616
122	NUM	O	O	1616
children	NOUN	O	O	1616
with	ADP	O	O	1616
ADHD	PROPN	O	O	1616
were	AUX	O	O	1616
randomly	ADV	O	O	1616
assigned	VERB	O	O	1616
to	PART	O	O	1616
clonidine	NOUN	O	Chemical	1616
(	PUNCT	O	O	1616
n	CCONJ	O	O	1616
=	PUNCT	O	O	1616
31	NUM	O	O	1616
)	PUNCT	O	O	1616
,	PUNCT	O	O	1616
methylphenidate	VERB	O	Chemical	1617
(	PUNCT	O	O	1617
n	CCONJ	O	O	1617
=	PUNCT	O	O	1617
29	NUM	O	O	1617
)	PUNCT	O	O	1617
,	PUNCT	O	O	1617
clonidine	NOUN	O	Chemical	1617
and	CCONJ	O	O	1617
methylphenidate	VERB	O	Chemical	1617
(	PUNCT	O	O	1617
n	CCONJ	O	O	1617
=	PUNCT	O	O	1617
32	NUM	O	O	1617
)	PUNCT	O	O	1617
,	PUNCT	O	O	1617
or	CCONJ	O	O	1617
placebo	NOUN	O	O	1617
(	PUNCT	O	O	1617
Doses	NOUN	O	O	1618
were	AUX	O	O	1618
flexibly	ADV	O	O	1618
titrated	VERB	O	O	1618
up	ADP	O	O	1618
to	PART	O	O	1618
0.6	NUM	O	O	1618
mg	VERB	O	O	1618
/	PUNCT	O	O	1618
day	NOUN	O	O	1618
for	ADP	O	O	1618
clonidine	NOUN	O	Chemical	1618
and	CCONJ	O	O	1618
60	NUM	O	O	1618
mg	VERB	O	O	1618
/	PUNCT	O	O	1618
day	NOUN	O	O	1618
for	ADP	O	O	1618
methylphenidate	VERB	O	Chemical	1618
(	PUNCT	O	O	1618
both	PRON	O	O	1618
with	ADP	O	O	1618
divided	VERB	O	O	1618
dosing	VERB	O	O	1618
)	PUNCT	O	O	1618
.	PUNCT	O	O	1618
There	ADV	O	O	1619
were	AUX	O	O	1619
more	ADJ	O	O	1619
incidents	NOUN	O	O	1619
of	ADP	O	O	1619
bradycardia	NOUN	O	Disease	1619
in	ADP	O	O	1619
subjects	NOUN	O	O	1619
treated	VERB	O	O	1619
with	ADP	O	O	1619
clonidine	NOUN	O	Chemical	1619
compared	VERB	O	O	1619
with	ADP	O	O	1619
those	PRON	O	O	1619
not	PART	O	O	1619
treated	VERB	O	O	1619
with	ADP	O	O	1619
clonidine	NOUN	O	Chemical	1619
(	PUNCT	O	O	1619
17.5%	NOUN	O	O	1619
versus	ADP	O	O	1619
3.4%	NOUN	O	O	1619
;	PUNCT	O	O	1619
p	NOUN	O	O	1619
=	PUNCT	O	O	1619
.02	NUM	O	O	1619
)	PUNCT	O	O	1619
,	PUNCT	O	O	1619
but	CCONJ	O	O	1619
no	PRON	O	O	1619
other	ADJ	O	O	1619
significant	ADJ	O	O	1619
group	NOUN	O	O	1619
differences	NOUN	O	O	1619
regarding	VERB	O	O	1619
electrocardiogram	PROPN	O	O	1619
and	CCONJ	O	O	1619
other	ADJ	O	O	1619
cardiovascular	ADJ	O	O	1619
outcomes	NOUN	O	O	1619
.	PUNCT	O	O	1619
There	ADV	O	O	1620
were	AUX	O	O	1620
no	PRON	O	O	1620
suggestions	NOUN	O	O	1620
of	ADP	O	O	1620
interactions	NOUN	O	O	1620
between	ADP	O	O	1620
clonidine	NOUN	O	Chemical	1620
and	CCONJ	O	O	1620
methylphenidate	VERB	O	Chemical	1620
regarding	VERB	O	O	1620
cardiovascular	ADJ	O	O	1620
outcomes	NOUN	O	O	1620
.	PUNCT	O	O	1620
Moderate	ADJ	O	O	1621
or	CCONJ	O	O	1621
severe	ADJ	O	O	1621
adverse	ADJ	O	O	1621
events	NOUN	O	O	1621
were	AUX	O	O	1621
more	ADJ	O	O	1621
common	ADJ	O	O	1621
in	ADP	O	O	1621
subjects	NOUN	O	O	1621
on	ADP	O	O	1621
clonidine	NOUN	O	Chemical	1621
(	PUNCT	O	O	1621
79.4%	NOUN	O	O	1621
versus	ADP	O	O	1621
49.2%	NOUN	O	O	1621
;	PUNCT	O	O	1621
p	NOUN	O	O	1621
=	PUNCT	O	O	1621
.0006	PUNCT	O	O	1621
)	PUNCT	O	O	1621
but	CCONJ	O	O	1621
not	PART	O	O	1621
associated	VERB	O	O	1621
with	ADP	O	O	1621
higher	ADJ	O	O	1621
rates	NOUN	O	O	1621
of	ADP	O	O	1621
early	ADV	O	O	1621
study	VERB	O	O	1621
withdrawal	NOUN	O	O	1621
.	PUNCT	O	O	1621
Drowsiness	PROPN	O	Disease	1622
was	AUX	O	O	1622
common	ADJ	O	O	1622
on	ADP	O	O	1622
clonidine	NOUN	O	Chemical	1622
,	PUNCT	O	O	1622
but	CCONJ	O	O	1622
generally	ADV	O	O	1622
resolved	VERB	O	O	1622
by	ADP	O	O	1622
6	NUM	O	O	1622
to	PART	O	O	1622
8	NUM	O	O	1622
weeks	NOUN	O	O	1622
.	PUNCT	O	O	1622
CONCLUSIONS	NOUN	O	O	1623
:	PUNCT	O	O	1623
Clonidine	NOUN	O	Chemical	1623
,	PUNCT	O	O	1623
used	VERB	O	O	1623
alone	ADV	O	O	1623
or	CCONJ	O	O	1623
with	ADP	O	O	1623
methylphenidate	VERB	O	Chemical	1623
,	PUNCT	O	O	1623
appears	VERB	O	O	1623
safe	ADJ	O	O	1623
and	CCONJ	O	O	1623
well	ADV	O	O	1623
tolerated	VERB	O	O	1623
in	ADP	O	O	1623
childhood	NOUN	O	O	1623
ADHD	PROPN	O	O	1623
.	PUNCT	O	O	1623
Physicians	NOUN	O	O	1624
prescribing	VERB	O	O	1624
clonidine	NOUN	O	Chemical	1624
should	AUX	O	O	1624
monitor	VERB	O	O	1624
for	ADP	O	O	1624
bradycardia	NOUN	O	Disease	1624
and	CCONJ	O	O	1624
advise	VERB	O	O	1624
patients	NOUN	O	O	1624
about	ADP	O	O	1624
the	PRON	O	O	1624
high	ADJ	O	O	1624
likelihood	NOUN	O	O	1624
of	ADP	O	O	1624
initial	ADJ	O	O	1624
drowsiness	NOUN	O	Disease	1624
.	PUNCT	O	O	1624
Thalidomide	NOUN	O	O	1627
has	VERB	O	O	1627
limited	VERB	O	O	1627
single	ADJ	O	O	1627
-	PUNCT	O	O	1627
agent	NOUN	O	O	1627
activity	NOUN	O	O	1627
in	ADP	O	O	1627
relapsed	VERB	O	O	1627
or	CCONJ	O	O	1627
refractory	ADJ	O	O	1627
indolent	ADJ	O	O	1627
non	ADJ	O	O	1627
-	PUNCT	O	O	1627
Hodgkin	PROPN	O	O	1627
lymphomas	NOUN	O	O	1627
:	PUNCT	O	O	1627
a	PRON	O	O	1627
phase	NOUN	O	O	1627
II	NUM	O	O	1627
trial	NOUN	O	O	1627
of	ADP	O	O	1627
the	PRON	O	O	1627
Cancer	NOUN	O	O	1627
and	CCONJ	O	O	1627
Leukemia	NOUN	O	O	1627
Group	PROPN	O	O	1627
B.	PROPN	O	O	1627
Thalidomide	NOUN	O	O	1627
is	AUX	O	O	1627
an	PRON	O	O	1627
immunomodulatory	NOUN	O	O	1627
agent	NOUN	O	O	1627
with	ADP	O	O	1627
demonstrated	VERB	O	O	1627
activity	NOUN	O	O	1627
in	ADP	O	O	1627
multiple myeloma	NOUN	O	Disease	1627
,	PUNCT	O	O	1627
mantle	NOUN	O	O	1627
cell	NOUN	O	O	1627
lymphoma	PROPN	O	Disease	1627
and	CCONJ	O	O	1627
lymphoplasmacytic	NOUN	O	O	1627
lymphoma	PROPN	O	Disease	1627
.	PUNCT	O	O	1627
Its	PRON	O	O	1628
activity	NOUN	O	O	1628
is	AUX	O	O	1628
believed	VERB	O	O	1628
to	PART	O	O	1628
be	AUX	O	O	1628
due	ADJ	O	O	1628
modulation	NOUN	O	O	1628
of	ADP	O	O	1628
the	PRON	O	O	1628
tumour	NOUN	O	O	1628
milieu	NOUN	O	O	1628
,	PUNCT	O	O	1628
including	VERB	O	O	1628
downregulation	NOUN	O	O	1628
of	ADP	O	O	1628
angiogenesis	NOUN	O	O	1628
and	CCONJ	O	O	1628
inflammatory	ADJ	O	O	1628
cytokines	NOUN	O	O	1628
.	PUNCT	O	O	1628
Between	ADP	O	O	1629
July	PROPN	O	O	1629
2001	NUM	O	O	1629
and	CCONJ	O	O	1629
April	PROPN	O	O	1629
2004	NUM	O	O	1629
,	PUNCT	O	O	1629
24	NUM	O	O	1629
patients	NOUN	O	O	1629
with	ADP	O	O	1629
relapsed	VERB	O	O	1629
/	PUNCT	O	O	1629
refractory	ADJ	O	O	1629
indolent	ADJ	O	O	1629
lymphomas	NOUN	O	O	1629
received	VERB	O	O	1629
thalidomide	NOUN	O	Chemical	1629
200	NUM	O	O	1629
mg	VERB	O	O	1629
daily	ADV	O	O	1629
with	ADP	O	O	1629
escalation	NOUN	O	O	1629
by	ADP	O	O	1629
100	NUM	O	O	1629
mg	VERB	O	O	1629
daily	ADV	O	O	1629
every	PRON	O	O	1629
1	X	O	O	1629
-	PUNCT	O	O	1629
2	X	O	O	1629
weeks	NOUN	O	O	1629
as	ADP	O	O	1629
tolerated	VERB	O	O	1629
,	PUNCT	O	O	1629
up	ADP	O	O	1629
to	PART	O	O	1629
a	PRON	O	O	1629
maximum	ADV	O	O	1629
of	ADP	O	O	1629
800	NUM	O	O	1629
mg	VERB	O	O	1629
daily	ADV	O	O	1629
.	PUNCT	O	O	1629
included	VERB	O	O	1630
myelosuppression	NOUN	O	Disease	1630
,	PUNCT	O	O	1630
fatigue	NOUN	O	Disease	1630
,	PUNCT	O	O	1630
somnolence	NOUN	O	Disease	1630
/	PUNCT	O	O	1630
depressed	ADJ	O	O	1630
mood	NOUN	O	O	1630
,	PUNCT	O	O	1630
neuropathy	NOUN	O	Disease	1630
and	CCONJ	O	O	1630
dyspnea	ADJ	O	O	1630
.	PUNCT	O	O	1630
Of	ADV	O	O	1631
concern	NOUN	O	O	1631
was	AUX	O	O	1631
the	PRON	O	O	1631
occurrence	NOUN	O	O	1631
of	ADP	O	O	1631
four	NUM	O	O	1631
thromboembolic	PROPN	O	Disease	1631
events	NOUN	O	O	1631
.	PUNCT	O	O	1631
Our	PRON	O	O	1632
results	VERB	O	O	1632
failed	VERB	O	O	1632
to	PART	O	O	1632
demonstrate	VERB	O	O	1632
an	PRON	O	O	1632
important	ADJ	O	O	1632
response	NOUN	O	O	1632
rate	NOUN	O	O	1632
to	PART	O	O	1632
single	ADJ	O	O	1632
agent	NOUN	O	O	1632
thalidomide	NOUN	O	Chemical	1632
in	ADP	O	O	1632
indolent	ADJ	O	O	1632
lymphomas	NOUN	O	O	1632
and	CCONJ	O	O	1632
contrast	NOUN	O	O	1632
with	ADP	O	O	1632
the	PRON	O	O	1632
higher	ADJ	O	O	1632
activity	NOUN	O	O	1632
level	VERB	O	O	1632
reported	VERB	O	O	1632
with	ADP	O	O	1632
the	PRON	O	O	1632
second	ADV	O	O	1632
generation	NOUN	O	O	1632
immunomodulatory	NOUN	O	O	1632
agent	NOUN	O	O	1632
,	PUNCT	O	O	1632
lenalidomide	PROPN	O	O	1632
.	PUNCT	O	O	1632
Intracavernous	PROPN	O	O	1635
epinephrine	NOUN	O	Chemical	1635
:	PUNCT	O	O	1635
a	PRON	O	O	1635
minimally	ADV	O	O	1635
invasive	ADJ	O	O	1635
treatment	NOUN	O	O	1635
for	ADP	O	O	1635
priapism	ADV	O	O	1635
in	ADP	O	O	1635
the	PRON	O	O	1635
emergency	NOUN	O	O	1635
department	NOUN	O	O	1635
.	PUNCT	O	O	1635
Priapism	INTJ	O	O	1636
is	AUX	O	O	1636
the	PRON	O	O	1636
prolonged	VERB	O	O	1636
erection	VERB	O	O	1636
of	ADP	O	O	1636
the	PRON	O	O	1636
penis	NOUN	O	O	1636
in	ADP	O	O	1636
the	PRON	O	O	1636
absence	NOUN	O	O	1636
of	ADP	O	O	1636
sexual	ADJ	O	O	1636
arousal	NOUN	O	O	1636
.	PUNCT	O	O	1636
A	PRON	O	O	1637
45-year	NOUN	O	O	1637
-	PUNCT	O	O	1637
old	ADJ	O	O	1637
man	NOUN	O	O	1637
,	PUNCT	O	O	1637
an	PRON	O	O	1637
admitted	VERB	O	O	1637
frequent	ADJ	O	O	1637
cocaine	NOUN	O	Chemical	1637
user	NOUN	O	O	1637
,	PUNCT	O	O	1637
presented	VERB	O	O	1637
to	PART	O	O	1637
the	PRON	O	O	1637
Emergency	NOUN	O	O	1637
Department	NOUN	O	O	1637
(	PUNCT	O	O	1637
ED	PROPN	O	O	1637
)	PUNCT	O	O	1637
on	ADP	O	O	1637
two	NUM	O	O	1637
separate	VERB	O	O	1637
occasions	NOUN	O	O	1637
with	ADP	O	O	1637
a	PRON	O	O	1637
history	NOUN	O	O	1637
of	ADP	O	O	1637
priapism	ADV	O	O	1637
after	ADP	O	O	1637
cocaine	NOUN	O	Chemical	1637
use	VERB	O	O	1637
.	PUNCT	O	O	1637
The	PRON	O	O	1638
management	NOUN	O	O	1638
options	NOUN	O	O	1638
in	ADP	O	O	1638
the	PRON	O	O	1638
ED	PROPN	O	O	1638
,	PUNCT	O	O	1638
as	ADP	O	O	1638
exemplified	VERB	O	O	1638
by	ADP	O	O	1638
four	NUM	O	O	1638
individual	ADJ	O	O	1638
case	NOUN	O	O	1638
reports	VERB	O	O	1638
,	PUNCT	O	O	1638
in	ADP	O	O	1638
particular	ADJ	O	O	1638
the	PRON	O	O	1638
use	VERB	O	O	1638
of	ADP	O	O	1638
a	PRON	O	O	1638
minimally	ADV	O	O	1638
invasive	ADJ	O	O	1638
method	NOUN	O	O	1638
of	ADP	O	O	1638
intracorporal	ADJ	O	O	1638
epinephrine	NOUN	O	Chemical	1638
instillation	NOUN	O	O	1638
,	PUNCT	O	O	1638
are	AUX	O	O	1638
discussed	VERB	O	O	1638
.	PUNCT	O	O	1638
Effect	VERB	O	O	1641
of	ADP	O	O	1641
green	ADJ	O	O	1641
tea	NOUN	O	O	1641
and	CCONJ	O	O	1641
vitamin E	NOUN	O	Chemical	1641
combination	NOUN	O	O	1641
in	ADP	O	O	1641
isoproterenol	NOUN	O	Chemical	1641
induced	VERB	O	O	1641
myocardial infarction	NOUN	O	Disease	1641
in	ADP	O	O	1641
rats	NOUN	O	O	1641
.	PUNCT	O	O	1641
The	PRON	O	O	1642
present	NOUN	O	O	1642
study	VERB	O	O	1642
was	AUX	O	O	1642
aimed	VERB	O	O	1642
to	PART	O	O	1642
investigate	VERB	O	O	1642
the	PRON	O	O	1642
combined	VERB	O	O	1642
effects	NOUN	O	O	1642
of	ADP	O	O	1642
green	ADJ	O	O	1642
tea	NOUN	O	O	1642
and	CCONJ	O	O	1642
vitamin E	NOUN	O	Chemical	1642
on	ADP	O	O	1642
heart	NOUN	O	O	1642
weight	NOUN	O	O	1642
,	PUNCT	O	O	1642
body	NOUN	O	O	1642
weight	NOUN	O	O	1642
,	PUNCT	O	O	1642
serum	NOUN	O	O	1642
marker	NOUN	O	O	1642
enzymes	NOUN	O	O	1642
,	PUNCT	O	O	1642
lipid	NOUN	O	O	1642
peroxidation	NOUN	O	O	1642
,	PUNCT	O	O	1642
endogenous	ADJ	O	O	1642
antioxidants	NOUN	O	O	1642
and	CCONJ	O	O	1642
membrane	NOUN	O	O	1642
bound	VERB	O	O	1642
ATPases	NOUN	O	O	1642
in	ADP	O	O	1642
isoproterenol	NOUN	O	Chemical	1642
(	PUNCT	O	O	1642
ISO)-induced	VERB	O	O	1642
myocardial infarction	NOUN	O	Disease	1642
in	ADP	O	O	1642
rats	NOUN	O	O	1642
.	PUNCT	O	O	1642
Adult	NOUN	O	O	1643
male	NOUN	O	O	1643
albino	PROPN	O	O	1643
rats	NOUN	O	O	1643
,	PUNCT	O	O	1643
treated	VERB	O	O	1643
with	ADP	O	O	1643
ISO	PROPN	O	Chemical	1643
(	PUNCT	O	O	1643
200	NUM	O	O	1643
mg	VERB	O	O	1643
/	PUNCT	O	O	1643
kg	VERB	O	O	1643
,	PUNCT	O	O	1643
s.c	PROPN	O	O	1643
.	PUNCT	O	O	1643
)	PUNCT	O	O	1643
for	ADP	O	O	1643
2	X	O	O	1643
days	NOUN	O	O	1643
at	ADP	O	O	1643
an	PRON	O	O	1643
interval	NOUN	O	O	1643
of	ADP	O	O	1643
24	NUM	O	O	1643
h	X	O	O	1643
caused	VERB	O	O	1643
a	PRON	O	O	1643
significant	ADJ	O	O	1643
(	PUNCT	O	O	1643
P<0.05	NOUN	O	O	1643
)	PUNCT	O	O	1643
elevation	NOUN	O	O	1643
of	ADP	O	O	1643
heart	NOUN	O	O	1643
weight	NOUN	O	O	1643
,	PUNCT	O	O	1643
serum	NOUN	O	O	1643
marker	NOUN	O	O	1643
enzymes	NOUN	O	O	1643
,	PUNCT	O	O	1643
lipid	NOUN	O	O	1643
peroxidation	NOUN	O	O	1643
and	CCONJ	O	O	1643
Ca+2	PROPN	O	O	1643
ATPase	X	O	O	1643
level	VERB	O	O	1643
whereas	SCONJ	O	O	1643
there	ADV	O	O	1643
was	AUX	O	O	1643
a	PRON	O	O	1643
significant	ADJ	O	O	1643
(	PUNCT	O	O	1643
P<0.05	NOUN	O	O	1643
)	PUNCT	O	O	1643
decrease	VERB	O	O	1643
in	ADP	O	O	1643
body	NOUN	O	O	1643
weight	NOUN	O	O	1643
,	PUNCT	O	O	1643
endogenous	ADJ	O	O	1643
antioxidants	NOUN	O	O	1643
,	PUNCT	O	O	1643
Na+/	NOUN	O	O	1643
K+	NOUN	O	O	1643
ATPase	X	O	O	1643
and	CCONJ	O	O	1643
Mg+2	NOUN	O	O	1643
ATPase	X	O	O	1643
levels	NOUN	O	O	1643
.	PUNCT	O	O	1643
Administration	NOUN	O	O	1644
of	ADP	O	O	1644
green	ADJ	O	O	1644
tea	NOUN	O	O	1644
(	PUNCT	O	O	1644
100	NUM	O	O	1644
mg	VERB	O	O	1644
/	PUNCT	O	O	1644
kg	VERB	O	O	1644
/	PUNCT	O	O	1644
day	NOUN	O	O	1644
,	PUNCT	O	O	1644
p.o	PROPN	O	O	1644
.	PUNCT	O	O	1644
)	PUNCT	O	O	1644
and	CCONJ	O	O	1644
vitamin E	NOUN	O	Chemical	1644
(	PUNCT	O	O	1644
100	NUM	O	O	1644
mg	VERB	O	O	1644
/	PUNCT	O	O	1644
kg	VERB	O	O	1644
/	PUNCT	O	O	1644
day	NOUN	O	O	1644
,	PUNCT	O	O	1644
p.o	PROPN	O	O	1644
.	PUNCT	O	O	1644
)	PUNCT	O	O	1644
together	ADV	O	O	1645
for	ADP	O	O	1645
30	NUM	O	O	1645
consecutive	ADJ	O	O	1645
days	NOUN	O	O	1645
and	CCONJ	O	O	1645
challenged	VERB	O	O	1645
with	ADP	O	O	1645
ISO	PROPN	O	Chemical	1645
on	ADP	O	O	1645
the	PRON	O	O	1645
day	NOUN	O	O	1645
29th	NOUN	O	O	1645
and	CCONJ	O	O	1645
30th	PROPN	O	O	1645
,	PUNCT	O	O	1645
showed	VERB	O	O	1645
a	PRON	O	O	1645
significant	ADJ	O	O	1645
(	PUNCT	O	O	1645
P<0.05	NOUN	O	O	1645
)	PUNCT	O	O	1645
decrease	VERB	O	O	1645
in	ADP	O	O	1645
heart	NOUN	O	O	1645
weight	NOUN	O	O	1645
,	PUNCT	O	O	1645
serum	NOUN	O	O	1645
marker	NOUN	O	O	1645
enzymes	NOUN	O	O	1645
,	PUNCT	O	O	1645
lipid	NOUN	O	O	1645
peroxidation	NOUN	O	O	1645
,	PUNCT	O	O	1645
Ca+2	PROPN	O	O	1645
ATPase	X	O	O	1645
and	CCONJ	O	O	1645
a	PRON	O	O	1645
significant	ADJ	O	O	1645
increase	VERB	O	O	1645
in	ADP	O	O	1645
the	PRON	O	O	1645
body	NOUN	O	O	1645
weight	NOUN	O	O	1645
,	PUNCT	O	O	1645
endogenous	ADJ	O	O	1645
antioxidants	NOUN	O	O	1645
,	PUNCT	O	O	1645
Na+/K+	NOUN	O	O	1645
ATPase	X	O	O	1645
and	CCONJ	O	O	1645
Mg+2	NOUN	O	O	1645
ATPase	X	O	O	1645
when	SCONJ	O	O	1645
compared	VERB	O	O	1645
with	ADP	O	O	1645
ISO	PROPN	O	Chemical	1645
treated	VERB	O	O	1645
group	NOUN	O	O	1645
and	CCONJ	O	O	1645
green	ADJ	O	O	1645
tea	NOUN	O	O	1645
or	CCONJ	O	O	1645
vitamin E	NOUN	O	Chemical	1645
alone	ADV	O	O	1645
treated	VERB	O	O	1645
groups	NOUN	O	O	1645
.	PUNCT	O	O	1645
These	PRON	O	O	1646
findings	NOUN	O	O	1646
indicate	VERB	O	O	1646
the	PRON	O	O	1646
synergistic	ADJ	O	O	1646
protective	ADJ	O	O	1646
effect	VERB	O	O	1646
of	ADP	O	O	1646
green	ADJ	O	O	1646
tea	NOUN	O	O	1646
and	CCONJ	O	O	1646
vitamin E	NOUN	O	Chemical	1646
during	ADP	O	O	1646
ISO	PROPN	O	Chemical	1646
induced	VERB	O	O	1646
myocardial infarction	NOUN	O	Disease	1646
in	ADP	O	O	1646
rats	NOUN	O	O	1646
.	PUNCT	O	O	1646
Development	NOUN	O	O	1649
of	ADP	O	O	1649
ocular	ADJ	O	O	1649
myasthenia	PROPN	O	O	1649
during	ADP	O	O	1649
pegylated	VERB	O	O	1649
interferon	PROPN	O	Chemical	1649
and	CCONJ	O	O	1649
ribavirin	NOUN	O	Chemical	1649
treatment	NOUN	O	O	1649
for	ADP	O	O	1649
chronic hepatitis C.	PROPN	O	O	1649
A	PRON	O	O	1650
63-year	NOUN	O	O	1650
-	PUNCT	O	O	1650
old	ADJ	O	O	1650
male	NOUN	O	O	1650
experienced	ADJ	O	O	1650
sudden	ADJ	O	O	1650
diplopia	NOUN	O	Disease	1650
after	ADP	O	O	1650
9	NUM	O	O	1650
weeks	NOUN	O	O	1650
of	ADP	O	O	1650
administration	NOUN	O	O	1650
of	ADP	O	O	1650
pegylated	VERB	O	O	1650
interferon	PROPN	O	Chemical	1650
(	PUNCT	O	O	1650
IFN	PROPN	O	O	1650
)	PUNCT	O	O	1650
alpha-2b	ADV	O	O	1650
and	CCONJ	O	O	1650
ribavirin	NOUN	O	Chemical	1650
for	ADP	O	O	1650
chronic hepatitis C	NOUN	O	Disease	1650
(	PUNCT	O	O	1650
CHC	PROPN	O	Disease	1650
)	PUNCT	O	O	1650
.	PUNCT	O	O	1650
Ophthalmologic	ADJ	O	O	1651
examinations	NOUN	O	O	1651
showed	VERB	O	O	1651
ptosis	NOUN	O	O	1651
on	ADP	O	O	1651
the	PRON	O	O	1651
right	ADV	O	O	1651
upper	ADJ	O	O	1651
lid	VERB	O	O	1651
and	CCONJ	O	O	1651
restricted	VERB	O	O	1651
right	ADV	O	O	1651
eye	NOUN	O	O	1651
movement	NOUN	O	O	1651
without	ADP	O	O	1651
any	PRON	O	O	1651
other	ADJ	O	O	1651
neurological	ADJ	O	O	1651
signs	NOUN	O	O	1651
.	PUNCT	O	O	1651
The	PRON	O	O	1652
acetylcholine	NOUN	O	Chemical	1652
receptor	NOUN	O	O	1652
antibody	NOUN	O	O	1652
titer	NOUN	O	O	1652
and	CCONJ	O	O	1652
response	NOUN	O	O	1652
to	PART	O	O	1652
acetylcholinesterase	NOUN	O	O	1652
inhibitors	NOUN	O	O	1652
were	AUX	O	O	1652
negative	ADJ	O	O	1652
,	PUNCT	O	O	1652
and	CCONJ	O	O	1652
the	PRON	O	O	1652
results	VERB	O	O	1652
of	ADP	O	O	1652
thyroid	NOUN	O	O	1652
function	NOUN	O	O	1652
tests	VERB	O	O	1652
were	AUX	O	O	1652
normal	ADJ	O	O	1652
.	PUNCT	O	O	1652
The	PRON	O	O	1653
patient	NOUN	O	O	1653
's	AUX	O	O	1653
ophthalmological	ADJ	O	O	1653
symptoms	NOUN	O	O	1653
improved	VERB	O	O	1653
rapidly	ADV	O	O	1653
3	X	O	O	1653
weeks	NOUN	O	O	1653
after	ADP	O	O	1653
discontinuation	NOUN	O	O	1653
of	ADP	O	O	1653
pegylated	VERB	O	O	1653
IFN	PROPN	O	O	1653
alpha-2b	ADV	O	O	1653
and	CCONJ	O	O	1653
ribavirin	NOUN	O	Chemical	1653
.	PUNCT	O	O	1653
The	PRON	O	O	1654
ocular	ADJ	O	O	1654
myasthenia	PROPN	O	O	1654
associated	VERB	O	O	1654
with	ADP	O	O	1654
combination	NOUN	O	O	1654
therapy	NOUN	O	O	1654
of	ADP	O	O	1654
pegylated	VERB	O	O	1654
IFN	PROPN	O	O	1654
alpha-2b	ADV	O	O	1654
and	CCONJ	O	O	1654
ribavirin	NOUN	O	Chemical	1654
for	ADP	O	O	1654
CHC	PROPN	O	Disease	1654
is	AUX	O	O	1654
very	ADV	O	O	1654
rarely	ADV	O	O	1654
reported	VERB	O	O	1654
;	PUNCT	O	O	1654
therefore	ADV	O	O	1654
,	PUNCT	O	O	1654
we	PRON	O	O	1654
present	NOUN	O	O	1654
this	PRON	O	O	1654
case	NOUN	O	O	1654
with	ADP	O	O	1654
a	PRON	O	O	1654
review	VERB	O	O	1654
of	ADP	O	O	1654
the	PRON	O	O	1654
various	ADJ	O	O	1654
eye	NOUN	O	O	1654
complications	NOUN	O	O	1654
of	ADP	O	O	1654
IFN	PROPN	O	O	1654
therapy	NOUN	O	O	1654
.	PUNCT	O	O	1654
The	PRON	O	O	1657
glycine	NOUN	O	Chemical	1657
transporter-1	PUNCT	O	O	1657
inhibitor	NOUN	O	O	1657
SSR103800	INTJ	O	O	1657
displays	VERB	O	O	1657
a	PRON	O	O	1657
selective	ADJ	O	O	1657
and	CCONJ	O	O	1657
specific	ADJ	O	O	1657
antipsychotic	ADJ	O	O	1657
-	PUNCT	O	O	1657
like	INTJ	O	O	1657
profile	NOUN	O	O	1657
in	ADP	O	O	1657
normal	ADJ	O	O	1657
and	CCONJ	O	O	1657
transgenic	NOUN	O	O	1657
mice	NOUN	O	O	1657
.	PUNCT	O	O	1657
Schizophrenia	PROPN	O	O	1658
has	VERB	O	O	1658
been	AUX	O	O	1658
initially	ADV	O	O	1658
associated	VERB	O	O	1658
with	ADP	O	O	1658
dysfunction	NOUN	O	O	1658
in	ADP	O	O	1658
dopamine	NOUN	O	Chemical	1658
neurotransmission	NOUN	O	O	1658
.	PUNCT	O	O	1658
However	ADV	O	O	1659
,	PUNCT	O	O	1659
the	PRON	O	O	1659
observation	NOUN	O	O	1659
that	SCONJ	O	O	1659
antagonists	NOUN	O	O	1659
of	ADP	O	O	1659
the	PRON	O	O	1659
glutamate	NOUN	O	Chemical	1659
N	NUM	O	O	1659
-	PUNCT	O	O	1659
methyl	NOUN	O	O	1659
-	PUNCT	O	O	1659
D	NOUN	O	O	1659
-	PUNCT	O	O	1659
aspartate	NOUN	O	Chemical	1659
(	PUNCT	O	O	1659
NMDA	PROPN	O	Chemical	1659
)	PUNCT	O	O	1659
receptor	NOUN	O	O	1659
produce	VERB	O	O	1659
schizophrenic	ADJ	O	Disease	1659
-	PUNCT	O	O	1659
like	INTJ	O	O	1659
symptoms	NOUN	O	O	1659
in	ADP	O	O	1659
humans	NOUN	O	O	1659
has	VERB	O	O	1659
led	VERB	O	O	1659
to	PART	O	O	1659
the	PRON	O	O	1659
idea	NOUN	O	O	1659
of	ADP	O	O	1659
a	PRON	O	O	1659
dysfunctioning	VERB	O	O	1659
of	ADP	O	O	1659
the	PRON	O	O	1659
glutamatergic	ADJ	O	O	1659
system	NOUN	O	O	1659
via	ADP	O	O	1659
its	PRON	O	O	1659
NMDA	PROPN	O	Chemical	1659
receptor	NOUN	O	O	1659
.	PUNCT	O	O	1659
As	ADP	O	O	1660
a	PRON	O	O	1660
result	VERB	O	O	1660
,	PUNCT	O	O	1660
there	ADV	O	O	1660
is	AUX	O	O	1660
a	PRON	O	O	1660
growing	VERB	O	O	1660
interest	NOUN	O	O	1660
in	ADP	O	O	1660
the	PRON	O	O	1660
development	NOUN	O	O	1660
of	ADP	O	O	1660
pharmacological	ADJ	O	O	1660
agents	NOUN	O	O	1660
with	ADP	O	O	1660
potential	ADJ	O	O	1660
antipsychotic	ADJ	O	O	1660
properties	NOUN	O	O	1660
that	SCONJ	O	O	1660
enhance	VERB	O	O	1660
the	PRON	O	O	1660
activity	NOUN	O	O	1660
of	ADP	O	O	1660
the	PRON	O	O	1660
glutamatergic	ADJ	O	O	1660
system	NOUN	O	O	1660
via	ADP	O	O	1660
a	PRON	O	O	1660
modulation	NOUN	O	O	1660
of	ADP	O	O	1660
the	PRON	O	O	1660
NMDA	PROPN	O	Chemical	1660
receptor	NOUN	O	O	1660
.	PUNCT	O	O	1660
Among	ADP	O	O	1661
them	PRON	O	O	1661
are	AUX	O	O	1661
glycine	NOUN	O	Chemical	1661
transporter-1	PUNCT	O	O	1661
(	PUNCT	O	O	1661
GlyT1	PROPN	O	O	1661
)	PUNCT	O	O	1661
inhibitors	NOUN	O	O	1662
such	ADJ	O	O	1662
as	ADP	O	O	1662
SSR103800	INTJ	O	O	1662
,	PUNCT	O	O	1662
which	PRON	O	O	1662
indirectly	ADV	O	O	1662
enhance	VERB	O	O	1662
NMDA	PROPN	O	Chemical	1662
receptor	NOUN	O	O	1662
function	NOUN	O	O	1662
by	ADP	O	O	1662
increasing	VERB	O	O	1662
the	PRON	O	O	1662
glycine	NOUN	O	Chemical	1662
(	PUNCT	O	O	1662
a	PRON	O	O	1662
co	NOUN	O	O	1662
-	PUNCT	O	O	1662
agonist	NOUN	O	O	1662
for	ADP	O	O	1662
the	PRON	O	O	1662
NMDA	PROPN	O	Chemical	1662
receptor	NOUN	O	O	1662
)	PUNCT	O	O	1662
levels	NOUN	O	O	1662
in	ADP	O	O	1662
the	PRON	O	O	1662
synapse	NOUN	O	O	1662
.	PUNCT	O	O	1662
This	PRON	O	O	1663
study	VERB	O	O	1663
aimed	VERB	O	O	1663
at	ADP	O	O	1663
investigating	VERB	O	O	1663
the	PRON	O	O	1663
potential	ADJ	O	O	1663
antipsychotic	ADJ	O	O	1663
-	PUNCT	O	O	1663
like	INTJ	O	O	1663
properties	NOUN	O	O	1663
of	ADP	O	O	1663
SSR103800	INTJ	O	O	1663
,	PUNCT	O	O	1663
with	ADP	O	O	1663
a	PRON	O	O	1663
particular	ADJ	O	O	1663
focus	NOUN	O	O	1663
on	ADP	O	O	1663
models	NOUN	O	O	1663
of	ADP	O	O	1663
hyperactivity	NOUN	O	Disease	1663
,	PUNCT	O	O	1663
involving	VERB	O	O	1663
either	ADV	O	O	1663
drug	NOUN	O	O	1663
challenge	NOUN	O	O	1663
(	PUNCT	O	O	1663
ie	ADV	O	O	1663
,	PUNCT	O	O	1663
amphetamine	NOUN	O	Chemical	1663
and	CCONJ	O	O	1663
MK-801	PROPN	O	Chemical	1663
)	PUNCT	O	O	1663
or	CCONJ	O	O	1663
transgenic	NOUN	O	O	1663
mice	NOUN	O	O	1663
(	PUNCT	O	O	1663
ie	ADV	O	O	1663
,	PUNCT	O	O	1663
NMDA	PROPN	O	Chemical	1663
Nr1(neo-/-	NUM	O	O	1663
)	PUNCT	O	O	1663
and	CCONJ	O	O	1663
DAT(-/-	NUM	O	O	1663
)	PUNCT	O	O	1663
)	PUNCT	O	O	1663
.	PUNCT	O	O	1663
Results	NOUN	O	O	1664
showed	VERB	O	O	1664
that	SCONJ	O	O	1664
SSR103800	INTJ	O	O	1664
(	PUNCT	O	O	1664
10	NUM	O	O	1664
-	PUNCT	O	O	1664
30	NUM	O	O	1664
mg	VERB	O	O	1664
/	PUNCT	O	O	1664
kg	VERB	O	O	1664
p.o	PROPN	O	O	1664
.	PUNCT	O	O	1664
)	PUNCT	O	O	1664
blocked	VERB	O	O	1665
hyperactivity	NOUN	O	Disease	1665
induced	VERB	O	O	1665
by	ADP	O	O	1665
the	PRON	O	O	1665
non	ADJ	O	O	1665
-	PUNCT	O	O	1665
competitive	ADJ	O	O	1665
NMDA	PROPN	O	Chemical	1665
receptor	NOUN	O	O	1665
antagonist	NOUN	O	O	1665
,	PUNCT	O	O	1665
MK-801	PROPN	O	Chemical	1665
and	CCONJ	O	O	1665
partially	ADV	O	O	1665
reversed	VERB	O	O	1665
spontaneous	ADJ	O	O	1665
hyperactivity	NOUN	O	Disease	1665
of	ADP	O	O	1665
NMDA	PROPN	O	Chemical	1665
Nr1(neo-/-	NUM	O	O	1665
)	PUNCT	O	O	1665
mice	NOUN	O	O	1665
.	PUNCT	O	O	1665
In	ADP	O	O	1666
contrast	NOUN	O	O	1666
,	PUNCT	O	O	1666
SSR103800	INTJ	O	O	1666
failed	VERB	O	O	1666
to	PART	O	O	1666
affect	VERB	O	O	1666
hyperactivity	NOUN	O	Disease	1666
induced	VERB	O	O	1666
by	ADP	O	O	1666
amphetamine	NOUN	O	Chemical	1666
or	CCONJ	O	O	1666
naturally	ADV	O	O	1666
observed	VERB	O	O	1666
in	ADP	O	O	1666
dopamine	NOUN	O	Chemical	1666
transporter	NOUN	O	O	1666
(	PUNCT	O	O	1666
DAT(-/-	NUM	O	O	1666
)	PUNCT	O	O	1666
)	PUNCT	O	O	1666
knockout	NOUN	O	O	1666
mice	NOUN	O	O	1666
Importantly	ADV	O	O	1667
,	PUNCT	O	O	1667
both	PRON	O	O	1667
classical	ADJ	O	O	1667
(	PUNCT	O	O	1667
haloperidol	NOUN	O	Chemical	1667
)	PUNCT	O	O	1667
and	CCONJ	O	O	1667
atypical	ADJ	O	O	1667
(	PUNCT	O	O	1667
olanzapine	NOUN	O	Chemical	1667
,	PUNCT	O	O	1667
clozapine	PROPN	O	Chemical	1667
and	CCONJ	O	O	1667
aripiprazole	NOUN	O	O	1667
)	PUNCT	O	O	1667
antipsychotics	NOUN	O	O	1668
were	AUX	O	O	1668
effective	ADJ	O	O	1668
in	ADP	O	O	1668
all	PRON	O	O	1668
these	PRON	O	O	1668
models	NOUN	O	O	1668
of	ADP	O	O	1668
hyperactivity	NOUN	O	Disease	1668
.	PUNCT	O	O	1668
However	ADV	O	O	1669
,	PUNCT	O	O	1669
unlike	ADP	O	O	1669
these	PRON	O	O	1669
latter	ADJ	O	O	1669
,	PUNCT	O	O	1669
SSR103800	INTJ	O	O	1669
did	VERB	O	O	1669
not	PART	O	O	1669
produce	VERB	O	O	1669
catalepsy	VERB	O	Disease	1669
(	PUNCT	O	O	1669
retention	NOUN	O	O	1669
on	ADP	O	O	1669
the	PRON	O	O	1669
bar	NOUN	O	O	1669
test	NOUN	O	O	1669
)	PUNCT	O	O	1669
up	ADP	O	O	1669
to	PART	O	O	1669
30	NUM	O	O	1669
mg	VERB	O	O	1669
/	PUNCT	O	O	1669
kg	VERB	O	O	1669
p.o	PROPN	O	O	1669
.	PUNCT	O	O	1669
Together	ADV	O	O	1670
these	PRON	O	O	1670
findings	NOUN	O	O	1670
show	VERB	O	O	1670
that	SCONJ	O	O	1670
the	PRON	O	O	1670
GlyT1	PROPN	O	O	1670
inhibitor	NOUN	O	O	1670
,	PUNCT	O	O	1670
SSR103800	INTJ	O	O	1670
,	PUNCT	O	O	1670
produces	VERB	O	O	1670
antipsychotic	ADJ	O	O	1670
-	PUNCT	O	O	1670
like	INTJ	O	O	1670
effects	NOUN	O	O	1670
,	PUNCT	O	O	1670
which	PRON	O	O	1670
differ	VERB	O	O	1670
from	ADP	O	O	1670
those	PRON	O	O	1670
observed	VERB	O	O	1670
with	ADP	O	O	1670
compounds	NOUN	O	O	1670
primarily	ADV	O	O	1670
targeting	VERB	O	O	1670
the	PRON	O	O	1670
dopaminergic	ADJ	O	O	1670
system	NOUN	O	O	1670
,	PUNCT	O	O	1670
and	CCONJ	O	O	1670
has	VERB	O	O	1670
a	PRON	O	O	1670
reduced	VERB	O	O	1670
side	NOUN	O	O	1670
-	PUNCT	O	O	1670
effect	VERB	O	O	1670
potential	ADJ	O	O	1670
as	ADP	O	O	1670
compared	VERB	O	O	1670
with	ADP	O	O	1670
these	PRON	O	O	1670
latter	ADJ	O	O	1670
drugs	NOUN	O	O	1670
.	PUNCT	O	O	1670
Phenylephrine	NOUN	O	O	1673
but	CCONJ	O	O	1673
not	PART	O	O	1673
ephedrine	NOUN	O	Chemical	1673
reduces	VERB	O	O	1673
frontal	ADJ	O	O	1673
lobe	NOUN	O	O	1673
oxygenation	NOUN	O	O	1673
following	VERB	O	O	1673
anesthesia	NOUN	O	O	1673
-	PUNCT	O	O	1673
induced	VERB	O	O	1673
hypotension	NOUN	O	Disease	1673
.	PUNCT	O	O	1673
Vasopressor	NOUN	O	O	1674
agents	NOUN	O	O	1674
are	AUX	O	O	1674
used	VERB	O	O	1674
to	PART	O	O	1674
correct	VERB	O	O	1674
anesthesia	NOUN	O	O	1674
-	PUNCT	O	O	1674
induced	VERB	O	O	1674
hypotension	NOUN	O	Disease	1674
.	PUNCT	O	O	1674
We	PRON	O	O	1675
describe	VERB	O	O	1675
the	PRON	O	O	1675
effect	VERB	O	O	1675
of	ADP	O	O	1675
phenylephrine	NOUN	O	Chemical	1675
and	CCONJ	O	O	1675
ephedrine	NOUN	O	Chemical	1675
on	ADP	O	O	1675
frontal	ADJ	O	O	1675
lobe	NOUN	O	O	1675
oxygenation	NOUN	O	O	1675
(	PUNCT	O	O	1675
S(c)O(2	X	O	O	1675
)	PUNCT	O	O	1675
)	PUNCT	O	O	1675
following	VERB	O	O	1675
anesthesia	NOUN	O	O	1675
-	PUNCT	O	O	1675
induced	VERB	O	O	1675
hypotension	NOUN	O	Disease	1675
.	PUNCT	O	O	1675
Following	VERB	O	O	1676
induction	NOUN	O	O	1676
of	ADP	O	O	1676
anesthesia	NOUN	O	O	1676
by	ADP	O	O	1676
fentanyl	ADJ	O	Chemical	1676
(	PUNCT	O	O	1676
0.15	NUM	O	O	1676
mg	VERB	O	O	1676
kg(-1	NOUN	O	O	1676
)	PUNCT	O	O	1676
)	PUNCT	O	O	1676
and	CCONJ	O	O	1676
propofol	VERB	O	Chemical	1676
(	PUNCT	O	O	1676
2.0	NUM	O	O	1676
mg	VERB	O	O	1676
kg(-1	NOUN	O	O	1676
)	PUNCT	O	O	1676
)	PUNCT	O	O	1676
,	PUNCT	O	O	1676
13	NUM	O	O	1676
patients	NOUN	O	O	1676
received	VERB	O	O	1676
phenylephrine	NOUN	O	Chemical	1676
(	PUNCT	O	O	1676
0.1	NUM	O	O	1676
mg	VERB	O	O	1676
iv	X	O	O	1676
)	PUNCT	O	O	1676
and	CCONJ	O	O	1676
12	NUM	O	O	1676
patients	NOUN	O	O	1676
received	VERB	O	O	1676
ephedrine	NOUN	O	Chemical	1676
(	PUNCT	O	O	1676
10	NUM	O	O	1676
mg	VERB	O	O	1676
iv	X	O	O	1676
)	PUNCT	O	O	1676
to	PART	O	O	1676
restore	VERB	O	O	1676
mean	VERB	O	O	1676
arterial	ADJ	O	O	1676
pressure	NOUN	O	O	1676
(	PUNCT	O	O	1676
MAP	PROPN	O	O	1676
)	PUNCT	O	O	1676
.	PUNCT	O	O	1676
MAP	PROPN	O	O	1677
,	PUNCT	O	O	1677
stroke	VERB	O	Disease	1677
volume	PROPN	O	O	1677
(	PUNCT	O	O	1677
SV	PROPN	O	O	1677
)	PUNCT	O	O	1677
,	PUNCT	O	O	1677
cardiac	ADJ	O	O	1677
output	NOUN	O	O	1677
(	PUNCT	O	O	1677
CO	PROPN	O	O	1677
)	PUNCT	O	O	1677
,	PUNCT	O	O	1677
and	CCONJ	O	O	1677
frontal	ADJ	O	O	1677
lobe	NOUN	O	O	1677
oxygenation	NOUN	O	O	1677
(	PUNCT	O	O	1677
S(c)O(2	X	O	O	1677
)	PUNCT	O	O	1677
)	PUNCT	O	O	1677
were	AUX	O	O	1677
registered	VERB	O	O	1677
.	PUNCT	O	O	1677
Induction	NOUN	O	O	1678
of	ADP	O	O	1678
anesthesia	NOUN	O	O	1678
was	AUX	O	O	1678
followed	VERB	O	O	1678
by	ADP	O	O	1678
a	PRON	O	O	1678
decrease	VERB	O	O	1678
in	ADP	O	O	1678
MAP	PROPN	O	O	1678
,	PUNCT	O	O	1678
HR	NOUN	O	O	1678
,	PUNCT	O	O	1678
SV	PROPN	O	O	1678
,	PUNCT	O	O	1678
and	CCONJ	O	O	1678
CO	PROPN	O	O	1678
concomitant	ADJ	O	O	1678
with	ADP	O	O	1678
an	PRON	O	O	1678
elevation	NOUN	O	O	1678
in	ADP	O	O	1678
S(c)O(2	X	O	O	1678
)	PUNCT	O	O	1678
.	PUNCT	O	O	1678
After	ADP	O	O	1679
administration	NOUN	O	O	1679
of	ADP	O	O	1679
phenylephrine	NOUN	O	Chemical	1679
,	PUNCT	O	O	1679
MAP	PROPN	O	O	1679
increased	VERB	O	O	1679
(	PUNCT	O	O	1679
51	NUM	O	O	1679
+	ADP	O	O	1679
/-	PUNCT	O	O	1679
The	PRON	O	O	1680
administration	NOUN	O	O	1680
of	ADP	O	O	1680
ephedrine	NOUN	O	Chemical	1680
led	VERB	O	O	1680
to	PART	O	O	1680
a	PRON	O	O	1680
similar	ADJ	O	O	1680
increase in MAP	PROPN	O	Disease	1680
(	PUNCT	O	O	1680
53	NUM	O	O	1680
+	ADP	O	O	1680
/-	PUNCT	O	O	1680
The	PRON	O	O	1681
utilization	NOUN	O	O	1681
of	ADP	O	O	1681
phenylephrine	NOUN	O	Chemical	1681
to	PART	O	O	1681
correct	VERB	O	O	1681
hypotension	NOUN	O	Disease	1681
induced	VERB	O	O	1681
by	ADP	O	O	1681
anesthesia	NOUN	O	O	1681
has	VERB	O	O	1681
a	PRON	O	O	1681
negative	ADJ	O	O	1681
impact	NOUN	O	O	1681
on	ADP	O	O	1681
S(c)O(2	X	O	O	1681
)	PUNCT	O	O	1681
while	SCONJ	O	O	1681
ephedrine	NOUN	O	Chemical	1681
maintains	VERB	O	O	1681
frontal	ADJ	O	O	1681
lobe	NOUN	O	O	1681
oxygenation	NOUN	O	O	1681
potentially	ADV	O	O	1681
related	ADJ	O	O	1681
to	PART	O	O	1681
an	PRON	O	O	1681
increase	VERB	O	O	1681
in	ADP	O	O	1681
CO	PROPN	O	O	1681
.	PUNCT	O	O	1681
A	PRON	O	O	1684
novel	NOUN	O	O	1684
,	PUNCT	O	O	1684
multiple	ADJ	O	O	1684
symptom	NOUN	O	O	1684
model	NOUN	O	O	1684
of	ADP	O	O	1684
obsessive	ADJ	O	O	1684
-	PUNCT	O	O	1684
compulsive	ADJ	O	O	1684
-	PUNCT	O	O	1684
like	INTJ	O	O	1684
behaviors	NOUN	O	O	1684
in	ADP	O	O	1684
animals	NOUN	O	O	1684
.	PUNCT	O	O	1684
Current	ADJ	O	O	1685
animal	NOUN	O	O	1685
models	NOUN	O	O	1685
of	ADP	O	O	1685
obsessive	ADJ	O	O	1685
-	PUNCT	O	O	1685
compulsive	ADJ	O	O	1685
disorder	NOUN	O	O	1685
(	PUNCT	O	O	1685
OCD	NOUN	O	O	1685
)	PUNCT	O	O	1685
typically	ADV	O	O	1685
involve	VERB	O	O	1685
acute	ADJ	O	O	1685
,	PUNCT	O	O	1685
drug	NOUN	O	O	1685
-	PUNCT	O	O	1685
induced	VERB	O	O	1685
symptom	NOUN	O	O	1685
provocation	NOUN	O	O	1685
or	CCONJ	O	O	1685
a	PRON	O	O	1685
genetic	ADJ	O	O	1685
association	PROPN	O	O	1685
with	ADP	O	O	1685
stereotypies	NOUN	O	Disease	1685
or	CCONJ	O	O	1685
anxiety	NOUN	O	Disease	1685
.	PUNCT	O	O	1685
None	NOUN	O	O	1686
of	ADP	O	O	1686
these	PRON	O	O	1686
current	ADJ	O	O	1686
models	NOUN	O	O	1686
demonstrate	VERB	O	O	1686
multiple	ADJ	O	O	1686
OCD	NOUN	O	O	1686
-	PUNCT	O	O	1686
like	INTJ	O	O	1686
behaviors	NOUN	O	O	1686
.	PUNCT	O	O	1686
Neonatal	NOUN	O	O	1687
rats	NOUN	O	O	1687
were	AUX	O	O	1687
treated	VERB	O	O	1687
with	ADP	O	O	1687
the	PRON	O	O	1687
tricyclic	ADJ	O	O	1687
antidepressant	NOUN	O	O	1687
clomipramine	NOUN	O	Chemical	1687
or	CCONJ	O	O	1687
vehicle	NOUN	O	O	1687
between	ADP	O	O	1687
days	NOUN	O	O	1687
9	NUM	O	O	1687
and	CCONJ	O	O	1687
16	NUM	O	O	1687
twice	ADV	O	O	1687
daily	ADV	O	O	1687
and	CCONJ	O	O	1687
behaviorally	ADV	O	O	1687
tested	VERB	O	O	1687
in	ADP	O	O	1687
adulthood	NOUN	O	O	1687
.	PUNCT	O	O	1687
RESULTS	VERB	O	O	1688
:	PUNCT	O	O	1688
Clomipramine	NOUN	O	O	1688
exposure	NOUN	O	O	1688
in	ADP	O	O	1688
immature	ADJ	O	O	1688
rats	NOUN	O	O	1688
produced	VERB	O	O	1688
significant	ADJ	O	O	1688
behavioral	ADJ	O	O	1688
and	CCONJ	O	O	1688
biochemical	ADJ	O	O	1688
changes	VERB	O	O	1688
that	SCONJ	O	O	1688
include	VERB	O	O	1688
enhanced	VERB	O	O	1688
anxiety	NOUN	O	Disease	1688
(	PUNCT	O	O	1688
elevated	ADJ	O	O	1688
plus	CCONJ	O	O	1688
maze	NOUN	O	O	1688
and	CCONJ	O	O	1688
marble	NOUN	O	O	1688
burying	VERB	O	O	1688
)	PUNCT	O	O	1688
,	PUNCT	O	O	1688
behavioral	ADJ	O	O	1688
inflexibility	NOUN	O	O	1688
(	PUNCT	O	O	1688
perseveration	NOUN	O	O	1688
in	ADP	O	O	1688
the	PRON	O	O	1688
spontaneous	ADJ	O	O	1688
alternation	NOUN	O	O	1688
task	NOUN	O	O	1688
and	CCONJ	O	O	1688
impaired	VERB	O	O	1688
reversal	NOUN	O	O	1688
learning	VERB	O	O	1688
)	PUNCT	O	O	1688
,	PUNCT	O	O	1688
working	VERB	O	O	1688
memory impairment	NOUN	O	Disease	1688
(	PUNCT	O	O	1688
e.g.	ADV	O	O	1688
,	PUNCT	O	O	1688
win	VERB	O	O	1688
-	PUNCT	O	O	1688
shift	NOUN	O	O	1688
paradigm	NOUN	O	O	1688
)	PUNCT	O	O	1688
,	PUNCT	O	O	1688
hoarding	NOUN	O	O	1688
,	PUNCT	O	O	1688
and	CCONJ	O	O	1688
corticostriatal	PROPN	O	O	1688
dysfunction	NOUN	O	O	1688
.	PUNCT	O	O	1688
Dopamine	NOUN	O	Chemical	1689
D2	NOUN	O	O	1689
receptors	NOUN	O	O	1689
were	AUX	O	O	1689
elevated	ADJ	O	O	1689
in	ADP	O	O	1689
the	PRON	O	O	1689
striatum	NOUN	O	O	1689
,	PUNCT	O	O	1689
whereas	SCONJ	O	O	1689
serotonin	PROPN	O	Chemical	1689
2C	PROPN	O	O	1689
,	PUNCT	O	O	1689
but	CCONJ	O	O	1689
not	PART	O	O	1689
serotonin	PROPN	O	Chemical	1689
1A	PROPN	O	O	1689
,	PUNCT	O	O	1689
receptors	NOUN	O	O	1689
were	AUX	O	O	1689
elevated	ADJ	O	O	1689
in	ADP	O	O	1689
the	PRON	O	O	1689
orbital	ADJ	O	O	1689
frontal	ADJ	O	O	1689
cortex	VERB	O	O	1689
.	PUNCT	O	O	1689
This	PRON	O	O	1690
is	AUX	O	O	1690
the	PRON	O	O	1690
first	ADV	O	O	1690
demonstration	NOUN	O	O	1690
of	ADP	O	O	1690
multiple	ADJ	O	O	1690
symptoms	NOUN	O	O	1690
consistent	ADJ	O	O	1690
with	ADP	O	O	1690
an	PRON	O	O	1690
OCD	NOUN	O	O	1690
-	PUNCT	O	O	1690
like	INTJ	O	O	1690
profile	NOUN	O	O	1690
in	ADP	O	O	1690
animals	NOUN	O	O	1690
.	PUNCT	O	O	1690
Moreover	ADV	O	O	1691
,	PUNCT	O	O	1691
these	PRON	O	O	1691
behaviors	NOUN	O	O	1691
are	AUX	O	O	1691
accompanied	VERB	O	O	1691
by	ADP	O	O	1691
biochemical	ADJ	O	O	1691
changes	VERB	O	O	1691
in	ADP	O	O	1691
brain	NOUN	O	O	1691
regions	NOUN	O	O	1691
previously	ADV	O	O	1691
identified	VERB	O	O	1691
as	ADP	O	O	1691
relevant	ADJ	O	O	1691
to	PART	O	O	1691
OCD	NOUN	O	O	1691
.	PUNCT	O	O	1691
This	PRON	O	O	1692
novel	NOUN	O	O	1692
model	NOUN	O	O	1692
of	ADP	O	O	1692
OCD	NOUN	O	O	1692
demonstrates	VERB	O	O	1692
that	SCONJ	O	O	1692
drug	NOUN	O	O	1692
exposure	NOUN	O	O	1692
during	ADP	O	O	1692
a	PRON	O	O	1692
sensitive	ADJ	O	O	1692
period	NOUN	O	O	1692
can	AUX	O	O	1692
program	PROPN	O	O	1692
disease	PROPN	O	O	1692
-	PUNCT	O	O	1692
like	INTJ	O	O	1692
systems	NOUN	O	O	1692
permanently	ADV	O	O	1692
,	PUNCT	O	O	1692
which	PRON	O	O	1692
could	AUX	O	O	1692
have	VERB	O	O	1692
implications	NOUN	O	O	1692
for	ADP	O	O	1692
current	ADJ	O	O	1692
and	CCONJ	O	O	1692
future	NOUN	O	O	1692
therapeutic	ADJ	O	O	1692
strategies	NOUN	O	O	1692
for	ADP	O	O	1692
this	PRON	O	O	1692
and	CCONJ	O	O	1692
other	ADJ	O	O	1692
psychiatric disorders	NOUN	O	Disease	1692
.	PUNCT	O	O	1692
Late	ADV	O	O	1695
recovery	NOUN	O	O	1695
of	ADP	O	O	1695
renal	ADJ	O	O	1695
function	NOUN	O	O	1695
in	ADP	O	O	1695
a	PRON	O	O	1695
woman	NOUN	O	O	1695
with	ADP	O	O	1695
the	PRON	O	O	1695
hemolytic uremic syndrome	NOUN	O	Disease	1695
.	PUNCT	O	O	1695
A	PRON	O	O	1696
case	NOUN	O	O	1696
is	AUX	O	O	1696
reported	VERB	O	O	1696
of	ADP	O	O	1696
the	PRON	O	O	1696
hemolytic uremic syndrome	NOUN	O	Disease	1696
(	PUNCT	O	O	1696
HUS	PROPN	O	Disease	1696
)	PUNCT	O	O	1696
in	ADP	O	O	1696
a	PRON	O	O	1696
woman	NOUN	O	O	1696
taking	VERB	O	O	1696
oral contraceptives	NOUN	O	Chemical	1696
.	PUNCT	O	O	1696
She	PRON	O	O	1697
was	AUX	O	O	1697
treated	VERB	O	O	1697
with	ADP	O	O	1697
heparin	NOUN	O	Chemical	1697
,	PUNCT	O	O	1697
dipyridamole	NOUN	O	Chemical	1697
and	CCONJ	O	O	1697
hemodialysis	NOUN	O	O	1697
;	PUNCT	O	O	1697
and	CCONJ	O	O	1697
after	ADP	O	O	1697
more	ADJ	O	O	1697
than	ADP	O	O	1697
three	NUM	O	O	1697
months	NOUN	O	O	1697
,	PUNCT	O	O	1697
her	PRON	O	O	1697
urinary	ADJ	O	O	1697
output	NOUN	O	O	1697
rose	VERB	O	O	1697
above	ADP	O	O	1697
500	NUM	O	O	1697
ml	ADP	O	O	1697
;	PUNCT	O	O	1697
and	CCONJ	O	O	1697
six	NUM	O	O	1697
months	NOUN	O	O	1697
after	ADP	O	O	1697
the	PRON	O	O	1697
onset	VERB	O	O	1697
of	ADP	O	O	1697
anuria	VERB	O	Disease	1697
,	PUNCT	O	O	1697
dialysis	NOUN	O	O	1697
treatment	NOUN	O	O	1697
was	AUX	O	O	1697
stopped	VERB	O	O	1697
.	PUNCT	O	O	1697
This	PRON	O	O	1698
case	NOUN	O	O	1698
emphasizes	VERB	O	O	1698
the	PRON	O	O	1698
possibility	NOUN	O	O	1698
that	SCONJ	O	O	1698
HUS	PROPN	O	Disease	1698
in	ADP	O	O	1698
adults	NOUN	O	O	1698
is	AUX	O	O	1698
not	PART	O	O	1698
invariably	ADV	O	O	1698
irreversible	ADJ	O	O	1698
and	CCONJ	O	O	1698
that	SCONJ	O	O	1698
,	PUNCT	O	O	1698
despite	SCONJ	O	O	1698
prolonged	VERB	O	O	1698
oliguria	PROPN	O	O	1698
,	PUNCT	O	O	1698
recovery	NOUN	O	O	1698
of	ADP	O	O	1698
renal	ADJ	O	O	1698
function	NOUN	O	O	1698
can	AUX	O	O	1698
be	AUX	O	O	1698
obtained	VERB	O	O	1698
.	PUNCT	O	O	1698
Therefore	ADV	O	O	1699
,	PUNCT	O	O	1699
in	ADP	O	O	1699
adult	NOUN	O	O	1699
patients	NOUN	O	O	1699
affected	VERB	O	O	1699
by	ADP	O	O	1699
HUS	PROPN	O	Disease	1699
,	PUNCT	O	O	1699
dialysis	NOUN	O	O	1699
should	AUX	O	O	1699
not	PART	O	O	1699
be	AUX	O	O	1699
discontinued	VERB	O	O	1699
prematurely	ADV	O	O	1699
;	PUNCT	O	O	1699
moreover	ADV	O	O	1699
,	PUNCT	O	O	1699
bilateral	ADJ	O	O	1699
nephrectomy	NOUN	O	O	1699
,	PUNCT	O	O	1699
for	ADP	O	O	1699
treatment	NOUN	O	O	1699
of	ADP	O	O	1699
severe	ADJ	O	O	1699
hypertension	NOUN	O	Disease	1699
and	CCONJ	O	O	1699
microangiopathic	ADV	O	O	1699
hemolytic anemia	NOUN	O	Disease	1699
,	PUNCT	O	O	1699
should	AUX	O	O	1699
be	AUX	O	O	1699
performed	VERB	O	O	1699
with	ADP	O	O	1699
caution	NOUN	O	O	1699
.	PUNCT	O	O	1699
Effects	NOUN	O	O	1702
of	ADP	O	O	1702
acetylsalicylic acid	NOUN	O	Chemical	1702
,	PUNCT	O	O	1702
dipyridamole	NOUN	O	Chemical	1702
,	PUNCT	O	O	1702
and	CCONJ	O	O	1702
hydrocortisone	NOUN	O	Chemical	1702
on	ADP	O	O	1702
epinephrine	NOUN	O	Chemical	1702
-	PUNCT	O	O	1702
induced	VERB	O	O	1702
myocardial injury	NOUN	O	Disease	1702
in	ADP	O	O	1702
dogs	NOUN	O	O	1702
.	PUNCT	O	O	1702
A	PRON	O	O	1703
reproducible	ADJ	O	O	1703
model	NOUN	O	O	1703
for	ADP	O	O	1703
producing	VERB	O	O	1703
diffuse	VERB	O	O	1703
myocardial injury	NOUN	O	Disease	1703
(	PUNCT	O	O	1703
epinephrine	NOUN	O	Chemical	1703
infusion	NOUN	O	O	1703
)	PUNCT	O	O	1703
has	VERB	O	O	1703
been	AUX	O	O	1703
developed	VERB	O	O	1703
to	PART	O	O	1703
study	VERB	O	O	1703
the	PRON	O	O	1703
cardioprotective	ADJ	O	O	1703
effects	NOUN	O	O	1703
of	ADP	O	O	1703
agents	NOUN	O	O	1703
or	CCONJ	O	O	1703
maneuvers	NOUN	O	O	1703
which	PRON	O	O	1703
might	AUX	O	O	1703
alter	VERB	O	O	1703
the	PRON	O	O	1703
evolution	NOUN	O	O	1703
of	ADP	O	O	1703
acute	ADJ	O	O	1703
myocardial infarction	NOUN	O	Disease	1703
.	PUNCT	O	O	1703
Infusions	NOUN	O	O	1704
of	ADP	O	O	1704
epinephrine	NOUN	O	Chemical	1704
(	PUNCT	O	O	1704
4	NUM	O	O	1704
mug	NOUN	O	O	1704
per	ADP	O	O	1704
kilogram	NOUN	O	O	1704
per	ADP	O	O	1704
minute	VERB	O	O	1704
for	ADP	O	O	1704
6	NUM	O	O	1704
hours	NOUN	O	O	1704
)	PUNCT	O	O	1704
increased	VERB	O	O	1704
radiocalcium	NOUN	O	O	1704
uptakes	NOUN	O	O	1704
into	ADP	O	O	1704
intact	ADJ	O	O	1704
myocardium	NOUN	O	O	1704
and	CCONJ	O	O	1704
each	PRON	O	O	1704
of	ADP	O	O	1704
its	PRON	O	O	1704
subcellular	ADJ	O	O	1704
components	NOUN	O	O	1704
with	ADP	O	O	1704
the	PRON	O	O	1704
mitochondrial	ADJ	O	O	1704
fraction	NOUN	O	O	1704
showing	VERB	O	O	1704
the	PRON	O	O	1704
most	ADV	O	O	1704
consistent	ADJ	O	O	1704
changes	VERB	O	O	1704
when	SCONJ	O	O	1704
compared	VERB	O	O	1704
to	PART	O	O	1704
saline	NOUN	O	O	1704
-	PUNCT	O	O	1704
infused	VERB	O	O	1704
control	VERB	O	O	1704
animals	NOUN	O	O	1704
(	PUNCT	O	O	1704
4,957	NUM	O	O	1704
vs.	CCONJ	O	O	1704
827	NUM	O	O	1704
counts	VERB	O	O	1704
per	ADP	O	O	1704
minute	VERB	O	O	1704
per	ADP	O	O	1704
gram	PROPN	O	O	1704
of	ADP	O	O	1704
dried	VERB	O	O	1704
tissue	NOUN	O	O	1704
or	CCONJ	O	O	1704
fraction	NOUN	O	O	1704
)	PUNCT	O	O	1704
.	PUNCT	O	O	1704
Myocardial	PROPN	O	O	1705
concentrations	NOUN	O	O	1705
of	ADP	O	O	1705
calcium	NOUN	O	Chemical	1705
also	ADV	O	O	1705
increased	VERB	O	O	1705
significantly	ADV	O	O	1705
(	PUNCT	O	O	1705
12.0	NUM	O	O	1705
vs.	CCONJ	O	O	1705
5.0	NUM	O	O	1705
mg.per	CCONJ	O	O	1705
100	NUM	O	O	1705
Gm	PROPN	O	O	1705
.	PUNCT	O	O	1705
Infusions	NOUN	O	O	1706
of	ADP	O	O	1706
calcium chloride	NOUN	O	Chemical	1706
sufficient	ADJ	O	O	1706
to	PART	O	O	1706
raise	VERB	O	O	1706
serum	NOUN	O	O	1706
calcium	NOUN	O	Chemical	1706
concentrations	NOUN	O	O	1706
2	X	O	O	1706
mEq	VERB	O	O	1706
.	PUNCT	O	O	1706
per	ADP	O	O	1707
liter	NOUN	O	O	1707
failed	VERB	O	O	1707
to	PART	O	O	1707
increase	VERB	O	O	1707
calcium	NOUN	O	Chemical	1707
influx	VERB	O	O	1707
into	ADP	O	O	1707
the	PRON	O	O	1707
myocardial	ADJ	O	O	1707
cell	NOUN	O	O	1707
.	PUNCT	O	O	1707
Mitochondrial	NOUN	O	O	1708
radiocalcium	NOUN	O	O	1708
uptakes	NOUN	O	O	1708
were	AUX	O	O	1708
significantly	ADV	O	O	1708
decreased	VERB	O	O	1708
in	ADP	O	O	1708
animals	NOUN	O	O	1708
pretreated	VERB	O	O	1708
with	ADP	O	O	1708
acetylsalicylic acid	NOUN	O	Chemical	1708
or	CCONJ	O	O	1708
dipyridamole	NOUN	O	Chemical	1708
or	CCONJ	O	O	1708
when	SCONJ	O	O	1708
hydrocortisone	NOUN	O	Chemical	1708
was	AUX	O	O	1708
added	VERB	O	O	1708
to	PART	O	O	1708
the	PRON	O	O	1708
epinephrine	NOUN	O	Chemical	1708
infusion	NOUN	O	O	1708
(	PUNCT	O	O	1708
2,682,2,803	NUM	O	O	1708
,	PUNCT	O	O	1708
and	CCONJ	O	O	1708
3,424	NUM	O	O	1708
counts	VERB	O	O	1708
per	ADP	O	O	1708
minute	VERB	O	O	1708
per	ADP	O	O	1708
gram	PROPN	O	O	1708
of	ADP	O	O	1708
dried	VERB	O	O	1708
fraction	NOUN	O	O	1708
,	PUNCT	O	O	1708
respectively	ADV	O	O	1708
)	PUNCT	O	O	1708
.	PUNCT	O	O	1708
Myocardial	PROPN	O	O	1709
calcium	NOUN	O	Chemical	1709
concentrations	NOUN	O	O	1709
also	ADV	O	O	1709
were	AUX	O	O	1709
decreased	VERB	O	O	1709
(	PUNCT	O	O	1709
11.2	NUM	O	O	1709
,	PUNCT	O	O	1709
8.3	NUM	O	O	1709
,	PUNCT	O	O	1709
and	CCONJ	O	O	1709
8.9	NUM	O	O	1709
mg	VERB	O	O	1709
.	PUNCT	O	O	1709
Acetylsalicylic	PROPN	O	O	1710
acid	PROPN	O	O	1710
,	PUNCT	O	O	1710
dipyridamole	NOUN	O	Chemical	1710
,	PUNCT	O	O	1710
and	CCONJ	O	O	1710
hydrocortisone	NOUN	O	Chemical	1710
all	PRON	O	O	1710
appear	VERB	O	O	1710
to	PART	O	O	1710
have	VERB	O	O	1710
cardioprotective	ADJ	O	O	1710
effects	NOUN	O	O	1710
when	SCONJ	O	O	1710
tested	VERB	O	O	1710
in	ADP	O	O	1710
this	PRON	O	O	1710
model	NOUN	O	O	1710
.	PUNCT	O	O	1710
Changes	NOUN	O	O	1713
in	ADP	O	O	1713
depressive	ADJ	O	Disease	1713
status	NOUN	O	O	1713
associated	VERB	O	O	1713
with	ADP	O	O	1713
topical	ADJ	O	O	1713
beta	NOUN	O	O	1713
-	PUNCT	O	O	1713
blockers	NOUN	O	O	1713
.	PUNCT	O	O	1713
Depression	NOUN	O	O	1714
and	CCONJ	O	O	1714
sexual dysfunction	NOUN	O	Disease	1714
have	VERB	O	O	1714
been	AUX	O	O	1714
related	ADJ	O	O	1714
to	PART	O	O	1714
side	NOUN	O	O	1714
effects	NOUN	O	O	1714
of	ADP	O	O	1714
topical	ADJ	O	O	1714
beta	NOUN	O	O	1714
-	PUNCT	O	O	1714
blockers	NOUN	O	O	1714
.	PUNCT	O	O	1714
We	PRON	O	O	1715
performed	VERB	O	O	1715
a	PRON	O	O	1715
preliminary	ADJ	O	O	1715
study	VERB	O	O	1715
in	ADP	O	O	1715
order	NOUN	O	O	1715
to	PART	O	O	1715
determine	VERB	O	O	1715
any	PRON	O	O	1715
difference	NOUN	O	O	1715
between	ADP	O	O	1715
a	PRON	O	O	1715
non	ADJ	O	O	1715
selective	ADJ	O	O	1715
beta	NOUN	O	O	1715
-	PUNCT	O	O	1715
blocker	NOUN	O	O	1715
(	PUNCT	O	O	1715
timolol	PROPN	O	Chemical	1715
)	PUNCT	O	O	1715
and	CCONJ	O	O	1715
a	PRON	O	O	1715
selective	ADJ	O	O	1715
beta	NOUN	O	O	1715
-	PUNCT	O	O	1715
blocker	NOUN	O	O	1715
(	PUNCT	O	O	1715
betaxolol	PROPN	O	O	1715
)	PUNCT	O	O	1715
regarding	VERB	O	O	1715
CNS	PROPN	O	O	1715
side	NOUN	O	O	1715
effects	NOUN	O	O	1715
.	PUNCT	O	O	1715
Eight	NUM	O	O	1716
glaucomatous	ADJ	O	O	1716
patients	NOUN	O	O	1716
chronically	ADV	O	O	1716
treated	VERB	O	O	1716
with	ADP	O	O	1716
timolol	PROPN	O	Chemical	1716
0.5%/12h	X	O	O	1716
,	PUNCT	O	O	1716
suffering	VERB	O	O	1716
from	ADP	O	O	1716
depression	PROPN	O	Disease	1716
diagnosed	VERB	O	O	1716
through	ADP	O	O	1716
DMS	PROPN	O	O	1716
-	PUNCT	O	O	1716
III	NUM	O	O	1716
-	PUNCT	O	O	1716
R	NOUN	O	O	1716
criteria	NOUN	O	O	1716
,	PUNCT	O	O	1716
were	AUX	O	O	1716
included	VERB	O	O	1716
in	ADP	O	O	1716
the	PRON	O	O	1716
study	VERB	O	O	1716
.	PUNCT	O	O	1716
During	ADP	O	O	1717
the	PRON	O	O	1717
six	NUM	O	O	1717
-	PUNCT	O	O	1717
month	NOUN	O	O	1717
follow	VERB	O	O	1717
up	ADP	O	O	1717
,	PUNCT	O	O	1717
depression	PROPN	O	Disease	1717
was	AUX	O	O	1717
quantified	VERB	O	O	1717
through	ADP	O	O	1717
the	PRON	O	O	1717
Beck	PROPN	O	O	1717
and	CCONJ	O	O	1717
Zung	PROPN	O	O	1717
-	PUNCT	O	O	1717
Conde	PROPN	O	O	1717
scales	NOUN	O	O	1717
every	PRON	O	O	1717
two	NUM	O	O	1717
months	NOUN	O	O	1717
.	PUNCT	O	O	1717
In	ADP	O	O	1718
a	PRON	O	O	1718
double	ADJ	O	O	1718
blind	ADJ	O	Disease	1718
cross	VERB	O	O	1718
-	PUNCT	O	O	1718
over	ADP	O	O	1718
study	VERB	O	O	1718
with	ADP	O	O	1718
control	VERB	O	O	1718
group	NOUN	O	O	1718
,	PUNCT	O	O	1718
the	PRON	O	O	1718
patients	NOUN	O	O	1718
under	ADP	O	O	1718
timolol	PROPN	O	Chemical	1718
treatment	NOUN	O	O	1718
presented	VERB	O	O	1718
higher	ADJ	O	O	1718
depression	PROPN	O	Disease	1718
values	NOUN	O	O	1718
measured	VERB	O	O	1718
through	ADP	O	O	1718
the	PRON	O	O	1718
Beck	PROPN	O	O	1718
and	CCONJ	O	O	1718
the	PRON	O	O	1718
Zung	PROPN	O	O	1718
-	PUNCT	O	O	1718
Conde	PROPN	O	O	1718
scales	NOUN	O	O	1718
(	PUNCT	O	O	1718
p	NOUN	O	O	1718
These	PRON	O	O	1719
results	VERB	O	O	1719
suggest	VERB	O	O	1719
that	SCONJ	O	O	1719
betaxolol	PROPN	O	O	1719
could	AUX	O	O	1719
be	AUX	O	O	1719
less	ADV	O	O	1719
of	ADP	O	O	1719
a	PRON	O	O	1719
depression	PROPN	O	Disease	1719
-	PUNCT	O	O	1719
inducer	NOUN	O	O	1719
than	ADP	O	O	1719
timolol	PROPN	O	Chemical	1719
in	ADP	O	O	1719
predisposed	ADJ	O	O	1719
patients	NOUN	O	O	1719
.	PUNCT	O	O	1719
Long	ADV	O	O	1722
-	PUNCT	O	O	1722
term	NOUN	O	O	1722
follow	VERB	O	O	1722
-	PUNCT	O	O	1722
up	ADP	O	O	1722
of	ADP	O	O	1722
ifosfamide	ADP	O	Chemical	1722
renal toxicity	NOUN	O	Disease	1722
in	ADP	O	O	1722
children	NOUN	O	O	1722
treated	VERB	O	O	1722
for	ADP	O	O	1722
malignant	ADJ	O	O	1722
mesenchymal	NOUN	O	O	1722
tumors	NOUN	O	Disease	1722
:	PUNCT	O	O	1722
an	PRON	O	O	1722
International	PROPN	O	O	1722
Society	NOUN	O	O	1722
of	ADP	O	O	1722
Pediatric	ADJ	O	O	1722
Oncology	NOUN	O	O	1722
report	VERB	O	O	1722
.	PUNCT	O	O	1722
The	PRON	O	O	1723
renal	ADJ	O	O	1723
function	NOUN	O	O	1723
of	ADP	O	O	1723
74	NUM	O	O	1723
children	NOUN	O	O	1723
with	ADP	O	O	1723
malignant	ADJ	O	O	1723
mesenchymal	NOUN	O	O	1723
tumors	NOUN	O	Disease	1723
in	ADP	O	O	1723
complete	VERB	O	O	1723
remission	NOUN	O	O	1723
and	CCONJ	O	O	1723
who	PRON	O	O	1723
have	VERB	O	O	1723
received	VERB	O	O	1723
the	PRON	O	O	1723
same	ADJ	O	O	1723
ifosfamide	ADP	O	Chemical	1723
chemotherapy	NOUN	O	O	1723
protocol	PROPN	O	O	1723
(	PUNCT	O	O	1723
International	PROPN	O	O	1723
Society	NOUN	O	O	1723
of	ADP	O	O	1723
Pediatric	ADJ	O	O	1723
Oncology	NOUN	O	O	1723
Malignant	ADJ	O	O	1723
Mesenchymal	PROPN	O	O	1723
Tumor	NOUN	O	O	1723
Study	NOUN	O	O	1723
84	NUM	O	O	1723
[	X	O	O	1723
SIOP	PROPN	O	O	1723
MMT	PROPN	O	O	1723
84	NUM	O	O	1723
]	PUNCT	O	O	1723
)	PUNCT	O	O	1723
were	AUX	O	O	1723
studied	VERB	O	O	1723
1	X	O	O	1723
year	NOUN	O	O	1723
after	ADP	O	O	1723
the	PRON	O	O	1723
completion	NOUN	O	O	1723
of	ADP	O	O	1723
treatment	NOUN	O	O	1723
.	PUNCT	O	O	1723
Total	ADJ	O	O	1724
cumulative	ADJ	O	O	1724
doses	NOUN	O	O	1724
were	AUX	O	O	1724
36	NUM	O	O	1724
or	CCONJ	O	O	1724
60	NUM	O	O	1724
g	X	O	O	1724
/	PUNCT	O	O	1724
m2	PROPN	O	O	1724
of	ADP	O	O	1724
ifosfamide	ADP	O	Chemical	1724
(	PUNCT	O	O	1724
six	NUM	O	O	1724
or	CCONJ	O	O	1724
10	NUM	O	O	1724
cycles	NOUN	O	O	1724
of	ADP	O	O	1724
ifosfamide	ADP	O	Chemical	1724
,	PUNCT	O	O	1724
vincristine	NOUN	O	Chemical	1724
,	PUNCT	O	O	1724
and	CCONJ	O	O	1724
dactinomycin	VERB	O	O	1724
[	X	O	O	1724
IVA	PROPN	O	O	1724
]	PUNCT	O	O	1724
)	PUNCT	O	O	1724
.	PUNCT	O	O	1724
None	NOUN	O	O	1725
of	ADP	O	O	1725
them	PRON	O	O	1725
had	VERB	O	O	1725
received	VERB	O	O	1725
cisplatin	NOUN	O	Chemical	1725
chemotherapy	NOUN	O	O	1725
.	PUNCT	O	O	1725
The	PRON	O	O	1726
most	ADV	O	O	1726
common	ADJ	O	O	1726
primary	NOUN	O	O	1726
tumor	NOUN	O	Disease	1726
site	NOUN	O	O	1726
was	AUX	O	O	1726
the	PRON	O	O	1726
head	NOUN	O	O	1726
and	CCONJ	O	O	1726
neck	NOUN	O	O	1726
.	PUNCT	O	O	1726
Renal	NOUN	O	O	1727
function	NOUN	O	O	1727
was	AUX	O	O	1727
investigated	VERB	O	O	1727
by	ADP	O	O	1727
measuring	VERB	O	O	1727
plasma	NOUN	O	O	1727
and	CCONJ	O	O	1727
urinary	ADJ	O	O	1727
electrolytes	NOUN	O	O	1727
,	PUNCT	O	O	1727
glucosuria	VERB	O	O	1727
,	PUNCT	O	O	1727
proteinuria	X	O	Disease	1727
,	PUNCT	O	O	1727
aminoaciduria	NOUN	O	O	1727
,	PUNCT	O	O	1727
urinary	ADJ	O	O	1727
pH	NOUN	O	O	1727
,	PUNCT	O	O	1727
osmolarity	NOUN	O	O	1727
,	PUNCT	O	O	1727
creatinine	PROPN	O	Chemical	1727
clearance	NOUN	O	O	1727
,	PUNCT	O	O	1727
phosphate	NOUN	O	Chemical	1727
tubular	ADJ	O	O	1727
reabsorption	NOUN	O	O	1727
,	PUNCT	O	O	1727
beta	NOUN	O	O	1727
2	X	O	O	1727
microglobulinuria	ADJ	O	O	1727
,	PUNCT	O	O	1727
and	CCONJ	O	O	1727
lysozymuria	VERB	O	O	1727
.	PUNCT	O	O	1727
Fifty	NUM	O	O	1728
-	PUNCT	O	O	1728
eight	NUM	O	O	1728
patients	NOUN	O	O	1728
(	PUNCT	O	O	1728
78%	NOUN	O	O	1728
)	PUNCT	O	O	1728
had	VERB	O	O	1728
normal	ADJ	O	O	1728
renal	ADJ	O	O	1728
tests	VERB	O	O	1728
,	PUNCT	O	O	1728
whereas	SCONJ	O	O	1728
16	NUM	O	O	1728
patients	NOUN	O	O	1728
(	PUNCT	O	O	1728
22%	NOUN	O	O	1728
)	PUNCT	O	O	1728
had	VERB	O	O	1728
renal	ADJ	O	O	1728
abnormalities	NOUN	O	O	1728
.	PUNCT	O	O	1728
the	PRON	O	O	1729
first	ADV	O	O	1729
included	VERB	O	O	1729
four	NUM	O	O	1729
patients	NOUN	O	O	1729
(	PUNCT	O	O	1729
5%	NOUN	O	O	1729
of	ADP	O	O	1729
the	PRON	O	O	1729
total	ADJ	O	O	1729
population	NOUN	O	O	1729
)	PUNCT	O	O	1729
who	PRON	O	O	1729
developed	VERB	O	O	1729
major	ADJ	O	O	1729
toxicity	NOUN	O	Disease	1729
resulting	VERB	O	O	1729
in	ADP	O	O	1729
Fanconi	NOUN	O	O	1729
's	AUX	O	O	1729
syndrome	NOUN	O	O	1729
(	PUNCT	O	O	1729
TDFS	NOUN	O	O	1729
)	PUNCT	O	O	1729
;	PUNCT	O	O	1729
and	CCONJ	O	O	1729
the	PRON	O	O	1729
second	ADV	O	O	1729
group	NOUN	O	O	1729
included	VERB	O	O	1729
five	NUM	O	O	1729
patients	NOUN	O	O	1729
with	ADP	O	O	1729
elevated	ADJ	O	O	1729
beta	NOUN	O	O	1729
2	X	O	O	1729
microglobulinuria	ADJ	O	O	1729
and	CCONJ	O	O	1729
low	ADJ	O	O	1729
phosphate	NOUN	O	Chemical	1729
reabsorption	NOUN	O	O	1729
.	PUNCT	O	O	1729
Severe	ADJ	O	O	1730
toxicity	NOUN	O	Disease	1730
was	AUX	O	O	1730
correlated	VERB	O	O	1730
with	ADP	O	O	1730
the	PRON	O	O	1730
higher	ADJ	O	O	1730
cumulative	ADJ	O	O	1730
dose	NOUN	O	O	1730
of	ADP	O	O	1730
60	NUM	O	O	1730
g	X	O	O	1730
/	PUNCT	O	O	1730
m2	PROPN	O	O	1730
of	ADP	O	O	1730
ifosfamide	ADP	O	Chemical	1730
,	PUNCT	O	O	1730
a	PRON	O	O	1730
younger	ADJ	O	O	1730
age	NOUN	O	O	1730
(	PUNCT	O	O	1730
less	ADV	O	O	1730
than	ADP	O	O	1730
2	X	O	O	1730
1/2	NUM	O	O	1730
years	NOUN	O	O	1730
old	ADJ	O	O	1730
)	PUNCT	O	O	1730
,	PUNCT	O	O	1730
and	CCONJ	O	O	1730
a	PRON	O	O	1730
predominance	NOUN	O	O	1730
of	ADP	O	O	1730
vesicoprostatic	ADJ	O	O	1730
tumor	NOUN	O	Disease	1730
involvement	NOUN	O	O	1730
.	PUNCT	O	O	1730
This	PRON	O	O	1731
low	ADJ	O	O	1731
percentage	NOUN	O	O	1731
(	PUNCT	O	O	1731
5%	NOUN	O	O	1731
)	PUNCT	O	O	1731
of	ADP	O	O	1731
TDFS	NOUN	O	O	1731
must	AUX	O	O	1731
be	AUX	O	O	1731
evaluated	VERB	O	O	1731
with	ADP	O	O	1731
respect	VERB	O	O	1731
to	PART	O	O	1731
the	PRON	O	O	1731
efficacy	NOUN	O	O	1731
of	ADP	O	O	1731
ifosfamide	ADP	O	Chemical	1731
in	ADP	O	O	1731
the	PRON	O	O	1731
treatment	NOUN	O	O	1731
of	ADP	O	O	1731
mesenchymal	NOUN	O	O	1731
tumors	NOUN	O	Disease	1731
in	ADP	O	O	1731
children	NOUN	O	O	1731
.	PUNCT	O	O	1731
Evidence	NOUN	O	O	1734
for	ADP	O	O	1734
an	PRON	O	O	1734
involvement	NOUN	O	O	1734
of	ADP	O	O	1734
D1	PROPN	O	O	1734
and	CCONJ	O	O	1734
D2	NOUN	O	O	1734
dopamine	NOUN	O	Chemical	1734
receptors	NOUN	O	O	1734
in	ADP	O	O	1734
mediating	VERB	O	O	1734
nicotine	NOUN	O	Chemical	1734
-	PUNCT	O	O	1734
induced	VERB	O	O	1734
hyperactivity	NOUN	O	Disease	1734
in	ADP	O	O	1734
rats	NOUN	O	O	1734
.	PUNCT	O	O	1734
Previous	ADJ	O	O	1735
studies	NOUN	O	O	1735
have	VERB	O	O	1735
suggested	VERB	O	O	1735
that	SCONJ	O	O	1735
repeated	VERB	O	O	1735
exposure	NOUN	O	O	1735
of	ADP	O	O	1735
rats	NOUN	O	O	1735
to	PART	O	O	1735
the	PRON	O	O	1735
drug	NOUN	O	O	1735
or	CCONJ	O	O	1735
to	PART	O	O	1735
the	PRON	O	O	1735
experimental	ADJ	O	O	1735
environment	NOUN	O	O	1735
is	AUX	O	O	1735
necessary	ADJ	O	O	1735
to	PART	O	O	1735
observe	VERB	O	O	1735
nicotine	NOUN	O	Chemical	1735
-	PUNCT	O	O	1735
induced	VERB	O	O	1735
locomotor	PROPN	O	O	1735
stimulation	NOUN	O	O	1735
.	PUNCT	O	O	1735
In	ADP	O	O	1736
the	PRON	O	O	1736
present	NOUN	O	O	1736
study	VERB	O	O	1736
the	PRON	O	O	1736
role	NOUN	O	O	1736
of	ADP	O	O	1736
habituation	NOUN	O	O	1736
to	PART	O	O	1736
the	PRON	O	O	1736
experimental	ADJ	O	O	1736
environment	NOUN	O	O	1736
on	ADP	O	O	1736
the	PRON	O	O	1736
stimulant	NOUN	O	O	1736
effect	VERB	O	O	1736
of	ADP	O	O	1736
nicotine	NOUN	O	Chemical	1736
in	ADP	O	O	1736
rats	NOUN	O	O	1736
was	AUX	O	O	1736
examined	VERB	O	O	1736
.	PUNCT	O	O	1736
In	ADP	O	O	1737
addition	NOUN	O	O	1737
,	PUNCT	O	O	1737
the	PRON	O	O	1737
role	NOUN	O	O	1737
of	ADP	O	O	1737
dopamine	NOUN	O	Chemical	1737
receptors	NOUN	O	O	1737
in	ADP	O	O	1737
mediating	VERB	O	O	1737
nicotine	NOUN	O	Chemical	1737
-	PUNCT	O	O	1737
induced	VERB	O	O	1737
locomotor	PROPN	O	O	1737
stimulation	NOUN	O	O	1737
was	AUX	O	O	1737
investigated	VERB	O	O	1737
by	ADP	O	O	1737
examining	VERB	O	O	1737
the	PRON	O	O	1737
effects	NOUN	O	O	1737
of	ADP	O	O	1737
selective	ADJ	O	O	1737
D1	PROPN	O	O	1737
and	CCONJ	O	O	1737
D2	NOUN	O	O	1737
dopamine	NOUN	O	Chemical	1737
receptor	NOUN	O	O	1737
antagonists	NOUN	O	O	1737
on	ADP	O	O	1737
activity	NOUN	O	O	1737
induced	VERB	O	O	1737
by	ADP	O	O	1737
nicotine	NOUN	O	Chemical	1737
.	PUNCT	O	O	1737
Nicotine	NOUN	O	Chemical	1738
(	PUNCT	O	O	1738
1.0	NUM	O	O	1738
mg	VERB	O	O	1738
/	PUNCT	O	O	1738
kg	VERB	O	O	1738
)	PUNCT	O	O	1738
caused	VERB	O	O	1738
a	PRON	O	O	1738
significant	ADJ	O	O	1738
increase	VERB	O	O	1738
in	ADP	O	O	1738
locomotor	PROPN	O	O	1738
activity	NOUN	O	O	1738
in	ADP	O	O	1738
rats	NOUN	O	O	1738
that	SCONJ	O	O	1738
were	AUX	O	O	1738
habituated	VERB	O	O	1738
to	PART	O	O	1738
the	PRON	O	O	1738
test	NOUN	O	O	1738
environment	NOUN	O	O	1738
,	PUNCT	O	O	1738
but	CCONJ	O	O	1738
had	VERB	O	O	1738
only	ADV	O	O	1738
a	PRON	O	O	1738
weak	ADJ	O	O	1738
and	CCONJ	O	O	1738
delayed	VERB	O	O	1738
stimulant	NOUN	O	O	1738
action	NOUN	O	O	1738
in	ADP	O	O	1738
rats	NOUN	O	O	1738
that	SCONJ	O	O	1738
were	AUX	O	O	1738
unfamiliar	ADJ	O	O	1738
with	ADP	O	O	1738
the	PRON	O	O	1738
test	NOUN	O	O	1738
environment	NOUN	O	O	1738
.	PUNCT	O	O	1738
The	PRON	O	O	1739
stimulant	NOUN	O	O	1739
action	NOUN	O	O	1739
of	ADP	O	O	1739
nicotine	NOUN	O	Chemical	1739
was	AUX	O	O	1739
blocked	VERB	O	O	1739
by	ADP	O	O	1739
the	PRON	O	O	1739
central	ADJ	O	O	1739
nicotinic	ADJ	O	O	1739
antagonist	NOUN	O	O	1739
mecamylamine	PROPN	O	Chemical	1739
but	CCONJ	O	O	1739
not	PART	O	O	1739
by	ADP	O	O	1739
the	PRON	O	O	1739
peripheral	ADJ	O	O	1739
nicotinic	ADJ	O	O	1739
blocker	NOUN	O	O	1739
hexamethonium	ADJ	O	Chemical	1739
,	PUNCT	O	O	1739
indicating	VERB	O	O	1739
that	SCONJ	O	O	1739
the	PRON	O	O	1739
response	NOUN	O	O	1739
is	AUX	O	O	1739
probably	ADV	O	O	1739
mediated	VERB	O	O	1739
by	ADP	O	O	1739
central	ADJ	O	O	1739
nicotinic	ADJ	O	O	1739
receptors	NOUN	O	O	1739
.	PUNCT	O	O	1739
Nicotine	NOUN	O	Chemical	1740
-	PUNCT	O	O	1740
induced	VERB	O	O	1740
hyperactivity	NOUN	O	Disease	1740
was	AUX	O	O	1740
blocked	VERB	O	O	1740
by	ADP	O	O	1740
the	PRON	O	O	1740
selective	ADJ	O	O	1740
D1	PROPN	O	O	1740
antagonist	NOUN	O	O	1740
SCH 23390	NUM	O	Chemical	1740
,	PUNCT	O	O	1740
the	PRON	O	O	1740
selective	ADJ	O	O	1740
D2	NOUN	O	O	1740
antagonist	NOUN	O	O	1740
raclopride	ADV	O	O	1740
and	CCONJ	O	O	1740
the	PRON	O	O	1740
D1/D2	PROPN	O	O	1740
antagonist	NOUN	O	O	1740
fluphenazine	NOUN	O	Chemical	1740
.	PUNCT	O	O	1740
Pretreatment	NOUN	O	O	1741
with	ADP	O	O	1741
the	PRON	O	O	1741
D2	NOUN	O	O	1741
agonist	NOUN	O	O	1741
PHNO	NOUN	O	O	1741
enhanced	VERB	O	O	1741
nicotine	NOUN	O	Chemical	1741
-	PUNCT	O	O	1741
induced	VERB	O	O	1741
hyperactivity	NOUN	O	Disease	1741
,	PUNCT	O	O	1741
whereas	SCONJ	O	O	1741
the	PRON	O	O	1741
D1	PROPN	O	O	1741
agonist	NOUN	O	O	1741
SKF 38393	NUM	O	Chemical	1741
had	VERB	O	O	1741
no	PRON	O	O	1741
effect	VERB	O	O	1741
.	PUNCT	O	O	1741
The	PRON	O	O	1742
results	VERB	O	O	1742
indicate	VERB	O	O	1742
that	SCONJ	O	O	1742
acute	ADJ	O	O	1742
nicotine	NOUN	O	Chemical	1742
injection	NOUN	O	O	1742
induces	VERB	O	O	1742
a	PRON	O	O	1742
pronounced	VERB	O	O	1742
hyperactivity	NOUN	O	Disease	1742
in	ADP	O	O	1742
rats	NOUN	O	O	1742
habituated	VERB	O	O	1742
to	PART	O	O	1742
the	PRON	O	O	1742
test	NOUN	O	O	1742
environment	NOUN	O	O	1742
.	PUNCT	O	O	1742
The	PRON	O	O	1743
effect	VERB	O	O	1743
appears	VERB	O	O	1743
to	PART	O	O	1743
be	AUX	O	O	1743
mediated	VERB	O	O	1743
by	ADP	O	O	1743
central	ADJ	O	O	1743
nicotine	NOUN	O	Chemical	1743
receptors	NOUN	O	O	1743
,	PUNCT	O	O	1743
possibly	ADV	O	O	1743
located	VERB	O	O	1743
on	ADP	O	O	1743
dopaminergic	ADJ	O	O	1743
neurons	NOUN	O	O	1743
,	PUNCT	O	O	1743
and	CCONJ	O	O	1743
also	ADV	O	O	1743
requires	VERB	O	O	1743
the	PRON	O	O	1743
activation	NOUN	O	O	1743
of	ADP	O	O	1743
both	PRON	O	O	1743
D1	PROPN	O	O	1743
and	CCONJ	O	O	1743
D2	NOUN	O	O	1743
dopamine	NOUN	O	Chemical	1743
receptors	NOUN	O	O	1743
.	PUNCT	O	O	1743
Neuropsychiatric	ADJ	O	O	1746
side	NOUN	O	O	1746
effects	NOUN	O	O	1746
after	ADP	O	O	1746
the	PRON	O	O	1746
use	VERB	O	O	1746
of	ADP	O	O	1746
mefloquine	PRON	O	O	1746
.	PUNCT	O	O	1746
This	PRON	O	O	1747
study	VERB	O	O	1747
describes	VERB	O	O	1747
neuropsychiatric	ADJ	O	O	1747
side	NOUN	O	O	1747
effects	NOUN	O	O	1747
in	ADP	O	O	1747
patients	NOUN	O	O	1747
after	ADP	O	O	1747
treatment	NOUN	O	O	1747
with	ADP	O	O	1747
mefloquine	PRON	O	O	1747
.	PUNCT	O	O	1747
Reactions	NOUN	O	O	1748
consisted	VERB	O	O	1748
mainly	ADV	O	O	1748
of	ADP	O	O	1748
seizures	NOUN	O	Disease	1748
,	PUNCT	O	O	1748
acute	ADJ	O	O	1748
psychoses	NOUN	O	Disease	1748
,	PUNCT	O	O	1748
anxiety	NOUN	O	Disease	1748
neurosis	NOUN	O	O	1748
,	PUNCT	O	O	1748
and	CCONJ	O	O	1748
major	ADJ	O	O	1748
disturbances	NOUN	O	O	1748
of	ADP	O	O	1748
sleep	VERB	O	O	1748
-	PUNCT	O	O	1748
wake	VERB	O	O	1748
rhythm	VERB	O	O	1748
.	PUNCT	O	O	1748
In	ADP	O	O	1749
a	PRON	O	O	1749
risk	NOUN	O	O	1749
analysis	NOUN	O	O	1749
of	ADP	O	O	1749
neuropsychiatric	ADJ	O	O	1749
side	NOUN	O	O	1749
effects	NOUN	O	O	1749
in	ADP	O	O	1749
Germany	PROPN	O	O	1749
,	PUNCT	O	O	1749
it	PRON	O	O	1749
is	AUX	O	O	1749
estimated	VERB	O	O	1749
that	SCONJ	O	O	1749
one	NUM	O	O	1749
of	ADP	O	O	1749
8,000	NUM	O	O	1749
mefloquine	PRON	O	O	1749
users	NOUN	O	O	1749
suffers	VERB	O	O	1749
from	ADP	O	O	1749
such	ADJ	O	O	1749
reactions	NOUN	O	O	1749
.	PUNCT	O	O	1749
The	PRON	O	O	1750
incidence	NOUN	O	O	1750
calculation	NOUN	O	O	1750
revealed	VERB	O	O	1750
that	SCONJ	O	O	1750
one	NUM	O	O	1750
of	ADP	O	O	1750
215	NUM	O	O	1750
therapeutic	ADJ	O	O	1750
users	NOUN	O	O	1750
had	VERB	O	O	1750
reactions	NOUN	O	O	1750
,	PUNCT	O	O	1750
compared	VERB	O	O	1750
with	ADP	O	O	1750
one	NUM	O	O	1750
of	ADP	O	O	1750
13,000	NUM	O	O	1750
in	ADP	O	O	1750
the	PRON	O	O	1750
prophylaxis	NOUN	O	O	1750
group	NOUN	O	O	1750
,	PUNCT	O	O	1750
making	VERB	O	O	1750
the	PRON	O	O	1750
risk	NOUN	O	O	1750
of	ADP	O	O	1750
neuropsychiatric	ADJ	O	O	1750
reactions	NOUN	O	O	1750
after	ADP	O	O	1750
mefloquine	PRON	O	O	1750
treatment	NOUN	O	O	1750
60	NUM	O	O	1750
times	NOUN	O	O	1750
higher	ADJ	O	O	1750
than	ADP	O	O	1750
after	ADP	O	O	1750
prophylaxis	NOUN	O	O	1750
.	PUNCT	O	O	1750
Therefore	ADV	O	O	1751
,	PUNCT	O	O	1751
certain	ADJ	O	O	1751
limitations	VERB	O	O	1751
for	ADP	O	O	1751
malaria	NOUN	O	O	1751
prophylaxis	NOUN	O	O	1751
and	CCONJ	O	O	1751
treatment	NOUN	O	O	1751
with	ADP	O	O	1751
mefloquine	PRON	O	O	1751
are	AUX	O	O	1751
recommended	VERB	O	O	1751
.	PUNCT	O	O	1751
Reduction	NOUN	O	O	1754
in	ADP	O	O	1754
injection	NOUN	O	O	1754
pain	NOUN	O	Disease	1754
using	VERB	O	O	1754
buffered	VERB	O	O	1754
lidocaine	NOUN	O	Chemical	1754
as	ADP	O	O	1754
a	PRON	O	O	1754
local	ADJ	O	O	1754
anesthetic	NOUN	O	O	1754
before	ADP	O	O	1754
cardiac	ADJ	O	O	1754
catheterization	NOUN	O	O	1754
.	PUNCT	O	O	1754
Previous	ADJ	O	O	1755
reports	VERB	O	O	1755
have	VERB	O	O	1755
suggested	VERB	O	O	1755
that	SCONJ	O	O	1755
pain	NOUN	O	Disease	1755
associated	VERB	O	O	1755
with	ADP	O	O	1755
the	PRON	O	O	1755
injection	NOUN	O	O	1755
of	ADP	O	O	1755
lidocaine	NOUN	O	Chemical	1755
is	AUX	O	O	1755
related	ADJ	O	O	1755
to	PART	O	O	1755
the	PRON	O	O	1755
acidic	ADJ	O	O	1755
pH	NOUN	O	O	1755
of	ADP	O	O	1755
the	PRON	O	O	1755
solution	NOUN	O	O	1755
.	PUNCT	O	O	1755
To	PART	O	O	1756
determine	VERB	O	O	1756
if	SCONJ	O	O	1756
the	PRON	O	O	1756
addition	NOUN	O	O	1756
of	ADP	O	O	1756
a	PRON	O	O	1756
buffering	VERB	O	O	1756
solution	NOUN	O	O	1756
to	PART	O	O	1756
adjust	VERB	O	O	1756
the	PRON	O	O	1756
pH	NOUN	O	O	1756
of	ADP	O	O	1756
lidocaine	NOUN	O	Chemical	1756
into	ADP	O	O	1756
the	PRON	O	O	1756
physiologic	ADJ	O	O	1756
range	VERB	O	O	1756
would	AUX	O	O	1756
reduce	VERB	O	O	1756
pain	NOUN	O	Disease	1756
during	ADP	O	O	1756
injection	NOUN	O	O	1756
,	PUNCT	O	O	1756
we	PRON	O	O	1756
performed	VERB	O	O	1756
a	PRON	O	O	1756
blinded	VERB	O	O	1756
randomized	VERB	O	O	1756
study	VERB	O	O	1756
in	ADP	O	O	1756
patients	NOUN	O	O	1756
undergoing	VERB	O	O	1756
cardiac	ADJ	O	O	1756
catheterization	NOUN	O	O	1756
.	PUNCT	O	O	1756
Twenty	NUM	O	O	1757
patients	NOUN	O	O	1757
were	AUX	O	O	1757
asked	VERB	O	O	1757
to	PART	O	O	1757
quantify	VERB	O	O	1757
the	PRON	O	O	1757
severity	NOUN	O	O	1757
of	ADP	O	O	1757
pain	NOUN	O	Disease	1757
after	ADP	O	O	1757
receiving	VERB	O	O	1757
standard	PROPN	O	O	1757
lidocaine	NOUN	O	Chemical	1757
in	ADP	O	O	1757
one	NUM	O	O	1757
femoral	ADJ	O	O	1757
area	NOUN	O	O	1757
and	CCONJ	O	O	1757
buffered	VERB	O	O	1757
lidocaine	NOUN	O	Chemical	1757
in	ADP	O	O	1757
the	PRON	O	O	1757
opposite	ADV	O	O	1757
femoral	ADJ	O	O	1757
area	NOUN	O	O	1757
.	PUNCT	O	O	1757
The	PRON	O	O	1758
mean	VERB	O	O	1758
pain	NOUN	O	Disease	1758
score	VERB	O	O	1758
for	ADP	O	O	1758
buffered	VERB	O	O	1758
lidocaine	NOUN	O	Chemical	1758
was	AUX	O	O	1758
significantly	ADV	O	O	1758
lower	ADJ	O	O	1758
than	ADP	O	O	1758
the	PRON	O	O	1758
mean	VERB	O	O	1758
score	VERB	O	O	1758
for	ADP	O	O	1758
standard	PROPN	O	O	1758
lidocaine	NOUN	O	Chemical	1758
(	PUNCT	O	O	1758
2.7	NUM	O	O	1758
+	ADP	O	O	1758
/-	PUNCT	O	O	1758
The	PRON	O	O	1759
pH	NOUN	O	O	1759
adjustment	NOUN	O	O	1759
of	ADP	O	O	1759
standard	PROPN	O	O	1759
lidocaine	NOUN	O	Chemical	1759
can	AUX	O	O	1759
be	AUX	O	O	1759
accomplished	VERB	O	O	1759
easily	ADV	O	O	1759
in	ADP	O	O	1759
the	PRON	O	O	1759
catheterization	NOUN	O	O	1759
laboratory	NOUN	O	O	1759
before	ADP	O	O	1759
injection	NOUN	O	O	1759
and	CCONJ	O	O	1759
results	VERB	O	O	1759
in	ADP	O	O	1759
a	PRON	O	O	1759
reduction	NOUN	O	O	1759
of	ADP	O	O	1759
the	PRON	O	O	1759
pain	NOUN	O	Disease	1759
occurring	VERB	O	O	1759
during	ADP	O	O	1759
the	PRON	O	O	1759
infiltration	NOUN	O	O	1759
of	ADP	O	O	1759
tissues	NOUN	O	O	1759
.	PUNCT	O	O	1759
Randomized	VERB	O	O	1762
,	PUNCT	O	O	1762
double	ADJ	O	O	1762
-	PUNCT	O	O	1762
blind	ADJ	O	Disease	1762
trial	NOUN	O	O	1762
of	ADP	O	O	1762
mazindol	VERB	O	O	1762
in	ADP	O	O	1762
Duchenne	PROPN	O	O	1762
dystrophy	NOUN	O	O	1762
.	PUNCT	O	O	1762
There	ADV	O	O	1763
is	AUX	O	O	1763
evidence	NOUN	O	O	1763
that	SCONJ	O	O	1763
growth	NOUN	O	O	1763
hormone	NOUN	O	O	1763
may	AUX	O	O	1763
be	AUX	O	O	1763
related	ADJ	O	O	1763
to	PART	O	O	1763
the	PRON	O	O	1763
progression	NOUN	O	O	1763
of	ADP	O	O	1763
weakness	NOUN	O	Disease	1763
in	ADP	O	O	1763
Duchenne	PROPN	O	O	1763
dystrophy	NOUN	O	O	1763
.	PUNCT	O	O	1763
We	PRON	O	O	1764
conducted	VERB	O	O	1764
a	PRON	O	O	1764
12-month	NOUN	O	O	1764
controlled	VERB	O	O	1764
trial	NOUN	O	O	1764
of	ADP	O	O	1764
mazindol	VERB	O	O	1764
,	PUNCT	O	O	1764
a	PRON	O	O	1764
putative	ADJ	O	O	1764
growth	NOUN	O	O	1764
hormone	NOUN	O	O	1764
secretion	NOUN	O	O	1764
inhibitor	NOUN	O	O	1764
,	PUNCT	O	O	1764
in	ADP	O	O	1764
83	NUM	O	O	1764
boys	NOUN	O	O	1764
with	ADP	O	O	1764
Duchenne	PROPN	O	O	1764
dystrophy	NOUN	O	O	1764
.	PUNCT	O	O	1764
Muscle	NOUN	O	O	1765
strength	NOUN	O	O	1765
,	PUNCT	O	O	1765
contractures	VERB	O	Disease	1765
,	PUNCT	O	O	1765
functional	ADJ	O	O	1765
ability	NOUN	O	O	1765
and	CCONJ	O	O	1765
pulmonary	ADJ	O	O	1765
function	NOUN	O	O	1765
were	AUX	O	O	1765
tested	VERB	O	O	1765
at	ADP	O	O	1765
baseline	VERB	O	O	1765
,	PUNCT	O	O	1765
and	CCONJ	O	O	1765
6	NUM	O	O	1765
and	CCONJ	O	O	1765
12	NUM	O	O	1765
months	NOUN	O	O	1765
after	ADP	O	O	1765
treatment	NOUN	O	O	1765
with	ADP	O	O	1765
mazindol	VERB	O	O	1765
(	PUNCT	O	O	1765
3	X	O	O	1765
mg	VERB	O	O	1765
/	PUNCT	O	O	1765
d	X	O	O	1765
)	PUNCT	O	O	1765
or	CCONJ	O	O	1765
placebo	NOUN	O	O	1765
.	PUNCT	O	O	1765
The	PRON	O	O	1766
study	VERB	O	O	1766
was	AUX	O	O	1766
designed	VERB	O	O	1766
to	PART	O	O	1766
have	VERB	O	O	1766
a	PRON	O	O	1766
power	NOUN	O	O	1766
of	ADP	O	O	1766
greater	ADJ	O	O	1766
than	ADP	O	O	1766
0.90	NUM	O	O	1766
to	PART	O	O	1766
detect	VERB	O	O	1766
a	PRON	O	O	1766
slowing	VERB	O	O	1766
to	PART	O	O	1766
25%	NOUN	O	O	1766
of	ADP	O	O	1766
the	PRON	O	O	1766
expected	VERB	O	O	1766
rate	NOUN	O	O	1766
of	ADP	O	O	1766
progression	NOUN	O	O	1766
of	ADP	O	O	1766
weakness	NOUN	O	Disease	1766
at	ADP	O	O	1766
P	NOUN	O	Chemical	1766
less	ADV	O	O	1766
than	ADP	O	O	1766
0.05	NUM	O	O	1766
.	PUNCT	O	O	1766
Mazindol	PROPN	O	O	1767
did	VERB	O	O	1767
not	PART	O	O	1767
benefit	VERB	O	O	1767
strength	NOUN	O	O	1767
at	ADP	O	O	1767
any	PRON	O	O	1767
point	VERB	O	O	1767
in	ADP	O	O	1767
the	PRON	O	O	1767
study	VERB	O	O	1767
.	PUNCT	O	O	1767
Side	NOUN	O	O	1768
effects	NOUN	O	O	1768
attributable	ADJ	O	O	1768
to	PART	O	O	1768
mazindol	VERB	O	O	1768
included	VERB	O	O	1768
decreased	VERB	O	O	1768
appetite	PROPN	O	O	1768
(	PUNCT	O	O	1768
36%	NOUN	O	O	1768
)	PUNCT	O	O	1768
,	PUNCT	O	O	1768
dry mouth	NOUN	O	Disease	1768
(	PUNCT	O	O	1768
10%	NOUN	O	O	1768
)	PUNCT	O	O	1768
,	PUNCT	O	O	1768
behavioral	ADJ	O	O	1768
change	VERB	O	O	1768
(	PUNCT	O	O	1768
22%	NOUN	O	O	1768
)	PUNCT	O	O	1768
,	PUNCT	O	O	1768
and	CCONJ	O	O	1768
gastrointestinal symptoms	NOUN	O	Disease	1768
(	PUNCT	O	O	1768
18%	NOUN	O	O	1768
)	PUNCT	O	O	1768
;	PUNCT	O	O	1768
mazindol	VERB	O	O	1768
dosage	NOUN	O	O	1768
was	AUX	O	O	1768
reduced	VERB	O	O	1768
in	ADP	O	O	1768
43%	NOUN	O	O	1768
of	ADP	O	O	1768
patients	NOUN	O	O	1768
.	PUNCT	O	O	1768
The	PRON	O	O	1769
effect	VERB	O	O	1769
of	ADP	O	O	1769
mazindol	VERB	O	O	1769
on	ADP	O	O	1769
GH	PROPN	O	O	1769
secretion	NOUN	O	O	1769
was	AUX	O	O	1769
estimated	VERB	O	O	1769
indirectly	ADV	O	O	1769
by	ADP	O	O	1769
comparing	VERB	O	O	1769
the	PRON	O	O	1769
postabsorptive	ADJ	O	O	1769
IGF	PROPN	O	O	1769
-	PUNCT	O	O	1769
I	PRON	O	O	1769
levels	NOUN	O	O	1769
obtained	VERB	O	O	1769
following	VERB	O	O	1769
3	X	O	O	1769
,	PUNCT	O	O	1769
6	NUM	O	O	1769
,	PUNCT	O	O	1769
9	NUM	O	O	1769
,	PUNCT	O	O	1769
and	CCONJ	O	O	1769
12	NUM	O	O	1769
months	NOUN	O	O	1769
in	ADP	O	O	1769
the	PRON	O	O	1769
mazindol	VERB	O	O	1769
treated	VERB	O	O	1769
to	PART	O	O	1769
those	PRON	O	O	1769
in	ADP	O	O	1769
the	PRON	O	O	1769
placebo	NOUN	O	O	1769
groups	NOUN	O	O	1769
.	PUNCT	O	O	1769
Although	SCONJ	O	O	1770
mazindol	VERB	O	O	1770
-	PUNCT	O	O	1770
treated	VERB	O	O	1770
patients	NOUN	O	O	1770
gained	VERB	O	O	1770
less	ADV	O	O	1770
weight	NOUN	O	O	1770
and	CCONJ	O	O	1770
height	NOUN	O	O	1770
than	ADP	O	O	1770
placebo	NOUN	O	O	1770
-	PUNCT	O	O	1770
treated	VERB	O	O	1770
patients	NOUN	O	O	1770
,	PUNCT	O	O	1770
no	PRON	O	O	1770
significant	ADJ	O	O	1770
effect	VERB	O	O	1770
on	ADP	O	O	1770
IGF	PROPN	O	O	1770
-	PUNCT	O	O	1770
I	PRON	O	O	1770
levels	NOUN	O	O	1770
was	AUX	O	O	1770
observed	VERB	O	O	1770
.	PUNCT	O	O	1770
Mazindol	PROPN	O	O	1771
doses	NOUN	O	O	1771
not	PART	O	O	1771
slow	VERB	O	O	1771
the	PRON	O	O	1771
progression	NOUN	O	O	1771
of	ADP	O	O	1771
weakness	NOUN	O	Disease	1771
in	ADP	O	O	1771
Duchenne	PROPN	O	O	1771
dystrophy	NOUN	O	O	1771
.	PUNCT	O	O	1771
Pentoxifylline	PROPN	O	O	1774
(	PUNCT	O	O	1774
Trental	ADJ	O	O	1774
)	PUNCT	O	O	1774
does	VERB	O	O	1774
not	PART	O	O	1774
inhibit	VERB	O	O	1774
dipyridamole	NOUN	O	Chemical	1774
-	PUNCT	O	O	1774
induced	VERB	O	O	1774
coronary	ADJ	O	O	1774
hyperemia	PROPN	O	Disease	1774
:	PUNCT	O	O	1774
implications	NOUN	O	O	1774
for	ADP	O	O	1774
dipyridamole	NOUN	O	Chemical	1774
-	PUNCT	O	O	1774
thallium-201	ADJ	O	O	1774
myocardial	ADJ	O	O	1774
imaging	VERB	O	O	1774
.	PUNCT	O	O	1774
Dipyridamole	PROPN	O	O	1775
-	PUNCT	O	O	1775
thallium-201	ADJ	O	O	1775
imaging	VERB	O	O	1775
is	AUX	O	O	1775
often	ADV	O	O	1775
performed	VERB	O	O	1775
in	ADP	O	O	1775
patients	NOUN	O	O	1775
unable	ADJ	O	O	1775
to	PART	O	O	1775
exercise	VERB	O	O	1775
because	SCONJ	O	O	1775
of	ADP	O	O	1775
peripheral	ADJ	O	O	1775
vascular	ADJ	O	O	1775
disease	PROPN	O	O	1775
.	PUNCT	O	O	1775
Many	ADJ	O	O	1776
of	ADP	O	O	1776
these	PRON	O	O	1776
patients	NOUN	O	O	1776
are	AUX	O	O	1776
taking	VERB	O	O	1776
pentoxifylline	NOUN	O	O	1776
(	PUNCT	O	O	1776
Trental	ADJ	O	O	1776
)	PUNCT	O	O	1776
,	PUNCT	O	O	1776
a	PRON	O	O	1776
methylxanthine	PROPN	O	O	1776
derivative	ADJ	O	O	1776
which	PRON	O	O	1776
may	AUX	O	O	1776
improve	VERB	O	O	1776
intermittent	ADJ	O	O	1776
claudication	NOUN	O	O	1776
.	PUNCT	O	O	1776
Whether	SCONJ	O	O	1777
pentoxifylline	NOUN	O	O	1777
inhibits	VERB	O	O	1777
dipyridamole	NOUN	O	Chemical	1777
-	PUNCT	O	O	1777
induced	VERB	O	O	1777
coronary	ADJ	O	O	1777
hyperemia	PROPN	O	Disease	1777
like	INTJ	O	O	1777
other	ADJ	O	O	1777
methylxanthines	VERB	O	O	1777
such	ADJ	O	O	1777
as	ADP	O	O	1777
theophylline	ADV	O	Chemical	1777
and	CCONJ	O	O	1777
should	AUX	O	O	1777
be	AUX	O	O	1777
stopped	VERB	O	O	1777
prior	ADV	O	O	1777
to	PART	O	O	1777
dipyridamole	NOUN	O	Chemical	1777
-	PUNCT	O	O	1777
thallium-201	ADJ	O	O	1777
imaging	VERB	O	O	1777
is	AUX	O	O	1777
unknown	ADJ	O	O	1777
.	PUNCT	O	O	1777
Therefore	ADV	O	O	1778
,	PUNCT	O	O	1778
we	PRON	O	O	1778
studied	VERB	O	O	1778
the	PRON	O	O	1778
hyperemic	ADJ	O	Disease	1778
response	NOUN	O	O	1778
to	PART	O	O	1778
dipyridamole	NOUN	O	Chemical	1778
in	ADP	O	O	1778
seven	NUM	O	O	1778
open	VERB	O	O	1778
-	PUNCT	O	O	1778
chest	NOUN	O	O	1778
anesthetized	VERB	O	O	1778
dogs	NOUN	O	O	1778
after	ADP	O	O	1778
pretreatment	NOUN	O	O	1778
with	ADP	O	O	1778
either	ADV	O	O	1778
pentoxifylline	NOUN	O	O	1778
(	PUNCT	O	O	1778
0	NUM	O	O	1778
,	PUNCT	O	O	1778
7.5	NUM	O	O	1779
,	PUNCT	O	O	1779
or	CCONJ	O	O	1779
15	NUM	O	O	1779
mg	VERB	O	O	1779
/	PUNCT	O	O	1779
kg	VERB	O	O	1779
i.v	NOUN	O	O	1779
.	PUNCT	O	O	1779
)	PUNCT	O	O	1779
or	CCONJ	O	O	1779
theophylline	ADV	O	Chemical	1779
(	PUNCT	O	O	1779
3	X	O	O	1779
mg	VERB	O	O	1779
/	PUNCT	O	O	1779
kg	VERB	O	O	1779
i.v	NOUN	O	O	1779
.	PUNCT	O	O	1779
)	PUNCT	O	O	1779
.	PUNCT	O	O	1779
Dipyridamole	PROPN	O	O	1780
significantly	ADV	O	O	1780
increased	VERB	O	O	1780
coronary	ADJ	O	O	1780
blood	NOUN	O	O	1780
flow	NOUN	O	O	1780
before	ADP	O	O	1780
and	CCONJ	O	O	1780
after	ADP	O	O	1780
7.5	NUM	O	O	1780
or	CCONJ	O	O	1780
15	NUM	O	O	1780
mm	INTJ	O	O	1780
/	PUNCT	O	O	1780
kg	VERB	O	O	1780
i.v	NOUN	O	O	1780
.	PUNCT	O	O	1780
pentoxifylline	NOUN	O	O	1781
(	PUNCT	O	O	1781
p	NOUN	O	O	1781
less	ADV	O	O	1781
than	ADP	O	O	1781
0.002	NUM	O	O	1781
)	PUNCT	O	O	1781
.	PUNCT	O	O	1781
Neither	PRON	O	O	1782
dose	NOUN	O	O	1782
of	ADP	O	O	1782
pentoxifylline	NOUN	O	O	1782
significantly	ADV	O	O	1782
decreased	VERB	O	O	1782
the	PRON	O	O	1782
dipyridamole	NOUN	O	Chemical	1782
-	PUNCT	O	O	1782
induced	VERB	O	O	1782
hyperemia	PROPN	O	Disease	1782
,	PUNCT	O	O	1782
while	SCONJ	O	O	1782
peak	PROPN	O	O	1782
coronary	ADJ	O	O	1782
blood	NOUN	O	O	1782
flow	NOUN	O	O	1782
was	AUX	O	O	1782
significantly	ADV	O	O	1782
lower	ADJ	O	O	1782
after	ADP	O	O	1782
theophylline	ADV	O	Chemical	1782
(	PUNCT	O	O	1782
p	NOUN	O	O	1782
less	ADV	O	O	1782
than	ADP	O	O	1782
0.01	NUM	O	O	1782
)	PUNCT	O	O	1782
.	PUNCT	O	O	1782
We	PRON	O	O	1783
conclude	VERB	O	O	1783
that	SCONJ	O	O	1783
pentoxyifylline	NOUN	O	O	1783
does	VERB	O	O	1783
not	PART	O	O	1783
inhibit	VERB	O	O	1783
dipyridamole	NOUN	O	Chemical	1783
-	PUNCT	O	O	1783
induced	VERB	O	O	1783
coronary	ADJ	O	O	1783
hyperemia	PROPN	O	Disease	1783
even	ADV	O	O	1783
at	ADP	O	O	1783
high	ADJ	O	O	1783
doses	NOUN	O	O	1783
.	PUNCT	O	O	1783
Cause	VERB	O	O	1786
of	ADP	O	O	1786
death	NOUN	O	O	1786
among	ADP	O	O	1786
patients	NOUN	O	O	1786
with	ADP	O	O	1786
Parkinson	NOUN	O	O	1786
's	AUX	O	O	1786
disease	PROPN	O	O	1786
:	PUNCT	O	O	1786
a	PRON	O	O	1786
rare	ADJ	O	O	1786
mortality	NOUN	O	O	1786
due	ADJ	O	O	1786
to	PART	O	O	1786
cerebral	ADJ	O	O	1786
haemorrhage	NOUN	O	Disease	1786
.	PUNCT	O	O	1786
Causes	VERB	O	O	1787
of	ADP	O	O	1787
death	NOUN	O	O	1787
,	PUNCT	O	O	1787
with	ADP	O	O	1787
special	ADJ	O	O	1787
reference	NOUN	O	O	1787
to	PART	O	O	1787
cerebral	ADJ	O	O	1787
haemorrhage	NOUN	O	Disease	1787
,	PUNCT	O	O	1787
among	ADP	O	O	1787
240	NUM	O	O	1787
patients	NOUN	O	O	1787
with	ADP	O	O	1787
pathologically	ADV	O	O	1787
verified	VERB	O	O	1787
Parkinson	NOUN	O	O	1787
's	AUX	O	O	1787
disease	PROPN	O	O	1787
were	AUX	O	O	1787
investigated	VERB	O	O	1787
using	VERB	O	O	1787
the	PRON	O	O	1787
Annuals	NOUN	O	O	1787
of	ADP	O	O	1787
the	PRON	O	O	1787
Pathological	ADJ	O	O	1787
Autopsy	PROPN	O	O	1787
Cases	NOUN	O	O	1787
in	ADP	O	O	1787
Japan	PROPN	O	O	1787
from	ADP	O	O	1787
1981	NUM	O	O	1787
to	PART	O	O	1787
1985	NUM	O	O	1787
.	PUNCT	O	O	1787
The	PRON	O	O	1788
leading	VERB	O	O	1788
causes	VERB	O	O	1788
of	ADP	O	O	1788
death	NOUN	O	O	1788
were	AUX	O	O	1788
pneumonia	NOUN	O	Disease	1788
and	CCONJ	O	O	1788
bronchitis	NOUN	O	O	1788
(	PUNCT	O	O	1788
44.1%	NOUN	O	O	1788
)	PUNCT	O	O	1788
,	PUNCT	O	O	1788
malignant	ADJ	O	O	1788
neoplasms	NOUN	O	O	1788
(	PUNCT	O	O	1788
11.6%	NOUN	O	O	1788
)	PUNCT	O	O	1788
,	PUNCT	O	O	1788
heart diseases	NOUN	O	O	1788
(	PUNCT	O	O	1788
4.1%	NOUN	O	O	1788
)	PUNCT	O	O	1788
,	PUNCT	O	O	1788
cerebral infarction	NOUN	O	Disease	1788
(	PUNCT	O	O	1788
3.7%	NOUN	O	O	1788
)	PUNCT	O	O	1788
and	CCONJ	O	O	1788
septicaemia	NOUN	O	O	1788
(	PUNCT	O	O	1788
3.3%	NOUN	O	O	1788
)	PUNCT	O	O	1788
.	PUNCT	O	O	1788
Cerebral	ADJ	O	O	1789
haemorrhage	NOUN	O	Disease	1789
was	AUX	O	O	1789
the	PRON	O	O	1789
11th	ADJ	O	O	1789
most	ADV	O	O	1789
frequent	ADJ	O	O	1789
cause	VERB	O	O	1789
of	ADP	O	O	1789
death	NOUN	O	O	1789
,	PUNCT	O	O	1789
accounting	VERB	O	O	1789
for	ADP	O	O	1789
only	ADV	O	O	1789
0.8%	NOUN	O	O	1789
of	ADP	O	O	1789
deaths	NOUN	O	O	1789
among	ADP	O	O	1789
the	PRON	O	O	1789
patients	NOUN	O	O	1789
,	PUNCT	O	O	1789
whereas	SCONJ	O	O	1789
it	PRON	O	O	1789
was	AUX	O	O	1789
the	PRON	O	O	1789
5th	ADJ	O	O	1789
most	ADV	O	O	1789
common	ADJ	O	O	1789
cause	VERB	O	O	1789
of	ADP	O	O	1789
death	NOUN	O	O	1789
among	ADP	O	O	1789
the	PRON	O	O	1789
Japanese	NOUN	O	O	1789
general	ADJ	O	O	1789
population	NOUN	O	O	1789
in	ADP	O	O	1789
1985	NUM	O	O	1789
.	PUNCT	O	O	1789
The	PRON	O	O	1790
low	ADJ	O	O	1790
incidence	NOUN	O	O	1790
of	ADP	O	O	1790
cerebral	ADJ	O	O	1790
haemorrhage	NOUN	O	Disease	1790
as	ADP	O	O	1790
a	PRON	O	O	1790
cause	VERB	O	O	1790
of	ADP	O	O	1790
death	NOUN	O	O	1790
in	ADP	O	O	1790
patients	NOUN	O	O	1790
with	ADP	O	O	1790
Parkinson	NOUN	O	O	1790
's	AUX	O	O	1790
disease	PROPN	O	O	1790
may	AUX	O	O	1790
reflect	VERB	O	O	1790
the	PRON	O	O	1790
hypotensive	ADJ	O	Disease	1790
effect	VERB	O	O	1790
of	ADP	O	O	1790
levodopa	NOUN	O	Chemical	1790
and	CCONJ	O	O	1790
a	PRON	O	O	1790
hypotensive	ADJ	O	Disease	1790
mechanism	NOUN	O	O	1790
due	ADJ	O	O	1790
to	PART	O	O	1790
reduced	VERB	O	O	1790
noradrenaline	NOUN	O	Chemical	1790
levels	NOUN	O	O	1790
in	ADP	O	O	1790
the	PRON	O	O	1790
parkinsonian	PROPN	O	Disease	1790
brain	NOUN	O	O	1790
.	PUNCT	O	O	1790
Tolerance	NOUN	O	O	1793
and	CCONJ	O	O	1793
antiviral	ADJ	O	O	1793
effect	VERB	O	O	1793
of	ADP	O	O	1793
ribavirin	NOUN	O	Chemical	1793
in	ADP	O	O	1793
patients	NOUN	O	O	1793
with	ADP	O	O	1793
Argentine	PROPN	O	O	1793
hemorrhagic	ADJ	O	Disease	1793
fever	NOUN	O	Disease	1793
.	PUNCT	O	O	1793
Tolerance	NOUN	O	O	1794
and	CCONJ	O	O	1794
antiviral	ADJ	O	O	1794
effect	VERB	O	O	1794
of	ADP	O	O	1794
ribavirin	NOUN	O	Chemical	1794
was	AUX	O	O	1794
studied	VERB	O	O	1794
in	ADP	O	O	1794
6	NUM	O	O	1794
patients	NOUN	O	O	1794
with	ADP	O	O	1794
Argentine	PROPN	O	O	1794
hemorrhagic	ADJ	O	Disease	1794
fever	NOUN	O	Disease	1794
(	PUNCT	O	O	1794
AHF	NOUN	O	O	1794
)	PUNCT	O	O	1794
of	ADP	O	O	1794
more	ADJ	O	O	1794
than	ADP	O	O	1794
8	NUM	O	O	1794
days	NOUN	O	O	1794
of	ADP	O	O	1794
evolution	NOUN	O	O	1794
.	PUNCT	O	O	1794
Administration	NOUN	O	O	1795
of	ADP	O	O	1795
ribavirin	NOUN	O	Chemical	1795
resulted	VERB	O	O	1795
in	ADP	O	O	1795
a	PRON	O	O	1795
neutralization	NOUN	O	O	1795
of	ADP	O	O	1795
viremia	NOUN	O	O	1795
and	CCONJ	O	O	1795
a	PRON	O	O	1795
drop	VERB	O	O	1795
of	ADP	O	O	1795
endogenous	ADJ	O	O	1795
interferon	PROPN	O	Chemical	1795
titers	NOUN	O	O	1795
.	PUNCT	O	O	1795
The	PRON	O	O	1796
average	ADJ	O	O	1796
time	NOUN	O	O	1796
of	ADP	O	O	1796
death	NOUN	O	O	1796
was	AUX	O	O	1796
delayed	VERB	O	O	1796
.	PUNCT	O	O	1796
A	PRON	O	O	1797
reversible	ADJ	O	O	1797
anemia	NOUN	O	Disease	1797
was	AUX	O	O	1797
the	PRON	O	O	1797
only	ADV	O	O	1797
adverse	ADJ	O	O	1797
effect	VERB	O	O	1797
observed	VERB	O	O	1797
.	PUNCT	O	O	1797
From	ADP	O	O	1798
these	PRON	O	O	1798
results	VERB	O	O	1798
,	PUNCT	O	O	1798
we	PRON	O	O	1798
conclude	VERB	O	O	1798
that	SCONJ	O	O	1798
ribavirin	NOUN	O	Chemical	1798
has	VERB	O	O	1798
an	PRON	O	O	1798
antiviral	ADJ	O	O	1798
effect	VERB	O	O	1798
in	ADP	O	O	1798
advanced	ADJ	O	O	1798
cases	NOUN	O	O	1798
of	ADP	O	O	1798
AHF	NOUN	O	O	1798
,	PUNCT	O	O	1798
and	CCONJ	O	O	1798
that	SCONJ	O	O	1798
anemia	NOUN	O	Disease	1798
,	PUNCT	O	O	1798
the	PRON	O	O	1798
only	ADV	O	O	1798
secondary	ADJ	O	O	1798
reaction	NOUN	O	O	1798
observed	VERB	O	O	1798
,	PUNCT	O	O	1798
can	AUX	O	O	1798
be	AUX	O	O	1798
easily	ADV	O	O	1798
managed	VERB	O	O	1798
.	PUNCT	O	O	1798
The	PRON	O	O	1799
possible	ADJ	O	O	1799
beneficial	ADJ	O	O	1799
effect	VERB	O	O	1799
of	ADP	O	O	1799
ribavirin	NOUN	O	Chemical	1799
during	ADP	O	O	1799
the	PRON	O	O	1799
initial	ADJ	O	O	1799
days	NOUN	O	O	1799
of	ADP	O	O	1799
AHF	NOUN	O	O	1799
is	AUX	O	O	1799
discussed	VERB	O	O	1799
.	PUNCT	O	O	1799
Dipyridamole	PROPN	O	O	1802
-	PUNCT	O	O	1802
induced	VERB	O	O	1802
myocardial ischemia	NOUN	O	Disease	1802
.	PUNCT	O	O	1802
Angina	NOUN	O	O	1803
and	CCONJ	O	O	1803
ischemic	VERB	O	Disease	1803
electrocardiographic	NOUN	O	O	1803
changes	VERB	O	O	1803
occurred	VERB	O	O	1803
after	ADP	O	O	1803
administration	NOUN	O	O	1803
of	ADP	O	O	1803
oral	ADJ	O	O	1803
dipyridamole	NOUN	O	Chemical	1803
in	ADP	O	O	1803
four	NUM	O	O	1803
patients	NOUN	O	O	1803
awaiting	VERB	O	O	1803
urgent	ADJ	O	O	1803
myocardial	ADJ	O	O	1803
revascularization	NOUN	O	O	1803
procedures	NOUN	O	O	1803
.	PUNCT	O	O	1803
To	PART	O	O	1804
our	PRON	O	O	1804
knowledge	NOUN	O	O	1804
,	PUNCT	O	O	1804
this	PRON	O	O	1804
has	VERB	O	O	1804
not	PART	O	O	1804
previously	ADV	O	O	1804
been	AUX	O	O	1804
reported	VERB	O	O	1804
as	ADP	O	O	1804
a	PRON	O	O	1804
side	NOUN	O	O	1804
effect	VERB	O	O	1804
of	ADP	O	O	1804
preoperative	ADJ	O	O	1804
dipyridamole	NOUN	O	Chemical	1804
therapy	NOUN	O	O	1804
,	PUNCT	O	O	1804
although	SCONJ	O	O	1804
dipyridamole	NOUN	O	Chemical	1804
-	PUNCT	O	O	1804
induced	VERB	O	O	1804
myocardial ischemia	NOUN	O	Disease	1804
has	VERB	O	O	1804
been	AUX	O	O	1804
demonstrated	VERB	O	O	1804
to	PART	O	O	1804
occur	VERB	O	O	1804
in	ADP	O	O	1804
animals	NOUN	O	O	1804
and	CCONJ	O	O	1804
humans	NOUN	O	O	1804
with	ADP	O	O	1804
coronary artery disease	NOUN	O	Disease	1804
.	PUNCT	O	O	1804
Epicardial	ADJ	O	O	1805
coronary	ADJ	O	O	1805
collateral	NOUN	O	O	1805
vessels	NOUN	O	O	1805
were	AUX	O	O	1805
demonstrated	VERB	O	O	1805
in	ADP	O	O	1805
all	PRON	O	O	1805
four	NUM	O	O	1805
patients	NOUN	O	O	1805
;	PUNCT	O	O	1805
a	PRON	O	O	1805
coronary	ADJ	O	O	1805
""""	PUNCT	O	O	1805
steal	VERB	O	O	1805
""""	PUNCT	O	O	1805
phenomenon	NOUN	O	O	1805
may	AUX	O	O	1805
be	AUX	O	O	1805
the	PRON	O	O	1805
mechanism	NOUN	O	O	1805
of	ADP	O	O	1805
the	PRON	O	O	1805
dipyridamole	NOUN	O	Chemical	1805
-	PUNCT	O	O	1805
induced	VERB	O	O	1805
ischemia	NOUN	O	Disease	1805
observed	VERB	O	O	1805
.	PUNCT	O	O	1805
Nitroprusside	PROPN	O	O	1808
-	PUNCT	O	O	1808
induced	VERB	O	O	1808
hypotension	NOUN	O	Disease	1808
evokes	VERB	O	O	1808
ACTH	PROPN	O	Chemical	1808
secretion	NOUN	O	O	1808
which	PRON	O	O	1808
is	AUX	O	O	1808
primarily	ADV	O	O	1808
mediated	VERB	O	O	1808
by	ADP	O	O	1808
enhanced	VERB	O	O	1808
secretion	NOUN	O	O	1808
of	ADP	O	O	1808
immunoreactive	ADP	O	O	1808
corticotropin	NOUN	O	O	1808
-	PUNCT	O	O	1808
releasing	VERB	O	O	1808
factor	NOUN	O	O	1808
(	PUNCT	O	O	1808
irCRF	PROPN	O	O	1808
)	PUNCT	O	O	1808
into	ADP	O	O	1808
the	PRON	O	O	1808
hypophysial	PROPN	O	O	1808
-	PUNCT	O	O	1808
portal	PROPN	O	O	1808
circulation	NOUN	O	O	1808
.	PUNCT	O	O	1808
Portal	NOUN	O	O	1809
plasma	NOUN	O	O	1809
concentrations	NOUN	O	O	1809
of	ADP	O	O	1809
neither	ADV	O	O	1809
arginine	PROPN	O	O	1809
vasopressin	NOUN	O	Chemical	1809
nor	CCONJ	O	O	1809
oxytocin	PROPN	O	Chemical	1809
are	AUX	O	O	1809
significantly	ADV	O	O	1809
altered	VERB	O	O	1809
in	ADP	O	O	1809
this	PRON	O	O	1809
paradigm	NOUN	O	O	1809
.	PUNCT	O	O	1809
Application	NOUN	O	O	1810
of	ADP	O	O	1810
a	PRON	O	O	1810
delayed	VERB	O	O	1810
feedback	VERB	O	O	1810
signal	VERB	O	O	1810
,	PUNCT	O	O	1810
in	ADP	O	O	1810
the	PRON	O	O	1810
form	NOUN	O	O	1810
of	ADP	O	O	1810
a	PRON	O	O	1810
2-h	NOUN	O	O	1810
systemic	ADJ	O	O	1810
corticosterone	NOUN	O	Chemical	1810
infusion	NOUN	O	O	1810
in	ADP	O	O	1810
urethane	NOUN	O	Chemical	1810
-	PUNCT	O	O	1810
anesthetized	VERB	O	O	1810
rats	NOUN	O	O	1810
with	ADP	O	O	1810
pharmacological	ADJ	O	O	1810
blockade	VERB	O	O	1810
of	ADP	O	O	1810
glucocorticoid	NOUN	O	O	1810
synthesis	NOUN	O	O	1810
,	PUNCT	O	O	1810
is	AUX	O	O	1810
without	ADP	O	O	1810
effect	VERB	O	O	1810
on	ADP	O	O	1810
the	PRON	O	O	1810
resting	VERB	O	O	1810
secretion	NOUN	O	O	1810
of	ADP	O	O	1810
arginine	PROPN	O	O	1810
vasopressin	NOUN	O	Chemical	1810
and	CCONJ	O	O	1810
oxytocin	PROPN	O	Chemical	1810
at	ADP	O	O	1810
any	PRON	O	O	1810
corticosterone	NOUN	O	Chemical	1810
feedback	VERB	O	O	1810
dose	NOUN	O	O	1810
tested	VERB	O	O	1810
.	PUNCT	O	O	1810
Resting	VERB	O	O	1811
irCRF	PROPN	O	O	1811
levels	NOUN	O	O	1811
are	AUX	O	O	1811
suppressed	VERB	O	O	1811
only	ADV	O	O	1811
at	ADP	O	O	1811
the	PRON	O	O	1811
highest	ADJ	O	O	1811
corticosterone	NOUN	O	Chemical	1811
infusion	NOUN	O	O	1811
rate	NOUN	O	O	1811
,	PUNCT	O	O	1811
which	PRON	O	O	1811
resulted	VERB	O	O	1811
in	ADP	O	O	1811
systemic	ADJ	O	O	1811
corticosterone	NOUN	O	Chemical	1811
levels	NOUN	O	O	1811
of	ADP	O	O	1811
40	NUM	O	O	1811
micrograms	NOUN	O	O	1811
/	PUNCT	O	O	1811
dl	X	O	O	1811
.	PUNCT	O	O	1811
Suppression	NOUN	O	O	1812
of	ADP	O	O	1812
irCRF	PROPN	O	O	1812
secretion	NOUN	O	O	1812
in	ADP	O	O	1812
response	NOUN	O	O	1812
to	PART	O	O	1812
nitroprusside	ADV	O	Chemical	1812
-	PUNCT	O	O	1812
induced	VERB	O	O	1812
hypotension	NOUN	O	Disease	1812
is	AUX	O	O	1812
observed	VERB	O	O	1812
and	CCONJ	O	O	1812
occurs	VERB	O	O	1812
at	ADP	O	O	1812
a	PRON	O	O	1812
plasma	NOUN	O	O	1812
corticosterone	NOUN	O	Chemical	1812
level	VERB	O	O	1812
between	ADP	O	O	1812
8	NUM	O	O	1812
-	PUNCT	O	O	1812
12	NUM	O	O	1812
micrograms	NOUN	O	O	1812
/	PUNCT	O	O	1812
dl	X	O	O	1812
.	PUNCT	O	O	1812
Noradrenergic	NOUN	O	O	1815
involvement	NOUN	O	O	1815
in	ADP	O	O	1815
catalepsy	VERB	O	Disease	1815
induced	VERB	O	O	1815
by	ADP	O	O	1815
delta	PROPN	O	O	1815
9-tetrahydrocannabinol	NOUN	O	O	1815
.	PUNCT	O	O	1815
In	ADP	O	O	1816
order	NOUN	O	O	1816
to	PART	O	O	1816
elucidate	VERB	O	O	1816
the	PRON	O	O	1816
role	NOUN	O	O	1816
of	ADP	O	O	1816
the	PRON	O	O	1816
catecholaminergic	PROPN	O	O	1816
system	NOUN	O	O	1816
in	ADP	O	O	1816
the	PRON	O	O	1816
cataleptogenic	NOUN	O	O	1816
effect	VERB	O	O	1816
of	ADP	O	O	1816
delta	PROPN	O	O	1816
9-tetrahydrocannabinol	NOUN	O	O	1816
(	PUNCT	O	O	1816
THC	PROPN	O	O	1816
)	PUNCT	O	O	1816
,	PUNCT	O	O	1816
the	PRON	O	O	1816
effect	VERB	O	O	1816
of	ADP	O	O	1816
pretreatment	NOUN	O	O	1816
with	ADP	O	O	1816
6-hydroxydopamine	NOUN	O	Chemical	1816
(	PUNCT	O	O	1816
6-OHDA	NOUN	O	Chemical	1816
)	PUNCT	O	O	1816
or	CCONJ	O	O	1816
with	ADP	O	O	1816
desipramine	NOUN	O	Chemical	1816
and	CCONJ	O	O	1816
6-OHDA	NOUN	O	Chemical	1816
and	CCONJ	O	O	1816
lesions	NOUN	O	O	1816
of	ADP	O	O	1816
the	PRON	O	O	1816
locus	NOUN	O	O	1816
coeruleus	PROPN	O	O	1816
were	AUX	O	O	1816
investigated	VERB	O	O	1816
in	ADP	O	O	1816
rats	NOUN	O	O	1816
.	PUNCT	O	O	1816
The	PRON	O	O	1817
cataleptogenic	NOUN	O	O	1817
effect	VERB	O	O	1817
of	ADP	O	O	1817
THC	PROPN	O	O	1817
was	AUX	O	O	1817
significantly	ADV	O	O	1817
reduced	VERB	O	O	1817
in	ADP	O	O	1817
rats	NOUN	O	O	1817
treated	VERB	O	O	1817
with	ADP	O	O	1817
6-OHDA	NOUN	O	Chemical	1817
and	CCONJ	O	O	1817
in	ADP	O	O	1817
rats	NOUN	O	O	1817
with	ADP	O	O	1817
lesions	NOUN	O	O	1817
of	ADP	O	O	1817
the	PRON	O	O	1817
locus	NOUN	O	O	1817
coeruleus	PROPN	O	O	1817
but	CCONJ	O	O	1817
not	PART	O	O	1817
in	ADP	O	O	1817
rats	NOUN	O	O	1817
treated	VERB	O	O	1817
with	ADP	O	O	1817
desipramine	NOUN	O	Chemical	1817
and	CCONJ	O	O	1817
6-OHDA	NOUN	O	Chemical	1817
,	PUNCT	O	O	1817
as	ADP	O	O	1817
compared	VERB	O	O	1817
with	ADP	O	O	1817
control	VERB	O	O	1817
rats	NOUN	O	O	1817
.	PUNCT	O	O	1817
On	ADP	O	O	1818
the	PRON	O	O	1818
contrary	ADV	O	O	1818
,	PUNCT	O	O	1818
the	PRON	O	O	1818
cataleptogenic	NOUN	O	O	1818
effect	VERB	O	O	1818
of	ADP	O	O	1818
haloperidol	NOUN	O	Chemical	1818
was	AUX	O	O	1818
significantly	ADV	O	O	1818
reduced	VERB	O	O	1818
in	ADP	O	O	1818
rats	NOUN	O	O	1818
treated	VERB	O	O	1818
with	ADP	O	O	1818
desipramine	NOUN	O	Chemical	1818
and	CCONJ	O	O	1818
6-OHDA	NOUN	O	Chemical	1818
but	CCONJ	O	O	1818
not	PART	O	O	1818
in	ADP	O	O	1818
rats	NOUN	O	O	1818
treated	VERB	O	O	1818
with	ADP	O	O	1818
6-OHDA	NOUN	O	Chemical	1818
or	CCONJ	O	O	1818
in	ADP	O	O	1818
rats	NOUN	O	O	1818
with	ADP	O	O	1818
lesions	NOUN	O	O	1818
of	ADP	O	O	1818
the	PRON	O	O	1818
locus	NOUN	O	O	1818
coeruleus	PROPN	O	O	1818
.	PUNCT	O	O	1818
These	PRON	O	O	1819
results	VERB	O	O	1819
indicate	VERB	O	O	1819
that	SCONJ	O	O	1819
noradrenergic	ADJ	O	O	1819
neurons	NOUN	O	O	1819
have	VERB	O	O	1819
an	PRON	O	O	1819
important	ADJ	O	O	1819
role	NOUN	O	O	1819
in	ADP	O	O	1819
the	PRON	O	O	1819
manifestation	NOUN	O	O	1819
of	ADP	O	O	1819
catalepsy	VERB	O	Disease	1819
induced	VERB	O	O	1819
by	ADP	O	O	1819
THC	PROPN	O	O	1819
,	PUNCT	O	O	1819
whereas	SCONJ	O	O	1819
dopaminergic	ADJ	O	O	1819
neurons	NOUN	O	O	1819
are	AUX	O	O	1819
important	ADJ	O	O	1819
in	ADP	O	O	1819
catalepsy	VERB	O	Disease	1819
induced	VERB	O	O	1819
by	ADP	O	O	1819
haloperidol	NOUN	O	Chemical	1819
.	PUNCT	O	O	1819
Intracranial	ADJ	O	O	1822
pressure	NOUN	O	O	1822
increases	VERB	O	O	1822
during	ADP	O	O	1822
alfentanil	NOUN	O	Chemical	1822
-	PUNCT	O	O	1822
induced	VERB	O	O	1822
rigidity	NOUN	O	Disease	1822
.	PUNCT	O	O	1822
Intracranial	ADJ	O	O	1823
pressure	NOUN	O	O	1823
(	PUNCT	O	O	1823
ICP	PROPN	O	O	1823
)	PUNCT	O	O	1823
was	AUX	O	O	1823
measured	VERB	O	O	1823
during	ADP	O	O	1823
alfentanil	NOUN	O	Chemical	1823
-	PUNCT	O	O	1823
induced	VERB	O	O	1823
rigidity	NOUN	O	Disease	1823
in	ADP	O	O	1823
rats	NOUN	O	O	1823
.	PUNCT	O	O	1823
Ten	NUM	O	O	1824
rats	NOUN	O	O	1824
had	VERB	O	O	1824
arterial	ADJ	O	O	1824
,	PUNCT	O	O	1824
central	ADJ	O	O	1824
venous	ADJ	O	O	1824
(	PUNCT	O	O	1824
CVP	PROPN	O	O	1824
)	PUNCT	O	O	1824
,	PUNCT	O	O	1824
and	CCONJ	O	O	1824
subdural	ADJ	O	O	1824
cannulae	NOUN	O	O	1824
inserted	VERB	O	O	1824
under	ADP	O	O	1824
halothane	VERB	O	Chemical	1824
anesthesia	NOUN	O	O	1824
.	PUNCT	O	O	1824
Following	VERB	O	O	1825
instrumentation	NOUN	O	O	1825
,	PUNCT	O	O	1825
halothane	VERB	O	Chemical	1825
was	AUX	O	O	1825
discontinued	VERB	O	O	1825
and	CCONJ	O	O	1825
alfentanil	NOUN	O	Chemical	1825
(	PUNCT	O	O	1825
125	NUM	O	O	1825
mu	NOUN	O	O	1825
/	PUNCT	O	O	1825
kg	VERB	O	O	1825
)	PUNCT	O	O	1825
administered	VERB	O	O	1825
iv	X	O	O	1825
during	ADP	O	O	1825
emergence	NOUN	O	O	1825
from	ADP	O	O	1825
halothane	VERB	O	Chemical	1825
anesthesia	NOUN	O	O	1825
.	PUNCT	O	O	1825
In	ADP	O	O	1826
the	PRON	O	O	1826
five	NUM	O	O	1826
rats	NOUN	O	O	1826
that	SCONJ	O	O	1826
developed	VERB	O	O	1826
somatic	ADJ	O	O	1826
rigidity	NOUN	O	Disease	1826
,	PUNCT	O	O	1826
ICP	PROPN	O	O	1826
and	CCONJ	O	O	1826
CVP	PROPN	O	O	1826
increased	VERB	O	O	1826
significantly	ADV	O	O	1826
above	ADP	O	O	1826
baseline	VERB	O	O	1826
(	PUNCT	O	O	1826
delta	PROPN	O	O	1826
ICP	PROPN	O	O	1826
7.5	NUM	O	O	1826
+	ADP	O	O	1826
/-	PUNCT	O	O	1826
These	PRON	O	O	1827
variables	NOUN	O	O	1827
returned	VERB	O	O	1827
to	PART	O	O	1827
baseline	VERB	O	O	1827
when	SCONJ	O	O	1827
rigidity	NOUN	O	Disease	1827
was	AUX	O	O	1827
abolished	VERB	O	O	1827
with	ADP	O	O	1827
metocurine	NOUN	O	O	1827
.	PUNCT	O	O	1827
In	ADP	O	O	1828
five	NUM	O	O	1828
rats	NOUN	O	O	1828
that	SCONJ	O	O	1828
did	VERB	O	O	1828
not	PART	O	O	1828
become	VERB	O	O	1828
rigid	ADJ	O	O	1828
,	PUNCT	O	O	1828
ICP	PROPN	O	O	1828
and	CCONJ	O	O	1828
CVP	PROPN	O	O	1828
did	VERB	O	O	1828
not	PART	O	O	1828
change	VERB	O	O	1828
following	VERB	O	O	1828
alfentanil	NOUN	O	Chemical	1828
.	PUNCT	O	O	1828
These	PRON	O	O	1829
observations	NOUN	O	O	1829
suggest	VERB	O	O	1829
that	SCONJ	O	O	1829
rigidity	NOUN	O	Disease	1829
should	AUX	O	O	1829
be	AUX	O	O	1829
prevented	VERB	O	O	1829
when	SCONJ	O	O	1829
alfentanil	NOUN	O	Chemical	1829
,	PUNCT	O	O	1829
and	CCONJ	O	O	1829
,	PUNCT	O	O	1829
presumably	ADV	O	O	1829
,	PUNCT	O	O	1829
other	ADJ	O	O	1829
opiates	NOUN	O	O	1829
,	PUNCT	O	O	1829
are	AUX	O	O	1829
used	VERB	O	O	1829
in	ADP	O	O	1829
the	PRON	O	O	1829
anesthetic	NOUN	O	O	1829
management	NOUN	O	O	1829
of	ADP	O	O	1829
patients	NOUN	O	O	1829
with	ADP	O	O	1829
ICP	PROPN	O	O	1829
problems	NOUN	O	O	1829
.	PUNCT	O	O	1829
Adverse	ADJ	O	O	1832
cardiac	ADJ	O	O	1832
effects	NOUN	O	O	1832
during	ADP	O	O	1832
induction	NOUN	O	O	1832
chemotherapy	NOUN	O	O	1832
treatment	NOUN	O	O	1832
with	ADP	O	O	1832
cis	PROPN	O	O	1832
-	PUNCT	O	O	1832
platin	PROPN	O	O	1832
and	CCONJ	O	O	1832
5-fluorouracil	NOUN	O	Chemical	1832
.	PUNCT	O	O	1832
Survival	NOUN	O	O	1833
for	ADP	O	O	1833
patients	NOUN	O	O	1833
with	ADP	O	O	1833
advanced	ADJ	O	O	1833
head	NOUN	O	O	1833
and	CCONJ	O	O	1833
neck	NOUN	O	O	1833
carcinoma	NOUN	O	Disease	1833
and	CCONJ	O	O	1833
esophageal	ADJ	O	O	1833
carcinoma	NOUN	O	Disease	1833
is	AUX	O	O	1833
poor	ADJ	O	O	1833
with	ADP	O	O	1833
radiotherapy	NOUN	O	O	1833
and/or	CCONJ	O	O	1833
surgery	NOUN	O	O	1833
.	PUNCT	O	O	1833
In	ADP	O	O	1834
the	PRON	O	O	1834
present	NOUN	O	O	1834
study	VERB	O	O	1834
,	PUNCT	O	O	1834
cis	PROPN	O	O	1834
-	PUNCT	O	O	1834
platin	PROPN	O	O	1834
(	PUNCT	O	O	1834
80	NUM	O	O	1834
-	PUNCT	O	O	1834
120	NUM	O	O	1834
mg	VERB	O	O	1834
/	PUNCT	O	O	1834
m2BSA	VERB	O	O	1834
)	PUNCT	O	O	1834
and	CCONJ	O	O	1834
5-FU	NOUN	O	Chemical	1834
(	PUNCT	O	O	1834
1000	NUM	O	O	1834
mg	VERB	O	O	1834
/	PUNCT	O	O	1834
m2BSA	VERB	O	O	1834
daily	ADV	O	O	1834
as	ADP	O	O	1834
a	PRON	O	O	1834
continuous	ADJ	O	O	1834
infusion	NOUN	O	O	1834
during	ADP	O	O	1834
5	NUM	O	O	1834
days	NOUN	O	O	1834
)	PUNCT	O	O	1834
were	AUX	O	O	1834
given	VERB	O	O	1834
to	PART	O	O	1834
76	NUM	O	O	1834
patients	NOUN	O	O	1834
before	ADP	O	O	1834
radiotherapy	NOUN	O	O	1834
and	CCONJ	O	O	1834
surgery	NOUN	O	O	1834
.	PUNCT	O	O	1834
In	ADP	O	O	1835
the	PRON	O	O	1835
pre	VERB	O	O	1835
-	PUNCT	O	O	1835
treatment	NOUN	O	O	1835
evaluation	NOUN	O	O	1835
,	PUNCT	O	O	1835
signs	NOUN	O	O	1835
of	ADP	O	O	1835
cardiovascular disease	NOUN	O	Disease	1835
were	AUX	O	O	1835
found	VERB	O	O	1835
in	ADP	O	O	1835
33	NUM	O	O	1835
patients	NOUN	O	O	1835
(	PUNCT	O	O	1835
43%	NOUN	O	O	1835
)	PUNCT	O	O	1835
.	PUNCT	O	O	1835
The	PRON	O	O	1836
incidence	NOUN	O	O	1836
of	ADP	O	O	1836
cardiotoxicity	NOUN	O	Disease	1836
was	AUX	O	O	1836
not	PART	O	O	1836
higher	ADJ	O	O	1836
in	ADP	O	O	1836
patients	NOUN	O	O	1836
with	ADP	O	O	1836
signs	NOUN	O	O	1836
of	ADP	O	O	1836
cardiovascular disease	NOUN	O	Disease	1836
than	ADP	O	O	1836
in	ADP	O	O	1836
those	PRON	O	O	1836
without	ADP	O	O	1836
in	ADP	O	O	1836
the	PRON	O	O	1836
pre	VERB	O	O	1836
-	PUNCT	O	O	1836
treatment	NOUN	O	O	1836
evaluation	NOUN	O	O	1836
.	PUNCT	O	O	1836
The	PRON	O	O	1837
most	ADV	O	O	1837
common	ADJ	O	O	1837
signs	NOUN	O	O	1837
of	ADP	O	O	1837
cardiotoxicity	NOUN	O	Disease	1837
were	AUX	O	O	1837
chest pain	NOUN	O	Disease	1837
,	PUNCT	O	O	1837
ST	PROPN	O	O	1837
-	PUNCT	O	O	1837
T	NOUN	O	Chemical	1837
wave	NOUN	O	O	1837
changes	VERB	O	O	1837
and	CCONJ	O	O	1837
atrial fibrillation	NOUN	O	Disease	1837
.	PUNCT	O	O	1837
This	PRON	O	O	1838
was	AUX	O	O	1838
followed	VERB	O	O	1838
by	ADP	O	O	1838
ventricular fibrillation	NOUN	O	Disease	1838
in	ADP	O	O	1838
one	NUM	O	O	1838
patient	NOUN	O	O	1838
and	CCONJ	O	O	1838
sudden death	NOUN	O	Disease	1838
in	ADP	O	O	1838
another	PRON	O	O	1838
.	PUNCT	O	O	1838
It	PRON	O	O	1839
is	AUX	O	O	1839
concluded	VERB	O	O	1839
that	SCONJ	O	O	1839
patients	NOUN	O	O	1839
on	ADP	O	O	1839
5-FU	NOUN	O	Chemical	1839
treatment	NOUN	O	O	1839
should	AUX	O	O	1839
be	AUX	O	O	1839
under	ADP	O	O	1839
close	ADV	O	O	1839
supervision	PROPN	O	O	1839
and	CCONJ	O	O	1839
that	SCONJ	O	O	1839
the	PRON	O	O	1839
treatment	NOUN	O	O	1839
should	AUX	O	O	1839
be	AUX	O	O	1839
discontinued	VERB	O	O	1839
if	SCONJ	O	O	1839
chest pain	NOUN	O	Disease	1839
or	CCONJ	O	O	1839
tachyarrhythmia	ADV	O	O	1839
is	AUX	O	O	1839
observed	VERB	O	O	1839
.	PUNCT	O	O	1839
Verapamil	PROPN	O	Chemical	1842
-	PUNCT	O	O	1842
induced	VERB	O	O	1842
carbamazepine	NOUN	O	Chemical	1842
neurotoxicity	NOUN	O	Disease	1842
.	PUNCT	O	O	1842
Two	NUM	O	O	1843
patients	NOUN	O	O	1843
with	ADP	O	O	1843
signs	NOUN	O	O	1843
of	ADP	O	O	1843
carbamazepine	NOUN	O	Chemical	1843
neurotoxicity	NOUN	O	Disease	1843
after	ADP	O	O	1843
combined	VERB	O	O	1843
treatment	NOUN	O	O	1843
with	ADP	O	O	1843
verapamil	PROPN	O	Chemical	1843
showed	VERB	O	O	1843
complete	VERB	O	O	1843
recovery	NOUN	O	O	1843
after	ADP	O	O	1843
discontinuation	NOUN	O	O	1843
of	ADP	O	O	1843
the	PRON	O	O	1843
calcium	NOUN	O	Chemical	1843
entry	NOUN	O	O	1843
blocker	NOUN	O	O	1843
.	PUNCT	O	O	1843
Use	VERB	O	O	1844
of	ADP	O	O	1844
verapamil	PROPN	O	Chemical	1844
in	ADP	O	O	1844
combination	NOUN	O	O	1844
with	ADP	O	O	1844
carbamazepine	NOUN	O	Chemical	1844
should	AUX	O	O	1844
either	ADV	O	O	1844
be	AUX	O	O	1844
avoided	VERB	O	O	1844
or	CCONJ	O	O	1844
prescribed	VERB	O	O	1844
only	ADV	O	O	1844
with	ADP	O	O	1844
appropriate	ADJ	O	O	1844
adjustment	NOUN	O	O	1844
of	ADP	O	O	1844
the	PRON	O	O	1844
carbamazepine	NOUN	O	Chemical	1844
dose	NOUN	O	O	1844
(	PUNCT	O	O	1844
usually	ADV	O	O	1844
reduction	NOUN	O	O	1844
of	ADP	O	O	1844
the	PRON	O	O	1844
carbamazepine	NOUN	O	Chemical	1844
dose	NOUN	O	O	1844
by	ADP	O	O	1844
one	NUM	O	O	1844
half	NOUN	O	O	1844
)	PUNCT	O	O	1844
.	PUNCT	O	O	1844
Serial	ADJ	O	O	1847
studies	NOUN	O	O	1847
of	ADP	O	O	1847
auditory	NOUN	O	O	1847
neurotoxicity	NOUN	O	Disease	1847
in	ADP	O	O	1847
patients	NOUN	O	O	1847
receiving	VERB	O	O	1847
deferoxamine	PROPN	O	Chemical	1847
therapy	NOUN	O	O	1847
.	PUNCT	O	O	1847
Visual	ADJ	O	O	1848
and	CCONJ	O	O	1848
auditory	NOUN	O	O	1848
neurotoxicity	NOUN	O	Disease	1848
was	AUX	O	O	1848
previously	ADV	O	O	1848
documented	VERB	O	O	1848
in	ADP	O	O	1848
42	NUM	O	O	1848
of	ADP	O	O	1848
89	NUM	O	O	1848
patients	NOUN	O	O	1848
with	ADP	O	O	1848
transfusion	NOUN	O	O	1848
-	PUNCT	O	O	1848
dependent	ADJ	O	O	1848
anemia	NOUN	O	Disease	1848
who	PRON	O	O	1848
were	AUX	O	O	1848
receiving	VERB	O	O	1848
iron	NOUN	O	Chemical	1848
chelation	NOUN	O	O	1848
therapy	NOUN	O	O	1848
with	ADP	O	O	1848
daily	ADV	O	O	1848
subcutaneous	ADJ	O	O	1848
deferoxamine	PROPN	O	Chemical	1848
.	PUNCT	O	O	1848
Twenty	NUM	O	O	1849
-	PUNCT	O	O	1849
two	NUM	O	O	1849
patients	NOUN	O	O	1849
in	ADP	O	O	1849
the	PRON	O	O	1849
affected	VERB	O	O	1849
group	NOUN	O	O	1849
had	VERB	O	O	1849
abnormal	ADJ	O	O	1849
audiograms	NOUN	O	O	1849
with	ADP	O	O	1849
deficits	NOUN	O	O	1849
mostly	ADV	O	O	1849
in	ADP	O	O	1849
the	PRON	O	O	1849
high	ADJ	O	O	1849
frequency	NOUN	O	O	1849
range	VERB	O	O	1849
of	ADP	O	O	1849
4,000	NUM	O	O	1849
to	PART	O	O	1849
8,000	NUM	O	O	1849
Hz	NOUN	O	O	1849
and	CCONJ	O	O	1849
in	ADP	O	O	1849
the	PRON	O	O	1849
hearing	NOUN	O	O	1849
threshold	NOUN	O	O	1849
levels	NOUN	O	O	1849
of	ADP	O	O	1849
30	NUM	O	O	1849
to	PART	O	O	1849
100	NUM	O	O	1849
decibels	NOUN	O	O	1849
.	PUNCT	O	O	1849
When	SCONJ	O	O	1850
deferoxamine	PROPN	O	Chemical	1850
therapy	NOUN	O	O	1850
was	AUX	O	O	1850
discontinued	VERB	O	O	1850
and	CCONJ	O	O	1850
serial	ADJ	O	O	1850
studies	NOUN	O	O	1850
were	AUX	O	O	1850
performed	VERB	O	O	1850
,	PUNCT	O	O	1850
audiograms	NOUN	O	O	1850
in	ADP	O	O	1850
seven	NUM	O	O	1850
cases	NOUN	O	O	1850
reverted	VERB	O	O	1850
to	PART	O	O	1850
normal	ADJ	O	O	1850
or	CCONJ	O	O	1850
near	ADP	O	O	1850
normal	ADJ	O	O	1850
within	ADP	O	O	1850
two	NUM	O	O	1850
to	PART	O	O	1850
three	NUM	O	O	1850
weeks	NOUN	O	O	1850
,	PUNCT	O	O	1850
and	CCONJ	O	O	1850
nine	NUM	O	O	1850
of	ADP	O	O	1850
13	NUM	O	O	1850
patients	NOUN	O	O	1850
with	ADP	O	O	1850
symptoms	NOUN	O	O	1850
became	VERB	O	O	1850
asymptomatic	ADJ	O	O	1850
.	PUNCT	O	O	1850
Audiograms	NOUN	O	O	1851
from	ADP	O	O	1851
15	NUM	O	O	1851
patients	NOUN	O	O	1851
remained	VERB	O	O	1851
abnormal	ADJ	O	O	1851
and	CCONJ	O	O	1851
four	NUM	O	O	1851
patients	NOUN	O	O	1851
required	VERB	O	O	1851
hearing	NOUN	O	O	1851
aids	PROPN	O	O	1851
because	SCONJ	O	O	1851
of	ADP	O	O	1851
permanent	ADJ	O	O	1851
disability	NOUN	O	O	1851
.	PUNCT	O	O	1851
Since	SCONJ	O	O	1852
18	NUM	O	O	1852
of	ADP	O	O	1852
the	PRON	O	O	1852
22	NUM	O	O	1852
patients	NOUN	O	O	1852
were	AUX	O	O	1852
initially	ADV	O	O	1852
receiving	VERB	O	O	1852
deferoxamine	PROPN	O	Chemical	1852
doses	NOUN	O	O	1852
in	ADP	O	O	1852
excess	ADJ	O	O	1852
of	ADP	O	O	1852
the	PRON	O	O	1852
commonly	ADV	O	O	1852
recommended	VERB	O	O	1852
50	NUM	O	O	1852
mg	VERB	O	O	1852
/	PUNCT	O	O	1852
kg	VERB	O	O	1852
per	ADP	O	O	1852
dose	NOUN	O	O	1852
,	PUNCT	O	O	1852
therapy	NOUN	O	O	1852
was	AUX	O	O	1852
restarted	VERB	O	O	1852
with	ADP	O	O	1852
lower	ADJ	O	O	1852
doses	NOUN	O	O	1852
,	PUNCT	O	O	1852
usually	ADV	O	O	1852
50	NUM	O	O	1852
mg	VERB	O	O	1852
/	PUNCT	O	O	1852
kg	VERB	O	O	1852
per	ADP	O	O	1852
dose	NOUN	O	O	1852
or	CCONJ	O	O	1852
less	ADV	O	O	1852
depending	VERB	O	O	1852
on	ADP	O	O	1852
the	PRON	O	O	1852
degree	PROPN	O	O	1852
of	ADP	O	O	1852
auditory	NOUN	O	O	1852
abnormality	NOUN	O	O	1852
,	PUNCT	O	O	1852
and	CCONJ	O	O	1852
with	ADP	O	O	1852
the	PRON	O	O	1852
exception	NOUN	O	O	1852
of	ADP	O	O	1852
two	NUM	O	O	1852
cases	NOUN	O	O	1852
no	PRON	O	O	1852
further	ADV	O	O	1852
toxicity	NOUN	O	Disease	1852
was	AUX	O	O	1852
demonstrated	VERB	O	O	1852
.	PUNCT	O	O	1852
Auditory	NOUN	O	O	1853
deterioration	NOUN	O	O	1853
and	CCONJ	O	O	1853
improvement	NOUN	O	O	1853
,	PUNCT	O	O	1853
demonstrated	VERB	O	O	1853
serially	ADV	O	O	1853
in	ADP	O	O	1853
individual	ADJ	O	O	1853
patients	NOUN	O	O	1853
receiving	VERB	O	O	1853
and	CCONJ	O	O	1853
not	PART	O	O	1853
receiving	VERB	O	O	1853
deferoxamine	PROPN	O	Chemical	1853
,	PUNCT	O	O	1853
respectively	ADV	O	O	1853
,	PUNCT	O	O	1853
provided	VERB	O	O	1853
convincing	ADJ	O	O	1853
evidence	NOUN	O	O	1853
for	ADP	O	O	1853
a	PRON	O	O	1853
cause	VERB	O	O	1853
-	PUNCT	O	O	1853
and	CCONJ	O	O	1853
-	PUNCT	O	O	1853
effect	VERB	O	O	1853
relation	NOUN	O	O	1853
between	ADP	O	O	1853
deferoxamine	PROPN	O	Chemical	1853
administration	NOUN	O	O	1853
and	CCONJ	O	O	1853
ototoxicity	NOUN	O	Disease	1853
.	PUNCT	O	O	1853
Based	VERB	O	O	1854
on	ADP	O	O	1854
these	PRON	O	O	1854
data	NOUN	O	O	1854
,	PUNCT	O	O	1854
a	PRON	O	O	1854
plan	NOUN	O	O	1854
of	ADP	O	O	1854
management	NOUN	O	O	1854
was	AUX	O	O	1854
developed	VERB	O	O	1854
that	SCONJ	O	O	1854
allows	VERB	O	O	1854
effective	ADJ	O	O	1854
yet	ADV	O	O	1854
safe	ADJ	O	O	1854
administration	NOUN	O	O	1854
of	ADP	O	O	1854
deferoxamine	PROPN	O	Chemical	1854
.	PUNCT	O	O	1854
With	ADP	O	O	1855
mild	ADJ	O	O	1855
toxicity	NOUN	O	Disease	1855
,	PUNCT	O	O	1855
a	PRON	O	O	1855
reduction	NOUN	O	O	1855
to	PART	O	O	1855
30	NUM	O	O	1855
or	CCONJ	O	O	1855
40	NUM	O	O	1855
mg	VERB	O	O	1855
/	PUNCT	O	O	1855
kg	VERB	O	O	1855
per	ADP	O	O	1855
dose	NOUN	O	O	1855
should	AUX	O	O	1855
result	VERB	O	O	1855
in	ADP	O	O	1855
a	PRON	O	O	1855
reversal	NOUN	O	O	1855
of	ADP	O	O	1855
the	PRON	O	O	1855
abnormal	ADJ	O	O	1855
results	VERB	O	O	1855
to	PART	O	O	1855
normal	ADJ	O	O	1855
within	ADP	O	O	1855
four	NUM	O	O	1855
weeks	NOUN	O	O	1855
.	PUNCT	O	O	1855
Moderate	ADJ	O	O	1856
abnormalities	NOUN	O	O	1856
require	VERB	O	O	1856
a	PRON	O	O	1856
reduction	NOUN	O	O	1856
of	ADP	O	O	1856
deferoxamine	PROPN	O	Chemical	1856
to	PART	O	O	1856
25	NUM	O	O	1856
mg	VERB	O	O	1856
/	PUNCT	O	O	1856
kg	VERB	O	O	1856
per	ADP	O	O	1856
dose	NOUN	O	O	1856
with	ADP	O	O	1856
careful	ADJ	O	O	1856
monitoring	NOUN	O	O	1856
.	PUNCT	O	O	1856
In	ADP	O	O	1857
those	PRON	O	O	1857
with	ADP	O	O	1857
symptoms	NOUN	O	O	1857
of	ADP	O	O	1857
hearing loss	NOUN	O	Disease	1857
,	PUNCT	O	O	1857
the	PRON	O	O	1857
drug	NOUN	O	O	1857
should	AUX	O	O	1857
be	AUX	O	O	1857
stopped	VERB	O	O	1857
for	ADP	O	O	1857
four	NUM	O	O	1857
weeks	NOUN	O	O	1857
,	PUNCT	O	O	1857
and	CCONJ	O	O	1857
when	SCONJ	O	O	1857
the	PRON	O	O	1857
audiogram	PROPN	O	O	1857
is	AUX	O	O	1857
stable	ADJ	O	O	1857
or	CCONJ	O	O	1857
improved	VERB	O	O	1857
,	PUNCT	O	O	1857
therapy	NOUN	O	O	1857
should	AUX	O	O	1857
be	AUX	O	O	1857
restarted	VERB	O	O	1857
at	ADP	O	O	1857
10	NUM	O	O	1857
to	PART	O	O	1857
25	NUM	O	O	1857
mg	VERB	O	O	1857
/	PUNCT	O	O	1857
kg	VERB	O	O	1857
per	ADP	O	O	1857
dose	NOUN	O	O	1857
.	PUNCT	O	O	1857
Serial	ADJ	O	O	1858
audiograms	NOUN	O	O	1858
should	AUX	O	O	1858
be	AUX	O	O	1858
performed	VERB	O	O	1858
every	PRON	O	O	1858
six	NUM	O	O	1858
months	NOUN	O	O	1858
in	ADP	O	O	1858
those	PRON	O	O	1858
without	ADP	O	O	1858
problems	NOUN	O	O	1858
and	CCONJ	O	O	1858
more	ADJ	O	O	1858
frequently	ADV	O	O	1858
in	ADP	O	O	1858
young	ADJ	O	O	1858
patients	NOUN	O	O	1858
with	ADP	O	O	1858
normal	ADJ	O	O	1858
serum	NOUN	O	O	1858
ferritin	NOUN	O	O	1858
values	NOUN	O	O	1858
and	CCONJ	O	O	1858
in	ADP	O	O	1858
those	PRON	O	O	1858
with	ADP	O	O	1858
auditory dysfunction	NOUN	O	Disease	1858
.	PUNCT	O	O	1858
Flurbiprofen	NOUN	O	O	1861
in	ADP	O	O	1861
the	PRON	O	O	1861
treatment	NOUN	O	O	1861
of	ADP	O	O	1861
juvenile	NOUN	O	O	1861
rheumatoid arthritis	NOUN	O	Disease	1861
.	PUNCT	O	O	1861
Thirty	NUM	O	O	1862
-	PUNCT	O	O	1862
four	NUM	O	O	1862
patients	NOUN	O	O	1862
with	ADP	O	O	1862
juvenile	NOUN	O	O	1862
rheumatoid arthritis	NOUN	O	Disease	1862
,	PUNCT	O	O	1862
who	PRON	O	O	1862
were	AUX	O	O	1862
treated	VERB	O	O	1862
with	ADP	O	O	1862
flurbiprofen	NOUN	O	O	1862
at	ADP	O	O	1862
a	PRON	O	O	1862
maximum	ADV	O	O	1862
dose	NOUN	O	O	1862
of	ADP	O	O	1862
4	NUM	O	O	1862
mg	VERB	O	O	1862
/	PUNCT	O	O	1862
kg	VERB	O	O	1862
/	PUNCT	O	O	1862
day	NOUN	O	O	1862
,	PUNCT	O	O	1862
had	VERB	O	O	1862
statistically	ADV	O	O	1862
significant	ADJ	O	O	1862
decreases	VERB	O	O	1862
from	ADP	O	O	1862
baseline	VERB	O	O	1862
in	ADP	O	O	1862
6	NUM	O	O	1862
arthritis	NOUN	O	Disease	1862
indices	NOUN	O	O	1862
after	ADP	O	O	1862
12	NUM	O	O	1862
weeks	NOUN	O	O	1862
of	ADP	O	O	1862
treatment	NOUN	O	O	1862
.	PUNCT	O	O	1862
Improvements	NOUN	O	O	1863
were	AUX	O	O	1863
seen	VERB	O	O	1863
in	ADP	O	O	1863
the	PRON	O	O	1863
number	NOUN	O	O	1863
of	ADP	O	O	1863
tender	ADJ	O	O	1863
joints	NOUN	O	O	1863
,	PUNCT	O	O	1863
the	PRON	O	O	1863
severity	NOUN	O	O	1863
of	ADP	O	O	1863
swelling	VERB	O	Disease	1863
and	CCONJ	O	O	1863
tenderness	NOUN	O	O	1863
,	PUNCT	O	O	1863
the	PRON	O	O	1863
time	NOUN	O	O	1863
of	ADP	O	O	1863
walk	VERB	O	O	1863
50	NUM	O	O	1863
feet	NOUN	O	O	1863
,	PUNCT	O	O	1863
the	PRON	O	O	1863
duration	NOUN	O	O	1863
of	ADP	O	O	1863
morning	NOUN	O	O	1863
stiffness	VERB	O	O	1863
and	CCONJ	O	O	1863
the	PRON	O	O	1863
circumference	NOUN	O	O	1863
of	ADP	O	O	1863
the	PRON	O	O	1863
left	VERB	O	O	1863
knee	VERB	O	O	1863
.	PUNCT	O	O	1863
The	PRON	O	O	1864
most	ADV	O	O	1864
frequently	ADV	O	O	1864
observed	VERB	O	O	1864
side	NOUN	O	O	1864
effect	VERB	O	O	1864
was	AUX	O	O	1864
fecal	ADJ	O	O	1864
occult	NOUN	O	O	1864
blood	NOUN	O	O	1864
(	PUNCT	O	O	1864
25%	NOUN	O	O	1864
of	ADP	O	O	1864
patients	NOUN	O	O	1864
)	PUNCT	O	O	1864
;	PUNCT	O	O	1864
however	ADV	O	O	1864
,	PUNCT	O	O	1864
there	ADV	O	O	1864
was	AUX	O	O	1864
no	PRON	O	O	1864
other	ADJ	O	O	1864
evidence	NOUN	O	O	1864
of	ADP	O	O	1864
gastrointestinal	ADJ	O	O	1864
(	PUNCT	O	O	1864
GI	PROPN	O	O	1864
)	PUNCT	O	O	1864
bleeding	VERB	O	Disease	1864
in	ADP	O	O	1864
these	PRON	O	O	1864
patients	NOUN	O	O	1864
.	PUNCT	O	O	1864
One	NUM	O	O	1865
patient	NOUN	O	O	1865
was	AUX	O	O	1865
prematurely	ADV	O	O	1865
discontinued	VERB	O	O	1865
from	ADP	O	O	1865
the	PRON	O	O	1865
study	VERB	O	O	1865
for	ADP	O	O	1865
severe	ADJ	O	O	1865
headache	PROPN	O	Disease	1865
and	CCONJ	O	O	1865
abdominal pain	NOUN	O	Disease	1865
.	PUNCT	O	O	1865
The	PRON	O	O	1868
correlation	NOUN	O	O	1868
between	ADP	O	O	1868
neurotoxic	ADJ	O	Disease	1868
esterase	NOUN	O	O	1868
inhibition	NOUN	O	O	1868
and	CCONJ	O	O	1868
mipafox	NOUN	O	O	1868
-	PUNCT	O	O	1868
induced	VERB	O	O	1868
neuropathic	ADJ	O	O	1868
damage	NOUN	O	O	1868
in	ADP	O	O	1868
rats	NOUN	O	O	1868
.	PUNCT	O	O	1868
The	PRON	O	O	1869
correlation	NOUN	O	O	1869
between	ADP	O	O	1869
neuropathic	ADJ	O	O	1869
damage	NOUN	O	O	1869
and	CCONJ	O	O	1869
inhibition	NOUN	O	O	1869
of	ADP	O	O	1869
neurotoxic	ADJ	O	Disease	1869
esterase	NOUN	O	O	1869
or	CCONJ	O	O	1869
neuropathy	NOUN	O	Disease	1869
target	NOUN	O	O	1869
enzyme	NOUN	O	O	1869
(	PUNCT	O	O	1869
NTE	PROPN	O	O	1869
)	PUNCT	O	O	1869
was	AUX	O	O	1869
examined	VERB	O	O	1869
in	ADP	O	O	1869
rats	NOUN	O	O	1869
acutely	ADV	O	O	1869
exposed	VERB	O	O	1869
to	PART	O	O	1869
Mipafox	PROPN	O	O	1869
(	PUNCT	O	O	1869
N	NUM	O	O	1869
,	PUNCT	O	O	1869
N'-diisopropylphosphorodiamidofluoridate	ADP	O	O	1869
)	PUNCT	O	O	1869
,	PUNCT	O	O	1869
a	PRON	O	O	1869
neurotoxic	ADJ	O	Disease	1869
organophosphate	NOUN	O	O	1869
.	PUNCT	O	O	1869
Brain	NOUN	O	O	1870
and	CCONJ	O	O	1870
spinal	NOUN	O	O	1870
cord	NOUN	O	O	1870
NTE	PROPN	O	O	1870
activities	NOUN	O	O	1870
were	AUX	O	O	1870
measured	VERB	O	O	1870
in	ADP	O	O	1870
Long	ADV	O	O	1870
-	PUNCT	O	O	1870
Evans	PROPN	O	O	1870
male	NOUN	O	O	1870
rats	NOUN	O	O	1870
1	X	O	O	1870
hr	NOUN	O	O	1870
post	VERB	O	O	1870
-	PUNCT	O	O	1870
exposure	NOUN	O	O	1870
to	PART	O	O	1870
various	ADJ	O	O	1870
dosages	NOUN	O	O	1870
of	ADP	O	O	1870
Mipafox	PROPN	O	O	1870
(	PUNCT	O	O	1870
ip	X	O	O	1870
,	PUNCT	O	O	1870
1	X	O	O	1870
-	PUNCT	O	O	1870
15	NUM	O	O	1870
mg	VERB	O	O	1870
/	PUNCT	O	O	1870
kg	VERB	O	O	1870
)	PUNCT	O	O	1870
.	PUNCT	O	O	1870
These	PRON	O	O	1871
data	NOUN	O	O	1871
were	AUX	O	O	1871
correlated	VERB	O	O	1871
with	ADP	O	O	1871
histologically	ADV	O	O	1871
scored	VERB	O	O	1871
cervical	ADJ	O	O	1871
cord	NOUN	O	O	1871
damage	NOUN	O	O	1871
in	ADP	O	O	1871
a	PRON	O	O	1871
separate	VERB	O	O	1871
group	NOUN	O	O	1871
of	ADP	O	O	1871
similarly	ADV	O	O	1871
dosed	VERB	O	O	1871
rats	NOUN	O	O	1871
sampled	VERB	O	O	1871
14	NUM	O	O	1871
-	PUNCT	O	O	1871
21	NUM	O	O	1871
days	NOUN	O	O	1871
post	VERB	O	O	1871
-	PUNCT	O	O	1871
exposure	NOUN	O	O	1871
.	PUNCT	O	O	1871
In	ADP	O	O	1872
contrast	NOUN	O	O	1872
,	PUNCT	O	O	1872
dosages	NOUN	O	O	1872
of	ADP	O	O	1872
Mipafox	PROPN	O	O	1872
(	PUNCT	O	O	1872
less	ADV	O	O	1872
than	ADP	O	O	1872
or	CCONJ	O	O	1872
equal	ADJ	O	O	1872
to	PART	O	O	1872
5	NUM	O	O	1872
mg	VERB	O	O	1872
/	PUNCT	O	O	1872
kg	VERB	O	O	1872
)	PUNCT	O	O	1872
which	PRON	O	O	1872
inhibited	VERB	O	O	1872
mean	VERB	O	O	1872
NTE	PROPN	O	O	1872
activity	NOUN	O	O	1872
in	ADP	O	O	1872
spinal	NOUN	O	O	1872
cord	NOUN	O	O	1872
less	ADV	O	O	1872
than	ADP	O	O	1872
or	CCONJ	O	O	1872
equal	ADJ	O	O	1872
to	PART	O	O	1872
61%	NOUN	O	O	1872
and	CCONJ	O	O	1872
brain	NOUN	O	O	1872
less	ADV	O	O	1872
than	ADP	O	O	1872
or	CCONJ	O	O	1872
equal	ADJ	O	O	1872
to	PART	O	O	1872
60%	NOUN	O	O	1872
produced	VERB	O	O	1872
this	PRON	O	O	1872
degree	PROPN	O	O	1872
of	ADP	O	O	1872
cord	NOUN	O	O	1872
damage	NOUN	O	O	1872
in	ADP	O	O	1872
only	ADV	O	O	1872
9%	NOUN	O	O	1872
of	ADP	O	O	1872
the	PRON	O	O	1872
animals	NOUN	O	O	1872
.	PUNCT	O	O	1872
These	PRON	O	O	1873
data	NOUN	O	O	1873
indicate	VERB	O	O	1873
that	SCONJ	O	O	1873
a	PRON	O	O	1873
critical	ADJ	O	O	1873
percentage	NOUN	O	O	1873
of	ADP	O	O	1873
NTE	PROPN	O	O	1873
inhibition	NOUN	O	O	1873
in	ADP	O	O	1873
brain	NOUN	O	O	1873
and	CCONJ	O	O	1873
spinal	NOUN	O	O	1873
cord	NOUN	O	O	1873
sampled	VERB	O	O	1873
shortly	ADV	O	O	1873
after	ADP	O	O	1873
Mipafox	PROPN	O	O	1873
exposure	NOUN	O	O	1873
can	AUX	O	O	1873
predict	VERB	O	O	1873
neuropathic	ADJ	O	O	1873
damage	NOUN	O	O	1873
in	ADP	O	O	1873
rats	NOUN	O	O	1873
several	ADJ	O	O	1873
weeks	NOUN	O	O	1873
later	ADV	O	O	1873
.	PUNCT	O	O	1873
Cerebral	ADJ	O	O	1876
infarction	NOUN	O	O	1876
with	ADP	O	O	1876
a	PRON	O	O	1876
single	ADJ	O	O	1876
oral	ADJ	O	O	1876
dose	NOUN	O	O	1876
of	ADP	O	O	1876
phenylpropanolamine	PROPN	O	Chemical	1876
.	PUNCT	O	O	1876
Phenylpropanolamine	NOUN	O	Chemical	1877
(	PUNCT	O	O	1877
PPA	PROPN	O	Chemical	1877
)	PUNCT	O	O	1877
,	PUNCT	O	O	1877
a	PRON	O	O	1877
synthetic	NOUN	O	O	1877
sympathomimetic	ADJ	O	O	1877
that	SCONJ	O	O	1877
is	AUX	O	O	1877
structurally	ADV	O	O	1877
similar	ADJ	O	O	1877
to	PART	O	O	1877
amphetamine	NOUN	O	Chemical	1877
,	PUNCT	O	O	1877
is	AUX	O	O	1877
available	ADJ	O	O	1877
over	ADP	O	O	1877
the	PRON	O	O	1877
counter	VERB	O	O	1877
in	ADP	O	O	1877
anorectics	NOUN	O	O	1877
,	PUNCT	O	O	1877
nasal	ADJ	O	O	1877
congestants	PROPN	O	O	1877
,	PUNCT	O	O	1877
and	CCONJ	O	O	1877
cold	ADJ	O	O	1877
preparations	NOUN	O	O	1877
.	PUNCT	O	O	1877
Its	PRON	O	O	1878
prolonged	VERB	O	O	1878
use	VERB	O	O	1878
or	CCONJ	O	O	1878
overuse	NOUN	O	O	1878
has	VERB	O	O	1878
been	AUX	O	O	1878
associated	VERB	O	O	1878
with	ADP	O	O	1878
seizures	NOUN	O	Disease	1878
,	PUNCT	O	O	1878
intracerebral hemorrhage	NOUN	O	Disease	1878
,	PUNCT	O	O	1878
neuropsychiatric	ADJ	O	O	1878
symptoms	NOUN	O	O	1878
,	PUNCT	O	O	1878
and	CCONJ	O	O	1878
nonhemorrhagic	ADJ	O	O	1878
cerebral infarction	NOUN	O	Disease	1878
.	PUNCT	O	O	1878
We	PRON	O	O	1879
report	VERB	O	O	1879
the	PRON	O	O	1879
case	NOUN	O	O	1879
of	ADP	O	O	1879
a	PRON	O	O	1879
young	ADJ	O	O	1879
woman	NOUN	O	O	1879
who	PRON	O	O	1879
suffered	VERB	O	O	1879
a	PRON	O	O	1879
cerebral infarction	NOUN	O	Disease	1879
after	ADP	O	O	1879
taking	VERB	O	O	1879
a	PRON	O	O	1879
single	ADJ	O	O	1879
oral	ADJ	O	O	1879
dose	NOUN	O	O	1879
of	ADP	O	O	1879
PPA	PROPN	O	Chemical	1879
.	PUNCT	O	O	1879
Treatment	NOUN	O	O	1882
of	ADP	O	O	1882
psoriasis	NOUN	O	Disease	1882
with	ADP	O	O	1882
azathioprine	ADV	O	Chemical	1882
.	PUNCT	O	O	1882
Azathioprine	ADV	O	Chemical	1883
treatment	NOUN	O	O	1883
benefited	VERB	O	O	1883
19	NUM	O	O	1883
(	PUNCT	O	O	1883
66%	NOUN	O	O	1883
)	PUNCT	O	O	1883
out	ADP	O	O	1883
of	ADP	O	O	1883
29	NUM	O	O	1883
patients	NOUN	O	O	1883
suffering	VERB	O	O	1883
from	ADP	O	O	1883
severe	ADJ	O	O	1883
psoriasis	NOUN	O	Disease	1883
.	PUNCT	O	O	1883
Minimal	ADJ	O	O	1884
cholestasis	NOUN	O	Disease	1884
was	AUX	O	O	1884
seen	VERB	O	O	1884
in	ADP	O	O	1884
two	NUM	O	O	1884
cases	NOUN	O	O	1884
and	CCONJ	O	O	1884
portal	PROPN	O	O	1884
fibrosis	NOUN	O	Disease	1884
of	ADP	O	O	1884
a	PRON	O	O	1884
reversible	ADJ	O	O	1884
degree	PROPN	O	O	1884
in	ADP	O	O	1884
eight	NUM	O	O	1884
.	PUNCT	O	O	1884
Liver	NOUN	O	O	1885
biopsies	NOUN	O	O	1885
should	AUX	O	O	1885
be	AUX	O	O	1885
undertaken	VERB	O	O	1885
at	ADP	O	O	1885
regular	ADJ	O	O	1885
intervals	NOUN	O	O	1885
if	SCONJ	O	O	1885
azathioprine	ADV	O	Chemical	1885
therapy	NOUN	O	O	1885
is	AUX	O	O	1885
continued	VERB	O	O	1885
so	ADV	O	O	1885
that	SCONJ	O	O	1885
structural	ADJ	O	O	1885
liver damage	NOUN	O	Disease	1885
may	AUX	O	O	1885
be	AUX	O	O	1885
detected	VERB	O	O	1885
at	ADP	O	O	1885
an	PRON	O	O	1885
early	ADV	O	O	1885
and	CCONJ	O	O	1885
reversible	ADJ	O	O	1885
stage	NOUN	O	O	1885
.	PUNCT	O	O	1885
Maternal	ADJ	O	O	1888
lithium	NOUN	O	Chemical	1888
and	CCONJ	O	O	1888
neonatal	NOUN	O	O	1888
Ebstein	VERB	O	O	1889
's	AUX	O	O	1889
anomaly	NOUN	O	O	1889
:	PUNCT	O	O	1889
evaluation	NOUN	O	O	1889
with	ADP	O	O	1889
cross	VERB	O	O	1889
-	PUNCT	O	O	1889
sectional	ADJ	O	O	1889
echocardiography	NOUN	O	O	1889
.	PUNCT	O	O	1889
Cross	PROPN	O	O	1890
-	PUNCT	O	O	1890
sectional	ADJ	O	O	1890
echocardiography	NOUN	O	O	1890
was	AUX	O	O	1890
used	VERB	O	O	1890
to	PART	O	O	1890
evaluate	VERB	O	O	1890
two	NUM	O	O	1890
neonates	NOUN	O	O	1890
whose	DET	O	O	1890
mothers	NOUN	O	O	1890
ingested	VERB	O	O	1890
lithium	NOUN	O	Chemical	1890
during	ADP	O	O	1890
pregnancy	NOUN	O	O	1890
.	PUNCT	O	O	1890
In	ADP	O	O	1891
one	NUM	O	O	1891
infant	NOUN	O	O	1891
,	PUNCT	O	O	1891
Ebstein	VERB	O	O	1891
's	AUX	O	O	1891
anomaly	NOUN	O	O	1891
of	ADP	O	O	1891
the	PRON	O	O	1891
tricuspid	PROPN	O	O	1891
valve	PROPN	O	O	1891
was	AUX	O	O	1891
identified	VERB	O	O	1891
.	PUNCT	O	O	1891
In	ADP	O	O	1892
the	PRON	O	O	1892
other	ADJ	O	O	1892
infant	NOUN	O	O	1892
cross	VERB	O	O	1892
-	PUNCT	O	O	1892
sectional	ADJ	O	O	1892
echocardiography	NOUN	O	O	1892
provided	VERB	O	O	1892
reassurance	NOUN	O	O	1892
that	SCONJ	O	O	1892
the	PRON	O	O	1892
infant	NOUN	O	O	1892
did	VERB	O	O	1892
not	PART	O	O	1892
have	VERB	O	O	1892
Ebstein	VERB	O	O	1892
's	AUX	O	O	1892
anomaly	NOUN	O	O	1892
.	PUNCT	O	O	1892
Cross	PROPN	O	O	1893
-	PUNCT	O	O	1893
sectional	ADJ	O	O	1893
echocardiographic	NOUN	O	O	1893
screening	VERB	O	O	1893
of	ADP	O	O	1893
newborns	NOUN	O	O	1893
exposed	VERB	O	O	1893
to	PART	O	O	1893
lithium	NOUN	O	Chemical	1893
during	ADP	O	O	1893
gestation	NOUN	O	O	1893
can	AUX	O	O	1893
provide	VERB	O	O	1893
highly	ADV	O	O	1893
accurate	ADJ	O	O	1893
,	PUNCT	O	O	1893
noninvasive	ADJ	O	O	1893
assessment	NOUN	O	O	1893
of	ADP	O	O	1893
the	PRON	O	O	1893
presence	NOUN	O	O	1893
or	CCONJ	O	O	1893
absence	NOUN	O	O	1893
of	ADP	O	O	1893
lithium	NOUN	O	Chemical	1893
-	PUNCT	O	O	1893
induced	VERB	O	O	1893
cardiac	ADJ	O	O	1893
malformations	NOUN	O	Disease	1893
.	PUNCT	O	O	1893
Effects	NOUN	O	O	1896
of	ADP	O	O	1896
training	NOUN	O	O	1896
on	ADP	O	O	1896
the	PRON	O	O	1896
extent	NOUN	O	O	1896
of	ADP	O	O	1896
experimental	ADJ	O	O	1896
myocardial infarction	NOUN	O	Disease	1896
in	ADP	O	O	1896
aging	VERB	O	O	1896
rats	NOUN	O	O	1896
.	PUNCT	O	O	1896
The	PRON	O	O	1897
effects	NOUN	O	O	1897
of	ADP	O	O	1897
exercise	VERB	O	O	1897
on	ADP	O	O	1897
the	PRON	O	O	1897
severity	NOUN	O	O	1897
of	ADP	O	O	1897
isoproterenol	NOUN	O	Chemical	1897
-	PUNCT	O	O	1897
induced	VERB	O	O	1897
myocardial infarction	NOUN	O	Disease	1897
were	AUX	O	O	1897
studied	VERB	O	O	1897
in	ADP	O	O	1897
female	ADJ	O	O	1897
albino	PROPN	O	O	1897
rats	NOUN	O	O	1897
of	ADP	O	O	1897
20,40,60	NUM	O	O	1897
and	CCONJ	O	O	1897
80	NUM	O	O	1897
weeks	NOUN	O	O	1897
of	ADP	O	O	1897
age	NOUN	O	O	1897
.	PUNCT	O	O	1897
The	PRON	O	O	1898
occurrence	NOUN	O	O	1898
of	ADP	O	O	1898
infarcts	VERB	O	O	1898
were	AUX	O	O	1898
confirmed	VERB	O	O	1898
by	ADP	O	O	1898
histological	ADJ	O	O	1898
methods	NOUN	O	O	1898
.	PUNCT	O	O	1898
Elevations	NOUN	O	O	1899
in	ADP	O	O	1899
the	PRON	O	O	1899
serum	NOUN	O	O	1899
GOT	VERB	O	O	1899
and	CCONJ	O	O	1899
GPT	PROPN	O	O	1899
were	AUX	O	O	1899
maximum	ADV	O	O	1899
in	ADP	O	O	1899
the	PRON	O	O	1899
sedentary	ADJ	O	O	1899
-	PUNCT	O	O	1899
isoproterenols	NOUN	O	O	1899
and	CCONJ	O	O	1899
minimum	ADJ	O	O	1899
in	ADP	O	O	1899
the	PRON	O	O	1899
exercise	VERB	O	O	1899
-	PUNCT	O	O	1899
controls	VERB	O	O	1899
.	PUNCT	O	O	1899
Studies	NOUN	O	O	1900
dealing	VERB	O	O	1900
with	ADP	O	O	1900
myocardial infarction	NOUN	O	Disease	1900
are	AUX	O	O	1900
more	ADJ	O	O	1900
informative	ADJ	O	O	1900
when	SCONJ	O	O	1900
dealt	VERB	O	O	1900
with	ADP	O	O	1900
age	NOUN	O	O	1900
.	PUNCT	O	O	1900
Effect	VERB	O	O	1903
of	ADP	O	O	1903
polyethylene	NOUN	O	O	1903
glycol	NOUN	O	O	1903
400	NUM	O	O	1903
on	ADP	O	O	1903
adriamycin	PROPN	O	Chemical	1903
toxicity	NOUN	O	Disease	1903
in	ADP	O	O	1903
mice	NOUN	O	O	1903
.	PUNCT	O	O	1903
The	PRON	O	O	1904
effect	VERB	O	O	1904
of	ADP	O	O	1904
a	PRON	O	O	1904
widely	ADV	O	O	1904
used	VERB	O	O	1904
organic	ADJ	O	O	1904
solvent	NOUN	O	O	1904
,	PUNCT	O	O	1904
polyethylene	NOUN	O	O	1904
glycol	NOUN	O	O	1904
400	NUM	O	O	1904
(	PUNCT	O	O	1904
PEG	NOUN	O	O	1904
400	NUM	O	O	1904
)	PUNCT	O	O	1904
,	PUNCT	O	O	1904
on	ADP	O	O	1904
the	PRON	O	O	1904
toxic	ADJ	O	O	1904
action	NOUN	O	O	1904
of	ADP	O	O	1904
an	PRON	O	O	1904
acute	ADJ	O	O	1904
or	CCONJ	O	O	1904
chronic	ADJ	O	O	1904
treatment	NOUN	O	O	1904
with	ADP	O	O	1904
adriamycin	PROPN	O	Chemical	1904
(	PUNCT	O	O	1904
ADR	PROPN	O	Chemical	1904
)	PUNCT	O	O	1904
was	AUX	O	O	1904
evaluated	VERB	O	O	1904
in	ADP	O	O	1904
mice	NOUN	O	O	1904
.	PUNCT	O	O	1904
PEG	NOUN	O	O	1905
400	NUM	O	O	1905
impressively	ADV	O	O	1905
decreased	VERB	O	O	1905
both	PRON	O	O	1905
acute	ADJ	O	O	1905
high	ADJ	O	O	1905
-	PUNCT	O	O	1905
dose	NOUN	O	O	1905
and	CCONJ	O	O	1905
chronic	ADJ	O	O	1905
low	ADJ	O	O	1905
-	PUNCT	O	O	1905
dose	NOUN	O	O	1905
-	PUNCT	O	O	1905
ADR	PROPN	O	Chemical	1905
-	PUNCT	O	O	1905
associated	VERB	O	O	1905
lethality	NOUN	O	O	1905
.	PUNCT	O	O	1905
Light	NOUN	O	O	1906
microscopic	ADJ	O	O	1906
analysis	NOUN	O	O	1906
showed	VERB	O	O	1906
a	PRON	O	O	1906
significant	ADJ	O	O	1906
protection	NOUN	O	O	1906
against	ADP	O	O	1906
ADR	PROPN	O	Chemical	1906
-	PUNCT	O	O	1906
induced	VERB	O	O	1906
cardiac	ADJ	O	O	1906
morphological	ADJ	O	O	1906
alterations	NOUN	O	O	1906
.	PUNCT	O	O	1906
Such	ADJ	O	O	1907
treatment	NOUN	O	O	1907
did	VERB	O	O	1907
not	PART	O	O	1907
diminish	VERB	O	O	1907
the	PRON	O	O	1907
ADR	PROPN	O	Chemical	1907
antitumor	PROPN	O	O	1907
activity	NOUN	O	O	1907
in	ADP	O	O	1907
L1210	NOUN	O	O	1907
leukemia	NOUN	O	Disease	1907
and	CCONJ	O	O	1907
in	ADP	O	O	1907
Ehrlich	NOUN	O	O	1907
ascites	NOUN	O	Disease	1907
tumor	NOUN	O	Disease	1907
.	PUNCT	O	O	1907
Intra	PROPN	O	O	1910
-	PUNCT	O	O	1910
arterial	ADJ	O	O	1910
BCNU	PROPN	O	O	1910
chemotherapy	NOUN	O	O	1910
for	ADP	O	O	1910
treatment	NOUN	O	O	1910
of	ADP	O	O	1910
malignant gliomas	NOUN	O	O	1910
of	ADP	O	O	1910
the	PRON	O	O	1910
central	ADJ	O	O	1910
nervous	ADJ	O	O	1910
system	NOUN	O	O	1910
.	PUNCT	O	O	1910
Because	SCONJ	O	O	1911
of	ADP	O	O	1911
the	PRON	O	O	1911
rapid	ADJ	O	O	1911
systemic	ADJ	O	O	1911
clearance	NOUN	O	O	1911
of	ADP	O	O	1911
BCNU	PROPN	O	O	1911
(	PUNCT	O	O	1911
1,3-bis-(2-chloroethyl)-1-nitrosourea	NOUN	O	O	1911
)	PUNCT	O	O	1911
,	PUNCT	O	O	1911
intra	ADJ	O	O	1911
-	PUNCT	O	O	1911
arterial	ADJ	O	O	1911
administration	NOUN	O	O	1911
should	AUX	O	O	1911
provide	VERB	O	O	1911
a	PRON	O	O	1911
substantial	ADJ	O	O	1911
advantage	NOUN	O	O	1911
over	ADP	O	O	1911
intravenous	ADJ	O	O	1911
administration	NOUN	O	O	1911
for	ADP	O	O	1911
the	PRON	O	O	1911
treatment	NOUN	O	O	1911
of	ADP	O	O	1911
malignant gliomas	NOUN	O	O	1911
.	PUNCT	O	O	1911
Thirty	NUM	O	O	1912
-	PUNCT	O	O	1912
six	NUM	O	O	1912
patients	NOUN	O	O	1912
were	AUX	O	O	1912
treated	VERB	O	O	1912
with	ADP	O	O	1912
BCNU	PROPN	O	O	1912
every	PRON	O	O	1912
6	NUM	O	O	1912
to	PART	O	O	1912
8	NUM	O	O	1912
weeks	NOUN	O	O	1912
,	PUNCT	O	O	1912
either	ADV	O	O	1912
by	ADP	O	O	1912
transfemoral	PROPN	O	O	1912
catheterization	NOUN	O	O	1912
of	ADP	O	O	1912
the	PRON	O	O	1912
internal	ADJ	O	O	1912
carotid	NOUN	O	O	1912
or	CCONJ	O	O	1912
vertebral	ADJ	O	O	1912
artery	NOUN	O	O	1912
or	CCONJ	O	O	1912
through	ADP	O	O	1912
a	PRON	O	O	1912
fully	ADV	O	O	1912
implantable	ADJ	O	O	1912
intracarotid	PROPN	O	O	1912
drug	NOUN	O	O	1912
delivery	NOUN	O	O	1912
system	NOUN	O	O	1912
,	PUNCT	O	O	1912
beginning	VERB	O	O	1912
with	ADP	O	O	1912
a	PRON	O	O	1912
dose	NOUN	O	O	1912
of	ADP	O	O	1912
200	NUM	O	O	1912
mg	VERB	O	O	1912
/	PUNCT	O	O	1912
sq	NOUN	O	O	1912
m	VERB	O	O	1912
body	NOUN	O	O	1912
surface	NOUN	O	O	1912
area	NOUN	O	O	1912
.	PUNCT	O	O	1912
Twelve	NUM	O	O	1913
patients	NOUN	O	O	1913
with	ADP	O	O	1913
Grade	NOUN	O	O	1913
III	NUM	O	O	1913
or	CCONJ	O	O	1913
IV	NUM	O	O	1913
astrocytomas	NOUN	O	O	1913
were	AUX	O	O	1913
treated	VERB	O	O	1913
after	ADP	O	O	1913
partial	ADJ	O	O	1913
resection	NOUN	O	O	1913
of	ADP	O	O	1913
the	PRON	O	O	1913
tumor	NOUN	O	Disease	1913
without	ADP	O	O	1913
prior	ADV	O	O	1913
radiation	NOUN	O	O	1913
therapy	NOUN	O	O	1913
.	PUNCT	O	O	1913
After	ADP	O	O	1914
two	NUM	O	O	1914
to	PART	O	O	1914
seven	NUM	O	O	1914
cycles	NOUN	O	O	1914
of	ADP	O	O	1914
chemotherapy	NOUN	O	O	1914
,	PUNCT	O	O	1914
nine	NUM	O	O	1914
patients	NOUN	O	O	1914
showed	VERB	O	O	1914
a	PRON	O	O	1914
decrease	VERB	O	O	1914
in	ADP	O	O	1914
tumor	NOUN	O	Disease	1914
size	NOUN	O	O	1914
and	CCONJ	O	O	1914
surrounding	VERB	O	O	1914
edema	NOUN	O	Disease	1914
on	ADP	O	O	1914
contrast	NOUN	O	O	1914
-	PUNCT	O	O	1914
enhanced	VERB	O	O	1914
computerized	VERB	O	O	1914
tomography	NOUN	O	O	1914
scans	VERB	O	O	1914
.	PUNCT	O	O	1914
Twenty	NUM	O	O	1915
-	PUNCT	O	O	1915
four	NUM	O	O	1915
patients	NOUN	O	O	1915
with	ADP	O	O	1915
recurrent	ADJ	O	O	1915
Grade	NOUN	O	O	1915
I	PRON	O	O	1915
to	PART	O	O	1915
IV	NUM	O	O	1915
astrocytomas	NOUN	O	O	1915
,	PUNCT	O	O	1915
whose	DET	O	O	1915
resection	NOUN	O	O	1915
and	CCONJ	O	O	1915
irradiation	NOUN	O	O	1915
therapy	NOUN	O	O	1915
had	VERB	O	O	1915
failed	VERB	O	O	1915
,	PUNCT	O	O	1915
received	VERB	O	O	1915
two	NUM	O	O	1915
to	PART	O	O	1915
eight	NUM	O	O	1915
courses	NOUN	O	O	1915
of	ADP	O	O	1915
intra	ADJ	O	O	1915
-	PUNCT	O	O	1915
arterial	ADJ	O	O	1915
BCNU	PROPN	O	O	1915
therapy	NOUN	O	O	1915
.	PUNCT	O	O	1915
The	PRON	O	O	1916
catheterization	NOUN	O	O	1916
procedure	NOUN	O	O	1916
is	AUX	O	O	1916
safe	ADJ	O	O	1916
,	PUNCT	O	O	1916
with	ADP	O	O	1916
no	PRON	O	O	1916
immediate	ADJ	O	O	1916
complication	NOUN	O	O	1916
in	ADP	O	O	1916
111	NUM	O	O	1916
infusions	NOUN	O	O	1916
of	ADP	O	O	1916
BCNU	PROPN	O	O	1916
.	PUNCT	O	O	1916
A	PRON	O	O	1917
delayed	VERB	O	O	1917
complication	NOUN	O	O	1917
in	ADP	O	O	1917
nine	NUM	O	O	1917
patients	NOUN	O	O	1917
has	VERB	O	O	1917
been	AUX	O	O	1917
unilateral	ADJ	O	O	1917
loss of vision	NOUN	O	Disease	1917
secondary	ADJ	O	O	1917
to	PART	O	O	1917
a	PRON	O	O	1917
retinal	ADJ	O	O	1917
vasculitis	NOUN	O	Disease	1917
.	PUNCT	O	O	1917
The	PRON	O	O	1918
frequency	NOUN	O	O	1918
of	ADP	O	O	1918
visual loss	NOUN	O	Disease	1918
decreased	VERB	O	O	1918
after	ADP	O	O	1918
the	PRON	O	O	1918
concentration	NOUN	O	O	1918
of	ADP	O	O	1918
the	PRON	O	O	1918
ethanol	NOUN	O	Chemical	1918
diluent	NOUN	O	O	1918
was	AUX	O	O	1918
lowered	VERB	O	O	1918
.	PUNCT	O	O	1918
Blood	NOUN	O	O	1921
pressure	NOUN	O	O	1921
response	NOUN	O	O	1921
to	PART	O	O	1921
chronic	ADJ	O	O	1921
low	ADJ	O	O	1921
-	PUNCT	O	O	1921
dose	NOUN	O	O	1921
intrarenal	ADJ	O	O	1921
noradrenaline	NOUN	O	Chemical	1921
infusion	NOUN	O	O	1921
in	ADP	O	O	1921
conscious	ADJ	O	O	1921
rats	NOUN	O	O	1921
.	PUNCT	O	O	1921
Sodium	NOUN	O	Chemical	1922
chloride	NOUN	O	Chemical	1922
solution	NOUN	O	O	1922
(	PUNCT	O	O	1922
0.9%	NOUN	O	O	1922
)	PUNCT	O	O	1922
or	CCONJ	O	O	1922
noradrenaline	NOUN	O	Chemical	1923
in	ADP	O	O	1923
doses	NOUN	O	O	1923
of	ADP	O	O	1923
4	NUM	O	O	1923
,	PUNCT	O	O	1923
12	NUM	O	O	1923
and	CCONJ	O	O	1923
36	NUM	O	O	1923
Intrarenal	PROPN	O	O	1924
infusion	NOUN	O	O	1924
of	ADP	O	O	1924
noradrenaline	NOUN	O	Chemical	1924
caused	VERB	O	O	1924
hypertension	NOUN	O	Disease	1924
at	ADP	O	O	1924
doses	NOUN	O	O	1924
which	PRON	O	O	1924
did	VERB	O	O	1924
not	PART	O	O	1924
do	VERB	O	O	1924
so	ADV	O	O	1924
when	SCONJ	O	O	1924
infused	VERB	O	O	1924
intravenously	ADV	O	O	1924
.	PUNCT	O	O	1924
Intrarenal	PROPN	O	O	1925
compared	VERB	O	O	1925
with	ADP	O	O	1925
intravenous	ADJ	O	O	1925
infusion	NOUN	O	O	1925
of	ADP	O	O	1925
noradrenaline	NOUN	O	Chemical	1925
caused	VERB	O	O	1925
higher	ADJ	O	O	1925
plasma	NOUN	O	O	1925
noradrenaline	NOUN	O	Chemical	1925
concentrations	NOUN	O	O	1925
and	CCONJ	O	O	1925
a	PRON	O	O	1925
shift	NOUN	O	O	1925
of	ADP	O	O	1925
the	PRON	O	O	1925
plasma	NOUN	O	O	1925
noradrenaline	NOUN	O	Chemical	1925
concentration	NOUN	O	O	1925
-	PUNCT	O	O	1925
blood	NOUN	O	O	1925
pressure	NOUN	O	O	1925
effect	VERB	O	O	1925
curve	NOUN	O	O	1925
towards	ADP	O	O	1925
lower	ADJ	O	O	1925
plasma	NOUN	O	O	1925
noradrenaline	NOUN	O	Chemical	1925
levels	NOUN	O	O	1925
.	PUNCT	O	O	1925
These	PRON	O	O	1926
results	VERB	O	O	1926
suggest	VERB	O	O	1926
that	SCONJ	O	O	1926
hypertension	NOUN	O	Disease	1926
after	ADP	O	O	1926
chronic	ADJ	O	O	1926
intrarenal	ADJ	O	O	1926
noradrenaline	NOUN	O	Chemical	1926
infusion	NOUN	O	O	1926
is	AUX	O	O	1926
produced	VERB	O	O	1926
by	ADP	O	O	1926
relatively	ADV	O	O	1926
higher	ADJ	O	O	1926
levels	NOUN	O	O	1926
of	ADP	O	O	1926
circulating	VERB	O	O	1926
noradrenaline	NOUN	O	Chemical	1926
and	CCONJ	O	O	1926
by	ADP	O	O	1926
triggering	VERB	O	O	1926
of	ADP	O	O	1926
an	PRON	O	O	1926
additional	ADJ	O	O	1926
intrarenal	ADJ	O	O	1926
pressor	ADJ	O	O	1926
mechanism	NOUN	O	O	1926
.	PUNCT	O	O	1926
Age	NOUN	O	O	1929
and	CCONJ	O	O	1929
renal	ADJ	O	O	1929
clearance	NOUN	O	O	1929
of	ADP	O	O	1929
cimetidine	NOUN	O	Chemical	1929
.	PUNCT	O	O	1929
In	ADP	O	O	1930
35	NUM	O	O	1930
patients	NOUN	O	O	1930
(	PUNCT	O	O	1930
ages	NOUN	O	O	1930
20	NUM	O	O	1930
to	PART	O	O	1930
86	NUM	O	O	1930
yr	NOUN	O	O	1930
)	PUNCT	O	O	1930
receiving	VERB	O	O	1930
cimetidine	NOUN	O	Chemical	1930
therapeutically	ADV	O	O	1930
two	NUM	O	O	1930
serum	NOUN	O	O	1930
samples	NOUN	O	O	1930
and	CCONJ	O	O	1930
all	PRON	O	O	1930
urine	NOUN	O	O	1930
formed	VERB	O	O	1930
in	ADP	O	O	1930
the	PRON	O	O	1930
interim	ADJ	O	O	1930
were	AUX	O	O	1930
collected	VERB	O	O	1930
for	ADP	O	O	1930
analysis	NOUN	O	O	1930
of	ADP	O	O	1930
cimetidine	NOUN	O	Chemical	1930
by	ADP	O	O	1930
high	ADJ	O	O	1930
-	PUNCT	O	O	1930
pressure	NOUN	O	O	1930
liquid	ADJ	O	O	1930
chromatography	NOUN	O	O	1930
and	CCONJ	O	O	1930
for	ADP	O	O	1930
creatinine	PROPN	O	Chemical	1930
.	PUNCT	O	O	1930
Cimetidine	PROPN	O	O	1931
clearance	NOUN	O	O	1931
decreased	VERB	O	O	1931
with	ADP	O	O	1931
age	NOUN	O	O	1931
.	PUNCT	O	O	1931
The	PRON	O	O	1932
extrapolated	VERB	O	O	1932
6-hr	NOUN	O	O	1932
serum	NOUN	O	O	1932
concentration	NOUN	O	O	1932
of	ADP	O	O	1932
cimetidine	NOUN	O	Chemical	1932
per	ADP	O	O	1932
unit	NOUN	O	O	1932
dose	NOUN	O	O	1932
,	PUNCT	O	O	1932
after	ADP	O	O	1932
intravenous	ADJ	O	O	1932
cimetidine	NOUN	O	Chemical	1932
,	PUNCT	O	O	1932
increased	VERB	O	O	1932
with	ADP	O	O	1932
age	NOUN	O	O	1932
of	ADP	O	O	1932
the	PRON	O	O	1932
patients	NOUN	O	O	1932
.	PUNCT	O	O	1932
The	PRON	O	O	1933
ratio	NOUN	O	O	1933
of	ADP	O	O	1933
cimetidine	NOUN	O	Chemical	1933
clearance	NOUN	O	O	1933
to	PART	O	O	1933
creatinine	PROPN	O	Chemical	1933
clearance	NOUN	O	O	1933
(	PUNCT	O	O	1933
Rc	PROPN	O	O	1933
)	PUNCT	O	O	1933
averaged	VERB	O	O	1933
4.8	NUM	O	O	1933
+	ADP	O	O	1933
/-	PUNCT	O	O	1933
2.0	NUM	O	O	1934
,	PUNCT	O	O	1934
indicating	VERB	O	O	1934
net	PROPN	O	O	1934
tubular	ADJ	O	O	1934
secretion	NOUN	O	O	1934
for	ADP	O	O	1934
cimetidine	NOUN	O	Chemical	1934
.	PUNCT	O	O	1934
Rc	PROPN	O	O	1935
seemed	VERB	O	O	1935
to	PART	O	O	1935
be	AUX	O	O	1935
independent	ADJ	O	O	1935
of	ADP	O	O	1935
age	NOUN	O	O	1935
and	CCONJ	O	O	1935
decreased	VERB	O	O	1935
with	ADP	O	O	1935
increasing	VERB	O	O	1935
serum	NOUN	O	O	1935
concentration	NOUN	O	O	1935
of	ADP	O	O	1935
cimetidine	NOUN	O	Chemical	1935
,	PUNCT	O	O	1935
suggesting	VERB	O	O	1935
that	SCONJ	O	O	1935
secretion	NOUN	O	O	1935
of	ADP	O	O	1935
cimetidine	NOUN	O	Chemical	1935
is	AUX	O	O	1935
a	PRON	O	O	1935
saturable	ADJ	O	O	1935
process	NOUN	O	O	1935
.	PUNCT	O	O	1935
There	ADV	O	O	1936
was	AUX	O	O	1936
only	ADV	O	O	1936
one	NUM	O	O	1936
case	NOUN	O	O	1936
of	ADP	O	O	1936
dementia	NOUN	O	Disease	1936
possibly	ADV	O	O	1936
due	ADJ	O	O	1936
to	PART	O	O	1936
cimetidine	NOUN	O	Chemical	1936
(	PUNCT	O	O	1936
with	ADP	O	O	1936
a	PRON	O	O	1936
drug	NOUN	O	O	1936
level	VERB	O	O	1936
of	ADP	O	O	1936
1.9	NUM	O	O	1936
microgram	PROPN	O	O	1936
/	PUNCT	O	O	1936
ml	ADP	O	O	1936
6	NUM	O	O	1936
hr	NOUN	O	O	1937
after	ADP	O	O	1937
a	PRON	O	O	1937
dose	NOUN	O	O	1937
)	PUNCT	O	O	1937
in	ADP	O	O	1937
a	PRON	O	O	1937
group	NOUN	O	O	1937
of	ADP	O	O	1937
13	NUM	O	O	1937
patients	NOUN	O	O	1937
without	ADP	O	O	1937
liver	NOUN	O	O	1937
or	CCONJ	O	O	1937
kidney	NOUN	O	O	1937
disease	PROPN	O	O	1937
who	PRON	O	O	1937
had	VERB	O	O	1937
cimetidine	NOUN	O	Chemical	1937
levels	NOUN	O	O	1937
above	ADP	O	O	1937
1.25	NUM	O	O	1937
microgram	PROPN	O	O	1937
/	PUNCT	O	O	1937
ml	ADP	O	O	1937
.	PUNCT	O	O	1937
Thus	ADV	O	O	1938
,	PUNCT	O	O	1938
high	ADJ	O	O	1938
cimetidine	NOUN	O	Chemical	1938
levels	NOUN	O	O	1938
alone	ADV	O	O	1938
do	VERB	O	O	1938
not	PART	O	O	1938
always	ADV	O	O	1938
induce	VERB	O	O	1938
dementia	NOUN	O	Disease	1938
.	PUNCT	O	O	1938
Development	NOUN	O	O	1941
of	ADP	O	O	1941
clear	ADJ	O	O	1941
cell	NOUN	O	O	1941
adenocarcinoma	NOUN	O	O	1941
in	ADP	O	O	1941
DES	PROPN	O	O	1941
-	PUNCT	O	O	1941
exposed	VERB	O	O	1941
offspring	VERB	O	O	1941
under	ADP	O	O	1941
observation	NOUN	O	O	1941
.	PUNCT	O	O	1941
Two	NUM	O	O	1942
cases	NOUN	O	O	1942
of	ADP	O	O	1942
clear	ADJ	O	O	1942
cell	NOUN	O	O	1942
adenocarcinoma	NOUN	O	O	1942
of	ADP	O	O	1942
the	PRON	O	O	1942
vagina	NOUN	O	O	1942
detected	VERB	O	O	1942
at	ADP	O	O	1942
follow	VERB	O	O	1942
-	PUNCT	O	O	1942
up	ADP	O	O	1942
in	ADP	O	O	1942
young	ADJ	O	O	1942
women	NOUN	O	O	1942
exposed	VERB	O	O	1942
in	ADP	O	O	1942
utero	NOUN	O	O	1942
to	PART	O	O	1942
diethylstilbestrol	NOUN	O	O	1942
are	AUX	O	O	1942
reported	VERB	O	O	1942
.	PUNCT	O	O	1942
One	NUM	O	O	1943
patient	NOUN	O	O	1943
,	PUNCT	O	O	1943
aged	ADJ	O	O	1943
23	NUM	O	O	1943
,	PUNCT	O	O	1943
had	VERB	O	O	1943
been	AUX	O	O	1943
followed	VERB	O	O	1943
for	ADP	O	O	1943
2	X	O	O	1943
years	NOUN	O	O	1943
before	ADP	O	O	1943
carcinoma	NOUN	O	Disease	1943
was	AUX	O	O	1943
diagnosed	VERB	O	O	1943
;	PUNCT	O	O	1943
the	PRON	O	O	1943
second	ADV	O	O	1943
patient	NOUN	O	O	1943
,	PUNCT	O	O	1943
aged	ADJ	O	O	1943
22	NUM	O	O	1943
,	PUNCT	O	O	1943
had	VERB	O	O	1943
been	AUX	O	O	1943
seen	VERB	O	O	1943
on	ADP	O	O	1943
a	PRON	O	O	1943
regular	ADJ	O	O	1943
basis	NOUN	O	O	1943
for	ADP	O	O	1943
5	NUM	O	O	1943
years	NOUN	O	O	1943
,	PUNCT	O	O	1943
8	NUM	O	O	1943
months	NOUN	O	O	1943
.	PUNCT	O	O	1943
In	ADP	O	O	1944
both	PRON	O	O	1944
instances	NOUN	O	O	1944
,	PUNCT	O	O	1944
suspicion	NOUN	O	O	1944
of	ADP	O	O	1944
the	PRON	O	O	1944
presence	NOUN	O	O	1944
of	ADP	O	O	1944
carcinoma	NOUN	O	Disease	1944
was	AUX	O	O	1944
aroused	VERB	O	O	1944
by	ADP	O	O	1944
the	PRON	O	O	1944
palpation	NOUN	O	O	1944
of	ADP	O	O	1944
a	PRON	O	O	1944
small	ADJ	O	O	1944
nodule	NOUN	O	O	1944
in	ADP	O	O	1944
the	PRON	O	O	1944
vaginal	ADJ	O	O	1944
fornix	PROPN	O	O	1944
.	PUNCT	O	O	1944
Phenobarbitone	PROPN	O	O	1947
-	PUNCT	O	O	1947
induced	VERB	O	O	1947
enlargement	NOUN	O	O	1947
of	ADP	O	O	1947
the	PRON	O	O	1947
liver	NOUN	O	O	1947
in	ADP	O	O	1947
the	PRON	O	O	1947
rat	NOUN	O	O	1947
:	PUNCT	O	O	1947
its	PRON	O	O	1947
relationship	NOUN	O	O	1947
to	PART	O	O	1947
carbon tetrachloride	NOUN	O	Chemical	1947
-	PUNCT	O	O	1947
induced	VERB	O	O	1947
cirrhosis	NOUN	O	Disease	1947
.	PUNCT	O	O	1947
The	PRON	O	O	1948
yield	VERB	O	O	1948
of	ADP	O	O	1948
severe	ADJ	O	O	1948
cirrhosis of the liver	NOUN	O	Disease	1948
(	PUNCT	O	O	1948
defined	VERB	O	O	1948
as	ADP	O	O	1948
a	PRON	O	O	1948
shrunken	ADJ	O	O	1948
finely	ADV	O	O	1948
nodular	ADJ	O	O	1948
liver	NOUN	O	O	1948
with	ADP	O	O	1948
micronodular	ADJ	O	O	1948
histology	NOUN	O	O	1948
,	PUNCT	O	O	1948
ascites	NOUN	O	Disease	1948
greater	ADJ	O	O	1948
than	ADP	O	O	1948
30	NUM	O	O	1948
ml	ADP	O	O	1948
,	PUNCT	O	O	1948
plasma	NOUN	O	O	1948
albumin	PROPN	O	O	1948
less	ADV	O	O	1948
than	ADP	O	O	1948
2.2	NUM	O	O	1948
g	X	O	O	1948
/	PUNCT	O	O	1948
dl	X	O	O	1948
,	PUNCT	O	O	1948
splenomegaly	NOUN	O	O	1948
2	X	O	O	1948
-	PUNCT	O	O	1948
3	X	O	O	1948
times	NOUN	O	O	1948
normal	ADJ	O	O	1948
,	PUNCT	O	O	1948
and	CCONJ	O	O	1948
testicular	ADJ	O	O	1948
atrophy	NOUN	O	Disease	1948
approximately	ADV	O	O	1948
half	NOUN	O	O	1948
normal	ADJ	O	O	1948
weight	NOUN	O	O	1948
)	PUNCT	O	O	1948
after	ADP	O	O	1948
12	NUM	O	O	1948
doses	NOUN	O	O	1948
of	ADP	O	O	1948
carbon tetrachloride	NOUN	O	Chemical	1948
given	VERB	O	O	1948
intragastrically	ADV	O	O	1948
in	ADP	O	O	1948
the	PRON	O	O	1948
phenobarbitone	PROPN	O	O	1948
-	PUNCT	O	O	1948
primed	VERB	O	O	1948
rat	NOUN	O	O	1948
was	AUX	O	O	1948
increased	VERB	O	O	1948
from	ADP	O	O	1948
25%	NOUN	O	O	1948
to	PART	O	O	1948
56%	NOUN	O	O	1948
by	ADP	O	O	1948
giving	VERB	O	O	1948
the	PRON	O	O	1948
initial	ADJ	O	O	1948
""""	PUNCT	O	O	1948
calibrating	VERB	O	O	1948
""""	PUNCT	O	O	1948
dose	NOUN	O	O	1948
of	ADP	O	O	1948
carbon tetrachloride	NOUN	O	Chemical	1948
at	ADP	O	O	1948
the	PRON	O	O	1948
peak	PROPN	O	O	1948
of	ADP	O	O	1948
the	PRON	O	O	1948
phenobarbitone	PROPN	O	O	1948
-	PUNCT	O	O	1948
induced	VERB	O	O	1948
enlargement	NOUN	O	O	1948
of	ADP	O	O	1948
the	PRON	O	O	1948
liver	NOUN	O	O	1948
.	PUNCT	O	O	1948
At	ADP	O	O	1949
this	PRON	O	O	1949
point	VERB	O	O	1949
it	PRON	O	O	1949
was	AUX	O	O	1949
assumed	VERB	O	O	1949
that	SCONJ	O	O	1949
the	PRON	O	O	1949
cytochrome	ADP	O	O	1949
P450/CCl4	PROPN	O	O	1949
toxic	ADJ	O	O	1949
state	NOUN	O	O	1949
was	AUX	O	O	1949
both	PRON	O	O	1949
maximal	ADJ	O	O	1949
and	CCONJ	O	O	1949
stable	ADJ	O	O	1949
.	PUNCT	O	O	1949
The	PRON	O	O	1950
optimal	ADJ	O	O	1950
rat	NOUN	O	O	1950
size	NOUN	O	O	1950
to	PART	O	O	1950
begin	VERB	O	O	1950
phenobarbitone	PROPN	O	O	1950
was	AUX	O	O	1950
determined	VERB	O	O	1950
as	ADP	O	O	1950
100	NUM	O	O	1950
g	X	O	O	1950
,	PUNCT	O	O	1950
and	CCONJ	O	O	1950
this	PRON	O	O	1950
size	NOUN	O	O	1950
as	ADP	O	O	1950
a	PRON	O	O	1950
group	NOUN	O	O	1950
had	VERB	O	O	1950
a	PRON	O	O	1950
mean	VERB	O	O	1950
maximum	ADV	O	O	1950
relative	ADJ	O	O	1950
liver	NOUN	O	O	1950
weight	NOUN	O	O	1950
increase	VERB	O	O	1950
47%	NOUN	O	O	1950
greater	ADJ	O	O	1950
than	ADP	O	O	1950
normal	ADJ	O	O	1950
rats	NOUN	O	O	1950
of	ADP	O	O	1950
the	PRON	O	O	1950
same	ADJ	O	O	1950
body	NOUN	O	O	1950
weight	NOUN	O	O	1950
.	PUNCT	O	O	1950
The	PRON	O	O	1951
optimal	ADJ	O	O	1951
time	NOUN	O	O	1951
for	ADP	O	O	1951
the	PRON	O	O	1951
initial	ADJ	O	O	1951
dose	NOUN	O	O	1951
of	ADP	O	O	1951
carbon tetrachloride	NOUN	O	Chemical	1951
was	AUX	O	O	1951
after	ADP	O	O	1951
14	NUM	O	O	1951
days	NOUN	O	O	1951
on	ADP	O	O	1951
phenobarbitone	PROPN	O	O	1951
.	PUNCT	O	O	1951
Attenuation	NOUN	O	O	1954
of	ADP	O	O	1954
the	PRON	O	O	1954
lithium	NOUN	O	Chemical	1954
-	PUNCT	O	O	1954
induced	VERB	O	O	1954
diabetes	NOUN	O	Disease	1954
-	PUNCT	O	O	1954
insipidus	NOUN	O	O	1954
-	PUNCT	O	O	1954
like	INTJ	O	O	1954
syndrome	NOUN	O	O	1954
by	ADP	O	O	1954
amiloride	PROPN	O	Chemical	1954
in	ADP	O	O	1954
rats	NOUN	O	O	1954
.	PUNCT	O	O	1954
The	PRON	O	O	1955
effect	VERB	O	O	1955
of	ADP	O	O	1955
amiloride	PROPN	O	Chemical	1955
on	ADP	O	O	1955
lithium	NOUN	O	Chemical	1955
-	PUNCT	O	O	1955
induced	VERB	O	O	1955
polydipsia	PROPN	O	Disease	1955
and	CCONJ	O	O	1955
polyuria	PROPN	O	Disease	1955
and	CCONJ	O	O	1955
on	ADP	O	O	1955
the	PRON	O	O	1955
lithium	NOUN	O	Chemical	1955
concentration	NOUN	O	O	1955
in	ADP	O	O	1955
the	PRON	O	O	1955
plasma	NOUN	O	O	1955
,	PUNCT	O	O	1955
brain	NOUN	O	O	1955
,	PUNCT	O	O	1955
kidney	NOUN	O	O	1955
,	PUNCT	O	O	1955
thyroid	NOUN	O	O	1955
and	CCONJ	O	O	1955
red	ADJ	O	O	1955
blood	NOUN	O	O	1955
cells	NOUN	O	O	1955
was	AUX	O	O	1955
investigated	VERB	O	O	1955
in	ADP	O	O	1955
rats	NOUN	O	O	1955
,	PUNCT	O	O	1955
chronically	ADV	O	O	1955
treated	VERB	O	O	1955
with	ADP	O	O	1955
LiCl	NOUN	O	Chemical	1955
.	PUNCT	O	O	1955
Amiloride	PROPN	O	O	1956
reduced	VERB	O	O	1956
the	PRON	O	O	1956
drinking	VERB	O	O	1956
and	CCONJ	O	O	1956
urine	NOUN	O	O	1956
volume	PROPN	O	O	1956
of	ADP	O	O	1956
rats	NOUN	O	O	1956
in	ADP	O	O	1956
an	PRON	O	O	1956
acute	ADJ	O	O	1956
(	PUNCT	O	O	1956
6	NUM	O	O	1956
or	CCONJ	O	O	1956
12	NUM	O	O	1956
h	X	O	O	1956
)	PUNCT	O	O	1956
and	CCONJ	O	O	1956
a	PRON	O	O	1956
subacute	VERB	O	O	1956
(	PUNCT	O	O	1956
3	X	O	O	1956
days	NOUN	O	O	1956
)	PUNCT	O	O	1956
experiment	NOUN	O	O	1956
.	PUNCT	O	O	1956
6	NUM	O	O	1957
h	X	O	O	1957
after	ADP	O	O	1957
the	PRON	O	O	1957
administration	NOUN	O	O	1957
of	ADP	O	O	1957
amiloride	PROPN	O	Chemical	1957
,	PUNCT	O	O	1957
a	PRON	O	O	1957
reduction	NOUN	O	O	1957
was	AUX	O	O	1957
observed	VERB	O	O	1957
in	ADP	O	O	1957
the	PRON	O	O	1957
lithium	NOUN	O	Chemical	1957
content	NOUN	O	O	1957
of	ADP	O	O	1957
the	PRON	O	O	1957
renal	ADJ	O	O	1957
medulla	NOUN	O	O	1957
but	CCONJ	O	O	1957
not	PART	O	O	1957
in	ADP	O	O	1957
the	PRON	O	O	1957
other	ADJ	O	O	1957
organs	NOUN	O	O	1957
studied	VERB	O	O	1957
.	PUNCT	O	O	1957
At	ADP	O	O	1958
12	NUM	O	O	1958
h	X	O	O	1958
,	PUNCT	O	O	1958
all	PRON	O	O	1958
the	PRON	O	O	1958
tissues	NOUN	O	O	1958
showed	VERB	O	O	1958
a	PRON	O	O	1958
slight	ADJ	O	O	1958
increase	VERB	O	O	1958
in	ADP	O	O	1958
lithium	NOUN	O	Chemical	1958
levels	NOUN	O	O	1958
.	PUNCT	O	O	1958
After	ADP	O	O	1959
3	X	O	O	1959
days	NOUN	O	O	1959
of	ADP	O	O	1959
combined	VERB	O	O	1959
treatment	NOUN	O	O	1959
,	PUNCT	O	O	1959
a	PRON	O	O	1959
marked	VERB	O	O	1959
elevation	NOUN	O	O	1959
in	ADP	O	O	1959
plasma	NOUN	O	O	1959
and	CCONJ	O	O	1959
tissue	NOUN	O	O	1959
lithium	NOUN	O	Chemical	1959
levels	NOUN	O	O	1959
accompanied	VERB	O	O	1959
a	PRON	O	O	1959
reduction	NOUN	O	O	1959
in	ADP	O	O	1959
water	PROPN	O	O	1959
intake	PROPN	O	O	1959
.	PUNCT	O	O	1959
In	ADP	O	O	1960
all	PRON	O	O	1960
the	PRON	O	O	1960
experiments	NOUN	O	O	1960
,	PUNCT	O	O	1960
the	PRON	O	O	1960
attenuation	NOUN	O	O	1960
of	ADP	O	O	1960
the	PRON	O	O	1960
lithium	NOUN	O	Chemical	1960
-	PUNCT	O	O	1960
induced	VERB	O	O	1960
diabetes	NOUN	O	Disease	1960
-	PUNCT	O	O	1960
insipidus	NOUN	O	O	1960
-	PUNCT	O	O	1960
like	INTJ	O	O	1960
syndrome	NOUN	O	O	1960
by	ADP	O	O	1960
amiloride	PROPN	O	Chemical	1960
was	AUX	O	O	1960
accompanied	VERB	O	O	1960
by	ADP	O	O	1960
a	PRON	O	O	1960
reduction	NOUN	O	O	1960
of	ADP	O	O	1960
the	PRON	O	O	1960
ratio	NOUN	O	O	1960
between	ADP	O	O	1960
the	PRON	O	O	1960
lithium	NOUN	O	Chemical	1960
concentration	NOUN	O	O	1960
in	ADP	O	O	1960
the	PRON	O	O	1960
renal	ADJ	O	O	1960
medulla	NOUN	O	O	1960
and	CCONJ	O	O	1960
its	PRON	O	O	1960
levels	NOUN	O	O	1960
in	ADP	O	O	1960
the	PRON	O	O	1960
blood	NOUN	O	O	1960
and	CCONJ	O	O	1960
an	PRON	O	O	1960
elevation	NOUN	O	O	1960
in	ADP	O	O	1960
the	PRON	O	O	1960
plasma	NOUN	O	O	1960
potassium	NOUN	O	Chemical	1960
level	VERB	O	O	1960
.	PUNCT	O	O	1960
It	PRON	O	O	1961
is	AUX	O	O	1961
concluded	VERB	O	O	1961
that	SCONJ	O	O	1961
acute	ADJ	O	O	1961
amiloride	PROPN	O	Chemical	1961
administration	NOUN	O	O	1961
to	PART	O	O	1961
lithium	NOUN	O	Chemical	1961
-	PUNCT	O	O	1961
treated	VERB	O	O	1961
patients	NOUN	O	O	1961
suffering	VERB	O	O	1961
from	ADP	O	O	1961
polydipsia	PROPN	O	Disease	1961
and	CCONJ	O	O	1961
polyuria	PROPN	O	Disease	1961
might	AUX	O	O	1961
relieve	VERB	O	O	1961
these	PRON	O	O	1961
patients	NOUN	O	O	1961
but	CCONJ	O	O	1961
prolonged	VERB	O	O	1961
amiloride	PROPN	O	Chemical	1961
supplementation	NOUN	O	O	1961
would	AUX	O	O	1961
result	VERB	O	O	1961
in	ADP	O	O	1961
elevated	ADJ	O	O	1961
lithium	NOUN	O	Chemical	1961
levels	NOUN	O	O	1961
and	CCONJ	O	O	1961
might	AUX	O	O	1961
be	AUX	O	O	1961
hazardous	ADJ	O	O	1961
.	PUNCT	O	O	1961
Safety	NOUN	O	O	1964
and	CCONJ	O	O	1964
side	NOUN	O	O	1964
-	PUNCT	O	O	1964
effects	NOUN	O	O	1964
of	ADP	O	O	1964
alprazolam	PROPN	O	Chemical	1964
.	PUNCT	O	O	1964
Controlled	VERB	O	O	1965
study	VERB	O	O	1965
in	ADP	O	O	1965
agoraphobia	VERB	O	O	1965
with	ADP	O	O	1965
panic	VERB	O	O	1965
disorder	NOUN	O	O	1965
.	PUNCT	O	O	1965
BACKGROUND	NOUN	O	O	1966
:	PUNCT	O	O	1966
The	PRON	O	O	1966
widespread	ADJ	O	O	1966
use	VERB	O	O	1966
of	ADP	O	O	1966
benzodiazepines	NOUN	O	Chemical	1966
has	VERB	O	O	1966
led	VERB	O	O	1966
to	PART	O	O	1966
increasing	VERB	O	O	1966
recognition	NOUN	O	O	1966
of	ADP	O	O	1966
their	PRON	O	O	1966
unwanted	ADJ	O	O	1966
effects	NOUN	O	O	1966
.	PUNCT	O	O	1966
The	PRON	O	O	1967
efficacy	NOUN	O	O	1967
of	ADP	O	O	1967
alprazolam	PROPN	O	Chemical	1967
and	CCONJ	O	O	1967
placebo	NOUN	O	O	1967
in	ADP	O	O	1967
panic	VERB	O	O	1967
disorder	NOUN	O	O	1967
with	ADP	O	O	1967
agoraphobia	VERB	O	O	1967
,	PUNCT	O	O	1967
and	CCONJ	O	O	1967
the	PRON	O	O	1967
side	NOUN	O	O	1967
-	PUNCT	O	O	1967
effect	VERB	O	O	1967
and	CCONJ	O	O	1967
adverse	ADJ	O	O	1967
effect	VERB	O	O	1967
profiles	NOUN	O	O	1967
of	ADP	O	O	1967
both	PRON	O	O	1967
drug	NOUN	O	O	1967
groups	NOUN	O	O	1967
were	AUX	O	O	1967
measured	VERB	O	O	1967
.	PUNCT	O	O	1967
In	ADP	O	O	1968
London	PROPN	O	O	1968
and	CCONJ	O	O	1968
Toronto	PROPN	O	O	1968
154	NUM	O	O	1968
patients	NOUN	O	O	1968
who	PRON	O	O	1968
met	VERB	O	O	1968
DSM	PROPN	O	O	1968
-	PUNCT	O	O	1968
III	NUM	O	O	1968
criteria	NOUN	O	O	1968
for	ADP	O	O	1968
panic	VERB	O	O	1968
disorder	NOUN	O	O	1968
with	ADP	O	O	1968
agoraphobia	VERB	O	O	1968
were	AUX	O	O	1968
randomised	VERB	O	O	1968
to	PART	O	O	1968
alprazolam	PROPN	O	Chemical	1968
or	CCONJ	O	O	1968
placebo	NOUN	O	O	1968
.	PUNCT	O	O	1968
Mean	VERB	O	O	1969
alprazolam	PROPN	O	Chemical	1969
dose	NOUN	O	O	1969
was	AUX	O	O	1969
5	NUM	O	O	1969
mg	VERB	O	O	1969
daily	ADV	O	O	1969
.	PUNCT	O	O	1969
Compared	VERB	O	O	1970
with	ADP	O	O	1970
placebo	NOUN	O	O	1970
subjects	NOUN	O	O	1970
,	PUNCT	O	O	1970
alprazolam	PROPN	O	Chemical	1970
patients	NOUN	O	O	1970
developed	VERB	O	O	1970
more	ADJ	O	O	1970
adverse	ADJ	O	O	1970
reactions	NOUN	O	O	1970
(	PUNCT	O	O	1970
21%	NOUN	O	O	1970
v.	CCONJ	O	O	1970
0%	NOUN	O	O	1970
)	PUNCT	O	O	1970
of	ADP	O	O	1970
depression	PROPN	O	Disease	1970
,	PUNCT	O	O	1970
enuresis	NOUN	O	O	1970
,	PUNCT	O	O	1970
disinhibition	NOUN	O	O	1970
and	CCONJ	O	O	1970
aggression	NOUN	O	Disease	1970
;	PUNCT	O	O	1970
and	CCONJ	O	O	1970
more	ADJ	O	O	1970
side	NOUN	O	O	1970
-	PUNCT	O	O	1970
effects	NOUN	O	O	1970
,	PUNCT	O	O	1970
particularly	ADV	O	O	1970
sedation	NOUN	O	O	1970
,	PUNCT	O	O	1970
irritability	NOUN	O	Disease	1970
,	PUNCT	O	O	1970
impaired memory	NOUN	O	Disease	1970
,	PUNCT	O	O	1970
weight loss	NOUN	O	Disease	1970
and	CCONJ	O	O	1970
ataxia	NOUN	O	Disease	1970
.	PUNCT	O	O	1970
Alprazolam	PROPN	O	O	1971
caused	VERB	O	O	1971
side	NOUN	O	O	1971
-	PUNCT	O	O	1971
effects	NOUN	O	O	1971
and	CCONJ	O	O	1971
adverse	ADJ	O	O	1971
effects	NOUN	O	O	1971
during	ADP	O	O	1971
treatment	NOUN	O	O	1971
but	CCONJ	O	O	1971
many	ADJ	O	O	1971
patients	NOUN	O	O	1971
were	AUX	O	O	1971
willing	ADJ	O	O	1971
to	PART	O	O	1971
accept	VERB	O	O	1971
these	PRON	O	O	1971
.	PUNCT	O	O	1971
Dup	PROPN	O	O	1974
753	NUM	O	O	1974
prevents	VERB	O	O	1974
the	PRON	O	O	1974
development	NOUN	O	O	1974
of	ADP	O	O	1974
puromycin aminonucleoside	NOUN	O	Chemical	1974
-	PUNCT	O	O	1974
induced	VERB	O	O	1974
nephrosis	NOUN	O	Disease	1974
.	PUNCT	O	O	1974
The	PRON	O	O	1975
appearance	NOUN	O	O	1975
of	ADP	O	O	1975
nephrotic syndromes	NOUN	O	O	1975
such	ADJ	O	O	1975
as	ADP	O	O	1975
proteinuria	X	O	Disease	1975
,	PUNCT	O	O	1975
hypoalbuminemia	ADV	O	Disease	1975
,	PUNCT	O	O	1975
hypercholesterolemia	NOUN	O	Disease	1975
and	CCONJ	O	O	1975
increase	VERB	O	O	1975
in	ADP	O	O	1975
blood	NOUN	O	O	1975
nitrogen	NOUN	O	O	1975
urea	PROPN	O	Chemical	1975
,	PUNCT	O	O	1975
induced	VERB	O	O	1975
in	ADP	O	O	1975
rats	NOUN	O	O	1975
by	ADP	O	O	1975
injection	NOUN	O	O	1975
of	ADP	O	O	1975
puromycin aminonucleoside	NOUN	O	Chemical	1975
was	AUX	O	O	1975
markedly	ADV	O	O	1975
inhibited	VERB	O	O	1975
by	ADP	O	O	1975
oral	ADJ	O	O	1975
administration	NOUN	O	O	1975
of	ADP	O	O	1975
Dup	PROPN	O	O	1975
753	NUM	O	O	1975
(	PUNCT	O	O	1975
losartan	NOUN	O	O	1975
)	PUNCT	O	O	1975
,	PUNCT	O	O	1975
a	PRON	O	O	1975
novel	NOUN	O	O	1975
angiotensin II	PROPN	O	Chemical	1975
receptor	NOUN	O	O	1975
antagonist	NOUN	O	O	1975
,	PUNCT	O	O	1975
at	ADP	O	O	1975
a	PRON	O	O	1975
dose	NOUN	O	O	1975
of	ADP	O	O	1975
1	X	O	O	1975
or	CCONJ	O	O	1975
2	X	O	O	1975
mg	VERB	O	O	1975
/	PUNCT	O	O	1975
kg	VERB	O	O	1975
per	ADP	O	O	1975
day	NOUN	O	O	1975
.	PUNCT	O	O	1975
The	PRON	O	O	1976
results	VERB	O	O	1976
suggest	VERB	O	O	1976
a	PRON	O	O	1976
possible	ADJ	O	O	1976
involvement	NOUN	O	O	1976
of	ADP	O	O	1976
the	PRON	O	O	1976
renin	PROPN	O	O	1976
-	PUNCT	O	O	1976
angiotensin	NOUN	O	Chemical	1976
system	NOUN	O	O	1976
in	ADP	O	O	1976
the	PRON	O	O	1976
development	NOUN	O	O	1976
of	ADP	O	O	1976
puromycin aminonucleoside	NOUN	O	Chemical	1976
-	PUNCT	O	O	1976
induced	VERB	O	O	1976
nephrosis	NOUN	O	Disease	1976
.	PUNCT	O	O	1976
Sodium	NOUN	O	Chemical	1979
bicarbonate	NOUN	O	O	1979
alleviates	VERB	O	O	1979
penile	NOUN	O	O	1979
pain	NOUN	O	Disease	1979
induced	VERB	O	O	1979
by	ADP	O	O	1979
intracavernous	ADJ	O	O	1979
injections	NOUN	O	O	1979
for	ADP	O	O	1979
erectile dysfunction	NOUN	O	Disease	1979
.	PUNCT	O	O	1979
In	ADP	O	O	1980
an	PRON	O	O	1980
attempt	VERB	O	O	1980
to	PART	O	O	1980
determine	VERB	O	O	1980
whether	SCONJ	O	O	1980
penile	NOUN	O	O	1980
pain	NOUN	O	Disease	1980
associated	VERB	O	O	1980
with	ADP	O	O	1980
intracorporeal	PROPN	O	O	1980
injections	NOUN	O	O	1980
could	AUX	O	O	1980
be	AUX	O	O	1980
due	ADJ	O	O	1980
to	PART	O	O	1980
the	PRON	O	O	1980
acidity	NOUN	O	O	1980
of	ADP	O	O	1980
the	PRON	O	O	1980
medication	NOUN	O	O	1980
,	PUNCT	O	O	1980
we	PRON	O	O	1980
performed	VERB	O	O	1980
a	PRON	O	O	1980
randomized	VERB	O	O	1980
study	VERB	O	O	1980
comparing	VERB	O	O	1980
the	PRON	O	O	1980
incidence	NOUN	O	O	1980
of	ADP	O	O	1980
penile	NOUN	O	O	1980
pain	NOUN	O	Disease	1980
following	VERB	O	O	1980
intracorporeal	PROPN	O	O	1980
injections	NOUN	O	O	1980
with	ADP	O	O	1980
or	CCONJ	O	O	1980
without	ADP	O	O	1980
the	PRON	O	O	1980
addition	NOUN	O	O	1980
of	ADP	O	O	1980
sodium bicarbonate	NOUN	O	Chemical	1980
to	PART	O	O	1980
the	PRON	O	O	1980
intracorporeal	PROPN	O	O	1980
medications	NOUN	O	O	1980
.	PUNCT	O	O	1980
A	PRON	O	O	1981
total	ADJ	O	O	1981
of	ADP	O	O	1981
38	NUM	O	O	1981
consecutive	ADJ	O	O	1981
patients	NOUN	O	O	1981
who	PRON	O	O	1981
presented	VERB	O	O	1981
to	PART	O	O	1981
our	PRON	O	O	1981
clinic	NOUN	O	O	1981
with	ADP	O	O	1981
impotence	NOUN	O	Disease	1981
received	VERB	O	O	1981
0.2	NUM	O	O	1981
ml	ADP	O	O	1981
.	PUNCT	O	O	1981
of	ADP	O	O	1981
a	PRON	O	O	1981
combination	NOUN	O	O	1981
of	ADP	O	O	1981
3	X	O	O	1981
drugs	NOUN	O	O	1981
:	PUNCT	O	O	1981
6	NUM	O	O	1981
mg	VERB	O	O	1981
.	PUNCT	O	O	1981
papaverine	NOUN	O	O	1982
,	PUNCT	O	O	1982
100	NUM	O	O	1982
micrograms	NOUN	O	O	1982
.	PUNCT	O	O	1982
phentolamine	ADV	O	Chemical	1983
and	CCONJ	O	O	1983
10	NUM	O	O	1983
micrograms	NOUN	O	O	1983
.	PUNCT	O	O	1983
prostaglandin E1	NOUN	O	O	1984
with	ADP	O	O	1984
(	PUNCT	O	O	1984
pH	NOUN	O	O	1984
7.05	NUM	O	O	1984
)	PUNCT	O	O	1984
or	CCONJ	O	O	1984
without	ADP	O	O	1984
(	PUNCT	O	O	1984
pH	NOUN	O	O	1984
4.17	NUM	O	O	1984
)	PUNCT	O	O	1984
the	PRON	O	O	1984
addition	NOUN	O	O	1984
of	ADP	O	O	1984
sodium bicarbonate	NOUN	O	Chemical	1984
(	PUNCT	O	O	1984
0.03	NUM	O	O	1984
mEq	VERB	O	O	1984
.	PUNCT	O	O	1984
)	PUNCT	O	O	1984
.	PUNCT	O	O	1984
Of	ADV	O	O	1985
the	PRON	O	O	1985
19	NUM	O	O	1985
patients	NOUN	O	O	1985
without	ADP	O	O	1985
sodium bicarbonate	NOUN	O	Chemical	1985
added	VERB	O	O	1985
to	PART	O	O	1985
the	PRON	O	O	1985
medication	NOUN	O	O	1985
11	NUM	O	O	1985
(	PUNCT	O	O	1985
58%	NOUN	O	O	1985
)	PUNCT	O	O	1985
complained	VERB	O	O	1985
of	ADP	O	O	1985
penile	NOUN	O	O	1985
pain	NOUN	O	Disease	1985
due	ADJ	O	O	1985
to	PART	O	O	1985
the	PRON	O	O	1985
medication	NOUN	O	O	1985
,	PUNCT	O	O	1985
while	SCONJ	O	O	1985
only	ADV	O	O	1985
1	X	O	O	1985
of	ADP	O	O	1985
the	PRON	O	O	1985
19	NUM	O	O	1985
men	NOUN	O	O	1985
(	PUNCT	O	O	1985
5%	NOUN	O	O	1985
)	PUNCT	O	O	1985
who	PRON	O	O	1985
received	VERB	O	O	1985
sodium bicarbonate	NOUN	O	Chemical	1985
complained	VERB	O	O	1985
of	ADP	O	O	1985
penile	NOUN	O	O	1985
pain	NOUN	O	Disease	1985
.	PUNCT	O	O	1985
From	ADP	O	O	1986
these	PRON	O	O	1986
data	NOUN	O	O	1986
we	PRON	O	O	1986
conclude	VERB	O	O	1986
that	SCONJ	O	O	1986
the	PRON	O	O	1986
penile	NOUN	O	O	1986
pain	NOUN	O	Disease	1986
following	VERB	O	O	1986
intracorporeal	PROPN	O	O	1986
injections	NOUN	O	O	1986
is	AUX	O	O	1986
most	ADV	O	O	1986
likely	ADV	O	O	1986
due	ADJ	O	O	1986
to	PART	O	O	1986
the	PRON	O	O	1986
acidity	NOUN	O	O	1986
of	ADP	O	O	1986
the	PRON	O	O	1986
medication	NOUN	O	O	1986
,	PUNCT	O	O	1986
which	PRON	O	O	1986
can	AUX	O	O	1986
be	AUX	O	O	1986
overcome	VERB	O	O	1986
by	ADP	O	O	1986
elevating	VERB	O	O	1986
the	PRON	O	O	1986
pH	NOUN	O	O	1986
to	PART	O	O	1986
a	PRON	O	O	1986
neutral	ADJ	O	O	1986
level	VERB	O	O	1986
.	PUNCT	O	O	1986
Prospective	PROPN	O	O	1989
study	VERB	O	O	1989
of	ADP	O	O	1989
the	PRON	O	O	1989
long	ADV	O	O	1989
-	PUNCT	O	O	1989
term	NOUN	O	O	1989
effects	NOUN	O	O	1989
of	ADP	O	O	1989
somatostatin	NOUN	O	O	1989
analog	NOUN	O	O	1989
(	PUNCT	O	O	1989
octreotide	ADV	O	O	1989
)	PUNCT	O	O	1989
on	ADP	O	O	1989
gallbladder	NOUN	O	O	1989
function	NOUN	O	O	1989
and	CCONJ	O	O	1989
gallstone	NOUN	O	O	1989
formation	NOUN	O	O	1989
in	ADP	O	O	1989
Chinese	PROPN	O	O	1989
acromegalic	ADV	O	O	1989
patients	NOUN	O	O	1989
.	PUNCT	O	O	1989
This	PRON	O	O	1990
article	NOUN	O	O	1990
reports	VERB	O	O	1990
the	PRON	O	O	1990
changes	VERB	O	O	1990
in	ADP	O	O	1990
gallbladder	NOUN	O	O	1990
function	NOUN	O	O	1990
examined	VERB	O	O	1990
by	ADP	O	O	1990
ultrasonography	NOUN	O	O	1990
in	ADP	O	O	1990
20	NUM	O	O	1990
Chinese	PROPN	O	O	1990
patients	NOUN	O	O	1990
with	ADP	O	O	1990
active	ADJ	O	O	1990
acromegaly	PROPN	O	O	1990
treated	VERB	O	O	1990
with	ADP	O	O	1990
sc	PROPN	O	O	1990
injection	NOUN	O	O	1990
of	ADP	O	O	1990
the	PRON	O	O	1990
somatostatin	NOUN	O	O	1990
analog	NOUN	O	O	1990
octreotide	ADV	O	O	1990
in	ADP	O	O	1990
dosages	NOUN	O	O	1990
of	ADP	O	O	1990
300	NUM	O	O	1990
-	PUNCT	O	O	1990
1500	NUM	O	O	1990
micrograms	NOUN	O	O	1990
/	PUNCT	O	O	1990
day	NOUN	O	O	1990
for	ADP	O	O	1990
a	PRON	O	O	1990
mean	VERB	O	O	1990
of	ADP	O	O	1990
24.2	NUM	O	O	1990
+	ADP	O	O	1990
/-	PUNCT	O	O	1990
During	ADP	O	O	1991
treatment	NOUN	O	O	1991
with	ADP	O	O	1991
octreotide	ADV	O	O	1991
,	PUNCT	O	O	1991
17	NUM	O	O	1991
patients	NOUN	O	O	1991
developed	VERB	O	O	1991
sludge	NOUN	O	O	1991
,	PUNCT	O	O	1991
10	NUM	O	O	1991
had	VERB	O	O	1991
gallstones	NOUN	O	O	1991
,	PUNCT	O	O	1991
and	CCONJ	O	O	1991
1	X	O	O	1991
developed	VERB	O	O	1991
acute	ADJ	O	O	1991
cholecystitis	NOUN	O	O	1991
requiring	VERB	O	O	1991
surgery	NOUN	O	O	1991
.	PUNCT	O	O	1991
In	ADP	O	O	1992
8	NUM	O	O	1992
patients	NOUN	O	O	1992
followed	VERB	O	O	1992
for	ADP	O	O	1992
24	NUM	O	O	1992
weeks	NOUN	O	O	1992
,	PUNCT	O	O	1992
gallbladder	NOUN	O	O	1992
contractility	NOUN	O	O	1992
remained	VERB	O	O	1992
depressed	ADJ	O	O	1992
throughout	ADP	O	O	1992
therapy	NOUN	O	O	1992
.	PUNCT	O	O	1992
After	ADP	O	O	1993
withdrawal	NOUN	O	O	1993
of	ADP	O	O	1993
octreotide	ADV	O	O	1993
in	ADP	O	O	1993
10	NUM	O	O	1993
patients	NOUN	O	O	1993
without	ADP	O	O	1993
gallstones	NOUN	O	O	1993
,	PUNCT	O	O	1993
8	NUM	O	O	1993
patients	NOUN	O	O	1993
assessed	VERB	O	O	1993
had	VERB	O	O	1993
return	VERB	O	O	1993
of	ADP	O	O	1993
normal	ADJ	O	O	1993
gallbladder	NOUN	O	O	1993
contractility	NOUN	O	O	1993
within	ADP	O	O	1993
1	X	O	O	1993
month	NOUN	O	O	1993
.	PUNCT	O	O	1993
In	ADP	O	O	1994
8	NUM	O	O	1994
of	ADP	O	O	1994
the	PRON	O	O	1994
remaining	VERB	O	O	1994
10	NUM	O	O	1994
patients	NOUN	O	O	1994
who	PRON	O	O	1994
developed	VERB	O	O	1994
gallstones	NOUN	O	O	1994
during	ADP	O	O	1994
treatment	NOUN	O	O	1994
,	PUNCT	O	O	1994
gallbladder	NOUN	O	O	1994
contractility	NOUN	O	O	1994
normalized	VERB	O	O	1994
in	ADP	O	O	1994
5	NUM	O	O	1994
patients	NOUN	O	O	1994
(	PUNCT	O	O	1994
3	X	O	O	1994
of	ADP	O	O	1994
whom	PRON	O	O	1994
has	VERB	O	O	1994
disappearance	NOUN	O	O	1994
of	ADP	O	O	1994
their	PRON	O	O	1994
stones	NOUN	O	O	1994
within	ADP	O	O	1994
3	X	O	O	1994
weeks	NOUN	O	O	1994
)	PUNCT	O	O	1994
,	PUNCT	O	O	1994
and	CCONJ	O	O	1994
remained	VERB	O	O	1994
depressed	ADJ	O	O	1994
in	ADP	O	O	1994
3	X	O	O	1994
(	PUNCT	O	O	1994
2	X	O	O	1994
of	ADP	O	O	1994
whom	PRON	O	O	1994
had	VERB	O	O	1994
stones	NOUN	O	O	1994
present	NOUN	O	O	1994
at	ADP	O	O	1994
6	NUM	O	O	1994
months	NOUN	O	O	1994
)	PUNCT	O	O	1994
.	PUNCT	O	O	1994
Our	PRON	O	O	1995
results	VERB	O	O	1995
suggest	VERB	O	O	1995
that	SCONJ	O	O	1995
the	PRON	O	O	1995
suppression	NOUN	O	O	1995
of	ADP	O	O	1995
gallbladder	NOUN	O	O	1995
contractility	NOUN	O	O	1995
is	AUX	O	O	1995
the	PRON	O	O	1995
cause	VERB	O	O	1995
of	ADP	O	O	1995
the	PRON	O	O	1995
successive	ADV	O	O	1995
formation	NOUN	O	O	1995
of	ADP	O	O	1995
bile	NOUN	O	O	1995
sludge	NOUN	O	O	1995
,	PUNCT	O	O	1995
gallstones	NOUN	O	O	1995
,	PUNCT	O	O	1995
and	CCONJ	O	O	1995
cholecystitis	NOUN	O	O	1995
during	ADP	O	O	1995
octreotide	ADV	O	O	1995
therapy	NOUN	O	O	1995
in	ADP	O	O	1995
Chinese	PROPN	O	O	1995
acromegalic	ADV	O	O	1995
patients	NOUN	O	O	1995
.	PUNCT	O	O	1995
It	PRON	O	O	1996
is	AUX	O	O	1996
therefore	ADV	O	O	1996
very	ADV	O	O	1996
important	ADJ	O	O	1996
to	PART	O	O	1996
follow	VERB	O	O	1996
the	PRON	O	O	1996
changes	VERB	O	O	1996
of	ADP	O	O	1996
gallbladder	NOUN	O	O	1996
function	NOUN	O	O	1996
during	ADP	O	O	1996
long	ADV	O	O	1996
-	PUNCT	O	O	1996
term	NOUN	O	O	1996
octreotide	ADV	O	O	1996
therapy	NOUN	O	O	1996
of	ADP	O	O	1996
acromegalic	ADV	O	O	1996
patients	NOUN	O	O	1996
.	PUNCT	O	O	1996
Improvement	NOUN	O	O	1999
of	ADP	O	O	1999
levodopa	NOUN	O	Chemical	1999
-	PUNCT	O	O	1999
induced	VERB	O	O	1999
dyskinesia	NOUN	O	Disease	1999
by	ADP	O	O	1999
propranolol	NOUN	O	Chemical	1999
in	ADP	O	O	1999
Parkinson	NOUN	O	O	1999
's	AUX	O	O	1999
disease	PROPN	O	O	1999
.	PUNCT	O	O	1999
Seven	NUM	O	O	2000
patients	NOUN	O	O	2000
suffering	VERB	O	O	2000
from	ADP	O	O	2000
Parkinson	NOUN	O	O	2000
's	AUX	O	O	2000
disease	PROPN	O	O	2000
(	PUNCT	O	O	2000
PD	PROPN	O	Disease	2000
)	PUNCT	O	O	2000
with	ADP	O	O	2000
severely	ADV	O	O	2000
disabling	VERB	O	O	2000
dyskinesia	NOUN	O	Disease	2000
received	VERB	O	O	2000
low	ADJ	O	O	2000
-	PUNCT	O	O	2000
dose	NOUN	O	O	2000
propranolol	NOUN	O	Chemical	2000
as	ADP	O	O	2000
an	PRON	O	O	2000
adjunct	NOUN	O	O	2000
to	PART	O	O	2000
the	PRON	O	O	2000
currently	ADV	O	O	2000
used	VERB	O	O	2000
medical	ADJ	O	O	2000
treatment	NOUN	O	O	2000
.	PUNCT	O	O	2000
There	ADV	O	O	2001
was	AUX	O	O	2001
a	PRON	O	O	2001
significant	ADJ	O	O	2001
40%	NOUN	O	O	2001
improvement	NOUN	O	O	2001
in	ADP	O	O	2001
the	PRON	O	O	2001
dyskinesia	NOUN	O	Disease	2001
score	VERB	O	O	2001
without	ADP	O	O	2001
increase	VERB	O	O	2001
of	ADP	O	O	2001
parkinsonian	PROPN	O	Disease	2001
motor	NOUN	O	O	2001
disability	NOUN	O	O	2001
.	PUNCT	O	O	2001
Ballistic	NOUN	O	O	2002
and	CCONJ	O	O	2002
choreic	PROPN	O	O	2002
dyskinesia	NOUN	O	Disease	2002
were	AUX	O	O	2002
markedly	ADV	O	O	2002
ameliorated	VERB	O	O	2002
,	PUNCT	O	O	2002
whereas	SCONJ	O	O	2002
dystonia	NOUN	O	Disease	2002
was	AUX	O	O	2002
not	PART	O	O	2002
.	PUNCT	O	O	2002
This	PRON	O	O	2003
study	VERB	O	O	2003
suggests	VERB	O	O	2003
that	SCONJ	O	O	2003
administration	NOUN	O	O	2003
of	ADP	O	O	2003
low	ADJ	O	O	2003
doses	NOUN	O	O	2003
of	ADP	O	O	2003
beta	NOUN	O	O	2003
-	PUNCT	O	O	2003
blockers	NOUN	O	O	2003
may	AUX	O	O	2003
improve	VERB	O	O	2003
levodopa	NOUN	O	Chemical	2003
-	PUNCT	O	O	2003
induced	VERB	O	O	2003
ballistic	ADJ	O	O	2003
and	CCONJ	O	O	2003
choreic	PROPN	O	O	2003
dyskinesia	NOUN	O	Disease	2003
in	ADP	O	O	2003
PD	PROPN	O	Disease	2003
.	PUNCT	O	O	2003
Morphological	ADJ	O	O	2006
features	VERB	O	O	2006
of	ADP	O	O	2006
encephalopathy	NOUN	O	Disease	2006
after	ADP	O	O	2006
chronic	ADJ	O	O	2006
administration	NOUN	O	O	2006
of	ADP	O	O	2006
the	PRON	O	O	2006
antiepileptic	ADJ	O	O	2006
drug	NOUN	O	O	2006
valproate	VERB	O	Chemical	2006
to	PART	O	O	2006
rats	NOUN	O	O	2006
.	PUNCT	O	O	2006
Long	ADV	O	O	2007
-	PUNCT	O	O	2007
term	NOUN	O	O	2007
intragastric	NOUN	O	O	2007
application	NOUN	O	O	2007
of	ADP	O	O	2007
the	PRON	O	O	2007
antiepileptic	ADJ	O	O	2007
drug	NOUN	O	O	2007
sodium valproate	VERB	O	Chemical	2007
(	PUNCT	O	O	2007
Vupral	PROPN	O	O	2007
""""	PUNCT	O	O	2007
Polfa	PROPN	O	O	2007
""""	PUNCT	O	O	2007
)	PUNCT	O	O	2007
at	ADP	O	O	2007
the	PRON	O	O	2007
effective	ADJ	O	O	2007
dose	NOUN	O	O	2007
of	ADP	O	O	2007
200	NUM	O	O	2007
mg	VERB	O	O	2007
/	PUNCT	O	O	2007
kg	VERB	O	O	2007
b.	PROPN	O	O	2007
w.	PROPN	O	O	2007
once	ADV	O	O	2007
daily	ADV	O	O	2007
to	PART	O	O	2007
rats	NOUN	O	O	2007
for	ADP	O	O	2007
1	X	O	O	2007
,	PUNCT	O	O	2007
3	X	O	O	2007
,	PUNCT	O	O	2007
6	NUM	O	O	2007
,	PUNCT	O	O	2007
9	NUM	O	O	2007
and	CCONJ	O	O	2007
12	NUM	O	O	2007
months	NOUN	O	O	2007
revealed	VERB	O	O	2007
neurological	ADJ	O	O	2007
disorders	NOUN	O	O	2007
indicating	VERB	O	O	2007
cerebellum	NOUN	O	O	2007
damage	NOUN	O	O	2007
(	PUNCT	O	O	2007
""""	PUNCT	O	O	2007
valproate	VERB	O	Chemical	2007
encephalopathy	NOUN	O	Disease	2007
""""	PUNCT	O	O	2007
)	PUNCT	O	O	2007
.	PUNCT	O	O	2007
Lesions	NOUN	O	O	2008
of	ADP	O	O	2008
the	PRON	O	O	2008
capillary	NOUN	O	O	2008
included	VERB	O	O	2008
necrosis	NOUN	O	Disease	2008
of	ADP	O	O	2008
endothelial	NOUN	O	O	2008
cells	NOUN	O	O	2008
.	PUNCT	O	O	2008
Reduced	VERB	O	O	2009
size	NOUN	O	O	2009
of	ADP	O	O	2009
capillary	NOUN	O	O	2009
lumen	NOUN	O	O	2009
and	CCONJ	O	O	2009
occlusion	NOUN	O	O	2009
were	AUX	O	O	2009
caused	VERB	O	O	2009
by	ADP	O	O	2009
swollen	ADJ	O	O	2009
endothelial	NOUN	O	O	2009
cells	NOUN	O	O	2009
which	PRON	O	O	2009
had	VERB	O	O	2009
luminal	ADJ	O	O	2009
protrusions	NOUN	O	O	2009
and	CCONJ	O	O	2009
swollen	ADJ	O	O	2009
microvilli	NOUN	O	O	2009
.	PUNCT	O	O	2009
Fragments	NOUN	O	O	2010
of	ADP	O	O	2010
necrotic	ADJ	O	O	2010
endothelial	NOUN	O	O	2010
cells	NOUN	O	O	2010
were	AUX	O	O	2010
in	ADP	O	O	2010
the	PRON	O	O	2010
vascular	ADJ	O	O	2010
lumens	NOUN	O	O	2010
and	CCONJ	O	O	2010
in	ADP	O	O	2010
these	PRON	O	O	2010
there	ADV	O	O	2010
was	AUX	O	O	2010
loosening	VERB	O	O	2010
and	CCONJ	O	O	2010
breaking	VERB	O	O	2010
of	ADP	O	O	2010
tight	ADJ	O	O	2010
cellular	NOUN	O	O	2010
junctions	NOUN	O	O	2010
.	PUNCT	O	O	2010
In	ADP	O	O	2011
electron	NOUN	O	O	2011
micrographs	NOUN	O	O	2011
both	PRON	O	O	2011
luminal	ADJ	O	O	2011
and	CCONJ	O	O	2011
antiluminal	ADJ	O	O	2011
sides	NOUN	O	O	2011
of	ADP	O	O	2011
the	PRON	O	O	2011
BBB	PROPN	O	O	2011
of	ADP	O	O	2011
the	PRON	O	O	2011
cerebellar	ADJ	O	O	2011
cortex	VERB	O	O	2011
had	VERB	O	O	2011
similar	ADJ	O	O	2011
lesions	NOUN	O	O	2011
.	PUNCT	O	O	2011
The	PRON	O	O	2012
possible	ADJ	O	O	2012
influence	NOUN	O	O	2012
of	ADP	O	O	2012
the	PRON	O	O	2012
hepatic damage	NOUN	O	Disease	2012
,	PUNCT	O	O	2012
mainly	ADV	O	O	2012
hyperammonemia	PROPN	O	Disease	2012
,	PUNCT	O	O	2012
upon	SCONJ	O	O	2012
the	PRON	O	O	2012
development	NOUN	O	O	2012
of	ADP	O	O	2012
valproate	VERB	O	Chemical	2012
encephalopathy	NOUN	O	Disease	2012
is	AUX	O	O	2012
discussed	VERB	O	O	2012
.	PUNCT	O	O	2012
Macula	VERB	O	O	2015
toxicity	NOUN	O	Disease	2015
after	ADP	O	O	2015
intravitreal	NOUN	O	O	2015
amikacin	VERB	O	Chemical	2015
.	PUNCT	O	O	2015
Although	SCONJ	O	O	2016
intravitreal	NOUN	O	O	2016
aminoglycosides	NOUN	O	Chemical	2016
have	VERB	O	O	2016
substantially	ADV	O	O	2016
improved	VERB	O	O	2016
visual	ADJ	O	O	2016
prognosis	VERB	O	O	2016
in	ADP	O	O	2016
endophthalmitis	NOUN	O	O	2016
,	PUNCT	O	O	2016
macular	ADJ	O	O	2016
infarction	NOUN	O	O	2016
may	AUX	O	O	2016
impair	VERB	O	O	2016
full	ADJ	O	O	2016
visual	ADJ	O	O	2016
recovery	NOUN	O	O	2016
.	PUNCT	O	O	2016
METHODS	NOUN	O	O	2017
:	PUNCT	O	O	2017
We	PRON	O	O	2017
present	NOUN	O	O	2017
a	PRON	O	O	2017
case	NOUN	O	O	2017
of	ADP	O	O	2017
presumed	VERB	O	O	2017
amikacin	VERB	O	Chemical	2017
retinal	ADJ	O	O	2017
toxicity	NOUN	O	Disease	2017
following	VERB	O	O	2017
treatment	NOUN	O	O	2017
with	ADP	O	O	2017
amikacin	VERB	O	Chemical	2017
and	CCONJ	O	O	2017
vancomycin	VERB	O	Chemical	2017
for	ADP	O	O	2017
alpha	PROPN	O	O	2017
-	PUNCT	O	O	2017
haemolytic	ADJ	O	O	2017
streptococcal	ADJ	O	O	2017
endophthalmitis	NOUN	O	O	2017
.	PUNCT	O	O	2017
Endophthalmitis	NOUN	O	O	2018
resolved	VERB	O	O	2018
with	ADP	O	O	2018
improvement	NOUN	O	O	2018
in	ADP	O	O	2018
visual	ADJ	O	O	2018
acuity	NOUN	O	O	2018
to	PART	O	O	2018
6/24	NUM	O	O	2018
at	ADP	O	O	2018
three	NUM	O	O	2018
months	NOUN	O	O	2018
.	PUNCT	O	O	2018
Fundus	NOUN	O	O	2019
fluorescein	VERB	O	O	2019
angiography	NOUN	O	O	2019
confirmed	VERB	O	O	2019
macular	ADJ	O	O	2019
capillary	NOUN	O	O	2019
closure	NOUN	O	O	2019
and	CCONJ	O	O	2019
telangiectasis	NOUN	O	O	2019
.	PUNCT	O	O	2019
CONCLUSIONS	NOUN	O	O	2020
:	PUNCT	O	O	2020
Currently	ADV	O	O	2020
accepted	VERB	O	O	2020
intravitreal	NOUN	O	O	2020
antibiotic	ADJ	O	O	2020
regimens	NOUN	O	O	2020
may	AUX	O	O	2020
cause	VERB	O	O	2020
retinal	ADJ	O	O	2020
toxicity	NOUN	O	Disease	2020
and	CCONJ	O	O	2020
macular	ADJ	O	O	2020
ischaemia	NOUN	O	O	2020
.	PUNCT	O	O	2020
Treatment	NOUN	O	O	2021
strategies	NOUN	O	O	2021
aimed	VERB	O	O	2021
at	ADP	O	O	2021
avoiding	VERB	O	O	2021
retinal	ADJ	O	O	2021
toxicity	NOUN	O	Disease	2021
are	AUX	O	O	2021
discussed	VERB	O	O	2021
.	PUNCT	O	O	2021
Iatrogenically	ADV	O	O	2024
induced	VERB	O	O	2024
intractable	ADJ	O	O	2024
atrioventricular	ADJ	O	O	2024
reentrant	ADJ	O	O	2024
tachycardia	PROPN	O	Disease	2024
after	ADP	O	O	2024
verapamil	PROPN	O	Chemical	2024
and	CCONJ	O	O	2024
catheter	VERB	O	O	2024
ablation	NOUN	O	O	2024
in	ADP	O	O	2024
a	PRON	O	O	2024
patient	NOUN	O	O	2024
with	ADP	O	O	2024
Wolff	NOUN	O	O	2024
-	PUNCT	O	O	2024
Parkinson	NOUN	O	O	2024
-	PUNCT	O	O	2024
White	ADJ	O	O	2024
syndrome	NOUN	O	O	2024
and	CCONJ	O	O	2024
idiopathic	ADJ	O	O	2024
dilated	ADJ	O	O	2024
cardiomyopathy	ADJ	O	Disease	2024
.	PUNCT	O	O	2024
In	ADP	O	O	2025
a	PRON	O	O	2025
patient	NOUN	O	O	2025
with	ADP	O	O	2025
WPW	PROPN	O	O	2025
syndrome	NOUN	O	O	2025
and	CCONJ	O	O	2025
idiopathic	ADJ	O	O	2025
dilated	ADJ	O	O	2025
cardiomyopathy	ADJ	O	Disease	2025
,	PUNCT	O	O	2025
intractable	ADJ	O	O	2025
atrioventricular	ADJ	O	O	2025
reentrant	ADJ	O	O	2025
tachycardia	PROPN	O	Disease	2025
(	PUNCT	O	O	2025
AVRT	PROPN	O	O	2025
)	PUNCT	O	O	2025
was	AUX	O	O	2025
iatrogenically	ADV	O	O	2025
induced	VERB	O	O	2025
.	PUNCT	O	O	2025
QRS	PROPN	O	O	2026
without	ADP	O	O	2026
preexcitation	VERB	O	O	2026
,	PUNCT	O	O	2026
caused	VERB	O	O	2026
by	ADP	O	O	2026
junctional	ADJ	O	O	2026
escape	VERB	O	O	2026
beats	NOUN	O	O	2026
after	ADP	O	O	2026
verapamil	PROPN	O	Chemical	2026
or	CCONJ	O	O	2026
unidirectional	ADJ	O	O	2026
antegrade	VERB	O	O	2026
block	NOUN	O	O	2026
of	ADP	O	O	2026
accessory	NOUN	O	O	2026
pathway	NOUN	O	O	2026
after	ADP	O	O	2026
catheter	VERB	O	O	2026
ablation	NOUN	O	O	2026
,	PUNCT	O	O	2026
established	VERB	O	O	2026
frequent	ADJ	O	O	2026
AVRT	PROPN	O	O	2026
attack	VERB	O	O	2026
.	PUNCT	O	O	2026
Epidemic	NOUN	O	O	2029
of	ADP	O	O	2029
liver disease	NOUN	O	Disease	2029
caused	VERB	O	O	2029
by	ADP	O	O	2029
hydrochlorofluorocarbons	NOUN	O	O	2029
used	VERB	O	O	2029
as	ADP	O	O	2029
ozone	NOUN	O	O	2029
-	PUNCT	O	O	2029
sparing	VERB	O	O	2029
substitutes	NOUN	O	O	2029
of	ADP	O	O	2029
chlorofluorocarbons	NOUN	O	O	2029
.	PUNCT	O	O	2029
BACKGROUND	NOUN	O	O	2030
:	PUNCT	O	O	2030
Hydrochlorofluorocarbons	NOUN	O	O	2030
(	PUNCT	O	O	2030
HCFCs	NOUN	O	O	2030
)	PUNCT	O	O	2030
are	AUX	O	O	2030
used	VERB	O	O	2030
increasingly	ADV	O	O	2030
in	ADP	O	O	2030
industry	NOUN	O	O	2030
as	ADP	O	O	2030
substitutes	NOUN	O	O	2030
for	ADP	O	O	2030
ozone	NOUN	O	O	2030
-	PUNCT	O	O	2030
depleting	VERB	O	O	2030
chlorofluorocarbons	NOUN	O	O	2030
(	PUNCT	O	O	2030
CFCs	PROPN	O	O	2030
)	PUNCT	O	O	2030
.	PUNCT	O	O	2030
Limited	ADJ	O	O	2031
studies	NOUN	O	O	2031
in	ADP	O	O	2031
animals	NOUN	O	O	2031
indicate	VERB	O	O	2031
potential	ADJ	O	O	2031
hepatotoxicity	NOUN	O	Disease	2031
of	ADP	O	O	2031
some	PRON	O	O	2031
of	ADP	O	O	2031
these	PRON	O	O	2031
compounds	NOUN	O	O	2031
.	PUNCT	O	O	2031
We	PRON	O	O	2032
investigated	VERB	O	O	2032
an	PRON	O	O	2032
epidemic	NOUN	O	O	2032
of	ADP	O	O	2032
liver disease	NOUN	O	Disease	2032
in	ADP	O	O	2032
nine	NUM	O	O	2032
industrial	ADJ	O	O	2032
workers	NOUN	O	O	2032
who	PRON	O	O	2032
had	VERB	O	O	2032
had	VERB	O	O	2032
repeated	VERB	O	O	2032
accidental	ADJ	O	O	2032
exposure	NOUN	O	O	2032
to	PART	O	O	2032
a	PRON	O	O	2032
mixture	NOUN	O	O	2032
of	ADP	O	O	2032
1,1-dichloro-2,2,2-trifluoroethane	NOUN	O	O	2032
(	PUNCT	O	O	2032
HCFC	NOUN	O	O	2032
123	NUM	O	O	2032
)	PUNCT	O	O	2032
and	CCONJ	O	O	2032
1-chloro-1,2,2,2-tetrafluoroethane	NOUN	O	O	2032
(	PUNCT	O	O	2033
HCFC	NOUN	O	O	2033
124	NUM	O	O	2033
)	PUNCT	O	O	2033
.	PUNCT	O	O	2033
Both	PRON	O	O	2034
compounds	NOUN	O	O	2034
are	AUX	O	O	2034
metabolised	VERB	O	O	2034
in	ADP	O	O	2034
the	PRON	O	O	2034
same	ADJ	O	O	2034
way	NOUN	O	O	2034
as	ADP	O	O	2034
1-bromo-1-chloro-2,2,2-trifluoroethane	NOUN	O	O	2034
(	PUNCT	O	O	2034
halothane	VERB	O	Chemical	2034
)	PUNCT	O	O	2034
to	PART	O	O	2034
form	NOUN	O	O	2034
reactive	ADJ	O	O	2034
trifluoroacetyl	VERB	O	Chemical	2034
halide	NOUN	O	O	2034
intermediates	NOUN	O	O	2034
,	PUNCT	O	O	2034
which	PRON	O	O	2034
have	VERB	O	O	2034
been	AUX	O	O	2034
implicated	VERB	O	O	2034
in	ADP	O	O	2034
the	PRON	O	O	2034
hepatotoxicity	NOUN	O	Disease	2034
of	ADP	O	O	2034
halothane	VERB	O	Chemical	2034
.	PUNCT	O	O	2034
We	PRON	O	O	2035
aimed	VERB	O	O	2035
to	PART	O	O	2035
test	NOUN	O	O	2035
whether	SCONJ	O	O	2035
HCFCs	NOUN	O	O	2035
123	NUM	O	O	2035
and	CCONJ	O	O	2035
124	NUM	O	O	2035
can	AUX	O	O	2035
result	VERB	O	O	2035
in	ADP	O	O	2035
serious	ADJ	O	O	2035
liver disease	NOUN	O	Disease	2035
.	PUNCT	O	O	2035
METHODS	NOUN	O	O	2036
:	PUNCT	O	O	2036
For	ADP	O	O	2036
one	NUM	O	O	2036
severely	ADV	O	O	2036
affected	VERB	O	O	2036
worker	NOUN	O	O	2036
liver	NOUN	O	O	2036
biopsy	PROPN	O	O	2036
and	CCONJ	O	O	2036
immunohistochemical	ADJ	O	O	2036
stainings	NOUN	O	O	2036
for	ADP	O	O	2036
the	PRON	O	O	2036
presence	NOUN	O	O	2036
of	ADP	O	O	2036
trifluoroacetyl	VERB	O	Chemical	2036
protein	NOUN	O	O	2036
adducts	VERB	O	O	2036
were	AUX	O	O	2036
done	VERB	O	O	2036
.	PUNCT	O	O	2036
The	PRON	O	O	2037
liver	NOUN	O	O	2037
biopsy	PROPN	O	O	2037
sample	NOUN	O	O	2037
showed	VERB	O	O	2037
hepatocellular	NOUN	O	O	2037
necrosis	NOUN	O	Disease	2037
which	PRON	O	O	2037
was	AUX	O	O	2037
prominent	ADJ	O	O	2037
in	ADP	O	O	2037
perivenular	ADJ	O	O	2037
zone	PROPN	O	O	2037
three	NUM	O	O	2037
and	CCONJ	O	O	2037
extended	VERB	O	O	2037
focally	ADV	O	O	2037
from	ADP	O	O	2037
portal	PROPN	O	O	2037
tracts	NOUN	O	O	2037
to	PART	O	O	2037
portal	PROPN	O	O	2037
tracts	NOUN	O	O	2037
and	CCONJ	O	O	2037
centrilobular	ADJ	O	O	2037
areas	NOUN	O	O	2037
(	PUNCT	O	O	2037
bridging	VERB	O	O	2037
necrosis	NOUN	O	Disease	2037
)	PUNCT	O	O	2037
.	PUNCT	O	O	2037
Trifluoroacetyl	PROPN	O	O	2038
-	PUNCT	O	O	2038
adducted	VERB	O	O	2038
proteins	NOUN	O	O	2038
were	AUX	O	O	2038
detected	VERB	O	O	2038
in	ADP	O	O	2038
surviving	VERB	O	O	2038
hepatocytes	VERB	O	O	2038
.	PUNCT	O	O	2038
Autoantibodies	NOUN	O	O	2039
against	ADP	O	O	2039
P450	VERB	O	O	2039
2E1	NUM	O	O	2039
or	CCONJ	O	O	2039
P58	NOUN	O	O	2039
,	PUNCT	O	O	2039
previously	ADV	O	O	2039
associated	VERB	O	O	2039
with	ADP	O	O	2039
halothane hepatitis	NOUN	O	Disease	2039
,	PUNCT	O	O	2039
were	AUX	O	O	2039
detected	VERB	O	O	2039
in	ADP	O	O	2039
the	PRON	O	O	2039
serum	NOUN	O	O	2039
of	ADP	O	O	2039
five	NUM	O	O	2039
affected	VERB	O	O	2039
workers	NOUN	O	O	2039
.	PUNCT	O	O	2039
INTERPRETATION	NOUN	O	O	2040
:	PUNCT	O	O	2040
Repeated	VERB	O	O	2040
exposure	NOUN	O	O	2040
of	ADP	O	O	2040
human	PROPN	O	O	2040
beings	NOUN	O	O	2040
to	PART	O	O	2040
HCFCs	NOUN	O	O	2040
123	NUM	O	O	2040
and	CCONJ	O	O	2040
124	NUM	O	O	2040
can	AUX	O	O	2040
result	VERB	O	O	2040
in	ADP	O	O	2040
serious	ADJ	O	O	2040
liver injury	NOUN	O	Disease	2040
in	ADP	O	O	2040
a	PRON	O	O	2040
large	ADJ	O	O	2040
proportion	NOUN	O	O	2040
of	ADP	O	O	2040
the	PRON	O	O	2040
exposed	VERB	O	O	2040
population	NOUN	O	O	2040
.	PUNCT	O	O	2040
Although	SCONJ	O	O	2041
the	PRON	O	O	2041
exact	VERB	O	O	2041
mechanism	NOUN	O	O	2041
of	ADP	O	O	2041
hepatotoxicity	NOUN	O	Disease	2041
of	ADP	O	O	2041
these	PRON	O	O	2041
agents	NOUN	O	O	2041
is	AUX	O	O	2041
not	PART	O	O	2041
known	VERB	O	O	2041
,	PUNCT	O	O	2041
the	PRON	O	O	2041
results	VERB	O	O	2041
suggest	VERB	O	O	2041
that	SCONJ	O	O	2041
trifluoroacetyl	VERB	O	Chemical	2041
-	PUNCT	O	O	2041
altered	VERB	O	O	2041
liver	NOUN	O	O	2041
proteins	NOUN	O	O	2041
are	AUX	O	O	2041
involved	VERB	O	O	2041
.	PUNCT	O	O	2041
The	PRON	O	O	2044
effect	VERB	O	O	2044
of	ADP	O	O	2044
different	ADJ	O	O	2044
anaesthetic	NOUN	O	O	2044
agents	NOUN	O	O	2044
in	ADP	O	O	2044
hearing loss	NOUN	O	Disease	2044
following	VERB	O	O	2044
spinal	NOUN	O	O	2044
anaesthesia	NOUN	O	O	2044
.	PUNCT	O	O	2044
The	PRON	O	O	2045
cause	VERB	O	O	2045
of	ADP	O	O	2045
hearing loss	NOUN	O	Disease	2045
after	ADP	O	O	2045
spinal	NOUN	O	O	2045
anaesthesia	NOUN	O	O	2045
is	AUX	O	O	2045
unknown	ADJ	O	O	2045
.	PUNCT	O	O	2045
Up	ADP	O	O	2046
until	ADP	O	O	2046
now	ADV	O	O	2046
,	PUNCT	O	O	2046
the	PRON	O	O	2046
only	ADV	O	O	2046
factor	NOUN	O	O	2046
studied	VERB	O	O	2046
has	VERB	O	O	2046
been	AUX	O	O	2046
the	PRON	O	O	2046
effect	VERB	O	O	2046
of	ADP	O	O	2046
the	PRON	O	O	2046
diameter	NOUN	O	O	2046
of	ADP	O	O	2046
the	PRON	O	O	2046
spinal	NOUN	O	O	2046
needle	NOUN	O	O	2046
on	ADP	O	O	2046
post	VERB	O	O	2046
-	PUNCT	O	O	2046
operative	NOUN	O	O	2046
sensorineural	ADJ	O	O	2046
hearing loss	NOUN	O	Disease	2046
.	PUNCT	O	O	2046
The	PRON	O	O	2047
aim	VERB	O	O	2047
of	ADP	O	O	2047
this	PRON	O	O	2047
study	VERB	O	O	2047
was	AUX	O	O	2047
to	PART	O	O	2047
describe	VERB	O	O	2047
this	PRON	O	O	2047
hearing loss	NOUN	O	Disease	2047
and	CCONJ	O	O	2047
to	PART	O	O	2047
investigate	VERB	O	O	2047
other	ADJ	O	O	2047
factors	NOUN	O	O	2047
influencing	VERB	O	O	2047
the	PRON	O	O	2047
degree	PROPN	O	O	2047
of	ADP	O	O	2047
hearing loss	NOUN	O	Disease	2047
.	PUNCT	O	O	2047
prilocaine	NOUN	O	O	2048
2%	NOUN	O	O	2048
;	PUNCT	O	O	2048
and	CCONJ	O	O	2048
the	PRON	O	O	2048
other	ADJ	O	O	2048
received	VERB	O	O	2048
3	X	O	O	2048
mL	PROPN	O	O	2048
bupivacaine	NOUN	O	Chemical	2048
0.5%	NOUN	O	O	2048
.	PUNCT	O	O	2048
Patients	NOUN	O	O	2049
given	VERB	O	O	2049
prilocaine	NOUN	O	O	2049
were	AUX	O	O	2049
more	ADJ	O	O	2049
likely	ADV	O	O	2049
to	PART	O	O	2049
develop	VERB	O	O	2049
hearing loss	NOUN	O	Disease	2049
(	PUNCT	O	O	2049
10	NUM	O	O	2049
out	ADP	O	O	2049
of	ADP	O	O	2049
22	NUM	O	O	2049
)	PUNCT	O	O	2049
than	ADP	O	O	2049
those	PRON	O	O	2049
given	VERB	O	O	2049
bupivacaine	NOUN	O	Chemical	2049
(	PUNCT	O	O	2049
4	NUM	O	O	2049
out	ADP	O	O	2049
of	ADP	O	O	2049
22	NUM	O	O	2049
)	PUNCT	O	O	2049
(	PUNCT	O	O	2049
P	NOUN	O	Chemical	2049
<	X	O	O	2049
0.05	NUM	O	O	2049
)	PUNCT	O	O	2049
.	PUNCT	O	O	2049
The	PRON	O	O	2050
average	ADJ	O	O	2050
hearing loss	NOUN	O	Disease	2050
for	ADP	O	O	2050
speech	NOUN	O	O	2050
frequencies	NOUN	O	O	2050
was	AUX	O	O	2050
about	ADP	O	O	2050
10	NUM	O	O	2050
dB	NOUN	O	O	2050
after	ADP	O	O	2050
prilocaine	NOUN	O	O	2050
and	CCONJ	O	O	2050
15	NUM	O	O	2050
dB	NOUN	O	O	2050
after	ADP	O	O	2050
bupivacaine	NOUN	O	Chemical	2050
.	PUNCT	O	O	2050
None	NOUN	O	O	2051
of	ADP	O	O	2051
the	PRON	O	O	2051
patients	NOUN	O	O	2051
complained	VERB	O	O	2051
of	ADP	O	O	2051
subjective	ADJ	O	O	2051
hearing loss	NOUN	O	Disease	2051
.	PUNCT	O	O	2051
A	PRON	O	O	2054
transient	ADJ	O	O	2054
neurological	ADJ	O	O	2054
deficit	NOUN	O	O	2054
following	VERB	O	O	2054
intrathecal	ADJ	O	O	2054
injection	NOUN	O	O	2054
of	ADP	O	O	2054
1%	NOUN	O	O	2054
hyperbaric	PROPN	O	O	2054
bupivacaine	NOUN	O	Chemical	2054
for	ADP	O	O	2054
unilateral	ADJ	O	O	2054
spinal	NOUN	O	O	2054
anaesthesia	NOUN	O	O	2054
.	PUNCT	O	O	2054
We	PRON	O	O	2055
describe	VERB	O	O	2055
a	PRON	O	O	2055
case	NOUN	O	O	2055
of	ADP	O	O	2055
transient	ADJ	O	O	2055
neurological	ADJ	O	O	2055
deficit	NOUN	O	O	2055
that	SCONJ	O	O	2055
occurred	VERB	O	O	2055
after	ADP	O	O	2055
unilateral	ADJ	O	O	2055
spinal	NOUN	O	O	2055
anaesthesia	NOUN	O	O	2055
with	ADP	O	O	2055
8	NUM	O	O	2055
mg	VERB	O	O	2055
of	ADP	O	O	2055
1%	NOUN	O	O	2055
hyperbaric	PROPN	O	O	2055
bupivacaine	NOUN	O	Chemical	2055
slowly	ADV	O	O	2055
injected	VERB	O	O	2055
through	ADP	O	O	2055
a	PRON	O	O	2055
25-gauge	NOUN	O	O	2055
pencil	NOUN	O	O	2055
-	PUNCT	O	O	2055
point	VERB	O	O	2055
spinal	NOUN	O	O	2055
needle	NOUN	O	O	2055
.	PUNCT	O	O	2055
The	PRON	O	O	2056
surgery	NOUN	O	O	2056
and	CCONJ	O	O	2056
anaesthesia	NOUN	O	O	2056
were	AUX	O	O	2056
uneventful	ADJ	O	O	2056
,	PUNCT	O	O	2056
but	CCONJ	O	O	2056
3	X	O	O	2056
days	NOUN	O	O	2056
after	ADP	O	O	2056
surgery	NOUN	O	O	2056
,	PUNCT	O	O	2056
the	PRON	O	O	2056
patient	NOUN	O	O	2056
reported	VERB	O	O	2056
an	PRON	O	O	2056
area	NOUN	O	O	2056
of	ADP	O	O	2056
hypoaesthesia	NOUN	O	O	2056
over	ADP	O	O	2056
L3-L4	PROPN	O	O	2056
dermatomes	NOUN	O	O	2056
of	ADP	O	O	2056
the	PRON	O	O	2056
leg	NOUN	O	O	2056
which	PRON	O	O	2056
had	VERB	O	O	2056
been	AUX	O	O	2056
operated	VERB	O	O	2056
on	ADP	O	O	2056
(	PUNCT	O	O	2056
loss	NOUN	O	O	2056
of	ADP	O	O	2056
pinprick	PROPN	O	O	2056
sensation	NOUN	O	O	2056
)	PUNCT	O	O	2056
without	ADP	O	O	2056
reduction	NOUN	O	O	2056
in	ADP	O	O	2056
muscular	ADJ	O	O	2056
strength	NOUN	O	O	2056
.	PUNCT	O	O	2056
However	ADV	O	O	2057
,	PUNCT	O	O	2057
we	PRON	O	O	2057
suggest	VERB	O	O	2057
that	SCONJ	O	O	2057
a	PRON	O	O	2057
low	ADJ	O	O	2057
solution	NOUN	O	O	2057
concentration	NOUN	O	O	2057
should	AUX	O	O	2057
be	AUX	O	O	2057
preferred	VERB	O	O	2057
for	ADP	O	O	2057
unilateral	ADJ	O	O	2057
spinal	NOUN	O	O	2057
anaesthesia	NOUN	O	O	2057
with	ADP	O	O	2057
a	PRON	O	O	2057
hyperbaric	PROPN	O	O	2057
anaesthetic	NOUN	O	O	2057
solution	NOUN	O	O	2057
(	PUNCT	O	O	2057
if	SCONJ	O	O	2057
pencil	NOUN	O	O	2057
-	PUNCT	O	O	2057
point	VERB	O	O	2057
needle	NOUN	O	O	2057
and	CCONJ	O	O	2057
slow	VERB	O	O	2057
injection	NOUN	O	O	2057
rate	NOUN	O	O	2057
are	AUX	O	O	2057
employed	VERB	O	O	2057
)	PUNCT	O	O	2057
,	PUNCT	O	O	2057
in	ADP	O	O	2057
order	NOUN	O	O	2057
to	PART	O	O	2057
minimize	VERB	O	O	2057
the	PRON	O	O	2057
risk	NOUN	O	O	2057
of	ADP	O	O	2057
a	PRON	O	O	2057
localized	VERB	O	O	2057
high	ADJ	O	O	2057
peak	PROPN	O	O	2057
anaesthetic	NOUN	O	O	2057
concentration	NOUN	O	O	2057
,	PUNCT	O	O	2057
which	PRON	O	O	2057
might	AUX	O	O	2057
lead	VERB	O	Chemical	2057
to	PART	O	O	2057
a	PRON	O	O	2057
transient	ADJ	O	O	2057
neurological	ADJ	O	O	2057
deficit	NOUN	O	O	2057
.	PUNCT	O	O	2057
Pethidine	NOUN	O	O	2060
-	PUNCT	O	O	2060
associated	VERB	O	O	2060
seizure	NOUN	O	Disease	2060
in	ADP	O	O	2060
a	PRON	O	O	2060
healthy	ADJ	O	O	2060
adolescent	ADJ	O	O	2060
receiving	VERB	O	O	2060
pethidine	NOUN	O	O	2060
for	ADP	O	O	2060
postoperative	ADJ	O	O	2060
pain	NOUN	O	Disease	2060
control	VERB	O	O	2060
.	PUNCT	O	O	2060
A	PRON	O	O	2061
healthy	ADJ	O	O	2061
17-year	NOUN	O	O	2061
-	PUNCT	O	O	2061
old	ADJ	O	O	2061
male	NOUN	O	O	2061
received	VERB	O	O	2061
standard	PROPN	O	O	2061
intermittent	ADJ	O	O	2061
doses	NOUN	O	O	2061
of	ADP	O	O	2061
pethidine	NOUN	O	O	2061
via	ADP	O	O	2061
a	PRON	O	O	2061
patient	NOUN	O	O	2061
-	PUNCT	O	O	2061
controlled	VERB	O	O	2061
analgesia	NOUN	O	Disease	2061
(	PUNCT	O	O	2061
PCA	PROPN	O	O	2061
)	PUNCT	O	O	2061
pump	VERB	O	O	2061
for	ADP	O	O	2061
management	NOUN	O	O	2061
of	ADP	O	O	2061
postoperative	ADJ	O	O	2061
pain	NOUN	O	Disease	2061
control	VERB	O	O	2061
.	PUNCT	O	O	2061
postoperatively	PROPN	O	O	2062
he	PRON	O	O	2062
developed	VERB	O	O	2062
a	PRON	O	O	2062
brief	PROPN	O	O	2062
self	VERB	O	O	2062
-	PUNCT	O	O	2062
limited	VERB	O	O	2062
seizure	NOUN	O	Disease	2062
.	PUNCT	O	O	2062
Both	PRON	O	O	2063
plasma	NOUN	O	O	2063
pethidine	NOUN	O	O	2063
and	CCONJ	O	O	2063
norpethidine	NOUN	O	O	2063
were	AUX	O	O	2063
elevated	ADJ	O	O	2063
in	ADP	O	O	2063
the	PRON	O	O	2063
range	VERB	O	O	2063
associated	VERB	O	O	2063
with	ADP	O	O	2063
clinical	ADJ	O	O	2063
manifestations	NOUN	O	O	2063
of	ADP	O	O	2063
central	ADJ	O	O	2063
nervous	ADJ	O	O	2063
system	NOUN	O	O	2063
excitation	NOUN	O	O	2063
.	PUNCT	O	O	2063
No	PRON	O	O	2064
other	ADJ	O	O	2064
risk	NOUN	O	O	2064
factors	NOUN	O	O	2064
for	ADP	O	O	2064
CNS	PROPN	O	O	2064
toxicity	NOUN	O	Disease	2064
were	AUX	O	O	2064
identified	VERB	O	O	2064
.	PUNCT	O	O	2064
This	PRON	O	O	2065
method	NOUN	O	O	2065
allowed	VERB	O	O	2065
frequent	ADJ	O	O	2065
self	VERB	O	O	2065
-	PUNCT	O	O	2065
dosing	VERB	O	O	2065
of	ADP	O	O	2065
pethidine	NOUN	O	O	2065
at	ADP	O	O	2065
short	ADJ	O	O	2065
time	NOUN	O	O	2065
intervals	NOUN	O	O	2065
and	CCONJ	O	O	2065
rapid	ADJ	O	O	2065
accumulation	NOUN	O	O	2065
of	ADP	O	O	2065
pethidine	NOUN	O	O	2065
and	CCONJ	O	O	2065
norpethidine	NOUN	O	O	2065
.	PUNCT	O	O	2065
The	PRON	O	O	2066
routine	ADJ	O	O	2066
use	VERB	O	O	2066
of	ADP	O	O	2066
pethidine	NOUN	O	O	2066
via	ADP	O	O	2066
PCA	PROPN	O	O	2066
even	ADV	O	O	2066
for	ADP	O	O	2066
a	PRON	O	O	2066
brief	PROPN	O	O	2066
postoperative	ADJ	O	O	2066
analgesia	NOUN	O	Disease	2066
should	AUX	O	O	2066
be	AUX	O	O	2066
reconsidered	VERB	O	O	2066
.	PUNCT	O	O	2066
Drug	NOUN	O	O	2069
-	PUNCT	O	O	2069
associated	VERB	O	O	2069
acute	ADJ	O	O	2069
-	PUNCT	O	O	2069
onset	VERB	O	O	2069
vanishing	VERB	O	O	2069
bile	NOUN	O	O	2069
duct	NOUN	O	O	2069
and	CCONJ	O	O	2069
Stevens	PROPN	O	O	2069
-	PUNCT	O	O	2069
Johnson	PROPN	O	O	2069
syndromes	NOUN	O	O	2069
in	ADP	O	O	2069
a	PRON	O	O	2069
child	NOUN	O	O	2069
.	PUNCT	O	O	2069
Acute	PROPN	O	O	2070
vanishing	VERB	O	O	2070
bile	NOUN	O	O	2070
duct	NOUN	O	O	2070
syndrome	NOUN	O	O	2070
is	AUX	O	O	2070
a	PRON	O	O	2070
rare	ADJ	O	O	2070
but	CCONJ	O	O	2070
established	VERB	O	O	2070
cause	VERB	O	O	2070
of	ADP	O	O	2070
progressive	ADJ	O	O	2070
cholestasis	NOUN	O	Disease	2070
in	ADP	O	O	2070
adults	NOUN	O	O	2070
,	PUNCT	O	O	2070
is	AUX	O	O	2070
most	ADV	O	O	2070
often	ADV	O	O	2070
drug	NOUN	O	O	2070
or	CCONJ	O	O	2070
toxin	NOUN	O	O	2070
related	ADJ	O	O	2070
,	PUNCT	O	O	2070
and	CCONJ	O	O	2070
is	AUX	O	O	2070
of	ADP	O	O	2070
unknown	ADJ	O	O	2070
pathogenesis	NOUN	O	O	2070
.	PUNCT	O	O	2070
Stevens	PROPN	O	O	2071
-	PUNCT	O	O	2071
Johnson	PROPN	O	O	2071
syndrome	NOUN	O	O	2071
is	AUX	O	O	2071
a	PRON	O	O	2071
well	ADV	O	O	2071
-	PUNCT	O	O	2071
recognized	VERB	O	O	2071
immune	NOUN	O	O	2071
complex	ADJ	O	O	2071
-	PUNCT	O	O	2071
mediated	VERB	O	O	2071
hypersensitivity	NOUN	O	Disease	2071
reaction	NOUN	O	O	2071
that	SCONJ	O	O	2071
affects	VERB	O	O	2071
all	PRON	O	O	2071
age	NOUN	O	O	2071
groups	NOUN	O	O	2071
,	PUNCT	O	O	2071
is	AUX	O	O	2071
drug	NOUN	O	O	2071
or	CCONJ	O	O	2071
infection	NOUN	O	Disease	2071
induced	VERB	O	O	2071
,	PUNCT	O	O	2071
and	CCONJ	O	O	2071
has	VERB	O	O	2071
classic	ADJ	O	O	2071
systemic	ADJ	O	O	2071
,	PUNCT	O	O	2071
mucosal	ADJ	O	O	2071
,	PUNCT	O	O	2071
and	CCONJ	O	O	2071
dermatologic	ADJ	O	O	2071
manifestations	NOUN	O	O	2071
.	PUNCT	O	O	2071
A	PRON	O	O	2072
previously	ADV	O	O	2072
healthy	ADJ	O	O	2072
child	NOUN	O	O	2072
who	PRON	O	O	2072
developed	VERB	O	O	2072
acute	ADJ	O	O	2072
,	PUNCT	O	O	2072
severe	ADJ	O	O	2072
,	PUNCT	O	O	2072
rapidly	ADV	O	O	2072
progressive	ADJ	O	O	2072
vanishing	VERB	O	O	2072
bile	NOUN	O	O	2072
duct	NOUN	O	O	2072
syndrome	NOUN	O	O	2072
shortly	ADV	O	O	2072
after	ADP	O	O	2072
Stevens	PROPN	O	O	2072
-	PUNCT	O	O	2072
Johnson	PROPN	O	O	2072
syndrome	NOUN	O	O	2072
is	AUX	O	O	2072
described	VERB	O	O	2072
;	PUNCT	O	O	2072
this	PRON	O	O	2072
was	AUX	O	O	2072
temporally	ADV	O	O	2072
associated	VERB	O	O	2072
with	ADP	O	O	2072
ibuprofen	PROPN	O	Chemical	2072
use	VERB	O	O	2072
.	PUNCT	O	O	2072
Despite	SCONJ	O	O	2073
therapy	NOUN	O	O	2073
with	ADP	O	O	2073
ursodeoxycholic acid	NOUN	O	O	2073
,	PUNCT	O	O	2073
prednisone	NOUN	O	Chemical	2073
,	PUNCT	O	O	2073
and	CCONJ	O	O	2073
then	ADV	O	O	2073
tacrolimus	NOUN	O	Chemical	2073
,	PUNCT	O	O	2073
her	PRON	O	O	2073
cholestatic	ADJ	O	Disease	2073
disease	PROPN	O	O	2073
was	AUX	O	O	2073
unrelenting	ADJ	O	O	2073
,	PUNCT	O	O	2073
with	ADP	O	O	2073
cirrhosis	NOUN	O	Disease	2073
shown	VERB	O	O	2073
by	ADP	O	O	2073
biopsy	PROPN	O	O	2073
6	NUM	O	O	2073
months	NOUN	O	O	2073
after	ADP	O	O	2073
presentation	NOUN	O	O	2073
.	PUNCT	O	O	2073
This	PRON	O	O	2074
case	NOUN	O	O	2074
documents	NOUN	O	O	2074
acute	ADJ	O	O	2074
drug	NOUN	O	O	2074
-	PUNCT	O	O	2074
related	ADJ	O	O	2074
vanishing	VERB	O	O	2074
bile	NOUN	O	O	2074
duct	NOUN	O	O	2074
syndrome	NOUN	O	O	2074
in	ADP	O	O	2074
the	PRON	O	O	2074
pediatric	ADJ	O	O	2074
age	NOUN	O	O	2074
group	NOUN	O	O	2074
and	CCONJ	O	O	2074
suggests	VERB	O	O	2074
shared	VERB	O	O	2074
immune	NOUN	O	O	2074
mechanisms	NOUN	O	O	2074
in	ADP	O	O	2074
the	PRON	O	O	2074
pathogenesis	NOUN	O	O	2074
of	ADP	O	O	2074
both	PRON	O	O	2074
Stevens	PROPN	O	O	2074
-	PUNCT	O	O	2074
Johnson	PROPN	O	O	2074
syndrome	NOUN	O	O	2074
and	CCONJ	O	O	2074
vanishing	VERB	O	O	2074
bile	NOUN	O	O	2074
duct	NOUN	O	O	2074
syndrome	NOUN	O	O	2074
.	PUNCT	O	O	2074
High	ADJ	O	O	2077
incidence	NOUN	O	O	2077
of	ADP	O	O	2077
primary	NOUN	O	O	2077
pulmonary hypertension	NOUN	O	Disease	2077
associated	VERB	O	O	2077
with	ADP	O	O	2077
appetite	PROPN	O	O	2077
suppressants	NOUN	O	O	2077
in	ADP	O	O	2077
Belgium	PROPN	O	O	2077
.	PUNCT	O	O	2077
Primary	NOUN	O	O	2078
pulmonary hypertension	NOUN	O	Disease	2078
is	AUX	O	O	2078
a	PRON	O	O	2078
rare	ADJ	O	O	2078
,	PUNCT	O	O	2078
progressive	ADJ	O	O	2078
and	CCONJ	O	O	2078
incurable	ADJ	O	O	2078
disease	PROPN	O	O	2078
,	PUNCT	O	O	2078
which	PRON	O	O	2078
has	VERB	O	O	2078
been	AUX	O	O	2078
associated	VERB	O	O	2078
with	ADP	O	O	2078
the	PRON	O	O	2078
intake	PROPN	O	O	2078
of	ADP	O	O	2078
appetite	PROPN	O	O	2078
suppressant	NOUN	O	O	2078
drugs	NOUN	O	O	2078
.	PUNCT	O	O	2078
The	PRON	O	O	2079
importance	NOUN	O	O	2079
of	ADP	O	O	2079
this	PRON	O	O	2079
association	PROPN	O	O	2079
was	AUX	O	O	2079
evaluated	VERB	O	O	2079
in	ADP	O	O	2079
Belgium	PROPN	O	O	2079
while	SCONJ	O	O	2079
this	PRON	O	O	2079
country	NOUN	O	O	2079
still	ADV	O	O	2079
had	VERB	O	O	2079
no	PRON	O	O	2079
restriction	NOUN	O	O	2079
on	ADP	O	O	2079
the	PRON	O	O	2079
prescription	NOUN	O	O	2079
of	ADP	O	O	2079
appetite	PROPN	O	O	2079
suppressants	NOUN	O	O	2079
.	PUNCT	O	O	2079
Thirty	NUM	O	O	2080
-	PUNCT	O	O	2080
five	NUM	O	O	2080
patients	NOUN	O	O	2080
with	ADP	O	O	2080
primary	NOUN	O	O	2080
pulmonary hypertension	NOUN	O	Disease	2080
and	CCONJ	O	O	2080
85	NUM	O	O	2080
matched	VERB	O	O	2080
controls	VERB	O	O	2080
were	AUX	O	O	2080
recruited	VERB	O	O	2080
over	ADP	O	O	2080
32	NUM	O	O	2080
months	NOUN	O	O	2080
(	PUNCT	O	O	2080
1992	NUM	O	O	2080
-	PUNCT	O	O	2080
1994	NUM	O	O	2080
)	PUNCT	O	O	2080
in	ADP	O	O	2080
Belgium	PROPN	O	O	2080
.	PUNCT	O	O	2080
Exposure	NOUN	O	O	2081
to	PART	O	O	2081
appetite	PROPN	O	O	2081
-	PUNCT	O	O	2081
suppressants	NOUN	O	O	2081
was	AUX	O	O	2081
assessed	VERB	O	O	2081
on	ADP	O	O	2081
the	PRON	O	O	2081
basis	NOUN	O	O	2081
of	ADP	O	O	2081
hospital	PROPN	O	O	2081
records	NOUN	O	O	2081
and	CCONJ	O	O	2081
standardized	VERB	O	O	2081
interview	VERB	O	O	2081
.	PUNCT	O	O	2081
Twenty	NUM	O	O	2082
-	PUNCT	O	O	2082
three	NUM	O	O	2082
of	ADP	O	O	2082
the	PRON	O	O	2082
patients	NOUN	O	O	2082
had	VERB	O	O	2082
previously	ADV	O	O	2082
taken	VERB	O	O	2082
appetite	PROPN	O	O	2082
suppressants	NOUN	O	O	2082
,	PUNCT	O	O	2082
mainly	ADV	O	O	2082
fenfluramines	NOUN	O	O	2082
,	PUNCT	O	O	2082
as	ADP	O	O	2082
compared	VERB	O	O	2082
with	ADP	O	O	2082
only	ADV	O	O	2082
5	NUM	O	O	2082
of	ADP	O	O	2082
the	PRON	O	O	2082
controls	VERB	O	O	2082
(	PUNCT	O	O	2082
66	NUM	O	O	2082
versus	ADP	O	O	2082
6%	NOUN	O	O	2082
,	PUNCT	O	O	2082
Five	NUM	O	O	2083
patients	NOUN	O	O	2083
died	VERB	O	O	2083
before	ADP	O	O	2083
the	PRON	O	O	2083
interview	VERB	O	O	2083
,	PUNCT	O	O	2083
all	PRON	O	O	2083
of	ADP	O	O	2083
them	PRON	O	O	2083
had	VERB	O	O	2083
taken	VERB	O	O	2083
appetite	PROPN	O	O	2083
suppressants	NOUN	O	O	2083
.	PUNCT	O	O	2083
In	ADP	O	O	2084
8	NUM	O	O	2084
patients	NOUN	O	O	2084
the	PRON	O	O	2084
diagnosis	NOUN	O	O	2084
of	ADP	O	O	2084
primary	NOUN	O	O	2084
pulmonary hypertension	NOUN	O	Disease	2084
was	AUX	O	O	2084
uncertain	ADJ	O	O	2084
,	PUNCT	O	O	2084
5	NUM	O	O	2084
of	ADP	O	O	2084
them	PRON	O	O	2084
had	VERB	O	O	2084
taken	VERB	O	O	2084
appetite	PROPN	O	O	2084
suppressants	NOUN	O	O	2084
.	PUNCT	O	O	2084
The	PRON	O	O	2085
patients	NOUN	O	O	2085
who	PRON	O	O	2085
had	VERB	O	O	2085
been	AUX	O	O	2085
exposed	VERB	O	O	2085
to	PART	O	O	2085
appetite	PROPN	O	O	2085
suppressants	NOUN	O	O	2085
tended	VERB	O	O	2085
to	PART	O	O	2085
be	AUX	O	O	2085
on	ADP	O	O	2085
average	ADJ	O	O	2085
more	ADJ	O	O	2085
severely	ADV	O	O	2085
ill	PROPN	O	O	2085
,	PUNCT	O	O	2085
and	CCONJ	O	O	2085
to	PART	O	O	2085
have	VERB	O	O	2085
a	PRON	O	O	2085
shorter	ADJ	O	O	2085
median	ADJ	O	O	2085
delay	NOUN	O	O	2085
between	ADP	O	O	2085
onset	VERB	O	O	2085
of	ADP	O	O	2085
symptoms	NOUN	O	O	2085
and	CCONJ	O	O	2085
diagnosis	NOUN	O	O	2085
.	PUNCT	O	O	2085
A	PRON	O	O	2086
policy	NOUN	O	O	2086
of	ADP	O	O	2086
unrestricted	ADJ	O	O	2086
prescription	NOUN	O	O	2086
of	ADP	O	O	2086
appetite	PROPN	O	O	2086
suppressants	NOUN	O	O	2086
may	AUX	O	O	2086
lead	VERB	O	Chemical	2086
to	PART	O	O	2086
a	PRON	O	O	2086
high	ADJ	O	O	2086
incidence	NOUN	O	O	2086
of	ADP	O	O	2086
associated	VERB	O	O	2086
primary	NOUN	O	O	2086
pulmonary hypertension	NOUN	O	Disease	2086
.	PUNCT	O	O	2086
Intake	PROPN	O	O	2087
of	ADP	O	O	2087
appetite	PROPN	O	O	2087
suppressants	NOUN	O	O	2087
may	AUX	O	O	2087
accelerate	VERB	O	O	2087
the	PRON	O	O	2087
progression	NOUN	O	O	2087
of	ADP	O	O	2087
the	PRON	O	O	2087
disease	PROPN	O	O	2087
.	PUNCT	O	O	2087
Choreoathetoid	NOUN	O	O	2090
movements	NOUN	O	O	2090
associated	VERB	O	O	2090
with	ADP	O	O	2090
rapid	ADJ	O	O	2090
adjustment	NOUN	O	O	2090
to	PART	O	O	2090
methadone	NOUN	O	Chemical	2090
.	PUNCT	O	O	2090
Choreatiform	NOUN	O	O	2091
hyperkinesias	VERB	O	O	2091
are	AUX	O	O	2091
known	VERB	O	O	2091
to	PART	O	O	2091
be	AUX	O	O	2091
occasional	ADJ	O	O	2091
movement	NOUN	O	O	2091
abnormalities	NOUN	O	O	2091
during	ADP	O	O	2091
intoxications	NOUN	O	O	2091
with	ADP	O	O	2091
cocaine	NOUN	O	Chemical	2091
but	CCONJ	O	O	2091
not	PART	O	O	2091
opiates	NOUN	O	O	2091
.	PUNCT	O	O	2091
This	PRON	O	O	2092
is	AUX	O	O	2092
a	PRON	O	O	2092
case	NOUN	O	O	2092
report	VERB	O	O	2092
of	ADP	O	O	2092
euphoria	PROPN	O	O	2092
and	CCONJ	O	O	2092
choreoathetoid	NOUN	O	Disease	2092
movements	NOUN	O	O	2092
both	PRON	O	O	2092
transiently	ADV	O	O	2092
induced	VERB	O	O	2092
by	ADP	O	O	2092
rapid	ADJ	O	O	2092
adjustment	NOUN	O	O	2092
to	PART	O	O	2092
the	PRON	O	O	2092
selective	ADJ	O	O	2092
mu	NOUN	O	O	2092
-	PUNCT	O	O	2092
opioid	NOUN	O	O	2092
receptor	NOUN	O	O	2092
agonist	NOUN	O	O	2092
methadone	NOUN	O	Chemical	2092
in	ADP	O	O	2092
an	PRON	O	O	2092
inpatient	ADJ	O	O	2092
previously	ADV	O	O	2092
abusing	VERB	O	O	2092
heroine	NOUN	O	O	2092
and	CCONJ	O	O	2092
cocaine	NOUN	O	Chemical	2092
.	PUNCT	O	O	2092
Cocaine	NOUN	O	Chemical	2095
-	PUNCT	O	O	2095
induced	VERB	O	O	2095
mood	NOUN	O	O	2095
disorder	NOUN	O	O	2095
:	PUNCT	O	O	2095
prevalence	NOUN	O	O	2095
rates	NOUN	O	O	2095
and	CCONJ	O	O	2095
psychiatric	ADJ	O	Disease	2095
symptoms	NOUN	O	O	2095
in	ADP	O	O	2095
an	PRON	O	O	2095
outpatient	NOUN	O	O	2095
cocaine	NOUN	O	Chemical	2095
-	PUNCT	O	O	2095
dependent	ADJ	O	O	2095
sample	NOUN	O	O	2095
.	PUNCT	O	O	2095
This	PRON	O	O	2096
paper	PROPN	O	O	2096
attempts	VERB	O	O	2096
to	PART	O	O	2096
examine	VERB	O	O	2096
and	CCONJ	O	O	2096
compare	VERB	O	O	2096
prevalence	NOUN	O	O	2096
rates	NOUN	O	O	2096
and	CCONJ	O	O	2096
symptom	NOUN	O	O	2096
patterns	NOUN	O	O	2096
of	ADP	O	O	2096
DSM	PROPN	O	O	2096
substance	NOUN	O	O	2096
-	PUNCT	O	O	2096
induced	VERB	O	O	2096
and	CCONJ	O	O	2096
other	ADJ	O	O	2096
mood	NOUN	O	O	2096
disorders	NOUN	O	O	2096
.	PUNCT	O	O	2096
243	NUM	O	O	2097
cocaine	NOUN	O	Chemical	2097
-	PUNCT	O	O	2097
dependent	ADJ	O	O	2097
outpatients	NOUN	O	O	2097
with	ADP	O	O	2097
cocaine	NOUN	O	Chemical	2097
-	PUNCT	O	O	2097
induced	VERB	O	O	2097
mood	NOUN	O	O	2097
disorder	NOUN	O	O	2097
(	PUNCT	O	O	2097
CIMD	X	O	O	2097
)	PUNCT	O	O	2097
,	PUNCT	O	O	2097
other	ADJ	O	O	2097
mood	NOUN	O	O	2097
disorders	NOUN	O	O	2097
,	PUNCT	O	O	2097
or	CCONJ	O	O	2097
no	PRON	O	O	2097
mood	NOUN	O	O	2097
disorder	NOUN	O	O	2097
were	AUX	O	O	2097
compared	VERB	O	O	2097
on	ADP	O	O	2097
measures	NOUN	O	O	2097
of	ADP	O	O	2097
psychiatric	ADJ	O	Disease	2097
symptoms	NOUN	O	O	2097
.	PUNCT	O	O	2097
The	PRON	O	O	2098
prevalence	NOUN	O	O	2098
rate	NOUN	O	O	2098
for	ADP	O	O	2098
CIMD	X	O	O	2098
was	AUX	O	O	2098
12%	NOUN	O	O	2098
at	ADP	O	O	2098
baseline	VERB	O	O	2098
.	PUNCT	O	O	2098
Introduction	NOUN	O	O	2099
of	ADP	O	O	2099
the	PRON	O	O	2099
DSM	PROPN	O	O	2099
-	PUNCT	O	O	2099
IV	NUM	O	O	2099
diagnosis	NOUN	O	O	2099
of	ADP	O	O	2099
CIMD	X	O	O	2099
did	VERB	O	O	2099
not	PART	O	O	2099
substantially	ADV	O	O	2099
affect	VERB	O	O	2099
rates	NOUN	O	O	2099
of	ADP	O	O	2099
the	PRON	O	O	2099
other	ADJ	O	O	2099
depressive	ADJ	O	Disease	2099
disorders	NOUN	O	O	2099
.	PUNCT	O	O	2099
Patients	NOUN	O	O	2100
with	ADP	O	O	2100
CIMD	X	O	O	2100
had	VERB	O	O	2100
symptom	NOUN	O	O	2100
severity	NOUN	O	O	2100
levels	NOUN	O	O	2100
between	ADP	O	O	2100
those	PRON	O	O	2100
of	ADP	O	O	2100
patients	NOUN	O	O	2100
with	ADP	O	O	2100
and	CCONJ	O	O	2100
without	ADP	O	O	2100
a	PRON	O	O	2100
mood	NOUN	O	O	2100
disorder	NOUN	O	O	2100
.	PUNCT	O	O	2100
These	PRON	O	O	2101
findings	NOUN	O	O	2101
suggest	VERB	O	O	2101
some	PRON	O	O	2101
validity	NOUN	O	O	2101
for	ADP	O	O	2101
the	PRON	O	O	2101
new	ADJ	O	O	2101
DSM	PROPN	O	O	2101
-	PUNCT	O	O	2101
IV	NUM	O	O	2101
diagnosis	NOUN	O	O	2101
of	ADP	O	O	2101
CIMD	X	O	O	2101
,	PUNCT	O	O	2101
but	CCONJ	O	O	2101
also	ADV	O	O	2101
suggest	VERB	O	O	2101
that	SCONJ	O	O	2101
it	PRON	O	O	2101
requires	VERB	O	O	2101
further	ADV	O	O	2101
specification	NOUN	O	O	2101
and	CCONJ	O	O	2101
replication	NOUN	O	O	2101
.	PUNCT	O	O	2101
Hemolysis	NOUN	O	O	2104
of	ADP	O	O	2104
human	PROPN	O	O	2104
erythrocytes	VERB	O	O	2104
induced	VERB	O	O	2104
by	ADP	O	O	2104
tamoxifen	PROPN	O	Chemical	2104
is	AUX	O	O	2104
related	ADJ	O	O	2104
to	PART	O	O	2104
disruption	NOUN	O	O	2104
of	ADP	O	O	2104
membrane	NOUN	O	O	2104
structure	NOUN	O	O	2104
.	PUNCT	O	O	2104
Tamoxifen	NOUN	O	Chemical	2105
(	PUNCT	O	O	2105
TAM	PROPN	O	O	2105
)	PUNCT	O	O	2105
,	PUNCT	O	O	2105
the	PRON	O	O	2105
antiestrogenic	ADJ	O	O	2105
drug	NOUN	O	O	2105
most	ADV	O	O	2105
widely	ADV	O	O	2105
prescribed	VERB	O	O	2105
in	ADP	O	O	2105
the	PRON	O	O	2105
chemotherapy	NOUN	O	O	2105
of	ADP	O	O	2105
breast cancer	NOUN	O	Disease	2105
,	PUNCT	O	O	2105
induces	VERB	O	O	2105
changes	VERB	O	O	2105
in	ADP	O	O	2105
normal	ADJ	O	O	2105
discoid	NOUN	O	O	2105
shape	NOUN	O	O	2105
of	ADP	O	O	2105
erythrocytes	VERB	O	O	2105
and	CCONJ	O	O	2105
hemolytic anemia	NOUN	O	Disease	2105
.	PUNCT	O	O	2105
This	PRON	O	O	2106
work	NOUN	O	O	2106
evaluates	VERB	O	O	2106
the	PRON	O	O	2106
effects	NOUN	O	O	2106
of	ADP	O	O	2106
TAM	PROPN	O	O	2106
on	ADP	O	O	2106
isolated	VERB	O	O	2106
human	PROPN	O	O	2106
erythrocytes	VERB	O	O	2106
,	PUNCT	O	O	2106
attempting	VERB	O	O	2106
to	PART	O	O	2106
identify	VERB	O	O	2106
the	PRON	O	O	2106
underlying	VERB	O	O	2106
mechanisms	NOUN	O	O	2106
on	ADP	O	O	2106
TAM	PROPN	O	O	2106
-	PUNCT	O	O	2106
induced	VERB	O	O	2106
hemolytic anemia	NOUN	O	Disease	2106
and	CCONJ	O	O	2106
the	PRON	O	O	2106
involvement	NOUN	O	O	2106
of	ADP	O	O	2106
biomembranes	NOUN	O	O	2106
in	ADP	O	O	2106
its	PRON	O	O	2106
cytostatic	ADJ	O	O	2106
action	NOUN	O	O	2106
mechanisms	NOUN	O	O	2106
.	PUNCT	O	O	2106
TAM	PROPN	O	O	2107
induces	VERB	O	O	2107
hemolysis	NOUN	O	Disease	2107
of	ADP	O	O	2107
erythrocytes	VERB	O	O	2107
as	ADP	O	O	2107
a	PRON	O	O	2107
function	NOUN	O	O	2107
of	ADP	O	O	2107
concentration	NOUN	O	O	2107
.	PUNCT	O	O	2107
The	PRON	O	O	2108
extension	NOUN	O	O	2108
of	ADP	O	O	2108
hemolysis	NOUN	O	Disease	2108
is	AUX	O	O	2108
variable	NOUN	O	O	2108
with	ADP	O	O	2108
erythrocyte	PROPN	O	O	2108
samples	NOUN	O	O	2108
,	PUNCT	O	O	2108
but	CCONJ	O	O	2108
12.5	NUM	O	O	2108
microM	ADJ	O	O	2108
TAM	PROPN	O	O	2108
induces	VERB	O	O	2108
total	ADJ	O	O	2108
hemolysis	NOUN	O	Disease	2108
of	ADP	O	O	2108
all	PRON	O	O	2108
tested	VERB	O	O	2108
suspensions	NOUN	O	O	2108
.	PUNCT	O	O	2108
Despite	SCONJ	O	O	2109
inducing	VERB	O	O	2109
extensive	ADJ	O	O	2109
erythrocyte	PROPN	O	O	2109
lysis	NOUN	O	O	2109
,	PUNCT	O	O	2109
TAM	PROPN	O	O	2109
does	VERB	O	O	2109
not	PART	O	O	2109
shift	NOUN	O	O	2109
the	PRON	O	O	2109
osmotic	NOUN	O	O	2109
fragility	NOUN	O	O	2109
curves	NOUN	O	O	2109
of	ADP	O	O	2109
erythrocytes	VERB	O	O	2109
.	PUNCT	O	O	2109
The	PRON	O	O	2110
hemolytic	ADJ	O	O	2110
effect	VERB	O	O	2110
of	ADP	O	O	2110
TAM	PROPN	O	O	2110
is	AUX	O	O	2110
prevented	VERB	O	O	2110
by	ADP	O	O	2110
low	ADJ	O	O	2110
concentrations	NOUN	O	O	2110
of	ADP	O	O	2110
alpha	PROPN	O	O	2110
-	PUNCT	O	O	2110
tocopherol	NOUN	O	O	2110
(	PUNCT	O	O	2110
alpha	PROPN	O	O	2110
-	PUNCT	O	O	2110
T	NOUN	O	Chemical	2110
)	PUNCT	O	O	2110
and	CCONJ	O	O	2110
alpha	PROPN	O	O	2110
-	PUNCT	O	O	2110
tocopherol	NOUN	O	O	2110
acetate	NOUN	O	O	2110
(	PUNCT	O	O	2110
alpha	PROPN	O	O	2110
-	PUNCT	O	O	2110
TAc	PROPN	O	O	2110
)	PUNCT	O	O	2110
(	PUNCT	O	O	2110
inactivated	VERB	O	O	2110
functional	ADJ	O	O	2110
hydroxyl	PROPN	O	O	2110
)	PUNCT	O	O	2110
indicating	VERB	O	O	2110
that	SCONJ	O	O	2110
TAM	PROPN	O	O	2110
-	PUNCT	O	O	2110
induced	VERB	O	O	2110
hemolysis	NOUN	O	Disease	2110
is	AUX	O	O	2110
not	PART	O	O	2110
related	ADJ	O	O	2110
to	PART	O	O	2110
oxidative	NOUN	O	O	2110
membrane	NOUN	O	O	2110
damage	NOUN	O	O	2110
.	PUNCT	O	O	2110
This	PRON	O	O	2111
was	AUX	O	O	2111
further	ADV	O	O	2111
evidenced	VERB	O	O	2111
by	ADP	O	O	2111
absence	NOUN	O	O	2111
of	ADP	O	O	2111
oxygen	NOUN	O	Chemical	2111
consumption	NOUN	O	O	2111
and	CCONJ	O	O	2111
hemoglobin	NOUN	O	O	2111
oxidation	ADV	O	O	2111
both	PRON	O	O	2111
determined	VERB	O	O	2111
in	ADP	O	O	2111
parallel	ADJ	O	O	2111
with	ADP	O	O	2111
TAM	PROPN	O	O	2111
-	PUNCT	O	O	2111
induced	VERB	O	O	2111
hemolysis	NOUN	O	Disease	2111
.	PUNCT	O	O	2111
Furthermore	ADV	O	O	2112
,	PUNCT	O	O	2112
it	PRON	O	O	2112
was	AUX	O	O	2112
observed	VERB	O	O	2112
that	SCONJ	O	O	2112
TAM	PROPN	O	O	2112
inhibits	VERB	O	O	2112
the	PRON	O	O	2112
peroxidation	NOUN	O	O	2112
of	ADP	O	O	2112
human	PROPN	O	O	2112
erythrocytes	VERB	O	O	2112
induced	VERB	O	O	2112
by	ADP	O	O	2112
AAPH	PROPN	O	O	2112
,	PUNCT	O	O	2112
thus	ADV	O	O	2112
ruling	VERB	O	O	2112
out	ADP	O	O	2112
TAM	PROPN	O	O	2112
-	PUNCT	O	O	2112
induced	VERB	O	O	2112
cell	NOUN	O	O	2112
oxidative	NOUN	O	O	2112
stress	NOUN	O	O	2112
.	PUNCT	O	O	2112
Hemolysis	NOUN	O	O	2113
caused	VERB	O	O	2113
by	ADP	O	O	2113
TAM	PROPN	O	O	2113
was	AUX	O	O	2113
not	PART	O	O	2113
preceded	VERB	O	O	2113
by	ADP	O	O	2113
the	PRON	O	O	2113
leakage	NOUN	O	O	2113
of	ADP	O	O	2113
K(+	NOUN	O	O	2113
)	PUNCT	O	O	2113
from	ADP	O	O	2113
the	PRON	O	O	2113
cells	NOUN	O	O	2113
,	PUNCT	O	O	2113
also	ADV	O	O	2113
excluding	VERB	O	O	2113
a	PRON	O	O	2113
colloid	PROPN	O	O	2113
-	PUNCT	O	O	2113
osmotic	NOUN	O	O	2113
type	NOUN	O	O	2113
mechanism	NOUN	O	O	2113
of	ADP	O	O	2113
hemolysis	NOUN	O	Disease	2113
,	PUNCT	O	O	2113
according	VERB	O	O	2113
to	PART	O	O	2113
the	PRON	O	O	2113
effects	NOUN	O	O	2113
on	ADP	O	O	2113
osmotic	NOUN	O	O	2113
fragility	NOUN	O	O	2113
curves	NOUN	O	O	2113
.	PUNCT	O	O	2113
However	ADV	O	O	2114
,	PUNCT	O	O	2114
TAM	PROPN	O	O	2114
induces	VERB	O	O	2114
release	NOUN	O	O	2114
of	ADP	O	O	2114
peripheral	ADJ	O	O	2114
proteins	NOUN	O	O	2114
of	ADP	O	O	2114
membrane	NOUN	O	O	2114
-	PUNCT	O	O	2114
cytoskeleton	NOUN	O	O	2114
and	CCONJ	O	O	2114
cytosol	PROPN	O	O	2114
proteins	NOUN	O	O	2114
essentially	ADV	O	O	2114
bound	VERB	O	O	2114
to	PART	O	O	2114
band	NOUN	O	O	2114
3	X	O	O	2114
.	PUNCT	O	O	2114
Either	ADV	O	O	2115
alpha	PROPN	O	O	2115
-	PUNCT	O	O	2115
T	NOUN	O	Chemical	2115
or	CCONJ	O	O	2115
alpha	PROPN	O	O	2115
-	PUNCT	O	O	2115
TAc	PROPN	O	O	2115
increases	VERB	O	O	2115
membrane	NOUN	O	O	2115
packing	VERB	O	O	2115
and	CCONJ	O	O	2115
prevents	VERB	O	O	2115
TAM	PROPN	O	O	2115
partition	NOUN	O	O	2115
into	ADP	O	O	2115
model	NOUN	O	O	2115
membranes	NOUN	O	O	2115
.	PUNCT	O	O	2115
These	PRON	O	O	2116
effects	NOUN	O	O	2116
suggest	VERB	O	O	2116
that	SCONJ	O	O	2116
the	PRON	O	O	2116
protection	NOUN	O	O	2116
from	ADP	O	O	2116
hemolysis	NOUN	O	Disease	2116
by	ADP	O	O	2116
tocopherols	NOUN	O	O	2116
is	AUX	O	O	2116
related	ADJ	O	O	2116
to	PART	O	O	2116
a	PRON	O	O	2116
decreased	VERB	O	O	2116
TAM	PROPN	O	O	2116
incorporation	NOUN	O	O	2116
in	ADP	O	O	2116
condensed	VERB	O	O	2116
membranes	NOUN	O	O	2116
and	CCONJ	O	O	2116
the	PRON	O	O	2116
structural	ADJ	O	O	2116
damage	NOUN	O	O	2116
of	ADP	O	O	2116
the	PRON	O	O	2116
erythrocyte	PROPN	O	O	2116
membrane	NOUN	O	O	2116
is	AUX	O	O	2116
consequently	ADV	O	O	2116
avoided	VERB	O	O	2116
.	PUNCT	O	O	2116
Therefore	ADV	O	O	2117
,	PUNCT	O	O	2117
TAM	PROPN	O	O	2117
-	PUNCT	O	O	2117
induced	VERB	O	O	2117
hemolysis	NOUN	O	Disease	2117
results	VERB	O	O	2117
from	ADP	O	O	2117
a	PRON	O	O	2117
structural	ADJ	O	O	2117
perturbation	NOUN	O	O	2117
of	ADP	O	O	2117
red	ADJ	O	O	2117
cell	NOUN	O	O	2117
membrane	NOUN	O	O	2117
,	PUNCT	O	O	2117
leading	VERB	O	O	2117
to	PART	O	O	2117
changes	VERB	O	O	2117
in	ADP	O	O	2117
the	PRON	O	O	2117
framework	NOUN	O	O	2117
of	ADP	O	O	2117
the	PRON	O	O	2117
erythrocyte	PROPN	O	O	2117
membrane	NOUN	O	O	2117
and	CCONJ	O	O	2117
its	PRON	O	O	2117
cytoskeleton	NOUN	O	O	2117
caused	VERB	O	O	2117
by	ADP	O	O	2117
its	PRON	O	O	2117
high	ADJ	O	O	2117
partition	NOUN	O	O	2117
in	ADP	O	O	2117
the	PRON	O	O	2117
membrane	NOUN	O	O	2117
.	PUNCT	O	O	2117
These	PRON	O	O	2118
defects	NOUN	O	O	2118
explain	VERB	O	O	2118
the	PRON	O	O	2118
abnormal	ADJ	O	O	2118
erythrocyte	PROPN	O	O	2118
shape	NOUN	O	O	2118
and	CCONJ	O	O	2118
decreased	VERB	O	O	2118
mechanical	ADJ	O	O	2118
stability	PROPN	O	O	2118
promoted	VERB	O	O	2118
by	ADP	O	O	2118
TAM	PROPN	O	O	2118
,	PUNCT	O	O	2118
resulting	VERB	O	O	2118
in	ADP	O	O	2118
hemolytic anemia	NOUN	O	Disease	2118
.	PUNCT	O	O	2118
Additionally	ADV	O	O	2119
,	PUNCT	O	O	2119
since	SCONJ	O	O	2119
membrane	NOUN	O	O	2119
leakage	NOUN	O	O	2119
is	AUX	O	O	2119
a	PRON	O	O	2119
final	ADJ	O	O	2119
stage	NOUN	O	O	2119
of	ADP	O	O	2119
cytotoxicity	NOUN	O	Disease	2119
,	PUNCT	O	O	2119
the	PRON	O	O	2119
disruption	NOUN	O	O	2119
of	ADP	O	O	2119
the	PRON	O	O	2119
structural	ADJ	O	O	2119
characteristics	NOUN	O	O	2119
of	ADP	O	O	2119
biomembranes	NOUN	O	O	2119
by	ADP	O	O	2119
TAM	PROPN	O	O	2119
may	AUX	O	O	2119
contribute	VERB	O	O	2119
to	PART	O	O	2119
the	PRON	O	O	2119
multiple	ADJ	O	O	2119
mechanisms	NOUN	O	O	2119
of	ADP	O	O	2119
its	PRON	O	O	2119
anticancer	NOUN	O	O	2119
action	NOUN	O	O	2119
.	PUNCT	O	O	2119
Changes	NOUN	O	O	2122
of	ADP	O	O	2122
sodium	NOUN	O	Chemical	2122
and	CCONJ	O	O	2122
ATP	PROPN	O	Chemical	2122
affinities	VERB	O	O	2122
of	ADP	O	O	2122
the	PRON	O	O	2122
cardiac	ADJ	O	O	2122
(	PUNCT	O	O	2122
Na	INTJ	O	Chemical	2122
,	PUNCT	O	O	2122
K)-ATPase	PROPN	O	O	2122
during	ADP	O	O	2122
and	CCONJ	O	O	2122
after	ADP	O	O	2122
nitric oxide	NOUN	O	Chemical	2122
deficient	ADJ	O	O	2122
hypertension	NOUN	O	Disease	2122
.	PUNCT	O	O	2122
In	ADP	O	O	2123
the	PRON	O	O	2123
cardiovascular	ADJ	O	O	2123
system	NOUN	O	O	2123
,	PUNCT	O	O	2123
NO	PRON	O	Chemical	2123
is	AUX	O	O	2123
involved	VERB	O	O	2123
in	ADP	O	O	2123
the	PRON	O	O	2123
regulation	NOUN	O	O	2123
of	ADP	O	O	2123
a	PRON	O	O	2123
variety	NOUN	O	O	2123
of	ADP	O	O	2123
functions	VERB	O	O	2123
.	PUNCT	O	O	2123
Inhibition	NOUN	O	O	2124
of	ADP	O	O	2124
NO	PRON	O	Chemical	2124
synthesis	NOUN	O	O	2124
induces	VERB	O	O	2124
sustained	VERB	O	O	2124
hypertension	NOUN	O	Disease	2124
.	PUNCT	O	O	2124
In	ADP	O	O	2125
several	ADJ	O	O	2125
models	NOUN	O	O	2125
of	ADP	O	O	2125
hypertension	NOUN	O	Disease	2125
,	PUNCT	O	O	2125
elevation	NOUN	O	O	2125
of	ADP	O	O	2125
intracellular	ADJ	O	O	2125
sodium	NOUN	O	Chemical	2125
level	VERB	O	O	2125
was	AUX	O	O	2125
documented	VERB	O	O	2125
in	ADP	O	O	2125
cardiac	ADJ	O	O	2125
tissue	NOUN	O	O	2125
.	PUNCT	O	O	2125
To	PART	O	O	2126
assess	VERB	O	O	2126
the	PRON	O	O	2126
molecular	ADJ	O	O	2126
basis	NOUN	O	O	2126
of	ADP	O	O	2126
disturbances	NOUN	O	O	2126
in	ADP	O	O	2126
transmembraneous	ADJ	O	O	2126
transport	NOUN	O	O	2126
of	ADP	O	O	2126
Na+	X	O	O	2126
,	PUNCT	O	O	2126
we	PRON	O	O	2126
studied	VERB	O	O	2126
the	PRON	O	O	2126
response	NOUN	O	O	2126
of	ADP	O	O	2126
cardiac	ADJ	O	O	2126
(	PUNCT	O	O	2126
Na	INTJ	O	Chemical	2126
,	PUNCT	O	O	2126
K)-ATPase	PROPN	O	O	2126
to	PART	O	O	2126
NO	PRON	O	Chemical	2126
-	PUNCT	O	O	2126
deficient	ADJ	O	O	2126
hypertension	NOUN	O	Disease	2126
induced	VERB	O	O	2126
in	ADP	O	O	2126
rats	NOUN	O	O	2126
by	ADP	O	O	2126
NO	PRON	O	Chemical	2126
-	PUNCT	O	O	2126
synthase	NOUN	O	O	2126
inhibition	NOUN	O	O	2126
with	ADP	O	O	2126
40	NUM	O	O	2126
mg	VERB	O	O	2126
/	PUNCT	O	O	2126
kg	VERB	O	O	2126
/	PUNCT	O	O	2126
day	NOUN	O	O	2126
N(G)-nitro	NUM	O	O	2127
-	PUNCT	O	O	2127
L	NOUN	O	O	2127
-	PUNCT	O	O	2127
arginine	PROPN	O	O	2127
methyl	NOUN	O	O	2127
ester	PROPN	O	O	2127
(	PUNCT	O	O	2127
L	NOUN	O	O	2127
-	PUNCT	O	O	2127
NAME	NOUN	O	O	2127
)	PUNCT	O	O	2127
for	ADP	O	O	2127
4	NUM	O	O	2127
four	NUM	O	O	2127
weeks	NOUN	O	O	2127
.	PUNCT	O	O	2127
After	ADP	O	O	2128
4-week	NOUN	O	O	2128
administration	NOUN	O	O	2128
of	ADP	O	O	2128
L	NOUN	O	O	2128
-	PUNCT	O	O	2128
NAME	NOUN	O	O	2128
,	PUNCT	O	O	2128
the	PRON	O	O	2128
systolic	ADV	O	O	2128
blood	NOUN	O	O	2128
pressure	NOUN	O	O	2128
(	PUNCT	O	O	2128
SBP	NOUN	O	O	2128
)	PUNCT	O	O	2128
increased	VERB	O	O	2128
by	ADP	O	O	2128
36%	NOUN	O	O	2128
.	PUNCT	O	O	2128
When	SCONJ	O	O	2129
activating	VERB	O	O	2129
the	PRON	O	O	2129
(	PUNCT	O	O	2129
Na	INTJ	O	Chemical	2129
,	PUNCT	O	O	2129
K)-ATPase	PROPN	O	O	2129
with	ADP	O	O	2129
its	PRON	O	O	2129
substrate	NOUN	O	O	2129
ATP	PROPN	O	Chemical	2129
,	PUNCT	O	O	2129
no	PRON	O	O	2129
changes	VERB	O	O	2129
in	ADP	O	O	2129
Km	PROPN	O	O	2129
and	CCONJ	O	O	2129
Vmax	PROPN	O	O	2129
values	NOUN	O	O	2129
were	AUX	O	O	2129
observed	VERB	O	O	2129
in	ADP	O	O	2129
NO	PRON	O	Chemical	2129
-	PUNCT	O	O	2129
deficient	ADJ	O	O	2129
rats	NOUN	O	O	2129
.	PUNCT	O	O	2129
During	ADP	O	O	2130
activation	NOUN	O	O	2130
with	ADP	O	O	2130
Na+	X	O	O	2130
,	PUNCT	O	O	2130
the	PRON	O	O	2130
Vmax	PROPN	O	O	2130
remained	VERB	O	O	2130
unchanged	ADJ	O	O	2130
,	PUNCT	O	O	2130
however	ADV	O	O	2130
the	PRON	O	O	2130
K(Na	ADP	O	O	2130
)	PUNCT	O	O	2130
increased	VERB	O	O	2130
by	ADP	O	O	2130
50%	NOUN	O	O	2130
,	PUNCT	O	O	2130
indicating	VERB	O	O	2130
a	PRON	O	O	2130
profound	ADJ	O	O	2130
decrease	VERB	O	O	2130
in	ADP	O	O	2130
the	PRON	O	O	2130
affinity	NOUN	O	O	2130
of	ADP	O	O	2130
the	PRON	O	O	2130
Na+-binding	VERB	O	O	2130
site	NOUN	O	O	2130
in	ADP	O	O	2130
NO	PRON	O	Chemical	2130
-	PUNCT	O	O	2130
deficient	ADJ	O	O	2130
rats	NOUN	O	O	2130
.	PUNCT	O	O	2130
After	ADP	O	O	2131
recovery	NOUN	O	O	2131
from	ADP	O	O	2131
hypertension	NOUN	O	Disease	2131
,	PUNCT	O	O	2131
the	PRON	O	O	2131
activity	NOUN	O	O	2131
of	ADP	O	O	2131
(	PUNCT	O	O	2131
Na	INTJ	O	Chemical	2131
,	PUNCT	O	O	2131
K)-ATPase	PROPN	O	O	2131
increased	VERB	O	O	2131
,	PUNCT	O	O	2131
due	ADJ	O	O	2131
to	PART	O	O	2131
higher	ADJ	O	O	2131
affinity	NOUN	O	O	2131
of	ADP	O	O	2131
the	PRON	O	O	2131
ATP	PROPN	O	Chemical	2131
-	PUNCT	O	O	2131
binding	VERB	O	O	2131
site	NOUN	O	O	2131
,	PUNCT	O	O	2131
as	ADP	O	O	2131
revealed	VERB	O	O	2131
from	ADP	O	O	2131
the	PRON	O	O	2131
lowered	VERB	O	O	2131
Km	PROPN	O	O	2131
value	NOUN	O	O	2131
for	ADP	O	O	2131
ATP	PROPN	O	Chemical	2131
.	PUNCT	O	O	2131
The	PRON	O	O	2132
K(Na	ADP	O	O	2132
)	PUNCT	O	O	2132
value	NOUN	O	O	2132
for	ADP	O	O	2132
Na+	X	O	O	2132
returned	VERB	O	O	2132
to	PART	O	O	2132
control	VERB	O	O	2132
value	NOUN	O	O	2132
.	PUNCT	O	O	2132
Inhibition	NOUN	O	O	2133
of	ADP	O	O	2133
NO	PRON	O	Chemical	2133
-	PUNCT	O	O	2133
synthase	NOUN	O	O	2133
induced	VERB	O	O	2133
a	PRON	O	O	2133
reversible	ADJ	O	O	2133
hypertension	NOUN	O	Disease	2133
accompanied	VERB	O	O	2133
by	ADP	O	O	2133
depressed	ADJ	O	O	2133
Na+-extrusion	NOUN	O	O	2133
from	ADP	O	O	2133
cardiac	ADJ	O	O	2133
cells	NOUN	O	O	2133
as	ADP	O	O	2133
a	PRON	O	O	2133
consequence	NOUN	O	O	2133
of	ADP	O	O	2133
deteriorated	VERB	O	O	2133
Na+-binding	VERB	O	O	2133
properties	NOUN	O	O	2133
of	ADP	O	O	2133
the	PRON	O	O	2133
(	PUNCT	O	O	2133
Na	INTJ	O	Chemical	2133
,	PUNCT	O	O	2133
K)-ATPase	PROPN	O	O	2133
.	PUNCT	O	O	2133
After	ADP	O	O	2134
recovery	NOUN	O	O	2134
of	ADP	O	O	2134
blood	NOUN	O	O	2134
pressure	NOUN	O	O	2134
to	PART	O	O	2134
control	VERB	O	O	2134
values	NOUN	O	O	2134
,	PUNCT	O	O	2134
the	PRON	O	O	2134
extrusion	NOUN	O	O	2134
of	ADP	O	O	2134
Na+	X	O	O	2134
from	ADP	O	O	2134
cardiac	ADJ	O	O	2134
cells	NOUN	O	O	2134
was	AUX	O	O	2134
normalized	VERB	O	O	2134
,	PUNCT	O	O	2134
as	ADP	O	O	2134
revealed	VERB	O	O	2134
by	ADP	O	O	2134
restoration	NOUN	O	O	2134
of	ADP	O	O	2134
the	PRON	O	O	2134
(	PUNCT	O	O	2134
Na	INTJ	O	Chemical	2134
,	PUNCT	O	O	2134
K)-ATPase	PROPN	O	O	2134
activity	NOUN	O	O	2134
.	PUNCT	O	O	2134
Effects	NOUN	O	O	2137
of	ADP	O	O	2137
long	ADV	O	O	2137
-	PUNCT	O	O	2137
term	NOUN	O	O	2137
pretreatment	NOUN	O	O	2137
with	ADP	O	O	2137
isoproterenol	NOUN	O	Chemical	2137
on	ADP	O	O	2137
bromocriptine	NOUN	O	Chemical	2137
-	PUNCT	O	O	2137
induced	VERB	O	O	2137
tachycardia	PROPN	O	Disease	2137
in	ADP	O	O	2137
conscious	ADJ	O	O	2137
rats	NOUN	O	O	2137
.	PUNCT	O	O	2137
It	PRON	O	O	2138
has	VERB	O	O	2138
been	AUX	O	O	2138
shown	VERB	O	O	2138
that	SCONJ	O	O	2138
bromocriptine	NOUN	O	Chemical	2138
-	PUNCT	O	O	2138
induced	VERB	O	O	2138
tachycardia	PROPN	O	Disease	2138
,	PUNCT	O	O	2138
which	PRON	O	O	2138
persisted	VERB	O	O	2138
after	ADP	O	O	2138
adrenalectomy	PROPN	O	O	2138
,	PUNCT	O	O	2138
is	AUX	O	O	2138
(	PUNCT	O	O	2138
i	PRON	O	O	2138
)	PUNCT	O	O	2138
mediated	VERB	O	O	2138
by	ADP	O	O	2138
central	ADJ	O	O	2138
dopamine	NOUN	O	Chemical	2138
D2	NOUN	O	O	2138
receptor	NOUN	O	O	2138
activation	NOUN	O	O	2138
and	CCONJ	O	O	2138
(	PUNCT	O	O	2138
ii	PROPN	O	O	2138
)	PUNCT	O	O	2138
reduced	VERB	O	O	2138
by	ADP	O	O	2138
5-day	NOUN	O	O	2138
isoproterenol	NOUN	O	Chemical	2138
pretreatment	NOUN	O	O	2138
,	PUNCT	O	O	2138
supporting	VERB	O	O	2138
therefore	ADV	O	O	2138
the	PRON	O	O	2138
hypothesis	NOUN	O	O	2138
that	SCONJ	O	O	2138
this	PRON	O	O	2138
effect	VERB	O	O	2138
is	AUX	O	O	2138
dependent	ADJ	O	O	2138
on	ADP	O	O	2138
sympathetic	ADJ	O	O	2138
outflow	NOUN	O	O	2138
to	PART	O	O	2138
the	PRON	O	O	2138
heart	NOUN	O	O	2138
.	PUNCT	O	O	2138
This	PRON	O	O	2139
study	VERB	O	O	2139
was	AUX	O	O	2139
conducted	VERB	O	O	2139
to	PART	O	O	2139
examine	VERB	O	O	2139
whether	SCONJ	O	O	2139
prolonged	VERB	O	O	2139
pretreatment	NOUN	O	O	2139
with	ADP	O	O	2139
isoproterenol	NOUN	O	Chemical	2139
could	AUX	O	O	2139
abolish	VERB	O	O	2139
bromocriptine	NOUN	O	Chemical	2139
-	PUNCT	O	O	2139
induced	VERB	O	O	2139
tachycardia	PROPN	O	Disease	2139
in	ADP	O	O	2139
conscious	ADJ	O	O	2139
rats	NOUN	O	O	2139
.	PUNCT	O	O	2139
Isoproterenol	NOUN	O	Chemical	2140
pretreatment	NOUN	O	O	2140
for	ADP	O	O	2140
15	NUM	O	O	2140
days	NOUN	O	O	2140
caused	VERB	O	O	2140
cardiac hypertrophy	NOUN	O	Disease	2140
without	ADP	O	O	2140
affecting	VERB	O	O	2140
baseline	VERB	O	O	2140
blood	NOUN	O	O	2140
pressure	NOUN	O	O	2140
and	CCONJ	O	O	2140
heart	NOUN	O	O	2140
rate	NOUN	O	O	2140
.	PUNCT	O	O	2140
In	ADP	O	O	2141
control	VERB	O	O	2141
rats	NOUN	O	O	2141
,	PUNCT	O	O	2141
intravenous	ADJ	O	O	2141
bromocriptine	NOUN	O	Chemical	2141
(	PUNCT	O	O	2141
150	NUM	O	O	2141
microg	PROPN	O	O	2141
/	PUNCT	O	O	2141
kg	VERB	O	O	2141
)	PUNCT	O	O	2141
induced	VERB	O	O	2141
significant	ADJ	O	O	2141
hypotension	NOUN	O	Disease	2141
and	CCONJ	O	O	2141
tachycardia	PROPN	O	Disease	2141
.	PUNCT	O	O	2141
Bromocriptine	PROPN	O	Chemical	2142
-	PUNCT	O	O	2142
induced	VERB	O	O	2142
hypotension	NOUN	O	Disease	2142
was	AUX	O	O	2142
unaffected	ADJ	O	O	2142
by	ADP	O	O	2142
isoproterenol	NOUN	O	Chemical	2142
pretreatment	NOUN	O	O	2142
,	PUNCT	O	O	2142
while	SCONJ	O	O	2142
tachycardia	PROPN	O	Disease	2142
was	AUX	O	O	2142
reversed	VERB	O	O	2142
to	PART	O	O	2142
significant	ADJ	O	O	2142
bradycardia	NOUN	O	Disease	2142
,	PUNCT	O	O	2142
an	PRON	O	O	2142
effect	VERB	O	O	2142
that	SCONJ	O	O	2142
was	AUX	O	O	2142
partly	ADV	O	O	2142
reduced	VERB	O	O	2142
by	ADP	O	O	2142
i.v	NOUN	O	O	2142
.	PUNCT	O	O	2142
domperidone	PROPN	O	O	2143
(	PUNCT	O	O	2143
0.5	NUM	O	O	2143
mg	VERB	O	O	2143
/	PUNCT	O	O	2143
kg	VERB	O	O	2143
)	PUNCT	O	O	2143
.	PUNCT	O	O	2143
Neither	PRON	O	O	2144
cardiac	ADJ	O	O	2144
vagal	ADJ	O	O	2144
nor	CCONJ	O	O	2144
sympathetic	ADJ	O	O	2144
tone	NOUN	O	O	2144
was	AUX	O	O	2144
altered	VERB	O	O	2144
by	ADP	O	O	2144
isoproterenol	NOUN	O	Chemical	2144
pretreatment	NOUN	O	O	2144
.	PUNCT	O	O	2144
In	ADP	O	O	2145
isolated	VERB	O	O	2145
perfused	VERB	O	O	2145
heart	NOUN	O	O	2145
preparations	NOUN	O	O	2145
from	ADP	O	O	2145
isoproterenol	NOUN	O	Chemical	2145
-	PUNCT	O	O	2145
pretreated	VERB	O	O	2145
rats	NOUN	O	O	2145
,	PUNCT	O	O	2145
the	PRON	O	O	2145
isoproterenol	NOUN	O	Chemical	2145
-	PUNCT	O	O	2145
induced	VERB	O	O	2145
maximal	ADJ	O	O	2145
increase	VERB	O	O	2145
in	ADP	O	O	2145
left	VERB	O	O	2145
ventricular	ADJ	O	O	2145
systolic	ADV	O	O	2145
pressure	NOUN	O	O	2145
was	AUX	O	O	2145
significantly	ADV	O	O	2145
reduced	VERB	O	O	2145
,	PUNCT	O	O	2145
compared	VERB	O	O	2145
with	ADP	O	O	2145
saline	NOUN	O	O	2145
-	PUNCT	O	O	2145
pretreated	VERB	O	O	2145
rats	NOUN	O	O	2145
(	PUNCT	O	O	2145
the	PRON	O	O	2145
EC50	NOUN	O	O	2145
of	ADP	O	O	2145
the	PRON	O	O	2145
isoproterenol	NOUN	O	Chemical	2145
-	PUNCT	O	O	2145
induced	VERB	O	O	2145
increase	VERB	O	O	2145
in	ADP	O	O	2145
left	VERB	O	O	2145
ventricular	ADJ	O	O	2145
systolic	ADV	O	O	2145
pressure	NOUN	O	O	2145
was	AUX	O	O	2145
enhanced	VERB	O	O	2145
approximately	ADV	O	O	2145
22-fold	ADV	O	O	2145
)	PUNCT	O	O	2145
.	PUNCT	O	O	2145
These	PRON	O	O	2146
results	VERB	O	O	2146
show	VERB	O	O	2146
that	SCONJ	O	O	2146
15-day	NOUN	O	O	2146
isoproterenol	NOUN	O	Chemical	2146
pretreatment	NOUN	O	O	2146
not	PART	O	O	2146
only	ADV	O	O	2146
abolished	VERB	O	O	2146
but	CCONJ	O	O	2146
reversed	VERB	O	O	2146
bromocriptine	NOUN	O	Chemical	2146
-	PUNCT	O	O	2146
induced	VERB	O	O	2146
tachycardia	PROPN	O	Disease	2146
to	PART	O	O	2146
bradycardia	NOUN	O	Disease	2146
,	PUNCT	O	O	2146
an	PRON	O	O	2146
effect	VERB	O	O	2146
that	SCONJ	O	O	2146
is	AUX	O	O	2146
mainly	ADV	O	O	2146
related	ADJ	O	O	2146
to	PART	O	O	2146
further	ADV	O	O	2146
cardiac	ADJ	O	O	2146
beta	NOUN	O	O	2146
-	PUNCT	O	O	2146
adrenoceptor	NOUN	O	O	2146
desensitization	NOUN	O	O	2146
rather	ADV	O	O	2146
than	ADP	O	O	2146
to	PART	O	O	2146
impairment	NOUN	O	O	2146
of	ADP	O	O	2146
autonomic	ADJ	O	O	2146
regulation	NOUN	O	O	2146
of	ADP	O	O	2146
the	PRON	O	O	2146
heart	NOUN	O	O	2146
.	PUNCT	O	O	2146
They	PRON	O	O	2147
suggest	VERB	O	O	2147
that	SCONJ	O	O	2147
,	PUNCT	O	O	2147
in	ADP	O	O	2147
normal	ADJ	O	O	2147
conscious	ADJ	O	O	2147
rats	NOUN	O	O	2147
,	PUNCT	O	O	2147
the	PRON	O	O	2147
central	ADJ	O	O	2147
tachycardia	PROPN	O	Disease	2147
of	ADP	O	O	2147
bromocriptine	NOUN	O	Chemical	2147
appears	VERB	O	O	2147
to	PART	O	O	2147
predominate	NOUN	O	O	2147
and	CCONJ	O	O	2147
to	PART	O	O	2147
mask	VERB	O	O	2147
the	PRON	O	O	2147
bradycardia	NOUN	O	Disease	2147
of	ADP	O	O	2147
this	PRON	O	O	2147
agonist	NOUN	O	O	2147
at	ADP	O	O	2147
peripheral	ADJ	O	O	2147
dopamine	NOUN	O	Chemical	2147
D2	NOUN	O	O	2147
receptors	NOUN	O	O	2147
.	PUNCT	O	O	2147
A	PRON	O	O	2150
developmental	ADJ	O	O	2150
analysis	NOUN	O	O	2150
of	ADP	O	O	2150
clonidine	NOUN	O	Chemical	2150
's	AUX	O	O	2150
effects	NOUN	O	O	2150
on	ADP	O	O	2150
cardiac	ADJ	O	O	2150
rate	NOUN	O	O	2150
and	CCONJ	O	O	2150
ultrasound	VERB	O	O	2150
production	NOUN	O	O	2150
in	ADP	O	O	2150
infant	NOUN	O	O	2150
rats	NOUN	O	O	2150
.	PUNCT	O	O	2150
adrenoceptor	NOUN	O	O	2151
agonist	NOUN	O	O	2151
,	PUNCT	O	O	2151
clonidine	NOUN	O	Chemical	2151
.	PUNCT	O	O	2151
Previous	ADJ	O	O	2152
investigations	NOUN	O	O	2152
have	VERB	O	O	2152
determined	VERB	O	O	2152
that	SCONJ	O	O	2152
,	PUNCT	O	O	2152
in	ADP	O	O	2152
response	NOUN	O	O	2152
to	PART	O	O	2152
clonidine	NOUN	O	Chemical	2152
,	PUNCT	O	O	2152
ultrasound	VERB	O	O	2152
production	NOUN	O	O	2152
increases	VERB	O	O	2152
through	ADP	O	O	2152
the	PRON	O	O	2152
2nd	NOUN	O	O	2152
-	PUNCT	O	O	2152
week	NOUN	O	O	2152
postpartum	PROPN	O	O	2152
and	CCONJ	O	O	2152
decreases	VERB	O	O	2152
thereafter	ADV	O	O	2152
.	PUNCT	O	O	2152
Given	VERB	O	O	2153
that	SCONJ	O	O	2153
sympathetic	ADJ	O	O	2153
neural	NOUN	O	O	2153
dominance	NOUN	O	O	2153
exhibits	VERB	O	O	2153
a	PRON	O	O	2153
similar	ADJ	O	O	2153
developmental	ADJ	O	O	2153
pattern	NOUN	O	O	2153
,	PUNCT	O	O	2153
and	CCONJ	O	O	2153
given	VERB	O	O	2153
that	SCONJ	O	O	2153
clonidine	NOUN	O	Chemical	2153
induces	VERB	O	O	2153
sympathetic	ADJ	O	O	2153
withdrawal	NOUN	O	O	2153
and	CCONJ	O	O	2153
bradycardia	NOUN	O	Disease	2153
,	PUNCT	O	O	2153
we	PRON	O	O	2153
hypothesized	VERB	O	O	2153
that	SCONJ	O	O	2153
clonidine	NOUN	O	Chemical	2153
's	AUX	O	O	2153
developmental	ADJ	O	O	2153
effects	NOUN	O	O	2153
on	ADP	O	O	2153
cardiac	ADJ	O	O	2153
rate	NOUN	O	O	2153
and	CCONJ	O	O	2153
ultrasound	VERB	O	O	2153
production	NOUN	O	O	2153
would	AUX	O	O	2153
mirror	PROPN	O	O	2153
each	PRON	O	O	2153
other	ADJ	O	O	2153
.	PUNCT	O	O	2153
Therefore	ADV	O	O	2154
,	PUNCT	O	O	2154
in	ADP	O	O	2154
the	PRON	O	O	2154
present	NOUN	O	O	2154
experiment	NOUN	O	O	2154
,	PUNCT	O	O	2154
the	PRON	O	O	2154
effects	NOUN	O	O	2154
of	ADP	O	O	2154
clonidine	NOUN	O	Chemical	2154
administration	NOUN	O	O	2154
(	PUNCT	O	O	2154
0.5	NUM	O	O	2154
mg	VERB	O	O	2154
/	PUNCT	O	O	2154
kg	VERB	O	O	2154
)	PUNCT	O	O	2154
on	ADP	O	O	2154
cardiac	ADJ	O	O	2154
rate	NOUN	O	O	2154
and	CCONJ	O	O	2154
ultrasound	VERB	O	O	2154
production	NOUN	O	O	2154
were	AUX	O	O	2154
examined	VERB	O	O	2154
in	ADP	O	O	2154
2-	X	O	O	2154
,	PUNCT	O	O	2154
8-	X	O	O	2154
,	PUNCT	O	O	2154
15-	NUM	O	O	2154
,	PUNCT	O	O	2154
and	CCONJ	O	O	2154
20-day	NOUN	O	O	2154
-	PUNCT	O	O	2154
old	ADJ	O	O	2154
rats	NOUN	O	O	2154
.	PUNCT	O	O	2154
Age	NOUN	O	O	2155
-	PUNCT	O	O	2155
related	ADJ	O	O	2155
changes	VERB	O	O	2155
in	ADP	O	O	2155
ultrasound	VERB	O	O	2155
production	NOUN	O	O	2155
corresponded	VERB	O	O	2155
with	ADP	O	O	2155
changes	VERB	O	O	2155
in	ADP	O	O	2155
cardiovascular	ADJ	O	O	2155
variables	NOUN	O	O	2155
,	PUNCT	O	O	2155
including	VERB	O	O	2155
baseline	VERB	O	O	2155
cardiac	ADJ	O	O	2155
rate	NOUN	O	O	2155
and	CCONJ	O	O	2155
clonidine	NOUN	O	Chemical	2155
-	PUNCT	O	O	2155
induced	VERB	O	O	2155
bradycardia	NOUN	O	Disease	2155
.	PUNCT	O	O	2155
This	PRON	O	O	2156
experiment	NOUN	O	O	2156
is	AUX	O	O	2156
discussed	VERB	O	O	2156
with	ADP	O	O	2156
regard	NOUN	O	O	2156
to	PART	O	O	2156
the	PRON	O	O	2156
hypothesis	NOUN	O	O	2156
that	SCONJ	O	O	2156
ultrasound	VERB	O	O	2156
production	NOUN	O	O	2156
is	AUX	O	O	2156
the	PRON	O	O	2156
acoustic	ADJ	O	O	2156
by	ADP	O	O	2156
-	PUNCT	O	O	2156
product	NOUN	O	O	2156
of	ADP	O	O	2156
a	PRON	O	O	2156
physiological	ADJ	O	O	2156
maneuver	VERB	O	O	2156
that	SCONJ	O	O	2156
compensates	VERB	O	O	2156
for	ADP	O	O	2156
clonidine	NOUN	O	Chemical	2156
's	AUX	O	O	2156
detrimental	ADJ	O	O	2156
effects	NOUN	O	O	2156
on	ADP	O	O	2156
cardiovascular	ADJ	O	O	2156
function	NOUN	O	O	2156
.	PUNCT	O	O	2156
Differential	ADJ	O	O	2159
effects	NOUN	O	O	2159
of	ADP	O	O	2159
systemically	ADV	O	O	2159
administered	VERB	O	O	2159
ketamine	VERB	O	Chemical	2159
and	CCONJ	O	O	2159
lidocaine	NOUN	O	Chemical	2159
on	ADP	O	O	2159
dynamic	ADJ	O	O	2159
and	CCONJ	O	O	2159
static	ADJ	O	O	2159
hyperalgesia	NOUN	O	Disease	2159
induced	VERB	O	O	2159
by	ADP	O	O	2159
intradermal	ADJ	O	O	2159
capsaicin	NOUN	O	Chemical	2159
in	ADP	O	O	2159
humans	NOUN	O	O	2159
.	PUNCT	O	O	2159
We	PRON	O	O	2160
have	VERB	O	O	2160
examined	VERB	O	O	2160
the	PRON	O	O	2160
effect	VERB	O	O	2160
of	ADP	O	O	2160
systemic	ADJ	O	O	2160
administration	NOUN	O	O	2160
of	ADP	O	O	2160
ketamine	VERB	O	Chemical	2160
and	CCONJ	O	O	2160
lidocaine	NOUN	O	Chemical	2160
on	ADP	O	O	2160
brush	NOUN	O	O	2160
-	PUNCT	O	O	2160
evoked	VERB	O	O	2160
(	PUNCT	O	O	2160
dynamic	ADJ	O	O	2160
)	PUNCT	O	O	2160
pain	NOUN	O	Disease	2160
and	CCONJ	O	O	2160
punctate	NOUN	O	O	2160
-	PUNCT	O	O	2160
evoked	VERB	O	O	2160
(	PUNCT	O	O	2160
static	ADJ	O	O	2160
)	PUNCT	O	O	2160
hyperalgesia	NOUN	O	Disease	2161
induced	VERB	O	O	2161
by	ADP	O	O	2161
capsaicin	NOUN	O	Chemical	2161
.	PUNCT	O	O	2161
Capsaicin	PROPN	O	O	2162
100	NUM	O	O	2162
micrograms	NOUN	O	O	2162
was	AUX	O	O	2162
injected	VERB	O	O	2162
intradermally	ADV	O	O	2162
on	ADP	O	O	2162
the	PRON	O	O	2162
volar	ADJ	O	O	2162
forearm	NOUN	O	O	2162
followed	VERB	O	O	2162
by	ADP	O	O	2162
an	PRON	O	O	2162
i.v	NOUN	O	O	2162
.	PUNCT	O	O	2162
infusion	NOUN	O	O	2163
of	ADP	O	O	2163
ketamine	VERB	O	Chemical	2163
(	PUNCT	O	O	2163
bolus	NOUN	O	O	2163
0.1	NUM	O	O	2163
mg	VERB	O	O	2163
kg-1	VERB	O	O	2163
over	ADP	O	O	2163
10	NUM	O	O	2163
min	NOUN	O	O	2163
followed	VERB	O	O	2163
by	ADP	O	O	2163
infusion	NOUN	O	O	2163
of	ADP	O	O	2163
7	NUM	O	O	2163
micrograms	NOUN	O	O	2163
kg-1	VERB	O	O	2163
min-1	VERB	O	O	2164
)	PUNCT	O	O	2164
,	PUNCT	O	O	2164
lidocaine	NOUN	O	Chemical	2164
5	NUM	O	O	2164
mg	VERB	O	O	2164
kg-1	VERB	O	O	2164
or	CCONJ	O	O	2164
saline	NOUN	O	O	2164
for	ADP	O	O	2164
50	NUM	O	O	2164
min	NOUN	O	O	2164
.	PUNCT	O	O	2164
Infusion	NOUN	O	O	2165
started	VERB	O	O	2165
15	NUM	O	O	2165
min	NOUN	O	O	2165
after	ADP	O	O	2165
injection	NOUN	O	O	2165
of	ADP	O	O	2165
capsaicin	NOUN	O	Chemical	2165
.	PUNCT	O	O	2165
The	PRON	O	O	2166
following	VERB	O	O	2166
were	AUX	O	O	2166
measured	VERB	O	O	2166
:	PUNCT	O	O	2166
spontaneous	ADJ	O	O	2166
pain	NOUN	O	Disease	2166
,	PUNCT	O	O	2166
pain	NOUN	O	Disease	2166
evoked	VERB	O	O	2166
by	ADP	O	O	2166
punctate	NOUN	O	O	2166
and	CCONJ	O	O	2166
brush	NOUN	O	O	2166
stimuli	NOUN	O	O	2166
(	PUNCT	O	O	2166
VAS	PROPN	O	O	2166
)	PUNCT	O	O	2166
,	PUNCT	O	O	2166
and	CCONJ	O	O	2166
areas	NOUN	O	O	2166
of	ADP	O	O	2166
brush	NOUN	O	O	2166
-	PUNCT	O	O	2166
evoked	VERB	O	O	2166
and	CCONJ	O	O	2166
punctate	NOUN	O	O	2166
-	PUNCT	O	O	2166
evoked	VERB	O	O	2166
hyperalgesia	NOUN	O	Disease	2166
.	PUNCT	O	O	2166
Ketamine	PROPN	O	Chemical	2167
reduced	VERB	O	O	2167
both	PRON	O	O	2167
the	PRON	O	O	2167
area	NOUN	O	O	2167
of	ADP	O	O	2167
brush	NOUN	O	O	2167
-	PUNCT	O	O	2167
evoked	VERB	O	O	2167
and	CCONJ	O	O	2167
punctate	NOUN	O	O	2167
-	PUNCT	O	O	2167
evoked	VERB	O	O	2167
hyperalgesia	NOUN	O	Disease	2168
significantly	ADV	O	O	2168
and	CCONJ	O	O	2169
it	PRON	O	O	2169
tended	VERB	O	O	2169
to	PART	O	O	2169
reduce	VERB	O	O	2169
brush	NOUN	O	O	2169
-	PUNCT	O	O	2169
evoked	VERB	O	O	2169
pain	NOUN	O	Disease	2169
.	PUNCT	O	O	2169
Lidocaine	PROPN	O	O	2170
reduced	VERB	O	O	2170
the	PRON	O	O	2170
area	NOUN	O	O	2170
of	ADP	O	O	2170
punctate	NOUN	O	O	2170
-	PUNCT	O	O	2170
evoked	VERB	O	O	2170
hyperalgesia	NOUN	O	Disease	2170
significantly	ADV	O	O	2170
.	PUNCT	O	O	2170
It	PRON	O	O	2171
tended	VERB	O	O	2171
to	PART	O	O	2171
reduce	VERB	O	O	2171
VAS	PROPN	O	O	2171
scores	NOUN	O	O	2171
of	ADP	O	O	2171
spontaneous	ADJ	O	O	2171
pain	NOUN	O	Disease	2171
but	CCONJ	O	O	2171
had	VERB	O	O	2171
no	PRON	O	O	2171
effect	VERB	O	O	2171
on	ADP	O	O	2171
evoked	VERB	O	O	2171
pain	NOUN	O	Disease	2171
.	PUNCT	O	O	2171
The	PRON	O	O	2172
differential	ADJ	O	O	2172
effects	NOUN	O	O	2172
of	ADP	O	O	2172
ketamine	VERB	O	Chemical	2172
and	CCONJ	O	O	2172
lidocaine	NOUN	O	Chemical	2172
on	ADP	O	O	2172
static	ADJ	O	O	2172
and	CCONJ	O	O	2172
dynamic	ADJ	O	O	2172
hyperalgesia	NOUN	O	Disease	2172
suggest	VERB	O	O	2172
that	SCONJ	O	O	2172
the	PRON	O	O	2172
two	NUM	O	O	2172
types	NOUN	O	O	2172
of	ADP	O	O	2172
hyperalgesia	NOUN	O	Disease	2172
are	AUX	O	O	2172
mediated	VERB	O	O	2172
by	ADP	O	O	2172
separate	VERB	O	O	2172
mechanisms	NOUN	O	O	2172
and	CCONJ	O	O	2172
have	VERB	O	O	2172
a	PRON	O	O	2172
distinct	ADJ	O	O	2172
pharmacology	NOUN	O	O	2172
.	PUNCT	O	O	2172
Cyclosporine	PROPN	O	O	2175
and	CCONJ	O	O	2175
tacrolimus	NOUN	O	Chemical	2175
-	PUNCT	O	O	2175
associated	VERB	O	O	2175
thrombotic	ADJ	O	Disease	2175
microangiopathy	VERB	O	Disease	2175
.	PUNCT	O	O	2175
The	PRON	O	O	2176
development	NOUN	O	O	2176
of	ADP	O	O	2176
thrombotic	ADJ	O	Disease	2176
microangiopathy	VERB	O	Disease	2176
(	PUNCT	O	O	2176
TMA	PROPN	O	Disease	2176
)	PUNCT	O	O	2176
associated	VERB	O	O	2176
with	ADP	O	O	2176
the	PRON	O	O	2176
use	VERB	O	O	2176
of	ADP	O	O	2176
cyclosporine	NOUN	O	Chemical	2176
has	VERB	O	O	2176
been	AUX	O	O	2176
well	ADV	O	O	2176
documented	VERB	O	O	2176
.	PUNCT	O	O	2176
Treatments	NOUN	O	O	2177
have	VERB	O	O	2177
included	VERB	O	O	2177
discontinuation	NOUN	O	O	2177
or	CCONJ	O	O	2177
reduction	NOUN	O	O	2177
of	ADP	O	O	2177
cyclosporine	NOUN	O	Chemical	2177
dose	NOUN	O	O	2177
with	ADP	O	O	2177
or	CCONJ	O	O	2177
without	ADP	O	O	2177
concurrent	ADJ	O	O	2177
plasma	NOUN	O	O	2177
exchange	VERB	O	O	2177
,	PUNCT	O	O	2177
plasma	NOUN	O	O	2177
infusion	NOUN	O	O	2177
,	PUNCT	O	O	2177
anticoagulation	NOUN	O	O	2177
,	PUNCT	O	O	2177
and	CCONJ	O	O	2177
intravenous	ADJ	O	O	2177
immunoglobulin	NOUN	O	O	2177
G	NOUN	O	O	2177
infusion	NOUN	O	O	2177
.	PUNCT	O	O	2177
The	PRON	O	O	2178
last	VERB	O	O	2178
decade	NOUN	O	O	2178
has	VERB	O	O	2178
seen	VERB	O	O	2178
the	PRON	O	O	2178
emergence	NOUN	O	O	2178
of	ADP	O	O	2178
tacrolimus	NOUN	O	Chemical	2178
as	ADP	O	O	2178
a	PRON	O	O	2178
potent	ADJ	O	O	2178
immunosuppressive	ADJ	O	O	2178
agent	NOUN	O	O	2178
with	ADP	O	O	2178
mechanisms	NOUN	O	O	2178
of	ADP	O	O	2178
action	NOUN	O	O	2178
virtually	ADV	O	O	2178
identical	ADJ	O	O	2178
to	PART	O	O	2178
those	PRON	O	O	2178
of	ADP	O	O	2178
cyclosporine	NOUN	O	Chemical	2178
.	PUNCT	O	O	2178
As	ADP	O	O	2179
a	PRON	O	O	2179
result	VERB	O	O	2179
,	PUNCT	O	O	2179
switching	VERB	O	O	2179
to	PART	O	O	2179
tacrolimus	NOUN	O	Chemical	2179
has	VERB	O	O	2179
been	AUX	O	O	2179
reported	VERB	O	O	2179
to	PART	O	O	2179
be	AUX	O	O	2179
a	PRON	O	O	2179
viable	ADJ	O	O	2179
therapeutic	ADJ	O	O	2179
option	NOUN	O	O	2179
in	ADP	O	O	2179
the	PRON	O	O	2179
setting	VERB	O	O	2179
of	ADP	O	O	2179
cyclosporine	NOUN	O	Chemical	2179
-	PUNCT	O	O	2179
induced	VERB	O	O	2179
TMA	PROPN	O	Disease	2179
.	PUNCT	O	O	2179
With	ADP	O	O	2180
the	PRON	O	O	2180
more	ADJ	O	O	2180
widespread	ADJ	O	O	2180
application	NOUN	O	O	2180
of	ADP	O	O	2180
tacrolimus	NOUN	O	Chemical	2180
in	ADP	O	O	2180
organ	NOUN	O	O	2180
transplantation	NOUN	O	O	2180
,	PUNCT	O	O	2180
tacrolimus	NOUN	O	Chemical	2180
-	PUNCT	O	O	2180
associated	VERB	O	O	2180
TMA	PROPN	O	Disease	2180
has	VERB	O	O	2180
also	ADV	O	O	2180
been	AUX	O	O	2180
recognized	VERB	O	O	2180
.	PUNCT	O	O	2180
However	ADV	O	O	2181
,	PUNCT	O	O	2181
literature	NOUN	O	O	2181
regarding	VERB	O	O	2181
the	PRON	O	O	2181
incidence	NOUN	O	O	2181
of	ADP	O	O	2181
the	PRON	O	O	2181
recurrence	NOUN	O	O	2181
of	ADP	O	O	2181
TMA	PROPN	O	Disease	2181
in	ADP	O	O	2181
patients	NOUN	O	O	2181
exposed	VERB	O	O	2181
sequentially	ADV	O	O	2181
to	PART	O	O	2181
cyclosporine	NOUN	O	Chemical	2181
and	CCONJ	O	O	2181
tacrolimus	NOUN	O	Chemical	2181
is	AUX	O	O	2181
limited	VERB	O	O	2181
.	PUNCT	O	O	2181
We	PRON	O	O	2182
report	VERB	O	O	2182
a	PRON	O	O	2182
case	NOUN	O	O	2182
of	ADP	O	O	2182
a	PRON	O	O	2182
living	VERB	O	O	2182
donor	NOUN	O	O	2182
renal	ADJ	O	O	2182
transplant	NOUN	O	O	2182
recipient	NOUN	O	O	2182
who	PRON	O	O	2182
developed	VERB	O	O	2182
cyclosporine	NOUN	O	Chemical	2182
-	PUNCT	O	O	2182
induced	VERB	O	O	2182
TMA	PROPN	O	Disease	2182
that	SCONJ	O	O	2182
responded	VERB	O	O	2182
to	PART	O	O	2182
the	PRON	O	O	2182
withdrawal	NOUN	O	O	2182
of	ADP	O	O	2182
cyclosporine	NOUN	O	Chemical	2182
in	ADP	O	O	2182
conjunction	NOUN	O	O	2182
with	ADP	O	O	2182
plasmapheresis	NOUN	O	O	2182
and	CCONJ	O	O	2182
fresh	ADJ	O	O	2182
frozen	ADJ	O	O	2182
plasma	NOUN	O	O	2182
replacement	NOUN	O	O	2182
therapy	NOUN	O	O	2182
.	PUNCT	O	O	2182
Introduction	NOUN	O	O	2183
of	ADP	O	O	2183
tacrolimus	NOUN	O	Chemical	2183
as	ADP	O	O	2183
an	PRON	O	O	2183
alternative	ADV	O	O	2183
immunosuppressive	ADJ	O	O	2183
agent	NOUN	O	O	2183
resulted	VERB	O	O	2183
in	ADP	O	O	2183
the	PRON	O	O	2183
recurrence	NOUN	O	O	2183
of	ADP	O	O	2183
TMA	PROPN	O	Disease	2183
and	CCONJ	O	O	2183
the	PRON	O	O	2183
subsequent	ADJ	O	O	2183
loss	NOUN	O	O	2183
of	ADP	O	O	2183
the	PRON	O	O	2183
renal	ADJ	O	O	2183
allograft	NOUN	O	O	2183
.	PUNCT	O	O	2183
Patients	NOUN	O	O	2184
who	PRON	O	O	2184
are	AUX	O	O	2184
switched	VERB	O	O	2184
from	ADP	O	O	2184
cyclosporine	NOUN	O	Chemical	2184
to	PART	O	O	2184
tacrolimus	NOUN	O	Chemical	2184
or	CCONJ	O	O	2184
vice	NOUN	O	O	2184
versa	VERB	O	O	2184
should	AUX	O	O	2184
be	AUX	O	O	2184
closely	ADV	O	O	2184
monitored	VERB	O	O	2184
for	ADP	O	O	2184
the	PRON	O	O	2184
signs	NOUN	O	O	2184
and	CCONJ	O	O	2184
symptoms	NOUN	O	O	2184
of	ADP	O	O	2184
recurrent	ADJ	O	O	2184
TMA	PROPN	O	Disease	2184
.	PUNCT	O	O	2184
Repeated	VERB	O	O	2187
transient	ADJ	O	O	2187
anuria	VERB	O	Disease	2187
following	VERB	O	O	2187
losartan	NOUN	O	O	2187
administration	NOUN	O	O	2187
in	ADP	O	O	2187
a	PRON	O	O	2187
patient	NOUN	O	O	2187
with	ADP	O	O	2187
a	PRON	O	O	2187
solitary	ADJ	O	O	2187
kidney	NOUN	O	O	2187
.	PUNCT	O	O	2187
We	PRON	O	O	2188
report	VERB	O	O	2188
the	PRON	O	O	2188
case	NOUN	O	O	2188
of	ADP	O	O	2188
a	PRON	O	O	2188
70-year	NOUN	O	O	2188
-	PUNCT	O	O	2188
old	ADJ	O	O	2188
hypertensive	ADJ	O	Disease	2188
man	NOUN	O	O	2188
with	ADP	O	O	2188
a	PRON	O	O	2188
solitary	ADJ	O	O	2188
kidney	NOUN	O	O	2188
and	CCONJ	O	O	2188
chronic	ADJ	O	O	2188
renal insufficiency	NOUN	O	Disease	2188
who	PRON	O	O	2188
developed	VERB	O	O	2188
two	NUM	O	O	2188
episodes	NOUN	O	O	2188
of	ADP	O	O	2188
transient	ADJ	O	O	2188
anuria	VERB	O	Disease	2188
after	ADP	O	O	2188
losartan	NOUN	O	O	2188
administration	NOUN	O	O	2188
.	PUNCT	O	O	2188
He	PRON	O	O	2189
was	AUX	O	O	2189
hospitalized	VERB	O	O	2189
for	ADP	O	O	2189
a	PRON	O	O	2189
myocardial infarction	NOUN	O	Disease	2189
with	ADP	O	O	2189
pulmonary edema	NOUN	O	Disease	2189
,	PUNCT	O	O	2189
treated	VERB	O	O	2189
with	ADP	O	O	2189
high	ADJ	O	O	2189
-	PUNCT	O	O	2189
dose	NOUN	O	O	2189
diuretics	NOUN	O	O	2189
.	PUNCT	O	O	2189
Due	ADP	O	O	2190
to	PART	O	O	2190
severe	ADJ	O	O	2190
systolic	ADV	O	O	2190
dysfunction	NOUN	O	O	2190
losartan	NOUN	O	O	2190
was	AUX	O	O	2190
prescribed	VERB	O	O	2190
.	PUNCT	O	O	2190
Surprisingly	ADV	O	O	2191
,	PUNCT	O	O	2191
the	PRON	O	O	2191
first	ADV	O	O	2191
dose	NOUN	O	O	2191
of	ADP	O	O	2191
50	NUM	O	O	2191
mg	VERB	O	O	2191
of	ADP	O	O	2191
losartan	NOUN	O	O	2191
resulted	VERB	O	O	2191
in	ADP	O	O	2191
a	PRON	O	O	2191
sudden	ADJ	O	O	2191
anuria	VERB	O	Disease	2191
,	PUNCT	O	O	2191
which	PRON	O	O	2191
lasted	VERB	O	O	2191
eight	NUM	O	O	2191
hours	NOUN	O	O	2191
despite	SCONJ	O	O	2191
high	ADJ	O	O	2191
-	PUNCT	O	O	2191
dose	NOUN	O	O	2191
furosemide	PROPN	O	Chemical	2191
and	CCONJ	O	O	2191
amine	NOUN	O	Chemical	2191
infusion	NOUN	O	O	2191
.	PUNCT	O	O	2191
One	NUM	O	O	2192
week	NOUN	O	O	2192
later	ADV	O	O	2192
,	PUNCT	O	O	2192
by	ADP	O	O	2192
mistake	NOUN	O	O	2192
,	PUNCT	O	O	2192
losartan	NOUN	O	O	2192
was	AUX	O	O	2192
prescribed	VERB	O	O	2192
again	ADV	O	O	2192
and	CCONJ	O	O	2192
after	ADP	O	O	2192
the	PRON	O	O	2192
second	ADV	O	O	2192
dose	NOUN	O	O	2192
of	ADP	O	O	2192
50	NUM	O	O	2192
mg	VERB	O	O	2192
,	PUNCT	O	O	2192
the	PRON	O	O	2192
patient	NOUN	O	O	2192
developed	VERB	O	O	2192
a	PRON	O	O	2192
second	ADV	O	O	2192
episode	PROPN	O	O	2192
of	ADP	O	O	2192
transient	ADJ	O	O	2192
anuria	VERB	O	Disease	2192
lasting	VERB	O	O	2192
10	NUM	O	O	2192
hours	NOUN	O	O	2192
.	PUNCT	O	O	2192
During	ADP	O	O	2193
these	PRON	O	O	2193
two	NUM	O	O	2193
episodes	NOUN	O	O	2193
,	PUNCT	O	O	2193
his	PRON	O	O	2193
blood	NOUN	O	O	2193
pressure	NOUN	O	O	2193
diminished	VERB	O	O	2193
but	CCONJ	O	O	2193
no	PRON	O	O	2193
severe	ADJ	O	O	2193
hypotension	NOUN	O	Disease	2193
was	AUX	O	O	2193
noted	VERB	O	O	2193
.	PUNCT	O	O	2193
Ultimately	ADV	O	O	2194
,	PUNCT	O	O	2194
an	PRON	O	O	2194
arteriography	PROPN	O	O	2194
showed	VERB	O	O	2194
a	PRON	O	O	2194
70	NUM	O	O	2194
-	PUNCT	O	O	2194
80%	NOUN	O	O	2194
renal	ADJ	O	O	2194
artery	NOUN	O	O	2194
stenosis	NOUN	O	O	2194
.	PUNCT	O	O	2194
In	ADP	O	O	2195
this	PRON	O	O	2195
patient	NOUN	O	O	2195
,	PUNCT	O	O	2195
renal	ADJ	O	O	2195
artery	NOUN	O	O	2195
stenosis	NOUN	O	O	2195
combined	VERB	O	O	2195
with	ADP	O	O	2195
heart failure	NOUN	O	Disease	2195
and	CCONJ	O	O	2195
diuretic	ADJ	O	Chemical	2195
therapy	NOUN	O	O	2195
certainly	ADV	O	O	2195
resulted	VERB	O	O	2195
in	ADP	O	O	2195
a	PRON	O	O	2195
strong	ADJ	O	O	2195
activation	NOUN	O	O	2195
of	ADP	O	O	2195
the	PRON	O	O	2195
renin	PROPN	O	O	2195
-	PUNCT	O	O	2195
angiotensin	NOUN	O	Chemical	2195
system	NOUN	O	O	2195
(	PUNCT	O	O	2195
RAS	PROPN	O	O	2195
)	PUNCT	O	O	2195
.	PUNCT	O	O	2195
Under	ADP	O	O	2196
such	ADJ	O	O	2196
conditions	NOUN	O	O	2196
,	PUNCT	O	O	2196
angiotensin II	PROPN	O	Chemical	2196
receptor	NOUN	O	O	2196
blockade	VERB	O	O	2196
by	ADP	O	O	2196
losartan	NOUN	O	O	2196
probably	ADV	O	O	2196
induced	VERB	O	O	2196
a	PRON	O	O	2196
critical	ADJ	O	O	2196
fall	VERB	O	O	2196
in	ADP	O	O	2196
glomerular	ADJ	O	O	2196
filtration	NOUN	O	O	2196
pressure	NOUN	O	O	2196
.	PUNCT	O	O	2196
This	PRON	O	O	2197
case	NOUN	O	O	2197
report	VERB	O	O	2197
highlights	VERB	O	O	2197
the	PRON	O	O	2197
fact	NOUN	O	O	2197
that	SCONJ	O	O	2197
the	PRON	O	O	2197
angiotensin II	PROPN	O	Chemical	2197
receptor	NOUN	O	O	2197
antagonist	NOUN	O	O	2197
losartan	NOUN	O	O	2197
can	AUX	O	O	2197
cause	VERB	O	O	2197
serious	ADJ	O	O	2197
unexpected	ADJ	O	O	2197
complications	NOUN	O	O	2197
in	ADP	O	O	2197
patients	NOUN	O	O	2197
with	ADP	O	O	2197
renovascular	NOUN	O	O	2197
disease	PROPN	O	O	2197
and	CCONJ	O	O	2197
should	AUX	O	O	2197
be	AUX	O	O	2197
used	VERB	O	O	2197
with	ADP	O	O	2197
extreme	ADJ	O	O	2197
caution	NOUN	O	O	2197
in	ADP	O	O	2197
this	PRON	O	O	2197
setting	VERB	O	O	2197
.	PUNCT	O	O	2197
In	ADP	O	O	2200
vivo	VERB	O	O	2200
protection	NOUN	O	O	2200
of	ADP	O	O	2200
dna	PROPN	O	O	2200
damage	NOUN	O	O	2200
associated	VERB	O	O	2200
apoptotic	ADJ	O	O	2200
and	CCONJ	O	O	2200
necrotic	ADJ	O	O	2200
cell	NOUN	O	O	2200
deaths	NOUN	O	O	2200
during	ADP	O	O	2200
acetaminophen	PROPN	O	Chemical	2200
-	PUNCT	O	O	2200
induced	VERB	O	O	2200
nephrotoxicity	NOUN	O	Disease	2200
,	PUNCT	O	O	2200
amiodarone	NOUN	O	Chemical	2200
-	PUNCT	O	O	2200
induced	VERB	O	O	2200
lung	NOUN	O	O	2200
toxicity	NOUN	O	Disease	2200
and	CCONJ	O	O	2200
doxorubicin	VERB	O	Chemical	2200
-	PUNCT	O	O	2200
induced	VERB	O	O	2200
cardiotoxicity	NOUN	O	Disease	2200
by	ADP	O	O	2200
a	PRON	O	O	2200
novel	NOUN	O	O	2200
IH636	NOUN	O	O	2200
grape	NOUN	O	O	2200
seed	NOUN	O	O	2200
proanthocyanidin	VERB	O	O	2200
extract	VERB	O	O	2200
.	PUNCT	O	O	2200
Grape	NOUN	O	O	2201
seed	NOUN	O	O	2201
extract	VERB	O	O	2201
,	PUNCT	O	O	2201
primarily	ADV	O	O	2201
a	PRON	O	O	2201
mixture	NOUN	O	O	2201
of	ADP	O	O	2201
proanthocyanidins	NOUN	O	O	2201
,	PUNCT	O	O	2201
has	VERB	O	O	2201
been	AUX	O	O	2201
shown	VERB	O	O	2201
to	PART	O	O	2201
modulate	VERB	O	O	2201
a	PRON	O	O	2201
wide	ADV	O	O	2201
-	PUNCT	O	O	2201
range	VERB	O	O	2201
of	ADP	O	O	2201
biological	ADJ	O	O	2201
,	PUNCT	O	O	2201
pharmacological	ADJ	O	O	2201
and	CCONJ	O	O	2201
toxicological	ADJ	O	O	2201
effects	NOUN	O	O	2201
which	PRON	O	O	2201
are	AUX	O	O	2201
mainly	ADV	O	O	2201
cytoprotective	NOUN	O	O	2201
.	PUNCT	O	O	2201
This	PRON	O	O	2202
study	VERB	O	O	2202
assessed	VERB	O	O	2202
the	PRON	O	O	2202
ability	NOUN	O	O	2202
of	ADP	O	O	2202
IH636	NOUN	O	O	2202
grape	NOUN	O	O	2202
seed	NOUN	O	O	2202
proanthocyanidin	VERB	O	O	2202
extract	VERB	O	O	2202
(	PUNCT	O	O	2202
GSPE	PROPN	O	O	2202
)	PUNCT	O	O	2202
to	PART	O	O	2202
prevent	VERB	O	O	2202
acetaminophen	PROPN	O	Chemical	2202
(	PUNCT	O	O	2202
AAP)-induced	ADJ	O	O	2202
nephrotoxicity	NOUN	O	Disease	2202
,	PUNCT	O	O	2202
amiodarone	NOUN	O	Chemical	2202
(	PUNCT	O	O	2202
AMI)-induced	NUM	O	O	2202
lung	NOUN	O	O	2202
toxicity	NOUN	O	Disease	2202
,	PUNCT	O	O	2202
and	CCONJ	O	O	2202
doxorubicin	VERB	O	Chemical	2202
(	PUNCT	O	O	2203
DOX)-induced	PROPN	O	O	2203
cardiotoxicity	NOUN	O	Disease	2203
in	ADP	O	O	2203
mice	NOUN	O	O	2203
.	PUNCT	O	O	2203
Experimental	ADJ	O	O	2204
design	NOUN	O	O	2204
consisted	VERB	O	O	2204
of	ADP	O	O	2204
four	NUM	O	O	2204
groups	NOUN	O	O	2204
:	PUNCT	O	O	2204
control	VERB	O	O	2204
(	PUNCT	O	O	2204
vehicle	NOUN	O	O	2204
alone	ADV	O	O	2204
)	PUNCT	O	O	2204
,	PUNCT	O	O	2204
GSPE	PROPN	O	O	2204
alone	ADV	O	O	2204
,	PUNCT	O	O	2204
drug	NOUN	O	O	2204
alone	ADV	O	O	2204
and	CCONJ	O	O	2204
GSPE+drug	VERB	O	O	2204
.	PUNCT	O	O	2204
For	ADP	O	O	2205
the	PRON	O	O	2205
cytoprotection	NOUN	O	O	2205
study	VERB	O	O	2205
,	PUNCT	O	O	2205
animals	NOUN	O	O	2205
were	AUX	O	O	2205
orally	ADV	O	O	2205
gavaged	VERB	O	O	2205
100	NUM	O	O	2205
mg	VERB	O	O	2205
/	PUNCT	O	O	2205
Kg	NOUN	O	O	2205
GSPE	PROPN	O	O	2205
for	ADP	O	O	2205
7	NUM	O	O	2205
-	PUNCT	O	O	2205
10	NUM	O	O	2205
days	NOUN	O	O	2205
followed	VERB	O	O	2205
by	ADP	O	O	2205
i.p	NOUN	O	O	2205
.	PUNCT	O	O	2205
injections	NOUN	O	O	2206
of	ADP	O	O	2206
organ	NOUN	O	O	2206
specific	ADJ	O	O	2206
three	NUM	O	O	2206
drugs	NOUN	O	O	2206
(	PUNCT	O	O	2206
AAP	PROPN	O	Chemical	2206
:	PUNCT	O	O	2206
500	NUM	O	O	2206
mg	VERB	O	O	2206
/	PUNCT	O	O	2206
Kg	NOUN	O	O	2206
for	ADP	O	O	2206
24	NUM	O	O	2206
h	X	O	O	2206
;	PUNCT	O	O	2206
AMI	PROPN	O	O	2206
:	PUNCT	O	O	2206
50	NUM	O	O	2206
mg	VERB	O	O	2206
/	PUNCT	O	O	2206
Kg	NOUN	O	O	2206
/	PUNCT	O	O	2206
day	NOUN	O	O	2206
for	ADP	O	O	2206
four	NUM	O	O	2206
days	NOUN	O	O	2206
;	PUNCT	O	O	2206
DOX	PROPN	O	Chemical	2207
:	PUNCT	O	O	2207
20	NUM	O	O	2207
mg	VERB	O	O	2207
/	PUNCT	O	O	2207
Kg	NOUN	O	O	2207
for	ADP	O	O	2207
48	NUM	O	O	2207
h	X	O	O	2207
)	PUNCT	O	O	2207
.	PUNCT	O	O	2207
Results	NOUN	O	O	2208
indicate	VERB	O	O	2208
that	SCONJ	O	O	2208
GSPE	PROPN	O	O	2208
preexposure	PROPN	O	O	2208
prior	ADV	O	O	2208
to	PART	O	O	2208
AAP	PROPN	O	Chemical	2208
,	PUNCT	O	O	2208
AMI	PROPN	O	O	2208
and	CCONJ	O	O	2208
DOX	PROPN	O	Chemical	2208
,	PUNCT	O	O	2208
provided	VERB	O	O	2208
near	ADP	O	O	2208
complete	VERB	O	O	2208
protection	NOUN	O	O	2208
in	ADP	O	O	2208
terms	NOUN	O	O	2208
of	ADP	O	O	2208
serum	NOUN	O	O	2208
chemistry	NOUN	O	O	2208
changes	VERB	O	O	2208
(	PUNCT	O	O	2208
ALT	PROPN	O	O	2208
,	PUNCT	O	O	2208
BUN	PROPN	O	Chemical	2208
and	CCONJ	O	O	2208
CPK	PROPN	O	O	2208
)	PUNCT	O	O	2208
,	PUNCT	O	O	2208
and	CCONJ	O	O	2208
significantly	ADV	O	O	2208
reduced	VERB	O	O	2208
DNA	NOUN	O	O	2208
fragmentation	NOUN	O	O	2208
.	PUNCT	O	O	2208
Histopathological	PROPN	O	O	2209
examination	NOUN	O	O	2209
of	ADP	O	O	2209
kidney	NOUN	O	O	2209
,	PUNCT	O	O	2209
heart	NOUN	O	O	2209
and	CCONJ	O	O	2209
lung	NOUN	O	O	2209
sections	NOUN	O	O	2209
revealed	VERB	O	O	2209
moderate	ADJ	O	O	2209
to	PART	O	O	2209
massive	ADJ	O	O	2209
tissue	NOUN	O	O	2209
damage	NOUN	O	O	2209
with	ADP	O	O	2209
a	PRON	O	O	2209
variety	NOUN	O	O	2209
of	ADP	O	O	2209
morphological	ADJ	O	O	2209
aberrations	NOUN	O	O	2209
by	ADP	O	O	2209
all	PRON	O	O	2209
the	PRON	O	O	2209
three	NUM	O	O	2209
drugs	NOUN	O	O	2209
in	ADP	O	O	2209
the	PRON	O	O	2209
absence	NOUN	O	O	2209
of	ADP	O	O	2209
GSPE	PROPN	O	O	2209
preexposure	PROPN	O	O	2209
than	ADP	O	O	2209
in	ADP	O	O	2209
its	PRON	O	O	2209
presence	NOUN	O	O	2209
.	PUNCT	O	O	2209
GSPE+drug	VERB	O	O	2210
exposed	VERB	O	O	2210
tissues	NOUN	O	O	2210
exhibited	VERB	O	O	2210
minor	ADJ	O	O	2210
residual	ADJ	O	O	2210
damage	NOUN	O	O	2210
or	CCONJ	O	O	2210
near	ADP	O	O	2210
total	ADJ	O	O	2210
recovery	NOUN	O	O	2210
.	PUNCT	O	O	2210
Interestingly	ADV	O	O	2211
,	PUNCT	O	O	2211
all	PRON	O	O	2211
the	PRON	O	O	2211
drugs	NOUN	O	O	2211
,	PUNCT	O	O	2211
such	ADJ	O	O	2211
as	ADP	O	O	2211
,	PUNCT	O	O	2211
AAP	PROPN	O	Chemical	2211
,	PUNCT	O	O	2211
AMI	PROPN	O	O	2211
and	CCONJ	O	O	2211
DOX	PROPN	O	Chemical	2211
induced	VERB	O	O	2211
apoptotic	ADJ	O	O	2211
death	NOUN	O	O	2211
in	ADP	O	O	2211
addition	NOUN	O	O	2211
to	PART	O	O	2211
necrosis	NOUN	O	Disease	2211
in	ADP	O	O	2211
the	PRON	O	O	2211
respective	ADJ	O	O	2211
organs	NOUN	O	O	2211
which	PRON	O	O	2211
was	AUX	O	O	2211
very	ADV	O	O	2211
effectively	ADV	O	O	2211
blocked	VERB	O	O	2211
by	ADP	O	O	2211
GSPE	PROPN	O	O	2211
.	PUNCT	O	O	2211
Since	SCONJ	O	O	2212
AAP	PROPN	O	Chemical	2212
,	PUNCT	O	O	2212
AMI	PROPN	O	O	2212
and	CCONJ	O	O	2212
DOX	PROPN	O	Chemical	2212
undergo	VERB	O	O	2212
biotransformation	NOUN	O	O	2212
and	CCONJ	O	O	2212
are	AUX	O	O	2212
known	VERB	O	O	2212
to	PART	O	O	2212
produce	VERB	O	O	2212
damaging	VERB	O	O	2212
radicals	NOUN	O	O	2212
in	ADP	O	O	2212
vivo	VERB	O	O	2212
,	PUNCT	O	O	2212
the	PRON	O	O	2212
protection	NOUN	O	O	2212
by	ADP	O	O	2212
GSPE	PROPN	O	O	2212
may	AUX	O	O	2212
be	AUX	O	O	2212
linked	VERB	O	O	2212
to	PART	O	O	2212
both	PRON	O	O	2212
inhibition	NOUN	O	O	2212
of	ADP	O	O	2212
metabolism	NOUN	O	O	2212
and/or	CCONJ	O	O	2212
detoxification	NOUN	O	O	2212
of	ADP	O	O	2212
cytotoxic	ADJ	O	O	2212
radicals	NOUN	O	O	2212
.	PUNCT	O	O	2212
Additionally	ADV	O	O	2213
,	PUNCT	O	O	2213
this	PRON	O	O	2213
may	AUX	O	O	2213
have	VERB	O	O	2213
been	AUX	O	O	2213
the	PRON	O	O	2213
first	ADV	O	O	2213
report	VERB	O	O	2213
on	ADP	O	O	2213
AMI	PROPN	O	O	2213
-	PUNCT	O	O	2213
induced	VERB	O	O	2213
apoptotic	ADJ	O	O	2213
death	NOUN	O	O	2213
in	ADP	O	O	2213
the	PRON	O	O	2213
lung	NOUN	O	O	2213
tissue	NOUN	O	O	2213
.	PUNCT	O	O	2213
Taken	VERB	O	O	2214
together	ADV	O	O	2214
,	PUNCT	O	O	2214
these	PRON	O	O	2214
events	NOUN	O	O	2214
undoubtedly	ADV	O	O	2214
establish	VERB	O	O	2214
GSPE	PROPN	O	O	2214
's	AUX	O	O	2214
abundant	ADJ	O	O	2214
bioavailability	NOUN	O	O	2214
,	PUNCT	O	O	2214
and	CCONJ	O	O	2214
the	PRON	O	O	2214
power	NOUN	O	O	2214
to	PART	O	O	2214
defend	VERB	O	O	2214
multiple	ADJ	O	O	2214
target	NOUN	O	O	2214
organs	NOUN	O	O	2214
from	ADP	O	O	2214
toxic	ADJ	O	O	2214
assaults	NOUN	O	O	2214
induced	VERB	O	O	2214
by	ADP	O	O	2214
structurally	ADV	O	O	2214
diverse	ADJ	O	O	2214
and	CCONJ	O	O	2214
functionally	ADV	O	O	2214
different	ADJ	O	O	2214
entities	NOUN	O	O	2214
in	ADP	O	O	2214
vivo	VERB	O	O	2214
.	PUNCT	O	O	2214
Palpebral	PROPN	O	O	2217
twitching	VERB	O	O	2217
in	ADP	O	O	2217
a	PRON	O	O	2217
depressed	ADJ	O	O	2217
adolescent	ADJ	O	O	2217
on	ADP	O	O	2217
citalopram	PROPN	O	Chemical	2217
.	PUNCT	O	O	2217
Current	ADJ	O	O	2218
estimates	VERB	O	O	2218
suggest	VERB	O	O	2218
that	SCONJ	O	O	2218
between	ADP	O	O	2218
0.4%	NOUN	O	O	2218
and	CCONJ	O	O	2218
8.3%	NOUN	O	O	2218
of	ADP	O	O	2218
children	NOUN	O	O	2218
and	CCONJ	O	O	2218
adolescents	NOUN	O	O	2218
are	AUX	O	O	2218
affected	VERB	O	O	2218
by	ADP	O	O	2218
major	ADJ	O	O	2218
depression	PROPN	O	Disease	2218
.	PUNCT	O	O	2218
We	PRON	O	O	2219
report	VERB	O	O	2219
a	PRON	O	O	2219
favorable	ADJ	O	O	2219
response	NOUN	O	O	2219
to	PART	O	O	2219
treatment	NOUN	O	O	2219
with	ADP	O	O	2219
citalopram	PROPN	O	Chemical	2219
by	ADP	O	O	2219
a	PRON	O	O	2219
15-year	NOUN	O	O	2219
-	PUNCT	O	O	2219
old	ADJ	O	O	2219
boy	NOUN	O	O	2219
with	ADP	O	O	2219
major	ADJ	O	O	2219
depression	PROPN	O	Disease	2219
who	PRON	O	O	2219
exhibited	VERB	O	O	2219
palpebral	ADJ	O	O	2219
twitching	VERB	O	O	2219
during	ADP	O	O	2219
his	PRON	O	O	2219
first	ADV	O	O	2219
2	X	O	O	2219
weeks	NOUN	O	O	2219
of	ADP	O	O	2219
treatment	NOUN	O	O	2219
.	PUNCT	O	O	2219
This	PRON	O	O	2220
may	AUX	O	O	2220
have	VERB	O	O	2220
been	AUX	O	O	2220
a	PRON	O	O	2220
side	NOUN	O	O	2220
effect	VERB	O	O	2220
of	ADP	O	O	2220
citalopram	PROPN	O	Chemical	2220
as	ADP	O	O	2220
it	PRON	O	O	2220
remitted	VERB	O	O	2220
with	ADP	O	O	2220
redistribution	NOUN	O	O	2220
of	ADP	O	O	2220
doses	NOUN	O	O	2220
.	PUNCT	O	O	2220
Metamizol	NOUN	O	O	2223
potentiates	VERB	O	O	2223
morphine	NOUN	O	Chemical	2223
antinociception	NOUN	O	O	2223
but	CCONJ	O	O	2223
not	PART	O	O	2223
constipation	NOUN	O	Disease	2223
after	ADP	O	O	2223
chronic	ADJ	O	O	2223
treatment	NOUN	O	O	2223
.	PUNCT	O	O	2223
This	PRON	O	O	2224
work	NOUN	O	O	2224
evaluates	VERB	O	O	2224
the	PRON	O	O	2224
antinociceptive	VERB	O	O	2224
and	CCONJ	O	O	2224
constipating	VERB	O	O	2224
effects	NOUN	O	O	2224
of	ADP	O	O	2224
the	PRON	O	O	2224
combination	NOUN	O	O	2224
of	ADP	O	O	2224
3.2	NUM	O	O	2224
mg	VERB	O	O	2224
/	PUNCT	O	O	2224
kg	VERB	O	O	2224
s.c	PROPN	O	O	2224
.	PUNCT	O	O	2224
morphine	NOUN	O	Chemical	2225
with	ADP	O	O	2225
177.8	NUM	O	O	2225
mg	VERB	O	O	2225
metamizol	PROPN	O	O	2226
in	ADP	O	O	2226
acutely	ADV	O	O	2226
and	CCONJ	O	O	2226
chronically	ADV	O	O	2226
treated	VERB	O	O	2226
(	PUNCT	O	O	2226
once	ADV	O	O	2226
a	PRON	O	O	2226
day	NOUN	O	O	2226
for	ADP	O	O	2226
12	NUM	O	O	2226
days	NOUN	O	O	2226
)	PUNCT	O	O	2226
rats	NOUN	O	O	2226
.	PUNCT	O	O	2226
On	ADP	O	O	2227
the	PRON	O	O	2227
13th	PROPN	O	O	2227
day	NOUN	O	O	2227
,	PUNCT	O	O	2227
antinociceptive	VERB	O	O	2227
effects	NOUN	O	O	2227
were	AUX	O	O	2227
assessed	VERB	O	O	2227
using	VERB	O	O	2227
a	PRON	O	O	2227
model	NOUN	O	O	2227
of	ADP	O	O	2227
inflammatory	ADJ	O	O	2227
nociception	NOUN	O	O	2227
,	PUNCT	O	O	2227
pain	NOUN	O	Disease	2227
-	PUNCT	O	O	2227
induced	VERB	O	O	2227
functional	ADJ	O	O	2227
impairment	NOUN	O	O	2227
model	NOUN	O	O	2227
,	PUNCT	O	O	2227
and	CCONJ	O	O	2227
the	PRON	O	O	2227
charcoal	NOUN	O	O	2227
meal	NOUN	O	O	2227
test	NOUN	O	O	2227
was	AUX	O	O	2227
used	VERB	O	O	2227
to	PART	O	O	2227
evaluate	VERB	O	O	2227
the	PRON	O	O	2227
intestinal	ADJ	O	Disease	2227
transit	NOUN	O	O	2227
.	PUNCT	O	O	2227
Simultaneous	ADJ	O	O	2228
administration	NOUN	O	O	2228
of	ADP	O	O	2228
morphine	NOUN	O	Chemical	2228
with	ADP	O	O	2228
metamizol	PROPN	O	O	2228
resulted	VERB	O	O	2228
in	ADP	O	O	2228
a	PRON	O	O	2228
markedly	ADV	O	O	2228
antinociceptive	VERB	O	O	2228
potentiation	NOUN	O	O	2228
and	CCONJ	O	O	2228
an	PRON	O	O	2228
increasing	VERB	O	O	2228
of	ADP	O	O	2228
the	PRON	O	O	2228
duration	NOUN	O	O	2228
of	ADP	O	O	2228
action	NOUN	O	O	2228
after	ADP	O	O	2228
a	PRON	O	O	2228
single	ADJ	O	O	2228
(	PUNCT	O	O	2228
298+/-7	X	O	O	2228
vs.	CCONJ	O	O	2228
139+/-36	NUM	O	O	2228
units	NOUN	O	O	2228
area	NOUN	O	O	2228
(	PUNCT	O	O	2228
ua	PROPN	O	O	2228
)	PUNCT	O	O	2228
;	PUNCT	O	O	2228
P<0.001	ADJ	O	O	2228
)	PUNCT	O	O	2228
and	CCONJ	O	O	2228
repeated	VERB	O	O	2228
administration	NOUN	O	O	2228
(	PUNCT	O	O	2228
280+/-17	NUM	O	O	2228
vs.	CCONJ	O	O	2228
131+/-22	NUM	O	O	2228
Antinociceptive	PROPN	O	O	2229
effect	VERB	O	O	2229
of	ADP	O	O	2229
morphine	NOUN	O	Chemical	2229
was	AUX	O	O	2229
reduced	VERB	O	O	2229
in	ADP	O	O	2229
chronically	ADV	O	O	2229
treated	VERB	O	O	2229
rats	NOUN	O	O	2229
(	PUNCT	O	O	2229
39+/-10	NUM	O	O	2229
vs.	CCONJ	O	O	2229
18+/-5	NOUN	O	O	2229
au	VERB	O	O	2229
)	PUNCT	O	O	2229
while	SCONJ	O	O	2229
the	PRON	O	O	2229
combination	NOUN	O	O	2229
-	PUNCT	O	O	2229
induced	VERB	O	O	2229
antinociception	NOUN	O	O	2229
was	AUX	O	O	2229
remained	VERB	O	O	2229
similar	ADJ	O	O	2229
as	ADP	O	O	2229
an	PRON	O	O	2229
acute	ADJ	O	O	2229
treatment	NOUN	O	O	2229
(	PUNCT	O	O	2229
298+/-7	X	O	O	2229
vs.	CCONJ	O	O	2229
280+/-17	NUM	O	O	2229
au	VERB	O	O	2229
)	PUNCT	O	O	2229
.	PUNCT	O	O	2229
Acute	PROPN	O	O	2230
antinociceptive	VERB	O	O	2230
effects	NOUN	O	O	2230
of	ADP	O	O	2230
the	PRON	O	O	2230
combination	NOUN	O	O	2230
were	AUX	O	O	2230
partially	ADV	O	O	2230
prevented	VERB	O	O	2230
by	ADP	O	O	2230
3.2	NUM	O	O	2230
mg	VERB	O	O	2230
/	PUNCT	O	O	2230
kg	VERB	O	O	2230
naloxone	NOUN	O	Chemical	2230
s.c	PROPN	O	O	2230
.	PUNCT	O	O	2230
In	ADP	O	O	2231
independent	ADJ	O	O	2231
groups	NOUN	O	O	2231
,	PUNCT	O	O	2231
morphine	NOUN	O	Chemical	2231
inhibited	VERB	O	O	2231
the	PRON	O	O	2231
intestinal	ADJ	O	Disease	2231
transit	NOUN	O	O	2231
in	ADP	O	O	2231
48+/-4%	NOUN	O	O	2231
and	CCONJ	O	O	2231
38+/-4%	NOUN	O	O	2231
after	ADP	O	O	2231
acute	ADJ	O	O	2231
and	CCONJ	O	O	2231
chronic	ADJ	O	O	2231
treatment	NOUN	O	O	2231
,	PUNCT	O	O	2231
respectively	ADV	O	O	2231
,	PUNCT	O	O	2231
suggesting	VERB	O	O	2231
that	SCONJ	O	O	2231
tolerance	NOUN	O	O	2231
did	VERB	O	O	2231
not	PART	O	O	2231
develop	VERB	O	O	2231
to	PART	O	O	2231
the	PRON	O	O	2231
constipating	VERB	O	O	2231
effects	NOUN	O	O	2231
.	PUNCT	O	O	2231
The	PRON	O	O	2232
combination	NOUN	O	O	2232
inhibited	VERB	O	O	2232
intestinal	ADJ	O	Disease	2232
transit	NOUN	O	O	2232
similar	ADJ	O	O	2232
to	PART	O	O	2232
that	SCONJ	O	O	2232
produced	VERB	O	O	2232
by	ADP	O	O	2232
morphine	NOUN	O	Chemical	2232
regardless	ADV	O	O	2232
of	ADP	O	O	2232
the	PRON	O	O	2232
time	NOUN	O	O	2232
of	ADP	O	O	2232
treatment	NOUN	O	O	2232
,	PUNCT	O	O	2232
suggesting	VERB	O	O	2232
that	SCONJ	O	O	2232
metamizol	PROPN	O	O	2232
did	VERB	O	O	2232
not	PART	O	O	2232
potentiate	VERB	O	O	2232
morphine	NOUN	O	Chemical	2232
-	PUNCT	O	O	2232
induced	VERB	O	O	2232
constipation	NOUN	O	Disease	2232
.	PUNCT	O	O	2232
These	PRON	O	O	2233
findings	NOUN	O	O	2233
show	VERB	O	O	2233
a	PRON	O	O	2233
significant	ADJ	O	O	2233
interaction	NOUN	O	O	2233
between	ADP	O	O	2233
morphine	NOUN	O	Chemical	2233
and	CCONJ	O	O	2233
metamizol	PROPN	O	O	2233
in	ADP	O	O	2233
chronically	ADV	O	O	2233
treated	VERB	O	O	2233
rats	NOUN	O	O	2233
,	PUNCT	O	O	2233
suggesting	VERB	O	O	2233
that	SCONJ	O	O	2233
this	PRON	O	O	2233
combination	NOUN	O	O	2233
could	AUX	O	O	2233
be	AUX	O	O	2233
useful	ADJ	O	O	2233
for	ADP	O	O	2233
the	PRON	O	O	2233
treatment	NOUN	O	O	2233
of	ADP	O	O	2233
chronic pain	NOUN	O	Disease	2233
.	PUNCT	O	O	2233
Ifosfamide	PROPN	O	Chemical	2236
encephalopathy	NOUN	O	Disease	2236
presenting	VERB	O	O	2236
with	ADP	O	O	2236
asterixis	PROPN	O	O	2236
.	PUNCT	O	O	2236
CNS	PROPN	O	O	2237
toxic	ADJ	O	O	2237
effects	NOUN	O	O	2237
of	ADP	O	O	2237
the	PRON	O	O	2237
antineoplastic	ADJ	O	O	2237
agent	NOUN	O	O	2237
ifosfamide	ADP	O	Chemical	2237
(	PUNCT	O	O	2237
IFX	PROPN	O	O	2237
)	PUNCT	O	O	2237
are	AUX	O	O	2237
frequent	ADJ	O	O	2237
and	CCONJ	O	O	2237
include	VERB	O	O	2237
a	PRON	O	O	2237
variety	NOUN	O	O	2237
of	ADP	O	O	2237
neurological	ADJ	O	O	2237
symptoms	NOUN	O	O	2237
that	SCONJ	O	O	2237
can	AUX	O	O	2237
limit	NOUN	O	O	2237
drug	NOUN	O	O	2237
use	VERB	O	O	2237
.	PUNCT	O	O	2237
We	PRON	O	O	2238
report	VERB	O	O	2238
a	PRON	O	O	2238
case	NOUN	O	O	2238
of	ADP	O	O	2238
a	PRON	O	O	2238
51-year	NOUN	O	O	2238
-	PUNCT	O	O	2238
old	ADJ	O	O	2238
man	NOUN	O	O	2238
who	PRON	O	O	2238
developed	VERB	O	O	2238
severe	ADJ	O	O	2238
,	PUNCT	O	O	2238
disabling	VERB	O	O	2238
negative	ADJ	O	O	2238
myoclonus	NOUN	O	Disease	2238
of	ADP	O	O	2238
the	PRON	O	O	2238
upper	ADJ	O	O	2238
and	CCONJ	O	O	2238
lower	ADJ	O	O	2238
extremities	NOUN	O	O	2238
after	ADP	O	O	2238
the	PRON	O	O	2238
infusion	NOUN	O	O	2238
of	ADP	O	O	2238
ifosfamide	ADP	O	Chemical	2238
for	ADP	O	O	2238
plasmacytoma	NOUN	O	O	2238
.	PUNCT	O	O	2238
Cranial	ADJ	O	O	2239
magnetic	ADJ	O	O	2239
resonance	NOUN	O	O	2239
imaging	VERB	O	O	2239
and	CCONJ	O	O	2239
extensive	ADJ	O	O	2239
laboratory	NOUN	O	O	2239
studies	NOUN	O	O	2239
failed	VERB	O	O	2239
to	PART	O	O	2239
reveal	VERB	O	O	2239
structural	ADJ	O	O	2239
lesions	NOUN	O	O	2239
of	ADP	O	O	2239
the	PRON	O	O	2239
brain	NOUN	O	O	2239
and	CCONJ	O	O	2239
metabolic	ADJ	O	O	2239
abnormalities	NOUN	O	O	2239
.	PUNCT	O	O	2239
An	PRON	O	O	2240
electroencephalogram	PROPN	O	O	2240
showed	VERB	O	O	2240
continuous	ADJ	O	O	2240
,	PUNCT	O	O	2240
generalized	VERB	O	O	2240
irregular	ADJ	O	O	2240
slowing	VERB	O	O	2240
with	ADP	O	O	2240
admixed	VERB	O	O	2240
periodic	ADJ	O	O	2240
triphasic	ADJ	O	O	2240
waves	NOUN	O	O	2240
indicating	VERB	O	O	2240
symptomatic	ADJ	O	O	2240
encephalopathy	NOUN	O	Disease	2240
.	PUNCT	O	O	2240
The	PRON	O	O	2241
administration	NOUN	O	O	2241
of	ADP	O	O	2241
ifosfamide	ADP	O	Chemical	2241
was	AUX	O	O	2241
discontinued	VERB	O	O	2241
and	CCONJ	O	O	2241
within	ADP	O	O	2241
12	NUM	O	O	2241
h	X	O	O	2241
the	PRON	O	O	2241
asterixis	PROPN	O	O	2241
resolved	VERB	O	O	2241
completely	ADV	O	O	2241
.	PUNCT	O	O	2241
In	ADP	O	O	2242
the	PRON	O	O	2242
patient	NOUN	O	O	2242
described	VERB	O	O	2242
,	PUNCT	O	O	2242
the	PRON	O	O	2242
presence	NOUN	O	O	2242
of	ADP	O	O	2242
asterixis	PROPN	O	O	2242
during	ADP	O	O	2242
infusion	NOUN	O	O	2242
of	ADP	O	O	2242
ifosfamide	ADP	O	Chemical	2242
,	PUNCT	O	O	2242
normal	ADJ	O	O	2242
laboratory	NOUN	O	O	2242
findings	NOUN	O	O	2242
and	CCONJ	O	O	2242
imaging	VERB	O	O	2242
studies	NOUN	O	O	2242
and	CCONJ	O	O	2242
the	PRON	O	O	2242
resolution	NOUN	O	O	2242
of	ADP	O	O	2242
symptoms	NOUN	O	O	2242
following	VERB	O	O	2242
the	PRON	O	O	2242
discontinuation	NOUN	O	O	2242
of	ADP	O	O	2242
the	PRON	O	O	2242
drug	NOUN	O	O	2242
suggest	VERB	O	O	2242
that	SCONJ	O	O	2242
negative	ADJ	O	O	2242
myoclonus	NOUN	O	Disease	2242
is	AUX	O	O	2242
associated	VERB	O	O	2242
with	ADP	O	O	2242
the	PRON	O	O	2242
use	VERB	O	O	2242
of	ADP	O	O	2242
IFX	PROPN	O	O	2242
.	PUNCT	O	O	2242
Sub	NOUN	O	O	2245
-	PUNCT	O	O	2245
chronic	ADJ	O	O	2245
low	ADJ	O	O	2245
dose	NOUN	O	O	2245
gamma	PROPN	O	O	2245
-	PUNCT	O	O	2245
vinyl	NOUN	O	O	2245
GABA	PROPN	O	Chemical	2245
(	PUNCT	O	O	2245
vigabatrin	PROPN	O	Chemical	2245
)	PUNCT	O	O	2245
inhibits	VERB	O	O	2245
cocaine	NOUN	O	Chemical	2245
-	PUNCT	O	O	2245
induced	VERB	O	O	2245
increases	VERB	O	O	2245
in	ADP	O	O	2245
nucleus	PROPN	O	O	2245
accumbens	NOUN	O	O	2245
dopamine	NOUN	O	Chemical	2245
.	PUNCT	O	O	2245
RATIONALE	PROPN	O	O	2246
:	PUNCT	O	O	2246
gamma	PROPN	O	O	2246
-	PUNCT	O	O	2246
Vinyl	NOUN	O	O	2246
GABA	PROPN	O	Chemical	2246
(	PUNCT	O	O	2246
GVG	PROPN	O	O	2246
)	PUNCT	O	O	2246
irreversibly	ADV	O	O	2246
inhibits	VERB	O	O	2246
GABA	PROPN	O	Chemical	2246
-	PUNCT	O	O	2246
transaminase	X	O	O	2246
.	PUNCT	O	O	2246
This	PRON	O	O	2247
non	ADJ	O	O	2247
-	PUNCT	O	O	2247
receptor	NOUN	O	O	2247
mediated	VERB	O	O	2247
inhibition	NOUN	O	O	2247
requires	VERB	O	O	2247
de	VERB	O	O	2247
novo	PROPN	O	O	2247
synthesis	NOUN	O	O	2247
for	ADP	O	O	2247
restoration	NOUN	O	O	2247
of	ADP	O	O	2247
functional	ADJ	O	O	2247
GABA	PROPN	O	Chemical	2247
catabolism	NOUN	O	O	2247
.	PUNCT	O	O	2247
Given	VERB	O	O	2248
its	PRON	O	O	2248
preclinical	ADJ	O	O	2248
success	NOUN	O	O	2248
for	ADP	O	O	2248
treating	VERB	O	O	2248
substance abuse	NOUN	O	Disease	2248
and	CCONJ	O	O	2248
the	PRON	O	O	2248
increased	VERB	O	O	2248
risk	NOUN	O	O	2248
of	ADP	O	O	2248
visual	ADJ	O	O	2248
field	NOUN	O	O	2248
defects	NOUN	O	O	2248
(	PUNCT	O	O	2248
VFD	NOUN	O	O	2248
)	PUNCT	O	O	2248
associated	VERB	O	O	2248
with	ADP	O	O	2248
cumulative	ADJ	O	O	2248
lifetime	NOUN	O	O	2248
exposure	NOUN	O	O	2248
,	PUNCT	O	O	2248
we	PRON	O	O	2248
explored	VERB	O	O	2248
the	PRON	O	O	2248
effects	NOUN	O	O	2248
of	ADP	O	O	2248
sub	ADJ	O	O	2248
-	PUNCT	O	O	2248
chronic	ADJ	O	O	2248
low	ADJ	O	O	2248
dose	NOUN	O	O	2248
GVG	PROPN	O	O	2248
on	ADP	O	O	2248
cocaine	NOUN	O	Chemical	2248
-	PUNCT	O	O	2248
induced	VERB	O	O	2248
increases	VERB	O	O	2248
in	ADP	O	O	2248
nucleus	PROPN	O	O	2248
accumbens	NOUN	O	O	2248
(	PUNCT	O	O	2248
NAcc	PROPN	O	O	2248
)	PUNCT	O	O	2248
dopamine	NOUN	O	Chemical	2248
(	PUNCT	O	O	2248
DA	NOUN	O	Chemical	2248
)	PUNCT	O	O	2248
.	PUNCT	O	O	2248
Sub	NOUN	O	O	2249
-	PUNCT	O	O	2249
chronic	ADJ	O	O	2249
GVG	PROPN	O	O	2249
exposure	NOUN	O	O	2249
inhibited	VERB	O	O	2249
the	PRON	O	O	2249
effect	VERB	O	O	2249
of	ADP	O	O	2249
cocaine	NOUN	O	Chemical	2249
for	ADP	O	O	2249
3	X	O	O	2249
days	NOUN	O	O	2249
,	PUNCT	O	O	2249
which	PRON	O	O	2249
exceeded	VERB	O	O	2249
in	ADP	O	O	2249
magnitude	NOUN	O	O	2249
and	CCONJ	O	O	2249
duration	NOUN	O	O	2249
the	PRON	O	O	2249
identical	ADJ	O	O	2249
acute	ADJ	O	O	2249
dose	NOUN	O	O	2249
.	PUNCT	O	O	2249
CONCLUSIONS	NOUN	O	O	2250
:	PUNCT	O	O	2250
Sub	NOUN	O	O	2250
-	PUNCT	O	O	2250
chronic	ADJ	O	O	2250
low	ADJ	O	O	2250
dose	NOUN	O	O	2250
GVG	PROPN	O	O	2250
potentiates	VERB	O	O	2250
and	CCONJ	O	O	2250
extends	VERB	O	O	2250
the	PRON	O	O	2250
inhibition	NOUN	O	O	2250
of	ADP	O	O	2250
cocaine	NOUN	O	Chemical	2250
-	PUNCT	O	O	2250
induced	VERB	O	O	2250
increases	VERB	O	O	2250
in	ADP	O	O	2250
dopamine	NOUN	O	Chemical	2250
,	PUNCT	O	O	2250
effectively	ADV	O	O	2250
reducing	VERB	O	O	2250
cumulative	ADJ	O	O	2250
exposures	NOUN	O	O	2250
and	CCONJ	O	O	2250
the	PRON	O	O	2250
risk	NOUN	O	O	2250
for	ADP	O	O	2250
VFDS	PROPN	O	O	2250
.	PUNCT	O	O	2250
Amount	NOUN	O	O	2253
of	ADP	O	O	2253
bleeding	VERB	O	Disease	2253
and	CCONJ	O	O	2253
hematoma	NOUN	O	Disease	2253
size	NOUN	O	O	2253
in	ADP	O	O	2253
the	PRON	O	O	2253
collagenase	NOUN	O	O	2253
-	PUNCT	O	O	2253
induced	VERB	O	O	2253
intracerebral hemorrhage	NOUN	O	Disease	2253
rat	NOUN	O	O	2253
model	NOUN	O	O	2253
.	PUNCT	O	O	2253
The	PRON	O	O	2254
aggravated	VERB	O	O	2254
risk	NOUN	O	O	2254
on	ADP	O	O	2254
intracerebral hemorrhage	NOUN	O	Disease	2254
(	PUNCT	O	O	2254
ICH	PROPN	O	Disease	2254
)	PUNCT	O	O	2254
with	ADP	O	O	2254
drugs	NOUN	O	O	2254
used	VERB	O	O	2254
for	ADP	O	O	2254
stroke	VERB	O	Disease	2254
patients	NOUN	O	O	2254
should	AUX	O	O	2254
be	AUX	O	O	2254
estimated	VERB	O	O	2254
carefully	ADV	O	O	2254
.	PUNCT	O	O	2254
We	PRON	O	O	2255
therefore	ADV	O	O	2255
established	VERB	O	O	2255
sensitive	ADJ	O	O	2255
quantification	NOUN	O	O	2255
methods	NOUN	O	O	2255
and	CCONJ	O	O	2255
provided	VERB	O	O	2255
a	PRON	O	O	2255
rat	NOUN	O	O	2255
ICH	PROPN	O	Disease	2255
model	NOUN	O	O	2255
for	ADP	O	O	2255
detection	NOUN	O	O	2255
of	ADP	O	O	2255
ICH	PROPN	O	Disease	2255
deterioration	NOUN	O	O	2255
.	PUNCT	O	O	2255
In	ADP	O	O	2256
ICH	PROPN	O	Disease	2256
intrastriatally	ADV	O	O	2256
induced	VERB	O	O	2256
by	ADP	O	O	2256
0.014-unit	NOUN	O	O	2256
,	PUNCT	O	O	2256
0.070-unit	NOUN	O	O	2256
,	PUNCT	O	O	2256
and	CCONJ	O	O	2256
0.350-unit	NOUN	O	O	2256
collagenase	NOUN	O	O	2256
,	PUNCT	O	O	2256
the	PRON	O	O	2256
amount	NOUN	O	O	2256
of	ADP	O	O	2256
bleeding	VERB	O	Disease	2256
was	AUX	O	O	2256
measured	VERB	O	O	2256
using	VERB	O	O	2256
a	PRON	O	O	2256
hemoglobin	NOUN	O	O	2256
assay	NOUN	O	O	2256
developed	VERB	O	O	2256
in	ADP	O	O	2256
the	PRON	O	O	2256
present	NOUN	O	O	2256
study	VERB	O	O	2256
and	CCONJ	O	O	2256
was	AUX	O	O	2256
compared	VERB	O	O	2256
with	ADP	O	O	2256
the	PRON	O	O	2256
morphologically	ADV	O	O	2256
determined	VERB	O	O	2256
hematoma	NOUN	O	Disease	2256
volume	PROPN	O	O	2256
.	PUNCT	O	O	2256
The	PRON	O	O	2257
blood	NOUN	O	O	2257
amounts	VERB	O	O	2257
and	CCONJ	O	O	2257
hematoma	NOUN	O	Disease	2257
volumes	NOUN	O	O	2257
were	AUX	O	O	2257
significantly	ADV	O	O	2257
correlated	VERB	O	O	2257
,	PUNCT	O	O	2257
and	CCONJ	O	O	2257
the	PRON	O	O	2257
hematoma	NOUN	O	Disease	2257
induced	VERB	O	O	2257
by	ADP	O	O	2257
0.014-unit	NOUN	O	O	2257
collagenase	NOUN	O	O	2257
was	AUX	O	O	2257
adequate	ADJ	O	O	2257
to	PART	O	O	2257
detect	VERB	O	O	2257
ICH	PROPN	O	Disease	2257
deterioration	NOUN	O	O	2257
.	PUNCT	O	O	2257
In	ADP	O	O	2258
ICH	PROPN	O	Disease	2258
induction	NOUN	O	O	2258
using	VERB	O	O	2258
0.014-unit	NOUN	O	O	2258
collagenase	NOUN	O	O	2258
,	PUNCT	O	O	2258
heparin	NOUN	O	Chemical	2258
enhanced	VERB	O	O	2258
the	PRON	O	O	2258
hematoma	NOUN	O	Disease	2258
volume	PROPN	O	O	2258
3.4-fold	ADV	O	O	2258
over	ADP	O	O	2258
that	SCONJ	O	O	2258
seen	VERB	O	O	2258
in	ADP	O	O	2258
control	VERB	O	O	2258
ICH	PROPN	O	Disease	2258
animals	NOUN	O	O	2258
and	CCONJ	O	O	2258
the	PRON	O	O	2258
bleeding	VERB	O	Disease	2258
7.6-fold	ADV	O	O	2258
.	PUNCT	O	O	2258
Data	NOUN	O	O	2259
suggest	VERB	O	O	2259
that	SCONJ	O	O	2259
this	PRON	O	O	2259
sensitive	ADJ	O	O	2259
hemoglobin	NOUN	O	O	2259
assay	NOUN	O	O	2259
is	AUX	O	O	2259
useful	ADJ	O	O	2259
for	ADP	O	O	2259
ICH	PROPN	O	Disease	2259
detection	NOUN	O	O	2259
,	PUNCT	O	O	2259
and	CCONJ	O	O	2259
that	SCONJ	O	O	2259
a	PRON	O	O	2259
model	NOUN	O	O	2259
with	ADP	O	O	2259
a	PRON	O	O	2259
small	ADJ	O	O	2259
ICH	PROPN	O	Disease	2259
induced	VERB	O	O	2259
with	ADP	O	O	2259
a	PRON	O	O	2259
low	ADJ	O	O	2259
-	PUNCT	O	O	2259
dose	NOUN	O	O	2259
collagenase	NOUN	O	O	2259
should	AUX	O	O	2259
be	AUX	O	O	2259
used	VERB	O	O	2259
for	ADP	O	O	2259
evaluation	NOUN	O	O	2259
of	ADP	O	O	2259
drugs	NOUN	O	O	2259
that	SCONJ	O	O	2259
may	AUX	O	O	2259
affect	VERB	O	O	2259
ICH	PROPN	O	Disease	2259
.	PUNCT	O	O	2259
Estradiol	NOUN	O	O	2262
reduces	VERB	O	O	2262
seizure	NOUN	O	Disease	2262
-	PUNCT	O	O	2262
induced	VERB	O	O	2262
hippocampal	NOUN	O	O	2262
injury	NOUN	O	O	2262
in	ADP	O	O	2262
ovariectomized	VERB	O	O	2262
female	ADJ	O	O	2262
but	CCONJ	O	O	2262
not	PART	O	O	2262
in	ADP	O	O	2262
male	NOUN	O	O	2262
rats	NOUN	O	O	2262
.	PUNCT	O	O	2262
Estrogens	NOUN	O	Chemical	2263
protect	VERB	O	O	2263
ovariectomized	VERB	O	O	2263
rats	NOUN	O	O	2263
from	ADP	O	O	2263
hippocampal	NOUN	O	O	2263
injury	NOUN	O	O	2263
induced	VERB	O	O	2263
by	ADP	O	O	2263
kainic acid	NOUN	O	Chemical	2263
-	PUNCT	O	O	2263
induced	VERB	O	O	2263
status epilepticus	VERB	O	Disease	2263
(	PUNCT	O	O	2263
SE	PROPN	O	O	2263
)	PUNCT	O	O	2263
.	PUNCT	O	O	2263
We	PRON	O	O	2264
compared	VERB	O	O	2264
the	PRON	O	O	2264
effects	NOUN	O	O	2264
of	ADP	O	O	2264
17beta	NUM	O	O	2264
-	PUNCT	O	O	2264
estradiol	VERB	O	Chemical	2264
in	ADP	O	O	2264
adult	NOUN	O	O	2264
male	NOUN	O	O	2264
and	CCONJ	O	O	2264
ovariectomized	VERB	O	O	2264
female	ADJ	O	O	2264
rats	NOUN	O	O	2264
subjected	VERB	O	O	2264
to	PART	O	O	2264
lithium	NOUN	O	Chemical	2264
-	PUNCT	O	O	2264
pilocarpine	NOUN	O	Chemical	2264
-	PUNCT	O	O	2264
induced	VERB	O	O	2264
SE	PROPN	O	O	2264
.	PUNCT	O	O	2264
Rats	NOUN	O	O	2265
received	VERB	O	O	2265
subcutaneous	ADJ	O	O	2265
injections	NOUN	O	O	2265
of	ADP	O	O	2265
17beta	NUM	O	O	2265
-	PUNCT	O	O	2265
estradiol	VERB	O	Chemical	2265
(	PUNCT	O	O	2265
2	X	O	O	2265
microg	PROPN	O	O	2265
/	PUNCT	O	O	2265
rat	NOUN	O	O	2265
)	PUNCT	O	O	2265
or	CCONJ	O	O	2265
oil	NOUN	O	O	2265
once	ADV	O	O	2265
daily	ADV	O	O	2265
for	ADP	O	O	2265
four	NUM	O	O	2265
consecutive	ADJ	O	O	2265
days	NOUN	O	O	2265
.	PUNCT	O	O	2265
SE	PROPN	O	O	2266
was	AUX	O	O	2266
induced	VERB	O	O	2266
20	NUM	O	O	2266
h	X	O	O	2266
following	VERB	O	O	2266
the	PRON	O	O	2266
second	ADV	O	O	2266
injection	NOUN	O	O	2266
and	CCONJ	O	O	2266
terminated	VERB	O	O	2266
3	X	O	O	2266
h	X	O	O	2266
later	ADV	O	O	2266
.	PUNCT	O	O	2266
The	PRON	O	O	2267
extent	NOUN	O	O	2267
of	ADP	O	O	2267
silver	NOUN	O	O	2267
-	PUNCT	O	O	2267
stained	VERB	O	O	2267
CA3	PROPN	O	O	2267
and	CCONJ	O	O	2267
CA1	PROPN	O	O	2267
hippocampal	NOUN	O	O	2267
neurons	NOUN	O	O	2267
was	AUX	O	O	2267
evaluated	VERB	O	O	2267
2	X	O	O	2267
days	NOUN	O	O	2267
after	ADP	O	O	2267
SE	PROPN	O	O	2267
.	PUNCT	O	O	2267
17beta	NUM	O	O	2268
-	PUNCT	O	O	2268
Estradiol	NOUN	O	O	2268
did	VERB	O	O	2268
not	PART	O	O	2268
alter	VERB	O	O	2268
the	PRON	O	O	2268
onset	VERB	O	O	2268
of	ADP	O	O	2268
first	ADV	O	O	2268
clonus	NOUN	O	O	2268
in	ADP	O	O	2268
ovariectomized	VERB	O	O	2268
rats	NOUN	O	O	2268
but	CCONJ	O	O	2268
accelerated	VERB	O	O	2268
it	PRON	O	O	2268
in	ADP	O	O	2268
males	NOUN	O	O	2268
.	PUNCT	O	O	2268
17beta	NUM	O	O	2269
-	PUNCT	O	O	2269
Estradiol	NOUN	O	O	2269
reduced	VERB	O	O	2269
the	PRON	O	O	2269
argyrophilic	ADV	O	O	2269
neurons	NOUN	O	O	2269
in	ADP	O	O	2269
the	PRON	O	O	2269
CA1	PROPN	O	O	2269
and	CCONJ	O	O	2269
CA3-C	PROPN	O	O	2269
sectors	NOUN	O	O	2269
of	ADP	O	O	2269
ovariectomized	VERB	O	O	2269
rats	NOUN	O	O	2269
.	PUNCT	O	O	2269
In	ADP	O	O	2270
males	NOUN	O	O	2270
,	PUNCT	O	O	2270
estradiol	VERB	O	Chemical	2270
increased	VERB	O	O	2270
the	PRON	O	O	2270
total	ADJ	O	O	2270
damage	NOUN	O	O	2270
score	VERB	O	O	2270
.	PUNCT	O	O	2270
These	PRON	O	O	2271
findings	NOUN	O	O	2271
suggest	VERB	O	O	2271
that	SCONJ	O	O	2271
the	PRON	O	O	2271
effects	NOUN	O	O	2271
of	ADP	O	O	2271
estradiol	VERB	O	Chemical	2271
on	ADP	O	O	2271
seizure	NOUN	O	Disease	2271
threshold	NOUN	O	O	2271
and	CCONJ	O	O	2271
damage	NOUN	O	O	2271
may	AUX	O	O	2271
be	AUX	O	O	2271
altered	VERB	O	O	2271
by	ADP	O	O	2271
sex	NOUN	O	O	2271
-	PUNCT	O	O	2271
related	ADJ	O	O	2271
differences	NOUN	O	O	2271
in	ADP	O	O	2271
the	PRON	O	O	2271
hormonal	ADJ	O	O	2271
environment	NOUN	O	O	2271
.	PUNCT	O	O	2271
Delirium	NOUN	O	O	2274
during	ADP	O	O	2274
clozapine	PROPN	O	Chemical	2274
treatment	NOUN	O	O	2274
:	PUNCT	O	O	2274
incidence	NOUN	O	O	2274
and	CCONJ	O	O	2274
associated	VERB	O	O	2274
risk	NOUN	O	O	2274
factors	NOUN	O	O	2274
.	PUNCT	O	O	2274
Incidence	NOUN	O	O	2275
and	CCONJ	O	O	2275
risk	NOUN	O	O	2275
factors	NOUN	O	O	2275
for	ADP	O	O	2275
delirium	NOUN	O	Disease	2275
during	ADP	O	O	2275
clozapine	PROPN	O	Chemical	2275
treatment	NOUN	O	O	2275
require	VERB	O	O	2275
further	ADV	O	O	2275
clarification	NOUN	O	O	2275
.	PUNCT	O	O	2275
We	PRON	O	O	2276
used	VERB	O	O	2276
computerized	VERB	O	O	2276
pharmacy	NOUN	O	O	2276
records	NOUN	O	O	2276
to	PART	O	O	2276
identify	VERB	O	O	2276
all	PRON	O	O	2276
adult	NOUN	O	O	2276
psychiatric	ADJ	O	Disease	2276
inpatients	NOUN	O	O	2276
treated	VERB	O	O	2276
with	ADP	O	O	2276
clozapine	PROPN	O	Chemical	2276
(	PUNCT	O	O	2276
1995	NUM	O	O	2276
-	PUNCT	O	O	2276
96	NUM	O	O	2276
)	PUNCT	O	O	2276
,	PUNCT	O	O	2276
reviewed	VERB	O	O	2276
their	PRON	O	O	2276
medical	ADJ	O	O	2276
records	NOUN	O	O	2276
to	PART	O	O	2276
score	VERB	O	O	2276
incidence	NOUN	O	O	2276
and	CCONJ	O	O	2276
severity	NOUN	O	O	2276
of	ADP	O	O	2276
delirium	NOUN	O	Disease	2276
,	PUNCT	O	O	2276
and	CCONJ	O	O	2276
tested	VERB	O	O	2276
associations	NOUN	O	O	2276
with	ADP	O	O	2276
potential	ADJ	O	O	2276
risk	NOUN	O	O	2276
factors	NOUN	O	O	2276
.	PUNCT	O	O	2276
23.3	NUM	O	O	2277
days	NOUN	O	O	2277
,	PUNCT	O	O	2277
and	CCONJ	O	O	2277
given	VERB	O	O	2277
clozapine	PROPN	O	Chemical	2277
,	PUNCT	O	O	2277
gradually	ADV	O	O	2277
increased	VERB	O	O	2277
to	PART	O	O	2277
an	PRON	O	O	2277
average	ADJ	O	O	2277
daily	ADV	O	O	2277
dose	NOUN	O	O	2277
of	ADP	O	O	2277
282	NUM	O	O	2277
+	ADP	O	O	2277
/-	PUNCT	O	O	2277
Delirium	NOUN	O	O	2278
was	AUX	O	O	2278
diagnosed	VERB	O	O	2278
in	ADP	O	O	2278
14	NUM	O	O	2278
(	PUNCT	O	O	2278
10.1	NUM	O	O	2278
%	INTJ	O	O	2278
incidence	NOUN	O	O	2278
,	PUNCT	O	O	2278
or	CCONJ	O	O	2278
1.48	NUM	O	O	2278
cases	NOUN	O	O	2278
/	PUNCT	O	O	2278
person	NOUN	O	O	2278
-	PUNCT	O	O	2278
years	NOUN	O	O	2278
of	ADP	O	O	2278
exposure	NOUN	O	O	2278
)	PUNCT	O	O	2278
;	PUNCT	O	O	2278
71.4	NUM	O	O	2278
%	INTJ	O	O	2278
of	ADP	O	O	2278
cases	NOUN	O	O	2278
were	AUX	O	O	2278
moderate	ADJ	O	O	2278
or	CCONJ	O	O	2278
severe	ADJ	O	O	2278
.	PUNCT	O	O	2278
Associated	NOUN	O	O	2279
factors	NOUN	O	O	2279
were	AUX	O	O	2279
co	NOUN	O	O	2279
-	PUNCT	O	O	2279
treatment	NOUN	O	O	2279
with	ADP	O	O	2279
other	ADJ	O	O	2279
centrally	ADV	O	O	2279
antimuscarinic	NOUN	O	O	2279
agents	NOUN	O	O	2279
,	PUNCT	O	O	2279
poor	ADJ	O	O	2279
clinical	ADJ	O	O	2279
outcome	NOUN	O	O	2279
,	PUNCT	O	O	2279
older	ADJ	O	O	2279
age	NOUN	O	O	2279
,	PUNCT	O	O	2279
and	CCONJ	O	O	2279
longer	ADV	O	O	2279
hospitalization	NOUN	O	O	2279
(	PUNCT	O	O	2279
by	ADP	O	O	2279
17.5	NUM	O	O	2279
days	NOUN	O	O	2279
,	PUNCT	O	O	2279
increasing	VERB	O	O	2279
cost	NOUN	O	O	2279
)	PUNCT	O	O	2279
;	PUNCT	O	O	2279
sex	NOUN	O	O	2279
,	PUNCT	O	O	2279
diagnosis	NOUN	O	O	2279
or	CCONJ	O	O	2279
medical	ADJ	O	O	2279
co	NOUN	O	O	2279
-	PUNCT	O	O	2279
morbidity	NOUN	O	O	2279
,	PUNCT	O	O	2279
and	CCONJ	O	O	2279
daily	ADV	O	O	2279
clozapine	PROPN	O	Chemical	2279
dose	NOUN	O	O	2279
,	PUNCT	O	O	2279
which	PRON	O	O	2279
fell	VERB	O	O	2279
with	ADP	O	O	2279
age	NOUN	O	O	2279
,	PUNCT	O	O	2279
were	AUX	O	O	2279
unrelated	ADJ	O	O	2279
.	PUNCT	O	O	2279
Delirium	NOUN	O	O	2280
was	AUX	O	O	2280
found	VERB	O	O	2280
in	ADP	O	O	2280
10	NUM	O	O	2280
%	INTJ	O	O	2280
of	ADP	O	O	2280
clozapine	PROPN	O	Chemical	2280
-	PUNCT	O	O	2280
treated	VERB	O	O	2280
inpatients	NOUN	O	O	2280
,	PUNCT	O	O	2280
particularly	ADV	O	O	2280
in	ADP	O	O	2280
older	ADJ	O	O	2280
patients	NOUN	O	O	2280
exposed	VERB	O	O	2280
to	PART	O	O	2280
other	ADJ	O	O	2280
central	ADJ	O	O	2280
anticholinergics	NOUN	O	O	2280
.	PUNCT	O	O	2280
Delirium	NOUN	O	O	2281
was	AUX	O	O	2281
inconsistently	ADV	O	O	2281
recognized	VERB	O	O	2281
clinically	ADV	O	O	2281
in	ADP	O	O	2281
milder	ADJ	O	O	2281
cases	NOUN	O	O	2281
and	CCONJ	O	O	2281
was	AUX	O	O	2281
associated	VERB	O	O	2281
with	ADP	O	O	2281
increased	VERB	O	O	2281
length	NOUN	O	O	2281
-	PUNCT	O	O	2281
of	ADP	O	O	2281
-	PUNCT	O	O	2281
stay	VERB	O	O	2281
and	CCONJ	O	O	2281
higher	ADJ	O	O	2281
costs	NOUN	O	O	2281
,	PUNCT	O	O	2281
and	CCONJ	O	O	2281
inferior	ADJ	O	O	2281
clinical	ADJ	O	O	2281
outcome	NOUN	O	O	2281
.	PUNCT	O	O	2281
Ketoconazole	PROPN	O	O	2284
-	PUNCT	O	O	2284
induced	VERB	O	O	2284
neurologic	ADJ	O	O	2284
sequelae	ADJ	O	O	2284
.	PUNCT	O	O	2284
A	PRON	O	O	2285
77-y	NOUN	O	O	2285
-	PUNCT	O	O	2285
old	ADJ	O	O	2285
patient	NOUN	O	O	2285
developed	VERB	O	O	2285
weakness	NOUN	O	Disease	2285
of	ADP	O	O	2285
extremities	NOUN	O	O	2285
,	PUNCT	O	O	2285
legs	NOUN	O	O	2285
paralysis	NOUN	O	Disease	2285
,	PUNCT	O	O	2285
dysarthria	NOUN	O	O	2285
and	CCONJ	O	O	2285
tremor	NOUN	O	Disease	2285
1	X	O	O	2285
h	X	O	O	2285
after	ADP	O	O	2285
ingestion	NOUN	O	O	2285
of	ADP	O	O	2285
200	NUM	O	O	2285
mg	VERB	O	O	2285
ketoconazole	PROPN	O	Chemical	2285
for	ADP	O	O	2285
the	PRON	O	O	2285
first	ADV	O	O	2285
time	NOUN	O	O	2285
in	ADP	O	O	2285
his	PRON	O	O	2285
life	NOUN	O	O	2285
.	PUNCT	O	O	2285
All	PRON	O	O	2286
complaints	NOUN	O	O	2286
faded	VERB	O	O	2286
away	ADV	O	O	2286
within	ADP	O	O	2286
24	NUM	O	O	2286
h.	PROPN	O	O	2286
Few	ADJ	O	O	2286
days	NOUN	O	O	2286
later	ADV	O	O	2286
,	PUNCT	O	O	2286
the	PRON	O	O	2286
patient	NOUN	O	O	2286
used	VERB	O	O	2286
another	PRON	O	O	2286
200	NUM	O	O	2286
mg	VERB	O	O	2286
ketoconazole	PROPN	O	Chemical	2286
tablet	PROPN	O	O	2286
,	PUNCT	O	O	2286
and	CCONJ	O	O	2286
within	ADP	O	O	2286
an	PRON	O	O	2286
hour	NOUN	O	O	2286
experienced	ADJ	O	O	2286
a	PRON	O	O	2286
similar	ADJ	O	O	2286
clinical	ADJ	O	O	2286
picture	NOUN	O	O	2286
,	PUNCT	O	O	2286
which	PRON	O	O	2286
resolved	VERB	O	O	2286
again	ADV	O	O	2286
spontaneously	ADV	O	O	2286
within	ADP	O	O	2286
hours	NOUN	O	O	2286
.	PUNCT	O	O	2286
This	PRON	O	O	2287
case	NOUN	O	O	2287
illustrates	VERB	O	O	2287
the	PRON	O	O	2287
need	VERB	O	O	2287
for	ADP	O	O	2287
close	ADV	O	O	2287
vigilance	NOUN	O	O	2287
in	ADP	O	O	2287
adverse	ADJ	O	O	2287
drug	NOUN	O	O	2287
reactions	NOUN	O	O	2287
,	PUNCT	O	O	2287
particularly	ADV	O	O	2287
in	ADP	O	O	2287
the	PRON	O	O	2287
elderly	ADJ	O	O	2287
.	PUNCT	O	O	2287
Noxious	ADJ	O	O	2290
chemical	PROPN	O	O	2290
stimulation	NOUN	O	O	2290
of	ADP	O	O	2290
rat	NOUN	O	O	2290
facial	ADJ	O	O	2290
mucosa	PROPN	O	O	2290
increases	VERB	O	O	2290
intracranial	ADJ	O	O	2290
blood	NOUN	O	O	2290
flow	NOUN	O	O	2290
through	ADP	O	O	2290
a	PRON	O	O	2290
trigemino	NOUN	O	O	2290
-	PUNCT	O	O	2290
parasympathetic	ADJ	O	O	2290
reflex	NOUN	O	O	2290
--	PUNCT	O	O	2290
an	PRON	O	O	2290
experimental	ADJ	O	O	2290
model	NOUN	O	O	2290
for	ADP	O	O	2290
vascular dysfunctions	NOUN	O	O	2290
in	ADP	O	O	2290
cluster headache	NOUN	O	Disease	2290
.	PUNCT	O	O	2290
Cluster	NOUN	O	O	2291
headache	PROPN	O	Disease	2291
is	AUX	O	O	2291
characterized	VERB	O	O	2291
by	ADP	O	O	2291
typical	ADJ	O	O	2291
autonomic	ADJ	O	O	2291
dysfunctions	NOUN	O	O	2291
including	VERB	O	O	2291
facial	ADJ	O	O	2291
and	CCONJ	O	O	2291
intracranial	ADJ	O	O	2291
vascular	ADJ	O	O	2291
disturbances	NOUN	O	O	2291
.	PUNCT	O	O	2291
Capsaicin	PROPN	O	O	2292
(	PUNCT	O	O	2292
0.01	NUM	O	O	2292
-	PUNCT	O	O	2292
1	X	O	O	2292
mm	INTJ	O	O	2292
)	PUNCT	O	O	2292
applied	VERB	O	O	2292
to	PART	O	O	2292
oral	ADJ	O	O	2292
or	CCONJ	O	O	2292
nasal	ADJ	O	O	2292
mucosa	PROPN	O	O	2292
induced	VERB	O	O	2292
increases	VERB	O	O	2292
in	ADP	O	O	2292
dural	NOUN	O	O	2292
and	CCONJ	O	O	2292
cortical	ADJ	O	O	2292
blood	NOUN	O	O	2292
flow	NOUN	O	O	2292
and	CCONJ	O	O	2292
provoked	VERB	O	O	2292
lacrimation	PROPN	O	O	2292
.	PUNCT	O	O	2292
These	PRON	O	O	2293
responses	NOUN	O	O	2293
were	AUX	O	O	2293
blocked	VERB	O	O	2293
by	ADP	O	O	2293
systemic	ADJ	O	O	2293
pre	VERB	O	O	2293
-	PUNCT	O	O	2293
administration	NOUN	O	O	2293
of	ADP	O	O	2293
hexamethonium	ADJ	O	Chemical	2293
chloride	NOUN	O	Chemical	2293
(	PUNCT	O	O	2293
20	NUM	O	O	2293
mg	VERB	O	O	2293
/	PUNCT	O	O	2293
kg	VERB	O	O	2293
)	PUNCT	O	O	2293
.	PUNCT	O	O	2293
The	PRON	O	O	2294
evoked	VERB	O	O	2294
increases	VERB	O	O	2294
in	ADP	O	O	2294
dural	NOUN	O	O	2294
blood	NOUN	O	O	2294
flow	NOUN	O	O	2294
were	AUX	O	O	2294
also	ADV	O	O	2294
abolished	VERB	O	O	2294
by	ADP	O	O	2294
topical	ADJ	O	O	2294
pre	VERB	O	O	2294
-	PUNCT	O	O	2294
administration	NOUN	O	O	2294
of	ADP	O	O	2294
atropine	NOUN	O	Chemical	2294
(	PUNCT	O	O	2294
1	X	O	O	2294
mm	INTJ	O	O	2294
)	PUNCT	O	O	2294
and	CCONJ	O	O	2294
[	X	O	O	2294
Lys1	NUM	O	O	2294
,	PUNCT	O	O	2294
Pro2,5	PUNCT	O	O	2294
,	PUNCT	O	O	2294
Arg3,4	ADJ	O	O	2294
,	PUNCT	O	O	2294
Tyr6]-VIP	VERB	O	O	2294
(	PUNCT	O	O	2294
0.1	NUM	O	O	2294
mm	INTJ	O	O	2294
)	PUNCT	O	O	2294
,	PUNCT	O	O	2294
a	PRON	O	O	2294
vasoactive	ADJ	O	O	2294
intestinal	ADJ	O	Disease	2294
polypeptide	ADP	O	O	2294
(	PUNCT	O	O	2294
VIP	VERB	O	O	2294
)	PUNCT	O	O	2294
antagonist	NOUN	O	O	2294
,	PUNCT	O	O	2294
onto	ADP	O	O	2294
the	PRON	O	O	2294
exposed	VERB	O	O	2294
dura	NOUN	O	O	2294
mater	NOUN	O	O	2294
.	PUNCT	O	O	2294
The	PRON	O	O	2295
blood	NOUN	O	O	2295
flow	NOUN	O	O	2295
responses	NOUN	O	O	2295
seem	VERB	O	O	2295
to	PART	O	O	2295
be	AUX	O	O	2295
mediated	VERB	O	O	2295
by	ADP	O	O	2295
the	PRON	O	O	2295
release	NOUN	O	O	2295
of	ADP	O	O	2295
acetylcholine	NOUN	O	Chemical	2295
and	CCONJ	O	O	2295
VIP	VERB	O	O	2295
within	ADP	O	O	2295
the	PRON	O	O	2295
meninges	NOUN	O	O	2295
.	PUNCT	O	O	2295
Similar	ADJ	O	O	2296
mechanisms	NOUN	O	O	2296
may	AUX	O	O	2296
be	AUX	O	O	2296
involved	VERB	O	O	2296
in	ADP	O	O	2296
the	PRON	O	O	2296
pathogenesis	NOUN	O	O	2296
of	ADP	O	O	2296
cluster headache	NOUN	O	Disease	2296
.	PUNCT	O	O	2296
Recurrent	ADJ	O	O	2299
excitation	NOUN	O	O	2299
in	ADP	O	O	2299
the	PRON	O	O	2299
dentate	ADJ	O	O	2299
gyrus	PROPN	O	O	2299
of	ADP	O	O	2299
a	PRON	O	O	2299
murine	ADJ	O	O	2299
model	NOUN	O	O	2299
of	ADP	O	O	2299
temporal lobe epilepsy	NOUN	O	Disease	2299
.	PUNCT	O	O	2299
Similar	ADJ	O	O	2300
to	PART	O	O	2300
rats	NOUN	O	O	2300
,	PUNCT	O	O	2300
systemic	ADJ	O	O	2300
pilocarpine	NOUN	O	Chemical	2300
injection	NOUN	O	O	2300
causes	VERB	O	O	2300
status epilepticus	VERB	O	Disease	2300
(	PUNCT	O	O	2300
SE	PROPN	O	O	2300
)	PUNCT	O	O	2300
and	CCONJ	O	O	2300
the	PRON	O	O	2300
eventual	ADJ	O	O	2300
development	NOUN	O	O	2300
of	ADP	O	O	2300
spontaneous	ADJ	O	O	2300
seizures	NOUN	O	Disease	2300
and	CCONJ	O	O	2300
mossy	NOUN	O	O	2300
fiber	PROPN	O	O	2300
sprouting	VERB	O	O	2300
in	ADP	O	O	2300
C57BL/6	NOUN	O	O	2300
and	CCONJ	O	O	2300
CD1	NOUN	O	O	2300
mice	NOUN	O	O	2300
,	PUNCT	O	O	2300
but	CCONJ	O	O	2300
the	PRON	O	O	2300
physiological	ADJ	O	O	2300
correlates	VERB	O	O	2300
of	ADP	O	O	2300
these	PRON	O	O	2300
events	NOUN	O	O	2300
have	VERB	O	O	2300
not	PART	O	O	2300
been	AUX	O	O	2300
identified	VERB	O	O	2300
in	ADP	O	O	2300
mice	NOUN	O	O	2300
.	PUNCT	O	O	2300
Population	NOUN	O	O	2301
responses	NOUN	O	O	2301
in	ADP	O	O	2301
granule	NOUN	O	O	2301
cells	NOUN	O	O	2301
of	ADP	O	O	2301
the	PRON	O	O	2301
dentate	ADJ	O	O	2301
gyrus	PROPN	O	O	2301
were	AUX	O	O	2301
examined	VERB	O	O	2301
in	ADP	O	O	2301
transverse	ADV	O	O	2301
slices	NOUN	O	O	2301
of	ADP	O	O	2301
the	PRON	O	O	2301
ventral	ADV	O	O	2301
hippocampus	NOUN	O	O	2301
from	ADP	O	O	2301
pilocarpine	NOUN	O	Chemical	2301
-	PUNCT	O	O	2301
treated	VERB	O	O	2301
and	CCONJ	O	O	2301
untreated	ADJ	O	O	2301
mice	NOUN	O	O	2301
.	PUNCT	O	O	2301
In	ADP	O	O	2302
Mg(2+)-free	NOUN	O	O	2302
bathing	VERB	O	O	2302
medium	ADJ	O	O	2302
containing	VERB	O	O	2302
bicuculline	PROPN	O	Chemical	2302
,	PUNCT	O	O	2302
conditions	NOUN	O	O	2302
designed	VERB	O	O	2302
to	PART	O	O	2302
increase	VERB	O	O	2302
excitability	NOUN	O	O	2302
in	ADP	O	O	2302
the	PRON	O	O	2302
slices	NOUN	O	O	2302
,	PUNCT	O	O	2302
electrical	ADJ	O	O	2302
stimulation	NOUN	O	O	2302
of	ADP	O	O	2302
the	PRON	O	O	2302
hilus	PROPN	O	O	2302
resulted	VERB	O	O	2302
in	ADP	O	O	2302
a	PRON	O	O	2302
single	ADJ	O	O	2302
population	NOUN	O	O	2302
spike	PROPN	O	O	2302
in	ADP	O	O	2302
granule	NOUN	O	O	2302
cells	NOUN	O	O	2302
from	ADP	O	O	2302
control	VERB	O	O	2302
mice	NOUN	O	O	2302
and	CCONJ	O	O	2302
pilocarpine	NOUN	O	Chemical	2302
-	PUNCT	O	O	2302
treated	VERB	O	O	2302
mice	NOUN	O	O	2302
that	SCONJ	O	O	2302
did	VERB	O	O	2302
not	PART	O	O	2302
experience	NOUN	O	O	2302
SE	PROPN	O	O	2302
.	PUNCT	O	O	2302
In	ADP	O	O	2303
SE	PROPN	O	O	2303
survivors	NOUN	O	O	2303
,	PUNCT	O	O	2303
similar	ADJ	O	O	2303
stimulation	NOUN	O	O	2303
resulted	VERB	O	O	2303
in	ADP	O	O	2303
a	PRON	O	O	2303
population	NOUN	O	O	2303
spike	PROPN	O	O	2303
followed	VERB	O	O	2303
,	PUNCT	O	O	2303
at	ADP	O	O	2303
a	PRON	O	O	2303
variable	NOUN	O	O	2303
latency	VERB	O	O	2303
,	PUNCT	O	O	2303
by	ADP	O	O	2303
negative	ADJ	O	O	2303
DC	PROPN	O	O	2303
shifts	NOUN	O	O	2303
and	CCONJ	O	O	2303
repetitive	ADJ	O	O	2303
afterdischarges	VERB	O	O	2303
of	ADP	O	O	2303
3	X	O	O	2303
-	PUNCT	O	O	2303
60	NUM	O	O	2303
s	X	O	O	2303
duration	NOUN	O	O	2303
,	PUNCT	O	O	2303
which	PRON	O	O	2303
were	AUX	O	O	2303
blocked	VERB	O	O	2303
by	ADP	O	O	2303
ionotropic	ADJ	O	O	2303
glutamate	NOUN	O	Chemical	2303
receptor	NOUN	O	O	2303
antagonists	NOUN	O	O	2303
.	PUNCT	O	O	2303
Focal	ADJ	O	O	2304
glutamate	NOUN	O	Chemical	2304
photostimulation	NOUN	O	O	2304
of	ADP	O	O	2304
the	PRON	O	O	2304
granule	NOUN	O	O	2304
cell	NOUN	O	O	2304
layer	NOUN	O	O	2304
at	ADP	O	O	2304
sites	NOUN	O	O	2304
distant	ADJ	O	O	2304
from	ADP	O	O	2304
the	PRON	O	O	2304
recording	NOUN	O	O	2304
pipette	VERB	O	O	2304
resulted	VERB	O	O	2304
in	ADP	O	O	2304
population	NOUN	O	O	2304
responses	NOUN	O	O	2304
of	ADP	O	O	2304
1	X	O	O	2304
-	PUNCT	O	O	2304
30	NUM	O	O	2304
s	X	O	O	2304
duration	NOUN	O	O	2304
in	ADP	O	O	2304
slices	NOUN	O	O	2304
from	ADP	O	O	2304
SE	PROPN	O	O	2304
survivors	NOUN	O	O	2304
but	CCONJ	O	O	2304
not	PART	O	O	2304
other	ADJ	O	O	2304
groups	NOUN	O	O	2304
.	PUNCT	O	O	2304
These	PRON	O	O	2305
data	NOUN	O	O	2305
support	NOUN	O	O	2305
the	PRON	O	O	2305
hypothesis	NOUN	O	O	2305
that	SCONJ	O	O	2305
SE	PROPN	O	O	2305
-	PUNCT	O	O	2305
induced	VERB	O	O	2305
mossy	NOUN	O	O	2305
fiber	PROPN	O	O	2305
sprouting	VERB	O	O	2305
and	CCONJ	O	O	2305
synaptic	ADJ	O	O	2305
reorganization	NOUN	O	O	2305
are	AUX	O	O	2305
relevant	ADJ	O	O	2305
characteristics	NOUN	O	O	2305
of	ADP	O	O	2305
seizure	NOUN	O	Disease	2305
development	NOUN	O	O	2305
in	ADP	O	O	2305
these	PRON	O	O	2305
murine	ADJ	O	O	2305
strains	VERB	O	O	2305
,	PUNCT	O	O	2305
resembling	VERB	O	O	2305
rat	NOUN	O	O	2305
models	NOUN	O	O	2305
of	ADP	O	O	2305
human	PROPN	O	O	2305
temporal lobe epilepsy	NOUN	O	Disease	2305
.	PUNCT	O	O	2305
The	PRON	O	O	2308
alpha3	NOUN	O	O	2308
and	CCONJ	O	O	2308
beta4	NOUN	O	O	2308
nicotinic	ADJ	O	O	2308
acetylcholine	NOUN	O	Chemical	2308
receptor	NOUN	O	O	2308
subunits	NOUN	O	O	2308
are	AUX	O	O	2308
necessary	ADJ	O	O	2308
for	ADP	O	O	2308
nicotine	NOUN	O	Chemical	2308
-	PUNCT	O	O	2308
induced	VERB	O	O	2308
seizures	NOUN	O	Disease	2308
and	CCONJ	O	O	2308
hypolocomotion	NOUN	O	O	2308
in	ADP	O	O	2308
mice	NOUN	O	O	2308
.	PUNCT	O	O	2308
Binding	NOUN	O	O	2309
of	ADP	O	O	2309
nicotine	NOUN	O	Chemical	2309
to	PART	O	O	2309
nicotinic	ADJ	O	O	2309
acetylcholine	NOUN	O	Chemical	2309
receptors	NOUN	O	O	2309
(	PUNCT	O	O	2309
nAChRs	NUM	O	O	2309
)	PUNCT	O	O	2309
elicits	VERB	O	O	2309
a	PRON	O	O	2309
series	PROPN	O	O	2309
of	ADP	O	O	2309
dose	NOUN	O	O	2309
-	PUNCT	O	O	2309
dependent	ADJ	O	O	2309
behaviors	NOUN	O	O	2309
that	SCONJ	O	O	2309
go	VERB	O	O	2309
from	ADP	O	O	2309
altered	VERB	O	O	2309
exploration	NOUN	O	O	2309
,	PUNCT	O	O	2309
sedation	NOUN	O	O	2309
,	PUNCT	O	O	2309
and	CCONJ	O	O	2309
tremors	NOUN	O	Disease	2309
,	PUNCT	O	O	2309
to	PART	O	O	2309
seizures	NOUN	O	Disease	2309
and	CCONJ	O	O	2309
death	NOUN	O	O	2309
.	PUNCT	O	O	2309
We	PRON	O	O	2310
examined	VERB	O	O	2310
the	PRON	O	O	2310
role	NOUN	O	O	2310
of	ADP	O	O	2310
the	PRON	O	O	2310
beta4	NOUN	O	O	2310
subunits	NOUN	O	O	2310
in	ADP	O	O	2310
nicotine	NOUN	O	Chemical	2310
-	PUNCT	O	O	2310
induced	VERB	O	O	2310
seizures	NOUN	O	Disease	2310
and	CCONJ	O	O	2310
hypolocomotion	NOUN	O	O	2310
in	ADP	O	O	2310
beta4	NOUN	O	O	2310
homozygous	ADJ	O	O	2310
null	ADJ	O	O	2310
(	PUNCT	O	O	2310
beta4	NOUN	O	O	2310
-/-	PROPN	O	O	2310
)	PUNCT	O	O	2310
and	CCONJ	O	O	2310
alpha3	NOUN	O	O	2310
heterozygous	ADJ	O	O	2310
(	PUNCT	O	O	2310
+	ADP	O	O	2310
/-	PUNCT	O	O	2310
mice	NOUN	O	O	2311
were	AUX	O	O	2311
less	ADV	O	O	2311
sensitive	ADJ	O	O	2311
to	PART	O	O	2311
the	PRON	O	O	2311
effects	NOUN	O	O	2311
of	ADP	O	O	2311
nicotine	NOUN	O	Chemical	2311
both	PRON	O	O	2311
at	ADP	O	O	2311
low	ADJ	O	O	2311
doses	NOUN	O	O	2311
,	PUNCT	O	O	2311
measured	VERB	O	O	2311
as	ADP	O	O	2311
decreased	VERB	O	O	2311
exploration	NOUN	O	O	2311
in	ADP	O	O	2311
an	PRON	O	O	2311
open	VERB	O	O	2311
field	NOUN	O	O	2311
,	PUNCT	O	O	2311
and	CCONJ	O	O	2311
at	ADP	O	O	2311
high	ADJ	O	O	2311
doses	NOUN	O	O	2311
,	PUNCT	O	O	2311
measured	VERB	O	O	2311
as	ADP	O	O	2311
sensitivity	NOUN	O	O	2311
to	PART	O	O	2311
nicotine	NOUN	O	Chemical	2311
-	PUNCT	O	O	2311
induced	VERB	O	O	2311
seizures	NOUN	O	Disease	2311
.	PUNCT	O	O	2311
mice	NOUN	O	O	2312
were	AUX	O	O	2312
partially	ADV	O	O	2312
resistant	ADJ	O	O	2312
to	PART	O	O	2312
nicotine	NOUN	O	Chemical	2312
-	PUNCT	O	O	2312
induced	VERB	O	O	2312
seizures	NOUN	O	Disease	2312
when	SCONJ	O	O	2312
compared	VERB	O	O	2312
to	PART	O	O	2312
wild	ADJ	O	O	2312
-	PUNCT	O	O	2312
type	NOUN	O	O	2312
littermates	NOUN	O	O	2312
.	PUNCT	O	O	2312
Together	ADV	O	O	2313
,	PUNCT	O	O	2313
these	PRON	O	O	2313
results	VERB	O	O	2313
suggest	VERB	O	O	2313
that	SCONJ	O	O	2313
the	PRON	O	O	2313
beta4	NOUN	O	O	2313
and	CCONJ	O	O	2313
the	PRON	O	O	2313
alpha3	NOUN	O	O	2313
subunits	NOUN	O	O	2313
are	AUX	O	O	2313
mediators	NOUN	O	O	2313
of	ADP	O	O	2313
nicotine	NOUN	O	Chemical	2313
-	PUNCT	O	O	2313
induced	VERB	O	O	2313
seizures	NOUN	O	Disease	2313
and	CCONJ	O	O	2313
hypolocomotion	NOUN	O	O	2313
.	PUNCT	O	O	2313
Recurrent	ADJ	O	O	2316
acute	ADJ	O	O	2316
interstitial nephritis	NOUN	O	Disease	2316
induced	VERB	O	O	2316
by	ADP	O	O	2316
azithromycin	PROPN	O	Chemical	2316
.	PUNCT	O	O	2316
A	PRON	O	O	2317
14-year	NOUN	O	O	2317
-	PUNCT	O	O	2317
old	ADJ	O	O	2317
girl	NOUN	O	O	2317
is	AUX	O	O	2317
reported	VERB	O	O	2317
with	ADP	O	O	2317
recurrent	ADJ	O	O	2317
,	PUNCT	O	O	2317
azithromycin	PROPN	O	Chemical	2317
-	PUNCT	O	O	2317
induced	VERB	O	O	2317
,	PUNCT	O	O	2317
acute	ADJ	O	O	2317
interstitial nephritis	NOUN	O	Disease	2317
.	PUNCT	O	O	2317
Although	SCONJ	O	O	2318
most	ADV	O	O	2318
cases	NOUN	O	O	2318
of	ADP	O	O	2318
antibiotic	ADJ	O	O	2318
induced	VERB	O	O	2318
acute	ADJ	O	O	2318
interstitial nephritis	NOUN	O	Disease	2318
are	AUX	O	O	2318
benign	ADJ	O	O	2318
and	CCONJ	O	O	2318
self	VERB	O	O	2318
-	PUNCT	O	O	2318
limited	VERB	O	O	2318
,	PUNCT	O	O	2318
some	PRON	O	O	2318
patients	NOUN	O	O	2318
are	AUX	O	O	2318
at	ADP	O	O	2318
risk	NOUN	O	O	2318
for	ADP	O	O	2318
permanent	ADJ	O	O	2318
renal injury	NOUN	O	Disease	2318
.	PUNCT	O	O	2318
Valproate	VERB	O	Chemical	2321
-	PUNCT	O	O	2321
induced	VERB	O	O	2321
encephalopathy	NOUN	O	Disease	2321
.	PUNCT	O	O	2321
Valproate	VERB	O	Chemical	2322
-	PUNCT	O	O	2322
induced	VERB	O	O	2322
encephalopathy	NOUN	O	Disease	2322
is	AUX	O	O	2322
a	PRON	O	O	2322
rare	ADJ	O	O	2322
syndrome	NOUN	O	O	2322
that	SCONJ	O	O	2322
may	AUX	O	O	2322
manifest	VERB	O	O	2322
in	ADP	O	O	2322
otherwise	ADV	O	O	2322
normal	ADJ	O	O	2322
epileptic	ADJ	O	Disease	2322
individuals	NOUN	O	O	2322
.	PUNCT	O	O	2322
It	PRON	O	O	2323
is	AUX	O	O	2323
usually	ADV	O	O	2323
but	CCONJ	O	O	2323
not	PART	O	O	2323
necessarily	ADV	O	O	2323
associated	VERB	O	O	2323
with	ADP	O	O	2323
hyperammonemia	PROPN	O	Disease	2323
.	PUNCT	O	O	2323
A	PRON	O	O	2324
case	NOUN	O	O	2324
of	ADP	O	O	2324
valproate	VERB	O	Chemical	2324
-	PUNCT	O	O	2324
induced	VERB	O	O	2324
encephalopathy	NOUN	O	Disease	2324
is	AUX	O	O	2324
presented	VERB	O	O	2324
.	PUNCT	O	O	2324
Nitro	NOUN	O	O	2327
-	PUNCT	O	O	2327
L	NOUN	O	O	2327
-	PUNCT	O	O	2327
arginine	PROPN	O	O	2327
methyl	NOUN	O	O	2327
ester	PROPN	O	O	2327
:	PUNCT	O	O	2327
a	PRON	O	O	2327
potential	ADJ	O	O	2327
protector	NOUN	O	O	2327
against	ADP	O	O	2327
gentamicin	VERB	O	Chemical	2327
ototoxicity	NOUN	O	Disease	2327
.	PUNCT	O	O	2327
The	PRON	O	O	2328
nitric oxide	NOUN	O	Chemical	2328
(	PUNCT	O	O	2328
NO	PRON	O	Chemical	2328
)	PUNCT	O	O	2328
inhibitor	NOUN	O	O	2328
nitro	NOUN	O	O	2328
-	PUNCT	O	O	2328
L	NOUN	O	O	2328
-	PUNCT	O	O	2328
arginine	PROPN	O	O	2328
methyl	NOUN	O	O	2328
ester	PROPN	O	O	2328
(	PUNCT	O	O	2328
L	NOUN	O	O	2328
-	PUNCT	O	O	2328
NAME	NOUN	O	O	2328
)	PUNCT	O	O	2328
may	AUX	O	O	2328
act	VERB	O	O	2328
as	ADP	O	O	2328
an	PRON	O	O	2328
otoprotectant	ADJ	O	O	2328
against	ADP	O	O	2328
high	ADJ	O	O	2328
-	PUNCT	O	O	2328
frequency	NOUN	O	O	2328
hearing loss	NOUN	O	Disease	2328
caused	VERB	O	O	2328
by	ADP	O	O	2328
gentamicin	VERB	O	Chemical	2328
,	PUNCT	O	O	2328
but	CCONJ	O	O	2328
further	ADV	O	O	2328
studies	NOUN	O	O	2328
are	AUX	O	O	2328
needed	VERB	O	O	2328
to	PART	O	O	2328
confirm	VERB	O	O	2328
this	PRON	O	O	2328
.	PUNCT	O	O	2328
Aminoglycoside	PROPN	O	O	2329
antibiotics	VERB	O	O	2329
are	AUX	O	O	2329
still	ADV	O	O	2329
widely	ADV	O	O	2329
used	VERB	O	O	2329
by	ADP	O	O	2329
virtue	NOUN	O	O	2329
of	ADP	O	O	2329
their	PRON	O	O	2329
efficacy	NOUN	O	O	2329
and	CCONJ	O	O	2329
low	ADJ	O	O	2329
cost	NOUN	O	O	2329
.	PUNCT	O	O	2329
Their	PRON	O	O	2330
ototoxicity	NOUN	O	Disease	2330
is	AUX	O	O	2330
a	PRON	O	O	2330
serious	ADJ	O	O	2330
health	NOUN	O	O	2330
problem	NOUN	O	O	2330
and	CCONJ	O	O	2330
,	PUNCT	O	O	2330
as	ADP	O	O	2330
their	PRON	O	O	2330
ototoxic	ADJ	O	O	2330
mechanism	NOUN	O	O	2330
involves	VERB	O	O	2330
the	PRON	O	O	2330
production	NOUN	O	O	2330
of	ADP	O	O	2330
NO	PRON	O	Chemical	2330
,	PUNCT	O	O	2330
we	PRON	O	O	2330
need	VERB	O	O	2330
to	PART	O	O	2330
assess	VERB	O	O	2330
the	PRON	O	O	2330
use	VERB	O	O	2330
of	ADP	O	O	2330
NO	PRON	O	Chemical	2330
inhibitors	NOUN	O	O	2330
for	ADP	O	O	2330
the	PRON	O	O	2330
prevention	NOUN	O	O	2330
of	ADP	O	O	2330
aminoglycoside	ADV	O	Chemical	2330
-	PUNCT	O	O	2330
induced	VERB	O	O	2330
sensorineural	ADJ	O	O	2330
hearing loss	NOUN	O	Disease	2330
.	PUNCT	O	O	2330
In	ADP	O	O	2331
this	PRON	O	O	2331
experimental	ADJ	O	O	2331
study	VERB	O	O	2331
we	PRON	O	O	2331
used	VERB	O	O	2331
30	NUM	O	O	2331
Sprague	PROPN	O	O	2331
-	PUNCT	O	O	2331
Dawley	NOUN	O	O	2331
rats	NOUN	O	O	2331
,	PUNCT	O	O	2331
27	NUM	O	O	2331
of	ADP	O	O	2331
which	PRON	O	O	2331
had	VERB	O	O	2331
gentamicin	VERB	O	Chemical	2331
instilled	VERB	O	O	2331
into	ADP	O	O	2331
the	PRON	O	O	2331
middle	ADJ	O	O	2331
ear	NOUN	O	O	2331
.	PUNCT	O	O	2331
The	PRON	O	O	2332
otoprotectant	ADJ	O	O	2332
L	NOUN	O	O	2332
-	PUNCT	O	O	2332
NAME	NOUN	O	O	2332
was	AUX	O	O	2332
administered	VERB	O	O	2332
topically	ADV	O	O	2332
to	PART	O	O	2332
12/27	NUM	O	O	2332
animals	NOUN	O	O	2332
.	PUNCT	O	O	2332
Its	PRON	O	O	2333
effect	VERB	O	O	2333
was	AUX	O	O	2333
determined	VERB	O	O	2333
in	ADP	O	O	2333
terms	NOUN	O	O	2333
of	ADP	O	O	2333
attenuation	NOUN	O	O	2333
of	ADP	O	O	2333
hearing loss	NOUN	O	Disease	2333
,	PUNCT	O	O	2333
measured	VERB	O	O	2333
by	ADP	O	O	2333
shifts	NOUN	O	O	2333
in	ADP	O	O	2333
the	PRON	O	O	2333
auditory	NOUN	O	O	2333
brainstem	NOUN	O	O	2333
response	NOUN	O	O	2333
threshold	NOUN	O	O	2333
.	PUNCT	O	O	2333
L	NOUN	O	O	2334
-	PUNCT	O	O	2334
NAME	NOUN	O	O	2334
reduced	VERB	O	O	2334
gentamicin	VERB	O	Chemical	2334
-	PUNCT	O	O	2334
induced	VERB	O	O	2334
hearing loss	NOUN	O	Disease	2334
in	ADP	O	O	2334
the	PRON	O	O	2334
high	ADJ	O	O	2334
-	PUNCT	O	O	2334
frequency	NOUN	O	O	2334
range	VERB	O	O	2334
,	PUNCT	O	O	2334
but	CCONJ	O	O	2334
gave	VERB	O	O	2334
no	PRON	O	O	2334
protection	NOUN	O	O	2334
in	ADP	O	O	2334
the	PRON	O	O	2334
middle	ADJ	O	O	2334
or	CCONJ	O	O	2334
low	ADJ	O	O	2334
frequencies	NOUN	O	O	2334
.	PUNCT	O	O	2334
Cerebral	ADJ	O	O	2337
vasculitis	NOUN	O	Disease	2337
following	VERB	O	O	2337
oral	ADJ	O	O	2337
methylphenidate	VERB	O	Chemical	2337
intake	PROPN	O	O	2337
in	ADP	O	O	2337
an	PRON	O	O	2337
adult	NOUN	O	O	2337
:	PUNCT	O	O	2337
a	PRON	O	O	2337
case	NOUN	O	O	2337
report	VERB	O	O	2337
.	PUNCT	O	O	2337
Methylphenidate	VERB	O	Chemical	2338
is	AUX	O	O	2338
structurally	ADV	O	O	2338
and	CCONJ	O	O	2338
functionally	ADV	O	O	2338
similar	ADJ	O	O	2338
to	PART	O	O	2338
amphetamine	NOUN	O	Chemical	2338
.	PUNCT	O	O	2338
Cerebral	ADJ	O	O	2339
vasculitis	NOUN	O	Disease	2339
associated	VERB	O	O	2339
with	ADP	O	O	2339
amphetamine abuse	NOUN	O	Disease	2339
is	AUX	O	O	2339
well	ADV	O	O	2339
documented	VERB	O	O	2339
,	PUNCT	O	O	2339
and	CCONJ	O	O	2339
in	ADP	O	O	2339
rare	ADJ	O	O	2339
cases	NOUN	O	O	2339
ischaemic	ADJ	O	O	2339
stroke	VERB	O	Disease	2339
has	VERB	O	O	2339
been	AUX	O	O	2339
reported	VERB	O	O	2339
after	ADP	O	O	2339
methylphenidate	VERB	O	Chemical	2339
intake	PROPN	O	O	2339
in	ADP	O	O	2339
children	NOUN	O	O	2339
.	PUNCT	O	O	2339
We	PRON	O	O	2340
report	VERB	O	O	2340
the	PRON	O	O	2340
case	NOUN	O	O	2340
of	ADP	O	O	2340
a	PRON	O	O	2340
63-year	NOUN	O	O	2340
-	PUNCT	O	O	2340
old	ADJ	O	O	2340
female	ADJ	O	O	2340
who	PRON	O	O	2340
was	AUX	O	O	2340
treated	VERB	O	O	2340
with	ADP	O	O	2340
methylphenidate	VERB	O	Chemical	2340
due	ADJ	O	O	2340
to	PART	O	O	2340
hyperactivity	NOUN	O	Disease	2340
and	CCONJ	O	O	2340
suffered	VERB	O	O	2340
from	ADP	O	O	2340
multiple	ADJ	O	O	2340
ischaemic	ADJ	O	O	2340
strokes	NOUN	O	Disease	2340
.	PUNCT	O	O	2340
We	PRON	O	O	2341
consider	VERB	O	O	2341
drug	NOUN	O	O	2341
-	PUNCT	O	O	2341
induced	VERB	O	O	2341
cerebral	ADJ	O	O	2341
vasculitis	NOUN	O	Disease	2341
as	ADP	O	O	2341
the	PRON	O	O	2341
most	ADV	O	O	2341
likely	ADV	O	O	2341
cause	VERB	O	O	2341
of	ADP	O	O	2341
recurrent	ADJ	O	O	2341
ischaemic	ADJ	O	O	2341
strokes	NOUN	O	Disease	2341
in	ADP	O	O	2341
the	PRON	O	O	2341
absence	NOUN	O	O	2341
of	ADP	O	O	2341
any	PRON	O	O	2341
pathological	ADJ	O	O	2341
findings	NOUN	O	O	2341
during	ADP	O	O	2341
the	PRON	O	O	2341
diagnostic	ADJ	O	O	2341
work	NOUN	O	O	2341
-	PUNCT	O	O	2341
up	ADP	O	O	2341
.	PUNCT	O	O	2341
We	PRON	O	O	2342
conclude	VERB	O	O	2342
that	SCONJ	O	O	2342
methylphenidate	VERB	O	Chemical	2342
mediated	VERB	O	O	2342
vasculitis	NOUN	O	Disease	2342
should	AUX	O	O	2342
be	AUX	O	O	2342
considered	VERB	O	O	2342
in	ADP	O	O	2342
patients	NOUN	O	O	2342
with	ADP	O	O	2342
neurological	ADJ	O	O	2342
symptoms	NOUN	O	O	2342
and	CCONJ	O	O	2342
a	PRON	O	O	2342
history	NOUN	O	O	2342
of	ADP	O	O	2342
methylphenidate	VERB	O	Chemical	2342
therapy	NOUN	O	O	2342
.	PUNCT	O	O	2342
This	PRON	O	O	2343
potential	ADJ	O	O	2343
side	NOUN	O	O	2343
-	PUNCT	O	O	2343
effect	VERB	O	O	2343
,	PUNCT	O	O	2343
though	SCONJ	O	O	2343
very	ADV	O	O	2343
rare	ADJ	O	O	2343
,	PUNCT	O	O	2343
represents	VERB	O	O	2343
one	NUM	O	O	2343
more	ADJ	O	O	2343
reason	NOUN	O	O	2343
to	PART	O	O	2343
be	AUX	O	O	2343
very	ADV	O	O	2343
restrictive	ADJ	O	O	2343
in	ADP	O	O	2343
the	PRON	O	O	2343
use	VERB	O	O	2343
of	ADP	O	O	2343
methylphenidate	VERB	O	Chemical	2343
.	PUNCT	O	O	2343
Cerebral	ADJ	O	O	2346
haemorrhage	NOUN	O	Disease	2346
induced	VERB	O	O	2346
by	ADP	O	O	2346
warfarin	VERB	O	Chemical	2346
-	PUNCT	O	O	2346
the	PRON	O	O	2346
influence	NOUN	O	O	2346
of	ADP	O	O	2346
drug	NOUN	O	O	2346
-	PUNCT	O	O	2346
drug	NOUN	O	O	2346
interactions	NOUN	O	O	2346
.	PUNCT	O	O	2346
PURPOSE	NOUN	O	O	2347
:	PUNCT	O	O	2347
To	PART	O	O	2347
evaluate	VERB	O	O	2347
the	PRON	O	O	2347
frequency	NOUN	O	O	2347
,	PUNCT	O	O	2347
severity	NOUN	O	O	2347
and	CCONJ	O	O	2347
preventability	PROPN	O	O	2347
of	ADP	O	O	2347
warfarin	VERB	O	Chemical	2347
-	PUNCT	O	O	2347
induced	VERB	O	O	2347
cerebral	ADJ	O	O	2347
haemorrhages	VERB	O	O	2347
due	ADJ	O	O	2347
to	PART	O	O	2347
warfarin	VERB	O	Chemical	2347
and	CCONJ	O	O	2347
warfarin	VERB	O	Chemical	2347
-	PUNCT	O	O	2347
drug	NOUN	O	O	2347
interactions	NOUN	O	O	2347
in	ADP	O	O	2347
patients	NOUN	O	O	2347
living	VERB	O	O	2347
in	ADP	O	O	2347
the	PRON	O	O	2347
county	NOUN	O	O	2347
of	ADP	O	O	2347
Osterg	PROPN	O	O	2347
tland	NOUN	O	O	2347
,	PUNCT	O	O	2347
Sweden	PROPN	O	O	2347
.	PUNCT	O	O	2347
All	PRON	O	O	2348
patients	NOUN	O	O	2348
with	ADP	O	O	2348
a	PRON	O	O	2348
diagnosed	VERB	O	O	2348
cerebral	ADJ	O	O	2348
haemorrhage	NOUN	O	Disease	2348
at	ADP	O	O	2348
three	NUM	O	O	2348
hospitals	NOUN	O	O	2348
during	ADP	O	O	2348
the	PRON	O	O	2348
period	NOUN	O	O	2348
2000	NUM	O	O	2348
-	PUNCT	O	O	2348
2002	NUM	O	O	2348
were	AUX	O	O	2348
identified	VERB	O	O	2348
.	PUNCT	O	O	2348
Medical	NOUN	O	O	2349
records	NOUN	O	O	2349
were	AUX	O	O	2349
studied	VERB	O	O	2349
retrospectively	ADV	O	O	2349
to	PART	O	O	2349
evaluate	VERB	O	O	2349
whether	SCONJ	O	O	2349
warfarin	VERB	O	Chemical	2349
and	CCONJ	O	O	2349
warfarin	VERB	O	Chemical	2349
-	PUNCT	O	O	2349
drug	NOUN	O	O	2349
interactions	NOUN	O	O	2349
could	AUX	O	O	2349
have	VERB	O	O	2349
caused	VERB	O	O	2349
the	PRON	O	O	2349
cerebral	ADJ	O	O	2349
haemorrhage	NOUN	O	Disease	2349
.	PUNCT	O	O	2349
Among	ADP	O	O	2350
593	NUM	O	O	2350
patients	NOUN	O	O	2350
with	ADP	O	O	2350
cerebral	ADJ	O	O	2350
haemorrhage	NOUN	O	Disease	2350
,	PUNCT	O	O	2350
59	NUM	O	O	2350
(	PUNCT	O	O	2350
10%	NOUN	O	O	2350
)	PUNCT	O	O	2350
were	AUX	O	O	2350
assessed	VERB	O	O	2350
as	ADP	O	O	2350
related	ADJ	O	O	2350
to	PART	O	O	2350
warfarin	VERB	O	Chemical	2350
treatment	NOUN	O	O	2350
.	PUNCT	O	O	2350
Of	ADV	O	O	2351
the	PRON	O	O	2351
59	NUM	O	O	2351
cases	NOUN	O	O	2351
,	PUNCT	O	O	2351
26	NUM	O	O	2351
(	PUNCT	O	O	2351
44%	NOUN	O	O	2351
)	PUNCT	O	O	2351
had	VERB	O	O	2351
a	PRON	O	O	2351
fatal	ADJ	O	O	2351
outcome	NOUN	O	O	2351
,	PUNCT	O	O	2351
compared	VERB	O	O	2351
to	PART	O	O	2351
136	NUM	O	O	2351
(	PUNCT	O	O	2351
25%	NOUN	O	O	2351
)	PUNCT	O	O	2351
among	ADP	O	O	2351
the	PRON	O	O	2351
non	ADJ	O	O	2351
-	PUNCT	O	O	2351
warfarin	VERB	O	Chemical	2351
patients	NOUN	O	O	2351
(	PUNCT	O	O	2351
p	NOUN	O	O	2351
<	X	O	O	2351
0.01	NUM	O	O	2351
)	PUNCT	O	O	2351
.	PUNCT	O	O	2351
A	PRON	O	O	2352
warfarin	VERB	O	Chemical	2352
-	PUNCT	O	O	2352
drug	NOUN	O	O	2352
interaction	NOUN	O	O	2352
could	AUX	O	O	2352
have	VERB	O	O	2352
contributed	VERB	O	O	2352
to	PART	O	O	2352
the	PRON	O	O	2352
haemorrhage	NOUN	O	Disease	2352
in	ADP	O	O	2352
24	NUM	O	O	2352
(	PUNCT	O	O	2352
41%	NOUN	O	O	2352
)	PUNCT	O	O	2352
of	ADP	O	O	2352
the	PRON	O	O	2352
warfarin	VERB	O	Chemical	2352
patients	NOUN	O	O	2352
and	CCONJ	O	O	2352
in	ADP	O	O	2352
7	NUM	O	O	2352
of	ADP	O	O	2352
these	PRON	O	O	2352
(	PUNCT	O	O	2352
12%	NOUN	O	O	2352
)	PUNCT	O	O	2352
the	PRON	O	O	2352
bleeding	VERB	O	Disease	2352
complication	NOUN	O	O	2352
was	AUX	O	O	2352
considered	VERB	O	O	2352
being	AUX	O	O	2352
possible	ADJ	O	O	2352
to	PART	O	O	2352
avoid	VERB	O	O	2352
.	PUNCT	O	O	2352
Warfarin	PROPN	O	Chemical	2353
-	PUNCT	O	O	2353
induced	VERB	O	O	2353
cerebral	ADJ	O	O	2353
haemorrhages	VERB	O	O	2353
are	AUX	O	O	2353
a	PRON	O	O	2353
major	ADJ	O	O	2353
clinical	ADJ	O	O	2353
problem	NOUN	O	O	2353
with	ADP	O	O	2353
a	PRON	O	O	2353
high	ADJ	O	O	2353
fatality	NOUN	O	O	2353
rate	NOUN	O	O	2353
.	PUNCT	O	O	2353
Almost	ADV	O	O	2354
half	NOUN	O	O	2354
of	ADP	O	O	2354
the	PRON	O	O	2354
cases	NOUN	O	O	2354
was	AUX	O	O	2354
related	ADJ	O	O	2354
to	PART	O	O	2354
a	PRON	O	O	2354
warfarin	VERB	O	Chemical	2354
-	PUNCT	O	O	2354
drug	NOUN	O	O	2354
interaction	NOUN	O	O	2354
.	PUNCT	O	O	2354
A	PRON	O	O	2355
significant	ADJ	O	O	2355
proportion	NOUN	O	O	2355
of	ADP	O	O	2355
warfarin	VERB	O	Chemical	2355
-	PUNCT	O	O	2355
related	ADJ	O	O	2355
cerebral	ADJ	O	O	2355
haemorrhages	VERB	O	O	2355
might	AUX	O	O	2355
have	VERB	O	O	2355
been	AUX	O	O	2355
prevented	VERB	O	O	2355
if	SCONJ	O	O	2355
greater	ADJ	O	O	2355
caution	NOUN	O	O	2355
had	VERB	O	O	2355
been	AUX	O	O	2355
taken	VERB	O	O	2355
when	SCONJ	O	O	2355
prescribing	VERB	O	O	2355
drugs	NOUN	O	O	2355
known	VERB	O	O	2355
to	PART	O	O	2355
interact	VERB	O	O	2355
with	ADP	O	O	2355
warfarin	VERB	O	Chemical	2355
.	PUNCT	O	O	2355
Side	NOUN	O	O	2358
effects	NOUN	O	O	2358
of	ADP	O	O	2358
postoperative	ADJ	O	O	2358
administration	NOUN	O	O	2358
of	ADP	O	O	2358
methylprednisolone	NOUN	O	Chemical	2358
and	CCONJ	O	O	2358
gentamicin	VERB	O	Chemical	2358
into	ADP	O	O	2358
the	PRON	O	O	2358
posterior	ADJ	O	O	2358
sub	ADJ	O	O	2358
-	PUNCT	O	O	2358
Tenon	PROPN	O	O	2358
's	AUX	O	O	2358
space	NOUN	O	O	2358
.	PUNCT	O	O	2358
To	PART	O	O	2359
assess	VERB	O	O	2359
the	PRON	O	O	2359
incidence	NOUN	O	O	2359
of	ADP	O	O	2359
postoperative	ADJ	O	O	2359
emetic	ADJ	O	O	2359
side	NOUN	O	O	2359
effects	NOUN	O	O	2359
after	ADP	O	O	2359
the	PRON	O	O	2359
administration	NOUN	O	O	2359
of	ADP	O	O	2359
methylprednisolone	NOUN	O	Chemical	2359
and	CCONJ	O	O	2359
gentamicin	VERB	O	Chemical	2359
into	ADP	O	O	2359
the	PRON	O	O	2359
posterior	ADJ	O	O	2359
sub	ADJ	O	O	2359
-	PUNCT	O	O	2359
Tenon	PROPN	O	O	2359
's	AUX	O	O	2359
space	NOUN	O	O	2359
at	ADP	O	O	2359
the	PRON	O	O	2359
end	VERB	O	O	2359
of	ADP	O	O	2359
routine	ADJ	O	O	2359
cataract	NOUN	O	Disease	2359
surgery	NOUN	O	O	2359
.	PUNCT	O	O	2359
A	PRON	O	O	2360
double	ADJ	O	O	2360
-	PUNCT	O	O	2360
blind	ADJ	O	Disease	2360
double	ADJ	O	O	2360
-	PUNCT	O	O	2360
armed	ADJ	O	O	2360
prospective	ADJ	O	O	2360
study	VERB	O	O	2360
comprised	VERB	O	O	2360
40	NUM	O	O	2360
patients	NOUN	O	O	2360
who	PRON	O	O	2360
had	VERB	O	O	2360
uneventful	ADJ	O	O	2360
sutureless	PROPN	O	O	2360
phacoemulsification	NOUN	O	O	2360
under	ADP	O	O	2360
sub	ADJ	O	O	2360
-	PUNCT	O	O	2360
Tenon	PROPN	O	O	2360
's	AUX	O	O	2360
local	ADJ	O	O	2360
infiltration	NOUN	O	O	2360
of	ADP	O	O	2360
3	X	O	O	2360
mL	PROPN	O	O	2360
of	ADP	O	O	2360
plain	ADV	O	O	2360
lignocaine	NOUN	O	Chemical	2360
.	PUNCT	O	O	2360
At	ADP	O	O	2361
the	PRON	O	O	2361
end	VERB	O	O	2361
of	ADP	O	O	2361
the	PRON	O	O	2361
procedure	NOUN	O	O	2361
,	PUNCT	O	O	2361
Group	PROPN	O	O	2361
A	PRON	O	O	2361
(	PUNCT	O	O	2361
n	CCONJ	O	O	2361
=	PUNCT	O	O	2361
20	NUM	O	O	2361
)	PUNCT	O	O	2361
had	VERB	O	O	2361
20	NUM	O	O	2361
mg/0.5	NUM	O	O	2361
mL	PROPN	O	O	2361
of	ADP	O	O	2361
methylprednisolone	NOUN	O	Chemical	2361
and	CCONJ	O	O	2361
10	NUM	O	O	2361
mg/0.5	NUM	O	O	2361
mL	PROPN	O	O	2361
of	ADP	O	O	2361
gentamicin	VERB	O	Chemical	2361
injected	VERB	O	O	2361
into	ADP	O	O	2361
the	PRON	O	O	2361
posterior	ADJ	O	O	2361
sub	ADJ	O	O	2361
Postoperatively	PROPN	O	O	2362
,	PUNCT	O	O	2362
all	PRON	O	O	2362
patients	NOUN	O	O	2362
were	AUX	O	O	2362
assessed	VERB	O	O	2362
for	ADP	O	O	2362
symptoms	NOUN	O	O	2362
of	ADP	O	O	2362
nausea	NOUN	O	Disease	2362
,	PUNCT	O	O	2362
vomiting	VERB	O	Disease	2362
,	PUNCT	O	O	2362
and	CCONJ	O	O	2362
headache	PROPN	O	Disease	2362
.	PUNCT	O	O	2362
Sixty	NUM	O	O	2363
percent	NOUN	O	O	2363
in	ADP	O	O	2363
Group	PROPN	O	O	2363
A	PRON	O	O	2363
developed	VERB	O	O	2363
postoperative	ADJ	O	O	2363
emetic	ADJ	O	O	2363
symptoms	NOUN	O	O	2363
,	PUNCT	O	O	2363
headache	PROPN	O	Disease	2363
,	PUNCT	O	O	2363
or	CCONJ	O	O	2363
both	PRON	O	O	2363
;	PUNCT	O	O	2363
1	X	O	O	2363
patient	NOUN	O	O	2363
in	ADP	O	O	2363
Group	PROPN	O	O	2363
B	NOUN	O	O	2363
developed	VERB	O	O	2363
symptoms	NOUN	O	O	2363
.	PUNCT	O	O	2363
The	PRON	O	O	2364
administration	NOUN	O	O	2364
of	ADP	O	O	2364
methylprednisolone	NOUN	O	Chemical	2364
and	CCONJ	O	O	2364
gentamicin	VERB	O	Chemical	2364
in	ADP	O	O	2364
the	PRON	O	O	2364
posterior	ADJ	O	O	2364
sub	ADJ	O	O	2364
-	PUNCT	O	O	2364
Tenon	PROPN	O	O	2364
's	AUX	O	O	2364
space	NOUN	O	O	2364
was	AUX	O	O	2364
related	ADJ	O	O	2364
to	PART	O	O	2364
a	PRON	O	O	2364
high	ADJ	O	O	2364
incidence	NOUN	O	O	2364
of	ADP	O	O	2364
side	NOUN	O	O	2364
effects	NOUN	O	O	2364
including	VERB	O	O	2364
nausea	NOUN	O	Disease	2364
,	PUNCT	O	O	2364
vomiting	VERB	O	Disease	2364
,	PUNCT	O	O	2364
and	CCONJ	O	O	2364
headache	PROPN	O	Disease	2364
.	PUNCT	O	O	2364
Cardiac	ADJ	O	O	2367
Angiography	NOUN	O	O	2367
in	ADP	O	O	2367
Renally	ADV	O	O	2367
Impaired	ADJ	O	O	2367
Patients	NOUN	O	O	2367
(	PUNCT	O	O	2367
CARE	VERB	O	O	2367
)	PUNCT	O	O	2367
study	VERB	O	O	2367
:	PUNCT	O	O	2367
a	PRON	O	O	2367
randomized	VERB	O	O	2367
double	ADJ	O	O	2367
-	PUNCT	O	O	2367
blind	ADJ	O	Disease	2367
trial	NOUN	O	O	2367
of	ADP	O	O	2367
contrast	NOUN	O	O	2367
-	PUNCT	O	O	2367
induced	VERB	O	O	2367
nephropathy	NOUN	O	Disease	2367
in	ADP	O	O	2367
patients	NOUN	O	O	2367
with	ADP	O	O	2367
chronic	ADJ	O	O	2367
kidney	NOUN	O	O	2367
disease	PROPN	O	O	2367
.	PUNCT	O	O	2367
No	PRON	O	O	2368
direct	ADJ	O	O	2368
comparisons	NOUN	O	O	2368
exist	VERB	O	O	2368
of	ADP	O	O	2368
the	PRON	O	O	2368
renal	ADJ	O	O	2368
tolerability	NOUN	O	O	2368
of	ADP	O	O	2368
the	PRON	O	O	2368
low	ADJ	O	O	2368
-	PUNCT	O	O	2368
osmolality	NOUN	O	O	2368
contrast	NOUN	O	O	2368
medium	ADJ	O	O	2368
iopamidol	VERB	O	O	2368
with	ADP	O	O	2368
that	SCONJ	O	O	2368
of	ADP	O	O	2368
the	PRON	O	O	2368
iso	VERB	O	O	2368
-	PUNCT	O	O	2368
osmolality	NOUN	O	O	2368
contrast	NOUN	O	O	2368
medium	ADJ	O	O	2368
iodixanol	NOUN	O	Chemical	2368
in	ADP	O	O	2368
high	ADJ	O	O	2368
-	PUNCT	O	O	2368
risk	NOUN	O	O	2368
patients	NOUN	O	O	2368
.	PUNCT	O	O	2368
The	PRON	O	O	2369
present	NOUN	O	O	2369
study	VERB	O	O	2369
is	AUX	O	O	2369
a	PRON	O	O	2369
multicenter	ADJ	O	O	2369
,	PUNCT	O	O	2369
randomized	VERB	O	O	2369
,	PUNCT	O	O	2369
double	ADJ	O	O	2369
-	PUNCT	O	O	2369
blind	ADJ	O	Disease	2369
comparison	NOUN	O	O	2369
of	ADP	O	O	2369
iopamidol	VERB	O	O	2369
and	CCONJ	O	O	2369
iodixanol	NOUN	O	Chemical	2369
in	ADP	O	O	2369
patients	NOUN	O	O	2369
with	ADP	O	O	2369
chronic	ADJ	O	O	2369
kidney	NOUN	O	O	2369
disease	PROPN	O	O	2369
(	PUNCT	O	O	2369
estimated	VERB	O	O	2369
glomerular	ADJ	O	O	2369
filtration	NOUN	O	O	2369
rate	NOUN	O	O	2369
,	PUNCT	O	O	2369
20	NUM	O	O	2369
to	PART	O	O	2369
59	NUM	O	O	2369
mL	PROPN	O	O	2369
/	PUNCT	O	O	2369
min	NOUN	O	O	2369
)	PUNCT	O	O	2369
who	PRON	O	O	2369
underwent	VERB	O	O	2369
cardiac	ADJ	O	O	2369
angiography	NOUN	O	O	2369
or	CCONJ	O	O	2369
percutaneous	ADJ	O	O	2369
coronary	ADJ	O	O	2369
interventions	NOUN	O	O	2369
.	PUNCT	O	O	2369
Serum	NOUN	O	O	2370
creatinine	PROPN	O	Chemical	2370
(	PUNCT	O	O	2370
SCr	PROPN	O	O	2370
)	PUNCT	O	O	2370
levels	NOUN	O	O	2370
and	CCONJ	O	O	2370
estimated	VERB	O	O	2370
glomerular	ADJ	O	O	2370
filtration	NOUN	O	O	2370
rate	NOUN	O	O	2370
were	AUX	O	O	2370
assessed	VERB	O	O	2370
at	ADP	O	O	2370
baseline	VERB	O	O	2370
and	CCONJ	O	O	2370
2	X	O	O	2370
to	PART	O	O	2370
5	NUM	O	O	2370
days	NOUN	O	O	2370
after	ADP	O	O	2370
receiving	VERB	O	O	2370
medications	NOUN	O	O	2370
.	PUNCT	O	O	2370
In	ADP	O	O	2371
414	NUM	O	O	2371
patients	NOUN	O	O	2371
,	PUNCT	O	O	2371
contrast	NOUN	O	O	2371
volume	PROPN	O	O	2371
,	PUNCT	O	O	2371
presence	NOUN	O	O	2371
of	ADP	O	O	2371
diabetes mellitus	ADJ	O	Disease	2371
,	PUNCT	O	O	2371
use	VERB	O	O	2371
of	ADP	O	O	2371
N	NUM	O	O	2371
-	PUNCT	O	O	2371
acetylcysteine	NOUN	O	O	2371
,	PUNCT	O	O	2371
mean	VERB	O	O	2371
baseline	VERB	O	O	2371
SCr	PROPN	O	O	2371
,	PUNCT	O	O	2371
and	CCONJ	O	O	2371
estimated	VERB	O	O	2371
glomerular	ADJ	O	O	2371
filtration	NOUN	O	O	2371
rate	NOUN	O	O	2371
were	AUX	O	O	2371
comparable	ADJ	O	O	2371
in	ADP	O	O	2371
the	PRON	O	O	2371
2	X	O	O	2371
groups	NOUN	O	O	2371
.	PUNCT	O	O	2371
>	PUNCT	O	O	2372
or	CCONJ	O	O	2372
=	PUNCT	O	O	2372
0.5	NUM	O	O	2372
mg	VERB	O	O	2372
/	PUNCT	O	O	2372
dL	VERB	O	O	2372
occurred	VERB	O	O	2372
in	ADP	O	O	2372
4.4%	NOUN	O	O	2372
(	PUNCT	O	O	2372
9	NUM	O	O	2372
of	ADP	O	O	2372
204	NUM	O	O	2372
patients	NOUN	O	O	2372
)	PUNCT	O	O	2372
after	ADP	O	O	2372
iopamidol	VERB	O	O	2372
and	CCONJ	O	O	2372
6.7%	NOUN	O	O	2372
(	PUNCT	O	O	2372
14	NUM	O	O	2372
of	ADP	O	O	2372
210	NUM	O	O	2372
patients	NOUN	O	O	2372
)	PUNCT	O	O	2372
after	ADP	O	O	2372
iodixanol	NOUN	O	Chemical	2372
(	PUNCT	O	O	2372
P=0.39	NOUN	O	O	2372
)	PUNCT	O	O	2372
,	PUNCT	O	O	2372
whereas	SCONJ	O	O	2372
rates	NOUN	O	O	2372
of	ADP	O	O	2372
SCr	PROPN	O	O	2372
increases	VERB	O	O	2372
>	PUNCT	O	O	2372
or	CCONJ	O	O	2372
=	PUNCT	O	O	2372
25%	NOUN	O	O	2372
were	AUX	O	O	2372
9.8%	NOUN	O	O	2372
and	CCONJ	O	O	2372
12.4%	NOUN	O	O	2372
,	PUNCT	O	O	2372
respectively	ADV	O	O	2372
(	PUNCT	O	O	2372
P=0.44	PROPN	O	O	2372
)	PUNCT	O	O	2372
.	PUNCT	O	O	2372
In	ADP	O	O	2373
patients	NOUN	O	O	2373
with	ADP	O	O	2373
diabetes	NOUN	O	Disease	2373
,	PUNCT	O	O	2373
SCr	PROPN	O	O	2373
increases	VERB	O	O	2373
>	PUNCT	O	O	2373
or	CCONJ	O	O	2373
=	PUNCT	O	O	2373
0.5	NUM	O	O	2373
mg	VERB	O	O	2373
/	PUNCT	O	O	2373
dL	VERB	O	O	2373
were	AUX	O	O	2373
5.1%	NOUN	O	O	2373
(	PUNCT	O	O	2373
4	NUM	O	O	2373
of	ADP	O	O	2373
78	NUM	O	O	2373
patients	NOUN	O	O	2373
)	PUNCT	O	O	2373
with	ADP	O	O	2373
iopamidol	VERB	O	O	2373
and	CCONJ	O	O	2373
13.0%	NOUN	O	O	2373
(	PUNCT	O	O	2373
12	NUM	O	O	2373
of	ADP	O	O	2373
92	NUM	O	O	2373
patients	NOUN	O	O	2373
)	PUNCT	O	O	2373
with	ADP	O	O	2373
iodixanol	NOUN	O	Chemical	2373
(	PUNCT	O	O	2373
P=0.11	NUM	O	O	2373
)	PUNCT	O	O	2373
,	PUNCT	O	O	2373
whereas	SCONJ	O	O	2373
SCr	PROPN	O	O	2373
increases	VERB	O	O	2373
>	PUNCT	O	O	2373
or	CCONJ	O	O	2373
=	PUNCT	O	O	2373
25%	NOUN	O	O	2373
were	AUX	O	O	2373
10.3%	NOUN	O	O	2373
and	CCONJ	O	O	2373
15.2%	NOUN	O	O	2373
,	PUNCT	O	O	2373
respectively	ADV	O	O	2373
(	PUNCT	O	O	2373
P=0.37	VERB	O	O	2373
)	PUNCT	O	O	2373
.	PUNCT	O	O	2373
Mean	VERB	O	O	2374
post	VERB	O	O	2374
-	PUNCT	O	O	2374
SCr	PROPN	O	O	2374
increases	VERB	O	O	2374
were	AUX	O	O	2374
significantly	ADV	O	O	2374
less	ADV	O	O	2374
with	ADP	O	O	2374
iopamidol	VERB	O	O	2374
(	PUNCT	O	O	2374
all	PRON	O	O	2374
patients	NOUN	O	O	2374
:	PUNCT	O	O	2374
0.07	NUM	O	O	2374
versus	ADP	O	O	2374
0.12	NUM	O	O	2374
mg	VERB	O	O	2374
/	PUNCT	O	O	2374
dL	VERB	O	O	2374
,	PUNCT	O	O	2374
6.2	NUM	O	O	2374
versus	ADP	O	O	2374
10.6	NUM	O	O	2374
micromol	NOUN	O	O	2374
/	PUNCT	O	O	2374
L	NOUN	O	O	2374
,	PUNCT	O	O	2374
P=0.03	ADJ	O	O	2374
;	PUNCT	O	O	2374
patients	NOUN	O	O	2374
with	ADP	O	O	2374
diabetes	NOUN	O	Disease	2374
:	PUNCT	O	O	2374
0.07	NUM	O	O	2374
versus	ADP	O	O	2374
0.16	NUM	O	O	2374
mg	VERB	O	O	2374
/	PUNCT	O	O	2374
dL	VERB	O	O	2374
,	PUNCT	O	O	2374
6.2	NUM	O	O	2374
versus	ADP	O	O	2374
14.1	NUM	O	O	2374
micromol	NOUN	O	O	2374
/	PUNCT	O	O	2374
L	NOUN	O	O	2374
,	PUNCT	O	O	2374
P=0.01	PROPN	O	O	2374
)	PUNCT	O	O	2374
.	PUNCT	O	O	2374
The	PRON	O	O	2375
rate	NOUN	O	O	2375
of	ADP	O	O	2375
contrast	NOUN	O	O	2375
-	PUNCT	O	O	2375
induced	VERB	O	O	2375
nephropathy	NOUN	O	Disease	2375
,	PUNCT	O	O	2375
defined	VERB	O	O	2375
by	ADP	O	O	2375
multiple	ADJ	O	O	2375
end	VERB	O	O	2375
points	VERB	O	O	2375
,	PUNCT	O	O	2375
is	AUX	O	O	2375
not	PART	O	O	2375
statistically	ADV	O	O	2375
different	ADJ	O	O	2375
after	ADP	O	O	2375
the	PRON	O	O	2375
intraarterial	ADJ	O	O	2375
administration	NOUN	O	O	2375
of	ADP	O	O	2375
iopamidol	VERB	O	O	2375
or	CCONJ	O	O	2375
iodixanol	NOUN	O	Chemical	2375
to	PART	O	O	2375
high	ADJ	O	O	2375
-	PUNCT	O	O	2375
risk	NOUN	O	O	2375
patients	NOUN	O	O	2375
,	PUNCT	O	O	2375
with	ADP	O	O	2375
or	CCONJ	O	O	2375
without	ADP	O	O	2375
diabetes mellitus	ADJ	O	Disease	2375
.	PUNCT	O	O	2375
A	PRON	O	O	2378
novel	NOUN	O	O	2378
compound	NOUN	O	O	2378
,	PUNCT	O	O	2378
maltolyl	VERB	O	O	2378
p	NOUN	O	O	2378
-	PUNCT	O	O	2378
coumarate	ADJ	O	O	2378
,	PUNCT	O	O	2378
attenuates	VERB	O	O	2378
cognitive deficits	NOUN	O	Disease	2378
and	CCONJ	O	O	2378
shows	VERB	O	O	2378
neuroprotective	ADJ	O	O	2378
effects	NOUN	O	O	2378
in	ADP	O	O	2378
vitro	X	O	O	2378
and	CCONJ	O	O	2378
in	ADP	O	O	2378
vivo	VERB	O	O	2378
dementia	NOUN	O	Disease	2378
models	NOUN	O	O	2378
.	PUNCT	O	O	2378
To	PART	O	O	2379
develop	VERB	O	O	2379
a	PRON	O	O	2379
novel	NOUN	O	O	2379
and	CCONJ	O	O	2379
effective	ADJ	O	O	2379
drug	NOUN	O	O	2379
that	SCONJ	O	O	2379
could	AUX	O	O	2379
enhance	VERB	O	O	2379
cognitive	ADJ	O	O	2379
function	NOUN	O	O	2379
and	CCONJ	O	O	2379
neuroprotection	NOUN	O	O	2379
,	PUNCT	O	O	2379
we	PRON	O	O	2379
newly	ADV	O	O	2379
synthesized	VERB	O	O	2379
maltolyl	VERB	O	O	2379
p	NOUN	O	O	2379
-	PUNCT	O	O	2379
coumarate	ADJ	O	O	2379
by	ADP	O	O	2379
the	PRON	O	O	2379
esterification	NOUN	O	O	2379
of	ADP	O	O	2379
maltol	NOUN	O	O	2379
and	CCONJ	O	O	2379
p	NOUN	O	O	2379
-	PUNCT	O	O	2379
coumaric	PROPN	O	O	2379
acid	PROPN	O	O	2379
.	PUNCT	O	O	2379
In	ADP	O	O	2380
the	PRON	O	O	2380
present	NOUN	O	O	2380
study	VERB	O	O	2380
,	PUNCT	O	O	2380
we	PRON	O	O	2380
investigated	VERB	O	O	2380
whether	SCONJ	O	O	2380
maltolyl	VERB	O	O	2380
p	NOUN	O	O	2380
-	PUNCT	O	O	2380
coumarate	ADJ	O	O	2380
could	AUX	O	O	2380
improve	VERB	O	O	2380
cognitive	ADJ	O	O	2380
decline	VERB	O	O	2380
in	ADP	O	O	2380
scopolamine	NOUN	O	Chemical	2380
-	PUNCT	O	O	2380
injected	VERB	O	O	2380
rats	NOUN	O	O	2380
and	CCONJ	O	O	2380
in	ADP	O	O	2380
amyloid	NOUN	O	O	2380
beta	NOUN	O	O	2380
peptide(1	PROPN	O	O	2380
-	PUNCT	O	O	2380
42)-infused	VERB	O	O	2380
rats	NOUN	O	O	2380
.	PUNCT	O	O	2380
Maltolyl	NOUN	O	O	2381
p	NOUN	O	O	2381
-	PUNCT	O	O	2381
coumarate	ADJ	O	O	2381
was	AUX	O	O	2381
found	VERB	O	O	2381
to	PART	O	O	2381
attenuate	VERB	O	O	2381
cognitive deficits	NOUN	O	Disease	2381
in	ADP	O	O	2381
both	PRON	O	O	2381
rat	NOUN	O	O	2381
models	NOUN	O	O	2381
using	VERB	O	O	2381
passive	ADJ	O	O	2381
avoidance	NOUN	O	O	2381
test	NOUN	O	O	2381
and	CCONJ	O	O	2381
to	PART	O	O	2381
reduce	VERB	O	O	2381
apoptotic	ADJ	O	O	2381
cell	NOUN	O	O	2381
death	NOUN	O	O	2381
observed	VERB	O	O	2381
in	ADP	O	O	2381
the	PRON	O	O	2381
hippocampus	NOUN	O	O	2381
of	ADP	O	O	2381
the	PRON	O	O	2381
amyloid	NOUN	O	O	2381
beta	NOUN	O	O	2381
peptide(1	PROPN	O	O	2381
-	PUNCT	O	O	2381
42)-infused	VERB	O	O	2381
rats	NOUN	O	O	2381
.	PUNCT	O	O	2381
We	PRON	O	O	2382
also	ADV	O	O	2382
examined	VERB	O	O	2382
the	PRON	O	O	2382
neuroprotective	ADJ	O	O	2382
effects	NOUN	O	O	2382
of	ADP	O	O	2382
maltolyl	VERB	O	O	2382
p	NOUN	O	O	2382
-	PUNCT	O	O	2382
coumarate	ADJ	O	O	2382
in	ADP	O	O	2382
vitro	X	O	O	2382
using	VERB	O	O	2382
SH	PROPN	O	O	2382
-	PUNCT	O	O	2382
SY5Y	NOUN	O	O	2382
cells	NOUN	O	O	2382
.	PUNCT	O	O	2382
Cells	NOUN	O	O	2383
were	AUX	O	O	2383
pretreated	VERB	O	O	2383
with	ADP	O	O	2383
maltolyl	VERB	O	O	2383
p	NOUN	O	O	2383
-	PUNCT	O	O	2383
coumarate	ADJ	O	O	2383
,	PUNCT	O	O	2383
before	ADP	O	O	2383
exposed	VERB	O	O	2383
to	PART	O	O	2383
amyloid	NOUN	O	O	2383
beta	NOUN	O	O	2383
peptide(1	PROPN	O	O	2383
-	PUNCT	O	O	2383
42	NUM	O	O	2383
)	PUNCT	O	O	2383
,	PUNCT	O	O	2383
glutamate	NOUN	O	Chemical	2383
or	CCONJ	O	O	2383
H2O2	NOUN	O	O	2383
.	PUNCT	O	O	2383
We	PRON	O	O	2384
found	VERB	O	O	2384
that	SCONJ	O	O	2384
maltolyl	VERB	O	O	2384
p	NOUN	O	O	2384
-	PUNCT	O	O	2384
coumarate	ADJ	O	O	2384
significantly	ADV	O	O	2384
decreased	VERB	O	O	2384
apoptotic	ADJ	O	O	2384
cell	NOUN	O	O	2384
death	NOUN	O	O	2384
and	CCONJ	O	O	2384
reduced	VERB	O	O	2384
reactive	ADJ	O	O	2384
oxygen	NOUN	O	Chemical	2384
species	NOUN	O	O	2384
,	PUNCT	O	O	2384
cytochrome	ADP	O	O	2384
c	X	O	O	2384
release	NOUN	O	O	2384
,	PUNCT	O	O	2384
and	CCONJ	O	O	2384
caspase	NOUN	O	O	2384
3	X	O	O	2384
activation	NOUN	O	O	2384
.	PUNCT	O	O	2384
Taking	VERB	O	O	2385
these	PRON	O	O	2385
in	ADP	O	O	2385
vitro	X	O	O	2385
and	CCONJ	O	O	2385
in	ADP	O	O	2385
vivo	VERB	O	O	2385
results	VERB	O	O	2385
together	ADV	O	O	2385
,	PUNCT	O	O	2385
our	PRON	O	O	2385
study	VERB	O	O	2385
suggests	VERB	O	O	2385
that	SCONJ	O	O	2385
maltolyl	VERB	O	O	2385
p	NOUN	O	O	2385
-	PUNCT	O	O	2385
coumarate	ADJ	O	O	2385
is	AUX	O	O	2385
a	PRON	O	O	2385
potentially	ADV	O	O	2385
effective	ADJ	O	O	2385
candidate	NOUN	O	O	2385
against	ADP	O	O	2385
Alzheimer	NOUN	O	Disease	2385
's	AUX	O	O	2385
disease	PROPN	O	O	2385
that	SCONJ	O	O	2385
is	AUX	O	O	2385
characterized	VERB	O	O	2385
by	ADP	O	O	2385
wide	ADV	O	O	2385
spread	VERB	O	O	2385
neuronal	ADJ	O	O	2385
death	NOUN	O	O	2385
and	CCONJ	O	O	2385
progressive	ADJ	O	O	2385
decline	VERB	O	O	2385
of	ADP	O	O	2385
cognitive	ADJ	O	O	2385
function	NOUN	O	O	2385
.	PUNCT	O	O	2385
Interaction	NOUN	O	O	2388
between	ADP	O	O	2388
warfarin	VERB	O	Chemical	2388
and	CCONJ	O	O	2388
levofloxacin	PROPN	O	Chemical	2388
:	PUNCT	O	O	2388
case	NOUN	O	O	2388
series	PROPN	O	O	2388
.	PUNCT	O	O	2388
Warfarin	PROPN	O	Chemical	2389
is	AUX	O	O	2389
the	PRON	O	O	2389
most	ADV	O	O	2389
widely	ADV	O	O	2389
used	VERB	O	O	2389
oral	ADJ	O	O	2389
anticoagulant	ADJ	O	O	2389
and	CCONJ	O	O	2389
is	AUX	O	O	2389
indicated	VERB	O	O	2389
for	ADP	O	O	2389
many	ADJ	O	O	2389
clinical	ADJ	O	O	2389
conditions	NOUN	O	O	2389
.	PUNCT	O	O	2389
Levofloxacin	PROPN	O	O	2390
,	PUNCT	O	O	2390
a	PRON	O	O	2390
fluoroquinolone	NOUN	O	O	2390
,	PUNCT	O	O	2390
is	AUX	O	O	2390
one	NUM	O	O	2390
of	ADP	O	O	2390
the	PRON	O	O	2390
most	ADV	O	O	2390
commonly	ADV	O	O	2390
prescribed	VERB	O	O	2390
antibiotics	VERB	O	O	2390
in	ADP	O	O	2390
clinical	ADJ	O	O	2390
practice	VERB	O	O	2390
and	CCONJ	O	O	2390
is	AUX	O	O	2390
effective	ADJ	O	O	2390
against	ADP	O	O	2390
Gram	PROPN	O	O	2390
-	PUNCT	O	O	2390
positive	ADJ	O	O	2390
,	PUNCT	O	O	2390
Gram	PROPN	O	O	2390
-	PUNCT	O	O	2390
negative	ADJ	O	O	2390
,	PUNCT	O	O	2390
and	CCONJ	O	O	2390
atypical	ADJ	O	O	2390
bacteria	NOUN	O	O	2390
.	PUNCT	O	O	2390
While	SCONJ	O	O	2391
small	ADJ	O	O	2391
prospective	ADJ	O	O	2391
studies	NOUN	O	O	2391
have	VERB	O	O	2391
not	PART	O	O	2391
revealed	VERB	O	O	2391
any	PRON	O	O	2391
significant	ADJ	O	O	2391
drug	NOUN	O	O	2391
-	PUNCT	O	O	2391
drug	NOUN	O	O	2391
interaction	NOUN	O	O	2391
between	ADP	O	O	2391
warfarin	VERB	O	Chemical	2391
and	CCONJ	O	O	2391
levofloxacin	PROPN	O	Chemical	2391
,	PUNCT	O	O	2391
several	ADJ	O	O	2391
case	NOUN	O	O	2391
reports	VERB	O	O	2391
have	VERB	O	O	2391
indicated	VERB	O	O	2391
that	SCONJ	O	O	2391
levofloxacin	PROPN	O	Chemical	2391
may	AUX	O	O	2391
significantly	ADV	O	O	2391
potentiate	VERB	O	O	2391
the	PRON	O	O	2391
anticoagulation	NOUN	O	O	2391
effect	VERB	O	O	2391
of	ADP	O	O	2391
warfarin	VERB	O	Chemical	2391
.	PUNCT	O	O	2391
We	PRON	O	O	2392
report	VERB	O	O	2392
3	X	O	O	2392
cases	NOUN	O	O	2392
of	ADP	O	O	2392
serious	ADJ	O	O	2392
bleeding	VERB	O	Disease	2392
complications	NOUN	O	O	2392
that	SCONJ	O	O	2392
appear	VERB	O	O	2392
to	PART	O	O	2392
be	AUX	O	O	2392
the	PRON	O	O	2392
result	VERB	O	O	2392
of	ADP	O	O	2392
the	PRON	O	O	2392
interaction	NOUN	O	O	2392
between	ADP	O	O	2392
warfarin	VERB	O	Chemical	2392
and	CCONJ	O	O	2392
levofloxacin	PROPN	O	Chemical	2392
.	PUNCT	O	O	2392
Physicians	NOUN	O	O	2393
should	AUX	O	O	2393
be	AUX	O	O	2393
aware	ADJ	O	O	2393
of	ADP	O	O	2393
this	PRON	O	O	2393
potential	ADJ	O	O	2393
interaction	NOUN	O	O	2393
and	CCONJ	O	O	2393
use	VERB	O	O	2393
caution	NOUN	O	O	2393
when	SCONJ	O	O	2393
prescribing	VERB	O	O	2393
levofloxacin	PROPN	O	Chemical	2393
to	PART	O	O	2393
patients	NOUN	O	O	2393
taking	VERB	O	O	2393
warfarin	VERB	O	Chemical	2393
.	PUNCT	O	O	2393
Mutations	NOUN	O	O	2396
associated	VERB	O	O	2396
with	ADP	O	O	2396
lamivudine	NOUN	O	Chemical	2396
-	PUNCT	O	O	2396
resistance	NOUN	O	O	2396
in	ADP	O	O	2396
therapy	NOUN	O	O	2396
-	PUNCT	O	O	2396
na	INTJ	O	O	2396
ve	VERB	O	O	2396
hepatitis B	PROPN	O	Disease	2396
virus	NOUN	O	O	2396
(	PUNCT	O	O	2396
HBV	NOUN	O	O	2396
)	PUNCT	O	O	2396
infected	VERB	O	O	2396
patients	NOUN	O	O	2396
with	ADP	O	O	2396
and	CCONJ	O	O	2396
without	ADP	O	O	2396
HIV	PROPN	O	O	2396
co	NOUN	O	O	2396
-	PUNCT	O	O	2396
infection	NOUN	O	Disease	2396
:	PUNCT	O	O	2396
implications	NOUN	O	O	2396
for	ADP	O	O	2396
antiretroviral	ADJ	O	O	2396
therapy	NOUN	O	O	2396
in	ADP	O	O	2396
HBV	NOUN	O	O	2396
and	CCONJ	O	O	2396
HIV	PROPN	O	O	2396
co	NOUN	O	O	2396
-	PUNCT	O	O	2396
infected	VERB	O	O	2396
South	NOUN	O	O	2396
African	ADJ	O	O	2396
patients	NOUN	O	O	2396
.	PUNCT	O	O	2396
This	PRON	O	O	2397
was	AUX	O	O	2397
an	PRON	O	O	2397
exploratory	ADJ	O	O	2397
study	VERB	O	O	2397
to	PART	O	O	2397
investigate	VERB	O	O	2397
lamivudine	NOUN	O	Chemical	2397
-	PUNCT	O	O	2397
resistant	ADJ	O	O	2397
hepatitis B	PROPN	O	Disease	2397
virus	NOUN	O	O	2397
(	PUNCT	O	O	2397
HBV	NOUN	O	O	2397
)	PUNCT	O	O	2397
strains	VERB	O	O	2397
in	ADP	O	O	2397
selected	VERB	O	O	2397
lamivudine	NOUN	O	Chemical	2397
-	PUNCT	O	O	2397
na	INTJ	O	O	2397
ve	VERB	O	O	2397
HBV	NOUN	O	O	2397
carriers	NOUN	O	O	2397
with	ADP	O	O	2397
and	CCONJ	O	O	2397
without	ADP	O	O	2397
human	PROPN	O	O	2397
immunodeficiency	NOUN	O	Disease	2397
virus	NOUN	O	O	2397
(	PUNCT	O	O	2397
HIV	PROPN	O	O	2397
)	PUNCT	O	O	2397
co	NOUN	O	O	2397
-	PUNCT	O	O	2397
infection	NOUN	O	Disease	2397
in	ADP	O	O	2397
South	NOUN	O	O	2397
African	ADJ	O	O	2397
patients	NOUN	O	O	2397
.	PUNCT	O	O	2397
Thirty	NUM	O	O	2398
-	PUNCT	O	O	2398
five	NUM	O	O	2398
lamivudine	NOUN	O	Chemical	2398
-	PUNCT	O	O	2398
na	INTJ	O	O	2398
ve	VERB	O	O	2399
HBV	NOUN	O	O	2399
infected	VERB	O	O	2399
patients	NOUN	O	O	2399
with	ADP	O	O	2399
or	CCONJ	O	O	2399
without	ADP	O	O	2399
HIV	PROPN	O	O	2399
co	NOUN	O	O	2399
-	PUNCT	O	O	2399
infection	NOUN	O	Disease	2399
were	AUX	O	O	2399
studied	VERB	O	O	2399
:	PUNCT	O	O	2399
15	NUM	O	O	2399
chronic	ADJ	O	O	2399
HBV	NOUN	O	O	2399
mono	PROPN	O	O	2399
-	PUNCT	O	O	2399
infected	VERB	O	O	2399
patients	NOUN	O	O	2399
and	CCONJ	O	O	2399
20	NUM	O	O	2399
HBV	NOUN	O	O	2399
-	PUNCT	O	O	2399
HIV	PROPN	O	O	2399
co	NOUN	O	O	2399
-	PUNCT	O	O	2399
infected	VERB	O	O	2399
patients	NOUN	O	O	2399
.	PUNCT	O	O	2399
The	PRON	O	O	2400
latter	ADJ	O	O	2400
group	NOUN	O	O	2400
was	AUX	O	O	2400
further	ADV	O	O	2400
sub	ADJ	O	O	2400
-	PUNCT	O	O	2400
divided	VERB	O	O	2400
into	ADP	O	O	2400
13	NUM	O	O	2400
occult	NOUN	O	O	2400
HBV	NOUN	O	O	2400
(	PUNCT	O	O	2400
HBsAg	PROPN	O	Chemical	2400
-	PUNCT	O	O	2400
negative	ADJ	O	O	2400
)	PUNCT	O	O	2400
and	CCONJ	O	O	2400
7	NUM	O	O	2400
overt	ADJ	O	O	2400
HBV	NOUN	O	O	2400
(	PUNCT	O	O	2400
HBsAg-	PROPN	O	O	2400
positive	ADJ	O	O	2400
)	PUNCT	O	O	2400
patients	NOUN	O	O	2400
.	PUNCT	O	O	2400
HBsAg	PROPN	O	Chemical	2401
,	PUNCT	O	O	2401
anti	ADJ	O	O	2401
-	PUNCT	O	O	2401
HBs	PROPN	O	O	2401
,	PUNCT	O	O	2401
anti	ADJ	O	O	2401
-	PUNCT	O	O	2401
HBc	PROPN	O	O	2401
,	PUNCT	O	O	2401
and	CCONJ	O	O	2401
anti	ADJ	O	O	2401
-	PUNCT	O	O	2401
HIV	PROPN	O	O	2401
1/2	NUM	O	O	2401
were	AUX	O	O	2401
determined	VERB	O	O	2401
as	ADP	O	O	2401
part	NOUN	O	O	2401
of	ADP	O	O	2401
routine	ADJ	O	O	2401
diagnosis	NOUN	O	O	2401
using	VERB	O	O	2401
Axsym	PROPN	O	O	2401
assays	NOUN	O	O	2401
(	PUNCT	O	O	2401
Abbott	PROPN	O	O	2401
Laboratories	NOUN	O	O	2401
,	PUNCT	O	O	2401
North	NOUN	O	O	2401
Chicago	PROPN	O	O	2401
,	PUNCT	O	O	2401
IL	PROPN	O	O	2401
)	PUNCT	O	O	2401
.	PUNCT	O	O	2401
Serum	NOUN	O	O	2402
samples	NOUN	O	O	2402
were	AUX	O	O	2402
PCR	PROPN	O	O	2402
amplified	VERB	O	O	2402
with	ADP	O	O	2402
HBV	NOUN	O	O	2402
reverse	VERB	O	O	2402
transcriptase	VERB	O	O	2402
(	PUNCT	O	O	2402
RT	PROPN	O	O	2402
)	PUNCT	O	O	2402
primers	NOUN	O	O	2402
,	PUNCT	O	O	2402
followed	VERB	O	O	2402
by	ADP	O	O	2402
direct	ADJ	O	O	2402
sequencing	VERB	O	O	2402
across	ADP	O	O	2402
the	PRON	O	O	2402
tyrosine	NOUN	O	Chemical	2402
-	PUNCT	O	O	2402
methionine	NOUN	O	O	2402
-	PUNCT	O	O	2402
aspartate	NOUN	O	Chemical	2402
-	PUNCT	O	O	2402
aspartate	NOUN	O	Chemical	2402
(	PUNCT	O	O	2402
YMDD	NOUN	O	O	2402
)	PUNCT	O	O	2402
motif	NOUN	O	O	2402
of	ADP	O	O	2402
the	PRON	O	O	2402
major	ADJ	O	O	2402
catalytic	ADJ	O	O	2402
region	NOUN	O	O	2402
in	ADP	O	O	2402
the	PRON	O	O	2402
C	NOUN	O	O	2402
domain	NOUN	O	O	2402
of	ADP	O	O	2402
the	PRON	O	O	2402
HBV	NOUN	O	O	2402
RT	PROPN	O	O	2402
enzyme	NOUN	O	O	2402
.	PUNCT	O	O	2402
HBV	NOUN	O	O	2403
lamivudine	NOUN	O	Chemical	2403
-	PUNCT	O	O	2403
resistant	ADJ	O	O	2403
strains	VERB	O	O	2403
were	AUX	O	O	2403
detected	VERB	O	O	2403
in	ADP	O	O	2403
3	X	O	O	2403
of	ADP	O	O	2403
15	NUM	O	O	2403
mono	PROPN	O	O	2403
-	PUNCT	O	O	2403
infected	VERB	O	O	2403
chronic	ADJ	O	O	2403
hepatitis B	PROPN	O	Disease	2403
patients	NOUN	O	O	2403
and	CCONJ	O	O	2403
10	NUM	O	O	2403
of	ADP	O	O	2403
20	NUM	O	O	2403
HBV	NOUN	O	O	2403
-	PUNCT	O	O	2403
HIV	PROPN	O	O	2403
co	NOUN	O	O	2403
-	PUNCT	O	O	2403
infected	VERB	O	O	2403
patients	NOUN	O	O	2403
.	PUNCT	O	O	2403
To	PART	O	O	2404
the	PRON	O	O	2404
best	ADV	O	O	2404
of	ADP	O	O	2404
our	PRON	O	O	2404
knowledge	NOUN	O	O	2404
,	PUNCT	O	O	2404
this	PRON	O	O	2404
constitutes	VERB	O	O	2404
the	PRON	O	O	2404
first	ADV	O	O	2404
report	VERB	O	O	2404
of	ADP	O	O	2404
HBV	NOUN	O	O	2404
lamivudine	NOUN	O	Chemical	2404
-	PUNCT	O	O	2404
resistant	ADJ	O	O	2404
strains	VERB	O	O	2404
in	ADP	O	O	2404
therapy	NOUN	O	O	2404
-	PUNCT	O	O	2404
na	INTJ	O	O	2404
ve	VERB	O	O	2404
HBV	NOUN	O	O	2404
-	PUNCT	O	O	2404
HIV	PROPN	O	O	2404
co	NOUN	O	O	2404
-	PUNCT	O	O	2404
infected	VERB	O	O	2404
patients	NOUN	O	O	2404
.	PUNCT	O	O	2404
It	PRON	O	O	2405
remains	VERB	O	O	2405
to	PART	O	O	2405
be	AUX	O	O	2405
seen	VERB	O	O	2405
whether	SCONJ	O	O	2405
such	ADJ	O	O	2405
pre	VERB	O	O	2405
-	PUNCT	O	O	2405
existing	VERB	O	O	2405
antiviral	ADJ	O	O	2405
mutations	NOUN	O	O	2405
could	AUX	O	O	2405
result	VERB	O	O	2405
in	ADP	O	O	2405
widespread	ADJ	O	O	2405
emergence	NOUN	O	O	2405
of	ADP	O	O	2405
HBV	NOUN	O	O	2405
resistant	ADJ	O	O	2405
strains	VERB	O	O	2405
when	SCONJ	O	O	2405
lamivudine	NOUN	O	Chemical	2405
-	PUNCT	O	O	2405
containing	VERB	O	O	2405
highly	ADV	O	O	2405
active	ADJ	O	O	2405
antiretroviral	ADJ	O	O	2405
(	PUNCT	O	O	2405
ARV	PROPN	O	O	2405
)	PUNCT	O	O	2405
treatment	NOUN	O	O	2405
(	PUNCT	O	O	2405
HAART	PROPN	O	O	2405
)	PUNCT	O	O	2405
regimens	NOUN	O	O	2405
become	VERB	O	O	2405
widely	ADV	O	O	2405
applied	VERB	O	O	2405
in	ADP	O	O	2405
South	NOUN	O	O	2405
Africa	PROPN	O	O	2405
,	PUNCT	O	O	2405
as	ADP	O	O	2405
this	PRON	O	O	2405
is	AUX	O	O	2405
likely	ADV	O	O	2405
to	PART	O	O	2405
have	VERB	O	O	2405
potential	ADJ	O	O	2405
implications	NOUN	O	O	2405
in	ADP	O	O	2405
the	PRON	O	O	2405
management	NOUN	O	O	2405
of	ADP	O	O	2405
HBV	NOUN	O	O	2405
-	PUNCT	O	O	2405
HIV	PROPN	O	O	2405
co	NOUN	O	O	2405
-	PUNCT	O	O	2405
infected	VERB	O	O	2405
patients	NOUN	O	O	2405
.	PUNCT	O	O	2405
Sex	NOUN	O	O	2408
differences	NOUN	O	O	2408
in	ADP	O	O	2408
NMDA	PROPN	O	Chemical	2408
antagonist	NOUN	O	O	2408
enhancement	NOUN	O	O	2408
of	ADP	O	O	2408
morphine	NOUN	O	Chemical	2408
antihyperalgesia	NOUN	O	O	2408
in	ADP	O	O	2408
a	PRON	O	O	2408
capsaicin	NOUN	O	Chemical	2408
model	NOUN	O	O	2408
of	ADP	O	O	2408
persistent	ADJ	O	O	2408
pain	NOUN	O	Disease	2408
:	PUNCT	O	O	2408
comparisons	NOUN	O	O	2408
to	PART	O	O	2408
two	NUM	O	O	2408
models	NOUN	O	O	2408
of	ADP	O	O	2408
acute pain	NOUN	O	Disease	2408
.	PUNCT	O	O	2408
In	ADP	O	O	2409
acute pain	NOUN	O	Disease	2409
models	NOUN	O	O	2409
,	PUNCT	O	O	2409
N	NUM	O	O	2409
-	PUNCT	O	O	2409
methyl	NOUN	O	O	2409
-	PUNCT	O	O	2409
D	NOUN	O	O	2409
-	PUNCT	O	O	2409
aspartate	NOUN	O	Chemical	2409
(	PUNCT	O	O	2409
NMDA	PROPN	O	Chemical	2409
)	PUNCT	O	O	2409
antagonists	NOUN	O	O	2409
enhance	VERB	O	O	2409
the	PRON	O	O	2409
antinociceptive	VERB	O	O	2409
effects	NOUN	O	O	2409
of	ADP	O	O	2409
morphine	NOUN	O	Chemical	2409
to	PART	O	O	2409
a	PRON	O	O	2409
greater	ADJ	O	O	2409
extent	NOUN	O	O	2409
in	ADP	O	O	2409
males	NOUN	O	O	2409
than	ADP	O	O	2409
females	NOUN	O	O	2409
.	PUNCT	O	O	2409
The	PRON	O	O	2410
purpose	NOUN	O	O	2410
of	ADP	O	O	2410
this	PRON	O	O	2410
investigation	NOUN	O	O	2410
was	AUX	O	O	2410
to	PART	O	O	2410
extend	VERB	O	O	2410
these	PRON	O	O	2410
findings	NOUN	O	O	2410
to	PART	O	O	2410
a	PRON	O	O	2410
persistent	ADJ	O	O	2410
pain	NOUN	O	Disease	2410
model	NOUN	O	O	2410
which	PRON	O	O	2410
could	AUX	O	O	2410
be	AUX	O	O	2410
distinguished	VERB	O	O	2410
from	ADP	O	O	2410
acute pain	NOUN	O	Disease	2410
models	NOUN	O	O	2410
on	ADP	O	O	2410
the	PRON	O	O	2410
basis	NOUN	O	O	2410
of	ADP	O	O	2410
the	PRON	O	O	2410
nociceptive	ADJ	O	O	2410
fibers	NOUN	O	O	2410
activated	VERB	O	O	2410
,	PUNCT	O	O	2410
neurochemical	ADJ	O	O	2410
substrates	NOUN	O	O	2410
,	PUNCT	O	O	2410
and	CCONJ	O	O	2410
duration	NOUN	O	O	2410
of	ADP	O	O	2410
the	PRON	O	O	2410
nociceptive	ADJ	O	O	2410
stimulus	NOUN	O	O	2410
.	PUNCT	O	O	2410
To	PART	O	O	2411
this	PRON	O	O	2411
end	VERB	O	O	2411
,	PUNCT	O	O	2411
persistent	ADJ	O	O	2411
hyperalgesia	NOUN	O	Disease	2411
was	AUX	O	O	2411
induced	VERB	O	O	2411
by	ADP	O	O	2411
administration	NOUN	O	O	2411
of	ADP	O	O	2411
capsaicin	NOUN	O	Chemical	2411
in	ADP	O	O	2411
the	PRON	O	O	2411
tail	NOUN	O	O	2411
of	ADP	O	O	2411
gonadally	ADV	O	O	2411
intact	ADJ	O	O	2411
F344	PROPN	O	O	2411
rats	NOUN	O	O	2411
,	PUNCT	O	O	2411
following	VERB	O	O	2411
which	PRON	O	O	2411
the	PRON	O	O	2411
tail	NOUN	O	O	2411
was	AUX	O	O	2411
immersed	VERB	O	O	2411
in	ADP	O	O	2411
a	PRON	O	O	2411
mildly	ADV	O	O	2411
noxious	ADJ	O	O	2411
thermal	PROPN	O	O	2411
stimulus	NOUN	O	O	2411
,	PUNCT	O	O	2411
and	CCONJ	O	O	2411
tail	NOUN	O	O	2411
-	PUNCT	O	O	2411
withdrawal	NOUN	O	O	2411
latencies	NOUN	O	O	2411
measured	VERB	O	O	2411
.	PUNCT	O	O	2411
For	ADP	O	O	2412
comparison	NOUN	O	O	2412
,	PUNCT	O	O	2412
tests	VERB	O	O	2412
were	AUX	O	O	2412
conducted	VERB	O	O	2412
in	ADP	O	O	2412
two	NUM	O	O	2412
acute pain	NOUN	O	Disease	2412
models	NOUN	O	O	2412
,	PUNCT	O	O	2412
the	PRON	O	O	2412
hotplate	PROPN	O	O	2412
and	CCONJ	O	O	2412
warm	ADJ	O	O	2412
water	PROPN	O	O	2412
tail	NOUN	O	O	2412
-	PUNCT	O	O	2412
withdrawal	NOUN	O	O	2412
procedures	NOUN	O	O	2412
.	PUNCT	O	O	2412
In	ADP	O	O	2413
males	NOUN	O	O	2413
,	PUNCT	O	O	2413
the	PRON	O	O	2413
non	ADJ	O	O	2413
-	PUNCT	O	O	2413
competitive	ADJ	O	O	2413
NMDA	PROPN	O	Chemical	2413
antagonist	NOUN	O	O	2413
dextromethorphan	PROPN	O	Chemical	2413
enhanced	VERB	O	O	2413
the	PRON	O	O	2413
antihyperalgesic	NOUN	O	O	2413
effect	VERB	O	O	2413
of	ADP	O	O	2413
low	ADJ	O	O	2413
to	PART	O	O	2413
moderate	ADJ	O	O	2413
doses	NOUN	O	O	2413
of	ADP	O	O	2413
morphine	NOUN	O	Chemical	2413
in	ADP	O	O	2413
a	PRON	O	O	2413
dose	NOUN	O	O	2413
-	PUNCT	O	O	2413
and	CCONJ	O	O	2413
time	NOUN	O	O	2413
-	PUNCT	O	O	2413
dependent	ADJ	O	O	2413
manner	VERB	O	O	2413
.	PUNCT	O	O	2413
Enhancement	NOUN	O	O	2414
of	ADP	O	O	2414
morphine	NOUN	O	Chemical	2414
antinociception	NOUN	O	O	2414
by	ADP	O	O	2414
dextromethorphan	PROPN	O	Chemical	2414
was	AUX	O	O	2414
seen	VERB	O	O	2414
in	ADP	O	O	2414
both	PRON	O	O	2414
males	NOUN	O	O	2414
and	CCONJ	O	O	2414
females	NOUN	O	O	2414
in	ADP	O	O	2414
the	PRON	O	O	2414
acute pain	NOUN	O	Disease	2414
models	NOUN	O	O	2414
,	PUNCT	O	O	2414
with	ADP	O	O	2414
the	PRON	O	O	2414
magnitude	NOUN	O	O	2414
of	ADP	O	O	2414
this	PRON	O	O	2414
effect	VERB	O	O	2414
being	AUX	O	O	2414
greater	ADJ	O	O	2414
in	ADP	O	O	2414
males	NOUN	O	O	2414
.	PUNCT	O	O	2414
These	PRON	O	O	2415
findings	NOUN	O	O	2415
demonstrate	VERB	O	O	2415
a	PRON	O	O	2415
sexually	ADV	O	O	2415
-	PUNCT	O	O	2415
dimorphic	ADJ	O	O	2415
interaction	NOUN	O	O	2415
between	ADP	O	O	2415
NMDA	PROPN	O	Chemical	2415
antagonists	NOUN	O	O	2415
and	CCONJ	O	O	2415
morphine	NOUN	O	Chemical	2415
in	ADP	O	O	2415
a	PRON	O	O	2415
persistent	ADJ	O	O	2415
pain	NOUN	O	Disease	2415
model	NOUN	O	O	2415
that	SCONJ	O	O	2415
can	AUX	O	O	2415
be	AUX	O	O	2415
distinguished	VERB	O	O	2415
from	ADP	O	O	2415
those	PRON	O	O	2415
observed	VERB	O	O	2415
in	ADP	O	O	2415
acute pain	NOUN	O	Disease	2415
models	NOUN	O	O	2415
.	PUNCT	O	O	2415
Development	NOUN	O	O	2418
of	ADP	O	O	2418
proteinuria	X	O	Disease	2418
after	ADP	O	O	2418
switch	VERB	O	O	2418
to	PART	O	O	2418
sirolimus	NOUN	O	Chemical	2418
-	PUNCT	O	O	2418
based	VERB	O	O	2418
immunosuppression	NOUN	O	O	2418
in	ADP	O	O	2418
long	ADV	O	O	2418
-	PUNCT	O	O	2418
term	NOUN	O	O	2418
cardiac	ADJ	O	O	2418
transplant	NOUN	O	O	2418
patients	NOUN	O	O	2418
.	PUNCT	O	O	2418
Calcineurin	NOUN	O	O	2419
-	PUNCT	O	O	2419
inhibitor	NOUN	O	O	2419
therapy	NOUN	O	O	2419
can	AUX	O	O	2419
lead	VERB	O	Chemical	2419
to	PART	O	O	2419
renal dysfunction	NOUN	O	Disease	2419
in	ADP	O	O	2419
heart	NOUN	O	O	2419
transplantation	NOUN	O	O	2419
patients	NOUN	O	O	2419
.	PUNCT	O	O	2419
The	PRON	O	O	2420
novel	NOUN	O	O	2420
immunosuppressive	ADJ	O	O	2420
(	PUNCT	O	O	2420
IS	AUX	O	O	2420
)	PUNCT	O	O	2420
drug	NOUN	O	O	2420
sirolmus	NOUN	O	O	2420
(	PUNCT	O	O	2420
Srl	NOUN	O	O	2420
)	PUNCT	O	O	2420
lacks	VERB	O	O	2420
nephrotoxic	NOUN	O	Disease	2420
effects	NOUN	O	O	2420
;	PUNCT	O	O	2420
however	ADV	O	O	2420
,	PUNCT	O	O	2420
proteinuria	X	O	Disease	2420
associated	VERB	O	O	2420
with	ADP	O	O	2420
Srl	NOUN	O	O	2420
has	VERB	O	O	2420
been	AUX	O	O	2420
reported	VERB	O	O	2420
following	VERB	O	O	2420
renal	ADJ	O	O	2420
transplantation	NOUN	O	O	2420
.	PUNCT	O	O	2420
In	ADP	O	O	2421
cardiac	ADJ	O	O	2421
transplantation	NOUN	O	O	2421
,	PUNCT	O	O	2421
the	PRON	O	O	2421
incidence	NOUN	O	O	2421
of	ADP	O	O	2421
proteinuria	X	O	Disease	2421
associated	VERB	O	O	2421
with	ADP	O	O	2421
Srl	NOUN	O	O	2421
is	AUX	O	O	2421
unknown	ADJ	O	O	2421
.	PUNCT	O	O	2421
In	ADP	O	O	2422
this	PRON	O	O	2422
study	VERB	O	O	2422
,	PUNCT	O	O	2422
long	ADV	O	O	2422
-	PUNCT	O	O	2422
term	NOUN	O	O	2422
cardiac	ADJ	O	O	2422
transplant	NOUN	O	O	2422
patients	NOUN	O	O	2422
were	AUX	O	O	2422
switched	VERB	O	O	2422
from	ADP	O	O	2422
cyclosporine	NOUN	O	Chemical	2422
to	PART	O	O	2422
Srl	NOUN	O	O	2422
-	PUNCT	O	O	2422
based	VERB	O	O	2422
IS	AUX	O	O	2422
.	PUNCT	O	O	2422
Concomitant	ADJ	O	O	2423
IS	AUX	O	O	2423
consisted	VERB	O	O	2423
of	ADP	O	O	2423
mycophenolate mofetil	PROPN	O	Chemical	2423
steroids	NOUN	O	Chemical	2424
.	PUNCT	O	O	2424
Before	ADP	O	O	2425
the	PRON	O	O	2425
switch	VERB	O	O	2425
,	PUNCT	O	O	2425
11.5%	NOUN	O	O	2425
of	ADP	O	O	2425
patients	NOUN	O	O	2425
had	VERB	O	O	2425
high	ADJ	O	O	2425
-	PUNCT	O	O	2425
grade	NOUN	O	O	2425
proteinuria	X	O	Disease	2425
(	PUNCT	O	O	2425
>	PUNCT	O	O	2425
1.0	NUM	O	O	2425
g	X	O	O	2425
/	PUNCT	O	O	2425
day	NOUN	O	O	2425
)	PUNCT	O	O	2425
;	PUNCT	O	O	2425
this	PRON	O	O	2425
increased	VERB	O	O	2425
to	PART	O	O	2425
22.9%	NOUN	O	O	2425
postswitch	X	O	O	2425
(	PUNCT	O	O	2425
p	NOUN	O	O	2425
=	PUNCT	O	O	2425
0.006	NUM	O	O	2425
)	PUNCT	O	O	2425
.	PUNCT	O	O	2425
ACE	PROPN	O	O	2426
inhibitor	NOUN	O	O	2426
and	CCONJ	O	O	2426
angiotensin	NOUN	O	Chemical	2426
-	PUNCT	O	O	2426
releasing	VERB	O	O	2426
blocker	NOUN	O	O	2426
(	PUNCT	O	O	2426
ARB	PROPN	O	O	2426
)	PUNCT	O	O	2426
therapy	NOUN	O	O	2426
reduced	VERB	O	O	2426
proteinuria	X	O	Disease	2426
development	NOUN	O	O	2426
.	PUNCT	O	O	2426
Patients	NOUN	O	O	2427
without	ADP	O	O	2427
proteinuria	X	O	Disease	2427
had	VERB	O	O	2427
increased	VERB	O	O	2427
renal	ADJ	O	O	2427
function	NOUN	O	O	2427
(	PUNCT	O	O	2427
median	ADJ	O	O	2427
42.5	NUM	O	O	2427
vs.	CCONJ	O	O	2427
64.1	NUM	O	O	2427
,	PUNCT	O	O	2427
p	NOUN	O	O	2427
=	PUNCT	O	O	2427
0.25	NUM	O	O	2427
)	PUNCT	O	O	2427
,	PUNCT	O	O	2427
whereas	SCONJ	O	O	2427
patients	NOUN	O	O	2427
who	PRON	O	O	2427
developed	VERB	O	O	2427
high	ADJ	O	O	2427
-	PUNCT	O	O	2427
grade	NOUN	O	O	2427
proteinuria	X	O	Disease	2427
showed	VERB	O	O	2427
decreased renal function	NOUN	O	Disease	2427
at	ADP	O	O	2427
the	PRON	O	O	2427
end	VERB	O	O	2427
of	ADP	O	O	2427
follow	VERB	O	O	2427
-	PUNCT	O	O	2427
up	ADP	O	O	2427
(	PUNCT	O	O	2427
median	ADJ	O	O	2427
39.6	NUM	O	O	2427
vs.	CCONJ	O	O	2427
29.2	NUM	O	O	2427
,	PUNCT	O	O	2427
p	NOUN	O	O	2427
=	PUNCT	O	O	2427
0.125	NUM	O	O	2427
)	PUNCT	O	O	2427
.	PUNCT	O	O	2427
Thus	ADV	O	O	2428
,	PUNCT	O	O	2428
proteinuria	X	O	Disease	2428
may	AUX	O	O	2428
develop	VERB	O	O	2428
in	ADP	O	O	2428
cardiac	ADJ	O	O	2428
transplant	NOUN	O	O	2428
patients	NOUN	O	O	2428
after	ADP	O	O	2428
switch	VERB	O	O	2428
to	PART	O	O	2428
Srl	NOUN	O	O	2428
,	PUNCT	O	O	2428
which	PRON	O	O	2428
may	AUX	O	O	2428
have	VERB	O	O	2428
an	PRON	O	O	2428
adverse	ADJ	O	O	2428
effect	VERB	O	O	2428
on	ADP	O	O	2428
renal	ADJ	O	O	2428
function	NOUN	O	O	2428
in	ADP	O	O	2428
these	PRON	O	O	2428
patients	NOUN	O	O	2428
.	PUNCT	O	O	2428
Srl	NOUN	O	O	2429
should	AUX	O	O	2429
be	AUX	O	O	2429
used	VERB	O	O	2429
with	ADP	O	O	2429
ACEi	PROPN	O	O	2429
/	PUNCT	O	O	2429
ARB	PROPN	O	O	2429
therapy	NOUN	O	O	2429
and	CCONJ	O	O	2429
patients	NOUN	O	O	2429
monitored	VERB	O	O	2429
for	ADP	O	O	2429
proteinuria	X	O	Disease	2429
and	CCONJ	O	O	2429
increased	VERB	O	O	2429
renal dysfunction	NOUN	O	Disease	2429
.	PUNCT	O	O	2429
Synthesis	NOUN	O	O	2432
of	ADP	O	O	2432
N	NUM	O	O	2432
-	PUNCT	O	O	2432
pyrimidinyl-2-phenoxyacetamides	NOUN	O	O	2432
as	ADP	O	O	2432
adenosine	PROPN	O	Chemical	2432
A2A	PROPN	O	O	2432
receptor	NOUN	O	O	2432
antagonists	NOUN	O	O	2432
.	PUNCT	O	O	2432
A	PRON	O	O	2433
series	PROPN	O	O	2433
of	ADP	O	O	2433
N	NUM	O	O	2433
-	PUNCT	O	O	2433
pyrimidinyl-2-phenoxyacetamide	NOUN	O	O	2433
adenosine	PROPN	O	Chemical	2433
A(2A	PROPN	O	O	2433
)	PUNCT	O	O	2433
antagonists	NOUN	O	O	2433
is	AUX	O	O	2433
described	VERB	O	O	2433
.	PUNCT	O	O	2433
>	PUNCT	O	O	2434
100	NUM	O	O	2434
)	PUNCT	O	O	2434
,	PUNCT	O	O	2434
and	CCONJ	O	O	2434
efficacy	NOUN	O	O	2434
(	PUNCT	O	O	2434
MED	NOUN	O	O	2434
10	NUM	O	O	2434
mg	VERB	O	O	2434
/	PUNCT	O	O	2434
kg	VERB	O	O	2434
p.o	PROPN	O	O	2434
.	PUNCT	O	O	2434
)	PUNCT	O	O	2434
in	ADP	O	O	2434
the	PRON	O	O	2434
rat	NOUN	O	O	2434
haloperidol	NOUN	O	Chemical	2434
-	PUNCT	O	O	2434
induced	VERB	O	O	2434
catalepsy	VERB	O	Disease	2434
model	NOUN	O	O	2434
for	ADP	O	O	2434
Parkinson	NOUN	O	O	2434
's	AUX	O	O	2434
disease	PROPN	O	O	2434
.	PUNCT	O	O	2434
Methamphetamine	NOUN	O	Chemical	2437
-	PUNCT	O	O	2437
induced	VERB	O	O	2437
neurotoxicity	NOUN	O	Disease	2437
and	CCONJ	O	O	2437
microglial	PROPN	O	O	2437
activation	NOUN	O	O	2437
are	AUX	O	O	2437
not	PART	O	O	2437
mediated	VERB	O	O	2437
by	ADP	O	O	2437
fractalkine	NOUN	O	O	2437
receptor	NOUN	O	O	2437
signaling	VERB	O	O	2437
.	PUNCT	O	O	2437
Methamphetamine	NOUN	O	Chemical	2438
(	PUNCT	O	O	2438
METH	NOUN	O	Chemical	2438
)	PUNCT	O	O	2438
damages	NOUN	O	O	2438
dopamine	NOUN	O	Chemical	2438
(	PUNCT	O	O	2438
DA	NOUN	O	Chemical	2438
)	PUNCT	O	O	2438
nerve	NOUN	O	O	2438
endings	NOUN	O	O	2438
by	ADP	O	O	2438
a	PRON	O	O	2438
process	NOUN	O	O	2438
that	SCONJ	O	O	2438
has	VERB	O	O	2438
been	AUX	O	O	2438
linked	VERB	O	O	2438
to	PART	O	O	2438
microglial	PROPN	O	O	2438
activation	NOUN	O	O	2438
but	CCONJ	O	O	2438
the	PRON	O	O	2438
signaling	VERB	O	O	2438
pathways	NOUN	O	O	2438
that	SCONJ	O	O	2438
mediate	VERB	O	O	2438
this	PRON	O	O	2438
response	NOUN	O	O	2438
have	VERB	O	O	2438
not	PART	O	O	2438
yet	ADV	O	O	2438
been	AUX	O	O	2438
delineated	VERB	O	O	2438
.	PUNCT	O	O	2438
Neurosci	NOUN	O	O	2439
.	PUNCT	O	O	2439
9	NUM	O	O	2439
(	PUNCT	O	O	2439
2006	NUM	O	O	2439
)	PUNCT	O	O	2439
,	PUNCT	O	O	2439
917	NUM	O	O	2439
]	PUNCT	O	O	2439
recently	ADV	O	O	2439
identified	VERB	O	O	2439
the	PRON	O	O	2439
microglial	PROPN	O	O	2439
-	PUNCT	O	O	2439
specific	ADJ	O	O	2439
fractalkine	NOUN	O	O	2439
receptor	NOUN	O	O	2439
(	PUNCT	O	O	2439
CX3CR1	X	O	O	2439
)	PUNCT	O	O	2439
as	ADP	O	O	2439
an	PRON	O	O	2439
important	ADJ	O	O	2439
mediator	NOUN	O	O	2439
of	ADP	O	O	2439
MPTP	PROPN	O	Chemical	2439
-	PUNCT	O	O	2439
induced	VERB	O	O	2439
neurodegeneration	NOUN	O	Disease	2439
of	ADP	O	O	2439
DA	NOUN	O	Chemical	2439
neurons	NOUN	O	O	2439
.	PUNCT	O	O	2439
Because	SCONJ	O	O	2440
the	PRON	O	O	2440
CNS	PROPN	O	O	2440
damage	NOUN	O	O	2440
caused	VERB	O	O	2440
by	ADP	O	O	2440
METH	NOUN	O	Chemical	2440
and	CCONJ	O	O	2440
MPTP	PROPN	O	Chemical	2440
is	AUX	O	O	2440
highly	ADV	O	O	2440
selective	ADJ	O	O	2440
for	ADP	O	O	2440
the	PRON	O	O	2440
DA	NOUN	O	Chemical	2440
neuronal	ADJ	O	O	2440
system	NOUN	O	O	2440
in	ADP	O	O	2440
mouse	PROPN	O	O	2440
models	NOUN	O	O	2440
of	ADP	O	O	2440
neurotoxicity	NOUN	O	Disease	2440
,	PUNCT	O	O	2440
we	PRON	O	O	2440
hypothesized	VERB	O	O	2440
that	SCONJ	O	O	2440
the	PRON	O	O	2440
CX3CR1	X	O	O	2440
plays	VERB	O	O	2440
a	PRON	O	O	2440
role	NOUN	O	O	2440
in	ADP	O	O	2440
METH	NOUN	O	Chemical	2440
-	PUNCT	O	O	2440
induced	VERB	O	O	2440
neurotoxicity	NOUN	O	Disease	2440
and	CCONJ	O	O	2440
microglial	PROPN	O	O	2440
activation	NOUN	O	O	2440
.	PUNCT	O	O	2440
Mice	NOUN	O	O	2441
in	ADP	O	O	2441
which	PRON	O	O	2441
the	PRON	O	O	2441
CX3CR1	X	O	O	2441
gene	NOUN	O	O	2441
has	VERB	O	O	2441
been	AUX	O	O	2441
deleted	VERB	O	O	2441
and	CCONJ	O	O	2441
replaced	VERB	O	O	2441
with	ADP	O	O	2441
a	PRON	O	O	2441
cDNA	PROPN	O	O	2441
encoding	VERB	O	O	2441
enhanced	VERB	O	O	2441
green	ADJ	O	O	2441
fluorescent	NOUN	O	O	2441
protein	NOUN	O	O	2441
(	PUNCT	O	O	2441
eGFP	NOUN	O	O	2441
)	PUNCT	O	O	2441
were	AUX	O	O	2441
treated	VERB	O	O	2441
with	ADP	O	O	2441
METH	NOUN	O	Chemical	2441
and	CCONJ	O	O	2441
examined	VERB	O	O	2441
for	ADP	O	O	2441
striatal	ADJ	O	O	2441
neurotoxicity	NOUN	O	Disease	2441
.	PUNCT	O	O	2441
METH	NOUN	O	Chemical	2442
depleted	VERB	O	O	2442
DA	NOUN	O	Chemical	2442
,	PUNCT	O	O	2442
caused	VERB	O	O	2442
microglial	PROPN	O	O	2442
activation	NOUN	O	O	2442
,	PUNCT	O	O	2442
and	CCONJ	O	O	2442
increased	VERB	O	O	2442
body	NOUN	O	O	2442
temperature	NOUN	O	O	2442
in	ADP	O	O	2442
CX3CR1	X	O	O	2442
knockout	NOUN	O	O	2442
mice	NOUN	O	O	2442
to	PART	O	O	2442
the	PRON	O	O	2442
same	ADJ	O	O	2442
extent	NOUN	O	O	2442
and	CCONJ	O	O	2442
over	ADP	O	O	2442
the	PRON	O	O	2442
same	ADJ	O	O	2442
time	NOUN	O	O	2442
course	NOUN	O	O	2442
seen	VERB	O	O	2442
in	ADP	O	O	2442
wild	ADJ	O	O	2442
-	PUNCT	O	O	2442
type	NOUN	O	O	2442
controls	VERB	O	O	2442
.	PUNCT	O	O	2442
The	PRON	O	O	2443
effects	NOUN	O	O	2443
of	ADP	O	O	2443
METH	NOUN	O	Chemical	2443
in	ADP	O	O	2443
CX3CR1	X	O	O	2443
knockout	NOUN	O	O	2443
mice	NOUN	O	O	2443
were	AUX	O	O	2443
not	PART	O	O	2443
gender	NOUN	O	O	2443
-	PUNCT	O	O	2443
dependent	ADJ	O	O	2443
and	CCONJ	O	O	2443
did	VERB	O	O	2443
not	PART	O	O	2443
extend	VERB	O	O	2443
beyond	ADP	O	O	2443
the	PRON	O	O	2443
striatum	NOUN	O	O	2443
.	PUNCT	O	O	2443
Striatal	PROPN	O	O	2444
microglia	PROPN	O	O	2444
expressing	VERB	O	O	2444
eGFP	NOUN	O	O	2444
constitutively	ADV	O	O	2444
show	VERB	O	O	2444
morphological	ADJ	O	O	2444
changes	VERB	O	O	2444
after	ADP	O	O	2444
METH	NOUN	O	Chemical	2444
that	SCONJ	O	O	2444
are	AUX	O	O	2444
characteristic	ADJ	O	O	2444
of	ADP	O	O	2444
activation	NOUN	O	O	2444
.	PUNCT	O	O	2444
This	PRON	O	O	2445
response	NOUN	O	O	2445
was	AUX	O	O	2445
restricted	VERB	O	O	2445
to	PART	O	O	2445
the	PRON	O	O	2445
striatum	NOUN	O	O	2445
and	CCONJ	O	O	2445
contrasted	VERB	O	O	2445
sharply	ADV	O	O	2445
with	ADP	O	O	2445
unresponsive	ADJ	O	O	2445
eGFP	NOUN	O	O	2445
-	PUNCT	O	O	2445
microglia	PROPN	O	O	2445
in	ADP	O	O	2445
surrounding	VERB	O	O	2445
brain	NOUN	O	O	2445
areas	NOUN	O	O	2445
that	SCONJ	O	O	2445
are	AUX	O	O	2445
not	PART	O	O	2445
damaged	VERB	O	O	2445
by	ADP	O	O	2445
METH	NOUN	O	Chemical	2445
.	PUNCT	O	O	2445
We	PRON	O	O	2446
conclude	VERB	O	O	2446
from	ADP	O	O	2446
these	PRON	O	O	2446
studies	NOUN	O	O	2446
that	SCONJ	O	O	2446
CX3CR1	X	O	O	2446
signaling	VERB	O	O	2446
does	VERB	O	O	2446
not	PART	O	O	2446
modulate	VERB	O	O	2446
METH	NOUN	O	Chemical	2446
neurotoxicity	NOUN	O	Disease	2446
or	CCONJ	O	O	2446
microglial	PROPN	O	O	2446
activation	NOUN	O	O	2446
.	PUNCT	O	O	2446
Furthermore	ADV	O	O	2447
,	PUNCT	O	O	2447
it	PRON	O	O	2447
appears	VERB	O	O	2447
that	SCONJ	O	O	2447
striatal	ADJ	O	O	2447
-	PUNCT	O	O	2447
resident	NOUN	O	O	2447
microglia	PROPN	O	O	2447
respond	VERB	O	O	2447
to	PART	O	O	2447
METH	NOUN	O	Chemical	2447
with	ADP	O	O	2447
an	PRON	O	O	2447
activation	NOUN	O	O	2447
cascade	NOUN	O	O	2447
and	CCONJ	O	O	2447
then	ADV	O	O	2447
return	VERB	O	O	2447
to	PART	O	O	2447
a	PRON	O	O	2447
surveying	VERB	O	O	2447
state	NOUN	O	O	2447
without	ADP	O	O	2447
undergoing	VERB	O	O	2447
apoptosis	NOUN	O	O	2447
or	CCONJ	O	O	2447
migration	NOUN	O	O	2447
.	PUNCT	O	O	2447
Recovery	NOUN	O	O	2450
of	ADP	O	O	2450
tacrolimus	NOUN	O	Chemical	2450
-	PUNCT	O	O	2450
associated	VERB	O	O	2450
brachial	ADJ	O	O	2450
neuritis	NOUN	O	O	2450
after	ADP	O	O	2450
conversion	NOUN	O	O	2450
to	PART	O	O	2450
everolimus	ADJ	O	Chemical	2450
in	ADP	O	O	2450
a	PRON	O	O	2450
pediatric	ADJ	O	O	2450
renal	ADJ	O	O	2450
transplant	NOUN	O	O	2450
recipient	NOUN	O	O	2450
--	PUNCT	O	O	2450
case	NOUN	O	O	2450
report	VERB	O	O	2450
and	CCONJ	O	O	2450
review	VERB	O	O	2450
of	ADP	O	O	2450
the	PRON	O	O	2450
literature	NOUN	O	O	2450
.	PUNCT	O	O	2450
TAC	PROPN	O	O	2451
has	VERB	O	O	2451
been	AUX	O	O	2451
shown	VERB	O	O	2451
to	PART	O	O	2451
be	AUX	O	O	2451
a	PRON	O	O	2451
potent	ADJ	O	O	2451
immunosuppressive	ADJ	O	O	2451
agent	NOUN	O	O	2451
for	ADP	O	O	2451
solid	ADJ	O	O	2451
organ	NOUN	O	O	2451
transplantation	NOUN	O	O	2451
in	ADP	O	O	2451
pediatrics	NOUN	O	O	2451
.	PUNCT	O	O	2451
Neurotoxicity	NOUN	O	Disease	2452
is	AUX	O	O	2452
a	PRON	O	O	2452
potentially	ADV	O	O	2452
serious	ADJ	O	O	2452
toxic	ADJ	O	O	2452
effect	VERB	O	O	2452
.	PUNCT	O	O	2452
It	PRON	O	O	2453
is	AUX	O	O	2453
characterized	VERB	O	O	2453
by	ADP	O	O	2453
encephalopathy	NOUN	O	Disease	2453
,	PUNCT	O	O	2453
headaches	NOUN	O	Disease	2453
,	PUNCT	O	O	2453
seizures	NOUN	O	Disease	2453
,	PUNCT	O	O	2453
or	CCONJ	O	O	2453
neurological deficits	NOUN	O	Disease	2453
.	PUNCT	O	O	2453
MRI	PROPN	O	O	2454
demonstrated	VERB	O	O	2454
hyperintense	NOUN	O	O	2454
T2	PROPN	O	O	2454
signals	VERB	O	O	2454
in	ADP	O	O	2454
the	PRON	O	O	2454
cervical	ADJ	O	O	2454
cord	NOUN	O	O	2454
and	CCONJ	O	O	2454
right	ADV	O	O	2454
brachial	ADJ	O	O	2454
plexus	NOUN	O	O	2454
roots	NOUN	O	O	2454
indicative	ADJ	O	O	2454
of	ADP	O	O	2454
both	PRON	O	O	2454
myelitis	NOUN	O	O	2454
and	CCONJ	O	O	2454
right	ADV	O	O	2454
brachial	ADJ	O	O	2454
plexitis	NOUN	O	O	2454
.	PUNCT	O	O	2454
Symptoms	NOUN	O	O	2455
persisted	VERB	O	O	2455
for	ADP	O	O	2455
three	NUM	O	O	2455
months	NOUN	O	O	2455
despite	SCONJ	O	O	2455
TAC	PROPN	O	O	2455
dose	NOUN	O	O	2455
reduction	NOUN	O	O	2455
,	PUNCT	O	O	2455
administration	NOUN	O	O	2455
of	ADP	O	O	2455
IVIG	PROPN	O	O	2455
and	CCONJ	O	O	2455
four	NUM	O	O	2455
doses	NOUN	O	O	2455
of	ADP	O	O	2455
methylprednisolone	NOUN	O	Chemical	2455
pulse	NOUN	O	O	2455
therapy	NOUN	O	O	2455
.	PUNCT	O	O	2455
Improvement	NOUN	O	O	2456
and	CCONJ	O	O	2456
eventually	ADV	O	O	2456
full	ADJ	O	O	2456
recovery	NOUN	O	O	2456
only	ADV	O	O	2456
occurred	VERB	O	O	2456
after	ADP	O	O	2456
TAC	PROPN	O	O	2456
was	AUX	O	O	2456
completely	ADV	O	O	2456
discontinued	VERB	O	O	2456
and	CCONJ	O	O	2456
successfully	ADV	O	O	2456
replaced	VERB	O	O	2456
by	ADP	O	O	2456
everolimus	ADJ	O	Chemical	2456
.	PUNCT	O	O	2456
Valvular	PROPN	O	O	2459
heart disease	NOUN	O	Disease	2459
in	ADP	O	O	2459
patients	NOUN	O	O	2459
with	ADP	O	O	2459
Parkinson	NOUN	O	O	2459
's	AUX	O	O	2459
disease	PROPN	O	O	2459
treated	VERB	O	O	2459
with	ADP	O	O	2459
pergolide	NOUN	O	O	2459
.	PUNCT	O	O	2459
Valvular	PROPN	O	O	2460
heart	NOUN	O	O	2460
abnormalities	NOUN	O	O	2460
have	VERB	O	O	2460
been	AUX	O	O	2460
reported	VERB	O	O	2460
in	ADP	O	O	2460
patients	NOUN	O	O	2460
with	ADP	O	O	2460
Parkinson	NOUN	O	O	2460
's	AUX	O	O	2460
disease	PROPN	O	O	2460
(	PUNCT	O	O	2460
PD	PROPN	O	Disease	2460
)	PUNCT	O	O	2460
treated	VERB	O	O	2460
with	ADP	O	O	2460
pergolide	NOUN	O	O	2460
.	PUNCT	O	O	2460
OBJECTIVES	NOUN	O	O	2461
:	PUNCT	O	O	2461
To	PART	O	O	2461
estimate	VERB	O	O	2461
the	PRON	O	O	2461
frequency	NOUN	O	O	2461
and	CCONJ	O	O	2461
severity	NOUN	O	O	2461
of	ADP	O	O	2461
valvular	ADJ	O	O	2461
heart	NOUN	O	O	2461
abnormality	NOUN	O	O	2461
and	CCONJ	O	O	2461
its	PRON	O	O	2461
possible	ADJ	O	O	2461
reversibility	NOUN	O	O	2461
after	ADP	O	O	2461
drug	NOUN	O	O	2461
withdrawal	NOUN	O	O	2461
in	ADP	O	O	2461
a	PRON	O	O	2461
case	NOUN	O	O	2461
-	PUNCT	O	O	2461
control	VERB	O	O	2461
study	VERB	O	O	2461
.	PUNCT	O	O	2461
All	PRON	O	O	2462
PD	PROPN	O	Disease	2462
patients	NOUN	O	O	2462
in	ADP	O	O	2462
the	PRON	O	O	2462
Amiens	NOUN	O	O	2462
area	NOUN	O	O	2462
treated	VERB	O	O	2462
with	ADP	O	O	2462
pergolide	NOUN	O	O	2462
were	AUX	O	O	2462
invited	VERB	O	O	2462
to	PART	O	O	2462
attend	VERB	O	O	2462
a	PRON	O	O	2462
cardiologic	VERB	O	O	2462
assessment	NOUN	O	O	2462
including	VERB	O	O	2462
transthoracic	PROPN	O	O	2462
echocardiography	NOUN	O	O	2462
.	PUNCT	O	O	2462
Thirty	NUM	O	O	2463
PD	PROPN	O	Disease	2463
patients	NOUN	O	O	2463
participated	VERB	O	O	2463
in	ADP	O	O	2463
the	PRON	O	O	2463
study	VERB	O	O	2463
.	PUNCT	O	O	2463
A	PRON	O	O	2464
second	ADV	O	O	2464
echocardiography	NOUN	O	O	2464
was	AUX	O	O	2464
performed	VERB	O	O	2464
(	PUNCT	O	O	2464
median	ADJ	O	O	2464
interval	NOUN	O	O	2464
:	PUNCT	O	O	2464
13	NUM	O	O	2464
months	NOUN	O	O	2464
)	PUNCT	O	O	2464
after	ADP	O	O	2464
pergolide	NOUN	O	O	2464
withdrawal	NOUN	O	O	2464
(	PUNCT	O	O	2464
n=10	VERB	O	O	2464
patients	NOUN	O	O	2464
)	PUNCT	O	O	2464
.	PUNCT	O	O	2464
Controls	NOUN	O	O	2465
were	AUX	O	O	2465
age-	ADJ	O	O	2465
and	CCONJ	O	O	2465
sex	NOUN	O	O	2465
-	PUNCT	O	O	2465
matched	VERB	O	O	2465
non	ADJ	O	O	2465
-	PUNCT	O	O	2465
PD	PROPN	O	Disease	2465
patients	NOUN	O	O	2465
referred	VERB	O	O	2465
to	PART	O	O	2465
the	PRON	O	O	2465
cardiology	NOUN	O	O	2465
department	NOUN	O	O	2465
.	PUNCT	O	O	2465
Compared	VERB	O	O	2466
to	PART	O	O	2466
controls	VERB	O	O	2466
,	PUNCT	O	O	2466
aortic regurgitation	NOUN	O	Disease	2466
(	PUNCT	O	O	2466
OR	CCONJ	O	O	2466
:	PUNCT	O	O	2466
3.1	NUM	O	O	2466
;	PUNCT	O	O	2466
95%	NOUN	O	O	2466
IC	PROPN	O	O	2466
:	PUNCT	O	O	2466
1.1	NUM	O	O	2466
-	PUNCT	O	O	2466
8.8	NUM	O	O	2466
)	PUNCT	O	O	2466
and	CCONJ	O	O	2466
mitral regurgitation	NOUN	O	Disease	2466
(	PUNCT	O	O	2466
OR	CCONJ	O	O	2466
:	PUNCT	O	O	2466
10.7	NUM	O	O	2466
;	PUNCT	O	O	2466
95%	NOUN	O	O	2466
IC	PROPN	O	O	2466
:	PUNCT	O	O	2466
2.1	NUM	O	O	2466
-	PUNCT	O	O	2466
53	NUM	O	O	2466
)	PUNCT	O	O	2466
were	AUX	O	O	2466
more	ADJ	O	O	2466
frequent	ADJ	O	O	2466
in	ADP	O	O	2466
PD	PROPN	O	Disease	2466
patients	NOUN	O	O	2466
(	PUNCT	O	O	2466
tricuspid	PROPN	O	O	2466
:	PUNCT	O	O	2466
NS	PROPN	O	Disease	2466
)	PUNCT	O	O	2466
.	PUNCT	O	O	2466
The	PRON	O	O	2467
number	NOUN	O	O	2467
of	ADP	O	O	2467
affected	VERB	O	O	2467
valves	NOUN	O	O	2467
(	PUNCT	O	O	2467
n=2.4+/-0.7	ADV	O	O	2467
)	PUNCT	O	O	2467
and	CCONJ	O	O	2467
the	PRON	O	O	2467
sum	NOUN	O	O	2467
of	ADP	O	O	2467
regurgitation	NOUN	O	O	2467
grades	NOUN	O	O	2467
(	PUNCT	O	O	2467
n=2.8+/-1.09	ADP	O	O	2467
)	PUNCT	O	O	2467
were	AUX	O	O	2467
higher	ADJ	O	O	2467
(	PUNCT	O	O	2467
p=0.008	NOUN	O	O	2467
and	CCONJ	O	O	2467
p=0.006	VERB	O	O	2467
,	PUNCT	O	O	2467
respectively	ADV	O	O	2467
)	PUNCT	O	O	2467
in	ADP	O	O	2467
the	PRON	O	O	2467
pergolide	NOUN	O	O	2467
group	NOUN	O	O	2467
.	PUNCT	O	O	2467
Severity	NOUN	O	O	2468
of	ADP	O	O	2468
regurgitation	NOUN	O	O	2468
was	AUX	O	O	2468
not	PART	O	O	2468
correlated	VERB	O	O	2468
with	ADP	O	O	2468
pergolide	NOUN	O	O	2468
cumulative	ADJ	O	O	2468
dose	NOUN	O	O	2468
.	PUNCT	O	O	2468
A	PRON	O	O	2469
restrictive	ADJ	O	O	2469
pattern	NOUN	O	O	2469
of	ADP	O	O	2469
valvular	ADJ	O	O	2469
regurgitation	NOUN	O	O	2469
,	PUNCT	O	O	2469
suggestive	ADJ	O	O	2469
of	ADP	O	O	2469
the	PRON	O	O	2469
role	NOUN	O	O	2469
of	ADP	O	O	2469
pergolide	NOUN	O	O	2469
,	PUNCT	O	O	2469
was	AUX	O	O	2469
observed	VERB	O	O	2469
in	ADP	O	O	2469
12/30	NUM	O	O	2469
(	PUNCT	O	O	2469
40%	NOUN	O	O	2469
)	PUNCT	O	O	2469
patients	NOUN	O	O	2469
including	VERB	O	O	2469
two	NUM	O	O	2469
with	ADP	O	O	2469
heart failure	NOUN	O	Disease	2469
.	PUNCT	O	O	2469
Pergolide	PROPN	O	O	2470
was	AUX	O	O	2470
discontinued	VERB	O	O	2470
in	ADP	O	O	2470
10	NUM	O	O	2470
patients	NOUN	O	O	2470
with	ADP	O	O	2470
valvular	ADJ	O	O	2470
heart disease	NOUN	O	Disease	2470
,	PUNCT	O	O	2470
resulting	VERB	O	O	2470
in	ADP	O	O	2470
a	PRON	O	O	2470
lower	ADJ	O	O	2470
regurgitation	NOUN	O	O	2470
grade	NOUN	O	O	2470
(	PUNCT	O	O	2470
p=0.01	PROPN	O	O	2470
)	PUNCT	O	O	2470
at	ADP	O	O	2470
the	PRON	O	O	2470
second	ADV	O	O	2470
transthoracic	PROPN	O	O	2470
echocardiography	NOUN	O	O	2470
and	CCONJ	O	O	2470
the	PRON	O	O	2470
two	NUM	O	O	2470
patients	NOUN	O	O	2470
with	ADP	O	O	2470
heart failure	NOUN	O	Disease	2470
returned	VERB	O	O	2470
to	PART	O	O	2470
nearly	ADV	O	O	2470
normal	ADJ	O	O	2470
clinical	ADJ	O	O	2470
examination	NOUN	O	O	2470
.	PUNCT	O	O	2470
This	PRON	O	O	2471
study	VERB	O	O	2471
supports	VERB	O	O	2471
the	PRON	O	O	2471
high	ADJ	O	O	2471
frequency	NOUN	O	O	2471
of	ADP	O	O	2471
restrictive	ADJ	O	O	2471
valve	PROPN	O	O	2471
regurgitation	NOUN	O	O	2471
in	ADP	O	O	2471
PD	PROPN	O	Disease	2471
patients	NOUN	O	O	2471
treated	VERB	O	O	2471
with	ADP	O	O	2471
pergolide	NOUN	O	O	2471
and	CCONJ	O	O	2471
reveals	VERB	O	O	2471
that	SCONJ	O	O	2471
a	PRON	O	O	2471
significant	ADJ	O	O	2471
improvement	NOUN	O	O	2471
is	AUX	O	O	2471
usual	ADJ	O	O	2471
when	SCONJ	O	O	2471
the	PRON	O	O	2471
treatment	NOUN	O	O	2471
is	AUX	O	O	2471
converted	VERB	O	O	2471
to	PART	O	O	2471
non	ADJ	O	O	2471
-	PUNCT	O	O	2471
ergot	PROPN	O	Chemical	2471
dopamine	NOUN	O	Chemical	2471
agonists	NOUN	O	O	2471
.	PUNCT	O	O	2471
Adverse	ADJ	O	O	2474
effects	NOUN	O	O	2474
of	ADP	O	O	2474
topical	ADJ	O	O	2474
papaverine	NOUN	O	O	2474
on	ADP	O	O	2474
auditory	NOUN	O	O	2474
nerve	NOUN	O	O	2474
function	NOUN	O	O	2474
.	PUNCT	O	O	2474
Papaverine	NOUN	O	O	2475
hydrochloride	NOUN	O	O	2475
is	AUX	O	O	2475
a	PRON	O	O	2475
direct	ADJ	O	O	2475
-	PUNCT	O	O	2475
acting	VERB	O	O	2475
vasodilator	NOUN	O	O	2475
used	VERB	O	O	2475
to	PART	O	O	2475
manage	VERB	O	O	2475
vasospasm	NOUN	O	Disease	2475
during	ADP	O	O	2475
various	ADJ	O	O	2475
neurosurgical	ADJ	O	O	2475
operations	NOUN	O	O	2475
.	PUNCT	O	O	2475
Transient	ADJ	O	O	2476
cranial	ADJ	O	O	2476
nerve	NOUN	O	O	2476
dysfunction	NOUN	O	O	2476
has	VERB	O	O	2476
been	AUX	O	O	2476
described	VERB	O	O	2476
in	ADP	O	O	2476
a	PRON	O	O	2476
few	ADJ	O	O	2476
cases	NOUN	O	O	2476
with	ADP	O	O	2476
topical	ADJ	O	O	2476
papaverine	NOUN	O	O	2476
.	PUNCT	O	O	2476
METHODS	NOUN	O	O	2477
:	PUNCT	O	O	2477
We	PRON	O	O	2477
conducted	VERB	O	O	2477
a	PRON	O	O	2477
retrospective	ADJ	O	O	2477
review	VERB	O	O	2477
of	ADP	O	O	2477
70	NUM	O	O	2477
consecutive	ADJ	O	O	2477
microvascular	ADJ	O	O	2477
decompression	NOUN	O	O	2477
operations	NOUN	O	O	2477
and	CCONJ	O	O	2477
studied	VERB	O	O	2477
those	PRON	O	O	2477
patients	NOUN	O	O	2477
who	PRON	O	O	2477
received	VERB	O	O	2477
topical	ADJ	O	O	2477
papaverine	NOUN	O	O	2477
for	ADP	O	O	2477
vasospasm	NOUN	O	Disease	2477
.	PUNCT	O	O	2477
Topical	PROPN	O	O	2478
papaverine	NOUN	O	O	2478
was	AUX	O	O	2478
used	VERB	O	O	2478
as	ADP	O	O	2478
a	PRON	O	O	2478
direct	ADJ	O	O	2478
therapeutic	ADJ	O	O	2478
action	NOUN	O	O	2478
to	PART	O	O	2478
manage	VERB	O	O	2478
vasospasm	NOUN	O	Disease	2478
in	ADP	O	O	2478
a	PRON	O	O	2478
total	ADJ	O	O	2478
of	ADP	O	O	2478
11	NUM	O	O	2478
patients	NOUN	O	O	2478
.	PUNCT	O	O	2478
The	PRON	O	O	2479
timing	NOUN	O	O	2479
of	ADP	O	O	2479
papaverine	NOUN	O	O	2479
application	NOUN	O	O	2479
and	CCONJ	O	O	2479
ongoing	ADJ	O	O	2479
operative	NOUN	O	O	2479
events	NOUN	O	O	2479
was	AUX	O	O	2479
reviewed	VERB	O	O	2479
relative	ADJ	O	O	2479
to	PART	O	O	2479
changes	VERB	O	O	2479
in	ADP	O	O	2479
neurophysiological	ADJ	O	O	2479
recordings	NOUN	O	O	2479
.	PUNCT	O	O	2479
A	PRON	O	O	2480
temporal	ADJ	O	O	2480
relationship	NOUN	O	O	2480
was	AUX	O	O	2480
found	VERB	O	O	2480
between	ADP	O	O	2480
topical	ADJ	O	O	2480
papaverine	NOUN	O	O	2480
and	CCONJ	O	O	2480
BAEP	NOUN	O	O	2480
changes	VERB	O	O	2480
leading	VERB	O	O	2480
to	PART	O	O	2480
complete	VERB	O	O	2480
waveform	NOUN	O	O	2480
loss	NOUN	O	O	2480
.	PUNCT	O	O	2480
The	PRON	O	O	2481
average	ADJ	O	O	2481
temporal	ADJ	O	O	2481
delay	NOUN	O	O	2481
between	ADP	O	O	2481
papaverine	NOUN	O	O	2481
and	CCONJ	O	O	2481
the	PRON	O	O	2481
onset	VERB	O	O	2481
of	ADP	O	O	2481
an	PRON	O	O	2481
adverse	ADJ	O	O	2481
BAEP	NOUN	O	O	2481
change	VERB	O	O	2481
was	AUX	O	O	2481
5	NUM	O	O	2481
min	NOUN	O	O	2481
.	PUNCT	O	O	2481
In	ADP	O	O	2482
10	NUM	O	O	2482
of	ADP	O	O	2482
11	NUM	O	O	2482
patients	NOUN	O	O	2482
,	PUNCT	O	O	2482
BAEP	NOUN	O	O	2482
waves	NOUN	O	O	2482
II	NUM	O	O	2482
/	PUNCT	O	O	2482
III	NUM	O	O	2482
-	PUNCT	O	O	2482
V	NOUN	O	O	2482
completely	ADV	O	O	2482
disappeared	VERB	O	O	2482
within	ADP	O	O	2482
2	X	O	O	2482
to	PART	O	O	2482
25	NUM	O	O	2482
min	NOUN	O	O	2482
after	ADP	O	O	2482
papaverine	NOUN	O	O	2482
.	PUNCT	O	O	2482
One	NUM	O	O	2483
patient	NOUN	O	O	2483
showed	VERB	O	O	2483
no	PRON	O	O	2483
recovery	NOUN	O	O	2483
of	ADP	O	O	2483
later	ADV	O	O	2483
waves	NOUN	O	O	2483
and	CCONJ	O	O	2483
a	PRON	O	O	2483
delayed	VERB	O	O	2483
profound	ADJ	O	O	2483
sensorineural	ADJ	O	O	2483
hearing loss	NOUN	O	Disease	2483
.	PUNCT	O	O	2483
The	PRON	O	O	2484
average	ADJ	O	O	2484
recovery	NOUN	O	O	2484
time	NOUN	O	O	2484
of	ADP	O	O	2484
BAEP	NOUN	O	O	2484
waveforms	NOUN	O	O	2484
to	PART	O	O	2484
pre	VERB	O	O	2484
-	PUNCT	O	O	2484
papaverine	NOUN	O	O	2484
baseline	VERB	O	O	2484
values	NOUN	O	O	2484
was	AUX	O	O	2484
39	NUM	O	O	2484
min	NOUN	O	O	2484
.	PUNCT	O	O	2484
Topical	PROPN	O	O	2485
papaverine	NOUN	O	O	2485
for	ADP	O	O	2485
the	PRON	O	O	2485
treatment	NOUN	O	O	2485
of	ADP	O	O	2485
vasospasm	NOUN	O	Disease	2485
was	AUX	O	O	2485
associated	VERB	O	O	2485
with	ADP	O	O	2485
the	PRON	O	O	2485
onset	VERB	O	O	2485
of	ADP	O	O	2485
a	PRON	O	O	2485
transient	ADJ	O	O	2485
disturbance	NOUN	O	O	2485
in	ADP	O	O	2485
neurophysiological	ADJ	O	O	2485
function	NOUN	O	O	2485
of	ADP	O	O	2485
the	PRON	O	O	2485
ascending	VERB	O	O	2485
auditory	NOUN	O	O	2485
brainstem	NOUN	O	O	2485
pathway	NOUN	O	O	2485
.	PUNCT	O	O	2485
The	PRON	O	O	2486
complete	VERB	O	O	2486
disappearance	NOUN	O	O	2486
of	ADP	O	O	2486
BAEP	NOUN	O	O	2486
waveforms	NOUN	O	O	2486
with	ADP	O	O	2486
a	PRON	O	O	2486
consistent	ADJ	O	O	2486
temporal	ADJ	O	O	2486
delay	NOUN	O	O	2486
suggests	VERB	O	O	2486
a	PRON	O	O	2486
possible	ADJ	O	O	2486
adverse	ADJ	O	O	2486
effect	VERB	O	O	2486
on	ADP	O	O	2486
the	PRON	O	O	2486
proximal	ADJ	O	O	2486
eighth	ADJ	O	O	2486
nerve	NOUN	O	O	2486
.	PUNCT	O	O	2486
Recommendations	NOUN	O	O	2487
to	PART	O	O	2487
avoid	VERB	O	O	2487
potential	ADJ	O	O	2487
cranial	ADJ	O	O	2487
nerve	NOUN	O	O	2487
deficits	NOUN	O	O	2487
from	ADP	O	O	2487
papaverine	NOUN	O	O	2487
are	AUX	O	O	2487
provided	VERB	O	O	2487
.	PUNCT	O	O	2487
Massive	ADJ	O	O	2490
proteinuria	X	O	Disease	2490
and	CCONJ	O	O	2490
acute	ADJ	O	O	2490
renal failure	NOUN	O	Disease	2490
after	ADP	O	O	2490
oral	ADJ	O	O	2490
bisphosphonate	NOUN	O	O	2490
(	PUNCT	O	O	2490
alendronate	NOUN	O	O	2490
)	PUNCT	O	O	2490
administration	NOUN	O	O	2490
in	ADP	O	O	2490
a	PRON	O	O	2490
patient	NOUN	O	O	2490
with	ADP	O	O	2490
focal	ADJ	O	O	2490
segmental	ADJ	O	O	2490
glomerulosclerosis	PROPN	O	O	2490
.	PUNCT	O	O	2490
A	PRON	O	O	2491
61-year	NOUN	O	O	2491
-	PUNCT	O	O	2491
old	ADJ	O	O	2491
Japanese	NOUN	O	O	2491
man	NOUN	O	O	2491
with	ADP	O	O	2491
nephrotic syndrome	NOUN	O	Disease	2491
due	ADJ	O	O	2491
to	PART	O	O	2491
focal	ADJ	O	O	2491
segmental	ADJ	O	O	2491
glomerulosclerosis	PROPN	O	O	2491
was	AUX	O	O	2491
initially	ADV	O	O	2491
responding	VERB	O	O	2491
well	ADV	O	O	2491
to	PART	O	O	2491
steroid	NOUN	O	Chemical	2491
therapy	NOUN	O	O	2491
.	PUNCT	O	O	2491
Within	ADP	O	O	2492
14	NUM	O	O	2492
days	NOUN	O	O	2492
of	ADP	O	O	2492
the	PRON	O	O	2492
oral	ADJ	O	O	2492
bisphosphonate	NOUN	O	O	2492
(	PUNCT	O	O	2492
alendronate	NOUN	O	O	2492
sodium	NOUN	O	Chemical	2492
)	PUNCT	O	O	2492
administration	NOUN	O	O	2492
,	PUNCT	O	O	2492
the	PRON	O	O	2492
amount	NOUN	O	O	2492
of	ADP	O	O	2492
daily	ADV	O	O	2492
urinary	ADJ	O	O	2492
protein	NOUN	O	O	2492
increased	VERB	O	O	2492
rapidly	ADV	O	O	2492
up	ADP	O	O	2492
to	PART	O	O	2492
12.8	NUM	O	O	2492
g	X	O	O	2492
with	ADP	O	O	2492
acute	ADJ	O	O	2492
renal failure	NOUN	O	Disease	2492
.	PUNCT	O	O	2492
After	ADP	O	O	2493
discontinuing	VERB	O	O	2493
the	PRON	O	O	2493
oral	ADJ	O	O	2493
alendronate	NOUN	O	O	2493
,	PUNCT	O	O	2493
the	PRON	O	O	2493
patient	NOUN	O	O	2493
underwent	VERB	O	O	2493
six	NUM	O	O	2493
cycles	NOUN	O	O	2493
of	ADP	O	O	2493
hemodialysis	NOUN	O	O	2493
and	CCONJ	O	O	2493
four	NUM	O	O	2493
cycles	NOUN	O	O	2493
of	ADP	O	O	2493
LDL	NOUN	O	O	2493
apheresis	NOUN	O	O	2493
.	PUNCT	O	O	2493
Urinary	NOUN	O	O	2494
volume	PROPN	O	O	2494
and	CCONJ	O	O	2494
serum	NOUN	O	O	2494
creatinine	PROPN	O	Chemical	2494
levels	NOUN	O	O	2494
recovered	VERB	O	O	2494
to	PART	O	O	2494
the	PRON	O	O	2494
normal	ADJ	O	O	2494
range	VERB	O	O	2494
,	PUNCT	O	O	2494
with	ADP	O	O	2494
urinary	ADJ	O	O	2494
protein	NOUN	O	O	2494
disappearing	VERB	O	O	2494
completely	ADV	O	O	2494
within	ADP	O	O	2494
40	NUM	O	O	2494
days	NOUN	O	O	2494
.	PUNCT	O	O	2494
This	PRON	O	O	2495
report	VERB	O	O	2495
demonstrates	VERB	O	O	2495
that	SCONJ	O	O	2495
not	PART	O	O	2495
only	ADV	O	O	2495
intravenous	ADJ	O	O	2495
,	PUNCT	O	O	2495
but	CCONJ	O	O	2495
also	ADV	O	O	2495
oral	ADJ	O	O	2495
bisphosphonates	VERB	O	O	2495
can	AUX	O	O	2495
aggravate	VERB	O	O	2495
proteinuria	X	O	Disease	2495
and	CCONJ	O	O	2495
acute	ADJ	O	O	2495
renal failure	NOUN	O	Disease	2495
.	PUNCT	O	O	2495
Serum-	PROPN	O	O	2498
and	CCONJ	O	O	2498
glucocorticoid	NOUN	O	O	2498
-	PUNCT	O	O	2498
inducible	VERB	O	O	2498
kinase	VERB	O	O	2498
1	X	O	O	2498
in	ADP	O	O	2498
doxorubicin	VERB	O	Chemical	2498
-	PUNCT	O	O	2498
induced	VERB	O	O	2498
nephrotic syndrome	NOUN	O	Disease	2498
.	PUNCT	O	O	2498
Doxorubicin	PROPN	O	Chemical	2499
-	PUNCT	O	O	2499
induced	VERB	O	O	2499
nephropathy	NOUN	O	Disease	2499
leads	VERB	O	O	2499
to	PART	O	O	2499
epithelial	ADJ	O	O	2499
sodium	NOUN	O	Chemical	2499
channel	PROPN	O	O	2499
(	PUNCT	O	O	2499
ENaC)-dependent	NOUN	O	O	2499
volume	PROPN	O	O	2499
retention	NOUN	O	O	2499
and	CCONJ	O	O	2499
renal	ADJ	O	O	2499
fibrosis	NOUN	O	Disease	2499
.	PUNCT	O	O	2499
The	PRON	O	O	2500
aldosterone	NOUN	O	Chemical	2500
-	PUNCT	O	O	2500
sensitive	ADJ	O	O	2500
serum-	ADJ	O	O	2500
and	CCONJ	O	O	2500
glucocorticoid	NOUN	O	O	2500
-	PUNCT	O	O	2501
inducible	VERB	O	O	2501
kinase	VERB	O	O	2501
SGK1	PROPN	O	O	2501
has	VERB	O	O	2501
been	AUX	O	O	2501
shown	VERB	O	O	2501
to	PART	O	O	2501
participate	VERB	O	O	2501
in	ADP	O	O	2501
the	PRON	O	O	2501
stimulation	NOUN	O	O	2501
of	ADP	O	O	2501
ENaC	PROPN	O	O	2501
and	CCONJ	O	O	2501
to	PART	O	O	2501
mediate	VERB	O	O	2501
renal	ADJ	O	O	2501
fibrosis	NOUN	O	Disease	2501
following	VERB	O	O	2501
mineralocorticoid	PROPN	O	O	2501
and	CCONJ	O	O	2501
salt	NOUN	O	O	2501
excess	ADJ	O	O	2501
.	PUNCT	O	O	2501
The	PRON	O	O	2502
present	NOUN	O	O	2502
study	VERB	O	O	2502
was	AUX	O	O	2502
performed	VERB	O	O	2502
to	PART	O	O	2502
elucidate	VERB	O	O	2502
the	PRON	O	O	2502
role	NOUN	O	O	2502
of	ADP	O	O	2502
SGK1	PROPN	O	O	2502
in	ADP	O	O	2502
the	PRON	O	O	2502
volume	PROPN	O	O	2502
retention	NOUN	O	O	2502
and	CCONJ	O	O	2502
fibrosis	NOUN	O	Disease	2502
during	ADP	O	O	2502
nephrotic syndrome	NOUN	O	Disease	2502
.	PUNCT	O	O	2502
To	PART	O	O	2503
this	PRON	O	O	2503
end	VERB	O	O	2503
,	PUNCT	O	O	2503
doxorubicin	VERB	O	Chemical	2503
(	PUNCT	O	O	2503
15	NUM	O	O	2503
mug	NOUN	O	O	2503
/	PUNCT	O	O	2503
g	X	O	O	2503
body	NOUN	O	O	2503
wt	NOUN	O	O	2503
)	PUNCT	O	O	2503
was	AUX	O	O	2503
injected	VERB	O	O	2503
intravenously	ADV	O	O	2503
into	ADP	O	O	2503
gene	NOUN	O	O	2503
-	PUNCT	O	O	2503
targeted	VERB	O	O	2503
mice	NOUN	O	O	2503
lacking	VERB	O	O	2503
SGK1	PROPN	O	O	2503
(	PUNCT	O	O	2503
sgk1(-/-	VERB	O	O	2503
)	PUNCT	O	O	2503
)	PUNCT	O	O	2503
and	CCONJ	O	O	2503
their	PRON	O	O	2503
wild	ADJ	O	O	2503
-	PUNCT	O	O	2503
type	NOUN	O	O	2503
littermates	NOUN	O	O	2503
(	PUNCT	O	O	2503
sgk1(+/+	VERB	O	O	2503
)	PUNCT	O	O	2503
)	PUNCT	O	O	2503
.	PUNCT	O	O	2503
Doxorubicin	PROPN	O	Chemical	2504
treatment	NOUN	O	O	2504
resulted	VERB	O	O	2504
in	ADP	O	O	2504
heavy	ADJ	O	O	2504
proteinuria	X	O	Disease	2504
(	PUNCT	O	O	2504
>	PUNCT	O	O	2504
100	NUM	O	O	2504
mg	VERB	O	O	2504
protein	NOUN	O	O	2504
/	PUNCT	O	O	2504
mg	VERB	O	O	2504
crea	PROPN	O	O	2504
)	PUNCT	O	O	2504
in	ADP	O	O	2504
15/44	NUM	O	O	2504
of	ADP	O	O	2504
sgk1(+/+	VERB	O	O	2504
)	PUNCT	O	O	2504
and	CCONJ	O	O	2504
15/44	NUM	O	O	2504
of	ADP	O	O	2504
sgk1(-/-	VERB	O	O	2504
)	PUNCT	O	O	2504
mice	NOUN	O	O	2504
leading	VERB	O	O	2504
to	PART	O	O	2504
severe	ADJ	O	O	2504
nephrotic syndrome	NOUN	O	Disease	2504
with	ADP	O	O	2504
ascites	NOUN	O	Disease	2504
,	PUNCT	O	O	2504
lipidemia	NOUN	O	O	2504
,	PUNCT	O	O	2504
and	CCONJ	O	O	2504
hypoalbuminemia	ADV	O	Disease	2504
in	ADP	O	O	2504
both	PRON	O	O	2504
genotypes	NOUN	O	O	2504
.	PUNCT	O	O	2504
Plasma	NOUN	O	O	2505
aldosterone	NOUN	O	Chemical	2505
levels	NOUN	O	O	2505
increased	VERB	O	O	2505
in	ADP	O	O	2505
nephrotic	NOUN	O	Disease	2505
mice	NOUN	O	O	2505
of	ADP	O	O	2505
both	PRON	O	O	2505
genotypes	NOUN	O	O	2505
and	CCONJ	O	O	2505
was	AUX	O	O	2505
followed	VERB	O	O	2505
by	ADP	O	O	2505
increased	VERB	O	O	2505
SGK1	PROPN	O	O	2505
protein	NOUN	O	O	2505
expression	NOUN	O	O	2505
in	ADP	O	O	2505
sgk1(+/+	VERB	O	O	2505
)	PUNCT	O	O	2505
mice	NOUN	O	O	2505
.	PUNCT	O	O	2505
Urinary	NOUN	O	O	2506
sodium	NOUN	O	Chemical	2506
excretion	NOUN	O	O	2506
reached	VERB	O	O	2506
signficantly	ADV	O	O	2506
lower	ADJ	O	O	2506
values	NOUN	O	O	2506
in	ADP	O	O	2506
sgk1(+/+	VERB	O	O	2506
)	PUNCT	O	O	2506
mice	NOUN	O	O	2506
(	PUNCT	O	O	2506
15	NUM	O	O	2506
+	ADP	O	O	2506
/-	PUNCT	O	O	2506
5	NUM	O	O	2507
mumol	PROPN	O	O	2507
/	PUNCT	O	O	2507
mg	VERB	O	O	2507
crea	PROPN	O	O	2507
)	PUNCT	O	O	2507
and	CCONJ	O	O	2507
was	AUX	O	O	2507
associated	VERB	O	O	2507
with	ADP	O	O	2507
a	PRON	O	O	2507
significantly	ADV	O	O	2507
higher	ADJ	O	O	2507
body	NOUN	O	O	2507
weight	NOUN	O	O	2507
gain	VERB	O	O	2507
in	ADP	O	O	2507
sgk1(+/+	VERB	O	O	2507
)	PUNCT	O	O	2507
compared	VERB	O	O	2507
with	ADP	O	O	2507
sgk1(-/-	VERB	O	O	2507
)	PUNCT	O	O	2507
mice	NOUN	O	O	2507
(	PUNCT	O	O	2507
+	ADP	O	O	2507
6.6	NUM	O	O	2507
+	ADP	O	O	2507
/-	PUNCT	O	O	2507
During	ADP	O	O	2508
the	PRON	O	O	2508
course	NOUN	O	O	2508
of	ADP	O	O	2508
nephrotic syndrome	NOUN	O	Disease	2508
,	PUNCT	O	O	2508
serum	NOUN	O	O	2508
urea	PROPN	O	Chemical	2508
concentrations	NOUN	O	O	2508
increased	VERB	O	O	2508
significantly	ADV	O	O	2508
faster	ADV	O	O	2508
in	ADP	O	O	2508
sgk1(-/-	VERB	O	O	2508
)	PUNCT	O	O	2508
mice	NOUN	O	O	2508
than	ADP	O	O	2508
in	ADP	O	O	2508
sgk1(+/+	VERB	O	O	2508
)	PUNCT	O	O	2508
mice	NOUN	O	O	2509
leading	VERB	O	O	2509
to	PART	O	O	2509
uremia	NOUN	O	Disease	2509
and	CCONJ	O	O	2509
a	PRON	O	O	2509
reduced	VERB	O	O	2509
median	ADJ	O	O	2509
survival	NOUN	O	O	2509
in	ADP	O	O	2509
sgk1(-/-	VERB	O	O	2509
)	PUNCT	O	O	2509
mice	NOUN	O	O	2509
(	PUNCT	O	O	2509
29	NUM	O	O	2509
vs.	CCONJ	O	O	2509
40	NUM	O	O	2509
days	NOUN	O	O	2509
in	ADP	O	O	2509
sgk1(+/+	VERB	O	O	2509
)	PUNCT	O	O	2509
mice	NOUN	O	O	2509
)	PUNCT	O	O	2509
.	PUNCT	O	O	2509
In	ADP	O	O	2510
conclusion	NOUN	O	O	2510
,	PUNCT	O	O	2510
gene	NOUN	O	O	2510
-	PUNCT	O	O	2510
targeted	VERB	O	O	2510
mice	NOUN	O	O	2510
lacking	VERB	O	O	2510
SGK1	PROPN	O	O	2510
showed	VERB	O	O	2510
blunted	VERB	O	O	2510
volume	PROPN	O	O	2510
retention	NOUN	O	O	2510
,	PUNCT	O	O	2510
yet	ADV	O	O	2510
were	AUX	O	O	2510
not	PART	O	O	2510
protected	VERB	O	O	2510
against	ADP	O	O	2510
renal	ADJ	O	O	2510
fibrosis	NOUN	O	Disease	2510
during	ADP	O	O	2510
experimental	ADJ	O	O	2510
nephrotic syndrome	NOUN	O	Disease	2510
.	PUNCT	O	O	2510
Severe	ADJ	O	O	2513
and	CCONJ	O	O	2513
long	ADV	O	O	2513
lasting	VERB	O	O	2513
cholestasis	NOUN	O	Disease	2513
after	ADP	O	O	2513
high	ADJ	O	O	2513
-	PUNCT	O	O	2513
dose	NOUN	O	O	2513
co	NOUN	O	O	2513
-	PUNCT	O	O	2513
trimoxazole	PROPN	O	O	2513
treatment	NOUN	O	O	2513
for	ADP	O	O	2513
Pneumocystis	NOUN	O	O	2513
pneumonia	NOUN	O	Disease	2513
in	ADP	O	O	2513
HIV	PROPN	O	O	2513
-	PUNCT	O	O	2513
infected	VERB	O	O	2513
patients	NOUN	O	O	2513
--	PUNCT	O	O	2513
a	PRON	O	O	2513
report	VERB	O	O	2513
of	ADP	O	O	2513
two	NUM	O	O	2513
cases	NOUN	O	O	2513
.	PUNCT	O	O	2513
Pneumocystis	NOUN	O	O	2514
pneumonia	NOUN	O	Disease	2514
(	PUNCT	O	O	2514
PCP	PROPN	O	O	2514
)	PUNCT	O	O	2514
,	PUNCT	O	O	2514
a	PRON	O	O	2514
common	ADJ	O	O	2514
opportunistic	ADJ	O	O	2514
infection	NOUN	O	Disease	2514
in	ADP	O	O	2514
HIV	PROPN	O	O	2514
-	PUNCT	O	O	2514
infected	VERB	O	O	2514
individuals	NOUN	O	O	2514
,	PUNCT	O	O	2514
is	AUX	O	O	2514
generally	ADV	O	O	2514
treated	VERB	O	O	2514
with	ADP	O	O	2514
high	ADJ	O	O	2514
doses	NOUN	O	O	2514
of	ADP	O	O	2514
co	NOUN	O	O	2514
-	PUNCT	O	O	2514
trimoxazole	PROPN	O	O	2514
.	PUNCT	O	O	2514
Here	ADV	O	O	2515
,	PUNCT	O	O	2515
we	PRON	O	O	2515
report	VERB	O	O	2515
two	NUM	O	O	2515
cases	NOUN	O	O	2515
of	ADP	O	O	2515
severely	ADV	O	O	2515
immunocompromised	ADJ	O	O	2515
HIV	PROPN	O	O	2515
-	PUNCT	O	O	2515
infected	VERB	O	O	2515
patients	NOUN	O	O	2515
who	PRON	O	O	2515
developed	VERB	O	O	2515
severe	ADJ	O	O	2515
intrahepatic	ADJ	O	O	2515
cholestasis	NOUN	O	Disease	2515
,	PUNCT	O	O	2515
and	CCONJ	O	O	2515
in	ADP	O	O	2515
one	NUM	O	O	2515
patient	NOUN	O	O	2515
lesions	NOUN	O	O	2515
mimicking	VERB	O	O	2515
liver	NOUN	O	O	2515
abscess	NOUN	O	O	2515
formation	NOUN	O	O	2515
on	ADP	O	O	2515
radiologic	ADJ	O	O	2515
exams	NOUN	O	O	2515
,	PUNCT	O	O	2515
during	ADP	O	O	2515
co	NOUN	O	O	2515
-	PUNCT	O	O	2515
trimoxazole	PROPN	O	O	2515
treatment	NOUN	O	O	2515
for	ADP	O	O	2515
PCP	PROPN	O	O	2515
.	PUNCT	O	O	2515
Whereas	SCONJ	O	O	2516
patient	NOUN	O	O	2516
1	X	O	O	2516
showed	VERB	O	O	2516
lesions	NOUN	O	O	2516
of	ADP	O	O	2516
up	ADP	O	O	2516
to	PART	O	O	2516
1	X	O	O	2516
cm	NOUN	O	O	2516
readily	ADV	O	O	2516
detectable	ADJ	O	O	2516
on	ADP	O	O	2516
magnetic	ADJ	O	O	2516
resonance	NOUN	O	O	2516
imaging	VERB	O	O	2516
under	ADP	O	O	2516
prolonged	VERB	O	O	2516
co	NOUN	O	O	2516
-	PUNCT	O	O	2516
trimoxazole	PROPN	O	O	2516
treatment	NOUN	O	O	2516
,	PUNCT	O	O	2516
therapy	NOUN	O	O	2516
of	ADP	O	O	2516
patient	NOUN	O	O	2516
2	X	O	O	2516
was	AUX	O	O	2516
switched	VERB	O	O	2516
early	ADV	O	O	2516
.	PUNCT	O	O	2516
Clinically	ADV	O	O	2519
significant	ADJ	O	O	2519
proteinuria	X	O	Disease	2519
following	VERB	O	O	2519
the	PRON	O	O	2519
administration	NOUN	O	O	2519
of	ADP	O	O	2519
sirolimus	NOUN	O	Chemical	2519
to	PART	O	O	2519
renal	ADJ	O	O	2519
transplant	NOUN	O	O	2519
recipients	NOUN	O	O	2519
.	PUNCT	O	O	2519
Sirolimus	NOUN	O	Chemical	2520
is	AUX	O	O	2520
the	PRON	O	O	2520
latest	ADJ	O	O	2520
immunosuppressive	ADJ	O	O	2520
agent	NOUN	O	O	2520
used	VERB	O	O	2520
to	PART	O	O	2520
prevent	VERB	O	O	2520
rejection	NOUN	O	O	2520
,	PUNCT	O	O	2520
and	CCONJ	O	O	2520
may	AUX	O	O	2520
have	VERB	O	O	2520
less	ADV	O	O	2520
nephrotoxicity	NOUN	O	Disease	2520
than	ADP	O	O	2520
calcineurin	NOUN	O	O	2520
inhibitor	NOUN	O	O	2520
(	PUNCT	O	O	2520
CNI)-based	VERB	O	O	2520
regimens	NOUN	O	O	2520
.	PUNCT	O	O	2520
To	PART	O	O	2521
date	PROPN	O	O	2521
there	ADV	O	O	2521
has	VERB	O	O	2521
been	AUX	O	O	2521
little	ADJ	O	O	2521
documentation	NOUN	O	O	2521
of	ADP	O	O	2521
clinically	ADV	O	O	2521
significant	ADJ	O	O	2521
proteinuria	X	O	Disease	2521
linked	VERB	O	O	2521
with	ADP	O	O	2521
the	PRON	O	O	2521
use	VERB	O	O	2521
of	ADP	O	O	2521
sirolimus	NOUN	O	Chemical	2521
.	PUNCT	O	O	2521
We	PRON	O	O	2522
have	VERB	O	O	2522
encountered	VERB	O	O	2522
several	ADJ	O	O	2522
patients	NOUN	O	O	2522
who	PRON	O	O	2522
developed	VERB	O	O	2522
substantial	ADJ	O	O	2522
proteinuria	X	O	Disease	2522
associated	VERB	O	O	2522
with	ADP	O	O	2522
sirolimus	NOUN	O	Chemical	2522
use	VERB	O	O	2522
.	PUNCT	O	O	2522
In	ADP	O	O	2523
each	PRON	O	O	2523
patient	NOUN	O	O	2523
,	PUNCT	O	O	2523
the	PRON	O	O	2523
close	ADV	O	O	2523
temporal	ADJ	O	O	2523
association	PROPN	O	O	2523
between	ADP	O	O	2523
the	PRON	O	O	2523
commencement	NOUN	O	O	2523
of	ADP	O	O	2523
sirolimus	NOUN	O	Chemical	2523
therapy	NOUN	O	O	2523
and	CCONJ	O	O	2523
proteinuria	X	O	Disease	2523
implicated	VERB	O	O	2523
sirolimus	NOUN	O	Chemical	2523
as	ADP	O	O	2523
the	PRON	O	O	2523
most	ADV	O	O	2523
likely	ADV	O	O	2523
etiology	NOUN	O	O	2523
of	ADP	O	O	2523
the	PRON	O	O	2523
proteinuria	X	O	Disease	2523
.	PUNCT	O	O	2523
METHODS	NOUN	O	O	2524
:	PUNCT	O	O	2524
We	PRON	O	O	2524
analyzed	VERB	O	O	2524
the	PRON	O	O	2524
clinical	ADJ	O	O	2524
and	CCONJ	O	O	2524
laboratory	NOUN	O	O	2524
information	NOUN	O	O	2524
available	ADJ	O	O	2524
for	ADP	O	O	2524
all	PRON	O	O	2524
119	NUM	O	O	2524
patients	NOUN	O	O	2524
transplanted	VERB	O	O	2524
at	ADP	O	O	2524
the	PRON	O	O	2524
Washington	PROPN	O	O	2524
Hospital	NOUN	O	O	2524
Center	NOUN	O	O	2524
between	ADP	O	O	2524
1999	NUM	O	O	2524
-	PUNCT	O	O	2524
2003	NUM	O	O	2524
for	ADP	O	O	2524
whom	PRON	O	O	2524
sirolimus	NOUN	O	Chemical	2524
was	AUX	O	O	2524
a	PRON	O	O	2524
component	NOUN	O	O	2524
of	ADP	O	O	2524
their	PRON	O	O	2524
immunosuppressant	ADJ	O	O	2524
regimen	NOUN	O	O	2524
.	PUNCT	O	O	2524
In	ADP	O	O	2525
these	PRON	O	O	2525
patients	NOUN	O	O	2525
,	PUNCT	O	O	2525
the	PRON	O	O	2525
magnitude	NOUN	O	O	2525
of	ADP	O	O	2525
proteinuria	X	O	Disease	2525
was	AUX	O	O	2525
assessed	VERB	O	O	2525
on	ADP	O	O	2525
morning	NOUN	O	O	2525
urine	NOUN	O	O	2525
samples	NOUN	O	O	2525
by	ADP	O	O	2525
turbidometric	NOUN	O	O	2525
measurement	NOUN	O	O	2525
or	CCONJ	O	O	2525
random	ADJ	O	O	2525
urine	NOUN	O	O	2525
protein	NOUN	O	O	2525
:	PUNCT	O	O	2525
creatinine	PROPN	O	Chemical	2525
ratios	VERB	O	O	2525
,	PUNCT	O	O	2525
an	PRON	O	O	2525
estimate	VERB	O	O	2525
of	ADP	O	O	2525
grams	NOUN	O	O	2525
of	ADP	O	O	2525
proteinuria	X	O	Disease	2525
/	PUNCT	O	O	2525
day	NOUN	O	O	2525
.	PUNCT	O	O	2525
Laboratory	NOUN	O	O	2526
results	VERB	O	O	2526
were	AUX	O	O	2526
compared	VERB	O	O	2526
between	ADP	O	O	2526
prior	ADV	O	O	2526
,	PUNCT	O	O	2526
during	ADP	O	O	2526
and	CCONJ	O	O	2526
following	VERB	O	O	2526
sirolimus	NOUN	O	Chemical	2526
use	VERB	O	O	2526
.	PUNCT	O	O	2526
Twenty	NUM	O	O	2527
-	PUNCT	O	O	2527
eight	NUM	O	O	2527
patients	NOUN	O	O	2527
(	PUNCT	O	O	2527
24%	NOUN	O	O	2527
)	PUNCT	O	O	2527
developed	VERB	O	O	2527
increased	VERB	O	O	2527
proteinuria	X	O	Disease	2527
from	ADP	O	O	2527
baseline	VERB	O	O	2527
during	ADP	O	O	2527
their	PRON	O	O	2527
post	VERB	O	O	2527
-	PUNCT	O	O	2527
transplantation	NOUN	O	O	2527
course	NOUN	O	O	2527
.	PUNCT	O	O	2527
In	ADP	O	O	2528
21	NUM	O	O	2528
patients	NOUN	O	O	2528
an	PRON	O	O	2528
alternative	ADV	O	O	2528
cause	VERB	O	O	2528
of	ADP	O	O	2528
proteinuria	X	O	Disease	2528
was	AUX	O	O	2528
either	ADV	O	O	2528
obvious	ADJ	O	O	2528
or	CCONJ	O	O	2528
insufficient	ADJ	O	O	2528
data	NOUN	O	O	2528
was	AUX	O	O	2528
available	ADJ	O	O	2528
to	PART	O	O	2528
be	AUX	O	O	2528
conclusive	ADJ	O	O	2528
.	PUNCT	O	O	2528
In	ADP	O	O	2529
7	NUM	O	O	2529
of	ADP	O	O	2529
the	PRON	O	O	2529
28	NUM	O	O	2529
patients	NOUN	O	O	2529
there	ADV	O	O	2529
was	AUX	O	O	2529
a	PRON	O	O	2529
striking	VERB	O	O	2529
temporal	ADJ	O	O	2529
association	PROPN	O	O	2529
between	ADP	O	O	2529
the	PRON	O	O	2529
initiation	NOUN	O	O	2529
of	ADP	O	O	2529
sirolimus	NOUN	O	Chemical	2529
and	CCONJ	O	O	2529
the	PRON	O	O	2529
development	NOUN	O	O	2529
of	ADP	O	O	2529
nephrotic	NOUN	O	Disease	2529
-	PUNCT	O	O	2529
range	VERB	O	O	2529
proteinuria	X	O	Disease	2529
.	PUNCT	O	O	2529
Proteinuria	PROPN	O	Disease	2530
correlated	VERB	O	O	2530
most	ADV	O	O	2530
strongly	ADV	O	O	2530
with	ADP	O	O	2530
sirolimus	NOUN	O	Chemical	2530
therapy	NOUN	O	O	2530
when	SCONJ	O	O	2530
compared	VERB	O	O	2530
to	PART	O	O	2530
other	ADJ	O	O	2530
demographic	ADJ	O	O	2530
and	CCONJ	O	O	2530
clinical	ADJ	O	O	2530
variables	NOUN	O	O	2530
.	PUNCT	O	O	2530
In	ADP	O	O	2531
most	ADV	O	O	2531
patients	NOUN	O	O	2531
,	PUNCT	O	O	2531
discontinuation	NOUN	O	O	2531
of	ADP	O	O	2531
sirolimus	NOUN	O	Chemical	2531
resulted	VERB	O	O	2531
in	ADP	O	O	2531
a	PRON	O	O	2531
decrease	VERB	O	O	2531
,	PUNCT	O	O	2531
but	CCONJ	O	O	2531
not	PART	O	O	2531
resolution	NOUN	O	O	2531
,	PUNCT	O	O	2531
of	ADP	O	O	2531
proteinuria	X	O	Disease	2531
.	PUNCT	O	O	2531
Sirolimus	NOUN	O	Chemical	2532
induces	VERB	O	O	2532
or	CCONJ	O	O	2532
aggravates	VERB	O	O	2532
pre	VERB	O	O	2532
-	PUNCT	O	O	2532
existing	VERB	O	O	2532
proteinuria	X	O	Disease	2532
in	ADP	O	O	2532
an	PRON	O	O	2532
unpredictable	ADJ	O	O	2532
subset	VERB	O	O	2532
of	ADP	O	O	2532
renal	ADJ	O	O	2532
allograft	NOUN	O	O	2532
recipients	NOUN	O	O	2532
.	PUNCT	O	O	2532
Proteinuria	PROPN	O	Disease	2533
may	AUX	O	O	2533
improve	VERB	O	O	2533
,	PUNCT	O	O	2533
but	CCONJ	O	O	2533
does	VERB	O	O	2533
not	PART	O	O	2533
resolve	VERB	O	O	2533
,	PUNCT	O	O	2533
when	SCONJ	O	O	2533
sirolimus	NOUN	O	Chemical	2533
is	AUX	O	O	2533
withdrawn	VERB	O	O	2533
.	PUNCT	O	O	2533
Comparative	ADJ	O	O	2536
cognitive	ADJ	O	O	2536
and	CCONJ	O	O	2536
subjective	ADJ	O	O	2536
side	NOUN	O	O	2536
effects	NOUN	O	O	2536
of	ADP	O	O	2536
immediate	ADJ	O	O	2536
-	PUNCT	O	O	2536
release	NOUN	O	O	2536
oxycodone	NOUN	O	O	2536
in	ADP	O	O	2536
healthy	ADJ	O	O	2536
middle	ADJ	O	O	2536
-	PUNCT	O	O	2536
aged	ADJ	O	O	2536
and	CCONJ	O	O	2536
older	ADJ	O	O	2536
adults	NOUN	O	O	2536
.	PUNCT	O	O	2536
This	PRON	O	O	2537
study	VERB	O	O	2537
measured	VERB	O	O	2537
the	PRON	O	O	2537
objective	VERB	O	O	2537
and	CCONJ	O	O	2537
subjective	ADJ	O	O	2537
neurocognitive	PROPN	O	O	2537
effects	NOUN	O	O	2537
of	ADP	O	O	2537
a	PRON	O	O	2537
single	ADJ	O	O	2537
10-mg	NOUN	O	O	2537
dose	NOUN	O	O	2537
of	ADP	O	O	2537
immediate	ADJ	O	O	2537
-	PUNCT	O	O	2537
release	NOUN	O	O	2537
oxycodone	NOUN	O	O	2537
in	ADP	O	O	2537
healthy	ADJ	O	O	2537
,	PUNCT	O	O	2537
older	ADJ	O	O	2537
(	PUNCT	O	O	2537
>	PUNCT	O	O	2537
65	NUM	O	O	2537
years	NOUN	O	O	2537
)	PUNCT	O	O	2537
,	PUNCT	O	O	2537
and	CCONJ	O	O	2537
middle	ADJ	O	O	2537
-	PUNCT	O	O	2537
aged	ADJ	O	O	2537
(	PUNCT	O	O	2537
35	NUM	O	O	2537
to	PART	O	O	2537
55	NUM	O	O	2537
years	NOUN	O	O	2537
)	PUNCT	O	O	2537
adults	NOUN	O	O	2537
who	PRON	O	O	2537
were	AUX	O	O	2537
not	PART	O	O	2537
suffering	VERB	O	O	2537
from	ADP	O	O	2537
chronic	ADJ	O	O	2537
or	CCONJ	O	O	2537
significant	ADJ	O	O	2537
daily	ADV	O	O	2537
pain	NOUN	O	Disease	2537
.	PUNCT	O	O	2537
Seventy	NUM	O	O	2538
-	PUNCT	O	O	2538
one	NUM	O	O	2538
participants	NOUN	O	O	2538
completed	VERB	O	O	2538
2	X	O	O	2538
separate	VERB	O	O	2538
study	VERB	O	O	2538
days	NOUN	O	O	2538
and	CCONJ	O	O	2538
were	AUX	O	O	2538
blind	ADJ	O	Disease	2538
to	PART	O	O	2538
medication	NOUN	O	O	2538
condition	NOUN	O	O	2538
(	PUNCT	O	O	2538
placebo	NOUN	O	O	2538
,	PUNCT	O	O	2538
10-mg	NOUN	O	O	2538
oxycodone	NOUN	O	O	2538
)	PUNCT	O	O	2538
.	PUNCT	O	O	2538
Plasma	NOUN	O	O	2539
oxycodone	NOUN	O	O	2539
concentration	NOUN	O	O	2539
peaked	VERB	O	O	2539
between	ADP	O	O	2539
60	NUM	O	O	2539
and	CCONJ	O	O	2539
90	NUM	O	O	2539
minutes	NOUN	O	O	2539
postdose	NOUN	O	O	2539
(	PUNCT	O	O	2539
P	NOUN	O	Chemical	2539
<	X	O	O	2539
.01	NUM	O	O	2539
)	PUNCT	O	O	2539
and	CCONJ	O	O	2539
pupil	NOUN	O	O	2539
size	NOUN	O	O	2539
,	PUNCT	O	O	2539
an	PRON	O	O	2539
indication	NOUN	O	O	2539
of	ADP	O	O	2539
physiological	ADJ	O	O	2539
effects	NOUN	O	O	2539
of	ADP	O	O	2539
the	PRON	O	O	2539
medication	NOUN	O	O	2539
,	PUNCT	O	O	2539
peaked	VERB	O	O	2539
at	ADP	O	O	2539
approximately	ADV	O	O	2539
90	NUM	O	O	2539
to	PART	O	O	2539
120	NUM	O	O	2539
minutes	NOUN	O	O	2539
postdose	NOUN	O	O	2539
(	PUNCT	O	O	2539
P	NOUN	O	Chemical	2539
<	X	O	O	2539
.01	NUM	O	O	2539
)	PUNCT	O	O	2539
.	PUNCT	O	O	2539
Significant	ADJ	O	O	2540
declines	VERB	O	O	2540
in	ADP	O	O	2540
simple	ADJ	O	O	2540
and	CCONJ	O	O	2540
sustained	VERB	O	O	2540
attention	NOUN	O	O	2540
,	PUNCT	O	O	2540
working	VERB	O	O	2540
memory	NOUN	O	O	2540
,	PUNCT	O	O	2540
and	CCONJ	O	O	2540
verbal	ADJ	O	O	2540
memory	NOUN	O	O	2540
were	AUX	O	O	2540
observed	VERB	O	O	2540
at	ADP	O	O	2540
1	X	O	O	2540
hour	NOUN	O	O	2540
postdose	NOUN	O	O	2540
compared	VERB	O	O	2540
to	PART	O	O	2540
baseline	VERB	O	O	2540
for	ADP	O	O	2540
both	PRON	O	O	2540
age	NOUN	O	O	2540
groups	NOUN	O	O	2540
with	ADP	O	O	2540
a	PRON	O	O	2540
trend	NOUN	O	O	2540
toward	ADP	O	O	2540
return	VERB	O	O	2540
to	PART	O	O	2540
baseline	VERB	O	O	2540
by	ADP	O	O	2540
5	NUM	O	O	2540
hours	NOUN	O	O	2540
postdose	NOUN	O	O	2540
.	PUNCT	O	O	2540
This	PRON	O	O	2541
study	VERB	O	O	2541
suggests	VERB	O	O	2541
that	SCONJ	O	O	2541
for	ADP	O	O	2541
healthy	ADJ	O	O	2541
older	ADJ	O	O	2541
adults	NOUN	O	O	2541
who	PRON	O	O	2541
are	AUX	O	O	2541
not	PART	O	O	2541
suffering	VERB	O	O	2541
from	ADP	O	O	2541
chronic pain	NOUN	O	Disease	2541
,	PUNCT	O	O	2541
neurocognitive	PROPN	O	O	2541
and	CCONJ	O	O	2541
pharmacodynamic	ADJ	O	O	2541
changes	VERB	O	O	2541
in	ADP	O	O	2541
response	NOUN	O	O	2541
to	PART	O	O	2541
a	PRON	O	O	2541
10-mg	NOUN	O	O	2541
dose	NOUN	O	O	2541
of	ADP	O	O	2541
immediate	ADJ	O	O	2541
-	PUNCT	O	O	2541
release	NOUN	O	O	2541
oxycodone	NOUN	O	O	2541
are	AUX	O	O	2541
similar	ADJ	O	O	2541
to	PART	O	O	2541
those	PRON	O	O	2541
observed	VERB	O	O	2541
for	ADP	O	O	2541
middle	ADJ	O	O	2541
-	PUNCT	O	O	2541
aged	ADJ	O	O	2541
adults	NOUN	O	O	2541
.	PUNCT	O	O	2541
Study	NOUN	O	O	2542
findings	NOUN	O	O	2542
indicate	VERB	O	O	2542
that	SCONJ	O	O	2542
the	PRON	O	O	2542
metabolism	NOUN	O	O	2542
,	PUNCT	O	O	2542
neurocognitive	PROPN	O	O	2542
effects	NOUN	O	O	2542
,	PUNCT	O	O	2542
and	CCONJ	O	O	2542
physical	ADJ	O	O	2542
side	NOUN	O	O	2542
effects	NOUN	O	O	2542
of	ADP	O	O	2542
oral	ADJ	O	O	2542
oxycodone	NOUN	O	O	2542
are	AUX	O	O	2542
similar	ADJ	O	O	2542
for	ADP	O	O	2542
healthy	ADJ	O	O	2542
middle	ADJ	O	O	2542
-	PUNCT	O	O	2542
aged	ADJ	O	O	2542
and	CCONJ	O	O	2542
older	ADJ	O	O	2542
adults	NOUN	O	O	2542
.	PUNCT	O	O	2542
Normalizing	VERB	O	O	2545
effects	NOUN	O	O	2545
of	ADP	O	O	2545
modafinil	PUNCT	O	O	2545
on	ADP	O	O	2545
sleep	VERB	O	O	2545
in	ADP	O	O	2545
chronic	ADJ	O	O	2545
cocaine	NOUN	O	Chemical	2545
users	NOUN	O	O	2545
.	PUNCT	O	O	2545
The	PRON	O	O	2546
purpose	NOUN	O	O	2546
of	ADP	O	O	2546
the	PRON	O	O	2546
present	NOUN	O	O	2546
study	VERB	O	O	2546
was	AUX	O	O	2546
to	PART	O	O	2546
determine	VERB	O	O	2546
the	PRON	O	O	2546
effect	VERB	O	O	2546
of	ADP	O	O	2546
morning	NOUN	O	O	2546
-	PUNCT	O	O	2546
dosed	VERB	O	O	2546
modafinil	PUNCT	O	O	2546
on	ADP	O	O	2546
sleep	VERB	O	O	2546
and	CCONJ	O	O	2546
daytime	ADV	O	O	2546
sleepiness	NOUN	O	O	2546
in	ADP	O	O	2546
chronic	ADJ	O	O	2546
cocaine	NOUN	O	Chemical	2546
users	NOUN	O	O	2546
.	PUNCT	O	O	2546
Twenty	NUM	O	O	2547
cocaine	NOUN	O	Chemical	2547
-	PUNCT	O	O	2547
dependent	ADJ	O	O	2547
participants	NOUN	O	O	2547
were	AUX	O	O	2547
randomly	ADV	O	O	2547
assigned	VERB	O	O	2547
to	PART	O	O	2547
receive	VERB	O	O	2547
modafinil	PUNCT	O	O	2547
,	PUNCT	O	O	2547
400	NUM	O	O	2547
mg	VERB	O	O	2547
(	PUNCT	O	O	2547
N=10	VERB	O	O	2547
)	PUNCT	O	O	2547
,	PUNCT	O	O	2547
or	CCONJ	O	O	2547
placebo	NOUN	O	O	2547
(	PUNCT	O	O	2547
N=10	VERB	O	O	2547
)	PUNCT	O	O	2547
every	PRON	O	O	2547
morning	NOUN	O	O	2547
at	ADP	O	O	2547
7:30	NUM	O	O	2547
a.m.	ADV	O	O	2547
for	ADP	O	O	2547
16	NUM	O	O	2547
days	NOUN	O	O	2547
in	ADP	O	O	2547
an	PRON	O	O	2547
inpatient	ADJ	O	O	2547
,	PUNCT	O	O	2547
double	ADJ	O	O	2547
-	PUNCT	O	O	2547
blind	ADJ	O	Disease	2547
randomized	VERB	O	O	2547
trial	NOUN	O	O	2547
.	PUNCT	O	O	2547
Progressive	PROPN	O	O	2548
abstinence	NOUN	O	O	2548
from	ADP	O	O	2548
cocaine	NOUN	O	Chemical	2548
was	AUX	O	O	2548
associated	VERB	O	O	2548
with	ADP	O	O	2548
worsening	VERB	O	O	2548
of	ADP	O	O	2548
all	PRON	O	O	2548
measured	VERB	O	O	2548
polysomnographic	ADV	O	O	2548
sleep	VERB	O	O	2548
outcomes	NOUN	O	O	2548
.	PUNCT	O	O	2548
Compared	VERB	O	O	2549
with	ADP	O	O	2549
placebo	NOUN	O	O	2549
,	PUNCT	O	O	2549
modafinil	PUNCT	O	O	2549
decreased	VERB	O	O	2549
nighttime	NOUN	O	O	2549
sleep	VERB	O	O	2549
latency	VERB	O	O	2549
and	CCONJ	O	O	2549
increased	VERB	O	O	2549
slow	VERB	O	O	2549
-	PUNCT	O	O	2549
wave	NOUN	O	O	2549
sleep	VERB	O	O	2549
time	NOUN	O	O	2549
in	ADP	O	O	2549
cocaine	NOUN	O	Chemical	2549
-	PUNCT	O	O	2549
dependent	ADJ	O	O	2549
participants	NOUN	O	O	2549
.	PUNCT	O	O	2549
The	PRON	O	O	2550
effect	VERB	O	O	2550
of	ADP	O	O	2550
modafinil	PUNCT	O	O	2550
interacted	VERB	O	O	2550
with	ADP	O	O	2550
the	PRON	O	O	2550
abstinence	NOUN	O	O	2550
week	NOUN	O	O	2550
and	CCONJ	O	O	2550
was	AUX	O	O	2550
associated	VERB	O	O	2550
with	ADP	O	O	2550
longer	ADV	O	O	2550
total	ADJ	O	O	2550
sleep	VERB	O	O	2550
time	NOUN	O	O	2550
and	CCONJ	O	O	2550
shorter	ADJ	O	O	2550
REM	NOUN	O	O	2550
sleep	VERB	O	O	2550
latency	VERB	O	O	2550
in	ADP	O	O	2550
the	PRON	O	O	2550
third	ADV	O	O	2550
week	NOUN	O	O	2550
of	ADP	O	O	2550
abstinence	NOUN	O	O	2550
.	PUNCT	O	O	2550
Comparison	NOUN	O	O	2551
of	ADP	O	O	2551
slow	VERB	O	O	2551
-	PUNCT	O	O	2551
wave	NOUN	O	O	2551
sleep	VERB	O	O	2551
time	NOUN	O	O	2551
,	PUNCT	O	O	2551
total	ADJ	O	O	2551
sleep	VERB	O	O	2551
time	NOUN	O	O	2551
,	PUNCT	O	O	2551
and	CCONJ	O	O	2551
sleep	VERB	O	O	2551
latency	VERB	O	O	2551
in	ADP	O	O	2551
cocaine	NOUN	O	Chemical	2551
-	PUNCT	O	O	2551
dependent	ADJ	O	O	2551
and	CCONJ	O	O	2551
healthy	ADJ	O	O	2551
participants	NOUN	O	O	2551
revealed	VERB	O	O	2551
a	PRON	O	O	2551
normalizing	VERB	O	O	2551
effect	VERB	O	O	2551
of	ADP	O	O	2551
modafinil	PUNCT	O	O	2551
in	ADP	O	O	2551
cocaine	NOUN	O	Chemical	2551
-	PUNCT	O	O	2551
dependent	ADJ	O	O	2551
participants	NOUN	O	O	2551
.	PUNCT	O	O	2551
Modafinil	PROPN	O	O	2552
was	AUX	O	O	2552
associated	VERB	O	O	2552
with	ADP	O	O	2552
increased	VERB	O	O	2552
daytime	ADV	O	O	2552
sleep	VERB	O	O	2552
latency	VERB	O	O	2552
,	PUNCT	O	O	2552
as	ADP	O	O	2552
measured	VERB	O	O	2552
by	ADP	O	O	2552
the	PRON	O	O	2552
Multiple	ADJ	O	O	2552
Sleep	VERB	O	O	2552
Latency	NOUN	O	O	2552
Test	NOUN	O	O	2552
,	PUNCT	O	O	2552
and	CCONJ	O	O	2552
a	PRON	O	O	2552
nearly	ADV	O	O	2552
significant	ADJ	O	O	2552
decrease	VERB	O	O	2552
in	ADP	O	O	2552
subjective	ADJ	O	O	2552
daytime	ADV	O	O	2552
sleepiness	NOUN	O	O	2552
.	PUNCT	O	O	2552
Morning	NOUN	O	O	2553
-	PUNCT	O	O	2553
dosed	VERB	O	O	2553
modafinil	PUNCT	O	O	2553
promotes	VERB	O	O	2553
nocturnal	ADJ	O	O	2553
sleep	VERB	O	O	2553
,	PUNCT	O	O	2553
normalizes	VERB	O	O	2553
sleep	VERB	O	O	2553
architecture	NOUN	O	O	2553
,	PUNCT	O	O	2553
and	CCONJ	O	O	2553
decreases	VERB	O	O	2553
daytime	ADV	O	O	2553
sleepiness	NOUN	O	O	2553
in	ADP	O	O	2553
abstinent	ADJ	O	O	2553
cocaine	NOUN	O	Chemical	2553
users	NOUN	O	O	2553
.	PUNCT	O	O	2553
These	PRON	O	O	2554
effects	NOUN	O	O	2554
may	AUX	O	O	2554
be	AUX	O	O	2554
relevant	ADJ	O	O	2554
in	ADP	O	O	2554
the	PRON	O	O	2554
treatment	NOUN	O	O	2554
of	ADP	O	O	2554
cocaine	NOUN	O	Chemical	2554
dependence	NOUN	O	O	2554
.	PUNCT	O	O	2554
Efficacy	NOUN	O	O	2557
and	CCONJ	O	O	2557
safety	NOUN	O	O	2557
of	ADP	O	O	2557
asenapine	PROPN	O	O	2557
in	ADP	O	O	2557
a	PRON	O	O	2557
placebo-	PROPN	O	O	2557
and	CCONJ	O	O	2557
haloperidol	NOUN	O	Chemical	2557
-	PUNCT	O	O	2557
controlled	VERB	O	O	2557
trial	NOUN	O	O	2557
in	ADP	O	O	2557
patients	NOUN	O	O	2557
with	ADP	O	O	2557
acute	ADJ	O	O	2557
exacerbation	NOUN	O	O	2557
of	ADP	O	O	2557
schizophrenia	PROPN	O	Disease	2557
.	PUNCT	O	O	2557
Asenapine	PROPN	O	O	2558
is	AUX	O	O	2558
approved	VERB	O	O	2558
by	ADP	O	O	2558
the	PRON	O	O	2558
Food	NOUN	O	O	2558
and	CCONJ	O	O	2558
Drugs	NOUN	O	O	2558
Administration	NOUN	O	O	2558
in	ADP	O	O	2558
adults	NOUN	O	O	2558
for	ADP	O	O	2558
acute	ADJ	O	O	2558
treatment	NOUN	O	O	2558
of	ADP	O	O	2558
schizophrenia	PROPN	O	Disease	2558
or	CCONJ	O	O	2558
of	ADP	O	O	2558
manic	ADJ	O	O	2558
or	CCONJ	O	O	2558
mixed	VERB	O	O	2558
episodes	NOUN	O	O	2558
associated	VERB	O	O	2558
with	ADP	O	O	2558
bipolar	ADJ	O	O	2558
I	PRON	O	O	2558
disorder	NOUN	O	O	2558
with	ADP	O	O	2558
or	CCONJ	O	O	2558
without	ADP	O	O	2558
psychotic	ADJ	O	O	2558
features	VERB	O	O	2558
.	PUNCT	O	O	2558
In	ADP	O	O	2559
a	PRON	O	O	2559
double	ADJ	O	O	2559
-	PUNCT	O	O	2559
blind	ADJ	O	Disease	2559
6-week	NOUN	O	O	2559
trial	NOUN	O	O	2559
,	PUNCT	O	O	2559
458	NUM	O	O	2559
patients	NOUN	O	O	2559
with	ADP	O	O	2559
acute	ADJ	O	O	2559
schizophrenia	PROPN	O	Disease	2559
were	AUX	O	O	2559
randomly	ADV	O	O	2559
assigned	VERB	O	O	2559
to	PART	O	O	2559
fixed	VERB	O	O	2559
-	PUNCT	O	O	2559
dose	NOUN	O	O	2559
treatment	NOUN	O	O	2559
with	ADP	O	O	2559
asenapine	PROPN	O	O	2559
at	ADP	O	O	2559
5	NUM	O	O	2559
mg	VERB	O	O	2559
twice	ADV	O	O	2559
daily	ADV	O	O	2559
(	PUNCT	O	O	2559
BID	VERB	O	O	2559
)	PUNCT	O	O	2559
,	PUNCT	O	O	2559
asenapine	PROPN	O	O	2559
at	ADP	O	O	2559
10	NUM	O	O	2559
mg	VERB	O	O	2559
BID	VERB	O	O	2559
,	PUNCT	O	O	2559
placebo	NOUN	O	O	2559
,	PUNCT	O	O	2559
or	CCONJ	O	O	2559
haloperidol	NOUN	O	Chemical	2559
at	ADP	O	O	2559
4	NUM	O	O	2559
mg	VERB	O	O	2559
BID	VERB	O	O	2559
(	PUNCT	O	O	2559
to	PART	O	O	2559
verify	VERB	O	O	2559
assay	NOUN	O	O	2559
sensitivity	NOUN	O	O	2559
)	PUNCT	O	O	2559
.	PUNCT	O	O	2559
With	ADP	O	O	2560
last	VERB	O	O	2560
observations	NOUN	O	O	2560
carried	VERB	O	O	2560
forward	ADV	O	O	2560
(	PUNCT	O	O	2560
LOCF	NOUN	O	O	2560
)	PUNCT	O	O	2560
,	PUNCT	O	O	2560
mean	VERB	O	O	2560
Positive	PROPN	O	O	2560
and	CCONJ	O	O	2560
Negative	ADJ	O	O	2560
Syndrome	NOUN	O	O	2560
Scale	NOUN	O	O	2560
total	ADJ	O	O	2560
score	VERB	O	O	2560
reductions	NOUN	O	O	2560
from	ADP	O	O	2560
baseline	VERB	O	O	2560
to	PART	O	O	2560
endpoint	NOUN	O	O	2560
were	AUX	O	O	2560
significantly	ADV	O	O	2560
greater	ADJ	O	O	2560
with	ADP	O	O	2560
asenapine	PROPN	O	O	2560
at	ADP	O	O	2560
5	NUM	O	O	2560
mg	VERB	O	O	2560
BID	VERB	O	O	2560
(	PUNCT	O	O	2560
-16.2	X	O	O	2560
)	PUNCT	O	O	2560
and	CCONJ	O	O	2560
haloperidol	NOUN	O	Chemical	2560
(	PUNCT	O	O	2560
-15.4	X	O	O	2560
)	PUNCT	O	O	2560
than	ADP	O	O	2560
placebo	NOUN	O	O	2560
(	PUNCT	O	O	2560
-10.7	X	O	O	2560
;	PUNCT	O	O	2560
both	PRON	O	O	2560
P	NOUN	O	Chemical	2560
<	X	O	O	2560
0.05	NUM	O	O	2560
)	PUNCT	O	O	2560
;	PUNCT	O	O	2560
using	VERB	O	O	2560
mixed	VERB	O	O	2560
model	NOUN	O	O	2560
for	ADP	O	O	2560
repeated	VERB	O	O	2560
measures	NOUN	O	O	2560
(	PUNCT	O	O	2560
MMRM	NOUN	O	O	2560
)	PUNCT	O	O	2560
,	PUNCT	O	O	2560
changes	VERB	O	O	2560
at	ADP	O	O	2560
day	NOUN	O	O	2560
42	NUM	O	O	2560
were	AUX	O	O	2560
significantly	ADV	O	O	2560
greater	ADJ	O	O	2560
with	ADP	O	O	2560
asenapine	PROPN	O	O	2560
at	ADP	O	O	2560
5	NUM	O	O	2560
and	CCONJ	O	O	2560
10	NUM	O	O	2560
mg	VERB	O	O	2560
BID	VERB	O	O	2560
(	PUNCT	O	O	2560
-21.3	PROPN	O	O	2560
and	CCONJ	O	O	2560
-19.4	VERB	O	O	2560
,	PUNCT	O	O	2560
respectively	ADV	O	O	2560
)	PUNCT	O	O	2560
and	CCONJ	O	O	2560
haloperidol	NOUN	O	Chemical	2560
(	PUNCT	O	O	2560
-20.0	NOUN	O	O	2560
)	PUNCT	O	O	2560
than	ADP	O	O	2560
placebo	NOUN	O	O	2560
(	PUNCT	O	O	2560
-14.6	PROPN	O	O	2560
;	PUNCT	O	O	2560
all	PRON	O	O	2560
P	NOUN	O	Chemical	2560
<	X	O	O	2560
0.05	NUM	O	O	2560
)	PUNCT	O	O	2560
.	PUNCT	O	O	2560
On	ADP	O	O	2561
the	PRON	O	O	2561
Positive	PROPN	O	O	2561
and	CCONJ	O	O	2561
Negative	ADJ	O	O	2561
Syndrome	NOUN	O	O	2561
Scale	NOUN	O	O	2561
positive	ADJ	O	O	2561
subscale	NOUN	O	O	2561
,	PUNCT	O	O	2561
all	PRON	O	O	2561
treatments	NOUN	O	O	2561
were	AUX	O	O	2561
superior	PROPN	O	O	2561
to	PART	O	O	2561
placebo	NOUN	O	O	2561
with	ADP	O	O	2561
LOCF	NOUN	O	O	2561
and	CCONJ	O	O	2561
MMRM	NOUN	O	O	2561
;	PUNCT	O	O	2561
asenapine	PROPN	O	O	2561
at	ADP	O	O	2561
5	NUM	O	O	2561
mg	VERB	O	O	2561
BID	VERB	O	O	2561
was	AUX	O	O	2561
superior	PROPN	O	O	2561
to	PART	O	O	2561
placebo	NOUN	O	O	2561
on	ADP	O	O	2561
the	PRON	O	O	2561
negative	ADJ	O	O	2561
subscale	NOUN	O	O	2561
with	ADP	O	O	2561
MMRM	NOUN	O	O	2561
and	CCONJ	O	O	2561
on	ADP	O	O	2561
the	PRON	O	O	2561
general	ADJ	O	O	2561
psychopathology	NOUN	O	O	2561
subscale	NOUN	O	O	2561
with	ADP	O	O	2561
LOCF	NOUN	O	O	2561
and	CCONJ	O	O	2561
MMRM	NOUN	O	O	2561
.	PUNCT	O	O	2561
Treatment	NOUN	O	O	2562
-	PUNCT	O	O	2562
related	ADJ	O	O	2562
adverse	ADJ	O	O	2562
events	NOUN	O	O	2562
(	PUNCT	O	O	2562
AEs	PROPN	O	O	2562
)	PUNCT	O	O	2562
occurred	VERB	O	O	2562
in	ADP	O	O	2562
44%	NOUN	O	O	2562
and	CCONJ	O	O	2562
52%	NOUN	O	O	2562
,	PUNCT	O	O	2562
57%	NOUN	O	O	2562
,	PUNCT	O	O	2562
and	CCONJ	O	O	2562
41%	NOUN	O	O	2562
of	ADP	O	O	2562
the	PRON	O	O	2562
asenapine	PROPN	O	O	2562
at	ADP	O	O	2562
5	NUM	O	O	2562
and	CCONJ	O	O	2562
10	NUM	O	O	2562
mg	VERB	O	O	2562
BID	VERB	O	O	2562
,	PUNCT	O	O	2562
haloperidol	NOUN	O	Chemical	2562
,	PUNCT	O	O	2562
and	CCONJ	O	O	2562
placebo	NOUN	O	O	2562
groups	NOUN	O	O	2562
,	PUNCT	O	O	2562
respectively	ADV	O	O	2562
.	PUNCT	O	O	2562
Extrapyramidal symptoms	NOUN	O	Disease	2563
reported	VERB	O	O	2563
as	ADP	O	O	2563
AEs	PROPN	O	O	2563
occurred	VERB	O	O	2563
in	ADP	O	O	2563
15%	NOUN	O	O	2563
and	CCONJ	O	O	2563
18%	NOUN	O	O	2563
,	PUNCT	O	O	2563
34%	NOUN	O	O	2563
,	PUNCT	O	O	2563
and	CCONJ	O	O	2563
10%	NOUN	O	O	2563
of	ADP	O	O	2563
the	PRON	O	O	2563
asenapine	PROPN	O	O	2563
at	ADP	O	O	2563
5	NUM	O	O	2563
and	CCONJ	O	O	2563
10	NUM	O	O	2563
mg	VERB	O	O	2563
BID	VERB	O	O	2563
,	PUNCT	O	O	2563
haloperidol	NOUN	O	Chemical	2563
,	PUNCT	O	O	2563
and	CCONJ	O	O	2563
placebo	NOUN	O	O	2563
groups	NOUN	O	O	2563
,	PUNCT	O	O	2563
respectively	ADV	O	O	2563
.	PUNCT	O	O	2563
Post	NOUN	O	O	2564
hoc	PROPN	O	O	2564
analyses	NOUN	O	O	2564
indicated	VERB	O	O	2564
that	SCONJ	O	O	2564
efficacy	NOUN	O	O	2564
was	AUX	O	O	2564
similar	ADJ	O	O	2564
with	ADP	O	O	2564
asenapine	PROPN	O	O	2564
and	CCONJ	O	O	2564
haloperidol	NOUN	O	Chemical	2564
;	PUNCT	O	O	2564
greater	ADJ	O	O	2564
contrasts	VERB	O	O	2564
were	AUX	O	O	2564
seen	VERB	O	O	2564
in	ADP	O	O	2564
AEs	PROPN	O	O	2564
,	PUNCT	O	O	2564
especially	ADV	O	O	2564
extrapyramidal symptoms	NOUN	O	Disease	2564
.	PUNCT	O	O	2564
Permeability	NOUN	O	O	2567
,	PUNCT	O	O	2567
ultrastructural	ADJ	O	O	2567
changes	VERB	O	O	2567
,	PUNCT	O	O	2567
and	CCONJ	O	O	2567
distribution	NOUN	O	O	2567
of	ADP	O	O	2567
novel	NOUN	O	O	2567
proteins	NOUN	O	O	2567
in	ADP	O	O	2567
the	PRON	O	O	2567
glomerular	ADJ	O	O	2567
barrier	NOUN	O	O	2567
in	ADP	O	O	2567
early	ADV	O	O	2567
puromycin aminonucleoside	NOUN	O	Chemical	2567
nephrosis	NOUN	O	Disease	2567
.	PUNCT	O	O	2567
BACKGROUND	NOUN	O	O	2568
/	PUNCT	O	O	2568
AIMS	VERB	O	O	2568
:	PUNCT	O	O	2568
It	PRON	O	O	2568
is	AUX	O	O	2568
still	ADV	O	O	2568
unclear	ADJ	O	O	2568
what	PRON	O	O	2568
happens	VERB	O	O	2568
in	ADP	O	O	2568
the	PRON	O	O	2568
glomerulus	NOUN	O	O	2568
when	SCONJ	O	O	2568
proteinuria	X	O	Disease	2568
starts	VERB	O	O	2568
.	PUNCT	O	O	2568
Using	VERB	O	O	2569
puromycin aminonucleoside	NOUN	O	Chemical	2569
nephrosis	NOUN	O	Disease	2569
(	PUNCT	O	O	2569
PAN	PROPN	O	Chemical	2569
)	PUNCT	O	O	2569
rats	NOUN	O	O	2569
,	PUNCT	O	O	2569
we	PRON	O	O	2569
studied	VERB	O	O	2569
early	ADV	O	O	2569
ultrastructural	ADJ	O	O	2569
and	CCONJ	O	O	2569
permeability	NOUN	O	O	2569
changes	VERB	O	O	2569
in	ADP	O	O	2569
relation	NOUN	O	O	2569
to	PART	O	O	2569
the	PRON	O	O	2569
expression	NOUN	O	O	2569
of	ADP	O	O	2569
the	PRON	O	O	2569
podocyte	PROPN	O	O	2569
-	PUNCT	O	O	2569
associated	VERB	O	O	2569
molecules	NOUN	O	O	2569
nephrin	NOUN	O	O	2569
,	PUNCT	O	O	2569
a	PRON	O	O	2569
-	PUNCT	O	O	2569
actinin	NOUN	O	O	2569
,	PUNCT	O	O	2569
dendrin	PROPN	O	O	2569
,	PUNCT	O	O	2569
and	CCONJ	O	O	2569
plekhh2	PROPN	O	O	2569
,	PUNCT	O	O	2569
the	PRON	O	O	2569
last	VERB	O	O	2569
two	NUM	O	O	2569
of	ADP	O	O	2569
which	PRON	O	O	2569
were	AUX	O	O	2569
only	ADV	O	O	2569
recently	ADV	O	O	2569
discovered	VERB	O	O	2569
in	ADP	O	O	2569
podocytes	NOUN	O	O	2569
.	PUNCT	O	O	2569
By	ADP	O	O	2570
day	NOUN	O	O	2570
2	X	O	O	2570
,	PUNCT	O	O	2570
some	PRON	O	O	2570
patchy	ADJ	O	O	2570
foot	NOUN	O	O	2570
process	NOUN	O	O	2570
effacement	NOUN	O	O	2570
,	PUNCT	O	O	2570
but	CCONJ	O	O	2570
no	PRON	O	O	2570
proteinuria	X	O	Disease	2570
,	PUNCT	O	O	2570
appeared	VERB	O	O	2570
.	PUNCT	O	O	2570
By	ADP	O	O	2571
day	NOUN	O	O	2571
4	NUM	O	O	2571
,	PUNCT	O	O	2571
foot	NOUN	O	O	2571
process	NOUN	O	O	2571
effacement	NOUN	O	O	2571
was	AUX	O	O	2571
complete	VERB	O	O	2571
and	CCONJ	O	O	2571
proteinuria	X	O	Disease	2571
appeared	VERB	O	O	2571
in	ADP	O	O	2571
parallel	ADJ	O	O	2571
with	ADP	O	O	2571
signs	NOUN	O	O	2571
of	ADP	O	O	2571
size	NOUN	O	O	2571
barrier	NOUN	O	O	2571
damage	NOUN	O	O	2571
.	PUNCT	O	O	2571
PAN	PROPN	O	Chemical	2572
glomeruli	VERB	O	O	2572
already	ADV	O	O	2572
showed	VERB	O	O	2572
significant	ADJ	O	O	2572
pathology	NOUN	O	O	2572
by	ADP	O	O	2572
day	NOUN	O	O	2572
4	NUM	O	O	2572
,	PUNCT	O	O	2572
despite	SCONJ	O	O	2572
relatively	ADV	O	O	2572
mild	ADJ	O	O	2572
proteinuria	X	O	Disease	2572
.	PUNCT	O	O	2572
Twin	NOUN	O	O	2575
preterm	NOUN	O	O	2575
neonates	NOUN	O	O	2575
with	ADP	O	O	2575
cardiac toxicity	NOUN	O	Disease	2575
related	ADJ	O	O	2575
to	PART	O	O	2575
lopinavir	VERB	O	O	2575
/	PUNCT	O	O	2575
ritonavir	NOUN	O	O	2575
therapy	NOUN	O	O	2575
.	PUNCT	O	O	2575
We	PRON	O	O	2576
report	VERB	O	O	2576
twin	ADJ	O	O	2576
neonates	NOUN	O	O	2576
who	PRON	O	O	2576
were	AUX	O	O	2576
born	VERB	O	O	2576
prematurely	ADV	O	O	2576
at	ADP	O	O	2576
32	NUM	O	O	2576
weeks	NOUN	O	O	2576
of	ADP	O	O	2576
gestation	NOUN	O	O	2576
to	PART	O	O	2576
a	PRON	O	O	2576
mother	NOUN	O	O	2576
with	ADP	O	O	2576
human	PROPN	O	O	2576
immunodeficiency	NOUN	O	Disease	2576
virus	NOUN	O	O	2576
infection	NOUN	O	Disease	2576
.	PUNCT	O	O	2576
One	NUM	O	O	2577
of	ADP	O	O	2577
the	PRON	O	O	2577
twins	NOUN	O	O	2577
developed	VERB	O	O	2577
complete	VERB	O	O	2577
heart block	NOUN	O	Disease	2577
and	CCONJ	O	O	2577
dilated	ADJ	O	O	2577
cardiomyopathy	ADJ	O	Disease	2577
related	ADJ	O	O	2577
to	PART	O	O	2577
lopinavir	VERB	O	O	2577
/	PUNCT	O	O	2577
ritonavir	NOUN	O	O	2577
therapy	NOUN	O	O	2577
,	PUNCT	O	O	2577
a	PRON	O	O	2577
boosted	VERB	O	O	2577
protease	NOUN	O	O	2577
-	PUNCT	O	O	2577
inhibitor	NOUN	O	O	2577
agent	NOUN	O	O	2577
,	PUNCT	O	O	2577
while	SCONJ	O	O	2577
the	PRON	O	O	2577
other	ADJ	O	O	2577
twin	ADJ	O	O	2577
developed	VERB	O	O	2577
mild	ADJ	O	O	2577
bradycardia	NOUN	O	Disease	2577
.	PUNCT	O	O	2577
We	PRON	O	O	2578
recommend	VERB	O	O	2578
caution	NOUN	O	O	2578
in	ADP	O	O	2578
the	PRON	O	O	2578
use	VERB	O	O	2578
of	ADP	O	O	2578
lopinavir	VERB	O	O	2578
/	PUNCT	O	O	2578
ritonavir	NOUN	O	O	2578
in	ADP	O	O	2578
the	PRON	O	O	2578
immediate	ADJ	O	O	2578
neonatal	NOUN	O	O	2578
period	NOUN	O	O	2578
.	PUNCT	O	O	2578
Learning	VERB	O	O	2581
of	ADP	O	O	2581
rats	NOUN	O	O	2581
under	ADP	O	O	2581
amnesia	NOUN	O	Disease	2581
caused	VERB	O	O	2581
by	ADP	O	O	2581
pentobarbital	NOUN	O	Chemical	2581
.	PUNCT	O	O	2581
Dissociated	VERB	O	O	2582
learning	VERB	O	O	2582
of	ADP	O	O	2582
rats	NOUN	O	O	2582
in	ADP	O	O	2582
the	PRON	O	O	2582
normal	ADJ	O	O	2582
state	NOUN	O	O	2582
and	CCONJ	O	O	2582
the	PRON	O	O	2582
state	NOUN	O	O	2582
of	ADP	O	O	2582
amnesia	NOUN	O	Disease	2582
produced	VERB	O	O	2582
by	ADP	O	O	2582
pentobarbital	NOUN	O	Chemical	2582
(	PUNCT	O	O	2582
15	NUM	O	O	2582
mg	VERB	O	O	2582
/	PUNCT	O	O	2582
kg	VERB	O	O	2582
,	PUNCT	O	O	2582
ip	X	O	O	2582
)	PUNCT	O	O	2582
was	AUX	O	O	2582
carried	VERB	O	O	2582
out	ADP	O	O	2582
.	PUNCT	O	O	2582
In	ADP	O	O	2583
Group	PROPN	O	O	2583
1	X	O	O	2583
the	PRON	O	O	2583
rats	NOUN	O	O	2583
were	AUX	O	O	2583
trained	VERB	O	O	2583
under	ADP	O	O	2583
the	PRON	O	O	2583
influence	NOUN	O	O	2583
of	ADP	O	O	2583
pentobarbital	NOUN	O	Chemical	2583
to	PART	O	O	2583
run	VERB	O	O	2583
to	PART	O	O	2583
the	PRON	O	O	2583
same	ADJ	O	O	2583
shelf	NOUN	O	O	2583
as	ADP	O	O	2583
in	ADP	O	O	2583
the	PRON	O	O	2583
normal	ADJ	O	O	2583
state	NOUN	O	O	2583
.	PUNCT	O	O	2583
It	PRON	O	O	2584
was	AUX	O	O	2584
shown	VERB	O	O	2584
that	SCONJ	O	O	2584
memory	NOUN	O	O	2584
dissociation	NOUN	O	O	2584
occurred	VERB	O	O	2584
in	ADP	O	O	2584
both	PRON	O	O	2584
groups	NOUN	O	O	2584
.	PUNCT	O	O	2584
Differences	NOUN	O	O	2585
in	ADP	O	O	2585
the	PRON	O	O	2585
parameters	NOUN	O	O	2585
of	ADP	O	O	2585
training	NOUN	O	O	2585
under	ADP	O	O	2585
the	PRON	O	O	2585
influence	NOUN	O	O	2585
of	ADP	O	O	2585
pentobarbital	NOUN	O	Chemical	2585
between	ADP	O	O	2585
Groups	NOUN	O	O	2585
1	X	O	O	2585
and	CCONJ	O	O	2585
2	X	O	O	2585
were	AUX	O	O	2585
revealed	VERB	O	O	2585
.	PUNCT	O	O	2585
These	PRON	O	O	2586
findings	NOUN	O	O	2586
show	VERB	O	O	2586
that	SCONJ	O	O	2586
the	PRON	O	O	2586
brain	NOUN	O	O	2586
-	PUNCT	O	O	2586
dissociated	VERB	O	O	2586
state	NOUN	O	O	2586
induced	VERB	O	O	2586
by	ADP	O	O	2586
pentobarbital	NOUN	O	Chemical	2586
is	AUX	O	O	2586
formed	VERB	O	O	2586
with	ADP	O	O	2586
the	PRON	O	O	2586
participation	NOUN	O	O	2586
of	ADP	O	O	2586
the	PRON	O	O	2586
mechanisms	NOUN	O	O	2586
of	ADP	O	O	2586
information	NOUN	O	O	2586
perception	NOUN	O	O	2586
.	PUNCT	O	O	2586
Angiosarcoma	PROPN	O	O	2589
of	ADP	O	O	2589
the	PRON	O	O	2589
liver	NOUN	O	O	2589
associated	VERB	O	O	2589
with	ADP	O	O	2589
diethylstilbestrol	NOUN	O	O	2589
.	PUNCT	O	O	2589
Angiosarcoma	PROPN	O	O	2590
of	ADP	O	O	2590
the	PRON	O	O	2590
liver	NOUN	O	O	2590
occurred	VERB	O	O	2590
in	ADP	O	O	2590
a	PRON	O	O	2590
76-year	NOUN	O	O	2590
-	PUNCT	O	O	2590
old	ADJ	O	O	2590
man	NOUN	O	O	2590
who	PRON	O	O	2590
had	VERB	O	O	2590
been	AUX	O	O	2590
treated	VERB	O	O	2590
for	ADP	O	O	2590
a	PRON	O	O	2590
well	ADV	O	O	2590
-	PUNCT	O	O	2590
differentiated	VERB	O	O	2590
adenocarcinoma	NOUN	O	O	2590
of	ADP	O	O	2590
the	PRON	O	O	2590
liver	NOUN	O	O	2590
with	ADP	O	O	2590
diethylstilbestrol	NOUN	O	O	2590
for	ADP	O	O	2590
13	NUM	O	O	2590
years	NOUN	O	O	2590
.	PUNCT	O	O	2590
Angiosarcoma	PROPN	O	O	2591
was	AUX	O	O	2591
also	ADV	O	O	2591
present	NOUN	O	O	2591
within	ADP	O	O	2591
pulmonary	ADJ	O	O	2591
and	CCONJ	O	O	2591
renal	ADJ	O	O	2591
arteries	NOUN	O	O	2591
.	PUNCT	O	O	2591
The	PRON	O	O	2592
possibility	NOUN	O	O	2592
that	SCONJ	O	O	2592
the	PRON	O	O	2592
intraarterial	ADJ	O	O	2592
lesions	NOUN	O	O	2592
might	AUX	O	O	2592
represent	VERB	O	O	2592
independent	ADJ	O	O	2592
primary	NOUN	O	O	2592
tumors	NOUN	O	Disease	2592
is	AUX	O	O	2592
considered	VERB	O	O	2592
.	PUNCT	O	O	2592
Role	NOUN	O	O	2595
of	ADP	O	O	2595
xanthine	NOUN	O	O	2595
oxidase	NOUN	O	O	2595
in	ADP	O	O	2595
dexamethasone	NOUN	O	Chemical	2595
-	PUNCT	O	O	2595
induced	VERB	O	O	2595
hypertension	NOUN	O	Disease	2595
in	ADP	O	O	2595
rats	NOUN	O	O	2595
.	PUNCT	O	O	2595
1	X	O	O	2595
.	PUNCT	O	O	2595
Glucocorticoid	PROPN	O	O	2596
-	PUNCT	O	O	2596
induced	VERB	O	O	2596
hypertension	NOUN	O	Disease	2596
(	PUNCT	O	O	2596
GC	PROPN	O	O	2596
-	PUNCT	O	O	2596
HT	PROPN	O	O	2596
)	PUNCT	O	O	2596
in	ADP	O	O	2596
the	PRON	O	O	2596
rat	NOUN	O	O	2596
is	AUX	O	O	2596
associated	VERB	O	O	2596
with	ADP	O	O	2596
nitric oxide	NOUN	O	Chemical	2596
-	PUNCT	O	O	2596
redox	PROPN	O	O	2596
imbalance	NOUN	O	O	2596
.	PUNCT	O	O	2596
We	PRON	O	O	2597
studied	VERB	O	O	2597
the	PRON	O	O	2597
role	NOUN	O	O	2597
of	ADP	O	O	2597
xanthine	NOUN	O	O	2597
oxidase	NOUN	O	O	2597
(	PUNCT	O	O	2597
XO	PROPN	O	O	2597
)	PUNCT	O	O	2597
,	PUNCT	O	O	2597
which	PRON	O	O	2597
is	AUX	O	O	2597
implicated	VERB	O	O	2597
in	ADP	O	O	2597
the	PRON	O	O	2597
production	NOUN	O	O	2597
of	ADP	O	O	2597
reactive	ADJ	O	O	2597
oxygen	NOUN	O	Chemical	2597
species	NOUN	O	O	2597
,	PUNCT	O	O	2597
in	ADP	O	O	2597
dexamethasone	NOUN	O	Chemical	2597
-	PUNCT	O	O	2597
induced	VERB	O	O	2597
hypertension	NOUN	O	Disease	2597
(	PUNCT	O	O	2597
dex	PROPN	O	Chemical	2597
-	PUNCT	O	O	2597
HT	PROPN	O	O	2597
)	PUNCT	O	O	2597
.	PUNCT	O	O	2597
Thirty	NUM	O	O	2598
male	NOUN	O	O	2598
Sprague	PROPN	O	O	2598
-	PUNCT	O	O	2598
Dawley	NOUN	O	O	2598
rats	NOUN	O	O	2598
were	AUX	O	O	2598
divided	VERB	O	O	2598
randomly	ADV	O	O	2598
into	ADP	O	O	2598
four	NUM	O	O	2598
treatment	NOUN	O	O	2598
groups	NOUN	O	O	2598
:	PUNCT	O	O	2598
saline	NOUN	O	O	2598
,	PUNCT	O	O	2598
dexamethasone	NOUN	O	Chemical	2598
(	PUNCT	O	O	2598
dex	PROPN	O	Chemical	2598
)	PUNCT	O	O	2598
,	PUNCT	O	O	2598
allopurinol	NOUN	O	Chemical	2598
plus	CCONJ	O	O	2598
saline	NOUN	O	O	2598
,	PUNCT	O	O	2598
and	CCONJ	O	O	2598
allopurinol	NOUN	O	Chemical	2598
plus	CCONJ	O	O	2598
dex	PROPN	O	Chemical	2598
.	PUNCT	O	O	2598
Thymus	PROPN	O	O	2599
weight	NOUN	O	O	2599
was	AUX	O	O	2599
used	VERB	O	O	2599
as	ADP	O	O	2599
a	PRON	O	O	2599
marker	NOUN	O	O	2599
of	ADP	O	O	2599
glucocorticoid	NOUN	O	O	2599
activity	NOUN	O	O	2599
,	PUNCT	O	O	2599
and	CCONJ	O	O	2599
serum	NOUN	O	O	2599
urate	NOUN	O	O	2599
to	PART	O	O	2599
assess	VERB	O	O	2599
XO	PROPN	O	O	2599
inhibition	NOUN	O	O	2599
.	PUNCT	O	O	2599
Dex	PROPN	O	Chemical	2600
increased	VERB	O	O	2600
SBP	NOUN	O	O	2600
(	PUNCT	O	O	2600
110	NUM	O	O	2600
+	ADP	O	O	2600
/-	PUNCT	O	O	2600
3	X	O	O	2601
mmHg	PROPN	O	O	2601
;	PUNCT	O	O	2601
P	NOUN	O	Chemical	2601
<	X	O	O	2601
0.001	NUM	O	O	2601
)	PUNCT	O	O	2601
and	CCONJ	O	O	2601
decreased	VERB	O	O	2601
thymus	NOUN	O	O	2601
(	PUNCT	O	O	2601
P	NOUN	O	Chemical	2601
<	X	O	O	2601
0.001	NUM	O	O	2601
)	PUNCT	O	O	2601
and	CCONJ	O	O	2601
bodyweights	NOUN	O	O	2601
(	PUNCT	O	O	2601
P	NOUN	O	Chemical	2601
""""	PUNCT	O	O	2601
<	X	O	O	2601
0.01	NUM	O	O	2601
)	PUNCT	O	O	2601
.	PUNCT	O	O	2601
Allopurinol	NOUN	O	O	2602
decreased	VERB	O	O	2602
serum	NOUN	O	O	2602
urate	NOUN	O	O	2602
from	ADP	O	O	2602
76	NUM	O	O	2602
+	ADP	O	O	2602
/-	PUNCT	O	O	2602
/	PUNCT	O	O	2603
L	NOUN	O	O	2603
in	ADP	O	O	2603
dex	PROPN	O	Chemical	2603
-	PUNCT	O	O	2603
treated	VERB	O	O	2603
(	PUNCT	O	O	2603
P	NOUN	O	Chemical	2603
<	X	O	O	2603
0.01	NUM	O	O	2603
)	PUNCT	O	O	2603
groups	NOUN	O	O	2603
.	PUNCT	O	O	2603
Allopurinol	NOUN	O	O	2604
did	VERB	O	O	2604
not	PART	O	O	2604
prevent	VERB	O	O	2604
dex	PROPN	O	Chemical	2604
-	PUNCT	O	O	2604
HT	PROPN	O	O	2604
.	PUNCT	O	O	2604
This	PRON	O	O	2605
,	PUNCT	O	O	2605
together	ADV	O	O	2605
with	ADP	O	O	2605
our	PRON	O	O	2605
previous	ADJ	O	O	2605
findings	NOUN	O	O	2605
that	SCONJ	O	O	2605
allopurinol	NOUN	O	Chemical	2605
failed	VERB	O	O	2605
to	PART	O	O	2605
prevent	VERB	O	O	2605
adrenocorticotrophic	PROPN	O	O	2605
hormone	NOUN	O	O	2605
induced	VERB	O	O	2605
hypertension	NOUN	O	Disease	2605
,	PUNCT	O	O	2605
suggests	VERB	O	O	2605
that	SCONJ	O	O	2605
XO	PROPN	O	O	2605
activity	NOUN	O	O	2605
is	AUX	O	O	2605
not	PART	O	O	2605
a	PRON	O	O	2605
major	ADJ	O	O	2605
determinant	NOUN	O	O	2605
of	ADP	O	O	2605
GC	PROPN	O	O	2605
-	PUNCT	O	O	2605
HT	PROPN	O	O	2605
in	ADP	O	O	2605
the	PRON	O	O	2605
rat	NOUN	O	O	2605
.	PUNCT	O	O	2605
Extrapyramidal	NOUN	O	O	2608
side	NOUN	O	O	2608
effects	NOUN	O	O	2608
with	ADP	O	O	2608
risperidone	VERB	O	Chemical	2608
and	CCONJ	O	O	2608
haloperidol	NOUN	O	Chemical	2608
at	ADP	O	O	2608
comparable	ADJ	O	O	2608
D2	NOUN	O	O	2608
receptor	NOUN	O	O	2608
occupancy	NOUN	O	O	2608
levels	NOUN	O	O	2608
.	PUNCT	O	O	2608
Risperidone	NOUN	O	Chemical	2609
is	AUX	O	O	2609
an	PRON	O	O	2609
antipsychotic	ADJ	O	O	2609
drug	NOUN	O	O	2609
with	ADP	O	O	2609
high	ADJ	O	O	2609
affinity	NOUN	O	O	2609
at	ADP	O	O	2609
dopamine	NOUN	O	Chemical	2609
D2	NOUN	O	O	2609
and	CCONJ	O	O	2609
serotonin	PROPN	O	Chemical	2609
5-HT2	PROPN	O	O	2609
receptors	NOUN	O	O	2609
.	PUNCT	O	O	2609
Previous	ADJ	O	O	2610
clinical	ADJ	O	O	2610
studies	NOUN	O	O	2610
have	VERB	O	O	2610
proposed	VERB	O	O	2610
that	SCONJ	O	O	2610
risperidone	VERB	O	Chemical	2610
's	AUX	O	O	2610
pharmacologic	ADJ	O	O	2610
profile	NOUN	O	O	2610
may	AUX	O	O	2610
produce	VERB	O	O	2610
improved	VERB	O	O	2610
efficacy	NOUN	O	O	2610
for	ADP	O	O	2610
negative	ADJ	O	O	2610
psychotic symptoms	NOUN	O	Disease	2610
and	CCONJ	O	O	2610
decreased	VERB	O	O	2610
propensity	NOUN	O	O	2610
for	ADP	O	O	2610
extrapyramidal	ADJ	O	O	2610
side	NOUN	O	O	2610
effects	NOUN	O	O	2610
;	PUNCT	O	O	2610
features	VERB	O	O	2610
shared	VERB	O	O	2610
by	ADP	O	O	2610
so	ADV	O	O	2610
-	PUNCT	O	O	2610
called	VERB	O	O	2610
'	PUNCT	O	O	2610
atypical	ADJ	O	O	2610
'	PUNCT	O	O	2610
neuroleptics	NOUN	O	O	2610
.	PUNCT	O	O	2610
To	PART	O	O	2611
determine	VERB	O	O	2611
if	SCONJ	O	O	2611
routine	ADJ	O	O	2611
risperidone	VERB	O	Chemical	2611
treatment	NOUN	O	O	2611
is	AUX	O	O	2611
associated	VERB	O	O	2611
with	ADP	O	O	2611
a	PRON	O	O	2611
unique	ADJ	O	O	2611
degree	PROPN	O	O	2611
of	ADP	O	O	2611
D2	NOUN	O	O	2611
receptor	NOUN	O	O	2611
occupancy	NOUN	O	O	2611
and	CCONJ	O	O	2611
pattern	NOUN	O	O	2611
of	ADP	O	O	2611
clinical	ADJ	O	O	2611
effects	NOUN	O	O	2611
,	PUNCT	O	O	2611
we	PRON	O	O	2611
used	VERB	O	O	2611
[	X	O	O	2611
123I]IBZM	NUM	O	O	2611
SPECT	PROPN	O	O	2611
to	PART	O	O	2611
determine	VERB	O	O	2611
D2	NOUN	O	O	2611
occupancy	NOUN	O	O	2611
in	ADP	O	O	2611
subjects	NOUN	O	O	2611
treated	VERB	O	O	2611
with	ADP	O	O	2611
routine	ADJ	O	O	2611
clinical	ADJ	O	O	2611
doses	NOUN	O	O	2611
of	ADP	O	O	2611
risperidone	VERB	O	Chemical	2611
(	PUNCT	O	O	2611
n	CCONJ	O	O	2611
=	PUNCT	O	O	2611
12	NUM	O	O	2611
)	PUNCT	O	O	2611
or	CCONJ	O	O	2611
haloperidol	NOUN	O	Chemical	2611
(	PUNCT	O	O	2611
n	CCONJ	O	O	2611
=	PUNCT	O	O	2611
7	NUM	O	O	2611
)	PUNCT	O	O	2611
.	PUNCT	O	O	2611
Both	PRON	O	O	2612
risperidone	VERB	O	Chemical	2612
and	CCONJ	O	O	2612
haloperidol	NOUN	O	Chemical	2612
produced	VERB	O	O	2612
D2	NOUN	O	O	2612
occupancy	NOUN	O	O	2612
levels	NOUN	O	O	2612
between	ADP	O	O	2612
approximately	ADV	O	O	2612
60	NUM	O	O	2612
and	CCONJ	O	O	2612
90%	NOUN	O	O	2612
at	ADP	O	O	2612
standard	PROPN	O	O	2612
clinical	ADJ	O	O	2612
doses	NOUN	O	O	2612
.	PUNCT	O	O	2612
There	ADV	O	O	2613
was	AUX	O	O	2613
no	PRON	O	O	2613
significant	ADJ	O	O	2613
difference	NOUN	O	O	2613
between	ADP	O	O	2613
occupancy	NOUN	O	O	2613
levels	NOUN	O	O	2613
obtained	VERB	O	O	2613
with	ADP	O	O	2613
haloperidol	NOUN	O	Chemical	2613
or	CCONJ	O	O	2613
risperidone	VERB	O	Chemical	2613
.	PUNCT	O	O	2613
Drug	NOUN	O	O	2614
-	PUNCT	O	O	2614
induced	VERB	O	O	2614
parkinsonism	NOUN	O	Disease	2614
was	AUX	O	O	2614
observed	VERB	O	O	2614
in	ADP	O	O	2614
subjects	NOUN	O	O	2614
treated	VERB	O	O	2614
with	ADP	O	O	2614
risperidone	VERB	O	Chemical	2614
(	PUNCT	O	O	2614
42%	NOUN	O	O	2614
)	PUNCT	O	O	2614
and	CCONJ	O	O	2614
haloperidol	NOUN	O	Chemical	2614
(	PUNCT	O	O	2614
29%	NOUN	O	O	2614
)	PUNCT	O	O	2614
and	CCONJ	O	O	2614
was	AUX	O	O	2614
observed	VERB	O	O	2614
at	ADP	O	O	2614
occupancy	NOUN	O	O	2614
levels	NOUN	O	O	2614
above	ADP	O	O	2614
60%	NOUN	O	O	2614
.	PUNCT	O	O	2614
Based	VERB	O	O	2615
on	ADP	O	O	2615
these	PRON	O	O	2615
observations	NOUN	O	O	2615
,	PUNCT	O	O	2615
it	PRON	O	O	2615
is	AUX	O	O	2615
concluded	VERB	O	O	2615
that	SCONJ	O	O	2615
5-HT2	PROPN	O	O	2615
blockade	VERB	O	O	2615
obtained	VERB	O	O	2615
with	ADP	O	O	2615
risperidone	VERB	O	Chemical	2615
at	ADP	O	O	2615
D2	NOUN	O	O	2615
occupancy	NOUN	O	O	2615
rates	NOUN	O	O	2615
of	ADP	O	O	2615
60%	NOUN	O	O	2615
and	CCONJ	O	O	2615
above	ADP	O	O	2615
does	VERB	O	O	2615
not	PART	O	O	2615
appear	VERB	O	O	2615
to	PART	O	O	2615
protect	VERB	O	O	2615
against	ADP	O	O	2615
the	PRON	O	O	2615
risk	NOUN	O	O	2615
for	ADP	O	O	2615
extrapyramidal	ADJ	O	O	2615
side	NOUN	O	O	2615
effects	NOUN	O	O	2615
.	PUNCT	O	O	2615
Simvastatin	PROPN	O	O	2618
-	PUNCT	O	O	2618
ezetimibe	ADJ	O	O	2618
-	PUNCT	O	O	2618
induced	VERB	O	O	2618
hepatic failure	NOUN	O	Disease	2618
necessitating	VERB	O	O	2618
liver	NOUN	O	O	2618
transplantation	NOUN	O	O	2618
.	PUNCT	O	O	2618
A	PRON	O	O	2619
reductase	NOUN	O	O	2619
inhibitor	NOUN	O	O	2619
(	PUNCT	O	O	2619
statin	PROPN	O	O	2619
)	PUNCT	O	O	2619
therapy	NOUN	O	O	2619
.	PUNCT	O	O	2619
However	ADV	O	O	2620
,	PUNCT	O	O	2620
hepatotoxic	ADJ	O	Disease	2620
events	NOUN	O	O	2620
have	VERB	O	O	2620
not	PART	O	O	2620
been	AUX	O	O	2620
widely	ADV	O	O	2620
published	VERB	O	O	2620
with	ADP	O	O	2620
ezetimibe	ADJ	O	O	2620
or	CCONJ	O	O	2620
the	PRON	O	O	2620
combination	NOUN	O	O	2620
agent	NOUN	O	O	2620
simvastatin	PROPN	O	Chemical	2620
-	PUNCT	O	O	2620
ezetimibe	ADJ	O	O	2620
.	PUNCT	O	O	2620
We	PRON	O	O	2621
describe	VERB	O	O	2621
a	PRON	O	O	2621
70-year	NOUN	O	O	2621
-	PUNCT	O	O	2621
old	ADJ	O	O	2621
Hispanic	ADJ	O	O	2621
woman	NOUN	O	O	2621
who	PRON	O	O	2621
developed	VERB	O	O	2621
fulminant	ADJ	O	O	2621
hepatic failure	NOUN	O	Disease	2621
necessitating	VERB	O	O	2621
liver	NOUN	O	O	2621
transplantation	NOUN	O	O	2621
10	NUM	O	O	2621
weeks	NOUN	O	O	2621
after	ADP	O	O	2621
conversion	NOUN	O	O	2621
from	ADP	O	O	2621
simvastatin	PROPN	O	Chemical	2621
40	NUM	O	O	2621
mg	VERB	O	O	2621
/	PUNCT	O	O	2621
day	NOUN	O	O	2621
to	PART	O	O	2621
simvastatin	PROPN	O	Chemical	2621
10	NUM	O	O	2621
mg	VERB	O	O	2621
-	PUNCT	O	O	2621
ezetimibe	ADJ	O	O	2621
40	NUM	O	O	2621
mg	VERB	O	O	2621
/	PUNCT	O	O	2621
day	NOUN	O	O	2621
.	PUNCT	O	O	2621
The	PRON	O	O	2622
patient	NOUN	O	O	2622
's	AUX	O	O	2622
lipid	NOUN	O	O	2622
panel	NOUN	O	O	2622
had	VERB	O	O	2622
been	AUX	O	O	2622
maintained	VERB	O	O	2622
with	ADP	O	O	2622
simvastatin	PROPN	O	Chemical	2622
for	ADP	O	O	2622
18	NUM	O	O	2622
months	NOUN	O	O	2622
before	ADP	O	O	2622
the	PRON	O	O	2622
conversion	NOUN	O	O	2622
without	ADP	O	O	2622
evidence	NOUN	O	O	2622
of	ADP	O	O	2622
hepatotoxicity	NOUN	O	Disease	2622
.	PUNCT	O	O	2622
Simvastatinezetimibe	NOUN	O	O	2623
and	CCONJ	O	O	2623
escitalopram	X	O	O	2623
(	PUNCT	O	O	2623
which	PRON	O	O	2623
she	PRON	O	O	2623
was	AUX	O	O	2623
taking	VERB	O	O	2623
for	ADP	O	O	2623
depression	PROPN	O	Disease	2623
)	PUNCT	O	O	2623
were	AUX	O	O	2623
discontinued	VERB	O	O	2623
,	PUNCT	O	O	2623
and	CCONJ	O	O	2623
other	ADJ	O	O	2623
potential	ADJ	O	O	2623
causes	VERB	O	O	2623
of	ADP	O	O	2623
hepatotoxicity	NOUN	O	Disease	2623
were	AUX	O	O	2623
excluded	VERB	O	O	2623
.	PUNCT	O	O	2623
A	PRON	O	O	2624
repeat	VERB	O	O	2624
work	NOUN	O	O	2624
-	PUNCT	O	O	2624
up	ADP	O	O	2624
revealed	VERB	O	O	2624
further	ADV	O	O	2624
elevations	NOUN	O	O	2624
in	ADP	O	O	2624
aminotransferase	PROPN	O	O	2624
levels	NOUN	O	O	2624
,	PUNCT	O	O	2624
and	CCONJ	O	O	2624
liver	NOUN	O	O	2624
biopsy	PROPN	O	O	2624
revealed	VERB	O	O	2624
evidence	NOUN	O	O	2624
of	ADP	O	O	2624
moderate	ADJ	O	O	2624
-	PUNCT	O	O	2624
to	PART	O	O	2624
-	PUNCT	O	O	2624
severe	ADJ	O	O	2624
drug	NOUN	O	O	2624
toxicity	NOUN	O	Disease	2624
.	PUNCT	O	O	2624
Ezetimibe	NOUN	O	O	2625
undergoes	VERB	O	O	2625
extensive	ADJ	O	O	2625
glucuronidation	NOUN	O	O	2625
by	ADP	O	O	2625
uridine	NOUN	O	Chemical	2625
diphosphate	NOUN	O	O	2625
glucoronosyltransferases	NOUN	O	O	2625
(	PUNCT	O	O	2625
UGT	PROPN	O	O	2625
)	PUNCT	O	O	2625
in	ADP	O	O	2625
the	PRON	O	O	2625
intestine	NOUN	O	O	2625
and	CCONJ	O	O	2625
liver	NOUN	O	O	2625
and	CCONJ	O	O	2625
may	AUX	O	O	2625
have	VERB	O	O	2625
inhibited	VERB	O	O	2625
the	PRON	O	O	2625
glucuronidation	NOUN	O	O	2625
of	ADP	O	O	2625
simvastatin	PROPN	O	Chemical	2625
hydroxy	X	O	O	2625
acid	PROPN	O	O	2625
,	PUNCT	O	O	2625
resulting	VERB	O	O	2625
in	ADP	O	O	2625
increased	VERB	O	O	2625
simvastatin	PROPN	O	Chemical	2625
exposure	NOUN	O	O	2625
and	CCONJ	O	O	2625
subsequent	ADJ	O	O	2625
hepatotoxicity	NOUN	O	Disease	2625
.	PUNCT	O	O	2625
To	PART	O	O	2626
our	PRON	O	O	2626
knowledge	NOUN	O	O	2626
,	PUNCT	O	O	2626
this	PRON	O	O	2626
is	AUX	O	O	2626
the	PRON	O	O	2626
first	ADV	O	O	2626
case	NOUN	O	O	2626
report	VERB	O	O	2626
of	ADP	O	O	2626
simvastatin	PROPN	O	Chemical	2626
-	PUNCT	O	O	2626
ezetimibe	ADJ	O	O	2626
-	PUNCT	O	O	2626
induced	VERB	O	O	2626
liver failure	NOUN	O	Disease	2626
that	SCONJ	O	O	2626
resulted	VERB	O	O	2626
in	ADP	O	O	2626
liver	NOUN	O	O	2626
transplantation	NOUN	O	O	2626
.	PUNCT	O	O	2626
We	PRON	O	O	2627
postulate	VERB	O	O	2627
that	SCONJ	O	O	2627
the	PRON	O	O	2627
mechanism	NOUN	O	O	2627
of	ADP	O	O	2627
the	PRON	O	O	2627
simvastatinezetimibe	NOUN	O	O	2627
-	PUNCT	O	O	2627
induced	VERB	O	O	2627
hepatotoxicity	NOUN	O	Disease	2627
is	AUX	O	O	2627
the	PRON	O	O	2627
increased	VERB	O	O	2627
simvastatin	PROPN	O	Chemical	2627
exposure	NOUN	O	O	2627
by	ADP	O	O	2627
ezetimibe	ADJ	O	O	2627
inhibition	NOUN	O	O	2627
of	ADP	O	O	2627
UGT	PROPN	O	O	2627
enzymes	NOUN	O	O	2627
.	PUNCT	O	O	2627
Clinicians	NOUN	O	O	2628
should	AUX	O	O	2628
be	AUX	O	O	2628
aware	ADJ	O	O	2628
of	ADP	O	O	2628
potential	ADJ	O	O	2628
hepatotoxicity	NOUN	O	Disease	2628
with	ADP	O	O	2628
simvastatin	PROPN	O	Chemical	2628
-	PUNCT	O	O	2628
ezetimibe	ADJ	O	O	2628
especially	ADV	O	O	2628
in	ADP	O	O	2628
elderly	ADJ	O	O	2628
patients	NOUN	O	O	2628
and	CCONJ	O	O	2628
should	AUX	O	O	2628
carefully	ADV	O	O	2628
monitor	VERB	O	O	2628
serum	NOUN	O	O	2628
aminotransferase	PROPN	O	O	2628
levels	NOUN	O	O	2628
when	SCONJ	O	O	2628
starting	VERB	O	O	2628
therapy	NOUN	O	O	2628
and	CCONJ	O	O	2628
titrating	VERB	O	O	2628
the	PRON	O	O	2628
dosage	NOUN	O	O	2628
.	PUNCT	O	O	2628
Oral	NOUN	O	O	2631
manifestations	NOUN	O	O	2631
of	ADP	O	O	2631
""""	PUNCT	O	O	2631
meth	ADJ	O	O	2631
mouth	PROPN	O	O	2631
""""	PUNCT	O	O	2631
:	PUNCT	O	O	2631
a	PRON	O	O	2631
case	NOUN	O	O	2631
report	VERB	O	O	2631
.	PUNCT	O	O	2631
The	PRON	O	O	2632
aim	VERB	O	O	2632
of	ADP	O	O	2632
the	PRON	O	O	2632
documentation	NOUN	O	O	2632
of	ADP	O	O	2632
this	PRON	O	O	2632
clinical	ADJ	O	O	2632
case	NOUN	O	O	2632
is	AUX	O	O	2632
to	PART	O	O	2632
make	VERB	O	O	2632
clinicians	NOUN	O	O	2632
aware	ADJ	O	O	2632
of	ADP	O	O	2632
""""	PUNCT	O	O	2632
meth	ADJ	O	O	2632
mouth	PROPN	O	O	2632
""""	PUNCT	O	O	2632
and	CCONJ	O	O	2632
the	PRON	O	O	2632
medical	ADJ	O	O	2632
risks	NOUN	O	O	2632
associated	VERB	O	O	2632
with	ADP	O	O	2632
this	PRON	O	O	2632
serious	ADJ	O	O	2632
condition	NOUN	O	O	2632
.	PUNCT	O	O	2632
Methamphetamine	NOUN	O	Chemical	2633
is	AUX	O	O	2633
a	PRON	O	O	2633
very	ADV	O	O	2633
addictive	ADJ	O	O	2633
,	PUNCT	O	O	2633
powerful	ADJ	O	O	2633
stimulant	NOUN	O	O	2633
that	SCONJ	O	O	2633
increases	VERB	O	O	2633
wakefulness	NOUN	O	O	2633
and	CCONJ	O	O	2633
physical	ADJ	O	O	2633
activity	NOUN	O	O	2633
and	CCONJ	O	O	2633
can	AUX	O	O	2633
produce	VERB	O	O	2633
other	ADJ	O	O	2633
effects	NOUN	O	O	2633
such	ADJ	O	O	2633
as	ADP	O	O	2633
cardiac	ADJ	O	O	2633
dysrhythmias	VERB	O	Disease	2633
,	PUNCT	O	O	2633
hypertension	NOUN	O	Disease	2633
,	PUNCT	O	O	2633
hallucinations	NOUN	O	Disease	2633
,	PUNCT	O	O	2633
and	CCONJ	O	O	2633
violent	ADJ	O	O	2633
behavior	NOUN	O	O	2633
.	PUNCT	O	O	2633
Dental	NOUN	O	O	2634
patients	NOUN	O	O	2634
abusing	VERB	O	O	2634
methamphetamine	NOUN	O	Chemical	2634
can	AUX	O	O	2634
present	NOUN	O	O	2634
with	ADP	O	O	2634
poor	ADJ	O	O	2634
oral	ADJ	O	O	2634
hygiene	PROPN	O	O	2634
,	PUNCT	O	O	2634
xerostomia	NOUN	O	O	2634
,	PUNCT	O	O	2634
rampant	ADJ	O	O	2634
caries	VERB	O	O	2634
(	PUNCT	O	O	2634
""""	PUNCT	O	O	2634
meth	ADJ	O	O	2634
mouth	PROPN	O	O	2634
""""	PUNCT	O	O	2634
)	PUNCT	O	O	2634
,	PUNCT	O	O	2634
and	CCONJ	O	O	2634
excessive	ADJ	O	O	2634
tooth	NOUN	O	O	2634
wear	VERB	O	O	2634
.	PUNCT	O	O	2634
Oral	NOUN	O	O	2635
rehabilitation	NOUN	O	O	2635
of	ADP	O	O	2635
patients	NOUN	O	O	2635
using	VERB	O	O	2635
methamphetamine	NOUN	O	Chemical	2635
can	AUX	O	O	2635
be	AUX	O	O	2635
challenging	VERB	O	O	2635
.	PUNCT	O	O	2635
CASE	NOUN	O	O	2636
DESCRIPTION	PROPN	O	O	2636
:	PUNCT	O	O	2636
A	PRON	O	O	2636
30-year	NOUN	O	O	2636
-	PUNCT	O	O	2636
old	ADJ	O	O	2636
Caucasian	ADJ	O	O	2636
woman	NOUN	O	O	2636
presented	VERB	O	O	2636
with	ADP	O	O	2636
dental	ADJ	O	O	2636
pain	NOUN	O	Disease	2636
,	PUNCT	O	O	2636
bad	ADJ	O	O	2636
breath	NOUN	O	O	2636
,	PUNCT	O	O	2636
and	CCONJ	O	O	2636
self	VERB	O	O	2636
-	PUNCT	O	O	2636
reported	VERB	O	O	2636
poor	ADJ	O	O	2636
esthetics	NOUN	O	O	2636
.	PUNCT	O	O	2636
A	PRON	O	O	2637
comprehensive	ADJ	O	O	2637
examination	NOUN	O	O	2637
including	VERB	O	O	2637
her	PRON	O	O	2637
medical	ADJ	O	O	2637
history	NOUN	O	O	2637
,	PUNCT	O	O	2637
panoramic	ADJ	O	O	2637
radiograph	NOUN	O	O	2637
,	PUNCT	O	O	2637
and	CCONJ	O	O	2637
intraoral	ADJ	O	O	2637
examination	NOUN	O	O	2637
revealed	VERB	O	O	2637
19	NUM	O	O	2637
carious	ADJ	O	O	2637
lesions	NOUN	O	O	2637
,	PUNCT	O	O	2637
which	PRON	O	O	2637
is	AUX	O	O	2637
not	PART	O	O	2637
very	ADV	O	O	2637
common	ADJ	O	O	2637
for	ADP	O	O	2637
a	PRON	O	O	2637
healthy	ADJ	O	O	2637
adult	NOUN	O	O	2637
.	PUNCT	O	O	2637
She	PRON	O	O	2638
reported	VERB	O	O	2638
her	PRON	O	O	2638
use	VERB	O	O	2638
of	ADP	O	O	2638
methamphetamine	NOUN	O	Chemical	2638
for	ADP	O	O	2638
five	NUM	O	O	2638
years	NOUN	O	O	2638
and	CCONJ	O	O	2638
had	VERB	O	O	2638
not	PART	O	O	2638
experienced	ADJ	O	O	2638
any	PRON	O	O	2638
major	ADJ	O	O	2638
carious	ADJ	O	O	2638
episodes	NOUN	O	O	2638
before	ADP	O	O	2638
she	PRON	O	O	2638
started	VERB	O	O	2638
using	VERB	O	O	2638
the	PRON	O	O	2638
drug	NOUN	O	O	2638
.	PUNCT	O	O	2638
The	PRON	O	O	2639
patient	NOUN	O	O	2639
's	AUX	O	O	2639
medical	ADJ	O	O	2639
and	CCONJ	O	O	2639
dental	ADJ	O	O	2639
histories	NOUN	O	O	2639
along	ADV	O	O	2639
with	ADP	O	O	2639
radiographic	ADJ	O	O	2639
and	CCONJ	O	O	2639
clinical	ADJ	O	O	2639
findings	NOUN	O	O	2639
lead	VERB	O	Chemical	2639
to	PART	O	O	2639
a	PRON	O	O	2639
diagnosis	NOUN	O	O	2639
of	ADP	O	O	2639
""""	PUNCT	O	O	2639
meth	ADJ	O	O	2639
mouth	PROPN	O	O	2639
.	PUNCT	O	O	2639
This	PRON	O	O	2640
clinical	ADJ	O	O	2640
case	NOUN	O	O	2640
showing	VERB	O	O	2640
oral	ADJ	O	O	2640
manifestations	NOUN	O	O	2640
of	ADP	O	O	2640
meth	ADJ	O	O	2640
mouth	PROPN	O	O	2640
was	AUX	O	O	2640
presented	VERB	O	O	2640
to	PART	O	O	2640
help	VERB	O	O	2640
dental	ADJ	O	O	2640
practitioners	NOUN	O	O	2640
recognize	VERB	O	O	2640
and	CCONJ	O	O	2640
manage	VERB	O	O	2640
patients	NOUN	O	O	2640
who	PRON	O	O	2640
may	AUX	O	O	2640
be	AUX	O	O	2640
abusing	VERB	O	O	2640
methamphetamines	NOUN	O	O	2640
.	PUNCT	O	O	2640
Thyroxine	NOUN	O	O	2643
abuse	VERB	O	O	2643
:	PUNCT	O	O	2643
an	PRON	O	O	2643
unusual	ADJ	O	O	2643
case	NOUN	O	O	2643
of	ADP	O	O	2643
thyrotoxicosis	VERB	O	O	2643
in	ADP	O	O	2643
pregnancy	NOUN	O	O	2643
.	PUNCT	O	O	2643
Eating	VERB	O	O	2644
disorders	NOUN	O	O	2644
and	CCONJ	O	O	2644
the	PRON	O	O	2644
associated	VERB	O	O	2644
behavioural	ADJ	O	O	2644
problems	NOUN	O	O	2644
and	CCONJ	O	O	2644
drug abuse	NOUN	O	Disease	2644
are	AUX	O	O	2644
uncommon	ADJ	O	O	2644
in	ADP	O	O	2644
pregnancy	NOUN	O	O	2644
.	PUNCT	O	O	2644
This	PRON	O	O	2645
case	NOUN	O	O	2645
illustrates	VERB	O	O	2645
a	PRON	O	O	2645
number	NOUN	O	O	2645
of	ADP	O	O	2645
problems	NOUN	O	O	2645
that	SCONJ	O	O	2645
may	AUX	O	O	2645
be	AUX	O	O	2645
encountered	VERB	O	O	2645
in	ADP	O	O	2645
women	NOUN	O	O	2645
with	ADP	O	O	2645
eating	VERB	O	O	2645
disorders	NOUN	O	O	2645
in	ADP	O	O	2645
pregnancy	NOUN	O	O	2645
,	PUNCT	O	O	2645
including	VERB	O	O	2645
prolonged	VERB	O	O	2645
and	CCONJ	O	O	2645
recurrent	ADJ	O	O	2645
metabolic	ADJ	O	O	2645
disturbances	NOUN	O	O	2645
and	CCONJ	O	O	2645
diuretic	ADJ	O	Chemical	2645
abuse	VERB	O	O	2645
.	PUNCT	O	O	2645
In	ADP	O	O	2646
particular	ADJ	O	O	2646
it	PRON	O	O	2646
illustrates	VERB	O	O	2646
the	PRON	O	O	2646
derangements	NOUN	O	O	2646
of	ADP	O	O	2646
thyroid	NOUN	O	O	2646
function	NOUN	O	O	2646
seen	VERB	O	O	2646
in	ADP	O	O	2646
pregnant	ADJ	O	O	2646
women	NOUN	O	O	2646
with	ADP	O	O	2646
eating	VERB	O	O	2646
disorders	NOUN	O	O	2646
and	CCONJ	O	O	2646
reminds	VERB	O	O	2646
us	PRON	O	O	2646
that	SCONJ	O	O	2646
when	SCONJ	O	O	2646
a	PRON	O	O	2646
cause	VERB	O	O	2646
for	ADP	O	O	2646
thyrotoxicosis	VERB	O	O	2646
remains	VERB	O	O	2646
obscure	ADJ	O	O	2646
,	PUNCT	O	O	2646
thyroxine	NOUN	O	Chemical	2646
abuse	VERB	O	O	2646
should	AUX	O	O	2646
be	AUX	O	O	2646
considered	VERB	O	O	2646
and	CCONJ	O	O	2646
explored	VERB	O	O	2646
.	PUNCT	O	O	2646
Attenuation	NOUN	O	O	2649
of	ADP	O	O	2649
methamphetamine	NOUN	O	Chemical	2649
-	PUNCT	O	O	2649
induced	VERB	O	O	2649
nigrostriatal	NOUN	O	O	2649
dopaminergic	ADJ	O	O	2649
neurotoxicity	NOUN	O	Disease	2649
in	ADP	O	O	2649
mice	NOUN	O	O	2649
by	ADP	O	O	2649
lipopolysaccharide	NOUN	O	O	2649
pretreatment	NOUN	O	O	2649
.	PUNCT	O	O	2649
Immunological	PROPN	O	O	2650
activation	NOUN	O	O	2650
has	VERB	O	O	2650
been	AUX	O	O	2650
proposed	VERB	O	O	2650
to	PART	O	O	2650
play	VERB	O	O	2650
a	PRON	O	O	2650
role	NOUN	O	O	2650
in	ADP	O	O	2650
methamphetamine	NOUN	O	Chemical	2650
-	PUNCT	O	O	2650
induced	VERB	O	O	2650
dopaminergic	ADJ	O	O	2650
terminal	PROPN	O	O	2650
damage	NOUN	O	O	2650
.	PUNCT	O	O	2650
In	ADP	O	O	2651
this	PRON	O	O	2651
study	VERB	O	O	2651
,	PUNCT	O	O	2651
we	PRON	O	O	2651
examined	VERB	O	O	2651
the	PRON	O	O	2651
roles	NOUN	O	O	2651
of	ADP	O	O	2651
lipopolysaccharide	NOUN	O	O	2651
,	PUNCT	O	O	2651
a	PRON	O	O	2651
pro	ADJ	O	O	2651
-	PUNCT	O	O	2651
inflammatory	ADJ	O	O	2651
and	CCONJ	O	O	2651
inflammatory	ADJ	O	O	2651
factor	NOUN	O	O	2651
,	PUNCT	O	O	2651
treatment	NOUN	O	O	2651
in	ADP	O	O	2651
modulating	VERB	O	O	2651
the	PRON	O	O	2651
methamphetamine	NOUN	O	Chemical	2651
-	PUNCT	O	O	2651
induced	VERB	O	O	2651
nigrostriatal	NOUN	O	O	2651
dopamine	NOUN	O	Chemical	2651
neurotoxicity	NOUN	O	Disease	2651
.	PUNCT	O	O	2651
Lipopolysaccharide	ADV	O	O	2652
pretreatment	NOUN	O	O	2652
did	VERB	O	O	2652
not	PART	O	O	2652
affect	VERB	O	O	2652
the	PRON	O	O	2652
basal	PROPN	O	O	2652
body	NOUN	O	O	2652
temperature	NOUN	O	O	2652
or	CCONJ	O	O	2652
methamphetamine	NOUN	O	Chemical	2652
-	PUNCT	O	O	2652
elicited	VERB	O	O	2652
hyperthermia	NOUN	O	Disease	2652
three	NUM	O	O	2652
days	NOUN	O	O	2652
later	ADV	O	O	2652
.	PUNCT	O	O	2652
Such	ADJ	O	O	2653
systemic	ADJ	O	O	2653
lipopolysaccharide	NOUN	O	O	2653
treatment	NOUN	O	O	2653
mitigated	VERB	O	O	2653
methamphetamine	NOUN	O	Chemical	2653
-	PUNCT	O	O	2653
induced	VERB	O	O	2653
striatal	ADJ	O	O	2653
dopamine	NOUN	O	Chemical	2653
and	CCONJ	O	O	2653
3,4-dihydroxyphenylacetic acid	NOUN	O	O	2653
depletions	NOUN	O	O	2653
in	ADP	O	O	2653
a	PRON	O	O	2653
dose	NOUN	O	O	2653
-	PUNCT	O	O	2653
dependent	ADJ	O	O	2653
manner	VERB	O	O	2653
.	PUNCT	O	O	2653
As	ADP	O	O	2654
the	PRON	O	O	2654
most	ADV	O	O	2654
potent	ADJ	O	O	2654
dose	NOUN	O	O	2654
(	PUNCT	O	O	2654
1	X	O	O	2654
mg	VERB	O	O	2654
/	PUNCT	O	O	2654
kg	VERB	O	O	2654
)	PUNCT	O	O	2654
of	ADP	O	O	2654
lipopolysaccharide	NOUN	O	O	2654
was	AUX	O	O	2654
administered	VERB	O	O	2654
two	NUM	O	O	2654
weeks	NOUN	O	O	2654
,	PUNCT	O	O	2654
one	NUM	O	O	2654
day	NOUN	O	O	2654
before	ADP	O	O	2654
or	CCONJ	O	O	2654
after	ADP	O	O	2654
the	PRON	O	O	2654
methamphetamine	NOUN	O	Chemical	2654
dosing	VERB	O	O	2654
regimen	NOUN	O	O	2654
,	PUNCT	O	O	2654
methamphetamine	NOUN	O	Chemical	2654
-	PUNCT	O	O	2654
induced	VERB	O	O	2654
striatal	ADJ	O	O	2654
dopamine	NOUN	O	Chemical	2654
and	CCONJ	O	O	2654
3,4-dihydroxyphenylacetic acid	NOUN	O	O	2654
depletions	NOUN	O	O	2654
remained	VERB	O	O	2654
unaltered	ADJ	O	O	2654
.	PUNCT	O	O	2654
Moreover	ADV	O	O	2655
,	PUNCT	O	O	2655
systemic	ADJ	O	O	2655
lipopolysaccharide	NOUN	O	O	2655
pretreatment	NOUN	O	O	2655
(	PUNCT	O	O	2655
1	X	O	O	2655
mg	VERB	O	O	2655
/	PUNCT	O	O	2655
kg	VERB	O	O	2655
)	PUNCT	O	O	2655
attenuated	VERB	O	O	2655
local	ADJ	O	O	2655
methamphetamine	NOUN	O	Chemical	2655
infusion	NOUN	O	O	2655
-	PUNCT	O	O	2655
produced	VERB	O	O	2655
dopamine	NOUN	O	Chemical	2655
and	CCONJ	O	O	2655
3,4-dihydroxyphenylacetic acid	NOUN	O	O	2655
depletions	NOUN	O	O	2655
in	ADP	O	O	2655
the	PRON	O	O	2655
striatum	NOUN	O	O	2655
,	PUNCT	O	O	2655
indicating	VERB	O	O	2655
that	SCONJ	O	O	2655
the	PRON	O	O	2655
protective	ADJ	O	O	2655
effect	VERB	O	O	2655
of	ADP	O	O	2655
lipopolysaccharide	NOUN	O	O	2655
is	AUX	O	O	2655
less	ADV	O	O	2655
likely	ADV	O	O	2655
due	ADJ	O	O	2655
to	PART	O	O	2655
interrupted	VERB	O	O	2655
peripheral	ADJ	O	O	2655
distribution	NOUN	O	O	2655
or	CCONJ	O	O	2655
metabolism	NOUN	O	O	2655
of	ADP	O	O	2655
methamphetamine	NOUN	O	Chemical	2655
.	PUNCT	O	O	2655
We	PRON	O	O	2656
concluded	VERB	O	O	2656
a	PRON	O	O	2656
critical	ADJ	O	O	2656
time	NOUN	O	O	2656
window	NOUN	O	O	2656
for	ADP	O	O	2656
systemic	ADJ	O	O	2656
lipopolysaccharide	NOUN	O	O	2656
pretreatment	NOUN	O	O	2656
in	ADP	O	O	2656
exerting	VERB	O	O	2656
effective	ADJ	O	O	2656
protection	NOUN	O	O	2656
against	ADP	O	O	2656
methamphetamine	NOUN	O	Chemical	2656
-	PUNCT	O	O	2656
induced	VERB	O	O	2656
nigrostriatal	NOUN	O	O	2656
dopamine	NOUN	O	Chemical	2656
neurotoxicity	NOUN	O	Disease	2656
.	PUNCT	O	O	2656
Effect	VERB	O	O	2659
of	ADP	O	O	2659
converting	VERB	O	O	2659
enzyme	NOUN	O	O	2659
inhibition	NOUN	O	O	2659
on	ADP	O	O	2659
the	PRON	O	O	2659
course	NOUN	O	O	2659
of	ADP	O	O	2659
adriamycin	PROPN	O	Chemical	2659
-	PUNCT	O	O	2659
induced	VERB	O	O	2659
nephropathy	NOUN	O	Disease	2659
.	PUNCT	O	O	2659
The	PRON	O	O	2660
effect	VERB	O	O	2660
of	ADP	O	O	2660
the	PRON	O	O	2660
converting	VERB	O	O	2660
enzyme	NOUN	O	O	2660
inhibitor	NOUN	O	O	2660
(	PUNCT	O	O	2660
CEI	PROPN	O	O	2660
)	PUNCT	O	O	2660
enalapril	PROPN	O	Chemical	2660
was	AUX	O	O	2660
assessed	VERB	O	O	2660
in	ADP	O	O	2660
Munich	PROPN	O	O	2660
-	PUNCT	O	O	2660
Wistar	PROPN	O	O	2660
rats	NOUN	O	O	2660
with	ADP	O	O	2660
established	VERB	O	O	2660
adriamycin	PROPN	O	Chemical	2660
nephrosis	NOUN	O	Disease	2660
.	PUNCT	O	O	2660
Rats	NOUN	O	O	2661
were	AUX	O	O	2661
given	VERB	O	O	2661
a	PRON	O	O	2661
single	ADJ	O	O	2661
dose	NOUN	O	O	2661
of	ADP	O	O	2661
adriamycin	PROPN	O	Chemical	2661
and	CCONJ	O	O	2661
one	NUM	O	O	2661
month	NOUN	O	O	2661
later	ADV	O	O	2661
divided	VERB	O	O	2661
into	ADP	O	O	2661
four	NUM	O	O	2661
groups	NOUN	O	O	2661
matched	VERB	O	O	2661
for	ADP	O	O	2661
albuminuria	PROPN	O	Disease	2661
,	PUNCT	O	O	2661
blood	NOUN	O	O	2661
pressure	NOUN	O	O	2661
,	PUNCT	O	O	2661
and	CCONJ	O	O	2661
plasma	NOUN	O	O	2661
albumin	PROPN	O	O	2661
concentration	NOUN	O	O	2661
.	PUNCT	O	O	2661
Groups	NOUN	O	O	2662
1	X	O	O	2662
and	CCONJ	O	O	2662
3	X	O	O	2662
remained	VERB	O	O	2662
untreated	ADJ	O	O	2662
while	SCONJ	O	O	2662
groups	NOUN	O	O	2662
2	X	O	O	2662
and	CCONJ	O	O	2662
4	NUM	O	O	2662
received	VERB	O	O	2662
enalapril	PROPN	O	Chemical	2662
.	PUNCT	O	O	2662
These	PRON	O	O	2663
short	ADJ	O	O	2663
-	PUNCT	O	O	2663
term	NOUN	O	O	2663
studies	NOUN	O	O	2663
showed	VERB	O	O	2663
that	SCONJ	O	O	2663
enalapril	PROPN	O	Chemical	2663
reduced	VERB	O	O	2663
arterial	ADJ	O	O	2663
blood	NOUN	O	O	2663
pressure	NOUN	O	O	2663
(	PUNCT	O	O	2663
101	NUM	O	O	2663
+	ADP	O	O	2663
/-	PUNCT	O	O	2663
2	X	O	O	2664
mm	INTJ	O	O	2664
Hg	PROPN	O	O	2664
,	PUNCT	O	O	2664
P	NOUN	O	Chemical	2664
less	ADV	O	O	2664
than	ADP	O	O	2664
0.05	NUM	O	O	2664
)	PUNCT	O	O	2664
without	ADP	O	O	2664
reducing	VERB	O	O	2664
albuminuria	PROPN	O	Disease	2664
(	PUNCT	O	O	2664
617	NUM	O	O	2664
+	ADP	O	O	2664
/-	PUNCT	O	O	2664
50	NUM	O	O	2664
vs.	CCONJ	O	O	2664
570	NUM	O	O	2664
+	ADP	O	O	2664
/-	PUNCT	O	O	2664
47	NUM	O	O	2664
mg	VERB	O	O	2664
/	PUNCT	O	O	2664
day	NOUN	O	O	2664
)	PUNCT	O	O	2664
or	CCONJ	O	O	2664
GFR	NOUN	O	O	2664
(	PUNCT	O	O	2664
1.03	NUM	O	O	2664
+	ADP	O	O	2664
/-	PUNCT	O	O	2664
Groups	NOUN	O	O	2665
3	X	O	O	2665
and	CCONJ	O	O	2665
4	NUM	O	O	2665
were	AUX	O	O	2665
studied	VERB	O	O	2665
at	ADP	O	O	2665
four	NUM	O	O	2665
and	CCONJ	O	O	2665
at	ADP	O	O	2665
six	NUM	O	O	2665
months	NOUN	O	O	2665
to	PART	O	O	2665
assess	VERB	O	O	2665
the	PRON	O	O	2665
effect	VERB	O	O	2665
of	ADP	O	O	2665
enalapril	PROPN	O	Chemical	2665
on	ADP	O	O	2665
progression	NOUN	O	O	2665
of	ADP	O	O	2665
renal injury	NOUN	O	Disease	2665
in	ADP	O	O	2665
adriamycin	PROPN	O	Chemical	2665
nephrosis	NOUN	O	Disease	2665
.	PUNCT	O	O	2665
Chronic	NOUN	O	O	2666
enalapril	PROPN	O	Chemical	2666
treatment	NOUN	O	O	2666
reduced	VERB	O	O	2666
blood	NOUN	O	O	2666
pressure	NOUN	O	O	2666
without	ADP	O	O	2666
reducing	VERB	O	O	2666
albuminuria	PROPN	O	Disease	2666
in	ADP	O	O	2666
group	NOUN	O	O	2666
4	NUM	O	O	2666
.	PUNCT	O	O	2666
Enalapril	PROPN	O	Chemical	2667
treatment	NOUN	O	O	2667
blunted	VERB	O	O	2667
but	CCONJ	O	O	2667
did	VERB	O	O	2667
not	PART	O	O	2667
prevent	VERB	O	O	2667
reduction	NOUN	O	O	2667
in	ADP	O	O	2667
GFR	NOUN	O	O	2667
in	ADP	O	O	2667
group	NOUN	O	O	2667
4	NUM	O	O	2667
(	PUNCT	O	O	2667
0.86	NUM	O	O	2667
+	ADP	O	O	2667
/-	PUNCT	O	O	2667
Reduction	NOUN	O	O	2668
in	ADP	O	O	2668
GFR	NOUN	O	O	2668
was	AUX	O	O	2668
associated	VERB	O	O	2668
with	ADP	O	O	2668
the	PRON	O	O	2668
development	NOUN	O	O	2668
of	ADP	O	O	2668
glomerular	ADJ	O	O	2668
sclerosis	NOUN	O	O	2668
in	ADP	O	O	2668
both	PRON	O	O	2668
treated	VERB	O	O	2668
and	CCONJ	O	O	2668
untreated	ADJ	O	O	2668
rats.(ABSTRACT	PROPN	O	O	2668
TRUNCATED	ADJ	O	O	2668
AT	ADP	O	O	2668
250	NUM	O	O	2668
WORDS	NOUN	O	O	2668
)	PUNCT	O	O	2668
Butyrylcholinesterase	NOUN	O	O	2671
gene	NOUN	O	O	2671
mutations	NOUN	O	O	2671
in	ADP	O	O	2671
patients	NOUN	O	O	2671
with	ADP	O	O	2671
prolonged	VERB	O	O	2671
apnea	PROPN	O	Disease	2671
after	ADP	O	O	2671
succinylcholine	NOUN	O	Chemical	2671
for	ADP	O	O	2671
electroconvulsive	VERB	O	O	2671
therapy	NOUN	O	O	2671
.	PUNCT	O	O	2671
patients	NOUN	O	O	2672
undergoing	VERB	O	O	2672
electroconvulsive	VERB	O	O	2672
therapy	NOUN	O	O	2672
(	PUNCT	O	O	2672
ECT	NOUN	O	O	2672
)	PUNCT	O	O	2672
often	ADV	O	O	2672
receive	VERB	O	O	2672
succinylcholine	NOUN	O	Chemical	2672
as	ADP	O	O	2672
part	NOUN	O	O	2672
of	ADP	O	O	2672
the	PRON	O	O	2672
anesthetic	NOUN	O	O	2672
procedure	NOUN	O	O	2672
.	PUNCT	O	O	2672
The	PRON	O	O	2673
aim	VERB	O	O	2673
of	ADP	O	O	2673
the	PRON	O	O	2673
study	VERB	O	O	2673
was	AUX	O	O	2673
to	PART	O	O	2673
assess	VERB	O	O	2673
the	PRON	O	O	2673
clinical	ADJ	O	O	2673
significance	NOUN	O	O	2673
of	ADP	O	O	2673
genetic	ADJ	O	O	2673
variants	NOUN	O	O	2673
in	ADP	O	O	2673
butyrylcholinesterase	NOUN	O	O	2673
gene	NOUN	O	O	2673
(	PUNCT	O	O	2673
BCHE	PROPN	O	O	2673
)	PUNCT	O	O	2673
in	ADP	O	O	2673
patients	NOUN	O	O	2673
with	ADP	O	O	2673
a	PRON	O	O	2673
suspected	VERB	O	O	2673
prolonged	VERB	O	O	2673
duration	NOUN	O	O	2673
of	ADP	O	O	2673
action	NOUN	O	O	2673
of	ADP	O	O	2673
succinylcholine	NOUN	O	Chemical	2673
after	ADP	O	O	2673
ECT	NOUN	O	O	2673
.	PUNCT	O	O	2673
We	PRON	O	O	2674
determined	VERB	O	O	2674
the	PRON	O	O	2674
BChE	PROPN	O	O	2674
activity	NOUN	O	O	2674
and	CCONJ	O	O	2674
the	PRON	O	O	2674
BCHE	PROPN	O	O	2674
genotype	NOUN	O	O	2674
using	VERB	O	O	2674
molecular	ADJ	O	O	2674
genetic	ADJ	O	O	2674
methods	NOUN	O	O	2674
,	PUNCT	O	O	2674
the	PRON	O	O	2674
duration	NOUN	O	O	2674
of	ADP	O	O	2674
apnea	PROPN	O	Disease	2674
,	PUNCT	O	O	2674
time	NOUN	O	O	2674
to	PART	O	O	2674
sufficient	ADJ	O	O	2674
spontaneous	ADJ	O	O	2674
ventilation	NOUN	O	O	2674
and	CCONJ	O	O	2674
whether	SCONJ	O	O	2674
neuromuscular	ADJ	O	O	2674
monitoring	NOUN	O	O	2674
was	AUX	O	O	2674
used	VERB	O	O	2674
.	PUNCT	O	O	2674
The	PRON	O	O	2675
duration	NOUN	O	O	2675
of	ADP	O	O	2675
apnea	PROPN	O	Disease	2675
was	AUX	O	O	2675
compared	VERB	O	O	2675
with	ADP	O	O	2675
published	VERB	O	O	2675
data	NOUN	O	O	2675
on	ADP	O	O	2675
normal	ADJ	O	O	2675
subjects	NOUN	O	O	2675
.	PUNCT	O	O	2675
The	PRON	O	O	2676
duration	NOUN	O	O	2676
of	ADP	O	O	2676
apnea	PROPN	O	Disease	2676
was	AUX	O	O	2676
5	NUM	O	O	2676
-	PUNCT	O	O	2676
15	NUM	O	O	2676
min	NOUN	O	O	2676
compared	VERB	O	O	2676
with	ADP	O	O	2676
3	X	O	O	2676
-	PUNCT	O	O	2676
5.3	NUM	O	O	2676
min	NOUN	O	O	2676
from	ADP	O	O	2676
the	PRON	O	O	2676
literature	NOUN	O	O	2676
.	PUNCT	O	O	2676
CONCLUSION	PROPN	O	O	2677
:	PUNCT	O	O	2677
eleven	NUM	O	O	2677
of	ADP	O	O	2677
13	NUM	O	O	2677
patients	NOUN	O	O	2677
with	ADP	O	O	2677
a	PRON	O	O	2677
prolonged	VERB	O	O	2677
duration	NOUN	O	O	2677
of	ADP	O	O	2677
action	NOUN	O	O	2677
of	ADP	O	O	2677
succinylcholine	NOUN	O	Chemical	2677
had	VERB	O	O	2677
mutations	NOUN	O	O	2677
in	ADP	O	O	2677
BCHE	PROPN	O	O	2677
,	PUNCT	O	O	2677
indicating	VERB	O	O	2677
that	SCONJ	O	O	2677
this	PRON	O	O	2677
is	AUX	O	O	2677
the	PRON	O	O	2677
possible	ADJ	O	O	2677
reason	NOUN	O	O	2677
for	ADP	O	O	2677
a	PRON	O	O	2677
prolonged	VERB	O	O	2677
period	NOUN	O	O	2677
of	ADP	O	O	2677
apnea	PROPN	O	Disease	2677
.	PUNCT	O	O	2677
Ketamine	PROPN	O	Chemical	2680
sedation	NOUN	O	O	2680
for	ADP	O	O	2680
the	PRON	O	O	2680
reduction	NOUN	O	O	2680
of	ADP	O	O	2680
children	NOUN	O	O	2680
's	AUX	O	O	2680
fractures	NOUN	O	Disease	2680
in	ADP	O	O	2680
the	PRON	O	O	2680
emergency	NOUN	O	O	2680
department	NOUN	O	O	2680
.	PUNCT	O	O	2680
There	ADV	O	O	2681
recently	ADV	O	O	2681
has	VERB	O	O	2681
been	AUX	O	O	2681
a	PRON	O	O	2681
resurgence	NOUN	O	O	2681
in	ADP	O	O	2681
the	PRON	O	O	2681
utilization	NOUN	O	O	2681
of	ADP	O	O	2681
ketamine	VERB	O	Chemical	2681
,	PUNCT	O	O	2681
a	PRON	O	O	2681
unique	ADJ	O	O	2681
anesthetic	NOUN	O	O	2681
,	PUNCT	O	O	2681
for	ADP	O	O	2681
emergency	NOUN	O	O	2681
-	PUNCT	O	O	2681
department	NOUN	O	O	2681
procedures	NOUN	O	O	2681
requiring	VERB	O	O	2681
sedation	NOUN	O	O	2681
.	PUNCT	O	O	2681
The	PRON	O	O	2682
purpose	NOUN	O	O	2682
of	ADP	O	O	2682
the	PRON	O	O	2682
present	NOUN	O	O	2682
study	VERB	O	O	2682
was	AUX	O	O	2682
to	PART	O	O	2682
examine	VERB	O	O	2682
the	PRON	O	O	2682
safety	NOUN	O	O	2682
and	CCONJ	O	O	2682
efficacy	NOUN	O	O	2682
of	ADP	O	O	2682
ketamine	VERB	O	Chemical	2682
for	ADP	O	O	2682
sedation	NOUN	O	O	2682
in	ADP	O	O	2682
the	PRON	O	O	2682
treatment	NOUN	O	O	2682
of	ADP	O	O	2682
children	NOUN	O	O	2682
's	AUX	O	O	2682
fractures	NOUN	O	Disease	2682
in	ADP	O	O	2682
the	PRON	O	O	2682
emergency	NOUN	O	O	2682
department	NOUN	O	O	2682
.	PUNCT	O	O	2682
One	NUM	O	O	2683
hundred	NUM	O	O	2683
and	CCONJ	O	O	2683
fourteen	NUM	O	O	2683
children	NOUN	O	O	2683
(	PUNCT	O	O	2683
average	ADJ	O	O	2683
age	NOUN	O	O	2683
,	PUNCT	O	O	2683
5.3	NUM	O	O	2683
years	NOUN	O	O	2683
;	PUNCT	O	O	2683
range	VERB	O	O	2683
,	PUNCT	O	O	2683
twelve	NUM	O	O	2683
months	NOUN	O	O	2683
to	PART	O	O	2683
ten	NUM	O	O	2683
years	NOUN	O	O	2683
and	CCONJ	O	O	2683
ten	NUM	O	O	2683
months	NOUN	O	O	2683
)	PUNCT	O	O	2683
who	PRON	O	O	2683
underwent	VERB	O	O	2683
closed	VERB	O	O	2683
reduction	NOUN	O	O	2683
of	ADP	O	O	2683
an	PRON	O	O	2683
isolated	VERB	O	O	2683
fracture	VERB	O	O	2683
or	CCONJ	O	O	2683
dislocation	NOUN	O	O	2683
in	ADP	O	O	2683
the	PRON	O	O	2683
emergency	NOUN	O	O	2683
department	NOUN	O	O	2683
at	ADP	O	O	2683
a	PRON	O	O	2683
level	VERB	O	O	2683
-	PUNCT	O	O	2683
I	PRON	O	O	2683
trauma	NOUN	O	O	2683
center	PROPN	O	O	2683
were	AUX	O	O	2683
prospectively	ADV	O	O	2683
evaluated	VERB	O	O	2683
.	PUNCT	O	O	2683
Ketamine	PROPN	O	Chemical	2684
hydrochloride	NOUN	O	O	2684
was	AUX	O	O	2684
administered	VERB	O	O	2684
intravenously	ADV	O	O	2684
(	PUNCT	O	O	2684
at	ADP	O	O	2684
a	PRON	O	O	2684
dose	NOUN	O	O	2684
of	ADP	O	O	2684
two	NUM	O	O	2684
milligrams	NOUN	O	O	2684
per	ADP	O	O	2684
kilogram	NOUN	O	O	2684
of	ADP	O	O	2684
body	NOUN	O	O	2684
weight	NOUN	O	O	2684
)	PUNCT	O	O	2684
in	ADP	O	O	2684
ninety	NUM	O	O	2684
-	PUNCT	O	O	2684
nine	NUM	O	O	2684
of	ADP	O	O	2684
the	PRON	O	O	2684
patients	NOUN	O	O	2684
and	CCONJ	O	O	2684
intramuscularly	ADV	O	O	2684
(	PUNCT	O	O	2684
at	ADP	O	O	2684
a	PRON	O	O	2684
dose	NOUN	O	O	2684
of	ADP	O	O	2684
four	NUM	O	O	2684
milligrams	NOUN	O	O	2684
per	ADP	O	O	2684
kilogram	NOUN	O	O	2684
of	ADP	O	O	2684
body	NOUN	O	O	2684
weight	NOUN	O	O	2684
)	PUNCT	O	O	2684
in	ADP	O	O	2684
the	PRON	O	O	2684
other	ADJ	O	O	2684
fifteen	NUM	O	O	2684
.	PUNCT	O	O	2684
Any	PRON	O	O	2685
pain	NOUN	O	Disease	2685
during	ADP	O	O	2685
the	PRON	O	O	2685
reduction	NOUN	O	O	2685
was	AUX	O	O	2685
rated	VERB	O	O	2685
by	ADP	O	O	2685
the	PRON	O	O	2685
orthopaedic	ADJ	O	O	2685
surgeon	NOUN	O	O	2685
treating	VERB	O	O	2685
the	PRON	O	O	2685
patient	NOUN	O	O	2685
according	VERB	O	O	2685
to	PART	O	O	2685
the	PRON	O	O	2685
Children	NOUN	O	O	2685
's	AUX	O	O	2685
Hospital	NOUN	O	O	2685
of	ADP	O	O	2685
Eastern	PROPN	O	O	2685
Ontario	NOUN	O	O	2685
Pain	NOUN	O	Disease	2685
Scale	NOUN	O	O	2685
(	PUNCT	O	O	2685
CHEOPS	NOUN	O	O	2685
)	PUNCT	O	O	2685
.	PUNCT	O	O	2685
The	PRON	O	O	2686
average	ADJ	O	O	2686
time	NOUN	O	O	2686
from	ADP	O	O	2686
intravenous	ADJ	O	O	2686
administration	NOUN	O	O	2686
of	ADP	O	O	2686
ketamine	VERB	O	Chemical	2686
to	PART	O	O	2686
manipulation	NOUN	O	O	2686
of	ADP	O	O	2686
the	PRON	O	O	2686
fracture	VERB	O	O	2686
or	CCONJ	O	O	2686
dislocation	NOUN	O	O	2686
was	AUX	O	O	2686
one	NUM	O	O	2686
minute	VERB	O	O	2686
and	CCONJ	O	O	2686
thirty	NUM	O	O	2686
-	PUNCT	O	O	2686
six	NUM	O	O	2686
seconds	NOUN	O	O	2686
(	PUNCT	O	O	2686
range	VERB	O	O	2686
,	PUNCT	O	O	2686
twenty	NUM	O	O	2686
seconds	NOUN	O	O	2686
to	PART	O	O	2686
five	NUM	O	O	2686
minutes	NOUN	O	O	2686
)	PUNCT	O	O	2686
,	PUNCT	O	O	2686
and	CCONJ	O	O	2686
the	PRON	O	O	2686
average	ADJ	O	O	2686
time	NOUN	O	O	2686
from	ADP	O	O	2686
intramuscular	ADJ	O	O	2686
administration	NOUN	O	O	2686
to	PART	O	O	2686
manipulation	NOUN	O	O	2686
was	AUX	O	O	2686
four	NUM	O	O	2686
minutes	NOUN	O	O	2686
and	CCONJ	O	O	2686
forty	NUM	O	O	2686
-	PUNCT	O	O	2686
two	NUM	O	O	2686
seconds	NOUN	O	O	2686
(	PUNCT	O	O	2686
range	VERB	O	O	2686
,	PUNCT	O	O	2686
sixty	NUM	O	O	2686
seconds	NOUN	O	O	2686
to	PART	O	O	2686
fifteen	NUM	O	O	2686
minutes	NOUN	O	O	2686
)	PUNCT	O	O	2686
.	PUNCT	O	O	2686
The	PRON	O	O	2687
average	ADJ	O	O	2687
score	VERB	O	O	2687
according	VERB	O	O	2687
to	PART	O	O	2687
the	PRON	O	O	2687
Children	NOUN	O	O	2687
's	AUX	O	O	2687
Hospital	NOUN	O	O	2687
of	ADP	O	O	2687
Eastern	PROPN	O	O	2687
Ontario	NOUN	O	O	2687
Pain	NOUN	O	Disease	2687
Scale	NOUN	O	O	2687
was	AUX	O	O	2687
6.4	NUM	O	O	2687
points	VERB	O	O	2687
(	PUNCT	O	O	2687
range	VERB	O	O	2687
,	PUNCT	O	O	2687
5	NUM	O	O	2687
to	PART	O	O	2687
10	NUM	O	O	2687
points	VERB	O	O	2687
)	PUNCT	O	O	2687
,	PUNCT	O	O	2687
reflecting	VERB	O	O	2687
minimal	ADJ	O	O	2687
or	CCONJ	O	O	2687
no	PRON	O	O	2687
pain	NOUN	O	Disease	2687
during	ADP	O	O	2687
fracture	VERB	O	O	2687
reduction	NOUN	O	O	2687
.	PUNCT	O	O	2687
Adequate	PROPN	O	O	2688
fracture	VERB	O	O	2688
reduction	NOUN	O	O	2688
was	AUX	O	O	2688
obtained	VERB	O	O	2688
in	ADP	O	O	2688
111	NUM	O	O	2688
of	ADP	O	O	2688
the	PRON	O	O	2688
children	NOUN	O	O	2688
.	PUNCT	O	O	2688
Minor	ADJ	O	O	2689
side	NOUN	O	O	2689
effects	NOUN	O	O	2689
included	VERB	O	O	2689
nausea	NOUN	O	Disease	2689
(	PUNCT	O	O	2689
thirteen	NUM	O	O	2689
patients	NOUN	O	O	2689
)	PUNCT	O	O	2689
,	PUNCT	O	O	2689
emesis	VERB	O	Disease	2689
(	PUNCT	O	O	2689
eight	NUM	O	O	2689
of	ADP	O	O	2689
the	PRON	O	O	2689
thirteen	NUM	O	O	2689
patients	NOUN	O	O	2689
with	ADP	O	O	2689
nausea	NOUN	O	Disease	2689
)	PUNCT	O	O	2689
,	PUNCT	O	O	2689
clumsiness	NOUN	O	O	2689
(	PUNCT	O	O	2689
evident	ADJ	O	O	2689
as	ADP	O	O	2689
ataxic	ADJ	O	O	2689
movements	NOUN	O	O	2689
in	ADP	O	O	2689
ten	NUM	O	O	2689
patients	NOUN	O	O	2689
)	PUNCT	O	O	2689
,	PUNCT	O	O	2689
and	CCONJ	O	O	2689
dysphoric	ADJ	O	O	2689
reaction	NOUN	O	O	2689
(	PUNCT	O	O	2689
one	NUM	O	O	2689
patient	NOUN	O	O	2689
)	PUNCT	O	O	2689
.	PUNCT	O	O	2689
No	PRON	O	O	2690
long	ADV	O	O	2690
-	PUNCT	O	O	2690
term	NOUN	O	O	2690
sequelae	ADJ	O	O	2690
were	AUX	O	O	2690
noted	VERB	O	O	2690
,	PUNCT	O	O	2690
and	CCONJ	O	O	2690
no	PRON	O	O	2690
patients	NOUN	O	O	2690
had	VERB	O	O	2690
hallucinations	NOUN	O	Disease	2690
or	CCONJ	O	O	2690
nightmares	NOUN	O	O	2690
.	PUNCT	O	O	2690
Ketamine	PROPN	O	Chemical	2691
reliably	ADV	O	O	2691
,	PUNCT	O	O	2691
safely	ADV	O	O	2691
,	PUNCT	O	O	2691
and	CCONJ	O	O	2691
quickly	ADV	O	O	2691
provided	VERB	O	O	2691
adequate	ADJ	O	O	2691
sedation	NOUN	O	O	2691
to	PART	O	O	2691
effectively	ADV	O	O	2691
facilitate	VERB	O	O	2691
the	PRON	O	O	2691
reduction	NOUN	O	O	2691
of	ADP	O	O	2691
children	NOUN	O	O	2691
's	AUX	O	O	2691
fractures	NOUN	O	Disease	2691
in	ADP	O	O	2691
the	PRON	O	O	2691
emergency	NOUN	O	O	2691
department	NOUN	O	O	2691
at	ADP	O	O	2691
our	PRON	O	O	2691
institution	NOUN	O	O	2691
.	PUNCT	O	O	2691
Ketamine	PROPN	O	Chemical	2692
should	AUX	O	O	2692
only	ADV	O	O	2692
be	AUX	O	O	2692
used	VERB	O	O	2692
in	ADP	O	O	2692
an	PRON	O	O	2692
environment	NOUN	O	O	2692
such	ADJ	O	O	2692
as	ADP	O	O	2692
the	PRON	O	O	2692
emergency	NOUN	O	O	2692
department	NOUN	O	O	2692
,	PUNCT	O	O	2692
where	SCONJ	O	O	2692
proper	ADJ	O	O	2692
one	NUM	O	O	2692
-	PUNCT	O	O	2692
on	ADP	O	O	2692
-	PUNCT	O	O	2692
one	NUM	O	O	2692
monitoring	NOUN	O	O	2692
is	AUX	O	O	2692
used	VERB	O	O	2692
and	CCONJ	O	O	2692
board	PROPN	O	O	2692
-	PUNCT	O	O	2692
certified	VERB	O	O	2692
physicians	NOUN	O	O	2692
skilled	ADJ	O	O	2692
in	ADP	O	O	2692
airway	NOUN	O	O	2692
management	NOUN	O	O	2692
are	AUX	O	O	2692
directly	ADV	O	O	2692
involved	VERB	O	O	2692
in	ADP	O	O	2692
the	PRON	O	O	2692
care	VERB	O	O	2692
of	ADP	O	O	2692
the	PRON	O	O	2692
patient	NOUN	O	O	2692
.	PUNCT	O	O	2692
Prophylactic	ADJ	O	O	2695
use	VERB	O	O	2695
of	ADP	O	O	2695
lamivudine	NOUN	O	Chemical	2695
with	ADP	O	O	2695
chronic	ADJ	O	O	2695
immunosuppressive	ADJ	O	O	2695
therapy	NOUN	O	O	2695
for	ADP	O	O	2695
rheumatologic	ADJ	O	O	2695
disorders	NOUN	O	O	2695
.	PUNCT	O	O	2695
The	PRON	O	O	2696
objective	VERB	O	O	2696
of	ADP	O	O	2696
this	PRON	O	O	2696
study	VERB	O	O	2696
was	AUX	O	O	2696
to	PART	O	O	2696
report	VERB	O	O	2696
our	PRON	O	O	2696
experience	NOUN	O	O	2696
concerning	VERB	O	O	2696
the	PRON	O	O	2696
effectiveness	NOUN	O	O	2696
of	ADP	O	O	2696
the	PRON	O	O	2696
prophylactic	ADJ	O	O	2696
administration	NOUN	O	O	2696
of	ADP	O	O	2696
lamivudine	NOUN	O	Chemical	2696
in	ADP	O	O	2696
hepatitis B	PROPN	O	Disease	2696
virus	NOUN	O	O	2696
surface	NOUN	O	O	2696
antigen	PROPN	O	O	2696
(	PUNCT	O	O	2696
HBs	PROPN	O	O	2696
Ag	PROPN	O	O	2696
)	PUNCT	O	O	2696
positive	ADJ	O	O	2696
patients	NOUN	O	O	2696
with	ADP	O	O	2696
rheumatologic	ADJ	O	O	2696
disease	PROPN	O	O	2696
.	PUNCT	O	O	2696
From	ADP	O	O	2697
June	PROPN	O	O	2697
2004	NUM	O	O	2697
to	PART	O	O	2697
October	PROPN	O	O	2697
2006	NUM	O	O	2697
,	PUNCT	O	O	2697
11	NUM	O	O	2697
HBs	PROPN	O	O	2697
Ag	PROPN	O	O	2697
positive	ADJ	O	O	2697
patients	NOUN	O	O	2697
with	ADP	O	O	2697
rheumatologic diseases	NOUN	O	Disease	2697
,	PUNCT	O	O	2697
who	PRON	O	O	2697
were	AUX	O	O	2697
on	ADP	O	O	2697
both	PRON	O	O	2697
immunosuppressive	ADJ	O	O	2697
and	CCONJ	O	O	2697
prophylactic	ADJ	O	O	2697
lamivudine	NOUN	O	Chemical	2697
therapies	NOUN	O	O	2697
,	PUNCT	O	O	2697
were	AUX	O	O	2697
retrospectively	ADV	O	O	2697
assessed	VERB	O	O	2697
.	PUNCT	O	O	2697
Liver	NOUN	O	O	2698
function	NOUN	O	O	2698
tests	VERB	O	O	2698
,	PUNCT	O	O	2698
hepatitis B	PROPN	O	Disease	2698
virus	NOUN	O	O	2698
(	PUNCT	O	O	2698
HBV	NOUN	O	O	2698
)	PUNCT	O	O	2698
serologic	NOUN	O	O	2698
markers	NOUN	O	O	2698
,	PUNCT	O	O	2698
and	CCONJ	O	O	2698
HBV	NOUN	O	O	2698
DNA	NOUN	O	O	2698
levels	NOUN	O	O	2698
of	ADP	O	O	2698
the	PRON	O	O	2698
patients	NOUN	O	O	2698
during	ADP	O	O	2698
follow	VERB	O	O	2698
-	PUNCT	O	O	2698
up	ADP	O	O	2698
were	AUX	O	O	2698
obtained	VERB	O	O	2698
from	ADP	O	O	2698
hospital	PROPN	O	O	2698
file	NOUN	O	O	2698
records	NOUN	O	O	2698
.	PUNCT	O	O	2698
Lamivudine	NOUN	O	O	2699
therapy	NOUN	O	O	2699
was	AUX	O	O	2699
started	VERB	O	O	2699
3	X	O	O	2699
-	PUNCT	O	O	2699
7	NUM	O	O	2699
days	NOUN	O	O	2699
prior	ADV	O	O	2699
to	PART	O	O	2699
immunosuppressive	ADJ	O	O	2699
therapy	NOUN	O	O	2699
in	ADP	O	O	2699
all	PRON	O	O	2699
patients	NOUN	O	O	2699
.	PUNCT	O	O	2699
Shortly	ADV	O	O	2700
after	ADP	O	O	2700
treatment	NOUN	O	O	2700
their	PRON	O	O	2700
tests	VERB	O	O	2700
normalized	VERB	O	O	2700
and	CCONJ	O	O	2700
during	ADP	O	O	2700
follow	VERB	O	O	2700
-	PUNCT	O	O	2700
up	ADP	O	O	2700
period	NOUN	O	O	2700
none	NOUN	O	O	2700
of	ADP	O	O	2700
the	PRON	O	O	2700
patients	NOUN	O	O	2700
had	VERB	O	O	2700
abnormal	ADJ	O	O	2700
liver	NOUN	O	O	2700
function	NOUN	O	O	2700
tests	VERB	O	O	2700
.	PUNCT	O	O	2700
Lamivudine	NOUN	O	O	2701
was	AUX	O	O	2701
well	ADV	O	O	2701
tolerated	VERB	O	O	2701
and	CCONJ	O	O	2701
was	AUX	O	O	2701
continued	VERB	O	O	2701
in	ADP	O	O	2701
all	PRON	O	O	2701
patients	NOUN	O	O	2701
.	PUNCT	O	O	2701
Prophylactic	ADJ	O	O	2702
administration	NOUN	O	O	2702
of	ADP	O	O	2702
lamivudine	NOUN	O	Chemical	2702
in	ADP	O	O	2702
patients	NOUN	O	O	2702
who	PRON	O	O	2702
required	VERB	O	O	2702
immunosuppressive	ADJ	O	O	2702
therapy	NOUN	O	O	2702
seems	VERB	O	O	2702
to	PART	O	O	2702
be	AUX	O	O	2702
safe	ADJ	O	O	2702
,	PUNCT	O	O	2702
well	ADV	O	O	2702
tolerated	VERB	O	O	2702
and	CCONJ	O	O	2702
effective	ADJ	O	O	2702
in	ADP	O	O	2702
preventing	VERB	O	O	2702
HBV	NOUN	O	O	2702
reactivation	NOUN	O	O	2702
.	PUNCT	O	O	2702
OBJECTIVE	VERB	O	O	2705
:	PUNCT	O	O	2705
to	PART	O	O	2705
analyze	VERB	O	O	2705
aspects	NOUN	O	O	2705
of	ADP	O	O	2705
TEE	NUM	O	O	2705
safety	NOUN	O	O	2705
associated	VERB	O	O	2705
to	PART	O	O	2705
the	PRON	O	O	2705
use	VERB	O	O	2705
of	ADP	O	O	2705
Midazolan	NOUN	O	O	2705
(	PUNCT	O	O	2705
MZ	PROPN	O	O	2705
)	PUNCT	O	O	2705
and	CCONJ	O	O	2705
Flumazenil	PROPN	O	Chemical	2705
(	PUNCT	O	O	2705
FL	PROPN	O	O	2705
)	PUNCT	O	O	2705
and	CCONJ	O	O	2705
the	PRON	O	O	2705
influence	NOUN	O	O	2705
of	ADP	O	O	2705
the	PRON	O	O	2705
clinical	ADJ	O	O	2705
variables	NOUN	O	O	2705
on	ADP	O	O	2705
the	PRON	O	O	2705
event	NOUN	O	O	2705
rate	NOUN	O	O	2705
.	PUNCT	O	O	2705
METHOD	NOUN	O	O	2706
:	PUNCT	O	O	2706
prospective	ADJ	O	O	2706
study	VERB	O	O	2706
with	ADP	O	O	2706
137	NUM	O	O	2706
patients	NOUN	O	O	2706
that	SCONJ	O	O	2706
underwent	VERB	O	O	2706
TEE	NUM	O	O	2706
with	ADP	O	O	2706
MZ	PROPN	O	O	2706
associated	VERB	O	O	2706
to	PART	O	O	2706
moderate	ADJ	O	O	2706
sedation	NOUN	O	O	2706
.	PUNCT	O	O	2706
We	PRON	O	O	2707
analyzed	VERB	O	O	2707
the	PRON	O	O	2707
following	VERB	O	O	2707
events	NOUN	O	O	2707
:	PUNCT	O	O	2707
complications	NOUN	O	O	2707
related	ADJ	O	O	2707
with	ADP	O	O	2707
the	PRON	O	O	2707
topical	ADJ	O	O	2707
anesthesia	NOUN	O	O	2707
,	PUNCT	O	O	2707
with	ADP	O	O	2707
MZ	PROPN	O	O	2707
use	VERB	O	O	2707
and	CCONJ	O	O	2707
with	ADP	O	O	2707
the	PRON	O	O	2707
procedure	NOUN	O	O	2707
.	PUNCT	O	O	2707
Uni-	ADV	O	O	2708
and	CCONJ	O	O	2708
multivariate	ADJ	O	O	2708
analyses	NOUN	O	O	2708
were	AUX	O	O	2708
used	VERB	O	O	2708
to	PART	O	O	2708
test	NOUN	O	O	2708
the	PRON	O	O	2708
influence	NOUN	O	O	2708
of	ADP	O	O	2708
the	PRON	O	O	2708
clinical	ADJ	O	O	2708
variables	NOUN	O	O	2708
:	PUNCT	O	O	2708
age	NOUN	O	O	2708
,	PUNCT	O	O	2708
sex	NOUN	O	O	2708
,	PUNCT	O	O	2708
stroke	VERB	O	Disease	2708
,	PUNCT	O	O	2708
myocardiopathy	ADJ	O	O	2708
(	PUNCT	O	O	2708
MP	PROPN	O	Chemical	2708
)	PUNCT	O	O	2708
,	PUNCT	O	O	2708
duration	NOUN	O	O	2708
of	ADP	O	O	2708
the	PRON	O	O	2708
test	NOUN	O	O	2708
,	PUNCT	O	O	2708
mitral regurgitation	NOUN	O	Disease	2708
(	PUNCT	O	O	2708
MR	PROPN	O	O	2708
)	PUNCT	O	O	2708
and	CCONJ	O	O	2708
the	PRON	O	O	2708
MZ	PROPN	O	O	2708
dose	NOUN	O	O	2708
.	PUNCT	O	O	2708
The	PRON	O	O	2709
mean	VERB	O	O	2709
doses	NOUN	O	O	2709
of	ADP	O	O	2709
MZ	PROPN	O	O	2709
and	CCONJ	O	O	2709
FL	PROPN	O	O	2709
were	AUX	O	O	2709
4.3+/-1.9	NUM	O	O	2709
mg	VERB	O	O	2709
and	CCONJ	O	O	2709
0.28+/-0.2	ADV	O	O	2709
mg	VERB	O	O	2709
,	PUNCT	O	O	2709
respectively	ADV	O	O	2709
.	PUNCT	O	O	2709
Mild	NOUN	O	O	2710
hypoxia	NOUN	O	Disease	2710
(	PUNCT	O	O	2710
SO2<90%	NOUN	O	O	2710
)	PUNCT	O	O	2710
was	AUX	O	O	2710
the	PRON	O	O	2710
most	ADV	O	O	2710
common	ADJ	O	O	2710
event	NOUN	O	O	2710
(	PUNCT	O	O	2710
11	NUM	O	O	2710
patients	NOUN	O	O	2710
)	PUNCT	O	O	2710
;	PUNCT	O	O	2710
3	X	O	O	2710
patients	NOUN	O	O	2710
(	PUNCT	O	O	2710
2%	NOUN	O	O	2710
)	PUNCT	O	O	2710
presented	VERB	O	O	2710
transient	ADJ	O	O	2710
hypoxia	NOUN	O	Disease	2710
due	ADJ	O	O	2710
to	PART	O	O	2710
upper	ADJ	O	O	2710
airway	NOUN	O	O	2710
obstruction	NOUN	O	O	2710
by	ADP	O	O	2710
probe	NOUN	O	O	2710
introduction	NOUN	O	O	2710
and	CCONJ	O	O	2710
8	NUM	O	O	2710
(	PUNCT	O	O	2710
5.8%	NOUN	O	O	2710
)	PUNCT	O	O	2710
due	ADJ	O	O	2710
to	PART	O	O	2710
hypoxia	NOUN	O	Disease	2710
caused	VERB	O	O	2710
by	ADP	O	O	2710
MZ	PROPN	O	O	2710
use	VERB	O	O	2710
.	PUNCT	O	O	2710
Transient	ADJ	O	O	2711
hypotension	NOUN	O	Disease	2711
(	PUNCT	O	O	2711
SAP<90mmHg	NUM	O	O	2711
)	PUNCT	O	O	2711
occurred	VERB	O	O	2711
in	ADP	O	O	2711
1	X	O	O	2711
patient	NOUN	O	O	2711
(	PUNCT	O	O	2711
0.7%	NOUN	O	O	2711
)	PUNCT	O	O	2711
.	PUNCT	O	O	2711
The	PRON	O	O	2712
multivariate	ADJ	O	O	2712
analysis	NOUN	O	O	2712
showed	VERB	O	O	2712
that	SCONJ	O	O	2712
severe	ADJ	O	O	2712
MR	PROPN	O	O	2712
,	PUNCT	O	O	2712
MP	PROPN	O	Chemical	2712
(	PUNCT	O	O	2712
EF<45%	NOUN	O	O	2712
)	PUNCT	O	O	2712
and	CCONJ	O	O	2712
high	ADJ	O	O	2712
doses	NOUN	O	O	2712
of	ADP	O	O	2712
MZ	PROPN	O	O	2712
(	PUNCT	O	O	2712
>	PUNCT	O	O	2712
5	NUM	O	O	2712
mg	VERB	O	O	2712
)	PUNCT	O	O	2712
were	AUX	O	O	2712
associated	VERB	O	O	2712
with	ADP	O	O	2712
events	NOUN	O	O	2712
(	PUNCT	O	O	2712
p<0.001	ADJ	O	O	2712
)	PUNCT	O	O	2712
.	PUNCT	O	O	2712
The	PRON	O	O	2713
EF	PROPN	O	O	2713
was	AUX	O	O	2713
40%	NOUN	O	O	2713
,	PUNCT	O	O	2713
in	ADP	O	O	2713
the	PRON	O	O	2713
group	NOUN	O	O	2713
with	ADP	O	O	2713
MP	PROPN	O	Chemical	2713
and	CCONJ	O	O	2713
44%	NOUN	O	O	2713
in	ADP	O	O	2713
the	PRON	O	O	2713
group	NOUN	O	O	2713
with	ADP	O	O	2713
severe	ADJ	O	O	2713
MR	PROPN	O	O	2713
and	CCONJ	O	O	2713
it	PRON	O	O	2713
can	AUX	O	O	2713
be	AUX	O	O	2713
a	PRON	O	O	2713
factor	NOUN	O	O	2713
associated	VERB	O	O	2713
with	ADP	O	O	2713
clinical	ADJ	O	O	2713
events	NOUN	O	O	2713
in	ADP	O	O	2713
the	PRON	O	O	2713
last	VERB	O	O	2713
group	NOUN	O	O	2713
.	PUNCT	O	O	2713
Effects	NOUN	O	O	2716
of	ADP	O	O	2716
calcium	NOUN	O	Chemical	2716
channel	PROPN	O	O	2716
blockers	NOUN	O	O	2716
on	ADP	O	O	2716
bupivacaine	NOUN	O	Chemical	2716
-	PUNCT	O	O	2716
induced	VERB	O	O	2716
toxicity	NOUN	O	Disease	2716
.	PUNCT	O	O	2716
The	PRON	O	O	2717
purpose	NOUN	O	O	2717
of	ADP	O	O	2717
this	PRON	O	O	2717
study	VERB	O	O	2717
was	AUX	O	O	2717
to	PART	O	O	2717
investigate	VERB	O	O	2717
the	PRON	O	O	2717
influence	NOUN	O	O	2717
of	ADP	O	O	2717
calcium	NOUN	O	Chemical	2717
channel	PROPN	O	O	2717
blockers	NOUN	O	O	2717
on	ADP	O	O	2717
bupivacaine	NOUN	O	Chemical	2717
-	PUNCT	O	O	2717
induced	VERB	O	O	2717
acute	ADJ	O	O	2717
toxicity	NOUN	O	Disease	2717
.	PUNCT	O	O	2717
For	ADP	O	O	2718
each	PRON	O	O	2718
of	ADP	O	O	2718
the	PRON	O	O	2718
three	NUM	O	O	2718
tested	VERB	O	O	2718
calcium	NOUN	O	Chemical	2718
channel	PROPN	O	O	2718
blockers	NOUN	O	O	2718
(	PUNCT	O	O	2718
diltiazem	VERB	O	Chemical	2718
,	PUNCT	O	O	2718
verapamil	PROPN	O	Chemical	2718
and	CCONJ	O	O	2718
bepridil	PROPN	O	O	2718
)	PUNCT	O	O	2718
6	NUM	O	O	2718
groups	NOUN	O	O	2718
of	ADP	O	O	2718
mice	NOUN	O	O	2718
were	AUX	O	O	2718
treated	VERB	O	O	2718
by	ADP	O	O	2718
two	NUM	O	O	2718
different	ADJ	O	O	2718
doses	NOUN	O	O	2718
,	PUNCT	O	O	2718
i.e.	X	O	O	2718
2	X	O	O	2718
and	CCONJ	O	O	2718
10	NUM	O	O	2718
mg	VERB	O	O	2718
/	PUNCT	O	O	2718
kg	VERB	O	O	2718
/	PUNCT	O	O	2718
i.p	NOUN	O	O	2718
.	PUNCT	O	O	2718
,	PUNCT	O	O	2718
or	CCONJ	O	O	2718
an	PRON	O	O	2718
equal	ADJ	O	O	2718
volume	PROPN	O	O	2718
of	ADP	O	O	2718
saline	NOUN	O	O	2718
for	ADP	O	O	2718
the	PRON	O	O	2718
control	VERB	O	O	2718
group	NOUN	O	O	2718
(	PUNCT	O	O	2718
n	CCONJ	O	O	2718
=	PUNCT	O	O	2718
20	NUM	O	O	2718
)	PUNCT	O	O	2718
;	PUNCT	O	O	2718
15	NUM	O	O	2718
minutes	NOUN	O	O	2718
later	ADV	O	O	2718
,	PUNCT	O	O	2718
all	PRON	O	O	2718
the	PRON	O	O	2718
animals	NOUN	O	O	2718
were	AUX	O	O	2718
injected	VERB	O	O	2718
with	ADP	O	O	2718
a	PRON	O	O	2718
single	ADJ	O	O	2718
50	NUM	O	O	2718
mg	VERB	O	O	2718
/	PUNCT	O	O	2718
kg	VERB	O	O	2718
/	PUNCT	O	O	2718
i.p	NOUN	O	O	2718
.	PUNCT	O	O	2718
dose	NOUN	O	O	2719
of	ADP	O	O	2719
bupivacaine	NOUN	O	Chemical	2719
.	PUNCT	O	O	2719
The	PRON	O	O	2720
local	ADJ	O	O	2720
anesthetic	NOUN	O	O	2720
-	PUNCT	O	O	2720
induced	VERB	O	O	2720
mortality	NOUN	O	O	2720
was	AUX	O	O	2720
significantly	ADV	O	O	2720
increased	VERB	O	O	2720
by	ADP	O	O	2720
the	PRON	O	O	2720
three	NUM	O	O	2720
different	ADJ	O	O	2720
calcium	NOUN	O	Chemical	2720
channel	PROPN	O	O	2720
blockers	NOUN	O	O	2720
.	PUNCT	O	O	2720
The	PRON	O	O	2721
convulsant	ADJ	O	O	2721
activity	NOUN	O	O	2721
of	ADP	O	O	2721
bupivacaine	NOUN	O	Chemical	2721
was	AUX	O	O	2721
not	PART	O	O	2721
significantly	ADV	O	O	2721
modified	VERB	O	O	2721
but	CCONJ	O	O	2721
calcium	NOUN	O	Chemical	2721
channel	PROPN	O	O	2721
blockers	NOUN	O	O	2721
decreased	VERB	O	O	2721
the	PRON	O	O	2721
time	NOUN	O	O	2721
of	ADP	O	O	2721
latency	VERB	O	O	2721
to	PART	O	O	2721
obtain	VERB	O	O	2721
bupivacaine	NOUN	O	Chemical	2721
-	PUNCT	O	O	2721
induced	VERB	O	O	2721
convulsions	NOUN	O	Disease	2721
;	PUNCT	O	O	2721
this	PRON	O	O	2721
effect	VERB	O	O	2721
was	AUX	O	O	2721
less	ADV	O	O	2721
pronounced	VERB	O	O	2721
with	ADP	O	O	2721
bepridil	PROPN	O	O	2721
.	PUNCT	O	O	2721
Selegiline	NOUN	O	O	2724
-	PUNCT	O	O	2724
induced	VERB	O	O	2724
postural	ADJ	O	O	2724
hypotension	NOUN	O	Disease	2724
in	ADP	O	O	2724
Parkinson	NOUN	O	O	2724
's	AUX	O	O	2724
disease	PROPN	O	O	2724
:	PUNCT	O	O	2724
a	PRON	O	O	2724
longitudinal	PROPN	O	O	2724
study	VERB	O	O	2724
on	ADP	O	O	2724
the	PRON	O	O	2724
effects	NOUN	O	O	2724
of	ADP	O	O	2724
drug	NOUN	O	O	2724
withdrawal	NOUN	O	O	2724
.	PUNCT	O	O	2724
The	PRON	O	O	2725
United	PROPN	O	O	2725
Kingdom	NOUN	O	O	2725
Parkinson	NOUN	O	O	2725
's	AUX	O	O	2725
Disease	NOUN	O	O	2725
Research	NOUN	O	O	2725
Group	PROPN	O	O	2725
(	PUNCT	O	O	2725
UKPDRG	PROPN	O	O	2725
)	PUNCT	O	O	2725
trial	NOUN	O	O	2725
found	VERB	O	O	2725
an	PRON	O	O	2725
increased	VERB	O	O	2725
mortality	NOUN	O	O	2725
in	ADP	O	O	2725
patients	NOUN	O	O	2725
with	ADP	O	O	2725
Parkinson	NOUN	O	O	2725
's	AUX	O	O	2725
disease	PROPN	O	O	2725
(	PUNCT	O	O	2725
PD	PROPN	O	Disease	2725
)	PUNCT	O	O	2725
randomized	VERB	O	O	2725
to	PART	O	O	2725
receive	VERB	O	O	2725
10	NUM	O	O	2725
mg	VERB	O	O	2725
selegiline	PROPN	O	O	2725
per	ADP	O	O	2725
day	NOUN	O	O	2725
and	CCONJ	O	O	2725
L	NOUN	O	O	2725
-	PUNCT	O	O	2725
dopa	PROPN	O	O	2725
compared	VERB	O	O	2725
with	ADP	O	O	2725
those	PRON	O	O	2725
taking	VERB	O	O	2725
L	NOUN	O	O	2725
-	PUNCT	O	O	2725
dopa	PROPN	O	O	2725
alone	ADV	O	O	2725
.	PUNCT	O	O	2725
Recently	ADV	O	O	2726
,	PUNCT	O	O	2726
we	PRON	O	O	2726
found	VERB	O	O	2726
that	SCONJ	O	O	2726
therapy	NOUN	O	O	2726
with	ADP	O	O	2726
selegiline	PROPN	O	O	2726
and	CCONJ	O	O	2726
L	NOUN	O	O	2726
-	PUNCT	O	O	2726
dopa	PROPN	O	O	2726
was	AUX	O	O	2726
associated	VERB	O	O	2726
with	ADP	O	O	2726
selective	ADJ	O	O	2726
systolic	ADV	O	O	2726
orthostatic hypotension	NOUN	O	Disease	2726
which	PRON	O	O	2726
was	AUX	O	O	2726
abolished	VERB	O	O	2726
by	ADP	O	O	2726
withdrawal	NOUN	O	O	2726
of	ADP	O	O	2726
selegiline	PROPN	O	O	2726
.	PUNCT	O	O	2726
The	PRON	O	O	2727
aims	VERB	O	O	2727
of	ADP	O	O	2727
this	PRON	O	O	2727
study	VERB	O	O	2727
were	AUX	O	O	2727
to	PART	O	O	2727
confirm	VERB	O	O	2727
our	PRON	O	O	2727
previous	ADJ	O	O	2727
findings	NOUN	O	O	2727
in	ADP	O	O	2727
a	PRON	O	O	2727
separate	VERB	O	O	2727
cohort	NOUN	O	O	2727
of	ADP	O	O	2727
patients	NOUN	O	O	2727
and	CCONJ	O	O	2727
to	PART	O	O	2727
determine	VERB	O	O	2727
the	PRON	O	O	2727
time	NOUN	O	O	2727
course	NOUN	O	O	2727
of	ADP	O	O	2727
the	PRON	O	O	2727
cardiovascular	ADJ	O	O	2727
consequences	NOUN	O	O	2727
of	ADP	O	O	2727
stopping	VERB	O	O	2727
selegiline	PROPN	O	O	2727
in	ADP	O	O	2727
the	PRON	O	O	2727
expectation	NOUN	O	O	2727
that	SCONJ	O	O	2727
this	PRON	O	O	2727
might	AUX	O	O	2727
shed	NOUN	O	O	2727
light	ADJ	O	O	2727
on	ADP	O	O	2727
the	PRON	O	O	2727
mechanisms	NOUN	O	O	2727
by	ADP	O	O	2727
which	PRON	O	O	2727
the	PRON	O	O	2727
drug	NOUN	O	O	2727
causes	VERB	O	O	2727
orthostatic hypotension	NOUN	O	Disease	2727
.	PUNCT	O	O	2727
The	PRON	O	O	2728
cardiovascular	ADJ	O	O	2728
responses	NOUN	O	O	2728
to	PART	O	O	2728
standing	VERB	O	O	2728
and	CCONJ	O	O	2728
head	NOUN	O	O	2728
-	PUNCT	O	O	2728
up	ADP	O	O	2728
tilt	NOUN	O	O	2728
were	AUX	O	O	2728
studied	VERB	O	O	2728
repeatedly	ADV	O	O	2728
in	ADP	O	O	2728
PD	PROPN	O	Disease	2728
patients	NOUN	O	O	2728
receiving	VERB	O	O	2728
selegiline	PROPN	O	O	2728
and	CCONJ	O	O	2728
as	ADP	O	O	2728
the	PRON	O	O	2728
drug	NOUN	O	O	2728
was	AUX	O	O	2728
withdrawn	VERB	O	O	2728
.	PUNCT	O	O	2728
Head	NOUN	O	O	2729
-	PUNCT	O	O	2729
up	ADP	O	O	2729
tilt	NOUN	O	O	2729
caused	VERB	O	O	2729
systolic	ADV	O	O	2729
orthostatic hypotension	NOUN	O	Disease	2729
which	PRON	O	O	2729
was	AUX	O	O	2729
marked	VERB	O	O	2729
in	ADP	O	O	2729
six	NUM	O	O	2729
of	ADP	O	O	2729
20	NUM	O	O	2729
PD	PROPN	O	Disease	2729
patients	NOUN	O	O	2729
on	ADP	O	O	2729
selegiline	PROPN	O	O	2729
,	PUNCT	O	O	2729
one	NUM	O	O	2729
of	ADP	O	O	2729
whom	PRON	O	O	2729
lost	VERB	O	O	2729
consciousness	NOUN	O	O	2729
with	ADP	O	O	2729
unrecordable	ADJ	O	O	2729
blood	NOUN	O	O	2729
pressures	NOUN	O	O	2729
.	PUNCT	O	O	2729
A	PRON	O	O	2730
lesser	ADJ	O	O	2730
degree	PROPN	O	O	2730
of	ADP	O	O	2730
orthostatic hypotension	NOUN	O	Disease	2730
occurred	VERB	O	O	2730
with	ADP	O	O	2730
standing	VERB	O	O	2730
.	PUNCT	O	O	2730
Orthostatic hypotension	NOUN	O	Disease	2731
was	AUX	O	O	2731
ameliorated	VERB	O	O	2731
4	NUM	O	O	2731
days	NOUN	O	O	2731
after	ADP	O	O	2731
withdrawal	NOUN	O	O	2731
of	ADP	O	O	2731
selegiline	PROPN	O	O	2731
and	CCONJ	O	O	2731
totally	ADV	O	O	2731
abolished	VERB	O	O	2731
7	NUM	O	O	2731
days	NOUN	O	O	2731
after	ADP	O	O	2731
discontinuation	NOUN	O	O	2731
of	ADP	O	O	2731
the	PRON	O	O	2731
drug	NOUN	O	O	2731
.	PUNCT	O	O	2731
Stopping	VERB	O	O	2732
selegiline	PROPN	O	O	2732
also	ADV	O	O	2732
significantly	ADV	O	O	2732
reduced	VERB	O	O	2732
the	PRON	O	O	2732
supine	ADJ	O	O	2732
systolic	ADV	O	O	2732
and	CCONJ	O	O	2732
diastolic	ADV	O	O	2732
blood	NOUN	O	O	2732
pressures	NOUN	O	O	2732
consistent	ADJ	O	O	2732
with	ADP	O	O	2732
a	PRON	O	O	2732
previously	ADV	O	O	2732
undescribed	ADJ	O	O	2732
supine	ADJ	O	O	2732
pressor	ADJ	O	O	2732
action	NOUN	O	O	2732
.	PUNCT	O	O	2732
This	PRON	O	O	2733
study	VERB	O	O	2733
confirms	VERB	O	O	2733
our	PRON	O	O	2733
previous	ADJ	O	O	2733
finding	VERB	O	O	2733
that	SCONJ	O	O	2733
selegiline	PROPN	O	O	2733
in	ADP	O	O	2733
combination	NOUN	O	O	2733
with	ADP	O	O	2733
L	NOUN	O	O	2733
-	PUNCT	O	O	2733
dopa	PROPN	O	O	2733
is	AUX	O	O	2733
associated	VERB	O	O	2733
with	ADP	O	O	2733
selective	ADJ	O	O	2733
orthostatic hypotension	NOUN	O	Disease	2733
.	PUNCT	O	O	2733
The	PRON	O	O	2734
possibilities	NOUN	O	O	2734
that	SCONJ	O	O	2734
these	PRON	O	O	2734
cardiovascular	ADJ	O	O	2734
findings	NOUN	O	O	2734
might	AUX	O	O	2734
be	AUX	O	O	2734
the	PRON	O	O	2734
result	VERB	O	O	2734
of	ADP	O	O	2734
non	ADJ	O	O	2734
-	PUNCT	O	O	2734
selective	ADJ	O	O	2734
inhibition	NOUN	O	O	2734
of	ADP	O	O	2734
monoamine	NOUN	O	O	2734
oxidase	NOUN	O	O	2734
or	CCONJ	O	O	2734
of	ADP	O	O	2734
amphetamine	NOUN	O	Chemical	2734
and	CCONJ	O	O	2734
metamphetamine	PROPN	O	O	2734
are	AUX	O	O	2734
discussed	VERB	O	O	2734
.	PUNCT	O	O	2734
Explicit	PROPN	O	O	2737
episodic	ADJ	O	O	2737
memory	NOUN	O	O	2737
for	ADP	O	O	2737
sensory	ADJ	O	O	2737
-	PUNCT	O	O	2737
discriminative	ADJ	O	O	2737
components	NOUN	O	O	2737
of	ADP	O	O	2737
capsaicin	NOUN	O	Chemical	2737
-	PUNCT	O	O	2737
induced	VERB	O	O	2737
pain	NOUN	O	Disease	2737
:	PUNCT	O	O	2737
immediate	ADJ	O	O	2737
and	CCONJ	O	O	2737
delayed	VERB	O	O	2737
ratings	NOUN	O	O	2737
.	PUNCT	O	O	2737
Pain	NOUN	O	Disease	2738
memory	NOUN	O	O	2738
is	AUX	O	O	2738
thought	VERB	O	O	2738
to	PART	O	O	2738
affect	VERB	O	O	2738
future	NOUN	O	O	2738
pain	NOUN	O	Disease	2738
sensitivity	NOUN	O	O	2738
and	CCONJ	O	O	2738
thus	ADV	O	O	2738
contribute	VERB	O	O	2738
to	PART	O	O	2738
clinical	ADJ	O	O	2738
pain	NOUN	O	Disease	2738
conditions	NOUN	O	O	2738
.	PUNCT	O	O	2738
Systematic	ADJ	O	O	2739
investigations	NOUN	O	O	2739
of	ADP	O	O	2739
the	PRON	O	O	2739
human	PROPN	O	O	2739
capacity	NOUN	O	O	2739
to	PART	O	O	2739
remember	VERB	O	O	2739
sensory	ADJ	O	O	2739
features	VERB	O	O	2739
of	ADP	O	O	2739
experimental	ADJ	O	O	2739
pain	NOUN	O	Disease	2739
are	AUX	O	O	2739
sparse	ADJ	O	O	2739
.	PUNCT	O	O	2739
In	ADP	O	O	2740
order	NOUN	O	O	2740
to	PART	O	O	2740
address	NOUN	O	O	2740
long	ADV	O	O	2740
-	PUNCT	O	O	2740
term	NOUN	O	O	2740
pain	NOUN	O	Disease	2740
memory	NOUN	O	O	2740
,	PUNCT	O	O	2740
nine	NUM	O	O	2740
healthy	ADJ	O	O	2740
male	NOUN	O	O	2740
volunteers	NOUN	O	O	2740
received	VERB	O	O	2740
intradermal	ADJ	O	O	2740
injections	NOUN	O	O	2740
of	ADP	O	O	2740
three	NUM	O	O	2740
doses	NOUN	O	O	2740
of	ADP	O	O	2740
capsaicin	NOUN	O	Chemical	2740
(	PUNCT	O	O	2740
0.05	NUM	O	O	2740
,	PUNCT	O	O	2740
1	X	O	O	2740
and	CCONJ	O	O	2740
20	NUM	O	O	2740
microg	PROPN	O	O	2740
,	PUNCT	O	O	2740
separated	VERB	O	O	2740
by	ADP	O	O	2740
15	NUM	O	O	2740
min	NOUN	O	O	2740
breaks	VERB	O	O	2740
)	PUNCT	O	O	2740
,	PUNCT	O	O	2740
each	PRON	O	O	2740
given	VERB	O	O	2740
three	NUM	O	O	2740
times	NOUN	O	O	2740
in	ADP	O	O	2740
a	PRON	O	O	2740
balanced	ADJ	O	O	2740
design	NOUN	O	O	2740
across	ADP	O	O	2740
three	NUM	O	O	2740
sessions	NOUN	O	O	2740
at	ADP	O	O	2740
one	NUM	O	O	2740
week	NOUN	O	O	2740
intervals	NOUN	O	O	2740
.	PUNCT	O	O	2740
Pain	NOUN	O	Disease	2741
rating	NOUN	O	O	2741
was	AUX	O	O	2741
performed	VERB	O	O	2741
using	VERB	O	O	2741
a	PRON	O	O	2741
computerized	VERB	O	O	2741
visual	ADJ	O	O	2741
analogue	NOUN	O	O	2741
scale	NOUN	O	O	2741
(	PUNCT	O	O	2741
0	NUM	O	O	2741
-	PUNCT	O	O	2741
100	NUM	O	O	2741
)	PUNCT	O	O	2741
digitized	VERB	O	O	2741
at	ADP	O	O	2741
1/s	NOUN	O	O	2741
,	PUNCT	O	O	2741
either	ADV	O	O	2741
immediately	ADV	O	O	2741
online	ADV	O	O	2741
or	CCONJ	O	O	2741
one	NUM	O	O	2741
hour	NOUN	O	O	2741
or	CCONJ	O	O	2741
one	NUM	O	O	2741
day	NOUN	O	O	2741
after	ADP	O	O	2741
injection	NOUN	O	O	2741
.	PUNCT	O	O	2741
Subjects	NOUN	O	O	2742
also	ADV	O	O	2742
recalled	VERB	O	O	2742
their	PRON	O	O	2742
pains	NOUN	O	O	2742
one	NUM	O	O	2742
week	NOUN	O	O	2742
later	ADV	O	O	2742
.	PUNCT	O	O	2742
Capsaicin	PROPN	O	O	2743
injection	NOUN	O	O	2743
reliably	ADV	O	O	2743
induced	VERB	O	O	2743
a	PRON	O	O	2743
dose	NOUN	O	O	2743
-	PUNCT	O	O	2743
dependent	ADJ	O	O	2743
flare	VERB	O	O	2743
(	PUNCT	O	O	2743
p<0.001	ADJ	O	O	2743
)	PUNCT	O	O	2743
without	ADP	O	O	2743
any	PRON	O	O	2743
difference	NOUN	O	O	2743
within	ADP	O	O	2743
or	CCONJ	O	O	2743
across	ADP	O	O	2743
sessions	NOUN	O	O	2743
.	PUNCT	O	O	2743
The	PRON	O	O	2744
strong	ADJ	O	O	2744
burning	VERB	O	O	2744
pain	NOUN	O	Disease	2744
decayed	VERB	O	O	2744
exponentially	ADV	O	O	2744
within	ADP	O	O	2744
a	PRON	O	O	2744
few	ADJ	O	O	2744
minutes	NOUN	O	O	2744
.	PUNCT	O	O	2744
Subjects	NOUN	O	O	2745
were	AUX	O	O	2745
able	ADJ	O	O	2745
to	PART	O	O	2745
reliably	ADV	O	O	2745
discriminate	VERB	O	O	2745
pain	NOUN	O	Disease	2745
magnitude	NOUN	O	O	2745
and	CCONJ	O	O	2745
duration	NOUN	O	O	2745
across	ADP	O	O	2745
capsaicin	NOUN	O	Chemical	2745
doses	NOUN	O	O	2745
(	PUNCT	O	O	2745
both	PRON	O	O	2745
p<0.001	ADJ	O	O	2745
)	PUNCT	O	O	2745
,	PUNCT	O	O	2745
regardless	ADV	O	O	2745
of	ADP	O	O	2745
whether	SCONJ	O	O	2745
first	ADV	O	O	2745
-	PUNCT	O	O	2745
time	NOUN	O	O	2745
ratings	NOUN	O	O	2745
were	AUX	O	O	2745
requested	VERB	O	O	2745
immediately	ADV	O	O	2745
,	PUNCT	O	O	2745
after	ADP	O	O	2745
one	NUM	O	O	2745
hour	NOUN	O	O	2745
or	CCONJ	O	O	2745
after	ADP	O	O	2745
one	NUM	O	O	2745
day	NOUN	O	O	2745
.	PUNCT	O	O	2745
Pain	NOUN	O	Disease	2746
recall	VERB	O	O	2746
after	ADP	O	O	2746
one	NUM	O	O	2746
week	NOUN	O	O	2746
was	AUX	O	O	2746
similarly	ADV	O	O	2746
precise	ADJ	O	O	2746
(	PUNCT	O	O	2746
magnitude	NOUN	O	O	2746
:	PUNCT	O	O	2746
These	PRON	O	O	2747
results	VERB	O	O	2747
indicate	VERB	O	O	2747
a	PRON	O	O	2747
reliable	ADJ	O	O	2747
memory	NOUN	O	O	2747
for	ADP	O	O	2747
magnitude	NOUN	O	O	2747
and	CCONJ	O	O	2747
duration	NOUN	O	O	2747
of	ADP	O	O	2747
experimentally	ADV	O	O	2747
induced	VERB	O	O	2747
pain	NOUN	O	Disease	2747
.	PUNCT	O	O	2747
Reversibility	NOUN	O	O	2750
of	ADP	O	O	2750
captopril	PROPN	O	Chemical	2750
-	PUNCT	O	O	2750
induced	VERB	O	O	2750
renal insufficiency	NOUN	O	Disease	2750
after	ADP	O	O	2750
prolonged	VERB	O	O	2750
use	VERB	O	O	2750
in	ADP	O	O	2750
an	PRON	O	O	2750
unusual	ADJ	O	O	2750
case	NOUN	O	O	2750
of	ADP	O	O	2750
renovascular	NOUN	O	O	2750
hypertension	NOUN	O	Disease	2750
.	PUNCT	O	O	2750
We	PRON	O	O	2751
report	VERB	O	O	2751
a	PRON	O	O	2751
case	NOUN	O	O	2751
of	ADP	O	O	2751
severe	ADJ	O	O	2751
hypertension	NOUN	O	Disease	2751
with	ADP	O	O	2751
an	PRON	O	O	2751
occluded	VERB	O	O	2751
renal	ADJ	O	O	2751
artery	NOUN	O	O	2751
to	PART	O	O	2751
a	PRON	O	O	2751
solitary	ADJ	O	O	2751
kidney	NOUN	O	O	2751
,	PUNCT	O	O	2751
who	PRON	O	O	2751
developed	VERB	O	O	2751
sudden	ADJ	O	O	2751
deterioration	NOUN	O	O	2751
of	ADP	O	O	2751
renal	ADJ	O	O	2751
function	NOUN	O	O	2751
following	VERB	O	O	2751
treatment	NOUN	O	O	2751
with	ADP	O	O	2751
captopril	PROPN	O	Chemical	2751
.	PUNCT	O	O	2751
His	PRON	O	O	2752
renal	ADJ	O	O	2752
function	NOUN	O	O	2752
remained	VERB	O	O	2752
impaired	VERB	O	O	2752
but	CCONJ	O	O	2752
stable	ADJ	O	O	2752
during	ADP	O	O	2752
2	X	O	O	2752
years	NOUN	O	O	2752
'	PUNCT	O	O	2752
treatment	NOUN	O	O	2752
with	ADP	O	O	2752
captopril	PROPN	O	Chemical	2752
but	CCONJ	O	O	2752
returned	VERB	O	O	2752
to	PART	O	O	2752
pre	VERB	O	O	2752
-	PUNCT	O	O	2752
treatment	NOUN	O	O	2752
levels	NOUN	O	O	2752
soon	ADV	O	O	2752
after	ADP	O	O	2752
cessation	NOUN	O	O	2752
of	ADP	O	O	2752
the	PRON	O	O	2752
drug	NOUN	O	O	2752
.	PUNCT	O	O	2752
This	PRON	O	O	2753
indicates	VERB	O	O	2753
reversibility	NOUN	O	O	2753
in	ADP	O	O	2753
captopril	PROPN	O	Chemical	2753
-	PUNCT	O	O	2753
induced	VERB	O	O	2753
renal failure	NOUN	O	Disease	2753
even	ADV	O	O	2753
after	ADP	O	O	2753
its	PRON	O	O	2753
prolonged	VERB	O	O	2753
use	VERB	O	O	2753
and	CCONJ	O	O	2753
suggests	VERB	O	O	2753
that	SCONJ	O	O	2753
no	PRON	O	O	2753
organic	ADJ	O	O	2753
damage	NOUN	O	O	2753
occurs	VERB	O	O	2753
to	PART	O	O	2753
glomerular	ADJ	O	O	2753
arterioles	NOUN	O	O	2753
following	VERB	O	O	2753
chronic	ADJ	O	O	2753
ACE	PROPN	O	O	2753
inhibition	NOUN	O	O	2753
.	PUNCT	O	O	2753
Liver	NOUN	O	O	2756
disease	PROPN	O	O	2756
caused	VERB	O	O	2756
by	ADP	O	O	2756
propylthiouracil	NOUN	O	Chemical	2756
.	PUNCT	O	O	2756
This	PRON	O	O	2757
report	VERB	O	O	2757
presents	VERB	O	O	2757
the	PRON	O	O	2757
clinical	ADJ	O	O	2757
,	PUNCT	O	O	2757
laboratory	NOUN	O	O	2757
,	PUNCT	O	O	2757
and	CCONJ	O	O	2757
light	ADJ	O	O	2757
and	CCONJ	O	O	2757
electron	NOUN	O	O	2757
microscopic	ADJ	O	O	2757
observations	NOUN	O	O	2757
on	ADP	O	O	2757
a	PRON	O	O	2757
patient	NOUN	O	O	2757
with	ADP	O	O	2757
chronic	ADJ	O	O	2757
active	ADJ	O	O	2757
(	PUNCT	O	O	2757
aggressive	ADJ	O	O	2757
)	PUNCT	O	O	2757
hepatitis	NOUN	O	Disease	2757
caused	VERB	O	O	2757
by	ADP	O	O	2757
the	PRON	O	O	2757
administration	NOUN	O	O	2757
of	ADP	O	O	2757
propylthiouracil	NOUN	O	Chemical	2757
.	PUNCT	O	O	2757
This	PRON	O	O	2758
is	AUX	O	O	2758
an	PRON	O	O	2758
addition	NOUN	O	O	2758
to	PART	O	O	2758
the	PRON	O	O	2758
list	NOUN	O	O	2758
of	ADP	O	O	2758
drugs	NOUN	O	O	2758
that	SCONJ	O	O	2758
must	AUX	O	O	2758
be	AUX	O	O	2758
considered	VERB	O	O	2758
in	ADP	O	O	2758
the	PRON	O	O	2758
evaluation	NOUN	O	O	2758
of	ADP	O	O	2758
chronic	ADJ	O	O	2758
liver disease	NOUN	O	Disease	2758
.	PUNCT	O	O	2758
Capsaicin	PROPN	O	O	2761
-	PUNCT	O	O	2761
induced	VERB	O	O	2761
muscle	NOUN	O	O	2761
pain	NOUN	O	Disease	2761
alters	VERB	O	O	2761
the	PRON	O	O	2761
excitability	NOUN	O	O	2761
of	ADP	O	O	2761
the	PRON	O	O	2761
human	PROPN	O	O	2761
jaw	INTJ	O	O	2761
-	PUNCT	O	O	2761
stretch	VERB	O	O	2761
reflex	NOUN	O	O	2761
.	PUNCT	O	O	2761
The	PRON	O	O	2762
pathophysiology	NOUN	O	O	2762
of	ADP	O	O	2762
painful	ADJ	O	Disease	2762
temporomandibular	ADJ	O	O	2762
disorders	NOUN	O	O	2762
is	AUX	O	O	2762
not	PART	O	O	2762
fully	ADV	O	O	2762
understood	VERB	O	O	2762
,	PUNCT	O	O	2762
but	CCONJ	O	O	2762
evidence	NOUN	O	O	2762
suggests	VERB	O	O	2762
that	SCONJ	O	O	2762
muscle	NOUN	O	O	2762
pain	NOUN	O	Disease	2762
modulates	VERB	O	O	2762
motor	NOUN	O	O	2762
function	NOUN	O	O	2762
in	ADP	O	O	2762
characteristic	ADJ	O	O	2762
ways	NOUN	O	O	2762
.	PUNCT	O	O	2762
This	PRON	O	O	2763
study	VERB	O	O	2763
tested	VERB	O	O	2763
the	PRON	O	O	2763
hypothesis	NOUN	O	O	2763
that	SCONJ	O	O	2763
activation	NOUN	O	O	2763
of	ADP	O	O	2763
nociceptive	ADJ	O	O	2763
muscle	NOUN	O	O	2763
afferent	NOUN	O	O	2763
fibers	NOUN	O	O	2763
would	AUX	O	O	2763
be	AUX	O	O	2763
linked	VERB	O	O	2763
to	PART	O	O	2763
an	PRON	O	O	2763
increased	VERB	O	O	2763
excitability	NOUN	O	O	2763
of	ADP	O	O	2763
the	PRON	O	O	2763
human	PROPN	O	O	2763
jaw	INTJ	O	O	2763
-	PUNCT	O	O	2763
stretch	VERB	O	O	2763
reflex	NOUN	O	O	2763
and	CCONJ	O	O	2763
whether	SCONJ	O	O	2763
this	PRON	O	O	2763
process	NOUN	O	O	2763
would	AUX	O	O	2763
be	AUX	O	O	2763
sensitive	ADJ	O	O	2763
to	PART	O	O	2763
length	NOUN	O	O	2763
and	CCONJ	O	O	2763
velocity	NOUN	O	O	2763
of	ADP	O	O	2763
the	PRON	O	O	2763
stretch	VERB	O	O	2763
.	PUNCT	O	O	2763
Capsaicin	PROPN	O	O	2764
(	PUNCT	O	O	2764
10	NUM	O	O	2764
micro	NOUN	O	O	2764
g	X	O	O	2764
)	PUNCT	O	O	2764
was	AUX	O	O	2764
injected	VERB	O	O	2764
into	ADP	O	O	2764
the	PRON	O	O	2764
masseter	PROPN	O	O	2764
muscle	NOUN	O	O	2764
to	PART	O	O	2764
induce	VERB	O	O	2764
pain	NOUN	O	Disease	2764
in	ADP	O	O	2764
11	NUM	O	O	2764
healthy	ADJ	O	O	2764
volunteers	NOUN	O	O	2764
.	PUNCT	O	O	2764
Short	ADJ	O	O	2765
-	PUNCT	O	O	2765
latency	VERB	O	O	2765
reflex	NOUN	O	O	2765
responses	NOUN	O	O	2765
were	AUX	O	O	2765
evoked	VERB	O	O	2765
in	ADP	O	O	2765
the	PRON	O	O	2765
masseter	PROPN	O	O	2765
and	CCONJ	O	O	2765
temporalis	NOUN	O	O	2765
muscles	NOUN	O	O	2765
by	ADP	O	O	2765
a	PRON	O	O	2765
stretch	VERB	O	O	2765
device	NOUN	O	O	2765
with	ADP	O	O	2765
different	ADJ	O	O	2765
velocities	NOUN	O	O	2765
and	CCONJ	O	O	2765
displacements	NOUN	O	O	2765
before	ADP	O	O	2765
,	PUNCT	O	O	2765
during	ADP	O	O	2765
,	PUNCT	O	O	2765
and	CCONJ	O	O	2765
after	ADP	O	O	2765
the	PRON	O	O	2765
pain	NOUN	O	Disease	2765
.	PUNCT	O	O	2765
The	PRON	O	O	2766
normalized	VERB	O	O	2766
reflex	NOUN	O	O	2766
amplitude	VERB	O	O	2766
was	AUX	O	O	2766
significantly	ADV	O	O	2766
higher	ADJ	O	O	2766
during	ADP	O	O	2766
pain	NOUN	O	Disease	2766
,	PUNCT	O	O	2766
but	CCONJ	O	O	2766
only	ADV	O	O	2766
at	ADP	O	O	2766
faster	ADV	O	O	2766
stretches	VERB	O	O	2766
in	ADP	O	O	2766
the	PRON	O	O	2766
painful	ADJ	O	Disease	2766
muscle	NOUN	O	O	2766
.	PUNCT	O	O	2766
Increased	VERB	O	O	2767
sensitivity	NOUN	O	O	2767
of	ADP	O	O	2767
the	PRON	O	O	2767
fusimotor	PROPN	O	O	2767
system	NOUN	O	O	2767
during	ADP	O	O	2767
acute	ADJ	O	O	2767
muscle	NOUN	O	O	2767
pain	NOUN	O	Disease	2767
could	AUX	O	O	2767
be	AUX	O	O	2767
one	NUM	O	O	2767
likely	ADV	O	O	2767
mechanism	NOUN	O	O	2767
to	PART	O	O	2767
explain	VERB	O	O	2767
the	PRON	O	O	2767
findings	NOUN	O	O	2767
.	PUNCT	O	O	2767
Repetitive	ADJ	O	O	2770
transcranial	NOUN	O	O	2770
magnetic	ADJ	O	O	2770
stimulation	NOUN	O	O	2770
for	ADP	O	O	2770
levodopa	NOUN	O	Chemical	2770
-	PUNCT	O	O	2770
induced	VERB	O	O	2770
dyskinesias	PROPN	O	Disease	2770
in	ADP	O	O	2770
Parkinson	NOUN	O	O	2770
's	AUX	O	O	2770
disease	PROPN	O	O	2770
.	PUNCT	O	O	2770
In	ADP	O	O	2771
a	PRON	O	O	2771
placebo	NOUN	O	O	2771
-	PUNCT	O	O	2771
controlled	VERB	O	O	2771
,	PUNCT	O	O	2771
single	ADJ	O	O	2771
-	PUNCT	O	O	2771
blinded	VERB	O	O	2771
,	PUNCT	O	O	2771
crossover	NOUN	O	O	2771
study	VERB	O	O	2771
,	PUNCT	O	O	2771
we	PRON	O	O	2771
assessed	VERB	O	O	2771
the	PRON	O	O	2771
effect	VERB	O	O	2771
of	ADP	O	O	2771
""""	PUNCT	O	O	2771
real	ADV	O	O	2771
""""	PUNCT	O	O	2771
repetitive	ADJ	O	O	2771
transcranial	NOUN	O	O	2771
magnetic	ADJ	O	O	2771
stimulation	NOUN	O	O	2771
(	PUNCT	O	O	2771
rTMS	X	O	O	2771
)	PUNCT	O	O	2771
versus	ADP	O	O	2771
""""	PUNCT	O	O	2771
sham	NOUN	O	O	2771
""""	PUNCT	O	O	2771
rTMS	X	O	O	2771
(	PUNCT	O	O	2771
placebo	NOUN	O	O	2771
)	PUNCT	O	O	2771
on	ADP	O	O	2771
peak	PROPN	O	O	2771
dose	NOUN	O	O	2771
dyskinesias	PROPN	O	Disease	2771
in	ADP	O	O	2771
patients	NOUN	O	O	2771
with	ADP	O	O	2771
Parkinson	NOUN	O	O	2771
's	AUX	O	O	2771
disease	PROPN	O	O	2771
(	PUNCT	O	O	2771
PD	PROPN	O	Disease	2771
)	PUNCT	O	O	2771
.	PUNCT	O	O	2771
Ten	NUM	O	O	2772
patients	NOUN	O	O	2772
with	ADP	O	O	2772
PD	PROPN	O	Disease	2772
and	CCONJ	O	O	2772
prominent	ADJ	O	O	2772
dyskinesias	PROPN	O	Disease	2772
had	VERB	O	O	2772
rTMS	X	O	O	2772
(	PUNCT	O	O	2772
1,800	NUM	O	O	2772
pulses	NOUN	O	O	2772
;	PUNCT	O	O	2772
1	X	O	O	2772
Hz	NOUN	O	O	2772
rate	NOUN	O	O	2772
)	PUNCT	O	O	2772
delivered	VERB	O	O	2772
over	ADP	O	O	2772
the	PRON	O	O	2772
motor	NOUN	O	O	2772
cortex	VERB	O	O	2772
for	ADP	O	O	2772
4	NUM	O	O	2772
consecutive	ADJ	O	O	2772
days	NOUN	O	O	2772
twice	ADV	O	O	2772
,	PUNCT	O	O	2772
once	ADV	O	O	2772
real	ADV	O	O	2772
stimuli	NOUN	O	O	2772
and	CCONJ	O	O	2772
once	ADV	O	O	2772
sham	NOUN	O	O	2772
stimulation	NOUN	O	O	2772
were	AUX	O	O	2772
used	VERB	O	O	2772
;	PUNCT	O	O	2772
evaluations	NOUN	O	O	2772
were	AUX	O	O	2772
done	VERB	O	O	2772
at	ADP	O	O	2772
the	PRON	O	O	2772
baseline	VERB	O	O	2772
and	CCONJ	O	O	2772
1	X	O	O	2772
day	NOUN	O	O	2772
after	ADP	O	O	2772
the	PRON	O	O	2772
end	VERB	O	O	2772
of	ADP	O	O	2772
each	PRON	O	O	2772
of	ADP	O	O	2772
the	PRON	O	O	2772
treatment	NOUN	O	O	2772
series	PROPN	O	O	2772
.	PUNCT	O	O	2772
Direct	ADJ	O	O	2773
comparison	NOUN	O	O	2773
between	ADP	O	O	2773
sham	NOUN	O	O	2773
and	CCONJ	O	O	2773
real	ADV	O	O	2773
rTMS	X	O	O	2773
effects	NOUN	O	O	2773
showed	VERB	O	O	2773
no	PRON	O	O	2773
significant	ADJ	O	O	2773
difference	NOUN	O	O	2773
in	ADP	O	O	2773
clinician	NOUN	O	O	2773
-	PUNCT	O	O	2773
assessed	VERB	O	O	2773
dyskinesia	NOUN	O	Disease	2773
severity	NOUN	O	O	2773
.	PUNCT	O	O	2773
However	ADV	O	O	2774
,	PUNCT	O	O	2774
comparison	NOUN	O	O	2774
with	ADP	O	O	2774
the	PRON	O	O	2774
baseline	VERB	O	O	2774
showed	VERB	O	O	2774
small	ADJ	O	O	2774
but	CCONJ	O	O	2774
significant	ADJ	O	O	2774
reduction	NOUN	O	O	2774
in	ADP	O	O	2774
dyskinesia	NOUN	O	Disease	2774
severity	NOUN	O	O	2774
following	VERB	O	O	2774
real	ADV	O	O	2774
rTMS	X	O	O	2774
but	CCONJ	O	O	2774
not	PART	O	O	2774
placebo	NOUN	O	O	2774
.	PUNCT	O	O	2774
The	PRON	O	O	2775
major	ADJ	O	O	2775
effect	VERB	O	O	2775
was	AUX	O	O	2775
on	ADP	O	O	2775
dystonia	NOUN	O	Disease	2775
subscore	NOUN	O	O	2775
.	PUNCT	O	O	2775
Similarly	ADV	O	O	2776
,	PUNCT	O	O	2776
in	ADP	O	O	2776
patient	NOUN	O	O	2776
diaries	NOUN	O	O	2776
,	PUNCT	O	O	2776
although	SCONJ	O	O	2776
both	PRON	O	O	2776
treatments	NOUN	O	O	2776
caused	VERB	O	O	2776
reduction	NOUN	O	O	2776
in	ADP	O	O	2776
subjective	ADJ	O	O	2776
dyskinesia	NOUN	O	Disease	2776
scores	NOUN	O	O	2776
during	ADP	O	O	2776
the	PRON	O	O	2776
days	NOUN	O	O	2776
of	ADP	O	O	2776
intervention	NOUN	O	O	2776
,	PUNCT	O	O	2776
the	PRON	O	O	2776
effect	VERB	O	O	2776
was	AUX	O	O	2776
sustained	VERB	O	O	2776
for	ADP	O	O	2776
3	X	O	O	2776
days	NOUN	O	O	2776
after	ADP	O	O	2776
the	PRON	O	O	2776
intervention	NOUN	O	O	2776
for	ADP	O	O	2776
the	PRON	O	O	2776
real	ADV	O	O	2776
rTMS	X	O	O	2776
only	ADV	O	O	2776
.	PUNCT	O	O	2776
Following	VERB	O	O	2777
rTMS	X	O	O	2777
,	PUNCT	O	O	2777
no	PRON	O	O	2777
side	NOUN	O	O	2777
effects	NOUN	O	O	2777
and	CCONJ	O	O	2777
no	PRON	O	O	2777
adverse	ADJ	O	O	2777
effects	NOUN	O	O	2777
on	ADP	O	O	2777
motor	NOUN	O	O	2777
function	NOUN	O	O	2777
and	CCONJ	O	O	2777
PD	PROPN	O	Disease	2777
symptoms	NOUN	O	O	2777
were	AUX	O	O	2777
noted	VERB	O	O	2777
.	PUNCT	O	O	2777
The	PRON	O	O	2778
results	VERB	O	O	2778
suggest	VERB	O	O	2778
the	PRON	O	O	2778
existence	NOUN	O	O	2778
of	ADP	O	O	2778
residual	ADJ	O	O	2778
beneficial	ADJ	O	O	2778
clinical	ADJ	O	O	2778
aftereffects	NOUN	O	O	2778
of	ADP	O	O	2778
consecutive	ADJ	O	O	2778
daily	ADV	O	O	2778
applications	NOUN	O	O	2778
of	ADP	O	O	2778
low	ADJ	O	O	2778
-	PUNCT	O	O	2778
frequency	NOUN	O	O	2778
rTMS	X	O	O	2778
on	ADP	O	O	2778
dyskinesias	PROPN	O	Disease	2778
in	ADP	O	O	2778
PD	PROPN	O	Disease	2778
.	PUNCT	O	O	2778
Disulfiram	PROPN	O	Chemical	2781
-	PUNCT	O	O	2781
like	INTJ	O	O	2781
syndrome	NOUN	O	O	2781
after	ADP	O	O	2781
hydrogen	PROPN	O	O	2781
cyanamide	NOUN	O	O	2781
professional	ADJ	O	O	2781
skin	NOUN	O	O	2781
exposure	NOUN	O	O	2781
:	PUNCT	O	O	2781
two	NUM	O	O	2781
case	NOUN	O	O	2781
reports	VERB	O	O	2781
in	ADP	O	O	2781
France	PROPN	O	O	2781
.	PUNCT	O	O	2781
Hydrogen	NOUN	O	O	2782
cyanamide	NOUN	O	O	2782
is	AUX	O	O	2782
a	PRON	O	O	2782
plant	NOUN	O	O	2782
growth	NOUN	O	O	2782
regulator	NOUN	O	O	2782
used	VERB	O	O	2782
in	ADP	O	O	2782
agriculture	NOUN	O	O	2782
to	PART	O	O	2782
induce	VERB	O	O	2782
bud	PUNCT	O	O	2782
break	VERB	O	O	2782
in	ADP	O	O	2782
fruit	NOUN	O	O	2782
trees	NOUN	O	O	2782
.	PUNCT	O	O	2782
Contact	NOUN	O	O	2783
with	ADP	O	O	2783
the	PRON	O	O	2783
skin	NOUN	O	O	2783
can	AUX	O	O	2783
result	VERB	O	O	2783
in	ADP	O	O	2783
percutaneous	ADJ	O	O	2783
absorption	NOUN	O	O	2783
of	ADP	O	O	2783
the	PRON	O	O	2783
substance	NOUN	O	O	2783
that	SCONJ	O	O	2783
inhibits	VERB	O	O	2783
aldehyde	NOUN	O	O	2783
dehydrogenase	NOUN	O	O	2783
and	CCONJ	O	O	2783
can	AUX	O	O	2783
induce	VERB	O	O	2783
acetaldehyde	PROPN	O	Chemical	2783
syndrome	NOUN	O	O	2783
in	ADP	O	O	2783
case	NOUN	O	O	2783
of	ADP	O	O	2783
alcohol	NOUN	O	Chemical	2783
use	VERB	O	O	2783
.	PUNCT	O	O	2783
The	PRON	O	O	2784
purpose	NOUN	O	O	2784
of	ADP	O	O	2784
this	PRON	O	O	2784
report	VERB	O	O	2784
is	AUX	O	O	2784
to	PART	O	O	2784
describe	VERB	O	O	2784
two	NUM	O	O	2784
cases	NOUN	O	O	2784
of	ADP	O	O	2784
a	PRON	O	O	2784
disulfiram	PROPN	O	Chemical	2784
-	PUNCT	O	O	2784
like	INTJ	O	O	2784
syndrome	NOUN	O	O	2784
following	VERB	O	O	2784
occupational	ADJ	O	O	2784
exposure	NOUN	O	O	2784
to	PART	O	O	2784
hydrogen	PROPN	O	O	2784
cyanamide	NOUN	O	O	2784
.	PUNCT	O	O	2784
The	PRON	O	O	2785
first	ADV	O	O	2785
case	NOUN	O	O	2785
involved	VERB	O	O	2785
a	PRON	O	O	2785
59-year	NOUN	O	O	2785
-	PUNCT	O	O	2785
old	ADJ	O	O	2785
man	NOUN	O	O	2785
who	PRON	O	O	2785
used	VERB	O	O	2785
Dormex	PROPN	O	O	2785
,	PUNCT	O	O	2785
which	PRON	O	O	2785
contains	VERB	O	O	2785
hydrogen	PROPN	O	O	2785
cyanamide	NOUN	O	O	2785
,	PUNCT	O	O	2785
without	ADP	O	O	2785
protection	NOUN	O	O	2785
after	ADP	O	O	2785
consuming	VERB	O	O	2785
a	PRON	O	O	2785
large	ADJ	O	O	2785
amount	NOUN	O	O	2785
of	ADP	O	O	2785
alcohol	NOUN	O	Chemical	2785
during	ADP	O	O	2785
a	PRON	O	O	2785
meal	NOUN	O	O	2785
.	PUNCT	O	O	2785
In	ADP	O	O	2786
less	ADV	O	O	2786
than	ADP	O	O	2786
1	X	O	O	2786
hour	NOUN	O	O	2786
after	ADP	O	O	2786
the	PRON	O	O	2786
ingestion	NOUN	O	O	2786
of	ADP	O	O	2786
alcohol	NOUN	O	Chemical	2786
,	PUNCT	O	O	2786
he	PRON	O	O	2786
developed	VERB	O	O	2786
malaise	NOUN	O	Disease	2786
with	ADP	O	O	2786
flushing	VERB	O	Disease	2786
of	ADP	O	O	2786
the	PRON	O	O	2786
face	NOUN	O	O	2786
,	PUNCT	O	O	2786
tachycardia	PROPN	O	Disease	2786
,	PUNCT	O	O	2786
and	CCONJ	O	O	2786
dyspnea	ADJ	O	O	2786
.	PUNCT	O	O	2786
The	PRON	O	O	2787
second	ADV	O	O	2787
case	NOUN	O	O	2787
occurred	VERB	O	O	2787
in	ADP	O	O	2787
a	PRON	O	O	2787
55-year	NOUN	O	O	2787
-	PUNCT	O	O	2787
old	ADJ	O	O	2787
farmer	NOUN	O	O	2787
following	VERB	O	O	2787
cutaneous	ADJ	O	O	2787
contact	NOUN	O	O	2787
with	ADP	O	O	2787
Dormex	PROPN	O	O	2787
.	PUNCT	O	O	2787
Five	NUM	O	O	2788
hours	NOUN	O	O	2788
after	ADP	O	O	2788
exposure	NOUN	O	O	2788
,	PUNCT	O	O	2788
he	PRON	O	O	2788
developed	VERB	O	O	2788
disulfiram	PROPN	O	Chemical	2788
-	PUNCT	O	O	2788
like	INTJ	O	O	2788
syndrome	NOUN	O	O	2788
with	ADP	O	O	2788
flushing	VERB	O	Disease	2788
,	PUNCT	O	O	2788
tachycardia	PROPN	O	Disease	2788
,	PUNCT	O	O	2788
and	CCONJ	O	O	2788
arterial	ADJ	O	O	2788
hypotension	NOUN	O	Disease	2788
after	ADP	O	O	2788
consuming	VERB	O	O	2788
three	NUM	O	O	2788
glasses	NOUN	O	O	2788
of	ADP	O	O	2788
wine	NOUN	O	O	2788
.	PUNCT	O	O	2788
These	PRON	O	O	2789
cases	NOUN	O	O	2789
confirm	VERB	O	O	2789
the	PRON	O	O	2789
necessity	NOUN	O	O	2789
of	ADP	O	O	2789
avoiding	VERB	O	O	2789
alcohol	NOUN	O	Chemical	2789
consumption	NOUN	O	O	2789
as	ADP	O	O	2789
recommended	VERB	O	O	2789
in	ADP	O	O	2789
the	PRON	O	O	2789
instructions	NOUN	O	O	2789
for	ADP	O	O	2789
use	VERB	O	O	2789
of	ADP	O	O	2789
Dormex	PROPN	O	O	2789
and	CCONJ	O	O	2789
of	ADP	O	O	2789
preventing	VERB	O	O	2789
cutaneous	ADJ	O	O	2789
contact	NOUN	O	O	2789
during	ADP	O	O	2789
use	VERB	O	O	2789
.	PUNCT	O	O	2789
Repeated	VERB	O	O	2792
trimipramine	PROPN	O	O	2792
induces	VERB	O	O	2792
dopamine	NOUN	O	Chemical	2792
D2/D3	PROPN	O	O	2792
and	CCONJ	O	O	2792
alpha1-adrenergic	NOUN	O	O	2792
up	ADP	O	O	2792
-	PUNCT	O	O	2792
regulation	NOUN	O	O	2792
.	PUNCT	O	O	2792
Trimipramine	NOUN	O	O	2793
(	PUNCT	O	O	2793
TRI	PROPN	O	O	2793
)	PUNCT	O	O	2793
,	PUNCT	O	O	2793
which	PRON	O	O	2793
shows	VERB	O	O	2793
a	PRON	O	O	2793
clinical	ADJ	O	O	2793
antidepressant	NOUN	O	O	2793
activity	NOUN	O	O	2793
,	PUNCT	O	O	2793
is	AUX	O	O	2793
chemically	ADV	O	O	2793
related	ADJ	O	O	2793
to	PART	O	O	2793
imipramine	X	O	O	2793
but	CCONJ	O	O	2793
does	VERB	O	O	2793
not	PART	O	O	2793
inhibit	VERB	O	O	2793
the	PRON	O	O	2793
reuptake	PROPN	O	O	2793
of	ADP	O	O	2793
noradrenaline	NOUN	O	Chemical	2793
and	CCONJ	O	O	2793
5-hydroxytryptamine	NOUN	O	Chemical	2793
,	PUNCT	O	O	2793
nor	CCONJ	O	O	2793
does	VERB	O	O	2793
it	PRON	O	O	2793
induce	VERB	O	O	2793
beta	NOUN	O	O	2793
-	PUNCT	O	O	2793
adrenergic	NOUN	O	O	2793
down	ADP	O	O	2793
-	PUNCT	O	O	2793
regulation	NOUN	O	O	2793
.	PUNCT	O	O	2793
The	PRON	O	O	2794
mechanism	NOUN	O	O	2794
of	ADP	O	O	2794
its	PRON	O	O	2794
antidepressant	NOUN	O	O	2794
activity	NOUN	O	O	2794
is	AUX	O	O	2794
still	ADV	O	O	2794
unknown	ADJ	O	O	2794
.	PUNCT	O	O	2794
The	PRON	O	O	2795
aim	VERB	O	O	2795
of	ADP	O	O	2795
the	PRON	O	O	2795
present	NOUN	O	O	2795
study	VERB	O	O	2795
was	AUX	O	O	2795
to	PART	O	O	2795
find	VERB	O	O	2795
out	ADP	O	O	2795
whether	SCONJ	O	O	2795
TRI	PROPN	O	O	2795
given	VERB	O	O	2795
repeatedly	ADV	O	O	2795
was	AUX	O	O	2795
able	ADJ	O	O	2795
to	PART	O	O	2795
induce	VERB	O	O	2795
adaptive	ADJ	O	O	2795
changes	VERB	O	O	2795
in	ADP	O	O	2795
the	PRON	O	O	2795
dopaminergic	ADJ	O	O	2795
and	CCONJ	O	O	2795
alpha1-adrenergic	NOUN	O	O	2795
systems	NOUN	O	O	2795
,	PUNCT	O	O	2795
demonstrated	VERB	O	O	2795
by	ADP	O	O	2795
us	PRON	O	O	2795
previously	ADV	O	O	2795
for	ADP	O	O	2795
various	ADJ	O	O	2795
antidepressants	NOUN	O	O	2795
.	PUNCT	O	O	2795
TRI	PROPN	O	O	2796
was	AUX	O	O	2796
given	VERB	O	O	2796
to	PART	O	O	2796
male	NOUN	O	O	2796
Wistar	PROPN	O	O	2796
rats	NOUN	O	O	2796
and	CCONJ	O	O	2796
male	NOUN	O	O	2796
Albino	PROPN	O	O	2796
Swiss	PROPN	O	O	2796
mice	NOUN	O	O	2796
perorally	ADV	O	O	2796
twice	ADV	O	O	2796
daily	ADV	O	O	2796
for	ADP	O	O	2796
14	NUM	O	O	2796
days	NOUN	O	O	2796
.	PUNCT	O	O	2796
In	ADP	O	O	2797
the	PRON	O	O	2797
acute	ADJ	O	O	2797
experiment	NOUN	O	O	2797
TRI	PROPN	O	O	2797
(	PUNCT	O	O	2797
given	VERB	O	O	2797
i.p	NOUN	O	O	2797
.	PUNCT	O	O	2797
)	PUNCT	O	O	2797
does	VERB	O	O	2798
not	PART	O	O	2798
antagonize	VERB	O	O	2798
the	PRON	O	O	2798
reserpine	NOUN	O	Chemical	2798
hypothermia	VERB	O	Disease	2798
in	ADP	O	O	2798
mice	NOUN	O	O	2798
and	CCONJ	O	O	2798
does	VERB	O	O	2798
not	PART	O	O	2798
potentiate	VERB	O	O	2798
the	PRON	O	O	2798
5-hydroxytryptophan	NOUN	O	Chemical	2798
head twitches	VERB	O	Disease	2798
in	ADP	O	O	2798
rats	NOUN	O	O	2798
.	PUNCT	O	O	2798
TRI	PROPN	O	O	2799
given	VERB	O	O	2799
repeatedly	ADV	O	O	2799
to	PART	O	O	2799
rats	NOUN	O	O	2799
increases	VERB	O	O	2799
the	PRON	O	O	2799
locomotor hyperactivity	NOUN	O	Disease	2799
induced	VERB	O	O	2799
by	ADP	O	O	2799
d	X	O	O	2799
-	PUNCT	O	O	2799
amphetamine	NOUN	O	Chemical	2799
,	PUNCT	O	O	2799
quinpirole	NOUN	O	Chemical	2799
and	CCONJ	O	O	2799
(	PUNCT	O	O	2799
+	ADP	O	O	2799
)	PUNCT	O	O	2799
-7-hydroxy	NOUN	O	O	2799
-	PUNCT	O	O	2799
dipropyloaminotetralin	VERB	O	O	2799
(	PUNCT	O	O	2799
dopamine	NOUN	O	Chemical	2800
D2	NOUN	O	O	2800
and	CCONJ	O	O	2800
D3	PROPN	O	O	2800
effects	NOUN	O	O	2800
)	PUNCT	O	O	2800
.	PUNCT	O	O	2800
The	PRON	O	O	2801
stereotypies	NOUN	O	Disease	2801
induced	VERB	O	O	2801
by	ADP	O	O	2801
d	X	O	O	2801
-	PUNCT	O	O	2801
amphetamine	NOUN	O	Chemical	2801
or	CCONJ	O	O	2801
apomorphine	PROPN	O	Chemical	2801
are	AUX	O	O	2801
not	PART	O	O	2801
potentiated	VERB	O	O	2801
by	ADP	O	O	2801
TRI	PROPN	O	O	2801
.	PUNCT	O	O	2801
It	PRON	O	O	2802
increases	VERB	O	O	2802
the	PRON	O	O	2802
behaviour	NOUN	O	O	2802
stimulation	NOUN	O	O	2802
evoked	VERB	O	O	2802
by	ADP	O	O	2802
phenylephrine	NOUN	O	Chemical	2802
(	PUNCT	O	O	2802
given	VERB	O	O	2802
intraventricularly	NOUN	O	O	2802
)	PUNCT	O	O	2802
in	ADP	O	O	2802
rats	NOUN	O	O	2802
,	PUNCT	O	O	2802
evaluated	VERB	O	O	2802
in	ADP	O	O	2802
the	PRON	O	O	2802
open	VERB	O	O	2802
field	NOUN	O	O	2802
test	NOUN	O	O	2802
as	ADP	O	O	2802
well	ADV	O	O	2802
as	ADP	O	O	2802
the	PRON	O	O	2802
aggressiveness	NOUN	O	Disease	2802
evoked	VERB	O	O	2802
by	ADP	O	O	2802
clonidine	NOUN	O	Chemical	2802
in	ADP	O	O	2802
mice	NOUN	O	O	2802
,	PUNCT	O	O	2802
both	PRON	O	O	2802
these	PRON	O	O	2802
effects	NOUN	O	O	2802
being	AUX	O	O	2802
mediated	VERB	O	O	2802
by	ADP	O	O	2802
an	PRON	O	O	2802
alpha1-adrenergic	NOUN	O	O	2802
receptor	NOUN	O	O	2802
.	PUNCT	O	O	2802
It	PRON	O	O	2803
may	AUX	O	O	2803
be	AUX	O	O	2803
concluded	VERB	O	O	2803
that	SCONJ	O	O	2803
,	PUNCT	O	O	2803
like	INTJ	O	O	2803
other	ADJ	O	O	2803
tricyclic	ADJ	O	O	2803
antidepressants	NOUN	O	O	2803
studied	VERB	O	O	2803
previously	ADV	O	O	2803
,	PUNCT	O	O	2803
TRI	PROPN	O	O	2803
given	VERB	O	O	2803
repeatedly	ADV	O	O	2803
increases	VERB	O	O	2803
the	PRON	O	O	2803
responsiveness	NOUN	O	O	2803
of	ADP	O	O	2803
brain	NOUN	O	O	2803
dopamine	NOUN	O	Chemical	2803
D2	NOUN	O	O	2803
and	CCONJ	O	O	2803
D3	PROPN	O	O	2803
(	PUNCT	O	O	2803
locomotor	PROPN	O	O	2803
activity	NOUN	O	O	2803
but	CCONJ	O	O	2803
not	PART	O	O	2803
stereotypy	PROPN	O	O	2803
)	PUNCT	O	O	2803
as	ADP	O	O	2803
well	ADV	O	O	2803
as	ADP	O	O	2803
alpha1-adrenergic	NOUN	O	O	2803
receptors	NOUN	O	O	2803
to	PART	O	O	2803
their	PRON	O	O	2803
agonists	NOUN	O	O	2803
.	PUNCT	O	O	2803
A	PRON	O	O	2804
question	NOUN	O	O	2804
arises	VERB	O	O	2804
whether	SCONJ	O	O	2804
the	PRON	O	O	2804
reuptake	PROPN	O	O	2804
inhibition	NOUN	O	O	2804
is	AUX	O	O	2804
of	ADP	O	O	2804
any	PRON	O	O	2804
importance	NOUN	O	O	2804
to	PART	O	O	2804
the	PRON	O	O	2804
adaptive	ADJ	O	O	2804
changes	VERB	O	O	2804
induced	VERB	O	O	2804
by	ADP	O	O	2804
repeated	VERB	O	O	2804
antidepressants	NOUN	O	O	2804
,	PUNCT	O	O	2804
suggested	VERB	O	O	2804
to	PART	O	O	2804
be	AUX	O	O	2804
responsible	ADJ	O	O	2804
for	ADP	O	O	2804
the	PRON	O	O	2804
antidepressant	NOUN	O	O	2804
activity	NOUN	O	O	2804
.	PUNCT	O	O	2804
Ranitidine	NOUN	O	O	2807
-	PUNCT	O	O	2807
induced	VERB	O	O	2807
acute	ADJ	O	O	2807
interstitial nephritis	NOUN	O	Disease	2807
in	ADP	O	O	2807
a	PRON	O	O	2807
cadaveric	ADJ	O	O	2807
renal	ADJ	O	O	2807
allograft	NOUN	O	O	2807
.	PUNCT	O	O	2807
Ranitidine	NOUN	O	O	2808
frequently	ADV	O	O	2808
is	AUX	O	O	2808
used	VERB	O	O	2808
for	ADP	O	O	2808
preventing	VERB	O	O	2808
peptic	ADJ	O	O	2808
ulceration	NOUN	O	O	2808
after	ADP	O	O	2808
renal	ADJ	O	O	2808
transplantation	NOUN	O	O	2808
.	PUNCT	O	O	2808
This	PRON	O	O	2809
drug	NOUN	O	O	2809
occasionally	ADV	O	O	2809
has	VERB	O	O	2809
been	AUX	O	O	2809
associated	VERB	O	O	2809
with	ADP	O	O	2809
acute	ADJ	O	O	2809
interstitial nephritis	NOUN	O	Disease	2809
in	ADP	O	O	2809
native	ADJ	O	O	2809
kidneys	NOUN	O	O	2809
.	PUNCT	O	O	2809
We	PRON	O	O	2810
report	VERB	O	O	2810
a	PRON	O	O	2810
case	NOUN	O	O	2810
of	ADP	O	O	2810
ranitidine	PROPN	O	Chemical	2810
-	PUNCT	O	O	2810
induced	VERB	O	O	2810
acute	ADJ	O	O	2810
interstitial nephritis	NOUN	O	Disease	2810
in	ADP	O	O	2810
a	PRON	O	O	2810
recipient	NOUN	O	O	2810
of	ADP	O	O	2810
a	PRON	O	O	2810
cadaveric	ADJ	O	O	2810
renal	ADJ	O	O	2810
allograft	NOUN	O	O	2810
presenting	VERB	O	O	2810
with	ADP	O	O	2810
acute	ADJ	O	O	2810
allograft	NOUN	O	O	2810
dysfunction	NOUN	O	O	2810
within	ADP	O	O	2810
48	NUM	O	O	2810
hours	NOUN	O	O	2810
of	ADP	O	O	2810
exposure	NOUN	O	O	2810
to	PART	O	O	2810
the	PRON	O	O	2810
drug	NOUN	O	O	2810
.	PUNCT	O	O	2810
Late	ADV	O	O	2813
,	PUNCT	O	O	2813
late	ADV	O	O	2813
doxorubicin	VERB	O	Chemical	2813
cardiotoxicity	NOUN	O	Disease	2813
.	PUNCT	O	O	2813
Cardiac toxicity	NOUN	O	Disease	2814
is	AUX	O	O	2814
a	PRON	O	O	2814
major	ADJ	O	O	2814
complication	NOUN	O	O	2814
which	PRON	O	O	2814
limits	NOUN	O	O	2814
the	PRON	O	O	2814
use	VERB	O	O	2814
of	ADP	O	O	2814
adriamycin	PROPN	O	Chemical	2814
as	ADP	O	O	2814
a	PRON	O	O	2814
chemotherapeutic	NOUN	O	O	2814
agent	NOUN	O	O	2814
.	PUNCT	O	O	2814
Cardiomyopathy	PROPN	O	O	2815
is	AUX	O	O	2815
frequent	ADJ	O	O	2815
when	SCONJ	O	O	2815
the	PRON	O	O	2815
total	ADJ	O	O	2815
dose	NOUN	O	O	2815
exceeds	VERB	O	O	2815
600	NUM	O	O	2815
mg	VERB	O	O	2815
/	PUNCT	O	O	2815
m2	PROPN	O	O	2815
and	CCONJ	O	O	2815
occurs	VERB	O	O	2815
within	ADP	O	O	2815
one	NUM	O	O	2815
to	PART	O	O	2815
six	NUM	O	O	2815
months	NOUN	O	O	2815
after	ADP	O	O	2815
cessation	NOUN	O	O	2815
of	ADP	O	O	2815
therapy	NOUN	O	O	2815
.	PUNCT	O	O	2815
A	PRON	O	O	2816
patient	NOUN	O	O	2816
is	AUX	O	O	2816
reported	VERB	O	O	2816
who	PRON	O	O	2816
developed	VERB	O	O	2816
progressive	ADJ	O	O	2816
cardiomyopathy	ADJ	O	Disease	2816
two	NUM	O	O	2816
and	CCONJ	O	O	2816
one	NUM	O	O	2816
-	PUNCT	O	O	2816
half	NOUN	O	O	2816
years	NOUN	O	O	2816
after	ADP	O	O	2816
receiving	VERB	O	O	2816
580	NUM	O	O	2816
mg	VERB	O	O	2816
/	PUNCT	O	O	2816
m2	PROPN	O	O	2816
which	PRON	O	O	2816
apparently	ADV	O	O	2816
represents	VERB	O	O	2816
late	ADV	O	O	2816
,	PUNCT	O	O	2816
late	ADV	O	O	2816
cardiotoxicity	NOUN	O	Disease	2816
.	PUNCT	O	O	2816
Acetazolamide	NOUN	O	Chemical	2819
-	PUNCT	O	O	2819
induced	VERB	O	O	2819
nephrolithiasis	NOUN	O	Disease	2819
:	PUNCT	O	O	2819
implications	NOUN	O	O	2819
for	ADP	O	O	2819
treatment	NOUN	O	O	2819
of	ADP	O	O	2819
neuromuscular	ADJ	O	O	2819
disorders	NOUN	O	O	2819
.	PUNCT	O	O	2819
Carbonic	PROPN	O	O	2820
anhydrase	NOUN	O	O	2820
inhibitors	NOUN	O	O	2820
can	AUX	O	O	2820
cause	VERB	O	O	2820
nephrolithiasis	NOUN	O	Disease	2820
.	PUNCT	O	O	2820
We	PRON	O	O	2821
studied	VERB	O	O	2821
20	NUM	O	O	2821
patients	NOUN	O	O	2821
receiving	VERB	O	O	2821
long	ADV	O	O	2821
-	PUNCT	O	O	2821
term	NOUN	O	O	2821
carbonic	ADJ	O	O	2821
anhydrase	NOUN	O	O	2821
inhibitor	NOUN	O	O	2821
treatment	NOUN	O	O	2821
for	ADP	O	O	2821
periodic	ADJ	O	O	2821
paralysis	NOUN	O	Disease	2821
and	CCONJ	O	O	2821
myotonia	NOUN	O	O	2821
.	PUNCT	O	O	2821
Three	NUM	O	O	2822
patients	NOUN	O	O	2822
on	ADP	O	O	2822
acetazolamide	PROPN	O	Chemical	2822
(	PUNCT	O	O	2822
15%	NOUN	O	O	2822
)	PUNCT	O	O	2822
developed	VERB	O	O	2822
renal	ADJ	O	O	2822
calculi	NOUN	O	O	2822
.	PUNCT	O	O	2822
Extracorporeal	VERB	O	O	2823
lithotripsy	NOUN	O	O	2823
successfully	ADV	O	O	2823
removed	VERB	O	O	2823
a	PRON	O	O	2823
renal	ADJ	O	O	2823
calculus	PROPN	O	O	2823
in	ADP	O	O	2823
one	NUM	O	O	2823
patient	NOUN	O	O	2823
and	CCONJ	O	O	2823
surgery	NOUN	O	O	2823
removed	VERB	O	O	2823
a	PRON	O	O	2823
staghorn	ADJ	O	O	2823
calculus	PROPN	O	O	2823
in	ADP	O	O	2823
another	PRON	O	O	2823
,	PUNCT	O	O	2823
permitting	VERB	O	O	2823
continued	VERB	O	O	2823
treatment	NOUN	O	O	2823
.	PUNCT	O	O	2823
Nephrolithiasis	NOUN	O	O	2824
is	AUX	O	O	2824
a	PRON	O	O	2824
complication	NOUN	O	O	2824
of	ADP	O	O	2824
acetazolamide	PROPN	O	Chemical	2824
but	CCONJ	O	O	2824
does	VERB	O	O	2824
not	PART	O	O	2824
preclude	VERB	O	O	2824
its	PRON	O	O	2824
use	VERB	O	O	2824
.	PUNCT	O	O	2824
Is	AUX	O	O	2827
the	PRON	O	O	2827
treatment	NOUN	O	O	2827
of	ADP	O	O	2827
scabies	NOUN	O	O	2827
hazardous	ADJ	O	O	2827
?	PUNCT	O	O	2827
Treatment	NOUN	O	O	2828
for	ADP	O	O	2828
scabies	NOUN	O	O	2828
is	AUX	O	O	2828
usually	ADV	O	O	2828
initiated	VERB	O	O	2828
by	ADP	O	O	2828
general	ADJ	O	O	2828
practitioners	NOUN	O	O	2828
;	PUNCT	O	O	2828
most	ADV	O	O	2828
consider	VERB	O	O	2828
lindane	NOUN	O	Chemical	2828
(	PUNCT	O	O	2828
gamma	PROPN	O	O	2828
benzene	PROPN	O	O	2828
hexachloride	NOUN	O	O	2828
)	PUNCT	O	O	2828
the	PRON	O	O	2828
treatment	NOUN	O	O	2828
of	ADP	O	O	2828
choice	NOUN	O	O	2828
.	PUNCT	O	O	2828
Lindane	NOUN	O	O	2829
is	AUX	O	O	2829
also	ADV	O	O	2829
widely	ADV	O	O	2829
used	VERB	O	O	2829
as	ADP	O	O	2829
an	PRON	O	O	2829
agricultural	ADJ	O	O	2829
and	CCONJ	O	O	2829
industrial	ADJ	O	O	2829
pesticide	NOUN	O	O	2829
,	PUNCT	O	O	2829
and	CCONJ	O	O	2829
as	ADP	O	O	2829
a	PRON	O	O	2829
result	VERB	O	O	2829
the	PRON	O	O	2829
toxic	ADJ	O	O	2829
profile	NOUN	O	O	2829
of	ADP	O	O	2829
this	PRON	O	O	2829
insecticide	NOUN	O	O	2829
is	AUX	O	O	2829
well	ADV	O	O	2829
understood	VERB	O	O	2829
.	PUNCT	O	O	2829
Evidence	NOUN	O	O	2830
is	AUX	O	O	2830
accumulating	VERB	O	O	2830
that	SCONJ	O	O	2830
lindane	NOUN	O	Chemical	2830
can	AUX	O	O	2830
be	AUX	O	O	2830
toxic	ADJ	O	O	2830
to	PART	O	O	2830
the	PRON	O	O	2830
central	ADJ	O	O	2830
nervous	ADJ	O	O	2830
system	NOUN	O	O	2830
and	CCONJ	O	O	2830
may	AUX	O	O	2830
be	AUX	O	O	2830
associated	VERB	O	O	2830
with	ADP	O	O	2830
aplastic	ADJ	O	O	2830
anaemia	NOUN	O	Disease	2830
.	PUNCT	O	O	2830
Preparations	NOUN	O	O	2831
containing	VERB	O	O	2831
lindane	NOUN	O	Chemical	2831
continue	VERB	O	O	2831
to	PART	O	O	2831
be	AUX	O	O	2831
sold	VERB	O	O	2831
over	ADP	O	O	2831
the	PRON	O	O	2831
counter	VERB	O	O	2831
and	CCONJ	O	O	2831
may	AUX	O	O	2831
represent	VERB	O	O	2831
a	PRON	O	O	2831
hazard	NOUN	O	O	2831
to	PART	O	O	2831
poorly	ADV	O	O	2831
informed	VERB	O	O	2831
patients	NOUN	O	O	2831
.	PUNCT	O	O	2831
This	PRON	O	O	2832
literature	NOUN	O	O	2832
review	VERB	O	O	2832
suggests	VERB	O	O	2832
that	SCONJ	O	O	2832
general	ADJ	O	O	2832
practitioners	NOUN	O	O	2832
should	AUX	O	O	2832
prescribe	VERB	O	O	2832
scabicides	VERB	O	O	2832
with	ADP	O	O	2832
increased	VERB	O	O	2832
caution	NOUN	O	O	2832
for	ADP	O	O	2832
certain	ADJ	O	O	2832
at	ADP	O	O	2832
-	PUNCT	O	O	2832
risk	NOUN	O	O	2832
groups	NOUN	O	O	2832
,	PUNCT	O	O	2832
and	CCONJ	O	O	2832
give	VERB	O	O	2832
adequate	ADJ	O	O	2832
warnings	NOUN	O	O	2832
regarding	VERB	O	O	2832
potential	ADJ	O	O	2832
toxicity	NOUN	O	Disease	2832
.	PUNCT	O	O	2832
Anaesthetists	NOUN	O	O	2835
'	PUNCT	O	O	2835
nightmare	NOUN	O	O	2835
:	PUNCT	O	O	2835
masseter	PROPN	O	O	2835
spasm	NOUN	O	Disease	2835
after	ADP	O	O	2835
induction	NOUN	O	O	2835
in	ADP	O	O	2835
an	PRON	O	O	2835
undiagnosed	ADJ	O	O	2835
case	NOUN	O	O	2835
of	ADP	O	O	2835
myotonia	NOUN	O	O	2835
congenita	NOUN	O	O	2835
.	PUNCT	O	O	2835
We	PRON	O	O	2836
report	VERB	O	O	2836
an	PRON	O	O	2836
undiagnosed	ADJ	O	O	2836
case	NOUN	O	O	2836
of	ADP	O	O	2836
myotonia	NOUN	O	O	2836
congenita	NOUN	O	O	2836
in	ADP	O	O	2836
a	PRON	O	O	2836
24-year	NOUN	O	O	2836
-	PUNCT	O	O	2836
old	ADJ	O	O	2836
previously	ADV	O	O	2836
healthy	ADJ	O	O	2836
primigravida	PROPN	O	O	2836
,	PUNCT	O	O	2836
who	PRON	O	O	2836
developed	VERB	O	O	2836
life	NOUN	O	O	2836
threatening	VERB	O	O	2836
masseter	PROPN	O	O	2836
spasm	NOUN	O	Disease	2836
following	VERB	O	O	2836
a	PRON	O	O	2836
standard	PROPN	O	O	2836
dose	NOUN	O	O	2836
of	ADP	O	O	2836
intravenous	ADJ	O	O	2836
suxamethonium	NOUN	O	O	2836
for	ADP	O	O	2836
induction	NOUN	O	O	2836
of	ADP	O	O	2836
anaesthesia	NOUN	O	O	2836
.	PUNCT	O	O	2836
Toxicity	NOUN	O	Disease	2839
in	ADP	O	O	2839
rhesus	NOUN	O	O	2839
monkeys	NOUN	O	O	2839
following	VERB	O	O	2839
administration	NOUN	O	O	2839
of	ADP	O	O	2839
the	PRON	O	O	2839
8-aminoquinoline	NOUN	O	O	2839
8-[(4-amino	NOUN	O	O	2840
-	PUNCT	O	O	2840
l	X	O	O	2840
-	PUNCT	O	O	2840
methylbutyl)amino]-	VERB	O	O	2840
5-(l	PUNCT	O	O	2840
-	PUNCT	O	O	2840
hexyloxy)-6-methoxy-4-methylquinoline	NOUN	O	O	2840
(	PUNCT	O	O	2840
WR242511	NOUN	O	O	2840
)	PUNCT	O	O	2840
.	PUNCT	O	O	2840
INTRODUCTION	NOUN	O	O	2841
:	PUNCT	O	O	2841
Many	ADJ	O	O	2841
substances	NOUN	O	O	2841
that	SCONJ	O	O	2841
form	NOUN	O	O	2841
methemoglobin	ADV	O	O	2841
(	PUNCT	O	O	2841
MHb	VERB	O	O	2841
)	PUNCT	O	O	2841
effectively	ADV	O	O	2841
counter	VERB	O	O	2841
cyanide	NOUN	O	O	2841
(	PUNCT	O	O	2841
CN	PROPN	O	O	2841
)	PUNCT	O	O	2841
toxicity	NOUN	O	Disease	2841
.	PUNCT	O	O	2841
Although	SCONJ	O	O	2842
MHb	VERB	O	O	2842
formers	NOUN	O	O	2842
are	AUX	O	O	2842
generally	ADV	O	O	2842
applied	VERB	O	O	2842
as	ADP	O	O	2842
treatments	NOUN	O	O	2842
for	ADP	O	O	2842
CN	PROPN	O	O	2842
poisoning	VERB	O	O	2842
,	PUNCT	O	O	2842
it	PRON	O	O	2842
has	VERB	O	O	2842
been	AUX	O	O	2842
proposed	VERB	O	O	2842
that	SCONJ	O	O	2842
a	PRON	O	O	2842
stable	ADJ	O	O	2842
,	PUNCT	O	O	2842
long	ADV	O	O	2842
-	PUNCT	O	O	2842
acting	VERB	O	O	2842
MHb	VERB	O	O	2842
former	ADJ	O	O	2842
could	AUX	O	O	2842
serve	VERB	O	O	2842
as	ADP	O	O	2842
a	PRON	O	O	2842
CN	PROPN	O	O	2842
pretreatment	NOUN	O	O	2842
.	PUNCT	O	O	2842
Using	VERB	O	O	2843
this	PRON	O	O	2843
rationale	NOUN	O	O	2843
,	PUNCT	O	O	2843
the	PRON	O	O	2843
8-aminoquinoline	NOUN	O	O	2843
WR242511	NOUN	O	O	2843
,	PUNCT	O	O	2843
a	PRON	O	O	2843
potent	ADJ	O	O	2843
long	ADV	O	O	2843
-	PUNCT	O	O	2843
lasting	VERB	O	O	2843
MHb	VERB	O	O	2843
former	ADJ	O	O	2843
in	ADP	O	O	2843
rodents	NOUN	O	O	2843
and	CCONJ	O	O	2843
beagle	PROPN	O	O	2843
dogs	NOUN	O	O	2843
,	PUNCT	O	O	2843
was	AUX	O	O	2843
studied	VERB	O	O	2843
in	ADP	O	O	2843
the	PRON	O	O	2843
rhesus	NOUN	O	O	2843
monkey	NOUN	O	O	2843
for	ADP	O	O	2843
advanced	ADJ	O	O	2843
development	NOUN	O	O	2843
as	ADP	O	O	2843
a	PRON	O	O	2843
potential	ADJ	O	O	2843
CN	PROPN	O	O	2843
pretreatment	NOUN	O	O	2843
.	PUNCT	O	O	2843
METHODS	NOUN	O	O	2844
:	PUNCT	O	O	2844
In	ADP	O	O	2844
this	PRON	O	O	2844
study	VERB	O	O	2844
,	PUNCT	O	O	2844
WR242511	NOUN	O	O	2844
was	AUX	O	O	2844
administered	VERB	O	O	2844
intravenously	ADV	O	O	2844
(	PUNCT	O	O	2844
IV	NUM	O	O	2844
)	PUNCT	O	O	2844
in	ADP	O	O	2844
2	X	O	O	2844
female	ADJ	O	O	2844
and	CCONJ	O	O	2844
4	NUM	O	O	2844
male	NOUN	O	O	2844
rhesus	NOUN	O	O	2844
monkeys	NOUN	O	O	2844
in	ADP	O	O	2844
doses	NOUN	O	O	2844
of	ADP	O	O	2844
3.5	NUM	O	O	2844
and/or	CCONJ	O	O	2844
7.0	X	O	O	2844
mg	VERB	O	O	2844
/	PUNCT	O	O	2844
kg	VERB	O	O	2844
;	PUNCT	O	O	2844
a	PRON	O	O	2844
single	ADJ	O	O	2844
male	NOUN	O	O	2844
also	ADV	O	O	2844
received	VERB	O	O	2844
WR242511	NOUN	O	O	2844
orally	ADV	O	O	2844
(	PUNCT	O	O	2844
PO	NOUN	O	O	2844
)	PUNCT	O	O	2844
at	ADP	O	O	2844
7.0	X	O	O	2844
mg	VERB	O	O	2844
/	PUNCT	O	O	2844
kg	VERB	O	O	2844
.	PUNCT	O	O	2844
The	PRON	O	O	2845
selected	VERB	O	O	2845
doses	NOUN	O	O	2845
of	ADP	O	O	2845
WR242511	NOUN	O	O	2845
,	PUNCT	O	O	2845
which	PRON	O	O	2845
produced	VERB	O	O	2845
significant	ADJ	O	O	2845
methemoglobinemia	NOUN	O	O	2845
in	ADP	O	O	2845
beagle	PROPN	O	O	2845
dogs	NOUN	O	O	2845
in	ADP	O	O	2845
earlier	ADV	O	O	2845
studies	NOUN	O	O	2845
conducted	VERB	O	O	2845
elsewhere	ADV	O	O	2845
,	PUNCT	O	O	2845
produced	VERB	O	O	2845
very	ADV	O	O	2845
little	ADJ	O	O	2845
MHb	VERB	O	O	2845
(	PUNCT	O	O	2845
mean	VERB	O	O	2845
<	X	O	O	2845
2.0%	NOUN	O	O	2845
)	PUNCT	O	O	2845
in	ADP	O	O	2845
the	PRON	O	O	2845
rhesus	NOUN	O	O	2845
monkey	NOUN	O	O	2845
.	PUNCT	O	O	2845
Furthermore	ADV	O	O	2846
,	PUNCT	O	O	2846
transient	ADJ	O	O	2846
hemoglobinuria	PROPN	O	O	2846
was	AUX	O	O	2846
noted	VERB	O	O	2846
approximately	ADV	O	O	2846
60	NUM	O	O	2846
minutes	NOUN	O	O	2846
postinjection	NOUN	O	O	2846
of	ADP	O	O	2846
WR242511	NOUN	O	O	2846
(	PUNCT	O	O	2846
3.5	NUM	O	O	2846
or	CCONJ	O	O	2846
7.0	X	O	O	2846
mg	VERB	O	O	2846
/	PUNCT	O	O	2846
kg	VERB	O	O	2846
)	PUNCT	O	O	2846
,	PUNCT	O	O	2846
and	CCONJ	O	O	2846
2	X	O	O	2846
lethalities	NOUN	O	O	2846
occurred	VERB	O	O	2846
(	PUNCT	O	O	2846
one	NUM	O	O	2846
IV	NUM	O	O	2846
and	CCONJ	O	O	2846
one	NUM	O	O	2846
PO	NOUN	O	O	2846
)	PUNCT	O	O	2846
following	VERB	O	O	2846
the	PRON	O	O	2846
7.0	X	O	O	2846
mg	VERB	O	O	2846
/	PUNCT	O	O	2846
kg	VERB	O	O	2846
dose	NOUN	O	O	2846
.	PUNCT	O	O	2846
Myoglobinuria	PROPN	O	O	2847
was	AUX	O	O	2847
also	ADV	O	O	2847
observed	VERB	O	O	2847
following	VERB	O	O	2847
the	PRON	O	O	2847
7.0	X	O	O	2847
mg	VERB	O	O	2847
/	PUNCT	O	O	2847
kg	VERB	O	O	2847
dose	NOUN	O	O	2847
.	PUNCT	O	O	2847
Histopathology	NOUN	O	O	2848
analyses	NOUN	O	O	2848
in	ADP	O	O	2848
the	PRON	O	O	2848
2	X	O	O	2848
animals	NOUN	O	O	2848
that	SCONJ	O	O	2848
died	VERB	O	O	2848
revealed	VERB	O	O	2848
liver	NOUN	O	O	2848
and	CCONJ	O	O	2848
kidney	NOUN	O	O	2848
toxicity	NOUN	O	Disease	2848
,	PUNCT	O	O	2848
with	ADP	O	O	2848
greater	ADJ	O	O	2848
severity	NOUN	O	O	2848
in	ADP	O	O	2848
the	PRON	O	O	2848
orally	ADV	O	O	2848
-	PUNCT	O	O	2848
treated	VERB	O	O	2848
animal	NOUN	O	O	2848
.	PUNCT	O	O	2848
These	PRON	O	O	2849
data	NOUN	O	O	2849
demonstrate	VERB	O	O	2849
direct	ADJ	O	O	2849
and/or	CCONJ	O	O	2849
indirect	ADJ	O	O	2849
drug	NOUN	O	O	2849
-	PUNCT	O	O	2849
induced	VERB	O	O	2849
toxicity	NOUN	O	Disease	2849
.	PUNCT	O	O	2849
It	PRON	O	O	2850
is	AUX	O	O	2850
concluded	VERB	O	O	2850
that	SCONJ	O	O	2850
WR242511	NOUN	O	O	2850
should	AUX	O	O	2850
not	PART	O	O	2850
be	AUX	O	O	2850
pursued	VERB	O	O	2850
as	ADP	O	O	2850
a	PRON	O	O	2850
pretreatment	NOUN	O	O	2850
for	ADP	O	O	2850
CN	PROPN	O	O	2850
poisoning	VERB	O	O	2850
unless	SCONJ	O	O	2850
the	PRON	O	O	2850
anti	ADJ	O	O	2850
-	PUNCT	O	O	2850
CN	PROPN	O	O	2850
characteristics	NOUN	O	O	2850
of	ADP	O	O	2850
this	PRON	O	O	2850
compound	NOUN	O	O	2850
can	AUX	O	O	2850
be	AUX	O	O	2850
successfully	ADV	O	O	2850
dissociated	VERB	O	O	2850
from	ADP	O	O	2850
those	PRON	O	O	2850
producing	VERB	O	O	2850
undesirable	ADJ	O	O	2850
toxicity	NOUN	O	Disease	2850
.	PUNCT	O	O	2850
Neuroplasticity	NOUN	O	O	2853
of	ADP	O	O	2853
the	PRON	O	O	2853
adult	NOUN	O	O	2853
primate	NOUN	O	O	2853
auditory	NOUN	O	O	2853
cortex	VERB	O	O	2853
following	VERB	O	O	2853
cochlear	VERB	O	O	2853
hearing loss	NOUN	O	Disease	2853
.	PUNCT	O	O	2853
The	PRON	O	O	2854
purpose	NOUN	O	O	2854
of	ADP	O	O	2854
this	PRON	O	O	2854
study	VERB	O	O	2854
was	AUX	O	O	2854
to	PART	O	O	2854
determine	VERB	O	O	2854
if	SCONJ	O	O	2854
changes	VERB	O	O	2854
occur	VERB	O	O	2854
in	ADP	O	O	2854
this	PRON	O	O	2854
tonotopic	NOUN	O	O	2854
organization	NOUN	O	O	2854
following	VERB	O	O	2854
cochlear	VERB	O	O	2854
hearing loss	NOUN	O	Disease	2854
.	PUNCT	O	O	2854
Following	VERB	O	O	2855
recovery	NOUN	O	O	2855
,	PUNCT	O	O	2855
the	PRON	O	O	2855
monkeys	NOUN	O	O	2855
were	AUX	O	O	2855
selectively	ADV	O	O	2855
deafened	VERB	O	O	2855
for	ADP	O	O	2855
high	ADJ	O	O	2855
frequencies	NOUN	O	O	2855
using	VERB	O	O	2855
kanamycin	VERB	O	Chemical	2855
and	CCONJ	O	O	2855
furosemide	PROPN	O	Chemical	2855
.	PUNCT	O	O	2855
The	PRON	O	O	2856
region	NOUN	O	O	2856
of	ADP	O	O	2856
cortex	VERB	O	O	2856
that	SCONJ	O	O	2856
represents	VERB	O	O	2856
the	PRON	O	O	2856
low	ADJ	O	O	2856
frequencies	NOUN	O	O	2856
was	AUX	O	O	2856
not	PART	O	O	2856
obviously	ADV	O	O	2856
affected	VERB	O	O	2856
by	ADP	O	O	2856
the	PRON	O	O	2856
cochlear	VERB	O	O	2856
hearing loss	NOUN	O	Disease	2856
.	PUNCT	O	O	2856
The	PRON	O	O	2859
site	NOUN	O	O	2859
of	ADP	O	O	2859
common	ADJ	O	O	2859
side	NOUN	O	O	2859
effects	NOUN	O	O	2859
of	ADP	O	O	2859
sumatriptan	PROPN	O	O	2859
.	PUNCT	O	O	2859
Atypical	ADJ	O	O	2860
sensations	NOUN	O	O	2860
following	VERB	O	O	2860
the	PRON	O	O	2860
use	VERB	O	O	2860
of	ADP	O	O	2860
subcutaneous	ADJ	O	O	2860
sumatriptan	PROPN	O	O	2860
are	AUX	O	O	2860
common	ADJ	O	O	2860
,	PUNCT	O	O	2860
but	CCONJ	O	O	2860
of	ADP	O	O	2860
uncertain	ADJ	O	O	2860
origin	NOUN	O	O	2860
.	PUNCT	O	O	2860
Two	NUM	O	O	2861
patients	NOUN	O	O	2861
are	AUX	O	O	2861
presented	VERB	O	O	2861
with	ADP	O	O	2861
tingling	VERB	O	O	2861
or	CCONJ	O	O	2861
burning	VERB	O	O	2861
sensations	NOUN	O	O	2861
limited	VERB	O	O	2861
to	PART	O	O	2861
areas	NOUN	O	O	2861
of	ADP	O	O	2861
heat	NOUN	O	O	2861
exposure	NOUN	O	O	2861
or	CCONJ	O	O	2861
sunburn	NOUN	O	O	2861
.	PUNCT	O	O	2861
Tremor	NOUN	O	O	2864
side	NOUN	O	O	2864
effects	NOUN	O	O	2864
of	ADP	O	O	2864
salbutamol	NOUN	O	Chemical	2864
,	PUNCT	O	O	2864
quantified	VERB	O	O	2864
by	ADP	O	O	2864
a	PRON	O	O	2864
laser	NOUN	O	O	2864
pointer	NOUN	O	O	2864
technique	NOUN	O	O	2864
.	PUNCT	O	O	2864
OBJECTIVE	VERB	O	O	2865
:	PUNCT	O	O	2865
To	PART	O	O	2865
study	VERB	O	O	2865
tremor	NOUN	O	Disease	2865
side	NOUN	O	O	2865
effects	NOUN	O	O	2865
of	ADP	O	O	2865
salbutamol	NOUN	O	Chemical	2865
an	PRON	O	O	2865
easily	ADV	O	O	2865
applicable	ADJ	O	O	2865
,	PUNCT	O	O	2865
quick	ADJ	O	O	2865
and	CCONJ	O	O	2865
low	ADJ	O	O	2865
-	PUNCT	O	O	2865
priced	VERB	O	O	2865
method	NOUN	O	O	2865
is	AUX	O	O	2865
needed	VERB	O	O	2865
.	PUNCT	O	O	2865
METHODS	NOUN	O	O	2866
:	PUNCT	O	O	2866
Tremor	NOUN	O	O	2866
was	AUX	O	O	2866
measured	VERB	O	O	2866
using	VERB	O	O	2866
a	PRON	O	O	2866
laser	NOUN	O	O	2866
pointer	NOUN	O	O	2866
technique	NOUN	O	O	2866
.	PUNCT	O	O	2866
To	PART	O	O	2867
determine	VERB	O	O	2867
sensitivity	NOUN	O	O	2867
we	PRON	O	O	2867
assessed	VERB	O	O	2867
tremor	NOUN	O	Disease	2867
in	ADP	O	O	2867
44	NUM	O	O	2867
patients	NOUN	O	O	2867
with	ADP	O	O	2867
obstructive	ADJ	O	O	2867
lung	NOUN	O	O	2867
disease	PROPN	O	O	2867
after	ADP	O	O	2867
administration	NOUN	O	O	2867
of	ADP	O	O	2867
cumulative	ADJ	O	O	2867
doses	NOUN	O	O	2867
of	ADP	O	O	2867
salbutamol	NOUN	O	Chemical	2867
.	PUNCT	O	O	2867
In	ADP	O	O	2868
another	PRON	O	O	2868
series	PROPN	O	O	2868
of	ADP	O	O	2868
measurements	NOUN	O	O	2868
,	PUNCT	O	O	2868
reproducibility	NOUN	O	O	2868
and	CCONJ	O	O	2868
reference	NOUN	O	O	2868
values	NOUN	O	O	2868
of	ADP	O	O	2868
the	PRON	O	O	2868
tremor	NOUN	O	Disease	2868
was	AUX	O	O	2868
assessed	VERB	O	O	2868
in	ADP	O	O	2868
65	NUM	O	O	2868
healthy	ADJ	O	O	2868
subjects	NOUN	O	O	2868
in	ADP	O	O	2868
three	NUM	O	O	2868
sessions	NOUN	O	O	2868
,	PUNCT	O	O	2868
at	ADP	O	O	2868
9	NUM	O	O	2868
a.m.	ADV	O	O	2868
,	PUNCT	O	O	2868
4	NUM	O	O	2868
p.m.	ADV	O	O	2868
and	CCONJ	O	O	2868
9	NUM	O	O	2868
a.m.	ADV	O	O	2868
,	PUNCT	O	O	2868
respectively	ADV	O	O	2868
,	PUNCT	O	O	2868
1	X	O	O	2868
week	NOUN	O	O	2868
later	ADV	O	O	2868
.	PUNCT	O	O	2868
Postural	ADJ	O	O	2869
tremor	NOUN	O	Disease	2869
was	AUX	O	O	2869
measured	VERB	O	O	2869
with	ADP	O	O	2869
the	PRON	O	O	2869
arm	VERB	O	O	2869
horizontally	ADV	O	O	2869
outstretched	VERB	O	O	2869
rest	VERB	O	O	2869
tremor	NOUN	O	Disease	2869
with	ADP	O	O	2869
the	PRON	O	O	2869
arm	VERB	O	O	2869
supported	VERB	O	O	2869
by	ADP	O	O	2869
an	PRON	O	O	2869
armrest	NOUN	O	O	2869
and	CCONJ	O	O	2869
finally	ADV	O	O	2869
tremor	NOUN	O	Disease	2869
was	AUX	O	O	2869
measured	VERB	O	O	2869
after	ADP	O	O	2869
holding	VERB	O	O	2869
a	PRON	O	O	2869
2-kg	NOUN	O	O	2869
weight	NOUN	O	O	2869
until	ADP	O	O	2869
exhaustion	NOUN	O	O	2869
.	PUNCT	O	O	2869
Tremor	NOUN	O	O	2870
was	AUX	O	O	2870
measured	VERB	O	O	2870
simultaneously	ADV	O	O	2870
by	ADP	O	O	2870
two	NUM	O	O	2870
independent	ADJ	O	O	2870
observers	NOUN	O	O	2870
.	PUNCT	O	O	2870
Salbutamol	PROPN	O	Chemical	2871
significantly	ADV	O	O	2871
increased	VERB	O	O	2871
tremor	NOUN	O	Disease	2871
severity	NOUN	O	O	2871
in	ADP	O	O	2871
patients	NOUN	O	O	2871
in	ADP	O	O	2871
a	PRON	O	O	2871
dose	NOUN	O	O	2871
-	PUNCT	O	O	2871
dependent	ADJ	O	O	2871
way	NOUN	O	O	2871
.	PUNCT	O	O	2871
There	ADV	O	O	2872
was	AUX	O	O	2872
no	PRON	O	O	2872
agreement	NOUN	O	O	2872
between	ADP	O	O	2872
the	PRON	O	O	2872
questionnaire	NOUN	O	O	2872
and	CCONJ	O	O	2872
tremor	NOUN	O	Disease	2872
severity	NOUN	O	O	2872
(	PUNCT	O	O	2872
r	X	O	O	2872
=	PUNCT	O	O	2872
0.093	NUM	O	O	2872
;	PUNCT	O	O	2872
P	NOUN	O	Chemical	2872
=	PUNCT	O	O	2872
0.53	NUM	O	O	2872
)	PUNCT	O	O	2872
.	PUNCT	O	O	2872
Postural	ADJ	O	O	2873
tremor	NOUN	O	Disease	2873
showed	VERB	O	O	2873
no	PRON	O	O	2873
significant	ADJ	O	O	2873
difference	NOUN	O	O	2873
between	ADP	O	O	2873
the	PRON	O	O	2873
first	ADV	O	O	2873
and	CCONJ	O	O	2873
third	ADV	O	O	2873
session	NOUN	O	O	2873
(	PUNCT	O	O	2873
P	NOUN	O	Chemical	2873
=	PUNCT	O	O	2873
0.07	NUM	O	O	2873
)	PUNCT	O	O	2873
.	PUNCT	O	O	2873
Support	NOUN	O	O	2874
of	ADP	O	O	2874
the	PRON	O	O	2874
arm	VERB	O	O	2874
decreased	VERB	O	O	2874
tremor	NOUN	O	Disease	2874
severity	NOUN	O	O	2874
,	PUNCT	O	O	2874
exhaustion	NOUN	O	O	2874
increased	VERB	O	O	2874
tremor	NOUN	O	Disease	2874
severity	NOUN	O	O	2874
significantly	ADV	O	O	2874
.	PUNCT	O	O	2874
DISCUSSION	NOUN	O	O	2875
:	PUNCT	O	O	2875
Quantifying	VERB	O	O	2875
tremor	NOUN	O	Disease	2875
by	ADP	O	O	2875
using	VERB	O	O	2875
an	PRON	O	O	2875
inexpensive	ADJ	O	O	2875
laser	NOUN	O	O	2875
pointer	NOUN	O	O	2875
is	AUX	O	O	2875
,	PUNCT	O	O	2875
with	ADP	O	O	2875
the	PRON	O	O	2875
exception	NOUN	O	O	2875
of	ADP	O	O	2875
children	NOUN	O	O	2875
(	PUNCT	O	O	2875
<	X	O	O	2875
12	NUM	O	O	2875
years	NOUN	O	O	2875
)	PUNCT	O	O	2875
a	PRON	O	O	2875
sensitive	ADJ	O	O	2875
and	CCONJ	O	O	2875
reproducible	ADJ	O	O	2875
method	NOUN	O	O	2875
.	PUNCT	O	O	2875
Increased	VERB	O	O	2878
frequency	NOUN	O	O	2878
of	ADP	O	O	2878
venous thromboembolism	NOUN	O	Disease	2878
with	ADP	O	O	2878
the	PRON	O	O	2878
combination	NOUN	O	O	2878
of	ADP	O	O	2878
docetaxel	VERB	O	O	2878
and	CCONJ	O	O	2878
thalidomide	NOUN	O	Chemical	2878
in	ADP	O	O	2878
patients	NOUN	O	O	2878
with	ADP	O	O	2878
metastatic	ADJ	O	O	2878
androgen	PROPN	O	Chemical	2878
-	PUNCT	O	O	2878
independent	ADJ	O	O	2878
prostate cancer	NOUN	O	Disease	2878
.	PUNCT	O	O	2878
STUDY	NOUN	O	O	2879
OBJECTIVE	VERB	O	O	2879
:	PUNCT	O	O	2879
To	PART	O	O	2879
evaluate	VERB	O	O	2879
the	PRON	O	O	2879
frequency	NOUN	O	O	2879
of	ADP	O	O	2879
venous thromboembolism	NOUN	O	Disease	2879
(	PUNCT	O	O	2879
VTE	PROPN	O	Disease	2879
)	PUNCT	O	O	2879
in	ADP	O	O	2879
patients	NOUN	O	O	2879
with	ADP	O	O	2879
advanced	ADJ	O	O	2879
androgen	PROPN	O	Chemical	2879
-	PUNCT	O	O	2879
independent	ADJ	O	O	2879
prostate cancer	NOUN	O	Disease	2879
who	PRON	O	O	2879
were	AUX	O	O	2879
treated	VERB	O	O	2879
with	ADP	O	O	2879
docetaxel	VERB	O	O	2879
alone	ADV	O	O	2879
or	CCONJ	O	O	2879
in	ADP	O	O	2879
combination	NOUN	O	O	2879
with	ADP	O	O	2879
thalidomide	NOUN	O	Chemical	2879
.	PUNCT	O	O	2879
PATIENTS	NOUN	O	O	2880
:	PUNCT	O	O	2880
Seventy	NUM	O	O	2880
men	NOUN	O	O	2880
,	PUNCT	O	O	2880
aged	ADJ	O	O	2880
50	NUM	O	O	2880
-	PUNCT	O	O	2880
80	NUM	O	O	2880
years	NOUN	O	O	2880
,	PUNCT	O	O	2880
with	ADP	O	O	2880
advanced	ADJ	O	O	2880
androgen	PROPN	O	Chemical	2880
-	PUNCT	O	O	2880
independent	ADJ	O	O	2880
prostate cancer	NOUN	O	Disease	2880
.	PUNCT	O	O	2880
Each	PRON	O	O	2881
patient	NOUN	O	O	2881
received	VERB	O	O	2881
either	ADV	O	O	2881
intravenous	ADJ	O	O	2881
docetaxel	VERB	O	O	2881
30	NUM	O	O	2881
mg	VERB	O	O	2881
/	PUNCT	O	O	2881
m2/week	NOUN	O	O	2881
for	ADP	O	O	2881
3	X	O	O	2881
consecutive	ADJ	O	O	2881
weeks	NOUN	O	O	2881
,	PUNCT	O	O	2881
followed	VERB	O	O	2881
by	ADP	O	O	2881
1	X	O	O	2881
week	NOUN	O	O	2881
off	ADP	O	O	2881
,	PUNCT	O	O	2881
or	CCONJ	O	O	2881
the	PRON	O	O	2881
combination	NOUN	O	O	2881
of	ADP	O	O	2881
continuous	ADJ	O	O	2881
oral	ADJ	O	O	2881
thalidomide	NOUN	O	Chemical	2881
200	NUM	O	O	2881
mg	VERB	O	O	2881
every	PRON	O	O	2881
evening	NOUN	O	O	2881
plus	CCONJ	O	O	2881
the	PRON	O	O	2881
same	ADJ	O	O	2881
docetaxel	VERB	O	O	2881
regimen	NOUN	O	O	2881
.	PUNCT	O	O	2881
This	PRON	O	O	2882
4-week	NOUN	O	O	2882
cycle	PROPN	O	O	2882
was	AUX	O	O	2882
repeated	VERB	O	O	2882
until	ADP	O	O	2882
there	ADV	O	O	2882
was	AUX	O	O	2882
evidence	NOUN	O	O	2882
of	ADP	O	O	2882
excessive	ADJ	O	O	2882
toxicity	NOUN	O	Disease	2882
or	CCONJ	O	O	2882
disease	PROPN	O	O	2882
progression	NOUN	O	O	2882
.	PUNCT	O	O	2882
MEASUREMENTS	NOUN	O	O	2883
AND	CCONJ	O	O	2883
MAIN	PROPN	O	O	2883
RESULTS	VERB	O	O	2883
:	PUNCT	O	O	2883
None	NOUN	O	O	2883
of	ADP	O	O	2883
23	NUM	O	O	2883
patients	NOUN	O	O	2883
who	PRON	O	O	2883
received	VERB	O	O	2883
docetaxel	VERB	O	O	2883
alone	ADV	O	O	2883
developed	VERB	O	O	2883
VTE	PROPN	O	Disease	2883
,	PUNCT	O	O	2883
whereas	SCONJ	O	O	2883
9	NUM	O	O	2883
of	ADP	O	O	2883
47	NUM	O	O	2883
patients	NOUN	O	O	2883
(	PUNCT	O	O	2883
19%	NOUN	O	O	2883
)	PUNCT	O	O	2883
who	PRON	O	O	2883
received	VERB	O	O	2883
docetaxel	VERB	O	O	2883
plus	CCONJ	O	O	2883
thalidomide	NOUN	O	Chemical	2883
developed	VERB	O	O	2883
VTE	PROPN	O	Disease	2883
(	PUNCT	O	O	2883
p=0.025	ADP	O	O	2883
)	PUNCT	O	O	2883
.	PUNCT	O	O	2883
The	PRON	O	O	2884
addition	NOUN	O	O	2884
of	ADP	O	O	2884
thalidomide	NOUN	O	Chemical	2884
to	PART	O	O	2884
docetaxel	VERB	O	O	2884
in	ADP	O	O	2884
the	PRON	O	O	2884
treatment	NOUN	O	O	2884
of	ADP	O	O	2884
prostate cancer	NOUN	O	Disease	2884
significantly	ADV	O	O	2884
increases	VERB	O	O	2884
the	PRON	O	O	2884
frequency	NOUN	O	O	2884
of	ADP	O	O	2884
VTE	PROPN	O	Disease	2884
.	PUNCT	O	O	2884
Clinicians	NOUN	O	O	2885
should	AUX	O	O	2885
be	AUX	O	O	2885
aware	ADJ	O	O	2885
of	ADP	O	O	2885
this	PRON	O	O	2885
potential	ADJ	O	O	2885
complication	NOUN	O	O	2885
when	SCONJ	O	O	2885
adding	VERB	O	O	2885
thalidomide	NOUN	O	Chemical	2885
to	PART	O	O	2885
chemotherapeutic	NOUN	O	O	2885
regimens	NOUN	O	O	2885
.	PUNCT	O	O	2885
Sublingual	PROPN	O	O	2888
absorption	NOUN	O	O	2888
of	ADP	O	O	2888
the	PRON	O	O	2888
quaternary	ADJ	O	O	2888
ammonium	NOUN	O	O	2888
antiarrhythmic	PROPN	O	O	2888
agent	NOUN	O	O	2888
,	PUNCT	O	O	2888
UM-272	NOUN	O	O	2888
.	PUNCT	O	O	2888
UM-272	NOUN	O	O	2889
(	PUNCT	O	O	2889
N	NUM	O	O	2889
,	PUNCT	O	O	2889
N	NUM	O	O	2889
-	PUNCT	O	O	2889
dimethylpropranolol	PROPN	O	O	2889
)	PUNCT	O	O	2889
,	PUNCT	O	O	2889
a	PRON	O	O	2889
quaternary	ADJ	O	O	2889
antiarrhythmic	PROPN	O	O	2889
agent	NOUN	O	O	2889
,	PUNCT	O	O	2889
was	AUX	O	O	2889
administered	VERB	O	O	2889
sublingually	ADV	O	O	2889
to	PART	O	O	2889
dogs	NOUN	O	O	2889
with	ADP	O	O	2889
ouabain	PROPN	O	Chemical	2889
-	PUNCT	O	O	2889
induced	VERB	O	O	2889
ventricular tachycardias	NOUN	O	O	2889
.	PUNCT	O	O	2889
Sublingual	PROPN	O	O	2890
UM-272	NOUN	O	O	2890
converted	VERB	O	O	2890
ventricular tachycardia	NOUN	O	Disease	2890
to	PART	O	O	2890
sinus	NOUN	O	O	2890
rhythm	VERB	O	O	2890
in	ADP	O	O	2890
all	PRON	O	O	2890
5	NUM	O	O	2890
dogs	NOUN	O	O	2890
.	PUNCT	O	O	2890
Severe	ADJ	O	O	2893
thrombocytopenia	PROPN	O	Disease	2893
and	CCONJ	O	O	2893
haemolytic	ADJ	O	O	2893
anaemia	NOUN	O	Disease	2893
associated	VERB	O	O	2893
with	ADP	O	O	2893
ciprofloxacin	VERB	O	Chemical	2893
:	PUNCT	O	O	2893
a	PRON	O	O	2893
case	NOUN	O	O	2893
report	VERB	O	O	2893
with	ADP	O	O	2893
fatal	ADJ	O	O	2893
outcome	NOUN	O	O	2893
.	PUNCT	O	O	2893
Haematological	PROPN	O	O	2894
adverse	ADJ	O	O	2894
reactions	NOUN	O	O	2894
associated	VERB	O	O	2894
with	ADP	O	O	2894
fatal	ADJ	O	O	2894
outcome	NOUN	O	O	2894
are	AUX	O	O	2894
rare	ADJ	O	O	2894
during	ADP	O	O	2894
treatment	NOUN	O	O	2894
with	ADP	O	O	2894
ciprofloxacin	VERB	O	Chemical	2894
.	PUNCT	O	O	2894
A	PRON	O	O	2895
30-year	NOUN	O	O	2895
old	ADJ	O	O	2895
Caucasian	ADJ	O	O	2895
man	NOUN	O	O	2895
reported	VERB	O	O	2895
with	ADP	O	O	2895
abdominal pain	NOUN	O	Disease	2895
and	CCONJ	O	O	2895
jaundice	NOUN	O	Disease	2895
after	ADP	O	O	2895
3-day	NOUN	O	O	2895
administration	NOUN	O	O	2895
of	ADP	O	O	2895
oral	ADJ	O	O	2895
ciprofloxacin	VERB	O	Chemical	2895
for	ADP	O	O	2895
a	PRON	O	O	2895
suspect	VERB	O	O	2895
of	ADP	O	O	2895
urinary	ADJ	O	O	2895
tract	NOUN	O	O	2895
infection	NOUN	O	Disease	2895
.	PUNCT	O	O	2895
Clinical	NOUN	O	O	2896
evaluations	NOUN	O	O	2896
suggested	VERB	O	O	2896
an	PRON	O	O	2896
initial	ADJ	O	O	2896
diagnosis	NOUN	O	O	2896
of	ADP	O	O	2896
severe	ADJ	O	O	2896
thrombocytopenia	PROPN	O	Disease	2896
and	CCONJ	O	O	2896
haemolysis	NOUN	O	O	2896
.	PUNCT	O	O	2896
The	PRON	O	O	2897
patient	NOUN	O	O	2897
progressively	ADV	O	O	2897
developed	VERB	O	O	2897
petechiae	VERB	O	O	2897
and	CCONJ	O	O	2897
purpura	NOUN	O	Disease	2897
on	ADP	O	O	2897
thorax	NOUN	O	O	2897
and	CCONJ	O	O	2897
lower	ADJ	O	O	2897
limbs	NOUN	O	O	2897
.	PUNCT	O	O	2897
An	PRON	O	O	2898
accurate	ADJ	O	O	2898
autopsy	ADJ	O	O	2898
revealed	VERB	O	O	2898
most	ADV	O	O	2898
organs	NOUN	O	O	2898
with	ADP	O	O	2898
diffuse	VERB	O	O	2898
petechial	NOUN	O	O	2898
haemorrhages	VERB	O	O	2898
.	PUNCT	O	O	2898
No	PRON	O	O	2899
signs	NOUN	O	O	2899
of	ADP	O	O	2899
bone	NOUN	O	O	2899
marrow	PROPN	O	O	2899
depression	PROPN	O	Disease	2899
were	AUX	O	O	2899
found	VERB	O	O	2899
.	PUNCT	O	O	2899
No	PRON	O	O	2900
thrombi	NOUN	O	Disease	2900
or	CCONJ	O	O	2900
signs	NOUN	O	O	2900
of	ADP	O	O	2900
microangiopathies	VERB	O	O	2900
were	AUX	O	O	2900
observed	VERB	O	O	2900
in	ADP	O	O	2900
arterial	ADJ	O	O	2900
vessels	NOUN	O	O	2900
.	PUNCT	O	O	2900
This	PRON	O	O	2901
case	NOUN	O	O	2901
report	VERB	O	O	2901
shows	VERB	O	O	2901
that	SCONJ	O	O	2901
ciprofloxacin	VERB	O	Chemical	2901
may	AUX	O	O	2901
precipitate	VERB	O	O	2901
life	NOUN	O	O	2901
-	PUNCT	O	O	2901
threatening	VERB	O	O	2901
thrombocytopenia	PROPN	O	Disease	2901
and	CCONJ	O	O	2901
haemolytic	ADJ	O	O	2901
anaemia	NOUN	O	Disease	2901
,	PUNCT	O	O	2901
even	ADV	O	O	2901
in	ADP	O	O	2901
the	PRON	O	O	2901
early	ADV	O	O	2901
phases	NOUN	O	O	2901
of	ADP	O	O	2901
treatment	NOUN	O	O	2901
and	CCONJ	O	O	2901
without	ADP	O	O	2901
apparent	ADJ	O	O	2901
previous	ADJ	O	O	2901
exposures	NOUN	O	O	2901
.	PUNCT	O	O	2901
Simvastatin	PROPN	O	O	2904
-	PUNCT	O	O	2904
induced	VERB	O	O	2904
bilateral	ADJ	O	O	2904
leg	NOUN	O	O	2904
compartment	NOUN	O	O	2904
syndrome	NOUN	O	O	2904
and	CCONJ	O	O	2904
myonecrosis	PROPN	O	O	2904
associated	VERB	O	O	2904
with	ADP	O	O	2904
hypothyroidism	PROPN	O	Disease	2904
.	PUNCT	O	O	2904
A	PRON	O	O	2905
54-year	NOUN	O	O	2905
-	PUNCT	O	O	2905
old	ADJ	O	O	2905
hypothyroid	PROPN	O	Disease	2905
male	NOUN	O	O	2905
taking	VERB	O	O	2905
thyroxine	NOUN	O	Chemical	2905
and	CCONJ	O	O	2905
simvastatin	PROPN	O	Chemical	2905
presented	VERB	O	O	2905
with	ADP	O	O	2905
bilateral	ADJ	O	O	2905
leg	NOUN	O	O	2905
compartment	NOUN	O	O	2905
syndrome	NOUN	O	O	2905
and	CCONJ	O	O	2905
myonecrosis	PROPN	O	O	2905
.	PUNCT	O	O	2905
Urgent	PROPN	O	O	2906
fasciotomies	VERB	O	O	2906
were	AUX	O	O	2906
performed	VERB	O	O	2906
and	CCONJ	O	O	2906
the	PRON	O	O	2906
patient	NOUN	O	O	2906
made	VERB	O	O	2906
an	PRON	O	O	2906
uneventful	ADJ	O	O	2906
recovery	NOUN	O	O	2906
with	ADP	O	O	2906
the	PRON	O	O	2906
withdrawal	NOUN	O	O	2906
of	ADP	O	O	2906
simvastatin	PROPN	O	Chemical	2906
.	PUNCT	O	O	2906
It	PRON	O	O	2907
is	AUX	O	O	2907
likely	ADV	O	O	2907
that	SCONJ	O	O	2907
this	PRON	O	O	2907
complication	NOUN	O	O	2907
will	AUX	O	O	2907
be	AUX	O	O	2907
seen	VERB	O	O	2907
more	ADJ	O	O	2907
often	ADV	O	O	2907
with	ADP	O	O	2907
the	PRON	O	O	2907
increased	VERB	O	O	2907
worldwide	ADV	O	O	2907
use	VERB	O	O	2907
of	ADP	O	O	2907
this	PRON	O	O	2907
drug	NOUN	O	O	2907
and	CCONJ	O	O	2907
its	PRON	O	O	2907
approval	NOUN	O	O	2907
for	ADP	O	O	2907
all	PRON	O	O	2907
arteriopathic	PROPN	O	O	2907
patients	NOUN	O	O	2907
.	PUNCT	O	O	2907
Bile	NOUN	O	O	2910
duct	NOUN	O	O	2910
hamartoma	VERB	O	Disease	2910
occurring	VERB	O	O	2910
in	ADP	O	O	2910
association	PROPN	O	O	2910
with	ADP	O	O	2910
long	ADV	O	O	2910
-	PUNCT	O	O	2910
term	NOUN	O	O	2910
treatment	NOUN	O	O	2910
with	ADP	O	O	2910
danazol	PROPN	O	O	2910
.	PUNCT	O	O	2910
We	PRON	O	O	2911
report	VERB	O	O	2911
a	PRON	O	O	2911
case	NOUN	O	O	2911
of	ADP	O	O	2911
bile	NOUN	O	O	2911
duct	NOUN	O	O	2911
hamartoma	VERB	O	Disease	2911
which	PRON	O	O	2911
developed	VERB	O	O	2911
in	ADP	O	O	2911
a	PRON	O	O	2911
patient	NOUN	O	O	2911
who	PRON	O	O	2911
had	VERB	O	O	2911
been	AUX	O	O	2911
on	ADP	O	O	2911
long	ADV	O	O	2911
-	PUNCT	O	O	2911
term	NOUN	O	O	2911
danazol	PROPN	O	O	2911
treatment	NOUN	O	O	2911
.	PUNCT	O	O	2911
If	SCONJ	O	O	2912
the	PRON	O	O	2912
patient	NOUN	O	O	2912
develops	VERB	O	O	2912
a	PRON	O	O	2912
liver	NOUN	O	O	2912
mass	PROPN	O	O	2912
,	PUNCT	O	O	2912
because	SCONJ	O	O	2912
of	ADP	O	O	2912
non	ADJ	O	O	2912
-	PUNCT	O	O	2912
specific	ADJ	O	O	2912
clinical	ADJ	O	O	2912
features	VERB	O	O	2912
and	CCONJ	O	O	2912
imaging	VERB	O	O	2912
appearances	NOUN	O	O	2912
,	PUNCT	O	O	2912
biopsy	PROPN	O	O	2912
may	AUX	O	O	2912
be	AUX	O	O	2912
the	PRON	O	O	2912
only	ADV	O	O	2912
way	NOUN	O	O	2912
to	PART	O	O	2912
achieve	VERB	O	O	2912
a	PRON	O	O	2912
definitive	ADJ	O	O	2912
diagnosis	NOUN	O	O	2912
.	PUNCT	O	O	2912
Granulomatous	ADJ	O	O	2915
hepatitis	NOUN	O	Disease	2915
due	ADJ	O	O	2915
to	PART	O	O	2915
combination	NOUN	O	O	2915
of	ADP	O	O	2915
amoxicillin	PROPN	O	O	2915
and	CCONJ	O	O	2915
clavulanic	NOUN	O	O	2915
acid	PROPN	O	O	2915
.	PUNCT	O	O	2915
We	PRON	O	O	2916
report	VERB	O	O	2916
the	PRON	O	O	2916
case	NOUN	O	O	2916
of	ADP	O	O	2916
a	PRON	O	O	2916
patient	NOUN	O	O	2916
with	ADP	O	O	2916
amoxicillin	PROPN	O	O	2916
-	PUNCT	O	O	2916
clavulanic	NOUN	O	O	2916
acid	PROPN	O	O	2916
-	PUNCT	O	O	2916
induced	VERB	O	O	2916
hepatitis	NOUN	O	Disease	2916
with	ADP	O	O	2916
histologic	ADJ	O	O	2916
multiple	ADJ	O	O	2916
granulomas	VERB	O	O	2916
.	PUNCT	O	O	2916
This	PRON	O	O	2917
type	NOUN	O	O	2917
of	ADP	O	O	2917
lesion	NOUN	O	O	2917
broadens	VERB	O	O	2917
the	PRON	O	O	2917
spectrum	NOUN	O	O	2917
of	ADP	O	O	2917
liver injury	NOUN	O	Disease	2917
due	ADJ	O	O	2917
to	PART	O	O	2917
this	PRON	O	O	2917
drug	NOUN	O	O	2917
combination	NOUN	O	O	2917
,	PUNCT	O	O	2917
mainly	ADV	O	O	2917
represented	VERB	O	O	2917
by	ADP	O	O	2917
a	PRON	O	O	2917
benign	ADJ	O	O	2917
cholestatic	ADJ	O	Disease	2917
syndrome	NOUN	O	O	2917
.	PUNCT	O	O	2917
The	PRON	O	O	2918
association	PROPN	O	O	2918
of	ADP	O	O	2918
granulomas	VERB	O	O	2918
and	CCONJ	O	O	2918
eosinophilia	PROPN	O	Disease	2918
favor	NOUN	O	O	2918
an	PRON	O	O	2918
immunoallergic	ADJ	O	O	2918
mechanism	NOUN	O	O	2918
.	PUNCT	O	O	2918
As	ADP	O	O	2919
penicillin	NOUN	O	Chemical	2919
derivatives	NOUN	O	O	2919
and	CCONJ	O	O	2919
amoxicillin	PROPN	O	O	2919
alone	ADV	O	O	2919
are	AUX	O	O	2919
known	VERB	O	O	2919
to	PART	O	O	2919
induce	VERB	O	O	2919
such	ADJ	O	O	2919
types	NOUN	O	O	2919
of	ADP	O	O	2919
lesions	NOUN	O	O	2919
,	PUNCT	O	O	2919
the	PRON	O	O	2919
amoxicillin	PROPN	O	O	2919
component	NOUN	O	O	2919
,	PUNCT	O	O	2919
with	ADP	O	O	2919
or	CCONJ	O	O	2919
without	ADP	O	O	2919
a	PRON	O	O	2919
potentiating	VERB	O	O	2919
effect	VERB	O	O	2919
of	ADP	O	O	2919
clavulanic	NOUN	O	O	2919
acid	PROPN	O	O	2919
,	PUNCT	O	O	2919
might	AUX	O	O	2919
have	VERB	O	O	2919
a	PRON	O	O	2919
major	ADJ	O	O	2919
role	NOUN	O	O	2919
.	PUNCT	O	O	2919
Intracranial	ADJ	O	O	2922
aneurysms	NOUN	O	O	2922
and	CCONJ	O	O	2922
cocaine abuse	NOUN	O	Disease	2922
:	PUNCT	O	O	2922
analysis	NOUN	O	O	2922
of	ADP	O	O	2922
prognostic	ADJ	O	O	2922
indicators	NOUN	O	O	2922
.	PUNCT	O	O	2922
The	PRON	O	O	2923
outcome	NOUN	O	O	2923
of	ADP	O	O	2923
subarachnoid hemorrhage	NOUN	O	Disease	2923
associated	VERB	O	O	2923
with	ADP	O	O	2923
cocaine abuse	NOUN	O	Disease	2923
is	AUX	O	O	2923
reportedly	ADV	O	O	2923
poor	ADJ	O	O	2923
.	PUNCT	O	O	2923
METHODS	NOUN	O	O	2924
:	PUNCT	O	O	2924
A	PRON	O	O	2924
review	VERB	O	O	2924
of	ADP	O	O	2924
admissions	NOUN	O	O	2924
during	ADP	O	O	2924
a	PRON	O	O	2924
6-year	NOUN	O	O	2924
period	NOUN	O	O	2924
revealed	VERB	O	O	2924
14	NUM	O	O	2924
patients	NOUN	O	O	2924
with	ADP	O	O	2924
cocaine	NOUN	O	Chemical	2924
-	PUNCT	O	O	2924
related	ADJ	O	O	2924
aneurysms	NOUN	O	O	2924
.	PUNCT	O	O	2924
This	PRON	O	O	2925
group	NOUN	O	O	2925
was	AUX	O	O	2925
compared	VERB	O	O	2925
with	ADP	O	O	2925
a	PRON	O	O	2925
control	VERB	O	O	2925
group	NOUN	O	O	2925
of	ADP	O	O	2925
135	NUM	O	O	2925
patients	NOUN	O	O	2925
with	ADP	O	O	2925
ruptured	VERB	O	O	2925
aneurysms	NOUN	O	O	2925
and	CCONJ	O	O	2925
no	PRON	O	O	2925
history	NOUN	O	O	2925
of	ADP	O	O	2925
cocaine abuse	NOUN	O	Disease	2925
.	PUNCT	O	O	2925
Age	NOUN	O	O	2926
at	ADP	O	O	2926
presentation	NOUN	O	O	2926
,	PUNCT	O	O	2926
time	NOUN	O	O	2926
of	ADP	O	O	2926
ictus	PROPN	O	O	2926
after	ADP	O	O	2926
intoxication	NOUN	O	O	2926
,	PUNCT	O	O	2926
Hunt	NOUN	O	O	2926
and	CCONJ	O	O	2926
Hess	PROPN	O	O	2926
grade	NOUN	O	O	2926
of	ADP	O	O	2926
subarachnoid hemorrhage	NOUN	O	Disease	2926
,	PUNCT	O	O	2926
size	NOUN	O	O	2926
of	ADP	O	O	2926
the	PRON	O	O	2926
aneurysm	PROPN	O	O	2926
,	PUNCT	O	O	2926
location	NOUN	O	O	2926
of	ADP	O	O	2926
the	PRON	O	O	2926
aneurysm	PROPN	O	O	2926
,	PUNCT	O	O	2926
and	CCONJ	O	O	2926
the	PRON	O	O	2926
Glasgow	PROPN	O	O	2926
Outcome	VERB	O	O	2926
Scale	NOUN	O	O	2926
score	VERB	O	O	2926
were	AUX	O	O	2926
assessed	VERB	O	O	2926
and	CCONJ	O	O	2926
compared	VERB	O	O	2926
.	PUNCT	O	O	2926
In	ADP	O	O	2927
patients	NOUN	O	O	2927
in	ADP	O	O	2927
the	PRON	O	O	2927
study	VERB	O	O	2927
group	NOUN	O	O	2927
,	PUNCT	O	O	2927
all	PRON	O	O	2927
aneurysms	NOUN	O	O	2927
were	AUX	O	O	2927
located	VERB	O	O	2927
in	ADP	O	O	2927
the	PRON	O	O	2927
anterior	PROPN	O	O	2927
circulation	NOUN	O	O	2927
.	PUNCT	O	O	2927
The	PRON	O	O	2928
majority	NOUN	O	O	2928
of	ADP	O	O	2928
these	PRON	O	O	2928
aneurysms	NOUN	O	O	2928
were	AUX	O	O	2928
smaller	ADJ	O	O	2928
than	ADP	O	O	2928
those	PRON	O	O	2928
of	ADP	O	O	2928
the	PRON	O	O	2928
control	VERB	O	O	2928
group	NOUN	O	O	2928
(	PUNCT	O	O	2928
8	NUM	O	O	2928
+	ADP	O	O	2928
/-	PUNCT	O	O	2928
0.007	NUM	O	O	2929
)	PUNCT	O	O	2929
were	AUX	O	O	2929
significant	ADJ	O	O	2929
predictors	NOUN	O	O	2929
of	ADP	O	O	2929
outcome	NOUN	O	O	2929
for	ADP	O	O	2929
the	PRON	O	O	2929
patients	NOUN	O	O	2929
with	ADP	O	O	2929
cocaine	NOUN	O	Chemical	2929
-	PUNCT	O	O	2929
related	ADJ	O	O	2929
aneurysms	NOUN	O	O	2929
.	PUNCT	O	O	2929
CONCLUSION	PROPN	O	O	2930
:	PUNCT	O	O	2930
Cocaine	NOUN	O	Chemical	2930
use	VERB	O	O	2930
predisposed	ADJ	O	O	2930
aneurysmal	VERB	O	Disease	2930
rupture	NOUN	O	Disease	2930
at	ADP	O	O	2930
a	PRON	O	O	2930
significantly	ADV	O	O	2930
earlier	ADV	O	O	2930
age	NOUN	O	O	2930
and	CCONJ	O	O	2930
in	ADP	O	O	2930
much	ADJ	O	O	2930
smaller	ADJ	O	O	2930
aneurysms	NOUN	O	O	2930
.	PUNCT	O	O	2930
Anti	ADJ	O	O	2933
-	PUNCT	O	O	2933
epileptic	ADJ	O	Disease	2933
drugs	NOUN	O	O	2933
-	PUNCT	O	O	2933
induced	VERB	O	O	2933
de	VERB	O	O	2933
novo	PROPN	O	O	2933
absence seizures	NOUN	O	Disease	2933
.	PUNCT	O	O	2933
The	PRON	O	O	2934
authors	NOUN	O	O	2934
present	NOUN	O	O	2934
three	NUM	O	O	2934
patients	NOUN	O	O	2934
with	ADP	O	O	2934
de	VERB	O	O	2934
novo	PROPN	O	O	2934
absence	NOUN	O	O	2934
epilepsy	NOUN	O	Disease	2934
after	ADP	O	O	2934
administration	NOUN	O	O	2934
of	ADP	O	O	2934
carbamazepine	NOUN	O	Chemical	2934
and	CCONJ	O	O	2934
vigabatrin	PROPN	O	Chemical	2934
.	PUNCT	O	O	2934
Despite	SCONJ	O	O	2935
the	PRON	O	O	2935
underlying	VERB	O	O	2935
diseases	NOUN	O	O	2935
,	PUNCT	O	O	2935
the	PRON	O	O	2935
prognosis	VERB	O	O	2935
for	ADP	O	O	2935
drug	NOUN	O	O	2935
-	PUNCT	O	O	2935
induced	VERB	O	O	2935
de	VERB	O	O	2935
novo	PROPN	O	O	2935
absence	NOUN	O	O	2935
seizure	NOUN	O	Disease	2935
is	AUX	O	O	2935
good	ADJ	O	O	2935
because	SCONJ	O	O	2935
it	PRON	O	O	2935
subsides	VERB	O	O	2935
rapidly	ADV	O	O	2935
after	ADP	O	O	2935
discontinuing	VERB	O	O	2935
the	PRON	O	O	2935
use	VERB	O	O	2935
of	ADP	O	O	2935
the	PRON	O	O	2935
offending	VERB	O	O	2935
drugs	NOUN	O	O	2935
.	PUNCT	O	O	2935
The	PRON	O	O	2936
gamma	PROPN	O	O	2936
-	PUNCT	O	O	2936
aminobutyric	PROPN	O	O	2936
acid	PROPN	O	O	2936
-	PUNCT	O	O	2936
transmitted	VERB	O	O	2936
thalamocortical	ADJ	O	O	2936
circuitry	NOUN	O	O	2936
accounts	VERB	O	O	2936
for	ADP	O	O	2936
a	PRON	O	O	2936
major	ADJ	O	O	2936
part	NOUN	O	O	2936
of	ADP	O	O	2936
the	PRON	O	O	2936
underlying	VERB	O	O	2936
neurophysiology	NOUN	O	O	2936
of	ADP	O	O	2936
the	PRON	O	O	2936
absence	NOUN	O	O	2936
epilepsy	NOUN	O	Disease	2936
.	PUNCT	O	O	2936
Because	SCONJ	O	O	2937
drug	NOUN	O	O	2937
-	PUNCT	O	O	2937
induced	VERB	O	O	2937
de	VERB	O	O	2937
novo	PROPN	O	O	2937
absence	NOUN	O	O	2937
seizure	NOUN	O	Disease	2937
is	AUX	O	O	2937
rare	ADJ	O	O	2937
,	PUNCT	O	O	2937
pro	ADJ	O	O	2937
-	PUNCT	O	O	2937
absence	NOUN	O	O	2937
drugs	NOUN	O	O	2937
can	AUX	O	O	2937
only	ADV	O	O	2937
be	AUX	O	O	2937
considered	VERB	O	O	2937
a	PRON	O	O	2937
promoting	VERB	O	O	2937
factor	NOUN	O	O	2937
.	PUNCT	O	O	2937
The	PRON	O	O	2938
underlying	VERB	O	O	2938
epileptogenecity	NOUN	O	O	2938
of	ADP	O	O	2938
the	PRON	O	O	2938
patients	NOUN	O	O	2938
or	CCONJ	O	O	2938
the	PRON	O	O	2938
synergistic	ADJ	O	O	2938
effects	NOUN	O	O	2938
of	ADP	O	O	2938
the	PRON	O	O	2938
accompanying	VERB	O	O	2938
drugs	NOUN	O	O	2938
is	AUX	O	O	2938
required	VERB	O	O	2938
to	PART	O	O	2938
trigger	NOUN	O	O	2938
the	PRON	O	O	2938
de	VERB	O	O	2938
novo	PROPN	O	O	2938
absence	NOUN	O	O	2938
seizure	NOUN	O	Disease	2938
.	PUNCT	O	O	2938
The	PRON	O	O	2939
possibility	NOUN	O	O	2939
of	ADP	O	O	2939
drug	NOUN	O	O	2939
-	PUNCT	O	O	2939
induced	VERB	O	O	2939
aggravation	NOUN	O	O	2939
should	AUX	O	O	2939
be	AUX	O	O	2939
considered	VERB	O	O	2939
whenever	SCONJ	O	O	2939
an	PRON	O	O	2939
unexpected	ADJ	O	O	2939
increase	VERB	O	O	2939
in	ADP	O	O	2939
seizure	NOUN	O	Disease	2939
frequency	NOUN	O	O	2939
and/or	CCONJ	O	O	2939
new	ADJ	O	O	2939
seizure	NOUN	O	Disease	2939
types	NOUN	O	O	2939
appear	VERB	O	O	2939
following	VERB	O	O	2939
a	PRON	O	O	2939
change	VERB	O	O	2939
in	ADP	O	O	2939
drug	NOUN	O	O	2939
treatment	NOUN	O	O	2939
.	PUNCT	O	O	2939
By	ADP	O	O	2940
understanding	NOUN	O	O	2940
the	PRON	O	O	2940
underlying	VERB	O	O	2940
mechanism	NOUN	O	O	2940
of	ADP	O	O	2940
absence	NOUN	O	O	2940
epilepsy	NOUN	O	Disease	2940
,	PUNCT	O	O	2940
we	PRON	O	O	2940
can	AUX	O	O	2940
avoid	VERB	O	O	2940
the	PRON	O	O	2940
inappropriate	ADJ	O	O	2940
use	VERB	O	O	2940
of	ADP	O	O	2940
anticonvulsants	NOUN	O	O	2940
in	ADP	O	O	2940
children	NOUN	O	O	2940
with	ADP	O	O	2940
epilepsy	NOUN	O	Disease	2940
and	CCONJ	O	O	2940
prevent	VERB	O	O	2940
drug	NOUN	O	O	2940
-	PUNCT	O	O	2940
induced	VERB	O	O	2940
absence seizures	NOUN	O	Disease	2940
.	PUNCT	O	O	2940
Procainamide	PROPN	O	O	2943
-	PUNCT	O	O	2943
induced	VERB	O	O	2943
polymorphous	ADJ	O	O	2943
ventricular tachycardia	NOUN	O	Disease	2943
.	PUNCT	O	O	2943
Seven	NUM	O	O	2944
cases	NOUN	O	O	2944
of	ADP	O	O	2944
procainamide	PROPN	O	Chemical	2944
-	PUNCT	O	O	2944
induced	VERB	O	O	2944
polymorphous	ADJ	O	O	2944
ventricular tachycardia	NOUN	O	Disease	2944
are	AUX	O	O	2944
presented	VERB	O	O	2944
.	PUNCT	O	O	2944
In	ADP	O	O	2945
four	NUM	O	O	2945
patients	NOUN	O	O	2945
,	PUNCT	O	O	2945
polymorphous	ADJ	O	O	2945
ventricular tachycardia	NOUN	O	Disease	2945
appeared	VERB	O	O	2945
after	ADP	O	O	2945
intravenous	ADJ	O	O	2945
administration	NOUN	O	O	2945
of	ADP	O	O	2945
200	NUM	O	O	2945
to	PART	O	O	2945
400	NUM	O	O	2945
mg	VERB	O	O	2945
of	ADP	O	O	2945
procainamide	PROPN	O	Chemical	2945
for	ADP	O	O	2945
the	PRON	O	O	2945
treatment	NOUN	O	O	2945
of	ADP	O	O	2945
sustained	VERB	O	O	2945
ventricular tachycardia	NOUN	O	Disease	2945
.	PUNCT	O	O	2945
In	ADP	O	O	2946
the	PRON	O	O	2946
remaining	VERB	O	O	2946
three	NUM	O	O	2946
patients	NOUN	O	O	2946
,	PUNCT	O	O	2946
procainamide	PROPN	O	Chemical	2946
was	AUX	O	O	2946
administered	VERB	O	O	2946
orally	ADV	O	O	2946
for	ADP	O	O	2946
treatment	NOUN	O	O	2946
of	ADP	O	O	2946
chronic	ADJ	O	O	2946
premature ventricular contractions	NOUN	O	Disease	2946
or	CCONJ	O	O	2946
atrial flutter	NOUN	O	Disease	2946
.	PUNCT	O	O	2946
These	PRON	O	O	2947
patients	NOUN	O	O	2947
had	VERB	O	O	2947
Q	NOUN	O	O	2947
-	PUNCT	O	O	2947
T	NOUN	O	Chemical	2947
prolongation	NOUN	O	O	2947
and	CCONJ	O	O	2947
recurrent	ADJ	O	O	2947
syncope	VERB	O	Disease	2947
due	ADJ	O	O	2947
to	PART	O	O	2947
polymorphous	ADJ	O	O	2947
ventricular tachycardia	NOUN	O	Disease	2947
.	PUNCT	O	O	2947
In	ADP	O	O	2948
four	NUM	O	O	2948
patients	NOUN	O	O	2948
,	PUNCT	O	O	2948
the	PRON	O	O	2948
arrhythmia	NOUN	O	Disease	2948
was	AUX	O	O	2948
rapidly	ADV	O	O	2948
diagnosed	VERB	O	O	2948
and	CCONJ	O	O	2948
treated	VERB	O	O	2948
with	ADP	O	O	2948
disappearance	NOUN	O	O	2948
of	ADP	O	O	2948
further	ADV	O	O	2948
episodes	NOUN	O	O	2948
of	ADP	O	O	2948
the	PRON	O	O	2948
arrhythmia	NOUN	O	Disease	2948
.	PUNCT	O	O	2948
In	ADP	O	O	2949
two	NUM	O	O	2949
patients	NOUN	O	O	2949
,	PUNCT	O	O	2949
the	PRON	O	O	2949
arrhythmia	NOUN	O	Disease	2949
degenerated	VERB	O	O	2949
into	ADP	O	O	2949
irreversible	ADJ	O	O	2949
ventricular fibrillation	NOUN	O	Disease	2949
and	CCONJ	O	O	2949
both	PRON	O	O	2949
patients	NOUN	O	O	2949
died	VERB	O	O	2949
.	PUNCT	O	O	2949
In	ADP	O	O	2950
the	PRON	O	O	2950
seventh	ADJ	O	O	2950
patient	NOUN	O	O	2950
,	PUNCT	O	O	2950
a	PRON	O	O	2950
permanent	ADJ	O	O	2950
ventricular	ADJ	O	O	2950
pacemaker	NOUN	O	O	2950
was	AUX	O	O	2950
inserted	VERB	O	O	2950
and	CCONJ	O	O	2950
,	PUNCT	O	O	2950
despite	SCONJ	O	O	2950
continuation	NOUN	O	O	2950
of	ADP	O	O	2950
procainamide	PROPN	O	Chemical	2950
therapy	NOUN	O	O	2950
,	PUNCT	O	O	2950
polymorphous	ADJ	O	O	2950
ventricular tachycardia	NOUN	O	Disease	2950
did	VERB	O	O	2950
not	PART	O	O	2950
reoccur	VERB	O	O	2950
.	PUNCT	O	O	2950
These	PRON	O	O	2951
seven	NUM	O	O	2951
cases	NOUN	O	O	2951
demonstrate	VERB	O	O	2951
that	SCONJ	O	O	2951
procainamide	PROPN	O	Chemical	2951
can	AUX	O	O	2951
produce	VERB	O	O	2951
an	PRON	O	O	2951
acquired	VERB	O	O	2951
prolonged	VERB	O	O	2951
Q	NOUN	O	O	2951
-	PUNCT	O	O	2951
T	NOUN	O	Chemical	2951
syndrome	NOUN	O	O	2951
with	ADP	O	O	2951
polymorphous	ADJ	O	O	2951
ventricular tachycardia	NOUN	O	Disease	2951
.	PUNCT	O	O	2951
Role	NOUN	O	O	2954
of	ADP	O	O	2954
activation	NOUN	O	O	2954
of	ADP	O	O	2954
bradykinin	NOUN	O	O	2954
B2	NOUN	O	O	2954
receptors	NOUN	O	O	2954
in	ADP	O	O	2954
disruption	NOUN	O	O	2954
of	ADP	O	O	2954
the	PRON	O	O	2954
blood	NOUN	O	O	2954
-	PUNCT	O	O	2954
brain	NOUN	O	O	2954
barrier	NOUN	O	O	2954
during	ADP	O	O	2954
acute	ADJ	O	O	2954
hypertension	NOUN	O	Disease	2954
.	PUNCT	O	O	2954
Cellular	NOUN	O	O	2955
mechanisms	NOUN	O	O	2955
which	PRON	O	O	2955
account	VERB	O	O	2955
for	ADP	O	O	2955
disruption	NOUN	O	O	2955
the	PRON	O	O	2955
blood	NOUN	O	O	2955
-	PUNCT	O	O	2955
brain	NOUN	O	O	2955
barrier	NOUN	O	O	2955
during	ADP	O	O	2955
acute	ADJ	O	O	2955
hypertension	NOUN	O	Disease	2955
are	AUX	O	O	2955
not	PART	O	O	2955
clear	ADJ	O	O	2955
.	PUNCT	O	O	2955
The	PRON	O	O	2956
goal	NOUN	O	O	2956
of	ADP	O	O	2956
this	PRON	O	O	2956
study	VERB	O	O	2956
was	AUX	O	O	2956
to	PART	O	O	2956
determine	VERB	O	O	2956
the	PRON	O	O	2956
role	NOUN	O	O	2956
of	ADP	O	O	2956
synthesis	NOUN	O	O	2956
/	PUNCT	O	O	2956
release	NOUN	O	O	2956
of	ADP	O	O	2956
bradykinin	NOUN	O	O	2956
to	PART	O	O	2956
activate	VERB	O	O	2956
B2	NOUN	O	O	2956
receptors	NOUN	O	O	2956
in	ADP	O	O	2956
disruption	NOUN	O	O	2956
of	ADP	O	O	2956
the	PRON	O	O	2956
blood	NOUN	O	O	2956
-	PUNCT	O	O	2956
brain	NOUN	O	O	2956
barrier	NOUN	O	O	2956
during	ADP	O	O	2956
acute	ADJ	O	O	2956
hypertension	NOUN	O	Disease	2956
.	PUNCT	O	O	2956
Permeability	NOUN	O	O	2957
of	ADP	O	O	2957
the	PRON	O	O	2957
blood	NOUN	O	O	2957
-	PUNCT	O	O	2957
brain	NOUN	O	O	2957
barrier	NOUN	O	O	2957
was	AUX	O	O	2957
quantitated	VERB	O	O	2957
by	ADP	O	O	2957
clearance	NOUN	O	O	2957
of	ADP	O	O	2957
fluorescent	NOUN	O	O	2957
-	PUNCT	O	O	2957
labeled	VERB	O	O	2957
dextran	NOUN	O	Chemical	2957
before	ADP	O	O	2957
and	CCONJ	O	O	2957
during	ADP	O	O	2957
phenylephrine	NOUN	O	Chemical	2957
-	PUNCT	O	O	2957
induced	VERB	O	O	2957
acute	ADJ	O	O	2957
hypertension	NOUN	O	Disease	2957
in	ADP	O	O	2957
rats	NOUN	O	O	2957
treated	VERB	O	O	2957
with	ADP	O	O	2957
vehicle	NOUN	O	O	2957
and	CCONJ	O	O	2957
Hoe-140	PROPN	O	O	2957
(	PUNCT	O	O	2957
0.1	NUM	O	O	2957
microM	ADJ	O	O	2957
)	PUNCT	O	O	2957
.	PUNCT	O	O	2957
Phenylephrine	NOUN	O	O	2958
infusion	NOUN	O	O	2958
increased	VERB	O	O	2958
arterial	ADJ	O	O	2958
pressure	NOUN	O	O	2958
,	PUNCT	O	O	2958
arteriolar	ADJ	O	O	2958
diameter	NOUN	O	O	2958
and	CCONJ	O	O	2958
clearance	NOUN	O	O	2958
of	ADP	O	O	2958
fluorescent	NOUN	O	O	2958
dextran	NOUN	O	Chemical	2958
by	ADP	O	O	2958
a	PRON	O	O	2958
similar	ADJ	O	O	2958
magnitude	NOUN	O	O	2958
in	ADP	O	O	2958
both	PRON	O	O	2958
groups	NOUN	O	O	2958
.	PUNCT	O	O	2958
These	PRON	O	O	2959
findings	NOUN	O	O	2959
suggest	VERB	O	O	2959
that	SCONJ	O	O	2959
disruption	NOUN	O	O	2959
of	ADP	O	O	2959
the	PRON	O	O	2959
blood	NOUN	O	O	2959
-	PUNCT	O	O	2959
brain	NOUN	O	O	2959
barrier	NOUN	O	O	2959
during	ADP	O	O	2959
acute	ADJ	O	O	2959
hypertension	NOUN	O	Disease	2959
is	AUX	O	O	2959
not	PART	O	O	2959
related	ADJ	O	O	2959
to	PART	O	O	2959
the	PRON	O	O	2959
synthesis	NOUN	O	O	2959
/	PUNCT	O	O	2959
release	NOUN	O	O	2959
of	ADP	O	O	2959
bradykinin	NOUN	O	O	2959
to	PART	O	O	2959
activate	VERB	O	O	2959
B2	NOUN	O	O	2959
receptors	NOUN	O	O	2959
.	PUNCT	O	O	2959
5-azacytidine	NOUN	O	O	2962
potentiates	VERB	O	O	2962
initiation	NOUN	O	O	2962
induced	VERB	O	O	2962
by	ADP	O	O	2962
carcinogens	NOUN	O	O	2962
in	ADP	O	O	2962
rat	NOUN	O	O	2962
liver	NOUN	O	O	2962
.	PUNCT	O	O	2962
To	PART	O	O	2963
test	NOUN	O	O	2963
the	PRON	O	O	2963
validity	NOUN	O	O	2963
of	ADP	O	O	2963
the	PRON	O	O	2963
hypothesis	NOUN	O	O	2963
that	SCONJ	O	O	2963
hypomethylation	NOUN	O	O	2963
of	ADP	O	O	2963
DNA	NOUN	O	O	2963
plays	VERB	O	O	2963
an	PRON	O	O	2963
important	ADJ	O	O	2963
role	NOUN	O	O	2963
in	ADP	O	O	2963
the	PRON	O	O	2963
initiation	NOUN	O	O	2963
of	ADP	O	O	2963
carcinogenic	ADJ	O	Disease	2963
process	NOUN	O	O	2963
,	PUNCT	O	O	2963
5-azacytidine	NOUN	O	O	2963
(	PUNCT	O	O	2963
5-AzC	NUM	O	O	2963
)	PUNCT	O	O	2963
(	PUNCT	O	O	2963
10	NUM	O	O	2963
mg	VERB	O	O	2963
/	PUNCT	O	O	2963
kg	VERB	O	O	2963
)	PUNCT	O	O	2963
,	PUNCT	O	O	2963
an	PRON	O	O	2963
inhibitor	NOUN	O	O	2963
of	ADP	O	O	2963
DNA	NOUN	O	O	2963
methylation	NOUN	O	O	2963
,	PUNCT	O	O	2963
was	AUX	O	O	2963
given	VERB	O	O	2963
to	PART	O	O	2963
rats	NOUN	O	O	2963
during	ADP	O	O	2963
the	PRON	O	O	2963
phase	NOUN	O	O	2963
of	ADP	O	O	2963
repair	PROPN	O	O	2963
synthesis	NOUN	O	O	2963
induced	VERB	O	O	2963
by	ADP	O	O	2963
the	PRON	O	O	2963
three	NUM	O	O	2963
carcinogens	NOUN	O	O	2963
,	PUNCT	O	O	2963
benzo[a]-pyrene	VERB	O	O	2963
(	PUNCT	O	O	2963
200	NUM	O	O	2963
mg	VERB	O	O	2963
/	PUNCT	O	O	2963
kg	VERB	O	O	2963
)	PUNCT	O	O	2963
,	PUNCT	O	O	2963
N	NUM	O	O	2963
-	PUNCT	O	O	2963
methyl	NOUN	O	O	2963
-	PUNCT	O	O	2963
N	NUM	O	O	2963
-	PUNCT	O	O	2963
nitrosourea	ADP	O	O	2963
(	PUNCT	O	O	2963
60	NUM	O	O	2963
mg	VERB	O	O	2963
/	PUNCT	O	O	2963
kg	VERB	O	O	2963
)	PUNCT	O	O	2963
and	CCONJ	O	O	2963
1,2-dimethylhydrazine	NOUN	O	O	2963
(	PUNCT	O	O	2963
1,2-DMH	PROPN	O	O	2963
)	PUNCT	O	O	2963
The	PRON	O	O	2964
initiated	VERB	O	O	2964
hepatocytes	VERB	O	O	2964
in	ADP	O	O	2964
the	PRON	O	O	2964
liver	NOUN	O	O	2964
were	AUX	O	O	2964
assayed	VERB	O	O	2964
as	ADP	O	O	2964
the	PRON	O	O	2964
gamma	PROPN	O	O	2964
-	PUNCT	O	O	2964
glutamyltransferase	PROPN	O	O	2964
(	PUNCT	O	O	2964
gamma	PROPN	O	O	2964
-	PUNCT	O	O	2964
GT	NOUN	O	O	2964
)	PUNCT	O	O	2964
positive	ADJ	O	O	2964
foci	VERB	O	O	2964
formed	VERB	O	O	2964
following	VERB	O	O	2964
a	PRON	O	O	2964
2-week	NOUN	O	O	2964
selection	NOUN	O	O	2964
regimen	NOUN	O	O	2964
consisting	VERB	O	O	2964
of	ADP	O	O	2964
dietary	ADJ	O	O	2964
0.02%	NOUN	O	O	2964
2-acetylaminofluorene	NOUN	O	O	2964
coupled	VERB	O	O	2964
with	ADP	O	O	2964
a	PRON	O	O	2964
necrogenic	ADJ	O	O	2964
dose	NOUN	O	O	2964
of	ADP	O	O	2964
CCl4	PROPN	O	Chemical	2964
.	PUNCT	O	O	2964
The	PRON	O	O	2965
results	VERB	O	O	2965
obtained	VERB	O	O	2965
indicate	VERB	O	O	2965
that	SCONJ	O	O	2965
with	ADP	O	O	2965
all	PRON	O	O	2965
three	NUM	O	O	2965
carcinogens	NOUN	O	O	2965
,	PUNCT	O	O	2965
administration	NOUN	O	O	2965
of	ADP	O	O	2965
5-AzC	NUM	O	O	2965
during	ADP	O	O	2965
repair	PROPN	O	O	2965
synthesis	NOUN	O	O	2965
increased	VERB	O	O	2965
the	PRON	O	O	2965
incidence	NOUN	O	O	2965
of	ADP	O	O	2965
initiated	VERB	O	O	2965
hepatocytes	VERB	O	O	2965
,	PUNCT	O	O	2965
for	ADP	O	O	2965
example	NOUN	O	O	2965
10	NUM	O	O	2965
-	PUNCT	O	O	2965
20	NUM	O	O	2965
foci	VERB	O	O	2965
/	PUNCT	O	O	2965
cm2	NOUN	O	O	2965
in	ADP	O	O	2965
5-AzC	NUM	O	O	2965
and	CCONJ	O	O	2965
carcinogen	PROPN	O	O	2965
-	PUNCT	O	O	2965
treated	VERB	O	O	2965
rats	NOUN	O	O	2965
compared	VERB	O	O	2965
with	ADP	O	O	2965
3	X	O	O	2965
-	PUNCT	O	O	2965
5	NUM	O	O	2965
foci	VERB	O	O	2965
/	PUNCT	O	O	2965
cm2	NOUN	O	O	2965
in	ADP	O	O	2965
rats	NOUN	O	O	2965
treated	VERB	O	O	2965
with	ADP	O	O	2965
carcinogen	PROPN	O	O	2965
only	ADV	O	O	2965
.	PUNCT	O	O	2965
Administration	NOUN	O	O	2966
of	ADP	O	O	2966
[	X	O	O	2966
3H]-5-azadeoxycytidine	NOUN	O	O	2966
during	ADP	O	O	2966
the	PRON	O	O	2966
repair	PROPN	O	O	2966
synthesis	NOUN	O	O	2966
induced	VERB	O	O	2966
by	ADP	O	O	2966
1,2-DMH	PROPN	O	O	2966
further	ADV	O	O	2966
showed	VERB	O	O	2966
that	SCONJ	O	O	2966
0.019	NUM	O	O	2966
mol	NOUN	O	O	2966
%	INTJ	O	O	2966
of	ADP	O	O	2966
cytosine	NOUN	O	O	2966
residues	NOUN	O	O	2966
in	ADP	O	O	2966
DNA	NOUN	O	O	2966
were	AUX	O	O	2966
substituted	VERB	O	O	2966
by	ADP	O	O	2966
the	PRON	O	O	2966
analogue	NOUN	O	O	2966
,	PUNCT	O	O	2966
indicating	VERB	O	O	2966
that	SCONJ	O	O	2966
incorporation	NOUN	O	O	2966
of	ADP	O	O	2966
5-AzC	NUM	O	O	2966
occurs	VERB	O	O	2966
during	ADP	O	O	2966
repair	PROPN	O	O	2966
synthesis	NOUN	O	O	2966
.	PUNCT	O	O	2966
In	ADP	O	O	2967
the	PRON	O	O	2967
absence	NOUN	O	O	2967
of	ADP	O	O	2967
the	PRON	O	O	2967
carcinogen	PROPN	O	O	2967
,	PUNCT	O	O	2967
5-AzC	NUM	O	O	2967
given	VERB	O	O	2967
after	ADP	O	O	2967
a	PRON	O	O	2967
two	NUM	O	O	2967
thirds	NOUN	O	O	2967
partial	ADJ	O	O	2967
hepatectomy	NOUN	O	O	2967
,	PUNCT	O	O	2967
when	SCONJ	O	O	2967
its	PRON	O	O	2967
incorporation	NOUN	O	O	2967
should	AUX	O	O	2967
be	AUX	O	O	2967
maximum	ADV	O	O	2967
,	PUNCT	O	O	2967
failed	VERB	O	O	2967
to	PART	O	O	2967
induce	VERB	O	O	2967
any	PRON	O	O	2967
gamma	PROPN	O	O	2967
-	PUNCT	O	O	2967
GT	NOUN	O	O	2967
positive	ADJ	O	O	2967
foci	VERB	O	O	2967
.	PUNCT	O	O	2967
Withdrawal	NOUN	O	O	2970
-	PUNCT	O	O	2970
emergent	ADJ	O	O	2970
rabbit	NOUN	O	O	2970
syndrome	NOUN	O	O	2970
during	ADP	O	O	2970
dose	NOUN	O	O	2970
reduction	NOUN	O	O	2970
of	ADP	O	O	2970
risperidone	VERB	O	Chemical	2970
.	PUNCT	O	O	2970
Rabbit	NOUN	O	O	2971
syndrome	NOUN	O	O	2971
(	PUNCT	O	O	2971
RS	NOUN	O	O	2971
)	PUNCT	O	O	2971
is	AUX	O	O	2971
a	PRON	O	O	2971
rare	ADJ	O	O	2971
extrapyramidal	ADJ	O	O	2971
side	NOUN	O	O	2971
effect	VERB	O	O	2971
caused	VERB	O	O	2971
by	ADP	O	O	2971
prolonged	VERB	O	O	2971
neuroleptic	NOUN	O	O	2971
medication	NOUN	O	O	2971
.	PUNCT	O	O	2971
Here	ADV	O	O	2972
we	PRON	O	O	2972
present	NOUN	O	O	2972
a	PRON	O	O	2972
case	NOUN	O	O	2972
of	ADP	O	O	2972
withdrawal	NOUN	O	O	2972
-	PUNCT	O	O	2972
emergent	ADJ	O	O	2972
RS	NOUN	O	O	2972
,	PUNCT	O	O	2972
which	PRON	O	O	2972
is	AUX	O	O	2972
the	PRON	O	O	2972
first	ADV	O	O	2972
of	ADP	O	O	2972
its	PRON	O	O	2972
kind	NOUN	O	O	2972
to	PART	O	O	2972
be	AUX	O	O	2972
reported	VERB	O	O	2972
.	PUNCT	O	O	2972
The	PRON	O	O	2973
patient	NOUN	O	O	2973
developed	VERB	O	O	2973
RS	NOUN	O	O	2973
during	ADP	O	O	2973
dose	NOUN	O	O	2973
reduction	NOUN	O	O	2973
of	ADP	O	O	2973
risperidone	VERB	O	Chemical	2973
.	PUNCT	O	O	2973
The	PRON	O	O	2974
symptom	NOUN	O	O	2974
was	AUX	O	O	2974
treated	VERB	O	O	2974
successfully	ADV	O	O	2974
with	ADP	O	O	2974
trihexyphenidyl	ADJ	O	Chemical	2974
anticholinergic	ADJ	O	O	2974
therapy	NOUN	O	O	2974
.	PUNCT	O	O	2974
The	PRON	O	O	2975
underlying	VERB	O	O	2975
mechanism	NOUN	O	O	2975
of	ADP	O	O	2975
withdrawal	NOUN	O	O	2975
-	PUNCT	O	O	2975
emergent	ADJ	O	O	2975
RS	NOUN	O	O	2975
in	ADP	O	O	2975
the	PRON	O	O	2975
present	NOUN	O	O	2975
case	NOUN	O	O	2975
may	AUX	O	O	2975
have	VERB	O	O	2975
been	AUX	O	O	2975
related	ADJ	O	O	2975
to	PART	O	O	2975
the	PRON	O	O	2975
pharmacological	ADJ	O	O	2975
profile	NOUN	O	O	2975
of	ADP	O	O	2975
risperidone	VERB	O	Chemical	2975
,	PUNCT	O	O	2975
a	PRON	O	O	2975
serotonin	PROPN	O	Chemical	2975
-	PUNCT	O	O	2975
dopamine	NOUN	O	Chemical	2975
antagonist	NOUN	O	O	2975
,	PUNCT	O	O	2975
suggesting	VERB	O	O	2975
the	PRON	O	O	2975
pathophysiologic	ADJ	O	O	2975
influence	NOUN	O	O	2975
of	ADP	O	O	2975
the	PRON	O	O	2975
serotonin	PROPN	O	Chemical	2975
system	NOUN	O	O	2975
in	ADP	O	O	2975
the	PRON	O	O	2975
development	NOUN	O	O	2975
of	ADP	O	O	2975
RS	NOUN	O	O	2975
.	PUNCT	O	O	2975
Verapamil	PROPN	O	Chemical	2978
withdrawal	NOUN	O	O	2978
as	ADP	O	O	2978
a	PRON	O	O	2978
possible	ADJ	O	O	2978
cause	VERB	O	O	2978
of	ADP	O	O	2978
myocardial infarction	NOUN	O	Disease	2978
in	ADP	O	O	2978
a	PRON	O	O	2978
hypertensive	ADJ	O	Disease	2978
woman	NOUN	O	O	2978
with	ADP	O	O	2978
a	PRON	O	O	2978
normal	ADJ	O	O	2978
coronary	ADJ	O	O	2978
angiogram	PROPN	O	O	2978
.	PUNCT	O	O	2978
Verapamil	PROPN	O	Chemical	2979
is	AUX	O	O	2979
an	PRON	O	O	2979
effective	ADJ	O	O	2979
and	CCONJ	O	O	2979
relatively	ADV	O	O	2979
-	PUNCT	O	O	2979
safe	ADJ	O	O	2979
antihypertensive	ADV	O	O	2979
drug	NOUN	O	O	2979
.	PUNCT	O	O	2979
Serious	ADJ	O	O	2980
adverse	ADJ	O	O	2980
effects	NOUN	O	O	2980
are	AUX	O	O	2980
uncommon	ADJ	O	O	2980
and	CCONJ	O	O	2980
mainly	ADV	O	O	2980
have	VERB	O	O	2980
been	AUX	O	O	2980
related	ADJ	O	O	2980
to	PART	O	O	2980
the	PRON	O	O	2980
depression	PROPN	O	Disease	2980
of	ADP	O	O	2980
cardiac	ADJ	O	O	2980
contractility	NOUN	O	O	2980
and	CCONJ	O	O	2980
conduction	NOUN	O	O	2980
,	PUNCT	O	O	2980
especially	ADV	O	O	2980
when	SCONJ	O	O	2980
the	PRON	O	O	2980
drug	NOUN	O	O	2980
is	AUX	O	O	2980
combined	VERB	O	O	2980
with	ADP	O	O	2980
beta	NOUN	O	O	2980
-	PUNCT	O	O	2980
blocking	VERB	O	O	2980
agents	NOUN	O	O	2980
.	PUNCT	O	O	2980
We	PRON	O	O	2981
report	VERB	O	O	2981
a	PRON	O	O	2981
case	NOUN	O	O	2981
in	ADP	O	O	2981
which	PRON	O	O	2981
myocardial infarction	NOUN	O	Disease	2981
coincided	VERB	O	O	2981
with	ADP	O	O	2981
the	PRON	O	O	2981
introduction	NOUN	O	O	2981
of	ADP	O	O	2981
captopril	PROPN	O	Chemical	2981
and	CCONJ	O	O	2981
the	PRON	O	O	2981
withdrawal	NOUN	O	O	2981
of	ADP	O	O	2981
verapamil	PROPN	O	Chemical	2981
in	ADP	O	O	2981
a	PRON	O	O	2981
previously	ADV	O	O	2981
asymptomatic	ADJ	O	O	2981
woman	NOUN	O	O	2981
with	ADP	O	O	2981
severe	ADJ	O	O	2981
hypertension	NOUN	O	Disease	2981
.	PUNCT	O	O	2981
Possible	ADJ	O	O	2982
mechanisms	NOUN	O	O	2982
that	SCONJ	O	O	2982
involve	VERB	O	O	2982
a	PRON	O	O	2982
verapamil	PROPN	O	Chemical	2982
-	PUNCT	O	O	2982
related	ADJ	O	O	2982
increase	VERB	O	O	2982
in	ADP	O	O	2982
platelet	NOUN	O	O	2982
and/or	CCONJ	O	O	2982
vascular	ADJ	O	O	2982
alpha	PROPN	O	O	2982
2-adrenoreceptor	NOUN	O	O	2982
affinity	NOUN	O	O	2982
for	ADP	O	O	2982
catecholamines	NOUN	O	Chemical	2982
are	AUX	O	O	2982
discussed	VERB	O	O	2982
.	PUNCT	O	O	2982
Remission	NOUN	O	O	2985
induction	NOUN	O	O	2985
of	ADP	O	O	2985
meningeal	PROPN	O	O	2985
leukemia	NOUN	O	Disease	2985
with	ADP	O	O	2985
high	ADJ	O	O	2985
-	PUNCT	O	O	2985
dose	NOUN	O	O	2985
intravenous	ADJ	O	O	2985
methotrexate	CCONJ	O	Chemical	2985
.	PUNCT	O	O	2985
Twenty	NUM	O	O	2986
children	NOUN	O	O	2986
with	ADP	O	O	2986
acute	ADJ	O	O	2986
lymphoblastic	NOUN	O	O	2986
leukemia	NOUN	O	Disease	2986
who	PRON	O	O	2986
developed	VERB	O	O	2986
meningeal	PROPN	O	O	2986
disease	PROPN	O	O	2986
were	AUX	O	O	2986
treated	VERB	O	O	2986
with	ADP	O	O	2986
a	PRON	O	O	2986
high	ADJ	O	O	2986
-	PUNCT	O	O	2986
dose	NOUN	O	O	2986
intravenous	ADJ	O	O	2986
methotrexate	CCONJ	O	Chemical	2986
regimen	NOUN	O	O	2986
that	SCONJ	O	O	2986
was	AUX	O	O	2986
designed	VERB	O	O	2986
to	PART	O	O	2986
achieve	VERB	O	O	2986
and	CCONJ	O	O	2986
maintain	VERB	O	O	2986
CSF	PROPN	O	O	2986
methotrexate	CCONJ	O	Chemical	2986
concentrations	NOUN	O	O	2986
of	ADP	O	O	2986
10(-5	NUM	O	O	2986
)	PUNCT	O	O	2986
The	PRON	O	O	2987
methotrexate	CCONJ	O	Chemical	2987
was	AUX	O	O	2987
administered	VERB	O	O	2987
as	ADP	O	O	2987
a	PRON	O	O	2987
loading	NOUN	O	O	2987
dose	NOUN	O	O	2987
of	ADP	O	O	2987
6,000	NUM	O	O	2987
mg	VERB	O	O	2987
/	PUNCT	O	O	2987
m2	PROPN	O	O	2987
for	ADP	O	O	2987
a	PRON	O	O	2987
period	NOUN	O	O	2987
of	ADP	O	O	2987
one	NUM	O	O	2987
hour	NOUN	O	O	2987
followed	VERB	O	O	2987
by	ADP	O	O	2987
an	PRON	O	O	2987
infusion	NOUN	O	O	2987
of	ADP	O	O	2987
1,200	NUM	O	O	2987
mg	VERB	O	O	2987
/	PUNCT	O	O	2987
m2/h	NOUN	O	O	2987
for	ADP	O	O	2987
23	NUM	O	O	2987
hours	NOUN	O	O	2987
.	PUNCT	O	O	2987
Leucovorin	PROPN	O	O	2988
rescue	NOUN	O	O	2988
was	AUX	O	O	2988
initiated	VERB	O	O	2988
12	NUM	O	O	2988
hours	NOUN	O	O	2988
after	ADP	O	O	2988
the	PRON	O	O	2988
end	VERB	O	O	2988
of	ADP	O	O	2988
the	PRON	O	O	2988
infusion	NOUN	O	O	2988
with	ADP	O	O	2988
a	PRON	O	O	2988
loading	NOUN	O	O	2988
dose	NOUN	O	O	2988
of	ADP	O	O	2988
200	NUM	O	O	2988
mg	VERB	O	O	2988
/	PUNCT	O	O	2988
m2	PROPN	O	O	2988
followed	VERB	O	O	2988
by	ADP	O	O	2988
12	NUM	O	O	2988
mg	VERB	O	O	2988
/	PUNCT	O	O	2988
m2	PROPN	O	O	2988
every	PRON	O	O	2988
three	NUM	O	O	2988
hours	NOUN	O	O	2988
for	ADP	O	O	2988
six	NUM	O	O	2988
doses	NOUN	O	O	2988
and	CCONJ	O	O	2988
then	ADV	O	O	2988
every	PRON	O	O	2988
six	NUM	O	O	2988
hours	NOUN	O	O	2988
until	ADP	O	O	2988
the	PRON	O	O	2988
plasma	NOUN	O	O	2988
methotrexate	CCONJ	O	Chemical	2988
level	VERB	O	O	2988
decreased	VERB	O	O	2988
to	PART	O	O	2988
less	ADV	O	O	2988
than	ADP	O	O	2988
1	X	O	O	2988
X	NOUN	O	O	2988
10(-7	NUM	O	O	2988
)	PUNCT	O	O	2988
mol	NOUN	O	O	2988
/	PUNCT	O	O	2988
L.	PROPN	O	O	2988
The	PRON	O	O	2989
mean	VERB	O	O	2989
steady	ADJ	O	O	2989
-	PUNCT	O	O	2989
state	NOUN	O	O	2989
plasma	NOUN	O	O	2989
and	CCONJ	O	O	2989
CSF	PROPN	O	O	2989
methotrexate	CCONJ	O	Chemical	2989
concentrations	NOUN	O	O	2989
achieved	VERB	O	O	2989
were	AUX	O	O	2989
1.1	NUM	O	O	2989
X	NOUN	O	O	2989
10(-3	PROPN	O	O	2989
)	PUNCT	O	O	2989
The	PRON	O	O	2990
most	ADV	O	O	2990
common	ADJ	O	O	2990
toxicities	NOUN	O	Disease	2990
encountered	VERB	O	O	2990
were	AUX	O	O	2990
transient	ADJ	O	O	2990
serum	NOUN	O	O	2990
transaminase	X	O	O	2990
and	CCONJ	O	O	2990
bilirubin	ADJ	O	Chemical	2990
elevations	NOUN	O	O	2990
,	PUNCT	O	O	2990
neutropenia	ADJ	O	Disease	2990
,	PUNCT	O	O	2990
and	CCONJ	O	O	2990
mucositis	NOUN	O	Disease	2990
.	PUNCT	O	O	2990
One	NUM	O	O	2991
patient	NOUN	O	O	2991
had	VERB	O	O	2991
focal	ADJ	O	O	2991
seizures	NOUN	O	Disease	2991
and	CCONJ	O	O	2991
transient	ADJ	O	O	2991
hemiparesis	PROPN	O	Disease	2991
but	CCONJ	O	O	2991
recovered	VERB	O	O	2991
completely	ADV	O	O	2991
.	PUNCT	O	O	2991
High	ADJ	O	O	2992
-	PUNCT	O	O	2992
dose	NOUN	O	O	2992
intravenous	ADJ	O	O	2992
methotrexate	CCONJ	O	Chemical	2992
is	AUX	O	O	2992
an	PRON	O	O	2992
effective	ADJ	O	O	2992
treatment	NOUN	O	O	2992
for	ADP	O	O	2992
the	PRON	O	O	2992
induction	NOUN	O	O	2992
of	ADP	O	O	2992
remission	NOUN	O	O	2992
after	ADP	O	O	2992
meningeal	PROPN	O	O	2992
relapse	VERB	O	O	2992
in	ADP	O	O	2992
acute	ADJ	O	O	2992
lymphoblastic	NOUN	O	O	2992
leukemia	NOUN	O	Disease	2992
.	PUNCT	O	O	2992
Hypersensitivity	NOUN	O	Disease	2995
to	PART	O	O	2995
carbamazepine	NOUN	O	Chemical	2995
presenting	VERB	O	O	2995
with	ADP	O	O	2995
a	PRON	O	O	2995
leukemoid	PROPN	O	O	2995
reaction	NOUN	O	O	2995
,	PUNCT	O	O	2995
eosinophilia	PROPN	O	Disease	2995
,	PUNCT	O	O	2995
erythroderma	ADP	O	O	2995
,	PUNCT	O	O	2995
and	CCONJ	O	O	2995
renal failure	NOUN	O	Disease	2995
.	PUNCT	O	O	2995
We	PRON	O	O	2996
report	VERB	O	O	2996
a	PRON	O	O	2996
patient	NOUN	O	O	2996
in	ADP	O	O	2996
whom	PRON	O	O	2996
hypersensitivity	NOUN	O	Disease	2996
to	PART	O	O	2996
carbamazepine	NOUN	O	Chemical	2996
presented	VERB	O	O	2996
with	ADP	O	O	2996
generalized	VERB	O	O	2996
erythroderma	ADP	O	O	2996
,	PUNCT	O	O	2996
a	PRON	O	O	2996
severe	ADJ	O	O	2996
leukemoid	PROPN	O	O	2996
reaction	NOUN	O	O	2996
,	PUNCT	O	O	2996
eosinophilia	PROPN	O	Disease	2996
,	PUNCT	O	O	2996
hyponatremia	NOUN	O	O	2996
,	PUNCT	O	O	2996
and	CCONJ	O	O	2996
renal failure	NOUN	O	Disease	2996
.	PUNCT	O	O	2996
This	PRON	O	O	2997
is	AUX	O	O	2997
the	PRON	O	O	2997
first	ADV	O	O	2997
report	VERB	O	O	2997
of	ADP	O	O	2997
such	ADJ	O	O	2997
an	PRON	O	O	2997
unusual	ADJ	O	O	2997
reaction	NOUN	O	O	2997
to	PART	O	O	2997
carbamazepine	NOUN	O	Chemical	2997
.	PUNCT	O	O	2997
The	PRON	O	O	3000
interpeduncular	ADJ	O	O	3000
nucleus	PROPN	O	O	3000
regulates	VERB	O	O	3000
nicotine	NOUN	O	Chemical	3000
's	AUX	O	O	3000
effects	NOUN	O	O	3000
on	ADP	O	O	3000
free	ADJ	O	O	3000
-	PUNCT	O	O	3000
field	NOUN	O	O	3000
activity	NOUN	O	O	3000
.	PUNCT	O	O	3000
Partial	ADJ	O	O	3001
lesions	NOUN	O	O	3001
were	AUX	O	O	3001
made	VERB	O	O	3001
with	ADP	O	O	3001
kainic acid	NOUN	O	Chemical	3001
in	ADP	O	O	3001
the	PRON	O	O	3001
interpeduncular	ADJ	O	O	3001
nucleus	PROPN	O	O	3001
of	ADP	O	O	3001
the	PRON	O	O	3001
ventral	ADV	O	O	3001
midbrain	NOUN	O	O	3001
of	ADP	O	O	3001
the	PRON	O	O	3001
rat	NOUN	O	O	3001
.	PUNCT	O	O	3001
Compared	VERB	O	O	3002
with	ADP	O	O	3002
sham	NOUN	O	O	3002
-	PUNCT	O	O	3002
operated	VERB	O	O	3002
controls	VERB	O	O	3002
,	PUNCT	O	O	3002
lesions	NOUN	O	O	3002
significantly	ADV	O	O	3002
(	PUNCT	O	O	3002
p	NOUN	O	O	3002
<	X	O	O	3002
0.25	NUM	O	O	3002
)	PUNCT	O	O	3002
blunted	VERB	O	O	3002
the	PRON	O	O	3002
early	ADV	O	O	3002
(	PUNCT	O	O	3002
<	X	O	O	3002
60	NUM	O	O	3002
min	NOUN	O	O	3002
)	PUNCT	O	O	3002
free	ADJ	O	O	3002
-	PUNCT	O	O	3002
field	NOUN	O	O	3002
locomotor	PROPN	O	O	3002
hypoactivity	NOUN	O	O	3002
caused	VERB	O	O	3002
by	ADP	O	O	3002
nicotine	NOUN	O	Chemical	3002
(	PUNCT	O	O	3002
0.5	NUM	O	O	3002
mg	VERB	O	O	3002
kg(-1	NOUN	O	O	3002
)	PUNCT	O	O	3002
,	PUNCT	O	O	3002
i.m	PROPN	O	O	3002
.	PUNCT	O	O	3002
)	PUNCT	O	O	3002
,	PUNCT	O	O	3002
enhanced	VERB	O	O	3002
the	PRON	O	O	3002
later	ADV	O	O	3002
(	PUNCT	O	O	3002
60	NUM	O	O	3002
-	PUNCT	O	O	3002
120	NUM	O	O	3002
min	NOUN	O	O	3002
)	PUNCT	O	O	3002
nicotine	NOUN	O	Chemical	3002
-	PUNCT	O	O	3002
induced	VERB	O	O	3002
hyperactivity	NOUN	O	Disease	3002
,	PUNCT	O	O	3002
and	CCONJ	O	O	3002
raised	VERB	O	O	3002
spontaneous	ADJ	O	O	3002
nocturnal	ADJ	O	O	3002
activity	NOUN	O	O	3002
.	PUNCT	O	O	3002
Lesions	NOUN	O	O	3003
reduced	VERB	O	O	3003
the	PRON	O	O	3003
extent	NOUN	O	O	3003
of	ADP	O	O	3003
immunohistological	ADJ	O	O	3003
staining	VERB	O	O	3003
for	ADP	O	O	3003
choline	NOUN	O	Chemical	3003
acetyltransferase	PROPN	O	O	3003
in	ADP	O	O	3003
the	PRON	O	O	3003
interpeduncular	ADJ	O	O	3003
nucleus	PROPN	O	O	3003
(	PUNCT	O	O	3003
p	NOUN	O	O	3003
<	X	O	O	3003
0.025	NUM	O	O	3003
)	PUNCT	O	O	3003
,	PUNCT	O	O	3003
but	CCONJ	O	O	3003
not	PART	O	O	3003
for	ADP	O	O	3003
tyrosine	NOUN	O	Chemical	3003
hydroxylase	NOUN	O	O	3003
in	ADP	O	O	3003
the	PRON	O	O	3003
surrounding	VERB	O	O	3003
catecholaminergic	PROPN	O	O	3003
A10	NOUN	O	O	3003
region	NOUN	O	O	3003
.	PUNCT	O	O	3003
We	PRON	O	O	3004
conclude	VERB	O	O	3004
that	SCONJ	O	O	3004
the	PRON	O	O	3004
interpeduncular	ADJ	O	O	3004
nucleus	PROPN	O	O	3004
mediates	VERB	O	O	3004
nicotinic	ADJ	O	O	3004
depression	PROPN	O	Disease	3004
of	ADP	O	O	3004
locomotor	PROPN	O	O	3004
activity	NOUN	O	O	3004
and	CCONJ	O	O	3004
dampens	VERB	O	O	3004
nicotinic	ADJ	O	O	3004
arousal	NOUN	O	O	3004
mechanisms	NOUN	O	O	3004
located	VERB	O	O	3004
elsewhere	ADV	O	O	3004
in	ADP	O	O	3004
the	PRON	O	O	3004
brain	NOUN	O	O	3004
.	PUNCT	O	O	3004
Assessment	NOUN	O	O	3007
of	ADP	O	O	3007
a	PRON	O	O	3007
new	ADJ	O	O	3007
non	ADJ	O	O	3007
-	PUNCT	O	O	3007
invasive	ADJ	O	O	3007
index	NOUN	O	O	3007
of	ADP	O	O	3007
cardiac	ADJ	O	O	3007
performance	NOUN	O	O	3007
for	ADP	O	O	3007
detection	NOUN	O	O	3007
of	ADP	O	O	3007
dobutamine	NOUN	O	Chemical	3007
-	PUNCT	O	O	3007
induced	VERB	O	O	3007
myocardial ischemia	NOUN	O	Disease	3007
.	PUNCT	O	O	3007
Electrocardiography	NOUN	O	O	3008
has	VERB	O	O	3008
a	PRON	O	O	3008
very	ADV	O	O	3008
low	ADJ	O	O	3008
sensitivity	NOUN	O	O	3008
in	ADP	O	O	3008
detecting	VERB	O	O	3008
dobutamine	NOUN	O	Chemical	3008
-	PUNCT	O	O	3008
induced	VERB	O	O	3008
myocardial ischemia	NOUN	O	Disease	3008
.	PUNCT	O	O	3008
To	PART	O	O	3009
assess	VERB	O	O	3009
the	PRON	O	O	3009
added	VERB	O	O	3009
diagnostic	ADJ	O	O	3009
value	NOUN	O	O	3009
of	ADP	O	O	3009
a	PRON	O	O	3009
new	ADJ	O	O	3009
cardiac	ADJ	O	O	3009
performance	NOUN	O	O	3009
index	NOUN	O	O	3009
(	PUNCT	O	O	3009
dP	X	O	O	3009
/	PUNCT	O	O	3009
dtejc	PROPN	O	O	3009
)	PUNCT	O	O	3009
measurement	NOUN	O	O	3009
,	PUNCT	O	O	3009
based	VERB	O	O	3009
on	ADP	O	O	3009
brachial	ADJ	O	O	3009
artery	NOUN	O	O	3009
flow	NOUN	O	O	3009
changes	VERB	O	O	3009
,	PUNCT	O	O	3009
as	ADP	O	O	3009
compared	VERB	O	O	3009
to	PART	O	O	3009
standard	PROPN	O	O	3009
12-lead	NOUN	O	O	3009
ECG	PROPN	O	O	3009
,	PUNCT	O	O	3009
for	ADP	O	O	3009
detecting	VERB	O	O	3009
dobutamine	NOUN	O	Chemical	3009
-	PUNCT	O	O	3009
induced	VERB	O	O	3009
myocardial ischemia	NOUN	O	Disease	3009
,	PUNCT	O	O	3009
using	VERB	O	O	3009
Tc99m	VERB	O	O	3009
-	PUNCT	O	O	3009
Sestamibi	NOUN	O	O	3009
single	ADJ	O	O	3009
-	PUNCT	O	O	3009
photon	NOUN	O	O	3009
emission	NOUN	O	O	3009
computed	VERB	O	O	3009
tomography	NOUN	O	O	3009
as	ADP	O	O	3009
the	PRON	O	O	3009
gold	NOUN	O	Chemical	3009
standard	PROPN	O	O	3009
of	ADP	O	O	3009
comparison	NOUN	O	O	3009
to	PART	O	O	3009
assess	VERB	O	O	3009
the	PRON	O	O	3009
presence	NOUN	O	O	3009
or	CCONJ	O	O	3009
absence	NOUN	O	O	3009
of	ADP	O	O	3009
ischemia	NOUN	O	Disease	3009
.	PUNCT	O	O	3009
:	PUNCT	O	O	3010
The	PRON	O	O	3010
study	VERB	O	O	3010
group	NOUN	O	O	3010
comprised	VERB	O	O	3010
40	NUM	O	O	3010
patients	NOUN	O	O	3010
undergoing	VERB	O	O	3010
Sestamibi	NOUN	O	O	3010
-	PUNCT	O	O	3010
SPECT	PROPN	O	O	3010
/	PUNCT	O	O	3010
dobutamine	NOUN	O	Chemical	3010
stress	NOUN	O	O	3010
test	NOUN	O	O	3010
.	PUNCT	O	O	3010
dtejc	PROPN	O	O	3011
were	AUX	O	O	3011
performed	VERB	O	O	3011
at	ADP	O	O	3011
each	PRON	O	O	3011
dobutamine	NOUN	O	Chemical	3011
level	VERB	O	O	3011
.	PUNCT	O	O	3011
In	ADP	O	O	3012
19	NUM	O	O	3012
of	ADP	O	O	3012
the	PRON	O	O	3012
40	NUM	O	O	3012
patients	NOUN	O	O	3012
perfusion	NOUN	O	O	3012
defects	NOUN	O	O	3012
compatible	ADJ	O	O	3012
with	ADP	O	O	3012
ischemia	NOUN	O	Disease	3012
were	AUX	O	O	3012
detected	VERB	O	O	3012
on	ADP	O	O	3012
SPECT	PROPN	O	O	3012
.	PUNCT	O	O	3012
The	PRON	O	O	3013
increase	VERB	O	O	3013
in	ADP	O	O	3013
dP	X	O	O	3013
/	PUNCT	O	O	3013
dtejc	PROPN	O	O	3013
during	ADP	O	O	3013
infusion	NOUN	O	O	3013
of	ADP	O	O	3013
dobutamine	NOUN	O	Chemical	3013
in	ADP	O	O	3013
this	PRON	O	O	3013
group	NOUN	O	O	3013
was	AUX	O	O	3013
severely	ADV	O	O	3013
impaired	VERB	O	O	3013
as	ADP	O	O	3013
compared	VERB	O	O	3013
to	PART	O	O	3013
the	PRON	O	O	3013
non	ADJ	O	O	3013
-	PUNCT	O	O	3013
ischemic	VERB	O	Disease	3013
group	NOUN	O	O	3013
.	PUNCT	O	O	3013
If	SCONJ	O	O	3014
ECG	PROPN	O	O	3014
alone	ADV	O	O	3014
is	AUX	O	O	3014
used	VERB	O	O	3014
for	ADP	O	O	3014
specificity	NOUN	O	O	3014
,	PUNCT	O	O	3014
the	PRON	O	O	3014
combination	NOUN	O	O	3014
with	ADP	O	O	3014
dP	X	O	O	3014
/	PUNCT	O	O	3014
dtejc	PROPN	O	O	3014
improved	VERB	O	O	3014
the	PRON	O	O	3014
sensitivity	NOUN	O	O	3014
of	ADP	O	O	3014
the	PRON	O	O	3014
test	NOUN	O	O	3014
and	CCONJ	O	O	3014
could	AUX	O	O	3014
be	AUX	O	O	3014
a	PRON	O	O	3014
cost	NOUN	O	O	3014
-	PUNCT	O	O	3014
savings	NOUN	O	O	3014
alternative	ADV	O	O	3014
to	PART	O	O	3014
cardiac	ADJ	O	O	3014
imaging	VERB	O	O	3014
or	CCONJ	O	O	3014
perfusion	NOUN	O	O	3014
studies	NOUN	O	O	3014
to	PART	O	O	3014
detect	VERB	O	O	3014
myocardial ischemia	NOUN	O	Disease	3014
,	PUNCT	O	O	3014
especially	ADV	O	O	3014
in	ADP	O	O	3014
patients	NOUN	O	O	3014
unable	ADJ	O	O	3014
to	PART	O	O	3014
exercise	VERB	O	O	3014
.	PUNCT	O	O	3014
Acute liver failure	NOUN	O	Disease	3017
in	ADP	O	O	3017
two	NUM	O	O	3017
patients	NOUN	O	O	3017
with	ADP	O	O	3017
regular	ADJ	O	O	3017
alcohol	NOUN	O	Chemical	3017
consumption	NOUN	O	O	3017
ingesting	VERB	O	O	3017
paracetamol	PROPN	O	Chemical	3017
at	ADP	O	O	3017
therapeutic	ADJ	O	O	3017
dosage	NOUN	O	O	3017
.	PUNCT	O	O	3017
The	PRON	O	O	3018
possible	ADJ	O	O	3018
role	NOUN	O	O	3018
of	ADP	O	O	3018
alcohol	NOUN	O	Chemical	3018
in	ADP	O	O	3018
the	PRON	O	O	3018
development	NOUN	O	O	3018
of	ADP	O	O	3018
hepatotoxicity	NOUN	O	Disease	3018
associated	VERB	O	O	3018
with	ADP	O	O	3018
therapeutic	ADJ	O	O	3018
doses	NOUN	O	O	3018
of	ADP	O	O	3018
paracetamol	PROPN	O	Chemical	3018
(	PUNCT	O	O	3018
acetaminophen	PROPN	O	Chemical	3018
)	PUNCT	O	O	3018
is	AUX	O	O	3018
currently	ADV	O	O	3018
debated	VERB	O	O	3018
.	PUNCT	O	O	3018
We	PRON	O	O	3019
describe	VERB	O	O	3019
2	X	O	O	3019
patients	NOUN	O	O	3019
who	PRON	O	O	3019
were	AUX	O	O	3019
regular	ADJ	O	O	3019
consumers	NOUN	O	O	3019
of	ADP	O	O	3019
alcohol	NOUN	O	Chemical	3019
and	CCONJ	O	O	3019
who	PRON	O	O	3019
developed	VERB	O	O	3019
liver failure	NOUN	O	Disease	3019
within	ADP	O	O	3019
3	X	O	O	3019
-	PUNCT	O	O	3019
5	NUM	O	O	3019
days	NOUN	O	O	3019
after	ADP	O	O	3019
hospitalization	NOUN	O	O	3019
and	CCONJ	O	O	3019
stopping	VERB	O	O	3019
alcohol	NOUN	O	Chemical	3019
consumption	NOUN	O	O	3019
while	SCONJ	O	O	3019
being	AUX	O	O	3019
treated	VERB	O	O	3019
with	ADP	O	O	3019
4	NUM	O	O	3019
g	X	O	O	3019
paracetamol	PROPN	O	Chemical	3019
/	PUNCT	O	O	3019
day	NOUN	O	O	3019
.	PUNCT	O	O	3019
A	PRON	O	O	3020
paracetamol	PROPN	O	Chemical	3020
serum	NOUN	O	O	3020
level	VERB	O	O	3020
obtained	VERB	O	O	3020
in	ADP	O	O	3020
one	NUM	O	O	3020
of	ADP	O	O	3020
these	PRON	O	O	3020
patients	NOUN	O	O	3020
was	AUX	O	O	3020
not	PART	O	O	3020
in	ADP	O	O	3020
the	PRON	O	O	3020
toxic	ADJ	O	O	3020
range	VERB	O	O	3020
.	PUNCT	O	O	3020
Possible	ADJ	O	O	3021
risk	NOUN	O	O	3021
factors	NOUN	O	O	3021
for	ADP	O	O	3021
the	PRON	O	O	3021
development	NOUN	O	O	3021
of	ADP	O	O	3021
hepatotoxicity	NOUN	O	Disease	3021
in	ADP	O	O	3021
patients	NOUN	O	O	3021
treated	VERB	O	O	3021
with	ADP	O	O	3021
therapeutic	ADJ	O	O	3021
doses	NOUN	O	O	3021
of	ADP	O	O	3021
paracetamol	PROPN	O	Chemical	3021
are	AUX	O	O	3021
discussed	VERB	O	O	3021
.	PUNCT	O	O	3021
In	ADP	O	O	3022
patients	NOUN	O	O	3022
with	ADP	O	O	3022
risk	NOUN	O	O	3022
factors	NOUN	O	O	3022
,	PUNCT	O	O	3022
e.g.	ADV	O	O	3022
regular	ADJ	O	O	3022
consumption	NOUN	O	O	3022
of	ADP	O	O	3022
alcohol	NOUN	O	Chemical	3022
,	PUNCT	O	O	3022
liver failure	NOUN	O	Disease	3022
is	AUX	O	O	3022
possible	ADJ	O	O	3022
when	SCONJ	O	O	3022
therapeutic	ADJ	O	O	3022
doses	NOUN	O	O	3022
are	AUX	O	O	3022
ingested	VERB	O	O	3022
.	PUNCT	O	O	3022
We	PRON	O	O	3023
propose	VERB	O	O	3023
that	SCONJ	O	O	3023
the	PRON	O	O	3023
paracetamol	PROPN	O	Chemical	3023
dose	NOUN	O	O	3023
should	AUX	O	O	3023
not	PART	O	O	3023
exceed	VERB	O	O	3023
2	X	O	O	3023
g	X	O	O	3023
/	PUNCT	O	O	3023
day	NOUN	O	O	3023
in	ADP	O	O	3023
such	ADJ	O	O	3023
patients	NOUN	O	O	3023
and	CCONJ	O	O	3023
that	SCONJ	O	O	3023
their	PRON	O	O	3023
liver	NOUN	O	O	3023
function	NOUN	O	O	3023
should	AUX	O	O	3023
be	AUX	O	O	3023
monitored	VERB	O	O	3023
closely	ADV	O	O	3023
while	SCONJ	O	O	3023
being	AUX	O	O	3023
treated	VERB	O	O	3023
with	ADP	O	O	3023
paracetamol	PROPN	O	Chemical	3023
.	PUNCT	O	O	3023
Cocaine	NOUN	O	Chemical	3026
related	ADJ	O	O	3026
chest pain	NOUN	O	Disease	3026
:	PUNCT	O	O	3026
The	PRON	O	O	3027
recreational	ADJ	O	O	3027
use	VERB	O	O	3027
of	ADP	O	O	3027
cocaine	NOUN	O	Chemical	3027
is	AUX	O	O	3027
on	ADP	O	O	3027
the	PRON	O	O	3027
increase	VERB	O	O	3027
.	PUNCT	O	O	3027
The	PRON	O	O	3028
emergency	NOUN	O	O	3028
nurse	NOUN	O	O	3028
ought	AUX	O	O	3028
to	PART	O	O	3028
be	AUX	O	O	3028
familiar	ADJ	O	O	3028
with	ADP	O	O	3028
some	PRON	O	O	3028
of	ADP	O	O	3028
the	PRON	O	O	3028
cardiovascular	ADJ	O	O	3028
consequences	NOUN	O	O	3028
of	ADP	O	O	3028
cocaine	NOUN	O	Chemical	3028
use	VERB	O	O	3028
.	PUNCT	O	O	3028
In	ADP	O	O	3029
particular	ADJ	O	O	3029
,	PUNCT	O	O	3029
the	PRON	O	O	3029
tendency	NOUN	O	O	3029
of	ADP	O	O	3029
cocaine	NOUN	O	Chemical	3029
to	PART	O	O	3029
produce	VERB	O	O	3029
chest pain	NOUN	O	Disease	3029
ought	AUX	O	O	3029
to	PART	O	O	3029
be	AUX	O	O	3029
in	ADP	O	O	3029
the	PRON	O	O	3029
mind	VERB	O	O	3029
of	ADP	O	O	3029
the	PRON	O	O	3029
emergency	NOUN	O	O	3029
nurse	NOUN	O	O	3029
when	SCONJ	O	O	3029
faced	VERB	O	O	3029
with	ADP	O	O	3029
a	PRON	O	O	3029
young	ADJ	O	O	3029
victim	NOUN	O	O	3029
of	ADP	O	O	3029
chest pain	NOUN	O	Disease	3029
who	PRON	O	O	3029
is	AUX	O	O	3029
otherwise	ADV	O	O	3029
at	ADP	O	O	3029
low	ADJ	O	O	3029
risk	NOUN	O	O	3029
.	PUNCT	O	O	3029
The	PRON	O	O	3030
mechanism	NOUN	O	O	3030
of	ADP	O	O	3030
chest pain	NOUN	O	Disease	3030
related	ADJ	O	O	3030
to	PART	O	O	3030
cocaine	NOUN	O	Chemical	3030
use	VERB	O	O	3030
is	AUX	O	O	3030
discussed	VERB	O	O	3030
and	CCONJ	O	O	3030
treatment	NOUN	O	O	3030
dilemmas	NOUN	O	O	3030
are	AUX	O	O	3030
discussed	VERB	O	O	3030
.	PUNCT	O	O	3030
Finally	ADV	O	O	3031
,	PUNCT	O	O	3031
moral	ADJ	O	O	3031
issues	NOUN	O	O	3031
relating	VERB	O	O	3031
to	PART	O	O	3031
the	PRON	O	O	3031
testing	NOUN	O	O	3031
of	ADP	O	O	3031
potential	ADJ	O	O	3031
cocaine	NOUN	O	Chemical	3031
users	NOUN	O	O	3031
will	AUX	O	O	3031
be	AUX	O	O	3031
addressed	VERB	O	O	3031
.	PUNCT	O	O	3031
Severe	ADJ	O	O	3034
rhabdomyolysis	NOUN	O	Disease	3034
and	CCONJ	O	O	3034
acute	ADJ	O	O	3034
renal failure	NOUN	O	Disease	3034
secondary	ADJ	O	O	3034
to	PART	O	O	3034
concomitant	ADJ	O	O	3034
use	VERB	O	O	3034
of	ADP	O	O	3034
simvastatin	PROPN	O	Chemical	3034
,	PUNCT	O	O	3034
amiodarone	NOUN	O	Chemical	3034
,	PUNCT	O	O	3034
and	CCONJ	O	O	3034
atazanavir	PROPN	O	O	3034
.	PUNCT	O	O	3034
OBJECTIVE	VERB	O	O	3035
:	PUNCT	O	O	3035
To	PART	O	O	3035
report	VERB	O	O	3035
a	PRON	O	O	3035
case	NOUN	O	O	3035
of	ADP	O	O	3035
a	PRON	O	O	3035
severe	ADJ	O	O	3035
interaction	NOUN	O	O	3035
between	ADP	O	O	3035
simvastatin	PROPN	O	Chemical	3035
,	PUNCT	O	O	3035
amiodarone	NOUN	O	Chemical	3035
,	PUNCT	O	O	3035
and	CCONJ	O	O	3035
atazanavir	PROPN	O	O	3035
resulting	VERB	O	O	3035
in	ADP	O	O	3035
rhabdomyolysis	NOUN	O	Disease	3035
and	CCONJ	O	O	3035
acute	ADJ	O	O	3035
renal failure	NOUN	O	Disease	3035
.	PUNCT	O	O	3035
A	PRON	O	O	3036
72-year	NOUN	O	O	3036
-	PUNCT	O	O	3036
old	ADJ	O	O	3036
white	ADJ	O	O	3036
man	NOUN	O	O	3036
with	ADP	O	O	3036
underlying	VERB	O	O	3036
human	PROPN	O	O	3036
immunodeficiency	NOUN	O	Disease	3036
virus	NOUN	O	O	3036
,	PUNCT	O	O	3036
atrial fibrillation	NOUN	O	Disease	3036
,	PUNCT	O	O	3036
coronary artery disease	NOUN	O	Disease	3036
,	PUNCT	O	O	3036
and	CCONJ	O	O	3036
hyperlipidemia	NOUN	O	Disease	3036
presented	VERB	O	O	3036
with	ADP	O	O	3036
generalized	VERB	O	O	3036
pain	NOUN	O	Disease	3036
,	PUNCT	O	O	3036
fatigue	NOUN	O	Disease	3036
,	PUNCT	O	O	3036
and	CCONJ	O	O	3036
dark	ADJ	O	O	3036
orange	PROPN	O	O	3036
urine	NOUN	O	O	3036
for	ADP	O	O	3036
3	X	O	O	3036
days	NOUN	O	O	3036
.	PUNCT	O	O	3036
The	PRON	O	O	3037
patient	NOUN	O	O	3037
was	AUX	O	O	3037
taking	VERB	O	O	3037
80	NUM	O	O	3037
mg	VERB	O	O	3037
simvastatin	PROPN	O	Chemical	3037
at	ADP	O	O	3037
bedtime	NOUN	O	O	3037
(	PUNCT	O	O	3037
initiated	VERB	O	O	3037
27	NUM	O	O	3037
days	NOUN	O	O	3037
earlier	ADV	O	O	3037
)	PUNCT	O	O	3037
;	PUNCT	O	O	3037
amiodarone	NOUN	O	Chemical	3037
at	ADP	O	O	3037
a	PRON	O	O	3037
dose	NOUN	O	O	3037
of	ADP	O	O	3037
400	NUM	O	O	3037
mg	VERB	O	O	3037
daily	ADV	O	O	3037
for	ADP	O	O	3037
7	NUM	O	O	3037
days	NOUN	O	O	3037
,	PUNCT	O	O	3037
then	ADV	O	O	3037
200	NUM	O	O	3037
mg	VERB	O	O	3037
daily	ADV	O	O	3037
(	PUNCT	O	O	3037
initiated	VERB	O	O	3037
19	NUM	O	O	3037
days	NOUN	O	O	3037
earlier	ADV	O	O	3037
)	PUNCT	O	O	3037
;	PUNCT	O	O	3037
and	CCONJ	O	O	3037
400	NUM	O	O	3037
mg	VERB	O	O	3037
atazanavir	PROPN	O	O	3037
daily	ADV	O	O	3037
(	PUNCT	O	O	3037
initiated	VERB	O	O	3037
at	ADP	O	O	3037
least	ADJ	O	O	3037
2	X	O	O	3037
years	NOUN	O	O	3037
previously	ADV	O	O	3037
)	PUNCT	O	O	3037
.	PUNCT	O	O	3037
Laboratory	NOUN	O	O	3038
evaluation	NOUN	O	O	3038
revealed	VERB	O	O	3038
66,680	NUM	O	O	3038
U	NOUN	O	O	3038
/	PUNCT	O	O	3038
L	NOUN	O	O	3038
creatine	PROPN	O	Chemical	3038
kinase	VERB	O	O	3038
,	PUNCT	O	O	3038
93	NUM	O	O	3038
mg	VERB	O	O	3038
/	PUNCT	O	O	3038
dL	VERB	O	O	3038
blood	NOUN	O	O	3038
urea nitrogen	NOUN	O	Chemical	3038
,	PUNCT	O	O	3038
4.6	NUM	O	O	3038
mg	VERB	O	O	3038
/	PUNCT	O	O	3038
dL	VERB	O	O	3038
creatinine	PROPN	O	Chemical	3038
,	PUNCT	O	O	3038
1579	NUM	O	O	3038
U	NOUN	O	O	3038
/	PUNCT	O	O	3038
L	NOUN	O	O	3038
aspartate	NOUN	O	Chemical	3038
aminotransferase	PROPN	O	O	3038
,	PUNCT	O	O	3038
and	CCONJ	O	O	3038
738	NUM	O	O	3038
U	NOUN	O	O	3038
/	PUNCT	O	O	3038
L	NOUN	O	O	3038
alanine	NOUN	O	Chemical	3038
aminotransferase	PROPN	O	O	3038
.	PUNCT	O	O	3038
Simvastatin	PROPN	O	O	3039
,	PUNCT	O	O	3039
amiodarone	NOUN	O	Chemical	3039
,	PUNCT	O	O	3039
and	CCONJ	O	O	3039
the	PRON	O	O	3039
patient	NOUN	O	O	3039
's	AUX	O	O	3039
human	PROPN	O	O	3039
immunodeficiency	NOUN	O	Disease	3039
virus	NOUN	O	O	3039
medications	NOUN	O	O	3039
were	AUX	O	O	3039
all	PRON	O	O	3039
temporarily	ADV	O	O	3039
discontinued	VERB	O	O	3039
and	CCONJ	O	O	3039
the	PRON	O	O	3039
patient	NOUN	O	O	3039
was	AUX	O	O	3039
given	VERB	O	O	3039
forced	VERB	O	O	3039
alkaline	NOUN	O	O	3039
diuresis	VERB	O	O	3039
and	CCONJ	O	O	3039
started	VERB	O	O	3039
on	ADP	O	O	3039
dialysis	NOUN	O	O	3039
.	PUNCT	O	O	3039
Nine	NUM	O	O	3040
days	NOUN	O	O	3040
later	ADV	O	O	3040
the	PRON	O	O	3040
patient	NOUN	O	O	3040
's	AUX	O	O	3040
creatine	PROPN	O	Chemical	3040
kinase	VERB	O	O	3040
had	VERB	O	O	3040
dropped	VERB	O	O	3040
to	PART	O	O	3040
1695	NUM	O	O	3040
U	NOUN	O	O	3040
/	PUNCT	O	O	3040
L	NOUN	O	O	3040
and	CCONJ	O	O	3040
creatinine	PROPN	O	Chemical	3040
was	AUX	O	O	3040
3.3	NUM	O	O	3040
mg	VERB	O	O	3040
/	PUNCT	O	O	3040
dL.	PROPN	O	O	3040
The	PRON	O	O	3040
patient	NOUN	O	O	3040
was	AUX	O	O	3040
discharged	VERB	O	O	3040
and	CCONJ	O	O	3040
continued	VERB	O	O	3040
outpatient	NOUN	O	O	3040
dialysis	NOUN	O	O	3040
for	ADP	O	O	3040
1	X	O	O	3040
month	NOUN	O	O	3040
until	ADP	O	O	3040
his	PRON	O	O	3040
renal	ADJ	O	O	3040
function	NOUN	O	O	3040
recovered	VERB	O	O	3040
.	PUNCT	O	O	3040
The	PRON	O	O	3041
risk	NOUN	O	O	3041
of	ADP	O	O	3041
rhabdomyolysis	NOUN	O	Disease	3041
is	AUX	O	O	3041
increased	VERB	O	O	3041
in	ADP	O	O	3041
the	PRON	O	O	3041
presence	NOUN	O	O	3041
of	ADP	O	O	3041
concomitant	ADJ	O	O	3041
drugs	NOUN	O	O	3041
that	SCONJ	O	O	3041
inhibit	VERB	O	O	3041
simvastatin	PROPN	O	Chemical	3041
metabolism	NOUN	O	O	3041
.	PUNCT	O	O	3041
Simvastatin	PROPN	O	O	3042
is	AUX	O	O	3042
metabolized	VERB	O	O	3042
by	ADP	O	O	3042
CYP3A4	PROPN	O	O	3042
.	PUNCT	O	O	3042
Amiodarone	NOUN	O	Chemical	3043
and	CCONJ	O	O	3043
atazanavir	PROPN	O	O	3043
are	AUX	O	O	3043
recognized	VERB	O	O	3043
CYP3A4	PROPN	O	O	3043
inhibitors	NOUN	O	O	3043
.	PUNCT	O	O	3043
CONCLUSIONS	NOUN	O	O	3044
:	PUNCT	O	O	3044
Pharmacokinetic	NOUN	O	O	3044
differences	NOUN	O	O	3044
in	ADP	O	O	3044
statins	NOUN	O	O	3044
are	AUX	O	O	3044
an	PRON	O	O	3044
important	ADJ	O	O	3044
consideration	NOUN	O	O	3044
for	ADP	O	O	3044
assessing	VERB	O	O	3044
the	PRON	O	O	3044
risk	NOUN	O	O	3044
of	ADP	O	O	3044
potential	ADJ	O	O	3044
drug	NOUN	O	O	3044
interactions	NOUN	O	O	3044
.	PUNCT	O	O	3044
In	ADP	O	O	3045
patients	NOUN	O	O	3045
requiring	VERB	O	O	3045
the	PRON	O	O	3045
concurrent	ADJ	O	O	3045
use	VERB	O	O	3045
of	ADP	O	O	3045
statins	NOUN	O	O	3045
and	CCONJ	O	O	3045
CYP3A4	PROPN	O	O	3045
inhibitors	NOUN	O	O	3045
,	PUNCT	O	O	3045
pravastatin	PROPN	O	Chemical	3045
,	PUNCT	O	O	3045
fluvastatin	NOUN	O	O	3045
,	PUNCT	O	O	3045
and	CCONJ	O	O	3045
rosuvastatin	NOUN	O	O	3045
carry	VERB	O	O	3045
the	PRON	O	O	3045
lowest	ADJ	O	O	3045
risk	NOUN	O	O	3045
of	ADP	O	O	3045
drug	NOUN	O	O	3045
interactions	NOUN	O	O	3045
;	PUNCT	O	O	3045
atorvastatin	PROPN	O	Chemical	3045
carries	VERB	O	O	3045
moderate	ADJ	O	O	3045
risk	NOUN	O	O	3045
,	PUNCT	O	O	3045
whereas	SCONJ	O	O	3045
simvastatin	PROPN	O	Chemical	3045
and	CCONJ	O	O	3045
lovastatin	NOUN	O	Chemical	3045
have	VERB	O	O	3045
the	PRON	O	O	3045
highest	ADJ	O	O	3045
risk	NOUN	O	O	3045
and	CCONJ	O	O	3045
should	AUX	O	O	3045
be	AUX	O	O	3045
avoided	VERB	O	O	3045
in	ADP	O	O	3045
patients	NOUN	O	O	3045
taking	VERB	O	O	3045
concomitant	ADJ	O	O	3045
CYP3A4	PROPN	O	O	3045
inhibitors	NOUN	O	O	3045
.	PUNCT	O	O	3045
Phase	NOUN	O	O	3048
II	NUM	O	O	3048
trial	NOUN	O	O	3048
of	ADP	O	O	3048
vinorelbine	VERB	O	O	3048
in	ADP	O	O	3048
metastatic	ADJ	O	O	3048
squamous	ADJ	O	O	3048
cell	NOUN	O	O	3048
esophageal	ADJ	O	O	3048
carcinoma	NOUN	O	Disease	3048
.	PUNCT	O	O	3048
European	ADJ	O	O	3049
Organization	PROPN	O	O	3049
for	ADP	O	O	3049
Research	NOUN	O	O	3049
and	CCONJ	O	O	3049
Treatment	NOUN	O	O	3049
of	ADP	O	O	3049
Cancer	NOUN	O	O	3049
Gastrointestinal	ADJ	O	O	3049
Treat	VERB	O	O	3049
Cancer	NOUN	O	O	3049
Cooperative	ADJ	O	O	3049
Group	PROPN	O	O	3049
.	PUNCT	O	O	3049
PURPOSE	NOUN	O	O	3050
:	PUNCT	O	O	3050
To	PART	O	O	3050
evaluate	VERB	O	O	3050
the	PRON	O	O	3050
response	NOUN	O	O	3050
rate	NOUN	O	O	3050
and	CCONJ	O	O	3050
toxic	ADJ	O	O	3050
effects	NOUN	O	O	3050
of	ADP	O	O	3050
vinorelbine	VERB	O	O	3050
(	PUNCT	O	O	3050
VNB	NOUN	O	O	3050
)	PUNCT	O	O	3050
administered	VERB	O	O	3050
as	ADP	O	O	3050
a	PRON	O	O	3050
single	ADJ	O	O	3050
agent	NOUN	O	O	3050
in	ADP	O	O	3050
metastatic	ADJ	O	O	3050
squamous	ADJ	O	O	3050
cell	NOUN	O	O	3050
esophageal	ADJ	O	O	3050
carcinoma	NOUN	O	Disease	3050
.	PUNCT	O	O	3050
Thirty	NUM	O	O	3051
patients	NOUN	O	O	3051
without	ADP	O	O	3051
prior	ADV	O	O	3051
chemotherapy	NOUN	O	O	3051
and	CCONJ	O	O	3051
16	NUM	O	O	3051
pretreated	VERB	O	O	3051
with	ADP	O	O	3051
cisplatin	NOUN	O	Chemical	3051
-	PUNCT	O	O	3051
based	VERB	O	O	3051
chemotherapy	NOUN	O	O	3051
were	AUX	O	O	3051
assessable	ADJ	O	O	3051
for	ADP	O	O	3051
toxicity	NOUN	O	Disease	3051
and	CCONJ	O	O	3051
response	NOUN	O	O	3051
.	PUNCT	O	O	3051
VNB	NOUN	O	O	3052
was	AUX	O	O	3052
administered	VERB	O	O	3052
weekly	ADV	O	O	3052
as	ADP	O	O	3052
a	PRON	O	O	3052
25-mg	NOUN	O	O	3052
/	PUNCT	O	O	3052
m2	PROPN	O	O	3052
short	ADJ	O	O	3052
intravenous	ADJ	O	O	3052
(	PUNCT	O	O	3052
i.v	NOUN	O	O	3052
.	PUNCT	O	O	3052
)	PUNCT	O	O	3052
VNB	NOUN	O	O	3053
was	AUX	O	O	3053
well	ADV	O	O	3053
tolerated	VERB	O	O	3053
and	CCONJ	O	O	3053
zero	NUM	O	O	3053
instances	NOUN	O	O	3053
of	ADP	O	O	3053
WHO	PRON	O	O	3053
grade	NOUN	O	O	3053
4	NUM	O	O	3053
nonhematologic toxicity	NOUN	O	O	3053
occurred	VERB	O	O	3053
.	PUNCT	O	O	3053
At	ADP	O	O	3054
least	ADJ	O	O	3054
one	NUM	O	O	3054
episode	PROPN	O	O	3054
of	ADP	O	O	3054
grade	NOUN	O	O	3054
3	X	O	O	3054
or	CCONJ	O	O	3054
4	NUM	O	O	3054
granulocytopenia	PROPN	O	Disease	3054
was	AUX	O	O	3054
seen	VERB	O	O	3054
in	ADP	O	O	3054
59%	NOUN	O	O	3054
of	ADP	O	O	3054
patients	NOUN	O	O	3054
.	PUNCT	O	O	3054
A	PRON	O	O	3055
grade	NOUN	O	O	3055
2	X	O	O	3055
or	CCONJ	O	O	3055
3	X	O	O	3055
infection	NOUN	O	Disease	3055
occurred	VERB	O	O	3055
in	ADP	O	O	3055
16%	NOUN	O	O	3055
of	ADP	O	O	3055
patients	NOUN	O	O	3055
,	PUNCT	O	O	3055
but	CCONJ	O	O	3055
no	PRON	O	O	3055
toxic	ADJ	O	O	3055
deaths	NOUN	O	O	3055
occurred	VERB	O	O	3055
.	PUNCT	O	O	3055
Other	ADJ	O	O	3056
side	NOUN	O	O	3056
effects	NOUN	O	O	3056
were	AUX	O	O	3056
rare	ADJ	O	O	3056
,	PUNCT	O	O	3056
and	CCONJ	O	O	3056
peripheral neurotoxicity	NOUN	O	Disease	3056
has	VERB	O	O	3056
been	AUX	O	O	3056
minor	ADJ	O	O	3056
(	PUNCT	O	O	3056
26%	NOUN	O	O	3056
grade	NOUN	O	O	3056
1	X	O	O	3056
)	PUNCT	O	O	3056
.	PUNCT	O	O	3056
CONCLUSION	PROPN	O	O	3057
:	PUNCT	O	O	3057
These	PRON	O	O	3057
data	NOUN	O	O	3057
indicate	VERB	O	O	3057
that	SCONJ	O	O	3057
VNB	NOUN	O	O	3057
is	AUX	O	O	3057
an	PRON	O	O	3057
active	ADJ	O	O	3057
agent	NOUN	O	O	3057
in	ADP	O	O	3057
metastatic	ADJ	O	O	3057
esophageal	ADJ	O	O	3057
squamous	ADJ	O	O	3057
cell	NOUN	O	O	3057
carcinoma	NOUN	O	Disease	3057
.	PUNCT	O	O	3057
Given	VERB	O	O	3058
its	PRON	O	O	3058
excellent	ADJ	O	O	3058
tolerance	NOUN	O	O	3058
profile	NOUN	O	O	3058
and	CCONJ	O	O	3058
low	ADJ	O	O	3058
toxicity	NOUN	O	Disease	3058
,	PUNCT	O	O	3058
further	ADV	O	O	3058
evaluation	NOUN	O	O	3058
of	ADP	O	O	3058
VNB	NOUN	O	O	3058
in	ADP	O	O	3058
combination	NOUN	O	O	3058
therapy	NOUN	O	O	3058
is	AUX	O	O	3058
warranted	VERB	O	O	3058
.	PUNCT	O	O	3058
Paclitaxel	PROPN	O	Chemical	3061
,	PUNCT	O	O	3061
cisplatin	NOUN	O	Chemical	3061
,	PUNCT	O	O	3061
and	CCONJ	O	O	3061
gemcitabine	NOUN	O	O	3061
combination	NOUN	O	O	3061
chemotherapy	NOUN	O	O	3061
within	ADP	O	O	3061
a	PRON	O	O	3061
multidisciplinary	ADJ	O	O	3061
therapeutic	ADJ	O	O	3061
approach	NOUN	O	O	3061
in	ADP	O	O	3061
metastatic	ADJ	O	O	3061
nonsmall	NOUN	O	O	3061
cell	NOUN	O	O	3061
lung	NOUN	O	O	3061
carcinoma	NOUN	O	Disease	3061
.	PUNCT	O	O	3061
Cisplatin	PROPN	O	O	3062
-	PUNCT	O	O	3062
based	VERB	O	O	3062
chemotherapy	NOUN	O	O	3062
combinations	NOUN	O	O	3062
improve	VERB	O	O	3062
quality	NOUN	O	O	3062
of	ADP	O	O	3062
life	NOUN	O	O	3062
and	CCONJ	O	O	3062
survival	NOUN	O	O	3062
in	ADP	O	O	3062
advanced	ADJ	O	O	3062
nonsmall	NOUN	O	O	3062
cell	NOUN	O	O	3062
lung	NOUN	O	O	3062
carcinoma	NOUN	O	Disease	3062
(	PUNCT	O	O	3062
NSCLC	PROPN	O	Disease	3062
)	PUNCT	O	O	3062
.	PUNCT	O	O	3062
The	PRON	O	O	3063
objective	VERB	O	O	3063
of	ADP	O	O	3063
this	PRON	O	O	3063
study	VERB	O	O	3063
was	AUX	O	O	3063
to	PART	O	O	3063
determine	VERB	O	O	3063
the	PRON	O	O	3063
feasibility	NOUN	O	O	3063
,	PUNCT	O	O	3063
response	NOUN	O	O	3063
rate	NOUN	O	O	3063
,	PUNCT	O	O	3063
and	CCONJ	O	O	3063
toxicity	NOUN	O	Disease	3063
of	ADP	O	O	3063
a	PRON	O	O	3063
paclitaxel	NOUN	O	Chemical	3063
,	PUNCT	O	O	3063
cisplatin	NOUN	O	Chemical	3063
,	PUNCT	O	O	3063
and	CCONJ	O	O	3063
gemcitabine	NOUN	O	O	3063
combination	NOUN	O	O	3063
to	PART	O	O	3063
treat	VERB	O	O	3063
metastatic	ADJ	O	O	3063
NSCLC	PROPN	O	Disease	3063
.	PUNCT	O	O	3063
Thirty	NUM	O	O	3064
-	PUNCT	O	O	3064
five	NUM	O	O	3064
consecutive	ADJ	O	O	3064
chemotherapy	NOUN	O	O	3064
-	PUNCT	O	O	3064
naive	ADJ	O	O	3064
patients	NOUN	O	O	3064
with	ADP	O	O	3064
Stage	NOUN	O	O	3064
IV	NUM	O	O	3064
NSCLC	PROPN	O	Disease	3064
and	CCONJ	O	O	3064
an	PRON	O	O	3064
Eastern	PROPN	O	O	3064
Cooperative	ADJ	O	O	3064
Oncology	NOUN	O	O	3064
Group	PROPN	O	O	3064
performance	NOUN	O	O	3064
status	NOUN	O	O	3064
of	ADP	O	O	3064
0	NUM	O	O	3064
-	PUNCT	O	O	3064
2	X	O	O	3064
were	AUX	O	O	3064
treated	VERB	O	O	3064
with	ADP	O	O	3064
a	PRON	O	O	3064
combination	NOUN	O	O	3064
of	ADP	O	O	3064
paclitaxel	NOUN	O	Chemical	3064
(	PUNCT	O	O	3064
135	NUM	O	O	3064
mg	VERB	O	O	3064
/	PUNCT	O	O	3064
m(2	NUM	O	O	3064
)	PUNCT	O	O	3064
given	VERB	O	O	3064
intravenously	ADV	O	O	3064
in	ADP	O	O	3064
3	X	O	O	3064
hours	NOUN	O	O	3064
)	PUNCT	O	O	3064
on	ADP	O	O	3064
Day	NOUN	O	O	3064
1	X	O	O	3064
,	PUNCT	O	O	3064
cisplatin	NOUN	O	Chemical	3064
(	PUNCT	O	O	3064
120	NUM	O	O	3064
mg	VERB	O	O	3064
/	PUNCT	O	O	3064
m(2	NUM	O	O	3064
)	PUNCT	O	O	3064
given	VERB	O	O	3064
intravenously	ADV	O	O	3064
in	ADP	O	O	3064
6	NUM	O	O	3064
hours	NOUN	O	O	3064
)	PUNCT	O	O	3064
on	ADP	O	O	3064
Day	NOUN	O	O	3064
1	X	O	O	3064
,	PUNCT	O	O	3064
and	CCONJ	O	O	3064
gemcitabine	NOUN	O	O	3064
(	PUNCT	O	O	3064
800	NUM	O	O	3064
mg	VERB	O	O	3064
/	PUNCT	O	O	3064
m(2	NUM	O	O	3064
)	PUNCT	O	O	3064
given	VERB	O	O	3064
intravenously	ADV	O	O	3064
in	ADP	O	O	3064
30	NUM	O	O	3064
minutes	NOUN	O	O	3064
)	PUNCT	O	O	3064
on	ADP	O	O	3064
Days	NOUN	O	O	3064
1	X	O	O	3064
and	CCONJ	O	O	3064
8	NUM	O	O	3064
,	PUNCT	O	O	3064
every	PRON	O	O	3064
4	NUM	O	O	3064
weeks	NOUN	O	O	3064
.	PUNCT	O	O	3064
Although	SCONJ	O	O	3065
responding	VERB	O	O	3065
patients	NOUN	O	O	3065
were	AUX	O	O	3065
scheduled	VERB	O	O	3065
to	PART	O	O	3065
receive	VERB	O	O	3065
consolidation	NOUN	O	O	3065
radiotherapy	NOUN	O	O	3065
and	CCONJ	O	O	3065
24	NUM	O	O	3065
patients	NOUN	O	O	3065
received	VERB	O	O	3065
preplanned	VERB	O	O	3065
second	ADV	O	O	3065
-	PUNCT	O	O	3065
line	NOUN	O	O	3065
chemotherapy	NOUN	O	O	3065
after	ADP	O	O	3065
disease	PROPN	O	O	3065
progression	NOUN	O	O	3065
,	PUNCT	O	O	3065
the	PRON	O	O	3065
response	NOUN	O	O	3065
and	CCONJ	O	O	3065
toxicity	NOUN	O	Disease	3065
rates	NOUN	O	O	3065
reported	VERB	O	O	3065
refer	VERB	O	O	3065
only	ADV	O	O	3065
to	PART	O	O	3065
the	PRON	O	O	3065
chemotherapy	NOUN	O	O	3065
regimen	NOUN	O	O	3065
given	VERB	O	O	3065
.	PUNCT	O	O	3065
All	PRON	O	O	3066
the	PRON	O	O	3066
patients	NOUN	O	O	3066
were	AUX	O	O	3066
examined	VERB	O	O	3066
for	ADP	O	O	3066
toxicity	NOUN	O	Disease	3066
;	PUNCT	O	O	3066
34	NUM	O	O	3066
were	AUX	O	O	3066
examinable	ADJ	O	O	3066
for	ADP	O	O	3066
response	NOUN	O	O	3066
.	PUNCT	O	O	3066
After	ADP	O	O	3067
154	NUM	O	O	3067
courses	NOUN	O	O	3067
of	ADP	O	O	3067
therapy	NOUN	O	O	3067
,	PUNCT	O	O	3067
the	PRON	O	O	3067
median	ADJ	O	O	3067
dose	NOUN	O	O	3067
intensity	NOUN	O	O	3067
was	AUX	O	O	3067
131	NUM	O	O	3067
mg	VERB	O	O	3067
/	PUNCT	O	O	3067
m(2	NUM	O	O	3067
)	PUNCT	O	O	3067
for	ADP	O	O	3067
paclitaxel	NOUN	O	Chemical	3067
(	PUNCT	O	O	3067
97.3%	NOUN	O	O	3067
)	PUNCT	O	O	3067
,	PUNCT	O	O	3067
117	NUM	O	O	3067
mg	VERB	O	O	3067
/	PUNCT	O	O	3067
m(2	NUM	O	O	3067
)	PUNCT	O	O	3067
for	ADP	O	O	3067
cisplatin	NOUN	O	Chemical	3067
(	PUNCT	O	O	3067
97.3%	NOUN	O	O	3067
)	PUNCT	O	O	3067
,	PUNCT	O	O	3067
and	CCONJ	O	O	3067
1378	NUM	O	O	3067
mg	VERB	O	O	3067
/	PUNCT	O	O	3067
m(2	NUM	O	O	3067
)	PUNCT	O	O	3067
for	ADP	O	O	3067
gemcitabine	NOUN	O	O	3067
(	PUNCT	O	O	3067
86.2%	NOUN	O	O	3067
)	PUNCT	O	O	3067
.	PUNCT	O	O	3067
World	NOUN	O	O	3068
Health	NOUN	O	O	3068
Organization	PROPN	O	O	3068
Grade	NOUN	O	O	3068
3	X	O	O	3068
-	PUNCT	O	O	3068
4	NUM	O	O	3068
neutropenia	ADJ	O	Disease	3068
and	CCONJ	O	O	3068
thrombocytopenia	PROPN	O	Disease	3068
occurred	VERB	O	O	3068
in	ADP	O	O	3068
39.9%	NOUN	O	O	3068
and	CCONJ	O	O	3068
11.4%	NOUN	O	O	3068
of	ADP	O	O	3068
patients	NOUN	O	O	3068
,	PUNCT	O	O	3068
respectively	ADV	O	O	3068
.	PUNCT	O	O	3068
There	ADV	O	O	3069
was	AUX	O	O	3069
one	NUM	O	O	3069
treatment	NOUN	O	O	3069
-	PUNCT	O	O	3069
related	ADJ	O	O	3069
death	NOUN	O	O	3069
.	PUNCT	O	O	3069
Nonhematologic	ADJ	O	O	3070
toxicities	NOUN	O	Disease	3070
were	AUX	O	O	3070
mild	ADJ	O	O	3070
.	PUNCT	O	O	3070
The	PRON	O	O	3071
combination	NOUN	O	O	3071
of	ADP	O	O	3071
paclitaxel	NOUN	O	Chemical	3071
,	PUNCT	O	O	3071
cisplatin	NOUN	O	Chemical	3071
,	PUNCT	O	O	3071
and	CCONJ	O	O	3071
gemcitabine	NOUN	O	O	3071
is	AUX	O	O	3071
well	ADV	O	O	3071
tolerated	VERB	O	O	3071
and	CCONJ	O	O	3071
shows	VERB	O	O	3071
high	ADJ	O	O	3071
activity	NOUN	O	O	3071
in	ADP	O	O	3071
metastatic	ADJ	O	O	3071
NSCLC	PROPN	O	Disease	3071
.	PUNCT	O	O	3071
This	PRON	O	O	3072
treatment	NOUN	O	O	3072
merits	NOUN	O	O	3072
further	ADV	O	O	3072
comparison	NOUN	O	O	3072
with	ADP	O	O	3072
other	ADJ	O	O	3072
cisplatin	NOUN	O	Chemical	3072
-	PUNCT	O	O	3072
based	VERB	O	O	3072
regimens	NOUN	O	O	3072
.	PUNCT	O	O	3072
Evaluation	NOUN	O	O	3075
of	ADP	O	O	3075
adverse	ADJ	O	O	3075
reactions	NOUN	O	O	3075
of	ADP	O	O	3075
aponidine	NOUN	O	O	3075
hydrochloride	NOUN	O	O	3075
ophthalmic	ADJ	O	O	3075
solution	NOUN	O	O	3075
.	PUNCT	O	O	3075
We	PRON	O	O	3076
prospectively	ADV	O	O	3076
evaluated	VERB	O	O	3076
the	PRON	O	O	3076
adverse	ADJ	O	O	3076
reactions	NOUN	O	O	3076
of	ADP	O	O	3076
apraclonidine	VERB	O	O	3076
in	ADP	O	O	3076
20	NUM	O	O	3076
normal	ADJ	O	O	3076
volunteers	NOUN	O	O	3076
by	ADP	O	O	3076
instilling	VERB	O	O	3076
a	PRON	O	O	3076
single	ADJ	O	O	3076
drop	VERB	O	O	3076
of	ADP	O	O	3076
1%	NOUN	O	O	3076
apraclonidine	VERB	O	O	3076
in	ADP	O	O	3076
their	PRON	O	O	3076
right	ADV	O	O	3076
eyes	NOUN	O	O	3076
.	PUNCT	O	O	3076
The	PRON	O	O	3077
ocular	ADJ	O	O	3077
hypotensive	ADJ	O	Disease	3077
effects	NOUN	O	O	3077
were	AUX	O	O	3077
statistically	ADV	O	O	3077
significant	ADJ	O	O	3077
for	ADP	O	O	3077
apraclonidine	VERB	O	O	3077
-	PUNCT	O	O	3077
treated	VERB	O	O	3077
eyes	NOUN	O	O	3077
throughout	ADP	O	O	3077
the	PRON	O	O	3077
study	VERB	O	O	3077
and	CCONJ	O	O	3077
also	ADV	O	O	3077
statistically	ADV	O	O	3077
significant	ADJ	O	O	3077
for	ADP	O	O	3077
contralateral	ADJ	O	O	3077
eyes	NOUN	O	O	3077
from	ADP	O	O	3077
three	NUM	O	O	3077
hours	NOUN	O	O	3077
after	ADP	O	O	3077
topical	ADJ	O	O	3077
administration	NOUN	O	O	3077
of	ADP	O	O	3077
1%	NOUN	O	O	3077
apraclonidine	VERB	O	O	3077
.	PUNCT	O	O	3077
Decreases	NOUN	O	O	3078
in	ADP	O	O	3078
systolic	ADV	O	O	3078
blood	NOUN	O	O	3078
pressure	NOUN	O	O	3078
were	AUX	O	O	3078
statistically	ADV	O	O	3078
,	PUNCT	O	O	3078
but	CCONJ	O	O	3078
not	PART	O	O	3078
clinically	ADV	O	O	3078
,	PUNCT	O	O	3078
significant	ADJ	O	O	3078
.	PUNCT	O	O	3078
Conjunctival	NOUN	O	O	3079
blanching	VERB	O	O	3079
and	CCONJ	O	O	3079
mydriasis	ADJ	O	Disease	3079
were	AUX	O	O	3079
commonly	ADV	O	O	3079
found	VERB	O	O	3079
.	PUNCT	O	O	3079
While	SCONJ	O	O	3080
the	PRON	O	O	3080
elevations	NOUN	O	O	3080
of	ADP	O	O	3080
the	PRON	O	O	3080
upper	ADJ	O	O	3080
lid	VERB	O	O	3080
margin	NOUN	O	O	3080
in	ADP	O	O	3080
most	ADV	O	O	3080
subjects	NOUN	O	O	3080
were	AUX	O	O	3080
not	PART	O	O	3080
more	ADJ	O	O	3080
than	ADP	O	O	3080
2	X	O	O	3080
mm	INTJ	O	O	3080
and	CCONJ	O	O	3080
did	VERB	O	O	3080
not	PART	O	O	3080
cause	VERB	O	O	3080
noticeable	ADJ	O	O	3080
change	VERB	O	O	3080
in	ADP	O	O	3080
appearance	NOUN	O	O	3080
,	PUNCT	O	O	3080
one	NUM	O	O	3080
subject	ADJ	O	O	3080
suffered	VERB	O	O	3080
from	ADP	O	O	3080
mechanical	ADJ	O	O	3080
entropion	NOUN	O	O	3080
and	CCONJ	O	O	3080
marked	VERB	O	O	3080
corneal	PROPN	O	O	3080
abrasion	NOUN	O	O	3080
3	X	O	O	3080
hours	NOUN	O	O	3080
after	ADP	O	O	3080
instillation	NOUN	O	O	3080
of	ADP	O	O	3080
the	PRON	O	O	3080
medication	NOUN	O	O	3080
.	PUNCT	O	O	3080
Carmofur	NOUN	O	O	3083
-	PUNCT	O	O	3083
induced	VERB	O	O	3083
organic	ADJ	O	O	3083
mental	ADJ	O	O	3083
disorders	NOUN	O	O	3083
.	PUNCT	O	O	3083
Organic	NOUN	O	O	3084
mental	ADJ	O	O	3084
disorder	NOUN	O	O	3084
was	AUX	O	O	3084
observed	VERB	O	O	3084
in	ADP	O	O	3084
a	PRON	O	O	3084
29-year	NOUN	O	O	3084
-	PUNCT	O	O	3084
old	ADJ	O	O	3084
female	ADJ	O	O	3084
in	ADP	O	O	3084
the	PRON	O	O	3084
prognostic	ADJ	O	O	3084
period	NOUN	O	O	3084
after	ADP	O	O	3084
the	PRON	O	O	3084
onset	VERB	O	O	3084
of	ADP	O	O	3084
carmofur	NOUN	O	Chemical	3084
-	PUNCT	O	O	3084
induced	VERB	O	O	3084
leukoencephalopathy	ADJ	O	Disease	3084
.	PUNCT	O	O	3084
Symptoms	NOUN	O	O	3085
such	ADJ	O	O	3085
as	ADP	O	O	3085
euphoria	PROPN	O	O	3085
,	PUNCT	O	O	3085
emotional	ADJ	O	O	3085
lability	NOUN	O	O	3085
and	CCONJ	O	O	3085
puerile	ADJ	O	O	3085
attitude	NOUN	O	O	3085
noted	VERB	O	O	3085
in	ADP	O	O	3085
the	PRON	O	O	3085
patient	NOUN	O	O	3085
were	AUX	O	O	3085
diagnosed	VERB	O	O	3085
as	ADP	O	O	3085
organic	ADJ	O	O	3085
personality	NOUN	O	O	3085
syndrome	NOUN	O	O	3085
according	VERB	O	O	3085
to	PART	O	O	3085
the	PRON	O	O	3085
criteria	NOUN	O	O	3085
defined	VERB	O	O	3085
in	ADP	O	O	3085
the	PRON	O	O	3085
DSM	PROPN	O	O	3085
-	PUNCT	O	O	3085
III	NUM	O	O	3085
-	PUNCT	O	O	3085
R.	PROPN	O	O	3085
It	PRON	O	O	3085
is	AUX	O	O	3085
referred	VERB	O	O	3085
to	PART	O	O	3085
as	ADP	O	O	3085
a	PRON	O	O	3085
frontal	ADJ	O	O	3085
lobe	NOUN	O	O	3085
syndrome	NOUN	O	O	3085
.	PUNCT	O	O	3085
Consequently	ADV	O	O	3086
,	PUNCT	O	O	3086
carmofur	NOUN	O	Chemical	3086
-	PUNCT	O	O	3086
induced	VERB	O	O	3086
leukoencephalopathy	ADJ	O	Disease	3086
may	AUX	O	O	3086
uncommonly	ADV	O	O	3086
result	VERB	O	O	3086
in	ADP	O	O	3086
organic	ADJ	O	O	3086
personality	NOUN	O	O	3086
syndrome	NOUN	O	O	3086
in	ADP	O	O	3086
the	PRON	O	O	3086
residual	ADJ	O	O	3086
state	NOUN	O	O	3086
.	PUNCT	O	O	3086
It	PRON	O	O	3087
may	AUX	O	O	3087
be	AUX	O	O	3087
attributed	VERB	O	O	3087
to	PART	O	O	3087
the	PRON	O	O	3087
structural	ADJ	O	O	3087
damage	NOUN	O	O	3087
to	PART	O	O	3087
the	PRON	O	O	3087
frontal	ADJ	O	O	3087
lobe	NOUN	O	O	3087
.	PUNCT	O	O	3087
International	PROPN	O	O	3090
mexiletine	NOUN	O	Chemical	3090
and	CCONJ	O	O	3090
placebo	NOUN	O	O	3090
antiarrhythmic	PROPN	O	O	3090
coronary	ADJ	O	O	3090
trial	NOUN	O	O	3090
:	PUNCT	O	O	3090
I.	NOUN	O	O	3090
Report	NOUN	O	O	3090
on	ADP	O	O	3090
arrhythmia	NOUN	O	Disease	3090
and	CCONJ	O	O	3090
other	ADJ	O	O	3090
findings	NOUN	O	O	3090
.	PUNCT	O	O	3090
The	PRON	O	O	3091
antiarrhythmic	PROPN	O	O	3091
effects	NOUN	O	O	3091
of	ADP	O	O	3091
the	PRON	O	O	3091
sustained	VERB	O	O	3091
release	NOUN	O	O	3091
form	NOUN	O	O	3091
of	ADP	O	O	3091
mexiletine	NOUN	O	Chemical	3091
(	PUNCT	O	O	3091
Mexitil	NOUN	O	O	3091
-	PUNCT	O	O	3091
Perlongets	NOUN	O	O	3091
)	PUNCT	O	O	3091
were	AUX	O	O	3091
evaluated	VERB	O	O	3091
in	ADP	O	O	3091
a	PRON	O	O	3091
double	ADJ	O	O	3091
-	PUNCT	O	O	3091
blind	ADJ	O	Disease	3091
placebo	NOUN	O	O	3091
trial	NOUN	O	O	3091
in	ADP	O	O	3091
630	NUM	O	O	3091
patients	NOUN	O	O	3091
with	ADP	O	O	3091
recent	ADJ	O	O	3091
documented	VERB	O	O	3091
myocardial infarction	NOUN	O	Disease	3091
.	PUNCT	O	O	3091
Large	ADJ	O	O	3092
differences	NOUN	O	O	3092
,	PUNCT	O	O	3092
regarded	VERB	O	O	3092
as	ADP	O	O	3092
statistically	ADV	O	O	3092
significant	ADJ	O	O	3092
,	PUNCT	O	O	3092
between	ADP	O	O	3092
the	PRON	O	O	3092
mexiletine	NOUN	O	Chemical	3092
and	CCONJ	O	O	3092
placebo	NOUN	O	O	3092
groups	NOUN	O	O	3092
were	AUX	O	O	3092
noted	VERB	O	O	3092
in	ADP	O	O	3092
that	SCONJ	O	O	3092
end	VERB	O	O	3092
point	VERB	O	O	3092
at	ADP	O	O	3092
months	NOUN	O	O	3092
1	X	O	O	3092
and	CCONJ	O	O	3092
4	NUM	O	O	3092
,	PUNCT	O	O	3092
but	CCONJ	O	O	3092
only	ADV	O	O	3092
trends	NOUN	O	O	3092
were	AUX	O	O	3092
observed	VERB	O	O	3092
at	ADP	O	O	3092
month	NOUN	O	O	3092
12	NUM	O	O	3092
.	PUNCT	O	O	3092
These	PRON	O	O	3093
differences	NOUN	O	O	3093
were	AUX	O	O	3093
observed	VERB	O	O	3093
even	ADV	O	O	3093
though	SCONJ	O	O	3093
the	PRON	O	O	3093
serum	NOUN	O	O	3093
mexiletine	NOUN	O	Chemical	3093
levels	NOUN	O	O	3093
obtained	VERB	O	O	3093
in	ADP	O	O	3093
this	PRON	O	O	3093
study	VERB	O	O	3093
were	AUX	O	O	3093
generally	ADV	O	O	3093
lower	ADJ	O	O	3093
than	ADP	O	O	3093
those	PRON	O	O	3093
observed	VERB	O	O	3093
in	ADP	O	O	3093
studies	NOUN	O	O	3093
that	SCONJ	O	O	3093
have	VERB	O	O	3093
used	VERB	O	O	3093
the	PRON	O	O	3093
regular	ADJ	O	O	3093
form	NOUN	O	O	3093
of	ADP	O	O	3093
the	PRON	O	O	3093
drug	NOUN	O	O	3093
.	PUNCT	O	O	3093
There	ADV	O	O	3094
were	AUX	O	O	3094
more	ADJ	O	O	3094
deaths	NOUN	O	O	3094
in	ADP	O	O	3094
the	PRON	O	O	3094
mexiletine	NOUN	O	Chemical	3094
group	NOUN	O	O	3094
(	PUNCT	O	O	3094
7.6%	NOUN	O	O	3094
)	PUNCT	O	O	3094
than	ADP	O	O	3094
in	ADP	O	O	3094
the	PRON	O	O	3094
placebo	NOUN	O	O	3094
group	NOUN	O	O	3094
(	PUNCT	O	O	3094
4.8%	NOUN	O	O	3094
)	PUNCT	O	O	3094
;	PUNCT	O	O	3094
the	PRON	O	O	3094
difference	NOUN	O	O	3094
was	AUX	O	O	3094
not	PART	O	O	3094
statistically	ADV	O	O	3094
significant	ADJ	O	O	3094
.	PUNCT	O	O	3094
Previously	ADV	O	O	3095
recognized	VERB	O	O	3095
side	NOUN	O	O	3095
effects	NOUN	O	O	3095
,	PUNCT	O	O	3095
particularly	ADV	O	O	3095
tremor	NOUN	O	Disease	3095
and	CCONJ	O	O	3095
gastrointestinal	ADJ	O	O	3095
problems	NOUN	O	O	3095
,	PUNCT	O	O	3095
were	AUX	O	O	3095
more	ADJ	O	O	3095
frequent	ADJ	O	O	3095
in	ADP	O	O	3095
the	PRON	O	O	3095
mexiletine	NOUN	O	Chemical	3095
group	NOUN	O	O	3095
than	ADP	O	O	3095
in	ADP	O	O	3095
the	PRON	O	O	3095
placebo	NOUN	O	O	3095
group	NOUN	O	O	3095
.	PUNCT	O	O	3095
Regional	ADJ	O	O	3098
localization	NOUN	O	O	3098
of	ADP	O	O	3098
the	PRON	O	O	3098
antagonism	NOUN	O	O	3098
of	ADP	O	O	3098
amphetamine	NOUN	O	Chemical	3098
-	PUNCT	O	O	3098
induced	VERB	O	O	3098
hyperactivity	NOUN	O	Disease	3098
by	ADP	O	O	3098
intracerebral	VERB	O	O	3098
calcitonin	NOUN	O	O	3098
injections	NOUN	O	O	3098
.	PUNCT	O	O	3098
Calcitonin	NOUN	O	O	3099
receptors	NOUN	O	O	3099
are	AUX	O	O	3099
found	VERB	O	O	3099
in	ADP	O	O	3099
the	PRON	O	O	3099
brain	NOUN	O	O	3099
,	PUNCT	O	O	3099
and	CCONJ	O	O	3099
intracerebral	VERB	O	O	3099
infusions	NOUN	O	O	3099
of	ADP	O	O	3099
calcitonin	NOUN	O	O	3099
can	AUX	O	O	3099
produce	VERB	O	O	3099
behavioral	ADJ	O	O	3099
effects	NOUN	O	O	3099
.	PUNCT	O	O	3099
Among	ADP	O	O	3100
these	PRON	O	O	3100
behavioral	ADJ	O	O	3100
effects	NOUN	O	O	3100
are	AUX	O	O	3100
decreases	VERB	O	O	3100
in	ADP	O	O	3100
food	NOUN	O	O	3100
intake	PROPN	O	O	3100
and	CCONJ	O	O	3100
decreases	VERB	O	O	3100
in	ADP	O	O	3100
amphetamine	NOUN	O	Chemical	3100
-	PUNCT	O	O	3100
induced	VERB	O	O	3100
locomotor	PROPN	O	O	3100
activity	NOUN	O	O	3100
.	PUNCT	O	O	3100
In	ADP	O	O	3101
previous	ADJ	O	O	3101
experiments	NOUN	O	O	3101
we	PRON	O	O	3101
found	VERB	O	O	3101
that	SCONJ	O	O	3101
decreases	VERB	O	O	3101
in	ADP	O	O	3101
food	NOUN	O	O	3101
intake	PROPN	O	O	3101
were	AUX	O	O	3101
induced	VERB	O	O	3101
by	ADP	O	O	3101
local	ADJ	O	O	3101
administration	NOUN	O	O	3101
of	ADP	O	O	3101
calcitonin	NOUN	O	O	3101
into	ADP	O	O	3101
several	ADJ	O	O	3101
hypothalamic	ADJ	O	O	3101
sites	NOUN	O	O	3101
and	CCONJ	O	O	3101
into	ADP	O	O	3101
the	PRON	O	O	3101
nucleus	PROPN	O	O	3101
accumbens	NOUN	O	O	3101
.	PUNCT	O	O	3101
In	ADP	O	O	3102
the	PRON	O	O	3102
present	NOUN	O	O	3102
experiment	NOUN	O	O	3102
calcitonin	NOUN	O	O	3102
decreased	VERB	O	O	3102
locomotor	PROPN	O	O	3102
activity	NOUN	O	O	3102
when	SCONJ	O	O	3102
locally	ADV	O	O	3102
injected	VERB	O	O	3102
into	ADP	O	O	3102
the	PRON	O	O	3102
same	ADJ	O	O	3102
sites	NOUN	O	O	3102
where	SCONJ	O	O	3102
it	PRON	O	O	3102
decreases	VERB	O	O	3102
food	NOUN	O	O	3102
intake	PROPN	O	O	3102
.	PUNCT	O	O	3102
The	PRON	O	O	3103
areas	NOUN	O	O	3103
where	SCONJ	O	O	3103
calcitonin	NOUN	O	O	3103
is	AUX	O	O	3103
most	ADV	O	O	3103
effective	ADJ	O	O	3103
in	ADP	O	O	3103
decreasing	VERB	O	O	3103
locomotor	PROPN	O	O	3103
activity	NOUN	O	O	3103
are	AUX	O	O	3103
located	VERB	O	O	3103
in	ADP	O	O	3103
the	PRON	O	O	3103
hypothalamus	PROPN	O	O	3103
and	CCONJ	O	O	3103
nucleus	PROPN	O	O	3103
accumbens	NOUN	O	O	3103
,	PUNCT	O	O	3103
suggesting	VERB	O	O	3103
that	SCONJ	O	O	3103
these	PRON	O	O	3103
areas	NOUN	O	O	3103
are	AUX	O	O	3103
the	PRON	O	O	3103
major	ADJ	O	O	3103
sites	NOUN	O	O	3103
of	ADP	O	O	3103
action	NOUN	O	O	3103
of	ADP	O	O	3103
calcitonin	NOUN	O	O	3103
in	ADP	O	O	3103
inhibiting	VERB	O	O	3103
amphetamine	NOUN	O	Chemical	3103
-	PUNCT	O	O	3103
induced	VERB	O	O	3103
locomotor	PROPN	O	O	3103
activity	NOUN	O	O	3103
.	PUNCT	O	O	3103
Fatal	ADJ	O	O	3106
intracranial bleeding	NOUN	O	Disease	3106
associated	VERB	O	O	3106
with	ADP	O	O	3106
prehospital	PROPN	O	O	3106
use	VERB	O	O	3106
of	ADP	O	O	3106
epinephrine	NOUN	O	Chemical	3106
.	PUNCT	O	O	3106
We	PRON	O	O	3107
present	NOUN	O	O	3107
a	PRON	O	O	3107
case	NOUN	O	O	3107
of	ADP	O	O	3107
paramedic	NOUN	O	O	3107
misjudgment	NOUN	O	O	3107
in	ADP	O	O	3107
the	PRON	O	O	3107
execution	NOUN	O	O	3107
of	ADP	O	O	3107
a	PRON	O	O	3107
protocol	PROPN	O	O	3107
for	ADP	O	O	3107
the	PRON	O	O	3107
treatment	NOUN	O	O	3107
of	ADP	O	O	3107
allergic	ADJ	O	O	3107
reaction	NOUN	O	O	3107
in	ADP	O	O	3107
a	PRON	O	O	3107
case	NOUN	O	O	3107
of	ADP	O	O	3107
pulmonary edema	NOUN	O	Disease	3107
with	ADP	O	O	3107
wheezing	VERB	O	O	3107
.	PUNCT	O	O	3107
The	PRON	O	O	3108
sudden	ADJ	O	O	3108
onset	VERB	O	O	3108
of	ADP	O	O	3108
respiratory	NOUN	O	O	3108
distress	NOUN	O	O	3108
,	PUNCT	O	O	3108
rash	ADJ	O	Disease	3108
,	PUNCT	O	O	3108
and	CCONJ	O	O	3108
a	PRON	O	O	3108
history	NOUN	O	O	3108
of	ADP	O	O	3108
a	PRON	O	O	3108
new	ADJ	O	O	3108
medicine	NOUN	O	O	3108
led	VERB	O	O	3108
the	PRON	O	O	3108
two	NUM	O	O	3108
paramedics	NOUN	O	O	3108
on	ADP	O	O	3108
the	PRON	O	O	3108
scene	NOUN	O	O	3108
to	PART	O	O	3108
administer	VERB	O	O	3108
subcutaneous	ADJ	O	O	3108
epinephrine	NOUN	O	Chemical	3108
.	PUNCT	O	O	3108
Subsequently	PROPN	O	O	3109
,	PUNCT	O	O	3109
acute	ADJ	O	O	3109
cardiac arrest	NOUN	O	Disease	3109
and	CCONJ	O	O	3109
fatal	ADJ	O	O	3109
subarachnoid hemorrhage	NOUN	O	Disease	3109
occurred	VERB	O	O	3109
.	PUNCT	O	O	3109
Epinephrine	NOUN	O	Chemical	3110
has	VERB	O	O	3110
a	PRON	O	O	3110
proven	VERB	O	O	3110
role	NOUN	O	O	3110
in	ADP	O	O	3110
cardiac arrest	NOUN	O	Disease	3110
in	ADP	O	O	3110
prehospital	PROPN	O	O	3110
care	VERB	O	O	3110
;	PUNCT	O	O	3110
however	ADV	O	O	3110
,	PUNCT	O	O	3110
use	VERB	O	O	3110
by	ADP	O	O	3110
paramedics	NOUN	O	O	3110
in	ADP	O	O	3110
patients	NOUN	O	O	3110
with	ADP	O	O	3110
suspected	VERB	O	O	3110
allergic	ADJ	O	O	3110
reaction	NOUN	O	O	3110
and	CCONJ	O	O	3110
severe	ADJ	O	O	3110
hypertension	NOUN	O	Disease	3110
should	AUX	O	O	3110
be	AUX	O	O	3110
viewed	VERB	O	O	3110
with	ADP	O	O	3110
caution	NOUN	O	O	3110
.	PUNCT	O	O	3110
A	PRON	O	O	3113
case	NOUN	O	O	3113
of	ADP	O	O	3113
massive	ADJ	O	O	3113
rhabdomyolysis	NOUN	O	Disease	3113
following	VERB	O	O	3113
molindone	NOUN	O	O	3113
administration	NOUN	O	O	3113
.	PUNCT	O	O	3113
Rhabdomyolysis	NOUN	O	O	3114
is	AUX	O	O	3114
a	PRON	O	O	3114
potentially	ADV	O	O	3114
lethal	ADJ	O	O	3114
syndrome	NOUN	O	O	3114
that	SCONJ	O	O	3114
psychiatric	ADJ	O	Disease	3114
patients	NOUN	O	O	3114
seem	VERB	O	O	3114
predisposed	ADJ	O	O	3114
to	PART	O	O	3114
develop	VERB	O	O	3114
.	PUNCT	O	O	3114
The	PRON	O	O	3115
clinical	ADJ	O	O	3115
signs	NOUN	O	O	3115
and	CCONJ	O	O	3115
symptoms	NOUN	O	O	3115
,	PUNCT	O	O	3115
typical	ADJ	O	O	3115
laboratory	NOUN	O	O	3115
features	VERB	O	O	3115
,	PUNCT	O	O	3115
and	CCONJ	O	O	3115
complications	NOUN	O	O	3115
of	ADP	O	O	3115
rhabdomyolysis	NOUN	O	Disease	3115
are	AUX	O	O	3115
presented	VERB	O	O	3115
.	PUNCT	O	O	3115
The	PRON	O	O	3116
case	NOUN	O	O	3116
of	ADP	O	O	3116
a	PRON	O	O	3116
schizophrenic	ADJ	O	Disease	3116
patient	NOUN	O	O	3116
is	AUX	O	O	3116
reported	VERB	O	O	3116
to	PART	O	O	3116
illustrate	VERB	O	O	3116
massive	ADJ	O	O	3116
rhabdomyolysis	NOUN	O	Disease	3116
and	CCONJ	O	O	3116
subsequent	ADJ	O	O	3116
acute	ADJ	O	O	3116
renal failure	NOUN	O	Disease	3116
following	VERB	O	O	3116
molindone	NOUN	O	O	3116
administration	NOUN	O	O	3116
.	PUNCT	O	O	3116
Physicians	NOUN	O	O	3117
who	PRON	O	O	3117
prescribe	VERB	O	O	3117
molindone	NOUN	O	O	3117
should	AUX	O	O	3117
be	AUX	O	O	3117
aware	ADJ	O	O	3117
of	ADP	O	O	3117
this	PRON	O	O	3117
reaction	NOUN	O	O	3117
.	PUNCT	O	O	3117
Cardiovascular	NOUN	O	O	3120
alterations	NOUN	O	O	3120
in	ADP	O	O	3120
rat	NOUN	O	O	3120
fetuses	NOUN	O	O	3120
exposed	VERB	O	O	3120
to	PART	O	O	3120
calcium	NOUN	O	Chemical	3120
channel	PROPN	O	O	3120
blockers	NOUN	O	O	3120
.	PUNCT	O	O	3120
Preclinical	PROPN	O	O	3121
toxicologic	ADV	O	O	3121
investigation	NOUN	O	O	3121
suggested	VERB	O	O	3121
that	SCONJ	O	O	3121
a	PRON	O	O	3121
new	ADJ	O	O	3121
calcium	NOUN	O	Chemical	3121
channel	PROPN	O	O	3121
blocker	NOUN	O	O	3121
,	PUNCT	O	O	3121
Ro	INTJ	O	O	3121
40	NUM	O	O	3121
-	PUNCT	O	O	3121
5967	NUM	O	O	3121
,	PUNCT	O	O	3121
induced	VERB	O	O	3121
cardiovascular alterations	NOUN	O	Disease	3121
in	ADP	O	O	3121
rat	NOUN	O	O	3121
fetuses	NOUN	O	O	3121
exposed	VERB	O	O	3121
to	PART	O	O	3121
this	PRON	O	O	3121
agent	NOUN	O	O	3121
during	ADP	O	O	3121
organogenesis	NOUN	O	O	3121
.	PUNCT	O	O	3121
The	PRON	O	O	3122
present	NOUN	O	O	3122
study	VERB	O	O	3122
was	AUX	O	O	3122
designed	VERB	O	O	3122
to	PART	O	O	3122
investigate	VERB	O	O	3122
the	PRON	O	O	3122
hypothesis	NOUN	O	O	3122
that	SCONJ	O	O	3122
calcium	NOUN	O	Chemical	3122
channel	PROPN	O	O	3122
blockers	NOUN	O	O	3122
in	ADP	O	O	3122
general	ADJ	O	O	3122
induce	VERB	O	O	3122
cardiovascular	ADJ	O	O	3122
malformations	NOUN	O	Disease	3122
indicating	VERB	O	O	3122
a	PRON	O	O	3122
pharmacologic	ADJ	O	O	3122
class	NOUN	O	O	3122
effect	VERB	O	O	3122
.	PUNCT	O	O	3122
We	PRON	O	O	3123
studied	VERB	O	O	3123
three	NUM	O	O	3123
calcium	NOUN	O	Chemical	3123
channel	PROPN	O	O	3123
blockers	NOUN	O	O	3123
of	ADP	O	O	3123
different	ADJ	O	O	3123
structure	NOUN	O	O	3123
,	PUNCT	O	O	3123
nifedipine	PROPN	O	Chemical	3123
,	PUNCT	O	O	3123
diltiazem	VERB	O	Chemical	3123
,	PUNCT	O	O	3123
and	CCONJ	O	O	3123
verapamil	PROPN	O	Chemical	3123
,	PUNCT	O	O	3123
along	ADV	O	O	3123
with	ADP	O	O	3123
the	PRON	O	O	3123
new	ADJ	O	O	3123
agent	NOUN	O	O	3123
.	PUNCT	O	O	3123
Pregnant	ADJ	O	O	3124
rats	NOUN	O	O	3124
were	AUX	O	O	3124
administered	VERB	O	O	3124
one	NUM	O	O	3124
of	ADP	O	O	3124
these	PRON	O	O	3124
calcium	NOUN	O	Chemical	3124
channel	PROPN	O	O	3124
blockers	NOUN	O	O	3124
during	ADP	O	O	3124
the	PRON	O	O	3124
period	NOUN	O	O	3124
of	ADP	O	O	3124
cardiac	ADJ	O	O	3124
morphogenesis	NOUN	O	O	3124
and	CCONJ	O	O	3124
the	PRON	O	O	3124
offspring	VERB	O	O	3124
examined	VERB	O	O	3124
on	ADP	O	O	3124
day	NOUN	O	O	3124
20	NUM	O	O	3124
of	ADP	O	O	3124
gestation	NOUN	O	O	3124
for	ADP	O	O	3124
cardiovascular	ADJ	O	O	3124
malformations	NOUN	O	Disease	3124
.	PUNCT	O	O	3124
A	PRON	O	O	3125
low	ADJ	O	O	3125
incidence	NOUN	O	O	3125
of	ADP	O	O	3125
cardiovascular	ADJ	O	O	3125
malformations	NOUN	O	Disease	3125
was	AUX	O	O	3125
observed	VERB	O	O	3125
after	ADP	O	O	3125
exposure	NOUN	O	O	3125
to	PART	O	O	3125
each	PRON	O	O	3125
of	ADP	O	O	3125
the	PRON	O	O	3125
four	NUM	O	O	3125
calcium	NOUN	O	Chemical	3125
channel	PROPN	O	O	3125
blockers	NOUN	O	O	3125
,	PUNCT	O	O	3125
but	CCONJ	O	O	3125
this	PRON	O	O	3125
incidence	NOUN	O	O	3125
was	AUX	O	O	3125
statistically	ADV	O	O	3125
significant	ADJ	O	O	3125
only	ADV	O	O	3125
for	ADP	O	O	3125
verapamil	PROPN	O	Chemical	3125
and	CCONJ	O	O	3125
nifedipine	PROPN	O	Chemical	3125
.	PUNCT	O	O	3125
All	PRON	O	O	3126
four	NUM	O	O	3126
agents	NOUN	O	O	3126
were	AUX	O	O	3126
associated	VERB	O	O	3126
with	ADP	O	O	3126
aortic	ADJ	O	O	3126
arch	ADJ	O	O	3126
branching	VERB	O	O	3126
variants	NOUN	O	O	3126
,	PUNCT	O	O	3126
although	SCONJ	O	O	3126
significantly	ADV	O	O	3126
increased	VERB	O	O	3126
only	ADV	O	O	3126
for	ADP	O	O	3126
Ro	INTJ	O	O	3126
40	NUM	O	O	3126
-	PUNCT	O	O	3126
5967	NUM	O	O	3126
and	CCONJ	O	O	3126
verapamil	PROPN	O	Chemical	3126
.	PUNCT	O	O	3126
Differential	ADJ	O	O	3129
impact	NOUN	O	O	3129
of	ADP	O	O	3129
immune	NOUN	O	O	3129
escape	VERB	O	O	3129
mutations	NOUN	O	O	3129
G145R	NOUN	O	O	3129
and	CCONJ	O	O	3129
P120	PROPN	O	O	3129
T	NOUN	O	Chemical	3129
on	ADP	O	O	3129
the	PRON	O	O	3129
replication	NOUN	O	O	3129
of	ADP	O	O	3129
lamivudine	NOUN	O	Chemical	3129
-	PUNCT	O	O	3129
resistant	ADJ	O	O	3129
hepatitis B	PROPN	O	Disease	3129
virus	NOUN	O	O	3129
e	X	O	O	3129
antigen	PROPN	O	O	3129
-	PUNCT	O	O	3129
positive	ADJ	O	O	3129
and	CCONJ	O	O	3129
-negative	PUNCT	O	O	3129
strains	VERB	O	O	3129
.	PUNCT	O	O	3129
Immune	PROPN	O	O	3130
escape	VERB	O	O	3130
variants	NOUN	O	O	3130
of	ADP	O	O	3130
the	PRON	O	O	3130
hepatitis B	PROPN	O	Disease	3130
virus	NOUN	O	O	3130
(	PUNCT	O	O	3130
HBV	NOUN	O	O	3130
)	PUNCT	O	O	3130
represent	VERB	O	O	3130
an	PRON	O	O	3130
emerging	VERB	O	O	3130
clinical	ADJ	O	O	3130
challenge	NOUN	O	O	3130
,	PUNCT	O	O	3130
because	SCONJ	O	O	3130
they	PRON	O	O	3130
can	AUX	O	O	3130
be	AUX	O	O	3130
associated	VERB	O	O	3130
with	ADP	O	O	3130
vaccine	NOUN	O	O	3130
escape	VERB	O	O	3130
,	PUNCT	O	O	3130
HBV	NOUN	O	O	3130
reactivation	NOUN	O	O	3130
,	PUNCT	O	O	3130
and	CCONJ	O	O	3130
failure	NOUN	O	O	3130
of	ADP	O	O	3130
diagnostic	ADJ	O	O	3130
tests	VERB	O	O	3130
.	PUNCT	O	O	3130
We	PRON	O	O	3131
therefore	ADV	O	O	3131
systematically	ADV	O	O	3131
analyzed	VERB	O	O	3131
the	PRON	O	O	3131
functional	ADJ	O	O	3131
impact	NOUN	O	O	3131
of	ADP	O	O	3131
the	PRON	O	O	3131
most	ADV	O	O	3131
prevalent	ADJ	O	O	3131
immune	NOUN	O	O	3131
escape	VERB	O	O	3131
variants	NOUN	O	O	3131
,	PUNCT	O	O	3131
the	PRON	O	O	3131
sG145R	NOUN	O	O	3131
and	CCONJ	O	O	3131
sP120	ADJ	O	O	3131
T	NOUN	O	Chemical	3131
mutants	NOUN	O	O	3131
,	PUNCT	O	O	3131
on	ADP	O	O	3131
the	PRON	O	O	3131
viral	ADJ	O	O	3131
replication	NOUN	O	O	3131
efficacy	NOUN	O	O	3131
and	CCONJ	O	O	3131
antiviral	ADJ	O	O	3131
drug	NOUN	O	O	3131
susceptibility	NOUN	O	O	3131
of	ADP	O	O	3131
common	ADJ	O	O	3131
treatment	NOUN	O	O	3131
-	PUNCT	O	O	3131
associated	VERB	O	O	3131
mutants	NOUN	O	O	3131
with	ADP	O	O	3131
resistance	NOUN	O	O	3131
to	PART	O	O	3131
lamivudine	NOUN	O	Chemical	3131
(	PUNCT	O	O	3131
LAM	NOUN	O	O	3131
)	PUNCT	O	O	3131
and/or	CCONJ	O	O	3131
HBeAg	PROPN	O	Chemical	3131
negativity	NOUN	O	O	3131
.	PUNCT	O	O	3131
Replication	NOUN	O	O	3132
-	PUNCT	O	O	3132
competent	ADJ	O	O	3132
HBV	NOUN	O	O	3132
strains	VERB	O	O	3132
with	ADP	O	O	3132
sG145R	NOUN	O	O	3132
or	CCONJ	O	O	3132
sP120	ADJ	O	O	3132
T	NOUN	O	Chemical	3132
and	CCONJ	O	O	3132
LAM	NOUN	O	O	3132
resistance	NOUN	O	O	3132
(	PUNCT	O	O	3132
rtM204I	PROPN	O	O	3132
or	CCONJ	O	O	3132
rtL180M	PROPN	O	O	3132
/	PUNCT	O	O	3133
rtM204V	ADJ	O	O	3133
)	PUNCT	O	O	3133
were	AUX	O	O	3133
generated	VERB	O	O	3133
on	ADP	O	O	3133
an	PRON	O	O	3133
HBeAg	PROPN	O	Chemical	3133
-	PUNCT	O	O	3133
positive	ADJ	O	O	3133
and	CCONJ	O	O	3133
an	PRON	O	O	3133
HBeAg	PROPN	O	Chemical	3133
-	PUNCT	O	O	3133
negative	ADJ	O	O	3133
background	NOUN	O	O	3133
with	ADP	O	O	3133
precore	NOUN	O	O	3133
(	PUNCT	O	O	3133
PC	NOUN	O	O	3133
)	PUNCT	O	O	3133
and	CCONJ	O	O	3133
basal	PROPN	O	O	3133
core	NOUN	O	O	3133
promoter	NOUN	O	O	3133
(	PUNCT	O	O	3133
BCP	PROPN	O	O	3133
)	PUNCT	O	O	3133
mutants	NOUN	O	O	3133
.	PUNCT	O	O	3133
The	PRON	O	O	3134
sG145R	NOUN	O	O	3134
mutation	NOUN	O	O	3134
strongly	ADV	O	O	3134
reduced	VERB	O	O	3134
HBsAg	PROPN	O	Chemical	3134
levels	NOUN	O	O	3134
and	CCONJ	O	O	3134
was	AUX	O	O	3134
able	ADJ	O	O	3134
to	PART	O	O	3134
fully	ADV	O	O	3134
restore	VERB	O	O	3134
the	PRON	O	O	3134
impaired	VERB	O	O	3134
replication	NOUN	O	O	3134
of	ADP	O	O	3134
LAM	NOUN	O	O	3134
-	PUNCT	O	O	3134
resistant	ADJ	O	O	3134
HBV	NOUN	O	O	3134
mutants	NOUN	O	O	3134
to	PART	O	O	3134
the	PRON	O	O	3134
levels	NOUN	O	O	3134
of	ADP	O	O	3134
wild	ADJ	O	O	3134
-	PUNCT	O	O	3134
type	NOUN	O	O	3134
HBV	NOUN	O	O	3134
,	PUNCT	O	O	3134
and	CCONJ	O	O	3134
PC	NOUN	O	O	3134
or	CCONJ	O	O	3134
BCP	PROPN	O	O	3134
mutations	NOUN	O	O	3134
further	ADV	O	O	3134
enhanced	VERB	O	O	3134
viral	ADJ	O	O	3134
replication	NOUN	O	O	3134
.	PUNCT	O	O	3134
Although	SCONJ	O	O	3135
the	PRON	O	O	3135
sP120	ADJ	O	O	3135
T	NOUN	O	Chemical	3135
substitution	NOUN	O	O	3135
also	ADV	O	O	3135
impaired	VERB	O	O	3135
HBsAg	PROPN	O	Chemical	3135
secretion	NOUN	O	O	3135
,	PUNCT	O	O	3135
it	PRON	O	O	3135
did	VERB	O	O	3135
not	PART	O	O	3135
enhance	VERB	O	O	3135
the	PRON	O	O	3135
replication	NOUN	O	O	3135
of	ADP	O	O	3135
LAM	NOUN	O	O	3135
-	PUNCT	O	O	3135
resistant	ADJ	O	O	3135
clones	NOUN	O	O	3135
.	PUNCT	O	O	3135
However	ADV	O	O	3136
,	PUNCT	O	O	3136
the	PRON	O	O	3136
concomitant	ADJ	O	O	3136
occurrence	NOUN	O	O	3136
of	ADP	O	O	3136
HBeAg	PROPN	O	Chemical	3136
negativity	NOUN	O	O	3136
(	PUNCT	O	O	3136
PC	NOUN	O	O	3136
/	PUNCT	O	O	3136
BCP	PROPN	O	O	3136
)	PUNCT	O	O	3136
,	PUNCT	O	O	3136
sP120	ADJ	O	O	3136
T	NOUN	O	Chemical	3136
,	PUNCT	O	O	3136
and	CCONJ	O	O	3136
LAM	NOUN	O	O	3136
resistance	NOUN	O	O	3136
resulted	VERB	O	O	3136
in	ADP	O	O	3136
the	PRON	O	O	3136
restoration	NOUN	O	O	3136
of	ADP	O	O	3136
replication	NOUN	O	O	3136
to	PART	O	O	3136
levels	NOUN	O	O	3136
of	ADP	O	O	3136
wild	ADJ	O	O	3136
-	PUNCT	O	O	3136
type	NOUN	O	O	3136
HBV	NOUN	O	O	3136
.	PUNCT	O	O	3136
In	ADP	O	O	3137
all	PRON	O	O	3137
clones	NOUN	O	O	3137
with	ADP	O	O	3137
combined	VERB	O	O	3137
immune	NOUN	O	O	3137
escape	VERB	O	O	3137
and	CCONJ	O	O	3137
LAM	NOUN	O	O	3137
resistance	NOUN	O	O	3137
mutations	NOUN	O	O	3137
,	PUNCT	O	O	3137
the	PRON	O	O	3137
nucleotide	NOUN	O	O	3137
analogues	NOUN	O	O	3137
adefovir	NOUN	O	O	3137
and	CCONJ	O	O	3137
tenofovir	NOUN	O	Chemical	3137
remained	VERB	O	O	3137
effective	ADJ	O	O	3137
in	ADP	O	O	3137
suppressing	VERB	O	O	3137
viral	ADJ	O	O	3137
replication	NOUN	O	O	3137
in	ADP	O	O	3137
vitro	X	O	O	3137
.	PUNCT	O	O	3137
The	PRON	O	O	3140
effects	NOUN	O	O	3140
of	ADP	O	O	3140
sevoflurane	VERB	O	Chemical	3140
on	ADP	O	O	3140
lidocaine	NOUN	O	Chemical	3140
-	PUNCT	O	O	3140
induced	VERB	O	O	3140
convulsions	NOUN	O	Disease	3140
.	PUNCT	O	O	3140
The	PRON	O	O	3141
influence	NOUN	O	O	3141
of	ADP	O	O	3141
sevoflurane	VERB	O	Chemical	3141
on	ADP	O	O	3141
lidocaine	NOUN	O	Chemical	3141
-	PUNCT	O	O	3141
induced	VERB	O	O	3141
convulsions	NOUN	O	Disease	3141
was	AUX	O	O	3141
studied	VERB	O	O	3141
in	ADP	O	O	3141
cats	NOUN	O	O	3141
.	PUNCT	O	O	3141
The	PRON	O	O	3142
convulsive	ADJ	O	Disease	3142
threshold	NOUN	O	O	3142
(	PUNCT	O	O	3142
mean	VERB	O	O	3142
+	ADP	O	O	3142
/-	PUNCT	O	O	3142
l(-1	VERB	O	O	3143
)	PUNCT	O	O	3143
with	ADP	O	O	3143
lidocaine	NOUN	O	Chemical	3143
infusion	NOUN	O	O	3143
(	PUNCT	O	O	3143
6	NUM	O	O	3143
mg.kg(-1).min(-1	VERB	O	O	3143
)	PUNCT	O	O	3143
)	PUNCT	O	O	3143
,	PUNCT	O	O	3143
increasing	VERB	O	O	3143
significantly	ADV	O	O	3143
to	PART	O	O	3143
66.6	NUM	O	O	3143
+	ADP	O	O	3143
/-	PUNCT	O	O	3143
l(-1	VERB	O	O	3144
)	PUNCT	O	O	3144
when	SCONJ	O	O	3144
the	PRON	O	O	3144
end	VERB	O	O	3144
-	PUNCT	O	O	3144
tidal	ADJ	O	O	3144
concentration	NOUN	O	O	3144
of	ADP	O	O	3144
sevoflurane	VERB	O	Chemical	3144
was	AUX	O	O	3144
0.8%	NOUN	O	O	3144
.	PUNCT	O	O	3144
l(-1	VERB	O	O	3145
)	PUNCT	O	O	3145
)	PUNCT	O	O	3145
during	ADP	O	O	3145
1.6%	NOUN	O	O	3145
sevoflurane	VERB	O	Chemical	3145
was	AUX	O	O	3145
not	PART	O	O	3145
significant	ADJ	O	O	3145
from	ADP	O	O	3145
that	SCONJ	O	O	3145
during	ADP	O	O	3145
0.8%	NOUN	O	O	3145
sevoflurane	VERB	O	Chemical	3145
,	PUNCT	O	O	3145
indicating	VERB	O	O	3145
a	PRON	O	O	3145
celling	NOUN	O	O	3145
effect	VERB	O	O	3145
.	PUNCT	O	O	3145
There	ADV	O	O	3146
was	AUX	O	O	3146
no	PRON	O	O	3146
significant	ADJ	O	O	3146
difference	NOUN	O	O	3146
in	ADP	O	O	3146
the	PRON	O	O	3146
convulsive	ADJ	O	Disease	3146
threshold	NOUN	O	O	3146
between	ADP	O	O	3146
sevoflurane	VERB	O	Chemical	3146
and	CCONJ	O	O	3146
enflurane	NOUN	O	Chemical	3146
.	PUNCT	O	O	3146
The	PRON	O	O	3147
rise	VERB	O	O	3147
in	ADP	O	O	3147
blood	NOUN	O	O	3147
pressure	NOUN	O	O	3147
became	VERB	O	O	3147
less	ADV	O	O	3147
marked	VERB	O	O	3147
when	SCONJ	O	O	3147
higher	ADJ	O	O	3147
concentrations	NOUN	O	O	3147
of	ADP	O	O	3147
sevoflurane	VERB	O	Chemical	3147
or	CCONJ	O	O	3147
enflurane	NOUN	O	Chemical	3147
were	AUX	O	O	3147
administered	VERB	O	O	3147
and	CCONJ	O	O	3147
the	PRON	O	O	3147
blood	NOUN	O	O	3147
pressure	NOUN	O	O	3147
at	ADP	O	O	3147
convulsions	NOUN	O	Disease	3147
decreased	VERB	O	O	3147
significantly	ADV	O	O	3147
in	ADP	O	O	3147
1.6%	NOUN	O	O	3147
sevoflurane	VERB	O	Chemical	3147
,	PUNCT	O	O	3147
and	CCONJ	O	O	3147
in	ADP	O	O	3147
0.8%	NOUN	O	O	3147
and	CCONJ	O	O	3147
1.6%	NOUN	O	O	3147
enflurane	NOUN	O	Chemical	3147
.	PUNCT	O	O	3147
However	ADV	O	O	3148
,	PUNCT	O	O	3148
there	ADV	O	O	3148
was	AUX	O	O	3148
no	PRON	O	O	3148
significant	ADJ	O	O	3148
difference	NOUN	O	O	3148
in	ADP	O	O	3148
the	PRON	O	O	3148
lidocaine	NOUN	O	Chemical	3148
concentrations	NOUN	O	O	3148
measured	VERB	O	O	3148
when	SCONJ	O	O	3148
the	PRON	O	O	3148
systolic	ADV	O	O	3148
blood	NOUN	O	O	3148
pressure	NOUN	O	O	3148
became	VERB	O	O	3148
70	NUM	O	O	3148
mmHg	PROPN	O	O	3148
.	PUNCT	O	O	3148
Apamin	PROPN	O	O	3149
,	PUNCT	O	O	3149
a	PRON	O	O	3149
selective	ADJ	O	O	3149
blocker	NOUN	O	O	3149
of	ADP	O	O	3149
calcium	NOUN	O	Chemical	3149
-	PUNCT	O	O	3149
dependent	ADJ	O	O	3149
potassium	NOUN	O	Chemical	3149
channels	NOUN	O	O	3149
,	PUNCT	O	O	3149
was	AUX	O	O	3149
administered	VERB	O	O	3149
intracerebroventricularly	ADV	O	O	3149
in	ADP	O	O	3149
rats	NOUN	O	O	3149
anesthetized	VERB	O	O	3149
with	ADP	O	O	3149
0.8%	NOUN	O	O	3149
sevoflurane	VERB	O	Chemical	3149
to	PART	O	O	3149
investigate	VERB	O	O	3149
the	PRON	O	O	3149
mechanism	NOUN	O	O	3149
of	ADP	O	O	3149
the	PRON	O	O	3149
anticonvulsive	ADJ	O	O	3149
effects	NOUN	O	O	3149
.	PUNCT	O	O	3149
Apamin	PROPN	O	O	3150
(	PUNCT	O	O	3150
10	NUM	O	O	3150
ng	PROPN	O	O	3150
)	PUNCT	O	O	3150
had	VERB	O	O	3150
a	PRON	O	O	3150
tendency	NOUN	O	O	3150
to	PART	O	O	3150
decrease	VERB	O	O	3150
the	PRON	O	O	3150
convulsive	ADJ	O	Disease	3150
threshold	NOUN	O	O	3150
(	PUNCT	O	O	3150
21.6	NUM	O	O	3150
+	ADP	O	O	3150
/-	PUNCT	O	O	3150
It	PRON	O	O	3151
is	AUX	O	O	3151
suggested	VERB	O	O	3151
that	SCONJ	O	O	3151
sevoflurane	VERB	O	Chemical	3151
reduces	VERB	O	O	3151
the	PRON	O	O	3151
convulsive	ADJ	O	Disease	3151
effect	VERB	O	O	3151
of	ADP	O	O	3151
lidocaine	NOUN	O	Chemical	3151
toxicity	NOUN	O	Disease	3151
but	CCONJ	O	O	3151
carries	VERB	O	O	3151
some	PRON	O	O	3151
risk	NOUN	O	O	3151
due	ADJ	O	O	3151
to	PART	O	O	3151
circulatory	ADJ	O	O	3151
depression	PROPN	O	Disease	3151
.	PUNCT	O	O	3151
Anti	ADJ	O	O	3154
-	PUNCT	O	O	3154
oxidant	ADJ	O	O	3154
effects	NOUN	O	O	3154
of	ADP	O	O	3154
atorvastatin	PROPN	O	Chemical	3154
in	ADP	O	O	3154
dexamethasone	NOUN	O	Chemical	3154
-	PUNCT	O	O	3154
induced	VERB	O	O	3154
hypertension	NOUN	O	Disease	3154
in	ADP	O	O	3154
the	PRON	O	O	3154
rat	NOUN	O	O	3154
.	PUNCT	O	O	3154
1	X	O	O	3154
.	PUNCT	O	O	3154
Dexamethasone	NOUN	O	Chemical	3155
(	PUNCT	O	O	3156
Dex)-induced	VERB	O	O	3156
hypertension	NOUN	O	Disease	3156
is	AUX	O	O	3156
characterized	VERB	O	O	3156
by	ADP	O	O	3156
endothelial	NOUN	O	O	3156
dysfunction	NOUN	O	O	3156
associated	VERB	O	O	3156
with	ADP	O	O	3156
nitric oxide	NOUN	O	Chemical	3156
(	PUNCT	O	O	3156
NO	PRON	O	Chemical	3156
)	PUNCT	O	O	3156
deficiency	NOUN	O	O	3156
and	CCONJ	O	O	3156
increased	VERB	O	O	3156
superoxide	NOUN	O	Chemical	3156
(	PUNCT	O	O	3156
O2-	ADV	O	O	3156
)	PUNCT	O	O	3156
production	NOUN	O	O	3156
.	PUNCT	O	O	3156
Atorvastatin	PROPN	O	Chemical	3157
(	PUNCT	O	O	3157
Ato	NOUN	O	O	3157
)	PUNCT	O	O	3157
possesses	VERB	O	O	3157
pleiotropic	ADP	O	O	3157
properties	NOUN	O	O	3157
that	SCONJ	O	O	3157
have	VERB	O	O	3157
been	AUX	O	O	3157
reported	VERB	O	O	3157
to	PART	O	O	3157
improve	VERB	O	O	3157
endothelial	NOUN	O	O	3157
function	NOUN	O	O	3157
through	ADP	O	O	3157
increased	VERB	O	O	3157
availability	NOUN	O	O	3157
of	ADP	O	O	3157
NO	PRON	O	Chemical	3157
and	CCONJ	O	O	3157
reduced	VERB	O	O	3157
O2-	ADV	O	O	3157
production	NOUN	O	O	3157
in	ADP	O	O	3157
various	ADJ	O	O	3157
forms	NOUN	O	O	3157
of	ADP	O	O	3157
hypertension	NOUN	O	Disease	3157
.	PUNCT	O	O	3157
,	PUNCT	O	O	3158
Ato	NOUN	O	O	3158
could	AUX	O	O	3158
prevent	VERB	O	O	3158
endothelial	NOUN	O	O	3158
NO	PRON	O	Chemical	3159
synthase	NOUN	O	O	3159
(	PUNCT	O	O	3159
eNOS	NUM	O	O	3159
)	PUNCT	O	O	3159
downregulation	NOUN	O	O	3160
and	CCONJ	O	O	3160
the	PRON	O	O	3160
increase	VERB	O	O	3160
in	ADP	O	O	3160
O2-	ADV	O	O	3160
in	ADP	O	O	3160
Sprague	PROPN	O	O	3160
-	PUNCT	O	O	3160
Dawley	NOUN	O	O	3160
(	PUNCT	O	O	3160
SD	NOUN	O	O	3160
)	PUNCT	O	O	3160
rats	NOUN	O	O	3160
,	PUNCT	O	O	3160
thereby	ADV	O	O	3160
reducing	VERB	O	O	3160
blood	NOUN	O	O	3160
pressure	NOUN	O	O	3160
.	PUNCT	O	O	3160
were	AUX	O	O	3161
treated	VERB	O	O	3161
with	ADP	O	O	3161
Ato	NOUN	O	O	3161
(	PUNCT	O	O	3161
50	NUM	O	O	3161
mg	VERB	O	O	3161
/	PUNCT	O	O	3161
kg	VERB	O	O	3161
per	ADP	O	O	3161
day	NOUN	O	O	3161
in	ADP	O	O	3161
drinking	VERB	O	O	3161
water	PROPN	O	O	3161
)	PUNCT	O	O	3161
or	CCONJ	O	O	3161
tap	NOUN	O	O	3161
water	PROPN	O	O	3161
for	ADP	O	O	3161
15	NUM	O	O	3161
days	NOUN	O	O	3161
.	PUNCT	O	O	3161
Dexamethasone	NOUN	O	Chemical	3162
(	PUNCT	O	O	3162
10	NUM	O	O	3162
microg	PROPN	O	O	3162
/	PUNCT	O	O	3162
kg	VERB	O	O	3162
per	ADP	O	O	3162
day	NOUN	O	O	3162
,	PUNCT	O	O	3162
s.c	PROPN	O	O	3162
.	PUNCT	O	O	3162
)	PUNCT	O	O	3162
or	CCONJ	O	O	3162
saline	NOUN	O	O	3162
was	AUX	O	O	3162
started	VERB	O	O	3162
after	ADP	O	O	3162
4	NUM	O	O	3162
days	NOUN	O	O	3162
in	ADP	O	O	3162
Ato	NOUN	O	O	3162
-	PUNCT	O	O	3162
treated	VERB	O	O	3162
and	CCONJ	O	O	3162
non	ADJ	O	O	3162
-	PUNCT	O	O	3162
treated	VERB	O	O	3162
rats	NOUN	O	O	3162
and	CCONJ	O	O	3162
continued	VERB	O	O	3162
for	ADP	O	O	3162
11	NUM	O	O	3162
-	PUNCT	O	O	3162
13	NUM	O	O	3162
days	NOUN	O	O	3162
.	PUNCT	O	O	3162
Endothelial	NOUN	O	O	3163
function	NOUN	O	O	3163
was	AUX	O	O	3163
assessed	VERB	O	O	3163
by	ADP	O	O	3163
acetylcholine	NOUN	O	Chemical	3163
-	PUNCT	O	O	3163
induced	VERB	O	O	3163
vasorelaxation	NOUN	O	O	3163
and	CCONJ	O	O	3163
phenylephrine	NOUN	O	Chemical	3163
-	PUNCT	O	O	3163
induced	VERB	O	O	3163
vasoconstriction	NOUN	O	O	3163
in	ADP	O	O	3163
aortic	ADJ	O	O	3163
segments	NOUN	O	O	3163
.	PUNCT	O	O	3163
In	ADP	O	O	3164
rats	NOUN	O	O	3164
treated	VERB	O	O	3164
with	ADP	O	O	3164
Dex	PROPN	O	Chemical	3164
alone	ADV	O	O	3164
,	PUNCT	O	O	3164
SBP	NOUN	O	O	3164
was	AUX	O	O	3164
increased	VERB	O	O	3164
from	ADP	O	O	3164
109	NUM	O	O	3164
+	ADP	O	O	3164
/-	PUNCT	O	O	3164
In	ADP	O	O	3165
the	PRON	O	O	3165
Ato	NOUN	O	O	3165
+	ADP	O	O	3165
Dex	PROPN	O	Chemical	3165
group	NOUN	O	O	3165
,	PUNCT	O	O	3165
SBP	NOUN	O	O	3165
was	AUX	O	O	3165
increased	VERB	O	O	3165
from	ADP	O	O	3165
113	NUM	O	O	3165
+	ADP	O	O	3165
/-	PUNCT	O	O	3165
<	X	O	O	3166
0.001	NUM	O	O	3166
)	PUNCT	O	O	3166
,	PUNCT	O	O	3166
but	CCONJ	O	O	3166
was	AUX	O	O	3166
significantly	ADV	O	O	3166
lower	ADJ	O	O	3166
than	ADP	O	O	3166
SBP	NOUN	O	O	3166
in	ADP	O	O	3166
the	PRON	O	O	3166
group	NOUN	O	O	3166
treated	VERB	O	O	3166
with	ADP	O	O	3166
Dex	PROPN	O	Chemical	3166
alone	ADV	O	O	3166
(	PUNCT	O	O	3166
P	NOUN	O	Chemical	3166
<	X	O	O	3166
0.05	NUM	O	O	3166
)	PUNCT	O	O	3166
.	PUNCT	O	O	3166
Endothelial	NOUN	O	O	3167
-	PUNCT	O	O	3167
dependent	ADJ	O	O	3167
relaxation	NOUN	O	O	3167
and	CCONJ	O	O	3167
eNOS	NUM	O	O	3167
mRNA	PROPN	O	O	3167
expression	NOUN	O	O	3167
were	AUX	O	O	3167
greater	ADJ	O	O	3167
in	ADP	O	O	3167
the	PRON	O	O	3167
Dex	PROPN	O	Chemical	3167
+	ADP	O	O	3167
Ato	NOUN	O	O	3167
group	NOUN	O	O	3167
than	ADP	O	O	3167
in	ADP	O	O	3167
the	PRON	O	O	3167
Dex	PROPN	O	Chemical	3167
only	ADV	O	O	3167
group	NOUN	O	O	3167
(	PUNCT	O	O	3167
P	NOUN	O	Chemical	3167
<	X	O	O	3167
0.05	NUM	O	O	3167
and	CCONJ	O	O	3167
P	NOUN	O	Chemical	3167
Aortic	ADJ	O	O	3168
superoxide	NOUN	O	Chemical	3168
production	NOUN	O	O	3168
was	AUX	O	O	3168
lower	ADJ	O	O	3168
in	ADP	O	O	3168
the	PRON	O	O	3168
Dex	PROPN	O	Chemical	3168
+	ADP	O	O	3168
Ato	NOUN	O	O	3168
group	NOUN	O	O	3168
compared	VERB	O	O	3168
with	ADP	O	O	3168
the	PRON	O	O	3168
group	NOUN	O	O	3168
treated	VERB	O	O	3168
with	ADP	O	O	3168
Dex	PROPN	O	Chemical	3168
alone	ADV	O	O	3168
(	PUNCT	O	O	3168
P	NOUN	O	Chemical	3168
<	X	O	O	3168
0.0001	NUM	O	O	3168
)	PUNCT	O	O	3168
.	PUNCT	O	O	3168
Treatment	NOUN	O	O	3169
with	ADP	O	O	3169
Ato	NOUN	O	O	3169
improved	VERB	O	O	3169
endothelial	NOUN	O	O	3169
function	NOUN	O	O	3169
,	PUNCT	O	O	3169
reduced	VERB	O	O	3169
superoxide	NOUN	O	Chemical	3169
production	NOUN	O	O	3169
and	CCONJ	O	O	3169
reduced	VERB	O	O	3169
SBP	NOUN	O	O	3169
in	ADP	O	O	3169
Dex	PROPN	O	Chemical	3169
-	PUNCT	O	O	3169
treated	VERB	O	O	3169
SD	NOUN	O	O	3169
rats	NOUN	O	O	3169
.	PUNCT	O	O	3169
99mTc	NUM	O	O	3172
-	PUNCT	O	O	3172
glucarate	NOUN	O	O	3172
for	ADP	O	O	3172
detection	NOUN	O	O	3172
of	ADP	O	O	3172
isoproterenol	NOUN	O	Chemical	3172
-	PUNCT	O	O	3172
induced	VERB	O	O	3172
myocardial infarction	NOUN	O	Disease	3172
in	ADP	O	O	3172
rats	NOUN	O	O	3172
.	PUNCT	O	O	3172
Infarct	NOUN	O	O	3173
-	PUNCT	O	O	3173
avid	ADJ	O	O	3173
radiopharmaceuticals	NOUN	O	O	3173
are	AUX	O	O	3173
necessary	ADJ	O	O	3173
for	ADP	O	O	3173
rapid	ADJ	O	O	3173
and	CCONJ	O	O	3173
timely	ADV	O	O	3173
diagnosis	NOUN	O	O	3173
of	ADP	O	O	3173
acute	ADJ	O	O	3173
myocardial infarction	NOUN	O	Disease	3173
.	PUNCT	O	O	3173
The	PRON	O	O	3174
animal	NOUN	O	O	3174
model	NOUN	O	O	3174
used	VERB	O	O	3174
to	PART	O	O	3174
produce	VERB	O	O	3174
infarction	NOUN	O	O	3174
implies	VERB	O	O	3174
artery	NOUN	O	O	3174
ligation	NOUN	O	O	3174
but	CCONJ	O	O	3174
chemical	PROPN	O	O	3174
induction	NOUN	O	O	3174
can	AUX	O	O	3174
be	AUX	O	O	3174
easily	ADV	O	O	3174
obtained	VERB	O	O	3174
with	ADP	O	O	3174
isoproterenol	NOUN	O	Chemical	3174
.	PUNCT	O	O	3174
A	PRON	O	O	3175
new	ADJ	O	O	3175
infarct	NOUN	O	Disease	3175
-	PUNCT	O	O	3175
avid	ADJ	O	O	3175
radiopharmaceutical	PROPN	O	O	3175
based	VERB	O	O	3175
on	ADP	O	O	3175
glucaric	PROPN	O	O	3175
acid	PROPN	O	O	3175
was	AUX	O	O	3175
prepared	VERB	O	O	3175
in	ADP	O	O	3175
the	PRON	O	O	3175
hospital	PROPN	O	O	3175
radiopharmacy	NOUN	O	O	3175
of	ADP	O	O	3175
the	PRON	O	O	3175
INCMNSZ	PROPN	O	O	3175
.	PUNCT	O	O	3175
99mTc	NUM	O	O	3176
-	PUNCT	O	O	3176
glucarate	NOUN	O	O	3176
was	AUX	O	O	3176
easy	ADV	O	O	3176
to	PART	O	O	3176
prepare	VERB	O	O	3176
,	PUNCT	O	O	3176
stable	ADJ	O	O	3176
for	ADP	O	O	3176
96	NUM	O	O	3176
h	X	O	O	3176
and	CCONJ	O	O	3176
was	AUX	O	O	3176
used	VERB	O	O	3176
to	PART	O	O	3176
study	VERB	O	O	3176
its	PRON	O	O	3176
biodistribution	NOUN	O	O	3176
in	ADP	O	O	3176
rats	NOUN	O	O	3176
with	ADP	O	O	3176
isoproterenol	NOUN	O	Chemical	3176
-	PUNCT	O	O	3176
induced	VERB	O	O	3176
acute	ADJ	O	O	3176
myocardial infarction	NOUN	O	Disease	3176
.	PUNCT	O	O	3176
Histological	NOUN	O	O	3177
studies	NOUN	O	O	3177
demonstrated	VERB	O	O	3177
that	SCONJ	O	O	3177
the	PRON	O	O	3177
rats	NOUN	O	O	3177
developed	VERB	O	O	3177
an	PRON	O	O	3177
infarct	NOUN	O	Disease	3177
18	NUM	O	O	3177
h	X	O	O	3177
after	ADP	O	O	3177
isoproterenol	NOUN	O	Chemical	3177
administration	NOUN	O	O	3177
.	PUNCT	O	O	3177
Thirty	NUM	O	O	3178
minutes	NOUN	O	O	3178
after	ADP	O	O	3178
99mTc	NUM	O	O	3178
-	PUNCT	O	O	3178
glucarate	NOUN	O	O	3178
administration	NOUN	O	O	3178
the	PRON	O	O	3178
standardised	VERB	O	O	3178
heart	NOUN	O	O	3178
uptake	NOUN	O	O	3178
value	NOUN	O	O	3178
S(h)UV	NUM	O	O	3178
was	AUX	O	O	3178
4.7	NUM	O	O	3178
in	ADP	O	O	3178
infarcted	VERB	O	O	3178
rat	NOUN	O	O	3178
heart	NOUN	O	O	3178
which	PRON	O	O	3178
is	AUX	O	O	3178
six	NUM	O	O	3178
times	NOUN	O	O	3178
more	ADJ	O	O	3178
than	ADP	O	O	3178
in	ADP	O	O	3178
normal	ADJ	O	O	3178
rats	NOUN	O	O	3178
.	PUNCT	O	O	3178
The	PRON	O	O	3179
high	ADJ	O	O	3179
image	NOUN	O	O	3179
quality	NOUN	O	O	3179
suggests	VERB	O	O	3179
that	SCONJ	O	O	3179
high	ADJ	O	O	3179
contrast	NOUN	O	O	3179
images	NOUN	O	O	3179
can	AUX	O	O	3179
be	AUX	O	O	3179
obtained	VERB	O	O	3179
in	ADP	O	O	3179
humans	NOUN	O	O	3179
and	CCONJ	O	O	3179
the	PRON	O	O	3179
96	NUM	O	O	3179
h	X	O	O	3179
stability	PROPN	O	O	3179
makes	VERB	O	O	3179
it	PRON	O	O	3179
an	PRON	O	O	3179
ideal	ADJ	O	O	3179
agent	NOUN	O	O	3179
to	PART	O	O	3179
detect	VERB	O	O	3179
,	PUNCT	O	O	3179
in	ADP	O	O	3179
patients	NOUN	O	O	3179
,	PUNCT	O	O	3179
early	ADV	O	O	3179
cardiac	ADJ	O	O	3179
infarction	NOUN	O	O	3179
.	PUNCT	O	O	3179
A	PRON	O	O	3182
randomized	VERB	O	O	3182
,	PUNCT	O	O	3182
placebo	NOUN	O	O	3182
-	PUNCT	O	O	3182
controlled	VERB	O	O	3182
dose	NOUN	O	O	3182
-	PUNCT	O	O	3182
comparison	NOUN	O	O	3182
trial	NOUN	O	O	3182
of	ADP	O	O	3182
haloperidol	NOUN	O	Chemical	3182
for	ADP	O	O	3182
psychosis	VERB	O	Disease	3182
and	CCONJ	O	O	3182
disruptive	ADJ	O	O	3182
behaviors	NOUN	O	O	3182
in	ADP	O	O	3182
Alzheimer	NOUN	O	Disease	3182
's	AUX	O	O	3182
disease	PROPN	O	O	3182
.	PUNCT	O	O	3182
OBJECTIVE	VERB	O	O	3183
:	PUNCT	O	O	3183
The	PRON	O	O	3183
goal	NOUN	O	O	3183
of	ADP	O	O	3183
this	PRON	O	O	3183
study	VERB	O	O	3183
was	AUX	O	O	3183
to	PART	O	O	3183
compare	VERB	O	O	3183
the	PRON	O	O	3183
efficacy	NOUN	O	O	3183
and	CCONJ	O	O	3183
side	NOUN	O	O	3183
effects	NOUN	O	O	3183
of	ADP	O	O	3183
two	NUM	O	O	3183
doses	NOUN	O	O	3183
of	ADP	O	O	3183
haloperidol	NOUN	O	Chemical	3183
and	CCONJ	O	O	3183
placebo	NOUN	O	O	3183
in	ADP	O	O	3183
the	PRON	O	O	3183
treatment	NOUN	O	O	3183
of	ADP	O	O	3183
psychosis	VERB	O	Disease	3183
and	CCONJ	O	O	3183
disruptive	ADJ	O	O	3183
behaviors	NOUN	O	O	3183
in	ADP	O	O	3183
patients	NOUN	O	O	3183
with	ADP	O	O	3183
Alzheimer	NOUN	O	Disease	3183
's	AUX	O	O	3183
disease	PROPN	O	O	3183
.	PUNCT	O	O	3183
In	ADP	O	O	3184
a	PRON	O	O	3184
6-week	NOUN	O	O	3184
random	ADJ	O	O	3184
-	PUNCT	O	O	3184
assignment	NOUN	O	O	3184
,	PUNCT	O	O	3184
double	ADJ	O	O	3184
-	PUNCT	O	O	3184
blind	ADJ	O	Disease	3184
,	PUNCT	O	O	3184
placebo	NOUN	O	O	3184
-	PUNCT	O	O	3184
controlled	VERB	O	O	3184
trial	NOUN	O	O	3184
(	PUNCT	O	O	3184
phase	NOUN	O	O	3184
A	PRON	O	O	3184
)	PUNCT	O	O	3184
,	PUNCT	O	O	3184
haloperidol	NOUN	O	Chemical	3184
,	PUNCT	O	O	3184
2	X	O	O	3184
-	PUNCT	O	O	3184
3	X	O	O	3184
mg	VERB	O	O	3184
/	PUNCT	O	O	3184
day	NOUN	O	O	3184
(	PUNCT	O	O	3184
standard	PROPN	O	O	3184
dose	NOUN	O	O	3184
)	PUNCT	O	O	3184
,	PUNCT	O	O	3184
and	CCONJ	O	O	3184
haloperidol	NOUN	O	Chemical	3184
,	PUNCT	O	O	3184
0.50	NUM	O	O	3184
-	PUNCT	O	O	3184
0.75	NUM	O	O	3184
mg	VERB	O	O	3184
/	PUNCT	O	O	3184
day	NOUN	O	O	3184
(	PUNCT	O	O	3184
low	ADJ	O	O	3184
dose	NOUN	O	O	3184
)	PUNCT	O	O	3184
,	PUNCT	O	O	3184
were	AUX	O	O	3184
compared	VERB	O	O	3184
in	ADP	O	O	3184
71	NUM	O	O	3184
outpatients	NOUN	O	O	3184
with	ADP	O	O	3184
Alzheimer	NOUN	O	Disease	3184
's	AUX	O	O	3184
disease	PROPN	O	O	3184
.	PUNCT	O	O	3184
For	ADP	O	O	3185
the	PRON	O	O	3185
subsequent	ADJ	O	O	3185
6-week	NOUN	O	O	3185
double	ADJ	O	O	3185
-	PUNCT	O	O	3185
blind	ADJ	O	Disease	3185
crossover	NOUN	O	O	3185
phase	NOUN	O	O	3185
(	PUNCT	O	O	3185
phase	NOUN	O	O	3185
B	NOUN	O	O	3185
)	PUNCT	O	O	3185
,	PUNCT	O	O	3185
patients	NOUN	O	O	3185
taking	VERB	O	O	3185
standard-	NOUN	O	O	3185
or	CCONJ	O	O	3185
low	ADJ	O	O	3185
-	PUNCT	O	O	3185
dose	NOUN	O	O	3185
haloperidol	NOUN	O	Chemical	3185
were	AUX	O	O	3185
switched	VERB	O	O	3185
to	PART	O	O	3185
placebo	NOUN	O	O	3185
,	PUNCT	O	O	3185
and	CCONJ	O	O	3185
patients	NOUN	O	O	3185
taking	VERB	O	O	3185
placebo	NOUN	O	O	3185
were	AUX	O	O	3185
randomly	ADV	O	O	3185
assigned	VERB	O	O	3185
to	PART	O	O	3185
standard-	NOUN	O	O	3185
or	CCONJ	O	O	3185
low	ADJ	O	O	3185
-	PUNCT	O	O	3185
dose	NOUN	O	O	3185
haloperidol	NOUN	O	Chemical	3185
.	PUNCT	O	O	3185
For	ADP	O	O	3186
the	PRON	O	O	3186
60	NUM	O	O	3186
patients	NOUN	O	O	3186
who	PRON	O	O	3186
completed	VERB	O	O	3186
phase	NOUN	O	O	3186
A	PRON	O	O	3186
,	PUNCT	O	O	3186
standard	PROPN	O	O	3186
-	PUNCT	O	O	3186
dose	NOUN	O	O	3186
haloperidol	NOUN	O	Chemical	3186
was	AUX	O	O	3186
efficacious	ADJ	O	O	3186
and	CCONJ	O	O	3186
superior	PROPN	O	O	3186
to	PART	O	O	3186
both	PRON	O	O	3186
low	ADJ	O	O	3186
-	PUNCT	O	O	3186
dose	NOUN	O	O	3186
haloperidol	NOUN	O	Chemical	3186
and	CCONJ	O	O	3186
placebo	NOUN	O	O	3186
for	ADP	O	O	3186
scores	NOUN	O	O	3186
on	ADP	O	O	3186
the	PRON	O	O	3186
Brief	VERB	O	O	3186
Psychiatric	NOUN	O	O	3186
Rating	NOUN	O	O	3186
Scale	NOUN	O	O	3186
psychosis	VERB	O	Disease	3186
factor	NOUN	O	O	3186
and	CCONJ	O	O	3186
on	ADP	O	O	3186
psychomotor	NOUN	O	O	3186
agitation	NOUN	O	Disease	3186
.	PUNCT	O	O	3186
In	ADP	O	O	3187
phase	NOUN	O	O	3187
A	PRON	O	O	3187
,	PUNCT	O	O	3187
extrapyramidal	ADJ	O	O	3187
signs	NOUN	O	O	3187
tended	VERB	O	O	3187
to	PART	O	O	3187
be	AUX	O	O	3187
greater	ADJ	O	O	3187
with	ADP	O	O	3187
the	PRON	O	O	3187
standard	PROPN	O	O	3187
dose	NOUN	O	O	3187
than	ADP	O	O	3187
in	ADP	O	O	3187
the	PRON	O	O	3187
other	ADJ	O	O	3187
two	NUM	O	O	3187
conditions	NOUN	O	O	3187
,	PUNCT	O	O	3187
primarily	ADV	O	O	3187
because	SCONJ	O	O	3187
of	ADP	O	O	3187
a	PRON	O	O	3187
subgroup	PROPN	O	O	3187
(	PUNCT	O	O	3187
20%	NOUN	O	O	3187
)	PUNCT	O	O	3187
who	PRON	O	O	3187
developed	VERB	O	O	3187
moderate	ADJ	O	O	3187
to	PART	O	O	3187
severe	ADJ	O	O	3187
signs	NOUN	O	O	3187
.	PUNCT	O	O	3187
Low	ADJ	O	O	3188
-	PUNCT	O	O	3188
dose	NOUN	O	O	3188
haloperidol	NOUN	O	Chemical	3188
did	VERB	O	O	3188
not	PART	O	O	3188
differ	VERB	O	O	3188
from	ADP	O	O	3188
placebo	NOUN	O	O	3188
on	ADP	O	O	3188
any	PRON	O	O	3188
measure	VERB	O	O	3188
of	ADP	O	O	3188
efficacy	NOUN	O	O	3188
or	CCONJ	O	O	3188
side	NOUN	O	O	3188
effects	NOUN	O	O	3188
.	PUNCT	O	O	3188
The	PRON	O	O	3189
results	VERB	O	O	3189
indicated	VERB	O	O	3189
a	PRON	O	O	3189
favorable	ADJ	O	O	3189
therapeutic	ADJ	O	O	3189
profile	NOUN	O	O	3189
for	ADP	O	O	3189
haloperidol	NOUN	O	Chemical	3189
in	ADP	O	O	3189
doses	NOUN	O	O	3189
of	ADP	O	O	3189
2	X	O	O	3189
-	PUNCT	O	O	3189
3	X	O	O	3189
mg	VERB	O	O	3189
/	PUNCT	O	O	3189
day	NOUN	O	O	3189
,	PUNCT	O	O	3189
although	SCONJ	O	O	3189
a	PRON	O	O	3189
subgroup	PROPN	O	O	3189
developed	VERB	O	O	3189
moderate	ADJ	O	O	3189
to	PART	O	O	3189
severe	ADJ	O	O	3189
extrapyramidal	ADJ	O	O	3189
signs	NOUN	O	O	3189
.	PUNCT	O	O	3189
The	PRON	O	O	3190
narrow	ADJ	O	O	3190
therapeutic	ADJ	O	O	3190
window	NOUN	O	O	3190
observed	VERB	O	O	3190
with	ADP	O	O	3190
haloperidol	NOUN	O	Chemical	3190
may	AUX	O	O	3190
also	ADV	O	O	3190
apply	VERB	O	O	3190
to	PART	O	O	3190
other	ADJ	O	O	3190
neuroleptics	NOUN	O	O	3190
used	VERB	O	O	3190
in	ADP	O	O	3190
Alzheimer	NOUN	O	Disease	3190
's	AUX	O	O	3190
disease	PROPN	O	O	3190
patients	NOUN	O	O	3190
with	ADP	O	O	3190
psychosis	VERB	O	Disease	3190
and	CCONJ	O	O	3190
disruptive	ADJ	O	O	3190
behaviors	NOUN	O	O	3190
.	PUNCT	O	O	3190
Individual	ADJ	O	O	3193
differences	NOUN	O	O	3193
in	ADP	O	O	3193
renal	ADJ	O	O	3193
ACE	PROPN	O	O	3193
activity	NOUN	O	O	3193
in	ADP	O	O	3193
healthy	ADJ	O	O	3193
rats	NOUN	O	O	3193
predict	VERB	O	O	3193
susceptibility	NOUN	O	O	3193
to	PART	O	O	3193
adriamycin	PROPN	O	Chemical	3193
-	PUNCT	O	O	3193
induced	VERB	O	O	3193
renal damage	NOUN	O	Disease	3193
.	PUNCT	O	O	3193
In	ADP	O	O	3194
man	NOUN	O	O	3194
,	PUNCT	O	O	3194
differences	NOUN	O	O	3194
in	ADP	O	O	3194
angiotensin	NOUN	O	Chemical	3194
-	PUNCT	O	O	3194
converting	VERB	O	O	3194
enzyme	NOUN	O	O	3194
(	PUNCT	O	O	3194
ACE	PROPN	O	O	3194
)	PUNCT	O	O	3194
levels	NOUN	O	O	3194
,	PUNCT	O	O	3194
related	ADJ	O	O	3194
to	PART	O	O	3194
ACE	PROPN	O	O	3194
(	PUNCT	O	O	3194
I	PRON	O	O	3194
/	PUNCT	O	O	3194
D	NOUN	O	O	3194
)	PUNCT	O	O	3194
genotype	NOUN	O	O	3194
,	PUNCT	O	O	3194
are	AUX	O	O	3194
associated	VERB	O	O	3194
with	ADP	O	O	3194
renal	ADJ	O	O	3194
prognosis	VERB	O	O	3194
.	PUNCT	O	O	3194
Therefore	ADV	O	O	3195
,	PUNCT	O	O	3195
we	PRON	O	O	3195
studied	VERB	O	O	3195
the	PRON	O	O	3195
predictive	ADJ	O	O	3195
effect	VERB	O	O	3195
of	ADP	O	O	3195
renal	ADJ	O	O	3195
ACE	PROPN	O	O	3195
activity	NOUN	O	O	3195
for	ADP	O	O	3195
the	PRON	O	O	3195
severity	NOUN	O	O	3195
of	ADP	O	O	3195
renal damage	NOUN	O	Disease	3195
induced	VERB	O	O	3195
by	ADP	O	O	3195
a	PRON	O	O	3195
single	ADJ	O	O	3195
injection	NOUN	O	O	3195
of	ADP	O	O	3195
adriamycin	PROPN	O	Chemical	3195
in	ADP	O	O	3195
rats	NOUN	O	O	3195
.	PUNCT	O	O	3195
METHODS	NOUN	O	O	3196
:	PUNCT	O	O	3196
Renal	NOUN	O	O	3196
ACE	PROPN	O	O	3196
activity	NOUN	O	O	3196
(	PUNCT	O	O	3196
Hip	NOUN	O	O	3196
-	PUNCT	O	O	3196
His	PRON	O	O	3196
-	PUNCT	O	O	3196
Leu	PROPN	O	O	3196
cleavage	NOUN	O	O	3196
by	ADP	O	O	3196
cortical	ADJ	O	O	3196
homogenates	VERB	O	O	3196
)	PUNCT	O	O	3196
was	AUX	O	O	3196
determined	VERB	O	O	3196
by	ADP	O	O	3196
renal	ADJ	O	O	3196
biopsy	PROPN	O	O	3196
in	ADP	O	O	3196
27	NUM	O	O	3196
adult	NOUN	O	O	3196
male	NOUN	O	O	3196
Wistar	PROPN	O	O	3196
rats	NOUN	O	O	3196
.	PUNCT	O	O	3196
After	ADP	O	O	3197
1	X	O	O	3197
week	NOUN	O	O	3197
of	ADP	O	O	3197
recovery	NOUN	O	O	3197
,	PUNCT	O	O	3197
proteinuria	X	O	Disease	3197
was	AUX	O	O	3197
induced	VERB	O	O	3197
by	ADP	O	O	3197
adriamycin	PROPN	O	Chemical	3197
[	X	O	O	3197
1.5	NUM	O	O	3197
mg	VERB	O	O	3197
/	PUNCT	O	O	3197
kg	VERB	O	O	3197
intravenously	ADV	O	O	3197
(	PUNCT	O	O	3197
i.v	NOUN	O	O	3197
.	PUNCT	O	O	3197
)	PUNCT	O	O	3197
Proteinuria	PROPN	O	Disease	3198
was	AUX	O	O	3198
measured	VERB	O	O	3198
every	PRON	O	O	3198
2	X	O	O	3198
weeks	NOUN	O	O	3198
.	PUNCT	O	O	3198
As	ADP	O	O	3199
anticipated	VERB	O	O	3199
,	PUNCT	O	O	3199
adriamycin	PROPN	O	Chemical	3199
elicited	VERB	O	O	3199
nephrotic	NOUN	O	Disease	3199
range	VERB	O	O	3199
proteinuria	X	O	Disease	3199
,	PUNCT	O	O	3199
renal	ADJ	O	O	3199
interstitial	ADJ	O	O	3199
damage	NOUN	O	O	3199
and	CCONJ	O	O	3199
mild	ADJ	O	O	3199
focal	ADJ	O	O	3199
glomerulosclerosis	PROPN	O	O	3199
.	PUNCT	O	O	3199
Baseline	PROPN	O	O	3200
renal	ADJ	O	O	3200
ACE	PROPN	O	O	3200
positively	ADV	O	O	3200
correlated	VERB	O	O	3200
with	ADP	O	O	3200
the	PRON	O	O	3200
relative	ADJ	O	O	3200
rise	VERB	O	O	3200
in	ADP	O	O	3200
proteinuria	X	O	Disease	3200
after	ADP	O	O	3200
adriamycin	PROPN	O	Chemical	3200
(	PUNCT	O	O	3200
r	X	O	O	3200
=	PUNCT	O	O	3200
0.62	NUM	O	O	3200
,	PUNCT	O	O	3200
P<0.01	ADV	O	O	3200
)	PUNCT	O	O	3200
,	PUNCT	O	O	3200
renal	ADJ	O	O	3200
interstitial	ADJ	O	O	3200
alpha	PROPN	O	O	3200
-	PUNCT	O	O	3200
smooth	VERB	O	O	3200
muscle	NOUN	O	O	3200
actin	PROPN	O	O	3200
(	PUNCT	O	O	3200
r	X	O	O	3200
=	PUNCT	O	O	3200
0.49	NUM	O	O	3200
,	PUNCT	O	O	3200
P<0.05	NOUN	O	O	3200
)	PUNCT	O	O	3200
,	PUNCT	O	O	3200
interstitial	ADJ	O	O	3200
macrophage	NOUN	O	O	3200
influx	VERB	O	O	3200
(	PUNCT	O	O	3200
r	X	O	O	3200
=	PUNCT	O	O	3200
0.56	NUM	O	O	3200
,	PUNCT	O	O	3200
P<0.05	NOUN	O	O	3200
)	PUNCT	O	O	3200
,	PUNCT	O	O	3200
interstitial	ADJ	O	O	3200
collagen	NOUN	O	O	3200
III	NUM	O	O	3200
(	PUNCT	O	O	3200
r	X	O	O	3200
=	PUNCT	O	O	3200
0.53	NUM	O	O	3200
,	PUNCT	O	O	3200
P<0.05	NOUN	O	O	3200
)	PUNCT	O	O	3200
,	PUNCT	O	O	3200
glomerular	ADJ	O	O	3200
alpha	PROPN	O	O	3200
-	PUNCT	O	O	3200
smooth	VERB	O	O	3200
muscle	NOUN	O	O	3200
actin	PROPN	O	O	3200
(	PUNCT	O	O	3200
r	X	O	O	3200
=	PUNCT	O	O	3200
0.74	NUM	O	O	3200
,	PUNCT	O	O	3200
P<0.01	ADV	O	O	3200
)	PUNCT	O	O	3200
and	CCONJ	O	O	3200
glomerular	ADJ	O	O	3200
desmin	PROPN	O	O	3200
(	PUNCT	O	O	3200
r	X	O	O	3200
=	PUNCT	O	O	3200
0.48	NUM	O	O	3200
,	PUNCT	O	O	3200
P<0.05	NOUN	O	O	3200
)	PUNCT	O	O	3200
.	PUNCT	O	O	3200
ACE	PROPN	O	O	3201
did	VERB	O	O	3201
not	PART	O	O	3201
correlate	VERB	O	O	3201
with	ADP	O	O	3201
focal	ADJ	O	O	3201
glomerulosclerosis	PROPN	O	O	3201
(	PUNCT	O	O	3201
r	X	O	O	3201
=	PUNCT	O	O	3201
0.22	NUM	O	O	3201
,	PUNCT	O	O	3201
NS	PROPN	O	Disease	3201
)	PUNCT	O	O	3201
.	PUNCT	O	O	3201
Individual	ADJ	O	O	3202
differences	NOUN	O	O	3202
in	ADP	O	O	3202
renal	ADJ	O	O	3202
ACE	PROPN	O	O	3202
activity	NOUN	O	O	3202
predict	VERB	O	O	3202
the	PRON	O	O	3202
severity	NOUN	O	O	3202
of	ADP	O	O	3202
adriamycin	PROPN	O	Chemical	3202
-	PUNCT	O	O	3202
induced	VERB	O	O	3202
renal damage	NOUN	O	Disease	3202
in	ADP	O	O	3202
this	PRON	O	O	3202
outbred	ADJ	O	O	3202
rat	NOUN	O	O	3202
strain	VERB	O	O	3202
.	PUNCT	O	O	3202
This	PRON	O	O	3203
supports	VERB	O	O	3203
the	PRON	O	O	3203
assumption	NOUN	O	O	3203
that	SCONJ	O	O	3203
differences	NOUN	O	O	3203
in	ADP	O	O	3203
renal	ADJ	O	O	3203
ACE	PROPN	O	O	3203
activity	NOUN	O	O	3203
predispose	VERB	O	O	3203
to	PART	O	O	3203
a	PRON	O	O	3203
less	ADV	O	O	3203
favourable	ADJ	O	O	3203
course	NOUN	O	O	3203
of	ADP	O	O	3203
renal damage	NOUN	O	Disease	3203
.	PUNCT	O	O	3203
Clinical	NOUN	O	O	3206
nephrotoxicity	NOUN	O	Disease	3206
of	ADP	O	O	3206
tobramycin	NOUN	O	Chemical	3206
and	CCONJ	O	O	3206
gentamicin	VERB	O	Chemical	3206
.	PUNCT	O	O	3206
Nearly	ADV	O	O	3207
3.2	NUM	O	O	3207
million	NUM	O	O	3207
people	NOUN	O	O	3207
in	ADP	O	O	3207
this	PRON	O	O	3207
country	NOUN	O	O	3207
receive	VERB	O	O	3207
aminoglycoside	ADV	O	Chemical	3207
antibiotics	VERB	O	O	3207
annually	ADV	O	O	3207
.	PUNCT	O	O	3207
Gentamicin	PROPN	O	Chemical	3208
sulfate	NOUN	O	O	3208
and	CCONJ	O	O	3208
tobramycin sulfate	VERB	O	Chemical	3208
continue	VERB	O	O	3208
to	PART	O	O	3208
demonstrate	VERB	O	O	3208
ototoxicity	NOUN	O	Disease	3208
and	CCONJ	O	O	3208
nephrotoxicity	NOUN	O	Disease	3208
in	ADP	O	O	3208
both	PRON	O	O	3208
animal	NOUN	O	O	3208
and	CCONJ	O	O	3208
clinical	ADJ	O	O	3208
studies	NOUN	O	O	3208
.	PUNCT	O	O	3208
In	ADP	O	O	3209
this	PRON	O	O	3209
study	VERB	O	O	3209
,	PUNCT	O	O	3209
62	NUM	O	O	3209
patients	NOUN	O	O	3209
with	ADP	O	O	3209
confirmed	VERB	O	O	3209
initial	ADJ	O	O	3209
normal	ADJ	O	O	3209
renal	ADJ	O	O	3209
function	NOUN	O	O	3209
and	CCONJ	O	O	3209
treated	VERB	O	O	3209
with	ADP	O	O	3209
2	X	O	O	3209
to	PART	O	O	3209
5	NUM	O	O	3209
mg	VERB	O	O	3209
/	PUNCT	O	O	3209
kg	VERB	O	O	3209
/	PUNCT	O	O	3209
day	NOUN	O	O	3209
of	ADP	O	O	3209
gentamicin	VERB	O	Chemical	3209
sulfate	NOUN	O	O	3209
or	CCONJ	O	O	3209
tobramycin sulfate	VERB	O	Chemical	3209
for	ADP	O	O	3209
a	PRON	O	O	3209
minimum	ADJ	O	O	3209
of	ADP	O	O	3209
seven	NUM	O	O	3209
days	NOUN	O	O	3209
were	AUX	O	O	3209
followed	VERB	O	O	3209
up	ADP	O	O	3209
prospectively	ADV	O	O	3209
for	ADP	O	O	3209
the	PRON	O	O	3209
development	NOUN	O	O	3209
of	ADP	O	O	3209
aminoglycoside	ADV	O	Chemical	3209
-	PUNCT	O	O	3209
related	ADJ	O	O	3209
renal failure	NOUN	O	Disease	3209
,	PUNCT	O	O	3209
defined	VERB	O	O	3209
as	ADP	O	O	3209
at	ADP	O	O	3209
least	ADJ	O	O	3209
a	PRON	O	O	3209
one	NUM	O	O	3209
-	PUNCT	O	O	3209
third	ADV	O	O	3209
reduction in renal function	NOUN	O	Disease	3209
.	PUNCT	O	O	3209
In	ADP	O	O	3210
these	PRON	O	O	3210
62	NUM	O	O	3210
patients	NOUN	O	O	3210
,	PUNCT	O	O	3210
no	PRON	O	O	3210
other	ADJ	O	O	3210
causes	VERB	O	O	3210
for	ADP	O	O	3210
renal failure	NOUN	O	Disease	3210
could	AUX	O	O	3210
be	AUX	O	O	3210
identified	VERB	O	O	3210
.	PUNCT	O	O	3210
Five	NUM	O	O	3211
of	ADP	O	O	3211
33	NUM	O	O	3211
(	PUNCT	O	O	3211
15%	NOUN	O	O	3211
)	PUNCT	O	O	3211
of	ADP	O	O	3211
the	PRON	O	O	3211
tobramycin	NOUN	O	Chemical	3211
-	PUNCT	O	O	3211
treated	VERB	O	O	3211
patients	NOUN	O	O	3211
and	CCONJ	O	O	3211
16	NUM	O	O	3211
of	ADP	O	O	3211
29	NUM	O	O	3211
(	PUNCT	O	O	3211
55.2%	NOUN	O	O	3211
)	PUNCT	O	O	3211
of	ADP	O	O	3211
the	PRON	O	O	3211
gentamicin	VERB	O	Chemical	3211
-	PUNCT	O	O	3211
treated	VERB	O	O	3211
patients	NOUN	O	O	3211
had	VERB	O	O	3211
renal failure	NOUN	O	Disease	3211
.	PUNCT	O	O	3211
Thus	ADV	O	O	3212
,	PUNCT	O	O	3212
gentamicin	VERB	O	Chemical	3212
was	AUX	O	O	3212
associated	VERB	O	O	3212
with	ADP	O	O	3212
renal failure	NOUN	O	Disease	3212
more	ADJ	O	O	3212
than	ADP	O	O	3212
three	NUM	O	O	3212
times	NOUN	O	O	3212
as	ADP	O	O	3212
often	ADV	O	O	3212
as	ADP	O	O	3212
was	AUX	O	O	3212
tobramycin	NOUN	O	Chemical	3212
.	PUNCT	O	O	3212
Neuroprotective	NOUN	O	O	3215
action	NOUN	O	O	3215
of	ADP	O	O	3215
MPEP	NOUN	O	O	3215
,	PUNCT	O	O	3215
a	PRON	O	O	3215
selective	ADJ	O	O	3215
mGluR5	VERB	O	O	3215
antagonist	NOUN	O	O	3215
,	PUNCT	O	O	3215
in	ADP	O	O	3215
methamphetamine	NOUN	O	Chemical	3215
-	PUNCT	O	O	3215
induced	VERB	O	O	3215
dopaminergic	ADJ	O	O	3215
neurotoxicity	NOUN	O	Disease	3215
is	AUX	O	O	3215
associated	VERB	O	O	3215
with	ADP	O	O	3215
a	PRON	O	O	3215
decrease	VERB	O	O	3215
in	ADP	O	O	3215
dopamine	NOUN	O	Chemical	3215
outflow	NOUN	O	O	3215
and	CCONJ	O	O	3215
inhibition	NOUN	O	O	3215
of	ADP	O	O	3215
hyperthermia	NOUN	O	Disease	3215
in	ADP	O	O	3215
rats	NOUN	O	O	3215
.	PUNCT	O	O	3215
The	PRON	O	O	3216
aim	VERB	O	O	3216
of	ADP	O	O	3216
this	PRON	O	O	3216
study	VERB	O	O	3216
was	AUX	O	O	3216
to	PART	O	O	3216
examine	VERB	O	O	3216
the	PRON	O	O	3216
role	NOUN	O	O	3216
of	ADP	O	O	3216
metabotropic	NOUN	O	O	3216
glutamate	NOUN	O	Chemical	3216
receptor	NOUN	O	O	3216
5	NUM	O	O	3216
(	PUNCT	O	O	3216
mGluR5	VERB	O	O	3216
)	PUNCT	O	O	3216
in	ADP	O	O	3216
the	PRON	O	O	3216
toxic	ADJ	O	O	3216
action	NOUN	O	O	3216
of	ADP	O	O	3216
methamphetamine	NOUN	O	Chemical	3216
on	ADP	O	O	3216
dopaminergic	ADJ	O	O	3216
neurones	NOUN	O	O	3216
in	ADP	O	O	3216
rats	NOUN	O	O	3216
.	PUNCT	O	O	3216
Methamphetamine	NOUN	O	Chemical	3217
(	PUNCT	O	O	3217
10	NUM	O	O	3217
mg	VERB	O	O	3217
/	PUNCT	O	O	3217
kg	VERB	O	O	3217
sc	PROPN	O	O	3217
)	PUNCT	O	O	3217
,	PUNCT	O	O	3217
administered	VERB	O	O	3217
five	NUM	O	O	3217
times	NOUN	O	O	3217
,	PUNCT	O	O	3217
reduced	VERB	O	O	3217
the	PRON	O	O	3217
levels	NOUN	O	O	3217
of	ADP	O	O	3217
dopamine	NOUN	O	Chemical	3217
and	CCONJ	O	O	3217
its	PRON	O	O	3217
metabolites	VERB	O	O	3217
in	ADP	O	O	3217
striatal	ADJ	O	O	3217
tissue	NOUN	O	O	3217
when	SCONJ	O	O	3217
measured	VERB	O	O	3217
72	NUM	O	O	3217
h	X	O	O	3217
after	ADP	O	O	3217
the	PRON	O	O	3217
last	VERB	O	O	3217
injection	NOUN	O	O	3217
.	PUNCT	O	O	3217
A	PRON	O	O	3218
selective	ADJ	O	O	3218
antagonist	NOUN	O	O	3218
of	ADP	O	O	3218
mGluR5	VERB	O	O	3218
,	PUNCT	O	O	3218
2-methyl-6-(phenylethynyl)pyridine	NOUN	O	O	3218
(	PUNCT	O	O	3218
MPEP	NOUN	O	O	3218
;	PUNCT	O	O	3218
5	NUM	O	O	3218
mg	VERB	O	O	3218
/	PUNCT	O	O	3218
kg	VERB	O	O	3218
ip	X	O	O	3218
)	PUNCT	O	O	3218
,	PUNCT	O	O	3218
when	SCONJ	O	O	3218
administered	VERB	O	O	3218
five	NUM	O	O	3218
times	NOUN	O	O	3218
immediately	ADV	O	O	3218
before	ADP	O	O	3218
each	PRON	O	O	3218
methamphetamine	NOUN	O	Chemical	3218
injection	NOUN	O	O	3218
reversed	VERB	O	O	3218
the	PRON	O	O	3218
above	ADP	O	O	3218
-	PUNCT	O	O	3218
mentioned	VERB	O	O	3218
methamphetamine	NOUN	O	Chemical	3218
effects	NOUN	O	O	3218
.	PUNCT	O	O	3218
A	PRON	O	O	3219
single	ADJ	O	O	3219
MPEP	NOUN	O	O	3219
(	PUNCT	O	O	3219
5	NUM	O	O	3219
mg	VERB	O	O	3219
/	PUNCT	O	O	3219
kg	VERB	O	O	3219
ip	X	O	O	3219
)	PUNCT	O	O	3219
injection	NOUN	O	O	3219
reduced	VERB	O	O	3219
the	PRON	O	O	3219
basal	PROPN	O	O	3219
extracellular	ADJ	O	O	3219
dopamine	NOUN	O	Chemical	3219
level	VERB	O	O	3219
in	ADP	O	O	3219
the	PRON	O	O	3219
striatum	NOUN	O	O	3219
,	PUNCT	O	O	3219
as	ADP	O	O	3219
well	ADV	O	O	3219
as	ADP	O	O	3219
dopamine	NOUN	O	Chemical	3219
release	NOUN	O	O	3219
stimulated	VERB	O	O	3219
either	ADV	O	O	3219
by	ADP	O	O	3219
methamphetamine	NOUN	O	Chemical	3219
(	PUNCT	O	O	3219
10	NUM	O	O	3219
mg	VERB	O	O	3219
/	PUNCT	O	O	3219
kg	VERB	O	O	3219
sc	PROPN	O	O	3219
)	PUNCT	O	O	3219
or	CCONJ	O	O	3219
by	ADP	O	O	3219
intrastriatally	ADV	O	O	3219
administered	VERB	O	O	3219
veratridine	NOUN	O	O	3219
(	PUNCT	O	O	3219
100	NUM	O	O	3219
microM	ADJ	O	O	3219
)	PUNCT	O	O	3219
.	PUNCT	O	O	3219
Moreover	ADV	O	O	3220
,	PUNCT	O	O	3220
it	PRON	O	O	3220
transiently	ADV	O	O	3220
diminished	VERB	O	O	3220
the	PRON	O	O	3220
methamphetamine	NOUN	O	Chemical	3220
(	PUNCT	O	O	3220
10	NUM	O	O	3220
mg	VERB	O	O	3220
/	PUNCT	O	O	3220
kg	VERB	O	O	3220
sc)-induced	VERB	O	O	3220
hyperthermia	NOUN	O	Disease	3220
and	CCONJ	O	O	3220
reduced	VERB	O	O	3220
basal	PROPN	O	O	3220
body	NOUN	O	O	3220
temperature	NOUN	O	O	3220
.	PUNCT	O	O	3220
MPEP	NOUN	O	O	3221
administered	VERB	O	O	3221
into	ADP	O	O	3221
the	PRON	O	O	3221
striatum	NOUN	O	O	3221
at	ADP	O	O	3221
high	ADJ	O	O	3221
concentrations	NOUN	O	O	3221
(	PUNCT	O	O	3221
500	NUM	O	O	3221
microM	ADJ	O	O	3221
)	PUNCT	O	O	3221
increased	VERB	O	O	3221
extracellular	ADJ	O	O	3221
dopamine	NOUN	O	Chemical	3221
levels	NOUN	O	O	3221
,	PUNCT	O	O	3221
while	SCONJ	O	O	3221
lower	ADJ	O	O	3221
concentrations	NOUN	O	O	3221
(	PUNCT	O	O	3221
50	NUM	O	O	3221
-	PUNCT	O	O	3221
100	NUM	O	O	3221
microM	ADJ	O	O	3221
)	PUNCT	O	O	3221
were	AUX	O	O	3221
devoid	ADJ	O	O	3221
of	ADP	O	O	3221
any	PRON	O	O	3221
effect	VERB	O	O	3221
.	PUNCT	O	O	3221
The	PRON	O	O	3222
results	VERB	O	O	3222
of	ADP	O	O	3222
this	PRON	O	O	3222
study	VERB	O	O	3222
suggest	VERB	O	O	3222
that	SCONJ	O	O	3222
the	PRON	O	O	3222
blockade	VERB	O	O	3222
of	ADP	O	O	3222
mGluR5	VERB	O	O	3222
by	ADP	O	O	3222
MPEP	NOUN	O	O	3222
may	AUX	O	O	3222
protect	VERB	O	O	3222
dopaminergic	ADJ	O	O	3222
neurones	NOUN	O	O	3222
against	ADP	O	O	3222
methamphetamine	NOUN	O	Chemical	3222
-	PUNCT	O	O	3222
induced	VERB	O	O	3222
toxicity	NOUN	O	Disease	3222
.	PUNCT	O	O	3222
Neuroprotection	NOUN	O	O	3223
rendered	VERB	O	O	3223
by	ADP	O	O	3223
MPEP	NOUN	O	O	3223
may	AUX	O	O	3223
be	AUX	O	O	3223
associated	VERB	O	O	3223
with	ADP	O	O	3223
the	PRON	O	O	3223
reduction	NOUN	O	O	3223
of	ADP	O	O	3223
the	PRON	O	O	3223
methamphetamine	NOUN	O	Chemical	3223
-	PUNCT	O	O	3223
induced	VERB	O	O	3223
dopamine	NOUN	O	Chemical	3223
efflux	NOUN	O	O	3223
in	ADP	O	O	3223
the	PRON	O	O	3223
striatum	NOUN	O	O	3223
due	ADJ	O	O	3223
to	PART	O	O	3223
the	PRON	O	O	3223
blockade	VERB	O	O	3223
of	ADP	O	O	3223
extrastriatal	PROPN	O	O	3223
mGluR5	VERB	O	O	3223
,	PUNCT	O	O	3223
and	CCONJ	O	O	3223
with	ADP	O	O	3223
a	PRON	O	O	3223
decrease	VERB	O	O	3223
in	ADP	O	O	3223
hyperthermia	NOUN	O	Disease	3223
.	PUNCT	O	O	3223
Pharmacokinetics	NOUN	O	O	3226
of	ADP	O	O	3226
desipramine	NOUN	O	Chemical	3226
HCl	PROPN	O	O	3226
when	SCONJ	O	O	3226
administered	VERB	O	O	3226
with	ADP	O	O	3226
cinacalcet	PROPN	O	O	3226
HCl	PROPN	O	O	3226
.	PUNCT	O	O	3226
In	ADP	O	O	3227
vitro	X	O	O	3227
work	NOUN	O	O	3227
has	VERB	O	O	3227
demonstrated	VERB	O	O	3227
that	SCONJ	O	O	3227
cinacalcet	PROPN	O	O	3227
is	AUX	O	O	3227
a	PRON	O	O	3227
strong	ADJ	O	O	3227
inhibitor	NOUN	O	O	3227
of	ADP	O	O	3227
cytochrome	ADP	O	O	3227
P450	VERB	O	O	3227
isoenzyme	VERB	O	O	3227
(	PUNCT	O	O	3227
CYP	PROPN	O	Chemical	3227
)	PUNCT	O	O	3227
2D6	X	O	O	3227
.	PUNCT	O	O	3227
The	PRON	O	O	3228
purpose	NOUN	O	O	3228
of	ADP	O	O	3228
this	PRON	O	O	3228
study	VERB	O	O	3228
was	AUX	O	O	3228
to	PART	O	O	3228
evaluate	VERB	O	O	3228
the	PRON	O	O	3228
effect	VERB	O	O	3228
of	ADP	O	O	3228
cinacalcet	PROPN	O	O	3228
on	ADP	O	O	3228
CYP2D6	VERB	O	O	3228
activity	NOUN	O	O	3228
,	PUNCT	O	O	3228
using	VERB	O	O	3228
desipramine	NOUN	O	Chemical	3228
as	ADP	O	O	3228
a	PRON	O	O	3228
probe	NOUN	O	O	3228
substrate	NOUN	O	O	3228
,	PUNCT	O	O	3228
in	ADP	O	O	3228
healthy	ADJ	O	O	3228
subjects	NOUN	O	O	3228
.	PUNCT	O	O	3228
Seventeen	NUM	O	O	3229
subjects	NOUN	O	O	3229
who	PRON	O	O	3229
were	AUX	O	O	3229
genotyped	VERB	O	O	3229
as	ADP	O	O	3229
CYP2D6	VERB	O	O	3229
extensive	ADJ	O	O	3229
metabolizers	NOUN	O	O	3229
were	AUX	O	O	3229
enrolled	VERB	O	O	3229
in	ADP	O	O	3229
this	PRON	O	O	3229
randomized	VERB	O	O	3229
,	PUNCT	O	O	3229
open	VERB	O	O	3229
-	PUNCT	O	O	3229
label	PROPN	O	O	3229
,	PUNCT	O	O	3229
crossover	NOUN	O	O	3229
study	VERB	O	O	3229
to	PART	O	O	3229
receive	VERB	O	O	3229
a	PRON	O	O	3229
single	ADJ	O	O	3229
oral	ADJ	O	O	3229
dose	NOUN	O	O	3229
of	ADP	O	O	3229
desipramine	NOUN	O	Chemical	3229
(	PUNCT	O	O	3229
50	NUM	O	O	3229
mg	VERB	O	O	3229
)	PUNCT	O	O	3229
on	ADP	O	O	3229
two	NUM	O	O	3229
separate	VERB	O	O	3229
occasions	NOUN	O	O	3229
,	PUNCT	O	O	3229
once	ADV	O	O	3229
alone	ADV	O	O	3229
and	CCONJ	O	O	3229
once	ADV	O	O	3229
after	ADP	O	O	3229
multiple	ADJ	O	O	3229
doses	NOUN	O	O	3229
of	ADP	O	O	3229
cinacalcet	PROPN	O	O	3229
(	PUNCT	O	O	3229
90	NUM	O	O	3229
mg	VERB	O	O	3229
for	ADP	O	O	3229
7	NUM	O	O	3229
days	NOUN	O	O	3229
)	PUNCT	O	O	3229
.	PUNCT	O	O	3229
Relative	ADJ	O	O	3230
to	PART	O	O	3230
desipramine	NOUN	O	Chemical	3230
alone	ADV	O	O	3230
,	PUNCT	O	O	3230
mean	VERB	O	O	3230
AUC	NOUN	O	O	3230
and	CCONJ	O	O	3230
C(max	NUM	O	O	3230
)	PUNCT	O	O	3230
of	ADP	O	O	3230
desipramine	NOUN	O	Chemical	3230
increased	VERB	O	O	3230
3.6-	NUM	O	O	3230
and	CCONJ	O	O	3230
1.8-fold	ADV	O	O	3230
when	SCONJ	O	O	3230
coadministered	VERB	O	O	3230
with	ADP	O	O	3230
cinacalcet	PROPN	O	O	3230
.	PUNCT	O	O	3230
The	PRON	O	O	3231
t	NOUN	O	O	3231
(	PUNCT	O	O	3231
1/2,z	NUM	O	O	3231
)	PUNCT	O	O	3231
of	ADP	O	O	3231
desipramine	NOUN	O	Chemical	3231
was	AUX	O	O	3231
longer	ADV	O	O	3231
when	SCONJ	O	O	3231
desipramine	NOUN	O	Chemical	3231
was	AUX	O	O	3231
coadministered	VERB	O	O	3231
with	ADP	O	O	3231
cinacalcet	PROPN	O	O	3231
(	PUNCT	O	O	3231
21.0	NUM	O	O	3231
versus	ADP	O	O	3231
43.3	NUM	O	O	3231
hs	PRON	O	O	3231
)	PUNCT	O	O	3231
.	PUNCT	O	O	3231
Fewer	ADJ	O	O	3232
subjects	NOUN	O	O	3232
reported	VERB	O	O	3232
adverse	ADJ	O	O	3232
events	NOUN	O	O	3232
following	VERB	O	O	3232
treatment	NOUN	O	O	3232
with	ADP	O	O	3232
desipramine	NOUN	O	Chemical	3232
alone	ADV	O	O	3232
than	ADP	O	O	3232
when	SCONJ	O	O	3232
receiving	VERB	O	O	3232
desipramine	NOUN	O	Chemical	3232
with	ADP	O	O	3232
cinacalcet	PROPN	O	O	3232
(	PUNCT	O	O	3232
33	NUM	O	O	3232
versus	ADP	O	O	3232
86%	NOUN	O	O	3232
)	PUNCT	O	O	3232
,	PUNCT	O	O	3232
the	PRON	O	O	3232
most	ADV	O	O	3232
frequent	ADJ	O	O	3232
of	ADP	O	O	3232
which	PRON	O	O	3232
(	PUNCT	O	O	3232
nausea	NOUN	O	Disease	3232
and	CCONJ	O	O	3232
headache	PROPN	O	Disease	3232
)	PUNCT	O	O	3232
have	VERB	O	O	3232
been	AUX	O	O	3232
reported	VERB	O	O	3232
for	ADP	O	O	3232
patients	NOUN	O	O	3232
treated	VERB	O	O	3232
with	ADP	O	O	3232
either	ADV	O	O	3232
desipramine	NOUN	O	Chemical	3232
or	CCONJ	O	O	3232
cinacalcet	PROPN	O	O	3232
.	PUNCT	O	O	3232
This	PRON	O	O	3233
study	VERB	O	O	3233
demonstrates	VERB	O	O	3233
that	SCONJ	O	O	3233
cinacalcet	PROPN	O	O	3233
is	AUX	O	O	3233
a	PRON	O	O	3233
strong	ADJ	O	O	3233
inhibitor	NOUN	O	O	3233
of	ADP	O	O	3233
CYP2D6	VERB	O	O	3233
.	PUNCT	O	O	3233
These	PRON	O	O	3234
data	NOUN	O	O	3234
suggest	VERB	O	O	3234
that	SCONJ	O	O	3234
during	ADP	O	O	3234
concomitant	ADJ	O	O	3234
treatment	NOUN	O	O	3234
with	ADP	O	O	3234
cinacalcet	PROPN	O	O	3234
,	PUNCT	O	O	3234
dose	NOUN	O	O	3234
adjustment	NOUN	O	O	3234
may	AUX	O	O	3234
be	AUX	O	O	3234
necessary	ADJ	O	O	3234
for	ADP	O	O	3234
drugs	NOUN	O	O	3234
that	SCONJ	O	O	3234
demonstrate	VERB	O	O	3234
a	PRON	O	O	3234
narrow	ADJ	O	O	3234
therapeutic	ADJ	O	O	3234
index	NOUN	O	O	3234
and	CCONJ	O	O	3234
are	AUX	O	O	3234
metabolized	VERB	O	O	3234
by	ADP	O	O	3234
CYP2D6	VERB	O	O	3234
.	PUNCT	O	O	3234
Proteomic	PROPN	O	O	3237
analysis	NOUN	O	O	3237
of	ADP	O	O	3237
striatal	ADJ	O	O	3237
proteins	NOUN	O	O	3237
in	ADP	O	O	3237
the	PRON	O	O	3237
rat	NOUN	O	O	3237
model	NOUN	O	O	3237
of	ADP	O	O	3237
L	NOUN	O	O	3237
-	PUNCT	O	O	3237
DOPA	PROPN	O	O	3237
-	PUNCT	O	O	3237
induced	VERB	O	O	3237
dyskinesia	NOUN	O	Disease	3237
.	PUNCT	O	O	3237
L	NOUN	O	O	3238
-	PUNCT	O	O	3238
DOPA	PROPN	O	O	3238
-	PUNCT	O	O	3238
induced	VERB	O	O	3238
dyskinesia	NOUN	O	Disease	3238
(	PUNCT	O	O	3238
LID	VERB	O	Disease	3238
)	PUNCT	O	O	3238
is	AUX	O	O	3238
among	ADP	O	O	3238
the	PRON	O	O	3238
motor	NOUN	O	O	3238
complications	NOUN	O	O	3238
that	SCONJ	O	O	3238
arise	VERB	O	O	3238
in	ADP	O	O	3238
Parkinson	NOUN	O	O	3238
's	AUX	O	O	3238
disease	PROPN	O	O	3238
(	PUNCT	O	O	3238
PD	PROPN	O	Disease	3238
)	PUNCT	O	O	3238
patients	NOUN	O	O	3238
after	ADP	O	O	3238
a	PRON	O	O	3238
prolonged	VERB	O	O	3238
treatment	NOUN	O	O	3238
with	ADP	O	O	3238
L	NOUN	O	O	3238
-	PUNCT	O	O	3238
DOPA	PROPN	O	O	3238
.	PUNCT	O	O	3238
To	PART	O	O	3239
this	PRON	O	O	3239
day	NOUN	O	O	3239
,	PUNCT	O	O	3239
transcriptome	NOUN	O	O	3239
analysis	NOUN	O	O	3239
has	VERB	O	O	3239
been	AUX	O	O	3239
performed	VERB	O	O	3239
in	ADP	O	O	3239
a	PRON	O	O	3239
rat	NOUN	O	O	3239
model	NOUN	O	O	3239
of	ADP	O	O	3239
LID	VERB	O	Disease	3239
[	X	O	O	3239
Neurobiol	PROPN	O	O	3239
.	PUNCT	O	O	3239
In	ADP	O	O	3240
the	PRON	O	O	3240
present	NOUN	O	O	3240
study	VERB	O	O	3240
,	PUNCT	O	O	3240
we	PRON	O	O	3240
investigated	VERB	O	O	3240
the	PRON	O	O	3240
changes	VERB	O	O	3240
occurring	VERB	O	O	3240
at	ADP	O	O	3240
the	PRON	O	O	3240
protein	NOUN	O	O	3240
level	VERB	O	O	3240
in	ADP	O	O	3240
striatal	ADJ	O	O	3240
samples	NOUN	O	O	3240
obtained	VERB	O	O	3240
from	ADP	O	O	3240
the	PRON	O	O	3240
unilaterally	ADV	O	O	3240
6-hydroxydopamine	NOUN	O	Chemical	3240
-	PUNCT	O	O	3240
lesion	NOUN	O	O	3240
rat	NOUN	O	O	3240
model	NOUN	O	O	3240
of	ADP	O	O	3240
PD	PROPN	O	Disease	3240
treated	VERB	O	O	3240
with	ADP	O	O	3240
saline	NOUN	O	O	3240
,	PUNCT	O	O	3240
L	NOUN	O	O	3240
-	PUNCT	O	O	3240
DOPA	PROPN	O	O	3240
or	CCONJ	O	O	3240
bromocriptine	NOUN	O	Chemical	3240
using	VERB	O	O	3240
two	NUM	O	O	3240
-	PUNCT	O	O	3240
dimensional	ADJ	O	O	3240
difference	NOUN	O	O	3240
gel	PROPN	O	O	3240
electrophoresis	NOUN	O	O	3240
and	CCONJ	O	O	3240
mass	PROPN	O	O	3240
spectrometry	NOUN	O	O	3240
(	PUNCT	O	O	3240
MS	NOUN	O	O	3240
)	PUNCT	O	O	3240
.	PUNCT	O	O	3240
Rats	NOUN	O	O	3241
treated	VERB	O	O	3241
with	ADP	O	O	3241
L	NOUN	O	O	3241
-	PUNCT	O	O	3241
DOPA	PROPN	O	O	3241
were	AUX	O	O	3241
allocated	VERB	O	O	3241
to	PART	O	O	3241
two	NUM	O	O	3241
groups	NOUN	O	O	3241
based	VERB	O	O	3241
on	ADP	O	O	3241
the	PRON	O	O	3241
presence	NOUN	O	O	3241
or	CCONJ	O	O	3241
absence	NOUN	O	O	3241
of	ADP	O	O	3241
LID	VERB	O	Disease	3241
.	PUNCT	O	O	3241
Out	ADP	O	O	3242
of	ADP	O	O	3242
these	PRON	O	O	3242
67	NUM	O	O	3242
proteins	NOUN	O	O	3242
,	PUNCT	O	O	3242
LID	VERB	O	Disease	3242
significantly	ADV	O	O	3242
changed	VERB	O	O	3242
the	PRON	O	O	3242
expression	NOUN	O	O	3242
level	VERB	O	O	3242
of	ADP	O	O	3242
five	NUM	O	O	3242
proteins	NOUN	O	O	3242
:	PUNCT	O	O	3242
alphabeta	ADJ	O	O	3242
-	PUNCT	O	O	3242
crystalin	PROPN	O	O	3242
,	PUNCT	O	O	3242
gamma	PROPN	O	O	3242
-	PUNCT	O	O	3242
enolase	ADJ	O	O	3242
,	PUNCT	O	O	3242
guanidoacetate	NOUN	O	O	3242
methyltransferase	NOUN	O	O	3242
,	PUNCT	O	O	3242
vinculin	PROPN	O	O	3242
,	PUNCT	O	O	3242
and	CCONJ	O	O	3242
proteasome	VERB	O	O	3242
alpha-2	NUM	O	O	3242
subunit	NOUN	O	O	3242
.	PUNCT	O	O	3242
In	ADP	O	O	3243
conclusion	NOUN	O	O	3243
,	PUNCT	O	O	3243
this	PRON	O	O	3243
study	VERB	O	O	3243
provides	VERB	O	O	3243
new	ADJ	O	O	3243
insights	NOUN	O	O	3243
into	ADP	O	O	3243
the	PRON	O	O	3243
protein	NOUN	O	O	3243
changes	VERB	O	O	3243
occurring	VERB	O	O	3243
in	ADP	O	O	3243
LID	VERB	O	Disease	3243
.	PUNCT	O	O	3243
Pseudo	NOUN	O	O	3246
-	PUNCT	O	O	3246
allergic	ADJ	O	O	3246
reactions	NOUN	O	O	3246
to	PART	O	O	3246
corticosteroids	NOUN	O	Chemical	3246
:	PUNCT	O	O	3246
diagnosis	NOUN	O	O	3246
and	CCONJ	O	O	3246
alternatives	NOUN	O	O	3246
.	PUNCT	O	O	3246
Two	NUM	O	O	3247
patients	NOUN	O	O	3247
treated	VERB	O	O	3247
with	ADP	O	O	3247
parenteral	ADJ	O	O	3247
paramethasone	NOUN	O	O	3247
(	PUNCT	O	O	3247
Triniol	NOUN	O	O	3247
)	PUNCT	O	O	3247
and	CCONJ	O	O	3247
dexamethasone	NOUN	O	Chemical	3247
(	PUNCT	O	O	3247
Sedionbel	NOUN	O	O	3247
)	PUNCT	O	O	3247
are	AUX	O	O	3247
described	VERB	O	O	3247
.	PUNCT	O	O	3247
A	PRON	O	O	3248
few	ADJ	O	O	3248
minutes	NOUN	O	O	3248
after	ADP	O	O	3248
administration	NOUN	O	O	3248
of	ADP	O	O	3248
the	PRON	O	O	3248
drugs	NOUN	O	O	3248
,	PUNCT	O	O	3248
they	PRON	O	O	3248
presented	VERB	O	O	3248
urticaria	PROPN	O	Disease	3248
(	PUNCT	O	O	3248
patients	NOUN	O	O	3248
1	X	O	O	3248
and	CCONJ	O	O	3248
2	X	O	O	3248
)	PUNCT	O	O	3248
and	CCONJ	O	O	3248
conjunctivitis	NOUN	O	O	3248
(	PUNCT	O	O	3248
patient	NOUN	O	O	3248
1	X	O	O	3248
)	PUNCT	O	O	3248
.	PUNCT	O	O	3248
Clinical	NOUN	O	O	3249
examinations	NOUN	O	O	3249
and	CCONJ	O	O	3249
skin	NOUN	O	O	3249
,	PUNCT	O	O	3249
oral	ADJ	O	O	3249
and	CCONJ	O	O	3249
parenteral	ADJ	O	O	3249
challenges	VERB	O	O	3249
with	ADP	O	O	3249
different	ADJ	O	O	3249
corticosteroids	NOUN	O	Chemical	3249
and	CCONJ	O	O	3249
ELISA	PROPN	O	O	3249
tests	VERB	O	O	3249
were	AUX	O	O	3249
performed	VERB	O	O	3249
.	PUNCT	O	O	3249
In	ADP	O	O	3250
the	PRON	O	O	3250
two	NUM	O	O	3250
patients	NOUN	O	O	3250
,	PUNCT	O	O	3250
skin	NOUN	O	O	3250
and	CCONJ	O	O	3250
ELISA	PROPN	O	O	3250
tests	VERB	O	O	3250
with	ADP	O	O	3250
paramethasone	NOUN	O	O	3250
were	AUX	O	O	3250
negative	ADJ	O	O	3250
,	PUNCT	O	O	3250
as	ADP	O	O	3250
was	AUX	O	O	3250
the	PRON	O	O	3250
prick	VERB	O	O	3250
test	NOUN	O	O	3250
with	ADP	O	O	3250
each	PRON	O	O	3250
of	ADP	O	O	3250
its	PRON	O	O	3250
excipients	NOUN	O	O	3250
.	PUNCT	O	O	3250
We	PRON	O	O	3251
also	ADV	O	O	3251
carried	VERB	O	O	3251
out	ADP	O	O	3251
oral	ADJ	O	O	3251
and	CCONJ	O	O	3251
parenteral	ADJ	O	O	3251
challenges	VERB	O	O	3251
with	ADP	O	O	3251
other	ADJ	O	O	3251
corticosteroids	NOUN	O	Chemical	3251
and	CCONJ	O	O	3251
found	VERB	O	O	3251
intolerance	NOUN	O	O	3251
to	PART	O	O	3251
some	PRON	O	O	3251
of	ADP	O	O	3251
them	PRON	O	O	3251
.	PUNCT	O	O	3251
These	PRON	O	O	3252
results	VERB	O	O	3252
suggest	VERB	O	O	3252
that	SCONJ	O	O	3252
paramethasone	NOUN	O	O	3252
caused	VERB	O	O	3252
pseudoallergic	VERB	O	O	3252
reactions	NOUN	O	O	3252
in	ADP	O	O	3252
our	PRON	O	O	3252
patients	NOUN	O	O	3252
.	PUNCT	O	O	3252
Corticosteroids	NOUN	O	O	3253
different	ADJ	O	O	3253
from	ADP	O	O	3253
paramethasone	NOUN	O	O	3253
also	ADV	O	O	3253
produced	VERB	O	O	3253
hypersensitivity	NOUN	O	Disease	3253
reactions	NOUN	O	O	3253
in	ADP	O	O	3253
these	PRON	O	O	3253
patients	NOUN	O	O	3253
;	PUNCT	O	O	3253
however	ADV	O	O	3253
,	PUNCT	O	O	3253
a	PRON	O	O	3253
few	ADJ	O	O	3253
of	ADP	O	O	3253
them	PRON	O	O	3253
were	AUX	O	O	3253
tolerated	VERB	O	O	3253
.	PUNCT	O	O	3253
To	PART	O	O	3254
our	PRON	O	O	3254
knowledge	NOUN	O	O	3254
,	PUNCT	O	O	3254
this	PRON	O	O	3254
is	AUX	O	O	3254
the	PRON	O	O	3254
first	ADV	O	O	3254
report	VERB	O	O	3254
of	ADP	O	O	3254
a	PRON	O	O	3254
pseudo	NOUN	O	O	3254
-	PUNCT	O	O	3254
allergy	PROPN	O	O	3254
caused	VERB	O	O	3254
by	ADP	O	O	3254
paramethasone	NOUN	O	O	3254
.	PUNCT	O	O	3254
Valproic acid	NOUN	O	Chemical	3257
induced	VERB	O	O	3257
encephalopathy--19	NUM	O	O	3257
new	ADJ	O	O	3257
cases	NOUN	O	O	3257
in	ADP	O	O	3257
Germany	PROPN	O	O	3257
from	ADP	O	O	3257
1994	NUM	O	O	3257
to	PART	O	O	3257
2003	NUM	O	O	3257
-	PUNCT	O	O	3257
-a	PUNCT	O	O	3257
side	NOUN	O	O	3257
effect	VERB	O	O	3257
associated	VERB	O	O	3257
to	PART	O	O	3257
VPA	PROPN	O	Chemical	3257
-	PUNCT	O	O	3257
therapy	NOUN	O	O	3257
not	PART	O	O	3257
only	ADV	O	O	3257
in	ADP	O	O	3257
young	ADJ	O	O	3257
children	NOUN	O	O	3257
.	PUNCT	O	O	3257
Valproic acid	NOUN	O	Chemical	3258
(	PUNCT	O	O	3258
VPA	PROPN	O	Chemical	3258
)	PUNCT	O	O	3258
is	AUX	O	O	3258
a	PRON	O	O	3258
broad	ADJ	O	O	3258
-	PUNCT	O	O	3258
spectrum	NOUN	O	O	3258
antiepileptic	ADJ	O	O	3258
drug	NOUN	O	O	3258
and	CCONJ	O	O	3258
is	AUX	O	O	3258
usually	ADV	O	O	3258
well	ADV	O	O	3258
-	PUNCT	O	O	3258
tolerated	VERB	O	O	3258
.	PUNCT	O	O	3258
Rare	ADJ	O	O	3259
serious	ADJ	O	O	3259
complications	NOUN	O	O	3259
may	AUX	O	O	3259
occur	VERB	O	O	3259
in	ADP	O	O	3259
some	PRON	O	O	3259
patients	NOUN	O	O	3259
,	PUNCT	O	O	3259
including	VERB	O	O	3259
haemorrhagic	ADJ	O	Disease	3259
pancreatitis	PROPN	O	O	3259
,	PUNCT	O	O	3259
bone	NOUN	O	O	3259
marrow suppression	NOUN	O	Disease	3259
,	PUNCT	O	O	3259
VPA	PROPN	O	Chemical	3259
-	PUNCT	O	O	3259
induced	VERB	O	O	3259
hepatotoxicity	NOUN	O	Disease	3259
and	CCONJ	O	O	3259
VPA	PROPN	O	Chemical	3259
-	PUNCT	O	O	3259
induced	VERB	O	O	3259
encephalopathy	NOUN	O	Disease	3259
.	PUNCT	O	O	3259
The	PRON	O	O	3260
typical	ADJ	O	O	3260
signs	NOUN	O	O	3260
of	ADP	O	O	3260
VPA	PROPN	O	Chemical	3260
-	PUNCT	O	O	3260
induced	VERB	O	O	3260
encephalopathy	NOUN	O	Disease	3260
are	AUX	O	O	3260
impaired	VERB	O	O	3260
consciousness	NOUN	O	O	3260
,	PUNCT	O	O	3260
sometimes	ADV	O	O	3260
marked	VERB	O	O	3260
EEG	NOUN	O	O	3260
background	NOUN	O	O	3260
slowing	VERB	O	O	3260
,	PUNCT	O	O	3260
increased	VERB	O	O	3260
seizure	NOUN	O	Disease	3260
frequency	NOUN	O	O	3260
,	PUNCT	O	O	3260
with	ADP	O	O	3260
or	CCONJ	O	O	3260
without	ADP	O	O	3260
hyperammonemia	PROPN	O	Disease	3260
.	PUNCT	O	O	3260
There	ADV	O	O	3261
is	AUX	O	O	3261
still	ADV	O	O	3261
no	PRON	O	O	3261
proof	NOUN	O	O	3261
of	ADP	O	O	3261
causative	ADJ	O	O	3261
effect	VERB	O	O	3261
of	ADP	O	O	3261
VPA	PROPN	O	Chemical	3261
in	ADP	O	O	3261
patients	NOUN	O	O	3261
with	ADP	O	O	3261
encephalopathy	NOUN	O	Disease	3261
,	PUNCT	O	O	3261
but	CCONJ	O	O	3261
only	ADV	O	O	3261
of	ADP	O	O	3261
an	PRON	O	O	3261
association	PROPN	O	O	3261
with	ADP	O	O	3261
an	PRON	O	O	3261
assumed	VERB	O	O	3261
causal	NOUN	O	O	3261
relation	NOUN	O	O	3261
.	PUNCT	O	O	3261
We	PRON	O	O	3262
report	VERB	O	O	3262
19	NUM	O	O	3262
patients	NOUN	O	O	3262
with	ADP	O	O	3262
VPA	PROPN	O	Chemical	3262
-	PUNCT	O	O	3262
associated	VERB	O	O	3262
encephalopathy	NOUN	O	Disease	3262
in	ADP	O	O	3262
Germany	PROPN	O	O	3262
from	ADP	O	O	3262
the	PRON	O	O	3262
years	NOUN	O	O	3262
1994	NUM	O	O	3262
to	PART	O	O	3262
2003	NUM	O	O	3262
,	PUNCT	O	O	3262
none	NOUN	O	O	3262
of	ADP	O	O	3262
whom	PRON	O	O	3262
had	VERB	O	O	3262
been	AUX	O	O	3262
published	VERB	O	O	3262
previously	ADV	O	O	3262
.	PUNCT	O	O	3262
Haemolytic	NOUN	O	O	3265
-	PUNCT	O	O	3265
uraemic	PROPN	O	O	3265
syndrome	NOUN	O	O	3265
after	ADP	O	O	3265
treatment	NOUN	O	O	3265
with	ADP	O	O	3265
metronidazole	VERB	O	O	3265
.	PUNCT	O	O	3265
This	PRON	O	O	3266
paper	PROPN	O	O	3266
describes	VERB	O	O	3266
the	PRON	O	O	3266
clinical	ADJ	O	O	3266
features	VERB	O	O	3266
of	ADP	O	O	3266
six	NUM	O	O	3266
children	NOUN	O	O	3266
who	PRON	O	O	3266
developed	VERB	O	O	3266
the	PRON	O	O	3266
haemolytic	ADJ	O	O	3266
-	PUNCT	O	O	3266
uraemic	PROPN	O	O	3266
syndrome	NOUN	O	O	3266
after	ADP	O	O	3266
treatment	NOUN	O	O	3266
with	ADP	O	O	3266
metronidazole	VERB	O	O	3266
.	PUNCT	O	O	3266
While	SCONJ	O	O	3267
the	PRON	O	O	3267
involvement	NOUN	O	O	3267
of	ADP	O	O	3267
metronidazole	VERB	O	O	3267
in	ADP	O	O	3267
the	PRON	O	O	3267
aetiology	NOUN	O	O	3267
of	ADP	O	O	3267
the	PRON	O	O	3267
haemolytic	ADJ	O	O	3267
-	PUNCT	O	O	3267
uraemic	PROPN	O	O	3267
syndrome	NOUN	O	O	3267
is	AUX	O	O	3267
not	PART	O	O	3267
established	VERB	O	O	3267
firmly	ADV	O	O	3267
,	PUNCT	O	O	3267
the	PRON	O	O	3267
action	NOUN	O	O	3267
of	ADP	O	O	3267
this	PRON	O	O	3267
drug	NOUN	O	O	3267
in	ADP	O	O	3267
sensitizing	VERB	O	O	3267
tissues	NOUN	O	O	3267
to	PART	O	O	3267
oxidation	ADV	O	O	3267
injury	NOUN	O	O	3267
and	CCONJ	O	O	3267
the	PRON	O	O	3267
reported	VERB	O	O	3267
evidence	NOUN	O	O	3267
of	ADP	O	O	3267
oxidation	ADV	O	O	3267
changes	VERB	O	O	3267
in	ADP	O	O	3267
the	PRON	O	O	3267
haemolytic	ADJ	O	O	3267
-	PUNCT	O	O	3267
uraemic	PROPN	O	O	3267
syndrome	NOUN	O	O	3267
suggest	VERB	O	O	3267
a	PRON	O	O	3267
possible	ADJ	O	O	3267
link	VERB	O	O	3267
between	ADP	O	O	3267
metronidazole	VERB	O	O	3267
treatment	NOUN	O	O	3267
and	CCONJ	O	O	3267
some	PRON	O	O	3267
cases	NOUN	O	O	3267
of	ADP	O	O	3267
the	PRON	O	O	3267
haemolytic	ADJ	O	O	3267
-	PUNCT	O	O	3267
uraemic	PROPN	O	O	3267
syndrome	NOUN	O	O	3267
.	PUNCT	O	O	3267
Risk	NOUN	O	O	3270
factors	NOUN	O	O	3270
of	ADP	O	O	3270
sensorineural	ADJ	O	O	3270
hearing loss	NOUN	O	Disease	3270
in	ADP	O	O	3270
preterm	NOUN	O	O	3270
infants	NOUN	O	O	3270
.	PUNCT	O	O	3270
Among	ADP	O	O	3271
547	NUM	O	O	3271
preterm	NOUN	O	O	3271
infants	NOUN	O	O	3271
of	ADP	O	O	3271
<	X	O	O	3271
or	CCONJ	O	O	3271
=	PUNCT	O	O	3271
34	NUM	O	O	3271
weeks	NOUN	O	O	3271
gestation	NOUN	O	O	3271
born	VERB	O	O	3271
between	ADP	O	O	3271
1987	NUM	O	O	3271
and	CCONJ	O	O	3271
1991	NUM	O	O	3271
,	PUNCT	O	O	3271
8	NUM	O	O	3271
children	NOUN	O	O	3271
(	PUNCT	O	O	3271
1.46%	NOUN	O	O	3271
)	PUNCT	O	O	3271
developed	VERB	O	O	3271
severe	ADJ	O	O	3271
progressive	ADJ	O	O	3271
and	CCONJ	O	O	3271
bilateral	ADJ	O	O	3271
sensorineural	ADJ	O	O	3271
hearing loss	NOUN	O	Disease	3271
.	PUNCT	O	O	3271
Perinatal	PROPN	O	O	3272
risk	NOUN	O	O	3272
factors	NOUN	O	O	3272
of	ADP	O	O	3272
infants	NOUN	O	O	3272
with	ADP	O	O	3272
hearing loss	NOUN	O	Disease	3272
were	AUX	O	O	3272
compared	VERB	O	O	3272
with	ADP	O	O	3272
those	PRON	O	O	3272
of	ADP	O	O	3272
two	NUM	O	O	3272
control	VERB	O	O	3272
groups	NOUN	O	O	3272
matched	VERB	O	O	3272
for	ADP	O	O	3272
gestation	NOUN	O	O	3272
and	CCONJ	O	O	3272
birth	NOUN	O	O	3272
weight	NOUN	O	O	3272
and	CCONJ	O	O	3272
for	ADP	O	O	3272
perinatal	ADJ	O	O	3272
complications	NOUN	O	O	3272
.	PUNCT	O	O	3272
Our	PRON	O	O	3273
observations	NOUN	O	O	3273
demonstrated	VERB	O	O	3273
an	PRON	O	O	3273
association	PROPN	O	O	3273
of	ADP	O	O	3273
hearing loss	NOUN	O	Disease	3273
with	ADP	O	O	3273
a	PRON	O	O	3273
higher	ADJ	O	O	3273
incidence	NOUN	O	O	3273
of	ADP	O	O	3273
perinatal	ADJ	O	O	3273
complications	NOUN	O	O	3273
.	PUNCT	O	O	3273
Ototoxicity	NOUN	O	Disease	3274
appeared	VERB	O	O	3274
closely	ADV	O	O	3274
related	ADJ	O	O	3274
to	PART	O	O	3274
a	PRON	O	O	3274
prolonged	VERB	O	O	3274
administration	NOUN	O	O	3274
and	CCONJ	O	O	3274
higher	ADJ	O	O	3274
total	ADJ	O	O	3274
dose	NOUN	O	O	3274
of	ADP	O	O	3274
ototoxic	ADJ	O	O	3274
drugs	NOUN	O	O	3274
,	PUNCT	O	O	3274
particularly	ADV	O	O	3274
aminoglycosides	NOUN	O	Chemical	3274
and	CCONJ	O	O	3274
furosemide	PROPN	O	Chemical	3274
.	PUNCT	O	O	3274
Finally	ADV	O	O	3275
,	PUNCT	O	O	3275
we	PRON	O	O	3275
strongly	ADV	O	O	3275
recommend	VERB	O	O	3275
to	PART	O	O	3275
prospectively	ADV	O	O	3275
and	CCONJ	O	O	3275
regularly	ADV	O	O	3275
perform	VERB	O	O	3275
audiologic	ADJ	O	O	3275
assessment	NOUN	O	O	3275
in	ADP	O	O	3275
sick	ADJ	O	O	3275
preterm	NOUN	O	O	3275
children	NOUN	O	O	3275
as	ADP	O	O	3275
hearing loss	NOUN	O	Disease	3275
is	AUX	O	O	3275
of	ADP	O	O	3275
delayed	VERB	O	O	3275
onset	VERB	O	O	3275
and	CCONJ	O	O	3275
in	ADP	O	O	3275
most	ADV	O	O	3275
cases	NOUN	O	O	3275
bilateral	ADJ	O	O	3275
and	CCONJ	O	O	3275
severe	ADJ	O	O	3275
.	PUNCT	O	O	3275
Pharmacokinetic	NOUN	O	O	3278
and	CCONJ	O	O	3278
clinical	ADJ	O	O	3278
studies	NOUN	O	O	3278
in	ADP	O	O	3278
patients	NOUN	O	O	3278
with	ADP	O	O	3278
cimetidine	NOUN	O	Chemical	3278
-	PUNCT	O	O	3278
associated	VERB	O	O	3278
mental	ADJ	O	O	3278
confusion	NOUN	O	Disease	3278
.	PUNCT	O	O	3278
15	NUM	O	O	3279
cases	NOUN	O	O	3279
of	ADP	O	O	3279
cimetidine	NOUN	O	Chemical	3279
-	PUNCT	O	O	3279
associated	VERB	O	O	3279
mental	ADJ	O	O	3279
confusion	NOUN	O	Disease	3279
have	VERB	O	O	3279
been	AUX	O	O	3279
reported	VERB	O	O	3279
.	PUNCT	O	O	3279
In	ADP	O	O	3280
order	NOUN	O	O	3280
that	SCONJ	O	O	3280
this	PRON	O	O	3280
syndrome	NOUN	O	O	3280
might	AUX	O	O	3280
be	AUX	O	O	3280
investigated	VERB	O	O	3280
changes	VERB	O	O	3280
in	ADP	O	O	3280
mental	ADJ	O	O	3280
status	NOUN	O	O	3280
(	PUNCT	O	O	3280
M.S.	PROPN	O	O	3280
)	PUNCT	O	O	3280
were	AUX	O	O	3280
correlated	VERB	O	O	3280
with	ADP	O	O	3280
serum	NOUN	O	O	3280
concentrations	NOUN	O	O	3280
and	CCONJ	O	O	3280
renal	ADJ	O	O	3280
and	CCONJ	O	O	3280
hepatic	ADJ	O	O	3280
function	NOUN	O	O	3280
in	ADP	O	O	3280
36	NUM	O	O	3280
patients	NOUN	O	O	3280
,	PUNCT	O	O	3280
30	NUM	O	O	3280
patients	NOUN	O	O	3280
had	VERB	O	O	3280
no	PRON	O	O	3280
M.S.	PROPN	O	O	3280
change	VERB	O	O	3280
on	ADP	O	O	3280
cimetidine	NOUN	O	Chemical	3280
and	CCONJ	O	O	3280
6	NUM	O	O	3280
had	VERB	O	O	3280
moderate	ADJ	O	O	3280
to	PART	O	O	3280
severe	ADJ	O	O	3280
changes	VERB	O	O	3280
.	PUNCT	O	O	3280
These	PRON	O	O	3281
6	NUM	O	O	3281
patients	NOUN	O	O	3281
had	VERB	O	O	3281
both	PRON	O	O	3281
renal	ADJ	O	O	3281
and	CCONJ	O	O	3281
liver dysfunction	NOUN	O	Disease	3281
(	PUNCT	O	O	3281
P	NOUN	O	Chemical	3281
less	ADV	O	O	3281
than	ADP	O	O	3281
0.05	NUM	O	O	3281
)	PUNCT	O	O	3281
,	PUNCT	O	O	3281
as	ADP	O	O	3281
well	ADV	O	O	3281
as	ADP	O	O	3281
cimetidine	NOUN	O	Chemical	3281
trough	NOUN	O	O	3281
-	PUNCT	O	O	3281
concentrations	NOUN	O	O	3281
of	ADP	O	O	3281
more	ADJ	O	O	3281
than	ADP	O	O	3281
1.25	NUM	O	O	3281
microgram	PROPN	O	O	3281
/	PUNCT	O	O	3281
ml	ADP	O	O	3281
(	PUNCT	O	O	3281
P	NOUN	O	Chemical	3281
less	ADV	O	O	3281
than	ADP	O	O	3281
0.05	NUM	O	O	3281
)	PUNCT	O	O	3281
.	PUNCT	O	O	3281
The	PRON	O	O	3282
cerebrospinal	ADJ	O	O	3282
fluid	NOUN	O	O	3282
:	PUNCT	O	O	3282
serum	NOUN	O	O	3282
ratio	NOUN	O	O	3282
of	ADP	O	O	3282
cimetidine	NOUN	O	Chemical	3282
concentrations	NOUN	O	O	3282
was	AUX	O	O	3282
0.24:1	NUM	O	O	3282
and	CCONJ	O	O	3282
indicates	VERB	O	O	3282
that	SCONJ	O	O	3282
cimetidine	NOUN	O	Chemical	3282
passes	VERB	O	O	3282
the	PRON	O	O	3282
blood	NOUN	O	O	3282
-	PUNCT	O	O	3282
brain	NOUN	O	O	3282
barrier	NOUN	O	O	3282
;	PUNCT	O	O	3282
it	PRON	O	O	3282
also	ADV	O	O	3282
raises	VERB	O	O	3282
the	PRON	O	O	3282
possibility	NOUN	O	O	3282
that	SCONJ	O	O	3282
M.S.	PROPN	O	O	3282
changes	VERB	O	O	3282
are	AUX	O	O	3282
due	ADJ	O	O	3282
to	PART	O	O	3282
blockade	VERB	O	O	3282
of	ADP	O	O	3282
histamine	NOUN	O	Chemical	3282
H2-receptors	NOUN	O	O	3282
in	ADP	O	O	3282
the	PRON	O	O	3282
central	ADJ	O	O	3282
nervous	ADJ	O	O	3282
system	NOUN	O	O	3282
.	PUNCT	O	O	3282
Patients	NOUN	O	O	3283
likely	ADV	O	O	3283
to	PART	O	O	3283
have	VERB	O	O	3283
both	PRON	O	O	3283
raised	VERB	O	O	3283
trough	NOUN	O	O	3283
-	PUNCT	O	O	3283
concentrations	NOUN	O	O	3283
and	CCONJ	O	O	3283
mental	ADJ	O	O	3283
confusion	NOUN	O	Disease	3283
are	AUX	O	O	3283
those	PRON	O	O	3283
with	ADP	O	O	3283
both	PRON	O	O	3283
severe	ADJ	O	O	3283
renal	ADJ	O	O	3283
and	CCONJ	O	O	3283
hepatic	ADJ	O	O	3283
dysfunction	NOUN	O	O	3283
.	PUNCT	O	O	3283
They	PRON	O	O	3284
should	AUX	O	O	3284
be	AUX	O	O	3284
closely	ADV	O	O	3284
observed	VERB	O	O	3284
and	CCONJ	O	O	3284
should	AUX	O	O	3284
be	AUX	O	O	3284
given	VERB	O	O	3284
reduced	VERB	O	O	3284
doses	NOUN	O	O	3284
of	ADP	O	O	3284
cimetidine	NOUN	O	Chemical	3284
.	PUNCT	O	O	3284
Different	ADJ	O	O	3287
lobular	ADJ	O	O	3287
distributions	NOUN	O	O	3287
of	ADP	O	O	3287
altered	VERB	O	O	3287
hepatocyte	NOUN	O	O	3287
tight	ADJ	O	O	3287
junctions	NOUN	O	O	3287
in	ADP	O	O	3287
rat	NOUN	O	O	3287
models	NOUN	O	O	3287
of	ADP	O	O	3287
intrahepatic	ADJ	O	O	3287
and	CCONJ	O	O	3287
extrahepatic	ADJ	O	O	3287
cholestasis	NOUN	O	Disease	3287
.	PUNCT	O	O	3287
Although	SCONJ	O	O	3288
hepatocyte	NOUN	O	O	3288
TJs	NOUN	O	O	3288
are	AUX	O	O	3288
impaired	VERB	O	O	3288
in	ADP	O	O	3288
cholestasis	NOUN	O	Disease	3288
,	PUNCT	O	O	3288
attempts	VERB	O	O	3288
to	PART	O	O	3288
localize	VERB	O	O	3288
the	PRON	O	O	3288
precise	ADJ	O	O	3288
site	NOUN	O	O	3288
of	ADP	O	O	3288
hepatocyte	NOUN	O	O	3288
TJ	PROPN	O	O	3288
damage	NOUN	O	O	3288
by	ADP	O	O	3288
freeze	VERB	O	O	3288
-	PUNCT	O	O	3288
fracture	VERB	O	O	3288
electron	NOUN	O	O	3288
microscopy	NOUN	O	O	3288
have	VERB	O	O	3288
produced	VERB	O	O	3288
limited	VERB	O	O	3288
information	NOUN	O	O	3288
.	PUNCT	O	O	3288
We	PRON	O	O	3289
used	VERB	O	O	3289
rat	NOUN	O	O	3289
models	NOUN	O	O	3289
of	ADP	O	O	3289
intrahepatic	ADJ	O	O	3289
cholestasis	NOUN	O	Disease	3289
by	ADP	O	O	3289
ethinyl estradiol	NOUN	O	Chemical	3289
(	PUNCT	O	O	3289
EE	NOUN	O	Chemical	3289
)	PUNCT	O	O	3289
treatment	NOUN	O	O	3289
and	CCONJ	O	O	3289
extrahepatic	ADJ	O	O	3289
cholestasis	NOUN	O	Disease	3289
by	ADP	O	O	3289
bile	NOUN	O	O	3289
duct	NOUN	O	O	3289
ligation	NOUN	O	O	3289
(	PUNCT	O	O	3289
BDL	NOUN	O	O	3289
)	PUNCT	O	O	3289
to	PART	O	O	3289
precisely	ADV	O	O	3289
determine	VERB	O	O	3289
the	PRON	O	O	3289
site	NOUN	O	O	3289
of	ADP	O	O	3289
TJ	PROPN	O	O	3289
damage	NOUN	O	O	3289
.	PUNCT	O	O	3289
After	ADP	O	O	3290
EE	NOUN	O	Chemical	3290
treatment	NOUN	O	O	3290
,	PUNCT	O	O	3290
changes	VERB	O	O	3290
in	ADP	O	O	3290
immunostaining	VERB	O	O	3290
for	ADP	O	O	3290
7H6	NUM	O	O	3290
and	CCONJ	O	O	3290
ZO-1	NUM	O	O	3290
were	AUX	O	O	3290
similar	ADJ	O	O	3290
to	PART	O	O	3290
those	PRON	O	O	3290
seen	VERB	O	O	3290
in	ADP	O	O	3290
periportal	VERB	O	O	3290
hepatocytes	VERB	O	O	3290
after	ADP	O	O	3290
BDL	NOUN	O	O	3290
,	PUNCT	O	O	3290
but	CCONJ	O	O	3290
distributed	VERB	O	O	3290
more	ADJ	O	O	3290
diffusely	ADV	O	O	3290
throughout	ADP	O	O	3290
the	PRON	O	O	3290
lobule	PROPN	O	O	3290
.	PUNCT	O	O	3290
This	PRON	O	O	3291
study	VERB	O	O	3291
is	AUX	O	O	3291
the	PRON	O	O	3291
first	ADV	O	O	3291
to	PART	O	O	3291
demonstrate	VERB	O	O	3291
that	SCONJ	O	O	3291
impairment	NOUN	O	O	3291
of	ADP	O	O	3291
hepatocyte	NOUN	O	O	3291
TJs	NOUN	O	O	3291
occurs	VERB	O	O	3291
heterogenously	PROPN	O	O	3291
in	ADP	O	O	3291
the	PRON	O	O	3291
liver	NOUN	O	O	3291
lobule	PROPN	O	O	3291
after	ADP	O	O	3291
BDL	NOUN	O	O	3291
and	CCONJ	O	O	3291
suggests	VERB	O	O	3291
that	SCONJ	O	O	3291
BDL	NOUN	O	O	3291
and	CCONJ	O	O	3291
EE	NOUN	O	Chemical	3291
treatments	NOUN	O	O	3291
produce	VERB	O	O	3291
different	ADJ	O	O	3291
lobular	ADJ	O	O	3291
distributions	NOUN	O	O	3291
of	ADP	O	O	3291
increased	VERB	O	O	3291
paracellular	ADJ	O	O	3291
permeability	NOUN	O	O	3291
.	PUNCT	O	O	3291
Long	ADV	O	O	3294
term	NOUN	O	O	3294
audiological	ADJ	O	O	3294
evaluation	NOUN	O	O	3294
of	ADP	O	O	3294
beta	NOUN	O	O	3294
-	PUNCT	O	O	3294
thalassemic	ADJ	O	O	3294
patients	NOUN	O	O	3294
.	PUNCT	O	O	3294
The	PRON	O	O	3295
objective	VERB	O	O	3295
of	ADP	O	O	3295
this	PRON	O	O	3295
study	VERB	O	O	3295
was	AUX	O	O	3295
to	PART	O	O	3295
identify	VERB	O	O	3295
the	PRON	O	O	3295
incidence	NOUN	O	O	3295
and	CCONJ	O	O	3295
to	PART	O	O	3295
monitor	VERB	O	O	3295
the	PRON	O	O	3295
progression	NOUN	O	O	3295
of	ADP	O	O	3295
hearing loss	NOUN	O	Disease	3295
in	ADP	O	O	3295
children	NOUN	O	O	3295
and	CCONJ	O	O	3295
young	ADJ	O	O	3295
adults	NOUN	O	O	3295
with	ADP	O	O	3295
beta	NOUN	O	O	3295
-	PUNCT	O	O	3295
thalassemia	NOUN	O	O	3295
major	ADJ	O	O	3295
.	PUNCT	O	O	3295
Subjects	NOUN	O	O	3296
were	AUX	O	O	3296
receiving	VERB	O	O	3296
desferrioxamine	NOUN	O	O	3296
(	PUNCT	O	O	3296
DFO	PROPN	O	Chemical	3296
)	PUNCT	O	O	3296
chelation	NOUN	O	O	3296
treatment	NOUN	O	O	3296
with	ADP	O	O	3296
a	PRON	O	O	3296
mean	VERB	O	O	3296
daily	ADV	O	O	3296
dose	NOUN	O	O	3296
of	ADP	O	O	3296
50	NUM	O	O	3296
-	PUNCT	O	O	3296
60	NUM	O	O	3296
mg	VERB	O	O	3296
/	PUNCT	O	O	3296
kg	VERB	O	O	3296
,	PUNCT	O	O	3296
5	NUM	O	O	3296
-	PUNCT	O	O	3296
6	NUM	O	O	3296
days	NOUN	O	O	3296
a	PRON	O	O	3296
week	NOUN	O	O	3296
during	ADP	O	O	3296
the	PRON	O	O	3296
first	ADV	O	O	3296
six	NUM	O	O	3296
years	NOUN	O	O	3296
of	ADP	O	O	3296
the	PRON	O	O	3296
study	VERB	O	O	3296
,	PUNCT	O	O	3296
which	PRON	O	O	3296
was	AUX	O	O	3296
then	ADV	O	O	3296
reduced	VERB	O	O	3296
to	PART	O	O	3296
40	NUM	O	O	3296
-	PUNCT	O	O	3296
50	NUM	O	O	3296
mg	VERB	O	O	3296
/	PUNCT	O	O	3296
kg	VERB	O	O	3296
for	ADP	O	O	3296
the	PRON	O	O	3296
following	VERB	O	O	3296
eight	NUM	O	O	3296
years	NOUN	O	O	3296
.	PUNCT	O	O	3296
Overall	ADV	O	O	3297
,	PUNCT	O	O	3297
21	NUM	O	O	3297
out	ADP	O	O	3297
of	ADP	O	O	3297
104	NUM	O	O	3297
patients	NOUN	O	O	3297
(	PUNCT	O	O	3297
20.2%	NOUN	O	O	3297
)	PUNCT	O	O	3297
presented	VERB	O	O	3297
with	ADP	O	O	3297
high	ADJ	O	O	3297
frequency	NOUN	O	O	3297
sensorineural	ADJ	O	O	3297
hearing loss	NOUN	O	Disease	3297
(	PUNCT	O	O	3297
SNHL	NOUN	O	O	3297
)	PUNCT	O	O	3297
,	PUNCT	O	O	3297
either	ADV	O	O	3297
unilateral	ADJ	O	O	3297
or	CCONJ	O	O	3297
bilateral	ADJ	O	O	3297
.	PUNCT	O	O	3297
No	PRON	O	O	3298
ototoxic	ADJ	O	O	3298
factor	NOUN	O	O	3298
,	PUNCT	O	O	3298
other	ADJ	O	O	3298
than	ADP	O	O	3298
DFO	PROPN	O	Chemical	3298
,	PUNCT	O	O	3298
was	AUX	O	O	3298
present	NOUN	O	O	3298
in	ADP	O	O	3298
any	PRON	O	O	3298
of	ADP	O	O	3298
the	PRON	O	O	3298
patients	NOUN	O	O	3298
.	PUNCT	O	O	3298
Patients	NOUN	O	O	3299
with	ADP	O	O	3299
SNHL	NOUN	O	O	3299
presented	VERB	O	O	3299
with	ADP	O	O	3299
relatively	ADV	O	O	3299
lower	ADJ	O	O	3299
serum	NOUN	O	O	3299
ferritin	NOUN	O	O	3299
levels	NOUN	O	O	3299
than	ADP	O	O	3299
those	PRON	O	O	3299
with	ADP	O	O	3299
normal	ADJ	O	O	3299
hearing	NOUN	O	O	3299
,	PUNCT	O	O	3299
however	ADV	O	O	3299
,	PUNCT	O	O	3299
no	PRON	O	O	3299
statistically	ADV	O	O	3299
significant	ADJ	O	O	3299
difference	NOUN	O	O	3299
was	AUX	O	O	3299
observed	VERB	O	O	3299
.	PUNCT	O	O	3299
Subjects	NOUN	O	O	3300
with	ADP	O	O	3300
SNHL	NOUN	O	O	3300
were	AUX	O	O	3300
submitted	VERB	O	O	3300
to	PART	O	O	3300
DFO	PROPN	O	Chemical	3300
reduction	NOUN	O	O	3300
or	CCONJ	O	O	3300
temporary	ADJ	O	O	3300
withdrawal	NOUN	O	O	3300
.	PUNCT	O	O	3300
CONCLUSION	PROPN	O	O	3301
:	PUNCT	O	O	3301
The	PRON	O	O	3301
findings	NOUN	O	O	3301
are	AUX	O	O	3301
indicative	ADJ	O	O	3301
of	ADP	O	O	3301
DFO	PROPN	O	Chemical	3301
's	AUX	O	O	3301
contributing	VERB	O	O	3301
role	NOUN	O	O	3301
in	ADP	O	O	3301
the	PRON	O	O	3301
development	NOUN	O	O	3301
of	ADP	O	O	3301
hearing impairment	NOUN	O	Disease	3301
.	PUNCT	O	O	3301
Regular	ADJ	O	O	3302
audiologic	ADJ	O	O	3302
evaluation	NOUN	O	O	3302
is	AUX	O	O	3302
imperative	ADJ	O	O	3302
in	ADP	O	O	3302
all	PRON	O	O	3302
thalassemic	ADJ	O	O	3302
patients	NOUN	O	O	3302
so	ADV	O	O	3302
that	SCONJ	O	O	3302
early	ADV	O	O	3302
changes	VERB	O	O	3302
may	AUX	O	O	3302
be	AUX	O	O	3302
recognized	VERB	O	O	3302
and	CCONJ	O	O	3302
treatment	NOUN	O	O	3302
may	AUX	O	O	3302
be	AUX	O	O	3302
judiciously	ADV	O	O	3302
adjusted	VERB	O	O	3302
in	ADP	O	O	3302
order	NOUN	O	O	3302
to	PART	O	O	3302
prevent	VERB	O	O	3302
or	CCONJ	O	O	3302
reverse	VERB	O	O	3302
hearing impairment	NOUN	O	Disease	3302
.	PUNCT	O	O	3302
Design	NOUN	O	O	3305
and	CCONJ	O	O	3305
analysis	NOUN	O	O	3305
of	ADP	O	O	3305
the	PRON	O	O	3305
HYPREN	PROPN	O	O	3305
-	PUNCT	O	O	3305
trial	NOUN	O	O	3305
:	PUNCT	O	O	3305
safety	NOUN	O	O	3305
of	ADP	O	O	3305
enalapril	PROPN	O	Chemical	3305
and	CCONJ	O	O	3305
prazosin	NOUN	O	Chemical	3305
in	ADP	O	O	3305
the	PRON	O	O	3305
initial	ADJ	O	O	3305
treatment	NOUN	O	O	3305
phase	NOUN	O	O	3305
of	ADP	O	O	3305
patients	NOUN	O	O	3305
with	ADP	O	O	3305
congestive	ADJ	O	O	3305
heart failure	NOUN	O	Disease	3305
.	PUNCT	O	O	3305
Since	SCONJ	O	O	3306
the	PRON	O	O	3306
introduction	NOUN	O	O	3306
of	ADP	O	O	3306
angiotensin	NOUN	O	Chemical	3306
converting	VERB	O	O	3306
enzyme	NOUN	O	O	3306
(	PUNCT	O	O	3306
ACE	PROPN	O	O	3306
)	PUNCT	O	O	3306
inhibitors	NOUN	O	O	3306
into	ADP	O	O	3306
the	PRON	O	O	3306
adjunctive	ADJ	O	O	3306
treatment	NOUN	O	O	3306
of	ADP	O	O	3306
patients	NOUN	O	O	3306
with	ADP	O	O	3306
congestive	ADJ	O	O	3306
heart failure	NOUN	O	Disease	3306
,	PUNCT	O	O	3306
cases	NOUN	O	O	3306
of	ADP	O	O	3306
severe	ADJ	O	O	3306
hypotension	NOUN	O	Disease	3306
,	PUNCT	O	O	3306
especially	ADV	O	O	3306
on	ADP	O	O	3306
the	PRON	O	O	3306
first	ADV	O	O	3306
day	NOUN	O	O	3306
of	ADP	O	O	3306
treatment	NOUN	O	O	3306
,	PUNCT	O	O	3306
have	VERB	O	O	3306
occasionally	ADV	O	O	3306
been	AUX	O	O	3306
reported	VERB	O	O	3306
.	PUNCT	O	O	3306
To	PART	O	O	3307
assess	VERB	O	O	3307
the	PRON	O	O	3307
safety	NOUN	O	O	3307
of	ADP	O	O	3307
the	PRON	O	O	3307
ACE	PROPN	O	O	3307
inhibitor	NOUN	O	O	3307
enalapril	PROPN	O	Chemical	3307
a	PRON	O	O	3307
multicenter	ADJ	O	O	3307
,	PUNCT	O	O	3307
randomized	VERB	O	O	3307
,	PUNCT	O	O	3307
prazosin	NOUN	O	Chemical	3307
-	PUNCT	O	O	3307
controlled	VERB	O	O	3307
trial	NOUN	O	O	3307
was	AUX	O	O	3307
designed	VERB	O	O	3307
that	SCONJ	O	O	3307
compared	VERB	O	O	3307
the	PRON	O	O	3307
incidence	NOUN	O	O	3307
and	CCONJ	O	O	3307
severity	NOUN	O	O	3307
of	ADP	O	O	3307
symptomatic	ADJ	O	O	3307
hypotension	NOUN	O	Disease	3307
on	ADP	O	O	3307
the	PRON	O	O	3307
first	ADV	O	O	3307
day	NOUN	O	O	3307
of	ADP	O	O	3307
treatment	NOUN	O	O	3307
.	PUNCT	O	O	3307
Trial	NOUN	O	O	3308
medication	NOUN	O	O	3308
was	AUX	O	O	3308
2.5	NUM	O	O	3308
mg	VERB	O	O	3308
enalapril	PROPN	O	Chemical	3308
or	CCONJ	O	O	3308
0.5	NUM	O	O	3308
prazosin	NOUN	O	Chemical	3308
.	PUNCT	O	O	3308
Patients	NOUN	O	O	3309
who	PRON	O	O	3309
received	VERB	O	O	3309
enalapril	PROPN	O	Chemical	3309
experienced	ADJ	O	O	3309
clinically	ADV	O	O	3309
and	CCONJ	O	O	3309
statistically	ADV	O	O	3309
significantly	ADV	O	O	3309
less	ADV	O	O	3309
symptomatic	ADJ	O	O	3309
hypotension	NOUN	O	Disease	3309
(	PUNCT	O	O	3309
5.2%	NOUN	O	O	3309
)	PUNCT	O	O	3309
than	ADP	O	O	3309
the	PRON	O	O	3309
patients	NOUN	O	O	3309
who	PRON	O	O	3309
received	VERB	O	O	3309
prazosin	NOUN	O	Chemical	3309
(	PUNCT	O	O	3309
12.9%	NOUN	O	O	3309
)	PUNCT	O	O	3309
.	PUNCT	O	O	3309
It	PRON	O	O	3310
was	AUX	O	O	3310
concluded	VERB	O	O	3310
that	SCONJ	O	O	3310
treatment	NOUN	O	O	3310
with	ADP	O	O	3310
enalapril	PROPN	O	Chemical	3310
was	AUX	O	O	3310
well	ADV	O	O	3310
tolerated	VERB	O	O	3310
and	CCONJ	O	O	3310
it	PRON	O	O	3310
is	AUX	O	O	3310
,	PUNCT	O	O	3310
therefore	ADV	O	O	3310
,	PUNCT	O	O	3310
unreasonable	ADJ	O	O	3310
to	PART	O	O	3310
restrict	VERB	O	O	3310
the	PRON	O	O	3310
initiation	NOUN	O	O	3310
of	ADP	O	O	3310
treatment	NOUN	O	O	3310
with	ADP	O	O	3310
enalapril	PROPN	O	Chemical	3310
to	PART	O	O	3310
inpatients	NOUN	O	O	3310
.	PUNCT	O	O	3310
Antagonism	NOUN	O	O	3313
between	ADP	O	O	3313
interleukin	ADJ	O	O	3313
3	X	O	O	3313
and	CCONJ	O	O	3313
erythropoietin	NOUN	O	O	3313
in	ADP	O	O	3313
mice	NOUN	O	O	3313
with	ADP	O	O	3313
azidothymidine	NOUN	O	Chemical	3313
-	PUNCT	O	O	3313
induced	VERB	O	O	3313
anemia	NOUN	O	Disease	3313
and	CCONJ	O	O	3313
in	ADP	O	O	3313
bone	NOUN	O	O	3313
marrow	PROPN	O	O	3313
endothelial	NOUN	O	O	3313
cells	NOUN	O	O	3313
.	PUNCT	O	O	3313
Azidothymidine	NOUN	O	Chemical	3314
(	PUNCT	O	O	3314
AZT)-induced	NOUN	O	O	3314
anemia	NOUN	O	Disease	3314
in	ADP	O	O	3314
mice	NOUN	O	O	3314
can	AUX	O	O	3314
be	AUX	O	O	3314
reversed	VERB	O	O	3314
by	ADP	O	O	3314
the	PRON	O	O	3314
administration	NOUN	O	O	3314
of	ADP	O	O	3314
IGF	PROPN	O	O	3314
-	PUNCT	O	O	3314
IL-3	NUM	O	O	3314
(	PUNCT	O	O	3314
fusion	NOUN	O	O	3314
protein	NOUN	O	O	3314
of	ADP	O	O	3314
insulin	NOUN	O	O	3314
-	PUNCT	O	O	3314
like	INTJ	O	O	3314
growth	NOUN	O	O	3314
factor	NOUN	O	O	3314
II	NUM	O	O	3314
(	PUNCT	O	O	3314
IGF	PROPN	O	O	3314
II	NUM	O	O	3314
)	PUNCT	O	O	3314
and	CCONJ	O	O	3314
interleukin	ADJ	O	O	3314
3	X	O	O	3314
)	PUNCT	O	O	3314
.	PUNCT	O	O	3314
Although	SCONJ	O	O	3315
interleukin	ADJ	O	O	3315
3	X	O	O	3315
(	PUNCT	O	O	3315
IL-3	NUM	O	O	3315
)	PUNCT	O	O	3315
and	CCONJ	O	O	3315
erythropoietin	NOUN	O	O	3315
(	PUNCT	O	O	3315
EPO	PROPN	O	O	3315
)	PUNCT	O	O	3315
are	AUX	O	O	3315
known	VERB	O	O	3315
to	PART	O	O	3315
act	VERB	O	O	3315
synergistically	ADV	O	O	3315
on	ADP	O	O	3315
hematopoietic	PROPN	O	O	3315
cell	NOUN	O	O	3315
proliferation	NOUN	O	O	3315
in	ADP	O	O	3315
vitro	X	O	O	3315
,	PUNCT	O	O	3315
injection	NOUN	O	O	3315
of	ADP	O	O	3315
IGF	PROPN	O	O	3315
-	PUNCT	O	O	3315
IL-3	NUM	O	O	3315
and	CCONJ	O	O	3315
EPO	PROPN	O	O	3315
in	ADP	O	O	3315
AZT	PROPN	O	Chemical	3315
-	PUNCT	O	O	3315
treated	VERB	O	O	3315
mice	NOUN	O	O	3315
resulted	VERB	O	O	3315
in	ADP	O	O	3315
a	PRON	O	O	3315
reduction	NOUN	O	O	3315
of	ADP	O	O	3315
red	ADJ	O	O	3315
cells	NOUN	O	O	3315
and	CCONJ	O	O	3315
an	PRON	O	O	3315
increase	VERB	O	O	3315
of	ADP	O	O	3315
plasma	NOUN	O	O	3315
EPO	PROPN	O	O	3315
levels	NOUN	O	O	3315
as	ADP	O	O	3315
compared	VERB	O	O	3315
to	PART	O	O	3315
animals	NOUN	O	O	3315
treated	VERB	O	O	3315
with	ADP	O	O	3315
IGF	PROPN	O	O	3315
-	PUNCT	O	O	3315
IL-3	NUM	O	O	3315
or	CCONJ	O	O	3315
EPO	PROPN	O	O	3315
alone	ADV	O	O	3315
.	PUNCT	O	O	3315
There	ADV	O	O	3316
was	AUX	O	O	3316
a	PRON	O	O	3316
significant	ADJ	O	O	3316
reduction	NOUN	O	O	3316
of	ADP	O	O	3316
thymidine	NOUN	O	Chemical	3316
incorporation	NOUN	O	O	3316
into	ADP	O	O	3316
both	PRON	O	O	3316
erythroid	PROPN	O	O	3316
and	CCONJ	O	O	3316
endothelial	NOUN	O	O	3316
cells	NOUN	O	O	3316
in	ADP	O	O	3316
cultures	NOUN	O	O	3316
pre	VERB	O	O	3316
-	PUNCT	O	O	3316
treated	VERB	O	O	3316
with	ADP	O	O	3316
IGF	PROPN	O	O	3316
-	PUNCT	O	O	3316
IL-3	NUM	O	O	3316
and	CCONJ	O	O	3316
EPO	PROPN	O	O	3316
.	PUNCT	O	O	3316
Endothelial	NOUN	O	O	3317
cell	NOUN	O	O	3317
culture	NOUN	O	O	3317
supernatants	NOUN	O	O	3317
separated	VERB	O	O	3317
by	ADP	O	O	3317
ultrafiltration	NOUN	O	O	3317
and	CCONJ	O	O	3317
ultracentrifugation	NOUN	O	O	3317
from	ADP	O	O	3317
cells	NOUN	O	O	3317
treated	VERB	O	O	3317
with	ADP	O	O	3317
EPO	PROPN	O	O	3317
and	CCONJ	O	O	3317
IL-3	NUM	O	O	3317
significantly	ADV	O	O	3317
reduced	VERB	O	O	3317
thymidine	NOUN	O	Chemical	3317
incorporation	NOUN	O	O	3317
into	ADP	O	O	3317
erythroid	PROPN	O	O	3317
cells	NOUN	O	O	3317
as	ADP	O	O	3317
compared	VERB	O	O	3317
to	PART	O	O	3317
identical	ADJ	O	O	3317
fractions	NOUN	O	O	3317
obtained	VERB	O	O	3317
from	ADP	O	O	3317
the	PRON	O	O	3317
media	NOUN	O	O	3317
of	ADP	O	O	3317
cells	NOUN	O	O	3317
cultured	ADJ	O	O	3317
with	ADP	O	O	3317
EPO	PROPN	O	O	3317
alone	ADV	O	O	3317
.	PUNCT	O	O	3317
Interactive	ADJ	O	O	3320
effects	NOUN	O	O	3320
of	ADP	O	O	3320
variations	NOUN	O	O	3320
in	ADP	O	O	3320
[	X	O	O	3320
Na]o	PROPN	O	O	3320
and	CCONJ	O	O	3320
[	X	O	O	3320
Ca]o	PROPN	O	O	3320
on	ADP	O	O	3320
rat	NOUN	O	O	3320
atrial	ADJ	O	O	3320
spontaneous	ADJ	O	O	3320
frequency	NOUN	O	O	3320
.	PUNCT	O	O	3320
The	PRON	O	O	3321
effects	NOUN	O	O	3321
of	ADP	O	O	3321
varying	VERB	O	O	3321
the	PRON	O	O	3321
extracellular	ADJ	O	O	3321
concentrations	NOUN	O	O	3321
of	ADP	O	O	3321
Na	INTJ	O	Chemical	3321
and	CCONJ	O	O	3321
Ca	AUX	O	Chemical	3321
(	PUNCT	O	O	3321
[	X	O	O	3321
Na]o	PROPN	O	O	3321
and	CCONJ	O	O	3321
[	X	O	O	3321
Ca]o	PROPN	O	O	3321
)	PUNCT	O	O	3321
on	ADP	O	O	3321
both	PRON	O	O	3321
,	PUNCT	O	O	3321
the	PRON	O	O	3321
spontaneous	ADJ	O	O	3321
beating	VERB	O	O	3321
and	CCONJ	O	O	3321
the	PRON	O	O	3321
negative	ADJ	O	O	3321
chronotropic	NOUN	O	O	3321
action	NOUN	O	O	3321
of	ADP	O	O	3321
verapamil	PROPN	O	Chemical	3321
,	PUNCT	O	O	3321
were	AUX	O	O	3321
studied	VERB	O	O	3321
in	ADP	O	O	3321
the	PRON	O	O	3321
isolated	VERB	O	O	3321
rat	NOUN	O	O	3321
atria	ADV	O	O	3321
.	PUNCT	O	O	3321
in	ADP	O	O	3322
control	VERB	O	O	3322
Krebs	PROPN	O	O	3322
-	PUNCT	O	O	3322
Ringer	NOUN	O	O	3322
containing	VERB	O	O	3322
137	NUM	O	O	3322
mM	ADJ	O	O	3322
Na	INTJ	O	Chemical	3322
and	CCONJ	O	O	3322
1.35	NUM	O	O	3322
mM	ADJ	O	O	3322
Ca	AUX	O	Chemical	3322
(	PUNCT	O	O	3322
N	NUM	O	O	3322
)	PUNCT	O	O	3322
.	PUNCT	O	O	3322
3%	NOUN	O	O	3323
by	ADP	O	O	3323
lowering	VERB	O	O	3323
[	X	O	O	3323
Na]o	PROPN	O	O	3323
to	PART	O	O	3323
78	NUM	O	O	3323
mM	ADJ	O	O	3323
(	PUNCT	O	O	3323
LNa	NOUN	O	O	3323
)	PUNCT	O	O	3323
,	PUNCT	O	O	3323
23	NUM	O	O	3323
[	X	O	O	3324
Na]o	PROPN	O	O	3324
to	PART	O	O	3324
78	NUM	O	O	3324
mM	ADJ	O	O	3324
and	CCONJ	O	O	3324
[	X	O	O	3324
Ca]o	PROPN	O	O	3324
to	PART	O	O	3324
0.675	NUM	O	O	3324
mM	ADJ	O	O	3324
(	PUNCT	O	O	3324
LNa+LCa	NOUN	O	O	3324
)	PUNCT	O	O	3324
and	CCONJ	O	O	3324
31	NUM	O	O	3324
+	ADP	O	O	3324
/-	PUNCT	O	O	3324
5%	NOUN	O	O	3325
by	ADP	O	O	3325
lowering	VERB	O	O	3325
[	X	O	O	3325
Na]o	PROPN	O	O	3325
to	PART	O	O	3325
78	NUM	O	O	3325
mM	ADJ	O	O	3326
plus	CCONJ	O	O	3326
increasing	VERB	O	O	3326
[	X	O	O	3326
Ca]o	PROPN	O	O	3326
to	PART	O	O	3326
3.6	NUM	O	O	3326
mM	ADJ	O	O	3326
(	PUNCT	O	O	3326
LNa+HCa	INTJ	O	O	3326
)	PUNCT	O	O	3326
.	PUNCT	O	O	3326
At	ADP	O	O	3327
normal	ADJ	O	O	3327
[	X	O	O	3327
Na]o	PROPN	O	O	3327
,	PUNCT	O	O	3327
decrease	VERB	O	O	3327
(	PUNCT	O	O	3327
0.675	NUM	O	O	3327
mM	ADJ	O	O	3327
)	PUNCT	O	O	3327
or	CCONJ	O	O	3327
increase	VERB	O	O	3327
(	PUNCT	O	O	3327
3.6	NUM	O	O	3327
mM	ADJ	O	O	3327
)	PUNCT	O	O	3327
of	ADP	O	O	3327
[	X	O	O	3327
Ca]o	PROPN	O	O	3327
did	VERB	O	O	3327
not	PART	O	O	3327
modify	VERB	O	O	3327
BF	PROPN	O	O	3327
;	PUNCT	O	O	3327
a	PRON	O	O	3327
reduction	NOUN	O	O	3327
of	ADP	O	O	3327
ten	NUM	O	O	3327
times	NOUN	O	O	3327
(	PUNCT	O	O	3327
0.135	NUM	O	O	3327
mM	ADJ	O	O	3327
of	ADP	O	O	3327
normal	ADJ	O	O	3327
[	X	O	O	3327
Ca]o	PROPN	O	O	3327
was	AUX	O	O	3327
effective	ADJ	O	O	3327
to	PART	O	O	3327
reduce	VERB	O	O	3327
BF	PROPN	O	O	3327
by	ADP	O	O	3327
40	NUM	O	O	3327
+	ADP	O	O	3327
/-	PUNCT	O	O	3327
Dose	NOUN	O	O	3328
-	PUNCT	O	O	3328
dependent	ADJ	O	O	3328
bradycardia	NOUN	O	Disease	3328
induced	VERB	O	O	3328
by	ADP	O	O	3328
verapamil	PROPN	O	Chemical	3328
was	AUX	O	O	3328
potentiated	VERB	O	O	3328
by	ADP	O	O	3328
LNa	NOUN	O	O	3328
,	PUNCT	O	O	3328
LCa	NOUN	O	O	3328
,	PUNCT	O	O	3328
and	CCONJ	O	O	3328
HCa	NOUN	O	O	3328
.	PUNCT	O	O	3328
Independent	ADJ	O	O	3329
but	CCONJ	O	O	3329
not	PART	O	O	3329
additive	NOUN	O	O	3329
effects	NOUN	O	O	3329
of	ADP	O	O	3329
Na	INTJ	O	Chemical	3329
and	CCONJ	O	O	3329
Ca	AUX	O	Chemical	3329
are	AUX	O	O	3329
shown	VERB	O	O	3329
by	ADP	O	O	3329
decreases	VERB	O	O	3329
in	ADP	O	O	3329
the	PRON	O	O	3329
values	NOUN	O	O	3329
of	ADP	O	O	3329
[	X	O	O	3329
verapamil]o	PROPN	O	O	3329
needed	VERB	O	O	3329
to	PART	O	O	3329
reduce	VERB	O	O	3329
BF	PROPN	O	O	3329
by	ADP	O	O	3329
30%	NOUN	O	O	3329
(	PUNCT	O	O	3329
IC30	PROPN	O	O	3329
)	PUNCT	O	O	3329
with	ADP	O	O	3329
the	PRON	O	O	3329
following	VERB	O	O	3329
order	NOUN	O	O	3329
of	ADP	O	O	3329
inhibitory	ADJ	O	O	3329
potency	NOUN	O	O	3329
:	PUNCT	O	O	3329
LNa	NOUN	O	O	3329
The	PRON	O	O	3330
[	X	O	O	3330
verapamil]o	PROPN	O	O	3330
that	SCONJ	O	O	3330
arrested	VERB	O	O	3330
atrial	ADJ	O	O	3330
beating	VERB	O	O	3330
(	PUNCT	O	O	3330
AC	PROPN	O	O	3330
)	PUNCT	O	O	3330
was	AUX	O	O	3330
also	ADV	O	O	3330
potentiated	VERB	O	O	3330
with	ADP	O	O	3330
the	PRON	O	O	3330
order	NOUN	O	O	3330
LNa	NOUN	O	O	3330
=	PUNCT	O	O	3330
The	PRON	O	O	3331
results	VERB	O	O	3331
indicate	VERB	O	O	3331
that	SCONJ	O	O	3331
rat	NOUN	O	O	3331
atrial	ADJ	O	O	3331
spontaneous	ADJ	O	O	3331
beating	VERB	O	O	3331
is	AUX	O	O	3331
more	ADJ	O	O	3331
dependent	ADJ	O	O	3331
on	ADP	O	O	3331
[	X	O	O	3331
Na]o	PROPN	O	O	3331
than	ADP	O	O	3331
on	ADP	O	O	3331
[	X	O	O	3331
Ca]o	PROPN	O	O	3331
in	ADP	O	O	3331
a	PRON	O	O	3331
range	VERB	O	O	3331
of	ADP	O	O	3331
+	ADP	O	O	3331
/-	PUNCT	O	O	3331
Also	ADV	O	O	3332
the	PRON	O	O	3332
enhancement	NOUN	O	O	3332
of	ADP	O	O	3332
verapamil	PROPN	O	Chemical	3332
effects	NOUN	O	O	3332
on	ADP	O	O	3332
atrial	ADJ	O	O	3332
beating	VERB	O	O	3332
was	AUX	O	O	3332
more	ADJ	O	O	3332
pronounced	VERB	O	O	3332
at	ADP	O	O	3332
LNa	NOUN	O	O	3332
than	ADP	O	O	3332
at	ADP	O	O	3332
LCa.(ABSTRACT	PROPN	O	O	3332
TRUNCATED	ADJ	O	O	3332
AT	ADP	O	O	3332
250	NUM	O	O	3332
WORDS	NOUN	O	O	3332
)	PUNCT	O	O	3332
Sodium	NOUN	O	Chemical	3335
status	NOUN	O	O	3335
influences	NOUN	O	O	3335
chronic	ADJ	O	O	3335
amphotericin B	NOUN	O	Chemical	3335
nephrotoxicity	NOUN	O	Disease	3335
in	ADP	O	O	3335
rats	NOUN	O	O	3335
.	PUNCT	O	O	3335
The	PRON	O	O	3336
nephrotoxic	NOUN	O	Disease	3336
potential	ADJ	O	O	3336
of	ADP	O	O	3336
amphotericin B	NOUN	O	Chemical	3336
(	PUNCT	O	O	3336
5	NUM	O	O	3336
mg	VERB	O	O	3336
/	PUNCT	O	O	3336
kg	VERB	O	O	3336
per	ADP	O	O	3336
day	NOUN	O	O	3336
intraperitoneally	ADV	O	O	3336
for	ADP	O	O	3336
3	X	O	O	3336
weeks	NOUN	O	O	3336
)	PUNCT	O	O	3336
has	VERB	O	O	3336
been	AUX	O	O	3336
investigated	VERB	O	O	3336
in	ADP	O	O	3336
salt	NOUN	O	O	3336
-	PUNCT	O	O	3336
depleted	VERB	O	O	3336
,	PUNCT	O	O	3336
normal	ADJ	O	O	3336
-	PUNCT	O	O	3336
salt	NOUN	O	O	3336
,	PUNCT	O	O	3336
and	CCONJ	O	O	3336
salt	NOUN	O	O	3336
-	PUNCT	O	O	3336
loaded	VERB	O	O	3336
rats	NOUN	O	O	3336
.	PUNCT	O	O	3336
In	ADP	O	O	3337
salt	NOUN	O	O	3337
-	PUNCT	O	O	3337
depleted	VERB	O	O	3337
rats	NOUN	O	O	3337
,	PUNCT	O	O	3337
amphotericin B	NOUN	O	Chemical	3337
decreased	VERB	O	O	3337
creatinine	PROPN	O	Chemical	3337
clearance	NOUN	O	O	3337
linearly	ADV	O	O	3337
with	ADP	O	O	3337
time	NOUN	O	O	3337
,	PUNCT	O	O	3337
with	ADP	O	O	3337
an	PRON	O	O	3337
85%	NOUN	O	O	3337
reduction	NOUN	O	O	3337
by	ADP	O	O	3337
week	NOUN	O	O	3337
3	X	O	O	3337
.	PUNCT	O	O	3337
In	ADP	O	O	3338
contrast	NOUN	O	O	3338
,	PUNCT	O	O	3338
in	ADP	O	O	3338
normal	ADJ	O	O	3338
-	PUNCT	O	O	3338
salt	NOUN	O	O	3338
rats	NOUN	O	O	3338
creatinine	PROPN	O	Chemical	3338
clearance	NOUN	O	O	3338
was	AUX	O	O	3338
decreased	VERB	O	O	3338
but	CCONJ	O	O	3338
to	PART	O	O	3338
a	PRON	O	O	3338
lesser	ADJ	O	O	3338
extent	NOUN	O	O	3338
at	ADP	O	O	3338
week	NOUN	O	O	3338
2	X	O	O	3338
and	CCONJ	O	O	3338
3	X	O	O	3338
,	PUNCT	O	O	3338
and	CCONJ	O	O	3338
in	ADP	O	O	3338
salt	NOUN	O	O	3338
-	PUNCT	O	O	3338
loaded	VERB	O	O	3338
rats	NOUN	O	O	3338
creatinine	PROPN	O	Chemical	3338
clearance	NOUN	O	O	3338
did	VERB	O	O	3338
not	PART	O	O	3338
change	VERB	O	O	3338
for	ADP	O	O	3338
2	X	O	O	3338
weeks	NOUN	O	O	3338
and	CCONJ	O	O	3338
was	AUX	O	O	3338
decreased	VERB	O	O	3338
by	ADP	O	O	3338
43%	NOUN	O	O	3338
at	ADP	O	O	3338
week	NOUN	O	O	3338
3	X	O	O	3338
.	PUNCT	O	O	3338
All	PRON	O	O	3339
rats	NOUN	O	O	3339
in	ADP	O	O	3339
the	PRON	O	O	3339
sodium	NOUN	O	Chemical	3339
-	PUNCT	O	O	3339
depleted	VERB	O	O	3339
group	NOUN	O	O	3339
had	VERB	O	O	3339
histopathological	ADJ	O	O	3339
evidence	NOUN	O	O	3339
of	ADP	O	O	3339
patchy	ADJ	O	O	3339
tubular	ADJ	O	O	3339
cytoplasmic	ADJ	O	O	3339
degeneration	NOUN	O	O	3339
in	ADP	O	O	3339
tubules	NOUN	O	O	3339
that	SCONJ	O	O	3339
was	AUX	O	O	3339
not	PART	O	O	3339
observed	VERB	O	O	3339
in	ADP	O	O	3339
any	PRON	O	O	3339
normal	ADJ	O	O	3339
-	PUNCT	O	O	3339
salt	NOUN	O	O	3339
or	CCONJ	O	O	3339
salt	NOUN	O	O	3339
-	PUNCT	O	O	3339
loaded	VERB	O	O	3339
rat	NOUN	O	O	3339
.	PUNCT	O	O	3339
Concentrations	NOUN	O	O	3340
of	ADP	O	O	3340
amphotericin B	NOUN	O	Chemical	3340
in	ADP	O	O	3340
plasma	NOUN	O	O	3340
were	AUX	O	O	3340
not	PART	O	O	3340
significantly	ADV	O	O	3340
different	ADJ	O	O	3340
among	ADP	O	O	3340
the	PRON	O	O	3340
three	NUM	O	O	3340
groups	NOUN	O	O	3340
at	ADP	O	O	3340
any	PRON	O	O	3340
time	NOUN	O	O	3340
during	ADP	O	O	3340
the	PRON	O	O	3340
study	VERB	O	O	3340
.	PUNCT	O	O	3340
However	ADV	O	O	3341
,	PUNCT	O	O	3341
at	ADP	O	O	3341
the	PRON	O	O	3341
end	VERB	O	O	3341
of	ADP	O	O	3341
3	X	O	O	3341
weeks	NOUN	O	O	3341
,	PUNCT	O	O	3341
amphotericin B	NOUN	O	Chemical	3341
levels	NOUN	O	O	3341
in	ADP	O	O	3341
the	PRON	O	O	3341
kidneys	NOUN	O	O	3341
and	CCONJ	O	O	3341
liver	NOUN	O	O	3341
were	AUX	O	O	3341
significantly	ADV	O	O	3341
higher	ADJ	O	O	3341
in	ADP	O	O	3341
salt	NOUN	O	O	3341
-	PUNCT	O	O	3341
depleted	VERB	O	O	3341
and	CCONJ	O	O	3341
normal	ADJ	O	O	3341
-	PUNCT	O	O	3341
salt	NOUN	O	O	3341
rats	NOUN	O	O	3341
than	ADP	O	O	3341
those	PRON	O	O	3341
in	ADP	O	O	3341
salt	NOUN	O	O	3341
-	PUNCT	O	O	3341
loaded	VERB	O	O	3341
rats	NOUN	O	O	3341
,	PUNCT	O	O	3341
with	ADP	O	O	3341
plasma	NOUN	O	O	3341
/	PUNCT	O	O	3341
kidney	NOUN	O	O	3341
ratios	VERB	O	O	3341
of	ADP	O	O	3341
21	NUM	O	O	3341
,	PUNCT	O	O	3341
14	NUM	O	O	3341
,	PUNCT	O	O	3341
and	CCONJ	O	O	3341
8	NUM	O	O	3341
in	ADP	O	O	3341
salt	NOUN	O	O	3341
-	PUNCT	O	O	3341
depleted	VERB	O	O	3341
,	PUNCT	O	O	3341
normal	ADJ	O	O	3341
-	PUNCT	O	O	3341
salt	NOUN	O	O	3341
,	PUNCT	O	O	3341
and	CCONJ	O	O	3341
salt	NOUN	O	O	3341
-	PUNCT	O	O	3341
loaded	VERB	O	O	3341
rats	NOUN	O	O	3341
,	PUNCT	O	O	3341
respectively	ADV	O	O	3341
.	PUNCT	O	O	3341
In	ADP	O	O	3342
conclusion	NOUN	O	O	3342
,	PUNCT	O	O	3342
reductions	NOUN	O	O	3342
in	ADP	O	O	3342
creatinine	PROPN	O	Chemical	3342
clearance	NOUN	O	O	3342
and	CCONJ	O	O	3342
renal	ADJ	O	O	3342
amphotericin B	NOUN	O	Chemical	3342
accumulation	NOUN	O	O	3342
after	ADP	O	O	3342
chronic	ADJ	O	O	3342
amphotericin B	NOUN	O	Chemical	3342
administration	NOUN	O	O	3342
were	AUX	O	O	3342
enhanced	VERB	O	O	3342
by	ADP	O	O	3342
salt	NOUN	O	O	3342
depletion	NOUN	O	O	3342
and	CCONJ	O	O	3342
attenuated	VERB	O	O	3342
by	ADP	O	O	3342
sodium	NOUN	O	Chemical	3342
loading	NOUN	O	O	3342
in	ADP	O	O	3342
rats	NOUN	O	O	3342
.	PUNCT	O	O	3342
Reversible	ADJ	O	O	3345
inferior	ADJ	O	O	3345
colliculus	NOUN	O	O	3345
lesion	NOUN	O	O	3345
in	ADP	O	O	3345
metronidazole	VERB	O	O	3345
-	PUNCT	O	O	3345
induced	VERB	O	O	3345
encephalopathy	NOUN	O	Disease	3345
:	PUNCT	O	O	3345
magnetic	ADJ	O	O	3345
resonance	NOUN	O	O	3345
findings	NOUN	O	O	3345
on	ADP	O	O	3345
diffusion	NOUN	O	O	3345
-	PUNCT	O	O	3345
weighted	VERB	O	O	3345
and	CCONJ	O	O	3345
fluid	NOUN	O	O	3345
attenuated	VERB	O	O	3345
inversion	NOUN	O	O	3345
recovery	NOUN	O	O	3345
imaging	VERB	O	O	3345
.	PUNCT	O	O	3345
OBJECTIVE	VERB	O	O	3346
:	PUNCT	O	O	3346
This	PRON	O	O	3346
is	AUX	O	O	3346
to	PART	O	O	3346
present	NOUN	O	O	3346
reversible	ADJ	O	O	3346
inferior	ADJ	O	O	3346
colliculus	NOUN	O	O	3346
lesions	NOUN	O	O	3346
in	ADP	O	O	3346
metronidazole	VERB	O	O	3346
-	PUNCT	O	O	3346
induced	VERB	O	O	3346
encephalopathy	NOUN	O	Disease	3346
,	PUNCT	O	O	3346
to	PART	O	O	3346
focus	NOUN	O	O	3346
on	ADP	O	O	3346
the	PRON	O	O	3346
diffusion	NOUN	O	O	3346
-	PUNCT	O	O	3346
weighted	VERB	O	O	3346
imaging	VERB	O	O	3346
(	PUNCT	O	O	3346
DWI	PROPN	O	O	3346
)	PUNCT	O	O	3346
and	CCONJ	O	O	3346
fluid	NOUN	O	O	3346
attenuated	VERB	O	O	3346
inversion	NOUN	O	O	3346
recovery	NOUN	O	O	3346
(	PUNCT	O	O	3346
FLAIR	PROPN	O	O	3346
)	PUNCT	O	O	3346
imaging	VERB	O	O	3346
.	PUNCT	O	O	3346
From	ADP	O	O	3347
November	PROPN	O	O	3347
2005	NUM	O	O	3347
to	PART	O	O	3347
September	PROPN	O	O	3347
2007	NUM	O	O	3347
,	PUNCT	O	O	3347
8	NUM	O	O	3347
patients	NOUN	O	O	3347
(	PUNCT	O	O	3347
5	NUM	O	O	3347
men	NOUN	O	O	3347
and	CCONJ	O	O	3347
3	X	O	O	3347
women	NOUN	O	O	3347
)	PUNCT	O	O	3347
were	AUX	O	O	3347
diagnosed	VERB	O	O	3347
as	ADP	O	O	3347
having	VERB	O	O	3347
metronidazole	VERB	O	O	3347
-	PUNCT	O	O	3347
induced	VERB	O	O	3347
encephalopathy	NOUN	O	Disease	3347
(	PUNCT	O	O	3347
age	NOUN	O	O	3347
range	VERB	O	O	3347
;	PUNCT	O	O	3347
43	NUM	O	O	3347
-	PUNCT	O	O	3347
78	NUM	O	O	3347
years	NOUN	O	O	3347
)	PUNCT	O	O	3347
.	PUNCT	O	O	3347
They	PRON	O	O	3348
had	VERB	O	O	3348
been	AUX	O	O	3348
taking	VERB	O	O	3348
metronidazole	VERB	O	O	3348
(	PUNCT	O	O	3348
total	ADJ	O	O	3348
dosage	NOUN	O	O	3348
,	PUNCT	O	O	3348
45	NUM	O	O	3348
-	PUNCT	O	O	3348
120	NUM	O	O	3348
g	X	O	O	3348
;	PUNCT	O	O	3348
duration	NOUN	O	O	3348
,	PUNCT	O	O	3348
30	NUM	O	O	3348
days	NOUN	O	O	3348
to	PART	O	O	3348
2	X	O	O	3348
months	NOUN	O	O	3348
)	PUNCT	O	O	3348
to	PART	O	O	3348
treat	VERB	O	O	3348
the	PRON	O	O	3348
infection	NOUN	O	Disease	3348
in	ADP	O	O	3348
various	ADJ	O	O	3348
organs	NOUN	O	O	3348
.	PUNCT	O	O	3348
Follow	VERB	O	O	3349
-	PUNCT	O	O	3349
up	ADP	O	O	3349
MRIs	NOUN	O	O	3349
were	AUX	O	O	3349
performed	VERB	O	O	3349
on	ADP	O	O	3349
5	NUM	O	O	3349
patients	NOUN	O	O	3349
from	ADP	O	O	3349
third	ADV	O	O	3349
to	PART	O	O	3349
14th	ADJ	O	O	3349
days	NOUN	O	O	3349
after	ADP	O	O	3349
discontinuation	NOUN	O	O	3349
of	ADP	O	O	3349
metronidazole	VERB	O	O	3349
administration	NOUN	O	O	3349
.	PUNCT	O	O	3349
All	PRON	O	O	3350
the	PRON	O	O	3350
lesions	NOUN	O	O	3350
in	ADP	O	O	3350
dentate	ADJ	O	O	3350
,	PUNCT	O	O	3350
inferior	ADJ	O	O	3350
colliculus	NOUN	O	O	3350
,	PUNCT	O	O	3350
pons	NOUN	O	O	3350
,	PUNCT	O	O	3350
and	CCONJ	O	O	3350
medullas	NOUN	O	O	3350
had	VERB	O	O	3350
been	AUX	O	O	3350
resolved	VERB	O	O	3350
completely	ADV	O	O	3350
on	ADP	O	O	3350
follow	VERB	O	O	3350
-	PUNCT	O	O	3350
up	ADP	O	O	3350
MRIs	NOUN	O	O	3350
in	ADP	O	O	3350
5	NUM	O	O	3350
patients	NOUN	O	O	3350
,	PUNCT	O	O	3350
but	CCONJ	O	O	3350
in	ADP	O	O	3350
1	X	O	O	3350
patient	NOUN	O	O	3350
of	ADP	O	O	3350
them	PRON	O	O	3350
,	PUNCT	O	O	3350
corpus	PROPN	O	O	3350
callosal	NOUN	O	O	3350
lesion	NOUN	O	O	3350
persisted	VERB	O	O	3350
.	PUNCT	O	O	3350
CONCLUSIONS	NOUN	O	O	3351
:	PUNCT	O	O	3351
Reversible	ADJ	O	O	3351
inferior	ADJ	O	O	3351
colliculus	NOUN	O	O	3351
lesions	NOUN	O	O	3351
could	AUX	O	O	3351
be	AUX	O	O	3351
considered	VERB	O	O	3351
as	ADP	O	O	3351
the	PRON	O	O	3351
characteristic	ADJ	O	O	3351
for	ADP	O	O	3351
metronidazole	VERB	O	O	3351
-	PUNCT	O	O	3351
induced	VERB	O	O	3351
encephalopathy	NOUN	O	Disease	3351
,	PUNCT	O	O	3351
next	ADV	O	O	3351
to	PART	O	O	3351
the	PRON	O	O	3351
dentate	ADJ	O	O	3351
nucleus	PROPN	O	O	3351
involvement	NOUN	O	O	3351
.	PUNCT	O	O	3351
infusions	NOUN	O	O	3354
of	ADP	O	O	3354
morphine	NOUN	O	Chemical	3354
and	CCONJ	O	O	3354
regional	ADJ	O	O	3354
analgesia	NOUN	O	Disease	3354
by	ADP	O	O	3354
extradural	ADJ	O	O	3354
block	NOUN	O	O	3354
.	PUNCT	O	O	3354
The	PRON	O	O	3355
incidence	NOUN	O	O	3355
of	ADP	O	O	3355
postoperative	ADJ	O	O	3355
respiratory	NOUN	O	O	3355
apnoea	NOUN	O	Disease	3355
was	AUX	O	O	3355
compared	VERB	O	O	3355
between	ADP	O	O	3355
five	NUM	O	O	3355
patients	NOUN	O	O	3355
receiving	VERB	O	O	3355
a	PRON	O	O	3355
continuous	ADJ	O	O	3355
i.v	NOUN	O	O	3355
.	PUNCT	O	O	3355
infusion	NOUN	O	O	3356
of	ADP	O	O	3356
morphine	NOUN	O	Chemical	3356
(	PUNCT	O	O	3356
mean	VERB	O	O	3356
73.6	NUM	O	O	3356
mg	VERB	O	O	3356
)	PUNCT	O	O	3356
and	CCONJ	O	O	3356
five	NUM	O	O	3356
patients	NOUN	O	O	3356
receiving	VERB	O	O	3356
a	PRON	O	O	3356
continuous	ADJ	O	O	3356
extradural	ADJ	O	O	3356
infusion	NOUN	O	O	3356
of	ADP	O	O	3356
0.25%	NOUN	O	O	3356
bupivacaine	NOUN	O	Chemical	3356
(	PUNCT	O	O	3356
mean	VERB	O	O	3356
192	NUM	O	O	3356
mg	VERB	O	O	3356
)	PUNCT	O	O	3356
in	ADP	O	O	3356
the	PRON	O	O	3356
24-h	NOUN	O	O	3356
period	NOUN	O	O	3356
following	VERB	O	O	3356
upper	ADJ	O	O	3356
abdominal	ADJ	O	O	3356
surgery	NOUN	O	O	3356
.	PUNCT	O	O	3356
Monitoring	VERB	O	O	3357
consisted	VERB	O	O	3357
of	ADP	O	O	3357
airflow	NOUN	O	O	3357
detection	NOUN	O	O	3357
by	ADP	O	O	3357
a	PRON	O	O	3357
carbon	NOUN	O	O	3357
dioxide	NOUN	O	O	3357
analyser	NOUN	O	O	3357
,	PUNCT	O	O	3357
chest	NOUN	O	O	3357
wall	PROPN	O	O	3357
movement	NOUN	O	O	3357
detected	VERB	O	O	3357
by	ADP	O	O	3357
pneumatic	ADJ	O	O	3357
capsules	NOUN	O	O	3357
,	PUNCT	O	O	3357
and	CCONJ	O	O	3357
continuous	ADJ	O	O	3357
electrocardiograph	NOUN	O	O	3357
recorded	VERB	O	O	3357
with	ADP	O	O	3357
a	PRON	O	O	3357
Holter	PROPN	O	O	3357
ambulatory	ADJ	O	O	3357
monitor	VERB	O	O	3357
.	PUNCT	O	O	3357
Both	PRON	O	O	3358
obstructive	ADJ	O	O	3358
(	PUNCT	O	O	3358
P	NOUN	O	Chemical	3358
less	ADV	O	O	3358
than	ADP	O	O	3358
0.05	NUM	O	O	3358
)	PUNCT	O	O	3358
and	CCONJ	O	O	3358
central	ADJ	O	O	3358
apnoea	NOUN	O	Disease	3358
(	PUNCT	O	O	3358
P	NOUN	O	Chemical	3358
less	ADV	O	O	3358
than	ADP	O	O	3358
0.05	NUM	O	O	3358
)	PUNCT	O	O	3358
occurred	VERB	O	O	3358
more	ADJ	O	O	3358
frequently	ADV	O	O	3358
in	ADP	O	O	3358
patients	NOUN	O	O	3358
who	PRON	O	O	3358
had	VERB	O	O	3358
a	PRON	O	O	3358
morphine	NOUN	O	Chemical	3358
infusion	NOUN	O	O	3358
.	PUNCT	O	O	3358
There	ADV	O	O	3359
was	AUX	O	O	3359
also	ADV	O	O	3359
a	PRON	O	O	3359
higher	ADJ	O	O	3359
incidence	NOUN	O	O	3359
of	ADP	O	O	3359
tachyarrhythmias	NOUN	O	Disease	3359
(	PUNCT	O	O	3359
P	NOUN	O	Chemical	3359
less	ADV	O	O	3359
than	ADP	O	O	3359
0.05	NUM	O	O	3359
)	PUNCT	O	O	3359
and	CCONJ	O	O	3359
ventricular ectopic beats	NOUN	O	Disease	3359
(	PUNCT	O	O	3359
P	NOUN	O	Chemical	3359
less	ADV	O	O	3359
than	ADP	O	O	3359
0.05	NUM	O	O	3359
)	PUNCT	O	O	3359
in	ADP	O	O	3359
the	PRON	O	O	3359
morphine	NOUN	O	Chemical	3359
infusion	NOUN	O	O	3359
group	NOUN	O	O	3359
.	PUNCT	O	O	3359
Magnetic	ADJ	O	O	3362
resonance	NOUN	O	O	3362
volumetry	NOUN	O	O	3362
of	ADP	O	O	3362
the	PRON	O	O	3362
cerebellum	NOUN	O	O	3362
in	ADP	O	O	3362
epileptic	ADJ	O	Disease	3362
patients	NOUN	O	O	3362
after	ADP	O	O	3362
phenytoin	NOUN	O	Chemical	3362
overdosages	VERB	O	O	3362
.	PUNCT	O	O	3362
The	PRON	O	O	3363
aim	VERB	O	O	3363
of	ADP	O	O	3363
this	PRON	O	O	3363
study	VERB	O	O	3363
was	AUX	O	O	3363
to	PART	O	O	3363
evaluate	VERB	O	O	3363
the	PRON	O	O	3363
relationship	NOUN	O	O	3363
between	ADP	O	O	3363
phenytoin	NOUN	O	Chemical	3363
medication	NOUN	O	O	3363
and	CCONJ	O	O	3363
cerebellar	ADJ	O	O	3363
atrophy	NOUN	O	Disease	3363
in	ADP	O	O	3363
patients	NOUN	O	O	3363
who	PRON	O	O	3363
had	VERB	O	O	3363
experienced	ADJ	O	O	3363
clinical	ADJ	O	O	3363
intoxication	NOUN	O	O	3363
.	PUNCT	O	O	3363
Using	VERB	O	O	3364
linear	ADJ	O	O	3364
regression	NOUN	O	O	3364
we	PRON	O	O	3364
found	VERB	O	O	3364
that	SCONJ	O	O	3364
no	PRON	O	O	3364
correlation	NOUN	O	O	3364
exists	VERB	O	O	3364
between	ADP	O	O	3364
seizure	NOUN	O	Disease	3364
duration	NOUN	O	O	3364
,	PUNCT	O	O	3364
elevation	NOUN	O	O	3364
of	ADP	O	O	3364
phenytoin	NOUN	O	Chemical	3364
serum	NOUN	O	O	3364
levels	NOUN	O	O	3364
and	CCONJ	O	O	3364
cerebellar	ADJ	O	O	3364
volume	PROPN	O	O	3364
.	PUNCT	O	O	3364
However	ADV	O	O	3365
,	PUNCT	O	O	3365
multiple	ADJ	O	O	3365
regression	NOUN	O	O	3365
for	ADP	O	O	3365
the	PRON	O	O	3365
daily	ADV	O	O	3365
dosage	NOUN	O	O	3365
,	PUNCT	O	O	3365
duration	NOUN	O	O	3365
of	ADP	O	O	3365
phenytoin	NOUN	O	Chemical	3365
treatment	NOUN	O	O	3365
and	CCONJ	O	O	3365
cerebellar	ADJ	O	O	3365
volume	PROPN	O	O	3365
revealed	VERB	O	O	3365
a	PRON	O	O	3365
correlation	NOUN	O	O	3365
of	ADP	O	O	3365
these	PRON	O	O	3365
parameters	NOUN	O	O	3365
.	PUNCT	O	O	3365
We	PRON	O	O	3366
conclude	VERB	O	O	3366
that	SCONJ	O	O	3366
phenytoin	NOUN	O	Chemical	3366
overdosage	NOUN	O	O	3366
does	VERB	O	O	3366
not	PART	O	O	3366
necessarily	ADV	O	O	3366
result	VERB	O	O	3366
in	ADP	O	O	3366
cerebellar	ADJ	O	O	3366
atrophy	NOUN	O	Disease	3366
and	CCONJ	O	O	3366
it	PRON	O	O	3366
is	AUX	O	O	3366
unlikely	ADJ	O	O	3366
that	SCONJ	O	O	3366
phenytoin	NOUN	O	Chemical	3366
medication	NOUN	O	O	3366
was	AUX	O	O	3366
the	PRON	O	O	3366
only	ADV	O	O	3366
cause	VERB	O	O	3366
of	ADP	O	O	3366
cerebellar	ADJ	O	O	3366
atrophy	NOUN	O	Disease	3366
in	ADP	O	O	3366
the	PRON	O	O	3366
remaining	VERB	O	O	3366
patients	NOUN	O	O	3366
.	PUNCT	O	O	3366
Quantitative	ADJ	O	O	3367
morphometric	PROPN	O	O	3367
studies	NOUN	O	O	3367
of	ADP	O	O	3367
the	PRON	O	O	3367
cerebellum	NOUN	O	O	3367
provide	VERB	O	O	3367
valuable	ADJ	O	O	3367
insights	NOUN	O	O	3367
into	ADP	O	O	3367
the	PRON	O	O	3367
pathogenesis	NOUN	O	O	3367
of	ADP	O	O	3367
cerebellar	ADJ	O	O	3367
disorders	NOUN	O	O	3367
.	PUNCT	O	O	3367
Evaluation	NOUN	O	O	3370
of	ADP	O	O	3370
cardiac	ADJ	O	O	3370
troponin	PROPN	O	O	3370
I	PRON	O	O	3370
and	CCONJ	O	O	3370
T	NOUN	O	Chemical	3370
levels	NOUN	O	O	3370
as	ADP	O	O	3370
markers	NOUN	O	O	3370
of	ADP	O	O	3370
myocardial damage	NOUN	O	Disease	3370
in	ADP	O	O	3370
doxorubicin	VERB	O	Chemical	3370
-	PUNCT	O	O	3370
induced	VERB	O	O	3370
cardiomyopathy	ADJ	O	Disease	3370
rats	NOUN	O	O	3370
,	PUNCT	O	O	3370
and	CCONJ	O	O	3370
their	PRON	O	O	3370
relationship	NOUN	O	O	3370
with	ADP	O	O	3370
echocardiographic	NOUN	O	O	3370
and	CCONJ	O	O	3370
histological	ADJ	O	O	3370
findings	NOUN	O	O	3370
.	PUNCT	O	O	3370
Cardiac	ADJ	O	O	3371
troponins	NOUN	O	O	3371
I	PRON	O	O	3371
(	PUNCT	O	O	3371
cTnI	VERB	O	O	3371
)	PUNCT	O	O	3371
and	CCONJ	O	O	3371
T	NOUN	O	Chemical	3371
(	PUNCT	O	O	3371
cTnT	VERB	O	O	3371
)	PUNCT	O	O	3371
have	VERB	O	O	3371
been	AUX	O	O	3371
shown	VERB	O	O	3371
to	PART	O	O	3371
be	AUX	O	O	3371
highly	ADV	O	O	3371
sensitive	ADJ	O	O	3371
and	CCONJ	O	O	3371
specific	ADJ	O	O	3371
markers	NOUN	O	O	3371
of	ADP	O	O	3371
myocardial	ADJ	O	O	3371
cell	NOUN	O	O	3371
injury	NOUN	O	O	3371
.	PUNCT	O	O	3371
We	PRON	O	O	3372
investigated	VERB	O	O	3372
the	PRON	O	O	3372
diagnostic	ADJ	O	O	3372
value	NOUN	O	O	3372
of	ADP	O	O	3372
cTnI	VERB	O	O	3372
and	CCONJ	O	O	3372
cTnT	VERB	O	O	3372
for	ADP	O	O	3372
the	PRON	O	O	3372
diagnosis	NOUN	O	O	3372
of	ADP	O	O	3372
myocardial damage	NOUN	O	Disease	3372
in	ADP	O	O	3372
a	PRON	O	O	3372
rat	NOUN	O	O	3372
model	NOUN	O	O	3372
of	ADP	O	O	3372
doxorubicin	VERB	O	Chemical	3372
(	PUNCT	O	O	3372
DOX)-induced	PROPN	O	O	3372
cardiomyopathy	ADJ	O	Disease	3372
,	PUNCT	O	O	3372
and	CCONJ	O	O	3372
we	PRON	O	O	3372
examined	VERB	O	O	3372
the	PRON	O	O	3372
relationship	NOUN	O	O	3372
between	ADP	O	O	3372
serial	ADJ	O	O	3372
cTnI	VERB	O	O	3372
and	CCONJ	O	O	3372
cTnT	VERB	O	O	3372
with	ADP	O	O	3372
the	PRON	O	O	3372
development	NOUN	O	O	3372
of	ADP	O	O	3372
cardiac	ADJ	O	O	3372
disorders	NOUN	O	O	3372
monitored	VERB	O	O	3372
by	ADP	O	O	3372
echocardiography	NOUN	O	O	3372
and	CCONJ	O	O	3372
histological	ADJ	O	O	3372
examinations	NOUN	O	O	3372
in	ADP	O	O	3372
this	PRON	O	O	3372
model	NOUN	O	O	3372
.	PUNCT	O	O	3372
Thirty	NUM	O	O	3373
-	PUNCT	O	O	3373
five	NUM	O	O	3373
Wistar	PROPN	O	O	3373
rats	NOUN	O	O	3373
were	AUX	O	O	3373
given	VERB	O	O	3373
1.5	NUM	O	O	3373
mg	VERB	O	O	3373
/	PUNCT	O	O	3373
kg	VERB	O	O	3373
DOX	PROPN	O	Chemical	3373
,	PUNCT	O	O	3373
i.v	NOUN	O	O	3373
.	PUNCT	O	O	3373
By	ADP	O	O	3374
using	VERB	O	O	3374
transthoracic	PROPN	O	O	3374
echocardiography	NOUN	O	O	3374
,	PUNCT	O	O	3374
anterior	PROPN	O	O	3374
and	CCONJ	O	O	3374
posterior	ADJ	O	O	3374
wall	PROPN	O	O	3374
thickness	NOUN	O	O	3374
,	PUNCT	O	O	3374
LV	PROPN	O	Disease	3374
diameters	NOUN	O	O	3374
and	CCONJ	O	O	3374
LV	PROPN	O	Disease	3374
fractional	ADJ	O	O	3374
shortening	NOUN	O	O	3374
(	PUNCT	O	O	3374
FS	NOUN	O	O	3374
)	PUNCT	O	O	3374
were	AUX	O	O	3374
measured	VERB	O	O	3374
in	ADP	O	O	3374
all	PRON	O	O	3374
rats	NOUN	O	O	3374
before	ADP	O	O	3374
DOX	PROPN	O	Chemical	3374
or	CCONJ	O	O	3374
saline	NOUN	O	O	3374
,	PUNCT	O	O	3374
and	CCONJ	O	O	3374
at	ADP	O	O	3374
weeks	NOUN	O	O	3374
6	NUM	O	O	3374
and	CCONJ	O	O	3374
9	NUM	O	O	3374
after	ADP	O	O	3374
treatment	NOUN	O	O	3374
in	ADP	O	O	3374
all	PRON	O	O	3374
surviving	VERB	O	O	3374
rats	NOUN	O	O	3374
.	PUNCT	O	O	3374
Histology	NOUN	O	O	3375
was	AUX	O	O	3375
performed	VERB	O	O	3375
in	ADP	O	O	3375
DOX	PROPN	O	Chemical	3375
-	PUNCT	O	O	3375
rats	NOUN	O	O	3375
at	ADP	O	O	3375
6	NUM	O	O	3375
and	CCONJ	O	O	3375
9	NUM	O	O	3375
weeks	NOUN	O	O	3375
after	ADP	O	O	3375
the	PRON	O	O	3375
last	VERB	O	O	3375
DOX	PROPN	O	Chemical	3375
dose	NOUN	O	O	3375
and	CCONJ	O	O	3375
in	ADP	O	O	3375
all	PRON	O	O	3375
controls	VERB	O	O	3375
.	PUNCT	O	O	3375
Eighteen	NUM	O	O	3376
of	ADP	O	O	3376
the	PRON	O	O	3376
DOX	PROPN	O	Chemical	3376
rats	NOUN	O	O	3376
died	VERB	O	O	3376
prematurely	ADV	O	O	3376
of	ADP	O	O	3376
general	ADJ	O	O	3376
toxicity	NOUN	O	Disease	3376
during	ADP	O	O	3376
the	PRON	O	O	3376
9-week	NOUN	O	O	3376
period	NOUN	O	O	3376
.	PUNCT	O	O	3376
/	PUNCT	O	O	3377
BW	NOUN	O	O	3377
significantly	ADV	O	O	3377
increased	VERB	O	O	3377
,	PUNCT	O	O	3377
whereas	SCONJ	O	O	3377
LV	PROPN	O	Disease	3377
FS	NOUN	O	O	3377
was	AUX	O	O	3377
decreased	VERB	O	O	3377
after	ADP	O	O	3377
9	NUM	O	O	3377
weeks	NOUN	O	O	3377
in	ADP	O	O	3377
the	PRON	O	O	3377
DOX	PROPN	O	Chemical	3377
group	NOUN	O	O	3377
(	PUNCT	O	O	3377
p<0.001	ADJ	O	O	3377
)	PUNCT	O	O	3377
.	PUNCT	O	O	3377
Histological	NOUN	O	O	3378
evaluation	NOUN	O	O	3378
of	ADP	O	O	3378
hearts	NOUN	O	O	3378
from	ADP	O	O	3378
all	PRON	O	O	3378
rats	NOUN	O	O	3378
given	VERB	O	O	3378
DOX	PROPN	O	Chemical	3378
revealed	VERB	O	O	3378
significant	ADJ	O	O	3378
slight	ADJ	O	O	3378
degrees	NOUN	O	O	3378
of	ADP	O	O	3378
perivascular	ADJ	O	O	3378
and	CCONJ	O	O	3378
interstitial	ADJ	O	O	3378
fibrosis	NOUN	O	Disease	3378
.	PUNCT	O	O	3378
Only	ADV	O	O	3379
five	NUM	O	O	3379
of	ADP	O	O	3379
the	PRON	O	O	3379
controls	VERB	O	O	3379
exhibited	VERB	O	O	3379
evidence	NOUN	O	O	3379
of	ADP	O	O	3379
very	ADV	O	O	3379
slight	ADJ	O	O	3379
perivascular	ADJ	O	O	3379
fibrosis	NOUN	O	Disease	3379
.	PUNCT	O	O	3379
A	PRON	O	O	3380
significant	ADJ	O	O	3380
rise	VERB	O	O	3380
in	ADP	O	O	3380
cTnT	VERB	O	O	3380
was	AUX	O	O	3380
found	VERB	O	O	3380
in	ADP	O	O	3380
DOX	PROPN	O	Chemical	3380
rats	NOUN	O	O	3380
after	ADP	O	O	3380
cumulative	ADJ	O	O	3380
doses	NOUN	O	O	3380
of	ADP	O	O	3380
7.5	NUM	O	O	3380
and	CCONJ	O	O	3380
12	NUM	O	O	3380
mg	VERB	O	O	3380
/	PUNCT	O	O	3380
kg	VERB	O	O	3380
in	ADP	O	O	3380
comparison	NOUN	O	O	3380
with	ADP	O	O	3380
baseline	VERB	O	O	3380
(	PUNCT	O	O	3380
p<0.05	NOUN	O	O	3380
)	PUNCT	O	O	3380
.	PUNCT	O	O	3380
/	PUNCT	O	O	3381
kg	VERB	O	O	3381
DOX	PROPN	O	Chemical	3381
.	PUNCT	O	O	3381
and	CCONJ	O	O	3382
cTnT	VERB	O	O	3382
levels	NOUN	O	O	3382
were	AUX	O	O	3382
significantly	ADV	O	O	3382
increased	VERB	O	O	3382
in	ADP	O	O	3382
DOX	PROPN	O	Chemical	3382
rats	NOUN	O	O	3382
compared	VERB	O	O	3382
with	ADP	O	O	3382
controls	VERB	O	O	3382
(	PUNCT	O	O	3382
p=0.006	VERB	O	O	3382
,	PUNCT	O	O	3382
0.007	NUM	O	O	3382
)	PUNCT	O	O	3382
.	PUNCT	O	O	3382
cTnI	VERB	O	O	3383
(	PUNCT	O	O	3383
ng	PROPN	O	O	3383
/	PUNCT	O	O	3383
ml	ADP	O	O	3383
)	PUNCT	O	O	3383
,	PUNCT	O	O	3383
CK	PROPN	O	O	3383
-	PUNCT	O	O	3383
MB	NOUN	O	O	3383
mass	PROPN	O	O	3383
and	CCONJ	O	O	3383
CK	PROPN	O	O	3383
remained	VERB	O	O	3383
unchanged	ADJ	O	O	3383
in	ADP	O	O	3383
DOX	PROPN	O	Chemical	3383
rats	NOUN	O	O	3383
compared	VERB	O	O	3383
with	ADP	O	O	3383
controls	VERB	O	O	3383
.	PUNCT	O	O	3383
CONCLUSIONS	NOUN	O	O	3384
:	PUNCT	O	O	3384
Among	ADP	O	O	3384
markers	NOUN	O	O	3384
of	ADP	O	O	3384
ischemic	VERB	O	Disease	3384
injury	NOUN	O	O	3384
after	ADP	O	O	3384
DOX	PROPN	O	Chemical	3384
in	ADP	O	O	3384
rats	NOUN	O	O	3384
,	PUNCT	O	O	3384
cTnT	VERB	O	O	3384
showed	VERB	O	O	3384
the	PRON	O	O	3384
greatest	ADJ	O	O	3384
ability	NOUN	O	O	3384
to	PART	O	O	3384
detect	VERB	O	O	3384
myocardial damage	NOUN	O	Disease	3384
assessed	VERB	O	O	3384
by	ADP	O	O	3384
echocardiographic	NOUN	O	O	3384
detection	NOUN	O	O	3384
and	CCONJ	O	O	3384
histological	ADJ	O	O	3384
changes	VERB	O	O	3384
.	PUNCT	O	O	3384
Although	SCONJ	O	O	3385
there	ADV	O	O	3385
was	AUX	O	O	3385
a	PRON	O	O	3385
discrepancy	NOUN	O	O	3385
between	ADP	O	O	3385
the	PRON	O	O	3385
amount	NOUN	O	O	3385
of	ADP	O	O	3385
cTnI	VERB	O	O	3385
and	CCONJ	O	O	3385
cTnT	VERB	O	O	3385
after	ADP	O	O	3385
DOX	PROPN	O	Chemical	3385
,	PUNCT	O	O	3385
probably	ADV	O	O	3385
due	ADJ	O	O	3385
to	PART	O	O	3385
heterogeneity	NOUN	O	O	3385
in	ADP	O	O	3385
cross	VERB	O	O	3385
-	PUNCT	O	O	3385
reactivities	NOUN	O	O	3385
of	ADP	O	O	3385
mAbs	PROPN	O	O	3385
to	PART	O	O	3385
various	ADJ	O	O	3385
cTnI	VERB	O	O	3385
and	CCONJ	O	O	3385
cTnT	VERB	O	O	3385
forms	NOUN	O	O	3385
,	PUNCT	O	O	3385
it	PRON	O	O	3385
is	AUX	O	O	3385
likely	ADV	O	O	3385
that	SCONJ	O	O	3385
cTnT	VERB	O	O	3385
in	ADP	O	O	3385
rats	NOUN	O	O	3385
after	ADP	O	O	3385
DOX	PROPN	O	Chemical	3385
indicates	VERB	O	O	3385
cell	NOUN	O	O	3385
damage	NOUN	O	O	3385
determined	VERB	O	O	3385
by	ADP	O	O	3385
the	PRON	O	O	3385
magnitude	NOUN	O	O	3385
of	ADP	O	O	3385
injury	NOUN	O	O	3385
induced	VERB	O	O	3385
and	CCONJ	O	O	3385
that	SCONJ	O	O	3385
cTnT	VERB	O	O	3385
should	AUX	O	O	3385
be	AUX	O	O	3385
a	PRON	O	O	3385
useful	ADJ	O	O	3385
marker	NOUN	O	O	3385
for	ADP	O	O	3385
the	PRON	O	O	3385
prediction	NOUN	O	O	3385
of	ADP	O	O	3385
experimentally	ADV	O	O	3385
induced	VERB	O	O	3385
cardiotoxicity	NOUN	O	Disease	3385
and	CCONJ	O	O	3385
possibly	ADV	O	O	3385
for	ADP	O	O	3385
cardioprotective	ADJ	O	O	3385
experiments	NOUN	O	O	3385
.	PUNCT	O	O	3385
Calcineurin	NOUN	O	O	3388
-	PUNCT	O	O	3388
inhibitor	NOUN	O	O	3388
induced	VERB	O	O	3388
pain	NOUN	O	Disease	3388
syndrome	NOUN	O	O	3388
(	PUNCT	O	O	3388
CIPS	NOUN	O	O	3388
)	PUNCT	O	O	3388
:	PUNCT	O	O	3388
a	PRON	O	O	3388
severe	ADJ	O	O	3388
disabling	VERB	O	O	3388
complication	NOUN	O	O	3388
after	ADP	O	O	3388
organ	NOUN	O	O	3388
transplantation	NOUN	O	O	3388
.	PUNCT	O	O	3388
Bone	NOUN	O	O	3389
pain	NOUN	O	Disease	3389
after	ADP	O	O	3389
transplantation	NOUN	O	O	3389
is	AUX	O	O	3389
a	PRON	O	O	3389
frequent	ADJ	O	O	3389
complication	NOUN	O	O	3389
that	SCONJ	O	O	3389
can	AUX	O	O	3389
be	AUX	O	O	3389
caused	VERB	O	O	3389
by	ADP	O	O	3389
several	ADJ	O	O	3389
diseases	NOUN	O	O	3389
.	PUNCT	O	O	3389
Treatment	NOUN	O	O	3390
strategies	NOUN	O	O	3390
depend	VERB	O	O	3390
on	ADP	O	O	3390
the	PRON	O	O	3390
correct	VERB	O	O	3390
diagnosis	NOUN	O	O	3390
of	ADP	O	O	3390
the	PRON	O	O	3390
pain	NOUN	O	Disease	3390
.	PUNCT	O	O	3390
Nine	NUM	O	O	3391
patients	NOUN	O	O	3391
with	ADP	O	O	3391
severe	ADJ	O	O	3391
pain	NOUN	O	Disease	3391
in	ADP	O	O	3391
their	PRON	O	O	3391
feet	NOUN	O	O	3391
,	PUNCT	O	O	3391
which	PRON	O	O	3391
was	AUX	O	O	3391
registered	VERB	O	O	3391
after	ADP	O	O	3391
transplantation	NOUN	O	O	3391
,	PUNCT	O	O	3391
were	AUX	O	O	3391
investigated	VERB	O	O	3391
.	PUNCT	O	O	3391
Magnetic	ADJ	O	O	3392
resonance	NOUN	O	O	3392
imaging	VERB	O	O	3392
demonstrated	VERB	O	O	3392
bone	NOUN	O	O	3392
marrow	PROPN	O	O	3392
oedema	NOUN	O	Disease	3392
in	ADP	O	O	3392
the	PRON	O	O	3392
painful	ADJ	O	Disease	3392
bones	NOUN	O	O	3392
.	PUNCT	O	O	3392
Pain	NOUN	O	Disease	3393
was	AUX	O	O	3393
not	PART	O	O	3393
explained	VERB	O	O	3393
by	ADP	O	O	3393
other	ADJ	O	O	3393
diseases	NOUN	O	O	3393
causing	VERB	O	O	3393
foot	NOUN	O	O	3393
pain	NOUN	O	Disease	3393
,	PUNCT	O	O	3393
like	INTJ	O	O	3393
reflex	NOUN	O	O	3393
sympathetic	ADJ	O	O	3393
dystrophy	NOUN	O	O	3393
,	PUNCT	O	O	3393
polyneuropathy	ADJ	O	Disease	3393
,	PUNCT	O	O	3393
Morton	PROPN	O	O	3393
's	AUX	O	O	3393
neuralgia	NOUN	O	Disease	3393
,	PUNCT	O	O	3393
gout	NOUN	O	Disease	3393
,	PUNCT	O	O	3393
osteoporosis	NOUN	O	Disease	3393
,	PUNCT	O	O	3393
avascular	ADJ	O	O	3393
necrosis	NOUN	O	Disease	3393
,	PUNCT	O	O	3393
intermittent	ADJ	O	O	3393
claudication	NOUN	O	O	3393
,	PUNCT	O	O	3393
orthopaedic	ADJ	O	O	3393
foot	NOUN	O	O	3393
deformities	NOUN	O	O	3393
,	PUNCT	O	O	3393
stress	NOUN	O	O	3393
fractures	NOUN	O	Disease	3393
,	PUNCT	O	O	3393
and	CCONJ	O	O	3393
hyperparathyroidism	NOUN	O	O	3393
.	PUNCT	O	O	3393
The	PRON	O	O	3394
reduction	NOUN	O	O	3394
of	ADP	O	O	3394
cyclosporine-	NOUN	O	O	3394
or	CCONJ	O	O	3394
tacrolimus	NOUN	O	Chemical	3394
trough	NOUN	O	O	3394
levels	NOUN	O	O	3394
and	CCONJ	O	O	3394
the	PRON	O	O	3394
administration	NOUN	O	O	3394
of	ADP	O	O	3394
calcium	NOUN	O	Chemical	3394
channel	PROPN	O	O	3394
blockers	NOUN	O	O	3394
led	VERB	O	O	3394
to	PART	O	O	3394
relief	NOUN	O	O	3394
of	ADP	O	O	3394
pain	NOUN	O	Disease	3394
.	PUNCT	O	O	3394
The	PRON	O	O	3395
Calcineurin	NOUN	O	O	3395
-	PUNCT	O	O	3395
inhibitor	NOUN	O	O	3395
Induced	VERB	O	O	3395
Pain	NOUN	O	Disease	3395
Syndrome	NOUN	O	O	3395
(	PUNCT	O	O	3395
CIPS	NOUN	O	O	3395
)	PUNCT	O	O	3395
is	AUX	O	O	3395
a	PRON	O	O	3395
rare	ADJ	O	O	3395
but	CCONJ	O	O	3395
severe	ADJ	O	O	3395
side	NOUN	O	O	3395
effect	VERB	O	O	3395
of	ADP	O	O	3395
cyclosporine	NOUN	O	Chemical	3395
or	CCONJ	O	O	3395
tacrolimus	NOUN	O	Chemical	3395
and	CCONJ	O	O	3395
is	AUX	O	O	3395
accurately	ADV	O	O	3395
diagnosed	VERB	O	O	3395
by	ADP	O	O	3395
its	PRON	O	O	3395
typical	ADJ	O	O	3395
presentation	NOUN	O	O	3395
,	PUNCT	O	O	3395
magnetic	ADJ	O	O	3395
resonance	NOUN	O	O	3395
imaging	VERB	O	O	3395
and	CCONJ	O	O	3395
bone	NOUN	O	O	3395
scans	VERB	O	O	3395
.	PUNCT	O	O	3395
Incorrect	ADJ	O	O	3396
diagnosis	NOUN	O	O	3396
of	ADP	O	O	3396
the	PRON	O	O	3396
syndrome	NOUN	O	O	3396
will	AUX	O	O	3396
lead	VERB	O	Chemical	3396
to	PART	O	O	3396
a	PRON	O	O	3396
significant	ADJ	O	O	3396
reduction	NOUN	O	O	3396
of	ADP	O	O	3396
life	NOUN	O	O	3396
quality	NOUN	O	O	3396
in	ADP	O	O	3396
patients	NOUN	O	O	3396
suffering	VERB	O	O	3396
from	ADP	O	O	3396
CIPS	NOUN	O	O	3396
.	PUNCT	O	O	3396
The	PRON	O	O	3399
haemodynamic	ADJ	O	O	3399
effects	NOUN	O	O	3399
of	ADP	O	O	3399
propofol	VERB	O	Chemical	3399
in	ADP	O	O	3399
combination	NOUN	O	O	3399
with	ADP	O	O	3399
ephedrine	NOUN	O	Chemical	3399
in	ADP	O	O	3399
elderly	ADJ	O	O	3399
patients	NOUN	O	O	3399
(	PUNCT	O	O	3399
ASA	PROPN	O	Chemical	3399
groups	NOUN	O	O	3399
3	X	O	O	3399
and	CCONJ	O	O	3399
4	NUM	O	O	3399
)	PUNCT	O	O	3399
.	PUNCT	O	O	3399
The	PRON	O	O	3400
marked	VERB	O	O	3400
vasodilator	NOUN	O	O	3400
and	CCONJ	O	O	3400
negative	ADJ	O	O	3400
inotropic	NOUN	O	O	3400
effects	NOUN	O	O	3400
of	ADP	O	O	3400
propofol	VERB	O	Chemical	3400
are	AUX	O	O	3400
disadvantages	NOUN	O	O	3400
in	ADP	O	O	3400
frail	ADJ	O	O	3400
elderly	ADJ	O	O	3400
patients	NOUN	O	O	3400
.	PUNCT	O	O	3400
We	PRON	O	O	3401
investigated	VERB	O	O	3401
the	PRON	O	O	3401
safety	NOUN	O	O	3401
and	CCONJ	O	O	3401
efficacy	NOUN	O	O	3401
of	ADP	O	O	3401
adding	VERB	O	O	3401
different	ADJ	O	O	3401
doses	NOUN	O	O	3401
of	ADP	O	O	3401
ephedrine	NOUN	O	Chemical	3401
to	PART	O	O	3401
propofol	VERB	O	Chemical	3401
in	ADP	O	O	3401
order	NOUN	O	O	3401
to	PART	O	O	3401
obtund	NOUN	O	O	3401
the	PRON	O	O	3401
hypotensive	ADJ	O	Disease	3401
response	NOUN	O	O	3401
.	PUNCT	O	O	3401
The	PRON	O	O	3402
haemodynamic	ADJ	O	O	3402
effects	NOUN	O	O	3402
of	ADP	O	O	3402
adding	VERB	O	O	3402
15	NUM	O	O	3402
,	PUNCT	O	O	3402
20	NUM	O	O	3402
or	CCONJ	O	O	3402
25	NUM	O	O	3402
mg	VERB	O	O	3402
of	ADP	O	O	3402
ephedrine	NOUN	O	Chemical	3402
to	PART	O	O	3402
200	NUM	O	O	3402
mg	VERB	O	O	3402
of	ADP	O	O	3402
propofol	VERB	O	Chemical	3402
were	AUX	O	O	3402
compared	VERB	O	O	3402
to	PART	O	O	3402
control	VERB	O	O	3402
in	ADP	O	O	3402
40	NUM	O	O	3402
ASA	PROPN	O	Chemical	3402
3/4	NUM	O	O	3402
patients	NOUN	O	O	3402
over	ADP	O	O	3402
60	NUM	O	O	3402
years	NOUN	O	O	3402
presenting	VERB	O	O	3402
for	ADP	O	O	3402
genito	PROPN	O	O	3402
-	PUNCT	O	O	3402
urinary	ADJ	O	O	3402
surgery	NOUN	O	O	3402
.	PUNCT	O	O	3402
The	PRON	O	O	3403
addition	NOUN	O	O	3403
of	ADP	O	O	3403
ephedrine	NOUN	O	Chemical	3403
to	PART	O	O	3403
propofol	VERB	O	Chemical	3403
appears	VERB	O	O	3403
to	PART	O	O	3403
be	AUX	O	O	3403
an	PRON	O	O	3403
effective	ADJ	O	O	3403
method	NOUN	O	O	3403
of	ADP	O	O	3403
obtunding	NOUN	O	O	3403
the	PRON	O	O	3403
hypotensive	ADJ	O	Disease	3403
response	NOUN	O	O	3403
to	PART	O	O	3403
propofol	VERB	O	Chemical	3403
at	ADP	O	O	3403
all	PRON	O	O	3403
doses	NOUN	O	O	3403
used	VERB	O	O	3403
in	ADP	O	O	3403
this	PRON	O	O	3403
study	VERB	O	O	3403
.	PUNCT	O	O	3403
However	ADV	O	O	3404
,	PUNCT	O	O	3404
marked	VERB	O	O	3404
tachycardia	PROPN	O	Disease	3404
associated	VERB	O	O	3404
with	ADP	O	O	3404
the	PRON	O	O	3404
use	VERB	O	O	3404
of	ADP	O	O	3404
ephedrine	NOUN	O	Chemical	3404
in	ADP	O	O	3404
combination	NOUN	O	O	3404
with	ADP	O	O	3404
propofol	VERB	O	Chemical	3404
occurred	VERB	O	O	3404
in	ADP	O	O	3404
the	PRON	O	O	3404
majority	NOUN	O	O	3404
of	ADP	O	O	3404
patients	NOUN	O	O	3404
,	PUNCT	O	O	3404
occasionally	ADV	O	O	3404
reaching	VERB	O	O	3404
high	ADJ	O	O	3404
levels	NOUN	O	O	3404
in	ADP	O	O	3404
individual	ADJ	O	O	3404
patients	NOUN	O	O	3404
.	PUNCT	O	O	3404
Due	ADP	O	O	3405
to	PART	O	O	3405
the	PRON	O	O	3405
risk	NOUN	O	O	3405
of	ADP	O	O	3405
this	PRON	O	O	3405
tachycardia	PROPN	O	Disease	3405
inducing	VERB	O	O	3405
myocardial ischemia	NOUN	O	Disease	3405
,	PUNCT	O	O	3405
we	PRON	O	O	3405
would	AUX	O	O	3405
not	PART	O	O	3405
recommend	VERB	O	O	3405
the	PRON	O	O	3405
use	VERB	O	O	3405
in	ADP	O	O	3405
elderly	ADJ	O	O	3405
patients	NOUN	O	O	3405
of	ADP	O	O	3405
any	PRON	O	O	3405
of	ADP	O	O	3405
the	PRON	O	O	3405
ephedrine	NOUN	O	Chemical	3405
/	PUNCT	O	O	3405
propofol	VERB	O	Chemical	3405
/	PUNCT	O	O	3405
mixtures	NOUN	O	O	3405
studied	VERB	O	O	3405
.	PUNCT	O	O	3405
Neurotoxicity	NOUN	O	Disease	3408
of	ADP	O	O	3408
halogenated	VERB	O	O	3408
hydroxyquinolines	NOUN	O	O	3408
:	PUNCT	O	O	3408
clinical	ADJ	O	O	3408
analysis	NOUN	O	O	3408
of	ADP	O	O	3408
cases	NOUN	O	O	3408
reported	VERB	O	O	3408
outside	ADV	O	O	3408
Japan	PROPN	O	O	3408
.	PUNCT	O	O	3408
An	PRON	O	O	3409
analysis	NOUN	O	O	3409
is	AUX	O	O	3409
presented	VERB	O	O	3409
of	ADP	O	O	3409
220	NUM	O	O	3409
cases	NOUN	O	O	3409
of	ADP	O	O	3409
possible	ADJ	O	O	3409
neurotoxic	ADJ	O	Disease	3409
reactions	NOUN	O	O	3409
to	PART	O	O	3409
halogenated	VERB	O	O	3409
hydroxyquinolines	NOUN	O	O	3409
reported	VERB	O	O	3409
from	ADP	O	O	3409
outside	ADV	O	O	3409
Japan	PROPN	O	O	3409
.	PUNCT	O	O	3409
In	ADP	O	O	3410
80	NUM	O	O	3410
cases	NOUN	O	O	3410
insufficient	ADJ	O	O	3410
information	NOUN	O	O	3410
was	AUX	O	O	3410
available	ADJ	O	O	3410
for	ADP	O	O	3410
adequate	ADJ	O	O	3410
comment	NOUN	O	O	3410
and	CCONJ	O	O	3410
in	ADP	O	O	3410
29	NUM	O	O	3410
a	PRON	O	O	3410
relationship	NOUN	O	O	3410
to	PART	O	O	3410
the	PRON	O	O	3410
administration	NOUN	O	O	3410
of	ADP	O	O	3410
clioquinol	NOUN	O	O	3410
could	AUX	O	O	3410
be	AUX	O	O	3410
excluded	VERB	O	O	3410
.	PUNCT	O	O	3410
Of	ADV	O	O	3411
the	PRON	O	O	3411
remainder	NOUN	O	O	3411
,	PUNCT	O	O	3411
a	PRON	O	O	3411
relationship	NOUN	O	O	3411
to	PART	O	O	3411
clioquinol	NOUN	O	O	3411
was	AUX	O	O	3411
considered	VERB	O	O	3411
probable	ADJ	O	O	3411
in	ADP	O	O	3411
42	NUM	O	O	3411
and	CCONJ	O	O	3411
possible	ADJ	O	O	3411
in	ADP	O	O	3411
69	NUM	O	O	3411
cases	NOUN	O	O	3411
.	PUNCT	O	O	3411
In	ADP	O	O	3412
six	NUM	O	O	3412
of	ADP	O	O	3412
the	PRON	O	O	3412
probable	ADJ	O	O	3412
cases	NOUN	O	O	3412
the	PRON	O	O	3412
neurological	ADJ	O	O	3412
disturbance	NOUN	O	O	3412
consisted	VERB	O	O	3412
of	ADP	O	O	3412
an	PRON	O	O	3412
acute	ADJ	O	O	3412
reversible	ADJ	O	O	3412
encephalopathy	NOUN	O	Disease	3412
usually	ADV	O	O	3412
related	ADJ	O	O	3412
to	PART	O	O	3412
the	PRON	O	O	3412
ingestion	NOUN	O	O	3412
of	ADP	O	O	3412
a	PRON	O	O	3412
high	ADJ	O	O	3412
dose	NOUN	O	O	3412
of	ADP	O	O	3412
clioquinol	NOUN	O	O	3412
over	ADP	O	O	3412
a	PRON	O	O	3412
short	ADJ	O	O	3412
period	NOUN	O	O	3412
.	PUNCT	O	O	3412
The	PRON	O	O	3413
most	ADV	O	O	3413
common	ADJ	O	O	3413
manifestation	NOUN	O	O	3413
,	PUNCT	O	O	3413
observed	VERB	O	O	3413
in	ADP	O	O	3413
15	NUM	O	O	3413
further	ADV	O	O	3413
cases	NOUN	O	O	3413
,	PUNCT	O	O	3413
was	AUX	O	O	3413
isolated	VERB	O	O	3413
optic	NOUN	O	O	3413
atrophy	NOUN	O	Disease	3413
.	PUNCT	O	O	3413
This	PRON	O	O	3414
was	AUX	O	O	3414
most	ADV	O	O	3414
frequently	ADV	O	O	3414
found	VERB	O	O	3414
in	ADP	O	O	3414
children	NOUN	O	O	3414
,	PUNCT	O	O	3414
many	ADJ	O	O	3414
of	ADP	O	O	3414
whom	PRON	O	O	3414
had	VERB	O	O	3414
received	VERB	O	O	3414
clioquinol	NOUN	O	O	3414
as	ADP	O	O	3414
treatment	NOUN	O	O	3414
for	ADP	O	O	3414
acrodermatitis	NOUN	O	O	3414
enteropathica	PROPN	O	O	3414
.	PUNCT	O	O	3414
In	ADP	O	O	3415
the	PRON	O	O	3415
remaining	VERB	O	O	3415
cases	NOUN	O	O	3415
,	PUNCT	O	O	3415
a	PRON	O	O	3415
combination	NOUN	O	O	3415
of	ADP	O	O	3415
myelopathy	PROPN	O	O	3415
,	PUNCT	O	O	3415
visual	ADJ	O	O	3415
disturbance	NOUN	O	O	3415
,	PUNCT	O	O	3415
and	CCONJ	O	O	3415
peripheral neuropathy	NOUN	O	Disease	3415
was	AUX	O	O	3415
the	PRON	O	O	3415
most	ADV	O	O	3415
common	ADJ	O	O	3415
manifestation	NOUN	O	O	3415
.	PUNCT	O	O	3415
Isolated	VERB	O	O	3416
myelopathy	PROPN	O	O	3416
or	CCONJ	O	O	3416
peripheral neuropathy	NOUN	O	Disease	3416
,	PUNCT	O	O	3416
or	CCONJ	O	O	3416
these	PRON	O	O	3416
manifestations	NOUN	O	O	3416
occurring	VERB	O	O	3416
together	ADV	O	O	3416
,	PUNCT	O	O	3416
were	AUX	O	O	3416
infrequent	ADJ	O	O	3416
.	PUNCT	O	O	3416
The	PRON	O	O	3417
onset	VERB	O	O	3417
of	ADP	O	O	3417
all	PRON	O	O	3417
manifestations	NOUN	O	O	3417
(	PUNCT	O	O	3417
except	SCONJ	O	O	3417
toxic	ADJ	O	O	3417
encephalopathy	NOUN	O	Disease	3417
)	PUNCT	O	O	3417
was	AUX	O	O	3417
usually	ADV	O	O	3417
subacute	VERB	O	O	3417
,	PUNCT	O	O	3417
with	ADP	O	O	3417
subsequent	ADJ	O	O	3417
partial	ADJ	O	O	3417
recovery	NOUN	O	O	3417
.	PUNCT	O	O	3417
The	PRON	O	O	3418
full	ADJ	O	O	3418
syndrome	NOUN	O	O	3418
of	ADP	O	O	3418
subacute	VERB	O	O	3418
myelo	NOUN	O	O	3418
-	PUNCT	O	O	3418
optic neuropathy	NOUN	O	Disease	3418
was	AUX	O	O	3418
more	ADJ	O	O	3418
frequent	ADJ	O	O	3418
in	ADP	O	O	3418
women	NOUN	O	O	3418
,	PUNCT	O	O	3418
but	CCONJ	O	O	3418
they	PRON	O	O	3418
tended	VERB	O	O	3418
to	PART	O	O	3418
have	VERB	O	O	3418
taken	VERB	O	O	3418
greater	ADJ	O	O	3418
quantities	NOUN	O	O	3418
of	ADP	O	O	3418
the	PRON	O	O	3418
drug	NOUN	O	O	3418
.	PUNCT	O	O	3418
Epileptic	ADJ	O	Disease	3421
seizures	NOUN	O	Disease	3421
following	VERB	O	O	3421
cortical	ADJ	O	O	3421
application	NOUN	O	O	3421
of	ADP	O	O	3421
fibrin	PROPN	O	O	3421
sealants	NOUN	O	O	3421
containing	VERB	O	O	3421
tranexamic acid	PROPN	O	Chemical	3421
in	ADP	O	O	3421
rats	NOUN	O	O	3421
.	PUNCT	O	O	3421
Recently	ADV	O	O	3422
,	PUNCT	O	O	3422
synthetic	NOUN	O	O	3422
fibrinolysis	VERB	O	O	3422
inhibitors	NOUN	O	O	3422
such	ADJ	O	O	3422
as	ADP	O	O	3422
tranexamic acid	PROPN	O	Chemical	3422
(	PUNCT	O	O	3422
tAMCA	NOUN	O	O	3422
)	PUNCT	O	O	3422
have	VERB	O	O	3422
been	AUX	O	O	3422
considered	VERB	O	O	3422
as	ADP	O	O	3422
substitutes	NOUN	O	O	3422
for	ADP	O	O	3422
aprotinin	PROPN	O	O	3422
.	PUNCT	O	O	3422
However	ADV	O	O	3423
,	PUNCT	O	O	3423
tAMCA	NOUN	O	O	3423
has	VERB	O	O	3423
been	AUX	O	O	3423
shown	VERB	O	O	3423
to	PART	O	O	3423
cause	VERB	O	O	3423
epileptic seizures	NOUN	O	Disease	3423
.	PUNCT	O	O	3423
We	PRON	O	O	3424
wanted	VERB	O	O	3424
to	PART	O	O	3424
study	VERB	O	O	3424
whether	SCONJ	O	O	3424
tAMCA	NOUN	O	O	3424
retains	VERB	O	O	3424
its	PRON	O	O	3424
convulsive	ADJ	O	Disease	3424
action	NOUN	O	O	3424
if	SCONJ	O	O	3424
incorporated	VERB	O	O	3424
into	ADP	O	O	3424
a	PRON	O	O	3424
FS	NOUN	O	O	3424
.	PUNCT	O	O	3424
FS	NOUN	O	O	3425
containing	VERB	O	O	3425
aprotinin	PROPN	O	O	3425
or	CCONJ	O	O	3425
different	ADJ	O	O	3425
concentrations	NOUN	O	O	3425
of	ADP	O	O	3425
tAMCA	NOUN	O	O	3425
(	PUNCT	O	O	3425
0.5	NUM	O	O	3425
-	PUNCT	O	O	3425
47.5	NUM	O	O	3425
mg	VERB	O	O	3425
/	PUNCT	O	O	3425
ml	ADP	O	O	3425
)	PUNCT	O	O	3425
were	AUX	O	O	3425
applied	VERB	O	O	3425
to	PART	O	O	3425
the	PRON	O	O	3425
pial	ADJ	O	O	3425
surface	NOUN	O	O	3425
of	ADP	O	O	3425
the	PRON	O	O	3425
cortex	VERB	O	O	3425
of	ADP	O	O	3425
anaesthetized	VERB	O	O	3425
rats	NOUN	O	O	3425
.	PUNCT	O	O	3425
FS	NOUN	O	O	3426
containing	VERB	O	O	3426
tAMCA	NOUN	O	O	3426
caused	VERB	O	O	3426
paroxysmal	ADJ	O	O	3426
brain	NOUN	O	O	3426
activity	NOUN	O	O	3426
which	PRON	O	O	3426
was	AUX	O	O	3426
associated	VERB	O	O	3426
with	ADP	O	O	3426
distinct	ADJ	O	O	3426
convulsive	ADJ	O	Disease	3426
behaviours	NOUN	O	O	3426
.	PUNCT	O	O	3426
The	PRON	O	O	3427
degree	PROPN	O	O	3427
of	ADP	O	O	3427
these	PRON	O	O	3427
seizures	NOUN	O	Disease	3427
increased	VERB	O	O	3427
with	ADP	O	O	3427
increasing	VERB	O	O	3427
concentration	NOUN	O	O	3427
of	ADP	O	O	3427
tAMCA	NOUN	O	O	3427
.	PUNCT	O	O	3427
Thus	ADV	O	O	3428
,	PUNCT	O	O	3428
FS	NOUN	O	O	3428
containing	VERB	O	O	3428
47.5	NUM	O	O	3428
mg	VERB	O	O	3428
/	PUNCT	O	O	3428
ml	ADP	O	O	3428
tAMCA	NOUN	O	O	3428
evoked	VERB	O	O	3428
generalized	VERB	O	O	3428
seizures	NOUN	O	Disease	3428
in	ADP	O	O	3428
all	PRON	O	O	3428
tested	VERB	O	O	3428
rats	NOUN	O	O	3428
(	PUNCT	O	O	3428
n=6	NOUN	O	O	3428
)	PUNCT	O	O	3428
while	SCONJ	O	O	3428
the	PRON	O	O	3428
lowest	ADJ	O	O	3428
concentration	NOUN	O	O	3428
of	ADP	O	O	3428
tAMCA	NOUN	O	O	3428
(	PUNCT	O	O	3428
0.5	NUM	O	O	3428
mg	VERB	O	O	3428
/	PUNCT	O	O	3428
ml	ADP	O	O	3428
)	PUNCT	O	O	3428
only	ADV	O	O	3428
evoked	VERB	O	O	3428
brief	PROPN	O	O	3428
episodes	NOUN	O	O	3428
of	ADP	O	O	3428
jerk	VERB	O	O	3428
-	PUNCT	O	O	3428
correlated	VERB	O	O	3428
convulsive	ADJ	O	Disease	3428
potentials	NOUN	O	O	3428
in	ADP	O	O	3428
1	X	O	O	3428
of	ADP	O	O	3428
6	NUM	O	O	3428
rats	NOUN	O	O	3428
.	PUNCT	O	O	3428
INTERPRETATION	NOUN	O	O	3429
:	PUNCT	O	O	3429
Tranexamic	NOUN	O	O	3429
acid	PROPN	O	O	3429
retains	VERB	O	O	3429
its	PRON	O	O	3429
convulsive	ADJ	O	Disease	3429
action	NOUN	O	O	3429
within	ADP	O	O	3429
FS	NOUN	O	O	3429
.	PUNCT	O	O	3429
Thus	ADV	O	O	3430
,	PUNCT	O	O	3430
use	VERB	O	O	3430
of	ADP	O	O	3430
FS	NOUN	O	O	3430
containing	VERB	O	O	3430
tAMCA	NOUN	O	O	3430
for	ADP	O	O	3430
surgery	NOUN	O	O	3430
within	ADP	O	O	3430
or	CCONJ	O	O	3430
close	ADV	O	O	3430
to	PART	O	O	3430
the	PRON	O	O	3430
CNS	PROPN	O	O	3430
may	AUX	O	O	3430
pose	VERB	O	O	3430
a	PRON	O	O	3430
substantial	ADJ	O	O	3430
risk	NOUN	O	O	3430
to	PART	O	O	3430
the	PRON	O	O	3430
patient	NOUN	O	O	3430
.	PUNCT	O	O	3430
A	PRON	O	O	3433
diet	PROPN	O	O	3433
promoting	VERB	O	O	3433
sugar	NOUN	O	O	3433
dependency	NOUN	O	O	3433
causes	VERB	O	O	3433
behavioral	ADJ	O	O	3433
cross	VERB	O	O	3433
-	PUNCT	O	O	3433
sensitization	NOUN	O	O	3433
to	PART	O	O	3433
a	PRON	O	O	3433
low	ADJ	O	O	3433
dose	NOUN	O	O	3433
of	ADP	O	O	3433
amphetamine	NOUN	O	Chemical	3433
.	PUNCT	O	O	3433
Previous	ADJ	O	O	3434
research	NOUN	O	O	3434
in	ADP	O	O	3434
this	PRON	O	O	3434
laboratory	NOUN	O	O	3434
has	VERB	O	O	3434
shown	VERB	O	O	3434
that	SCONJ	O	O	3434
a	PRON	O	O	3434
diet	PROPN	O	O	3434
of	ADP	O	O	3434
intermittent	ADJ	O	O	3434
excessive	ADJ	O	O	3434
sugar	NOUN	O	O	3434
consumption	NOUN	O	O	3434
produces	VERB	O	O	3434
a	PRON	O	O	3434
state	NOUN	O	O	3434
with	ADP	O	O	3434
neurochemical	ADJ	O	O	3434
and	CCONJ	O	O	3434
behavioral	ADJ	O	O	3434
similarities	VERB	O	O	3434
to	PART	O	O	3434
drug	NOUN	O	O	3434
dependency	NOUN	O	O	3434
.	PUNCT	O	O	3434
The	PRON	O	O	3435
present	NOUN	O	O	3435
study	VERB	O	O	3435
examined	VERB	O	O	3435
whether	SCONJ	O	O	3435
female	ADJ	O	O	3435
rats	NOUN	O	O	3435
on	ADP	O	O	3435
various	ADJ	O	O	3435
regimens	NOUN	O	O	3435
of	ADP	O	O	3435
sugar	NOUN	O	O	3435
access	NOUN	O	O	3435
would	AUX	O	O	3435
show	VERB	O	O	3435
behavioral	ADJ	O	O	3435
cross	VERB	O	O	3435
-	PUNCT	O	O	3435
sensitization	NOUN	O	O	3435
to	PART	O	O	3435
a	PRON	O	O	3435
low	ADJ	O	O	3435
dose	NOUN	O	O	3435
of	ADP	O	O	3435
amphetamine	NOUN	O	Chemical	3435
.	PUNCT	O	O	3435
After	ADP	O	O	3436
a	PRON	O	O	3436
30-min	NOUN	O	O	3436
baseline	VERB	O	O	3436
measure	VERB	O	O	3436
of	ADP	O	O	3436
locomotor	PROPN	O	O	3436
activity	NOUN	O	O	3436
(	PUNCT	O	O	3436
day	NOUN	O	O	3436
0	NUM	O	O	3436
)	PUNCT	O	O	3436
,	PUNCT	O	O	3436
animals	NOUN	O	O	3436
were	AUX	O	O	3436
maintained	VERB	O	O	3436
on	ADP	O	O	3436
a	PRON	O	O	3436
cyclic	PROPN	O	O	3436
diet	PROPN	O	O	3436
of	ADP	O	O	3436
12-h	NOUN	O	O	3436
deprivation	NOUN	O	O	3436
followed	VERB	O	O	3436
by	ADP	O	O	3436
12-h	NOUN	O	O	3436
access	NOUN	O	O	3436
to	PART	O	O	3436
10%	NOUN	O	O	3436
sucrose	VERB	O	O	3436
solution	NOUN	O	O	3436
and	CCONJ	O	O	3436
chow	PROPN	O	O	3436
pellets	NOUN	O	O	3436
(	PUNCT	O	O	3436
12	NUM	O	O	3436
h	X	O	O	3436
access	NOUN	O	O	3436
starting	VERB	O	O	3436
4	NUM	O	O	3436
h	X	O	O	3436
after	ADP	O	O	3436
onset	VERB	O	O	3436
of	ADP	O	O	3436
the	PRON	O	O	3436
dark	ADJ	O	O	3436
period	NOUN	O	O	3436
)	PUNCT	O	O	3436
for	ADP	O	O	3436
21	NUM	O	O	3436
days	NOUN	O	O	3436
.	PUNCT	O	O	3436
Nine	NUM	O	O	3437
days	NOUN	O	O	3437
later	ADV	O	O	3437
locomotor	PROPN	O	O	3437
activity	NOUN	O	O	3437
was	AUX	O	O	3437
measured	VERB	O	O	3437
in	ADP	O	O	3437
response	NOUN	O	O	3437
to	PART	O	O	3437
a	PRON	O	O	3437
single	ADJ	O	O	3437
low	ADJ	O	O	3437
dose	NOUN	O	O	3437
of	ADP	O	O	3437
amphetamine	NOUN	O	Chemical	3437
(	PUNCT	O	O	3437
0.5	NUM	O	O	3437
mg	VERB	O	O	3437
/	PUNCT	O	O	3437
kg	VERB	O	O	3437
)	PUNCT	O	O	3437
.	PUNCT	O	O	3437
The	PRON	O	O	3438
animals	NOUN	O	O	3438
that	SCONJ	O	O	3438
had	VERB	O	O	3438
experienced	ADJ	O	O	3438
cyclic	PROPN	O	O	3438
sucrose	VERB	O	O	3438
and	CCONJ	O	O	3438
chow	PROPN	O	O	3438
were	AUX	O	O	3438
hyperactive	ADJ	O	O	3438
in	ADP	O	O	3438
response	NOUN	O	O	3438
to	PART	O	O	3438
amphetamine	NOUN	O	Chemical	3438
compared	VERB	O	O	3438
with	ADP	O	O	3438
four	NUM	O	O	3438
control	VERB	O	O	3438
groups	NOUN	O	O	3438
(	PUNCT	O	O	3438
ad	NOUN	O	O	3438
libitum	NOUN	O	O	3438
10%	NOUN	O	O	3438
sucrose	VERB	O	O	3438
and	CCONJ	O	O	3438
chow	PROPN	O	O	3438
followed	VERB	O	O	3438
by	ADP	O	O	3438
amphetamine	NOUN	O	Chemical	3438
injection	NOUN	O	O	3438
,	PUNCT	O	O	3438
cyclic	PROPN	O	O	3438
chow	PROPN	O	O	3438
followed	VERB	O	O	3438
by	ADP	O	O	3438
amphetamine	NOUN	O	Chemical	3438
injection	NOUN	O	O	3438
,	PUNCT	O	O	3438
ad	NOUN	O	O	3438
libitum	NOUN	O	O	3438
chow	PROPN	O	O	3438
with	ADP	O	O	3438
amphetamine	NOUN	O	Chemical	3438
,	PUNCT	O	O	3438
or	CCONJ	O	O	3438
cyclic	PROPN	O	O	3438
10%	NOUN	O	O	3438
sucrose	VERB	O	O	3438
and	CCONJ	O	O	3438
chow	PROPN	O	O	3438
with	ADP	O	O	3438
a	PRON	O	O	3438
saline	NOUN	O	O	3438
injection	NOUN	O	O	3438
)	PUNCT	O	O	3438
.	PUNCT	O	O	3438
These	PRON	O	O	3439
results	VERB	O	O	3439
suggest	VERB	O	O	3439
that	SCONJ	O	O	3439
a	PRON	O	O	3439
diet	PROPN	O	O	3439
comprised	VERB	O	O	3439
of	ADP	O	O	3439
alternating	VERB	O	O	3439
deprivation	NOUN	O	O	3439
and	CCONJ	O	O	3439
access	NOUN	O	O	3439
to	PART	O	O	3439
a	PRON	O	O	3439
sugar	NOUN	O	O	3439
solution	NOUN	O	O	3439
and	CCONJ	O	O	3439
chow	PROPN	O	O	3439
produces	VERB	O	O	3439
bingeing	VERB	O	O	3439
on	ADP	O	O	3439
sugar	NOUN	O	O	3439
that	SCONJ	O	O	3439
leads	VERB	O	O	3439
to	PART	O	O	3439
a	PRON	O	O	3439
long	ADV	O	O	3439
lasting	VERB	O	O	3439
state	NOUN	O	O	3439
of	ADP	O	O	3439
increased	VERB	O	O	3439
sensitivity	NOUN	O	O	3439
to	PART	O	O	3439
amphetamine	NOUN	O	Chemical	3439
,	PUNCT	O	O	3439
possibly	ADV	O	O	3439
due	ADJ	O	O	3439
to	PART	O	O	3439
a	PRON	O	O	3439
lasting	VERB	O	O	3439
alteration	NOUN	O	O	3439
in	ADP	O	O	3439
the	PRON	O	O	3439
dopamine	NOUN	O	Chemical	3439
system	NOUN	O	O	3439
.	PUNCT	O	O	3439
D	NOUN	O	O	3442
-	PUNCT	O	O	3442
penicillamine	NOUN	O	Chemical	3442
-	PUNCT	O	O	3442
induced	VERB	O	O	3442
angiopathy	PROPN	O	O	3442
in	ADP	O	O	3442
rats	NOUN	O	O	3442
.	PUNCT	O	O	3442
The	PRON	O	O	3443
effect	VERB	O	O	3443
of	ADP	O	O	3443
high	ADJ	O	O	3443
dose	NOUN	O	O	3443
D	NOUN	O	O	3443
-	PUNCT	O	O	3443
penicillamine	NOUN	O	Chemical	3443
treatment	NOUN	O	O	3443
on	ADP	O	O	3443
aortic	ADJ	O	O	3443
permeability	NOUN	O	O	3443
to	PART	O	O	3443
albumin	PROPN	O	O	3443
and	CCONJ	O	O	3443
on	ADP	O	O	3443
the	PRON	O	O	3443
ultrastructure	NOUN	O	O	3443
of	ADP	O	O	3443
the	PRON	O	O	3443
vessel	NOUN	O	O	3443
.	PUNCT	O	O	3443
Male	NOUN	O	O	3444
Sprague	PROPN	O	O	3444
-	PUNCT	O	O	3444
Dawley	NOUN	O	O	3444
rats	NOUN	O	O	3444
were	AUX	O	O	3444
treated	VERB	O	O	3444
with	ADP	O	O	3444
D	NOUN	O	O	3444
-	PUNCT	O	O	3444
penicillamine	NOUN	O	Chemical	3444
(	PUNCT	O	O	3444
D	NOUN	O	O	3444
-	PUNCT	O	O	3444
pen	NOUN	O	O	3444
)	PUNCT	O	O	3444
500	NUM	O	O	3444
mg	VERB	O	O	3444
/	PUNCT	O	O	3444
kg	VERB	O	O	3444
/	PUNCT	O	O	3444
day	NOUN	O	O	3444
for	ADP	O	O	3444
10	NUM	O	O	3444
or	CCONJ	O	O	3444
42	NUM	O	O	3444
days	NOUN	O	O	3444
.	PUNCT	O	O	3444
TEM	PROPN	O	O	3445
revealed	VERB	O	O	3445
extensive	ADJ	O	O	3445
elastolysis	VERB	O	O	3445
in	ADP	O	O	3445
the	PRON	O	O	3445
arterial	ADJ	O	O	3445
wall	PROPN	O	O	3445
of	ADP	O	O	3445
D	NOUN	O	O	3445
-	PUNCT	O	O	3445
pen	NOUN	O	O	3445
-	PUNCT	O	O	3445
treated	VERB	O	O	3445
rats	NOUN	O	O	3445
,	PUNCT	O	O	3445
consistent	ADJ	O	O	3445
with	ADP	O	O	3445
an	PRON	O	O	3445
inhibitory	ADJ	O	O	3445
effect	VERB	O	O	3445
on	ADP	O	O	3445
crosslink	VERB	O	O	3445
formation	NOUN	O	O	3445
.	PUNCT	O	O	3445
The	PRON	O	O	3446
aorta	NOUN	O	O	3446
/	PUNCT	O	O	3446
serum	NOUN	O	O	3446
-	PUNCT	O	O	3446
ratio	NOUN	O	O	3446
and	CCONJ	O	O	3446
the	PRON	O	O	3446
radioactive	ADJ	O	O	3446
build	VERB	O	O	3446
-	PUNCT	O	O	3446
up	ADP	O	O	3446
24	NUM	O	O	3446
and	CCONJ	O	O	3446
48	NUM	O	O	3446
hours	NOUN	O	O	3446
after	ADP	O	O	3446
injection	NOUN	O	O	3446
of	ADP	O	O	3446
131I	NUM	O	O	3446
-	PUNCT	O	O	3446
HSA	PROPN	O	O	3446
was	AUX	O	O	3446
reduced	VERB	O	O	3446
in	ADP	O	O	3446
animals	NOUN	O	O	3446
treated	VERB	O	O	3446
with	ADP	O	O	3446
D	NOUN	O	O	3446
-	PUNCT	O	O	3446
pen	NOUN	O	O	3446
for	ADP	O	O	3446
42	NUM	O	O	3446
days	NOUN	O	O	3446
,	PUNCT	O	O	3446
indicating	VERB	O	O	3446
an	PRON	O	O	3446
impeded	VERB	O	O	3446
transmural	ADJ	O	O	3446
transport	NOUN	O	O	3446
of	ADP	O	O	3446
tracer	NOUN	O	O	3446
which	PRON	O	O	3446
may	AUX	O	O	3446
be	AUX	O	O	3446
caused	VERB	O	O	3446
by	ADP	O	O	3446
a	PRON	O	O	3446
steric	PROPN	O	O	3446
exclusion	NOUN	O	O	3446
effect	VERB	O	O	3446
of	ADP	O	O	3446
abundant	ADJ	O	O	3446
hyaluronate	NOUN	O	O	3446
.	PUNCT	O	O	3446
The	PRON	O	O	3447
endothelial	NOUN	O	O	3447
ultrastructure	NOUN	O	O	3447
was	AUX	O	O	3447
unaffected	ADJ	O	O	3447
by	ADP	O	O	3447
D	NOUN	O	O	3447
-	PUNCT	O	O	3447
pen	NOUN	O	O	3447
,	PUNCT	O	O	3447
and	CCONJ	O	O	3447
no	PRON	O	O	3447
differences	NOUN	O	O	3447
in	ADP	O	O	3447
aortic	ADJ	O	O	3447
131I	NUM	O	O	3447
-	PUNCT	O	O	3447
HSA	PROPN	O	O	3447
radioactivity	NOUN	O	O	3447
or	CCONJ	O	O	3447
aorta	NOUN	O	O	3447
/	PUNCT	O	O	3447
serum	NOUN	O	O	3447
-	PUNCT	O	O	3447
ratio	NOUN	O	O	3447
were	AUX	O	O	3447
recorded	VERB	O	O	3447
between	ADP	O	O	3447
experimental	ADJ	O	O	3447
and	CCONJ	O	O	3447
control	VERB	O	O	3447
groups	NOUN	O	O	3447
10	NUM	O	O	3447
minutes	NOUN	O	O	3447
after	ADP	O	O	3447
tracer	NOUN	O	O	3447
injection	NOUN	O	O	3447
,	PUNCT	O	O	3447
indicating	VERB	O	O	3447
that	SCONJ	O	O	3447
the	PRON	O	O	3447
permeability	NOUN	O	O	3447
of	ADP	O	O	3447
the	PRON	O	O	3447
endothelial	NOUN	O	O	3447
barrier	NOUN	O	O	3447
to	PART	O	O	3447
albumin	PROPN	O	O	3447
remained	VERB	O	O	3447
unaffected	ADJ	O	O	3447
by	ADP	O	O	3447
D	NOUN	O	O	3447
-	PUNCT	O	O	3447
pen	NOUN	O	O	3447
treatment	NOUN	O	O	3447
.	PUNCT	O	O	3447
These	PRON	O	O	3448
observations	NOUN	O	O	3448
support	NOUN	O	O	3448
the	PRON	O	O	3448
hypothesis	NOUN	O	O	3448
that	SCONJ	O	O	3448
treatment	NOUN	O	O	3448
with	ADP	O	O	3448
high	ADJ	O	O	3448
doses	NOUN	O	O	3448
of	ADP	O	O	3448
D	NOUN	O	O	3448
-	PUNCT	O	O	3448
pen	NOUN	O	O	3448
may	AUX	O	O	3448
induce	VERB	O	O	3448
a	PRON	O	O	3448
fibroproliferative	ADJ	O	O	3448
response	NOUN	O	O	3448
in	ADP	O	O	3448
rat	NOUN	O	O	3448
aorta	NOUN	O	O	3448
,	PUNCT	O	O	3448
possibly	ADV	O	O	3448
by	ADP	O	O	3448
an	PRON	O	O	3448
inhibitory	ADJ	O	O	3448
effect	VERB	O	O	3448
on	ADP	O	O	3448
the	PRON	O	O	3448
cross	VERB	O	O	3448
-	PUNCT	O	O	3448
linking	VERB	O	O	3448
of	ADP	O	O	3448
collagen	NOUN	O	O	3448
and	CCONJ	O	O	3448
elastin	VERB	O	O	3448
.	PUNCT	O	O	3448
Brain	NOUN	O	O	3451
natriuretic	ADJ	O	O	3451
peptide	NOUN	O	O	3451
is	AUX	O	O	3451
a	PRON	O	O	3451
predictor	NOUN	O	O	3451
of	ADP	O	O	3451
anthracycline	NOUN	O	Chemical	3451
-	PUNCT	O	O	3451
induced	VERB	O	O	3451
cardiotoxicity	NOUN	O	Disease	3451
.	PUNCT	O	O	3451
Anthracyclines	NOUN	O	O	3452
are	AUX	O	O	3452
effective	ADJ	O	O	3452
antineoplastic	ADJ	O	O	3452
drugs	NOUN	O	O	3452
,	PUNCT	O	O	3452
but	CCONJ	O	O	3452
they	PRON	O	O	3452
frequently	ADV	O	O	3452
cause	VERB	O	O	3452
dose	NOUN	O	O	3452
-	PUNCT	O	O	3452
related	ADJ	O	O	3452
cardiotoxicity	NOUN	O	Disease	3452
.	PUNCT	O	O	3452
The	PRON	O	O	3453
cardiotoxicity	NOUN	O	Disease	3453
of	ADP	O	O	3453
conventional	ADJ	O	O	3453
anthracycline	NOUN	O	Chemical	3453
therapy	NOUN	O	O	3453
highlights	VERB	O	O	3453
a	PRON	O	O	3453
need	VERB	O	O	3453
to	PART	O	O	3453
search	NOUN	O	O	3453
for	ADP	O	O	3453
methods	NOUN	O	O	3453
that	SCONJ	O	O	3453
are	AUX	O	O	3453
highly	ADV	O	O	3453
sensitive	ADJ	O	O	3453
and	CCONJ	O	O	3453
capable	ADJ	O	O	3453
of	ADP	O	O	3453
predicting	VERB	O	O	3453
cardiac dysfunction	NOUN	O	Disease	3453
.	PUNCT	O	O	3453
We	PRON	O	O	3454
measured	VERB	O	O	3454
the	PRON	O	O	3454
plasma	NOUN	O	O	3454
level	VERB	O	O	3454
of	ADP	O	O	3454
brain	NOUN	O	O	3454
natriuretic	ADJ	O	O	3454
peptide	NOUN	O	O	3454
(	PUNCT	O	O	3454
BNP	PROPN	O	O	3454
)	PUNCT	O	O	3454
to	PART	O	O	3454
determine	VERB	O	O	3454
whether	SCONJ	O	O	3454
BNP	PROPN	O	O	3454
might	AUX	O	O	3454
serve	VERB	O	O	3454
as	ADP	O	O	3454
a	PRON	O	O	3454
simple	ADJ	O	O	3454
diagnostic	ADJ	O	O	3454
indicator	NOUN	O	O	3454
of	ADP	O	O	3454
anthracycline	NOUN	O	Chemical	3454
-	PUNCT	O	O	3454
induced	VERB	O	O	3454
cardiotoxicity	NOUN	O	Disease	3454
in	ADP	O	O	3454
patients	NOUN	O	O	3454
with	ADP	O	O	3454
acute	ADJ	O	O	3454
leukemia	NOUN	O	Disease	3454
treated	VERB	O	O	3454
with	ADP	O	O	3454
a	PRON	O	O	3454
daunorubicin	VERB	O	Chemical	3454
(	PUNCT	O	O	3454
DNR)-containing	VERB	O	O	3454
regimen	NOUN	O	O	3454
.	PUNCT	O	O	3454
Thirteen	NUM	O	O	3455
patients	NOUN	O	O	3455
with	ADP	O	O	3455
acute	ADJ	O	O	3455
leukemia	NOUN	O	Disease	3455
were	AUX	O	O	3455
treated	VERB	O	O	3455
with	ADP	O	O	3455
a	PRON	O	O	3455
DNR	PROPN	O	O	3455
-	PUNCT	O	O	3455
containing	VERB	O	O	3455
regimen	NOUN	O	O	3455
.	PUNCT	O	O	3455
Three	NUM	O	O	3456
patients	NOUN	O	O	3456
developed	VERB	O	O	3456
congestive	ADJ	O	O	3456
heart failure	NOUN	O	Disease	3456
after	ADP	O	O	3456
the	PRON	O	O	3456
completion	NOUN	O	O	3456
of	ADP	O	O	3456
chemotherapy	NOUN	O	O	3456
.	PUNCT	O	O	3456
Five	NUM	O	O	3457
patients	NOUN	O	O	3457
were	AUX	O	O	3457
diagnosed	VERB	O	O	3457
as	ADP	O	O	3457
having	VERB	O	O	3457
subclinical	ADJ	O	O	3457
heart failure	NOUN	O	Disease	3457
after	ADP	O	O	3457
the	PRON	O	O	3457
completion	NOUN	O	O	3457
of	ADP	O	O	3457
chemotherapy	NOUN	O	O	3457
.	PUNCT	O	O	3457
The	PRON	O	O	3458
plasma	NOUN	O	O	3458
levels	NOUN	O	O	3458
of	ADP	O	O	3458
BNP	PROPN	O	O	3458
in	ADP	O	O	3458
all	PRON	O	O	3458
the	PRON	O	O	3458
patients	NOUN	O	O	3458
with	ADP	O	O	3458
clinical	ADJ	O	O	3458
and	CCONJ	O	O	3458
subclinical	ADJ	O	O	3458
heart failure	NOUN	O	Disease	3458
increased	VERB	O	O	3458
above	ADP	O	O	3458
the	PRON	O	O	3458
normal	ADJ	O	O	3458
limit	NOUN	O	O	3458
(	PUNCT	O	O	3458
40	NUM	O	O	3458
pg	PROPN	O	Chemical	3458
/	PUNCT	O	O	3458
ml	ADP	O	O	3458
)	PUNCT	O	O	3458
before	ADP	O	O	3458
the	PRON	O	O	3458
detection	NOUN	O	O	3458
of	ADP	O	O	3458
clinical	ADJ	O	O	3458
or	CCONJ	O	O	3458
subclinical	ADJ	O	O	3458
heart failure	NOUN	O	Disease	3458
by	ADP	O	O	3458
radionuclide	NOUN	O	O	3458
angiography	NOUN	O	O	3458
.	PUNCT	O	O	3458
On	ADP	O	O	3459
the	PRON	O	O	3459
other	ADJ	O	O	3459
hand	NOUN	O	O	3459
,	PUNCT	O	O	3459
BNP	PROPN	O	O	3459
did	VERB	O	O	3459
not	PART	O	O	3459
increase	VERB	O	O	3459
in	ADP	O	O	3459
the	PRON	O	O	3459
patients	NOUN	O	O	3459
without	ADP	O	O	3459
heart failure	NOUN	O	Disease	3459
given	VERB	O	O	3459
DNR	PROPN	O	O	3459
,	PUNCT	O	O	3459
even	ADV	O	O	3459
at	ADP	O	O	3459
more	ADJ	O	O	3459
than	ADP	O	O	3459
700	NUM	O	O	3459
mg	VERB	O	O	3459
/	PUNCT	O	O	3459
m(2	NUM	O	O	3459
)	PUNCT	O	O	3459
.	PUNCT	O	O	3459
The	PRON	O	O	3460
plasma	NOUN	O	O	3460
level	VERB	O	O	3460
of	ADP	O	O	3460
ANP	NOUN	O	O	3460
did	VERB	O	O	3460
not	PART	O	O	3460
always	ADV	O	O	3460
increase	VERB	O	O	3460
in	ADP	O	O	3460
all	PRON	O	O	3460
the	PRON	O	O	3460
patients	NOUN	O	O	3460
with	ADP	O	O	3460
clinical	ADJ	O	O	3460
and	CCONJ	O	O	3460
subclinical	ADJ	O	O	3460
heart failure	NOUN	O	Disease	3460
.	PUNCT	O	O	3460
These	PRON	O	O	3461
preliminary	ADJ	O	O	3461
results	VERB	O	O	3461
suggest	VERB	O	O	3461
that	SCONJ	O	O	3461
BNP	PROPN	O	O	3461
may	AUX	O	O	3461
be	AUX	O	O	3461
useful	ADJ	O	O	3461
as	ADP	O	O	3461
an	PRON	O	O	3461
early	ADV	O	O	3461
and	CCONJ	O	O	3461
sensitive	ADJ	O	O	3461
indicator	NOUN	O	O	3461
of	ADP	O	O	3461
anthracycline	NOUN	O	Chemical	3461
-	PUNCT	O	O	3461
induced	VERB	O	O	3461
cardiotoxicity	NOUN	O	Disease	3461
.	PUNCT	O	O	3461
Antibacterial	PROPN	O	O	3464
medication	NOUN	O	O	3464
use	VERB	O	O	3464
during	ADP	O	O	3464
pregnancy	NOUN	O	O	3464
and	CCONJ	O	O	3464
risk	NOUN	O	O	3464
of	ADP	O	O	3464
birth defects	NOUN	O	Disease	3464
:	PUNCT	O	O	3464
National	ADJ	O	O	3464
Birth	NOUN	O	O	3464
Defects	NOUN	O	O	3464
Prevention	NOUN	O	O	3464
Study	NOUN	O	O	3464
.	PUNCT	O	O	3464
OBJECTIVE	VERB	O	O	3465
:	PUNCT	O	O	3465
To	PART	O	O	3465
estimate	VERB	O	O	3465
the	PRON	O	O	3465
association	PROPN	O	O	3465
between	ADP	O	O	3465
antibacterial	ADJ	O	O	3465
medications	NOUN	O	O	3465
and	CCONJ	O	O	3465
selected	VERB	O	O	3465
birth defects	NOUN	O	Disease	3465
.	PUNCT	O	O	3465
Population	NOUN	O	O	3466
-	PUNCT	O	O	3466
based	VERB	O	O	3466
,	PUNCT	O	O	3466
multisite	ADJ	O	O	3466
,	PUNCT	O	O	3466
case	NOUN	O	O	3466
-	PUNCT	O	O	3466
control	VERB	O	O	3466
study	VERB	O	O	3466
of	ADP	O	O	3466
women	NOUN	O	O	3466
who	PRON	O	O	3466
had	VERB	O	O	3466
pregnancies	NOUN	O	O	3466
affected	VERB	O	O	3466
by	ADP	O	O	3466
1	X	O	O	3466
of	ADP	O	O	3466
more	ADJ	O	O	3466
than	ADP	O	O	3466
30	NUM	O	O	3466
eligible	ADJ	O	O	3466
major	ADJ	O	O	3466
birth defects	NOUN	O	Disease	3466
identified	VERB	O	O	3466
via	ADP	O	O	3466
birth	NOUN	O	O	3466
defect	NOUN	O	O	3466
surveillance	NOUN	O	O	3466
programs	NOUN	O	O	3466
in	ADP	O	O	3466
10	NUM	O	O	3466
states	VERB	O	O	3466
(	PUNCT	O	O	3466
n	CCONJ	O	O	3466
=	PUNCT	O	O	3466
13	NUM	O	O	3466
155	NUM	O	O	3466
)	PUNCT	O	O	3466
and	CCONJ	O	O	3466
control	VERB	O	O	3466
women	NOUN	O	O	3466
randomly	ADV	O	O	3466
selected	VERB	O	O	3466
from	ADP	O	O	3466
the	PRON	O	O	3466
same	ADJ	O	O	3466
geographical	ADJ	O	O	3466
regions	NOUN	O	O	3466
(	PUNCT	O	O	3466
n	CCONJ	O	O	3466
=	PUNCT	O	O	3466
4941	NUM	O	O	3466
)	PUNCT	O	O	3466
.	PUNCT	O	O	3466
Odds	NOUN	O	O	3467
ratios	VERB	O	O	3467
(	PUNCT	O	O	3467
ORs	NOUN	O	O	3467
)	PUNCT	O	O	3467
measuring	VERB	O	O	3467
the	PRON	O	O	3467
association	PROPN	O	O	3467
between	ADP	O	O	3467
antibacterial	ADJ	O	O	3467
use	VERB	O	O	3467
and	CCONJ	O	O	3467
selected	VERB	O	O	3467
birth defects	NOUN	O	Disease	3467
adjusted	VERB	O	O	3467
for	ADP	O	O	3467
potential	ADJ	O	O	3467
confounders	NOUN	O	O	3467
.	PUNCT	O	O	3467
Sulfonamides	NOUN	O	O	3468
were	AUX	O	O	3468
associated	VERB	O	O	3468
with	ADP	O	O	3468
anencephaly	ADJ	O	O	3468
(	PUNCT	O	O	3468
adjusted	VERB	O	O	3468
OR	CCONJ	O	O	3468
[	X	O	O	3468
AOR	PROPN	O	O	3468
]	PUNCT	O	O	3468
=	PUNCT	O	O	3468
3.4	NUM	O	O	3468
;	PUNCT	O	O	3468
95%	NOUN	O	O	3468
confidence	NOUN	O	O	3468
interval	NOUN	O	O	3468
[	X	O	O	3468
CI	NOUN	O	O	3468
]	PUNCT	O	O	3468
,	PUNCT	O	O	3468
1.3	NUM	O	O	3468
-	PUNCT	O	O	3468
8.8	NUM	O	O	3468
)	PUNCT	O	O	3468
,	PUNCT	O	O	3468
hypoplastic	ADJ	O	O	3468
left	VERB	O	O	3468
heart	NOUN	O	O	3468
syndrome	NOUN	O	O	3468
(	PUNCT	O	O	3468
AOR	PROPN	O	O	3468
=	PUNCT	O	O	3468
3.2	NUM	O	O	3468
;	PUNCT	O	O	3468
95%	NOUN	O	O	3468
CI	NOUN	O	O	3468
,	PUNCT	O	O	3468
1.3	NUM	O	O	3468
-	PUNCT	O	O	3468
7.6	NUM	O	O	3468
)	PUNCT	O	O	3468
,	PUNCT	O	O	3468
coarctation	NOUN	O	O	3468
of	ADP	O	O	3468
the	PRON	O	O	3468
aorta	NOUN	O	O	3468
(	PUNCT	O	O	3468
AOR	PROPN	O	O	3468
=	PUNCT	O	O	3468
2.7	NUM	O	O	3468
;	PUNCT	O	O	3468
95%	NOUN	O	O	3468
CI	NOUN	O	O	3468
,	PUNCT	O	O	3468
1.3	NUM	O	O	3468
-	PUNCT	O	O	3468
5.6	NUM	O	O	3468
)	PUNCT	O	O	3468
,	PUNCT	O	O	3468
choanal	ADV	O	O	3468
atresia	PRON	O	O	3468
(	PUNCT	O	O	3469
AOR	PROPN	O	O	3469
=	PUNCT	O	O	3469
8.0	NUM	O	O	3469
;	PUNCT	O	O	3469
95%	NOUN	O	O	3469
CI	NOUN	O	O	3469
,	PUNCT	O	O	3469
2.7	NUM	O	O	3469
-	PUNCT	O	O	3469
23.5	NUM	O	O	3469
)	PUNCT	O	O	3469
,	PUNCT	O	O	3469
transverse	ADV	O	O	3469
limb	NOUN	O	O	3469
deficiency	NOUN	O	O	3469
(	PUNCT	O	O	3469
AOR	PROPN	O	O	3469
=	PUNCT	O	O	3469
2.5	NUM	O	O	3469
;	PUNCT	O	O	3469
95%	NOUN	O	O	3469
CI	NOUN	O	O	3469
,	PUNCT	O	O	3469
1.0	NUM	O	O	3469
-	PUNCT	O	O	3469
5.9	NUM	O	O	3469
)	PUNCT	O	O	3469
,	PUNCT	O	O	3469
and	CCONJ	O	O	3469
diaphragmatic hernia	NOUN	O	Disease	3469
(	PUNCT	O	O	3469
AOR	PROPN	O	O	3469
=	PUNCT	O	O	3469
2.4	NUM	O	O	3469
;	PUNCT	O	O	3469
95%	NOUN	O	O	3469
CI	NOUN	O	O	3469
,	PUNCT	O	O	3469
1.1	NUM	O	O	3469
-	PUNCT	O	O	3469
5.4	NUM	O	O	3469
)	PUNCT	O	O	3469
.	PUNCT	O	O	3469
Nitrofurantoins	NOUN	O	O	3470
were	AUX	O	O	3470
associated	VERB	O	O	3470
with	ADP	O	O	3470
anophthalmia	NOUN	O	O	3470
or	CCONJ	O	O	3470
microphthalmos	ADV	O	O	3470
(	PUNCT	O	O	3470
AOR	PROPN	O	O	3470
=	PUNCT	O	O	3470
3.7	NUM	O	O	3470
;	PUNCT	O	O	3470
95%	NOUN	O	O	3470
CI	NOUN	O	O	3470
,	PUNCT	O	O	3470
1.1	NUM	O	O	3470
-	PUNCT	O	O	3470
12.2	NUM	O	O	3470
)	PUNCT	O	O	3470
,	PUNCT	O	O	3470
hypoplastic	ADJ	O	O	3470
left	VERB	O	O	3470
heart	NOUN	O	O	3470
syndrome	NOUN	O	O	3470
(	PUNCT	O	O	3470
AOR	PROPN	O	O	3470
=	PUNCT	O	O	3470
4.2	NUM	O	O	3470
;	PUNCT	O	O	3470
95%	NOUN	O	O	3470
CI	NOUN	O	O	3470
,	PUNCT	O	O	3470
1.9	NUM	O	O	3470
-	PUNCT	O	O	3470
9.1	NUM	O	O	3470
)	PUNCT	O	O	3470
,	PUNCT	O	O	3471
atrial	ADJ	O	O	3471
septal	ADJ	O	O	3471
defects	NOUN	O	O	3471
(	PUNCT	O	O	3471
AOR	PROPN	O	O	3471
=	PUNCT	O	O	3471
1.9	NUM	O	O	3471
;	PUNCT	O	O	3471
95%	NOUN	O	O	3471
CI	NOUN	O	O	3471
,	PUNCT	O	O	3471
1.1	NUM	O	O	3471
-	PUNCT	O	O	3471
3.4	NUM	O	O	3471
)	PUNCT	O	O	3471
,	PUNCT	O	O	3471
and	CCONJ	O	O	3471
cleft lip	NOUN	O	Disease	3471
with	ADP	O	O	3471
cleft palate	NOUN	O	Disease	3471
(	PUNCT	O	O	3471
AOR	PROPN	O	O	3471
=	PUNCT	O	O	3471
2.1	NUM	O	O	3471
;	PUNCT	O	O	3471
Other	ADJ	O	O	3472
antibacterial	ADJ	O	O	3472
agents	NOUN	O	O	3472
that	SCONJ	O	O	3472
showed	VERB	O	O	3472
associations	NOUN	O	O	3472
included	VERB	O	O	3472
erythromycins	VERB	O	O	3472
(	PUNCT	O	O	3472
2	X	O	O	3472
defects	NOUN	O	O	3472
)	PUNCT	O	O	3472
,	PUNCT	O	O	3472
penicillins	NOUN	O	Chemical	3472
(	PUNCT	O	O	3472
1	X	O	O	3472
defect	NOUN	O	O	3472
)	PUNCT	O	O	3472
,	PUNCT	O	O	3472
cephalosporins	VERB	O	Chemical	3472
(	PUNCT	O	O	3472
1	X	O	O	3472
defect	NOUN	O	O	3472
)	PUNCT	O	O	3472
,	PUNCT	O	O	3472
and	CCONJ	O	O	3472
quinolones	NOUN	O	O	3472
(	PUNCT	O	O	3472
1	X	O	O	3472
defect	NOUN	O	O	3472
)	PUNCT	O	O	3472
.	PUNCT	O	O	3472
CONCLUSIONS	NOUN	O	O	3473
:	PUNCT	O	O	3473
Reassuringly	ADV	O	O	3473
,	PUNCT	O	O	3473
penicillins	NOUN	O	Chemical	3473
,	PUNCT	O	O	3473
erythromycins	VERB	O	O	3473
,	PUNCT	O	O	3473
and	CCONJ	O	O	3473
cephalosporins	VERB	O	Chemical	3473
,	PUNCT	O	O	3473
although	SCONJ	O	O	3473
used	VERB	O	O	3473
commonly	ADV	O	O	3473
by	ADP	O	O	3473
pregnant	ADJ	O	O	3473
women	NOUN	O	O	3473
,	PUNCT	O	O	3473
were	AUX	O	O	3473
not	PART	O	O	3473
associated	VERB	O	O	3473
with	ADP	O	O	3473
many	ADJ	O	O	3473
birth defects	NOUN	O	Disease	3473
.	PUNCT	O	O	3473
Sulfonamides	NOUN	O	O	3474
and	CCONJ	O	O	3474
nitrofurantoins	NOUN	O	O	3474
were	AUX	O	O	3474
associated	VERB	O	O	3474
with	ADP	O	O	3474
several	ADJ	O	O	3474
birth defects	NOUN	O	Disease	3474
,	PUNCT	O	O	3474
indicating	VERB	O	O	3474
a	PRON	O	O	3474
need	VERB	O	O	3474
for	ADP	O	O	3474
additional	ADJ	O	O	3474
scrutiny	NOUN	O	O	3474
.	PUNCT	O	O	3474
Incidence	NOUN	O	O	3477
of	ADP	O	O	3477
neoplasms	NOUN	O	O	3477
in	ADP	O	O	3477
patients	NOUN	O	O	3477
with	ADP	O	O	3477
rheumatoid arthritis	NOUN	O	Disease	3477
exposed	VERB	O	O	3477
to	PART	O	O	3477
different	ADJ	O	O	3477
treatment	NOUN	O	O	3477
regimens	NOUN	O	O	3477
.	PUNCT	O	O	3477
Immunosuppressive	NOUN	O	O	3478
drugs	NOUN	O	O	3478
have	VERB	O	O	3478
been	AUX	O	O	3478
used	VERB	O	O	3478
during	ADP	O	O	3478
the	PRON	O	O	3478
last	VERB	O	O	3478
30	NUM	O	O	3478
years	NOUN	O	O	3478
in	ADP	O	O	3478
treatment	NOUN	O	O	3478
of	ADP	O	O	3478
patients	NOUN	O	O	3478
with	ADP	O	O	3478
severe	ADJ	O	O	3478
rheumatoid arthritis	NOUN	O	Disease	3478
.	PUNCT	O	O	3478
The	PRON	O	O	3479
drugs	NOUN	O	O	3479
commonly	ADV	O	O	3479
used	VERB	O	O	3479
are	AUX	O	O	3479
cyclophosphamide	VERB	O	Chemical	3479
and	CCONJ	O	O	3479
chlorambucil	NOUN	O	O	3479
(	PUNCT	O	O	3479
alkylating	VERB	O	O	3479
agents	NOUN	O	O	3479
)	PUNCT	O	O	3479
,	PUNCT	O	O	3479
azathioprine	ADV	O	Chemical	3479
(	PUNCT	O	O	3479
purine	NOUN	O	Chemical	3479
analogue	NOUN	O	O	3479
)	PUNCT	O	O	3479
,	PUNCT	O	O	3479
and	CCONJ	O	O	3479
methotrexate	CCONJ	O	Chemical	3479
(	PUNCT	O	O	3479
folic acid	NOUN	O	Chemical	3479
analogue	NOUN	O	O	3479
)	PUNCT	O	O	3479
.	PUNCT	O	O	3479
There	ADV	O	O	3480
is	AUX	O	O	3480
evidence	NOUN	O	O	3480
that	SCONJ	O	O	3480
all	PRON	O	O	3480
four	NUM	O	O	3480
immunosuppressive	ADJ	O	O	3480
drugs	NOUN	O	O	3480
can	AUX	O	O	3480
reduce	VERB	O	O	3480
synovitis	NOUN	O	Disease	3480
,	PUNCT	O	O	3480
but	CCONJ	O	O	3480
disease	PROPN	O	O	3480
activity	NOUN	O	O	3480
almost	ADV	O	O	3480
always	ADV	O	O	3480
recurs	VERB	O	O	3480
after	ADP	O	O	3480
therapy	NOUN	O	O	3480
is	AUX	O	O	3480
stopped	VERB	O	O	3480
.	PUNCT	O	O	3480
Patients	NOUN	O	O	3481
treated	VERB	O	O	3481
with	ADP	O	O	3481
alkylating	VERB	O	O	3481
agents	NOUN	O	O	3481
have	VERB	O	O	3481
an	PRON	O	O	3481
increased	VERB	O	O	3481
risk	NOUN	O	O	3481
of	ADP	O	O	3481
development	NOUN	O	O	3481
of	ADP	O	O	3481
acute	ADJ	O	O	3481
nonlymphocytic	ADJ	O	O	3481
leukemia	NOUN	O	Disease	3481
,	PUNCT	O	O	3481
and	CCONJ	O	O	3481
both	PRON	O	O	3481
alkylating	VERB	O	O	3481
agents	NOUN	O	O	3481
and	CCONJ	O	O	3481
azathioprine	ADV	O	Chemical	3481
are	AUX	O	O	3481
associated	VERB	O	O	3481
with	ADP	O	O	3481
the	PRON	O	O	3481
development	NOUN	O	O	3481
of	ADP	O	O	3481
non	ADJ	O	O	3481
-	PUNCT	O	O	3481
Hodgkin	PROPN	O	O	3481
's	AUX	O	O	3481
lymphoma	PROPN	O	Disease	3481
.	PUNCT	O	O	3481
Cyclophosphamide	PROPN	O	Chemical	3482
therapy	NOUN	O	O	3482
increases	VERB	O	O	3482
the	PRON	O	O	3482
risk	NOUN	O	O	3482
of	ADP	O	O	3482
carcinoma	NOUN	O	Disease	3482
of	ADP	O	O	3482
the	PRON	O	O	3482
bladder	NOUN	O	O	3482
.	PUNCT	O	O	3482
There	ADV	O	O	3483
have	VERB	O	O	3483
been	AUX	O	O	3483
several	ADJ	O	O	3483
long	ADV	O	O	3483
-	PUNCT	O	O	3483
term	NOUN	O	O	3483
studies	NOUN	O	O	3483
of	ADP	O	O	3483
patients	NOUN	O	O	3483
with	ADP	O	O	3483
rheumatoid arthritis	NOUN	O	Disease	3483
treated	VERB	O	O	3483
with	ADP	O	O	3483
azathioprine	ADV	O	Chemical	3483
and	CCONJ	O	O	3483
cyclophosphamide	VERB	O	Chemical	3483
and	CCONJ	O	O	3483
the	PRON	O	O	3483
incidence	NOUN	O	O	3483
of	ADP	O	O	3483
most	ADV	O	O	3483
of	ADP	O	O	3483
the	PRON	O	O	3483
common	ADJ	O	O	3483
cancers	NOUN	O	Disease	3483
is	AUX	O	O	3483
not	PART	O	O	3483
increased	VERB	O	O	3483
.	PUNCT	O	O	3483
Data	NOUN	O	O	3484
on	ADP	O	O	3484
the	PRON	O	O	3484
possible	ADJ	O	O	3484
increased	VERB	O	O	3484
risk	NOUN	O	O	3484
of	ADP	O	O	3484
malignancy	NOUN	O	Disease	3484
in	ADP	O	O	3484
rheumatoid arthritis	NOUN	O	Disease	3484
are	AUX	O	O	3484
still	ADV	O	O	3484
being	AUX	O	O	3484
collected	VERB	O	O	3484
,	PUNCT	O	O	3484
and	CCONJ	O	O	3484
until	ADP	O	O	3484
further	ADV	O	O	3484
information	NOUN	O	O	3484
is	AUX	O	O	3484
available	ADJ	O	O	3484
,	PUNCT	O	O	3484
the	PRON	O	O	3484
use	VERB	O	O	3484
of	ADP	O	O	3484
immunosuppressive	ADJ	O	O	3484
drugs	NOUN	O	O	3484
,	PUNCT	O	O	3484
particularly	ADV	O	O	3484
alkylating	VERB	O	O	3484
agents	NOUN	O	O	3484
,	PUNCT	O	O	3484
in	ADP	O	O	3484
the	PRON	O	O	3484
treatment	NOUN	O	O	3484
of	ADP	O	O	3484
rheumatoid arthritis	NOUN	O	Disease	3484
should	AUX	O	O	3484
be	AUX	O	O	3484
reserved	VERB	O	O	3484
for	ADP	O	O	3484
patients	NOUN	O	O	3484
with	ADP	O	O	3484
severe	ADJ	O	O	3484
progressive	ADJ	O	O	3484
disease	PROPN	O	O	3484
or	CCONJ	O	O	3484
life	NOUN	O	O	3484
-	PUNCT	O	O	3484
threatening	VERB	O	O	3484
complications	NOUN	O	O	3484
.	PUNCT	O	O	3484
Patterns	NOUN	O	O	3487
of	ADP	O	O	3487
hepatic injury	NOUN	O	Disease	3487
induced	VERB	O	O	3487
by	ADP	O	O	3487
methyldopa	ADJ	O	Chemical	3487
.	PUNCT	O	O	3487
Twelve	NUM	O	O	3488
patients	NOUN	O	O	3488
with	ADP	O	O	3488
liver disease	NOUN	O	Disease	3488
related	ADJ	O	O	3488
to	PART	O	O	3488
methyldopa	ADJ	O	Chemical	3488
were	AUX	O	O	3488
seen	VERB	O	O	3488
between	ADP	O	O	3488
1967	NUM	O	O	3488
and	CCONJ	O	O	3488
1977	NUM	O	O	3488
.	PUNCT	O	O	3488
Jaundice	NOUN	O	O	3489
with	ADP	O	O	3489
tender	ADJ	O	O	3489
hepatomegaly	NOUN	O	Disease	3489
,	PUNCT	O	O	3489
usually	ADV	O	O	3489
preceded	VERB	O	O	3489
by	ADP	O	O	3489
symptoms	NOUN	O	O	3489
of	ADP	O	O	3489
malaise	NOUN	O	Disease	3489
,	PUNCT	O	O	3489
anorexia	X	O	Disease	3489
,	PUNCT	O	O	3489
nausea	NOUN	O	Disease	3489
and	CCONJ	O	O	3489
vomiting	VERB	O	Disease	3489
,	PUNCT	O	O	3489
and	CCONJ	O	O	3489
associated	VERB	O	O	3489
with	ADP	O	O	3489
upper	ADJ	O	O	3489
abdominal pain	NOUN	O	Disease	3489
,	PUNCT	O	O	3489
was	AUX	O	O	3489
an	PRON	O	O	3489
invariable	ADJ	O	O	3489
finding	VERB	O	O	3489
in	ADP	O	O	3489
all	PRON	O	O	3489
patients	NOUN	O	O	3489
.	PUNCT	O	O	3489
Biochemical	ADJ	O	O	3490
liver	NOUN	O	O	3490
function	NOUN	O	O	3490
tests	VERB	O	O	3490
indicated	VERB	O	O	3490
hepatocellular	NOUN	O	O	3490
necrosis	NOUN	O	Disease	3490
and	CCONJ	O	O	3490
correlated	VERB	O	O	3490
with	ADP	O	O	3490
histopathological	ADJ	O	O	3490
evidence	NOUN	O	O	3490
of	ADP	O	O	3490
hepatic injury	NOUN	O	Disease	3490
,	PUNCT	O	O	3490
the	PRON	O	O	3490
spectrum	NOUN	O	O	3490
of	ADP	O	O	3490
which	PRON	O	O	3490
ranged	VERB	O	O	3490
from	ADP	O	O	3490
fatty	ADJ	O	O	3490
change	VERB	O	O	3490
and	CCONJ	O	O	3490
focal	ADJ	O	O	3490
hepatocellular	NOUN	O	O	3490
necrosis	NOUN	O	Disease	3490
to	PART	O	O	3490
massive	ADJ	O	O	3490
hepatic	ADJ	O	O	3490
necrosis	NOUN	O	Disease	3490
.	PUNCT	O	O	3490
Most	ADV	O	O	3491
patients	NOUN	O	O	3491
showed	VERB	O	O	3491
moderate	ADJ	O	O	3491
to	PART	O	O	3491
severe	ADJ	O	O	3491
acute	ADJ	O	O	3491
hepatitis	NOUN	O	Disease	3491
or	CCONJ	O	O	3491
chronic	ADJ	O	O	3491
active	ADJ	O	O	3491
hepatitis	NOUN	O	Disease	3491
with	ADP	O	O	3491
associated	VERB	O	O	3491
cholestasis	NOUN	O	Disease	3491
.	PUNCT	O	O	3491
One	NUM	O	O	3492
patient	NOUN	O	O	3492
died	VERB	O	O	3492
,	PUNCT	O	O	3492
having	VERB	O	O	3492
presented	VERB	O	O	3492
in	ADP	O	O	3492
hepatic failure	NOUN	O	Disease	3492
,	PUNCT	O	O	3492
and	CCONJ	O	O	3492
another	PRON	O	O	3492
,	PUNCT	O	O	3492
who	PRON	O	O	3492
had	VERB	O	O	3492
been	AUX	O	O	3492
taking	VERB	O	O	3492
methyldopa	ADJ	O	Chemical	3492
for	ADP	O	O	3492
7	NUM	O	O	3492
years	NOUN	O	O	3492
,	PUNCT	O	O	3492
showed	VERB	O	O	3492
slower	ADJ	O	O	3492
clinical	ADJ	O	O	3492
and	CCONJ	O	O	3492
biochemical	ADJ	O	O	3492
resolution	NOUN	O	O	3492
over	ADP	O	O	3492
a	PRON	O	O	3492
period	NOUN	O	O	3492
of	ADP	O	O	3492
several	ADJ	O	O	3492
months	NOUN	O	O	3492
.	PUNCT	O	O	3492
The	PRON	O	O	3493
remaining	VERB	O	O	3493
patient	NOUN	O	O	3493
in	ADP	O	O	3493
the	PRON	O	O	3493
series	PROPN	O	O	3493
developed	VERB	O	O	3493
fulminant	ADJ	O	O	3493
hepatitis	NOUN	O	Disease	3493
when	SCONJ	O	O	3493
the	PRON	O	O	3493
drug	NOUN	O	O	3493
was	AUX	O	O	3493
accidentally	ADV	O	O	3493
recommenced	VERB	O	O	3493
1	X	O	O	3493
year	NOUN	O	O	3493
after	ADP	O	O	3493
a	PRON	O	O	3493
prior	ADV	O	O	3493
episode	PROPN	O	O	3493
of	ADP	O	O	3493
methyldopa	ADJ	O	Chemical	3493
-	PUNCT	O	O	3493
induced	VERB	O	O	3493
hepatitis	NOUN	O	Disease	3493
.	PUNCT	O	O	3493
In	ADP	O	O	3494
this	PRON	O	O	3494
latter	ADJ	O	O	3494
patient	NOUN	O	O	3494
,	PUNCT	O	O	3494
and	CCONJ	O	O	3494
in	ADP	O	O	3494
2	X	O	O	3494
others	NOUN	O	O	3494
,	PUNCT	O	O	3494
the	PRON	O	O	3494
causal	NOUN	O	O	3494
relationship	NOUN	O	O	3494
between	ADP	O	O	3494
methyldopa	ADJ	O	Chemical	3494
and	CCONJ	O	O	3494
hepatic	ADJ	O	O	3494
dysfunction	NOUN	O	O	3494
was	AUX	O	O	3494
proved	VERB	O	O	3494
with	ADP	O	O	3494
the	PRON	O	O	3494
recurrence	NOUN	O	O	3494
of	ADP	O	O	3494
hepatitis	NOUN	O	Disease	3494
within	ADP	O	O	3494
2	X	O	O	3494
weeks	NOUN	O	O	3494
of	ADP	O	O	3494
re	ADP	O	O	3494
-	PUNCT	O	O	3494
exposure	NOUN	O	O	3494
to	PART	O	O	3494
the	PRON	O	O	3494
drug	NOUN	O	O	3494
.	PUNCT	O	O	3494
A	PRON	O	O	3497
phase	NOUN	O	O	3497
I	PRON	O	O	3497
/	PUNCT	O	O	3497
II	NUM	O	O	3497
study	VERB	O	O	3497
of	ADP	O	O	3497
paclitaxel	NOUN	O	Chemical	3497
plus	CCONJ	O	O	3497
cisplatin	NOUN	O	Chemical	3497
as	ADP	O	O	3497
first	ADV	O	O	3497
-	PUNCT	O	O	3497
line	NOUN	O	O	3497
therapy	NOUN	O	O	3497
for	ADP	O	O	3497
head	NOUN	O	O	3497
and	CCONJ	O	O	3497
neck	NOUN	O	O	3497
cancers	NOUN	O	Disease	3497
:	PUNCT	O	O	3497
preliminary	ADJ	O	O	3497
results	VERB	O	O	3497
.	PUNCT	O	O	3497
Improved	VERB	O	O	3498
outcomes	NOUN	O	O	3498
among	ADP	O	O	3498
patients	NOUN	O	O	3498
with	ADP	O	O	3498
head	NOUN	O	O	3498
and	CCONJ	O	O	3498
neck	NOUN	O	O	3498
carcinomas	VERB	O	O	3498
require	VERB	O	O	3498
investigations	NOUN	O	O	3498
of	ADP	O	O	3498
new	ADJ	O	O	3498
drugs	NOUN	O	O	3498
for	ADP	O	O	3498
induction	NOUN	O	O	3498
therapy	NOUN	O	O	3498
.	PUNCT	O	O	3498
Preliminary	PROPN	O	O	3499
results	VERB	O	O	3499
of	ADP	O	O	3499
an	PRON	O	O	3499
Eastern	PROPN	O	O	3499
Cooperative	ADJ	O	O	3499
Oncology	NOUN	O	O	3499
Group	PROPN	O	O	3499
study	VERB	O	O	3499
of	ADP	O	O	3499
single	ADJ	O	O	3499
-	PUNCT	O	O	3499
agent	NOUN	O	O	3499
paclitaxel	NOUN	O	Chemical	3499
(	PUNCT	O	O	3499
Taxol	PROPN	O	Chemical	3499
;	PUNCT	O	O	3499
Bristol	PROPN	O	O	3499
-	PUNCT	O	O	3499
Myers	PROPN	O	O	3499
Squibb	PROPN	O	O	3499
Company	NOUN	O	O	3499
,	PUNCT	O	O	3499
Princeton	PROPN	O	O	3499
,	PUNCT	O	O	3499
NJ	PROPN	O	O	3499
)	PUNCT	O	O	3499
reported	VERB	O	O	3499
a	PRON	O	O	3499
37%	NOUN	O	O	3499
response	NOUN	O	O	3499
rate	NOUN	O	O	3499
in	ADP	O	O	3499
patients	NOUN	O	O	3499
with	ADP	O	O	3499
head	NOUN	O	O	3499
and	CCONJ	O	O	3499
neck	NOUN	O	O	3499
cancer	NOUN	O	Disease	3499
,	PUNCT	O	O	3499
and	CCONJ	O	O	3499
the	PRON	O	O	3499
paclitaxel	NOUN	O	Chemical	3499
/	PUNCT	O	O	3499
cisplatin	NOUN	O	Chemical	3499
combination	NOUN	O	O	3499
has	VERB	O	O	3499
been	AUX	O	O	3499
used	VERB	O	O	3499
successfully	ADV	O	O	3499
and	CCONJ	O	O	3499
has	VERB	O	O	3499
significantly	ADV	O	O	3499
improved	VERB	O	O	3499
median	ADJ	O	O	3499
response	NOUN	O	O	3499
duration	NOUN	O	O	3499
in	ADP	O	O	3499
ovarian cancer	NOUN	O	Disease	3499
patients	NOUN	O	O	3499
.	PUNCT	O	O	3499
We	PRON	O	O	3500
initiated	VERB	O	O	3500
a	PRON	O	O	3500
phase	NOUN	O	O	3500
I	PRON	O	O	3500
/	PUNCT	O	O	3500
II	NUM	O	O	3500
trial	NOUN	O	O	3500
to	PART	O	O	3500
determine	VERB	O	O	3500
the	PRON	O	O	3500
response	NOUN	O	O	3500
and	CCONJ	O	O	3500
toxicity	NOUN	O	Disease	3500
of	ADP	O	O	3500
escalating	VERB	O	O	3500
paclitaxel	NOUN	O	Chemical	3500
doses	NOUN	O	O	3500
combined	VERB	O	O	3500
with	ADP	O	O	3500
fixed	VERB	O	O	3500
-	PUNCT	O	O	3500
dose	NOUN	O	O	3500
cisplatin	NOUN	O	Chemical	3500
with	ADP	O	O	3500
granulocyte	NOUN	O	O	3500
colony	NOUN	O	O	3500
-	PUNCT	O	O	3500
stimulating	VERB	O	O	3500
factor	NOUN	O	O	3500
support	NOUN	O	O	3500
in	ADP	O	O	3500
patients	NOUN	O	O	3500
with	ADP	O	O	3500
untreated	ADJ	O	O	3500
locally	ADV	O	O	3500
advanced	ADJ	O	O	3500
inoperable	ADJ	O	O	3500
head	NOUN	O	O	3500
and	CCONJ	O	O	3500
neck	NOUN	O	O	3500
carcinoma	NOUN	O	Disease	3500
.	PUNCT	O	O	3500
Primary	NOUN	O	O	3501
tumor	NOUN	O	Disease	3501
sites	NOUN	O	O	3501
were	AUX	O	O	3501
oropharynx	NOUN	O	O	3501
,	PUNCT	O	O	3501
10	NUM	O	O	3501
patients	NOUN	O	O	3501
;	PUNCT	O	O	3501
hypopharynx	NOUN	O	O	3501
,	PUNCT	O	O	3501
four	NUM	O	O	3501
;	PUNCT	O	O	3501
larynx	NOUN	O	O	3501
,	PUNCT	O	O	3501
two	NUM	O	O	3501
;	PUNCT	O	O	3501
oral	ADJ	O	O	3501
cavity	NOUN	O	O	3501
,	PUNCT	O	O	3501
three	NUM	O	O	3501
;	PUNCT	O	O	3501
unknown	ADJ	O	O	3501
primary	NOUN	O	O	3501
,	PUNCT	O	O	3501
two	NUM	O	O	3501
;	PUNCT	O	O	3501
and	CCONJ	O	O	3501
nasal	ADJ	O	O	3501
cavity	NOUN	O	O	3501
and	CCONJ	O	O	3501
parotid	NOUN	O	O	3501
gland	NOUN	O	O	3501
,	PUNCT	O	O	3501
one	NUM	O	O	3501
each	PRON	O	O	3501
.	PUNCT	O	O	3501
Of	ADV	O	O	3502
20	NUM	O	O	3502
patients	NOUN	O	O	3502
evaluable	ADJ	O	O	3502
for	ADP	O	O	3502
toxicity	NOUN	O	Disease	3502
,	PUNCT	O	O	3502
four	NUM	O	O	3502
had	VERB	O	O	3502
stage	NOUN	O	O	3502
III	NUM	O	O	3502
and	CCONJ	O	O	3502
16	NUM	O	O	3502
had	VERB	O	O	3502
stage	NOUN	O	O	3502
IV	NUM	O	O	3502
disease	PROPN	O	O	3502
.	PUNCT	O	O	3502
Treatment	NOUN	O	O	3503
,	PUNCT	O	O	3503
given	VERB	O	O	3503
every	PRON	O	O	3503
21	NUM	O	O	3503
days	NOUN	O	O	3503
for	ADP	O	O	3503
a	PRON	O	O	3503
maximum	ADV	O	O	3503
of	ADP	O	O	3503
three	NUM	O	O	3503
cycles	NOUN	O	O	3503
,	PUNCT	O	O	3503
consisted	VERB	O	O	3503
of	ADP	O	O	3503
paclitaxel	NOUN	O	Chemical	3503
by	ADP	O	O	3503
3-hour	NOUN	O	O	3503
infusion	NOUN	O	O	3503
followed	VERB	O	O	3503
the	PRON	O	O	3503
next	ADV	O	O	3503
day	NOUN	O	O	3503
by	ADP	O	O	3503
a	PRON	O	O	3503
fixed	VERB	O	O	3503
dose	NOUN	O	O	3503
of	ADP	O	O	3503
cisplatin	NOUN	O	Chemical	3503
(	PUNCT	O	O	3503
75	NUM	O	O	3503
mg	VERB	O	O	3503
/	PUNCT	O	O	3503
m2	PROPN	O	O	3503
)	PUNCT	O	O	3503
.	PUNCT	O	O	3503
The	PRON	O	O	3504
dose	NOUN	O	O	3504
levels	NOUN	O	O	3504
incorporate	VERB	O	O	3504
escalating	VERB	O	O	3504
paclitaxel	NOUN	O	Chemical	3504
doses	NOUN	O	O	3504
,	PUNCT	O	O	3504
and	CCONJ	O	O	3504
intrapatient	NOUN	O	O	3504
escalations	NOUN	O	O	3504
within	ADP	O	O	3504
a	PRON	O	O	3504
given	VERB	O	O	3504
dose	NOUN	O	O	3504
level	VERB	O	O	3504
are	AUX	O	O	3504
permitted	VERB	O	O	3504
if	SCONJ	O	O	3504
toxicity	NOUN	O	Disease	3504
permits	VERB	O	O	3504
.	PUNCT	O	O	3504
With	ADP	O	O	3505
paclitaxel	NOUN	O	Chemical	3505
doses	NOUN	O	O	3505
of	ADP	O	O	3505
200	NUM	O	O	3505
mg	VERB	O	O	3505
/	PUNCT	O	O	3505
m2	PROPN	O	O	3505
and	CCONJ	O	O	3505
higher	ADJ	O	O	3505
,	PUNCT	O	O	3505
granulocyte	NOUN	O	O	3505
colony	NOUN	O	O	3505
-	PUNCT	O	O	3505
stimulating	VERB	O	O	3505
factor	NOUN	O	O	3505
5	NUM	O	O	3505
micrograms	NOUN	O	O	3505
/	PUNCT	O	O	3505
kg	VERB	O	O	3505
/	PUNCT	O	O	3505
d	X	O	O	3505
is	AUX	O	O	3505
given	VERB	O	O	3505
(	PUNCT	O	O	3505
days	NOUN	O	O	3505
4	NUM	O	O	3505
through	ADP	O	O	3505
12	NUM	O	O	3505
)	PUNCT	O	O	3505
.	PUNCT	O	O	3505
Alopecia	NOUN	O	O	3506
,	PUNCT	O	O	3506
paresthesias	PROPN	O	O	3506
,	PUNCT	O	O	3506
and	CCONJ	O	O	3506
arthralgias	NOUN	O	O	3506
/	PUNCT	O	O	3507
myalgias	PROPN	O	O	3507
have	VERB	O	O	3507
occurred	VERB	O	O	3507
frequently	ADV	O	O	3507
,	PUNCT	O	O	3507
but	CCONJ	O	O	3507
with	ADP	O	O	3507
one	NUM	O	O	3507
exception	NOUN	O	O	3507
(	PUNCT	O	O	3507
a	PRON	O	O	3507
grade	NOUN	O	O	3507
3	X	O	O	3507
myalgia	NOUN	O	Disease	3507
)	PUNCT	O	O	3507
they	PRON	O	O	3507
have	VERB	O	O	3507
been	AUX	O	O	3507
grade	NOUN	O	O	3507
1	X	O	O	3507
or	CCONJ	O	O	3507
2	X	O	O	3507
.	PUNCT	O	O	3507
No	PRON	O	O	3508
dose	NOUN	O	O	3508
-	PUNCT	O	O	3508
limiting	VERB	O	O	3508
hematologic toxicity	NOUN	O	Disease	3508
has	VERB	O	O	3508
been	AUX	O	O	3508
seen	VERB	O	O	3508
.	PUNCT	O	O	3508
Paclitaxel	PROPN	O	Chemical	3509
/	PUNCT	O	O	3509
cisplatin	NOUN	O	Chemical	3509
is	AUX	O	O	3509
an	PRON	O	O	3509
effective	ADJ	O	O	3509
first	ADV	O	O	3509
-	PUNCT	O	O	3509
line	NOUN	O	O	3509
regimen	NOUN	O	O	3509
for	ADP	O	O	3509
locoregionally	ADV	O	O	3509
advanced	ADJ	O	O	3509
head	NOUN	O	O	3509
and	CCONJ	O	O	3509
neck	NOUN	O	O	3509
cancer	NOUN	O	Disease	3509
and	CCONJ	O	O	3509
continued	VERB	O	O	3509
study	VERB	O	O	3509
is	AUX	O	O	3509
warranted	VERB	O	O	3509
.	PUNCT	O	O	3509
Results	NOUN	O	O	3510
thus	ADV	O	O	3510
far	ADV	O	O	3510
suggest	VERB	O	O	3510
no	PRON	O	O	3510
dose	NOUN	O	O	3510
-	PUNCT	O	O	3510
response	NOUN	O	O	3510
effect	VERB	O	O	3510
for	ADP	O	O	3510
paclitaxel	NOUN	O	Chemical	3510
doses	NOUN	O	O	3510
above	ADP	O	O	3510
200	NUM	O	O	3510
mg	VERB	O	O	3510
/	PUNCT	O	O	3510
m2	PROPN	O	O	3510
.	PUNCT	O	O	3510
A	PRON	O	O	3513
phase	NOUN	O	O	3513
I	PRON	O	O	3513
study	VERB	O	O	3513
of	ADP	O	O	3513
4'-0-tetrahydropyranyladriamycin	NOUN	O	O	3513
.	PUNCT	O	O	3513
A	PRON	O	O	3514
Phase	NOUN	O	O	3514
I	PRON	O	O	3514
study	VERB	O	O	3514
of	ADP	O	O	3514
intravenous	ADJ	O	O	3514
(	PUNCT	O	O	3514
IV	NUM	O	O	3514
)	PUNCT	O	O	3514
bolus	NOUN	O	O	3514
4'-0-tetrahydropyranyladriamycin	NOUN	O	O	3514
(	PUNCT	O	O	3514
Pirarubicin	PROPN	O	O	3514
)	PUNCT	O	O	3514
was	AUX	O	O	3514
done	VERB	O	O	3514
in	ADP	O	O	3514
55	NUM	O	O	3514
patients	NOUN	O	O	3514
in	ADP	O	O	3514
good	ADJ	O	O	3514
performance	NOUN	O	O	3514
status	NOUN	O	O	3514
with	ADP	O	O	3514
refractory	ADJ	O	O	3514
tumors	NOUN	O	Disease	3514
.	PUNCT	O	O	3514
Twenty	NUM	O	O	3515
-	PUNCT	O	O	3515
six	NUM	O	O	3515
had	VERB	O	O	3515
minimal	ADJ	O	O	3515
prior	ADV	O	O	3515
therapy	NOUN	O	O	3515
(	PUNCT	O	O	3515
good	ADJ	O	O	3515
risk	NOUN	O	O	3515
)	PUNCT	O	O	3515
,	PUNCT	O	O	3515
23	NUM	O	O	3515
had	VERB	O	O	3515
extensive	ADJ	O	O	3515
prior	ADV	O	O	3515
therapy	NOUN	O	O	3515
(	PUNCT	O	O	3515
poor	ADJ	O	O	3515
risk	NOUN	O	O	3515
)	PUNCT	O	O	3515
,	PUNCT	O	O	3515
and	CCONJ	O	O	3515
six	NUM	O	O	3515
had	VERB	O	O	3515
renal	ADJ	O	O	3515
and/or	CCONJ	O	O	3515
hepatic	ADJ	O	O	3515
dysfunction	NOUN	O	O	3515
.	PUNCT	O	O	3515
The	PRON	O	O	3516
dose	NOUN	O	O	3516
-	PUNCT	O	O	3516
limiting	VERB	O	O	3516
toxic	ADJ	O	O	3516
effect	VERB	O	O	3516
was	AUX	O	O	3516
transient	ADJ	O	O	3516
noncumulative	ADJ	O	O	3516
granulocytopenia	PROPN	O	Disease	3516
.	PUNCT	O	O	3516
Less	ADV	O	O	3517
frequent	ADJ	O	O	3517
toxic	ADJ	O	O	3517
effects	NOUN	O	O	3517
included	VERB	O	O	3517
thrombocytopenia	PROPN	O	Disease	3517
,	PUNCT	O	O	3517
anemia	NOUN	O	Disease	3517
,	PUNCT	O	O	3517
nausea	NOUN	O	Disease	3517
,	PUNCT	O	O	3517
mild	ADJ	O	O	3517
alopecia	NOUN	O	O	3517
,	PUNCT	O	O	3517
phlebitis	NOUN	O	O	3517
,	PUNCT	O	O	3517
and	CCONJ	O	O	3517
mucositis	NOUN	O	Disease	3517
.	PUNCT	O	O	3517
Myelosuppression	NOUN	O	O	3518
was	AUX	O	O	3518
more	ADJ	O	O	3518
in	ADP	O	O	3518
patients	NOUN	O	O	3518
with	ADP	O	O	3518
hepatic	ADJ	O	O	3518
dysfunction	NOUN	O	O	3518
.	PUNCT	O	O	3518
Pharmacokinetic	NOUN	O	O	3519
analyses	NOUN	O	O	3519
in	ADP	O	O	3519
21	NUM	O	O	3519
patients	NOUN	O	O	3519
revealed	VERB	O	O	3519
Pirarubicin	PROPN	O	O	3519
plasma	NOUN	O	O	3519
T	NOUN	O	Chemical	3519
1/2	NUM	O	O	3519
alpha	PROPN	O	O	3519
(	PUNCT	O	O	3519
+	ADP	O	O	3519
/-	PUNCT	O	O	3519
Adriamycinol	NOUN	O	O	3520
,	PUNCT	O	O	3520
doxorubicin	VERB	O	Chemical	3520
,	PUNCT	O	O	3520
adriamycinone	NOUN	O	O	3520
,	PUNCT	O	O	3520
and	CCONJ	O	O	3520
tetrahydropyranyladriamycinol	NOUN	O	O	3520
were	AUX	O	O	3520
the	PRON	O	O	3520
metabolites	VERB	O	O	3520
detected	VERB	O	O	3520
in	ADP	O	O	3520
plasma	NOUN	O	O	3520
and	CCONJ	O	O	3520
the	PRON	O	O	3520
amount	NOUN	O	O	3520
of	ADP	O	O	3520
doxorubicin	VERB	O	Chemical	3520
was	AUX	O	O	3520
less	ADV	O	O	3520
than	ADP	O	O	3520
or	CCONJ	O	O	3520
equal	ADJ	O	O	3520
to	PART	O	O	3520
10%	NOUN	O	O	3520
of	ADP	O	O	3520
the	PRON	O	O	3520
total	ADJ	O	O	3520
metabolites	VERB	O	O	3520
.	PUNCT	O	O	3520
Urinary	NOUN	O	O	3521
excretion	NOUN	O	O	3521
of	ADP	O	O	3521
Pirarubicin	PROPN	O	O	3521
in	ADP	O	O	3521
the	PRON	O	O	3521
first	ADV	O	O	3521
24	NUM	O	O	3521
hours	NOUN	O	O	3521
was	AUX	O	O	3521
less	ADV	O	O	3521
than	ADP	O	O	3521
or	CCONJ	O	O	3521
equal	ADJ	O	O	3521
to	PART	O	O	3521
10%	NOUN	O	O	3521
.	PUNCT	O	O	3521
Activity	NOUN	O	O	3522
was	AUX	O	O	3522
noted	VERB	O	O	3522
in	ADP	O	O	3522
mesothelioma	NOUN	O	Disease	3522
,	PUNCT	O	O	3522
leiomyosarcoma	PROPN	O	O	3522
,	PUNCT	O	O	3522
and	CCONJ	O	O	3522
basal	PROPN	O	O	3522
cell	NOUN	O	O	3522
carcinoma	NOUN	O	Disease	3522
.	PUNCT	O	O	3522
Differential	ADJ	O	O	3525
effects	NOUN	O	O	3525
of	ADP	O	O	3525
gamma	PROPN	O	O	3525
-	PUNCT	O	O	3525
hexachlorocyclohexane	VERB	O	O	3525
(	PUNCT	O	O	3525
lindane	NOUN	O	Chemical	3525
)	PUNCT	O	O	3525
on	ADP	O	O	3525
pharmacologically	ADV	O	O	3525
-	PUNCT	O	O	3525
induced	VERB	O	O	3525
seizures	NOUN	O	Disease	3525
.	PUNCT	O	O	3525
Gamma	PROPN	O	O	3526
-	PUNCT	O	O	3526
hexachlorocyclohexane	VERB	O	O	3526
(	PUNCT	O	O	3526
gamma	PROPN	O	O	3526
-	PUNCT	O	O	3526
HCH	PROPN	O	O	3526
)	PUNCT	O	O	3526
,	PUNCT	O	O	3526
the	PRON	O	O	3526
active	ADJ	O	O	3526
ingredient	NOUN	O	O	3526
of	ADP	O	O	3526
the	PRON	O	O	3526
insecticide	NOUN	O	O	3526
lindane	NOUN	O	Chemical	3526
,	PUNCT	O	O	3526
has	VERB	O	O	3526
been	AUX	O	O	3526
shown	VERB	O	O	3526
to	PART	O	O	3526
decrease	VERB	O	O	3526
seizure	NOUN	O	Disease	3526
threshold	NOUN	O	O	3526
to	PART	O	O	3526
pentylenetrazol	NOUN	O	O	3526
(	PUNCT	O	O	3526
PTZ	PROPN	O	Chemical	3526
)	PUNCT	O	O	3526
3	X	O	O	3526
h	X	O	O	3526
after	ADP	O	O	3526
exposure	NOUN	O	O	3526
to	PART	O	O	3526
gamma	PROPN	O	O	3526
-	PUNCT	O	O	3526
HCH	PROPN	O	O	3526
and	CCONJ	O	O	3526
conversely	ADV	O	O	3526
increase	VERB	O	O	3526
threshold	NOUN	O	O	3526
to	PART	O	O	3526
PTZ	PROPN	O	Chemical	3526
-	PUNCT	O	O	3526
induced	VERB	O	O	3526
seizures	NOUN	O	Disease	3526
24	NUM	O	O	3526
h	X	O	O	3526
after	ADP	O	O	3526
exposure	NOUN	O	O	3526
to	PART	O	O	3526
gamma	PROPN	O	O	3526
-	PUNCT	O	O	3526
HCH	PROPN	O	O	3526
(	PUNCT	O	O	3526
Vohland	PROPN	O	O	3526
et	PRON	O	O	3526
al	PROPN	O	O	3526
.	PUNCT	O	O	3526
1981	NUM	O	O	3526
)	PUNCT	O	O	3526
.	PUNCT	O	O	3526
In	ADP	O	O	3527
this	PRON	O	O	3527
study	VERB	O	O	3527
,	PUNCT	O	O	3527
the	PRON	O	O	3527
severity	NOUN	O	O	3527
of	ADP	O	O	3527
response	NOUN	O	O	3527
to	PART	O	O	3527
other	ADJ	O	O	3527
seizure	NOUN	O	Disease	3527
-	PUNCT	O	O	3527
inducing	VERB	O	O	3527
agents	NOUN	O	O	3527
was	AUX	O	O	3527
tested	VERB	O	O	3527
in	ADP	O	O	3527
mice	NOUN	O	O	3527
1	X	O	O	3527
and	CCONJ	O	O	3527
24	NUM	O	O	3527
h	X	O	O	3527
after	ADP	O	O	3527
intraperitoneal	ADJ	O	O	3527
administration	NOUN	O	O	3527
of	ADP	O	O	3527
80	NUM	O	O	3527
mg	VERB	O	O	3527
/	PUNCT	O	O	3528
kg	VERB	O	O	3528
gamma	PROPN	O	O	3528
-	PUNCT	O	O	3528
HCH	PROPN	O	O	3528
.	PUNCT	O	O	3528
One	NUM	O	O	3529
hour	NOUN	O	O	3529
after	ADP	O	O	3529
the	PRON	O	O	3529
administration	NOUN	O	O	3529
of	ADP	O	O	3529
gamma	PROPN	O	O	3529
-	PUNCT	O	O	3529
HCH	PROPN	O	O	3529
,	PUNCT	O	O	3529
the	PRON	O	O	3529
activity	NOUN	O	O	3529
of	ADP	O	O	3529
seizure	NOUN	O	Disease	3529
-	PUNCT	O	O	3529
inducing	VERB	O	O	3529
agents	NOUN	O	O	3529
was	AUX	O	O	3529
increased	VERB	O	O	3529
,	PUNCT	O	O	3529
regardless	ADV	O	O	3529
of	ADP	O	O	3529
their	PRON	O	O	3529
mechanism	NOUN	O	O	3529
,	PUNCT	O	O	3529
while	SCONJ	O	O	3529
24	NUM	O	O	3529
h	X	O	O	3529
after	ADP	O	O	3529
gamma	PROPN	O	O	3529
-	PUNCT	O	O	3529
HCH	PROPN	O	O	3529
a	PRON	O	O	3529
differential	ADJ	O	O	3529
response	NOUN	O	O	3529
was	AUX	O	O	3529
observed	VERB	O	O	3529
.	PUNCT	O	O	3529
Seizure	NOUN	O	Disease	3530
activity	NOUN	O	O	3530
due	ADJ	O	O	3530
to	PART	O	O	3530
PTZ	PROPN	O	Chemical	3530
and	CCONJ	O	O	3530
picrotoxin	PROPN	O	Chemical	3530
(	PUNCT	O	O	3530
PTX	NOUN	O	O	3530
)	PUNCT	O	O	3530
was	AUX	O	O	3530
significantly	ADV	O	O	3530
decreased	VERB	O	O	3530
;	PUNCT	O	O	3530
however	ADV	O	O	3530
,	PUNCT	O	O	3530
seizure	NOUN	O	Disease	3530
activity	NOUN	O	O	3530
due	ADJ	O	O	3530
to	PART	O	O	3530
3-mercaptopropionic	ADJ	O	O	3530
acid	PROPN	O	O	3530
(	PUNCT	O	O	3530
MPA	PROPN	O	O	3530
)	PUNCT	O	O	3530
,	PUNCT	O	O	3530
bicuculline	PROPN	O	Chemical	3530
(	PUNCT	O	O	3530
BCC	PROPN	O	O	3530
)	PUNCT	O	O	3530
,	PUNCT	O	O	3530
methyl	NOUN	O	O	3530
6,7-dimethoxy-4-ethyl	NOUN	O	O	3530
-	PUNCT	O	O	3530
B	NOUN	O	O	3530
-	PUNCT	O	O	3530
carboline-3-carboxylate	NOUN	O	O	3530
(	PUNCT	O	O	3530
DMCM	PROPN	O	O	3530
)	PUNCT	O	O	3530
,	PUNCT	O	O	3530
or	CCONJ	O	O	3530
strychnine	PROPN	O	O	3530
(	PUNCT	O	O	3530
STR	NOUN	O	O	3530
)	PUNCT	O	O	3530
was	AUX	O	O	3530
not	PART	O	O	3530
different	ADJ	O	O	3530
from	ADP	O	O	3530
control	VERB	O	O	3530
.	PUNCT	O	O	3530
In	ADP	O	O	3531
vitro	X	O	O	3531
,	PUNCT	O	O	3531
gamma	PROPN	O	O	3531
-	PUNCT	O	O	3531
HCH	PROPN	O	O	3531
,	PUNCT	O	O	3531
pentylenetetrazol	NOUN	O	O	3531
and	CCONJ	O	O	3531
picrotoxin	PROPN	O	Chemical	3531
were	AUX	O	O	3531
shown	VERB	O	O	3531
to	PART	O	O	3531
inhibit	VERB	O	O	3531
3H	NOUN	O	O	3531
-	PUNCT	O	O	3531
TBOB	NOUN	O	O	3531
binding	VERB	O	O	3531
in	ADP	O	O	3531
mouse	PROPN	O	O	3531
whole	NOUN	O	O	3531
brain	NOUN	O	O	3531
,	PUNCT	O	O	3531
with	ADP	O	O	3531
IC50	NOUN	O	O	3531
values	NOUN	O	O	3531
of	ADP	O	O	3531
4.6	NUM	O	O	3531
,	PUNCT	O	O	3531
404	NUM	O	O	3531
and	CCONJ	O	O	3531
9.4	NUM	O	O	3531
microM	ADJ	O	O	3531
,	PUNCT	O	O	3531
respectively	ADV	O	O	3531
.	PUNCT	O	O	3531
MPA	PROPN	O	O	3532
,	PUNCT	O	O	3532
BCC	PROPN	O	O	3532
,	PUNCT	O	O	3532
DMCM	PROPN	O	O	3532
,	PUNCT	O	O	3532
and	CCONJ	O	O	3532
STR	NOUN	O	O	3532
showed	VERB	O	O	3532
no	PRON	O	O	3532
inhibition	NOUN	O	O	3532
of	ADP	O	O	3532
3H	NOUN	O	O	3532
-	PUNCT	O	O	3532
TBOB	NOUN	O	O	3532
(	PUNCT	O	O	3532
t	NOUN	O	O	3532
-	PUNCT	O	O	3532
butyl	NOUN	O	O	3532
bicyclo	VERB	O	O	3532
-	PUNCT	O	O	3532
orthobenzoate	VERB	O	O	3532
)	PUNCT	O	O	3532
binding	VERB	O	O	3532
at	ADP	O	O	3532
concentrations	NOUN	O	O	3532
of	ADP	O	O	3532
100	NUM	O	O	3532
micron	NOUN	O	O	3532
.	PUNCT	O	O	3532
The	PRON	O	O	3533
pharmacological	ADJ	O	O	3533
challenge	NOUN	O	O	3533
data	NOUN	O	O	3533
suggest	VERB	O	O	3533
that	SCONJ	O	O	3533
tolerance	NOUN	O	O	3533
may	AUX	O	O	3533
occur	VERB	O	O	3533
to	PART	O	O	3533
seizure	NOUN	O	Disease	3533
activity	NOUN	O	O	3533
induced	VERB	O	O	3533
by	ADP	O	O	3533
PTZ	PROPN	O	Chemical	3533
and	CCONJ	O	O	3533
PTX	NOUN	O	O	3533
24	NUM	O	O	3533
h	X	O	O	3533
after	ADP	O	O	3533
gamma	PROPN	O	O	3533
-	PUNCT	O	O	3533
HCH	PROPN	O	O	3533
,	PUNCT	O	O	3533
since	SCONJ	O	O	3533
the	PRON	O	O	3533
response	NOUN	O	O	3533
to	PART	O	O	3533
only	ADV	O	O	3533
these	PRON	O	O	3533
two	NUM	O	O	3533
seizure	NOUN	O	Disease	3533
-	PUNCT	O	O	3533
inducing	VERB	O	O	3533
agents	NOUN	O	O	3533
is	AUX	O	O	3533
decreased	VERB	O	O	3533
.	PUNCT	O	O	3533
The	PRON	O	O	3534
in	ADP	O	O	3534
vitro	X	O	O	3534
data	NOUN	O	O	3534
suggest	VERB	O	O	3534
that	SCONJ	O	O	3534
the	PRON	O	O	3534
site	NOUN	O	O	3534
responsible	ADJ	O	O	3534
for	ADP	O	O	3534
the	PRON	O	O	3534
decrease	VERB	O	O	3534
in	ADP	O	O	3534
seizure	NOUN	O	Disease	3534
activity	NOUN	O	O	3534
24	NUM	O	O	3534
h	X	O	O	3534
after	ADP	O	O	3534
gamma	PROPN	O	O	3534
-	PUNCT	O	O	3534
HCH	PROPN	O	O	3534
may	AUX	O	O	3534
be	AUX	O	O	3534
the	PRON	O	O	3534
GABA	PROPN	O	Chemical	3534
-	PUNCT	O	O	3534
A	PRON	O	O	3534
receptor	NOUN	O	O	3534
-	PUNCT	O	O	3534
linked	VERB	O	O	3534
chloride	NOUN	O	Chemical	3534
channel	PROPN	O	O	3534
.	PUNCT	O	O	3534
Severe	ADJ	O	O	3537
ocular	ADJ	O	O	3537
and	CCONJ	O	O	3537
orbital	ADJ	O	O	3537
toxicity	NOUN	O	Disease	3537
after	ADP	O	O	3537
intracarotid	PROPN	O	O	3537
injection	NOUN	O	O	3537
of	ADP	O	O	3537
carboplatin	PROPN	O	Chemical	3537
for	ADP	O	O	3537
recurrent	ADJ	O	O	3537
glioblastomas	NOUN	O	O	3537
.	PUNCT	O	O	3537
Glioblastoma	NOUN	O	O	3538
is	AUX	O	O	3538
a	PRON	O	O	3538
malignant	ADJ	O	O	3538
tumor	NOUN	O	Disease	3538
that	SCONJ	O	O	3538
occurs	VERB	O	O	3538
in	ADP	O	O	3538
the	PRON	O	O	3538
cerebrum	VERB	O	O	3538
during	ADP	O	O	3538
adulthood	NOUN	O	O	3538
.	PUNCT	O	O	3538
Therefore	ADV	O	O	3539
,	PUNCT	O	O	3539
patients	NOUN	O	O	3539
with	ADP	O	O	3539
glioblastoma	NOUN	O	Disease	3539
sometimes	ADV	O	O	3539
have	VERB	O	O	3539
intracarotid	PROPN	O	O	3539
injection	NOUN	O	O	3539
of	ADP	O	O	3539
carcinostatics	NOUN	O	O	3539
added	VERB	O	O	3539
to	PART	O	O	3539
the	PRON	O	O	3539
treatment	NOUN	O	O	3539
regimen	NOUN	O	O	3539
.	PUNCT	O	O	3539
Generally	ADV	O	O	3540
,	PUNCT	O	O	3540
carboplatin	PROPN	O	Chemical	3540
is	AUX	O	O	3540
said	VERB	O	O	3540
to	PART	O	O	3540
have	VERB	O	O	3540
milder	ADJ	O	O	3540
side	NOUN	O	O	3540
effects	NOUN	O	O	3540
than	ADP	O	O	3540
cisplatin	NOUN	O	Chemical	3540
,	PUNCT	O	O	3540
whose	DET	O	O	3540
ocular	ADJ	O	O	3540
and	CCONJ	O	O	3540
orbital	ADJ	O	O	3540
toxicity	NOUN	O	Disease	3540
are	AUX	O	O	3540
well	ADV	O	O	3540
known	VERB	O	O	3540
.	PUNCT	O	O	3540
However	ADV	O	O	3541
,	PUNCT	O	O	3541
we	PRON	O	O	3541
experienced	ADJ	O	O	3541
a	PRON	O	O	3541
case	NOUN	O	O	3541
of	ADP	O	O	3541
severe	ADJ	O	O	3541
ocular	ADJ	O	O	3541
and	CCONJ	O	O	3541
orbital	ADJ	O	O	3541
toxicity	NOUN	O	Disease	3541
after	ADP	O	O	3541
intracarotid	PROPN	O	O	3541
injection	NOUN	O	O	3541
of	ADP	O	O	3541
carboplatin	PROPN	O	Chemical	3541
,	PUNCT	O	O	3541
which	PRON	O	O	3541
is	AUX	O	O	3541
infrequently	ADV	O	O	3541
reported	VERB	O	O	3541
.	PUNCT	O	O	3541
A	PRON	O	O	3542
58-year	NOUN	O	O	3542
-	PUNCT	O	O	3542
old	ADJ	O	O	3542
man	NOUN	O	O	3542
received	VERB	O	O	3542
an	PRON	O	O	3542
intracarotid	PROPN	O	O	3542
injection	NOUN	O	O	3542
of	ADP	O	O	3542
carboplatin	PROPN	O	Chemical	3542
for	ADP	O	O	3542
recurrent	ADJ	O	O	3542
glioblastomas	NOUN	O	O	3542
in	ADP	O	O	3542
his	PRON	O	O	3542
left	VERB	O	O	3542
temporal	ADJ	O	O	3542
lobe	NOUN	O	O	3542
.	PUNCT	O	O	3542
He	PRON	O	O	3543
complained	VERB	O	O	3543
of	ADP	O	O	3543
pain	NOUN	O	Disease	3543
and	CCONJ	O	O	3543
visual	ADJ	O	O	3543
disturbance	NOUN	O	O	3543
in	ADP	O	O	3543
the	PRON	O	O	3543
ipsilateral	ADJ	O	O	3543
eye	NOUN	O	O	3543
30	NUM	O	O	3543
h	X	O	O	3543
after	ADP	O	O	3543
the	PRON	O	O	3543
injection	NOUN	O	O	3543
.	PUNCT	O	O	3543
Various	ADJ	O	O	3544
ocular	ADJ	O	O	3544
symptoms	NOUN	O	O	3544
and	CCONJ	O	O	3544
findings	NOUN	O	O	3544
caused	VERB	O	O	3544
by	ADP	O	O	3544
carboplatin	PROPN	O	Chemical	3544
toxicity	NOUN	O	Disease	3544
were	AUX	O	O	3544
seen	VERB	O	O	3544
.	PUNCT	O	O	3544
He	PRON	O	O	3545
was	AUX	O	O	3545
treated	VERB	O	O	3545
with	ADP	O	O	3545
intravenous	ADJ	O	O	3545
administration	NOUN	O	O	3545
of	ADP	O	O	3545
corticosteroids	NOUN	O	Chemical	3545
and	CCONJ	O	O	3545
glycerin	NOUN	O	O	3545
for	ADP	O	O	3545
6	NUM	O	O	3545
days	NOUN	O	O	3545
after	ADP	O	O	3545
the	PRON	O	O	3545
injection	NOUN	O	O	3545
.	PUNCT	O	O	3545
Although	SCONJ	O	O	3546
the	PRON	O	O	3546
intraocular	ADJ	O	O	3546
pressure	NOUN	O	O	3546
elevation	NOUN	O	O	3546
caused	VERB	O	O	3546
by	ADP	O	O	3546
secondary	ADJ	O	O	3546
acute	ADJ	O	O	3546
angle	NOUN	O	O	3546
-	PUNCT	O	O	3546
closure	NOUN	O	O	3546
glaucoma	NOUN	O	Disease	3546
decreased	VERB	O	O	3546
and	CCONJ	O	O	3546
ocular pain	NOUN	O	Disease	3546
diminished	VERB	O	O	3546
,	PUNCT	O	O	3546
inexorable	ADJ	O	O	3546
papilledema	NOUN	O	O	3546
and	CCONJ	O	O	3546
exudative	VERB	O	O	3546
retinal	ADJ	O	O	3546
detachment	NOUN	O	O	3546
continued	VERB	O	O	3546
for	ADP	O	O	3546
3	X	O	O	3546
weeks	NOUN	O	O	3546
.	PUNCT	O	O	3546
Finally	ADV	O	O	3547
,	PUNCT	O	O	3547
6	NUM	O	O	3547
weeks	NOUN	O	O	3547
later	ADV	O	O	3547
,	PUNCT	O	O	3547
diffuse	VERB	O	O	3547
chorioretinal	NOUN	O	O	3547
atrophy	NOUN	O	Disease	3547
with	ADP	O	O	3547
optic	NOUN	O	O	3547
atrophy	NOUN	O	Disease	3547
occurred	VERB	O	O	3547
and	CCONJ	O	O	3547
the	PRON	O	O	3547
vision	PROPN	O	O	3547
in	ADP	O	O	3547
his	PRON	O	O	3547
left	VERB	O	O	3547
eye	NOUN	O	O	3547
was	AUX	O	O	3547
lost	VERB	O	O	3547
.	PUNCT	O	O	3547
CONCLUSION	PROPN	O	O	3548
:	PUNCT	O	O	3548
When	SCONJ	O	O	3548
performing	VERB	O	O	3548
intracarotid	PROPN	O	O	3548
injection	NOUN	O	O	3548
of	ADP	O	O	3548
carboplatin	PROPN	O	Chemical	3548
,	PUNCT	O	O	3548
we	PRON	O	O	3548
must	AUX	O	O	3548
be	AUX	O	O	3548
aware	ADJ	O	O	3548
of	ADP	O	O	3548
its	PRON	O	O	3548
potentially	ADV	O	O	3548
blinding	VERB	O	O	3548
ocular toxicity	NOUN	O	Disease	3548
.	PUNCT	O	O	3548
Phase	NOUN	O	O	3551
II	NUM	O	O	3551
study	VERB	O	O	3551
of	ADP	O	O	3551
the	PRON	O	O	3551
amsacrine	ADJ	O	O	3551
analogue	NOUN	O	O	3551
CI-921	NOUN	O	O	3551
(	PUNCT	O	O	3551
NSC	PROPN	O	O	3551
343499	NUM	O	O	3551
)	PUNCT	O	O	3551
in	ADP	O	O	3551
non	ADJ	O	O	3551
-	PUNCT	O	O	3551
small	ADJ	O	O	3551
cell	NOUN	O	O	3551
lung cancer	NOUN	O	Disease	3551
.	PUNCT	O	O	3551
CI-921	NOUN	O	O	3552
(	PUNCT	O	O	3552
NSC	PROPN	O	O	3552
343499	NUM	O	O	3552
;	PUNCT	O	O	3552
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino	NOUN	O	O	3552
]	PUNCT	O	O	3552
-N,5-dimethyl-	NOUN	O	O	3552
4-acridinecarboxamide	NOUN	O	O	3552
)	PUNCT	O	O	3552
is	AUX	O	O	3552
a	PRON	O	O	3552
topoisomerase	NOUN	O	O	3552
II	NUM	O	O	3552
poison	NOUN	O	O	3552
with	ADP	O	O	3552
high	ADJ	O	O	3552
experimental	ADJ	O	O	3552
antitumour	NOUN	O	O	3552
activity	NOUN	O	O	3552
.	PUNCT	O	O	3552
It	PRON	O	O	3553
was	AUX	O	O	3553
administered	VERB	O	O	3553
by	ADP	O	O	3553
15	NUM	O	O	3553
min	NOUN	O	O	3553
infusion	NOUN	O	O	3553
to	PART	O	O	3553
16	NUM	O	O	3553
evaluable	ADJ	O	O	3553
patients	NOUN	O	O	3553
with	ADP	O	O	3553
non	ADJ	O	O	3553
-	PUNCT	O	O	3553
small	ADJ	O	O	3553
cell	NOUN	O	O	3553
lung cancer	NOUN	O	Disease	3553
(	PUNCT	O	O	3553
NSCLC	PROPN	O	Disease	3553
)	PUNCT	O	O	3553
(	PUNCT	O	O	3553
7	NUM	O	O	3553
with	ADP	O	O	3553
no	PRON	O	O	3553
prior	ADV	O	O	3553
treatment	NOUN	O	O	3553
,	PUNCT	O	O	3553
9	NUM	O	O	3553
patients	NOUN	O	O	3553
in	ADP	O	O	3553
relapse	VERB	O	O	3553
following	VERB	O	O	3553
surgery	NOUN	O	O	3553
/	PUNCT	O	O	3553
radiotherapy	NOUN	O	O	3553
)	PUNCT	O	O	3553
at	ADP	O	O	3553
a	PRON	O	O	3553
dose	NOUN	O	O	3553
(	PUNCT	O	O	3553
648	NUM	O	O	3553
mg	VERB	O	O	3553
/	PUNCT	O	O	3553
m2	PROPN	O	O	3553
divided	VERB	O	O	3553
over	ADP	O	O	3553
3	X	O	O	3553
days	NOUN	O	O	3553
,	PUNCT	O	O	3553
repeated	VERB	O	O	3553
every	PRON	O	O	3553
3	X	O	O	3553
weeks	NOUN	O	O	3553
)	PUNCT	O	O	3553
determined	VERB	O	O	3553
by	ADP	O	O	3553
phase	NOUN	O	O	3553
I	PRON	O	O	3553
trial	NOUN	O	O	3553
.	PUNCT	O	O	3553
The	PRON	O	O	3554
histology	NOUN	O	O	3554
comprised	VERB	O	O	3554
squamous	ADJ	O	O	3554
carcinoma	NOUN	O	Disease	3554
(	PUNCT	O	O	3554
11	NUM	O	O	3554
)	PUNCT	O	O	3554
,	PUNCT	O	O	3554
adenocarcinoma	NOUN	O	O	3554
(	PUNCT	O	O	3554
1	X	O	O	3554
)	PUNCT	O	O	3554
,	PUNCT	O	O	3554
mixed	VERB	O	O	3554
histology	NOUN	O	O	3554
(	PUNCT	O	O	3554
2	X	O	O	3554
)	PUNCT	O	O	3554
,	PUNCT	O	O	3554
bronchio	NOUN	O	O	3554
-	PUNCT	O	O	3554
alveolar	ADJ	O	O	3554
carcinoma	NOUN	O	Disease	3554
(	PUNCT	O	O	3554
1	X	O	O	3554
)	PUNCT	O	O	3554
and	CCONJ	O	O	3554
large	ADJ	O	O	3554
cell	NOUN	O	O	3554
undifferentiated	ADJ	O	O	3554
carcinoma	NOUN	O	Disease	3554
(	PUNCT	O	O	3554
1	X	O	O	3554
)	PUNCT	O	O	3554
.	PUNCT	O	O	3554
Neutropenia	NOUN	O	O	3555
grade	NOUN	O	O	3555
greater	ADJ	O	O	3555
than	ADP	O	O	3555
or	CCONJ	O	O	3555
equal	ADJ	O	O	3555
to	PART	O	O	3555
3	X	O	O	3555
was	AUX	O	O	3555
seen	VERB	O	O	3555
in	ADP	O	O	3555
15	NUM	O	O	3555
patients	NOUN	O	O	3555
,	PUNCT	O	O	3555
infections	NOUN	O	Disease	3555
with	ADP	O	O	3555
recovery	NOUN	O	O	3555
in	ADP	O	O	3555
3	X	O	O	3555
,	PUNCT	O	O	3555
and	CCONJ	O	O	3555
grand mal seizures	NOUN	O	Disease	3555
in	ADP	O	O	3555
1	X	O	O	3555
patient	NOUN	O	O	3555
.	PUNCT	O	O	3555
Grade	NOUN	O	O	3556
less	ADV	O	O	3556
than	ADP	O	O	3556
or	CCONJ	O	O	3556
equal	ADJ	O	O	3556
to	PART	O	O	3556
2	X	O	O	3556
nausea	NOUN	O	Disease	3556
and	CCONJ	O	O	3556
vomiting	VERB	O	Disease	3556
occurred	VERB	O	O	3556
in	ADP	O	O	3556
66%	NOUN	O	O	3556
courses	NOUN	O	O	3556
and	CCONJ	O	O	3556
phlebitis	NOUN	O	O	3556
in	ADP	O	O	3556
the	PRON	O	O	3556
infusion	NOUN	O	O	3556
arm	VERB	O	O	3556
in	ADP	O	O	3556
37%	NOUN	O	O	3556
.	PUNCT	O	O	3556
1	X	O	O	3557
patient	NOUN	O	O	3557
with	ADP	O	O	3557
squamous	ADJ	O	O	3557
cell	NOUN	O	O	3557
carcinoma	NOUN	O	Disease	3557
achieved	VERB	O	O	3557
a	PRON	O	O	3557
partial	ADJ	O	O	3557
response	NOUN	O	O	3557
lasting	VERB	O	O	3557
5	NUM	O	O	3557
months	NOUN	O	O	3557
.	PUNCT	O	O	3557
Further	ADV	O	O	3558
testing	NOUN	O	O	3558
in	ADP	O	O	3558
this	PRON	O	O	3558
and	CCONJ	O	O	3558
other	ADJ	O	O	3558
tumour	NOUN	O	O	3558
types	NOUN	O	O	3558
using	VERB	O	O	3558
multiple	ADJ	O	O	3558
daily	ADV	O	O	3558
schedules	NOUN	O	O	3558
is	AUX	O	O	3558
warranted	VERB	O	O	3558
.	PUNCT	O	O	3558
Alpha	NOUN	O	O	3561
-	PUNCT	O	O	3561
lipoic	ADV	O	O	3561
acid	PROPN	O	O	3561
prevents	VERB	O	O	3561
mitochondrial	ADJ	O	O	3561
damage	NOUN	O	O	3561
and	CCONJ	O	O	3561
neurotoxicity	NOUN	O	Disease	3561
in	ADP	O	O	3561
experimental	ADJ	O	O	3561
chemotherapy	NOUN	O	O	3561
neuropathy	NOUN	O	Disease	3561
.	PUNCT	O	O	3561
The	PRON	O	O	3562
study	VERB	O	O	3562
investigates	VERB	O	O	3562
if	SCONJ	O	O	3562
alpha	PROPN	O	O	3562
-	PUNCT	O	O	3562
lipoic	ADV	O	O	3562
acid	PROPN	O	O	3562
is	AUX	O	O	3562
neuroprotective	ADJ	O	O	3562
against	ADP	O	O	3562
chemotherapy	NOUN	O	O	3562
induced	VERB	O	O	3562
neurotoxicity	NOUN	O	Disease	3562
,	PUNCT	O	O	3562
if	SCONJ	O	O	3562
mitochondrial	ADJ	O	O	3562
damage	NOUN	O	O	3562
plays	VERB	O	O	3562
a	PRON	O	O	3562
critical	ADJ	O	O	3562
role	NOUN	O	O	3562
in	ADP	O	O	3562
toxic	ADJ	O	O	3562
neurodegenerative	ADV	O	O	3562
cascade	NOUN	O	O	3562
,	PUNCT	O	O	3562
and	CCONJ	O	O	3562
if	SCONJ	O	O	3562
neuroprotective	ADJ	O	O	3562
effects	NOUN	O	O	3562
of	ADP	O	O	3562
alpha	PROPN	O	O	3562
-	PUNCT	O	O	3562
lipoic	ADV	O	O	3562
acid	PROPN	O	O	3562
depend	VERB	O	O	3562
on	ADP	O	O	3562
mitochondria	PROPN	O	O	3562
protection	NOUN	O	O	3562
.	PUNCT	O	O	3562
We	PRON	O	O	3563
used	VERB	O	O	3563
an	PRON	O	O	3563
in	ADP	O	O	3563
vitro	X	O	O	3563
model	NOUN	O	O	3563
of	ADP	O	O	3563
chemotherapy	NOUN	O	O	3563
induced	VERB	O	O	3563
peripheral neuropathy	NOUN	O	Disease	3563
that	SCONJ	O	O	3563
closely	ADV	O	O	3563
mimic	VERB	O	O	3563
the	PRON	O	O	3563
in	ADP	O	O	3563
vivo	VERB	O	O	3563
condition	NOUN	O	O	3563
by	ADP	O	O	3563
exposing	VERB	O	O	3563
primary	NOUN	O	O	3563
cultures	NOUN	O	O	3563
of	ADP	O	O	3563
dorsal	PROPN	O	O	3563
root	NOUN	O	O	3563
ganglion	NOUN	O	O	3563
(	PUNCT	O	O	3563
DRG	PROPN	O	O	3563
)	PUNCT	O	O	3563
sensory	ADJ	O	O	3563
neurons	NOUN	O	O	3563
to	PART	O	O	3563
paclitaxel	NOUN	O	Chemical	3563
and	CCONJ	O	O	3563
cisplatin	NOUN	O	Chemical	3563
,	PUNCT	O	O	3563
two	NUM	O	O	3563
widely	ADV	O	O	3563
used	VERB	O	O	3563
and	CCONJ	O	O	3563
highly	ADV	O	O	3563
effective	ADJ	O	O	3563
chemotherapeutic	NOUN	O	O	3563
drugs	NOUN	O	O	3563
.	PUNCT	O	O	3563
This	PRON	O	O	3564
approach	NOUN	O	O	3564
allowed	VERB	O	O	3564
investigating	VERB	O	O	3564
the	PRON	O	O	3564
efficacy	NOUN	O	O	3564
of	ADP	O	O	3564
alpha	PROPN	O	O	3564
-	PUNCT	O	O	3564
lipoic	ADV	O	O	3564
acid	PROPN	O	O	3564
in	ADP	O	O	3564
preventing	VERB	O	O	3564
axonal	ADJ	O	O	3564
damage	NOUN	O	O	3564
and	CCONJ	O	O	3564
apoptosis	NOUN	O	O	3564
and	CCONJ	O	O	3564
the	PRON	O	O	3564
function	NOUN	O	O	3564
and	CCONJ	O	O	3564
ultrastructural	ADJ	O	O	3564
morphology	NOUN	O	O	3564
of	ADP	O	O	3564
mitochondria	PROPN	O	O	3564
after	ADP	O	O	3564
exposure	NOUN	O	O	3564
to	PART	O	O	3564
toxic	ADJ	O	O	3564
agents	NOUN	O	O	3564
and	CCONJ	O	O	3564
alpha	PROPN	O	O	3564
-	PUNCT	O	O	3564
lipoic	ADV	O	O	3564
acid	PROPN	O	O	3564
.	PUNCT	O	O	3564
Our	PRON	O	O	3565
results	VERB	O	O	3565
demonstrate	VERB	O	O	3565
that	SCONJ	O	O	3565
both	PRON	O	O	3565
cisplatin	NOUN	O	Chemical	3565
and	CCONJ	O	O	3565
paclitaxel	NOUN	O	Chemical	3565
cause	VERB	O	O	3565
early	ADV	O	O	3565
mitochondrial	ADJ	O	O	3565
impairment	NOUN	O	O	3565
with	ADP	O	O	3565
loss	NOUN	O	O	3565
of	ADP	O	O	3565
membrane	NOUN	O	O	3565
potential	ADJ	O	O	3565
and	CCONJ	O	O	3565
induction	NOUN	O	O	3565
of	ADP	O	O	3565
autophagic	PROPN	O	O	3565
vacuoles	NOUN	O	O	3565
in	ADP	O	O	3565
neurons	NOUN	O	O	3565
.	PUNCT	O	O	3565
Alpha	NOUN	O	O	3566
-	PUNCT	O	O	3566
lipoic	ADV	O	O	3566
acid	PROPN	O	O	3566
exerts	VERB	O	O	3566
neuroprotective	ADJ	O	O	3566
effects	NOUN	O	O	3566
against	ADP	O	O	3566
chemotherapy	NOUN	O	O	3566
induced	VERB	O	O	3566
neurotoxicity	NOUN	O	Disease	3566
in	ADP	O	O	3566
sensory	ADJ	O	O	3566
neurons	NOUN	O	O	3566
:	PUNCT	O	O	3566
it	PRON	O	O	3566
rescues	VERB	O	O	3566
the	PRON	O	O	3566
mitochondrial	ADJ	O	O	3566
toxicity	NOUN	O	Disease	3566
and	CCONJ	O	O	3566
induces	VERB	O	O	3566
the	PRON	O	O	3566
expression	NOUN	O	O	3566
of	ADP	O	O	3566
frataxin	PROPN	O	O	3566
,	PUNCT	O	O	3566
an	PRON	O	O	3566
essential	ADJ	O	O	3566
mitochondrial	ADJ	O	O	3566
protein	NOUN	O	O	3566
with	ADP	O	O	3566
anti	ADJ	O	O	3566
-	PUNCT	O	O	3566
oxidant	ADJ	O	O	3566
and	CCONJ	O	O	3566
chaperone	NOUN	O	O	3566
properties	NOUN	O	O	3566
.	PUNCT	O	O	3566
In	ADP	O	O	3567
conclusion	NOUN	O	O	3567
mitochondrial	ADJ	O	O	3567
toxicity	NOUN	O	Disease	3567
is	AUX	O	O	3567
an	PRON	O	O	3567
early	ADV	O	O	3567
common	ADJ	O	O	3567
event	NOUN	O	O	3567
both	PRON	O	O	3567
in	ADP	O	O	3567
paclitaxel	NOUN	O	Chemical	3567
and	CCONJ	O	O	3567
cisplatin	NOUN	O	Chemical	3567
induced	VERB	O	O	3567
neurotoxicity	NOUN	O	Disease	3567
.	PUNCT	O	O	3567
Alpha	NOUN	O	O	3568
-	PUNCT	O	O	3568
lipoic	ADV	O	O	3568
acid	PROPN	O	O	3568
protects	VERB	O	O	3568
sensory	ADJ	O	O	3568
neurons	NOUN	O	O	3568
through	ADP	O	O	3568
its	PRON	O	O	3568
anti	ADJ	O	O	3568
-	PUNCT	O	O	3568
oxidant	ADJ	O	O	3568
and	CCONJ	O	O	3568
mitochondrial	ADJ	O	O	3568
regulatory	ADJ	O	O	3568
functions	VERB	O	O	3568
,	PUNCT	O	O	3568
possibly	ADV	O	O	3568
inducing	VERB	O	O	3568
the	PRON	O	O	3568
expression	NOUN	O	O	3568
of	ADP	O	O	3568
frataxin	PROPN	O	O	3568
.	PUNCT	O	O	3568
These	PRON	O	O	3569
findings	NOUN	O	O	3569
suggest	VERB	O	O	3569
that	SCONJ	O	O	3569
alpha	PROPN	O	O	3569
-	PUNCT	O	O	3569
lipoic	ADV	O	O	3569
acid	PROPN	O	O	3569
might	AUX	O	O	3569
reduce	VERB	O	O	3569
the	PRON	O	O	3569
risk	NOUN	O	O	3569
of	ADP	O	O	3569
developing	VERB	O	O	3569
peripheral	ADJ	O	O	3569
nerve	NOUN	O	O	3569
toxicity	NOUN	O	Disease	3569
in	ADP	O	O	3569
patients	NOUN	O	O	3569
undergoing	VERB	O	O	3569
chemotherapy	NOUN	O	O	3569
and	CCONJ	O	O	3569
encourage	VERB	O	O	3569
further	ADV	O	O	3569
confirmatory	NOUN	O	O	3569
clinical	ADJ	O	O	3569
trials	NOUN	O	O	3569
.	PUNCT	O	O	3569
Optimising	VERB	O	O	3572
stroke	VERB	O	Disease	3572
prevention	NOUN	O	O	3572
in	ADP	O	O	3572
non	ADJ	O	O	3572
-	PUNCT	O	O	3572
valvular	ADJ	O	O	3572
atrial fibrillation	NOUN	O	Disease	3572
.	PUNCT	O	O	3572
Atrial fibrillation	NOUN	O	Disease	3573
is	AUX	O	O	3573
associated	VERB	O	O	3573
with	ADP	O	O	3573
substantial	ADJ	O	O	3573
morbidity	NOUN	O	O	3573
and	CCONJ	O	O	3573
mortality	NOUN	O	O	3573
.	PUNCT	O	O	3573
Pooled	VERB	O	O	3574
data	NOUN	O	O	3574
from	ADP	O	O	3574
trials	NOUN	O	O	3574
comparing	VERB	O	O	3574
antithrombotic	ADJ	O	O	3574
treatment	NOUN	O	O	3574
with	ADP	O	O	3574
placebo	NOUN	O	O	3574
have	VERB	O	O	3574
shown	VERB	O	O	3574
that	SCONJ	O	O	3574
warfarin	VERB	O	Chemical	3574
reduces	VERB	O	O	3574
the	PRON	O	O	3574
risk	NOUN	O	O	3574
of	ADP	O	O	3574
stroke	VERB	O	Disease	3574
by	ADP	O	O	3574
62%	NOUN	O	O	3574
,	PUNCT	O	O	3574
and	CCONJ	O	O	3574
that	SCONJ	O	O	3574
aspirin	NOUN	O	Chemical	3574
alone	ADV	O	O	3574
reduces	VERB	O	O	3574
the	PRON	O	O	3574
risk	NOUN	O	O	3574
by	ADP	O	O	3574
22%	NOUN	O	O	3574
.	PUNCT	O	O	3574
Overall	ADV	O	O	3575
,	PUNCT	O	O	3575
in	ADP	O	O	3575
high	ADJ	O	O	3575
-	PUNCT	O	O	3575
risk	NOUN	O	O	3575
patients	NOUN	O	O	3575
,	PUNCT	O	O	3575
warfarin	VERB	O	Chemical	3575
is	AUX	O	O	3575
superior	PROPN	O	O	3575
to	PART	O	O	3575
aspirin	NOUN	O	Chemical	3575
in	ADP	O	O	3575
preventing	VERB	O	O	3575
strokes	NOUN	O	Disease	3575
,	PUNCT	O	O	3575
with	ADP	O	O	3575
a	PRON	O	O	3575
relative	ADJ	O	O	3575
risk	NOUN	O	O	3575
reduction	NOUN	O	O	3575
of	ADP	O	O	3575
36%	NOUN	O	O	3575
.	PUNCT	O	O	3575
Ximelagatran	NOUN	O	O	3576
,	PUNCT	O	O	3576
an	PRON	O	O	3576
oral	ADJ	O	O	3576
direct	ADJ	O	O	3576
thrombin	PROPN	O	O	3576
inhibitor	NOUN	O	O	3576
,	PUNCT	O	O	3576
was	AUX	O	O	3576
found	VERB	O	O	3576
to	PART	O	O	3576
be	AUX	O	O	3576
as	ADP	O	O	3576
efficient	ADJ	O	O	3576
as	ADP	O	O	3576
vitamin	NOUN	O	O	3576
K	PROPN	O	Chemical	3576
antagonist	NOUN	O	O	3576
drugs	NOUN	O	O	3576
in	ADP	O	O	3576
the	PRON	O	O	3576
prevention	NOUN	O	O	3576
of	ADP	O	O	3576
embolic	NOUN	O	O	3576
events	NOUN	O	O	3576
,	PUNCT	O	O	3576
but	CCONJ	O	O	3576
has	VERB	O	O	3576
been	AUX	O	O	3576
recently	ADV	O	O	3576
withdrawn	VERB	O	O	3576
because	SCONJ	O	O	3576
of	ADP	O	O	3576
abnormal	ADJ	O	O	3576
liver	NOUN	O	O	3576
function	NOUN	O	O	3576
tests	VERB	O	O	3576
.	PUNCT	O	O	3576
The	PRON	O	O	3577
ACTIVE	ADJ	O	O	3577
-	PUNCT	O	O	3577
W	NOUN	O	O	3577
(	PUNCT	O	O	3577
Atrial	PROPN	O	O	3577
Fibrillation	NOUN	O	O	3577
Clopidogrel	NOUN	O	O	3577
Trial	NOUN	O	O	3577
with	ADP	O	O	3577
Irbesartan	PROPN	O	O	3577
for	ADP	O	O	3577
Prevention	NOUN	O	O	3577
of	ADP	O	O	3577
Vascular	NOUN	O	O	3577
Events	NOUN	O	O	3577
)	PUNCT	O	O	3577
study	VERB	O	O	3577
has	VERB	O	O	3577
demonstrated	VERB	O	O	3577
that	SCONJ	O	O	3577
warfarin	VERB	O	Chemical	3577
is	AUX	O	O	3577
superior	PROPN	O	O	3577
to	PART	O	O	3577
platelet	NOUN	O	O	3577
therapy	NOUN	O	O	3577
(	PUNCT	O	O	3577
clopidogrel	NOUN	O	O	3577
plus	CCONJ	O	O	3577
aspirin	NOUN	O	Chemical	3577
)	PUNCT	O	O	3577
in	ADP	O	O	3577
the	PRON	O	O	3577
prevention	NOUN	O	O	3577
af	X	O	O	3577
embolic	NOUN	O	O	3577
events	NOUN	O	O	3577
.	PUNCT	O	O	3577
Idraparinux	NOUN	O	O	3578
,	PUNCT	O	O	3578
a	PRON	O	O	3578
Factor	NOUN	O	O	3578
Xa	PROPN	O	O	3578
inhibitor	NOUN	O	O	3578
,	PUNCT	O	O	3578
is	AUX	O	O	3578
being	AUX	O	O	3578
evaluated	VERB	O	O	3578
in	ADP	O	O	3578
patients	NOUN	O	O	3578
with	ADP	O	O	3578
atrial fibrillation	NOUN	O	Disease	3578
.	PUNCT	O	O	3578
Angiotensin	NOUN	O	O	3579
-	PUNCT	O	O	3579
converting	VERB	O	O	3579
enzyme	NOUN	O	O	3579
inhibitors	NOUN	O	O	3579
and	CCONJ	O	O	3579
angiotensin II	PROPN	O	Chemical	3579
receptor	NOUN	O	O	3579
-	PUNCT	O	O	3579
blocking	VERB	O	O	3579
drugs	NOUN	O	O	3579
hold	VERB	O	O	3579
promise	VERB	O	O	3579
in	ADP	O	O	3579
atrial fibrillation	NOUN	O	Disease	3579
through	ADP	O	O	3579
cardiac	ADJ	O	O	3579
remodelling	VERB	O	O	3579
.	PUNCT	O	O	3579
Preliminary	PROPN	O	O	3580
studies	NOUN	O	O	3580
suggest	VERB	O	O	3580
that	SCONJ	O	O	3580
statins	NOUN	O	O	3580
could	AUX	O	O	3580
interfere	VERB	O	O	3580
with	ADP	O	O	3580
the	PRON	O	O	3580
risk	NOUN	O	O	3580
of	ADP	O	O	3580
recurrence	NOUN	O	O	3580
after	ADP	O	O	3580
electrical	ADJ	O	O	3580
cardioversion	NOUN	O	O	3580
.	PUNCT	O	O	3580
Interaction	NOUN	O	O	3583
of	ADP	O	O	3583
cyclosporin A	PRON	O	Chemical	3583
with	ADP	O	O	3583
antineoplastic	ADJ	O	O	3583
agents	NOUN	O	O	3583
.	PUNCT	O	O	3583
A	PRON	O	O	3584
synergistic	ADJ	O	O	3584
effect	VERB	O	O	3584
of	ADP	O	O	3584
etoposide	ADV	O	Chemical	3584
and	CCONJ	O	O	3584
cyclosporin A	PRON	O	Chemical	3584
was	AUX	O	O	3584
observed	VERB	O	O	3584
in	ADP	O	O	3584
a	PRON	O	O	3584
patient	NOUN	O	O	3584
with	ADP	O	O	3584
acute	ADJ	O	O	3584
T	NOUN	O	Chemical	3584
-	PUNCT	O	O	3584
lymphocytic	NOUN	O	O	3584
leukemia	NOUN	O	Disease	3584
in	ADP	O	O	3584
relapse	VERB	O	O	3584
.	PUNCT	O	O	3584
The	PRON	O	O	3585
concomitant	ADJ	O	O	3585
administration	NOUN	O	O	3585
of	ADP	O	O	3585
etoposide	ADV	O	Chemical	3585
and	CCONJ	O	O	3585
cyclosporin A	PRON	O	Chemical	3585
resulted	VERB	O	O	3585
in	ADP	O	O	3585
eradication	NOUN	O	O	3585
of	ADP	O	O	3585
hitherto	ADV	O	O	3585
refractory	ADJ	O	O	3585
leukemic	ADJ	O	O	3585
infiltration	NOUN	O	O	3585
of	ADP	O	O	3585
bone	NOUN	O	O	3585
marrow	PROPN	O	O	3585
.	PUNCT	O	O	3585
Severe	ADJ	O	O	3586
side	NOUN	O	O	3586
effects	NOUN	O	O	3586
in	ADP	O	O	3586
terms	NOUN	O	O	3586
of	ADP	O	O	3586
mental	ADJ	O	O	3586
confusion	NOUN	O	Disease	3586
and	CCONJ	O	O	3586
progressive	ADJ	O	O	3586
hyperbilirubinemia	PROPN	O	Disease	3586
,	PUNCT	O	O	3586
however	ADV	O	O	3586
,	PUNCT	O	O	3586
point	VERB	O	O	3586
to	PART	O	O	3586
an	PRON	O	O	3586
enhancement	NOUN	O	O	3586
not	PART	O	O	3586
only	ADV	O	O	3586
of	ADP	O	O	3586
antineoplastic	ADJ	O	O	3586
effects	NOUN	O	O	3586
but	CCONJ	O	O	3586
also	ADV	O	O	3586
of	ADP	O	O	3586
toxicity	NOUN	O	Disease	3586
in	ADP	O	O	3586
normal	ADJ	O	O	3586
tissues	NOUN	O	O	3586
.	PUNCT	O	O	3586
This	PRON	O	O	3587
report	VERB	O	O	3587
demonstrates	VERB	O	O	3587
for	ADP	O	O	3587
the	PRON	O	O	3587
first	ADV	O	O	3587
time	NOUN	O	O	3587
that	SCONJ	O	O	3587
the	PRON	O	O	3587
pharmacodynamic	ADJ	O	O	3587
properties	NOUN	O	O	3587
of	ADP	O	O	3587
cyclosporin A	PRON	O	Chemical	3587
may	AUX	O	O	3587
not	PART	O	O	3587
be	AUX	O	O	3587
confined	VERB	O	O	3587
strictly	ADV	O	O	3587
to	PART	O	O	3587
suppression	NOUN	O	O	3587
of	ADP	O	O	3587
normal	ADJ	O	O	3587
T	NOUN	O	Chemical	3587
-	PUNCT	O	O	3587
cell	NOUN	O	O	3587
functions	VERB	O	O	3587
.	PUNCT	O	O	3587
The	PRON	O	O	3590
hematologic	ADJ	O	O	3590
effects	NOUN	O	O	3590
of	ADP	O	O	3590
cefonicid	PROPN	O	O	3590
and	CCONJ	O	O	3590
cefazedone	NOUN	O	O	3590
in	ADP	O	O	3590
the	PRON	O	O	3590
dog	NOUN	O	O	3590
:	PUNCT	O	O	3590
a	PRON	O	O	3590
potential	ADJ	O	O	3590
model	NOUN	O	O	3590
of	ADP	O	O	3590
cephalosporin	PROPN	O	O	3590
hematotoxicity	PROPN	O	O	3590
in	ADP	O	O	3590
man	NOUN	O	O	3590
.	PUNCT	O	O	3590
Cephalosporin	PROPN	O	O	3591
antibiotics	VERB	O	O	3591
cause	VERB	O	O	3591
a	PRON	O	O	3591
variety	NOUN	O	O	3591
of	ADP	O	O	3591
hematologic	ADJ	O	O	3591
disturbances	NOUN	O	O	3591
in	ADP	O	O	3591
man	NOUN	O	O	3591
,	PUNCT	O	O	3591
the	PRON	O	O	3591
pathogeneses	NOUN	O	O	3591
and	CCONJ	O	O	3591
hematopathology	NOUN	O	O	3591
of	ADP	O	O	3591
which	PRON	O	O	3591
remain	VERB	O	O	3591
poorly	ADV	O	O	3591
characterized	VERB	O	O	3591
.	PUNCT	O	O	3591
There	ADV	O	O	3592
is	AUX	O	O	3592
a	PRON	O	O	3592
need	VERB	O	O	3592
for	ADP	O	O	3592
a	PRON	O	O	3592
well	ADV	O	O	3592
-	PUNCT	O	O	3592
defined	VERB	O	O	3592
animal	NOUN	O	O	3592
model	NOUN	O	O	3592
in	ADP	O	O	3592
which	PRON	O	O	3592
these	PRON	O	O	3592
blood	NOUN	O	O	3592
dyscrasias	PROPN	O	O	3592
can	AUX	O	O	3592
be	AUX	O	O	3592
studied	VERB	O	O	3592
.	PUNCT	O	O	3592
In	ADP	O	O	3593
four	NUM	O	O	3593
subacute	VERB	O	O	3593
toxicity	NOUN	O	Disease	3593
studies	NOUN	O	O	3593
,	PUNCT	O	O	3593
the	PRON	O	O	3593
intravenous	ADJ	O	O	3593
administration	NOUN	O	O	3593
of	ADP	O	O	3593
cefonicid	PROPN	O	O	3593
or	CCONJ	O	O	3593
cefazedone	NOUN	O	O	3593
to	PART	O	O	3593
beagle	PROPN	O	O	3593
dogs	NOUN	O	O	3593
caused	VERB	O	O	3593
a	PRON	O	O	3593
dose	NOUN	O	O	3593
-	PUNCT	O	O	3593
dependent	ADJ	O	O	3593
incidence	NOUN	O	O	3593
of	ADP	O	O	3593
anemia	NOUN	O	Disease	3593
,	PUNCT	O	O	3593
neutropenia	ADJ	O	Disease	3593
,	PUNCT	O	O	3593
and	CCONJ	O	O	3593
thrombocytopenia	PROPN	O	Disease	3593
after	ADP	O	O	3593
1	X	O	O	3593
-	PUNCT	O	O	3593
3	X	O	O	3593
months	NOUN	O	O	3593
of	ADP	O	O	3593
treatment	NOUN	O	O	3593
.	PUNCT	O	O	3593
A	PRON	O	O	3594
nonregenerative	PROPN	O	O	3594
anemia	NOUN	O	Disease	3594
was	AUX	O	O	3594
the	PRON	O	O	3594
most	ADV	O	O	3594
compromising	VERB	O	O	3594
of	ADP	O	O	3594
the	PRON	O	O	3594
cytopenias	PROPN	O	O	3594
and	CCONJ	O	O	3594
occurred	VERB	O	O	3594
in	ADP	O	O	3594
approximately	ADV	O	O	3594
50%	NOUN	O	O	3594
of	ADP	O	O	3594
dogs	NOUN	O	O	3594
receiving	VERB	O	O	3594
400	NUM	O	O	3594
-	PUNCT	O	O	3594
500	NUM	O	O	3594
mg	VERB	O	O	3594
/	PUNCT	O	O	3594
kg	VERB	O	O	3594
cefonicid	PROPN	O	O	3594
or	CCONJ	O	O	3594
540	NUM	O	O	3594
-	PUNCT	O	O	3594
840	NUM	O	O	3594
mg	VERB	O	O	3594
/	PUNCT	O	O	3595
kg	VERB	O	O	3595
cefazedone	NOUN	O	O	3595
.	PUNCT	O	O	3595
All	PRON	O	O	3596
three	NUM	O	O	3596
cytopenias	PROPN	O	O	3596
were	AUX	O	O	3596
completely	ADV	O	O	3596
reversible	ADJ	O	O	3596
following	VERB	O	O	3596
cessation	NOUN	O	O	3596
of	ADP	O	O	3596
treatment	NOUN	O	O	3596
;	PUNCT	O	O	3596
the	PRON	O	O	3596
time	NOUN	O	O	3596
required	VERB	O	O	3596
for	ADP	O	O	3596
recovery	NOUN	O	O	3596
of	ADP	O	O	3596
the	PRON	O	O	3596
erythron	VERB	O	O	3596
(	PUNCT	O	O	3596
approximately	ADV	O	O	3596
1	X	O	O	3596
month	NOUN	O	O	3596
)	PUNCT	O	O	3596
was	AUX	O	O	3596
considerably	ADV	O	O	3596
longer	ADV	O	O	3596
than	ADP	O	O	3596
that	SCONJ	O	O	3596
of	ADP	O	O	3596
the	PRON	O	O	3596
granulocytes	VERB	O	O	3596
and	CCONJ	O	O	3596
platelets	VERB	O	O	3596
(	PUNCT	O	O	3596
hours	NOUN	O	O	3596
to	PART	O	O	3596
a	PRON	O	O	3596
few	ADJ	O	O	3596
days	NOUN	O	O	3596
)	PUNCT	O	O	3596
.	PUNCT	O	O	3596
Upon	SCONJ	O	O	3597
rechallenge	VERB	O	O	3597
with	ADP	O	O	3597
either	ADV	O	O	3597
cephalosporin	PROPN	O	O	3597
,	PUNCT	O	O	3597
the	PRON	O	O	3597
hematologic	ADJ	O	O	3597
syndrome	NOUN	O	O	3597
was	AUX	O	O	3597
reproduced	VERB	O	O	3597
in	ADP	O	O	3597
most	ADV	O	O	3597
dogs	NOUN	O	O	3597
tested	VERB	O	O	3597
;	PUNCT	O	O	3597
cefonicid	PROPN	O	O	3597
(	PUNCT	O	O	3597
but	CCONJ	O	O	3597
not	PART	O	O	3597
cefazedone)-treated	VERB	O	O	3597
dogs	NOUN	O	O	3597
showed	VERB	O	O	3597
a	PRON	O	O	3597
substantially	ADV	O	O	3597
reduced	VERB	O	O	3597
induction	NOUN	O	O	3597
period	NOUN	O	O	3597
(	PUNCT	O	O	3597
15	NUM	O	O	3597
+	ADP	O	O	3597
/-	PUNCT	O	O	3597
This	PRON	O	O	3598
observation	NOUN	O	O	3598
,	PUNCT	O	O	3598
along	ADV	O	O	3598
with	ADP	O	O	3598
the	PRON	O	O	3598
rapid	ADJ	O	O	3598
rate	NOUN	O	O	3598
of	ADP	O	O	3598
decline	VERB	O	O	3598
in	ADP	O	O	3598
red	ADJ	O	O	3598
cell	NOUN	O	O	3598
mass	PROPN	O	O	3598
parameters	NOUN	O	O	3598
of	ADP	O	O	3598
affected	VERB	O	O	3598
dogs	NOUN	O	O	3598
,	PUNCT	O	O	3598
suggests	VERB	O	O	3598
that	SCONJ	O	O	3598
a	PRON	O	O	3598
hemolytic	ADJ	O	O	3598
component	NOUN	O	O	3598
complicated	VERB	O	O	3598
the	PRON	O	O	3598
red	ADJ	O	O	3598
cell	NOUN	O	O	3598
production	NOUN	O	O	3598
problem	NOUN	O	O	3598
and	CCONJ	O	O	3598
that	SCONJ	O	O	3598
multiple	ADJ	O	O	3598
toxicologic	ADV	O	O	3598
mechanisms	NOUN	O	O	3598
contributed	VERB	O	O	3598
to	PART	O	O	3598
the	PRON	O	O	3598
cytopenia	NOUN	O	O	3598
.	PUNCT	O	O	3598
We	PRON	O	O	3599
conclude	VERB	O	O	3599
that	SCONJ	O	O	3599
the	PRON	O	O	3599
administration	NOUN	O	O	3599
of	ADP	O	O	3599
high	ADJ	O	O	3599
doses	NOUN	O	O	3599
of	ADP	O	O	3599
cefonicid	PROPN	O	O	3599
or	CCONJ	O	O	3599
cefazedone	NOUN	O	O	3599
to	PART	O	O	3599
dogs	NOUN	O	O	3599
can	AUX	O	O	3599
induce	VERB	O	O	3599
hematotoxicity	PROPN	O	O	3599
similar	ADJ	O	O	3599
to	PART	O	O	3599
the	PRON	O	O	3599
cephalosporin	PROPN	O	O	3599
-	PUNCT	O	O	3599
induced	VERB	O	O	3599
blood	NOUN	O	O	3599
dyscrasias	PROPN	O	O	3599
described	VERB	O	O	3599
in	ADP	O	O	3599
man	NOUN	O	O	3599
and	CCONJ	O	O	3599
thus	ADV	O	O	3599
provides	VERB	O	O	3599
a	PRON	O	O	3599
useful	ADJ	O	O	3599
model	NOUN	O	O	3599
for	ADP	O	O	3599
studying	VERB	O	O	3599
the	PRON	O	O	3599
mechanisms	NOUN	O	O	3599
of	ADP	O	O	3599
these	PRON	O	O	3599
disorders	NOUN	O	O	3599
.	PUNCT	O	O	3599
A	PRON	O	O	3602
pyridoxine	NOUN	O	O	3602
-	PUNCT	O	O	3602
dependent	ADJ	O	O	3602
behavioral	ADJ	O	O	3602
disorder	NOUN	O	O	3602
unmasked	ADJ	O	O	3602
by	ADP	O	O	3602
isoniazid	NOUN	O	Chemical	3602
.	PUNCT	O	O	3602
A	PRON	O	O	3603
3-year	NOUN	O	O	3603
-	PUNCT	O	O	3603
old	ADJ	O	O	3603
girl	NOUN	O	O	3603
had	VERB	O	O	3603
behavioral	ADJ	O	O	3603
deterioration	NOUN	O	O	3603
,	PUNCT	O	O	3603
with	ADP	O	O	3603
hyperkinesis	NOUN	O	Disease	3603
,	PUNCT	O	O	3603
irritability	NOUN	O	Disease	3603
,	PUNCT	O	O	3603
and	CCONJ	O	O	3603
sleeping	VERB	O	O	3603
difficulties	NOUN	O	O	3603
after	ADP	O	O	3603
the	PRON	O	O	3603
therapeutic	ADJ	O	O	3603
administration	NOUN	O	O	3603
of	ADP	O	O	3603
isoniazid	NOUN	O	Chemical	3603
.	PUNCT	O	O	3603
The	PRON	O	O	3604
administration	NOUN	O	O	3604
of	ADP	O	O	3604
pharmacologic	ADJ	O	O	3604
doses	NOUN	O	O	3604
of	ADP	O	O	3604
pyridoxine	NOUN	O	O	3604
hydrochloride	NOUN	O	O	3604
led	VERB	O	O	3604
to	PART	O	O	3604
a	PRON	O	O	3604
disappearance	NOUN	O	O	3604
of	ADP	O	O	3604
symptoms	NOUN	O	O	3604
.	PUNCT	O	O	3604
After	ADP	O	O	3605
discontinuing	VERB	O	O	3605
isoniazid	NOUN	O	Chemical	3605
therapy	NOUN	O	O	3605
a	PRON	O	O	3605
similar	ADJ	O	O	3605
pattern	NOUN	O	O	3605
of	ADP	O	O	3605
behavior	NOUN	O	O	3605
was	AUX	O	O	3605
noted	VERB	O	O	3605
that	SCONJ	O	O	3605
was	AUX	O	O	3605
controlled	VERB	O	O	3605
by	ADP	O	O	3605
pyridoxine	NOUN	O	O	3605
.	PUNCT	O	O	3605
A	PRON	O	O	3606
placebo	NOUN	O	O	3606
had	VERB	O	O	3606
no	PRON	O	O	3606
effect	VERB	O	O	3606
,	PUNCT	O	O	3606
but	CCONJ	O	O	3606
niacinamide	NOUN	O	O	3606
was	AUX	O	O	3606
as	ADP	O	O	3606
effective	ADJ	O	O	3606
as	ADP	O	O	3606
pyridoxine	NOUN	O	O	3606
.	PUNCT	O	O	3606
Periodic	ADJ	O	O	3607
withdrawal	NOUN	O	O	3607
of	ADP	O	O	3607
pyridoxine	NOUN	O	O	3607
was	AUX	O	O	3607
associated	VERB	O	O	3607
with	ADP	O	O	3607
return	VERB	O	O	3607
of	ADP	O	O	3607
the	PRON	O	O	3607
hyperkinesis	NOUN	O	Disease	3607
.	PUNCT	O	O	3607
The	PRON	O	O	3608
level	VERB	O	O	3608
of	ADP	O	O	3608
pyridoxal	PROPN	O	O	3608
in	ADP	O	O	3608
the	PRON	O	O	3608
blood	NOUN	O	O	3608
was	AUX	O	O	3608
normal	ADJ	O	O	3608
during	ADP	O	O	3608
the	PRON	O	O	3608
periods	NOUN	O	O	3608
of	ADP	O	O	3608
relapse	VERB	O	O	3608
.	PUNCT	O	O	3608
Metabolic	NOUN	O	O	3609
studies	NOUN	O	O	3609
suggested	VERB	O	O	3609
a	PRON	O	O	3609
block	NOUN	O	O	3609
in	ADP	O	O	3609
the	PRON	O	O	3609
kynurenine	NOUN	O	O	3609
pathway	NOUN	O	O	3609
of	ADP	O	O	3609
tryptophan	PROPN	O	O	3609
metabolism	NOUN	O	O	3609
.	PUNCT	O	O	3609
The	PRON	O	O	3610
patient	NOUN	O	O	3610
has	VERB	O	O	3610
been	AUX	O	O	3610
followed	VERB	O	O	3610
for	ADP	O	O	3610
six	NUM	O	O	3610
years	NOUN	O	O	3610
and	CCONJ	O	O	3610
has	VERB	O	O	3610
required	VERB	O	O	3610
pharmacologic	ADJ	O	O	3610
doses	NOUN	O	O	3610
of	ADP	O	O	3610
pyridoxine	NOUN	O	O	3610
to	PART	O	O	3610
control	VERB	O	O	3610
her	PRON	O	O	3610
behavior	NOUN	O	O	3610
.	PUNCT	O	O	3610
A	PRON	O	O	3613
selective	ADJ	O	O	3613
dopamine	NOUN	O	Chemical	3613
D4	PROPN	O	O	3613
receptor	NOUN	O	O	3613
antagonist	NOUN	O	O	3613
,	PUNCT	O	O	3613
NRA0160	PROPN	O	O	3613
:	PUNCT	O	O	3613
a	PRON	O	O	3613
preclinical	ADJ	O	O	3613
neuropharmacological	ADJ	O	O	3613
profile	NOUN	O	O	3613
.	PUNCT	O	O	3613
NRA0160	PROPN	O	O	3614
,	PUNCT	O	O	3614
5	NUM	O	O	3614
-	PUNCT	O	O	3614
[	X	O	O	3614
2-	X	O	O	3614
(	PUNCT	O	O	3614
4-	X	O	O	3614
(	PUNCT	O	O	3614
3	X	O	O	3614
-	PUNCT	O	O	3614
fluorobenzylidene	X	O	O	3614
)	PUNCT	O	O	3614
piperidin-1-yl	NOUN	O	O	3614
)	PUNCT	O	O	3614
ethyl	PROPN	O	O	3614
]	PUNCT	O	O	3614
-	PUNCT	O	O	3614
4	NUM	O	O	3614
-(4-fluorophenyl	NOUN	O	O	3614
)	PUNCT	O	O	3614
thiazole-2-carboxamide	NOUN	O	O	3614
,	PUNCT	O	O	3614
has	VERB	O	O	3614
a	PRON	O	O	3614
high	ADJ	O	O	3614
affinity	NOUN	O	O	3614
for	ADP	O	O	3614
human	PROPN	O	O	3614
cloned	VERB	O	O	3614
dopamine	NOUN	O	Chemical	3614
D4.2	NOUN	O	O	3614
,	PUNCT	O	O	3614
D4.4	NOUN	O	O	3614
and	CCONJ	O	O	3614
D4.7	NOUN	O	O	3614
receptors	NOUN	O	O	3614
,	PUNCT	O	O	3614
with	ADP	O	O	3614
Ki	PROPN	O	O	3614
values	NOUN	O	O	3614
of	ADP	O	O	3614
0.5	NUM	O	O	3614
,	PUNCT	O	O	3614
0.9	NUM	O	O	3614
and	CCONJ	O	O	3614
2.7	NUM	O	O	3614
nM	NOUN	O	O	3614
,	PUNCT	O	O	3614
respectively	ADV	O	O	3614
.	PUNCT	O	O	3614
NRA0160	PROPN	O	O	3615
is	AUX	O	O	3615
over	ADP	O	O	3615
20,000fold	NUM	O	O	3615
more	ADJ	O	O	3615
potent	ADJ	O	O	3615
at	ADP	O	O	3615
the	PRON	O	O	3615
dopamine	NOUN	O	Chemical	3615
D4.2	NOUN	O	O	3615
receptor	NOUN	O	O	3615
compared	VERB	O	O	3615
with	ADP	O	O	3615
the	PRON	O	O	3615
human	PROPN	O	O	3615
cloned	VERB	O	O	3615
dopamine	NOUN	O	Chemical	3615
D2L	PROPN	O	O	3615
receptor	NOUN	O	O	3615
.	PUNCT	O	O	3615
NRA0160	PROPN	O	O	3616
has	VERB	O	O	3616
negligible	ADJ	O	O	3616
affinity	NOUN	O	O	3616
for	ADP	O	O	3616
the	PRON	O	O	3616
human	PROPN	O	O	3616
cloned	VERB	O	O	3616
dopamine	NOUN	O	Chemical	3616
D3	PROPN	O	O	3616
receptor	NOUN	O	O	3616
(	PUNCT	O	O	3616
Ki=39	PROPN	O	O	3616
nM	NOUN	O	O	3616
)	PUNCT	O	O	3616
,	PUNCT	O	O	3616
rat	NOUN	O	O	3616
serotonin	PROPN	O	Chemical	3616
(	PUNCT	O	O	3616
5-HT)2A	NOUN	O	O	3616
receptors	NOUN	O	O	3616
(	PUNCT	O	O	3616
Ki=180	PROPN	O	O	3616
nM	NOUN	O	O	3616
)	PUNCT	O	O	3616
and	CCONJ	O	O	3616
rat	NOUN	O	O	3616
alpha1	NOUN	O	O	3616
adrenoceptor	NOUN	O	O	3616
(	PUNCT	O	O	3616
Ki=237	NOUN	O	O	3616
nM	NOUN	O	O	3616
)	PUNCT	O	O	3616
.	PUNCT	O	O	3616
NRA0160	PROPN	O	O	3617
and	CCONJ	O	O	3617
clozapine	PROPN	O	Chemical	3617
antagonized	VERB	O	O	3617
locomotor hyperactivity	NOUN	O	Disease	3617
induced	VERB	O	O	3617
by	ADP	O	O	3617
methamphetamine	NOUN	O	Chemical	3617
(	PUNCT	O	O	3617
MAP	PROPN	O	O	3617
)	PUNCT	O	O	3617
in	ADP	O	O	3617
mice	NOUN	O	O	3617
.	PUNCT	O	O	3617
NRA0160	PROPN	O	O	3618
and	CCONJ	O	O	3618
clozapine	PROPN	O	Chemical	3618
antagonized	VERB	O	O	3618
MAP	PROPN	O	O	3618
-	PUNCT	O	O	3618
induced	VERB	O	O	3618
stereotyped	VERB	O	O	3618
behavior	NOUN	O	O	3618
in	ADP	O	O	3618
mice	NOUN	O	O	3618
,	PUNCT	O	O	3618
although	SCONJ	O	O	3618
their	PRON	O	O	3618
effects	NOUN	O	O	3618
did	VERB	O	O	3618
not	PART	O	O	3618
exceed	VERB	O	O	3618
50%	NOUN	O	O	3618
inhibition	NOUN	O	O	3618
,	PUNCT	O	O	3618
even	ADV	O	O	3618
at	ADP	O	O	3618
the	PRON	O	O	3618
highest	ADJ	O	O	3618
dose	NOUN	O	O	3618
given	VERB	O	O	3618
.	PUNCT	O	O	3618
NRA0160	PROPN	O	O	3619
and	CCONJ	O	O	3619
clozapine	PROPN	O	Chemical	3619
significantly	ADV	O	O	3619
induced	VERB	O	O	3619
catalepsy	VERB	O	Disease	3619
in	ADP	O	O	3619
rats	NOUN	O	O	3619
,	PUNCT	O	O	3619
although	SCONJ	O	O	3619
their	PRON	O	O	3619
effects	NOUN	O	O	3619
did	VERB	O	O	3619
not	PART	O	O	3619
exceed	VERB	O	O	3619
50%	NOUN	O	O	3619
induction	NOUN	O	O	3619
even	ADV	O	O	3619
at	ADP	O	O	3619
the	PRON	O	O	3619
highest	ADJ	O	O	3619
dose	NOUN	O	O	3619
given	VERB	O	O	3619
.	PUNCT	O	O	3619
NRA0160	PROPN	O	O	3620
and	CCONJ	O	O	3620
clozapine	PROPN	O	Chemical	3620
significantly	ADV	O	O	3620
reversed	VERB	O	O	3620
the	PRON	O	O	3620
disruption	NOUN	O	O	3620
of	ADP	O	O	3620
prepulse	NOUN	O	O	3620
inhibition	NOUN	O	O	3620
(	PUNCT	O	O	3620
PPI	PROPN	O	O	3620
)	PUNCT	O	O	3620
in	ADP	O	O	3620
rats	NOUN	O	O	3620
produced	VERB	O	O	3620
by	ADP	O	O	3620
apomorphine	PROPN	O	Chemical	3620
.	PUNCT	O	O	3620
NRA0160	PROPN	O	O	3621
and	CCONJ	O	O	3621
clozapine	PROPN	O	Chemical	3622
significantly	ADV	O	O	3622
shortened	VERB	O	O	3622
the	PRON	O	O	3622
phencyclidine	NOUN	O	Chemical	3622
(	PUNCT	O	O	3622
PCP)-induced	ADJ	O	O	3622
prolonged	VERB	O	O	3622
swimming	VERB	O	O	3622
latency	VERB	O	O	3622
in	ADP	O	O	3622
rats	NOUN	O	O	3622
in	ADP	O	O	3622
a	PRON	O	O	3622
water	PROPN	O	O	3622
maze	NOUN	O	O	3622
task	NOUN	O	O	3622
.	PUNCT	O	O	3622
These	PRON	O	O	3623
findings	NOUN	O	O	3623
suggest	VERB	O	O	3623
that	SCONJ	O	O	3623
NRA0160	PROPN	O	O	3623
may	AUX	O	O	3623
have	VERB	O	O	3623
unique	ADJ	O	O	3623
antipsychotic	ADJ	O	O	3623
activities	NOUN	O	O	3623
without	ADP	O	O	3623
the	PRON	O	O	3623
liability	NOUN	O	O	3623
of	ADP	O	O	3623
motor	NOUN	O	O	3623
side	NOUN	O	O	3623
effects	NOUN	O	O	3623
typical	ADJ	O	O	3623
of	ADP	O	O	3623
classical	ADJ	O	O	3623
antipsychotics	NOUN	O	O	3623
.	PUNCT	O	O	3623
Prolonged	VERB	O	O	3626
cholestasis	NOUN	O	Disease	3626
after	ADP	O	O	3626
troleandomycin	NOUN	O	O	3626
-	PUNCT	O	O	3626
induced	VERB	O	O	3626
acute	ADJ	O	O	3626
hepatitis	NOUN	O	Disease	3626
.	PUNCT	O	O	3626
We	PRON	O	O	3627
report	VERB	O	O	3627
the	PRON	O	O	3627
case	NOUN	O	O	3627
of	ADP	O	O	3627
a	PRON	O	O	3627
patient	NOUN	O	O	3627
in	ADP	O	O	3627
whom	PRON	O	O	3627
troleandomycin	NOUN	O	O	3627
-	PUNCT	O	O	3627
induced	VERB	O	O	3627
hepatitis	NOUN	O	Disease	3627
was	AUX	O	O	3627
followed	VERB	O	O	3627
by	ADP	O	O	3627
prolonged	VERB	O	O	3627
anicteric	PROPN	O	O	3627
cholestasis	NOUN	O	Disease	3627
.	PUNCT	O	O	3627
Jaundice	NOUN	O	O	3628
occurred	VERB	O	O	3628
after	ADP	O	O	3628
administration	NOUN	O	O	3628
of	ADP	O	O	3628
troleandomycin	NOUN	O	O	3628
for	ADP	O	O	3628
7	NUM	O	O	3628
days	NOUN	O	O	3628
and	CCONJ	O	O	3628
was	AUX	O	O	3628
associated	VERB	O	O	3628
with	ADP	O	O	3628
hypereosinophilia	NOUN	O	O	3628
.	PUNCT	O	O	3628
Jaundice	NOUN	O	O	3629
disappeared	VERB	O	O	3629
within	ADP	O	O	3629
3	X	O	O	3629
months	NOUN	O	O	3629
but	CCONJ	O	O	3629
was	AUX	O	O	3629
followed	VERB	O	O	3629
by	ADP	O	O	3629
prolonged	VERB	O	O	3629
anicteric	PROPN	O	O	3629
cholestasis	NOUN	O	Disease	3629
marked	VERB	O	O	3629
by	ADP	O	O	3629
pruritus	PROPN	O	Disease	3629
and	CCONJ	O	O	3629
high	ADJ	O	O	3629
levels	NOUN	O	O	3629
of	ADP	O	O	3629
alkaline	NOUN	O	O	3629
phosphatase	ADJ	O	O	3629
and	CCONJ	O	O	3629
gammaglutamyltransferase	NOUN	O	O	3629
activities	NOUN	O	O	3629
.	PUNCT	O	O	3629
Finally	ADV	O	O	3630
,	PUNCT	O	O	3630
pruritus	PROPN	O	Disease	3630
disappeared	VERB	O	O	3630
within	ADP	O	O	3630
19	NUM	O	O	3630
months	NOUN	O	O	3630
,	PUNCT	O	O	3630
and	CCONJ	O	O	3630
liver	NOUN	O	O	3630
tests	VERB	O	O	3630
returned	VERB	O	O	3630
to	PART	O	O	3630
normal	ADJ	O	O	3630
27	NUM	O	O	3630
months	NOUN	O	O	3630
after	ADP	O	O	3630
the	PRON	O	O	3630
onset	VERB	O	O	3630
of	ADP	O	O	3630
hepatitis	NOUN	O	Disease	3630
.	PUNCT	O	O	3630
This	PRON	O	O	3631
observation	NOUN	O	O	3631
demonstrates	VERB	O	O	3631
that	SCONJ	O	O	3631
prolonged	VERB	O	O	3631
cholestasis	NOUN	O	Disease	3631
can	AUX	O	O	3631
follow	VERB	O	O	3631
troleandomycin	NOUN	O	O	3631
-	PUNCT	O	O	3631
induced	VERB	O	O	3631
acute	ADJ	O	O	3631
hepatitis	NOUN	O	Disease	3631
.	PUNCT	O	O	3631
Lovastatin	PROPN	O	Chemical	3634
and	CCONJ	O	O	3634
simvastatin	PROPN	O	Chemical	3634
are	AUX	O	O	3634
the	PRON	O	O	3634
2	X	O	O	3634
best	ADV	O	O	3634
-	PUNCT	O	O	3634
known	VERB	O	O	3634
members	NOUN	O	O	3634
of	ADP	O	O	3634
the	PRON	O	O	3634
class	NOUN	O	O	3634
of	ADP	O	O	3634
hypolipidaemic	ADJ	O	O	3634
agents	NOUN	O	O	3634
known	VERB	O	O	3634
as	ADP	O	O	3634
HMG	PROPN	O	O	3634
CoA	PROPN	O	O	3634
reductase	NOUN	O	O	3634
inhibitors	NOUN	O	O	3634
.	PUNCT	O	O	3634
Clinical	NOUN	O	O	3635
experience	NOUN	O	O	3635
with	ADP	O	O	3635
lovastatin	NOUN	O	Chemical	3635
includes	VERB	O	O	3635
over	ADP	O	O	3635
5000	NUM	O	O	3635
patients	NOUN	O	O	3635
,	PUNCT	O	O	3635
700	NUM	O	O	3635
of	ADP	O	O	3635
whom	PRON	O	O	3635
have	VERB	O	O	3635
been	AUX	O	O	3635
treated	VERB	O	O	3635
for	ADP	O	O	3635
2	X	O	O	3635
years	NOUN	O	O	3635
or	CCONJ	O	O	3635
more	ADJ	O	O	3635
,	PUNCT	O	O	3635
and	CCONJ	O	O	3635
experience	NOUN	O	O	3635
with	ADP	O	O	3635
simvastatin	PROPN	O	Chemical	3635
includes	VERB	O	O	3635
over	ADP	O	O	3635
3500	NUM	O	O	3635
patients	NOUN	O	O	3635
,	PUNCT	O	O	3635
of	ADP	O	O	3635
whom	PRON	O	O	3635
350	NUM	O	O	3635
have	VERB	O	O	3635
been	AUX	O	O	3635
treated	VERB	O	O	3635
for	ADP	O	O	3635
18	NUM	O	O	3635
months	NOUN	O	O	3635
or	CCONJ	O	O	3635
more	ADJ	O	O	3635
.	PUNCT	O	O	3635
Lovastatin	PROPN	O	Chemical	3636
has	VERB	O	O	3636
been	AUX	O	O	3636
marketed	VERB	O	O	3636
in	ADP	O	O	3636
the	PRON	O	O	3636
United	PROPN	O	O	3636
States	NOUN	O	O	3636
for	ADP	O	O	3636
over	ADP	O	O	3636
6	NUM	O	O	3636
months	NOUN	O	O	3636
.	PUNCT	O	O	3636
Both	PRON	O	O	3637
agents	NOUN	O	O	3637
show	VERB	O	O	3637
substantial	ADJ	O	O	3637
clinical	ADJ	O	O	3637
efficacy	NOUN	O	O	3637
,	PUNCT	O	O	3637
with	ADP	O	O	3637
reductions	NOUN	O	O	3637
in	ADP	O	O	3637
total	ADJ	O	O	3637
cholesterol	NOUN	O	Chemical	3637
of	ADP	O	O	3637
over	ADP	O	O	3637
30%	NOUN	O	O	3637
and	CCONJ	O	O	3637
in	ADP	O	O	3637
LDL	NOUN	O	O	3637
-	PUNCT	O	O	3637
cholesterol	NOUN	O	Chemical	3637
of	ADP	O	O	3637
40%	NOUN	O	O	3637
in	ADP	O	O	3637
clinical	ADJ	O	O	3637
studies	NOUN	O	O	3637
.	PUNCT	O	O	3637
Modest	ADJ	O	O	3638
increases	VERB	O	O	3638
in	ADP	O	O	3638
HDL	PROPN	O	O	3638
-	PUNCT	O	O	3638
cholesterol	NOUN	O	Chemical	3638
levels	NOUN	O	O	3638
of	ADP	O	O	3638
about	ADP	O	O	3638
10%	NOUN	O	O	3638
are	AUX	O	O	3638
also	ADV	O	O	3638
reported	VERB	O	O	3638
.	PUNCT	O	O	3638
Minor	ADJ	O	O	3639
elevations	NOUN	O	O	3639
of	ADP	O	O	3639
creatine	PROPN	O	Chemical	3639
kinase	VERB	O	O	3639
levels	NOUN	O	O	3639
are	AUX	O	O	3639
reported	VERB	O	O	3639
in	ADP	O	O	3639
about	ADP	O	O	3639
5%	NOUN	O	O	3639
of	ADP	O	O	3639
patients	NOUN	O	O	3639
.	PUNCT	O	O	3639
Myopathy	PROPN	O	Disease	3640
,	PUNCT	O	O	3640
associated	VERB	O	O	3640
in	ADP	O	O	3640
some	PRON	O	O	3640
cases	NOUN	O	O	3640
with	ADP	O	O	3640
myoglobinuria	PROPN	O	O	3640
,	PUNCT	O	O	3640
and	CCONJ	O	O	3640
in	ADP	O	O	3640
2	X	O	O	3640
cases	NOUN	O	O	3640
with	ADP	O	O	3640
transient	ADJ	O	O	3640
renal failure	NOUN	O	Disease	3640
,	PUNCT	O	O	3640
has	VERB	O	O	3640
been	AUX	O	O	3640
rarely	ADV	O	O	3640
reported	VERB	O	O	3640
with	ADP	O	O	3640
lovastatin	NOUN	O	Chemical	3640
,	PUNCT	O	O	3640
especially	ADV	O	O	3640
in	ADP	O	O	3640
patients	NOUN	O	O	3640
concomitantly	ADV	O	O	3640
treated	VERB	O	O	3640
with	ADP	O	O	3640
cyclosporin	NOUN	O	O	3640
,	PUNCT	O	O	3640
gemfibrozil	PROPN	O	O	3640
or	CCONJ	O	O	3640
niacin	PROPN	O	O	3640
.	PUNCT	O	O	3640
Lovastatin	PROPN	O	Chemical	3641
and	CCONJ	O	O	3641
simvastatin	PROPN	O	Chemical	3641
are	AUX	O	O	3641
both	PRON	O	O	3641
effective	ADJ	O	O	3641
and	CCONJ	O	O	3641
well	ADV	O	O	3641
-	PUNCT	O	O	3641
tolerated	VERB	O	O	3641
agents	NOUN	O	O	3641
for	ADP	O	O	3641
lowering	VERB	O	O	3641
elevated	ADJ	O	O	3641
levels	NOUN	O	O	3641
of	ADP	O	O	3641
serum	NOUN	O	O	3641
cholesterol	NOUN	O	Chemical	3641
.	PUNCT	O	O	3641
As	ADP	O	O	3642
wider	ADJ	O	O	3642
use	VERB	O	O	3642
confirms	VERB	O	O	3642
their	PRON	O	O	3642
safety	NOUN	O	O	3642
profile	NOUN	O	O	3642
,	PUNCT	O	O	3642
they	PRON	O	O	3642
will	AUX	O	O	3642
gain	VERB	O	O	3642
increasing	VERB	O	O	3642
importance	NOUN	O	O	3642
in	ADP	O	O	3642
the	PRON	O	O	3642
therapeutic	ADJ	O	O	3642
approach	NOUN	O	O	3642
to	PART	O	O	3642
hypercholesterolaemia	NOUN	O	O	3642
and	CCONJ	O	O	3642
its	PRON	O	O	3642
consequences	NOUN	O	O	3642
.	PUNCT	O	O	3642
Sulfasalazine	NOUN	O	O	3645
-	PUNCT	O	O	3645
induced	VERB	O	O	3645
lupus	PROPN	O	Disease	3645
erythematosus	NOUN	O	O	3645
.	PUNCT	O	O	3645
Pneumonitis	NOUN	O	O	3646
,	PUNCT	O	O	3646
bilateral	ADJ	O	O	3646
pleural effusions	NOUN	O	Disease	3646
,	PUNCT	O	O	3646
echocardiographic	NOUN	O	O	3646
evidence	NOUN	O	O	3646
of	ADP	O	O	3646
cardiac	ADJ	O	O	3646
tamponade	NOUN	O	O	3646
,	PUNCT	O	O	3646
and	CCONJ	O	O	3646
positive	ADJ	O	O	3646
autoantibodies	NOUN	O	O	3646
developed	VERB	O	O	3646
in	ADP	O	O	3646
a	PRON	O	O	3646
43-year	NOUN	O	O	3646
-	PUNCT	O	O	3646
old	ADJ	O	O	3646
man	NOUN	O	O	3646
,	PUNCT	O	O	3646
who	PRON	O	O	3646
was	AUX	O	O	3646
receiving	VERB	O	O	3646
long	ADV	O	O	3646
-	PUNCT	O	O	3646
term	NOUN	O	O	3646
sulfasalazine	PROPN	O	Chemical	3646
therapy	NOUN	O	O	3646
for	ADP	O	O	3646
chronic	ADJ	O	O	3646
ulcerative colitis	NOUN	O	Disease	3646
.	PUNCT	O	O	3646
After	ADP	O	O	3647
cessation	NOUN	O	O	3647
of	ADP	O	O	3647
the	PRON	O	O	3647
sulfasalazine	PROPN	O	Chemical	3647
and	CCONJ	O	O	3647
completion	NOUN	O	O	3647
of	ADP	O	O	3647
a	PRON	O	O	3647
six	NUM	O	O	3647
-	PUNCT	O	O	3647
week	NOUN	O	O	3647
course	NOUN	O	O	3647
of	ADP	O	O	3647
corticosteroids	NOUN	O	Chemical	3647
,	PUNCT	O	O	3647
these	PRON	O	O	3647
problems	NOUN	O	O	3647
resolved	VERB	O	O	3647
over	ADP	O	O	3647
a	PRON	O	O	3647
period	NOUN	O	O	3647
of	ADP	O	O	3647
four	NUM	O	O	3647
to	PART	O	O	3647
six	NUM	O	O	3647
months	NOUN	O	O	3647
.	PUNCT	O	O	3647
It	PRON	O	O	3648
is	AUX	O	O	3648
suggested	VERB	O	O	3648
that	SCONJ	O	O	3648
the	PRON	O	O	3648
patient	NOUN	O	O	3648
had	VERB	O	O	3648
sulfasalazine	PROPN	O	Chemical	3648
-	PUNCT	O	O	3648
induced	VERB	O	O	3648
lupus	PROPN	O	Disease	3648
,	PUNCT	O	O	3648
which	PRON	O	O	3648
manifested	VERB	O	O	3648
with	ADP	O	O	3648
serositis	NOUN	O	O	3648
and	CCONJ	O	O	3648
pulmonary	ADJ	O	O	3648
parenchymal	ADJ	O	O	3648
involvement	NOUN	O	O	3648
in	ADP	O	O	3648
the	PRON	O	O	3648
absence	NOUN	O	O	3648
of	ADP	O	O	3648
joint	ADJ	O	O	3648
symptoms	NOUN	O	O	3648
.	PUNCT	O	O	3648
Physicians	NOUN	O	O	3649
who	PRON	O	O	3649
use	VERB	O	O	3649
sulfasalazine	PROPN	O	Chemical	3649
to	PART	O	O	3649
treat	VERB	O	O	3649
patients	NOUN	O	O	3649
with	ADP	O	O	3649
inflammatory	ADJ	O	O	3649
bowel	ADJ	O	O	3649
disease	PROPN	O	O	3649
should	AUX	O	O	3649
be	AUX	O	O	3649
aware	ADJ	O	O	3649
of	ADP	O	O	3649
the	PRON	O	O	3649
signs	NOUN	O	O	3649
of	ADP	O	O	3649
sulfasalazine	PROPN	O	Chemical	3649
-	PUNCT	O	O	3649
induced	VERB	O	O	3649
lupus	PROPN	O	Disease	3649
syndrome	NOUN	O	O	3649
.	PUNCT	O	O	3649
Optimization	NOUN	O	O	3652
of	ADP	O	O	3652
levodopa	NOUN	O	Chemical	3652
therapy	NOUN	O	O	3652
.	PUNCT	O	O	3652
While	SCONJ	O	O	3653
there	ADV	O	O	3653
is	AUX	O	O	3653
no	PRON	O	O	3653
single	ADJ	O	O	3653
correct	VERB	O	O	3653
starting	VERB	O	O	3653
dose	NOUN	O	O	3653
for	ADP	O	O	3653
levodopa	NOUN	O	Chemical	3653
therapy	NOUN	O	O	3653
,	PUNCT	O	O	3653
many	ADJ	O	O	3653
individuals	NOUN	O	O	3653
can	AUX	O	O	3653
be	AUX	O	O	3653
started	VERB	O	O	3653
on	ADP	O	O	3653
either	ADV	O	O	3653
the	PRON	O	O	3653
25/100	NUM	O	O	3653
or	CCONJ	O	O	3653
controlled	VERB	O	O	3653
-	PUNCT	O	O	3653
release	NOUN	O	O	3653
formula	NOUN	O	O	3653
,	PUNCT	O	O	3653
following	VERB	O	O	3653
the	PRON	O	O	3653
general	ADJ	O	O	3653
rule	NOUN	O	O	3653
not	PART	O	O	3653
to	PART	O	O	3653
attempt	VERB	O	O	3653
to	PART	O	O	3653
titrate	VERB	O	O	3653
carbidopa	NOUN	O	O	3653
-	PUNCT	O	O	3653
levodopa	NOUN	O	Chemical	3653
to	PART	O	O	3653
the	PRON	O	O	3653
point	VERB	O	O	3653
of	ADP	O	O	3653
""""	PUNCT	O	O	3653
normality	NOUN	O	O	3653
,	PUNCT	O	O	3653
""""	PUNCT	O	O	3653
which	PRON	O	O	3653
can	AUX	O	O	3653
lead	VERB	O	Chemical	3653
to	PART	O	O	3653
toxicity	NOUN	O	Disease	3653
.	PUNCT	O	O	3653
Following	VERB	O	O	3654
the	PRON	O	O	3654
initial	ADJ	O	O	3654
period	NOUN	O	O	3654
of	ADP	O	O	3654
therapy	NOUN	O	O	3654
,	PUNCT	O	O	3654
emerging	VERB	O	O	3654
difficulties	NOUN	O	O	3654
require	VERB	O	O	3654
a	PRON	O	O	3654
reassessment	NOUN	O	O	3654
of	ADP	O	O	3654
therapeutic	ADJ	O	O	3654
approaches	VERB	O	O	3654
,	PUNCT	O	O	3654
such	ADJ	O	O	3654
as	ADP	O	O	3654
dosage	NOUN	O	O	3654
adjustment	NOUN	O	O	3654
or	CCONJ	O	O	3654
introduction	NOUN	O	O	3654
of	ADP	O	O	3654
a	PRON	O	O	3654
dopamine	NOUN	O	Chemical	3654
agonist	NOUN	O	O	3654
.	PUNCT	O	O	3654
Other	ADJ	O	O	3655
possible	ADJ	O	O	3655
adverse	ADJ	O	O	3655
effects	NOUN	O	O	3655
--	PUNCT	O	O	3655
such	ADJ	O	O	3655
as	ADP	O	O	3655
gastrointestinal	ADJ	O	O	3655
disorders	NOUN	O	O	3655
,	PUNCT	O	O	3655
orthostatic hypotension	NOUN	O	Disease	3655
,	PUNCT	O	O	3655
levodopa	NOUN	O	Chemical	3655
-	PUNCT	O	O	3655
induced	VERB	O	O	3655
psychosis	VERB	O	Disease	3655
,	PUNCT	O	O	3655
sleep	VERB	O	O	3655
disturbances	NOUN	O	O	3655
or	CCONJ	O	O	3655
parasomnias	NOUN	O	O	3655
,	PUNCT	O	O	3655
or	CCONJ	O	O	3655
drug	NOUN	O	O	3655
interactions	NOUN	O	O	3655
--	PUNCT	O	O	3655
also	ADV	O	O	3655
require	VERB	O	O	3655
carefully	ADV	O	O	3655
monitored	VERB	O	O	3655
individual	ADJ	O	O	3655
treatment	NOUN	O	O	3655
.	PUNCT	O	O	3655
Nonpharmacologic	PROPN	O	O	3656
concerns	NOUN	O	O	3656
can	AUX	O	O	3656
help	VERB	O	O	3656
the	PRON	O	O	3656
Parkinson	NOUN	O	O	3656
's	AUX	O	O	3656
disease	PROPN	O	O	3656
patient	NOUN	O	O	3656
achieve	VERB	O	O	3656
and	CCONJ	O	O	3656
maintain	VERB	O	O	3656
optimal	ADJ	O	O	3656
functioning	VERB	O	O	3656
,	PUNCT	O	O	3656
including	VERB	O	O	3656
daily	ADV	O	O	3656
exercise	VERB	O	O	3656
,	PUNCT	O	O	3656
physical	ADJ	O	O	3656
therapy	NOUN	O	O	3656
,	PUNCT	O	O	3656
and	CCONJ	O	O	3656
involvement	NOUN	O	O	3656
with	ADP	O	O	3656
support	NOUN	O	O	3656
groups	NOUN	O	O	3656
.	PUNCT	O	O	3656
Alpha	NOUN	O	O	3659
and	CCONJ	O	O	3659
beta	NOUN	O	O	3659
coma	NOUN	O	Disease	3659
in	ADP	O	O	3659
drug	NOUN	O	O	3659
intoxication	NOUN	O	O	3659
uncomplicated	ADJ	O	O	3659
by	ADP	O	O	3659
cerebral	ADJ	O	O	3659
hypoxia	NOUN	O	Disease	3659
.	PUNCT	O	O	3659
Four	NUM	O	O	3660
patients	NOUN	O	O	3660
who	PRON	O	O	3660
were	AUX	O	O	3660
rendered	VERB	O	O	3660
comatose	ADJ	O	O	3660
or	CCONJ	O	O	3660
stuporous	PROPN	O	O	3660
by	ADP	O	O	3660
drug	NOUN	O	O	3660
intoxication	NOUN	O	O	3660
,	PUNCT	O	O	3660
but	CCONJ	O	O	3660
who	PRON	O	O	3660
were	AUX	O	O	3660
not	PART	O	O	3660
hypoxic	ADJ	O	Disease	3660
,	PUNCT	O	O	3660
are	AUX	O	O	3660
described	VERB	O	O	3660
.	PUNCT	O	O	3660
Three	NUM	O	O	3661
patients	NOUN	O	O	3661
received	VERB	O	O	3661
high	ADJ	O	O	3661
doses	NOUN	O	O	3661
of	ADP	O	O	3661
chlormethiazole	NOUN	O	O	3661
for	ADP	O	O	3661
alcohol	NOUN	O	Chemical	3661
withdrawal	NOUN	O	O	3661
symptoms	NOUN	O	O	3661
,	PUNCT	O	O	3661
and	CCONJ	O	O	3661
one	NUM	O	O	3661
took	VERB	O	O	3661
a	PRON	O	O	3661
suicidal	ADJ	O	O	3661
overdose	NOUN	O	Disease	3661
of	ADP	O	O	3661
nitrazepam	NOUN	O	Chemical	3661
.	PUNCT	O	O	3661
The	PRON	O	O	3662
patient	NOUN	O	O	3662
with	ADP	O	O	3662
nitrazepam	NOUN	O	Chemical	3662
overdose	NOUN	O	Disease	3662
and	CCONJ	O	O	3662
two	NUM	O	O	3662
of	ADP	O	O	3662
those	PRON	O	O	3662
with	ADP	O	O	3662
chlormethiazole	NOUN	O	O	3662
intoxication	NOUN	O	O	3662
conformed	VERB	O	O	3662
to	PART	O	O	3662
the	PRON	O	O	3662
criteria	NOUN	O	O	3662
of	ADP	O	O	3662
'	PUNCT	O	O	3662
alpha	PROPN	O	O	3662
coma	NOUN	O	Disease	3662
'	PUNCT	O	O	3662
,	PUNCT	O	O	3662
showing	VERB	O	O	3662
non	ADJ	O	O	3662
-	PUNCT	O	O	3662
reactive	ADJ	O	O	3662
generalized	VERB	O	O	3662
or	CCONJ	O	O	3662
frontally	ADV	O	O	3662
predominant	ADJ	O	O	3662
alpha	PROPN	O	O	3662
activity	NOUN	O	O	3662
in	ADP	O	O	3662
the	PRON	O	O	3662
EEG	NOUN	O	O	3662
.	PUNCT	O	O	3662
The	PRON	O	O	3663
fourth	ADV	O	O	3663
patient	NOUN	O	O	3663
who	PRON	O	O	3663
was	AUX	O	O	3663
unconscious	ADJ	O	O	3663
after	ADP	O	O	3663
chlormethiazole	NOUN	O	O	3663
administration	NOUN	O	O	3663
exhibite	PRON	O	O	3663
generalized	VERB	O	O	3663
non	ADJ	O	O	3663
-	PUNCT	O	O	3663
reactive	ADJ	O	O	3663
activity	NOUN	O	O	3663
in	ADP	O	O	3663
the	PRON	O	O	3663
slow	VERB	O	O	3663
beta	NOUN	O	O	3663
range	VERB	O	O	3663
.	PUNCT	O	O	3663
All	PRON	O	O	3664
four	NUM	O	O	3664
recovered	VERB	O	O	3664
completely	ADV	O	O	3664
without	ADP	O	O	3664
neurological	ADJ	O	O	3664
sequelae	ADJ	O	O	3664
following	VERB	O	O	3664
the	PRON	O	O	3664
withdrawal	NOUN	O	O	3664
of	ADP	O	O	3664
the	PRON	O	O	3664
offending	VERB	O	O	3664
agents	NOUN	O	O	3664
.	PUNCT	O	O	3664
The	PRON	O	O	3665
similarities	VERB	O	O	3665
between	ADP	O	O	3665
the	PRON	O	O	3665
effects	NOUN	O	O	3665
of	ADP	O	O	3665
structural	ADJ	O	O	3665
lesions	NOUN	O	O	3665
and	CCONJ	O	O	3665
pharmacological	ADJ	O	O	3665
depression	PROPN	O	Disease	3665
of	ADP	O	O	3665
the	PRON	O	O	3665
brain	NOUN	O	O	3665
stem	VERB	O	O	3665
reticular	ADJ	O	O	3665
formation	NOUN	O	O	3665
are	AUX	O	O	3665
discussed	VERB	O	O	3665
.	PUNCT	O	O	3665
It	PRON	O	O	3666
is	AUX	O	O	3666
suggested	VERB	O	O	3666
that	SCONJ	O	O	3666
in	ADP	O	O	3666
both	PRON	O	O	3666
situations	NOUN	O	O	3666
disturbed	ADJ	O	O	3666
reticulo	PROPN	O	O	3666
-	PUNCT	O	O	3666
thalamic	ADJ	O	O	3666
interactions	NOUN	O	O	3666
are	AUX	O	O	3666
important	ADJ	O	O	3666
in	ADP	O	O	3666
the	PRON	O	O	3666
pathogenesis	NOUN	O	O	3666
of	ADP	O	O	3666
alpha	PROPN	O	O	3666
coma	NOUN	O	Disease	3666
.	PUNCT	O	O	3666
It	PRON	O	O	3667
is	AUX	O	O	3667
concluded	VERB	O	O	3667
that	SCONJ	O	O	3667
when	SCONJ	O	O	3667
this	PRON	O	O	3667
electroencephalographic	ADJ	O	O	3667
and	CCONJ	O	O	3667
behavioural	ADJ	O	O	3667
picture	NOUN	O	O	3667
is	AUX	O	O	3667
seen	VERB	O	O	3667
in	ADP	O	O	3667
drug	NOUN	O	O	3667
intoxication	NOUN	O	O	3667
,	PUNCT	O	O	3667
in	ADP	O	O	3667
the	PRON	O	O	3667
absence	NOUN	O	O	3667
of	ADP	O	O	3667
significant	ADJ	O	O	3667
hypoxaemia	ADV	O	O	3667
,	PUNCT	O	O	3667
a	PRON	O	O	3667
favourable	ADJ	O	O	3667
outcome	NOUN	O	O	3667
may	AUX	O	O	3667
be	AUX	O	O	3667
anticipated	VERB	O	O	3667
.	PUNCT	O	O	3667
Omitting	VERB	O	O	3670
fentanyl	ADJ	O	Chemical	3670
reduces	VERB	O	O	3670
nausea	NOUN	O	Disease	3670
and	CCONJ	O	O	3670
vomiting	VERB	O	Disease	3670
,	PUNCT	O	O	3670
without	ADP	O	O	3670
increasing	VERB	O	O	3670
pain	NOUN	O	Disease	3670
,	PUNCT	O	O	3670
after	ADP	O	O	3670
sevoflurane	VERB	O	Chemical	3670
for	ADP	O	O	3670
day	NOUN	O	O	3670
surgery	NOUN	O	O	3670
.	PUNCT	O	O	3670
Despite	SCONJ	O	O	3671
advantages	NOUN	O	O	3671
of	ADP	O	O	3671
induction	NOUN	O	O	3671
and	CCONJ	O	O	3671
maintenance	NOUN	O	O	3671
of	ADP	O	O	3671
anaesthesia	NOUN	O	O	3671
with	ADP	O	O	3671
sevoflurane	VERB	O	Chemical	3671
,	PUNCT	O	O	3671
postoperative	ADJ	O	O	3671
nausea	NOUN	O	Disease	3671
and	CCONJ	O	O	3671
vomiting	VERB	O	Disease	3671
occurs	VERB	O	O	3671
frequently	ADV	O	O	3671
.	PUNCT	O	O	3671
Fentanyl	NOUN	O	O	3672
is	AUX	O	O	3672
a	PRON	O	O	3672
commonly	ADV	O	O	3672
used	VERB	O	O	3672
supplement	NOUN	O	O	3672
that	SCONJ	O	O	3672
may	AUX	O	O	3672
contribute	VERB	O	O	3672
to	PART	O	O	3672
this	PRON	O	O	3672
,	PUNCT	O	O	3672
although	SCONJ	O	O	3672
it	PRON	O	O	3672
may	AUX	O	O	3672
also	ADV	O	O	3672
improve	VERB	O	O	3672
analgesia	NOUN	O	Disease	3672
.	PUNCT	O	O	3672
This	PRON	O	O	3673
double	ADJ	O	O	3673
-	PUNCT	O	O	3673
blind	ADJ	O	Disease	3673
study	VERB	O	O	3673
examined	VERB	O	O	3673
the	PRON	O	O	3673
incidence	NOUN	O	O	3673
and	CCONJ	O	O	3673
severity	NOUN	O	O	3673
of	ADP	O	O	3673
postoperative	ADJ	O	O	3673
nausea	NOUN	O	Disease	3673
and	CCONJ	O	O	3673
vomiting	VERB	O	Disease	3673
and	CCONJ	O	O	3673
pain	NOUN	O	Disease	3673
in	ADP	O	O	3673
the	PRON	O	O	3673
first	ADV	O	O	3673
24	NUM	O	O	3673
h	X	O	O	3673
after	ADP	O	O	3673
sevoflurane	VERB	O	Chemical	3673
anaesthesia	NOUN	O	O	3673
in	ADP	O	O	3673
216	NUM	O	O	3673
adult	NOUN	O	O	3673
day	NOUN	O	O	3673
surgery	NOUN	O	O	3673
patients	NOUN	O	O	3673
.	PUNCT	O	O	3673
Patients	NOUN	O	O	3674
were	AUX	O	O	3674
randomly	ADV	O	O	3674
allocated	VERB	O	O	3674
to	PART	O	O	3674
either	ADV	O	O	3674
receive	VERB	O	O	3674
or	CCONJ	O	O	3674
not	PART	O	O	3674
receive	VERB	O	O	3674
1	X	O	O	3674
1	X	O	O	3674
fentanyl	ADJ	O	Chemical	3674
,	PUNCT	O	O	3674
while	SCONJ	O	O	3674
a	PRON	O	O	3674
third	ADV	O	O	3674
group	NOUN	O	O	3674
received	VERB	O	O	3674
dexamethasone	NOUN	O	Chemical	3674
in	ADP	O	O	3674
addition	NOUN	O	O	3674
to	PART	O	O	3674
fentanyl	ADJ	O	Chemical	3674
.	PUNCT	O	O	3674
Omission	NOUN	O	O	3675
of	ADP	O	O	3675
fentanyl	ADJ	O	Chemical	3675
did	VERB	O	O	3675
not	PART	O	O	3675
reduce	VERB	O	O	3675
the	PRON	O	O	3675
overall	ADV	O	O	3675
incidence	NOUN	O	O	3675
of	ADP	O	O	3675
postoperative	ADJ	O	O	3675
nausea	NOUN	O	Disease	3675
and	CCONJ	O	O	3675
vomiting	VERB	O	Disease	3675
,	PUNCT	O	O	3675
but	CCONJ	O	O	3675
did	VERB	O	O	3675
reduce	VERB	O	O	3675
the	PRON	O	O	3675
incidence	NOUN	O	O	3675
of	ADP	O	O	3675
vomiting	VERB	O	Disease	3675
and/or	CCONJ	O	O	3675
moderate	ADJ	O	O	3675
to	PART	O	O	3675
severe	ADJ	O	O	3675
nausea	NOUN	O	Disease	3675
prior	ADV	O	O	3675
to	PART	O	O	3675
discharge	VERB	O	O	3675
from	ADP	O	O	3675
20%	NOUN	O	O	3675
and	CCONJ	O	O	3675
17%	NOUN	O	O	3675
with	ADP	O	O	3675
fentanyl	ADJ	O	Chemical	3675
and	CCONJ	O	O	3675
fentanyl	ADJ	O	Chemical	3675
-	PUNCT	O	O	3675
dexamethasone	NOUN	O	Chemical	3675
,	PUNCT	O	O	3675
respectively	ADV	O	O	3675
,	PUNCT	O	O	3675
to	PART	O	O	3675
5%	NOUN	O	O	3675
(	PUNCT	O	O	3675
P	NOUN	O	Chemical	3675
=	PUNCT	O	O	3675
0.013	NUM	O	O	3675
)	PUNCT	O	O	3675
.	PUNCT	O	O	3675
Dexamethasone	NOUN	O	Chemical	3676
had	VERB	O	O	3676
no	PRON	O	O	3676
significant	ADJ	O	O	3676
effect	VERB	O	O	3676
on	ADP	O	O	3676
the	PRON	O	O	3676
incidence	NOUN	O	O	3676
or	CCONJ	O	O	3676
severity	NOUN	O	O	3676
of	ADP	O	O	3676
postoperative	ADJ	O	O	3676
nausea	NOUN	O	Disease	3676
and	CCONJ	O	O	3676
vomiting	VERB	O	Disease	3676
.	PUNCT	O	O	3676
Combining	VERB	O	O	3677
the	PRON	O	O	3677
two	NUM	O	O	3677
fentanyl	ADJ	O	Chemical	3677
groups	NOUN	O	O	3677
revealed	VERB	O	O	3677
further	ADV	O	O	3677
significant	ADJ	O	O	3677
benefits	NOUN	O	O	3677
from	ADP	O	O	3677
the	PRON	O	O	3677
avoidance	NOUN	O	O	3677
of	ADP	O	O	3677
opioids	NOUN	O	O	3677
,	PUNCT	O	O	3677
reducing	VERB	O	O	3677
postoperative	ADJ	O	O	3677
nausea	NOUN	O	Disease	3677
and	CCONJ	O	O	3677
vomiting	VERB	O	Disease	3677
and	CCONJ	O	O	3677
nausea	NOUN	O	Disease	3677
prior	ADV	O	O	3677
to	PART	O	O	3677
discharge	VERB	O	O	3677
from	ADP	O	O	3677
35%	NOUN	O	O	3677
and	CCONJ	O	O	3677
33%	NOUN	O	O	3677
to	PART	O	O	3677
22%	NOUN	O	O	3677
and	CCONJ	O	O	3677
19%	NOUN	O	O	3677
(	PUNCT	O	O	3677
P	NOUN	O	Chemical	3677
=	PUNCT	O	O	3677
0.049	NUM	O	O	3677
and	CCONJ	O	O	3677
P	NOUN	O	Chemical	3677
=	PUNCT	O	O	3677
0.035	NUM	O	O	3677
)	PUNCT	O	O	3677
,	PUNCT	O	O	3677
respectively	ADV	O	O	3677
,	PUNCT	O	O	3677
while	SCONJ	O	O	3677
nausea	NOUN	O	Disease	3677
in	ADP	O	O	3677
the	PRON	O	O	3677
first	ADV	O	O	3677
24	NUM	O	O	3677
h	X	O	O	3677
was	AUX	O	O	3677
decreased	VERB	O	O	3677
from	ADP	O	O	3677
42%	NOUN	O	O	3677
to	PART	O	O	3677
27%	NOUN	O	O	3677
(	PUNCT	O	O	3677
P	NOUN	O	Chemical	3677
=	PUNCT	O	O	3677
0.034	NUM	O	O	3677
)	PUNCT	O	O	3677
.	PUNCT	O	O	3677
Pain	NOUN	O	Disease	3678
severity	NOUN	O	O	3678
and	CCONJ	O	O	3678
analgesic	PROPN	O	O	3678
requirements	NOUN	O	O	3678
were	AUX	O	O	3678
unaffected	ADJ	O	O	3678
by	ADP	O	O	3678
the	PRON	O	O	3678
omission	NOUN	O	O	3678
of	ADP	O	O	3678
fentanyl	ADJ	O	Chemical	3678
.	PUNCT	O	O	3678
Fentanyl	NOUN	O	O	3679
did	VERB	O	O	3679
reduce	VERB	O	O	3679
minor	ADJ	O	O	3679
intraoperative	ADJ	O	O	3679
movement	NOUN	O	O	3679
but	CCONJ	O	O	3679
had	VERB	O	O	3679
no	PRON	O	O	3679
sevoflurane	VERB	O	Chemical	3679
-	PUNCT	O	O	3679
sparing	VERB	O	O	3679
effect	VERB	O	O	3679
and	CCONJ	O	O	3679
increased	VERB	O	O	3679
respiratory depression	NOUN	O	Disease	3679
,	PUNCT	O	O	3679
hypotension	NOUN	O	Disease	3679
and	CCONJ	O	O	3679
bradycardia	NOUN	O	Disease	3679
.	PUNCT	O	O	3679
As	ADP	O	O	3680
fentanyl	ADJ	O	Chemical	3680
exacerbated	VERB	O	O	3680
postoperative	ADJ	O	O	3680
nausea	NOUN	O	Disease	3680
and	CCONJ	O	O	3680
vomiting	VERB	O	Disease	3680
without	ADP	O	O	3680
an	PRON	O	O	3680
improvement	NOUN	O	O	3680
in	ADP	O	O	3680
postoperative	ADJ	O	O	3680
pain	NOUN	O	Disease	3680
and	CCONJ	O	O	3680
also	ADV	O	O	3680
had	VERB	O	O	3680
adverse	ADJ	O	O	3680
cardiorespiratory	NOUN	O	O	3680
effects	NOUN	O	O	3680
,	PUNCT	O	O	3680
it	PRON	O	O	3680
appears	VERB	O	O	3680
to	PART	O	O	3680
be	AUX	O	O	3680
an	PRON	O	O	3680
unnecessary	ADJ	O	O	3680
and	CCONJ	O	O	3680
possibly	ADV	O	O	3680
detrimental	ADJ	O	O	3680
supplement	NOUN	O	O	3680
to	PART	O	O	3680
sevoflurane	VERB	O	Chemical	3680
in	ADP	O	O	3680
day	NOUN	O	O	3680
surgery	NOUN	O	O	3680
.	PUNCT	O	O	3680
Renal	NOUN	O	O	3683
Fanconi syndrome	NOUN	O	Disease	3683
and	CCONJ	O	O	3683
myopathy	PROPN	O	Disease	3683
after	ADP	O	O	3683
liver	NOUN	O	O	3683
transplantation	NOUN	O	O	3683
:	PUNCT	O	O	3683
drug	NOUN	O	O	3684
-	PUNCT	O	O	3684
related	ADJ	O	O	3684
mitochondrial	ADJ	O	O	3684
cytopathy	ADJ	O	O	3684
?	PUNCT	O	O	3684
We	PRON	O	O	3685
describe	VERB	O	O	3685
a	PRON	O	O	3685
15-yr	NOUN	O	O	3685
-	PUNCT	O	O	3685
old	ADJ	O	O	3685
girl	NOUN	O	O	3685
who	PRON	O	O	3685
had	VERB	O	O	3685
orthotopic	NOUN	O	O	3685
liver	NOUN	O	O	3685
transplantation	NOUN	O	O	3685
because	SCONJ	O	O	3685
of	ADP	O	O	3685
Wilson	PROPN	O	O	3685
's	AUX	O	O	3685
disease	PROPN	O	O	3685
.	PUNCT	O	O	3685
Tacrolimus	PROPN	O	Chemical	3686
,	PUNCT	O	O	3686
MMF	PROPN	O	O	3686
,	PUNCT	O	O	3686
and	CCONJ	O	O	3686
steroids	NOUN	O	Chemical	3686
were	AUX	O	O	3686
given	VERB	O	O	3686
as	ADP	O	O	3686
immunosuppressant	ADJ	O	O	3686
.	PUNCT	O	O	3686
Lamivudine	NOUN	O	O	3687
was	AUX	O	O	3687
added	VERB	O	O	3687
because	SCONJ	O	O	3687
of	ADP	O	O	3687
de	VERB	O	O	3687
nova	PROPN	O	O	3687
hepatitis B	PROPN	O	Disease	3687
infection	NOUN	O	Disease	3687
during	ADP	O	O	3687
her	PRON	O	O	3687
follow	VERB	O	O	3687
-	PUNCT	O	O	3687
up	ADP	O	O	3687
.	PUNCT	O	O	3687
Three	NUM	O	O	3688
yr	NOUN	O	O	3688
after	ADP	O	O	3688
transplantation	NOUN	O	O	3688
she	PRON	O	O	3688
developed	VERB	O	O	3688
renal	ADJ	O	O	3688
Fanconi syndrome	NOUN	O	Disease	3688
with	ADP	O	O	3688
severe	ADJ	O	O	3688
metabolic acidosis	NOUN	O	Disease	3688
,	PUNCT	O	O	3688
hypophosphatemia	NOUN	O	O	3688
,	PUNCT	O	O	3688
glycosuria	VERB	O	Disease	3688
,	PUNCT	O	O	3688
and	CCONJ	O	O	3688
aminoaciduria	NOUN	O	O	3688
.	PUNCT	O	O	3688
Although	SCONJ	O	O	3689
tacrolimus	NOUN	O	Chemical	3689
was	AUX	O	O	3689
suspected	VERB	O	O	3689
to	PART	O	O	3689
be	AUX	O	O	3689
the	PRON	O	O	3689
cause	VERB	O	O	3689
of	ADP	O	O	3689
late	ADV	O	O	3689
post	VERB	O	O	3689
-	PUNCT	O	O	3689
transplant	NOUN	O	O	3689
renal	ADJ	O	O	3689
acidosis	NOUN	O	Disease	3689
and	CCONJ	O	O	3689
was	AUX	O	O	3689
replaced	VERB	O	O	3689
by	ADP	O	O	3689
sirolimus	NOUN	O	Chemical	3689
,	PUNCT	O	O	3689
acidosis	NOUN	O	Disease	3689
,	PUNCT	O	O	3689
and	CCONJ	O	O	3689
electrolyte	NOUN	O	O	3689
imbalance	NOUN	O	O	3689
got	VERB	O	O	3689
worse	ADJ	O	O	3689
.	PUNCT	O	O	3689
Proximal	ADJ	O	O	3690
muscle weakness	NOUN	O	Disease	3690
has	VERB	O	O	3690
developed	VERB	O	O	3690
during	ADP	O	O	3690
her	PRON	O	O	3690
follow	VERB	O	O	3690
-	PUNCT	O	O	3690
up	ADP	O	O	3690
.	PUNCT	O	O	3690
Fanconi syndrome	NOUN	O	Disease	3691
,	PUNCT	O	O	3691
as	ADP	O	O	3691
well	ADV	O	O	3691
as	ADP	O	O	3691
myopathy	PROPN	O	Disease	3691
,	PUNCT	O	O	3691
is	AUX	O	O	3691
well	ADV	O	O	3691
recognized	VERB	O	O	3691
in	ADP	O	O	3691
patients	NOUN	O	O	3691
with	ADP	O	O	3691
mitochondrial	ADJ	O	O	3691
disorders	NOUN	O	O	3691
and	CCONJ	O	O	3691
caused	VERB	O	O	3691
by	ADP	O	O	3691
depletion	NOUN	O	O	3691
of	ADP	O	O	3691
mtDNA	PROPN	O	O	3691
.	PUNCT	O	O	3691
We	PRON	O	O	3692
suggest	VERB	O	O	3692
that	SCONJ	O	O	3692
our	PRON	O	O	3692
patient	NOUN	O	O	3692
's	AUX	O	O	3692
tubular	ADJ	O	O	3692
dysfunction	NOUN	O	O	3692
and	CCONJ	O	O	3692
myopathy	PROPN	O	Disease	3692
may	AUX	O	O	3692
have	VERB	O	O	3692
resulted	VERB	O	O	3692
from	ADP	O	O	3692
mitochondrial	ADJ	O	O	3692
dysfunction	NOUN	O	O	3692
which	PRON	O	O	3692
is	AUX	O	O	3692
triggered	VERB	O	O	3692
by	ADP	O	O	3692
tacrolimus	NOUN	O	Chemical	3692
and	CCONJ	O	O	3692
augmented	VERB	O	O	3692
by	ADP	O	O	3692
lamivudine	NOUN	O	Chemical	3692
.	PUNCT	O	O	3692
Antipsychotic	PROPN	O	O	3695
-	PUNCT	O	O	3695
like	INTJ	O	O	3695
profile	NOUN	O	O	3695
of	ADP	O	O	3695
thioperamide	NOUN	O	O	3695
,	PUNCT	O	O	3695
a	PRON	O	O	3695
selective	ADJ	O	O	3695
H3-receptor	NOUN	O	O	3695
antagonist	NOUN	O	O	3695
in	ADP	O	O	3695
mice	NOUN	O	O	3695
.	PUNCT	O	O	3695
Experimental	ADJ	O	O	3696
and	CCONJ	O	O	3696
clinical	ADJ	O	O	3696
evidence	NOUN	O	O	3696
points	VERB	O	O	3696
to	PART	O	O	3696
a	PRON	O	O	3696
role	NOUN	O	O	3696
of	ADP	O	O	3696
central	ADJ	O	O	3696
histaminergic	ADJ	O	O	3696
system	NOUN	O	O	3696
in	ADP	O	O	3696
the	PRON	O	O	3696
pathogenesis	NOUN	O	O	3696
of	ADP	O	O	3696
schizophrenia	PROPN	O	Disease	3696
.	PUNCT	O	O	3696
The	PRON	O	O	3697
present	NOUN	O	O	3697
study	VERB	O	O	3697
was	AUX	O	O	3697
designed	VERB	O	O	3697
to	PART	O	O	3697
study	VERB	O	O	3697
the	PRON	O	O	3697
effect	VERB	O	O	3697
of	ADP	O	O	3697
histamine	NOUN	O	Chemical	3697
H(3)-receptor	ADV	O	O	3697
ligands	NOUN	O	O	3697
on	ADP	O	O	3697
neuroleptic	NOUN	O	O	3697
-	PUNCT	O	O	3697
induced	VERB	O	O	3697
catalepsy	VERB	O	Disease	3697
,	PUNCT	O	O	3697
apomorphine	PROPN	O	Chemical	3697
-	PUNCT	O	O	3697
induced	VERB	O	O	3697
climbing	VERB	O	O	3697
behavior	NOUN	O	O	3697
and	CCONJ	O	O	3697
amphetamine	NOUN	O	Chemical	3697
-	PUNCT	O	O	3697
induced	VERB	O	O	3697
locomotor	PROPN	O	O	3697
activities	NOUN	O	O	3697
in	ADP	O	O	3697
mice	NOUN	O	O	3697
.	PUNCT	O	O	3697
Catalepsy	NOUN	O	Disease	3698
was	AUX	O	O	3698
induced	VERB	O	O	3698
by	ADP	O	O	3698
haloperidol	NOUN	O	Chemical	3698
(	PUNCT	O	O	3698
2	X	O	O	3698
mg	VERB	O	O	3698
/	PUNCT	O	O	3698
kg	VERB	O	O	3698
p.o	PROPN	O	O	3698
.	PUNCT	O	O	3698
)	PUNCT	O	O	3698
,	PUNCT	O	O	3698
while	SCONJ	O	O	3698
apomorphine	PROPN	O	Chemical	3698
(	PUNCT	O	O	3698
1.5	NUM	O	O	3698
mg	VERB	O	O	3698
/	PUNCT	O	O	3698
kg	VERB	O	O	3698
s.c	PROPN	O	O	3698
.	PUNCT	O	O	3698
)	PUNCT	O	O	3698
and	CCONJ	O	O	3698
amphetamine	NOUN	O	Chemical	3698
(	PUNCT	O	O	3698
2	X	O	O	3698
mg	VERB	O	O	3698
/	PUNCT	O	O	3698
kg	VERB	O	O	3698
s.c	PROPN	O	O	3698
.	PUNCT	O	O	3698
)	PUNCT	O	O	3698
(	PUNCT	O	O	3699
R)-alpha	NOUN	O	O	3699
-	PUNCT	O	O	3699
methylhistamine	VERB	O	O	3699
(	PUNCT	O	O	3699
RAMH	NOUN	O	O	3699
)	PUNCT	O	O	3699
(	PUNCT	O	O	3699
5	NUM	O	O	3699
microg	PROPN	O	O	3699
i.c.v	NOUN	O	O	3699
.	PUNCT	O	O	3699
)	PUNCT	O	O	3699
and	CCONJ	O	O	3699
thioperamide	NOUN	O	O	3699
(	PUNCT	O	O	3699
THP	PROPN	O	O	3699
)	PUNCT	O	O	3699
(	PUNCT	O	O	3699
15	NUM	O	O	3699
mg	VERB	O	O	3699
/	PUNCT	O	O	3699
kg	VERB	O	O	3699
i.p	NOUN	O	O	3699
.	PUNCT	O	O	3699
)	PUNCT	O	O	3699
,	PUNCT	O	O	3699
per	ADP	O	O	3699
se	X	O	O	3699
did	VERB	O	O	3699
not	PART	O	O	3699
cause	VERB	O	O	3699
catalepsy	VERB	O	Disease	3699
.	PUNCT	O	O	3699
Administration	NOUN	O	O	3700
of	ADP	O	O	3700
THP	PROPN	O	O	3700
(	PUNCT	O	O	3700
3.75	NUM	O	O	3700
,	PUNCT	O	O	3700
7.5	NUM	O	O	3700
and	CCONJ	O	O	3700
15	NUM	O	O	3700
mg	VERB	O	O	3700
/	PUNCT	O	O	3700
kg	VERB	O	O	3700
i.p	NOUN	O	O	3700
.	PUNCT	O	O	3700
)	PUNCT	O	O	3700
1	X	O	O	3700
h	X	O	O	3701
prior	ADV	O	O	3701
to	PART	O	O	3701
haloperidol	NOUN	O	Chemical	3701
resulted	VERB	O	O	3701
in	ADP	O	O	3701
a	PRON	O	O	3701
dose	NOUN	O	O	3701
-	PUNCT	O	O	3701
dependent	ADJ	O	O	3701
increase	VERB	O	O	3701
in	ADP	O	O	3701
the	PRON	O	O	3701
catalepsy	VERB	O	Disease	3701
times	NOUN	O	O	3701
(	PUNCT	O	O	3701
P	NOUN	O	Chemical	3701
<	X	O	O	3701
0.05	NUM	O	O	3701
)	PUNCT	O	O	3701
.	PUNCT	O	O	3701
However	ADV	O	O	3702
,	PUNCT	O	O	3702
pretreatment	NOUN	O	O	3702
with	ADP	O	O	3702
RAMH	NOUN	O	O	3702
significantly	ADV	O	O	3702
reversed	VERB	O	O	3702
such	ADJ	O	O	3702
an	PRON	O	O	3702
effect	VERB	O	O	3702
of	ADP	O	O	3702
THP	PROPN	O	O	3702
(	PUNCT	O	O	3702
15	NUM	O	O	3702
mg	VERB	O	O	3702
/	PUNCT	O	O	3702
kg	VERB	O	O	3702
i.p	NOUN	O	O	3702
.	PUNCT	O	O	3702
)	PUNCT	O	O	3702
.	PUNCT	O	O	3702
RAMH	NOUN	O	O	3703
per	ADP	O	O	3703
se	X	O	O	3703
showed	VERB	O	O	3703
significant	ADJ	O	O	3703
reduction	NOUN	O	O	3703
in	ADP	O	O	3703
locomotor	PROPN	O	O	3703
time	NOUN	O	O	3703
,	PUNCT	O	O	3703
distance	NOUN	O	O	3703
traveled	VERB	O	O	3703
and	CCONJ	O	O	3703
average	ADJ	O	O	3703
speed	NOUN	O	O	3703
but	CCONJ	O	O	3703
THP	PROPN	O	O	3703
(	PUNCT	O	O	3703
15	NUM	O	O	3703
mg	VERB	O	O	3703
/	PUNCT	O	O	3703
kg	VERB	O	O	3703
i.p	NOUN	O	O	3703
.	PUNCT	O	O	3703
)	PUNCT	O	O	3703
On	ADP	O	O	3704
amphetamine	NOUN	O	Chemical	3704
-	PUNCT	O	O	3704
induced	VERB	O	O	3704
hyperactivity	NOUN	O	Disease	3704
,	PUNCT	O	O	3704
THP	PROPN	O	O	3704
(	PUNCT	O	O	3704
3.75	NUM	O	O	3704
and	CCONJ	O	O	3704
7.5	NUM	O	O	3704
mg	VERB	O	O	3704
/	PUNCT	O	O	3704
kg	VERB	O	O	3704
i.p	NOUN	O	O	3704
.	PUNCT	O	O	3704
)	PUNCT	O	O	3704
Pretreatment	NOUN	O	O	3705
with	ADP	O	O	3705
RAMH	NOUN	O	O	3705
(	PUNCT	O	O	3705
5	NUM	O	O	3705
microg	PROPN	O	O	3705
i.c.v	NOUN	O	O	3705
.	PUNCT	O	O	3705
)	PUNCT	O	O	3705
could	AUX	O	O	3705
partially	ADV	O	O	3705
reverse	VERB	O	O	3705
such	ADJ	O	O	3705
effects	NOUN	O	O	3705
of	ADP	O	O	3705
THP	PROPN	O	O	3705
(	PUNCT	O	O	3705
3.75	NUM	O	O	3705
mg	VERB	O	O	3705
Climbing	VERB	O	O	3706
behavior	NOUN	O	O	3706
induced	VERB	O	O	3706
by	ADP	O	O	3706
apomorphine	PROPN	O	Chemical	3706
was	AUX	O	O	3706
reduced	VERB	O	O	3706
in	ADP	O	O	3706
animals	NOUN	O	O	3706
treated	VERB	O	O	3706
with	ADP	O	O	3706
THP	PROPN	O	O	3706
.	PUNCT	O	O	3706
Such	ADJ	O	O	3707
an	PRON	O	O	3707
effect	VERB	O	O	3707
was	AUX	O	O	3707
,	PUNCT	O	O	3707
however	ADV	O	O	3707
,	PUNCT	O	O	3707
reversed	VERB	O	O	3707
in	ADP	O	O	3707
presence	NOUN	O	O	3707
of	ADP	O	O	3707
RAMH	NOUN	O	O	3707
.	PUNCT	O	O	3707
THP	PROPN	O	O	3708
exhibited	VERB	O	O	3708
an	PRON	O	O	3708
antipsychotic	ADJ	O	O	3708
-	PUNCT	O	O	3708
like	INTJ	O	O	3708
profile	NOUN	O	O	3708
by	ADP	O	O	3708
potentiating	VERB	O	O	3708
haloperidol	NOUN	O	Chemical	3708
-	PUNCT	O	O	3708
induced	VERB	O	O	3708
catalepsy	VERB	O	Disease	3708
,	PUNCT	O	O	3708
reducing	VERB	O	O	3708
amphetamine	NOUN	O	Chemical	3708
-	PUNCT	O	O	3708
induced	VERB	O	O	3708
hyperactivity	NOUN	O	Disease	3708
and	CCONJ	O	O	3708
reducing	VERB	O	O	3708
apomorphine	PROPN	O	Chemical	3708
-	PUNCT	O	O	3708
induced	VERB	O	O	3708
climbing	VERB	O	O	3708
in	ADP	O	O	3708
mice	NOUN	O	O	3708
.	PUNCT	O	O	3708
Such	ADJ	O	O	3709
effects	NOUN	O	O	3709
of	ADP	O	O	3709
THP	PROPN	O	O	3709
were	AUX	O	O	3709
reversed	VERB	O	O	3709
by	ADP	O	O	3709
RAMH	NOUN	O	O	3709
indicating	VERB	O	O	3709
the	PRON	O	O	3709
involvement	NOUN	O	O	3709
of	ADP	O	O	3709
histamine	NOUN	O	Chemical	3709
H(3)-receptors	X	O	O	3709
.	PUNCT	O	O	3709
Findings	NOUN	O	O	3710
suggest	VERB	O	O	3710
a	PRON	O	O	3710
potential	ADJ	O	O	3710
for	ADP	O	O	3710
H(3)-receptor	ADV	O	O	3710
antagonists	NOUN	O	O	3710
in	ADP	O	O	3710
improving	VERB	O	O	3710
the	PRON	O	O	3710
refractory	ADJ	O	O	3710
cases	NOUN	O	O	3710
of	ADP	O	O	3710
schizophrenia	PROPN	O	Disease	3710
.	PUNCT	O	O	3710
Transient	ADJ	O	O	3713
platypnea	PROPN	O	O	3713
-	PUNCT	O	O	3713
orthodeoxia	NOUN	O	O	3713
-	PUNCT	O	O	3713
like	INTJ	O	O	3713
syndrome	NOUN	O	O	3713
induced	VERB	O	O	3713
by	ADP	O	O	3713
propafenone	NOUN	O	O	3713
overdose	NOUN	O	Disease	3713
in	ADP	O	O	3713
a	PRON	O	O	3713
young	ADJ	O	O	3713
woman	NOUN	O	O	3713
with	ADP	O	O	3713
Ebstein	VERB	O	O	3713
's	AUX	O	O	3713
anomaly	NOUN	O	O	3713
.	PUNCT	O	O	3713
In	ADP	O	O	3714
this	PRON	O	O	3714
report	VERB	O	O	3714
we	PRON	O	O	3714
describe	VERB	O	O	3714
the	PRON	O	O	3714
case	NOUN	O	O	3714
of	ADP	O	O	3714
a	PRON	O	O	3714
37-year	NOUN	O	O	3714
-	PUNCT	O	O	3714
old	ADJ	O	O	3714
white	ADJ	O	O	3714
woman	NOUN	O	O	3714
with	ADP	O	O	3714
Ebstein	VERB	O	O	3714
's	AUX	O	O	3714
anomaly	NOUN	O	O	3714
,	PUNCT	O	O	3714
who	PRON	O	O	3714
developed	VERB	O	O	3714
a	PRON	O	O	3714
rare	ADJ	O	O	3714
syndrome	NOUN	O	O	3714
called	VERB	O	O	3714
platypnea	PROPN	O	O	3714
-	PUNCT	O	O	3714
orthodeoxia	NOUN	O	O	3714
,	PUNCT	O	O	3714
characterized	VERB	O	O	3714
by	ADP	O	O	3714
massive	ADJ	O	O	3714
right	ADV	O	O	3714
-	PUNCT	O	O	3714
to	PART	O	O	3714
-	PUNCT	O	O	3714
left	VERB	O	O	3714
interatrial	PROPN	O	O	3714
shunting	VERB	O	O	3714
with	ADP	O	O	3714
transient	ADJ	O	O	3714
profound	ADJ	O	O	3714
hypoxia	NOUN	O	Disease	3714
and	CCONJ	O	O	3714
cyanosis	NOUN	O	Disease	3714
.	PUNCT	O	O	3714
This	PRON	O	O	3715
shunt	VERB	O	O	3715
of	ADP	O	O	3715
blood	NOUN	O	O	3715
via	ADP	O	O	3715
a	PRON	O	O	3715
patent	NOUN	O	O	3715
foramen	VERB	O	O	3715
ovale	ADV	O	O	3715
occurred	VERB	O	O	3715
in	ADP	O	O	3715
the	PRON	O	O	3715
presence	NOUN	O	O	3715
of	ADP	O	O	3715
a	PRON	O	O	3715
normal	ADJ	O	O	3715
pulmonary	ADJ	O	O	3715
artery	NOUN	O	O	3715
pressure	NOUN	O	O	3715
,	PUNCT	O	O	3715
and	CCONJ	O	O	3715
was	AUX	O	O	3715
probably	ADV	O	O	3715
precipitated	VERB	O	O	3715
by	ADP	O	O	3715
a	PRON	O	O	3715
propafenone	NOUN	O	O	3715
overdose	NOUN	O	Disease	3715
.	PUNCT	O	O	3715
This	PRON	O	O	3716
drug	NOUN	O	O	3716
caused	VERB	O	O	3716
biventricular	PROPN	O	O	3716
dysfunction	NOUN	O	O	3716
,	PUNCT	O	O	3716
due	ADJ	O	O	3716
to	PART	O	O	3716
its	PRON	O	O	3716
negative	ADJ	O	O	3716
inotropic	NOUN	O	O	3716
effect	VERB	O	O	3716
,	PUNCT	O	O	3716
and	CCONJ	O	O	3716
hypotension	NOUN	O	Disease	3716
,	PUNCT	O	O	3716
due	ADJ	O	O	3716
to	PART	O	O	3716
its	PRON	O	O	3716
peripheral	ADJ	O	O	3716
vasodilatory	NOUN	O	O	3716
effect	VERB	O	O	3716
.	PUNCT	O	O	3716
A	PRON	O	O	3719
Phase	NOUN	O	O	3719
II	NUM	O	O	3719
trial	NOUN	O	O	3719
of	ADP	O	O	3719
cisplatin	NOUN	O	Chemical	3719
plus	CCONJ	O	O	3719
WR-2721	NOUN	O	O	3719
(	PUNCT	O	O	3719
amifostine	NOUN	O	O	3719
)	PUNCT	O	O	3719
for	ADP	O	O	3719
metastatic	ADJ	O	O	3719
breast carcinoma	NOUN	O	Disease	3719
:	PUNCT	O	O	3719
an	PRON	O	O	3719
Eastern	PROPN	O	O	3719
Cooperative	ADJ	O	O	3719
Oncology	NOUN	O	O	3719
Group	PROPN	O	O	3719
Study	NOUN	O	O	3719
(	PUNCT	O	O	3719
E8188	NOUN	O	O	3719
)	PUNCT	O	O	3719
.	PUNCT	O	O	3719
Cisplatin	PROPN	O	O	3720
has	VERB	O	O	3720
minimal	ADJ	O	O	3720
antitumor	PROPN	O	O	3720
activity	NOUN	O	O	3720
when	SCONJ	O	O	3720
used	VERB	O	O	3720
as	ADP	O	O	3720
second-	NOUN	O	O	3720
or	CCONJ	O	O	3720
third	ADV	O	O	3720
-	PUNCT	O	O	3720
line	NOUN	O	O	3720
treatment	NOUN	O	O	3720
of	ADP	O	O	3720
metastatic	ADJ	O	O	3720
breast carcinoma	NOUN	O	Disease	3720
.	PUNCT	O	O	3720
Older	ADJ	O	O	3721
reports	VERB	O	O	3721
suggest	VERB	O	O	3721
an	PRON	O	O	3721
objective	VERB	O	O	3721
response	NOUN	O	O	3721
rate	NOUN	O	O	3721
of	ADP	O	O	3721
8%	NOUN	O	O	3721
when	SCONJ	O	O	3721
60	NUM	O	O	3721
-	PUNCT	O	O	3721
120	NUM	O	O	3721
mg	VERB	O	O	3721
/	PUNCT	O	O	3721
m2	PROPN	O	O	3721
of	ADP	O	O	3721
cisplatin	NOUN	O	Chemical	3721
is	AUX	O	O	3721
administered	VERB	O	O	3721
every	PRON	O	O	3721
3	X	O	O	3721
-	PUNCT	O	O	3721
4	NUM	O	O	3721
weeks	NOUN	O	O	3721
.	PUNCT	O	O	3721
Although	SCONJ	O	O	3722
a	PRON	O	O	3722
dose	NOUN	O	O	3722
-	PUNCT	O	O	3722
response	NOUN	O	O	3722
effect	VERB	O	O	3722
has	VERB	O	O	3722
been	AUX	O	O	3722
observed	VERB	O	O	3722
with	ADP	O	O	3722
cisplatin	NOUN	O	Chemical	3722
,	PUNCT	O	O	3722
the	PRON	O	O	3722
dose	NOUN	O	O	3722
-	PUNCT	O	O	3722
limiting	VERB	O	O	3722
toxicities	NOUN	O	Disease	3722
associated	VERB	O	O	3722
with	ADP	O	O	3722
cisplatin	NOUN	O	Chemical	3722
(	PUNCT	O	O	3722
e.g.	ADV	O	O	3722
,	PUNCT	O	O	3722
nephrotoxicity	NOUN	O	Disease	3722
,	PUNCT	O	O	3722
ototoxicity	NOUN	O	Disease	3722
,	PUNCT	O	O	3722
and	CCONJ	O	O	3722
neurotoxicity	NOUN	O	Disease	3722
)	PUNCT	O	O	3722
have	VERB	O	O	3722
limited	VERB	O	O	3722
its	PRON	O	O	3722
use	VERB	O	O	3722
as	ADP	O	O	3722
a	PRON	O	O	3722
treatment	NOUN	O	O	3722
for	ADP	O	O	3722
breast carcinoma	NOUN	O	Disease	3722
.	PUNCT	O	O	3722
WR-2721	NOUN	O	O	3723
or	CCONJ	O	O	3724
amifostine	NOUN	O	O	3724
initially	ADV	O	O	3724
was	AUX	O	O	3724
developed	VERB	O	O	3724
to	PART	O	O	3724
protect	VERB	O	O	3724
military	PROPN	O	O	3724
personnel	NOUN	O	O	3724
in	ADP	O	O	3724
the	PRON	O	O	3724
event	NOUN	O	O	3724
of	ADP	O	O	3724
nuclear	ADJ	O	O	3724
war	NOUN	O	O	3724
.	PUNCT	O	O	3724
Amifostine	NOUN	O	O	3725
subsequently	ADV	O	O	3725
was	AUX	O	O	3725
shown	VERB	O	O	3725
to	PART	O	O	3725
protect	VERB	O	O	3725
normal	ADJ	O	O	3725
tissues	NOUN	O	O	3725
from	ADP	O	O	3725
the	PRON	O	O	3725
toxic	ADJ	O	O	3725
effects	NOUN	O	O	3725
of	ADP	O	O	3725
alkylating	VERB	O	O	3725
agents	NOUN	O	O	3725
and	CCONJ	O	O	3725
cisplatin	NOUN	O	Chemical	3725
without	ADP	O	O	3725
decreasing	VERB	O	O	3725
the	PRON	O	O	3725
antitumor	PROPN	O	O	3725
effect	VERB	O	O	3725
of	ADP	O	O	3725
the	PRON	O	O	3725
chemotherapy	NOUN	O	O	3725
.	PUNCT	O	O	3725
Early	ADJ	O	O	3726
trials	NOUN	O	O	3726
of	ADP	O	O	3726
cisplatin	NOUN	O	Chemical	3726
and	CCONJ	O	O	3726
amifostine	NOUN	O	O	3726
also	ADV	O	O	3726
suggested	VERB	O	O	3726
that	SCONJ	O	O	3726
the	PRON	O	O	3726
incidence	NOUN	O	O	3726
and	CCONJ	O	O	3726
severity	NOUN	O	O	3726
of	ADP	O	O	3726
cisplatin	NOUN	O	Chemical	3726
-	PUNCT	O	O	3726
induced	VERB	O	O	3726
nephrotoxicity	NOUN	O	Disease	3726
,	PUNCT	O	O	3726
ototoxicity	NOUN	O	Disease	3726
,	PUNCT	O	O	3726
and	CCONJ	O	O	3726
neuropathy	NOUN	O	Disease	3726
were	AUX	O	O	3726
reduced	VERB	O	O	3726
.	PUNCT	O	O	3726
METHODS	NOUN	O	O	3727
:	PUNCT	O	O	3727
A	PRON	O	O	3727
Phase	NOUN	O	O	3727
II	NUM	O	O	3727
study	VERB	O	O	3727
of	ADP	O	O	3727
the	PRON	O	O	3727
combination	NOUN	O	O	3727
of	ADP	O	O	3727
cisplatin	NOUN	O	Chemical	3727
plus	CCONJ	O	O	3727
amifostine	NOUN	O	O	3727
was	AUX	O	O	3727
conducted	VERB	O	O	3727
in	ADP	O	O	3727
patients	NOUN	O	O	3727
with	ADP	O	O	3727
progressive	ADJ	O	O	3727
metastatic	ADJ	O	O	3727
breast carcinoma	NOUN	O	Disease	3727
who	PRON	O	O	3727
had	VERB	O	O	3727
received	VERB	O	O	3727
one	NUM	O	O	3727
,	PUNCT	O	O	3727
but	CCONJ	O	O	3727
not	PART	O	O	3727
more	ADJ	O	O	3727
than	ADP	O	O	3727
one	NUM	O	O	3727
,	PUNCT	O	O	3727
chemotherapy	NOUN	O	O	3727
regimen	NOUN	O	O	3727
for	ADP	O	O	3727
metastatic	ADJ	O	O	3727
disease	PROPN	O	O	3727
.	PUNCT	O	O	3727
Patients	NOUN	O	O	3728
received	VERB	O	O	3728
amifostine	NOUN	O	O	3728
,	PUNCT	O	O	3728
910	NUM	O	O	3728
mg	VERB	O	O	3728
/	PUNCT	O	O	3728
m2	PROPN	O	O	3728
intravenously	ADV	O	O	3728
over	ADP	O	O	3728
15	NUM	O	O	3728
minutes	NOUN	O	O	3728
.	PUNCT	O	O	3728
After	ADP	O	O	3729
completion	NOUN	O	O	3729
of	ADP	O	O	3729
the	PRON	O	O	3729
amifostine	NOUN	O	O	3729
infusion	NOUN	O	O	3729
,	PUNCT	O	O	3729
cisplatin	NOUN	O	Chemical	3729
120	NUM	O	O	3729
mg	VERB	O	O	3729
/	PUNCT	O	O	3729
m2	PROPN	O	O	3729
was	AUX	O	O	3729
administered	VERB	O	O	3729
over	ADP	O	O	3729
30	NUM	O	O	3729
minutes	NOUN	O	O	3729
.	PUNCT	O	O	3729
Intravenous	PROPN	O	O	3730
hydration	NOUN	O	O	3730
and	CCONJ	O	O	3730
mannitol	PROPN	O	Chemical	3730
was	AUX	O	O	3730
administered	VERB	O	O	3730
before	ADP	O	O	3730
and	CCONJ	O	O	3730
after	ADP	O	O	3730
cisplatin	NOUN	O	Chemical	3730
.	PUNCT	O	O	3730
Neurologic	ADJ	O	O	3731
toxicity	NOUN	O	Disease	3731
was	AUX	O	O	3731
reported	VERB	O	O	3731
in	ADP	O	O	3731
52%	NOUN	O	O	3731
of	ADP	O	O	3731
patients	NOUN	O	O	3731
.	PUNCT	O	O	3731
Seven	NUM	O	O	3732
different	ADJ	O	O	3732
life	NOUN	O	O	3732
-	PUNCT	O	O	3732
threatening	VERB	O	O	3732
toxicities	NOUN	O	Disease	3732
were	AUX	O	O	3732
observed	VERB	O	O	3732
in	ADP	O	O	3732
patients	NOUN	O	O	3732
while	SCONJ	O	O	3732
receiving	VERB	O	O	3732
treatment	NOUN	O	O	3732
.	PUNCT	O	O	3732
The	PRON	O	O	3733
combination	NOUN	O	O	3733
of	ADP	O	O	3733
cisplatin	NOUN	O	Chemical	3733
and	CCONJ	O	O	3733
amifostine	NOUN	O	O	3733
in	ADP	O	O	3733
this	PRON	O	O	3733
study	VERB	O	O	3733
resulted	VERB	O	O	3733
in	ADP	O	O	3733
an	PRON	O	O	3733
overall	ADV	O	O	3733
response	NOUN	O	O	3733
rate	NOUN	O	O	3733
of	ADP	O	O	3733
16%	NOUN	O	O	3733
.	PUNCT	O	O	3733
Neither	PRON	O	O	3734
a	PRON	O	O	3734
tumor	NOUN	O	Disease	3734
-	PUNCT	O	O	3734
protective	ADJ	O	O	3734
effect	VERB	O	O	3734
nor	CCONJ	O	O	3734
reduced	VERB	O	O	3734
toxicity	NOUN	O	Disease	3734
to	PART	O	O	3734
normal	ADJ	O	O	3734
tissues	NOUN	O	O	3734
was	AUX	O	O	3734
observed	VERB	O	O	3734
with	ADP	O	O	3734
the	PRON	O	O	3734
addition	NOUN	O	O	3734
of	ADP	O	O	3734
amifostine	NOUN	O	O	3734
to	PART	O	O	3734
cisplatin	NOUN	O	Chemical	3734
in	ADP	O	O	3734
this	PRON	O	O	3734
trial	NOUN	O	O	3734
.	PUNCT	O	O	3734
Warfarin	PROPN	O	Chemical	3737
-	PUNCT	O	O	3737
induced	VERB	O	O	3737
iliopsoas	PROPN	O	O	3737
hemorrhage	NOUN	O	Disease	3737
with	ADP	O	O	3737
subsequent	ADJ	O	O	3737
femoral	ADJ	O	O	3737
nerve	NOUN	O	O	3737
palsy	PROPN	O	O	3737
.	PUNCT	O	O	3737
We	PRON	O	O	3738
present	NOUN	O	O	3738
the	PRON	O	O	3738
case	NOUN	O	O	3738
of	ADP	O	O	3738
a	PRON	O	O	3738
28-year	NOUN	O	O	3738
-	PUNCT	O	O	3738
old	ADJ	O	O	3738
man	NOUN	O	O	3738
on	ADP	O	O	3738
chronic	ADJ	O	O	3738
warfarin	VERB	O	Chemical	3738
therapy	NOUN	O	O	3738
who	PRON	O	O	3738
sustained	VERB	O	O	3738
a	PRON	O	O	3738
minor	ADJ	O	O	3738
muscle	NOUN	O	O	3738
tear	NOUN	O	O	3738
and	CCONJ	O	O	3738
developed	VERB	O	O	3738
increasing	VERB	O	O	3738
pain	NOUN	O	Disease	3738
and	CCONJ	O	O	3738
a	PRON	O	O	3738
flexure	NOUN	O	O	3738
contracture	NOUN	O	O	3738
of	ADP	O	O	3738
the	PRON	O	O	3738
right	ADV	O	O	3738
hip	NOUN	O	O	3738
.	PUNCT	O	O	3738
Surgical	ADJ	O	O	3739
exploration	NOUN	O	O	3739
revealed	VERB	O	O	3739
an	PRON	O	O	3739
iliopsoas	PROPN	O	O	3739
hematoma	NOUN	O	Disease	3739
and	CCONJ	O	O	3739
femoral	ADJ	O	O	3739
nerve	NOUN	O	O	3739
entrapment	NOUN	O	O	3739
,	PUNCT	O	O	3739
resulting	VERB	O	O	3739
in	ADP	O	O	3739
a	PRON	O	O	3739
femoral	ADJ	O	O	3739
nerve	NOUN	O	O	3739
palsy	PROPN	O	O	3739
and	CCONJ	O	O	3739
partial	ADJ	O	O	3739
loss	NOUN	O	O	3739
of	ADP	O	O	3739
quadriceps	NOUN	O	O	3739
functions	VERB	O	O	3739
.	PUNCT	O	O	3739
Anticoagulant	NOUN	O	O	3740
-	PUNCT	O	O	3740
induced	VERB	O	O	3740
femoral	ADJ	O	O	3740
nerve	NOUN	O	O	3740
palsy	PROPN	O	O	3740
represents	VERB	O	O	3740
the	PRON	O	O	3740
most	ADV	O	O	3740
common	ADJ	O	O	3740
form	NOUN	O	O	3740
of	ADP	O	O	3740
warfarin	VERB	O	Chemical	3740
-	PUNCT	O	O	3740
induced	VERB	O	O	3740
peripheral neuropathy	NOUN	O	Disease	3740
;	PUNCT	O	O	3740
it	PRON	O	O	3740
is	AUX	O	O	3740
characterized	VERB	O	O	3740
by	ADP	O	O	3740
severe	ADJ	O	O	3740
pain	NOUN	O	Disease	3740
in	ADP	O	O	3740
the	PRON	O	O	3740
inguinal	ADJ	O	O	3740
region	NOUN	O	O	3740
,	PUNCT	O	O	3740
varying	VERB	O	O	3740
degrees	NOUN	O	O	3740
of	ADP	O	O	3740
motor	NOUN	O	O	3740
and	CCONJ	O	O	3740
sensory	ADJ	O	O	3740
impairment	NOUN	O	O	3740
,	PUNCT	O	O	3740
and	CCONJ	O	O	3740
flexure	NOUN	O	O	3740
contracture	NOUN	O	O	3740
of	ADP	O	O	3740
the	PRON	O	O	3740
involved	VERB	O	O	3740
extremity	NOUN	O	O	3740
.	PUNCT	O	O	3740
Myasthenia	PROPN	O	O	3743
gravis	PROPN	O	O	3743
caused	VERB	O	O	3743
by	ADP	O	O	3743
penicillamine	NOUN	O	Chemical	3743
and	CCONJ	O	O	3743
chloroquine	ADJ	O	Chemical	3743
therapy	NOUN	O	O	3743
for	ADP	O	O	3743
rheumatoid arthritis	NOUN	O	Disease	3743
.	PUNCT	O	O	3743
We	PRON	O	O	3744
have	VERB	O	O	3744
described	VERB	O	O	3744
a	PRON	O	O	3744
unique	ADJ	O	O	3744
patient	NOUN	O	O	3744
who	PRON	O	O	3744
had	VERB	O	O	3744
reversible	ADJ	O	O	3744
and	CCONJ	O	O	3744
dose	NOUN	O	O	3744
-	PUNCT	O	O	3744
related	ADJ	O	O	3744
myasthenia gravis	PROPN	O	Disease	3744
after	ADP	O	O	3744
penicillamine	NOUN	O	Chemical	3744
and	CCONJ	O	O	3744
chloroquine	ADJ	O	Chemical	3744
therapy	NOUN	O	O	3744
for	ADP	O	O	3744
rheumatoid arthritis	NOUN	O	Disease	3744
.	PUNCT	O	O	3744
Although	SCONJ	O	O	3745
acetylcholine	NOUN	O	Chemical	3745
receptor	NOUN	O	O	3745
antibodies	NOUN	O	O	3745
were	AUX	O	O	3745
not	PART	O	O	3745
detectable	ADJ	O	O	3745
,	PUNCT	O	O	3745
the	PRON	O	O	3745
time	NOUN	O	O	3745
course	NOUN	O	O	3745
was	AUX	O	O	3745
consistent	ADJ	O	O	3745
with	ADP	O	O	3745
an	PRON	O	O	3745
autoimmune	PROPN	O	O	3745
process	NOUN	O	O	3745
.	PUNCT	O	O	3745
Nephrotoxicity	NOUN	O	Disease	3748
of	ADP	O	O	3748
combined	VERB	O	O	3748
cephalothin	VERB	O	O	3748
-	PUNCT	O	O	3748
gentamicin	VERB	O	Chemical	3748
regimen	NOUN	O	O	3748
.	PUNCT	O	O	3748
Two	NUM	O	O	3749
patients	NOUN	O	O	3749
developed	VERB	O	O	3749
acute	ADJ	O	O	3749
tubular necrosis	NOUN	O	Disease	3749
,	PUNCT	O	O	3749
characterized	VERB	O	O	3749
clinically	ADV	O	O	3749
by	ADP	O	O	3749
acute	ADJ	O	O	3749
oliguric	PROPN	O	O	3749
renal failure	NOUN	O	Disease	3749
,	PUNCT	O	O	3749
while	SCONJ	O	O	3749
they	PRON	O	O	3749
were	AUX	O	O	3749
receiving	VERB	O	O	3749
a	PRON	O	O	3749
combination	NOUN	O	O	3749
of	ADP	O	O	3749
cephalothin	VERB	O	O	3749
sodium	NOUN	O	Chemical	3749
and	CCONJ	O	O	3749
gentamicin	VERB	O	Chemical	3749
sulfate	NOUN	O	O	3749
therapy	NOUN	O	O	3749
.	PUNCT	O	O	3749
Patients	NOUN	O	O	3750
who	PRON	O	O	3750
are	AUX	O	O	3750
given	VERB	O	O	3750
this	PRON	O	O	3750
drug	NOUN	O	O	3750
regimen	NOUN	O	O	3750
should	AUX	O	O	3750
be	AUX	O	O	3750
observed	VERB	O	O	3750
very	ADV	O	O	3750
carefully	ADV	O	O	3750
for	ADP	O	O	3750
early	ADV	O	O	3750
signs	NOUN	O	O	3750
of	ADP	O	O	3750
nephrotoxicity	NOUN	O	Disease	3750
.	PUNCT	O	O	3750
Patients	NOUN	O	O	3751
with	ADP	O	O	3751
renal insufficiency	NOUN	O	Disease	3751
should	AUX	O	O	3751
not	PART	O	O	3751
be	AUX	O	O	3751
given	VERB	O	O	3751
this	PRON	O	O	3751
regimen	NOUN	O	O	3751
.	PUNCT	O	O	3751
Components	NOUN	O	O	3754
of	ADP	O	O	3754
lemon	NOUN	O	O	3754
essential	ADJ	O	O	3754
oil	NOUN	O	O	3754
attenuate	VERB	O	O	3754
dementia	NOUN	O	Disease	3754
induced	VERB	O	O	3754
by	ADP	O	O	3754
scopolamine	NOUN	O	Chemical	3754
.	PUNCT	O	O	3754
The	PRON	O	O	3755
anti	ADJ	O	O	3755
-	PUNCT	O	O	3755
dementia	NOUN	O	Disease	3755
effects	NOUN	O	O	3755
of	ADP	O	O	3755
s	X	O	O	3755
-	PUNCT	O	O	3755
limonene	NOUN	O	O	3755
and	CCONJ	O	O	3755
s	X	O	O	3755
-	PUNCT	O	O	3755
perillyl	NOUN	O	O	3755
alcohol	NOUN	O	Chemical	3755
were	AUX	O	O	3755
observed	VERB	O	O	3755
using	VERB	O	O	3755
the	PRON	O	O	3755
passive	ADJ	O	O	3755
avoidance	NOUN	O	O	3755
test	NOUN	O	O	3755
(	PUNCT	O	O	3755
PA	PROPN	O	Disease	3755
)	PUNCT	O	O	3755
and	CCONJ	O	O	3755
the	PRON	O	O	3755
open	VERB	O	O	3755
field	NOUN	O	O	3755
habituation	NOUN	O	O	3755
test	NOUN	O	O	3755
(	PUNCT	O	O	3755
OFH	PROPN	O	O	3755
)	PUNCT	O	O	3755
.	PUNCT	O	O	3755
These	PRON	O	O	3756
lemon	NOUN	O	O	3756
essential	ADJ	O	O	3756
oils	NOUN	O	O	3756
showed	VERB	O	O	3756
strong	ADJ	O	O	3756
ability	NOUN	O	O	3756
to	PART	O	O	3756
improve	VERB	O	O	3756
memory	NOUN	O	O	3756
impaired	VERB	O	O	3756
by	ADP	O	O	3756
scopolamine	NOUN	O	Chemical	3756
;	PUNCT	O	O	3756
however	ADV	O	O	3756
,	PUNCT	O	O	3756
s	X	O	O	3756
-	PUNCT	O	O	3756
perillyl	NOUN	O	O	3756
alcohol	NOUN	O	Chemical	3756
relieved	VERB	O	O	3756
the	PRON	O	O	3756
deficit	NOUN	O	O	3756
of	ADP	O	O	3756
associative	ADJ	O	O	3756
memory	NOUN	O	O	3756
in	ADP	O	O	3756
PA	PROPN	O	Disease	3756
only	ADV	O	O	3756
,	PUNCT	O	O	3756
and	CCONJ	O	O	3756
did	VERB	O	O	3756
not	PART	O	O	3756
improve	VERB	O	O	3756
non	ADJ	O	O	3756
-	PUNCT	O	O	3756
associative	ADJ	O	O	3756
memory	NOUN	O	O	3756
significantly	ADV	O	O	3756
in	ADP	O	O	3756
OFH	PROPN	O	O	3756
.	PUNCT	O	O	3756
Analysis	NOUN	O	O	3757
of	ADP	O	O	3757
neurotransmitter	NOUN	O	O	3757
concentration	NOUN	O	O	3757
in	ADP	O	O	3757
some	PRON	O	O	3757
brain	NOUN	O	O	3757
regions	NOUN	O	O	3757
on	ADP	O	O	3757
the	PRON	O	O	3757
test	NOUN	O	O	3757
day	NOUN	O	O	3757
showed	VERB	O	O	3757
that	SCONJ	O	O	3757
dopamine	NOUN	O	Chemical	3757
concentration	NOUN	O	O	3757
of	ADP	O	O	3757
the	PRON	O	O	3757
vehicle	NOUN	O	O	3757
/	PUNCT	O	O	3757
scopolamine	NOUN	O	Chemical	3757
group	NOUN	O	O	3757
was	AUX	O	O	3757
significantly	ADV	O	O	3757
lower	ADJ	O	O	3757
than	ADP	O	O	3757
that	SCONJ	O	O	3757
of	ADP	O	O	3757
the	PRON	O	O	3757
vehicle	NOUN	O	O	3757
/	PUNCT	O	O	3757
vehicle	NOUN	O	O	3757
group	NOUN	O	O	3757
,	PUNCT	O	O	3757
but	CCONJ	O	O	3757
this	PRON	O	O	3757
phenomenon	NOUN	O	O	3757
was	AUX	O	O	3757
reversed	VERB	O	O	3757
when	SCONJ	O	O	3757
s	X	O	O	3757
-	PUNCT	O	O	3757
limonene	NOUN	O	O	3757
or	CCONJ	O	O	3757
s	X	O	O	3757
-	PUNCT	O	O	3757
perillyl	NOUN	O	O	3757
alcohol	NOUN	O	Chemical	3757
were	AUX	O	O	3757
administered	VERB	O	O	3757
before	ADP	O	O	3757
the	PRON	O	O	3757
injection	NOUN	O	O	3757
of	ADP	O	O	3757
scopolamine	NOUN	O	Chemical	3757
.	PUNCT	O	O	3757
The	PRON	O	O	3760
selective	ADJ	O	O	3760
5-HT6	PROPN	O	O	3760
receptor	NOUN	O	O	3760
antagonist	NOUN	O	O	3760
Ro4368554	X	O	O	3760
restores	VERB	O	O	3760
memory	NOUN	O	O	3760
performance	NOUN	O	O	3760
in	ADP	O	O	3760
cholinergic	ADJ	O	O	3760
and	CCONJ	O	O	3760
serotonergic	ADJ	O	O	3760
models	NOUN	O	O	3760
of	ADP	O	O	3760
memory	NOUN	O	O	3760
deficiency	NOUN	O	O	3760
in	ADP	O	O	3760
the	PRON	O	O	3760
rat	NOUN	O	O	3760
.	PUNCT	O	O	3760
Antagonists	NOUN	O	O	3761
at	ADP	O	O	3761
serotonin	PROPN	O	Chemical	3761
type	NOUN	O	O	3761
6	NUM	O	O	3761
(	PUNCT	O	O	3761
5-HT(6	NOUN	O	O	3761
)	PUNCT	O	O	3761
)	PUNCT	O	O	3761
receptors	NOUN	O	O	3761
show	VERB	O	O	3761
activity	NOUN	O	O	3761
in	ADP	O	O	3761
models	NOUN	O	O	3761
of	ADP	O	O	3761
learning	VERB	O	O	3761
and	CCONJ	O	O	3761
memory	NOUN	O	O	3761
.	PUNCT	O	O	3761
Although	SCONJ	O	O	3762
the	PRON	O	O	3762
underlying	VERB	O	O	3762
mechanism(s	NOUN	O	O	3762
)	PUNCT	O	O	3762
are	AUX	O	O	3762
not	PART	O	O	3762
well	ADV	O	O	3762
understood	VERB	O	O	3762
,	PUNCT	O	O	3762
these	PRON	O	O	3762
effects	NOUN	O	O	3762
may	AUX	O	O	3762
involve	VERB	O	O	3762
an	PRON	O	O	3762
increase	VERB	O	O	3762
in	ADP	O	O	3762
acetylcholine	NOUN	O	Chemical	3762
(	PUNCT	O	O	3762
ACh	PROPN	O	Chemical	3762
)	PUNCT	O	O	3762
levels	NOUN	O	O	3762
.	PUNCT	O	O	3762
The	PRON	O	O	3763
present	NOUN	O	O	3763
study	VERB	O	O	3763
sought	VERB	O	O	3763
to	PART	O	O	3763
characterize	VERB	O	O	3763
the	PRON	O	O	3763
cognitive	ADJ	O	O	3763
-	PUNCT	O	O	3763
enhancing	VERB	O	O	3763
effects	NOUN	O	O	3763
of	ADP	O	O	3763
the	PRON	O	O	3763
5-HT(6	NOUN	O	O	3763
)	PUNCT	O	O	3763
antagonist	NOUN	O	O	3763
Ro4368554	X	O	O	3763
(	PUNCT	O	O	3763
3-benzenesulfonyl-7-(4-methyl	NOUN	O	O	3763
-	PUNCT	O	O	3763
piperazin-1-yl)1H	NOUN	O	O	3763
-	PUNCT	O	O	3763
indole	PROPN	O	O	3763
)	PUNCT	O	O	3763
in	ADP	O	O	3763
a	PRON	O	O	3763
rat	NOUN	O	O	3763
object	NOUN	O	O	3763
recognition	NOUN	O	O	3763
task	NOUN	O	O	3763
employing	VERB	O	O	3763
a	PRON	O	O	3763
cholinergic	ADJ	O	O	3763
(	PUNCT	O	O	3763
scopolamine	NOUN	O	Chemical	3763
pretreatment	NOUN	O	O	3763
)	PUNCT	O	O	3763
and	CCONJ	O	O	3763
a	PRON	O	O	3763
serotonergic-	NOUN	O	O	3763
(	PUNCT	O	O	3763
tryptophan	PROPN	O	O	3763
(	PUNCT	O	O	3763
TRP	PROPN	O	O	3763
)	PUNCT	O	O	3763
depletion	NOUN	O	O	3763
)	PUNCT	O	O	3763
deficient	ADJ	O	O	3763
model	NOUN	O	O	3763
,	PUNCT	O	O	3763
and	CCONJ	O	O	3763
compared	VERB	O	O	3763
its	PRON	O	O	3763
pattern	NOUN	O	O	3763
of	ADP	O	O	3763
action	NOUN	O	O	3763
with	ADP	O	O	3763
that	SCONJ	O	O	3763
of	ADP	O	O	3763
the	PRON	O	O	3763
acetylcholinesterase	NOUN	O	O	3763
inhibitor	NOUN	O	O	3763
metrifonate	PROPN	O	O	3763
.	PUNCT	O	O	3763
Initial	ADJ	O	O	3764
testing	NOUN	O	O	3764
in	ADP	O	O	3764
a	PRON	O	O	3764
time	NOUN	O	O	3764
-	PUNCT	O	O	3764
dependent	ADJ	O	O	3764
forgetting	VERB	O	O	3764
task	NOUN	O	O	3764
employing	VERB	O	O	3764
a	PRON	O	O	3764
24-h	NOUN	O	O	3764
delay	NOUN	O	O	3764
between	ADP	O	O	3764
training	NOUN	O	O	3764
and	CCONJ	O	O	3764
testing	NOUN	O	O	3764
showed	VERB	O	O	3764
that	SCONJ	O	O	3764
metrifonate	PROPN	O	O	3764
improved	VERB	O	O	3764
object	NOUN	O	O	3764
recognition	NOUN	O	O	3764
(	PUNCT	O	O	3764
at	ADP	O	O	3764
10	NUM	O	O	3764
and	CCONJ	O	O	3764
30	NUM	O	O	3764
mg	VERB	O	O	3764
/	PUNCT	O	O	3764
kg	VERB	O	O	3764
,	PUNCT	O	O	3764
p.o	PROPN	O	O	3764
.	PUNCT	O	O	3764
)	PUNCT	O	O	3764
,	PUNCT	O	O	3764
whereas	SCONJ	O	O	3764
Ro4368554	X	O	O	3764
was	AUX	O	O	3764
inactive	ADJ	O	O	3764
.	PUNCT	O	O	3764
Both	PRON	O	O	3765
,	PUNCT	O	O	3765
Ro4368554	X	O	O	3765
(	PUNCT	O	O	3765
3	X	O	O	3765
and	CCONJ	O	O	3765
10	NUM	O	O	3765
mg	VERB	O	O	3765
/	PUNCT	O	O	3765
kg	VERB	O	O	3765
,	PUNCT	O	O	3765
intraperitoneally	ADV	O	O	3765
(	PUNCT	O	O	3765
i.p	NOUN	O	O	3765
.	PUNCT	O	O	3765
)	PUNCT	O	O	3765
)	PUNCT	O	O	3765
and	CCONJ	O	O	3765
metrifonate	PROPN	O	O	3765
(	PUNCT	O	O	3765
10	NUM	O	O	3765
mg	VERB	O	O	3765
/	PUNCT	O	O	3765
kg	VERB	O	O	3765
,	PUNCT	O	O	3765
p.o	PROPN	O	O	3765
.	PUNCT	O	O	3765
,	PUNCT	O	O	3766
respectively	ADV	O	O	3766
)	PUNCT	O	O	3766
reversed	VERB	O	O	3766
memory	NOUN	O	O	3766
deficits	NOUN	O	O	3766
induced	VERB	O	O	3766
by	ADP	O	O	3766
scopolamine	NOUN	O	Chemical	3766
and	CCONJ	O	O	3766
TRP	PROPN	O	O	3766
depletion	NOUN	O	O	3766
(	PUNCT	O	O	3766
10	NUM	O	O	3766
mg	VERB	O	O	3766
/	PUNCT	O	O	3766
kg	VERB	O	O	3766
,	PUNCT	O	O	3766
i.p	NOUN	O	O	3766
.	PUNCT	O	O	3766
,	PUNCT	O	O	3766
and	CCONJ	O	O	3766
3	X	O	O	3766
mg	VERB	O	O	3766
/	PUNCT	O	O	3766
kg	VERB	O	O	3766
,	PUNCT	O	O	3766
p.o	PROPN	O	O	3766
.	PUNCT	O	O	3766
In	ADP	O	O	3767
conclusion	NOUN	O	O	3767
,	PUNCT	O	O	3767
although	SCONJ	O	O	3767
Ro4368554	X	O	O	3767
did	VERB	O	O	3767
not	PART	O	O	3767
improve	VERB	O	O	3767
a	PRON	O	O	3767
time	NOUN	O	O	3767
-	PUNCT	O	O	3767
related	ADJ	O	O	3767
retention	NOUN	O	O	3767
deficit	NOUN	O	O	3767
,	PUNCT	O	O	3767
it	PRON	O	O	3767
reversed	VERB	O	O	3767
a	PRON	O	O	3767
cholinergic	ADJ	O	O	3767
and	CCONJ	O	O	3767
a	PRON	O	O	3767
serotonergic	ADJ	O	O	3767
memory	NOUN	O	O	3767
deficit	NOUN	O	O	3767
,	PUNCT	O	O	3767
suggesting	VERB	O	O	3767
that	SCONJ	O	O	3767
both	PRON	O	O	3767
mechanisms	NOUN	O	O	3767
may	AUX	O	O	3767
be	AUX	O	O	3767
involved	VERB	O	O	3767
in	ADP	O	O	3767
the	PRON	O	O	3767
facilitation	NOUN	O	O	3767
of	ADP	O	O	3767
object	NOUN	O	O	3767
memory	NOUN	O	O	3767
by	ADP	O	O	3767
Ro4368554	X	O	O	3767
and	CCONJ	O	O	3767
,	PUNCT	O	O	3767
possibly	ADV	O	O	3767
,	PUNCT	O	O	3767
other	ADJ	O	O	3767
5-HT(6	NOUN	O	O	3767
)	PUNCT	O	O	3767
receptor	NOUN	O	O	3767
antagonists	NOUN	O	O	3767
.	PUNCT	O	O	3767
Lone	NOUN	O	O	3770
atrial fibrillation	NOUN	O	Disease	3770
associated	VERB	O	O	3770
with	ADP	O	O	3770
creatine	PROPN	O	Chemical	3770
monohydrate	ADJ	O	O	3770
supplementation	NOUN	O	O	3770
.	PUNCT	O	O	3770
Atrial fibrillation	NOUN	O	Disease	3771
in	ADP	O	O	3771
young	ADJ	O	O	3771
patients	NOUN	O	O	3771
without	ADP	O	O	3771
structural	ADJ	O	O	3771
heart disease	NOUN	O	Disease	3771
is	AUX	O	O	3771
rare	ADJ	O	O	3771
.	PUNCT	O	O	3771
Therefore	ADV	O	O	3772
,	PUNCT	O	O	3772
when	SCONJ	O	O	3772
the	PRON	O	O	3772
arrhythmia	NOUN	O	Disease	3772
is	AUX	O	O	3772
present	NOUN	O	O	3772
in	ADP	O	O	3772
this	PRON	O	O	3772
population	NOUN	O	O	3772
,	PUNCT	O	O	3772
reversible	ADJ	O	O	3772
causes	VERB	O	O	3772
must	AUX	O	O	3772
be	AUX	O	O	3772
identified	VERB	O	O	3772
and	CCONJ	O	O	3772
resolved	VERB	O	O	3772
.	PUNCT	O	O	3772
Thyroid	PROPN	O	O	3773
disorders	NOUN	O	O	3773
,	PUNCT	O	O	3773
illicit	ADJ	O	O	3773
drug	NOUN	O	O	3773
or	CCONJ	O	O	3773
stimulant	NOUN	O	O	3773
use	VERB	O	O	3773
,	PUNCT	O	O	3773
and	CCONJ	O	O	3773
acute	ADJ	O	O	3773
alcohol	NOUN	O	Chemical	3773
intoxication	NOUN	O	O	3773
are	AUX	O	O	3773
among	ADP	O	O	3773
these	PRON	O	O	3773
causes	VERB	O	O	3773
.	PUNCT	O	O	3773
We	PRON	O	O	3774
report	VERB	O	O	3774
the	PRON	O	O	3774
case	NOUN	O	O	3774
of	ADP	O	O	3774
a	PRON	O	O	3774
30-year	NOUN	O	O	3774
-	PUNCT	O	O	3774
old	ADJ	O	O	3774
Caucasian	ADJ	O	O	3774
man	NOUN	O	O	3774
who	PRON	O	O	3774
came	VERB	O	O	3774
to	PART	O	O	3774
the	PRON	O	O	3774
emergency	NOUN	O	O	3774
department	NOUN	O	O	3774
in	ADP	O	O	3774
atrial fibrillation	NOUN	O	Disease	3774
with	ADP	O	O	3774
rapid	ADJ	O	O	3774
ventricular	ADJ	O	O	3774
response	NOUN	O	O	3774
.	PUNCT	O	O	3774
His	PRON	O	O	3775
medical	ADJ	O	O	3775
history	NOUN	O	O	3775
was	AUX	O	O	3775
unremarkable	ADJ	O	O	3775
,	PUNCT	O	O	3775
except	SCONJ	O	O	3775
for	ADP	O	O	3775
minor	ADJ	O	O	3775
fractures	NOUN	O	Disease	3775
of	ADP	O	O	3775
the	PRON	O	O	3775
fingers	NOUN	O	O	3775
and	CCONJ	O	O	3775
foot	NOUN	O	O	3775
.	PUNCT	O	O	3775
Thyroid	PROPN	O	O	3776
-	PUNCT	O	O	3776
stimulating	VERB	O	O	3776
hormone	NOUN	O	O	3776
,	PUNCT	O	O	3776
magnesium	NOUN	O	Chemical	3776
,	PUNCT	O	O	3776
and	CCONJ	O	O	3776
potassium	NOUN	O	Chemical	3776
levels	NOUN	O	O	3776
were	AUX	O	O	3776
within	ADP	O	O	3776
normal	ADJ	O	O	3776
limits	NOUN	O	O	3776
,	PUNCT	O	O	3776
urine	NOUN	O	O	3776
drug	NOUN	O	O	3776
screen	NOUN	O	O	3776
was	AUX	O	O	3776
negative	ADJ	O	O	3776
,	PUNCT	O	O	3776
and	CCONJ	O	O	3776
alcohol	NOUN	O	Chemical	3776
use	VERB	O	O	3776
was	AUX	O	O	3776
denied	VERB	O	O	3776
.	PUNCT	O	O	3776
However	ADV	O	O	3777
,	PUNCT	O	O	3777
when	SCONJ	O	O	3777
the	PRON	O	O	3777
patient	NOUN	O	O	3777
was	AUX	O	O	3777
questioned	VERB	O	O	3777
about	ADP	O	O	3777
use	VERB	O	O	3777
of	ADP	O	O	3777
herbal	ADJ	O	O	3777
products	NOUN	O	O	3777
and	CCONJ	O	O	3777
supplements	NOUN	O	O	3777
,	PUNCT	O	O	3777
the	PRON	O	O	3777
use	VERB	O	O	3777
of	ADP	O	O	3777
creatine	PROPN	O	Chemical	3777
monohydrate	ADJ	O	O	3777
was	AUX	O	O	3777
revealed	VERB	O	O	3777
.	PUNCT	O	O	3777
The	PRON	O	O	3778
patient	NOUN	O	O	3778
was	AUX	O	O	3778
admitted	VERB	O	O	3778
to	PART	O	O	3778
the	PRON	O	O	3778
hospital	PROPN	O	O	3778
,	PUNCT	O	O	3778
anticoagulated	VERB	O	O	3778
with	ADP	O	O	3778
unfractionated	VERB	O	O	3778
heparin	NOUN	O	Chemical	3778
,	PUNCT	O	O	3778
and	CCONJ	O	O	3778
given	VERB	O	O	3778
intravenous	ADJ	O	O	3778
diltiazem	VERB	O	Chemical	3778
for	ADP	O	O	3778
rate	NOUN	O	O	3778
control	VERB	O	O	3778
and	CCONJ	O	O	3778
intravenous	ADJ	O	O	3778
amiodarone	NOUN	O	Chemical	3778
for	ADP	O	O	3778
rate	NOUN	O	O	3778
and	CCONJ	O	O	3778
rhythm	VERB	O	O	3778
control	VERB	O	O	3778
.	PUNCT	O	O	3778
When	SCONJ	O	O	3779
discharged	VERB	O	O	3779
less	ADV	O	O	3779
than	ADP	O	O	3779
24	NUM	O	O	3779
hours	NOUN	O	O	3779
later	ADV	O	O	3779
,	PUNCT	O	O	3779
he	PRON	O	O	3779
was	AUX	O	O	3779
receiving	VERB	O	O	3779
metoprolol	NOUN	O	Chemical	3779
and	CCONJ	O	O	3779
aspirin	NOUN	O	Chemical	3779
,	PUNCT	O	O	3779
with	ADP	O	O	3779
follow	VERB	O	O	3779
-	PUNCT	O	O	3779
up	ADP	O	O	3779
plans	VERB	O	O	3779
for	ADP	O	O	3779
echocardiography	NOUN	O	O	3779
and	CCONJ	O	O	3779
nuclear	ADJ	O	O	3779
imaging	VERB	O	O	3779
to	PART	O	O	3779
assess	VERB	O	O	3779
perfusion	NOUN	O	O	3779
.	PUNCT	O	O	3779
Exogenous	ADJ	O	O	3780
creatine	PROPN	O	Chemical	3780
is	AUX	O	O	3780
used	VERB	O	O	3780
by	ADP	O	O	3780
athletes	NOUN	O	O	3780
to	PART	O	O	3780
theoretically	ADV	O	O	3780
improve	VERB	O	O	3780
exercise	VERB	O	O	3780
performance	NOUN	O	O	3780
.	PUNCT	O	O	3780
Vegetarians	NOUN	O	O	3781
may	AUX	O	O	3781
also	ADV	O	O	3781
take	VERB	O	O	3781
creatine	PROPN	O	Chemical	3781
to	PART	O	O	3781
replace	VERB	O	O	3781
what	PRON	O	O	3781
they	PRON	O	O	3781
are	AUX	O	O	3781
not	PART	O	O	3781
consuming	VERB	O	O	3781
from	ADP	O	O	3781
meat	NOUN	O	O	3781
,	PUNCT	O	O	3781
fish	NOUN	O	O	3781
,	PUNCT	O	O	3781
and	CCONJ	O	O	3781
other	ADJ	O	O	3781
animal	NOUN	O	O	3781
products	NOUN	O	O	3781
.	PUNCT	O	O	3781
Previous	ADJ	O	O	3782
anecdotal	ADJ	O	O	3782
reports	VERB	O	O	3782
have	VERB	O	O	3782
linked	VERB	O	O	3782
creatine	PROPN	O	Chemical	3782
to	PART	O	O	3782
the	PRON	O	O	3782
development	NOUN	O	O	3782
of	ADP	O	O	3782
arrhythmia	NOUN	O	Disease	3782
.	PUNCT	O	O	3782
Comparison	NOUN	O	O	3785
of	ADP	O	O	3785
developmental	ADJ	O	O	3785
toxicity	NOUN	O	Disease	3785
of	ADP	O	O	3785
selective	ADJ	O	O	3785
and	CCONJ	O	O	3785
non	ADJ	O	O	3785
-	PUNCT	O	O	3785
selective	ADJ	O	O	3785
cyclooxygenase-2	NUM	O	O	3785
inhibitors	NOUN	O	O	3785
in	ADP	O	O	3785
CRL:(WI)WUBR	NOUN	O	O	3785
Wistar	PROPN	O	O	3785
rats	NOUN	O	O	3785
--	PUNCT	O	O	3785
DFU	PROPN	O	O	3785
and	CCONJ	O	O	3785
piroxicam	VERB	O	O	3785
study	VERB	O	O	3785
.	PUNCT	O	O	3785
Unlike	ADP	O	O	3786
general	ADJ	O	O	3786
toxicity	NOUN	O	Disease	3786
data	NOUN	O	O	3786
,	PUNCT	O	O	3786
their	PRON	O	O	3786
prenatal	ADJ	O	O	3786
toxic	ADJ	O	O	3786
effects	NOUN	O	O	3786
were	AUX	O	O	3786
not	PART	O	O	3786
extensively	ADV	O	O	3786
studied	VERB	O	O	3786
before	ADP	O	O	3786
.	PUNCT	O	O	3786
The	PRON	O	O	3787
aim	VERB	O	O	3787
of	ADP	O	O	3787
the	PRON	O	O	3787
experiment	NOUN	O	O	3787
was	AUX	O	O	3787
to	PART	O	O	3787
evaluate	VERB	O	O	3787
the	PRON	O	O	3787
developmental	ADJ	O	O	3787
toxicity	NOUN	O	Disease	3787
of	ADP	O	O	3787
the	PRON	O	O	3787
non	ADJ	O	O	3787
-	PUNCT	O	O	3787
selective	ADJ	O	O	3787
(	PUNCT	O	O	3787
piroxicam	VERB	O	O	3787
)	PUNCT	O	O	3787
and	CCONJ	O	O	3787
selective	ADJ	O	O	3787
(	PUNCT	O	O	3787
DFU	PROPN	O	O	3787
;	PUNCT	O	O	3787
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl	NOUN	O	O	3787
)	PUNCT	O	O	3787
phenyl-2(5H)-furanon	NUM	O	O	3787
)	PUNCT	O	O	3787
COX-2	ADJ	O	O	3787
inhibitors	NOUN	O	O	3787
.	PUNCT	O	O	3787
Doses	NOUN	O	O	3788
were	AUX	O	O	3788
set	VERB	O	O	3788
at	ADP	O	O	3788
0.3	NUM	O	O	3788
,	PUNCT	O	O	3788
3.0	NUM	O	O	3788
and	CCONJ	O	O	3788
30.0mg	NOUN	O	O	3788
/	PUNCT	O	O	3788
kg	VERB	O	O	3788
for	ADP	O	O	3788
piroxicam	VERB	O	O	3788
and	CCONJ	O	O	3788
0.2	NUM	O	O	3788
,	PUNCT	O	O	3788
2.0	NUM	O	O	3788
and	CCONJ	O	O	3788
20.0mg	NOUN	O	O	3788
/	PUNCT	O	O	3788
kg	VERB	O	O	3788
for	ADP	O	O	3788
DFU	PROPN	O	O	3788
.	PUNCT	O	O	3788
The	PRON	O	O	3789
pooled	VERB	O	O	3789
statistical	ADJ	O	O	3789
analysis	NOUN	O	O	3789
for	ADP	O	O	3789
ventricular	ADJ	O	O	3789
septal	ADJ	O	O	3789
(	PUNCT	O	O	3789
VSD	PROPN	O	Disease	3789
)	PUNCT	O	O	3789
and	CCONJ	O	O	3789
midline	NOUN	O	O	3789
(	PUNCT	O	O	3789
MD	PROPN	O	Disease	3789
)	PUNCT	O	O	3789
defects	NOUN	O	O	3789
was	AUX	O	O	3789
performed	VERB	O	O	3789
for	ADP	O	O	3789
rat	NOUN	O	O	3789
fetuses	NOUN	O	O	3789
exposed	VERB	O	O	3789
to	PART	O	O	3789
piroxicam	VERB	O	O	3789
,	PUNCT	O	O	3789
selective	ADJ	O	O	3789
and	CCONJ	O	O	3789
non	ADJ	O	O	3789
-	PUNCT	O	O	3789
selective	ADJ	O	O	3789
COX-2	ADJ	O	O	3789
inhibitor	NOUN	O	O	3789
based	VERB	O	O	3789
on	ADP	O	O	3789
present	NOUN	O	O	3789
and	CCONJ	O	O	3789
historic	ADJ	O	O	3789
data	NOUN	O	O	3789
.	PUNCT	O	O	3789
RESULTS	VERB	O	O	3790
:	PUNCT	O	O	3790
Maternal	ADJ	O	O	3790
toxicity	NOUN	O	Disease	3790
,	PUNCT	O	O	3790
intrauterine	ADJ	O	O	3790
growth	NOUN	O	O	3790
retardation	NOUN	O	O	3790
,	PUNCT	O	O	3790
and	CCONJ	O	O	3790
increase	VERB	O	O	3790
of	ADP	O	O	3790
external	ADJ	O	O	3790
and	CCONJ	O	O	3790
skeletal	ADJ	O	O	3790
variations	NOUN	O	O	3790
were	AUX	O	O	3790
found	VERB	O	O	3790
in	ADP	O	O	3790
rats	NOUN	O	O	3790
treated	VERB	O	O	3790
with	ADP	O	O	3790
the	PRON	O	O	3790
highest	ADJ	O	O	3790
dose	NOUN	O	O	3790
of	ADP	O	O	3790
piroxicam	VERB	O	O	3790
.	PUNCT	O	O	3790
Decrease	VERB	O	O	3791
of	ADP	O	O	3791
fetal	ADJ	O	O	3791
length	NOUN	O	O	3791
was	AUX	O	O	3791
the	PRON	O	O	3791
only	ADV	O	O	3791
signs	NOUN	O	O	3791
of	ADP	O	O	3791
the	PRON	O	O	3791
DFU	PROPN	O	O	3791
developmental	ADJ	O	O	3791
toxicity	NOUN	O	Disease	3791
observed	VERB	O	O	3791
in	ADP	O	O	3791
pups	NOUN	O	O	3791
exposed	VERB	O	O	3791
to	PART	O	O	3791
the	PRON	O	O	3791
highest	ADJ	O	O	3791
compound	NOUN	O	O	3791
dose	NOUN	O	O	3791
.	PUNCT	O	O	3791
Lack	NOUN	O	O	3792
of	ADP	O	O	3792
teratogenicity	NOUN	O	O	3792
was	AUX	O	O	3792
found	VERB	O	O	3792
in	ADP	O	O	3792
piroxicam	VERB	O	O	3792
and	CCONJ	O	O	3792
DFU	PROPN	O	O	3792
-	PUNCT	O	O	3792
exposed	VERB	O	O	3792
groups	NOUN	O	O	3792
.	PUNCT	O	O	3792
Unlike	ADP	O	O	3793
DFU	PROPN	O	O	3793
,	PUNCT	O	O	3793
piroxicam	VERB	O	O	3793
was	AUX	O	O	3793
also	ADV	O	O	3793
highly	ADV	O	O	3793
toxic	ADJ	O	O	3793
to	PART	O	O	3793
the	PRON	O	O	3793
dams	NOUN	O	O	3793
.	PUNCT	O	O	3793
Prenatal	NOUN	O	O	3794
exposure	NOUN	O	O	3794
to	PART	O	O	3794
selective	ADJ	O	O	3794
COX-2	ADJ	O	O	3794
inhibitors	NOUN	O	O	3794
does	VERB	O	O	3794
not	PART	O	O	3794
increase	VERB	O	O	3794
the	PRON	O	O	3794
risk	NOUN	O	O	3794
of	ADP	O	O	3794
ventricular	ADJ	O	O	3794
septal	ADJ	O	O	3794
and	CCONJ	O	O	3794
midline defects	NOUN	O	Disease	3794
in	ADP	O	O	3794
rat	NOUN	O	O	3794
when	SCONJ	O	O	3794
compared	VERB	O	O	3794
to	PART	O	O	3794
non	ADJ	O	O	3794
-	PUNCT	O	O	3794
selective	ADJ	O	O	3794
drugs	NOUN	O	O	3794
and	CCONJ	O	O	3794
historic	ADJ	O	O	3794
control	VERB	O	O	3794
.	PUNCT	O	O	3794
Protective	NOUN	O	O	3797
efficacy	NOUN	O	O	3797
of	ADP	O	O	3797
neuroactive	PROPN	O	O	3797
steroids	NOUN	O	Chemical	3797
against	ADP	O	O	3797
cocaine	NOUN	O	Chemical	3797
kindled	VERB	O	O	3797
-	PUNCT	O	O	3797
seizures	NOUN	O	Disease	3797
in	ADP	O	O	3797
mice	NOUN	O	O	3797
.	PUNCT	O	O	3797
Neuroactive	NOUN	O	O	3798
steroids	NOUN	O	Chemical	3798
demonstrate	VERB	O	O	3798
pharmacological	ADJ	O	O	3798
actions	NOUN	O	O	3798
that	SCONJ	O	O	3798
have	VERB	O	O	3798
relevance	NOUN	O	O	3798
for	ADP	O	O	3798
a	PRON	O	O	3798
host	NOUN	O	O	3798
of	ADP	O	O	3798
neurological	ADJ	O	O	3798
and	CCONJ	O	O	3798
psychiatric disorders	NOUN	O	Disease	3798
.	PUNCT	O	O	3798
They	PRON	O	O	3799
offer	VERB	O	O	3799
protection	NOUN	O	O	3799
against	ADP	O	O	3799
seizures	NOUN	O	Disease	3799
in	ADP	O	O	3799
a	PRON	O	O	3799
range	VERB	O	O	3799
of	ADP	O	O	3799
models	NOUN	O	O	3799
and	CCONJ	O	O	3799
seem	VERB	O	O	3799
to	PART	O	O	3799
inhibit	VERB	O	O	3799
certain	ADJ	O	O	3799
stages	NOUN	O	O	3799
of	ADP	O	O	3799
drug	NOUN	O	O	3799
dependence	NOUN	O	O	3799
in	ADP	O	O	3799
preclinical	ADJ	O	O	3799
assessments	NOUN	O	O	3799
.	PUNCT	O	O	3799
The	PRON	O	O	3800
present	NOUN	O	O	3800
study	VERB	O	O	3800
was	AUX	O	O	3800
designed	VERB	O	O	3800
to	PART	O	O	3800
evaluate	VERB	O	O	3800
two	NUM	O	O	3800
endogenous	ADJ	O	O	3800
and	CCONJ	O	O	3800
one	NUM	O	O	3800
synthetic	NOUN	O	O	3800
neuroactive	PROPN	O	O	3800
steroid	NOUN	O	Chemical	3800
that	SCONJ	O	O	3800
positively	ADV	O	O	3800
modulate	VERB	O	O	3800
the	PRON	O	O	3800
gamma	PROPN	O	O	3800
-	PUNCT	O	O	3800
aminobutyric	PROPN	O	O	3800
acid	PROPN	O	O	3800
(	PUNCT	O	O	3800
GABA(A	X	O	O	3800
)	PUNCT	O	O	3800
)	PUNCT	O	O	3800
receptor	NOUN	O	O	3800
against	ADP	O	O	3800
the	PRON	O	O	3800
increase	VERB	O	O	3800
in	ADP	O	O	3800
sensitivity	NOUN	O	O	3800
to	PART	O	O	3800
the	PRON	O	O	3800
convulsant	ADJ	O	O	3800
effects	NOUN	O	O	3800
of	ADP	O	O	3800
cocaine	NOUN	O	Chemical	3800
engendered	VERB	O	O	3800
by	ADP	O	O	3800
repeated	VERB	O	O	3800
cocaine	NOUN	O	Chemical	3800
administration	NOUN	O	O	3800
(	PUNCT	O	O	3800
seizure	NOUN	O	Disease	3800
kindling	VERB	O	O	3800
)	PUNCT	O	O	3800
.	PUNCT	O	O	3800
Allopregnanolone	NOUN	O	O	3801
(	PUNCT	O	O	3801
3alpha	NUM	O	O	3801
-	PUNCT	O	O	3801
hydroxy-5alpha	PUNCT	O	O	3801
-	PUNCT	O	O	3801
pregnan-20-one	NUM	O	O	3801
)	PUNCT	O	O	3801
,	PUNCT	O	O	3801
pregnanolone	NOUN	O	O	3801
(	PUNCT	O	O	3801
3alpha	NUM	O	O	3801
-	PUNCT	O	O	3801
hydroxy-5beta	NOUN	O	O	3801
-	PUNCT	O	O	3801
pregnan-20-one	NUM	O	O	3801
)	PUNCT	O	O	3801
and	CCONJ	O	O	3801
ganaxolone	NOUN	O	O	3801
(	PUNCT	O	O	3801
a	PRON	O	O	3801
synthetic	NOUN	O	O	3801
derivative	ADJ	O	O	3801
of	ADP	O	O	3801
allopregnanolone	NOUN	O	O	3801
3alpha	NUM	O	O	3801
-	PUNCT	O	O	3801
hydroxy-3beta	VERB	O	O	3801
-	PUNCT	O	O	3801
methyl-5alpha	PUNCT	O	O	3801
-	PUNCT	O	O	3801
pregnan-20-one	NUM	O	O	3801
)	PUNCT	O	O	3801
were	AUX	O	O	3801
tested	VERB	O	O	3801
for	ADP	O	O	3801
their	PRON	O	O	3801
ability	NOUN	O	O	3801
to	PART	O	O	3801
suppress	VERB	O	O	3801
the	PRON	O	O	3801
expression	NOUN	O	O	3801
(	PUNCT	O	O	3801
anticonvulsant	ADJ	O	O	3801
effect	VERB	O	O	3801
)	PUNCT	O	O	3801
and	CCONJ	O	O	3801
development	NOUN	O	O	3801
(	PUNCT	O	O	3801
antiepileptogenic	ADJ	O	O	3801
effect	VERB	O	O	3801
)	PUNCT	O	O	3801
of	ADP	O	O	3801
cocaine	NOUN	O	Chemical	3801
-	PUNCT	O	O	3801
kindled	VERB	O	O	3801
seizures	NOUN	O	Disease	3801
in	ADP	O	O	3801
male	NOUN	O	O	3801
,	PUNCT	O	O	3801
Swiss	PROPN	O	O	3801
-	PUNCT	O	O	3801
Webster	PROPN	O	O	3801
mice	NOUN	O	O	3801
.	PUNCT	O	O	3801
Kindled	VERB	O	O	3802
seizures	NOUN	O	Disease	3802
were	AUX	O	O	3802
induced	VERB	O	O	3802
by	ADP	O	O	3802
daily	ADV	O	O	3802
administration	NOUN	O	O	3802
of	ADP	O	O	3802
60	NUM	O	O	3802
mg	VERB	O	O	3802
/	PUNCT	O	O	3802
kg	VERB	O	O	3802
cocaine	NOUN	O	Chemical	3802
for	ADP	O	O	3802
5	NUM	O	O	3802
days	NOUN	O	O	3802
.	PUNCT	O	O	3802
All	PRON	O	O	3803
of	ADP	O	O	3803
these	PRON	O	O	3803
positive	ADJ	O	O	3803
GABA(A	X	O	O	3803
)	PUNCT	O	O	3803
modulators	NOUN	O	O	3803
suppressed	VERB	O	O	3803
the	PRON	O	O	3803
expression	NOUN	O	O	3803
of	ADP	O	O	3803
kindled	VERB	O	O	3803
seizures	NOUN	O	Disease	3803
,	PUNCT	O	O	3803
whereas	SCONJ	O	O	3803
only	ADV	O	O	3803
allopregnanolone	NOUN	O	O	3803
and	CCONJ	O	O	3803
ganaxolone	NOUN	O	O	3803
inhibited	VERB	O	O	3803
the	PRON	O	O	3803
development	NOUN	O	O	3803
of	ADP	O	O	3803
kindling	VERB	O	O	3803
.	PUNCT	O	O	3803
Allopregnanolone	NOUN	O	O	3804
and	CCONJ	O	O	3804
pregnanolone	NOUN	O	O	3804
,	PUNCT	O	O	3804
but	CCONJ	O	O	3804
not	PART	O	O	3804
ganaxolone	NOUN	O	O	3804
,	PUNCT	O	O	3804
also	ADV	O	O	3804
reduced	VERB	O	O	3804
cumulative	ADJ	O	O	3804
lethality	NOUN	O	O	3804
associated	VERB	O	O	3804
with	ADP	O	O	3804
kindling	VERB	O	O	3804
.	PUNCT	O	O	3804
These	PRON	O	O	3805
findings	NOUN	O	O	3805
demonstrate	VERB	O	O	3805
that	SCONJ	O	O	3805
some	PRON	O	O	3805
neuroactive	PROPN	O	O	3805
steroids	NOUN	O	Chemical	3805
attenuate	VERB	O	O	3805
convulsant	ADJ	O	O	3805
and	CCONJ	O	O	3805
sensitizing	VERB	O	O	3805
properties	NOUN	O	O	3805
of	ADP	O	O	3805
cocaine	NOUN	O	Chemical	3805
and	CCONJ	O	O	3805
add	VERB	O	O	3805
to	PART	O	O	3805
a	PRON	O	O	3805
growing	VERB	O	O	3805
literature	NOUN	O	O	3805
on	ADP	O	O	3805
their	PRON	O	O	3805
potential	ADJ	O	O	3805
use	VERB	O	O	3805
in	ADP	O	O	3805
the	PRON	O	O	3805
modulation	NOUN	O	O	3805
of	ADP	O	O	3805
effects	NOUN	O	O	3805
of	ADP	O	O	3805
drugs	NOUN	O	O	3805
of	ADP	O	O	3805
abuse	VERB	O	O	3805
.	PUNCT	O	O	3805
Kidney	NOUN	O	O	3808
function	NOUN	O	O	3808
and	CCONJ	O	O	3808
morphology	NOUN	O	O	3808
after	ADP	O	O	3808
short	ADJ	O	O	3808
-	PUNCT	O	O	3808
term	NOUN	O	O	3808
combination	NOUN	O	O	3808
therapy	NOUN	O	O	3808
with	ADP	O	O	3808
cyclosporine	NOUN	O	Chemical	3808
A	PRON	O	O	3808
,	PUNCT	O	O	3808
tacrolimus	NOUN	O	Chemical	3808
and	CCONJ	O	O	3808
sirolimus	NOUN	O	Chemical	3808
in	ADP	O	O	3808
the	PRON	O	O	3808
rat	NOUN	O	O	3808
.	PUNCT	O	O	3808
BACKGROUND	NOUN	O	O	3809
:	PUNCT	O	O	3809
Sirolimus	NOUN	O	Chemical	3809
(	PUNCT	O	O	3809
SRL	PROPN	O	O	3809
)	PUNCT	O	O	3809
may	AUX	O	O	3809
supplement	NOUN	O	O	3809
calcineurin	NOUN	O	O	3809
inhibitors	NOUN	O	O	3809
in	ADP	O	O	3809
clinical	ADJ	O	O	3809
organ	NOUN	O	O	3809
transplantation	NOUN	O	O	3809
.	PUNCT	O	O	3809
These	PRON	O	O	3810
are	AUX	O	O	3810
nephrotoxic	NOUN	O	Disease	3810
,	PUNCT	O	O	3810
but	CCONJ	O	O	3810
SRL	PROPN	O	O	3810
seems	VERB	O	O	3810
to	PART	O	O	3810
act	VERB	O	O	3810
differently	ADV	O	O	3810
displaying	VERB	O	O	3810
only	ADV	O	O	3810
minor	ADJ	O	O	3810
nephrotoxic	NOUN	O	Disease	3810
effects	NOUN	O	O	3810
,	PUNCT	O	O	3810
although	SCONJ	O	O	3810
this	PRON	O	O	3810
question	NOUN	O	O	3810
is	AUX	O	O	3810
still	ADV	O	O	3810
open	VERB	O	O	3810
.	PUNCT	O	O	3810
In	ADP	O	O	3811
a	PRON	O	O	3811
number	NOUN	O	O	3811
of	ADP	O	O	3811
treatment	NOUN	O	O	3811
protocols	NOUN	O	O	3811
where	SCONJ	O	O	3811
SRL	PROPN	O	O	3811
was	AUX	O	O	3811
combined	VERB	O	O	3811
with	ADP	O	O	3811
a	PRON	O	O	3811
calcineurin	NOUN	O	O	3811
inhibitor	NOUN	O	O	3811
indications	NOUN	O	O	3811
of	ADP	O	O	3811
a	PRON	O	O	3811
synergistic	ADJ	O	O	3811
nephrotoxic	NOUN	O	Disease	3811
effect	VERB	O	O	3811
were	AUX	O	O	3811
described	VERB	O	O	3811
.	PUNCT	O	O	3811
The	PRON	O	O	3812
aim	VERB	O	O	3812
of	ADP	O	O	3812
this	PRON	O	O	3812
study	VERB	O	O	3812
was	AUX	O	O	3812
to	PART	O	O	3812
examine	VERB	O	O	3812
further	ADV	O	O	3812
the	PRON	O	O	3812
renal	ADJ	O	O	3812
function	NOUN	O	O	3812
,	PUNCT	O	O	3812
including	VERB	O	O	3812
morphological	ADJ	O	O	3812
analysis	NOUN	O	O	3812
of	ADP	O	O	3812
the	PRON	O	O	3812
kidneys	NOUN	O	O	3812
of	ADP	O	O	3812
male	NOUN	O	O	3812
Sprague	PROPN	O	O	3812
-	PUNCT	O	O	3812
Dawley	NOUN	O	O	3812
rats	NOUN	O	O	3812
treated	VERB	O	O	3812
with	ADP	O	O	3812
either	ADV	O	O	3812
cyclosporine	NOUN	O	Chemical	3812
A	PRON	O	O	3812
(	PUNCT	O	O	3812
CsA	PROPN	O	Chemical	3812
)	PUNCT	O	O	3812
,	PUNCT	O	O	3812
tacrolimus	NOUN	O	Chemical	3812
(	PUNCT	O	O	3812
FK506	NOUN	O	Chemical	3812
)	PUNCT	O	O	3812
or	CCONJ	O	O	3812
SRL	PROPN	O	O	3812
as	ADP	O	O	3812
monotherapies	NOUN	O	O	3812
or	CCONJ	O	O	3812
in	ADP	O	O	3812
different	ADJ	O	O	3812
combinations	NOUN	O	O	3812
.	PUNCT	O	O	3812
METHODS	NOUN	O	O	3813
:	PUNCT	O	O	3813
For	ADP	O	O	3813
a	PRON	O	O	3813
period	NOUN	O	O	3813
of	ADP	O	O	3813
2	X	O	O	3813
weeks	NOUN	O	O	3813
,	PUNCT	O	O	3813
CsA	PROPN	O	Chemical	3813
15	NUM	O	O	3813
mg	VERB	O	O	3813
/	PUNCT	O	O	3813
kg	VERB	O	O	3813
/	PUNCT	O	O	3813
day	NOUN	O	O	3813
(	PUNCT	O	O	3813
given	VERB	O	O	3813
orally	ADV	O	O	3813
)	PUNCT	O	O	3813
,	PUNCT	O	O	3813
FK506	NOUN	O	Chemical	3813
3.0	NUM	O	O	3813
mg	VERB	O	O	3813
/	PUNCT	O	O	3813
kg	VERB	O	O	3813
/	PUNCT	O	O	3813
day	NOUN	O	O	3813
(	PUNCT	O	O	3813
given	VERB	O	O	3813
orally	ADV	O	O	3813
)	PUNCT	O	O	3813
or	CCONJ	O	O	3813
SRL	PROPN	O	O	3813
0.4	NUM	O	O	3813
mg	VERB	O	O	3813
/	PUNCT	O	O	3813
kg	VERB	O	O	3813
/	PUNCT	O	O	3813
day	NOUN	O	O	3813
(	PUNCT	O	O	3813
given	VERB	O	O	3813
intraperitoneally	ADV	O	O	3813
)	PUNCT	O	O	3813
was	AUX	O	O	3813
administered	VERB	O	O	3813
once	ADV	O	O	3813
a	PRON	O	O	3813
day	NOUN	O	O	3813
as	ADP	O	O	3813
these	PRON	O	O	3813
doses	NOUN	O	O	3813
have	VERB	O	O	3813
earlier	ADV	O	O	3813
been	AUX	O	O	3813
found	VERB	O	O	3813
to	PART	O	O	3813
achieve	VERB	O	O	3813
a	PRON	O	O	3813
significant	ADJ	O	O	3813
immunosuppressive	ADJ	O	O	3813
effect	VERB	O	O	3813
in	ADP	O	O	3813
Sprague	PROPN	O	O	3813
-	PUNCT	O	O	3813
Dawley	NOUN	O	O	3813
rats	NOUN	O	O	3813
.	PUNCT	O	O	3813
The	PRON	O	O	3814
morphological	ADJ	O	O	3814
analysis	NOUN	O	O	3814
of	ADP	O	O	3814
the	PRON	O	O	3814
kidneys	NOUN	O	O	3814
included	VERB	O	O	3814
a	PRON	O	O	3814
semi	ADJ	O	O	3814
-	PUNCT	O	O	3814
quantitative	ADJ	O	O	3814
scoring	NOUN	O	O	3814
system	NOUN	O	O	3814
analysing	VERB	O	O	3814
the	PRON	O	O	3814
degree	PROPN	O	O	3814
of	ADP	O	O	3814
striped	ADJ	O	O	3814
fibrosis	NOUN	O	Disease	3814
,	PUNCT	O	O	3814
subcapsular	PROPN	O	O	3814
fibrosis	NOUN	O	Disease	3814
and	CCONJ	O	O	3814
the	PRON	O	O	3814
number	NOUN	O	O	3814
of	ADP	O	O	3814
basophilic	NOUN	O	O	3814
tubules	NOUN	O	O	3814
,	PUNCT	O	O	3814
plus	CCONJ	O	O	3814
an	PRON	O	O	3814
additional	ADJ	O	O	3814
stereological	ADJ	O	O	3814
analysis	NOUN	O	O	3814
of	ADP	O	O	3814
the	PRON	O	O	3814
total	ADJ	O	O	3814
grade	NOUN	O	O	3814
of	ADP	O	O	3814
fibrosis	NOUN	O	Disease	3814
in	ADP	O	O	3814
the	PRON	O	O	3814
cortex	VERB	O	O	3814
stained	VERB	O	O	3814
with	ADP	O	O	3814
Sirius	PROPN	O	O	3814
Red	NOUN	O	O	3814
.	PUNCT	O	O	3814
CsA	PROPN	O	Chemical	3815
,	PUNCT	O	O	3815
FK506	NOUN	O	Chemical	3815
and	CCONJ	O	O	3815
SRL	PROPN	O	O	3815
all	PRON	O	O	3815
significantly	ADV	O	O	3815
decreased	VERB	O	O	3815
the	PRON	O	O	3815
GFR	NOUN	O	O	3815
.	PUNCT	O	O	3815
A	PRON	O	O	3816
further	ADV	O	O	3816
deterioration	NOUN	O	O	3816
was	AUX	O	O	3816
seen	VERB	O	O	3816
when	SCONJ	O	O	3816
CsA	PROPN	O	Chemical	3816
was	AUX	O	O	3816
combined	VERB	O	O	3816
with	ADP	O	O	3816
either	ADV	O	O	3816
FK506	NOUN	O	Chemical	3816
or	CCONJ	O	O	3816
SRL	PROPN	O	O	3816
,	PUNCT	O	O	3816
whereas	SCONJ	O	O	3816
the	PRON	O	O	3816
GFR	NOUN	O	O	3816
remained	VERB	O	O	3816
unchanged	ADJ	O	O	3816
in	ADP	O	O	3816
the	PRON	O	O	3816
group	NOUN	O	O	3816
treated	VERB	O	O	3816
with	ADP	O	O	3816
FK506	NOUN	O	Chemical	3816
plus	CCONJ	O	O	3816
SRL	PROPN	O	O	3816
when	SCONJ	O	O	3816
compared	VERB	O	O	3816
with	ADP	O	O	3816
treatment	NOUN	O	O	3816
with	ADP	O	O	3816
any	PRON	O	O	3816
of	ADP	O	O	3816
the	PRON	O	O	3816
single	ADJ	O	O	3816
substances	NOUN	O	O	3816
.	PUNCT	O	O	3816
The	PRON	O	O	3817
semi	ADJ	O	O	3817
-	PUNCT	O	O	3817
quantitative	ADJ	O	O	3817
scoring	NOUN	O	O	3817
was	AUX	O	O	3817
significantly	ADV	O	O	3817
worst	ADJ	O	O	3817
in	ADP	O	O	3817
the	PRON	O	O	3817
group	NOUN	O	O	3817
treated	VERB	O	O	3817
with	ADP	O	O	3817
CsA	PROPN	O	Chemical	3817
plus	CCONJ	O	O	3817
SRL	PROPN	O	O	3817
(	PUNCT	O	O	3817
P<0.001	ADJ	O	O	3817
compared	VERB	O	O	3817
with	ADP	O	O	3817
controls	VERB	O	O	3817
)	PUNCT	O	O	3817
and	CCONJ	O	O	3817
the	PRON	O	O	3817
analysis	NOUN	O	O	3817
of	ADP	O	O	3817
the	PRON	O	O	3817
total	ADJ	O	O	3817
grade	NOUN	O	O	3817
of	ADP	O	O	3817
fibrosis	NOUN	O	Disease	3817
also	ADV	O	O	3817
showed	VERB	O	O	3817
the	PRON	O	O	3817
highest	ADJ	O	O	3817
proportion	NOUN	O	O	3817
in	ADP	O	O	3817
the	PRON	O	O	3817
same	ADJ	O	O	3817
group	NOUN	O	O	3817
and	CCONJ	O	O	3817
was	AUX	O	O	3817
significantly	ADV	O	O	3817
different	ADJ	O	O	3817
from	ADP	O	O	3817
controls	VERB	O	O	3817
(	PUNCT	O	O	3817
P<0.02	PROPN	O	O	3817
)	PUNCT	O	O	3817
.	PUNCT	O	O	3817
The	PRON	O	O	3818
FK506	NOUN	O	Chemical	3818
plus	CCONJ	O	O	3818
SRL	PROPN	O	O	3818
combination	NOUN	O	O	3818
showed	VERB	O	O	3818
only	ADV	O	O	3818
a	PRON	O	O	3818
marginally	ADV	O	O	3818
higher	ADJ	O	O	3818
degree	PROPN	O	O	3818
of	ADP	O	O	3818
fibrosis	NOUN	O	Disease	3818
as	ADP	O	O	3818
compared	VERB	O	O	3818
with	ADP	O	O	3818
controls	VERB	O	O	3818
(	PUNCT	O	O	3818
P=0.05	PROPN	O	O	3818
)	PUNCT	O	O	3818
.	PUNCT	O	O	3818
This	PRON	O	O	3819
rat	NOUN	O	O	3819
study	VERB	O	O	3819
demonstrated	VERB	O	O	3819
a	PRON	O	O	3819
synergistic	ADJ	O	O	3819
nephrotoxic	NOUN	O	Disease	3819
effect	VERB	O	O	3819
of	ADP	O	O	3819
CsA	PROPN	O	Chemical	3819
plus	CCONJ	O	O	3819
SRL	PROPN	O	O	3819
,	PUNCT	O	O	3819
whereas	SCONJ	O	O	3819
FK506	NOUN	O	Chemical	3819
plus	CCONJ	O	O	3819
SRL	PROPN	O	O	3819
was	AUX	O	O	3819
better	ADV	O	O	3819
tolerated	VERB	O	O	3819
.	PUNCT	O	O	3819
Effect	VERB	O	O	3822
of	ADP	O	O	3822
fucoidan	PROPN	O	O	3822
treatment	NOUN	O	O	3822
on	ADP	O	O	3822
collagenase	NOUN	O	O	3822
-	PUNCT	O	O	3822
induced	VERB	O	O	3822
intracerebral hemorrhage	NOUN	O	Disease	3822
in	ADP	O	O	3822
rats	NOUN	O	O	3822
.	PUNCT	O	O	3822
Inflammatory	ADJ	O	O	3823
cells	NOUN	O	O	3823
are	AUX	O	O	3823
postulated	VERB	O	O	3823
to	PART	O	O	3823
mediate	VERB	O	O	3823
some	PRON	O	O	3823
of	ADP	O	O	3823
the	PRON	O	O	3823
brain damage	NOUN	O	Disease	3823
following	VERB	O	O	3823
ischemic	VERB	O	Disease	3823
stroke	VERB	O	Disease	3823
.	PUNCT	O	O	3823
Intracerebral hemorrhage	NOUN	O	O	3824
is	AUX	O	O	3824
associated	VERB	O	O	3824
with	ADP	O	O	3824
more	ADJ	O	O	3824
inflammation	NOUN	O	Disease	3824
than	ADP	O	O	3824
ischemic	VERB	O	Disease	3824
stroke	VERB	O	Disease	3824
.	PUNCT	O	O	3824
We	PRON	O	O	3825
tested	VERB	O	O	3825
the	PRON	O	O	3825
sulfated	VERB	O	O	3825
polysaccharide	NOUN	O	O	3825
fucoidan	PROPN	O	O	3825
,	PUNCT	O	O	3825
which	PRON	O	O	3825
has	VERB	O	O	3825
been	AUX	O	O	3825
reported	VERB	O	O	3825
to	PART	O	O	3825
reduce	VERB	O	O	3825
inflammatory	ADJ	O	O	3825
brain damage	NOUN	O	Disease	3825
,	PUNCT	O	O	3825
in	ADP	O	O	3825
a	PRON	O	O	3825
rat	NOUN	O	O	3825
model	NOUN	O	O	3825
of	ADP	O	O	3825
intracerebral hemorrhage	NOUN	O	Disease	3825
induced	VERB	O	O	3825
by	ADP	O	O	3825
injection	NOUN	O	O	3825
of	ADP	O	O	3825
bacterial	ADJ	O	O	3825
collagenase	NOUN	O	O	3825
into	ADP	O	O	3825
the	PRON	O	O	3825
caudate	ADJ	O	O	3825
nucleus	PROPN	O	O	3825
.	PUNCT	O	O	3825
Rats	NOUN	O	O	3826
were	AUX	O	O	3826
treated	VERB	O	O	3826
with	ADP	O	O	3826
seven	NUM	O	O	3826
day	NOUN	O	O	3826
intravenous	ADJ	O	O	3826
infusion	NOUN	O	O	3826
of	ADP	O	O	3826
fucoidan	PROPN	O	O	3826
(	PUNCT	O	O	3826
30	NUM	O	O	3826
micrograms	NOUN	O	O	3826
h-1	NOUN	O	O	3826
)	PUNCT	O	O	3826
or	CCONJ	O	O	3826
vehicle	NOUN	O	O	3826
.	PUNCT	O	O	3826
The	PRON	O	O	3827
hematoma	NOUN	O	Disease	3827
was	AUX	O	O	3827
assessed	VERB	O	O	3827
in	ADP	O	O	3827
vivo	VERB	O	O	3827
by	ADP	O	O	3827
magnetic	ADJ	O	O	3827
resonance	NOUN	O	O	3827
imaging	VERB	O	O	3827
.	PUNCT	O	O	3827
Fucoidan	PROPN	O	O	3828
-	PUNCT	O	O	3828
treated	VERB	O	O	3828
rats	NOUN	O	O	3828
exhibited	VERB	O	O	3828
evidence	NOUN	O	O	3828
of	ADP	O	O	3828
impaired	VERB	O	O	3828
blood	NOUN	O	O	3828
clotting	VERB	O	O	3828
and	CCONJ	O	O	3828
hemodilution	NOUN	O	O	3828
,	PUNCT	O	O	3828
had	VERB	O	O	3828
larger	ADJ	O	O	3828
hematomas	VERB	O	Disease	3828
,	PUNCT	O	O	3828
and	CCONJ	O	O	3828
tended	VERB	O	O	3828
to	PART	O	O	3828
have	VERB	O	O	3828
less	ADV	O	O	3828
inflammation	NOUN	O	Disease	3828
in	ADP	O	O	3828
the	PRON	O	O	3828
vicinity	NOUN	O	O	3828
of	ADP	O	O	3828
the	PRON	O	O	3828
hematoma	NOUN	O	Disease	3828
after	ADP	O	O	3828
three	NUM	O	O	3828
days	NOUN	O	O	3828
.	PUNCT	O	O	3828
They	PRON	O	O	3829
showed	VERB	O	O	3829
significantly	ADV	O	O	3829
more	ADJ	O	O	3829
rapid	ADJ	O	O	3829
improvement	NOUN	O	O	3829
of	ADP	O	O	3829
motor	NOUN	O	O	3829
function	NOUN	O	O	3829
in	ADP	O	O	3829
the	PRON	O	O	3829
first	ADV	O	O	3829
week	NOUN	O	O	3829
following	VERB	O	O	3829
hemorrhage	NOUN	O	Disease	3829
and	CCONJ	O	O	3829
better	ADV	O	O	3829
memory	NOUN	O	O	3829
retention	NOUN	O	O	3829
in	ADP	O	O	3829
the	PRON	O	O	3829
passive	ADJ	O	O	3829
avoidance	NOUN	O	O	3829
test	NOUN	O	O	3829
.	PUNCT	O	O	3829
Acute	PROPN	O	O	3830
white	ADJ	O	O	3830
matter	VERB	O	O	3830
edema	NOUN	O	Disease	3830
and	CCONJ	O	O	3830
eventual	ADJ	O	O	3830
neuronal loss	NOUN	O	Disease	3830
in	ADP	O	O	3830
the	PRON	O	O	3830
striatum	NOUN	O	O	3830
adjacent	ADJ	O	O	3830
to	PART	O	O	3830
the	PRON	O	O	3830
hematoma	NOUN	O	Disease	3830
did	VERB	O	O	3830
not	PART	O	O	3830
differ	VERB	O	O	3830
between	ADP	O	O	3830
the	PRON	O	O	3830
two	NUM	O	O	3830
groups	NOUN	O	O	3830
.	PUNCT	O	O	3830
Investigation	NOUN	O	O	3831
of	ADP	O	O	3831
more	ADJ	O	O	3831
specific	ADJ	O	O	3831
anti	ADJ	O	O	3831
-	PUNCT	O	O	3831
inflammatory	ADJ	O	O	3831
agents	NOUN	O	O	3831
and	CCONJ	O	O	3831
hemodiluting	VERB	O	O	3831
agents	NOUN	O	O	3831
are	AUX	O	O	3831
warranted	VERB	O	O	3831
in	ADP	O	O	3831
intracerebral hemorrhage	NOUN	O	Disease	3831
.	PUNCT	O	O	3831
Paracetamol	PROPN	O	Chemical	3834
-	PUNCT	O	O	3834
associated	VERB	O	O	3834
coma	NOUN	O	Disease	3834
,	PUNCT	O	O	3834
metabolic acidosis	NOUN	O	Disease	3834
,	PUNCT	O	O	3834
renal	ADJ	O	O	3834
and	CCONJ	O	O	3834
hepatic failure	NOUN	O	Disease	3834
.	PUNCT	O	O	3834
A	PRON	O	O	3835
case	NOUN	O	O	3835
of	ADP	O	O	3835
metabolic acidosis	NOUN	O	Disease	3835
,	PUNCT	O	O	3835
acute	ADJ	O	O	3835
renal failure	NOUN	O	Disease	3835
and	CCONJ	O	O	3835
hepatic failure	NOUN	O	Disease	3835
following	VERB	O	O	3835
paracetamol	PROPN	O	Chemical	3835
ingestion	NOUN	O	O	3835
is	AUX	O	O	3835
presented	VERB	O	O	3835
.	PUNCT	O	O	3835
Hepatic	ADJ	O	O	3838
reactions	NOUN	O	O	3838
associated	VERB	O	O	3838
with	ADP	O	O	3838
ketoconazole	PROPN	O	Chemical	3838
in	ADP	O	O	3838
the	PRON	O	O	3838
United	PROPN	O	O	3838
Kingdom	NOUN	O	O	3838
.	PUNCT	O	O	3838
Ketoconazole	PROPN	O	O	3839
was	AUX	O	O	3839
introduced	VERB	O	O	3839
in	ADP	O	O	3839
the	PRON	O	O	3839
United	PROPN	O	O	3839
Kingdom	NOUN	O	O	3839
in	ADP	O	O	3839
1981	NUM	O	O	3839
.	PUNCT	O	O	3839
By	ADP	O	O	3840
November	PROPN	O	O	3840
1984	NUM	O	O	3840
the	PRON	O	O	3840
Committee	PROPN	O	O	3840
on	ADP	O	O	3840
Safety	NOUN	O	O	3840
of	ADP	O	O	3840
Medicines	NOUN	O	O	3840
had	VERB	O	O	3840
received	VERB	O	O	3840
82	NUM	O	O	3840
reports	VERB	O	O	3840
of	ADP	O	O	3840
possible	ADJ	O	O	3840
hepatotoxicity	NOUN	O	Disease	3840
associated	VERB	O	O	3840
with	ADP	O	O	3840
the	PRON	O	O	3840
drug	NOUN	O	O	3840
,	PUNCT	O	O	3840
including	VERB	O	O	3840
five	NUM	O	O	3840
deaths	NOUN	O	O	3840
.	PUNCT	O	O	3840
An	PRON	O	O	3841
analysis	NOUN	O	O	3841
of	ADP	O	O	3841
the	PRON	O	O	3841
75	NUM	O	O	3841
cases	NOUN	O	O	3841
that	SCONJ	O	O	3841
had	VERB	O	O	3841
been	AUX	O	O	3841
adequately	ADV	O	O	3841
followed	VERB	O	O	3841
up	ADP	O	O	3841
suggested	VERB	O	O	3841
that	SCONJ	O	O	3841
16	NUM	O	O	3841
,	PUNCT	O	O	3841
including	VERB	O	O	3841
three	NUM	O	O	3841
deaths	NOUN	O	O	3841
,	PUNCT	O	O	3841
were	AUX	O	O	3841
probably	ADV	O	O	3841
related	ADJ	O	O	3841
to	PART	O	O	3841
treatment	NOUN	O	O	3841
with	ADP	O	O	3841
the	PRON	O	O	3841
drug	NOUN	O	O	3841
.	PUNCT	O	O	3841
The	PRON	O	O	3842
mean	VERB	O	O	3842
age	NOUN	O	O	3842
of	ADP	O	O	3842
patients	NOUN	O	O	3842
in	ADP	O	O	3842
the	PRON	O	O	3842
16	NUM	O	O	3842
probable	ADJ	O	O	3842
cases	NOUN	O	O	3842
was	AUX	O	O	3842
57.9	NUM	O	O	3842
,	PUNCT	O	O	3842
with	ADP	O	O	3842
hepatotoxicity	NOUN	O	Disease	3842
being	AUX	O	O	3842
more	ADJ	O	O	3842
common	ADJ	O	O	3842
in	ADP	O	O	3842
women	NOUN	O	O	3842
.	PUNCT	O	O	3842
The	PRON	O	O	3843
average	ADJ	O	O	3843
duration	NOUN	O	O	3843
of	ADP	O	O	3843
treatment	NOUN	O	O	3843
before	ADP	O	O	3843
the	PRON	O	O	3843
onset	VERB	O	O	3843
of	ADP	O	O	3843
jaundice	NOUN	O	Disease	3843
was	AUX	O	O	3843
61	NUM	O	O	3843
days	NOUN	O	O	3843
.	PUNCT	O	O	3843
The	PRON	O	O	3844
results	VERB	O	O	3844
of	ADP	O	O	3844
serum	NOUN	O	O	3844
liver	NOUN	O	O	3844
function	NOUN	O	O	3844
tests	VERB	O	O	3844
suggested	VERB	O	O	3844
hepatocellular	NOUN	O	O	3844
injury	NOUN	O	O	3844
in	ADP	O	O	3844
10	NUM	O	O	3844
(	PUNCT	O	O	3844
63%	NOUN	O	O	3844
)	PUNCT	O	O	3844
;	PUNCT	O	O	3844
the	PRON	O	O	3844
rest	VERB	O	O	3844
showed	VERB	O	O	3844
a	PRON	O	O	3844
mixed	VERB	O	O	3844
pattern	NOUN	O	O	3844
.	PUNCT	O	O	3844
In	ADP	O	O	3845
contrast	NOUN	O	O	3845
,	PUNCT	O	O	3845
the	PRON	O	O	3845
results	VERB	O	O	3845
of	ADP	O	O	3845
histological	ADJ	O	O	3845
examination	NOUN	O	O	3845
of	ADP	O	O	3845
the	PRON	O	O	3845
liver	NOUN	O	O	3845
often	ADV	O	O	3845
showed	VERB	O	O	3845
evidence	NOUN	O	O	3845
of	ADP	O	O	3845
cholestasis	NOUN	O	Disease	3845
.	PUNCT	O	O	3845
Allergic	ADJ	O	O	3846
manifestations	NOUN	O	O	3846
such	ADJ	O	O	3846
as	ADP	O	O	3846
rash	ADJ	O	Disease	3846
and	CCONJ	O	O	3846
eosinophilia	PROPN	O	Disease	3846
were	AUX	O	O	3846
rare	ADJ	O	O	3846
.	PUNCT	O	O	3846
Hepatitis	NOUN	O	O	3847
was	AUX	O	O	3847
usually	ADV	O	O	3847
reversible	ADJ	O	O	3847
when	SCONJ	O	O	3847
treatment	NOUN	O	O	3847
was	AUX	O	O	3847
stopped	VERB	O	O	3847
,	PUNCT	O	O	3847
with	ADP	O	O	3847
the	PRON	O	O	3847
results	VERB	O	O	3847
of	ADP	O	O	3847
liver	NOUN	O	O	3847
function	NOUN	O	O	3847
tests	VERB	O	O	3847
returning	VERB	O	O	3847
to	PART	O	O	3847
normal	ADJ	O	O	3847
after	ADP	O	O	3847
an	PRON	O	O	3847
average	ADJ	O	O	3847
of	ADP	O	O	3847
3.1	NUM	O	O	3847
months	NOUN	O	O	3847
.	PUNCT	O	O	3847
In	ADP	O	O	3848
two	NUM	O	O	3848
of	ADP	O	O	3848
the	PRON	O	O	3848
three	NUM	O	O	3848
deaths	NOUN	O	O	3848
probably	ADV	O	O	3848
associated	VERB	O	O	3848
with	ADP	O	O	3848
ketoconazole	PROPN	O	Chemical	3848
treatment	NOUN	O	O	3848
the	PRON	O	O	3848
drug	NOUN	O	O	3848
had	VERB	O	O	3848
been	AUX	O	O	3848
continued	VERB	O	O	3848
after	ADP	O	O	3848
the	PRON	O	O	3848
onset	VERB	O	O	3848
of	ADP	O	O	3848
jaundice	NOUN	O	Disease	3848
and	CCONJ	O	O	3848
other	ADJ	O	O	3848
symptoms	NOUN	O	O	3848
of	ADP	O	O	3848
hepatitis	NOUN	O	Disease	3848
.	PUNCT	O	O	3848
Clinical	NOUN	O	O	3849
and	CCONJ	O	O	3849
biochemical	ADJ	O	O	3849
monitoring	NOUN	O	O	3849
at	ADP	O	O	3849
regular	ADJ	O	O	3849
intervals	NOUN	O	O	3849
for	ADP	O	O	3849
evidence	NOUN	O	O	3849
of	ADP	O	O	3849
hepatitis	NOUN	O	Disease	3849
is	AUX	O	O	3849
advised	VERB	O	O	3849
during	ADP	O	O	3849
long	ADV	O	O	3849
term	NOUN	O	O	3849
treatment	NOUN	O	O	3849
with	ADP	O	O	3849
ketoconazole	PROPN	O	Chemical	3849
to	PART	O	O	3849
prevent	VERB	O	O	3849
possible	ADJ	O	O	3849
serious	ADJ	O	O	3849
hepatic injury	NOUN	O	Disease	3849
.	PUNCT	O	O	3849
Combined	VERB	O	O	3852
effects	NOUN	O	O	3852
of	ADP	O	O	3852
prolonged	VERB	O	O	3852
prostaglandin E1-induced	VERB	O	O	3852
hypotension	NOUN	O	Disease	3852
and	CCONJ	O	O	3852
haemodilution	NOUN	O	O	3852
on	ADP	O	O	3852
human	PROPN	O	O	3852
hepatic	ADJ	O	O	3852
function	NOUN	O	O	3852
.	PUNCT	O	O	3852
Combined	VERB	O	O	3853
effects	NOUN	O	O	3853
of	ADP	O	O	3853
prolonged	VERB	O	O	3853
prostaglandin E1	NOUN	O	O	3853
(	PUNCT	O	O	3854
PGE1)-induced	VERB	O	O	3854
hypotension	NOUN	O	Disease	3854
and	CCONJ	O	O	3854
haemodilution	NOUN	O	O	3854
on	ADP	O	O	3854
hepatic	ADJ	O	O	3854
function	NOUN	O	O	3854
were	AUX	O	O	3854
studied	VERB	O	O	3854
in	ADP	O	O	3854
30	NUM	O	O	3854
patients	NOUN	O	O	3854
undergoing	VERB	O	O	3854
hip	NOUN	O	O	3854
surgery	NOUN	O	O	3854
.	PUNCT	O	O	3854
The	PRON	O	O	3855
patients	NOUN	O	O	3855
were	AUX	O	O	3855
randomly	ADV	O	O	3855
allocated	VERB	O	O	3855
to	PART	O	O	3855
one	NUM	O	O	3855
of	ADP	O	O	3855
three	NUM	O	O	3855
groups	NOUN	O	O	3855
;	PUNCT	O	O	3855
those	PRON	O	O	3855
in	ADP	O	O	3855
group	NOUN	O	O	3855
A	PRON	O	O	3855
(	PUNCT	O	O	3855
n	CCONJ	O	O	3855
=	PUNCT	O	O	3855
10	NUM	O	O	3855
)	PUNCT	O	O	3855
were	AUX	O	O	3855
subjected	VERB	O	O	3855
to	PART	O	O	3855
controlled	VERB	O	O	3855
hypotension	NOUN	O	Disease	3855
alone	ADV	O	O	3855
,	PUNCT	O	O	3855
those	PRON	O	O	3855
in	ADP	O	O	3855
group	NOUN	O	O	3855
B	NOUN	O	O	3855
(	PUNCT	O	O	3855
n	CCONJ	O	O	3855
=	PUNCT	O	O	3855
10	NUM	O	O	3855
)	PUNCT	O	O	3855
to	PART	O	O	3855
haemodilution	NOUN	O	O	3855
alone	ADV	O	O	3855
and	CCONJ	O	O	3855
those	PRON	O	O	3855
in	ADP	O	O	3855
group	NOUN	O	O	3855
C	NOUN	O	O	3855
(	PUNCT	O	O	3855
n	CCONJ	O	O	3855
=	PUNCT	O	O	3855
10	NUM	O	O	3855
)	PUNCT	O	O	3855
to	PART	O	O	3855
both	PRON	O	O	3855
controlled	VERB	O	O	3855
hypotension	NOUN	O	Disease	3855
and	CCONJ	O	O	3855
haemodilution	NOUN	O	O	3855
.	PUNCT	O	O	3855
Haemodilution	NOUN	O	O	3856
in	ADP	O	O	3856
groups	NOUN	O	O	3856
B	NOUN	O	O	3856
and	CCONJ	O	O	3856
C	NOUN	O	O	3856
was	AUX	O	O	3856
produced	VERB	O	O	3856
by	ADP	O	O	3856
withdrawing	VERB	O	O	3856
approximately	ADV	O	O	3856
1000	NUM	O	O	3856
mL	PROPN	O	O	3856
of	ADP	O	O	3856
blood	NOUN	O	O	3856
and	CCONJ	O	O	3856
replacing	VERB	O	O	3856
it	PRON	O	O	3856
with	ADP	O	O	3856
the	PRON	O	O	3856
same	ADJ	O	O	3856
amount	NOUN	O	O	3856
of	ADP	O	O	3856
dextran	NOUN	O	Chemical	3856
solution	NOUN	O	O	3856
,	PUNCT	O	O	3856
and	CCONJ	O	O	3856
final	ADJ	O	O	3856
haematocrit	VERB	O	O	3856
values	NOUN	O	O	3856
were	AUX	O	O	3856
21	NUM	O	O	3856
or	CCONJ	O	O	3856
22%	NOUN	O	O	3856
.	PUNCT	O	O	3856
Controlled	VERB	O	O	3857
hypotension	NOUN	O	Disease	3857
in	ADP	O	O	3857
groups	NOUN	O	O	3857
A	PRON	O	O	3857
and	CCONJ	O	O	3857
C	NOUN	O	O	3857
was	AUX	O	O	3857
induced	VERB	O	O	3857
with	ADP	O	O	3857
PGE1	NOUN	O	O	3857
to	PART	O	O	3857
maintain	VERB	O	O	3857
mean	VERB	O	O	3857
arterial	ADJ	O	O	3857
blood	NOUN	O	O	3857
pressure	NOUN	O	O	3857
at	ADP	O	O	3857
55	NUM	O	O	3857
mmHg	PROPN	O	O	3857
for	ADP	O	O	3857
180	NUM	O	O	3857
min	NOUN	O	O	3857
.	PUNCT	O	O	3857
Measurements	NOUN	O	O	3858
included	VERB	O	O	3858
arterial	ADJ	O	O	3858
ketone	NOUN	O	Chemical	3858
body	NOUN	O	O	3858
ratio	NOUN	O	O	3858
(	PUNCT	O	O	3858
AKBR	PROPN	O	O	3858
,	PUNCT	O	O	3858
aceto	PROPN	O	O	3858
-	PUNCT	O	O	3858
acetate/3-hydroxybutyrate	NOUN	O	O	3858
)	PUNCT	O	O	3858
and	CCONJ	O	O	3858
clinical	ADJ	O	O	3858
hepatic	ADJ	O	O	3858
function	NOUN	O	O	3858
parameters	NOUN	O	O	3858
.	PUNCT	O	O	3858
In	ADP	O	O	3859
group	NOUN	O	O	3859
C	NOUN	O	O	3859
,	PUNCT	O	O	3859
AKBR	PROPN	O	O	3859
showed	VERB	O	O	3859
a	PRON	O	O	3859
significant	ADJ	O	O	3859
decrease	VERB	O	O	3859
at	ADP	O	O	3859
120	NUM	O	O	3859
min	NOUN	O	O	3859
(	PUNCT	O	O	3859
-40%	NOUN	O	O	3859
)	PUNCT	O	O	3859
and	CCONJ	O	O	3859
at	ADP	O	O	3859
180	NUM	O	O	3859
min	NOUN	O	O	3859
(	PUNCT	O	O	3859
-49%	NOUN	O	O	3859
)	PUNCT	O	O	3859
after	ADP	O	O	3859
the	PRON	O	O	3859
start	VERB	O	O	3859
of	ADP	O	O	3859
hypotension	NOUN	O	Disease	3859
and	CCONJ	O	O	3859
at	ADP	O	O	3859
60	NUM	O	O	3859
min	NOUN	O	O	3859
(	PUNCT	O	O	3859
-32%	NOUN	O	O	3859
)	PUNCT	O	O	3859
after	ADP	O	O	3859
recovery	NOUN	O	O	3859
of	ADP	O	O	3859
normotension	NOUN	O	O	3859
,	PUNCT	O	O	3859
and	CCONJ	O	O	3859
SGOT	NOUN	O	O	3859
,	PUNCT	O	O	3859
SGPT	PROPN	O	O	3859
,	PUNCT	O	O	3859
LDH	PROPN	O	O	3859
and	CCONJ	O	O	3859
total	ADJ	O	O	3859
bilirubin	ADJ	O	Chemical	3859
showed	VERB	O	O	3859
significant	ADJ	O	O	3859
increases	VERB	O	O	3859
after	ADP	O	O	3859
operation	NOUN	O	O	3859
.	PUNCT	O	O	3859
The	PRON	O	O	3860
results	VERB	O	O	3860
suggest	VERB	O	O	3860
that	SCONJ	O	O	3860
a	PRON	O	O	3860
prolonged	VERB	O	O	3860
combination	NOUN	O	O	3860
of	ADP	O	O	3860
more	ADJ	O	O	3860
than	ADP	O	O	3860
120	NUM	O	O	3860
min	NOUN	O	O	3860
of	ADP	O	O	3860
PGE1-induced	VERB	O	O	3860
hypotension	NOUN	O	Disease	3860
and	CCONJ	O	O	3860
moderate	ADJ	O	O	3860
haemodilution	NOUN	O	O	3860
would	AUX	O	O	3860
cause	VERB	O	O	3860
impairment	NOUN	O	O	3860
of	ADP	O	O	3860
hepatic	ADJ	O	O	3860
function	NOUN	O	O	3860
.	PUNCT	O	O	3860
Levodopa	NOUN	O	Chemical	3863
-	PUNCT	O	O	3863
induced	VERB	O	O	3863
dyskinesias	PROPN	O	Disease	3863
in	ADP	O	O	3863
patients	NOUN	O	O	3863
with	ADP	O	O	3863
Parkinson	NOUN	O	O	3863
's	AUX	O	O	3863
disease	PROPN	O	O	3863
:	PUNCT	O	O	3863
filling	VERB	O	O	3863
the	PRON	O	O	3863
bench	NOUN	O	O	3863
-	PUNCT	O	O	3863
to	PART	O	O	3863
-	PUNCT	O	O	3863
bedside	NOUN	O	O	3863
gap	NOUN	O	O	3863
.	PUNCT	O	O	3863
Levodopa	NOUN	O	Chemical	3864
is	AUX	O	O	3864
the	PRON	O	O	3864
most	ADV	O	O	3864
effective	ADJ	O	O	3864
drug	NOUN	O	O	3864
for	ADP	O	O	3864
the	PRON	O	O	3864
treatment	NOUN	O	O	3864
of	ADP	O	O	3864
Parkinson	NOUN	O	O	3864
's	AUX	O	O	3864
disease	PROPN	O	O	3864
.	PUNCT	O	O	3864
However	ADV	O	O	3865
,	PUNCT	O	O	3865
the	PRON	O	O	3865
long	ADV	O	O	3865
-	PUNCT	O	O	3865
term	NOUN	O	O	3865
use	VERB	O	O	3865
of	ADP	O	O	3865
this	PRON	O	O	3865
dopamine	NOUN	O	Chemical	3865
precursor	NOUN	O	O	3865
is	AUX	O	O	3865
complicated	VERB	O	O	3865
by	ADP	O	O	3865
highly	ADV	O	O	3865
disabling	VERB	O	O	3865
fluctuations	NOUN	O	O	3865
and	CCONJ	O	O	3865
dyskinesias	PROPN	O	Disease	3865
.	PUNCT	O	O	3865
Although	SCONJ	O	O	3866
preclinical	ADJ	O	O	3866
and	CCONJ	O	O	3866
clinical	ADJ	O	O	3866
findings	NOUN	O	O	3866
suggest	VERB	O	O	3866
pulsatile	ADJ	O	O	3866
stimulation	NOUN	O	O	3866
of	ADP	O	O	3866
striatal	ADJ	O	O	3866
postsynaptic	ADJ	O	O	3866
receptors	NOUN	O	O	3866
as	ADP	O	O	3866
a	PRON	O	O	3866
key	NOUN	O	O	3866
mechanism	NOUN	O	O	3866
underlying	VERB	O	O	3866
levodopa	NOUN	O	Chemical	3866
-	PUNCT	O	O	3866
induced	VERB	O	O	3866
dyskinesias	PROPN	O	Disease	3866
,	PUNCT	O	O	3866
their	PRON	O	O	3866
pathogenesis	NOUN	O	O	3866
is	AUX	O	O	3866
still	ADV	O	O	3866
unclear	ADJ	O	O	3866
.	PUNCT	O	O	3866
In	ADP	O	O	3867
recent	ADJ	O	O	3867
years	NOUN	O	O	3867
,	PUNCT	O	O	3867
evidence	NOUN	O	O	3867
from	ADP	O	O	3867
animal	NOUN	O	O	3867
models	NOUN	O	O	3867
of	ADP	O	O	3867
Parkinson	NOUN	O	O	3867
's	AUX	O	O	3867
disease	PROPN	O	O	3867
has	VERB	O	O	3867
provided	VERB	O	O	3867
important	ADJ	O	O	3867
information	NOUN	O	O	3867
to	PART	O	O	3867
understand	VERB	O	O	3867
the	PRON	O	O	3867
effect	VERB	O	O	3867
of	ADP	O	O	3867
specific	ADJ	O	O	3867
receptor	NOUN	O	O	3867
and	CCONJ	O	O	3867
post	VERB	O	O	3867
-	PUNCT	O	O	3867
receptor	NOUN	O	O	3867
molecular	ADJ	O	O	3867
mechanisms	NOUN	O	O	3867
underlying	VERB	O	O	3867
the	PRON	O	O	3867
development	NOUN	O	O	3867
of	ADP	O	O	3867
dyskinetic	VERB	O	Disease	3867
movements	NOUN	O	O	3867
.	PUNCT	O	O	3867
Recent	ADJ	O	O	3868
preclinical	ADJ	O	O	3868
and	CCONJ	O	O	3868
clinical	ADJ	O	O	3868
data	NOUN	O	O	3868
from	ADP	O	O	3868
promising	VERB	O	O	3868
lines	NOUN	O	O	3868
of	ADP	O	O	3868
research	NOUN	O	O	3868
focus	NOUN	O	O	3868
on	ADP	O	O	3868
the	PRON	O	O	3868
differential	ADJ	O	O	3868
role	NOUN	O	O	3868
of	ADP	O	O	3868
presynaptic	ADJ	O	O	3868
versus	ADP	O	O	3868
postsynaptic	ADJ	O	O	3868
mechanisms	NOUN	O	O	3868
,	PUNCT	O	O	3868
dopamine	NOUN	O	Chemical	3868
receptor	NOUN	O	O	3868
subtypes	NOUN	O	O	3868
,	PUNCT	O	O	3868
ionotropic	ADJ	O	O	3868
and	CCONJ	O	O	3868
metabotropic	NOUN	O	O	3868
glutamate	NOUN	O	Chemical	3868
receptors	NOUN	O	O	3868
,	PUNCT	O	O	3868
and	CCONJ	O	O	3868
non	ADJ	O	O	3868
-	PUNCT	O	O	3868
dopaminergic	ADJ	O	O	3868
neurotransmitter	NOUN	O	O	3868
systems	NOUN	O	O	3868
in	ADP	O	O	3868
the	PRON	O	O	3868
pathophysiology	NOUN	O	O	3868
of	ADP	O	O	3868
levodopa	NOUN	O	Chemical	3868
-	PUNCT	O	O	3868
induced	VERB	O	O	3868
dyskinesias	PROPN	O	Disease	3868
.	PUNCT	O	O	3868
Prevention	NOUN	O	O	3871
of	ADP	O	O	3871
seizures	NOUN	O	Disease	3871
and	CCONJ	O	O	3871
reorganization	NOUN	O	O	3871
of	ADP	O	O	3871
hippocampal	NOUN	O	O	3871
functions	VERB	O	O	3871
by	ADP	O	O	3871
transplantation	NOUN	O	O	3871
of	ADP	O	O	3871
bone	NOUN	O	O	3871
marrow	PROPN	O	O	3871
cells	NOUN	O	O	3871
in	ADP	O	O	3871
the	PRON	O	O	3871
acute	ADJ	O	O	3871
phase	NOUN	O	O	3871
of	ADP	O	O	3871
experimental	ADJ	O	O	3871
epilepsy	NOUN	O	Disease	3871
.	PUNCT	O	O	3871
In	ADP	O	O	3872
this	PRON	O	O	3872
study	VERB	O	O	3872
,	PUNCT	O	O	3872
we	PRON	O	O	3872
investigated	VERB	O	O	3872
the	PRON	O	O	3872
therapeutic	ADJ	O	O	3872
potential	ADJ	O	O	3872
of	ADP	O	O	3872
bone	NOUN	O	O	3872
marrow	PROPN	O	O	3872
mononuclear	PROPN	O	O	3872
cells	NOUN	O	O	3872
(	PUNCT	O	O	3872
BMCs	NOUN	O	O	3872
)	PUNCT	O	O	3872
in	ADP	O	O	3872
a	PRON	O	O	3872
model	NOUN	O	O	3872
of	ADP	O	O	3872
epilepsy	NOUN	O	Disease	3872
induced	VERB	O	O	3872
by	ADP	O	O	3872
pilocarpine	NOUN	O	Chemical	3872
in	ADP	O	O	3872
rats	NOUN	O	O	3872
.	PUNCT	O	O	3872
BMCs	NOUN	O	O	3873
obtained	VERB	O	O	3873
from	ADP	O	O	3873
green	ADJ	O	O	3873
fluorescent	NOUN	O	O	3873
protein	NOUN	O	O	3873
(	PUNCT	O	O	3873
GFP	PROPN	O	O	3873
)	PUNCT	O	O	3873
transgenic	NOUN	O	O	3873
mice	NOUN	O	O	3873
or	CCONJ	O	O	3873
rats	NOUN	O	O	3873
were	AUX	O	O	3873
transplanted	VERB	O	O	3873
intravenously	ADV	O	O	3873
after	ADP	O	O	3873
induction	NOUN	O	O	3873
of	ADP	O	O	3873
status epilepticus	VERB	O	Disease	3873
(	PUNCT	O	O	3873
SE	PROPN	O	O	3873
)	PUNCT	O	O	3873
.	PUNCT	O	O	3873
Spontaneous	ADJ	O	O	3874
recurrent	ADJ	O	O	3874
seizures	NOUN	O	Disease	3874
(	PUNCT	O	O	3874
SRS	PROPN	O	O	3874
)	PUNCT	O	O	3874
were	AUX	O	O	3874
monitored	VERB	O	O	3874
using	VERB	O	O	3874
Racine	PROPN	O	O	3874
's	AUX	O	O	3874
seizure	NOUN	O	Disease	3874
severity	NOUN	O	O	3874
scale	NOUN	O	O	3874
.	PUNCT	O	O	3874
All	PRON	O	O	3875
of	ADP	O	O	3875
the	PRON	O	O	3875
rats	NOUN	O	O	3875
in	ADP	O	O	3875
the	PRON	O	O	3875
saline	NOUN	O	O	3875
-	PUNCT	O	O	3875
treated	VERB	O	O	3875
epileptic	ADJ	O	Disease	3875
control	VERB	O	O	3875
group	NOUN	O	O	3875
developed	VERB	O	O	3875
SRS	PROPN	O	O	3875
,	PUNCT	O	O	3875
whereas	SCONJ	O	O	3875
none	NOUN	O	O	3875
of	ADP	O	O	3875
the	PRON	O	O	3875
BMC	PROPN	O	O	3875
-	PUNCT	O	O	3875
treated	VERB	O	O	3875
epileptic	ADJ	O	Disease	3875
animals	NOUN	O	O	3875
had	VERB	O	O	3875
seizures	NOUN	O	Disease	3875
in	ADP	O	O	3875
the	PRON	O	O	3875
short	ADJ	O	O	3875
term	NOUN	O	O	3875
(	PUNCT	O	O	3875
15	NUM	O	O	3875
days	NOUN	O	O	3875
after	ADP	O	O	3875
transplantation	NOUN	O	O	3875
)	PUNCT	O	O	3875
,	PUNCT	O	O	3875
regardless	ADV	O	O	3875
of	ADP	O	O	3875
the	PRON	O	O	3875
BMC	PROPN	O	O	3875
source	NOUN	O	O	3875
.	PUNCT	O	O	3875
Over	ADP	O	O	3876
the	PRON	O	O	3876
long	ADV	O	O	3876
-	PUNCT	O	O	3876
term	NOUN	O	O	3876
chronic	ADJ	O	O	3876
phase	NOUN	O	O	3876
(	PUNCT	O	O	3876
120	NUM	O	O	3876
days	NOUN	O	O	3876
after	ADP	O	O	3876
transplantation	NOUN	O	O	3876
)	PUNCT	O	O	3876
,	PUNCT	O	O	3876
only	ADV	O	O	3876
25%	NOUN	O	O	3876
of	ADP	O	O	3876
BMC	PROPN	O	O	3876
-	PUNCT	O	O	3876
treated	VERB	O	O	3876
epileptic	ADJ	O	Disease	3876
animals	NOUN	O	O	3876
had	VERB	O	O	3876
seizures	NOUN	O	Disease	3876
,	PUNCT	O	O	3876
but	CCONJ	O	O	3876
with	ADP	O	O	3876
a	PRON	O	O	3876
lower	ADJ	O	O	3876
frequency	NOUN	O	O	3876
and	CCONJ	O	O	3876
duration	NOUN	O	O	3876
compared	VERB	O	O	3876
to	PART	O	O	3876
the	PRON	O	O	3876
epileptic	ADJ	O	Disease	3876
control	VERB	O	O	3876
group	NOUN	O	O	3876
.	PUNCT	O	O	3876
At	ADP	O	O	3877
hippocampal	NOUN	O	O	3877
Schaeffer	PROPN	O	O	3877
collateral	NOUN	O	O	3877
-	PUNCT	O	O	3877
CA1	PROPN	O	O	3877
synapses	NOUN	O	O	3877
,	PUNCT	O	O	3877
long	ADV	O	O	3877
-	PUNCT	O	O	3877
term	NOUN	O	O	3877
potentiation	NOUN	O	O	3877
was	AUX	O	O	3877
preserved	VERB	O	O	3877
in	ADP	O	O	3877
BMC	PROPN	O	O	3877
-	PUNCT	O	O	3877
transplanted	VERB	O	O	3877
rats	NOUN	O	O	3877
compared	VERB	O	O	3877
to	PART	O	O	3877
epileptic	ADJ	O	Disease	3877
controls	VERB	O	O	3877
.	PUNCT	O	O	3877
cells	NOUN	O	O	3878
were	AUX	O	O	3878
rarely	ADV	O	O	3878
found	VERB	O	O	3878
in	ADP	O	O	3878
the	PRON	O	O	3878
brains	NOUN	O	O	3878
of	ADP	O	O	3878
transplanted	VERB	O	O	3878
epileptic	ADJ	O	Disease	3878
rats	NOUN	O	O	3878
.	PUNCT	O	O	3878
In	ADP	O	O	3879
conclusion	NOUN	O	O	3879
,	PUNCT	O	O	3879
treatment	NOUN	O	O	3879
with	ADP	O	O	3879
BMCs	NOUN	O	O	3879
can	AUX	O	O	3879
prevent	VERB	O	O	3879
the	PRON	O	O	3879
development	NOUN	O	O	3879
of	ADP	O	O	3879
chronic	ADJ	O	O	3879
seizures	NOUN	O	Disease	3879
,	PUNCT	O	O	3879
reduce	VERB	O	O	3879
neuronal loss	NOUN	O	Disease	3879
,	PUNCT	O	O	3879
and	CCONJ	O	O	3879
influence	NOUN	O	O	3879
the	PRON	O	O	3879
reorganization	NOUN	O	O	3879
of	ADP	O	O	3879
the	PRON	O	O	3879
hippocampal	NOUN	O	O	3879
neuronal	ADJ	O	O	3879
network	NOUN	O	O	3879
.	PUNCT	O	O	3879
Cardioprotective	PROPN	O	O	3882
effect	VERB	O	O	3882
of	ADP	O	O	3882
salvianolic	ADJ	O	O	3882
acid	PROPN	O	O	3882
A	PRON	O	O	3882
on	ADP	O	O	3882
isoproterenol	NOUN	O	Chemical	3882
-	PUNCT	O	O	3882
induced	VERB	O	O	3882
myocardial infarction	NOUN	O	Disease	3882
in	ADP	O	O	3882
rats	NOUN	O	O	3882
.	PUNCT	O	O	3882
The	PRON	O	O	3883
present	NOUN	O	O	3883
study	VERB	O	O	3883
was	AUX	O	O	3883
designed	VERB	O	O	3883
to	PART	O	O	3883
evaluate	VERB	O	O	3883
the	PRON	O	O	3883
cardioprotective	ADJ	O	O	3883
potential	ADJ	O	O	3883
of	ADP	O	O	3883
salvianolic	ADJ	O	O	3883
acid	PROPN	O	O	3883
A	PRON	O	O	3883
on	ADP	O	O	3883
isoproterenol	NOUN	O	Chemical	3883
-	PUNCT	O	O	3883
induced	VERB	O	O	3883
myocardial infarction	NOUN	O	Disease	3883
in	ADP	O	O	3883
rats	NOUN	O	O	3883
.	PUNCT	O	O	3883
Isoproterenol	NOUN	O	Chemical	3884
-	PUNCT	O	O	3884
treated	VERB	O	O	3884
rats	NOUN	O	O	3884
showed	VERB	O	O	3884
significant	ADJ	O	O	3884
increases	VERB	O	O	3884
in	ADP	O	O	3884
the	PRON	O	O	3884
levels	NOUN	O	O	3884
of	ADP	O	O	3884
lactate	NOUN	O	Chemical	3884
dehydrogenase	NOUN	O	O	3884
,	PUNCT	O	O	3884
aspartate	NOUN	O	Chemical	3884
transaminase	X	O	O	3884
,	PUNCT	O	O	3884
creatine	PROPN	O	Chemical	3884
kinase	VERB	O	O	3884
and	CCONJ	O	O	3884
malondialdehyde	PROPN	O	Chemical	3884
and	CCONJ	O	O	3884
significant	ADJ	O	O	3884
decreases	VERB	O	O	3884
in	ADP	O	O	3884
the	PRON	O	O	3884
activities	NOUN	O	O	3884
of	ADP	O	O	3884
superoxide	NOUN	O	Chemical	3884
dismutase	ADP	O	O	3884
,	PUNCT	O	O	3884
catalase	VERB	O	O	3884
and	CCONJ	O	O	3884
glutathione	NOUN	O	Chemical	3884
peroxidase	NOUN	O	O	3884
in	ADP	O	O	3884
serum	NOUN	O	O	3884
and	CCONJ	O	O	3884
heart	NOUN	O	O	3884
.	PUNCT	O	O	3884
In	ADP	O	O	3885
addition	NOUN	O	O	3885
,	PUNCT	O	O	3885
mitochondrial	ADJ	O	O	3885
respiratory	NOUN	O	O	3885
dysfunction	NOUN	O	O	3885
characterized	VERB	O	O	3885
by	ADP	O	O	3885
decreased	VERB	O	O	3885
respiratory	NOUN	O	O	3885
control	VERB	O	O	3885
ratio	NOUN	O	O	3885
and	CCONJ	O	O	3885
ADP	PROPN	O	Chemical	3885
/	PUNCT	O	O	3885
O	INTJ	O	O	3885
was	AUX	O	O	3885
observed	VERB	O	O	3885
in	ADP	O	O	3885
isoproterenol	NOUN	O	Chemical	3885
-	PUNCT	O	O	3885
treated	VERB	O	O	3885
rats	NOUN	O	O	3885
.	PUNCT	O	O	3885
Administration	NOUN	O	O	3886
of	ADP	O	O	3886
salvianolic	ADJ	O	O	3886
acid	PROPN	O	O	3886
A	PRON	O	O	3886
for	ADP	O	O	3886
a	PRON	O	O	3886
period	NOUN	O	O	3886
of	ADP	O	O	3886
8	NUM	O	O	3886
days	NOUN	O	O	3886
significantly	ADV	O	O	3886
attenuated	VERB	O	O	3886
isoproterenol	NOUN	O	Chemical	3886
-	PUNCT	O	O	3886
induced	VERB	O	O	3886
cardiac dysfunction	NOUN	O	Disease	3886
and	CCONJ	O	O	3886
myocardial injury	NOUN	O	Disease	3886
and	CCONJ	O	O	3886
improved	VERB	O	O	3886
mitochondrial	ADJ	O	O	3886
respiratory	NOUN	O	O	3886
function	NOUN	O	O	3886
.	PUNCT	O	O	3886
The	PRON	O	O	3887
protective	ADJ	O	O	3887
role	NOUN	O	O	3887
of	ADP	O	O	3887
salvianolic	ADJ	O	O	3887
acid	PROPN	O	O	3887
A	PRON	O	O	3887
against	ADP	O	O	3887
isoproterenol	NOUN	O	Chemical	3887
-	PUNCT	O	O	3887
induced	VERB	O	O	3887
myocardial damage	NOUN	O	Disease	3887
was	AUX	O	O	3887
further	ADV	O	O	3887
confirmed	VERB	O	O	3887
by	ADP	O	O	3887
histopathological	ADJ	O	O	3887
examination	NOUN	O	O	3887
.	PUNCT	O	O	3887
The	PRON	O	O	3888
results	VERB	O	O	3888
of	ADP	O	O	3888
our	PRON	O	O	3888
study	VERB	O	O	3888
suggest	VERB	O	O	3888
that	SCONJ	O	O	3888
salvianolic	ADJ	O	O	3888
acid	PROPN	O	O	3888
A	PRON	O	O	3888
possessing	VERB	O	O	3888
antioxidant	ADJ	O	O	3888
activity	NOUN	O	O	3888
has	VERB	O	O	3888
a	PRON	O	O	3888
significant	ADJ	O	O	3888
protective	ADJ	O	O	3888
effect	VERB	O	O	3888
against	ADP	O	O	3888
isoproterenol	NOUN	O	Chemical	3888
-	PUNCT	O	O	3888
induced	VERB	O	O	3888
myocardial infarction	NOUN	O	Disease	3888
.	PUNCT	O	O	3888
Acute	PROPN	O	O	3891
effects	NOUN	O	O	3891
of	ADP	O	O	3891
N-(2-propylpentanoyl)urea	NOUN	O	O	3891
on	ADP	O	O	3891
hippocampal	NOUN	O	O	3891
amino acid	NOUN	O	Chemical	3891
neurotransmitters	NOUN	O	O	3891
in	ADP	O	O	3891
pilocarpine	NOUN	O	Chemical	3891
-	PUNCT	O	O	3891
induced	VERB	O	O	3891
seizure	NOUN	O	Disease	3891
in	ADP	O	O	3891
rats	NOUN	O	O	3891
.	PUNCT	O	O	3891
The	PRON	O	O	3892
present	NOUN	O	O	3892
study	VERB	O	O	3892
aimed	VERB	O	O	3892
to	PART	O	O	3892
investigate	VERB	O	O	3892
the	PRON	O	O	3892
anticonvulsant	ADJ	O	O	3892
activity	NOUN	O	O	3892
as	ADP	O	O	3892
well	ADV	O	O	3892
as	ADP	O	O	3892
the	PRON	O	O	3892
effects	NOUN	O	O	3892
on	ADP	O	O	3892
the	PRON	O	O	3892
level	VERB	O	O	3892
of	ADP	O	O	3892
hippocampal	NOUN	O	O	3892
amino acid	NOUN	O	Chemical	3892
neurotransmitters	NOUN	O	O	3892
(	PUNCT	O	O	3892
glutamate	NOUN	O	Chemical	3892
,	PUNCT	O	O	3892
aspartate	NOUN	O	Chemical	3892
,	PUNCT	O	O	3892
glycine	NOUN	O	Chemical	3892
and	CCONJ	O	O	3892
GABA	PROPN	O	Chemical	3892
)	PUNCT	O	O	3892
of	ADP	O	O	3892
N-(2-propylpentanoyl)urea	NOUN	O	O	3892
(	PUNCT	O	O	3892
VPU	PROPN	O	O	3892
)	PUNCT	O	O	3892
in	ADP	O	O	3892
comparison	NOUN	O	O	3892
to	PART	O	O	3892
its	PRON	O	O	3892
parent	NOUN	O	O	3892
compound	NOUN	O	O	3892
,	PUNCT	O	O	3892
valproic acid	NOUN	O	Chemical	3892
(	PUNCT	O	O	3892
VPA	PROPN	O	Chemical	3892
)	PUNCT	O	O	3892
.	PUNCT	O	O	3892
VPU	PROPN	O	O	3893
was	AUX	O	O	3893
more	ADJ	O	O	3893
potent	ADJ	O	O	3893
than	ADP	O	O	3893
VPA	PROPN	O	Chemical	3893
,	PUNCT	O	O	3893
exhibiting	VERB	O	O	3893
the	PRON	O	O	3893
median	ADJ	O	O	3893
effective	ADJ	O	O	3893
dose	NOUN	O	O	3893
(	PUNCT	O	O	3893
ED(50	NOUN	O	O	3893
)	PUNCT	O	O	3893
)	PUNCT	O	O	3893
of	ADP	O	O	3893
49	NUM	O	O	3893
mg	VERB	O	O	3893
/	PUNCT	O	O	3893
kg	VERB	O	O	3893
in	ADP	O	O	3893
protecting	VERB	O	O	3893
rats	NOUN	O	O	3893
against	ADP	O	O	3893
pilocarpine	NOUN	O	Chemical	3893
-	PUNCT	O	O	3893
induced	VERB	O	O	3893
seizure	NOUN	O	Disease	3893
whereas	SCONJ	O	O	3893
the	PRON	O	O	3893
corresponding	VERB	O	O	3893
value	NOUN	O	O	3893
for	ADP	O	O	3893
VPA	PROPN	O	Chemical	3893
was	AUX	O	O	3893
322	NUM	O	O	3893
mg	VERB	O	O	3893
/	PUNCT	O	O	3893
kg	VERB	O	O	3893
.	PUNCT	O	O	3893
In	ADP	O	O	3894
vivo	VERB	O	O	3894
microdialysis	NOUN	O	O	3894
demonstrated	VERB	O	O	3894
that	SCONJ	O	O	3894
an	PRON	O	O	3894
intraperitoneal	ADJ	O	O	3894
administration	NOUN	O	O	3894
of	ADP	O	O	3894
pilocarpine	NOUN	O	Chemical	3894
induced	VERB	O	O	3894
a	PRON	O	O	3894
pronounced	VERB	O	O	3894
increment	NOUN	O	O	3894
of	ADP	O	O	3894
hippocampal	NOUN	O	O	3894
glutamate	NOUN	O	Chemical	3894
and	CCONJ	O	O	3894
aspartate	NOUN	O	Chemical	3894
whereas	SCONJ	O	O	3894
no	PRON	O	O	3894
significant	ADJ	O	O	3894
change	VERB	O	O	3894
was	AUX	O	O	3894
observed	VERB	O	O	3894
on	ADP	O	O	3894
the	PRON	O	O	3894
level	VERB	O	O	3894
of	ADP	O	O	3894
glycine	NOUN	O	Chemical	3894
and	CCONJ	O	O	3894
GABA	PROPN	O	Chemical	3894
.	PUNCT	O	O	3894
Pretreatment	NOUN	O	O	3895
with	ADP	O	O	3895
either	ADV	O	O	3895
VPU	PROPN	O	O	3895
(	PUNCT	O	O	3895
50	NUM	O	O	3895
and	CCONJ	O	O	3895
100	NUM	O	O	3895
mg	VERB	O	O	3895
/	PUNCT	O	O	3895
kg	VERB	O	O	3895
)	PUNCT	O	O	3895
or	CCONJ	O	O	3895
VPA	PROPN	O	Chemical	3895
(	PUNCT	O	O	3895
300	NUM	O	O	3895
and	CCONJ	O	O	3895
600	NUM	O	O	3895
mg	VERB	O	O	3895
/	PUNCT	O	O	3895
kg	VERB	O	O	3895
)	PUNCT	O	O	3895
completely	ADV	O	O	3895
abolished	VERB	O	O	3895
pilocarpine	NOUN	O	Chemical	3895
-	PUNCT	O	O	3895
evoked	VERB	O	O	3895
increases	VERB	O	O	3895
in	ADP	O	O	3895
extracellular	ADJ	O	O	3895
glutamate	NOUN	O	Chemical	3895
and	CCONJ	O	O	3895
aspartate	NOUN	O	Chemical	3895
.	PUNCT	O	O	3895
In	ADP	O	O	3896
addition	NOUN	O	O	3896
,	PUNCT	O	O	3896
a	PRON	O	O	3896
statistically	ADV	O	O	3896
significant	ADJ	O	O	3896
reduction	NOUN	O	O	3896
was	AUX	O	O	3896
also	ADV	O	O	3896
observed	VERB	O	O	3896
on	ADP	O	O	3896
the	PRON	O	O	3896
level	VERB	O	O	3896
of	ADP	O	O	3896
GABA	PROPN	O	Chemical	3896
and	CCONJ	O	O	3896
glycine	NOUN	O	Chemical	3896
but	CCONJ	O	O	3896
less	ADV	O	O	3896
than	ADP	O	O	3896
a	PRON	O	O	3896
drastic	ADJ	O	O	3896
reduction	NOUN	O	O	3896
of	ADP	O	O	3896
glutamate	NOUN	O	Chemical	3896
and	CCONJ	O	O	3896
aspartate	NOUN	O	Chemical	3896
level	VERB	O	O	3896
.	PUNCT	O	O	3896
Based	VERB	O	O	3897
on	ADP	O	O	3897
the	PRON	O	O	3897
finding	VERB	O	O	3897
that	SCONJ	O	O	3897
VPU	PROPN	O	O	3897
and	CCONJ	O	O	3897
VPA	PROPN	O	Chemical	3897
could	AUX	O	O	3897
protect	VERB	O	O	3897
the	PRON	O	O	3897
animals	NOUN	O	O	3897
against	ADP	O	O	3897
pilocarpine	NOUN	O	Chemical	3897
-	PUNCT	O	O	3897
induced	VERB	O	O	3897
seizure	NOUN	O	Disease	3897
it	PRON	O	O	3897
is	AUX	O	O	3897
suggested	VERB	O	O	3897
that	SCONJ	O	O	3897
the	PRON	O	O	3897
reduction	NOUN	O	O	3897
of	ADP	O	O	3897
inhibitory	ADJ	O	O	3897
amino acid	NOUN	O	Chemical	3897
neurotransmitters	NOUN	O	O	3897
was	AUX	O	O	3897
comparatively	ADV	O	O	3897
minor	ADJ	O	O	3897
and	CCONJ	O	O	3897
offset	VERB	O	O	3897
by	ADP	O	O	3897
a	PRON	O	O	3897
pronounced	VERB	O	O	3897
reduction	NOUN	O	O	3897
of	ADP	O	O	3897
glutamate	NOUN	O	Chemical	3897
and	CCONJ	O	O	3897
aspartate	NOUN	O	Chemical	3897
.	PUNCT	O	O	3897
Therefore	ADV	O	O	3898
,	PUNCT	O	O	3898
like	INTJ	O	O	3898
VPA	PROPN	O	Chemical	3898
,	PUNCT	O	O	3898
the	PRON	O	O	3898
finding	VERB	O	O	3898
that	SCONJ	O	O	3898
VPU	PROPN	O	O	3898
could	AUX	O	O	3898
drastically	ADV	O	O	3898
reduce	VERB	O	O	3898
pilocarpine	NOUN	O	Chemical	3898
-	PUNCT	O	O	3898
induced	VERB	O	O	3898
increases	VERB	O	O	3898
in	ADP	O	O	3898
glutamate	NOUN	O	Chemical	3898
and	CCONJ	O	O	3898
aspartate	NOUN	O	Chemical	3898
should	AUX	O	O	3898
account	VERB	O	O	3898
,	PUNCT	O	O	3898
at	ADP	O	O	3898
least	ADJ	O	O	3898
partly	ADV	O	O	3898
,	PUNCT	O	O	3898
for	ADP	O	O	3898
its	PRON	O	O	3898
anticonvulsant	ADJ	O	O	3898
activity	NOUN	O	O	3898
observed	VERB	O	O	3898
in	ADP	O	O	3898
pilocarpine	NOUN	O	Chemical	3898
-	PUNCT	O	O	3898
induced	VERB	O	O	3898
seizure	NOUN	O	Disease	3898
in	ADP	O	O	3898
experimental	ADJ	O	O	3898
animals	NOUN	O	O	3898
.	PUNCT	O	O	3898
Acute	PROPN	O	O	3901
hepatitis	NOUN	O	Disease	3901
attack	VERB	O	O	3901
after	ADP	O	O	3901
exposure	NOUN	O	O	3901
to	PART	O	O	3901
telithromycin	PROPN	O	O	3901
.	PUNCT	O	O	3901
INTRODUCTION	NOUN	O	O	3902
:	PUNCT	O	O	3902
Antibiotic	NOUN	O	O	3902
-	PUNCT	O	O	3902
associated	VERB	O	O	3902
hepatotoxicity	NOUN	O	Disease	3902
is	AUX	O	O	3902
rare	ADJ	O	O	3902
.	PUNCT	O	O	3902
With	ADP	O	O	3903
widespread	ADJ	O	O	3903
use	VERB	O	O	3903
of	ADP	O	O	3903
antimicrobial	ADJ	O	O	3903
agents	NOUN	O	O	3903
,	PUNCT	O	O	3903
however	ADV	O	O	3903
,	PUNCT	O	O	3903
hepatic injury	NOUN	O	Disease	3903
occurs	VERB	O	O	3903
frequently	ADV	O	O	3903
,	PUNCT	O	O	3903
and	CCONJ	O	O	3903
among	ADP	O	O	3903
adverse	ADJ	O	O	3903
drug	NOUN	O	O	3903
reactions	NOUN	O	O	3903
,	PUNCT	O	O	3903
idiosyncratic	ADJ	O	O	3903
reactions	NOUN	O	O	3903
are	AUX	O	O	3903
the	PRON	O	O	3903
most	ADV	O	O	3903
serious	ADJ	O	O	3903
.	PUNCT	O	O	3903
Hospital	NOUN	O	O	3904
Emergency	NOUN	O	O	3904
Department	NOUN	O	O	3904
,	PUNCT	O	O	3904
Istanbul	PROPN	O	O	3904
,	PUNCT	O	O	3904
Turkey	PROPN	O	O	3904
,	PUNCT	O	O	3904
with	ADP	O	O	3904
5	NUM	O	O	3904
days	NOUN	O	O	3904
'	PUNCT	O	O	3904
history	NOUN	O	O	3904
of	ADP	O	O	3904
jaundice	NOUN	O	Disease	3904
,	PUNCT	O	O	3904
malaise	NOUN	O	Disease	3904
,	PUNCT	O	O	3904
nausea	NOUN	O	Disease	3904
,	PUNCT	O	O	3904
and	CCONJ	O	O	3904
vomiting	VERB	O	Disease	3904
.	PUNCT	O	O	3904
He	PRON	O	O	3905
had	VERB	O	O	3905
been	AUX	O	O	3905
prescribed	VERB	O	O	3905
telithromycin	PROPN	O	O	3905
400	NUM	O	O	3905
mg	VERB	O	O	3905
/	PUNCT	O	O	3905
d	X	O	O	3906
PO	NOUN	O	O	3906
to	PART	O	O	3906
treat	VERB	O	O	3906
an	PRON	O	O	3906
upper	ADJ	O	O	3906
respiratory	NOUN	O	O	3906
tract	NOUN	O	O	3906
infection	NOUN	O	Disease	3906
7	NUM	O	O	3906
days	NOUN	O	O	3906
prior	ADV	O	O	3906
.	PUNCT	O	O	3906
Admission	NOUN	O	O	3907
laboratory	NOUN	O	O	3907
tests	VERB	O	O	3907
were	AUX	O	O	3907
as	ADP	O	O	3907
follows	VERB	O	O	3907
:	PUNCT	O	O	3907
alanine	NOUN	O	Chemical	3907
aminotransferase	PROPN	O	O	3907
,	PUNCT	O	O	3907
67	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
(	PUNCT	O	O	3907
reference	NOUN	O	O	3907
range	VERB	O	O	3907
,	PUNCT	O	O	3907
10	NUM	O	O	3907
-	PUNCT	O	O	3907
37	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
)	PUNCT	O	O	3907
;	PUNCT	O	O	3907
aspartate	NOUN	O	Chemical	3907
aminotransferase	PROPN	O	O	3907
,	PUNCT	O	O	3907
98	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
(	PUNCT	O	O	3907
10	NUM	O	O	3907
-	PUNCT	O	O	3907
40	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
)	PUNCT	O	O	3907
;	PUNCT	O	O	3907
alkaline	NOUN	O	O	3907
phosphatase	ADJ	O	O	3907
,	PUNCT	O	O	3907
513	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
(	PUNCT	O	O	3907
0	NUM	O	O	3907
-	PUNCT	O	O	3907
270	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
)	PUNCT	O	O	3907
;	PUNCT	O	O	3907
gamma	PROPN	O	O	3907
-	PUNCT	O	O	3907
glutamyltransferase	PROPN	O	O	3907
,	PUNCT	O	O	3907
32	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
(	PUNCT	O	O	3907
7	NUM	O	O	3907
-	PUNCT	O	O	3907
49	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
)	PUNCT	O	O	3907
;	PUNCT	O	O	3907
amylase	PROPN	O	O	3907
,	PUNCT	O	O	3907
46	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
(	PUNCT	O	O	3907
0	NUM	O	O	3907
-	PUNCT	O	O	3907
220	NUM	O	O	3907
U	NOUN	O	O	3907
/	PUNCT	O	O	3907
L	NOUN	O	O	3907
)	PUNCT	O	O	3907
;	PUNCT	O	O	3907
total	ADJ	O	O	3907
bilirubin	ADJ	O	Chemical	3907
,	PUNCT	O	O	3907
20.1	NUM	O	O	3907
mg	VERB	O	O	3907
/	PUNCT	O	O	3907
dL	VERB	O	O	3907
(	PUNCT	O	O	3907
0.2	NUM	O	O	3907
-	PUNCT	O	O	3907
1.0	NUM	O	O	3907
mg	VERB	O	O	3907
/	PUNCT	O	O	3907
dL	VERB	O	O	3907
)	PUNCT	O	O	3907
;	PUNCT	O	O	3907
direct	ADJ	O	O	3907
bilirubin	ADJ	O	Chemical	3907
,	PUNCT	O	O	3907
14.8	NUM	O	O	3907
mg	VERB	O	O	3907
/	PUNCT	O	O	3907
dL	VERB	O	O	3907
(	PUNCT	O	O	3907
0	NUM	O	O	3907
-	PUNCT	O	O	3907
0.3	NUM	O	O	3907
mg	VERB	O	O	3907
/	PUNCT	O	O	3907
dL	VERB	O	O	3907
)	PUNCT	O	O	3907
;	PUNCT	O	O	3907
and	CCONJ	O	O	3907
albumin	PROPN	O	O	3907
,	PUNCT	O	O	3907
4.7	NUM	O	O	3907
mg	VERB	O	O	3907
/	PUNCT	O	O	3907
dL	VERB	O	O	3907
(	PUNCT	O	O	3907
3.5	NUM	O	O	3907
-	PUNCT	O	O	3907
5.4	NUM	O	O	3907
mg	VERB	O	O	3907
/	PUNCT	O	O	3907
dL	VERB	O	O	3907
)	PUNCT	O	O	3907
.	PUNCT	O	O	3907
No	PRON	O	O	3908
toxin	NOUN	O	O	3908
,	PUNCT	O	O	3908
alcohol	NOUN	O	Chemical	3908
,	PUNCT	O	O	3908
or	CCONJ	O	O	3908
other	ADJ	O	O	3908
drugs	NOUN	O	O	3908
were	AUX	O	O	3908
reported	VERB	O	O	3908
.	PUNCT	O	O	3908
The	PRON	O	O	3909
patient	NOUN	O	O	3909
had	VERB	O	O	3909
suffered	VERB	O	O	3909
a	PRON	O	O	3909
previous	ADJ	O	O	3909
episode	PROPN	O	O	3909
of	ADP	O	O	3909
""""	PUNCT	O	O	3909
acute	ADJ	O	O	3909
hepatitis	NOUN	O	Disease	3909
of	ADP	O	O	3909
unknown	ADJ	O	O	3909
origin	NOUN	O	O	3909
,	PUNCT	O	O	3909
""""	PUNCT	O	O	3909
that	SCONJ	O	O	3909
occurred	VERB	O	O	3909
after	ADP	O	O	3909
telithromycin	PROPN	O	O	3909
usage	NOUN	O	O	3909
.	PUNCT	O	O	3909
Telithromycin	PROPN	O	O	3910
is	AUX	O	O	3910
the	PRON	O	O	3910
first	ADV	O	O	3910
of	ADP	O	O	3910
the	PRON	O	O	3910
ketolide	NOUN	O	O	3910
antibacterials	NOUN	O	O	3910
to	PART	O	O	3910
receive	VERB	O	O	3910
US	PROPN	O	O	3910
Food	NOUN	O	O	3910
and	CCONJ	O	O	3910
Drug	NOUN	O	O	3910
Administration	NOUN	O	O	3910
approval	NOUN	O	O	3910
for	ADP	O	O	3910
clinical	ADJ	O	O	3910
use	VERB	O	O	3910
.	PUNCT	O	O	3910
It	PRON	O	O	3911
has	VERB	O	O	3911
been	AUX	O	O	3911
associated	VERB	O	O	3911
with	ADP	O	O	3911
infrequent	ADJ	O	O	3911
and	CCONJ	O	O	3911
usually	ADV	O	O	3911
reversible	ADJ	O	O	3911
severe	ADJ	O	O	3911
hepatic	ADJ	O	O	3911
dysfunction	NOUN	O	O	3911
.	PUNCT	O	O	3911
Based	VERB	O	O	3912
on	ADP	O	O	3912
a	PRON	O	O	3912
score	VERB	O	O	3912
of	ADP	O	O	3912
8	NUM	O	O	3912
on	ADP	O	O	3912
the	PRON	O	O	3912
Naranjo	PROPN	O	O	3912
adverse	ADJ	O	O	3912
drug	NOUN	O	O	3912
reaction	NOUN	O	O	3912
probability	NOUN	O	O	3912
scale	NOUN	O	O	3912
,	PUNCT	O	O	3912
telithromycin	PROPN	O	O	3912
was	AUX	O	O	3912
the	PRON	O	O	3912
probable	ADJ	O	O	3912
cause	VERB	O	O	3912
of	ADP	O	O	3912
acute	ADJ	O	O	3912
hepatitis	NOUN	O	Disease	3912
in	ADP	O	O	3912
this	PRON	O	O	3912
patient	NOUN	O	O	3912
,	PUNCT	O	O	3912
and	CCONJ	O	O	3912
pathological	ADJ	O	O	3912
findings	NOUN	O	O	3912
suggested	VERB	O	O	3912
drug	NOUN	O	O	3912
-	PUNCT	O	O	3912
induced	VERB	O	O	3912
toxic	ADJ	O	O	3912
hepatitis	NOUN	O	Disease	3912
.	PUNCT	O	O	3912
Recurrence	NOUN	O	O	3913
of	ADP	O	O	3913
hepatitis	NOUN	O	Disease	3913
attack	VERB	O	O	3913
might	AUX	O	O	3913
have	VERB	O	O	3913
been	AUX	O	O	3913
avoided	VERB	O	O	3913
if	SCONJ	O	O	3913
the	PRON	O	O	3913
initial	ADJ	O	O	3913
incident	NOUN	O	O	3913
had	VERB	O	O	3913
been	AUX	O	O	3913
communicated	VERB	O	O	3913
to	PART	O	O	3913
the	PRON	O	O	3913
attending	VERB	O	O	3913
physician	NOUN	O	O	3913
who	PRON	O	O	3913
prescribed	VERB	O	O	3913
telithromycin	PROPN	O	O	3913
the	PRON	O	O	3913
second	ADV	O	O	3913
time	NOUN	O	O	3913
.	PUNCT	O	O	3913
Here	ADV	O	O	3914
we	PRON	O	O	3914
report	VERB	O	O	3914
a	PRON	O	O	3914
case	NOUN	O	O	3914
of	ADP	O	O	3914
acute	ADJ	O	O	3914
hepatitis	NOUN	O	Disease	3914
probably	ADV	O	O	3914
associated	VERB	O	O	3914
with	ADP	O	O	3914
the	PRON	O	O	3914
administration	NOUN	O	O	3914
of	ADP	O	O	3914
telithromycin	PROPN	O	O	3914
.	PUNCT	O	O	3914
Spironolactone	NOUN	O	Chemical	3917
-	PUNCT	O	O	3917
induced	VERB	O	O	3917
renal insufficiency	NOUN	O	Disease	3917
and	CCONJ	O	O	3917
hyperkalemia	NOUN	O	O	3917
in	ADP	O	O	3917
patients	NOUN	O	O	3917
with	ADP	O	O	3917
heart failure	NOUN	O	Disease	3917
.	PUNCT	O	O	3917
A	PRON	O	O	3918
previous	ADJ	O	O	3918
randomized	VERB	O	O	3918
controlled	VERB	O	O	3918
trial	NOUN	O	O	3918
evaluating	VERB	O	O	3918
the	PRON	O	O	3918
use	VERB	O	O	3918
of	ADP	O	O	3918
spironolactone	NOUN	O	Chemical	3918
in	ADP	O	O	3918
heart failure	NOUN	O	Disease	3918
patients	NOUN	O	O	3918
reported	VERB	O	O	3918
a	PRON	O	O	3918
low	ADJ	O	O	3918
risk	NOUN	O	O	3918
of	ADP	O	O	3918
hyperkalemia	NOUN	O	O	3918
(	PUNCT	O	O	3918
2%	NOUN	O	O	3918
)	PUNCT	O	O	3918
and	CCONJ	O	O	3918
renal insufficiency	NOUN	O	Disease	3918
(	PUNCT	O	O	3918
0%	NOUN	O	O	3918
)	PUNCT	O	O	3918
.	PUNCT	O	O	3918
Because	SCONJ	O	O	3919
treatments	NOUN	O	O	3919
for	ADP	O	O	3919
heart failure	NOUN	O	Disease	3919
have	VERB	O	O	3919
changed	VERB	O	O	3919
since	SCONJ	O	O	3919
the	PRON	O	O	3919
benefits	NOUN	O	O	3919
of	ADP	O	O	3919
spironolactone	NOUN	O	Chemical	3919
were	AUX	O	O	3919
reported	VERB	O	O	3919
,	PUNCT	O	O	3919
the	PRON	O	O	3919
prevalence	NOUN	O	O	3919
of	ADP	O	O	3919
these	PRON	O	O	3919
complications	NOUN	O	O	3919
may	AUX	O	O	3919
differ	VERB	O	O	3919
in	ADP	O	O	3919
current	ADJ	O	O	3919
clinical	ADJ	O	O	3919
practice	VERB	O	O	3919
.	PUNCT	O	O	3919
We	PRON	O	O	3920
therefore	ADV	O	O	3920
sought	VERB	O	O	3920
to	PART	O	O	3920
determine	VERB	O	O	3920
the	PRON	O	O	3920
prevalence	NOUN	O	O	3920
and	CCONJ	O	O	3920
clinical	ADJ	O	O	3920
associations	NOUN	O	O	3920
of	ADP	O	O	3920
hyperkalemia	NOUN	O	O	3920
and	CCONJ	O	O	3920
renal insufficiency	NOUN	O	Disease	3920
in	ADP	O	O	3920
heart failure	NOUN	O	Disease	3920
patients	NOUN	O	O	3920
treated	VERB	O	O	3920
with	ADP	O	O	3920
spironolactone	NOUN	O	Chemical	3920
.	PUNCT	O	O	3920
:	PUNCT	O	O	3921
We	PRON	O	O	3921
performed	VERB	O	O	3921
a	PRON	O	O	3921
case	NOUN	O	O	3921
control	VERB	O	O	3921
study	VERB	O	O	3921
of	ADP	O	O	3921
heart failure	NOUN	O	Disease	3921
patients	NOUN	O	O	3921
treated	VERB	O	O	3921
with	ADP	O	O	3921
spironolactone	NOUN	O	Chemical	3921
in	ADP	O	O	3921
our	PRON	O	O	3921
clinical	ADJ	O	O	3921
practice	VERB	O	O	3921
.	PUNCT	O	O	3921
Cases	NOUN	O	O	3922
were	AUX	O	O	3922
patients	NOUN	O	O	3922
who	PRON	O	O	3922
developed	VERB	O	O	3922
hyperkalemia	NOUN	O	O	3922
(	PUNCT	O	O	3922
K(+	NOUN	O	O	3922
)	PUNCT	O	O	3922
>	PUNCT	O	O	3923
5.0	NUM	O	O	3923
mEq	VERB	O	O	3923
/	PUNCT	O	O	3923
L	NOUN	O	O	3923
)	PUNCT	O	O	3923
or	CCONJ	O	O	3923
renal insufficiency	NOUN	O	Disease	3923
(	PUNCT	O	O	3924
Cr	NOUN	O	Chemical	3924
>	PUNCT	O	O	3924
or=2.5	NOUN	O	O	3924
mg	VERB	O	O	3924
/	PUNCT	O	O	3924
dL	VERB	O	O	3924
)	PUNCT	O	O	3924
,	PUNCT	O	O	3924
and	CCONJ	O	O	3924
Sixty	NUM	O	O	3925
-	PUNCT	O	O	3925
seven	NUM	O	O	3925
of	ADP	O	O	3925
926	NUM	O	O	3925
patients	NOUN	O	O	3925
(	PUNCT	O	O	3925
7.2%	NOUN	O	O	3925
)	PUNCT	O	O	3925
required	VERB	O	O	3925
discontinuation	NOUN	O	O	3925
of	ADP	O	O	3925
spironolactone	NOUN	O	Chemical	3925
due	ADJ	O	O	3925
to	PART	O	O	3925
hyperkalemia	NOUN	O	O	3925
(	PUNCT	O	O	3925
n	CCONJ	O	O	3925
=	PUNCT	O	O	3925
33	NUM	O	O	3925
)	PUNCT	O	O	3925
or	CCONJ	O	O	3925
renal failure	NOUN	O	Disease	3925
(	PUNCT	O	O	3925
n	CCONJ	O	O	3925
=	PUNCT	O	O	3925
34	NUM	O	O	3925
)	PUNCT	O	O	3925
.	PUNCT	O	O	3925
Patients	NOUN	O	O	3926
who	PRON	O	O	3926
developed	VERB	O	O	3926
hyperkalemia	NOUN	O	O	3926
were	AUX	O	O	3926
older	ADJ	O	O	3926
and	CCONJ	O	O	3926
more	ADJ	O	O	3926
likely	ADV	O	O	3926
to	PART	O	O	3926
have	VERB	O	O	3926
diabetes	NOUN	O	Disease	3926
,	PUNCT	O	O	3926
had	VERB	O	O	3926
higher	ADJ	O	O	3926
baseline	VERB	O	O	3926
serum	NOUN	O	O	3926
potassium	NOUN	O	Chemical	3926
levels	NOUN	O	O	3926
and	CCONJ	O	O	3926
lower	ADJ	O	O	3926
baseline	VERB	O	O	3926
potassium	NOUN	O	Chemical	3926
supplement	NOUN	O	O	3926
doses	NOUN	O	O	3926
,	PUNCT	O	O	3926
and	CCONJ	O	O	3926
were	AUX	O	O	3926
more	ADJ	O	O	3926
likely	ADV	O	O	3926
to	PART	O	O	3926
be	AUX	O	O	3926
treated	VERB	O	O	3926
with	ADP	O	O	3926
beta	NOUN	O	O	3926
-	PUNCT	O	O	3926
blockers	NOUN	O	O	3926
than	ADP	O	O	3926
controls	VERB	O	O	3926
(	PUNCT	O	O	3926
n	CCONJ	O	O	3926
=	PUNCT	O	O	3926
134	NUM	O	O	3926
)	PUNCT	O	O	3926
.	PUNCT	O	O	3926
Patients	NOUN	O	O	3927
who	PRON	O	O	3927
developed	VERB	O	O	3927
renal insufficiency	NOUN	O	Disease	3927
had	VERB	O	O	3927
lower	ADJ	O	O	3927
baseline	VERB	O	O	3927
body	NOUN	O	O	3927
weight	NOUN	O	O	3927
and	CCONJ	O	O	3927
higher	ADJ	O	O	3927
baseline	VERB	O	O	3927
serum	NOUN	O	O	3927
creatinine	PROPN	O	Chemical	3927
,	PUNCT	O	O	3927
required	VERB	O	O	3927
higher	ADJ	O	O	3927
doses	NOUN	O	O	3927
of	ADP	O	O	3927
loop	NOUN	O	O	3927
diuretics	NOUN	O	O	3927
,	PUNCT	O	O	3927
and	CCONJ	O	O	3927
were	AUX	O	O	3927
more	ADJ	O	O	3927
likely	ADV	O	O	3927
to	PART	O	O	3927
be	AUX	O	O	3927
treated	VERB	O	O	3927
with	ADP	O	O	3927
thiazide	ADJ	O	Chemical	3927
diuretics	NOUN	O	O	3927
than	ADP	O	O	3927
controls	VERB	O	O	3927
.	PUNCT	O	O	3927
CONCLUSIONS	NOUN	O	O	3928
:	PUNCT	O	O	3928
Spironolactone	NOUN	O	Chemical	3928
-	PUNCT	O	O	3928
induced	VERB	O	O	3928
hyperkalemia	NOUN	O	O	3928
and	CCONJ	O	O	3928
renal insufficiency	NOUN	O	Disease	3928
are	AUX	O	O	3928
more	ADJ	O	O	3928
common	ADJ	O	O	3928
in	ADP	O	O	3928
our	PRON	O	O	3928
clinical	ADJ	O	O	3928
experience	NOUN	O	O	3928
than	ADP	O	O	3928
reported	VERB	O	O	3928
previously	ADV	O	O	3928
.	PUNCT	O	O	3928
End	NOUN	O	O	3931
-	PUNCT	O	O	3931
stage	NOUN	O	O	3931
renal disease	NOUN	O	Disease	3931
(	PUNCT	O	O	3931
ESRD	PROPN	O	Disease	3931
)	PUNCT	O	O	3931
after	ADP	O	O	3931
orthotopic	NOUN	O	O	3931
liver	NOUN	O	O	3931
transplantation	NOUN	O	O	3931
(	PUNCT	O	O	3931
OLTX	NOUN	O	O	3931
)	PUNCT	O	O	3931
using	VERB	O	O	3931
calcineurin	NOUN	O	O	3931
-	PUNCT	O	O	3931
based	VERB	O	O	3931
immunotherapy	NOUN	O	O	3931
:	PUNCT	O	O	3931
The	PRON	O	O	3932
calcineurin	NOUN	O	O	3932
inhibitors	NOUN	O	O	3932
cyclosporine	NOUN	O	Chemical	3932
and	CCONJ	O	O	3932
tacrolimus	NOUN	O	Chemical	3932
are	AUX	O	O	3932
both	PRON	O	O	3932
known	VERB	O	O	3932
to	PART	O	O	3932
be	AUX	O	O	3932
nephrotoxic	NOUN	O	Disease	3932
.	PUNCT	O	O	3932
Recently	ADV	O	O	3933
,	PUNCT	O	O	3933
however	ADV	O	O	3933
,	PUNCT	O	O	3933
we	PRON	O	O	3933
have	VERB	O	O	3933
had	VERB	O	O	3933
an	PRON	O	O	3933
increase	VERB	O	O	3933
of	ADP	O	O	3933
patients	NOUN	O	O	3933
who	PRON	O	O	3933
are	AUX	O	O	3933
presenting	VERB	O	O	3933
after	ADP	O	O	3933
OLTX	NOUN	O	O	3933
with	ADP	O	O	3933
end	VERB	O	O	3933
-	PUNCT	O	O	3933
stage	NOUN	O	O	3933
renal disease	NOUN	O	Disease	3933
(	PUNCT	O	O	3933
ESRD	PROPN	O	Disease	3933
)	PUNCT	O	O	3933
.	PUNCT	O	O	3933
This	PRON	O	O	3934
retrospective	ADJ	O	O	3934
study	VERB	O	O	3934
examines	VERB	O	O	3934
the	PRON	O	O	3934
incidence	NOUN	O	O	3934
and	CCONJ	O	O	3934
treatment	NOUN	O	O	3934
of	ADP	O	O	3934
ESRD	PROPN	O	Disease	3934
and	CCONJ	O	O	3934
chronic	ADJ	O	O	3934
renal failure	NOUN	O	Disease	3934
(	PUNCT	O	O	3934
CRF	PROPN	O	O	3934
)	PUNCT	O	O	3934
in	ADP	O	O	3934
OLTX	NOUN	O	O	3934
patients	NOUN	O	O	3934
.	PUNCT	O	O	3934
Patients	NOUN	O	O	3935
were	AUX	O	O	3935
divided	VERB	O	O	3935
into	ADP	O	O	3935
three	NUM	O	O	3935
groups	NOUN	O	O	3935
:	PUNCT	O	O	3935
Controls	NOUN	O	O	3935
,	PUNCT	O	O	3935
no	PRON	O	O	3935
CRF	PROPN	O	O	3935
or	CCONJ	O	O	3935
ESRD	PROPN	O	Disease	3935
,	PUNCT	O	O	3935
n=748	NOUN	O	O	3935
;	PUNCT	O	O	3935
CRF	PROPN	O	O	3935
,	PUNCT	O	O	3935
sustained	VERB	O	O	3935
serum	NOUN	O	O	3935
creatinine	PROPN	O	Chemical	3935
>	PUNCT	O	O	3935
2.5	NUM	O	O	3935
mg	VERB	O	O	3935
/	PUNCT	O	O	3935
dl	X	O	O	3935
,	PUNCT	O	O	3935
n=41	VERB	O	O	3935
;	PUNCT	O	O	3935
and	CCONJ	O	O	3935
ESRD	PROPN	O	Disease	3935
,	PUNCT	O	O	3935
n=45	NOUN	O	O	3935
.	PUNCT	O	O	3935
Groups	NOUN	O	O	3936
were	AUX	O	O	3936
compared	VERB	O	O	3936
for	ADP	O	O	3936
preoperative	ADJ	O	O	3936
laboratory	NOUN	O	O	3936
variables	NOUN	O	O	3936
,	PUNCT	O	O	3936
diagnosis	NOUN	O	O	3936
,	PUNCT	O	O	3936
postoperative	ADJ	O	O	3936
variables	NOUN	O	O	3936
,	PUNCT	O	O	3936
survival	NOUN	O	O	3936
,	PUNCT	O	O	3936
type	NOUN	O	O	3936
of	ADP	O	O	3936
ESRD	PROPN	O	Disease	3936
therapy	NOUN	O	O	3936
,	PUNCT	O	O	3936
and	CCONJ	O	O	3936
survival	NOUN	O	O	3936
from	ADP	O	O	3936
onset	VERB	O	O	3936
of	ADP	O	O	3936
ESRD	PROPN	O	Disease	3936
.	PUNCT	O	O	3936
At	ADP	O	O	3937
13	NUM	O	O	3937
years	NOUN	O	O	3937
after	ADP	O	O	3937
OLTX	NOUN	O	O	3937
,	PUNCT	O	O	3937
the	PRON	O	O	3937
incidence	NOUN	O	O	3937
of	ADP	O	O	3937
severe	ADJ	O	O	3937
renal dysfunction	NOUN	O	Disease	3937
was	AUX	O	O	3937
18.1%	NOUN	O	O	3937
(	PUNCT	O	O	3937
CRF	PROPN	O	O	3937
8.6%	NOUN	O	O	3937
and	CCONJ	O	O	3937
ESRD	PROPN	O	Disease	3937
9.5%	NOUN	O	O	3937
)	PUNCT	O	O	3937
.	PUNCT	O	O	3937
Compared	VERB	O	O	3938
with	ADP	O	O	3938
control	VERB	O	O	3938
patients	NOUN	O	O	3938
,	PUNCT	O	O	3938
CRF	PROPN	O	O	3938
and	CCONJ	O	O	3938
ESRD	PROPN	O	Disease	3938
patients	NOUN	O	O	3938
had	VERB	O	O	3938
higher	ADJ	O	O	3938
preoperative	ADJ	O	O	3938
serum	NOUN	O	O	3938
creatinine	PROPN	O	Chemical	3938
levels	NOUN	O	O	3938
,	PUNCT	O	O	3938
a	PRON	O	O	3938
greater	ADJ	O	O	3938
percentage	NOUN	O	O	3938
of	ADP	O	O	3938
patients	NOUN	O	O	3938
with	ADP	O	O	3938
hepatorenal	ADJ	O	O	3938
syndrome	NOUN	O	O	3938
,	PUNCT	O	O	3938
higher	ADJ	O	O	3938
percentage	NOUN	O	O	3938
requirement	NOUN	O	O	3938
for	ADP	O	O	3938
dialysis	NOUN	O	O	3938
in	ADP	O	O	3938
the	PRON	O	O	3938
first	ADV	O	O	3938
3	X	O	O	3938
months	NOUN	O	O	3938
postoperatively	PROPN	O	O	3938
,	PUNCT	O	O	3938
and	CCONJ	O	O	3938
a	PRON	O	O	3938
higher	ADJ	O	O	3938
1-year	NOUN	O	O	3938
serum	NOUN	O	O	3938
creatinine	PROPN	O	Chemical	3938
.	PUNCT	O	O	3938
Multivariate	NOUN	O	O	3939
stepwise	ADJ	O	O	3939
logistic	ADJ	O	O	3939
regression	NOUN	O	O	3939
analysis	NOUN	O	O	3939
using	VERB	O	O	3939
preoperative	ADJ	O	O	3939
and	CCONJ	O	O	3939
postoperative	ADJ	O	O	3939
variables	NOUN	O	O	3939
identified	VERB	O	O	3939
that	SCONJ	O	O	3939
an	PRON	O	O	3939
increase	VERB	O	O	3939
of	ADP	O	O	3939
serum	NOUN	O	O	3939
creatinine	PROPN	O	Chemical	3939
compared	VERB	O	O	3939
with	ADP	O	O	3939
average	ADJ	O	O	3939
at	ADP	O	O	3939
1	X	O	O	3939
year	NOUN	O	O	3939
,	PUNCT	O	O	3939
3	X	O	O	3939
months	NOUN	O	O	3939
,	PUNCT	O	O	3939
and	CCONJ	O	O	3939
4	NUM	O	O	3939
weeks	NOUN	O	O	3939
postoperatively	PROPN	O	O	3939
were	AUX	O	O	3939
independent	ADJ	O	O	3939
risk	NOUN	O	O	3939
factors	NOUN	O	O	3939
for	ADP	O	O	3939
the	PRON	O	O	3939
development	NOUN	O	O	3939
of	ADP	O	O	3939
CRF	PROPN	O	O	3939
or	CCONJ	O	O	3939
ESRD	PROPN	O	Disease	3939
with	ADP	O	O	3939
odds	NOUN	O	O	3939
ratios	VERB	O	O	3939
of	ADP	O	O	3939
2.6	NUM	O	O	3939
,	PUNCT	O	O	3939
2.2	NUM	O	O	3939
,	PUNCT	O	O	3939
and	CCONJ	O	O	3939
1.6	NUM	O	O	3939
,	PUNCT	O	O	3939
respectively	ADV	O	O	3939
.	PUNCT	O	O	3939
Overall	ADV	O	O	3940
survival	NOUN	O	O	3940
from	ADP	O	O	3940
the	PRON	O	O	3940
time	NOUN	O	O	3940
of	ADP	O	O	3940
OLTX	NOUN	O	O	3940
was	AUX	O	O	3940
not	PART	O	O	3940
significantly	ADV	O	O	3940
different	ADJ	O	O	3940
among	ADP	O	O	3940
groups	NOUN	O	O	3940
,	PUNCT	O	O	3940
but	CCONJ	O	O	3940
by	ADP	O	O	3940
year	NOUN	O	O	3940
13	NUM	O	O	3940
,	PUNCT	O	O	3940
the	PRON	O	O	3940
survival	NOUN	O	O	3940
of	ADP	O	O	3940
the	PRON	O	O	3940
patients	NOUN	O	O	3940
who	PRON	O	O	3940
had	VERB	O	O	3940
ESRD	PROPN	O	Disease	3940
was	AUX	O	O	3940
only	ADV	O	O	3940
28.2%	NOUN	O	O	3940
compared	VERB	O	O	3940
with	ADP	O	O	3940
54.6%	NOUN	O	O	3940
in	ADP	O	O	3940
the	PRON	O	O	3940
control	VERB	O	O	3940
group	NOUN	O	O	3940
.	PUNCT	O	O	3940
Patients	NOUN	O	O	3941
developing	VERB	O	O	3941
ESRD	PROPN	O	Disease	3941
had	VERB	O	O	3941
a	PRON	O	O	3941
6-year	NOUN	O	O	3941
survival	NOUN	O	O	3941
after	ADP	O	O	3941
onset	VERB	O	O	3941
of	ADP	O	O	3941
ESRD	PROPN	O	Disease	3941
of	ADP	O	O	3941
27%	NOUN	O	O	3941
for	ADP	O	O	3941
the	PRON	O	O	3941
patients	NOUN	O	O	3941
receiving	VERB	O	O	3941
hemodialysis	NOUN	O	O	3941
versus	ADP	O	O	3941
71.4%	NOUN	O	O	3941
for	ADP	O	O	3941
the	PRON	O	O	3941
patients	NOUN	O	O	3941
developing	VERB	O	O	3941
ESRD	PROPN	O	Disease	3941
who	PRON	O	O	3941
subsequently	ADV	O	O	3941
received	VERB	O	O	3941
kidney	NOUN	O	O	3941
transplants	NOUN	O	O	3941
.	PUNCT	O	O	3941
Patients	NOUN	O	O	3942
who	PRON	O	O	3942
are	AUX	O	O	3942
more	ADJ	O	O	3942
than	ADP	O	O	3942
10	NUM	O	O	3942
years	NOUN	O	O	3942
post	VERB	O	O	3942
-	PUNCT	O	O	3942
OLTX	NOUN	O	O	3942
have	VERB	O	O	3942
CRF	PROPN	O	O	3942
and	CCONJ	O	O	3942
ESRD	PROPN	O	Disease	3942
at	ADP	O	O	3942
a	PRON	O	O	3942
high	ADJ	O	O	3942
rate	NOUN	O	O	3942
.	PUNCT	O	O	3942
The	PRON	O	O	3943
development	NOUN	O	O	3943
of	ADP	O	O	3943
ESRD	PROPN	O	Disease	3943
decreases	VERB	O	O	3943
survival	NOUN	O	O	3943
,	PUNCT	O	O	3943
particularly	ADV	O	O	3943
in	ADP	O	O	3943
those	PRON	O	O	3943
patients	NOUN	O	O	3943
treated	VERB	O	O	3943
with	ADP	O	O	3943
dialysis	NOUN	O	O	3943
only	ADV	O	O	3943
.	PUNCT	O	O	3943
Patients	NOUN	O	O	3944
who	PRON	O	O	3944
develop	VERB	O	O	3944
ESRD	PROPN	O	Disease	3944
have	VERB	O	O	3944
a	PRON	O	O	3944
higher	ADJ	O	O	3944
preoperative	ADJ	O	O	3944
and	CCONJ	O	O	3944
1-year	NOUN	O	O	3944
serum	NOUN	O	O	3944
creatinine	PROPN	O	Chemical	3944
and	CCONJ	O	O	3944
are	AUX	O	O	3944
more	ADJ	O	O	3944
likely	ADV	O	O	3944
to	PART	O	O	3944
have	VERB	O	O	3944
hepatorenal	ADJ	O	O	3944
syndrome	NOUN	O	O	3944
.	PUNCT	O	O	3944
However	ADV	O	O	3945
,	PUNCT	O	O	3945
an	PRON	O	O	3945
increase	VERB	O	O	3945
of	ADP	O	O	3945
serum	NOUN	O	O	3945
creatinine	PROPN	O	Chemical	3945
at	ADP	O	O	3945
various	ADJ	O	O	3945
times	NOUN	O	O	3945
postoperatively	PROPN	O	O	3945
is	AUX	O	O	3945
more	ADJ	O	O	3945
predictive	ADJ	O	O	3945
of	ADP	O	O	3945
the	PRON	O	O	3945
development	NOUN	O	O	3945
of	ADP	O	O	3945
CRF	PROPN	O	O	3945
or	CCONJ	O	O	3945
ESRD	PROPN	O	Disease	3945
.	PUNCT	O	O	3945
Effect	VERB	O	O	3948
of	ADP	O	O	3948
intravenous	ADJ	O	O	3948
nimodipine	NOUN	O	Chemical	3948
on	ADP	O	O	3948
blood	NOUN	O	O	3948
pressure	NOUN	O	O	3948
and	CCONJ	O	O	3948
outcome	NOUN	O	O	3948
after	ADP	O	O	3948
acute	ADJ	O	O	3948
stroke	VERB	O	Disease	3948
.	PUNCT	O	O	3948
The	PRON	O	O	3949
Intravenous	PROPN	O	O	3949
Nimodipine	NOUN	O	Chemical	3949
West	NOUN	O	O	3949
European	ADJ	O	O	3949
Stroke	VERB	O	Disease	3949
Trial	NOUN	O	O	3949
(	PUNCT	O	O	3949
INWEST	NOUN	O	O	3949
)	PUNCT	O	O	3949
found	VERB	O	O	3949
a	PRON	O	O	3949
correlation	NOUN	O	O	3949
between	ADP	O	O	3949
nimodipine	NOUN	O	Chemical	3949
-	PUNCT	O	O	3949
induced	VERB	O	O	3949
reduction	NOUN	O	O	3949
in	ADP	O	O	3949
blood	NOUN	O	O	3949
pressure	NOUN	O	O	3949
(	PUNCT	O	O	3949
BP	PROPN	O	O	3949
)	PUNCT	O	O	3949
and	CCONJ	O	O	3949
an	PRON	O	O	3949
unfavorable	ADJ	O	O	3949
outcome	NOUN	O	O	3949
in	ADP	O	O	3949
acute	ADJ	O	O	3949
stroke	VERB	O	Disease	3949
.	PUNCT	O	O	3949
We	PRON	O	O	3950
sought	VERB	O	O	3950
to	PART	O	O	3950
confirm	VERB	O	O	3950
this	PRON	O	O	3950
correlation	NOUN	O	O	3950
with	ADP	O	O	3950
and	CCONJ	O	O	3950
without	ADP	O	O	3950
adjustment	NOUN	O	O	3950
for	ADP	O	O	3950
prognostic	ADJ	O	O	3950
variables	NOUN	O	O	3950
and	CCONJ	O	O	3950
to	PART	O	O	3950
investigate	VERB	O	O	3950
outcome	NOUN	O	O	3950
in	ADP	O	O	3950
subgroups	NOUN	O	O	3950
with	ADP	O	O	3950
increasing	VERB	O	O	3950
levels	NOUN	O	O	3950
of	ADP	O	O	3950
BP	PROPN	O	O	3950
reduction	NOUN	O	O	3950
.	PUNCT	O	O	3950
Patients	NOUN	O	O	3951
with	ADP	O	O	3951
a	PRON	O	O	3951
clinical	ADJ	O	O	3951
diagnosis	NOUN	O	O	3951
of	ADP	O	O	3951
ischemic	VERB	O	Disease	3951
stroke	VERB	O	Disease	3951
(	PUNCT	O	O	3951
within	ADP	O	O	3951
24	NUM	O	O	3951
hours	NOUN	O	O	3951
)	PUNCT	O	O	3951
were	AUX	O	O	3951
consecutively	ADV	O	O	3951
allocated	VERB	O	O	3951
to	PART	O	O	3951
receive	VERB	O	O	3951
placebo	NOUN	O	O	3951
(	PUNCT	O	O	3951
n=100	NUM	O	O	3951
)	PUNCT	O	O	3951
,	PUNCT	O	O	3951
1	X	O	O	3951
mg	VERB	O	O	3951
/	PUNCT	O	O	3951
h	X	O	O	3951
(	PUNCT	O	O	3951
low	ADJ	O	O	3951
-	PUNCT	O	O	3951
dose	NOUN	O	O	3951
)	PUNCT	O	O	3951
nimodipine	NOUN	O	Chemical	3952
(	PUNCT	O	O	3952
n=101	NOUN	O	O	3952
)	PUNCT	O	O	3952
,	PUNCT	O	O	3952
or	CCONJ	O	O	3952
2	X	O	O	3952
mg	VERB	O	O	3952
/	PUNCT	O	O	3952
h	X	O	O	3952
(	PUNCT	O	O	3952
high	ADJ	O	O	3952
-	PUNCT	O	O	3952
dose	NOUN	O	O	3952
)	PUNCT	O	O	3952
nimodipine	NOUN	O	Chemical	3952
(	PUNCT	O	O	3952
n=94	PROPN	O	O	3952
)	PUNCT	O	O	3952
.	PUNCT	O	O	3952
Nimodipine	NOUN	O	Chemical	3953
treatment	NOUN	O	O	3953
resulted	VERB	O	O	3953
in	ADP	O	O	3953
a	PRON	O	O	3953
statistically	ADV	O	O	3953
significant	ADJ	O	O	3953
reduction	NOUN	O	O	3953
in	ADP	O	O	3953
systolic	ADV	O	O	3953
BP	PROPN	O	O	3953
(	PUNCT	O	O	3953
SBP	NOUN	O	O	3953
)	PUNCT	O	O	3953
and	CCONJ	O	O	3953
diastolic	ADV	O	O	3953
BP	PROPN	O	O	3953
(	PUNCT	O	O	3953
DBP	PROPN	O	O	3953
)	PUNCT	O	O	3953
from	ADP	O	O	3953
baseline	VERB	O	O	3953
compared	VERB	O	O	3953
with	ADP	O	O	3953
placebo	NOUN	O	O	3953
during	ADP	O	O	3953
the	PRON	O	O	3953
first	ADV	O	O	3953
few	ADJ	O	O	3953
days	NOUN	O	O	3953
.	PUNCT	O	O	3953
In	ADP	O	O	3954
multivariate	ADJ	O	O	3954
analysis	NOUN	O	O	3954
,	PUNCT	O	O	3954
a	PRON	O	O	3954
significant	ADJ	O	O	3954
correlation	NOUN	O	O	3954
between	ADP	O	O	3954
DBP	PROPN	O	O	3954
reduction	NOUN	O	O	3954
and	CCONJ	O	O	3954
worsening	VERB	O	O	3954
of	ADP	O	O	3954
the	PRON	O	O	3954
neurological	ADJ	O	O	3954
score	VERB	O	O	3954
was	AUX	O	O	3954
found	VERB	O	O	3954
for	ADP	O	O	3954
the	PRON	O	O	3954
high	ADJ	O	O	3954
-	PUNCT	O	O	3954
dose	NOUN	O	O	3954
group	NOUN	O	O	3954
(	PUNCT	O	O	3954
beta=0.49	PROPN	O	O	3954
,	PUNCT	O	O	3954
P=0	NOUN	O	O	3954
.	PUNCT	O	O	3954
Patients	NOUN	O	O	3955
with	ADP	O	O	3955
a	PRON	O	O	3955
DBP	PROPN	O	O	3955
reduction	NOUN	O	O	3955
of	ADP	O	O	3955
>	PUNCT	O	O	3955
or	CCONJ	O	O	3955
=	PUNCT	O	O	3955
20%	NOUN	O	O	3955
in	ADP	O	O	3955
the	PRON	O	O	3955
high	ADJ	O	O	3955
-	PUNCT	O	O	3955
dose	NOUN	O	O	3955
group	NOUN	O	O	3955
had	VERB	O	O	3955
a	PRON	O	O	3955
significantly	ADV	O	O	3955
increased	VERB	O	O	3955
adjusted	VERB	O	O	3955
OR	CCONJ	O	O	3955
for	ADP	O	O	3955
the	PRON	O	O	3955
compound	NOUN	O	O	3955
outcome	NOUN	O	O	3955
variable	NOUN	O	O	3955
death	NOUN	O	O	3955
or	CCONJ	O	O	3955
dependency	NOUN	O	O	3955
(	PUNCT	O	O	3956
n	CCONJ	O	O	3956
/	PUNCT	O	O	3956
N=25/26	INTJ	O	O	3956
,	PUNCT	O	O	3956
OR	CCONJ	O	O	3956
10	NUM	O	O	3956
.	PUNCT	O	O	3956
16	NUM	O	O	3956
,	PUNCT	O	O	3956
95%	NOUN	O	O	3956
CI	NOUN	O	O	3956
1.02	NUM	O	O	3956
to	PART	O	O	3956
101.74	NUM	O	O	3956
)	PUNCT	O	O	3956
and	CCONJ	O	O	3956
death	NOUN	O	O	3956
alone	ADV	O	O	3956
(	PUNCT	O	O	3956
n	CCONJ	O	O	3956
/	PUNCT	O	O	3956
N=9/26	PROPN	O	O	3956
,	PUNCT	O	O	3956
OR	CCONJ	O	O	3956
4.336	NUM	O	O	3956
,	PUNCT	O	O	3956
95%	NOUN	O	O	3956
CI	NOUN	O	O	3956
1.131	NUM	O	O	3956
16.619	NUM	O	O	3956
)	PUNCT	O	O	3956
compared	VERB	O	O	3956
with	ADP	O	O	3956
all	PRON	O	O	3956
placebo	NOUN	O	O	3956
patients	NOUN	O	O	3956
(	PUNCT	O	O	3956
n	CCONJ	O	O	3956
/	PUNCT	O	O	3956
N=62/92	INTJ	O	O	3956
and	CCONJ	O	O	3956
14/92	NUM	O	O	3956
,	PUNCT	O	O	3956
respectively	ADV	O	O	3956
)	PUNCT	O	O	3956
.	PUNCT	O	O	3956
DBP	PROPN	O	O	3957
,	PUNCT	O	O	3957
but	CCONJ	O	O	3957
not	PART	O	O	3957
SBP	NOUN	O	O	3957
,	PUNCT	O	O	3957
reduction	NOUN	O	O	3957
was	AUX	O	O	3957
associated	VERB	O	O	3957
with	ADP	O	O	3957
neurological	ADJ	O	O	3957
worsening	VERB	O	O	3957
after	ADP	O	O	3957
the	PRON	O	O	3957
intravenous	ADJ	O	O	3957
administration	NOUN	O	O	3957
of	ADP	O	O	3957
high	ADJ	O	O	3957
-	PUNCT	O	O	3957
dose	NOUN	O	O	3957
nimodipine	NOUN	O	Chemical	3957
after	ADP	O	O	3957
acute	ADJ	O	O	3957
stroke	VERB	O	Disease	3957
.	PUNCT	O	O	3957
For	ADP	O	O	3958
low	ADJ	O	O	3958
-	PUNCT	O	O	3958
dose	NOUN	O	O	3958
nimodipine	NOUN	O	Chemical	3958
,	PUNCT	O	O	3958
the	PRON	O	O	3958
results	VERB	O	O	3958
were	AUX	O	O	3958
not	PART	O	O	3958
conclusive	ADJ	O	O	3958
.	PUNCT	O	O	3958
These	PRON	O	O	3959
results	VERB	O	O	3959
do	VERB	O	O	3959
not	PART	O	O	3959
confirm	VERB	O	O	3959
or	CCONJ	O	O	3959
exclude	VERB	O	O	3959
a	PRON	O	O	3959
neuroprotective	ADJ	O	O	3959
property	NOUN	O	O	3959
of	ADP	O	O	3959
nimodipine	NOUN	O	Chemical	3959
.	PUNCT	O	O	3959
Transient	ADJ	O	O	3962
neurologic	ADJ	O	O	3962
symptoms	NOUN	O	O	3962
after	ADP	O	O	3962
spinal	NOUN	O	O	3962
anesthesia	NOUN	O	O	3962
:	PUNCT	O	O	3962
a	PRON	O	O	3962
lower	ADJ	O	O	3962
incidence	NOUN	O	O	3962
with	ADP	O	O	3962
prilocaine	NOUN	O	O	3962
and	CCONJ	O	O	3962
bupivacaine	NOUN	O	Chemical	3962
than	ADP	O	O	3962
with	ADP	O	O	3962
lidocaine	NOUN	O	Chemical	3962
.	PUNCT	O	O	3962
Recent	ADJ	O	O	3963
evidence	NOUN	O	O	3963
suggests	VERB	O	O	3963
that	SCONJ	O	O	3963
transient	ADJ	O	O	3963
neurologic	ADJ	O	O	3963
symptoms	NOUN	O	O	3963
(	PUNCT	O	O	3963
TNSs	NOUN	O	O	3963
)	PUNCT	O	O	3963
frequently	ADV	O	O	3963
follow	VERB	O	O	3963
lidocaine	NOUN	O	Chemical	3963
spinal	NOUN	O	O	3963
anesthesia	NOUN	O	O	3963
but	CCONJ	O	O	3963
are	AUX	O	O	3963
infrequent	ADJ	O	O	3963
with	ADP	O	O	3963
bupivacaine	NOUN	O	Chemical	3963
.	PUNCT	O	O	3963
However	ADV	O	O	3964
,	PUNCT	O	O	3964
identification	NOUN	O	O	3964
of	ADP	O	O	3964
a	PRON	O	O	3964
short	ADJ	O	O	3964
-	PUNCT	O	O	3964
acting	VERB	O	O	3964
local	ADJ	O	O	3964
anesthetic	NOUN	O	O	3964
to	PART	O	O	3964
substitute	NOUN	O	O	3964
for	ADP	O	O	3964
lidocaine	NOUN	O	Chemical	3964
for	ADP	O	O	3964
brief	PROPN	O	O	3964
surgical	ADJ	O	O	3964
procedures	NOUN	O	O	3964
remains	VERB	O	O	3964
an	PRON	O	O	3964
important	ADJ	O	O	3964
goal	NOUN	O	O	3964
.	PUNCT	O	O	3964
Prilocaine	NOUN	O	O	3965
is	AUX	O	O	3965
an	PRON	O	O	3965
amide	PROPN	O	O	3965
local	ADJ	O	O	3965
anesthetic	NOUN	O	O	3965
with	ADP	O	O	3965
a	PRON	O	O	3965
duration	NOUN	O	O	3965
of	ADP	O	O	3965
action	NOUN	O	O	3965
similar	ADJ	O	O	3965
to	PART	O	O	3965
that	SCONJ	O	O	3965
of	ADP	O	O	3965
lidocaine	NOUN	O	Chemical	3965
.	PUNCT	O	O	3965
Accordingly	ADV	O	O	3966
,	PUNCT	O	O	3966
the	PRON	O	O	3966
present	NOUN	O	O	3966
,	PUNCT	O	O	3966
prospective	ADJ	O	O	3966
double	ADJ	O	O	3966
-	PUNCT	O	O	3966
blind	ADJ	O	Disease	3966
study	VERB	O	O	3966
compares	VERB	O	O	3966
prilocaine	NOUN	O	O	3966
with	ADP	O	O	3966
lidocaine	NOUN	O	Chemical	3966
and	CCONJ	O	O	3966
bupivacaine	NOUN	O	Chemical	3966
with	ADP	O	O	3966
respect	VERB	O	O	3966
to	PART	O	O	3966
duration	NOUN	O	O	3966
of	ADP	O	O	3966
action	NOUN	O	O	3966
and	CCONJ	O	O	3966
relative	ADJ	O	O	3966
risk	NOUN	O	O	3966
of	ADP	O	O	3966
TNSs	NOUN	O	O	3966
.	PUNCT	O	O	3966
2%	NOUN	O	O	3967
lidocaine	NOUN	O	Chemical	3967
in	ADP	O	O	3967
7.5%	NOUN	O	O	3967
glucose	NOUN	O	Chemical	3967
,	PUNCT	O	O	3967
2%	NOUN	O	O	3967
prilocaine	NOUN	O	O	3967
in	ADP	O	O	3967
7.5%	NOUN	O	O	3967
glucose	NOUN	O	Chemical	3967
,	PUNCT	O	O	3967
or	CCONJ	O	O	3967
0.5%	NOUN	O	O	3967
bupivacaine	NOUN	O	Chemical	3967
in	ADP	O	O	3967
7.5%	NOUN	O	O	3967
glucose	NOUN	O	Chemical	3967
.	PUNCT	O	O	3967
In	ADP	O	O	3968
the	PRON	O	O	3968
evening	NOUN	O	O	3968
of	ADP	O	O	3968
postoperative	ADJ	O	O	3968
day	NOUN	O	O	3968
1	X	O	O	3968
,	PUNCT	O	O	3968
patients	NOUN	O	O	3968
were	AUX	O	O	3968
evaluated	VERB	O	O	3968
for	ADP	O	O	3968
TNSs	NOUN	O	O	3968
by	ADP	O	O	3968
a	PRON	O	O	3968
physician	NOUN	O	O	3968
unaware	ADJ	O	O	3968
of	ADP	O	O	3968
the	PRON	O	O	3968
drug	NOUN	O	O	3968
administered	VERB	O	O	3968
and	CCONJ	O	O	3968
the	PRON	O	O	3968
details	NOUN	O	O	3968
of	ADP	O	O	3968
the	PRON	O	O	3968
anesthetic	NOUN	O	O	3968
procedure	NOUN	O	O	3968
.	PUNCT	O	O	3968
Nine	NUM	O	O	3969
of	ADP	O	O	3969
30	NUM	O	O	3969
patients	NOUN	O	O	3969
receiving	VERB	O	O	3969
lidocaine	NOUN	O	Chemical	3969
experienced	ADJ	O	O	3969
TNSs	NOUN	O	O	3969
,	PUNCT	O	O	3969
1	X	O	O	3969
of	ADP	O	O	3969
30	NUM	O	O	3969
patients	NOUN	O	O	3969
receiving	VERB	O	O	3969
prilocaine	NOUN	O	O	3969
(	PUNCT	O	O	3969
P	NOUN	O	Chemical	3969
=	PUNCT	O	O	3969
0.03	NUM	O	O	3969
)	PUNCT	O	O	3969
had	VERB	O	O	3969
them	PRON	O	O	3969
,	PUNCT	O	O	3969
and	CCONJ	O	O	3969
none	NOUN	O	O	3969
of	ADP	O	O	3969
30	NUM	O	O	3969
patients	NOUN	O	O	3969
receiving	VERB	O	O	3969
bupivacaine	NOUN	O	Chemical	3969
had	VERB	O	O	3969
TNSs	NOUN	O	O	3969
.	PUNCT	O	O	3969
Times	NOUN	O	O	3970
to	PART	O	O	3970
ambulate	VERB	O	O	3970
and	CCONJ	O	O	3970
to	PART	O	O	3970
void	VERB	O	O	3970
were	AUX	O	O	3970
similar	ADJ	O	O	3970
after	ADP	O	O	3970
lidocaine	NOUN	O	Chemical	3970
and	CCONJ	O	O	3970
prilocaine	NOUN	O	O	3970
(	PUNCT	O	O	3970
150	NUM	O	O	3970
vs.	CCONJ	O	O	3970
165	NUM	O	O	3970
min	NOUN	O	O	3970
and	CCONJ	O	O	3970
238	NUM	O	O	3970
vs.	CCONJ	O	O	3970
253	NUM	O	O	3970
min	NOUN	O	O	3970
,	PUNCT	O	O	3970
respectively	ADV	O	O	3970
)	PUNCT	O	O	3970
but	CCONJ	O	O	3970
prolonged	VERB	O	O	3970
after	ADP	O	O	3970
bupivacaine	NOUN	O	Chemical	3970
(	PUNCT	O	O	3970
200	NUM	O	O	3970
and	CCONJ	O	O	3970
299	NUM	O	O	3970
min	NOUN	O	O	3970
,	PUNCT	O	O	3970
respectively	ADV	O	O	3970
;	PUNCT	O	O	3970
Prilocaine	NOUN	O	O	3971
may	AUX	O	O	3971
be	AUX	O	O	3971
preferable	ADJ	O	O	3971
to	PART	O	O	3971
lidocaine	NOUN	O	Chemical	3971
for	ADP	O	O	3971
short	ADJ	O	O	3971
surgical	ADJ	O	O	3971
procedures	NOUN	O	O	3971
because	SCONJ	O	O	3971
it	PRON	O	O	3971
has	VERB	O	O	3971
a	PRON	O	O	3971
similar	ADJ	O	O	3971
duration	NOUN	O	O	3971
of	ADP	O	O	3971
action	NOUN	O	O	3971
but	CCONJ	O	O	3971
a	PRON	O	O	3971
lower	ADJ	O	O	3971
incidence	NOUN	O	O	3971
of	ADP	O	O	3971
TNSs	NOUN	O	O	3971
.	PUNCT	O	O	3971
The	PRON	O	O	3974
role	NOUN	O	O	3974
of	ADP	O	O	3974
nicotine	NOUN	O	Chemical	3974
in	ADP	O	O	3974
smoking	VERB	O	O	3974
-	PUNCT	O	O	3974
related	ADJ	O	O	3974
cardiovascular disease	NOUN	O	Disease	3974
.	PUNCT	O	O	3974
Nicotine	NOUN	O	Chemical	3975
activates	VERB	O	O	3975
the	PRON	O	O	3975
sympathetic	ADJ	O	O	3975
nervous	ADJ	O	O	3975
system	NOUN	O	O	3975
and	CCONJ	O	O	3975
in	ADP	O	O	3975
this	PRON	O	O	3975
way	NOUN	O	O	3975
could	AUX	O	O	3975
contribute	VERB	O	O	3975
to	PART	O	O	3975
cardiovascular disease	NOUN	O	Disease	3975
.	PUNCT	O	O	3975
Animal	NOUN	O	O	3976
studies	NOUN	O	O	3976
and	CCONJ	O	O	3976
mechanistic	ADJ	O	O	3976
studies	NOUN	O	O	3976
indicate	VERB	O	O	3976
that	SCONJ	O	O	3976
nicotine	NOUN	O	Chemical	3976
could	AUX	O	O	3976
play	VERB	O	O	3976
a	PRON	O	O	3976
role	NOUN	O	O	3976
in	ADP	O	O	3976
accelerating	VERB	O	O	3976
atherosclerosis	NOUN	O	Disease	3976
,	PUNCT	O	O	3976
but	CCONJ	O	O	3976
evidence	NOUN	O	O	3976
among	ADP	O	O	3976
humans	NOUN	O	O	3976
is	AUX	O	O	3976
too	ADV	O	O	3976
inadequate	ADJ	O	O	3976
to	PART	O	O	3976
be	AUX	O	O	3976
definitive	ADJ	O	O	3976
about	ADP	O	O	3976
such	ADJ	O	O	3976
an	PRON	O	O	3976
effect	VERB	O	O	3976
.	PUNCT	O	O	3976
Almost	ADV	O	O	3977
certainly	ADV	O	O	3977
,	PUNCT	O	O	3977
nicotine	NOUN	O	Chemical	3977
via	ADP	O	O	3977
its	PRON	O	O	3977
hemodynamic	ADJ	O	O	3977
effects	NOUN	O	O	3977
contributes	VERB	O	O	3977
to	PART	O	O	3977
acute	ADJ	O	O	3977
cardiovascular events	NOUN	O	O	3977
,	PUNCT	O	O	3977
although	SCONJ	O	O	3977
current	ADJ	O	O	3977
evidence	NOUN	O	O	3977
suggests	VERB	O	O	3977
that	SCONJ	O	O	3977
the	PRON	O	O	3977
effects	NOUN	O	O	3977
of	ADP	O	O	3977
nicotine	NOUN	O	Chemical	3977
are	AUX	O	O	3977
much	ADJ	O	O	3977
less	ADV	O	O	3977
important	ADJ	O	O	3977
than	ADP	O	O	3977
are	AUX	O	O	3977
the	PRON	O	O	3977
prothrombotic	NOUN	O	O	3977
effects	NOUN	O	O	3977
of	ADP	O	O	3977
cigarette	NOUN	O	O	3977
smoking	VERB	O	O	3977
or	CCONJ	O	O	3977
the	PRON	O	O	3977
effects	NOUN	O	O	3977
of	ADP	O	O	3977
carbon	NOUN	O	O	3977
monoxide	NOUN	O	O	3977
.	PUNCT	O	O	3977
Nicotine	NOUN	O	Chemical	3978
does	VERB	O	O	3978
not	PART	O	O	3978
appear	VERB	O	O	3978
to	PART	O	O	3978
enhance	VERB	O	O	3978
thrombosis	NOUN	O	Disease	3978
among	ADP	O	O	3978
humans	NOUN	O	O	3978
.	PUNCT	O	O	3978
Clinical	NOUN	O	O	3979
studies	NOUN	O	O	3979
of	ADP	O	O	3979
pipe	NOUN	O	O	3979
smokers	NOUN	O	O	3979
and	CCONJ	O	O	3979
people	NOUN	O	O	3979
using	VERB	O	O	3979
transdermal	NOUN	O	O	3979
nicotine	NOUN	O	Chemical	3979
support	NOUN	O	O	3979
the	PRON	O	O	3979
idea	NOUN	O	O	3979
that	SCONJ	O	O	3979
toxins	VERB	O	O	3979
other	ADJ	O	O	3979
than	ADP	O	O	3979
nicotine	NOUN	O	Chemical	3979
are	AUX	O	O	3979
the	PRON	O	O	3979
most	ADV	O	O	3979
important	ADJ	O	O	3979
causes	VERB	O	O	3979
of	ADP	O	O	3979
acute	ADJ	O	O	3979
cardiovascular events	NOUN	O	O	3979
.	PUNCT	O	O	3979
Finally	ADV	O	O	3980
,	PUNCT	O	O	3980
the	PRON	O	O	3980
dose	NOUN	O	O	3980
response	NOUN	O	O	3980
for	ADP	O	O	3980
cardiovascular events	NOUN	O	O	3980
of	ADP	O	O	3980
nicotine	NOUN	O	Chemical	3980
appears	VERB	O	O	3980
to	PART	O	O	3980
be	AUX	O	O	3980
flat	ADJ	O	O	3980
,	PUNCT	O	O	3980
suggesting	VERB	O	O	3980
that	SCONJ	O	O	3980
if	SCONJ	O	O	3980
nicotine	NOUN	O	Chemical	3980
is	AUX	O	O	3980
involved	VERB	O	O	3980
,	PUNCT	O	O	3980
adverse	ADJ	O	O	3980
effects	NOUN	O	O	3980
might	AUX	O	O	3980
be	AUX	O	O	3980
seen	VERB	O	O	3980
with	ADP	O	O	3980
relatively	ADV	O	O	3980
low	ADJ	O	O	3980
-	PUNCT	O	O	3980
level	VERB	O	O	3980
cigarette	NOUN	O	O	3980
exposures	NOUN	O	O	3980
.	PUNCT	O	O	3980
Seizure	NOUN	O	Disease	3983
resulting	VERB	O	O	3983
from	ADP	O	O	3983
a	PRON	O	O	3983
venlafaxine	NOUN	O	Chemical	3983
overdose	NOUN	O	Disease	3983
.	PUNCT	O	O	3983
OBJECTIVE	VERB	O	O	3984
:	PUNCT	O	O	3984
To	PART	O	O	3984
report	VERB	O	O	3984
a	PRON	O	O	3984
case	NOUN	O	O	3984
of	ADP	O	O	3984
venlafaxine	NOUN	O	Chemical	3984
overdose	NOUN	O	Disease	3984
.	PUNCT	O	O	3984
A	PRON	O	O	3985
40-year	NOUN	O	O	3985
-	PUNCT	O	O	3985
old	ADJ	O	O	3985
woman	NOUN	O	O	3985
with	ADP	O	O	3985
major	ADJ	O	O	3985
depression	PROPN	O	Disease	3985
took	VERB	O	O	3985
an	PRON	O	O	3985
overdose	NOUN	O	Disease	3985
of	ADP	O	O	3985
venlafaxine	NOUN	O	Chemical	3985
in	ADP	O	O	3985
an	PRON	O	O	3985
apparent	ADJ	O	O	3985
suicide	NOUN	O	O	3985
attempt	VERB	O	O	3985
.	PUNCT	O	O	3985
After	ADP	O	O	3986
the	PRON	O	O	3986
ingestion	NOUN	O	O	3986
of	ADP	O	O	3986
26	NUM	O	O	3986
venlafaxine	NOUN	O	Chemical	3986
50-mg	NOUN	O	O	3986
tablets	NOUN	O	O	3986
,	PUNCT	O	O	3986
the	PRON	O	O	3986
patient	NOUN	O	O	3986
experienced	ADJ	O	O	3986
a	PRON	O	O	3986
witnessed	VERB	O	O	3986
generalized	VERB	O	O	3986
seizure	NOUN	O	Disease	3986
.	PUNCT	O	O	3986
She	PRON	O	O	3987
was	AUX	O	O	3987
admitted	VERB	O	O	3987
to	PART	O	O	3987
the	PRON	O	O	3987
medical	ADJ	O	O	3987
intensive	ADJ	O	O	3987
care	VERB	O	O	3987
unit	NOUN	O	O	3987
,	PUNCT	O	O	3987
venlafaxine	NOUN	O	Chemical	3987
was	AUX	O	O	3987
discontinued	VERB	O	O	3987
,	PUNCT	O	O	3987
and	CCONJ	O	O	3987
no	PRON	O	O	3987
further	ADV	O	O	3987
sequelae	ADJ	O	O	3987
were	AUX	O	O	3987
seen	VERB	O	O	3987
.	PUNCT	O	O	3987
To	PART	O	O	3988
our	PRON	O	O	3988
knowledge	NOUN	O	O	3988
,	PUNCT	O	O	3988
this	PRON	O	O	3988
is	AUX	O	O	3988
the	PRON	O	O	3988
first	ADV	O	O	3988
reported	VERB	O	O	3988
case	NOUN	O	O	3988
of	ADP	O	O	3988
venlafaxine	NOUN	O	Chemical	3988
overdose	NOUN	O	Disease	3988
that	SCONJ	O	O	3988
resulted	VERB	O	O	3988
in	ADP	O	O	3988
a	PRON	O	O	3988
generalized	VERB	O	O	3988
seizure	NOUN	O	Disease	3988
.	PUNCT	O	O	3988
Based	VERB	O	O	3989
on	ADP	O	O	3989
nonoverdose	NOUN	O	O	3989
pharmacokinetics	NOUN	O	O	3989
and	CCONJ	O	O	3989
pharmacodynamics	NOUN	O	O	3989
of	ADP	O	O	3989
venlafaxine	NOUN	O	Chemical	3989
and	CCONJ	O	O	3989
the	PRON	O	O	3989
potential	ADJ	O	O	3989
risks	NOUN	O	O	3989
of	ADP	O	O	3989
available	ADJ	O	O	3989
interventions	NOUN	O	O	3989
,	PUNCT	O	O	3989
no	PRON	O	O	3989
emergent	ADJ	O	O	3989
therapy	NOUN	O	O	3989
was	AUX	O	O	3989
instituted	VERB	O	O	3989
.	PUNCT	O	O	3989
The	PRON	O	O	3990
venlafaxine	NOUN	O	Chemical	3990
overdose	NOUN	O	Disease	3990
in	ADP	O	O	3990
our	PRON	O	O	3990
patient	NOUN	O	O	3990
resulted	VERB	O	O	3990
in	ADP	O	O	3990
a	PRON	O	O	3990
single	ADJ	O	O	3990
episode	PROPN	O	O	3990
of	ADP	O	O	3990
generalized	VERB	O	O	3990
seizure	NOUN	O	Disease	3990
but	CCONJ	O	O	3990
elicited	VERB	O	O	3990
no	PRON	O	O	3990
further	ADV	O	O	3990
sequelae	ADJ	O	O	3990
.	PUNCT	O	O	3990
Effect	VERB	O	O	3993
of	ADP	O	O	3993
nifedipine	PROPN	O	Chemical	3993
on	ADP	O	O	3993
renal	ADJ	O	O	3993
function	NOUN	O	O	3993
in	ADP	O	O	3993
liver	NOUN	O	O	3993
transplant	NOUN	O	O	3993
recipients	NOUN	O	O	3993
receiving	VERB	O	O	3993
tacrolimus	NOUN	O	Chemical	3993
.	PUNCT	O	O	3993
The	PRON	O	O	3994
effect	VERB	O	O	3994
of	ADP	O	O	3994
nifedipine	PROPN	O	Chemical	3994
on	ADP	O	O	3994
renal	ADJ	O	O	3994
function	NOUN	O	O	3994
in	ADP	O	O	3994
liver	NOUN	O	O	3994
transplant	NOUN	O	O	3994
recipients	NOUN	O	O	3994
who	PRON	O	O	3994
were	AUX	O	O	3994
receiving	VERB	O	O	3994
tacrolimus	NOUN	O	Chemical	3994
was	AUX	O	O	3994
evaluated	VERB	O	O	3994
between	ADP	O	O	3994
January	PROPN	O	O	3994
1992	NUM	O	O	3994
and	CCONJ	O	O	3994
January	PROPN	O	O	3994
1996	NUM	O	O	3994
.	PUNCT	O	O	3994
Two	NUM	O	O	3995
groups	NOUN	O	O	3995
of	ADP	O	O	3995
patients	NOUN	O	O	3995
receiving	VERB	O	O	3995
tacrolimus	NOUN	O	Chemical	3995
were	AUX	O	O	3995
compared	VERB	O	O	3995
over	ADP	O	O	3995
a	PRON	O	O	3995
period	NOUN	O	O	3995
of	ADP	O	O	3995
1	X	O	O	3995
year	NOUN	O	O	3995
,	PUNCT	O	O	3995
one	NUM	O	O	3995
group	NOUN	O	O	3995
comprising	VERB	O	O	3995
hypertensive	ADJ	O	Disease	3995
patients	NOUN	O	O	3995
who	PRON	O	O	3995
were	AUX	O	O	3995
receiving	VERB	O	O	3995
nifedipine	PROPN	O	Chemical	3995
,	PUNCT	O	O	3995
and	CCONJ	O	O	3995
the	PRON	O	O	3995
other	ADJ	O	O	3995
comprising	VERB	O	O	3995
nonhypertensive	PROPN	O	O	3995
patients	NOUN	O	O	3995
not	PART	O	O	3995
receiving	VERB	O	O	3995
nifedipine	PROPN	O	Chemical	3995
.	PUNCT	O	O	3995
Nifedipine	NOUN	O	O	3996
significantly	ADV	O	O	3996
improved	VERB	O	O	3996
kidney	NOUN	O	O	3996
function	NOUN	O	O	3996
as	ADP	O	O	3996
indicated	VERB	O	O	3996
by	ADP	O	O	3996
a	PRON	O	O	3996
significant	ADJ	O	O	3996
lowering	VERB	O	O	3996
of	ADP	O	O	3996
serum	NOUN	O	O	3996
creatinine	PROPN	O	Chemical	3996
levels	NOUN	O	O	3996
at	ADP	O	O	3996
6	NUM	O	O	3996
and	CCONJ	O	O	3996
12	NUM	O	O	3996
months	NOUN	O	O	3996
.	PUNCT	O	O	3996
The	PRON	O	O	3997
observed	VERB	O	O	3997
positive	ADJ	O	O	3997
impact	NOUN	O	O	3997
of	ADP	O	O	3997
nifedipine	PROPN	O	Chemical	3997
on	ADP	O	O	3997
reducing	VERB	O	O	3997
the	PRON	O	O	3997
nephrotoxicity	NOUN	O	Disease	3997
associated	VERB	O	O	3997
with	ADP	O	O	3997
tacrolimus	NOUN	O	Chemical	3997
in	ADP	O	O	3997
liver	NOUN	O	O	3997
transplant	NOUN	O	O	3997
recipients	NOUN	O	O	3997
should	AUX	O	O	3997
be	AUX	O	O	3997
an	PRON	O	O	3997
important	ADJ	O	O	3997
factor	NOUN	O	O	3997
in	ADP	O	O	3997
selecting	VERB	O	O	3997
an	PRON	O	O	3997
agent	NOUN	O	O	3997
to	PART	O	O	3997
treat	VERB	O	O	3997
hypertension	NOUN	O	Disease	3997
in	ADP	O	O	3997
this	PRON	O	O	3997
population	NOUN	O	O	3997
.	PUNCT	O	O	3997
Sinus	NOUN	O	O	4000
arrest	VERB	O	O	4000
associated	VERB	O	O	4000
with	ADP	O	O	4000
continuous	ADJ	O	O	4000
-	PUNCT	O	O	4000
infusion	NOUN	O	O	4000
cimetidine	NOUN	O	Chemical	4000
.	PUNCT	O	O	4000
The	PRON	O	O	4001
administration	NOUN	O	O	4001
of	ADP	O	O	4001
intermittent	ADJ	O	O	4001
intravenous	ADJ	O	O	4001
infusions	NOUN	O	O	4001
of	ADP	O	O	4001
cimetidine	NOUN	O	Chemical	4001
is	AUX	O	O	4001
infrequently	ADV	O	O	4001
associated	VERB	O	O	4001
with	ADP	O	O	4001
the	PRON	O	O	4001
development	NOUN	O	O	4001
of	ADP	O	O	4001
bradyarrhythmias	PROPN	O	Disease	4001
.	PUNCT	O	O	4001
A	PRON	O	O	4002
40-year	NOUN	O	O	4002
-	PUNCT	O	O	4002
old	ADJ	O	O	4002
man	NOUN	O	O	4002
with	ADP	O	O	4002
leukemia	NOUN	O	Disease	4002
and	CCONJ	O	O	4002
no	PRON	O	O	4002
history	NOUN	O	O	4002
of	ADP	O	O	4002
cardiac disease	NOUN	O	Disease	4002
developed	VERB	O	O	4002
recurrent	ADJ	O	O	4002
,	PUNCT	O	O	4002
brief	PROPN	O	O	4002
episodes	NOUN	O	O	4002
of	ADP	O	O	4002
apparent	ADJ	O	O	4002
sinus	NOUN	O	O	4002
arrest	VERB	O	O	4002
while	SCONJ	O	O	4002
receiving	VERB	O	O	4002
continuous	ADJ	O	O	4002
-	PUNCT	O	O	4002
infusion	NOUN	O	O	4002
cimetidine	NOUN	O	Chemical	4002
50	NUM	O	O	4002
mg	VERB	O	O	4002
/	PUNCT	O	O	4002
hour	NOUN	O	O	4002
.	PUNCT	O	O	4002
The	PRON	O	O	4003
arrhythmias	VERB	O	Disease	4003
were	AUX	O	O	4003
temporally	ADV	O	O	4003
related	ADJ	O	O	4003
to	PART	O	O	4003
cimetidine	NOUN	O	Chemical	4003
administration	NOUN	O	O	4003
,	PUNCT	O	O	4003
disappeared	VERB	O	O	4003
after	ADP	O	O	4003
dechallenge	NOUN	O	O	4003
,	PUNCT	O	O	4003
and	CCONJ	O	O	4003
did	VERB	O	O	4003
not	PART	O	O	4003
recur	VERB	O	O	4003
during	ADP	O	O	4003
ranitidine	PROPN	O	Chemical	4003
treatment	NOUN	O	O	4003
.	PUNCT	O	O	4003
This	PRON	O	O	4004
is	AUX	O	O	4004
the	PRON	O	O	4004
first	ADV	O	O	4004
reported	VERB	O	O	4004
case	NOUN	O	O	4004
of	ADP	O	O	4004
sinus	NOUN	O	O	4004
arrest	VERB	O	O	4004
associated	VERB	O	O	4004
with	ADP	O	O	4004
continuous	ADJ	O	O	4004
-	PUNCT	O	O	4004
infusion	NOUN	O	O	4004
cimetidine	NOUN	O	Chemical	4004
.	PUNCT	O	O	4004
Composition	NOUN	O	O	4007
of	ADP	O	O	4007
gall	NOUN	O	O	4007
bladder	NOUN	O	O	4007
stones	NOUN	O	O	4007
associated	VERB	O	O	4007
with	ADP	O	O	4007
octreotide	ADV	O	O	4007
:	PUNCT	O	O	4007
response	NOUN	O	O	4007
to	PART	O	O	4007
oral	ADJ	O	O	4007
ursodeoxycholic acid	NOUN	O	O	4007
.	PUNCT	O	O	4007
Octreotide	PROPN	O	O	4008
,	PUNCT	O	O	4008
an	PRON	O	O	4008
effective	ADJ	O	O	4008
treatment	NOUN	O	O	4008
for	ADP	O	O	4008
acromegaly	PROPN	O	O	4008
,	PUNCT	O	O	4008
induces	VERB	O	O	4008
gall	NOUN	O	O	4008
bladder	NOUN	O	O	4008
stones	NOUN	O	O	4008
in	ADP	O	O	4008
13	NUM	O	O	4008
-	PUNCT	O	O	4008
60%	NOUN	O	O	4008
of	ADP	O	O	4008
patients	NOUN	O	O	4008
.	PUNCT	O	O	4008
Because	SCONJ	O	O	4009
knowledge	NOUN	O	O	4009
of	ADP	O	O	4009
stone	PROPN	O	O	4009
composition	NOUN	O	O	4009
is	AUX	O	O	4009
essential	ADJ	O	O	4009
for	ADP	O	O	4009
studies	NOUN	O	O	4009
of	ADP	O	O	4009
their	PRON	O	O	4009
pathogenesis	NOUN	O	O	4009
,	PUNCT	O	O	4009
treatment	NOUN	O	O	4009
,	PUNCT	O	O	4009
and	CCONJ	O	O	4009
prevention	NOUN	O	O	4009
,	PUNCT	O	O	4009
this	PRON	O	O	4009
was	AUX	O	O	4009
investigated	VERB	O	O	4009
by	ADP	O	O	4009
direct	ADJ	O	O	4009
and	CCONJ	O	O	4009
indirect	ADJ	O	O	4009
methods	NOUN	O	O	4009
in	ADP	O	O	4009
14	NUM	O	O	4009
octreotide	ADV	O	O	4009
treated	VERB	O	O	4009
acromegalic	ADV	O	O	4009
patients	NOUN	O	O	4009
with	ADP	O	O	4009
gall	NOUN	O	O	4009
stones	NOUN	O	O	4009
.	PUNCT	O	O	4009
Chemical	NOUN	O	O	4010
analysis	NOUN	O	O	4010
of	ADP	O	O	4010
gall	NOUN	O	O	4010
stones	NOUN	O	O	4010
retrieved	VERB	O	O	4010
at	ADP	O	O	4010
cholecystectomy	NOUN	O	O	4010
from	ADP	O	O	4010
two	NUM	O	O	4010
patients	NOUN	O	O	4010
,	PUNCT	O	O	4010
showed	VERB	O	O	4010
that	SCONJ	O	O	4010
they	PRON	O	O	4010
contained	VERB	O	O	4010
71%	NOUN	O	O	4010
and	CCONJ	O	O	4010
87%	NOUN	O	O	4010
cholesterol	NOUN	O	Chemical	4010
by	ADP	O	O	4010
weight	NOUN	O	O	4010
.	PUNCT	O	O	4010
In	ADP	O	O	4011
the	PRON	O	O	4011
remaining	VERB	O	O	4011
12	NUM	O	O	4011
patients	NOUN	O	O	4011
,	PUNCT	O	O	4011
localised	VERB	O	O	4011
computed	VERB	O	O	4011
tomography	NOUN	O	O	4011
of	ADP	O	O	4011
the	PRON	O	O	4011
gall	NOUN	O	O	4011
bladder	NOUN	O	O	4011
showed	VERB	O	O	4011
that	SCONJ	O	O	4011
eight	NUM	O	O	4011
had	VERB	O	O	4011
stones	NOUN	O	O	4011
with	ADP	O	O	4011
maximum	ADV	O	O	4011
attenuation	NOUN	O	O	4011
scores	NOUN	O	O	4011
of	ADP	O	O	4011
<	X	O	O	4011
100	NUM	O	O	4011
Hounsfield	PROPN	O	O	4011
units	NOUN	O	O	4011
(	PUNCT	O	O	4011
values	NOUN	O	O	4011
of	ADP	O	O	4011
<	X	O	O	4011
100	NUM	O	O	4011
HU	PROPN	O	O	4011
predict	VERB	O	O	4011
cholesterol	NOUN	O	Chemical	4011
rich	ADJ	O	O	4011
,	PUNCT	O	O	4011
dissolvable	ADJ	O	O	4011
stones	NOUN	O	O	4011
)	PUNCT	O	O	4011
.	PUNCT	O	O	4011
All	PRON	O	O	4012
six	NUM	O	O	4012
patients	NOUN	O	O	4012
had	VERB	O	O	4012
supersaturated	ADJ	O	O	4012
bile	NOUN	O	O	4012
(	PUNCT	O	O	4012
mean	VERB	O	O	4012
(	PUNCT	O	O	4012
SEM	INTJ	O	O	4012
)	PUNCT	O	O	4012
cholesterol	NOUN	O	Chemical	4012
saturation	NOUN	O	O	4012
index	NOUN	O	O	4012
of	ADP	O	O	4012
1.19	NUM	O	O	4012
(	PUNCT	O	O	4012
0.08	NUM	O	O	4012
)	PUNCT	O	O	4012
(	PUNCT	O	O	4012
range	VERB	O	O	4012
1.01	NUM	O	O	4012
-	PUNCT	O	O	4012
1.53	NUM	O	O	4012
)	PUNCT	O	O	4012
)	PUNCT	O	O	4012
and	CCONJ	O	O	4012
all	PRON	O	O	4012
had	VERB	O	O	4012
abnormally	ADV	O	O	4012
rapid	ADJ	O	O	4012
cholesterol	NOUN	O	Chemical	4012
microcrystal	ADJ	O	O	4012
nucleation	NOUN	O	O	4012
times	NOUN	O	O	4012
(	PUNCT	O	O	4012
<	X	O	O	4012
4	NUM	O	O	4012
days	NOUN	O	O	4012
(	PUNCT	O	O	4012
range	VERB	O	O	4012
1	X	O	O	4012
-	PUNCT	O	O	4012
4	NUM	O	O	4012
)	PUNCT	O	O	4012
)	PUNCT	O	O	4012
,	PUNCT	O	O	4012
whilst	SCONJ	O	O	4012
in	ADP	O	O	4012
four	NUM	O	O	4012
,	PUNCT	O	O	4013
the	PRON	O	O	4013
bile	NOUN	O	O	4013
contained	VERB	O	O	4013
cholesterol	NOUN	O	Chemical	4013
microcrystals	VERB	O	O	4013
immediately	ADV	O	O	4013
after	ADP	O	O	4013
sampling	NOUN	O	O	4013
.	PUNCT	O	O	4013
Of	ADV	O	O	4014
the	PRON	O	O	4014
12	NUM	O	O	4014
patients	NOUN	O	O	4014
considered	VERB	O	O	4014
for	ADP	O	O	4014
oral	ADJ	O	O	4014
ursodeoxycholic acid	NOUN	O	O	4014
(	PUNCT	O	O	4014
UDCA	PROPN	O	O	4014
)	PUNCT	O	O	4014
treatment	NOUN	O	O	4014
,	PUNCT	O	O	4014
two	NUM	O	O	4014
had	VERB	O	O	4014
a	PRON	O	O	4014
blocked	VERB	O	O	4014
cystic	PROPN	O	O	4014
duct	NOUN	O	O	4014
and	CCONJ	O	O	4014
were	AUX	O	O	4014
not	PART	O	O	4014
started	VERB	O	O	4014
on	ADP	O	O	4014
UDCA	PROPN	O	O	4014
while	SCONJ	O	O	4014
one	NUM	O	O	4014
was	AUX	O	O	4014
lost	VERB	O	O	4014
to	PART	O	O	4014
follow	VERB	O	O	4014
up	ADP	O	O	4014
.	PUNCT	O	O	4014
n	CCONJ	O	O	4015
=	PUNCT	O	O	4015
2	X	O	O	4015
)	PUNCT	O	O	4015
gall	NOUN	O	O	4015
stone	PROPN	O	O	4015
dissolution	NOUN	O	O	4015
,	PUNCT	O	O	4015
suggesting	VERB	O	O	4015
that	SCONJ	O	O	4015
their	PRON	O	O	4015
stones	NOUN	O	O	4015
were	AUX	O	O	4015
cholesterol	NOUN	O	Chemical	4015
rich	ADJ	O	O	4015
.	PUNCT	O	O	4015
This	PRON	O	O	4016
corresponds	VERB	O	O	4016
,	PUNCT	O	O	4016
by	ADP	O	O	4016
actuarial	ADJ	O	O	4016
(	PUNCT	O	O	4016
life	NOUN	O	O	4016
table	NOUN	O	O	4016
)	PUNCT	O	O	4016
analysis	NOUN	O	O	4016
,	PUNCT	O	O	4016
to	PART	O	O	4016
a	PRON	O	O	4016
combined	VERB	O	O	4016
gall	NOUN	O	O	4016
stone	PROPN	O	O	4016
dissolution	NOUN	O	O	4016
rate	NOUN	O	O	4016
of	ADP	O	O	4016
58.3	NUM	O	O	4016
(	PUNCT	O	O	4016
15.9%	NOUN	O	O	4016
)	PUNCT	O	O	4016
.	PUNCT	O	O	4016
In	ADP	O	O	4017
conclusion	NOUN	O	O	4017
,	PUNCT	O	O	4017
octreotide	ADV	O	O	4017
induced	VERB	O	O	4017
gall	NOUN	O	O	4017
stones	NOUN	O	O	4017
are	AUX	O	O	4017
generally	ADV	O	O	4017
small	ADJ	O	O	4017
,	PUNCT	O	O	4017
multiple	ADJ	O	O	4017
,	PUNCT	O	O	4017
and	CCONJ	O	O	4017
cholesterol	NOUN	O	Chemical	4017
rich	ADJ	O	O	4017
although	SCONJ	O	O	4017
,	PUNCT	O	O	4017
in	ADP	O	O	4017
common	ADJ	O	O	4017
with	ADP	O	O	4017
spontaneous	ADJ	O	O	4017
gall	NOUN	O	O	4017
stone	PROPN	O	O	4017
disease	PROPN	O	O	4017
,	PUNCT	O	O	4017
at	ADP	O	O	4017
presentation	NOUN	O	O	4017
some	PRON	O	O	4017
patients	NOUN	O	O	4017
will	AUX	O	O	4017
have	VERB	O	O	4017
a	PRON	O	O	4017
blocked	VERB	O	O	4017
cystic	PROPN	O	O	4017
duct	NOUN	O	O	4017
and	CCONJ	O	O	4017
some	PRON	O	O	4017
gall	NOUN	O	O	4017
stones	NOUN	O	O	4017
containing	VERB	O	O	4017
calcium	NOUN	O	Chemical	4017
.	PUNCT	O	O	4017
Cardiovascular	NOUN	O	O	4020
complications	NOUN	O	O	4020
associated	VERB	O	O	4020
with	ADP	O	O	4020
terbutaline	NOUN	O	Chemical	4020
treatment	NOUN	O	O	4020
for	ADP	O	O	4020
preterm	NOUN	O	O	4020
labor	NOUN	O	O	4020
.	PUNCT	O	O	4020
Severe	ADJ	O	O	4021
cardiovascular	ADJ	O	O	4021
complications	NOUN	O	O	4021
occurred	VERB	O	O	4021
in	ADP	O	O	4021
eight	NUM	O	O	4021
of	ADP	O	O	4021
160	NUM	O	O	4021
patients	NOUN	O	O	4021
treated	VERB	O	O	4021
with	ADP	O	O	4021
terbutaline	NOUN	O	Chemical	4021
for	ADP	O	O	4021
preterm	NOUN	O	O	4021
labor	NOUN	O	O	4021
.	PUNCT	O	O	4021
Neurologic	ADJ	O	O	4024
effects	NOUN	O	O	4024
of	ADP	O	O	4024
subarachnoid	NOUN	O	O	4024
administration	NOUN	O	O	4024
of	ADP	O	O	4024
2-chloroprocaine	NOUN	O	O	4024
-	PUNCT	O	O	4024
CE	PROPN	O	O	4024
,	PUNCT	O	O	4024
bupivacaine	NOUN	O	Chemical	4024
,	PUNCT	O	O	4024
and	CCONJ	O	O	4024
low	ADJ	O	O	4024
pH	NOUN	O	O	4024
The	PRON	O	O	4025
purpose	NOUN	O	O	4025
of	ADP	O	O	4025
this	PRON	O	O	4025
study	VERB	O	O	4025
was	AUX	O	O	4025
to	PART	O	O	4025
evaluate	VERB	O	O	4025
the	PRON	O	O	4025
neurologic	ADJ	O	O	4025
consequences	NOUN	O	O	4025
of	ADP	O	O	4025
deliberate	VERB	O	O	4025
subarachnoid	NOUN	O	O	4025
injection	NOUN	O	O	4025
of	ADP	O	O	4025
large	ADJ	O	O	4025
volumes	NOUN	O	O	4025
of	ADP	O	O	4025
2-chloroprocaine	NOUN	O	O	4025
-	PUNCT	O	O	4025
CE	PROPN	O	O	4025
in	ADP	O	O	4025
experimental	ADJ	O	O	4025
animals	NOUN	O	O	4025
.	PUNCT	O	O	4025
The	PRON	O	O	4026
possible	ADJ	O	O	4026
role	NOUN	O	O	4026
of	ADP	O	O	4026
low	ADJ	O	O	4026
pH	NOUN	O	O	4026
as	ADP	O	O	4026
well	ADV	O	O	4026
as	ADP	O	O	4026
total	ADJ	O	O	4026
volume	PROPN	O	O	4026
as	ADP	O	O	4026
potential	ADJ	O	O	4026
factors	NOUN	O	O	4026
in	ADP	O	O	4026
causing	VERB	O	O	4026
neurotoxicity	NOUN	O	Disease	4026
was	AUX	O	O	4026
evaluated	VERB	O	O	4026
.	PUNCT	O	O	4026
The	PRON	O	O	4027
65	NUM	O	O	4027
dogs	NOUN	O	O	4027
in	ADP	O	O	4027
the	PRON	O	O	4027
study	VERB	O	O	4027
received	VERB	O	O	4027
injections	NOUN	O	O	4027
in	ADP	O	O	4027
the	PRON	O	O	4027
subarachnoid	NOUN	O	O	4027
space	NOUN	O	O	4027
as	ADP	O	O	4027
follows	VERB	O	O	4027
:	PUNCT	O	O	4027
6	NUM	O	O	4027
to	PART	O	O	4027
8	NUM	O	O	4027
ml	ADP	O	O	4027
of	ADP	O	O	4027
bupivacaine	NOUN	O	Chemical	4027
(	PUNCT	O	O	4027
N	NUM	O	O	4028
=	PUNCT	O	O	4028
15	NUM	O	O	4028
)	PUNCT	O	O	4028
,	PUNCT	O	O	4028
2-chloroprocaine	NOUN	O	O	4028
-	PUNCT	O	O	4028
CE	PROPN	O	O	4028
(	PUNCT	O	O	4028
N	NUM	O	O	4028
=	PUNCT	O	O	4028
20	NUM	O	O	4028
)	PUNCT	O	O	4028
,	PUNCT	O	O	4028
low	ADJ	O	O	4028
pH	NOUN	O	O	4028
normal	ADJ	O	O	4028
saline	NOUN	O	O	4028
(	PUNCT	O	O	4028
pH	NOUN	O	O	4028
3.0	NUM	O	O	4028
)	PUNCT	O	O	4028
(	PUNCT	O	O	4028
N	NUM	O	O	4028
=	PUNCT	O	O	4028
20	NUM	O	O	4028
)	PUNCT	O	O	4028
,	PUNCT	O	O	4028
or	CCONJ	O	O	4028
normal	ADJ	O	O	4028
saline	NOUN	O	O	4028
(	PUNCT	O	O	4028
N	NUM	O	O	4028
=	PUNCT	O	O	4028
10	NUM	O	O	4028
)	PUNCT	O	O	4028
.	PUNCT	O	O	4028
Of	ADV	O	O	4029
the	PRON	O	O	4029
20	NUM	O	O	4029
animals	NOUN	O	O	4029
that	SCONJ	O	O	4029
received	VERB	O	O	4029
subarachnoid	NOUN	O	O	4029
injection	NOUN	O	O	4029
of	ADP	O	O	4029
2-chloroprocaine	NOUN	O	O	4029
-	PUNCT	O	O	4029
CE	PROPN	O	O	4029
seven	NUM	O	O	4029
(	PUNCT	O	O	4029
35%	NOUN	O	O	4029
)	PUNCT	O	O	4029
developed	VERB	O	O	4029
hind	NOUN	O	O	4029
-	PUNCT	O	O	4029
limb	NOUN	O	O	4029
paralysis	NOUN	O	Disease	4029
.	PUNCT	O	O	4029
None	NOUN	O	O	4030
of	ADP	O	O	4030
the	PRON	O	O	4030
animals	NOUN	O	O	4030
that	SCONJ	O	O	4030
received	VERB	O	O	4030
bupivacaine	NOUN	O	Chemical	4030
,	PUNCT	O	O	4030
normal	ADJ	O	O	4030
saline	NOUN	O	O	4030
,	PUNCT	O	O	4030
or	CCONJ	O	O	4030
normal	ADJ	O	O	4030
saline	NOUN	O	O	4030
titrated	VERB	O	O	4030
to	PART	O	O	4030
a	PRON	O	O	4030
pH	NOUN	O	O	4030
3.0	NUM	O	O	4030
developed	VERB	O	O	4030
hind	NOUN	O	O	4030
-	PUNCT	O	O	4030
limb	NOUN	O	O	4030
paralysis	NOUN	O	Disease	4030
.	PUNCT	O	O	4030
Of	ADV	O	O	4031
the	PRON	O	O	4031
15	NUM	O	O	4031
spinal	NOUN	O	O	4031
cords	NOUN	O	O	4031
of	ADP	O	O	4031
the	PRON	O	O	4031
animals	NOUN	O	O	4031
that	SCONJ	O	O	4031
received	VERB	O	O	4031
2-chloroprocaine	NOUN	O	O	4031
-	PUNCT	O	O	4031
CE	PROPN	O	O	4031
,	PUNCT	O	O	4031
13	NUM	O	O	4031
showed	VERB	O	O	4031
subpial	ADJ	O	O	4031
necrosis	NOUN	O	Disease	4031
;	PUNCT	O	O	4031
the	PRON	O	O	4031
nerve	NOUN	O	O	4031
roots	NOUN	O	O	4031
and	CCONJ	O	O	4031
subarachnoid	NOUN	O	O	4031
vessels	NOUN	O	O	4031
were	AUX	O	O	4031
normal	ADJ	O	O	4031
.	PUNCT	O	O	4031
The	PRON	O	O	4032
spinal	NOUN	O	O	4032
cords	NOUN	O	O	4032
of	ADP	O	O	4032
the	PRON	O	O	4032
animals	NOUN	O	O	4032
that	SCONJ	O	O	4032
received	VERB	O	O	4032
bupivacaine	NOUN	O	Chemical	4032
,	PUNCT	O	O	4032
low	ADJ	O	O	4032
pH	NOUN	O	O	4032
normal	ADJ	O	O	4032
saline	NOUN	O	O	4032
(	PUNCT	O	O	4032
pH	NOUN	O	O	4032
3.0	NUM	O	O	4032
)	PUNCT	O	O	4032
,	PUNCT	O	O	4032
or	CCONJ	O	O	4032
normal	ADJ	O	O	4032
saline	NOUN	O	O	4032
did	VERB	O	O	4032
not	PART	O	O	4032
show	VERB	O	O	4032
abnormal	ADJ	O	O	4032
findings	NOUN	O	O	4032
.	PUNCT	O	O	4032
Early	ADJ	O	O	4035
adjuvant	NOUN	O	O	4035
adriamycin	PROPN	O	Chemical	4035
in	ADP	O	O	4035
superficial	ADJ	O	O	4035
bladder	NOUN	O	O	4035
carcinoma	NOUN	O	Disease	4035
.	PUNCT	O	O	4035
A	PRON	O	O	4036
multicenter	ADJ	O	O	4036
study	VERB	O	O	4036
was	AUX	O	O	4036
performed	VERB	O	O	4036
in	ADP	O	O	4036
110	NUM	O	O	4036
patients	NOUN	O	O	4036
with	ADP	O	O	4036
superficial	ADJ	O	O	4036
transitional	ADJ	O	O	4036
cell	NOUN	O	O	4036
carcinoma	NOUN	O	Disease	4036
of	ADP	O	O	4036
the	PRON	O	O	4036
bladder	NOUN	O	O	4036
.	PUNCT	O	O	4036
Adriamycin	PROPN	O	Chemical	4037
(	PUNCT	O	O	4037
50	NUM	O	O	4037
mg/50	PROPN	O	O	4037
ml	ADP	O	O	4037
)	PUNCT	O	O	4037
was	AUX	O	O	4037
administered	VERB	O	O	4037
intravesically	ADV	O	O	4037
within	ADP	O	O	4037
24	NUM	O	O	4037
h	X	O	O	4037
after	ADP	O	O	4037
transurethral	NOUN	O	O	4037
resection	NOUN	O	O	4037
of	ADP	O	O	4037
TA	PROPN	O	O	4037
-	PUNCT	O	O	4037
T1	PROPN	O	O	4037
(	PUNCT	O	O	4037
O	INTJ	O	O	4037
-	PUNCT	O	O	4037
A	PRON	O	O	4037
)	PUNCT	O	O	4037
bladder tumors	NOUN	O	Disease	4037
.	PUNCT	O	O	4037
In	ADP	O	O	4038
24	NUM	O	O	4038
of	ADP	O	O	4038
these	PRON	O	O	4038
patients	NOUN	O	O	4038
chemical	PROPN	O	O	4038
cystitis	NOUN	O	Disease	4038
was	AUX	O	O	4038
severe	ADJ	O	O	4038
enough	ADV	O	O	4038
for	ADP	O	O	4038
them	PRON	O	O	4038
to	PART	O	O	4038
drop	VERB	O	O	4038
out	ADP	O	O	4038
of	ADP	O	O	4038
the	PRON	O	O	4038
study	VERB	O	O	4038
.	PUNCT	O	O	4038
Of	ADV	O	O	4039
these	PRON	O	O	4039
recurrences	NOUN	O	O	4039
,	PUNCT	O	O	4039
27	NUM	O	O	4039
were	AUX	O	O	4039
T1	PROPN	O	O	4039
tumors	NOUN	O	Disease	4039
while	SCONJ	O	O	4039
five	NUM	O	O	4039
progressed	VERB	O	O	4039
to	PART	O	O	4039
more	ADJ	O	O	4039
highly	ADV	O	O	4039
invasive	ADJ	O	O	4039
lesions	NOUN	O	O	4039
.	PUNCT	O	O	4039
In	ADP	O	O	4040
patients	NOUN	O	O	4040
that	SCONJ	O	O	4040
were	AUX	O	O	4040
free	ADJ	O	O	4040
of	ADP	O	O	4040
recurrence	NOUN	O	O	4040
during	ADP	O	O	4040
the	PRON	O	O	4040
first	ADV	O	O	4040
year	NOUN	O	O	4040
,	PUNCT	O	O	4040
80%	NOUN	O	O	4040
remained	VERB	O	O	4040
tumor	NOUN	O	Disease	4040
-	PUNCT	O	O	4040
free	ADJ	O	O	4040
during	ADP	O	O	4040
the	PRON	O	O	4040
2-	X	O	O	4040
to	PART	O	O	4040
3-year	NOUN	O	O	4040
follow	VERB	O	O	4040
-	PUNCT	O	O	4040
up	ADP	O	O	4040
period	NOUN	O	O	4040
.	PUNCT	O	O	4040
The	PRON	O	O	4041
beneficial	ADJ	O	O	4041
effect	VERB	O	O	4041
of	ADP	O	O	4041
Adriamycin	PROPN	O	Chemical	4041
appears	VERB	O	O	4041
obvious	ADJ	O	O	4041
and	CCONJ	O	O	4041
might	AUX	O	O	4041
be	AUX	O	O	4041
related	ADJ	O	O	4041
to	PART	O	O	4041
the	PRON	O	O	4041
drug	NOUN	O	O	4041
itself	PRON	O	O	4041
,	PUNCT	O	O	4041
the	PRON	O	O	4041
early	ADV	O	O	4041
and	CCONJ	O	O	4041
repeated	VERB	O	O	4041
instillations	NOUN	O	O	4041
after	ADP	O	O	4041
TUR	PROPN	O	O	4041
,	PUNCT	O	O	4041
or	CCONJ	O	O	4041
both	PRON	O	O	4041
.	PUNCT	O	O	4041
Hyperkalemia	NOUN	O	O	4044
associated	VERB	O	O	4044
with	ADP	O	O	4044
sulindac	PROPN	O	Chemical	4044
therapy	NOUN	O	O	4044
.	PUNCT	O	O	4044
Hyperkalemia	NOUN	O	O	4045
has	VERB	O	O	4045
recently	ADV	O	O	4045
been	AUX	O	O	4045
recognized	VERB	O	O	4045
as	ADP	O	O	4045
a	PRON	O	O	4045
complication	NOUN	O	O	4045
of	ADP	O	O	4045
nonsteroidal	ADJ	O	O	4045
antiinflammatory	ADJ	O	O	4045
agents	NOUN	O	O	4045
(	PUNCT	O	O	4045
NSAID	PROPN	O	Chemical	4045
)	PUNCT	O	O	4045
such	ADJ	O	O	4045
as	ADP	O	O	4045
indomethacin	VERB	O	Chemical	4045
.	PUNCT	O	O	4045
Several	ADJ	O	O	4046
recent	ADJ	O	O	4046
studies	NOUN	O	O	4046
have	VERB	O	O	4046
stressed	VERB	O	O	4046
the	PRON	O	O	4046
renal	ADJ	O	O	4046
sparing	VERB	O	O	4046
features	VERB	O	O	4046
of	ADP	O	O	4046
sulindac	PROPN	O	Chemical	4046
,	PUNCT	O	O	4046
owing	VERB	O	O	4046
to	PART	O	O	4046
its	PRON	O	O	4046
lack	VERB	O	O	4046
of	ADP	O	O	4046
interference	NOUN	O	O	4046
with	ADP	O	O	4046
renal	ADJ	O	O	4046
prostacyclin	NOUN	O	Chemical	4046
synthesis	NOUN	O	O	4046
.	PUNCT	O	O	4046
We	PRON	O	O	4047
describe	VERB	O	O	4047
4	NUM	O	O	4047
patients	NOUN	O	O	4047
in	ADP	O	O	4047
whom	PRON	O	O	4047
hyperkalemia	NOUN	O	O	4047
ranging	VERB	O	O	4047
from	ADP	O	O	4047
6.1	NUM	O	O	4047
to	PART	O	O	4047
6.9	NUM	O	O	4047
mEq	VERB	O	O	4047
/	PUNCT	O	O	4047
l	X	O	O	4047
developed	VERB	O	O	4047
within	ADP	O	O	4047
3	X	O	O	4047
to	PART	O	O	4047
8	NUM	O	O	4047
days	NOUN	O	O	4047
of	ADP	O	O	4047
sulindac	PROPN	O	Chemical	4047
administration	NOUN	O	O	4047
.	PUNCT	O	O	4047
In	ADP	O	O	4048
all	PRON	O	O	4048
of	ADP	O	O	4048
them	PRON	O	O	4048
normal	ADJ	O	O	4048
serum	NOUN	O	O	4048
potassium	NOUN	O	Chemical	4048
levels	NOUN	O	O	4048
reached	VERB	O	O	4048
within	ADP	O	O	4048
2	X	O	O	4048
to	PART	O	O	4048
4	NUM	O	O	4048
days	NOUN	O	O	4048
of	ADP	O	O	4048
stopping	VERB	O	O	4048
sulindac	PROPN	O	Chemical	4048
.	PUNCT	O	O	4048
As	ADP	O	O	4049
no	PRON	O	O	4049
other	ADJ	O	O	4049
medications	NOUN	O	O	4049
known	VERB	O	O	4049
to	PART	O	O	4049
effect	VERB	O	O	4049
serum	NOUN	O	O	4049
potassium	NOUN	O	Chemical	4049
had	VERB	O	O	4049
been	AUX	O	O	4049
given	VERB	O	O	4049
concomitantly	ADV	O	O	4049
,	PUNCT	O	O	4049
this	PRON	O	O	4049
course	NOUN	O	O	4049
of	ADP	O	O	4049
events	NOUN	O	O	4049
is	AUX	O	O	4049
suggestive	ADJ	O	O	4049
of	ADP	O	O	4049
a	PRON	O	O	4049
cause	VERB	O	O	4049
-	PUNCT	O	O	4049
and	CCONJ	O	O	4049
-	PUNCT	O	O	4049
effect	VERB	O	O	4049
relationship	NOUN	O	O	4049
between	ADP	O	O	4049
sulindac	PROPN	O	Chemical	4049
and	CCONJ	O	O	4049
hyperkalemia	NOUN	O	O	4049
.	PUNCT	O	O	4049
These	PRON	O	O	4050
observations	NOUN	O	O	4050
indicate	VERB	O	O	4050
that	SCONJ	O	O	4050
initial	ADJ	O	O	4050
hopes	VERB	O	O	4050
that	SCONJ	O	O	4050
sulindac	PROPN	O	Chemical	4050
may	AUX	O	O	4050
not	PART	O	O	4050
be	AUX	O	O	4050
associated	VERB	O	O	4050
with	ADP	O	O	4050
the	PRON	O	O	4050
adverse	ADJ	O	O	4050
renal	ADJ	O	O	4050
effects	NOUN	O	O	4050
of	ADP	O	O	4050
other	ADJ	O	O	4050
NSAID	PROPN	O	Chemical	4050
are	AUX	O	O	4050
probably	ADV	O	O	4050
not	PART	O	O	4050
justified	VERB	O	O	4050
.	PUNCT	O	O	4050
Ventricular	PROPN	O	O	4053
tachyarrhythmias	NOUN	O	Disease	4053
during	ADP	O	O	4053
cesarean	PROPN	O	O	4053
section	NOUN	O	O	4053
after	ADP	O	O	4053
ritodrine	ADJ	O	O	4053
therapy	NOUN	O	O	4053
:	PUNCT	O	O	4053
This	PRON	O	O	4054
case	NOUN	O	O	4054
illustrates	VERB	O	O	4054
that	SCONJ	O	O	4054
patients	NOUN	O	O	4054
receiving	VERB	O	O	4054
ritodrine	ADJ	O	O	4054
for	ADP	O	O	4054
preterm	NOUN	O	O	4054
labor	NOUN	O	O	4054
may	AUX	O	O	4054
risk	NOUN	O	O	4054
interactions	NOUN	O	O	4054
between	ADP	O	O	4054
the	PRON	O	O	4054
residual	ADJ	O	O	4054
betamimetic	ADJ	O	O	4054
effects	NOUN	O	O	4054
of	ADP	O	O	4054
ritodrine	ADJ	O	O	4054
and	CCONJ	O	O	4054
the	PRON	O	O	4054
effects	NOUN	O	O	4054
of	ADP	O	O	4054
anesthetics	NOUN	O	O	4054
during	ADP	O	O	4054
cesarean	PROPN	O	O	4054
section	NOUN	O	O	4054
.	PUNCT	O	O	4054
Such	ADJ	O	O	4055
interactions	NOUN	O	O	4055
may	AUX	O	O	4055
result	VERB	O	O	4055
in	ADP	O	O	4055
serious	ADJ	O	O	4055
cardiovascular	ADJ	O	O	4055
complications	NOUN	O	O	4055
even	ADV	O	O	4055
after	ADP	O	O	4055
cessation	NOUN	O	O	4055
of	ADP	O	O	4055
an	PRON	O	O	4055
infusion	NOUN	O	O	4055
of	ADP	O	O	4055
ritodrine	ADJ	O	O	4055
.	PUNCT	O	O	4055
Preoperative	PROPN	O	O	4056
assessment	NOUN	O	O	4056
should	AUX	O	O	4056
focus	NOUN	O	O	4056
on	ADP	O	O	4056
cardiovascular	ADJ	O	O	4056
status	NOUN	O	O	4056
and	CCONJ	O	O	4056
serum	NOUN	O	O	4056
potassium	NOUN	O	Chemical	4056
level	VERB	O	O	4056
.	PUNCT	O	O	4056
Careful	ADJ	O	O	4057
fluid	NOUN	O	O	4057
administration	NOUN	O	O	4057
and	CCONJ	O	O	4057
cautious	ADJ	O	O	4057
use	VERB	O	O	4057
of	ADP	O	O	4057
titrated	VERB	O	O	4057
doses	NOUN	O	O	4057
of	ADP	O	O	4057
ephedrine	NOUN	O	Chemical	4057
are	AUX	O	O	4057
advised	VERB	O	O	4057
.	PUNCT	O	O	4057
After	ADP	O	O	4058
delivery	NOUN	O	O	4058
of	ADP	O	O	4058
the	PRON	O	O	4058
infant	NOUN	O	O	4058
,	PUNCT	O	O	4058
there	ADV	O	O	4058
should	AUX	O	O	4058
be	AUX	O	O	4058
no	PRON	O	O	4058
contraindication	NOUN	O	O	4058
to	PART	O	O	4058
the	PRON	O	O	4058
use	VERB	O	O	4058
of	ADP	O	O	4058
an	PRON	O	O	4058
alpha	PROPN	O	O	4058
-	PUNCT	O	O	4058
adrenergic	NOUN	O	O	4058
vasopressor	NOUN	O	O	4058
such	ADJ	O	O	4058
as	ADP	O	O	4058
phenylephrine	NOUN	O	Chemical	4058
to	PART	O	O	4058
treat	VERB	O	O	4058
hypotensive	ADJ	O	Disease	4058
patients	NOUN	O	O	4058
with	ADP	O	O	4058
tachycardia	PROPN	O	Disease	4058
.	PUNCT	O	O	4058
Immunohistochemical	PROPN	O	O	4061
,	PUNCT	O	O	4061
electron	NOUN	O	O	4061
microscopic	ADJ	O	O	4061
and	CCONJ	O	O	4061
morphometric	PROPN	O	O	4061
studies	NOUN	O	O	4061
of	ADP	O	O	4061
estrogen	PROPN	O	Chemical	4061
-	PUNCT	O	O	4061
induced	VERB	O	O	4061
rat	NOUN	O	O	4061
prolactinomas	PROPN	O	Disease	4061
after	ADP	O	O	4061
bromocriptine	NOUN	O	Chemical	4061
treatment	NOUN	O	O	4061
.	PUNCT	O	O	4061
To	PART	O	O	4062
clarify	VERB	O	O	4062
the	PRON	O	O	4062
effects	NOUN	O	O	4062
of	ADP	O	O	4062
bromocriptine	NOUN	O	Chemical	4062
on	ADP	O	O	4062
prolactinoma	PROPN	O	O	4062
cells	NOUN	O	O	4062
in	ADP	O	O	4062
vivo	VERB	O	O	4062
,	PUNCT	O	O	4062
immunohistochemical	ADJ	O	O	4062
,	PUNCT	O	O	4062
ultrastructural	ADJ	O	O	4062
and	CCONJ	O	O	4062
morphometrical	VERB	O	O	4062
analyses	NOUN	O	O	4062
were	AUX	O	O	4062
applied	VERB	O	O	4062
to	PART	O	O	4062
estrogen	PROPN	O	Chemical	4062
-	PUNCT	O	O	4062
induced	VERB	O	O	4062
rat	NOUN	O	O	4062
prolactinoma	PROPN	O	O	4062
cells	NOUN	O	O	4062
1	X	O	O	4062
h	X	O	O	4062
and	CCONJ	O	O	4062
6	NUM	O	O	4062
h	X	O	O	4062
after	ADP	O	O	4062
injection	NOUN	O	O	4062
of	ADP	O	O	4062
bromocriptine	NOUN	O	Chemical	4062
(	PUNCT	O	O	4062
3	X	O	O	4062
mg	VERB	O	O	4062
/	PUNCT	O	O	4062
kg	VERB	O	O	4062
of	ADP	O	O	4062
body	NOUN	O	O	4062
weight	NOUN	O	O	4062
)	PUNCT	O	O	4062
.	PUNCT	O	O	4062
Golgi	PROPN	O	O	4063
cisternae	NOUN	O	O	4063
in	ADP	O	O	4063
the	PRON	O	O	4063
prolactinoma	PROPN	O	O	4063
cells	NOUN	O	O	4063
.	PUNCT	O	O	4063
These	PRON	O	O	4064
findings	NOUN	O	O	4064
suggest	VERB	O	O	4064
that	SCONJ	O	O	4064
lowered	VERB	O	O	4064
serum	NOUN	O	O	4064
prolactin	PROPN	O	O	4064
levels	NOUN	O	O	4064
in	ADP	O	O	4064
the	PRON	O	O	4064
early	ADV	O	O	4064
phase	NOUN	O	O	4064
of	ADP	O	O	4064
bromocriptine	NOUN	O	Chemical	4064
treatment	NOUN	O	O	4064
may	AUX	O	O	4064
result	VERB	O	O	4064
from	ADP	O	O	4064
an	PRON	O	O	4064
impaired	VERB	O	O	4064
secretion	NOUN	O	O	4064
of	ADP	O	O	4064
prolactin	PROPN	O	O	4064
due	ADJ	O	O	4064
to	PART	O	O	4064
decreasing	VERB	O	O	4064
numbers	NOUN	O	O	4064
of	ADP	O	O	4064
cytoplasmic	ADJ	O	O	4064
microtubules	NOUN	O	O	4064
.	PUNCT	O	O	4064
The	PRON	O	O	4065
prolactinoma	PROPN	O	O	4065
cells	NOUN	O	O	4065
at	ADP	O	O	4065
this	PRON	O	O	4065
time	NOUN	O	O	4065
were	AUX	O	O	4065
well	ADV	O	O	4065
granulated	PROPN	O	O	4065
,	PUNCT	O	O	4065
with	ADP	O	O	4065
vesiculated	VERB	O	O	4065
rough	ADJ	O	O	4065
endoplasmic	NOUN	O	O	4065
reticulum	NOUN	O	O	4065
and	CCONJ	O	O	4065
markedly	ADV	O	O	4065
dilated	ADJ	O	O	4065
Golgi	PROPN	O	O	4065
cisternae	NOUN	O	O	4065
.	PUNCT	O	O	4065
Electron	NOUN	O	O	4066
microscopical	ADJ	O	O	4066
immunohistochemistry	NOUN	O	O	4066
revealed	VERB	O	O	4066
positive	ADJ	O	O	4066
reaction	NOUN	O	O	4066
products	NOUN	O	O	4066
noted	VERB	O	O	4066
on	ADP	O	O	4066
the	PRON	O	O	4066
secretory	NOUN	O	O	4066
granules	VERB	O	O	4066
,	PUNCT	O	O	4066
Golgi	PROPN	O	O	4066
cisternae	NOUN	O	O	4066
,	PUNCT	O	O	4066
and	CCONJ	O	O	4066
endoplasmic	NOUN	O	O	4066
reticulum	NOUN	O	O	4066
of	ADP	O	O	4066
the	PRON	O	O	4066
untreated	ADJ	O	O	4066
rat	NOUN	O	O	4066
prolactinoma	PROPN	O	O	4066
cells	NOUN	O	O	4066
.	PUNCT	O	O	4066
However	ADV	O	O	4067
,	PUNCT	O	O	4067
only	ADV	O	O	4067
secretory	NOUN	O	O	4067
granules	VERB	O	O	4067
showed	VERB	O	O	4067
the	PRON	O	O	4067
positive	ADJ	O	O	4067
reaction	NOUN	O	O	4067
products	NOUN	O	O	4067
for	ADP	O	O	4067
prolactin	PROPN	O	O	4067
6	NUM	O	O	4067
h	X	O	O	4067
after	ADP	O	O	4067
bromocriptine	NOUN	O	Chemical	4067
treatment	NOUN	O	O	4067
of	ADP	O	O	4067
the	PRON	O	O	4067
adenoma	INTJ	O	Disease	4067
cells	NOUN	O	O	4067
.	PUNCT	O	O	4067
An	PRON	O	O	4068
increase	VERB	O	O	4068
in	ADP	O	O	4068
the	PRON	O	O	4068
volume	PROPN	O	O	4068
density	NOUN	O	O	4068
of	ADP	O	O	4068
secretory	NOUN	O	O	4068
granules	VERB	O	O	4068
and	CCONJ	O	O	4068
a	PRON	O	O	4068
decrease	VERB	O	O	4068
in	ADP	O	O	4068
the	PRON	O	O	4068
volume	PROPN	O	O	4068
densities	NOUN	O	O	4068
of	ADP	O	O	4068
rough	ADJ	O	O	4068
endoplasmic	NOUN	O	O	4068
reticulum	NOUN	O	O	4068
and	CCONJ	O	O	4068
microtubules	NOUN	O	O	4068
was	AUX	O	O	4068
determined	VERB	O	O	4068
by	ADP	O	O	4068
morphometric	PROPN	O	O	4068
analysis	NOUN	O	O	4068
,	PUNCT	O	O	4068
suggesting	VERB	O	O	4068
that	SCONJ	O	O	4068
bromocriptine	NOUN	O	Chemical	4068
inhibits	VERB	O	O	4068
protein	NOUN	O	O	4068
synthesis	NOUN	O	O	4068
as	ADP	O	O	4068
well	ADV	O	O	4068
as	ADP	O	O	4068
bringing	VERB	O	O	4068
about	ADP	O	O	4068
a	PRON	O	O	4068
disturbance	NOUN	O	O	4068
of	ADP	O	O	4068
the	PRON	O	O	4068
prolactin	PROPN	O	O	4068
secretion	NOUN	O	O	4068
.	PUNCT	O	O	4068
On	ADP	O	O	4071
two	NUM	O	O	4071
paradoxical	ADJ	O	O	4071
side	NOUN	O	O	4071
-	PUNCT	O	O	4071
effects	NOUN	O	O	4071
of	ADP	O	O	4071
prednisolone	NOUN	O	Chemical	4071
in	ADP	O	O	4071
rats	NOUN	O	O	4071
,	PUNCT	O	O	4071
ribosomal	PROPN	O	O	4071
RNA	PROPN	O	O	4071
biosyntheses	NOUN	O	O	4071
,	PUNCT	O	O	4071
and	CCONJ	O	O	4071
a	PRON	O	O	4071
mechanism	NOUN	O	O	4071
of	ADP	O	O	4071
action	NOUN	O	O	4071
.	PUNCT	O	O	4071
Liver	NOUN	O	O	4072
enlargement	NOUN	O	O	4072
and	CCONJ	O	O	4072
muscle	NOUN	O	O	4072
wastage	NOUN	O	O	4072
occurred	VERB	O	O	4072
in	ADP	O	O	4072
Wistar	PROPN	O	O	4072
rats	NOUN	O	O	4072
following	VERB	O	O	4072
the	PRON	O	O	4072
subcutaneous	ADJ	O	O	4072
administration	NOUN	O	O	4072
of	ADP	O	O	4072
prednisolone	NOUN	O	Chemical	4072
.	PUNCT	O	O	4072
This	PRON	O	O	4073
view	VERB	O	O	4073
supports	VERB	O	O	4073
the	PRON	O	O	4073
contention	NOUN	O	O	4073
that	SCONJ	O	O	4073
the	PRON	O	O	4073
liver	NOUN	O	O	4073
and	CCONJ	O	O	4073
muscle	NOUN	O	O	4073
are	AUX	O	O	4073
independent	ADJ	O	O	4073
sites	NOUN	O	O	4073
of	ADP	O	O	4073
prednisolone	NOUN	O	Chemical	4073
action	NOUN	O	O	4073
.	PUNCT	O	O	4073
Possible	ADJ	O	O	4076
intramuscular	ADJ	O	O	4076
midazolam	PROPN	O	Chemical	4076
-	PUNCT	O	O	4076
associated	VERB	O	O	4076
cardiorespiratory arrest	NOUN	O	O	4076
and	CCONJ	O	O	4076
death	NOUN	O	O	4076
.	PUNCT	O	O	4076
Midazolam	PROPN	O	Chemical	4077
hydrochloride	NOUN	O	O	4077
is	AUX	O	O	4077
commonly	ADV	O	O	4077
used	VERB	O	O	4077
for	ADP	O	O	4077
dental	ADJ	O	O	4077
or	CCONJ	O	O	4077
endoscopic	ADJ	O	O	4077
procedures	NOUN	O	O	4077
.	PUNCT	O	O	4077
Although	SCONJ	O	O	4078
generally	ADV	O	O	4078
consisted	VERB	O	O	4078
safe	ADJ	O	O	4078
when	SCONJ	O	O	4078
given	VERB	O	O	4078
intramuscularly	ADV	O	O	4078
,	PUNCT	O	O	4078
intravenous	ADJ	O	O	4078
administration	NOUN	O	O	4078
is	AUX	O	O	4078
known	VERB	O	O	4078
to	PART	O	O	4078
cause	VERB	O	O	4078
respiratory	NOUN	O	O	4078
and	CCONJ	O	O	4078
cardiovascular depression	NOUN	O	Disease	4078
.	PUNCT	O	O	4078
This	PRON	O	O	4079
report	VERB	O	O	4079
describes	VERB	O	O	4079
the	PRON	O	O	4079
first	ADV	O	O	4079
published	VERB	O	O	4079
case	NOUN	O	O	4079
of	ADP	O	O	4079
cardiorespiratory arrest	NOUN	O	O	4079
and	CCONJ	O	O	4079
death	NOUN	O	O	4079
associated	VERB	O	O	4079
with	ADP	O	O	4079
intramuscular	ADJ	O	O	4079
administration	NOUN	O	O	4079
of	ADP	O	O	4079
midazolam	PROPN	O	Chemical	4079
.	PUNCT	O	O	4079
Information	NOUN	O	O	4080
regarding	VERB	O	O	4080
midazolam	PROPN	O	Chemical	4080
use	VERB	O	O	4080
is	AUX	O	O	4080
reviewed	VERB	O	O	4080
to	PART	O	O	4080
provide	VERB	O	O	4080
recommendation	NOUN	O	O	4080
for	ADP	O	O	4080
safe	ADJ	O	O	4080
administration	NOUN	O	O	4080
.	PUNCT	O	O	4080
Serial	ADJ	O	O	4083
epilepsy	NOUN	O	Disease	4083
caused	VERB	O	O	4083
by	ADP	O	O	4083
levodopa	NOUN	O	Chemical	4083
/	PUNCT	O	O	4083
carbidopa	NOUN	O	O	4083
administration	NOUN	O	O	4083
in	ADP	O	O	4083
two	NUM	O	O	4083
patients	NOUN	O	O	4083
on	ADP	O	O	4083
hemodialysis	NOUN	O	O	4083
.	PUNCT	O	O	4083
Two	NUM	O	O	4084
patients	NOUN	O	O	4084
with	ADP	O	O	4084
similar	ADJ	O	O	4084
clinical	ADJ	O	O	4084
features	VERB	O	O	4084
are	AUX	O	O	4084
presented	VERB	O	O	4084
:	PUNCT	O	O	4084
both	PRON	O	O	4084
patients	NOUN	O	O	4084
had	VERB	O	O	4084
chronic	ADJ	O	O	4084
renal failure	NOUN	O	Disease	4084
,	PUNCT	O	O	4084
on	ADP	O	O	4084
hemodialysis	NOUN	O	O	4084
for	ADP	O	O	4084
many	ADJ	O	O	4084
years	NOUN	O	O	4084
but	CCONJ	O	O	4084
recently	ADV	O	O	4084
begun	VERB	O	O	4084
on	ADP	O	O	4084
a	PRON	O	O	4084
high	ADJ	O	O	4084
-	PUNCT	O	O	4084
flux	PROPN	O	O	4084
dialyzer	PROPN	O	O	4084
;	PUNCT	O	O	4084
both	PRON	O	O	4084
had	VERB	O	O	4084
been	AUX	O	O	4084
receiving	VERB	O	O	4084
a	PRON	O	O	4084
carbidopa	NOUN	O	O	4084
/	PUNCT	O	O	4084
levodopa	NOUN	O	Chemical	4084
preparation	NOUN	O	O	4084
;	PUNCT	O	O	4084
and	CCONJ	O	O	4084
both	PRON	O	O	4084
had	VERB	O	O	4084
the	PRON	O	O	4084
onset	VERB	O	O	4084
of	ADP	O	O	4084
hallucinosis	PROPN	O	O	4084
and	CCONJ	O	O	4084
recurrent	ADJ	O	O	4084
seizures	NOUN	O	Disease	4084
,	PUNCT	O	O	4084
which	PRON	O	O	4084
were	AUX	O	O	4084
refractory	ADJ	O	O	4084
to	PART	O	O	4084
anticonvulsants	NOUN	O	O	4084
.	PUNCT	O	O	4084
The	PRON	O	O	4085
first	ADV	O	O	4085
patient	NOUN	O	O	4085
died	VERB	O	O	4085
without	ADP	O	O	4085
a	PRON	O	O	4085
diagnosis	NOUN	O	O	4085
;	PUNCT	O	O	4085
the	PRON	O	O	4085
second	ADV	O	O	4085
patient	NOUN	O	O	4085
had	VERB	O	O	4085
a	PRON	O	O	4085
dramatic	ADJ	O	O	4085
recovery	NOUN	O	O	4085
following	VERB	O	O	4085
the	PRON	O	O	4085
administration	NOUN	O	O	4085
of	ADP	O	O	4085
vitamin	NOUN	O	O	4085
B6	NOUN	O	O	4085
.	PUNCT	O	O	4085
Effect	VERB	O	O	4088
of	ADP	O	O	4088
L	NOUN	O	O	4088
-	PUNCT	O	O	4088
alpha	PROPN	O	O	4088
-	PUNCT	O	O	4088
glyceryl	PROPN	O	O	4088
-	PUNCT	O	O	4088
phosphorylcholine	PROPN	O	O	4088
on	ADP	O	O	4088
amnesia	NOUN	O	Disease	4088
caused	VERB	O	O	4088
by	ADP	O	O	4088
scopolamine	NOUN	O	Chemical	4088
.	PUNCT	O	O	4088
The	PRON	O	O	4089
present	NOUN	O	O	4089
study	VERB	O	O	4089
was	AUX	O	O	4089
carried	VERB	O	O	4089
out	ADP	O	O	4089
to	PART	O	O	4089
test	NOUN	O	O	4089
the	PRON	O	O	4089
effects	NOUN	O	O	4089
of	ADP	O	O	4089
L	NOUN	O	O	4089
-	PUNCT	O	O	4089
alpha	PROPN	O	O	4089
-	PUNCT	O	O	4089
glycerylphosphorylcholine	PROPN	O	O	4089
(	PUNCT	O	O	4089
L	NOUN	O	O	4089
-	PUNCT	O	O	4089
alpha	PROPN	O	O	4089
-	PUNCT	O	O	4089
GFC	PROPN	O	O	4089
)	PUNCT	O	O	4089
on	ADP	O	O	4089
memory impairment	NOUN	O	Disease	4089
induced	VERB	O	O	4089
by	ADP	O	O	4089
scopolamine	NOUN	O	Chemical	4089
in	ADP	O	O	4089
man	NOUN	O	O	4089
.	PUNCT	O	O	4089
They	PRON	O	O	4090
were	AUX	O	O	4090
given	VERB	O	O	4090
a	PRON	O	O	4090
ten	NUM	O	O	4090
day	NOUN	O	O	4090
pretreatment	NOUN	O	O	4090
with	ADP	O	O	4090
either	ADV	O	O	4090
L	NOUN	O	O	4090
-	PUNCT	O	O	4090
alpha	PROPN	O	O	4090
-	PUNCT	O	O	4090
GFC	PROPN	O	O	4090
or	CCONJ	O	O	4090
placebo	NOUN	O	O	4090
,	PUNCT	O	O	4090
p.o	PROPN	O	O	4090
.	PUNCT	O	O	4090
,	PUNCT	O	O	4091
and	CCONJ	O	O	4091
on	ADP	O	O	4091
the	PRON	O	O	4091
eleventh	ADJ	O	O	4091
day	NOUN	O	O	4091
either	ADV	O	O	4091
scopolamine	NOUN	O	Chemical	4091
or	CCONJ	O	O	4091
placebo	NOUN	O	O	4091
,	PUNCT	O	O	4091
i.m	PROPN	O	O	4091
.	PUNCT	O	O	4091
The	PRON	O	O	4092
findings	NOUN	O	O	4092
of	ADP	O	O	4092
this	PRON	O	O	4092
study	VERB	O	O	4092
indicate	VERB	O	O	4092
that	SCONJ	O	O	4092
the	PRON	O	O	4092
drug	NOUN	O	O	4092
is	AUX	O	O	4092
able	ADJ	O	O	4092
to	PART	O	O	4092
antagonize	VERB	O	O	4092
impairment	NOUN	O	O	4092
of	ADP	O	O	4092
attention	NOUN	O	O	4092
and	CCONJ	O	O	4092
memory	NOUN	O	O	4092
induced	VERB	O	O	4092
by	ADP	O	O	4092
scopolamine	NOUN	O	Chemical	4092
.	PUNCT	O	O	4092
Seizures	NOUN	O	Disease	4095
induced	VERB	O	O	4095
by	ADP	O	O	4095
the	PRON	O	O	4095
cocaine	NOUN	O	Chemical	4095
metabolite	NOUN	O	O	4095
benzoylecgonine	ADJ	O	Chemical	4095
in	ADP	O	O	4095
rats	NOUN	O	O	4095
.	PUNCT	O	O	4095
The	PRON	O	O	4096
half	NOUN	O	O	4096
-	PUNCT	O	O	4096
life	NOUN	O	O	4096
(	PUNCT	O	O	4096
t1/2	NUM	O	O	4096
)	PUNCT	O	O	4096
of	ADP	O	O	4096
cocaine	NOUN	O	Chemical	4096
is	AUX	O	O	4096
relatively	ADV	O	O	4096
short	ADJ	O	O	4096
,	PUNCT	O	O	4096
but	CCONJ	O	O	4096
some	PRON	O	O	4096
of	ADP	O	O	4096
the	PRON	O	O	4096
consequences	NOUN	O	O	4096
of	ADP	O	O	4096
its	PRON	O	O	4096
use	VERB	O	O	4096
,	PUNCT	O	O	4096
such	ADJ	O	O	4096
as	ADP	O	O	4096
seizures	NOUN	O	Disease	4096
and	CCONJ	O	O	4096
strokes	NOUN	O	Disease	4096
,	PUNCT	O	O	4096
can	AUX	O	O	4096
occur	VERB	O	O	4096
hours	NOUN	O	O	4096
after	ADP	O	O	4096
exposure	NOUN	O	O	4096
.	PUNCT	O	O	4096
This	PRON	O	O	4097
led	VERB	O	O	4097
us	PRON	O	O	4097
to	PART	O	O	4097
hypothesize	VERB	O	O	4097
that	SCONJ	O	O	4097
a	PRON	O	O	4097
metabolite	NOUN	O	O	4097
of	ADP	O	O	4097
cocaine	NOUN	O	Chemical	4097
may	AUX	O	O	4097
be	AUX	O	O	4097
responsible	ADJ	O	O	4097
for	ADP	O	O	4097
some	PRON	O	O	4097
of	ADP	O	O	4097
those	PRON	O	O	4097
delayed	VERB	O	O	4097
sequelae	ADJ	O	O	4097
.	PUNCT	O	O	4097
We	PRON	O	O	4098
evaluated	VERB	O	O	4098
the	PRON	O	O	4098
potential	ADJ	O	O	4098
of	ADP	O	O	4098
the	PRON	O	O	4098
major	ADJ	O	O	4098
metabolite	NOUN	O	O	4098
of	ADP	O	O	4098
cocaine	NOUN	O	Chemical	4098
,	PUNCT	O	O	4098
benzoylecgonine	ADJ	O	Chemical	4098
(	PUNCT	O	O	4098
BE	AUX	O	O	4098
)	PUNCT	O	O	4098
,	PUNCT	O	O	4098
to	PART	O	O	4098
cause	VERB	O	O	4098
seizures	NOUN	O	Disease	4098
.	PUNCT	O	O	4098
Two	NUM	O	O	4099
separate	VERB	O	O	4099
equimolar	NOUN	O	O	4099
doses	NOUN	O	O	4099
(	PUNCT	O	O	4099
0.2	NUM	O	O	4099
and	CCONJ	O	O	4099
0.4	NUM	O	O	4099
mumol	PROPN	O	O	4099
)	PUNCT	O	O	4099
of	ADP	O	O	4099
either	ADV	O	O	4099
cocaine	NOUN	O	Chemical	4099
or	CCONJ	O	O	4099
BE	AUX	O	O	4099
were	AUX	O	O	4099
injected	VERB	O	O	4099
ventricularly	NOUN	O	O	4099
in	ADP	O	O	4099
unanesthetized	ADJ	O	O	4099
juvenile	NOUN	O	O	4099
rats	NOUN	O	O	4099
.	PUNCT	O	O	4099
Treated	VERB	O	O	4100
rats	NOUN	O	O	4100
were	AUX	O	O	4100
then	ADV	O	O	4100
evaluated	VERB	O	O	4100
for	ADP	O	O	4100
incidence	NOUN	O	O	4100
,	PUNCT	O	O	4100
latency	VERB	O	O	4100
,	PUNCT	O	O	4100
and	CCONJ	O	O	4100
seizure	NOUN	O	Disease	4100
pattern	NOUN	O	O	4100
or	CCONJ	O	O	4100
for	ADP	O	O	4100
locomotor	PROPN	O	O	4100
activity	NOUN	O	O	4100
in	ADP	O	O	4100
animals	NOUN	O	O	4100
without	ADP	O	O	4100
seizures	NOUN	O	Disease	4100
.	PUNCT	O	O	4100
BE	AUX	O	O	4101
-	PUNCT	O	O	4101
Induced	VERB	O	O	4101
seizures	NOUN	O	Disease	4101
occurred	VERB	O	O	4101
more	ADJ	O	O	4101
frequently	ADV	O	O	4101
and	CCONJ	O	O	4101
had	VERB	O	O	4101
significantly	ADV	O	O	4101
longer	ADV	O	O	4101
latencies	NOUN	O	O	4101
than	ADP	O	O	4101
those	PRON	O	O	4101
induced	VERB	O	O	4101
by	ADP	O	O	4101
equimolar	NOUN	O	O	4101
amounts	VERB	O	O	4101
of	ADP	O	O	4101
cocaine	NOUN	O	Chemical	4101
.	PUNCT	O	O	4101
Whereas	SCONJ	O	O	4102
cocaine	NOUN	O	Chemical	4102
-	PUNCT	O	O	4102
induced	VERB	O	O	4102
seizures	NOUN	O	Disease	4102
were	AUX	O	O	4102
best	ADV	O	O	4102
characterized	VERB	O	O	4102
as	ADP	O	O	4102
brief	PROPN	O	O	4102
,	PUNCT	O	O	4102
generalized	VERB	O	O	4102
,	PUNCT	O	O	4102
and	CCONJ	O	O	4102
tonic	PROPN	O	O	4102
and	CCONJ	O	O	4102
resulted	VERB	O	O	4102
in	ADP	O	O	4102
death	NOUN	O	O	4102
,	PUNCT	O	O	4102
those	PRON	O	O	4102
induced	VERB	O	O	4102
by	ADP	O	O	4102
BE	AUX	O	O	4102
were	AUX	O	O	4102
prolonged	VERB	O	O	4102
,	PUNCT	O	O	4102
often	ADV	O	O	4102
multiple	ADJ	O	O	4102
and	CCONJ	O	O	4102
mixed	VERB	O	O	4102
in	ADP	O	O	4102
type	NOUN	O	O	4102
,	PUNCT	O	O	4102
and	CCONJ	O	O	4102
rarely	ADV	O	O	4102
resulted	VERB	O	O	4102
in	ADP	O	O	4102
death	NOUN	O	O	4102
.	PUNCT	O	O	4102
Electrical	ADJ	O	O	4103
recordings	NOUN	O	O	4103
from	ADP	O	O	4103
the	PRON	O	O	4103
hippocampus	NOUN	O	O	4103
showed	VERB	O	O	4103
a	PRON	O	O	4103
rhythmic	ADJ	O	O	4103
progression	NOUN	O	O	4103
in	ADP	O	O	4103
EEG	NOUN	O	O	4103
frequency	NOUN	O	O	4103
and	CCONJ	O	O	4103
voltage	NOUN	O	O	4103
with	ADP	O	O	4103
clinical	ADJ	O	O	4103
seizure	NOUN	O	Disease	4103
expression	NOUN	O	O	4103
.	PUNCT	O	O	4103
BE	AUX	O	O	4104
-	PUNCT	O	O	4104
Injected	VERB	O	O	4104
rats	NOUN	O	O	4104
that	SCONJ	O	O	4104
did	VERB	O	O	4104
not	PART	O	O	4104
have	VERB	O	O	4104
seizures	NOUN	O	Disease	4104
had	VERB	O	O	4104
significantly	ADV	O	O	4104
more	ADJ	O	O	4104
locomotor	PROPN	O	O	4104
activity	NOUN	O	O	4104
than	ADP	O	O	4104
cocaine	NOUN	O	Chemical	4104
-	PUNCT	O	O	4104
injected	VERB	O	O	4104
animals	NOUN	O	O	4104
without	ADP	O	O	4104
seizures	NOUN	O	Disease	4104
.	PUNCT	O	O	4104
The	PRON	O	O	4105
finding	VERB	O	O	4105
that	SCONJ	O	O	4105
cocaine-	NOUN	O	O	4105
and	CCONJ	O	O	4105
BE	AUX	O	O	4105
-	PUNCT	O	O	4105
induced	VERB	O	O	4105
seizures	NOUN	O	Disease	4105
differ	VERB	O	O	4105
in	ADP	O	O	4105
several	ADJ	O	O	4105
respects	VERB	O	O	4105
suggests	VERB	O	O	4105
more	ADJ	O	O	4105
than	ADP	O	O	4105
one	NUM	O	O	4105
mechanism	NOUN	O	O	4105
for	ADP	O	O	4105
cocaine	NOUN	O	Chemical	4105
-	PUNCT	O	O	4105
induced	VERB	O	O	4105
seizures	NOUN	O	Disease	4105
and	CCONJ	O	O	4105
emphasizes	VERB	O	O	4105
the	PRON	O	O	4105
importance	NOUN	O	O	4105
of	ADP	O	O	4105
a	PRON	O	O	4105
cocaine	NOUN	O	Chemical	4105
metabolite	NOUN	O	O	4105
,	PUNCT	O	O	4105
BE	AUX	O	O	4105
.	PUNCT	O	O	4105
Protection	NOUN	O	O	4108
against	ADP	O	O	4108
amphetamine	NOUN	O	Chemical	4108
-	PUNCT	O	O	4108
induced	VERB	O	O	4108
neurotoxicity	NOUN	O	Disease	4108
toward	ADP	O	O	4108
striatal	ADJ	O	O	4108
dopamine	NOUN	O	Chemical	4108
neurons	NOUN	O	O	4108
in	ADP	O	O	4108
rodents	NOUN	O	O	4108
by	ADP	O	O	4108
LY274614	PROPN	O	O	4108
,	PUNCT	O	O	4108
an	PRON	O	O	4108
excitatory	ADJ	O	O	4108
amino acid	NOUN	O	Chemical	4108
antagonist	NOUN	O	O	4108
.	PUNCT	O	O	4108
LY274614	PROPN	O	O	4109
,	PUNCT	O	O	4109
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr	NUM	O	O	4109
oisoquinoline-3-	PROPN	O	O	4109
carboxylic	ADV	O	O	4109
acid	PROPN	O	O	4109
,	PUNCT	O	O	4109
has	VERB	O	O	4109
been	AUX	O	O	4109
described	VERB	O	O	4109
as	ADP	O	O	4109
a	PRON	O	O	4109
potent	ADJ	O	O	4109
antagonist	NOUN	O	O	4109
of	ADP	O	O	4109
the	PRON	O	O	4109
N	NUM	O	O	4109
-	PUNCT	O	O	4109
methyl	NOUN	O	O	4109
-	PUNCT	O	O	4109
D	NOUN	O	O	4109
-	PUNCT	O	O	4109
aspartate	NOUN	O	Chemical	4109
(	PUNCT	O	O	4109
NMDA	PROPN	O	Chemical	4109
)	PUNCT	O	O	4109
subtype	NOUN	O	O	4110
of	ADP	O	O	4110
glutamate	NOUN	O	Chemical	4110
receptor	NOUN	O	O	4110
.	PUNCT	O	O	4110
Here	ADV	O	O	4111
its	PRON	O	O	4111
ability	NOUN	O	O	4111
to	PART	O	O	4111
antagonize	VERB	O	O	4111
the	PRON	O	O	4111
prolonged	VERB	O	O	4111
depletion	NOUN	O	O	4111
of	ADP	O	O	4111
dopamine	NOUN	O	Chemical	4111
in	ADP	O	O	4111
the	PRON	O	O	4111
striatum	NOUN	O	O	4111
by	ADP	O	O	4111
amphetamine	NOUN	O	Chemical	4111
in	ADP	O	O	4111
iprindole	ADJ	O	O	4111
-	PUNCT	O	O	4111
treated	VERB	O	O	4111
rats	NOUN	O	O	4111
is	AUX	O	O	4111
reported	VERB	O	O	4111
.	PUNCT	O	O	4111
dose	NOUN	O	O	4112
of	ADP	O	O	4112
(	PUNCT	O	O	4112
+	ADP	O	O	4112
/-)-amphetamine	PUNCT	O	O	4112
hemisulfate	NOUN	O	O	4112
,	PUNCT	O	O	4112
given	VERB	O	O	4112
to	PART	O	O	4112
rats	NOUN	O	O	4112
pretreated	VERB	O	O	4112
with	ADP	O	O	4112
iprindole	ADJ	O	O	4112
,	PUNCT	O	O	4112
resulted	VERB	O	O	4112
in	ADP	O	O	4112
persistent	ADJ	O	O	4112
depletion	NOUN	O	O	4112
of	ADP	O	O	4112
dopamine	NOUN	O	Chemical	4112
in	ADP	O	O	4112
the	PRON	O	O	4112
striatum	NOUN	O	O	4112
1	X	O	O	4112
week	NOUN	O	O	4112
later	ADV	O	O	4112
.	PUNCT	O	O	4112
This	PRON	O	O	4113
prolonged	VERB	O	O	4113
depletion	NOUN	O	O	4113
of	ADP	O	O	4113
dopamine	NOUN	O	Chemical	4113
in	ADP	O	O	4113
the	PRON	O	O	4113
striatum	NOUN	O	O	4113
was	AUX	O	O	4113
antagonized	VERB	O	O	4113
by	ADP	O	O	4113
dizocilpine	PROPN	O	Chemical	4113
(	PUNCT	O	O	4113
MK-801	PROPN	O	Chemical	4113
,	PUNCT	O	O	4113
a	PRON	O	O	4113
non	ADJ	O	O	4113
-	PUNCT	O	O	4113
competitive	ADJ	O	O	4113
antagonist	NOUN	O	O	4113
of	ADP	O	O	4113
NMDA	PROPN	O	Chemical	4113
receptors	NOUN	O	O	4113
)	PUNCT	O	O	4113
or	CCONJ	O	O	4113
by	ADP	O	O	4113
LY274614	PROPN	O	O	4113
(	PUNCT	O	O	4113
a	PRON	O	O	4113
competitive	ADJ	O	O	4113
antagonist	NOUN	O	O	4113
of	ADP	O	O	4113
NMDA	PROPN	O	Chemical	4113
receptors	NOUN	O	O	4113
)	PUNCT	O	O	4113
.	PUNCT	O	O	4113
The	PRON	O	O	4114
protective	ADJ	O	O	4114
effect	VERB	O	O	4114
of	ADP	O	O	4114
LY274614	PROPN	O	O	4114
was	AUX	O	O	4114
dose	NOUN	O	O	4114
-	PUNCT	O	O	4114
dependent	ADJ	O	O	4114
,	PUNCT	O	O	4114
being	AUX	O	O	4114
maximum	ADV	O	O	4114
at	ADP	O	O	4114
10	NUM	O	O	4114
-	PUNCT	O	O	4114
40	NUM	O	O	4114
mgkg	PROPN	O	O	4114
(	PUNCT	O	O	4114
i.p	NOUN	O	O	4114
.	PUNCT	O	O	4114
)	PUNCT	O	O	4114
.	PUNCT	O	O	4114
A	PRON	O	O	4115
10	NUM	O	O	4115
mg	VERB	O	O	4115
/	PUNCT	O	O	4115
kg	VERB	O	O	4115
dose	NOUN	O	O	4115
of	ADP	O	O	4115
LY274614	PROPN	O	O	4115
was	AUX	O	O	4115
effective	ADJ	O	O	4115
in	ADP	O	O	4115
antagonizing	VERB	O	O	4115
the	PRON	O	O	4115
depletion	NOUN	O	O	4115
of	ADP	O	O	4115
dopamine	NOUN	O	Chemical	4115
in	ADP	O	O	4115
the	PRON	O	O	4115
striatum	NOUN	O	O	4115
,	PUNCT	O	O	4115
when	SCONJ	O	O	4115
given	VERB	O	O	4115
as	ADP	O	O	4115
long	ADV	O	O	4115
as	ADP	O	O	4115
8	NUM	O	O	4115
hr	NOUN	O	O	4115
prior	ADV	O	O	4115
to	PART	O	O	4115
amphetamine	NOUN	O	Chemical	4115
but	CCONJ	O	O	4115
not	PART	O	O	4115
when	SCONJ	O	O	4115
given	VERB	O	O	4115
24	NUM	O	O	4115
hr	NOUN	O	O	4115
prior	ADV	O	O	4115
to	PART	O	O	4115
amphetamine	NOUN	O	Chemical	4115
.	PUNCT	O	O	4115
Depletion	NOUN	O	O	4116
of	ADP	O	O	4116
dopamine	NOUN	O	Chemical	4116
in	ADP	O	O	4116
the	PRON	O	O	4116
striatum	NOUN	O	O	4116
was	AUX	O	O	4116
also	ADV	O	O	4116
antagonized	VERB	O	O	4116
when	SCONJ	O	O	4116
LY274614	PROPN	O	O	4116
was	AUX	O	O	4116
given	VERB	O	O	4116
after	ADP	O	O	4116
the	PRON	O	O	4116
injection	NOUN	O	O	4116
of	ADP	O	O	4116
amphetamine	NOUN	O	Chemical	4116
;	PUNCT	O	O	4116
LY274614	PROPN	O	O	4116
protected	VERB	O	O	4116
when	SCONJ	O	O	4116
given	VERB	O	O	4116
up	ADP	O	O	4116
to	PART	O	O	4116
4	NUM	O	O	4116
hr	NOUN	O	O	4116
after	ADP	O	O	4116
but	CCONJ	O	O	4116
not	PART	O	O	4116
when	SCONJ	O	O	4116
given	VERB	O	O	4116
8	NUM	O	O	4116
or	CCONJ	O	O	4116
24	NUM	O	O	4116
hr	NOUN	O	O	4116
after	ADP	O	O	4116
amphetamine	NOUN	O	Chemical	4116
.	PUNCT	O	O	4116
The	PRON	O	O	4117
prolonged	VERB	O	O	4117
depletion	NOUN	O	O	4117
of	ADP	O	O	4117
dopamine	NOUN	O	Chemical	4117
in	ADP	O	O	4117
the	PRON	O	O	4117
striatum	NOUN	O	O	4117
in	ADP	O	O	4117
mice	NOUN	O	O	4117
,	PUNCT	O	O	4117
given	VERB	O	O	4117
multiple	ADJ	O	O	4117
injections	NOUN	O	O	4117
of	ADP	O	O	4117
methamphetamine	NOUN	O	Chemical	4117
,	PUNCT	O	O	4117
was	AUX	O	O	4117
also	ADV	O	O	4117
antagonized	VERB	O	O	4117
dose	NOUN	O	O	4117
-	PUNCT	O	O	4117
dependently	ADV	O	O	4117
and	CCONJ	O	O	4117
completely	ADV	O	O	4117
by	ADP	O	O	4117
LY274614	PROPN	O	O	4117
.	PUNCT	O	O	4117
The	PRON	O	O	4118
data	NOUN	O	O	4118
strengthen	VERB	O	O	4118
the	PRON	O	O	4118
evidence	NOUN	O	O	4118
that	SCONJ	O	O	4118
the	PRON	O	O	4118
neurotoxic	ADJ	O	Disease	4118
effect	VERB	O	O	4118
of	ADP	O	O	4118
amphetamine	NOUN	O	Chemical	4118
and	CCONJ	O	O	4118
related	ADJ	O	O	4118
compounds	NOUN	O	O	4118
toward	ADP	O	O	4118
nigrostriatal	NOUN	O	O	4118
dopamine	NOUN	O	Chemical	4118
neurons	NOUN	O	O	4118
involves	VERB	O	O	4118
NMDA	PROPN	O	Chemical	4118
receptors	NOUN	O	O	4118
and	CCONJ	O	O	4118
that	SCONJ	O	O	4118
LY274614	PROPN	O	O	4118
is	AUX	O	O	4118
an	PRON	O	O	4118
NMDA	PROPN	O	Chemical	4118
receptor	NOUN	O	O	4118
antagonist	NOUN	O	O	4118
with	ADP	O	O	4118
long	ADV	O	O	4118
-	PUNCT	O	O	4118
lasting	VERB	O	O	4118
in	ADP	O	O	4118
vivo	VERB	O	O	4118
effects	NOUN	O	O	4118
in	ADP	O	O	4118
rats	NOUN	O	O	4118
.	PUNCT	O	O	4118
Neonatal	NOUN	O	O	4121
pyridoxine	NOUN	O	O	4121
responsive	ADJ	O	O	4121
convulsions	NOUN	O	Disease	4121
due	ADJ	O	O	4121
to	PART	O	O	4121
isoniazid	NOUN	O	Chemical	4121
therapy	NOUN	O	O	4121
.	PUNCT	O	O	4121
A	PRON	O	O	4122
17-day	NOUN	O	O	4122
-	PUNCT	O	O	4122
old	ADJ	O	O	4122
infant	NOUN	O	O	4122
on	ADP	O	O	4122
isoniazid	NOUN	O	Chemical	4122
therapy	NOUN	O	O	4122
13	NUM	O	O	4123
mg	VERB	O	O	4123
/	PUNCT	O	O	4123
kg	VERB	O	O	4123
daily	ADV	O	O	4123
from	ADP	O	O	4123
birth	NOUN	O	O	4123
because	SCONJ	O	O	4123
of	ADP	O	O	4123
maternal	ADJ	O	O	4123
tuberculosis	NOUN	O	Disease	4123
was	AUX	O	O	4123
admitted	VERB	O	O	4123
after	ADP	O	O	4123
4	NUM	O	O	4123
days	NOUN	O	O	4123
of	ADP	O	O	4123
clonic	ADJ	O	O	4123
fits	VERB	O	O	4123
.	PUNCT	O	O	4123
The	PRON	O	O	4124
fits	VERB	O	O	4124
ceased	VERB	O	O	4124
within	ADP	O	O	4124
4	NUM	O	O	4124
hours	NOUN	O	O	4124
of	ADP	O	O	4124
administering	VERB	O	O	4124
intramuscular	ADJ	O	O	4124
pyridoxine	NOUN	O	O	4124
,	PUNCT	O	O	4124
suggesting	VERB	O	O	4124
an	PRON	O	O	4124
aetiology	NOUN	O	O	4124
of	ADP	O	O	4124
pyridoxine	NOUN	O	O	4124
deficiency	NOUN	O	O	4124
secondary	ADJ	O	O	4124
to	PART	O	O	4124
isoniazid	NOUN	O	Chemical	4124
medication	NOUN	O	O	4124
.	PUNCT	O	O	4124
Reversal	NOUN	O	O	4127
by	ADP	O	O	4127
phenylephrine	NOUN	O	Chemical	4127
of	ADP	O	O	4127
the	PRON	O	O	4127
beneficial	ADJ	O	O	4127
effects	NOUN	O	O	4127
of	ADP	O	O	4127
intravenous	ADJ	O	O	4127
nitroglycerin	PROPN	O	Chemical	4127
in	ADP	O	O	4127
patients	NOUN	O	O	4127
with	ADP	O	O	4127
acute	ADJ	O	O	4127
myocardial infarction	NOUN	O	Disease	4127
.	PUNCT	O	O	4127
Nitroglycerin	PROPN	O	O	4128
has	VERB	O	O	4128
been	AUX	O	O	4128
shown	VERB	O	O	4128
to	PART	O	O	4128
reduce	VERB	O	O	4128
ST	PROPN	O	O	4128
-	PUNCT	O	O	4128
segment	NOUN	O	O	4128
elevation	NOUN	O	O	4128
during	ADP	O	O	4128
acute	ADJ	O	O	4128
myocardial infarction	NOUN	O	Disease	4128
,	PUNCT	O	O	4128
an	PRON	O	O	4128
effect	VERB	O	O	4128
potentiated	VERB	O	O	4128
in	ADP	O	O	4128
the	PRON	O	O	4128
dog	NOUN	O	O	4128
by	ADP	O	O	4128
agents	NOUN	O	O	4128
that	SCONJ	O	O	4128
reverse	VERB	O	O	4128
nitroglycerin	PROPN	O	Chemical	4128
-	PUNCT	O	O	4128
induced	VERB	O	O	4128
hypotension	NOUN	O	Disease	4128
.	PUNCT	O	O	4128
Our	PRON	O	O	4129
study	VERB	O	O	4129
was	AUX	O	O	4129
designed	VERB	O	O	4129
to	PART	O	O	4129
determine	VERB	O	O	4129
the	PRON	O	O	4129
effects	NOUN	O	O	4129
of	ADP	O	O	4129
combined	VERB	O	O	4129
nitroglycerin	PROPN	O	Chemical	4129
and	CCONJ	O	O	4129
phenylephrine	NOUN	O	Chemical	4129
therapy	NOUN	O	O	4129
.	PUNCT	O	O	4129
Ten	NUM	O	O	4130
patients	NOUN	O	O	4130
with	ADP	O	O	4130
acute	ADJ	O	O	4130
transmural	ADJ	O	O	4130
myocardial infarctions	NOUN	O	O	4130
received	VERB	O	O	4130
intravenous	ADJ	O	O	4130
nitroglycerin	PROPN	O	Chemical	4130
,	PUNCT	O	O	4130
sufficient	ADJ	O	O	4130
to	PART	O	O	4130
reduce	VERB	O	O	4130
mean	VERB	O	O	4130
arterial	ADJ	O	O	4130
pressure	NOUN	O	O	4130
from	ADP	O	O	4130
107	NUM	O	O	4130
+	ADP	O	O	4130
/-	PUNCT	O	O	4130
SigmaST	PUNCT	O	O	4131
,	PUNCT	O	O	4131
the	PRON	O	O	4131
sum	NOUN	O	O	4131
of	ADP	O	O	4131
ST	PROPN	O	O	4131
-	PUNCT	O	O	4131
segment	NOUN	O	O	4131
elevations	NOUN	O	O	4131
in	ADP	O	O	4131
16	NUM	O	O	4131
precordial	ADJ	O	O	4131
leads	VERB	O	O	4131
,	PUNCT	O	O	4131
decreased	VERB	O	O	4131
(	PUNCT	O	O	4131
P	NOUN	O	Chemical	4131
less	ADV	O	O	4131
than	ADP	O	O	4131
0.02	NUM	O	O	4131
)	PUNCT	O	O	4131
with	ADP	O	O	4131
intravenous	ADJ	O	O	4131
nitroglycerin	PROPN	O	Chemical	4131
.	PUNCT	O	O	4131
Subsequent	PROPN	O	O	4132
addition	NOUN	O	O	4132
of	ADP	O	O	4132
phenylephrine	NOUN	O	Chemical	4132
infusion	NOUN	O	O	4132
,	PUNCT	O	O	4132
sufficient	ADJ	O	O	4132
to	PART	O	O	4132
re	ADP	O	O	4132
-	PUNCT	O	O	4132
elevate	VERB	O	O	4132
mean	VERB	O	O	4132
arterial	ADJ	O	O	4132
pressure	NOUN	O	O	4132
to	PART	O	O	4132
106	NUM	O	O	4132
+	ADP	O	O	4132
/-	PUNCT	O	O	4132
Our	PRON	O	O	4133
results	VERB	O	O	4133
suggest	VERB	O	O	4133
that	SCONJ	O	O	4133
addition	NOUN	O	O	4133
of	ADP	O	O	4133
phenylephrine	NOUN	O	Chemical	4133
to	PART	O	O	4133
nitroglycerin	PROPN	O	Chemical	4133
is	AUX	O	O	4133
not	PART	O	O	4133
beneficial	ADJ	O	O	4133
in	ADP	O	O	4133
the	PRON	O	O	4133
treatment	NOUN	O	O	4133
of	ADP	O	O	4133
patients	NOUN	O	O	4133
with	ADP	O	O	4133
acute	ADJ	O	O	4133
myocardial infarction	NOUN	O	Disease	4133
.	PUNCT	O	O	4133
Elevation	NOUN	O	O	4136
of	ADP	O	O	4136
ADAM10	PUNCT	O	O	4136
,	PUNCT	O	O	4136
ADAM17	X	O	O	4136
,	PUNCT	O	O	4136
MMP-2	NOUN	O	O	4136
and	CCONJ	O	O	4136
MMP-9	ADJ	O	O	4136
expression	NOUN	O	O	4136
with	ADP	O	O	4136
media	NOUN	O	O	4136
degeneration	NOUN	O	O	4136
features	VERB	O	O	4136
CaCl2-induced	VERB	O	O	4136
thoracic	ADJ	O	O	4136
aortic	ADJ	O	O	4136
aneurysm	PROPN	O	O	4136
in	ADP	O	O	4136
a	PRON	O	O	4136
rat	NOUN	O	O	4136
model	NOUN	O	O	4136
.	PUNCT	O	O	4136
This	PRON	O	O	4137
study	VERB	O	O	4137
was	AUX	O	O	4137
designed	VERB	O	O	4137
to	PART	O	O	4137
establish	VERB	O	O	4137
a	PRON	O	O	4137
rat	NOUN	O	O	4137
model	NOUN	O	O	4137
of	ADP	O	O	4137
thoracic	ADJ	O	O	4137
aortic	ADJ	O	O	4137
aneurysm	PROPN	O	O	4137
(	PUNCT	O	O	4137
TAA	X	O	O	4137
)	PUNCT	O	O	4137
by	ADP	O	O	4137
calcium chloride	NOUN	O	Chemical	4137
(	PUNCT	O	O	4137
CaCl(2))-induced	VERB	O	O	4137
arterial	ADJ	O	O	4137
injury	NOUN	O	O	4137
and	CCONJ	O	O	4137
to	PART	O	O	4137
explore	VERB	O	O	4137
the	PRON	O	O	4137
potential	ADJ	O	O	4137
role	NOUN	O	O	4137
of	ADP	O	O	4137
a	PRON	O	O	4137
disintegrin	VERB	O	O	4137
and	CCONJ	O	O	4137
metalloproteinase	NOUN	O	O	4137
(	PUNCT	O	O	4137
ADAM	PROPN	O	O	4137
)	PUNCT	O	O	4137
,	PUNCT	O	O	4137
matrix	NOUN	O	O	4137
metalloproteinases	NOUN	O	O	4137
(	PUNCT	O	O	4137
MMPs	NOUN	O	O	4137
)	PUNCT	O	O	4137
and	CCONJ	O	O	4137
their	PRON	O	O	4137
endogenous	ADJ	O	O	4137
inhibitors	NOUN	O	O	4137
(	PUNCT	O	O	4137
TIMPs	NOUN	O	O	4137
)	PUNCT	O	O	4137
in	ADP	O	O	4137
TAA	X	O	O	4137
formation	NOUN	O	O	4137
.	PUNCT	O	O	4137
Thoracic	NOUN	O	O	4138
aorta	NOUN	O	O	4138
of	ADP	O	O	4138
male	NOUN	O	O	4138
Sprague	PROPN	O	O	4138
-	PUNCT	O	O	4138
Dawley	NOUN	O	O	4138
rats	NOUN	O	O	4138
was	AUX	O	O	4138
exposed	VERB	O	O	4138
to	PART	O	O	4138
0.5	NUM	O	O	4138
M	NOUN	O	Chemical	4138
CaCl(2	ADP	O	O	4138
)	PUNCT	O	O	4138
or	CCONJ	O	O	4138
normal	ADJ	O	O	4138
saline	NOUN	O	O	4138
(	PUNCT	O	O	4138
NaCl	NOUN	O	O	4138
)	PUNCT	O	O	4138
.	PUNCT	O	O	4138
After	ADP	O	O	4139
12weeks	X	O	O	4139
,	PUNCT	O	O	4139
animals	NOUN	O	O	4139
were	AUX	O	O	4139
euthanized	VERB	O	O	4139
,	PUNCT	O	O	4139
and	CCONJ	O	O	4139
CaCl(2)-treated	VERB	O	O	4139
,	PUNCT	O	O	4139
CaCl(2)-untreated	VERB	O	O	4139
(	PUNCT	O	O	4139
n=12	ADV	O	O	4139
)	PUNCT	O	O	4139
and	CCONJ	O	O	4139
NaCl	NOUN	O	O	4140
-	PUNCT	O	O	4140
treated	VERB	O	O	4140
aortic	ADJ	O	O	4140
segments	NOUN	O	O	4140
(	PUNCT	O	O	4140
n=12	ADV	O	O	4140
)	PUNCT	O	O	4140
were	AUX	O	O	4140
collected	VERB	O	O	4140
for	ADP	O	O	4140
histological	ADJ	O	O	4140
and	CCONJ	O	O	4140
molecular	ADJ	O	O	4140
assessments	NOUN	O	O	4140
.	PUNCT	O	O	4140
Despite	SCONJ	O	O	4141
similar	ADJ	O	O	4141
external	ADJ	O	O	4141
diameters	NOUN	O	O	4141
among	ADP	O	O	4141
CaCl(2)-treated	VERB	O	O	4141
,	PUNCT	O	O	4141
non	ADJ	O	O	4141
-	PUNCT	O	O	4141
CaCl(2)-treated	VERB	O	O	4141
and	CCONJ	O	O	4141
NaCl	NOUN	O	O	4141
-	PUNCT	O	O	4141
treated	VERB	O	O	4141
segments	NOUN	O	O	4141
,	PUNCT	O	O	4141
aneurymal	VERB	O	O	4141
alteration	NOUN	O	O	4141
(	PUNCT	O	O	4141
n=6	NOUN	O	O	4141
,	PUNCT	O	O	4141
50%	NOUN	O	O	4141
)	PUNCT	O	O	4141
,	PUNCT	O	O	4141
media	NOUN	O	O	4141
degeneration	NOUN	O	O	4141
with	ADP	O	O	4141
regional	ADJ	O	O	4141
disruption	NOUN	O	O	4141
,	PUNCT	O	O	4141
fragmentation	NOUN	O	O	4141
of	ADP	O	O	4141
elastic	ADJ	O	O	4141
fiber	PROPN	O	O	4141
,	PUNCT	O	O	4141
and	CCONJ	O	O	4141
increased	VERB	O	O	4141
collagen	NOUN	O	O	4141
deposition	NOUN	O	O	4141
(	PUNCT	O	O	4141
n=12	ADV	O	O	4141
,	PUNCT	O	O	4141
100%	NOUN	O	O	4141
)	PUNCT	O	O	4141
were	AUX	O	O	4141
demonstrated	VERB	O	O	4141
in	ADP	O	O	4141
CaCl(2)-treated	VERB	O	O	4141
segments	NOUN	O	O	4141
.	PUNCT	O	O	4141
MMP-2	NOUN	O	O	4142
,	PUNCT	O	O	4142
MMP-9	ADJ	O	O	4142
,	PUNCT	O	O	4142
ADAM-10	PROPN	O	O	4142
and	CCONJ	O	O	4142
ADAM-17	NOUN	O	O	4142
mRNA	PROPN	O	O	4142
levels	NOUN	O	O	4142
were	AUX	O	O	4142
increased	VERB	O	O	4142
in	ADP	O	O	4142
CaCl(2)-treated	VERB	O	O	4142
segments	NOUN	O	O	4142
(	PUNCT	O	O	4142
all	PRON	O	O	4142
p<0.01	ADV	O	O	4142
)	PUNCT	O	O	4142
,	PUNCT	O	O	4142
with	ADP	O	O	4142
trends	NOUN	O	O	4142
of	ADP	O	O	4142
elevation	NOUN	O	O	4142
in	ADP	O	O	4142
CaCl(2)-untreated	VERB	O	O	4142
segments	NOUN	O	O	4142
,	PUNCT	O	O	4142
as	ADP	O	O	4142
compared	VERB	O	O	4142
with	ADP	O	O	4142
NaCl	NOUN	O	O	4142
-	PUNCT	O	O	4142
treated	VERB	O	O	4142
segments	NOUN	O	O	4142
.	PUNCT	O	O	4142
Immunohistochemistry	NOUN	O	O	4143
displayed	VERB	O	O	4143
significantly	ADV	O	O	4143
increased	VERB	O	O	4143
expressions	NOUN	O	O	4143
of	ADP	O	O	4143
MMP-2	NOUN	O	O	4143
,	PUNCT	O	O	4143
MMP-9	ADJ	O	O	4143
,	PUNCT	O	O	4143
ADAM-10	PROPN	O	O	4143
and	CCONJ	O	O	4143
ADAM-17	NOUN	O	O	4143
(	PUNCT	O	O	4143
all	PRON	O	O	4143
p<0.01	ADV	O	O	4143
)	PUNCT	O	O	4143
in	ADP	O	O	4143
intima	X	O	O	4143
and	CCONJ	O	O	4143
media	NOUN	O	O	4143
for	ADP	O	O	4143
CaCl(2)-treated	VERB	O	O	4143
segments	NOUN	O	O	4143
.	PUNCT	O	O	4143
This	PRON	O	O	4144
study	VERB	O	O	4144
establishes	VERB	O	O	4144
a	PRON	O	O	4144
TAA	X	O	O	4144
model	NOUN	O	O	4144
by	ADP	O	O	4144
periarterial	ADJ	O	O	4144
CaCl(2	ADP	O	O	4144
)	PUNCT	O	O	4144
exposure	NOUN	O	O	4144
in	ADP	O	O	4144
rats	NOUN	O	O	4144
,	PUNCT	O	O	4144
and	CCONJ	O	O	4144
demonstrates	VERB	O	O	4144
a	PRON	O	O	4144
significant	ADJ	O	O	4144
elevation	NOUN	O	O	4144
of	ADP	O	O	4144
expression	NOUN	O	O	4144
of	ADP	O	O	4144
MMP-2	NOUN	O	O	4144
,	PUNCT	O	O	4144
MMP-9	ADJ	O	O	4144
,	PUNCT	O	O	4144
ADAM10	PUNCT	O	O	4144
and	CCONJ	O	O	4144
ADAM17	X	O	O	4144
in	ADP	O	O	4144
the	PRON	O	O	4144
pathogenesis	NOUN	O	O	4144
of	ADP	O	O	4144
vascular	ADJ	O	O	4144
remodeling	VERB	O	O	4144
.	PUNCT	O	O	4144
Twenty	NUM	O	O	4147
-	PUNCT	O	O	4147
three	NUM	O	O	4147
hours	NOUN	O	O	4147
after	ADP	O	O	4147
heart	NOUN	O	O	4147
transplantation	NOUN	O	O	4147
,	PUNCT	O	O	4147
life	NOUN	O	O	4147
-	PUNCT	O	O	4147
threatening	VERB	O	O	4147
acute	ADJ	O	O	4147
right	ADV	O	O	4147
heart failure	NOUN	O	Disease	4147
was	AUX	O	O	4147
diagnosed	VERB	O	O	4147
in	ADP	O	O	4147
a	PRON	O	O	4147
patient	NOUN	O	O	4147
requiring	VERB	O	O	4147
continuous	ADJ	O	O	4147
venovenous	ADJ	O	O	4147
hemodiafiltration	NOUN	O	O	4147
(	PUNCT	O	O	4147
CVVHDF	PROPN	O	O	4147
)	PUNCT	O	O	4147
.	PUNCT	O	O	4147
Increasing	VERB	O	O	4148
doses	NOUN	O	O	4148
of	ADP	O	O	4148
catecholamines	NOUN	O	Chemical	4148
,	PUNCT	O	O	4148
sedatives	NOUN	O	O	4148
,	PUNCT	O	O	4148
and	CCONJ	O	O	4148
muscle	NOUN	O	O	4148
relaxants	NOUN	O	O	4148
administered	VERB	O	O	4148
through	ADP	O	O	4148
a	PRON	O	O	4148
central	ADJ	O	O	4148
venous	ADJ	O	O	4148
catheter	VERB	O	O	4148
were	AUX	O	O	4148
ineffective	ADJ	O	O	4148
.	PUNCT	O	O	4148
However	ADV	O	O	4149
,	PUNCT	O	O	4149
a	PRON	O	O	4149
bolus	NOUN	O	O	4149
of	ADP	O	O	4149
epinephrine	NOUN	O	Chemical	4149
injected	VERB	O	O	4149
through	ADP	O	O	4149
an	PRON	O	O	4149
alternative	ADV	O	O	4149
catheter	VERB	O	O	4149
provoked	VERB	O	O	4149
a	PRON	O	O	4149
hypertensive	ADJ	O	Disease	4149
crisis	NOUN	O	O	4149
.	PUNCT	O	O	4149
The	PRON	O	O	4150
catheters	NOUN	O	O	4150
were	AUX	O	O	4150
changed	VERB	O	O	4150
,	PUNCT	O	O	4150
and	CCONJ	O	O	4150
hemodynamics	NOUN	O	O	4150
stabilized	VERB	O	O	4150
at	ADP	O	O	4150
lower	ADJ	O	O	4150
catecholamine	ADJ	O	Chemical	4150
doses	NOUN	O	O	4150
.	PUNCT	O	O	4150
Long	ADV	O	O	4153
-	PUNCT	O	O	4153
term	NOUN	O	O	4153
glutamate	NOUN	O	Chemical	4153
supplementation	NOUN	O	O	4153
failed	VERB	O	O	4153
to	PART	O	O	4153
protect	VERB	O	O	4153
against	ADP	O	O	4153
peripheral neurotoxicity	NOUN	O	Disease	4153
of	ADP	O	O	4153
paclitaxel	NOUN	O	Chemical	4153
.	PUNCT	O	O	4153
Toxic	ADJ	O	O	4154
peripheral neuropathy	NOUN	O	Disease	4154
is	AUX	O	O	4154
still	ADV	O	O	4154
a	PRON	O	O	4154
significant	ADJ	O	O	4154
limiting	VERB	O	O	4154
factor	NOUN	O	O	4154
for	ADP	O	O	4154
chemotherapy	NOUN	O	O	4154
with	ADP	O	O	4154
paclitaxel	NOUN	O	Chemical	4154
(	PUNCT	O	O	4154
PAC	PROPN	O	O	4154
)	PUNCT	O	O	4154
,	PUNCT	O	O	4154
although	SCONJ	O	O	4154
glutamate	NOUN	O	Chemical	4154
and	CCONJ	O	O	4154
its	PRON	O	O	4154
closely	ADV	O	O	4154
related	ADJ	O	O	4154
amino acid	NOUN	O	Chemical	4154
glutamine	PROPN	O	O	4154
were	AUX	O	O	4154
claimed	VERB	O	O	4154
to	PART	O	O	4154
ameliorate	VERB	O	O	4154
PAC	PROPN	O	O	4154
neurotoxicity	NOUN	O	Disease	4154
.	PUNCT	O	O	4154
This	PRON	O	O	4155
pilot	NOUN	O	O	4155
trial	NOUN	O	O	4155
aimed	VERB	O	O	4155
to	PART	O	O	4155
evaluate	VERB	O	O	4155
the	PRON	O	O	4155
role	NOUN	O	O	4155
of	ADP	O	O	4155
glutamate	NOUN	O	Chemical	4155
supplementation	NOUN	O	O	4155
for	ADP	O	O	4155
preventing	VERB	O	O	4155
PAC	PROPN	O	O	4155
-	PUNCT	O	O	4155
induced	VERB	O	O	4155
peripheral neuropathy	NOUN	O	Disease	4155
in	ADP	O	O	4155
a	PRON	O	O	4155
randomized	VERB	O	O	4155
,	PUNCT	O	O	4155
placebo	NOUN	O	O	4155
-	PUNCT	O	O	4155
controlled	VERB	O	O	4155
,	PUNCT	O	O	4155
double	ADJ	O	O	4155
-	PUNCT	O	O	4155
blinded	VERB	O	O	4155
clinical	ADJ	O	O	4155
and	CCONJ	O	O	4155
electro	VERB	O	O	4155
-	PUNCT	O	O	4155
diagnostic	ADJ	O	O	4155
study	VERB	O	O	4155
.	PUNCT	O	O	4155
Forty	NUM	O	O	4156
-	PUNCT	O	O	4156
three	NUM	O	O	4156
ovarian cancer	NOUN	O	Disease	4156
patients	NOUN	O	O	4156
were	AUX	O	O	4156
available	ADJ	O	O	4156
for	ADP	O	O	4156
analysis	NOUN	O	O	4156
following	VERB	O	O	4156
six	NUM	O	O	4156
cycles	NOUN	O	O	4156
of	ADP	O	O	4156
the	PRON	O	O	4156
same	ADJ	O	O	4156
PAC	PROPN	O	O	4156
-	PUNCT	O	O	4156
containing	VERB	O	O	4156
regimen	NOUN	O	O	4156
:	PUNCT	O	O	4156
23	NUM	O	O	4156
had	VERB	O	O	4156
been	AUX	O	O	4156
supplemented	VERB	O	O	4156
by	ADP	O	O	4156
glutamate	NOUN	O	Chemical	4156
all	PRON	O	O	4156
along	ADV	O	O	4156
the	PRON	O	O	4156
treatment	NOUN	O	O	4156
period	NOUN	O	O	4156
,	PUNCT	O	O	4156
at	ADP	O	O	4156
a	PRON	O	O	4156
daily	ADV	O	O	4156
dose	NOUN	O	O	4156
of	ADP	O	O	4156
three	NUM	O	O	4156
times	NOUN	O	O	4156
500	NUM	O	O	4156
mg	VERB	O	O	4156
(	PUNCT	O	O	4156
group	NOUN	O	O	4156
G	NOUN	O	O	4156
)	PUNCT	O	O	4156
,	PUNCT	O	O	4156
and	CCONJ	O	O	4156
20	NUM	O	O	4156
had	VERB	O	O	4156
received	VERB	O	O	4156
a	PRON	O	O	4156
placebo	NOUN	O	O	4156
(	PUNCT	O	O	4156
group	NOUN	O	O	4156
P	NOUN	O	Chemical	4156
)	PUNCT	O	O	4156
.	PUNCT	O	O	4156
There	ADV	O	O	4157
was	AUX	O	O	4157
no	PRON	O	O	4157
significant	ADJ	O	O	4157
difference	NOUN	O	O	4157
in	ADP	O	O	4157
the	PRON	O	O	4157
frequency	NOUN	O	O	4157
of	ADP	O	O	4157
signs	NOUN	O	O	4157
or	CCONJ	O	O	4157
symptoms	NOUN	O	O	4157
between	ADP	O	O	4157
the	PRON	O	O	4157
two	NUM	O	O	4157
groups	NOUN	O	O	4157
although	SCONJ	O	O	4157
neurotoxicity	NOUN	O	Disease	4157
symptoms	NOUN	O	O	4157
presented	VERB	O	O	4157
mostly	ADV	O	O	4157
with	ADP	O	O	4157
lower	ADJ	O	O	4157
scores	NOUN	O	O	4157
of	ADP	O	O	4157
severity	NOUN	O	O	4157
in	ADP	O	O	4157
group	NOUN	O	O	4157
G.	PROPN	O	O	4157
However	ADV	O	O	4158
,	PUNCT	O	O	4158
this	PRON	O	O	4158
difference	NOUN	O	O	4158
reached	VERB	O	O	4158
statistical	ADJ	O	O	4158
significance	NOUN	O	O	4158
only	ADV	O	O	4158
with	ADP	O	O	4158
regard	NOUN	O	O	4158
to	PART	O	O	4158
reported	VERB	O	O	4158
pain	NOUN	O	Disease	4158
sensation	NOUN	O	O	4158
(	PUNCT	O	O	4158
P	NOUN	O	Chemical	4158
=	PUNCT	O	O	4158
0.011	NUM	O	O	4158
)	PUNCT	O	O	4158
.	PUNCT	O	O	4158
This	PRON	O	O	4159
pilot	NOUN	O	O	4159
study	VERB	O	O	4159
leads	VERB	O	O	4159
to	PART	O	O	4159
the	PRON	O	O	4159
conclusion	NOUN	O	O	4159
that	SCONJ	O	O	4159
glutamate	NOUN	O	Chemical	4159
supplementation	NOUN	O	O	4159
at	ADP	O	O	4159
the	PRON	O	O	4159
chosen	VERB	O	O	4159
regimen	NOUN	O	O	4159
fails	VERB	O	O	4159
to	PART	O	O	4159
protect	VERB	O	O	4159
against	ADP	O	O	4159
peripheral neurotoxicity	NOUN	O	Disease	4159
of	ADP	O	O	4159
PAC	PROPN	O	O	4159
.	PUNCT	O	O	4159
Attentional	PROPN	O	O	4162
modulation	NOUN	O	O	4162
of	ADP	O	O	4162
perceived	VERB	O	O	4162
pain	NOUN	O	Disease	4162
intensity	NOUN	O	O	4162
in	ADP	O	O	4162
capsaicin	NOUN	O	Chemical	4162
-	PUNCT	O	O	4162
induced	VERB	O	O	4162
secondary	ADJ	O	O	4162
hyperalgesia	NOUN	O	Disease	4162
.	PUNCT	O	O	4162
Perceived	VERB	O	O	4163
pain	NOUN	O	Disease	4163
intensity	NOUN	O	O	4163
is	AUX	O	O	4163
modulated	VERB	O	O	4163
by	ADP	O	O	4163
attention	NOUN	O	O	4163
.	PUNCT	O	O	4163
However	ADV	O	O	4164
,	PUNCT	O	O	4164
it	PRON	O	O	4164
is	AUX	O	O	4164
not	PART	O	O	4164
known	VERB	O	O	4164
that	SCONJ	O	O	4164
how	SCONJ	O	O	4164
pain	NOUN	O	Disease	4164
intensity	NOUN	O	O	4164
ratings	NOUN	O	O	4164
are	AUX	O	O	4164
affected	VERB	O	O	4164
by	ADP	O	O	4164
attention	NOUN	O	O	4164
in	ADP	O	O	4164
capsaicin	NOUN	O	Chemical	4164
-	PUNCT	O	O	4164
induced	VERB	O	O	4164
secondary	ADJ	O	O	4164
hyperalgesia	NOUN	O	Disease	4164
.	PUNCT	O	O	4164
Here	ADV	O	O	4165
we	PRON	O	O	4165
show	VERB	O	O	4165
that	SCONJ	O	O	4165
perceived	VERB	O	O	4165
pain	NOUN	O	Disease	4165
intensity	NOUN	O	O	4165
in	ADP	O	O	4165
secondary	ADJ	O	O	4165
hyperalgesia	NOUN	O	Disease	4165
is	AUX	O	O	4165
decreased	VERB	O	O	4165
when	SCONJ	O	O	4165
attention	NOUN	O	O	4165
is	AUX	O	O	4165
distracted	VERB	O	O	4165
away	ADV	O	O	4165
from	ADP	O	O	4165
the	PRON	O	O	4165
painful	ADJ	O	Disease	4165
pinprick	PROPN	O	O	4165
stimulus	NOUN	O	O	4165
with	ADP	O	O	4165
a	PRON	O	O	4165
visual	ADJ	O	O	4165
task	NOUN	O	O	4165
.	PUNCT	O	O	4165
Furthermore	ADV	O	O	4166
,	PUNCT	O	O	4166
it	PRON	O	O	4166
was	AUX	O	O	4166
found	VERB	O	O	4166
that	SCONJ	O	O	4166
the	PRON	O	O	4166
magnitude	NOUN	O	O	4166
of	ADP	O	O	4166
attentional	ADJ	O	O	4166
modulation	NOUN	O	O	4166
in	ADP	O	O	4166
secondary	ADJ	O	O	4166
hyperalgesia	NOUN	O	Disease	4166
is	AUX	O	O	4166
very	ADV	O	O	4166
similar	ADJ	O	O	4166
to	PART	O	O	4166
that	SCONJ	O	O	4166
of	ADP	O	O	4166
capsaicin	NOUN	O	Chemical	4166
-	PUNCT	O	O	4166
untreated	ADJ	O	O	4166
,	PUNCT	O	O	4166
control	VERB	O	O	4166
condition	NOUN	O	O	4166
.	PUNCT	O	O	4166
Our	PRON	O	O	4167
findings	NOUN	O	O	4167
,	PUNCT	O	O	4167
showing	VERB	O	O	4167
no	PRON	O	O	4167
interaction	NOUN	O	O	4167
between	ADP	O	O	4167
capsaicin	NOUN	O	Chemical	4167
treatment	NOUN	O	O	4167
and	CCONJ	O	O	4167
attentional	ADJ	O	O	4167
modulation	NOUN	O	O	4167
suggest	VERB	O	O	4167
that	SCONJ	O	O	4167
capsaicin	NOUN	O	Chemical	4167
-	PUNCT	O	O	4167
induced	VERB	O	O	4167
secondary	ADJ	O	O	4167
hyperalgesia	NOUN	O	Disease	4167
and	CCONJ	O	O	4167
attention	NOUN	O	O	4167
might	AUX	O	O	4167
affect	VERB	O	O	4167
mechanical	ADJ	O	O	4167
pain	NOUN	O	Disease	4167
through	ADP	O	O	4167
independent	ADJ	O	O	4167
mechanisms	NOUN	O	O	4167
.	PUNCT	O	O	4167
Testosterone	PROPN	O	O	4170
-	PUNCT	O	O	4170
dependent	ADJ	O	O	4170
hypertension	NOUN	O	Disease	4170
and	CCONJ	O	O	4170
upregulation	NOUN	O	O	4170
of	ADP	O	O	4170
intrarenal	ADJ	O	O	4170
angiotensinogen	PROPN	O	O	4170
in	ADP	O	O	4170
Dahl	PROPN	O	O	4170
salt	NOUN	O	O	4170
-	PUNCT	O	O	4170
sensitive	ADJ	O	O	4170
rats	NOUN	O	O	4170
.	PUNCT	O	O	4170
Blood	NOUN	O	O	4171
pressure	NOUN	O	O	4171
(	PUNCT	O	O	4171
BP	PROPN	O	O	4171
)	PUNCT	O	O	4171
is	AUX	O	O	4171
more	ADJ	O	O	4171
salt	NOUN	O	O	4171
sensitive	ADJ	O	O	4171
in	ADP	O	O	4171
men	NOUN	O	O	4171
than	ADP	O	O	4171
in	ADP	O	O	4171
premenopausal	ADJ	O	O	4171
women	NOUN	O	O	4171
.	PUNCT	O	O	4171
In	ADP	O	O	4172
Dahl	PROPN	O	O	4172
salt	NOUN	O	O	4172
-	PUNCT	O	O	4172
sensitive	ADJ	O	O	4172
rats	NOUN	O	O	4172
(	PUNCT	O	O	4172
DS	PROPN	O	O	4172
)	PUNCT	O	O	4172
,	PUNCT	O	O	4172
high	ADJ	O	O	4172
-	PUNCT	O	O	4172
salt	NOUN	O	O	4172
(	PUNCT	O	O	4172
HS	PROPN	O	O	4172
)	PUNCT	O	O	4172
diet	PROPN	O	O	4172
increases	VERB	O	O	4172
BP	PROPN	O	O	4172
more	ADJ	O	O	4172
in	ADP	O	O	4172
males	NOUN	O	O	4172
than	ADP	O	O	4172
females	NOUN	O	O	4172
.	PUNCT	O	O	4172
In	ADP	O	O	4173
contrast	NOUN	O	O	4173
to	PART	O	O	4173
the	PRON	O	O	4173
systemic	ADJ	O	O	4173
renin	PROPN	O	O	4173
-	PUNCT	O	O	4173
angiotensin	NOUN	O	Chemical	4173
system	NOUN	O	O	4173
,	PUNCT	O	O	4173
which	PRON	O	O	4173
is	AUX	O	O	4173
suppressed	VERB	O	O	4173
in	ADP	O	O	4173
response	NOUN	O	O	4173
to	PART	O	O	4173
HS	PROPN	O	O	4173
in	ADP	O	O	4173
male	NOUN	O	O	4173
DS	PROPN	O	O	4173
,	PUNCT	O	O	4173
intrarenal	ADJ	O	O	4173
angiotensinogen	PROPN	O	O	4173
expression	NOUN	O	O	4173
is	AUX	O	O	4173
increased	VERB	O	O	4173
,	PUNCT	O	O	4173
and	CCONJ	O	O	4173
intrarenal	ADJ	O	O	4173
levels	NOUN	O	O	4173
of	ADP	O	O	4173
ANG	PROPN	O	O	4173
II	NUM	O	O	4173
are	AUX	O	O	4173
not	PART	O	O	4173
suppressed	VERB	O	O	4173
.	PUNCT	O	O	4173
In	ADP	O	O	4174
this	PRON	O	O	4174
study	VERB	O	O	4174
,	PUNCT	O	O	4174
the	PRON	O	O	4174
hypothesis	NOUN	O	O	4174
was	AUX	O	O	4174
tested	VERB	O	O	4174
that	SCONJ	O	O	4174
there	ADV	O	O	4174
is	AUX	O	O	4174
a	PRON	O	O	4174
sexual	ADJ	O	O	4174
dimorphism	NOUN	O	O	4174
in	ADP	O	O	4174
HS	PROPN	O	O	4174
-	PUNCT	O	O	4174
induced	VERB	O	O	4174
upregulation	NOUN	O	O	4174
of	ADP	O	O	4174
intrarenal	ADJ	O	O	4174
angiotensinogen	PROPN	O	O	4174
mediated	VERB	O	O	4174
by	ADP	O	O	4174
testosterone	PROPN	O	Chemical	4174
that	SCONJ	O	O	4174
also	ADV	O	O	4174
causes	VERB	O	O	4174
increases	VERB	O	O	4174
in	ADP	O	O	4174
BP	PROPN	O	O	4174
and	CCONJ	O	O	4174
renal injury	NOUN	O	Disease	4174
.	PUNCT	O	O	4174
On	ADP	O	O	4175
a	PRON	O	O	4175
low	ADJ	O	O	4175
-	PUNCT	O	O	4175
salt	NOUN	O	O	4175
(	PUNCT	O	O	4175
LS	PROPN	O	O	4175
)	PUNCT	O	O	4175
diet	PROPN	O	O	4175
,	PUNCT	O	O	4175
male	NOUN	O	O	4175
DS	PROPN	O	O	4175
had	VERB	O	O	4175
higher	ADJ	O	O	4175
levels	NOUN	O	O	4175
of	ADP	O	O	4175
intrarenal	ADJ	O	O	4175
angiotensinogen	PROPN	O	O	4175
mRNA	PROPN	O	O	4175
than	ADP	O	O	4175
females	NOUN	O	O	4175
.	PUNCT	O	O	4175
HS	PROPN	O	O	4176
diet	PROPN	O	O	4176
for	ADP	O	O	4176
4	NUM	O	O	4176
wk	X	O	O	4176
caused	VERB	O	O	4176
a	PRON	O	O	4176
progressive	ADJ	O	O	4176
increase	VERB	O	O	4176
in	ADP	O	O	4176
BP	PROPN	O	O	4176
,	PUNCT	O	O	4176
protein	NOUN	O	O	4176
and	CCONJ	O	O	4176
albumin	PROPN	O	O	4176
excretion	NOUN	O	O	4176
,	PUNCT	O	O	4176
and	CCONJ	O	O	4176
glomerular	ADJ	O	O	4176
sclerosis	NOUN	O	O	4176
in	ADP	O	O	4176
male	NOUN	O	O	4176
DS	PROPN	O	O	4176
rats	NOUN	O	O	4176
,	PUNCT	O	O	4176
which	PRON	O	O	4176
were	AUX	O	O	4176
attenuated	VERB	O	O	4176
by	ADP	O	O	4176
castration	NOUN	O	O	4176
.	PUNCT	O	O	4176
Testosterone	PROPN	O	O	4177
replacement	NOUN	O	O	4177
in	ADP	O	O	4177
castrated	VERB	O	O	4177
DS	PROPN	O	O	4177
rats	NOUN	O	O	4177
increased	VERB	O	O	4177
BP	PROPN	O	O	4177
,	PUNCT	O	O	4177
renal injury	NOUN	O	Disease	4177
,	PUNCT	O	O	4177
and	CCONJ	O	O	4177
upregulation	NOUN	O	O	4177
of	ADP	O	O	4177
renal	ADJ	O	O	4177
angiotensinogen	PROPN	O	O	4177
associated	VERB	O	O	4177
with	ADP	O	O	4177
HS	PROPN	O	O	4177
diet	PROPN	O	O	4177
.	PUNCT	O	O	4177
Testosterone	PROPN	O	O	4178
contributes	VERB	O	O	4178
to	PART	O	O	4178
the	PRON	O	O	4178
development	NOUN	O	O	4178
of	ADP	O	O	4178
hypertension	NOUN	O	Disease	4178
and	CCONJ	O	O	4178
renal injury	NOUN	O	Disease	4178
in	ADP	O	O	4178
male	NOUN	O	O	4178
DS	PROPN	O	O	4178
rats	NOUN	O	O	4178
on	ADP	O	O	4178
HS	PROPN	O	O	4178
diet	PROPN	O	O	4178
possibly	ADV	O	O	4178
through	ADP	O	O	4178
upregulation	NOUN	O	O	4178
of	ADP	O	O	4178
the	PRON	O	O	4178
intrarenal	ADJ	O	O	4178
renin	PROPN	O	O	4178
-	PUNCT	O	O	4178
angiotensin	NOUN	O	Chemical	4178
system	NOUN	O	O	4178
.	PUNCT	O	O	4178
Prenatal	NOUN	O	O	4181
protein	NOUN	O	O	4181
deprivation	NOUN	O	O	4181
alters	VERB	O	O	4181
dopamine	NOUN	O	Chemical	4181
-	PUNCT	O	O	4181
mediated	VERB	O	O	4181
behaviors	NOUN	O	O	4181
and	CCONJ	O	O	4181
dopaminergic	ADJ	O	O	4181
and	CCONJ	O	O	4181
glutamatergic	ADJ	O	O	4181
receptor	NOUN	O	O	4181
binding	VERB	O	O	4181
.	PUNCT	O	O	4181
Epidemiological	ADJ	O	O	4182
evidence	NOUN	O	O	4182
indicates	VERB	O	O	4182
that	SCONJ	O	O	4182
prenatal	ADJ	O	O	4182
nutritional	ADJ	O	O	4182
deprivation	NOUN	O	O	4182
may	AUX	O	O	4182
increase	VERB	O	O	4182
the	PRON	O	O	4182
risk	NOUN	O	O	4182
of	ADP	O	O	4182
schizophrenia	PROPN	O	Disease	4182
.	PUNCT	O	O	4182
The	PRON	O	O	4183
goal	NOUN	O	O	4183
of	ADP	O	O	4183
these	PRON	O	O	4183
studies	NOUN	O	O	4183
was	AUX	O	O	4183
to	PART	O	O	4183
use	VERB	O	O	4183
an	PRON	O	O	4183
animal	NOUN	O	O	4183
model	NOUN	O	O	4183
to	PART	O	O	4183
examine	VERB	O	O	4183
the	PRON	O	O	4183
effects	NOUN	O	O	4183
of	ADP	O	O	4183
prenatal	ADJ	O	O	4183
protein	NOUN	O	O	4183
deprivation	NOUN	O	O	4183
on	ADP	O	O	4183
behaviors	NOUN	O	O	4183
and	CCONJ	O	O	4183
receptor	NOUN	O	O	4183
binding	VERB	O	O	4183
with	ADP	O	O	4183
relevance	NOUN	O	O	4183
to	PART	O	O	4183
schizophrenia	PROPN	O	Disease	4183
.	PUNCT	O	O	4183
We	PRON	O	O	4184
report	VERB	O	O	4184
that	SCONJ	O	O	4184
prenatally	ADV	O	O	4184
protein	NOUN	O	O	4184
deprived	VERB	O	O	4184
(	PUNCT	O	O	4184
PD	PROPN	O	Disease	4184
)	PUNCT	O	O	4184
female	ADJ	O	O	4184
rats	NOUN	O	O	4184
showed	VERB	O	O	4184
an	PRON	O	O	4184
increased	VERB	O	O	4184
stereotypic	ADJ	O	O	4184
response	NOUN	O	O	4184
to	PART	O	O	4184
apomorphine	PROPN	O	Chemical	4184
and	CCONJ	O	O	4184
an	PRON	O	O	4184
increased	VERB	O	O	4184
locomotor	PROPN	O	O	4184
response	NOUN	O	O	4184
to	PART	O	O	4184
amphetamine	NOUN	O	Chemical	4184
in	ADP	O	O	4184
adulthood	NOUN	O	O	4184
.	PUNCT	O	O	4184
No	PRON	O	O	4185
changes	VERB	O	O	4185
in	ADP	O	O	4185
haloperidol	NOUN	O	Chemical	4185
-	PUNCT	O	O	4185
induced	VERB	O	O	4185
catalepsy	VERB	O	Disease	4185
or	CCONJ	O	O	4185
MK-801-induced	VERB	O	O	4185
locomotion	NOUN	O	O	4185
were	AUX	O	O	4185
seen	VERB	O	O	4185
following	VERB	O	O	4185
PD	PROPN	O	Disease	4185
.	PUNCT	O	O	4185
In	ADP	O	O	4186
addition	NOUN	O	O	4186
,	PUNCT	O	O	4186
PD	PROPN	O	Disease	4186
female	ADJ	O	O	4186
rats	NOUN	O	O	4186
showed	VERB	O	O	4186
increased	VERB	O	O	4186
(	PUNCT	O	O	4186
3)H	NUM	O	O	4186
-	PUNCT	O	O	4186
MK-801	PROPN	O	Chemical	4186
binding	VERB	O	O	4186
in	ADP	O	O	4186
the	PRON	O	O	4186
striatum	NOUN	O	O	4186
and	CCONJ	O	O	4186
hippocampus	NOUN	O	O	4186
,	PUNCT	O	O	4186
but	CCONJ	O	O	4186
not	PART	O	O	4186
in	ADP	O	O	4186
the	PRON	O	O	4186
cortex	VERB	O	O	4186
.	PUNCT	O	O	4186
PD	PROPN	O	Disease	4187
female	ADJ	O	O	4187
rats	NOUN	O	O	4187
also	ADV	O	O	4187
showed	VERB	O	O	4187
increased	VERB	O	O	4187
(	PUNCT	O	O	4187
3)H	NUM	O	O	4187
-	PUNCT	O	O	4187
haloperidol	NOUN	O	Chemical	4187
binding	VERB	O	O	4187
and	CCONJ	O	O	4187
decreased	VERB	O	O	4187
dopamine	NOUN	O	Chemical	4187
transporter	NOUN	O	O	4187
binding	VERB	O	O	4187
in	ADP	O	O	4187
striatum	NOUN	O	O	4187
.	PUNCT	O	O	4187
No	PRON	O	O	4188
statistically	ADV	O	O	4188
significant	ADJ	O	O	4188
changes	VERB	O	O	4188
in	ADP	O	O	4188
behavior	NOUN	O	O	4188
or	CCONJ	O	O	4188
receptor	NOUN	O	O	4188
binding	VERB	O	O	4188
were	AUX	O	O	4188
found	VERB	O	O	4188
in	ADP	O	O	4188
PD	PROPN	O	Disease	4188
males	NOUN	O	O	4188
with	ADP	O	O	4188
the	PRON	O	O	4188
exception	NOUN	O	O	4188
of	ADP	O	O	4188
increased	VERB	O	O	4188
(	PUNCT	O	O	4188
3)H	NUM	O	O	4188
-	PUNCT	O	O	4188
MK-801	PROPN	O	Chemical	4188
binding	VERB	O	O	4188
in	ADP	O	O	4188
cortex	VERB	O	O	4188
.	PUNCT	O	O	4188
This	PRON	O	O	4189
animal	NOUN	O	O	4189
model	NOUN	O	O	4189
may	AUX	O	O	4189
be	AUX	O	O	4189
useful	ADJ	O	O	4189
to	PART	O	O	4189
explore	VERB	O	O	4189
the	PRON	O	O	4189
mechanisms	NOUN	O	O	4189
by	ADP	O	O	4189
which	PRON	O	O	4189
prenatal	ADJ	O	O	4189
nutritional	ADJ	O	O	4189
deficiency	NOUN	O	O	4189
enhances	VERB	O	O	4189
risk	NOUN	O	O	4189
for	ADP	O	O	4189
schizophrenia	PROPN	O	Disease	4189
in	ADP	O	O	4189
humans	NOUN	O	O	4189
and	CCONJ	O	O	4189
may	AUX	O	O	4189
also	ADV	O	O	4189
have	VERB	O	O	4189
implications	NOUN	O	O	4189
for	ADP	O	O	4189
developmental	ADJ	O	O	4189
processes	NOUN	O	O	4189
leading	VERB	O	O	4189
to	PART	O	O	4189
differential	ADJ	O	O	4189
sensitivity	NOUN	O	O	4189
to	PART	O	O	4189
drugs	NOUN	O	O	4189
of	ADP	O	O	4189
abuse	VERB	O	O	4189
.	PUNCT	O	O	4189
inhibitors	NOUN	O	O	4192
-	PUNCT	O	O	4192
induced	VERB	O	O	4192
proteinuria	X	O	Disease	4192
:	PUNCT	O	O	4192
mechanisms	NOUN	O	O	4192
,	PUNCT	O	O	4192
significance	NOUN	O	O	4192
,	PUNCT	O	O	4192
and	CCONJ	O	O	4192
management	NOUN	O	O	4192
.	PUNCT	O	O	4192
Massive	ADJ	O	O	4193
urinary	ADJ	O	O	4193
protein excretion	NOUN	O	Disease	4193
has	VERB	O	O	4193
been	AUX	O	O	4193
observed	VERB	O	O	4193
after	ADP	O	O	4193
conversion	NOUN	O	O	4193
from	ADP	O	O	4193
calcineurin	NOUN	O	O	4193
inhibitors	NOUN	O	O	4193
to	PART	O	O	4193
mammalian	ADJ	O	O	4193
target	NOUN	O	O	4193
of	ADP	O	O	4193
rapamycin	NOUN	O	Chemical	4193
(	PUNCT	O	O	4193
mToR	PROPN	O	O	4193
)	PUNCT	O	O	4193
inhibitors	NOUN	O	O	4193
,	PUNCT	O	O	4193
especially	ADV	O	O	4193
sirolimus	NOUN	O	Chemical	4193
,	PUNCT	O	O	4193
in	ADP	O	O	4193
renal	ADJ	O	O	4193
transplant	NOUN	O	O	4193
recipients	NOUN	O	O	4193
with	ADP	O	O	4193
chronic	ADJ	O	O	4193
allograft	NOUN	O	O	4193
nephropathy	NOUN	O	Disease	4193
.	PUNCT	O	O	4193
Because	SCONJ	O	O	4194
proteinuria	X	O	Disease	4194
is	AUX	O	O	4194
a	PRON	O	O	4194
major	ADJ	O	O	4194
predictive	ADJ	O	O	4194
factor	NOUN	O	O	4194
of	ADP	O	O	4194
poor	ADJ	O	O	4194
transplantation	NOUN	O	O	4194
outcome	NOUN	O	O	4194
,	PUNCT	O	O	4194
many	ADJ	O	O	4194
studies	NOUN	O	O	4194
focused	VERB	O	O	4194
on	ADP	O	O	4194
this	PRON	O	O	4194
adverse	ADJ	O	O	4194
event	NOUN	O	O	4194
during	ADP	O	O	4194
the	PRON	O	O	4194
past	ADP	O	O	4194
years	NOUN	O	O	4194
.	PUNCT	O	O	4194
Whether	SCONJ	O	O	4195
proteinuria	X	O	Disease	4195
was	AUX	O	O	4195
due	ADJ	O	O	4195
to	PART	O	O	4195
sirolimus	NOUN	O	Chemical	4195
or	CCONJ	O	O	4195
only	ADV	O	O	4195
a	PRON	O	O	4195
consequence	NOUN	O	O	4195
of	ADP	O	O	4195
calcineurin	NOUN	O	O	4195
inhibitors	NOUN	O	O	4195
withdrawal	NOUN	O	O	4195
remained	VERB	O	O	4195
unsolved	ADJ	O	O	4195
until	ADP	O	O	4195
high	ADJ	O	O	4195
range	VERB	O	O	4195
proteinuria	X	O	Disease	4195
has	VERB	O	O	4195
been	AUX	O	O	4195
observed	VERB	O	O	4195
during	ADP	O	O	4195
sirolimus	NOUN	O	Chemical	4195
therapy	NOUN	O	O	4195
in	ADP	O	O	4195
islet	NOUN	O	O	4195
transplantation	NOUN	O	O	4195
and	CCONJ	O	O	4195
in	ADP	O	O	4195
patients	NOUN	O	O	4195
who	PRON	O	O	4195
received	VERB	O	O	4195
sirolimus	NOUN	O	Chemical	4195
de	VERB	O	O	4195
novo	PROPN	O	O	4195
.	PUNCT	O	O	4195
Podocyte	NOUN	O	O	4196
injury	NOUN	O	O	4196
and	CCONJ	O	O	4196
focal	ADJ	O	O	4196
segmental	ADJ	O	O	4196
glomerulosclerosis	PROPN	O	O	4196
have	VERB	O	O	4196
been	AUX	O	O	4196
related	ADJ	O	O	4196
to	PART	O	O	4196
mToR	PROPN	O	O	4196
inhibition	NOUN	O	O	4196
in	ADP	O	O	4196
some	PRON	O	O	4196
patients	NOUN	O	O	4196
,	PUNCT	O	O	4196
but	CCONJ	O	O	4196
the	PRON	O	O	4196
pathways	NOUN	O	O	4196
underlying	VERB	O	O	4196
these	PRON	O	O	4196
lesions	NOUN	O	O	4196
remain	VERB	O	O	4196
hypothetic	ADJ	O	O	4196
.	PUNCT	O	O	4196
We	PRON	O	O	4197
discuss	VERB	O	O	4197
herein	VERB	O	O	4197
the	PRON	O	O	4197
possible	ADJ	O	O	4197
mechanisms	NOUN	O	O	4197
and	CCONJ	O	O	4197
the	PRON	O	O	4197
significance	NOUN	O	O	4197
of	ADP	O	O	4197
mToR	PROPN	O	O	4197
blockade	VERB	O	O	4197
-	PUNCT	O	O	4197
induced	VERB	O	O	4197
proteinuria	X	O	Disease	4197
.	PUNCT	O	O	4197
Hypothalamic	PROPN	O	O	4200
prolactin	PROPN	O	O	4200
receptor	NOUN	O	O	4200
messenger	NOUN	O	O	4200
ribonucleic	ADJ	O	O	4200
acid	PROPN	O	O	4200
levels	NOUN	O	O	4200
,	PUNCT	O	O	4200
prolactin	PROPN	O	O	4200
signaling	VERB	O	O	4200
,	PUNCT	O	O	4200
and	CCONJ	O	O	4200
hyperprolactinemic	ADJ	O	O	4200
inhibition	NOUN	O	O	4200
of	ADP	O	O	4200
pulsatile	ADJ	O	O	4200
luteinizing	VERB	O	O	4200
hormone	NOUN	O	O	4200
secretion	NOUN	O	O	4200
are	AUX	O	O	4200
dependent	ADJ	O	O	4200
on	ADP	O	O	4200
estradiol	VERB	O	Chemical	4200
.	PUNCT	O	O	4200
Hyperprolactinemia	PROPN	O	Disease	4201
can	AUX	O	O	4201
reduce	VERB	O	O	4201
fertility	NOUN	O	O	4201
and	CCONJ	O	O	4201
libido	VERB	O	O	4201
.	PUNCT	O	O	4201
We	PRON	O	O	4202
first	ADV	O	O	4202
tested	VERB	O	O	4202
whether	SCONJ	O	O	4202
chronic	ADJ	O	O	4202
hyperprolactinemia	NOUN	O	Disease	4202
inhibited	VERB	O	O	4202
two	NUM	O	O	4202
neuroendocrine	ADJ	O	O	4202
parameters	NOUN	O	O	4202
necessary	ADJ	O	O	4202
for	ADP	O	O	4202
female	ADJ	O	O	4202
fertility	NOUN	O	O	4202
:	PUNCT	O	O	4202
pulsatile	ADJ	O	O	4202
LH	PROPN	O	O	4202
secretion	NOUN	O	O	4202
and	CCONJ	O	O	4202
the	PRON	O	O	4202
estrogen	PROPN	O	Chemical	4202
-	PUNCT	O	O	4202
induced	VERB	O	O	4202
LH	PROPN	O	O	4202
surge	VERB	O	O	4202
.	PUNCT	O	O	4202
Chronic	NOUN	O	O	4203
hyperprolactinemia	NOUN	O	Disease	4203
induced	VERB	O	O	4203
by	ADP	O	O	4203
the	PRON	O	O	4203
dopamine	NOUN	O	Chemical	4203
antagonist	NOUN	O	O	4203
sulpiride	NOUN	O	Chemical	4203
caused	VERB	O	O	4203
a	PRON	O	O	4203
40%	NOUN	O	O	4203
reduction	NOUN	O	O	4203
LH	PROPN	O	O	4203
pulse	NOUN	O	O	4203
frequency	NOUN	O	O	4203
in	ADP	O	O	4203
ovariectomized	VERB	O	O	4203
rats	NOUN	O	O	4203
,	PUNCT	O	O	4203
but	CCONJ	O	O	4203
only	ADV	O	O	4203
in	ADP	O	O	4203
the	PRON	O	O	4203
presence	NOUN	O	O	4203
of	ADP	O	O	4203
chronic	ADJ	O	O	4203
low	ADJ	O	O	4203
levels	NOUN	O	O	4203
of	ADP	O	O	4203
estradiol	VERB	O	Chemical	4203
.	PUNCT	O	O	4203
Sulpiride	NOUN	O	O	4204
did	VERB	O	O	4204
not	PART	O	O	4204
affect	VERB	O	O	4204
the	PRON	O	O	4204
magnitude	NOUN	O	O	4204
of	ADP	O	O	4204
a	PRON	O	O	4204
steroid	NOUN	O	Chemical	4204
-	PUNCT	O	O	4204
induced	VERB	O	O	4204
LH	PROPN	O	O	4204
surge	VERB	O	O	4204
or	CCONJ	O	O	4204
the	PRON	O	O	4204
percentage	NOUN	O	O	4204
of	ADP	O	O	4204
GnRH	PROPN	O	O	4204
neurons	NOUN	O	O	4204
activated	VERB	O	O	4204
during	ADP	O	O	4204
the	PRON	O	O	4204
surge	VERB	O	O	4204
.	PUNCT	O	O	4204
Estradiol	NOUN	O	O	4205
is	AUX	O	O	4205
known	VERB	O	O	4205
to	PART	O	O	4205
influence	NOUN	O	O	4205
expression	NOUN	O	O	4205
of	ADP	O	O	4205
the	PRON	O	O	4205
long	ADV	O	O	4205
form	NOUN	O	O	4205
of	ADP	O	O	4205
prolactin	PROPN	O	O	4205
receptors	NOUN	O	O	4205
(	PUNCT	O	O	4205
PRL	NOUN	O	Chemical	4205
-	PUNCT	O	O	4205
R	NOUN	O	O	4205
)	PUNCT	O	O	4205
and	CCONJ	O	O	4205
components	NOUN	O	O	4205
of	ADP	O	O	4205
prolactin	PROPN	O	O	4205
's	AUX	O	O	4205
signaling	VERB	O	O	4205
pathway	NOUN	O	O	4205
.	PUNCT	O	O	4205
To	PART	O	O	4206
test	NOUN	O	O	4206
the	PRON	O	O	4206
hypothesis	NOUN	O	O	4206
that	SCONJ	O	O	4206
estrogen	PROPN	O	Chemical	4206
increases	VERB	O	O	4206
PRL	NOUN	O	Chemical	4206
-	PUNCT	O	O	4206
R	NOUN	O	O	4206
expression	NOUN	O	O	4206
and	CCONJ	O	O	4206
sensitivity	NOUN	O	O	4206
to	PART	O	O	4206
prolactin	PROPN	O	O	4206
,	PUNCT	O	O	4206
we	PRON	O	O	4206
next	ADV	O	O	4206
demonstrated	VERB	O	O	4206
that	SCONJ	O	O	4206
estradiol	VERB	O	Chemical	4206
greatly	ADV	O	O	4206
augments	VERB	O	O	4206
prolactin	PROPN	O	O	4206
-	PUNCT	O	O	4206
induced	VERB	O	O	4206
STAT5	PROPN	O	O	4206
activation	NOUN	O	O	4206
.	PUNCT	O	O	4206
Lastly	PROPN	O	O	4207
,	PUNCT	O	O	4207
we	PRON	O	O	4207
measured	VERB	O	O	4207
PRL	NOUN	O	Chemical	4207
-	PUNCT	O	O	4207
R	NOUN	O	O	4207
and	CCONJ	O	O	4207
suppressor	NOUN	O	O	4207
of	ADP	O	O	4207
cytokine	NOUN	O	O	4207
signaling	VERB	O	O	4207
(	PUNCT	O	O	4207
SOCS-1	NUM	O	O	4207
and	CCONJ	O	O	4207
-3	PUNCT	O	O	4207
and	CCONJ	O	O	4207
CIS	PROPN	O	O	4207
,	PUNCT	O	O	4207
which	PRON	O	O	4207
reflect	VERB	O	O	4207
the	PRON	O	O	4207
level	VERB	O	O	4207
of	ADP	O	O	4207
prolactin	PROPN	O	O	4207
signaling	VERB	O	O	4207
)	PUNCT	O	O	4207
mRNAs	NUM	O	O	4207
in	ADP	O	O	4207
response	NOUN	O	O	4207
to	PART	O	O	4207
sulpiride	NOUN	O	Chemical	4207
and	CCONJ	O	O	4207
estradiol	VERB	O	Chemical	4207
.	PUNCT	O	O	4207
Sulpiride	NOUN	O	O	4208
induced	VERB	O	O	4208
only	ADV	O	O	4208
SOCS-1	NUM	O	O	4208
in	ADP	O	O	4208
the	PRON	O	O	4208
medial	ADJ	O	O	4208
preoptic	ADJ	O	O	4208
area	NOUN	O	O	4208
,	PUNCT	O	O	4208
where	SCONJ	O	O	4208
GnRH	PROPN	O	O	4208
neurons	NOUN	O	O	4208
are	AUX	O	O	4208
regulated	VERB	O	O	4208
,	PUNCT	O	O	4208
but	CCONJ	O	O	4208
in	ADP	O	O	4208
the	PRON	O	O	4208
arcuate	ADJ	O	O	4208
nucleus	PROPN	O	O	4208
and	CCONJ	O	O	4208
choroid	PROPN	O	O	4208
plexus	NOUN	O	O	4208
,	PUNCT	O	O	4208
PRL	NOUN	O	Chemical	4208
-	PUNCT	O	O	4208
R	NOUN	O	O	4208
,	PUNCT	O	O	4208
SOCS-3	VERB	O	O	4208
,	PUNCT	O	O	4208
and	CCONJ	O	O	4208
CIS	PROPN	O	O	4208
mRNA	PROPN	O	O	4208
levels	NOUN	O	O	4208
were	AUX	O	O	4208
also	ADV	O	O	4208
induced	VERB	O	O	4208
.	PUNCT	O	O	4208
Estradiol	NOUN	O	O	4209
enhanced	VERB	O	O	4209
these	PRON	O	O	4209
effects	NOUN	O	O	4209
on	ADP	O	O	4209
SOCS-3	VERB	O	O	4209
and	CCONJ	O	O	4209
CIS	PROPN	O	O	4209
.	PUNCT	O	O	4209
Interestingly	ADV	O	O	4210
,	PUNCT	O	O	4210
estradiol	VERB	O	Chemical	4210
also	ADV	O	O	4210
induced	VERB	O	O	4210
PRL	NOUN	O	Chemical	4210
-	PUNCT	O	O	4210
R	NOUN	O	O	4210
,	PUNCT	O	O	4210
SOCS-3	VERB	O	O	4210
,	PUNCT	O	O	4210
and	CCONJ	O	O	4210
CIS	PROPN	O	O	4210
mRNA	PROPN	O	O	4210
levels	NOUN	O	O	4210
independently	ADV	O	O	4210
.	PUNCT	O	O	4210
These	PRON	O	O	4211
data	NOUN	O	O	4211
show	VERB	O	O	4211
that	SCONJ	O	O	4211
GnRH	PROPN	O	O	4211
pulse	NOUN	O	O	4211
frequency	NOUN	O	O	4211
is	AUX	O	O	4211
inhibited	VERB	O	O	4211
by	ADP	O	O	4211
chronic	ADJ	O	O	4211
hyperprolactinemia	NOUN	O	Disease	4211
in	ADP	O	O	4211
a	PRON	O	O	4211
steroid	NOUN	O	Chemical	4211
-	PUNCT	O	O	4211
dependent	ADJ	O	O	4211
manner	VERB	O	O	4211
.	PUNCT	O	O	4211
They	PRON	O	O	4212
also	ADV	O	O	4212
provide	VERB	O	O	4212
evidence	NOUN	O	O	4212
for	ADP	O	O	4212
estradiol	VERB	O	Chemical	4212
-	PUNCT	O	O	4212
dependent	ADJ	O	O	4212
and	CCONJ	O	O	4212
brain	NOUN	O	O	4212
region	NOUN	O	O	4212
-	PUNCT	O	O	4212
specific	ADJ	O	O	4212
regulation	NOUN	O	O	4212
of	ADP	O	O	4212
PRL	NOUN	O	Chemical	4212
-	PUNCT	O	O	4212
R	NOUN	O	O	4212
expression	NOUN	O	O	4212
and	CCONJ	O	O	4212
signaling	VERB	O	O	4212
responses	NOUN	O	O	4212
by	ADP	O	O	4212
prolactin	PROPN	O	O	4212
.	PUNCT	O	O	4212
Estrogen	NOUN	O	O	4215
prevents	VERB	O	O	4215
cholesteryl	PROPN	O	O	4215
ester	PROPN	O	O	4215
accumulation	NOUN	O	O	4215
in	ADP	O	O	4215
macrophages	VERB	O	O	4215
induced	VERB	O	O	4215
by	ADP	O	O	4215
the	PRON	O	O	4215
HIV	PROPN	O	O	4215
protease	NOUN	O	O	4215
inhibitor	NOUN	O	O	4215
ritonavir	NOUN	O	O	4215
.	PUNCT	O	O	4215
Individuals	NOUN	O	O	4216
with	ADP	O	O	4216
HIV	PROPN	O	O	4216
can	AUX	O	O	4216
now	ADV	O	O	4216
live	VERB	O	O	4216
long	ADV	O	O	4216
lives	VERB	O	O	4216
with	ADP	O	O	4216
drug	NOUN	O	O	4216
therapy	NOUN	O	O	4216
that	SCONJ	O	O	4216
often	ADV	O	O	4216
includes	VERB	O	O	4216
protease	NOUN	O	O	4216
inhibitors	NOUN	O	O	4216
such	ADJ	O	O	4216
as	ADP	O	O	4216
ritonavir	NOUN	O	O	4216
.	PUNCT	O	O	4216
Many	ADJ	O	O	4217
patients	NOUN	O	O	4217
,	PUNCT	O	O	4217
however	ADV	O	O	4217
,	PUNCT	O	O	4217
develop	VERB	O	O	4217
negative	ADJ	O	O	4217
long	ADV	O	O	4217
-	PUNCT	O	O	4217
term	NOUN	O	O	4217
side	NOUN	O	O	4217
effects	NOUN	O	O	4217
such	ADJ	O	O	4217
as	ADP	O	O	4217
premature	ADJ	O	O	4217
atherosclerosis	NOUN	O	Disease	4217
.	PUNCT	O	O	4217
We	PRON	O	O	4218
have	VERB	O	O	4218
previously	ADV	O	O	4218
demonstrated	VERB	O	O	4218
that	SCONJ	O	O	4218
ritonavir	NOUN	O	O	4218
treatment	NOUN	O	O	4218
increases	VERB	O	O	4218
atherosclerotic	ADJ	O	O	4218
lesion	NOUN	O	O	4218
formation	NOUN	O	O	4218
in	ADP	O	O	4218
male	NOUN	O	O	4218
mice	NOUN	O	O	4218
to	PART	O	O	4218
a	PRON	O	O	4218
greater	ADJ	O	O	4218
extent	NOUN	O	O	4218
than	ADP	O	O	4218
in	ADP	O	O	4218
female	ADJ	O	O	4218
mice	NOUN	O	O	4218
.	PUNCT	O	O	4218
Furthermore	ADV	O	O	4219
,	PUNCT	O	O	4219
peripheral	ADJ	O	O	4219
blood	NOUN	O	O	4219
monocytes	NOUN	O	O	4219
isolated	VERB	O	O	4219
from	ADP	O	O	4219
ritonavir	NOUN	O	O	4219
-	PUNCT	O	O	4219
treated	VERB	O	O	4219
females	NOUN	O	O	4219
had	VERB	O	O	4219
less	ADV	O	O	4219
cholesteryl	PROPN	O	O	4219
ester	PROPN	O	O	4219
accumulation	NOUN	O	O	4219
.	PUNCT	O	O	4219
In	ADP	O	O	4220
the	PRON	O	O	4220
present	NOUN	O	O	4220
study	VERB	O	O	4220
,	PUNCT	O	O	4220
we	PRON	O	O	4220
have	VERB	O	O	4220
investigated	VERB	O	O	4220
the	PRON	O	O	4220
molecular	ADJ	O	O	4220
mechanisms	NOUN	O	O	4220
by	ADP	O	O	4220
which	PRON	O	O	4220
female	ADJ	O	O	4220
hormones	NOUN	O	O	4220
influence	NOUN	O	O	4220
cholesterol	NOUN	O	Chemical	4220
metabolism	NOUN	O	O	4220
in	ADP	O	O	4220
macrophages	VERB	O	O	4220
in	ADP	O	O	4220
response	NOUN	O	O	4220
to	PART	O	O	4220
the	PRON	O	O	4220
HIV	PROPN	O	O	4220
protease	NOUN	O	O	4220
inhibitor	NOUN	O	O	4220
ritonavir	NOUN	O	O	4220
.	PUNCT	O	O	4220
Briefly	ADV	O	O	4221
,	PUNCT	O	O	4221
cells	NOUN	O	O	4221
were	AUX	O	O	4221
differentiated	VERB	O	O	4221
for	ADP	O	O	4221
72	NUM	O	O	4221
h	X	O	O	4221
with	ADP	O	O	4221
100	NUM	O	O	4221
nM	NOUN	O	O	4221
PMA	PROPN	O	O	4221
to	PART	O	O	4221
obtain	VERB	O	O	4221
a	PRON	O	O	4221
macrophage	NOUN	O	O	4221
-	PUNCT	O	O	4221
like	INTJ	O	O	4221
phenotype	NOUN	O	O	4221
in	ADP	O	O	4221
the	PRON	O	O	4221
presence	NOUN	O	O	4221
or	CCONJ	O	O	4221
absence	NOUN	O	O	4221
of	ADP	O	O	4221
1	X	O	O	4221
nM	NOUN	O	O	4221
17beta	NUM	O	O	4221
-	PUNCT	O	O	4221
estradiol	VERB	O	Chemical	4221
(	PUNCT	O	O	4221
E2	NOUN	O	Chemical	4221
)	PUNCT	O	O	4221
,	PUNCT	O	O	4221
100	NUM	O	O	4221
nM	NOUN	O	O	4221
progesterone	NOUN	O	Chemical	4221
or	CCONJ	O	O	4221
vehicle	NOUN	O	O	4221
(	PUNCT	O	O	4221
0.01%	NOUN	O	O	4221
ethanol	NOUN	O	Chemical	4221
)	PUNCT	O	O	4221
.	PUNCT	O	O	4221
Cells	NOUN	O	O	4222
were	AUX	O	O	4222
then	ADV	O	O	4222
treated	VERB	O	O	4222
with	ADP	O	O	4222
30	NUM	O	O	4222
ng	PROPN	O	O	4222
/	PUNCT	O	O	4222
ml	ADP	O	O	4222
ritonavir	NOUN	O	O	4222
or	CCONJ	O	O	4222
vehicle	NOUN	O	O	4222
in	ADP	O	O	4222
the	PRON	O	O	4222
presence	NOUN	O	O	4222
of	ADP	O	O	4222
aggregated	VERB	O	O	4222
LDL	NOUN	O	O	4222
for	ADP	O	O	4222
24	NUM	O	O	4222
h.	PROPN	O	O	4222
Cell	NOUN	O	O	4222
extracts	VERB	O	O	4222
were	AUX	O	O	4222
harvested	VERB	O	O	4222
,	PUNCT	O	O	4222
and	CCONJ	O	O	4222
lipid	NOUN	O	O	4222
or	CCONJ	O	O	4222
total	ADJ	O	O	4222
RNA	PROPN	O	O	4222
was	AUX	O	O	4222
isolated	VERB	O	O	4222
.	PUNCT	O	O	4222
E2	NOUN	O	Chemical	4223
decreased	VERB	O	O	4223
the	PRON	O	O	4223
accumulation	NOUN	O	O	4223
of	ADP	O	O	4223
cholesteryl esters	NOUN	O	Chemical	4223
in	ADP	O	O	4223
macrophages	VERB	O	O	4223
following	VERB	O	O	4223
ritonavir	NOUN	O	O	4223
treatment	NOUN	O	O	4223
.	PUNCT	O	O	4223
Ritonavir	NOUN	O	O	4224
increased	VERB	O	O	4224
the	PRON	O	O	4224
expression	NOUN	O	O	4224
of	ADP	O	O	4224
the	PRON	O	O	4224
scavenger	NOUN	O	O	4224
receptor	NOUN	O	O	4224
,	PUNCT	O	O	4224
CD36	NOUN	O	O	4224
mRNA	PROPN	O	O	4224
,	PUNCT	O	O	4224
responsible	ADJ	O	O	4224
for	ADP	O	O	4224
the	PRON	O	O	4224
uptake	NOUN	O	O	4224
of	ADP	O	O	4224
LDL	NOUN	O	O	4224
.	PUNCT	O	O	4224
Additionally	ADV	O	O	4225
,	PUNCT	O	O	4225
ritonavir	NOUN	O	O	4225
treatment	NOUN	O	O	4225
selectively	ADV	O	O	4225
increased	VERB	O	O	4225
the	PRON	O	O	4225
relative	ADJ	O	O	4225
levels	NOUN	O	O	4225
of	ADP	O	O	4225
PPARgamma	PROPN	O	O	4225
mRNA	PROPN	O	O	4225
,	PUNCT	O	O	4225
a	PRON	O	O	4225
transcription	PROPN	O	O	4225
factor	NOUN	O	O	4225
responsible	ADJ	O	O	4225
for	ADP	O	O	4225
the	PRON	O	O	4225
regulation	NOUN	O	O	4225
of	ADP	O	O	4225
CD36	NOUN	O	O	4225
mRNA	PROPN	O	O	4225
expression	NOUN	O	O	4225
.	PUNCT	O	O	4225
Treatment	NOUN	O	O	4226
with	ADP	O	O	4226
E2	NOUN	O	Chemical	4226
,	PUNCT	O	O	4226
however	ADV	O	O	4226
,	PUNCT	O	O	4226
failed	VERB	O	O	4226
to	PART	O	O	4226
prevent	VERB	O	O	4226
these	PRON	O	O	4226
increases	VERB	O	O	4226
at	ADP	O	O	4226
the	PRON	O	O	4226
mRNA	PROPN	O	O	4226
level	VERB	O	O	4226
.	PUNCT	O	O	4226
E2	NOUN	O	Chemical	4227
did	VERB	O	O	4227
,	PUNCT	O	O	4227
however	ADV	O	O	4227
,	PUNCT	O	O	4227
significantly	ADV	O	O	4227
suppress	VERB	O	O	4227
CD36	NOUN	O	O	4227
protein	NOUN	O	O	4227
levels	NOUN	O	O	4227
as	ADP	O	O	4227
measured	VERB	O	O	4227
by	ADP	O	O	4227
fluorescent	NOUN	O	O	4227
immunocytochemistry	NOUN	O	O	4227
.	PUNCT	O	O	4227
This	PRON	O	O	4228
data	NOUN	O	O	4228
suggests	VERB	O	O	4228
that	SCONJ	O	O	4228
E2	NOUN	O	Chemical	4228
modifies	VERB	O	O	4228
the	PRON	O	O	4228
expression	NOUN	O	O	4228
of	ADP	O	O	4228
CD36	NOUN	O	O	4228
at	ADP	O	O	4228
the	PRON	O	O	4228
level	VERB	O	O	4228
of	ADP	O	O	4228
protein	NOUN	O	O	4228
expression	NOUN	O	O	4228
in	ADP	O	O	4228
monocyte	PROPN	O	O	4228
-	PUNCT	O	O	4228
derived	VERB	O	O	4228
macrophages	VERB	O	O	4228
resulting	VERB	O	O	4228
in	ADP	O	O	4228
reduced	VERB	O	O	4228
cholesteryl	PROPN	O	O	4228
ester	PROPN	O	O	4228
accumulation	NOUN	O	O	4228
following	VERB	O	O	4228
ritonavir	NOUN	O	O	4228
treatment	NOUN	O	O	4228
.	PUNCT	O	O	4228
Upregulation	PROPN	O	O	4231
of	ADP	O	O	4231
brain	NOUN	O	O	4231
expression	NOUN	O	O	4231
of	ADP	O	O	4231
P	NOUN	O	Chemical	4231
-	PUNCT	O	O	4231
glycoprotein	NOUN	O	O	4231
in	ADP	O	O	4231
MRP2-deficient	ADJ	O	O	4231
TR(-	NOUN	O	O	4231
)	PUNCT	O	O	4231
rats	NOUN	O	O	4231
resembles	VERB	O	O	4231
seizure	NOUN	O	Disease	4231
-	PUNCT	O	O	4231
induced	VERB	O	O	4231
up	ADP	O	O	4231
-	PUNCT	O	O	4231
regulation	NOUN	O	O	4231
of	ADP	O	O	4231
this	PRON	O	O	4231
drug	NOUN	O	O	4231
efflux	NOUN	O	O	4231
transporter	NOUN	O	O	4231
in	ADP	O	O	4231
normal	ADJ	O	O	4231
rats	NOUN	O	O	4231
.	PUNCT	O	O	4231
By	ADP	O	O	4232
using	VERB	O	O	4232
this	PRON	O	O	4232
strategy	NOUN	O	O	4232
to	PART	O	O	4232
study	VERB	O	O	4232
the	PRON	O	O	4232
involvement	NOUN	O	O	4232
of	ADP	O	O	4232
MRP2	PROPN	O	O	4232
in	ADP	O	O	4232
brain	NOUN	O	O	4232
access	NOUN	O	O	4232
of	ADP	O	O	4232
antiepileptic	ADJ	O	O	4232
drugs	NOUN	O	O	4232
(	PUNCT	O	O	4232
AEDs	PROPN	O	O	4232
)	PUNCT	O	O	4232
,	PUNCT	O	O	4232
we	PRON	O	O	4232
recently	ADV	O	O	4232
reported	VERB	O	O	4232
that	SCONJ	O	O	4232
phenytoin	NOUN	O	Chemical	4232
is	AUX	O	O	4232
a	PRON	O	O	4232
substrate	NOUN	O	O	4232
for	ADP	O	O	4232
MRP2	PROPN	O	O	4232
in	ADP	O	O	4232
the	PRON	O	O	4232
BBB	PROPN	O	O	4232
.	PUNCT	O	O	4232
A	PRON	O	O	4233
comparable	ADJ	O	O	4233
overexpression	NOUN	O	O	4233
of	ADP	O	O	4233
Pgp	VERB	O	O	4233
in	ADP	O	O	4233
the	PRON	O	O	4233
BBB	PROPN	O	O	4233
was	AUX	O	O	4233
obtained	VERB	O	O	4233
after	ADP	O	O	4233
pilocarpine	NOUN	O	Chemical	4233
-	PUNCT	O	O	4233
induced	VERB	O	O	4233
seizures	NOUN	O	Disease	4233
in	ADP	O	O	4233
wild	ADJ	O	O	4233
-	PUNCT	O	O	4233
type	NOUN	O	O	4233
Wistar	PROPN	O	O	4233
rats	NOUN	O	O	4233
.	PUNCT	O	O	4233
Experiments	NOUN	O	O	4234
with	ADP	O	O	4234
systemic	ADJ	O	O	4234
administration	NOUN	O	O	4234
of	ADP	O	O	4234
the	PRON	O	O	4234
Pgp	VERB	O	O	4234
substrate	NOUN	O	O	4234
phenobarbital	NOUN	O	Chemical	4234
and	CCONJ	O	O	4234
the	PRON	O	O	4234
selective	ADJ	O	O	4234
Pgp	VERB	O	O	4234
inhibitor	NOUN	O	O	4234
tariquidar	VERB	O	O	4234
in	ADP	O	O	4234
TR(-	NOUN	O	O	4234
)	PUNCT	O	O	4234
rats	NOUN	O	O	4234
substantiated	VERB	O	O	4234
that	SCONJ	O	O	4234
Pgp	VERB	O	O	4234
is	AUX	O	O	4234
functional	ADJ	O	O	4234
and	CCONJ	O	O	4234
compensates	VERB	O	O	4234
for	ADP	O	O	4234
the	PRON	O	O	4234
lack	VERB	O	O	4234
of	ADP	O	O	4234
MRP2	PROPN	O	O	4234
in	ADP	O	O	4234
the	PRON	O	O	4234
BBB	PROPN	O	O	4234
.	PUNCT	O	O	4234
Because	SCONJ	O	O	4235
such	ADJ	O	O	4235
a	PRON	O	O	4235
compensatory	ADJ	O	O	4235
mechanism	NOUN	O	O	4235
most	ADV	O	O	4235
likely	ADV	O	O	4235
occurs	VERB	O	O	4235
to	PART	O	O	4235
reduce	VERB	O	O	4235
injury	NOUN	O	O	4235
to	PART	O	O	4235
the	PRON	O	O	4235
brain	NOUN	O	O	4235
from	ADP	O	O	4235
cytotoxic	ADJ	O	O	4235
compounds	NOUN	O	O	4235
,	PUNCT	O	O	4235
the	PRON	O	O	4235
present	NOUN	O	O	4235
data	NOUN	O	O	4235
substantiate	VERB	O	O	4235
the	PRON	O	O	4235
concept	NOUN	O	O	4235
that	SCONJ	O	O	4235
MRP2	PROPN	O	O	4235
performs	VERB	O	O	4235
a	PRON	O	O	4235
protective	ADJ	O	O	4235
role	NOUN	O	O	4235
in	ADP	O	O	4235
the	PRON	O	O	4235
BBB	PROPN	O	O	4235
.	PUNCT	O	O	4235
Furthermore	ADV	O	O	4236
,	PUNCT	O	O	4236
our	PRON	O	O	4236
data	NOUN	O	O	4236
suggest	VERB	O	O	4236
that	SCONJ	O	O	4236
TR(-	NOUN	O	O	4236
)	PUNCT	O	O	4236
rats	NOUN	O	O	4236
are	AUX	O	O	4236
an	PRON	O	O	4236
interesting	ADJ	O	O	4236
tool	NOUN	O	O	4236
to	PART	O	O	4236
study	VERB	O	O	4236
consequences	NOUN	O	O	4236
of	ADP	O	O	4236
overexpression	NOUN	O	O	4236
of	ADP	O	O	4236
Pgp	VERB	O	O	4236
in	ADP	O	O	4236
the	PRON	O	O	4236
BBB	PROPN	O	O	4236
on	ADP	O	O	4236
access	NOUN	O	O	4236
of	ADP	O	O	4236
drugs	NOUN	O	O	4236
in	ADP	O	O	4236
the	PRON	O	O	4236
brain	NOUN	O	O	4236
,	PUNCT	O	O	4236
without	ADP	O	O	4236
the	PRON	O	O	4236
need	VERB	O	O	4236
of	ADP	O	O	4236
inducing	VERB	O	O	4236
seizures	NOUN	O	Disease	4236
or	CCONJ	O	O	4236
other	ADJ	O	O	4236
Pgp	VERB	O	O	4236
-	PUNCT	O	O	4236
enhancing	VERB	O	O	4236
events	NOUN	O	O	4236
for	ADP	O	O	4236
this	PRON	O	O	4236
purpose	NOUN	O	O	4236
.	PUNCT	O	O	4236
Use	VERB	O	O	4239
of	ADP	O	O	4239
chromosome	NOUN	O	O	4239
substitution	NOUN	O	O	4239
strains	VERB	O	O	4239
to	PART	O	O	4239
identify	VERB	O	O	4239
seizure	NOUN	O	Disease	4239
susceptibility	NOUN	O	O	4239
loci	NOUN	O	O	4239
in	ADP	O	O	4239
mice	NOUN	O	O	4239
.	PUNCT	O	O	4239
Seizure	NOUN	O	Disease	4240
susceptibility	NOUN	O	O	4240
varies	VERB	O	O	4240
among	ADP	O	O	4240
inbred	ADJ	O	O	4240
mouse	PROPN	O	O	4240
strains	VERB	O	O	4240
.	PUNCT	O	O	4240
Chromosome	NOUN	O	O	4241
substitution	NOUN	O	O	4241
strains	VERB	O	O	4241
(	PUNCT	O	O	4241
CSS	PROPN	O	O	4241
)	PUNCT	O	O	4241
,	PUNCT	O	O	4241
in	ADP	O	O	4241
which	PRON	O	O	4241
a	PRON	O	O	4241
single	ADJ	O	O	4241
chromosome	NOUN	O	O	4241
from	ADP	O	O	4241
one	NUM	O	O	4241
inbred	ADJ	O	O	4241
strain	VERB	O	O	4241
(	PUNCT	O	O	4241
donor	NOUN	O	O	4241
)	PUNCT	O	O	4241
has	VERB	O	O	4241
been	AUX	O	O	4241
transferred	VERB	O	O	4241
onto	ADP	O	O	4241
a	PRON	O	O	4241
second	ADV	O	O	4241
strain	VERB	O	O	4241
(	PUNCT	O	O	4241
host	NOUN	O	O	4241
)	PUNCT	O	O	4241
by	ADP	O	O	4241
repeated	VERB	O	O	4241
backcrossing	VERB	O	O	4241
,	PUNCT	O	O	4241
may	AUX	O	O	4241
be	AUX	O	O	4241
used	VERB	O	O	4241
to	PART	O	O	4241
identify	VERB	O	O	4241
quantitative	ADJ	O	O	4241
trait	NOUN	O	O	4241
loci	NOUN	O	O	4241
(	PUNCT	O	O	4241
QTLs	NOUN	O	O	4241
)	PUNCT	O	O	4241
that	SCONJ	O	O	4241
contribute	VERB	O	O	4241
to	PART	O	O	4241
seizure	NOUN	O	Disease	4241
susceptibility	NOUN	O	O	4241
.	PUNCT	O	O	4241
QTLs	NOUN	O	O	4242
for	ADP	O	O	4242
susceptibility	NOUN	O	O	4242
to	PART	O	O	4242
pilocarpine	NOUN	O	Chemical	4242
-	PUNCT	O	O	4242
induced	VERB	O	O	4242
seizures	NOUN	O	Disease	4242
,	PUNCT	O	O	4242
a	PRON	O	O	4242
model	NOUN	O	O	4242
of	ADP	O	O	4242
temporal lobe epilepsy	NOUN	O	Disease	4242
,	PUNCT	O	O	4242
have	VERB	O	O	4242
not	PART	O	O	4242
been	AUX	O	O	4242
reported	VERB	O	O	4242
,	PUNCT	O	O	4242
and	CCONJ	O	O	4242
CSS	PROPN	O	O	4242
have	VERB	O	O	4242
not	PART	O	O	4242
previously	ADV	O	O	4242
been	AUX	O	O	4242
used	VERB	O	O	4242
to	PART	O	O	4242
localize	VERB	O	O	4242
seizure	NOUN	O	Disease	4242
susceptibility	NOUN	O	O	4242
genes	NOUN	O	O	4242
.	PUNCT	O	O	4242
CSS	PROPN	O	O	4243
panel	NOUN	O	O	4243
to	PART	O	O	4243
localize	VERB	O	O	4243
genes	NOUN	O	O	4243
involved	VERB	O	O	4243
in	ADP	O	O	4243
susceptibility	NOUN	O	O	4243
to	PART	O	O	4243
pilocarpine	NOUN	O	Chemical	4243
-	PUNCT	O	O	4243
induced	VERB	O	O	4243
seizures	NOUN	O	Disease	4243
.	PUNCT	O	O	4243
A	PRON	O	O	4244
/	PUNCT	O	O	4244
J	PROPN	O	O	4244
were	AUX	O	O	4244
tested	VERB	O	O	4244
for	ADP	O	O	4244
susceptibility	NOUN	O	O	4244
to	PART	O	O	4244
pilocarpine	NOUN	O	Chemical	4244
-	PUNCT	O	O	4244
induced	VERB	O	O	4244
seizures	NOUN	O	Disease	4244
.	PUNCT	O	O	4244
B6	NOUN	O	O	4245
mice	NOUN	O	O	4245
were	AUX	O	O	4245
resistant	ADJ	O	O	4245
to	PART	O	O	4245
seizures	NOUN	O	Disease	4245
and	CCONJ	O	O	4245
slower	ADJ	O	O	4245
to	PART	O	O	4245
reach	VERB	O	O	4245
stages	NOUN	O	O	4245
compared	VERB	O	O	4245
to	PART	O	O	4245
A	PRON	O	O	4245
/	PUNCT	O	O	4245
J	PROPN	O	O	4245
mice	NOUN	O	O	4245
.	PUNCT	O	O	4245
CSS	PROPN	O	O	4246
mapping	NOUN	O	O	4246
suggests	VERB	O	O	4246
seizure	NOUN	O	Disease	4246
susceptibility	NOUN	O	O	4246
loci	NOUN	O	O	4246
on	ADP	O	O	4246
mouse	PROPN	O	O	4246
Chromosomes	NOUN	O	O	4246
10	NUM	O	O	4246
and	CCONJ	O	O	4246
18	NUM	O	O	4246
.	PUNCT	O	O	4246
This	PRON	O	O	4247
approach	NOUN	O	O	4247
provides	VERB	O	O	4247
a	PRON	O	O	4247
framework	NOUN	O	O	4247
for	ADP	O	O	4247
identifying	VERB	O	O	4247
potentially	ADV	O	O	4247
novel	NOUN	O	O	4247
homologous	ADJ	O	O	4247
candidate	NOUN	O	O	4247
genes	NOUN	O	O	4247
for	ADP	O	O	4247
human	PROPN	O	O	4247
temporal lobe epilepsy	NOUN	O	Disease	4247
.	PUNCT	O	O	4247
Investigation	NOUN	O	O	4250
of	ADP	O	O	4250
mitochondrial	ADJ	O	O	4250
involvement	NOUN	O	O	4250
in	ADP	O	O	4250
the	PRON	O	O	4250
experimental	ADJ	O	O	4250
model	NOUN	O	O	4250
of	ADP	O	O	4250
epilepsy	NOUN	O	Disease	4250
induced	VERB	O	O	4250
by	ADP	O	O	4250
pilocarpine	NOUN	O	Chemical	4250
.	PUNCT	O	O	4250
Mitochondrial	NOUN	O	O	4251
abnormalities	NOUN	O	O	4251
have	VERB	O	O	4251
been	AUX	O	O	4251
associated	VERB	O	O	4251
with	ADP	O	O	4251
several	ADJ	O	O	4251
aspects	NOUN	O	O	4251
of	ADP	O	O	4251
epileptogenesis	NOUN	O	O	4251
,	PUNCT	O	O	4251
such	ADJ	O	O	4251
as	ADP	O	O	4251
energy	PROPN	O	O	4251
generation	NOUN	O	O	4251
,	PUNCT	O	O	4251
control	VERB	O	O	4251
of	ADP	O	O	4251
cell	NOUN	O	O	4251
death	NOUN	O	O	4251
,	PUNCT	O	O	4251
neurotransmitter	NOUN	O	O	4251
synthesis	NOUN	O	O	4251
,	PUNCT	O	O	4251
and	CCONJ	O	O	4251
free	ADJ	O	O	4251
radical	ADJ	O	O	4251
(	PUNCT	O	O	4251
FR	PROPN	O	O	4251
)	PUNCT	O	O	4251
production	NOUN	O	O	4251
.	PUNCT	O	O	4251
In	ADP	O	O	4252
this	PRON	O	O	4252
study	VERB	O	O	4252
,	PUNCT	O	O	4252
we	PRON	O	O	4252
investigated	VERB	O	O	4252
whether	SCONJ	O	O	4252
increased	VERB	O	O	4252
generation	NOUN	O	O	4252
of	ADP	O	O	4252
FR	PROPN	O	O	4252
during	ADP	O	O	4252
status epilepticus	VERB	O	Disease	4252
would	AUX	O	O	4252
be	AUX	O	O	4252
sufficient	ADJ	O	O	4252
to	PART	O	O	4252
provoke	VERB	O	O	4252
abnormalities	NOUN	O	O	4252
in	ADP	O	O	4252
mtDNA	PROPN	O	O	4252
and	CCONJ	O	O	4252
in	ADP	O	O	4252
the	PRON	O	O	4252
expression	NOUN	O	O	4252
and	CCONJ	O	O	4252
activity	NOUN	O	O	4252
of	ADP	O	O	4252
cytochrome	ADP	O	O	4252
c	X	O	O	4252
oxidase	NOUN	O	O	4252
(	PUNCT	O	O	4252
CCO	PROPN	O	O	4252
)	PUNCT	O	O	4252
,	PUNCT	O	O	4252
complex	ADJ	O	O	4252
IV	NUM	O	O	4252
of	ADP	O	O	4252
the	PRON	O	O	4252
respiratory	NOUN	O	O	4252
chain	NOUN	O	O	4252
,	PUNCT	O	O	4252
in	ADP	O	O	4252
the	PRON	O	O	4252
chronic	ADJ	O	O	4252
phase	NOUN	O	O	4252
of	ADP	O	O	4252
the	PRON	O	O	4252
pilocarpine	NOUN	O	Chemical	4252
model	NOUN	O	O	4252
of	ADP	O	O	4252
temporal lobe epilepsy	NOUN	O	Disease	4252
.	PUNCT	O	O	4252
Although	SCONJ	O	O	4253
evidences	NOUN	O	O	4253
of	ADP	O	O	4253
mitochondrial	ADJ	O	O	4253
abnormalities	NOUN	O	O	4253
were	AUX	O	O	4253
found	VERB	O	O	4253
in	ADP	O	O	4253
previously	ADV	O	O	4253
published	VERB	O	O	4253
studies	NOUN	O	O	4253
,	PUNCT	O	O	4253
our	PRON	O	O	4253
results	VERB	O	O	4253
do	VERB	O	O	4253
not	PART	O	O	4253
suggest	VERB	O	O	4253
that	SCONJ	O	O	4253
the	PRON	O	O	4253
FRs	PROPN	O	O	4253
,	PUNCT	O	O	4253
generated	VERB	O	O	4253
during	ADP	O	O	4253
the	PRON	O	O	4253
acute	ADJ	O	O	4253
phase	NOUN	O	O	4253
,	PUNCT	O	O	4253
determined	VERB	O	O	4253
important	ADJ	O	O	4253
abnormalities	NOUN	O	O	4253
in	ADP	O	O	4253
mtDNA	PROPN	O	O	4253
,	PUNCT	O	O	4253
in	ADP	O	O	4253
expression	NOUN	O	O	4253
of	ADP	O	O	4253
CCO	PROPN	O	O	4253
-	PUNCT	O	O	4253
I	PRON	O	O	4253
,	PUNCT	O	O	4253
and	CCONJ	O	O	4253
in	ADP	O	O	4253
CCO	PROPN	O	O	4253
activity	NOUN	O	O	4253
.	PUNCT	O	O	4253
Causes	VERB	O	O	4256
of	ADP	O	O	4256
acute	ADJ	O	O	4256
thrombotic	ADJ	O	Disease	4256
microangiopathy	VERB	O	Disease	4256
in	ADP	O	O	4256
patients	NOUN	O	O	4256
receiving	VERB	O	O	4256
kidney	NOUN	O	O	4256
transplantation	NOUN	O	O	4256
.	PUNCT	O	O	4256
Thrombotic	ADJ	O	Disease	4257
microangiopathy	VERB	O	Disease	4257
is	AUX	O	O	4257
a	PRON	O	O	4257
well	ADV	O	O	4257
-	PUNCT	O	O	4257
known	VERB	O	O	4257
problem	NOUN	O	O	4257
in	ADP	O	O	4257
patients	NOUN	O	O	4257
following	VERB	O	O	4257
renal	ADJ	O	O	4257
transplantation	NOUN	O	O	4257
.	PUNCT	O	O	4257
In	ADP	O	O	4258
postrenal	PROPN	O	O	4258
transplantation	NOUN	O	O	4258
,	PUNCT	O	O	4258
thrombotic	ADJ	O	Disease	4258
microangiopathy	VERB	O	Disease	4258
is	AUX	O	O	4258
often	ADV	O	O	4258
a	PRON	O	O	4258
reflection	NOUN	O	O	4258
of	ADP	O	O	4258
hemolytic uremic syndrome	NOUN	O	Disease	4258
.	PUNCT	O	O	4258
We	PRON	O	O	4259
aimed	VERB	O	O	4259
to	PART	O	O	4259
determine	VERB	O	O	4259
the	PRON	O	O	4259
causes	VERB	O	O	4259
of	ADP	O	O	4259
thrombotic	ADJ	O	Disease	4259
microangiopathy	VERB	O	Disease	4259
in	ADP	O	O	4259
a	PRON	O	O	4259
population	NOUN	O	O	4259
of	ADP	O	O	4259
renal	ADJ	O	O	4259
transplantation	NOUN	O	O	4259
recipients	NOUN	O	O	4259
and	CCONJ	O	O	4259
discuss	VERB	O	O	4259
the	PRON	O	O	4259
literature	NOUN	O	O	4259
.	PUNCT	O	O	4259
:	PUNCT	O	O	4260
We	PRON	O	O	4260
investigated	VERB	O	O	4260
the	PRON	O	O	4260
causes	VERB	O	O	4260
of	ADP	O	O	4260
thrombotic	ADJ	O	Disease	4260
microangiopathy	VERB	O	Disease	4260
during	ADP	O	O	4260
a	PRON	O	O	4260
1-year	NOUN	O	O	4260
period	NOUN	O	O	4260
,	PUNCT	O	O	4260
from	ADP	O	O	4260
June	PROPN	O	O	4260
2003	NUM	O	O	4260
to	PART	O	O	4260
June	PROPN	O	O	4260
2004	NUM	O	O	4260
,	PUNCT	O	O	4260
at	ADP	O	O	4260
the	PRON	O	O	4260
King	NOUN	O	O	4260
Fahad	NOUN	O	O	4260
National	ADJ	O	O	4260
Guard	NOUN	O	O	4260
Hospital	NOUN	O	O	4260
in	ADP	O	O	4260
Riyadh	PROPN	O	O	4260
,	PUNCT	O	O	4260
Saudi	ADJ	O	O	4260
Arabia	PROPN	O	O	4260
,	PUNCT	O	O	4260
by	ADP	O	O	4260
reviewing	VERB	O	O	4260
the	PRON	O	O	4260
slides	VERB	O	O	4260
of	ADP	O	O	4260
all	PRON	O	O	4260
transplant	NOUN	O	O	4260
biopsies	NOUN	O	O	4260
Five	NUM	O	O	4261
cases	NOUN	O	O	4261
of	ADP	O	O	4261
thrombotic	ADJ	O	Disease	4261
microangiopathy	VERB	O	Disease	4261
were	AUX	O	O	4261
found	VERB	O	O	4261
.	PUNCT	O	O	4261
Three	NUM	O	O	4262
cases	NOUN	O	O	4262
were	AUX	O	O	4262
related	ADJ	O	O	4262
to	PART	O	O	4262
cyclosporine	NOUN	O	Chemical	4262
,	PUNCT	O	O	4262
and	CCONJ	O	O	4262
1	X	O	O	4262
case	NOUN	O	O	4262
was	AUX	O	O	4262
secondary	ADJ	O	O	4262
to	PART	O	O	4262
both	PRON	O	O	4262
cyclosporine	NOUN	O	Chemical	4262
and	CCONJ	O	O	4262
tacrolimus	NOUN	O	Chemical	4262
.	PUNCT	O	O	4262
The	PRON	O	O	4263
fifth	ADJ	O	O	4263
case	NOUN	O	O	4263
had	VERB	O	O	4263
features	VERB	O	O	4263
of	ADP	O	O	4263
thrombotic	ADJ	O	Disease	4263
microangiopathy	VERB	O	Disease	4263
related	ADJ	O	O	4263
to	PART	O	O	4263
an	PRON	O	O	4263
antiphospholipid	NOUN	O	O	4263
syndrome	NOUN	O	O	4263
in	ADP	O	O	4263
a	PRON	O	O	4263
patient	NOUN	O	O	4263
with	ADP	O	O	4263
systemic lupus erythematosus	PROPN	O	Disease	4263
.	PUNCT	O	O	4263
In	ADP	O	O	4264
the	PRON	O	O	4264
literature	NOUN	O	O	4264
,	PUNCT	O	O	4264
the	PRON	O	O	4264
most	ADV	O	O	4264
-	PUNCT	O	O	4264
frequent	ADJ	O	O	4264
cause	VERB	O	O	4264
of	ADP	O	O	4264
hemolytic uremic syndrome	NOUN	O	Disease	4264
in	ADP	O	O	4264
patients	NOUN	O	O	4264
following	VERB	O	O	4264
renal	ADJ	O	O	4264
transplantation	NOUN	O	O	4264
is	AUX	O	O	4264
recurrence	NOUN	O	O	4264
of	ADP	O	O	4264
the	PRON	O	O	4264
hemolytic uremic syndrome	NOUN	O	Disease	4264
.	PUNCT	O	O	4264
cyclosporine	NOUN	O	Chemical	4265
,	PUNCT	O	O	4265
tacrolimus	NOUN	O	Chemical	4265
)	PUNCT	O	O	4265
toxicity	NOUN	O	Disease	4266
,	PUNCT	O	O	4266
procoagulant	NOUN	O	O	4266
status	NOUN	O	O	4266
,	PUNCT	O	O	4266
and	CCONJ	O	O	4266
antibody	NOUN	O	O	4266
-	PUNCT	O	O	4266
mediated	VERB	O	O	4266
rejection	NOUN	O	O	4266
.	PUNCT	O	O	4266
We	PRON	O	O	4267
found	VERB	O	O	4267
that	SCONJ	O	O	4267
the	PRON	O	O	4267
most	ADV	O	O	4267
-	PUNCT	O	O	4267
frequent	ADJ	O	O	4267
cause	VERB	O	O	4267
of	ADP	O	O	4267
thrombotic	ADJ	O	Disease	4267
microangiopathy	VERB	O	Disease	4267
was	AUX	O	O	4267
drug	NOUN	O	O	4267
related	ADJ	O	O	4267
,	PUNCT	O	O	4267
secondary	ADJ	O	O	4267
mainly	ADV	O	O	4267
to	PART	O	O	4267
cyclosporine	NOUN	O	Chemical	4267
.	PUNCT	O	O	4267
In	ADP	O	O	4268
the	PRON	O	O	4268
current	ADJ	O	O	4268
study	VERB	O	O	4268
,	PUNCT	O	O	4268
the	PRON	O	O	4268
frequency	NOUN	O	O	4268
of	ADP	O	O	4268
thrombotic	ADJ	O	Disease	4268
microangiopathy	VERB	O	Disease	4268
was	AUX	O	O	4268
similar	ADJ	O	O	4268
to	PART	O	O	4268
the	PRON	O	O	4268
percentage	NOUN	O	O	4268
reported	VERB	O	O	4268
in	ADP	O	O	4268
the	PRON	O	O	4268
literature	NOUN	O	O	4268
(	PUNCT	O	O	4268
20%	NOUN	O	O	4268
)	PUNCT	O	O	4268
.	PUNCT	O	O	4268
Severe	ADJ	O	O	4271
reversible	ADJ	O	O	4271
left	VERB	O	O	4271
ventricular	ADJ	O	O	4271
systolic	ADV	O	O	4271
and	CCONJ	O	O	4271
diastolic	ADV	O	O	4271
dysfunction	NOUN	O	O	4271
due	ADJ	O	O	4271
to	PART	O	O	4271
accidental	ADJ	O	O	4271
iatrogenic	ADJ	O	O	4271
epinephrine	NOUN	O	Chemical	4271
overdose	NOUN	O	Disease	4271
.	PUNCT	O	O	4271
Catecholamine	NOUN	O	O	4272
-	PUNCT	O	O	4272
induced	VERB	O	O	4272
cardiomyopathy	ADJ	O	Disease	4272
due	ADJ	O	O	4272
to	PART	O	O	4272
chronic	ADJ	O	O	4272
excess	ADJ	O	O	4272
of	ADP	O	O	4272
endogenous	ADJ	O	O	4272
catecholamines	NOUN	O	Chemical	4272
has	VERB	O	O	4272
been	AUX	O	O	4272
recognized	VERB	O	O	4272
for	ADP	O	O	4272
decades	NOUN	O	O	4272
as	ADP	O	O	4272
a	PRON	O	O	4272
clinical	ADJ	O	O	4272
phenomenon	NOUN	O	O	4272
.	PUNCT	O	O	4272
In	ADP	O	O	4273
contrast	NOUN	O	O	4273
,	PUNCT	O	O	4273
reports	VERB	O	O	4273
of	ADP	O	O	4273
myocardial	ADJ	O	O	4273
dysfunction	NOUN	O	O	4273
due	ADJ	O	O	4273
to	PART	O	O	4273
acute	ADJ	O	O	4273
iatrogenic	ADJ	O	O	4273
overdose	NOUN	O	Disease	4273
are	AUX	O	O	4273
rare	ADJ	O	O	4273
.	PUNCT	O	O	4273
A	PRON	O	O	4274
35-year	NOUN	O	O	4274
-	PUNCT	O	O	4274
old	ADJ	O	O	4274
woman	NOUN	O	O	4274
whose	DET	O	O	4274
cervix	NOUN	O	O	4274
uteri	NOUN	O	O	4274
was	AUX	O	O	4274
inadvertently	ADV	O	O	4274
injected	VERB	O	O	4274
with	ADP	O	O	4274
8	NUM	O	O	4274
mg	VERB	O	O	4274
of	ADP	O	O	4274
epinephrine	NOUN	O	Chemical	4274
developed	VERB	O	O	4274
myocardial	ADJ	O	O	4274
stunning	ADJ	O	O	4274
that	SCONJ	O	O	4274
was	AUX	O	O	4274
characterized	VERB	O	O	4274
by	ADP	O	O	4274
severe	ADJ	O	O	4274
hemodynamic	ADJ	O	O	4274
compromise	NOUN	O	O	4274
,	PUNCT	O	O	4274
profound	ADJ	O	O	4274
,	PUNCT	O	O	4274
albeit	SCONJ	O	O	4274
transient	ADJ	O	O	4274
,	PUNCT	O	O	4274
left	VERB	O	O	4274
ventricular	ADJ	O	O	4274
systolic	ADV	O	O	4274
and	CCONJ	O	O	4274
diastolic	ADV	O	O	4274
dysfunction	NOUN	O	O	4274
,	PUNCT	O	O	4274
and	CCONJ	O	O	4274
only	ADV	O	O	4274
modestly	ADV	O	O	4274
elevated	ADJ	O	O	4274
biochemical	ADJ	O	O	4274
markers	NOUN	O	O	4274
of	ADP	O	O	4274
myocardial	ADJ	O	O	4274
necrosis	NOUN	O	Disease	4274
.	PUNCT	O	O	4274
Urinary	NOUN	O	O	4277
bladder cancer	NOUN	O	Disease	4277
in	ADP	O	O	4277
Wegener	PROPN	O	O	4277
's	AUX	O	O	4277
granulomatosis	NOUN	O	O	4277
:	PUNCT	O	O	4277
risks	NOUN	O	O	4278
and	CCONJ	O	O	4278
relation	NOUN	O	O	4278
to	PART	O	O	4278
cyclophosphamide	VERB	O	Chemical	4278
.	PUNCT	O	O	4278
OBJECTIVE	VERB	O	O	4279
:	PUNCT	O	O	4279
To	PART	O	O	4279
assess	VERB	O	O	4279
and	CCONJ	O	O	4279
characterise	VERB	O	O	4279
the	PRON	O	O	4279
risk	NOUN	O	O	4279
of	ADP	O	O	4279
bladder cancer	NOUN	O	Disease	4279
,	PUNCT	O	O	4279
and	CCONJ	O	O	4279
its	PRON	O	O	4279
relation	NOUN	O	O	4279
to	PART	O	O	4279
cyclophosphamide	VERB	O	Chemical	4279
,	PUNCT	O	O	4279
in	ADP	O	O	4279
patients	NOUN	O	O	4279
with	ADP	O	O	4279
Wegener	PROPN	O	O	4279
's	AUX	O	O	4279
granulomatosis	NOUN	O	O	4279
.	PUNCT	O	O	4279
METHODS	NOUN	O	O	4280
:	PUNCT	O	O	4280
In	ADP	O	O	4280
the	PRON	O	O	4280
population	NOUN	O	O	4280
based	VERB	O	O	4280
,	PUNCT	O	O	4280
nationwide	ADV	O	O	4280
Swedish	ADJ	O	O	4280
Inpatient	NOUN	O	O	4280
Register	VERB	O	O	4280
a	PRON	O	O	4280
cohort	NOUN	O	O	4280
of	ADP	O	O	4280
1065	NUM	O	O	4280
patients	NOUN	O	O	4280
with	ADP	O	O	4280
Wegener	PROPN	O	O	4280
's	AUX	O	O	4280
granulomatosis	NOUN	O	O	4280
,	PUNCT	O	O	4280
1969	NUM	O	O	4280
-	PUNCT	O	O	4280
95	NUM	O	O	4280
,	PUNCT	O	O	4280
was	AUX	O	O	4280
identified	VERB	O	O	4280
.	PUNCT	O	O	4280
Through	ADP	O	O	4281
linkage	NOUN	O	O	4281
with	ADP	O	O	4281
the	PRON	O	O	4281
Swedish	ADJ	O	O	4281
Cancer	NOUN	O	O	4281
Register	VERB	O	O	4281
,	PUNCT	O	O	4281
all	PRON	O	O	4281
subjects	NOUN	O	O	4281
in	ADP	O	O	4281
this	PRON	O	O	4281
cohort	NOUN	O	O	4281
diagnosed	VERB	O	O	4281
with	ADP	O	O	4281
bladder cancer	NOUN	O	Disease	4281
were	AUX	O	O	4281
identified	VERB	O	O	4281
.	PUNCT	O	O	4281
Nested	VERB	O	O	4282
within	ADP	O	O	4282
the	PRON	O	O	4282
cohort	NOUN	O	O	4282
,	PUNCT	O	O	4282
a	PRON	O	O	4282
matched	VERB	O	O	4282
case	NOUN	O	O	4282
-	PUNCT	O	O	4282
control	VERB	O	O	4282
study	VERB	O	O	4282
was	AUX	O	O	4282
performed	VERB	O	O	4282
to	PART	O	O	4282
estimate	VERB	O	O	4282
the	PRON	O	O	4282
association	PROPN	O	O	4282
between	ADP	O	O	4282
cyclophosphamide	VERB	O	Chemical	4282
and	CCONJ	O	O	4282
bladder cancer	NOUN	O	Disease	4282
using	VERB	O	O	4282
odds	NOUN	O	O	4282
ratios	VERB	O	O	4282
(	PUNCT	O	O	4282
ORs	NOUN	O	O	4282
)	PUNCT	O	O	4282
as	ADP	O	O	4282
relative	ADJ	O	O	4282
risk	NOUN	O	O	4282
.	PUNCT	O	O	4282
In	ADP	O	O	4283
the	PRON	O	O	4283
cohort	NOUN	O	O	4283
the	PRON	O	O	4283
cumulative	ADJ	O	O	4283
risk	NOUN	O	O	4283
of	ADP	O	O	4283
bladder cancer	NOUN	O	Disease	4283
after	ADP	O	O	4283
Wegener	PROPN	O	O	4283
's	AUX	O	O	4283
granulomatosis	NOUN	O	O	4283
,	PUNCT	O	O	4283
and	CCONJ	O	O	4283
the	PRON	O	O	4283
relative	ADJ	O	O	4283
prevalence	NOUN	O	O	4283
of	ADP	O	O	4283
a	PRON	O	O	4283
history	NOUN	O	O	4283
of	ADP	O	O	4283
bladder cancer	NOUN	O	Disease	4283
at	ADP	O	O	4283
the	PRON	O	O	4283
time	NOUN	O	O	4283
of	ADP	O	O	4283
diagnosis	NOUN	O	O	4283
of	ADP	O	O	4283
Wegener	PROPN	O	O	4283
's	AUX	O	O	4283
granulomatosis	NOUN	O	O	4283
,	PUNCT	O	O	4283
were	AUX	O	O	4283
also	ADV	O	O	4283
estimated	VERB	O	O	4283
.	PUNCT	O	O	4283
The	PRON	O	O	4284
median	ADJ	O	O	4284
cumulative	ADJ	O	O	4284
doses	NOUN	O	O	4284
of	ADP	O	O	4284
cyclophosphamide	VERB	O	Chemical	4284
among	ADP	O	O	4284
cases	NOUN	O	O	4284
(	PUNCT	O	O	4284
n	CCONJ	O	O	4284
=	PUNCT	O	O	4284
11	NUM	O	O	4284
)	PUNCT	O	O	4284
and	CCONJ	O	O	4284
controls	VERB	O	O	4284
(	PUNCT	O	O	4284
n	CCONJ	O	O	4284
=	PUNCT	O	O	4284
25	NUM	O	O	4284
)	PUNCT	O	O	4284
were	AUX	O	O	4284
113	NUM	O	O	4284
g	X	O	O	4284
and	CCONJ	O	O	4284
25	NUM	O	O	4284
g	X	O	O	4284
,	PUNCT	O	O	4284
respectively	ADV	O	O	4284
.	PUNCT	O	O	4284
The	PRON	O	O	4285
risk	NOUN	O	O	4285
of	ADP	O	O	4285
bladder cancer	NOUN	O	Disease	4285
doubled	VERB	O	O	4285
for	ADP	O	O	4285
every	PRON	O	O	4285
10	NUM	O	O	4285
g	X	O	O	4285
increment	NOUN	O	O	4285
in	ADP	O	O	4285
cyclophosphamide	VERB	O	Chemical	4285
(	PUNCT	O	O	4285
OR	CCONJ	O	O	4285
=	PUNCT	O	O	4285
2.0	NUM	O	O	4285
,	PUNCT	O	O	4285
95%	NOUN	O	O	4285
confidence	NOUN	O	O	4285
interval	NOUN	O	O	4285
(	PUNCT	O	O	4285
CI	NOUN	O	O	4285
)	PUNCT	O	O	4285
0.8	NUM	O	O	4285
to	PART	O	O	4285
4.9	NUM	O	O	4285
)	PUNCT	O	O	4285
.	PUNCT	O	O	4285
The	PRON	O	O	4286
absolute	ADJ	O	O	4286
risk	NOUN	O	O	4286
for	ADP	O	O	4286
bladder cancer	NOUN	O	Disease	4286
in	ADP	O	O	4286
the	PRON	O	O	4286
cohort	NOUN	O	O	4286
reached	VERB	O	O	4286
10%	NOUN	O	O	4286
16	NUM	O	O	4286
years	NOUN	O	O	4286
after	ADP	O	O	4286
diagnosis	NOUN	O	O	4286
of	ADP	O	O	4286
Wegener	PROPN	O	O	4286
's	AUX	O	O	4286
granulomatosis	NOUN	O	O	4286
,	PUNCT	O	O	4286
and	CCONJ	O	O	4286
a	PRON	O	O	4286
history	NOUN	O	O	4286
of	ADP	O	O	4286
bladder cancer	NOUN	O	Disease	4286
was	AUX	O	O	4286
(	PUNCT	O	O	4286
non	ADJ	O	O	4286
-	PUNCT	O	O	4286
significantly	ADV	O	O	4286
)	PUNCT	O	O	4286
twice	ADV	O	O	4286
as	ADP	O	O	4286
common	ADJ	O	O	4286
as	ADP	O	O	4286
expected	VERB	O	O	4286
at	ADP	O	O	4286
the	PRON	O	O	4286
time	NOUN	O	O	4286
of	ADP	O	O	4286
diagnosis	NOUN	O	O	4286
of	ADP	O	O	4286
Wegener	PROPN	O	O	4286
's	AUX	O	O	4286
granulomatosis	NOUN	O	O	4286
.	PUNCT	O	O	4286
CONCLUSION	PROPN	O	O	4287
:	PUNCT	O	O	4287
The	PRON	O	O	4287
results	VERB	O	O	4287
indicate	VERB	O	O	4287
a	PRON	O	O	4287
dose	NOUN	O	O	4287
-	PUNCT	O	O	4287
response	NOUN	O	O	4287
relationship	NOUN	O	O	4287
between	ADP	O	O	4287
cyclophosphamide	VERB	O	Chemical	4287
and	CCONJ	O	O	4287
the	PRON	O	O	4287
risk	NOUN	O	O	4287
of	ADP	O	O	4287
bladder cancer	NOUN	O	Disease	4287
,	PUNCT	O	O	4287
high	ADJ	O	O	4287
cumulative	ADJ	O	O	4287
risks	NOUN	O	O	4287
in	ADP	O	O	4287
the	PRON	O	O	4287
entire	ADJ	O	O	4287
cohort	NOUN	O	O	4287
,	PUNCT	O	O	4287
and	CCONJ	O	O	4287
also	ADV	O	O	4287
the	PRON	O	O	4287
possibility	NOUN	O	O	4287
of	ADP	O	O	4287
risk	NOUN	O	O	4287
factors	NOUN	O	O	4287
operating	VERB	O	O	4287
even	ADV	O	O	4287
before	ADP	O	O	4287
Wegener	PROPN	O	O	4287
's	AUX	O	O	4287
granulomatosis	NOUN	O	O	4287
.	PUNCT	O	O	4287
L	NOUN	O	O	4290
-	PUNCT	O	O	4290
arginine	PROPN	O	O	4290
transport	NOUN	O	O	4290
in	ADP	O	O	4290
humans	NOUN	O	O	4290
with	ADP	O	O	4290
cortisol	NOUN	O	O	4290
-	PUNCT	O	O	4290
induced	VERB	O	O	4290
hypertension	NOUN	O	Disease	4290
.	PUNCT	O	O	4290
A	PRON	O	O	4291
deficient	ADJ	O	O	4291
L	NOUN	O	O	4291
-	PUNCT	O	O	4291
arginine	PROPN	O	O	4291
-	PUNCT	O	O	4291
nitric oxide	NOUN	O	Chemical	4291
system	NOUN	O	O	4291
is	AUX	O	O	4291
implicated	VERB	O	O	4291
in	ADP	O	O	4291
cortisol	NOUN	O	O	4291
-	PUNCT	O	O	4291
induced	VERB	O	O	4291
hypertension	NOUN	O	Disease	4291
.	PUNCT	O	O	4291
We	PRON	O	O	4292
investigate	VERB	O	O	4292
whether	SCONJ	O	O	4292
abnormalities	NOUN	O	O	4292
in	ADP	O	O	4292
L	NOUN	O	O	4292
-	PUNCT	O	O	4292
arginine	PROPN	O	O	4292
uptake	NOUN	O	O	4292
contribute	VERB	O	O	4292
to	PART	O	O	4292
this	PRON	O	O	4292
deficiency	NOUN	O	O	4292
.	PUNCT	O	O	4292
Hydrocortisone	PROPN	O	Chemical	4293
acetate	NOUN	O	O	4293
(	PUNCT	O	O	4293
50	NUM	O	O	4293
mg	VERB	O	O	4293
)	PUNCT	O	O	4293
was	AUX	O	O	4293
given	VERB	O	O	4293
orally	ADV	O	O	4293
every	PRON	O	O	4293
6	NUM	O	O	4293
hours	NOUN	O	O	4293
for	ADP	O	O	4293
24	NUM	O	O	4293
hours	NOUN	O	O	4293
after	ADP	O	O	4293
a	PRON	O	O	4293
5-day	NOUN	O	O	4293
fixed	VERB	O	O	4293
-	PUNCT	O	O	4293
salt	NOUN	O	O	4293
diet	PROPN	O	O	4293
(	PUNCT	O	O	4293
150	NUM	O	O	4293
mmol	NOUN	O	O	4293
/	PUNCT	O	O	4293
d	X	O	O	4293
)	PUNCT	O	O	4293
.	PUNCT	O	O	4293
L	NOUN	O	O	4294
-	PUNCT	O	O	4294
arginine	PROPN	O	O	4294
uptake	NOUN	O	O	4294
was	AUX	O	O	4294
assessed	VERB	O	O	4294
in	ADP	O	O	4294
mononuclear	PROPN	O	O	4294
cells	NOUN	O	O	4294
incubated	VERB	O	O	4294
with	ADP	O	O	4294
L	NOUN	O	O	4294
-	PUNCT	O	O	4294
arginine	PROPN	O	O	4294
(	PUNCT	O	O	4294
1	X	O	O	4294
to	PART	O	O	4294
300	NUM	O	O	4294
micromol	NOUN	O	O	4294
/	PUNCT	O	O	4294
L	NOUN	O	O	4294
)	PUNCT	O	O	4294
,	PUNCT	O	O	4294
incorporating	VERB	O	O	4294
100	NUM	O	O	4294
nmol	PROPN	O	O	4294
/	PUNCT	O	O	4294
L	NOUN	O	O	4295
[	X	O	O	4295
3H]-l	NUM	O	O	4295
-	PUNCT	O	O	4295
arginine	PROPN	O	O	4295
for	ADP	O	O	4295
a	PRON	O	O	4295
period	NOUN	O	O	4295
of	ADP	O	O	4295
5	NUM	O	O	4295
minutes	NOUN	O	O	4295
at	ADP	O	O	4295
37	NUM	O	O	4295
degrees	NOUN	O	O	4295
C.	PROPN	O	O	4295
Forearm	NOUN	O	O	4295
[	X	O	O	4295
3H]-L	NUM	O	O	4295
-	PUNCT	O	O	4295
arginine	PROPN	O	O	4295
extraction	NOUN	O	O	4295
was	AUX	O	O	4295
calculated	VERB	O	O	4295
after	ADP	O	O	4295
infusion	NOUN	O	O	4295
of	ADP	O	O	4295
[	X	O	O	4295
3H]-L	NUM	O	O	4295
-	PUNCT	O	O	4295
arginine	PROPN	O	O	4295
into	ADP	O	O	4295
the	PRON	O	O	4295
brachial	ADJ	O	O	4295
artery	NOUN	O	O	4295
at	ADP	O	O	4295
a	PRON	O	O	4295
rate	NOUN	O	O	4295
of	ADP	O	O	4295
100	NUM	O	O	4295
nCi	NOUN	O	O	4295
/	PUNCT	O	O	4295
min	NOUN	O	O	4295
for	ADP	O	O	4295
80	NUM	O	O	4295
minutes	NOUN	O	O	4295
.	PUNCT	O	O	4295
Deep	ADJ	O	O	4296
forearm	NOUN	O	O	4296
venous	ADJ	O	O	4296
samples	NOUN	O	O	4296
were	AUX	O	O	4296
collected	VERB	O	O	4296
for	ADP	O	O	4296
determination	NOUN	O	O	4296
of	ADP	O	O	4296
L	NOUN	O	O	4296
-	PUNCT	O	O	4296
arginine	PROPN	O	O	4296
extraction	NOUN	O	O	4296
.	PUNCT	O	O	4296
Plasma	NOUN	O	O	4297
cortisol	NOUN	O	O	4297
concentrations	NOUN	O	O	4297
were	AUX	O	O	4297
significantly	ADV	O	O	4297
raised	VERB	O	O	4297
during	ADP	O	O	4297
the	PRON	O	O	4297
active	ADJ	O	O	4297
phase	NOUN	O	O	4297
(	PUNCT	O	O	4297
323+/-43	NUM	O	O	4297
to	PART	O	O	4297
1082+/-245	NUM	O	O	4297
mmol	NOUN	O	O	4297
/	PUNCT	O	O	4297
Neither	PRON	O	O	4298
L	NOUN	O	O	4298
-	PUNCT	O	O	4298
arginine	PROPN	O	O	4298
transport	NOUN	O	O	4298
into	ADP	O	O	4298
mononuclear	PROPN	O	O	4298
cells	NOUN	O	O	4298
(	PUNCT	O	O	4298
placebo	NOUN	O	O	4298
vs	ADP	O	O	4298
active	ADJ	O	O	4298
,	PUNCT	O	O	4298
26.3+/-3.6	NUM	O	O	4298
vs	ADP	O	O	4298
29.0+/-2.1	NUM	O	O	4298
pmol/10	ADP	O	O	4299
000	NUM	O	O	4299
cells	NOUN	O	O	4299
per	ADP	O	O	4299
5	NUM	O	O	4299
minutes	NOUN	O	O	4299
,	PUNCT	O	O	4299
respectively	ADV	O	O	4299
,	PUNCT	O	O	4299
at	ADP	O	O	4299
an	PRON	O	O	4299
l	X	O	O	4299
-	PUNCT	O	O	4299
arginine	PROPN	O	O	4299
concentration	NOUN	O	O	4299
of	ADP	O	O	4299
300	NUM	O	O	4299
micromol	NOUN	O	O	4299
/	PUNCT	O	O	4299
L	NOUN	O	O	4299
)	PUNCT	O	O	4299
nor	CCONJ	O	O	4299
L	NOUN	O	O	4299
-	PUNCT	O	O	4299
arginine	PROPN	O	O	4299
extraction	NOUN	O	O	4299
in	ADP	O	O	4299
the	PRON	O	O	4299
forearm	NOUN	O	O	4299
(	PUNCT	O	O	4299
at	ADP	O	O	4299
80	NUM	O	O	4299
minutes	NOUN	O	O	4299
,	PUNCT	O	O	4299
placebo	NOUN	O	O	4299
vs	ADP	O	O	4299
active	ADJ	O	O	4299
,	PUNCT	O	O	4299
1	X	O	O	4299
868	NUM	O	O	4299
904+/-434	NUM	O	O	4299
962	NUM	O	O	4299
vs	ADP	O	O	4299
2	X	O	O	4299
013	NUM	O	O	4299
910+/-770	NUM	O	O	4299
619	NUM	O	O	4299
disintegrations	NOUN	O	O	4299
per	ADP	O	O	4299
minute	VERB	O	O	4299
)	PUNCT	O	O	4299
was	AUX	O	O	4299
affected	VERB	O	O	4299
by	ADP	O	O	4299
cortisol	NOUN	O	O	4299
treatment	NOUN	O	O	4299
;	PUNCT	O	O	4299
ie	ADV	O	O	4300
,	PUNCT	O	O	4300
that	SCONJ	O	O	4300
L	NOUN	O	O	4300
-	PUNCT	O	O	4300
arginine	PROPN	O	O	4300
uptake	NOUN	O	O	4300
is	AUX	O	O	4300
not	PART	O	O	4300
affected	VERB	O	O	4300
by	ADP	O	O	4300
short	ADJ	O	O	4300
-	PUNCT	O	O	4300
term	NOUN	O	O	4300
cortisol	NOUN	O	O	4300
treatment	NOUN	O	O	4300
.	PUNCT	O	O	4300
We	PRON	O	O	4301
conclude	VERB	O	O	4301
that	SCONJ	O	O	4301
cortisol	NOUN	O	O	4301
-	PUNCT	O	O	4301
induced	VERB	O	O	4301
increases	VERB	O	O	4301
in	ADP	O	O	4301
blood	NOUN	O	O	4301
pressure	NOUN	O	O	4301
are	AUX	O	O	4301
not	PART	O	O	4301
associated	VERB	O	O	4301
with	ADP	O	O	4301
abnormalities	NOUN	O	O	4301
in	ADP	O	O	4301
the	PRON	O	O	4301
l	X	O	O	4301
-	PUNCT	O	O	4301
arginine	PROPN	O	O	4301
transport	NOUN	O	O	4301
system	NOUN	O	O	4301
.	PUNCT	O	O	4301
MR	PROPN	O	O	4304
imaging	VERB	O	O	4304
with	ADP	O	O	4304
quantitative	ADJ	O	O	4304
diffusion	NOUN	O	O	4304
mapping	NOUN	O	O	4304
of	ADP	O	O	4304
tacrolimus	NOUN	O	Chemical	4304
-	PUNCT	O	O	4304
induced	VERB	O	O	4304
neurotoxicity	NOUN	O	Disease	4304
in	ADP	O	O	4304
organ	NOUN	O	O	4304
transplant	NOUN	O	O	4304
patients	NOUN	O	O	4304
.	PUNCT	O	O	4304
Our	PRON	O	O	4305
objective	VERB	O	O	4305
was	AUX	O	O	4305
to	PART	O	O	4305
investigate	VERB	O	O	4305
brain	NOUN	O	O	4305
MR	PROPN	O	O	4305
imaging	VERB	O	O	4305
findings	NOUN	O	O	4305
and	CCONJ	O	O	4305
the	PRON	O	O	4305
utility	NOUN	O	O	4305
of	ADP	O	O	4305
diffusion	NOUN	O	O	4305
-	PUNCT	O	O	4305
weighted	VERB	O	O	4305
(	PUNCT	O	O	4305
DW	PROPN	O	O	4305
)	PUNCT	O	O	4305
imaging	VERB	O	O	4305
in	ADP	O	O	4305
organ	NOUN	O	O	4305
transplant	NOUN	O	O	4305
patients	NOUN	O	O	4305
who	PRON	O	O	4305
developed	VERB	O	O	4305
neurologic	ADJ	O	O	4305
symptoms	NOUN	O	O	4305
during	ADP	O	O	4305
tacrolimus	NOUN	O	Chemical	4305
therapy	NOUN	O	O	4305
.	PUNCT	O	O	4305
Brain	NOUN	O	O	4306
MR	PROPN	O	O	4306
studies	NOUN	O	O	4306
,	PUNCT	O	O	4306
including	VERB	O	O	4306
DW	PROPN	O	O	4306
imaging	VERB	O	O	4306
,	PUNCT	O	O	4306
were	AUX	O	O	4306
prospectively	ADV	O	O	4306
performed	VERB	O	O	4306
in	ADP	O	O	4306
14	NUM	O	O	4306
organ	NOUN	O	O	4306
transplant	NOUN	O	O	4306
patients	NOUN	O	O	4306
receiving	VERB	O	O	4306
tacrolimus	NOUN	O	Chemical	4306
who	PRON	O	O	4306
developed	VERB	O	O	4306
neurologic	ADJ	O	O	4306
complications	NOUN	O	O	4306
.	PUNCT	O	O	4306
Of	ADV	O	O	4307
the	PRON	O	O	4307
14	NUM	O	O	4307
patients	NOUN	O	O	4307
,	PUNCT	O	O	4307
5	NUM	O	O	4307
(	PUNCT	O	O	4307
35.7%	NOUN	O	O	4307
)	PUNCT	O	O	4307
had	VERB	O	O	4307
white matter abnormalities	NOUN	O	Disease	4307
,	PUNCT	O	O	4307
1	X	O	O	4308
(	PUNCT	O	O	4308
7.1%	NOUN	O	O	4308
)	PUNCT	O	O	4308
had	VERB	O	O	4308
putaminal	ADJ	O	O	4308
hemorrhage	NOUN	O	Disease	4308
,	PUNCT	O	O	4308
and	CCONJ	O	O	4308
8	NUM	O	O	4308
(	PUNCT	O	O	4308
57.1%	NOUN	O	O	4308
)	PUNCT	O	O	4308
had	VERB	O	O	4308
normal	ADJ	O	O	4308
findings	NOUN	O	O	4308
on	ADP	O	O	4308
initial	ADJ	O	O	4308
MR	PROPN	O	O	4308
images	NOUN	O	O	4308
.	PUNCT	O	O	4308
Among	ADP	O	O	4309
the	PRON	O	O	4309
5	NUM	O	O	4309
patients	NOUN	O	O	4309
with	ADP	O	O	4309
white matter abnormalities	NOUN	O	Disease	4309
,	PUNCT	O	O	4309
4	NUM	O	O	4309
patients	NOUN	O	O	4309
(	PUNCT	O	O	4309
80.0%	NOUN	O	O	4309
)	PUNCT	O	O	4309
showed	VERB	O	O	4309
higher	ADJ	O	O	4309
than	ADP	O	O	4309
normal	ADJ	O	O	4309
ADC	PROPN	O	O	4309
values	NOUN	O	O	4309
on	ADP	O	O	4309
initial	ADJ	O	O	4309
MR	PROPN	O	O	4309
images	NOUN	O	O	4309
,	PUNCT	O	O	4309
and	CCONJ	O	O	4309
all	PRON	O	O	4309
showed	VERB	O	O	4309
complete	VERB	O	O	4309
resolution	NOUN	O	O	4309
on	ADP	O	O	4309
follow	VERB	O	O	4309
-	PUNCT	O	O	4309
up	ADP	O	O	4309
images	NOUN	O	O	4309
.	PUNCT	O	O	4309
The	PRON	O	O	4310
remaining	VERB	O	O	4310
1	X	O	O	4310
patient	NOUN	O	O	4310
(	PUNCT	O	O	4310
20.0%	NOUN	O	O	4310
)	PUNCT	O	O	4310
showed	VERB	O	O	4310
lower	ADJ	O	O	4310
than	ADP	O	O	4310
normal	ADJ	O	O	4310
ADC	PROPN	O	O	4310
value	NOUN	O	O	4310
and	CCONJ	O	O	4310
showed	VERB	O	O	4310
incomplete	ADJ	O	O	4310
resolution	NOUN	O	O	4310
with	ADP	O	O	4310
cortical	ADJ	O	O	4310
laminar	ADJ	O	O	4310
necrosis	NOUN	O	Disease	4310
.	PUNCT	O	O	4310
Diffusion	NOUN	O	O	4311
-	PUNCT	O	O	4311
weighted	VERB	O	O	4311
imaging	VERB	O	O	4311
may	AUX	O	O	4311
be	AUX	O	O	4311
useful	ADJ	O	O	4311
in	ADP	O	O	4311
predicting	VERB	O	O	4311
the	PRON	O	O	4311
outcomes	NOUN	O	O	4311
of	ADP	O	O	4311
the	PRON	O	O	4311
lesions	NOUN	O	O	4311
of	ADP	O	O	4311
tacrolimus	NOUN	O	Chemical	4311
-	PUNCT	O	O	4311
induced	VERB	O	O	4311
neurotoxicity	NOUN	O	Disease	4311
.	PUNCT	O	O	4311
Octreotide	PROPN	O	O	4314
-	PUNCT	O	O	4314
induced	VERB	O	O	4314
hypoxemia	NOUN	O	Disease	4314
and	CCONJ	O	O	4314
pulmonary hypertension	NOUN	O	Disease	4314
in	ADP	O	O	4314
premature	ADJ	O	O	4314
neonates	NOUN	O	O	4314
.	PUNCT	O	O	4314
The	PRON	O	O	4315
authors	NOUN	O	O	4315
report	VERB	O	O	4315
2	X	O	O	4315
cases	NOUN	O	O	4315
of	ADP	O	O	4315
premature	ADJ	O	O	4315
neonates	NOUN	O	O	4315
who	PRON	O	O	4315
had	VERB	O	O	4315
enterocutaneous	VERB	O	O	4315
fistula	NOUN	O	O	4315
complicating	VERB	O	O	4315
necrotizing	VERB	O	Disease	4315
enterocolitis	ADJ	O	O	4315
.	PUNCT	O	O	4315
Pulmonary	NOUN	O	O	4316
hypertension	NOUN	O	Disease	4316
developed	VERB	O	O	4316
after	ADP	O	O	4316
administration	NOUN	O	O	4316
of	ADP	O	O	4316
a	PRON	O	O	4316
somatostatin	NOUN	O	O	4316
analogue	NOUN	O	O	4316
,	PUNCT	O	O	4316
octreotide	ADV	O	O	4316
,	PUNCT	O	O	4316
to	PART	O	O	4316
enhance	VERB	O	O	4316
resolution	NOUN	O	O	4316
of	ADP	O	O	4316
the	PRON	O	O	4316
fistula	NOUN	O	O	4316
.	PUNCT	O	O	4316
Sequential	ADJ	O	O	4319
observations	NOUN	O	O	4319
of	ADP	O	O	4319
exencephaly	PROPN	O	O	4319
and	CCONJ	O	O	4319
subsequent	ADJ	O	O	4319
morphological	ADJ	O	O	4319
changes	VERB	O	O	4319
by	ADP	O	O	4319
mouse	PROPN	O	O	4319
exo	PROPN	O	O	4319
utero	NOUN	O	O	4319
development	NOUN	O	O	4319
system	NOUN	O	O	4319
:	PUNCT	O	O	4319
analysis	NOUN	O	O	4319
of	ADP	O	O	4319
the	PRON	O	O	4319
mechanism	NOUN	O	O	4319
of	ADP	O	O	4319
transformation	NOUN	O	O	4319
from	ADP	O	O	4319
exencephaly	PROPN	O	O	4319
to	PART	O	O	4319
anencephaly	ADJ	O	O	4319
.	PUNCT	O	O	4319
Anencephaly	PROPN	O	O	4320
has	VERB	O	O	4320
been	AUX	O	O	4320
suggested	VERB	O	O	4320
to	PART	O	O	4320
develop	VERB	O	O	4320
from	ADP	O	O	4320
exencephaly	PROPN	O	O	4320
;	PUNCT	O	O	4320
however	ADV	O	O	4320
,	PUNCT	O	O	4320
there	ADV	O	O	4320
is	AUX	O	O	4320
little	ADJ	O	O	4320
direct	ADJ	O	O	4320
experimental	ADJ	O	O	4320
evidence	NOUN	O	O	4320
to	PART	O	O	4320
support	NOUN	O	O	4320
this	PRON	O	O	4320
,	PUNCT	O	O	4320
and	CCONJ	O	O	4320
the	PRON	O	O	4320
mechanism	NOUN	O	O	4320
of	ADP	O	O	4320
transformation	NOUN	O	O	4320
remains	VERB	O	O	4320
unclear	ADJ	O	O	4320
.	PUNCT	O	O	4320
We	PRON	O	O	4321
observed	VERB	O	O	4321
the	PRON	O	O	4321
exencephaly	PROPN	O	O	4321
induced	VERB	O	O	4321
by	ADP	O	O	4321
5-azacytidine	NOUN	O	O	4321
at	ADP	O	O	4321
embryonic	ADJ	O	O	4321
day	NOUN	O	O	4321
13.5	NUM	O	O	4321
(	PUNCT	O	O	4321
E13.5	PRON	O	O	4321
)	PUNCT	O	O	4321
,	PUNCT	O	O	4321
let	VERB	O	O	4321
the	PRON	O	O	4321
embryos	NOUN	O	O	4321
develop	VERB	O	O	4321
exo	PROPN	O	O	4321
utero	NOUN	O	O	4321
until	ADP	O	O	4321
E18.5	VERB	O	O	4321
,	PUNCT	O	O	4321
and	CCONJ	O	O	4321
re	ADP	O	O	4321
-	PUNCT	O	O	4321
observed	VERB	O	O	4321
the	PRON	O	O	4321
same	ADJ	O	O	4321
embryos	NOUN	O	O	4321
at	ADP	O	O	4321
E18.5	VERB	O	O	4321
.	PUNCT	O	O	4321
We	PRON	O	O	4322
confirmed	VERB	O	O	4322
several	ADJ	O	O	4322
cases	NOUN	O	O	4322
of	ADP	O	O	4322
transformation	NOUN	O	O	4322
from	ADP	O	O	4322
exencephaly	PROPN	O	O	4322
to	PART	O	O	4322
anencephaly	ADJ	O	O	4322
.	PUNCT	O	O	4322
However	ADV	O	O	4323
,	PUNCT	O	O	4323
in	ADP	O	O	4323
many	ADJ	O	O	4323
cases	NOUN	O	O	4323
,	PUNCT	O	O	4323
the	PRON	O	O	4323
exencephalic	VERB	O	O	4323
brain	NOUN	O	O	4323
tissue	NOUN	O	O	4323
was	AUX	O	O	4323
preserved	VERB	O	O	4323
with	ADP	O	O	4323
more	ADJ	O	O	4323
or	CCONJ	O	O	4323
less	ADV	O	O	4323
reduction	NOUN	O	O	4323
during	ADP	O	O	4323
this	PRON	O	O	4323
period	NOUN	O	O	4323
.	PUNCT	O	O	4323
To	PART	O	O	4324
analyze	VERB	O	O	4324
the	PRON	O	O	4324
transformation	NOUN	O	O	4324
patterns	NOUN	O	O	4324
,	PUNCT	O	O	4324
we	PRON	O	O	4324
classified	VERB	O	O	4324
the	PRON	O	O	4324
exencephaly	PROPN	O	O	4324
by	ADP	O	O	4324
size	NOUN	O	O	4324
and	CCONJ	O	O	4324
shape	NOUN	O	O	4324
of	ADP	O	O	4324
the	PRON	O	O	4324
exencephalic	VERB	O	O	4324
tissue	NOUN	O	O	4324
into	ADP	O	O	4324
several	ADJ	O	O	4324
types	NOUN	O	O	4324
at	ADP	O	O	4324
E13.5	PRON	O	O	4324
and	CCONJ	O	O	4324
E18.5	VERB	O	O	4324
.	PUNCT	O	O	4324
It	PRON	O	O	4325
was	AUX	O	O	4325
found	VERB	O	O	4325
that	SCONJ	O	O	4325
the	PRON	O	O	4325
transformation	NOUN	O	O	4325
of	ADP	O	O	4325
exencephalic	VERB	O	O	4325
tissue	NOUN	O	O	4325
was	AUX	O	O	4325
not	PART	O	O	4325
simply	ADV	O	O	4325
size	NOUN	O	O	4325
-	PUNCT	O	O	4325
dependent	ADJ	O	O	4325
,	PUNCT	O	O	4325
and	CCONJ	O	O	4325
all	PRON	O	O	4325
cases	NOUN	O	O	4325
of	ADP	O	O	4325
anencephaly	ADJ	O	O	4325
at	ADP	O	O	4325
E18.5	VERB	O	O	4325
resulted	VERB	O	O	4325
from	ADP	O	O	4325
embryos	NOUN	O	O	4325
with	ADP	O	O	4325
a	PRON	O	O	4325
large	ADJ	O	O	4325
amount	NOUN	O	O	4325
of	ADP	O	O	4325
exencephalic	VERB	O	O	4325
tissue	NOUN	O	O	4325
at	ADP	O	O	4325
E13.5	PRON	O	O	4325
.	PUNCT	O	O	4325
Microscopic	ADJ	O	O	4326
observation	NOUN	O	O	4326
showed	VERB	O	O	4326
the	PRON	O	O	4326
configuration	NOUN	O	O	4326
of	ADP	O	O	4326
exencephaly	PROPN	O	O	4326
at	ADP	O	O	4326
E13.5	PRON	O	O	4326
,	PUNCT	O	O	4326
frequent	ADJ	O	O	4326
hemorrhaging	VERB	O	O	4326
and	CCONJ	O	O	4326
detachment	NOUN	O	O	4326
of	ADP	O	O	4326
the	PRON	O	O	4326
neural	NOUN	O	O	4326
plate	NOUN	O	O	4326
from	ADP	O	O	4326
surface	NOUN	O	O	4326
ectoderm	PROPN	O	O	4326
in	ADP	O	O	4326
the	PRON	O	O	4326
exencephalic	VERB	O	O	4326
head	NOUN	O	O	4326
at	ADP	O	O	4326
E15.5	NOUN	O	O	4326
,	PUNCT	O	O	4326
and	CCONJ	O	O	4326
multiple	ADJ	O	O	4326
modes	NOUN	O	O	4326
of	ADP	O	O	4326
reduction	NOUN	O	O	4326
in	ADP	O	O	4326
the	PRON	O	O	4326
exencephalic	VERB	O	O	4326
tissue	NOUN	O	O	4326
at	ADP	O	O	4326
E18.5	VERB	O	O	4326
.	PUNCT	O	O	4326
From	ADP	O	O	4327
observations	NOUN	O	O	4327
of	ADP	O	O	4327
the	PRON	O	O	4327
vasculature	NOUN	O	O	4327
,	PUNCT	O	O	4327
altered	VERB	O	O	4327
distribution	NOUN	O	O	4327
patterns	NOUN	O	O	4327
of	ADP	O	O	4327
vessels	NOUN	O	O	4327
were	AUX	O	O	4327
identified	VERB	O	O	4327
in	ADP	O	O	4327
the	PRON	O	O	4327
exencephalic	VERB	O	O	4327
head	NOUN	O	O	4327
.	PUNCT	O	O	4327
These	PRON	O	O	4328
findings	NOUN	O	O	4328
suggest	VERB	O	O	4328
that	SCONJ	O	O	4328
overgrowth	NOUN	O	O	4328
of	ADP	O	O	4328
the	PRON	O	O	4328
exencephalic	VERB	O	O	4328
neural	NOUN	O	O	4328
tissue	NOUN	O	O	4328
causes	VERB	O	O	4328
the	PRON	O	O	4328
altered	VERB	O	O	4328
distribution	NOUN	O	O	4328
patterns	NOUN	O	O	4328
of	ADP	O	O	4328
vessels	NOUN	O	O	4328
,	PUNCT	O	O	4328
subsequent	ADJ	O	O	4328
peripheral	ADJ	O	O	4328
circulatory	ADJ	O	O	4328
failure	NOUN	O	O	4328
and/or	CCONJ	O	O	4328
hemorrhaging	VERB	O	O	4328
in	ADP	O	O	4328
various	ADJ	O	O	4328
parts	NOUN	O	O	4328
of	ADP	O	O	4328
the	PRON	O	O	4328
exencephalic	VERB	O	O	4328
head	NOUN	O	O	4328
,	PUNCT	O	O	4328
leading	VERB	O	O	4328
to	PART	O	O	4328
the	PRON	O	O	4328
multiple	ADJ	O	O	4328
modes	NOUN	O	O	4328
of	ADP	O	O	4328
tissue	NOUN	O	O	4328
reduction	NOUN	O	O	4328
during	ADP	O	O	4328
transformation	NOUN	O	O	4328
from	ADP	O	O	4328
exencephaly	PROPN	O	O	4328
to	PART	O	O	4328
anencephaly	ADJ	O	O	4328
.	PUNCT	O	O	4328
Acute	PROPN	O	O	4331
cocaine	NOUN	O	Chemical	4331
-	PUNCT	O	O	4331
induced	VERB	O	O	4331
seizures	NOUN	O	Disease	4331
:	PUNCT	O	O	4331
differential	ADJ	O	O	4331
sensitivity	NOUN	O	O	4331
of	ADP	O	O	4331
six	NUM	O	O	4331
inbred	ADJ	O	O	4331
mouse	PROPN	O	O	4331
strains	VERB	O	O	4331
.	PUNCT	O	O	4331
Mature	ADJ	O	O	4332
male	NOUN	O	O	4332
and	CCONJ	O	O	4332
female	ADJ	O	O	4332
mice	NOUN	O	O	4332
from	ADP	O	O	4332
six	NUM	O	O	4332
inbred	ADJ	O	O	4332
stains	NOUN	O	O	4332
were	AUX	O	O	4332
tested	VERB	O	O	4332
for	ADP	O	O	4332
susceptibility	NOUN	O	O	4332
to	PART	O	O	4332
behavioral	ADJ	O	O	4332
seizures	NOUN	O	Disease	4332
induced	VERB	O	O	4332
by	ADP	O	O	4332
a	PRON	O	O	4332
single	ADJ	O	O	4332
injection	NOUN	O	O	4332
of	ADP	O	O	4332
cocaine	NOUN	O	Chemical	4332
.	PUNCT	O	O	4332
Cocaine	NOUN	O	Chemical	4333
was	AUX	O	O	4333
injected	VERB	O	O	4333
ip	X	O	O	4333
over	ADP	O	O	4333
a	PRON	O	O	4333
range	VERB	O	O	4333
of	ADP	O	O	4333
doses	NOUN	O	O	4333
(	PUNCT	O	O	4333
50	NUM	O	O	4333
-	PUNCT	O	O	4333
100	NUM	O	O	4333
mg	VERB	O	O	4333
/	PUNCT	O	O	4333
kg	VERB	O	O	4333
)	PUNCT	O	O	4333
and	CCONJ	O	O	4333
behavior	NOUN	O	O	4333
was	AUX	O	O	4333
monitored	VERB	O	O	4333
for	ADP	O	O	4333
20	NUM	O	O	4333
minutes	NOUN	O	O	4333
.	PUNCT	O	O	4333
Seizure	NOUN	O	Disease	4334
end	VERB	O	O	4334
points	VERB	O	O	4334
included	VERB	O	O	4334
latency	VERB	O	O	4334
to	PART	O	O	4334
forelimb	PROPN	O	O	4334
or	CCONJ	O	O	4334
hindlimb	NOUN	O	O	4334
clonus	NOUN	O	O	4334
,	PUNCT	O	O	4334
latency	VERB	O	O	4334
to	PART	O	O	4334
clonic	ADJ	O	O	4334
running	VERB	O	O	4334
seizure	NOUN	O	Disease	4334
and	CCONJ	O	O	4334
latency	VERB	O	O	4334
to	PART	O	O	4334
jumping	VERB	O	O	4334
bouncing	VERB	O	O	4334
seizure	NOUN	O	Disease	4334
.	PUNCT	O	O	4334
Additionally	ADV	O	O	4335
,	PUNCT	O	O	4335
levels	NOUN	O	O	4335
of	ADP	O	O	4335
cocaine	NOUN	O	Chemical	4335
determined	VERB	O	O	4335
in	ADP	O	O	4335
hippocampus	NOUN	O	O	4335
and	CCONJ	O	O	4335
cortex	VERB	O	O	4335
were	AUX	O	O	4335
not	PART	O	O	4335
different	ADJ	O	O	4335
between	ADP	O	O	4335
sensitive	ADJ	O	O	4335
and	CCONJ	O	O	4335
resistant	ADJ	O	O	4335
strains	VERB	O	O	4335
.	PUNCT	O	O	4335
Additional	ADJ	O	O	4336
studies	NOUN	O	O	4336
of	ADP	O	O	4336
these	PRON	O	O	4336
murine	ADJ	O	O	4336
strains	VERB	O	O	4336
may	AUX	O	O	4336
be	AUX	O	O	4336
useful	ADJ	O	O	4336
for	ADP	O	O	4336
investigating	VERB	O	O	4336
genetic	ADJ	O	O	4336
influences	NOUN	O	O	4336
on	ADP	O	O	4336
cocaine	NOUN	O	Chemical	4336
-	PUNCT	O	O	4336
induced	VERB	O	O	4336
seizures	NOUN	O	Disease	4336
.	PUNCT	O	O	4336
Microangiopathic	PROPN	O	O	4339
hemolytic anemia	NOUN	O	Disease	4339
complicating	VERB	O	O	4339
FK506	NOUN	O	Chemical	4339
(	PUNCT	O	O	4339
tacrolimus	NOUN	O	Chemical	4339
)	PUNCT	O	O	4339
therapy	NOUN	O	O	4339
.	PUNCT	O	O	4339
We	PRON	O	O	4340
describe	VERB	O	O	4340
3	X	O	O	4340
episodes	NOUN	O	O	4340
of	ADP	O	O	4340
microangiopathic	ADV	O	O	4340
hemolytic anemia	NOUN	O	Disease	4340
(	PUNCT	O	O	4340
MAHA	PROPN	O	O	4340
)	PUNCT	O	O	4340
in	ADP	O	O	4340
2	X	O	O	4340
solid	ADJ	O	O	4340
organ	NOUN	O	O	4340
recipients	NOUN	O	O	4340
under	ADP	O	O	4340
FK506	NOUN	O	Chemical	4340
(	PUNCT	O	O	4340
tacrolimus	NOUN	O	Chemical	4340
)	PUNCT	O	O	4340
therapy	NOUN	O	O	4340
.	PUNCT	O	O	4340
In	ADP	O	O	4341
both	PRON	O	O	4341
cases	NOUN	O	O	4341
,	PUNCT	O	O	4341
discontinuation	NOUN	O	O	4341
of	ADP	O	O	4341
FK506	NOUN	O	Chemical	4341
and	CCONJ	O	O	4341
treatment	NOUN	O	O	4341
with	ADP	O	O	4341
plasma	NOUN	O	O	4341
exchange	VERB	O	O	4341
,	PUNCT	O	O	4341
fresh	ADJ	O	O	4341
frozen	ADJ	O	O	4341
plasma	NOUN	O	O	4341
replacement	NOUN	O	O	4341
,	PUNCT	O	O	4341
corticosteroids	NOUN	O	Chemical	4341
,	PUNCT	O	O	4341
aspirin	NOUN	O	Chemical	4341
,	PUNCT	O	O	4341
and	CCONJ	O	O	4341
dipyridamole	NOUN	O	Chemical	4341
led	VERB	O	O	4341
to	PART	O	O	4341
resolution	NOUN	O	O	4341
of	ADP	O	O	4341
MAHA	PROPN	O	O	4341
.	PUNCT	O	O	4341
In	ADP	O	O	4342
one	NUM	O	O	4342
patient	NOUN	O	O	4342
,	PUNCT	O	O	4342
reintroduction	NOUN	O	O	4342
of	ADP	O	O	4342
FK506	NOUN	O	Chemical	4342
led	VERB	O	O	4342
to	PART	O	O	4342
rapid	ADJ	O	O	4342
recurrence	NOUN	O	O	4342
of	ADP	O	O	4342
MAHA	PROPN	O	O	4342
.	PUNCT	O	O	4342
FK506-associated	VERB	O	O	4343
MAHA	PROPN	O	O	4343
is	AUX	O	O	4343
probably	ADV	O	O	4343
rare	ADJ	O	O	4343
but	CCONJ	O	O	4343
physicians	NOUN	O	O	4343
must	AUX	O	O	4343
be	AUX	O	O	4343
aware	ADJ	O	O	4343
of	ADP	O	O	4343
this	PRON	O	O	4343
severe	ADJ	O	O	4343
complication	NOUN	O	O	4343
.	PUNCT	O	O	4343
In	ADP	O	O	4344
our	PRON	O	O	4344
experience	NOUN	O	O	4344
and	CCONJ	O	O	4344
according	VERB	O	O	4344
to	PART	O	O	4344
the	PRON	O	O	4344
literature	NOUN	O	O	4344
,	PUNCT	O	O	4344
FK506	NOUN	O	Chemical	4344
does	VERB	O	O	4344
not	PART	O	O	4344
seem	VERB	O	O	4344
to	PART	O	O	4344
cross	VERB	O	O	4344
-	PUNCT	O	O	4344
react	VERB	O	O	4344
with	ADP	O	O	4344
cyclosporin A	PRON	O	Chemical	4344
(	PUNCT	O	O	4344
CyA	NOUN	O	O	4344
)	PUNCT	O	O	4344
,	PUNCT	O	O	4344
an	PRON	O	O	4344
immuno	PROPN	O	O	4344
-	PUNCT	O	O	4344
suppressive	ADJ	O	O	4344
drug	NOUN	O	O	4344
already	ADV	O	O	4344
known	VERB	O	O	4344
to	PART	O	O	4344
induce	VERB	O	O	4344
MAHA	PROPN	O	O	4344
.	PUNCT	O	O	4344
Variant	NOUN	O	O	4347
ventricular tachycardia	NOUN	O	Disease	4347
in	ADP	O	O	4347
desipramine	NOUN	O	Chemical	4347
toxicity	NOUN	O	Disease	4347
.	PUNCT	O	O	4347
We	PRON	O	O	4348
report	VERB	O	O	4348
a	PRON	O	O	4348
case	NOUN	O	O	4348
of	ADP	O	O	4348
variant	NOUN	O	O	4348
ventricular tachycardia	NOUN	O	Disease	4348
induced	VERB	O	O	4348
by	ADP	O	O	4348
desipramine	NOUN	O	Chemical	4348
toxicity	NOUN	O	Disease	4348
.	PUNCT	O	O	4348
Unusual	ADJ	O	O	4349
features	VERB	O	O	4349
of	ADP	O	O	4349
the	PRON	O	O	4349
arrhythmia	NOUN	O	Disease	4349
are	AUX	O	O	4349
repetitive	ADJ	O	O	4349
group	NOUN	O	O	4349
beating	VERB	O	O	4349
,	PUNCT	O	O	4349
progressive	ADJ	O	O	4349
shortening	NOUN	O	O	4349
of	ADP	O	O	4349
the	PRON	O	O	4349
R	NOUN	O	O	4349
-	PUNCT	O	O	4349
R	NOUN	O	O	4349
interval	NOUN	O	O	4349
,	PUNCT	O	O	4349
progressive	ADJ	O	O	4349
widening	VERB	O	O	4349
of	ADP	O	O	4349
the	PRON	O	O	4349
QRS	PROPN	O	O	4349
complex	ADJ	O	O	4349
with	ADP	O	O	4349
eventual	ADJ	O	O	4349
failure	NOUN	O	O	4349
of	ADP	O	O	4349
intraventricular	PROPN	O	O	4349
conduction	NOUN	O	O	4349
,	PUNCT	O	O	4349
and	CCONJ	O	O	4349
changes	VERB	O	O	4349
in	ADP	O	O	4349
direction	NOUN	O	O	4349
of	ADP	O	O	4349
the	PRON	O	O	4349
QRS	PROPN	O	O	4349
axis	NOUN	O	O	4349
.	PUNCT	O	O	4349
Recognition	NOUN	O	O	4350
of	ADP	O	O	4350
variant	NOUN	O	O	4350
ventricular tachycardia	NOUN	O	Disease	4350
is	AUX	O	O	4350
important	ADJ	O	O	4350
because	SCONJ	O	O	4350
therapy	NOUN	O	O	4350
differs	VERB	O	O	4350
from	ADP	O	O	4350
that	SCONJ	O	O	4350
of	ADP	O	O	4350
classic	ADJ	O	O	4350
ventricular tachycardia	NOUN	O	Disease	4350
.	PUNCT	O	O	4350
Desipramine	NOUN	O	Chemical	4353
-	PUNCT	O	O	4353
induced	VERB	O	O	4353
delirium	NOUN	O	Disease	4353
at	ADP	O	O	4353
""""	PUNCT	O	O	4353
subtherapeutic	ADJ	O	O	4353
""""	PUNCT	O	O	4353
concentrations	NOUN	O	O	4353
:	PUNCT	O	O	4353
a	PRON	O	O	4353
case	NOUN	O	O	4353
report	VERB	O	O	4353
.	PUNCT	O	O	4353
An	PRON	O	O	4354
elderly	ADJ	O	O	4354
patient	NOUN	O	O	4354
treated	VERB	O	O	4354
with	ADP	O	O	4354
low	ADJ	O	O	4354
dose	NOUN	O	O	4354
Desipramine	NOUN	O	Chemical	4354
developed	VERB	O	O	4354
a	PRON	O	O	4354
delirium	NOUN	O	Disease	4354
while	SCONJ	O	O	4354
her	PRON	O	O	4354
plasma	NOUN	O	O	4354
level	VERB	O	O	4354
was	AUX	O	O	4354
in	ADP	O	O	4354
the	PRON	O	O	4354
""""	PUNCT	O	O	4354
subtherapeutic	ADJ	O	O	4354
""""	PUNCT	O	O	4354
range	VERB	O	O	4354
.	PUNCT	O	O	4354
Delirium	NOUN	O	O	4355
,	PUNCT	O	O	4355
which	PRON	O	O	4355
may	AUX	O	O	4355
be	AUX	O	O	4355
induced	VERB	O	O	4355
by	ADP	O	O	4355
tricyclic	ADJ	O	O	4355
drug	NOUN	O	O	4355
therapy	NOUN	O	O	4355
in	ADP	O	O	4355
the	PRON	O	O	4355
elderly	ADJ	O	O	4355
,	PUNCT	O	O	4355
can	AUX	O	O	4355
be	AUX	O	O	4355
caused	VERB	O	O	4355
by	ADP	O	O	4355
tricyclics	NOUN	O	O	4355
with	ADP	O	O	4355
low	ADJ	O	O	4355
anticholinergic	ADJ	O	O	4355
potency	NOUN	O	O	4355
.	PUNCT	O	O	4355
Therapeutic	ADJ	O	O	4356
ranges	VERB	O	O	4356
for	ADP	O	O	4356
antidepressants	NOUN	O	O	4356
that	SCONJ	O	O	4356
have	VERB	O	O	4356
been	AUX	O	O	4356
derived	VERB	O	O	4356
from	ADP	O	O	4356
general	ADJ	O	O	4356
adult	NOUN	O	O	4356
population	NOUN	O	O	4356
studies	NOUN	O	O	4356
may	AUX	O	O	4356
not	PART	O	O	4356
be	AUX	O	O	4356
appropriate	ADJ	O	O	4356
for	ADP	O	O	4356
the	PRON	O	O	4356
elderly	ADJ	O	O	4356
.	PUNCT	O	O	4356
Mouse	NOUN	O	O	4359
strain	VERB	O	O	4359
-	PUNCT	O	O	4359
dependent	ADJ	O	O	4359
effect	VERB	O	O	4359
of	ADP	O	O	4359
amantadine	NOUN	O	O	4359
on	ADP	O	O	4359
motility	NOUN	O	O	4359
and	CCONJ	O	O	4359
brain	NOUN	O	O	4359
biogenic	ADJ	O	O	4359
amines	NOUN	O	Chemical	4359
.	PUNCT	O	O	4359
The	PRON	O	O	4360
effect	VERB	O	O	4360
of	ADP	O	O	4360
amantadine	NOUN	O	O	4360
hydrochloride	NOUN	O	O	4360
,	PUNCT	O	O	4360
injected	VERB	O	O	4360
i.p	NOUN	O	O	4360
.	PUNCT	O	O	4360
in	ADP	O	O	4361
6	NUM	O	O	4361
increments	NOUN	O	O	4361
of	ADP	O	O	4361
100	NUM	O	O	4361
mg	VERB	O	O	4361
/	PUNCT	O	O	4361
kg	VERB	O	O	4361
each	PRON	O	O	4361
over	ADP	O	O	4361
30	NUM	O	O	4361
hr	NOUN	O	O	4361
,	PUNCT	O	O	4361
on	ADP	O	O	4361
mouse	PROPN	O	O	4361
motility	NOUN	O	O	4361
and	CCONJ	O	O	4361
whole	NOUN	O	O	4361
brain	NOUN	O	O	4361
content	NOUN	O	O	4361
of	ADP	O	O	4361
selected	VERB	O	O	4361
biogenic	ADJ	O	O	4361
amines	NOUN	O	Chemical	4361
and	CCONJ	O	O	4361
major	ADJ	O	O	4361
metabolites	VERB	O	O	4361
was	AUX	O	O	4361
studied	VERB	O	O	4361
in	ADP	O	O	4361
4	NUM	O	O	4361
strains	VERB	O	O	4361
of	ADP	O	O	4361
mice	NOUN	O	O	4361
.	PUNCT	O	O	4361
Amantadine	NOUN	O	O	4362
treatment	NOUN	O	O	4362
produced	VERB	O	O	4362
a	PRON	O	O	4362
biphasic	ADJ	O	O	4362
effect	VERB	O	O	4362
on	ADP	O	O	4362
mouse	PROPN	O	O	4362
motility	NOUN	O	O	4362
.	PUNCT	O	O	4362
The	PRON	O	O	4363
initial	ADJ	O	O	4363
dose	NOUN	O	O	4363
of	ADP	O	O	4363
amantadine	NOUN	O	O	4363
depressed	ADJ	O	O	4363
locomotor	PROPN	O	O	4363
activity	NOUN	O	O	4363
in	ADP	O	O	4363
all	PRON	O	O	4363
mouse	PROPN	O	O	4363
strains	VERB	O	O	4363
studied	VERB	O	O	4363
with	ADP	O	O	4363
the	PRON	O	O	4363
BALB	PROPN	O	O	4363
/	PUNCT	O	O	4363
C	NOUN	O	O	4363
mice	NOUN	O	O	4363
being	AUX	O	O	4363
the	PRON	O	O	4363
most	ADV	O	O	4363
sensitive	ADJ	O	O	4363
.	PUNCT	O	O	4363
Subsequent	PROPN	O	O	4364
amantadine	NOUN	O	O	4364
treatments	NOUN	O	O	4364
produced	VERB	O	O	4364
enhancement	NOUN	O	O	4364
of	ADP	O	O	4364
motility	NOUN	O	O	4364
from	ADP	O	O	4364
corresponding	VERB	O	O	4364
control	VERB	O	O	4364
in	ADP	O	O	4364
all	PRON	O	O	4364
mouse	PROPN	O	O	4364
strains	VERB	O	O	4364
with	ADP	O	O	4364
the	PRON	O	O	4364
BALB	PROPN	O	O	4364
/	PUNCT	O	O	4364
C	NOUN	O	O	4364
mice	NOUN	O	O	4364
being	AUX	O	O	4364
the	PRON	O	O	4364
least	ADJ	O	O	4364
sensitive	ADJ	O	O	4364
.	PUNCT	O	O	4364
The	PRON	O	O	4365
locomotor	PROPN	O	O	4365
activity	NOUN	O	O	4365
was	AUX	O	O	4365
decreased	VERB	O	O	4365
from	ADP	O	O	4365
corresponding	VERB	O	O	4365
controls	VERB	O	O	4365
in	ADP	O	O	4365
all	PRON	O	O	4365
strains	VERB	O	O	4365
studied	VERB	O	O	4365
,	PUNCT	O	O	4365
except	SCONJ	O	O	4365
for	ADP	O	O	4365
the	PRON	O	O	4365
ICR	PROPN	O	O	4365
mice	NOUN	O	O	4365
,	PUNCT	O	O	4365
during	ADP	O	O	4365
an	PRON	O	O	4365
overnight	ADV	O	O	4365
drug	NOUN	O	O	4365
-	PUNCT	O	O	4365
free	ADJ	O	O	4365
period	NOUN	O	O	4365
following	VERB	O	O	4365
the	PRON	O	O	4365
fourth	ADV	O	O	4365
amantadine	NOUN	O	O	4365
treatment	NOUN	O	O	4365
.	PUNCT	O	O	4365
Readministration	NOUN	O	O	4366
of	ADP	O	O	4366
amantadine	NOUN	O	O	4366
,	PUNCT	O	O	4366
after	ADP	O	O	4366
a	PRON	O	O	4366
drug	NOUN	O	O	4366
-	PUNCT	O	O	4366
free	ADJ	O	O	4366
overnight	ADV	O	O	4366
period	NOUN	O	O	4366
,	PUNCT	O	O	4366
increased	VERB	O	O	4366
motility	NOUN	O	O	4366
from	ADP	O	O	4366
respective	ADJ	O	O	4366
saline	NOUN	O	O	4366
control	VERB	O	O	4366
in	ADP	O	O	4366
all	PRON	O	O	4366
strains	VERB	O	O	4366
with	ADP	O	O	4366
exception	NOUN	O	O	4366
of	ADP	O	O	4366
the	PRON	O	O	4366
BALB	PROPN	O	O	4366
/	PUNCT	O	O	4366
C	NOUN	O	O	4366
mice	NOUN	O	O	4366
where	SCONJ	O	O	4366
suppression	NOUN	O	O	4366
of	ADP	O	O	4366
motility	NOUN	O	O	4366
occurred	VERB	O	O	4366
.	PUNCT	O	O	4366
Treatment	NOUN	O	O	4367
with	ADP	O	O	4367
amantadine	NOUN	O	O	4367
did	VERB	O	O	4367
not	PART	O	O	4367
alter	VERB	O	O	4367
whole	NOUN	O	O	4367
brain	NOUN	O	O	4367
dopamine	NOUN	O	Chemical	4367
levels	NOUN	O	O	4367
but	CCONJ	O	O	4367
decreased	VERB	O	O	4367
the	PRON	O	O	4367
amounts	VERB	O	O	4367
of	ADP	O	O	4367
3,4-dihydroxyphenylacetic acid	NOUN	O	O	4367
in	ADP	O	O	4367
the	PRON	O	O	4367
BALB	PROPN	O	O	4367
/	PUNCT	O	O	4367
C	NOUN	O	O	4367
mice	NOUN	O	O	4367
compared	VERB	O	O	4367
to	PART	O	O	4367
saline	NOUN	O	O	4367
control	VERB	O	O	4367
.	PUNCT	O	O	4367
Conversely	ADV	O	O	4368
,	PUNCT	O	O	4368
brain	NOUN	O	O	4368
normetanephrine	NOUN	O	O	4368
concentration	NOUN	O	O	4368
was	AUX	O	O	4368
increased	VERB	O	O	4368
from	ADP	O	O	4368
saline	NOUN	O	O	4368
control	VERB	O	O	4368
by	ADP	O	O	4368
amantadine	NOUN	O	O	4368
in	ADP	O	O	4368
the	PRON	O	O	4368
BALB	PROPN	O	O	4368
/	PUNCT	O	O	4368
C	NOUN	O	O	4368
mice	NOUN	O	O	4368
.	PUNCT	O	O	4368
The	PRON	O	O	4369
results	VERB	O	O	4369
suggest	VERB	O	O	4369
a	PRON	O	O	4369
strain	VERB	O	O	4369
-	PUNCT	O	O	4369
dependent	ADJ	O	O	4369
effect	VERB	O	O	4369
of	ADP	O	O	4369
amantadine	NOUN	O	O	4369
on	ADP	O	O	4369
motility	NOUN	O	O	4369
and	CCONJ	O	O	4369
indicate	VERB	O	O	4369
a	PRON	O	O	4369
differential	ADJ	O	O	4369
response	NOUN	O	O	4369
to	PART	O	O	4369
the	PRON	O	O	4369
acute	ADJ	O	O	4369
and	CCONJ	O	O	4369
multiple	ADJ	O	O	4369
dose	NOUN	O	O	4369
regimens	NOUN	O	O	4369
used	VERB	O	O	4369
.	PUNCT	O	O	4369
The	PRON	O	O	4370
BALB	PROPN	O	O	4370
/	PUNCT	O	O	4370
C	NOUN	O	O	4370
mouse	PROPN	O	O	4370
was	AUX	O	O	4370
the	PRON	O	O	4370
most	ADV	O	O	4370
sensitive	ADJ	O	O	4370
strain	VERB	O	O	4370
and	CCONJ	O	O	4370
could	AUX	O	O	4370
serve	VERB	O	O	4370
as	ADP	O	O	4370
the	PRON	O	O	4370
strain	VERB	O	O	4370
of	ADP	O	O	4370
choice	NOUN	O	O	4370
for	ADP	O	O	4370
evaluating	VERB	O	O	4370
the	PRON	O	O	4370
side	NOUN	O	O	4370
effects	NOUN	O	O	4370
of	ADP	O	O	4370
amantadine	NOUN	O	O	4370
.	PUNCT	O	O	4370
The	PRON	O	O	4371
biochemical	ADJ	O	O	4371
results	VERB	O	O	4371
of	ADP	O	O	4371
brain	NOUN	O	O	4371
biogenic	ADJ	O	O	4371
amines	NOUN	O	Chemical	4371
of	ADP	O	O	4371
BALB	PROPN	O	O	4371
/	PUNCT	O	O	4371
C	NOUN	O	O	4371
mouse	PROPN	O	O	4371
strain	VERB	O	O	4371
suggest	VERB	O	O	4371
a	PRON	O	O	4371
probable	ADJ	O	O	4371
decrease	VERB	O	O	4371
of	ADP	O	O	4371
catecholamine	ADJ	O	Chemical	4371
turnover	NOUN	O	O	4371
rate	NOUN	O	O	4371
and/or	CCONJ	O	O	4371
metabolism	NOUN	O	O	4371
by	ADP	O	O	4371
monoamine	NOUN	O	O	4371
oxidase	NOUN	O	O	4371
and	CCONJ	O	O	4371
a	PRON	O	O	4371
resulting	VERB	O	O	4371
increase	VERB	O	O	4371
in	ADP	O	O	4371
O	INTJ	O	O	4371
-	PUNCT	O	O	4371
methylation	NOUN	O	O	4371
of	ADP	O	O	4371
norepinephrine	NOUN	O	Chemical	4371
which	PRON	O	O	4371
may	AUX	O	O	4371
account	VERB	O	O	4371
for	ADP	O	O	4371
a	PRON	O	O	4371
behavioral	ADJ	O	O	4371
depression	PROPN	O	Disease	4371
caused	VERB	O	O	4371
by	ADP	O	O	4371
amantadine	NOUN	O	O	4371
in	ADP	O	O	4371
the	PRON	O	O	4371
BALB	PROPN	O	O	4371
/	PUNCT	O	O	4371
C	NOUN	O	O	4371
mice	NOUN	O	O	4371
.	PUNCT	O	O	4371
No	PRON	O	O	4374
enhancement	NOUN	O	O	4374
by	ADP	O	O	4374
phenobarbital	NOUN	O	Chemical	4374
of	ADP	O	O	4374
the	PRON	O	O	4374
hepatocarcinogenicity	NOUN	O	O	4374
of	ADP	O	O	4374
a	PRON	O	O	4374
choline	NOUN	O	Chemical	4374
-	PUNCT	O	O	4374
devoid	ADJ	O	O	4374
diet	PROPN	O	O	4374
in	ADP	O	O	4374
the	PRON	O	O	4374
rat	NOUN	O	O	4374
.	PUNCT	O	O	4374
An	PRON	O	O	4375
experiment	NOUN	O	O	4375
was	AUX	O	O	4375
performed	VERB	O	O	4375
to	PART	O	O	4375
test	NOUN	O	O	4375
whether	SCONJ	O	O	4375
inclusion	NOUN	O	O	4375
of	ADP	O	O	4375
phenobarbital	NOUN	O	Chemical	4375
in	ADP	O	O	4375
a	PRON	O	O	4375
choline	NOUN	O	Chemical	4375
-	PUNCT	O	O	4375
devoid	ADJ	O	O	4375
diet	PROPN	O	O	4375
would	AUX	O	O	4375
increase	VERB	O	O	4375
the	PRON	O	O	4375
hepatocarcinogenicity	NOUN	O	O	4375
of	ADP	O	O	4375
the	PRON	O	O	4375
diet	PROPN	O	O	4375
.	PUNCT	O	O	4375
semipurified	VERB	O	O	4376
choline	NOUN	O	Chemical	4376
-	PUNCT	O	O	4376
devoid	ADJ	O	O	4376
or	CCONJ	O	O	4376
choline	NOUN	O	Chemical	4376
-	PUNCT	O	O	4376
supplemented	VERB	O	O	4376
diets	NOUN	O	O	4376
,	PUNCT	O	O	4376
containing	VERB	O	O	4376
or	CCONJ	O	O	4376
not	PART	O	O	4376
0.06%	NOUN	O	O	4376
phenobarbital	NOUN	O	Chemical	4376
.	PUNCT	O	O	4376
No	PRON	O	O	4377
hepatic	ADJ	O	O	4377
preneoplastic	PROPN	O	O	4377
nodules	NOUN	O	O	4377
or	CCONJ	O	O	4377
hepatocellular carcinomas	NOUN	O	O	4377
developed	VERB	O	O	4377
in	ADP	O	O	4377
rats	NOUN	O	O	4377
fed	VERB	O	O	4377
the	PRON	O	O	4377
plain	ADV	O	O	4377
choline	NOUN	O	Chemical	4377
-	PUNCT	O	O	4377
supplemented	VERB	O	O	4377
diet	PROPN	O	O	4377
,	PUNCT	O	O	4377
while	SCONJ	O	O	4377
one	NUM	O	O	4377
preneoplastic	PROPN	O	O	4377
nodule	NOUN	O	O	4377
and	CCONJ	O	O	4377
one	NUM	O	O	4377
hepatocellular carcinoma	NOUN	O	Disease	4377
developed	VERB	O	O	4377
in	ADP	O	O	4377
two	NUM	O	O	4377
rats	NOUN	O	O	4377
fed	VERB	O	O	4377
the	PRON	O	O	4377
same	ADJ	O	O	4377
diet	PROPN	O	O	4377
containing	VERB	O	O	4377
phenobarbital	NOUN	O	Chemical	4377
.	PUNCT	O	O	4377
The	PRON	O	O	4378
incidence	NOUN	O	O	4378
of	ADP	O	O	4378
preneoplastic	PROPN	O	O	4378
nodules	NOUN	O	O	4378
and	CCONJ	O	O	4378
of	ADP	O	O	4378
hepatocellular carcinomas	NOUN	O	O	4378
was	AUX	O	O	4378
10%	NOUN	O	O	4378
and	CCONJ	O	O	4378
37%	NOUN	O	O	4378
,	PUNCT	O	O	4378
respectively	ADV	O	O	4378
,	PUNCT	O	O	4378
in	ADP	O	O	4378
rats	NOUN	O	O	4378
fed	VERB	O	O	4378
the	PRON	O	O	4378
plain	ADV	O	O	4378
choline	NOUN	O	Chemical	4378
-	PUNCT	O	O	4378
devoid	ADJ	O	O	4378
diet	PROPN	O	O	4378
,	PUNCT	O	O	4378
and	CCONJ	O	O	4378
17%	NOUN	O	O	4378
and	CCONJ	O	O	4378
30%	NOUN	O	O	4378
,	PUNCT	O	O	4378
in	ADP	O	O	4378
rats	NOUN	O	O	4378
fed	VERB	O	O	4378
the	PRON	O	O	4378
phenobarbital	NOUN	O	Chemical	4378
-	PUNCT	O	O	4378
containing	VERB	O	O	4378
choline	NOUN	O	Chemical	4378
-	PUNCT	O	O	4378
devoid	ADJ	O	O	4378
diet	PROPN	O	O	4378
.	PUNCT	O	O	4378
The	PRON	O	O	4379
results	VERB	O	O	4379
evinced	VERB	O	O	4379
no	PRON	O	O	4379
enhancement	NOUN	O	O	4379
of	ADP	O	O	4379
the	PRON	O	O	4379
hepatocarcinogenicity	NOUN	O	O	4379
of	ADP	O	O	4379
the	PRON	O	O	4379
choline	NOUN	O	Chemical	4379
-	PUNCT	O	O	4379
devoid	ADJ	O	O	4379
diet	PROPN	O	O	4379
by	ADP	O	O	4379
phenobarbital	NOUN	O	Chemical	4379
.	PUNCT	O	O	4379
Effect	VERB	O	O	4382
of	ADP	O	O	4382
direct	ADJ	O	O	4382
intracoronary	NOUN	O	O	4382
administration	NOUN	O	O	4382
of	ADP	O	O	4382
methylergonovine	PROPN	O	O	4382
in	ADP	O	O	4382
patients	NOUN	O	O	4382
with	ADP	O	O	4382
and	CCONJ	O	O	4382
without	ADP	O	O	4382
variant angina	NOUN	O	Disease	4382
.	PUNCT	O	O	4382
The	PRON	O	O	4383
effects	NOUN	O	O	4383
of	ADP	O	O	4383
intracoronary	NOUN	O	O	4383
administration	NOUN	O	O	4383
of	ADP	O	O	4383
methylergonovine	PROPN	O	O	4383
were	AUX	O	O	4383
studied	VERB	O	O	4383
in	ADP	O	O	4383
21	NUM	O	O	4383
patients	NOUN	O	O	4383
with	ADP	O	O	4383
variant angina	NOUN	O	Disease	4383
and	CCONJ	O	O	4383
22	NUM	O	O	4383
patients	NOUN	O	O	4383
with	ADP	O	O	4383
atypical	ADJ	O	O	4383
chest pain	NOUN	O	Disease	4383
and	CCONJ	O	O	4383
in	ADP	O	O	4383
others	NOUN	O	O	4383
without	ADP	O	O	4383
angina	NOUN	O	Disease	4383
pectoris	VERB	O	O	4383
(	PUNCT	O	O	4383
control	VERB	O	O	4383
group	NOUN	O	O	4383
)	PUNCT	O	O	4383
.	PUNCT	O	O	4383
Methylergonovine	PROPN	O	O	4384
was	AUX	O	O	4384
administered	VERB	O	O	4384
continuously	ADV	O	O	4384
at	ADP	O	O	4384
a	PRON	O	O	4384
rate	NOUN	O	O	4384
of	ADP	O	O	4384
10	NUM	O	O	4384
micrograms	NOUN	O	O	4384
/	PUNCT	O	O	4384
min	NOUN	O	O	4384
up	ADP	O	O	4384
to	PART	O	O	4384
50	NUM	O	O	4384
micrograms	NOUN	O	O	4384
.	PUNCT	O	O	4384
In	ADP	O	O	4385
all	PRON	O	O	4385
patients	NOUN	O	O	4385
with	ADP	O	O	4385
variant angina	NOUN	O	Disease	4385
,	PUNCT	O	O	4385
coronary spasm	NOUN	O	Disease	4385
was	AUX	O	O	4385
provoked	VERB	O	O	4385
at	ADP	O	O	4385
a	PRON	O	O	4385
mean	VERB	O	O	4385
dose	NOUN	O	O	4385
of	ADP	O	O	4385
28	NUM	O	O	4385
+	ADP	O	O	4385
/-	PUNCT	O	O	4385
In	ADP	O	O	4386
the	PRON	O	O	4386
control	VERB	O	O	4386
group	NOUN	O	O	4386
neither	ADV	O	O	4386
ischemic	VERB	O	Disease	4386
ST	PROPN	O	O	4386
change	VERB	O	O	4386
nor	CCONJ	O	O	4386
localized	VERB	O	O	4386
spasm	NOUN	O	Disease	4386
occurred	VERB	O	O	4386
.	PUNCT	O	O	4386
These	PRON	O	O	4387
results	VERB	O	O	4387
suggest	VERB	O	O	4387
that	SCONJ	O	O	4387
spasm	NOUN	O	Disease	4387
provocation	NOUN	O	O	4387
tests	VERB	O	O	4387
,	PUNCT	O	O	4387
which	PRON	O	O	4387
use	VERB	O	O	4387
an	PRON	O	O	4387
intracoronary	NOUN	O	O	4387
injection	NOUN	O	O	4387
of	ADP	O	O	4387
a	PRON	O	O	4387
relatively	ADV	O	O	4387
low	ADJ	O	O	4387
dose	NOUN	O	O	4387
of	ADP	O	O	4387
methylergonovine	PROPN	O	O	4387
,	PUNCT	O	O	4387
have	VERB	O	O	4387
a	PRON	O	O	4387
high	ADJ	O	O	4387
sensitivity	NOUN	O	O	4387
in	ADP	O	O	4387
variant angina	NOUN	O	Disease	4387
and	CCONJ	O	O	4387
the	PRON	O	O	4387
vasoreactivity	NOUN	O	O	4387
of	ADP	O	O	4387
the	PRON	O	O	4387
right	ADV	O	O	4387
coronary	ADJ	O	O	4387
artery	NOUN	O	O	4387
may	AUX	O	O	4387
be	AUX	O	O	4387
greater	ADJ	O	O	4387
than	ADP	O	O	4387
that	SCONJ	O	O	4387
of	ADP	O	O	4387
the	PRON	O	O	4387
other	ADJ	O	O	4387
coronary	ADJ	O	O	4387
arteries	NOUN	O	O	4387
.	PUNCT	O	O	4387
Dobutamine	NOUN	O	Chemical	4390
stress	NOUN	O	O	4390
echocardiography	NOUN	O	O	4390
:	PUNCT	O	O	4390
a	PRON	O	O	4390
sensitive	ADJ	O	O	4390
indicator	NOUN	O	O	4390
of	ADP	O	O	4390
diminished	VERB	O	O	4390
myocardial	ADJ	O	O	4390
function	NOUN	O	O	4390
in	ADP	O	O	4390
asymptomatic	ADJ	O	O	4390
doxorubicin	VERB	O	Chemical	4390
-	PUNCT	O	O	4390
treated	VERB	O	O	4390
long	ADV	O	O	4390
-	PUNCT	O	O	4390
term	NOUN	O	O	4390
survivors	NOUN	O	O	4390
of	ADP	O	O	4390
childhood	NOUN	O	O	4390
cancer	NOUN	O	Disease	4390
.	PUNCT	O	O	4390
Doxorubicin	PROPN	O	Chemical	4391
is	AUX	O	O	4391
an	PRON	O	O	4391
effective	ADJ	O	O	4391
anticancer	NOUN	O	O	4391
chemotherapeutic	NOUN	O	O	4391
agent	NOUN	O	O	4391
known	VERB	O	O	4391
to	PART	O	O	4391
cause	VERB	O	O	4391
acute	ADJ	O	O	4391
and	CCONJ	O	O	4391
chronic	ADJ	O	O	4391
cardiomyopathy	ADJ	O	Disease	4391
.	PUNCT	O	O	4391
To	PART	O	O	4392
develop	VERB	O	O	4392
a	PRON	O	O	4392
more	ADJ	O	O	4392
sensitive	ADJ	O	O	4392
echocardiographic	NOUN	O	O	4392
screening	VERB	O	O	4392
test	NOUN	O	O	4392
for	ADP	O	O	4392
cardiac damage	NOUN	O	Disease	4392
due	ADJ	O	O	4392
to	PART	O	O	4392
doxorubicin	VERB	O	Chemical	4392
,	PUNCT	O	O	4392
a	PRON	O	O	4392
cohort	NOUN	O	O	4392
study	VERB	O	O	4392
was	AUX	O	O	4392
performed	VERB	O	O	4392
using	VERB	O	O	4392
dobutamine	NOUN	O	Chemical	4392
infusion	NOUN	O	O	4392
to	PART	O	O	4392
differentiate	VERB	O	O	4392
asymptomatic	ADJ	O	O	4392
long	ADV	O	O	4392
-	PUNCT	O	O	4392
term	NOUN	O	O	4392
survivors	NOUN	O	O	4392
of	ADP	O	O	4392
childhood	NOUN	O	O	4392
cancer	NOUN	O	Disease	4392
treated	VERB	O	O	4392
with	ADP	O	O	4392
doxorubicin	VERB	O	Chemical	4392
from	ADP	O	O	4392
healthy	ADJ	O	O	4392
control	VERB	O	O	4392
subjects	NOUN	O	O	4392
.	PUNCT	O	O	4392
5	NUM	O	O	4393
years	NOUN	O	O	4393
)	PUNCT	O	O	4393
treated	VERB	O	O	4393
from	ADP	O	O	4393
1.6	NUM	O	O	4393
to	PART	O	O	4393
14.3	NUM	O	O	4393
years	NOUN	O	O	4393
(	PUNCT	O	O	4393
median	ADJ	O	O	4393
5.3	NUM	O	O	4393
)	PUNCT	O	O	4393
before	ADP	O	O	4393
this	PRON	O	O	4393
study	VERB	O	O	4393
with	ADP	O	O	4393
27	NUM	O	O	4393
to	PART	O	O	4393
532	NUM	O	O	4393
mg	VERB	O	O	4393
/	PUNCT	O	O	4393
m2	PROPN	O	O	4393
of	ADP	O	O	4393
doxorubicin	VERB	O	Chemical	4393
(	PUNCT	O	O	4393
mean	VERB	O	O	4393
196	NUM	O	O	4393
)	PUNCT	O	O	4393
were	AUX	O	O	4393
compared	VERB	O	O	4393
with	ADP	O	O	4393
echocardiographic	NOUN	O	O	4393
data	NOUN	O	O	4393
from	ADP	O	O	4393
12	NUM	O	O	4393
normal	ADJ	O	O	4393
age	NOUN	O	O	4393
-	PUNCT	O	O	4393
matched	VERB	O	O	4393
control	VERB	O	O	4393
subjects	NOUN	O	O	4393
.	PUNCT	O	O	4393
Graded	VERB	O	O	4394
dobutamine	NOUN	O	Chemical	4394
infusions	NOUN	O	O	4394
of	ADP	O	O	4394
0.5	NUM	O	O	4394
,	PUNCT	O	O	4394
2.5	NUM	O	O	4394
,	PUNCT	O	O	4394
5	NUM	O	O	4394
and	CCONJ	O	O	4394
10	NUM	O	O	4394
micrograms	NOUN	O	O	4394
/	PUNCT	O	O	4394
kg	VERB	O	O	4394
per	ADP	O	O	4394
min	NOUN	O	O	4394
were	AUX	O	O	4394
administered	VERB	O	O	4394
.	PUNCT	O	O	4394
Dobutamine	NOUN	O	Chemical	4395
infusion	NOUN	O	O	4395
at	ADP	O	O	4395
10	NUM	O	O	4395
micrograms	NOUN	O	O	4395
The	PRON	O	O	4396
most	ADV	O	O	4396
important	ADJ	O	O	4396
findings	NOUN	O	O	4396
were	AUX	O	O	4396
that	SCONJ	O	O	4396
compared	VERB	O	O	4396
with	ADP	O	O	4396
values	NOUN	O	O	4396
in	ADP	O	O	4396
control	VERB	O	O	4396
subjects	NOUN	O	O	4396
,	PUNCT	O	O	4396
end	VERB	O	O	4396
-	PUNCT	O	O	4396
systolic	ADV	O	O	4396
left	VERB	O	O	4396
ventricular	ADJ	O	O	4396
posterior	ADJ	O	O	4396
wall	PROPN	O	O	4396
dimension	NOUN	O	O	4396
and	CCONJ	O	O	4396
percent	NOUN	O	O	4396
of	ADP	O	O	4396
left	VERB	O	O	4396
ventricular	ADJ	O	O	4396
posterior	ADJ	O	O	4396
wall	PROPN	O	O	4396
thickening	NOUN	O	O	4396
in	ADP	O	O	4396
doxorubicin	VERB	O	Chemical	4396
-	PUNCT	O	O	4396
treated	VERB	O	O	4396
patients	NOUN	O	O	4396
were	AUX	O	O	4396
decreased	VERB	O	O	4396
at	ADP	O	O	4396
baseline	VERB	O	O	4396
study	VERB	O	O	4396
and	CCONJ	O	O	4396
these	PRON	O	O	4396
findings	NOUN	O	O	4396
were	AUX	O	O	4396
more	ADJ	O	O	4396
clearly	ADV	O	O	4396
delineated	VERB	O	O	4396
with	ADP	O	O	4396
dobutamine	NOUN	O	Chemical	4396
stimulation	NOUN	O	O	4396
.	PUNCT	O	O	4396
End	NOUN	O	O	4397
-	PUNCT	O	O	4397
systolic	ADV	O	O	4397
left	VERB	O	O	4397
ventricular	ADJ	O	O	4397
posterior	ADJ	O	O	4397
wall	PROPN	O	O	4397
dimension	NOUN	O	O	4397
at	ADP	O	O	4397
baseline	VERB	O	O	4397
for	ADP	O	O	4397
the	PRON	O	O	4397
doxorubicin	VERB	O	Chemical	4397
-	PUNCT	O	O	4397
treated	VERB	O	O	4397
group	NOUN	O	O	4397
was	AUX	O	O	4397
11	NUM	O	O	4397
+	ADP	O	O	4397
/-	PUNCT	O	O	4397
End	NOUN	O	O	4398
-	PUNCT	O	O	4398
systolic	ADV	O	O	4398
left	VERB	O	O	4398
ventricular	ADJ	O	O	4398
posterior	ADJ	O	O	4398
wall	PROPN	O	O	4398
dimension	NOUN	O	O	4398
at	ADP	O	O	4398
the	PRON	O	O	4398
5-micrograms	NOUN	O	O	4398
/	PUNCT	O	O	4398
kg	VERB	O	O	4398
per	ADP	O	O	4398
min	NOUN	O	O	4398
dobutamine	NOUN	O	Chemical	4398
infusion	NOUN	O	O	4398
for	ADP	O	O	4398
the	PRON	O	O	4398
doxorubicin	VERB	O	Chemical	4398
-	PUNCT	O	O	4398
treated	VERB	O	O	4398
group	NOUN	O	O	4398
was	AUX	O	O	4398
14.1	NUM	O	O	4398
+	ADP	O	O	4398
/-	PUNCT	O	O	4398
Effects	NOUN	O	O	4401
of	ADP	O	O	4401
aminophylline	VERB	O	Chemical	4401
on	ADP	O	O	4401
the	PRON	O	O	4401
threshold	NOUN	O	O	4401
for	ADP	O	O	4401
initiating	VERB	O	O	4401
ventricular fibrillation	NOUN	O	Disease	4401
during	ADP	O	O	4401
respiratory failure	NOUN	O	Disease	4401
.	PUNCT	O	O	4401
Cardiac	ADJ	O	O	4402
arrhythmias	VERB	O	Disease	4402
have	VERB	O	O	4402
frequently	ADV	O	O	4402
been	AUX	O	O	4402
reported	VERB	O	O	4402
in	ADP	O	O	4402
association	PROPN	O	O	4402
with	ADP	O	O	4402
respiratory failure	NOUN	O	Disease	4402
.	PUNCT	O	O	4402
The	PRON	O	O	4403
possible	ADJ	O	O	4403
additive	NOUN	O	O	4403
role	NOUN	O	O	4403
of	ADP	O	O	4403
pharmacologic	ADJ	O	O	4403
agents	NOUN	O	O	4403
in	ADP	O	O	4403
precipitating	VERB	O	O	4403
cardiac	ADJ	O	O	4403
disturbances	NOUN	O	O	4403
in	ADP	O	O	4403
patients	NOUN	O	O	4403
with	ADP	O	O	4403
respiratory failure	NOUN	O	Disease	4403
has	VERB	O	O	4403
only	ADV	O	O	4403
recently	ADV	O	O	4403
been	AUX	O	O	4403
emphasized	VERB	O	O	4403
.	PUNCT	O	O	4403
The	PRON	O	O	4404
effects	NOUN	O	O	4404
of	ADP	O	O	4404
aminophylline	VERB	O	Chemical	4404
on	ADP	O	O	4404
the	PRON	O	O	4404
ventricular fibrillation	NOUN	O	Disease	4404
threshold	NOUN	O	O	4404
during	ADP	O	O	4404
normal	ADJ	O	O	4404
acid	PROPN	O	O	4404
-	PUNCT	O	O	4404
base	PROPN	O	O	4404
conditions	NOUN	O	O	4404
and	CCONJ	O	O	4404
during	ADP	O	O	4404
respiratory failure	NOUN	O	Disease	4404
were	AUX	O	O	4404
studied	VERB	O	O	4404
in	ADP	O	O	4404
anesthetized	VERB	O	O	4404
open	VERB	O	O	4404
chest	NOUN	O	O	4404
dogs	NOUN	O	O	4404
.	PUNCT	O	O	4404
The	PRON	O	O	4405
ventricular fibrillation	NOUN	O	Disease	4405
threshold	NOUN	O	O	4405
was	AUX	O	O	4405
measured	VERB	O	O	4405
by	ADP	O	O	4405
passing	VERB	O	O	4405
a	PRON	O	O	4405
gated	VERB	O	O	4405
train	VERB	O	O	4405
of	ADP	O	O	4405
12	NUM	O	O	4405
constant	ADJ	O	O	4405
current	ADJ	O	O	4405
pulses	NOUN	O	O	4405
through	ADP	O	O	4405
the	PRON	O	O	4405
ventricular	ADJ	O	O	4405
myocardium	NOUN	O	O	4405
during	ADP	O	O	4405
the	PRON	O	O	4405
vulnerable	ADJ	O	O	4405
period	NOUN	O	O	4405
of	ADP	O	O	4405
the	PRON	O	O	4405
cardiac	ADJ	O	O	4405
cycle	PROPN	O	O	4405
.	PUNCT	O	O	4405
During	ADP	O	O	4406
the	PRON	O	O	4406
infusion	NOUN	O	O	4406
of	ADP	O	O	4406
aminophylline	VERB	O	Chemical	4406
,	PUNCT	O	O	4406
the	PRON	O	O	4406
ventricular fibrillation	NOUN	O	Disease	4406
threshold	NOUN	O	O	4406
was	AUX	O	O	4406
reduced	VERB	O	O	4406
by	ADP	O	O	4406
30	NUM	O	O	4406
to	PART	O	O	4406
40	NUM	O	O	4406
percent	NOUN	O	O	4406
of	ADP	O	O	4406
the	PRON	O	O	4406
control	VERB	O	O	4406
when	SCONJ	O	O	4406
pH	NOUN	O	O	4406
and	CCONJ	O	O	4406
partial	ADJ	O	O	4406
pressures	NOUN	O	O	4406
of	ADP	O	O	4406
oxygen	NOUN	O	Chemical	4406
(	PUNCT	O	O	4406
PO2	PROPN	O	O	4406
)	PUNCT	O	O	4406
and	CCONJ	O	O	4406
carbon	NOUN	O	O	4406
dioxide	NOUN	O	O	4406
(	PUNCT	O	O	4406
CO2	PROPN	O	Chemical	4406
)	PUNCT	O	O	4406
were	AUX	O	O	4406
kept	VERB	O	O	4406
within	ADP	O	O	4406
normal	ADJ	O	O	4406
limits	NOUN	O	O	4406
.	PUNCT	O	O	4406
When	SCONJ	O	O	4407
respiratory failure	NOUN	O	Disease	4407
was	AUX	O	O	4407
produced	VERB	O	O	4407
by	ADP	O	O	4407
hypoventilation	NOUN	O	Disease	4407
(	PUNCT	O	O	4407
pH	NOUN	O	O	4407
7.05	NUM	O	O	4407
to	PART	O	O	4407
7.25	NUM	O	O	4407
;	PUNCT	O	O	4407
PC02	PROPN	O	O	4407
70	NUM	O	O	4407
to	PART	O	O	4407
100	NUM	O	O	4407
mm	INTJ	O	O	4407
P02	NOUN	O	O	4408
20	NUM	O	O	4408
to	PART	O	O	4408
40	NUM	O	O	4408
mm	INTJ	O	O	4408
Hg	PROPN	O	O	4408
)	PUNCT	O	O	4408
,	PUNCT	O	O	4408
infusion	NOUN	O	O	4408
of	ADP	O	O	4408
aminophylline	VERB	O	Chemical	4408
resulted	VERB	O	O	4408
in	ADP	O	O	4408
an	PRON	O	O	4408
even	ADV	O	O	4408
greater	ADJ	O	O	4408
decrease	VERB	O	O	4408
in	ADP	O	O	4408
ventricular fibrillation	NOUN	O	Disease	4408
threshold	NOUN	O	O	4408
to	PART	O	O	4408
60	NUM	O	O	4408
percent	NOUN	O	O	4408
of	ADP	O	O	4408
the	PRON	O	O	4408
control	VERB	O	O	4408
level	VERB	O	O	4408
.	PUNCT	O	O	4408
These	PRON	O	O	4409
experiments	NOUN	O	O	4409
suggest	VERB	O	O	4409
that	SCONJ	O	O	4409
although	SCONJ	O	O	4409
many	ADJ	O	O	4409
factors	NOUN	O	O	4409
may	AUX	O	O	4409
contribute	VERB	O	O	4409
to	PART	O	O	4409
the	PRON	O	O	4409
increased	VERB	O	O	4409
incidence	NOUN	O	O	4409
of	ADP	O	O	4409
ventricular arrhythmias	NOUN	O	Disease	4409
in	ADP	O	O	4409
respiratory failure	NOUN	O	Disease	4409
,	PUNCT	O	O	4409
pharmacologic	ADJ	O	O	4409
agents	NOUN	O	O	4409
,	PUNCT	O	O	4409
particularly	ADV	O	O	4409
aminophylline	VERB	O	Chemical	4409
,	PUNCT	O	O	4409
may	AUX	O	O	4409
play	VERB	O	O	4409
a	PRON	O	O	4409
significant	ADJ	O	O	4409
role	NOUN	O	O	4409
.	PUNCT	O	O	4409
Case	NOUN	O	O	4412
report	VERB	O	O	4412
:	PUNCT	O	O	4412
acute	ADJ	O	O	4412
unintentional	ADJ	O	O	4412
carbachol	NOUN	O	Chemical	4412
intoxication	NOUN	O	O	4412
.	PUNCT	O	O	4412
INTRODUCTION	NOUN	O	O	4413
:	PUNCT	O	O	4413
Intoxications	NOUN	O	O	4413
with	ADP	O	O	4413
carbachol	NOUN	O	Chemical	4413
,	PUNCT	O	O	4413
a	PRON	O	O	4413
muscarinic	PROPN	O	O	4413
cholinergic	ADJ	O	O	4413
receptor	NOUN	O	O	4413
agonist	NOUN	O	O	4413
are	AUX	O	O	4413
rare	ADJ	O	O	4413
.	PUNCT	O	O	4413
We	PRON	O	O	4414
report	VERB	O	O	4414
an	PRON	O	O	4414
interesting	ADJ	O	O	4414
case	NOUN	O	O	4414
investigating	VERB	O	O	4414
a	PRON	O	O	4414
(	PUNCT	O	O	4414
near	ADP	O	O	4414
)	PUNCT	O	O	4414
fatal	ADJ	O	O	4414
poisoning	VERB	O	O	4414
.	PUNCT	O	O	4414
METHODS	NOUN	O	O	4415
:	PUNCT	O	O	4415
The	PRON	O	O	4415
son	NOUN	O	O	4415
of	ADP	O	O	4415
an	PRON	O	O	4415
84-year	NOUN	O	O	4415
-	PUNCT	O	O	4415
old	ADJ	O	O	4415
male	NOUN	O	O	4415
discovered	VERB	O	O	4415
a	PRON	O	O	4415
newspaper	NOUN	O	O	4415
report	VERB	O	O	4415
stating	VERB	O	O	4415
clinical	ADJ	O	O	4415
success	NOUN	O	O	4415
with	ADP	O	O	4415
plant	NOUN	O	O	4415
extracts	VERB	O	O	4415
in	ADP	O	O	4415
Alzheimer	NOUN	O	Disease	4415
's	AUX	O	O	4415
disease	PROPN	O	O	4415
.	PUNCT	O	O	4415
The	PRON	O	O	4416
mode	PROPN	O	O	4416
of	ADP	O	O	4416
action	NOUN	O	O	4416
was	AUX	O	O	4416
said	VERB	O	O	4416
to	PART	O	O	4416
be	AUX	O	O	4416
comparable	ADJ	O	O	4416
to	PART	O	O	4416
that	SCONJ	O	O	4416
of	ADP	O	O	4416
the	PRON	O	O	4416
synthetic	NOUN	O	O	4416
compound	NOUN	O	O	4416
'	PUNCT	O	O	4416
carbamylcholin	PROPN	O	O	4416
'	PUNCT	O	O	4416
;	PUNCT	O	O	4416
that	SCONJ	O	O	4416
is	AUX	O	O	4416
,	PUNCT	O	O	4416
carbachol	NOUN	O	Chemical	4416
.	PUNCT	O	O	4416
He	PRON	O	O	4417
bought	VERB	O	O	4417
25	NUM	O	O	4417
g	X	O	O	4417
of	ADP	O	O	4417
carbachol	NOUN	O	Chemical	4417
as	ADP	O	O	4417
pure	ADJ	O	O	4417
substance	NOUN	O	O	4417
in	ADP	O	O	4417
a	PRON	O	O	4417
pharmacy	NOUN	O	O	4417
,	PUNCT	O	O	4417
and	CCONJ	O	O	4417
the	PRON	O	O	4417
father	NOUN	O	O	4417
was	AUX	O	O	4417
administered	VERB	O	O	4417
400	NUM	O	O	4417
to	PART	O	O	4417
500	NUM	O	O	4417
mg	VERB	O	O	4417
.	PUNCT	O	O	4417
Carbachol	NOUN	O	O	4418
concentrations	NOUN	O	O	4418
in	ADP	O	O	4418
serum	NOUN	O	O	4418
and	CCONJ	O	O	4418
urine	NOUN	O	O	4418
on	ADP	O	O	4418
day	NOUN	O	O	4418
1	X	O	O	4418
and	CCONJ	O	O	4418
RESULTS	VERB	O	O	4419
:	PUNCT	O	O	4419
Minutes	NOUN	O	O	4419
after	ADP	O	O	4419
oral	ADJ	O	O	4419
administration	NOUN	O	O	4419
,	PUNCT	O	O	4419
the	PRON	O	O	4419
patient	NOUN	O	O	4419
developed	VERB	O	O	4419
nausea	NOUN	O	Disease	4419
,	PUNCT	O	O	4419
sweating	VERB	O	O	4419
and	CCONJ	O	O	4419
hypotension	NOUN	O	Disease	4419
,	PUNCT	O	O	4419
and	CCONJ	O	O	4419
finally	ADV	O	O	4419
collapsed	VERB	O	O	4419
.	PUNCT	O	O	4419
Bradycardia	PROPN	O	Disease	4420
,	PUNCT	O	O	4420
cholinergic	ADJ	O	O	4420
symptoms	NOUN	O	O	4420
and	CCONJ	O	O	4420
asystole	NOUN	O	Disease	4420
occurred	VERB	O	O	4420
.	PUNCT	O	O	4420
Initial	ADJ	O	O	4421
cardiopulmonary	VERB	O	O	4421
resuscitation	NOUN	O	O	4421
and	CCONJ	O	O	4421
immediate	ADJ	O	O	4421
treatment	NOUN	O	O	4421
with	ADP	O	O	4421
adrenaline	NOUN	O	Chemical	4421
(	PUNCT	O	O	4421
epinephrine	NOUN	O	Chemical	4421
)	PUNCT	O	O	4421
,	PUNCT	O	O	4421
atropine	NOUN	O	Chemical	4421
and	CCONJ	O	O	4421
furosemide	PROPN	O	Chemical	4421
was	AUX	O	O	4421
successful	ADJ	O	O	4421
.	PUNCT	O	O	4421
Further	ADV	O	O	4422
signs	NOUN	O	O	4422
were	AUX	O	O	4422
hyperhidrosis	PROPN	O	O	4422
,	PUNCT	O	O	4422
hypersalivation	NOUN	O	O	4422
,	PUNCT	O	O	4422
bronchorrhoea	VERB	O	O	4422
,	PUNCT	O	O	4422
and	CCONJ	O	O	4422
severe	ADJ	O	O	4422
miosis	ADV	O	O	4422
;	PUNCT	O	O	4422
the	PRON	O	O	4422
electrocardiographic	NOUN	O	O	4422
finding	VERB	O	O	4422
was	AUX	O	O	4422
atrio	ADJ	O	O	4422
-	PUNCT	O	O	4422
ventricular	ADJ	O	O	4422
dissociation	NOUN	O	O	4422
.	PUNCT	O	O	4422
High	ADJ	O	O	4423
doses	NOUN	O	O	4423
of	ADP	O	O	4423
atropine	NOUN	O	Chemical	4423
(	PUNCT	O	O	4423
up	ADP	O	O	4423
to	PART	O	O	4423
50	NUM	O	O	4423
mg	VERB	O	O	4423
per	ADP	O	O	4423
24	NUM	O	O	4423
hours	NOUN	O	O	4423
)	PUNCT	O	O	4423
,	PUNCT	O	O	4423
adrenaline	NOUN	O	Chemical	4423
and	CCONJ	O	O	4423
dopamine	NOUN	O	Chemical	4423
were	AUX	O	O	4423
necessary	ADJ	O	O	4423
.	PUNCT	O	O	4423
However	ADV	O	O	4424
,	PUNCT	O	O	4424
increased	VERB	O	O	4424
dyspnoea	NOUN	O	Disease	4424
and	CCONJ	O	O	4424
bronchospasm	NOUN	O	O	4424
necessitated	VERB	O	O	4424
reintubation	NOUN	O	O	4424
.	PUNCT	O	O	4424
Respiratory	NOUN	O	O	4425
insufficiency	NOUN	O	O	4425
was	AUX	O	O	4425
further	ADV	O	O	4425
worsened	VERB	O	O	4425
by	ADP	O	O	4425
Proteus	PROPN	O	O	4425
mirabilis	PROPN	O	O	4425
infection	NOUN	O	Disease	4425
and	CCONJ	O	O	4425
severe	ADJ	O	O	4425
bronchoconstriction	VERB	O	O	4425
.	PUNCT	O	O	4425
On	ADP	O	O	4426
the	PRON	O	O	4426
next	ADV	O	O	4426
day	NOUN	O	O	4426
he	PRON	O	O	4426
died	VERB	O	O	4426
,	PUNCT	O	O	4426
probably	ADV	O	O	4426
as	ADP	O	O	4426
a	PRON	O	O	4426
result	VERB	O	O	4426
of	ADP	O	O	4426
heart failure	NOUN	O	Disease	4426
.	PUNCT	O	O	4426
Serum	NOUN	O	O	4427
samples	NOUN	O	O	4427
from	ADP	O	O	4427
the	PRON	O	O	4427
first	ADV	O	O	4427
and	CCONJ	O	O	4427
second	ADV	O	O	4427
days	NOUN	O	O	4427
contained	VERB	O	O	4427
3.6	NUM	O	O	4427
and	CCONJ	O	O	4427
1.9	NUM	O	O	4427
mg	VERB	O	O	4427
/	PUNCT	O	O	4427
l	X	O	O	4427
carbachol	NOUN	O	Chemical	4427
,	PUNCT	O	O	4427
respectively	ADV	O	O	4427
.	PUNCT	O	O	4427
For	ADP	O	O	4428
the	PRON	O	O	4428
first	ADV	O	O	4428
time	NOUN	O	O	4428
,	PUNCT	O	O	4428
an	PRON	O	O	4428
analytical	ADJ	O	O	4428
method	NOUN	O	O	4428
for	ADP	O	O	4428
the	PRON	O	O	4428
determination	NOUN	O	O	4428
of	ADP	O	O	4428
carbachol	NOUN	O	Chemical	4428
in	ADP	O	O	4428
plasma	NOUN	O	O	4428
and	CCONJ	O	O	4428
urine	NOUN	O	O	4428
has	VERB	O	O	4428
been	AUX	O	O	4428
developed	VERB	O	O	4428
.	PUNCT	O	O	4428
The	PRON	O	O	4429
analysed	VERB	O	O	4429
carbachol	NOUN	O	Chemical	4429
concentration	NOUN	O	O	4429
exceeded	VERB	O	O	4429
the	PRON	O	O	4429
supposed	VERB	O	O	4429
serum	NOUN	O	O	4429
level	VERB	O	O	4429
resulting	VERB	O	O	4429
from	ADP	O	O	4429
a	PRON	O	O	4429
therapeutic	ADJ	O	O	4429
dose	NOUN	O	O	4429
by	ADP	O	O	4429
a	PRON	O	O	4429
factor	NOUN	O	O	4429
of	ADP	O	O	4429
130	NUM	O	O	4429
to	PART	O	O	4429
260	NUM	O	O	4429
.	PUNCT	O	O	4429
Especially	ADV	O	O	4430
in	ADP	O	O	4430
old	ADJ	O	O	4430
patients	NOUN	O	O	4430
,	PUNCT	O	O	4430
intensivists	NOUN	O	O	4430
should	AUX	O	O	4430
consider	VERB	O	O	4430
intoxications	NOUN	O	O	4430
(	PUNCT	O	O	4430
with	ADP	O	O	4430
cholinergics	NOUN	O	O	4430
)	PUNCT	O	O	4430
as	ADP	O	O	4430
a	PRON	O	O	4430
cause	VERB	O	O	4430
of	ADP	O	O	4430
acute	ADJ	O	O	4430
cardiovascular	ADJ	O	O	4430
failure	NOUN	O	O	4430
.	PUNCT	O	O	4430
Crossover	NOUN	O	O	4433
comparison	NOUN	O	O	4433
of	ADP	O	O	4433
efficacy	NOUN	O	O	4433
and	CCONJ	O	O	4433
preference	NOUN	O	O	4433
for	ADP	O	O	4433
rizatriptan	NOUN	O	O	4433
10	NUM	O	O	4433
mg	VERB	O	O	4433
versus	ADP	O	O	4433
ergotamine	PROPN	O	O	4433
/	PUNCT	O	O	4433
caffeine	NOUN	O	Chemical	4433
in	ADP	O	O	4433
migraine	NOUN	O	Disease	4433
.	PUNCT	O	O	4433
Rizatriptan	PROPN	O	O	4434
is	AUX	O	O	4434
a	PRON	O	O	4434
selective	ADJ	O	O	4434
5-HT(1B/1D	NOUN	O	O	4434
)	PUNCT	O	O	4434
receptor	NOUN	O	O	4434
agonist	NOUN	O	O	4434
with	ADP	O	O	4434
rapid	ADJ	O	O	4434
oral	ADJ	O	O	4434
absorption	NOUN	O	O	4434
and	CCONJ	O	O	4434
early	ADV	O	O	4434
onset	VERB	O	O	4434
of	ADP	O	O	4434
action	NOUN	O	O	4434
in	ADP	O	O	4434
the	PRON	O	O	4434
acute	ADJ	O	O	4434
treatment	NOUN	O	O	4434
of	ADP	O	O	4434
migraine	NOUN	O	Disease	4434
.	PUNCT	O	O	4434
This	PRON	O	O	4435
randomized	VERB	O	O	4435
double-	PROPN	O	O	4435
blind	ADJ	O	Disease	4435
crossover	NOUN	O	O	4435
outpatient	NOUN	O	O	4435
study	VERB	O	O	4435
assessed	VERB	O	O	4435
the	PRON	O	O	4435
preference	NOUN	O	O	4435
for	ADP	O	O	4435
1	X	O	O	4435
rizatriptan	NOUN	O	O	4435
10	NUM	O	O	4435
mg	VERB	O	O	4435
tablet	PROPN	O	O	4435
to	PART	O	O	4435
2	X	O	O	4435
ergotamine	PROPN	O	O	4435
1	X	O	O	4435
mg	VERB	O	O	4435
/	PUNCT	O	O	4435
caffeine	NOUN	O	Chemical	4435
100	NUM	O	O	4435
mg	VERB	O	O	4435
tablets	NOUN	O	O	4435
in	ADP	O	O	4435
439	NUM	O	O	4435
patients	NOUN	O	O	4435
treating	VERB	O	O	4435
a	PRON	O	O	4435
single	ADJ	O	O	4435
migraine	NOUN	O	Disease	4435
attack	VERB	O	O	4435
with	ADP	O	O	4435
each	PRON	O	O	4435
therapy	NOUN	O	O	4435
.	PUNCT	O	O	4435
Of	ADV	O	O	4436
patients	NOUN	O	O	4436
expressing	VERB	O	O	4436
a	PRON	O	O	4436
preference	NOUN	O	O	4436
(	PUNCT	O	O	4436
89.1%	NOUN	O	O	4436
)	PUNCT	O	O	4436
,	PUNCT	O	O	4436
more	ADJ	O	O	4436
than	ADP	O	O	4436
twice	ADV	O	O	4436
as	ADP	O	O	4436
many	ADJ	O	O	4436
preferred	VERB	O	O	4436
rizatriptan	NOUN	O	O	4436
to	PART	O	O	4436
ergotamine	PROPN	O	O	4436
/	PUNCT	O	O	4436
caffeine	NOUN	O	Chemical	4436
(	PUNCT	O	O	4436
69.9	NUM	O	O	4436
vs.	CCONJ	O	O	4436
30.1%	NOUN	O	O	4436
,	PUNCT	O	O	4436
p	NOUN	O	O	4436
<	X	O	O	4436
or	CCONJ	O	O	4436
=	PUNCT	O	O	4436
0.001	NUM	O	O	4436
)	PUNCT	O	O	4436
.	PUNCT	O	O	4436
Faster	ADV	O	O	4437
relief	NOUN	O	O	4437
of	ADP	O	O	4437
headache	PROPN	O	Disease	4437
was	AUX	O	O	4437
the	PRON	O	O	4437
most	ADV	O	O	4437
important	ADJ	O	O	4437
reason	NOUN	O	O	4437
for	ADP	O	O	4437
preference	NOUN	O	O	4437
,	PUNCT	O	O	4437
cited	VERB	O	O	4437
by	ADP	O	O	4437
67.3%	NOUN	O	O	4437
of	ADP	O	O	4437
patients	NOUN	O	O	4437
preferring	VERB	O	O	4437
rizatriptan	NOUN	O	O	4437
and	CCONJ	O	O	4437
54.2%	NOUN	O	O	4437
of	ADP	O	O	4437
patients	NOUN	O	O	4437
who	PRON	O	O	4437
preferred	VERB	O	O	4437
ergotamine	PROPN	O	O	4437
/	PUNCT	O	O	4437
caffeine	NOUN	O	Chemical	4437
.	PUNCT	O	O	4437
The	PRON	O	O	4438
co	NOUN	O	O	4438
-	PUNCT	O	O	4438
primary	NOUN	O	O	4438
endpoint	NOUN	O	O	4438
of	ADP	O	O	4438
being	AUX	O	O	4438
pain	NOUN	O	Disease	4438
free	ADJ	O	O	4438
at	ADP	O	O	4438
2	X	O	O	4438
h	X	O	O	4438
was	AUX	O	O	4438
also	ADV	O	O	4438
in	ADP	O	O	4438
favor	NOUN	O	O	4438
of	ADP	O	O	4438
rizatriptan	NOUN	O	O	4438
.	PUNCT	O	O	4438
Forty	NUM	O	O	4439
-	PUNCT	O	O	4439
nine	NUM	O	O	4439
percent	NOUN	O	O	4439
of	ADP	O	O	4439
patients	NOUN	O	O	4439
were	AUX	O	O	4439
pain	NOUN	O	Disease	4439
free	ADJ	O	O	4439
2	X	O	O	4439
h	X	O	O	4439
after	ADP	O	O	4439
rizatriptan	NOUN	O	O	4439
,	PUNCT	O	O	4439
compared	VERB	O	O	4439
with	ADP	O	O	4439
24.3%	NOUN	O	O	4439
treated	VERB	O	O	4439
with	ADP	O	O	4439
ergotamine	PROPN	O	O	4439
/	PUNCT	O	O	4439
caffeine	NOUN	O	Chemical	4439
(	PUNCT	O	O	4439
p	NOUN	O	O	4439
<	X	O	O	4439
or	CCONJ	O	O	4439
=	PUNCT	O	O	4439
0.001	NUM	O	O	4439
)	PUNCT	O	O	4439
,	PUNCT	O	O	4439
rizatriptan	NOUN	O	O	4439
being	AUX	O	O	4439
superior	PROPN	O	O	4439
within	ADP	O	O	4439
1	X	O	O	4439
h	X	O	O	4439
of	ADP	O	O	4439
treatment	NOUN	O	O	4439
.	PUNCT	O	O	4439
Headache	NOUN	O	Disease	4440
relief	NOUN	O	O	4440
at	ADP	O	O	4440
2	X	O	O	4440
h	X	O	O	4440
was	AUX	O	O	4440
75.9%	NOUN	O	O	4440
for	ADP	O	O	4440
rizatriptan	NOUN	O	O	4440
and	CCONJ	O	O	4440
47.3%	NOUN	O	O	4440
for	ADP	O	O	4440
ergotamine	PROPN	O	O	4440
/	PUNCT	O	O	4440
caffeine	NOUN	O	Chemical	4440
(	PUNCT	O	O	4440
p	NOUN	O	O	4441
<	X	O	O	4441
or	CCONJ	O	O	4441
=	PUNCT	O	O	4441
0.001	NUM	O	O	4441
)	PUNCT	O	O	4441
,	PUNCT	O	O	4441
with	ADP	O	O	4441
rizatriptan	NOUN	O	O	4441
being	AUX	O	O	4441
superior	PROPN	O	O	4441
to	PART	O	O	4441
ergotamine	PROPN	O	O	4441
/	PUNCT	O	O	4441
caffeine	NOUN	O	Chemical	4441
within	ADP	O	O	4441
30	NUM	O	O	4441
min	NOUN	O	O	4441
of	ADP	O	O	4441
dosing	VERB	O	O	4441
.	PUNCT	O	O	4441
Almost	ADV	O	O	4442
36%	NOUN	O	O	4442
of	ADP	O	O	4442
patients	NOUN	O	O	4442
taking	VERB	O	O	4442
rizatriptan	NOUN	O	O	4442
were	AUX	O	O	4442
pain	NOUN	O	Disease	4442
free	ADJ	O	O	4442
at	ADP	O	O	4442
2	X	O	O	4442
h	X	O	O	4442
and	CCONJ	O	O	4442
had	VERB	O	O	4442
no	PRON	O	O	4442
recurrence	NOUN	O	O	4442
or	CCONJ	O	O	4442
need	VERB	O	O	4442
for	ADP	O	O	4442
additional	ADJ	O	O	4442
medication	NOUN	O	O	4442
within	ADP	O	O	4442
24	NUM	O	O	4442
h	X	O	O	4442
,	PUNCT	O	O	4442
compared	VERB	O	O	4442
to	PART	O	O	4442
20%	NOUN	O	O	4442
of	ADP	O	O	4442
patients	NOUN	O	O	4442
on	ADP	O	O	4442
ergotamine	PROPN	O	O	4442
/	PUNCT	O	O	4442
caffeine	NOUN	O	Chemical	4442
(	PUNCT	O	O	4442
p	NOUN	O	O	4442
<	X	O	O	4442
or	CCONJ	O	O	4442
=	PUNCT	O	O	4442
0.001	NUM	O	O	4442
)	PUNCT	O	O	4442
.	PUNCT	O	O	4442
Rizatriptan	PROPN	O	O	4443
was	AUX	O	O	4443
also	ADV	O	O	4443
superior	PROPN	O	O	4443
to	PART	O	O	4443
ergotamine	PROPN	O	O	4443
/	PUNCT	O	O	4443
caffeine	NOUN	O	Chemical	4443
in	ADP	O	O	4443
the	PRON	O	O	4443
proportions	NOUN	O	O	4443
of	ADP	O	O	4443
patients	NOUN	O	O	4443
with	ADP	O	O	4443
no	PRON	O	O	4443
nausea	NOUN	O	Disease	4443
,	PUNCT	O	O	4443
vomiting	VERB	O	Disease	4443
,	PUNCT	O	O	4443
phonophobia	NOUN	O	O	4443
or	CCONJ	O	O	4443
photophobia	NOUN	O	Disease	4443
and	CCONJ	O	O	4443
for	ADP	O	O	4443
patients	NOUN	O	O	4443
with	ADP	O	O	4443
normal	ADJ	O	O	4443
function	NOUN	O	O	4443
2	X	O	O	4443
h	X	O	O	4443
after	ADP	O	O	4443
drug	NOUN	O	O	4443
intake	PROPN	O	O	4443
(	PUNCT	O	O	4443
More	ADJ	O	O	4444
patients	NOUN	O	O	4444
were	AUX	O	O	4444
(	PUNCT	O	O	4444
completely	ADV	O	O	4444
,	PUNCT	O	O	4444
very	ADV	O	O	4444
or	CCONJ	O	O	4444
somewhat	ADV	O	O	4444
)	PUNCT	O	O	4444
satisfied	ADJ	O	O	4444
2	X	O	O	4444
h	X	O	O	4444
after	ADP	O	O	4444
treatment	NOUN	O	O	4444
with	ADP	O	O	4444
rizatriptan	NOUN	O	O	4444
(	PUNCT	O	O	4444
69.8%	NOUN	O	O	4444
)	PUNCT	O	O	4444
than	ADP	O	O	4444
at	ADP	O	O	4444
2	X	O	O	4444
h	X	O	O	4444
after	ADP	O	O	4444
treatment	NOUN	O	O	4444
with	ADP	O	O	4444
ergotamine	PROPN	O	O	4444
/	PUNCT	O	O	4444
caffeine	NOUN	O	Chemical	4444
(	PUNCT	O	O	4444
38.6%	NOUN	O	O	4444
,	PUNCT	O	O	4444
p	NOUN	O	O	4444
<	X	O	O	4444
or	CCONJ	O	O	4444
=	PUNCT	O	O	4444
0.001	NUM	O	O	4444
)	PUNCT	O	O	4444
.	PUNCT	O	O	4444
Recurrence	NOUN	O	O	4445
rates	NOUN	O	O	4445
were	AUX	O	O	4445
31.4%	NOUN	O	O	4445
with	ADP	O	O	4445
rizatriptan	NOUN	O	O	4445
and	CCONJ	O	O	4445
15.3%	NOUN	O	O	4445
with	ADP	O	O	4445
ergotamine	PROPN	O	O	4445
/	PUNCT	O	O	4445
caffeine	NOUN	O	Chemical	4445
.	PUNCT	O	O	4445
The	PRON	O	O	4446
most	ADV	O	O	4446
common	ADJ	O	O	4446
adverse	ADJ	O	O	4446
events	NOUN	O	O	4446
(	PUNCT	O	O	4446
incidence	NOUN	O	O	4446
>	PUNCT	O	O	4446
or	CCONJ	O	O	4446
=	PUNCT	O	O	4446
5%	NOUN	O	O	4446
in	ADP	O	O	4446
one	NUM	O	O	4446
group	NOUN	O	O	4446
)	PUNCT	O	O	4446
after	ADP	O	O	4446
rizatriptan	NOUN	O	O	4446
and	CCONJ	O	O	4446
ergotamine	PROPN	O	O	4446
/	PUNCT	O	O	4446
caffeine	NOUN	O	Chemical	4446
,	PUNCT	O	O	4446
respectively	ADV	O	O	4446
,	PUNCT	O	O	4446
were	AUX	O	O	4446
dizziness	NOUN	O	Disease	4446
(	PUNCT	O	O	4446
6.7	NUM	O	O	4446
and	CCONJ	O	O	4446
5.3%	NOUN	O	O	4446
)	PUNCT	O	O	4446
,	PUNCT	O	O	4446
nausea	NOUN	O	Disease	4446
(	PUNCT	O	O	4446
4.2	NUM	O	O	4446
and	CCONJ	O	O	4446
8.5%	NOUN	O	O	4446
)	PUNCT	O	O	4446
and	CCONJ	O	O	4446
somnolence	NOUN	O	Disease	4446
(	PUNCT	O	O	4446
5.5	NUM	O	O	4446
and	CCONJ	O	O	4446
2.3%	NOUN	O	O	4446
)	PUNCT	O	O	4446
.	PUNCT	O	O	4446
Thrombotic	ADJ	O	Disease	4449
microangiopathy	VERB	O	Disease	4449
and	CCONJ	O	O	4449
renal failure	NOUN	O	Disease	4449
associated	VERB	O	O	4449
with	ADP	O	O	4449
antineoplastic	ADJ	O	O	4449
chemotherapy	NOUN	O	O	4449
.	PUNCT	O	O	4449
Five	NUM	O	O	4450
patients	NOUN	O	O	4450
with	ADP	O	O	4450
carcinoma	NOUN	O	Disease	4450
developed	VERB	O	O	4450
thrombotic	ADJ	O	Disease	4450
microangiopathy	VERB	O	Disease	4450
(	PUNCT	O	O	4450
characterized	VERB	O	O	4450
by	ADP	O	O	4450
renal insufficiency	NOUN	O	Disease	4450
,	PUNCT	O	O	4450
microangiopathic	ADV	O	O	4450
hemolytic anemia	NOUN	O	Disease	4450
,	PUNCT	O	O	4450
and	CCONJ	O	O	4450
usually	ADV	O	O	4450
thrombocytopenia	PROPN	O	Disease	4450
)	PUNCT	O	O	4450
after	ADP	O	O	4450
treatment	NOUN	O	O	4450
with	ADP	O	O	4450
cisplatin	NOUN	O	Chemical	4450
,	PUNCT	O	O	4450
bleomycin	VERB	O	O	4450
,	PUNCT	O	O	4450
and	CCONJ	O	O	4450
a	PRON	O	O	4450
vinca	VERB	O	O	4450
alkaloid	NOUN	O	O	4450
.	PUNCT	O	O	4450
One	NUM	O	O	4451
patient	NOUN	O	O	4451
had	VERB	O	O	4451
thrombotic	ADJ	O	Disease	4451
thrombocytopenic	NOUN	O	O	4451
purpura	NOUN	O	Disease	4451
,	PUNCT	O	O	4451
three	NUM	O	O	4451
the	PRON	O	O	4451
hemolytic	ADJ	O	O	4451
-	PUNCT	O	O	4451
uremic	ADJ	O	O	4451
syndrome	NOUN	O	O	4451
,	PUNCT	O	O	4451
and	CCONJ	O	O	4451
one	NUM	O	O	4451
an	PRON	O	O	4451
apparent	ADJ	O	O	4451
forme	VERB	O	O	4451
fruste	PROPN	O	O	4451
of	ADP	O	O	4451
one	NUM	O	O	4451
of	ADP	O	O	4451
these	PRON	O	O	4451
disorders	NOUN	O	O	4451
.	PUNCT	O	O	4451
Histologic	NOUN	O	O	4452
examination	NOUN	O	O	4452
of	ADP	O	O	4452
the	PRON	O	O	4452
renal	ADJ	O	O	4452
tissue	NOUN	O	O	4452
showed	VERB	O	O	4452
evidence	NOUN	O	O	4452
of	ADP	O	O	4452
intravascular	ADJ	O	O	4452
coagulation	NOUN	O	O	4452
,	PUNCT	O	O	4452
primarily	ADV	O	O	4452
affecting	VERB	O	O	4452
the	PRON	O	O	4452
small	ADJ	O	O	4452
arteries	NOUN	O	O	4452
,	PUNCT	O	O	4452
arterioles	NOUN	O	O	4452
,	PUNCT	O	O	4452
and	CCONJ	O	O	4452
glomeruli	VERB	O	O	4452
.	PUNCT	O	O	4452
Because	SCONJ	O	O	4453
each	PRON	O	O	4453
patient	NOUN	O	O	4453
was	AUX	O	O	4453
tumor	NOUN	O	Disease	4453
-	PUNCT	O	O	4453
free	ADJ	O	O	4453
or	CCONJ	O	O	4453
had	VERB	O	O	4453
only	ADV	O	O	4453
a	PRON	O	O	4453
small	ADJ	O	O	4453
tumor	NOUN	O	Disease	4453
at	ADP	O	O	4453
the	PRON	O	O	4453
onset	VERB	O	O	4453
of	ADP	O	O	4453
this	PRON	O	O	4453
syndrome	NOUN	O	O	4453
,	PUNCT	O	O	4453
the	PRON	O	O	4453
thrombotic	ADJ	O	Disease	4453
microangiopathy	VERB	O	Disease	4453
may	AUX	O	O	4453
have	VERB	O	O	4453
been	AUX	O	O	4453
induced	VERB	O	O	4453
by	ADP	O	O	4453
chemotherapy	NOUN	O	O	4453
.	PUNCT	O	O	4453
Diagnosis	NOUN	O	O	4454
of	ADP	O	O	4454
this	PRON	O	O	4454
potentially	ADV	O	O	4454
fatal	ADJ	O	O	4454
complication	NOUN	O	O	4454
may	AUX	O	O	4454
be	AUX	O	O	4454
delayed	VERB	O	O	4454
or	CCONJ	O	O	4454
missed	VERB	O	O	4454
if	SCONJ	O	O	4454
renal	ADJ	O	O	4454
tissue	NOUN	O	O	4454
or	CCONJ	O	O	4454
the	PRON	O	O	4454
peripheral	ADJ	O	O	4454
blood	NOUN	O	O	4454
smear	VERB	O	O	4454
is	AUX	O	O	4454
not	PART	O	O	4454
examined	VERB	O	O	4454
,	PUNCT	O	O	4454
because	SCONJ	O	O	4454
renal failure	NOUN	O	Disease	4454
may	AUX	O	O	4454
be	AUX	O	O	4454
ascribed	VERB	O	O	4454
to	PART	O	O	4454
cisplatin	NOUN	O	Chemical	4454
nephrotoxicity	NOUN	O	Disease	4454
and	CCONJ	O	O	4454
the	PRON	O	O	4454
anemia	NOUN	O	Disease	4454
and	CCONJ	O	O	4454
thrombocytopenia	PROPN	O	Disease	4454
to	PART	O	O	4454
drug	NOUN	O	O	4454
-	PUNCT	O	O	4454
induced	VERB	O	O	4454
bone	NOUN	O	O	4454
marrow suppression	NOUN	O	Disease	4454
.	PUNCT	O	O	4454
Salvage	NOUN	O	O	4457
therapy	NOUN	O	O	4457
with	ADP	O	O	4457
nelarabine	NOUN	O	O	4457
,	PUNCT	O	O	4457
etoposide	ADV	O	Chemical	4457
,	PUNCT	O	O	4457
and	CCONJ	O	O	4457
cyclophosphamide	VERB	O	Chemical	4457
in	ADP	O	O	4457
relapsed	VERB	O	O	4457
/	PUNCT	O	O	4457
refractory	ADJ	O	O	4457
paediatric	ADJ	O	O	4457
T	NOUN	O	Chemical	4457
-	PUNCT	O	O	4457
cell	NOUN	O	O	4457
lymphoblastic	NOUN	O	O	4457
leukaemia	NOUN	O	Disease	4457
and	CCONJ	O	O	4457
lymphoma	PROPN	O	Disease	4457
.	PUNCT	O	O	4457
A	PRON	O	O	4458
combination	NOUN	O	O	4458
of	ADP	O	O	4458
5	NUM	O	O	4458
d	X	O	O	4458
of	ADP	O	O	4458
nelarabine	NOUN	O	O	4458
(	PUNCT	O	O	4458
AraG	NUM	O	O	4458
)	PUNCT	O	O	4458
with	ADP	O	O	4458
5	NUM	O	O	4458
d	X	O	O	4458
of	ADP	O	O	4458
etoposide	ADV	O	Chemical	4458
(	PUNCT	O	O	4458
VP	PROPN	O	O	4458
)	PUNCT	O	O	4458
and	CCONJ	O	O	4458
cyclophosphamide	VERB	O	Chemical	4458
(	PUNCT	O	O	4458
CPM	PROPN	O	O	4458
)	PUNCT	O	O	4458
and	CCONJ	O	O	4458
prophylactic	ADJ	O	O	4458
intrathecal	ADJ	O	O	4458
chemotherapy	NOUN	O	O	4458
was	AUX	O	O	4458
used	VERB	O	O	4458
as	ADP	O	O	4458
salvage	NOUN	O	O	4458
therapy	NOUN	O	O	4458
in	ADP	O	O	4458
seven	NUM	O	O	4458
children	NOUN	O	O	4458
with	ADP	O	O	4458
refractory	ADJ	O	O	4458
or	CCONJ	O	O	4458
relapsed	VERB	O	O	4458
T	NOUN	O	Chemical	4458
-	PUNCT	O	O	4458
cell	NOUN	O	O	4458
leukaemia	NOUN	O	Disease	4458
or	CCONJ	O	O	4458
lymphoma	PROPN	O	Disease	4458
.	PUNCT	O	O	4458
The	PRON	O	O	4459
most	ADV	O	O	4459
common	ADJ	O	O	4459
side	NOUN	O	O	4459
effects	NOUN	O	O	4459
attributable	ADJ	O	O	4459
to	PART	O	O	4459
the	PRON	O	O	4459
AraG	NUM	O	O	4459
included	VERB	O	O	4459
Grade	NOUN	O	O	4459
2	X	O	O	4459
and	CCONJ	O	O	4459
3	X	O	O	4459
sensory	ADJ	O	O	4459
and	CCONJ	O	O	4459
motor	NOUN	O	O	4459
neuropathy	NOUN	O	Disease	4459
and	CCONJ	O	O	4459
musculoskeletal	ADJ	O	O	4459
pain	NOUN	O	Disease	4459
.	PUNCT	O	O	4459
Haematological	PROPN	O	O	4460
toxicity	NOUN	O	Disease	4460
was	AUX	O	O	4460
greater	ADJ	O	O	4460
for	ADP	O	O	4460
the	PRON	O	O	4460
combination	NOUN	O	O	4460
than	ADP	O	O	4460
AraG	NUM	O	O	4460
alone	ADV	O	O	4460
,	PUNCT	O	O	4460
although	SCONJ	O	O	4460
median	ADJ	O	O	4460
time	NOUN	O	O	4460
to	PART	O	O	4460
neutrophil	ADJ	O	O	4460
and	CCONJ	O	O	4460
platelet	NOUN	O	O	4460
recovery	NOUN	O	O	4460
was	AUX	O	O	4460
consistent	ADJ	O	O	4460
with	ADP	O	O	4460
other	ADJ	O	O	4460
salvage	NOUN	O	O	4460
therapies	NOUN	O	O	4460
.	PUNCT	O	O	4460
All	PRON	O	O	4461
patients	NOUN	O	O	4461
had	VERB	O	O	4461
some	PRON	O	O	4461
response	NOUN	O	O	4461
to	PART	O	O	4461
the	PRON	O	O	4461
combined	VERB	O	O	4461
therapy	NOUN	O	O	4461
and	CCONJ	O	O	4461
five	NUM	O	O	4461
of	ADP	O	O	4461
the	PRON	O	O	4461
seven	NUM	O	O	4461
went	VERB	O	O	4461
into	ADP	O	O	4461
complete	VERB	O	O	4461
remission	NOUN	O	O	4461
after	ADP	O	O	4461
one	NUM	O	O	4461
or	CCONJ	O	O	4461
two	NUM	O	O	4461
courses	NOUN	O	O	4461
of	ADP	O	O	4461
AraG	NUM	O	O	4461
/	PUNCT	O	O	4461
VP	PROPN	O	O	4461
/	PUNCT	O	O	4461
CPM	PROPN	O	O	4461
.	PUNCT	O	O	4461
Our	PRON	O	O	4462
experience	NOUN	O	O	4462
supports	VERB	O	O	4462
the	PRON	O	O	4462
safety	NOUN	O	O	4462
of	ADP	O	O	4462
giving	VERB	O	O	4462
AraG	NUM	O	O	4462
as	ADP	O	O	4462
salvage	NOUN	O	O	4462
therapy	NOUN	O	O	4462
in	ADP	O	O	4462
synchrony	NOUN	O	O	4462
with	ADP	O	O	4462
etoposide	ADV	O	Chemical	4462
and	CCONJ	O	O	4462
cyclophosphamide	VERB	O	Chemical	4462
,	PUNCT	O	O	4462
although	SCONJ	O	O	4462
neurological	ADJ	O	O	4462
toxicity	NOUN	O	Disease	4462
must	AUX	O	O	4462
be	AUX	O	O	4462
closely	ADV	O	O	4462
monitored	VERB	O	O	4462
.	PUNCT	O	O	4462
The	PRON	O	O	4465
3-week	NOUN	O	O	4465
sulphasalazine	VERB	O	Chemical	4465
syndrome	NOUN	O	O	4465
strikes	VERB	O	O	4465
again	ADV	O	O	4465
.	PUNCT	O	O	4465
A	PRON	O	O	4466
34-year	NOUN	O	O	4466
-	PUNCT	O	O	4466
old	ADJ	O	O	4466
lady	PROPN	O	O	4466
developed	VERB	O	O	4466
a	PRON	O	O	4466
constellation	NOUN	O	O	4466
of	ADP	O	O	4466
dermatitis	NOUN	O	Disease	4466
,	PUNCT	O	O	4466
fever	NOUN	O	Disease	4466
,	PUNCT	O	O	4466
lymphadenopathy	ADJ	O	O	4466
and	CCONJ	O	O	4466
hepatitis	NOUN	O	Disease	4466
,	PUNCT	O	O	4466
beginning	VERB	O	O	4466
on	ADP	O	O	4466
the	PRON	O	O	4466
17th	ADV	O	O	4466
day	NOUN	O	O	4466
of	ADP	O	O	4466
a	PRON	O	O	4466
course	NOUN	O	O	4466
of	ADP	O	O	4466
oral	ADJ	O	O	4466
sulphasalazine	VERB	O	Chemical	4466
for	ADP	O	O	4466
sero	NOUN	O	O	4466
-	PUNCT	O	O	4466
negative	ADJ	O	O	4466
rheumatoid arthritis	NOUN	O	Disease	4466
.	PUNCT	O	O	4466
Cervical	ADJ	O	O	4467
and	CCONJ	O	O	4467
inguinal	ADJ	O	O	4467
lymph	NOUN	O	O	4467
node	NOUN	O	O	4467
biopsies	NOUN	O	O	4467
showed	VERB	O	O	4467
the	PRON	O	O	4467
features	VERB	O	O	4467
of	ADP	O	O	4467
severe	ADJ	O	O	4467
necrotising	VERB	O	O	4467
lymphadenitis	PROPN	O	O	4467
,	PUNCT	O	O	4467
associated	VERB	O	O	4467
with	ADP	O	O	4467
erythrophagocytosis	NOUN	O	O	4467
and	CCONJ	O	O	4467
prominent	ADJ	O	O	4467
eosinophilic	ADJ	O	Disease	4467
infiltrates	VERB	O	O	4467
,	PUNCT	O	O	4467
without	ADP	O	O	4467
viral	ADJ	O	O	4467
inclusion	NOUN	O	O	4467
bodies	NOUN	O	O	4467
,	PUNCT	O	O	4467
suggestive	ADJ	O	O	4467
of	ADP	O	O	4467
an	PRON	O	O	4467
adverse	ADJ	O	O	4467
drug	NOUN	O	O	4467
reaction	NOUN	O	O	4467
.	PUNCT	O	O	4467
A	PRON	O	O	4468
week	NOUN	O	O	4468
later	ADV	O	O	4468
,	PUNCT	O	O	4468
fulminant	ADJ	O	O	4468
drug	NOUN	O	O	4468
-	PUNCT	O	O	4468
induced	VERB	O	O	4468
hepatitis	NOUN	O	Disease	4468
,	PUNCT	O	O	4468
associated	VERB	O	O	4468
with	ADP	O	O	4468
the	PRON	O	O	4468
presence	NOUN	O	O	4468
of	ADP	O	O	4468
anti	ADJ	O	O	4468
-	PUNCT	O	O	4468
nuclear	ADJ	O	O	4468
autoantibodies	NOUN	O	O	4468
(	PUNCT	O	O	4468
but	CCONJ	O	O	4468
not	PART	O	O	4468
with	ADP	O	O	4468
other	ADJ	O	O	4468
markers	NOUN	O	O	4468
of	ADP	O	O	4468
autoimmunity	NOUN	O	O	4468
)	PUNCT	O	O	4468
,	PUNCT	O	O	4468
and	CCONJ	O	O	4468
accompanied	VERB	O	O	4468
by	ADP	O	O	4468
multi	ADJ	O	O	4468
-	PUNCT	O	O	4468
organ	NOUN	O	O	4468
failure	NOUN	O	O	4468
and	CCONJ	O	O	4468
sepsis	NOUN	O	Disease	4468
,	PUNCT	O	O	4468
supervened	VERB	O	O	4468
.	PUNCT	O	O	4468
Post	NOUN	O	O	4469
-	PUNCT	O	O	4469
mortem	PROPN	O	O	4469
examination	NOUN	O	O	4469
showed	VERB	O	O	4469
evidence	NOUN	O	O	4469
of	ADP	O	O	4469
massive	ADJ	O	O	4469
hepatocellular	NOUN	O	O	4469
necrosis	NOUN	O	Disease	4469
,	PUNCT	O	O	4469
acute	ADJ	O	O	4469
hypersensitivity	NOUN	O	Disease	4469
myocarditis	ADV	O	Disease	4469
,	PUNCT	O	O	4469
focal	ADJ	O	O	4469
acute	ADJ	O	O	4469
tubulo	NOUN	O	O	4469
-	PUNCT	O	O	4469
interstitial nephritis	NOUN	O	Disease	4469
and	CCONJ	O	O	4469
extensive	ADJ	O	O	4469
bone	NOUN	O	O	4469
marrow	PROPN	O	O	4469
necrosis	NOUN	O	Disease	4469
,	PUNCT	O	O	4469
with	ADP	O	O	4469
no	PRON	O	O	4469
evidence	NOUN	O	O	4469
of	ADP	O	O	4469
malignancy	NOUN	O	Disease	4469
.	PUNCT	O	O	4469
It	PRON	O	O	4470
is	AUX	O	O	4470
thought	VERB	O	O	4470
that	SCONJ	O	O	4470
the	PRON	O	O	4470
clinico	NOUN	O	O	4470
-	PUNCT	O	O	4470
pathological	ADJ	O	O	4470
features	VERB	O	O	4470
and	CCONJ	O	O	4470
chronology	NOUN	O	O	4470
of	ADP	O	O	4470
this	PRON	O	O	4470
case	NOUN	O	O	4470
bore	VERB	O	O	4470
the	PRON	O	O	4470
hallmarks	NOUN	O	O	4470
of	ADP	O	O	4470
the	PRON	O	O	4470
so	ADV	O	O	4470
-	PUNCT	O	O	4470
called	VERB	O	O	4470
""""	PUNCT	O	O	4470
3-week	NOUN	O	O	4470
sulphasalazine	VERB	O	Chemical	4470
syndrome	NOUN	O	O	4470
""""	PUNCT	O	O	4470
,	PUNCT	O	O	4470
a	PRON	O	O	4470
rare	ADJ	O	O	4470
,	PUNCT	O	O	4470
but	CCONJ	O	O	4470
often	ADV	O	O	4470
fatal	ADJ	O	O	4470
,	PUNCT	O	O	4470
immunoallergic	ADJ	O	O	4470
reaction	NOUN	O	O	4470
to	PART	O	O	4470
sulphasalazine	VERB	O	Chemical	4470
.	PUNCT	O	O	4470
Bupropion	NOUN	O	O	4473
(	PUNCT	O	O	4473
Zyban	PROPN	O	O	4473
)	PUNCT	O	O	4473
toxicity	NOUN	O	Disease	4473
.	PUNCT	O	O	4473
Bupropion	NOUN	O	O	4474
is	AUX	O	O	4474
a	PRON	O	O	4474
monocyclic	PROPN	O	O	4474
antidepressant	NOUN	O	O	4474
structurally	ADV	O	O	4474
related	ADJ	O	O	4474
to	PART	O	O	4474
amphetamine	NOUN	O	Chemical	4474
.	PUNCT	O	O	4474
Zyban	PROPN	O	O	4475
,	PUNCT	O	O	4475
a	PRON	O	O	4475
sustained	VERB	O	O	4475
-	PUNCT	O	O	4475
release	NOUN	O	O	4475
formulation	NOUN	O	O	4475
of	ADP	O	O	4475
bupropion hydrochloride	NOUN	O	Chemical	4475
,	PUNCT	O	O	4475
was	AUX	O	O	4475
recently	ADV	O	O	4475
released	VERB	O	O	4475
in	ADP	O	O	4475
Ireland	PROPN	O	O	4475
,	PUNCT	O	O	4475
as	ADP	O	O	4475
a	PRON	O	O	4475
smoking	VERB	O	O	4475
cessation	NOUN	O	O	4475
aid	NOUN	O	O	4475
.	PUNCT	O	O	4475
In	ADP	O	O	4476
the	PRON	O	O	4476
initial	ADJ	O	O	4476
6	NUM	O	O	4476
months	NOUN	O	O	4476
since	SCONJ	O	O	4476
it	PRON	O	O	4476
's	AUX	O	O	4476
introduction	NOUN	O	O	4476
,	PUNCT	O	O	4476
12	NUM	O	O	4476
overdose	NOUN	O	Disease	4476
cases	NOUN	O	O	4476
have	VERB	O	O	4476
been	AUX	O	O	4476
reported	VERB	O	O	4476
to	PART	O	O	4476
The	PRON	O	O	4476
National	ADJ	O	O	4476
Poisons	NOUN	O	O	4476
Information	NOUN	O	O	4476
Centre	NOUN	O	O	4476
.	PUNCT	O	O	4476
8	NUM	O	O	4477
patients	NOUN	O	O	4477
developed	VERB	O	O	4477
symptoms	NOUN	O	O	4477
of	ADP	O	O	4477
toxicity	NOUN	O	Disease	4477
.	PUNCT	O	O	4477
Common	ADJ	O	O	4478
features	VERB	O	O	4478
included	VERB	O	O	4478
tachycardia	PROPN	O	Disease	4478
,	PUNCT	O	O	4478
drowsiness	NOUN	O	Disease	4478
,	PUNCT	O	O	4478
hallucinations	NOUN	O	Disease	4478
and	CCONJ	O	O	4478
convulsions	NOUN	O	Disease	4478
.	PUNCT	O	O	4478
Two	NUM	O	O	4479
patients	NOUN	O	O	4479
developed	VERB	O	O	4479
severe	ADJ	O	O	4479
cardiac arrhythmias	VERB	O	Disease	4479
,	PUNCT	O	O	4479
including	VERB	O	O	4479
one	NUM	O	O	4479
patient	NOUN	O	O	4479
who	PRON	O	O	4479
was	AUX	O	O	4479
resuscitated	VERB	O	O	4479
following	VERB	O	O	4479
a	PRON	O	O	4479
cardiac arrest	NOUN	O	Disease	4479
.	PUNCT	O	O	4479
We	PRON	O	O	4480
report	VERB	O	O	4480
a	PRON	O	O	4480
case	NOUN	O	O	4480
of	ADP	O	O	4480
a	PRON	O	O	4480
31	NUM	O	O	4480
year	NOUN	O	O	4480
old	ADJ	O	O	4480
female	ADJ	O	O	4480
who	PRON	O	O	4480
required	VERB	O	O	4480
admission	NOUN	O	O	4480
to	PART	O	O	4480
the	PRON	O	O	4480
Intensive	PROPN	O	O	4480
Care	VERB	O	O	4480
Unit	NOUN	O	O	4480
for	ADP	O	O	4480
ventilation	NOUN	O	O	4480
and	CCONJ	O	O	4480
full	ADJ	O	O	4480
supportive	ADJ	O	O	4480
therapy	NOUN	O	O	4480
,	PUNCT	O	O	4480
following	VERB	O	O	4480
ingestion	NOUN	O	O	4480
of	ADP	O	O	4480
13.5	NUM	O	O	4480
g	X	O	O	4480
bupropion	NOUN	O	Chemical	4480
.	PUNCT	O	O	4480
Recurrent	ADJ	O	O	4481
seizures	NOUN	O	Disease	4481
were	AUX	O	O	4481
treated	VERB	O	O	4481
with	ADP	O	O	4481
diazepam	NOUN	O	Chemical	4481
and	CCONJ	O	O	4481
broad	ADJ	O	O	4481
complex	ADJ	O	O	4481
tachycardia	PROPN	O	Disease	4481
was	AUX	O	O	4481
successfully	ADV	O	O	4481
treated	VERB	O	O	4481
with	ADP	O	O	4481
adenosine	PROPN	O	Chemical	4481
.	PUNCT	O	O	4481
Zyban	PROPN	O	O	4482
caused	VERB	O	O	4482
significant	ADJ	O	O	4482
neurological	ADJ	O	O	4482
and	CCONJ	O	O	4482
cardiovascular toxicity	NOUN	O	Disease	4482
in	ADP	O	O	4482
overdose	NOUN	O	Disease	4482
.	PUNCT	O	O	4482
Survey	NOUN	O	O	4485
of	ADP	O	O	4485
complications	NOUN	O	O	4485
of	ADP	O	O	4485
indocyanine	NOUN	O	O	4485
green	ADJ	O	O	4485
angiography	NOUN	O	O	4485
in	ADP	O	O	4485
Japan	PROPN	O	O	4485
.	PUNCT	O	O	4485
We	PRON	O	O	4486
evaluated	VERB	O	O	4486
the	PRON	O	O	4486
safety	NOUN	O	O	4486
of	ADP	O	O	4486
indocyanine	NOUN	O	O	4486
green	ADJ	O	O	4486
for	ADP	O	O	4486
use	VERB	O	O	4486
in	ADP	O	O	4486
fundus	NOUN	O	O	4486
angiography	NOUN	O	O	4486
.	PUNCT	O	O	4486
:	PUNCT	O	O	4487
We	PRON	O	O	4487
sent	VERB	O	O	4487
a	PRON	O	O	4487
questionnaire	NOUN	O	O	4487
concerning	VERB	O	O	4487
complications	NOUN	O	O	4487
of	ADP	O	O	4487
indocyanine	NOUN	O	O	4487
green	ADJ	O	O	4487
to	PART	O	O	4487
32	NUM	O	O	4487
institutions	NOUN	O	O	4487
in	ADP	O	O	4487
Japan	PROPN	O	O	4487
,	PUNCT	O	O	4487
which	PRON	O	O	4487
were	AUX	O	O	4487
selected	VERB	O	O	4487
on	ADP	O	O	4487
the	PRON	O	O	4487
basis	NOUN	O	O	4487
of	ADP	O	O	4487
the	PRON	O	O	4487
client	NOUN	O	O	4487
list	NOUN	O	O	4487
from	ADP	O	O	4487
the	PRON	O	O	4487
Topcon	PROPN	O	O	4487
Company	NOUN	O	O	4487
,	PUNCT	O	O	4487
which	PRON	O	O	4487
manufactures	VERB	O	O	4487
the	PRON	O	O	4487
indocyanine	NOUN	O	O	4487
green	ADJ	O	O	4487
fundus	NOUN	O	O	4487
camera	NOUN	O	O	4487
.	PUNCT	O	O	4487
Ophthalmologists	NOUN	O	O	4488
at	ADP	O	O	4488
15	NUM	O	O	4488
institutions	NOUN	O	O	4488
responded	VERB	O	O	4488
,	PUNCT	O	O	4488
reporting	VERB	O	O	4488
a	PRON	O	O	4488
total	ADJ	O	O	4488
of	ADP	O	O	4488
3,774	NUM	O	O	4488
indocyanine	NOUN	O	O	4488
green	ADJ	O	O	4488
angiograms	VERB	O	O	4488
performed	VERB	O	O	4488
on	ADP	O	O	4488
2,820	NUM	O	O	4488
patients	NOUN	O	O	4488
between	ADP	O	O	4488
June	PROPN	O	O	4488
1984	NUM	O	O	4488
and	CCONJ	O	O	4488
September	PROPN	O	O	4488
1992	NUM	O	O	4488
.	PUNCT	O	O	4488
Before	ADP	O	O	4489
angiography	NOUN	O	O	4489
,	PUNCT	O	O	4489
intradermal	ADJ	O	O	4489
or	CCONJ	O	O	4489
intravenous	ADJ	O	O	4489
indocyanine	NOUN	O	O	4489
green	ADJ	O	O	4489
testing	NOUN	O	O	4489
,	PUNCT	O	O	4489
or	CCONJ	O	O	4489
both	PRON	O	O	4489
was	AUX	O	O	4489
performed	VERB	O	O	4489
at	ADP	O	O	4489
13	NUM	O	O	4489
of	ADP	O	O	4489
15	NUM	O	O	4489
institutions	NOUN	O	O	4489
.	PUNCT	O	O	4489
The	PRON	O	O	4490
dosage	NOUN	O	O	4490
of	ADP	O	O	4490
indocyanine	NOUN	O	O	4490
green	ADJ	O	O	4490
used	VERB	O	O	4490
for	ADP	O	O	4490
angiography	NOUN	O	O	4490
varied	ADJ	O	O	4490
from	ADP	O	O	4490
25	NUM	O	O	4490
to	PART	O	O	4490
75	NUM	O	O	4490
mg	VERB	O	O	4490
,	PUNCT	O	O	4490
depending	VERB	O	O	4490
upon	SCONJ	O	O	4490
the	PRON	O	O	4490
institution	NOUN	O	O	4490
.	PUNCT	O	O	4490
There	ADV	O	O	4491
were	AUX	O	O	4491
13	NUM	O	O	4491
cases	NOUN	O	O	4491
of	ADP	O	O	4491
adverse	ADJ	O	O	4491
reactions	NOUN	O	O	4491
(	PUNCT	O	O	4491
0.34%	NOUN	O	O	4491
)	PUNCT	O	O	4491
,	PUNCT	O	O	4491
ten	NUM	O	O	4491
of	ADP	O	O	4491
which	PRON	O	O	4491
were	AUX	O	O	4491
mild	ADJ	O	O	4491
reactions	NOUN	O	O	4491
such	ADJ	O	O	4491
as	ADP	O	O	4491
nausea	NOUN	O	Disease	4491
,	PUNCT	O	O	4491
exanthema	NOUN	O	O	4491
,	PUNCT	O	O	4491
urtication	NOUN	O	O	4491
,	PUNCT	O	O	4491
itchiness	VERB	O	O	4491
,	PUNCT	O	O	4491
and	CCONJ	O	O	4491
urgency	NOUN	O	O	4491
to	PART	O	O	4491
defecate	VERB	O	O	4491
,	PUNCT	O	O	4491
and	CCONJ	O	O	4491
did	VERB	O	O	4491
not	PART	O	O	4491
require	VERB	O	O	4491
treatment	NOUN	O	O	4491
.	PUNCT	O	O	4491
Also	ADV	O	O	4492
recorded	VERB	O	O	4492
were	AUX	O	O	4492
one	NUM	O	O	4492
case	NOUN	O	O	4492
of	ADP	O	O	4492
pain	NOUN	O	Disease	4492
of	ADP	O	O	4492
the	PRON	O	O	4492
vein	NOUN	O	O	4492
,	PUNCT	O	O	4492
which	PRON	O	O	4492
required	VERB	O	O	4492
treatment	NOUN	O	O	4492
,	PUNCT	O	O	4492
and	CCONJ	O	O	4492
two	NUM	O	O	4492
cases	NOUN	O	O	4492
of	ADP	O	O	4492
hypotension	NOUN	O	Disease	4492
.	PUNCT	O	O	4492
The	PRON	O	O	4493
two	NUM	O	O	4493
hypotensive	ADJ	O	Disease	4493
patients	NOUN	O	O	4493
required	VERB	O	O	4493
treatment	NOUN	O	O	4493
for	ADP	O	O	4493
shock	NOUN	O	O	4493
.	PUNCT	O	O	4493
A	PRON	O	O	4494
comparison	NOUN	O	O	4494
of	ADP	O	O	4494
frequency	NOUN	O	O	4494
of	ADP	O	O	4494
adverse	ADJ	O	O	4494
reactions	NOUN	O	O	4494
to	PART	O	O	4494
indocyanine	NOUN	O	O	4494
green	ADJ	O	O	4494
with	ADP	O	O	4494
the	PRON	O	O	4494
previously	ADV	O	O	4494
reported	VERB	O	O	4494
frequency	NOUN	O	O	4494
of	ADP	O	O	4494
such	ADJ	O	O	4494
reactions	NOUN	O	O	4494
to	PART	O	O	4494
fluorescein	VERB	O	O	4494
sodium	NOUN	O	Chemical	4494
indicated	VERB	O	O	4494
that	SCONJ	O	O	4494
indocyanine	NOUN	O	O	4494
green	ADJ	O	O	4494
is	AUX	O	O	4494
a	PRON	O	O	4494
safe	ADJ	O	O	4494
as	ADP	O	O	4494
fluorescein	VERB	O	O	4494
for	ADP	O	O	4494
use	VERB	O	O	4494
in	ADP	O	O	4494
angiography	NOUN	O	O	4494
.	PUNCT	O	O	4494
Bradykinin	NOUN	O	O	4497
receptors	NOUN	O	O	4497
antagonists	NOUN	O	O	4497
and	CCONJ	O	O	4497
nitric oxide	NOUN	O	Chemical	4497
synthase	NOUN	O	O	4497
inhibitors	NOUN	O	O	4497
in	ADP	O	O	4497
vincristine	NOUN	O	Chemical	4497
and	CCONJ	O	O	4497
streptozotocin	PROPN	O	Chemical	4497
induced	VERB	O	O	4497
hyperalgesia	NOUN	O	Disease	4497
in	ADP	O	O	4497
chemotherapy	NOUN	O	O	4497
and	CCONJ	O	O	4497
diabetic	ADJ	O	Disease	4497
neuropathy	NOUN	O	Disease	4497
rat	NOUN	O	O	4497
model	NOUN	O	O	4497
.	PUNCT	O	O	4497
NO	PRON	O	Chemical	4498
synthase	NOUN	O	O	4498
(	PUNCT	O	O	4498
L	NOUN	O	O	4498
-	PUNCT	O	O	4498
NOArg	ADJ	O	O	4498
;	PUNCT	O	O	4498
1.0	NUM	O	O	4498
mg	VERB	O	O	4498
/	PUNCT	O	O	4498
kg	VERB	O	O	4498
ip	X	O	O	4498
)	PUNCT	O	O	4498
,	PUNCT	O	O	4498
a	PRON	O	O	4498
relatively	ADV	O	O	4498
selective	ADJ	O	O	4498
inhibitor	NOUN	O	O	4498
of	ADP	O	O	4498
inducible	VERB	O	O	4498
NO	PRON	O	Chemical	4498
synthase	NOUN	O	O	4498
(	PUNCT	O	O	4498
L	NOUN	O	O	4498
-	PUNCT	O	O	4498
NIL	X	O	O	4498
;	PUNCT	O	O	4498
1.0	NUM	O	O	4498
mg	VERB	O	O	4498
/	PUNCT	O	O	4498
kg	VERB	O	O	4498
ip	X	O	O	4498
)	PUNCT	O	O	4498
and	CCONJ	O	O	4498
a	PRON	O	O	4498
relatively	ADV	O	O	4498
specific	ADJ	O	O	4498
inhibitor	NOUN	O	O	4498
of	ADP	O	O	4498
neuronal	ADJ	O	O	4498
NO	PRON	O	Chemical	4498
synthase	NOUN	O	O	4498
(	PUNCT	O	O	4498
7-NI	NOUN	O	O	4498
;	PUNCT	O	O	4498
0.1	NUM	O	O	4498
mg	VERB	O	O	4498
/	PUNCT	O	O	4498
kg	VERB	O	O	4498
ip	X	O	O	4498
)	PUNCT	O	O	4498
,	PUNCT	O	O	4498
on	ADP	O	O	4498
antihyperalgesic	NOUN	O	O	4498
action	NOUN	O	O	4498
of	ADP	O	O	4498
selective	ADJ	O	O	4498
antagonists	NOUN	O	O	4498
of	ADP	O	O	4498
B2	NOUN	O	O	4498
and	CCONJ	O	O	4498
B1	NOUN	O	O	4498
receptors	NOUN	O	O	4498
:	PUNCT	O	O	4498
D	NOUN	O	O	4498
-	PUNCT	O	O	4498
Arg-[Hyp3,Thi5,D	NOUN	O	O	4498
-	PUNCT	O	O	4498
Tic7,Oic8	NOUN	O	O	4498
]	PUNCT	O	O	4498
bradykinin	NOUN	O	O	4498
(	PUNCT	O	O	4498
HOE	VERB	O	O	4498
140	NUM	O	O	4498
;	PUNCT	O	O	4498
70	NUM	O	O	4498
nmol	PROPN	O	O	4498
/	PUNCT	O	O	4498
kg	VERB	O	O	4498
ip	X	O	O	4498
)	PUNCT	O	O	4498
or	CCONJ	O	O	4498
des	PROPN	O	O	4498
Arg10	NUM	O	O	4498
HOE	VERB	O	O	4498
140	NUM	O	O	4498
(	PUNCT	O	O	4498
70	NUM	O	O	4498
nmol	PROPN	O	O	4498
/	PUNCT	O	O	4498
kg	VERB	O	O	4498
ip	X	O	O	4499
)	PUNCT	O	O	4499
respectively	ADV	O	O	4499
,	PUNCT	O	O	4499
in	ADP	O	O	4499
model	NOUN	O	O	4499
of	ADP	O	O	4499
diabetic	ADJ	O	Disease	4499
(	PUNCT	O	O	4499
streptozotocin	PROPN	O	Chemical	4499
-	PUNCT	O	O	4499
induced	VERB	O	O	4499
)	PUNCT	O	O	4499
and	CCONJ	O	O	4499
toxic	ADJ	O	O	4499
(	PUNCT	O	O	4499
vincristine	NOUN	O	Chemical	4499
-	PUNCT	O	O	4499
induced	VERB	O	O	4499
)	PUNCT	O	O	4499
neuropathy	NOUN	O	Disease	4499
was	AUX	O	O	4499
investigated	VERB	O	O	4499
.	PUNCT	O	O	4499
The	PRON	O	O	4500
changes	VERB	O	O	4500
in	ADP	O	O	4500
pain	NOUN	O	Disease	4500
thresholds	NOUN	O	O	4500
were	AUX	O	O	4500
determined	VERB	O	O	4500
using	VERB	O	O	4500
mechanical	ADJ	O	O	4500
stimuli	NOUN	O	O	4500
--	PUNCT	O	O	4500
the	PRON	O	O	4500
modification	NOUN	O	O	4500
of	ADP	O	O	4500
the	PRON	O	O	4500
classic	ADJ	O	O	4500
paw	PROPN	O	O	4500
withdrawal	NOUN	O	O	4500
test	NOUN	O	O	4500
described	VERB	O	O	4500
by	ADP	O	O	4500
Randall	PROPN	O	O	4500
-	PUNCT	O	O	4500
Selitto	PROPN	O	O	4500
.	PUNCT	O	O	4500
The	PRON	O	O	4501
results	VERB	O	O	4501
of	ADP	O	O	4501
this	PRON	O	O	4501
paper	PROPN	O	O	4501
confirm	VERB	O	O	4501
that	SCONJ	O	O	4501
inhibition	NOUN	O	O	4501
of	ADP	O	O	4501
bradykinin	NOUN	O	O	4501
receptors	NOUN	O	O	4501
and	CCONJ	O	O	4501
inducible	VERB	O	O	4501
NO	PRON	O	Chemical	4502
synthase	NOUN	O	O	4502
but	CCONJ	O	O	4502
not	PART	O	O	4502
neuronal	ADJ	O	O	4502
NO	PRON	O	Chemical	4503
synthase	NOUN	O	O	4503
activity	NOUN	O	O	4503
reduces	VERB	O	O	4503
diabetic	ADJ	O	Disease	4503
hyperalgesia	NOUN	O	Disease	4503
.	PUNCT	O	O	4503
both	PRON	O	O	4504
HOE	VERB	O	O	4504
140	NUM	O	O	4504
and	CCONJ	O	O	4504
des	PROPN	O	O	4504
Arg10	NUM	O	O	4504
HOE	VERB	O	O	4504
140	NUM	O	O	4504
.	PUNCT	O	O	4504
It	PRON	O	O	4505
was	AUX	O	O	4505
also	ADV	O	O	4505
shown	VERB	O	O	4505
that	SCONJ	O	O	4505
both	PRON	O	O	4505
products	NOUN	O	O	4505
of	ADP	O	O	4505
inducible	VERB	O	O	4505
NO	PRON	O	Chemical	4505
synthase	NOUN	O	O	4505
and	CCONJ	O	O	4505
neuronal	ADJ	O	O	4505
NO	PRON	O	Chemical	4505
synthase	NOUN	O	O	4505
activation	NOUN	O	O	4505
as	ADP	O	O	4505
well	ADV	O	O	4505
as	ADP	O	O	4505
bradykinin	NOUN	O	O	4505
are	AUX	O	O	4505
involved	VERB	O	O	4505
in	ADP	O	O	4505
hyperalgesia	NOUN	O	Disease	4505
produced	VERB	O	O	4505
by	ADP	O	O	4505
vincristine	NOUN	O	Chemical	4505
.	PUNCT	O	O	4505
Moreover	ADV	O	O	4506
,	PUNCT	O	O	4506
L	NOUN	O	O	4506
-	PUNCT	O	O	4506
NOArg	ADJ	O	O	4506
and	CCONJ	O	O	4506
7-NI	NOUN	O	O	4506
but	CCONJ	O	O	4506
not	PART	O	O	4506
L	NOUN	O	O	4506
-	PUNCT	O	O	4506
NIL	X	O	O	4506
intensify	VERB	O	O	4506
antihyperalgesic	NOUN	O	O	4506
activity	NOUN	O	O	4506
of	ADP	O	O	4506
HOE	VERB	O	O	4506
140	NUM	O	O	4506
or	CCONJ	O	O	4506
des	PROPN	O	O	4506
-	PUNCT	O	O	4506
Arg10HOE	PUNCT	O	O	4506
140	NUM	O	O	4506
in	ADP	O	O	4506
toxic	ADJ	O	O	4506
neuropathy	NOUN	O	Disease	4506
.	PUNCT	O	O	4506
Results	NOUN	O	O	4507
of	ADP	O	O	4507
these	PRON	O	O	4507
studies	NOUN	O	O	4507
suggest	VERB	O	O	4507
that	SCONJ	O	O	4507
B1	NOUN	O	O	4507
and	CCONJ	O	O	4507
B2	NOUN	O	O	4507
receptors	NOUN	O	O	4507
are	AUX	O	O	4507
engaged	VERB	O	O	4507
in	ADP	O	O	4507
transmission	NOUN	O	O	4507
of	ADP	O	O	4507
nociceptive	ADJ	O	O	4507
stimuli	NOUN	O	O	4507
in	ADP	O	O	4507
both	PRON	O	O	4507
diabetic	ADJ	O	Disease	4507
and	CCONJ	O	O	4507
toxic	ADJ	O	O	4507
neuropathy	NOUN	O	Disease	4507
.	PUNCT	O	O	4507
In	ADP	O	O	4508
streptozotocin	PROPN	O	Chemical	4508
-	PUNCT	O	O	4508
induced	VERB	O	O	4508
hyperalgesia	NOUN	O	Disease	4508
,	PUNCT	O	O	4508
inducible	VERB	O	O	4508
NO	PRON	O	Chemical	4509
synthase	NOUN	O	O	4509
participates	VERB	O	O	4509
in	ADP	O	O	4509
pronociceptive	ADJ	O	O	4509
activity	NOUN	O	O	4509
of	ADP	O	O	4509
bradykinin	NOUN	O	O	4509
,	PUNCT	O	O	4509
whereas	SCONJ	O	O	4509
in	ADP	O	O	4509
vincristine	NOUN	O	Chemical	4509
-	PUNCT	O	O	4509
induced	VERB	O	O	4509
hyperalgesia	NOUN	O	Disease	4509
bradykinin	NOUN	O	O	4509
seemed	VERB	O	O	4509
to	PART	O	O	4509
activate	VERB	O	O	4509
neuronal	ADJ	O	O	4509
NO	PRON	O	Chemical	4509
synthase	NOUN	O	O	4509
pathway	NOUN	O	O	4509
.	PUNCT	O	O	4509
Therefore	ADV	O	O	4510
,	PUNCT	O	O	4510
concomitant	ADJ	O	O	4510
administration	NOUN	O	O	4510
of	ADP	O	O	4510
small	ADJ	O	O	4510
doses	NOUN	O	O	4510
of	ADP	O	O	4510
bradykinin	NOUN	O	O	4510
receptor	NOUN	O	O	4510
antagonists	NOUN	O	O	4510
and	CCONJ	O	O	4510
NO	PRON	O	Chemical	4510
synthase	NOUN	O	O	4510
inhibitors	NOUN	O	O	4510
can	AUX	O	O	4510
be	AUX	O	O	4510
effective	ADJ	O	O	4510
in	ADP	O	O	4510
alleviation	NOUN	O	O	4510
of	ADP	O	O	4510
neuropathic pain	NOUN	O	Disease	4510
,	PUNCT	O	O	4510
even	ADV	O	O	4510
in	ADP	O	O	4510
hospital	PROPN	O	O	4510
care	VERB	O	O	4510
.	PUNCT	O	O	4510
Cardiac toxicity	NOUN	O	Disease	4513
observed	VERB	O	O	4513
in	ADP	O	O	4513
association	PROPN	O	O	4513
with	ADP	O	O	4513
high	ADJ	O	O	4513
-	PUNCT	O	O	4513
dose	NOUN	O	O	4513
cyclophosphamide	VERB	O	Chemical	4513
-	PUNCT	O	O	4513
based	VERB	O	O	4513
chemotherapy	NOUN	O	O	4513
for	ADP	O	O	4513
metastatic	ADJ	O	O	4513
breast cancer	NOUN	O	Disease	4513
.	PUNCT	O	O	4513
Cyclophosphamide	PROPN	O	Chemical	4514
is	AUX	O	O	4514
an	PRON	O	O	4514
alkylating	VERB	O	O	4514
agent	NOUN	O	O	4514
given	VERB	O	O	4514
frequently	ADV	O	O	4514
as	ADP	O	O	4514
a	PRON	O	O	4514
component	NOUN	O	O	4514
of	ADP	O	O	4514
many	ADJ	O	O	4514
conditioning	NOUN	O	O	4514
regimens	NOUN	O	O	4514
.	PUNCT	O	O	4514
In	ADP	O	O	4515
high	ADJ	O	O	4515
doses	NOUN	O	O	4515
,	PUNCT	O	O	4515
its	PRON	O	O	4515
nonhematological	ADJ	O	O	4515
dose	NOUN	O	O	4515
-	PUNCT	O	O	4515
limiting	VERB	O	O	4515
toxicity	NOUN	O	Disease	4515
is	AUX	O	O	4515
cardiomyopathy	ADJ	O	Disease	4515
.	PUNCT	O	O	4515
We	PRON	O	O	4516
combined	VERB	O	O	4516
paclitaxel	NOUN	O	Chemical	4516
,	PUNCT	O	O	4516
melphalan	NOUN	O	O	4516
and	CCONJ	O	O	4516
high	ADJ	O	O	4516
-	PUNCT	O	O	4516
dose	NOUN	O	O	4516
cyclophosphamide	VERB	O	Chemical	4516
,	PUNCT	O	O	4516
thiotepa	NOUN	O	O	4516
,	PUNCT	O	O	4516
and	CCONJ	O	O	4516
carboplatin	PROPN	O	Chemical	4516
in	ADP	O	O	4516
a	PRON	O	O	4516
triple	ADV	O	O	4516
sequential	ADJ	O	O	4516
high	ADJ	O	O	4516
-	PUNCT	O	O	4516
dose	NOUN	O	O	4516
regimen	NOUN	O	O	4516
for	ADP	O	O	4516
patients	NOUN	O	O	4516
with	ADP	O	O	4516
metastatic	ADJ	O	O	4516
breast cancer	NOUN	O	Disease	4516
.	PUNCT	O	O	4516
Analysis	NOUN	O	O	4517
was	AUX	O	O	4517
performed	VERB	O	O	4517
on	ADP	O	O	4517
61	NUM	O	O	4517
women	NOUN	O	O	4517
with	ADP	O	O	4517
chemotherapy	NOUN	O	O	4517
-	PUNCT	O	O	4517
responsive	ADJ	O	O	4517
metastatic	ADJ	O	O	4517
breast cancer	NOUN	O	Disease	4517
receiving	VERB	O	O	4517
96-h	NOUN	O	O	4517
infusional	NOUN	O	O	4517
cyclophosphamide	VERB	O	Chemical	4517
as	ADP	O	O	4517
part	NOUN	O	O	4517
of	ADP	O	O	4517
a	PRON	O	O	4517
triple	ADV	O	O	4517
sequential	ADJ	O	O	4517
high	ADJ	O	O	4517
-	PUNCT	O	O	4517
dose	NOUN	O	O	4517
regimen	NOUN	O	O	4517
to	PART	O	O	4517
assess	VERB	O	O	4517
association	PROPN	O	O	4517
between	ADP	O	O	4517
presence	NOUN	O	O	4517
of	ADP	O	O	4517
peritransplant	NOUN	O	O	4517
congestive	ADJ	O	O	4517
heart failure	NOUN	O	Disease	4517
(	PUNCT	O	O	4517
CHF	PROPN	O	Disease	4517
)	PUNCT	O	O	4517
and	CCONJ	O	O	4517
the	PRON	O	O	4517
following	VERB	O	O	4517
pretreatment	NOUN	O	O	4517
characteristics	NOUN	O	O	4517
:	PUNCT	O	O	4517
presence	NOUN	O	O	4517
of	ADP	O	O	4517
electrocardiogram	PROPN	O	O	4517
(	PUNCT	O	O	4517
EKG	PROPN	O	O	4517
)	PUNCT	O	O	4517
abnormalities	NOUN	O	O	4517
,	PUNCT	O	O	4517
age	NOUN	O	O	4517
,	PUNCT	O	O	4517
hypertension	NOUN	O	Disease	4517
,	PUNCT	O	O	4517
prior	ADV	O	O	4517
cardiac	ADJ	O	O	4517
history	NOUN	O	O	4517
,	PUNCT	O	O	4517
smoking	VERB	O	O	4517
,	PUNCT	O	O	4517
diabetes mellitus	ADJ	O	Disease	4517
,	PUNCT	O	O	4517
prior	ADV	O	O	4517
use	VERB	O	O	4517
of	ADP	O	O	4517
anthracyclines	NOUN	O	Chemical	4517
,	PUNCT	O	O	4517
and	CCONJ	O	O	4517
left	VERB	O	O	4517
-	PUNCT	O	O	4517
sided	VERB	O	O	4517
chest	NOUN	O	O	4517
irradiation	NOUN	O	O	4517
.	PUNCT	O	O	4517
Six	NUM	O	O	4518
of	ADP	O	O	4518
61	NUM	O	O	4518
women	NOUN	O	O	4518
(	PUNCT	O	O	4518
10%	NOUN	O	O	4518
)	PUNCT	O	O	4518
developed	VERB	O	O	4518
clinically	ADV	O	O	4518
reversible	ADJ	O	O	4518
grade	NOUN	O	O	4518
3	X	O	O	4518
CHF	PROPN	O	Disease	4518
following	VERB	O	O	4518
infusional	NOUN	O	O	4518
cyclophosphamide	VERB	O	Chemical	4518
with	ADP	O	O	4518
a	PRON	O	O	4518
median	ADJ	O	O	4518
percent	NOUN	O	O	4518
decline	VERB	O	O	4518
in	ADP	O	O	4518
ejection	NOUN	O	O	4518
fraction	NOUN	O	O	4518
of	ADP	O	O	4518
31%	NOUN	O	O	4518
.	PUNCT	O	O	4518
Incidence	NOUN	O	O	4519
of	ADP	O	O	4519
transient	ADJ	O	O	4519
cyclophosphamide	VERB	O	Chemical	4519
-	PUNCT	O	O	4519
related	ADJ	O	O	4519
cardiac toxicity	NOUN	O	Disease	4519
(	PUNCT	O	O	4519
10%	NOUN	O	O	4519
)	PUNCT	O	O	4519
is	AUX	O	O	4519
comparable	ADJ	O	O	4519
to	PART	O	O	4519
previous	ADJ	O	O	4519
recorded	VERB	O	O	4519
literature	NOUN	O	O	4519
.	PUNCT	O	O	4519
Older	ADJ	O	O	4520
age	NOUN	O	O	4520
was	AUX	O	O	4520
significantly	ADV	O	O	4520
correlated	VERB	O	O	4520
with	ADP	O	O	4520
the	PRON	O	O	4520
CHF	PROPN	O	Disease	4520
development	NOUN	O	O	4520
;	PUNCT	O	O	4520
with	ADP	O	O	4520
median	ADJ	O	O	4520
ages	NOUN	O	O	4520
for	ADP	O	O	4520
the	PRON	O	O	4520
entire	ADJ	O	O	4520
group	NOUN	O	O	4520
and	CCONJ	O	O	4520
for	ADP	O	O	4520
patients	NOUN	O	O	4520
developing	VERB	O	O	4520
CHF	PROPN	O	Disease	4520
of	ADP	O	O	4520
45	NUM	O	O	4520
and	CCONJ	O	O	4520
59	NUM	O	O	4520
,	PUNCT	O	O	4520
respectively	ADV	O	O	4520
.	PUNCT	O	O	4520
Routine	NOUN	O	O	4521
EKG	PROPN	O	O	4521
monitoring	NOUN	O	O	4521
during	ADP	O	O	4521
infusional	NOUN	O	O	4521
cyclophosphamide	VERB	O	Chemical	4521
did	VERB	O	O	4521
not	PART	O	O	4521
predict	VERB	O	O	4521
CHF	PROPN	O	Disease	4521
development	NOUN	O	O	4521
.	PUNCT	O	O	4521
Inappropriate	ADJ	O	O	4524
use	VERB	O	O	4524
of	ADP	O	O	4524
carbamazepine	NOUN	O	Chemical	4524
and	CCONJ	O	O	4524
vigabatrin	PROPN	O	Chemical	4524
in	ADP	O	O	4524
typical	ADJ	O	O	4524
absence seizures	NOUN	O	Disease	4524
.	PUNCT	O	O	4524
Carbamazepine	NOUN	O	Chemical	4525
and	CCONJ	O	O	4525
vigabatrin	PROPN	O	Chemical	4525
are	AUX	O	O	4525
contraindicated	VERB	O	O	4525
in	ADP	O	O	4525
typical	ADJ	O	O	4525
absence seizures	NOUN	O	Disease	4525
.	PUNCT	O	O	4525
Of	ADV	O	O	4526
18	NUM	O	O	4526
consecutive	ADJ	O	O	4526
referrals	NOUN	O	O	4526
of	ADP	O	O	4526
children	NOUN	O	O	4526
with	ADP	O	O	4526
resistant	ADJ	O	O	4526
typical	ADJ	O	O	4526
absences	NOUN	O	O	4526
only	ADV	O	O	4526
,	PUNCT	O	O	4526
eight	NUM	O	O	4526
were	AUX	O	O	4526
erroneously	ADV	O	O	4526
treated	VERB	O	O	4526
with	ADP	O	O	4526
carbamazepine	NOUN	O	Chemical	4526
either	ADV	O	O	4526
as	ADP	O	O	4526
monotherapy	X	O	O	4526
or	CCONJ	O	O	4526
as	ADP	O	O	4526
an	PRON	O	O	4526
add	VERB	O	O	4526
-	PUNCT	O	O	4526
on	ADP	O	O	4526
.	PUNCT	O	O	4526
Vigabatrin	PROPN	O	O	4527
was	AUX	O	O	4527
also	ADV	O	O	4527
used	VERB	O	O	4527
in	ADP	O	O	4527
the	PRON	O	O	4527
treatment	NOUN	O	O	4527
of	ADP	O	O	4527
two	NUM	O	O	4527
children	NOUN	O	O	4527
.	PUNCT	O	O	4527
Frequency	NOUN	O	O	4528
of	ADP	O	O	4528
absences	NOUN	O	O	4528
increased	VERB	O	O	4528
in	ADP	O	O	4528
four	NUM	O	O	4528
children	NOUN	O	O	4528
treated	VERB	O	O	4528
with	ADP	O	O	4528
carbamazepine	NOUN	O	Chemical	4528
and	CCONJ	O	O	4528
two	NUM	O	O	4528
of	ADP	O	O	4528
these	PRON	O	O	4528
developed	VERB	O	O	4528
myoclonic jerks	NOUN	O	Disease	4528
,	PUNCT	O	O	4528
which	PRON	O	O	4528
resolved	VERB	O	O	4528
on	ADP	O	O	4528
withdrawal	NOUN	O	O	4528
of	ADP	O	O	4528
carbamazepine	NOUN	O	Chemical	4528
.	PUNCT	O	O	4528
Absences	NOUN	O	O	4529
were	AUX	O	O	4529
aggravated	VERB	O	O	4529
in	ADP	O	O	4529
both	PRON	O	O	4529
cases	NOUN	O	O	4529
where	SCONJ	O	O	4529
vigabatrin	PROPN	O	Chemical	4529
was	AUX	O	O	4529
added	VERB	O	O	4529
on	ADP	O	O	4529
to	PART	O	O	4529
concurrent	ADJ	O	O	4529
treatment	NOUN	O	O	4529
.	PUNCT	O	O	4529
Optimal	ADJ	O	O	4530
control	VERB	O	O	4530
of	ADP	O	O	4530
the	PRON	O	O	4530
absences	NOUN	O	O	4530
was	AUX	O	O	4530
achieved	VERB	O	O	4530
with	ADP	O	O	4530
sodium valproate	VERB	O	Chemical	4530
,	PUNCT	O	O	4530
lamotrigine	X	O	Chemical	4530
,	PUNCT	O	O	4530
or	CCONJ	O	O	4530
ethosuximide	VERB	O	O	4530
alone	ADV	O	O	4530
or	CCONJ	O	O	4530
in	ADP	O	O	4530
combination	NOUN	O	O	4530
.	PUNCT	O	O	4530
Hemolytic anemia	NOUN	O	Disease	4533
associated	VERB	O	O	4533
with	ADP	O	O	4533
the	PRON	O	O	4533
use	VERB	O	O	4533
of	ADP	O	O	4533
omeprazole	NOUN	O	O	4533
.	PUNCT	O	O	4533
Omeprazole	NOUN	O	O	4534
is	AUX	O	O	4534
the	PRON	O	O	4534
first	ADV	O	O	4534
drug	NOUN	O	O	4534
designed	VERB	O	O	4534
to	PART	O	O	4534
block	NOUN	O	O	4534
the	PRON	O	O	4534
final	ADJ	O	O	4534
step	VERB	O	O	4534
in	ADP	O	O	4534
the	PRON	O	O	4534
acid	PROPN	O	O	4534
secretory	NOUN	O	O	4534
process	NOUN	O	O	4534
within	ADP	O	O	4534
the	PRON	O	O	4534
parietal	ADJ	O	O	4534
cell	NOUN	O	O	4534
.	PUNCT	O	O	4534
It	PRON	O	O	4535
has	VERB	O	O	4535
been	AUX	O	O	4535
shown	VERB	O	O	4535
to	PART	O	O	4535
be	AUX	O	O	4535
extremely	ADV	O	O	4535
effective	ADJ	O	O	4535
in	ADP	O	O	4535
the	PRON	O	O	4535
treatment	NOUN	O	O	4535
of	ADP	O	O	4535
peptic	ADJ	O	O	4535
ulcer	NOUN	O	O	4535
disease	PROPN	O	O	4535
,	PUNCT	O	O	4535
reflux	VERB	O	O	4535
esophagitis	NOUN	O	O	4535
,	PUNCT	O	O	4535
and	CCONJ	O	O	4535
the	PRON	O	O	4535
Zollinger	NOUN	O	O	4535
-	PUNCT	O	O	4535
Ellison	NOUN	O	O	4535
syndrome	NOUN	O	O	4535
.	PUNCT	O	O	4535
Although	SCONJ	O	O	4536
clinical	ADJ	O	O	4536
experience	NOUN	O	O	4536
with	ADP	O	O	4536
omeprazole	NOUN	O	O	4536
is	AUX	O	O	4536
still	ADV	O	O	4536
limited	VERB	O	O	4536
,	PUNCT	O	O	4536
many	ADJ	O	O	4536
controlled	VERB	O	O	4536
studies	NOUN	O	O	4536
have	VERB	O	O	4536
established	VERB	O	O	4536
the	PRON	O	O	4536
short	ADJ	O	O	4536
-	PUNCT	O	O	4536
term	NOUN	O	O	4536
safety	NOUN	O	O	4536
of	ADP	O	O	4536
this	PRON	O	O	4536
drug	NOUN	O	O	4536
.	PUNCT	O	O	4536
We	PRON	O	O	4537
report	VERB	O	O	4537
the	PRON	O	O	4537
first	ADV	O	O	4537
case	NOUN	O	O	4537
of	ADP	O	O	4537
a	PRON	O	O	4537
serious	ADJ	O	O	4537
short	ADJ	O	O	4537
-	PUNCT	O	O	4537
term	NOUN	O	O	4537
adverse	ADJ	O	O	4537
reaction	NOUN	O	O	4537
with	ADP	O	O	4537
the	PRON	O	O	4537
use	VERB	O	O	4537
of	ADP	O	O	4537
omeprazole	NOUN	O	O	4537
:	PUNCT	O	O	4537
hemolytic anemia	NOUN	O	Disease	4537
.	PUNCT	O	O	4537
The	PRON	O	O	4538
patient	NOUN	O	O	4538
developed	VERB	O	O	4538
weakness	NOUN	O	Disease	4538
,	PUNCT	O	O	4538
lethargy	NOUN	O	Disease	4538
,	PUNCT	O	O	4538
and	CCONJ	O	O	4538
shortness	PROPN	O	O	4538
of	ADP	O	O	4538
breath	NOUN	O	O	4538
2	X	O	O	4538
days	NOUN	O	O	4538
after	ADP	O	O	4538
starting	VERB	O	O	4538
therapy	NOUN	O	O	4538
with	ADP	O	O	4538
omeprazole	NOUN	O	O	4538
.	PUNCT	O	O	4538
Two	NUM	O	O	4539
weeks	NOUN	O	O	4539
after	ADP	O	O	4539
the	PRON	O	O	4539
initiation	NOUN	O	O	4539
of	ADP	O	O	4539
therapy	NOUN	O	O	4539
,	PUNCT	O	O	4539
her	PRON	O	O	4539
hematocrit	PROPN	O	O	4539
had	VERB	O	O	4539
decreased	VERB	O	O	4539
from	ADP	O	O	4539
44.1%	NOUN	O	O	4539
to	PART	O	O	4539
20.4%	NOUN	O	O	4539
,	PUNCT	O	O	4539
and	CCONJ	O	O	4539
she	PRON	O	O	4539
had	VERB	O	O	4539
a	PRON	O	O	4539
positive	ADJ	O	O	4539
direct	ADJ	O	O	4539
Coombs	NOUN	O	O	4539
antiglobulin	PROPN	O	O	4539
test	NOUN	O	O	4539
and	CCONJ	O	O	4539
an	PRON	O	O	4539
elevated	ADJ	O	O	4539
indirect	ADJ	O	O	4539
bilirubin	ADJ	O	Chemical	4539
.	PUNCT	O	O	4539
After	ADP	O	O	4540
she	PRON	O	O	4540
discontinued	VERB	O	O	4540
the	PRON	O	O	4540
omeprazole	NOUN	O	O	4540
,	PUNCT	O	O	4540
her	PRON	O	O	4540
hemoglobin	NOUN	O	O	4540
and	CCONJ	O	O	4540
hematocrit	PROPN	O	O	4540
gradually	ADV	O	O	4540
returned	VERB	O	O	4540
to	PART	O	O	4540
normal	ADJ	O	O	4540
.	PUNCT	O	O	4540
The	PRON	O	O	4541
mechanism	NOUN	O	O	4541
by	ADP	O	O	4541
which	PRON	O	O	4541
omeprazole	NOUN	O	O	4541
caused	VERB	O	O	4541
the	PRON	O	O	4541
patient	NOUN	O	O	4541
's	AUX	O	O	4541
hemolytic anemia	NOUN	O	Disease	4541
is	AUX	O	O	4541
uncertain	ADJ	O	O	4541
,	PUNCT	O	O	4541
but	CCONJ	O	O	4541
physicians	NOUN	O	O	4541
should	AUX	O	O	4541
be	AUX	O	O	4541
alerted	VERB	O	O	4541
to	PART	O	O	4541
this	PRON	O	O	4541
possible	ADJ	O	O	4541
adverse	ADJ	O	O	4541
effect	VERB	O	O	4541
.	PUNCT	O	O	4541
The	PRON	O	O	4544
use	VERB	O	O	4544
and	CCONJ	O	O	4544
toxicity	NOUN	O	Disease	4544
of	ADP	O	O	4544
didanosine	VERB	O	Chemical	4544
(	PUNCT	O	O	4544
ddI	NUM	O	O	4544
)	PUNCT	O	O	4544
in	ADP	O	O	4544
HIV	PROPN	O	O	4544
antibody	NOUN	O	O	4544
-	PUNCT	O	O	4544
positive	ADJ	O	O	4544
individuals	NOUN	O	O	4544
intolerant	ADJ	O	O	4544
to	PART	O	O	4544
zidovudine	NOUN	O	Chemical	4544
(	PUNCT	O	O	4544
AZT	PROPN	O	Chemical	4544
)	PUNCT	O	O	4544
One	NUM	O	O	4545
hundred	NUM	O	O	4545
and	CCONJ	O	O	4545
fifty	NUM	O	O	4545
-	PUNCT	O	O	4545
one	NUM	O	O	4545
patients	NOUN	O	O	4545
intolerant	ADJ	O	O	4545
to	PART	O	O	4545
zidovudine	NOUN	O	Chemical	4545
(	PUNCT	O	O	4545
AZT	PROPN	O	Chemical	4545
)	PUNCT	O	O	4545
received	VERB	O	O	4545
didanosine	VERB	O	Chemical	4545
(	PUNCT	O	O	4545
ddI	NUM	O	O	4545
)	PUNCT	O	O	4545
to	PART	O	O	4545
a	PRON	O	O	4545
maximum	ADV	O	O	4545
dose	NOUN	O	O	4545
of	ADP	O	O	4545
12.5	NUM	O	O	4545
mg	VERB	O	O	4545
/	PUNCT	O	O	4545
kg	VERB	O	O	4545
/	PUNCT	O	O	4545
day	NOUN	O	O	4545
.	PUNCT	O	O	4545
Seventy	NUM	O	O	4546
patients	NOUN	O	O	4546
developed	VERB	O	O	4546
major	ADJ	O	O	4546
opportunistic	ADJ	O	O	4546
infections	NOUN	O	Disease	4546
whilst	SCONJ	O	O	4546
on	ADP	O	O	4546
therapy	NOUN	O	O	4546
;	PUNCT	O	O	4546
this	PRON	O	O	4546
was	AUX	O	O	4546
the	PRON	O	O	4546
first	ADV	O	O	4546
AIDS	PROPN	O	Disease	4546
diagnosis	NOUN	O	O	4546
in	ADP	O	O	4546
17	NUM	O	O	4546
.	PUNCT	O	O	4546
+	ADP	O	O	4547
lymphocyte	NOUN	O	O	4547
subset	VERB	O	O	4547
count	VERB	O	O	4547
were	AUX	O	O	4547
observed	VERB	O	O	4547
in	ADP	O	O	4547
AIDS	PROPN	O	Disease	4547
patients	NOUN	O	O	4547
,	PUNCT	O	O	4547
although	SCONJ	O	O	4547
a	PRON	O	O	4547
more	ADJ	O	O	4547
significant	ADJ	O	O	4547
rise	VERB	O	O	4547
occurred	VERB	O	O	4547
in	ADP	O	O	4547
those	PRON	O	O	4547
with	ADP	O	O	4547
earlier	ADV	O	O	4547
stages	NOUN	O	O	4547
of	ADP	O	O	4547
disease	PROPN	O	O	4547
.	PUNCT	O	O	4547
Adverse	ADJ	O	O	4548
reactions	NOUN	O	O	4548
possibly	ADV	O	O	4548
attributable	ADJ	O	O	4548
to	PART	O	O	4548
didanosine	VERB	O	Chemical	4548
were	AUX	O	O	4548
common	ADJ	O	O	4548
.	PUNCT	O	O	4548
The	PRON	O	O	4549
most	ADV	O	O	4549
common	ADJ	O	O	4549
side	NOUN	O	O	4549
-	PUNCT	O	O	4549
effect	VERB	O	O	4549
was	AUX	O	O	4549
diarrhoea	NOUN	O	Disease	4549
,	PUNCT	O	O	4549
which	PRON	O	O	4549
resulted	VERB	O	O	4549
in	ADP	O	O	4549
cessation	NOUN	O	O	4549
of	ADP	O	O	4549
therapy	NOUN	O	O	4549
in	ADP	O	O	4549
19	NUM	O	O	4549
individuals	NOUN	O	O	4549
.	PUNCT	O	O	4549
Peripheral neuropathy	NOUN	O	Disease	4550
occurred	VERB	O	O	4550
in	ADP	O	O	4550
12	NUM	O	O	4550
patients	NOUN	O	O	4550
and	CCONJ	O	O	4550
pancreatitis	PROPN	O	O	4550
in	ADP	O	O	4550
six	NUM	O	O	4550
.	PUNCT	O	O	4550
Thirteen	NUM	O	O	4551
patients	NOUN	O	O	4551
developed	VERB	O	O	4551
a	PRON	O	O	4551
raised	VERB	O	O	4551
serum	NOUN	O	O	4551
amylase	PROPN	O	O	4551
without	ADP	O	O	4551
abdominal pain	NOUN	O	Disease	4551
.	PUNCT	O	O	4551
Seven	NUM	O	O	4552
patients	NOUN	O	O	4552
developed	VERB	O	O	4552
glucose	NOUN	O	Chemical	4552
tolerance	NOUN	O	O	4552
curves	NOUN	O	O	4552
characteristic	ADJ	O	O	4552
of	ADP	O	O	4552
diabetes	NOUN	O	Disease	4552
but	CCONJ	O	O	4552
these	PRON	O	O	4552
were	AUX	O	O	4552
mild	ADJ	O	O	4552
,	PUNCT	O	O	4552
did	VERB	O	O	4552
not	PART	O	O	4552
require	VERB	O	O	4552
treatment	NOUN	O	O	4552
and	CCONJ	O	O	4552
returned	VERB	O	O	4552
to	PART	O	O	4552
normal	ADJ	O	O	4552
on	ADP	O	O	4552
ceasing	VERB	O	O	4552
didanosine	VERB	O	Chemical	4552
.	PUNCT	O	O	4552
Can	AUX	O	O	4555
angiogenesis	NOUN	O	O	4555
be	AUX	O	O	4555
a	PRON	O	O	4555
target	NOUN	O	O	4555
of	ADP	O	O	4555
treatment	NOUN	O	O	4555
for	ADP	O	O	4555
ribavirin	NOUN	O	Chemical	4555
associated	VERB	O	O	4555
hemolytic anemia	NOUN	O	Disease	4555
?	PUNCT	O	O	4555
Recently	ADV	O	O	4556
ribavirin	NOUN	O	Chemical	4556
has	VERB	O	O	4556
been	AUX	O	O	4556
found	VERB	O	O	4556
to	PART	O	O	4556
inhibit	VERB	O	O	4556
angiogenesis	NOUN	O	O	4556
and	CCONJ	O	O	4556
a	PRON	O	O	4556
number	NOUN	O	O	4556
of	ADP	O	O	4556
angiogenesis	NOUN	O	O	4556
inhibitors	NOUN	O	O	4556
such	ADJ	O	O	4556
as	ADP	O	O	4556
sunitinib	NOUN	O	O	4556
and	CCONJ	O	O	4556
sorafenib	PROPN	O	Chemical	4556
have	VERB	O	O	4556
been	AUX	O	O	4556
found	VERB	O	O	4556
to	PART	O	O	4556
cause	VERB	O	O	4556
acute	ADJ	O	O	4556
hemolysis	NOUN	O	Disease	4556
.	PUNCT	O	O	4556
We	PRON	O	O	4557
aimed	VERB	O	O	4557
to	PART	O	O	4557
investigate	VERB	O	O	4557
whether	SCONJ	O	O	4557
there	ADV	O	O	4557
is	AUX	O	O	4557
a	PRON	O	O	4557
relation	NOUN	O	O	4557
between	ADP	O	O	4557
hemoglobin	NOUN	O	O	4557
,	PUNCT	O	O	4557
haptoglobin	PROPN	O	O	4557
and	CCONJ	O	O	4557
angiogenesis	NOUN	O	O	4557
soluble	ADJ	O	O	4557
markers	NOUN	O	O	4557
which	PRON	O	O	4557
are	AUX	O	O	4557
modifiable	ADJ	O	O	4557
and	CCONJ	O	O	4557
can	AUX	O	O	4557
help	VERB	O	O	4557
in	ADP	O	O	4557
developing	VERB	O	O	4557
strategies	NOUN	O	O	4557
against	ADP	O	O	4557
anemia	NOUN	O	Disease	4557
.	PUNCT	O	O	4557
METHODS	NOUN	O	O	4558
:	PUNCT	O	O	4558
Fourteen	NUM	O	O	4558
patients	NOUN	O	O	4558
chronically	ADV	O	O	4558
infected	VERB	O	O	4558
with	ADP	O	O	4558
hepatitis C	PROPN	O	Disease	4558
virus	NOUN	O	O	4558
were	AUX	O	O	4558
treated	VERB	O	O	4558
by	ADP	O	O	4558
pegylated	VERB	O	O	4558
interferon	PROPN	O	Chemical	4558
alpha	PROPN	O	O	4558
2a	NUM	O	O	4558
and	CCONJ	O	O	4558
ribavirin	NOUN	O	Chemical	4558
.	PUNCT	O	O	4558
In	ADP	O	O	4559
contrast	NOUN	O	O	4559
with	ADP	O	O	4559
the	PRON	O	O	4559
literature	NOUN	O	O	4559
,	PUNCT	O	O	4559
serum	NOUN	O	O	4559
levels	NOUN	O	O	4559
of	ADP	O	O	4559
angiogenesis	NOUN	O	O	4559
factors	NOUN	O	O	4559
did	VERB	O	O	4559
not	PART	O	O	4559
change	VERB	O	O	4559
significantly	ADV	O	O	4559
by	ADP	O	O	4559
pegylated	VERB	O	O	4559
interferon	PROPN	O	Chemical	4559
and	CCONJ	O	O	4559
ribavirin	NOUN	O	Chemical	4559
therapy	NOUN	O	O	4559
.	PUNCT	O	O	4559
This	PRON	O	O	4560
is	AUX	O	O	4560
the	PRON	O	O	4560
first	ADV	O	O	4560
study	VERB	O	O	4560
in	ADP	O	O	4560
the	PRON	O	O	4560
literature	NOUN	O	O	4560
investigating	VERB	O	O	4560
a	PRON	O	O	4560
link	VERB	O	O	4560
between	ADP	O	O	4560
angiogenesis	NOUN	O	O	4560
soluble	ADJ	O	O	4560
markers	NOUN	O	O	4560
and	CCONJ	O	O	4560
ribavirin	NOUN	O	Chemical	4560
induced	VERB	O	O	4560
anemia	NOUN	O	Disease	4560
in	ADP	O	O	4560
patients	NOUN	O	O	4560
with	ADP	O	O	4560
hepatitis C	PROPN	O	Disease	4560
and	CCONJ	O	O	4560
we	PRON	O	O	4560
could	AUX	O	O	4560
not	PART	O	O	4560
find	VERB	O	O	4560
any	PRON	O	O	4560
relation	NOUN	O	O	4560
.	PUNCT	O	O	4560
Future	NOUN	O	O	4561
research	NOUN	O	O	4561
with	ADP	O	O	4561
larger	ADJ	O	O	4561
number	NOUN	O	O	4561
of	ADP	O	O	4561
patients	NOUN	O	O	4561
is	AUX	O	O	4561
needed	VERB	O	O	4561
to	PART	O	O	4561
find	VERB	O	O	4561
out	ADP	O	O	4561
modifiable	ADJ	O	O	4561
factors	NOUN	O	O	4561
that	SCONJ	O	O	4561
will	AUX	O	O	4561
improve	VERB	O	O	4561
the	PRON	O	O	4561
safety	NOUN	O	O	4561
of	ADP	O	O	4561
ribavirin	NOUN	O	Chemical	4561
therapy	NOUN	O	O	4561
.	PUNCT	O	O	4561
Cocaine	NOUN	O	Chemical	4564
causes	VERB	O	O	4564
memory	NOUN	O	O	4564
and	CCONJ	O	O	4564
learning impairments	NOUN	O	O	4564
in	ADP	O	O	4564
rats	NOUN	O	O	4564
:	PUNCT	O	O	4564
involvement	NOUN	O	O	4564
of	ADP	O	O	4564
nuclear	ADJ	O	O	4564
factor	NOUN	O	O	4564
kappa	PROPN	O	O	4564
B	NOUN	O	O	4564
and	CCONJ	O	O	4564
oxidative	NOUN	O	O	4564
stress	NOUN	O	O	4564
,	PUNCT	O	O	4564
and	CCONJ	O	O	4564
prevention	NOUN	O	O	4564
by	ADP	O	O	4564
topiramate	VERB	O	Chemical	4564
.	PUNCT	O	O	4564
Different	ADJ	O	O	4565
mechanisms	NOUN	O	O	4565
have	VERB	O	O	4565
been	AUX	O	O	4565
suggested	VERB	O	O	4565
for	ADP	O	O	4565
cocaine	NOUN	O	Chemical	4565
toxicity	NOUN	O	Disease	4565
including	VERB	O	O	4565
an	PRON	O	O	4565
increase	VERB	O	O	4565
in	ADP	O	O	4565
oxidative	NOUN	O	O	4565
stress	NOUN	O	O	4565
but	CCONJ	O	O	4565
the	PRON	O	O	4565
association	PROPN	O	O	4565
between	ADP	O	O	4565
oxidative	NOUN	O	O	4565
status	NOUN	O	O	4565
in	ADP	O	O	4565
the	PRON	O	O	4565
brain	NOUN	O	O	4565
and	CCONJ	O	O	4565
cocaine	NOUN	O	Chemical	4565
induced	VERB	O	O	4565
-	PUNCT	O	O	4565
behaviour	NOUN	O	O	4565
is	AUX	O	O	4565
poorly	ADV	O	O	4565
understood	VERB	O	O	4565
.	PUNCT	O	O	4565
Nuclear	NOUN	O	O	4566
factor	NOUN	O	O	4566
kappa	PROPN	O	O	4566
B	NOUN	O	O	4566
(	PUNCT	O	O	4566
NFkappaB	NUM	O	O	4566
)	PUNCT	O	O	4566
is	AUX	O	O	4566
a	PRON	O	O	4566
sensor	NOUN	O	O	4566
of	ADP	O	O	4566
oxidative	NOUN	O	O	4566
stress	NOUN	O	O	4566
and	CCONJ	O	O	4566
participates	VERB	O	O	4566
in	ADP	O	O	4566
memory	NOUN	O	O	4566
formation	NOUN	O	O	4566
that	SCONJ	O	O	4566
could	AUX	O	O	4566
be	AUX	O	O	4566
involved	VERB	O	O	4566
in	ADP	O	O	4566
drug	NOUN	O	O	4566
toxicity	NOUN	O	Disease	4566
and	CCONJ	O	O	4566
addiction	NOUN	O	O	4566
mechanisms	NOUN	O	O	4566
.	PUNCT	O	O	4566
Therefore	ADV	O	O	4567
NFkappaB	NUM	O	O	4567
activity	NOUN	O	O	4567
,	PUNCT	O	O	4567
oxidative	NOUN	O	O	4567
stress	NOUN	O	O	4567
,	PUNCT	O	O	4567
neuronal	ADJ	O	O	4567
nitric oxide	NOUN	O	Chemical	4567
synthase	NOUN	O	O	4567
(	PUNCT	O	O	4567
nNOS	PUNCT	O	O	4567
)	PUNCT	O	O	4567
activity	NOUN	O	O	4567
,	PUNCT	O	O	4567
spatial	PROPN	O	O	4567
learning	VERB	O	O	4567
and	CCONJ	O	O	4567
memory	NOUN	O	O	4567
as	ADP	O	O	4567
well	ADV	O	O	4567
as	ADP	O	O	4567
the	PRON	O	O	4567
effect	VERB	O	O	4567
of	ADP	O	O	4567
topiramate	VERB	O	Chemical	4567
,	PUNCT	O	O	4567
a	PRON	O	O	4567
previously	ADV	O	O	4567
proposed	VERB	O	O	4567
therapy	NOUN	O	O	4567
for	ADP	O	O	4567
cocaine	NOUN	O	Chemical	4567
addiction	NOUN	O	O	4567
,	PUNCT	O	O	4567
were	AUX	O	O	4567
evaluated	VERB	O	O	4567
in	ADP	O	O	4567
an	PRON	O	O	4567
experimental	ADJ	O	O	4567
model	NOUN	O	O	4567
of	ADP	O	O	4567
cocaine	NOUN	O	Chemical	4567
administration	NOUN	O	O	4567
in	ADP	O	O	4567
rats	NOUN	O	O	4567
.	PUNCT	O	O	4567
NFkappaB	NUM	O	O	4568
activity	NOUN	O	O	4568
was	AUX	O	O	4568
decreased	VERB	O	O	4568
in	ADP	O	O	4568
the	PRON	O	O	4568
frontal	ADJ	O	O	4568
cortex	VERB	O	O	4568
of	ADP	O	O	4568
cocaine	NOUN	O	Chemical	4568
treated	VERB	O	O	4568
rats	NOUN	O	O	4568
,	PUNCT	O	O	4568
as	ADP	O	O	4568
well	ADV	O	O	4568
as	ADP	O	O	4568
GSH	PROPN	O	O	4568
concentration	NOUN	O	O	4568
and	CCONJ	O	O	4568
glutathione	NOUN	O	Chemical	4568
peroxidase	NOUN	O	O	4568
activity	NOUN	O	O	4568
in	ADP	O	O	4568
the	PRON	O	O	4568
hippocampus	NOUN	O	O	4568
,	PUNCT	O	O	4568
whereas	SCONJ	O	O	4568
nNOS	PUNCT	O	O	4568
activity	NOUN	O	O	4568
in	ADP	O	O	4568
the	PRON	O	O	4568
hippocampus	NOUN	O	O	4568
was	AUX	O	O	4568
increased	VERB	O	O	4568
.	PUNCT	O	O	4568
Memory	NOUN	O	O	4569
retrieval	PROPN	O	O	4569
of	ADP	O	O	4569
experiences	NOUN	O	O	4569
acquired	VERB	O	O	4569
prior	ADV	O	O	4569
to	PART	O	O	4569
cocaine	NOUN	O	Chemical	4569
administration	NOUN	O	O	4569
was	AUX	O	O	4569
impaired	VERB	O	O	4569
and	CCONJ	O	O	4569
negatively	ADV	O	O	4569
correlated	VERB	O	O	4569
with	ADP	O	O	4569
NFkappaB	NUM	O	O	4569
activity	NOUN	O	O	4569
in	ADP	O	O	4569
the	PRON	O	O	4569
frontal	ADJ	O	O	4569
cortex	VERB	O	O	4569
.	PUNCT	O	O	4569
In	ADP	O	O	4570
contrast	NOUN	O	O	4570
,	PUNCT	O	O	4570
learning	VERB	O	O	4570
of	ADP	O	O	4570
new	ADJ	O	O	4570
tasks	NOUN	O	O	4570
was	AUX	O	O	4570
enhanced	VERB	O	O	4570
and	CCONJ	O	O	4570
correlated	VERB	O	O	4570
with	ADP	O	O	4570
the	PRON	O	O	4570
increase	VERB	O	O	4570
of	ADP	O	O	4570
nNOS	PUNCT	O	O	4570
activity	NOUN	O	O	4570
and	CCONJ	O	O	4570
the	PRON	O	O	4570
decrease	VERB	O	O	4570
of	ADP	O	O	4570
glutathione	NOUN	O	Chemical	4570
peroxidase	NOUN	O	O	4570
.	PUNCT	O	O	4570
These	PRON	O	O	4571
results	VERB	O	O	4571
provide	VERB	O	O	4571
evidence	NOUN	O	O	4571
for	ADP	O	O	4571
a	PRON	O	O	4571
possible	ADJ	O	O	4571
mechanistic	ADJ	O	O	4571
role	NOUN	O	O	4571
of	ADP	O	O	4571
oxidative	NOUN	O	O	4571
and	CCONJ	O	O	4571
nitrosative	PROPN	O	O	4571
stress	NOUN	O	O	4571
and	CCONJ	O	O	4571
NFkappaB	NUM	O	O	4571
in	ADP	O	O	4571
the	PRON	O	O	4571
alterations	NOUN	O	O	4571
induced	VERB	O	O	4571
by	ADP	O	O	4571
cocaine	NOUN	O	Chemical	4571
.	PUNCT	O	O	4571
Topiramate	PROPN	O	Chemical	4572
prevented	VERB	O	O	4572
all	PRON	O	O	4572
the	PRON	O	O	4572
alterations	NOUN	O	O	4572
observed	VERB	O	O	4572
,	PUNCT	O	O	4572
showing	VERB	O	O	4572
novel	NOUN	O	O	4572
neuroprotective	ADJ	O	O	4572
properties	NOUN	O	O	4572
.	PUNCT	O	O	4572
Antinociceptive	PROPN	O	O	4575
and	CCONJ	O	O	4575
antiamnesic	PROPN	O	O	4575
properties	NOUN	O	O	4575
of	ADP	O	O	4575
the	PRON	O	O	4575
presynaptic	ADJ	O	O	4575
cholinergic	ADJ	O	O	4575
amplifier	NOUN	O	O	4575
PG-9	NUM	O	O	4575
.	PUNCT	O	O	4575
The	PRON	O	O	4576
antinociceptive	VERB	O	O	4576
effect	VERB	O	O	4576
of	ADP	O	O	4576
3	X	O	O	4576
alpha	PROPN	O	O	4576
-	PUNCT	O	O	4576
tropyl	NOUN	O	O	4576
2-(p	NUM	O	O	4576
-	PUNCT	O	O	4576
bromophenyl)propionate	PRON	O	O	4576
[	X	O	O	4576
(	PUNCT	O	O	4576
+	ADP	O	O	4576
/-)-PG-9	PUNCT	O	O	4576
]	PUNCT	O	O	4576
(	PUNCT	O	O	4576
10	NUM	O	O	4576
-	PUNCT	O	O	4576
40	NUM	O	O	4576
mg	VERB	O	O	4576
kg-1	VERB	O	O	4576
s.c	PROPN	O	O	4576
.	PUNCT	O	O	4576
(	PUNCT	O	O	4577
+	ADP	O	O	4577
/-)-PG-9	PUNCT	O	O	4577
antinociception	NOUN	O	O	4577
peaked	VERB	O	O	4577
15	NUM	O	O	4577
min	NOUN	O	O	4577
after	ADP	O	O	4577
injection	NOUN	O	O	4577
and	CCONJ	O	O	4577
then	ADV	O	O	4577
slowly	ADV	O	O	4577
diminished	VERB	O	O	4577
.	PUNCT	O	O	4577
The	PRON	O	O	4578
antinociception	NOUN	O	O	4578
produced	VERB	O	O	4578
by	ADP	O	O	4578
(	PUNCT	O	O	4578
+	ADP	O	O	4578
/-)-PG-9	PUNCT	O	O	4578
was	AUX	O	O	4578
prevented	VERB	O	O	4578
by	ADP	O	O	4578
the	PRON	O	O	4578
unselective	PROPN	O	O	4578
muscarinic	PROPN	O	O	4578
antagonist	NOUN	O	O	4578
atropine	NOUN	O	Chemical	4578
,	PUNCT	O	O	4578
the	PRON	O	O	4578
M1-selective	PROPN	O	O	4578
antagonists	NOUN	O	O	4578
pirenzepine	NOUN	O	O	4578
and	CCONJ	O	O	4578
dicyclomine	PROPN	O	O	4578
and	CCONJ	O	O	4578
the	PRON	O	O	4578
acetylcholine	NOUN	O	Chemical	4578
depletor	PROPN	O	O	4578
hemicholinium-3	X	O	O	4578
,	PUNCT	O	O	4578
but	CCONJ	O	O	4578
not	PART	O	O	4578
by	ADP	O	O	4578
the	PRON	O	O	4578
opioid	NOUN	O	O	4578
antagonist	NOUN	O	O	4578
naloxone	NOUN	O	Chemical	4578
,	PUNCT	O	O	4578
the	PRON	O	O	4578
gamma	PROPN	O	O	4578
-	PUNCT	O	O	4578
aminobutyric	PROPN	O	O	4578
acidB	VERB	O	O	4578
antagonist	NOUN	O	O	4578
3-aminopropyl	PROPN	O	O	4578
-	PUNCT	O	O	4578
diethoxy	PROPN	O	O	4578
-	PUNCT	O	O	4578
methyl	NOUN	O	O	4578
-	PUNCT	O	O	4578
phosphinic	ADJ	O	O	4578
acid	PROPN	O	O	4578
,	PUNCT	O	O	4578
the	PRON	O	O	4578
H3	NOUN	O	O	4578
agonist	NOUN	O	O	4578
R-(alpha)-methylhistamine	NOUN	O	O	4578
,	PUNCT	O	O	4578
the	PRON	O	O	4578
D2	NOUN	O	O	4578
antagonist	NOUN	O	O	4578
quinpirole	NOUN	O	Chemical	4578
,	PUNCT	O	O	4578
the	PRON	O	O	4578
5-hydroxytryptamine4	NOUN	O	O	4578
antagonist	NOUN	O	O	4578
2-methoxy-4-amino-5-chlorobenzoic	ADJ	O	O	4578
acid	PROPN	O	O	4578
2-(diethylamino)ethyl	NUM	O	O	4578
ester	PROPN	O	O	4578
hydrochloride	NOUN	O	O	4578
,	PUNCT	O	O	4578
the	PRON	O	O	4578
5-hydroxytryptamin1A	PROPN	O	O	4578
antagonist	NOUN	O	O	4578
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine	NUM	O	O	4578
hydrobromide	NOUN	O	O	4578
and	CCONJ	O	O	4578
the	PRON	O	O	4578
polyamines	NOUN	O	O	4578
depletor	PROPN	O	O	4578
reserpine	NOUN	O	Chemical	4578
.	PUNCT	O	O	4578
Based	VERB	O	O	4579
on	ADP	O	O	4579
these	PRON	O	O	4579
data	NOUN	O	O	4579
,	PUNCT	O	O	4579
it	PRON	O	O	4579
can	AUX	O	O	4579
be	AUX	O	O	4579
postulated	VERB	O	O	4579
that	SCONJ	O	O	4579
(	PUNCT	O	O	4579
+	ADP	O	O	4579
/-)-PG-9	PUNCT	O	O	4579
exerted	VERB	O	O	4579
an	PRON	O	O	4579
antinociceptive	VERB	O	O	4579
effect	VERB	O	O	4579
mediated	VERB	O	O	4579
by	ADP	O	O	4579
a	PRON	O	O	4579
central	ADJ	O	O	4579
potentiation	NOUN	O	O	4579
of	ADP	O	O	4579
cholinergic	ADJ	O	O	4579
transmission	NOUN	O	O	4579
.	PUNCT	O	O	4579
(	PUNCT	O	O	4580
+	ADP	O	O	4580
/-)-PG-9	PUNCT	O	O	4580
(	PUNCT	O	O	4580
10	NUM	O	O	4580
-	PUNCT	O	O	4580
40	NUM	O	O	4580
mg	VERB	O	O	4580
kg-1	VERB	O	O	4580
i.p	NOUN	O	O	4580
.	PUNCT	O	O	4580
)	PUNCT	O	O	4580
was	AUX	O	O	4580
able	ADJ	O	O	4580
to	PART	O	O	4580
prevent	VERB	O	O	4580
amnesia	NOUN	O	Disease	4580
induced	VERB	O	O	4580
by	ADP	O	O	4580
scopolamine	NOUN	O	Chemical	4580
(	PUNCT	O	O	4580
1	X	O	O	4580
mg	VERB	O	O	4580
kg-1	VERB	O	O	4580
i.p	NOUN	O	O	4580
.	PUNCT	O	O	4580
)	PUNCT	O	O	4580
and	CCONJ	O	O	4580
dicyclomine	PROPN	O	O	4580
(	PUNCT	O	O	4580
2	X	O	O	4580
mg	VERB	O	O	4580
kg-1	VERB	O	O	4580
i.p	NOUN	O	O	4580
.	PUNCT	O	O	4580
)	PUNCT	O	O	4580
in	ADP	O	O	4580
the	PRON	O	O	4580
mouse	PROPN	O	O	4580
passive	ADJ	O	O	4580
-	PUNCT	O	O	4580
avoidance	NOUN	O	O	4580
test	NOUN	O	O	4580
.	PUNCT	O	O	4580
Affinity	NOUN	O	O	4581
profiles	NOUN	O	O	4581
of	ADP	O	O	4581
(	PUNCT	O	O	4581
+	ADP	O	O	4581
/-)-PG-9	PUNCT	O	O	4581
for	ADP	O	O	4581
muscarinic	PROPN	O	O	4581
receptor	NOUN	O	O	4581
subtypes	NOUN	O	O	4581
,	PUNCT	O	O	4581
determined	VERB	O	O	4581
by	ADP	O	O	4581
functional	ADJ	O	O	4581
studies	NOUN	O	O	4581
(	PUNCT	O	O	4581
rabbit	NOUN	O	O	4581
vas	X	O	O	4581
deferens	NOUN	O	O	4581
for	ADP	O	O	4581
M1	PROPN	O	O	4581
,	PUNCT	O	O	4581
guinea	NOUN	O	O	4581
pig	NOUN	O	O	4581
atrium	NOUN	O	O	4581
for	ADP	O	O	4581
M2	PROPN	O	O	4581
,	PUNCT	O	O	4581
,	PUNCT	O	O	4582
have	VERB	O	O	4582
shown	VERB	O	O	4582
an	PRON	O	O	4582
M4/M1	PROPN	O	O	4582
selectivity	NOUN	O	O	4582
ratio	NOUN	O	O	4582
of	ADP	O	O	4582
10.2	NUM	O	O	4582
that	SCONJ	O	O	4582
might	AUX	O	O	4582
be	AUX	O	O	4582
responsible	ADJ	O	O	4582
for	ADP	O	O	4582
the	PRON	O	O	4582
antinociception	NOUN	O	O	4582
and	CCONJ	O	O	4582
the	PRON	O	O	4582
anti	ADJ	O	O	4582
-	PUNCT	O	O	4582
amnesic	ADJ	O	Disease	4582
effect	VERB	O	O	4582
induced	VERB	O	O	4582
by	ADP	O	O	4582
(	PUNCT	O	O	4582
+	ADP	O	O	4582
/-)-PG-9	PUNCT	O	O	4582
through	ADP	O	O	4582
an	PRON	O	O	4582
increase	VERB	O	O	4582
in	ADP	O	O	4582
acetylcholine	NOUN	O	Chemical	4582
extracellular	ADJ	O	O	4582
levels	NOUN	O	O	4582
.	PUNCT	O	O	4582
In	ADP	O	O	4583
the	PRON	O	O	4583
antinociceptive	VERB	O	O	4583
and	CCONJ	O	O	4583
antiamnesic	PROPN	O	O	4583
dose	NOUN	O	O	4583
range	VERB	O	O	4583
,	PUNCT	O	O	4583
(	PUNCT	O	O	4583
+	ADP	O	O	4583
/-)-PG-9	PUNCT	O	O	4583
did	VERB	O	O	4583
not	PART	O	O	4583
impair	VERB	O	O	4583
mouse	PROPN	O	O	4583
performance	NOUN	O	O	4583
evaluated	VERB	O	O	4583
by	ADP	O	O	4583
the	PRON	O	O	4583
rota	NOUN	O	O	4583
-	PUNCT	O	O	4583
rod	NOUN	O	O	4583
test	NOUN	O	O	4583
and	CCONJ	O	O	4583
Animex	PROPN	O	O	4583
apparatus	NOUN	O	O	4583
.	PUNCT	O	O	4583
Hyperbaric	NOUN	O	O	4586
oxygen	NOUN	O	Chemical	4586
therapy	NOUN	O	O	4586
for	ADP	O	O	4586
control	VERB	O	O	4586
of	ADP	O	O	4586
intractable	ADJ	O	O	4586
cyclophosphamide	VERB	O	Chemical	4586
-	PUNCT	O	O	4586
induced	VERB	O	O	4586
hemorrhagic cystitis	NOUN	O	Disease	4586
.	PUNCT	O	O	4586
We	PRON	O	O	4587
report	VERB	O	O	4587
a	PRON	O	O	4587
case	NOUN	O	O	4587
of	ADP	O	O	4587
intractable	ADJ	O	O	4587
hemorrhagic cystitis	NOUN	O	Disease	4587
due	ADJ	O	O	4587
to	PART	O	O	4587
cyclophosphamide	VERB	O	Chemical	4587
therapy	NOUN	O	O	4587
for	ADP	O	O	4587
Wegener	PROPN	O	O	4587
's	AUX	O	O	4587
granulomatosis	NOUN	O	O	4587
.	PUNCT	O	O	4587
Conservative	ADJ	O	O	4588
treatment	NOUN	O	O	4588
,	PUNCT	O	O	4588
including	VERB	O	O	4588
bladder	NOUN	O	O	4588
irrigation	NOUN	O	O	4588
with	ADP	O	O	4588
physiological	ADJ	O	O	4588
saline	NOUN	O	O	4588
and	CCONJ	O	O	4588
instillation	NOUN	O	O	4588
of	ADP	O	O	4588
prostaglandin F2 alpha	NOUN	O	Chemical	4588
,	PUNCT	O	O	4588
failed	VERB	O	O	4588
to	PART	O	O	4588
totally	ADV	O	O	4588
control	VERB	O	O	4588
hemorrhage	NOUN	O	Disease	4588
.	PUNCT	O	O	4588
We	PRON	O	O	4589
then	ADV	O	O	4589
used	VERB	O	O	4589
hyperbaric	PROPN	O	O	4589
oxygen	NOUN	O	Chemical	4589
at	ADP	O	O	4589
an	PRON	O	O	4589
absolute	ADJ	O	O	4589
pressure	NOUN	O	O	4589
of	ADP	O	O	4589
2	X	O	O	4589
atm	ADV	O	O	4589
,	PUNCT	O	O	4589
5	NUM	O	O	4589
days	NOUN	O	O	4589
a	PRON	O	O	4589
week	NOUN	O	O	4589
for	ADP	O	O	4589
8	NUM	O	O	4589
consecutive	ADJ	O	O	4589
weeks	NOUN	O	O	4589
.	PUNCT	O	O	4589
The	PRON	O	O	4590
bleeding	VERB	O	Disease	4590
ceased	VERB	O	O	4590
completely	ADV	O	O	4590
by	ADP	O	O	4590
the	PRON	O	O	4590
end	VERB	O	O	4590
of	ADP	O	O	4590
treatment	NOUN	O	O	4590
and	CCONJ	O	O	4590
the	PRON	O	O	4590
patient	NOUN	O	O	4590
remained	VERB	O	O	4590
free	ADJ	O	O	4590
of	ADP	O	O	4590
hematuria	PROPN	O	Disease	4590
thereafter	ADV	O	O	4590
.	PUNCT	O	O	4590
In	ADP	O	O	4591
future	NOUN	O	O	4591
,	PUNCT	O	O	4591
this	PRON	O	O	4591
form	NOUN	O	O	4591
of	ADP	O	O	4591
therapy	NOUN	O	O	4591
can	AUX	O	O	4591
offer	VERB	O	O	4591
a	PRON	O	O	4591
safe	ADJ	O	O	4591
alternative	ADV	O	O	4591
in	ADP	O	O	4591
the	PRON	O	O	4591
treatment	NOUN	O	O	4591
of	ADP	O	O	4591
cyclophosphamide	VERB	O	Chemical	4591
-	PUNCT	O	O	4591
induced	VERB	O	O	4591
hemorrhagic cystitis	NOUN	O	Disease	4591
.	PUNCT	O	O	4591
The	PRON	O	O	4594
results	VERB	O	O	4594
have	VERB	O	O	4594
shown	VERB	O	O	4594
that	SCONJ	O	O	4594
the	PRON	O	O	4594
degradation	NOUN	O	O	4594
product	NOUN	O	O	4594
p	NOUN	O	O	4594
-	PUNCT	O	O	4594
choloroaniline	NOUN	O	O	4594
is	AUX	O	O	4594
not	PART	O	O	4594
a	PRON	O	O	4594
significant	ADJ	O	O	4594
factor	NOUN	O	O	4594
in	ADP	O	O	4594
chlorhexidine	NOUN	O	O	4594
-	PUNCT	O	O	4594
digluconate	NOUN	O	O	4594
associated	VERB	O	O	4594
erosive	ADJ	O	O	4594
cystitis	NOUN	O	Disease	4594
.	PUNCT	O	O	4594
A	PRON	O	O	4595
high	ADJ	O	O	4595
percentage	NOUN	O	O	4595
of	ADP	O	O	4595
kanamycin	VERB	O	Chemical	4595
-	PUNCT	O	O	4595
colistin	PROPN	O	O	4595
and	CCONJ	O	O	4595
povidone	NOUN	O	O	4595
-	PUNCT	O	O	4595
iodine	PROPN	O	O	4595
irrigations	NOUN	O	O	4595
were	AUX	O	O	4595
associated	VERB	O	O	4595
with	ADP	O	O	4595
erosive	ADJ	O	O	4595
cystitis	NOUN	O	Disease	4595
and	CCONJ	O	O	4595
suggested	VERB	O	O	4595
a	PRON	O	O	4595
possible	ADJ	O	O	4595
complication	NOUN	O	O	4595
with	ADP	O	O	4595
human	PROPN	O	O	4595
usage	NOUN	O	O	4595
.	PUNCT	O	O	4595
Picloxydine	PROPN	O	O	4596
irrigations	NOUN	O	O	4596
appeared	VERB	O	O	4596
to	PART	O	O	4596
have	VERB	O	O	4596
a	PRON	O	O	4596
lower	ADJ	O	O	4596
incidence	NOUN	O	O	4596
of	ADP	O	O	4596
erosive	ADJ	O	O	4596
cystitis	NOUN	O	Disease	4596
but	CCONJ	O	O	4596
further	ADV	O	O	4596
studies	NOUN	O	O	4596
would	AUX	O	O	4596
have	VERB	O	O	4596
to	PART	O	O	4596
be	AUX	O	O	4596
performed	VERB	O	O	4596
before	ADP	O	O	4596
it	PRON	O	O	4596
could	AUX	O	O	4596
be	AUX	O	O	4596
recommended	VERB	O	O	4596
for	ADP	O	O	4596
use	VERB	O	O	4596
in	ADP	O	O	4596
urological	ADJ	O	O	4596
procedures	NOUN	O	O	4596
.	PUNCT	O	O	4596
A	PRON	O	O	4599
total	ADJ	O	O	4599
of	ADP	O	O	4599
sixty	NUM	O	O	4599
patients	NOUN	O	O	4599
were	AUX	O	O	4599
trated	VERB	O	O	4599
with	ADP	O	O	4599
bromperidol	NOUN	O	O	4599
first	ADV	O	O	4599
in	ADP	O	O	4599
open	VERB	O	O	4599
conditions	NOUN	O	O	4599
(	PUNCT	O	O	4599
20	NUM	O	O	4599
patients	NOUN	O	O	4599
)	PUNCT	O	O	4599
,	PUNCT	O	O	4599
then	ADV	O	O	4599
on	ADP	O	O	4599
a	PRON	O	O	4599
double	ADJ	O	O	4599
blind	ADJ	O	Disease	4599
basis	NOUN	O	O	4599
(	PUNCT	O	O	4599
40	NUM	O	O	4599
patients	NOUN	O	O	4599
)	PUNCT	O	O	4599
with	ADP	O	O	4599
haloperidol	NOUN	O	Chemical	4599
as	ADP	O	O	4599
the	PRON	O	O	4599
reference	NOUN	O	O	4599
substance	NOUN	O	O	4599
.	PUNCT	O	O	4599
Nine	NUM	O	O	4600
patients	NOUN	O	O	4600
exhibited	VERB	O	O	4600
mild	ADJ	O	O	4600
to	PART	O	O	4600
moderate	ADJ	O	O	4600
extrapyramidal	ADJ	O	O	4600
concomitant	ADJ	O	O	4600
symptoms	NOUN	O	O	4600
;	PUNCT	O	O	4600
no	PRON	O	O	4600
other	ADJ	O	O	4600
side	NOUN	O	O	4600
effects	NOUN	O	O	4600
were	AUX	O	O	4600
observed	VERB	O	O	4600
.	PUNCT	O	O	4600
In	ADP	O	O	4601
the	PRON	O	O	4601
double	ADJ	O	O	4601
blind	ADJ	O	Disease	4601
study	VERB	O	O	4601
with	ADP	O	O	4601
haloperidol	NOUN	O	Chemical	4601
,	PUNCT	O	O	4601
both	PRON	O	O	4601
substances	NOUN	O	O	4601
were	AUX	O	O	4601
found	VERB	O	O	4601
to	PART	O	O	4601
be	AUX	O	O	4601
highly	ADV	O	O	4601
effective	ADJ	O	O	4601
in	ADP	O	O	4601
the	PRON	O	O	4601
treatment	NOUN	O	O	4601
of	ADP	O	O	4601
psychotic	ADJ	O	O	4601
syndromes	NOUN	O	O	4601
belonging	VERB	O	O	4601
predominantly	ADV	O	O	4601
to	PART	O	O	4601
the	PRON	O	O	4601
schizophrenia	PROPN	O	Disease	4601
group	NOUN	O	O	4601
.	PUNCT	O	O	4601
Certain	ADJ	O	O	4602
clues	NOUN	O	O	4602
,	PUNCT	O	O	4602
including	VERB	O	O	4602
the	PRON	O	O	4602
onset	VERB	O	O	4602
of	ADP	O	O	4602
action	NOUN	O	O	4602
,	PUNCT	O	O	4602
seem	VERB	O	O	4602
to	PART	O	O	4602
be	AUX	O	O	4602
indicative	ADJ	O	O	4602
of	ADP	O	O	4602
the	PRON	O	O	4602
superiority	NOUN	O	O	4602
of	ADP	O	O	4602
bromperidol	NOUN	O	O	4602
.	PUNCT	O	O	4602
Curcumin	NOUN	O	O	4605
ameliorates	VERB	O	O	4605
cognitive dysfunction	NOUN	O	Disease	4605
and	CCONJ	O	O	4605
oxidative	NOUN	O	O	4605
damage	NOUN	O	O	4605
in	ADP	O	O	4605
phenobarbitone	PROPN	O	O	4605
and	CCONJ	O	O	4605
carbamazepine	NOUN	O	Chemical	4605
administered	VERB	O	O	4605
rats	NOUN	O	O	4605
.	PUNCT	O	O	4605
The	PRON	O	O	4606
antiepileptic	ADJ	O	O	4606
drugs	NOUN	O	O	4606
,	PUNCT	O	O	4606
phenobarbitone	PROPN	O	O	4606
and	CCONJ	O	O	4606
carbamazepine	NOUN	O	Chemical	4606
are	AUX	O	O	4606
well	ADV	O	O	4606
known	VERB	O	O	4606
to	PART	O	O	4606
cause	VERB	O	O	4606
cognitive impairment	NOUN	O	Disease	4606
on	ADP	O	O	4606
chronic	ADJ	O	O	4606
use	VERB	O	O	4606
.	PUNCT	O	O	4606
The	PRON	O	O	4607
increase	VERB	O	O	4607
in	ADP	O	O	4607
free	ADJ	O	O	4607
radical	ADJ	O	O	4607
generation	NOUN	O	O	4607
has	VERB	O	O	4607
been	AUX	O	O	4607
implicated	VERB	O	O	4607
as	ADP	O	O	4607
one	NUM	O	O	4607
of	ADP	O	O	4607
the	PRON	O	O	4607
important	ADJ	O	O	4607
mechanisms	NOUN	O	O	4607
of	ADP	O	O	4607
cognitive impairment	NOUN	O	Disease	4607
by	ADP	O	O	4607
antiepileptic	ADJ	O	O	4607
drugs	NOUN	O	O	4607
.	PUNCT	O	O	4607
Curcumin	NOUN	O	O	4608
has	VERB	O	O	4608
shown	VERB	O	O	4608
antioxidant	ADJ	O	O	4608
,	PUNCT	O	O	4608
anti	ADJ	O	O	4608
-	PUNCT	O	O	4608
inflammatory	ADJ	O	O	4608
and	CCONJ	O	O	4608
neuro	PROPN	O	O	4608
-	PUNCT	O	O	4608
protective	ADJ	O	O	4608
properties	NOUN	O	O	4608
.	PUNCT	O	O	4608
Therefore	ADV	O	O	4609
,	PUNCT	O	O	4609
the	PRON	O	O	4609
present	NOUN	O	O	4609
study	VERB	O	O	4609
was	AUX	O	O	4609
carried	VERB	O	O	4609
out	ADP	O	O	4609
to	PART	O	O	4609
investigate	VERB	O	O	4609
the	PRON	O	O	4609
effect	VERB	O	O	4609
of	ADP	O	O	4609
chronic	ADJ	O	O	4609
curcumin	PROPN	O	O	4609
administration	NOUN	O	O	4609
on	ADP	O	O	4609
phenobarbitone-	NOUN	O	O	4609
and	CCONJ	O	O	4609
carbamazepine	NOUN	O	Chemical	4609
-	PUNCT	O	O	4609
induced	VERB	O	O	4609
cognitive impairment	NOUN	O	Disease	4609
and	CCONJ	O	O	4609
oxidative	NOUN	O	O	4609
stress	NOUN	O	O	4609
in	ADP	O	O	4609
rats	NOUN	O	O	4609
.	PUNCT	O	O	4609
Pharmacokinetic	NOUN	O	O	4610
interactions	NOUN	O	O	4610
of	ADP	O	O	4610
curcumin	PROPN	O	O	4610
with	ADP	O	O	4610
phenobarbitone	PROPN	O	O	4610
and	CCONJ	O	O	4610
carbamazepine	NOUN	O	Chemical	4610
were	AUX	O	O	4610
also	ADV	O	O	4610
studied	VERB	O	O	4610
.	PUNCT	O	O	4610
At	ADP	O	O	4611
the	PRON	O	O	4611
end	VERB	O	O	4611
of	ADP	O	O	4611
study	VERB	O	O	4611
period	NOUN	O	O	4611
,	PUNCT	O	O	4611
serum	NOUN	O	O	4611
phenobarbitone	PROPN	O	O	4611
and	CCONJ	O	O	4611
carbamazepine	NOUN	O	Chemical	4611
,	PUNCT	O	O	4611
whole	NOUN	O	O	4611
brain	NOUN	O	O	4611
malondialdehyde	PROPN	O	Chemical	4611
and	CCONJ	O	O	4611
reduced glutathione	NOUN	O	Chemical	4611
levels	NOUN	O	O	4611
were	AUX	O	O	4611
estimated	VERB	O	O	4611
.	PUNCT	O	O	4611
The	PRON	O	O	4612
administration	NOUN	O	O	4612
of	ADP	O	O	4612
phenobarbitone	PROPN	O	O	4612
and	CCONJ	O	O	4612
carbamazepine	NOUN	O	Chemical	4612
for	ADP	O	O	4612
21days	PUNCT	O	O	4612
caused	VERB	O	O	4612
a	PRON	O	O	4612
significant	ADJ	O	O	4612
impairment	NOUN	O	O	4612
of	ADP	O	O	4612
learning	VERB	O	O	4612
and	CCONJ	O	O	4612
memory	NOUN	O	O	4612
as	ADP	O	O	4612
well	ADV	O	O	4612
as	ADP	O	O	4612
an	PRON	O	O	4612
increased	VERB	O	O	4612
oxidative	NOUN	O	O	4612
stress	NOUN	O	O	4612
.	PUNCT	O	O	4612
Concomitant	ADJ	O	O	4613
curcumin	PROPN	O	O	4613
administration	NOUN	O	O	4613
prevented	VERB	O	O	4613
the	PRON	O	O	4613
cognitive impairment	NOUN	O	Disease	4613
and	CCONJ	O	O	4613
decreased	VERB	O	O	4613
the	PRON	O	O	4613
increased	VERB	O	O	4613
oxidative	NOUN	O	O	4613
stress	NOUN	O	O	4613
induced	VERB	O	O	4613
by	ADP	O	O	4613
these	PRON	O	O	4613
antiepileptic	ADJ	O	O	4613
drugs	NOUN	O	O	4613
.	PUNCT	O	O	4613
Curcumin	NOUN	O	O	4614
co	NOUN	O	O	4614
-	PUNCT	O	O	4614
administration	NOUN	O	O	4614
did	VERB	O	O	4614
not	PART	O	O	4614
cause	VERB	O	O	4614
any	PRON	O	O	4614
significant	ADJ	O	O	4614
alteration	NOUN	O	O	4614
in	ADP	O	O	4614
the	PRON	O	O	4614
serum	NOUN	O	O	4614
concentrations	NOUN	O	O	4614
of	ADP	O	O	4614
both	PRON	O	O	4614
phenobarbitone	PROPN	O	O	4614
as	ADP	O	O	4614
well	ADV	O	O	4614
as	ADP	O	O	4614
carbamazepine	NOUN	O	Chemical	4614
.	PUNCT	O	O	4614
These	PRON	O	O	4615
results	VERB	O	O	4615
show	VERB	O	O	4615
that	SCONJ	O	O	4615
curcumin	PROPN	O	O	4615
has	VERB	O	O	4615
beneficial	ADJ	O	O	4615
effect	VERB	O	O	4615
in	ADP	O	O	4615
mitigating	VERB	O	O	4615
the	PRON	O	O	4615
deterioration	NOUN	O	O	4615
of	ADP	O	O	4615
cognitive	ADJ	O	O	4615
functions	VERB	O	O	4615
and	CCONJ	O	O	4615
oxidative	NOUN	O	O	4615
damage	NOUN	O	O	4615
in	ADP	O	O	4615
rats	NOUN	O	O	4615
treated	VERB	O	O	4615
with	ADP	O	O	4615
phenobarbitone	PROPN	O	O	4615
and	CCONJ	O	O	4615
carbamazepine	NOUN	O	Chemical	4615
without	ADP	O	O	4615
significantly	ADV	O	O	4615
altering	VERB	O	O	4615
their	PRON	O	O	4615
serum	NOUN	O	O	4615
concentrations	NOUN	O	O	4615
.	PUNCT	O	O	4615
The	PRON	O	O	4616
findings	NOUN	O	O	4616
suggest	VERB	O	O	4616
that	SCONJ	O	O	4616
curcumin	PROPN	O	O	4616
can	AUX	O	O	4616
be	AUX	O	O	4616
considered	VERB	O	O	4616
as	ADP	O	O	4616
a	PRON	O	O	4616
potential	ADJ	O	O	4616
safe	ADJ	O	O	4616
and	CCONJ	O	O	4616
effective	ADJ	O	O	4616
adjuvant	NOUN	O	O	4616
to	PART	O	O	4616
phenobarbitone	PROPN	O	O	4616
and	CCONJ	O	O	4616
carbamazepine	NOUN	O	Chemical	4616
therapy	NOUN	O	O	4616
in	ADP	O	O	4616
preventing	VERB	O	O	4616
cognitive impairment	NOUN	O	Disease	4616
associated	VERB	O	O	4616
with	ADP	O	O	4616
these	PRON	O	O	4616
drugs	NOUN	O	O	4616
.	PUNCT	O	O	4616
Pyrrolidine	PROPN	O	O	4619
dithiocarbamate	NOUN	O	O	4619
protects	VERB	O	O	4619
the	PRON	O	O	4619
piriform	NOUN	O	O	4619
cortex	VERB	O	O	4619
in	ADP	O	O	4619
the	PRON	O	O	4619
pilocarpine	NOUN	O	Chemical	4619
status epilepticus	VERB	O	Disease	4619
model	NOUN	O	O	4619
.	PUNCT	O	O	4619
Pyrrolidine	PROPN	O	O	4620
dithiocarbamate	NOUN	O	O	4620
(	PUNCT	O	O	4620
PDTC	NOUN	O	O	4620
)	PUNCT	O	O	4620
has	VERB	O	O	4620
a	PRON	O	O	4620
dual	ADJ	O	O	4620
mechanism	NOUN	O	O	4620
of	ADP	O	O	4620
action	NOUN	O	O	4620
as	ADP	O	O	4620
an	PRON	O	O	4620
antioxidant	ADJ	O	O	4620
and	CCONJ	O	O	4620
an	PRON	O	O	4620
inhibitor	NOUN	O	O	4620
of	ADP	O	O	4620
the	PRON	O	O	4620
transcription	PROPN	O	O	4620
factor	NOUN	O	O	4620
kappa	PROPN	O	O	4620
-	PUNCT	O	O	4620
beta	NOUN	O	O	4620
.	PUNCT	O	O	4620
Both	PRON	O	O	4621
,	PUNCT	O	O	4621
production	NOUN	O	O	4621
of	ADP	O	O	4621
reactive	ADJ	O	O	4621
oxygen	NOUN	O	Chemical	4621
species	NOUN	O	O	4621
as	ADP	O	O	4621
well	ADV	O	O	4621
as	ADP	O	O	4621
activation	NOUN	O	O	4621
of	ADP	O	O	4621
NF	PROPN	O	O	4621
-	PUNCT	O	O	4621
kappaB	NOUN	O	O	4621
have	VERB	O	O	4621
been	AUX	O	O	4621
implicated	VERB	O	O	4621
in	ADP	O	O	4621
severe	ADJ	O	O	4621
neuronal damage	NOUN	O	Disease	4621
in	ADP	O	O	4621
different	ADJ	O	O	4621
sub	ADJ	O	O	4621
-	PUNCT	O	O	4621
regions	NOUN	O	O	4621
of	ADP	O	O	4621
the	PRON	O	O	4621
hippocampus	NOUN	O	O	4621
as	ADP	O	O	4621
well	ADV	O	O	4621
as	ADP	O	O	4621
in	ADP	O	O	4621
the	PRON	O	O	4621
surrounding	VERB	O	O	4621
cortices	NOUN	O	O	4621
.	PUNCT	O	O	4621
The	PRON	O	O	4622
effect	VERB	O	O	4622
of	ADP	O	O	4622
PDTC	NOUN	O	O	4622
on	ADP	O	O	4622
status epilepticus	VERB	O	Disease	4622
-	PUNCT	O	O	4622
associated	VERB	O	O	4622
cell	NOUN	O	O	4622
loss	NOUN	O	O	4622
in	ADP	O	O	4622
the	PRON	O	O	4622
hippocampus	NOUN	O	O	4622
and	CCONJ	O	O	4622
piriform	NOUN	O	O	4623
cortex	VERB	O	O	4623
was	AUX	O	O	4623
evaluated	VERB	O	O	4623
in	ADP	O	O	4623
the	PRON	O	O	4623
rat	NOUN	O	O	4623
fractionated	VERB	O	O	4623
pilocarpine	NOUN	O	Chemical	4623
model	NOUN	O	O	4623
.	PUNCT	O	O	4623
PDTC	NOUN	O	O	4624
before	ADP	O	O	4624
and	CCONJ	O	O	4624
following	VERB	O	O	4624
status epilepticus	VERB	O	Disease	4624
significantly	ADV	O	O	4624
increased	VERB	O	O	4624
the	PRON	O	O	4624
mortality	NOUN	O	O	4624
rate	NOUN	O	O	4624
to	PART	O	O	4624
100%	NOUN	O	O	4624
.	PUNCT	O	O	4624
Administration	NOUN	O	O	4625
of	ADP	O	O	4625
50	NUM	O	O	4625
mg	VERB	O	O	4625
/	PUNCT	O	O	4625
kg	VERB	O	O	4625
PDTC	NOUN	O	O	4625
(	PUNCT	O	O	4625
low	ADJ	O	O	4625
-	PUNCT	O	O	4625
dose	NOUN	O	O	4625
)	PUNCT	O	O	4625
did	VERB	O	O	4625
not	PART	O	O	4625
exert	VERB	O	O	4625
major	ADJ	O	O	4625
effects	NOUN	O	O	4625
on	ADP	O	O	4625
the	PRON	O	O	4625
development	NOUN	O	O	4625
of	ADP	O	O	4625
a	PRON	O	O	4625
status epilepticus	VERB	O	Disease	4625
or	CCONJ	O	O	4625
the	PRON	O	O	4625
mortality	NOUN	O	O	4625
rate	NOUN	O	O	4625
.	PUNCT	O	O	4625
In	ADP	O	O	4626
vehicle	NOUN	O	O	4626
-	PUNCT	O	O	4626
treated	VERB	O	O	4626
rats	NOUN	O	O	4626
,	PUNCT	O	O	4626
status epilepticus	VERB	O	Disease	4626
caused	VERB	O	O	4626
pronounced	VERB	O	O	4626
neuronal damage	NOUN	O	Disease	4626
in	ADP	O	O	4626
the	PRON	O	O	4626
piriform	NOUN	O	O	4626
cortex	VERB	O	O	4626
comprising	VERB	O	O	4626
both	PRON	O	O	4626
pyramidal	ADJ	O	O	4626
cells	NOUN	O	O	4626
and	CCONJ	O	O	4626
interneurons	NOUN	O	O	4626
.	PUNCT	O	O	4626
Low	ADJ	O	O	4627
-	PUNCT	O	O	4627
dose	NOUN	O	O	4627
PDTC	NOUN	O	O	4627
treatment	NOUN	O	O	4627
almost	ADV	O	O	4627
completely	ADV	O	O	4627
protected	VERB	O	O	4627
from	ADP	O	O	4627
lesions	NOUN	O	O	4627
in	ADP	O	O	4627
the	PRON	O	O	4627
piriform	NOUN	O	O	4627
cortex	VERB	O	O	4627
.	PUNCT	O	O	4627
A	PRON	O	O	4628
significant	ADJ	O	O	4628
decrease	VERB	O	O	4628
in	ADP	O	O	4628
neuronal	ADJ	O	O	4628
density	NOUN	O	O	4628
of	ADP	O	O	4628
the	PRON	O	O	4628
hippocampal	NOUN	O	O	4628
hilar	ADJ	O	O	4628
formation	NOUN	O	O	4628
was	AUX	O	O	4628
identified	VERB	O	O	4628
in	ADP	O	O	4628
vehicle-	ADJ	O	O	4628
and	CCONJ	O	O	4628
PDTC	NOUN	O	O	4628
-	PUNCT	O	O	4628
treated	VERB	O	O	4628
rats	NOUN	O	O	4628
following	VERB	O	O	4628
status epilepticus	VERB	O	Disease	4628
.	PUNCT	O	O	4628
In	ADP	O	O	4629
conclusion	NOUN	O	O	4629
,	PUNCT	O	O	4629
the	PRON	O	O	4629
NF	PROPN	O	O	4629
-	PUNCT	O	O	4629
kappaB	NOUN	O	O	4629
inhibitor	NOUN	O	O	4629
and	CCONJ	O	O	4629
antioxidant	ADJ	O	O	4629
PDTC	NOUN	O	O	4629
protected	VERB	O	O	4629
the	PRON	O	O	4629
piriform	NOUN	O	O	4629
cortex	VERB	O	O	4629
,	PUNCT	O	O	4629
whereas	SCONJ	O	O	4629
it	PRON	O	O	4629
did	VERB	O	O	4629
not	PART	O	O	4629
affect	VERB	O	O	4629
hilar	ADJ	O	O	4629
neuronal loss	NOUN	O	Disease	4629
.	PUNCT	O	O	4629
These	PRON	O	O	4630
data	NOUN	O	O	4630
might	AUX	O	O	4630
indicate	VERB	O	O	4630
that	SCONJ	O	O	4630
the	PRON	O	O	4630
generation	NOUN	O	O	4630
of	ADP	O	O	4630
reactive	ADJ	O	O	4630
oxygen	NOUN	O	Chemical	4630
species	NOUN	O	O	4630
and	CCONJ	O	O	4630
activation	NOUN	O	O	4630
of	ADP	O	O	4630
NF	PROPN	O	O	4630
-	PUNCT	O	O	4630
kappaB	NOUN	O	O	4630
plays	VERB	O	O	4630
a	PRON	O	O	4630
more	ADJ	O	O	4630
central	ADJ	O	O	4630
role	NOUN	O	O	4630
in	ADP	O	O	4630
seizure	NOUN	O	Disease	4630
-	PUNCT	O	O	4630
associated	VERB	O	O	4630
neuronal damage	NOUN	O	Disease	4630
in	ADP	O	O	4630
the	PRON	O	O	4630
temporal	ADJ	O	O	4630
cortex	VERB	O	O	4630
as	ADP	O	O	4630
compared	VERB	O	O	4630
to	PART	O	O	4630
the	PRON	O	O	4630
hippocampal	NOUN	O	O	4630
hilus	PROPN	O	O	4630
.	PUNCT	O	O	4630
However	ADV	O	O	4631
,	PUNCT	O	O	4631
future	NOUN	O	O	4631
investigations	NOUN	O	O	4631
are	AUX	O	O	4631
necessary	ADJ	O	O	4631
to	PART	O	O	4631
exactly	ADV	O	O	4631
analyze	VERB	O	O	4631
the	PRON	O	O	4631
biochemical	ADJ	O	O	4631
mechanisms	NOUN	O	O	4631
by	ADP	O	O	4631
which	PRON	O	O	4631
PDTC	NOUN	O	O	4631
exerted	VERB	O	O	4631
its	PRON	O	O	4631
beneficial	ADJ	O	O	4631
effects	NOUN	O	O	4631
in	ADP	O	O	4631
the	PRON	O	O	4631
piriform	NOUN	O	O	4631
cortex	VERB	O	O	4631
.	PUNCT	O	O	4631
Safety	NOUN	O	O	4634
profile	NOUN	O	O	4634
of	ADP	O	O	4634
a	PRON	O	O	4634
nicotine	NOUN	O	Chemical	4634
lozenge	PROPN	O	O	4634
compared	VERB	O	O	4634
with	ADP	O	O	4634
that	SCONJ	O	O	4634
of	ADP	O	O	4634
nicotine	NOUN	O	Chemical	4634
gum	NOUN	O	O	4634
in	ADP	O	O	4634
adult	NOUN	O	O	4634
smokers	NOUN	O	O	4634
with	ADP	O	O	4634
underlying	VERB	O	O	4634
medical	ADJ	O	O	4634
conditions	NOUN	O	O	4634
:	PUNCT	O	O	4634
a	PRON	O	O	4634
12-week	NOUN	O	O	4634
,	PUNCT	O	O	4634
randomized	VERB	O	O	4634
,	PUNCT	O	O	4634
open	VERB	O	O	4634
-	PUNCT	O	O	4634
label	PROPN	O	O	4634
study	VERB	O	O	4634
.	PUNCT	O	O	4634
Nicotine	NOUN	O	Chemical	4635
polacrilex	NOUN	O	O	4635
lozenges	NOUN	O	O	4635
deliver	VERB	O	O	4635
25%	NOUN	O	O	4635
to	PART	O	O	4635
27%	NOUN	O	O	4635
more	ADJ	O	O	4635
nicotine	NOUN	O	Chemical	4635
compared	VERB	O	O	4635
with	ADP	O	O	4635
equivalent	ADJ	O	O	4635
doses	NOUN	O	O	4635
of	ADP	O	O	4635
nicotine	NOUN	O	Chemical	4635
polacrilex	NOUN	O	O	4635
gum	NOUN	O	O	4635
.	PUNCT	O	O	4635
The	PRON	O	O	4636
increased	VERB	O	O	4636
nicotine	NOUN	O	Chemical	4636
exposure	NOUN	O	O	4636
from	ADP	O	O	4636
the	PRON	O	O	4636
lozenge	PROPN	O	O	4636
has	VERB	O	O	4636
raised	VERB	O	O	4636
questions	NOUN	O	O	4636
about	ADP	O	O	4636
the	PRON	O	O	4636
relative	ADJ	O	O	4636
safety	NOUN	O	O	4636
of	ADP	O	O	4636
the	PRON	O	O	4636
lozenge	PROPN	O	O	4636
and	CCONJ	O	O	4636
gum	NOUN	O	O	4636
.	PUNCT	O	O	4636
The	PRON	O	O	4637
objective	VERB	O	O	4637
of	ADP	O	O	4637
this	PRON	O	O	4637
study	VERB	O	O	4637
was	AUX	O	O	4637
to	PART	O	O	4637
compare	VERB	O	O	4637
the	PRON	O	O	4637
safety	NOUN	O	O	4637
profiles	NOUN	O	O	4637
of	ADP	O	O	4637
the	PRON	O	O	4637
4-mg	NOUN	O	O	4637
nicotine	NOUN	O	Chemical	4637
lozenge	PROPN	O	O	4637
and	CCONJ	O	O	4637
4-mg	NOUN	O	O	4637
nicotine	NOUN	O	Chemical	4637
gum	NOUN	O	O	4637
in	ADP	O	O	4637
smokers	NOUN	O	O	4637
with	ADP	O	O	4637
selected	VERB	O	O	4637
label	PROPN	O	O	4637
-	PUNCT	O	O	4637
restricted	VERB	O	O	4637
diseases	NOUN	O	O	4637
.	PUNCT	O	O	4637
This	PRON	O	O	4638
was	AUX	O	O	4638
a	PRON	O	O	4638
multicenter	ADJ	O	O	4638
,	PUNCT	O	O	4638
randomized	VERB	O	O	4638
,	PUNCT	O	O	4638
open	VERB	O	O	4638
-	PUNCT	O	O	4638
label	PROPN	O	O	4638
study	VERB	O	O	4638
in	ADP	O	O	4638
adult	NOUN	O	O	4638
smokers	NOUN	O	O	4638
with	ADP	O	O	4638
heart disease	NOUN	O	Disease	4638
,	PUNCT	O	O	4638
hypertension	NOUN	O	Disease	4638
not	PART	O	O	4638
controlled	VERB	O	O	4638
by	ADP	O	O	4638
medication	NOUN	O	O	4638
,	PUNCT	O	O	4638
and/or	CCONJ	O	O	4638
diabetes mellitus	ADJ	O	Disease	4638
.	PUNCT	O	O	4638
Patients	NOUN	O	O	4639
were	AUX	O	O	4639
randomized	VERB	O	O	4639
in	ADP	O	O	4639
a	PRON	O	O	4639
1:1	NUM	O	O	4639
ratio	NOUN	O	O	4639
to	PART	O	O	4639
receive	VERB	O	O	4639
the	PRON	O	O	4639
4-mg	NOUN	O	O	4639
nicotine	NOUN	O	Chemical	4639
lozenge	PROPN	O	O	4639
or	CCONJ	O	O	4639
4-mg	NOUN	O	O	4639
nicotine	NOUN	O	Chemical	4639
gum	NOUN	O	O	4639
.	PUNCT	O	O	4639
The	PRON	O	O	4640
nicotine	NOUN	O	Chemical	4640
lozenge	PROPN	O	O	4640
and	CCONJ	O	O	4640
nicotine	NOUN	O	Chemical	4640
gum	NOUN	O	O	4640
were	AUX	O	O	4640
equally	ADV	O	O	4640
well	ADV	O	O	4640
tolerated	VERB	O	O	4640
,	PUNCT	O	O	4640
despite	SCONJ	O	O	4640
increased	VERB	O	O	4640
nicotine	NOUN	O	Chemical	4640
exposure	NOUN	O	O	4640
from	ADP	O	O	4640
the	PRON	O	O	4640
lozenge	PROPN	O	O	4640
.	PUNCT	O	O	4640
The	PRON	O	O	4641
most	ADV	O	O	4641
common	ADJ	O	O	4641
adverse	ADJ	O	O	4641
events	NOUN	O	O	4641
were	AUX	O	O	4641
nausea	NOUN	O	Disease	4641
(	PUNCT	O	O	4641
17.2%	NOUN	O	O	4641
and	CCONJ	O	O	4641
16.1%	NOUN	O	O	4641
;	PUNCT	O	O	4641
95%	NOUN	O	O	4641
CI	NOUN	O	O	4641
,	PUNCT	O	O	4641
-3.7	NOUN	O	O	4641
to	PART	O	O	4641
6.0	NUM	O	O	4641
)	PUNCT	O	O	4641
,	PUNCT	O	O	4641
hiccups	VERB	O	Disease	4641
(	PUNCT	O	O	4641
10.7%	NOUN	O	O	4641
and	CCONJ	O	O	4641
6.6%	NOUN	O	O	4641
;	PUNCT	O	O	4641
95%	NOUN	O	O	4641
CI	NOUN	O	O	4641
,	PUNCT	O	O	4641
0.5	NUM	O	O	4641
to	PART	O	O	4641
7.8	NUM	O	O	4641
)	PUNCT	O	O	4641
,	PUNCT	O	O	4641
and	CCONJ	O	O	4641
headache	PROPN	O	Disease	4641
(	PUNCT	O	O	4641
8.7%	NOUN	O	O	4641
and	CCONJ	O	O	4641
9.9%	NOUN	O	O	4641
;	PUNCT	O	O	4641
95%	NOUN	O	O	4641
Cl	NOUN	O	Chemical	4641
,	PUNCT	O	O	4641
-5.0	NOUN	O	O	4641
to	PART	O	O	4641
2.6	NUM	O	O	4641
)	PUNCT	O	O	4641
.	PUNCT	O	O	4641
The	PRON	O	O	4642
4-mg	NOUN	O	O	4642
nicotine	NOUN	O	Chemical	4642
lozenge	PROPN	O	O	4642
and	CCONJ	O	O	4642
4-mg	NOUN	O	O	4642
nicotine	NOUN	O	Chemical	4642
gum	NOUN	O	O	4642
had	VERB	O	O	4642
comparable	ADJ	O	O	4642
safety	NOUN	O	O	4642
profiles	NOUN	O	O	4642
in	ADP	O	O	4642
these	PRON	O	O	4642
patients	NOUN	O	O	4642
with	ADP	O	O	4642
label	PROPN	O	O	4642
-	PUNCT	O	O	4642
restricted	VERB	O	O	4642
medical	ADJ	O	O	4642
conditions	NOUN	O	O	4642
.	PUNCT	O	O	4642
Development	NOUN	O	O	4645
of	ADP	O	O	4645
levodopa	NOUN	O	Chemical	4645
-	PUNCT	O	O	4645
induced	VERB	O	O	4645
dyskinesias	PROPN	O	Disease	4645
in	ADP	O	O	4645
parkinsonian	PROPN	O	Disease	4645
monkeys	NOUN	O	O	4645
may	AUX	O	O	4645
depend	VERB	O	O	4645
upon	SCONJ	O	O	4645
rate	NOUN	O	O	4645
of	ADP	O	O	4645
symptom	NOUN	O	O	4645
onset	VERB	O	O	4645
and/or	CCONJ	O	O	4645
duration	NOUN	O	O	4645
of	ADP	O	O	4645
symptoms	NOUN	O	O	4645
.	PUNCT	O	O	4645
Levodopa	NOUN	O	Chemical	4646
-	PUNCT	O	O	4646
induced	VERB	O	O	4646
dyskinesias	PROPN	O	Disease	4646
(	PUNCT	O	O	4646
LIDs	NOUN	O	O	4646
)	PUNCT	O	O	4646
present	NOUN	O	O	4646
a	PRON	O	O	4646
major	ADJ	O	O	4646
problem	NOUN	O	O	4646
for	ADP	O	O	4646
the	PRON	O	O	4646
long	ADV	O	O	4646
-	PUNCT	O	O	4646
term	NOUN	O	O	4646
management	NOUN	O	O	4646
of	ADP	O	O	4646
Parkinson	NOUN	O	O	4646
's	AUX	O	O	4646
disease	PROPN	O	O	4646
(	PUNCT	O	O	4646
PD	PROPN	O	Disease	4646
)	PUNCT	O	O	4646
patients	NOUN	O	O	4646
.	PUNCT	O	O	4646
Due	ADP	O	O	4647
to	PART	O	O	4647
the	PRON	O	O	4647
interdependence	NOUN	O	O	4647
of	ADP	O	O	4647
risk	NOUN	O	O	4647
factors	NOUN	O	O	4647
in	ADP	O	O	4647
clinical	ADJ	O	O	4647
populations	NOUN	O	O	4647
,	PUNCT	O	O	4647
it	PRON	O	O	4647
is	AUX	O	O	4647
difficult	ADJ	O	O	4647
to	PART	O	O	4647
independently	ADV	O	O	4647
examine	VERB	O	O	4647
factors	NOUN	O	O	4647
that	SCONJ	O	O	4647
may	AUX	O	O	4647
influence	NOUN	O	O	4647
the	PRON	O	O	4647
development	NOUN	O	O	4647
of	ADP	O	O	4647
LIDs	NOUN	O	O	4647
.	PUNCT	O	O	4647
Using	VERB	O	O	4648
macaque	PROPN	O	O	4648
monkeys	NOUN	O	O	4648
with	ADP	O	O	4648
different	ADJ	O	O	4648
types	NOUN	O	O	4648
of	ADP	O	O	4648
MPTP	PROPN	O	Chemical	4648
-	PUNCT	O	O	4648
induced	VERB	O	O	4648
parkinsonism	NOUN	O	Disease	4648
,	PUNCT	O	O	4648
the	PRON	O	O	4648
current	ADJ	O	O	4648
study	VERB	O	O	4648
evaluated	VERB	O	O	4648
the	PRON	O	O	4648
degree	PROPN	O	O	4648
to	PART	O	O	4648
which	PRON	O	O	4648
rate	NOUN	O	O	4648
of	ADP	O	O	4648
symptom	NOUN	O	O	4648
progression	NOUN	O	O	4648
,	PUNCT	O	O	4648
symptom	NOUN	O	O	4648
severity	NOUN	O	O	4648
,	PUNCT	O	O	4648
and	CCONJ	O	O	4648
response	NOUN	O	O	4648
to	PART	O	O	4648
and	CCONJ	O	O	4648
duration	NOUN	O	O	4648
of	ADP	O	O	4648
levodopa	NOUN	O	Chemical	4648
therapy	NOUN	O	O	4648
may	AUX	O	O	4648
be	AUX	O	O	4648
involved	VERB	O	O	4648
in	ADP	O	O	4648
the	PRON	O	O	4648
development	NOUN	O	O	4648
of	ADP	O	O	4648
LIDs	NOUN	O	O	4648
.	PUNCT	O	O	4648
MPTP	PROPN	O	Chemical	4649
exposure	NOUN	O	O	4649
,	PUNCT	O	O	4649
rapid	ADJ	O	O	4649
symptom	NOUN	O	O	4649
onset	VERB	O	O	4649
and	CCONJ	O	O	4649
short	ADJ	O	O	4649
symptom	NOUN	O	O	4649
duration	NOUN	O	O	4649
prior	ADV	O	O	4649
to	PART	O	O	4649
initiation	NOUN	O	O	4649
of	ADP	O	O	4649
levodopa	NOUN	O	Chemical	4649
therapy	NOUN	O	O	4649
developed	VERB	O	O	4649
dyskinesia	NOUN	O	Disease	4649
between	ADP	O	O	4649
11	NUM	O	O	4649
and	CCONJ	O	O	4649
24	NUM	O	O	4649
days	NOUN	O	O	4649
of	ADP	O	O	4649
daily	ADV	O	O	4649
levodopa	NOUN	O	Chemical	4649
administration	NOUN	O	O	4649
.	PUNCT	O	O	4649
In	ADP	O	O	4650
contrast	NOUN	O	O	4650
,	PUNCT	O	O	4650
monkeys	NOUN	O	O	4650
with	ADP	O	O	4650
long	ADV	O	O	4650
-	PUNCT	O	O	4650
term	NOUN	O	O	4650
MPTP	PROPN	O	Chemical	4650
exposure	NOUN	O	O	4650
,	PUNCT	O	O	4650
slow	VERB	O	O	4650
symptom	NOUN	O	O	4650
progression	NOUN	O	O	4650
and/or	CCONJ	O	O	4650
long	ADV	O	O	4650
symptom	NOUN	O	O	4650
duration	NOUN	O	O	4650
prior	ADV	O	O	4650
to	PART	O	O	4650
initiation	NOUN	O	O	4650
of	ADP	O	O	4650
levodopa	NOUN	O	Chemical	4650
therapy	NOUN	O	O	4650
were	AUX	O	O	4650
more	ADJ	O	O	4650
resistant	ADJ	O	O	4650
to	PART	O	O	4650
developing	VERB	O	O	4650
LIDs	NOUN	O	O	4650
(	PUNCT	O	O	4650
e.g.	ADV	O	O	4650
,	PUNCT	O	O	4650
dyskinesia	NOUN	O	Disease	4650
developed	VERB	O	O	4650
no	PRON	O	O	4650
sooner	ADV	O	O	4650
than	ADP	O	O	4650
146	NUM	O	O	4650
days	NOUN	O	O	4650
of	ADP	O	O	4650
chronic	ADJ	O	O	4650
levodopa	NOUN	O	Chemical	4650
administration	NOUN	O	O	4650
)	PUNCT	O	O	4650
.	PUNCT	O	O	4650
All	PRON	O	O	4651
animals	NOUN	O	O	4651
were	AUX	O	O	4651
similarly	ADV	O	O	4651
symptomatic	ADJ	O	O	4651
at	ADP	O	O	4651
the	PRON	O	O	4651
start	VERB	O	O	4651
of	ADP	O	O	4651
levodopa	NOUN	O	Chemical	4651
treatment	NOUN	O	O	4651
and	CCONJ	O	O	4651
had	VERB	O	O	4651
similar	ADJ	O	O	4651
therapeutic	ADJ	O	O	4651
responses	NOUN	O	O	4651
to	PART	O	O	4651
the	PRON	O	O	4651
drug	NOUN	O	O	4651
.	PUNCT	O	O	4651
These	PRON	O	O	4652
data	NOUN	O	O	4652
suggest	VERB	O	O	4652
distinct	ADJ	O	O	4652
differences	NOUN	O	O	4652
in	ADP	O	O	4652
the	PRON	O	O	4652
propensity	NOUN	O	O	4652
to	PART	O	O	4652
develop	VERB	O	O	4652
LIDs	NOUN	O	O	4652
in	ADP	O	O	4652
monkeys	NOUN	O	O	4652
with	ADP	O	O	4652
different	ADJ	O	O	4652
rates	NOUN	O	O	4652
of	ADP	O	O	4652
symptom	NOUN	O	O	4652
progression	NOUN	O	O	4652
or	CCONJ	O	O	4652
symptom	NOUN	O	O	4652
durations	NOUN	O	O	4652
prior	ADV	O	O	4652
to	PART	O	O	4652
levodopa	NOUN	O	Chemical	4652
and	CCONJ	O	O	4652
demonstrate	VERB	O	O	4652
the	PRON	O	O	4652
value	NOUN	O	O	4652
of	ADP	O	O	4652
these	PRON	O	O	4652
models	NOUN	O	O	4652
for	ADP	O	O	4652
further	ADV	O	O	4652
studying	VERB	O	O	4652
the	PRON	O	O	4652
pathophysiology	NOUN	O	O	4652
of	ADP	O	O	4652
LIDs	NOUN	O	O	4652
.	PUNCT	O	O	4652
Propylthiouracil	NOUN	O	O	4655
-	PUNCT	O	O	4655
induced	VERB	O	O	4655
perinuclear	PROPN	O	O	4655
-	PUNCT	O	O	4655
staining	VERB	O	O	4655
antineutrophil	PROPN	O	O	4655
cytoplasmic	ADJ	O	O	4655
autoantibody	ADV	O	O	4655
-	PUNCT	O	O	4655
positive	ADJ	O	O	4655
vasculitis	NOUN	O	Disease	4655
in	ADP	O	O	4655
conjunction	NOUN	O	O	4655
with	ADP	O	O	4655
pericarditis	PROPN	O	O	4655
.	PUNCT	O	O	4655
OBJECTIVE	VERB	O	O	4656
:	PUNCT	O	O	4656
To	PART	O	O	4656
describe	VERB	O	O	4656
a	PRON	O	O	4656
case	NOUN	O	O	4656
of	ADP	O	O	4656
propylthiouracil	NOUN	O	Chemical	4656
-	PUNCT	O	O	4656
induced	VERB	O	O	4656
vasculitis	NOUN	O	Disease	4656
manifesting	VERB	O	O	4656
with	ADP	O	O	4656
pericarditis	PROPN	O	O	4656
.	PUNCT	O	O	4656
METHODS	NOUN	O	O	4657
:	PUNCT	O	O	4657
We	PRON	O	O	4657
present	NOUN	O	O	4657
the	PRON	O	O	4657
first	ADV	O	O	4657
case	NOUN	O	O	4657
report	VERB	O	O	4657
of	ADP	O	O	4657
a	PRON	O	O	4657
woman	NOUN	O	O	4657
with	ADP	O	O	4657
hyperthyroidism	NOUN	O	Disease	4657
treated	VERB	O	O	4657
with	ADP	O	O	4657
propylthiouracil	NOUN	O	Chemical	4657
in	ADP	O	O	4657
whom	PRON	O	O	4657
a	PRON	O	O	4657
syndrome	NOUN	O	O	4657
of	ADP	O	O	4657
pericarditis	PROPN	O	O	4657
,	PUNCT	O	O	4657
fever	NOUN	O	Disease	4657
,	PUNCT	O	O	4657
and	CCONJ	O	O	4657
glomerulonephritis	NOUN	O	Disease	4657
developed	VERB	O	O	4657
.	PUNCT	O	O	4657
A	PRON	O	O	4658
25-year	NOUN	O	O	4658
-	PUNCT	O	O	4658
old	ADJ	O	O	4658
woman	NOUN	O	O	4658
with	ADP	O	O	4658
Graves	NOUN	O	O	4658
'	PUNCT	O	O	4658
disease	PROPN	O	O	4658
had	VERB	O	O	4658
a	PRON	O	O	4658
febrile	ADJ	O	O	4658
illness	VERB	O	O	4658
and	CCONJ	O	O	4658
evidence	NOUN	O	O	4658
of	ADP	O	O	4658
pericarditis	PROPN	O	O	4658
,	PUNCT	O	O	4658
which	PRON	O	O	4658
was	AUX	O	O	4658
confirmed	VERB	O	O	4658
by	ADP	O	O	4658
biopsy	PROPN	O	O	4658
.	PUNCT	O	O	4658
Propylthiouracil	NOUN	O	O	4659
therapy	NOUN	O	O	4659
was	AUX	O	O	4659
withdrawn	VERB	O	O	4659
,	PUNCT	O	O	4659
and	CCONJ	O	O	4659
she	PRON	O	O	4659
was	AUX	O	O	4659
treated	VERB	O	O	4659
with	ADP	O	O	4659
a	PRON	O	O	4659
1-month	NOUN	O	O	4659
course	NOUN	O	O	4659
of	ADP	O	O	4659
prednisone	NOUN	O	Chemical	4659
,	PUNCT	O	O	4659
which	PRON	O	O	4659
alleviated	VERB	O	O	4659
her	PRON	O	O	4659
symptoms	NOUN	O	O	4659
.	PUNCT	O	O	4659
A	PRON	O	O	4660
literature	NOUN	O	O	4660
review	VERB	O	O	4660
revealed	VERB	O	O	4660
no	PRON	O	O	4660
prior	ADV	O	O	4660
reports	VERB	O	O	4660
of	ADP	O	O	4660
pericarditis	PROPN	O	O	4660
in	ADP	O	O	4660
anti	ADJ	O	O	4660
-	PUNCT	O	O	4660
MPO	PROPN	O	O	4660
pANCA	PROPN	O	O	4660
-	PUNCT	O	O	4660
positive	ADJ	O	O	4660
vasculitis	NOUN	O	Disease	4660
associated	VERB	O	O	4660
with	ADP	O	O	4660
propylthio-	PROPN	O	O	4660
uracil	NOUN	O	O	4660
therapy	NOUN	O	O	4660
.	PUNCT	O	O	4660
Pericarditis	PROPN	O	O	4661
may	AUX	O	O	4661
be	AUX	O	O	4661
the	PRON	O	O	4661
initial	ADJ	O	O	4661
manifestation	NOUN	O	O	4661
of	ADP	O	O	4661
drug	NOUN	O	O	4661
-	PUNCT	O	O	4661
induced	VERB	O	O	4661
vasculitis	NOUN	O	Disease	4661
attributable	ADJ	O	O	4661
to	PART	O	O	4661
propylthio-	PROPN	O	O	4661
uracil	NOUN	O	O	4661
therapy	NOUN	O	O	4661
.	PUNCT	O	O	4661
Two	NUM	O	O	4664
mouse	PROPN	O	O	4664
lines	NOUN	O	O	4664
selected	VERB	O	O	4664
for	ADP	O	O	4664
differential	ADJ	O	O	4664
sensitivities	NOUN	O	O	4664
to	PART	O	O	4664
beta	NOUN	O	O	4664
-	PUNCT	O	O	4664
carboline	PROPN	O	O	4664
-	PUNCT	O	O	4664
induced	VERB	O	O	4664
seizures	NOUN	O	Disease	4664
are	AUX	O	O	4664
also	ADV	O	O	4664
differentially	ADV	O	O	4664
sensitive	ADJ	O	O	4664
to	PART	O	O	4664
various	ADJ	O	O	4664
pharmacological	ADJ	O	O	4664
effects	NOUN	O	O	4664
of	ADP	O	O	4664
other	ADJ	O	O	4664
GABA(A	X	O	O	4664
)	PUNCT	O	O	4664
Two	NUM	O	O	4665
mouse	PROPN	O	O	4665
lines	NOUN	O	O	4665
were	AUX	O	O	4665
selectively	ADV	O	O	4665
bred	VERB	O	O	4665
according	VERB	O	O	4665
to	PART	O	O	4665
their	PRON	O	O	4665
sensitivity	NOUN	O	O	4665
(	PUNCT	O	O	4665
BS	PROPN	O	O	4665
line	NOUN	O	O	4665
)	PUNCT	O	O	4665
or	CCONJ	O	O	4665
resistance	NOUN	O	O	4665
(	PUNCT	O	O	4665
BR	PROPN	O	O	4665
line	NOUN	O	O	4665
)	PUNCT	O	O	4665
to	PART	O	O	4665
seizures	NOUN	O	Disease	4665
induced	VERB	O	O	4665
by	ADP	O	O	4665
a	PRON	O	O	4665
single	ADJ	O	O	4665
i.p	NOUN	O	O	4665
.	PUNCT	O	O	4665
injection	NOUN	O	O	4666
of	ADP	O	O	4666
methyl	NOUN	O	O	4666
beta	NOUN	O	O	4666
-	PUNCT	O	O	4666
carboline-3-carboxylate	NOUN	O	O	4666
(	PUNCT	O	O	4666
beta	NOUN	O	O	4666
-	PUNCT	O	O	4666
CCM	NOUN	O	O	4666
)	PUNCT	O	O	4666
,	PUNCT	O	O	4666
an	PRON	O	O	4666
inverse	VERB	O	O	4666
agonist	NOUN	O	O	4666
of	ADP	O	O	4666
the	PRON	O	O	4666
GABA(A	X	O	O	4666
)	PUNCT	O	O	4666
receptor	NOUN	O	O	4666
benzodiazepine	PROPN	O	Chemical	4666
site	NOUN	O	O	4666
.	PUNCT	O	O	4666
Our	PRON	O	O	4667
aim	VERB	O	O	4667
was	AUX	O	O	4667
to	PART	O	O	4667
characterize	VERB	O	O	4667
both	PRON	O	O	4667
lines	NOUN	O	O	4667
'	PUNCT	O	O	4667
sensitivities	NOUN	O	O	4667
to	PART	O	O	4667
various	ADJ	O	O	4667
physiological	ADJ	O	O	4667
effects	NOUN	O	O	4667
of	ADP	O	O	4667
other	ADJ	O	O	4667
ligands	NOUN	O	O	4667
of	ADP	O	O	4667
the	PRON	O	O	4667
GABA(A	X	O	O	4667
)	PUNCT	O	O	4667
receptor	NOUN	O	O	4667
.	PUNCT	O	O	4667
We	PRON	O	O	4668
measured	VERB	O	O	4668
diazepam	NOUN	O	Chemical	4668
-	PUNCT	O	O	4668
induced	VERB	O	O	4668
anxiolysis	VERB	O	O	4668
with	ADP	O	O	4668
the	PRON	O	O	4668
elevated	ADJ	O	O	4668
plus	CCONJ	O	O	4668
-	PUNCT	O	O	4668
maze	NOUN	O	O	4668
test	NOUN	O	O	4668
,	PUNCT	O	O	4668
diazepam	NOUN	O	Chemical	4668
-	PUNCT	O	O	4668
induced	VERB	O	O	4668
sedation	NOUN	O	O	4668
by	ADP	O	O	4668
recording	NOUN	O	O	4668
the	PRON	O	O	4668
vigilance	NOUN	O	O	4668
states	VERB	O	O	4668
,	PUNCT	O	O	4668
and	CCONJ	O	O	4668
picrotoxin-	PROPN	O	O	4668
and	CCONJ	O	O	4668
pentylenetetrazol	NOUN	O	O	4668
-	PUNCT	O	O	4668
induced	VERB	O	O	4668
seizures	NOUN	O	Disease	4668
after	ADP	O	O	4668
i.p	NOUN	O	O	4668
.	PUNCT	O	O	4668
Results	NOUN	O	O	4669
presented	VERB	O	O	4669
here	ADV	O	O	4669
show	VERB	O	O	4669
that	SCONJ	O	O	4669
the	PRON	O	O	4669
differential	ADJ	O	O	4669
sensitivities	NOUN	O	O	4669
of	ADP	O	O	4669
BS	PROPN	O	O	4669
and	CCONJ	O	O	4669
BR	PROPN	O	O	4669
lines	NOUN	O	O	4669
to	PART	O	O	4669
beta	NOUN	O	O	4669
-	PUNCT	O	O	4669
CCM	NOUN	O	O	4669
can	AUX	O	O	4669
be	AUX	O	O	4669
extended	VERB	O	O	4669
to	PART	O	O	4669
diazepam	NOUN	O	Chemical	4669
,	PUNCT	O	O	4669
picrotoxin	PROPN	O	Chemical	4669
,	PUNCT	O	O	4669
and	CCONJ	O	O	4669
pentylenetetrazol	NOUN	O	O	4669
,	PUNCT	O	O	4669
suggesting	VERB	O	O	4669
a	PRON	O	O	4669
genetic	ADJ	O	O	4669
selection	NOUN	O	O	4669
of	ADP	O	O	4669
a	PRON	O	O	4669
general	ADJ	O	O	4669
sensitivity	NOUN	O	O	4669
and	CCONJ	O	O	4669
resistance	NOUN	O	O	4669
to	PART	O	O	4669
several	ADJ	O	O	4669
ligands	NOUN	O	O	4669
of	ADP	O	O	4669
the	PRON	O	O	4669
GABA(A	X	O	O	4669
)	PUNCT	O	O	4669
receptor	NOUN	O	O	4669
.	PUNCT	O	O	4669
Analgesic	NOUN	O	O	4672
effect	VERB	O	O	4672
of	ADP	O	O	4672
intravenous	ADJ	O	O	4672
ketamine	VERB	O	Chemical	4672
in	ADP	O	O	4672
cancer	NOUN	O	Disease	4672
patients	NOUN	O	O	4672
on	ADP	O	O	4672
morphine	NOUN	O	Chemical	4672
therapy	NOUN	O	O	4672
:	PUNCT	O	O	4672
a	PRON	O	O	4672
randomized	VERB	O	O	4672
,	PUNCT	O	O	4672
controlled	VERB	O	O	4672
,	PUNCT	O	O	4672
double	ADJ	O	O	4672
-	PUNCT	O	O	4672
blind	ADJ	O	Disease	4672
,	PUNCT	O	O	4672
crossover	NOUN	O	O	4672
,	PUNCT	O	O	4672
double	ADJ	O	O	4672
-	PUNCT	O	O	4672
dose	NOUN	O	O	4672
study	VERB	O	O	4672
.	PUNCT	O	O	4672
Pain	NOUN	O	Disease	4673
not	PART	O	O	4673
responsive	ADJ	O	O	4673
to	PART	O	O	4673
morphine	NOUN	O	Chemical	4673
is	AUX	O	O	4673
often	ADV	O	O	4673
problematic	ADJ	O	O	4673
.	PUNCT	O	O	4673
Animal	NOUN	O	O	4674
and	CCONJ	O	O	4674
clinical	ADJ	O	O	4674
studies	NOUN	O	O	4674
have	VERB	O	O	4674
suggested	VERB	O	O	4674
that	SCONJ	O	O	4674
N	NUM	O	O	4674
-	PUNCT	O	O	4674
methyl	NOUN	O	O	4674
-	PUNCT	O	O	4674
D	NOUN	O	O	4674
-	PUNCT	O	O	4674
aspartate	NOUN	O	Chemical	4674
(	PUNCT	O	O	4674
NMDA	PROPN	O	Chemical	4674
)	PUNCT	O	O	4674
antagonists	NOUN	O	O	4674
,	PUNCT	O	O	4674
such	ADJ	O	O	4674
as	ADP	O	O	4674
ketamine	VERB	O	Chemical	4674
,	PUNCT	O	O	4674
may	AUX	O	O	4674
be	AUX	O	O	4674
effective	ADJ	O	O	4674
in	ADP	O	O	4674
improving	VERB	O	O	4674
opioid	NOUN	O	O	4674
analgesia	NOUN	O	Disease	4674
in	ADP	O	O	4674
difficult	ADJ	O	O	4674
pain	NOUN	O	Disease	4674
syndromes	NOUN	O	O	4674
,	PUNCT	O	O	4674
such	ADJ	O	O	4674
as	ADP	O	O	4674
neuropathic pain	NOUN	O	Disease	4674
.	PUNCT	O	O	4674
A	PRON	O	O	4675
slow	VERB	O	O	4675
bolus	NOUN	O	O	4675
of	ADP	O	O	4675
subhypnotic	ADJ	O	O	4675
doses	NOUN	O	O	4675
of	ADP	O	O	4675
ketamine	VERB	O	Chemical	4675
(	PUNCT	O	O	4675
0.25	NUM	O	O	4675
mg	VERB	O	O	4675
/	PUNCT	O	O	4675
kg	VERB	O	O	4675
or	CCONJ	O	O	4675
0.50	NUM	O	O	4675
mg	VERB	O	O	4675
/	PUNCT	O	O	4675
kg	VERB	O	O	4675
)	PUNCT	O	O	4675
was	AUX	O	O	4675
given	VERB	O	O	4675
to	PART	O	O	4675
10	NUM	O	O	4675
cancer	NOUN	O	Disease	4675
patients	NOUN	O	O	4675
whose	DET	O	O	4675
pain	NOUN	O	Disease	4675
was	AUX	O	O	4675
unrelieved	ADJ	O	O	4675
by	ADP	O	O	4675
morphine	NOUN	O	Chemical	4675
in	ADP	O	O	4675
a	PRON	O	O	4675
randomized	VERB	O	O	4675
,	PUNCT	O	O	4675
double	ADJ	O	O	4675
-	PUNCT	O	O	4675
blind	ADJ	O	Disease	4675
,	PUNCT	O	O	4675
crossover	NOUN	O	O	4675
,	PUNCT	O	O	4675
double	ADJ	O	O	4675
-	PUNCT	O	O	4675
dose	NOUN	O	O	4675
study	VERB	O	O	4675
.	PUNCT	O	O	4675
Pain	NOUN	O	Disease	4676
intensity	NOUN	O	O	4676
on	ADP	O	O	4676
a	PRON	O	O	4676
0	NUM	O	O	4676
to	PART	O	O	4676
10	NUM	O	O	4676
numerical	ADJ	O	O	4676
scale	NOUN	O	O	4676
;	PUNCT	O	O	4676
nausea	NOUN	O	Disease	4677
and	CCONJ	O	O	4677
vomiting	VERB	O	Disease	4677
,	PUNCT	O	O	4677
drowsiness	NOUN	O	Disease	4677
,	PUNCT	O	O	4677
confusion	NOUN	O	Disease	4677
,	PUNCT	O	O	4677
and	CCONJ	O	O	4677
dry mouth	NOUN	O	Disease	4677
,	PUNCT	O	O	4677
using	VERB	O	O	4677
a	PRON	O	O	4677
scale	NOUN	O	O	4677
from	ADP	O	O	4677
0	NUM	O	O	4677
to	PART	O	O	4677
3	X	O	O	4677
(	PUNCT	O	O	4677
not	PART	O	O	4677
at	ADP	O	O	4677
all	PRON	O	O	4677
,	PUNCT	O	O	4677
slight	ADJ	O	O	4677
,	PUNCT	O	O	4677
a	PRON	O	O	4677
lot	NOUN	O	O	4677
,	PUNCT	O	O	4677
awful	ADJ	O	O	4677
)	PUNCT	O	O	4677
;	PUNCT	O	O	4677
Mini	NOUN	O	O	4677
-	PUNCT	O	O	4677
Mental	ADJ	O	O	4677
State	NOUN	O	O	4677
Examination	NOUN	O	O	4677
(	PUNCT	O	O	4677
MMSE	PROPN	O	O	4677
)	PUNCT	O	O	4677
(	PUNCT	O	O	4677
0	NUM	O	O	4677
-	PUNCT	O	O	4677
30	NUM	O	O	4677
)	PUNCT	O	O	4677
;	PUNCT	O	O	4677
and	CCONJ	O	O	4677
arterial	ADJ	O	O	4677
pressure	NOUN	O	O	4677
were	AUX	O	O	4677
recorded	VERB	O	O	4677
before	ADP	O	O	4677
administration	NOUN	O	O	4677
of	ADP	O	O	4677
drugs	NOUN	O	O	4677
(	PUNCT	O	O	4677
T0	PROPN	O	O	4677
)	PUNCT	O	O	4677
and	CCONJ	O	O	4677
after	ADP	O	O	4677
30	NUM	O	O	4677
minutes	NOUN	O	O	4677
(	PUNCT	O	O	4677
T30	PROPN	O	O	4677
)	PUNCT	O	O	4677
,	PUNCT	O	O	4677
60	NUM	O	O	4677
minutes	NOUN	O	O	4677
(	PUNCT	O	O	4677
T60	NOUN	O	O	4677
)	PUNCT	O	O	4677
,	PUNCT	O	O	4677
120	NUM	O	O	4677
minutes	NOUN	O	O	4677
(	PUNCT	O	O	4677
T120	NUM	O	O	4677
)	PUNCT	O	O	4677
,	PUNCT	O	O	4677
and	CCONJ	O	O	4677
180	NUM	O	O	4677
minutes	NOUN	O	O	4677
(	PUNCT	O	O	4677
T180	NOUN	O	O	4677
)	PUNCT	O	O	4677
.	PUNCT	O	O	4677
Ketamine	PROPN	O	Chemical	4678
,	PUNCT	O	O	4678
but	CCONJ	O	O	4678
not	PART	O	O	4678
saline	NOUN	O	O	4678
solution	NOUN	O	O	4678
,	PUNCT	O	O	4678
significantly	ADV	O	O	4678
reduced	VERB	O	O	4678
the	PRON	O	O	4678
pain	NOUN	O	Disease	4678
intensity	NOUN	O	O	4678
in	ADP	O	O	4678
almost	ADV	O	O	4678
all	PRON	O	O	4678
the	PRON	O	O	4678
patients	NOUN	O	O	4678
at	ADP	O	O	4678
both	PRON	O	O	4678
doses	NOUN	O	O	4678
.	PUNCT	O	O	4678
Hallucinations	NOUN	O	Disease	4679
occurred	VERB	O	O	4679
in	ADP	O	O	4679
4	NUM	O	O	4679
patients	NOUN	O	O	4679
,	PUNCT	O	O	4679
and	CCONJ	O	O	4679
an	PRON	O	O	4679
unpleasant	ADJ	O	O	4679
sensation	NOUN	O	O	4679
(	PUNCT	O	O	4679
""""	PUNCT	O	O	4679
empty	ADJ	O	O	4679
head	NOUN	O	O	4679
""""	PUNCT	O	O	4679
)	PUNCT	O	O	4679
was	AUX	O	O	4679
also	ADV	O	O	4679
reported	VERB	O	O	4679
by	ADP	O	O	4679
2	X	O	O	4679
patients	NOUN	O	O	4679
.	PUNCT	O	O	4679
These	PRON	O	O	4680
episodes	NOUN	O	O	4680
reversed	VERB	O	O	4680
after	ADP	O	O	4680
the	PRON	O	O	4680
administration	NOUN	O	O	4680
of	ADP	O	O	4680
diazepam	NOUN	O	Chemical	4680
1	X	O	O	4680
mg	VERB	O	O	4680
intravenously	ADV	O	O	4680
.	PUNCT	O	O	4680
Significant	ADJ	O	O	4681
increases	VERB	O	O	4681
in	ADP	O	O	4681
drowsiness	NOUN	O	Disease	4681
were	AUX	O	O	4681
reported	VERB	O	O	4681
in	ADP	O	O	4681
patients	NOUN	O	O	4681
treated	VERB	O	O	4681
with	ADP	O	O	4681
ketamine	VERB	O	Chemical	4681
in	ADP	O	O	4681
both	PRON	O	O	4681
groups	NOUN	O	O	4681
and	CCONJ	O	O	4681
were	AUX	O	O	4681
more	ADJ	O	O	4681
marked	VERB	O	O	4681
with	ADP	O	O	4681
ketamine	VERB	O	Chemical	4681
0.50	NUM	O	O	4681
mg	VERB	O	O	4681
/	PUNCT	O	O	4681
kg	VERB	O	O	4681
.	PUNCT	O	O	4681
A	PRON	O	O	4682
significant	ADJ	O	O	4682
difference	NOUN	O	O	4682
in	ADP	O	O	4682
MMSE	PROPN	O	O	4682
was	AUX	O	O	4682
observed	VERB	O	O	4682
at	ADP	O	O	4682
T30	PROPN	O	O	4682
in	ADP	O	O	4682
patients	NOUN	O	O	4682
who	PRON	O	O	4682
received	VERB	O	O	4682
0.50	NUM	O	O	4682
mg	VERB	O	O	4682
/	PUNCT	O	O	4682
kg	VERB	O	O	4682
of	ADP	O	O	4682
ketamine	VERB	O	Chemical	4682
.	PUNCT	O	O	4682
Ketamine	PROPN	O	Chemical	4683
can	AUX	O	O	4683
improve	VERB	O	O	4683
morphine	NOUN	O	Chemical	4683
analgesia	NOUN	O	Disease	4683
in	ADP	O	O	4683
difficult	ADJ	O	O	4683
pain	NOUN	O	Disease	4683
syndromes	NOUN	O	O	4683
,	PUNCT	O	O	4683
such	ADJ	O	O	4683
as	ADP	O	O	4683
neuropathic pain	NOUN	O	Disease	4683
.	PUNCT	O	O	4683
This	PRON	O	O	4684
observation	NOUN	O	O	4684
should	AUX	O	O	4684
be	AUX	O	O	4684
tested	VERB	O	O	4684
in	ADP	O	O	4684
studies	NOUN	O	O	4684
of	ADP	O	O	4684
prolonged	VERB	O	O	4684
ketamine	VERB	O	Chemical	4684
administration	NOUN	O	O	4684
.	PUNCT	O	O	4684
Endocrine	NOUN	O	O	4687
screening	VERB	O	O	4687
in	ADP	O	O	4687
1,022	NUM	O	O	4687
men	NOUN	O	O	4687
with	ADP	O	O	4687
erectile dysfunction	NOUN	O	Disease	4687
:	PUNCT	O	O	4687
clinical	ADJ	O	O	4687
significance	NOUN	O	O	4687
and	CCONJ	O	O	4687
cost	NOUN	O	O	4687
-	PUNCT	O	O	4687
effective	ADJ	O	O	4687
strategy	NOUN	O	O	4687
.	PUNCT	O	O	4687
We	PRON	O	O	4688
reviewed	VERB	O	O	4688
the	PRON	O	O	4688
results	VERB	O	O	4688
of	ADP	O	O	4688
serum	NOUN	O	O	4688
testosterone	PROPN	O	Chemical	4688
and	CCONJ	O	O	4688
prolactin	PROPN	O	O	4688
determination	NOUN	O	O	4688
in	ADP	O	O	4688
1,022	NUM	O	O	4688
patients	NOUN	O	O	4688
referred	VERB	O	O	4688
because	SCONJ	O	O	4688
of	ADP	O	O	4688
erectile dysfunction	NOUN	O	Disease	4688
and	CCONJ	O	O	4688
compared	VERB	O	O	4688
the	PRON	O	O	4688
data	NOUN	O	O	4688
with	ADP	O	O	4688
history	NOUN	O	O	4688
,	PUNCT	O	O	4688
results	VERB	O	O	4688
of	ADP	O	O	4688
physical	ADJ	O	O	4688
examination	NOUN	O	O	4688
,	PUNCT	O	O	4688
other	ADJ	O	O	4688
etiological	ADJ	O	O	4688
investigations	NOUN	O	O	4688
and	CCONJ	O	O	4688
effects	NOUN	O	O	4688
of	ADP	O	O	4688
endocrine	NOUN	O	O	4688
therapy	NOUN	O	O	4688
to	PART	O	O	4688
refine	VERB	O	O	4688
the	PRON	O	O	4688
rules	NOUN	O	O	4688
of	ADP	O	O	4688
cost	NOUN	O	O	4688
-	PUNCT	O	O	4688
effective	ADJ	O	O	4688
endocrine	NOUN	O	O	4688
screening	VERB	O	O	4688
and	CCONJ	O	O	4688
to	PART	O	O	4688
pinpoint	VERB	O	O	4688
actual	ADJ	O	O	4688
responsibility	NOUN	O	O	4688
for	ADP	O	O	4688
hormonal	ADJ	O	O	4688
abnormalities	NOUN	O	O	4688
.	PUNCT	O	O	4688
MATERIALS	NOUN	O	O	4689
AND	CCONJ	O	O	4689
METHODS	NOUN	O	O	4689
:	PUNCT	O	O	4689
Testosterone	PROPN	O	O	4689
and	CCONJ	O	O	4689
prolactin	PROPN	O	O	4689
were	AUX	O	O	4689
determined	VERB	O	O	4689
by	ADP	O	O	4689
radioimmunoassay	PROPN	O	O	4689
.	PUNCT	O	O	4689
Every	PRON	O	O	4690
patient	NOUN	O	O	4690
was	AUX	O	O	4690
screened	VERB	O	O	4690
for	ADP	O	O	4690
testosterone	PROPN	O	Chemical	4690
and	CCONJ	O	O	4690
451	NUM	O	O	4690
were	AUX	O	O	4690
screened	VERB	O	O	4690
for	ADP	O	O	4690
prolactin	PROPN	O	O	4690
on	ADP	O	O	4690
the	PRON	O	O	4690
basis	NOUN	O	O	4690
of	ADP	O	O	4690
low	ADJ	O	O	4690
sexual	ADJ	O	O	4690
desire	VERB	O	O	4690
,	PUNCT	O	O	4690
gynecomastia	PROPN	O	O	4690
or	CCONJ	O	O	4690
testosterone	PROPN	O	Chemical	4690
less	ADV	O	O	4690
than	ADP	O	O	4690
4	NUM	O	O	4690
ng./ml	NUM	O	O	4690
.	PUNCT	O	O	4690
Prolactin	NOUN	O	O	4691
results	VERB	O	O	4691
were	AUX	O	O	4691
compared	VERB	O	O	4691
with	ADP	O	O	4691
those	PRON	O	O	4691
of	ADP	O	O	4691
a	PRON	O	O	4691
previous	ADJ	O	O	4691
personal	ADJ	O	O	4691
cohort	NOUN	O	O	4691
of	ADP	O	O	4691
1,340	NUM	O	O	4691
patients	NOUN	O	O	4691
with	ADP	O	O	4691
erectile dysfunction	NOUN	O	Disease	4691
and	CCONJ	O	O	4691
systematic	ADJ	O	O	4691
prolactin	PROPN	O	O	4691
determination	NOUN	O	O	4691
.	PUNCT	O	O	4691
Main	NOUN	O	O	4692
clinical	ADJ	O	O	4692
criteria	NOUN	O	O	4692
tested	VERB	O	O	4692
regarding	VERB	O	O	4692
efficiency	NOUN	O	O	4692
in	ADP	O	O	4692
hormone	NOUN	O	O	4692
determination	NOUN	O	O	4692
were	AUX	O	O	4692
low	ADJ	O	O	4692
sexual	ADJ	O	O	4692
desire	VERB	O	O	4692
,	PUNCT	O	O	4692
small	ADJ	O	O	4692
testes	NOUN	O	O	4692
and	CCONJ	O	O	4692
gynecomastia	PROPN	O	O	4692
.	PUNCT	O	O	4692
Endocrine	NOUN	O	O	4693
therapy	NOUN	O	O	4693
consisted	VERB	O	O	4693
of	ADP	O	O	4693
testosterone	PROPN	O	Chemical	4693
heptylate	PROPN	O	O	4693
or	CCONJ	O	O	4693
human	PROPN	O	O	4693
chorionic	ADJ	O	O	4693
gonadotropin	ADP	O	O	4693
for	ADP	O	O	4693
hypogonadism	NOUN	O	O	4693
and	CCONJ	O	O	4693
bromocriptine	NOUN	O	Chemical	4693
for	ADP	O	O	4693
hyperprolactinemia	NOUN	O	Disease	4693
.	PUNCT	O	O	4693
Testosterone	PROPN	O	O	4694
was	AUX	O	O	4694
less	ADV	O	O	4694
than	ADP	O	O	4694
3	X	O	O	4694
ng./ml	NUM	O	O	4694
.	PUNCT	O	O	4694
The	PRON	O	O	4695
prevalence	NOUN	O	O	4695
of	ADP	O	O	4695
repeatedly	ADV	O	O	4695
low	ADJ	O	O	4695
testosterone	PROPN	O	Chemical	4695
increased	VERB	O	O	4695
with	ADP	O	O	4695
age	NOUN	O	O	4695
(	PUNCT	O	O	4695
4%	NOUN	O	O	4695
before	ADP	O	O	4695
age	NOUN	O	O	4695
50	NUM	O	O	4695
years	NOUN	O	O	4695
and	CCONJ	O	O	4695
9%	NOUN	O	O	4695
50	NUM	O	O	4695
years	NOUN	O	O	4695
or	CCONJ	O	O	4695
older	ADJ	O	O	4695
)	PUNCT	O	O	4695
.	PUNCT	O	O	4695
Two	NUM	O	O	4696
pituitary tumors	NOUN	O	Disease	4696
were	AUX	O	O	4696
discovered	VERB	O	O	4696
after	ADP	O	O	4696
testosterone	PROPN	O	Chemical	4696
determination	NOUN	O	O	4696
.	PUNCT	O	O	4696
Most	ADV	O	O	4697
of	ADP	O	O	4697
the	PRON	O	O	4697
other	ADJ	O	O	4697
low	ADJ	O	O	4697
testosterone	PROPN	O	Chemical	4697
levels	NOUN	O	O	4697
seemed	VERB	O	O	4697
to	PART	O	O	4697
result	VERB	O	O	4697
from	ADP	O	O	4697
nonorganic	ADJ	O	O	4697
hypothalamic	ADJ	O	O	4697
dysfunction	NOUN	O	O	4697
because	SCONJ	O	O	4697
of	ADP	O	O	4697
normal	ADJ	O	O	4697
serum	NOUN	O	O	4697
luteinizing	VERB	O	O	4697
hormone	NOUN	O	O	4697
and	CCONJ	O	O	4697
prolactin	PROPN	O	O	4697
and	CCONJ	O	O	4697
to	PART	O	O	4697
have	VERB	O	O	4697
only	ADV	O	O	4697
a	PRON	O	O	4697
small	ADJ	O	O	4697
role	NOUN	O	O	4697
in	ADP	O	O	4697
erectile dysfunction	NOUN	O	Disease	4697
(	PUNCT	O	O	4697
definite	ADJ	O	O	4697
improvement	NOUN	O	O	4697
in	ADP	O	O	4697
only	ADV	O	O	4697
16	NUM	O	O	4697
of	ADP	O	O	4697
44	NUM	O	O	4697
[	X	O	O	4697
36%	NOUN	O	O	4697
]	PUNCT	O	O	4697
after	ADP	O	O	4697
androgen	PROPN	O	Chemical	4697
therapy	NOUN	O	O	4697
,	PUNCT	O	O	4697
normal	ADJ	O	O	4697
morning	NOUN	O	O	4697
or	CCONJ	O	O	4697
nocturnal	ADJ	O	O	4697
erections	NOUN	O	O	4697
in	ADP	O	O	4697
30%	NOUN	O	O	4697
and	CCONJ	O	O	4697
definite	ADJ	O	O	4697
vasculogenic	PROPN	O	O	4697
contributions	NOUN	O	O	4697
in	ADP	O	O	4697
42%	NOUN	O	O	4697
)	PUNCT	O	O	4697
.	PUNCT	O	O	4697
Determining	VERB	O	O	4698
testosterone	PROPN	O	Chemical	4698
only	ADV	O	O	4698
in	ADP	O	O	4698
cases	NOUN	O	O	4698
of	ADP	O	O	4698
low	ADJ	O	O	4698
sexual	ADJ	O	O	4698
desire	VERB	O	O	4698
or	CCONJ	O	O	4698
abnormal	ADJ	O	O	4698
physical	ADJ	O	O	4698
examination	NOUN	O	O	4698
would	AUX	O	O	4698
have	VERB	O	O	4698
missed	VERB	O	O	4698
40%	NOUN	O	O	4698
of	ADP	O	O	4698
the	PRON	O	O	4698
cases	NOUN	O	O	4698
with	ADP	O	O	4698
low	ADJ	O	O	4698
testosterone	PROPN	O	Chemical	4698
,	PUNCT	O	O	4698
including	VERB	O	O	4698
37%	NOUN	O	O	4698
of	ADP	O	O	4698
those	PRON	O	O	4698
subsequently	ADV	O	O	4698
improved	VERB	O	O	4698
by	ADP	O	O	4698
androgen	PROPN	O	Chemical	4698
therapy	NOUN	O	O	4698
.	PUNCT	O	O	4698
Only	ADV	O	O	4699
1	X	O	O	4699
prolactinoma	PROPN	O	O	4699
was	AUX	O	O	4699
discovered	VERB	O	O	4699
.	PUNCT	O	O	4699
in	ADP	O	O	4700
1.86%	NOUN	O	O	4700
of	ADP	O	O	4700
1,821	NUM	O	O	4700
patients	NOUN	O	O	4700
,	PUNCT	O	O	4700
prolactinomas	PROPN	O	Disease	4700
in	ADP	O	O	4700
7	NUM	O	O	4700
,	PUNCT	O	O	4700
0.38%	NOUN	O	O	4700
)	PUNCT	O	O	4700
.	PUNCT	O	O	4700
Bromocriptine	PROPN	O	Chemical	4701
was	AUX	O	O	4701
definitely	ADV	O	O	4701
effective	ADJ	O	O	4701
in	ADP	O	O	4701
cases	NOUN	O	O	4701
with	ADP	O	O	4701
prolactin	PROPN	O	O	4701
greater	ADJ	O	O	4701
than	ADP	O	O	4701
35	NUM	O	O	4701
ng./ml	NUM	O	O	4701
.	PUNCT	O	O	4701
Testosterone	PROPN	O	O	4702
was	AUX	O	O	4702
low	ADJ	O	O	4702
in	ADP	O	O	4702
less	ADV	O	O	4702
than	ADP	O	O	4702
50%	NOUN	O	O	4702
of	ADP	O	O	4702
cases	NOUN	O	O	4702
with	ADP	O	O	4702
prolactin	PROPN	O	O	4702
greater	ADJ	O	O	4702
than	ADP	O	O	4702
35	NUM	O	O	4702
ng./ml	NUM	O	O	4702
.	PUNCT	O	O	4702
Low	ADJ	O	O	4703
prevalences	NOUN	O	O	4703
and	CCONJ	O	O	4703
effects	NOUN	O	O	4703
of	ADP	O	O	4703
low	ADJ	O	O	4703
testosterone	PROPN	O	Chemical	4703
and	CCONJ	O	O	4703
high	ADJ	O	O	4703
prolactin	PROPN	O	O	4703
in	ADP	O	O	4703
erectile dysfunction	NOUN	O	Disease	4703
can	AUX	O	O	4703
not	PART	O	O	4703
justify	VERB	O	O	4703
their	PRON	O	O	4703
routine	ADJ	O	O	4703
determination	NOUN	O	O	4703
.	PUNCT	O	O	4703
However	ADV	O	O	4704
,	PUNCT	O	O	4704
cost	NOUN	O	O	4704
-	PUNCT	O	O	4704
effective	ADJ	O	O	4704
screening	VERB	O	O	4704
strategies	NOUN	O	O	4704
recommended	VERB	O	O	4704
so	ADV	O	O	4704
far	ADV	O	O	4704
missed	VERB	O	O	4704
40	NUM	O	O	4704
to	PART	O	O	4704
50%	NOUN	O	O	4704
of	ADP	O	O	4704
cases	NOUN	O	O	4704
improved	VERB	O	O	4704
with	ADP	O	O	4704
endocrine	NOUN	O	O	4704
therapy	NOUN	O	O	4704
and	CCONJ	O	O	4704
the	PRON	O	O	4704
pituitary tumors	NOUN	O	Disease	4704
.	PUNCT	O	O	4704
We	PRON	O	O	4705
now	ADV	O	O	4705
advocate	NOUN	O	O	4705
that	SCONJ	O	O	4705
before	ADP	O	O	4705
age	NOUN	O	O	4705
50	NUM	O	O	4705
years	NOUN	O	O	4705
testosterone	PROPN	O	Chemical	4705
be	AUX	O	O	4705
determined	VERB	O	O	4705
only	ADV	O	O	4705
in	ADP	O	O	4705
cases	NOUN	O	O	4705
of	ADP	O	O	4705
low	ADJ	O	O	4705
sexual	ADJ	O	O	4705
desire	VERB	O	O	4705
and	CCONJ	O	O	4705
abnormal	ADJ	O	O	4705
physical	ADJ	O	O	4705
examination	NOUN	O	O	4705
but	CCONJ	O	O	4705
that	SCONJ	O	O	4705
it	PRON	O	O	4705
be	AUX	O	O	4705
measured	VERB	O	O	4705
in	ADP	O	O	4705
all	PRON	O	O	4705
men	NOUN	O	O	4705
older	ADJ	O	O	4705
than	ADP	O	O	4705
50	NUM	O	O	4705
years	NOUN	O	O	4705
.	PUNCT	O	O	4705
Prolactin	NOUN	O	O	4706
should	AUX	O	O	4706
be	AUX	O	O	4706
determined	VERB	O	O	4706
only	ADV	O	O	4706
in	ADP	O	O	4706
cases	NOUN	O	O	4706
of	ADP	O	O	4706
low	ADJ	O	O	4706
sexual	ADJ	O	O	4706
desire	VERB	O	O	4706
,	PUNCT	O	O	4706
gynecomastia	PROPN	O	O	4706
and/or	CCONJ	O	O	4706
testosterone	PROPN	O	Chemical	4706
less	ADV	O	O	4706
than	ADP	O	O	4706
4	NUM	O	O	4706
ng./ml	NUM	O	O	4706
.	PUNCT	O	O	4706
Thiopentone	NOUN	O	O	4709
pretreatment	NOUN	O	O	4709
for	ADP	O	O	4709
propofol	VERB	O	Chemical	4709
injection	NOUN	O	O	4709
pain	NOUN	O	Disease	4709
in	ADP	O	O	4709
ambulatory	ADJ	O	O	4709
patients	NOUN	O	O	4709
.	PUNCT	O	O	4709
This	PRON	O	O	4710
study	VERB	O	O	4710
investigated	VERB	O	O	4710
propofol	VERB	O	Chemical	4710
injection	NOUN	O	O	4710
pain	NOUN	O	Disease	4710
in	ADP	O	O	4710
patients	NOUN	O	O	4710
undergoing	VERB	O	O	4710
ambulatory	ADJ	O	O	4710
anaesthesia	NOUN	O	O	4710
.	PUNCT	O	O	4710
In	ADP	O	O	4711
a	PRON	O	O	4711
randomized	VERB	O	O	4711
,	PUNCT	O	O	4711
double	ADJ	O	O	4711
-	PUNCT	O	O	4711
blind	ADJ	O	Disease	4711
trial	NOUN	O	O	4711
,	PUNCT	O	O	4711
90	NUM	O	O	4711
women	NOUN	O	O	4711
were	AUX	O	O	4711
allocated	VERB	O	O	4711
to	PART	O	O	4711
receive	VERB	O	O	4711
one	NUM	O	O	4711
of	ADP	O	O	4711
three	NUM	O	O	4711
treatments	NOUN	O	O	4711
prior	ADV	O	O	4711
to	PART	O	O	4711
induction	NOUN	O	O	4711
of	ADP	O	O	4711
anaesthesia	NOUN	O	O	4711
with	ADP	O	O	4711
propofol	VERB	O	Chemical	4711
.	PUNCT	O	O	4711
Patients	NOUN	O	O	4712
in	ADP	O	O	4712
Group	PROPN	O	O	4712
C	NOUN	O	O	4712
received	VERB	O	O	4712
2	X	O	O	4712
ml	ADP	O	O	4712
normal	ADJ	O	O	4712
saline	NOUN	O	O	4712
,	PUNCT	O	O	4712
Group	PROPN	O	O	4712
L	NOUN	O	O	4712
,	PUNCT	O	O	4712
2	X	O	O	4712
ml	ADP	O	O	4712
,	PUNCT	O	O	4712
lidocaine	NOUN	O	Chemical	4712
2%	NOUN	O	O	4712
(	PUNCT	O	O	4712
40	NUM	O	O	4712
mg	VERB	O	O	4712
)	PUNCT	O	O	4712
and	CCONJ	O	O	4712
Group	PROPN	O	O	4712
T	NOUN	O	Chemical	4712
,	PUNCT	O	O	4712
2	X	O	O	4712
ml	ADP	O	O	4712
thiopentone	NOUN	O	Chemical	4713
2.5%	NOUN	O	O	4713
(	PUNCT	O	O	4713
50	NUM	O	O	4713
mg	VERB	O	O	4713
)	PUNCT	O	O	4713
.	PUNCT	O	O	4713
Venous	ADJ	O	O	4714
discomfort	VERB	O	O	4714
was	AUX	O	O	4714
assessed	VERB	O	O	4714
with	ADP	O	O	4714
a	PRON	O	O	4714
visual	ADJ	O	O	4714
analogue	NOUN	O	O	4714
scale	NOUN	O	O	4714
(	PUNCT	O	O	4714
VAS	PROPN	O	O	4714
)	PUNCT	O	O	4714
5	NUM	O	O	4714
-	PUNCT	O	O	4714
15	NUM	O	O	4714
sec	PROPN	O	O	4714
after	ADP	O	O	4714
commencing	VERB	O	O	4714
propofol	VERB	O	Chemical	4714
administration	NOUN	O	O	4714
using	VERB	O	O	4714
an	PRON	O	O	4714
infusion	NOUN	O	O	4714
pump	VERB	O	O	4714
(	PUNCT	O	O	4714
rate	NOUN	O	O	4714
1000	NUM	O	O	4714
micrograms.kg-1.min-1	VERB	O	O	4714
)	PUNCT	O	O	4714
.	PUNCT	O	O	4714
Loss	NOUN	O	O	4715
of	ADP	O	O	4715
consciousness	NOUN	O	O	4715
occurred	VERB	O	O	4715
in	ADP	O	O	4715
60	NUM	O	O	4715
-	PUNCT	O	O	4715
90	NUM	O	O	4715
sec	PROPN	O	O	4715
.	PUNCT	O	O	4715
The	PRON	O	O	4716
VAS	PROPN	O	O	4716
scores	NOUN	O	O	4716
for	ADP	O	O	4716
recall	VERB	O	O	4716
of	ADP	O	O	4716
pain	NOUN	O	Disease	4716
in	ADP	O	O	4716
the	PRON	O	O	4716
recovery	NOUN	O	O	4716
room	NOUN	O	O	4716
were	AUX	O	O	4716
correlated	VERB	O	O	4716
with	ADP	O	O	4716
the	PRON	O	O	4716
VAS	PROPN	O	O	4716
scores	NOUN	O	O	4716
during	ADP	O	O	4716
induction	NOUN	O	O	4716
(	PUNCT	O	O	4716
r	X	O	O	4716
=	PUNCT	O	O	4716
0.7045	NUM	O	O	4716
;	PUNCT	O	O	4716
P	NOUN	O	Chemical	4716
<	X	O	O	4716
0.0001	NUM	O	O	4716
)	PUNCT	O	O	4716
.	PUNCT	O	O	4716
Assessing	VERB	O	O	4717
their	PRON	O	O	4717
overall	ADV	O	O	4717
satisfaction	NOUN	O	O	4717
,	PUNCT	O	O	4717
89.7%	NOUN	O	O	4717
would	AUX	O	O	4717
choose	VERB	O	O	4717
propofol	VERB	O	Chemical	4717
anaesthesia	NOUN	O	O	4717
again	ADV	O	O	4717
.	PUNCT	O	O	4717
We	PRON	O	O	4718
conclude	VERB	O	O	4718
that	SCONJ	O	O	4718
lidocaine	NOUN	O	Chemical	4718
reduces	VERB	O	O	4718
the	PRON	O	O	4718
incidence	NOUN	O	O	4718
and	CCONJ	O	O	4718
severity	NOUN	O	O	4718
of	ADP	O	O	4718
propofol	VERB	O	Chemical	4718
injection	NOUN	O	O	4718
pain	NOUN	O	Disease	4718
in	ADP	O	O	4718
ambulatory	ADJ	O	O	4718
patients	NOUN	O	O	4718
whereas	SCONJ	O	O	4718
thiopentone	NOUN	O	Chemical	4718
only	ADV	O	O	4718
reduces	VERB	O	O	4718
its	PRON	O	O	4718
severity	NOUN	O	O	4718
.	PUNCT	O	O	4718
glycopyrrolate	VERB	O	Chemical	4721
and	CCONJ	O	O	4721
atropine	NOUN	O	Chemical	4721
in	ADP	O	O	4721
the	PRON	O	O	4721
prevention	NOUN	O	O	4721
of	ADP	O	O	4721
bradycardia	NOUN	O	Disease	4721
and	CCONJ	O	O	4721
arrhythmias	VERB	O	Disease	4721
following	VERB	O	O	4721
repeated	VERB	O	O	4721
doses	NOUN	O	O	4721
of	ADP	O	O	4721
suxamethonium	NOUN	O	O	4721
in	ADP	O	O	4721
children	NOUN	O	O	4721
.	PUNCT	O	O	4721
The	PRON	O	O	4722
effectiveness	NOUN	O	O	4722
of	ADP	O	O	4722
administration	NOUN	O	O	4722
of	ADP	O	O	4722
glycopyrrolate	VERB	O	Chemical	4722
5	NUM	O	O	4722
and	CCONJ	O	O	4722
10	NUM	O	O	4722
micrograms	NOUN	O	O	4722
kg-1	VERB	O	O	4722
and	CCONJ	O	O	4722
atropine	NOUN	O	Chemical	4722
10	NUM	O	O	4722
and	CCONJ	O	O	4722
20	NUM	O	O	4722
micrograms	NOUN	O	O	4722
kg-1	VERB	O	O	4722
immediately	ADV	O	O	4723
before	ADP	O	O	4723
the	PRON	O	O	4723
induction	NOUN	O	O	4723
of	ADP	O	O	4723
anaesthesia	NOUN	O	O	4723
,	PUNCT	O	O	4723
to	PART	O	O	4723
prevent	VERB	O	O	4723
arrhythmia	NOUN	O	Disease	4723
and	CCONJ	O	O	4723
bradycardia	NOUN	O	Disease	4723
following	VERB	O	O	4723
repeated	VERB	O	O	4723
doses	NOUN	O	O	4723
of	ADP	O	O	4723
suxamethonium	NOUN	O	O	4723
in	ADP	O	O	4723
children	NOUN	O	O	4723
,	PUNCT	O	O	4723
was	AUX	O	O	4723
studied	VERB	O	O	4723
.	PUNCT	O	O	4723
A	PRON	O	O	4724
control	VERB	O	O	4724
group	NOUN	O	O	4724
was	AUX	O	O	4724
included	VERB	O	O	4724
for	ADP	O	O	4724
comparison	NOUN	O	O	4724
with	ADP	O	O	4724
the	PRON	O	O	4724
lower	ADJ	O	O	4724
dose	NOUN	O	O	4724
range	VERB	O	O	4724
of	ADP	O	O	4724
glycopyrrolate	VERB	O	Chemical	4724
and	CCONJ	O	O	4724
atropine	NOUN	O	Chemical	4724
.	PUNCT	O	O	4724
A	PRON	O	O	4725
frequency	NOUN	O	O	4725
of	ADP	O	O	4725
bradycardia	NOUN	O	Disease	4725
of	ADP	O	O	4725
50%	NOUN	O	O	4725
was	AUX	O	O	4725
noted	VERB	O	O	4725
in	ADP	O	O	4725
the	PRON	O	O	4725
control	VERB	O	O	4725
group	NOUN	O	O	4725
,	PUNCT	O	O	4725
but	CCONJ	O	O	4725
this	PRON	O	O	4725
was	AUX	O	O	4725
not	PART	O	O	4725
significantly	ADV	O	O	4725
different	ADJ	O	O	4725
from	ADP	O	O	4725
the	PRON	O	O	4725
frequency	NOUN	O	O	4725
with	ADP	O	O	4725
the	PRON	O	O	4725
active	ADJ	O	O	4725
drugs	NOUN	O	O	4725
.	PUNCT	O	O	4725
Bradycardia	PROPN	O	Disease	4726
(	PUNCT	O	O	4726
defined	VERB	O	O	4726
as	ADP	O	O	4726
a	PRON	O	O	4726
decrease	VERB	O	O	4726
in	ADP	O	O	4726
heart	NOUN	O	O	4726
rate	NOUN	O	O	4726
to	PART	O	O	4726
less	ADV	O	O	4726
than	ADP	O	O	4726
50	NUM	O	O	4726
beat	VERB	O	O	4726
min-1	VERB	O	O	4726
)	PUNCT	O	O	4726
was	AUX	O	O	4726
prevented	VERB	O	O	4726
when	SCONJ	O	O	4726
the	PRON	O	O	4726
larger	ADJ	O	O	4726
dose	NOUN	O	O	4726
of	ADP	O	O	4726
either	ADV	O	O	4726
active	ADJ	O	O	4726
drug	NOUN	O	O	4726
was	AUX	O	O	4726
used	VERB	O	O	4726
.	PUNCT	O	O	4726
It	PRON	O	O	4727
is	AUX	O	O	4727
recommended	VERB	O	O	4727
that	SCONJ	O	O	4727
either	ADV	O	O	4727
glycopyrrolate	VERB	O	Chemical	4727
10	NUM	O	O	4727
micrograms	NOUN	O	O	4727
kg-1	VERB	O	O	4727
or	CCONJ	O	O	4727
atropine	NOUN	O	Chemical	4727
20	NUM	O	O	4727
micrograms	NOUN	O	O	4727
kg-1	VERB	O	O	4727
i.v	NOUN	O	O	4727
.	PUNCT	O	O	4727
should	AUX	O	O	4728
immediately	ADV	O	O	4728
precede	VERB	O	O	4728
induction	NOUN	O	O	4728
of	ADP	O	O	4728
anaesthesia	NOUN	O	O	4728
,	PUNCT	O	O	4728
in	ADP	O	O	4728
children	NOUN	O	O	4728
,	PUNCT	O	O	4728
if	SCONJ	O	O	4728
the	PRON	O	O	4728
repeated	VERB	O	O	4728
administration	NOUN	O	O	4728
of	ADP	O	O	4728
suxamethonium	NOUN	O	O	4728
is	AUX	O	O	4728
anticipated	VERB	O	O	4728
.	PUNCT	O	O	4728
Reduction	NOUN	O	O	4731
in	ADP	O	O	4731
caffeine	NOUN	O	Chemical	4731
toxicity	NOUN	O	Disease	4731
by	ADP	O	O	4731
acetaminophen	PROPN	O	Chemical	4731
.	PUNCT	O	O	4731
A	PRON	O	O	4732
patient	NOUN	O	O	4732
who	PRON	O	O	4732
allegedly	ADV	O	O	4732
consumed	VERB	O	O	4732
100	NUM	O	O	4732
tablets	NOUN	O	O	4732
of	ADP	O	O	4732
an	PRON	O	O	4732
over	ADP	O	O	4732
-	PUNCT	O	O	4732
the	PRON	O	O	4732
-	PUNCT	O	O	4732
counter	VERB	O	O	4732
analgesic	PROPN	O	O	4732
containing	VERB	O	O	4732
sodium	NOUN	O	Chemical	4732
acetylsalicylate	NOUN	O	Chemical	4732
,	PUNCT	O	O	4732
caffeine	NOUN	O	Chemical	4732
,	PUNCT	O	O	4732
and	CCONJ	O	O	4732
acetaminophen	PROPN	O	Chemical	4732
displayed	VERB	O	O	4732
no	PRON	O	O	4732
significant	ADJ	O	O	4732
CNS	PROPN	O	O	4732
stimulation	NOUN	O	O	4732
despite	SCONJ	O	O	4732
the	PRON	O	O	4732
presence	NOUN	O	O	4732
of	ADP	O	O	4732
175	NUM	O	O	4732
micrograms	NOUN	O	O	4732
of	ADP	O	O	4732
caffeine	NOUN	O	Chemical	4732
per	ADP	O	O	4732
mL	PROPN	O	O	4732
of	ADP	O	O	4732
serum	NOUN	O	O	4732
.	PUNCT	O	O	4732
Because	SCONJ	O	O	4733
salicylates	NOUN	O	Chemical	4733
have	VERB	O	O	4733
been	AUX	O	O	4733
reported	VERB	O	O	4733
to	PART	O	O	4733
augment	VERB	O	O	4733
the	PRON	O	O	4733
stimulatory	ADJ	O	O	4733
effects	NOUN	O	O	4733
of	ADP	O	O	4733
caffeine	NOUN	O	Chemical	4733
on	ADP	O	O	4733
the	PRON	O	O	4733
CNS	PROPN	O	O	4733
,	PUNCT	O	O	4733
attention	NOUN	O	O	4733
was	AUX	O	O	4733
focused	VERB	O	O	4733
on	ADP	O	O	4733
the	PRON	O	O	4733
possibility	NOUN	O	O	4733
that	SCONJ	O	O	4733
the	PRON	O	O	4733
presence	NOUN	O	O	4733
of	ADP	O	O	4733
acetaminophen	PROPN	O	Chemical	4733
(	PUNCT	O	O	4733
52	NUM	O	O	4733
micrograms	NOUN	O	O	4733
/	PUNCT	O	O	4733
mL	PROPN	O	O	4733
)	PUNCT	O	O	4733
reduced	VERB	O	O	4733
the	PRON	O	O	4733
CNS	PROPN	O	O	4733
toxicity	NOUN	O	Disease	4733
of	ADP	O	O	4733
caffeine	NOUN	O	Chemical	4733
.	PUNCT	O	O	4733
Studies	NOUN	O	O	4734
in	ADP	O	O	4734
DBA/2J	NUM	O	O	4734
mice	NOUN	O	O	4734
showed	VERB	O	O	4734
that	SCONJ	O	O	4734
:	PUNCT	O	O	4734
1	X	O	O	4734
)	PUNCT	O	O	4734
pretreatment	NOUN	O	O	4734
with	ADP	O	O	4734
acetaminophen	PROPN	O	Chemical	4734
(	PUNCT	O	O	4734
100	NUM	O	O	4734
mg	VERB	O	O	4734
/	PUNCT	O	O	4734
kg	VERB	O	O	4734
)	PUNCT	O	O	4734
increased	VERB	O	O	4734
the	PRON	O	O	4734
interval	NOUN	O	O	4734
between	ADP	O	O	4734
the	PRON	O	O	4734
administration	NOUN	O	O	4734
of	ADP	O	O	4734
caffeine	NOUN	O	Chemical	4734
(	PUNCT	O	O	4734
300	NUM	O	O	4734
to	PART	O	O	4734
450	NUM	O	O	4734
mg	VERB	O	O	4734
/	PUNCT	O	O	4734
kg	VERB	O	O	4734
IP	PROPN	O	O	4734
)	PUNCT	O	O	4734
and	CCONJ	O	O	4734
the	PRON	O	O	4734
onset	VERB	O	O	4734
of	ADP	O	O	4734
fatal	ADJ	O	O	4734
convulsions	NOUN	O	Disease	4734
by	ADP	O	O	4734
a	PRON	O	O	4734
factor	NOUN	O	O	4734
of	ADP	O	O	4734
about	ADP	O	O	4734
two	NUM	O	O	4734
;	PUNCT	O	O	4734
and	CCONJ	O	O	4734
2	X	O	O	4734
)	PUNCT	O	O	4734
pretreatment	NOUN	O	O	4734
with	ADP	O	O	4734
acetaminophen	PROPN	O	Chemical	4734
(	PUNCT	O	O	4734
75	NUM	O	O	4734
mg	VERB	O	O	4734
/	PUNCT	O	O	4734
kg	VERB	O	O	4734
)	PUNCT	O	O	4734
reduced	VERB	O	O	4734
the	PRON	O	O	4734
incidence	NOUN	O	O	4734
of	ADP	O	O	4734
audiogenic	ADJ	O	O	4734
seizures	NOUN	O	Disease	4734
produced	VERB	O	O	4734
in	ADP	O	O	4734
the	PRON	O	O	4734
presence	NOUN	O	O	4734
of	ADP	O	O	4734
caffeine	NOUN	O	Chemical	4734
(	PUNCT	O	O	4734
12.5	NUM	O	O	4734
to	PART	O	O	4734
75	NUM	O	O	4734
mg	VERB	O	O	4734
/	PUNCT	O	O	4734
kg	VERB	O	O	4734
IP	PROPN	O	O	4734
)	PUNCT	O	O	4734
.	PUNCT	O	O	4734
The	PRON	O	O	4735
frequency	NOUN	O	O	4735
of	ADP	O	O	4735
sound	NOUN	O	O	4735
-	PUNCT	O	O	4735
induced	VERB	O	O	4735
seizures	NOUN	O	Disease	4735
after	ADP	O	O	4735
12.5	NUM	O	O	4735
or	CCONJ	O	O	4735
25	NUM	O	O	4735
mg	VERB	O	O	4735
/	PUNCT	O	O	4735
kg	VERB	O	O	4735
caffeine	NOUN	O	Chemical	4735
was	AUX	O	O	4735
reduced	VERB	O	O	4735
from	ADP	O	O	4735
50	NUM	O	O	4735
to	PART	O	O	4735
5%	NOUN	O	O	4735
by	ADP	O	O	4735
acetaminophen	PROPN	O	Chemical	4735
.	PUNCT	O	O	4735
In	ADP	O	O	4736
the	PRON	O	O	4736
absence	NOUN	O	O	4736
of	ADP	O	O	4736
caffeine	NOUN	O	Chemical	4736
,	PUNCT	O	O	4736
acetaminophen	PROPN	O	Chemical	4736
(	PUNCT	O	O	4736
up	ADP	O	O	4736
to	PART	O	O	4736
300	NUM	O	O	4736
mg	VERB	O	O	4736
/	PUNCT	O	O	4736
kg	VERB	O	O	4736
)	PUNCT	O	O	4736
did	VERB	O	O	4736
not	PART	O	O	4736
modify	VERB	O	O	4736
the	PRON	O	O	4736
seizures	NOUN	O	Disease	4736
induced	VERB	O	O	4736
by	ADP	O	O	4736
maximal	ADJ	O	O	4736
electroshock	NOUN	O	O	4736
and	CCONJ	O	O	4736
did	VERB	O	O	4736
not	PART	O	O	4736
alter	VERB	O	O	4736
the	PRON	O	O	4736
convulsant	ADJ	O	O	4736
dose	NOUN	O	O	4736
of	ADP	O	O	4736
pentylenetetrezol	NOUN	O	O	4736
in	ADP	O	O	4736
mice	NOUN	O	O	4736
(	PUNCT	O	O	4736
tests	VERB	O	O	4736
performed	VERB	O	O	4736
by	ADP	O	O	4736
the	PRON	O	O	4736
Anticonvulsant	NOUN	O	O	4736
Screening	VERB	O	O	4736
Project	NOUN	O	O	4736
of	ADP	O	O	4736
NINCDS	PROPN	O	O	4736
)	PUNCT	O	O	4736
.	PUNCT	O	O	4736
Acetaminophen	PROPN	O	O	4737
(	PUNCT	O	O	4737
up	ADP	O	O	4737
to	PART	O	O	4737
150	NUM	O	O	4737
micrograms	NOUN	O	O	4737
/	PUNCT	O	O	4737
mL	PROPN	O	O	4737
)	PUNCT	O	O	4737
did	VERB	O	O	4737
not	PART	O	O	4737
retard	NOUN	O	O	4737
the	PRON	O	O	4737
incorporation	NOUN	O	O	4737
of	ADP	O	O	4737
radioactive	ADJ	O	O	4737
adenosine	PROPN	O	Chemical	4737
into	ADP	O	O	4737
ATP	PROPN	O	Chemical	4737
in	ADP	O	O	4737
slices	NOUN	O	O	4737
of	ADP	O	O	4737
rat	NOUN	O	O	4737
cerebral	ADJ	O	O	4737
cortex	VERB	O	O	4737
.	PUNCT	O	O	4737
Thus	ADV	O	O	4738
the	PRON	O	O	4738
mechanism	NOUN	O	O	4738
by	ADP	O	O	4738
which	PRON	O	O	4738
acetaminophen	PROPN	O	Chemical	4738
antagonizes	VERB	O	O	4738
the	PRON	O	O	4738
actions	NOUN	O	O	4738
of	ADP	O	O	4738
caffeine	NOUN	O	Chemical	4738
in	ADP	O	O	4738
the	PRON	O	O	4738
CNS	PROPN	O	O	4738
remains	VERB	O	O	4738
unknown	ADJ	O	O	4738
.	PUNCT	O	O	4738
Flestolol	NOUN	O	O	4741
:	PUNCT	O	O	4741
Flestolol	NOUN	O	O	4742
(	PUNCT	O	O	4742
ACC-9089	PROPN	O	O	4742
)	PUNCT	O	O	4742
is	AUX	O	O	4742
a	PRON	O	O	4742
nonselective	ADJ	O	O	4742
,	PUNCT	O	O	4742
competitive	ADJ	O	O	4742
,	PUNCT	O	O	4742
ultra	ADJ	O	O	4742
-	PUNCT	O	O	4742
short	ADJ	O	O	4742
-	PUNCT	O	O	4742
acting	VERB	O	O	4742
beta	NOUN	O	O	4742
-	PUNCT	O	O	4742
adrenergic	NOUN	O	O	4742
blocking	VERB	O	O	4742
agent	NOUN	O	O	4742
,	PUNCT	O	O	4742
without	ADP	O	O	4742
any	PRON	O	O	4742
intrinsic	ADJ	O	O	4742
sympathomimetic	ADJ	O	O	4742
activity	NOUN	O	O	4742
.	PUNCT	O	O	4742
Flestolol	NOUN	O	O	4743
is	AUX	O	O	4743
metabolized	VERB	O	O	4743
by	ADP	O	O	4743
plasma	NOUN	O	O	4743
esterases	VERB	O	O	4743
and	CCONJ	O	O	4743
has	VERB	O	O	4743
an	PRON	O	O	4743
elimination	NOUN	O	O	4743
half	NOUN	O	O	4743
-	PUNCT	O	O	4743
life	NOUN	O	O	4743
of	ADP	O	O	4743
approximately	ADV	O	O	4743
6.5	NUM	O	O	4743
minutes	NOUN	O	O	4743
.	PUNCT	O	O	4743
In	ADP	O	O	4744
long	ADV	O	O	4744
-	PUNCT	O	O	4744
term	NOUN	O	O	4744
infusion	NOUN	O	O	4744
studies	NOUN	O	O	4744
,	PUNCT	O	O	4744
flestolol	PROPN	O	O	4744
was	AUX	O	O	4744
well	ADV	O	O	4744
tolerated	VERB	O	O	4744
at	ADP	O	O	4744
the	PRON	O	O	4744
effective	ADJ	O	O	4744
beta	NOUN	O	O	4744
-	PUNCT	O	O	4744
blocking	VERB	O	O	4744
dose	NOUN	O	O	4744
(	PUNCT	O	O	4744
5	NUM	O	O	4744
micrograms	NOUN	O	O	4744
/	PUNCT	O	O	4744
kg	VERB	O	O	4744
/	PUNCT	O	O	4744
min	NOUN	O	O	4744
)	PUNCT	O	O	4744
for	ADP	O	O	4744
up	ADP	O	O	4744
to	PART	O	O	4744
seven	NUM	O	O	4744
days	NOUN	O	O	4744
.	PUNCT	O	O	4744
Flestolol	NOUN	O	O	4745
blood	NOUN	O	O	4745
concentrations	NOUN	O	O	4745
increased	VERB	O	O	4745
linearly	ADV	O	O	4745
with	ADP	O	O	4745
increasing	VERB	O	O	4745
dose	NOUN	O	O	4745
and	CCONJ	O	O	4745
good	ADJ	O	O	4745
correlation	NOUN	O	O	4745
exists	VERB	O	O	4745
between	ADP	O	O	4745
blood	NOUN	O	O	4745
concentrations	NOUN	O	O	4745
of	ADP	O	O	4745
flestolol	PROPN	O	O	4745
and	CCONJ	O	O	4745
beta	NOUN	O	O	4745
-	PUNCT	O	O	4745
adrenergic	NOUN	O	O	4745
blockade	VERB	O	O	4745
.	PUNCT	O	O	4745
Flestolol	NOUN	O	O	4746
produced	VERB	O	O	4746
a	PRON	O	O	4746
dose	NOUN	O	O	4746
-	PUNCT	O	O	4746
dependent	ADJ	O	O	4746
attenuation	NOUN	O	O	4746
of	ADP	O	O	4746
isoproterenol	NOUN	O	Chemical	4746
-	PUNCT	O	O	4746
induced	VERB	O	O	4746
tachycardia	PROPN	O	Disease	4746
.	PUNCT	O	O	4746
Electrophysiologic	PROPN	O	O	4747
and	CCONJ	O	O	4747
hemodynamic	ADJ	O	O	4747
effects	NOUN	O	O	4747
of	ADP	O	O	4747
flestolol	PROPN	O	O	4747
are	AUX	O	O	4747
similar	ADJ	O	O	4747
to	PART	O	O	4747
those	PRON	O	O	4747
of	ADP	O	O	4747
other	ADJ	O	O	4747
beta	NOUN	O	O	4747
blockers	NOUN	O	O	4747
.	PUNCT	O	O	4747
In	ADP	O	O	4748
contrast	NOUN	O	O	4748
with	ADP	O	O	4748
other	ADJ	O	O	4748
beta	NOUN	O	O	4748
blockers	NOUN	O	O	4748
,	PUNCT	O	O	4748
flestolol	PROPN	O	O	4748
-	PUNCT	O	O	4748
induced	VERB	O	O	4748
effects	NOUN	O	O	4748
reverse	VERB	O	O	4748
rapidly	ADV	O	O	4748
(	PUNCT	O	O	4748
within	ADP	O	O	4748
30	NUM	O	O	4748
minutes	NOUN	O	O	4748
)	PUNCT	O	O	4748
following	VERB	O	O	4748
discontinuation	NOUN	O	O	4748
because	SCONJ	O	O	4748
of	ADP	O	O	4748
its	PRON	O	O	4748
short	ADJ	O	O	4748
half	NOUN	O	O	4748
-	PUNCT	O	O	4748
life	NOUN	O	O	4748
.	PUNCT	O	O	4748
Flestolol	NOUN	O	O	4749
effectively	ADV	O	O	4749
reduced	VERB	O	O	4749
heart	NOUN	O	O	4749
rate	NOUN	O	O	4749
in	ADP	O	O	4749
patients	NOUN	O	O	4749
with	ADP	O	O	4749
supraventricular	ADJ	O	O	4749
tachyarrhythmia	ADV	O	O	4749
.	PUNCT	O	O	4749
In	ADP	O	O	4750
patients	NOUN	O	O	4750
with	ADP	O	O	4750
unstable angina	NOUN	O	O	4750
,	PUNCT	O	O	4750
flestolol	PROPN	O	O	4750
infusion	NOUN	O	O	4750
was	AUX	O	O	4750
found	VERB	O	O	4750
to	PART	O	O	4750
be	AUX	O	O	4750
safe	ADJ	O	O	4750
and	CCONJ	O	O	4750
effective	ADJ	O	O	4750
in	ADP	O	O	4750
controlling	VERB	O	O	4750
chest pain	NOUN	O	Disease	4750
.	PUNCT	O	O	4750
It	PRON	O	O	4751
is	AUX	O	O	4751
concluded	VERB	O	O	4751
that	SCONJ	O	O	4751
flestolol	PROPN	O	O	4751
is	AUX	O	O	4751
a	PRON	O	O	4751
potent	ADJ	O	O	4751
,	PUNCT	O	O	4751
well	ADV	O	O	4751
-	PUNCT	O	O	4751
tolerated	VERB	O	O	4751
,	PUNCT	O	O	4751
ultra	ADJ	O	O	4751
-	PUNCT	O	O	4751
short	ADJ	O	O	4751
-	PUNCT	O	O	4751
acting	VERB	O	O	4751
beta	NOUN	O	O	4751
-	PUNCT	O	O	4751
adrenergic	NOUN	O	O	4751
blocking	VERB	O	O	4751
agent	NOUN	O	O	4751
.	PUNCT	O	O	4751
Use	VERB	O	O	4752
of	ADP	O	O	4752
flestolol	PROPN	O	O	4752
in	ADP	O	O	4752
the	PRON	O	O	4752
critical	ADJ	O	O	4752
care	VERB	O	O	4752
setting	VERB	O	O	4752
is	AUX	O	O	4752
currently	ADV	O	O	4752
undergoing	VERB	O	O	4752
investigation	NOUN	O	O	4752
.	PUNCT	O	O	4752
Adverse	ADJ	O	O	4755
effect	VERB	O	O	4755
of	ADP	O	O	4755
the	PRON	O	O	4755
calcium	NOUN	O	Chemical	4755
channel	PROPN	O	O	4755
blocker	NOUN	O	O	4755
nitrendipine	ADJ	O	O	4755
on	ADP	O	O	4755
nephrosclerosis	VERB	O	O	4755
in	ADP	O	O	4755
rats	NOUN	O	O	4755
with	ADP	O	O	4755
renovascular	NOUN	O	O	4755
hypertension	NOUN	O	Disease	4755
.	PUNCT	O	O	4755
The	PRON	O	O	4756
effect	VERB	O	O	4756
of	ADP	O	O	4756
a	PRON	O	O	4756
6-week	NOUN	O	O	4756
treatment	NOUN	O	O	4756
with	ADP	O	O	4756
the	PRON	O	O	4756
calcium	NOUN	O	Chemical	4756
channel	PROPN	O	O	4756
blocker	NOUN	O	O	4756
nitrendipine	ADJ	O	O	4756
or	CCONJ	O	O	4756
the	PRON	O	O	4756
angiotensin	NOUN	O	Chemical	4756
converting	VERB	O	O	4756
enzyme	NOUN	O	O	4756
inhibitor	NOUN	O	O	4756
enalapril	PROPN	O	Chemical	4756
on	ADP	O	O	4756
blood	NOUN	O	O	4756
pressure	NOUN	O	O	4756
,	PUNCT	O	O	4756
albuminuria	PROPN	O	Disease	4756
,	PUNCT	O	O	4756
renal	ADJ	O	O	4756
hemodynamics	NOUN	O	O	4756
,	PUNCT	O	O	4756
and	CCONJ	O	O	4756
morphology	NOUN	O	O	4756
of	ADP	O	O	4756
the	PRON	O	O	4756
nonclipped	VERB	O	O	4756
kidney	NOUN	O	O	4756
was	AUX	O	O	4756
studied	VERB	O	O	4756
in	ADP	O	O	4756
rats	NOUN	O	O	4756
with	ADP	O	O	4756
two	NUM	O	O	4756
-	PUNCT	O	O	4756
kidney	NOUN	O	O	4756
,	PUNCT	O	O	4756
one	NUM	O	O	4756
clip	NOUN	O	O	4756
renovascular	NOUN	O	O	4756
hypertension	NOUN	O	Disease	4756
.	PUNCT	O	O	4756
Six	NUM	O	O	4757
weeks	NOUN	O	O	4757
after	ADP	O	O	4757
clipping	VERB	O	O	4757
of	ADP	O	O	4757
one	NUM	O	O	4757
renal	ADJ	O	O	4757
artery	NOUN	O	O	4757
,	PUNCT	O	O	4757
hypertensive	ADJ	O	Disease	4757
rats	NOUN	O	O	4757
(	PUNCT	O	O	4757
178	NUM	O	O	4757
+	ADP	O	O	4757
/-	PUNCT	O	O	4757
4	NUM	O	O	4758
mm	INTJ	O	O	4758
Hg	PROPN	O	O	4758
)	PUNCT	O	O	4758
were	AUX	O	O	4758
randomly	ADV	O	O	4758
assigned	VERB	O	O	4758
to	PART	O	O	4758
three	NUM	O	O	4758
groups	NOUN	O	O	4758
:	PUNCT	O	O	4758
untreated	ADJ	O	O	4758
hypertensive	ADJ	O	Disease	4758
controls	VERB	O	O	4758
(	PUNCT	O	O	4758
n	CCONJ	O	O	4758
=	PUNCT	O	O	4758
8)	NUM	O	O	4758
,	PUNCT	O	O	4758
enalapril	PROPN	O	Chemical	4758
-	PUNCT	O	O	4758
treated	VERB	O	O	4758
(	PUNCT	O	O	4758
n	CCONJ	O	O	4758
=	PUNCT	O	O	4758
8)	NUM	O	O	4758
,	PUNCT	O	O	4758
or	CCONJ	O	O	4758
nitrendipine	ADJ	O	O	4758
-	PUNCT	O	O	4758
treated	VERB	O	O	4758
(	PUNCT	O	O	4758
Enalapril	PROPN	O	Chemical	4759
but	CCONJ	O	O	4759
not	PART	O	O	4759
nitrendipine	ADJ	O	O	4759
reduced	VERB	O	O	4759
blood	NOUN	O	O	4759
pressure	NOUN	O	O	4759
significantly	ADV	O	O	4759
.	PUNCT	O	O	4759
Renal	NOUN	O	O	4760
plasma	NOUN	O	O	4760
flow	NOUN	O	O	4760
increased	VERB	O	O	4760
,	PUNCT	O	O	4760
but	CCONJ	O	O	4760
albumin	PROPN	O	O	4760
excretion	NOUN	O	O	4760
and	CCONJ	O	O	4760
glomerulosclerosis	PROPN	O	O	4760
did	VERB	O	O	4760
not	PART	O	O	4760
change	VERB	O	O	4760
after	ADP	O	O	4760
enalapril	PROPN	O	Chemical	4760
treatment	NOUN	O	O	4760
.	PUNCT	O	O	4760
In	ADP	O	O	4761
contrast	NOUN	O	O	4761
,	PUNCT	O	O	4761
in	ADP	O	O	4761
the	PRON	O	O	4761
nitrendipine	ADJ	O	O	4761
-	PUNCT	O	O	4761
treated	VERB	O	O	4761
group	NOUN	O	O	4761
albuminuria	PROPN	O	Disease	4761
increased	VERB	O	O	4761
from	ADP	O	O	4761
12.8	NUM	O	O	4761
+	ADP	O	O	4761
/-	PUNCT	O	O	4761
9	NUM	O	O	4762
mg/24	NOUN	O	O	4762
hr	NOUN	O	O	4762
in	ADP	O	O	4762
the	PRON	O	O	4762
hypertensive	ADJ	O	Disease	4762
controls	VERB	O	O	4762
.	PUNCT	O	O	4762
Furthermore	ADV	O	O	4763
,	PUNCT	O	O	4763
glomerulosclerosis	PROPN	O	O	4763
index	NOUN	O	O	4763
was	AUX	O	O	4763
significantly	ADV	O	O	4763
increased	VERB	O	O	4763
in	ADP	O	O	4763
the	PRON	O	O	4763
nitrendipine	ADJ	O	O	4763
-	PUNCT	O	O	4763
treated	VERB	O	O	4763
group	NOUN	O	O	4763
compared	VERB	O	O	4763
with	ADP	O	O	4763
the	PRON	O	O	4763
hypertensive	ADJ	O	Disease	4763
controls	VERB	O	O	4763
(	PUNCT	O	O	4763
0.38	NUM	O	O	4763
+	ADP	O	O	4763
/-	PUNCT	O	O	4763
In	ADP	O	O	4764
addition	NOUN	O	O	4764
,	PUNCT	O	O	4764
glomerular	ADJ	O	O	4764
size	NOUN	O	O	4764
was	AUX	O	O	4764
higher	ADJ	O	O	4764
in	ADP	O	O	4764
the	PRON	O	O	4764
nitrendipine	ADJ	O	O	4764
-	PUNCT	O	O	4764
treated	VERB	O	O	4764
group	NOUN	O	O	4764
(	PUNCT	O	O	4764
14.9	NUM	O	O	4764
+	ADP	O	O	4764
/-	PUNCT	O	O	4764
0.17	NUM	O	O	4765
10(-3	PROPN	O	O	4765
)	PUNCT	O	O	4765
mm2	NUM	O	O	4765
)	PUNCT	O	O	4765
but	CCONJ	O	O	4765
lower	ADJ	O	O	4765
in	ADP	O	O	4765
the	PRON	O	O	4765
enalapril	PROPN	O	Chemical	4765
-	PUNCT	O	O	4765
treated	VERB	O	O	4765
group	NOUN	O	O	4765
(	PUNCT	O	O	4765
11.5	NUM	O	O	4765
+	ADP	O	O	4765
/-	PUNCT	O	O	4765
mm2	NUM	O	O	4766
)	PUNCT	O	O	4766
compared	VERB	O	O	4766
with	ADP	O	O	4766
the	PRON	O	O	4766
hypertensive	ADJ	O	Disease	4766
controls	VERB	O	O	4766
(	PUNCT	O	O	4766
12.1	NUM	O	O	4766
+	ADP	O	O	4766
/-	PUNCT	O	O	4766
Treatment	NOUN	O	O	4769
of	ADP	O	O	4769
tinnitus	PROPN	O	O	4769
by	ADP	O	O	4769
intratympanic	NOUN	O	O	4769
instillation	NOUN	O	O	4769
of	ADP	O	O	4769
lignocaine	NOUN	O	Chemical	4769
(	PUNCT	O	O	4769
lidocaine	NOUN	O	Chemical	4769
)	PUNCT	O	O	4769
2	X	O	O	4769
per	ADP	O	O	4769
cent	NOUN	O	O	4769
through	ADP	O	O	4769
ventilation	NOUN	O	O	4769
tubes	NOUN	O	O	4769
.	PUNCT	O	O	4769
Idiopathic	ADJ	O	O	4770
subjective	ADJ	O	O	4770
tinnitus	PROPN	O	O	4770
(	PUNCT	O	O	4770
IST	PROPN	O	O	4770
)	PUNCT	O	O	4770
is	AUX	O	O	4770
one	NUM	O	O	4770
of	ADP	O	O	4770
the	PRON	O	O	4770
most	ADV	O	O	4770
obscure	ADJ	O	O	4770
otological	ADJ	O	O	4770
pathologies	NOUN	O	O	4770
.	PUNCT	O	O	4770
This	PRON	O	O	4771
paper	PROPN	O	O	4771
presents	VERB	O	O	4771
the	PRON	O	O	4771
results	VERB	O	O	4771
of	ADP	O	O	4771
treating	VERB	O	O	4771
IST	PROPN	O	O	4771
by	ADP	O	O	4771
intratympanic	NOUN	O	O	4771
instillation	NOUN	O	O	4771
of	ADP	O	O	4771
lignocaine	NOUN	O	Chemical	4771
(	PUNCT	O	O	4771
lidocaine	NOUN	O	Chemical	4771
)	PUNCT	O	O	4771
2	X	O	O	4771
per	ADP	O	O	4771
cent	NOUN	O	O	4771
through	ADP	O	O	4771
a	PRON	O	O	4771
grommet	NOUN	O	O	4771
,	PUNCT	O	O	4771
for	ADP	O	O	4771
five	NUM	O	O	4771
weekly	ADV	O	O	4771
courses	NOUN	O	O	4771
.	PUNCT	O	O	4771
Fifty	NUM	O	O	4772
-	PUNCT	O	O	4772
two	NUM	O	O	4772
patients	NOUN	O	O	4772
suffering	VERB	O	O	4772
from	ADP	O	O	4772
intractable	ADJ	O	O	4772
tinnitus	PROPN	O	O	4772
entered	VERB	O	O	4772
this	PRON	O	O	4772
therapeutic	ADJ	O	O	4772
trial	NOUN	O	O	4772
,	PUNCT	O	O	4772
but	CCONJ	O	O	4772
only	ADV	O	O	4772
nine	NUM	O	O	4772
finished	VERB	O	O	4772
all	PRON	O	O	4772
five	NUM	O	O	4772
courses	NOUN	O	O	4772
.	PUNCT	O	O	4772
In	ADP	O	O	4773
one	NUM	O	O	4773
patient	NOUN	O	O	4773
,	PUNCT	O	O	4773
the	PRON	O	O	4773
tinnitus	PROPN	O	O	4773
was	AUX	O	O	4773
almost	ADV	O	O	4773
completely	ADV	O	O	4773
abolished	VERB	O	O	4773
,	PUNCT	O	O	4773
but	CCONJ	O	O	4773
in	ADP	O	O	4773
all	PRON	O	O	4773
the	PRON	O	O	4773
nine	NUM	O	O	4773
patients	NOUN	O	O	4773
the	PRON	O	O	4773
decompensated	VERB	O	O	4773
tinnitus	PROPN	O	O	4773
changed	VERB	O	O	4773
to	PART	O	O	4773
a	PRON	O	O	4773
compensated	VERB	O	O	4773
one	NUM	O	O	4773
.	PUNCT	O	O	4773
Patients	NOUN	O	O	4774
should	AUX	O	O	4774
be	AUX	O	O	4774
warned	VERB	O	O	4774
about	ADP	O	O	4774
the	PRON	O	O	4774
side	NOUN	O	O	4774
effects	NOUN	O	O	4774
of	ADP	O	O	4774
vertigo	PROPN	O	O	4774
and	CCONJ	O	O	4774
vomiting	VERB	O	Disease	4774
,	PUNCT	O	O	4774
which	PRON	O	O	4774
subsides	VERB	O	O	4774
gradually	ADV	O	O	4774
with	ADP	O	O	4774
every	PRON	O	O	4774
new	ADJ	O	O	4774
instillation	NOUN	O	O	4774
,	PUNCT	O	O	4774
and	CCONJ	O	O	4774
that	SCONJ	O	O	4774
the	PRON	O	O	4774
tinnitus	PROPN	O	O	4774
may	AUX	O	O	4774
not	PART	O	O	4774
disappear	VERB	O	O	4774
but	CCONJ	O	O	4774
will	AUX	O	O	4774
be	AUX	O	O	4774
alleviated	VERB	O	O	4774
,	PUNCT	O	O	4774
enabling	VERB	O	O	4774
them	PRON	O	O	4774
to	PART	O	O	4774
cope	VERB	O	O	4774
more	ADJ	O	O	4774
easily	ADV	O	O	4774
with	ADP	O	O	4774
the	PRON	O	O	4774
disease	PROPN	O	O	4774
and	CCONJ	O	O	4774
lead	VERB	O	Chemical	4774
a	PRON	O	O	4774
more	ADJ	O	O	4774
normal	ADJ	O	O	4774
life	NOUN	O	O	4774
.	PUNCT	O	O	4774
Perhexiline	PROPN	O	O	4777
maleate	NOUN	O	O	4777
and	CCONJ	O	O	4777
peripheral neuropathy	NOUN	O	Disease	4777
.	PUNCT	O	O	4777
Peripheral neuropathy	NOUN	O	Disease	4778
has	VERB	O	O	4778
been	AUX	O	O	4778
noted	VERB	O	O	4778
as	ADP	O	O	4778
a	PRON	O	O	4778
complication	NOUN	O	O	4778
of	ADP	O	O	4778
therapy	NOUN	O	O	4778
with	ADP	O	O	4778
perhexiline	NOUN	O	O	4778
maleate	NOUN	O	O	4778
,	PUNCT	O	O	4778
a	PRON	O	O	4778
drug	NOUN	O	O	4778
widely	ADV	O	O	4778
used	VERB	O	O	4778
in	ADP	O	O	4778
France	PROPN	O	O	4778
(	PUNCT	O	O	4778
and	CCONJ	O	O	4778
in	ADP	O	O	4778
clinical	ADJ	O	O	4778
trials	NOUN	O	O	4778
in	ADP	O	O	4778
the	PRON	O	O	4778
United	PROPN	O	O	4778
States	NOUN	O	O	4778
)	PUNCT	O	O	4778
for	ADP	O	O	4778
the	PRON	O	O	4778
prophylactic	ADJ	O	O	4778
treatment	NOUN	O	O	4778
of	ADP	O	O	4778
angina	NOUN	O	Disease	4778
pectoris	VERB	O	O	4778
.	PUNCT	O	O	4778
In	ADP	O	O	4779
24	NUM	O	O	4779
patients	NOUN	O	O	4779
with	ADP	O	O	4779
this	PRON	O	O	4779
complication	NOUN	O	O	4779
,	PUNCT	O	O	4779
the	PRON	O	O	4779
marked	VERB	O	O	4779
slowing	VERB	O	O	4779
of	ADP	O	O	4779
motor	NOUN	O	O	4779
nerve	NOUN	O	O	4779
conduction	NOUN	O	O	4779
velocity	NOUN	O	O	4779
and	CCONJ	O	O	4779
the	PRON	O	O	4779
electromyographic	ADJ	O	O	4779
changes	VERB	O	O	4779
imply	VERB	O	O	4779
mainly	ADV	O	O	4779
a	PRON	O	O	4779
demyelinating	VERB	O	O	4779
disorder	NOUN	O	O	4779
.	PUNCT	O	O	4779
The	PRON	O	O	4780
underlying	VERB	O	O	4780
mechanism	NOUN	O	O	4780
causing	VERB	O	O	4780
the	PRON	O	O	4780
neuropathy	NOUN	O	Disease	4780
is	AUX	O	O	4780
not	PART	O	O	4780
yet	ADV	O	O	4780
fully	ADV	O	O	4780
known	VERB	O	O	4780
,	PUNCT	O	O	4780
although	SCONJ	O	O	4780
some	PRON	O	O	4780
evidence	NOUN	O	O	4780
indicates	VERB	O	O	4780
that	SCONJ	O	O	4780
it	PRON	O	O	4780
may	AUX	O	O	4780
be	AUX	O	O	4780
a	PRON	O	O	4780
lipid	NOUN	O	O	4780
storage	NOUN	O	O	4780
process	NOUN	O	O	4780
.	PUNCT	O	O	4780
Effect	VERB	O	O	4783
of	ADP	O	O	4783
humoral	ADJ	O	O	4783
modulators	NOUN	O	O	4783
of	ADP	O	O	4783
morphine	NOUN	O	Chemical	4783
-	PUNCT	O	O	4783
induced	VERB	O	O	4783
increase	VERB	O	O	4783
in	ADP	O	O	4783
locomotor	PROPN	O	O	4783
activity	NOUN	O	O	4783
of	ADP	O	O	4783
mice	NOUN	O	O	4783
.	PUNCT	O	O	4783
The	PRON	O	O	4784
effect	VERB	O	O	4784
of	ADP	O	O	4784
humoral	ADJ	O	O	4784
modulators	NOUN	O	O	4784
on	ADP	O	O	4784
the	PRON	O	O	4784
morphine	NOUN	O	Chemical	4784
-	PUNCT	O	O	4784
induced	VERB	O	O	4784
increase	VERB	O	O	4784
in	ADP	O	O	4784
locomotor	PROPN	O	O	4784
activity	NOUN	O	O	4784
of	ADP	O	O	4784
mice	NOUN	O	O	4784
was	AUX	O	O	4784
studied	VERB	O	O	4784
.	PUNCT	O	O	4784
The	PRON	O	O	4785
subcutaneous	ADJ	O	O	4785
administration	NOUN	O	O	4785
of	ADP	O	O	4785
10	NUM	O	O	4785
mg	VERB	O	O	4785
/	PUNCT	O	O	4785
kg	VERB	O	O	4785
of	ADP	O	O	4785
morphine	NOUN	O	Chemical	4785
-	PUNCT	O	O	4785
HC1	PROPN	O	O	4785
produced	VERB	O	O	4785
a	PRON	O	O	4785
marked	VERB	O	O	4785
increase	VERB	O	O	4785
in	ADP	O	O	4785
locomotor	PROPN	O	O	4785
activity	NOUN	O	O	4785
in	ADP	O	O	4785
mice	NOUN	O	O	4785
.	PUNCT	O	O	4785
The	PRON	O	O	4786
morphine	NOUN	O	Chemical	4786
-	PUNCT	O	O	4786
induced	VERB	O	O	4786
hyperactivity	NOUN	O	Disease	4786
was	AUX	O	O	4786
potentiated	VERB	O	O	4786
by	ADP	O	O	4786
scopolamine	NOUN	O	Chemical	4786
and	CCONJ	O	O	4786
attenuated	VERB	O	O	4786
by	ADP	O	O	4786
physostigmine	NOUN	O	Chemical	4786
.	PUNCT	O	O	4786
In	ADP	O	O	4787
contrast	NOUN	O	O	4787
,	PUNCT	O	O	4787
both	PRON	O	O	4787
methscopolamine	NOUN	O	O	4787
and	CCONJ	O	O	4787
neostigmine	NOUN	O	O	4787
,	PUNCT	O	O	4787
which	PRON	O	O	4787
do	VERB	O	O	4787
not	PART	O	O	4787
penetrate	VERB	O	O	4787
the	PRON	O	O	4787
blood	NOUN	O	O	4787
-	PUNCT	O	O	4787
brain	NOUN	O	O	4787
barrier	NOUN	O	O	4787
,	PUNCT	O	O	4787
had	VERB	O	O	4787
no	PRON	O	O	4787
effect	VERB	O	O	4787
on	ADP	O	O	4787
the	PRON	O	O	4787
hyperactivity	NOUN	O	Disease	4787
produced	VERB	O	O	4787
by	ADP	O	O	4787
morphine	NOUN	O	Chemical	4787
.	PUNCT	O	O	4787
Pretreatment	NOUN	O	O	4788
of	ADP	O	O	4788
mice	NOUN	O	O	4788
with	ADP	O	O	4788
alpha	PROPN	O	O	4788
-	PUNCT	O	O	4788
methyltyrosine	PROPN	O	O	4788
(	PUNCT	O	O	4788
20	NUM	O	O	4788
mg	VERB	O	O	4788
/	PUNCT	O	O	4788
kg	VERB	O	O	4788
i.p	NOUN	O	O	4788
.	PUNCT	O	O	4788
,	PUNCT	O	O	4789
one	NUM	O	O	4789
hour	NOUN	O	O	4789
)	PUNCT	O	O	4789
,	PUNCT	O	O	4789
an	PRON	O	O	4789
inhibitor	NOUN	O	O	4789
of	ADP	O	O	4789
tyrosine	NOUN	O	Chemical	4789
hydroxylase	NOUN	O	O	4789
,	PUNCT	O	O	4789
significantly	ADV	O	O	4789
decreased	VERB	O	O	4789
the	PRON	O	O	4789
activity	NOUN	O	O	4789
-	PUNCT	O	O	4789
increasing	VERB	O	O	4789
effects	NOUN	O	O	4789
of	ADP	O	O	4789
morphine	NOUN	O	Chemical	4789
.	PUNCT	O	O	4789
On	ADP	O	O	4790
the	PRON	O	O	4790
other	ADJ	O	O	4790
hand	NOUN	O	O	4790
,	PUNCT	O	O	4790
pretreatment	NOUN	O	O	4790
with	ADP	O	O	4790
p	NOUN	O	O	4790
-	PUNCT	O	O	4790
chlorophenylalamine	PROPN	O	O	4790
(	PUNCT	O	O	4790
3	X	O	O	4790
X	NOUN	O	O	4790
320	NUM	O	O	4790
mg	VERB	O	O	4790
/	PUNCT	O	O	4790
kg	VERB	O	O	4790
i.p	NOUN	O	O	4790
.	PUNCT	O	O	4790
,	PUNCT	O	O	4791
24	NUM	O	O	4791
hr	NOUN	O	O	4791
)	PUNCT	O	O	4791
,	PUNCT	O	O	4791
a	PRON	O	O	4791
serotonin	PROPN	O	Chemical	4791
depletor	PROPN	O	O	4791
,	PUNCT	O	O	4791
caused	VERB	O	O	4791
no	PRON	O	O	4791
significant	ADJ	O	O	4791
change	VERB	O	O	4791
in	ADP	O	O	4791
the	PRON	O	O	4791
hyperactivity	NOUN	O	Disease	4791
.	PUNCT	O	O	4791
The	PRON	O	O	4792
study	VERB	O	O	4792
suggests	VERB	O	O	4792
that	SCONJ	O	O	4792
the	PRON	O	O	4792
activity	NOUN	O	O	4792
-	PUNCT	O	O	4792
increasing	VERB	O	O	4792
effects	NOUN	O	O	4792
of	ADP	O	O	4792
morphine	NOUN	O	Chemical	4792
are	AUX	O	O	4792
mediated	VERB	O	O	4792
by	ADP	O	O	4792
the	PRON	O	O	4792
release	NOUN	O	O	4792
of	ADP	O	O	4792
catecholamines	NOUN	O	Chemical	4792
from	ADP	O	O	4792
adrenergic	NOUN	O	O	4792
neurons	NOUN	O	O	4792
in	ADP	O	O	4792
the	PRON	O	O	4792
brain	NOUN	O	O	4792
.	PUNCT	O	O	4792
And	CCONJ	O	O	4793
the	PRON	O	O	4793
results	VERB	O	O	4793
are	AUX	O	O	4793
consistent	ADJ	O	O	4793
with	ADP	O	O	4793
the	PRON	O	O	4793
hypothesis	NOUN	O	O	4793
that	SCONJ	O	O	4793
morphine	NOUN	O	Chemical	4793
acts	VERB	O	O	4793
by	ADP	O	O	4793
retarding	VERB	O	O	4793
the	PRON	O	O	4793
release	NOUN	O	O	4793
of	ADP	O	O	4793
acetylcholine	NOUN	O	Chemical	4793
at	ADP	O	O	4793
some	PRON	O	O	4793
central	ADJ	O	O	4793
cholinergic	ADJ	O	O	4793
synapses	NOUN	O	O	4793
.	PUNCT	O	O	4793
It	PRON	O	O	4794
is	AUX	O	O	4794
also	ADV	O	O	4794
suggested	VERB	O	O	4794
from	ADP	O	O	4794
collected	VERB	O	O	4794
evidence	NOUN	O	O	4794
that	SCONJ	O	O	4794
the	PRON	O	O	4794
activity	NOUN	O	O	4794
-	PUNCT	O	O	4794
increasing	VERB	O	O	4794
effects	NOUN	O	O	4794
of	ADP	O	O	4794
morphine	NOUN	O	Chemical	4794
in	ADP	O	O	4794
mice	NOUN	O	O	4794
are	AUX	O	O	4794
mediated	VERB	O	O	4794
by	ADP	O	O	4794
mechanisms	NOUN	O	O	4794
different	ADJ	O	O	4794
from	ADP	O	O	4794
those	PRON	O	O	4794
which	PRON	O	O	4794
mediate	VERB	O	O	4794
the	PRON	O	O	4794
activity	NOUN	O	O	4794
-	PUNCT	O	O	4794
increasing	VERB	O	O	4794
effects	NOUN	O	O	4794
of	ADP	O	O	4794
morphine	NOUN	O	Chemical	4794
in	ADP	O	O	4794
rats	NOUN	O	O	4794
.	PUNCT	O	O	4794
Mechanisms	NOUN	O	O	4797
of	ADP	O	O	4797
FK	PROPN	O	O	4797
506-induced	VERB	O	O	4797
hypertension	NOUN	O	Disease	4797
in	ADP	O	O	4797
the	PRON	O	O	4797
rat	NOUN	O	O	4797
.	PUNCT	O	O	4797
-Tacrolimus	NOUN	O	O	4798
(	PUNCT	O	O	4798
FK	PROPN	O	O	4798
506	NUM	O	O	4798
)	PUNCT	O	O	4798
is	AUX	O	O	4798
a	PRON	O	O	4798
powerful	ADJ	O	O	4798
,	PUNCT	O	O	4798
widely	ADV	O	O	4798
used	VERB	O	O	4798
immunosuppressant	ADJ	O	O	4798
.	PUNCT	O	O	4798
The	PRON	O	O	4799
clinical	ADJ	O	O	4799
utility	NOUN	O	O	4799
of	ADP	O	O	4799
FK	PROPN	O	O	4799
506	NUM	O	O	4799
is	AUX	O	O	4799
complicated	VERB	O	O	4799
by	ADP	O	O	4799
substantial	ADJ	O	O	4799
hypertension	NOUN	O	Disease	4799
and	CCONJ	O	O	4799
nephrotoxicity	NOUN	O	Disease	4799
.	PUNCT	O	O	4799
To	PART	O	O	4800
clarify	VERB	O	O	4800
the	PRON	O	O	4800
mechanisms	NOUN	O	O	4800
of	ADP	O	O	4800
FK	PROPN	O	O	4800
506-induced	VERB	O	O	4800
hypertension	NOUN	O	Disease	4800
,	PUNCT	O	O	4800
we	PRON	O	O	4800
studied	VERB	O	O	4800
the	PRON	O	O	4800
chronic	ADJ	O	O	4800
effects	NOUN	O	O	4800
of	ADP	O	O	4800
FK	PROPN	O	O	4800
506	NUM	O	O	4800
on	ADP	O	O	4800
the	PRON	O	O	4800
synthesis	NOUN	O	O	4800
of	ADP	O	O	4800
endothelin-1	NUM	O	O	4800
(	PUNCT	O	O	4800
ET-1	ADV	O	O	4800
)	PUNCT	O	O	4800
,	PUNCT	O	O	4800
the	PRON	O	O	4800
expression	NOUN	O	O	4800
of	ADP	O	O	4800
mRNA	PROPN	O	O	4800
of	ADP	O	O	4800
ET-1	ADV	O	O	4800
and	CCONJ	O	O	4800
endothelin	PROPN	O	O	4800
-	PUNCT	O	O	4800
converting	VERB	O	O	4800
enzyme-1	PUNCT	O	O	4800
(	PUNCT	O	O	4800
ECE-1	NUM	O	O	4800
)	PUNCT	O	O	4800
,	PUNCT	O	O	4800
the	PRON	O	O	4800
endothelial	NOUN	O	O	4800
nitric oxide	NOUN	O	Chemical	4800
synthase	NOUN	O	O	4800
(	PUNCT	O	O	4800
eNOS	NUM	O	O	4800
)	PUNCT	O	O	4800
activity	NOUN	O	O	4800
,	PUNCT	O	O	4800
and	CCONJ	O	O	4800
the	PRON	O	O	4800
expression	NOUN	O	O	4800
of	ADP	O	O	4800
mRNA	PROPN	O	O	4800
of	ADP	O	O	4800
eNOS	NUM	O	O	4800
and	CCONJ	O	O	4800
C	NOUN	O	O	4800
-	PUNCT	O	O	4800
type	NOUN	O	O	4800
natriuretic	ADJ	O	O	4800
peptide	NOUN	O	O	4800
(	PUNCT	O	O	4800
CNP	PROPN	O	O	4800
)	PUNCT	O	O	4800
in	ADP	O	O	4800
rat	NOUN	O	O	4800
blood	NOUN	O	O	4800
vessels	NOUN	O	O	4800
.	PUNCT	O	O	4800
In	ADP	O	O	4801
addition	NOUN	O	O	4801
,	PUNCT	O	O	4801
the	PRON	O	O	4801
effect	VERB	O	O	4801
of	ADP	O	O	4801
the	PRON	O	O	4801
specific	ADJ	O	O	4801
endothelin	PROPN	O	O	4801
type	NOUN	O	O	4801
A	PRON	O	O	4801
receptor	NOUN	O	O	4801
antagonist	NOUN	O	O	4801
FR	PROPN	O	O	4801
139317	NUM	O	O	4801
on	ADP	O	O	4801
FK	PROPN	O	O	4801
506-induced	VERB	O	O	4801
hypertension	NOUN	O	Disease	4801
in	ADP	O	O	4801
rats	NOUN	O	O	4801
was	AUX	O	O	4801
studied	VERB	O	O	4801
.	PUNCT	O	O	4801
FK	PROPN	O	O	4802
506	NUM	O	O	4802
,	PUNCT	O	O	4802
5	NUM	O	O	4802
mg	VERB	O	O	4802
.	PUNCT	O	O	4802
FK	PROPN	O	O	4803
506	NUM	O	O	4803
decreased	VERB	O	O	4803
eNOS	NUM	O	O	4803
activity	NOUN	O	O	4803
and	CCONJ	O	O	4803
the	PRON	O	O	4803
levels	NOUN	O	O	4803
of	ADP	O	O	4803
eNOS	NUM	O	O	4803
mRNA	PROPN	O	O	4803
in	ADP	O	O	4803
the	PRON	O	O	4803
aorta	NOUN	O	O	4803
(	PUNCT	O	O	4803
48%	NOUN	O	O	4803
and	CCONJ	O	O	4803
55%	NOUN	O	O	4803
,	PUNCT	O	O	4803
respectively	ADV	O	O	4803
)	PUNCT	O	O	4803
.	PUNCT	O	O	4803
The	PRON	O	O	4804
administration	NOUN	O	O	4804
of	ADP	O	O	4804
FR	PROPN	O	O	4804
139317	NUM	O	O	4804
(	PUNCT	O	O	4804
10	NUM	O	O	4804
mg	VERB	O	O	4804
.	PUNCT	O	O	4804
d-1	PROPN	O	O	4805
)	PUNCT	O	O	4805
prevented	VERB	O	O	4805
FK	PROPN	O	O	4805
506-induced	VERB	O	O	4805
hypertension	NOUN	O	Disease	4805
in	ADP	O	O	4805
rats	NOUN	O	O	4805
.	PUNCT	O	O	4805
These	PRON	O	O	4806
results	VERB	O	O	4806
indicate	VERB	O	O	4806
that	SCONJ	O	O	4806
FK	PROPN	O	O	4806
506	NUM	O	O	4806
may	AUX	O	O	4806
increase	VERB	O	O	4806
blood	NOUN	O	O	4806
pressure	NOUN	O	O	4806
not	PART	O	O	4806
only	ADV	O	O	4806
by	ADP	O	O	4806
increasing	VERB	O	O	4806
ET-1	ADV	O	O	4806
production	NOUN	O	O	4806
but	CCONJ	O	O	4806
also	ADV	O	O	4806
by	ADP	O	O	4806
decreasing	VERB	O	O	4806
NO	PRON	O	Chemical	4806
synthesis	NOUN	O	O	4806
in	ADP	O	O	4806
the	PRON	O	O	4806
vasculature	NOUN	O	O	4806
.	PUNCT	O	O	4806
Suxamethonium	NOUN	O	O	4809
induced	VERB	O	O	4809
prolonged	VERB	O	O	4809
apnea	PROPN	O	Disease	4809
in	ADP	O	O	4809
a	PRON	O	O	4809
patient	NOUN	O	O	4809
receiving	VERB	O	O	4809
electroconvulsive	VERB	O	O	4809
therapy	NOUN	O	O	4809
.	PUNCT	O	O	4809
Suxamethonium	NOUN	O	O	4810
causes	VERB	O	O	4810
prolonged	VERB	O	O	4810
apnea	PROPN	O	Disease	4810
in	ADP	O	O	4810
patients	NOUN	O	O	4810
in	ADP	O	O	4810
whom	PRON	O	O	4810
pseudocholinesterase	PROPN	O	O	4810
enzyme	NOUN	O	O	4810
gets	VERB	O	O	4810
deactivated	VERB	O	O	4810
by	ADP	O	O	4810
organophosphorus	PROPN	O	Chemical	4810
(	PUNCT	O	O	4810
OP	NOUN	O	O	4810
)	PUNCT	O	O	4810
poisons	NOUN	O	O	4810
.	PUNCT	O	O	4810
Here	ADV	O	O	4811
,	PUNCT	O	O	4811
we	PRON	O	O	4811
present	NOUN	O	O	4811
a	PRON	O	O	4811
similar	ADJ	O	O	4811
incident	NOUN	O	O	4811
in	ADP	O	O	4811
a	PRON	O	O	4811
severely	ADV	O	O	4811
depressed	ADJ	O	O	4811
patient	NOUN	O	O	4811
who	PRON	O	O	4811
received	VERB	O	O	4811
electroconvulsive	VERB	O	O	4811
therapy	NOUN	O	O	4811
(	PUNCT	O	O	4811
ECT	NOUN	O	O	4811
)	PUNCT	O	O	4811
.	PUNCT	O	O	4811
Prolonged	VERB	O	O	4812
apnea	PROPN	O	Disease	4812
in	ADP	O	O	4812
our	PRON	O	O	4812
case	NOUN	O	O	4812
ensued	VERB	O	O	4812
because	SCONJ	O	O	4812
the	PRON	O	O	4812
information	NOUN	O	O	4812
about	ADP	O	O	4812
suicidal	ADJ	O	O	4812
attempt	VERB	O	O	4812
by	ADP	O	O	4812
OP	NOUN	O	O	4812
compound	NOUN	O	O	4812
was	AUX	O	O	4812
concealed	VERB	O	O	4812
from	ADP	O	O	4812
the	PRON	O	O	4812
treating	VERB	O	O	4812
team	NOUN	O	O	4812
.	PUNCT	O	O	4812
The	PRON	O	O	4815
effects	NOUN	O	O	4815
of	ADP	O	O	4815
the	PRON	O	O	4815
adjunctive	ADJ	O	O	4815
bupropion	NOUN	O	Chemical	4815
on	ADP	O	O	4815
male	NOUN	O	O	4815
sexual dysfunction	NOUN	O	Disease	4815
induced	VERB	O	O	4815
by	ADP	O	O	4815
a	PRON	O	O	4815
selective	ADJ	O	O	4815
serotonin	PROPN	O	Chemical	4815
reuptake	PROPN	O	O	4815
inhibitor	NOUN	O	O	4815
:	PUNCT	O	O	4815
a	PRON	O	O	4815
double	ADJ	O	O	4815
-	PUNCT	O	O	4815
blind	ADJ	O	Disease	4815
placebo	NOUN	O	O	4815
-	PUNCT	O	O	4815
controlled	VERB	O	O	4815
and	CCONJ	O	O	4815
randomized	VERB	O	O	4815
study	VERB	O	O	4815
.	PUNCT	O	O	4815
OBJECTIVE	VERB	O	O	4816
:	PUNCT	O	O	4816
To	PART	O	O	4816
determine	VERB	O	O	4816
the	PRON	O	O	4816
safety	NOUN	O	O	4816
and	CCONJ	O	O	4816
efficacy	NOUN	O	O	4816
of	ADP	O	O	4816
adjunctive	ADJ	O	O	4816
bupropion	NOUN	O	Chemical	4816
sustained	VERB	O	O	4816
-	PUNCT	O	O	4816
release	NOUN	O	O	4816
(	PUNCT	O	O	4816
SR	PROPN	O	O	4816
)	PUNCT	O	O	4816
on	ADP	O	O	4816
male	NOUN	O	O	4816
sexual dysfunction	NOUN	O	Disease	4816
(	PUNCT	O	O	4816
SD	NOUN	O	O	4816
)	PUNCT	O	O	4816
induced	VERB	O	O	4816
by	ADP	O	O	4816
a	PRON	O	O	4816
selective	ADJ	O	O	4816
serotonin	PROPN	O	Chemical	4816
reuptake	PROPN	O	O	4816
inhibitor	NOUN	O	O	4816
(	PUNCT	O	O	4816
SSRI	NOUN	O	O	4816
)	PUNCT	O	O	4816
,	PUNCT	O	O	4816
as	ADP	O	O	4816
SD	NOUN	O	O	4816
is	AUX	O	O	4816
a	PRON	O	O	4816
common	ADJ	O	O	4816
side	NOUN	O	O	4816
-	PUNCT	O	O	4816
effect	VERB	O	O	4816
of	ADP	O	O	4816
SSRIs	NOUN	O	O	4816
and	CCONJ	O	O	4816
the	PRON	O	O	4816
most	ADV	O	O	4816
effective	ADJ	O	O	4816
treatments	NOUN	O	O	4816
have	VERB	O	O	4816
yet	ADV	O	O	4816
to	PART	O	O	4816
be	AUX	O	O	4816
determined	VERB	O	O	4816
.	PUNCT	O	O	4816
The	PRON	O	O	4817
randomized	VERB	O	O	4817
sample	NOUN	O	O	4817
consisted	VERB	O	O	4817
of	ADP	O	O	4817
234	NUM	O	O	4817
euthymic	ADJ	O	O	4817
men	NOUN	O	O	4817
who	PRON	O	O	4817
were	AUX	O	O	4817
receiving	VERB	O	O	4817
some	PRON	O	O	4817
type	NOUN	O	O	4817
of	ADP	O	O	4817
SSRI	NOUN	O	O	4817
.	PUNCT	O	O	4817
The	PRON	O	O	4818
men	NOUN	O	O	4818
were	AUX	O	O	4818
randomly	ADV	O	O	4818
assigned	VERB	O	O	4818
to	PART	O	O	4818
bupropion	NOUN	O	Chemical	4818
SR	PROPN	O	O	4818
(	PUNCT	O	O	4818
150	NUM	O	O	4818
mg	VERB	O	O	4818
twice	ADV	O	O	4818
daily	ADV	O	O	4818
,	PUNCT	O	O	4818
117	NUM	O	O	4818
)	PUNCT	O	O	4818
or	CCONJ	O	O	4818
placebo	NOUN	O	O	4818
(	PUNCT	O	O	4818
twice	ADV	O	O	4818
daily	ADV	O	O	4818
,	PUNCT	O	O	4818
117	NUM	O	O	4818
)	PUNCT	O	O	4818
for	ADP	O	O	4818
12	NUM	O	O	4818
weeks	NOUN	O	O	4818
.	PUNCT	O	O	4818
Efficacy	NOUN	O	O	4819
was	AUX	O	O	4819
evaluated	VERB	O	O	4819
using	VERB	O	O	4819
the	PRON	O	O	4819
Clinical	NOUN	O	O	4819
Global	ADJ	O	O	4819
Impression	NOUN	O	O	4819
-	PUNCT	O	O	4819
Sexual	ADJ	O	O	4819
Function	NOUN	O	O	4819
(	PUNCT	O	O	4819
CGI	PROPN	O	O	4819
-	PUNCT	O	O	4819
SF	NOUN	O	O	4819
;	PUNCT	O	O	4819
the	PRON	O	O	4819
primary	NOUN	O	O	4819
outcome	NOUN	O	O	4819
measure	VERB	O	O	4819
)	PUNCT	O	O	4819
,	PUNCT	O	O	4819
the	PRON	O	O	4819
International	PROPN	O	O	4819
Index	NOUN	O	O	4819
of	ADP	O	O	4819
Erectile	PROPN	O	O	4819
Function	NOUN	O	O	4819
(	PUNCT	O	O	4819
IIEF	PROPN	O	O	4819
)	PUNCT	O	O	4819
,	PUNCT	O	O	4819
Arizona	PROPN	O	O	4819
Sexual	ADJ	O	O	4819
Experience	NOUN	O	O	4819
Scale	NOUN	O	O	4819
(	PUNCT	O	O	4819
ASEX	PROPN	O	O	4819
)	PUNCT	O	O	4819
,	PUNCT	O	O	4819
and	CCONJ	O	O	4819
Erectile	PROPN	O	O	4819
Dysfunction	NOUN	O	O	4819
Inventory	NOUN	O	O	4819
of	ADP	O	O	4819
Treatment	NOUN	O	O	4819
Satisfaction	NOUN	O	O	4819
(	PUNCT	O	O	4819
EDITS	PROPN	O	O	4819
)	PUNCT	O	O	4819
(	PUNCT	O	O	4819
secondary	ADJ	O	O	4819
outcome	NOUN	O	O	4819
measures	NOUN	O	O	4819
)	PUNCT	O	O	4819
.	PUNCT	O	O	4819
After	ADP	O	O	4820
12	NUM	O	O	4820
weeks	NOUN	O	O	4820
of	ADP	O	O	4820
treatment	NOUN	O	O	4820
,	PUNCT	O	O	4820
the	PRON	O	O	4820
mean	VERB	O	O	4820
(	PUNCT	O	O	4820
sd	NOUN	O	O	4820
)	PUNCT	O	O	4820
scores	NOUN	O	O	4820
for	ADP	O	O	4820
CGI	PROPN	O	O	4820
-	PUNCT	O	O	4820
SF	NOUN	O	O	4820
were	AUX	O	O	4820
significantly	ADV	O	O	4820
lower	ADJ	O	O	4820
,	PUNCT	O	O	4820
i.e.	X	O	O	4820
better	ADV	O	O	4820
,	PUNCT	O	O	4820
in	ADP	O	O	4820
patients	NOUN	O	O	4820
on	ADP	O	O	4820
bupropion	NOUN	O	Chemical	4820
SR	PROPN	O	O	4820
,	PUNCT	O	O	4820
at	ADP	O	O	4820
2.4	NUM	O	O	4820
(	PUNCT	O	O	4820
1.2	NUM	O	O	4820
)	PUNCT	O	O	4820
,	PUNCT	O	O	4820
than	ADP	O	O	4820
in	ADP	O	O	4820
the	PRON	O	O	4820
placebo	NOUN	O	O	4820
group	NOUN	O	O	4820
,	PUNCT	O	O	4820
at	ADP	O	O	4820
3.9	NUM	O	O	4820
(	PUNCT	O	O	4820
1.1	NUM	O	O	4820
)	PUNCT	O	O	4820
Men	NOUN	O	O	4821
who	PRON	O	O	4821
received	VERB	O	O	4821
bupropion	NOUN	O	Chemical	4821
had	VERB	O	O	4821
a	PRON	O	O	4821
significant	ADJ	O	O	4821
increase	VERB	O	O	4821
in	ADP	O	O	4821
the	PRON	O	O	4821
total	ADJ	O	O	4821
IIEF	PROPN	O	O	4821
score	VERB	O	O	4821
(	PUNCT	O	O	4821
54.4%	NOUN	O	O	4821
vs	ADP	O	O	4821
1.2%	NOUN	O	O	4821
;	PUNCT	O	O	4821
P=	VERB	O	O	4821
0.003	NUM	O	O	4821
)	PUNCT	O	O	4821
,	PUNCT	O	O	4821
and	CCONJ	O	O	4821
in	ADP	O	O	4821
the	PRON	O	O	4821
five	NUM	O	O	4821
different	ADJ	O	O	4821
domains	NOUN	O	O	4821
of	ADP	O	O	4821
the	PRON	O	O	4821
IIEF	PROPN	O	O	4821
.	PUNCT	O	O	4821
Total	ADJ	O	O	4822
ASEX	PROPN	O	O	4822
scores	NOUN	O	O	4822
were	AUX	O	O	4822
significantly	ADV	O	O	4822
lower	ADJ	O	O	4822
,	PUNCT	O	O	4822
i.e.	X	O	O	4822
better	ADV	O	O	4822
,	PUNCT	O	O	4822
among	ADP	O	O	4822
men	NOUN	O	O	4822
who	PRON	O	O	4822
received	VERB	O	O	4822
bupropion	NOUN	O	Chemical	4822
than	ADP	O	O	4822
placebo	NOUN	O	O	4822
,	PUNCT	O	O	4822
at	ADP	O	O	4822
15.5	NUM	O	O	4822
(	PUNCT	O	O	4822
4.3	NUM	O	O	4822
)	PUNCT	O	O	4822
vs	ADP	O	O	4822
21.5	NUM	O	O	4822
(	PUNCT	O	O	4822
4.7	NUM	O	O	4822
)	PUNCT	O	O	4822
(	PUNCT	O	O	4822
P=	VERB	O	O	4822
0.002	NUM	O	O	4822
)	PUNCT	O	O	4822
.	PUNCT	O	O	4822
The	PRON	O	O	4823
EDITS	PROPN	O	O	4823
scores	NOUN	O	O	4823
were	AUX	O	O	4823
67.4	NUM	O	O	4823
(	PUNCT	O	O	4823
10.2	NUM	O	O	4823
)	PUNCT	O	O	4823
for	ADP	O	O	4823
the	PRON	O	O	4823
bupropion	NOUN	O	Chemical	4823
and	CCONJ	O	O	4823
36.3	NUM	O	O	4823
(	PUNCT	O	O	4823
11.7	NUM	O	O	4823
)	PUNCT	O	O	4823
for	ADP	O	O	4823
the	PRON	O	O	4823
placebo	NOUN	O	O	4823
group	NOUN	O	O	4823
(	PUNCT	O	O	4823
P=	VERB	O	O	4823
0.001	NUM	O	O	4823
)	PUNCT	O	O	4823
.	PUNCT	O	O	4823
In	ADP	O	O	4824
linear	ADJ	O	O	4824
regression	NOUN	O	O	4824
analyses	NOUN	O	O	4824
the	PRON	O	O	4824
CGI	PROPN	O	O	4824
-	PUNCT	O	O	4824
SF	NOUN	O	O	4824
score	VERB	O	O	4824
was	AUX	O	O	4824
not	PART	O	O	4824
affected	VERB	O	O	4824
significantly	ADV	O	O	4824
by	ADP	O	O	4824
the	PRON	O	O	4824
duration	NOUN	O	O	4824
of	ADP	O	O	4824
SD	NOUN	O	O	4824
,	PUNCT	O	O	4824
type	NOUN	O	O	4824
of	ADP	O	O	4824
SSRI	NOUN	O	O	4824
used	VERB	O	O	4824
and	CCONJ	O	O	4824
age	NOUN	O	O	4824
.	PUNCT	O	O	4824
Bupropion	NOUN	O	O	4825
is	AUX	O	O	4825
an	PRON	O	O	4825
effective	ADJ	O	O	4825
treatment	NOUN	O	O	4825
for	ADP	O	O	4825
male	NOUN	O	O	4825
SD	NOUN	O	O	4825
induced	VERB	O	O	4825
by	ADP	O	O	4825
SSRIs	NOUN	O	O	4825
.	PUNCT	O	O	4825
These	PRON	O	O	4826
results	VERB	O	O	4826
provide	VERB	O	O	4826
empirical	ADJ	O	O	4826
support	NOUN	O	O	4826
for	ADP	O	O	4826
conducting	VERB	O	O	4826
a	PRON	O	O	4826
further	ADV	O	O	4826
study	VERB	O	O	4826
of	ADP	O	O	4826
bupropion	NOUN	O	Chemical	4826
.	PUNCT	O	O	4826
Lamivudine	NOUN	O	O	4829
for	ADP	O	O	4829
the	PRON	O	O	4829
prevention	NOUN	O	O	4829
of	ADP	O	O	4829
hepatitis B	PROPN	O	Disease	4829
virus	NOUN	O	O	4829
reactivation	NOUN	O	O	4829
in	ADP	O	O	4829
hepatitis	NOUN	O	Disease	4829
-	PUNCT	O	O	4829
B	NOUN	O	O	4829
surface	NOUN	O	O	4829
antigen	PROPN	O	O	4829
(	PUNCT	O	O	4829
HBSAG	PROPN	O	O	4829
)	PUNCT	O	O	4829
seropositive	ADJ	O	O	4829
cancer	NOUN	O	Disease	4829
patients	NOUN	O	O	4829
undergoing	VERB	O	O	4829
cytotoxic	ADJ	O	O	4829
chemotherapy	NOUN	O	O	4829
.	PUNCT	O	O	4829
Hepatitis B	PROPN	O	Disease	4830
virus	NOUN	O	O	4830
(	PUNCT	O	O	4830
HBV	NOUN	O	O	4830
)	PUNCT	O	O	4830
is	AUX	O	O	4830
one	NUM	O	O	4830
of	ADP	O	O	4830
the	PRON	O	O	4830
major	ADJ	O	O	4830
causes	VERB	O	O	4830
of	ADP	O	O	4830
chronic	ADJ	O	O	4830
liver disease	NOUN	O	Disease	4830
worldwide	ADV	O	O	4830
.	PUNCT	O	O	4830
Cancer	NOUN	O	O	4831
patients	NOUN	O	O	4831
who	PRON	O	O	4831
are	AUX	O	O	4831
chronic	ADJ	O	O	4831
carriers	NOUN	O	O	4831
of	ADP	O	O	4831
HBV	NOUN	O	O	4831
have	VERB	O	O	4831
a	PRON	O	O	4831
higher	ADJ	O	O	4831
hepatic	ADJ	O	O	4831
complication	NOUN	O	O	4831
rate	NOUN	O	O	4831
while	SCONJ	O	O	4831
receiving	VERB	O	O	4831
cytotoxic	ADJ	O	O	4831
chemotherapy	NOUN	O	O	4831
(	PUNCT	O	O	4831
CT	PROPN	O	O	4831
)	PUNCT	O	O	4831
and	CCONJ	O	O	4831
this	PRON	O	O	4831
has	VERB	O	O	4831
mainly	ADV	O	O	4831
been	AUX	O	O	4831
attributed	VERB	O	O	4831
to	PART	O	O	4831
HBV	NOUN	O	O	4831
reactivation	NOUN	O	O	4831
.	PUNCT	O	O	4831
In	ADP	O	O	4832
this	PRON	O	O	4832
study	VERB	O	O	4832
,	PUNCT	O	O	4832
cancer	NOUN	O	Disease	4832
patients	NOUN	O	O	4832
who	PRON	O	O	4832
have	VERB	O	O	4832
solid	ADJ	O	O	4832
and	CCONJ	O	O	4832
hematological	ADJ	O	O	4832
malignancies	NOUN	O	O	4832
with	ADP	O	O	4832
chronic	ADJ	O	O	4832
HBV	NOUN	O	O	4832
infection	NOUN	O	Disease	4832
received	VERB	O	O	4832
the	PRON	O	O	4832
antiviral	ADJ	O	O	4832
agent	NOUN	O	O	4832
lamivudine	NOUN	O	Chemical	4832
prior	ADV	O	O	4832
and	CCONJ	O	O	4833
during	ADP	O	O	4833
CT	PROPN	O	O	4833
compared	VERB	O	O	4833
with	ADP	O	O	4833
historical	ADJ	O	O	4833
control	VERB	O	O	4833
group	NOUN	O	O	4833
who	PRON	O	O	4833
did	VERB	O	O	4833
not	PART	O	O	4833
receive	VERB	O	O	4833
lamivudine	NOUN	O	Chemical	4833
.	PUNCT	O	O	4833
The	PRON	O	O	4834
objectives	NOUN	O	O	4834
were	AUX	O	O	4834
to	PART	O	O	4834
assess	VERB	O	O	4834
the	PRON	O	O	4834
efficacy	NOUN	O	O	4834
of	ADP	O	O	4834
lamivudine	NOUN	O	Chemical	4834
in	ADP	O	O	4834
reducing	VERB	O	O	4834
the	PRON	O	O	4834
incidence	NOUN	O	O	4834
of	ADP	O	O	4834
HBV	NOUN	O	O	4834
reactivation	NOUN	O	O	4834
,	PUNCT	O	O	4834
and	CCONJ	O	O	4834
diminishing	VERB	O	O	4834
morbidity	NOUN	O	O	4834
and	CCONJ	O	O	4834
mortality	NOUN	O	O	4834
during	ADP	O	O	4834
CT	PROPN	O	O	4834
.	PUNCT	O	O	4834
The	PRON	O	O	4835
prophylactic	ADJ	O	O	4835
lamivudin	VERB	O	O	4835
group	NOUN	O	O	4835
consisted	VERB	O	O	4835
of	ADP	O	O	4835
37	NUM	O	O	4835
patients	NOUN	O	O	4835
who	PRON	O	O	4835
received	VERB	O	O	4835
prophylactic	ADJ	O	O	4835
lamivudine	NOUN	O	Chemical	4835
treatment	NOUN	O	O	4835
.	PUNCT	O	O	4835
The	PRON	O	O	4836
historical	ADJ	O	O	4836
controls	VERB	O	O	4836
consisted	VERB	O	O	4836
of	ADP	O	O	4836
50	NUM	O	O	4836
consecutive	ADJ	O	O	4836
patients	NOUN	O	O	4836
who	PRON	O	O	4836
underwent	VERB	O	O	4836
CT	PROPN	O	O	4836
without	ADP	O	O	4836
prophylactic	ADJ	O	O	4836
lamivudine	NOUN	O	Chemical	4836
.	PUNCT	O	O	4836
Of	ADV	O	O	4837
our	PRON	O	O	4837
control	VERB	O	O	4837
group	NOUN	O	O	4837
(	PUNCT	O	O	4837
n=	PUNCT	O	O	4837
50	NUM	O	O	4837
)	PUNCT	O	O	4837
,	PUNCT	O	O	4837
21	NUM	O	O	4837
patients	NOUN	O	O	4837
(	PUNCT	O	O	4837
42%	NOUN	O	O	4837
)	PUNCT	O	O	4837
were	AUX	O	O	4837
established	VERB	O	O	4837
hepatitis	NOUN	O	Disease	4837
.	PUNCT	O	O	4837
Twelve	NUM	O	O	4838
(	PUNCT	O	O	4838
24%	NOUN	O	O	4838
)	PUNCT	O	O	4838
of	ADP	O	O	4838
them	PRON	O	O	4838
were	AUX	O	O	4838
evaluated	VERB	O	O	4838
as	ADP	O	O	4838
severe	ADJ	O	O	4838
hepatitis	NOUN	O	Disease	4838
.	PUNCT	O	O	4838
In	ADP	O	O	4839
the	PRON	O	O	4839
prophylactic	ADJ	O	O	4839
lamivudine	NOUN	O	Chemical	4839
group	NOUN	O	O	4839
severe	ADJ	O	O	4839
hepatitis	NOUN	O	Disease	4839
were	AUX	O	O	4839
observed	VERB	O	O	4839
only	ADV	O	O	4839
in	ADP	O	O	4839
1	X	O	O	4839
patient	NOUN	O	O	4839
(	PUNCT	O	O	4839
2.7%	NOUN	O	O	4839
)	PUNCT	O	O	4839
of	ADP	O	O	4839
37	NUM	O	O	4839
patients	NOUN	O	O	4839
(	PUNCT	O	O	4839
p	NOUN	O	O	4839
<	X	O	O	4839
0.006	NUM	O	O	4839
)	PUNCT	O	O	4839
.	PUNCT	O	O	4839
Comparison	NOUN	O	O	4840
of	ADP	O	O	4840
the	PRON	O	O	4840
mean	VERB	O	O	4840
ALT	PROPN	O	O	4840
values	NOUN	O	O	4840
revealed	VERB	O	O	4840
significantly	ADV	O	O	4840
higher	ADJ	O	O	4840
mean	VERB	O	O	4840
alanine	NOUN	O	Chemical	4840
aminotransferase	PROPN	O	O	4840
(	PUNCT	O	O	4840
ALT	PROPN	O	O	4840
)	PUNCT	O	O	4840
values	NOUN	O	O	4840
in	ADP	O	O	4840
the	PRON	O	O	4840
control	VERB	O	O	4840
group	NOUN	O	O	4840
than	ADP	O	O	4840
the	PRON	O	O	4840
prophylactic	ADJ	O	O	4840
lamivudine	NOUN	O	Chemical	4840
group	NOUN	O	O	4840
;	PUNCT	O	O	4840
154:64	NUM	O	O	4840
(	PUNCT	O	O	4840
p	NOUN	O	O	4840
<	X	O	O	4840
0.32	NUM	O	O	4840
)	PUNCT	O	O	4840
.	PUNCT	O	O	4840
Our	PRON	O	O	4841
study	VERB	O	O	4841
suggests	VERB	O	O	4841
that	SCONJ	O	O	4841
prophylactic	ADJ	O	O	4841
lamivudine	NOUN	O	Chemical	4841
significantly	ADV	O	O	4841
decreases	VERB	O	O	4841
the	PRON	O	O	4841
incidence	NOUN	O	O	4841
of	ADP	O	O	4841
HBV	NOUN	O	O	4841
reactivation	NOUN	O	O	4841
and	CCONJ	O	O	4841
overall	ADV	O	O	4841
morbidity	NOUN	O	O	4841
in	ADP	O	O	4841
cancer	NOUN	O	Disease	4841
patients	NOUN	O	O	4841
during	ADP	O	O	4841
and	CCONJ	O	O	4841
after	ADP	O	O	4841
immunosuppressive	ADJ	O	O	4841
therapy	NOUN	O	O	4841
.	PUNCT	O	O	4841
Further	ADV	O	O	4842
studies	NOUN	O	O	4842
are	AUX	O	O	4842
needed	VERB	O	O	4842
to	PART	O	O	4842
determine	VERB	O	O	4842
the	PRON	O	O	4842
most	ADV	O	O	4842
appropriate	ADJ	O	O	4842
nucleoside	NOUN	O	O	4842
or	CCONJ	O	O	4842
nucleotide	NOUN	O	O	4842
analogue	NOUN	O	O	4842
for	ADP	O	O	4842
antiviral	ADJ	O	O	4842
prophylaxis	NOUN	O	O	4842
during	ADP	O	O	4842
CT	PROPN	O	O	4842
and	CCONJ	O	O	4842
the	PRON	O	O	4842
optimal	ADJ	O	O	4842
duration	NOUN	O	O	4842
of	ADP	O	O	4842
administration	NOUN	O	O	4842
after	ADP	O	O	4842
completion	NOUN	O	O	4842
of	ADP	O	O	4842
CT	PROPN	O	O	4842
.	PUNCT	O	O	4842
Ginsenoside	NOUN	O	O	4845
Rg1	NOUN	O	O	4845
restores	VERB	O	O	4845
the	PRON	O	O	4845
impairment	NOUN	O	O	4845
of	ADP	O	O	4845
learning	VERB	O	O	4845
induced	VERB	O	O	4845
by	ADP	O	O	4845
chronic	ADJ	O	O	4845
morphine	NOUN	O	Chemical	4845
administration	NOUN	O	O	4845
in	ADP	O	O	4845
rats	NOUN	O	O	4845
.	PUNCT	O	O	4845
Rg1	NOUN	O	O	4846
,	PUNCT	O	O	4846
as	ADP	O	O	4846
a	PRON	O	O	4846
ginsenoside	NOUN	O	O	4846
extracted	VERB	O	O	4846
from	ADP	O	O	4846
Panax	NOUN	O	O	4846
ginseng	PROPN	O	O	4846
,	PUNCT	O	O	4846
could	AUX	O	O	4846
ameliorate	VERB	O	O	4846
spatial	PROPN	O	O	4846
learning impairment	NOUN	O	Disease	4846
.	PUNCT	O	O	4846
Previous	ADJ	O	O	4847
studies	NOUN	O	O	4847
have	VERB	O	O	4847
demonstrated	VERB	O	O	4847
that	SCONJ	O	O	4847
Rg1	NOUN	O	O	4847
might	AUX	O	O	4847
be	AUX	O	O	4847
a	PRON	O	O	4847
useful	ADJ	O	O	4847
agent	NOUN	O	O	4847
for	ADP	O	O	4847
the	PRON	O	O	4847
prevention	NOUN	O	O	4847
and	CCONJ	O	O	4847
treatment	NOUN	O	O	4847
of	ADP	O	O	4847
the	PRON	O	O	4847
adverse	ADJ	O	O	4847
effects	NOUN	O	O	4847
of	ADP	O	O	4847
morphine	NOUN	O	Chemical	4847
.	PUNCT	O	O	4847
The	PRON	O	O	4848
aim	VERB	O	O	4848
of	ADP	O	O	4848
this	PRON	O	O	4848
study	VERB	O	O	4848
was	AUX	O	O	4848
to	PART	O	O	4848
investigate	VERB	O	O	4848
the	PRON	O	O	4848
effect	VERB	O	O	4848
of	ADP	O	O	4848
Rg1	NOUN	O	O	4848
on	ADP	O	O	4848
learning impairment	NOUN	O	Disease	4848
by	ADP	O	O	4848
chronic	ADJ	O	O	4848
morphine	NOUN	O	Chemical	4848
administration	NOUN	O	O	4848
and	CCONJ	O	O	4848
the	PRON	O	O	4848
mechanism	NOUN	O	O	4848
responsible	ADJ	O	O	4848
for	ADP	O	O	4848
this	PRON	O	O	4848
effect	VERB	O	O	4848
.	PUNCT	O	O	4848
Male	NOUN	O	O	4849
rats	NOUN	O	O	4849
were	AUX	O	O	4849
subcutaneously	ADV	O	O	4849
injected	VERB	O	O	4849
with	ADP	O	O	4849
morphine	NOUN	O	Chemical	4849
(	PUNCT	O	O	4849
10	NUM	O	O	4849
mg	VERB	O	O	4849
/	PUNCT	O	O	4849
kg	VERB	O	O	4849
)	PUNCT	O	O	4849
twice	ADV	O	O	4849
a	PRON	O	O	4849
day	NOUN	O	O	4849
at	ADP	O	O	4849
12	NUM	O	O	4849
hour	NOUN	O	O	4849
intervals	NOUN	O	O	4849
for	ADP	O	O	4849
10	NUM	O	O	4849
days	NOUN	O	O	4849
,	PUNCT	O	O	4849
and	CCONJ	O	O	4849
Rg1	NOUN	O	O	4849
(	PUNCT	O	O	4849
30	NUM	O	O	4849
mg	VERB	O	O	4849
/	PUNCT	O	O	4849
kg	VERB	O	O	4849
)	PUNCT	O	O	4849
was	AUX	O	O	4849
intraperitoneally	ADV	O	O	4849
injected	VERB	O	O	4849
2	X	O	O	4849
hours	NOUN	O	O	4849
after	ADP	O	O	4849
the	PRON	O	O	4849
second	ADV	O	O	4849
injection	NOUN	O	O	4849
of	ADP	O	O	4849
morphine	NOUN	O	Chemical	4849
once	ADV	O	O	4849
a	PRON	O	O	4849
day	NOUN	O	O	4849
for	ADP	O	O	4849
10	NUM	O	O	4849
days	NOUN	O	O	4849
.	PUNCT	O	O	4849
The	PRON	O	O	4850
results	VERB	O	O	4850
showed	VERB	O	O	4850
that	SCONJ	O	O	4850
rats	NOUN	O	O	4850
treated	VERB	O	O	4850
with	ADP	O	O	4850
Morphine	NOUN	O	Chemical	4850
/	PUNCT	O	O	4850
Rg1	NOUN	O	O	4850
decreased	VERB	O	O	4850
escape	VERB	O	O	4850
latency	VERB	O	O	4850
and	CCONJ	O	O	4850
increased	VERB	O	O	4850
the	PRON	O	O	4850
time	NOUN	O	O	4850
spent	VERB	O	O	4850
in	ADP	O	O	4850
platform	NOUN	O	O	4850
quadrant	NOUN	O	O	4850
and	CCONJ	O	O	4850
entering	VERB	O	O	4850
frequency	NOUN	O	O	4850
.	PUNCT	O	O	4850
By	ADP	O	O	4851
implantation	NOUN	O	O	4851
of	ADP	O	O	4851
electrodes	NOUN	O	O	4851
and	CCONJ	O	O	4851
electrophysiological	ADJ	O	O	4851
recording	NOUN	O	O	4851
in	ADP	O	O	4851
vivo	VERB	O	O	4851
,	PUNCT	O	O	4851
the	PRON	O	O	4851
results	VERB	O	O	4851
showed	VERB	O	O	4851
that	SCONJ	O	O	4851
Rg1	NOUN	O	O	4851
restored	VERB	O	O	4851
the	PRON	O	O	4851
long	ADV	O	O	4851
-	PUNCT	O	O	4851
term	NOUN	O	O	4851
potentiation	NOUN	O	O	4851
(	PUNCT	O	O	4851
LTP	PROPN	O	O	4851
)	PUNCT	O	O	4851
impaired	VERB	O	O	4851
by	ADP	O	O	4851
morphine	NOUN	O	Chemical	4851
in	ADP	O	O	4851
both	PRON	O	O	4851
freely	ADV	O	O	4851
moving	VERB	O	O	4851
and	CCONJ	O	O	4851
anaesthetised	VERB	O	O	4851
rats	NOUN	O	O	4851
.	PUNCT	O	O	4851
The	PRON	O	O	4852
electrophysiological	ADJ	O	O	4852
recording	NOUN	O	O	4852
in	ADP	O	O	4852
vitro	X	O	O	4852
showed	VERB	O	O	4852
that	SCONJ	O	O	4852
Rg1	NOUN	O	O	4852
restored	VERB	O	O	4852
the	PRON	O	O	4852
LTP	PROPN	O	O	4852
in	ADP	O	O	4852
slices	NOUN	O	O	4852
from	ADP	O	O	4852
the	PRON	O	O	4852
rats	NOUN	O	O	4852
treated	VERB	O	O	4852
with	ADP	O	O	4852
morphine	NOUN	O	Chemical	4852
,	PUNCT	O	O	4852
but	CCONJ	O	O	4852
not	PART	O	O	4852
changed	VERB	O	O	4852
LTP	PROPN	O	O	4852
in	ADP	O	O	4852
the	PRON	O	O	4852
slices	NOUN	O	O	4852
from	ADP	O	O	4852
normal	ADJ	O	O	4852
saline-	ADP	O	O	4852
or	CCONJ	O	O	4852
morphine	NOUN	O	Chemical	4852
/	PUNCT	O	O	4852
Rg1-treated	VERB	O	O	4852
rats	NOUN	O	O	4852
;	PUNCT	O	O	4852
this	PRON	O	O	4852
restoration	NOUN	O	O	4852
could	AUX	O	O	4852
be	AUX	O	O	4852
inhibited	VERB	O	O	4852
by	ADP	O	O	4852
N	NUM	O	O	4852
-	PUNCT	O	O	4852
methyl	NOUN	O	O	4852
-	PUNCT	O	O	4852
D	NOUN	O	O	4852
-	PUNCT	O	O	4852
aspartate	NOUN	O	Chemical	4852
(	PUNCT	O	O	4852
NMDA	PROPN	O	Chemical	4852
)	PUNCT	O	O	4852
receptor	NOUN	O	O	4852
antagonist	NOUN	O	O	4852
MK801	PROPN	O	O	4852
.	PUNCT	O	O	4852
We	PRON	O	O	4853
conclude	VERB	O	O	4853
that	SCONJ	O	O	4853
Rg1	NOUN	O	O	4853
may	AUX	O	O	4853
significantly	ADV	O	O	4853
improve	VERB	O	O	4853
the	PRON	O	O	4853
spatial	PROPN	O	O	4853
learning	VERB	O	O	4853
capacity	NOUN	O	O	4853
impaired	VERB	O	O	4853
by	ADP	O	O	4853
chonic	ADJ	O	O	4853
morphine	NOUN	O	Chemical	4853
administration	NOUN	O	O	4853
and	CCONJ	O	O	4853
restore	VERB	O	O	4853
the	PRON	O	O	4853
morphine	NOUN	O	Chemical	4853
-	PUNCT	O	O	4853
inhibited	VERB	O	O	4853
LTP	PROPN	O	O	4853
.	PUNCT	O	O	4853
This	PRON	O	O	4854
effect	VERB	O	O	4854
is	AUX	O	O	4854
NMDA	PROPN	O	Chemical	4854
receptor	NOUN	O	O	4854
dependent	ADJ	O	O	4854
.	PUNCT	O	O	4854
A	PRON	O	O	4857
study	VERB	O	O	4857
on	ADP	O	O	4857
the	PRON	O	O	4857
effect	VERB	O	O	4857
of	ADP	O	O	4857
the	PRON	O	O	4857
duration	NOUN	O	O	4857
of	ADP	O	O	4857
subcutaneous	ADJ	O	O	4857
heparin	NOUN	O	Chemical	4857
injection	NOUN	O	O	4857
on	ADP	O	O	4857
bruising	VERB	O	O	4857
and	CCONJ	O	O	4857
pain	NOUN	O	Disease	4857
.	PUNCT	O	O	4857
This	PRON	O	O	4858
study	VERB	O	O	4858
was	AUX	O	O	4858
carried	VERB	O	O	4858
out	ADP	O	O	4858
to	PART	O	O	4858
determine	VERB	O	O	4858
the	PRON	O	O	4858
effect	VERB	O	O	4858
of	ADP	O	O	4858
injection	NOUN	O	O	4858
duration	NOUN	O	O	4858
on	ADP	O	O	4858
bruising	VERB	O	O	4858
and	CCONJ	O	O	4858
pain	NOUN	O	Disease	4858
following	VERB	O	O	4858
the	PRON	O	O	4858
administration	NOUN	O	O	4858
of	ADP	O	O	4858
the	PRON	O	O	4858
subcutaneous	ADJ	O	O	4858
injection	NOUN	O	O	4858
of	ADP	O	O	4858
heparin	NOUN	O	Chemical	4858
.	PUNCT	O	O	4858
Although	SCONJ	O	O	4859
different	ADJ	O	O	4859
methods	NOUN	O	O	4859
to	PART	O	O	4859
prevent	VERB	O	O	4859
bruising	VERB	O	O	4859
and	CCONJ	O	O	4859
pain	NOUN	O	Disease	4859
following	VERB	O	O	4859
the	PRON	O	O	4859
subcutaneous	ADJ	O	O	4859
injection	NOUN	O	O	4859
of	ADP	O	O	4859
heparin	NOUN	O	Chemical	4859
have	VERB	O	O	4859
been	AUX	O	O	4859
widely	ADV	O	O	4859
studied	VERB	O	O	4859
and	CCONJ	O	O	4859
described	VERB	O	O	4859
,	PUNCT	O	O	4859
the	PRON	O	O	4859
effect	VERB	O	O	4859
of	ADP	O	O	4859
injection	NOUN	O	O	4859
duration	NOUN	O	O	4859
on	ADP	O	O	4859
the	PRON	O	O	4859
occurrence	NOUN	O	O	4859
of	ADP	O	O	4859
bruising	VERB	O	O	4859
and	CCONJ	O	O	4859
pain	NOUN	O	Disease	4859
is	AUX	O	O	4859
little	ADJ	O	O	4859
documented	VERB	O	O	4859
.	PUNCT	O	O	4859
The	PRON	O	O	4860
sample	NOUN	O	O	4860
for	ADP	O	O	4860
the	PRON	O	O	4860
study	VERB	O	O	4860
consisted	VERB	O	O	4860
of	ADP	O	O	4860
50	NUM	O	O	4860
patients	NOUN	O	O	4860
to	PART	O	O	4860
whom	PRON	O	O	4860
subcutaneous	ADJ	O	O	4860
heparin	NOUN	O	Chemical	4860
was	AUX	O	O	4860
administered	VERB	O	O	4860
.	PUNCT	O	O	4860
Heparin	PROPN	O	Chemical	4861
was	AUX	O	O	4861
injected	VERB	O	O	4861
over	ADP	O	O	4861
10	NUM	O	O	4861
seconds	NOUN	O	O	4861
on	ADP	O	O	4861
the	PRON	O	O	4861
right	ADV	O	O	4861
abdominal	ADJ	O	O	4861
site	NOUN	O	O	4861
and	CCONJ	O	O	4861
30	NUM	O	O	4861
seconds	NOUN	O	O	4861
on	ADP	O	O	4861
the	PRON	O	O	4861
left	VERB	O	O	4861
abdominal	ADJ	O	O	4861
site	NOUN	O	O	4861
.	PUNCT	O	O	4861
Injections	NOUN	O	O	4862
areas	NOUN	O	O	4862
were	AUX	O	O	4862
assessed	VERB	O	O	4862
for	ADP	O	O	4862
the	PRON	O	O	4862
presence	NOUN	O	O	4862
of	ADP	O	O	4862
bruising	VERB	O	O	4862
at	ADP	O	O	4862
48	NUM	O	O	4862
and	CCONJ	O	O	4862
72	NUM	O	O	4862
hours	NOUN	O	O	4862
after	ADP	O	O	4862
each	PRON	O	O	4862
injection	NOUN	O	O	4862
.	PUNCT	O	O	4862
Dimensions	NOUN	O	O	4863
of	ADP	O	O	4863
the	PRON	O	O	4863
bruising	VERB	O	O	4863
on	ADP	O	O	4863
the	PRON	O	O	4863
heparin	NOUN	O	Chemical	4863
applied	VERB	O	O	4863
areas	NOUN	O	O	4863
were	AUX	O	O	4863
measured	VERB	O	O	4863
using	VERB	O	O	4863
transparent	ADJ	O	O	4863
millimetric	ADV	O	O	4863
measuring	VERB	O	O	4863
paper	PROPN	O	O	4863
.	PUNCT	O	O	4863
The	PRON	O	O	4864
visual	ADJ	O	O	4864
analog	NOUN	O	O	4864
scale	NOUN	O	O	4864
(	PUNCT	O	O	4864
VAS	PROPN	O	O	4864
)	PUNCT	O	O	4864
was	AUX	O	O	4864
used	VERB	O	O	4864
to	PART	O	O	4864
measure	VERB	O	O	4864
pain	NOUN	O	Disease	4864
intensity	NOUN	O	O	4864
and	CCONJ	O	O	4864
a	PRON	O	O	4864
stop	VERB	O	O	4864
-	PUNCT	O	O	4864
watch	VERB	O	O	4864
was	AUX	O	O	4864
used	VERB	O	O	4864
to	PART	O	O	4864
time	NOUN	O	O	4864
the	PRON	O	O	4864
pain	NOUN	O	Disease	4864
period	NOUN	O	O	4864
.	PUNCT	O	O	4864
The	PRON	O	O	4865
percentage	NOUN	O	O	4865
of	ADP	O	O	4865
bruising	VERB	O	O	4865
occurrence	NOUN	O	O	4865
was	AUX	O	O	4865
64%	NOUN	O	O	4865
with	ADP	O	O	4865
the	PRON	O	O	4865
injection	NOUN	O	O	4865
of	ADP	O	O	4865
10	NUM	O	O	4865
seconds	NOUN	O	O	4865
duration	NOUN	O	O	4865
and	CCONJ	O	O	4865
42%	NOUN	O	O	4865
in	ADP	O	O	4865
the	PRON	O	O	4865
30-second	NOUN	O	O	4865
injection	NOUN	O	O	4865
.	PUNCT	O	O	4865
It	PRON	O	O	4866
was	AUX	O	O	4866
determined	VERB	O	O	4866
that	SCONJ	O	O	4866
the	PRON	O	O	4866
size	NOUN	O	O	4866
of	ADP	O	O	4866
the	PRON	O	O	4866
bruising	VERB	O	O	4866
was	AUX	O	O	4866
smaller	ADJ	O	O	4866
in	ADP	O	O	4866
the	PRON	O	O	4866
30-second	NOUN	O	O	4866
injection	NOUN	O	O	4866
.	PUNCT	O	O	4866
Pain	NOUN	O	Disease	4867
intensity	NOUN	O	O	4867
and	CCONJ	O	O	4867
pain	NOUN	O	Disease	4867
period	NOUN	O	O	4867
were	AUX	O	O	4867
statistically	ADV	O	O	4867
significantly	ADV	O	O	4867
lower	ADJ	O	O	4867
for	ADP	O	O	4867
the	PRON	O	O	4867
30-second	NOUN	O	O	4867
injection	NOUN	O	O	4867
than	ADP	O	O	4867
for	ADP	O	O	4867
the	PRON	O	O	4867
10-second	NOUN	O	O	4867
injection	NOUN	O	O	4867
.	PUNCT	O	O	4867
CONCLUSIONS	NOUN	O	O	4868
:	PUNCT	O	O	4868
It	PRON	O	O	4868
was	AUX	O	O	4868
determined	VERB	O	O	4868
that	SCONJ	O	O	4868
injection	NOUN	O	O	4868
duration	NOUN	O	O	4868
had	VERB	O	O	4868
an	PRON	O	O	4868
effect	VERB	O	O	4868
on	ADP	O	O	4868
bruising	VERB	O	O	4868
and	CCONJ	O	O	4868
pain	NOUN	O	Disease	4868
following	VERB	O	O	4868
the	PRON	O	O	4868
subcutaneous	ADJ	O	O	4868
administration	NOUN	O	O	4868
of	ADP	O	O	4868
heparin	NOUN	O	Chemical	4868
.	PUNCT	O	O	4868
PRACTICE	VERB	O	O	4869
:	PUNCT	O	O	4869
When	SCONJ	O	O	4869
administering	VERB	O	O	4869
subcutaneous	ADJ	O	O	4869
heparin	NOUN	O	Chemical	4869
injections	NOUN	O	O	4869
,	PUNCT	O	O	4869
it	PRON	O	O	4869
is	AUX	O	O	4869
important	ADJ	O	O	4869
to	PART	O	O	4869
extend	VERB	O	O	4869
the	PRON	O	O	4869
duration	NOUN	O	O	4869
of	ADP	O	O	4869
the	PRON	O	O	4869
injection	NOUN	O	O	4869
.	PUNCT	O	O	4869
Acute	PROPN	O	O	4872
reserpine	NOUN	O	Chemical	4872
and	CCONJ	O	O	4872
subchronic	VERB	O	O	4872
haloperidol	NOUN	O	Chemical	4872
treatments	NOUN	O	O	4872
change	VERB	O	O	4872
synaptosomal	PROPN	O	O	4872
brain	NOUN	O	O	4872
glutamate	NOUN	O	Chemical	4872
uptake	NOUN	O	O	4872
and	CCONJ	O	O	4872
elicit	VERB	O	O	4872
orofacial dyskinesia	NOUN	O	Disease	4872
in	ADP	O	O	4872
rats	NOUN	O	O	4872
.	PUNCT	O	O	4872
Reserpine-	PROPN	O	O	4873
and	CCONJ	O	O	4873
haloperidol	NOUN	O	Chemical	4873
-	PUNCT	O	O	4873
induced	VERB	O	O	4873
orofacial dyskinesia	NOUN	O	Disease	4873
are	AUX	O	O	4873
putative	ADJ	O	O	4873
animal	NOUN	O	O	4873
models	NOUN	O	O	4873
of	ADP	O	O	4873
tardive dyskinesia	NOUN	O	Disease	4873
(	PUNCT	O	O	4873
TD	PROPN	O	O	4873
)	PUNCT	O	O	4873
whose	DET	O	O	4873
pathophysiology	NOUN	O	O	4873
has	VERB	O	O	4873
been	AUX	O	O	4873
related	ADJ	O	O	4873
to	PART	O	O	4873
free	ADJ	O	O	4873
radical	ADJ	O	O	4873
generation	NOUN	O	O	4873
and	CCONJ	O	O	4873
oxidative	NOUN	O	O	4873
stress	NOUN	O	O	4873
.	PUNCT	O	O	4873
In	ADP	O	O	4874
the	PRON	O	O	4874
present	NOUN	O	O	4874
study	VERB	O	O	4874
,	PUNCT	O	O	4874
the	PRON	O	O	4874
authors	NOUN	O	O	4874
induced	VERB	O	O	4874
orofacial dyskinesia	NOUN	O	Disease	4874
by	ADP	O	O	4874
acute	ADJ	O	O	4874
reserpine	NOUN	O	Chemical	4874
and	CCONJ	O	O	4874
subchronic	VERB	O	O	4874
haloperidol	NOUN	O	Chemical	4874
administration	NOUN	O	O	4874
to	PART	O	O	4874
rats	NOUN	O	O	4874
.	PUNCT	O	O	4874
Reserpine	NOUN	O	Chemical	4875
injection	NOUN	O	O	4875
(	PUNCT	O	O	4875
one	NUM	O	O	4875
dose	NOUN	O	O	4875
of	ADP	O	O	4875
1	X	O	O	4875
mg	VERB	O	O	4875
Haloperidol	NOUN	O	Chemical	4876
administration	NOUN	O	O	4876
(	PUNCT	O	O	4876
one	NUM	O	O	4876
dose	NOUN	O	O	4876
of	ADP	O	O	4876
12	NUM	O	O	4876
mg	VERB	O	O	4876
/	PUNCT	O	O	4876
kg	VERB	O	O	4876
once	ADV	O	O	4876
a	PRON	O	O	4876
week	NOUN	O	O	4876
s.c	PROPN	O	O	4876
.	PUNCT	O	O	4876
)	PUNCT	O	O	4876
After	ADP	O	O	4877
the	PRON	O	O	4877
treatments	NOUN	O	O	4877
and	CCONJ	O	O	4877
behavioral	ADJ	O	O	4877
observation	NOUN	O	O	4877
,	PUNCT	O	O	4877
glutamate	NOUN	O	Chemical	4877
uptake	NOUN	O	O	4877
by	ADP	O	O	4877
segments	NOUN	O	O	4877
of	ADP	O	O	4877
the	PRON	O	O	4877
brain	NOUN	O	O	4877
was	AUX	O	O	4877
analyzed	VERB	O	O	4877
.	PUNCT	O	O	4877
A	PRON	O	O	4878
decreased	VERB	O	O	4878
glutamate	NOUN	O	Chemical	4878
uptake	NOUN	O	O	4878
was	AUX	O	O	4878
observed	VERB	O	O	4878
in	ADP	O	O	4878
the	PRON	O	O	4878
subcortical	ADJ	O	O	4878
parts	NOUN	O	O	4878
of	ADP	O	O	4878
animals	NOUN	O	O	4878
treated	VERB	O	O	4878
with	ADP	O	O	4878
reserpine	NOUN	O	Chemical	4878
and	CCONJ	O	O	4878
haloperidol	NOUN	O	Chemical	4878
,	PUNCT	O	O	4878
compared	VERB	O	O	4878
to	PART	O	O	4878
the	PRON	O	O	4878
control	VERB	O	O	4878
.	PUNCT	O	O	4878
Importantly	ADV	O	O	4879
,	PUNCT	O	O	4879
a	PRON	O	O	4879
decrease	VERB	O	O	4879
in	ADP	O	O	4879
glutamate	NOUN	O	Chemical	4879
uptake	NOUN	O	O	4879
correlates	VERB	O	O	4879
negatively	ADV	O	O	4879
with	ADP	O	O	4879
an	PRON	O	O	4879
increase	VERB	O	O	4879
in	ADP	O	O	4879
the	PRON	O	O	4879
incidence	NOUN	O	O	4879
of	ADP	O	O	4879
orofacial	ADJ	O	O	4879
diskinesia	NOUN	O	O	4879
.	PUNCT	O	O	4879
These	PRON	O	O	4880
results	VERB	O	O	4880
indicate	VERB	O	O	4880
that	SCONJ	O	O	4880
early	ADV	O	O	4880
changes	VERB	O	O	4880
in	ADP	O	O	4880
glutamate	NOUN	O	Chemical	4880
transport	NOUN	O	O	4880
may	AUX	O	O	4880
be	AUX	O	O	4880
related	ADJ	O	O	4880
to	PART	O	O	4880
the	PRON	O	O	4880
development	NOUN	O	O	4880
of	ADP	O	O	4880
vacuous	ADJ	O	O	4880
chewing	VERB	O	O	4880
movements	NOUN	O	O	4880
in	ADP	O	O	4880
rats	NOUN	O	O	4880
.	PUNCT	O	O	4880
Acute	PROPN	O	O	4883
psychosis	VERB	O	Disease	4883
due	ADJ	O	O	4883
to	PART	O	O	4883
treatment	NOUN	O	O	4883
with	ADP	O	O	4883
phenytoin	NOUN	O	Chemical	4883
in	ADP	O	O	4883
a	PRON	O	O	4883
nonepileptic	PROPN	O	O	4883
patient	NOUN	O	O	4883
.	PUNCT	O	O	4883
The	PRON	O	O	4884
development	NOUN	O	O	4884
of	ADP	O	O	4884
psychosis	VERB	O	Disease	4884
related	ADJ	O	O	4884
to	PART	O	O	4884
antiepileptic	ADJ	O	O	4884
drug	NOUN	O	O	4884
treatment	NOUN	O	O	4884
is	AUX	O	O	4884
usually	ADV	O	O	4884
attributed	VERB	O	O	4884
to	PART	O	O	4884
the	PRON	O	O	4884
interaction	NOUN	O	O	4884
between	ADP	O	O	4884
the	PRON	O	O	4884
epileptic	ADJ	O	Disease	4884
brain	NOUN	O	O	4884
substratum	NOUN	O	O	4884
and	CCONJ	O	O	4884
the	PRON	O	O	4884
antiepileptic	ADJ	O	O	4884
drugs	NOUN	O	O	4884
.	PUNCT	O	O	4884
The	PRON	O	O	4885
case	NOUN	O	O	4885
of	ADP	O	O	4885
a	PRON	O	O	4885
nonepileptic	PROPN	O	O	4885
patient	NOUN	O	O	4885
who	PRON	O	O	4885
developed	VERB	O	O	4885
psychosis	VERB	O	Disease	4885
following	VERB	O	O	4885
phenytoin	NOUN	O	Chemical	4885
treatment	NOUN	O	O	4885
for	ADP	O	O	4885
trigeminal	ADJ	O	O	4885
neuralgia	NOUN	O	Disease	4885
is	AUX	O	O	4885
described	VERB	O	O	4885
.	PUNCT	O	O	4885
This	PRON	O	O	4886
case	NOUN	O	O	4886
suggests	VERB	O	O	4886
that	SCONJ	O	O	4886
the	PRON	O	O	4886
psychotic symptoms	NOUN	O	Disease	4886
that	SCONJ	O	O	4886
occur	VERB	O	O	4886
following	VERB	O	O	4886
phenytoin	NOUN	O	Chemical	4886
treatment	NOUN	O	O	4886
in	ADP	O	O	4886
some	PRON	O	O	4886
epileptic	ADJ	O	Disease	4886
patients	NOUN	O	O	4886
may	AUX	O	O	4886
be	AUX	O	O	4886
the	PRON	O	O	4886
direct	ADJ	O	O	4886
result	VERB	O	O	4886
of	ADP	O	O	4886
medication	NOUN	O	O	4886
,	PUNCT	O	O	4886
unrelated	ADJ	O	O	4886
to	PART	O	O	4886
seizures	NOUN	O	Disease	4886
.	PUNCT	O	O	4886
The	PRON	O	O	4889
effect	VERB	O	O	4889
of	ADP	O	O	4889
treatment	NOUN	O	O	4889
with	ADP	O	O	4889
gum	NOUN	O	O	4889
Arabic	PROPN	O	O	4889
on	ADP	O	O	4889
gentamicin	VERB	O	Chemical	4889
nephrotoxicity	NOUN	O	Disease	4889
in	ADP	O	O	4889
rats	NOUN	O	O	4889
:	PUNCT	O	O	4889
a	PRON	O	O	4889
preliminary	ADJ	O	O	4889
study	VERB	O	O	4889
.	PUNCT	O	O	4889
In	ADP	O	O	4890
the	PRON	O	O	4890
present	NOUN	O	O	4890
work	NOUN	O	O	4890
we	PRON	O	O	4890
assessed	VERB	O	O	4890
the	PRON	O	O	4890
effect	VERB	O	O	4890
of	ADP	O	O	4890
treatment	NOUN	O	O	4890
of	ADP	O	O	4890
rats	NOUN	O	O	4890
with	ADP	O	O	4890
gum	NOUN	O	O	4890
Arabic	PROPN	O	O	4890
on	ADP	O	O	4890
acute	ADJ	O	O	4890
renal failure	NOUN	O	Disease	4890
induced	VERB	O	O	4890
by	ADP	O	O	4890
gentamicin	VERB	O	Chemical	4890
(	PUNCT	O	O	4890
GM	PROPN	O	O	4890
)	PUNCT	O	O	4890
nephrotoxicity	NOUN	O	Disease	4890
.	PUNCT	O	O	4890
kg	VERB	O	O	4891
of	ADP	O	O	4891
distilled	VERB	O	O	4891
water	PROPN	O	O	4891
and	CCONJ	O	O	4891
5%	NOUN	O	O	4891
w	X	O	O	4891
/	PUNCT	O	O	4891
v	NOUN	O	O	4891
cellulose	NOUN	O	O	4891
,	PUNCT	O	O	4891
10	NUM	O	O	4891
days	NOUN	O	O	4891
)	PUNCT	O	O	4891
,	PUNCT	O	O	4891
gum	NOUN	O	O	4891
Arabic	PROPN	O	O	4891
(	PUNCT	O	O	4891
2	X	O	O	4891
mL	PROPN	O	O	4891
/	PUNCT	O	O	4891
kg	VERB	O	O	4892
of	ADP	O	O	4892
a	PRON	O	O	4892
10%	NOUN	O	O	4892
w	X	O	O	4892
/	PUNCT	O	O	4892
v	NOUN	O	O	4892
aqueous	ADJ	O	O	4892
suspension	NOUN	O	O	4892
of	ADP	O	O	4892
gum	NOUN	O	O	4892
Arabic	PROPN	O	O	4892
powder	NOUN	O	O	4892
,	PUNCT	O	O	4892
orally	ADV	O	O	4892
for	ADP	O	O	4892
10	NUM	O	O	4892
days	NOUN	O	O	4892
)	PUNCT	O	O	4892
,	PUNCT	O	O	4892
or	CCONJ	O	O	4892
gum	NOUN	O	O	4892
Arabic	PROPN	O	O	4892
concomitantly	ADV	O	O	4892
with	ADP	O	O	4892
GM	PROPN	O	O	4892
(	PUNCT	O	O	4892
80mg	NOUN	O	O	4892
/	PUNCT	O	O	4892
kg	VERB	O	O	4892
/	PUNCT	O	O	4892
day	NOUN	O	O	4892
intramuscularly	ADV	O	O	4892
,	PUNCT	O	O	4892
during	ADP	O	O	4892
the	PRON	O	O	4892
last	VERB	O	O	4892
six	NUM	O	O	4892
days	NOUN	O	O	4892
of	ADP	O	O	4892
the	PRON	O	O	4892
treatment	NOUN	O	O	4892
period	NOUN	O	O	4892
)	PUNCT	O	O	4892
.	PUNCT	O	O	4892
Nephrotoxicity	NOUN	O	Disease	4893
was	AUX	O	O	4893
assessed	VERB	O	O	4893
by	ADP	O	O	4893
measuring	VERB	O	O	4893
the	PRON	O	O	4893
concentrations	NOUN	O	O	4893
of	ADP	O	O	4893
creatinine	PROPN	O	Chemical	4893
and	CCONJ	O	O	4893
urea	PROPN	O	Chemical	4893
in	ADP	O	O	4893
the	PRON	O	O	4893
plasma	NOUN	O	O	4893
and	CCONJ	O	O	4893
reduced glutathione	NOUN	O	Chemical	4893
(	PUNCT	O	O	4893
GSH	PROPN	O	O	4893
)	PUNCT	O	O	4893
in	ADP	O	O	4893
the	PRON	O	O	4893
kidney	NOUN	O	O	4893
cortex	VERB	O	O	4893
,	PUNCT	O	O	4893
and	CCONJ	O	O	4893
by	ADP	O	O	4893
light	ADJ	O	O	4893
microscopic	ADJ	O	O	4893
examination	NOUN	O	O	4893
of	ADP	O	O	4893
kidney	NOUN	O	O	4893
sections	NOUN	O	O	4893
.	PUNCT	O	O	4893
The	PRON	O	O	4894
results	VERB	O	O	4894
indicated	VERB	O	O	4894
that	SCONJ	O	O	4894
concomitant	ADJ	O	O	4894
treatment	NOUN	O	O	4894
with	ADP	O	O	4894
gum	NOUN	O	O	4894
Arabic	PROPN	O	O	4894
and	CCONJ	O	O	4894
GM	PROPN	O	O	4894
significantly	ADV	O	O	4894
increased	VERB	O	O	4894
creatinine	PROPN	O	Chemical	4894
and	CCONJ	O	O	4894
urea	PROPN	O	Chemical	4894
by	ADP	O	O	4894
about	ADP	O	O	4894
183	NUM	O	O	4894
and	CCONJ	O	O	4894
239%	NOUN	O	O	4894
,	PUNCT	O	O	4894
respectively	ADV	O	O	4894
(	PUNCT	O	O	4894
compared	VERB	O	O	4894
to	PART	O	O	4894
432	NUM	O	O	4894
and	CCONJ	O	O	4894
346%	NOUN	O	O	4894
,	PUNCT	O	O	4894
respectively	ADV	O	O	4894
,	PUNCT	O	O	4894
in	ADP	O	O	4894
rats	NOUN	O	O	4894
treated	VERB	O	O	4894
with	ADP	O	O	4894
cellulose	NOUN	O	O	4894
and	CCONJ	O	O	4894
GM	PROPN	O	O	4894
)	PUNCT	O	O	4894
,	PUNCT	O	O	4894
and	CCONJ	O	O	4894
decreased	VERB	O	O	4894
that	SCONJ	O	O	4894
of	ADP	O	O	4894
cortical	ADJ	O	O	4894
GSH	PROPN	O	O	4894
by	ADP	O	O	4894
21%	NOUN	O	O	4894
(	PUNCT	O	O	4894
compared	VERB	O	O	4894
to	PART	O	O	4894
27%	NOUN	O	O	4894
in	ADP	O	O	4894
the	PRON	O	O	4894
cellulose	NOUN	O	O	4894
plus	CCONJ	O	O	4894
GM	PROPN	O	O	4894
group	NOUN	O	O	4894
)	PUNCT	O	O	4894
The	PRON	O	O	4895
GM	PROPN	O	O	4895
-	PUNCT	O	O	4895
induced	VERB	O	O	4895
proximal	ADJ	O	O	4895
tubular necrosis	NOUN	O	Disease	4895
appeared	VERB	O	O	4895
to	PART	O	O	4895
be	AUX	O	O	4895
slightly	ADV	O	O	4895
less	ADV	O	O	4895
severe	ADJ	O	O	4895
in	ADP	O	O	4895
rats	NOUN	O	O	4895
given	VERB	O	O	4895
GM	PROPN	O	O	4895
together	ADV	O	O	4895
with	ADP	O	O	4895
gum	NOUN	O	O	4895
Arabic	PROPN	O	O	4895
than	ADP	O	O	4895
in	ADP	O	O	4895
those	PRON	O	O	4895
given	VERB	O	O	4895
GM	PROPN	O	O	4895
and	CCONJ	O	O	4895
cellulose	NOUN	O	O	4895
.	PUNCT	O	O	4895
It	PRON	O	O	4896
could	AUX	O	O	4896
be	AUX	O	O	4896
inferred	VERB	O	O	4896
that	SCONJ	O	O	4896
gum	NOUN	O	O	4896
Arabic	PROPN	O	O	4896
treatment	NOUN	O	O	4896
has	VERB	O	O	4896
induced	VERB	O	O	4896
a	PRON	O	O	4896
modest	ADJ	O	O	4896
amelioration	NOUN	O	O	4896
of	ADP	O	O	4896
some	PRON	O	O	4896
of	ADP	O	O	4896
the	PRON	O	O	4896
histological	ADJ	O	O	4896
and	CCONJ	O	O	4896
biochemical	ADJ	O	O	4896
indices	NOUN	O	O	4896
of	ADP	O	O	4896
GM	PROPN	O	O	4896
nephrotoxicity	NOUN	O	Disease	4896
.	PUNCT	O	O	4896
Further	ADV	O	O	4897
work	NOUN	O	O	4897
is	AUX	O	O	4897
warranted	VERB	O	O	4897
on	ADP	O	O	4897
the	PRON	O	O	4897
effect	VERB	O	O	4897
of	ADP	O	O	4897
the	PRON	O	O	4897
treatments	NOUN	O	O	4897
on	ADP	O	O	4897
renal	ADJ	O	O	4897
functional	ADJ	O	O	4897
aspects	NOUN	O	O	4897
in	ADP	O	O	4897
models	NOUN	O	O	4897
of	ADP	O	O	4897
chronic	ADJ	O	O	4897
renal failure	NOUN	O	Disease	4897
,	PUNCT	O	O	4897
and	CCONJ	O	O	4897
on	ADP	O	O	4897
the	PRON	O	O	4897
mechanism(s	NOUN	O	O	4897
)	PUNCT	O	O	4897
involved	VERB	O	O	4897
.	PUNCT	O	O	4897
Visual hallucinations	NOUN	O	Disease	4900
associated	VERB	O	O	4900
with	ADP	O	O	4900
zonisamide	ADV	O	Chemical	4900
.	PUNCT	O	O	4900
Zonisamide	PROPN	O	O	4901
is	AUX	O	O	4901
a	PRON	O	O	4901
broad	ADJ	O	O	4901
-	PUNCT	O	O	4901
spectrum	NOUN	O	O	4901
antiepileptic	ADJ	O	O	4901
drug	NOUN	O	O	4901
used	VERB	O	O	4901
to	PART	O	O	4901
treat	VERB	O	O	4901
various	ADJ	O	O	4901
types	NOUN	O	O	4901
of	ADP	O	O	4901
seizures	NOUN	O	Disease	4901
.	PUNCT	O	O	4901
Although	SCONJ	O	O	4902
visual hallucinations	NOUN	O	Disease	4902
have	VERB	O	O	4902
not	PART	O	O	4902
been	AUX	O	O	4902
reported	VERB	O	O	4902
as	ADP	O	O	4902
an	PRON	O	O	4902
adverse	ADJ	O	O	4902
effect	VERB	O	O	4902
of	ADP	O	O	4902
this	PRON	O	O	4902
agent	NOUN	O	O	4902
,	PUNCT	O	O	4902
we	PRON	O	O	4902
describe	VERB	O	O	4902
three	NUM	O	O	4902
patients	NOUN	O	O	4902
who	PRON	O	O	4902
experienced	ADJ	O	O	4902
complex	ADJ	O	O	4902
visual hallucinations	NOUN	O	Disease	4902
and	CCONJ	O	O	4902
altered	VERB	O	O	4902
mental	ADJ	O	O	4902
status	NOUN	O	O	4902
after	ADP	O	O	4902
zonisamide	ADV	O	Chemical	4902
treatment	NOUN	O	O	4902
was	AUX	O	O	4902
begun	VERB	O	O	4902
or	CCONJ	O	O	4902
its	PRON	O	O	4902
dosage	NOUN	O	O	4902
increased	VERB	O	O	4902
.	PUNCT	O	O	4902
All	PRON	O	O	4903
three	NUM	O	O	4903
had	VERB	O	O	4903
been	AUX	O	O	4903
diagnosed	VERB	O	O	4903
earlier	ADV	O	O	4903
with	ADP	O	O	4903
epilepsy	NOUN	O	Disease	4903
,	PUNCT	O	O	4903
and	CCONJ	O	O	4903
their	PRON	O	O	4903
electroencephalogram	PROPN	O	O	4903
(	PUNCT	O	O	4903
EEG	NOUN	O	O	4903
)	PUNCT	O	O	4903
During	ADP	O	O	4904
monitoring	NOUN	O	O	4904
,	PUNCT	O	O	4904
visual hallucinations	NOUN	O	Disease	4904
did	VERB	O	O	4904
not	PART	O	O	4904
correlate	VERB	O	O	4904
with	ADP	O	O	4904
EEG	NOUN	O	O	4904
readings	NOUN	O	O	4904
,	PUNCT	O	O	4904
nor	CCONJ	O	O	4904
did	VERB	O	O	4904
video	NOUN	O	O	4904
recording	NOUN	O	O	4904
capture	VERB	O	O	4904
any	PRON	O	O	4904
of	ADP	O	O	4904
the	PRON	O	O	4904
described	VERB	O	O	4904
events	NOUN	O	O	4904
.	PUNCT	O	O	4904
None	NOUN	O	O	4905
of	ADP	O	O	4905
the	PRON	O	O	4905
patients	NOUN	O	O	4905
had	VERB	O	O	4905
experienced	ADJ	O	O	4905
visual hallucinations	NOUN	O	Disease	4905
before	ADP	O	O	4905
this	PRON	O	O	4905
event	NOUN	O	O	4905
.	PUNCT	O	O	4905
The	PRON	O	O	4906
only	ADV	O	O	4906
recent	ADJ	O	O	4906
change	VERB	O	O	4906
in	ADP	O	O	4906
their	PRON	O	O	4906
treatment	NOUN	O	O	4906
was	AUX	O	O	4906
the	PRON	O	O	4906
introduction	NOUN	O	O	4906
or	CCONJ	O	O	4906
increased	VERB	O	O	4906
dosage	NOUN	O	O	4906
of	ADP	O	O	4906
zonisamide	ADV	O	Chemical	4906
.	PUNCT	O	O	4906
Until	ADP	O	O	4907
then	ADV	O	O	4907
,	PUNCT	O	O	4907
clinicians	NOUN	O	O	4907
need	VERB	O	O	4907
to	PART	O	O	4907
be	AUX	O	O	4907
aware	ADJ	O	O	4907
of	ADP	O	O	4907
this	PRON	O	O	4907
possible	ADJ	O	O	4907
complication	NOUN	O	O	4907
associated	VERB	O	O	4907
with	ADP	O	O	4907
zonisamide	ADV	O	Chemical	4907
.	PUNCT	O	O	4907
GLEPP1	PROPN	O	O	4910
receptor	NOUN	O	O	4910
tyrosine	NOUN	O	Chemical	4910
phosphatase	ADJ	O	O	4910
(	PUNCT	O	O	4910
Ptpro	PROPN	O	O	4910
)	PUNCT	O	O	4910
in	ADP	O	O	4910
rat	NOUN	O	O	4910
PAN	PROPN	O	Chemical	4910
nephrosis	NOUN	O	Disease	4910
.	PUNCT	O	O	4910
Glomerular	PROPN	O	O	4911
epithelial	ADJ	O	O	4911
protein	NOUN	O	O	4911
1	X	O	O	4911
(	PUNCT	O	O	4911
GLEPP1	PROPN	O	O	4911
)	PUNCT	O	O	4911
is	AUX	O	O	4911
a	PRON	O	O	4911
podocyte	PROPN	O	O	4911
receptor	NOUN	O	O	4911
membrane	NOUN	O	O	4911
protein	NOUN	O	O	4911
tyrosine	NOUN	O	Chemical	4911
phosphatase	ADJ	O	O	4911
located	VERB	O	O	4911
on	ADP	O	O	4911
the	PRON	O	O	4911
apical	ADJ	O	O	4911
cell	NOUN	O	O	4911
membrane	NOUN	O	O	4911
of	ADP	O	O	4911
visceral	ADJ	O	O	4911
glomerular	ADJ	O	O	4911
epithelial	ADJ	O	O	4911
cell	NOUN	O	O	4911
and	CCONJ	O	O	4911
foot	NOUN	O	O	4911
processes	NOUN	O	O	4911
.	PUNCT	O	O	4911
To	PART	O	O	4912
better	ADV	O	O	4912
understand	VERB	O	O	4912
the	PRON	O	O	4912
utility	NOUN	O	O	4912
of	ADP	O	O	4912
GLEPP1	PROPN	O	O	4912
as	ADP	O	O	4912
a	PRON	O	O	4912
marker	NOUN	O	O	4912
of	ADP	O	O	4912
glomerular	ADJ	O	O	4912
injury	NOUN	O	O	4912
,	PUNCT	O	O	4912
the	PRON	O	O	4912
amount	NOUN	O	O	4912
and	CCONJ	O	O	4912
distribution	NOUN	O	O	4912
of	ADP	O	O	4912
GLEPP1	PROPN	O	O	4912
protein	NOUN	O	O	4912
and	CCONJ	O	O	4912
mRNA	PROPN	O	O	4912
were	AUX	O	O	4912
examined	VERB	O	O	4912
by	ADP	O	O	4912
immunohistochemistry	NOUN	O	O	4912
,	PUNCT	O	O	4912
Western	ADJ	O	O	4912
blot	NOUN	O	O	4912
and	CCONJ	O	O	4912
RNase	PROPN	O	O	4912
protection	NOUN	O	O	4912
assay	NOUN	O	O	4912
in	ADP	O	O	4912
a	PRON	O	O	4912
model	NOUN	O	O	4912
of	ADP	O	O	4912
podocyte	PROPN	O	O	4912
injury	NOUN	O	O	4912
in	ADP	O	O	4912
the	PRON	O	O	4912
rat	NOUN	O	O	4912
.	PUNCT	O	O	4912
Puromycin aminonucleoside	NOUN	O	Chemical	4913
nephrosis	NOUN	O	Disease	4913
was	AUX	O	O	4913
induced	VERB	O	O	4913
by	ADP	O	O	4913
single	ADJ	O	O	4913
intraperitoneal	ADJ	O	O	4913
injection	NOUN	O	O	4913
of	ADP	O	O	4913
puromycin aminonucleoside	NOUN	O	Chemical	4913
(	PUNCT	O	O	4913
PAN	PROPN	O	Chemical	4913
,	PUNCT	O	O	4913
20	NUM	O	O	4913
mg/100	VERB	O	O	4913
g	X	O	O	4913
BW	NOUN	O	O	4913
)	PUNCT	O	O	4913
.	PUNCT	O	O	4913
Tissues	NOUN	O	O	4914
were	AUX	O	O	4914
analyzed	VERB	O	O	4914
at	ADP	O	O	4914
0	NUM	O	O	4914
,	PUNCT	O	O	4914
5	NUM	O	O	4914
,	PUNCT	O	O	4914
7	NUM	O	O	4914
,	PUNCT	O	O	4914
11	NUM	O	O	4914
,	PUNCT	O	O	4914
21	NUM	O	O	4914
,	PUNCT	O	O	4914
45	NUM	O	O	4914
,	PUNCT	O	O	4914
80	NUM	O	O	4914
and	CCONJ	O	O	4914
126	NUM	O	O	4914
days	NOUN	O	O	4914
after	ADP	O	O	4914
PAN	PROPN	O	Chemical	4914
injection	NOUN	O	O	4914
so	ADV	O	O	4914
as	ADP	O	O	4914
to	PART	O	O	4914
include	VERB	O	O	4914
both	PRON	O	O	4914
the	PRON	O	O	4914
acute	ADJ	O	O	4914
phase	NOUN	O	O	4914
of	ADP	O	O	4914
proteinuria	X	O	Disease	4914
associated	VERB	O	O	4914
with	ADP	O	O	4914
foot	NOUN	O	O	4914
process	NOUN	O	O	4914
effacement	NOUN	O	O	4914
(	PUNCT	O	O	4914
days	NOUN	O	O	4914
5	NUM	O	O	4914
-	PUNCT	O	O	4914
11	NUM	O	O	4914
)	PUNCT	O	O	4914
and	CCONJ	O	O	4914
the	PRON	O	O	4914
chronic	ADJ	O	O	4914
phase	NOUN	O	O	4914
of	ADP	O	O	4914
proteinuria	X	O	Disease	4914
associated	VERB	O	O	4914
with	ADP	O	O	4914
glomerulosclerosis	PROPN	O	O	4914
(	PUNCT	O	O	4914
days	NOUN	O	O	4914
45	NUM	O	O	4914
-	PUNCT	O	O	4914
126	NUM	O	O	4914
)	PUNCT	O	O	4914
.	PUNCT	O	O	4914
We	PRON	O	O	4915
conclude	VERB	O	O	4915
that	SCONJ	O	O	4915
GLEPP1	PROPN	O	O	4915
expression	NOUN	O	O	4915
,	PUNCT	O	O	4915
unlike	ADP	O	O	4915
podocalyxin	NOUN	O	O	4915
,	PUNCT	O	O	4915
reflects	VERB	O	O	4915
podocyte	PROPN	O	O	4915
injury	NOUN	O	O	4915
induced	VERB	O	O	4915
by	ADP	O	O	4915
PAN	PROPN	O	Chemical	4915
.	PUNCT	O	O	4915
Ticlopidine	NOUN	O	O	4918
-	PUNCT	O	O	4918
induced	VERB	O	O	4918
aplastic anemia	NOUN	O	Disease	4918
:	PUNCT	O	O	4918
In	ADP	O	O	4919
this	PRON	O	O	4919
study	VERB	O	O	4919
,	PUNCT	O	O	4919
three	NUM	O	O	4919
Chinese	PROPN	O	O	4919
patients	NOUN	O	O	4919
with	ADP	O	O	4919
ticlopidine	ADV	O	O	4919
-	PUNCT	O	O	4919
induced	VERB	O	O	4919
aplastic anemia	NOUN	O	Disease	4919
were	AUX	O	O	4919
reported	VERB	O	O	4919
and	CCONJ	O	O	4919
another	PRON	O	O	4919
13	NUM	O	O	4919
patients	NOUN	O	O	4919
in	ADP	O	O	4919
the	PRON	O	O	4919
English	PROPN	O	O	4919
literature	NOUN	O	O	4919
were	AUX	O	O	4919
reviewed	VERB	O	O	4919
.	PUNCT	O	O	4919
Agranulocytosis	ADJ	O	O	4920
occurred	VERB	O	O	4920
3	X	O	O	4920
-	PUNCT	O	O	4920
20	NUM	O	O	4920
weeks	NOUN	O	O	4920
after	ADP	O	O	4920
initiation	NOUN	O	O	4920
of	ADP	O	O	4920
ticlopidine	ADV	O	O	4920
,	PUNCT	O	O	4920
so	ADV	O	O	4920
frequent	ADJ	O	O	4920
examination	NOUN	O	O	4920
of	ADP	O	O	4920
white	ADJ	O	O	4920
cell	NOUN	O	O	4920
count	VERB	O	O	4920
during	ADP	O	O	4920
treatment	NOUN	O	O	4920
is	AUX	O	O	4920
recommended	VERB	O	O	4920
.	PUNCT	O	O	4920
There	ADV	O	O	4921
seemed	VERB	O	O	4921
to	PART	O	O	4921
be	AUX	O	O	4921
no	PRON	O	O	4921
direct	ADJ	O	O	4921
correlation	NOUN	O	O	4921
between	ADP	O	O	4921
the	PRON	O	O	4921
dose	NOUN	O	O	4921
or	CCONJ	O	O	4921
duration	NOUN	O	O	4921
used	VERB	O	O	4921
and	CCONJ	O	O	4921
the	PRON	O	O	4921
severity	NOUN	O	O	4921
of	ADP	O	O	4921
bone	NOUN	O	O	4921
marrow suppression	NOUN	O	Disease	4921
.	PUNCT	O	O	4921
Treatment	NOUN	O	O	4922
for	ADP	O	O	4922
ticlopidine	ADV	O	O	4922
-	PUNCT	O	O	4922
induced	VERB	O	O	4922
aplastic anemia	NOUN	O	Disease	4922
with	ADP	O	O	4922
colony	NOUN	O	O	4922
-	PUNCT	O	O	4922
stimulating	VERB	O	O	4922
factors	NOUN	O	O	4922
seemed	VERB	O	O	4922
to	PART	O	O	4922
have	VERB	O	O	4922
little	ADJ	O	O	4922
effect	VERB	O	O	4922
.	PUNCT	O	O	4922
The	PRON	O	O	4923
fact	NOUN	O	O	4923
that	SCONJ	O	O	4923
5	NUM	O	O	4923
of	ADP	O	O	4923
the	PRON	O	O	4923
6	NUM	O	O	4923
patients	NOUN	O	O	4923
who	PRON	O	O	4923
received	VERB	O	O	4923
concurrent	ADJ	O	O	4923
calcium	NOUN	O	Chemical	4923
channel	PROPN	O	O	4923
blockers	NOUN	O	O	4923
died	VERB	O	O	4923
,	PUNCT	O	O	4923
should	AUX	O	O	4923
alert	ADJ	O	O	4923
clinicians	NOUN	O	O	4923
to	PART	O	O	4923
be	AUX	O	O	4923
more	ADJ	O	O	4923
cautious	ADJ	O	O	4923
when	SCONJ	O	O	4923
using	VERB	O	O	4923
these	PRON	O	O	4923
two	NUM	O	O	4923
drugs	NOUN	O	O	4923
simultaneously	ADV	O	O	4923
.	PUNCT	O	O	4923
Facilitation	NOUN	O	O	4926
of	ADP	O	O	4926
memory	NOUN	O	O	4926
retrieval	PROPN	O	O	4926
by	ADP	O	O	4926
pre	VERB	O	O	4926
-	PUNCT	O	O	4926
test	NOUN	O	O	4926
morphine	NOUN	O	Chemical	4926
and	CCONJ	O	O	4926
its	PRON	O	O	4926
state	NOUN	O	O	4926
dependency	NOUN	O	O	4926
in	ADP	O	O	4926
the	PRON	O	O	4926
step	VERB	O	O	4926
-	PUNCT	O	O	4926
through	ADP	O	O	4926
type	NOUN	O	O	4926
passive	ADJ	O	O	4926
avoidance	NOUN	O	O	4926
learning	VERB	O	O	4926
test	NOUN	O	O	4926
in	ADP	O	O	4926
mice	NOUN	O	O	4926
.	PUNCT	O	O	4926
Amnesia	NOUN	O	O	4927
produced	VERB	O	O	4927
by	ADP	O	O	4927
scopolamine	NOUN	O	Chemical	4927
and	CCONJ	O	O	4927
cycloheximide	NOUN	O	Chemical	4927
were	AUX	O	O	4927
reversed	VERB	O	O	4927
by	ADP	O	O	4927
morphine	NOUN	O	Chemical	4927
given	VERB	O	O	4927
30	NUM	O	O	4927
min	NOUN	O	O	4927
before	ADP	O	O	4927
the	PRON	O	O	4927
test	NOUN	O	O	4927
trial	NOUN	O	O	4927
(	PUNCT	O	O	4927
pre	VERB	O	O	4927
-	PUNCT	O	O	4927
test	NOUN	O	O	4927
)	PUNCT	O	O	4927
,	PUNCT	O	O	4927
and	CCONJ	O	O	4927
pre	VERB	O	O	4927
-	PUNCT	O	O	4927
test	NOUN	O	O	4927
morphine	NOUN	O	Chemical	4927
also	ADV	O	O	4927
facilitated	VERB	O	O	4927
the	PRON	O	O	4927
memory	NOUN	O	O	4927
retrieval	PROPN	O	O	4927
in	ADP	O	O	4927
the	PRON	O	O	4927
animals	NOUN	O	O	4927
administered	VERB	O	O	4927
naloxone	NOUN	O	Chemical	4927
during	ADP	O	O	4927
the	PRON	O	O	4927
training	NOUN	O	O	4927
trial	NOUN	O	O	4927
.	PUNCT	O	O	4927
Similarly	ADV	O	O	4928
,	PUNCT	O	O	4928
pre	VERB	O	O	4928
-	PUNCT	O	O	4928
test	NOUN	O	O	4928
scopolamine	NOUN	O	Chemical	4928
partially	ADV	O	O	4928
reversed	VERB	O	O	4928
the	PRON	O	O	4928
scopolamine	NOUN	O	Chemical	4928
-	PUNCT	O	O	4928
induced	VERB	O	O	4928
amnesia	NOUN	O	Disease	4928
,	PUNCT	O	O	4928
but	CCONJ	O	O	4928
not	PART	O	O	4928
significantly	ADV	O	O	4928
;	PUNCT	O	O	4928
and	CCONJ	O	O	4928
pre	VERB	O	O	4928
-	PUNCT	O	O	4928
test	NOUN	O	O	4928
cycloheximide	NOUN	O	Chemical	4928
failed	VERB	O	O	4928
to	PART	O	O	4928
reverse	VERB	O	O	4928
the	PRON	O	O	4928
cycloheximide	NOUN	O	Chemical	4928
-	PUNCT	O	O	4928
induced	VERB	O	O	4928
amnesia	NOUN	O	Disease	4928
.	PUNCT	O	O	4928
These	PRON	O	O	4929
results	VERB	O	O	4929
suggest	VERB	O	O	4929
that	SCONJ	O	O	4929
the	PRON	O	O	4929
facilitation	NOUN	O	O	4929
of	ADP	O	O	4929
memory	NOUN	O	O	4929
retrieval	PROPN	O	O	4929
by	ADP	O	O	4929
pre	VERB	O	O	4929
-	PUNCT	O	O	4929
test	NOUN	O	O	4929
morphine	NOUN	O	Chemical	4929
might	AUX	O	O	4929
be	AUX	O	O	4929
the	PRON	O	O	4929
direct	ADJ	O	O	4929
action	NOUN	O	O	4929
of	ADP	O	O	4929
morphine	NOUN	O	Chemical	4929
rather	ADV	O	O	4929
than	ADP	O	O	4929
a	PRON	O	O	4929
state	NOUN	O	O	4929
dependent	ADJ	O	O	4929
effect	VERB	O	O	4929
.	PUNCT	O	O	4929
Apomorphine	PROPN	O	Chemical	4932
,	PUNCT	O	O	4932
a	PRON	O	O	4932
nonselective	ADJ	O	O	4932
dopamine	NOUN	O	Chemical	4932
agonist	NOUN	O	O	4932
,	PUNCT	O	O	4932
was	AUX	O	O	4932
selected	VERB	O	O	4932
due	ADJ	O	O	4932
to	PART	O	O	4932
its	PRON	O	O	4932
biphasic	ADJ	O	O	4932
behavioral	ADJ	O	O	4932
effects	NOUN	O	O	4932
,	PUNCT	O	O	4932
its	PRON	O	O	4932
ability	NOUN	O	O	4932
to	PART	O	O	4932
induce	VERB	O	O	4932
hypothermia	VERB	O	Disease	4932
,	PUNCT	O	O	4932
and	CCONJ	O	O	4932
to	PART	O	O	4932
produce	VERB	O	O	4932
distinct	ADJ	O	O	4932
changes	VERB	O	O	4932
to	PART	O	O	4932
dopamine	NOUN	O	Chemical	4932
turnover	NOUN	O	O	4932
in	ADP	O	O	4932
the	PRON	O	O	4932
rodent	NOUN	O	O	4932
brain	NOUN	O	O	4932
.	PUNCT	O	O	4932
From	ADP	O	O	4933
such	ADJ	O	O	4933
experiments	NOUN	O	O	4933
there	ADV	O	O	4933
is	AUX	O	O	4933
evidence	NOUN	O	O	4933
that	SCONJ	O	O	4933
characterization	NOUN	O	O	4933
and	CCONJ	O	O	4933
detection	NOUN	O	O	4933
of	ADP	O	O	4933
apomorphine	PROPN	O	Chemical	4933
-	PUNCT	O	O	4933
induced	VERB	O	O	4933
activity	NOUN	O	O	4933
in	ADP	O	O	4933
rodents	NOUN	O	O	4933
critically	ADV	O	O	4933
depends	VERB	O	O	4933
upon	SCONJ	O	O	4933
the	PRON	O	O	4933
test	NOUN	O	O	4933
conditions	NOUN	O	O	4933
employed	VERB	O	O	4933
.	PUNCT	O	O	4933
In	ADP	O	O	4934
rats	NOUN	O	O	4934
,	PUNCT	O	O	4934
detection	NOUN	O	O	4934
of	ADP	O	O	4934
apomorphine	PROPN	O	Chemical	4934
-	PUNCT	O	O	4934
induced	VERB	O	O	4934
hyperactivity	NOUN	O	Disease	4934
was	AUX	O	O	4934
facilitated	VERB	O	O	4934
by	ADP	O	O	4934
a	PRON	O	O	4934
period	NOUN	O	O	4934
of	ADP	O	O	4934
acclimatization	NOUN	O	O	4934
to	PART	O	O	4934
the	PRON	O	O	4934
test	NOUN	O	O	4934
conditions	NOUN	O	O	4934
.	PUNCT	O	O	4934
Moreover	ADV	O	O	4935
,	PUNCT	O	O	4935
test	NOUN	O	O	4935
conditions	NOUN	O	O	4935
can	AUX	O	O	4935
impact	NOUN	O	O	4935
upon	SCONJ	O	O	4935
other	ADJ	O	O	4935
physiological	ADJ	O	O	4935
responses	NOUN	O	O	4935
to	PART	O	O	4935
apomorphine	PROPN	O	Chemical	4935
such	ADJ	O	O	4935
as	ADP	O	O	4935
drug	NOUN	O	O	4935
-	PUNCT	O	O	4935
induced	VERB	O	O	4935
hypothermia	VERB	O	Disease	4935
.	PUNCT	O	O	4935
In	ADP	O	O	4936
mice	NOUN	O	O	4936
,	PUNCT	O	O	4936
apomorphine	PROPN	O	Chemical	4936
produced	VERB	O	O	4936
qualitatively	ADV	O	O	4936
different	ADJ	O	O	4936
responses	NOUN	O	O	4936
under	ADP	O	O	4936
novel	NOUN	O	O	4936
conditions	NOUN	O	O	4936
when	SCONJ	O	O	4936
compared	VERB	O	O	4936
to	PART	O	O	4936
those	PRON	O	O	4936
behaviors	NOUN	O	O	4936
elicited	VERB	O	O	4936
in	ADP	O	O	4936
the	PRON	O	O	4936
home	NOUN	O	O	4936
test	NOUN	O	O	4936
cage	NOUN	O	O	4936
.	PUNCT	O	O	4936
By	ADP	O	O	4937
contrast	NOUN	O	O	4937
,	PUNCT	O	O	4937
apomorphine	PROPN	O	Chemical	4937
-	PUNCT	O	O	4937
induced	VERB	O	O	4937
locomotion	NOUN	O	O	4937
was	AUX	O	O	4937
more	ADJ	O	O	4937
prominent	ADJ	O	O	4937
in	ADP	O	O	4937
the	PRON	O	O	4937
novel	NOUN	O	O	4937
exploratory	ADJ	O	O	4937
box	NOUN	O	O	4937
.	PUNCT	O	O	4937
Dopamine	NOUN	O	Chemical	4938
turnover	NOUN	O	O	4938
ratios	VERB	O	O	4938
(	PUNCT	O	O	4938
DOPAC	PROPN	O	Chemical	4938
:	PUNCT	O	O	4938
DA	NOUN	O	Chemical	4938
and	CCONJ	O	O	4938
HVA	PROPN	O	O	4938
:	PUNCT	O	O	4938
DA	NOUN	O	Chemical	4939
)	PUNCT	O	O	4939
were	AUX	O	O	4939
found	VERB	O	O	4939
to	PART	O	O	4939
be	AUX	O	O	4939
lower	ADJ	O	O	4939
in	ADP	O	O	4939
those	PRON	O	O	4939
animals	NOUN	O	O	4939
exposed	VERB	O	O	4939
to	PART	O	O	4939
the	PRON	O	O	4939
exploratory	ADJ	O	O	4939
box	NOUN	O	O	4939
when	SCONJ	O	O	4939
compared	VERB	O	O	4939
to	PART	O	O	4939
their	PRON	O	O	4939
home	NOUN	O	O	4939
cage	NOUN	O	O	4939
counterparts	NOUN	O	O	4939
.	PUNCT	O	O	4939
However	ADV	O	O	4940
,	PUNCT	O	O	4940
apomorphine	PROPN	O	Chemical	4940
-	PUNCT	O	O	4940
induced	VERB	O	O	4940
reductions	NOUN	O	O	4940
in	ADP	O	O	4940
striatal	ADJ	O	O	4940
dopamine	NOUN	O	Chemical	4940
turnover	NOUN	O	O	4940
were	AUX	O	O	4940
detected	VERB	O	O	4940
in	ADP	O	O	4940
both	PRON	O	O	4940
novel	NOUN	O	O	4940
and	CCONJ	O	O	4940
home	NOUN	O	O	4940
cage	NOUN	O	O	4940
environments	NOUN	O	O	4940
.	PUNCT	O	O	4940
